FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ji, B
   Genever, PG
   Patton, RJ
   Fagan, MJ
AF Ji, Bing
   Genever, Paul G.
   Patton, Ronald J.
   Fagan, Michael J.
TI Mathematical modelling of the pathogenesis of multiple myeloma induced
   bone disease
SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING
LA English
DT Article
DE multiple myeloma; MM induced bone disease; bone microenvironment;
   mathematical model; osteoblast and osteoclast activities
ID GROWTH FACTOR BETA; SERUM OSTEOPROTEGERIN LEVELS; RECEPTOR ACTIVATOR;
   PARATHYROID HORMONE; OSTEOBLAST; TUMOR; MARROW; LIGAND; CELLS;
   RANKL/RANK/OPG
AB Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM induced bone disease and forms a vicious cycle' of tumour development and bone destruction, intensified by suppression of osteoblast activity and promotion of osteoclast activity. In this paper, a mathematical model is proposed to simulate how the interaction between MM cells and the bone microenvironment facilitates the development of the tumour cells and the resultant bone destruction. It includes both the roles of inhibited osteoblast activity and stimulated osteoclast activity. The model is able to mimic the temporal variation of bone cell concentrations and resultant bone volume after the invasion and then removal of the tumour cells and explains why MM induced bone lesions rarely heal even after the complete removal of MM cells. The behaviour of the model compares well with published experimental data. The model serves as a first step to understand the development of MM induced bone disease and could be applied further to evaluate the current therapies against MM induced bone disease and even suggests new potential therapeutic targets. (c) 2014 The Authors. International Journal for Numerical Methods in Biomedical Engineering published by John Wiley & Sons Ltd
C1 [Ji, Bing] Shandong Univ, Sch Control Sci & Engn, Jinan 250061, Peoples R China.
   [Genever, Paul G.] Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England.
   [Patton, Ronald J.; Fagan, Michael J.] Univ Hull, Sch Engn, Kingston Upon Hull HU6 7RX, N Humberside, England.
C3 Shandong University; University of York   UK; University of Hull
RP Fagan, MJ (通讯作者)，Univ Hull, Sch Engn, Cottingham Rd, Kingston Upon Hull HU6 7RX, N Humberside, England.
EM m.j.fagan@hull.ac.uk
RI ; 姬, 冰/GRS 6888 2022
OI Genever, Paul/0000 0002 5730 8976; JI, Bing/0000 0003 1326 4120; 
FU UK Engineering and Physical Sciences Research Council [EP/E057365/1];
   National Natural Science Foundation of China [81301294]; Independent
   Innovation Foundation of SHANDONG University [2013HW009]; Engineering
   and Physical Sciences Research Council [EP/E057365/1] Funding Source:
   researchfish; EPSRC [EP/E057365/1] Funding Source: UKRI
FX This work was partly supported by the UK Engineering and Physical
   Sciences Research Council through grant EP/E057365/1, National Natural
   Science Foundation of China through grant 81301294 and the Independent
   Innovation Foundation of SHANDONG University through grant 2013HW009.
CR Alexandrakis MG, 2003, AM J HEMATOL, V72, P229, DOI 10.1002/ajh.10304
   Alexandrakis MG, 2002, CLIN CHIM ACTA, V325, P51, DOI 10.1016/S0009 8981(02)00246 2
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   BATAILLE R, 1990, BRIT J HAEMATOL, V76, P484, DOI 10.1111/j.1365 2141.1990.tb07904.x
   BATAILLE R, 1986, BRIT J CANCER, V53, P805, DOI 10.1038/bjc.1986.136
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Blum B, 2004, ORTHOPEDICS, V27, pS161
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Calmelet C, 2010, MATH MODEL NAT PHENO, V5, P40, DOI 10.1051/mmnp/20105304
   Calvani N, 2004, LEUKEMIA LYMPHOMA, V45, P377, DOI 10.1080/10428190310001595696
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200
   Cowins SC, 2001, BONE MECH HDB
   CRISTY M, 1981, PHYS MED BIOL, V26, P389, DOI 10.1088/0031 9155/26/3/003
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   Dingli D, 2006, MATH BIOSCI, V199, P55, DOI 10.1016/j.mbs.2005.11.001
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Eriksen E.F., 1992, TRIANGLE, V31, P45
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fowler JA, 2011, BONE, V48, P121, DOI 10.1016/j.bone.2010.06.029
   Goranova Marinova V., 2007, CLIN CORRELATIONS HA, V92, P1000, DOI DOI 10.3324/HAEMAT0L.10943
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Ji BB, 2012, BIOMECH MODEL MECHAN, V11, P973, DOI 10.1007/s10237 011 0366 3
   Jis B., 2012, THESIS U HULL UK
   KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Lipton A, 2002, CLIN CANCER RES, V8, P2306
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Mundy G. R., 1996, P301
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Ryser MD, 2010, SIAM J APPL MATH, V70, P1899, DOI 10.1137/090746094
   SALMON SE, 1970, J CLIN INVEST, V49, P1114, DOI 10.1172/JCI106327
   Schmitt CP, 1998, J AM SOC NEPHROL, V9, P1832
   Seidel C, 2001, BLOOD, V98, P2269, DOI 10.1182/blood.V98.7.2269
   Shay G., 2011, OSTEOPOROSIS REV, V19, P9
   Silva AS, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 25
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Stewart JP, 2006, J CELL BIOCHEM, V98, P1, DOI 10.1002/jcb.20774
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889 8588(05)70413 5
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Urashima M, 1996, BLOOD, V87, P1928
   vanZaanen HCT, 1996, J CLIN INVEST, V98, P1441, DOI 10.1172/JCI118932
   WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wols HAM, 2002, J IMMUNOL, V169, P4213, DOI 10.4049/jimmunol.169.8.4213
   Wong PKK, 2003, ARTHRITIS RHEUM US, V48, P1177, DOI 10.1002/art.10943
   Yaccoby S, 2010, LEUKEMIA LYMPHOMA, V51, P213, DOI 10.3109/10428190903503438
   Yeh HS, 2006, EUR J CANCER, V42, P1554, DOI 10.1016/j.ejca.2005.11.035
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
   Zwartz G, 2004, BIOPHYS J, V86, P1243, DOI 10.1016/S0006 3495(04)74198 3
NR 73
TC 18
Z9 19
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2040 7939
EI 2040 7947
J9 INT J NUMER METH BIO
JI Int. J. Numer. Meth. Biomed.
PD NOV
PY 2014
VL 30
IS 11
BP 1085
EP 1102
DI 10.1002/cnm.2645
PG 18
WC Engineering, Biomedical; Mathematical & Computational Biology;
   Mathematics, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Mathematical & Computational Biology; Mathematics
GA AS9WU
UT WOS:000344590100001
PM 24817420
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yun, HM
   Lee, JY
   Kim, B
   Park, KR
AF Yun, Hyung Mun
   Lee, Joon Yeop
   Kim, Bomi
   Park, Kyung Ran
TI Suffruticosol B Is an Osteogenic Inducer through Osteoblast
   Differentiation, Autophagy, Adhesion, and Migration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoblasts; phytomedicine; Paeonia suffruticosa; RUNX2; Suf B
ID MESENCHYMAL STEM CELLS; ALKALINE PHOSPHATASE; PAEONIA SUFFRUTICOSA;
   SIGNALING PATHWAYS; BONE; CONSTITUENTS; OSTEOPOROSIS; PATHOGENESIS;
   RESVERATROL; MECHANISMS
AB Suffruticosol B (Suf B) is a stilbene found in Paeonia suffruticosa ANDR., which has been traditionally used in medicine. Stilbenes and their derivatives possess various pharmacological effects, such as anticancer, anti inflammatory, and anti osteoporotic activities. This study aimed to explore the bone forming activities and mechanisms of Suf B in pre osteoblasts. Herein, >99.9% pure Suf B was isolated from P. suffruticosa methanolic extracts. High concentrations of Suf B were cytotoxic, whereas low concentrations did not affect cytotoxicity in pre osteoblasts. Under zero levels of cytotoxicity, Suf B exhibited bone forming abilities by enhancing alkaline phosphatase enzyme activities, bone matrix calcification, and expression levels with non collagenous proteins. Suf B induces intracellular signal transduction, leading to nuclear RUNX2 expression. Suf B stimulated differentiation showed increases in autophagy proteins and autophagosomes, as well as enhancement of osteoblast adhesion and transmigration on the ECM. These results indicate that Suf B has osteogenic qualities related to differentiation, autophagy, adhesion, and migration. This also suggests that Suf B could have a therapeutic effect as a phytomedicine in skeletal disorders.
C1 [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Lee, Joon Yeop; Kim, Bomi] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
   [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
C3 Kyung Hee University; Korea Basic Science Institute (KBSI)
RP Park, KR (通讯作者)，Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
EM krpark83@kbsi.re.kr
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1C1C1003491]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (2022R1C1C1003491).
CR Almosnid NM, 2016, INT J ONCOL, V48, P646, DOI 10.3892/ijo.2015.3269
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Aryaei A, 2014, J BIOMED MATER RES A, V102, P3282, DOI 10.1002/jbm.a.34993
   Cai TG, 2011, BIOL PHARM BULL, V34, P1501, DOI 10.1248/bpb.34.1501
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chung HJ, 2017, J NAT PROD, V80, P434, DOI 10.1021/acs.jnatprod.6b00964
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   di Giacomo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082789
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Gu SM, 2016, ONCOTARGET, V7, P15382, DOI 10.18632/oncotarget.8097
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   He CN, 2010, CHEM PHARM BULL, V58, P843, DOI 10.1248/cpb.58.843
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Javed A, 2010, ORAL MAXIL SURG CLIN, V22, P283, DOI 10.1016/j.coms.2010.05.001
   Jiang TM, 2015, CELL PHYSIOL BIOCHEM, V36, P2327, DOI 10.1159/000430196
   Kalbacova M, 2010, CARBON, V48, P4323, DOI 10.1016/j.carbon.2010.07.045
   Kang JH, 2003, EXP MOL MED, V35, P467, DOI 10.1038/emm.2003.61
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim HJ, 2002, ARCH PHARM RES, V25, P293, DOI 10.1007/BF02976629
   Kim HJ, 2002, BIOSCI BIOTECH BIOCH, V66, P1990, DOI 10.1271/bbb.66.1990
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Lee JH, 2019, BIOFOULING, V35, P758, DOI 10.1080/08927014.2019.1657418
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li G, 2004, ARCH PHARM RES, V27, P1123, DOI 10.1007/BF02975116
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu ZG, 2021, FOOD FUNCT, V12, P11777, DOI [10.1039/D1FO02341A, 10.1039/d1fo02341a]
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Ogata Y, 2008, J PERIODONTAL RES, V43, P127, DOI 10.1111/j.1600 0765.2007.01014.x
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park KR, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106423
   Park KR, 2022, J CELL MOL MED, V26, P4520, DOI 10.1111/jcmm.17476
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2021, AM J CHINESE MED, V49, P883, DOI 10.1142/S0192415X21500427
   Park KR, 2022, AM J CHINESE MED, V50, P295, DOI 10.1142/S0192415X22500112
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155332
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reinisalo M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/340520
   Ryu G, 2001, ARCH PHARM RES, V24, P105, DOI 10.1007/BF02976476
   Sarker SD, 1999, TETRAHEDRON, V55, P513, DOI 10.1016/S0040 4020(98)01049 7
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Shen YS, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01705 8
   Simoni D, 2009, BIOORGAN MED CHEM, V17, P512, DOI 10.1016/j.bmc.2008.12.002
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Suo ZL, 2005, HORTSCIENCE, V40, P329, DOI 10.21273/HORTSCI.40.2.329
   Tong ZC, 2020, NANOSCALE RES LETT, V15, DOI 10.1186/s11671 020 03415 9
   Wang X, 2005, J CHROMATOGR A, V1075, P127, DOI 10.1016/j.chroma.2005.04.017
   Wang YQ, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109807
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Xue XF, 2017, BIOMATERIALS, V134, P22, DOI 10.1016/j.biomaterials.2017.04.039
   Yang X, 2019, NAT PROD COMMUN, V14, DOI 10.1177/1934578X19860313
   Yoshikawa M, 2000, CHEM PHARM BULL, V48, P1327, DOI 10.1248/cpb.48.1327
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2007, J BIOL CHEM, V282, P5496, DOI 10.1074/jbc.M606215200
   Yun HM, 2023, BIOFACTORS, V49, P127, DOI 10.1002/biof.1878
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Zhang JJ, 2019, PHYTOTHER RES, V33, P442, DOI 10.1002/ptr.6240
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 67
TC 2
Z9 2
U1 1
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2022
VL 23
IS 21
AR 13559
DI 10.3390/ijms232113559
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6E7IO
UT WOS:000883549800001
PM 36362346
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Kim, WJ
   Shin, HR
   Yoon, HI
   Moon, J
   Lee, E
   Lim, JM
   Cho, YD
   Lee, MH
   Kim, HG
   Ryoo, HM
AF Kim, Hyun Jung
   Kim, Woo Jin
   Shin, Hye Rim
   Yoon, Hee In
   Moon, Jae , I
   Lee, Eunji
   Lim, Jin Muk
   Cho, Young Dan
   Lee, Mi Hye
   Kim, Hong Gee
   Ryoo, Hyun Mo
TI ROS induced PADI2 downregulation accelerates cellular senescence via the
   stimulation of SASP production and NFκB activation
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Senescence; Reactive oxygen species; Peptidyl arginine deiminase 2;
   Senescence associated secretory phenotype; NF kappa B; Osteoblast
ID OXIDATIVE STRESS; BONE MASS; SECRETORY PHENOTYPE; PARATHYROID HORMONE;
   CELLS; PROTEIN; GENE; EXPRESSION; AGE; DIFFERENTIATION
AB Cellular senescence is closely related to tissue aging including bone. Bone homeostasis is maintained by the tight balance between bone forming osteoblasts and bone resorting osteoclasts, but it undergoes deregulation with age, causing age associated osteoporosis, a main cause of which is osteoblast dysfunction. Oxidative stress caused by the accumulation of reactive oxygen species (ROS) in bone tissues with aging can accelerate osteoblast senescence and dysfunction. However, the regulatory mechanism that controls the ROS induced senescence of osteoblasts is poorly understood. Here, we identified Peptidyl arginine deiminase 2 (PADI2), a post translational modifying enzyme, as a regulator of ROS accelerated senescence of osteoblasts via RNA sequencing and further functional validations. PADI2 downregulation by treatment with H2O2 or its siRNA promoted cellular senescence and suppressed osteoblast differentiation. CCL2, 5, and 7 known as the elements of the senescence associated secretory phenotype (SASP) which is a secretome including proinflammatory cytokines and chemokines emitted by senescent cells and a representative feature of senescence, were upregulated by H2O2 treatment or Padi2 knockdown. Furthermore, blocking these SASP factors with neutralizing antibodies or siRNAs alleviated the senescence and dysfunction of osteoblasts induced by H2O2 treatment or Padi2 knockdown. The elevated production of these SASP factors was mediated by the activation of NF kappa B signaling pathway. The inhibition of NF kappa B using the pharmacological inhibitor or siRNA effectively relieved H2O2 treatment  or Padi2 knockdown induced senescence and osteoblast dysfunction. Together, our study for the first time uncover the role of PADI2 in ROS accelerated cellular senescence of osteoblasts and provide new mechanistic and therapeutic insights into excessive ROS promoted cellular senescence and aging related bone diseases.
C1 [Kim, Hyun Jung; Kim, Woo Jin; Shin, Hye Rim; Yoon, Hee In; Moon, Jae , I; Lee, Eunji; Ryoo, Hyun Mo] Seoul Natl Univ, Sch Dent, Dept Mol Genet & Dent Pharmacol, Seoul, South Korea.
   [Kim, Hyun Jung; Kim, Woo Jin; Shin, Hye Rim; Yoon, Hee In; Moon, Jae , I; Lee, Eunji; Ryoo, Hyun Mo] Seoul Natl Univ, Dent Res Inst, Dept Mol Genet & Dent Pharmacol, Seoul, South Korea.
   [Lim, Jin Muk; Kim, Hong Gee] Seoul Natl Univ, Sch Dent, Biomed Knowledge Engn Lab, Seoul, South Korea.
   [Lim, Jin Muk; Kim, Hong Gee] Seoul Natl Univ, Dent Res Inst, Biomed Knowledge Engn Lab, Seoul, South Korea.
   [Lim, Jin Muk] Alopax Algo Co Ltd, Seoul, South Korea.
   [Cho, Young Dan] Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul, South Korea.
   [Cho, Young Dan] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea.
   [Lee, Mi Hye] Georgetown Univ, Dept Biol, Washington, DC 20057 USA.
   [Lee, Mi Hye] Georgetown Univ, Ctr Cell Reprogramming, Washington, DC 20057 USA.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Georgetown
   University; Georgetown University
RP Ryoo, HM (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Mol Genet & Dent Pharmacol, Seoul, South Korea.; Ryoo, HM (通讯作者)，Seoul Natl Univ, Dent Res Inst, Dept Mol Genet & Dent Pharmacol, Seoul, South Korea.
EM hmryoo@snu.ac.kr
RI Yoon, Hyung In/L 6707 2013; Bin Kim, Hong/J 5452 2012; kim,
   woojin/HPG 7753 2023; Ryoo, Hyun Mo/D 5839 2012; Cho,
   Young Dan/AAR 4573 2021
OI Kim, Hyun Jung/0000 0002 5360 1809; Kim, Hong Gee/0000 0002 2610 4321; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2017R1A4A1014584,
   2020R1A4A1019423, 2017R1A2B3011778, 2020R1A2B5B02002658,
   2021R1A2C1007715]
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (2017R1A4A1014584, 2020R1A4A1019423, 2017R1A2B3011778, and
   2020R1A2B5B02002658 to HM Ryoo; 2021R1A2C1007715 to HJ Kim).
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bhattacharya SK, 2008, AGING CELL, V7, P441, DOI 10.1111/j.1474 9726.2008.00376.x
   Bicker KL, 2013, BIOPOLYMERS, V99, P155, DOI 10.1002/bip.22127
   BROCKSTEDT H, 1993, BONE, V14, P681, DOI 10.1016/8756 3282(93)90092 O
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev physiol 030212 183653
   CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460 2075.1986.tb04440.x
   Chang XT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081259
   Chang XT, 2009, RHEUMATOL INT, V29, P1337, DOI 10.1007/s00296 009 0863 1
   Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008 5472.CAN 06 1236
   Debacq Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   DESBOIS C, 1994, J BIOL CHEM, V269, P1183
   Falcao AM, 2019, CELL REP, V27, P1090, DOI 10.1016/j.celrep.2019.03.108
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Funayama R, 2017, CANCER SCI, V108, P713, DOI 10.1111/cas.13179
   Gabet Yankel, 2011, Curr Osteoporos Rep, V9, P177, DOI 10.1007/s11914 011 0072 1
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Guo W, 2017, ONCOTARGETS THER, V10, P1475, DOI 10.2147/OTT.S92389
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Hanagata N, 2007, J BIOMED MATER RES A, V83A, P362, DOI 10.1002/jbm.a.31240
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587 019 0201 4
   Kong L, 2010, MATRIX BIOL, V29, P276, DOI 10.1016/j.matbio.2010.01.007
   Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936
   Lee HJ, 2010, J BIOL CHEM, V285, P39655, DOI 10.1074/jbc.M110.170290
   Li KY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02509 0
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Liu LD, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02528 0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Pérez Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Sanchez Pernaute O, 2013, ANN RHEUM DIS, V72, P1400, DOI 10.1136/annrheumdis 2012 201906
   Sapieha P, 2018, TRENDS CELL BIOL, V28, P595, DOI 10.1016/j.tcb.2018.03.003
   Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095
   Sedelnikova OA, 2010, MUTAT RES REV MUTAT, V704, P152, DOI 10.1016/j.mrrev.2009.12.005
   Shen L, 2019, J CELL PHYSIOL, V234, P22554, DOI 10.1002/jcp.28819
   SKURNICK ID, 1979, MECH AGEING DEV, V10, P157, DOI 10.1016/0047 6374(79)90032 0
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Sun B, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal3062
   Syed Farhan A, 2010, Curr Osteoporos Rep, V8, P235, DOI 10.1007/s11914 010 0035 y
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Wang S, 2013, BBA GENE REGUL MECH, V1829, P1126, DOI 10.1016/j.bbagrm.2013.07.003
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Xi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096351
   Xue T, 2021, ADV SCI, V8, DOI 10.1002/advs.202002831
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
   Yano S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005 0065
   Yousefzadeh MJ, 2018, AGING CELL, V17, DOI 10.1111/acel.12706
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
NR 64
TC 46
Z9 49
U1 3
U2 42
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2022
VL 79
IS 3
AR 155
DI 10.1007/s00018 022 04186 5
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ZI0QX
UT WOS:000761332700003
PM 35218410
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yu, CH
   Hu, XY
   Hu, QA
   Mou, YB
   Ding, L
AF Yu, Chenhang
   Hu, Xinyang
   Hu, Qingang
   Mou, Yongbin
   Ding, Liang
TI Teriparatide induced alleviation of medication related osteonecrosis of
   the jaw: Potential molecular mechanisms
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Teriparatide; Medication  related osteonecrosis of the jaw; Signaling
   pathways
ID PARATHYROID HORMONE; BONE ANABOLISM; IN VITRO; EXPRESSION; ANGIOGENESIS;
   RECEPTOR; RANKL; CELLS
AB Medication related osteonecrosis of the jaw (MRONJ) is a significant side effect of drugs such as bone modifying agents (BMA) or angiogenesis inhibitors. The incidence has been rising but the clinical prognosis is dismal. Teriparatide (TPTD), a synthetic derivative of parathyroid hormone (PTH), is occasionally demonstrated to efficiently reduced the clinical incidence of MRONJ in particular patients. However, the precise signaling mechanisms involved in TPTD induced MRONJ repair are unknown. Currently, MRONJ progression is involved with decreased expression of the Wnt/8 catenin signaling pathway, inhibition of angiogenic function, and upregulated inflammatory cytokines (IL 18, TNF alpha, and IL 6). Notably, in animal model experiments, TPTD increased 8 catenin expression in alveolar bone and skeletal muscle; similarly, TPTD was able to reduce the area of cerebral infarction, restore cerebral blood flow, and improve neovascularization by increasing the number of blood vessels in bone tunnels and enlarging the diameter of blood vessels in the bone marrow. Furthermore, TPTD can also treat osteoarthritis in animals by suppressing inflammatory markers such as TNF  and IL 6. Thus, we propose that TPTD can cure MRONJ by dynamically modulating various signaling pathways (stimulation of the Wnt/8 catenin signaling pathway, promotion of angiogenesis, and down regulation of inflammatory markers).
C1 [Yu, Chenhang; Hu, Xinyang; Hu, Qingang; Ding, Liang] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Cent Lab Stomatol, 22 Hankou Rd, Nanjing 210093, Peoples R China.
   [Mou, Yongbin] Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Dept Oral Implantol,Med Sch, 30 Zhongyang Rd, Nanjing 210008, Peoples R China.
C3 Nanjing University; Nanjing University
RP Hu, QA; Ding, L (通讯作者)，Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Cent Lab Stomatol, 22 Hankou Rd, Nanjing 210093, Peoples R China.; Mou, YB (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Dept Oral Implantol,Med Sch, 30 Zhongyang Rd, Nanjing 210008, Peoples R China.
EM qghu@nju.edu.cn; yongbinmou@163.com; 879269339@qq.com
RI ; Ding, Liang/AGL 0393 2022; mou, yongbin/AAR 9889 2020
OI Ding, Liang/0000 0002 1043 0923; 
FU National Natural Science Foundation of China [82373037, 82002865];
   Natural Science Foundation of Jiangsu Province [BK20190304, BE2020628];
   Nanjing Medical Science and Technology Development Foundation, Nanjing
   Department of Health [YKK21182, YKK20151]
FX Research was supported by grants by the National Natural Science
   Foundation of China (Grant No. 82373037, 82002865) ; Natural Science
   Foundation of Jiangsu Province (No. BK20190304, BE2020628) ; Nanjing
   Medical Science and Technology Development Foundation, Nanjing
   Department of Health (No. YKK21182, YKK20151) .
CR Agas D, 2020, J CELL PHYSIOL, V235, P7516, DOI 10.1002/jcp.29654
   Anabtawi M, 2021, INT J ORAL MAX SURG, V50, P501, DOI 10.1016/j.ijom.2020.07.021
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chen TH, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114669
   Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078 0432.CCR 07 4478
   de Oliveira D, 2019, CLIN ORAL INVEST, V23, P2313, DOI 10.1007/s00784 018 2672 y
   Ferreira VCD, 2021, CLIN ORAL INVEST, V25, P673, DOI 10.1007/s00784 020 03551 7
   DeLisser HM, 1997, AM J PATHOL, V151, P671
   Ferreira LD, 2021, OSTEOPOROSIS INT, V32, P2449, DOI 10.1007/s00198 021 06078 z
   Ervolino E, 2019, BONE, V120, P101, DOI 10.1016/j.bone.2018.10.014
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Fournier P, 2002, CANCER RES, V62, P6538
   Fujimaki T, 2021, BONE, V151, DOI 10.1016/j.bone.2021.116029
   Gao SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179248
   Goltzman D, 2018, ENDOCRIN METAB CLIN, V47, P743, DOI 10.1016/j.ecl.2018.07.003
   Harper RP, 2007, J ORAL MAXIL SURG, V65, P573, DOI 10.1016/j.joms.2006.10.076
   Heckt T, 2016, BONE, V92, P85, DOI 10.1016/j.bone.2016.08.016
   KUTZNER H, 1993, J AM ACAD DERMATOL, V28, P613, DOI 10.1016/0190 9622(93)70083 6
   Li GQ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38597 0
   Li Y, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120984
   Liang X, 2023, CONNECT TISSUE RES, V64, P274, DOI 10.1080/03008207.2022.2157723
   Marciano A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph182111362
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Morita M, 2017, SCI REP UK, V7, DOI 10.1038/srep46322
   Otto S, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57050463
   Pabst Andreas Max, 2016, Dent J (Basel), V5, DOI 10.3390/dj5010002
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Sharma D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 02637 w
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shibahara T, 2019, TOHOKU J EXP MED, V247, P75, DOI 10.1620/tjem.247.75
   Shirakawa J, 2016, CALCIFIED TISSUE INT, V98, P306, DOI 10.1007/s00223 015 0083 5
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Smargiassi A, 2020, MOL CELL ENDOCRINOL, V513, DOI 10.1016/j.mce.2020.110817
   Sun NY, 2019, J BIOL CHEM, V294, P9722, DOI 10.1074/jbc.RA118.007312
   Sun P, 2020, BIOCHEM BIOPH RES CO, V525, P850, DOI 10.1016/j.bbrc.2020.02.177
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Wang DS, 1996, J BONE MINER RES, V11, P472
   Wang GY, 2022, ACS APPL MATER INTER, DOI 10.1021/acsami.2c06159
   Xiong ML, 2022, BIOMED PHARMACOTHER, V148, DOI 10.1016/j.biopha.2022.112728
   Yang MY, 2019, J BONE MINER RES, V34, P1952, DOI 10.1002/jbmr.3811
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Yu MC, 2018, EMBO REP, V19, P156, DOI 10.15252/embr.201744421
   Yu WL, 2020, ORAL DIS, V26, P609, DOI 10.1111/odi.13275
   Zhang QZ, 2015, J BONE MINER RES, V30, P2300, DOI 10.1002/jbmr.2577
   Zheng Y, 2023, BMC ORAL HEALTH, V23, DOI 10.1186/s12903 022 02678 1
   Zhou CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178781
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V42, P551, DOI 10.1159/000477605
   Zhu WY, 2022, J ORTHOP TRANSL, V33, P153, DOI 10.1016/j.jot.2022.03.004
   Zirk M, 2017, J CRANIO MAXILL SURG, V45, P1183, DOI 10.1016/j.jcms.2017.05.027
NR 52
TC 1
Z9 1
U1 4
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2023
VL 179
AR 111161
DI 10.1016/j.mehy.2023.111161
EA SEP 2023
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA T4XF4
UT WOS:001078026400001
DA 2025 08 17
ER

PT J
AU Veri, A
   D'Andrea, MR
   Bonginelli, P
   Gasparini, G
AF Veri, A.
   D'Andrea, M. R.
   Bonginelli, P.
   Gasparini, G.
TI Clinical usefulness of bisphosphonates in oncology: treatment of bone
   metastases, antitumoral activity and effect on bone resorption markers
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE bone metastases; bisphosphonates; zoledronic acid; cancer; quality of
   life
ID BREAST CANCER PATIENTS; LONG TERM EFFICACY; REDUCES SKELETAL
   COMPLICATIONS; ZOLEDRONIC ACID; DOUBLE BLIND; PROSTATE CANCER; ORAL
   IBANDRONATE; PHASE III; PAMIDRONATE DISODIUM; RANDOMIZED TRIAL
AB The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal related events, and pain control. Bisphosphonates are used to prevent pathological fractures by inhibition of osteoclasts. Recent studies suggest that bisphosphonates have some direct antitumoral activity, mainly mediated through the blockade of angiogenic pathways. Further clinical studies are needed to determine the optimal treatment duration, timing and schedule of bisphosphonates, assess their role as adjuvant therapy for the prevention of bone metastases, and establish their antiangiogenic activity in association with standard cytotoxic and hormonal drugs for treatment of patients with advanced disease.
C1 San Filippo Neri Hosp, Div Med Oncol, Rome, Italy.
C3 San Filippo Neri Hospital
RP Gasparini, G (通讯作者)，Azienda Complesso Osped Rilevanza Nazl San Filipp, Div Med Oncol, Via G Martinotti 20, I 00135 Rome, Italy.
EM gasparini.oncology@tiscalinet.it
CR Ali SM, 2004, ANN ONCOL, V15, P455, DOI 10.1093/annonc/mdh089
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   BOWN HK, 2001, CANC PRINCIPLES PRAI, P2713
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Chung YC, 2006, CANCER EPIDEM BIOMAR, V15, P424, DOI 10.1158/1055 9965.EPI 04 0842
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Coleman RE, 1999, ANN ONCOL, V10, P311, DOI 10.1023/A:1008386501738
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2002, CANCER, V94, P2521, DOI 10.1002/cncr.10522
   COLEMAN RE, 2001, BONE METASTASES BREA, P152
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   Dannemann C, 2006, SWISS MED WKLY, V136, P504
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   DIMOPOULOS M, 2006, P AN M AM SOC CLIN, V24, P7505
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Fournier P, 2002, CANCER RES, V62, P6538
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   HEI Y, 2005, SANT ANT BREAST CANC
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Koizumi M, 2003, ANTICANCER RES, V23, P4095
   Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365 2796.1999.00507.x
   Lichinitser M, 2005, EJC SUPPL, V3, P113
   Lipton A, 1998, EUR J CANCER, V34, P2021, DOI 10.1016/S0959 8049(98)00277 9
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MAJOR PP, 2003, P AN M AM SOC CLIN, V22, P762
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MASON MD, 2004, P AM SOC CLIN ONC LA, V16
   MATCZAK E, 2006, P AN M AM SOC CLIN, V24, P7228
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Polascik TJ, 2005, UROLOGY, V66, P1054, DOI 10.1016/j.urology.2005.05.035
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   ROBINSON RG, 1995, JAMA J AM MED ASSOC, V274, P420, DOI 10.1001/jama.274.5.420
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   RYAN CW, 2006, P PROST CANC S ASCO
   Saad F, 2003, J UROLOGY, V169, P394
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Schlosser K, 1997, SCAND J CLIN LAB INV, V57, P21
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   TERMOS E, 2005, ANN ONCOL, V16, P1223
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tubiana Hulin M, 2001, B CANCER, V88, P701
   VANHOOF VO, 1992, CLIN CHEM, V38, P2546
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Weinfurt KP, 2006, ANN ONCOL, V17, P986, DOI 10.1093/annonc/mdl041
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 63
TC 19
Z9 20
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393 6155
EI 1724 6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD JAN MAR
PY 2007
VL 22
IS 1
BP 24
EP 33
DI 10.1177/172460080702200104
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA 170BW
UT WOS:000246637300004
PM 17393358
OA Bronze
DA 2025 08 17
ER

PT J
AU An, J
   Yang, H
   Zhang, Q
   Liu, CC
   Zhao, JJ
   Zhang, LL
   Chen, B
AF An, Jing
   Yang, Hao
   Zhang, Qian
   Liu, Cuicui
   Zhao, Jingjing
   Zhang, Lingling
   Chen, Bo
TI Natural products for treatment of osteoporosis: The effects and
   mechanisms on promoting osteoblast mediated bone formation
SO LIFE SCIENCES
LA English
DT Article
DE Osteoporosis; Osteoblasts; Traditional Chinese medicines; Natural
   products; Molecular mechanism
ID MORPHOGENETIC PROTEIN 2 EXPRESSION; ESTROGEN RECEPTOR ALPHA; NF KAPPA B;
   MESENCHYMAL STEM CELLS; GENE EXPRESSION; ALKALINE PHOSPHATASE;
   OXIDATIVE STRESS; MESSENGER RNA; NITRIC OXIDE; MG 63 CELLS
AB Osteoporosis is a systemic metabolic bone disease characterized by a reduction in bone mass, bone quality, and microarchitectural deterioration. An imbalance in bone remodeling that is caused by more osteoclast mediated bone resorption than osteoblast mediated bone formation results in such pathologic bone disorder. Traditional Chinese medicines (TCM) have long been used to prevent and treat osteoporosis and have received extensive attentions and researches at home and abroad, because they have fewer adverse reactions and are more suitable for long term use compared with chemically synthesized medicines. Here, we put the emphasis on osteoblasts, summarized the detailed research progress on the active compounds derived from TCM with potential anti osteoporosis effects and their molecular mechanisms on promoting osteoblast mediated bone formation. It could be concluded that TCM with kidney tonifying, spleen tonifying, and stasis removing effects all have the potential effects on treating osteoporosis. The active ingredients derived from TCM that possess effects on promoting osteoblasts proliferation and differentiation include flavonoids, glycosides, coumarins, terpenoids (sesquiterpenoids, monoterpenoids, diterpenoids), phenolic acids, phenols and others (tetrameric stilbene, anthraquinones, diarylheptanoids). And it was confirmed that the bone formation effect induced by the above natural products was regulated by the expressions of bone specific matrix proteins (ALP, BSP, OCN, OPN, COL I), transcription factor (Runx2, Cbfa1, Osx), signal pathways (MAPK, BMP), local factors (ROS, NO), OPG/RANKL system of osteoblasts and estrogen like biological activities. All the studies provided theoretical basis for clinical application, as well as new drug research and development on treating osteoporosis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [An, Jing; Yang, Hao; Zhang, Qian; Liu, Cuicui; Zhao, Jingjing; Zhang, Lingling; Chen, Bo] Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Translat Med Ctr, Xian 710054, Peoples R China.
C3 Xi'an Jiaotong University
RP An, J (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Translat Med Ctr, Xian 710054, Peoples R China.
EM anjing198812@126.com
FU National Natural Science Foundation of China [81403278]
FX The authors acknowledge financial support from the Youth Fund of
   National Natural Science Foundation of China (No. 81403278).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   [Anonymous], 2001, ENDOCRINOLOGY, V142, P5050
   Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05 0963
   Audran M, 2006, JOINT BONE SPINE, V73, P374, DOI 10.1016/j.jbspin.2006.02.004
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Zanchetta MB, 2014, J BONE MINER RES, V29, P999, DOI 10.1002/jbmr.2107
   Beral Valerie, 2003, Lancet, V362, P419
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BREMNER I, 1995, P NUTR SOC, V54, P489, DOI 10.1079/PNS19950017
   Buencamino MCA, 2009, J WOMENS HEALTH, V18, P873, DOI 10.1089/jwh.2008.0897
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253
   Choi EM, 2011, INT IMMUNOPHARMACOL, V11, P1541, DOI 10.1016/j.intimp.2011.05.011
   Dahlman Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Don MJ, 2012, PHYTOMEDICINE, V19, P551, DOI 10.1016/j.phymed.2012.01.006
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   FARLEY JR, 1994, J BONE MINER RES, V9, P497
   Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008
   Gutiérrez S, 2010, CELL PROLIFERAT, V43, P505, DOI 10.1111/j.1365 2184.2010.00700.x
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Hu C., 2008, CHIN J GERONTOL, V11, P2178
   Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100
   Huang Q, 2015, BONE, V74, P18, DOI 10.1016/j.bone.2015.01.002
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Ikeda T, 2001, J BONE MINER RES, V16, P1416, DOI 10.1359/jbmr.2001.16.8.1416
   Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kihara T, 2011, BIOCHEM BIOPH RES CO, V406, P211, DOI 10.1016/j.bbrc.2011.02.017
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kwak JH, 2013, INT IMMUNOPHARMACOL, V17, P704, DOI 10.1016/j.intimp.2013.08.015
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Lee CH, 2012, EUR J PHARMACOL, V676, P26, DOI 10.1016/j.ejphar.2011.12.001
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Lee SR, 2011, INT IMMUNOPHARMACOL, V11, P1251, DOI 10.1016/j.intimp.2011.04.004
   Lee YS, 2011, CELL IMMUNOL, V270, P224, DOI 10.1016/j.cellimm.2011.05.011
   Lee YS, 2011, INT IMMUNOPHARMACOL, V11, P712, DOI 10.1016/j.intimp.2011.01.018
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Manolagas S.C., 2010, JOINT BONE SPINE, V31, P266
   Marcus R, 2000, ATLAS OF CLINICAL ENDOCRINOLOGY, VOLUME 3, P1
   Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019
   Mathews S, 2012, DIFFERENTIATION, V84, P185, DOI 10.1016/j.diff.2012.05.001
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   MERRY K, 1993, J CELL SCI, V104, P1013
   Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185
   Mizuno M, 2001, J BIOCHEM TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Pinkerton JV, 2014, J STEROID BIOCHEM, V142, P142, DOI 10.1016/j.jsbmb.2013.12.011
   Piscitelli P, 2007, OSTEOPOROSIS INT, V18, P211, DOI 10.1007/s00198 006 0224 9
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Pratap J, 2003, CANCER RES, V63, P5357
   Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rokutanda S, 2009, DEV BIOL, V328, P78, DOI 10.1016/j.ydbio.2009.01.009
   Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Suh KS, 2013, FITOTERAPIA, V89, P33, DOI 10.1016/j.fitote.2013.05.016
   Sun H, 2013, FITOTERAPIA, V84, P174, DOI 10.1016/j.fitote.2012.11.010
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tiyasatkulkovit W, 2012, PHYTOMEDICINE, V19, P1147, DOI 10.1016/j.phymed.2012.07.010
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Uihlein AV, 2012, ENDOCRIN METAB CLIN, V41, P507, DOI 10.1016/j.ecl.2012.05.002
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Wang Y, 2013, PHYTOMEDICINE, V20, P787, DOI 10.1016/j.phymed.2013.03.005
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Xiao HH, 2014, J STEROID BIOCHEM, V144, P382, DOI 10.1016/j.jsbmb.2014.08.002
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Xu H, 2005, AM J CHINESE MED, V33, P299, DOI 10.1142/S0192415X05002916
   Yoon HY, 2011, EUR J PHARMACOL, V664, P54, DOI 10.1016/j.ejphar.2011.04.047
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   Zhang JK, 2012, EUR J PHARMACOL, V689, P31, DOI 10.1016/j.ejphar.2012.05.045
NR 124
TC 442
Z9 483
U1 31
U2 518
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD FEB 15
PY 2016
VL 147
BP 46
EP 58
DI 10.1016/j.lfs.2016.01.024
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DE0ZN
UT WOS:000370354800007
PM 26796578
DA 2025 08 17
ER

PT J
AU Tsubaki, M
   Satou, T
   Itoh, T
   Imano, M
   Yanae, M
   Kato, C
   Takagoshi, R
   Komai, M
   Nishida, S
AF Tsubaki, Masanobu
   Satou, Takao
   Itoh, Tatsuki
   Imano, Motohiro
   Yanae, Masashi
   Kato, Chisato
   Takagoshi, Risa
   Komai, Makiko
   Nishida, Shozo
TI Bisphosphonate  and statin induced enhancement of OPG expression and
   inhibition of CD9, M CSF, and RANKL expressions via inhibition of the
   Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow
   stromal cell line ST2
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Bisphosphonates; Statins; Osteoprotegerin; Macrophage colony stimulating
   factor; CD9
ID KAPPA B LIGAND; COLONY STIMULATING FACTOR; HYPERCHOLESTEROLEMIC
   POSTMENOPAUSAL WOMEN; NITROGEN CONTAINING BISPHOSPHONATE; OSTEOCLAST
   DIFFERENTIATION FACTOR; MINERAL DENSITY; OVARIECTOMIZED RATS; RECEPTOR
   ACTIVATOR; OSTEOBLAST DIFFERENTIATION; OSTEOPROTEGERIN LEVELS
AB Osteoclast differentiation is influenced by receptor activator of the NF kappa B ligand (RANKL), macrophage colony stimulating factor (M CSF), and CD9, which are expressed on bone marrow stromal cells and osteoblasts. In addition, osteoprotegerin (OPG) is known as an osteoclastogenesis inhibitory factor. In this study, we investigated whether bisphosphonates and statins increase OPG expression and inhibit the expression of CD9, M CSF, and RANKL in the bone marrow derived stromal cell line ST2. We found that bisphosphonates and statins enhanced OPG mRNA expression and inhibited the expression of CD9, M CSF, and RANKL mRNA. Futhermore, bisphosphonates and statins decreased the membrane localization of Ras and phosphorylated ERK1/2, and activated the p38MAPK. This indicates that bisphosphonates and statins enhanced OPG expression, and inhibited the expression of CD9. M CSF, and RANKL through blocking the Ras/ERK pathway and activating p38MAPK. Accordingly, we believe that its clinical applications will be investigated in the future for the development of osteoporosis therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Tsubaki, Masanobu; Yanae, Masashi; Kato, Chisato; Takagoshi, Risa; Komai, Makiko; Nishida, Shozo] Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 5778502, Japan.
   [Satou, Takao; Itoh, Tatsuki] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan.
   [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan.
   [Yanae, Masashi] Kinki Univ, Sch Med, Sakai Hosp, Dept Pharm,Minami Ku, Sakai, Osaka 5900132, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University); Kindai University
   (Kinki University)
RP Nishida, S (通讯作者)，Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 5778502, Japan.
EM nishida@phar.kindai.ac.jp
RI 正寛, 椿/JDF 1457 2023
FU "High Tech Research Center" Project for Private Universities: from MEXT
   (Ministry of Education, Culture, Sports, Science and Technology)
FX This work was supported by the "High Tech Research Center" Project for
   Private Universities: matching fund subsidy from MEXT (Ministry of
   Education, Culture, Sports, Science and Technology) 2007 2011.
CR Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594
   Atmani H, 2003, J CELL BIOCHEM, V89, P364, DOI 10.1002/jcb.10507
   Bakhireva LN, 2010, PHARMACOTHERAPY, V30, P879, DOI 10.1592/phco.30.9.879
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Chuengsamarn S, 2010, BONE, V46, P1011, DOI 10.1016/j.bone.2009.12.023
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Edwards CJ, 2001, CALCIFIED TISSUE INT, V69, P63, DOI 10.1007/s00223 001 2017 7
   Eslami B, 2011, CALCIFIED TISSUE INT, V88, P272, DOI 10.1007/s00223 011 9473 5
   Fernández M, 2010, J CELL BIOCHEM, V111, P130, DOI 10.1002/jcb.22676
   Fujiwara K, 2008, YAKUGAKU ZASSHI, V128, P153, DOI 10.1248/yakushi.128.153
   Horiguchi A, 2004, CLIN CANCER RES, V10, P8648, DOI 10.1158/1078 0432.CCR 04 1568
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Jackson S M, 1997, Subcell Biochem, V28, P1
   Kaji H, 2005, HORM METAB RES, V37, P589, DOI 10.1055/s 2005 870538
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Kawane T, 2004, ENDOCRINE, V24, P121, DOI 10.1385/ENDO:24:2:121
   Kim IS, 2008, DEV GROWTH DIFFER, V50, P553, DOI 10.1111/j.1440 169X.2008.01052.x
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Liu W, 2008, EXP MOL PATHOL, V84, P213, DOI 10.1016/j.yexmp.2008.02.004
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Moll PR, 2004, J STEROID BIOCHEM, V89 90, P261, DOI 10.1016/j.jsbmb.2004.03.077
   Mori K, 2010, ANGIOLOGY, V61, P86, DOI 10.1177/0003319708330525
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nagai M, 1999, BIOCHEM BIOPH RES CO, V257, P719, DOI 10.1006/bbrc.1999.0524
   Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P45, DOI 10.1006/bbrc.1999.1621
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nezami N, 2010, CLIN BIOCHEM, V43, P1294, DOI 10.1016/j.clinbiochem.2010.08.012
   Nishida S, 2005, MOL CELL BIOCHEM, V269, P109, DOI 10.1007/s11010 005 3086 0
   Nishida S, 2005, BIOCHEM BIOPH RES CO, V328, P91, DOI 10.1016/j.bbrc.2004.12.145
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Omland T, 2008, J AM COLL CARDIOL, V51, P627, DOI 10.1016/j.jacc.2007.09.058
   Pantouli E, 2005, BIOCHEM BIOPH RES CO, V329, P224, DOI 10.1016/j.bbrc.2005.01.122
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Rubin J, 1996, CALCIFIED TISSUE INT, V59, P291, DOI 10.1007/s002239900125
   Russell RGG, 2006, BONE, V38, pS7, DOI 10.1016/j.bone.2006.01.151
   Seo SW, 2007, ANN NY ACAD SCI, V1117, P151, DOI 10.1196/annals.1402.027
   Smith BB, 2003, INT J TOXICOL, V22, P403, DOI 10.1080/713936670
   Solomon DH, 2005, PHARMACOEPIDEM DR S, V14, P219, DOI 10.1002/pds.984
   Sondergaard TE, 2009, HEMATOL ONCOL, V27, P17, DOI 10.1002/hon.869
   Tanimori Y, 2010, CLIN EXP METASTAS, V27, P529, DOI 10.1007/s10585 010 9342 z
   Tanio Y, 1999, EXP HEMATOL, V27, P853, DOI 10.1016/S0301 472X(99)00011 9
   Tanishima Shinji, 2007, Mod Rheumatol, V17, P198, DOI 10.1007/s10165 007 0566 y
   Tanriverdi HA, 2005, EUR J OBSTET GYN R B, V120, P63, DOI 10.1016/j.ejogrb.2004.08.007
   Tsubaki M, 2008, CANCER SCI, V99, P152, DOI 10.1111/j.1349 7006.2007.00651.x
   Tsubaki M, 2007, MOL CELL BIOCHEM, V304, P53, DOI 10.1007/s11010 007 9485 7
   Tsubaki M, 2011, CYTOKINE, V54, P100, DOI 10.1016/j.cyto.2011.01.005
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   Vega D., 2007, J CLIN ENDOCR METAB, V92, P337
   Viereck V, 2005, J CELL BIOCHEM, V96, P1244, DOI 10.1002/jcb.20598
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   von Knoch F, 2005, BIOMATERIALS, V26, P5783, DOI 10.1016/j.biomaterials.2005.02.008
   Wang Y, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 34
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   Yanae M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756 9966 30 74
   Yue JR, 2010, MENOPAUSE, V17, P1071, DOI 10.1097/gme.0b013e3181d3e036
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
NR 64
TC 60
Z9 65
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD SEP 25
PY 2012
VL 361
IS 1 2
BP 219
EP 231
DI 10.1016/j.mce.2012.05.002
PG 13
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 991HN
UT WOS:000307692200023
PM 22579611
DA 2025 08 17
ER

PT J
AU Jähn Rickert, K
   Wölfel, EM
   Jobke, B
   Riedel, C
   Hellmich, M
   Werner, M
   McDonald, MM
   Busse, B
AF Jaehn Rickert, Katharina
   Woelfel, Eva M.
   Jobke, Bjorn
   Riedel, Christoph
   Hellmich, Maya
   Werner, Mathias
   McDonald, Michelle M.
   Busse, Bjoern
TI Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower
   Osteocyte Viability During Discontinuation
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteoporosis treatment; denosumab; rebound fractures; treatment
   discontinuation; osteocytes; osteoblasts; osteoclasts; extracellular
   matrix
ID MULTIPLE VERTEBRAL OSTEONECROSES; POSTMENOPAUSAL WOMEN; FRACTURES;
   OSTEOPOROSIS; APOPTOSIS; DISEASE; PREVENTION; SCLEROSTIN; QUALITY
AB Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless patients were transitioned to an alternative antiresorptive medication. How denosumab affects the interaction of mechanosensitive osteocytes and bone quality remains unknown. We hypothesized that denosumab influences osteocyte function contributing to bone reorganization and increased fractures during discontinuation. Bone quality and osteocytes were assessed in archived iliac crest bone biopsies obtained from patients with high fracture occurrence from 2011 to 2016. Biopsies were obtained due to high fracture occurrence prior and during osteoporosis therapy from (i) patients with at least two semiannual subcutaneous injections of 60 mg denosumab, (ii) patients with rebound fractures during discontinuation, and (iii) patients of a treatment naive group. In total, biopsies from 43 individuals were analyzed (mean age, 65.5 +/  12.1 years). Our results showed that during denosumab treatment, iliac cortical bone had a higher bone tissue hardness compared to treatment naive bone (p=0.0077) and a higher percentage of mineralized osteocyte lacunae (p=0.0095). The density of empty osteocyte lacunae was higher with denosumab compared to treatment naive (p=0.014) and remained high in trabecular bone during discontinuation (p=0.0071). We conclude that during denosumab treatment, increased bone hardness may contribute to improved fracture resistance. In biopsies from patients with high fracture occurrence, denosumab treatment reduced osteocyte viability, an effect that persisted during treatment discontinuation. High resolution imaging of osteocyte viability indicates a role for osteocytes as a potential future mechanistic target to understand rebound bone loss and increased fractures with denosumab discontinuation.
C1 [Jaehn Rickert, Katharina; Woelfel, Eva M.; Riedel, Christoph; Busse, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
   [Jobke, Bjorn] Unilabs, Telemed Clin, Barcelona, Spain.
   [Hellmich, Maya] MEDICOVER Berlin Charlottenburg, Berlin, Germany.
   [Werner, Mathias] Vivantes Klinikum Friedrichshain, Berlin, Germany.
   [McDonald, Michelle M.] Garvan Inst Med Res, Bone Microenvironm Grp, Darlinghurst, NSW, Australia.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Garvan Institute of Medical Research
RP Busse, B (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
EM b.busse@uke.uni hamburg.de
RI McDonald, Michelle/AAD 4760 2019; Wölfel, Eva/KTI 5506 2024; Busse,
   Björn/AAC 4033 2020
OI Busse, Bjorn/0000 0002 3099 8073; McDonald,
   Michelle/0000 0002 3928 2506; Wolfel, Eva Maria/0000 0001 5292 5679;
   Jahn Rickert, Katharina/0000 0002 9338 831X; Riedel,
   Christoph/0000 0001 8342 296X
FU German Research Foundation (DFG) [JA2654/1 1]; DFG [BU 2562/3 1]
FX KJ R is a fellow of the German Research Foundation (DFG) under grant no.
   JA2654/1 1 and BB is a fellow of the DFG under grant no. BU 2562/3 1. MM
   is a Cancer Institute NSW Fellow. KJ R has been awarded the 2018 IFMRS
   fellowship.
CR Anastasilakis AD, 2016, OSTEOPOROSIS INT, V27, P1929, DOI 10.1007/s00198 015 3459 5
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Biamonte F, 2018, CALCIFIED TISSUE INT, V103, P109, DOI 10.1007/s00223 017 0386 9
   Binkley N, 2017, J BONE MINER RES, V32, P1391, DOI 10.1002/jbmr.3182
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Busse B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006286
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   Cohn MR, 2018, J ORTHOP TRAUMA, V32, P480, DOI 10.1097/BOT.0000000000001244
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2018, J CLIN ENDOCR METAB, V103, P2498, DOI 10.1210/jc.2017 02669
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Maugars Y, 2018, CALCIFIED TISSUE INT, V102, P368, DOI 10.1007/s00223 017 0357 1
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McDonald MM, 2017, CURR OSTEOPOROS REP, V15, P532, DOI 10.1007/s11914 017 0403 y
   Milovanovic P, 2020, ENDOCR CONNECT, V9, pR70, DOI 10.1530/EC 19 0531
   Milovanovic P, 2019, CURR OSTEOPOROS REP, V17, P105, DOI 10.1007/s11914 019 00508 y
   Milovanovic P, 2017, SMALL, V13, DOI 10.1002/smll.201602215
   Milovanovic P, 2015, BIOMATERIALS, V45, P46, DOI 10.1016/j.biomaterials.2014.12.024
   Milovanovic P, 2013, ACS NANO, V7, P7542, DOI 10.1021/nn401360u
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Oliver W.C., 1992, J MAT RES, V7, P20, DOI DOI 10.1557/JMR.1992.1564
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pasco JA, 2006, OSTEOPOROSIS INT, V17, P1404, DOI 10.1007/s00198 006 0135 9
   Pietri M, 2007, CLIN CASES MINER BON, V4, P108
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Rolvien T, 2020, J BONE MINER RES, V35, P1343, DOI 10.1002/jbmr.3970
   Thomasius F, 2018, OSTEOLOGIE, V27, P154, DOI 10.1055/s 0038 1673537
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tu Kristie N, 2018, P T, V43, P92
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Zimmermann EA, 2016, SCI REP UK, V6, DOI 10.1038/srep21072
   Zimmermann EA, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.112
   Zimmermann EA, 2015, J BONE MINER RES, V30, P264, DOI 10.1002/jbmr.2340
NR 45
TC 28
Z9 33
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 15
PY 2020
VL 11
AR 250
DI 10.3389/fendo.2020.00250
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MW0PU
UT WOS:000556750400001
PM 32499755
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sousa, DM
   Baldock, PA
   Enriquez, RF
   Zhang, L
   Sainsbury, A
   Lamghari, M
   Herzog, H
AF Sousa, Daniela M.
   Baldock, Paul A.
   Enriquez, Ronaldo F.
   Zhang, Lei
   Sainsbury, Amanda
   Lamghari, Meriem
   Herzog, Herbert
TI Neuropeptide Y Y1 receptor antagonism increases bone mass in mice
SO BONE
LA English
DT Article
DE Neuropeptide Y; Y1 receptor antagonism; Oral drug administration;
   Osteopenia
ID LIPID OXIDATION; DEFICIENT MICE; KNOCKOUT MICE; NPY; SYSTEM;
   HOMEOSTASIS; DISORDERS; FRACTURES; PATHWAYS; DURATION
AB The neuropeptide Y system has emerged as one of the major neural signalling pathways regulating bone homeostasis. Absence of Y1 receptor signalling from bone forming osteoblasts is responsible for an enhancement on bone mass in mice, suggesting that pharmacological blockade of Y1 receptors may offer a novel anabolic treatment option for improving bone mass. Here we show that oral administration of the selective Y1 receptor antagonist BIBO3304 for 8 weeks dose dependently increases bone mass in mice. Histomorphometric analysis revealed a significant 1.5 fold increase in cancellous bone volume in the femora of mice treated with BIBO3304. Furthermore, bone microarchitecture was improved, with greater trabecular number and trabecular thickness. This increase in bone mass was associated with a significant increase in bone anabolic activity of osteoblasts and, interestingly, was evident despite a coincident increase in bone resorption, as evidenced by an increase in the number of the osteolytic osteoclasts. Changes were also evident in cortical bone, with a significant increase in periosteal mineral apposition rate. Importantly, no adverse extra skeletal side effects were observed through Y1 receptor antagonism over the 8 week treatment period, with no effects of even the higher BIBO3304 dose on body weight, adiposity, energy metabolism or circulating corticosterone levels. Taken together, this work describes the first NPY based anabolic treatment for improving bone mass, and highlights the therapeutic potential of blocking Y1 receptor signalling for the prevention of, or recovery from, degenerative skeletal diseases. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Baldock, Paul A.; Enriquez, Ronaldo F.; Zhang, Lei; Sainsbury, Amanda; Herzog, Herbert] St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Sydney, NSW 2010, Australia.
   [Sousa, Daniela M.; Lamghari, Meriem] Univ Porto, INEB Inst Engn Biomed, NEWTherapies Grp, P 4150180 Oporto, Portugal.
   [Sousa, Daniela M.; Lamghari, Meriem] Univ Porto, Fac Engn, Dept Met & Mat Engn, P 4100 Oporto, Portugal.
   [Sainsbury, Amanda] Univ NSW, Sch Med Sci, Sydney, NSW, Australia.
   [Baldock, Paul A.; Herzog, Herbert] Univ NSW, Fac Med, Sydney, NSW, Australia.
C3 Garvan Institute of Medical Research; NSW Health; St Vincents Hospital
   Sydney; Universidade do Porto; Universidade do Porto; University of New
   South Wales Sydney; University of New South Wales Sydney
RP Herzog, H (通讯作者)，St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.
EM h.herzog@garvan.org.au
RI Baldock, Paul/B 3840 2012; Herzog, Herbert/B 8294 2008; Sousa,
   Daniela/C 1485 2014; Zhang, Lei/B 6258 2012; Salis, Amanda/A 3187 2011;
   Lamghari, Meriem/K 2159 2013
OI Sousa, Daniela/0000 0001 8498 0664; Salis, Amanda/0000 0001 9176 1574;
   Lamghari, Meriem/0000 0002 2500 4548; Herzog,
   Herbert/0000 0002 1713 1029
FU FEDER funds through the Programa Operacional Factores de
   Competitividade COMPETE; Portuguese funds through FCT Fundacao para a
   Ciencia e a Tecnologia [PTDC/SAU OSM/101469/2008, SFRH/BD/37654/2007];
   National Health and Medical Research Council (NHMRC) of Australia;
   Fundação para a Ciência e a Tecnologia [PTDC/SAU OSM/101469/2008,
   SFRH/BD/37654/2007] Funding Source: FCT
FX We are grateful to the staff of the Garvan Institute Biological Testing
   Facility for facilitation of these experiments. This research was
   financed by FEDER funds through the Programa Operacional Factores de
   Competitividade COMPETE and by Portuguese funds through FCT Fundacao
   para a Ciencia e a Tecnologia in the framework of the project
   PTDC/SAU OSM/101469/2008 and the PhD scholarship SFRH/BD/37654/2007.
   PAB, AS and HH were supported by fellowships from the National Health
   and Medical Research Council (NHMRC) of Australia.
CR Allison SJ, 2009, J BONE MINER RES, V24, P294, DOI 10.1359/JBMR.081013
   Amano S, 2007, BBA GEN SUBJECTS, V1770, P966, DOI 10.1016/j.bbagen.2007.02.009
   Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Bedoui S, 2003, J NEUROIMMUNOL, V134, P1, DOI 10.1016/S0165 5728(02)00424 1
   Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166 2236(96)01057 0
   Buckwalter J A, 1987, Instr Course Lect, V36, P27
   Burcelin R, 2001, PEPTIDES, V22, P421, DOI 10.1016/S0196 9781(01)00357 6
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Dailey MJ, 2009, AM J PHYSIOL REG I, V296, pR877, DOI 10.1152/ajpregu.90568.2008
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   El Sherif N, 2011, CARDIOL J, V18, P233
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601
   Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294
   Jorgensen Niklas R, 2011, Curr Osteoporos Rep, V9, P149, DOI 10.1007/s11914 011 0065 0
   Karaguzel G, 2010, REV ENDOCR METAB DIS, V11, P237, DOI 10.1007/s11154 010 9154 0
   Kempná P, 2010, MOL CELL ENDOCRINOL, V314, P101, DOI 10.1016/j.mce.2009.08.010
   Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659
   Lee NJ, 2011, BONE, V48, P461, DOI 10.1016/j.bone.2010.10.174
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   Matsuda H, 2002, J COMP NEUROL, V449, P390, DOI 10.1002/cne.10303
   Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05 4770fje
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Painsipp E, 2010, J PSYCHOPHARMACOL, V24, P1541, DOI 10.1177/0269881109104851
   Polidori C, 2000, PEPTIDES, V21, P29, DOI 10.1016/S0196 9781(99)00170 9
   Teixeira L, 2009, J CELL BIOCHEM, V107, P908, DOI 10.1002/jcb.22194
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Wheway J, 2005, J EXP MED, V202, P1527, DOI 10.1084/jem.20051971
   Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084
   Yulyaningsih E, 2011, BRIT J PHARMACOL, V163, P1170, DOI 10.1111/j.1476 5381.2011.01363.x
   Zhang L, 2010, DIABETES OBES METAB, V12, P591, DOI 10.1111/j.1463 1326.2009.01193.x
   Zhang L, 2010, INT J OBESITY, V34, P357, DOI 10.1038/ijo.2009.232
   Zhang L, 2011, PHARMACOL THERAPEUT, V131, P91, DOI 10.1016/j.pharmthera.2011.03.011
NR 37
TC 52
Z9 69
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUL
PY 2012
VL 51
IS 1
BP 8
EP 16
DI 10.1016/j.bone.2012.03.020
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 960HS
UT WOS:000305379200002
PM 22484690
DA 2025 08 17
ER

PT J
AU Wang, J
   Chen, G
   Zhang, QQ
   Zhao, FL
   Yu, XL
   Ma, XM
   Liu, M
AF Wang, Jing
   Chen, Gang
   Zhang, Qianqian
   Zhao, Fuli
   Yu, Xiaolu
   Ma, Xuemei
   Liu, Mei
TI Phillyrin Attenuates Osteoclast Formation and Function and Prevents
   LPS Induced Osteolysis in Mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE phillyrin; osteoclast formation; bone resorption; MAPK signaling
   pathway; osteolysis
ID SODIUM FLUORIDE; DIFFERENTIATION; RANKL; DISEASE; LIPOPOLYSACCHARIDE;
   OSTEOBLASTS; MECHANISMS; EXPRESSION; PHOSPHATE; MODULATE
AB As the sole cell type responsible for bone resorption, osteoclasts play a pivotal role in a variety of lytic bone diseases. Suppression of osteoclast formation and activation has been proposed as an effective protective therapy for new bone. In this study, we reported for the first time that phillyrin (Phil), an active ingredient extracted from forsythia, significantly inhibited RANKL induced osteoclastogenesis and bone resorption in vitro and protected against lipopolysaccharide induced osteolysis in vivo. Further molecular investigations demonstrated that Phil effectively blocked RANKL induced activations of c Jun N terminal kinase and extracellular signal regulated kinase, which suppressed the expression of c Fos and nuclear factor of activated T cells cytoplasmic 1. Taken together, these data suggested that Phil might be a potential antiosteoclastogenesis agent for treating osteoclast related bone lytic diseases.
C1 [Wang, Jing; Chen, Gang; Zhang, Qianqian; Zhao, Fuli; Yu, Xiaolu; Ma, Xuemei; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Normal University
RP Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Jiangsu, Peoples R China.
EM meiliunj@163.com
RI Zhang, Qianqian/HPG 9773 2023
FU National Natural Science Foundation of China [31870895, 31171135];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Top notch Academic Programs Project of Jiangsu
   Higher Education Institutions (TAPP)
FX This study was supported by the National Natural Science Foundation of
   China (grants 31870895, 31171135), the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), and
   Top notch Academic Programs Project of Jiangsu Higher Education
   Institutions (TAPP).
CR Abu Amer Y, 2008, AUTOIMMUNITY, V41, P204, DOI 10.1080/08916930701694543
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bi Y., 2010, J BONE MINER RES, V16, P2082
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Cheng YW, 2017, XENOBIOTICA, V47, P297, DOI 10.1080/00498254.2016.1193262
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   ERIKSEN EF, 1985, BONE, V6, P381, DOI 10.1016/8756 3282(85)90337 0
   Fu FS, 2019, J CELL PHYSIOL, V234, P11951, DOI 10.1002/jcp.27888
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   HASLING C, 1987, MINER ELECTROL METAB, V13, P96
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Iezaki T, 2016, MOL CELL BIOL, V36, P2451, DOI 10.1128/MCB.01075 15
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kaji K, 2001, J BONE MINER RES, V16, P1593, DOI 10.1359/jbmr.2001.16.9.1593
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   KIM MJ, 2006, KOREAN J BIOTECHNOL, V21, P444
   Kong LB, 2017, INT IMMUNOPHARMACOL, V51, P31, DOI 10.1016/j.intimp.2017.07.003
   Kong PR, 2014, PLANTA MED, V80, P880, DOI 10.1055/s 0034 1368614
   Kuang H X, 1988, Zhong Yao Tong Bao, V13, P32
   Kuo PC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/304830
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee SW, 2002, J BIOCHEM MOL BIOL, V35, P371
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113698
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu M, 2015, AM J PATHOL, V185, P2653, DOI 10.1016/j.ajpath.2015.06.017
   Liu WJ, 2017, RSC ADV, V7, P40418, DOI 10.1039/c7ra06302d
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Pan XL, 2014, INFLAMM RES, V63, P597, DOI 10.1007/s00011 014 0731 7
   Qu HH, 2008, J PHARM PHARMACOL, V60, P261, DOI 10.1211/jpp.60.2.0016
   Qu XY, 2016, ARCH PHARM RES, V39, P998, DOI 10.1007/s12272 016 0775 z
   Reddy SV, 2004, J CELL BIOCHEM, V93, P688, DOI 10.1002/jcb.20256
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Rosen C. J., 2013, OSTEOCLAST BIOL BONE, DOI [10.1002/9781118453926.ch3, DOI 10.1002/9781118453926.CH3]
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Wada N, 2004, BONE, V35, P629, DOI 10.1016/j.bone.2004.04.023
   Wang ZY, 2018, J ETHNOPHARMACOL, V210, P318, DOI 10.1016/j.jep.2017.08.040
   Wei T, 2014, CELL MOL NEUROBIOL, V34, P1165, DOI 10.1007/s10571 014 0091 4
   Wei Z., 2010, J BONE MINER METAB O, V17, P1211, DOI [10.1359/jbmr.2002.17.7.1211, DOI 10.1359/JBMR.2002.17.7.1211]
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang LF, 2004, AQUAT INSECT, V26, P65, DOI 10.1076/aqin.26.1.65.35372
   Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008 5472.CAN 04 1687
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zhong WT, 2013, FITOTERAPIA, V90, P132, DOI 10.1016/j.fitote.2013.06.003
   Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200
NR 53
TC 18
Z9 20
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 17
PY 2019
VL 10
AR 1188
DI 10.3389/fphar.2019.01188
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JO4JC
UT WOS:000497544900001
PM 31680965
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU He, LQ
   Ma, CY
   Cai, SQ
   Hou, RL
   Xu, HF
   Liu, JQ
   Liu, X
   Huang, Q
AF He, Luqing
   Ma, Chenyu
   Cai, Shuiqi
   Hou, Ruolin
   Xu, Hongfeng
   Liu, Jianqiang
   Liu, Xin
   Huang, Qun
TI 被撤回的出版物: Study on the Mechanism of Treating Femoral Head Necrosis with
   Drynariae Rhizoma Based on Network Pharmacology (Retracted Article)
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article; Retracted Publication
ID SIGNALING PATHWAY; NARINGIN; BONE; DIFFERENTIATION; OSTEOPOROSIS
AB Through the network pharmacology thought, the action target of the active ingredients of Drynariae Rhizoma was predicted, and the mapping was combined with the related targets of ONFH, and the key nodes of interaction were identified for enrichment analysis, so as to comprehensively explore the pharmacological mechanism of Drynariae Rhizoma against ONFH. The main active ingredients of Drynariae Rhizoma were screened based on pharmacokinetic characteristics in pharmacokinetic database and analysis platform of TCM system (TCMSP). We used the organic small molecule bioactivity database (PubChem) and Swiss target prediction database to predict related targets based on 2D or 3D structural similarity and then mined the known ONFH therapeutic targets through the Human Mendelian Genetic Database (OMIM) and Pubmed texts. Combined with the predicted targets, String database was imported to construct the OP target interaction network diagram of bone fracture therapy. CytoNCA software was used to topology the key nodes of interaction according to relevant node parameters, and String was imported again to construct the protein interaction network diagram. Finally, biological functions and metabolic pathways of key nodes were analyzed through DAVID database. It was revealed that Drynariae Rhizoma may regulate stem cells, osteoblasts, osteoclasts, and immune cells through multiple pathways, including proliferation, differentiation, immunity, and oxidative stress. Conclusion: Pharmacological studies based on network indicate that Drynariae Rhizoma may participate in the regulation of several major signaling pathways through direct or indirect action targets and affect the proliferation and differentiation of multiple types of cells, thus playing an anti ONFH role, which provides a scientific basis for explaining the material basis and mechanism of its anti  ONFH.
C1 [He, Luqing] Third Peoples Hosp Cixi, Cent Lab Tradit Chinese Med Orthopaed, Cixi, Peoples R China.
   [Ma, Chenyu] Third Peoples Hosp Cixi, Dept Crit Care Med, Cixi, Peoples R China.
   [Cai, Shuiqi; Huang, Qun] Third Peoples Hosp Cixi, Dept Orthoped & Traumatol Tradit Chinese Med, Cixi, Peoples R China.
   [Hou, Ruolin; Liu, Xin] Third Peoples Hosp Cixi, Dept Pharm, Cixi, Peoples R China.
   [Xu, Hongfeng] Third Peoples Hosp Cixi, Dept Gen Surg, Cixi, Peoples R China.
   [Liu, Jianqiang] Third Peoples Hosp Cixi, Dept Rehabil, Cixi, Peoples R China.
RP Huang, Q (通讯作者)，Third Peoples Hosp Cixi, Dept Orthoped & Traumatol Tradit Chinese Med, Cixi, Peoples R China.
EM helq619@163.com; machenyu1@sina.com; caishuiuqi3rd@163.com;
   ruolinhou93@163.com; 295007425@qq.com; ljq520family@sina.com;
   13305027599@163.com; huangqun3rd@163.com
RI Hou, Ruolin/JDD 4009 2023; Xu, HF/KOD 6035 2024
FU Ningbo Natural Science Foundation [2019A610251]; Ningbo Traditional
   Discipline of Traditional Chinese Medicine
FX AcknowledgmentsThis study was supported by the Ningbo Natural Science
   Foundation (2019A610251) and Ningbo Traditional Discipline of
   Traditional Chinese Medicine (LaoShi ShangKe).
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Boran ADW, 2010, CURR OPIN DRUG DISC, V13, P297
   BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   Curry SJ, 2018, JAMA J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Kim HK, 2013, MOLECULES, V18, P15474, DOI 10.3390/molecules181215474
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Li HX, 2008, MOL CELL ENDOCRINOL, V291, P116, DOI 10.1016/j.mce.2008.05.005
   Li JS, 2015, SCI REP UK, V5, DOI 10.1038/srep15290
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   Liu X, 2011, EXPERT OPIN THER TAR, V15, P903, DOI 10.1517/14728222.2011.586635
   Ma C, 2011, J CHEM INF MODEL, V51, P1521, DOI 10.1021/ci1004948
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Twinkle G., 2018, J DIET SUPPL, V16, P699
   Wang JL, 2009, MED MICROBIOL IMMUN, V198, P5, DOI 10.1007/s00430 008 0098 x
   Wang SL, 2017, ONCOTARGET, V8, P14549, DOI 10.18632/oncotarget.14675
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Wu Q, 2015, MED SCI MONITOR, V21
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 30
TC 3
Z9 4
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748 670X
EI 1748 6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD JUN 6
PY 2022
VL 2022
AR 3631722
DI 10.1155/2022/3631722
PG 8
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematical & Computational Biology
GA 2G9WB
UT WOS:000813950400006
PM 35707043
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Vadivalagan, C
   Krishnan, A
   Chen, SJ
   Hseu, YC
   Muthu, S
   Dhar, R
   Aljabali, AAA
   Tambuwala, MM
AF Vadivalagan, Chithravel
   Krishnan, Anand
   Chen, Siang Jyun
   Hseu, You Cheng
   Muthu, Sathish
   Dhar, Rajib
   Aljabali, Alaa A. A.
   Tambuwala, Murtaza M.
TI The Warburg effect in osteoporosis: Cellular signaling and epigenetic
   regulation of energy metabolic events to targeting the osteocalcin for
   phenotypic alteration
SO CELLULAR SIGNALLING
LA English
DT Article
DE Glycolysis; Warburg effect; Glucose metabolism; ATP production;
   Osteoblast; Osteoporosis; Alternative therapy
ID PARATHYROID HORMONE STIMULATION; AEROBIC GLYCOLYSIS; BONE FORMATION;
   GLUCOSE HOMEOSTASIS; ANDROGEN RECEPTOR; MESENCHYMAL STEM; IN VITRO;
   ACTIVATION; EXPRESSION; CELLS
AB Osteoporosis is a silent disease of skeletal morphology that induces fragility and fracture risk in aged persons irrespective of gender. Juvenile secondary osteoporosis is rare and is influenced by familial genetic abnormalities. Despite the currently available therapeutic options, more acute treatments are in need. Women suffer from oste oporosis after menopause, which is characterized by a decline in the secretion of sex hormones in the later phase of life. Several studies in the past two decades emphasized hormone related pathways to combat osteoporosis. Some studies partially examined energy related pathways, but achieving a more vivid picture of metabolism and bone remodeling in terms of the Warburg phenomenon is still warranted. Each cell requires sufficient energy for cellular propagation and growth; in particular, osteoporosis is an energy dependent mechanism affected by a decreased cellular mass of the bone morphology. Energy utilization is the actual propagation of such diseases, and narrowing down these criteria will hopefully provide clues to formulate better therapeutic strategies. Oxidative glycolysis is a particular type of energy metabolic pathway in cancer cells that influences cellular proliferation. Therefore, the prospect of utilizing collective glucose metabolism by inducing the Warburg effect may improve cell propagation. The benefits of utilizing the energy from the Warburg effect may be a difficult task. However, it seems to improve their effectiveness in the osteoblast phenotype by connecting the selected pathways such as WNT, Notch, AKT, and Insulin signaling by targeting osteocalcin resulting in phenotypic alteration. Osteocalcin directs ATP utilization through the sclerostin SOST gene in the bone microenvironment. Thus, selective activation of ATP production involved in osteoblast maturation remains a prime strategy to fight osteoporosis.
C1 [Vadivalagan, Chithravel; Krishnan, Anand; Hseu, You Cheng; Tambuwala, Murtaza M.] China Med Univ, Coll Biopharmaceut & Food Sci, Dept Cosmeceut, Taichung 40402, Taiwan.
   [Krishnan, Anand] Univ Free State, Fac Hlth Sci, Sch Pathol, Dept Chem Pathol, ZA 9300 Bloemfontein, South Africa.
   [Chen, Siang Jyun] China Med Univ, Inst Nutr, Coll Hlth Care, 406040, Taichung, Taiwan.
   [Muthu, Sathish] Govt Med Coll & Hosp, Dept Orthopaed, Dindigul 624003, Tamil Nadu, India.
   [Dhar, Rajib] SRM Inst Sci & Technol, Dept Genet Engn, Kattankulathur 603203, Tamilnadu, India.
   [Hseu, You Cheng] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
   [Hseu, You Cheng] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
   [Hseu, You Cheng] China Med Univ, Res Ctr Chinese Herbal Med, Taichung 40402, Taiwan.
   [Aljabali, Alaa A. A.] Yarmouk Univ, Dept Pharmaceut & Pharmaceut Technol, Irbid 21163, Jordan.
   [Tambuwala, Murtaza M.] Univ Lincoln, Lincoln Med Sch, Brayford Pool Campus, Lincoln LN6 7TS, England.
C3 China Medical University Taiwan; University of the Free State; China
   Medical University Taiwan; SRM Institute of Science & Technology
   Chennai; Asia University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; Yarmouk University; University of Lincoln
RP Vadivalagan, C; Krishnan, A; Tambuwala, MM (通讯作者)，China Med Univ, Coll Biopharmaceut & Food Sci, Dept Cosmeceut, Taichung 40402, Taiwan.; Tambuwala, MM (通讯作者)，Univ Lincoln, Lincoln Med Sch, Brayford Pool Campus, Lincoln LN6 7TS, England.
EM marinedrug.9@gmail.com; krishnana@ufs.ac.za; m.tambuwala@lincoln.ac.uk
RI Tambuwala, Murtaza/HNP 0828 2023; Aljabali, Alaa/A 6509 2008;
   Chithravel, VADIVALAGAN/AGK 6224 2022; Hsu, Fei Ting/AAC 9238 2020;
   Muthu, Sathish/G 5756 2018; Krishnan, Anand/C 5178 2015
OI Tambuwala, Murtaza/0000 0001 8499 9891; VADIVALAGAN,
   Chithravel/0000 0002 1751 4361; Krishnan, Anand/0000 0002 8886 8482;
   Dhar, Rajib/0000 0003 3924 9367; Muthu, Sathish/0000 0002 7143 4354; 
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Ackerman KE, 2012, BONE, V51, P680, DOI 10.1016/j.bone.2012.07.019
   Ackerman KE, 2011, J CLIN ENDOCR METAB, V96, P3123, DOI 10.1210/jc.2011 1614
   Atsumi T, 2002, CANCER RES, V62, P5881
   Balemans W., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P355
   Barrack MT, 2014, AM J SPORT MED, V42, P949, DOI 10.1177/0363546513520295
   Bellido T, 2013, ACTUAL OSTEOL, V9, P56
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   BORLE AB, 1960, J BIOL CHEM, V235, P1206
   Bozec A, 2013, J CELL SCI, V126, P5432, DOI 10.1242/jcs.134510
   Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522
   BROWN JP, 1984, LANCET, V1, P1091
   Brun J, 2017, DIABETES, V66, P2541, DOI 10.2337/db17 0116
   Chauhan S, 2016, DEV CELL, V39, P13, DOI 10.1016/j.devcel.2016.08.003
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   COHN DV, 1962, J BIOL CHEM, V237, P615
   Cooper G.M., 2000, The Cell: A Molecular Approach
   Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007
   de Paula FJA, 2013, BONE RES, V1, DOI 10.4248/BR201301005
   Edwards JR, 2012, DISCOV MED, V13, P201
   Epstein T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185085
   Epstein T, 2014, CANCER METAB, V2, DOI 10.1186/2049 3002 2 7
   Esen E, 2014, CURR OSTEOPOROS REP, V12, P433, DOI 10.1007/s11914 014 0235 y
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fernandes TAP, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9021314
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   Frödin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551
   Fulzele K, 2022, CELL, V185, P746, DOI 10.1016/j.cell.2022.01.016
   Gao JJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7215
   Golds G, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/4602129
   Goudy S, 2009, CLEFT PALATE CRAN J, V46, P610, DOI 10.1597/08 126.1
   Gundberg CM, 2012, ADV NUTR, V3, P149, DOI 10.3945/an.112.001834
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Izawa T, 2015, CELL REP, V11, P1625, DOI 10.1016/j.celrep.2015.05.019
   Jähn K, 2017, J BONE MINER RES, V32, P1761, DOI 10.1002/jbmr.3167
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Katz Seymour, 2010, Gastroenterol Hepatol (N Y), V6, P506
   Kinsella Kevin, 2001, SERIES J SPAN ECON, VP95/01 1
   Lane AN, 2009, METABOLOMICS, V5, P163, DOI 10.1007/s11306 008 0142 2
   Lecka Czernik B, 2015, J BONE MINER RES, V30, P1356, DOI 10.1002/jbmr.2574
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lindner U, 2010, TRANSFUS MED HEMOTH, V37, P75, DOI 10.1159/000290897
   Liu Yi, 2022, FRONT PHYSIOL, V1538
   Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014
   Lodish H., 1999, MOL CELL BIOL, V4th
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Loucks AB, 2007, SPORTS MED, V37, P348, DOI 10.2165/00007256 200737040 00019
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev cellbio 092910 154237
   Marcucci G, 2015, CLIN CASES MINER BON, V12, P151, DOI 10.11138/ccmbm/2015.12.2.151
   Montel Hagen A, 2008, CELL, V132, P1039, DOI 10.1016/j.cell.2008.01.042
   Mookerjee SA, 2015, BBA BIOENERGETICS, V1847, P171, DOI 10.1016/j.bbabio.2014.10.005
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Mosialou I, 2020, J EXP MED, V217, DOI 10.1084/jem.20191261
   Motyl KJ, 2017, TOXICOL PATHOL, V45, P887, DOI 10.1177/0192623317737065
   Mountjoy M, 2014, BRIT J SPORT MED, V48, P491, DOI 10.1136/bjsports 2014 093502
   Muñoz R, 2012, AM J PHYSIOL REG I, V303, pR985, DOI 10.1152/ajpregu.00262.2012
   National Institutes of Health, 2018, OSTEOPOROSIS OVERVIE
   NICHOLS FC, 1987, BONE, V8, P105, DOI 10.1016/8756 3282(87)90078 0
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Oldknow KJ, 2015, J ENDOCRINOL, V225, pR1, DOI 10.1530/JOE 14 0584
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   PECK WA, 1964, SCIENCE, V146, P1476, DOI 10.1126/science.146.3650.1476
   Prakasam G, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00022
   Reid IR, 2010, ARCH BIOCHEM BIOPHYS, V503, P20, DOI 10.1016/j.abb.2010.06.027
   Rich PR, 2003, BIOCHEM SOC T, V31, P1095
   Riddle RC, 2017, PHYSIOL REV, V97, P667, DOI 10.1152/physrev.00022.2016
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   RODAN GA, 1978, ENDOCRINOLOGY, V102, P1501, DOI 10.1210/endo 102 5 1501
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Sakai H, 2016, METAL IONS LIFE SCI, V16, P459, DOI 10.1007/978 3 319 21756 7_13
   Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205 3208.1998
   Shestov AA, 2014, ELIFE, V3, DOI 10.7554/eLife.03342
   Slaninova V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150155
   Smith RL, 2018, ENDOCR REV, V39, P489, DOI 10.1210/er.2017 00211
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Ucer S, 2015, J BONE MINER RES, V30, P1138, DOI 10.1002/jbmr.2485
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Warburg O, 1924, BIOCHEM Z, V152, P309
   Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Weivoda MM, 2014, CURR OSTEOPOROS REP, V12, P107, DOI 10.1007/s11914 014 0188 1
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Zanatta LCB, 2014, ARQ BRAS ENDOCRINOL, V58, P444, DOI 10.1590/0004 2730000003333
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang Q, 2015, J INTERN MED, V277, P681, DOI 10.1111/joim.12348
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
NR 104
TC 8
Z9 8
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD DEC
PY 2022
VL 100
AR 110488
DI 10.1016/j.cellsig.2022.110488
EA OCT 2022
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 6P0WB
UT WOS:000890655500001
PM 36208706
OA hybrid
DA 2025 08 17
ER

PT J
AU Li, SF
   Teguh, D
   Wu, DP
   Liu, LS
   Hu, CF
   Yuan, JB
   Inderjeeth, CA
   Xu, JK
AF Li, Shangfu
   Teguh, Dian
   Wu, Depeng
   Liu, Lesong
   Hu, Chaofeng
   Yuan, Jinbo
   Inderjeeth, Charles A.
   Xu, Jiake
TI Antidementia medication acetylcholinesterase inhibitors have therapeutic
   benefits on osteoporotic bone by attenuating osteoclastogenesis and bone
   resorption
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE acetylcholinesterase inhibitors; drug choice; osteoclast; osteoporosis
ID INDUCED MUSCLE PARALYSIS; ALZHEIMERS DISEASE; MECHANISMS; EXPRESSION;
   FRACTURES; RECEPTORS; MEMANTINE; CLONING; HEALTH; BOTOX
AB This study was designed to determine whether the use of acetylcholinesterase inhibitors (AChEIs), a group of drugs that stimulate acetylcholine receptors and are used to treat Alzheimer's disease (AD), is associated with osteoporosis protection and inhibition of osteoclast differentiation and function. Firstly, we examined the effects of AChEIs on RANKL induced osteoclast differentiation and function with osteoclastogenesis and bone resorption assays. Next, we investigated the impacts of AChEIs on RANKL induced nuclear factor kappa B and NFATc1 activation and expression of osteoclast marker proteins CA 2, CTSK and NFATc1, and dissected the MAPK signaling in osteoclasts in vitro by using luciferase assay and Western blot. Finally, we assessed the in vivo efficacy of AChEIs using an ovariectomy induced osteoporosis mouse model, which was analyzed using microcomputed tomography, in vivo osteoclast and osteoblast parameters were assessed using histomorphometry. We found that Donepezil and Rivastigmine inhibited RANKL induced osteoclastogenesis and impaired osteoclastic bone resorption. Moreover, AChEIs reduced the RANKL induced transcription of Nfatc1, and expression of osteoclast marker genes to varying degrees (mainly Donepezil and Rivastigmine but not Galantamine). Furthermore, AChEIs variably inhibited RANKL induced MAPK signaling accompanied by downregulation of AChE transcription. Finally, AChEIs protected against OVX induced bone loss mainly by inhibiting osteoclast activity. Taken together, AChEIs (mainly Donepezil and Rivastigmine) exerted a positive effect on bone protection by inhibiting osteoclast function through MAPK and NFATc1 signaling pathways through downregulating AChE. Our findings have important clinical implications that elderly patients with dementia who are at risk of developing osteoporosis may potentially benefit from therapy with the AChEI drugs. Our study may influence drug choice in those patients with both AD and osteoporosis.
C1 [Li, Shangfu; Wu, Depeng; Liu, Lesong; Hu, Chaofeng] Sun Yat sen Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou 510630, Guangdong, Peoples R China.
   [Teguh, Dian; Yuan, Jinbo; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Inderjeeth, Charles A.] Univ Western Australia, Sch Med, North Metropolitan Hlth Serv, Nedlands, WA, Australia.
   [Inderjeeth, Charles A.] Univ Western Australia, Fac Hlth & Med Sci, Sch Med, Nedlands, WA, Australia.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China.
   [Inderjeeth, Charles A.] Univ Western Australia, North Metropolitan Hlth Serv, Nedlands, WA 6009, Australia.
   [Inderjeeth, Charles A.] Univ Western Australia, Med Sch, Nedlands, WA 6009, Australia.
C3 Sun Yat Sen University; University of Western Australia; North
   Metropolitan Health Service; University of Western Australia; University
   of Western Australia; Chinese Academy of Sciences; Shenzhen Institute of
   Advanced Technology, CAS; North Metropolitan Health Service; University
   of Western Australia; University of Western Australia
RP Li, SF (通讯作者)，Sun Yat sen Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou 510630, Guangdong, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.; Inderjeeth, CA (通讯作者)，Univ Western Australia, North Metropolitan Hlth Serv, Nedlands, WA 6009, Australia.; Inderjeeth, CA (通讯作者)，Univ Western Australia, Med Sch, Nedlands, WA 6009, Australia.
EM lishangfu@mail.sysu.edu.cn; charles.inderjeeth@health.wa.gov.au;
   jiake.xu@uwa.edu.au
RI ; Wu, DePeng/KFR 8165 2024
OI Yuan, Jinbo/0000 0002 6240 9333; Xu, Jiake/0000 0003 2021 8309
FU Guangdong Basic and Applied Basic Research Foundation [2021A1515010316];
   Guangzhou Science and Technology Project, China [202102010187]; Research
   Advisory Committee, Sir Charles Gairdner Hospital, Australia
   [2015 16/047]; Australian National Health and Medical Research Council
   (NHMRC) [APP1107828, APP1127156, APP1163933]
FX Guangdong Basic and Applied Basic Research Foundation, Grant/Award
   Number:2021A1515010316; the Guangzhou Science and Technology Project,
   China, Grant/Award Number: 202102010187;Research Advisory Committee, Sir
   Charles Gairdner Hospital, Australia, Grant/Award Number:
   2015 16/047;Australian National Health and Medical Research Council
   (NHMRC), Grant/Award Numbers: APP1107828, APP1127156, APP1163933
CR Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Eimar H, 2013, J MUSCULOSKEL NEURON, V13, P124
   Fan LY, 2014, NEUROPSYCH DIS TREAT, V10, P439, DOI 10.2147/NDT.S45143
   Grimston SK, 2007, ANN NY ACAD SCI, V1116, P444, DOI 10.1196/annals.1402.009
   LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706
   Lauwers M, 2021, OSTEOARTHR CARTILAGE, V29, P643, DOI 10.1016/j.joca.2021.02.005
   Li SF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02947 3
   Li SF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101683
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lin XX, 2020, J CELL PHYSIOL, V235, P5951, DOI 10.1002/jcp.29520
   Liu PS, 2011, EUR J PHARMACOL, V650, P34, DOI 10.1016/j.ejphar.2010.09.031
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Luo XH, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.620543
   Mohammad AF, 2009, EUR NEUROL, V62, P369, DOI 10.1159/000242444
   Ogunwale AN, 2020, J BONE MINER RES, V35, P440, DOI 10.1002/jbmr.3916
   Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640 013 9398 z
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sato T, 2015, HELIYON, V1, DOI 10.1016/j.heliyon.2015.e00013
   Sato T, 2010, FEBS LETT, V584, P817, DOI 10.1016/j.febslet.2010.01.001
   Shi Y, 2010, CELL METAB, V11, P231, DOI 10.1016/j.cmet.2010.01.005
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tamimi I, 2018, OSTEOPOROSIS INT, V29, P849, DOI 10.1007/s00198 017 4346 z
   Tamimi I, 2012, J BONE MINER RES, V27, P1518, DOI 10.1002/jbmr.1616
   Tan CC, 2014, J ALZHEIMERS DIS, V41, P615, DOI 10.3233/JAD 132690
   Tanaka H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059402
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yang B, 2020, FASEB J, V34, P3583, DOI 10.1096/fj.201901550R
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhou R, 2014, CURR ALZHEIMER RES, V11, P706, DOI 10.2174/1567205011666140812115818
NR 33
TC 5
Z9 5
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2023
VL 238
IS 8
BP 1823
EP 1835
DI 10.1002/jcp.31057
EA JUN 2023
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FO9Z6
UT WOS:001010180300001
PM 37334837
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhan, YF
   Liang, JM
   Tian, K
   Che, ZG
   Wang, ZY
   Yang, X
   Su, YG
   Lin, XX
   Song, FM
   Zhao, JM
   Xu, JK
   Liu, Q
   Zhou, B
AF Zhan, Yunfei
   Liang, Jiamin
   Tian, Kun
   Che, Zhigang
   Wang, Ziyi
   Yang, Xue
   Su, Yuangang
   Lin, Xixi
   Song, Fangming
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
   Zhou, Bo
TI Vindoline Inhibits RANKL Induced Osteoclastogenesis and Prevents
   Ovariectomy Induced Bone Loss in Mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE vindoline; MAPK; osteoclast; osteoporosis; NFATc1
ID UP REGULATION; OSTEOPOROSIS; DIFFERENTIATION; ACTIVATION; DEGRADATION;
   EXPRESSION
AB Osteolytic bone diseases, for example postmenopausal osteoporosis, arise from the imbalances between osteoclasts and osteoblasts in the bone remodeling process, whereby osteoclastic bone resorption greatly exceeds osteoblastic bone formation resulting in severe bone loss and deterioration in bone structure and microarchitecture. Therefore, the identification of agents that can inhibit osteoclast formation and/or function for the treatment of osteolytic bone disease has been the focus of bone and orthopedic research. Vindoline (Vin), an indole alkaloid extracted from the medicinal plant Catharanthus roseus, has been shown to possess extensive biological and pharmacological benefits, but its effects on bone metabolism remains to be documented. Our study demonstrated for the first time, that Vin could inhibit osteoclast differentiation from bone marrow macrophages (BMMs) precursor cells as well as mature osteoclastic bone resorption. We further determined that the underlying molecular mechanism of action of Vin is in part due to its inhibitory effect against the activation of MAPK including p38, JNK, and ERK and intracellular reactive oxygen species (ROS) production. This effect ultimately suppressed the induction of c Fos and NFATc1, which consequently downregulated the expression of the genes required for osteoclast formation and bone resorption. Consistent with our in vitro findings, in vivo administration of Vin protected mice against ovariectomy (OVX) induced bone loss and trabecular bone deterioration. These results provided promising evidence for the potential therapeutic application of Vin as a novel treatment option against osteolytic diseases.
C1 [Zhan, Yunfei; Liang, Jiamin; Tian, Kun; Che, Zhigang; Yang, Xue; Su, Yuangang; Lin, Xixi; Song, Fangming; Zhao, Jinmin; Xu, Jiake; Liu, Qian; Zhou, Bo] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Wang, Ziyi; Song, Fangming; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Res Ctr Regenerat Med, Dept Trauma Orthoped & Hand Surg, Affiliated Hosp 1, Nanning, Peoples R China.
C3 Guangxi Medical University; University of Western Australia; Guangxi
   Medical University
RP Liu, Q; Zhou, B (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.; Liu, Q (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Dept Trauma Orthoped & Hand Surg, Affiliated Hosp 1, Nanning, Peoples R China.
EM luoboqian@hotmail.com; gxzhoubo520@126.com
RI ; Su, Yuangang/KKU 6952 2024; zhao, jin/LBH 0351 2024; Zhang,
   Ge/N 4150 2013; xi, lin/JOK 1026 2023
OI Xu, Jiake/0000 0003 2021 8309; Wang, Ziyi/0000 0002 1334 7287
FU Guangxi Science and Technology project [Guikehe1599005 2 12]; Guangxi
   Science and Technology Department [AD17195086]; Guangxi Natural Science
   Foundation [2018GXNSFAA294053, 2018GXNSFAA050092]; Guangxi Collaborative
   Innovation Center for Biomedicine talent cultivation [GCICB TC 2017001,
   GCICB TC 2017002]; Australian Health and Medical Research Council
   (NHMRC) [APP1107828]
FX This study was supported by Guangxi Science and Technology project
   (Guikehe1599005 2 12), Guangxi Science and Technology Department funded
   project (AD17195086), Guangxi Natural Science Foundation,
   (2018GXNSFAA294053, 2018GXNSFAA050092), and the Guangxi Collaborative
   Innovation Center for Biomedicine talent cultivation (GCICB TC 2017001,
   GCICB TC 2017002). This study was also funded by the Australian Health
   and Medical Research Council (NHMRC No: APP1107828). Funding statement
   is not included in the manuscript.
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217
   Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806
   Bartelt A, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0006 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Goboza M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108638
   HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Koh JM, 2006, J BONE MINER RES, V21, P1003, DOI 10.1359/JBMR.060406
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li XH, 2019, AM J TRANSL RES, V11, P1154
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Mathes E, 2008, EMBO J, V27, P1357, DOI 10.1038/emboj.2008.73
   Németh ZH, 2004, MOL PHARMACOL, V65, P342, DOI 10.1124/mol.65.2.342
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rasineni K, 2010, PHARMACOGN RES, V2, P195, DOI 10.4103/0974 8490.65523
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Saito H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08778 x
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Xi YH, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108850
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zur Y, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002979
NR 39
TC 23
Z9 23
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 22
PY 2020
VL 10
AR 1587
DI 10.3389/fphar.2019.01587
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KI5EK
UT WOS:000511372600001
PM 32038256
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Branstetter, D
   Rohrbach, K
   Huang, LY
   Soriano, R
   Tometsko, M
   Blake, M
   Jacob, AP
   Dougall, WC
AF Branstetter, Daniel
   Rohrbach, Kathy
   Huang, Li Ya
   Soriano, Rosalia
   Tometsko, Mark
   Blake, Michelle
   Jacob, Allison P.
   Dougall, William C.
TI RANK and RANK ligand expression in primary human osteosarcoma
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE RANK; RANKL; Human osteosarcoma; Antibodies; Protein expression;
   Immunohistochemistry
ID FACTOR KAPPA B; METASTASIS FREE SURVIVAL; GIANT CELL TUMOR; RECEPTOR
   ACTIVATOR; BREAST CANCER; ZOLEDRONIC ACID; DENOSUMAB; BONE;
   PROLIFERATION; MIGRATION
AB Receptor activator of nuclear factor kappa B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using denosumab, a fully human monoclonal antibody (mAb) specific to RANKL, has been demonstrated to prevent tumor induced osteolysis and subsequent skeletal complications. Recently, a prominent functional role for the RANKL pathway has emerged in the primary bone tumor giant cell tumor of bone (GCTB). Expression of both RANKL and RANK is extremely high in GCTB tumors and denosumab treatment was associated with tumor regression and reduced tumor associated bone lysis in GCTB patients. In order to address the potential role of the RANKL pathway in another primary bone tumor, this study assessed human RANKL and RANK expression in human primary osteosarcoma (OS) using specific mAbs, validated and optimized for immunohistochemistry (IHC) or flow cytometry.
   Our results demonstrate RANKL expression was observed in the tumor element in 68% of human OS using IHC. However, the staining intensity was relatively low and only 37% (29/79) of samples exhibited >= 10% RANKL positive tumor cells. RANK expression was not observed in OS tumor cells. In contrast, RANK expression was clearly observed in other cells within OS samples, including the myeloid osteoclast precursor compartment, osteoclasts and in giant osteoclast cells. The intensity and frequency of RANKL and RANK staining in OS samples were substantially less than that observed in GCTB samples. The observation that RANKL is expressed in OS cells themselves suggests that these tumors may mediate an osteoclastic response, and anti RANKL therapy may potentially be protective against bone pathologies in OS. However, the absence of RANK expression in primary human OS cells suggests that any autocrine RANKL/RANK signaling in human OS tumor cells is not operative, and anti RANKL therapy would not directly affect the tumor. (C) 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY NC ND license.
C1 [Branstetter, Daniel; Rohrbach, Kathy; Huang, Li Ya; Soriano, Rosalia] Amgen Inc, Dept Pathol, Seattle, WA USA.
   [Tometsko, Mark; Jacob, Allison P.; Dougall, William C.] Amgen Inc, Therapeut Innovat Unit, Seattle, WA USA.
   [Blake, Michelle] Amgen Inc, Dept Hematol Oncol Res, Seattle, WA USA.
C3 Amgen; Amgen; Amgen
RP Dougall, WC (通讯作者)，Amgen Inc, Therapeut Innovat Unit, Seattle, WA USA.
EM dougallw@amgen.com
OI Dougall, William/0000 0001 9487 251X
FU Amgen Inc.
FX This study was funded by Amgen Inc.
CR Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585 010 9319 y
   Akiyama T, 2010, J PHARM PHARMACOL, V62, P470, DOI 10.1211/jpp.62.04.0009
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Bago Horvath Z, 2014, PATHOLOGY, V46, P411, DOI 10.1097/PAT.0000000000000116
   Barger AM, 2007, J VET INTERN MED, V21, P133, DOI 10.1892/0891 6640(2007)21[133:EORAON]2.0.CO;2
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Blake MG, 2013, NEUROBIOL LEARN MEM, V106, P193, DOI 10.1016/j.nlm.2013.09.001
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Dougall William C, 2014, Bonekey Rep, V3, P519, DOI 10.1038/bonekey.2014.14
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Itoh K, 2000, J BONE MINER RES, V15, P1766, DOI 10.1359/jbmr.2000.15.9.1766
   Klein MJ, 2006, AM J CLIN PATHOL, V125, P555, DOI 10.1309/UC6KQHLD9LV2KENN
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535 7163.MCT 08 0497
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391
   Mori K, 2007, J PATHOL, V211, P555, DOI 10.1002/path.2140
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Papanastasiou AD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3234
   Smith KB, 1999, J IMMUNOL METHODS, V228, P29, DOI 10.1016/S0022 1759(99)00087 3
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
NR 33
TC 43
Z9 48
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1366
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD SEP
PY 2015
VL 4
IS 3
BP 59
EP 68
DI 10.1016/j.jbo.2015.06.002
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DD4MB
UT WOS:000369896000001
PM 27556008
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lewiecki, EM
AF Lewiecki, E. Michael
TI Sclerostin monoclonal antibody therapy with AMG 785: a potential
   treatment for osteoporosis
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE anabolic; inhibition; osteoanabolic; osteoporosis; PTH; sclerostin
ID BONE MINERAL DENSITY; VAN BUCHEM DISEASE; POSTMENOPAUSAL WOMEN;
   NONVERTEBRAL FRACTURES; VERTEBRAL FRACTURE; RANDOMIZED TRIAL;
   PARATHYROID HORMONE; BISPHOSPHONATE THERAPY; ANABOLIC THERAPIES;
   STRONTIUM RANELATE
AB Importance of the field: Osteoporosis is a common skeletal disease characterized by loss of bone strength that leads to increased risk of fractures. Fractures of the hip and spine are associated with disability, increased risk of death and high healthcare costs. Recent improvement in the understanding of the molecular regulators of bone metabolism has led to the investigation and development of new therapeutic agents with novel mechanisms of action that may offer advantages over currently available treatments for osteoporosis.
   Areas covered in this review: Sclerostin is a small protein secreted by osteocytes that downregulates osteoblast mediated bone formation. This is a review of the rationale, mechanism of action, preclinical and clinical development of AMG 785 (CDP7851), an investigational humanized mAb that inhibits the activity of sclerostin, resulting in increased bone formation.
   What the reader will gain: The reader will gain an insight into the potential use of sclerostin mAb therapy for the treatment of osteoporosis.
   Take home message: Preclinical studies and an early report of a clinical study suggest that inhibition of sclerostin with AMG 785 may provide skeletal benefit for patients with osteoporosis.
C1 New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM 87106 USA.
C3 New Mexico Clinical Research & Osteoporosis Center
RP Lewiecki, EM (通讯作者)，New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
EM lewiecki@aol.com
RI Lewiecki, E./B 3706 2018
FU Amgen; Merck; Eli Lilly; Novartis; Warner Chilcott; Genentech
FX The author has received grant/research support from Amgen, Merck, Eli
   Lilly, Novartis, Warner Chilcott, and Genentech. He has served as a
   consultant, advisory board member, speakers' bureau participant, or
   given presentations at sponsored speaking events for Amgen, Eli Lilly,
   Novartis, and Genentech.
CR Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2004, Bone health and osteoporosis: A report of the surgeon general
   [Anonymous], 2002, Americas bone health: the state of osteoporosis and low bone mass in our nation
   Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   BEIGHTON P, 1977, CLIN GENET, V11, P1
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   BILEZIKIAN JP, 2008, PRIMER METABOL BONE, V7, P252
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonewald LF, 2008, OSTEOCYTES PRIMER ME, P22
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   BUENO M, 1994, J MED GENET, V31, P976, DOI 10.1136/jmg.31.12.976
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756
   COSMAN F, 2009, J BONE MINER RES S1, V24
   COWIN SC, 1991, J BIOMECH ENG T ASME, V113, P191, DOI 10.1115/1.2891234
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cummings S, 2008, J BONE MINER RES, V23, pS68
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2008, J BONE MINER RES, V23, P1061, DOI [10.1359/jbmr.080232, 10.1359/JBMR.080232]
   Delmas PD, 2005, J BONE MINER RES, V20, P557, DOI 10.1359/JBMR.041214
   Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000053299
   Downey TW, 2006, SOUTH MED J, V99, P570, DOI 10.1097/01.smj.0000221637.90495.66
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Ettinger B, 1998, AM J MANAG CARE, V4, P1377
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Halleux C., 2009, Journal of Bone and Mineral Research, V24
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   HAUSEN H, 1967, SKLEROSTEOSE, P351
   Kanis J.A., 2007, BEHALF WHO SCI GROUP
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kiebzak GM, 2002, ARCH INTERN MED, V162, P2217, DOI 10.1001/archinte.162.19.2217
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198 004 1636 z
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415
   Lewiecki EM, 2010, J CLIN DENSITOM, V13, P1, DOI 10.1016/j.jocd.2009.12.003
   Lewiecki EM, 2009, EXPERT OPIN EMERG DR, V14, P129, DOI [10.1517/14728210902766813 , 10.1517/14728210902766813]
   LI C, 2010, J BONE MINER RES, V24
   Li X., 2009, J BONE MINER RES, V24
   LI X, 2008, J BONE MINER RES S, V23, pS60
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin CJ, 2009, J GASTROEN HEPATOL, V24, pA116
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niikura T, 2006, J ORTHOP RES, V24, P1463, DOI 10.1002/jor.20182
   OMINSKY M, 2009, J BONE MINER RES, V24
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D., 2010, J Bone Miner Res
   Panneman MJM, 2004, OSTEOPOROSIS INT, V15, P120, DOI 10.1007/s00198 003 1544 7
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rey JP, 2010, DEV DYNAM, V239, P102, DOI 10.1002/dvdy.22181
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rubin MR, 2003, CLIN GERIATR MED, V19, P415, DOI 10.1016/S0749 0690(02)00074 5
   Silverman SL, 2008, J BONE MINER RES, V23, pS472
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Solomon DH, 2003, AM J MED, V115, P398, DOI 10.1016/S0002 9343(03)00357 7
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267
   SUGIURA Y, 1975, J BONE JOINT SURG AM, VA 57, P273, DOI 10.2106/00004623 197557020 00026
   Tacconi P, 1998, CLIN GENET, V53, P497
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   TRUSWELL AS, 1958, J BONE JOINT SURG BR, V40, P208, DOI 10.1302/0301 620X.40B2.208
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vestergaard P, 2005, OSTEOPOROSIS INT, V16, P134, DOI 10.1007/s00198 004 1680 8
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
NR 94
TC 35
Z9 61
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JAN
PY 2011
VL 11
IS 1
BP 117
EP 127
DI 10.1517/14712598.2011.540565
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 691BV
UT WOS:000285056200012
PM 21114421
DA 2025 08 17
ER

PT J
AU Simonetti, M
   Agarwal, N
   Stösser, S
   Bali, KK
   Karaulanov, E
   Kamble, R
   Pospisilova, B
   Kurejova, M
   Birchmeier, W
   Niehrs, C
   Heppenstall, P
   Kuner, R
AF Simonetti, Manuela
   Agarwal, Nitin
   Stoesser, Sebastian
   Bali, Kiran Kumar
   Karaulanov, Emil
   Kamble, Rashmi
   Pospisilova, Blanka
   Kurejova, Martina
   Birchmeier, Walter
   Niehrs, Christof
   Heppenstall, Paul
   Kuner, Rohini
TI Wnt Fzd Signaling Sensitizes Peripheral Sensory Neurons via Distinct
   Noncanonical Pathways
SO NEURON
LA English
DT Article
ID CONDITIONAL GENE DELETION; BONE CANCER PAIN; CATENIN; PATHOGENESIS;
   MECHANISMS; EXPRESSION; MUTATIONS; RECEPTORS; PROTEINS; BEHAVIOR
AB Wnt signaling represents a highly versatile signaling system, which plays diverse and critical roles in various aspects of neural development. Sensory neurons of the dorsal root ganglia require Wnt signaling for initial cell fate determination as well as patterning and synapse formation. Here we report that Wnt signaling pathways persist in adult sensory neurons and play a functional role in their sensitization in a pathophysiological context. We observed that Wnt3a recruits the Wnt calcium signaling pathway and the Wnt planar cell polarity pathway in peripheral nerves to alter pain sensitivity in a modality specific manner and we elucidated underlying mechanisms. In contrast, biochemical, pharmacological, and genetic studies revealed lack of functional relevance for the classical canonical beta catenin pathway in peripheral sensory neurons in acute modulation of nociception. Finally, this study provides proof of concept for a translational potential for Wnt3a Frizzled3 signaling in alleviating disease related pain hypersensitivity in cancer associated pain in vivo.
C1 [Simonetti, Manuela; Agarwal, Nitin; Stoesser, Sebastian; Bali, Kiran Kumar; Kamble, Rashmi; Pospisilova, Blanka; Kurejova, Martina; Kuner, Rohini] Heidelberg Univ, Inst Pharmacol, D 69120 Heidelberg, Germany.
   [Karaulanov, Emil; Niehrs, Christof] IMB, D 55128 Mainz, Germany.
   [Birchmeier, Walter] Max Delbruck Ctr Mol Med MDC, D 13092 Berlin, Germany.
   [Niehrs, Christof] DKFZ ZMBH Alliance, Div Mol Embryol, D 69120 Heidelberg, Germany.
   [Heppenstall, Paul] European Mol Biol Lab, I 00015 Monterotondo, Italy.
   [Simonetti, Manuela; Bali, Kiran Kumar; Heppenstall, Paul; Kuner, Rohini] Otto Meyerhof Ctr, Mol Med Partnership Unit, D 69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Institute of Molecular Biology
   (IMB); Helmholtz Association; Max Delbruck Center for Molecular
   Medicine; Helmholtz Association; German Cancer Research Center (DKFZ);
   European Molecular Biology Laboratory (EMBL)
RP Simonetti, M (通讯作者)，Heidelberg Univ, Inst Pharmacol, Neuenheimer Feld 366, D 69120 Heidelberg, Germany.
EM manuela.simonetti@pharma.uni heidelberg.de;
   rohini.kuner@pharma.uni heidelberg.de
RI Kuner, Rohini/AGU 0204 2022; Simonetti, Manuela/IAN 9449 2023; Bali,
   Kiran/F 6828 2013
OI Bali, Kiran/0000 0002 9503 1402; Simonetti, Manuela/0000 0003 0056 7595
FU Association of International Cancer Research; ERC advanced Investigator
   grant from the European Research Council (ERC) [294293]; CellNetworks
   Postdoctoral Fellowship program; European Research Council (ERC)
   [294293] Funding Source: European Research Council (ERC)
FX The authors thank Rose LeFaucheur for secretarial help, Hans Joseph
   Wrede, Karin Meyer, Nadine Gehrig, and Dunja Baumgartner Ahlert for
   technical assistance. The authors thank Stefano Piccolo, University of
   Padua, Italy for kindly providing BAT GAL mice and David Julius, UCSF,
   USA for generously providing the TRPV1 antibody. The authors acknowledge
   core facilities of the University and the DKFZ Heidelberg for their
   microarray and sequencing services. This work was supported by grants
   from the Association of International Cancer Research and an ERC
   advanced Investigator grant 294293 from the European Research Council
   (ERC) to R. K. R. K. is a principal investigator in the Excellence
   Cluster CellNetworks of Heidelberg University and M. S. was supported by
   the CellNetworks Postdoctoral Fellowship program.
CR Agarwal N, 2004, GENESIS, V38, P122, DOI 10.1002/gene.20010
   Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Budnik V, 2011, CURR OPIN NEUROBIOL, V21, P151, DOI 10.1016/j.conb.2010.12.002
   Cain DM, 2001, J NEUROSCI, V21, P9367, DOI 10.1523/JNEUROSCI.21 23 09367.2001
   Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106
   Durand J, 2011, J CLIN ENDOCR METAB, V96, pE1206, DOI 10.1210/jc.2010 2143
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208
   Hartmann B, 2004, NEURON, V44, P637, DOI 10.1016/j.neuron.2004.10.029
   Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092 8674(01)00336 1
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Kaan TKY, 2010, BRAIN, V133, P2549, DOI 10.1093/brain/awq194
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Koltzenburg M, 1997, J NEUROPHYSIOL, V78, P1841, DOI 10.1152/jn.1997.78.4.1841
   Komekado H, 2007, GENES CELLS, V12, P521, DOI 10.1111/j.1365 2443.2007.01068.x
   Komiya Yuko, 2008, Organogenesis, V4, P68
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959 4388(00)00100 8
   Petrus M, 2007, MOL PAIN, V3, DOI 10.1186/1744 8069 3 40
   Schweizerhof M, 2009, NAT MED, V15, P802, DOI 10.1038/nm.1976
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Stösser S, 2010, PAIN, V148, P206, DOI 10.1016/j.pain.2009.09.024
   Tsuda M, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20 15 j0007.2000
   Yuan SB, 2012, J NEUROIMMUNE PHARM, V7, P904, DOI 10.1007/s11481 012 9370 3
   Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893
   Zhang YK, 2013, J CLIN INVEST, V123, P2268, DOI 10.1172/JCI65364
   Zurborg S, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 66
NR 32
TC 70
Z9 77
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896 6273
EI 1097 4199
J9 NEURON
JI Neuron
PD JUL 2
PY 2014
VL 83
IS 1
BP 104
EP 121
DI 10.1016/j.neuron.2014.05.037
PG 18
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA AN3HJ
UT WOS:000340476800011
PM 24991956
OA Bronze
DA 2025 08 17
ER

PT J
AU Mikusková, K
   Vanuga, P
   Adamicová, K
   Statelová, D
   Janicková, M
   Malachovsky, I
   Siebert, T
AF Mikuskova, Katarina
   Vanuga, Peter
   Adamicova, Katarina
   Statelova, Dagmar
   Janickova, Maria
   Malachovsky, Igor
   Siebert, Tomas
TI Multiple idiopathic external cervical root resorption in patient treated
   continuously with denosumab: a case report
SO BMC ORAL HEALTH
LA English
DT Article
DE External cervical root resorption; Denosumab; Bone turnover;
   Osteoporosis; Antiresorptive therapy
ID OSTEOCLAST DIFFERENTIATION; RANKL; DISCONTINUATION
AB Background External root resorption is an irreversible loss of dental hard tissue as a result of odontoclastic action. Multiple external cervical root resorptions in permanent teeth are rare. The exact cause of external cervical root resorption is unclear. It is currently well established that RANK/RANKL signaling is essential for osteoclastogenesis and osteoclast mediated bone resorption. Denosumab is an anti RANKL antibody used for the treatment of postmenopausal osteoporosis. RANK/RANKL pathway suppression by denosumab is expected to suppress the activity of clastic cells responsible for hard tissue resorption involving both osteoclasts and odontoclasts. Case presentation This case report demonstrates aggressive and generalized idiopathic external cervical root resorption that started and advanced during ongoing antiresorptive therapy with the human monoclonal RANKL blocking antibody denosumab without discontinuation of therapy in a 74 year old female patient treated for postmenopausal osteoporosis. The extent of resorptive defects was too large and progressively led to fractures of the teeth. The number of teeth involved and the extend of destruction excluded conservative treatment. The affected teeth had to be extracted for functional prosthetic reconstruction. Conclusions This finding suggests that treatment with denosumab may be associated with severe and aggressive odontoclastic resorption of multiple dental roots despite an adequate inhibitory effect on osteoclasts in the treatment of osteoporosis. The RANKL independent pathways of clastic cell formation are likely to be involved in this pathological process.
C1 [Mikuskova, Katarina; Statelova, Dagmar; Janickova, Maria; Malachovsky, Igor; Siebert, Tomas] Comenius Univ, Univ Hosp, Jessenius Fac Med Martin, Dept Stomatol & Maxillofacial Surg, Kollarova 2, Martin 03601, Slovakia.
   [Vanuga, Peter] Natl Inst Endocrinol & Diabetol, Kollarova 282 3, Lubochna 03491, Slovakia.
   [Adamicova, Katarina] Comenius Univ, Univ Hosp, Jessenius Fac Med Martin, Dept Pathol, Kollarova 2, Martin 03601, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava
RP Siebert, T (通讯作者)，Comenius Univ, Univ Hosp, Jessenius Fac Med Martin, Dept Stomatol & Maxillofacial Surg, Kollarova 2, Martin 03601, Slovakia.
EM tomas.siebert@uniba.sk
RI Janickova, Maria/X 6194 2018
OI Janickova, Maria/0000 0003 1819 7780; Siebert, Tomas/0000 0003 4676 1035
CR Abass S.e., 2007, SEMIN ORTHOD, V13, P246, DOI [10.1053/j.sodo.2007.08.006, DOI 10.1053/J.SODO.2007.08.006]
   Alyahya L, 2021, J ENDODONT, V47, P366, DOI 10.1016/j.joen.2020.12.011
   [Anonymous], 1930, J AM DENT ASSOC, DOI DOI 10.14219/JADA.ARCHIVE.1930.0051
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Chang YC, 2012, J DENT SCI, V7, P395, DOI 10.1016/j.jds.2012.04.001
   Chen YM, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00121 9
   Christian M, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14484
   Chu EY, 2021, FRONT DENT MED, V2, DOI 10.3389/fdmed.2021.652605
   Consolaro Alberto, 2016, Dental Press J. Orthod., V21, P19
   Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492
   Deeb JG, 2019, J ENDODONT, V45, P640, DOI 10.1016/j.joen.2019.02.013
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Edwards PC, 2005, ORAL SURG ORAL MED O, V100, P585, DOI 10.1016/j.tripleo.2005.02.069
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Fukushima H, 2003, EUR J ORAL SCI, V111, P346, DOI 10.1034/j.1600 0722.2003.00051.x
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gabay E, 2010, ORAL SURG ORAL MED O, V110, pE75, DOI 10.1016/j.tripleo.2010.04.002
   Iwamatsu Kobayashi Y, 2005, ORAL SURG ORAL MED O, V100, P772, DOI 10.1016/j.tripleo.2004.11.047
   Jebril A, 2020, J ENDODONT, V46, P778, DOI 10.1016/j.joen.2020.03.006
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Liang H, 2003, DENTOMAXILLOFAC RAD, V32, P150, DOI 10.1259/dmfr/12925020
   Lossdörfer S, 2002, CALCIFIED TISSUE INT, V71, P45, DOI 10.1007/s00223 001 2086 7
   Mavridou AM, 2016, J ENDODONT, V42, P1737, DOI 10.1016/j.joen.2016.06.007
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   Mona M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063181
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   Ohori F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031130
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Patel J, 2019, BRIT DENT J, V227, P695, DOI 10.1038/s41415 019 0781 x
   Patel S, 2018, INT ENDOD J, V51, P1205, DOI 10.1111/iej.12942
   Patel S, 2015, J ENDODONT, V41, P742, DOI 10.1016/j.joen.2015.01.035
   Pichardo Sarina E C, 2020, Oral Surg Oral Med Oral Pathol Oral Radiol, V129, P411, DOI 10.1016/j.oooo.2019.09.010
   Rao S, 2018, TRENDS CELL BIOL, V28, P213, DOI 10.1016/j.tcb.2017.11.001
   Gonzales JR, 2007, ORAL SURG ORAL MED O, V104, pE70, DOI 10.1016/j.tripleo.2007.01.023
   Roig M, 2010, ORAL SURG ORAL MED O, V110, pE64, DOI 10.1016/j.tripleo.2010.03.006
   Rosenberg SA, 2021, OR SURG OR MED OR PA, V131, P422, DOI 10.1016/j.oooo.2020.12.001
   Schriber M, 2020, INT J ORAL MAX SURG, V49, P666, DOI 10.1016/j.ijom.2019.09.016
   Melo SLS, 2017, AM J ORTHOD DENTOFAC, V151, P1073, DOI 10.1016/j.ajodo.2016.10.041
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tunçer NI, 2019, AM J ORTHOD DENTOFAC, V156, P137, DOI 10.1016/j.ajodo.2019.02.012
   Wang Z, 2011, ORAL DIS, V17, P129, DOI 10.1111/j.1601 0825.2010.01718.x
NR 42
TC 12
Z9 12
U1 2
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD APR 15
PY 2022
VL 22
IS 1
AR 129
DI 10.1186/s12903 022 02165 7
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 0N3UW
UT WOS:000782767900003
PM 35428235
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ruiz Gómez, G
   Salbach Hirsch, J
   Dürig, JN
   Köhler, L
   Balamurugan, K
   Rother, S
   Heidig, SL
   Moeller, S
   Schnabelrauch, M
   Furesi, G
   Pählig, S
   Guillem Gloria, PM
   Hofbauer, C
   Hintze, V
   Pisabarro, MT
   Rademann, J
   Hofbauer, LC
AF Ruiz Gomez, Gloria
   Salbach Hirsch, Juliane
   Duerig, Jan Niklas
   Koehler, Linda
   Balamurugan, Kanagasabai
   Rother, Sandra
   Heidig, Sophie Luise
   Moeller, Stephanie
   Schnabelrauch, Matthias
   Furesi, Giulia
   Paehlig, Sophie
   Guillem Gloria, Pedro M.
   Hofbauer, Christine
   Hintze, Vera
   Pisabarro, M. Teresa
   Rademann, Joerg
   Hofbauer, Lorenz C.
TI Rational engineering of glycosaminoglycan based Dickkopf 1 scavengers to
   improve bone regeneration
SO BIOMATERIALS
LA English
DT Article
DE Bone healing; De novo rational design; Pharmacophore modeling;
   Dickkopf 1; Glycosaminoglycans; WNT signaling
ID FORCE FIELD; ACCURATE DOCKING; BINDING; SCLEROSTIN; ROMOSOZUMAB;
   DERIVATIVES; PARAMETERS; STRENGTH; COMPLEX; DOMAIN
AB The WNT signaling pathway is a central regulator of bone development and regeneration. Functional alterations of WNT ligands and inhibitors are associated with a variety of bone diseases that affect bone fragility and result in a high medical and socioeconomic burden. Hence, this cellular pathway has emerged as a novel target for bone protective therapies, e.g. in osteoporosis. Here, we investigated glycosaminoglycan (GAG) recognition by Dickkopf 1 (DKK1), a potent endogenous WNT inhibitor, and the underlying functional implications in order to develop WNT signaling regulators. In a multidisciplinary approach we applied in silico structure based de novo design strategies and molecular dynamics simulations combined with synthetic chemistry and surface plasmon resonance spectroscopy to Rationally Engineer oligomeric Glycosaminoglycan derivatives (REGAG) with improved neutralizing properties for DKK1. In vitro and in vivo assays show that the GAG modification to obtain REGAG translated into increased WNT pathway activity and improved bone regeneration in a mouse calvaria defect model with critical size bone lesions. Importantly, the developed REGAG outperformed polymeric high  sulfated hyaluronan (sHA3) in enhancing bone healing up to 50% due to their improved DKK1 binding prop erties. Thus, rationally engineered GAG variants may represent an innovative strategy to develop novel thera peutic approaches for regenerative medicine.
C1 [Ruiz Gomez, Gloria; Balamurugan, Kanagasabai; Heidig, Sophie Luise; Guillem Gloria, Pedro M.; Pisabarro, M. Teresa] Tech Univ Dresden, Struct Bioinformat, BIOTEC, Tatzberg 47 51, D 01307 Dresden, Germany.
   [Salbach Hirsch, Juliane; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.
   [Duerig, Jan Niklas; Rademann, Joerg] Free Univ Berlin, Inst Pharm Med Chem, Konigin Luise Str 2 4, D 14195 Berlin, Germany.
   [Koehler, Linda; Rother, Sandra; Hintze, Vera] Tech Univ Dresden, Inst Mat Sci, Max Bergmann Ctr Biomat, Budapester Str 27, D 01069 Dresden, Germany.
   [Moeller, Stephanie; Schnabelrauch, Matthias] INNOVENT e V, Biomat Dept, D 07745 Jena, Germany.
   [Hofbauer, Christine] Tech Univ Dresden, Univ Canc Ctr Dresden, Natl Ctr Tumor Dis, Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Fetscherstr 105, D 01307 Dresden, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Fetscherstr 74, D 01307 Dresden, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
   [Hintze, Vera] Tech Univ Dresden, Inst Mat Sci, Max Bergmann Ctr Biomat, Budapester Str 27, D 01069 Dresden, Germany.
   [Rother, Sandra] Saarland Univ, Ctr Mol Signaling PZMS, Sch Med, Kirrberger Str, D 66421 Homburg, Germany.
   [Furesi, Giulia] Washington Univ St Louis, Sch Med, Dept Orthoped, 660 S Euclid Ave, St Louis, MO 63130 USA.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Free
   University of Berlin; Technische Universitat Dresden; Technische
   Universitat Dresden; Technische Universitat Dresden; Technische
   Universitat Dresden; Technische Universitat Dresden; Technische
   Universitat Dresden; Universitatsklinikum des Saarlandes; Washington
   University (WUSTL)
RP Pisabarro, MT (通讯作者)，Tech Univ Dresden, Struct Bioinformat, BIOTEC, Tatzberg 47 51, D 01307 Dresden, Germany.; Rademann, J (通讯作者)，Free Univ Berlin, Inst Pharm Med Chem, Konigin Luise Str 2 4, D 14195 Berlin, Germany.; Hofbauer, LC (通讯作者)，Tech Univ Dresden, Ctr Hlth Aging, Fetscherstr 74, D 01307 Dresden, Germany.; Hofbauer, LC (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.; Hintze, V (通讯作者)，Tech Univ Dresden, Inst Mat Sci, Max Bergmann Ctr Biomat, Budapester Str 27, D 01069 Dresden, Germany.
EM vera.hintze@tu dresden.de; maria_teresa.pisabarro@tu dresden.de;
   joerg.rademann@fu berlin.de; lorenz.hofbauer@ukdd.de
RI ; Salbach Hirsch, Juliane/ABE 4830 2021; Rademann, Jörg/F 4893 2017;
   Hofbauer, Lorenz C./G 2490 2010; Salbach Hirsch, Juliane/H 9409 2013;
   Guillem Gloria, Pedro Manuel/ADX 9518 2022; Rother,
   Sandra/JWA 0289 2024; Hofbauer, Lorenz/G 2490 2010; Pisabarro,
   M./D 4270 2012
OI Guillem Gloria, Pedro Manuel/0000 0003 0808 0044; Pisabarro, Maria
   Teresa/0000 0002 5175 9311; Heidig, Sophie Luise/0000 0002 2251 9060;
   Hintze, Vera/0000 0002 5611 9903; Hofbauer, Lorenz
   C./0000 0002 8691 8423; Rother, Sandra/0000 0003 0631 752X;
   Salbach Hirsch, Juliane/0000 0001 7097 9953; Furesi,
   Giulia/0000 0002 4542 1955; 
FU German Research Council [DFG SFB TRR67 59307082]; MeDDrive; women's
   Habilitation program of the medical faculty of the TU Dresden;  [DFG PI
   600/3 1]
FX This work was funded by the German Research Council: DFG SFB TRR67
   59307082 (subprojects A3, A7, A8, B2, Z3) and DFG PI 600/3 1. JSH was
   further supported by the MeDDrive and the women's Habilitation program
   of the medical faculty of the TU Dresden.
CR A.S. Inc, 2012, Discovery studio modeling environment, release 3.5, Accelrys Discovery Studio
   Ahn VE, 2011, DEV CELL, V21, P862, DOI 10.1016/j.devcel.2011.09.003
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   [Anonymous], 2019, SCHROD REL 2019 4 20
   Berryman J.T., 2015, AMBER 2015
   Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476 5381.2009.00190.x
   Chen S, 2011, DEV CELL, V21, P848, DOI 10.1016/j.devcel.2011.09.007
   Cheng ZH, 2011, NAT STRUCT MOL BIOL, V18, P1204, DOI 10.1038/nsmb.2139
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822 006 9087 6
   Donnelly PS, 2008, CHEM COMMUN, P2459, DOI 10.1039/b719724a
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hintze V, 2014, BIOMACROMOLECULES, V15, P3083, DOI 10.1021/bm5006855
   Hintze V, 2009, BIOMACROMOLECULES, V10, P3290, DOI 10.1021/bm9008827
   Hirai H, 2019, NAT STRUCT MOL BIOL, V26, P372, DOI 10.1038/s41594 019 0216 z
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Hsu M. N., MOL THER
   HUIGE CJM, 1995, J COMPUT CHEM, V16, P56, DOI 10.1002/jcc.540160106
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kanis JA, 2017, OSTEOPOROSIS INT, V28, P2023, DOI 10.1007/s00198 017 4009 0
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   Koehler L., SCI REP UK, P9
   Köhling S, 2016, CHEM EUR J, V22, P5563, DOI 10.1002/chem.201504459
   Köhling S, 2019, CHEM SCI, V10, P866, DOI 10.1039/c8sc03649g
   Kunze R, 2010, GLYCOCONJUGATE J, V27, P151, DOI 10.1007/s10719 009 9270 9
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Molecular Operating Environment (MOE), 2016, US
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   Okuchi Y, 2021, NAT MATER, V20, P108, DOI 10.1038/s41563 020 0786 5
   Ominsky MS, 2017, J BONE MINER RES, V32, P788, DOI 10.1002/jbmr.3036
   Origin, 2019, MESQUITE MODULAR SYS
   Picke AK, 2016, BIOMATERIALS, V96, P11, DOI 10.1016/j.biomaterials.2016.04.013
   Rauner M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040787
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Salbach J, 2012, BIOMATERIALS, V33, P8418, DOI 10.1016/j.biomaterials.2012.08.028
   Salbach Hirsch J, 2021, BIOL CHEM, V402, P1415, DOI 10.1515/hsz 2021 0174
   Salbach Hirsch J, 2015, BIOMATERIALS, V67, P335, DOI 10.1016/j.biomaterials.2015.07.021
   Samsonraj RM, 2017, TISSUE ENG PART C ME, V23, P686, DOI [10.1089/ten.tec.2017.0205, 10.1089/ten.TEC.2017.0205]
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Schrodinger L., 2021, PyMol molecular graphics system
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822 007 9133 z
   Sonavane P.R., 2021, CONTROLLING WNT SIGN, P3
   Tsourdi E, 2014, J BIOACT COMPAT POL, V29, P474, DOI 10.1177/0883911514546983
   van der Smissen A, 2013, ACTA BIOMATER, V9, P7775, DOI 10.1016/j.actbio.2013.04.023
   Veverka V., J BIOL CHEM
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
NR 53
TC 2
Z9 2
U1 0
U2 14
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2023
VL 297
AR 122105
DI 10.1016/j.biomaterials.2023.122105
EA APR 2023
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA F2OA6
UT WOS:000980778000001
PM 37031548
DA 2025 08 17
ER

PT J
AU Takita, M
   Inada, M
   Miyaura, C
AF Takita, Morichika
   Inada, Masaki
   Miyaura, Chisato
TI Capsaicin, a ligand for vanilloid receptor 1, transduces suppressive
   signal for osteoclast differentiation in bone
SO JOURNAL OF HEALTH SCIENCE
LA English
DT Article
DE vanilloid receptor 1; bone; capsaicin; osteoclast formation; bone
   resorption
ID RESORPTION; ACTIVATION; MACROPHAGES; INDUCTION; CHANNELS; PEPPERS
AB Vanilloid receptor 1 (VR1) has been reported to exhibit multiple functions which can transduce pain sensitive signals in nerve systems. A VR1 ligand, capsaicin, has been reported to show activities against inflammation and cancer growth, however, its role in bone metabolism is still unknown. Here, we examined the effect of capsaicin on cytokine induced inflammatory bone resorption. Capsaicin suppressed interleukin 1 induced bone resorption in a mouse calvarial organ ex vivo culture in a dose dependent manner. An assay using cocultures of osteoblasts and bone marrow cells clearly showed the inhibition of osteoclast formation by treatment with capsaicin. Receptor activator of NF kappa B ligand (RANKL), the sole inducer of osteoclast formation, is known to be produced by osteoblasts. In the cocultures of bone marrow cells and osteoblasts, the expression of RANKL was suppressed by capsaicin. VR1 showed expression predominantly in osteoblasts, suggesting that capsaicin directly modulates osteoclast differentiation through the suppression of RANKL expression. VR1 ligands like capsaicin have the potential for use as clinical drugs targeting some bone diseases involving cytokine induced bone resorption.
C1 Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan.
C3 Tokyo University of Agriculture & Technology
RP Miyaura, C (通讯作者)，Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2 24 16 Nakamachi, Koganei, Tokyo 1848588, Japan.
EM miyaura@cc.tuat.ac.jp
RI miyaura, chisato/D 1864 2013; Takita, Morichika/I 2927 2019; inada,
   masaki/D 1581 2013
OI inada, masaki/0000 0002 5066 8506
CR Adam C, 2000, EXP PHYSIOL, V85, P61, DOI 10.1111/j.1469 445X.2000.01930.x
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Chen CW, 2003, BRIT J PHARMACOL, V140, P1077, DOI 10.1038/sj.bjp.0705533
   Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196
   Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076
   DSOUZA SM, 1986, ENDOCRINOLOGY, V119, P58, DOI 10.1210/endo 119 1 58
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306 4522(91)90094 5
   Ikegame M, 2004, BONE, V35, P27, DOI 10.1016/j.bone.2004.03.018
   Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959 4388(03)00101 6
   Kim CS, 2003, CELL SIGNAL, V15, P299, DOI 10.1016/S0898 6568(02)00086 4
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   O'Connell PJ, 2005, FEBS LETT, V579, P5135, DOI 10.1016/j.febslet.2005.08.023
   Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141
   Sancho R, 2002, EUR J IMMUNOL, V32, P1753, DOI 10.1002/1521 4141(200206)32:6<1753::AID IMMU1753>3.0.CO;2 2
   Suzuki K, 2006, J PHARMACOL SCI, V100, P189, DOI 10.1254/jphs.FMJ05004X2
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   ZAIDI M, 1987, CALCIFIED TISSUE INT, V40, P149, DOI 10.1007/BF02555699
NR 19
TC 0
Z9 0
U1 0
U2 2
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 1344 9702
EI 1347 5207
J9 J HEALTH SCI
JI J. Health Sci.
PD APR
PY 2007
VL 53
IS 2
BP 240
EP 244
DI 10.1248/jhs.53.240
PG 5
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA 166OC
UT WOS:000246387400015
OA Bronze
DA 2025 08 17
ER

PT J
AU Wei, Q
   Niu, ZC
   Fu, XY
   Ouyang, MH
   Guo, XT
   Li, J
   Chang, YX
   Mao, HP
   Gao, XM
AF Wei, Qiu
   Niu, Zi Chang
   Fu, Xiao Yu
   Ouyang, Ming Hui
   Guo, Xiao Tong
   Li, Jin
   Chang, Yan Xu
   Mao, Hao Ping
   Gao, Xiu Mei
TI S6K/FLNC/ITG(33 signaling pathway regulates osteoclastogenesis and the
   inhibition of osteoclastogenesis by columbianadin
SO PHYTOMEDICINE
LA English
DT Article
DE Filamin c; Osteoclast; Osteoporosis; Columbianadin
ID FILAMIN BINDING
AB Background: Over activation of osteoclastogenesis is a significant factor contributing to bone loss, leading to increased resorption of bone. Columbianadin (CBN), a compound derived from Angelicae Pubescentis Radix, has traditionally been used in Chinese medicine to treat bone related disorders. However, the specific effects of CBN on bone loss are still poorly understood. Study design: This study aims to identify a novel target for inhibiting osteoclast differentiation and to elucidate the effects and underlying mechanisms of CBN on osteoclastogenesis. Methods: We employed a transcriptomics approach to identify genes that undergo significant changes during osteoclast differentiation. These findings were validated using reverse transcription polymerase chain reaction (RT PCR) and Western blot (WB) analysis. Subsequently, we utilized adenoviral transfection to investigate the effects of target genes on osteoclast differentiation. Additionally, we employed proteomics to elucidate the signaling pathways that regulate osteoclast differentiation. We examined the effect of CBN on S6K/FLNC/ITG(33 signaling pathway and osteoclast differentiation. Results: Our results revealed a dramatic increase in filamin C (FLNC) levels during osteoclast differentiation. Inhibition of FLNC expression significantly suppressed markers of osteoclast differentiation such as tartrateresistant acid phosphatase (TRAP), nuclear factor activated T cell 1 (NFATc1), and c Fos, as well as inhibited the activity of bone resorption. We further conducted a proteomic analysis and found S6 K protein might be involved in this process. Then we utilized an S6K specific inhibitor (PF 4,708,671) and demonstrated that inhibiting the S6 K protein reduced FLNC expression and the interaction between FLNC and integrin (33 (ITG(33) in osteoclasts. Finally, we found that CBN inhibited osteoclast differentiation and bone loss in ovariectomized mice by targeting the S6K/FLNC/ITG(33 signaling pathway. Conclusion: FLNC was identified as a critical protein in osteoclastogenesis. The S6K/FLNC/ITG(33 signaling pathway played a significant role in osteoclast differentiation and bone loss. Furthermore, CBN exhibited antiosteoporotic effects by inhibiting the S6K/FLNC/ITG(33 signaling pathway.
C1 [Wei, Qiu; Fu, Xiao Yu; Ouyang, Ming Hui; Guo, Xiao Tong; Li, Jin; Mao, Hao Ping; Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin 301617, Peoples R China.
   [Wei, Qiu; Fu, Xiao Yu; Ouyang, Ming Hui; Guo, Xiao Tong; Li, Jin; Chang, Yan Xu; Mao, Hao Ping; Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
   [Niu, Zi Chang] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 1, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine; Tianjin University of Traditional
   Chinese Medicine
RP Mao, HP; Gao, XM (通讯作者)，Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin 301617, Peoples R China.; Chang, YX; Mao, HP; Gao, XM (通讯作者)，Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
EM Tcmcyx@tjutcm.edu.cn; maohaoping@tjutcm.edu.cn; gaoxiumei@tjutcm.edu.cn
RI mao, haoping/KIH 6773 2024; GAO, Xiumei/IWD 8697 2023; Wei,
   qiu/MGW 5625 2025
FU National Key R&D Program of China [2022YFC3500300, 2022YFC3500305];
   National Natural Science Foundation of China [81630106, 82474073]; Key
   Projects of the Tianjin Education Commission's Research Program
   [2021ZD007]
FX This work was supported by the National Key R&D Program of China
   (2022YFC3500300; 2022YFC3500305) , the National Natural Science
   Foundation of China (Grant No. 81630106; 82474073) , and the Key
   Projects of the Tianjin Education Commission's Research Program
   (2021ZD007) .
CR Akisaka T, 2019, CYTOSKELETON, V76, P303, DOI 10.1002/cm.21543
   Doms S, 2024, BONE RES, V12, DOI 10.1038/s41413 024 00343 7
   Dong XR, 2022, ACUPUNCT HERB MED, V2, P130, DOI 10.1097/HM9.0000000000000031
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Goldberg S, 2015, CALCIFIED TISSUE INT, V97, P113, DOI 10.1007/s00223 015 9994 4
   Henkels KM, 2015, FASEB J, V29, P1299, DOI 10.1096/fj.14 260992
   Jin SH, 2018, BMB REP, V51, P356, DOI 10.5483/BMBRep.2018.51.7.106
   Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011
   Leung R, 2010, J BONE MINER RES, V25, P1077, DOI 10.1359/jbmr.091114
   Li J, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/8568303
   Lim HJ, 2014, J ETHNOPHARMACOL, V155, P1353, DOI 10.1016/j.jep.2014.07.033
   Ortiz Genga MF, 2016, J AM COLL CARDIOL, V68, P2440, DOI 10.1016/j.jacc.2016.09.927
   Root SH, 2021, BLOOD ADV, V5, P4435, DOI 10.1182/bloodadvances.2021004552
   Rosa JP, 2019, BLOOD, V134, P1279, DOI 10.1182/blood.2019000014
   Su XL, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01522
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Truong T, 2015, INTEGR BIOL UK, V7, P1285, DOI 10.1039/c5ib00133a
   Verdonschot JAJ, 2020, HUM MUTAT, V41, P1091, DOI 10.1002/humu.24004
   Wilson SG, 2009, J BONE MINER RES, V24, P1989, DOI [10.1359/JBMR.090530, 10.1359/jbmr.090530]
   Xu QM, 2017, J GENET GENOMICS, V44, P335, DOI 10.1016/j.jgg.2017.04.007
   Yang CS, 2022, CELL SIGNAL, V90, DOI 10.1016/j.cellsig.2021.110191
   Zeidan A, 2011, MOL CELL BIOCHEM, V352, P99, DOI 10.1007/s11010 011 0744 2
   Zhao JY, 2024, ADV SCI, V11, DOI 10.1002/advs.202404518
NR 23
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2025
VL 136
AR 156276
DI 10.1016/j.phymed.2024.156276
EA NOV 2024
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA W0V5H
UT WOS:001415857600001
PM 39612888
DA 2025 08 17
ER

PT J
AU Sugie Oya, A
   Takakura, A
   Takao Kawabata, R
   Sano, H
   Shimazu, Y
   Isogai, Y
   Yamaguchi, A
   Ishizuya, T
AF Sugie Oya, Ayano
   Takakura, Aya
   Takao Kawabata, Ryoko
   Sano, Hiroko
   Shimazu, Yukari
   Isogai, Yukihiro
   Yamaguchi, Akira
   Ishizuya, Toshinori
TI Comparison of treatment effects of teriparatide and the bisphosphonate
   risedronate in an aged, osteopenic, ovariectomized rat model under
   various clinical conditions
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Teriparatide; Risedronate; Three times weekly; Ovariectomized rat; Drug
   mechanism
ID ONCE WEEKLY TERIPARATIDE; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   PARATHYROID HORMONE 1 34; BONE MINERAL DENSITY; HIGH FRACTURE RISK;
   POSTMENOPAUSAL OSTEOPOROSIS; BIOMECHANICAL PROPERTIES; VERTEBRAL
   FRACTURES; FEMORAL NECK; WOMEN
AB Teriparatide and bisphosphonates are osteoporosis medications that increase bone mineral density (BMD) and prevent fracture, but each has a different mechanism of action. Teriparatide promotes bone formation, while bisphosphonates suppress bone resorption. In the clinical setting, however, drug selection is not always tailored to the particular clinical condition of the patient or mechanism of action of the drug. We compared the effects of teriparatide and the bisphosphonate risedronate on bone metabolism using two ovariectomized rat models to elucidate the optimal use of these two drugs in the clinical setting. We first performed dose finding experiments to determine the equivalent effective doses of each drug (5.6 and 3.0 A mu g/kg for teriparatide and risedronate, respectively). We then compared the effects of these doses on bone metabolism after subcutaneous administration three times weekly for 4 months starting either the day after ovariectomy (preventive study) or 12 months after ovariectomy (therapeutic study). The increase in proximal tibial BMD under the physical conditions that increased bone turnover at 1 to 2 months after ovariectomy was greater in the risedronate group than in the teriparatide group. In contrast, the increases in lumbar vertebral BMD and bone strength under the physical conditions that significantly decreased BMD and bone strength at 12 months after ovariectomy were greater in the teriparatide group than in the risedronate group. The present study provides important information on the selection of antiosteoporotic drugs, including teriparatide and risedronate, in treatment protocols tailored to the clinical conditions of patients and drug mechanisms.
C1 [Sugie Oya, Ayano; Takakura, Aya; Takao Kawabata, Ryoko; Sano, Hiroko; Shimazu, Yukari; Isogai, Yukihiro; Ishizuya, Toshinori] Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Shizuoka 4102321, Japan.
   [Yamaguchi, Akira] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Tokyo, Japan.
C3 Asahi Kasei Pharma Corporation; Institute of Science Tokyo; Tokyo
   Medical & Dental University (TMDU)
RP Sugie Oya, A (通讯作者)，Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Shizuoka 4102321, Japan.
EM sugie.ab@om.asahi kasei.co.jp
RI Yamaguchi, Akira/AAX 9286 2020; Takao Kawabata, Ryoko/AGF 7646 2022
OI Takao Kawabata, Ryoko/0000 0002 6811 7526
FU Asahi Kasei Pharma Corp.
FX This study was funded by Asahi Kasei Pharma Corp. The authors thank
   Ichiro Ikegaki, VMD, and Hiroshi Kuriyama, VMD, for providing technical
   assistance and Ms. Masako Onotogi from Ina Research, Inc., for assisting
   with the animal management.
CR Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cree MW, 2003, OSTEOPOROSIS INT, V14, P722, DOI 10.1007/s00198 003 1430 3
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Eriksen EF, 2014, BONE, V67, P246, DOI 10.1016/j.bone.2014.07.014
   Fujita T, 1999, OSTEOPOROSIS INT, V9, P296, DOI 10.1007/s001980050151
   Hagino H, 2009, OSTEOPOROSIS INT, V20, P695, DOI 10.1007/s00198 008 0761 5
   Ito M, 2014, OSTEOPOROSIS INT, V25, P1163, DOI 10.1007/s00198 013 2596 y
   Iwaniec UT, 2001, BONE, V29, P352, DOI 10.1016/S8756 3282(01)00582 8
   Li CY, 2003, CALCIFIED TISSUE INT, V72, P42, DOI 10.1007/s00223 001 1086 y
   LI M, 1995, BONE, V16, P629, DOI 10.1016/8756 3282(95)00115 T
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Macedo JMS, 1998, J CLIN PHARM THER, V23, P345, DOI 10.1046/j.1365 2710.1998.00168.x
   Miki T, 2004, J BONE MINER METAB, V22, P569, DOI 10.1007/s00774 004 0525 z
   Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928
   MOLSTER AO, 1986, CLIN ORTHOP RELAT R, P278
   Mosekilde L, 1997, BONE, V20, P429, DOI 10.1016/S8756 3282(97)00024 0
   MOSEKILDE L, 1993, BONE, V14, P1, DOI 10.1016/8756 3282(93)90248 9
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ogura Y, 2004, J BONE MINER METAB, V22, P111, DOI 10.1007/s00774 003 0458 y
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P2197, DOI 10.1210/jc.85.6.2197
   QI H, 1995, J BONE MINER RES, V10, P948
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Samnegård E, 2001, BONE, V28, P414, DOI 10.1016/S8756 3282(01)00408 2
   Shiraki M, 2013, OSTEOPOROSIS INT, V24, P219, DOI 10.1007/s00198 012 2159 7
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   SOGAARD CH, 1994, ENDOCRINOLOGY, V134, P650, DOI 10.1210/en.134.2.650
   Sone T, 2014, BONE, V64, P75, DOI 10.1016/j.bone.2014.04.004
   Ste Marie LG, 2004, CALCIFIED TISSUE INT, V75, P469, DOI 10.1007/s00223 004 0039 7
   Sugimoto T, 2014, OSTEOPOROSIS INT, V25, P1173, DOI 10.1007/s00198 013 2516 1
   TSURUKAMI H, 1994, CALCIFIED TISSUE INT, V54, P142, DOI 10.1007/BF00296065
   UZAWA T, 1995, BONE, V16, P477
   WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823
NR 40
TC 12
Z9 15
U1 0
U2 7
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2016
VL 34
IS 3
BP 303
EP 314
DI 10.1007/s00774 015 0670 6
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA DJ9YE
UT WOS:000374568400006
PM 26104116
DA 2025 08 17
ER

PT J
AU Modarresi, R
   Xiang, ZY
   Yin, M
   Laurence, J
AF Modarresi, Rozbeh
   Xiang, Zhaoying
   Yin, Michael
   Laurence, Jeffrey
TI WNT/β Catenin Signaling Is Involved in Regulation of Osteoclast
   Differentiation by Human Immunodeficiency Virus Protease Inhibitor
   Ritonavir Relationship to Human Immunodeficiency Virus Linked Bone
   Mineral Loss
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID NF KAPPA B; HIV INFECTED PATIENTS; COLONY STIMULATING FACTOR; IN VITRO;
   RECEPTOR ACTIVATOR; BLOCKS OSTEOCLASTOGENESIS; ANTIRETROVIRAL THERAPY;
   GROWTH FACTOR; BETA CATENIN; CROSS TALK
AB Untreated human immunodeficiency virus (HIV) infection is accompanied by reduced bone mineral density, which appears to be exacerbated by certain HIV protease inhibitors (PIs). The mechanisms leading to this apparent paradox, however, remain unclear. We have previously shown that, the HIV envelope glycoprotein gp120 used at levels similar those in plasmas of untreated HIV+ patients, induced expression of the osteoclast (OC) differentiation factor RANKL in CD4+ T cells. in addition, the HIV PI ritonavir abrogated the interferon gamma mediated degradation of the RANKL nuclear adapter protein TRAF6, a physiological block to RANKL activity. Here, using oligonucleotide microarrays and quantitative polymerase chain reaction, we explored potential upstream mechanisms for these effects. Ritonavir, but not the HIV PIs indinavir or nelfinavir, up regulated the production of transcripts for OC growth factors and the non canonical Wnt Proteins 513 and 711 as well as activated promoters of nuclear factor kappa B signaling, but suppressed genes involved in canonical Wnt signaling. Similarly, ritonavir blocked the cytoplasmic to nuclear translocation of beta catenin, the molecular node of the Wnt signaling pathway, in association with enhanced beta catenin ubiquitination. Exposure of OC precursors to LiCl, an inhibitor of the canonical Wnt antagonist GSK 3 beta, suppressed OC differentiation, as did adenovirus mediated overexpression of beta catenin. These data identify, for the first time, a biologically relevant role for Wnt signaling via beta catenin in isolated OC precursors and the modulation of Wnt signaling by ritonavir. The reversal of these ritonavir mediated changes by interferon gamma provides a model for possible intervention in this metabolic complication of HIV therapy. (Am J Pathol 2009, 174:123 135; DOI: 10.2353/ajpath.2009.080484)
C1 [Laurence, Jeffrey] Cornell Univ, Weill Med Coll, Lab AIDS Virus Res, Div Hematol Oncol, New York, NY 10021 USA.
   [Xiang, Zhaoying] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
   [Yin, Michael] Columbia Univ, Coll Phys & Surg, New York, NY USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Columbia University
RP Laurence, J (通讯作者)，Cornell Univ, Weill Med Coll, Lab AIDS Virus Res, Div Hematol Oncol, 411 E 69th St, New York, NY 10021 USA.
EM jlaurenc@med.cornell.edu
OI Yin, Michael T/0000 0002 9346 9056
FU National Institutes of Health [DK65511, A165200, HL55646]; Angelo
   Donghia and Hagedorn Funds
FX Supported by the National Institutes of Health (grants DK65511, A165200,
   and HL55646) and the Angelo Donghia and Hagedorn Funds (to J.L.).
CR Adamopoulos IE, 2006, BIOCHEM BIOPH RES CO, V350, P478, DOI 10.1016/j.bbrc.2006.09.076
   André P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120
   Arnsten JH, 2007, AIDS, V21, P617, DOI 10.1097/QAD.0b013e3280148c05
   Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145
   Bai ST, 2005, J CLIN INVEST, V115, P2742, DOI 10.1172/JCI24921
   Bose S, 2004, BIOCHEM J, V378, P177, DOI 10.1042/BJ20031122
   Bouyer P, 2007, ENDOCRINOLOGY, V148, P831, DOI 10.1210/en.2006 0547
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Cheng SL, 2008, J BIOL CHEM, V283, P20505, DOI 10.1074/jbc.M800851200
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406
   Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Esser R, 1998, BLOOD, V91, P4752, DOI 10.1182/blood.V91.12.4752.412k06_4752_4760
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   FAKRUDDIN JM, 2005, 12 C RETR OPP INF FE
   FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Gorny G, 2004, EXP CELL RES, V294, P149, DOI 10.1016/j.yexcr.2003.11.009
   Hanriot D, 2008, THROMB HAEMOSTASIS, V99, P558, DOI 10.1160/TH07 06 0410
   Häusler KD, 2004, J BONE MINER RES, V19, P1873, DOI 10.1359/JBMR.040807
   Heink S, 2005, P NATL ACAD SCI USA, V102, P9241, DOI 10.1073/pnas.0501711102
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jain RG, 2002, J BIOL CHEM, V277, P19247, DOI 10.1074/jbc.C200069200
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030 200104130 00022
   Konishi M, 2005, AIDS, V19, P1240, DOI 10.1097/01.aids.0000176231.24652.02
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lagumdzija A, 2005, PEPTIDES, V26, P1661, DOI 10.1016/j.peptides.2005.02.007
   Laurence J, 2007, AM J PATHOL, V171, P1724, DOI 10.2353/ajpath.2007.070667
   Malizia AP, 2007, AIDS RES HUM RETROV, V23, P243, DOI 10.1089/aid.2006.0084
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Mbalaviele G, 1998, J CELL BIOL, V141, P1467, DOI 10.1083/jcb.141.6.1467
   Monaghan H, 2001, HISTOPATHOLOGY, V39, P611, DOI 10.1046/j.1365 2559.2001.01287.x
   Nakamura Y, 2005, AM J PATHOL, V167, P97, DOI 10.1016/S0002 9440(10)62957 4
   Nolan D, 2001, AIDS, V15, P1275, DOI 10.1097/00002030 200107060 00009
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Piliero PJ, 2002, AIDS, V16, P1565, DOI 10.1097/00002030 200207260 00019
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Rivas P, 2008, HIV MED, V9, P89, DOI 10.1111/j.1468 1293.2007.00525.x
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734
   SERRANO S, 1995, BONE, V16, P185, DOI 10.1016/8756 3282(94)00028 X
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200
   Yamada N, 2002, BONE, V30, P901, DOI 10.1016/S8756 3282(02)00722 6
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zhou HP, 2005, MOL PHARMACOL, V68, P690, DOI 10.1124/mol.105.012898
NR 60
TC 43
Z9 46
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2009
VL 174
IS 1
BP 123
EP 135
DI 10.2353/ajpath.2009.080484
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 391FO
UT WOS:000262219400013
PM 19095956
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Krause, U
   Ryan, DM
   Clough, BH
   Gregory, CA
AF Krause, U.
   Ryan, D. M.
   Clough, B. H.
   Gregory, C. A.
TI An unexpected role for a Wnt inhibitor: Dickkopf 1 triggers a novel
   cancer survival mechanism through modulation of aldehyde dehydrogenase 1
   activity
SO CELL DEATH & DISEASE
LA English
DT Article
DE osteosarcoma; Wnt signaling; Dkk 1; MOS J; ALDH1
ID MESENCHYMAL STEM CELLS; BETA CATENIN; OSTEOSARCOMA; METASTASIS;
   EXPRESSION; DKK1; DECREASES; SARCOMAS; TUMOR; MINERALIZATION
AB It is widely accepted that canonical Wnt (cWnt) signaling is required for the differentiation of osteoprogenitors into osteoblasts. Furthermore, tumor derived secretion of the cWnt antagonist Dickkopf 1 (Dkk 1) is known to cause bone destruction, inhibition of repair and metastasis in many bone malignancies, but its role in osteosarcoma (OS) is still under debate. In this study, we examined the role of Dkk 1in OS by engineering its overexpression in the osteochondral sarcoma line MOS J. Consistent with the known role of Dkk 1 in osteoblast differentiation, Dkk 1 inhibited osteogenesis by the MOSJ cells themselves and also in surrounding tissue when implanted in vivo. Surprisingly, Dkk 1 also had unexpected effects on MOSJ cells in that it increased proliferation and resistance to metabolic stress in vitro and caused the formation of larger and more destructive tumors than controls upon orthotopic implantation. These effects were attributed in part to upregulation of the stress response enzyme and cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1). Direct inhibition of ALDH1 reduced viability under stressful culture conditions, whereas pharmacological inhibition of cWnt or overexpression of ALDH1 had a protective effect. Furthermore, we observed that ALDH1 was transcriptionally activated in a c Jun dependent manner through a pathway consisting of RhoA, MAPkinase  kinase 4 and Jun N terminal Kinase (JNK), indicating that noncanonical planar cell polarity like Wnt signaling was the mechanism responsible. Together, our results therefore demonstrate that Dkk 1 enhances resistance of OS cells to stress by tipping the balance of Wnt signaling in favor of the non canonical Jun mediated Wnt pathways. In turn, this results in transcriptional activation of ALDH1 through Jun responsive promoter elements. This is the first report linking Dkk 1 to tumor stress resistance, further supporting the targeting of Dkk 1 not only to prevent and treat osteolytic bone lesions but also to reduce numbers of stress resistant tumor cells.
C1 [Krause, U.; Clough, B. H.; Gregory, C. A.] Scott & White Hosp, Inst Regenerat Med, Texas A&M Hlth Sci Ctr, Temple, TX USA.
   [Krause, U.] Scott & White Hosp, Dept Orthopaed, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA.
   [Ryan, D. M.] Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA.
   [Ryan, D. M.] Tulane Univ, Dept Med, Hlth Sci Ctr, New Orleans, LA 70118 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center; Tulane
   University; Tulane University
RP Gregory, CA (通讯作者)，Texas A&M Hlth Sci Ctr, Inst Regenerat Med, 5701 Airport Rd, Temple, TX 76502 USA.
EM cgregory@medicine.tamhsc.edu
OI Gregory, Carl/0000 0001 6444 5541
FU Institute for Regenerative Medicine Program Funds from Texas A&M Health
   Science Center; Start Up Funds from ScottWhite Hospital; NIH
   [R21DK071780, P20RR020152]; Louisiana Gene Therapy Research Consortium;
   Scott&White Hospital Research [90172]; International Myeloma Foundation
FX We thank Katie Coble, BS, and Joni Ylostalo, PhD, for help with the
   microarray analysis, Kent Claypool, BS, for assistance with cell
   sorting, and Ludvik R. Donner, MD/PhD, for expert advice on tumor
   histology. This project was funded in part by The Institute for
   Regenerative Medicine Program Funds from Texas A&M Health Science Center
   and Start Up Funds from Scott&White Hospital, NIH Grants R21DK071780,
   P20RR020152, the Louisiana Gene Therapy Research Consortium, Scott&White
   Hospital Research Project Grant 90172, and the International Myeloma
   Foundation.
CR Alnouti Y, 2008, TOXICOL SCI, V101, P51, DOI 10.1093/toxsci/kfm280
   [Anonymous], 2012, Science Translational Medicine
   Arndt CAS, 2012, MAYO CLIN PROC, V87, P475, DOI 10.1016/j.mayocp.2012.01.015
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092 8674(00)00122 7
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Charafe Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008 5472.CAN 08 2741
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008 5472.CAN 10 1028
   Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P229, DOI 10.1309/AJCP90YNOKBAGCDM
   Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Gregory CA, 2006, STEM CELLS, V24, P2232, DOI 10.1634/stemcells.2005 0612
   Gunn WG, 2011, BLOOD, V117, P1641, DOI 10.1182/blood 2010 09 308171
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Joliat MJ, 2002, IN VIVO, V16, P223
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kast RE, 2009, CURR STEM CELL RES T, V4, P314, DOI 10.2174/157488809789649241
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Killick R, 2014, MOL PSYCHIATR, V19, P88, DOI 10.1038/mp.2012.163
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Makia NL, 2012, MOL PHARMACOL, V82, P601, DOI 10.1124/mol.112.078147
   Makia NL, 2011, CHEM BIOL INTERACT, V191, P278, DOI 10.1016/j.cbi.2011.01.013
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449
   Moreb JS, 2012, CHEM BIOL INTERACT, V195, P52, DOI 10.1016/j.cbi.2011.10.007
   Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317
   Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809
   Shultz MD, 2012, J MED CHEM, V55, P1127, DOI 10.1021/jm2011222
   Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016
   Tao YM, 2013, DIGEST LIVER DIS, V45, P251, DOI 10.1016/j.dld.2012.10.020
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vasiliou Vasilis, 2005, Human Genomics, V2, P138
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Wang Jingcai, 2012, Commun Integr Biol, V5, P319, DOI 10.4161/cib.20216
   Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898
NR 56
TC 62
Z9 71
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2014
VL 5
AR e1093
DI 10.1038/cddis.2014.67
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AC0ZJ
UT WOS:000332223700050
PM 24577091
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, P
   Liu, YP
   Xie, J
   Li, JS
AF Yu, Peng
   Liu, Yanpeng
   Xie, Jing
   Li, Jianshu
TI Spatiotemporally controlled calcitonin delivery: Long term and targeted
   therapy of skeletal diseases
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Calcitonin; Long term delivery; Targeted delivery; Bone; Osteoclast;
   Osteoblasts; Skeletal diseases
ID ORAL SALMON CALCITONIN; IN VIVO; POSTMENOPAUSAL WOMEN; DOUBLE BLIND;
   BONE LOSS; BIOMEDICAL APPLICATIONS; RECOMBINANT CALCITONIN;
   DRUG DELIVERY; NASAL SPRAY; BACK PAIN
AB Bone is a connective tissue that support the entire body and protect the internal organs. However, there are great challenges on curing intractable skeletal diseases such as hypercalcemia, osteoporosis and osteoarthritis. To address these issues, calcitonin (CT) therapy is an effective treatment alternative to regulate calcium metabolism and suppress inflammation response, which are closely related to skeletal diseases. Traditional calcitonin formulation requires frequent administration due to the low bioavailability resulting from the short half life and abundant calcitonin receptors distributed through the whole body. Therefore, long term and targeted calcitonin delivery systems (LCDS and TCDS) have been widely explored as the popular strategies to overcome the intrinsic limitations of calcitonin and improve the functions of calcium management and inflammation inhibition in recent years. In this review, we first explain the physiological effects of calcitonin on bone remodeling: (i) inhibitory effects on osteoclasts and (ii) facilitated effects on osteoblasts. Then we summarized four strategies for spatiotemporally controlled delivery of calcitonin: micro /nanomedicine (e.g. inorganic micro /nanomedicine, polymeric micro /nanomedicine and supramolecular assemblies), hydrogels (especially thermosensitive hydrogels), prodrug (PEGylation and targeting design) and hybrid biomaterials. Subsequently, we discussed the application of LCDS and TCDS in treating hypercalcemia, osteoporosis, and arthritis. Understanding and analyzing these advanced calcitonin delivery applications are essential for future development of calcitonin therapies toward skeletal diseases with superior efficacy in clinic.
C1 [Yu, Peng; Xie, Jing; Li, Jianshu] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
   [Liu, Yanpeng] Zhejiang Univ, Hangzhou Global Sci & Technol Innovat Ctr, Hangzhou 311200, Peoples R China.
   [Li, Jianshu] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Li, Jianshu] Sichuan Univ, Med X Ctr Mat, Chengdu 610041, Peoples R China.
C3 Sichuan University; Zhejiang University; Sichuan University; Sichuan
   University
RP Xie, J; Li, JS (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
EM xiej@scu.edu.cn; jianshu_li@scu.edu.cn
RI ; Yu, Peng/LEM 9696 2024; Xie, Jing/AAJ 5073 2021
OI Yu, Peng/0000 0002 3363 8911; 
FU National Natural Science Foundation of China [51925304, 52073191,
   51773128]
FX Acknowledgement Financial supports from the National Natural Science
   Foundation of China (No. 51925304, 52073191 and 51773128) are gratefully
   acknowledged.
CR Aguirre TAS, 2016, J CONTROL RELEASE, V238, P242, DOI 10.1016/j.jconrel.2016.07.047
   Aguirre TAS, 2015, EUR J PHARM SCI, V79, P102, DOI 10.1016/j.ejps.2015.09.001
   Ahmadipour S, 2021, PHARM DEV TECHNOL, V26, P220, DOI 10.1080/10837450.2020.1858318
   Antony B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11071205
   Aoki M, 2012, EUR J PHARMACOL, V696, P62, DOI 10.1016/j.ejphar.2012.09.007
   Armagan O, 2012, J KOREAN MED SCI, V27, P1405, DOI 10.3346/jkms.2012.27.11.1405
   Arnala IO, 2012, SCAND J SURG, V101, P249, DOI 10.1177/145749691210100405
   Atbinici H, 2015, ACTA ORTHOP TRAUMATO, V49, P160, DOI 10.3944/AOTT.2015.3035
   Bai MX, 2019, EXP THER MED, V18, P2079, DOI 10.3892/etm.2019.7806
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   Becklund BR, 2009, P NATL ACAD SCI USA, V106, P5276, DOI 10.1073/pnas.0813312106
   Bhandari KH, 2015, CURR DRUG DELIV, V12, P98, DOI 10.2174/156720181201150310154026
   Bhandari KH, 2012, J CONTROL RELEASE, V158, P44, DOI 10.1016/j.jconrel.2011.09.096
   Bhandari KH, 2010, INT J PHARMACEUT, V394, P26, DOI 10.1016/j.ijpharm.2010.04.015
   Binkley N, 2014, OSTEOPOROSIS INT, V25, P2649, DOI 10.1007/s00198 014 2796 0
   Binkley N, 2012, J BONE MINER RES, V27, P1821, DOI 10.1002/jbmr.1602
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Braun K, 2017, MOL SYST DES ENG, V2, P393, DOI 10.1039/c7me00059f
   Brayden DJ, 2020, ADV DRUG DELIVER REV, V157, P2, DOI 10.1016/j.addr.2020.05.007
   Brodowicz T, 2017, CANCER TREAT REV, V61, P23, DOI 10.1016/j.ctrv.2017.09.008
   Cao SQ, 2017, J CONTROL RELEASE, V256, P182, DOI 10.1016/j.jconrel.2017.04.014
   Cetin M, 2012, J MICROENCAPSUL, V29, P156, DOI 10.3109/02652048.2011.635426
   Cevaal PM, 2021, ACS NANO, V15, P3736, DOI 10.1021/acsnano.0c09514
   Chakraborty R, 2019, JAMA ONCOL, V5, P1095, DOI 10.1001/jamaoncol.2019.1598
   Chen MH, 2020, ACTA BIOMATER, V105, P304, DOI 10.1016/j.actbio.2020.01.029
   Chen XB, 2020, SMALL METHODS, V4, DOI 10.1002/smtd.202000310
   Chen ZX, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/abd1b9
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Clarke MV, 2015, ENDOCRINOLOGY, V156, P3203, DOI 10.1210/en.2015 1345
   Cui LG, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119617
   Cui SQ, 2019, MACROMOLECULES, V52, P3697, DOI 10.1021/acs.macromol.9b00534
   Davey RA, 2013, J BONE MINER RES, V28, P973, DOI 10.1002/jbmr.1869
   Düring J, 2013, ANGEW CHEM INT EDIT, V52, P8742, DOI 10.1002/anie.201302773
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Elsheikh NA, 2016, PAIN PHYSICIAN, V19, P139
   Ernst AU, 2019, ADV DRUG DELIVER REV, V139, P116, DOI 10.1016/j.addr.2019.01.013
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Feng K, 2019, J COLLOID INTERF SCI, V552, P186, DOI 10.1016/j.jcis.2019.05.037
   FRANCHIMONT P, 1989, J CLIN ENDOCR METAB, V69, P259, DOI 10.1210/jcem 69 2 259
   GarciaDelgado I, 1997, CALCIFIED TISSUE INT, V60, P155, DOI 10.1007/s002239900206
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Gooding S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12296 1
   Gou Y, 2019, BONE, V127, P17, DOI 10.1016/j.bone.2019.02.024
   Gradauer K, 2013, J CONTROL RELEASE, V172, P872, DOI 10.1016/j.jconrel.2013.10.011
   Gupta V, 2013, J CONTROL RELEASE, V172, P753, DOI 10.1016/j.jconrel.2013.09.004
   Gupta V, 2013, J CONTROL RELEASE, V172, P541, DOI 10.1016/j.jconrel.2013.05.002
   Habraken W, 2016, MATER TODAY, V19, P69, DOI 10.1016/j.mattod.2015.10.008
   Hajjaji HE, 2004, OSTEOARTHR CARTILAGE, V12, P904, DOI 10.1016/j.joca.2004.08.005
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Haumer A, 2018, ADV DRUG DELIVER REV, V129, P285, DOI 10.1016/j.addr.2018.01.010
   Hellio MP, 1997, OSTEOARTHR CARTILAGE, V5, P121, DOI 10.1016/S1063 4584(97)80005 2
   Henrich SE, 2019, J AM CHEM SOC, V141, P9753, DOI 10.1021/jacs.9b00651
   Henriksen K, 2016, BONE, V91, P122, DOI 10.1016/j.bone.2016.07.019
   Herberg S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2476
   Hernandez Garcia A, 2019, ADV SCI, V6, DOI 10.1002/advs.201801458
   Hibbins AR, 2018, J PHARM SCI US, V107, P1605, DOI 10.1016/j.xphs.2018.02.004
   Holstein SA, 2019, EXPERT OPIN THER PAT, V29, P315, DOI 10.1080/13543776.2019.1608180
   Hongo M, 2015, J BONE MINER METAB, V33, P432, DOI 10.1007/s00774 014 0603 9
   Hsiao CY, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00613
   Huang R, 2012, J MOL BIOL, V416, P108, DOI 10.1016/j.jmb.2011.12.023
   Huang TB, 2019, BIOMATER SCI UK, V7, P1101, DOI 10.1039/c8bm01411f
   Jiang LB, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201901314
   Johnell O, 1997, Am J Med, V103, p20S, DOI 10.1016/S0002 9343(97)90023 1
   Jones MW, 2012, J AM CHEM SOC, V134, P7406, DOI 10.1021/ja211855q
   Jones MW, 2012, J AM CHEM SOC, V134, P1847, DOI 10.1021/ja210335f
   Kao P C, 1995, Zhonghua Yi Xue Za Zhi (Taipei), V55, P209
   Karponis A, 2015, J MUSCULOSKEL NEURON, V15, P186
   Karsdal MA, 2006, OSTEOARTHR CARTILAGE, V14, P617, DOI 10.1016/j.joca.2006.03.014
   Karsdal MA, 2015, OSTEOARTHR CARTILAGE, V23, P532, DOI 10.1016/j.joca.2014.12.019
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kim HK, 2014, THYROID, V24, P599, DOI 10.1089/thy.2013.0121
   Koetting MC, 2016, J CONTROL RELEASE, V221, P18, DOI 10.1016/j.jconrel.2015.11.023
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Kotak DJ, 2020, NANOMED NANOTECHNOL, V24, DOI 10.1016/j.nano.2020.102153
   Kyrkos MJ, 2013, OSTEOARTHR CARTILAGE, V21, P973, DOI 10.1016/j.joca.2013.03.011
   Lantz R, 2020, CHEM EUR J, V26, P13063, DOI 10.1002/chem.202002027
   Lantz R, 2020, BIOPOLYMERS, V111, DOI 10.1002/bip.23343
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Lee KC, 1999, PHARM DEV TECHNOL, V4, P269, DOI 10.1081/PDT 100101361
   Li C, 2018, RSC ADV, V8, P9762, DOI 10.1039/c8ra00385h
   Li N, 2012, BIOMATERIALS, V33, P8881, DOI 10.1016/j.biomaterials.2012.08.047
   Licciardi M, 2013, EUR J PHARM BIOPHARM, V84, P21, DOI 10.1016/j.ejpb.2012.12.011
   Lin WF, 2021, ADV MATER, V33, DOI 10.1002/adma.202005513
   Lipp L, 2019, ACS OMEGA, V4, P1157, DOI 10.1021/acsomega.8b02781
   Liu L, 2019, INT J PHARMACEUT, V557, P170, DOI 10.1016/j.ijpharm.2018.12.053
   Liu P, 2014, GENET MOL RES, V13, P5285, DOI 10.4238/2014.July.24.7
   Liu Y, 2016, ADV MATER, V28, P8740, DOI 10.1002/adma.201602628
   Liu YP, 2019, J CONTROL RELEASE, V304, P39, DOI 10.1016/j.jconrel.2019.04.042
   Liu YP, 2017, ACS APPL MATER INTER, V9, P23428, DOI 10.1021/acsami.7b05740
   Luo LJ, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119464
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   MACKIE IG, 1989, ANN RHEUM DIS, V48, P464, DOI 10.1136/ard.48.6.464
   Manglani K, 2019, BONE, V122, P123, DOI 10.1016/j.bone.2019.02.019
   Marrella A, 2018, MATER TODAY, V21, P362, DOI 10.1016/j.mattod.2017.10.005
   Mathiesen DS, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.617400
   Maudens P, 2018, SMALL, V14, DOI 10.1002/smll.201703108
   Mazur CM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0070 y
   Mehta S, 2021, CURR OPIN RHEUMATOL, V33, P94, DOI 10.1097/BOR.0000000000000761
   Mero A, 2014, J CONTROL RELEASE, V187, P30, DOI 10.1016/j.jconrel.2014.05.008
   Mero A, 2011, J CONTROL RELEASE, V154, P27, DOI 10.1016/j.jconrel.2011.04.024
   Migliorati CA, 2011, NAT REV ENDOCRINOL, V7, P34, DOI 10.1038/nrendo.2010.195
   Mora Raimundo P, 2021, ADV SCI, V8, DOI 10.1002/advs.202101107
   Moreira LM, 2020, NATURE, V587, P460, DOI 10.1038/s41586 020 2890 8
   Naot D, 2019, PHYSIOL REV, V99, P781, DOI 10.1152/physrev.00066.2017
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   Nielsen RH, 2011, OSTEOARTHR CARTILAGE, V19, P466, DOI 10.1016/j.joca.2011.01.008
   Onishi H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091546
   Ordikhani F, 2021, MED RES REV, V41, P1221, DOI 10.1002/med.21759
   Pan Q, 2021, CYTOTHERAPY, V23, P590, DOI 10.1016/j.jcyt.2020.12.005
   Parks KA, 2017, AM J PSYCHIAT, V174, P620, DOI 10.1176/appi.ajp.2017.16111226
   Perrier ND, 2006, WORLD J SURG, V30, P686, DOI 10.1007/s00268 005 0361 x
   Renawala HK, 2021, BIOPHYS J, V120, P86, DOI 10.1016/j.bpj.2020.11.009
   Rigoldi F, 2017, J BIOL CHEM, V292, P7348, DOI 10.1074/jbc.M116.770271
   Rizzoli R, 2015, OSTEOPOROSIS INT, V26, P383, DOI 10.1007/s00198 014 2937 5
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Robin MP, 2013, J AM CHEM SOC, V135, P2875, DOI 10.1021/ja3105494
   Rong HQ, 1997, CLIN CHEM, V43, P71
   Rouhani Alireza, 2016, Eur J Orthop Surg Traumatol, V26, P575, DOI 10.1007/s00590 016 1816 5
   Ryan SM, 2013, J CONTROL RELEASE, V167, P120, DOI 10.1016/j.jconrel.2013.01.027
   Saeedi T, 2020, ADV COLLOID INTERFAC, V285, DOI 10.1016/j.cis.2020.102273
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Severcan I, 2010, NAT CHEM, V2, P772, DOI [10.1038/nchem.733, 10.1038/NCHEM.733]
   Shang H, 2018, ACTA BIOMATER, V78, P178, DOI 10.1016/j.actbio.2018.07.045
   Shang H, 2017, INT J PHARMACEUT, V527, P52, DOI 10.1016/j.ijpharm.2017.05.006
   Shih YV, 2019, BIOMATERIALS, V198, P107, DOI 10.1016/j.biomaterials.2018.06.005
   Shyu JF, 2007, BONE, V40, P1329, DOI 10.1016/j.bone.2007.01.014
   Silverman SL, 2003, ENDOCRIN METAB CLIN, V32, P273, DOI 10.1016/S0889 8529(02)00060 9
   Siviero P, 2016, ARTHRITIS RHEUMATOL, V68, P2662, DOI 10.1002/art.39757
   Sondergaard BC, 2006, OSTEOARTHR CARTILAGE, V14, P759, DOI 10.1016/j.joca.2006.01.014
   Sondergaard BC, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 62
   Steinberg J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21593 7
   Sullivan R, 2018, CALCIFIED TISSUE INT, V102, P666, DOI 10.1007/s00223 017 0382 0
   Sun LL, 2020, MOL PHARMACEUT, V17, P757, DOI 10.1021/acs.molpharmaceut.9b00827
   Tabrizi R, 2016, INT J ORAL MAX SURG, V45, P756, DOI 10.1016/j.ijom.2016.02.016
   Takakuwa M, 2012, BIOL PHARM BULL, V35, P1159, DOI 10.1248/bpb.b12 00200
   Tejero R, 2014, PROG POLYM SCI, V39, P1406, DOI 10.1016/j.progpolymsci.2014.01.001
   Tewes F, 2016, ACS APPL MATER INTER, V8, P1164, DOI 10.1021/acsami.5b09023
   Torres Lugo M, 2000, BIOMATERIALS, V21, P1191, DOI 10.1016/S0142 9612(00)00011 9
   Tryfonidou MA, 2020, ADV DRUG DELIVER REV, V160, P170, DOI 10.1016/j.addr.2020.10.012
   Umerska A, 2017, CARBOHYD POLYM, V156, P276, DOI 10.1016/j.carbpol.2016.09.035
   Umerska A, 2014, INT J PHARMACEUT, V477, P102, DOI 10.1016/j.ijpharm.2014.10.023
   Umerska A, 2014, J BIOMED NANOTECHNOL, V10, P3658, DOI 10.1166/jbn.2014.1878
   Varshosaz J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/932615
   Vik A, 2013, BIPOLAR DISORD, V15, P359, DOI 10.1111/bdi.12062
   Villa I, 2003, AM J PHYSIOL ENDOC M, V284, pE627, DOI 10.1152/ajpendo.00307.2002
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Wang L, 2019, J DRUG DELIV SCI TEC, V52, P838, DOI 10.1016/j.jddst.2019.05.045
   Wang XN, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249 020 1619 1
   Wang YJ, 2016, PROG POLYM SCI, V57, P153, DOI 10.1016/j.progpolymsci.2016.01.002
   Wang ZW, 2020, ACS BIOMATER SCI ENG, V6, P485, DOI 10.1021/acsbiomaterials.9b01680
   WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003 4819 108 5 669
   Washimi Y, 2007, BONE, V41, P786, DOI 10.1016/j.bone.2007.06.019
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
   Wei Y, 2016, J COLLOID INTERF SCI, V478, P46, DOI 10.1016/j.jcis.2016.05.045
   Wei Y, 2014, THER APHER DIAL, V18, P618, DOI 10.1111/1744 9987.12178
   Wen ZH, 2016, SCI REP UK, V6, DOI 10.1038/srep28862
   Wilson P, 2015, J AM CHEM SOC, V137, P4215, DOI 10.1021/jacs.5b01140
   Wu RX, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.45486
   Xie JB, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/3236828
   Xing JQ, 2021, CARBOHYD POLYM, V270, DOI 10.1016/j.carbpol.2021.118382
   Xue X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009432
   Yang M, 2012, EUR J PHARM SCI, V46, P374, DOI 10.1016/j.ejps.2012.02.024
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Ye HX, 2019, J INORG BIOCHEM, V196, DOI 10.1016/j.jinorgbio.2019.03.026
   Youn YS, 2007, J CONTROL RELEASE, V117, P371, DOI 10.1016/j.jconrel.2006.11.013
   Youn YS, 2006, J CONTROL RELEASE, V114, P334, DOI 10.1016/j.jconrel.2006.06.007
   Yousef AA, 2017, PAIN MED, V18, P1745, DOI 10.1093/pm/pnw249
   Yu P, 2019, MATER TODAY CHEM, V14, DOI 10.1016/j.mtchem.2019.08.008
   Yu P, 2021, INT J PHARMACEUT, V593, DOI 10.1016/j.ijpharm.2020.120171
   Yu P, 2020, ACS BIOMATER SCI ENG, V6, P4077, DOI 10.1021/acsbiomaterials.0c00591
   Yu P, 2020, J MATER CHEM B, V8, P270, DOI 10.1039/c9tb02049g
   Zagzag J, 2018, CA CANCER J CLIN, V68, P377, DOI 10.3322/caac.21489
   Zhang HL, 2016, DRUG DELIV, V23, P2419, DOI 10.3109/10717544.2014.1002946
   Zhang LB, 2017, MOL IMMUNOL, V87, P249, DOI 10.1016/j.molimm.2017.05.002
   [张萌萌 Zhang Mengmeng], 2020, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V26, P1059
   Zhang YX, 2021, CHEM SCI, V12, P9124, DOI 10.1039/d1sc01133b
   Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756 3282(02)00834 7
   Zhao DY, 2021, BIOACT MATER, V6, P346, DOI 10.1016/j.bioactmat.2020.08.016
   Zhao YN, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05898 6
   Zheng J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00978 7
   Zhu TT, 2020, BIOACT MATER, V5, P584, DOI 10.1016/j.bioactmat.2020.04.008
   Zhu XW, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00143 3
NR 183
TC 22
Z9 24
U1 3
U2 98
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 10
PY 2021
VL 338
BP 486
EP 504
DI 10.1016/j.jconrel.2021.08.056
EA SEP 2021
PG 19
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA WA3AW
UT WOS:000702763000007
PM 34481022
DA 2025 08 17
ER

PT J
AU Mercatali, L
   Spadazzi, C
   Miserocchi, G
   Liverani, C
   De Vita, A
   Bongiovanni, A
   Recine, F
   Amadori, D
   Ibrahim, T
AF Mercatali, Laura
   Spadazzi, Chiara
   Miserocchi, Giacomo
   Liverani, Chiara
   De Vita, Alessandro
   Bongiovanni, Alberto
   Recine, Federica
   Amadori, Dino
   Ibrahim, Toni
TI The Effect of Everolimus in an In Vitro Model of Triple Negative Breast
   Cancer and Osteoclasts
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE breast cancer; bone metastasis; everolimus; triple negative
ID ZOLEDRONIC ACID; BONE METASTASES; MECHANISMS; SURVIVAL; DIFFERENTIATION;
   COMBINATION; DENOSUMAB; DISEASE; ROLES; MTOR
AB Metastatic bone disease has a major impact on morbidity of breast cancer (BC) patients. Alterations in mTOR signaling are involved both in cancer progression and in osteoclast differentiation. The purpose of this study was to assess the role of mTOR inhibitor Everolimus (Eve) on osteoclastogenesis induced by triple negative BC cells. To this aim, we developed an in vitro human model of osteoclastogenesis from peripheral blood monocytes co cultured with the triple negative SCP2 and the hormonal receptor positive MCF7 cell lines. Osteoclastogenesis was evaluated by TRAP staining, evaluation of F actin rings and Calcitonin Receptor expression. Eve significantly reduced differentiation induced by cancer cells and resulted more effective when evaluated in combination with Denosumab and Zoledronic Acid (Zol). Combination with Zol showed a total abrogation of osteoclast differentiation induced by the triple negative cell line, not by MCF7. Finally, we observed that Eve was active in the inhibition of the crosstalk between cancer cells and osteoclasts reproduced by our model, highlighting a new therapeutic choice for the subsetting of triple negative BC patients. We observed a difference in the response to bone targeted therapy with respect to BC subtypes. Our model may represent a valid platform for preclinical trials on bone targeted drugs and for the study of the interplay of BC with bone stromal cells.
C1 [Mercatali, Laura; Spadazzi, Chiara; Miserocchi, Giacomo; Liverani, Chiara; De Vita, Alessandro; Bongiovanni, Alberto; Recine, Federica; Amadori, Dino; Ibrahim, Toni] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, I 47014 Meldola, Italy.
C3 IRCCS Meldola (IRST)
RP Mercatali, L (通讯作者)，IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, I 47014 Meldola, Italy.
EM laura.mercatali@irst.emr.it; chiara.spadazzi@irst.emr.it;
   giacomo.miserocchi@irst.emr.it; chiara.liverani@irst.emr.it;
   alessandro.devita@irst.emr.it; alberto.bongiovanni@irst.emr.it;
   federica.recine@irst.emr.it; dino.amadori@irst.emr.it;
   toni.ibrahim@irst.emr.it
RI Miserocchi, Giacomo/AAA 7159 2021; Spadazzi, Chiara/AAB 5917 2021; De
   Vita, Alessandro/K 1534 2016; Liverani, Chiara/K 3913 2016; Ibrahim,
   Toni/IQR 9219 2023; Bongiovanni, Alberto/J 9802 2018; Mercatali,
   Laura/J 9154 2016
OI Spadazzi, Chiara/0000 0001 6710 5980; De Vita,
   Alessandro/0000 0002 1677 5797; Liverani, Chiara/0000 0002 4279 1926;
   Bongiovanni, Alberto/0000 0002 3845 4687; 
CR [Anonymous], 2010, BREAST CANCER RES, V12, P215, DOI [10.1186/bcr2781, DOI 10.1186/BCR2781]
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bertoldo F, 2014, BBA REV CANCER, V1845, P248, DOI 10.1016/j.bbcan.2014.01.009
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   Faggiano A, 2012, J CELL MOL MED, V16, P1563, DOI 10.1111/j.1582 4934.2011.01438.x
   Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097 4644(19990101)72:1<67::AID JCB8>3.0.CO;2 A
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hasegawa Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143643
   Hussein O, 2012, CANCER LETT, V314, P176, DOI 10.1016/j.canlet.2011.09.026
   Ibrahim T, 2013, ONCOL LETT, V6, P306, DOI 10.3892/ol.2013.1372
   Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   Maggiani F., 2011, J CLIN PATHOL
   Patel, 2006, ANN N Y R ACAD S MEC, V1092, P385
   Patel LR, 2011, FUTURE ONCOL, V7, P1285, DOI [10.2217/fon.11.112, 10.2217/FON.11.112]
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rossi M, 2012, CURR CANCER DRUG TAR, V12, P757, DOI 10.2174/156800912802429300
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Simone V, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1717 8
   Singh JC, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3634
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008 5472.CAN 12 0122
NR 36
TC 26
Z9 26
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2016
VL 17
IS 11
AR 1827
DI 10.3390/ijms17111827
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ED4HV
UT WOS:000388809600061
PM 27809291
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Li, Z
   Xing, X
   Gomez Salazar, MA
   Xu, MX
   Negri, S
   Xu, JJ
   James, AW
AF Li, Zhao
   Xing, Xin
   Gomez Salazar, Mario Armando
   Xu, Mingxin
   Negri, Stefano
   Xu, Jiajia
   James, Aaron W.
TI Pharmacological inhibition of DKK1 promotes spine fusion in an
   ovariectomized rat model
SO BONE
LA English
DT Article
DE Spine fusion; Bone repair; DKK1; Osteoporosis; Small molecule
   inhibitors; Wnt signaling
ID BONE REGENERATION; SMALL MOLECULES; OSTEOPOROSIS; ROLES; DRUGS
AB Osteoporosis is common in patients undergoing spine surgery, and carries a considerable risk of adverse out comes. New methods to positively influence bone regeneration and spine fusion under osteoporotic conditions would be impactful. Neutralizing anti Dickkopf 1 (DKK1) antibodies has been used as a bone anabolic agent, and recently reported by our group to aid in stem cell mediated appendicular bone regeneration. Here, a small molecule designed as a DKK1 inhibitor, WAY 262611, was used to induce posterolateral spine fusion in an ovariectomized rat model. In vitro, pharmacological inhibition of DKK1 enhanced osteogenesis and Wnt signaling activity among rat bone marrow derived stem/stromal cells (BMSCs). In vivo, systemic treatment with WAY 262611 promoted both chondrogenesis and osteogenesis within the spinal fusion site, and ultimately led to significant improvements in lumbar fusion as assessed by XR, mu CT, histology and manual palpation assessments. No significant effect on osteoclast numbers or fusion site angiogenesis was detected, suggesting a primary direct effect on mesenchymal cells of the implantation site. Finally, evidence from human stem/stromal cells further demonstrated that pharmacologic inhibition of DKK1 promoted osteogenic differentiation in vitro. Taken together, our results suggest that targeting DKK1 promotes local bone formation and suggests potential clinical value for osteoporotic bone repair.
C1 [Li, Zhao; Xing, Xin; Gomez Salazar, Mario Armando; Xu, Mingxin; Negri, Stefano; Xu, Jiajia; James, Aaron W.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA.
   [Negri, Stefano] Univ Verona, Dept Orthopaed & Traumatol, I 37129 Verona, Italy.
C3 Johns Hopkins University; University of Verona
RP James, AW (通讯作者)，720 Rutland Ave,Room 524A, Baltimore, MD 21205 USA.
EM awjames@jhmi.edu
RI Negri, Stefano/AAH 1947 2020; Xing, Xin/HJP 0675 2023; Xu,
   Mingxin/AAK 7932 2021; Li, Zhao/IUQ 2715 2023; Xu, Jiawen/JEF 5028 2023
OI Li, Zhao/0000 0002 9276 9129; Xu, Jiajia/0000 0002 6084 2029; Xing,
   Xin/0000 0001 6417 0664; Xu, Mingxin/0009 0002 5228 3623
FU National Institutes of Health [R21 DE027922, R01 DE031028, R01
   AR070773]; Department of Defense [USAMRAA W81XWH 18 1 0336, USAMRAA
   W81XWH 18 1 0121, USAMRAA W81XWH 20 1 0795, USAMRAA W81XWH 20 1 0302];
   American Cancer Society [RSG 18 027 01 CSM]; Maryland Stem Cell Research
   Foundation; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [R01AR070773] Funding Source: NIH RePORTER; National Institute
   of Dental and Craniofacial Research [R01DE031028] Funding Source: NIH
   RePORTER
FX National Institutes of Health grant R21 DE027922 (Aaron W. James) .
   National Institutes of Health grant R01 DE031028 (Aaron W. James) .
   National Institutes of Health grant R01 AR070773 (Aaron W. James) .
   Department of Defense grant USAMRAA W81XWH 18 1 0336 (Aaron W. James) .
   Department of Defense grant USAMRAA W81XWH 18 1 0121 (Aaron W. James) .
   Department of Defense grant USAMRAA W81XWH 20 1 0795 (Aaron W. James) .
   Department of Defense grant USAMRAA W81XWH 20 1 0302 (Aaron W. James) .
   American Cancer Society grant RSG 18 027 01 CSM (Aaron W. James) .
   Maryland Stem Cell Research Foundation (Aaron W. James) . The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Health or
   Department of Defense.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Andersen T, 2010, EUR SPINE J, V19, P2200, DOI 10.1007/s00586 010 1373 2
   Chandrasegaran AL, 2007, CHEM EDUC RES PRACT, V8, P293
   Cho JH, 2018, J ORTHOP SCI, V23, P870, DOI 10.1016/j.jos.2018.06.009
   Chung CG, 2014, STEM CELL TRANSL MED, V3, P1231, DOI 10.5966/sctm.2014 0027
   Datta Mannan A, 2019, DRUG METAB DISPOS, V47, P1100, DOI 10.1124/dmd.119.086488
   EMERY SE, 1994, J BONE JOINT SURG AM, V76A, P540, DOI 10.2106/00004623 199404000 00008
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Govindarajan V, 2021, NEUROSURG FOCUS, V50, DOI 10.3171/2021.3.FOCUS2175
   Grisanti M., 2006, J BONE MINER RES, V21
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Han QQ, 2013, FUTURE MED CHEM, V5, P1671, DOI 10.4155/fmc.13.133
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kobayashi Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.82
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Lee S, 2015, STEM CELLS, V33, P3158, DOI 10.1002/stem.2103
   Lehmann J, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102224
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Lu BS, 2014, DRUG DISCOV TODAY, V19, P801, DOI 10.1016/j.drudis.2013.11.011
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Min JK, 2011, J CLIN INVEST, V121, P1882, DOI 10.1172/JCI42556
   Morimoto T, 2015, SPINE J, V15, P1379, DOI 10.1016/j.spinee.2015.02.034
   Negri S, 2021, STEM CELL TRANSL MED, V10, P610, DOI 10.1002/sctm.20 0293
   Negri S, 2020, STEM CELL TRANSL MED, V9, P1617, DOI 10.1002/sctm.20 0152
   Ngo HX, 2018, MEDCHEMCOMM, V9, P757, DOI 10.1039/c8md90019a
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Ovacik M, 2018, CTS CLIN TRANSL SCI, V11, P540, DOI 10.1111/cts.12567
   Park H, 2014, ANGIOGENESIS, V17, P221, DOI 10.1007/s10456 013 9390 5
   Park SB, 2017, J KOREAN NEUROSURG S, V60, P348, DOI 10.3340/jkns.2016.0707.002
   Pelletier JC, 2009, J MED CHEM, V52, P6962, DOI 10.1021/jm9014197
   Poon B, 2016, J PHARM PHARMACOL, V68, P139, DOI 10.1111/jphp.12506
   Smadja DM, 2010, ARTERIOSCL THROM VAS, V30, P2544, DOI 10.1161/ATVBAHA.110.213751
   Wagner SC, 2016, SPINE, V41, pE1279, DOI 10.1097/BRS.0000000000001612
   Wang YY, 2020, STEM CELLS DEV, V29, P1007, DOI 10.1089/scd.2020.0070
   Witcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673
   Xu JJ, 2020, ELIFE, V9, DOI 10.7554/eLife.58990
   Yoshihara H, 2015, SPINE J, V15, P265, DOI 10.1016/j.spinee.2014.09.026
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Yuan W, 2013, J ORTHOP SCI, V18, P646, DOI 10.1007/s00776 013 0390 5
   Zhang YD, 2021, J ORTHOP TRANSL, V31, P73, DOI 10.1016/j.jot.2021.11.001
NR 43
TC 3
Z9 3
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2022
VL 162
AR 116456
DI 10.1016/j.bone.2022.116456
EA JUN 2022
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 2O5SL
UT WOS:000819117500009
PM 35688363
OA Bronze
DA 2025 08 17
ER

PT J
AU Gong, WM
   Li, ML
   Zhao, LZ
   Wang, PT
   Wang, XF
   Wang, B
   Liu, X
   Tu, XL
AF Gong, Weimin
   Li, Molin
   Zhao, Lizhou
   Wang, Pengtao
   Wang, Xiaofang
   Wang, Bo
   Liu, Xing
   Tu, Xiaolin
TI Sustained release of a highly specific GSK3β inhibitor SB216763 in the
   PCL scaffold creates an osteogenic niche for osteogenesis,
   anti adipogenesis, and potential angiogenesis
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE SB216763; Wnt signaling; osteogenesis; adipogenesis; angiogenesis; PCL
   and cell integrated 3D scaffold; sustained release
ID SMALL MOLECULE INHIBITORS; POSTMENOPAUSAL WOMEN; BONE; ROMOSOZUMAB;
   CONSTRUCTS; MECHANISMS; HYDROGELS; DISEASE
AB The safe and effective use of Wnt signaling is a hot topic in developing osteogenic drugs. SB216763 (S33) is a widely used highly specificGSK3 beta inhibitor. Here, we show that S33 initiates canonical Wnt signaling by inhibiting GSK3 beta activity in the bone marrow stromal cell line ST2 and increases osteoblast marker alkaline phosphatase activity, osteoblast marker gene expression including Alpl, Col1a1, and Runx2, promoting osteogenic differentiation and mineralization of ST2 cells. In addition, S33 suppressed the expression of adipogenic transcription factors Pparg and Cebpa in ST2 cells to suppress adipogenesis. ICRT 14, a specific transcriptional inhibitor of Wnt signaling, reversed the effects of S33 on the differentiation of ST2 cells. S33 also increased the expression of osteoclast cytokines RANKL and Opg but decreased the RANKL/Opg ratio and had the potential to inhibit osteoclast differentiation. In addition, we printed the PSCI3D (polycaprolactone, S33, cell integrated 3D) scaffolds using a newly established integrated 3D printing system for hard materials and cells. S33 sustained release in the hydrogel of the scaffold with 25.4% release on day 1% and 81.7% release over 7 days. Cells in the scaffolds had good cell viability. The ratio of live/dead cells remained above 94% for 7 days, while the cells in the scaffolds proliferated linearly, and the proliferative activity of the PSCI3D scaffold group increased 1.4 fold and 1.7 fold on days 4 and 7, respectively. Similarly, in PSCI3D scaffolds, osteogenic differentiation of st2 cells was increased. The alkaline phosphatase activity increased 1.4  and 4.0 fold on days 7 and 14, respectively, and mineralization increased 1.7 fold at 21 days. In addition, PSCI3D conditioned medium promoted migration and tubulogenesis ofHUVECs, and S33 upregulated the expression of Vegfa, a key factor in angiogenesis. In conclusion, our study suggests that S33 functions in osteogenesis, anti adipogenesis, and potential inhibition of osteoclast differentiation. And the sustained release of S33 in PSCI3D scaffolds creates a safe osteogenic niche, which promotes cell proliferation, osteogenesis, and angiogenesis and has application prospects.
C1 [Gong, Weimin; Li, Molin; Zhao, Lizhou; Wang, Pengtao; Wang, Xiaofang; Wang, Bo; Tu, Xiaolin] Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing, Peoples R China.
   [Liu, Xing] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Key Lab Child Dev & Disorders, Dept Orthoped,Childrens Hosp,Minist Educ, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Tu, XL (通讯作者)，Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing, Peoples R China.; Liu, X (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Key Lab Child Dev & Disorders, Dept Orthoped,Childrens Hosp,Minist Educ, Chongqing, Peoples R China.
EM xtu@cqmu.edu.cn; liuxingda@126.com
RI gong, weimin/HTL 9563 2023
FU National Natural Science Foundation of China [U1601220, 81672118,
   82072450]; Chongqing Science and Technology Commission Basic Science and
   Frontier Technology Key Project [cstc2015jcyjBX0119,
   CSTB2022NSCQ LZX0048]; CQMU Program for Youth Innovation in Future
   Medicine [W0203]
FX This research was funded by the National Natural Science Foundation of
   China U1601220, 81672118, and 82072450 (XT), and Chongqing Science and
   Technology Commission Basic Science and Frontier Technology Key Project
   cstc2015jcyjBX0119 and CSTB2022NSCQ LZX0048 (XT), and CQMU Program for
   Youth Innovation in Future Medicine (No. W0203) (XL).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Billiet T, 2014, BIOMATERIALS, V35, P49, DOI 10.1016/j.biomaterials.2013.09.078
   Cha GD, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801660
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Cohn Schwartz D, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050897
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Golledge J, 2022, ARTERIOSCL THROM VAS, V42, pE187, DOI 10.1161/ATVBAHA.122.317635
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Herrmann M, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00079
   Hummler SC, 2013, AM J RESP CELL MOL, V48, P578, DOI 10.1165/rcmb.2012 0383OC
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kang HW, 2016, NAT BIOTECHNOL, V34, P312, DOI 10.1038/nbt.3413
   Kang X, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1036375
   Lieben Liesbet, 2016, Nat Rev Rheumatol, V12, P191, DOI 10.1038/nrrheum.2016.29
   Liu YX, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050831
   Luo C, 2022, FREE RADICAL BIO MED, V188, P337, DOI 10.1016/j.freeradbiomed.2022.06.236
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malda J, 2016, TRENDS BIOTECHNOL, V34, P356, DOI 10.1016/j.tibtech.2016.03.003
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Oliva N, 2017, ACCOUNTS CHEM RES, V50, P669, DOI 10.1021/acs.accounts.6b00536
   Pashuck ET, 2016, NAT BIOTECHNOL, V34, P295, DOI 10.1038/nbt.3503
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sun WJ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 63
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Valot L, 2019, CHEM SOC REV, V48, P4049, DOI 10.1039/c7cs00718c
   Vargason AM, 2021, NAT BIOMED ENG, V5, P951, DOI 10.1038/s41551 021 00698 w
   Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010
   Wang B, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.926622
   Wang L, 2021, ACTA BIOMATER, V122, P160, DOI 10.1016/j.actbio.2020.12.031
   Wang PT, 2022, BIO DES MANUF, V5, P497, DOI 10.1007/s42242 022 00196 1
   Wang SQ, 2022, SMALL, V18, DOI 10.1002/smll.202201869
   Wang XF, 2023, BIOACT MATER, V21, P110, DOI 10.1016/j.bioactmat.2022.07.017
   Weng J, 2018, NEURAL REGEN RES, V13, P324, DOI 10.4103/1673 5374.226403
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Zhang Y, 2017, GASTROENTEROLOGY, V153, P154, DOI 10.1053/j.gastro.2017.03.019
   Zhu B, 2019, J CELL MOL MED, V23, P5782, DOI 10.1111/jcmm.14503
NR 44
TC 5
Z9 5
U1 1
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD JUL 28
PY 2023
VL 11
AR 1215233
DI 10.3389/fbioe.2023.1215233
PG 15
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA O8ZM9
UT WOS:001046647200001
PM 37576993
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Smith, RL
   Schwarz, EM
AF Smith, R. Lane
   Schwarz, Edward M.
TI Are Biologic Treatments a Potential Approach to Wear  and
   Corrosion related Problems?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID BONE MINERAL DENSITY; INDUCED INFLAMMATORY OSTEOLYSIS; TOTAL
   HIP ARTHROPLASTY; ZOLEDRONIC ACID; DOUBLE BLIND; DEBRIS; INHIBITION;
   ALENDRONATE; BISPHOSPHONATES; PARTICLES
AB Where Are We Now? Biological treatments, defined as any nonsurgical intervention whose primary mechanism of action is reducing the host response to wear and/or corrosion products, have long been postulated as solutions for osteolysis and aseptic loosening of total joint arthroplasties. Despite extensive research on drugs that target the inflammatory, osteoclastic, and osteogenic responses to wear debris, no biological treatment has emerged as an approved therapy. We review the extensive preclinical research and modest clinical research to date, which has led to the central conclusion that the osteoclast is the primary target. We also allude to the significant changes in health care, unabated safety concerns about chronic immunosuppressive/antiinflammatory therapies, industry's complete lack of interest in developing an intervention for this condition, and the practical issues that have narrowly focused the possibilities for a biologic treatment for wear debris induced osteolysis.
   Where Do We Need to Go? Based on the conclusions from research, and the economic, regulatory, and practical issues that limit the future directions toward the development of a biologic treatment, there are a few rational approaches that warrant investigation. These largely focus on FDA approved osteoporosis therapies that target the osteoclast (bisphosphonates and anti RANK ligand) and recombinant parathyroid hormone (teriparatide) prophylactic treatment to increase osseous integration of the prosthesis to overcome high risk susceptibility to aseptic loosening. The other roadblock that must be overcome if there is to be an approved biologic therapy to prevent the progression of periprosthetic osteolysis and aseptic loosening is the development of radiological measures that can quantify a significant drug effect in a randomized, placebo controlled clinical trial. We review the progress of volumetric quantification of osteolysis in animal studies and clinical pilots.
   How Do We Get There? Accepting the aforementioned rigid boundaries, we describe the emergence of repurposing FDA approved drugs for new indications and public (National Institutes of Health, FDA, Centers for Disease Control and Prevention) and private (universities and drug and device manufactures) partnerships as the future road map for clinical translation. In the case of biologic treatments for wear debris induced osteolysis, this will involve combined federal and industry funding of multi center clinical trials that will be run by thought leaders at large medical centers.
C1 [Smith, R. Lane] Stanford Univ, Dept Orthopaed Surg, Redwood City, CA USA.
   [Schwarz, Edward M.] Univ Rochester, Dept Orthopaed, Rochester, NY 14642 USA.
   [Schwarz, Edward M.] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14642 USA.
C3 Stanford University; University of Rochester; University of Rochester
RP Schwarz, EM (通讯作者)，Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.
EM edward_schwarz@urmc.rochester.edu
FU Amgen Inc (Thousand Oaks, CA, USA); Lilly Inc (Indianapolis, IN, USA)
FX One of the authors (EMS) certifies that he or she, or a member of his or
   her immediate family, has received or may receive payments or benefits,
   during the study period, an amount of USD (note less than USD 10,000),
   from Amgen Inc (Thousand Oaks, CA, USA), and an amount of USD (USD
   10,000 to USD 100,000) from Lilly Inc (Indianapolis, IN, USA).
CR Arabmotlagh M, 2009, J ORTHOP RES, V27, P183, DOI 10.1002/jor.20748
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Barra L, 2009, J RHEUMATOL, V36, P1421, DOI 10.3899/jrheum.081122
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bragdon CR, 2005, J ARTHROPLASTY, V20, P258, DOI 10.1016/j.arth.2004.03.027
   Chen DS, 2012, INFLAMMATION, V35, P1798, DOI 10.1007/s10753 012 9500 3
   Chen DS, 2012, INT J MOL MED, V30, P1417, DOI 10.3892/ijmm.2012.1145
   Darowish M, 2009, BONE, V45, P661, DOI 10.1016/j.bone.2009.06.004
   Daugaard H, 2011, CALCIFIED TISSUE INT, V88, P294, DOI 10.1007/s00223 010 9458 9
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Fang Q, 2011, J SURG RES, V168, pE163, DOI 10.1016/j.jss.2010.12.006
   Friedl G, 2009, J BONE JOINT SURG AM, V91A, P274, DOI 10.2106/JBJS.G.01193
   Geng DC, 2010, J BIOMED MATER RES A, V95A, P321, DOI 10.1002/jbm.a.32836
   Green JM, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0325 3
   Hansson U, 2009, ACTA ORTHOP, V80, P41, DOI 10.1080/17453670902804968
   Kauther MD, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 186
   Keystone E, 2009, CURR OPIN RHEUMATOL, V21, P231, DOI 10.1097/BOR.0b013e328329f84f
   Landgraeber S, 2009, APOPTOSIS, V14, P173, DOI 10.1007/s10495 008 0297 3
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Liu S, 2012, ARTHRITIS RHEUM US, V64, P4012, DOI 10.1002/art.37697
   Ma T, 2009, J BIOMED MATER RES A, V89A, P117, DOI 10.1002/jbm.a.31957
   Mao X, 2012, INFLAMMATION, V35, P1411, DOI 10.1007/s10753 012 9454 5
   Mao X, 2012, INFLAMMATION, V35, P905, DOI 10.1007/s10753 011 9392 7
   Markel DC, 2009, INFLAMM RES, V58, P413, DOI 10.1007/s00011 009 0007 9
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Nich C, 2013, BIOMATERIALS, V34, P641, DOI 10.1016/j.biomaterials.2012.10.030
   Niu S, 2013, J SURG RES, V179, pE107, DOI 10.1016/j.jss.2012.02.003
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Prieto Alhambra D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7222
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Qu SX, 2013, J BIOMED MATER RES A, V101, P394, DOI 10.1002/jbm.a.34327
   Rao AJ, 2013, J BIOMED MATER RES A, V101, P1925, DOI 10.1002/jbm.a.34486
   Ren WP, 2010, INFLAMM RES, V59, P1091, DOI 10.1007/s00011 010 0229 x
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Schwarz EM, 2008, J AM ACAD ORTHOP SUR, V16, pS72, DOI 10.5435/00124635 200800001 00015
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Scott DF, 2013, J ARTHROPLASTY, V28, P671, DOI 10.1016/j.arth.2012.08.007
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Singh JA, 2011, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD008794.PUB2
   Sköldenberg OG, 2011, J BONE JOINT SURG AM, V93A, P1857, DOI 10.2106/JBJS.J.01646
   Talmo CT, 2006, CLIN ORTHOP RELAT R, P254, DOI 10.1097/01.blo.0000246531.59876.a8
   Taylor PC, 2003, CURR PHARM DESIGN, V9, P1095, DOI 10.2174/1381612033454991
   Thillemann TM, 2010, BONE, V46, P946, DOI 10.1016/j.bone.2010.01.377
   Trevisan C, 2010, CALCIFIED TISSUE INT, V86, P436, DOI 10.1007/s00223 010 9356 1
   Trevisan C, 2013, CLIN CASES MINER BON, V10, P61, DOI 10.11138/ccmbm/2013.10.1.061
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   Tuan RS, 2008, J AM ACAD ORTHOP SUR, V16, pS42, DOI 10.5435/00124635 200800001 00010
   von Knoch F, 2005, BIOMATERIALS, V26, P5783, DOI 10.1016/j.biomaterials.2005.02.008
   Wang CJ, 2003, J BONE JOINT SURG AM, V85A, P2121, DOI 10.2106/00004623 200311000 00009
   Wang Y, 2013, J SURG RES, V180, pE73, DOI 10.1016/j.jss.2012.04.016
   Wang Y, 2012, CONNECT TISSUE RES, V53, P528, DOI 10.3109/03008207.2012.702817
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Yamanaka Y, 2013, J ORTHOP RES, V31, P67, DOI 10.1002/jor.22200
   Yu XW, 2013, INT ORTHOP, V37, P137, DOI 10.1007/s00264 012 1668 5
   Zhang W, 2011, INT ORTHOP, V35, P1883, DOI 10.1007/s00264 011 1252 4
   Zhang W, 2011, J INT MED RES, V39, P798, DOI 10.1177/147323001103900312
   Zhao X, 2012, ULTRASOUND MED BIOL, V38, P238, DOI 10.1016/j.ultrasmedbio.2011.11.005
   Zhu FB, 2010, J ORTHOP RES, V28, P893, DOI 10.1002/jor.21062
NR 62
TC 21
Z9 23
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD DEC
PY 2014
VL 472
IS 12
BP 3740
EP 3746
DI 10.1007/s11999 014 3765 9
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA AT0TH
UT WOS:000344647200019
PM 24993143
OA Green Published
DA 2025 08 17
ER

PT J
AU Liu, R
   Xu, LX
   Tong, LJ
   Wu, HY
   Guo, Q
   Sun, ZM
   Yan, H
AF Liu, Rui
   Xu, Li Xia
   Tong, Lin Jian
   Wu, Hai  Yang
   Guo, Qiang
   Sun, Zhi Ming
   Yan, Hua
TI Therapeutic effects of ginsenosides on osteoporosis for novel drug
   applications
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Ginsenosides; Osteoporosis; Osteoblasts; Osteoclasts; Bone marrow
   stromal cells
ID INHIBITS OSTEOCLAST DIFFERENTIATION; NF KAPPA B; GINSENG EXTRACT;
   MC3T3 E1 CELLS; MINERALIZATION; OSTEOBLASTS; RANKL; MAPK; RG3; RB1
AB Osteoporosis (OP) is a metabolic bone disease with a high incidence rate worldwide. Its main features are decreased bone mass, increased bone fragility and deterioration of bone microstructure. It is caused by an imbalance between bone formation and bone resorption. Ginsenoside is a safe and effective traditional Chinese medicine (TCM) usually extracted from ginseng plants, having various therapeutic effects, of which the effect against osteoporosis has been extensively studied. We searched a total of 44 relevant articles with using keywords including osteoporosis, ginsenosides, bone mesenchymal cells, osteoblasts, osteoclasts and bone remodeling, all of which investigated the cellular mechanisms of different types of ginsenosides affecting the activity of bone remodeling by mesenchymal stem cells, osteoblasts and osteoclasts to counteract osteoporosis. This review describes the different types of ginsenosides used to treat osteoporosis from different perspectives, providing a solid theoretical basis for future clinical applications.
C1 [Liu, Rui; Tong, Lin Jian; Sun, Zhi Ming; Yan, Hua] Tianjin Med Univ, Clin Coll Neurol Neurosurg & Neurorehabil, Tianjin 300070, Peoples R China.
   [Xu, Li Xia] Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Dis, Tianjin 300350, Peoples R China.
   [Wu, Hai  Yang] Duke Univ, Sch Med, Duke Mol Physiol Inst, Durham, NC USA.
   [Guo, Qiang] Tianjin Med Univ, Dept Orthoped, Baodi Clin Coll, Tianjin 301800, Peoples R China.
C3 Tianjin Medical University; Duke University; Tianjin Medical University
RP Sun, ZM; Yan, H (通讯作者)，Tianjin Med Univ, Clin Coll Neurol Neurosurg & Neurorehabil, Tianjin 300070, Peoples R China.
EM renzushanxiaoguai@163.com; yanhua20042007@sina.com
RI Tong, Linjian/GRS 1308 2022; Xu, Lixia/CAJ 5305 2022
FU Tianjin Natural Science Foundation [S24YBL069]
FX <BOLD>Funding</BOLD> This research is supported by Tianjin Natural
   Science Foundation (S24YBL069) .
CR Beekman KM, 2023, CURR OSTEOPOROS REP, V21, P45, DOI 10.1007/s11914 022 00768 1
   Bei JX, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202885
   Chen B, 2012, PHYTOMEDICINE, V19, P1029, DOI 10.1016/j.phymed.2012.06.002
   Chen M, 2023, CYTOKINE GROWTH F R, V70, P54, DOI 10.1016/j.cytogfr.2023.03.002
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Cheung Ching Lung, 2018, Osteoporos Sarcopenia, V4, P16, DOI 10.1016/j.afos.2018.03.003
   Cong F, 2017, BIOMED PHARMACOTHER, V92, P927, DOI 10.1016/j.biopha.2017.05.115
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Ding LL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.855393
   Ding L, 2023, BIOMED PHARMACOTHER, V158, DOI 10.1016/j.biopha.2022.114096
   Du J, 2011, J IMMUNOL, V187, P942, DOI 10.4049/jimmunol.1002579
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Gao B, 2015, STEM CELLS DEV, V24, P781, DOI 10.1089/scd.2014.0367
   Gong YS, 2006, J ASIAN NAT PROD RES, V8, P649, DOI 10.1080/10286020500246063
   Gopinath V, 2023, MED CLIN N AM, V107, P213, DOI 10.1016/j.mcna.2022.10.013
   Gu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep25282
   Guo DJ, 2023, CRIT REV FOOD SCI, V63, P125, DOI 10.1080/10408398.2021.1944975
   Guo HL, 2021, ACS APPL MATER INTER, V13, P61638, DOI 10.1021/acsami.1c18701
   Harris K, 2023, AM FAM PHYSICIAN, V107, P238
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Jung SJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103352
   Kiernan J, 2017, STEM CELL TRANSL MED, V6, P1930, DOI 10.1002/sctm.17 0054
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, BMB REP, V44, P659, DOI 10.5483/BMBRep.2011.44.10.659
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim HM, 2017, MOLECULES, V22, DOI 10.3390/molecules22010042
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Laird C, 2023, OSTEOPOROSIS INT, V34, P239, DOI 10.1007/s00198 022 06561 1
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lee HY, 2015, J FUNCT FOODS, V13, P192, DOI 10.1016/j.jff.2014.12.039
   Lee SH, 2023, BMB REP, V56, P551, DOI 10.5483/BMBRep.2023 0100
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Li JW, 2023, AM J CHINESE MED, V51, P883, DOI 10.1142/S0192415X23500416
   Li XD, 2011, J ETHNOPHARMACOL, V134, P268, DOI 10.1016/j.jep.2010.11.075
   Li XM, 2021, J CELL MOL MED, V25, P11278, DOI 10.1111/jcmm.17054
   Lin Y, 2012, BIOMOL THER, V20, P75, DOI 10.4062/biomolther.2012.20.1.075
   Liu J, 2009, BIOORG MED CHEM LETT, V19, P3320, DOI 10.1016/j.bmcl.2009.04.054
   Liu Q, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.593820
   Liu Y, 2016, INT J MOL MED, V38, P537, DOI 10.3892/ijmm.2016.2652
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Paik S, 2023, INT IMMUNOPHARMACOL, V121, DOI 10.1016/j.intimp.2023.110461
   Park CM, 2016, MOL CELLS, V39, P855, DOI 10.14348/molcells.2016.0111
   Patel D, 2023, DRUG DELIV TRANSL RE, V13, P419, DOI 10.1007/s13346 022 01222 6
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qi L, 2022, FRONT NEUROSCI SWITZ, V16, DOI 10.3389/fnins.2022.969056
   Seo K, 2023, NANOSCALE, V15, P5798, DOI 10.1039/d2nr07018a
   Siddiqi MH, 2015, PHYTOTHER RES, V29, P1286, DOI 10.1002/ptr.5374
   Siddiqi MH, 2014, J PHARM PHARMACOL, V66, P1763, DOI 10.1111/jphp.12306
   Siddiqi MH, 2014, PHYTOTHER RES, V28, P1447, DOI 10.1002/ptr.5146
   Siddiqi MZ, 2015, J MED FOOD, V18, P542, DOI 10.1089/jmf.2014.3251
   Song M, 2020, BIOL TRACE ELEM RES, V198, P557, DOI 10.1007/s12011 020 02089 9
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Sugiyama T, 2015, OSTEOPOROSIS INT, V26, P443, DOI 10.1007/s00198 014 2923 y
   Sun MM, 2023, ORAL DIS, V29, P3460, DOI 10.1111/odi.14352
   Wang CS, 2019, ARTIF CELL NANOMED B, V47, P603, DOI 10.1080/21691401.2019.1573189
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Wu YT, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01434 w
   Yang N, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116187
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Zhang D, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154205
   Zhang XN, 2020, DRUG DEVELOP RES, V81, P875, DOI 10.1002/ddr.21705
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
   Zhang YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010199
   Zhao S, 2017, INT IMMUNOPHARMACOL, V47, P118, DOI 10.1016/j.intimp.2017.03.018
   Zhou W, 2018, J GINSENG RES, V42, P199, DOI 10.1016/j.jgr.2017.03.004
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
   Zhu YZ, 2016, TOXICOLOGY, V368, P183, DOI 10.1016/j.tox.2016.07.014
NR 73
TC 1
Z9 3
U1 5
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUL 5
PY 2024
VL 974
AR 176604
DI 10.1016/j.ejphar.2024.176604
EA APR 2024
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SS3K4
UT WOS:001236396800001
PM 38649090
OA hybrid
DA 2025 08 17
ER

PT J
AU Ren, BL
   Ren, XL
   Wang, L
   Tu, C
   Zhang, WC
   Liu, ZY
   Qi, L
   Wan, L
   Pang, K
   Tao, C
   Li, ZH
AF Ren, Bolin
   Ren, Xiaolei
   Wang, Lu
   Tu, Chao
   Zhang, Wenchao
   Liu, Zhongyue
   Qi, Lin
   Wan, Lu
   Pang, Ke
   Tao, Cheng
   Li, Zhihong
TI A bibliometric research based on hotspots and frontier trends of
   denosumab
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE denosumab; bibliometric and network analysis; RANKL; osteoporosis;
   biclustering analysis
ID SKELETAL RELATED EVENTS; METASTASIS FREE SURVIVAL; ZOLEDRONIC ACID; BONE
   METASTASES; VERTEBRAL FRACTURES; POSTMENOPAUSAL OSTEOPOROSIS;
   DOUBLE BLIND; LUNG CANCER; RANKL; DISCONTINUATION
AB Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor kappa B ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK RANKL OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.
C1 [Ren, Bolin; Ren, Xiaolei; Wang, Lu; Tu, Chao; Zhang, Wenchao; Liu, Zhongyue; Qi, Lin; Wan, Lu; Pang, Ke; Tao, Cheng; Li, Zhihong] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.
   [Ren, Bolin; Ren, Xiaolei; Tu, Chao; Zhang, Wenchao; Liu, Zhongyue; Qi, Lin; Wan, Lu; Pang, Ke; Li, Zhihong] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Peoples R China.
C3 Central South University; Central South University
RP Tao, C; Li, ZH (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.; Li, ZH (通讯作者)，Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Peoples R China.
EM taochoney@126.com; lizhihong@csu.edu.cn
RI Zhang, Wenchao/JCE 0609 2023; Qi, Lin/AAB 9074 2022; Li,
   Zhihong/M 4989 2019; Tu, Chao/AAF 2504 2019; Pang, Ke/GUD 4072 2022
OI Li, Zhihong/0000 0002 1944 9671
FU National Natural Science Foundation of China; Natural Science Foundation
   of Hunan Province, China [81902745, 82103228]; Hunan Provincial Research
   and Development Program in Key Areas [2018JJ3716]; China Postdoctoral
   Science Foundation [2019WK 2071];  [2021M693557]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81902745 and 82103228), the Natural Science
   Foundation of Hunan Province, China (grant number 2018JJ3716), Hunan
   Provincial Research and Development Program in Key Areas (2019WK 2071),
   and China Postdoctoral Science Foundation (no. 2021M693557).
CR Adami S, 2012, J BONE JOINT SURG AM, V94A, P2113, DOI 10.2106/JBJS.K.00774
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Anastasilakis AD, 2017, EUR J ENDOCRINOL, V176, P677, DOI 10.1530/EJE 16 1027
   Aro HT, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10217
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Bonani M, 2017, TRANSPLANTATION, V101, P2139, DOI 10.1097/TP.0000000000001547
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Bouquegneau A, 2016, CLIN J AM SOC NEPHRO, V11, P1282, DOI 10.2215/CJN.11371015
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Bryant JP, 2021, NEUROSURG FOCUS, V50, DOI 10.3171/2021.3.FOCUS201049
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chen CM, 2012, EXPERT OPIN BIOL TH, V12, P593, DOI 10.1517/14712598.2012.674507
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Cuyàs E, 2017, CELL CYCLE, V16, P1022, DOI 10.1080/15384101.2017.1310353
   Damasiewicz MJ, 2017, NEPHROLOGY, V22, P65, DOI 10.1111/nep.13028
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Deligiorgi MV, 2020, EXPERT OPIN BIOL TH, V20, P1331, DOI 10.1080/14712598.2020.1790522
   Dell'Aquila E, 2020, EXPERT OPIN BIOL TH, V20, P1261, DOI 10.1080/14712598.2020.1814731
   Ferrari S, 2019, J BONE MINER RES, V34, P1033, DOI 10.1002/jbmr.3722
   Girgis CM, 2020, OSTEOPOROSIS INT, V31, P1189, DOI 10.1007/s00198 020 05413 0
   GOLDRING SR, 1987, J CLIN INVEST, V79, P483, DOI 10.1172/JCI112838
   Hendriks LEL, 2016, J THORAC ONCOL, V11, P155, DOI 10.1016/j.jtho.2015.10.001
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hirooka Y, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.753185
   Hirooka Y, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100293
   Hu MI, 2014, J CLIN ENDOCR METAB, V99, P3144, DOI 10.1210/jc.2014 1001
   Huang SY, 2020, ADV THER, V37, P3404, DOI 10.1007/s12325 020 01395 x
   Ide M, 2018, ORTHOP TRAUMATOL SUR, V104, P1043, DOI 10.1016/j.otsr.2018.07.015
   Kendler D, 2020, J CLIN ENDOCR METAB, V105, pE255, DOI 10.1210/clinem/dgz095
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Li HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580605
   Li RR, 2020, J PAIN RES, V13, P1901, DOI 10.2147/JPR.S258739
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Müller DA, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957 016 1034 y
   Nakamura Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.21
   Nakamura Y, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0371 y
   Nakamura Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.55
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Otto S, 2015, J CRANIO MAXILL SURG, V43, P847, DOI 10.1016/j.jcms.2015.03.039
   Ozsoy Z, 2018, OBES SURG, V28, P2353, DOI 10.1007/s11695 018 3202 3
   Palmerini E, 2018, TUMORI J, V104, P344, DOI 10.1177/0300891618784808
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549 014 2955 1
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Ren BL, 2021, INT ORTHOP, V45, P2773, DOI 10.1007/s00264 021 05163 6
   Rosner MH, 2012, CLIN J AM SOC NEPHRO, V7, P1722, DOI 10.2215/CJN.02470312
   Saag KG, 2019, ARTHRITIS RHEUMATOL, V71, P1174, DOI 10.1002/art.40874
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Samelson EJ, 2014, J BONE MINER RES, V29, P450, DOI 10.1002/jbmr.2043
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Shibuya I, 2019, PATHOL ONCOL RES, V25, P409, DOI 10.1007/s12253 017 0362 8
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Solling AS, 2020, J BONE MINER RES, V35, P1858, DOI 10.1002/jbmr.4098
   Stopeck Alison, 2012, J Med Econ, V15, P712, DOI 10.3111/13696998.2012.675380
   Suzuki T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030272
   Synnestvedt Marie B, 2005, AMIA Annu Symp Proc, P724
   Takahashi Toshifumi, 2020, Hinyokika Kiyo, V66, P23, DOI 10.14989/ActaUrolJap_66_1_23
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tsai JN, 2016, J CLIN ENDOCR METAB, V101, P2023, DOI 10.1210/jc.2016 1160
   Uehara M, 2017, TOHOKU J EXP MED, V242, P115, DOI 10.1620/tjem.242.115
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Wei WJ, 2019, NEURAL REGEN RES, V14, P1823, DOI 10.4103/1673 5374.257535
   Yang KD, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.556022
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Yu EW, 2020, J BONE MINER RES, V35, P1009, DOI 10.1002/jbmr.4049
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhu YL, 2020, J ORTHOP TRANSL, V22, P7, DOI 10.1016/j.jot.2019.08.004
NR 85
TC 4
Z9 4
U1 1
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 19
PY 2022
VL 13
AR 929223
DI 10.3389/fphar.2022.929223
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5B3PE
UT WOS:000863483900001
PM 36199692
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, LF
   Liang, YJ
   Zhou, XH
   Tian, YX
   Miao, Z
   Ko, CC
   Hu, XX
AF Wang, Lufei
   Liang, Yajing
   Zhou, Xuhua
   Tian, Yuxing
   Miao, Zhe
   Ko, Ching Chang
   Hu, Xiangxiang
TI Nrf2 differentially regulates osteoclast and osteoblast differentiation
   for bone homeostasis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Nrf2; Antioxidant; Osteoclasts; Osteoblasts; Bone remodeling; Bone
   metabolism
ID OXIDATIVE STRESS; MINERALIZATION; PROLIFERATION; CURCUMIN
AB Nuclear factor erythroid derived factor 2 related factor 2 (Nrf2) is a master regulator of antioxidant response and protects cells from excessive oxidative stress. Nrf2 emerges as a prospective therapeutic target for metabolic bone disorders, in which the balance between osteoblastic bone formation and osteoclastic bone resorption is disrupted. However, the molecular mechanism through which Nrf2 modulates bone homeostasis remains unclear. In this study, we compared the differences in Nrf2 mediated antioxidant response and ROS regulation in osteoblasts and osteoclasts, both in vitro and in vivo. Findings indicated a close connection between the Nrf2 expression and its related antioxidant response with osteoclasts than osteoblasts. We next pharmacologically manipulated the Nrf2 mediated antioxidant response during osteoclast or osteoblast differentiation. Nrf2 inhibition enhanced osteo clastogenesis, while its activation suppressed it. In contrast, osteogenesis decreased irrespective of whether Nrf2 was inhibited or activated. These findings highlight the distinct ways in which the Nrf2 mediated antioxidant response regulates osteoclast and osteoblast differentiation, thereby contributing to the development of Nrf2 targeted therapies for metabolic bone diseases.& COPY; 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Wang, Lufei] Guangxi Med Univ, Guangxi Key Lab Rehabil & Reconstruct Oral & Maxil, Nanning, Peoples R China.
   [Wang, Lufei] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Orthodont, Nanning, Peoples R China.
   [Wang, Lufei; Miao, Zhe; Hu, Xiangxiang] Univ North Carolina Chapel Hill, Adams Sch Dent, Oral & Craniofacial Biomed Program, Chapel Hill, NC 27599 USA.
   [Liang, Yajing] Capital Med Univ, Beijing Stomatol Hosp, Beijing, Peoples R China.
   [Zhou, Xuhua] Ankang Cent Hosp, Dept Orthoped, Ankang, Peoples R China.
   [Tian, Yuxing] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Peoples R China.
   [Ko, Ching Chang; Hu, Xiangxiang] Ohio State Univ, Coll Dent, Div Orthodont, Columbus, OH USA.
C3 Guangxi Medical University; Guangxi Medical University; University of
   North Carolina; University of North Carolina Chapel Hill; University of
   North Carolina School of Medicine; Capital Medical University; Sichuan
   University; University System of Ohio; Ohio State University
RP Hu, XX (通讯作者)，Univ North Carolina Chapel Hill, Adams Sch Dent, Oral & Craniofacial Biomed Program, Chapel Hill, NC 27599 USA.
EM hu.2378@osu.edu
RI ; Hu, Xiangxiang/GRY 6511 2022
OI tian, yuxing/0009 0007 4808 3350; Hu, Xiangxiang/0000 0003 4029 056X; 
CR Ashrafizadeh M, 2020, PHYTOTHER RES, V34, P1745, DOI 10.1002/ptr.6642
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Han J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.813057
   He F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134777
   Hu XX, 2023, SCI ADV, V9, DOI 10.1126/sciadv.ade6998
   Hur W, 2011, CURR OPIN CHEM BIOL, V15, P162, DOI 10.1016/j.cbpa.2010.12.009
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu ZY, 2019, TOXICOL APPL PHARM, V367, P62, DOI 10.1016/j.taap.2019.02.003
   Moran JM, 2012, INT J MOL SCI, V13, P16104, DOI 10.3390/ijms131216104
   Notoya M, 2006, EUR J PHARMACOL, V534, P55, DOI 10.1016/j.ejphar.2006.01.028
   Park PSU, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092133
   Robledinos Antón N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Schmitt A, 2021, BLOOD, V138, P871, DOI 10.1182/blood.2020009404
   Shang GG, 2015, J NUTR BIOCHEM, V26, P596, DOI 10.1016/j.jnutbio.2014.12.008
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Tao ZS, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00503 7
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Xue P, 2021, EXP MOL MED, V53, P667, DOI 10.1038/s12276 021 00596 w
   Xue P, 2019, BIOCHEM BIOPH RES CO, V511, P637, DOI 10.1016/j.bbrc.2019.02.095
   Yang RL, 2022, FREE RADICAL BIO MED, V178, P246, DOI 10.1016/j.freeradbiomed.2021.12.010
   Zou DB, 2021, AGING CELL, V20, DOI 10.1111/acel.13367
NR 25
TC 15
Z9 17
U1 2
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 24
PY 2023
VL 674
BP 19
EP 26
DI 10.1016/j.bbrc.2023.06.080
EA JUN 2023
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA M4NA1
UT WOS:001029977900001
PM 37393640
OA hybrid
DA 2025 08 17
ER

PT J
AU Shi, JX
   Cai, XQ
   Zhao, ZH
   Deng, Y
   Zhou, ZK
AF Shi, Jian Xin
   Cai, Xiao Qun
   Zhao, Ze Hao
   Deng, Yu
   Zhou, Zhi Kun
TI Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast
   Differentiation Based on Network Pharmacology
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE; BISPHOSPHONATES
AB Osteoclasts (OCs) have been the unique cell type exhibiting the bone resorption activity in body. It is important to identify drugs to resist osteoclastogenesis to manage the bone loss disorders. Huangqi Sanxian decoction (HQSXD) is utilized for the treatment of postmenopausal osteoporosis (PMOP) for a long history in East Asia. This work aimed to examine HQSXD's activity in OC differentiation. Based on staining with tartrate resistant acid phosphatase (TRAP), it was found that HQSXD suppressed OC generation under the induction of RANKL produced in the bone marrow derived monocytes/macrophages (BMMs), with no cytotoxic effect. Later analysis like molecular exploration and network pharmacology (NP) suggested the role of HQSXD in suppressing genes associated with osteoclastogenesis via PI3K/Akt mediated mechanism dose dependently. This work might illustrate the molecular pharmacological mechanism involved in HQSXD's effect on treating OC associated disorders. Moreover, NP was found to modernize traditional Chinese medicine (TCM) research.
C1 [Shi, Jian Xin; Cai, Xiao Qun; Zhao, Ze Hao; Deng, Yu; Zhou, Zhi Kun] Guangdong Med Univ, Dept Pharm, 1 Xincheng Dadao,Songshan Lake Sci & Technol Ind P, Dongguan 523808, Peoples R China.
   [Shi, Jian Xin] Guangdong Med Univ, Huizhou Womens & Childrens Hosp, 10 Daling Rd, Huizhou 516001, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University
RP Zhou, ZK (通讯作者)，Guangdong Med Univ, Dept Pharm, 1 Xincheng Dadao,Songshan Lake Sci & Technol Ind P, Dongguan 523808, Peoples R China.
EM 675773367@qq.com; circus28@icloud.com; 289410730@qq.com;
   470404725@qq.com; zhikunzhou@126.com
RI Cai, xiaoqun/JTV 6037 2023
FU National Natural Science foundation of China [81774344]
FX AcknowledgmentsThis work was supported by the grant from the National
   Natural Science foundation of China (no. 81774344).
CR Alwahhabi BK, 2017, SAUDI MED J, V38, P604, DOI 10.15537/smj.2017.6.19793
   Bergner R, 2015, PHARMACOL RES, V99, P16, DOI 10.1016/j.phrs.2015.04.016
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boardman HMP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002229.pub4
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V561, P13, DOI 10.1016/j.abb.2014.08.009
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kibble M, 2015, NAT PROD REP, V32, P1249, DOI 10.1039/c5np00005j
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Koh A, 2017, BONE JOINT J, V99B, P295, DOI 10.1302/0301 620X.99B3.BJJ 2016 0276.R2
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rissanen J, 2002, BONE, V30, p21S
   Shim JH, 2018, CALCIFIED TISSUE INT, V102, P533, DOI 10.1007/s00223 017 0373 1
   Siddiqui JA, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00049
   Simin J, 2017, EUR J CANCER, V84, P60, DOI 10.1016/j.ejca.2017.07.012
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tuck SP, 2017, RHEUMATOLOGY, V56, P2050, DOI 10.1093/rheumatology/kew430
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu MR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13015 6
   Xu X, 2018, J CELL BIOCHEM, V119, P4680, DOI 10.1002/jcb.26646
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Yuan HD, 2017, MOLECULES, V22, DOI 10.3390/molecules22071135
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
NR 33
TC 1
Z9 1
U1 1
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD JUN 8
PY 2022
VL 2022
AR 8769531
DI 10.1155/2022/8769531
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 2M3FU
UT WOS:000817590500001
PM 35754697
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, L
   Huang, Q
   Tian, SJ
   Ge, JF
   Zhu, HY
   Dong, QR
AF Zhao, Lei
   Huang, Qun
   Tian, Shoujin
   Ge, Jianfei
   Zhu, Hongyan
   Dong, Qirong
TI Integrative identification of unexpected kinase inhibitor interactions
   in the MAPK mediated proliferation and differentiation of Mc3T3 E1
   osteoblasts
SO GENERAL PHYSIOLOGY AND BIOPHYSICS
LA English
DT Article
DE Mitogen activated protein kinase; Kinase inhibitor; Off target;
   Unexpected interaction; Molecular modeling; Osteoblast; MC3T3 E1
ID ACTIVATED PROTEIN KINASE; SELF BINDING PEPTIDES; SIGNALING PATHWAY;
   BONE; GROWTH; REVEALS; RECOGNITION; METABOLISM; PREDICTION; MECHANISM
AB Kinase targeted therapy is a new and promising approach to disease treatment. However, some kinase inhibitors have been observed to cause an off target adverse risk for skeletal system by influencing the growth of osteoblasts. It is known that the proliferation and differentiation of osteoblasts are essentially regulated by MAPK signaling pathway, and many off target events are considered to influence this pathway. Here, the unexpected MAPK inhibitor interactions in mouse MC3T3 E1 osteoblastic cells were investigated in detail using an integrative protocol. With bioinformatics analysis we successfully profiled a systematic noncognate interaction spectrum for off target kinase inhibitors against mouse MAPK kinases, from which 13 potential MAPK inhibitor interactions were identified. the inhibitors Nilotinib, Dasatinib and Bosutinib were suggested as promising candidates; their cytotoxicity on MC3T3 E1 and inhibitory activity against MAPK kinase were tested at cellular and molecular levels, respectively. We also tested two known MAPK inhibitors SP600125 and SB203580 as positive controls. Consequently, the Dasatinib was found to have high off target risk for unexpectedly targeting osteoblast MAPK signaling pathway.
C1 [Zhao, Lei; Dong, Qirong] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
   [Zhao, Lei; Huang, Qun; Tian, Shoujin; Ge, Jianfei] First Peoples Hosp Zhangjiagang City, Dept Orthoped, Zhangjiagang 215600, Peoples R China.
   [Zhu, Hongyan] First Peoples Hosp Zhangjiagang City, Dept Translat Med, Res & Dev Ctr, Zhangjiagang 215600, Peoples R China.
C3 Soochow University   China
RP Dong, QR (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
EM dongqirong@suda.edu.cn
RI Zhu, Hongyan/GRS 7215 2022
FU Science and Technology Support Project of Zhangjiagang Science and
   Technology Bureau [Zks1741]
FX This work was supported by the Science and Technology Support Project of
   Zhangjiagang Science and Technology Bureau (No. Zks1741).
CR Alemán JO, 2014, ENDOCR RELAT CANCER, V21, pR247, DOI 10.1530/ERC 12 0400
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022 2836(05)80360 2
   Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017
   Bai ZY, 2017, J CHEM INF MODEL, V57, P835, DOI 10.1021/acs.jcim.6b00673
   Bao NR, 2013, INT J CLIN EXP PATHO, V6, P2082
   Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989
   BAYLY CI, 1993, J PHYS CHEM US, V97, P10269, DOI 10.1021/j100142a004
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0804 2
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Cui YH, 2015, COMPUT BIOL CHEM, V54, P57, DOI 10.1016/j.compbiolchem.2015.01.001
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   De Moliner E, 2003, EUR J BIOCHEM, V270, P3174, DOI 10.1046/j.1432 1033.2003.03697.x
   Dumka D, 2009, LEUKEMIA LYMPHOMA, V50, P2017, DOI 10.3109/10428190903147637
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Geourjon C, 2001, PROTEIN SCI, V10, P788, DOI 10.1110/ps.30001
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Karahashi H, 2000, BBA MOL BASIS DIS, V1502, P207, DOI 10.1016/S0925 4439(00)00045 4
   Kim JW, 2017, EUR J PHARMACOL, V806, P10, DOI 10.1016/j.ejphar.2017.03.032
   Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395
   Lefloch R, 2008, MOL CELL BIOL, V28, P511, DOI 10.1128/MCB.00800 07
   Luo H, 2015, COMB CHEM HIGH T SCR, V18, P296, DOI 10.2174/1386207318666150305144015
   Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272
   Martí Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Meng L, 2018, COMPUT BIOL CHEM, V75, P196, DOI 10.1016/j.compbiolchem.2018.05.012
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nishimoto S, 2006, EMBO REP, V7, P782, DOI 10.1038/sj.embor.7400755
   O'Sullivan S, 2011, BONE, V49, P281, DOI 10.1016/j.bone.2011.04.014
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021 9991(77)90098 5
   Ryu J, 2016, NUCLEIC ACIDS RES, V44, pW416, DOI 10.1093/nar/gkw368
   Shen XK, 2016, J RECEPT SIG TRANSD, V36, P89, DOI 10.3109/10799893.2015.1049361
   Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639
   Stierand K, 2006, BIOINFORMATICS, V22, P1710, DOI 10.1093/bioinformatics/btl150
   Tauer JT, 2013, MED SCI MONIT BASIC, V19, P274, DOI 10.12659/MSMBR.889518
   ten Hove T, 2002, GUT, V50, P507, DOI 10.1136/gut.50.4.507
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Tian FF, 2014, J MOL MODEL, V20, DOI 10.1007/s00894 014 2257 x
   Tian FF, 2011, J COMPUT AID MOL DES, V25, P947, DOI 10.1007/s10822 011 9474 5
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Vulpetti Anna, 2005, Current Medicinal Chemistry   Anti Cancer Agents, V5, P561, DOI 10.2174/1568011054866928
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Yamamoto N, 2015, PROSTAG OTH LIPID M, V116, P57, DOI 10.1016/j.prostaglandins.2015.01.003
   Yang C, 2016, MOL BIOSYST, V12, P1201, DOI 10.1039/c5mb00800j
   Yang C, 2015, MOL SIMULAT, V41, P741, DOI 10.1080/08927022.2014.929127
   Yang C, 2015, J CHEM INF MODEL, V55, P329, DOI 10.1021/ci500522v
   Yu H, 2014, J CHEM INF MODEL, V54, P2022, DOI 10.1021/ci5000246
   Zhan CY, 2015, CHEM BIOL DRUG DES, V85, P418, DOI 10.1111/cbdd.12424
   Zhang YY, 2012, BIOSCI TRENDS, V6, P130, DOI 10.5582/bst.2012.v6.3.130
   Zhou P, 2018, ARTIF CELL NANOMED B, V46, P1122, DOI 10.1080/21691401.2017.1360327
   Zhou P, 2016, J BIOMOL STRUCT DYN, V34, P1806, DOI 10.1080/07391102.2015.1092476
   Zhou P, 2013, FOOD CHEM, V141, P2967, DOI 10.1016/j.foodchem.2013.05.140
   Zhou P, 2013, J COMPUT AID MOL DES, V27, P67, DOI 10.1007/s10822 012 9625 3
NR 62
TC 18
Z9 18
U1 0
U2 8
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0231 5882
EI 1338 4325
J9 GEN PHYSIOL BIOPHYS
JI Gen. Physiol. Biophys.
PY 2019
VL 38
IS 1
BP 1
EP 13
DI 10.4149/gpb_2018030
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Physiology
GA HL3HP
UT WOS:000458604800001
PM 30657460
OA gold
DA 2025 08 17
ER

PT J
AU Andrew, TW
   Koepke, LS
   Wang, YT
   Lopez, M
   Steininger, H
   Struck, D
   Boyko, T
   Ambrosi, TH
   Tong, XM
   Sun, YX
   Gulati, GS
   Murphy, MP
   Marecic, O
   Telvin, R
   Schallmoser, K
   Strunk, D
   Seita, J
   Goodman, SB
   Yang, F
   Longaker, MT
   Yang, GP
   Chan, CKF
AF Andrew, Tom W.
   Koepke, Lauren S.
   Wang, Yuting
   Lopez, Michael
   Steininger, Holly
   Struck, Danielle
   Boyko, Tatiana
   Ambrosi, Thomas H.
   Tong, Xinming
   Sun, Yuxi
   Gulati, Gunsagar S.
   Murphy, Matthew P.
   Marecic, Owen
   Telvin, Ruth
   Schallmoser, Katharina
   Strunk, Dirk
   Seita, Jun
   Goodman, Stuart B.
   Yang, Fan
   Longaker, Michael T.
   Yang, George P.
   Chan, Charles K. F.
TI Sexually dimorphic estrogen sensing in skeletal stem cells controls
   skeletal regeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; BONE LOSS; FRACTURE; HIP; IDENTIFICATION;
   GROWTH; PROGESTERONE; EXPRESSION; CARTILAGE; ANDROGENS
AB How bone related sexually dimorphic traits are regulated hasn't been examined at the stem cell level. Here the authors show that skeletal stem cells (SSC), in female but not male mice, are directly controlled by estrogen signaling, which could be augmented to improve fracture repair.
   Sexually dimorphic tissues are formed by cells that are regulated by sex hormones. While a number of systemic hormones and transcription factors are known to regulate proliferation and differentiation of osteoblasts and osteoclasts, the mechanisms that determine sexually dimorphic differences in bone regeneration are unclear. To explore how sex hormones regulate bone regeneration, we compared bone fracture repair between adult male and female mice. We found that skeletal stem cell (SSC) mediated regeneration in female mice is dependent on estrogen signaling but SSCs from male mice do not exhibit similar estrogen responsiveness. Mechanistically, we found that estrogen acts directly on the SSC lineage in mice and humans by up regulating multiple skeletogenic pathways and is necessary for the stem cell's ability to self  renew and differentiate. Our results also suggest a clinically applicable strategy to accelerate bone healing using localized estrogen hormone therapy.
C1 [Andrew, Tom W.; Koepke, Lauren S.; Wang, Yuting; Lopez, Michael; Steininger, Holly; Struck, Danielle; Boyko, Tatiana; Ambrosi, Thomas H.; Gulati, Gunsagar S.; Murphy, Matthew P.; Marecic, Owen; Longaker, Michael T.; Chan, Charles K. F.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA.
   [Andrew, Tom W.; Gulati, Gunsagar S.; Murphy, Matthew P.; Longaker, Michael T.; Chan, Charles K. F.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Sch Med, Stanford, CA 94305 USA.
   [Wang, Yuting] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthopaed Surg, Wuhan, Peoples R China.
   [Tong, Xinming; Yang, Fan] Stanford Univ, Dept Bioengn, Palo Alto, CA 94305 USA.
   [Sun, Yuxi; Yang, George P.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA.
   [Sun, Yuxi; Yang, George P.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
   [Telvin, Ruth] Stanford Hosp & Clin, Div Plast & Reconstruct Surg, Palo Alto, CA USA.
   [Schallmoser, Katharina; Strunk, Dirk] Paracelsus Med Univ Salzburg, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Dept Transfus Med, Salzburg, Austria.
   [Strunk, Dirk] Paracelsus Med Univ Salzburg, Cell Therapy Inst, Salzburg, Austria.
   [Seita, Jun] RIKEN, Ctr Integrat Med Sci & Adv Data Sci Project, Tokyo, Japan.
   [Goodman, Stuart B.; Yang, Fan] Stanford Univ, Dept Orthoped Surg, Palo Alto, CA 94305 USA.
C3 Stanford University; Stanford University; Huazhong University of Science
   & Technology; Stanford University; University of Alabama System;
   University of Alabama Birmingham; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Veterans Affairs Medical Center  
   Birmingham; Stanford University; Stanford Medicine; Paracelsus Private
   Medical University; Paracelsus Private Medical University; RIKEN;
   Stanford University
RP Chan, CKF (通讯作者)，Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA.; Chan, CKF (通讯作者)，Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Sch Med, Stanford, CA 94305 USA.; Yang, GP (通讯作者)，Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA.; Yang, GP (通讯作者)，Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
EM gyang@uabmc.edu; chazchan@stanford.edu
RI ; Yang, Fan/AAD 4705 2019; Strunk, Dirk/V 4598 2017; Schallmoser,
   Katharina/V 4734 2017; Sun, Yuxi/AAL 6010 2021; Murphy,
   Matthew/ABD 5403 2021; Boyko, Tatiana/ABA 1947 2020; Goodman,
   Stuart/AAZ 7499 2020; Seita, Jun/AAM 1478 2020; Tong,
   Xinming/F 4393 2016; Ambrosi, Thomas/HNI 0862 2023
OI Ambrosi, Thomas/0000 0002 7149 041X; Gulati,
   Gunsagar/0000 0003 2798 6220; sun, yuxi/0000 0003 3026 3904; Murphy,
   Matthew/0000 0003 0885 4089; Steininger, Holly/0000 0001 8098 3753;
   Goodman, Stuart/0000 0002 1919 3717; Struck,
   Danielle/0000 0001 9521 3671; Tong, Xinming/0000 0001 7585 3866; 
FU NIH NIA [K99 R00 AG049958 01A1, 1K99AG066963]; Stanford Wu Tsai Human
   Performance Alliance Funds; Siebel Foundation; Heritage Medical
   Foundation; Prostate Cancer Foundation; American Federation for Aging
   Research (AFAR) Arthritis National Research Foundation (ANRF); WHSDM
   Stanford Women's Health and Ses Differences in Medicine Center; NIH
   [(I01)VA I01BX003754, I01BX003754, K08GM069677, R56 DE025597, R01
   DE026730, R01 DE021683, R21 DE024230, R01 DE027323, HL099776, U24
   DE026914, R21 DE019274, S10 RR02933801, S10 1S10OD028493 01A1, S10
   1S10OD02349701]; German Research Foundation (DFG Fellowship)
   [399915929]; CIRMTR1 01249; Oak Foundation; Hagey Laboratory; Pitch
   Johnson Fund; Gunn/Olivier Research Fund; European Union's Horizon 2020
   research innovation program [733006, 731377]; Land Salzburg WISS [2025F
   2000237 FIP]; National Institute of Dental and Craniofacial Research
   [R01DE026730, R01DE027323] Funding Source: NIH RePORTER; National
   Institute on Aging [K99AG066963] Funding Source: NIH RePORTER; H2020
   Societal Challenges Programme [731377] Funding Source: H2020 Societal
   Challenges Programme
FX We thank A. McCarthy and C. Wang for mouse colony management; L. Quinn,
   V. Ford, C. McQuarrie, C. Queen, T. Naik and L. Jerabek for laboratory
   management; P. Lovelace, S. Weber and C. Carswell Crumpton for FACS
   support; M. R. Eckart and the Stanford Gene Expression Facility (PAN
   Facility) as well as the Stanford Human Immune Monitoring Center (HIMC)
   for technical support, assistance and/or advice on this project; and L.
   Penland, B. Yu and M. Tan from the Chan Zuckerberg BioHub for support
   with scRNA seq. This work was supported by NIH NIA K99 R00
   AG049958 01A1, Stanford Wu Tsai Human Performance Alliance Funds, Siebel
   Foundation, the Heritage Medical Foundation, Prostate Cancer Foundation,
   the American Federation for Aging Research (AFAR) Arthritis National
   Research Foundation (ANRF), a seed grant from the WHSDM Stanford Women's
   Health and Ses Differences in Medicine Center, and an endowment from the
   DiGenova Family to C.K.F.C.; NIH (I01)VA I01BX003754 and NIH K08GM069677
   to G.Y.; the German Research Foundation (DFG Fellowship) 399915929 and
   NIH NIA 1K99AG066963 to T.H.A.; NIH (R56 DE025597, R01 DE026730, R01
   DE021683, R21 DE024230, R01 DE027323, HL099776, U24 DE026914 and R21
   DE019274), CIRMTR1 01249, the Oak Foundation, the Hagey Laboratory, the
   Pitch Johnson Fund and the Gunn/Olivier Research Fund to M.T.L.; and
   European Union's Horizon 2020 research innovation program (grant
   agreement no. 733006 to DS and no. 731377 to KS) and Land Salzburg WISS
   2025F 2000237 FIP "STEBS" to DS. Additional support came from NIH S10
   RR02933801 to the Stanford University Stem Cell FACS core, NIH S10
   1S10OD028493 01A1 for acquisition of a microfluidic chip based system
   for cluster sorting and dispensing(Principal Investigator: Charles.K.F.
   Chan) and NIH S10 1S10OD02349701 to the Stanford University Clark
   Imaging Center (Principal Investigator: T. Doyle).
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Beil FT, 2011, J TRAUMA, V70, P857, DOI 10.1097/TA.0b013e3181de3dd9
   Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140 6736(05)66455 0
   Beral Valerie, 2003, Lancet, V362, P419
   BIDLINGMAIER F, 1973, PEDIATR RES, V7, P901, DOI 10.1203/00006450 197311000 00006
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532 5415.1990.tb01378.x
   Brinton RD, 2012, ENDOCRINOLOGY, V153, P3571, DOI 10.1210/en.2012 1340
   Buyuk E., 2010, 1128 MENOPAUSE HORMO, V11
   Canonico M, 2008, BMJ BRIT MED J, V336, P1227, DOI 10.1136/bmj.39555.441944.BE
   Cattaneo MG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10139 x
   Chahal HS, 2007, J PATHOL, V211, P173, DOI 10.1002/path.2110
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chan CKF, 2013, P NATL ACAD SCI USA, V110, P12643, DOI 10.1073/pnas.1310212110
   CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Duan YB, 2003, J BONE MINER RES, V18, P1766, DOI 10.1359/jbmr.2003.18.10.1766
   El Brolosy MA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006780
   Elmlinger MW, 2002, CLIN CHEM LAB MED, V40, P1151, DOI 10.1515/CCLM.2002.202
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Finan B, 2015, NAT MED, V21, P27, DOI 10.1038/nm.3761
   FINCH CE, 1984, ENDOCR REV, V5, P467, DOI 10.1210/edrv 5 4 467
   Galloway JL, 2009, NATURE, V460, P400, DOI 10.1038/nature08117
   Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014 1045
   Gulati GS, 2018, NAT PROTOC, V13, P1294, DOI 10.1038/nprot.2018.041
   Herber CB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08046 4
   Hudry B, 2016, NATURE, V530, P344, DOI 10.1038/nature16953
   JENSEN JS, 1982, ACTA ORTHOP SCAND, V53, P97, DOI 10.3109/17453678208992185
   Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 182
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008
   Karvande A, 2017, J PHARM PHARMACOL, V69, P1381, DOI 10.1111/jphp.12764
   Kim HN, 2019, AGING CELL, V18, DOI 10.1111/acel.12923
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Marecic O, 2015, P NATL ACAD SCI USA, V112, P9920, DOI 10.1073/pnas.1513066112
   Muir AM, 2014, HUM MOL GENET, V23, P3085, DOI 10.1093/hmg/ddu013
   Nakada D, 2014, NATURE, V505, P555, DOI 10.1038/nature12932
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nerenz RD, 2022, J APPL LAB MED, V7, P1006, DOI 10.1093/jalm/jfac022
   Nicks KM, 2016, J BONE MINER RES, V31, P606, DOI 10.1002/jbmr.2723
   Nistala H, 2010, J CELL BIOL, V190, P1107, DOI 10.1083/jcb.201003089
   O'Brien LE, 2011, CELL, V147, P603, DOI 10.1016/j.cell.2011.08.048
   Oguro H, 2017, J CLIN INVEST, V127, P3398, DOI 10.1172/JCI94027
   Ono W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11277
   Parker CR, 2000, J CLIN ENDOCR METAB, V85, P48, DOI 10.1210/jc.85.1.48
   Parker MJ, 2007, CLIN ORTHOP RELAT R, P175, DOI 10.1097/BLO.0b013e3180325a42
   Pomatto LCD, 2018, J GERONTOL A BIOL, V73, P141, DOI 10.1093/gerona/glx083
   Reinisch A, 2016, NAT MED, V22, P812, DOI 10.1038/nm.4103
   Richman S, 2006, MENOPAUSE, V13, P148, DOI 10.1097/01.gme.0000191205.20738.01
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schmid GJ, 2009, DEV DYNAM, V238, P766, DOI 10.1002/dvdy.21882
   Seeman E, 2001, J CLIN ENDOCR METAB, V86, P4576, DOI 10.1210/jc.86.10.4576
   Seita J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040321
   Sims Natalie A, 2014, Bonekey Rep, V3, P527, DOI 10.1038/bonekey.2014.22
   Sousa Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867
   Tamate K, 1997, CLIN CHEM, V43, P1159
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Ucer S, 2017, J BONE MINER RES, V32, P560, DOI 10.1002/jbmr.3014
   Van Kempen TA, 2011, BRAIN RES, V1379, P176, DOI 10.1016/j.brainres.2010.12.064
   Velardi E, 2018, NAT MED, V24, P239, DOI 10.1038/nm.4470
   Williams TM, 2009, NAT REV GENET, V10, P797, DOI 10.1038/nrg2687
   Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059 017 1382 0
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
NR 71
TC 29
Z9 31
U1 2
U2 27
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 30
PY 2022
VL 13
IS 1
AR 6491
DI 10.1038/s41467 022 34063 5
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 5U5OI
UT WOS:000876595700013
PM 36310174
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, YJ
   Jeong, JK
   Seol, JW
   Xue, ML
   Jackson, C
   Park, SY
AF Lee, You Jin
   Jeong, Jae Kyo
   Seol, Jae Won
   Xue, Meilang
   Jackson, Chris
   Park, Sang Youel
TI Activated protein C differentially regulates both viability and
   differentiation of osteoblasts mediated by bisphosphonates
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE activated protein C; bisphosphonates; EPCR; MG63; osteoblast
ID PARATHYROID HORMONE; OSTEOCYTE APOPTOSIS; CELL PROLIFERATION; IN VITRO;
   RECEPTOR; BONE; ALENDRONATE; EXPRESSION; OSTEONECROSIS; ANGIOGENESIS
AB Activated protein C (APC) is a cytoprotective anticoagulant that can promote cutaneous healing. We examined the effect of APC on viability and differentiation of the osteoblastic line, MG63, in the presence and absence of bisphosphonates (BPs). Osteoblasts were cultured and treated for 24 or 48 h with Alendronate (Aln), Zoledronate (Zol) or Pamidronate (Pam) at concentrations ranging from 10( 4) to 10( 6) M. Cell differentiation was measured using type 1 collagen production, Alizarin red staining and alkaline phosphatase activity, whereas cell viability was assessed using MTT and crystal violet assays. All three BPs induced MG63 cell death in a dose  and time dependent manner. Pam  and Zol related cell death was prevented by APC treatment; however, cell death induced by Aln was accelerated by APC. APC induced MG63 cell differentiation that was enhanced by Aln, but inhibited by Pam or Zol. Endothelial protein C receptor (EPCR) was expressed by MG63 cells and mediated the protective effect of APC on Zol induced viability. In summary, we have demonstrated that (1) APC favorably regulates MG63 viability and differentiation toward bone growth, (2) APC differentially regulates the effects of specific BPs and (3) at least part of the effects of APC is mediated through EPCR. These findings highlight the potential importance of the PC pathway in bone physiology and provide strong evidence that APC may influence bone cells and has potential to be a therapeutic drug for bone regeneration, depending on concurrent BP treatment. Experimental & Molecular Medicine (2013) 45, e9; doi:10.1038/emm.2013.16; published online 15 February 2013
C1 [Lee, You Jin; Jeong, Jae Kyo; Seol, Jae Won; Park, Sang Youel] Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, Jeonju 561756, South Korea.
   [Xue, Meilang; Jackson, Chris] Univ Sydney, Royal N Shore Hosp, Inst Bone & Joint Res, Kolling Inst, St Leonards, NSW 2065, Australia.
C3 Jeonbuk National University; University of Sydney; Kolling Institute of
   Medical Research; Royal North Shore Hospital
RP Park, SY (通讯作者)，Chonbuk Natl Univ, Coll Vet Med, Jeonju 561756, South Korea.
EM sypark@chonbuk.ac.kr
RI LEE, WON YOUNG/C 7249 2018; Park, Sang Youel/D 5966 2012
OI Jackson, Christopher/0000 0002 9234 9116; Xue,
   Meilang/0000 0002 8563 7216
FU National Research Foundation of Korea; Korean Government [2010 E00019]
FX This study was supported by a grant from the National Research
   Foundation of Korea funded by the Korean Government (2010 E00019).
CR Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Esmon CT, 2004, MATURITAS, V47, P305, DOI 10.1016/j.maturitas.2003.10.015
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Feistritzer C, 2003, J ALLERGY CLIN IMMUN, V112, P375, DOI 10.1067/mai.2003.1609
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   Galligan L, 2001, BRIT J HAEMATOL, V115, P408, DOI 10.1046/j.1365 2141.2001.03187.x
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   HERRON GS, 1986, J BIOL CHEM, V261, P2814
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Iwaki T, 2005, BLOOD, V105, P2364, DOI 10.1182/blood 2004 06 2456
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Jackson CJ, 2008, INT J BIOCHEM CELL B, V40, P2692, DOI 10.1016/j.biocel.2007.12.013
   Jackson CJ, 2005, WOUND REPAIR REGEN, V13, P284, DOI 10.1111/j.1067 1927.2005.00130311.x
   Joyce DE, 2004, CRIT CARE MED, V32, pS280, DOI 10.1097/01.CCM.0000128037.72072.22
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kurata T, 2010, THROMB RES, V125, P184, DOI 10.1016/j.thromres.2009.09.005
   Laszik Z, 1997, CIRCULATION, V96, P3633
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Sturn DH, 2003, BLOOD, V102, P1499, DOI 10.1182/blood 2002 12 3880
   Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Whitmont K, 2008, ARCH DERMATOL, V144, P1479, DOI 10.1001/archderm.144.11.1479
   Xue ML, 2008, J INVEST DERMATOL, V128, P2676, DOI 10.1038/jid.2008.136
   Xue ML, 2005, J INVEST DERMATOL, V125, P1279, DOI 10.1111/j.0022 202X.2005.23952.x
   Xue ML, 2004, EXP CELL RES, V299, P119, DOI 10.1016/j.yexcr.2004.05.015
NR 41
TC 12
Z9 12
U1 0
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD FEB
PY 2013
VL 45
AR e9
DI 10.1038/emm.2013.16
PG 7
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 115CC
UT WOS:000316789000003
PM 23412516
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, YM
   Yang, YY
   Jing, YX
   Yuan, TJ
   Sun, LH
   Tao, B
   Liu, JM
   Zhao, HY
AF Zhou, Yan Man
   Yang, Yu Ying
   Jing, Yi Xuan
   Yuan, Tian Jiao
   Sun, Li Hao
   Tao, Bei
   Liu, Jian Min
   Zhao, Hong Yan
TI BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone
   Remodeling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BMP9; BONE REMODELING; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS;
   THERAPEUTICS
ID STEM CELLS; OSTEOCLAST DIFFERENTIATION; R SPONDINS; LGR4; OSTEOPOROSIS;
   MECHANISMS; PREVENTION; RECEPTORS; GLUCOSE; RANKL
AB Bone remodeling is dynamic and is tightly regulated through bone resorption dominated by osteoclasts and bone formation dominated by osteoblasts. Imbalances in this process can cause various pathological conditions, such as osteoporosis. Bone morphogenetic protein 9 (BMP9), a biomolecule produced and secreted by the liver, has many pharmacological effects, including anti liver fibrosis, antitumor, anti heart failure, and antidiabetic activities. However, the effects of BMP9 on the regulation of osteoblast and osteoclast functions and the underlying molecular mechanism(s) have not yet been investigated. In this study, BMP9 increased the expression of osteoblastogenic gene markers, such as ALP, Cola1, OCN, RUNX2, and OSX, and ALP activity in MC3T3 E1 cells by upregulating LGR6 and activating the Wnt/beta catenin pathway. BMP9 also suppressed receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclast differentiation of bone marrow macrophages (BMMs) by inhibiting the Akt NF kappa B NFATc1 pathway. More importantly, in an ovariectomy (OVX) mouse model, BMP9 attenuated bone loss and improved bone biomechanical properties in vivo by increasing bone forming activity and suppressing bone resorption activity. Accordingly, our current work highlights the dual regulatory effects that BMP9 exerts on bone remodeling by promoting bone anabolic activity and inhibiting osteoclast differentiation in OVX mice. (c) 2020 American Society for Bone and Mineral Research.
C1 [Zhou, Yan Man; Yang, Yu Ying; Jing, Yi Xuan; Yuan, Tian Jiao; Sun, Li Hao; Tao, Bei; Liu, Jian Min; Zhao, Hong Yan] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Shanghai Inst Endocrine & Metab Dis,Sch Med,Dept, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Liu, JM; Zhao, HY (通讯作者)，Shanghai Jiao Tong Univ, Dept Endocrine & Metab Dis, Ruijin Hosp, Sch Med, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.
EM ljm10586@rjh.com.cn; hyanzhao@163.com
RI Yang, Yu Ying/KEI 9974 2024; Liu, Jianmin/KEI 9744 2024; yang,
   yy/KEI 9974 2024; Liu, Jian min/KEI 9744 2024
OI Yang, Yu Ying/0000 0001 5167 3262; YUAN, Tianjiao/0000 0003 2525 1343;
   Liu, Jian min/0000 0002 0179 1751
FU National Natural Science Foundation of China [81870619, 81570796]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81870619 and 81570796).
CR Abdul Ghani M, 2017, DIABETES, V66, P2495, DOI 10.2337/db17 0055
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Breitkopf Heinlein K, 2017, GUT, V66, P939, DOI 10.1136/gutjnl 2016 313314
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Carey HA, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0011 1
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Cheon YH, 2016, J BONE MINER RES, V31, P403, DOI 10.1002/jbmr.2612
   Cui J, 2019, LAB INVEST, V99, P58, DOI 10.1038/s41374 018 0087 7
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   DeFronzo RA, 2013, DIABETES CARE, V36, P3169, DOI 10.2337/dc13 0387
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Desroches Castan A, 2019, HEPATOLOGY, V70, P1392, DOI 10.1002/hep.30655
   Gong X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037137
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Huang X, 2019, STEM CELLS DEV, V28, P683, DOI 10.1089/scd.2018.0230
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   KANATANI M, 1995, J BONE MINER RES, V10, P1681, DOI 10.1002/jbmr.5650101110
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Knight MN, 2014, MATRIX BIOL, V37, P157, DOI 10.1016/j.matbio.2014.06.003
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lehoczky JA, 2015, P NATL ACAD SCI USA, V112, P13249, DOI 10.1073/pnas.1518874112
   Li YY, 2019, J BONE MINER RES, V34, P1938, DOI 10.1002/jbmr.3810
   Liu ZC, 2019, FASEB J, V33, P9828, DOI 10.1096/fj.201802242RR
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maurer T, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/171209
   Menale C, 2019, J BONE MINER RES, V34, P2133, DOI 10.1002/jbmr.3829
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Morine KJ, 2018, CIRCULATION, V138, P513, DOI 10.1161/CIRCULATIONAHA.117.031635
   Nakashima Tomoki, 2014, Clin Calcium, V24, P853, DOI CliCa1406853861
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   Niu HY, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.05.027
   Porcù E, 2018, CELL DEATH DIFFER, V25, P1808, DOI 10.1038/s41418 018 0149 9
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rastogi A, 2019, J DIABETES, V11, P703, DOI 10.1111/1753 0407.12902
   Rubin J, 2007, J BONE MINER RES, V22, P1408, DOI 10.1359/jbmr.070601
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sreekumar V, 2017, ARCH TOXICOL, V91, P1353, DOI 10.1007/s00204 016 1796 6
   Styrkarsdottir U, 2013, NATURE, V497, P517, DOI 10.1038/nature12124
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   van Andel H, 2017, P NATL ACAD SCI USA, V114, P376, DOI 10.1073/pnas.1618650114
   Wan C, 2006, J ORTHOP RES, V24, P29, DOI 10.1002/jor.20010
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang M, 2008, J CELL PHYSIOL, V215, P497, DOI 10.1002/jcp.21331
   Yang M, 2019, FASEB J, V33, P10077, DOI 10.1096/fj.201802544RR
   Yu L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08278 4
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zheng YN, 2012, TISSUE ENG PT A, V18, P621, DOI [10.1089/ten.tea.2011.0366, 10.1089/ten.TEA.2011.0366]
   Zhou M, 2017, J MOL HISTOL, V48, P389, DOI 10.1007/s10735 017 9737 0
NR 63
TC 37
Z9 47
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2020
VL 35
IS 5
BP 978
EP 993
DI 10.1002/jbmr.3957
EA JAN 2020
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LL2YE
UT WOS:000509827800001
PM 31914211
OA Bronze
DA 2025 08 17
ER

PT J
AU Hirbe, AC
   Roelofs, AJ
   Floyd, DH
   Deng, HJ
   Becker, SN
   Lanigan, LG
   Apicelli, AJ
   Xu, ZQ
   Prior, JL
   Eagleton, MC
   Piwnica Worms, D
   Rogers, MJ
   Weilbaecher, K
AF Hirbe, Angela C.
   Roelofs, Anke J.
   Floyd, Desiree H.
   Deng, Hongju
   Becker, Stephanie N.
   Lanigan, Lisa G.
   Apicelli, Anthony J.
   Xu, Zhiqiang
   Prior, Julie L.
   Eagleton, Mark C.
   Piwnica Worms, David
   Rogers, Michael J.
   Weilbaecher, Katherine
TI The bisphosphonate zoledronic acid decreases tumor growth in bone in
   mice with defective osteoclasts
SO BONE
LA English
DT Article
DE Tumor; Osteoclast; Biphosphonate; Risodronate; FPP synthase; Src
ID BREAST CANCER CELLS; HORMONE RELATED PROTEIN; IN VITRO; RAB PRENYLATION;
   MURINE MODEL; PROSTATE; INHIBIT; METASTASES; ANGIOGENESIS; MECHANISMS
AB Bisphosphonates (BPs), bone targeted drugs that disrupt osteoclast function, are routinely used to treat complications of bone metastasis. Studies in preclinical models of cancer have shown that BPs reduce skeletal tumor burden and increase Survival. Similarly, we observed in the present study that administration of the Nitrogen containing BP (N BP), zoledronic acid (ZA) to osteolytic tumor bearing Tax+ mice beginning at 6 months of age led to resolution of radiographic skeletal lesions. N BPs inhibit farnesyl diphosphate (FPP) synthase, thereby inhibiting protein prenylation and causing cellular toxicity. We found that ZA decreased Tax+ tumor and 1316 melanoma viability and caused the accumulation of unprenylated Rap1a proteins in vitro. However, it is presently unclear whether N BPs exert anti tumor effects in bone independent of inhibition of osteoclast (OC) function in vivo. Therefore, we evaluated the impact of treatment with ZA on B16 melanoma bone tumor burden in irradiated mice transplanted with splenic cells from src( / ) mice, which have non functioning OCs. OC defective mice treated with ZA demonstrated a significant 88% decrease in tumor growth in bone compared to vehicle treated OC defective mice. These data support an osteoclast independent role for N BP therapy in bone metastasis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Hirbe, Angela C.; Floyd, Desiree H.; Deng, Hongju; Becker, Stephanie N.; Apicelli, Anthony J.; Xu, Zhiqiang; Eagleton, Mark C.; Weilbaecher, Katherine] Washington Univ, Sch Med, Div Mol Oncol, Dept Med, St Louis, MO 63110 USA.
   [Prior, Julie L.; Piwnica Worms, David] Washington Univ, Sch Med, Dept Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA.
   [Roelofs, Anke J.; Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Res Programme, Aberdeen AB25 2ZD, Scotland.
   [Lanigan, Lisa G.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); University
   of Aberdeen; University System of Ohio; Ohio State University
RP Weilbaecher, K (通讯作者)，Washington Univ, Sch Med, Div Mol Oncol, Dept Med, 660 S Euclid,Box 8069, St Louis, MO 63110 USA.
EM kweilbae@im.wustl.edu
RI ; Apicelli, Anthony/AAB 8879 2021; Roelofs, Anke/ABG 5019 2021; Xu,
   Zhiqiang/B 9009 2009
OI Rogers, Michael/0000 0002 1818 9249; Lanigan, Lisa/0000 0001 8969 7411;
   Apicelli, Anthony/0000 0001 6791 8113; 
FU Hematology Training Grant [T32 HL007088, R01 CA097250, PPG CA100730, P50
   CA94056]; St. Louis Men's Group Against Cancer; Cancer Research UK
   [C13325/A7166]
FX We would like to thank Dr. Steven Teitelbaum, Dr. Paddy Ross, Michael
   Tomasson, Dr. Elizabeth Morgan, Dr. Haibo Zhao, Dr. Tom Rosol, Nikki
   Sloan, Deb Novack, Lee Ratner, and Dr. Jonathan Green, for helpful
   discussions.ACH and DF were supported by Hematology Training Grant (T32
   HL007088), KW by (R01 CA097250), PPG CA100730, HD, LGL, and ZX by (PPG
   CA100730) JLP and DP W by the Molecular Imaging Center (P50 CA94056).
   SNB was supported by St. Louis Men's Group Against Cancer. AJR and MJR
   were supported by a grant from Cancer Research UK (C13325/A7166).
CR Amling M, 2000, BONE, V27, P603, DOI 10.1016/S8756 3282(00)00373 2
   Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464 6474.2005
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   DUMAS A, 2008, OSTEOPOROS INT
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fournier P, 2002, CANCER RES, V62, P6538
   Gao L, 2005, BLOOD, V106, P4294, DOI 10.1182/blood 2005 04 1730
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622 200211000 00004
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   Guise TA, 1997, CANCER AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1572::AID CNCR7>3.3.CO;2 D
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hapidin H, 2007, J BONE MINER METAB, V25, P93, DOI 10.1007/s00774 006 0733 9
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hirbe AC, 2007, BLOOD, V109, P3424, DOI 10.1182/blood 2006 09 048686
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Liao JH, 2006, CANCER RES, V66, P9065, DOI 10.1158/0008 5472.CAN 06 0317
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101 1194
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roelofs AJ, 2006, INT J CANCER, V119, P1254, DOI 10.1002/ijc.21977
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008 5472.CAN 04 2853
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Wang LP, 2005, BLOOD, V106, P3650, DOI 10.1182/blood 2005 02 0582
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
NR 53
TC 53
Z9 59
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2009
VL 44
IS 5
BP 908
EP 916
DI 10.1016/j.bone.2009.01.010
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 436SO
UT WOS:000265436000023
PM 19442620
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, AS
   Taylor, VE
   Castro Martinez, A
   Dhakal, S
   Zamerli, A
   Mohanty, S
   Xiao, Y
   Simic, MK
   Wen, JC
   Chai, RY
   Croucher, P
   Center, JR
   Girgis, CM
   McDonald, MM
AF Kim, Albert S.
   Taylor, Victoria E.
   Castro Martinez, Ariel
   Dhakal, Suraj
   Zamerli, Amjad
   Mohanty, Sindhu
   Xiao, Ya
   Simic, Marija K.
   Wen, Jinchen
   Chai, Ryan
   Croucher, Peter, I
   Center, Jacqueline R.
   Girgis, Christian M.
   McDonald, Michelle M.
TI Temporal patterns of osteoclast formation and activity following
   withdrawal of RANKL inhibition
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoclast; RANKL; Denosumab; osteoporosis
ID BONE RESORPTION; DENOSUMAB; INCREASES
AB Rebound bone loss following denosumab discontinuation is an important clinical challenge. Current treatment strategies to prevent this fail to suppress the rise and overshoot in osteoclast mediated bone resorption. In this study, we use a murine model of denosumab treatment and discontinuation to show the temporal changes in osteoclast formation and activity during RANKL inhibition and withdrawal. We show that the cellular processes that drive the formation of osteoclasts and subsequent bone resorption following withdrawal of RANKL inhibition precede the rebound bone loss. Furthermore, a rise in serum TRAP and RANKL levels is detected before markers of bone turnover used in current clinical practice. These mechanistic advances may provide insight into a more defined window of opportunity to intervene with sequential therapy following denosumab discontinuation.
   Stopping denosumab, a medication commonly used to improve bone mass by blocking formation of bone resorbing osteoclasts, leads to a rebound loss in the bone which was gained during treatment. Current strategies to prevent this bone loss fail in most cases as they are unable to prevent the rise and overshoot in bone resorption by osteoclasts. Thie stems from an incomplete understanding of how osteoclasts behave during denosumab treatment and after treatment is discontinued. We use a mouse model of this phenomenon to show how osteoclast formation and activity changes throughout this process. We show that increases in the processes that drive the formation of osteoclasts can be detected in the circulation before bone loss occurs. These findings could therefore provide insight into a targeted 'window of opportunity' to intervene and prevent the rebound bone loss following stopping denosumab in patients.
   Graphical Abstract
C1 [Kim, Albert S.; Taylor, Victoria E.; Castro Martinez, Ariel; Dhakal, Suraj; Zamerli, Amjad; Mohanty, Sindhu; Xiao, Ya; Simic, Marija K.; Chai, Ryan; Croucher, Peter, I; Center, Jacqueline R.; McDonald, Michelle M.] Garvan Inst Med Res, Skeletal Dis Program, Sydney, NSW 2010, Australia.
   [Kim, Albert S.; Chai, Ryan; Croucher, Peter, I; Center, Jacqueline R.; McDonald, Michelle M.] UNSW Sydney, Fac Med, St Vincents Clin Sch, Sydney, NSW 2010, Australia.
   [Kim, Albert S.; Girgis, Christian M.] Westmead Hosp, Dept Diabet & Endocrinol, Sydney, NSW 2145, Australia.
   [Kim, Albert S.; Girgis, Christian M.; McDonald, Michelle M.] Univ Sydney, Fac Hlth & Med, Sydney, NSW 2050, Australia.
   [Simic, Marija K.] NYU, Dept Pathol, Grossman Sch Med, New York, NY 10016 USA.
   [Wen, Jinchen] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA.
   [McDonald, Michelle M.] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sci Rd, Camperdown, NSW 2050, Australia.
C3 Garvan Institute of Medical Research; University of New South Wales
   Sydney; University of Sydney; NSW Health; Westmead Hospital; University
   of Sydney; New York University; Duke University; University of Sydney
RP McDonald, MM (通讯作者)，Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sci Rd, Camperdown, NSW 2050, Australia.
EM a.kim@garvan.org.au; v.taylor@garvan.org.au;
   a.castro martinez@garvan.org.au; s.dhakal@garvan.org.au;
   a.zamerli@garvan.org.au; sindhumohanty@googlemail.com;
   xiaoya_aries@hotmail.com; marija.simic@nyulangone.org;
   jinchen.wen@duke.edu; r.chai@garvan.org.au;
   christian.girgis@sydney.edu.au; michelle.mcdonald@sydney.edu.au
RI Center, Jacqueline/AAY 8712 2021; McDonald, Michelle/AAD 4760 2019
OI Chai, Ryan/0000 0001 7628 4175; McDonald, Michelle/0000 0002 3928 2506;
   Wen, Jinchen/0000 0002 3754 1500
FU UNSW Sydney University Postgraduate Award; Amgen Inc.
FX OPG:Fc used in this study was provided by Amgen Inc.
CR Anastasilakis AD, 2021, CALCIFIED TISSUE INT, V108, P587, DOI 10.1007/s00223 020 00785 1
   Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Burckhardt P, 2021, J BONE MINER RES, V36, P1717, DOI 10.1002/jbmr.4335
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Everts Graber J, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115830
   Everts Graber J, 2020, J BONE MINER RES, V35, P1207, DOI 10.1002/jbmr.3962
   Fassio A, 2019, BONE, V123, P191, DOI 10.1016/j.bone.2019.03.019
   Fontalis A., 2020, Bone Rep, V13, P100457, DOI [10.1016/j.bonr.2020.100457, DOI 10.1016/J.BONR.2020.100457]
   Fu Q, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.167790
   Gossiel F, 2022, OSTEOPOROSIS INT, V33, P1357, DOI 10.1007/s00198 022 06311 3
   Janckila AJ, 2009, CALCIFIED TISSUE INT, V85, P465, DOI 10.1007/s00223 009 9309 8
   Kim AS, 2022, CURR OSTEOPOROS REP, DOI 10.1007/s11914 022 00756 5
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Limaye A, 2012, PROC SPIE, V8506, DOI 10.1117/12.935640
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   McDonald MM, 2013, J BONE MINER RES, V28, P1550, DOI 10.1002/jbmr.1889
   Mira Pascual L, 2020, CALCIFIED TISSUE INT, V106, P194, DOI 10.1007/s00223 019 00618 w
   Mori Y, 2018, OSTEOPOROSIS INT, V29, P1155, DOI 10.1007/s00198 018 4376 1
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Naylor KE, 2010, BONE, V46, P592, DOI 10.1016/j.bone.2009.10.043
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Solling AS, 2023, OSTEOPOROSIS INT, V34, P599, DOI 10.1007/s00198 022 06651 0
   Solling AS, 2020, J BONE MINER RES, V35, P1858, DOI 10.1002/jbmr.4098
   Trémollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
NR 36
TC 12
Z9 13
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY 2
PY 2024
VL 39
IS 4
BP 484
EP 497
DI 10.1093/jbmr/zjae023
EA MAR 2024
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RE1V1
UT WOS:001225910300001
PM 38477789
OA hybrid
DA 2025 08 17
ER

PT J
AU Chowdhury, K
   Sharma, A
   Sharma, T
   Kumar, S
   Mandal, CC
AF Chowdhury, Kaushik
   Sharma, Ankit
   Sharma, Tanu
   Kumar, Suresh
   Mandal, Chandi C.
TI Simvastatin and MBCD Inhibit Breast Cancer Induced Osteoclast Activity
   by Targeting Osteoclastogenic Factors
SO CANCER INVESTIGATION
LA English
DT Article
DE Breast cancer; Bone metastasis; Osteoclast activity; Simvastatin; Methyl
   beta cyclodextrin; CSF 1; RANKL
ID NF KAPPA B; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; BONE
   METASTASIS; EXPRESSION; IDENTIFICATION; STIMULATION; ACTIVATION;
   MECHANISMS; PATHWAY
AB Previous reports have documented that cholesterol lowering simvastatin prevented osteolytic metastasis of breast cancer in animal model in which cancer cells were placed into blood circulation. Thus, simvastatin treatment might have a preventive effect in inhibiting osteoclast activity of metastatic bone microenvironment. This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre osteoclast RAW264.7 cells, and osteoclastogenic CSF 1 and RANKL expressions in breast cancer MCF 7 cells. Thus, these findings unravel a molecular mechanism of simvastatin /MBCD mediated inhibition of breast cancer driven osteoclast activity.
C1 [Chowdhury, Kaushik; Sharma, Ankit; Sharma, Tanu; Kumar, Suresh; Mandal, Chandi C.] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH 8 Bandarsindri, Ajmer 305817, Rajasthan, India.
C3 Central University of Rajasthan (CURAJ)
RP Mandal, CC (通讯作者)，Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH 8 Bandarsindri, Ajmer 305817, Rajasthan, India.
EM ccmandal@curaj.ac.in
OI Mandal, Chandi/0000 0002 2292 6635; Chowdhury,
   Kaushik/0000 0001 5359 2458; SHARMA, TANU/0000 0002 6095 3052
FU UGC(BSR) [30 49/2014]; DBT [6242 P9/RGCB/PMD/DBT/CCML/2015]; Central
   University of Rajasthan, India; DST INSPIRE fellowship   Department of
   Science and Technology, India [IF140765]
FX Dr. Chandi C. Mandal was supported by UGC [30 49/2014 (BSR)], DBT
   [6242 P9/RGCB/PMD/DBT/CCML/2015], and Central University of Rajasthan,
   India. Tanu Sharma was supported by DST INSPIRE fellowship [IF140765]
   provided by the Department of Science and Technology, India.
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Babcook MA, 2014, MOL CANCER THER, V13, P2288, DOI 10.1158/1535 7163.MCT 14 0451
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Chiou WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089159
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Ghosh Choudhury N, 2006, J BIOL CHEM, V281, P20160, DOI 10.1074/jbc.M511071200
   Ghosh Choudhury N, 2013, J BIOL CHEM, V288, P24503, DOI 10.1074/jbc.M113.455733
   Ghosh Choudhury N, 2010, CELL SIGNAL, V22, P749, DOI 10.1016/j.cellsig.2009.12.010
   Hanania R, 2012, J BIOL CHEM, V287, P8468, DOI 10.1074/jbc.M111.290676
   Kogawa M, 2010, ENDOCRINOLOGY, V151, P4613, DOI 10.1210/en.2010 0334
   Liu H, 2013, NEOPLASMA, V60, P240, DOI 10.4149/neo_2013_032
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Mandal CC, 2016, TUMOR BIOL, V37, P9635, DOI 10.1007/s13277 016 4799 2
   Mandal Chandi C, 2014, J Cancer Sci Ther, V6, P510
   Mandal CC, 2016, J BIOL CHEM, V291, P1148, DOI 10.1074/jbc.M115.668939
   Mandal CC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00165
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009 0026
   Mandal CC, 2012, CARCINOGENESIS, V33, P1897, DOI 10.1093/carcin/bgs198
   Mandal CC, 2011, J BIOL CHEM, V286, P11314, DOI 10.1074/jbc.M110.193714
   Mandal CC, 2010, CALCIFIED TISSUE INT, V87, P533, DOI 10.1007/s00223 010 9419 3
   Mikhailova M, 2012, MATRIX BIOL, V31, P380, DOI 10.1016/j.matbio.2012.10.001
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakashima Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072033
   Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Rubin J, 2006, J BIOL CHEM, V281, P1412, DOI 10.1074/jbc.M508639200
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Thysell E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014175
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 38
TC 27
Z9 27
U1 2
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735 7907
EI 1532 4192
J9 CANCER INVEST
JI Cancer Invest.
PY 2017
VL 35
IS 6
BP 403
EP 413
DI 10.1080/07357907.2017.1309548
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FC0EZ
UT WOS:000406512600005
PM 28463564
DA 2025 08 17
ER

PT J
AU Chagin, AS
AF Chagin, Andrei S.
TI Effectors of mTOR autophagy pathway: targeting cancer, affecting the
   skeleton
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID REGULATES AUTOPHAGY; BONE RESORPTION; CELL DEATH; INHIBITION;
   TUMORIGENESIS; SUPPRESSION; CARTILAGE; RAPAMYCIN; DELETION; GROWTH
AB Although some modulators of autophagy are emerging as drugs or supplements for anti cancer therapy, the effects of these compounds on normal tissues must be examined carefully. Here, I review the role of autophagy in skeletal tissues in this context.First, I briefly review preclinical studies indicating the role of autophagy in cancer, as well as related on going clinical trials. Thereafter, the role of autophagy in the physiology of skeletal tissues is discussed, with a focus on recent genetic preclinical studies. Specifically, I discuss the mTOR autophagy pathway in relationship to epiphyseal chondrocytes, articular chondrocytes, osteoblasts, osteocytes and osteoclasts and potential side effects of targeting either mTOR pathway or autophagy in general in connection with anti cancer therapy.Current preclinical findings indicate that inhibiting autophagy will not seriously reduce bone mass and enhance osteoporosis. However, inhibition of autophagy might damage articular cartilage and cause osteoarthritis, whereas treatment with rapalogs might result in relatively beneficial effects on articular cartilage. Modulation of the mTOR pathway or autophagy during childhood may have an undesirable influence on adult height, as well as acquisition of bone mass.
C1 [Chagin, Andrei S.] Karolinska Inst, Dept Physiol & Pharmacol, S 10401 Stockholm, Sweden.
C3 Karolinska Institutet
RP Chagin, AS (通讯作者)，Karolinska Inst, Dept Physiol & Pharmacol, S 10401 Stockholm, Sweden.
EM Andrei.chagin@ki.se
RI Chagin, Andrei/F 4080 2014
OI Chagin, Andrei/0000 0002 2696 5850
FU Swedish Research Council [521 2012 1543]; Karolinska Institutet; Swedish
   Society for Medical Research
FX I would like to thank Drs. Phillip T. Newton and Boris Zhivotovsky (both
   at Karolinska Institutet) for their critical reading of the manuscript.
   My own work described here financed by the Swedish Research Council
   (Grant #521 2012 1543), Karolinska Institutet and Swedish Society for
   Medical Research.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008 5472.CAN 07 0562
   Beyer C, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis 2013 204698
   Bouderlique T, 2016, ANN RHEUM DIS, V75, P627, DOI 10.1136/annrheumdis 2015 207742
   Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Caramés B, 2010, ARTHRITIS RHEUM US, V62, P791, DOI 10.1002/art.27305
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood 2006 10 050260
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chagin AS, 2009, HORM RES, V71, P41, DOI 10.1159/000192435
   Chen JQ, 2014, DEVELOPMENT, V141, P2848, DOI 10.1242/dev.108811
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Cinque L, 2015, NATURE
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535 7163.MCT 08 1169
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Firat E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047357
   Füllgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goldring MB, 2012, THER ADV MUSCULOSKEL, V4, P269, DOI 10.1177/1759720X12448454
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Ikebuchi K, 2009, INT J CANCER, V125, P861, DOI 10.1002/ijc.24466
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Mariño G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Martin N, 2008, MOL CELL BIOL, V28, P2771, DOI 10.1128/MCB.01210 07
   Meléndez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008 5472.CAN 04 4142
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mok C. C., 2005, Lupus, V14, P106, DOI 10.1191/0961203305lu2039oa
   Newton PT, 2015, AUTOPHAGY, V11, P1594, DOI 10.1080/15548627.2015.1068489
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Ochi Y, 2011, ONCOL REP, V26, P805, DOI 10.3892/or.2011.1329
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Pan F, 2010, J HUM GENET, V55, P441, DOI 10.1038/jhg.2010.44
   Phornphutkul C, 2009, J ORTHOP RES, V27, P1157, DOI 10.1002/jor.20894
   Piemontese M, 2015, BONE, V75, P18, DOI 10.1016/j.bone.2015.02.005
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sanchez CP, 2009, BMC PEDIATR, V9, DOI 10.1186/1471 2431 9 3
   Singer Nora G., 1998, Current Opinion in Rheumatology, V10, P169, DOI 10.1097/00002281 199805000 00003
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003 4819 144 5 200603070 00008
   Stenbeck G, 2014, CURR OPIN PHARMACOL, V16, P7, DOI 10.1016/j.coph.2014.01.003
   Suri P, 2012, PM&R, V4, pS10, DOI 10.1016/j.pmrj.2012.01.007
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takayama K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0482 4
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thomè R, 2013, IMMUNOL LETT, V153, P50, DOI 10.1016/j.imlet.2013.07.004
   Vuppalapati KK, 2015, J BONE MINER RES, V30, P2249, DOI 10.1002/jbmr.2575
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhang Y, 2015, ANN RHEUM DIS, V74, P1432, DOI 10.1136/annrheumdis 2013 204599
NR 63
TC 58
Z9 67
U1 0
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2016
VL 28
BP 1
EP 7
DI 10.1016/j.coph.2016.02.004
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DM4QM
UT WOS:000376331800002
PM 26921601
DA 2025 08 17
ER

PT J
AU Imtiyaz, Z
   Lin, YT
   Cheong, UH
   Jassey, A
   Liu, HK
   Lee, MH
AF Imtiyaz, Zuha
   Lin, Yi Tzu
   Cheong, Ut Hang
   Jassey, Alagie
   Liu, Hui Kang
   Lee, Mei Hsien
TI Compounds isolated from Euonymus spraguei Hayata induce
   ossification through multiple pathways
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Euonymus spraguei Hayata; Human osteoblast cells; Syringin;
   ( ) Epicatechin; Osteogenesis; Multi target drugs
ID METHANOL EXTRACT; DRUG DISCOVERY; IN VITRO; BONE; MINERALIZATION;
   RECEPTORS; AUTOPHAGY; ESTROGEN; CELL; DIFFERENTIATION
AB The process of bone metabolism includes catabolism of old or mature bone and anabolism of new bone, carried out by osteoclasts and osteoblasts respectively. Any imbalance in this process results in loss of bone mass or osteoporosis. Drugs available to combat osteoporosis have certain adverse effects and are unable to improve bone formation, hence identifying new agents to fulfil these therapeutic gaps is required. To expand the scope of potential agents that enhance bone formation, we identified Euonymus spraguei Hayata as a plant material that possesses robust osteogenic potential using human osteoblast cells. We isolated three compounds, syringaresinol (1), syringin (2), and ( ) epicatechin (3), from E. spraguei. Results demonstrated that syringin (2), and ( ) epicatechin (3), increased alkaline phosphatase activity significantly up to 131.01% and 130.67%, respectively; they also elevated mineral deposition with respective values of up to 139.39% and 138.33%. In addition, 2 and 3 modulated autophagy and the bone morphogenetic protein (BMP) 2 signaling pathway. Our findings demonstrated that 2 and 3 induced osteogenesis by targeting multiple pathways and therefore can be considered as potent multi targeted drugs for bone formation against osteoporosis. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
C1 [Imtiyaz, Zuha; Lin, Yi Tzu; Lee, Mei Hsien] Taipei Med Univ, Coll Pharm, Program Clin Drug Dev Herbal Med, Taipei 110, Taiwan.
   [Cheong, Ut Hang; Lee, Mei Hsien] Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei 110, Taiwan.
   [Jassey, Alagie] Taipei Med Univ, Coll Med, Taipei 110, Taiwan.
   [Liu, Hui Kang] Minist Hlth & Welf, Natl Res Inst Chinese Med, Div Basic Chinese Med, Taipei 112, Taiwan.
   [Lee, Mei Hsien] Taipei Med Univ Hosp, Ctr Reprod Med & Sci, Taipei 110, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Medical
   University; National Research Institute of Chinese Medicine; Taipei
   Medical University; Taipei Medical University Hospital
RP Lee, MH (通讯作者)，Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei 110, Taiwan.
EM lmh@tmu.edu.tw
RI ; Jassey, Alagie/NJR 2086 2025
OI Imtiyaz, Zuha/0000 0001 6927 8623; 
FU Ministry of Science and Technology, Taiwan [MOST106 2320 B 038 016 MY3]
FX This study was funded by the Ministry of Science and Technology, Taiwan
   under grant number MOST106 2320 B 038 016 MY3.
CR Alarcón J, 2015, J AGR FOOD CHEM, V63, P10250, DOI 10.1021/acs.jafc.5b04168
   [Anonymous], 2019, MOLECULES, DOI DOI 10.3390/MOLECULES24010120
   [Anonymous], 2017, RES CHEM INTERMEDIAT, DOI DOI 10.1007/S11164 016 2619 3
   [Anonymous], 2015, PLOS ONE
   [Anonymous], 2017, RES CHEM INTERMEDIAT, DOI DOI 10.1007/S11164 016 2434 X
   [Anonymous], 2019, PHYTOMEDICINE, DOI DOI 10.1016/J.PHYMED.2018.09.192
   [Anonymous], 2019, INT J MOL SCI, DOI DOI 10.3390/IJMS20236001
   Aoki H, 2001, J CELL SCI, V114, P1483
   Aubin J.E., 2002, PRINCIPLES BONE BIOL, P59
   Bailey S, 2017, ANN NY ACAD SCI, V1409, P79, DOI 10.1111/nyas.13470
   Bakhsh A, 2013, NUTRITION, V29, P667, DOI 10.1016/j.nut.2012.09.005
   Bolognesi ML, 2016, CHEMMEDCHEM, V11, P1190, DOI 10.1002/cmdc.201600161
   Boskey AL, 2007, ELEMENTS, V3, P385, DOI 10.2113/GSELEMENTS.3.6.385
   Bouleftour W, 2016, MATRIX BIOL, V52 54, P60, DOI 10.1016/j.matbio.2015.12.011
   Byun MR, 2014, J BIOL CHEM, V289, P9926, DOI 10.1074/jbc.M113.522870
   Cha BY, 2003, J ETHNOPHARMACOL, V85, P163, DOI 10.1016/S0378 8741(02)00373 2
   Chang B, 2012, AM J CHINESE MED, V40, P1177, DOI 10.1142/S0192415X12500875
   Cho JY, 2001, J PHARM PHARMACOL, V53, P1287, DOI 10.1211/0022357011776577
   Choi J, 2004, PLANTA MED, V70, P1027, DOI 10.1055/s 2004 832642
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Fan YC, 2018, MOLECULES, V23, DOI 10.3390/molecules23061361
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Imtiyaz Z., 2019, INT J MOL SCI, V20, P1
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Jimi E, 2010, JPN DENT SCI REV, V46, P33, DOI 10.1016/j.jdsr.2009.10.003
   Jolly J.J., 2018, INT J ENV RES PUBLIC, V15, P1
   Katsimbri P., 2017, EUR J CANC CARE, V26, P1
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Kim SJ, 2010, ARCH PHARM RES, V33, P867, DOI 10.1007/s12272 010 0609 3
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Koeberle A, 2014, DRUG DISCOV TODAY, V19, P1871, DOI 10.1016/j.drudis.2014.08.006
   Koul M, 2016, PLANTA MED, V82, P344, DOI 10.1055/s 0035 1558308
   Krishnan SSC, 2014, BIOMED PREV NUTR, V4, P105, DOI 10.1016/j.bionut.2013.12.009
   Kusumoto K, 2002, J INT MED RES, V30, P251, DOI 10.1177/147323000203000305
   Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Liu LM, 2014, FOOD CHEM TOXICOL, V70, P179, DOI 10.1016/j.fct.2014.05.004
   Mahadeva Rao U., 2015, ASIAN J PHARM CLIN R, V8, P20
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Mao YW, 2014, J AGR FOOD CHEM, V62, P5581, DOI 10.1021/jf5012177
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Medicine U.S.N.L.o., 2018, SAF EFF STUD LAD MIL
   Mikami Y, 2016, J BONE MINER METAB, V34, P627, DOI 10.1007/s00774 015 0719 6
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Morphy R, 2010, J MED CHEM, V53, P1413, DOI 10.1021/jm901132v
   Ni JC, 2019, NAT PROD RES, V33, P101, DOI 10.1080/14786419.2018.1437434
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Pan F, 2010, J HUM GENET, V55, P441, DOI 10.1038/jhg.2010.44
   Prakash M, 2019, J FUNCT FOODS, V52, P14, DOI 10.1016/j.jff.2018.10.021
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ramsay RR, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169 017 0181 2
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Sams Dodd F, 2005, DRUG DISCOV TODAY, V10, P139, DOI 10.1016/S1359 6446(04)03316 1
   Shao J., 2016, TIANJIN AGR SCI, V1, P37
   Sharma A, 2012, MINI REV ORG CHEM, V9, P341, DOI 10.2174/157019312804699500
   Shim KS, 2015, INTEGR MED RES, V4, P102, DOI 10.1016/j.imr.2015.02.002
   Sun CR, 2009, MOLECULES, V14, P2650, DOI 10.3390/molecules14072650
   Sun Z., 2019, BIOMED PHARMACOTHER, V120, P1
   Tai C.J., 2020, CELLS, V9, P1
   Van der Schyf Cornelis J, 2011, Expert Rev Clin Pharmacol, V4, P293, DOI 10.1586/ecp.11.13
   Wan Osman W.N., 2019, J FOOD BIOCH, V43
   Wei Q., 2016, CHIN J APP CHEM, V33, P719
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu XW, 2019, NANOSCALE, V11, P21953, DOI 10.1039/c9nr07017f
   Yan CY, 2019, CARBOHYD POLYM, V210, P110, DOI 10.1016/j.carbpol.2019.01.026
   Yang EJ, 2010, ARCH PHARM RES, V33, P531, DOI 10.1007/s12272 010 0406 z
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
NR 71
TC 6
Z9 7
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319 562X
EI 2213 7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD SEP
PY 2020
VL 27
IS 9
BP 2227
EP 2237
DI 10.1016/j.sjbs.2020.06.036
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA NA6MH
UT WOS:000559932100004
PM 32884403
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Wang, H
   Zhang, HW
   Srinivasan, V
   Tao, JG
   Sun, W
   Lin, X
   Wu, T
   Boyce, BF
   Ebetino, FH
   Boeckman, RK
   Xing, LP
AF Wang, Hua
   Zhang, Hengwei
   Srinivasan, Venkat
   Tao, Jianguo
   Sun, Wen
   Lin, Xi
   Wu, Tao
   Boyce, Brendan F.
   Ebetino, Frank H.
   Boeckman, Robert K., Jr.
   Xing, Lianping
TI Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and
   Reduces Systemic Adverse Effects in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE TARGETING; BORTEZOMIB; OSTEOPOROSIS; FRACTURE; AGING; BONE VOLUME;
   BISPHOSPHONATES
ID REGULATES OSTEOBLAST DIFFERENTIATION; INDUCED PERIPHERAL NEUROTOXICITY;
   E3 LIGASE ITCH; MULTIPLE MYELOMA; MECHANICAL PROPERTIES;
   CELL DIFFERENTIATION; FRACTURE REPAIR; MOUSE MODEL; STEM CELLS;
   INHIBITION
AB Bortezomib (Btz) is a proteasome inhibitor approved by the FDA to treat multiple myeloma. It also increases bone volume by promoting osteoblast differentiation and inhibiting osteoclastogenesis in mice. However, Btz has severe systemic adverse effects, which would limit its use as a bone anabolic agent. Here, we designed and synthesized a bone targeted form of Btz by conjugating it to a bisphosphonate (BP) with no antiresorptive activity. We report that BP Btz inhibited osteoclast formation and bone resorption and stimulated osteoblast differentiation in vitro similar to Btz. In vivo, BP Btz increased bone volume more effectively than Btz in three mouse models: untreated wild type mice, mice with ovariectomy, and aged mice with tibial factures. Importantly, BP Btz had significantly less systemic side effects than Btz, including less thymic cell death, sympathetic nerve damage, and thrombocytopenia, and it improved survival rates in aged mice. Thus, BP Btz represents a novel anabolic agent to treat conditions, such as postmenopausal and age related bone loss. Bone targeting is an attractive approach to repurpose approved drugs to treat skeletal diseases. (c) 2019 American Society for Bone and Mineral Research. (c) 2019 American Society for Bone and Mineral Research.
C1 [Wang, Hua; Zhang, Hengwei; Tao, Jianguo; Sun, Wen; Lin, Xi; Wu, Tao; Boyce, Brendan F.; Xing, Lianping] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   [Wang, Hua] Nanjing Med Univ, Inst Stomatol, Jiangsu Key Lab Oral Dis, Nanjing, Jiangsu, Peoples R China.
   [Srinivasan, Venkat; Ebetino, Frank H.; Boeckman, Robert K., Jr.] Univ Rochester, Dept Chem, Rochester, NY USA.
   [Wu, Tao] Hebei Med Univ, Dept Bone Dis, Hosp 3, Shijiazhuang, Hebei, Peoples R China.
   [Boyce, Brendan F.; Xing, Lianping] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Ebetino, Frank H.] BioVinc, Pasadena, CA USA.
C3 University of Rochester; Nanjing Medical University; University of
   Rochester; Hebei Medical University; University of Rochester
RP Xing, LP (通讯作者)，Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM lianping_xing@urmc.rochester.edu
RI ; Zhang, hengwei/S 9114 2019; Wang, Hua/MHP 9513 2025
OI Sun, Wen/0000 0002 8111 8865; Tao, Jianguo/0000 0002 3473 9212
FU National Institute of Health [AR063650, AR069789, AR043510, AG049994];
   NYSTEM [C029548]; National Natural Science Foundation of China
   [81970961]; National Institute of Health USA PHS awards [P30 AR069655,
   1S10RR027340 01]; Technology Development Fund of University of Rochester
FX This work was supported by research grants from National Institute of
   Health awards (AR063650, AR069789, AR043510, AG049994), NYSTEM
   (C029548), Technology Development Fund of University of Rochester,
   National Natural Science Foundation of China (81970961). Some
   experiments were performed by the Center for Musculoskeletal Research
   Center cores (mu CT) or using core equipment (frozen sectioning,
   microscopes, and whole slide imaging), which are supported by grants
   from National Institute of Health USA PHS awards (P30 AR069655,
   1S10RR027340 01).
CR Agyin JK, 2013, BIOORG MED CHEM LETT, V23, P6455, DOI 10.1016/j.bmcl.2013.09.043
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Bonvini P, 2007, LEUKEMIA, V21, P838, DOI 10.1038/sj.leu.2404528
   Brown ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099656
   Cavaletti G, 2007, EXP NEUROL, V204, P317, DOI 10.1016/j.expneurol.2006.11.010
   Chen Y, 2011, NAT NEUROSCI, V14, P437, DOI 10.1038/nn.2780
   Cheng Q, 2014, NEURAL REGEN RES, V9, P2142, DOI 10.4103/1673 5374.147948
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Huang HM, 2009, LEUKEMIA RES, V33, P115, DOI 10.1016/j.leukres.2008.07.028
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Kung MH, 2012, J CELL PHYSIOL, V227, P1062, DOI 10.1002/jcp.22819
   Li X, 2017, SCI REP UK, V7, DOI 10.1038/srep41358
   Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Lonial S, 2005, BLOOD, V106, P3777, DOI 10.1182/blood 2005 03 1173
   Maseda D, 2008, CELL DEATH DIFFER, V15, P600, DOI 10.1038/sj.cdd.4402297
   Meregalli C, 2015, J BIOL REG HOMEOS AG, V29, P115
   Mohty B, 2010, HAEMATOL HEMATOL J, V95, P311, DOI 10.3324/haematol.2009.012674
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Murai K, 2014, EUR J HAEMATOL, V93, P290, DOI 10.1111/ejh.12342
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Reynolds DG, 2009, J BONE MINER RES, V24, P899, DOI 10.1359/JBMR.081232
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Shi DS, 2014, J CLIN INVEST, V124, P3757, DOI 10.1172/JCI75247
   Stockstill K, 2018, J EXP MED, V215, P1301, DOI 10.1084/jem.20170584
   Sun W, 2017, J BONE MINER RES, V32, P1469, DOI 10.1002/jbmr.3117
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Undale A, 2011, J ORTHOP RES, V29, P1804, DOI 10.1002/jor.21480
   Vidal B, 2012, ACTA REUMATOL PORT, V37, P294
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Weathington NM, 2014, J CLIN INVEST, V124, P6, DOI 10.1172/JCI71602
   Xing LP, 2010, J CELL BIOCHEM, V110, P554, DOI 10.1002/jcb.22586
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhang H, 2016, BONE, V90, P80, DOI 10.1016/j.bone.2016.06.003
   Zhang HW, 2014, J CLIN INVEST, V124, P3200, DOI 10.1172/JCI68901
   Zhang HW, 2013, STEM CELLS, V31, P1574, DOI 10.1002/stem.1395
   Zhang H, 2015, J BONE MINER RES, V30, P742, DOI 10.1002/jbmr.2391
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
NR 50
TC 22
Z9 23
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2020
VL 35
IS 2
BP 343
EP 356
DI 10.1002/jbmr.3889
EA NOV 2019
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KJ7HG
UT WOS:000497127700001
PM 31610066
OA Bronze
DA 2025 08 17
ER

PT J
AU Fromigué, O
   Haÿ, E
   Barbara, A
   Petrel, C
   Traiffort, E
   Ruat, M
   Marie, PJ
AF Fromigue, Olivia
   Hay, Eric
   Barbara, Alain
   Petrel, Christophe
   Traiffort, Elisabeth
   Ruat, Martial
   Marie, Pierre J.
TI Calcium sensing receptor dependent and receptor independent activation
   of osteoblast replication and survival by strontium ranelate
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE strontium ranelate; osteoblasts; ERK1; 2; Akt; calcium sensing receptor;
   replication; apoptosis
ID EXTRACELLULAR CALCIUM; BONE FORMATION; IN VITRO; PREVENT APOPTOSIS;
   MOLECULAR TARGET; GROWTH FACTORS; CELL LINE; OSTEOPOROSIS;
   DIFFERENTIATION; KINASE
AB Age related osteopenia is characterized by a negative balance between bone resorption and formation. The anti osteoporotic drug strontium ranelate was found to reduce bone resorption and to promote bone formation. Here, we investigated the implication of the calcium sensing receptor (CaSR) in the response to strontium ranelate using osteoblasts from CaSR knockout [CaSR / ] and wild type [CaSR+/+] mice. We showed that calcium and strontium ranelates increased cell replication in [CaSR / ] and [CaSR+/+] osteoblasts. Strontium ranelate rapidly increased ERK1/2 phosphorylation in [CaSR+/+] but not in [CaSR / ] osteoblasts, indicating that strontium ranelate can act independent of the CaSR/ERK1/2 cascade to promote osteoblast replication. We also showed that strontium ranelate prevented cell apoptosis induced by serum deprivation or the pro inflammatory cytokines IL 1 beta and TNF alpha in [CaSR / ] and [CaSR+/+] osteoblasts, indicating that CaSR is not the only receptor involved in the protective effect of strontium ranelate on osteoblast apoptosis. Strontium ranelate activated the Akt pro survival pathway in [CaSR / ] and [CaSR+/+] osteoblasts, and pharmacological inhibition of Akt abrogated the anti apoptotic effect of strontium ranelate. Furthermore, both the proliferative and anti apoptotic effects of strontium ranelate in [CaSR / ] and [CaSR+/+] osteoblasts were abrogated by selective inhibition of COX 2. The results provide genetic and biochemical evidence that the effects of strontium ranelate on osteoblast replication and survival involve ERK1/2 and Akt signalling and PGE2 production, independent of CaSR expression. The finding that CaSR dependent and CaSR independent pathways mediate the beneficial effects of strontium ranelate on osteoblasts, provides novel insight into the mechanism of action of this anti osteoporotic agent on osteoblastogenesis.
C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Fromigue, Olivia; Hay, Eric; Barbara, Alain; Marie, Pierre J.] Univ Paris 07, Paris, France.
   [Petrel, Christophe; Traiffort, Elisabeth; Ruat, Martial] CNRS, Cellular & Mol Neurobiol Lab, UPR 9040, CNRS,IFR 2118, Gif Sur Yvette, France.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Cite; Centre National de la Recherche Scientifique (CNRS);
   Universite Paris Saclay
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI ; Haÿ, Eric/HNS 9912 2023; Traiffort, Elisabeth/B 2042 2019; Ruat,
   Martial/E 5544 2016; Fromigue, Olivia/B 8225 2013
OI Hay, Eric/0000 0002 0131 9983; Traiffort, Elisabeth/0000 0002 9645 6269;
   Fromigue, Olivia/0000 0002 3050 6155
FU Institut de Recherches Servier (IRIS, Courbevoie, France); Association
   Rhumatisme et Travail (Hopital Lariboisiere, Paris, France)
FX We thank Professors C. Seidman and J. Seidman (Department of Genetics,
   Harvard Medical School, Boston, MA, USA) for allowing access to
   [CaSR / ] mice. Financial support was provided in part by Institut de
   Recherches Servier (IRIS, Courbevoie, France) and Association Rhumatisme
   et Travail (Hopital Lariboisiere, Paris, France), which were not
   involved in planning, performance, data analysis or manuscript writing.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Brown EM, 2007, NAT CLIN PRACT ENDOC, V3, P122, DOI 10.1038/ncpendmet0388
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003 1127
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009
   Dufour C, 2008, AM J PHYSIOL ENDOC M, V294, pE794, DOI 10.1152/ajpendo.00791.2007
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigué O, 2005, CRIT REV EUKAR GENE, V15, P75, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i1.50
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Hajnoczky Gyorgy, 2007, Novartis Found Symp, V287, P105
   Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849
   HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295 389
   Hott M, 2003, BONE, V33, P115, DOI 10.1016/S8756 3282(03)00115 7
   House MG, 1997, J BONE MINER RES, V12, P1959, DOI 10.1359/jbmr.1997.12.12.1959
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006 291X(03)00820 9
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Lin KI, 1998, BIOCHEM BIOPH RES CO, V249, P325, DOI 10.1006/bbrc.1998.9124
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Marie PJ, 2005, CURR OPIN PHARMACOL, V5, P633, DOI 10.1016/j.coph.2005.05.005
   McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200
   Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114
   Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256
   PILBEAM CC, 2002, PRINCIPLES BONE BIOL, V2, P979
   Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393
   Raisz LG, 2006, CLIN REV BONE MINER, V4, P123, DOI 10.1385/BMM:4:2:123
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Tsuboi M, 1999, J LAB CLIN MED, V134, P222, DOI 10.1016/S0022 2143(99)90201 9
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530
   Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178
   Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
NR 56
TC 110
Z9 118
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2009
VL 13
IS 8B
BP 2189
EP 2199
DI 10.1111/j.1582 4934.2009.00673.x
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 525CN
UT WOS:000272190800052
PM 20141614
OA Bronze
DA 2025 08 17
ER

PT J
AU Bishop, RT
   Marino, S
   de Ridder, D
   Allen, RJ
   Lefley, DV
   Sims, AH
   Wang, N
   Ottewell, PD
   Idris, AI
AF Bishop, Ryan T.
   Marino, Silvia
   de Ridder, Danielle
   Allen, Richard J.
   Lefley, Diane V.
   Sims, Andrew H.
   Wang, Ning
   Ottewell, Penelope D.
   Idris, Aymen I.
TI Pharmacological inhibition of the IKKε/TBK 1 axis potentiates the
   anti tumour and anti metastatic effects of Docetaxel in mouse models of
   breast cancer
SO CANCER LETTERS
LA English
DT Article
DE IKK epsilon; NF kappa B; Breast cancer; Combination treatment; Bone
   metastasis; Osteolysis; Osteoclast; Osteoblast; Bone
ID NF KAPPA B; TYPE 2 CANNABINOID RECEPTOR; OSTEOLYTIC BONE METASTASIS;
   IKK EPSILON; AUTONOMOUS CONTRIBUTION; TAMOXIFEN RESISTANCE; KINASE
   EPSILON; TBK1; PHOSPHORYLATION; ACTIVATION
AB I kappa B kinase subunit epsilon (IKK epsilon), a key component of NF kappa B and interferon signalling, has been identified as a breast cancer oncogene. Here we report that the IKK epsilon/TBK1 axis plays a role in the initiation and progression of breast cancer osteolytic metastasis. Cancer specific knockdown of IKK epsilon in the human MDA MB 231 BT cells and treatment with the verified IKK epsilon/TBK1 inhibitor Amlexanox reduced skeletal tumour growth and osteolysis in mice. In addition, combined administration of Amlexanox with Docetaxel reduced mammary tumour growth of syngeneic 4T1 cells, inhibited metastases and improved survival in mice after removal of the primary tumour. Functional and mechanistic studies in breast cancer cells, osteoclasts and osteoblasts revealed that IKK epsilon inhibition reduces the ability of breast cancer cells to grow, move and enhance osteoclastogenesis by engaging both IRF and NF kappa B signalling pathways. Thus, therapeutic targeting of the IKK epsilon/TBK1 axis may be of value in the treatment of advanced triple negative breast cancer.
C1 [Bishop, Ryan T.; Marino, Silvia; de Ridder, Danielle; Allen, Richard J.; Lefley, Diane V.; Wang, Ning; Ottewell, Penelope D.; Idris, Aymen I.] Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Marino, Silvia; Idris, Aymen I.] Univ Edinburgh, Western Gen Hosp, Bone & Canc Grp, Edinburgh Canc Res Ctr, Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Sims, Andrew H.] Univ Edinburgh, Western Gen Hosp, Appl Bioinforrnat Canc, MRC Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh
RP Idris, AI (通讯作者)，Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM aymen.idris@sheffield.ac.uk
RI Wang, Ning/HKO 8446 2023; Sims, Andrew/E 4819 2012; Idris,
   Aymen/AAX 1138 2020
OI Sims, Andrew/0000 0001 9082 3665; Allen, Richard/0000 0003 2448 7987;
   WANG, NING/0000 0002 2663 7515; Ottewell, Penelope/0000 0002 4826 0771;
   Bishop, Ryan/0000 0002 1332 4798; Idris, Aymen/0000 0003 4327 5306
FU Cancer Research UK Development Fund (University of Edinburgh); Breast
   Cancer Now [2014NovPhD390]
FX These studies were supported in part by Cancer Research UK Development
   Fund (University of Edinburgh) and funding from Breast Cancer Now  
   2014NovPhD390 (University of Sheffield).
CR Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200
   Chau TL, 2008, TRENDS BIOCHEM SCI, V33, P171, DOI 10.1016/j.tibs.2008.01.002
   Codony Servat J, 2013, PROSTATE, V73, P512, DOI 10.1002/pros.22591
   Corr M, 2009, ANN RHEUM DIS, V68, P257, DOI 10.1136/ard.2008.095356
   Guo JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063636
   Guo JP, 2011, J BIOL CHEM, V286, P37389, DOI 10.1074/jbc.M111.287433
   Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212
   Hammaker D, 2012, RHEUMATOLOGY, V51, P610, DOI 10.1093/rheumatology/ker154
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 86
   Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008 5472.CAN 08 0107
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Korherr C, 2006, P NATL ACAD SCI USA, V103, P4240, DOI 10.1073/pnas.0511319103
   Logan JG, 2013, J BONE MINER RES, V28, P1229, DOI 10.1002/jbmr.1847
   Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 179
   Marino S, 2017, CANCER LETT, V410, P180, DOI 10.1016/j.canlet.2017.09.034
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Orriss IR, 2012, METHODS MOL BIOL, V816, P31, DOI 10.1007/978 1 61779 415 5_3
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14
   Peramuhendige P, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18327 5
   Reilly SM, 2013, NAT MED, V19, P313, DOI 10.1038/nm.3082
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rucci N, 2004, BONE, V34, P697, DOI 10.1016/j.bone.2003.07.012
   Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078 0432.CCR 08 1383
   Shen RR, 2012, MOL CELL BIOL, V32, P4756, DOI 10.1128/MCB.00468 12
   Sophocleous A, 2015, J BIOL CHEM, V290, P22049, DOI 10.1074/jbc.M115.649608
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Sun QH, 2014, J BONE MINER RES, V29, P90, DOI 10.1002/jbmr.2026
   Sweeney SE, 2007, ARTHRITIS RHEUM US, V56, P743, DOI 10.1002/art.22421
   Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721
   Wei CW, 2014, P NATL ACAD SCI USA, V111, pE601, DOI 10.1073/pnas.1316255111
   Williams V, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3321 6
   Zeichner SB, 2016, BREAST CANCER BASIC, V10, DOI 10.4137/BCBCR.S32783
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006
NR 42
TC 17
Z9 18
U1 0
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PY 2019
VL 450
BP 76
EP 87
DI 10.1016/j.canlet.2019.02.032
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HT3TB
UT WOS:000464485000008
PM 30790681
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Tang, L
   Kang, YT
   Sun, SX
   Zhao, TT
   Cao, WX
   Fan, XH
   Guo, JH
   Sun, LJ
   Ta, D
AF Tang, Liang
   Kang, Yiting
   Sun, Shuxin
   Zhao, Tingting
   Cao, Wenxin
   Fan, Xiushan
   Guo, Jianzhong
   Sun, Lijun
   Ta, Dean
TI Inhibition of MSTN signal pathway may participate in LIPUS preventing
   bone loss in ovariectomized rats
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoporosis; Low intensity pulsed ultrasound; Bone defect healing; Bone
   microstructure; Myostatin
ID SKELETAL MUSCLE MASS; GROWTH FACTOR BETA; OSTEOGENIC DIFFERENTIATION;
   TGF BETA; OSTEOBLAST DIFFERENTIATION; MYOSTATIN GENE; WNT; FRACTURE;
   PROLIFERATION; OSTEOPOROSIS
AB Introduction Menopause can lead to osteoporosis, which is characterized by destruction of bone microstructure, poor mechanical properties, and prone to fracture. LIPUS can effectively promote bone formation and fracture healing. MSTN is a transforming growth factor beta family member that acts as a negative regulator of skeletal muscle growth. A MSTN deficiency also has a positive effect on bone formation. However, whether LIPUS could inhibit bone loss and promote healing of bone injury of menopause through the inhibition of the MSTN signaling pathway has not been previously investigated. We herein investigated the effects of LIPUS on bone architecture, mechanical properties, the healing of bone defects, and its potential molecular mechanisms in ovariectomized rats. Materials and methods The rats were randomly divided into three groups: sham ovariectomized group (Sham), ovariectomized model group (OVX), ovariectomized model with LIPUS therapy group (OVX + LIPUS). The OVX + LIPUS rats were treated with LIPUS (1.5 MHz, 30 mW/cm(2)) on the femur for 20 min/day that lasted for 19 days. Results LIPUS effectively improved the bone microstructure, increased mechanical properties and promoted the healing of bone defects in ovariectomized rats. Moreover, LIPUS effectively decreased the MSTN content in serum and quadriceps muscle in ovariectomized rats, and inhibited the expression of MSTN downstream signaling molecules and activated the Wnt signaling pathway in the femur. Conclusions The present study shows that LIPUS improved osteoporosis and promoted bone defect healing in the ovariectomized rats may through the inhibition of the MSTN signal pathway.
C1 [Tang, Liang; Kang, Yiting; Zhao, Tingting; Cao, Wenxin; Fan, Xiushan; Sun, Lijun] Shaanxi Normal Univ, Inst Sports Biol, Xian, Peoples R China.
   [Sun, Shuxin; Ta, Dean] Fudan Univ, Dept Elect Engn, Shanghai, Shanghai, Peoples R China.
   [Guo, Jianzhong] Shaanxi Normal Univ, Shaanxi Key Lab Ultrason, Xian, Peoples R China.
   [Kang, Yiting] Xi'an Jiaotong Univ, Sch Life Sci, Key Lab BioMed Informat Engn Minist Educ, Technol, Xian, Peoples R China.
   [Ta, Dean] Fudan Univ, Human Phenome Inst, Shanghai, Shanghai, Peoples R China.
   [Ta, Dean] Key Lab Med Imaging Comp, Comp Assisted Intervent, MICCAI, Shanghai, Shanghai, Shanghai, Peoples R China.
C3 Shaanxi Normal University; Fudan University; Shaanxi Normal University;
   Xi'an Jiaotong University; Fudan University
RP Sun, LJ (通讯作者)，Shaanxi Normal Univ, Inst Sports Biol, Xian, Peoples R China.; Ta, D (通讯作者)，Fudan Univ, Human Phenome Inst, Shanghai, Shanghai, Peoples R China.; Ta, D (通讯作者)，Key Lab Med Imaging Comp, Comp Assisted Intervent, MICCAI, Shanghai, Shanghai, Shanghai, Peoples R China.
EM sunlijun@snnu.edu.cn; tda@fudan.edu.cn
OI Guo, Jianzhong/0000 0003 1909 3510
CR Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002
   Brotto M, 2015, BONE, V80, P109, DOI 10.1016/j.bone.2015.02.010
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Clynes MA, 2015, CALCIFIED TISSUE INT, V97, P445, DOI 10.1007/s00223 015 0044 z
   Cory E, 2010, J BIOMECH, V43, P953, DOI 10.1016/j.jbiomech.2009.10.047
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Di Monaco M, 2011, ARCH GERONTOL GERIAT, V52, P71, DOI 10.1016/j.archger.2010.02.002
   Elkasrawy MN, 2010, J MUSCULOSKEL NEURON, V10, P56
   Fung CH, 2014, ULTRASONICS, V54, P1358, DOI 10.1016/j.ultras.2014.02.003
   Hadjiargyrou M, 1998, CLIN ORTHOP RELAT R, pS216, DOI 10.1097/00003086 199810001 00022
   Hamilton Celeste J, 2013, Bonekey Rep, V2, P259, DOI 10.1038/bonekey.2012.259
   Hamrick MW, 2007, BONE, V40, P1544, DOI 10.1016/j.bone.2007.02.012
   Hamrick MW, 2003, ANAT REC PART A, V272A, P388, DOI 10.1002/ar.a.10044
   Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252
   Joulia Ekaza D, 2007, CURR OPIN PHARMACOL, V7, P310, DOI 10.1016/j.coph.2006.11.011
   Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Lei HG, 2015, UROLOGY, V86, DOI 10.1016/j.urology.2015.07.026
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   LI C, 1973, J LAB CLIN MED, V82, P446
   Li F, 2018, ULTRASOUND MED BIOL, V44, P1044, DOI 10.1016/j.ultrasmedbio.2018.01.005
   Liu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep32260
   Liu YJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1605, DOI 10.1159/000470896
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   Morissette MR, 2009, AGING CELL, V8, P573, DOI 10.1111/j.1474 9726.2009.00508.x
   MOSS DW, 1982, CLIN CHEM, V28, P2007
   Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230 7242.2003
   Rutten S, 2008, BONE, V43, P348, DOI 10.1016/j.bone.2008.04.010
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Szulc P, 2005, J BONE MINER RES, V20, P721, DOI 10.1359/JBMR.041230
   Tagliaferri C, 2015, AGEING RES REV, V21, P55, DOI 10.1016/j.arr.2015.03.002
   Takikawa S, 2001, J ULTRAS MED, V20, P197, DOI 10.7863/jum.2001.20.3.197
   Tang L, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395 017 0145 7
   Tang L, 2017, ULTRASOUND MED BIOL, V43, P1411, DOI 10.1016/j.ultrasmedbio.2017.02.017
   Uddin SMZ, 2015, BONE, V75, P8, DOI 10.1016/j.bone.2015.01.020
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wu LF, 2018, J CELL MOL MED, V22, P1329, DOI 10.1111/jcmm.13438
   Wu SL, 2009, PATHOBIOLOGY, V76, P99, DOI 10.1159/000209387
   Yarasheski K E, 2002, J Nutr Health Aging, V6, P343
   ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V159, P68, DOI 10.1016/0006 291X(89)92405 4
   Zhang ZL, 2008, OSTEOPOROSIS INT, V19, P39, DOI 10.1007/s00198 007 0435 8
   Zhou J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0408 2
NR 47
TC 20
Z9 22
U1 0
U2 32
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2020
VL 38
IS 1
BP 14
EP 26
DI 10.1007/s00774 019 01029 5
PG 13
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA KI9RN
UT WOS:000511695300003
PM 31414284
DA 2025 08 17
ER

PT J
AU Brunetti, G
   Papadia, F
   Tummolo, A
   Fischetto, R
   Nicastro, F
   Piacente, L
   Ventura, A
   Mori, G
   Oranger, A
   Gigante, I
   Colucci, S
   Ciccarelli, M
   Grano, M
   Cavallo, L
   Delvecchio, M
   Faienza, MF
AF Brunetti, G.
   Papadia, F.
   Tummolo, A.
   Fischetto, R.
   Nicastro, F.
   Piacente, L.
   Ventura, A.
   Mori, G.
   Oranger, A.
   Gigante, I.
   Colucci, S.
   Ciccarelli, M.
   Grano, M.
   Cavallo, L.
   Delvecchio, M.
   Faienza, M. F.
TI Impaired bone remodeling in children with osteogenesis imperfecta
   treated and untreated with bisphosphonates: the role of DKK1, RANKL, and
   TNF α
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE DKK1; Osteoblasts; Osteoclasts; Osteogenesis imperfecta; RANKL
ID MOUSE MODEL; ALENDRONATE TREATMENT; DECREASED BONE; SERUM LEVELS;
   DICKKOPF 1; INHIBITION; INCREASE; OSTEOCLASTOGENESIS; DIFFERENTIATION;
   NERIDRONATE
AB In this study, we investigated the bone cell activity in patients with osteogenesis imperfecta (OI) treated and untreated with neridronate. We demonstrated the key role of Dickkopf 1 (DKK1), receptor activator of nuclear factor kappa B ligand (RANKL), and tumor necrosis factor alpha (TNF alpha) in regulating bone cell of untreated and treated OI subjects. These cytokines could represent new pharmacological targets for OI.
   Bisphosphonates are widely used in the treatment of children with osteogenesis imperfecta (OI) with the objective of reducing the risk of fractures. Although bisphosphonates increase bone mineral density in OI subjects, the effects on fracture incidence are conflicting. The aim of this study was to investigate the mechanisms underlying bone cell activity in subjects with mild untreated forms of OI and in a group of subjects with severe OI treated with cycles of intravenous neridronate.
   Sclerostin, DKK1, TNF alpha, RANKL, osteoprotegerin (OPG), and bone turnover markers were quantified in serum of 18 OI patients (12 females, mean age 8.86 +/  3.90), 8 of which were receiving cyclic intravenous neridronate, and 21 sex  and age matched controls. The effects on osteoblastogenesis and OPG expression of media conditioned by the serum of OI patients and anti DKK1 neutralizing antibody were evaluated. Osteoclastogenesis was assessed in cultures from patients and controls.
   DKK1 and RANKL levels were significantly increased both in untreated and in treated OI subjects with respect to controls. The serum from patients with high DKK1 levels inhibited both osteoblast differentiation and OPG expression in vitro. High RANKL and low OPG messenger RNA (mRNA) levels were found in lymphomonocytes from patients. High amounts of TNF alpha were expressed by monocytes, and an elevated percentage of circulating CD11b CD51/CD61+ osteoclast precursors was observed in patients.
   Our study demonstrated the key role of DKK1, RANKL, and TNF alpha in regulating bone cell activity of subjects with OI untreated and treated with bisphosphonates. These cytokines could represent new pharmacological targets for OI patients.
C1 [Brunetti, G.; Oranger, A.; Gigante, I.; Colucci, S.; Grano, M.] Univ A Moro Bari, Sect Human Anat & Histol, Dept Basic Med Sci Neurosci & Sense Organs, Piazza Giulio Cesare 11, I 70124 Bari, Italy.
   [Papadia, F.; Tummolo, A.; Fischetto, R.; Nicastro, F.] Giovanni XXIII Childrens Hosp, Dept Metab Dis Clin Genet & Diabetol, Bari, Italy.
   [Piacente, L.; Ventura, A.; Ciccarelli, M.; Cavallo, L.; Delvecchio, M.; Faienza, M. F.] Univ A Moro Bari, Pediat Sect, Dept Biomed Sci & Human Oncol, Piazza G Cesare 11, I 70124 Bari, Italy.
   [Mori, G.] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; University of Foggia
RP Brunetti, G (通讯作者)，Univ A Moro Bari, Sect Human Anat & Histol, Dept Basic Med Sci Neurosci & Sense Organs, Piazza Giulio Cesare 11, I 70124 Bari, Italy.; Faienza, MF (通讯作者)，Univ A Moro Bari, Pediat Sect, Dept Biomed Sci & Human Oncol, Piazza G Cesare 11, I 70124 Bari, Italy.
EM giacomina.brunetti@uniba.it; mariafelicia.faienza@uniba.it
RI Papadia, Francesco Saverio/NMK 4983 2025; Delvecchio,
   Maurizio/K 8762 2012; Faienza, Maria/K 6779 2016; Gigante,
   Isabella/AAC 3409 2022; Giacomina, Brunetti/J 7692 2016; Mori,
   Giorgio/P 1370 2014; Brunetti, Giacomina/J 7692 2016; Fischetto,
   Rita/C 4808 2018
OI Delvecchio, Maurizio/0000 0002 1528 0012; oranger,
   angela/0000 0003 0881 6840; Mori, Giorgio/0000 0001 6731 0247; Brunetti,
   Giacomina/0000 0002 0681 1432; 
FU Ministero dell'Istruzione Universita e Ricerca
FX The authors thank Ministero dell'Istruzione Universita e Ricerca (ex 60
   % grant to Maria Grano).
CR Aicher A, 2008, CIRC RES, V103, P796, DOI 10.1161/CIRCRESAHA.107.172718
   Bargman R, 2012, OSTEOPOROSIS INT, V23, P1141, DOI 10.1007/s00198 011 1742 7
   Bargman R, 2012, PEDIATR RES, V72, P495, DOI 10.1038/pr.2012.118
   Bargman R, 2010, CONNECT TISSUE RES, V51, P123, DOI 10.3109/03008200903108472
   BARON R, 1983, PEDIATR RES, V17, P204, DOI 10.1203/00006450 198303000 00007
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Braga V, 2004, BONE, V34, P1013, DOI 10.1016/j.bone.2004.02.023
   Brunetti G, 2013, AM J PHYSIOL ENDOC M, V304, pE546, DOI 10.1152/ajpendo.00535.2012
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Cheung MS, 2008, REV ENDOCR METAB DIS, V9, P153, DOI 10.1007/s11154 008 9074 4
   D'Eufemia P, 2008, PEDIATR RES, V63, P203, DOI 10.1203/PDR.0b013e31815efd63
   Dalbeth N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3123
   Delos D, 2008, J ORTHOP RES, V26, P153, DOI 10.1002/jor.20469
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Eghbali Fatourechi G, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200 014 0109 y
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Giordano P, 2016, BRIT J HAEMATOL, V172, P293, DOI 10.1111/bjh.13481
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Kalajzic I, 2002, ENDOCRINOLOGY, V143, P1594, DOI 10.1210/en.143.5.1594
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Marini JC, 2001, NELSON TXB PEDIAT, P2336
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Mori G, 2012, INT J MED SCI, V9, P480, DOI 10.7150/ijms.4583
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rohrbach M, 2012, AM J MED GENET C, V160C, P175, DOI 10.1002/ajmg.c.31334
   Rossini M, 2015, CLIN EXP RHEUMATOL, V33, P77
   Rossini M, 2015, CALCIFIED TISSUE INT, V96, P410, DOI 10.1007/s00223 015 9969 5
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022 1759(00)00238 6
   Zeitlin L, 2003, J PEDIATR ORTHOP B, V12, P77, DOI 10.1097/01.bpb.0000049567.52224.fa
   Zhang H, 2007, J CELL BIOCHEM, V102, P1011, DOI 10.1002/jcb.21337
NR 45
TC 51
Z9 54
U1 0
U2 15
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUL
PY 2016
VL 27
IS 7
BP 2355
EP 2365
DI 10.1007/s00198 016 3501 2
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DO8AQ
UT WOS:000378004800022
PM 26856585
OA Green Submitted
DA 2025 08 17
ER

PT J
AU D'Oronzo, S
   Wood, S
   Brown, JE
AF D'Oronzo, S.
   Wood, S.
   Brown, J. E.
TI "The use of bisphosphonates to treat skeletal complications in solid
   tumours"
SO BONE
LA English
DT Article
DE Bisphosphonates; Skeletal related events; Hypercalcaemia; Bone
   metastasis; Breast cancer; Prostate cancer; Lung cancer
ID METASTATIC BONE DISEASE; BREAST CANCER PATIENTS; RANDOMIZED
   CONTROLLED TRIAL; SENSITIVE PROSTATE CANCER; RENAL CELL CARCINOMA;
   LONG TERM EFFICACY; QUALITY OF LIFE; ZOLEDRONIC ACID; DOUBLE BLIND;
   LUNG CANCER
AB The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with up to 80% of patients with advanced disease developing bone metastases (BM). The proportion is also substantial in advanced lung cancer (20%?40%). Because of the high prevalence of cancers of the breast, prostate and lung, these cancers account for more than 80% of cases of metastatic bone disease occurring in solid tumours. Metastatic bone disease is associated with greatly increased bone resorption by osteoclasts, leading to moderate to severe pain and other skeletal complications, with major impact on quality of life (QoL). Skeletal Related Events (SREs) have been defined as: pathological long bone or vertebral fractures; spinal cord compression; need for radiation for pain relief or to prevent fracture/spinal cord compression, need for surgery to bone and hypercalcaemia. More recently, Symptomatic Skeletal Events (SSEs) have been defined to monitor QoL. Although there are currently no curative treatments for metastatic bone disease, patients with breast or prostate cancer and BM are now surviving for several years and sometimes longer, and prevention of SREs is the key aim to optimization of QoL. Since their discovery 50 years ago and their introduction more than 30 years ago into the field of metastatic bone disease, a range of oral and intravenous bisphosphonate drugs have made a major contribution to prevention of SREs. Large trials have clearly demonstrated the clinical value of different bisphosphonate based drugs (including the oral drugs ibandronate and clodronate and intravenous agents such as zoledronate and pamidronate), in treatment of hypercalcaemia of malignancy and the reduction of SREs and SSEs in a range of cancers. Despite the success of denosumab in reducing osteolysis, bisphosphonates also remain mainstay drugs for treatment of metastatic bone disease. Recognizing the 50th Anniversary of the discovery of bisphosphonates, this review focuses on their continuing value in BM treatment and their future potential, for example in providing a bone targeting vehicle for cytotoxic drugs.
C1 [D'Oronzo, S.] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Med Oncol Unit, Pza Giulio Cesare 11, I 70124 Bari, Italy.
   [Wood, S.] Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Brown, J. E.] Univ Sheffield, Acad Unit Clin Oncol, Weston Pk Hosp, Dept Oncol & Metab, Whitham Rd,Broomhill, Sheffield S10 2SJ, S Yorkshire, England.
C3 Universita degli Studi di Bari Aldo Moro; Weston Park Hospital;
   University of Sheffield
RP Wood, S (通讯作者)，Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM s.l.wood@sheffield.ac.uk
RI D'Oronzo, Stella/AAA 9784 2019
FU University of Sheffield; University of Bari Aldo Moro
FX This work was funded by the University of Sheffield (SLW, JEB) and the
   University of Bari Aldo Moro (SD) .
CR Ahmad I, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3286
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   [Anonymous], 2019, INT J MOL SCI
   Awan AA, 2019, BREAST CANCER RES TR, V176, P507, DOI 10.1007/s10549 019 05265 1
   Baek YH, 2019, CANCER EPIDEMIOL, V61, P104, DOI 10.1016/j.canep.2019.05.013
   Barrett Lee P, 2014, LANCET ONCOL, V15, P114, DOI 10.1016/S1470 2045(13)70539 4
   Berruti A, 1999, CLIN CHEM, V45, P1240
   Biskup E., 2017, SWISS MED WEEKLY, V147
   Bockman R, 2003, SEMIN ONCOL, V30, P5, DOI 10.1016/S0093 7754(03)00170 2
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Bonzi G, 2015, BIOCONJUGATE CHEM, V26, P489, DOI 10.1021/bc500614b
   Boussios S, 2018, ANTICANCER RES, V38, P4987, DOI 10.21873/anticanres.12817
   Braal CL, 2021, DRUGS, V81, P317, DOI 10.1007/s40265 020 01461 2
   Broom RJ, 2015, CLIN GENITOURIN CANC, V13, P50, DOI 10.1016/j.clgc.2014.07.002
   Brown J, 2018, JNCI J NATL CANCER I, V110, P871, DOI 10.1093/jnci/djx280
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Cabillic F, 2010, CANCER IMMUNOL IMMUN, V59, P1611, DOI 10.1007/s00262 010 0887 0
   Cardoso F., ANN ONCOLOGY, V31, P1623
   Chow Edward, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P461, DOI 10.1586/erp.09.50
   Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI [10.1016/j.annonc.2020.01.002, 10.1093/annonc/mdz396]
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman R.E., 2012, J CLIN ONCOLOGY
   Coleman R.E., 2000, ONCOLOGIST, V5
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   COLEMAN RE, 1988, BRIT J CANCER, V58, P205, DOI 10.1038/bjc.1988.194
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   COLEMAN RE, 1988, BRIT J CANCER, V58, P621, DOI 10.1038/bjc.1988.272
   Coleman R, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115570
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Cremers S., 2019, BR J CLIN PHARM, V85
   Cui XX, 2019, ONCOL LETT, V18, P5437, DOI 10.3892/ol.2019.10870
   Dearnaley D.P., 2003, J NATL CANC I, V95
   Dedes PG, 2012, BBA GEN SUBJECTS, V1820, P1926, DOI 10.1016/j.bbagen.2012.07.013
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Feng CJ, 2016, ONCOL REP, V35, P3460, DOI 10.3892/or.2016.4741
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Francini F, 2011, INT J CLIN ONCOL, V16, P264, DOI 10.1007/s10147 010 0179 x
   Goldshtein I, 2016, ADV THER, V33, P1374, DOI 10.1007/s12325 016 0360 3
   Henry D.H., 2011, J CLIN ONCOL, V29
   Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Hosaka S, 2018, INT J CLIN ONCOL, V23, P1127, DOI 10.1007/s10147 018 1310 7
   Hu MI, 2014, J CLIN ENDOCR METAB, V99, P3144, DOI 10.1210/jc.2014 1001
   Hultborn R, 1999, ANTICANCER RES, V19, P3383
   Hussain A, 2019, CRIT REV ONCOL HEMAT, V139, P108, DOI 10.1016/j.critrevonc.2019.04.020
   James N, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20530
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Kalyan S, 2014, CELL MOL LIFE SCI, V71, P2335, DOI 10.1007/s00018 013 1495 x
   Klaassen Z, 2017, CANCER AM CANCER SOC, V123, P1528, DOI 10.1002/cncr.30505
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365 2796.1999.00507.x
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lin Chung Ying, 2016, Asian Pac J Cancer Prev, V17, P1405
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A., 2013, CLIN ONCOL R COLL RA, V25
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lumachi F, 2009, ANTICANCER RES, V29, P1551
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Major PP, 2001, SEMIN ONCOL, V28, P17, DOI 10.1053/sonc.2001.24156
   MARTIN TJ, 1989, HORM RES, V32, P84, DOI 10.1159/000181252
   McCloskey E, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115715
   Migliorati CA, 2011, NAT REV ENDOCRINOL, V7, P34, DOI 10.1038/nrendo.2010.195
   Milgrom DP, 2017, CURR OSTEOPOROS REP, V15, P76, DOI 10.1007/s11914 017 0354 3
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Naoe M, 2010, ONCOL RES, V18, P493, DOI 10.3727/096504010X12671222663638
   Ng K, 2020, ONCOL THER, V8, P209, DOI 10.1007/s40487 020 00119 z
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   Ottewell P, 2019, BREAST CANCER BASIC, V13, DOI 10.1177/1178223419843501
   Palmieri C, 2013, CLIN CANCER RES, V19, P6863, DOI 10.1158/1078 0432.CCR 13 2275
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Pettifer A, 2013, INT J PALLIAT NURS, V19, P326, DOI 10.12968/ijpn.2013.19.7.327
   Pignatello R, 2012, J FUNCT BIOMATER, V3, P79, DOI 10.3390/jfb3010079
   PUROHIT OP, 1995, BRIT J CANCER, V72, P1289, DOI 10.1038/bjc.1995.502
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Ropper AE, 2017, NEW ENGL J MED, V376, P1358, DOI 10.1056/NEJMra1516539
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2017, PROSTATE CANCER P D, V20, P110, DOI 10.1038/pcan.2016.62
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Sartor O, 2014, ASIAN J ANDROL, V16, P426, DOI 10.4103/1008 682X.126378
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Spizzo G, 2009, ANTICANCER RES, V29, P5245
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tharmalingam Sukirtha, 2008, J Pain Res, V1, P49
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Ulas A, 2016, TUMOR BIOL, V37, P1131, DOI 10.1007/s13277 015 3907 z
   Van Poznak CH, 2011, J ONCOL PRACT, V7, P117, DOI 10.1200/JOP.2011.000212
   VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983
   Wong M.H., 2012, COCHRANE DB SYST REV, V2
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078 0432.CCR 09 1691
   Zinnen SP, 2019, ONCOLOGIST, V24, P303, DOI 10.1634/theoncologist.2018 0707
NR 120
TC 27
Z9 27
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2021
VL 147
DI 10.1016/j.bone.2021.115907
EA MAR 2021
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RS3UL
UT WOS:000643707100018
PM 33676057
DA 2025 08 17
ER

PT J
AU Qin, Y
   Zhang, Z
   Guo, XB
   Li, WH
   Xia, WY
   Ge, GR
   Li, YY
   Guan, M
   Gao, A
   Mao, L
   Wang, HY
   Chu, PK
   Geng, DC
AF Qin, Yi
   Zhang, Zhen
   Guo, Xiaobin
   Li, Wenhao
   Xia, Wenyu
   Ge, Gaoran
   Li, Yanyue
   Guan, Min
   Gao, Ang
   Mao, Lu
   Wang, Huaiyu
   Chu, Paul K.
   Geng, Dechun
TI A Bone Targeting Hydrogen Sulfide Delivery System for Treatment of
   Osteoporotic Fracture via Macrophage Reprogramming and
   Osteoblast Osteoclast Coupling
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone targeting; hydrogen sulfide; macrophage polarization; metabolic
   reprogramming; osteoporotic fracture
ID SUCCINATE; POLARIZATION; SIGNAL
AB The demand for systemic treatment of osteoporotic fractures to reduce recurrence is increasing, but current anti osteoporosis medications exhibit unsatisfactory efficacy due to adverse events and limited effects on fracture healing. Herein, a bone targeting zeolitic imidazolate framework 8 (ZIF) based hydrogen sulfide (H2S) delivery system (ZIF H2S SDSSD) is designed to simultaneously promote fracture healing and alleviate osteoporosis. With bone targeting peptide SDSSD grafted on the surface, ZIF H2S SDSSD nanoparticles release H2S in bone tissues without affecting the serum H2S level, thereby mitigating potential risks of systematic H2S delivery. Upon cellular uptake, the acidic environment in lysosomes drives the release of H2S from the encapsulated zinc sulfide in conjunction with the degradation of ZIF. The synergistic effects of released Zn2+ and H2S promote macrophage metabolic reprogramming by suppressing succinate accumulation and mitochondrial reactive oxygen species (mtROS) production, and further regulate osteoblast osteoclast coupling. Overall, this strategy holds great promise in the clinical treatment of osteoporotic fractures and broadens the application of nanomedicine therapy for orthopedic diseases.
C1 [Qin, Yi; Li, Wenhao; Xia, Wenyu; Ge, Gaoran; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Med Coll, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhang, Zhen; Li, Yanyue; Guan, Min; Gao, Ang; Wang, Huaiyu] Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Human Tissues & Organs Degenerat, Shenzhen 518055, Peoples R China.
   [Guo, Xiaobin] Xinjiang Med Univ, Affiliated Hosp 1, Dept Orthoped, Urumqi 830054, Xinjiang, Peoples R China.
   [Mao, Lu] Southeast Univ, ZhongDa Hosp, Dept Spine Surg, Nanjing 210009, Jiangsu, Peoples R China.
   [Wang, Huaiyu] Chinese Acad Sci, Key Lab Biomed Imaging Sci & Syst, Shenzhen 518055, Peoples R China.
   [Chu, Paul K.] City Univ Hong Kong, Dept Phys, Kowloon, Tat Chee Ave, Hong Kong 999077, Peoples R China.
   [Chu, Paul K.] City Univ Hong Kong, Dept Mat Sci & Engn, Kowloon, Tat Chee Ave, Hong Kong 999077, Peoples R China.
   [Chu, Paul K.] City Univ Hong Kong, Dept Biomed Engn, Kowloon, Tat Chee Ave, Hong Kong 999077, Peoples R China.
C3 Soochow University   China; Chinese Academy of Sciences; Shenzhen
   Institute of Advanced Technology, CAS; Xinjiang Medical University;
   Southeast University   China; Chinese Academy of Sciences; City
   University of Hong Kong; City University of Hong Kong; City University
   of Hong Kong
RP Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Med Coll, Suzhou 215006, Jiangsu, Peoples R China.; Gao, A; Wang, HY (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Human Tissues & Organs Degenerat, Shenzhen 518055, Peoples R China.; Mao, L (通讯作者)，Southeast Univ, ZhongDa Hosp, Dept Spine Surg, Nanjing 210009, Jiangsu, Peoples R China.
EM ang.gao1@siat.ac.cn; 101012005@seu.edu.cn; hy.wang1@siat.ac.cn;
   szgengdc@suda.edu.cn
RI Guo, Xiaobin/LKL 6231 2024; Geng, Dechun/LMO 1733 2024; Li,
   Wenhao/GOV 4356 2022; Ouyang, Zhengxiao/Q 1461 2019; Chu,
   Paul/B 5923 2013; Wang, Huaiyu/S 7019 2019; GAO, Ang/LRS 8202 2024
OI Qin, Yi/0000 0001 8706 5007; Chu, Paul/0000 0002 5581 4883; 
FU National Natural Science Foundation of China; Natural Science Foundation
   of Jiangsu Province [BK2021650]; China Postdoctoral Science Foundation
   [:2017T100320]; Shenzhen Science and Technology Program
   [JCYJ20210324101800002]; Guangdong Basic and Applied Basic Research
   Foundation [2022A1515010528, 2024A1515012397]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu
   Medical Research Project [ZD2022014]; Program of Suzhou Health
   Commission [GSWS2022002]; Tianshan Talent Training Program of Xinjiang
   Uygur Autonomous Region [2023TSYCQNTJ0018]; National and Local
   Engineering Laboratory of New Functional Polymer Materials [SDGC2205];
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [KYCX22_3217]; City University of Hong Kong Donation Research Grants
   [DON RMG 9229021, 9229021];  [82072425];  [82072498];  [82272567]; 
   [82350710800]
FX Y.Q., Z.Z., and X.G. contributed equally to this work. The schematic
   illustrations in this work were partially drawn using . This work was
   supported by the National Natural Science Foundation of China (82072425,
   82072498, 82272567, 82350710800), the Natural Science Foundation of
   Jiangsu Province (BK2021650), the China Postdoctoral Science Foundation
   (No.:2017T100320), the Shenzhen Science and Technology Program
   (JCYJ20210324101800002), the Guangdong Basic and Applied Basic Research
   Foundation (2022A1515010528, 2024A1515012397), Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu
   Medical Research Project (ZD2022014), the Program of Suzhou Health
   Commission (GSWS2022002), the Tianshan Talent Training Program of
   Xinjiang Uygur Autonomous Region: Youth Support Talent Project
   (2023TSYCQNTJ0018), the National and Local Engineering Laboratory of New
   Functional Polymer Materials (SDGC2205), the Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (KYCX22_3217), as well
   as City University of Hong Kong Donation Research Grants (Nos. DON RMG
   9229021 and 9229021).
CR Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Byun SE, 2023, OSTEOPOROSIS INT, V34, P1323, DOI 10.1007/s00198 023 06768 w
   Chattaris T, 2022, J BONE MINER RES, V37, P2103, DOI 10.1002/jbmr.4693
   Chen L, 2021, BIOACT MATER, V6, P191, DOI 10.1016/j.bioactmat.2020.08.001
   Chen X, 2023, INNOVATION AMSTERDAM, V4, DOI 10.1016/j.xinn.2023.100483
   Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909
   Cirino G, 2023, PHYSIOL REV, V103, P31, DOI 10.1152/physrev.00028.2021
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Corcoran SE, 2016, J CLIN INVEST, V126, P3699, DOI 10.1172/JCI84431
   Dilek N, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105119
   Dong JL, 2024, BIOMATERIALS, V307, DOI 10.1016/j.biomaterials.2024.122515
   Du ZY, 2024, INNOVATION AMSTERDAM, V5, DOI 10.1016/j.xinn.2024.100671
   Ettlinger R, 2022, CHEM SOC REV, V51, P464, DOI 10.1039/d1cs00918d
   Gao XT, 2023, NANO TODAY, V53, DOI 10.1016/j.nantod.2023.102047
   Ge GR, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202315849
   Gong HS, 2012, J BONE JOINT SURG AM, V94A, P1729, DOI 10.2106/JBJS.K.01434
   Hao YM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.661601
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hu KY, 2023, J INFLAMM RES, V16, P3563, DOI 10.2147/JIR.S423819
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Jin GD, 2014, BIOMATERIALS, V35, P7699, DOI 10.1016/j.biomaterials.2014.05.074
   Li JH, 2021, ADV MATER, V33, DOI 10.1002/adma.202004172
   Liu Shubo, 2024, Engineered Regeneration, V5, P375, DOI 10.1016/j.engreg.2024.01.003
   Liu SQ, 2021, EMBO REP, V22, DOI 10.15252/embr.202051606
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008
   Mosquera J, 2018, ACCOUNTS CHEM RES, V51, P2305, DOI 10.1021/acs.accounts.8b00292
   Rapp K, 2022, BMC MED, V20, DOI 10.1186/s12916 021 02226 8
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Sattui SE, 2014, NAT REV ENDOCRINOL, V10, P592, DOI 10.1038/nrendo.2014.125
   Saul D, 2022, ENDOCR REV, V43, P984, DOI 10.1210/endrev/bnac008
   Schlundt C, 2021, ACTA BIOMATER, V133, P46, DOI 10.1016/j.actbio.2021.04.052
   Shin WC, 2019, BONE, V128, DOI 10.1016/j.bone.2019.08.006
   Sing CW, 2023, J BONE MINER RES, V38, P1064, DOI 10.1002/jbmr.4821
   Stoltzfus AT, 2024, ANGEW CHEM INT EDIT, V63, DOI 10.1002/anie.202401003
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Taylor CT, 2022, NAT REV NEPHROL, V18, P573, DOI 10.1038/s41581 022 00587 8
   Tong L., 2024, Innovation Life, V2, DOI [10.59717/j.xinn life.2024.100078, DOI 10.59717/J.XINN LIFE.2024.100078]
   Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002
   Wu DD, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.112750
   Wu Y, 2023, INNOVATION AMSTERDAM, V4, DOI 10.1016/j.xinn.2023.100500
   Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006
   Yang B, 2023, INNOVATION AMSTERDAM, V4, DOI 10.1016/j.xinn.2023.100462
   Yoshinari N, 2023, COORDIN CHEM REV, V474, DOI 10.1016/j.ccr.2022.214857
   Yue TH, 2023, CANCER RES, V83, P595, DOI 10.1158/0008 5472.CAN 22 1837
   Zhao FL, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202311812
   Zheng K., 2023, ADV FUNCT MATER, V33
NR 51
TC 1
Z9 1
U1 40
U2 74
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD APR
PY 2025
VL 35
IS 17
DI 10.1002/adfm.202418822
EA DEC 2024
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 1UZ5U
UT WOS:001381608000001
DA 2025 08 17
ER

PT J
AU Perdu, B
   Van Hul, W
AF Perdu, Bram
   Van Hul, Wim
TI Sclerosing Bone Disorders: Too Much of a Good Thing
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE osteoporosis; sclerosing bone dysplasias; osteoclast; osteoblast; new
   drug targets
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; PROGRESSIVE ANKYLOSIS GENE;
   LATENCY ASSOCIATED PEPTIDE; DOMAIN SPECIFIC MUTATIONS; ANHYDRASE II
   DEFICIENCY; VACUOLAR H+ ATPASE; KAPPA B; RECESSIVE OSTEOPETROSIS;
   CATHEPSIN K; CRANIOMETAPHYSEAL DYSPLASIA
AB Osteoporosis is, because of its high prevalence and morbidity, a major health problem in our aging population. Epidemiological studies clearly indicated a heritability of up to 80% for relevant bone parameters with an additional role for environmental factors, such as food intake and physical exercise. A major contribution to our current understanding of bone homeostasis is obtained by studying monogenic diseases with an increased bone density, the sclerosing bone dysplasias. Gene identifications have revealed relevant pathways and mechanisms both in the bone resorbing osteoclasts and bone forming osteoblasts. Furthermore, natural variants within these genes turned out to have an influence on bone mineral density in the general population. Finally, interesting drug targets for the prevention and treatment of osteoporosis were revealed. Although many major breakthroughs have been realized, still a huge amount of significant information is hidden in these pathologies as the function of many of these genes and newly identified pathways is not, or only partially, clear.
C1 [Perdu, Bram; Van Hul, Wim] Univ & Univ Hosp Antwerp, Dept Med Genet, B 2650 Edegem, Belgium.
RP Perdu, B (通讯作者)，Univ & Univ Hosp Antwerp, Dept Med Genet, Prins Boudewijnlaan 43, B 2650 Edegem, Belgium.
EM wim.vanhul@ua.ac.be
OI Van Hul, Wim/0000 0002 5065 7858
FU Fonds voor Wetenschappelijk Onderzoek [G.0065.10N]; European Commission
   [HEALTH F2 2008 201099]; University of Antwerp; European Calcified
   Tissue Society
FX This work was supported by grants from the 'Fonds voor Wetenschappelijk
   Onderzoek' (Grant No. G.0065.10N), from the European Commission (FP7
   program) (Grant No. HEALTH F2 2008 201099) (TALOS), a NOI and
   TOP project from the Special Research Funds (B.O.F.) of the University
   of Antwerp, all to W.V.H. B.P. holds a PhD studentship from the European
   Calcified Tissue Society.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   ANDREN L., 1962, ACTA CHIR SCAND, V124, P496
   Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223 005 0027 6
   Balemans W, 1999, AM J HUM GENET, V64, P1661, DOI 10.1086/302416
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2007, J BONE MINER RES, V22, P708, DOI 10.1359/JBMR.070211
   Bastani B, 1996, CALCIFIED TISSUE INT, V58, P332, DOI 10.1007/BF02509381
   Baynam G, 2009, AM J MED GENET A, V149A, P1331, DOI 10.1002/ajmg.a.32875
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   BEIGHTON P, 1977, CLIN GENET, V11, P1
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   BOLLERSLEV J, 1987, J LARYNGOL OTOL, V101, P1088, DOI 10.1017/S0022215100103287
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004
   de Vernejoul MC, 2008, BEST PRACT RES CL RH, V22, P71, DOI 10.1016/j.berh.2007.12.011
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Donnarumma Michela, 2007, Hum Mutat, V28, P524, DOI 10.1002/humu.9490
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   HURT RL, 1953, J BONE JOINT SURG BR, V35, P89, DOI 10.1302/0301 620X.35B1.89
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Jenkins ZA, 2009, NAT GENET, V41, P95, DOI 10.1038/ng.270
   JOSEPH DJ, J CLIN ENDOCRINOL ME, V95, P1506
   Karsdal MA, 2008, BIOCHEM BIOPH RES CO, V366, P483, DOI 10.1016/j.bbrc.2007.11.168
   Katoh M, 2002, INT J ONCOL, V21, P1269
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128
   Kirsch T, 2009, CELLS TISSUES ORGANS, V189, P158, DOI 10.1159/000151725
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lotan D, 2006, PEDIATR NEPHROL, V21, P423, DOI 10.1007/s00467 005 2125 0
   MAROTEAUX P, 1962, PRESSE MED, V70, P999
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nürnberg P, 2001, NAT GENET, V28, P37, DOI 10.1038/ng0501 37
   Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403
   Perdu B, 2010, J BONE MINER RES, V25, P82, DOI 10.1359/jbmr.090707
   PITERS E, 2010, HUM MUTAT IN PRESS, V7, P1526
   Piters E, 2010, BONE, V46, pS55, DOI 10.1016/j.bone.2010.01.129
   Ramírez A, 2004, HUM MUTAT, V23, P471, DOI 10.1002/humu.20028
   Reichenberger E, 2001, AM J HUM GENET, V68, P1321, DOI 10.1086/320612
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Rivera MN, 2009, P NATL ACAD SCI USA, V106, P8338, DOI 10.1073/pnas.0811349106
   Roth P, 1992, Curr Top Microbiol Immunol, V181, P141
   Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200
   SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014 5793(94)01349 6
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302
   Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Styrkarsdottir U, 2009, NAT GENET, V41, P15, DOI 10.1038/ng.284
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Van Hul E, 2002, J BONE MINER RES, V17, P1111, DOI 10.1359/jbmr.2002.17.6.1111
   Van Hul W, 1998, AM J HUM GENET, V62, P391, DOI 10.1086/301721
   Van Wesenbeeck L, 2005, CRIT REV EUKAR GENE, V15, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.40
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
   Voorhoeve N, 1924, ACTA RADIOL, V3, P407, DOI 10.3109/00016922409133734
   Waguespack SG, 2003, J BONE MINER RES, V18, P1513, DOI 10.1359/jbmr.2003.18.8.1513
   Wang XL, 2007, NAT GENET, V39, P836, DOI 10.1038/ng2057
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Yadav VK, 2009, AGING US, V1, P954, DOI 10.18632/aging.100100
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 100
TC 13
Z9 14
U1 0
U2 4
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045 4403
EI 2162 6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2010
VL 20
IS 3
BP 195
EP 212
DI 10.1615/CritRevEukarGeneExpr.v20.i3.20
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 705PR
UT WOS:000286150600002
PM 21175411
DA 2025 08 17
ER

PT J
AU Hanyu, R
   Wehbi, VL
   Hayata, T
   Moriya, S
   Feinstein, TN
   Ezura, Y
   Nagao, M
   Saita, Y
   Hemmi, H
   Notomi, T
   Nakamoto, T
   Schipani, E
   Takeda, S
   Kaneko, K
   Kurosawa, H
   Karsenty, G
   Kronenberg, HM
   Vilardaga, JP
   Noda, M
AF Hanyu, Ryo
   Wehbi, Vanessa L.
   Hayata, Tadayoshi
   Moriya, Shuichi
   Feinstein, Timothy N.
   Ezura, Yoichi
   Nagao, Masashi
   Saita, Yoshitomo
   Hemmi, Hiroaki
   Notomi, Takuya
   Nakamoto, Tetsuya
   Schipani, Ernestina
   Takeda, Shu
   Kaneko, Kazuo
   Kurosawa, Hisashi
   Karsenty, Gerard
   Kronenberg, Henry M.
   Vilardaga, Jean Pierre
   Noda, Masaki
TI Anabolic action of parathyroid hormone regulated by the
   β2 adrenergic receptor
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone anabolism; bone cells
ID SYMPATHETIC NERVOUS SYSTEM; ELEMENT BINDING PROTEIN; BONE MINERAL
   DENSITY; POSTMENOPAUSAL WOMEN; IN VIVO; OSTEOPOROSIS; EXPRESSION;
   THERAPY; OSTEOPROTEGERIN; TERIPARATIDE
AB Parathyroid hormone (PTH), the major calcium regulating hormone, and norepinephrine (NE), the principal neurotransmitter of sympathetic nerves, regulate bone remodeling by activating distinct cell surface G protein coupled receptors in osteoblasts: the parathyroid hormone type 1 receptor (PTHR) and the beta(2) adrenergic receptor (beta(2)AR), respectively. These receptors activate a common cAMP/PKA signal transduction pathway mediated through the stimulatory heterotrimeric G protein. Activation of beta(2)AR via the sympathetic nervous system decreases bone formation and increases bone resorption. Conversely, daily injection of PTH (1 34), a regimen known as intermittent (i) PTH treatment, increases bone mass through the stimulation of trabecular and cortical bone formation and decreases fracture incidences in severe cases of osteoporosis. Here, we show that iPTH has no osteoanabolic activity in mice lacking the beta(2)AR. beta(2)AR deficiency suppressed both iPTH induced increase in bone formation and resorption. We showed that the lack of beta(2)AR blocks expression of iPTH target genes involved in bone formation and resorption that are regulated by the cAMP/PKA pathway. These data implicate an unexpected functional interaction between PTHR and beta(2)AR, two G protein coupled receptors from distinct families, which control bone formation and PTH anabolism.
C1 [Wehbi, Vanessa L.; Feinstein, Timothy N.; Vilardaga, Jean Pierre] Univ Pittsburgh, Lab Prot Coupled Receptor Biol G, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
   [Hanyu, Ryo; Hayata, Tadayoshi; Moriya, Shuichi; Ezura, Yoichi; Nagao, Masashi; Saita, Yoshitomo; Hemmi, Hiroaki; Notomi, Takuya; Nakamoto, Tetsuya; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Tokyo 1138510, Japan.
   [Hanyu, Ryo; Hayata, Tadayoshi; Ezura, Yoichi; Hemmi, Hiroaki; Notomi, Takuya; Nakamoto, Tetsuya; Takeda, Shu; Noda, Masaki] Tokyo Med & Dent Univ, Global Ctr Excellence Program, Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo 1138510, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Adv Bone Joint Sci Ctr, Tokyo 1138510, Japan.
   [Hanyu, Ryo; Moriya, Shuichi; Nagao, Masashi; Saita, Yoshitomo; Kaneko, Kazuo; Kurosawa, Hisashi] Juntendo Univ, Sch Med, Dept Orthoped, Tokyo 1138421, Japan.
   [Hemmi, Hiroaki; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Tokyo 1010062, Japan.
   [Schipani, Ernestina; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Schipani, Ernestina; Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Karsenty, Gerard] Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10027 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Juntendo University; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU); Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   University; Harvard Medical School; Columbia University
RP Vilardaga, JP (通讯作者)，Univ Pittsburgh, Lab Prot Coupled Receptor Biol G, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
EM jpv@pitt.edu; noda.mph@tmd.ac.jp
RI Hayata, Tadayoshi/AAE 9712 2021; Hemmi, Hiroaki/MTA 6997 2025;
   Feinstein, Timothy/G 3110 2011; KRONENBERG, HENRY/MXK 0923 2025; Ezura,
   Yoichi/L 9485 2016
OI Nagao, Masashi/0000 0002 8909 4650; Karsenty,
   Gerard/0000 0002 9253 7627; Vilardaga, Jean Pierre/0000 0002 1217 1435
FU Japanese Ministry of Education [18109011, 18659438, 18123456, 20013014,
   23659868]; Japan Space Forum; National Institutes of Health
   [R01DK087688]; Grants in Aid for Scientific Research [23659868,
   18109011, 20013014, 24119505, 23791626, 18659438, 23791628, 22591680]
   Funding Source: KAKEN
FX This work was supported by the Japanese Ministry of Education [Global
   Center of Excellence (COE) Program, International Research Center for
   Molecular Science in Tooth and Bone Diseases Grants in Aid 18109011,
   18659438, 18123456, 20013014, and 23659868), grants from the Japan Space
   Forum (to M. Noda), and National Institutes of Health Grant R01DK087688
   (to J. P.V).
CR Calvi LM, 2000, J ENDOCRINOL INVEST, V23, P545, DOI 10.1007/BF03343773
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Delmas PD, 2002, BONE, V30, P14, DOI 10.1016/S8756 3282(01)00667 6
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Hanyu R, 2011, J CELL BIOCHEM, V112, P433, DOI 10.1002/jcb.22957
   Keaveny TM, 2008, J BONE MINER RES, V23, P1974, DOI [10.1359/jbmr.080805, 10.1359/JBMR.080805]
   Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002 220996
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Sosa Henriquez M, 2007, MED INTERNA, V24, P87
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255
NR 21
TC 58
Z9 65
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 8
PY 2012
VL 109
IS 19
BP 7433
EP 7438
DI 10.1073/pnas.1109036109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 942ZQ
UT WOS:000304090600064
PM 22538810
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU You, CJ
   Shen, FY
   Yang, PY
   Cui, JY
   Ren, QY
   Liu, MY
   Hu, YJ
   Li, B
   Ye, L
   Shi, Y
AF You, Chengjia
   Shen, Fangyuan
   Yang, Puying
   Cui, Jingyao
   Ren, Qiaoyue
   Liu, Moyu
   Hu, Yujie
   Li, Boer
   Ye, Ling
   Shi, Yu
TI O GlcNAcylation mediates Wnt stimulated bone formation by rewiring
   aerobic glycolysis
SO EMBO REPORTS
LA English
DT Article
DE Wnt; O GlcNAcylation; Glucose Metabolism; Bone Formation; Fracture
   Healing
ID HEXOSAMINE BIOSYNTHESIS; SCLEROSTIN ANTIBODY; N ACETYLGLUCOSAMINE;
   GLUTAMINE FRUCTOSE 6 PHOSPHATE AMIDOTRANSFERASE; GLCNAC MODIFICATION;
   UP REGULATION; GLUCOSE; METABOLISM; GLUTAMINE; DIFFERENTIATION
AB Wnt signaling is an important target for anabolic therapies in osteoporosis. A sclerostin neutralizing antibody (Scl Ab), that blocks the Wnt signaling inhibitor (sclerostin), has been shown to promote bone mass in animal models and clinical studies. However, the cellular mechanisms by which Wnt signaling promotes osteogenesis remain to be further investigated. O GlcNAcylation, a dynamic post translational modification of proteins, controls multiple critical biological processes including transcription, translation, and cell fate determination. Here, we report that Wnt3a either induces O GlcNAcylation rapidly via the Ca2+ PKA Gfat1 axis, or increases it in a Wnt beta catenin dependent manner following prolonged stimulation. Importantly, we find O GlcNAcylation indispensable for osteoblastogenesis both in vivo and in vitro. Genetic ablation of O GlcNAcylation in the osteoblast lineage diminishes bone formation and delays bone fracture healing in response to Wnt stimulation in vivo. Mechanistically, Wnt3a induces O GlcNAcylation at Serine 174 of PDK1 to stabilize the protein, resulting in increased glycolysis and osteogenesis. These findings highlight O GlcNAcylation as an important mechanism regulating Wnt induced glucose metabolism and bone anabolism.
   Wnt signaling stimulates O GlcNAcylation either through the CaMKKII PKA GFAT1 axis or in a beta catenin dependent manner, which stabilizes PDK1 protein levels and increases aerobic glycolysis, thereby facilitating osteogenesis, bone formation, and fracture healing.O GlcNAcylation induced by Wnt3a or Scl Ab promotes osteogenesis, bone formation, and fracture healing.Wnt/beta catenin or Wnt CaMKKII PKA GFAT1 axes increase O GlcNAcylation.Wnt mediated O GlcNAcylation enhances aerobic glycolysis.O GlcNAcylation on Ser174 of PDK1 mediates Wnt3a induced osteogenic differentiation.
   Wnt signaling stimulates O GlcNAcylation either through the CaMKKII PKA GFAT1 axis or in a beta catenin dependent manner, which stabilizes PDK1 protein levels and increases aerobic glycolysis, thereby facilitating osteogenesis, bone formation and fracture healing.
C1 [You, Chengjia; Shen, Fangyuan; Yang, Puying; Cui, Jingyao; Ren, Qiaoyue; Liu, Moyu; Li, Boer; Ye, Ling; Shi, Yu] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [You, Chengjia; Shen, Fangyuan; Yang, Puying; Cui, Jingyao; Ren, Qiaoyue; Liu, Moyu; Li, Boer; Ye, Ling; Shi, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Cui, Jingyao; Hu, Yujie; Li, Boer; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, Dept Endodont, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Ye, L; Shi, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.; Ye, L; Shi, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.; Ye, L (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Endodont, Chengdu, Peoples R China.
EM yeling@scu.edu.cn; yushi1105@scu.edu.cn
RI Li, Bo/AAA 8968 2020; ye, ling/AFP 0048 2022
OI chengjia, you/0000 0002 3423 7167
FU MOST | National Natural Science Foundation of China (NSFC) [82071091,
   82001040]; National Natural Science Foundation of China [81825005];
   National Science Fund for Distinguished Young Scholars of China
   [RD 03 202304, QDJF2021 1]; West China Hospital of Stomatology Sichuan
   University
FX We thank Dr. Bei Yin and Dr. Feng Lou for the assistance with the
   phenotypic analysis of the mice. This work was supported by the National
   Natural Science Foundation of China (Grant No: 82071091 to YS, 82001040
   to BL), the National Science Fund for Distinguished Young Scholars of
   China (Grant No: 81825005 to LY), West China Hospital of Stomatology
   Sichuan University (Grant No: RD 03 202304 and QDJF2021 1 to YS).
CR Avila ME, 2010, J BIOL CHEM, V285, P18939, DOI 10.1074/jbc.M110.103028
   Bacigalupa ZA, 2018, J BIOENERG BIOMEMBR, V50, P189, DOI 10.1007/s10863 018 9742 3
   Buse MG, 2006, AM J PHYSIOL ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005
   Chatham JC, 2021, PHYSIOL REV, V101, P427, DOI 10.1152/physrev.00043.2019
   Chaveroux C, 2016, SCI REP UK, V6, DOI 10.1038/srep27278
   Chen H, 2019, FASEB J, V33, P7810, DOI 10.1096/fj.201900201RR
   Collette NM, 2016, BONE, V88, P20, DOI 10.1016/j.bone.2016.04.005
   da Silva CC, 2021, MOL GENET GENOM MED, V9, DOI 10.1002/mgg3.1681
   Dreyer T, 2021, J ORTHOP TRANSL, V29, P134, DOI 10.1016/j.jot.2021.05.005
   Duan FF, 2018, J HEPATOL, V68, P1191, DOI 10.1016/j.jhep.2018.02.003
   Eguchi S, 2009, GENES CELLS, V14, P179, DOI 10.1111/j.1365 2443.2008.01260.x
   Erdem A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28737 3
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2014, CURR OSTEOPOROS REP, V12, P433, DOI 10.1007/s11914 014 0235 y
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Feng G, 2015, INT IMMUNOPHARMACOL, V24, P7, DOI 10.1016/j.intimp.2014.11.010
   Gélinas R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02795 4
   Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200
   Gu H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010202
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim SH, 2007, BIOCHEM BIOPH RES CO, V362, P325, DOI 10.1016/j.bbrc.2007.07.149
   Korvala J, 2012, EUR J MED GENET, V55, P515, DOI 10.1016/j.ejmg.2012.06.011
   Koyama T, 2015, EXP CELL RES, V338, P194, DOI 10.1016/j.yexcr.2015.08.009
   Lee SY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07316 5
   Lee SY, 2018, J CLIN INVEST, V128, P5573, DOI 10.1172/JCI96221
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lei YR, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389 020 0208 1
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li MD, 2013, CELL METAB, V17, P303, DOI 10.1016/j.cmet.2012.12.015
   Li Y, 2017, ONCOGENE, V36, P6293, DOI 10.1038/onc.2017.223
   Li YN, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00218 9
   Liu B, 2019, CELL MOL NEUROBIOL, V39, P415, DOI 10.1007/s10571 019 00659 7
   Liu Y, 2016, CALCIFIED TISSUE INT, V98, P263, DOI 10.1007/s00223 015 0085 3
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Ma JF, 2021, CHEM REV, V121, P1513, DOI 10.1021/acs.chemrev.0c00884
   Manzari B, 2007, INT J IMMUNOPATH PH, V20, P47, DOI 10.1177/039463200702000106
   Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200
   MARSHALL S, 1991, J BIOL CHEM, V266, P4706
   Moloughney JG, 2018, J BIOL CHEM, V293, P16464, DOI 10.1074/jbc.RA118.003991
   Moloughney JG, 2016, MOL CELL, V63, P811, DOI 10.1016/j.molcel.2016.07.015
   Mouilleron S, 2008, J MOL BIOL, V377, P1174, DOI 10.1016/j.jmb.2008.01.077
   Nagel AK, 2014, MOL CELL PROTEOMICS, V13, P3381, DOI 10.1074/mcp.M114.040691
   Nagel AK, 2013, MOL CELL PROTEOMICS, V12, P945, DOI 10.1074/mcp.M112.026633
   Ni QA, 2011, NAT CHEM BIOL, V7, P34, DOI 10.1038/NCHEMBIO.478
   Nian FG, 2022, BIOCHEM BIOPH RES CO, V615, P31, DOI 10.1016/j.bbrc.2022.05.028
   Nie H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 13601 8
   Nie XB, 2022, AM J PATHOL, V192, P503, DOI 10.1016/j.ajpath.2021.11.007
   Oki T, 1999, GENOMICS, V57, P227, DOI 10.1006/geno.1999.5785
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Park J, 2009, BBA PROTEINS PROTEOM, V1794, P254, DOI 10.1016/j.bbapap.2008.10.003
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Qu F, 2013, FRONT BIOSCI LANDMRK, V18, P493, DOI 10.2741/4116
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Ruegenberg S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22320 y
   Ruegenberg S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14524 5
   Sayeski PP, 1997, NUCLEIC ACIDS RES, V25, P1458, DOI 10.1093/nar/25.7.1458
   Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011
   Velázquez Cruz R, 2014, AGE, V36, P1483, DOI 10.1007/s11357 014 9635 2
   Wang ZV, 2014, CELL, V156, P1179, DOI 10.1016/j.cell.2014.01.014
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Weng Y, 2021, BIOFACTORS, V47, P992, DOI 10.1002/biof.1774
   Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22
   Yang YY, 2021, J BONE MINER RES, V36, P1605, DOI 10.1002/jbmr.4321
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
   Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   You CJ, 2022, COLLOID INTERFAC SCI, V50, DOI 10.1016/j.colcom.2022.100665
   Zhang ZD, 2023, ELIFE, V12, DOI 10.7554/eLife.85464
   Zhou JX, 1998, DIABETES, V47, P1836, DOI 10.2337/diabetes.47.12.1836
   Zibrova D, 2017, BIOCHEM J, V474, P983, DOI 10.1042/BCJ20160980
NR 74
TC 6
Z9 6
U1 27
U2 37
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1469 221X
EI 1469 3178
J9 EMBO REP
JI EMBO Rep.
PD OCT 10
PY 2024
VL 25
IS 10
BP 4465
EP 4487
DI 10.1038/s44319 024 00237 z
EA SEP 2024
PG 23
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA J4T5L
UT WOS:001309276200002
PM 39256595
OA gold
DA 2025 08 17
ER

PT J
AU Chen, RB
   Yang, YD
   Sun, K
   Liu, S
   Guo, W
   Zhang, JX
   Li, Y
AF Chen, Rong Bin
   Yang, Ying Dong
   Sun, Kai
   Liu, Shan
   Guo, Wei
   Zhang, Jin Xin
   Li, Yong
TI Potential mechanism of Ziyin Tongluo Formula in the treatment of
   postmenopausal osteoporosis: based on network pharmacology and
   ovariectomized rat model
SO CHINESE MEDICINE
LA English
DT Article
DE Postmenopausal osteoporosis; Ziyin Tongluo Formula; Traditional Chinese
   medicine; Ovariectomy; Network pharmacology; Molecular docking
ID RECEPTOR ALPHA; ASSOCIATION; KAEMPFEROL; MICE
AB Background Amending from ancient classic, Ziyin Tongluo Formula (ZYTLF) has been prescribed to treat postmenopausal osteoporosis (PMOP) for decades with good curative effect. However, the possible mechanisms of it are still unknown. Methods Ovariectomized rat model was established to validate the therapeutic effect of ZYTLF on PMOP by Micro CT bone analysis and pathological observation. Subsequently, active ingredients of ZYTLF and corresponding putative targets were identified by online databases. Overlapping genes were first obtained from mining genes associated with PMOP and then overlapped them with the putative targets. Key genes were selected from the multiple constructed and analyzed networks. GO and KEGG pathway enrichment analysis were performed by importing the key genes to the DAVID database. Moreover, validation of the binding association between key targets and their corresponding active compounds were accomplished by AutoDock Tools and other software. Lastly, Enzyme linked immunosorbent assay (Elisa) detection and Western blot analysis were utilized to further explore the possible mechanism of ZYTLF on PMOP. Results With 129 target genes interacting with PMOP, 92 active compounds of ZYTLF corresponded to 243 targets, and 50 key genes were chosen. Network analysis revealed the top 10 active ingredients, such as quercetin and kaempferol and the top 50 key genes, such as ER alpha, p38 MAPK, p AKT and TGF beta 1. Enrichment analysis uncovered multiple signaling pathways, including estrogen signaling pathway, TNF signaling pathway, PI3K Akt signaling pathway and MAPK signaling pathway. Furthermore, our finding of the foremost active compounds was tightly bound to the core proteins, which were verified by molecular docking analysis. Through experimental studies, we confirmed that the prescription of ZYTLF could ameliorate the OVX induced bone loss, suppress the osteoclast activity and boost osteoblast ability through experimental studies. Conclusion The potential mechanisms and therapeutic effects of ZYTLF against PMOP may be ascribed to inhibition of osteoclast activity, boost of osteoblast activity and enhancement of the expression of ER alpha.
C1 [Chen, Rong Bin; Yang, Ying Dong; Sun, Kai] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou 510006, Peoples R China.
   [Chen, Rong Bin; Zhang, Jin Xin; Li, Yong] Guangdong Prov Hosp Tradit Chinese Med, Zhuhai Branch, Zhuhai 519015, Peoples R China.
   [Liu, Shan; Guo, Wei] Guangzhou Univ Chinese Med, Guangzhou 510006, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Li, Y (通讯作者)，Guangdong Prov Hosp Tradit Chinese Med, Zhuhai Branch, Zhuhai 519015, Peoples R China.
EM lyzhuhai666@126.com
RI Sun, Kai/ABI 2598 2020
FU Traditional Chinese Medicine Bureau of Guangdong Province of China for
   Arranged Project of Experiential prescription [20194010]; Scientific
   research project of Traditional Chinese Medicine Bureau Of Guangdong
   Province of China [20212213]
FX This study was supported by grants from Traditional Chinese Medicine
   Bureau of Guangdong Province of China for Arranged Project of
   Experiential prescription (No. 20194010) and Scientific research project
   of Traditional Chinese Medicine Bureau Of Guangdong Province of China
   (No. 20212213). Funder provided financial support for the study.
CR Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   Babujanarthanam R, 2011, MOL CELL BIOCHEM, V358, P121, DOI 10.1007/s11010 011 0927 x
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Camacho PM, 2020, ENDOCR PRACT, V26, P564, DOI 10.4158/GL 2020 0524
   Chen BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22091469
   Chen MS., 2019, CLIN J CHINE MED, V11, P108
   Cruz EA, 2008, INT IMMUNOPHARMACOL, V8, P1616, DOI 10.1016/j.intimp.2008.07.006
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fujiwara Saeko, 2016, Clin Calcium, V26, P1387
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang L, 2018, NUCLEIC ACIDS RES, V46, pD1117, DOI 10.1093/nar/gkx1028
   Huang Q, 2015, BONE, V74, P18, DOI 10.1016/j.bone.2015.01.002
   Kim JA, 2011, PHYTOTHER RES, V25, P1612, DOI 10.1002/ptr.3465
   Li HY, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/495840
   Li S, 2021, WORLD J TRAD CHINESE, V7, P146, DOI 10.4103/wjtcm.wjtcm_11_21
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu GF, 2018, J CELL BIOCHEM, V119, P4469, DOI 10.1002/jcb.26550
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Moriarty K, 2006, ENDOCRINOLOGY, V147, P5557, DOI 10.1210/en.2006 0729
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Safran M, 2003, NUCLEIC ACIDS RES, V31, P142, DOI 10.1093/nar/gkg050
   Saikia S, 2019, CURR DRUG TARGETS, V20, P501, DOI 10.2174/1389450119666181022153016
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Shoukry A, 2015, MOL CELL BIOCHEM, V405, P23, DOI 10.1007/s11010 015 2391 5
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Ward AB, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1400 z
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Yu F, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 018 0549 y
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang YQ, 2016, INT J BIOL SCI, V12, P594, DOI 10.7150/ijbs.14151
   Zheng JH, 2018, CANCERS, V10, DOI 10.3390/cancers10110461
NR 44
TC 10
Z9 11
U1 1
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD SEP 16
PY 2021
VL 16
IS 1
AR 88
DI 10.1186/s13020 021 00503 5
PG 19
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA UR1SZ
UT WOS:000696536700003
PM 34530875
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ikebuchi, Y
   Aoki, S
   Honma, M
   Hayashi, M
   Sugamori, Y
   Khan, M
   Kariya, Y
   Kato, G
   Tabata, Y
   Penninger, JM
   Udagawa, N
   Aoki, K
   Suzuki, H
AF Ikebuchi, Yuki
   Aoki, Shigeki
   Honma, Masashi
   Hayashi, Madoka
   Sugamori, Yasutaka
   Khan, Masud
   Kariya, Yoshiaki
   Kato, Genki
   Tabata, Yasuhiko
   Penninger, Josef M.
   Udagawa, Nobuyuki
   Aoki, Kazuhiro
   Suzuki, Hiroshi
TI Coupling of bone resorption and formation by RANKL reverse signalling
SO NATURE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOCLASTOGENESIS;
   GROWTH; MICE; PROLIFERATION; SUPPRESSION; EXPRESSION; VESICLES
AB Receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) binds RANK on the surface of osteoclast precursors to trigger osteoclastogenesis. Recent studies have indicated that osteocytic RANKL has an important role in osteoclastogenesis during bone remodelling; however, the role of osteoblastic RANKL remains unclear. Here we show that vesicular RANK, which is secreted from the maturing osteoclasts, binds osteoblastic RANKL and promotes bone formation by triggering RANKL reverse signalling, which activates Runt related transcription factor 2 (Runx2). The proline rich motif in the RANKL cytoplasmic tail is required for reverse signalling, and a RANKL(Pro29Ala) point mutation reduces activation of the reverse signalling pathway. The coupling of bone resorption and formation is disrupted in RANKL(Pro29Ala) mutant mice, indicating that osteoblastic RANKL functions as a coupling signal acceptor that recognizes vesicular RANK. RANKL reverse signalling is therefore a potential pharmacological target for avoiding the reduced bone formation associated with inhibition of osteoclastogenesis.
C1 [Ikebuchi, Yuki; Aoki, Shigeki; Honma, Masashi; Hayashi, Madoka; Kariya, Yoshiaki; Suzuki, Hiroshi] Univ Tokyo, Univ Tokyo Hosp, Dept Pharm, Fac Med, Tokyo, Japan.
   [Sugamori, Yasutaka; Khan, Masud; Aoki, Kazuhiro] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Basic Oral Hlth Engn, Tokyo, Japan.
   [Kato, Genki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Biomatrix Pharmacol, Tokyo, Japan.
   [Tabata, Yasuhiko] Kyoto Univ, Inst Frontier Life & Med Sci, Dept Regenerat Sci & Engn, Lab Biomat, Kyoto, Japan.
   [Penninger, Josef M.] Austrian Acad Sci, Vienna Bioctr, Inst Mol Biotechnol, Vienna, Austria.
   [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Shiojiri, Japan.
C3 University of Tokyo; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Kyoto University; Austrian Academy of Sciences;
   Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA);
   Matsumoto Dental University
RP Honma, M (通讯作者)，Univ Tokyo, Univ Tokyo Hosp, Dept Pharm, Fac Med, Tokyo, Japan.
EM mhonma tky@umin.ac.jp
RI AOKI, Kazuhiro/GRO 6475 2022; Penninger, Josef/I 6860 2013; AOKI,
   Kazuhiro/G 2258 2016; Aoki, Shigeki/ABB 2942 2020
OI Aoki, Shigeki/0000 0003 2821 0651; Penninger, Josef/0000 0002 8194 3777;
   AOKI, Kazuhiro/0000 0001 6643 6315; Biresaw, Samuel
   Shiferaw/0000 0001 5508 8511
FU JSPS KAKENHI [JP16H05445, JP24390349, JP26713045, JP24890048,
   JP25670632]; MEXT KAKENHI [JP22136015]
FX We thank K. Toritani, M. Maeda, and M. A. Al Mamun for their technical
   assistance. This work was supported in part by JSPS KAKENHI grant
   numbers JP16H05445, JP24390349, JP26713045, JP24890048, JP25670632; and
   by MEXT KAKENHI grant number JP22136015.
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fei QM, 2010, ACTA BIOCH BIOPH SIN, V42, P801, DOI 10.1093/abbs/gmq086
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   George J, 2006, BIOTECHNOL BIOENG, V95, P404, DOI 10.1002/bit.20939
   Huynh N, 2016, J DENT RES, V95, P673, DOI 10.1177/0022034516633189
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kariya Y, 2009, J BONE MINER RES, V24, P1741, DOI [10.1359/JBMR.090409, 10.1359/jbmr.090409]
   Kisiswa L, 2013, NAT NEUROSCI, V16, P865, DOI 10.1038/nn.3430
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769
   Sakai A, 1998, BONE, V23, P443, DOI 10.1016/S8756 3282(98)00121 5
   SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460 2075.1995.tb07024.x
   Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugamori Y, 2016, BIOESSAYS, V38, P717, DOI 10.1002/bies.201600104
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185
   Vizcaíno JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Watzl C., 2006, CURR PROTOC PROTEIN, V19
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 34
TC 422
Z9 470
U1 11
U2 258
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD SEP 13
PY 2018
VL 561
IS 7722
BP 195
EP +
DI 10.1038/s41586 018 0482 7
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GT3XQ
UT WOS:000444437900034
PM 30185903
DA 2025 08 17
ER

PT B
AU Leibbrandt, A
   Penninger, JM
AF Leibbrandt, Andreas
   Penninger, Josef M.
BE Rose, NR
TI RANK/RANKL: Regulators of Immune Responses and Bone Physiology
SO YEAR IN IMMUNOLOGY 2008
SE Annals of the New York Academy of Sciences Series
LA English
DT Article
DE RANK; RANKL; OPG; osteoclastogenesis; osteoimmunology; RANK RANKL
   signaling; osteoporosis; rheumatoid arthritis; lymph node formation;
   mammary gland biology
ID TUMOR NECROSIS FACTOR; NF KAPPA B; OSTEOCLAST DIFFERENTIATION FACTOR;
   OSTEOPROTEGERIN MESSENGER RNA; TNF FAMILY MEMBER; COLLAGEN INDUCED
   ARTHRITIS; EXPANSILE SKELETAL HYPERPHOSPHATASIA; FACTOR RECEPTOR FAMILY;
   LYMPH NODE GENESIS; T CELL
AB Bone related diseases, such as osteoporosis and rheumatoid arthritis, affect hundreds of millions of people worldwide and pose a tremendous burden to health care. By deepening our understanding of the molecular mechanisms of bone metabolism and bone turnover, it became possible over the past years to devise new and promising strategies for treating such diseases. In particular, three tumor necrosis factor (TNF) family molecules, the receptor activator of NF kappa B (RANK), its ligand RANKL, and the decoy receptor of RANKL, osteoprotegerin (OPG), have attracted the attention of scientists and pharmaceutical companies alike. Genetic experiments revolving around these molecules established their pivotal role as central regulators of osteoclast development at Ad osteoclast function. RANK RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast: development, but crosstalk with other signaling pathways also fine tunes bone homeostasis both in normal physiology an(] disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.
C1 [Leibbrandt, Andreas; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A 1030 Vienna, Austria.
C3 Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of
   Molecular Biotechnology (IMBA)
RP Penninger, JM (通讯作者)，Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Dr Bohr Gasse 3, A 1030 Vienna, Austria.
EM josef.Penninger@imba.oeaw.ac.at
RI Penninger, Josef/I 6860 2013
OI Penninger, Josef/0000 0002 8194 3777
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Akiyama T, 2005, SCIENCE, V308, P248, DOI 10.1126/science.1105677
   Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Anderson G, 2007, NAT REV IMMUNOL, V7, P954, DOI 10.1038/nri2187
   Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794
   Bolon B, 2002, CELL MOL LIFE SCI, V59, P1569, DOI 10.1007/s00018 002 8530 7
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V248, P454, DOI 10.1006/bbrc.1998.8993
   Brandt J, 2000, ARTHRITIS RHEUM US, V43, P1346, DOI 10.1002/1529 0131(200006)43:6<1346::AID ANR18>3.0.CO;2 E
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074 7613(00)00041 8
   Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351
   Chen Q, 2004, HORM METAB RES, V36, P674, DOI 10.1055/s 2004 826013
   Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200
   Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982
   Chong B, 2003, J BONE MINER RES, V18, P2095, DOI 10.1359/jbmr.2003.18.12.2095
   Cohen SB, 2006, ARTHRITIS RHEUM, V54, pS831
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   De T.P., 1994, SCIENCE, V264, P703
   Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807
   Dore R, 2006, ARTHRITIS RHEUM, V54, pS240
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Durán A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534 5807(03)00403 9
   Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399
   Fütterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074 7613(00)80588 9
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   Green EA, 2000, IMMUNITY, V12, P459, DOI 10.1016/S1074 7613(00)80198 3
   Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074 7613(02)00279 0
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 2001, BIOCHEM BIOPH RES CO, V280, P334, DOI 10.1006/bbrc.2000.4130
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   HOLBAUER LC, 1999, ENDOCRINOLOGY, V140, P4367
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ikeda T, 2003, J BIOL CHEM, V278, P47217, DOI 10.1074/jbc.M304636200
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133
   Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Josien R, 1999, J IMMUNOL, V162, P2562
   Kanatan M, 2003, J CELL PHYSIOL, V196, P180, DOI 10.1002/jcp.10270
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kido S, 2003, BONE, V32, P621, DOI 10.1016/S8756 3282(03)00049 8
   Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074 7613(03)00230 9
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074 7613(00)80292 7
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   KOSCKI T, 2002, CELL SIGNAL, V14, P31
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845
   Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Lane NE, 2006, ARTHRITIS RHEUM, V54, pS225
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mahamed DA, 2005, DIABETES, V54, P1477, DOI 10.2337/diabetes.54.5.1477
   ManourySchwartz B, 1997, J IMMUNOL, V158, P5501
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054
   Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074 7613(00)80371 4
   Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615
   Min JK, 2003, J BIOL CHEM, V278, P39548, DOI 10.1074/jbc.M300539200
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Mori H, 2002, HISTOCHEM CELL BIOL, V117, P283, DOI 10.1007/s00418 001 0376 9
   Muller Ladner U, 1998, Curr Opin Rheumatol, V10, P212
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Nagasawa T, 2002, CLIN EXP IMMUNOL, V130, P338, DOI 10.1046/j.1365 2249.2002.01990.x
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281 200305000 00016
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45
   Otsuka E, 2000, ENDOCRINOLOGY, V141, P3006, DOI 10.1210/en.141.8.3006
   Oxenius A, 1996, J EXP MED, V183, P2209, DOI 10.1084/jem.183.5.2209
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   PANAYI GS, 1992, ARTHRITIS RHEUM US, V35, P729, DOI 10.1002/art.1780350702
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s 2007 979106
   Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627
   Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074 7613(00)80589 0
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813
   ROY M, 1993, J IMMUNOL, V151, P2497
   Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002 020656
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schlöndorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200
   SEITZ M, 1985, ANN RHEUM DIS, V44, P438, DOI 10.1136/ard.44.7.438
   Seriwatanachai D, 2008, BONE, V42, P535, DOI 10.1016/j.bone.2007.11.008
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107
   Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040
   STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016 5085(85)90212 4
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Suzuki J, 2004, BIOCHEM BIOPH RES CO, V314, P1021, DOI 10.1016/j.bbrc.2003.12.191
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Takami M, 2000, ENDOCRINOLOGY, V141, P4711, DOI 10.1210/en.141.12.4711
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378 1119(97)00509 X
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Usui M, 2008, J BONE MINER RES, V23, P314, DOI 10.1359/JBMR.071025
   Vermeire K, 1997, J IMMUNOL, V158, P5507
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Vidal ONA, 1998, BIOCHEM BIOPH RES CO, V248, P696, DOI 10.1006/bbrc.1998.9035
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092 8674(00)80605 4
   WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330
   Williamson E, 2002, J IMMUNOL, V169, P3606, DOI 10.4049/jimmunol.169.7.3606
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Yun TJ, 2001, J IMMUNOL, V166, P1482, DOI 10.4049/jimmunol.166.3.1482
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 202
TC 314
Z9 349
U1 0
U2 41
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
BN 978 1 57331 729 0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2008
VL 1143
BP 123
EP 150
DI 10.1196/annals.1443.016
PG 28
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA BIP75
UT WOS:000261717900008
PM 19076348
DA 2025 08 17
ER

PT J
AU Huang, J
   Wu, T
   Jiang, YR
   Zheng, XQ
   Wang, H
   Liu, H
   Wang, H
   Leng, HJ
   Fan, DW
   Yuan, WQ
   Song, CL
AF Huang, Jie
   Wu, Tong
   Jiang, Yi Rong
   Zheng, Xuan Qi
   Wang, Huan
   Liu, Hao
   Wang, Hong
   Leng, Hui Jie
   Fan, Dong Wei
   Yuan, Wan Qiong
   Song, Chun Li
TI β Receptor blocker enhances the anabolic effect of PTH after
   osteoporotic fracture
SO BONE RESEARCH
LA English
DT Article
ID BONE TURNOVER MARKERS; MINERAL DENSITY; NERVOUS SYSTEM; TERIPARATIDE;
   PROPRANOLOL; DEPRESSION; MECHANISM; THERAPY
AB The autonomic nervous system plays a crucial role in regulating bone metabolism, with sympathetic activation stimulating bone resorption and inhibiting bone formation. We found that fractures lead to increased sympathetic tone, enhanced osteoclast resorption, decreased osteoblast formation, and thus hastened systemic bone loss in ovariectomized (OVX) mice. However, the combined administration of parathyroid hormone (PTH) and the beta receptor blocker propranolol dramatically promoted systemic bone formation and osteoporotic fracture healing in OVX mice. The effect of this treatment is superior to that of treatment with PTH or propranolol alone. In vitro, the sympathetic neurotransmitter norepinephrine (NE) suppressed PTH induced osteoblast differentiation and mineralization, which was rescued by propranolol. Moreover, NE decreased the PTH induced expression of Runx2 but enhanced the expression of Rankl and the effect of PTH stimulated osteoblasts on osteoclastic differentiation, whereas these effects were reversed by propranolol. Furthermore, PTH increased the expression of the circadian clock gene Bmal1, which was inhibited by NE beta AR signaling. Bmal1 knockdown blocked the rescue effect of propranolol on the NE induced decrease in PTH stimulated osteoblast differentiation. Taken together, these results suggest that propranolol enhances the anabolic effect of PTH in preventing systemic bone loss following osteoporotic fracture by blocking the negative effects of sympathetic signaling on PTH anabolism.
C1 [Huang, Jie; Wu, Tong; Jiang, Yi Rong; Zheng, Xuan Qi; Wang, Huan; Liu, Hao; Wang, Hong; Leng, Hui Jie; Fan, Dong Wei; Yuan, Wan Qiong; Song, Chun Li] Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.
   [Wang, Hong; Leng, Hui Jie; Fan, Dong Wei; Yuan, Wan Qiong; Song, Chun Li] Beijing Key Lab Spinal Dis, Beijing 100191, Peoples R China.
   [Wang, Hong; Leng, Hui Jie; Fan, Dong Wei; Yuan, Wan Qiong; Song, Chun Li] Engn Res Ctr Bone & Joint Precis Med, Beijing 100191, Peoples R China.
C3 Peking University
RP Song, CL (通讯作者)，Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.; Song, CL (通讯作者)，Beijing Key Lab Spinal Dis, Beijing 100191, Peoples R China.; Song, CL (通讯作者)，Engn Res Ctr Bone & Joint Precis Med, Beijing 100191, Peoples R China.
EM schl@bjmu.edu.cn
RI Leng, Huijie/AGQ 9574 2022
FU National Natural Science Foundation of China (National Science
   Foundation of China) [82330078, 81874010]; National Natural Science
   Foundation of China [2020YFC2009004, 2021YFC2501700]; National Key
   Research and Development Program
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 82330078, 81874010) and the National Key Research and
   Development Program (Grant Nos. 2020YFC2009004, 2021YFC2501700).
CR Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Bhandari M, 2016, CLIN ORTHOP RELAT R, V474, P1234, DOI 10.1007/s11999 015 4669 z
   Chen GJ, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117636
   Chen RY, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2312677120
   Christiansen BA, 2018, OSTEOPOROSIS INT, V29, P2201, DOI 10.1007/s00198 018 4606 6
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Diemar SS, 2023, CALCIFIED TISSUE INT, V112, P126, DOI 10.1007/s00223 022 00965 1
   El Jamal N, 2023, CIRC RES, V132, P223, DOI 10.1161/CIRCRESAHA.122.321369
   Elefteriou F, 2018, PHYSIOL REV, V98, P1083, DOI 10.1152/physrev.00014.2017
   Emami AJ, 2019, J BONE MINER RES, V34, P157, DOI 10.1002/jbmr.3579
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Gamble KL, 2014, NAT REV ENDOCRINOL, V10, P466, DOI 10.1038/nrendo.2014.78
   Gorter EA, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101117
   Guan ZY, 2023, BONE, V166, DOI 10.1016/j.bone.2022.116596
   Guzon Illescas O, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1226 6
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Jin ZX, 2022, J CACHEXIA SARCOPENI, V13, P1403, DOI 10.1002/jcsm.12938
   Johansson T, 2016, ACTA ORTHOP, V87, P79, DOI 10.3109/17453674.2015.1073050
   Jorgensen Niklas R, 2011, Curr Osteoporos Rep, V9, P149, DOI 10.1007/s11914 011 0065 0
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Ko DT, 2002, JAMA J AM MED ASSOC, V288, P351, DOI 10.1001/jama.288.3.351
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Langley A, 2015, BRIT J DERMATOL, V172, P13, DOI 10.1111/bjd.13379
   Leach S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01235
   Luchavova M, 2011, EUR J ENDOCRINOL, V164, P643, DOI 10.1530/EJE 10 1108
   Luo BB, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03068 x
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Michalska D, 2012, OSTEOPOROSIS INT, V23, P2885, DOI 10.1007/s00198 012 1955 4
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Qin Y, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114019
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Riganello F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16132336
   Samsa WE, 2016, BONE, V84, P194, DOI 10.1016/j.bone.2016.01.006
   Sato M, 2020, J PERIODONTAL RES, V55, P734, DOI 10.1111/jre.12762
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Song C, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9156478
   Swanson CM, 2017, J CLIN ENDOCR METAB, V102, P3722, DOI 10.1210/jc.2017 01147
   Wang K, 2015, ENDOCRINE, V49, P538, DOI 10.1007/s12020 014 0493 6
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yamashita J, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10250
   Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103
   Yukata K, 2018, BONE, V110, P150, DOI 10.1016/j.bone.2018.02.001
   Zhang CG, 2021, J BONE MINER RES, V36, P567, DOI 10.1002/jbmr.4211
   Zhang W, 2018, J ORTHOP RES, V36, P1145, DOI 10.1002/jor.23750
   Zheng XQ, 2023, J ADV RES, V49, P63, DOI 10.1016/j.jare.2022.08.019
NR 49
TC 14
Z9 19
U1 3
U2 16
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAR 21
PY 2024
VL 12
IS 1
AR 18
DI 10.1038/s41413 024 00321 z
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LZ1J7
UT WOS:001190540900001
PM 38514644
OA gold
DA 2025 08 17
ER

PT J
AU Liu, H
   Li, X
   Lin, JG
   Lin, MK
AF Liu, Hui
   Li, Xi
   Lin, Jingui
   Lin, Miaokuo
TI Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR
   signaling
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Morroniside; osteogenesis; osteoblast; PI3K; mTOR
ID BONE; DIFFERENTIATION; PROTEIN; PATHWAY; TARGET; AKT
AB Morroniside exerts a proosteogenic effect, which can prevent bone loss. However, the detailed mechanism underlying Morroniside regulated bone formation is unclear. Morroniside can maintain cell homeostasis by promoting PI3K/Akt/mTOR signaling. The purpose of this study is to explore the significance of PI3K/Akt/mTOR signaling in Morroniside regulated osteogenesis. The results showed that Morroniside promoted the activities of PI3K, Akt, and mTOR in osteoblast precursor MC3T3 E1. The differentiation of MC3T3 E1 to mature osteoblasts promoted by Morroniside can be reversed by the pharmacological inhibition of PI3K or mTOR. Importantly, in the presence of Morroniside, the osteoblast differentiation suppressed by PI3K inhibitor was reversed by mTOR overexpression. In vivo assays showed that in bone tissue of ovariectomized mice, Morroniside enhanced osteoblast formation was reversed by the pharmacological inhibition of PI3K or mTOR. In conclusion, Morroniside can promote the osteogenesis through PI3K/Akt/mTOR signaling, which provides a novel clue for the strategy of Morroniside in treating osteoporosis.
C1 [Liu, Hui; Li, Xi; Lin, Jingui; Lin, Miaokuo] Xiamen Univ, Dept Orthoped, Fuzhou Hosp 2, Fuzhou, Fujian, Peoples R China.
C3 Xiamen University
RP Lin, MK (通讯作者)，Xiamen Univ, Dept Orthoped, Fuzhou Hosp 2, Fuzhou, Fujian, Peoples R China.
EM Miaokuofzey@aliyun.com
FU Project of Fujian Health Commission [2017022]
FX This work was supported by the Project of Fujian Health Commission
   (2017022).
CR Chalhoub N, 2009, ANNU REV PATHOL MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Cheng L, 2015, J CELL MOL MED, V19, P1877, DOI 10.1111/jcmm.12559
   Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Karvande A, 2018, BONE, V117, P98, DOI 10.1016/j.bone.2018.09.007
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Liu Q, 2014, NEURO ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Smink JJ, 2012, J MOL MED, V90, P25, DOI 10.1007/s00109 011 0823 6
   Sun Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12866
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Watabe H, 2011, EXP CELL RES, V317, P2642, DOI 10.1016/j.yexcr.2011.07.015
   Wu C, 2020, J SEP SCI, V43, P2105, DOI 10.1002/jssc.201901203
   Xiao ZH, 2020, BIOSCI BIOTECH BIOCH, V84, P989, DOI 10.1080/09168451.2020.1717925
   Zhan JK, 2015, INT J CARDIOL, V189, P188, DOI 10.1016/j.ijcard.2015.04.086
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zhou HM, 2019, BIOL TRACE ELEM RES, V190, P327, DOI 10.1007/s12011 018 1574 9
NR 22
TC 31
Z9 35
U1 5
U2 40
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0916 8451
EI 1347 6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD FEB 18
PY 2021
VL 85
IS 2
BP 332
EP 339
DI 10.1093/bbb/zbaa010
EA JAN 2021
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA RV4OR
UT WOS:000645814600018
PM 33604633
OA Bronze
DA 2025 08 17
ER

PT J
AU Greiner, S
   Kadow Romacker, A
   Wildemann, B
   Schwabe, P
   Schmidmaier, G
AF Greiner, Stefan
   Kadow Romacker, Anke
   Wildemann, Britt
   Schwabe, Philipp
   Schmidmaier, Gerhard
TI Bisphosphonates incorporated in a poly(D,L lactide) implant coating
   inhibit osteoclast like cells in vitro
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE bisphosphonates; osteoclast; TRAP; pit formation assay; coating
ID BONE MINERAL DENSITY; NITROGEN CONTAINING BISPHOSPHONATES; ZOLEDRONIC
   ACID; PROTEIN GERANYLGERANYLATION; OSTEOPROTEGERIN PRODUCTION;
   RESORPTION ACTIVITY; MEVALONATE PATHWAY; RAT MODEL; ALENDRONATE;
   DIFFERENTIATION
AB Nitrogen containing bisphosphonates such as zoledronic acid (ZOL) are clinically used to prevent osteoclast induced bone loss. Previous studies indicated that bisphosphonates prevent osteoclast formation, decreases their resorption activity and lead to osteoclast apoptosis. Aim of the study was to investigate the effect of ZOL on fusion and resorption activity of osteoclast like cells (OLC) derived from human peripheral blood mononuclear cells (PBMNC) in vitro. For application of ZOL a local drug delivery system based on a coating for medical devices was used. ZOL was incorporated in the coating based on Poly(D,L Lactide) (PDLLA) in different concentrations (1050 mu M). Control groups were treated without ZOL or ZOL pure substance in corresponding concentrations. Human PBMNCs were isolated and stimulated to form OLCs. After an experimental period of 144 h, TRAP staining of polynucleated cells was performed and TRAP positive cells were counted. A pit formation assay was performed and resorption lacunas on dentin chips were counted. Results showed a significant dose dependent decrease in the number of TRAP positive cells after exposure to ZOL incorporated in the drug delivery system or applied as pure substance. The amount of resorption lacunas was also dose dependent decreased using both application methods. In conclusion, exposure to specific concentrations of ZOL incorporated in a drug delivery system showed a significant decrease in OLC formation and activity comparable to the effect of pure substance. The effect on osteoclasts might be of clinical benefit to reduce orthopedic implant loosening and to support fracture healing. (c) 2007 Wiley Periodicals, Inc.
C1 [Greiner, Stefan; Kadow Romacker, Anke; Wildemann, Britt; Schwabe, Philipp; Schmidmaier, Gerhard] Charite Univ Med Berlin, Ctr Musculoskeletal Surg, Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Greiner, S (通讯作者)，Charite Univ Med Berlin, Ctr Musculoskeletal Surg, Berlin, Germany.
EM Stefan.greiner@charite.de
RI Wildemann, Britt/G 7732 2012
OI Wildemann, Britt/0000 0002 8365 1188
CR Adachi JD, 2001, ARTHRITIS RHEUM US, V44, P202, DOI 10.1002/1529 0131(200101)44:1<202::AID ANR27>3.0.CO;2 W
   Amanat N, 2005, J ORTHOP RES, V23, P1029, DOI 10.1016/j.orthres.2005.03.004
   Åstrand J, 2004, J ORTHOP RES, V22, P244, DOI 10.1016/j.orthres.2003.08.008
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Diel I J, 2000, Clin Breast Cancer, V1, P43, DOI 10.3816/CBC.2000.n.003
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   Emkey R, 2003, ARTHRITIS RHEUM, V48, P1102, DOI 10.1002/art.10861
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Ito M, 1998, CALCIFIED TISSUE INT, V63, P143, DOI 10.1007/s002239900505
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li J, 1998, BONE, V23, P459, DOI 10.1016/S8756 3282(98)00123 9
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lipton A, 2002, CANCER INVEST, V20, P45, DOI 10.1081/CNV 120014886
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   Schmidmaier G, 2003, J BIOMED MATER RES B, V65B, P157, DOI 10.1002/jbm.b.10513
   Schmidmaier G, 2001, J BIOMED MATER RES, V58, P449
   Schmidmaier G, 2001, BONE, V28, P341, DOI 10.1016/S8756 3282(00)00456 7
   Skoglund B, 2004, J ORTHOP RES, V22, P1108, DOI 10.1016/j.orthres.2003.12.015
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Tokuda H, 1998, J CELL BIOCHEM, V69, P252, DOI 10.1002/(SICI)1097 4644(19980601)69:3<252::AID JCB3>3.0.CO;2 Q
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Wildemann B, 2005, CALCIFIED TISSUE INT, V76, P50, DOI 10.1007/s00223 004 0040 1
NR 44
TC 29
Z9 35
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD DEC 15
PY 2007
VL 83A
IS 4
BP 1184
EP 1191
DI 10.1002/jbm.a.31444
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 235XN
UT WOS:000251267700033
PM 17595027
DA 2025 08 17
ER

PT J
AU Wang, JB
   Wang, Y
   Li, LY
   Cai, SQ
   Mao, DD
   Lou, HK
   Zhao, J
AF Wang, Jianbo
   Wang, Yi
   Li, Leyan
   Cai, Shuiqi
   Mao, Dandan
   Lou, Hongkan
   Zhao, Jian
TI Network pharmacology based pharmacological mechanism prediction of Lycii
   Fructus against postmenopausal osteoporosis
SO MEDICINE
LA English
DT Article
DE Lycii Fructus; network pharmacology; postmenopausal osteoporosis
ID OSTEOCLAST DIFFERENTIATION; ANGIOGENESIS; OSTEOGENESIS; POLARIZATION;
   QUERCETIN
AB Postmenopausal osteoporosis (PMOP) has become one of most frequent bone diseases worldwide with aging population. Lycii Fructus, a common plant fruit with the property of drug homologous food, has long since been used to treat PMOP. The aim of this study is to explore pharmacological mechanisms of Lycii Fructus against PMOP through using network pharmacology approach. The active ingredients of Lycii Fructus were obtained from Traditional Chinese Medicine System Pharmacology database. Target fishing was performed on these ingredients in UniProt database for identification of the relative targets. Then, we screened the targets related to PMOP using GeneCards database and DisGeNET database. The overlapping genes between PMOP and Lycii Fructus were obtained to perform protein protein interaction, gene ontology analysis, Kyoto Encyclopedia of Genes and Genomes analysis. A total of 35 active ingredients were identified in Lycii Fructus, and fished 158 related targets. Simultaneously, 292 targets associated with PMOP were obtained from GeneCards database and DisGeNET database. By drawing Venn diagram, 41 overlapping genes were obtained, and were considered as therapeutically relevant. Gene ontology enrichment analysis predicted that anti inflammation and promotion of angiogenesis might be 2 potential mechanism of Lycii Fructus for PMOP treatment. Kyoto Encyclopedia of Genes and Genomes enrichment analysis revealed several pathways, such as IL 17 pathway, TNF pathway, MAPK pathway, PI3K Akt signaling pathway and HIF signaling pathway were involved in regulating these 2 biological processes. Through the method of network pharmacology, we systematically investigated the mechanisms of Lycii Fructus against PMOP. The identified multi targets and multi pathways provide new insights to further determinate its exact pharmacological mechanisms.
C1 [Wang, Jianbo; Cai, Shuiqi] Hlth Care Grp Cixi, Peoples Hosp 3, Dept Orthoped Surg, Ningbo, Peoples R China.
   [Wang, Yi] Ningbo Municipal Hosp Tradit Chinese Med, Dept Oncol, Ningbo, Peoples R China.
   [Li, Leyan] Zhejiang Chinese Med Univ, Sch Clin Med 3, Hangzhou, Peoples R China.
   [Mao, Dandan; Lou, Hongkan] Ningbo Municipal Hosp Tradit Chinese Med, Dept Orthoped Surg, Ningbo, Peoples R China.
   [Zhao, Jian] Nanjing Med Univ, Changzhou 2 Peoples Hosp, 68 Gehu Lake Rd, Changzhou 213000, Jiangsu, Peoples R China.
C3 Zhejiang Chinese Medical University; Nanjing Medical University
RP Zhao, J (通讯作者)，Nanjing Med Univ, Changzhou 2 Peoples Hosp, 68 Gehu Lake Rd, Changzhou 213000, Jiangsu, Peoples R China.
EM mumian_1987@163.com; mumian_1987@163.com; Lileyan1030@126.com;
   464359247@qq.com; jessicamdd@163.cm; louhongkan303@163.com;
   zhaojian1125@hotmail.com
RI Li, Le Yan/HNQ 8443 2023
FU Natural Science Foundation of Ningbo City [2021J308]; Traditional
   Chinese Medical Administration of Zhejiang Province [2022ZB312]
FX The study was supported by Natural Science Foundation of Ningbo City
   (2021J308) and Traditional Chinese Medical Administration of Zhejiang
   Province (2022ZB312)
CR Ahluwalia A, 2012, CURR MED CHEM, V19, P90, DOI 10.2174/092986712803413944
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bischoff L, 2008, Minerva Med, V99, P55
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Chen GZ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022178
   Fang H, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23016
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176
   Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523
   Hu YX, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.986384
   Jiang XY, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000032693
   Khan MA, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106642
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Li Bo, 2022, Phytomedicine, V102, P154198, DOI 10.1016/j.phymed.2022.154198
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Lian GH, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819849068
   Liu C, 2018, J AM ACAD ORTHOP SUR, V26, pE153, DOI 10.5435/JAAOS D 17 00918
   Livshits G, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120847
   Mangiavini L, 2022, ANN MED, V54, P37, DOI 10.1080/07853890.2021.2015798
   Neelam K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010246
   Nogués X, 2018, MED CLIN BARCELONA, V150, P479, DOI 10.1016/j.medcli.2017.10.019
   Pan SF, 2023, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1098851
   Park E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112784
   Park E, 2016, MOLECULES, V21, DOI 10.3390/molecules21091260
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Shao Y, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000029257
   Shu B, 2015, CHIN J INTEGR MED, V21, P656, DOI 10.1007/s11655 015 2306 z
   Wang SJ, 2016, CURR PHARM DESIGN, V22, P312
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Wang TY, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 41101 9
   Wang TY, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000029593
   Wang TY, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000029762
   Wang YJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723988
   Wei JX, 2021, ACTA BIOCH BIOPH SIN, V53, P683, DOI 10.1093/abbs/gmab037
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   Winzer M, 2010, WIEN MED WOCHENSCHR, V160, P446, DOI 10.1007/s10354 010 0811 4
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xia CJ, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03696 7
   Yan L, 2015, GENET MOL RES, V14, P19225, DOI 10.4238/2015.December.29.32
   Ying YG, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000029658
   Yu JS, 2022, J APPL MICROBIOL, V133, P1555, DOI 10.1111/jam.15662
   Zhang XF, 2018, TALANTA, V180, P389, DOI 10.1016/j.talanta.2017.12.078
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
   Zhao L, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116306
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
NR 48
TC 3
Z9 3
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 1
PY 2023
VL 102
IS 48
AR e36292
DI 10.1097/MD.0000000000036292
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AE1P0
UT WOS:001116697500122
PM 38050297
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Eleniste, PP
   Patel, V
   Posritong, S
   Zero, O
   Largura, H
   Cheng, YH
   Himes, ER
   Hamilton, M
   Ekwealor, JTB
   Kacena, MA
   Bruzzaniti, A
AF Eleniste, Pierre P.
   Patel, Vruti
   Posritong, Sumana
   Zero, Odette
   Largura, Heather
   Cheng, Ying Hua
   Himes, Evan R.
   Hamilton, Matthew
   Ekwealor, Jenna T. B.
   Kacena, Melissa A.
   Bruzzaniti, Angela
TI Pyk2 and Megakaryocytes Regulate Osteoblast Differentiation and
   Migration Via Distinct and Overlapping Mechanisms
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BONE FORMATION; ALKALINE PHOSPHATASE; MINERALIZATION; TYROSINE KINASE;
   PHOSPHORYLATION
ID TYROSINE KINASE 2; SMALL MOLECULE INHIBITORS; ALPHA(V)BETA(3) INTEGRIN;
   ADHESION KINASE; BONE; SRC; PHOSPHORYLATION; CELLS; PROLIFERATION;
   OSTEOCLASTS
AB Osteoblast differentiation and migration are necessary for bone formation during bone remodeling. Mice lacking the proline rich tyrosine kinase Pyk2 (Pyk2 KO) have increased bone mass, in part due to increased osteoblast proliferation. Megakaryocytes (MKs), the platelet producing cells, also promote osteoblast proliferation in vitro and bone formation in vivo via a pathway that involves Pyk2. In the current study, we examined the mechanism of action of Pyk2, and the role of MKs, on osteoblast differentiation and migration. We found that Pyk2 KO osteoblasts express elevated alkaline phosphatase (ALP), type I collagen and osteocalcin mRNA levels as well as increased ALP activity, and mineralization, confirming that Pyk2 negatively regulates osteoblast function. Since Pyk2 Y402 phosphorylation is important for its catalytic activity and for its protein scaffolding functions, we expressed the phosphorylation mutant (Pyk2(Y402F)) and kinase mutant (Pyk2(K457A)) in Pyk2 KO osteoblasts. Both Pyk2(Y402F) and Pyk2(K457A) reduced ALP activity, whereas only kinase inactive Pyk2(K457A) inhibited Pyk2 KO osteoblast migration. Consistent with a role for Pyk2 on ALP activity, co culture of MKs with osteoblasts led to a decrease in the level of phosphorylated Pyk2 (pY402) as well as a decrease in ALP activity. Although, Pyk2 KO osteoblasts exhibited increased migration compared to wild type osteoblasts, Pyk2 expression was not required necessary for the ability of MKs to stimulate osteoblast migration. Together, these data suggest that osteoblast differentiation and migration are inversely regulated by MKs via distinct Pyk2 dependent and independent signaling pathways. Novel drugs that distinguish between the kinase dependent or protein scaffolding functions of Pyk2 may provide therapeutic specificity for the control of bone related diseases. J. Cell. Biochem. 117: 1396 1406, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Eleniste, Pierre P.; Patel, Vruti; Posritong, Sumana; Zero, Odette; Largura, Heather; Bruzzaniti, Angela] Indiana Univ, Sch Dent, Dept Biomed & Appl Sci, Indianapolis, IN 46202 USA.
   [Cheng, Ying Hua; Himes, Evan R.; Hamilton, Matthew; Ekwealor, Jenna T. B.; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Bloomington
RP Bruzzaniti, A (通讯作者)，Indiana Univ, Sch Dent, 1121 W Michigan St,DS243, Indianapolis, IN 46202 USA.
EM abruzzan@iu.edu
RI Bruzzaniti, Angela/AAP 2225 2020; Ekwealor, Jenna/K 6733 2019
OI Ekwealor, Jenna T. B./0000 0001 9014 8786; 
FU National Institute of Health NIAMS [R01 AR060332]; Indiana Clinical and
   Translational Science Institute Collaboration in
   Biomedical/Translational Research (CBR/CTR) [RR025761, TR000006]; IUPUI
   Office of the Vice Chancellor for Research (OVCR); IUPUI Biomechanics
   and Biomaterials Research Center
FX Grant sponsor: National Institute of Health NIAMS; Grant number:
   R01 AR060332; Grant sponsor: Indiana Clinical and Translational Science
   Institute Collaboration in Biomedical/Translational Research (CBR/CTR);
   Grant numbers: RR025761, TR000006; Grant sponsor: IUPUI Office of the
   Vice Chancellor for Research (OVCR); Grant sponsor: IUPUI Biomechanics
   and Biomaterials Research Center.
CR Allen JG, 2009, BIOORG MED CHEM LETT, V19, P4924, DOI 10.1016/j.bmcl.2009.07.084
   Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898 6568(99)00076 5
   AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742
   Bruzzaniti A, 2009, MOL CELL BIOL, V29, P3644, DOI 10.1128/MCB.00851 08
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Cheng YH, 2015, J CELL PHYSIOL, V230, P578, DOI 10.1002/jcp.24774
   Cheng YH, 2013, J BONE MINER RES, V28, P1434, DOI 10.1002/jbmr.1876
   Ciovacco WA, 2010, J CELL BIOCHEM, V109, P774, DOI 10.1002/jcb.22456
   Ciovacco WA, 2009, BONE, V44, P80, DOI 10.1016/j.bone.2008.08.117
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0
   Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200
   Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097 0169(200011)47:3<174::AID CM2>3.0.CO;2 N
   Eleniste Pierre P, 2012, J Signal Transduct, V2012, P296450, DOI 10.1155/2012/296450
   Eleniste PP, 2012, INT J BIOCHEM CELL B, V44, P790, DOI 10.1016/j.biocel.2012.01.022
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Han S, 2009, J BIOL CHEM, V284, P13193, DOI 10.1074/jbc.M809038200
   HOROWITZ MC, 1994, ENDOCRINOLOGY, V135, P1032, DOI 10.1210/en.135.3.1032
   JILKA RL, 1981, ENDOCRINOLOGY, V109, P743, DOI 10.1210/endo 109 3 743
   Kacena MA, 2005, BONE, V36, P215, DOI 10.1016/j.bone.2004.09.024
   Kacena MA, 2004, J BONE MINER RES, V19, P652, DOI 10.1359/JBMR.0301254
   Kacena MA, 2006, BONE, V39, P991, DOI 10.1016/j.bone.2006.05.004
   Kacena MA, 2013, J CELL PHYSIOL, V228, P1594, DOI 10.1002/jcp.24322
   Kacena MA, 2012, J BIOL CHEM, V287, P17257, DOI 10.1074/jbc.M111.309880
   Kintscher U, 2001, HYPERTENSION, V37, P587, DOI 10.1161/01.HYP.37.2.587
   Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200
   Lemieux JM, 2010, J CELL BIOCHEM, V109, P927, DOI 10.1002/jcb.22468
   Meijome TE, 2015, J CELL PHYSIOL, V230, P783, DOI 10.1002/jcp.24803
   Meyer AN, 2004, J BIOL CHEM, V279, P28450, DOI 10.1074/jbc.M403335200
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Ohmori T, 2000, BIOCHEM J, V347, P561, DOI 10.1042/0264 6021:3470561
   Park SY, 2004, J BIOL CHEM, V279, P33315, DOI 10.1074/jbc.M313527200
   Pfaff M, 2001, J CELL SCI, V114, P2775
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SIMMONS DJ, 1982, CALCIFIED TISSUE INT, V34, P291, DOI 10.1007/BF02411253
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Tse KWK, 2012, CELL IMMUNOL, V275, P47, DOI 10.1016/j.cellimm.2012.03.002
   Villeval JL, 1997, BLOOD, V90, P4369
   Walker DP, 2009, BIOORG MED CHEM LETT, V19, P3253, DOI 10.1016/j.bmcl.2009.04.093
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167
   Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756 3282(02)00834 7
NR 47
TC 26
Z9 28
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2016
VL 117
IS 6
BP 1396
EP 1406
DI 10.1002/jcb.25430
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DI8HB
UT WOS:000373741000012
PM 26552846
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhou, L
   Su, PR
   Luo, XY
   Zhong, XL
   Liu, Q
   Su, YG
   Zeng, CP
   Li, G
AF Zhou, Lin
   Su, Peiru
   Luo, Xiangya
   Zhong, Xuanli
   Liu, Qian
   Su, Yuangang
   Zeng, Chunping
   Li, Ge
TI Regorafenib Attenuates Osteoclasts Differentiation by Inhibiting the
   NF κB, NFAT, ERK, and p38 Signaling Pathways
SO ACS OMEGA
LA English
DT Article
ID NETWORK PHARMACOLOGY; OSTEOPOROSIS; GENES
AB Osteolytic diseases such as osteoporosis and neoplastic bone metastases are caused by the excessive activation of osteoclasts. Inhibiting the excessive activation of osteoclasts is a crucial strategy for treating osteolytic diseases. This study investigated the roles and mechanisms of regorafenib, a tyrosine kinase inhibitor, on osteoclasts and osteolytic diseases. We first identified the potential targets and mechanisms of regorafenib on osteoclast related osteolytic diseases using network pharmacological analysis and molecular docking techniques. Then, we verified its role and mechanism on osteoclasts via cellular and animal experiments. Network pharmacology analysis identified 89 common targets shared by regorafenib and osteoclast related osteolytic diseases. Enrichment analysis suggested that regorafenib may act on osteoclast related osteolytic diseases by modulating targets such as AKT1, CASP3, MMP9, and MAPK3, regulating biological processes such as cell proliferation, apoptosis, and phosphorylation regulation, and influencing signaling pathways such as MAPK, PI3K/AKT, and osteoclast differentiation. The molecular docking results indicated that regorafenib and AKT1, CASP3, MMP9, MAPK3, and MAPK14 were stably docked. Cell experiments demonstrated that regorafenib significantly inhibited osteoclast differentiation and bone resorption in RAW 264.7 cells and bone marrow macrophages in a dose dependent manner, with up to 50% reduction at 800 nM concentration without exhibiting cytotoxic effects. Furthermore, Western blot and RT qPCR results demonstrated that regorafenib inhibited osteoclast differentiation by blocking the transduction of RANKL induced NF kappa B, p38, ERK, and NFAT signaling pathways. In vivo studies using an ovariectomized mouse model showed that regorafenib significantly improved bone volume fraction (BV/TV), bone surface to total volume (BS/TV), and number of trabeculae (TB.N), as well as reduced trabecular separation (Tb.Sp) compared to the OVX groups (P < 0.05). TRAcP staining results revealed a reduction in the number of osteoclasts with regorafenib treatment (P < 0.01). These results indicate that regorafenib exerts its protective effects against osteoclast related osteolytic disease by inhibiting the RANKL induced NF kappa B, NFAT, ERK, and p38 signaling pathways. This study proves that regorafenib may serve as a potential therapeutic agent for osteoclast related osteolytic diseases.
C1 [Zhou, Lin; Su, Peiru; Luo, Xiangya; Zeng, Chunping] Guangzhou Med Univ, Guangdong Higher Educ Inst, Key Lab Biol Targeting Diag Therapy & Rehabil, Dept Endocrinol,Affiliated Hosp 5, Guangzhou 510700, Guangdong, Peoples R China.
   [Zhong, Xuanli; Li, Ge] Jinan Univ, Affiliated Shunde Hosp, Dept Endocrinol, Foshan 528305, Guangdong, Peoples R China.
   [Liu, Qian; Su, Yuangang] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
C3 Guangzhou Medical University; Southern Medical University   China;
   Guangxi Medical University
RP Zeng, CP (通讯作者)，Guangzhou Med Univ, Guangdong Higher Educ Inst, Key Lab Biol Targeting Diag Therapy & Rehabil, Dept Endocrinol,Affiliated Hosp 5, Guangzhou 510700, Guangdong, Peoples R China.; Li, G (通讯作者)，Jinan Univ, Affiliated Shunde Hosp, Dept Endocrinol, Foshan 528305, Guangdong, Peoples R China.
EM zcp193@163.com; ligeyisheng2019@163.com
RI luo, Xiangya/LUA 1280 2024
FU Guangdong Basic and Applied Basic Research Foundation [2019A1515110723];
   Medical Joint Fund of Jinan University [MF220206]; Key Laboratory of
   Guangdong Higher Education Institutes [2021KSYS009]
FX This work was supported by Guangdong Basic and Applied Basic Research
   Foundation (2019A1515110723),Medical Joint Fund of Jinan University
   (MF220206), and Key Laboratory of Guangdong Higher Education Institutes
   (2021KSYS009).
CR Asl ER, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119499
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Bateman A, 2023, NUCLEIC ACIDS RES, V51, pD523, DOI 10.1093/nar/gkac1052
   Breitkreutz I, 2018, ANN HEMATOL, V97, P839, DOI 10.1007/s00277 018 3237 5
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   Chen L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184129
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Cui LJ, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00958 x
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Davis AP, 2023, NUCLEIC ACIDS RES, V51, pD1257, DOI 10.1093/nar/gkac833
   De Leon Oliva D, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59101752
   Deng W, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015693
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Ding P, 2022, ELIFE, V11, DOI 10.7554/eLife.81480
   Doleschel D, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02043 0
   Ferrari S, 2023, NAT REV RHEUMATOL, V19, P307, DOI 10.1038/s41584 023 00935 3
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Grothey A, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.101993
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Han KM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9071655
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Heilmann T, 2020, ARCH GYNECOL OBSTET, V301, P1493, DOI 10.1007/s00404 020 05496 4
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hume DA, 2022, CURR OSTEOPOROS REP, DOI 10.1007/s11914 022 00757 4
   Ihn HJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158299
   Ihn HJ, 2019, BMB REP, V52, P409, DOI 10.5483/BMBRep.2019.52.6.063
   Jiang JW, 2020, AUTOPHAGY, V16, P106, DOI 10.1080/15548627.2019.1598752
   Jiang T, 2023, BIOORG CHEM, V132, DOI 10.1016/j.bioorg.2022.106321
   Kim HJ, 2014, J LEUKOCYTE BIOL, V95, P337, DOI 10.1189/jlb.0713356
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kroschwald LM, 2019, ONCOL LETT, V18, P2102, DOI 10.3892/ol.2019.10518
   Kuan FC, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242417610
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Liu CL, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115392
   Liu CX, 2023, EUR J PHARMACOL, V960, DOI 10.1016/j.ejphar.2023.176121
   Majeed Aqsa, 2023, Methods Mol Biol, V2690, P419, DOI 10.1007/978 1 0716 3327 4_32
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mao Y, 2023, BIOCHEM PHARMACOL, V215, DOI 10.1016/j.bcp.2023.115704
   Marahleh A, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1121727
   Markovics A, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02250 8
   McDonald MM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10539
   Min HK, 2023, INT J RHEUM DIS, V26, P718, DOI 10.1111/1756 185X.14627
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Oh K, 2023, BMB REP, V56, P439, DOI 10.5483/BMBRep.2023 0072
   Ou DL, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc 2020 001657
   Park JJ, 2023, EXP MOL MED, V55, P794, DOI 10.1038/s12276 023 00966 6
   Qiu JX, 2022, BIOCHEM PHARMACOL, V205, DOI 10.1016/j.bcp.2022.115155
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168 9525(97)01103 7
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822 010 9352 6
   Sheng SR, 2023, PHYTOMEDICINE, V114, DOI 10.1016/j.phymed.2023.154739
   Sing CW, 2023, J BONE MINER RES, V38, P1064, DOI 10.1002/jbmr.4821
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Veeroju S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031502
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang B, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.961941
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wen JC, 2023, EUR J MED CHEM, V245, DOI 10.1016/j.ejmech.2022.114884
   Weng MC, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171264
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Xie G, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114579
   Yang T, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04706 2
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yu YF, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1147360
   Zhou WJ, 2023, BIOMED PHARMACOTHER, V168, DOI 10.1016/j.biopha.2023.115810
NR 76
TC 0
Z9 1
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD JUL 23
PY 2024
VL 9
IS 31
BP 33574
EP 33593
DI 10.1021/acsomega.4c01308
EA JUL 2024
PG 20
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA A9Q4P
UT WOS:001275536200001
PM 39130575
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, SY
   Xue, ST
   Li, ZR
AF Li, Si yan
   Xue, Si tu
   Li, Zhuo rong
TI Osteoporosis: Emerging targets on the classical signaling pathways of
   bone formation
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Crosstalk targets; Emerging targets; Osteoporosis; Osteogenesis
ID T REGULATORY CELLS; TRANSCRIPTION FACTOR; OSTEOGENESIS; ACTIVATION;
   NOTCH; DIFFERENTIATION; IDENTIFICATION; ANGIOGENESIS; OSTEOADHERIN;
   OSTEOBLASTS
AB Osteoporosis is a multifaceted skeletal disorder characterized by reduced bone mass and structural deterioration, posing a significant public health challenge, particularly in the elderly population. Treatment strategies for osteoporosis primarily focus on inhibiting bone resorption and promoting bone formation. However, the effectiveness and limitations of current therapeutic approaches underscore the need for innovative methods. This review explores emerging molecular targets within crucial signaling pathways, including wingless/integrated (WNT), bone morphogenetic protein (BMP), hedgehog (HH), and Notch signaling pathway, to understand their roles in osteogenesis regulation. The identification of crosstalk targets between these pathways further enhances our comprehension of the intricate bone metabolism cycle. In summary, unraveling the molecular complexity of osteoporosis provides insights into potential therapeutic targets beyond conventional methods, offering a promising avenue for the development of new anabolic drugs.
C1 [Li, Si yan; Xue, Si tu; Li, Zhuo rong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing 100050, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Medicinal Biotechnology   CAMS; Peking Union Medical
   College
RP Xue, ST (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing 100050, Peoples R China.
EM lisiyan@imb.pumc.edu.cn; xuesitu@imb.pumc.edu.cn;
   lizhuorong@imb.pumc.edu.cn
RI Siyan, Li/JCN 9257 2023
FU National Natural Science Foundation of China [82073711, 82273800]; CAMS
   Innovation Fund for Medical Sciences [2022 I2M 2 002]
FX This work was supported by grants from the National Natural Science
   Foundation of China (82073711 and 82273800) , and CAMS Innovation Fund
   for Medical Sciences (2022 I2M 2 002) .
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Bandeira L, 2022, ARCH ENDOCRIN METAB, V66, P707, DOI 10.20945/2359 3997000000566
   Bian ZY, 2010, HYPERTENSION, V55, P257, DOI 10.1161/HYPERTENSIONAHA.109.135665
   Bishop B, 2009, NAT STRUCT MOL BIOL, V16, P698, DOI 10.1038/nsmb.1607
   Bozec A, 2017, CURR OSTEOPOROS REP, V15, P121, DOI 10.1007/s11914 017 0356 1
   Buchner G, 2000, GENOMICS, V65, P16, DOI 10.1006/geno.2000.6146
   Caliskan C, 2023, GENE, V854, DOI 10.1016/j.gene.2022.147109
   Canalis E, 2018, OSTEOPOROSIS INT, V29, P2611, DOI 10.1007/s00198 018 4694 3
   Chang CY, 2012, ONCOGENE, V31, P2640, DOI 10.1038/onc.2011.440
   Chen K, 2021, THERANOSTICS, V11, P9738, DOI 10.7150/thno.60902
   Chen M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04147 y
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Chi Bojing, 2016, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V30, P1545, DOI 10.7507/1002 1892.20160318
   Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Couble ML, 2004, HISTOCHEM CELL BIOL, V121, P47, DOI 10.1007/s00418 003 0608 2
   Dong BZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34869 3
   Esposito A, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115521
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Fu R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14076 3
   Gao B, 2012, CURR TOP DEV BIOL, V101, P263, DOI 10.1016/B978 0 12 394592 1.00008 9
   Gao YG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030483
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Goldberg S, 2015, CALCIFIED TISSUE INT, V97, P113, DOI 10.1007/s00223 015 9994 4
   Granstein RD, 2002, NAT MED, V8, P336, DOI 10.1038/nm0402 336
   Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hauser AS, 2018, CELL, V172, P41, DOI 10.1016/j.cell.2017.11.033
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hojo H, 2015, REGEN THER, V1, P57, DOI 10.1016/j.reth.2014.10.002
   Huang DL, 2018, ONCOL LETT, V15, P6077, DOI 10.3892/ol.2018.8142
   Huang K, 2024, CELL PROLIFERAT, V57, DOI 10.1111/cpr.13522
   Jenkins BJ, 2007, BLOOD, V109, P2380, DOI 10.1182/blood 2006 08 040352
   Brito FMJD, 2021, FASEB J, V35, DOI 10.1096/fj.202002024R
   Johnstone CN, 2015, CYTOKINE GROWTH F R, V26, P489, DOI 10.1016/j.cytogfr.2015.07.015
   Kadam Nidhi S, 2018, Indian J Endocrinol Metab, V22, P67, DOI 10.4103/ijem.IJEM_438_17
   Kalinkovich A, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105794
   Katayama K, 2009, PLOS ONE, V4, pA151, DOI 10.1371/journal.pone.0007786
   Kaya B, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107979
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kespohl B, 2021, CYTOKINE GROWTH F R, V60, P18, DOI 10.1016/j.cytogfr.2021.04.002
   KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432 1033.1990.tb19383.x
   Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis 2011 201052
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Langdahl B, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115516
   Li HR, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00413 0
   Li SD, 2023, EXP MOL MED, V55, P443, DOI 10.1038/s12276 023 00942 0
   Li SD, 2022, INFECT DIS THER, V11, P1057, DOI 10.1007/s40121 022 00622 y
   Lin WZ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03404 5
   Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev immunol 051116 052406
   Lojk J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910840
   Lu WG, 2023, CELL MOL LIFE SCI, V80, DOI 10.1007/s00018 023 04821 9
   McConnell M, 2022, CLIN GERIATR MED, V38, P715, DOI 10.1016/j.cger.2022.05.011
   McKenzie JA, 2019, J ORTHOP RES, V37, P51, DOI 10.1002/jor.24017
   Mei HX, 2022, CELL SIGNAL, V97, DOI 10.1016/j.cellsig.2022.110394
   Milart P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42646 4
   Moore ER, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115738
   Nakamura F, 2011, CELL ADHES MIGR, V5, P160, DOI 10.4161/cam.5.2.14401
   Nakamura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08729 6
   Nosho S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217967
   PECK WA, 1993, AM J MED, V94, P646
   Peng SL, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02163 6
   Qi Q, 2020, CELL MOL LIFE SCI, V77, P2407, DOI 10.1007/s00018 019 03289 w
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rao PC, 2021, CELL SIGNAL, V87, DOI 10.1016/j.cellsig.2021.110138
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Rehn AP, 2006, BIOCHEM BIOPH RES CO, V349, P1057, DOI 10.1016/j.bbrc.2006.08.133
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Sanchez C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194591
   Schiavon V, 2019, P NATL ACAD SCI USA, V116, P6298, DOI 10.1073/pnas.1812471116
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shen JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02487 3
   Shi Y, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109542
   Sigafoos AN, 2021, CANCERS, V13, DOI 10.3390/cancers13143410
   Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756
   Sun HJ, 2020, J BONE MINER RES, V35, P583, DOI 10.1002/jbmr.3921
   Sun J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24819 w
   Takagi T, 1998, DEVELOPMENT, V125, P21
   Tang CY, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009233
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Thomas S, 2022, J CELL COMMUN SIGNAL, V16, P47, DOI 10.1007/s12079 021 00635 1
   Tian F, 2021, J CELL MOL MED, V25, P2426, DOI 10.1111/jcmm.16128
   Tian LJ, 2020, METABOLISM, V105, DOI 10.1016/j.metabol.2020.154189
   Urs S, 2010, FASEB J, V24, P3264, DOI 10.1096/fj.10 155127
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092 8674(91)90382 9
   Wagley Y., 2020, Canonical Notch Signaling Is Required for Bone Morphogenetic ProteinMediated Human Osteoblast Differentiation
   Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200
   Wang H, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0277 4
   Wang XP, 2023, BIOCHEM PHARMACOL, V217, DOI 10.1016/j.bcp.2023.115829
   Watts NB, 2021, ENDOCR PRACT, V27, P379, DOI 10.1016/j.eprac.2021.02.001
   Wei HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108252
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wu J, 2022, INT J BIOL SCI, V18, P956, DOI 10.7150/ijbs.65954
   Wu TL, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13234
   Wu WB, 2020, MOL THER, V28, P1518, DOI 10.1016/j.ymthe.2020.04.003
   Wu ZX, 2023, FASEB J, V37, DOI 10.1096/fj.202300488R
   Xiao CY, 2019, IUBMB LIFE, V71, P854, DOI 10.1002/iub.2016
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xu ZH, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110593
   Xue Y, 2022, INT J BIOL SCI, V18, P572, DOI 10.7150/ijbs.63505
   Yang CS, 2022, CELL SIGNAL, V90, DOI 10.1016/j.cellsig.2021.110191
   Yang Z, 2022, CLIMACTERIC, V25, P257, DOI 10.1080/13697137.2021.1941848
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Yoshimori T, 2008, CURR OPIN CELL BIOL, V20, P401, DOI 10.1016/j.ceb.2008.03.010
   Zanotti S, 2017, BONE, V103, P159, DOI 10.1016/j.bone.2017.06.027
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang X, 2019, MOL THER, V27, P1963, DOI 10.1016/j.ymthe.2019.07.014
   Zhang Y, 2021, BIOCHEM BIOPH RES CO, V556, P171, DOI 10.1016/j.bbrc.2021.03.084
   Zhang YQ, 2023, BBA MOL BASIS DIS, V1869, DOI 10.1016/j.bbadis.2023.166693
   Zhou H, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13162
   Zhu B, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1876 7
   Zhu Y, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01631 9
   Zieba JT, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020332
NR 116
TC 5
Z9 6
U1 6
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 15
PY 2024
VL 973
AR 176574
DI 10.1016/j.ejphar.2024.176574
EA APR 2024
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SE4Z7
UT WOS:001232782200001
PM 38642670
DA 2025 08 17
ER

PT J
AU Sinha, P
   Aarnisalo, P
   Chubb, R
   Poulton, IJ
   Guo, J
   Nachtrab, G
   Kimura, T
   Swami, S
   Saeed, H
   Chen, M
   Weinstein, LS
   Schipani, E
   Sims, NA
   Kronenberg, HM
   Wu, JY
AF Sinha, Partha
   Aarnisalo, Piia
   Chubb, Rhiannon
   Poulton, Ingrid J.
   Guo, Jun
   Nachtrab, Gregory
   Kimura, Takaharu
   Swami, Srilatha
   Saeed, Hamid
   Chen, Min
   Weinstein, Lee S.
   Schipani, Ernestina
   Sims, Natalie A.
   Kronenberg, Henry M.
   Wu, Joy Y.
TI Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass
   and a Blunted Response to Anabolic Parathyroid Hormone Therapy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OSTEOBLASTIC CELLS; MESENCHYMAL PROGENITORS; POSTMENOPAUSAL WOMEN;
   INTERMITTENT PTH; PHOSPHOLIPASE C; MINERAL DENSITY; PROTEIN KINASE;
   IN VIVO; DIFFERENTIATION; RECEPTOR
AB Parathyroid hormone (PTH) is an important regulator of osteoblast function and is the only anabolic therapy currently approved for treatment of osteoporosis. The PTH receptor (PTH1R) is a G protein coupled receptor that signals via multiple G proteins including G(s)alpha. Mice expressing a constitutively active mutant PTH1R exhibited a dramatic increase in trabecular bone that was dependent upon expression of G(s)alpha in the osteoblast lineage. Postnatal removal of G(s)alpha in the osteoblast lineage (P G(s)alpha(OsxKO) mice) yielded markedly reduced trabecular and cortical bone mass. Treatment with anabolic PTH(1 34) (80 mu g/kg/day) for 4 weeks failed to increase trabecular bone volume or cortical thickness in male and female P G(s)alpha(OsxKO) mice. Surprisingly, in both male and female mice, PTH administration significantly increased osteoblast numbers and bone formation rate in both control and P G(s)alpha(OsxKO) mice. In mice that express a mutated PTH1R that activates adenylyl cyclase and protein kinase A (PKA) via G(s)alpha but not phospholipase C via G(q/11) (D/D mice), PTH significantly enhanced bone formation, indicating that phospholipase C activation is not required for increased bone turnover in response to PTH. Therefore, although the anabolic effect of intermittent PTH treatment on trabecular bone volume is blunted by deletion of G(s)alpha in osteoblasts, PTH can stimulate osteoblast differentiation and bone formation. Together these findings suggest that alternative signaling pathways beyond G(s)alpha and G(q/11) act downstream of PTH on osteoblast differentiation.
C1 [Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon; Guo, Jun; Nachtrab, Gregory; Kronenberg, Henry M.; Wu, Joy Y.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Aarnisalo, Piia] Univ Helsinki, Dept Clin Chem, Helsinki 00029, Finland.
   [Aarnisalo, Piia] Univ Helsinki, Cent Hosp, HUSLAB, Lab Serv, Helsinki 00029, Finland.
   [Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia.
   [Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
   [Kimura, Takaharu; Swami, Srilatha; Saeed, Hamid; Wu, Joy Y.] Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S 025, Stanford, CA 94305 USA.
   [Chen, Min; Weinstein, Lee S.] NIDDK, NIH, Metab Dis Branch, Bethesda, MD 20892 USA.
   [Schipani, Ernestina] Univ Michigan, Dept Orthoped Surg, Ann Arbor, MI 48109 USA.
   [Schipani, Ernestina] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; University of Helsinki; University of Helsinki;
   Helsinki University Central Hospital; St. Vincent's Institute of Medical
   Research; University of Melbourne; NSW Health; St Vincents Hospital
   Sydney; St Vincent's Health; St Vincent's Hospital Melbourne; University
   of Melbourne; Stanford University; Stanford Medicine; National
   Institutes of Health (NIH)   USA; NIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK); University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Wu, JY (通讯作者)，Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S 025, Stanford, CA 94305 USA.
EM jywu1@stanford.edu
RI ; Weinstein, Lee/I 5575 2015; Saeed, Hamid/AGB 4145 2022; KRONENBERG,
   HENRY/MXK 0923 2025; Sims, Natalie/A 7192 2012
OI Saeed, HAMID/0000 0002 1400 4825; Weinstein, Lee/0000 0002 1899 5152;
   Sims, Natalie/0000 0003 1421 8468
FU National Institutes of Health [AR054741, AR059942, AR061228, DK011794];
   NIDDK Intramural Research Program
FX This work was supported by National Institutes of Health Grants AR054741
   and AR059942 (to J. Y. W.), AR061228 (to P. S.), and DK011794 (to H. M.
   K.) and the NIDDK Intramural Research Program (to M. C. and L. S. W.).
   The authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009 1494
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   Hsiao EC, 2010, J BONE MINER RES, V25, P584, DOI 10.1002/jbmr.3
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Kedlaya R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006627
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo 111 1 178
   Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349
   Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Singh ATK, 2005, ENDOCRINOLOGY, V146, P2171, DOI 10.1210/en.2004 1283
   Sinha P, 2014, J BONE MINER RES, V29, P2414, DOI 10.1002/jbmr.2270
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007 0826
NR 50
TC 33
Z9 40
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 22
PY 2016
VL 291
IS 4
BP 1631
EP 1642
DI 10.1074/jbc.M115.679753
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DB6JI
UT WOS:000368620700008
PM 26598522
OA Green Published
DA 2025 08 17
ER

PT J
AU Ng, KW
   Martin, TJ
AF Ng, Kong Wah
   Martin, T. John
TI New therapeutics for osteoporosis
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID CATHEPSIN K INHIBITOR; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   MATRIX DEGRADATION; ODANACATIB; MASS; RESORPTION; SOST; TURNOVER;
   THERAPY
AB Two new approaches for the treatment of osteoporosis are summarized, each having arisen out of important new discoveries in bone biology. Odanacatib (ODN) inhibits the enzyme, cathepsin K, that is essential for the resorbing activity of osteoclasts. It is effective in preventing ovariectomy induced bone loss in preclinical studies, and a phase II clinical study has shown inhibition of resorption sustained over five years. Outcome of a phase III study is awaited. The finding from mouse and human genetics that Wnt signaling is a powerful inducer of bone formation led to developments aimed at enhancing this pathway. Of the several approaches towards this, the most advanced is with a neutralizing antibody against sclerostin, the osteocyte derived inhibitor of Wnt signaling. Preclinical studies show a powerful bone anabolic effect, and a clinical phase II study shows dose dependent increases in bone formation and decreases in bone resorption markers.
C1 [Ng, Kong Wah; Martin, T. John] Univ Melbourne, St Vincents Inst Med Res, Dept Med, Fitzroy, Vic 3065, Australia.
C3 St. Vincent's Institute of Medical Research; University of Melbourne
RP Martin, TJ (通讯作者)，Univ Melbourne, St Vincents Inst Med Res, Dept Med, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM jmartin@svi.edu.au
CR Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Dong JJ, 2005, CANCER RES, V65, P1961, DOI 10.1158/0008 5472.CAN 04 2501
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Frost HM., 1964, Bone Biodyn, V6, P315
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Grey A, 2009, J CLIN ENDOCR METAB, V94, P538, DOI 10.1210/jc.2008 2241
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   MAROTEAUX P, 1962, ARCH FR PEDIATR, V19, P267
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Neele SJM, 2002, BONE, V30, P599, DOI 10.1016/S8756 3282(01)00706 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ng KW, 2012, CLIN INTERV AGING, V7, P235, DOI 10.2147/CIA.S26729
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Podgorski I, 2009, FUTURE MED CHEM, V1, P21, DOI 10.4155/FMC.09.4
   Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918
   Rodan S.B., 2008, IBMS BONEKEY, V5, P16
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756 3282(98)00138 0
   Zerbini CAF, 2013, THER ADV MUSCULOSKEL, V5, P199, DOI 10.1177/1759720X13490860
NR 61
TC 21
Z9 24
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2014
VL 16
BP 58
EP 63
DI 10.1016/j.coph.2014.03.004
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AK0HU
UT WOS:000338094300010
PM 24699340
DA 2025 08 17
ER

PT J
AU Téletchéa, S
   Stresing, V
   Hervouet, S
   Baud'huin, M
   Heymann, MF
   Bertho, G
   Charrier, C
   Ando, K
   Heymann, D
AF Teletchea, Stephane
   Stresing, Verena
   Hervouet, Soizic
   Baud'huin, Marc
   Heymann, Marie Francoise
   Bertho, Gildas
   Charrier, Celine
   Ando, Kosei
   Heymann, Dominique
TI Novel RANK Antagonists for the Treatment of Bone Resorptive Disease:
   Theoretical Predictions and Experimental Validation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE RESORPTION; DRUG DESIGN; RANK; RANKL; PEPTIDE INHIBITORS
ID NF KAPPA B; RECEPTOR ACTIVATOR; TNF RECEPTOR; ZOLEDRONIC ACID; PEPTIDE;
   OSTEOPROTEGERIN; EXCITATION; DENOSUMAB; CELLS; BISPHOSPHONATES
AB Receptor activator of nuclear factor B (RANK) and RANK ligand (RANKL) play a pivotal role in bone metabolism, and selective targeting of RANK signaling has become a promising therapeutic strategy in the management of resorptive bone diseases. Existing antibody based therapies and novel inhibitors currently in development were designed to target the ligand, rather than the membrane receptor expressed on osteoclast precursors. We describe here an alternative approach to designing small peptides able to specifically bind to the hinge region of membrane RANK responsible for the conformational change upon RANKL association. A nonapeptide generated by this method was validated for its biological activity in vitro and in vivo and served as a lead compound for the generation of a series of peptide RANK antagonists derived from the original sequence. Our study presents a structure  and knowledge based strategy for the design of novel effective and affordable small peptide inhibitors specifically targeting the receptor RANK and opens a new therapeutic opportunity for the treatment of resorptive bone disease. (c) 2014 American Society for Bone and Mineral Research.
C1 [Teletchea, Stephane; Stresing, Verena; Hervouet, Soizic; Baud'huin, Marc; Heymann, Marie Francoise; Charrier, Celine; Ando, Kosei; Heymann, Dominique] Univ Nantes, Lab Physiopathol Bone Resorpt & Therapy Primary B, INSERM, UMR 957,Equipe Labellisee LIGUE, F 44035 Nantes, France.
   [Baud'huin, Marc; Heymann, Marie Francoise; Heymann, Dominique] Nantes Hosp, Nantes, France.
   [Bertho, Gildas] Univ Paris 05, CNRS, UMR8601, Paris, France.
C3 Nantes Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Nantes Universite; CHU de Nantes; Universite Paris
   Cite; Centre National de la Recherche Scientifique (CNRS); CNRS  
   Institute of Chemistry (INC)
RP Heymann, D (通讯作者)，Univ Nantes, Fac Med, INSERM, UMR 957, 1 Rue Gaston Veil, F 44035 Nantes, France.
EM dominique.heymann@univ nantes.fr
RI ; Teletchea, Stephane/B 1082 2009; Charrier, Céline/K 9198 2015; Bertho,
   Gildas/JHS 9333 2023; Téletchéa, Stéphane/N 8897 2019; Baud'huin,
   Marc/K 8519 2015; Heymann, Dominique/AAC 6014 2019
OI Heymann, Marie Francoise/0000 0002 5585 8261; Teletchea,
   Stephane/0000 0002 2402 028X; Heymann, Dominique/0000 0001 7777 0669;
   Baud'huin, Marc/0000 0002 3357 329X; Bertho, Gildas/0000 0002 4929 763X
FU Fond Unique Interministeriel [08 90 6214]; Ligue Nantionale Contre le
   Cancer; Region des Pays de La Loire (France)
FX Pep8 and Pep8 derivatives have been filed under patent number
   EP11306766.4 210. This study was supported by the Fond Unique
   Interministeriel no08 90 6214 (GELTOP project) and the Ligue Nantionale
   Contre le Cancer (Equipe LIGUE 2012). KA received a postdoctoral
   fellowship from the Region des Pays de La Loire (France).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Aubin J. E., 2002, PRINCIPLES BONE BIOL, V1, P59, DOI [10.1016/B978 012098652 1.50106 2, DOI 10.1016/B978 012098652 1.50106 2]
   Baud'Huin M, 2012, METHODS MOL BIOL, V836, P323, DOI 10.1007/978 1 61779 498 8_21
   Baud'Huin M, 2010, J PATHOL, V221, P77, DOI 10.1002/path.2684
   Baud'huin M, 2009, J BIOL CHEM, V284, P31704, DOI 10.1074/jbc.M109.030312
   BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022 2364(85)90018 6
   Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cutting B, 2007, MAGN RESON CHEM, V45, P720, DOI 10.1002/mrc.2033
   Duheron V, 2011, P NATL ACAD SCI USA, V108, P5342, DOI 10.1073/pnas.1013054108
   Edelstein SJ, 2013, J MOL BIOL, V425, P1424, DOI 10.1016/j.jmb.2013.03.011
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Fleishman SJ, 2011, J MOL BIOL, V414, P289, DOI 10.1016/j.jmb.2011.09.031
   Gobin B, 2014, CANCER LETT, V344, P291, DOI 10.1016/j.canlet.2013.11.017
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   Hasegawa A, 2004, P NATL ACAD SCI USA, V101, P6599, DOI 10.1073/pnas.0401597101
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359 6446(04)03265 9
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Heymann D, 2012, J BONE ONCOL, V1, P2, DOI 10.1016/j.jbo.2012.03.001
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Jules J, 2010, EXPERT OPIN THER TAR, V14, P923, DOI 10.1517/14728222.2010.511179
   Kajiwara K, 2004, BBA PROTEINS PROTEOM, V1699, P131, DOI 10.1016/j.bbapap.2004.02.016
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008
   Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535 7163.MCT 08 0497
   Lamoureux F, 2009, CANCER RES, V69, P526, DOI 10.1158/0008 5472.CAN 08 2648
   Lien S, 2003, TRENDS BIOTECHNOL, V21, P556, DOI 10.1016/j.tibtech.2003.10.005
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   McGregor DP, 2008, CURR OPIN PHARMACOL, V8, P616, DOI 10.1016/j.coph.2008.06.002
   Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006
   Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968 0004(97)01164 X
   Pangrazio A, 2012, J BONE MINER RES, V27, P342, DOI 10.1002/jbmr.559
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Pons J, 2011, MINI REV MED CHEM, V11, P283, DOI 10.2174/138955711795305344
   Pons J, 2007, BIOCHEMISTRY US, V46, P2958, DOI 10.1021/bi061401f
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022 2364(82)90279 7
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197 1266
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Vanhee P, 2009, STRUCTURE, V17, P1128, DOI 10.1016/j.str.2009.06.013
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weinkam P, 2013, J MOL BIOL, V425, P647, DOI 10.1016/j.jmb.2012.11.041
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Xia YL, 2010, MAGN RESON CHEM, V48, P918, DOI 10.1002/mrc.2687
   Xie JP, 2011, J MANAGE CARE PHARM, V17, P621, DOI 10.18553/jmcp.2011.17.8.621
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 65
TC 12
Z9 12
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2014
VL 29
IS 6
BP 1466
EP 1477
DI 10.1002/jbmr.2170
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AH3DJ
UT WOS:000336001500019
PM 24390798
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Kou, YY
   Yang, PP
   Rong, X
   Tang, R
   Liu, HR
   Li, MQ
AF Zhang, Yuan
   Kou, Yuying
   Yang, Panpan
   Rong, Xing
   Tang, Rong
   Liu, Hongrui
   Li, Minqi
TI ED 71 inhibited osteoclastogenesis by enhancing EphrinB2 EphB4 signaling
   between osteoclasts and osteoblasts in osteoporosis
SO CELLULAR SIGNALLING
LA English
DT Article
DE Osteoporosis; Oxidative stress; ED 71; Osteoclasts; EphrinB2 EphB4
ID ACTIVE VITAMIN D; OXIDATIVE STRESS; BONE RESORPTION; D ANALOG;
   POSTMENOPAUSAL OSTEOPOROSIS; DOUBLE BLIND; ELDECALCITOL; PREVENTS;
   ESTROGEN; DAMAGE
AB Background: Osteoporosis is a degenerative skeletal disease essentially caused by bone remodeling disorder. EphrinB2 EphB4 signaling play critical regulatory roles in bone remodeling via communication between osteoclasts and osteoblasts. Eldecalcitol (ED 71), a new vitamin D analog, is a high potential drug for treating osteoporosis; however, its mechanism has yet to be determined. This study aims to investigate whether EphrinB2 EphB4 signal mediates the process of osteoporosis improved by ED 71. Materials and methods: An ovariectomized (OVX) rat model was constructed in vivo. ED 71 at 30 ng/kg was orally administered once daily for 8 weeks. Osteoclast activity and EphrinB2 EphB4 expression were evaluated by hematoxylin and eosin staining, tartrate resistant acid phosphatase (TRAP) staining, and immunohistochemical staining. The mRNA levels of oxidation stress factors in the bone tissue were tested by reverse transcription polymerase chain reaction (RT PCR). An H2O2 stimulated model in vitro was established to simulate the status of osteoporosis. Osteoclastogenesis and associated protein were detected by TRAP staining, F actin ring formation assay, PCR, and Western blot analysis. EprhrinB2 and EphB4 levels were determined by immunofluorescence, PCR, and Western blot analysis. EprhrinB2 small interfering RNA knocked down the EprhrinB2 in osteoclasts, and an EphB4 antibody blocked EphB4 in osteoblasts. Results: ED 71 prevented bone loss and decreased the number of osteoclasts in vivo relative to the OVX group. In addition, the bone tissue of OVX rat displayed as an increased level of oxidation stress, which could be inhibited by ED 71. In vitro, in the simulation of osteoporosis with H2O2, ED 71 reversed the increase H2O2 induced oxidative stress. ED 71 then inhibited osteoclastogenesis and osteoclast function, accompanied by increased EphrinB2 expression in osteoclasts. Notably, EphrinB2 knockdown reversed the inhibitory effect of ED 71 on osteoclasts. ED 71 also enhanced EphB4 expression in osteoblasts in vivo and in vitro. Further research showed that ED 71 inhibited osteoclastogenesis in co culture systems, which was weakened by blocking EphB4 in osteoblasts. Conclusions: ED 71 inhibited osteoclastogenesis by enhancing EphrinB2 EphB4 signaling between osteoclasts and osteoblasts, preventing osteoporosis. This theory explains the role of ED 71 in the treatment of osteoporosis.
C1 [Zhang, Yuan; Kou, Yuying; Yang, Panpan; Rong, Xing; Tang, Rong; Liu, Hongrui; Li, Minqi] Shandong Univ, Cheeloo Coll Med, Dept Bone Metab,Sch & Hosp Stomatol, Jinan, Peoples R China.
   [Zhang, Yuan; Kou, Yuying; Yang, Panpan; Rong, Xing; Tang, Rong; Liu, Hongrui; Li, Minqi] Shandong Key Lab Oral Tissue Regenerat, Shandong Engn Lab Dent Mat & Oral Tissue Regenerat, Jinan, Peoples R China.
   [Zhang, Yuan; Kou, Yuying; Yang, Panpan; Rong, Xing; Tang, Rong; Liu, Hongrui; Li, Minqi] Shandong Univ, Ctr Osteoporosis & Bone Mineral Res, Jinan, Peoples R China.
   [Liu, Hongrui; Li, Minqi] Shandong Univ, Ctr Osteoporosis & Bone Mineral Res, Sch Stomatol, Dept Bone Metab, Wenhua West Rd 44 1, Jinan 250012, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Liu, HR; Li, MQ (通讯作者)，Shandong Univ, Ctr Osteoporosis & Bone Mineral Res, Sch Stomatol, Dept Bone Metab, Wenhua West Rd 44 1, Jinan 250012, Peoples R China.
EM yf1blhr@126.com; liminqi@sdu.edu.cn
RI 寇, 雨莹/HOA 9046 2023; Liu, Hong Rui/AAH 5073 2019
FU National Natural Science Foundation of China [81800982]; Construction
   En gineering Special Fund of ? [tsqn202103177]; Taishan Young Scholars?;
   Shandong Province
FX Funding This study was partially supported by the National Natural
   Science Foundation of China (No. 81972072) to Li M, the National Natural
   Science Foundation of China (No. 81800982) and the Construction
   En gineering Special Fund of ?Taishan Young Scholars? of Shandong
   Province (No. tsqn202103177) to Liu H.
CR Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Badila AE, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020318
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Cao XC, 2020, J BONE MINER METAB, V38, P27, DOI 10.1007/s00774 019 01038 4
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Fu C, 2015, J CELL PHYSIOL, V230, P2184, DOI 10.1002/jcp.24947
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Ge YW, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1404915
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Harada S, 2012, J BONE MINER RES, V27, P461, DOI 10.1002/jbmr.555
   Huang CC, 2020, DRUG DES DEV THER, V14, P4901, DOI 10.2147/DDDT.S269223
   Huang M, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2982480
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kumar SSD, 2018, MOLECULES, V23, DOI 10.3390/molecules23040835
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li C, 2015, J DENT RES, V94, P455, DOI 10.1177/0022034514566431
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Lu Y., STEM CELL RES THER, V13, P113
   de Freitas PHL, 2011, BONE, V49, P335, DOI 10.1016/j.bone.2011.05.022
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Matsumoto T, 2005, J CLIN ENDOCR METAB, V90, P5031, DOI 10.1210/jc.2004 2552
   Matsumoto T, 2011, BONE, V49, P605, DOI 10.1016/j.bone.2011.07.011
   Meier C, 2006, CLIN LAB, V52, P1
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Prestwood Karen M, 2002, Clin Cornerstone, V4, P31, DOI 10.1016/S1098 3597(02)90034 7
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768
   Schemitsch EH, 2019, J ORTHOP TRAUMA, V33, P292, DOI 10.1097/BOT.0000000000001444
   SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660
   Sieberath A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030912
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Takahashi Naoyuki, 2014, Bonekey Rep, V3, P495, DOI 10.1038/bonekey.2013.229
   Takahashi N, 2013, J STEROID BIOCHEM, V136, P171, DOI 10.1016/j.jsbmb.2012.11.010
   Wang J, 2018, MOL MED REP, V17, P1125, DOI 10.3892/mmr.2017.7954
   Wang LM, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12311
   Wu M, 2016, INT J MOL MED, V37, P565, DOI 10.3892/ijmm.2016.2457
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yan X, 2015, INT J CLIN EXP MED, V8, P5470
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829830
   Yang LL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122974
   Yang RL, 2022, FREE RADICAL BIO MED, V178, P246, DOI 10.1016/j.freeradbiomed.2021.12.010
   Yoon JH, 2018, CANCER GENOM PROTEOM, V15, P485, DOI 10.21873/cgp.20107
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
   Zhou XM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791585
NR 55
TC 14
Z9 16
U1 2
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD AUG
PY 2022
VL 96
AR 110376
DI 10.1016/j.cellsig.2022.110376
EA JUN 2022
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 2L3BT
UT WOS:000816894500005
PM 35690294
DA 2025 08 17
ER

PT J
AU Peng, L
   Zhang, DM
   Tu, H
   Wu, D
   Xiang, SX
   Yang, WB
   Zhao, Y
   Yang, J
AF Peng, Li
   Zhang, Demao
   Tu, Heng
   Wu, Dan
   Xiang, Shuaixi
   Yang, Wenbin
   Zhao, Yun
   Yang, Jing
TI The role of Map1b in regulating osteoblast polarity, proliferation,
   differentiation and migration
SO BONE
LA English
DT Article
DE Osteoblast; Map1b; Cytoskeleton; Polarity; Proliferation; Migration
ID RESPONSE GENE; CELL INVASION; WNT5A; GROWTH; RGC32
AB Osteoblast polarity, proliferation, differentiation, and migration are essential for maintaining normal bone structure and function. While the microtubule associated protein Map1b has been extensively studied in nerve cells, its role in bone cells is less known. We investigated the functional significance of Map1b in mouse bone marrow stromal cells (ST2) and elucidated its relationship and influence on cytoskeletal polarity and Golgi organization. Our results suggest that Map1b, as a microtubule regulatory protein, can also regulate the expression of cyclin PCNA, p H3(S10) and migration related protein integrin beta 1, thereby affecting the proliferation and migration of osteoblasts. The downstream target gene Rgc32 was screened by RNA sequencing. Furthermore, Map1b, as a downstream mediator, regulates the Wnt5a signaling pathway. This study expands our understanding of the involvement of Map1b in bone biology and highlights its crucial role in governing osteoblast polarity, proliferation, and migration, thereby providing a basis for developing novel therapeutic strategies targeting Map1b in orthopedic medicine and promoting precision treatment modalities. Further investigations on the precise mechanisms underlying Map1b's influence on bone cell function and disease progression are needed.
C1 [Peng, Li; Zhao, Yun] Sichuan Univ, Coll Life Sci, Key Lab Bioresource & Ecoenvironm, Minist Educ, Chengdu, Peoples R China.
   [Peng, Li; Zhang, Demao; Tu, Heng; Wu, Dan; Xiang, Shuaixi; Yang, Wenbin; Yang, Jing] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Natl Ctr Stomatol,State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Yang, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Natl Ctr Stomatol,State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM yangj7@scu.edu.cn
RI 彭, 丽/HZI 5413 2023; Yang, Wenbin/CAG 2902 2022
FU National Natural Science Founda  tion of China (NSFC) [82071108]; Youth
   Science Fund Project of Sichuan Provincial Science and Technology
   Department, Sichuan Natural Science Foundation [2023NSFSC1523]
FX This study was supported by the National Natural Science Founda  tion of
   China (NSFC) (NO. 82071108) and the Youth Science Fund Project of
   Sichuan Provincial Science and Technology Department, Sichuan Natural
   Science Foundation (NO. 2023NSFSC1523) . This research was made possible
   with their generous financial assistance, and we extend our heartfelt
   appreciation for their invaluable contribution. Additionally, we would
   like to express our special gratitude to Mr. Wang Runze for his
   contributions to the experimental process and Ms. Li Xin for her
   contributions to the article editing. Their dedication has provided
   valuable assistance to our research and publication, and we are deeply
   thankful for their invaluable contributions.
CR Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079
   Budnik V, 2011, CURR OPIN NEUROBIOL, V21, P151, DOI 10.1016/j.conb.2010.12.002
   Casati L, 2014, CELL ADHES MIGR, V8, P595, DOI 10.4161/19336918.2014.972785
   Etienne Manneville S, 2013, ANNU REV CELL DEV BI, V29, P471, DOI 10.1146/annurev cellbio 101011 155711
   Frye M, 2016, DEVELOPMENT, V143, P3871, DOI 10.1242/dev.136556
   Fuster JJ, 2015, DIABETES, V64, P1235, DOI 10.2337/db14 1164
   Hao HW, 2020, EMBO REP, V21, DOI 10.15252/embr.201948385
   Hawkins T, 2010, J BIOMECH, V43, P23, DOI 10.1016/j.jbiomech.2009.09.005
   He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526
   Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748 1716.2011.02294.x
   Kini U., 2012, Radionuclide and Hybrid Bone Imaging, P29, DOI [10.1007/978 3 642 02400 92, DOI 10.1007/978 3 642 02400 9_2]
   Lin MK, 2011, DEV DYNAM, V240, P432, DOI 10.1002/dvdy.22550
   Lojk J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910840
   Luzina IG, 2022, AM J RESP CELL MOL, V66, P146, DOI 10.1165/rcmb.2021 0022OC
   Mascanzoni F, 2022, CELLS BASEL, V11, DOI 10.3390/cells11030354
   Montenegro Venegas C, 2010, MOL BIOL CELL, V21, P3518, DOI 10.1091/mbc.E09 08 0709
   Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092 8674(00)80225 1
   Rasmussen ML, 2018, GENES BASEL, V9, DOI 10.3390/genes9020109
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Saigusa K, 2007, ONCOGENE, V26, P1110, DOI 10.1038/sj.onc.1210148
   Sanders AAWM, 2015, FRONT NEUROSCI SWITZ, V9, DOI 10.3389/fnins.2015.00431
   Schlick SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028638
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Su PH, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116238
   Sun QY, 2013, TUMOR BIOL, V34, P2995, DOI 10.1007/s13277 013 0864 2
   Tessema M, 2015, J THORAC ONCOL, V10, P1181, DOI 10.1097/JTO.0000000000000592
   Tymanskyj SR, 2012, MOL CELL NEUROSCI, V49, P110, DOI 10.1016/j.mcn.2011.10.003
   Villarroel Campos D, 2014, DEV NEUROBIOL, V74, P953, DOI 10.1002/dneu.22178
   Vivancos V, 2009, NEURAL DEV, V4, DOI 10.1186/1749 8104 4 7
   Vlaicu SI, 2019, IMMUNOL RES, V67, P267, DOI 10.1007/s12026 019 09080 0
   Vlaicu SI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01054
   Vlaicu SI, 2013, IMMUNOL RES, V56, P109, DOI 10.1007/s12026 012 8381 8
   Wang Z, 2021, CELL SIGNAL, V84, DOI 10.1016/j.cellsig.2021.110004
   Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250
   Xu R, 2014, MOL CELL BIOCHEM, V394, P109, DOI 10.1007/s11010 014 2086 3
   Yadav S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005322
   You Y, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12183
NR 40
TC 3
Z9 3
U1 7
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2024
VL 181
AR 117038
DI 10.1016/j.bone.2024.117038
EA FEB 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KR1W1
UT WOS:001181612200001
PM 38316337
DA 2025 08 17
ER

PT J
AU Marino, S
   Bishop, RT
   Carrasco, G
   Logan, JG
   Li, BY
   Idris, AI
AF Marino, Silvia
   Bishop, Ryan T.
   Carrasco, Giovana
   Logan, John G.
   Li, Boya
   Idris, Aymen I.
TI Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related
   Osteoclastogenesis In Vitro and Osteolysis Ex Vivo
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Osteolysis; NF kappa B; Osteoclast; Prostate cancer; Bone;
   Osteoclastogenesis
ID DEFECTIVE INTERLEUKIN 1; NUCLEAR LOCALIZATION; TRANSCRIPTION FACTOR;
   BONE METASTASIS; RANK LIGAND; IKK ALPHA; KINASE; CELLS; DIFFERENTIATION;
   EXPRESSION
AB NF kappa B is implicated in cancer and bone remodelling, and we have recently reported that the verified NF kappa B inhibitor Parthenolide (PTN) reduced osteolysis and skeletal tumour growth in models of metastatic breast cancer. Here, we took advantage of in vitro and ex vivo bone cell and organ cultures to study the effects of PTN on the ability of prostate cancer cells and their derived factors to regulate bone cell activity and osteolysis. PTN inhibited the in vitro growth of a panel of human, mouse and rat prostate cancer cells in a concentration dependent manner with a varying degree of potency. In prostate cancer cell osteoclast co cultures, the rat Mat Ly Lu, but not human PC3 or mouse RM1 BT, enhanced RANKL stimulated osteoclast formation and PTN reduced these effects without affecting prostate cancer cell viability. In the absence of cancer cells, PTN reduced the support of Mat Ly Lu conditioned medium for the adhesion and spreading of osteoclast precursors, and survival of mature osteoclasts. Pre exposure of osteoblasts to PTN prior to the addition of conditioned medium from Mat Ly Lu cells suppressed their ability to support the formation of osteoclasts by inhibition of RANKL/OPG ratio. PTN enhanced the ability of Mat Ly Lu derived factors to increase calvarial osteoblast differentiation and growth. Ex vivo, PTN enhanced bone volume in calvaria organ Mat Ly Lu cell co culture, without affecting Mat Ly Lu viability or apoptosis. Mechanistic studies in osteoclasts and osteoblasts confirmed that PTN inhibit NF kappa B activation related to derived factors from Mat Ly Lu cells. Collectively, these findings suggest that pharmacological inhibition of the skeletal NF kappa B signalling pathway reduces prostate cancer related osteolysis, but further studies in the therapeutic implications of NF kappa B inhibition in cells of the osteoblastic lineage are needed.
C1 [Marino, Silvia; Bishop, Ryan T.; Carrasco, Giovana; Li, Boya; Idris, Aymen I.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Marino, Silvia; Logan, John G.; Idris, Aymen I.] Univ Edinburgh, MRC Inst Genet & Mol Med, Edinburgh Canc Res Ctr, Bone & Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland.
C3 University of Sheffield; University of Edinburgh
RP Idris, AI (通讯作者)，Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.; Idris, AI (通讯作者)，Univ Edinburgh, MRC Inst Genet & Mol Med, Edinburgh Canc Res Ctr, Bone & Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland.
EM aymen.idris@sheffield.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Logan, John/0000 0003 2801 700X; 
FU Cancer Research UK (University of Edinburgh); Breast Cancer Now
   (University of Sheffield)
FX This work was supported in part by a pump prime grant from Cancer
   Research UK (University of Edinburgh) and Breast Cancer Now (University
   of Sheffield) grants to Aymen I. Idris.
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Andela VB, 2003, CLIN ORTHOP RELAT R, pS75, DOI 10.1097/01.blo.0000093048.96273.aa
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Atienza JM, 2005, J BIOMOL SCREEN, V10, P795, DOI 10.1177/1087057105279635
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   de GorterDavid J., 2013, PRIMER METABOLIC BON, V8th, P15, DOI DOI 10.1002/9781118453926.CH2
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078 0432.CCR 04 0764
   Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039
   Gasparian AV, 2002, J CELL SCI, V115, P141
   Gloeckner H, 2001, J IMMUNOL METHODS, V252, P131, DOI 10.1016/S0022 1759(01)00347 7
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hehner SP, 1999, J IMMUNOL, V163, P5617
   Holen I, 2002, CANCER RES, V62, P1619
   Idris AI, 2004, BONE, V35, P636, DOI 10.1016/j.bone.2004.03.036
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P525, DOI 10.1007/s00223 010 9417 5
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Idris AI, 2009, ENDOCRINOLOGY, V150, P5, DOI 10.1210/en.2008 0998
   Ismail H, 2004, PROSTATE, V58, P308, DOI 10.1002/pros.10335
   Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008 5472.CAN 08 0107
   Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074 5521(01)00049 7
   Lessard L, 2003, BJU INT, V91, P417, DOI 10.1046/j.1464 410X.2003.04104.x
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Marino S, 2014, BONEKEY REP
   Marino S, 2018, CALCIFIED TISSUE INT, V103, P206, DOI 10.1007/s00223 018 0406 4
   Marino Silvia, 2018, Oncotarget, V9, P16134, DOI 10.18632/oncotarget.24743
   Marino S, 2017, CANCER LETT, V410, P180, DOI 10.1016/j.canlet.2017.09.034
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Otero JE, 2010, J BONE MINER RES, V25, P1282, DOI 10.1002/jbmr.4
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Péant B, 2017, ONCOTARGET, V8, P14487, DOI 10.18632/oncotarget.11629
   Péant B, 2009, PROSTATE, V69, P706, DOI 10.1002/pros.20912
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Vela I, 2007, BJU INT, V99, P735, DOI 10.1111/j.1464 410X.2006.06670.x
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066
NR 59
TC 19
Z9 19
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2019
VL 105
IS 2
BP 193
EP 204
DI 10.1007/s00223 019 00538 9
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IM0FJ
UT WOS:000477661400009
PM 30929064
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Bonnet, N
   Brun, J
   Rousseau, JC
   Duong, LT
   Ferrari, SL
AF Bonnet, Nicolas
   Brun, Julia
   Rousseau, Jean Charles
   Duong, Le T.
   Ferrari, Serge L.
TI Cathepsin K Controls Cortical Bone Formation by Degrading Periostin
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PERIOSTIN; CATHEPSIN K; MODELING; CORTICAL BONE; MECHANICAL LOADING
ID POSTMENOPAUSAL WOMEN; ODANACATIB TREATMENT; PRECLINICAL MODEL; MINERAL
   DENSITY; INHIBITOR; OSTEOPOROSIS; OSTEOCLAST; EXPRESSION; OSTEOCYTES;
   RESORPTION
AB Although inhibitors of bone resorption concomitantly reduce bone formation because of the coupling between osteoclasts and osteoblasts, inhibition or deletion of cathepsin k (CatK) stimulates bone formation despite decreasing resorption. The molecular mechanisms responsible for this increase in bone formation, particularly at periosteal surfaces where osteoclasts are relatively poor, remain unclear. Here we show that CatK pharmacological inhibition or deletion (Ctsk( / )mice) potentiates mechanotransduction signals mediating cortical bone formation. We identify periostin (Postn) as a direct molecular target for degradation by CatK and show that CatK deletion increases Postn and b catenin expression in vivo, particularly at the periosteum. In turn, Postn deletion selectively abolishes cortical, but not trabecular, bone formation in CatK deficient mice. Taken together, these data indicate that CatK not only plays a major role in bone remodeling but also modulates modeling based cortical bone formation by degrading periostin and thereby moderating Wnt b catenin signaling. These findings provide novel insights into the role of CatK on bone homeostasis and the mechanisms of increased cortical bone volume with CatK mutations and pharmacological inhibitors. (C) 2017 American Society for Bone and Mineral Research.
C1 [Bonnet, Nicolas; Brun, Julia; Ferrari, Serge L.] Geneva Univ Hosp, Dept Internal Med Specialties, Div Bone Dis, 64 Ave Roseraie, CH 1205 Geneva 14, Switzerland.
   [Bonnet, Nicolas; Brun, Julia; Ferrari, Serge L.] Fac Med, 64 Ave Roseraie, CH 1205 Geneva 14, Switzerland.
   [Rousseau, Jean Charles] INSERM, UMR 1033, Lyon, France.
   [Rousseau, Jean Charles] Univ Lyon, Villeurbanne, France.
   [Duong, Le T.] Merck & Co Inc, Dept Bone Biol, Kenilworth, NJ USA.
C3 University of Geneva; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Claude Bernard Lyon 1; Merck & Company;
   Merck & Company USA
RP Bonnet, N (通讯作者)，Geneva Univ Hosp, Dept Internal Med Specialties, Div Bone Dis, 64 Ave Roseraie, CH 1205 Geneva 14, Switzerland.; Bonnet, N (通讯作者)，Fac Med, 64 Ave Roseraie, CH 1205 Geneva 14, Switzerland.
EM nicolas.bonnet@unige.ch
RI Ferrari, Serge/ABD 2730 2020
OI Bonnet, Nicolas/0000 0001 9832 5767; ferrari, serge/0000 0002 1372 4417
FU Swiss National Science Foundation [3100A0 116633/1]; MSD
FX These studies were supported by a Swiss National Science Foundation
   grant No 3100A0 116633/1 (to SF). This work was further supported by a
   grant from the MSD (to NB and SF).
CR BALENA R, 1992, J BONE MINER RES, V7, P1475
   Bliziotes M, 2006, J BONE MINER RES, V21, P1060, DOI 10.1359/JBMR.060414
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonnet N, 2015, J CLIN ENDOCR METAB, V100, pE1014, DOI 10.1210/jc.2015 1183
   Bonnet N, 2010, BONE S, V47, ps46
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chappard D, 2001, BONE, V28, P72, DOI 10.1016/S8756 3282(00)00438 5
   Cheung AM, 2014, J BONE MINER RES, V29, P1786, DOI 10.1002/jbmr.2194
   Contié S, 2010, CALCIFIED TISSUE INT, V87, P341, DOI 10.1007/s00223 010 9391 y
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Duong LT, 2014, MOL CANCER THER, V13, P2898, DOI 10.1158/1535 7163.MCT 14 0253
   Engelke K, 2014, J BONE MINER RES, V29, P629, DOI 10.1002/jbmr.2080
   Frey SP, 2013, SCI WORLD J, DOI 10.1155/2013/341078
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gerbaix M, 2015, BONE, V71, P94, DOI 10.1016/j.bone.2014.10.011
   Gillan L, 2002, CANCER RES, V62, P5358
   Jayakar RY, 2012, BONE, V50, P1379, DOI 10.1016/j.bone.2012.03.017
   Jerome C, 2012, OSTEOPOROSIS INT, V23, P339, DOI 10.1007/s00198 011 1593 2
   Kogawa M, 2013, J BONE MINER RES, V28, P2436, DOI 10.1002/jbmr.2003
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017
   Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428 011 1151 5
   Motyckova Gabriela, 2002, Current Molecular Medicine (Hilversum), V2, P407, DOI 10.2174/1566524023362401
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Prideaux M, 2016, BONE, V88, P64, DOI 10.1016/j.bone.2016.04.017
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rani S, 2009, BONE, V44, P502, DOI 10.1016/j.bone.2008.11.012
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131 11144.2005
   Schilling AF, 2007, OSTEOPOROSIS INT, V18, P659, DOI 10.1007/s00198 006 0311 y
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Stadelmann VA, 2009, COMPUT METHOD BIOMEC, V12, P95, DOI [10.1080/10255840802178053, 10.1080/10255840903077287]
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
   Williams DS, 2013, BONE, V56, P489, DOI 10.1016/j.bone.2013.06.008
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 49
TC 60
Z9 68
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2017
VL 32
IS 7
BP 1432
EP 1441
DI 10.1002/jbmr.3136
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EZ0FB
UT WOS:000404375300006
PM 28322464
OA Bronze
DA 2025 08 17
ER

PT J
AU Faccio, R
   Teitelbaum, SL
   Fujikawa, K
   Chappel, J
   Zallone, A
   Tybulewicz, VL
   Ross, FP
   Swat, W
AF Faccio, R
   Teitelbaum, SL
   Fujikawa, K
   Chappel, J
   Zallone, A
   Tybulewicz, VL
   Ross, FP
   Swat, W
TI Vav3 regulates osteoclast function and bone mass
SO NATURE MEDICINE
LA English
DT Article
ID GTP BINDING PROTEIN; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT;
   FAMILY PROTEINS; RHO GTPASES; CYTOSKELETAL ORGANIZATION; INTEGRIN
   ENGAGEMENT; BETA 3 INTEGRIN; MICE LACKING; KINASE SYK
AB Osteoporosis, a leading cause of morbidity in the elderly, is characterized by progressive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bone formation. Here we identify Vav3, a Rho family guanine nucleotide exchange factor, as essential for stimulated osteoclast activation and bone density in vivo. Vav3 deficient osteoclasts show defective actin cytoskeleton organization, polarization, spreading and resorptive activity resulting from impaired signaling downstream of the M CSF receptor and alpha(v)beta(3) integrin. Vav3 deficient mice have increased bone mass and are protected from bone loss induced by systemic bone resorption stimuli such as parathyroid hormone or RANKL. Moreover, we provide genetic and biochemical evidence for the role of Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts. Thus, Vav3 is a potential new target for antiosteoporosis therapy.
C1 Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA.
   Univ Bari, Sch Med, I 70100 Bari, Italy.
   Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England.
C3 Washington University (WUSTL); Washington University (WUSTL); Universita
   degli Studi di Bari Aldo Moro; MRC National Institute for Medical
   Research
RP Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.
EM rossf@wustl.edu; swat@pathbox.wustl.edu
OI Teitelbaum, Steven/0000 0002 4054 6679; Tybulewicz,
   Victor/0000 0003 2439 0798
FU NIAMS NIH HHS [AR32788, AR48812, AR48853, AR46523, AR46852] Funding
   Source: Medline
CR Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780
   Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood 2003 04 1259
   Cella M, 2004, J EXP MED, V200, P817, DOI 10.1084/jem.20031847
   Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544
   del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748
   Durán A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534 5807(03)00403 9
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694
   Faccio R, 2002, J CELL SCI, V115, P2919
   Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040
   Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960 9822(98)70224 6
   Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874
   Fukuda A, 2003, J BONE MINER RES, V18, pS79
   Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166
   Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960 9822(98)70225 8
   Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763 3774.2001
   Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960 9822(07)00559 3
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Mócsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074 7613(02)00303 5
   Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364 6373.2000
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Ridley AJ, 2001, J CELL SCI, V114, P2713
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962 8924(01)02153 5
   Riteau B, 2003, J EXP MED, V198, P469, DOI 10.1084/jem.20021995
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0
   Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840
   Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600 065X.2003.00032.x
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388
   ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014 4827(89)90266 8
   Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212 9224.2000
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481
   Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431
NR 50
TC 230
Z9 260
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2005
VL 11
IS 3
BP 284
EP 290
DI 10.1038/nm1194
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 905BA
UT WOS:000227541300023
PM 15711558
DA 2025 08 17
ER

PT J
AU Li, J
   Zeng, L
   Xie, J
   Yue, ZY
   Deng, HY
   Ma, XY
   Zheng, CB
   Wu, XS
   Luo, J
   Liu, MY
AF Li, Jing
   Zeng, Li
   Xie, Juan
   Yue, Zhiying
   Deng, Huayun
   Ma, Xueyun
   Zheng, Chunbing
   Wu, Xiushan
   Luo, Jian
   Liu, Mingyao
TI Inhibition of Osteoclastogenesis and Bone Resorption in vitro and
   in vivo by a prenylflavonoid xanthohumol from hops
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF KAPPA B; RECEPTOR ACTIVATOR; SIGNAL TRANSDUCTION; DIFFERENTIATION;
   MECHANISMS; METASTASIS; OSTEOLYSIS; PROTEIN 1; FAMILY; IMMUNE
AB Excessive RANKL signaling leads to superfluous osteoclast formation and bone resorption, is widespread in the pathologic bone loss and destruction. Therefore, targeting RANKL or its signaling pathway has been a promising and successful strategy for this osteoclast related diseases. In this study, we examined the effects of xanthohumol (XN), an abundant prenylflavonoid from hops plant, on osteoclastogenesis, osteoclast resorption, and RANKL induced signaling pathway using both in vitro and in vivo assay systems. In mouse and human, XN inhibited osteoclast differentiation and osteoclast formation at the early stage. Furthermore, XN inhibited osteoclast actin ring formation and bone resorption in a dose dependent manner. In ovariectomized induced bone loss mouse model and RANKL injection induced bone resorption model, we found that administration of XN markedly inhibited bone loss and resorption by suppressing osteoclast activity. At the molecular level, XN disrupted the association of RANK and TRAF6, resulted in the inhibition of NF kappa B and Ca2+/NFATc1 signaling pathway during osteoclastogenesis. As a results, XN suppressed the expression of osteoclastogenesis related marker genes, including CtsK, Nfatc1, Trap, Ctr. Therefore, our data demonstrated that XN inhibits osteoclastogenesis and bone resorption through RANK/TRAF6 signaling pathways. XN could be a promising drug candidate in the treatment of osteoclast related diseases such as postmenopausal osteoporosis.
C1 [Li, Jing; Zeng, Li; Xie, Juan; Yue, Zhiying; Deng, Huayun; Ma, Xueyun; Zheng, Chunbing; Luo, Jian; Liu, Mingyao] E China Normal Univ, Shanghai Fengxian Dist Cent Hosp, Shanghai 200241, Peoples R China.
   [Li, Jing; Zeng, Li; Xie, Juan; Yue, Zhiying; Deng, Huayun; Ma, Xueyun; Zheng, Chunbing; Luo, Jian; Liu, Mingyao] E China Normal Univ, East China Normal Univ Joint Ctr Translat Med, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Li, Jing; Zeng, Li; Xie, Juan; Yue, Zhiying; Deng, Huayun; Ma, Xueyun; Zheng, Chunbing; Luo, Jian; Liu, Mingyao] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Xie, Juan; Wu, Xiushan] Human Normal Univ, Key Lab MOE Dev Biol & Prot Chem, Coll Life Sci, Ctr Heart Dev, Changsha 410081, Human, Peoples R China.
   [Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Dept Mol & Cellular Med, Houston, TX 77030 USA.
C3 East China Normal University; East China Normal University; East China
   Normal University; Hunan Normal University; University of Texas System;
   University of Texas Health Science Center Houston; Texas A&M University
   System; Texas A&M University College Station; Texas A&M Health Science
   Center
RP Luo, J (通讯作者)，E China Normal Univ, Shanghai Fengxian Dist Cent Hosp, Shanghai 200241, Peoples R China.
EM jluo@bio.ecnu.edu.cn; myliu@bio.ecnu.edu.cn
RI Luo, Jian/H 3362 2016; Yue, Zhiying/AET 6441 2022
OI Luo, Jian/0000 0003 3583 0154; Liu, Mingyao/0000 0001 7339 5048; Zeng,
   Li/0000 0002 8879 951X
FU National Basic Research Program of China [2012CB910402]; National
   Natural Science Foundation of China [81472048, 81272911, 81330049,
   31200678]; Innovation Program of Shanghai Municipal Education Commission
   [14ZZ051]; Science and Technology Commission of Shanghai Municipality
   [12ZR1447900, 15140903600]
FX This work is supported by grants from the National Basic Research
   Program of China (2012CB910402), the National Natural Science Foundation
   of China (81472048, 81272911, 81330049, 31200678), Innovation Program of
   Shanghai Municipal Education Commission (14ZZ051), and the Science and
   Technology Commission of Shanghai Municipality (12ZR1447900,
   15140903600).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chambers TJ, 2000, J PATHOL, V192, P4
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Fang YZ, 2013, JNCI J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ivashkiv LB, 2009, NAT IMMUNOL, V10, P340, DOI 10.1038/ni.1706
   Jeong HM, 2011, BIOCHEM BIOPH RES CO, V409, P82, DOI 10.1016/j.bbrc.2011.04.113
   Kim HJ, 2010, INT IMMUNOPHARMACOL, V10, P1440, DOI 10.1016/j.intimp.2010.08.017
   Kirkwood JS, 2013, J BIOL CHEM, V288, P19000, DOI 10.1074/jbc.M112.445452
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li Z, 2012, CURR MOL MED, V12, P967, DOI 10.2174/156652412802480871
   Liu M, 2015, MOLECULES, V20, P754, DOI 10.3390/molecules20010754
   Qi B, 2014, SCI REP UK, V4, DOI 10.1038/srep07158
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021
   Tang XL, 2013, CANCER RES, V73, P6206, DOI 10.1158/0008 5472.CAN 13 1049
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Vives V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7218
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Zhang BX, 2015, J MED CHEM, V58, P1795, DOI 10.1021/jm5016507
NR 36
TC 40
Z9 43
U1 0
U2 31
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 1
PY 2015
VL 5
AR 17605
DI 10.1038/srep17605
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CX4DQ
UT WOS:000365649200003
PM 26620037
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kremer, KN
   Dudakovic, A
   Hess, AD
   Smith, BD
   Karp, JE
   Kaufmann, SH
   Westendorf, JJ
   van Wijnen, AJ
   Hedin, KE
AF Kremer, Kimberly N.
   Dudakovic, Amel
   Hess, Allan D.
   Smith, B. Douglas
   Karp, Judith E.
   Kaufmann, Scott H.
   Westendorf, Jennifer J.
   van Wijnen, Andre J.
   Hedin, Karen E.
TI Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by
   Enhancing a Nherf1 Protein Phosphatase 1α TAZ Signaling Pathway in
   Osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACUTE MYELOID LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; STEM CELL
   DIFFERENTIATION; MESENCHYMAL STROMAL CELLS; BONE MARROW; IN VIVO;
   TRANSCRIPTIONAL COACTIVATOR; MYELODYSPLASTIC SYNDROME; MAMMALIAN CELLS;
   HIPPO PATHWAY
AB Disrupting the protective signals provided by the bone marrow microenvironment will be critical for more effective combination drug therapies for acute myeloid leukemia (AML). Cells of the osteoblast lineage that reside in the endosteal niche have been implicated in promoting survival of AML cells. Here, we investigated how to prevent this protective interaction. We previously showed that SDF 1, a chemokine abundant in the bone marrow, induces apoptosis of AML cells, unless the leukemic cells receive protective signals provided by differentiating osteoblasts (8, 10). Wenow identify a novel signaling pathway in differentiating osteoblasts that can be manipulated to disrupt the osteoblast mediated protection of AML cells. Treating differentiating osteoblasts with histone deacetylase inhibitors (HDACi) abrogated their ability to protect co cultured AML cells from SDF 1 induced apoptosis. HDACi prominently up regulated expression of the Nherf1 scaffold protein, which played a major role in preventing osteoblast mediated protection of AML cells. Protein phosphatase 1 alpha (PP1 alpha) was identified as a novel Nherf1 interacting protein that acts as the downstream mediator of this response by promoting nuclear localization of the TAZ transcriptional modulator. Moreover, independent activation of either PP1 alpha or TAZ was sufficient to prevent osteoblast mediated protection of AML cells even in the absence of HDACi. Together, these results indicate that HDACi target the AML microenvironment by enhancing activation of the Nherf1 PP1 alpha  TAZ pathway in osteoblasts. Selective drug targeting of this osteoblast signaling pathway may improve treatments of AML by rendering leukemic cells in the bone marrow more susceptible to apoptosis.
C1 [Kremer, Kimberly N.; Hedin, Karen E.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA.
   [Dudakovic, Amel; Westendorf, Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
   [Kaufmann, Scott H.] Mayo Clin, Coll Med, Dept Oncol, Rochester, MN USA.
   [Kaufmann, Scott H.] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
   [Westendorf, Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Coll Med, Ctr Regenerat Med, Rochester, MN USA.
   [Hess, Allan D.; Smith, B. Douglas; Karp, Judith E.] Sidney Kimmel Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Johns
   Hopkins University; Johns Hopkins Medicine
RP Hedin, KE (通讯作者)，Guggenheim Bldg 3rd Floor,200 First St Southwest, Rochester, MN 55905 USA.
EM hedin.karen@mayo.edu
RI ; van Wijnen, Andre/AAG 3578 2019
OI van Wijnen, Andre J./0000 0002 4458 0946; Dudakovic,
   Amel/0000 0002 8850 3977; Kremer, Kimberly/0000 0003 0017 1195;
   Kaufmann, Scott/0000 0002 4900 7145; Hedin, Karen/0000 0003 1010 923X
FU Mayo Clinic Foundation for Medical Research; Joanne G. and Gary N. Owen
   Fund in Immunology Research; Alma B. Stevenson Endowment Fund for
   Medical Research; National Institutes of Health [R01 CA166741, U01
   CA70095, R01 AR049069]
FX This work was supported by the Mayo Clinic Foundation for Medical
   Research, the Joanne G. and Gary N. Owen Fund in Immunology Research,
   the Alma B. Stevenson Endowment Fund for Medical Research, and National
   Institutes of Health Grants R01 CA166741 (to S. H. K) and U01 CA70095
   (to J. E. K) and R01 AR049069 (to A. J. v. W.). The authors declare that
   they have no conflicts of interest with the contents of this article.
CR Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Byun MR, 2014, J BIOL CHEM, V289, P9926, DOI 10.1074/jbc.M113.522870
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Chen Y, 2012, BLOOD, V119, P4971, DOI 10.1182/blood 2011 11 389957
   Choy MS, 2012, BIOCHEM SOC T, V40, P969, DOI 10.1042/BST20120094
   De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346
   Dudakovic A, 2015, J CELL PHYSIOL, V230, P52, DOI 10.1002/jcp.24680
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Garcia Manero G, 2008, BLOOD, V112, P981, DOI 10.1182/blood 2007 10 115873
   Garcia Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood 2007 06 098061
   Garcia Manero G, 2012, BEST PRACT RES CL HA, V25, P427, DOI 10.1016/j.beha.2012.10.005
   Garcia Manero G, 2012, J CLIN ONCOL, V30, P2204, DOI 10.1200/JCO.2011.38.3265
   Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078 0432.CCR 06 0511
   Gojo I, 2013, CLIN CANCER RES, V19, P1838, DOI 10.1158/1078 0432.CCR 12 3165
   Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835
   Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Kojima K, 2011, BLOOD, V118, P4431, DOI 10.1182/blood 2011 02 334136
   Konopleva M, 2009, DRUG RESIST UPDATE, V12, P103, DOI 10.1016/j.drup.2009.06.001
   Krause DS, 2013, NAT MED, V19, P1513, DOI 10.1038/nm.3364
   Kremer KN, 2014, J CELL BIOCHEM, V115, P1128, DOI 10.1002/jcb.24755
   Kremer KN, 2013, J BIOL CHEM, V288, P22899, DOI 10.1074/jbc.M113.449926
   Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015
   Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874 07
   Liersch R, 2012, BLOOD, V119, P5215, DOI 10.1182/blood 2011 11 389692
   Liu CY, 2011, J BIOL CHEM, V286, P5558, DOI 10.1074/jbc.M110.194019
   Liu Chenying, 2011, Int J Biochem Mol Biol, V2, P247
   Liu L, 2012, J BIOL CHEM, V287, P43312, DOI 10.1074/jbc.M112.422766
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365 2141.2003.04217.x
   Ninomiya M, 2007, LEUKEMIA, V21, P136, DOI 10.1038/sj.leu.2404432
   Nwajei Felix, 2013, Adv Hematol, V2013, P953982, DOI 10.1155/2013/953982
   Petruccelli LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020987
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Prebet T, 2011, EXPERT OPIN INV DRUG, V20, P287, DOI 10.1517/13543784.2011.542750
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 362
   Silva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053766
   Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324
   Tabe Y, 2014, BRIT J HAEMATOL, V164, P767, DOI 10.1111/bjh.12725
   Trinkle Mulcahy L, 2001, J CELL SCI, V114, P4219
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Wang B, 2013, BONE, V52, P268, DOI 10.1016/j.bone.2012.10.001
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050
   Weinman EJ, 2001, AM J PHYSIOL RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374
   Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610 09
NR 54
TC 19
Z9 21
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 4
PY 2015
VL 290
IS 49
BP 29478
EP 29492
DI 10.1074/jbc.M115.668160
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CY7TY
UT WOS:000366613400031
PM 26491017
OA Green Published
DA 2025 08 17
ER

PT J
AU Chen, ZW
   Jiang, MY
   Mo, L
   Zhou, C
   Huang, HR
   Ma, C
   Wang, ZZ
   Fan, YN
   Chen, ZQ
   Fang, B
   Liu, YH
AF Chen, Zhiwen
   Jiang, Mengyu
   Mo, Liang
   Zhou, Chi
   Huang, Haoran
   Ma, Chao
   Wang, Zhangzheng
   Fan, Yinuo
   Chen, Zhenqiu
   Fang, Bin
   Liu, Yuhao
TI A natural agent, 5 deoxycajanin, mitigates estrogen deficiency bone loss
   via modulating osteoclast osteoblast homeostasis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE 5 Deoxycajanin; Osteoclasts; Osteoblasts; Bone loss
ID POSTMENOPAUSAL WOMEN; DOUBLE BLIND; KAPPA B; DIFFERENTIATION;
   OSTEOPOROSIS; ACTIVATION; FLAVONOIDS; NFATC1; CELLS; RISK
AB Hyperactive osteoclasts and hypoactive osteoblasts usually result in osteolytic conditions such as estrogendeficiency bone loss. Few natural compounds that both attenuating bone resorption and enhancing bone formation could exert effects on this imbalance. 5 Deoxycajanin (5 D), an isoflavonoid extracted from Cajan leaf with estrogen like properties, were found to have beneficial pharmacological effects on rebalancing the activities of osteoclasts and osteoblasts. This study revealed that 5 D at the same concentration could inhibit osteoclastogenesis of BMMs and promoted osteoblast differentiation of BMSCs. 5 D not only attenuated the fluorescent formation of RANKL induced F actin belts and NFATc1, but also activated ALP and RUNX2 expressions. As to downstream factor expressions, 5 D could block osteoclast specific genes and proteins including NFATc1 and CTSK, while increased osteogenic genes and proteins including OPG and OCN, as confirmed by Real time PCR and Western Blotting. Additionally, the network pharmacology and molecular docking identified the involvement of 5 D in the MIF and MAPK signaling pathways and the stable binding between 5 D and MAPK2K1. Further Western blot studies showed that 5 D decreased the phosphorylation of p38 and ERK in osteoclasts, but promoted these phosphorylations in osteoblasts. In a female C57BL/6J mouse model of estrogen deficiency induced bone loss, 5 D demonstrated efficacy in enhancing BMD through attenuating osteoclast activities and promoting osteogenesis. These results underscore the potential application of 5 D on treating osteolysis resulting from hyperactive osteoclasts and hypoactive osteoblasts, shedding light on modulating osteoclast osteoblast homeostasis.
C1 [Chen, Zhiwen; Jiang, Mengyu; Zhou, Chi; Huang, Haoran; Wang, Zhangzheng; Chen, Zhenqiu; Fang, Bin; Liu, Yuhao] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Zhou, Chi; Chen, Zhenqiu; Fang, Bin; Liu, Yuhao] Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China.
   [Chen, Zhiwen; Jiang, Mengyu; Mo, Liang; Zhou, Chi; Ma, Chao; Wang, Zhangzheng; Fan, Yinuo; Chen, Zhenqiu; Fang, Bin; Liu, Yuhao] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Huang, Haoran] Yangjiang Hosp Tradit Chinese Med, Yangjiang, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine
RP Chen, ZQ; Fang, B; Liu, YH (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Chen, ZQ; Fang, B; Liu, YH (通讯作者)，Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China.; Chen, ZQ; Fang, B; Liu, YH (通讯作者)，Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
EM chenzhenqiu2012@126.com; 2352199836@qq.com; doctor_yuhaoliu@126.com
RI huang, haoran/S 8994 2018; Liu, Yuhao/LDE 7575 2024
OI Ma, Chao/0000 0002 1049 6172; 
FU National Natural Science Foundation of China [82104883, 82374475];
   Guangzhou Science and Technology Bureau [2024A04J9998]; Young Elite
   Scientists Sponsorship Program from Guangzhou Association for Science
   and Technology [QT 2024 033]; First Affiliated Hospital of Guangzhou
   University of Chinese Medicine [2022ZJ05, ZYYY2023 186]; Guangzhou
   Municipal Health Commission [ZYYY2023 186]
FX This research was sponsored by National Natural Science Foundation of
   China (No. 82104883, No. 82374475), Guangzhou Science and Technology
   Bureau (No. 2024A04J9998), Young Elite Scientists Sponsorship Program
   from Guangzhou Association for Science and Technology (No. QT 2024 033),
   The First Affiliated Hospital of Guangzhou University of Chinese
   Medicine (No. 2022ZJ05, No. ZYYY2023 186) and Guangzhou Municipal Health
   Commission (No. 2023P TS22).
CR [Anonymous], 2020, MED LETT DRUGS THER, V62, P105
   Assefa F, 2022, TISSUE ENG REGEN MED, V19, P189, DOI 10.1007/s13770 021 00408 2
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P846, DOI 10.1016/j.tem.2021.07.011
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Chen Q, 2023, BIOCHEM BIOPH RES CO, V682, P349, DOI 10.1016/j.bbrc.2023.10.032
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Delaisse JM, 2020, BONE, V141, DOI [10.1016/j/bone.2020.115628, 10.1016/j.bone.2020.115628]
   Gan K, 2024, CELL DEATH DISCOV, V10, DOI 10.1038/s41420 024 01856 0
   Gómez Zorita S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123853
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu W, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16008 x
   Jiang YX, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897221107636
   Jolly JJ, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050963
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Klein Nulend J, 2015, J BIOMECH, V48, P855, DOI 10.1016/j.jbiomech.2014.12.007
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Kondapalli AV, 2023, OSTEOPOROSIS INT, V34, P1477, DOI 10.1007/s00198 023 06793 9
   Kumari S, 2023, MOL BIOL REP, V50, P9453, DOI 10.1007/s11033 023 08751 4
   Lee J, 2023, EUR J ENDOCRINOL, V189, P527, DOI 10.1093/ejendo/lvad156
   Liu H, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42467 5
   Liu Y, 2022, NUCLEIC ACIDS RES, V50, pW159, DOI 10.1093/nar/gkac394
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   McNamara LM, 2021, CURR OSTEOPOROS REP, V19, P592, DOI 10.1007/s11914 021 00702 x
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Nakai S, 2020, J NUTR SCI VITAMINOL, V66, P502, DOI 10.3177/jnsv.66.502
   Oury J, 2018, M S MED SCI, V34, P54, DOI 10.1051/medsci/20183401014
   Park JH, 2017, MOL CELLS, V40, P706
   Pérez Campo FM, 2016, CALCIFIED TISSUE INT, V99, P302, DOI 10.1007/s00223 016 0144 4
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Sharifi Rad J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3268136
   Shu HS, 2021, CELL STEM CELL, V28, P2122, DOI 10.1016/j.stem.2021.08.010
   Slupski W, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051609
   Su ZK, 2024, PHYTOTHER RES, V38, P214, DOI 10.1002/ptr.8032
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Wu J, 2007, MENOPAUSE, V14, P866, DOI 10.1097/gme.0b013e3180305299
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang JC, 2010, PHARM BIOL, V48, P89, DOI 10.3109/13880200903046179
NR 50
TC 0
Z9 0
U1 6
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV 15
PY 2024
VL 141
AR 112906
DI 10.1016/j.intimp.2024.112906
EA AUG 2024
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA E2E5D
UT WOS:001301186500001
PM 39173403
DA 2025 08 17
ER

PT J
AU Liu, J
   Liang, C
   Guo, BS
   Wu, XH
   Li, DF
   Zhang, ZK
   Zheng, K
   Dang, L
   He, XJ
   Lu, CW
   Peng, SL
   Pan, XH
   Zhang, BT
   Lu, AP
   Zhang, G
AF Liu, Jin
   Liang, Chao
   Guo, Baosheng
   Wu, Xiaohao
   Li, Defang
   Zhang, Zongkang
   Zheng, Kang
   Dang, Lei
   He, Xiaojuan
   Lu, Changwei
   Peng, Songlin
   Pan, Xiaohua
   Zhang, Bao Ting
   Lu, Aiping
   Zhang, Ge
TI Increased PLEKHO1 within osteoblasts suppresses Smad dependent BMP
   signaling to inhibit bone formation during aging
SO AGING CELL
LA English
DT Article
DE aging; BMP signaling; osteoblast; osteoporosis
ID UBIQUITIN LIGASE SMURF1; DIFFERENTIATION; DEGRADATION; OSTEOPOROSIS;
   CKIP 1; CELLS; PROTEIN 1; THERAPY; TARGETS; SYSTEM
AB Emerging evidence indicates that the dysregulation of protein ubiquitination plays a crucial role in aging associated diseases. Smad dependent canonical BMP signaling pathway is indispensable for osteoblastic bone formation, which could be disrupted by the ubiquitination and subsequent proteasomal degradation of Smad1/5, the key molecules for BMP signaling transduction. However, whether the dysregulation of Smad1/5 ubiquitination and disrupted BMP signaling pathway is responsible for the age related bone formation reduction is still underexplored. Pleckstrin homology domain containing family O member 1 (PLEKHO1) is a previously identified ubiquitination related molecule that could specifically target the linker region between the WW domains of Smurf1 to promote the ubiquitination of Smad1/5. Here, we found an age related increase in the expression of PLEKHO1 in bone specimens from either fractured patients or aging rodents, which was associated with the age related reduction in Smad dependent BMP signaling and bone formation. By genetic approach, we demonstrated that loss of Plekho1 in osteoblasts could promote the Smad dependent BMP signaling and alleviated the age related bone formation reduction. In addition, osteoblast specific Smad1 overexpression had beneficial effect on bone formation during aging, which could be counteracted after overexpressing Plekho1 within osteoblasts. By pharmacological approach, we showed that osteoblast targeted Plekho1 siRNA treatment could enhance Smad dependent BMP signaling and promote bone formation in aging rodents. Taken together, it suggests that the increased PLEKHO1 could suppress Smad dependent BMP signaling to inhibit bone formation during aging, indicating the translational potential of targeting PLEKHO1 in osteoblast as a novel bone anabolic strategy for reversing established osteoporosis during aging.
C1 [Liu, Jin; Liang, Chao; Guo, Baosheng; Wu, Xiaohao; Li, Defang; Zheng, Kang; Dang, Lei; He, Xiaojuan; Lu, Changwei; Peng, Songlin; Pan, Xiaohua; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Jockey Club Sch Chinese Med Bldg, Kowloon, Hong Kong, Peoples R China.
   [Liu, Jin; Liang, Chao; Guo, Baosheng; Wu, Xiaohao; Li, Defang; Dang, Lei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Integrated Bioinfomed & Translat Sci, Sch Chinese Med, Kowloon, Hong Kong, Peoples R China.
   [Liu, Jin; Liang, Chao; Guo, Baosheng; Wu, Xiaohao; Li, Defang; Dang, Lei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Precis Med & Innovat Drug Discovery, Kowloon, Hong Kong, Peoples R China.
   [Zhang, Zongkang; Zhang, Bao Ting] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Zheng, Kang; He, Xiaojuan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Lu, Changwei] Xian Third Hosp, Dept Orthopaed, Xian, Chinajing, Peoples R China.
   [Peng, Songlin] Ji Nan Univ, Shenzhen Peoples Hosp, Dept Spine Surg, Coll Med 2, Shenzhen, Peoples R China.
   [Pan, Xiaohua] Southern Med Univ, Baoan Hosp, Dept Orthopaed & Traumatol, Shenzhen, Peoples R China.
   [Pan, Xiaohua] Shenzhen 8th People Hosp, Shenzhen, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; Hong Kong
   Baptist University; Chinese University of Hong Kong; China Academy of
   Chinese Medical Sciences; Institute of Basic Research In Clinical
   Medicine, CACMS; Jinan University; Southern Medical University   China
RP Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Jockey Club Sch Chinese Med Bldg, Kowloon, Hong Kong, Peoples R China.; Zhang, BT (通讯作者)，Chinese Univ Hong Kong, Sch Chinese Med, Fac Med, Chung Chi Coll, Room 101 E,Li Wai Chun Bldg, Hong Kong, Hong Kong, Peoples R China.
EM zhangbaoting@cuhk.edu.hk; aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI Zhang, Baoting/B 6273 2015; Guo, Baosheng/ABD 4800 2021; peng,
   sl/ISA 1370 2023; Zhang, Ge/N 4150 2013; Zhang, Zongkang/AAB 2564 2020;
   ZHANG, Ge/N 4150 2013; Zheng, Kang/C 4254 2013; LU,
   Aiping/JDX 0577 2023; Liang, Chao/AAF 7703 2019; Xiaohao,
   Wu/HNI 5943 2023
OI Guo, Baosheng/0000 0002 4510 5418; Liang, Chao/0000 0002 5617 3483;
   Zhang, Bao Ting/0000 0003 1421 0212; Li, Defang/0000 0003 4151 9151;
   ZHANG, Ge/0000 0002 7807 7695; Peng, Songlin/0000 0002 4042 7071; Wu,
   Xiaohao/0000 0002 0984 7414
FU Ministry of Science and Technology of China [2013ZX09301307]; Hong Kong
   General Research Fund [HKBU479111, HKBU478312, HKBU262913, HKBU261113,
   CUHK 14108816, CUHK14112915, CUHK489213]; Natural Science Foundation
   Council of China [81272045, 81401833, 81470072]; Research Grants Council
   & Natural Science Foundation Council of China [N_HKBU435/12]; Croucher
   Foundation (Gnt) [CAS14BU/CAS14201]; Interdisciplinary Research Matching
   Scheme (IRMS) of Hong Kong Baptist University [RCIRMS/12 13/02,
   RC IRMS/13 14/02]; Hong Kong Baptist University Strategic Development
   Fund (SDF) [SDF13 1209 P01]; Hong Kong Research Grants Council (RGC)
   Early Career Scheme (ECS) [489213]; Inter institutional Collaborative
   Research Scheme of Hong Kong Baptist University [RC ICRS/14 15/01];
   Faculty Research Grant of Hong Kong Baptist University [FRG1/13 14/024,
   FRG2/12 13/027, FRG2/14 15/010]; China Academy of Chinese Medical
   Sciences [Z0252, Z0293]
FX This study was supported by the Ministry of Science and Technology of
   China (2013ZX09301307 to A.L.), the Hong Kong General Research Fund
   (HKBU479111 to G.Z., HKBU478312 to G.Z., HKBU262913 to G.Z., HKBU261113
   to A.L., CUHK 14108816 to B.Z., CUHK14112915 to B.Z. and CUHK489213 to
   B.Z.), the Natural Science Foundation Council of China (81272045 to G.Z.
   81272045 to B.G., 81401833 to B.G. and 81470072 to X.H.), the Research
   Grants Council & Natural Science Foundation Council of China
   (N_HKBU435/12 to G.Z.), the Croucher Foundation (Gnt#CAS14BU/CAS14201 to
   G.Z.), the Interdisciplinary Research Matching Scheme (IRMS) of Hong
   Kong Baptist University (RCIRMS/12 13/02 to A.L. and RC IRMS/13 14/02 to
   G.Z.), the Hong Kong Baptist University Strategic Development Fund (SDF)
   (SDF13 1209 P01 to A.L.), the Hong Kong Research Grants Council (RGC)
   Early Career Scheme (ECS) (489213 to G.Z.), the Inter institutional
   Collaborative Research Scheme of Hong Kong Baptist University
   (RC ICRS/14 15/01 to G.Z.), the Faculty Research Grant of Hong Kong
   Baptist University (FRG1/13 14/024 to G.Z. FRG2/12 13/027 to G.Z. and
   FRG2/14 15/010 to G.Z.), and the China Academy of Chinese Medical
   Sciences (Z0252 and Z0293 to A.L.).
CR Black DM, 2013, J BONE MINER RES, V28, P2263, DOI 10.1002/jbmr.2104
   Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791
   Bragdon B, 2010, BIOPHYS J, V99, P897, DOI 10.1016/j.bpj.2010.04.070
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi YH, 2015, BONE, V75, P201, DOI 10.1016/j.bone.2015.02.026
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Juhász K, 2013, IMMUNOL LETT, V152, P55, DOI 10.1016/j.imlet.2013.04.001
   Kannan M, 2012, DEVELOPMENT, V139, P3600, DOI 10.1242/dev.081786
   Kheirolomoom A, 2007, BIOMATERIALS, V28, P4311, DOI 10.1016/j.biomaterials.2007.06.008
   Kim JY, 2011, FEBS LETT, V585, P1121, DOI 10.1016/j.febslet.2011.03.053
   Li DH, 2014, J MOL CELL BIOL, V6, P368, DOI 10.1093/jmcb/mju034
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Ling SK, 2012, CIRCULATION, V126, P3028, DOI 10.1161/CIRCULATIONAHA.112.102780
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Morel E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3250
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Olsten MEK, 2004, J BIOL CHEM, V279, P42114, DOI 10.1074/jbc.M407628200
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qiang YW, 2012, SEMIN HEMATOL, V49, P243, DOI 10.1053/j.seminhematol.2012.04.011
   Qin L, 2001, J BONE MINER METAB, V19, P359, DOI 10.1007/s007740170005
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Sévère N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.217
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Song B, 2009, CYTOKINE GROWTH F R, V20, P379, DOI 10.1016/j.cytogfr.2009.10.010
   Tsubakihara Y, 2015, J BIOCHEM, V158, P61, DOI 10.1093/jb/mvv024
   Wan LX, 2011, MOL CELL, V44, P721, DOI 10.1016/j.molcel.2011.09.024
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xing LP, 2010, J CELL BIOCHEM, V110, P554, DOI 10.1002/jcb.22586
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang HW, 2013, STEM CELLS, V31, P1574, DOI 10.1002/stem.1395
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
NR 38
TC 35
Z9 41
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1474 9726
J9 AGING CELL
JI Aging Cell
PD APR
PY 2017
VL 16
IS 2
BP 360
EP 376
DI 10.1111/acel.12566
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EM5UP
UT WOS:000395379500018
PM 28083909
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ricarte, FR
   Le Henaff, C
   Kolupaeva, VG
   Gardella, TJ
   Partridge, NC
AF Ricarte, Florante R.
   Le Henaff, Carole
   Kolupaeva, Victoria G.
   Gardella, Thomas J.
   Partridge, Nicola C.
TI Parathyroid hormone(1 34) and its analogs differentially modulate
   osteoblastic Rankl expression via PKA/SIK2/SIK3 and
   PP1/PP2A CRTC3 signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE osteoblast; parathyroid hormone; osteoporosis; protein kinase A (PKA);
   phosphoprotein phosphatase; abaloparatide; age related diseases;
   parathyroid hormone related protein; Rankl; salt inducible kinases
ID PROTEIN PHOSPHATASE 2A; KAPPA B LIGAND; INCREASED BONE MASS; RECEPTOR
   ACTIVATOR; GENE EXPRESSION; POSTMENOPAUSAL WOMEN; C ALPHA; PTH;
   PHOSPHORYLATION; BINDING
AB Osteoporosis can result from the loss of sex hormones and/or aging. Abaloparatide (ABL), an analog of parathyroid hormone related protein (PTHrP(1 36)), is the second osteoanabolic therapy approved by the United States Food and Drug Administration after teriparatide (PTH(1 34)). All three peptides bind PTH/PTHrP receptor type 1 (PTHR1), but the effects of PTHrP(1 36) or ABL in the osteoblast remain unclear. We show that, in primary calvarial osteoblasts, PTH(1 34) promotes a more robust cAMP response than PTHrP(1 36) and ABL and causes a greater activation of protein kinase A (PKA) and cAMP response element binding protein (CREB). All three peptides similarly inhibited sclerostin (Sost). Interestingly, the three peptides differentially modulated two other PKA target genes, c Fos and receptor activator of NF B ligand (Rankl), and the latter both in vitro and in vivo. Knockdown of salt inducible kinases (SIKs) 2 and 3 and CREB regulated transcription coactivator 3 (CRTC3), indicated that all three are part of the pathway that regulates osteoblastic Rankl expression. We also show that the peptides differentially regulate the nuclear localization of CRTC2 and CRTC3, and that this correlates with PKA activation. Moreover, inhibition of protein phosphatases 1 and 2A (PP1/PP2A) activity revealed that they play a major role in both PTH induced Rankl expression and the effects of PTH(1 34) on CRTC3 localization. In summary, in the osteoblast, the effects of PTH(1 34), PTHrP(1 36), and ABL on Rankl are mediated by differential stimulation of cAMP/PKA signaling and by their downstream effects on SIK2 and  3, PP1/PP2A, and CRTC3.
C1 [Ricarte, Florante R.; Partridge, Nicola C.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
   [Le Henaff, Carole; Kolupaeva, Victoria G.; Partridge, Nicola C.] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, 345 East 24th St,902A, New York, NY 10010 USA.
   [Gardella, Thomas J.] Harvard Med Sch, Endocrine Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA.
C3 New York University; New York University; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Massachusetts
   General Hospital
RP Partridge, NC (通讯作者)，NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, 345 East 24th St,902A, New York, NY 10010 USA.
EM ncp234@nyu.edu
OI Partridge, Nicola/0000 0002 5406 4814
FU National Institutes of Health [DK47420, DK4742051, T32 GM066704]
FX This work was supported by National Institutes of Health Grants DK47420,
   DK4742051, and T32 GM066704. The authors declare that they have no
   conflicts of interest with the contents of this article. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074 5521(00)00069 7
   Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104
   Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Doyle N, 2018, OSTEOPOROSIS INT, V29, P685, DOI 10.1007/s00198 017 4323 6
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Galli C, 2009, J BIOL CHEM, V284, P12654, DOI 10.1074/jbc.M806628200
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Henriksson E, 2015, J CELL SCI, V128, P472, DOI 10.1242/jcs.153932
   Henriksson E, 2012, BIOCHEM J, V444, P503, DOI 10.1042/BJ20111932
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Itoh Y, 2015, J BIOL CHEM, V290, P17879, DOI 10.1074/jbc.M115.640821
   Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264 6021:3530417
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim JH, 2017, P NATL ACAD SCI USA, V114, P11739, DOI 10.1073/pnas.1712616114
   Kim S, 2007, MOL ENDOCRINOL, V21, P197, DOI 10.1210/me.2006 0315
   Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415 09
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Lee CW, 2014, J BIOL CHEM, V289, P21108, DOI 10.1074/jbc.M113.540229
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Lombardi MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185426
   MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014 5793(88)81331 0
   Martowicz ML, 2011, J CELL BIOCHEM, V112, P2030, DOI 10.1002/jcb.23123
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Okamura H, 2013, FEBS LETT, V587, P48, DOI 10.1016/j.febslet.2012.10.041
   Okamura H, 2011, BONE, V49, P368, DOI 10.1016/j.bone.2011.06.004
   Onal M, 2016, J BONE MINER RES, V31, P416, DOI 10.1002/jbmr.2698
   Patel K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5535
   Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sasagawa S, 2012, DEVELOPMENT, V139, P1153, DOI 10.1242/dev.072652
   Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015
   Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   St John HC, 2015, BONE, V72, P81, DOI 10.1016/j.bone.2014.11.010
   Tseng W, 2010, J BIOL CHEM, V285, P29925, DOI 10.1074/jbc.M110.117366
   Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255
   URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617
   Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014 5793(98)00684 X
   Varela A, 2017, BONE, V95, P143, DOI 10.1016/j.bone.2016.11.027
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
NR 60
TC 53
Z9 61
U1 1
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 28
PY 2018
VL 293
IS 52
BP 20200
EP 20213
DI 10.1074/jbc.RA118.004751
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA HG1BW
UT WOS:000454685900026
PM 30377251
OA Green Published
DA 2025 08 17
ER

PT J
AU Idris, AI
   Coste, E
   Greig, IR
   Ralston, SH
   van't Hof, RJ
AF Idris, Aymen I.
   Coste, Emmanuel
   Greig, Iain R.
   Ralston, Stuart H.
   van't Hof, Rob J.
TI The Biphenyl Carboxylate Derivative ABD328 is a Novel Orally Active
   Antiresorptive Agent
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Osteoclast; Metabolic bone diseases; Animal models; Osteoblast
ID FORMATION IN VITRO; PARATHYROID HORMONE; BONE RESORPTION;
   ACID DERIVATIVES; ALENDRONATE; MICE; PTH; AMINOBISPHOSPHONATES;
   IDENTIFICATION; OSTEOPOROSIS
AB We previously described a novel series of biphenyl carboxylic acid derivatives which have potent antiresorptive effects in vitro and in vivo and do not affect osteoblast function. However, none of the previous compounds showed oral activity, probably because they were esters, which would be expected to be metabolized very rapidly. Here, we tested whether derivatives where the ester link was replaced by a ketone link were orally active. Compounds were tested in murine osteoclast and osteoblast cultures and in the mouse ovariectomy (OVX) model of osteoporosis. The ketones were at least as potent at inhibiting osteoclast formation and RANKL signaling in vitro as the esters and did not inhibit osteoblast differentiation or function. The basic ketone linked compound ABD68 was only partially able to inhibit OVX induced bone loss at an oral dose of 20 mg/kg daily. Substitutions on the phenyl rings increased the potency of the compounds in vitro and may prevent metabolism of the compounds in vivo. The most promising derivative, ABD328, completely prevented OVX induced bone loss when administered by intraperitoneal injection at 3 mg/kg daily. Furthermore, ABD328 was also able to fully prevent OVX induced bone loss when given orally at 10 mg/kg daily. The results indicate that biphenyl carboxylates like ABD328 are oral candidate drugs for the treatment of diseases characterized by increased bone resorption, such as postmenopausal osteoporosis.
C1 [Idris, Aymen I.; Coste, Emmanuel; Ralston, Stuart H.; van't Hof, Rob J.] Univ Edinburgh, Rheumat Dis Unit, Mol Med Ctr, Inst Genet & Mol Med,Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Greig, Iain R.] Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.
C3 University of Edinburgh; University of Aberdeen
RP Idris, AI (通讯作者)，Univ Edinburgh, Rheumat Dis Unit, Mol Med Ctr, Inst Genet & Mol Med,Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
EM aymen.idris@ed.ac.uk; rvanthof@staffmail.ed.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Idris, Aymen/0000 0003 4327 5306; Greig, Iain/0000 0003 0603 3383; van
   't Hof, Rob/0000 0002 8193 6788; 
FU Arthritis Research Campaign UK; Scottish Enterprise; ECTS/Amgen
FX This study was supported in part by grants from the Arthritis Research
   Campaign UK and Scottish Enterprise and by an ECTS/Amgen fellowship
   award to A. I. I.
CR [Anonymous], BONE RES PROTOCOLS
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Idris AI, 2009, ENDOCRINOLOGY, V150, P5, DOI 10.1210/en.2008 0998
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Stewart TL, 2005, CALCIFIED TISSUE INT, V77, P113, DOI 10.1007/s00223 004 0188 8
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   van't Hof RJ, 2004, J BONE MINER RES, V19, P1651, DOI 10.1359/jbmr.2004.19.10.1651
   Yamane H, 2009, BONE, V44, P1055, DOI 10.1016/j.bone.2008.05.010
NR 19
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD DEC
PY 2010
VL 87
IS 6
BP 525
EP 532
DI 10.1007/s00223 010 9417 5
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 679JT
UT WOS:000284158400006
PM 20852852
DA 2025 08 17
ER

PT J
AU Yang, YM
   Tseng, WJ
   Wang, B
AF Yang, Yanmei
   Tseng, Wei Ju
   Wang, Bin
TI Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via
   1,25 Dihydroxyvitamin D/osteocalcin Signaling Pathway
SO ENDOCRINOLOGY
LA English
DT Article
DE abaloparatide; osteocalcin; carboxylation; 1; 25 dihydroxyvitamin D;
   blood calcium; bone biomarker
ID PARATHYROID HORMONE; VITAMIN D; UNDERCARBOXYLATED OSTEOCALCIN;
   BONE FORMATION; SERUM LEVELS; PROTEIN; HOMEOSTASIS; KIDNEY;
   HYPERCALCEMIA; METABOLISM
AB The PTH related peptide(1 34) analog, abaloparatide (ABL), is the second anabolic drug available for the treatment of osteoporosis. Previous research demonstrated that ABL had a potent anabolic effect but caused hypercalcemia at a significantly lower rate. However, the mechanism by which ABL maintains the stability of blood calcium levels remains poorly understood. Our in vivo data showed that ABL treatment (40 & mu;g/kg/day for 7 days) significantly increased rat blood level of 1,25 dihydroxyvitamin D [1,25 (OH)(2)D] without raising the blood calcium value. ABL also significantly augmented the carboxylated osteocalcin (Gla Ocn) in the blood and bone that is synthesized by osteoblasts, and increased noncarboxylated Ocn, which is released from the bone matrix to the circulation because of osteoclast activation. The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25 (OH)(2)D synthesis and Gla Ocn formation in nonrenal cells (rat osteoblast like cells). However, ABL significantly promoted both 1,25 (OH)(2)D and Gla Ocn formation when 25 hydroxyvitamin D, the substrate of 1 & alpha; hydroxylase, was added to the cells. Thus, the increased 1,25 (OH)(2)D levels in rats treated by ABL result in high levels of Gla Ocn and transient calcium increase in the circulation. Gla Ocn then mediates calcium ions in the extracellular fluid at bone sites to bind to hydroxyapatite at bone surfaces. This regulation by Gla Ocn at least, in part, maintains the stability of blood calcium levels during ABL treatment. We conclude that the signaling pathway of ABL/1,25 (OH)(2)D/Gla Ocn contributes to calcium homeostasis and may help understand the mechanism of ABL for osteoporosis therapy.
C1 [Yang, Yanmei; Tseng, Wei Ju; Wang, Bin] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Med, Philadelphia, PA 19107 USA.
   [Wang, Bin] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
C3 Thomas Jefferson University; Thomas Jefferson University
RP Wang, B (通讯作者)，Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Med, Philadelphia, PA 19107 USA.
EM bin.wang@jefferson.edu
RI ; Tseng, Wei Ju/AAC 2819 2022
OI Wang, Bin/0000 0002 5396 6111; 
FU National Institutes of Health [R01DK119280, R01AR077666, R01AG071025]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01DK119280, R01AR077666, and R01AG071025 to B.W.
CR Anderson RL, 2010, AM J PHYSIOL ENDOC M, V299, pE959, DOI 10.1152/ajpendo.00218.2010
   Armbrecht HJ, 1998, ENDOCRINOLOGY, V139, P3375, DOI 10.1210/en.139.8.3375
   Binkley N, 2009, J BONE MINER RES, V24, P983, DOI [10.1359/JBMR.081254, 10.1359/jbmr.081254]
   Dempster DW, 2021, J BONE MINER RES, V36, P644, DOI 10.1002/jbmr.4243
   Diegel CR, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008361
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Dusso AS, 2011, KIDNEY INT SUPPL, V1, P136, DOI 10.1038/kisup.2011.30
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   FRASER DR, 1973, NATURE NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   HENRY HL, 1985, ENDOCRINOLOGY, V116, P503, DOI 10.1210/endo 116 2 503
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200
   Kägi L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195427
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lambert LJ, 2016, DIS MODEL MECH, V9, P1169, DOI 10.1242/dmm.025247
   LIAN JB, 1985, J BIOL CHEM, V260, P8706
   Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Maser RE, 2018, ENDOCR RES, V43, P21, DOI 10.1080/07435800.2017.1369432
   Matikainen N, 2021, ENDOCRIN METAB CLIN, V50, P575, DOI 10.1016/j.ecl.2021.07.005
   Matsumoto T, 2022, J CLIN ENDOCR METAB, V107, pE4222, DOI 10.1210/clinem/dgac486
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moriishi T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008586
   Nakayama K, 1996, J CLIN ENDOCR METAB, V81, P607, DOI 10.1210/jc.81.2.607
   PRICE PA, 1981, BIOCHEM BIOPH RES CO, V99, P928, DOI 10.1016/0006 291X(81)91252 3
   Samadfam R, 2008, J BONE MINER RES, V23, P1257, DOI 10.1359/JBMR.080318
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Talmage RV, 2009, GEN COMP ENDOCR, V162, P245, DOI 10.1016/j.ygcen.2009.03.027
   Teguh DA, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115801
   van Driel M, 2006, FASEB J, V20, P2417, DOI 10.1096/fj.06 6374fje
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Vitale JA, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.669704
   Wang B, 2009, MOL PHARMACOL, V75, P1189, DOI 10.1124/mol.108.054486
   Wang W, 1999, EUR J CLIN INVEST, V29, P309
   Yang Y., 2023, Data from: abaloparatide maintains normal rat blood calcium levels in part via 1,25 dihydroxyvitamin D/osteocalcin signaling pathway, DOI [10.6084/m9.figshare.23726451, DOI 10.6084/M9.FIGSHARE.23726451]
   Yang YM, 2019, BIOCHEM BIOPH RES CO, V509, P960, DOI 10.1016/j.bbrc.2019.01.049
   Yang YM, 2017, MOL BIOL CELL, V28, P1792, DOI 10.1091/mbc.E17 02 0096
   ZERWEKH JE, 1985, J CLIN ENDOCR METAB, V60, P615, DOI 10.1210/jcem 60 3 615
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 45
TC 3
Z9 3
U1 2
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG 1
PY 2023
VL 164
IS 9
AR bqad117
DI 10.1210/endocr/bqad117
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA P0WT6
UT WOS:001047936500001
PM 37493045
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Toriumi, S
   Kobayashi, A
   Sueki, H
   Yamamoto, M
   Uesawa, Y
AF Toriumi, Shinya
   Kobayashi, Akinobu
   Sueki, Hitoshi
   Yamamoto, Munehiro
   Uesawa, Yoshihiro
TI Exploring the Mechanisms Underlying Drug Induced Fractures Using the
   Japanese Adverse Drug Event Reporting Database
SO PHARMACEUTICALS
LA English
DT Article
DE drug induced fracture; atypical femoral fracture; bisphosphonates;
   denosumab; spontaneous reporting system; Japanese Adverse Drug Event
   Report (JADER); pharmacovigilance; volcano plot; multiple logistic
   regression analysis; principal component analysis
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   MEDICATION RELATED OSTEONECROSIS; ATYPICAL FEMORAL FRACTURES;
   RISK INCREASING DRUGS; SLEEP ATTACKS; ANTIRETROVIRAL THERAPY;
   POSTMENOPAUSAL WOMEN; PARKINSONS DISEASE; DOPAMINE AGONISTS
AB Fractures occur when bones become fragile and are subjected to external forces as occurring during falls. The use of drugs that increase bone fragility or fall risk increases the risk of fracture. This study investigates drug induced fractures reported in the Japanese Adverse Drug Event Report (JADER) database in patients using 4892 drugs. Atypical femur fracture was the most frequently reported fracture, and 58 other fractures were also reported. Using Volcano plots and multiple logistic regression analysis, we identified the risk factors for drug induced fractures as being female, of older age, higher body mass index, and using one of 90 drugs. The drug groups significantly associated with drug induced fractures included bone resorption inhibitors, antiviral drugs, dopaminergic drugs, corticosteroids, and sleep sedatives. Principal component analysis was used to examine the relationship between the use of specific drugs and the site of drug induced fracture. Bone resorption inhibitors and corticosteroids were associated with atypical femur fractures, jaw fractures, and ulna fractures through an osteoclast mediated process. Other drugs were found to increase fracture risk via non osteoclast mediated mechanisms. These findings suggest that many drugs can result in drug induced fractures through a variety of mechanisms.
C1 [Toriumi, Shinya; Uesawa, Yoshihiro] Meiji Pharmaceut Univ, Dept Med Mol Informat, Kiyose 2048588, Japan.
   [Toriumi, Shinya; Kobayashi, Akinobu] Natl Hosp Org Kanagawa Hosp, Dept Pharm, Hadano 2578585, Japan.
   [Sueki, Hitoshi; Yamamoto, Munehiro] Natl Hosp Org Kanagawa Hosp, Dept Orthoped Surg, Hadano 2578585, Japan.
C3 Meiji Pharmaceutical University
RP Toriumi, S; Uesawa, Y (通讯作者)，Meiji Pharmaceut Univ, Dept Med Mol Informat, Kiyose 2048588, Japan.; Toriumi, S (通讯作者)，Natl Hosp Org Kanagawa Hosp, Dept Pharm, Hadano 2578585, Japan.
EM sn.toriumi@gmail.com; kobayashi.akinobu.tk@mail.hosp.go.jp;
   hitoshi.sueki@gmail.com; mohey mohey@kanagawa hosp.org;
   uesawa@my pharm.ac.jp
RI ; , uesawa/AAA 1691 2020
OI toriumi, shinya/0000 0001 5521 0820; Uesawa,
   Yoshihiro/0000 0002 5773 991X; 
CR Abe K, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03824 y
   Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   Allcock LM, 2009, PARKINSONISM RELAT D, V15, P110, DOI 10.1016/j.parkreldis.2008.03.010
   [Anonymous], 1996, Arthritis Rheum, V39, P1791
   Arai K, 2006, J BONE MINER METAB, V24, P118, DOI 10.1007/s00774 005 0657 9
   Borderi M, 2009, AIDS, V23, P1297, DOI 10.1097/QAD.0b013e32832ce85a
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Chen JJ, 2007, PHARMACOGENOMICS J, V7, P212, DOI 10.1038/sj.tpj.6500412
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de Groot MH, 2013, DRUG AGING, V30, P901, DOI 10.1007/s40266 013 0113 9
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Ekstam AK, 2016, CLIN INTERV AGING, V11, P489, DOI 10.2147/CIA.S101832
   Feldstein AC, 2012, J BONE MINER RES, V27, P977, DOI 10.1002/jbmr.1550
   FitzGerald G, 2012, J BONE MINER RES, V27, P1907, DOI 10.1002/jbmr.1652
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fujiwara S, 2003, J BONE MINER RES, V18, P1547, DOI 10.1359/jbmr.2003.18.8.1547
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Hirooka T., 2012, P SAS USER GEN ASSEM, P263
   Homann CN, 2002, BMJ BRIT MED J, V324, P1483, DOI 10.1136/bmj.324.7352.1483
   Hosoya R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172057
   Iki M, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 165
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P897, DOI 10.1007/s00198 004 1627 0
   Jolliffe I T., 2002, Principal Component Analysis (Springer Series in Statistics), V2nd ed., P338
   Kan Y, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 88958 2
   Kang Dong Yoon, 2012, J Prev Med Public Health, V45, P219, DOI 10.3961/jpmph.2012.45.4.219
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kurosaki K, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070944
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Lumini A, 2018, CURR PHARM DESIGN, V24, P4007, DOI 10.2174/1381612824666181112113438
   Manolagas SC, 2000, J BONE MINER RES, V15, P1001, DOI 10.1359/jbmr.2000.15.6.1001
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   Matinolli M, 2011, ACTA NEUROL SCAND, V123, P193, DOI 10.1111/j.1600 0404.2010.01386.x
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Nagai J, 2017, CLIN J PAIN, V33, P667, DOI 10.1097/AJP.0000000000000457
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Okunaka M, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14070681
   Palvanen M, 2000, OSTEOPOROSIS INT, V11, P822, DOI 10.1007/s001980070040
   Pariente A, 2008, DRUG AGING, V25, P61, DOI 10.2165/00002512 200825010 00007
   Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183
   Paus S, 2003, MOVEMENT DISORD, V18, P659, DOI 10.1002/mds.10417
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sánchez A, 2017, OSTEOPOROSIS INT, V28, P1145, DOI 10.1007/s00198 016 3840 z
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Seppala LJ, 2018, J AM MED DIR ASSOC, V19, DOI 10.1016/j.jamda.2017.12.098
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Takahashi M, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6236 6
   Tan SHS, 2015, OSTEOPOROSIS INT, V26, P421, DOI 10.1007/s00198 014 2885 0
   Taormina DP, 2014, BONE, V63, P1, DOI 10.1016/j.bone.2014.02.006
   Thompson RN, 2014, BONE, V61, P44, DOI 10.1016/j.bone.2013.12.027
   Thorell K, 2014, BMC GERIATR, V14, DOI 10.1186/1471 2318 14 131
   Toriumi S, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13120467
   van Geel TACM, 2009, EUR J ENDOCRINOL, V160, P681, DOI 10.1530/EJE 08 0702
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Velasco S, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0171 6
   Walsh JS, 2013, NAT REV ENDOCRINOL, V9, P637, DOI 10.1038/nrendo.2013.171
   Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344
   Watanabe H., 2004, Jpn J Biomet, V25, P37, DOI [10.5691/jjb.25.37, DOI 10.5691/JJB.25.37]
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357
   Yeung EYH, 2014, MOV DISORD CLIN PRAC, V1, P307, DOI 10.1002/mdc3.12063
   Yoshimura N, 1999, CALCIFIED TISSUE INT, V65, P198
   Zenke Yukichi, 2016, Journal of UOEH, V38, P207, DOI 10.7888/juoeh.38.207
NR 70
TC 7
Z9 8
U1 0
U2 8
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD DEC
PY 2021
VL 14
IS 12
AR 1299
DI 10.3390/ph14121299
PG 18
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XX9OI
UT WOS:000736615000001
PM 34959699
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schott, S
   Vallet, S
   Tower, RJ
   Noor, S
   Tiwari, S
   Schem, C
   Busch, C
AF Schott, Sarah
   Vallet, Sonia
   Tower, Robert J.
   Noor, Seema
   Tiwari, Sanjay
   Schem, Christian
   Busch, Christian
TI In vitro and in vivo toxicity of 5 FdU alendronate, a novel cytotoxic
   bone seeking duplex drug against bone metastasis
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Bone metastasis; Chemotherapy; Bisphosphonate antimetabolite;
   Bone targeting; Duplex drug
ID BREAST CANCER; CELL LINES; BISPHOSPHONATES; CONJUGATE; AGENT; MODEL;
   OSTEOSARCOMA; METHOTREXATE; MELANOMA; DELIVERY
AB Background Bone remains one of the most common anatomic sites for cancer metastases, and the limited therapeutic options aggravate cancer related morbidity and mortality in multiple malignancies. The covalent conjugation of the amino bisphosphonate alendronate (ale) with the antimetabolite 5 fluoro 2' desoxyuridine (5 FdU) results in N 4 (butyl (4 hydroxy 4 phosphono)phosphate) 5 fluoro 2' desoxyuridine (5 FdU alendronat, 5 FdU ale), an effective, novel bone targeting duplex drug directed against skeletal cancer manifestations. Methods In vitro cytotoxicity of ale, 5 FdU or 5 FdU ale was measured with Alamar Blue and MUH cell viability assays in 14 malignant melanoma, multiple myeloma, bone marrow derived stromal cell and osteoblast like cell lines. In vivo toxicity was evaluated using the chicken embryo assay and evaluation of nephrotoxicity and the systemic toxicity in Balb/c nude mice. The effect of 5 FdU ale on osteoclast was evaluated with Balb/c nude mice in a metastatic breast cancer mouse model. Results A cell line specific, dose related cytotoxicity was observed for 5 FdU ale in all cancer cell lines tested, which was significantly less toxic than 5 FdU alone when compared to the benign osteoblasts or stromal cells. The embryotoxicity of 5 FdU ale was significantly less than that of the parental drugs alendronate or 5 FdU. 5 FdU ale showed no signs of unwanted side effects, weight loss or nephrotoxicity in mice. In a bone metastasis mouse model, 5 FdU ale reduced the number of tumor associated osteoclasts. Conclusion The coupling of an amino bisphosphonate with an antimetabolite via an N alkyl bonding offers a new strategy for the preparation of amino bisphosphonates conjugates with a cancer cell specific, efficacious cytotoxic bone targeting potential along with a reduced systemic toxicity. The innovative duplex drug 5 FdU ale therefore warrants further clinical investigation.
C1 [Schott, Sarah] Heidelberg Univ, Dept Gynecol & Obstet, D 69120 Heidelberg, Germany.
   [Schott, Sarah; Vallet, Sonia] Univ Heidelberg Hosp, Dept Med Oncol, Natl Ctr Tumor Dis Heidelberg, D 69120 Heidelberg, Germany.
   [Tower, Robert J.; Tiwari, Sanjay] Univ Hosp Schleswig Holstein, Sect Biomed Imaging, Dept Radiol & Neuroradiol, D 24118 Kiel, Germany.
   [Noor, Seema; Busch, Christian] Univ Tubingen, Sect Dermatooncol, Dept Dermatol & Allergol, D 72076 Tubingen, Germany.
   [Schem, Christian] Univ Med Ctr Schleswig Holstein, Dept Gynecol & Obstet, D 24105 Kiel, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; University of Kiel; Schleswig Holstein University Hospital;
   Eberhard Karls University of Tubingen; University of Kiel; Schleswig
   Holstein University Hospital
RP Schott, S (通讯作者)，Heidelberg Univ, Dept Gynecol & Obstet, Neuenheimer Feld 460, D 69120 Heidelberg, Germany.
EM sarah.schott@med.uni heidelberg.de
RI ; Vallet, Sonia/AHE 3935 2022; Tiwari, Sanjay/Q 1853 2016; Schott,
   Sarah/D 5242 2018
OI Vallet, Sonia/0000 0003 0146 8089; Tiwari, Sanjay/0000 0002 3804 3300;
   Schott, Sarah/0000 0002 1714 1147; Tower, Robert/0000 0001 5856 5758
FU DFG [SFB 773]; University of Heidelberg; Stiftung fur Krebs und
   Scharlachforschung Mannheim
FX The research was conducted in the absence of any commercial or financial
   relationships that could be construed as a potential conflict of
   interest. This work was supported by grants from the DFG SFB 773:
   "Understanding and overcoming drug resistance of solid tumors" to CB. SS
   received a research scholarship from the University of Heidelberg. SS
   and SV received a research grant from the "Stiftung fur Krebs und
   Scharlachforschung Mannheim". The sponsors had no involvement in the
   study design, the collection, analysis and interpretation of data, the
   writing of the manuscript or in the decision to submit the manuscript
   for publication.
CR Barcellos Hoff MH, 2013, NAT REV CANCER, V13, P511, DOI 10.1038/nrc3536
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   El Mabhouh AA, 2011, ONCOL RES, V19, P287, DOI 10.3727/096504011X13021877989874
   Fabulet O, 1995, PHOSPHORUS SULFUR, V101, P225, DOI 10.1080/10426509508042521
   Fechner S, 2008, ULTRASOUND OBST GYN, V31, P277, DOI 10.1002/uog.5244
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   HARIGAYA K, 1985, P NATL ACAD SCI USA, V82, P3477, DOI 10.1073/pnas.82.10.3477
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hosain F, 1996, J NUCL MED, V37, P105
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555 013 9420 1
   Schem C, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 32
   Schott H, 2011, BIOORGAN MED CHEM, V19, P3520, DOI 10.1016/j.bmc.2011.04.015
   Schott S, 2012, INT J CANCER, V131, P2165, DOI 10.1002/ijc.27476
   Schott S, 2012, INVEST NEW DRUG, V30, P1750, DOI 10.1007/s10637 011 9688 3
   STEWART WR, 1978, J BONE JOINT SURG AM, V60, P645, DOI 10.2106/00004623 197860050 00009
   STURTZ G, 1992, EUR J MED CHEM, V27, P825, DOI 10.1016/0223 5234(92)90117 J
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Tower RJ, 2015, BONE, V74, P171, DOI 10.1016/j.bone.2015.01.009
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weinreich J, 2012, ANTICANCER RES, V32, P4299
   WINGEN F, 1986, J CANCER RES CLIN, V111, P209, DOI 10.1007/BF00389236
NR 26
TC 10
Z9 10
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167 6997
EI 1573 0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD AUG
PY 2015
VL 33
IS 4
BP 816
EP 826
DI 10.1007/s10637 015 0253 3
PG 11
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA CM1TH
UT WOS:000357462700004
PM 25986684
DA 2025 08 17
ER

PT J
AU Cusano, NE
   Bilezikian, JP
AF Cusano, Natalie E.
   Bilezikian, John P.
TI Combination Anabolic and Antiresorptive Therapy for Osteoporosis
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Combination therapy; PTH(1 34); Teriparatide; PTH(1 84); Antiresorptive;
   Bisphosphonate
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS; FRACTURE RISK
   REDUCTION; PARATHYROID HORMONE; POSTMENOPAUSAL OSTEOPOROSIS;
   CONTROLLED TRIAL; TERIPARATIDE TREATMENT; RALOXIFENE THERAPY; ZOLEDRONIC
   ACID; DOUBLE BLIND
AB Osteoanabolic agents directly stimulate bone formation to improve bone mass and skeletal microarchitecture. At present, parathyroid hormone (PTH), in the form of the full length molecule (PTH(1 84)) and its fully active, but truncated amino terminal fragment, PTH(1 34) (teriparatide), are the only medications that belong to the osteoanabolic class. It is appealing to consider simultaneous combination therapy with antiresorptive and osteoanabolic drugs as potentially more beneficial than monotherapy with either class, given that their mechanisms of action differ. This review focuses on the research that has been conducted on combination therapy with PTH and an antiresorptive drug.
C1 [Cusano, Natalie E.; Bilezikian, John P.] Columbia Univ Coll Phys & Surg, Dept Med, Div Endocrinol, New York, NY 10032 USA.
C3 Columbia University
RP Bilezikian, JP (通讯作者)，Columbia Univ Coll Phys & Surg, Dept Med, Div Endocrinol, 630 W 168th St,PH 8W 864, New York, NY 10032 USA.
EM jpb2@columbia.edu
FU NPS Pharmaceuticals; GSK
FX Dr Bilezikian is a consultant for Eli Lilly, NPS Pharmaceuticals, Merck,
   Warner Chilcott, GSK, Novartis, and Amgen, and receives research support
   from NPS Pharmaceuticals and GSK. Dr Cusano has no conflicts of interest
   to report.
CR Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Boonen S, 2011, CURR MED RES OPIN, V27, P1149, DOI 10.1185/03007995.2011.573545
   Cosman F, 2008, OSTEOPOROSIS INT, V19, P529, DOI 10.1007/s00198 007 0475 0
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cusano N.E., 2010, IBMS BoneKEy, V7, P84
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   GASSER JA, 2006, AM SOC BON MIN RES 2
   Graeff C, 2007, J BONE MINER RES, V22, P1426, DOI 10.1359/jbmr.070603
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198 004 1636 z
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
NR 33
TC 21
Z9 25
U1 0
U2 7
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2012
VL 41
IS 3
BP 643
EP +
DI 10.1016/j.ecl.2012.04.005
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 000IO
UT WOS:000308380100012
PM 22877434
DA 2025 08 17
ER

PT J
AU Kwak, SC
   Cheon, YH
   Lee, CH
   Jun, HY
   Yoon, KH
   Lee, MS
   Kim, JY
AF Kwak, Sung Chul
   Cheon, Yoon Hee
   Lee, Chang Hoon
   Jun, Hong Young
   Yoon, Kwon Ha
   Lee, Myeung Su
   Kim, Ju Young
TI Grape Seed Proanthocyanidin Extract Prevents Bone Loss via Regulation of
   Osteoclast Differentiation, Apoptosis, and Proliferation
SO NUTRIENTS
LA English
DT Article
DE grape seed proanthocyanidin extract; osteoclast; proliferation;
   differentiation; apoptosis; bone disease
ID ACTIVATION; MECHANISM; HEALTH; RANKL
AB Dietary procyanidin has been shown to be an important bioactive component that regulates various pharmacological activities to maintain metabolic homeostasis. In particular, grape seed proanthocyanidin extract (GSPE) is a commercially available medicine for the treatment of venous and lymphatic dysfunction. This study aimed to investigate whether GSPE protects against lipopolysaccharide (LPS) induced bone loss in vivo and the related mechanism of action in vitro. The administration of GSPE restored the inflammatory bone loss phenotype stimulated by acute systemic injection of LPS in vivo. GSPE strongly suppressed receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and bone resorption activity of mature osteoclasts by decreasing the RANKL induced nuclear factor kappa B transcription activity. GSPE mediates this effect through decreased phosphorylation and degradation of NF kappa B inhibitor (I kappa B) by I kappa B kinase beta, subsequently inhibiting proto oncogene cellular Fos and nuclear factor of activated T cells. Additionally, GSPE promotes osteoclast proliferation by increasing the phosphorylation of components of the Akt and mitogen activated protein kinase signaling pathways and it also inhibits apoptosis by decreasing the activity of caspase 8, caspase 9, and caspase 3, as corroborated by a decrease in the Terminal deoxynucleotidyl transferase dUTP nick end labeling  positive cells. Our study suggests a direct effect of GSPE on the proliferation, differentiation, and apoptosis of osteoclasts and reveals the mechanism responsible for the therapeutic potential of GSPE in osteoclast associated bone metabolism disease.
C1 [Kwak, Sung Chul] Wonkwang Univ, Sch Med, Dept Anat, Iksan 54538, South Korea.
   [Cheon, Yoon Hee; Lee, Chang Hoon; Lee, Myeung Su; Kim, Ju Young] Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, Iksan 54538, South Korea.
   [Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, Iksan 54538, South Korea.
   [Jun, Hong Young; Yoon, Kwon Ha] Wonkwang Univ Hosp, Med Convergence Res Ctr, Iksan 54538, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Lee, MS; Kim, JY (通讯作者)，Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, Iksan 54538, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, Iksan 54538, South Korea.
EM ksc960@naver.com; hanleuni@naver.com; lch110@wonkwang.ac.kr;
   zip80@wku.ac.kr; khy1646@wku.ac.kr; ckhlms@wku.ac.kr;
   kimjy1014@gmail.com
RI ; Lee, Sang Hoon/ABH 6210 2020
OI Kim, Ju Young/0000 0002 4493 0264; Yoon, Kwon Ha/0000 0002 2634 8510
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2018R1D1A1B07049679,
   NRF 2019R1I1A1A02059434]
FX This study was supported by a grant from the Basic Science Research
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education (NRF 2018R1D1A1B07049679 and
   NRF 2019R1I1A1A02059434).
CR Bagchi D, 2014, MUTAT RES FUND MOL M, V768, P69, DOI 10.1016/j.mrfmmm.2014.04.004
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cho ML, 2009, IMMUNOL LETT, V124, P102, DOI 10.1016/j.imlet.2009.05.001
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Henriet J. P., 1993, Phlebologie, V46, P313
   Huang WC, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 3
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jhun JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078843
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779 6798.2000
   Lerner UH, 2019, PEDIATR ENDOCR REV P, V17, P84, DOI 10.17458/per.vol17.2019.l.osteoclastshealthdisease
   Li WG, 2001, ACTA PHARMACOL SIN, V22, P1117
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma ZF, 2017, ANTIOXIDANTS BASEL, V6, DOI 10.3390/antiox6030071
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Song QC, 2015, J ORTHOP SCI, V20, P196, DOI 10.1007/s00776 014 0654 8
   Soysa NS, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100225
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tofani I., 2004, Pediatr Dent J, V14, P47
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Woo YJ, 2011, EXP MOL MED, V43, P561, DOI 10.3858/emm.2011.43.10.062
   Xhu W., 2019, BIOCHEM BIOPH RES CO, V509, P294
   Yahara N., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P162
NR 31
TC 32
Z9 35
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2020
VL 12
IS 10
AR 3164
DI 10.3390/nu12103164
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA ON8GE
UT WOS:000586931300001
PM 33081167
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhu, XQ
   Zhao, YH
   Jiang, YX
   Qin, TX
   Chen, JT
   Chu, X
   Yi, Q
   Gao, SJ
   Wang, SQ
AF Zhu, Xiaoqing
   Zhao, Yinghua
   Jiang, Yuxue
   Qin, Tianxue
   Chen, Jintong
   Chu, Xiao
   Yi, Qing
   Gao, Sujun
   Wang, Siqing
TI Dectin 1 signaling inhibits osteoclastogenesis via IL 33 induced
   inhibition of NFATc1
SO ONCOTARGET
LA English
DT Article
DE osteoclast; dectin 1; NFATc1; IL 33; multiple myeloma
ID MYELOMA BONE DISEASE; MULTIPLE MYELOMA; RHEUMATOID ARTHRITIS;
   THERAPEUTIC TARGET; CELLS; BISPHOSPHONATES; RECEPTOR; INTERLEUKIN 33;
   OSTEOPOROSIS; RECOGNITION
AB Abnormal osteoclast activation contributes to osteolytic bone diseases (OBDs). It was reported that curdlan, an agonist of dectin 1, inhibits osteoclastogenesis. However, the underlying mechanisms are not fully elucidated. In this study, we found that curdlan potently inhibited RANKL induced osteoclast differentiation and the resultant bone resorption. Curdlan inhibited the expression of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), the key transcriptional factor for osteoclastogenesis. Notably, dectin 1 activation increased the expression of MafB, an inhibitor of NFATc1, and IL 33 in osteoclast precursors. Mechanistic studies revealed that IL 33 enhanced the expression of MafB in osteoclast precursors and inhibited osteoclast precursors to differentiate into mature osteoclasts. Furthermore, blocking ST2, the IL 33 receptor, partially abrogated curdlan induced inhibition of NFATc1 expression and osteoclast differentiation. Thus, our study has provided new insights into the mechanisms of dectin 1 induced inhibition of osteoclastogenesis and may provide new targets for the therapy of OBDs.
C1 [Zhu, Xiaoqing; Qin, Tianxue; Gao, Sujun] Jilin Univ, Hosp 1, Dept Hematol, Changchun 130061, Jilin, Peoples R China.
   [Zhao, Yinghua; Jiang, Yuxue; Chen, Jintong; Chu, Xiao; Yi, Qing; Wang, Siqing] Jilin Univ, Hosp 1, Inst Translat Med, Dept Canc Immunol, Changchun 130061, Jilin, Peoples R China.
   [Yi, Qing] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.
   [Zhu, Xiaoqing] Ningbo Hangzhou Bay Hosp, Dept Hematol, Ningbo 315336, Zhejiang, Peoples R China.
C3 Jilin University; Jilin University; Cleveland Clinic Foundation
RP Gao, SJ (通讯作者)，Jilin Univ, Hosp 1, Dept Hematol, Changchun 130061, Jilin, Peoples R China.; Wang, SQ (通讯作者)，Jilin Univ, Hosp 1, Inst Translat Med, Dept Canc Immunol, Changchun 130061, Jilin, Peoples R China.
EM sujung1963@sina.com; siw1970@yahoo.com
RI Chen, Jintong/JCO 5814 2023
FU First Hospital of Jilin University; National Natural Science Foundation
   of China [81372536, 81502452, 81602485]; Science and Technology
   department of Jilin Province [20160101140J]; Jinlin Health Department
   [2015Z003]
FX This work was supported by startup fund from The First Hospital of Jilin
   University and grants from National Natural Science Foundation of China
   (No. 81372536, 81502452 and 81602485), and by grants from Science and
   Technology department of Jilin Province (20160101140J) and Jinlin Health
   Department (2015Z003). We thank G. Brown (University of Aberdeen,
   Aberdeen, Scotland) for providing dectin 1 deficiency mice.
CR Aung K, 2017, ANN INTERN MED, V166, pJC34, DOI 10.7326/ACPJC 2017 166 6 034
   Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620
   Eda Homare, 2016, Cancer Treat Res, V169, P251
   Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013
   Hyung KE, 2016, INT IMMUNOPHARMACOL, V32, P125, DOI 10.1016/j.intimp.2016.01.020
   Karnam A, 2015, MOL IMMUNOL, V68, P280, DOI 10.1016/j.molimm.2015.09.013
   Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Lee EG, 2014, JOINT BONE SPINE, V81, P520, DOI 10.1016/j.jbspin.2014.04.012
   Lefrançais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111
   Lüthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007
   McCarthy HS, 2010, EXPERT OPIN THER TAR, V14, P221, DOI 10.1517/14728220903525720
   Miller CH, 2016, J IMMUNOL, V196, P4977, DOI 10.4049/jimmunol.1502044
   Modi ND, 2012, LEUKEMIA, V26, P589, DOI 10.1038/leu.2011.282
   Nose M, 2009, J BONE MINER METAB, V27, P57, DOI 10.1007/s00774 008 0011 0
   Nunes T, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/423957
   Ohno T, 2009, J IMMUNOL, V183, P7890, DOI 10.4049/jimmunol.0802449
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Park JH, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1514 4
   Pathak JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131041
   Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756 3282(01)00654 8
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Rosean TR, 2014, IMMUNOL RES, V59, P188, DOI 10.1007/s12026 014 8528 x
   Saleh H, 2011, ENDOCRINOLOGY, V152, P1911, DOI 10.1210/en.2010 1268
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Sezer O, 2009, ONCOLOGIST, V14, P276, DOI 10.1634/theoncologist.2009 0003
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wanasaengsakul S, 2004, MICROB PATHOGENESIS, V36, P211, DOI 10.1016/j.micpath.2003.12.003
   Yamasaki T, 2014, J BIOL CHEM, V289, P19191, DOI 10.1074/jbc.M114.551416
   Zhao YH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12368
NR 34
TC 19
Z9 22
U1 2
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 8
PY 2017
VL 8
IS 32
BP 53366
EP 53374
DI 10.18632/oncotarget.18411
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FC8XE
UT WOS:000407124100110
PM 28881817
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, M
   Kim, JH
   Hong, S
   Lee, S
   Lee, SH
   Choi, JW
   Jung, HS
   Sohn, Y
AF Kim, Minsun
   Kim, Jae Hyun
   Hong, Sooyeon
   Lee, Sumin
   Lee, Seung Hoon
   Choi, Jun Won
   Jung, Hyuk Sang
   Sohn, Youngjoo
TI Dolichos Lablab Linne Inhibits Bone Density Loss and Promotes Bone Union
   in Senile Osteoporosis through Osteogenesis
SO PHARMACEUTICALS
LA English
DT Article
DE Dolichos lablab Linne; osteoblast; senile osteoporosis; fractured model;
   BMP 2; Wnt
ID OSTEOBLAST DIFFERENTIATION; MATRIX MINERALIZATION; EXPRESSION;
   BISPHOSPHONATES; MARKERS
AB As populations continue to age, osteoporosis has emerged as an increasingly critical concern. Most advancements in osteoporosis treatment are predominantly directed toward addressing abnormal osteoclast activity associated with menopause, with limited progress in developing therapies that enhance osteoblast activity, particularly in the context of aging and fractures, and serious side effects associated with existing treatments have highlighted the necessity for natural product based treatments targeting senile osteoporosis and fractures. Dolichos lablab Linne (DL) is a natural product traditionally used for gastrointestinal disorders, and its potential role in addressing bone diseases has not been extensively studied. In this research, we investigated the anti osteoporosis and bone union stimulating effects of DL using the SAMP6 model, a naturally aged mouse model. Additionally, we employed MC3T3 E1 cells to validate DL's osteoblast promoting effect and to assess the involvement of core mechanisms such as the BMP 2/Smad and Wnt/beta catenin pathways. The experimental results revealed that DL promoted the formation of osteoblasts and calcified nodules by upregulating both the BMP 2/Smad and Wnt/beta catenin mechanisms. Based on its observed effects, DL demonstrated the potential to enhance bone mineral density in aged osteoporotic mice and promote bone union in fractured mice. These findings indicate the promising therapeutic potential of DL for the treatment of osteoporosis and bone related conditions, thus warranting further investigation and potential clinical applications.
C1 [Kim, Minsun; Kim, Jae Hyun; Hong, Sooyeon; Lee, Sumin; Lee, Seung Hoon; Choi, Jun Won; Jung, Hyuk Sang; Sohn, Youngjoo] Kyung Hee Univ, Coll Korean Med, Dept Anat, Seoul 02447, South Korea.
C3 Kyung Hee University
RP Jung, HS; Sohn, Y (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Anat, Seoul 02447, South Korea.
EM alstjs8644@naver.com; jhk1@khu.ac.kr; ghdtndus121@naver.com;
   00sumin0209@naver.com; sknight2230@naver.com; wnsdnjs5805@gmail.com;
   jhs@khu.ac.kr; youngjoos@khu.ac.kr
RI ; Choi, Jun Won/L 1202 2016; Lee, Seunghoon/A 6892 2012
OI Kim, Jae hyun/0000 0003 3593 3049; Sohn, Youngjoo/0000 0002 2159 1386;
   Jung, Hyuk Sang/0000 0002 7256 9672; sooyeon, hong/0000 0002 2492 3980; 
FU Korea Health Industry Development Institute (KHIDI)   Ministry of Health
   and Welfare, Republic of Korea [HF21C0092]
FX This work was supported by a grant from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health and Welfare, Republic of Korea (Grant
   Number: HF21C0092)
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Azuma K, 2018, MED MOL MORPHOL, V51, P139, DOI 10.1007/s00795 018 0188 9
   Brennan Speranza TC, 2015, CALCIFIED TISSUE INT, V96, P1, DOI 10.1007/s00223 014 9931 y
   Burghardt AJ, 2011, CLIN ORTHOP RELAT R, V469, P2179, DOI 10.1007/s11999 010 1766 x
   Chen H, 2004, HISTOL HISTOPATHOL, V19, P677, DOI 10.14670/HH 19.677
   Chen HY, 2009, EXP GERONTOL, V44, P792, DOI 10.1016/j.exger.2009.09.009
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Chun E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101475
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Garcia T, 2002, BONE, V31, P205, DOI 10.1016/S8756 3282(02)00781 0
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Habib HM, 2017, FOOD FUNCT, V8, P872, DOI [10.1039/C6FO01162D, 10.1039/c6fo01162d]
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Hawarden A, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00766 9
   Hwang PW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44575 8
   Im AR, 2017, J MED FOOD, V20, P1222, DOI 10.1089/jmf.2017.4036
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Johnell O, 2004, Osteoporos Int, V15, P175
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Le PM, 2019, J PHARMACEUT BIOMED, V165, P155, DOI 10.1016/j.jpba.2018.11.062
   Sadat Ali M, 2017, SAUDI MED J, V38, P873, DOI 10.15537/smj.2017.8.20748
   Suh DH, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600895
   Uebelhart D, 2003, Z RHEUMATOL, V62, P512, DOI 10.1007/s00393 003 0560 5
   Vescini F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413640
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Vitaca T, 2022, LANCET DIABETES ENDO, V10, P273, DOI 10.1016/S2213 8587(22)00012 2
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530
NR 35
TC 2
Z9 2
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD OCT
PY 2023
VL 16
IS 10
AR 1350
DI 10.3390/ph16101350
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA W2CJ2
UT WOS:001089759300001
PM 37895821
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, CJ
   Shim, KS
   Ma, JY
AF Lee, Chung Jo
   Shim, Ki Shuk
   Ma, Jin Yeul
TI Artemisia capillaris Alleviates Bone Loss by Stimulating
   Osteoblast Mineralization and Suppressing Osteoclast Differentiation and
   Bone Resorption
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Artemisia capillaris; Receptor Activator of Nuclear Factor Kappa B
   Ligand; Osteoblast; Osteoclast; Osterix; Nuclear Factor of Activated T
   cells Cytoplasmic 1
ID NF KAPPA B; TRANSCRIPTIONAL REGULATION; RECEPTOR ACTIVATOR; C FOS;
   EXPRESSION; EXTRACT; FUSION; RANKL
AB Artemisia capillaris has been used to treat jaundice and relieve high liver heat in traditional medicine. In this study, we found that the administration of a water extract from A. capillaris (WEAC) to the receptor activator of nuclear factor kappa B ligand (RANKL)induced bone loss model significantly prevents osteoporotic bone loss, increasing bone volume/trabecular volume by 22% and trabecular number by 24%, and decreasing trabecular separation by 29%. WEAC stimulated in vitro osteoblast mineralization from primary osteoblasts in association with increasing expression of osterix, nuclear factor of activated T cells cytoplasmic 1, and activator protein 1, as well as phosphorylation of extracellular signal regulated kinase. In contrast to the anabolic effect of WEAC, WEAC significantly suppressed in vitro osteoclast formation from bone marrow macrophages by inhibiting the RANKL signaling pathways and bone resorption by downregulating the expression of resorption markers. Therefore, this study demonstrated that WEAC has a beneficial effect on bone loss through the regulation of osteoblast mineralization, as well as osteoclast formation and bone resorption. These results suggest that A. capillaris may be a promising herbal candidate for therapeutic agents to treat or prevent osteoporotic bone diseases.
C1 [Lee, Chung Jo; Shim, Ki Shuk; Ma, Jin Yeul] Korea Inst Oriental Med, KM Applicat Ctr, 70 Cheomdanro Dong Gu 41062, Daegu 701300, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Applicat Ctr, 70 Cheomdanro Dong Gu 41062, Daegu 701300, South Korea.
EM jyma@kiom.re.kr
FU Ministry of Science, ICT and Future Planning, Korea [K16281]
FX This work was supported by a grant (K16281) for the Korea Institute of
   Oriental Medicine from Ministry of Science, ICT and Future Planning,
   Korea. We thank Dr. Hyunil Ha and Dr. Taesoo Kim for helpful discussion.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Brandi M. L., 2009, RHEUMATOLOGY, P3
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Chen PQ, 2007, J BONE MINER RES, V22, P1173, DOI 10.1359/JBMR.070413
   Choi MK, 2013, J ETHNOPHARMACOL, V147, P662, DOI 10.1016/j.jep.2013.03.065
   Chun Kyung Soo, 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P131
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Ha H, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 352
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   서지은, 2011, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V40, P1532
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Iwamoto K, 2004, BIOCHEM BIOPH RES CO, V325, P229, DOI 10.1016/j.bbrc.2004.10.024
   Kim D. G., 2003, HERB MED PHARMACOGNO, P331
   Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Koo BS, 2004, PHYTOTHER RES, V18, P142, DOI 10.1002/ptr.1382
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lee JH, 2009, J BIOL CHEM, V284, P13725, DOI 10.1074/jbc.M806941200
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee S., 2013, IN VITRO IN VIVO PRO, P208
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li YJ, 2007, J ETHNOPHARMACOL, V113, P191, DOI 10.1016/j.jep.2007.04.020
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Scott JC, 1997, REV RHUM, V64, pS10
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu FF, 2013, J ETHNOPHARMACOL, V145, P403, DOI 10.1016/j.jep.2012.12.008
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zenger S, 2007, BONE, V41, P820, DOI 10.1016/j.bone.2007.07.010
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 41
TC 6
Z9 6
U1 0
U2 2
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2016
VL 44
IS 8
BP 1675
EP 1691
DI 10.1142/S0192415X16500944
PG 17
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA EF5PA
UT WOS:000390380900010
PM 27852127
DA 2025 08 17
ER

PT J
AU Song, DY
   He, GX
   Song, FF
   Wang, ZP
   Liu, XC
   Liao, LL
   Ni, JD
   Silva, MJ
   Long, FX
AF Song, Deye
   He, Guangxu
   Song, Fangfang
   Wang, Zhepeng
   Liu, Xiaochen
   Liao, Lele
   Ni, Jiangdong
   Silva, Matthew J.
   Long, Fanxin
TI Inducible expression of Wnt7b promotes bone formation in aged mice and
   enhances fracture healing
SO BONE RESEARCH
LA English
DT Article
ID SOST GENE; MUTATIONS; OSTEOBLASTS; WNT16; DIFFERENTIATION; METABOLISM;
   ACTIVATION; INCREASES; THERAPY; CELLS
AB There remain unmet clinical needs for safe and effective bone anabolic therapies to treat aging related osteoporosis and to improve fracture healing in cases of nonunion or delayed union. Wnt signaling has emerged as a promising target pathway for developing novel bone anabolic drugs. Although neutralizing antibodies against the Wnt antagonist sclerostin have been tested, Wnt ligands themselves have not been fully explored as a potential therapy. Previous work has demonstrated Wnt7b as an endogenous ligand upregulated during osteoblast differentiation, and that Wnt7b overexpression potently stimulates bone accrual in the mouse. The earlier studies however did not address whether Wnt7b could promote bone formation when specifically applied to aged or fractured bones. Here we have developed a doxycycline inducible strategy where Wnt7b is temporally induced in the bones of aged mice or during fracture healing. We report that forced expression of Wnt7b for 1 month starting at 15 months of age greatly stimulated trabecular and endosteal bone formation, resulting in a marked increase in bone mass. We further tested the effect of Wnt7b on bone healing in a murine closed femur fracture model. Induced expression of Wnt7b at the onset of fracture did not affect the initial cartilage formation but promoted mineralization of the subsequent bone callus. Thus, targeted delivery of Wnt7b to aged bones or fracture sites may be explored as a potential therapy.
C1 [Song, Deye; He, Guangxu; Liao, Lele; Ni, Jiangdong] Cent S Univ, Xiangya Hosp 2, Dept Orthoped, Changsha 410011, Hunan, Peoples R China.
   [Song, Deye; He, Guangxu; Wang, Zhepeng; Liu, Xiaochen; Silva, Matthew J.; Long, Fanxin] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.
   [Song, Fangfang; Long, Fanxin] Univ Penn, Childrens Hosp Philadelphia, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.
C3 Central South University; Washington University (WUSTL); University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.; Long, FX (通讯作者)，Univ Penn, Childrens Hosp Philadelphia, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.
EM longf1@email.chop.edu
RI ; liu, xiaochen/KJL 7936 2024
OI He, Guangxu/0000 0003 4084 8252; 
FU Washington University Musculoskeletal Research Center [AR060456,
   AR047867];  [NIH P30 AR057235]
FX The work is supported by AR060456 (F.L.), AR047867 (M.J.S.), and the
   Washington University Musculoskeletal Research Center (NIH P30
   AR057235).
CR Alam I, 2016, ENDOCRINOLOGY, V157, P722, DOI 10.1210/en.2015 1281
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Clark D, 2017, CURR OSTEOPOROS REP, V15, P601, DOI 10.1007/s11914 017 0413 9
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Joeng KS, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.4
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lee HH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000450
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lim J, 2016, DEVELOPMENT, V143, P339, DOI 10.1242/dev.126227
   Lin CX, 2009, GENESIS, V47, P352, DOI 10.1002/dvg.20506
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Malinauskas T, 2014, CURR OPIN STRUC BIOL, V29, P77, DOI 10.1016/j.sbi.2014.10.003
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   McBride Gagyi SH, 2015, BONE, V81, P533, DOI 10.1016/j.bone.2015.09.003
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Movérare Skrtic S, 2015, P NATL ACAD SCI USA, V112, P14972, DOI 10.1073/pnas.1520408112
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Payne JB, 2011, PHARMACOL RES, V63, P121, DOI 10.1016/j.phrs.2010.10.006
   Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Ramchand SK, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00505
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Shen LX, 2009, J CELL BIOCHEM, V106, P337, DOI 10.1002/jcb.22010
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Sun WW, 2016, BONE, V85, P1, DOI 10.1016/j.bone.2016.01.013
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 49
TC 40
Z9 42
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD FEB 3
PY 2020
VL 8
IS 1
AR 4
DI 10.1038/s41413 019 0081 8
PG 8
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KI2QS
UT WOS:000511195800001
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Negishi Koga, T
   Shinohara, M
   Komatsu, N
   Bito, H
   Kodama, T
   Friedel, RH
   Takayanagi, H
AF Negishi Koga, Takako
   Shinohara, Masahiro
   Komatsu, Noriko
   Bito, Haruhiko
   Kodama, Tatsuhiko
   Friedel, Roland H.
   Takayanagi, Hiroshi
TI Suppression of bone formation by osteoclastic expression of semaphorin
   4D
SO NATURE MEDICINE
LA English
DT Article
ID NERVOUS SYSTEM; OSTEOBLAST DIFFERENTIATION; BIOLOGICAL ACTIVITY; SOLUBLE
   CD100; GROWTH CONE; PDZ RHOGEF; B CELL; RECEPTORS; MECHANISMS; PLEXIN B1
AB Most of the currently available drugs for osteoporosis inhibit osteoclastic bone resorption; only a few drugs promote osteoblastic bone formation. It is thus becoming increasingly necessary to identify the factors that regulate bone formation. We found that osteoclasts express semaphorin 4D (Sema4D), previously shown to be an axon guidance molecule, which potently inhibits bone formation. The binding of Sema4D to its receptor Plexin B1 on osteoblasts resulted in the activation of the small GTPase RhoA, which inhibits bone formation by suppressing insulin like growth factor 1 (IGF 1) signaling and by modulating osteoblast motility. Sema4d( / ) mice, Plxnb1( / ) mice and mice expressing a dominant negative RhoA specifically in osteoblasts showed an osteosclerotic phenotype due to augmented bone formation. Notably, Sema4D specific antibody treatment markedly prevented bone loss in a model of postmenopausal osteoporosis. Thus, Sema4D has emerged as a new therapeutic target for the discovery and development of bone increasing drugs.
C1 [Negishi Koga, Takako; Shinohara, Masahiro; Komatsu, Noriko; Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Tokyo, Japan.
   [Negishi Koga, Takako; Shinohara, Masahiro; Komatsu, Noriko; Takayanagi, Hiroshi] Japan Sci & Technol Agcy, Takayanagi Osteonetwork Project, Tokyo, Japan.
   [Negishi Koga, Takako; Shinohara, Masahiro; Komatsu, Noriko; Takayanagi, Hiroshi] Int Res Ctr Mol Sci Tooth & Bone Dis, Global Ctr Excellence Program, Tokyo, Japan.
   [Bito, Haruhiko] Univ Tokyo, Dept Neurochem, Grad Sch Med, Tokyo, Japan.
   [Kodama, Tatsuhiko] Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo, Japan.
   [Friedel, Roland H.] Mt Sinai Sch Med, Dept Neurosurg, New York, NY USA.
   [Takayanagi, Hiroshi] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Japan Science & Technology Agency (JST); University of Tokyo; University
   of Tokyo; Icahn School of Medicine at Mount Sinai; University of Western
   Australia
RP Takayanagi, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Tokyo, Japan.
EM taka.csi@tmd.ac.jp
RI ; Bito, Haruhiko/A 8635 2008
OI Bito, Haruhiko/0000 0001 6315 9594; Friedel, Roland/0000 0002 7513 3604;
   Shinohara, Masahiro/0000 0002 5532 1042
FU Japan Science and Technology Agency; JSPS; Ministry of Education,
   Culture, Sports, Science and Technology of Japan; Ichiro Kanehara
   Foundation; Uehara Memorial Foundation; Naito Foundation; Grants in Aid
   for Scientific Research [22689048, 20670002, 23659149] Funding Source:
   KAKEN
FX We are grateful to G. Karsenty (Columbia University), K. Kobayashi
   (Fukushima Medical University School of Medicine), A. Kumanogoh (Osaka
   University) and T. Kitamura (The University of Tokyo) for kindly
   providing alpha(1)I Cre mice, CAT RhoA DN mice, recombinant Fc sema4D
   protein, and the retrovirus vectors and Plat E cells, respectively. We
   also thank E. Sumiya, A. Suematsu, Y. Kunisawa, T. Ando, K. Okamoto, T.
   Nakashima, M. Oh hora, M. Hayashi, A. Terashima, Y. Nagai and H. Negishi
   for discussion and assistance. This work was supported in part by a
   grant for the Exploratory Research for Advanced Technology, Takayanagi
   Osteonetwork Project from the Japan Science and Technology Agency,
   Grant in Aid for Young Scientist A, Grant in Aid for Challenging
   Exploratory Research and Grant in Aid for JSPS Fellows from the Japan
   Society for the Promotion of Science, a grant for the Global Center of
   Excellence Program from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan, and grants from the Ichiro Kanehara
   Foundation, the Uehara Memorial Foundation and the Naito Foundation.
CR Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Delaire S, 2001, J IMMUNOL, V166, P4348, DOI 10.4049/jimmunol.166.7.4348
   Delorme G, 2005, BIOL CELL, V97, P589
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165
   Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014 5793(02)03323 9
   Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341
   Friedel RH, 2005, P NATL ACAD SCI USA, V102, P13188, DOI 10.1073/pnas.0505474102
   Gomez C, 2005, DEV DYNAM, V234, P393, DOI 10.1002/dvdy.20512
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   HAYDEN JM, 1995, BONE, V17, P93
   Hirschberg A, 2010, MOL CELL BIOL, V30, P764, DOI 10.1128/MCB.01458 09
   Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Kitsukawa T, 1995, DEVELOPMENT, V121, P4309
   Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295 04.2004
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Koh JM, 2006, J HUM GENET, V51, P112, DOI 10.1007/s10038 005 0331 z
   Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740
   Kumanogoh A, 2002, J IMMUNOL, V169, P1175, DOI 10.4049/jimmunol.169.3.1175
   Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074 7613(00)00062 5
   Larrivée B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545
   Okuno T, 2010, J IMMUNOL, V184, P1499, DOI 10.4049/jimmunol.0903302
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200
   Regev A, 2005, FERTIL STERIL, V84, P1210, DOI 10.1016/j.fertnstert.2005.05.011
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Shi W, 2000, IMMUNITY, V13, P633, DOI 10.1016/S1074 7613(00)00063 7
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092 8674(00)81402 6
   Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534 5807(02)00162 4
   Sotobori T, 2006, EXP CELL RES, V312, P3927, DOI 10.1016/j.yexcr.2006.08.024
   Sutton ALM, 2008, MOL ENDOCRINOL, V22, P1370, DOI 10.1210/me.2007 0363
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200
   Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896 6273(02)00750 X
   TAKAHASHI H, 1964, Surg Forum, V15, P437
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416
   Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092 8674(00)80063 X
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962 8924(00)01816 X
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 55
TC 385
Z9 456
U1 0
U2 58
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2011
VL 17
IS 11
BP 1473
EP U181
DI 10.1038/nm.2489
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 844VV
UT WOS:000296779300039
PM 22019888
DA 2025 08 17
ER

PT J
AU Scarpa, E
   Janeczek, AA
   Hailes, A
   de Andrés, MC
   De Grazia, A
   Oreffo, ROC
   Newman, TA
   Evans, ND
AF Scarpa, Edoardo
   Janeczek, Agnieszka A.
   Hailes, Alethia
   de Andres, Maria C.
   De Grazia, Antonio
   Oreffo, Richard O. C.
   Newman, Tracey A.
   Evans, Nicholas D.
TI Polymersome nanoparticles for delivery of Wnt activating small molecules
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Polymersomes; Wnt; Drug delivery
ID BLOCK COPOLYMERS; FRACTURE REPAIR; DRUG DELIVERY; STEM CELLS; IN VIVO;
   BONE; VESICLES; THERAPY; DOXORUBICIN; INHIBITOR
AB Spatiotemporal control of drug delivery is important for a number of medical applications and may be achieved using polymersome nanoparticles (PMs). Wnt signalling is a molecular pathway activated in various physiological processes, including bone repair, that requires precise control of activation. Here, we hypothesise that PMs can be stably loaded with a small molecule Wnt agonist, 6 bromoindirubin 3' oxime (BIO), and activate Wnt signalling promoting the osteogenic differentiation in human primary bone marrow stromal cells (BMSCs). We showed that BIO PMs induced a 40% increase in Wnt signaling activation in reporter cell lines without cytotoxicity induced by free BIO. BMSCs incubated with BIO PMs showed a significant up regulation of the Wnt target gene AXIN2 (14 +/  4 fold increase, P < 0.001) and a prolonged activation of the osteogenic gene RUNX2. We conclude that BIO PMs could represent an innovative approach for the controlled activation of Wnt signaling for promoting bone regeneration after fracture. (C) 2018 The Authors. Published by Elsevier Inc.
C1 [Scarpa, Edoardo; Janeczek, Agnieszka A.; Hailes, Alethia; de Andres, Maria C.; De Grazia, Antonio; Oreffo, Richard O. C.; Evans, Nicholas D.] Univ Southampton, Fac Med, Ctr Human Dev Stem Cells & Regenerat, Bone & Joint Res Grp, Southampton, Hants, England.
   [Scarpa, Edoardo; Hailes, Alethia; Oreffo, Richard O. C.; Newman, Tracey A.; Evans, Nicholas D.] Univ Southampton, Ctr Biol Sci, Inst Life Sci, B85,Univ Rd, Southampton, Hants, England.
   [Evans, Nicholas D.] Univ Southampton, Fac Engn & Environm, Bioengn Sci Grp, Southampton, Hants, England.
   [Newman, Tracey A.] Univ Southampton, Clin & Expt Sci, Med, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; University of Southampton
RP Newman, TA; Evans, ND (通讯作者)，Univ Southampton, Ctr Biol Sci, Inst Life Sci, B85,Univ Rd, Southampton, Hants, England.
EM tan@soton.ac.uk; n.d.evans@soton.ac.uk
RI ; Oreffo, Richard/A 4615 2011; Scarpa, Edoardo/KII 5254 2024; Newman,
   Tracey A/I 8884 2012; de+Andrés, María/AAP 1473 2020
OI Hailes, Alethia/0000 0001 6819 6781; Evans,
   Nicholas/0000 0002 3255 4388; Scarpa, Edoardo/0000 0002 5886 6929; de
   Andres, Maria C./0000 0003 2260 6356; Janeczek,
   Agnieszka/0000 0002 9745 8346; Oreffo, Richard/0000 0001 5995 6726;
   Newman, Tracey A/0000 0002 3727 9258; 
FU Medical Research Council, United Kingdom [MR/J004103/1]; Wessex Medical
   Research, UoS Research Management Committee, Nanoear FP6 [FP 6
   NMP4 CT 2006]; Malaya University, Malaysia; Institute for Life Sciences,
   Southampton, U.K.
FX We gratefully acknowledge support from the Medical Research Council,
   United Kingdom, (Grant number MR/J004103/1), Wessex Medical Research,
   UoS Research Management Committee, Nanoear FP6 (FP 6 NMP4 CT 2006), a
   Vice Chancellor's award from Malaya University, Malaysia, awarded to
   TAN, and the Institute for Life Sciences, Southampton, U.K.
CR Ahmed F, 2004, J CONTROL RELEASE, V96, P37, DOI 10.1016/j.jconrel.2003.12.021
   Ahmed F, 2006, J CONTROL RELEASE, V116, P150, DOI 10.1016/j.jconrel.2006.07.012
   Anchordoquy TJ, 2017, WATCHING GORILLA QUE, V262, DOI [10.1016/j.jconrel.2017.07.021, DOI 10.1016/J.JCONREL.2017.07.021]
   Arioka M, 2013, BIOCHEM BIOPH RES CO, V440, P677, DOI 10.1016/j.bbrc.2013.09.126
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Brandi ML, 2012, EXPERT OPIN INV DRUG, V21, P1169, DOI 10.1517/13543784.2012.696610
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Buckiová D, 2012, NANOMEDICINE UK, V7, P1339, DOI 10.2217/NNM.12.5
   Cabane E, 2010, MACROMOL CHEM PHYS, V211, P1847, DOI 10.1002/macp.201000151
   Chan JM, 2010, P NATL ACAD SCI USA, V107, P2213, DOI 10.1073/pnas.0914585107
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chernenko T, 2009, ACS NANO, V3, P3552, DOI 10.1021/nn9010973
   Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143
   Gaboriaud Kolar N, 2015, EXPERT OPIN THER PAT, V25, P583, DOI 10.1517/13543776.2015.1019865
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Guan LJ, 2015, NANOMEDICINE UK, V10, P2757, DOI 10.2217/nnm.15.110
   Gunn WG, 2011, BLOOD, V117, P1641, DOI 10.1182/blood 2010 09 308171
   Janeczek AA, 2017, NANOMEDICINE UK, V12, P845, DOI 10.2217/nnm 2016 0386
   Janeczek AA, 2016, STEM CELLS, V34, P418, DOI 10.1002/stem.2241
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Lack WD, 2014, J BONE JOINT SURG AM, V96A, P1066, DOI 10.2106/JBJS.M.00385
   Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Liu L, 2011, CANCER RES, V71, P3972, DOI 10.1158/0008 5472.CAN 10 3852
   Lomas H, 2010, MACROMOL BIOSCI, V10, P513, DOI 10.1002/mabi.201000083
   Low SA, 2017, NANOMEDICINE UK, V12, P185, DOI 10.2217/nnm 2016 0340
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   McClung MR, 2015, ENDOCRINOL METAB, V30, P429, DOI 10.3803/EnM.2015.30.4.429
   Mehta M, 2012, ADV DRUG DELIVER REV, V64, P1257, DOI 10.1016/j.addr.2012.05.006
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Nahire R, 2014, BIOMATERIALS, V35, P6482, DOI 10.1016/j.biomaterials.2014.04.026
   Neves VCM, 2017, SCI REP UK, V7, DOI 10.1038/srep39654
   Oltra NS, 2014, ANNU REV CHEM BIOMOL, V5, P281, DOI 10.1146/annurev chembioeng 060713 040447
   Patel SK, 2010, BIOMATERIALS, V31, P1780, DOI 10.1016/j.biomaterials.2009.11.060
   Petersen MA, 2013, BIOCONJUGATE CHEM, V24, P533, DOI 10.1021/bc3003259
   Photos PJ, 2003, J CONTROL RELEASE, V90, P323, DOI 10.1016/S0168 3659(03)00201 3
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Qin SH, 2006, ADV MATER, V18, P2905, DOI 10.1002/adma.200601019
   Rameez S, 2008, BIOCONJUGATE CHEM, V19, P1025, DOI 10.1021/bc700465v
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Scarpa E, 2016, SCI REP UK, V6, DOI 10.1038/srep29460
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Shuai XT, 2004, J CONTROL RELEASE, V98, P415, DOI 10.1016/j.jconrel.2004.06.003
   Simón Gracia L, 2016, MOL CANCER THER, V15, P670, DOI 10.1158/1535 7163.MCT 15 0713 T
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Tian XH, 2015, SCI REP UK, V5, DOI 10.1038/srep11990
   Vougogiannopoulou K, 2008, J MED CHEM, V51, P6421, DOI 10.1021/jm800648y
   Wayakanon K, 2013, FASEB J, V27, P4455, DOI 10.1096/fj.12 225219
   Xin HL, 2011, BIOMATERIALS, V32, P4293, DOI 10.1016/j.biomaterials.2011.02.044
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
   Zahoor M, 2014, BONE, V65, P60, DOI 10.1016/j.bone.2014.05.003
   Zhen Y, 2007, ONCOGENE, V26, P6372, DOI 10.1038/sj.onc.1210473
   Zimmermann G, 2009, Injury, V40 Suppl 3, pS50, DOI 10.1016/S0020 1383(09)70012 9
NR 55
TC 18
Z9 19
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JUN
PY 2018
VL 14
IS 4
BP 1267
EP 1277
DI 10.1016/j.nano.2018.02.014
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA GL9MB
UT WOS:000437630000018
PM 29555223
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU McGregor, NE
   Murat, M
   Elango, J
   Poulton, IJ
   Walker, EC
   Crimeen Irwin, B
   Ho, PWM
   Gooi, JH
   Martin, TJ
   Sims, NA
AF McGregor, Narelle E.
   Murat, Melissa
   Elango, Jeevithan
   Poulton, Ingrid J.
   Walker, Emma C.
   Crimeen Irwin, Blessing
   Ho, Patricia W. M.
   Gooi, Jonathan H.
   Martin, T. John
   Sims, Natalie A.
TI IL 6 exhibits both cis  and trans signaling in osteocytes
   and osteoblasts, but only trans signaling promotes bone formation
   and osteoclastogenesis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE osteoblast; osteocyte; osteoclast; interleukin 6 (IL 6); STAT3; cell
   signaling; bone; cytokine; inflammation; bone growth; osteopenia
ID SOLUBLE INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN
   M; DESIGNER CYTOKINE; IN VIVO; DIFFERENTIATION; EXPRESSION; ACTIVATOR;
   CELLS; BLOCKADE
AB Interleukin 6 (IL 6) supports development of bone resorbing osteoclasts by acting early in the osteoblast lineage via membrane bound (cis) or soluble (trans) receptors. Here, we investigated how IL 6 signals and modifies gene expression in differentiated osteoblasts and osteocytes and determined whether these activities can promote bone formation or support osteoclastogenesis. Moreover, we used a genetically altered mouse with circulating levels of the pharmacological IL 6 trans signaling inhibitor sgp130 Fc to determine whether IL 6 trans signaling is required for normal bone growth and remodeling. We found that IL 6 increases suppressor of cytokine signaling 3 (Socs3) and CCAAT enhancer binding protein (Cebpd) mRNA levels and promotes signal transducer and activator of transcription 3 (STAT3) phosphorylation by both cis  and trans signaling in cultured osteocytes. In contrast, RANKL (Tnfsf11) mRNA levels were elevated only by trans signaling. Furthermore, we observed soluble IL 6 receptor release and ADAM metallopeptidase domain 17 (ADAM17) sheddase expression by osteocytes. Despite the observation that IL 6 cis signaling occurs, IL 6 stimulated bone formation in vivo only via trans signaling. Although IL 6 stimulated RANKL (Tnfsf11) mRNA in osteocytes, these cells did not support osteoclast formation in response to IL 6 alone; binucleated TRAP+ cells formed, and only in response to trans signaling. Finally, pharmacological, sgp130 Fc mediated inhibition of IL 6 trans signaling did not impair bone growth or remodeling unless mice had circulating sgp130 Fc levels > 10 g/ml. At those levels, osteopenia and impaired bone growth occurred, reducing bone strength. We conclude that high sgp130 Fc levels may have detrimental off target effects on the skeleton.
C1 [McGregor, Narelle E.; Murat, Melissa; Elango, Jeevithan; Poulton, Ingrid J.; Walker, Emma C.; Crimeen Irwin, Blessing; Ho, Patricia W. M.; Martin, T. John; Sims, Natalie A.] St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, Melbourne, Vic 3065, Australia.
   [Elango, Jeevithan] Shanghai Ocean Univ, Coll Food Sci & Technol, Dept Marine Biopharmacol, Shanghai 201306, Peoples R China.
   [Murat, Melissa] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia.
   [Gooi, Jonathan H.; Martin, T. John; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic 3065, Australia.
   [Gooi, Jonathan H.] St Vincents Inst Med Res, Struct Biol Unit, Melbourne, Vic 3065, Australia.
C3 St. Vincent's Institute of Medical Research; Shanghai Ocean University;
   La Trobe University; University of Melbourne; St Vincent's Health; St
   Vincent's Hospital Melbourne; NSW Health; St Vincents Hospital Sydney;
   St. Vincent's Institute of Medical Research
RP Sims, NA (通讯作者)，St Vincents Inst Med Res, Bone Biol & Dis Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI ; Elango, Jeevithan/Y 8106 2019; Sims, Natalie/A 7192 2012; Gooi,
   Jonathan/AAS 7982 2020; Elango, Jeevithan/MCK 4236 2025
OI Gooi, Jonathan/0000 0002 8839 1602; Elango,
   Jeevithan/0000 0003 4115 9918; Sims, Natalie/0000 0003 1421 8468; 
FU National Health and Medical Research Council (Australia); Victorian
   State Government Operational Infrastructure Support scheme
FX This work was supported by the National Health and Medical Research
   Council (Australia) through project grant funding (to N. A. S. and T. J.
   M.). St. Vincent's Institute is supported by the Victorian State
   Government Operational Infrastructure Support scheme. The authors
   declare that they have no conflicts of interest with the contents of
   this article.
CR Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068
   Bakker AD, 2014, J DENT RES, V93, P394, DOI 10.1177/0022034514522485
   Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Chia LY, 2015, BONE, V72, P34, DOI 10.1016/j.bone.2014.11.005
   Cho DC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00920 x
   CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   Dame JB, 2000, EARLY HUM DEV, V58, P25, DOI 10.1016/S0378 3782(00)00064 5
   Dreymueller D, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9621724
   Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297 142
   Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756 3282(98)00040 4
   Garbers C, 2011, J BIOL CHEM, V286, P42959, DOI 10.1074/jbc.M111.295758
   Garbers C, 2011, J BIOL CHEM, V286, P14804, DOI 10.1074/jbc.M111.229393
   Girasole G, 1999, CLIN ENDOCRINOL, V51, P801, DOI 10.1046/j.1365 2265.1999.00896.x
   Hall KC, 2013, MOL CELL BIOL, V33, P3077, DOI 10.1128/MCB.00291 13
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   HONDA M, 1992, J IMMUNOL, V148, P2175
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Jepsen KJ, 2015, J BONE MINER RES, V30, P951, DOI 10.1002/jbmr.2539
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Johnson RW, 2015, BONE, V81, P343, DOI 10.1016/j.bone.2015.08.005
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432 1327.2001.01867.x
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Kartsogiannis V, 2008, J BIOL CHEM, V283, P30850, DOI 10.1074/jbc.M801761200
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kyrtsonis MC, 1996, BRIT J HAEMATOL, V93, P398, DOI 10.1046/j.1365 2141.1996.4721018.x
   Lazzaro L, 2018, BONE, V112, P120, DOI 10.1016/j.bone.2018.04.015
   Li Y, 2008, CYTOKINE, V43, P165, DOI 10.1016/j.cyto.2008.05.007
   LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo 129 3 1513
   MARTIN TJ, 1987, METHOD ENZYMOL, V145, P324
   Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200
   MITSUYAMA K, 1995, GUT, V36, P45, DOI 10.1136/gut.36.1.45
   MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Poulton IJ, 2012, J BONE MINER RES, V27, P586, DOI 10.1002/jbmr.1485
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Rabe B, 2008, BLOOD, V111, P1021, DOI 10.1182/blood 2007 07 102137
   Rakemann T, 1999, J BIOL CHEM, V274, P1257, DOI 10.1074/jbc.274.3.1257
   Richards CD, 2000, CYTOKINE, V12, P613, DOI 10.1006/cyto.1999.0635
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Rose John S, 2017, CLIN PHARMACOL THER, V102, P591, DOI 10.1002/cpt.782
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Schlöndorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Walker EC, 2016, J BIOL CHEM, V291, P21703, DOI 10.1074/jbc.M116.748483
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Wu Andy C, 2014, Bonekey Rep, V3, P571, DOI 10.1038/bonekey.2014.66
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 61
TC 66
Z9 70
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 10
PY 2019
VL 294
IS 19
BP 7850
EP 7863
DI 10.1074/jbc.RA119.008074
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IB3FL
UT WOS:000470153300026
PM 30923130
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Ahn, SJ
   Baek, JM
   Cheon, YH
   Park, SH
   Lee, MS
   Oh, J
   Kim, JY
AF Ahn, Sung Jun
   Baek, Jong Min
   Cheon, Yoon Hee
   Park, Sun Hyang
   Lee, Myeung Su
   Oh, Jaemin
   Kim, Ju Young
TI The Inhibitory Effect of Angelica tenuissima Water Extract
   on Receptor Activator of Nuclear Factor Kappa B Ligand Induced
   Osteoclast Differentiation and Bone Resorbing Activity of Mature
   Osteoclasts
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Angelica tenuissima; Bone Resorption; Osteoclast; Osteoporosis; RANKL
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; PARATHYROID HORMONE;
   GENE EXPRESSION; POSTMENOPAUSAL WOMEN; PROTEIN KINASE; OSTEOPOROSIS;
   CELLS; RANKL; OSTEOPETROSIS; RESORPTION
AB Angelica tenuissima has been traditionally used in oriental medicine for its therapeutic effects in headache, toothache, and flu symptoms. It also exerts anti inflammatory activity via the inhibition of the expression of cyclooxygenase 2 (COX 2). However, the effect of Angelica tenuissima on osteoclast differentiation has not been identified until recently. In this study, we first confirmed that Angelica tenuissima water extract (ATWE) significantly interrupted the formation of tartrate resistant acid phosphatase (TRAP) positive multinucleated cells (MNCs) in a dose dependent manner without any cytotoxicity. Next, we clarified the underlying mechanisms linking the suppression effects of ATWE on the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis. At the molecular level, ATWE induced the dephosphorylation of c Jun N terminal kinase (JNK) and Akt and decreased the degradation of I kappa B in RANKL dependent early signaling pathways. Subsequently, ATWE caused impaired activation of the protein and mRNA levels of c Fos and nuclear factor of activated T cell c1 (NFATc1). Moreover, the disassembly of filamentous actin (F actin) ring and anti resorptive activity of mature osteoclasts were triggered by ATWE treatment. Although ATWE did not enhance osteogenesis in primary osteoblasts, our results showed that ATWE is a potential candidate for anti resorptive agent in osteoporosis, a common metabolic bone disorder.
C1 [Ahn, Sung Jun; Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Oh, Jaemin] Wonkwang Univ, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Ahn, Sung Jun; Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Oh, Jaemin] Wonkwang Univ, Grad Sch, BK21plus Program, Iksan 570749, Jeonbuk, South Korea.
   [Ahn, Sung Jun; Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Oh, Jaemin] Wonkwang Univ, Grad Sch, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin; Kim, Ju Young] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Rheumatol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM jmoh@wku.ac.kr; kimjy1014@gmail.com
RI Lee, Sang Hoon/ABH 6210 2020
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2013R1A1A2059831]
FX This study was supported by a grant from Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (NRF 2013R1A1A2059831).
CR Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736 0266(03)00156 6
   Cremasco V, 2012, J BONE MINER RES, V27, P2452, DOI 10.1002/jbmr.1701
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Feuerer M, 2003, NAT MED, V9, P1151, DOI 10.1038/nm914
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Ka MH, 2005, J AGR FOOD CHEM, V53, P4124, DOI 10.1021/jf047932x
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Lee SH, 2010, NEUROL RES, V32, pS58, DOI 10.1179/016164109X12537002794048
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   LEUNG KS, 1993, J BONE JOINT SURG BR, V75, P288, DOI 10.1302/0301 620X.75B2.8444951
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Stepan J J, 2003, Endocr Regul, V37, P225
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WARREN MK, 1985, J IMMUNOL, V134, P982
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yi S, 2009, BASIC CLIN PHARMACOL, V105, P249, DOI 10.1111/j.1742 7843.2009.00423.x
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 37
TC 8
Z9 8
U1 1
U2 5
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2015
VL 43
IS 4
BP 715
EP 729
DI 10.1142/S0192415X15500445
PG 15
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA CN8LP
UT WOS:000358692400008
PM 26119955
DA 2025 08 17
ER

PT J
AU Lee, SJ
   Lee, EH
   Park, SY
   Kim, JE
AF Lee, So Jeong
   Lee, Eun Hye
   Park, Seung Yoon
   Kim, Jung Eun
TI Induction of fibrillin 2 and periostin expression in Osterix knockdown
   MC3T3 E1 cells
SO GENE
LA English
DT Article
DE Osterix; Knockdown; Differentiation; Fibrillin 2; Periostin
ID TRANSCRIPTION FACTOR OSTERIX; BONE FORMATION; OSTEOBLAST
   DIFFERENTIATION; OSTEOPOROSIS; THERAPIES; MICE; SP7
AB Osteoporosis is the most common age related bone disease that is characterized by an imbalance between osteoblasts for bone formation and osteoclasts for bone resorption. Anti catabolic drugs have been developed to inhibit osteoclast activity and to prevent bone loss in osteoporosis. However, because it is difficult to increase bone mass in osteoporotic bone, it would be beneficial to simultaneously enhance osteoblast function and thus form bone. Osterix (Osx) is an essential transcription factor for osteoblast differentiation. To date, many studies have focused on discovering Osx target genes and on increasing osteoblast differentiation. However, Osx targets and the mechanisms controlling osteoblast differentiation, are not well known. Here, we generated stable Osx knock down cell lines by employing shRNA in MC3T3 E1 osteoblastic cells. Stable Osx knockdown osteoblasts exhibited a significant reduction in cell differentiation and nodule formation, which was similar to the reduced osteoblast activity observed in an Osx deficient mouse model. Using an Affymetrix GeneChip microarray, we determined the differential gene expression profile in response to Osx knockdown, which provided insight into molecular mechanisms underlying osteoblast differentiation. Of 2743 genes with roles in cell differentiation, 15 were up regulated and 2 were downregulated in Osx knockdown osteoblasts. In particular, the expression of fibrillin 2 and periostin was significantly increased in Osx knockdown osteoblasts compared to that in control cells, as validated by RT PCR and quantitative real time PCR. Finally, this study showed differential gene expression profiles for Osx mediated osteoblast differentiation, suggesting that fibrillin 2 and periostin will be target candidates of Osx in osteoblast differentiation. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Lee, So Jeong; Lee, Eun Hye; Kim, Jung Eun] Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Mol Med, Daegu 700422, South Korea.
   [Lee, So Jeong; Lee, Eun Hye; Kim, Jung Eun] Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu 700422, South Korea.
   [Park, Seung Yoon] Dongguk Univ, Sch Med, Dept Biochem, Gyeongju 780714, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Dongguk University
RP Kim, JE (通讯作者)，Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Mol Med, Daegu 700422, South Korea.
EM kjeun@knu.ac.kr
RI ; Lee, Eun Hye/KDN 5679 2024
OI Lee, Eun Hye/0000 0001 8090 6571; 
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF)   Ministry of Education, Science and Technology [2013R1A1A20
   60115]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2013R1A1A20 60115).
CR Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Bonnet N, 2016, MOL CELL ENDOCRINOL, V432, P85, DOI 10.1016/j.mce.2015.12.014
   Chaible LM, 2010, GENET MOL RES, V9, P1469, DOI 10.4238/vol9 3gmr867
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Gierut Jessica J, 2014, Cold Spring Harb Protoc, V2014, P339, DOI 10.1101/pdb.top069807
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Lee YJ, 2015, OSTEOARTHR CARTILAGE, V23, P1421, DOI 10.1016/j.joca.2015.03.035
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Merle B, 2012, OSTEOPOROSIS INT, V23, P1199, DOI 10.1007/s00198 011 1892 7
   Milona M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471 2164 4 43
   Montagnani A, 2014, WORLD J ORTHOP, V5, P247, DOI 10.5312/wjo.v5.i3.247
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nistala H, 2010, J CELL BIOL, V190, P1107, DOI 10.1083/jcb.201003089
   Nistala H, 2010, J BIOL CHEM, V285, P34126, DOI 10.1074/jbc.M110.125328
   Park SY, 2013, GENE, V518, P368, DOI 10.1016/j.gene.2012.12.102
   Pazianas M., 2016, ANN N Y ACA IN PRESS
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131 11144.2005
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
   Zhu FC, 2012, J CELL PHYSIOL, V227, P2677, DOI 10.1002/jcp.23010
NR 26
TC 12
Z9 13
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JAN 5
PY 2017
VL 596
BP 123
EP 129
DI 10.1016/j.gene.2016.10.018
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA ED8CF
UT WOS:000389098800012
PM 27751812
DA 2025 08 17
ER

PT J
AU Simfia, I
   Schiavi, J
   Mcnamara, LM
AF Simfia, Irene
   Schiavi, Jessica
   Mcnamara, Laoise M.
TI Alterations in osteocyte mediated osteoclastogenesis during estrogen
   deficiency and under ROCK II inhibition: An in vitro study using a novel
   postmenopausal multicellular niche model
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Osteoporosis; Estrogen; Mechanobiology; Rho associated coiled kinase
   (ROCK); Osteocyte; Osteoclast
ID COLONY STIMULATING FACTOR; HORMONE REPLACEMENT THERAPY; SCLEROSTIN
   ANTIBODY; FLUID FLOW; BONE FORMATION; CORTICAL BONE; OSTEOGENIC
   DIFFERENTIATION; PARATHYROID HORMONE; OSTEOBLAST LINEAGE;
   GENE EXPRESSION
AB This study sought to derive an enhanced understanding of the complex intracellular interactions that drive bone loss in postmenopausal osteoporosis. We applied an in vitro multicellular niche to recapitulate cell cell signalling between osteocytes, osteoblasts and osteoclasts to investigate (1) how estrogen deficient and mechanically loaded osteocytes regulate osteoclastogenesis and (2) whether ROCK II inhibition affects these mechanobiological responses. We report that mechanically stimulated and estrogen deficient osteocytes upregulated RANKL/OPG and M CSF gene expression, when compared to those treated with 10 nM estradiol. Osteoclast precursors (RAW 264.7) cultured within this niche underwent significant reduction in osteoclastogenic gene expression (CTSK), and there was an increasing trend in the area covered by TRAP(+) osteoclasts (24% vs. 19.4%, p = 0.06). Most interestingly, upon treatment with the ROCK II inhibitor, RANKL/OPG and M CSF gene expression by estrogen deficient osteocytes were downregulated. Yet, this inhibition of the pro osteoclastogenic factors by osteocytes did not ultimately reduce the differentiation of osteoclast precursors. Indeed, TRAP and CTSK gene expressions in osteoclast precursors were upregulated, and there was an increased trend for osteoclast area (30.4% vs. 24%, p = 0.07), which may have been influenced by static osteoblasts (MC3T3 E1) that were included in the niche. We conclude that ROCK II inhibition can attenuate bone loss driven by osteocytes during estrogen deficiency.
C1 [Simfia, Irene; Schiavi, Jessica; Mcnamara, Laoise M.] Natl Univ Ireland Galway, Coll Engn & Informat, Biomed Engn, Mechanobiol & Med Device Res Grp,Biomech Res Ctr, Galway, Ireland.
C3 Ollscoil na Gaillimhe University of Galway
RP Mcnamara, LM (通讯作者)，Natl Univ Ireland Galway, Coll Engn & Informat, Biomed Engn, Galway, Ireland.
EM laoise.mcnamara@nuigalway.ie
RI ; SCHIAVI TRITZ, Jessica/J 1261 2019
OI Schiavi Tritz, Jessica/0000 0003 2872 2067; 
FU Irish Research Council (IRC) under the EMBARK program; European Research
   Council [258,992 BONEMECHBIO]; Science Foundation Ireland Investigators
   Grant; European Regional Development fund [14/IA/2884]
FX This study was funded by Irish Research Council (IRC) under the EMBARK
   program, the European Research Council Grant ERC 2010 StG Grant 258,992
   BONEMECHBIO and the Science Foundation Ireland Investigators Grant
   co funded under the European Regional Development fund (14/IA/2884).
CR Alford AI, 2003, BONE, V33, P64, DOI 10.1016/S8756 3282(03)00167 4
   Allison H, 2019, AM J PHYSIOL CELL PH, V317, pC969, DOI 10.1152/ajpcell.00168.2019
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bakker AD, 2005, OSTEOPOROSIS INT, V16, P983, DOI 10.1007/s00198 004 1785 0
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Blixt NC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185441
   Boeyens JCA, 2014, NUTRIENTS, V6, P2584, DOI 10.3390/nu6072584
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyce RW, 2017, BONE, V101, P77, DOI 10.1016/j.bone.2017.04.005
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brennan M., 2014, HORMONE METABOLIC RE
   Brennan MA, 2014, HORM METAB RES, V46, P537, DOI 10.1055/s 0033 1363265
   Brennan M A, 2011, Eur Cell Mater, V21, P396
   Brennan M. A., 2012, IMPACT SHEAR STRESS
   Brennan O, 2012, HORM METAB RES, V44, P47, DOI 10.1055/s 0031 1291358
   Brennan O, 2011, J BIOMECH, V44, P386, DOI 10.1016/j.jbiomech.2010.10.023
   Brennan O., 2012, CALCIF TISSUE INT
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Castillo AB, 2014, AM J PHYSIOL ENDOC M, V306, pE937, DOI 10.1152/ajpendo.00458.2013
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chavassieux P, 2017, J BONE MINER RES, V32, pS25
   Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249
   Christiansen C, 1996, MATURITAS, V23, pS71
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Deepak V, 2017, FASEB J, V31, P3027, DOI 10.1096/fj.201601280R
   Deepak V, 2015, CONNECT TISSUE RES, V56, P195, DOI 10.3109/03008207.2014.989320
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482
   Frei A., 2015, STUDIES ROLE 2 PROTE
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632
   Gardinier J, 2014, AM J PHYSIOL CELL PH, V306, pC1058, DOI 10.1152/ajpcell.00254.2013
   Gardner CR, 2007, CELL TISSUE RES, V330, P111, DOI 10.1007/s00441 007 0450 2
   Gardner CR, 2007, CELL BIOL INT, V31, P672, DOI 10.1016/j.cellbi.2006.12.008
   Geoghegan IP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41095 3
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006 291X(91)92015 C
   Haugh MG, 2015, J MECH BEHAV BIOMED, V42, P67, DOI 10.1016/j.jmbbm.2014.11.001
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hodge JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021462
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Hoon JL, 2016, CELLS BASEL, V5, DOI 10.3390/cells5020017
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jia J, 2017, MOL MED REP, V15, P1539, DOI 10.3892/mmr.2017.6168
   Jin ZX, 2015, MOL ENDOCRINOL, V29, P730, DOI 10.1210/me.2014 1365
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kim CH, 2006, BONE, V39, P1043, DOI 10.1016/j.bone.2006.05.017
   Klein Nulend J, 2015, J BIOMECH, V48, P855, DOI 10.1016/j.jbiomech.2014.12.007
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Krassas G. E., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P143
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li J, 2012, J BIOMECH, V45, P247, DOI 10.1016/j.jbiomech.2011.10.037
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin C, 2009, J GEN INTERN MED, V24, P103
   Lovato C, 2017, EXPERT OPIN EMERG DR, V22, P247, DOI 10.1080/14728214.2017.1362389
   Madsen SH, 2011, CARTILAGE, V2, P265, DOI 10.1177/1947603510383855
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McClung MR, 2017, THER ADV MUSCULOSKEL, V9, P263, DOI 10.1177/1759720X17726744
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   McCreadie BR, 2006, BONE, V39, P1190, DOI 10.1016/j.bone.2006.06.008
   McNamara LM, 2006, BONE, V39, P392, DOI 10.1016/j.bone.2006.02.070
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Melton LJ, 2005, J BONE MINER RES, V20, P886, DOI 10.1359/jbmr.2005.20.5.886
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   OkmanKilic T., 2015, ADV OSTEOPOROSIS
   Ominsky MS, 2017, J BONE MINER RES, V32, P788, DOI 10.1002/jbmr.3036
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Randell KM, 2002, J BONE MINER RES, V17, P528, DOI 10.1359/jbmr.2002.17.3.528
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Ren J, 2013, BONE, V53, P587, DOI 10.1016/j.bone.2012.12.004
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Vaughan TJ, 2015, J BIOMECH ENG, V137
   Verbruggen SW, 2016, J MECH BEHAV BIOMED, V62, P158, DOI 10.1016/j.jmbbm.2016.05.004
   Verbruggen SW, 2015, BIOPHYS J, V108, P1587, DOI 10.1016/j.bpj.2015.02.031
   Verbruggen SW, 2012, J R SOC INTERFACE, V9, P2735, DOI 10.1098/rsif.2012.0286
   Voisin M, 2015, ANAT REC, V298, P1548, DOI 10.1002/ar.23173
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yeh CR, 2010, J BONE MINER RES, V25, P627, DOI 10.1359/jbmr.091008
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   Zaman G, 2006, J BONE MINER RES, V21, P1297, DOI 10.1359/JBMR.060504
   Zhang DY, 2016, BONE, V87, P161, DOI 10.1016/j.bone.2016.02.005
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhu XH, 2008, TRANSL RES, V152, P18, DOI 10.1016/j.trsl.2008.05.003
NR 119
TC 16
Z9 17
U1 0
U2 3
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUL 1
PY 2020
VL 392
IS 1
AR 112005
DI 10.1016/j.yexcr.2020.112005
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA LR2AV
UT WOS:000535499100003
PM 32330507
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yamaguchi, M
   Weitzmann, MN
AF Yamaguchi, Masayoshi
   Weitzmann, M. Neale
TI Vitamin K2 stimulates osteoblastogenesis and suppresses
   osteoclastogenesis by suppressing NF κB activation
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE vitamin K; menaquinone 7; NF kappa B; osteoclast; osteoblast;
   osteoporosis
ID TISSUES IN VITRO; SERUM UNDERCARBOXYLATED OSTEOCALCIN; BONE RESORPTION;
   MENAQUINONE 7 VITAMIN K 2; RHEUMATOID ARTHRITIS; BETA CRYPTOXANTHIN;
   SMAD ACTIVATION; MC3T3 E1 CELLS; ELDERLY WOMEN; TNF ALPHA
AB Several bone protective factors are reported to exhibit stimulatory activities on bone formation coupled with inhibitory effects on bone resorption; one such factor is vitamin K2. Vitamin K species [K1 (phylloquinone) and K2 (menaquinone)] have long been associated with bone protective activities and are receiving intense interest as nutritional supplements for the prevention or amelioration of bone disease in humans. However, the mechanisms of vitamin K action on the skeleton are poorly defined. Activation of the nuclear factor KB (NF kappa B) signal transduction pathway is essential for osteoclast formation and resorption. By contrast, NF kappa B signaling potently antagonizes osteoblast differentiation and function, prompting us to speculate that NF kappa B antagonists may represent a novel class of dual anti catabolic and pro anabolic agents. We now show that vitamin K2 action on osteoblast and osteoclast formation and activity is accomplished by down regulating basal and cytokineinduced NF kappa B activation, by increasing I kappa B mRNA, in a gamma carboxylation independent manner. Furthermore, vitamin K2 prevented repression by tumor necrosis factor alpha (TNF alpha) of SMAD signaling induced by either transforming growth factor beta (TGF beta) or bone morphogenetic protein 2 (BMP 2). Vitamin K2 further antagonized receptor activator of NF kappa B (RANK) ligand (RANKL) induced NF kappa B activation in osteoclast precursors. Our data provide a novel mechanism to explain the dual pro anabolic and anti catabolic activities of vitamin K2, and may further support the concept that pharmacological modulation of NF kappa B signal transduction may constitute an effective mechanism for ameliorating pathological bone loss and for promoting bone health.
C1 [Yamaguchi, Masayoshi; Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Atlanta VA Med Ctr, Decatur, GA 30033 USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Medical Center; Atlanta
   VA Health Care System
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMRB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
CR Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Atkins GJ, 2009, AM J PHYSIOL CELL PH, V297, pC1358, DOI 10.1152/ajpcell.00216.2009
   Binkley N, 2009, J BONE MINER RES, V24, P983, DOI [10.1359/JBMR.081254, 10.1359/jbmr.081254]
   Blonska M, 2009, IMMUNOL REV, V228, P199, DOI 10.1111/j.1600 065X.2008.00749.x
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cheung AM, 2008, PLOS MED, V5, P1461, DOI 10.1371/journal.pmed.0050196
   Colucci S, 2007, J PATHOL, V212, P47, DOI 10.1002/path.2153
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756 3282(94)00027 W
   HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kamao M, 2007, J NUTR SCI VITAMINOL, V53, P464, DOI 10.3177/jnsv.53.464
   Katsuyama H, 2005, INT J MOL MED, V15, P231
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   LOTSOVA V, 1997, NAT MED, V3, P1285
   Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143
   Morishita M, 2008, J RHEUMATOL, V35, P407
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Okamoto H, 2008, IUBMB LIFE, V60, P355, DOI 10.1002/iub.41
   Ozaki I, 2007, CLIN CANCER RES, V13, P2236, DOI 10.1158/1078 0432.CCR 06 2308
   PRICE PA, 1985, VITAM HORM, V42, P65
   Sakagami H, 2000, CELL MOL BIOL, V46, P129
   Shea MK, 2008, NUTR REV, V66, P549, DOI 10.1111/j.1753 4887.2008.00106.x
   Strait K, 2008, INT J MOL MED, V21, P521
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   SZULC P, 1994, J BONE MINER RES, V9, P1591
   SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Uchiyama S, 2008, MOL CELL BIOCHEM, V307, P209, DOI 10.1007/s11010 007 9600 9
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Wahl EC, 2010, J BONE MINER RES, V25, P114, DOI 10.1359/jbmr.090708
   Yamaguchi M, 2003, MOL CELL BIOCHEM, V245, P115, DOI 10.1023/A:1022818111655
   Yamaguchi M, 2002, INT J MOL MED, V10, P729
   Yamaguchi M, 2001, MOL CELL BIOCHEM, V228, P39, DOI 10.1023/A:1013360308946
   Yamaguchi M, 2001, MOL CELL BIOCHEM, V223, P131, DOI 10.1023/A:1017930931736
   Yamaguchi M, 1999, J BONE MINER METAB, V17, P23, DOI 10.1007/s007740050059
   Yamaguchi M, 2009, INT J MOL MED, V24, P671, DOI 10.3892/ijmm_00000278
   Yamaguchi M, 2009, INT J MOL MED, V23, P297, DOI 10.3892/ijmm_00000131
   Zhang FJ, 2009, J BONE MINER RES, V24, P1224, DOI [10.1359/jbmr.090204, 10.1359/JBMR.090204]
NR 50
TC 99
Z9 103
U1 1
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2011
VL 27
IS 1
BP 3
EP 14
DI 10.3892/ijmm.2010.562
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 707NK
UT WOS:000286293100001
PM 21072493
OA Bronze
DA 2025 08 17
ER

PT J
AU Rothe, R
   Sehulze, S
   Neuber, C
   Hausera, S
   Rammelt, S
   Pietzsch, J
AF Rothe, Rebecca
   Sehulze, Sabine
   Neuber, Christin
   Hausera, Sandra
   Rammelt, Stefan
   Pietzsch, Jens
TI Adjuvant drug assisted bone healing: Part III   Further strategies for
   local and systemic modulation
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Bisphosphonates; bone metabolism; critical size bone defects; small
   molecules; statins; strontium; Wnt signaling
ID NF KAPPA B; CONVERTING ENZYME INHIBITOR; FRIZZLED RELATED PROTEIN 1;
   RENIN ANGIOTENSIN SYSTEM; GROWTH FACTOR EXPRESSION; VERTEBRAL FRACTURE
   RISK; PROMOTES OSTEOGENIC DIFFERENTIATION; CORTICOSTEROID INDUCED
   OSTEOPOROSIS; NITROGEN CONTAINING BISPHOSPHONATES; INTRAVENOUS
   IBANDRONATE INJECTIONS
AB In this third in a series of reviews on adjuvant drug assisted bone healing, further approaches aiming at influencing the healing process are discussed. Local and systemic modulation of bone metabolism is pursued with use of a number of drugs with completely different indications, which are characterized by a pleiotropic spectrum of action. These include drugs used to treat lipid disorders (HMG CoA reductase inhibitors), hypertension (ACE inhibitors), osteoporosis (bisphosphonates), cancer (proteasome inhibitors) and others. Potential applications to enhance bone healing are discussed.
C1 [Rothe, Rebecca; Neuber, Christin; Hausera, Sandra; Pietzsch, Jens] Helmholtz Zentrum Dresden Rossendorf, Dept Radiopharmaceut & Chem Biol, Inst Radiopharmaceut Canc Res, Bautzner Landstr 400, D 01328 Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Univ Hosp Carl Gustav Carus, Univ Ctr Orthopaed & Traumatol OUC, Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Fac Med, Dresden, Germany.
   [Rammelt, Stefan] CRTD, Tatzberg 4, Dresden, Germany.
   [Pietzsch, Jens] Tech Univ Dresden, Sch Sci, Fac Chem & Food Chem, Dresden, Germany.
C3 Helmholtz Association; Helmholtz Zentrum Dresden Rossendorf (HZDR);
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Technische Universitat Dresden;
   Technische Universitat Dresden
RP Pietzsch, J (通讯作者)，Helmholtz Zentrum Dresden Rossendorf, Dept Radiopharmaceut & Chem Biol, Inst Radiopharmaceut Canc Res, Bautzner Landstr 400, D 01328 Dresden, Germany.; Rammelt, S (通讯作者)，Univ Hosp Carl Gustav Carus, Univ Ctr Orthopaed & Traumatol, Fetscherstr 74, D 01307 Dresden, Germany.
EM stefan.rammelt@uniklinikum dresden.de; j.pietzsch@hzdr.de
RI Pietzsch, Jens/O 5070 2017; Rammelt, Stefan/AAE 5863 2019
OI Pietzsch, Jens/0000 0002 1610 1493; Neuber,
   Christin/0000 0002 0646 5808; Hauser, Sandra/0000 0001 8206 6000; Rothe,
   Rebecca/0000 0002 0615 1112; Rammelt, Stefan/0000 0003 1141 6493
FU Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research
   Center Transregio 67 "Functional Biomaterials for Controlling Healing
   Processes in Bone und Skin   From Material Science to Clinical
   Application" [CRC/TRR 67/3]; Helmholtz Association through the Helmholtz
   Cross Programme Initiative "Technology and Medicine   Adaptive Systems"
FX We wish to apologize to those researchers whose works have not been
   mentioned due to restrictions in space. The authors are thankful to the
   Deutsche Forschungsgemeinschaft (DFG) for supporting this work within
   the Collaborative Research Center Transregio 67 "Functional Biomaterials
   for Controlling Healing Processes in Bone und Skin   From Material
   Science to Clinical Application" (CRC/TRR 67/3). The authors also thank
   the Helmholtz Association for funding a part of this work through the
   Helmholtz Cross Programme Initiative "Technology and Medicine   Adaptive
   Systems".
CR Abass B, 2009, IRAQI J VET SCI, V23
   Adolphson P, 2000, ACTA ORTHOP SCAND, V71, P195, DOI 10.1080/000164700317413193
   Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.572252, 10.3109/17453674.2011.625539]
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Al Zube L, 2009, J ORTHOP RES, V27, P1074, DOI 10.1002/jor.20842
   Alaee F, 2014, J ORTHOP RES, V32, P197, DOI 10.1002/jor.22498
   Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Alegre DN, 2012, RHEUMATOL INT, V32, P439, DOI 10.1007/s00296 010 1687 8
   Altintas Faik, 2007, Acta Orthop Traumatol Turc, V41, P132
   Alvarez Lloret P, 2018, BIOL TRACE ELEM RES, V186, P457, DOI 10.1007/s12011 018 1322 1
   Alzahrani MM, 2016, CLIN ORTHOP RELAT R, V474, P1294, DOI 10.1007/s11999 015 4640 z
   Amanat N, 2005, J ORTHOP RES, V23, P1029, DOI 10.1016/j.orthres.2005.03.004
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Amelio PD, 2008, J BONE MINER RES, V23, P373, DOI 10.1359/JBMR.071031
   Ammann P, 2007, J BONE MINER RES, V22, P1419, DOI 10.1359/jbmr.070607
   Anbinder Ana Lia, 2006, Braz. Dent. J., V17, P267, DOI 10.1590/S0103 64402006000400001
   [Anonymous], PHYSL ROLE GROWTH FA
   Aoki M, 2015, GERIATR GERONTOL INT, V15, P1064, DOI 10.1111/ggi.12406
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Ay SA, 2013, RENAL FAILURE, V35, P691, DOI 10.3109/0886022X.2013.780976
   Ayukawa Y, 2010, J ORAL REHABIL, V37, P123, DOI 10.1111/j.1365 2842.2009.02011.x
   Ayukawa Y, 2009, ORAL SURG ORAL MED O, V107, P336, DOI 10.1016/j.tripleo.2008.07.013
   Bae MS, 2011, BIOMATERIALS, V32, P8161, DOI 10.1016/j.biomaterials.2011.07.045
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198 002 1323 x
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bayar A, 2015, CLIN INVEST MED, V38, pE164
   Beamer B, 2010, HSS J, V6, P85, DOI [10.1007/s11420 009 9129 4, DOI 10.1007/S11420 009 9129 4]
   Bellahcène A, 2007, ENDOTHELIUM J ENDOTH, V14, P123, DOI 10.1080/10623320701347187
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Benoit DSW, 2007, ADV FUNCT MATER, V17, P2085, DOI 10.1002/adfm.200700012
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Berthold HK, 2004, OSTEOPOROSIS INT, V15, P459, DOI 10.1007/s00198 004 1598 1
   Bilston LE, 2002, CLIN BIOMECH, V17, P716, DOI 10.1016/S0268 0033(02)00108 0
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P380, DOI 10.1007/s001980170106
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Blagodatski Artem, 2014, Mol Cell Ther, V2, P28
   Bleedorn JA, 2014, J ORTHOP RES, V32, P210, DOI 10.1002/jor.22502
   Bobyn JD, 2005, J BONE JOINT SURG BR, V87B, P416, DOI 10.1302/0301 620X.87B3
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Bone HG, 2007, J CLIN ENDOCR METAB, V92, P4671, DOI 10.1210/jc.2006 1909
   Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boyd SK, 2011, BONE, V48, P1109, DOI 10.1016/j.bone.2011.01.004
   Braatvedt GD, 2004, BONE, V35, P766, DOI 10.1016/j.bone.2004.05.001
   Bransford R, 2007, EUR SPINE J, V16, P557, DOI 10.1007/s00586 006 0212 y
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Broulík PD, 2001, PHYSIOL RES, V50, P353, DOI 10.33549/physiolres.9300102
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Brüel A, 2011, CALCIFIED TISSUE INT, V88, P142, DOI 10.1007/s00223 010 9439 z
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Burnier M, 2001, CIRCULATION, V103, P904, DOI 10.1161/01.CIR.103.6.904
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Cao GL, 2018, MED SCI MONITOR, V24, P6525, DOI 10.12659/MSM.911573
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Carvalho NNC, 2011, J CLIN ENDOCR METAB, V96, P2675, DOI 10.1210/jc.2011 0593
   Cebesoy O, 2007, JOINT BONE SPINE, V74, P590, DOI 10.1016/j.jbspin.2007.01.034
   Cecilia D, 2009, OSTEOPOROSIS INT, V20, P903, DOI 10.1007/s00198 008 0767 z
   Cesareo R, 2010, INT J WOMENS HEALTH, V2, P1
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   Chen XF, 2018, PHARMACOL REP, V70, P705, DOI 10.1016/j.pharep.2018.02.008
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Chen ZG, 2014, ARCH GERONTOL GERIAT, V59, P515, DOI 10.1016/j.archger.2014.07.006
   Cheng CX, 2014, INJURY, V45, P501, DOI 10.1016/j.injury.2013.11.023
   Chesnut CH, 2005, CURR MED RES OPIN, V21, P391, DOI 10.1185/030079905X30752
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chissas D, 2010, INJURY, V41, P687, DOI 10.1016/j.injury.2009.10.011
   Cho HY, 2010, BONE, V47, P263, DOI 10.1016/j.bone.2010.05.010
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Clement EV, 2000, J BONE MINER RES, V15, P586
   Clement EVP, 2002, J BONE MINER RES, V17, P2247, DOI 10.1359/jbmr.2002.17.12.2247
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Colón Emeric C, 2011, OSTEOPOROSIS INT, V22, P2329, DOI 10.1007/s00198 010 1473 1
   Corciulo C., 2018, The Adenosine Receptors, P515, DOI [10.1007/978 3 319 90808 3_21, DOI 10.1007/978 3 319 90808 3_21]
   Cui YY, 2013, BIOMATERIALS, V34, P9373, DOI 10.1016/j.biomaterials.2013.08.060
   Delaney MF, 2006, AM J OBSTET GYNECOL, V194, pS12, DOI 10.1016/j.ajog.2005.08.049
   Deleu S, 2009, CANCER RES, V69, P5307, DOI 10.1158/0008 5472.CAN 08 4472
   Delmas PD, 2004, OSTEOPOROSIS INT, V15, P792, DOI 10.1007/s00198 004 1602 9
   Devescovi Valentina, 2008, Chir Organi Mov, V92, P161, DOI 10.1007/s12306 008 0064 1
   Diao TY, 2014, J BONE MINER METAB, V32, P261, DOI 10.1007/s00774 013 0500 7
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Dip RG, 2009, VET J, V179, P38, DOI 10.1016/j.tvjl.2007.08.005
   Donmez BO, 2017, J BONE MINER METAB, V35, P161, DOI 10.1007/s00774 016 0748 9
   Donmez BO, 2012, PHARMACOL REP, V64, P878, DOI 10.1016/S1734 1140(12)70882 4
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Du XL, 2012, J CELL PHYSIOL, V227, P3731, DOI 10.1002/jcp.24083
   Du ZB, 2009, CLIN ORAL IMPLAN RES, V20, P145, DOI 10.1111/j.1600 0501.2008.01630.x
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   Eda H, 2014, LEUKEMIA, V28, P1892, DOI 10.1038/leu.2014.69
   Engler TA, 2004, J MED CHEM, V47, P3934, DOI 10.1021/jm049768a
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Evans K D, 2009, Open Orthop J, V3, P83, DOI 10.2174/1874325000903010083
   Farlay D, 2005, J BONE MINER RES, V20, P1569, DOI 10.1359/JBMR.050405
   Faucheux C, 2009, J BIOMED MATER RES A, V89A, P46, DOI 10.1002/jbm.a.31989
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Fu DL, 2012, J ZHEJIANG UNIV SC B, V13, P364, DOI 10.1631/jzus.B1100381
   Fu LJ, 2013, ACTA PHARMACOL SIN, V34, P387, DOI 10.1038/aps.2012.170
   Fukui T, 2012, J BONE MINER RES, V27, P1118, DOI 10.1002/jbmr.1558
   Galli C, 2010, J DENT RES, V89, P331, DOI 10.1177/0022034510363963
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Gao S., 2013, Open J. Regen. Medicine, V02, P53, DOI [DOI 10.4236/OJRM.2013.23009, 10.4236/ojrm.2013.23009]
   Gao Y, 2009, J CONTROL RELEASE, V139, P15, DOI 10.1016/j.jconrel.2009.05.032
   Gao ZG, 2018, BIOCHEM PHARMACOL, V151, P201, DOI 10.1016/j.bcp.2017.12.003
   Garcia P, 2010, BRIT J PHARMACOL, V159, P1672, DOI 10.1111/j.1476 5381.2010.00651.x
   Garcia Gomez A, 2014, CLIN CANCER RES, V20, P1542, DOI 10.1158/1078 0432.CCR 13 1657
   Garrett IR, 2007, J ORTHOP RES, V25, P1351, DOI 10.1002/jor.20391
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Gebru Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/932691
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Ghanbari H., 2016, Advanced Techniques in Bone Regeneration
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Gilmore T.D., 2010, NF KB HLTH DIS, P245
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Gong HS, 2012, J BONE JOINT SURG AM, V94A, P1729, DOI 10.2106/JBJS.K.01434
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P1633, DOI 10.1517/13543780903241607
   Greiner SH, 2008, ACTA ORTHOP, V79, P717, DOI 10.1080/17453670810016768
   Gutierrez GE, 2006, OSTEOPOROSIS INT, V17, P1033, DOI 10.1007/s00198 006 0079 0
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hak DJ, 2018, INJURY, V49, P1461, DOI 10.1016/j.injury.2018.04.016
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Ham Jack, 2012, Front Endocrinol (Lausanne), V3, P113
   Hamann C, 2013, J BONE MINER RES, V28, P627, DOI 10.1002/jbmr.1803
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Harding AK, 2011, ACTA ORTHOP, V82, P465, DOI 10.3109/17453674.2011.594231
   Harris ST, 2008, CURR MED RES OPIN, V24, P237, DOI 10.1185/030079908X253717
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Haulica I, 2005, J RENIN ANGIO ALDO S, V6, P121, DOI 10.3317/jraas.2005.018
   He W, 2012, PURINERG SIGNAL, V8, P327, DOI 10.1007/s11302 012 9292 9
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hollinger JO, 2008, J BONE JOINT SURG AM, V90A, P48, DOI 10.2106/JBJS.G.01231
   Hollinger JO, 2008, J ORTHOP RES, V26, P83, DOI 10.1002/jor.20453
   Hu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074191
   Huang X, 2014, MOL MED REP, V9, P2152, DOI 10.3892/mmr.2014.2101
   Huang ZN, 2007, TISSUE ENG, V13, P2311, DOI 10.1089/ten.2006.0423
   Hughes A, 2007, CALCIFIED TISSUE INT, V81, P403, DOI 10.1007/s00223 007 9078 1
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Ibrahim HK, 2016, DRUG DELIV, V23, P3181, DOI 10.3109/10717544.2016.1160458
   Ibrahim MRM, 2016, BMC VET RES, V12, DOI 10.1186/s12917 016 0724 6
   Ibrahim NI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115595
   Ishack S, 2017, J BIOMED MATER RES B, V105, P366, DOI 10.1002/jbm.b.33561
   Iwata A, 2012, CLIN EXP IMMUNOL, V168, P234, DOI 10.1111/j.1365 2249.2012.04564.x
   Izu Y, 2009, J BIOL CHEM, V284, P4857, DOI 10.1074/jbc.M807610200
   Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983
   Jawad MU, 2013, J ORTHOP RES, V31, P155, DOI 10.1002/jor.22186
   Jia Z, 2015, J CONTROL RELEASE, V200, P23, DOI 10.1016/j.jconrel.2014.12.028
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Jorgensen Niklas R, 2011, Curr Osteoporos Rep, V9, P149, DOI 10.1007/s11914 011 0065 0
   Junqueira Juliana C, 2002, J Oral Sci, V44, P117
   Kaigler D, 2006, J BONE MINER RES, V21, P735, DOI 10.1359/JBMR.060120
   Kaji H, 2005, HORM METAB RES, V37, P589, DOI 10.1055/s 2005 870538
   Kanazawa I, 2009, INTERNAL MED, V48, P1869, DOI 10.2169/internalmedicine.48.2645
   Kanczler JA, 2008, BIOMATERIALS, V29, P1892, DOI 10.1016/j.biomaterials.2007.12.031
   Kaneko K, 2011, J BONE MINER RES, V26, P2959, DOI 10.1002/jbmr.501
   Kang JH, 2010, ANAT REC, V293, P786, DOI 10.1002/ar.21092
   Kang KY, 2013, J KOREAN MED SCI, V28, P1139, DOI 10.3346/jkms.2013.28.8.1139
   Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020 1383(16)30015 8
   Kawaguchi H, 2007, J ORTHOP RES, V25, P480, DOI 10.1002/jor.20315
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim TY, 2012, J BONE JOINT SURG BR, V94B, P956, DOI 10.1302/0301 620X.94B7.29079
   Kleinheinz J, 2005, J ORAL MAXIL SURG, V63, P1310, DOI 10.1016/j.joms.2005.05.303
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Koivukangas A, 2003, CLIN ORTHOP RELAT R, P268, DOI 10.1097/01.blo.0000053054.62337.e1
   Kolli V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096323
   Komaki H, 2006, BIOMATERIALS, V27, P5118, DOI 10.1016/j.biomaterials.2006.05.031
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Kwak HB, 2009, BIOL PHARM BULL, V32, P1193, DOI 10.1248/bpb.32.1193
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Larsson S, 2014, ARCH ORTHOP TRAUM SU, V134, P291, DOI 10.1007/s00402 012 1558 8
   Lauing KL, 2014, ALCOHOL ALCOHOLISM, V49, P399, DOI 10.1093/alcalc/agu006
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lavet C, 2017, OSTEOPOROSIS INT, V28, P3475, DOI 10.1007/s00198 017 4156 3
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Lee YJ, 2008, BIOMATERIALS, V29, P1940, DOI 10.1016/j.biomaterials.2007.12.045
   Lee YS, 2001, EUR J PEDIATR, V160, P641, DOI 10.1007/s004310100844
   Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002 9440(10)61170 4
   Letocha AD, 2005, J BONE MINER RES, V20, P977, DOI 10.1359/JBMR.050109
   Leucht P, 2019, BIOMATERIALS, V196, P46, DOI 10.1016/j.biomaterials.2018.03.029
   Li CY, 2001, J BONE MINER RES, V16, P429, DOI 10.1359/jbmr.2001.16.3.429
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042
   Li R, 2009, J ORTHOP RES, V27, P8, DOI 10.1002/jor.20658
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Li YF, 2010, OSTEOPOROSIS INT, V21, P1889, DOI 10.1007/s00198 009 1140 6
   Li YT, 2015, OSTEOPOROSIS INT, V26, P431, DOI 10.1007/s00198 014 2903 2
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lim SS, 2017, OR SURG OR MED OR PA, V123, P8, DOI 10.1016/j.oooo.2016.08.009
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Lin TK, 2018, CLIN EPIDEMIOL, V10, P159, DOI 10.2147/CLEP.S145311
   Link DP, 2008, BIOMATERIALS, V29, P675, DOI 10.1016/j.biomaterials.2007.10.029
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Little DG, 2003, J BONE MINER RES, V18, P1300, DOI 10.1359/jbmr.2003.18.7.1300
   Little DG, 2001, INJURY, V32, pD14
   Little DG, 2001, J BONE JOINT SURG BR, V83B, P1069, DOI 10.1302/0301 620X.83B7.10542
   Liu F, 2011, J MATER SCI MATER M, V22, P683, DOI 10.1007/s10856 011 4247 1
   Liu J, 2017, BONE JOINT RES, V6, P154, DOI 10.1302/2046 3758.63.BJR 2016 0237.R1
   Liu JX, 2015, BIOL PHARM BULL, V38, P869, DOI 10.1248/bpb.b14 00829
   Liu S, 2012, ARTHRITIS RHEUM US, V64, P4012, DOI 10.1002/art.37697
   Liu YY, 2011, J BONE MINER METAB, V29, P149, DOI 10.1007/s00774 010 0209 9
   Lopez CD, 2019, ADV DRUG DELIVER REV, V146, P240, DOI 10.1016/j.addr.2018.06.010
   Lourenço AH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04866 4
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   Ma B, 2008, ACTA BIOMATER, V4, P149, DOI 10.1016/j.actbio.2007.05.004
   Ma YFL, 2011, ENDOCRINOLOGY, V152, P1767, DOI 10.1210/en.2010 1112
   Ma YF, 1997, J ENDOCRINOL, V154, P467, DOI 10.1677/joe.0.1540467
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maehara H, 2010, J ORTHOP RES, V28, P677, DOI 10.1002/jor.21032
   Majima T, 2007, INTERNAL MED, V46, P1967, DOI 10.2169/internalmedicine.46.0419
   Majima T, 2007, ENDOCR J, V54, P145, DOI 10.1507/endocrj.K06 127
   Manabe T, 2012, CALCIFIED TISSUE INT, V90, P193, DOI 10.1007/s00223 011 9563 4
   Marie PJ, 2011, OSTEOPOROSIS INT, V22, P1659, DOI 10.1007/s00198 010 1369 0
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   Mashiba T, 2001, BONE, V29, P271, DOI 10.1016/S8756 3282(01)00575 0
   Mason JJ, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/460120
   Matos MA, 2010, J ORTHOP TRAUMATOL, V11, P7, DOI 10.1007/s10195 010 0083 1
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   McCloskey EV, 2009, OSTEOPOROSIS INT, V20, P811, DOI 10.1007/s00198 008 0786 9
   McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   McClung MR, 2004, J BONE MINER RES, V19, P11, DOI 10.1359/JBMR.0301202
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   McDonald MM, 2012, J ORTHOP RES, V30, P1541, DOI 10.1002/jor.22109
   Mediero A, 2015, FASEB J, V29, P1577, DOI 10.1096/fj.14 265066
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Menzdorf L, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1113 9
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Miura S, 2011, J RENIN ANGIO ALDO S, V12, P1, DOI 10.1177/1470320310370852
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Molvik H, 2015, OSTEOPOROSIS INT, V26, P1251, DOI 10.1007/s00198 014 3007 8
   Monjo M, 2010, ACTA BIOMATER, V6, P1405, DOI 10.1016/j.actbio.2009.09.027
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002 9440(10)63749 2
   Montesinos MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002 9440(10)61151 0
   Moon HJ, 2011, EXP MOL MED, V43, P605, DOI 10.3858/emm.2011.43.11.067
   Morello S, 2009, J RECEPT LIGAND CH R, V2, P11, DOI 10.2147/JRLCR.S4710
   Moriyama Y, 2008, CLIN ORAL IMPLAN RES, V19, P600, DOI 10.1111/j.1600 0501.2007.01508.x
   Morse LR, 2018, ACTUAL OSTEOL, V14, P31
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Moshiri A, 2016, CLIN EXP PHARMACOL P, V43, P659, DOI 10.1111/1440 1681.12577
   Müller CE, 2011, BBA BIOMEMBRANES, V1808, P1290, DOI 10.1016/j.bbamem.2010.12.017
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Mulinari Santos G, 2018, CLIN ORAL IMPLAN RES, V29, P1126, DOI 10.1111/clr.13376
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Murphy CM, 2014, ACTA BIOMATER, V10, P2250, DOI 10.1016/j.actbio.2014.01.016
   Myers TJ, 2012, GROWTH FACTORS, V30, P230, DOI 10.3109/08977194.2012.683188
   Nagahama K, 2011, J NEUROSURG SPINE, V14, P500, DOI 10.3171/2010.11.SPINE10245
   Nagareddy PR, 2006, J PHARM PHARMACOL, V58, P513, DOI 10.1211/jpp.58.4.0011
   Nakajima F, 2007, CALCIFIED TISSUE INT, V81, P132, DOI 10.1007/s00223 007 9048 7
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nauth A, 2011, INJURY, V42, P574, DOI 10.1016/j.injury.2011.03.034
   Nistala H, 2010, HUM MOL GENET, V19, P4790, DOI 10.1093/hmg/ddq409
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Nyan M, 2010, J BIOMED MATER RES B, V93B, P65, DOI 10.1002/jbm.b.31559
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ogilvie Christian M, 2012, Iowa Orthop J, V32, P90
   Ohno T, 2003, TRANSPLANTATION, V76, P869, DOI 10.1097/01.TP.0000074992.49236.58
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Oxlund H, 2001, CALCIFIED TISSUE INT, V69, P299, DOI 10.1007/s00223 001 2027 5
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Özec I, 2007, J CRANIOFAC SURG, V18, P546
   Ozturan KE, 2011, J ORTHOP RES, V29, P138, DOI 10.1002/jor.21204
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papadaki HA, 2004, J BONE MINER METAB, V22, P577, DOI 10.1007/s00774 004 0526 y
   Park JB, 2009, MED ORAL PATOL ORAL, V14, pE485
   Park YJ, 2000, J CONTROL RELEASE, V67, P385, DOI 10.1016/S0168 3659(00)00232 7
   Patil S, 2009, J ORTHOP RES, V27, P281, DOI 10.1002/jor.20572
   Pauly S, 2009, BONE, V45, P505, DOI 10.1016/j.bone.2009.05.010
   Pauly S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 208
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Pérez Castrillón JL, 2003, AM J HYPERTENS, V16, P453, DOI 10.1016/S0895 7061(03)00845 8
   Peters R, 2010, AGE AGEING, V39, P609, DOI 10.1093/ageing/afq071
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Piskin E, 2009, J BIOMED MATER RES A, V90A, P1137, DOI 10.1002/jbm.a.32157
   Piters E, 2008, ARCH BIOCHEM BIOPHYS, V473, P112, DOI 10.1016/j.abb.2008.03.006
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Qiang YW, 2012, SEMIN HEMATOL, V49, P243, DOI 10.1053/j.seminhematol.2012.04.011
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059 011 0107 6
   Rajkumar DSR, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/325693
   Ramakers BP, 2006, CYTOKINE, V35, P95, DOI 10.1016/j.cyto.2006.07.014
   Recker R, 2005, CURR MED RES OPIN, V21, P185, DOI 10.1185/030079904X20259
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recker RR, 2009, J BONE MINER RES, V24, P1358, DOI [10.1359/jbmr.090315, 10.1359/JBMR.090315]
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reis M, 2013, EXP CELL RES, V319, P1317, DOI 10.1016/j.yexcr.2012.12.023
   Reitmaier S, 2018, J ORTHOP RES, V36, P106, DOI 10.1002/jor.23623
   Rejnmark L, 2004, J BONE MINER RES, V19, P737, DOI 10.1359/JBMR.040209
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Ringe JD, 2003, OSTEOPOROSIS INT, V14, P801, DOI 10.1007/s00198 003 1425 0
   Ringe JD, 2005, OSTEOPOROSIS INT, V16, P2063, DOI 10.1007/s00198 005 2001 6
   Ringe JD, 2003, RHEUMATOLOGY, V42, P743, DOI 10.1093/rheumatology/keg205
   Ringe JD, 2001, J CLIN ENDOCR METAB, V86, P5252, DOI 10.1210/jc.86.11.5252
   Rizzoli R, 2010, RHEUMATOL INT, V30, P1341, DOI 10.1007/s00296 010 1542 y
   Roberts SJ, 2018, CURR OSTEOPOROS REP, V16, P289, DOI 10.1007/s11914 018 0440 1
   Rosenson RS, 2005, OSTEOPOROSIS INT, V16, P1272, DOI 10.1007/s00198 005 1897 1
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Rothe R, 2019, CLIN HEMORHEOL MICRO, V73, P409, DOI 10.3233/CH 199103
   Rothea R, 2019, CLIN HEMORHEOL MICRO, V73, P381, DOI 10.3233/CH 199102
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Safaei H, 2007, ACTA DIABETOL, V44, P76, DOI 10.1007/s00592 007 0246 6
   Saito M, 2010, BONE, V46, P1170, DOI 10.1016/j.bone.2009.12.008
   Sanvoranart T, 2014, BIOCHEM BIOPH RES CO, V447, P580, DOI 10.1016/j.bbrc.2014.04.044
   Saraf S., 2007, Effect of simvastatin on fracture healing an experimental study
   Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301 620X.95B9.31562
   Scaglione M, 2016, OSTEOPOROSIS INT, V27, P211, DOI 10.1007/s00198 015 3266 z
   Schmid GJ, 2009, DEV DYNAM, V238, P766, DOI 10.1002/dvdy.21882
   Schmidmaier G, 2002, BONE, V31, P165, DOI 10.1016/S8756 3282(02)00798 6
   Schmidmaier G, 2004, J ORTHOP RES, V22, P514, DOI 10.1016/j.orthres.2003.09.009
   Schmidmaier G, 2003, ACTA ORTHOP SCAND, V74, P604, DOI 10.1080/00016470310018036
   Schumacher M, 2013, ACTA BIOMATER, V9, P9547, DOI 10.1016/j.actbio.2013.07.027
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Shah SR, 2015, NATL SCI REV, V2, P85, DOI 10.1093/nsr/nwu028
   Shahrezaee M, 2018, ENDOCRINE, V60, P138, DOI 10.1007/s12020 018 1531 6
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shimizu H, 2009, HYPERTENS RES, V32, P786, DOI 10.1038/hr.2009.99
   Siffledeen JS, 2005, CLIN GASTROENTEROL H, V3, P122, DOI 10.1016/S1542 3565(04)00663 9
   Silkstone D, 2008, NAT CLIN PRACT RHEUM, V4, P413, DOI 10.1038/ncprheum0838
   Simpson AHRW, 2006, J BONE JOINT SURG BR, V88B, P701, DOI 10.1302/0301 620X.88B6
   Sirbu PD, 2017, REV CHIM BUCHAREST, V68, P1825
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Skoglund B, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 98
   Sloan AV, 2010, BONE, V47, P235, DOI 10.1016/j.bone.2010.05.015
   Smith EJ, 2004, J BONE MINER RES, V19, P1698, DOI 10.1359/JBMR.040709
   Soininvaara TA, 2002, CALCIFIED TISSUE INT, V71, P472, DOI 10.1007/s00223 002 1022 9
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stakkestad JA, 2003, ANN RHEUM DIS, V62, P969, DOI 10.1136/ard.62.10.969
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   Stojadinovic O., 2010, EXPERT REV DERMATOL, V5, P689, DOI DOI 10.1586/EDM.10.60
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Su N, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.3
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Takechi M, 2008, J MATER SCI MATER M, V19, P2949, DOI 10.1007/s10856 008 3416 3
   Tamargo J, 2015, CLIN REV BONE MINER, V13, P125, DOI 10.1007/s12018 015 9189 6
   Tanabe K, 2012, DENT MATER J, V31, P489, DOI 10.4012/dmj.2012 008
   Tang QO, 2008, EXPERT OPIN INV DRUG, V17, P1435, DOI [10.1517/13543784.17.10.1435, 10.1517/13543784.17.10.1435 ]
   Tankó LB, 2003, J INTERN MED, V254, P159, DOI 10.1046/j.1365 2796.2003.01174.x
   Tao ZS, 2018, J BIOMATER APPL, V33, P3, DOI 10.1177/0885328218765847
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Terpos Evangelos, 2013, Bonekey Rep, V2, P395, DOI 10.1038/bonekey.2013.129
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tian XY, 2010, BONE, V47, P529, DOI 10.1016/j.bone.2010.05.032
   Tikiz C, 2005, CLIN RHEUMATOL, V24, P447, DOI 10.1007/s10067 004 1053 x
   Trincavelli ML, 2014, BBA MOL CELL RES, V1843, P2957, DOI 10.1016/j.bbamcr.2014.09.013
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Türer A, 2016, J CRANIOFAC SURG, V27, pE758, DOI 10.1097/SCS.0000000000003120
   Türer A, 2016, J CRANIO MAXILL SURG, V44, P1327, DOI 10.1016/j.jcms.2016.04.021
   Uchiyama S, 2013, BONE JOINT J, V95B, P1544, DOI 10.1302/0301 620X.95B11.31652
   Ueda H, 2002, BIOMATERIALS, V23, P1003, DOI 10.1016/S0142 9612(01)00211 3
   Ulker P, 2018, CLIN HEMORHEOL MICRO, V68, P89, DOI 10.3233/CH 170326
   Valls MD, 2009, BIOCHEM PHARMACOL, V77, P1117, DOI 10.1016/j.bcp.2008.11.002
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Vasconcelos Jose Wanderley, 2013, Rev. bras. ortop., V48, P191, DOI 10.1016/j.rboe.2012.10.003
   Victor Vega C, 2002, INFLAMMATION, V26, P19, DOI 10.1023/A:1014417728325
   Virk MS, 2013, J BONE JOINT SURG AM, V95A, P694, DOI 10.2106/JBJS.L.00285
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   von Stechow D, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471 2474 4 8
   Wagner Eric R, 2011, Curr Mol Pharmacol, V4, P14
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wang JW, 2007, OSTEOPOROSIS INT, V18, P1641, DOI 10.1007/s00198 007 0412 2
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Wang YC, 2018, EUR J PHARM BIOPHARM, V127, P223, DOI 10.1016/j.ejpb.2018.02.023
   Watts NB, 2003, OSTEOPOROSIS INT, V14, P437, DOI 10.1007/s00198 003 1401 8
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wernike E, 2010, EUR CELLS MATER, V19, P30
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wise JK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012987
   Wong CT, 2004, J BIOMED MATER RES A, V68A, P513, DOI 10.1002/jbm.a.20089
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Xu HY, 2014, BMB REP, V47, P666, DOI 10.5483/BMBRep.2014.47.12.193
   Xue QY, 2010, INT ORTHOP, V34, P447, DOI 10.1007/s00264 009 0759 4
   Xue WC, 2007, SURF COAT TECH, V201, P4685, DOI 10.1016/j.surfcoat.2006.10.012
   Xue WC, 2006, J BIOMED MATER RES A, V79A, P804, DOI 10.1002/jbm.a.30815
   Yan J, 2013, J BIOMED MATER RES A, V101, P2465, DOI 10.1002/jbm.a.34548
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yang SY, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa68bc
   Yao GQ, 2011, J BONE MINER METAB, V29, P141, DOI 10.1007/s00774 010 0202 3
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
   Yoshii T, 2015, J ORTHOP RES, V33, P1197, DOI 10.1002/jor.22849
   Yoshii T, 2014, J TISSUE ENG REGEN M, V8, P589, DOI 10.1002/term.1547
   Yoshii T, 2010, TISSUE ENG PT A, V16, P2369, DOI [10.1089/ten.tea.2009.0585, 10.1089/ten.TEA.2009.0585]
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
   Yu NYC, 2010, EUR CELLS MATER, V20, P431
   Yu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031771
   Zacchetti G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/549785
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05 0855
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zhang M, 2018, EUR REV MED PHARMACO, V22, P2896, DOI 10.26355/eurrev_201805_14992
   Zhang YF, 2012, J BONE MINER METAB, V30, P666, DOI 10.1007/s00774 012 0363 3
   Zhang Y, 2017, BONE, V97, P222, DOI 10.1016/j.bone.2017.01.029
   Zhang YJ, 2016, PHARM RES DORDR, V33, P1959, DOI 10.1007/s11095 016 1932 2
   Zhang YT, 2014, ENDOCRINE, V47, P598, DOI 10.1007/s12020 014 0196 z
   Zhao X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092085
   Zhao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033228
   Zhou Y, 2017, CELLS TISSUES ORGANS, V204, P25, DOI 10.1159/000464461
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
   Zreiqat H, 2010, BIOMATERIALS, V31, P3175, DOI 10.1016/j.biomaterials.2010.01.024
NR 487
TC 9
Z9 10
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386 0291
EI 1875 8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2019
VL 73
IS 3
BP 439
EP 488
DI 10.3233/CH 199104
PG 50
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA KA3DN
UT WOS:000505678600004
PM 31177207
DA 2025 08 17
ER

PT J
AU Deng, Q
   Li, P
   Che, MJ
   Liu, JJ
   Biswas, S
   Ma, G
   He, L
   Wei, ZY
   Zhang, ZL
   Yang, YZ
   Liu, HJ
   Li, BJ
AF Deng, Qi
   Li, Ping
   Che, Manju
   Liu, Jiajia
   Biswas, Soma
   Ma, Gang
   He, Lin
   Wei, Zhanying
   Zhang, Zhenlin
   Yang, Yingzi
   Liu, Huijuan
   Li, Baojie
TI Activation of hedgehog signaling in mesenchymal stem cells induces
   cartilage and bone tumor formation via Wnt/β Catenin
SO ELIFE
LA English
DT Article
ID INDIAN HEDGEHOG; GROWTH PLATE; OLLIER DISEASE; LIMB; OSTEOBLASTS;
   MUTATIONS; PATCHED1; ROLES; DIFFERENTIATION; MEDULLOBLASTOMA
AB Indian Hedgehog (IHH) signaling, a key regulator of skeletal development, is highly activated in cartilage and bone tumors. Yet deletion of Ptch1, encoding an inhibitor of IHH receptor Smoothened (SMO), in chondrocyte or osteoblasts does not cause tumorigenesis. Here, we show that Ptch1 deletion in mice Prrx1(+) mesenchymal stem/stromal cells (MSCs) promotes MSC proliferation and osteogenic and chondrogenic differentiation but inhibits adipogenic differentiation. Moreover, Ptch1 deletion led to development of osteoarthritis like phenotypes, exostoses, enchondroma, and osteosarcoma in Smo Gli1/2 dependent manners. The cartilage and bone tumors are originated from Prrx1(+) lineage cells and express low levels of osteoblast and chondrocyte markers, respectively. Mechanistically, Ptch1 deletion increases the expression of Wnt5a/6 and leads to enhanced beta Catenin activation. Inhibiting Wnt/beta Catenin pathway suppresses development of skeletal anomalies including enchondroma and osteosarcoma. These findings suggest that cartilage/bone tumors arise from their early progenitor cells and identify the Wnt/beta Catenin pathway as a pharmacological target for cartilage/bone neoplasms.
C1 [Deng, Qi; Li, Ping; Che, Manju; Liu, Jiajia; Biswas, Soma; Ma, Gang; He, Lin; Liu, Huijuan; Li, Baojie] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai, Peoples R China.
   [Wei, Zhanying; Zhang, Zhenlin; Li, Baojie] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Dept Osteoporosis & Bone Dis,Metab Bone Dis & Gen, Shanghai, Peoples R China.
   [Yang, Yingzi] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA.
   [Li, Baojie] Shanghai Jiao Tong Univ, Bio X Renji Hosp, State Key Lab Oncogenes & Related Genes, Sch Med,Renji Hosp,Res Ctr, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Harvard
   University; Harvard School of Dental Medicine; Shanghai Jiao Tong
   University
RP Liu, HJ; Li, BJ (通讯作者)，Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai, Peoples R China.; Li, BJ (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Dept Osteoporosis & Bone Dis,Metab Bone Dis & Gen, Shanghai, Peoples R China.; Li, BJ (通讯作者)，Shanghai Jiao Tong Univ, Bio X Renji Hosp, State Key Lab Oncogenes & Related Genes, Sch Med,Renji Hosp,Res Ctr, Shanghai, Peoples R China.
EM liuhj@sjtu.edu.cn; libj@sjtu.edu.cn
RI Wang, Zhengtao/AAH 7360 2019; Yang, Yingzi/J 3501 2012; HE,
   Lin/KZU 4337 2024; liu, jiajia/ISS 0316 2023
OI Biswas, Soma/0000 0002 1427 2678; 
FU National Key Research and Development Program of China [2017YFA0103602,
   2018YFA0800803]; National Natural Science Foundation of China
   [81520108012, 91542120]; Columbia University
FX National Key Research and Development Program of China 2017YFA0103602
   Huijuan Liu National Key Research and Development Program of China
   2018YFA0800803 Baojie Li National Natural Science Foundation of China
   81520108012 Baojie Li National Natural Science Foundation of China
   91542120 Baojie Li Columbia University Schaefer Research Scholarship
   Baojie Li
CR Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008 5472.CAN 05 2146
   Alman BA, 2015, NAT REV RHEUMATOL, V11, P552, DOI 10.1038/nrrheum.2015.84
   Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389
   Amano K, 2015, J BONE MINER RES, V30, P2262, DOI 10.1002/jbmr.2582
   Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Bruce SJ, 2010, J BIOL CHEM, V285, P27967, DOI 10.1074/jbc.M109.091785
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chan LH, 2014, ONCOGENE, V33, P4857, DOI 10.1038/onc.2013.433
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092 8674(00)81268 4
   Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hirata M, 2015, P NATL ACAD SCI USA, V112, P2829, DOI 10.1073/pnas.1424400112
   Hopyan S, 2002, NAT GENET, V30, P306, DOI 10.1038/ng844
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jeong MH, 2017, P NATL ACAD SCI USA, V114, pE1345, DOI 10.1073/pnas.1615105114
   Jones KB, 2010, P NATL ACAD SCI USA, V107, P2054, DOI 10.1073/pnas.0910875107
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567
   Kindblom JM, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.174R001
   Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Li P, 2019, J BONE MINER RES, V34, P295, DOI 10.1002/jbmr.3596
   Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055
   Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Miwa H, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.155879
   Nazeri E, 2018, CRIT REV ONCOL HEMAT, V131, P102, DOI 10.1016/j.critrevonc.2018.09.001
   Noor A, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001267
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   Schüller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Tarpey PS, 2013, NAT GENET, V45, P923, DOI 10.1038/ng.2668
   Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001
   Williams JN, 2018, J BONE MINER RES, V33, P930, DOI 10.1002/jbmr.3379
   Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192
   Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Yuan X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11024
   Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214 05
NR 46
TC 89
Z9 102
U1 0
U2 23
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD SEP 4
PY 2019
VL 8
AR e50208
DI 10.7554/eLife.50208
PG 24
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA JA7TU
UT WOS:000488050500001
PM 31482846
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Corso, A
   Ferretti, E
   Lazzarino, M
AF Corso, A
   Ferretti, E
   Lazzarino, M
TI Zoledronic acid exerts its antitumor effect in multiple myeloma
   interfering with the bone marrow microenvironment
SO HEMATOLOGY
LA English
DT Article
DE myeloma; zoledronic acid; stromal cells; antitumor activity; plasma
   cells
ID NITROGEN CONTAINING BISPHOSPHONATES; BREAST CANCER CELLS; FARNESYL
   DIPHOSPHATE SYNTHASE; OSTEOCLASTS IN VITRO; RESISTANCE CAM DR; STROMAL
   CELLS; PLASMA CELLS; THERAPEUTIC APPLICATIONS; INDUCE APOPTOSIS;
   ADHESION
AB Multiple myeloma (MM) is a B cell malignancy characterized by an excess of monotypic plasma cells which localize almost exclusively in the bone marrow provoking bone destruction via the activation of the osteoclasts. The bone marrow microenvironment, mainly through stromal cells, is strictly involved in the evolution of the disease supporting MM cell growth and survival [1]. MM plasma cells reside in the bone marrow by binding to adhesion molecule of extracellular matrix (ECM) and stromal cells. The activation of some signaling pathways within the stromal cells increases the production of several cytokines which in turn favors the myeloma cell proliferation and survival [2 6], and enhance the drug resistance by antiapoptotic mechanisms [1,7 9]. Novel therapeutic agents target not only the myeloma cells but also the interaction between MM cells and the bone marrow microenvironment [8]. Bisphosphonates (Bps) interfere as well with bone microenvironment inhibiting the survival of stromal cells and hampering the contact between plasma and stromal cells.
   In this review we will revise preclinical evidences, and the potential mechanisms of the antitumor activity of zoledronic acid.
C1 Univ Pavia, Policlin San Matteo, IRCCS, Div Hematol, I 27100 Pavia, Italy.
C3 University of Pavia; IRCCS Fondazione San Matteo
RP Corso, A (通讯作者)，Univ Pavia, Policlin San Matteo, IRCCS, Div Hematol, Via Golgi 2, I 27100 Pavia, Italy.
EM a.corso@smatteo.pv.it
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Alsina M, 2004, BLOOD, V103, P3271, DOI 10.1182/blood 2003 08 2764
   Anderson KC, 2001, SEMIN HEMATOL, V38, P286, DOI 10.1053/shem.2001.26010
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Berenson JR, 1999, ANNU REV MED, V50, P237
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Boissier S, 1997, CANCER RES, V57, P3890
   Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234
   Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   CORSO A, IN PRESS CANCER
   Croucher P, 2003, BREAST, V12, pS30, DOI 10.1016/S0960 9776(03)80161 3
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Gordon S, 2002, BRIT J HAEMATOL, V119, P475, DOI 10.1046/j.1365 2141.2002.03824.x
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600 065X.2003.00053.x
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   KAWANO MM, 1991, BRIT J HAEMATOL, V79, P583, DOI 10.1111/j.1365 2141.1991.tb08085.x
   Kunzmann V, 2000, BLOOD, V96, P384
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Sanz Rodríguez F, 1999, BRIT J HAEMATOL, V107, P825, DOI 10.1046/j.1365 2141.1999.01762.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889 8588(05)70413 5
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   UCHIYAMA H, 1993, BLOOD, V82, P3712
   Urashima M, 1996, LEUKEMIA RES, V20, P507, DOI 10.1016/0145 2126(95)00098 4
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   WELCH DR, 2003, ONCOLOGY S, V17, P18
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yoneda T, 1998, EUR J CANCER, V34, P240, DOI 10.1016/S0959 8049(97)10132 0
   Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood 2002 06 1737
NR 74
TC 27
Z9 30
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1024 5332
J9 HEMATOLOGY
JI Hematology
PD JUN
PY 2005
VL 10
IS 3
BP 215
EP 224
DI 10.1080/10245330500094714
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 949LL
UT WOS:000230790100006
PM 16019470
DA 2025 08 17
ER

PT J
AU Wang, N
   Yang, SD
   Tan, T
   Huang, YR
   Chen, YM
   Dong, CQ
   Chen, J
   Luo, XJ
AF Wang, Nan
   Yang, Shengdong
   Tan, Tao
   Huang, Yanran
   Chen, Yangmei
   Dong, Chaoqun
   Chen, Jin
   Luo, Xiaoji
TI Tetrandrine suppresses the growth of human osteosarcoma cells by
   regulating multiple signaling pathways
SO BIOENGINEERED
LA English
DT Article
DE Osteosarcoma; tetrandrine; cell growth; anticancer effect; multiple
   signaling pathways
ID TUMOR GROWTH; MAPK; DIFFERENTIATION; CYTOTOXICITY; ANGIOGENESIS;
   CHEMOTHERAPY; APOPTOSIS; ADJUVANT; KINASE; ASSAY
AB Although osteosarcoma (OS) is the most common malignant tumor among juvenile bone tumors, its treatment plan and clinical outcome have not improved significantly in recent decades. Tetrandrine (TET), a Chinese medicine that is usually used in the therapy of silicosis, hypertension and arthritis, has been confirmed by many studies to possess potent antitumour growth properties, but there are different limitations when describing specific mechanisms. Here, we found that TET can obviously prevent the proliferation, migration and invasion of both 143B and MG63 cells and promote their apoptosis in vitro. Our results for luciferase reporter and Western blotting assays show that TET may exert its antitumour activity by regulating multiplex signaling pathways, including the MAPK/Erk, PTEN/Akt, Juk and Wnt signaling pathways. Furthermore, the regulatory effect of TET on OS cells and related signaling pathways was verified again in vivo. Our findings suggest that the anticancer function of TET on human OS may be mediated by its targeting of multiple signaling pathways and that TET may be used as a single drug or in combination with other drugs during the treatment of OS.
C1 [Wang, Nan] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 3, Chongqing, Peoples R China.
   [Yang, Shengdong] Chongqing Med Univ, Dept Orthoped, Univ Town Hosp, Chongqing, Peoples R China.
   [Tan, Tao; Huang, Yanran; Luo, Xiaoji] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
   [Chen, Yangmei; Chen, Jin] Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Dong, Chaoqun] Chongqing Tradit Chinese Med Hosp, Dept Gen Surg, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University
RP Luo, XJ (通讯作者)，Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
EM cy2982@163.com
RI Chen, Yaoliang/AAP 3042 2020
FU National Natural Science Foundation of China [81873998]; Natural Science
   Foundation Project of Chongqing Science and Technology Commission [cstc
   2017jcyjAX]
FX This study was funded by the National Natural Science Foundation of
   China (81873998) and the Natural Science Foundation Project of Chongqing
   Science and Technology Commission (No. cstc 2017jcyjAX).
CR Bajelan E, 2012, J PHARM PHARM SCI, V15, P568, DOI 10.18433/J3SC7J
   Benjamin RS, 2020, ADV EXP MED BIOL, V1257, P1, DOI 10.1007/978 3 030 43032 0_1
   Chew MH, 2015, ANN ACAD MED SINGAP, V44, P290
   Conley LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 85
   Gao JL, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/265061
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   Heymann MF, 2016, EXPERT OPIN INV DRUG, V25, P1265, DOI 10.1080/13543784.2016.1237503
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Jaffe N, 2009, CANCER TREAT RES, V152, P239, DOI 10.1007/978 1 4419 0284 9_12
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Lee MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8769
   Leelahavanichkul K, 2014, MOL ONCOL, V8, P105, DOI 10.1016/j.molonc.2013.10.003
   Li XD, 2011, J SURG RES, V166, pE45, DOI 10.1016/j.jss.2010.10.034
   Liu CY, 2011, INT J CANCER, V129, P1519, DOI 10.1002/ijc.25817
   Liu T, 2016, ONCOTARGET, V7, P40800, DOI 10.18632/oncotarget.8315
   Lu JJ, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/485042
   Luan F, 2020, J PHARM PHARMACOL, V72, P1491, DOI 10.1111/jphp.13339
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037
   ROSEN G, 1982, CANCER AM CANCER SOC, V49, P1221, DOI 10.1002/1097 0142(19820315)49:6<1221::AID CNCR2820490625>3.0.CO;2 E
   Rosen G., 2015, CANCER, V35, P936
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Shi Duo Xuan, 2014, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V22, P723, DOI 10.7534/j.issn.1009 2137.2014.03.028
   Tang CL, 2014, INT J CLIN EXP PATHO, V7, P959
   Wang N, 2017, ONCOTARGET, V8, P109661, DOI 10.18632/oncotarget.22763
   Wu JM, 2010, CANCER LETT, V287, P187, DOI 10.1016/j.canlet.2009.06.009
   Xiao F, 2012, WORLD J GASTROENTERO, V18, P7348, DOI 10.3748/wjg.v18.i48.7348
   Xu HE, 2016, J BIOMED NANOTECHNOL, V12, P1699, DOI 10.1166/jbn.2016.2293
   Zhao P, 2015, ONCOTARGET, V6, P31901, DOI 10.18632/oncotarget.5043
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
NR 32
TC 7
Z9 9
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN 1
PY 2021
VL 12
IS 1
BP 5870
EP 5882
DI 10.1080/21655979.2021.1967034
PG 13
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA UK9AM
UT WOS:000692256400001
PM 34477474
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yamaguchi, M
   Weitzmann, MN
AF Yamaguchi, Masayoshi
   Weitzmann, M. Neale
TI Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by
   antagonizing NF κB activation
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Zinc; Nuclear factor kappa B; Osteoclast; Osteoblast; Bone resorption;
   Bone formation
ID TUMOR NECROSIS FACTOR; FEMORAL METAPHYSEAL TISSUES; BONE RESORPTION;
   BETA CRYPTOXANTHIN; ESTROGEN DEFICIENCY; TNF ALPHA; INFLAMMATORY
   ARTHRITIS; MC3T3 PREOSTEOBLASTS; SMAD ACTIVATION; IN VITRO
AB Zinc is essential for numerous biochemical pathways in the body and is known to significantly affect the skeleton. Zinc has a profound effect on bone turnover promoting bone formation and mineralization, but paradoxically inhibiting osteoclastic bone breakdown (resorption). How zinc regulates these disparate effects on bone cells, however, is poorly understood. We recently characterized several pharmacological and nutritional factors that are likewise endowed with the capacity to promote bone formation and suppress bone resorption and demonstrated that a common centralized mechanism for achieving such actions is through suppression of NF kappa B activation. NF kappa B is a pathway required for osteoclastogenesis, but suppresses osteoblast differentiation. In this study, we investigated the actions of zinc on NF kappa B activation in osteoclast and osteoblast precursors in vitro. Our data show that zinc suppressed osteoclast differentiation and promoted osteoblast mineralization and did indeed act as a potent NF kappa B activation antagonist in both osteoclast and osteoblast precursors. Importantly, zinc antagonized NF kappa B activation driven by TNF alpha, a potent inflammatory mediator or bone resorption and suppressor of bone formation in vitro and in vivo. Zinc further alleviated the suppressive effect of TNF alpha on Smad activation induced by TGF beta and BMP2, cytokines that play critical roles in osteoblast commitment, differentiation, and recruitment to sites of bone remodeling. In conclusion, our data reveal for the first time that a major mechanism by which zinc promotes osteoblastogenesis and suppresses osteoclastogenesis may center on the antagonism of NF kappa B activation.
C1 [Yamaguchi, Masayoshi; Weitzmann, M. Neale] Emory Univ, Dept Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Emory University
RP Yamaguchi, M (通讯作者)，Emory Univ, Dept Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1329 WMRB, Atlanta, GA 30322 USA.
EM yamamasa1155@yahoo.co.jp; mweitzm@emory.edu
CR ANGUS RM, 1988, BONE MINER, V4, P265
   Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763
   Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   Bao SY, 2010, AM J PHYSIOL LUNG C, V298, pL744, DOI 10.1152/ajplung.00368.2009
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736 0266(03)00156 6
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Dimai HP, 1998, CALCIFIED TISSUE INT, V62, P309, DOI 10.1007/s002239900437
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ehara Y, 1996, RES EXP MED, V196, P171
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hadley KB, 2010, J NUTR BIOCHEM, V21, P297, DOI 10.1016/j.jnutbio.2009.01.002
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   LEEK JC, 1984, AM J CLIN NUTR, V40, P1203, DOI 10.1093/ajcn/40.6.1203
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143
   MOONGA BS, 1995, J BONE MINER RES, V10, P453
   Nagata M, 2011, J NUTR BIOCHEM, V22, P172, DOI 10.1016/j.jnutbio.2010.01.003
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   SANSTEAD HH, 1967, AM J CLIN NUTR, V20, P422, DOI 10.1093/ajcn/20.5.422
   SEGAWA Y, 1993, BIOL PHARM BULL, V16, P656
   Strait K, 2008, INT J MOL MED, V21, P521
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Uchiyama S, 2008, MOL CELL BIOCHEM, V307, P209, DOI 10.1007/s11010 007 9600 9
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Wahl EC, 2010, J BONE MINER RES, V25, P114, DOI 10.1359/jbmr.090708
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yamaguchi M, 1998, MOL CELL BIOCHEM, V178, P377, DOI 10.1023/A:1006809031836
   Yamaguchi M, 2008, INT J MOL MED, V22, P221, DOI 10.3892/ijmm_00000012
   Yamaguchi M, 2010, MOL CELL BIOCHEM, V338, P241, DOI 10.1007/s11010 009 0358 0
   Yamaguchi M, 2009, INT J MOL MED, V24, P671, DOI 10.3892/ijmm_00000278
   Yamaguchi M, 2009, MOL MED REP, V2, P641, DOI 10.3892/mmr_00000150
   Yamaguchi M, 2009, INT J MOL MED, V23, P297, DOI 10.3892/ijmm_00000131
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 49
TC 169
Z9 180
U1 2
U2 66
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD SEP
PY 2011
VL 355
IS 1 2
BP 179
EP 186
DI 10.1007/s11010 011 0852 z
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 800ZD
UT WOS:000293405300021
PM 21533765
DA 2025 08 17
ER

PT J
AU Kim, JH
   Kim, K
   Kim, I
   Seong, S
   Che, XG
   Choi, JY
   Koh, JT
   Kim, N
AF Kim, Jung Ha
   Kim, Kabsun
   Kim, Inyoung
   Seong, Semun
   Che, Xiangguo
   Choi, Je Yong
   Koh, Jeong Tae
   Kim, Nacksung
TI The MCP 3/Ccr3 axis contributes to increased bone mass by affecting
   osteoblast and osteoclast differentiation
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID INDUCTION; MICE
AB Several CC subfamily chemokines have been reported to regulate bone metabolism by affecting osteoblast or osteoclast differentiation. However, the role of monocyte chemotactic protein 3 (MCP 3), a CC chemokine, in bone remodeling is not well understood. Here, we show that MCP 3 regulates bone remodeling by promoting osteoblast differentiation and inhibiting osteoclast differentiation. In a Ccr3 dependent manner, MCP 3 promoted osteoblast differentiation by stimulating p38 phosphorylation and suppressed osteoclast differentiation by upregulating interferon beta. MCP 3 increased bone morphogenetic protein 2 induced ectopic bone formation, and mice with MCP 3 overexpressing osteoblast precursor cells presented increased bone mass. Moreover, MCP 3 exhibited therapeutic effects by abrogating receptor activator of nuclear factor kappa B ligand induced bone loss. Therefore, MCP 3 has therapeutic potential for diseases involving bone loss due to its positive role in osteoblast differentiation and negative role in osteoclast differentiation.
   Our bones are always changing, needing a balance between bone creation and bone breakdown. Researchers investigates how a specific protein, MCP 3, affects this balance. They found that MCP 3 promotes the creation of osteoblasts and stops the creation of osteoclasts. The study involved both in vitro and in vivo methods, looking at how changing MCP 3 levels impacts bone change processes. Researchers found that increasing MCP 3 levels in bone making cells resulted in stronger bones in mice, suggesting MCP 3 is key in promoting bone creation and stopping excessive bone loss. This was partly due to MCP 3's interaction with specific cell receptors and signaling pathways that affect bone cell activity. This research paves the way for future studies on MCP 3 as a target for bone strengthening therapies, potentially leading to new treatments for diseases that weaken bones. This summary was initially drafted using artificial intelligence, then revised and fact checked by the author.
C1 [Kim, Jung Ha; Kim, Kabsun; Kim, Inyoung; Seong, Semun; Kim, Nacksung] Chonnam Natl Univ, Med Sch, Dept Pharmacol, Gwangju, South Korea.
   [Kim, Inyoung; Seong, Semun; Koh, Jeong Tae; Kim, Nacksung] Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju, South Korea.
   [Che, Xiangguo; Choi, Je Yong] Kyungpook Natl Univ, Cell Matrix Res Inst, Sch Med, Korea Mouse Phenotyping Ctr KMPC,Dept Biochem & Ce, Daegu, South Korea.
   [Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju, South Korea.
C3 Chonnam National University; Chonnam National University; Kyungpook
   National University (KNU); Chonnam National University
RP Kim, N (通讯作者)，Chonnam Natl Univ, Med Sch, Dept Pharmacol, Gwangju, South Korea.; Kim, N (通讯作者)，Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju, South Korea.
EM nacksung@jnu.ac.kr
RI ; Choi, Je Yong/AAR 7334 2021
OI Choi, Je Yong/0000 0002 5057 8842; Koh, Jeong Tae/0000 0001 6279 6487
FU National Research Foundation of Korea (NRF) [NRF 2019R1A5A2027521,
   RS 2023 00243446]; National Research Foundation of Korea (NRF)   Korean
   government (MSIT)
FX This work was supported by National Research Foundation of Korea (NRF)
   grants funded by the Korean government (MSIT; NRF 2019R1A5A2027521 and
   RS 2023 00243446).
CR BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Ford J, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03063
   Hu JY, 2002, WORLD J GASTROENTERO, V8, P1067, DOI 10.3748/wjg.v8.i6.1067
   Hu XL, 2024, J ADV RES, V62, P175, DOI 10.1016/j.jare.2023.09.001
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Kim Jung Ha, 2020, Chonnam Med J, V56, P94
   Kim Kabsun, 2022, J Bone Metab, V29, P165, DOI 10.11005/jbm.2022.29.3.165
   Kitase Y, 2014, J DENT RES, V93, P1108, DOI 10.1177/0022034514553008
   Lee Hwa Yeong, 2023, J Bone Metab, V30, P253, DOI 10.11005/jbm.2023.30.3.253
   Lee J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222559
   LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395 267
   Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Park JH, 2017, MOL CELLS, V40, P706
   Rosendahl S, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015571
   SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59
   Wintges K, 2013, J BONE MINER RES, V28, P2070, DOI 10.1002/jbmr.1937
   Yamada N, 2002, BONE, V30, P901, DOI 10.1016/S8756 3282(02)00722 6
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
   Zhang J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.56
NR 27
TC 0
Z9 0
U1 1
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD NOV
PY 2024
VL 56
IS 11
BP 2465
EP 2474
DI 10.1038/s12276 024 01344 6
EA NOV 2024
PG 10
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA P1W4D
UT WOS:001345373500009
PM 39482538
OA gold
DA 2025 08 17
ER

PT J
AU Agholme, F
   Aspenberg, P
AF Agholme, Fredrik
   Aspenberg, Per
TI Wnt signaling and orthopedics, an overview
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID INCREASES BONE FORMATION; RECEPTOR RELATED PROTEIN 5; SCLEROSTIN
   ANTIBODY; FRACTURE REPAIR; MINERAL DENSITY; DICKKOPF 1 DKK1; RAT MODEL;
   IN VIVO; MASS; GENE
AB Wnt signaling is a ubiquitous system for intercellular communication, with multiple functions during development and in homeostasis of the body. It comprises several ligands, receptors, and inhibitors. Some molecules, such as sclerostin, appear to have bone specific functions, and can be targeted by potential drugs. Now, ongoing clinical trials are testing these drugs as treatments for osteoporosis. Animal studies have also suggested that these drugs can accelerate fracture healing and implant fixation. This brief overview focuses on currently available information on the effects of manipulations of Wnt signaling on bone healing.
C1 [Agholme, Fredrik; Aspenberg, Per] Linkoping Univ, Dept Clin & Expt Med, IKE, Fac Hlth Sci, Linkoping, Sweden.
C3 Linkoping University
RP Agholme, F (通讯作者)，Linkoping Univ, Dept Clin & Expt Med, IKE, Fac Hlth Sci, Linkoping, Sweden.
EM fredrik.agholme@liu.se
RI ; Isaksson, Hanna/L 1340 2015; Agholme, Fredrik/G 9615 2012
OI Li, Xiaodong/0000 0002 2089 5046; Isaksson, Hanna/0000 0002 9690 8907; 
CR Agarwal R, 2009, J NEUROSURG SPINE, V11, P729, DOI 10.3171/2009.6.SPINE08669
   AGHOLME F, 2011, BONE
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Case N, 2010, J CELL BIOCHEM, V110, P545, DOI 10.1002/jcb.22574
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Galli C, 2010, J DENT RES, V89, P331, DOI 10.1177/0022034510363963
   GAMBARDELLA A, 2010, J BONE MINER RES
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Komatsu DE, 2010, J CELL BIOCHEM, V109, P302, DOI 10.1002/jcb.22418
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   MCDONALD M, 2010, J BONE MINER RES S1, V25
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2015, DOI 10.1016/j.biomaterials.2009.11.071
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Ominsky MS., 2010, J BONE MINER RES
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Riancho JA, 2011, EUR J ENDOCRINOL, V164, P123, DOI 10.1530/EJE 10 0582
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092 8674(87)90038 9
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P1, DOI 10.1007/s00223 004 0258 y
   Wise JK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012987
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
NR 53
TC 54
Z9 66
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745 3674
EI 1745 3682
J9 ACTA ORTHOP
JI Acta Orthop.
PD APR
PY 2011
VL 82
IS 2
BP 125
EP 130
DI 10.3109/17453674.2011.572252
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 745NA
UT WOS:000289170900001
PM 21438671
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Shuai, Y
   Yang, R
   Mu, R
   Yu, Y
   Rong, L
   Jin, L
AF Shuai, Yi
   Yang, Rui
   Mu, Rui
   Yu, Yang
   Rong, Liang
   Jin, Lei
TI MiR 199a 3p mediates the adipogenic differentiation of bone
   marrow derived mesenchymal stem cells by regulating KDM6A/WNT signaling
SO LIFE SCIENCES
LA English
DT Article
DE miR 199a 3p; KDM6A; WNT signaling; Adipogenic differentiation
ID OSTEOGENIC DIFFERENTIATION; STROMAL CELLS; ADIPOCYTE; EXPRESSION;
   IMPROVES; EZH2; SUPPRESSION; MICRORNAS; PREVENTS; PATHWAY
AB A number of evidences suggest that microRNAs are involved in the adipogenic commitment of mesenchymal stem cells (MSCs). Recent studies have investigated that miR 199a 3p played a pivotal role in adipocyte differentiation. However, the detailed mechanism in this complex biological process remains largely unknown. In current study, we found that the expression of miR 199a 3p was gradually increased during adipogenic differentiation of bone marrow derived mesenchymal stem cells (BMMSCs). Enhanced expression of miR 199a 3p promoted adipogenesis, whereas silence of miR 199a 3p rescued BMMSCs from adipogenic commitment. For further mechanism exploration, KDM6A was confirmed to be the target of miR 199a 3p and the expression of KDM6A was gradually decreased during adipogenic differentiation of BMMSCs. Furthermore, up regulation of KDM6A markedly abolished the miR 199a 3p overexpression induced adipogenic augmentation, whereas down regulation of KDM6A suppressed the adipogenic reduction caused by miR 199a 3p silence. In addition, WNT signaling was also verified to be the downstream of miR 199a 3p/KDM6A to regulate adipogenic differentiation of BMMSCs. Taken together, current results indicate that miR 199a 3p regulate adipogenesis of BMMSCs by targeting KDM6A/WNT signaling, which highlights a new insight for a better understanding of molecular mechanism and stem cell based therapy on osteoporotic diseases.
C1 [Shuai, Yi; Mu, Rui; Rong, Liang; Jin, Lei] Nanjing Univ, Sch Med, Nanjing Mil Command, Jin Ling Hosp,Nanjing Gen Hosp,Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China.
   [Yang, Rui] PLA Army Gen Hosp, Dept Stomatol, Beijing 100000, Peoples R China.
   [Yu, Yang] Chongqing Med Univ, Dept Endodont, Affiliated Stomatol Hosp, Chongqing 404100, Peoples R China.
C3 Nanjing General Hospital; Nanjing University; Chongqing Medical
   University
RP Jin, L (通讯作者)，Nanjing Univ, Sch Med, Nanjing Mil Command, Jin Ling Hosp,Nanjing Gen Hosp,Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China.
EM Ljin@nju.edu.cn
RI Shuai, Yi/ABQ 4038 2022
FU Natural Science Foundation of China [81571817, 81771992, 81800979]
FX This project was funded by the Natural Science Foundation of China
   (grant nos. 81571817, 81771992, 81800979).
CR Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003
   Asgharzadeh A, 2018, BOSNIAN J BASIC MED, V18, P328, DOI 10.17305/bjbms.2018.2633
   Bai GY, 2018, ZYGOTE, V26, P24, DOI 10.1017/S0967199417000673
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bolamperti S, 2018, BONE, V112, P136, DOI 10.1016/j.bone.2018.04.014
   Chou RH, 2011, AM J TRANSL RES, V3, P243
   Cregan S, 2017, INT J ONCOL, V50, P1044, DOI 10.3892/ijo.2017.3870
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Gao Y, 2018, MOL CELL ENDOCRINOL, V476, P155, DOI 10.1016/j.mce.2018.05.005
   Gu N, 2016, MOL MED REP, V14, P1180, DOI 10.3892/mmr.2016.5379
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Ji H, 2018, BIOCHEM BIOPH RES CO, V504, P352, DOI 10.1016/j.bbrc.2018.08.196
   Jiang W, 2013, CELL RES, V23, P122, DOI 10.1038/cr.2012.119
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kokabu S, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3753581
   Kong XY, 2017, INT J BIOL SCI, V13, P480, DOI 10.7150/ijbs.18430
   Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312
   Li BB, 2018, CURR STEM CELL RES T, V13, P26, DOI 10.2174/1574888X12666170605112727
   Li XN, 2018, MOL CELL BIOCHEM, V449, P295, DOI 10.1007/s11010 018 3366 0
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Liu JM, 2018, PATHOL RES PRACT, V214, P806, DOI 10.1016/j.prp.2018.05.005
   Liu SY, 2015, CELL METAB, V22, P606, DOI 10.1016/j.cmet.2015.08.018
   Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078 0432.CCR 14 0330
   Phatak Pornima, 2018, Oncotarget, V9, P28391, DOI 10.18632/oncotarget.25375
   Porntaveetus T, 2018, INT J BIOL SCI, V14, P381, DOI 10.7150/ijbs.23517
   Qu F, 2017, ONCOTARGET, V8, P52465, DOI 10.18632/oncotarget.17191
   Shuai Y, 2016, THERANOSTICS, V6, P1899, DOI 10.7150/thno.15412
   Tan ZD, 2017, BIOCHEM BIOPH RES CO, V492, P82, DOI 10.1016/j.bbrc.2017.08.030
   Teng ZW, 2016, J BIOL REG HOMEOS AG, V30, P345
   Terashima M, 2017, BIOCHEM BIOPH RES CO, V490, P1407, DOI 10.1016/j.bbrc.2017.07.048
   Trohatou O, 2017, STEM CELLS DEV, V26, P482, DOI 10.1089/scd.2016.0203
   Ukita M, 2016, J CELL BIOCHEM, V117, P1419, DOI 10.1002/jcb.25432
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang HQ, 2017, CELL PHYSIOL BIOCHEM, V41, P530, DOI 10.1159/000457013
   Wang PT, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12413
   Wang YL, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0980 4
   Wu MR, 2017, P NATL ACAD SCI USA, V114, P10119, DOI 10.1073/pnas.1619294114
   Ye XH, 2014, CYTOTHERAPY, V16, P1643, DOI 10.1016/j.jcyt.2014.07.009
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhang W, 2017, J RECEPT SIG TRANSD, V37, P217, DOI 10.1080/10799893.2016.1212375
   Zhou J, 2017, FASEB J, V31, P1939, DOI 10.1096/fj.201600975RR
   Zhu ED, 2018, J MOL ENDOCRINOL, V60, P225, DOI 10.1530/JME 17 0183
NR 42
TC 29
Z9 34
U1 0
U2 30
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD MAR 1
PY 2019
VL 220
BP 84
EP 91
DI 10.1016/j.lfs.2019.01.051
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HL0RF
UT WOS:000458400900010
PM 30710639
DA 2025 08 17
ER

PT J
AU Gong, XY
   Sun, SY
   Yang, YL
   Huang, XR
   Gao, X
   Jin, AT
   Xu, HY
   Wang, XJ
   Liu, YQ
   Liu, JY
   Dai, QG
   Jiang, LY
AF Gong, Xinyi
   Sun, Siyuan
   Yang, Yiling
   Huang, Xiangru
   Gao, Xin
   Jin, Anting
   Xu, Hongyuan
   Wang, Xijun
   Liu, Yuanqi
   Liu, Jingyi
   Dai, Qinggang
   Jiang, Lingyong
TI Osteoblastic STAT3 Is Crucial for Orthodontic Force Driving Alveolar
   Bone Remodeling and Tooth Movement
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE MECHANICAL FORCE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3
   (STAT3); BONE REMODELING; ORTHODONTIC TOOTH MOVEMENT;
   OSTEOBLAST OSTEOCLAST CROSS TALK
ID ENDOTHELIAL CELLS; MALOCCLUSION; EXPRESSION
AB Mechanical force is essential to shape the internal architecture and external form of the skeleton by regulating the bone remodeling process. However, the underlying mechanism of how the bone responds to mechanical force remains elusive. Here, we generated both orthodontic tooth movement (OTM) model in vivo and a cyclic stretch loading model in vitro to investigate biomechanical regulation of the alveolar bone. In this study, signal transducer and activator of transcription 3 (STAT3) was screened as one of the mechanosensitive proteins by protein array analysis of cyclic stretch loaded bone mesenchymal stem cells (BMSCs) and was also proven to be activated in osteoblasts in response to the mechanical force during OTM. With an inducible osteoblast linage specific Stat3 knockout model, we found that Stat3 deletion decelerated the OTM rate and reduced orthodontic force induced bone remodeling, as indicated by both decreased bone resorption and formation. Both genetic deletion and pharmacological inhibition of STAT3 in BMSCs directly inhibited mechanical force induced osteoblast differentiation and impaired osteoclast formation via osteoblast osteoclast cross talk under mechanical force loading. According to RNA seq analysis of Stat3 deleted BMSCs under mechanical force, matrix metalloproteinase 3 (Mmp3) was screened and predicted to be a downstream target of STAT3. The luciferase and ChIP assays identified that Stat3 could bind to the Mmp3 promotor and upregulate its transcription activity. Furthermore, STAT3 inhibitor decelerated tooth movement through inhibition of the bone resorption activity, as well as MMP3 expression. In summary, our study identified the mechanosensitive characteristics of STAT3 in osteoblasts and highlighted its critical role in force induced bone remodeling during orthodontic tooth movement via osteoblast osteoclast cross talk. (C) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Gong, Xinyi; Sun, Siyuan; Yang, Yiling; Huang, Xiangru; Gao, Xin; Jin, Anting; Xu, Hongyuan; Wang, Xijun; Liu, Yuanqi; Liu, Jingyi; Jiang, Lingyong] Shanghai Jiao Tong Univ, Sch Med,Shaghai Peoples Hosp 9, Shanghai Peoples Hosp 9,Dept Oral & Craniomaxillof, Coll Stomatol,Ctr Craniofacial Orthodont, Shanghai, Peoples R China.
   [Gong, Xinyi; Sun, Siyuan; Yang, Yiling; Huang, Xiangru; Gao, Xin; Jin, Anting; Xu, Hongyuan; Wang, Xijun; Liu, Yuanqi; Liu, Jingyi; Jiang, Lingyong] Natl Ctr Stomatol, Shanghai, Peoples R China.
   [Gong, Xinyi; Sun, Siyuan; Yang, Yiling; Huang, Xiangru; Gao, Xin; Jin, Anting; Xu, Hongyuan; Wang, Xijun; Liu, Yuanqi; Liu, Jingyi; Jiang, Lingyong] Shanghai Res Inst Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Dai, Qinggang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dent Ctr 2, Sch Med, Shanghai, Peoples R China.
   [Jiang, Lingyong] Shanghai Jiao Tong Univ, Sch Med,Shaghai Peoples Hosp 9, Shanghai Peoples Hosp 9,Dept Oral & Craniomaxillof, Coll Stomatol,Ctr Craniofacial Orthodont, Shanghai 200011, Peoples R China.
   [Jiang, Lingyong] Natl Ctr Stomatol, Shanghai 200011, Peoples R China.
   [Jiang, Lingyong] Shanghai Res Inst Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.
   [Dai, Qinggang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dent Ctr 2, Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University
RP Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med,Shaghai Peoples Hosp 9, Shanghai Peoples Hosp 9,Dept Oral & Craniomaxillof, Coll Stomatol,Ctr Craniofacial Orthodont, Shanghai 200011, Peoples R China.; Jiang, LY (通讯作者)，Natl Ctr Stomatol, Shanghai 200011, Peoples R China.; Jiang, LY (通讯作者)，Shanghai Res Inst Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.; Dai, QG (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dent Ctr 2, Sch Med, Shanghai 200011, Peoples R China.
EM daiqinggang@126.com; jianglingyong@sjtu.edu.cn
RI Sun, Siyuan/ITV 0582 2023; huang, xiangru/HJH 8638 2023; Qinggang,
   Dai/HLV 8212 2023
OI Dai, Qinggang/0000 0002 8177 2496; 
FU National Natural Science Foundation of China [82271006, 82101048,
   82071083, 81870740, 81570950]; Natural Science Foundation of Shanghai
   [21ZR1436900, 22ZR1436700]; Program of Shanghai Academic/Technology
   Research Leader [20XD1422300]; Clinical Research Plan of SHDC
   [SHDC2020CR4084]; Cross disciplinary Research Fund of Shanghai Ninth
   People's Hospital, Shanghai Jiao Tong University School of Medicine
   [JYJC201902, JYJC202116]; Innovation Research Team of High Level Local
   Universities in Shanghai [SSMU ZLCX20180501]; Ninth People's Hospital,
   Shanghai Jiao Tong University School of Medicine, and College of
   Stomatology, Shanghai Jiao Tong University [KQYJXK2020]; Original
   Exploration Project of Shanghai Ninth People's Hospital, Shanghai Jiao
   Tong University School of Medicine [JYYC003]; Two Hundred Talent Project
   of Shanghai Jiao Tong University School of Medicine
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (82271006, 82101048, 82071083, 81870740,
   81570950); the Natural Science Foundation of Shanghai (21ZR1436900,
   22ZR1436700); the Program of Shanghai Academic/Technology Research
   Leader (20XD1422300); Clinical Research Plan of SHDC (SHDC2020CR4084);
   the Cross disciplinary Research Fund of Shanghai Ninth People's
   Hospital, Shanghai Jiao Tong University School of Medicine (JYJC201902,
   JYJC202116); the Innovation Research Team of High Level Local
   Universities in Shanghai (SSMU ZLCX20180501); the Research Discipline
   Fund no. KQYJXK2020 from Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine, and College of Stomatology, Shanghai Jiao
   Tong University; Original Exploration Project of Shanghai Ninth People's
   Hospital, Shanghai Jiao Tong University School of Medicine (JYYC003);
   Two Hundred Talent Project of Shanghai Jiao Tong University School of
   Medicine.
CR An S, 2019, AM J ORTHOD DENTOFAC, V155, P642, DOI 10.1016/j.ajodo.2018.05.026
   Birks S, 2021, BONE, V151, DOI 10.1016/j.bone.2021.116023
   Cao H, 2014, J DENT RES, V93, P1163, DOI 10.1177/0022034514551769
   Corry KA, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100218
   Dai QG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04422 0
   Dowlati A, 2004, MOL CANCER THER, V3, P459
   Egic B, 2022, EUR J PAEDIATR DENT, V23, P39, DOI 10.23804/ejpd.2022.23.01.07
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Frost HM, 2000, J BONE MINER METAB, V18, P305, DOI 10.1007/s007740070001
   Garcia AJ, 2013, J BONE MINER RES, V28, P283, DOI 10.1002/jbmr.1747
   Góis EG, 2012, ANGLE ORTHOD, V82, P495, DOI 10.2319/033011 230.1
   Gu QG, 2018, CELL PHYSIOL BIOCHEM, V48, P215, DOI 10.1159/000491721
   Guadagnin E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082265
   Hamzeh MT, 2015, AM J PHYSIOL RENAL, V308, pF425, DOI 10.1152/ajprenal.00589.2014
   Hardy E, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00047
   He LJ, 2017, J CLIN INVEST, V127, P2968, DOI 10.1172/JCI93868
   Huang CY, 2013, TRENDS MOL MED, V19, P555, DOI 10.1016/j.molmed.2013.05.005
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jin A, 2022, J DENT RES, V101, P196, DOI 10.1177/00220345211021534
   Jin YQ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68068 1
   Johnson GP, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115846
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Liu F, 2017, J DENT RES, V96, P694, DOI 10.1177/0022034517690388
   Liu Y, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12974
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ransom RC, 2018, NATURE, V563, P514, DOI 10.1038/s41586 018 0650 9
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Saikia B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626593
   Sibonga JD, 2013, CURR OSTEOPOROS REP, V11, P92, DOI 10.1007/s11914 013 0136 5
   Paiva KBS, 2014, ARCH BIOCHEM BIOPHYS, V561, P74, DOI 10.1016/j.abb.2014.07.034
   Tahimic CGT, 2016, J BIOL CHEM, V291, P8140, DOI 10.1074/jbc.M115.693598
   van de Veen W, 2019, ALLERGY, V74, P2394, DOI 10.1111/all.13969
   Wang CD, 2017, EXP CELL RES, V352, P346, DOI 10.1016/j.yexcr.2017.02.021
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wolff J., 1893, Dtsch Med Wochenschr, V19, P1222, DOI [DOI 10.1055/S 0028 1144106, 10.1055/s 0028 1144106]
   Wolfson RK, 2014, MICROVASC RES, V92, P50, DOI 10.1016/j.mvr.2013.12.005
   Xie YH, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108811
   Xu HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12743
   Xu LJ, 2018, J CELL BIOCHEM, V119, P3819, DOI 10.1002/jcb.26332
   Yang CY, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 017 0004 8
   Yang YH, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01635 5
   Yu X, 2018, BIOL CHEM, V399, P1313, DOI 10.1515/hsz 2018 0253
   Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
NR 46
TC 12
Z9 15
U1 2
U2 37
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2023
VL 38
IS 1
BP 214
EP 227
DI 10.1002/jbmr.4744
EA DEC 2022
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8L2LH
UT WOS:000898562300001
PM 36370067
DA 2025 08 17
ER

PT J
AU Jayan, A
   Raghavendra, AS
   Bassett, R
   Barcenas, CH
AF Jayan, Athira
   Raghavendra, Akshara Singareeka
   Bassett, Roland
   Barcenas, Carlos H.
TI Bone Targeted Therapy Regimen and Skeletal Related Events in Patients
   Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone
   Metastasis
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Adverse events; Bisphosphonates; Compression factures; Denosumab
ID QUALITY OF LIFE; ZOLEDRONIC ACID; OPEN LABEL; AMERICAN SOCIETY;
   DOUBLE BLIND; DENOSUMAB; SAFETY; OSTEONECROSIS; COMPLICATIONS; EFFICACY
AB We evaluated the effect of at least 2 years of bone targeted therapy in 224 patients with metastatic breast cancer to the bone. We compared zoledronic acid only, denosumab only, and both, and we found no difference in skeletal related events, except for lower rates of compression fractures with denosumab. Associated harms were also similar across treatment patterns.Background: Bone targeted therapy (BTT) including zoledronic acid (ZA) and denosumab decreases the risk of skeletal related events (SREs) in patients with metastatic breast cancer (MBC) and bone metastasis. The impacts from prolonged BTT on SREs and BTT associated harms are unknown and are becoming important to understand as these patients survive for longer periods. Methods and Materials: We conducted a retrospective study of 224 patients with MBC and bone metastasis who survived for more than 2 years after diagnosis and received treatment at our institution between 2016 and 2021. We defined 3 BTT patterns: (1) ZA only, (2) denosumab only, (3) both ZA and denosumab. The association between these BTT patterns and SREs and harms was assessed using Fisher exact test and logistic regression. Results: Rates of SREs overall were 21.2% of patients given ZA only, 8.8% of those given denosumab only, and 20% of those given both, without statistically significant differences ( p = .32). However, those treated with denosumab only had significantly fewer compression fractures (0.7%) ( p = .02). BTT associated harm was observed in 5.8% of the ZA only group, 11.7% of the denosumab only group, and 14.3% of the group given both, without statistically significant differences ( p = .37). Conclusion: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT associated harms between the BTT regimens evaluated.
C1 [Jayan, Athira] Univ Texas Hlth Sci Ctr Houston, Internal Med, Houston, TX USA.
   [Raghavendra, Akshara Singareeka; Barcenas, Carlos H.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Bassett, Roland] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Barcenas, CH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM CHBarcenas@mdanderson.org
RI ; Raghavendra, Akshara/AAZ 3416 2020
OI Barcenas, Carlos/0000 0001 5377 9167; 
FU National Cancer Institute through The University of Texas MD Anderson's
   Cancer Center
FX <B>Acknowledgments</B> This research was supported by the National
   Cancer Institute through The University of Texas MD Anderson's Cancer
   Center
CR Abdel Rahman O, 2016, EXPERT REV ANTICANC, V16, P885, DOI 10.1080/14737140.2016.1192466
   Al Farii H, 2020, JAAOS Global Res Rev., V4
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Barrett Lee P, 2014, LANCET ONCOL, V15, P114, DOI 10.1016/S1470 2045(13)70539 4
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434 010 0985 4
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Facchini G, 2007, J EXP CLIN CANC RES, V26, P307
   Friedl TWP, 2021, JAMA ONCOL, V7, P1149, DOI 10.1001/jamaoncol.2021.1854
   Goldvaser H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0623 8
   Gradishar WJ, 2022, J NATL COMPR CANC NE, V20, P691, DOI 10.6004/jnccn.2022.0030
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Ibrahim MFK, 2015, ANN ONCOL, V26, P2205, DOI 10.1093/annonc/mdv284
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Quispe D, 2011, BREAST J, V17, P510, DOI 10.1111/j.1524 4741.2011.01119.x
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039 6109(03)00034 3
   Sinha AK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170081
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tesfamariam Y, 2019, CRIT REV ONCOL HEMAT, V137, P1, DOI 10.1016/j.critrevonc.2019.02.004
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013 0953 SA]
   Wu EQ, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.27_suppl.151
   Wutzl A, 2006, WIEN KLIN WOCHENSCHR, V118, P473, DOI 10.1007/s00508 006 0644 8
NR 37
TC 1
Z9 1
U1 1
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1526 8209
EI 1938 0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD DEC
PY 2023
VL 23
IS 8
BP E515
EP E522
DI 10.1016/j.clbc.2023.08.008
EA NOV 2023
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CD9O0
UT WOS:001123430600001
PM 37735019
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, LW
   Yang, YJ
   Liao, ZR
   Liu, QB
   Lei, XH
   Li, M
   Saijilafu
   Zhang, ZY
   Hong, D
   Zhu, M
   Li, B
   Yang, HL
   Chen, JQ
AF Zhang, Liwei
   Yang, Yanjun
   Liao, Zirui
   Liu, Qingbai
   Lei, Xinhuan
   Li, Meng
   Saijilafu
   Zhang, Zunyi
   Hong, Dun
   Zhu, Min
   Li, Bin
   Yang, Huilin
   Chen, Jianquan
TI Genetic and pharmacological activation of Hedgehog signaling inhibits
   osteoclastogenesis and attenuates titanium particle induced osteolysis
   partly through suppressing the JNK/c Fos NFATc1 cascade
SO THERANOSTICS
LA English
DT Article
DE peri prosthetic osteolysis; titanium particle; Hh signaling;
   osteoclatogenesis
ID RANKL INDUCED OSTEOCLASTOGENESIS; TOTAL JOINT ARTHROPLASTY; SONIC
   HEDGEHOG; BONE FORMATION; DIFFERENTIATION; PATHWAY; GROWTH; WEAR;
   INCREASES; MACROPHAGES
AB Rationale: Wear particle induced periprosthetic osteolysis (PPO) is a common long term complication of total joint arthroplasty, and represents the major cause of aseptic loosening and subsequent implant failure. Previous studies have identified the central role of osteoclast mediated bone resorption in the pathogenesis of PPO. Thus, therapeutic approaches of inhibiting osteoclast formation and activity are considered to be of great potential to prevent and treat this osteolytic disease. Hedgehog (Hh) signaling has been shown to play an important role in promoting osteoblast differentiation and bone formation. While Hh signaling is also implicated in regulating osteoclastogenesis, whether it can directly inhibit osteoclast differentiation and bone resorption remains controversial. Moreover, its potential therapeutic effects on PPO have never been assessed. In this study, we explored the cell autonomous role of Hh signaling in regulating osteoclastogenesis and its therapeutic potential in preventing wear particle induced osteolysis.
   Methods: Hh signaling was activated in macrophages by genetically ablating Sufu in these cells using LysM Cre or by treating them with purmorphamine (PM), a pharmacological activator of Smoothened (Smo). In vitro cell autonomous effects of Hh pathway activation on RANKL induced osteoclast differentiation and activity were evaluated by TRAP staining, phalloidin staining, qPCR analyses, and bone resorption assays. In vivo evaluation of its therapeutic efficacy against PPO was performed in a murine calvarial model of titanium particle induced osteolysis by mu CT and histological analyses. Mechanistic details were explored in RANKL treated macrophages through Western blot analyses.
   Results: We found that Sufu deletion or PM treatment potently activated Hh signaling in macrophages, and strongly inhibited RANKL induced TRAP(+) osteoclast production, F actin ring formation, osteoclast specific gene expression, and osteoclast activity in vitro. Furthermore, we found that Sufu deletion or PM administration significantly attenuated titanium particle induced osteoclast formation and bone loss in vivo. Our mechanistic study revealed that activation of Hh signaling suppressed RANKL induced activation of JNK pathway and downregulated protein levels of two key osteoclastic transcriptional factors, c Fos and its downstream target NFATc1.
   Conclusions: Both genetic and pharmacological activation of Hh signaling can cell autonomously inhibit RANKL induced osteoclast differentiation and activity in vitro and protect against titanium particle induced osteolysis in vivo. Mechanistically, Hh signaling hinders osteoclastogenesis partly through suppressing the JNIQc Fos NFATc1 cascade. Thus, Hh signaling may serve as a promising therapeutic target for the prevention and treatment of PPO and other osteolytic diseases.
C1 [Zhang, Liwei; Yang, Yanjun; Liu, Qingbai; Li, Meng; Saijilafu; Li, Bin; Yang, Huilin; Chen, Jianquan] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhang, Liwei; Yang, Yanjun; Liao, Zirui; Li, Meng; Saijilafu; Li, Bin; Yang, Huilin; Chen, Jianquan] Soochow Univ, Med Coll, Orthoped Inst, Suzhou 215007, Jiangsu, Peoples R China.
   [Lei, Xinhuan; Hong, Dun; Zhu, Min] Wenzhou Med Univ, Taizhou Hosp, Orthoped Dept, Linhai 317000, Zhejiang, Peoples R China.
   [Zhang, Zunyi] Hangzhou Normal Univ, Inst Life Sci, Coll Life & Environm Sci, Key Lab Mammalian Organogenesis & Regenerat, Hangzhou 310036, Zhejiang, Peoples R China.
C3 Soochow University   China; Soochow University   China; Wenzhou Medical
   University; Hangzhou Normal University
RP Chen, JQ (通讯作者)，Soochow Univ, Orthoped Inst, 708 Renmin Rd, Suzhou 215007, Jiangsu, Peoples R China.
EM chenjianquan@suda.edu.cn
RI Saijilafu, Saijilafu/AAV 3704 2021; Yang, Yanjun/AAD 7141 2022; Zhang,
   Zunyi/JQJ 6807 2023; Li, Bin/B 7802 2012; Hong, Dun/IUP 2161 2023; lei,
   xh/KFR 2496 2024
OI Hong, Dun/0000 0002 2094 4987; , Saijilafu/0000 0003 2290 9808; 
FU National Natural Science Foundation of China [81974344, 81772294];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Experimental Animal Science Project of Zhejiang
   Province [2018C37123]; Natural Science Foundation of Zhejiang Province
   [LY16H070008]; Medical and Health Science and Technology Program Project
   of Zhejiang Province [2015KYB435]; Basic and Public Research Project of
   Zhejiang Province [LGF20H250004]
FX This study was funded by the National Natural Science Foundation of
   China (81974344, 81772294), the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD), the Experimental Animal
   Science Project of Zhejiang Province (2018C37123), the Natural Science
   Foundation of Zhejiang Province (LY16H070008), the Medical and Health
   Science and Technology Program Project of Zhejiang Province
   (2015KYB435), and the Basic and Public Research Project of Zhejiang
   Province (LGF20H250004).
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Alman BA, 2015, NAT REV RHEUMATOL, V11, P552, DOI 10.1038/nrrheum.2015.84
   Amano K, 2015, J BONE MINER RES, V30, P2262, DOI 10.1002/jbmr.2582
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bangs F, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028175
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Das S, 2011, J BIOL CHEM, V286, P9612, DOI 10.1074/jbc.M110.174920
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200
   Geng DC, 2010, BIOMATERIALS, V31, P1996, DOI 10.1016/j.biomaterials.2009.11.069
   Gu DD, 2017, MOL MED REP, V16, P7993, DOI 10.3892/mmr.2017.7652
   Gu XH, 2018, J CELL BIOCHEM, V119, P1041, DOI 10.1002/jcb.26272
   Gu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.275
   Hall Margaret Jean, 2010, Natl Health Stat Report, P1
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Heller E, 2012, CANCER RES, V72, P897, DOI 10.1158/0008 5472.CAN 11 2681
   Hojo H, 2012, J BIOL CHEM, V287, P17860, DOI 10.1074/jbc.M112.347716
   Hu Q, 2017, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00306
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Ledin H, 2017, ACTA ORTHOP, V88, P255, DOI 10.1080/17453674.2017.1300746
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Li JY, 2017, J BIOL CHEM, V292, P15814, DOI 10.1074/jbc.M117.777532
   Li JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128006
   Li K, 2019, J CELL PHYSIOL, V234, P2058, DOI 10.1002/jcp.27635
   Li XJ, 2016, PROG BIOPHYS MOL BIO, V122, P101, DOI 10.1016/j.pbiomolbio.2016.05.008
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lo JC, 2019, OSTEOPOROSIS INT, V30, P2515, DOI 10.1007/s00198 019 05112 5
   Lv WT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163981
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Matsumoto K, 2016, IN VIVO, V30, P99
   Mundy GR, 2008, DEV CELL, V14, P637, DOI 10.1016/j.devcel.2008.04.010
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Namchaiw P, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1374 y
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Ottenhoff THM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045839
   Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Rakshit DS, 2006, J BONE JOINT SURG AM, V88A, P788, DOI 10.2106/JBJS.E.00711
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Shi M, 2018, OSTEOPOROSIS INT, V29, P1525, DOI 10.1007/s00198 018 4488 7
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   Shimo T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151731
   Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753
   Sloan M, 2018, J BONE JOINT SURG AM, V100, P1455, DOI 10.2106/JBJS.17.01617
   Smith RL, 2014, CLIN ORTHOP RELAT R, V472, P3740, DOI 10.1007/s11999 014 3765 9
   Spinella Jaegle S, 2001, J CELL SCI, V114, P2085
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Svärd J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tibullo D, 2020, CANCERS, V12, DOI 10.3390/cancers12020323
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong LB, 2019, THERANOSTICS, V9, P7140, DOI 10.7150/thno.35988
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Yuan Q, 2019, THERANOSTICS, V9, P1825, DOI 10.7150/thno.31893
NR 70
TC 39
Z9 41
U1 0
U2 49
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 15
BP 6638
EP 6660
DI 10.7150/thno.44793
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA LP9CT
UT WOS:000534614200006
PM 32550895
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU García, SG
   Clemons, M
   Amir, E
AF Garcia, Susana Gomez
   Clemons, Mark
   Amir, Eitan
TI Rethinking end points for bone targeted therapy in advanced cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE End points; Clinical trials; Bone metastases; Bisphosphonates;
   Denosumab; Solid tumours
ID PROGRESSION FREE SURVIVAL; SKELETAL RELATED EVENTS; QUALITY OF LIFE;
   CLINICAL TRIALS; BREAST CANCER; SOLID TUMORS; PHASE III; COMPLICATIONS;
   ONCOLOGY; VALIDATION
AB The principal objective for any medical therapy is to improve either the duration of life and/or its quality. Metastases in bone can lead to clinically defined events termed skeletal related events (SREs) which are a quantifiable measure of skeletal morbidity. Avoidance and/or delay of SREs have become the principal objective in trials exploring the efficacy of bone targeted therapy in patients with skeletal metastases. Despite reductions in the frequency or rate of SRE occurrence, trials of bone targeted therapy have failed to show any effect on either progression free or overall survival when compared with placebo or other bone targeting agents. Similarly, trials of bone targeted therapy have not shown consistent effects on quality of life. The validity of SRE based primary outcome measures in cancer clinical trials is therefore, questionable. More novel end point selection for trials of bone targeted therapy seems warranted. Composite measures comprising occurrence of symptomatic skeletal events and patient reported outcomes may be an effective solution and warrants further investigation. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Garcia, Susana Gomez] Hosp Alvaro Cunqueiro, Dept Med Oncol, Estruct Org Xest Integrada EOXI Vigo, Vigo, Pontevedra, Spain.
   [Clemons, Mark] Ottawa Hosp, Div Med Oncol, Ottawa, ON, Canada.
   [Clemons, Mark] Univ Ottawa, Ottawa, ON, Canada.
   [Amir, Eitan] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 610 Univ Ave,5 124, Toronto, ON M5G 2M9, Canada.
   [Amir, Eitan] Univ Toronto, Dept Med, Toronto, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Toronto; University Health Network Toronto;
   Princess Margaret Cancer Centre; University of Toronto
RP Amir, E (通讯作者)，Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 610 Univ Ave,5 124, Toronto, ON M5G 2M9, Canada.
EM eitan.amir@uhn.ca
RI ; Amir, Eitan/L 6052 2019
OI Amir, Eitan/0000 0002 3706 525X; 
CR Amir E, 2012, EUR J CANCER, V48, P385, DOI 10.1016/j.ejca.2011.10.028
   Booth CM, 2008, J CLIN ONCOL, V26, P6, DOI 10.1200/JCO.2007.13.8156
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cheung YB, 2005, J CLIN ONCOL, V23, P4936, DOI 10.1200/JCO.2005.07.141
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Lim E, 2008, ANN INTERN MED, V149, P612, DOI 10.7326/0003 4819 149 9 200811040 00004
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lüftner D, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 328
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Ocana A, 2011, JNCI J NATL CANCER I, V103, P16, DOI 10.1093/jnci/djq463
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140 6736(11)61613 9
   Robinson AG, 2014, EUR J CANCER, V50, P2303, DOI 10.1016/j.ejca.2014.05.024
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Srikanthan A, 2016, CANCER TREAT REV, V43, P67, DOI 10.1016/j.ctrv.2015.12.006
   Srikanthan A, 2015, EUR J CANCER, V51, P905, DOI 10.1016/j.ejca.2015.03.017
   Sullivan R, 2011, LANCET ONCOL, V12, P933, DOI 10.1016/S1470 2045(11)70141 3
   Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934
   Trinkaus M, 2010, SUPPORT CARE CANCER, V18, P197, DOI 10.1007/s00520 009 0645 z
   Venook AP, 2015, J CLIN ONCOL, V33, P4, DOI 10.1200/JCO.2014.57.9557
   Zhao FM, 2016, J CLIN ONCOL, V34, P1436, DOI 10.1200/JCO.2016.66.4581
NR 27
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD AUG
PY 2016
VL 63
BP 105
EP 109
DI 10.1016/j.ejca.2016.05.014
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DR1WP
UT WOS:000379695900012
PM 27299662
DA 2025 08 17
ER

PT J
AU Kalyanaraman, H
   Ramdani, G
   Joshua, J
   Schall, N
   Boss, GR
   Cory, E
   Sah, RL
   Casteel, DE
   Pilz, RB
AF Kalyanaraman, Hema
   Ramdani, Ghania
   Joshua, Jisha
   Schall, Nadine
   Boss, Gerry R.
   Cory, Esther
   Sah, Robert L.
   Casteel, Darren E.
   Pilz, Renate B.
TI A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions
   and Increases Bone Mass in Ovariectomized Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; PRECLINICAL STUDIES; ANABOLICS; MOLECULAR
   PATHWAYS REMODELING
ID NITRIC OXIDE SYNTHASE; DEPENDENT PROTEIN KINASE; ORGANIC NITRATES;
   MINERAL DENSITY; ISOSORBIDE MONONITRATE; NITROGLYCERIN THERAPY;
   POSTMENOPAUSAL WOMEN; NITROSYL COBINAMIDE; ESTROGEN DEFICIENCY; ANABOLIC
   RESPONSE
AB Most US Food and Drug Administration (FDA) approved treatments for osteoporosis target osteoclastic bone resorption. Only PTH derivatives improve bone formation, but they have drawbacks, and novel bone anabolic agents are needed. Nitrates, which generate NO, improved BMD in estrogen deficient rats and may improve bone formation markers and BMD in postmenopausal women. However, nitrates are limited by induction of oxidative stress and development of tolerance, and may increase cardiovascular mortality after long term use. Here we studied nitrosyl cobinamide (NO Cbi), a novel, direct NO releasing agent, in a mouse model of estrogen deficiency induced osteoporosis. In murine primary osteoblasts, NO Cbi increased intracellular cGMP, Wnt/ catenin signaling, proliferation, and osteoblastic gene expression, and protected cells from apoptosis. Correspondingly, in intact and ovariectomized (OVX) female C57Bl/6 mice, NO Cbi increased serum cGMP concentrations, bone formation, and osteoblastic gene expression, and in OVX mice, it prevented osteocyte apoptosis. NO Cbi reduced osteoclasts in intact mice and prevented the known increase in osteoclasts in OVX mice, partially through a reduction in the RANKL/osteoprotegerin gene expression ratio, which regulates osteoclast differentiation, and partially through direct inhibition of osteoclast differentiation, observed in vitro in the presence of excess RANKL. The positive NO effects in osteoblasts were mediated by cGMP/protein kinase G (PKG), but some of the osteoclast inhibitory effects appeared to be cGMP independent. NO Cbi increased trabecular bone mass in both intact and OVX mice, consistent with its in vitro effects on osteoblasts and osteoclasts. NO Cbi is a novel direct NO releasing agent that, in contrast to nitrates, does not generate oxygen radicals, and combines anabolic and antiresorptive effects in bone, making it an excellent candidate for treating osteoporosis. (c) 2016 American Society for Bone and Mineral Research.
C1 [Kalyanaraman, Hema; Ramdani, Ghania; Joshua, Jisha; Boss, Gerry R.; Casteel, Darren E.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Schall, Nadine] Univ Bonn, Inst Pharmacol & Toxicol, Bonn, Germany.
   [Cory, Esther; Sah, Robert L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of Bonn; University of California System; University of
   California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
OI Boss, Gerry/0000 0002 9758 8714
FU NIH [R01 AR051300, R21 AR065658, U01 NS58030, P01 AG007996,
   P30 CA023100, P30 NS047101, P30 AR04603]; Deutsche
   Forschungsgemeinschaft [KI 1303/2 1]
FX This work was supported by NIH grants R01 AR051300 and R21 AR065658 (to
   RBP); U01 NS58030 (to GRB, CounterACT Program, Office of the Director,
   NIH and NINDS); P01 AG007996 (RLS); P30 CA023100 (UCSD Gene Targeting
   and Transgenic Mouse Core); P30 NS047101 (UCSD Neuroscience Microscopy
   Shared Facility); and P30 AR04603 (University of Alabama, Birmingham,
   Center for Metabolic Bone Disease). NS was supported by the Deutsche
   Forschungsgemeinschaft (Project KI 1303/2 1). We are grateful to Ella
   Kothari, Jennifer Santini, Dana Smith, and Dezhi Wang for their expert
   assistance.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Barrett Connor E, 2005, ANNU REV PUBL HEALTH, V26, P115, DOI 10.1146/annurev.publhealth.26.021304.144637
   Barrett Connor E, 2012, OSTEOPOROSIS INT, V23, P733, DOI 10.1007/s00198 011 1620 3
   Bartell SM, 2013, MOL ENDOCRINOL, V27, P649, DOI 10.1210/me.2012 1368
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Broderick KE, 2007, EXP BIOL MED, V232, P1432, DOI 10.3181/0703 RM 70
   Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dong SS, 1999, J CELL BIOCHEM, V73, P478, DOI 10.1002/(SICI)1097 4644(19990615)73:4<478::AID JCB6>3.3.CO;2 K
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fox SW, 1996, AM J PHYSIOL ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955
   Fuller K, 2006, ENDOCRINOLOGY, V147, P1979, DOI 10.1210/en.2005 1340
   Grassi F, 2006, ENDOCRINOLOGY, V147, P4392, DOI 10.1210/en.2006 0334
   Hamilton Celeste J, 2013, Bonekey Rep, V2, P259, DOI 10.1038/bonekey.2012.259
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Ishikawa K, 1996, JPN CIRC J, V60, P779, DOI 10.1253/jcj.60.779
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Jiang JJ, 2016, SCI REP UK, V6, DOI 10.1038/srep20831
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Jung JY, 2003, J CELL BIOCHEM, V89, P613, DOI 10.1002/jcb.10527
   Kalyanaraman H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004911
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Khosla S, 2011, J BONE MINER RES, V26, P2565, DOI 10.1002/jbmr.488
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   Lundberg JO, 2015, NAT REV DRUG DISCOV, V14, P623, DOI 10.1038/nrd4623
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Mendelsohn ME, 2010, J CLIN INVEST, V120, P2277, DOI 10.1172/JCI43756
   Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjp.0707224
   Mödder UIL, 2004, ENDOCRINOLOGY, V145, P913, DOI 10.1210/en.2003 1089
   Münzel T, 2007, J AM COLL CARDIOL, V49, P1296, DOI 10.1016/j.jacc.2007.01.007
   Nabhan AF, 2008, INT J GYNECOL OBSTET, V103, P213, DOI 10.1016/j.ijgo.2008.07.011
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakamura Y, 1999, AM HEART J, V138, P577, DOI 10.1016/S0002 8703(99)70163 8
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Parker JD, 2004, J CLIN INVEST, V113, P352, DOI 10.1172/JCI200421003
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Ralston SH, 1996, BONE, V19, P29, DOI 10.1016/8756 3282(96)00101 9
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Samuels A, 2001, BONE, V29, P24, DOI 10.1016/S8756 3282(01)00471 9
   Sharma VS, 2003, BIOCHEMISTRY US, V42, P8900, DOI 10.1021/bi034469t
   Spitler R, 2013, CELL SIGNAL, V25, P2374, DOI 10.1016/j.cellsig.2013.07.029
   Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267
   Syed Farhan A, 2011, Curr Osteoporos Rep, V9, P219, DOI 10.1007/s11914 011 0074 z
   Syed FA, 2010, J BONE MINER RES, V25, P2438, DOI 10.1002/jbmr.129
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thomas GR, 2007, J AM COLL CARDIOL, V49, P1289, DOI 10.1016/j.jacc.2006.10.074
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Turner CH, 1997, BONE, V21, P487, DOI 10.1016/S8756 3282(97)00202 0
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 76
TC 72
Z9 80
U1 0
U2 27
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2017
VL 32
IS 1
BP 46
EP 59
DI 10.1002/jbmr.2909
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EH7YU
UT WOS:000391989400007
PM 27391172
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Canalis, E
AF Canalis, Ernesto
TI Growth Factor Control of Bone Mass
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OSTEOBLASTS; GROWTH FACTORS; DIFFERENTIATION; GROWTH FACTOR ANTAGONISTS;
   OSTEOPOROSIS
ID FRIZZLED RELATED PROTEIN 1; FACTOR I; TRANSGENIC MICE; IGF I; SKELETAL
   OVEREXPRESSION; PARATHYROID HORMONE; NEGATIVE REGULATOR; MINERAL
   DENSITY; BINDING; SCLEROSTIN
AB Bone formation is determined by the number and function of osteoblasts. Cell number is governed by factors that regulate the replication and differentiation of pre osteoblasts and factors that regulate osteoblastic cell death. Cell function is controlled by signals acting on the mature osteoblast. Platelet derived and fibroblast growth factors are bone cell mitogens. Bone morphogenetic proteins (BMPs) and Writ induce the differentiation of mesenchymal cells toward osteoblasts, and insulin like growth factor (IGF) I stimulates the function of mature osteoblasts and prevents their death. The activity of BMP, Writ, and IGF I is modulated by extracellular antagonists or binding proteins. Changes in growth factor synthesis and activity may play a role in the pathogenesis of selected forms of osteoporosis, and alterations in the expression or binding of the extracellular antagonists can be associated with changes in bone mass. Current approaches to bone anabolic therapies for osteoporosis include the administration of a growth factor, such as IGF I, or the neutralization of an antagonist. Ideally, the targeting of an anabolic agent should be specific to bone to preclude non skeletal unwanted side effects. Clinical trials are needed to determine the long term effectiveness and safety of novel anabolic agents for the management of osteoporosis. J. Cell. Biochem. 108: 769777, 2009. (C) 2009 Wiley Liss, Inc.
C1 [Canalis, Ernesto] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Canalis, Ernesto] Univ Connecticut, Sch Med, Farmington, CT USA.
C3 Saint Francis Hospital & Medical Center; University of Connecticut
RP Canalis, E (通讯作者)，St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.
EM ecanalis@stfranciscare.org
FU National institute of Arthritis and Musculoskeletal and Skin Diseases
   [AR021707]; National institute of Diabetes & Digestive & Kidney Diseases
   [DK042424, DK045227]
FX Grant sponsor: National institute of Arthritis and Musculoskeletal and
   Skin Diseases; Grant number: AR021707; Grant sponsor: National institute
   of Diabetes & Digestive & Kidney Diseases; Grant numbers: DK042424,
   DK045227.
CR ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend 5 11 1677
   Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   BEAMER WG, 1976, J ENDOCRINOL, V71, P37, DOI 10.1677/joe.0.0710037
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   CANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   CANALIS E, 1994, J CLIN ENDOCR METAB, V78, P1009, DOI 10.1210/jc.78.5.1009
   CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490
   CANALIS E, 1993, ENDOCRINOLOGY, V133, P33, DOI 10.1210/en.133.1.33
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Canalis E, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P529
   CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   DeMambro VE, 2008, ENDOCRINOLOGY, V149, P2051, DOI 10.1210/en.2007 1068
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Devlin RD, 2002, ENDOCRINOLOGY, V143, P3955, DOI 10.1210/en.2002 220129
   Eckstein F, 2002, ANAT EMBRYOL, V206, P139, DOI 10.1007/s00429 002 0282 5
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 2007, J BIOL CHEM, V282, P31549, DOI 10.1074/jbc.M701317200
   Gazzerro Elisabetta, 2006, Expert Rev Endocrinol Metab, V1, P47, DOI 10.1586/17446651.1.1.47
   Gazzerro E, 2006, BONE, V39, P1252, DOI 10.1016/j.bone.2006.06.028
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883
   Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3864, DOI 10.1210/jc.81.11.3864
   Grisanti M, 2006, J BONE MINER RES, V21, pS25
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092 8674(05)80084 4
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Misra M, 2006, REV ENDOCR METAB DIS, V7, P91, DOI 10.1007/s11154 006 9005 1
   Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756 3282(99)00113 1
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Ning Y, 2006, MOL ENDOCRINOL, V20, P2173, DOI 10.1210/me.2005 0196
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297
   Silha JV, 2003, J BONE MINER RES, V18, P1834, DOI 10.1359/jbmr.2003.18.10.1834
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Tanner SJ, 2008, J BONE MINER RES, V23, P655, DOI 10.1359/JBMR.071210
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Yakar S, 2009, J BONE MINER RES, V24, P1481, DOI [10.1359/JBMR.090226, 10.1359/jbmr.090226]
   Zhang M, 2003, J BONE MINER RES, V18, P836, DOI 10.1359/jbmr.2003.18.5.836
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang YL, 2009, BIOCHEM BIOPH RES CO, V383, P1, DOI 10.1016/j.bbrc.2009.03.086
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
   Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092 8674(00)80133 6
NR 65
TC 91
Z9 109
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV 1
PY 2009
VL 108
IS 4
BP 769
EP 777
DI 10.1002/jcb.22322
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 515TI
UT WOS:000271495400005
PM 19718659
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhou, J
   Wang, S
   Qi, Q
   Yang, XY
   Zhu, ED
   Yuan, HR
   Li, XM
   Liu, Y
   Li, XX
   Wang, BL
AF Zhou, Jie
   Wang, Shan
   Qi, Qi
   Yang, Xiaoyue
   Zhu, Endong
   Yuan, Hairui
   Li, Xuemei
   Liu, Ying
   Li, Xiaoxia
   Wang, Baoli
TI Nuclear factor I C reciprocally regulates adipocyte and osteoblast
   differentiation via control of canonical Wnt signaling
SO FASEB JOURNAL
LA English
DT Article
DE adipogenesis; osteogenesis; Wnt/b; catenin; Lrp5
ID TOOTH ROOT DEVELOPMENT; MESENCHYMAL STEM CELLS; OSTEOGENIC
   DIFFERENTIATION; BETA CATENIN; ODONTOBLAST DIFFERENTIATION;
   BRAIN DEVELOPMENT; GENE EXPRESSION; ADIPOSE TISSUE; BONE FORMATION;
   C/EBP ALPHA
AB Nuclear factor I C (NFIC) has recently been identified as an important player in osteogenesis and bone homeostasis in vivo. However, the molecular mechanisms involved have yet to be defined. In the current study, Nfic expression was altered in primary marrow stromal cells and established progenitor lines after adipogenic and osteogenic treatment. Overexpression of Nfic in stromal cells ST2, mesenchymal cells C3H10T1/2, and primary marrow stromal cells inhibited adipogenic differentiation, whereas it promoted osteogenic differentiation. Conversely, silencing of endogenous Nfic in the cell lines enhanced adipogenic differentiation, whereas it blocked osteogenic differentiation. Mechanism investigations revealed that Nfic overexpression promoted nuclear translocation of beta catenin and increased nuclear protein levels of b catenin and transcription factor 7 like 2 (TCF7L2). Promoter studies and the chromatin immunoprecipitation (ChIP) assay revealed that NFIC directly binds to the promoter of low density lipoprotein receptor related protein 5 (Lrp5) and thereafter transactivates the promoter. Finally, inactivation of canonical Wnt signaling in ST2 attenuated the inhibition of adipogenic differentiation and stimulation of osteogenic differentiation by NFIC. Our study suggests that NFIC balances adipogenic and osteogenic differentiation from progenitor cells through controlling canonical Wnt signaling and highlights the potential of NFIC as a target for new therapies to control metabolic disorders like osteoporosis and obesity. Zhou, J., Wang, S., Qi, Q., Yang, X., Zhu, E., Yuan, H., Li, X., Liu, Y., Li, X., Wang, B. Nuclear factor I C reciprocally regulates adipocyte and osteoblast differentiation via control of canonical Wnt signaling.
C1 [Zhou, Jie; Qi, Qi; Zhu, Endong; Yuan, Hairui; Li, Xuemei; Wang, Baoli] Tianjin Med Univ, Tianjin Key Lab Metab Dis, Minist Hlth, Key Lab Hormones & Dev, Tianjin, Peoples R China.
   [Zhou, Jie; Wang, Baoli] Tianjin Med Univ, Collaborat Innovat Ctr Metab Dis 2011, Metab Dis Hosp, Tianjin, Peoples R China.
   [Zhou, Jie; Wang, Baoli] Tianjin Med Univ, Inst Endocrinol, Tianjin, Peoples R China.
   [Wang, Shan; Li, Xiaoxia] Tianjin Med Univ, Coll Basic Med Sci, Tianjin, Peoples R China.
   [Yang, Xiaoyue; Liu, Ying] Tianjin Med Univ, Stomatol Hosp, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University; Tianjin Medical University
RP Wang, BL (通讯作者)，Tianjin Med Univ, 22 Qi Xiang Tai Rd,Box 126, Tianjin 300070, Tianjin, Peoples R China.
EM blwang@tmu.edu.cn
RI 朱, 恩东/JVN 8473 2024
FU Natural Science Foundation of China [81672116, 81472040, 81271977,
   81101596, 81501846]; Key Laboratory of Hormones and Development,
   Ministry of Health
FX This work was supported by Natural Science Foundation of China Grants
   81672116, 81472040, and 81271977 (to B.W.), Grant 81101596 (to X.L.),
   and Grant 81501846 (to E.Z.); and by an Open Grant from the Key
   Laboratory of Hormones and Development, Ministry of Health. The authors
   declare no conflicts of interest.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Campbell CE, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 52
   Cheng HC, 2011, ACTA BIOCH BIOPH SIN, V43, P204, DOI 10.1093/abbs/gmq130
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Driller K, 2007, MOL CELL BIOL, V27, P3855, DOI 10.1128/MCB.02293 06
   Felber K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144982
   FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Guan XH, 2015, STEM CELLS, V33, P1589, DOI 10.1002/stem.1947
   Harris L, 2015, DEV DYNAM, V244, P227, DOI 10.1002/dvdy.24182
   He W, 2014, J DENT RES, V93, P496, DOI 10.1177/0022034514525200
   Heng YHE, 2014, CEREB CORTEX, V24, P261, DOI 10.1093/cercor/bhs307
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P323, DOI 10.1038/nrrheum.2016.48
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kook SH, 2015, MOL CELL BIOCHEM, V402, P213, DOI 10.1007/s11010 015 2329 y
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lee DS, 2014, STEM CELLS, V32, P2467, DOI 10.1002/stem.1733
   Lee DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029160
   Lee DS, 2009, J BIOL CHEM, V284, P17293, DOI 10.1074/jbc.M109.009084
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Liu Y, 2015, DEVELOPMENT, V142, P3374, DOI 10.1242/dev.127068
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Mason S, 2009, MOL NEUROBIOL, V39, P10, DOI 10.1007/s12035 008 8048 6
   Miclea RL, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471 213X 9 26
   Nemoto E, 2016, J PERIODONTAL RES, V51, P164, DOI 10.1111/jre.12294
   Oh HJ, 2012, J CELL BIOCHEM, V113, P877, DOI 10.1002/jcb.23421
   Pignolo RJ, 2015, APPL CLIN GENET, V8, P37, DOI 10.2147/TACG.S51064
   Pjanic M, 2011, BMC GENOMICS, V12, DOI 10.1186/1471 2164 12 181
   Plachez C, 2012, J COMP NEUROL, V520, P3135, DOI 10.1002/cne.23081
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Smink JJ, 2012, GENE, V497, P10, DOI 10.1016/j.gene.2012.01.043
   Steele Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685 698.2005
   Steele Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075 1084.2003
   Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.356
   WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wong YW, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 5 r72
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
NR 50
TC 35
Z9 36
U1 0
U2 19
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2017
VL 31
IS 5
BP 1939
EP 1952
DI 10.1096/fj.201600975RR
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA ES0DE
UT WOS:000399195500016
PM 28122918
DA 2025 08 17
ER

PT J
AU An, J
   Hao, DJ
   Zhang, Q
   Chen, B
   Zhang, R
   Wang, Y
   Yang, H
AF An, Jing
   Hao, Dingjun
   Zhang, Qian
   Chen, Bo
   Zhang, Rui
   Wang, Yi
   Yang, Hao
TI Natural products for treatment of bone erosive diseases: The effects and
   mechanisms on inhibiting osteoclastogenesis and bone resorption
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Natural products; Medical plants; Osteoclastogenesis; Bone resorption;
   Molecular mechanism
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; PARTICLE INDUCED
   OSTEOLYSIS; DOWN REGULATING NFATC1; SUPPRESSES RECEPTOR ACTIVATOR;
   LIGAND INDUCED OSTEOCLASTOGENESIS; RAW 264.7 CELLS; IN VITRO; C FOS;
   MODULATING RANKL
AB Excessive bone resorption plays a central role on the development of bone erosive diseases, including osteoporosis, rheumatoid arthritis, and periodontitis. Osteoclasts, bone resorbing multinucleated cells, are differentiated from hemopoietic progenitors of the monocyte/macrophage lineage. Regulation of osteoclast differentiation is considered an effective therapeutic target to the treatment of pathological bone loss. Natural plant derived products, with potential therapeutic and preventive activities against bone lytic diseases, have received increasing attention in recent years because of their whole regulative effects and specific pharmacological activities, which are more suitable for long term use than chemically synthesized medicines. In this review, we summarized the detailed research progress on the active compounds derived from medical plants with potential anti resorptive effects and their molecular mechanisms on inhibiting osteoclast formation and function. The active ingredients derived from natural plants that are efficacious in suppressing osteoclastogenesis and bone resorption include flavonoids, terpenoids (sesquiterpenoids, diterpenoids, triterpenoids), glycosides, lignans, coumarins, alkaloids, polyphenols, limonoids, quinones and others (steroid, oxoxishhone, fatty acid). Studies have shown that above natural products exert the inhibitory effects via regulating many factors involved in the process of osteoclast differentiation and bone resorption, including the essential cytokines (RANKL, M CSF), transcription factors (NFATc1, c Fos), signaling pathways (NF kappa B, MAPKs, Src/PI3K/Akt, the calcium ion signaling), osteoclast specific genes (TRAP, CTSK, MMP 9, integrin beta 3, OSCAR, DC STAMP, Atp6v0d2) and local factors (ROS, LPS, NO). The development of osteoclast targeting natural products is of great value for the prevention or treatment of bone diseases and for bone regenerative medicine. (C) 2016 Elsevier B.V. All rights reserved.
C1 [An, Jing; Hao, Dingjun; Zhang, Qian; Chen, Bo; Zhang, Rui; Wang, Yi; Yang, Hao] Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Translat Med Ctr, Xian 710054, Peoples R China.
C3 Xi'an Jiaotong University
RP Yang, H (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Translat Med Ctr, Xian 710054, Peoples R China.
EM yanghao.71_99@yahoo.com
RI Zhang, Qian/R 2981 2018
FU Research Foundation of Xi'an Hong Hui Hospital [YJ2016015]
FX The authors acknowledge financial support from the Research Foundation
   of Xi'an Hong Hui Hospital (No. YJ2016015).
CR Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   [Anonymous], 2009, J RHEUMATOL, V36, P1575
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   Baek JM, 2015, PHYTOMEDICINE, V22, P27, DOI 10.1016/j.phymed.2014.10.008
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bu SY, 2008, CALCIFIED TISSUE INT, V82, P475, DOI 10.1007/s00223 008 9139 0
   Çetinkaya MB, 2002, J BONE MINER METAB, V20, P44, DOI 10.1007/s774 002 8446 8
   Chae HJ, 1998, PHARMACOL TOXICOL, V82, P223, DOI 10.1111/j.1600 0773.1998.tb01429.x
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   Cremasco V, 2012, J BONE MINER RES, V27, P2452, DOI 10.1002/jbmr.1701
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Egusa H, 2011, BONE, V49, P264, DOI 10.1016/j.bone.2011.04.003
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Faccio R, 2010, ANN NY ACAD SCI, V1192, P124, DOI 10.1111/j.1749 6632.2009.05217.x
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001
   Halleen JM, 2003, J BONE MINER RES, V18, P1908, DOI 10.1359/jbmr.2003.18.10.1908
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Han KY, 2007, BIOCHEM PHARMACOL, V74, P911, DOI 10.1016/j.bcp.2007.06.044
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   He Y, 2014, BIOCHEM BIOPH RES CO, V449, P344, DOI 10.1016/j.bbrc.2014.05.034
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Huang JB, 2015, MOL CELL ENDOCRINOL, V399, P346, DOI 10.1016/j.mce.2014.10.016
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   Iotsova V., 1997, NAT MED, V3, P1285
   Ishibashi O, 2006, LIFE SCI, V79, P1657, DOI 10.1016/j.lfs.2006.05.024
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Jeong Eun H, 2013, EUR J PHARMACOL, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756 3282(90)90082 A
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim AR, 2012, EUR J PHARMACOL, V682, P29, DOI 10.1016/j.ejphar.2012.02.026
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kim HJ, 2014, EUR J PHARMACOL, V723, P473, DOI 10.1016/j.ejphar.2013.10.027
   Kim HJ, 2010, INT IMMUNOPHARMACOL, V10, P1440, DOI 10.1016/j.intimp.2010.08.017
   Kim J, 2015, INT IMMUNOPHARMACOL, V29, P628, DOI 10.1016/j.intimp.2015.09.018
   Kim JY, 2014, INT IMMUNOPHARMACOL, V20, P213, DOI 10.1016/j.intimp.2014.03.001
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim KJ, 2015, BONE, V81, P208, DOI 10.1016/j.bone.2015.07.023
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kim SN, 2008, CELL BIOL INT, V32, P1064, DOI 10.1016/j.cellbi.2008.04.017
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kimira Y, 2015, PHYTOMEDICINE, V22, P1120, DOI 10.1016/j.phymed.2015.08.013
   Ko SY, 2012, ARCH ORAL BIOL, V57, P1623, DOI 10.1016/j.archoralbio.2012.06.012
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Kwon JO, 2015, EUR J PHARMACOL, V768, P189, DOI 10.1016/j.ejphar.2015.10.053
   Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2015, EXP CELL RES, V331, P267, DOI 10.1016/j.yexcr.2014.12.018
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Nepal M, 2013, EUR J PHARMACOL, V715, P96, DOI 10.1016/j.ejphar.2013.06.002
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park B, 2014, BIOCHIMIE, V105, P129, DOI 10.1016/j.biochi.2014.07.003
   Park CK, 2008, BIOCHEM PHARMACOL, V75, P2175, DOI 10.1016/j.bcp.2008.03.007
   Park EK, 2004, BIOCHEM BIOPH RES CO, V325, P1472, DOI 10.1016/j.bbrc.2004.10.197
   Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Qiu SX, 2007, CHEM BIOL, V14, P860, DOI 10.1016/j.chembiol.2007.06.010
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Taketa T, 2008, J BONE MINER METAB, V26, P143, DOI 10.1007/s00774 007 0808 2
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tanaka S, 2006, ANN NY ACAD SCI, V1068, P180, DOI 10.1196/annals.1346.020
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Wang YJ, 2015, INT IMMUNOPHARMACOL, V29, P513, DOI 10.1016/j.intimp.2015.10.004
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wisutsitthiwong C, 2011, BIOCHEM BIOPH RES CO, V415, P361, DOI 10.1016/j.bbrc.2011.10.073
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang S, 2015, BIOCHEM BIOPH RES CO, V466, P615, DOI 10.1016/j.bbrc.2015.09.093
   Yeon JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088974
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Yoon WJ, 2013, BIOCHEM BIOPH RES CO, V434, P892, DOI 10.1016/j.bbrc.2013.04.046
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yu MX, 2014, BIOCHEM BIOPH RES CO, V447, P364, DOI 10.1016/j.bbrc.2014.04.009
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhou C, 2015, INT IMMUNOPHARMACOL, V25, P49, DOI 10.1016/j.intimp.2015.01.010
NR 121
TC 107
Z9 116
U1 6
U2 76
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2016
VL 36
BP 118
EP 131
DI 10.1016/j.intimp.2016.04.024
PG 14
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA DP4GB
UT WOS:000378453300016
PM 27131574
DA 2025 08 17
ER

PT J
AU Jacobsen, CM
   Schwartz, MA
   Roberts, HJ
   Lim, KE
   Spevak, L
   Boskey, AL
   Zurakowski, D
   Robling, AG
   Warman, ML
AF Jacobsen, Christina M.
   Schwartz, Marissa A.
   Roberts, Heather J.
   Lim, Kyung Eun
   Spevak, Lyudmila
   Boskey, Adele L.
   Zurakowski, David
   Robling, Alexander G.
   Warman, Matthew L.
TI Enhanced Wnt signaling improves bone mass and strength, but not
   brittleness, in the Col1a1<SUP>+/mov13</SUP> mouse model of type
   I Osteogenesis Imperfecta
SO BONE
LA English
DT Article
DE Lrp5; Osteogenesis Imperfecta; Wnt signaling; Mov13
ID QUALITY OF LIFE; TERIPARATIDE TREATMENT; FRACTURE; MUTATIONS; CHILDREN;
   BEHAVIOR; LRP5
AB Osteogenesis Imperfecta (OI) comprises a group of genetic skeletal fragility disorders. The mildest form of OI, Osteogenesis Imperfecta type 1, is frequently caused by haploinsufficiency mutations in COL1A1, the gene encoding the alpha(1)(I) chain of type 1 collagen. Children with OI type I have a 95 fold higher fracture rate compared to unaffected children. Therapies for OI type 1 in the pediatric population are limited to anti catabolic agents. In adults with osteoporosis, anabolic therapies that enhance Wnt signaling in bone improve bone mass, and ongoing clinical trials are determining if these therapies also reduce fracture risk. We performed a proof of principle experiment in mice to determine whether enhancing Wnt signaling in bone could benefit children with OI type I. We crossed a mouse model of OI type I (Col1a1(+/MOV13)) with a high bone mass (HBM) mouse (Lrp5(+/P.A214v)) that has increased bone strength from enhanced Wnt signaling. Offspring that inherited the CH and HBM alleles had higher bone mass and strength than mice that inherited the CH allele alone. However, OI + HBM and OI mice still had bones with lower ductility compared to wild type mice. We conclude that enhancing Wnt signaling does not make OI bone normal, but does improve bone properties that could reduce fracture risk. Therefore, agents that enhance Wnt signaling are likely to benefit children and adults with OI type 1. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Jacobsen, Christina M.; Schwartz, Marissa A.; Roberts, Heather J.; Warman, Matthew L.] Boston Childrens Hosp, Dept Orthopaed Surg, Orthopaed Res Labs, Boston, MA USA.
   [Jacobsen, Christina M.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
   [Jacobsen, Christina M.] Boston Childrens Hosp, Div Genet, Boston, MA USA.
   [Jacobsen, Christina M.] Harvard Med Sch, Dept Pediat, Boston, MA USA.
   [Warman, Matthew L.] Harvard Med Sch, Dept Genet, Boston, MA USA.
   [Lim, Kyung Eun] Indiana Univ, Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Spevak, Lyudmila; Boskey, Adele L.] Hosp Special Surg, Mineralized Tissues Lab, New York, NY USA.
   [Boskey, Adele L.] Weill Cornel Med Coll, New York, NY USA.
   [Zurakowski, David] Boston Childrens Hosp, Dept Anesthesia, Boston, MA USA.
   [Warman, Matthew L.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Harvard University; Harvard University Medical
   Affiliates; Boston Children's Hospital; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Indiana University System; Indiana University Indianapolis;
   Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Howard Hughes Medical Institute; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital
RP Jacobsen, CM (通讯作者)，Boston Childrens Hosp, 320 Longwood Ave,Enders 250, Boston, MA 02115 USA.
EM Christina.Jacobsen@childrens.harvard.edu
RI Park, Mi Kyung/J 9643 2017
FU Osteogenesis Imperfecta Foundation Michael Geisman Fellowship; Pediatric
   Endocrinology Society Research Fellowship; Howard Hughes Medical
   Institute Medical Research Fellows Program; NIH [AR063813, AR53237,
   AR062326]; Howard Hughes Medical Institute
FX The authors thank the other members of their laboratories for technical
   support, Animal Resources at Children's Hospital for assistance with
   DEXA analysis and mouse care. This work was supported by the following
   grants: Osteogenesis Imperfecta Foundation Michael Geisman Fellowship
   (CMJ), Pediatric Endocrinology Society Research Fellowship (CMJ), Howard
   Hughes Medical Institute Medical Research Fellows Program (MAS), NIH
   grants AR063813 (CMJ), AR53237 (AGR), and AR062326 (MLW) and Howard
   Hughes Medical Institute (MLW). At the time these studies were
   performed, none of the authors reported any financial or other conflicts
   of interest.
CR Atta I, 2014, JCPSP J COLL PHYSICI, V24, P653, DOI 09.2014/JCPSP.653657
   Bardai G., 2015, CALCIF TISSUE INT
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Ben Amor IM, 2013, J BONE MINER RES, V28, P2001, DOI 10.1002/jbmr.1942
   BONADIO J, 1993, J CLIN INVEST, V92, P1697, DOI 10.1172/JCI116756
   BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Cundy T, 2012, CALCIFIED TISSUE INT, V90, P439, DOI 10.1007/s00223 012 9588 3
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223 013 9770 2
   HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Jepsen KJ, 1996, J ORTHOP RES, V14, P493, DOI 10.1002/jor.1100140320
   Jepsen KJ, 1997, J BIOMECH, V30, P1141, DOI 10.1016/S0021 9290(97)00088 2
   Ljunggren Ö, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 251
   Masci M, 2016, BONE, V87, P120, DOI 10.1016/j.bone.2016.04.011
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Rajzbaum G, 2014, JOINT BONE SPINE, V81, P69, DOI 10.1016/j.jbspin.2013.05.001
   Rijks EBG, 2015, HORM RES PAEDIAT, V84, P26, DOI 10.1159/000381713
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Shapiro JR, 2010, CALCIFIED TISSUE INT, V87, P120, DOI 10.1007/s00223 010 9383 y
   SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3 4.591
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Sokal R. R., 1995, PRINCIPLES PRACTICE
   Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
NR 27
TC 19
Z9 21
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2016
VL 90
BP 127
EP 132
DI 10.1016/j.bone.2016.06.005
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DT1MK
UT WOS:000381246600016
PM 27297606
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zheng, NY
   Tang, N
   Qin, L
AF Zheng, Nianye
   Tang, Ning
   Qin, Ling
TI Atypical femoral fractures and current management
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE atypical femoral fractures; bisphosphonates; bone remodelling; fracture
   healing; parathyroid hormone
ID SUPPRESSED BONE TURNOVER; HIGH FREQUENCY VIBRATION; POSTMENOPAUSAL
   WOMEN; BISPHOSPHONATE USE; FEMUR FRACTURES; IN VITRO; SHORT TERM;
   MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES;
   MECHANICAL PROPERTIES
AB With the rapid increase in patients receiving bisphosphonates (BPs) for treating osteoporosis, one of the clinical complications associated with its long term use is atypical femoral fractures (AFFs). Although the absolute risk for AFFs is low and it was a consensus that AFFs were acceptable compared with the amount of osteoporotic fractures BPs have prevented, epidemiological studies have proved that BPs had a strong association with AFFs and possibly more people were going to suffer from this adverse effect with wide prescriptions of this drug. In addition, AFFs seemed to have impaired ability to heal. Thus, to understand the mechanism(s) behind AFFs is important and desirable for considering preventive measures. This article reviewed the clinical features of AFFs as well as potential underlining pathological characteristics, such as the decreased turnover rate caused by BPs that led to multiple level alternations, e.g., changes not only at cellular and tissue levels, but also related to changes in bone micro and macrostructure and organic/inorganic contents, leading to potentially compromised mechanical properties of cortical bone when exposed to prolonged BP therapy. Severely suppressed bone turnover may also be the underlying mechanism for impaired fracture healing in patients with AFFs. The rising concerns about the risk for AFFs in nonosteoporotic patients receiving high dose BPs to treat cancers were also discussed. Detailed investigation will help develop potential targeted pharmacological treatments such as parathyroid hormone. In addition, potential innovative internal fixation implants were discussed with regard to dynamic and biological fixation for enhancing AFF repair. (C) 2016 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society.
C1 [Zheng, Nianye; Tang, Ning; Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Qin, L (通讯作者)，Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab, Shatin, Hong Kong, Peoples R China.
EM lingqin@cuhk.edu.hk
RI Qin, Ling/J 9047 2018; Qin, Ling/JBR 9155 2023
OI Qin, Ling/0000 0001 6173 6167; 
CR Acevedo C, 2015, BONE, V81, P352, DOI 10.1016/j.bone.2015.08.002
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Alaee F, 2014, J ORTHOP RES, V32, P197, DOI 10.1002/jor.22498
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Allen MR, 2007, J BONE MINER RES, V22, P1759, DOI 10.1359/JBMR.070720
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Androjna C, 2014, BIOELECTROMAGNETICS, V35, P396, DOI 10.1002/bem.21855
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Balach T, 2015, J AM ACAD ORTHOP SUR, V23, P550, DOI 10.5435/JAAOS D 14 00024
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Barrett JG, 2007, J ORTHOP RES, V25, P1070, DOI 10.1002/jor.20395
   Blood T, 2015, JBJS REV, V3, DOI 10.2106/JBJS.RVW.N.00062
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   Carvalho NNC, 2011, J CLIN ENDOCR METAB, V96, P2675, DOI 10.1210/jc.2011 0593
   Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Chaya A, 2015, ACTA BIOMATER, V18, P262, DOI 10.1016/j.actbio.2015.02.010
   Cheung WH, 2012, ULTRASOUND MED BIOL, V38, P2120, DOI 10.1016/j.ultrasmedbio.2012.07.025
   Chisin R, 2001, CRC SER EXERC PHSIOL, P279
   Chow DHK, 2011, J ORTHOP RES, V29, P746, DOI 10.1002/jor.21303
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Das De S, 2010, J BONE JOINT SURG BR, V92B, P679, DOI 10.1302/0301 620X.92B5.22941
   Dell R, 2010, J BONE MINER RES, V25, P61
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Donnelly E, 2012, CURR OPIN SUPPORT PA, V6, P348, DOI 10.1097/SPC.0b013e3283552d7d
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Ebetino F, 2010, BONE, V46, pS70, DOI 10.1016/j.bone.2010.01.170
   Edwards B J., 2016, J Bone Miner Res
   Egol KA, 2014, CLIN ORTHOP RELAT R, V472, P2728, DOI 10.1007/s11999 013 2963 1
   Einhorn TA, 2011, INDIAN J ORTHOP, V45, P489, DOI 10.4103/0019 5413.87113
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Fournier P, 2002, CANCER RES, V62, P6538
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   Han P, 2015, BIOMATERIALS, V64, P57, DOI 10.1016/j.biomaterials.2015.06.031
   Ho CY, 2015, TISSUE ENG PT A, V21, P594, DOI [10.1089/ten.tea.2013.0762, 10.1089/ten.TEA.2013.0762]
   Im Gun Il, 2015, J Bone Metab, V22, P1
   Ishtiaq S, 2015, CYTOKINE, V71, P154, DOI 10.1016/j.cyto.2014.10.025
   Jamal SA, 2011, NEW ENGL J MED, V365, P1261, DOI 10.1056/NEJMc1107029
   Tarazona Santabalbina FJ, 2013, AGING CLIN EXP RES, V25, P605, DOI 10.1007/s40520 013 0137 3
   Komrakova M, 2010, BONE, V47, P480, DOI 10.1016/j.bone.2010.05.013
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Leung KS, 2009, J ORTHOP RES, V27, P458, DOI 10.1002/jor.20753
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Li ZJ, 2008, BIOMATERIALS, V29, P1329, DOI 10.1016/j.biomaterials.2007.12.021
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Malhotra R, 2013, CLIN CASES MINER BON, V10, P210, DOI 10.11138/ccmbm/2013.10.3.210
   Maravic M, 2012, J BONE MINER RES, V27, P130, DOI 10.1002/jbmr.517
   de Albornoz PM, 2011, BRIT MED BULL, V100, P39, DOI 10.1093/bmb/ldr006
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Milovanovic P, 2015, BIOMATERIALS, V45, P46, DOI 10.1016/j.biomaterials.2014.12.024
   Miyakoshi N, 2015, J BONE MINER METAB, V33, P553, DOI 10.1007/s00774 014 0617 3
   Morawska Chochól A, 2015, MAT SCI ENG C MATER, V51, P99, DOI 10.1016/j.msec.2015.02.043
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nieves JW, 2010, OSTEOPOROSIS INT, V21, P399, DOI 10.1007/s00198 009 0962 6
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Oh Y, 2014, INJURY, V45, P1764, DOI 10.1016/j.injury.2014.08.037
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Padilla F, 2014, ULTRASONICS, V54, P1125, DOI 10.1016/j.ultras.2014.01.004
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Poundarik AA, 2015, J MECH BEHAV BIOMED, V50, P82, DOI 10.1016/j.jmbbm.2015.05.025
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Qin L, 2002, OSTEOPOROSIS INT, V13, P962, DOI 10.1007/s001980200134
   Qin L, 2014, J ORTHOP TRANSL, V2, P43, DOI 10.1016/j.jot.2013.12.001
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Reddy SVB, 2012, SINGAP MED J, V53, pE52
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415
   Resmini G, 2011, AGING CLIN EXP RES, V23, P30
   Sasaki S, 2012, J BONE MINER METAB, V30, P561, DOI 10.1007/s00774 012 0358 0
   Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301 620X.95B9.31562
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2014, ACTA ORTHOP, V85, P280, DOI 10.3109/17453674.2014.916488
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schober H, 2009, J BONE MINER RES, V24
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shi HF, 2010, BONE, V46, P1299, DOI 10.1016/j.bone.2009.11.028
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Sloan AV, 2010, BONE, V47, P235, DOI 10.1016/j.bone.2010.05.015
   Smith ER, 2013, J ORTHOP RES, V31, P1317, DOI 10.1002/jor.22343
   Somford MP, 2009, J BONE MINER RES, V24, P1736, DOI [10.1359/jbmr.090408, 10.1359/JBMR.090408]
   Stepan JJ, 2007, BONE, V41, P378, DOI 10.1016/j.bone.2007.04.198
   Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056
   Teo BJX, 2014, BONE JOINT J, V96B, P658, DOI 10.1302/0301 620X.96B5.32887
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   Uchiyama S, 2015, BONE, V75, P84, DOI 10.1016/j.bone.2015.02.018
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Van der Meijden K, 2015, J STEROID BIOCH MOL, V2015
   Verdonk R, 2015, ARTHROSCOPY, V31, P715, DOI 10.1016/j.arthro.2014.11.045
   Wang JB, 2015, MAT SCI ENG C MATER, V55, P556, DOI 10.1016/j.msec.2015.05.082
   Wang Z, 2011, J BONE MINER RES, V26, P553, DOI 10.1002/jbmr.233
   Weil YA, 2011, J TRAUMA, V71, P186, DOI 10.1097/TA.0b013e31821957e3
   Yoshizawa S, 2014, CONNECT TISSUE RES, V55, P155, DOI 10.3109/03008207.2014.923877
   Yue B, 2015, ANN ROY COLL SURG, V97, P333, DOI 10.1308/003588415X14181254789321
   Zhao YP, 2013, BIOMATERIALS, V34, P6412, DOI 10.1016/j.biomaterials.2013.05.030
NR 102
TC 15
Z9 21
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD OCT
PY 2016
VL 7
BP 7
EP 22
DI 10.1016/j.jot.2016.06.029
PG 16
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA EC4OK
UT WOS:000388112200002
PM 30035084
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kawazoe, M
   Kaneko, K
   Shikano, K
   Kusunoki, N
   Nanki, T
   Kawai, S
AF Kawazoe, Mai
   Kaneko, Kaichi
   Shikano, Kotaro
   Kusunoki, Natsuko
   Nanki, Toshihiro
   Kawai, Shinichi
TI Glucocorticoid therapy causes contradictory changes of serum Wnt
   signaling related molecules in systemic autoimmune diseases
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Dickkopf 1; Glucocorticoid; Osteoporosis; Sclerostin; Wnt signaling
ID SCLEROSTIN ANTIBODY TREATMENT; C REACTIVE PROTEIN; INDUCED OSTEOPOROSIS;
   BONE FORMATION; ALKALINE PHOSPHATASE; POSTMENOPAUSAL WOMEN; FUTURE
   PERSPECTIVES; JAPANESE SOCIETY; DICKKOPF 1; DIFFERENTIATION
AB The objective of this study was to investigate the clinical significance of the Wnt/beta catenin signaling pathway in glucocorticoid induced osteoporosis. A total of 91 patients with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30 60 mg daily) were prospectively enrolled. We measured serum levels of N terminal peptide of type I procollagen (P1NP), bone alkaline phosphatase (BAP), tartrate resistant acid phosphatase isoform 5b (TRACP 5b), N telopeptide cross linked type I collagen (NTX), sclerostin, Dickkopf 1 (Dkk 1), and Wnt3a before starting glucocorticoid therapy and every week for 4 weeks after its initiation. The effects of dexamethasone on expression of mRNA and protein of sclerostin and Dkk 1 by cultured normal human osteoblasts (NHOst) were evaluated by RT PCR and ELISA, respectively. Serum levels of sclerostin and Dkk 1 increased significantly by 1 week of glucocorticoid therapy and then decreased from the second week onward. Serum Wnt3a tended to decrease and serum P1NP showed a significant decrease. However, TRACP 5b was significantly elevated from the first week of treatment onwards. In vitro study, dexamethasone increased Dkk 1 mRNA expression in cultured NHOst, but sclerostin mRNA was not detected. Dexamethasone also increased Dkk 1 protein production by osteoblasts, whereas sclerostin protein was not detected. Bone formation might be impaired at least in the first week of the initiation of glucocorticoid therapy by increase of the serum Wnt signaling inhibitors; however, their reductions in the subsequent weeks were contradictory to the maintained suppression of the bone formation markers after glucocorticoid therapy for patients with systemic autoimmune diseases.
C1 [Kawazoe, Mai; Nanki, Toshihiro] Toho Univ, Grad Sch Med, Dept Internal Med, Tokyo, Japan.
   [Kawazoe, Mai; Kaneko, Kaichi; Shikano, Kotaro; Kusunoki, Natsuko; Nanki, Toshihiro] Toho Univ, Sch Med, Div Rheumatol, Dept Internal Med, Tokyo, Japan.
   [Kawai, Shinichi] Toho Univ, Sch Med, Dept Inflammat & Pain Control Res, Ota Ku, 5 21 16 Omori Nishi, Tokyo 1438540, Japan.
C3 Toho University; Toho University; Toho University
RP Kawai, S (通讯作者)，Toho Univ, Sch Med, Dept Inflammat & Pain Control Res, Ota Ku, 5 21 16 Omori Nishi, Tokyo 1438540, Japan.
EM skawai@med.toho u.ac.jp
OI KANEKO, KAICHI/0000 0002 2082 6948; Kawazoe, Mai/0000 0002 9822 8067
FU Strategic Research Foundation Project for Private Schools in Heisei 23
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan [S1101016]; Japan Agency for Medical Research and Development
   on Regulatory Science of Pharmaceuticals and Medical Devices [20152016]
FX We thank Sonoko Sakurai for secretarial assistance. This study was
   partly supported by a grant from the Strategic Research Foundation
   Project for Private Schools in Heisei 23 (S1101016) from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (2011 2015)
   to Toho University and a grant from the Japan Agency for Medical
   Research and Development on Regulatory Science of Pharmaceuticals and
   Medical Devices (20152016) to SK.
CR Bagnari V, 2010, RHEUMATOL INT, V30, pCP9, DOI 10.1007/s00296 009 1291 y
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   BERTOUCH JV, 1983, ANN RHEUM DIS, V42, P655, DOI 10.1136/ard.42.6.655
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chung YE, 2012, OSTEOPOROSIS INT, V23, P1235, DOI 10.1007/s00198 011 1675 1
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   Dovjak P, 2014, GERONTOLOGY, V60, P493, DOI 10.1159/000358303
   GABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Gifre L, 2013, BONE, V57, P272, DOI 10.1016/j.bone.2013.08.016
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Hoes JN, 2010, CLIN EXP RHEUMATOL, V28, P354
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kermani TA, 2012, SEMIN ARTHRITIS RHEU, V41, P866, DOI 10.1016/j.semarthrit.2011.10.005
   Kuroki Y, 2008, J BONE MINER METAB, V26, P271, DOI 10.1007/s00774 007 0821 5
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Maresova KB, 2013, CALCIFIED TISSUE INT, V92, P354, DOI 10.1007/s00223 012 9684 4
   Matsumoto T, 2009, OSTEOPOROSIS INT, V20, P1429, DOI 10.1007/s00198 008 0816 7
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774 004 0596 x
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shikano K, 2016, INTERNAL MED, V55, P1997, DOI 10.2169/internalmedicine.55.6230
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Tse WY, 1998, POSTGRAD MED J, V74, P1, DOI 10.1136/pgmj.74.867.1
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   WALTON RJ, 1975, CLIN CHIM ACTA, V63, P227, DOI 10.1016/0009 8981(75)90167 9
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   WEISS MJ, 1988, J BIOL CHEM, V263, P12002
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
NR 45
TC 21
Z9 22
U1 0
U2 14
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD AUG
PY 2018
VL 37
IS 8
BP 2169
EP 2178
DI 10.1007/s10067 017 3689 3
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA GM6KZ
UT WOS:000438277700018
PM 28551822
DA 2025 08 17
ER

PT J
AU Zou, YG
   Yang, JX
   Jiang, DM
AF Zou, Yonggen
   Yang, Jiexiang
   Jiang, Dianming
TI Resveratrol inhibits canonical Wnt signaling in human MG 63 osteosarcoma
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteosarcoma; Wnt signaling pathway; beta catenin; high content
   screening
ID BETA CATENIN; CANCER CELLS; CYCLIN D1; C MYC; EXPRESSION; APC;
   ACTIVATION; MUTATIONS; APOPTOSIS; GENES
AB In the last 30 years, the 5 year survival rate of patients with osteosarcoma has not improved as a result of the low prevalence and large tumor heterogeneity. Therefore, the development of novel drugs for the treatment of osteosarcoma is urgently required. The present study aimed to identify potential novel drugs for the treatment of osteosarcoma, thus used beta catenin as a target and performed high content screening. In a total of 14 botanical extracts assessed, resveratrol markedly downregulated the expression of beta catenin and significantly inhibited MG 63 cell proliferation. CCK 8 assay was used to confirm the anti osteosarcoma effect of resveratrol and flow cytometry and western blotting were performed to analyze the underlying mechanisms of the proapoptotic effects of resveratrol. beta catenin is a vital member of the canonical Wnt signaling pathway and, therefore, the target genes of this pathway were further analyzed. The results of this analysis demonstrated that resveratrol suppressed the MG 63 cells by inhibiting the canonical Wnt signaling pathway.
C1 [Zou, Yonggen; Jiang, Dianming] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Chongqing 400016, Peoples R China.
   [Yang, Jiexiang] Luzhou Med Coll, Affiliated Tradit Chinese Med Hosp, Dept Orthoped, Luzhou 646000, Sichuan, Peoples R China.
C3 Chongqing Medical University; Southwest Medical University
RP Jiang, DM (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM jdm571026@vip.163.com
FU National Natural Foundation of China [60171009]
FX This study was supported by the National Natural Foundation of China
   (grant. no. 60171009).
CR Alkhalaf M, 2008, ARCH MED RES, V39, P162, DOI 10.1016/j.arcmed.2007.09.003
   Alkhalaf M, 2006, FREE RADICAL BIO MED, V41, P318, DOI 10.1016/j.freeradbiomed.2006.04.019
   Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   He NB, 2015, MOL CELL BIOCHEM, V405, P187, DOI 10.1007/s11010 015 2410 6
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hedberg Y, 2003, BRIT J CANCER, V88, P1417, DOI 10.1038/sj.bjc.6600922
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Joe AK, 2002, CLIN CANCER RES, V8, P893
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Linabery AM, 2008, CANCER, V112, P416, DOI 10.1002/cncr.23169
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Miyaki M, 1999, CANCER RES, V59, P4506
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521 1878(199912)22:1<1021::AID BIES6>3.0.CO;2 P
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365 2443.1998.00198.x
   Ng TL, 2005, MODERN PATHOL, V18, P68, DOI 10.1038/modpathol.3800272
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959 437X(99)80003 3
   Polakis P, 2000, GENE DEV, V14, P1837
   Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Yamamoto N, 2013, EXPERT OPIN PHARMACO, V14, P2183, DOI 10.1517/14656566.2013.827171
   Yang LQ, 2004, WORLD J GASTROENTERO, V10, P22
NR 34
TC 31
Z9 34
U1 0
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2015
VL 12
IS 5
BP 7221
EP 7226
DI 10.3892/mmr.2015.4338
PN B
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CW3JR
UT WOS:000364889100004
PM 26398440
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Kang, XP
   Chen, L
   Yang, SC
   Gong, ZB
   Hu, HY
   Zhang, XL
   Liang, C
   Xu, YW
AF Kang, Xiangping
   Chen, Long
   Yang, Shuchen
   Gong, Zhangbin
   Hu, Haiyan
   Zhang, Xueli
   Liang, Chao
   Xu, Yanwu
TI Zuogui Wan slowed senescence of bone marrow mesenchymal stem cells by
   suppressing Wnt/? catenin signaling
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Zuogui Wan; Network pharmacology; Mesenchymal stem cells; Wnt signaling
   pathway; Aging
ID DNA DAMAGE; OXIDATIVE STRESS; BETA CATENIN; ACCUMULATION; STIGMASTEROL;
   MECHANISMS; RATS; P53
AB Ethnopharmacological relevance: In traditional Chinese medicine (TCM), Zuogui Wan (ZGW) is a classical prescription for senile disorders and delay aging. Modern studies show that ZGW promotes central nerve cell regeneration, prevents and cures osteoporosis, enhances the body's antioxidant capacity, regulates the body's immune function, and promotes mesenchymal stem cells (MSCs) proliferation. Aim of the study: It has been shown that MSCs aging is closely associated with organism's aging and age related disorders. The study aimed to define the effects of ZGW on the aging bone marrow mesenchymal stem cells (BMSCs) and to identify the mechanisms of ZGW delaying BMSCs senescence. Materials and methods: Network pharmacology analysis combined with GEO data mining, molecular docking and experimental validation were used to evaluate the mechanisms by which ZGW delays MSCs senescence (MSCS). LC MS was used for quality control analysis of ZGW. Results: PPI network analysis revealed that EGF, TNF, JUN, MMPs, IL 6, MAPK8, and MYC are components of the core PPI network. GO and KEGG analyses revealed that oxidative stress, regulation of response to DNA damage stimuli, and Wnt signaling were significantly enriched. GEO database validation also indicated that Wnt signaling closely correlated with MSCs aging. Molecular docking analysis of the top 13 active components in the "ZGW Targets MSCS" network indicated that most components have strong affinity for key proteins in Wnt signaling, suggesting that modulation of Wnt signaling is an important mechanism of ZGW activity against MSCS. Further experimental validation found that ZGW indeed regulates Wnt signaling and suppresses the expression of age related factors to enhance cell proliferation, ameliorate DNA damage, and reduce senescence related secretory phenotype (SASP) secretion, thereby maintaining multidirectional differentiation of rat BMSCs. Similar results were obtained using the Wnt inhibitor, XAV 939. Conclusions: Together, our data show that ZGW slows BMSCs aging by suppressing Wnt signaling.
C1 [Kang, Xiangping; Yang, Shuchen; Gong, Zhangbin; Hu, Haiyan; Zhang, Xueli; Liang, Chao; Xu, Yanwu] Shanghai Univ Tradit Chinese Med, Coll Basic Med, Shanghai, Peoples R China.
   [Chen, Long] Shanghai Univ Tradit Chinese Med, Expt Ctr Sci & Technol, Shanghai, Peoples R China.
   [Zhang, Xueli; Liang, Chao; Xu, Yanwu] 1200 Cailun Rd,Pudong Dist, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Zhang, XL; Liang, C; Xu, YW (通讯作者)，1200 Cailun Rd,Pudong Dist, Shanghai 201203, Peoples R China.
EM kxp5025@163.com; 13621765696@163.com; 1443681871@qq.com;
   zhangbingong@126.com; happyan88@sina.com; zhangxueli8403@163.com;
   ysw141@126.com; xyw551268@live.cn
RI Yang, Shuchen/LQK 0762 2024; hu, hai/LBH 4948 2024; Xu,
   Yanwu/AAK 6357 2020
FU National Natural Science Foundation of China [81803987]; National
   Natural Science Founda tion of China [82174102]
FX Acknowledgments This work was supported by the National Natural Science
   Foundation of China (81803987) to X.K and the National Natural Science
   Founda tion of China (82174102) to Z.G. We thank all lab members for
   invaluable comments on the manuscript.
CR Alves H, 2010, J CELL MOL MED, V14, P2729, DOI 10.1111/j.1582 4934.2009.00931.x
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Benameur L, 2015, BIO MED MATER ENG, V25, pS41, DOI 10.3233/BME 141247
   Charif N, 2017, BIO MED MATER ENG, V28, pS57, DOI 10.3233/BME 171624
   Chen Y, 2015, CHIN J NAT MEDICINES, V13, P578, DOI 10.1016/S1875 5364(15)30053 4
   Cheng SM, 2020, AM J CHINESE MED, V48, P391, DOI 10.1142/S0192415X20500202
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cui H, 2019, STEM CELL REV REP, V15, P448, DOI 10.1007/s12015 019 09880 9
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Du Rong, 2018, Sichuan Da Xue Xue Bao Yi Xue Ban, V49, P369
   Feng SM, 2018, BBA MOL CELL BIOL L, V1863, P1274, DOI 10.1016/j.bbalip.2018.08.004
   Haÿ E, 2014, J CELL PHYSIOL, V229, P1765, DOI 10.1002/jcp.24629
   Hayashi Y, 2021, CELL MOL GASTROENTER, V11, P117, DOI 10.1016/j.jcmgh.2020.07.011
   Heo JS, 2016, INT J MOL MED, V37, P115, DOI 10.3892/ijmm.2015.2413
   Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159
   Jin Z., 2010, MODERNIZATION TRADIT, V12, P550
   Kang X., 2015, ALTERNATIVE INTEGRAT, V04
   Khan F, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090529
   Li BJ, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.152982
   Li CM, 2015, FOOD FUNCT, V6, P2266, DOI 10.1039/c5fo00031a
   Li XY, 2017, CHIN J INTEGR MED, V23, P190, DOI 10.1007/s11655 016 2095 4
   [梁超 Liang Chao], 2018, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V33, P3279
   Liu FX, 2018, BIOMED PHARMACOTHER, V103, P1052, DOI 10.1016/j.biopha.2018.04.102
   Liu HP, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/2960372
   Liu J, 2005, ANGEW CHEM INT EDIT, V44, P1987, DOI 10.1002/anie.200462552
   Luo LW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.648201
   Marasini S, 2017, MOL CELLS, V40, P598, DOI 10.14348/molcells.2017.0095
   Mo XB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121811
   Mosteiro L, 2016, SCIENCE, V354, DOI 10.1126/science.aaf4445
   Neves J, 2017, CELL STEM CELL, V20, P161, DOI 10.1016/j.stem.2017.01.008
   Oh J, 2014, NAT MED, V20, P870, DOI 10.1038/nm.3651
   Peng HJ, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111855
   Price AM, 2018, J VIROL, V92, DOI 10.1128/JVI.01178 17
   Rai P, 2009, P NATL ACAD SCI USA, V106, P169, DOI 10.1073/pnas.0809834106
   Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Schmitz Y, 2013, CELL SIGNAL, V25, P2210, DOI 10.1016/j.cellsig.2013.07.005
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Tichon A, 2013, CURR MOL MED, V13, P1010, DOI 10.2174/1566524011313060013
   Uddin N, 2020, MOLECULES, V25, DOI 10.3390/molecules25215011
   [徐广润 Xu Guangrun], 2006, [山东大学学报. 医学版, Journal of Shandong University. Health Science], V44, P146
   Xu TF, 2017, J PHARMACEUT BIOMED, V141, P95, DOI 10.1016/j.jpba.2017.04.012
   Yahata T, 2011, BLOOD, V118, P2941, DOI 10.1182/blood 2011 01 330050
   Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744 08
   Yu JM, 2011, AGING CELL, V10, P66, DOI 10.1111/j.1474 9726.2010.00646.x
   Yu QJ, 2015, CELL REP, V11, P785, DOI 10.1016/j.celrep.2015.03.069
   Zhan Fei Zhan Fei, 2015, China Journal of Traditional Chinese Medicine and Pharmacy, V30, P2518
   Zhang DY, 2013, MOL CELL BIOCHEM, V374, P13, DOI 10.1007/s11010 012 1498 1
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 49
TC 29
Z9 33
U1 3
U2 47
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2022
VL 294
AR 115323
DI 10.1016/j.jep.2022.115323
EA MAY 2022
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1T1LG
UT WOS:000804498600005
PM 35483559
OA hybrid
DA 2025 08 17
ER

PT J
AU Gao, T
   Yu, CH
   Shi, XF
   Hu, YH
   Chang, YY
   Zhang, JW
   Wang, YT
   Zhai, ZJ
   Jia, XL
   Mao, YQ
AF Gao, Tian
   Yu, Chaohong
   Shi, Xiaofeng
   Hu, Yuehao
   Chang, Yongyun
   Zhang, Jingwei
   Wang, Yitian
   Zhai, Zanjing
   Jia, Xinlin
   Mao, Yuanqing
TI Artemisinic acid attenuates osteoclast formation and titanium
   particle induced osteolysis via inhibition of RANKL induced ROS
   accumulation and MAPK and NF κB signaling pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE artemisinic acid; osteoclastogenesis; reactive oxygen species; NF kappa
   B; MAPK; osteolysis
ID TOTAL HIP ARTHROPLASTY; BONE RESORPTION; PERIPROSTHETIC OSTEOLYSIS;
   TNF ALPHA; REVISION; OSTEOPOROSIS; BIOLOGY; WEAR; EPIDEMIOLOGY;
   EXPRESSION
AB Periprosthetic osteolysis (PPO) is the most common cause of joint arthroplasty failure. Its progression involves both biological and mechanical factors. Osteoclastogenesis induced by wear from debris cell interactions, ultimately leading to excessive bone erosion, is considered the primary cause of PPO; therefore, targeting osteoclasts is a promising treatment approach. Currently available drugs have various side effects and limitations. Artemisinic acid (ArA) is a sesquiterpene isolated from the traditional herb Artemisia annua L. that has various pharmacological effects, such as antimalarial, anti inflammatory, and antioxidant activities. Therefore, this study was aimed at investigating the effect of ArA on osteoclast formation and bone resorption function in vitro, as well as wear particle induced osteolysis in vivo, and to explore its molecular mechanism of action. Here, we report that ArA inhibits RANKL stimulated osteoclast formation and function. Mechanistically, ArA suppresses intracellular reactive oxygen species levels by activating the antioxidant response via nuclear factor erythroid 2 related factor 2 (Nrf2) pathway upregulation. It also inhibits the mitogen activated kinases (MAPK) and nuclear factor kappa B (NF kappa B) pathways, as well as the transcription and expression of NFATc1 and c Fos. In vivo experiments demonstrated that ArA reduces osteoclast formation and alleviates titanium particle induced calvarial osteolysis. Collectively, our study highlights that ArA, with its osteoprotective and antioxidant effects, is a promising therapeutic agent for preventing and treating PPO and other osteoclast mediated osteolytic diseases.
C1 [Gao, Tian; Yu, Chaohong; Shi, Xiaofeng; Hu, Yuehao; Chang, Yongyun; Zhang, Jingwei; Wang, Yitian; Zhai, Zanjing; Jia, Xinlin; Mao, Yuanqing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhai, ZJ; Jia, XL; Mao, YQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.
EM zanjing_zhai@163.com; xinlin_jia@126.com; yuanqingmao@163.com
RI ; Wang, Yitian/CAA 1350 2022; Shi, Xiaofeng/KHZ 7437 2024; zhang,
   xuyang/GQH 3712 2022
OI Gao, Tian/0000 0001 7770 4645; Shi, Xiaofeng/0009 0002 9855 6981
FU Shanghai Municipal Health and Family Planning
   Commission10.13039/501100014175
FX No Statement Available
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Bilia AR, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/159819
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozic KJ, 2009, J BONE JOINT SURG AM, V91A, P128, DOI 10.2106/JBJS.H.00155
   Chaturvedi D, 2010, CHEM SOC REV, V39, P435, DOI 10.1039/b816679j
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Deng LJ, 2020, J LEUKOCYTE BIOL, V108, P493, DOI 10.1002/JLB.3MR0320 444R
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Ferreira JFS, 2010, J AGR FOOD CHEM, V58, P1691, DOI 10.1021/jf903222j
   Fu CQ, 2021, ACS OMEGA, V6, P889, DOI 10.1021/acsomega.0c05465
   Gallo J, 2014, ACTA BIOMATER, V10, P2354, DOI 10.1016/j.actbio.2014.02.003
   Garbe AI, 2012, J BONE MINER RES, V27, P2085, DOI 10.1002/jbmr.1670
   Girard J, 2013, ORTHOP TRAUMATOL SUR, V99, P549, DOI 10.1016/j.otsr.2013.03.026
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Goodman SB, 2007, BIOMATERIALS, V28, P5044, DOI 10.1016/j.biomaterials.2007.06.035
   Goodman SB, 2022, CURR OSTEOPOROS REP, V20, P43, DOI 10.1007/s11914 022 00720 3
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Guo SW, 2022, FRONT VET SCI, V9, DOI 10.3389/fvets.2022.934021
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Jung MK, 2002, J MED CHEM, V45, P4940, DOI 10.1021/jm020244p
   Katiyar Chandrakant, 2012, Ayu, V33, P10, DOI 10.4103/0974 8520.100295
   Kendler D, 2011, CLIMACTERIC, V14, P604
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140 6736(07)60457 7
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17427 6
   Li HT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.778041
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Liang XY, 2023, INT J ORAL SCI, V15, DOI 10.1038/s41368 023 00245 0
   Liao SJ, 2021, J CELL PHYSIOL, V236, P1432, DOI 10.1002/jcp.29948
   Liao SJ, 2019, J CELL PHYSIOL, V234, P17600, DOI 10.1002/jcp.28384
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Madry H, 2022, OSTEOARTHR CARTILAGE, V30, P1019, DOI 10.1016/j.joca.2022.01.012
   McArthur BA, 2019, HSS J, V15, P286, DOI 10.1007/s11420 018 9641 5
   Nam NH, 2006, MINI REV MED CHEM, V6, P945, DOI 10.2174/138955706777934937
   Niu JQ, 2024, J ARTHROPLASTY, V39, P1845, DOI 10.1016/j.arth.2024.01.062
   Patel A, 2015, BONE JOINT J, V97B, P1076, DOI 10.1302/0301 620X.97B8.35170
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Qu RZ, 2019, INFLAMMATION, V42, P1652, DOI 10.1007/s10753 019 01026 w
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Simon D, 2017, BONE, V105, P35, DOI 10.1016/j.bone.2017.08.013
   Suda T, 2001, Novartis Found Symp, V232, P235
   Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778078
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Taylor S, 2010, METHODS, V50, pS1, DOI 10.1016/j.ymeth.2010.01.005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teschke R, 2015, WORLD J GASTROENTERO, V21, P4466, DOI 10.3748/wjg.v21.i15.4466
   Toro EJ, 2012, J BIOL CHEM, V287, P17894, DOI 10.1074/jbc.M111.280511
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Wilson I, 2019, EFORT OPEN REV, V4, P357, DOI 10.1302/2058 5241.4.180080
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Wu ZX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.793087
   Yamada C, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111503
   Zhang J, 2020, ENVIRON TOXICOL PHAR, V76, DOI 10.1016/j.etap.2020.103358
   ZHENG GQ, 1994, PLANTA MED, V60, P54, DOI 10.1055/s 2006 959408
NR 61
TC 4
Z9 4
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 1
PY 2024
VL 15
AR 1345380
DI 10.3389/fphar.2024.1345380
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QR0D3
UT WOS:001222470100001
PM 38751789
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xiao, W
   Wei, YY
   Yang, F
   Lu, XY
   Liu, SW
   Long, YL
   Yu, Y
AF Xiao, Wen
   Wei, Yanyan
   Yang, Fang
   Lu, Xiangyi
   Liu, Shuowen
   Long, Yongling
   Yu, Yang
TI Cistanche deserticola polysaccharide inhibits OVX induced
   bone loss in mice and RANKL induced osteoclastogenesis
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Osteoporosis; Cistanche deserticola polysaccharide; Ovariectomy;
   Osteoclast
ID ACTIVATED T CELLS; B LIGAND RANKL; RECEPTOR ACTIVATOR; NUCLEAR FACTOR;
   DIFFERENTIATION; OSTEOPOROSIS; NFATC1; IMMUNE; EXPRESSION; INDUCTION
AB Osteoporosis is a serious bone disease affecting the aging population. Cistanche deserticola (CD), a tonic and medicinal food widely used in China, has been proved to provide effective treatment for osteoporosis. Cistanche deserticola polysaccharide (CDP), extracted from CD, possesses various pharmacological properties, but its role in osteoclastic formation and function as well as osteoporosis remains unknown. The purpose of this study was to extract and purify CDP to further explore its potential mechanism of action on osteoporosis. Results showed that the CDP treatment prevented OVX induced osteoporosis and ameliorated bone loss by repressing osteoclast activity and function. Furthermore, CDP treatment significantly inhibited RANKL induced osteoclastogenesis, bone resorption, and osteoclast specific gene expression. Mechanistically, CDP inhibited RANKL induced NF kappa B and MAPKs signaling pathways activation and consequently affected the downstream NFATc1 activation. The findings in this study suggest that CDP is a potentially safe drug for treating osteoporosis.
C1 [Xiao, Wen; Wei, Yanyan; Yang, Fang; Lu, Xiangyi; Liu, Shuowen; Long, Yongling; Yu, Yang] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
   [Wei, Yanyan] Guangxi Med Univ, Pharmaceut Coll, Nanning 530021, Guangxi, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangxi Medical University
RP Long, YL; Yu, Y (通讯作者)，Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
EM longyongling@gzucm.edu.cn; yuyang@gzucm.edu.cn
OI Long, Yongling/0000 0003 2533 7614
CR Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Baek JM, 2014, MOLECULES, V19, P11628, DOI 10.3390/molecules190811628
   Beral Valerie, 2003, Lancet, V362, P419
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Davis HM, 2019, BONE, V124, P89, DOI 10.1016/j.bone.2019.04.012
   De Martinis M, 2006, INFLAMM RES, V55, P399, DOI 10.1007/s00011 006 6034 x
   Fan XL, 2019, J CELL BIOCHEM, V120, P5505, DOI 10.1002/jcb.27833
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   Gu CM, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00289
   Guo YH, 2016, INT J BIOL MACROMOL, V93, P678, DOI 10.1016/j.ijbiomac.2016.09.039
   Hu YB, 2020, J CELL MOL MED, V24, P4023, DOI 10.1111/jcmm.15038
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ihde LL, 2011, RADIOGRAPHICS, V31, P1865, DOI 10.1148/rg.317115093
   Jiang ZH, 2016, J ETHNOPHARMACOL, V193, P321, DOI 10.1016/j.jep.2016.07.033
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Kim MJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040431
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li SB, 2018, EXP THER MED, V16, P643, DOI 10.3892/etm.2018.6199
   Li TM, 2012, J PHARM PHARMACOL, V64, P897, DOI 10.1111/j.2042 7158.2012.01483.x
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Wang T, 2012, AM J CHINESE MED, V40, P1123, DOI 10.1142/S0192415X12500838
   Wehrle E, 2015, DIS MODEL MECH, V8, P93, DOI 10.1242/dmm.018622
   Xu XX, 2017, MOLECULES, V22, DOI 10.3390/molecules22020197
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yan CY, 2019, INT J BIOL MACROMOL, V133, P446, DOI 10.1016/j.ijbiomac.2019.04.084
   Zhang AL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191356
   Zhang Q, 2019, P NATL ACAD SCI USA, V116, P24463, DOI 10.1073/pnas.1907956116
   Zhang SJ, 2018, CARBOHYD POLYM, V184, P288, DOI 10.1016/j.carbpol.2017.12.070
   Zhao P, 2019, CARBOHYD POLYM, V214, P44, DOI 10.1016/j.carbpol.2019.03.014
   Zheng H, 2020, INT J BIOL MACROMOL, V156, P1135, DOI 10.1016/j.ijbiomac.2019.11.145
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 50
TC 14
Z9 15
U1 7
U2 72
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
EI 2214 9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUN
PY 2021
VL 81
AR 104464
DI 10.1016/j.jff.2021.104464
EA APR 2021
PG 11
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA SB1DL
UT WOS:000649742500005
OA gold
DA 2025 08 17
ER

PT J
AU Bodine, PVN
   Stauffer, B
   Ponce de Leon, H
   Bhat, RA
   Mangine, A
   Seestaller Wehr, LM
   Moran, RA
   Billiard, J
   Fukayama, S
   Komm, BS
   Pitts, K
   Krishnamurthy, G
   Gopalsamy, A
   Shi, MX
   Kern, JC
   Commons, TJ
   Woodworth, RP
   Wilson, MA
   Welmaker, GS
   Trybulski, EJ
   Moore, WJ
AF Bodine, Peter V. N.
   Stauffer, Barbara
   Ponce de Leon, Helga
   Bhat, Ramesh A.
   Mangine, Annamarie
   Seestaller Wehr, Laura M.
   Moran, Robert A.
   Billiard, Julia
   Fukayama, Shoichi
   Komm, Barry S.
   Pitts, Keith
   Krishnamurthy, Girija
   Gopalsamy, Ariamala
   Shi, Mengxiao
   Kern, Jeffrey C.
   Commons, Thomas J.
   Woodworth, Richard P.
   Wilson, Matthew A.
   Welmaker, Gregory S.
   Trybulski, Eugene J.
   Moore, William J.
TI A small molecule inhibitor of the Wnt antagonist secreted
   frizzled related protein 1 stimulates bone formation
SO BONE
LA English
DT Article
DE sFRP 1; Wnt; Bone; Inhibitors; Diarylsulfone sulfonamide
ID INCREASES MARKERS; SIGNALING PATHWAY; IN VITRO; REGULATOR; LITHIUM;
   GENE; MASS; OSTEOBLASTS; ACTIVATION; EXPRESSION
AB Canonical Wnt signaling has been demonstrated to increase bone formation, and Wnt pathway components are being pursued as potential drug targets for osteoporosis and other metabolic bone diseases, Deletion of the Writ antagonist secreted frizzled related protein (sFRP) 1 in mice activates canonical signaling in bone and increases trabecular bone formation in aged animals. We have developed small molecules that bind to and inhibit sFRP 1 in vitro and demonstrate robust anabolic activity in an ex vivo organ culture assay. A library of over 440,000 drug like compounds was screened for inhibitors of human sFRP 1 using a cell based functional assay that measured activation of canonical Wnt signaling with an optimized T cell factor (TCF)luciferase reporter gene assay. One of the hits in this screen, a diarylsulfone suifonamide, bound to sFRP 1 with a K D of 0.35 mu M in a tryptophan fluorescence quenching assay. This Compound also selectively inhibited sFRP 1 with an EC50 of 3.9 mu M in the cell based functional assay. Optimization of this high throughput screening hit for binding and functional potency as well as metabolic stability and other pharmaceutical properties led to improved lead compounds. One of these leads (WAY 316606) bound to sFRP 1 with a KD of 0.08 mu M and inhibited it with an EC50 of 0.65 mu M. Moreover, this compound increased total bone area in a murine calvarial organ culture assay at concentrations as low as 0.0001 mu M. This work demonstrates the feasibility of developing small molecules that inhibit sFRP 1 and stimulate canonical Wnt signaling to increase bone formation. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Bodine, Peter V. N.; Stauffer, Barbara; Ponce de Leon, Helga; Bhat, Ramesh A.; Mangine, Annamarie; Seestaller Wehr, Laura M.; Moran, Robert A.; Billiard, Julia; Komm, Barry S.] Wyeth Res, Womens Hlth & Musculoskeletal Biol, Collegeville, PA 19426 USA.
   [Fukayama, Shoichi] Wyeth Res, Womens Hlth & Musculoskeletal Biol, Cambridge, MA 02140 USA.
   [Pitts, Keith; Krishnamurthy, Girija; Gopalsamy, Ariamala; Shi, Mengxiao] Wyeth Res, Chem & Screening Sci, Pearl River, NY 10965 USA.
   [Kern, Jeffrey C.; Commons, Thomas J.; Woodworth, Richard P.; Wilson, Matthew A.; Welmaker, Gregory S.; Trybulski, Eugene J.; Moore, William J.] Wyeth Res, Chem & Screening Sci, Collegeville, PA 19426 USA.
C3 Pfizer; Pfizer USA; Wyeth; Pfizer; Wyeth; Pfizer USA; Pfizer; Pfizer
   USA; Wyeth; Pfizer; Pfizer USA; Wyeth
RP Bodine, PVN (通讯作者)，Wyeth Res, Womens Hlth & Musculoskeletal Biol, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM bodinep@wyeth.com
RI Moore, William/AAW 5165 2020
CR Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bhat RA, 2004, PROTEIN EXPRES PURIF, V37, P327, DOI 10.1016/j.pep.2004.06.029
   Bhat RA, 2007, J CELL BIOCHEM, V102, P1519, DOI 10.1002/jcb.21372
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gaur T, 2006, J CELL PHYSIOL, V208, P87, DOI 10.1002/jcp.20637
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Gopalsamy A, 2008, J MED CHEM, V51, P7670, DOI 10.1021/jm801069w
   Gregory CA, 2006, DRUG NEWS PERSPECT, V19, P445, DOI 10.1358/dnp.2006.19.8.1043960
   Grisanti M, 2006, J BONE MINER RES, V21, pS25
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165 6147(03)00206 2
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kiselyov AS, 2007, EXPERT OPIN THER TAR, V11, P1087, DOI 10.1517/14728222.11.8.1087
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Liu P, 2005, J BONE MINER RES, V20, pS17
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   Martin TJ, 2008, OSTEOPOROSIS INT, V19, P1125, DOI 10.1007/s00198 008 0575 5
   Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Moore WJ, 2009, J MED CHEM, V52, P105, DOI 10.1021/jm801144h
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Trevant B, 2008, J CELL PHYSIOL, V217, P113, DOI 10.1002/jcp.21482
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P1, DOI 10.1007/s00223 004 0258 y
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wilting I, 2007, BONE, V40, P1252, DOI 10.1016/j.bone.2006.12.055
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zhong XT, 2007, J BIOL CHEM, V282, P20523, DOI 10.1074/jbc.M609096200
NR 47
TC 105
Z9 134
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2009
VL 44
IS 6
BP 1063
EP 1068
DI 10.1016/j.bone.2009.02.013
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 449RM
UT WOS:000266347700006
PM 19254787
DA 2025 08 17
ER

PT J
AU Dong, J
   Xu, XQ
   Zhang, QY
   Yuan, ZN
   Tan, BY
AF Dong, Jun
   Xu, Xiqiang
   Zhang, Qingyu
   Yuan, Zenong
   Tan, Bingyi
TI Critical implication of the PTEN/PI3K/AKT pathway during BMP2 induced
   heterotopic ossification
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE PTEN; PI3K; AKT; heterotopic ossification; osteoblast differentiation
AB Heterotopic ossification (HO) is characterized by extraskeletal ossification in soft tissue. Thus far, there is a lack of effective drug therapy against HO. Loss of PTEN in osteoblasts has been reported to accumulate bone mass in skeletal development and promote fracture healing in association with the activation of the PI3K/AKT pathway. However, the role of the PTEN/PI3K/AKT signaling in HO pathogenesis remains unknown. The present study investigated the implication of this pathway during BMP2 induced osteogenic differentiation and ectopic bone formation. It was shown that overexpression of PTEN inhibited proliferation but stimulated apoptosis in mesenchymal pluripotent C3H10T1/2 cells. PTEN also inhibited BMP2 induced osteoblast differentiation, whereas BMP2 repressed PTEN expression and subsequently activated PI3K/AKT. The PI3K inhibitor, LY294002, blocked BMP2 induced osteoblastogenesis, suggesting that the PI3K/AKT pathway is critically required for BMP2 to initiate osteoblastogenesis. In vivo, implantation of BMP2 in muscle induced ectopic endochondral ossification. Strikingly, this bone forming capacity was notably suppressed by the PI3K inhibitor LY294002. Hence, the results of the present study demonstrated that the PI3K/AKT signaling activity is indispensable for BMP2 to induce ectopic new bone. Targeting the PI3K/AKT pathway using inhibitor(s) may represent a potential molecular therapy for the treatment against HO.
C1 [Dong, Jun; Xu, Xiqiang; Zhang, Qingyu; Yuan, Zenong; Tan, Bingyi] Shandong First Med Univ, Shandong Prov Hosp, Dept Orthopaed, 324 Five Weft Seven Rd, Jinan 250021, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences
RP Tan, BY (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Orthopaed, 324 Five Weft Seven Rd, Jinan 250021, Shandong, Peoples R China.
EM bingytan07@gmail.com
FU Shandong Provincial Medical Technology Development Project [2019WS459]
FX This study was supported by the Shandong Provincial Medical Technology
   Development Project to J.D. (grant no. 2019WS459).
CR Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Beck SE, 2007, CANCER BIOL THER, V6, P1313
   Biz C, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0317 2
   Burgers TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063857
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Ford Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Hashimoto K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61825 2
   Hoshi K, 1997, BONE, V21, P155, DOI 10.1016/S8756 3282(97)00106 3
   Iwasa K, 2014, J ORTHOP RES, V32, P231, DOI 10.1002/jor.22506
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Lee CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120051
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Legosz P, 2018, CLIN EXP PHARMACOL P, V45, P1229, DOI 10.1111/1440 1681.13025
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Papa A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040153
   Pulido R, 2018, MOLECULES, V23, DOI 10.3390/molecules23020285
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Shi LJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007413
   Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069
   Xiong Y, 2019, MOL THER NUCL ACIDS, V17, P223, DOI 10.1016/j.omtn.2019.06.001
   Yamada KM, 2001, J CELL SCI, V114, P2375
   Yan L, 2017, AGING DIS, V8, P570, DOI 10.14336/AD.2017.0201
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0954 x
   Zhao L, 2009, CALCIFIED TISSUE INT, V84, P56, DOI 10.1007/s00223 008 9189 3
NR 31
TC 14
Z9 16
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2021
VL 23
IS 4
AR 254
DI 10.3892/mmr.2021.11893
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA QK8KK
UT WOS:000620628600001
PM 33537834
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Siegenthaler, B
   Ghayor, C
   Gjoksi Cosandey, B
   Ruangsawasdi, N
   Weber, FE
AF Siegenthaler, Barbara
   Ghayor, Chafik
   Gjoksi Cosandey, Bebeka
   Ruangsawasdi, Nisarat
   Weber, Franz E.
TI The Bromodomain Inhibitor N Methyl pyrrolidone Prevents
   Osteoporosis and BMP Triggered Sclerostin Expression in Osteocytes
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteocyte; osteoporosis; sclerostin; bromodomain; N methyl pyrrolidone
ID POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; PARATHYROID HORMONE;
   BONE RESORPTION; IN VITRO; ESTROGEN; GENE; DIFFERENTIATION; CELLS;
   MECHANISMS
AB (1) Background: In an adult skeleton, bone is constantly renewed in a cycle of bone resorption, followed by bone formation. This coupling process, called bone remodeling, adjusts the quality and quantity of bone to the local needs. It is generally accepted that osteoporosis develops when bone resorption surpasses bone formation. Osteoclasts and osteoblasts, bone resorbing and bone forming cells respectively, are the major target in osteoporosis treatment. Inside bone and forming a complex network, the third and most abundant cells, the osteocytes, have long remained a mystery. Osteocytes are responsible for mechano sensation and  transduction. Increased expression of the osteocyte derived bone inhibitor sclerostin has been linked to estrogen deficiency induced osteoporosis and is therefore a promising target for osteoporosis management. (2) Methods: Recently we showed in vitro and in vivo that NMP (N Methyl 2 pyrrolidone) is a bioactive drug enhancing the BMP 2 (Bone Morphogenetic Protein 2) induced effect on bone formation while blocking bone resorption. Here we tested the effect of NMP on the expression of osteocyte derived sclerostin. (3) Results: We found that NMP significantly decreased sclerostin mRNA and protein levels. In an animal model of osteoporosis, NMP prevented the estrogen deficiency induced increased expression of sclerostin. (4) Conclusions: These results support the potential of NMP as a novel therapeutic compound for osteoporosis management, since it preserves bone by a direct interference with osteoblasts and osteoclasts and an indirect one via a decrease in sclerostin expression by osteocytes.
C1 [Siegenthaler, Barbara; Ghayor, Chafik; Gjoksi Cosandey, Bebeka; Weber, Franz E.] Univ Zurich, Ctr Dent Med Oral Biotechnol & Bioengn, Plattenstr 11, CH 8032 Zurich, Switzerland.
   [Ruangsawasdi, Nisarat] Mahidol Univ, Dept Pharmacol, Fac Dent, Bangkok 10400, Thailand.
C3 University of Zurich; Mahidol University
RP Weber, FE (通讯作者)，Univ Zurich, Ctr Dent Med Oral Biotechnol & Bioengn, Plattenstr 11, CH 8032 Zurich, Switzerland.
EM barbara.m.siegenthaler@gmail.com; chafik.ghayor@usz.ch;
   bebeka.cosandey@gmail.com; nisarat_mac@hotmail.com;
   franz.weber@zzm.uzh.ch
RI ; Ruangsawasdi, Nisarat/AAA 4621 2022; Weber, Franz/I 7831 2019
OI , Nisarat/0000 0002 4710 8022; Ghayor, Chafik/0000 0002 3016 3412;
   Weber, Franz/0000 0003 1670 2296; 
FU Swiss National Science Foundation [31003A_140868]; Swiss National
   Science Foundation (SNF) [31003A_140868] Funding Source: Swiss National
   Science Foundation (SNF)
FX This research work was supported by grants from the Swiss National
   Science Foundation (31003A_140868) to FEW.
CR Almeida MM, 2016, TISSUE CELL, V48, P183, DOI 10.1016/j.tice.2016.03.009
   Baertschi S, 2014, J BIOL CHEM, V289, P24995, DOI 10.1074/jbc.M114.564997
   Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078 0432.CCR 13 2281
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Boschert V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160120
   Costa AG, 2014, EXPERT OPIN BIOL TH, V14, P697, DOI 10.1517/14712598.2014.895808
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dede AD, 2017, EXPERT OPIN INV DRUG, V26, P1137, DOI 10.1080/13543784.2017.1371136
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Devaiah BN, 2016, J LEUKOCYTE BIOL, V100, P679, DOI 10.1189/jlb.2RI0616 250R
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   FLANAGAN B, 1969, J CLIN INVEST, V48, P607, DOI 10.1172/JCI106019
   Foundation I. O, WHAT IS OST
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Galea GL, 2017, BONE, V96, P38, DOI 10.1016/j.bone.2016.10.008
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Gjoksi B, 2015, BONE, V78, P114, DOI 10.1016/j.bone.2015.05.004
   Gong FD, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006272
   Grimston SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044222
   Hannon R, 1998, J BONE MINER RES, V13, P1124, DOI 10.1359/jbmr.1998.13.7.1124
   Heino TJ, 2002, J CELL BIOCHEM, V85, P185, DOI 10.1002/jcb.10109
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960 9822(06)00296 X
   Kim RY, 2015, TISSUE ENG PT A, V21, P2076, DOI [10.1089/ten.tea.2014.0585, 10.1089/ten.TEA.2014.0585]
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Kress BC, 1999, DRUG TODAY, V35, P181, DOI 10.1358/dot.1999.35.3.533847
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mc Garrigle MJ, 2016, EUR CELLS MATER, V31, P323, DOI 10.22203/eCM.v031a21
   Miguel BS, 2009, TISSUE ENG PT A, V15, P2955, DOI [10.1089/ten.tea.2009.0009, 10.1089/ten.TEA.2009.0009]
   Mirguet O, 2014, CHEMMEDCHEM, V9, P580, DOI 10.1002/cmdc.201300259
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Morse A, 2014, J BONE MINER RES, V29, P2456, DOI 10.1002/jbmr.2278
   Pajevic P.D., 2009, International Bone Mineral Society, V6, P63, DOI DOI 10.1138/20090363
   Palazzini S, 1998, ANAT EMBRYOL, V197, P349, DOI 10.1007/s004290050145
   Philpott M, 2011, MOL BIOSYST, V7, P2899, DOI 10.1039/c1mb05099k
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Reginster JY, 2015, OSTEOPOROSIS INT, V26, P1667, DOI 10.1007/s00198 015 3109 y
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Saenz DT, 2017, LEUKEMIA, V31, P678, DOI 10.1038/leu.2016.260
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   Shortt J, 2014, CELL REP, V7, P1009, DOI 10.1016/j.celrep.2014.04.008
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357 2725(03)00241 3
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Wang LM, 2016, ONCOL REP, V36, P1989, DOI 10.3892/or.2016.5037
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Weivoda MM, 2014, CURR OSTEOPOROS REP, V12, P107, DOI 10.1007/s11914 014 0188 1
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 60
TC 10
Z9 10
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3332
DI 10.3390/ijms19113332
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500048
PM 30366476
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, RR
   Ou, JJ
   Li, L
   Yang, Y
   Zhao, JP
   Wu, RR
AF Li, Ranran
   Ou, Jianjun
   Li, Li
   Yang, Ye
   Zhao, Jingping
   Wu, Renrong
TI The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine Induced
   Weight Gain and Insulin Resistance
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE olanzapine; Wnt signaling pathway; atypical antipsychotics; TCF7L2;
   weight gain; insulin resistance
ID DRUG NAIVE PATIENTS; VISCERAL FAT DISTRIBUTION; MIDDLE AGED MEN;
   ATYPICAL ANTIPSYCHOTICS; METABOLIC SYNDROME; CARDIOVASCULAR DISEASE;
   GLUCOSE INTOLERANCE; OXIDATIVE STRESS; TREATED PATIENTS; BODY WEIGHT
AB Olanzapine is a widely used atypical antipsychotic medication for treatment of schizophrenia and is often associated with serious metabolic abnormalities including weight gain and impaired glucose tolerance. These metabolic side effects are severe clinical problems but the underpinning mechanism remains poorly understood. Recently, growing evidence suggests that Wnt signaling pathway has a critical role in the pathogenesis of schizophrenia and molecular cascades of antipsychotics action, of which Wnt signaling pathway key effector TCF7L2 is strongly associated with glucose homeostasis. In this study, we aim to explore the characteristics of metabolic disturbance induced by olanzapine and to elucidate the role of TCF7L2 in this process. C57BL/6 mice were subject to olanzapine (4 mg/kg/day), or olanzapine plus metformin (150 mg/kg/day), or saline, respectively, for 8 weeks. Metabolic indices and TCF7L2 expression levels in liver, skeletal muscle, adipose, and pancreatic tissues were closely monitored. Olanzapine challenge induced remarkably increased body weight, fasting insulin, homeostasis model assessment insulin resistance index, and TCF7L2 protein expression in liver, skeletal muscle, and adipose tissues. Notably, these effects could be effectively ameliorated by metformin. In addition, we found that olanzapine induced body weight gain and insulin resistance actively influence the expression of TCF7L2 in liver and skeletal muscle, and elevated level of insulin determines the increased expression of TCF7L2 in adipose tissue. Our results demonstrate that TCF7L2 participates in olanzapine induced metabolic disturbance, which presents a novel mechanism for olanzapine induced metabolic disturbance and a potential therapeutic target to prevent the associated metabolic side effects.
C1 [Li, Ranran; Ou, Jianjun; Li, Li; Yang, Ye; Zhao, Jingping; Wu, Renrong] Cent S Univ, Xiangya Hosp 2, Dept Psychiat, Changsha, Hunan, Peoples R China.
   [Wu, Renrong] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
C3 Central South University; Chinese Academy of Sciences
RP Wu, RR (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Psychiat, Changsha, Hunan, Peoples R China.; Wu, RR (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
EM wurenrong@csu.edu.cn
FU National Key Research and Development Program of China [2016YFC1306900];
   National Natural Science Foundation of China [81371481, 81622018]
FX The research was supported by grant 2016YFC1306900 from the National Key
   Research and Development Program of China and the National Natural
   Science Foundation of China (Grant Nos. 81371481 and 81622018).
CR Albaugh VL, 2006, OBESITY, V14, P36, DOI 10.1038/oby.2006.6
   Albaugh VL, 2012, SCHIZOPHRENIA BULL, V38, P153, DOI 10.1093/schbul/sbq053
   Alimohamad H, 2005, J NEUROCHEM, V95, P513, DOI 10.1111/j.1471 4159.2005.03388.x
   Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036
   Alkelai A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029228
   Alvarez Jiménez M, 2008, CNS DRUGS, V22, P547, DOI 10.2165/00023210 200822070 00002
   Ando K, 2009, FREE RADICAL BIO MED, V47, P213, DOI 10.1016/j.freeradbiomed.2009.04.030
   Andreazza AC, 2015, NEUROSCI LETT, V591, P36, DOI 10.1016/j.neulet.2015.02.028
   Baig MR, 2010, J PSYCHIATR PRACT, V16, P325, DOI 10.1097/01.pra.0000388627.36781.6a
   Bailey KA, 2015, HUM MOL GENET, V24, P1646, DOI 10.1093/hmg/ddu577
   Boj SF, 2012, CELL, V151, P1595, DOI 10.1016/j.cell.2012.10.053
   Boyda HN, 2014, PROG NEURO PSYCHOPH, V48, P170, DOI 10.1016/j.pnpbp.2013.10.006
   Chadda RK, 2013, J PHARMACOL PHARMACO, V4, P176, DOI 10.4103/0976 500X.114596
   Chen CH, 2013, J CLIN PSYCHIAT, V74, pE424, DOI 10.4088/JCP.12m08186
   Chen ZL, 2015, CELL SIGNAL, V27, P587, DOI 10.1016/j.cellsig.2014.12.012
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coccurello R, 2009, J CLIN PSYCHOPHARM, V29, P576, DOI 10.1097/JCP.0b013e3181bfe13e
   Cooper GD, 2007, J PSYCHOPHARMACOL, V21, P405, DOI 10.1177/0269881106069637
   De Hert M, 2011, EUR PSYCHIAT, V26, P144, DOI 10.1016/j.eurpsy.2010.09.011
   Dietrich Muszalska A, 2013, NEUROCHEM RES, V38, P1490, DOI 10.1007/s11064 013 1050 z
   Dora Jose Miguel, 2008, Diabetes Care, V31, pe45, DOI 10.2337/dc08 0109
   Flatow J, 2013, BIOL PSYCHIAT, V74, P400, DOI 10.1016/j.biopsych.2013.03.018
   Freyberg Z, 2010, AM J PSYCHIAT, V167, P388, DOI 10.1176/appi.ajp.2009.08121873
   Gilca M, 2014, PSYCHOPHARMACOLOGY, V231, P4703, DOI 10.1007/s00213 014 3624 0
   Girault EM, 2014, N S ARCH PHARMACOL, V387, P185, DOI 10.1007/s00210 013 0933 5
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Grant SFA, 2012, DIABETES, V61, P2657, DOI 10.2337/db12 0891
   Hansen T, 2011, BIOL PSYCHIAT, V70, P59, DOI 10.1016/j.biopsych.2011.01.031
   Hennekens CH, 2005, AM HEART J, V150, P1115, DOI 10.1016/j.ahj.2005.02.007
   Horska K, 2016, PSYCHONEUROENDOCRINO, V73, P177, DOI 10.1016/j.psyneuen.2016.07.218
   Ip W, 2015, DIABETES, V64, P1923, DOI 10.2337/db14 1329
   Irvin MR, 2009, SCHIZOPHR RES, V114, P50, DOI 10.1016/j.schres.2009.07.008
   Jarskog LF, 2013, AM J PSYCHIAT, V170, P1032, DOI 10.1176/appi.ajp.2013.12010127
   Jin T, 2008, MOL ENDOCRINOL, V22, P2383, DOI 10.1210/me.2008 0135
   Kaminska D, 2012, DIABETES, V61, P2807, DOI 10.2337/db12 0239
   Karczewska Kupczewska M, 2016, J CLIN ENDOCR METAB, V101, P3079, DOI 10.1210/jc.2016 1594
   Kaushal J, 2012, SINGAP MED J, V53, P488
   Kim H, 2014, PSYCHOPHARMACOLOGY, V231, P4059, DOI 10.1007/s00213 014 3540 3
   Kirpichnikov D, 2002, ANN INTERN MED, V137, P25, DOI 10.7326/0003 4819 137 1 200207020 00009
   Komossa K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006654.pub2
   Koro CE, 2002, ARCH GEN PSYCHIAT, V59, P1021, DOI 10.1001/archpsyc.59.11.1021
   Koros E, 2007, DRUG NEWS PERSPECT, V20, P437, DOI 10.1358/dnp.2007.20.7.1149632
   Kroeze WK, 2003, NEUROPSYCHOPHARMACOL, V28, P519, DOI 10.1038/sj.npp.1300027
   Lakka HM, 2002, JAMA J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709
   Le Bacquer O, 2011, HUM MOL GENET, V20, P1906, DOI 10.1093/hmg/ddr072
   Li QZ, 2016, J CLIN PSYCHOPHARM, V36, P643, DOI 10.1097/JCP.0000000000000594
   Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JCI30706
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malhotra Nidhi, 2013, Indian J Psychol Med, V35, P227, DOI 10.4103/0253 7176.119471
   Martins MR, 2008, NEUROTOX RES, V13, P63, DOI 10.1007/BF03033368
   Mather K, 2009, AM J PHYSIOL ENDOC M, V296, pE398, DOI 10.1152/ajpendo.90889.2008
   Mathieu P, 2009, HYPERTENSION, V53, P577, DOI 10.1161/HYPERTENSIONAHA.108.110320
   Matsui Y, 2010, BIOL PHARM BULL, V33, P963, DOI 10.1248/bpb.33.963
   Mitchell AJ, 2013, SCHIZOPHRENIA BULL, V39, P306, DOI 10.1093/schbul/sbr148
   Mitchell AJ, 2013, SCHIZOPHRENIA BULL, V39, P295, DOI 10.1093/schbul/sbs082
   Newcomer JW, 2007, J CLIN PSYCHIAT, V68, P8
   NRCU Research, 1996, GUIDE FOR THE CARE A
   Parikh V, 2003, J PSYCHIATR RES, V37, P43, DOI 10.1016/S0022 3956(02)00048 1
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Pérez Iglesias R, 2014, INT J NEUROPSYCHOPH, V17, P41, DOI 10.1017/S1461145713001053
   Praharaj SK, 2011, BRIT J CLIN PHARMACO, V71, P377, DOI 10.1111/j.1365 2125.2010.03783.x
   Pramyothin P, 2010, CURR OPIN ENDOCRINOL, V17, P460, DOI 10.1097/MED.0b013e32833de61c
   Raedler TJ, 2010, CURR OPIN PSYCHIATR, V23, P574, DOI 10.1097/YCO.0b013e32833f46c9
   Rethelyi Janos, 2011, Orvosi Hetilap, V152, P505, DOI 10.1556/OH.2011.29079
   Rheaume C, 2009, CIRCULATION, V119, pE275
   Ryan MCM, 2004, LIFE SCI, V74, P1999, DOI 10.1016/j.lfs.2003.08.044
   Ryan MCM, 2003, AM J PSYCHIAT, V160, P284, DOI 10.1176/appi.ajp.160.2.284
   Savic D, 2011, GENOME RES, V21, P1417, DOI 10.1101/gr.123745.111
   Savoy YE, 2010, SCHIZOPHRENIA BULL, V36, P410, DOI 10.1093/schbul/sbn104
   Schiavone S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00787
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schreiner A, 2012, J CLIN PSYCHOPHARM, V32, P449, DOI 10.1097/JCP.0b013e31825cccad
   Shao Ping, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P365, DOI 10.3969/j.issn.1672 7347.2013.04.005
   Shao WJ, 2013, DIABETES, V62, P789, DOI 10.2337/db12 0365
   Singh KK, 2013, CLIN GENET, V83, P511, DOI 10.1111/cge.12111
   Singh R, 2013, CELL METAB, V17, P197, DOI 10.1016/j.cmet.2013.01.009
   Skrede S, 2012, INT J NEUROPSYCHOPH, V15, P163, DOI 10.1017/S1461145711001271
   Spelman LM, 2007, DIABETIC MED, V24, P481, DOI 10.1111/j.1464 5491.2007.02092.x
   Struewing I, 2010, BIOCHEM BIOPH RES CO, V399, P245, DOI 10.1016/j.bbrc.2010.07.062
   Sutton LP, 2011, NEUROSCIENCE, V199, P116, DOI 10.1016/j.neuroscience.2011.09.056
   Sutton LP, 2007, J NEUROCHEM, V102, P153, DOI 10.1111/j.1471 4159.2007.04527.x
   Teff KL, 2013, DIABETES, V62, P3232, DOI 10.2337/db13 0430
   Tek C, 2016, EARLY INTERV PSYCHIA, V10, P193, DOI 10.1111/eip.12251
   Thakore JH, 2002, INT J OBESITY, V26, P137, DOI 10.1038/sj.ijo.0801840
   Wang M, 2012, SCHIZOPHR RES, V138, P54, DOI 10.1016/j.schres.2012.02.021
   Wu RR, 2007, J CLIN PSYCHOPHARM, V27, P374, DOI 10.1097/JCP.0b013e3180cac8db
   Xu MQ, 2007, J CLIN PSYCHIAT, V68, P1358, DOI 10.4088/JCP.v68n0906
   Yang H, 2012, INT J BIOL SCI, V8, P791, DOI 10.7150/ijbs.4568
   Zugno AI, 2012, REV BRAS PSIQUIATR, V34, P168, DOI 10.1590/S1516 44462012000200009
NR 89
TC 21
Z9 25
U1 0
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 16
PY 2018
VL 9
AR 379
DI 10.3389/fphar.2018.00379
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA GC9DW
UT WOS:000430098700001
PM 29713286
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Florio, F
   Vencato, S
   Papa, FT
   Libergoli, M
   Kheir, E
   Ghzaiel, I
   Rando, TA
   Torrente, Y
   Biressi, S
AF Florio, Francesca
   Vencato, Sara
   Papa, Filomena T.
   Libergoli, Michela
   Kheir, Eyemen
   Ghzaiel, Imen
   Rando, Thomas A.
   Torrente, Yvan
   Biressi, Stefano
TI Combinatorial activation of the WNT dependent fibrogenic program by
   distinct complement subunits in dystrophic muscle
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE complement C1 complex; Duchenne muscular dystrophy; fibro adipogenic
   progenitors; fibrosis; skeletal muscle regeneration
ID DUCHENNE MUSCULAR DYSTROPHY; MEMBRANE ATTACK COMPLEX; SKELETAL MUSCLE;
   FIBRO/ADIPOGENIC PROGENITORS; SIGNALING PATHWAY; BASIC MECHANISMS;
   SATELLITE CELLS; PDGFR ALPHA; STEM CELLS; FIBROSIS
AB Fibrosis is associated with compromised muscle functionality in Duchenne muscular dystrophy (DMD). We report observations with tissues from dystrophic patients and mice supporting a model to explain fibrosis in DMD, which relies on the crosstalk between the complement and the WNT signaling pathways and the functional interactions of two cellular types. Fibro adipogenic progenitors and macrophages, which populate the inflamed dystrophic muscles, act as a combinatorial source of WNT activity by secreting distinct subunits of the C1 complement complex. The resulting aberrant activation of the WNT signaling in responsive cells, such as fibro adipogenic progenitors, contributes to fibrosis. Indeed, pharmacological inhibition of the C1r/s subunits in a murine model of DMD mitigated the activation of the WNT signaling pathway, reduced the fibrogenic characteristics of the fibro adipogenic progenitors, and ameliorated the dystrophic phenotype. These studies shed new light on the molecular and cellular mechanisms responsible for fibrosis in muscular dystrophy and open to new therapeutic strategies.
C1 [Florio, Francesca; Vencato, Sara; Papa, Filomena T.; Libergoli, Michela; Kheir, Eyemen; Ghzaiel, Imen; Biressi, Stefano] Univ Trento, Dept Cellular Computat & Integrat Biol CIBIO, Trento, Italy.
   [Florio, Francesca; Vencato, Sara; Papa, Filomena T.; Libergoli, Michela; Kheir, Eyemen; Ghzaiel, Imen; Biressi, Stefano] Univ Trento, Dulbecco Telethon Inst, Trento, Italy.
   [Florio, Francesca; Torrente, Yvan] Fdn IRCCS CaGranda Osped Maggiore Policlin, Neurol Unit, Milan, Italy.
   [Rando, Thomas A.] Univ Calif Los Angeles, Broad Stem Cell Res Ctr, Los Angeles, CA USA.
   [Torrente, Yvan] Univ Milan, Stem Cell Lab, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.
C3 University of Trento; Fondazione Telethon; Dulbecco Telethon Institute
   (DTI); University of Trento; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; University of California System; University of California
   Los Angeles; University of Milan
RP Biressi, S (通讯作者)，Univ Trento, Dept Cellular Computat & Integrat Biol CIBIO, Trento, Italy.; Biressi, S (通讯作者)，Univ Trento, Dulbecco Telethon Inst, Trento, Italy.
EM stefano.biressi@unitn.it
RI TORRENTE, YVAN/A 2964 2015; Torrente, Yvan/A 2964 2015; Biressi,
   Stefano/AAD 8956 2020
OI TORRENTE, YVAN/0000 0002 2705 3984; Papa, Filomena
   Tiziana/0000 0001 7821 8198; Biressi, Stefano Augusto
   Maria/0000 0001 8631 3419; Florio, Francesca/0000 0001 8183 5226;
   Libergoli, Michela/0000 0003 4329 3221; Kheir,
   Eyemen/0000 0001 5646 8751; Rando, Thomas/0000 0001 5843 8564
FU Telethon Italy [GTB12001]; EuroBioBank network; European Regional
   Development Fund (ERDF); Muscular Dystrophy Association United States
   [874294]; Association Francaise contre les Myopathies (AFM) France
   [23758]; Fondazione Telethon; Provincia autonoma di Trento Italy
   [TCP13007]; POR FESR Regione Lombardia 16 (FORCE 4 CURE) [2526393];
   Ministero della Salute [RF 2016 02362263]; GFB ONLUS [PR 0394]; National
   Institute on Aging [R01AG071783] Funding Source: NIH RePORTER
FX We thank Bert Blaauw, Ted Yednock, Rick Artis, and Luciano Conti for
   their helpful discussions. We acknowledge CSL Behring for kindly
   providing us with the C1r/s inhibitor Berinert. We thank Alessandro
   Alaimo, Silvia Accordini, Vaibhav Gharat, and Sofia Gaspari for their
   technical help and suggestions. We are grateful to Maurizio Moggio,
   director of the Biobank at IRCCS Fondazione Ca ' Granda Ospedale
   Maggiore Policlinico, for providing us with human specimens. The Biobank
   of skeletal muscle, peripheral nerve, DNA, and cell lines is a member of
   the Telethon Network of Genetic Biobanks (project No. GTB12001), funded
   by Telethon Italy, and of the EuroBioBank network. CIBIO Core Facilities
   are supported by the European Regional Development Fund (ERDF)
   2014 2020. Work in the authors' laboratory is supported by the Muscular
   Dystrophy Association United States (innovation grant No. 874294 to SB),
   Association Francaise contre les Myopathies (AFM) France (grant No.
   23758 to SB), Fondazione Telethon and Provincia autonoma di Trento Italy
   (grant No. TCP13007 to SB), POR FESR Regione Lombardia 16 (FORCE 4 CURE,
   grant No. 2526393 to YT), Ministero della Salute (grant No.
   RF 2016 02362263 to YT), and GFB ONLUS (grant No. PR 0394 to YT).
CR Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734
   Babaeijandaghi F, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abg7504
   Biressi S, 2020, J CLIN INVEST, V130, P5652, DOI 10.1172/JCI142031
   Biressi S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008411
   Biressi S, 2013, DEV BIOL, V379, P195, DOI 10.1016/j.ydbio.2013.04.021
   Birnkrant DJ, 2018, LANCET NEUROL, V17, P251, DOI 10.1016/S1474 4422(18)30024 3
   Blyszczuk P, 2017, EUR HEART J, V38, P1413, DOI 10.1093/eurheartj/ehw116
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054
   Carthy JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019809
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Ciciliot S, 2010, CURR PHARM DESIGN, V16, P906, DOI 10.2174/138161210790883453
   Cisternas P, 2014, CURR MOL MED, V14, P510, DOI 10.2174/1566524014666140414210346
   Contreras O, 2016, CELL TISSUE RES, V364, P647, DOI 10.1007/s00441 015 2343 0
   de Morrée A, 2017, P NATL ACAD SCI USA, V114, pE8996, DOI 10.1073/pnas.1708725114
   Desguerre I, 2012, MUSCLE NERVE, V45, P803, DOI 10.1002/mus.23341
   Desguerre I, 2009, J NEUROPATH EXP NEUR, V68, P762, DOI 10.1097/NEN.0b013e3181aa31c2
   Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848
   Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140 6736(02)07815 7
   ENGEL AG, 1982, ANN NEUROL, V12, P289, DOI 10.1002/ana.410120314
   Epelman S, 2015, NAT REV IMMUNOL, V15, P117, DOI 10.1038/nri3800
   Farup J, 2021, CELL METAB, V33, P2201, DOI 10.1016/j.cmet.2021.10.001
   Feussner A, 2014, TRANSFUSION, V54, P2566, DOI 10.1111/trf.12678
   Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446
   Florio F, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.834705
   FOIDART M, 1981, ARCH NEUROL CHICAGO, V38, P152, DOI 10.1001/archneur.1981.00510030046006
   George RM, 2013, P NATL ACAD SCI USA, V110, P18549, DOI 10.1073/pnas.1311628110
   Girardi F, 2018, PROG MOL BIOL TRANSL, V153, P157, DOI 10.1016/bs.pmbts.2017.11.026
   GULATI P, 1994, RHEUMATOL INT, V14, P13, DOI 10.1007/BF00302666
   Heredia JE, 2013, CELL, V153, P376, DOI 10.1016/j.cell.2013.02.053
   Ieronimakis N, 2016, J PATHOL, V240, P410, DOI 10.1002/path.4801
   Jäger U, 2019, BLOOD, V133, P893, DOI 10.1182/blood 2018 06 856930
   Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015
   Jones RC, 2022, SCIENCE, V376, P711, DOI 10.1126/science.abl4896
   Judson RN, 2017, METHODS MOL BIOL, V1668, P93, DOI 10.1007/978 1 4939 7283 8_7
   KUSUMOTO H, 1988, P NATL ACAD SCI USA, V85, P7307, DOI 10.1073/pnas.85.19.7307
   Lemos DR, 2015, NAT MED, V21, P786, DOI 10.1038/nm.3869
   Liu FC, 2016, J CLIN NEUROL, V12, P351
   Liu L, 2015, NAT PROTOC, V10, P1612, DOI 10.1038/nprot.2015.110
   Liu XG, 2017, CELL BIOL INT, V41, P228, DOI 10.1002/cbin.10705
   McDonald CM, 2018, LANCET, V391, P451, DOI 10.1016/S0140 6736(17)32160 8
   McGreevy JW, 2015, DIS MODEL MECH, V8, P195, DOI 10.1242/dmm.018424
   Mercuri E, 2019, LANCET, V394, P2025, DOI 10.1016/S0140 6736(19)32910 1
   Molina T, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.210110
   Mozzetta C, 2013, EMBO MOL MED, V5, P626, DOI 10.1002/emmm.201202096
   Mueller AA, 2016, NATURE, V540, P276, DOI 10.1038/nature20160
   NAGAO N, 1987, BIOCHEM MED METAB B, V37, P385, DOI 10.1016/0885 4505(87)90052 1
   Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047
   O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220
   Pessina P, 2015, STEM CELL REP, V4, P1046, DOI 10.1016/j.stemcr.2015.04.007
   Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263
   Purcu DU, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0265196
   RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275
   Reis ES, 2015, CLIN IMMUNOL, V161, P225, DOI 10.1016/j.clim.2015.08.009
   Scharner J, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044 5040 1 28
   Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586 018 0590 4
   SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481
   Seo HH, 2019, CELL DEATH DIFFER, V26, P1107, DOI 10.1038/s41418 018 0187 3
   Serrano AL, 2010, EXP CELL RES, V316, P3050, DOI 10.1016/j.yexcr.2010.05.035
   SEWRY CA, 1987, J NEUROL SCI, V81, P141, DOI 10.1016/0022 510X(87)90091 8
   Shen W, 2008, J CELL PHYSIOL, V214, P405, DOI 10.1002/jcp.21212
   Sousa Victor P, 2022, NAT REV MOL CELL BIO, V23, P204, DOI 10.1038/s41580 021 00421 2
   Spuler S, 1998, NEUROLOGY, V50, P41, DOI 10.1212/WNL.50.1.41
   Sumida T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7241
   Tao H, 2016, METABOLISM, V65, P30, DOI 10.1016/j.metabol.2015.10.013
   Tidball JG, 2010, AM J PHYSIOL REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009
   Trensz F, 2010, AM J PHYSIOL CELL PH, V299, pC939, DOI 10.1152/ajpcell.00253.2010
   Tripodi L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9101447
   Uezumi A, 2011, J CELL SCI, V124, P3654, DOI 10.1242/jcs.086629
   Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014
   Villalta SA, 2009, HUM MOL GENET, V18, P482, DOI 10.1093/hmg/ddn376
   Wang XY, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.952249
   Wang XY, 2020, P NATL ACAD SCI USA, V117, P20729, DOI 10.1073/pnas.1915950117
   Wang XY, 2016, J IMMUNOL, V197, P4750, DOI 10.4049/jimmunol.1601308
   Wosczyna MN, 2019, CELL REP, V27, P2029, DOI 10.1016/j.celrep.2019.04.074
   Wosczyna MN, 2018, DEV CELL, V46, P135, DOI 10.1016/j.devcel.2018.06.018
NR 76
TC 3
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1757 4676
EI 1757 4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD DEC 7
PY 2023
VL 15
IS 12
DI 10.15252/emmm.202317405
EA NOV 2023
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AY1C5
UT WOS:001099834000001
PM 37927228
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Perrotta, I
   Cristofaro, MG
   Amantea, M
   Russo, E
   De Fazio, S
   Zuccalà, V
   Conforti, F
   Amorosi, A
   Donato, G
   Tripepi, S
   Giudice, M
AF Perrotta, I.
   Cristofaro, M. G.
   Amantea, M.
   Russo, E.
   De Fazio, S.
   Zuccala, V.
   Conforti, F.
   Amorosi, A.
   Donato, G.
   Tripepi, S.
   Giudice, M.
TI Jaw Osteonecrosis in Patients Treated with Bisphosphonates: An
   Ultrastructural Study
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE bisphosphonates; jaw osteonecrosis; bone metastases
ID OSTEOCLASTS IN VITRO; ZOLEDRONIC ACID; INDUCE APOPTOSIS; BONE
   METASTASES; BREAST CANCER; AVASCULAR NECROSIS; MEVALONATE PATHWAY;
   CELLS; MECHANISMS; RESORPTION
AB Osteonecrosis of the jaw is a severe bone disorder traditionally associated with periodontal disease, local malignancy, chemotherapy, glucocorticoid therapy, or trauma. Recently a growing number of publications reported the occurrence of osteonecrosis of the jaw in patients undergoing treatment with bisphosphonates. The mechanism by which bisphosphonates might contribute to the development of osteonecrosis of the jaw is far from being fully elucidated. Suppression of bone turnover, infection, tissue hypoxia and cellular toxicity were proposed as possible mechanisms by which bisphosphonates may exert adverse effects on bone metabolism. Here, we studied 25 consecutive patients treated with bisphosphonates for osteoporosis or tumoral pathologies. We provide good evidence of hyperactive osteoclastic bone resorption and suggest a direct cytotoxic effect of bisphosphonates on bone tissue through induction of osteocyte cell death. We also demonstrate that bisphosphonates only have limited adverse effects on bone vascular network.
C1 [Perrotta, I.; Tripepi, S.] Univ Calabria, Dept Ecol, I 87036 Cosenza, Italy.
   [Cristofaro, M. G.; Amantea, M.] Magna Graecia Univ Catanzaro, Dept Oral & Maxillofacial Surg, Catanzaro, Italy.
   [Russo, E.; De Fazio, S.] Univ Catanzaro, Sch Med, Dept Expt & Clin Med, Catanzaro, Italy.
   [Zuccala, V.; Conforti, F.; Amorosi, A.; Donato, G.] Fdn Ric & Cura Tumori Tommaso Campanella, Catanzaro, Italy.
   [Zuccala, V.; Conforti, F.; Amorosi, A.; Donato, G.] Magna Graecia Univ Catanzaro, Sch Med, Dept Pathol, Catanzaro, Italy.
C3 University of Calabria; Magna Graecia University of Catanzaro; Magna
   Graecia University of Catanzaro; Magna Graecia University of Catanzaro
RP Perrotta, I (通讯作者)，Univ Calabria, Dept Ecol, I 87036 Cosenza, Italy.
EM idaperrotta@yahoo.it
RI ; Conforti, Francesco/HTO 0053 2023; GIUDICE, Mario/AAH 9363 2020;
   DONATO, GIUSEPPE/E 1080 2016; Russo, Emilio/G 5241 2010; Tripepi,
   Sandro/C 7651 2016; Cristofaro, Maria/AAP 3759 2020
OI GIUDICE, Mario/0000 0001 9374 0566; Perrotta, Ida/0000 0002 9061 9776;
   Conforti, Francesco/0009 0001 1835 6078; DONATO,
   GIUSEPPE/0000 0002 3065 5492; Russo, Emilio/0000 0002 1279 8123;
   CRISTOFARO, Maria Giulia/0000 0002 6365 8518; Tripepi,
   Sandro/0000 0002 4158 911X; 
CR Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Baldi D, 2009, MUTAT RES FUND MOL M, V667, P118, DOI 10.1016/j.mrfmmm.2008.11.005
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022
   Favus MJ, 2007, J CLIN ENDOCR METAB, V92, P817, DOI 10.1210/jc.2007 0098
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fournier P, 2002, CANCER RES, V62, P6538
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Gebara SN, 2009, AM J HEALTH SYST PH, V66, P1541, DOI 10.2146/ajhp080251
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ibrahim T, 2008, ONCOLOGIST, V13, P330, DOI 10.1634/theoncologist.2007 0159
   Igarashi K, 1996, J DENT RES, V75, P1644, DOI 10.1177/00220345960750090501
   Iizuka T, 2008, BONE, V42, pS54, DOI 10.1016/j.bone.2007.12.093
   Lenz JH, 2005, J CRANIO MAXILL SURG, V33, P395, DOI 10.1016/j.jcms.2005.07.007
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mehsen N, 2009, JOINT BONE SPINE, V76, P166, DOI 10.1016/j.jbspin.2008.04.019
   Nastro E, 2007, ACTA HAEMATOL BASEL, V117, P181, DOI 10.1159/000097876
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SILVERMAN SL, 2008, AM J MED, V122, pS33
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Tas F, 2008, MED ONCOL, V25, P346, DOI 10.1007/s12032 008 9043 5
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yamada J, 2009, J SURG RES, V151, P115, DOI 10.1016/j.jss.2008.01.031
NR 33
TC 12
Z9 14
U1 0
U2 2
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0191 3123
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD AUG
PY 2010
VL 34
IS 4
BP 207
EP 213
DI 10.3109/01913121003729806
PG 7
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microscopy; Pathology
GA 660LK
UT WOS:000282644000004
PM 20594040
DA 2025 08 17
ER

PT J
AU Kootala, S
   Ossipov, D
   van den Beucken, JJJP
   Leeuwenburgh, S
   Hilborn, J
AF Kootala, Sujit
   Ossipov, Dmitri
   van den Beucken, Jeroen J. J. P.
   Leeuwenburgh, Sander
   Hilborn, Jons
TI Bisphosphonate functionalized hyaluronic acid showing selective affinity
   for osteoclasts as a potential treatment for osteoporosis
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID BONE CELL BIOLOGY; FRACTURE; OSTEOBLASTS; DERIVATIVES; EXPRESSION;
   PREVENTION; PHYSIOLOGY; INSIGHTS; THERAPY
AB Current treatments for osteoporosis involve the administration of high doses of bisphosphonates (BPs) over a number of years. However, the efficiency of the absorption of these drugs and specificity towards targeted osteoclastic cells is still suboptimal. In this study, we have exploited the natural affinity of high (H) and low (L) molecular weight hyaluronic acid (HA) towards a cluster of differentiation 44 (CD44) receptors on osteoclasts to use it as a biodegradable targeting vehicle. We covalently bonded BP to functionalised HA (HA BP) and found that HA BP conjugates were highly specific to osteoclastic cells and reduced mature osteoclast numbers significantly more than free BP. To study the uptake of HA BP, we fluorescently derivatised the polymer drug with fluorescein B isothiocyanate (FITC) and found that L HA BP could seamlessly enter osteoclastic cells. Alternatively, we tested polyvinyl alcohol (PVA) as a synthetic polymer delivery vehicle using similar chemistry to link BP and found that osteoclast numbers did not reduce in the same way. These findings could pave the way for biodegradable polymers to be used as vehicles for targeted delivery of anti osteoporotic drugs.
C1 [Kootala, Sujit; Ossipov, Dmitri; Hilborn, Jons] Uppsala Univ, Div Polymer Chem, Sci Life Lab, Dept Chem, SE 75121 Uppsala, Sweden.
   [van den Beucken, Jeroen J. J. P.; Leeuwenburgh, Sander] Radboud Umc 309, Dept Biomat, NL 6500 HB Nijmegen, Netherlands.
C3 Uppsala University; Radboud University Nijmegen
RP Kootala, S (通讯作者)，Uppsala Univ, Div Polymer Chem, Sci Life Lab, Dept Chem, POB 538,Lagerhyddsvagen 1, SE 75121 Uppsala, Sweden.
EM Jons.Hilborn@kemi.uu.se
RI Kootala, Sujit/I 9004 2014; Leeuwenburgh, S.C.G./L 4483 2015; van den
   Beucken, Jeroen/N 2910 2013; Leeuwenburgh, Sander/L 4483 2015
OI Kootala, Sujit/0000 0001 7800 3533; Ossipov, Dmitri/0000 0003 2332 3665;
   van den Beucken, Jeroen/0000 0002 0301 1966; Leeuwenburgh,
   Sander/0000 0003 1471 6133
FU European Community's Seventh Framework Programme (MultiTERM) [238551];
   Swedish Research Council (VR) [2014 6099]
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme (MultiTERM, grant no.
   238551).We extend our gratitude to Mr Fredrik Edin, Department of
   Surgical Sciences, Otolaryngology and Head & Neck Surgery, Akademiska
   Sjukhuset, Uppsala, for his time and advice on microscopic evaluation of
   the materials. We also extend our gratitude to Dr Xi Lu for his help and
   insights while reviewing the figures. We would like to thank the Swedish
   Research Council (VR) for financial support through Grant number
   2014 6099.
CR BARON R, 1995, BONE, V17, pS55, DOI 10.1016/8756 3282(95)00178 G
   Bastow ER, 2008, CELL MOL LIFE SCI, V65, P395, DOI 10.1007/s00018 007 7360 z
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Buck DW, 2012, PLAST RECONSTR SURG, V129, P1314, DOI 10.1097/PRS.0b013e31824eca94
   Cenni E, 2012, J BIOMAT SCI POLYM E, V23, P1285, DOI 10.1163/092050611X580373
   CIELINSKI MJ, 1994, J CELL BIOCHEM, V56, P315, DOI 10.1002/jcb.240560307
   Cyphert J. M., INT J CELL IN PRESS, V563818
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Downey PA, 2006, PHYS THER, V86, P77, DOI 10.1093/ptj/86.1.77
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Ganda K, 2014, OSTEOPOROSIS INT, V25, P1345, DOI 10.1007/s00198 013 2610 4
   Gao JB, 2013, BBA GEN SUBJECTS, V1830, P3635, DOI 10.1016/j.bbagen.2013.02.011
   Garcia T, 2002, BONE, V31, P205, DOI 10.1016/S8756 3282(02)00781 0
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Sillero MAG, 2009, BIOCHEM PHARMACOL, V78, P335, DOI 10.1016/j.bcp.2009.04.028
   Harada H, 2007, J BIOL CHEM, V282, P5597, DOI 10.1074/jbc.M608358200
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   HUGHES DE, 1994, J BONE MINER RES, V9, P39
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kanis JA, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0144 1
   Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050
   Kung AW, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472 6874 13 7
   Lems WF, 2014, CURR OPIN RHEUMATOL, V26, P245, DOI 10.1097/BOR.0000000000000057
   Lloyd SA, 2009, J BONE MINER METAB, V27, P546, DOI 10.1007/s00774 009 0071 9
   Makita K, 2015, J BONE MINER METAB, V33, P55, DOI 10.1007/s00774 013 0553 7
   Miyakoshi Naohisa, 2014, Clin Calcium, V24, P93, DOI CliCa14019399
   Nejadnik MR, 2014, BIOMATERIALS, V35, P6918, DOI 10.1016/j.biomaterials.2014.05.003
   Ossipov DA, 2008, MACROMOLECULES, V41, P3971, DOI 10.1021/ma800332c
   Ossipov DA, 2010, BIOMACROMOLECULES, V11, P2247, DOI 10.1021/bm1007986
   Outeiriño Fernández A, 2013, AN SIST SANIT NAVAR, V36, P87, DOI 10.4321/s1137 66272013000100009
   Pervaiz K, 2013, J SHOULDER ELB SURG, V22, pE1, DOI 10.1016/j.jse.2012.05.029
   REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schwarz P, 2014, EXPERT OPIN DRUG DIS, V9, P245, DOI 10.1517/17460441.2014.884067
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Steinmüller Nethl D, 2006, BIOMATERIALS, V27, P4547, DOI 10.1016/j.biomaterials.2006.04.036
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Viswanathan HN, 2012, APPL HEALTH ECON HEA, V10, P163, DOI 10.2165/11598590 000000000 00000
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Wilson C., 2011, ENDOCRINOLOGY, V7, P693
   Wu LG, 2014, ANNU REV PHYSIOL, V76, P301, DOI 10.1146/annurev physiol 021113 170305
   Yano Shozo, 2013, Rinsho Byori, V61, P852
NR 46
TC 20
Z9 23
U1 2
U2 66
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PY 2015
VL 3
IS 8
BP 1197
EP 1207
DI 10.1039/c5bm00096c
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CM8GR
UT WOS:000357937400003
PM 26222035
DA 2025 08 17
ER

PT J
AU Saad, F
   Mulders, P
AF Saad, Fred
   Mulders, Peter
TI Bisphosphonate Anticancer Activity in Prostate Cancer and Other
   Genitourinary Cancers
SO ANTI CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Anticancer; Bisphosphonate; Genitourinary cancers; Prostate cancer;
   Zoledronic acid
ID ANDROGEN DEPRIVATION THERAPY; PLACEBO CONTROLLED TRIAL; DISSEMINATED
   TUMOR CELLS; METASTATIC BONE DISEASE; DELTA T CELLS; LONG TERM EFFICACY;
   ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; SOLID TUMORS; OSTEOCLAST
   ACTIVITY
AB Anticancer therapies have traditionally been targeted directly against cancer cell growth. However, newer treatment strategies also target the microenvironment that supports metastatic cancer cell growth. Bisphosphonates are the standard of care for maintaining bone health in patients with bone metastases from solid tumors and bone lesions from multiple myeloma, and emerging evidence supports potential anticancer activity of bisphosphonates. Zoledronic acid (ZOL), a third generation nitrogen containing bisphosphonate, is currently advised for reducing the risk of skeletal morbidity in patients with bone metastases from prostate cancer and other genitourinary cancers, such as renal cell carcinoma and bladder cancer. Clinical studies indicate that ZOL can normalize bone marker levels (a potential measure of skeletal disease burden), which may improve survival in patients with aggressive bone disease from prostate and other genitourinary cancers, supporting a broader therapeutic role for ZOL in genitourinary malignancies. This review examines the rationale and emerging evidence supporting the anticancer activity of bisphosphonates, especially ZOL, against prostate and other genitourinary cancers.
C1 [Saad, Fred] Univ Montreal, Ctr Hosp, Montreal, PQ H2L 4MI, Canada.
   [Saad, Fred] CRCHUM, Montreal, PQ H2L 4MI, Canada.
   [Mulders, Peter] Radbound Univ Med Ctr Nijmegen, Nijmegen, Netherlands.
C3 Universite de Montreal; Universite de Montreal; Radboud University
   Nijmegen
RP Saad, F (通讯作者)，Univ Montreal, Ctr Hosp, 1560 Sherbrooke E, Montreal, PQ H2L 4MI, Canada.
EM fred.saad@umontreal.ca
RI Saad, Fred/ADN 9925 2022; Mulders, Peter/H 8076 2014
FU Novartis Pharmaceuticals Corporation
FX Financial support for medical editorial assistance was provided by
   Novartis Pharmaceuticals Corporation. We thank Duprane Pedaci Young,
   PhD, of ProEd Communications, Inc.(R), for her medical editorial
   assistance with this manuscript.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Abrahamsson P.A., 2008, 23 ANN EAU C MARCH 2
   [Anonymous], 9 INT M CANC IND BON
   [Anonymous], 2007, Global Cancer Facts Figures 2007
   Berg A, 2007, INT J CANCER, V120, P1603, DOI 10.1002/ijc.22488
   Bhoopalam N, 2009, J UROLOGY, V182, P2257, DOI 10.1016/j.juro.2009.07.046
   Boissier S, 2000, CANCER RES, V60, P2949
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown J.E., 2009, 2009 ASCO GEN CANC S
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Casey R, 2010, CAN J UROL, V17, P5170
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Costa L, 2009, 9 INT M CANC IND BON
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Donat DA, 2006, ANN ONCOL, V17, P156
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Facchini G, 2010, CANCER BIOL THER, V10, P543, DOI 10.4161/cbt.10.6.12611
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fritz G, 2009, CURR CANCER DRUG TAR, V9, P626, DOI 10.2174/156800909789057033
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hatoum HT, 2011, CURR MED RES OPIN, V27, P55, DOI 10.1185/03007995.2010.535511
   Heidenreich A, 2009, GUIDELINES PROSTATE
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hering Flavio, 2003, Int. braz j urol., V29, P228
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e
   Israeli RS, 2007, CLIN GENITOURIN CANC, V5, P271, DOI 10.3816/CGC.2007.n.003
   IZUMI K, 2010, 2010 ASCO GEN CANC S
   Izumi K, 2009, UROLOGY, V73, P1342, DOI 10.1016/j.urology.2009.01.046
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016
   Köllermann J, 2008, J CLIN ONCOL, V26, P4928, DOI 10.1200/JCO.2007.15.0441
   KOUL HK, 2010, 2010 ASCO GEN CANC S
   Lipton A, 2002, CANCER INVEST, V20, P45, DOI 10.1081/CNV 120014886
   LIPTON A, 2004, WHAT IS NEW BISPH 7
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton A, 2007, ONCOLOGIST, V12, P1035, DOI 10.1634/theoncologist.12 9 1035
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Morgan C, 2007, ACTA ONCOL, V46, P669, DOI 10.1080/02841860600996447
   Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078 0432.CCR 08 1754
   Mulders P.F., 2007, 22 ANN EAU C MARCH 2
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Naoe M, 2010, ONCOL RES, V18, P493, DOI 10.3727/096504010X12671222663638
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Noguchi M, 2003, UROLOGY, V61, P993, DOI 10.1016/S0090 4295(02)02583 9
   Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806 875
   *NOV PHARM CORP, 2008, RECL ZOL AC INJ PACK
   Novartis, 2011, ZOM ZOL AC INJ PACK
   Padalecici SS, 2002, 24 ANN M AM SOC BON
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Planas J, 2009, BJU INT, V104, P1637, DOI 10.1111/j.1464 410X.2009.08622.x
   Prescribing information, 2010, FOS AL SOD TABL OR S
   *PROCT GAMBL PHARM, 2009, ACT RIS SOD TABL PAC
   Rodrigues P, 2004, PROSTATE CANCER P D, V7, P350, DOI 10.1038/sj.pcan.4500752
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Rucci Nadia, 2010, Front Biosci (Schol Ed), V2, P907
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saad F, 2005, BJU INT, V96, P964, DOI 10.1111/j.1464 410X.2005.05740.x
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2008, CANCER TREAT REV, V34, P183, DOI 10.1016/j.ctrv.2007.10.002
   Saad F, 2007, SEMIN ONCOL, V34, pS17, DOI 10.1053/j.seminoncol.2007.10.006
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Shiozawa Y, 2008, LEUKEMIA, V22, P941, DOI 10.1038/leu.2008.48
   Smith M.R., 2011, AM UR ASS ANN M MAY
   Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Soltau J, 2008, ANTICANCER RES, V28, P933
   Taxel P, 2010, BJU INT, V106, P1473, DOI 10.1111/j.1464 410X.2010.09329.x
   U.S. National Institutes of Health, 2008, ZOL PLUS STAND THER
   Ullén A, 2009, SCAND J UROL NEPHROL, V43, P98, DOI 10.1080/00365590802475904
   *US NIH, RADAR TRIAL RAND AND
   Yuasa T, 2009, CANCER IMMUNOL IMMUN, V58, P493, DOI 10.1007/s00262 008 0571 9
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
NR 86
TC 5
Z9 5
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5206
J9 ANTI CANCER AGENT ME
JI Anti Cancer Agents Med. Chem.
PD FEB
PY 2012
VL 12
IS 2
BP 129
EP 136
DI 10.2174/187152012799014995
PG 8
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 936TK
UT WOS:000303612700006
PM 21864229
DA 2025 08 17
ER

PT J
AU Stroup, J
   Kane, MP
   Abu Baker, AM
AF Stroup, Jeffrey
   Kane, Michael P.
   Abu Baker, Asim M.
TI Teriparatide in the treatment of osteoporosis
SO AMERICAN JOURNAL OF HEALTH SYSTEM PHARMACY
LA English
DT Article
DE costs; fractures; hormones; mechanism of action; osteoporosis;
   postmenopause; teriparatide; toxicity
ID BONE MINERAL DENSITY; PARATHYROID HORMONE (1 34); FRACTURE RISK
   REDUCTION; GLUCOCORTICOID INDUCED OSTEOPOROSIS; CONTROLLED
   CLINICAL TRIAL; POSTMENOPAUSAL WOMEN; INITIAL EXPERIENCE; UNITED STATES;
   ALENDRONATE; THERAPY
AB Purpose. The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed.
   Summary. Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost effective in selected patients.
   Conclusion. Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.
C1 [Stroup, Jeffrey] Oklahoma State Univ, Hlth Sci Ctr, Tulsa, OK 74127 USA.
   [Kane, Michael P.] Albany Coll Pharm, Albany, NY USA.
   [Abu Baker, Asim M.] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA.
C3 Oklahoma State University System; Oklahoma State University Center for
   Health Sciences; Albany College of Pharmacy & Health Sciences; Saint
   John Fisher University
RP Stroup, J (通讯作者)，Oklahoma State Univ, Hlth Sci Ctr, 635 W 11th St, Tulsa, OK 74127 USA.
RI Abu Baker, Asim/O 3459 2018
OI Abu Baker, Asim/0000 0002 2040 1878
CR ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Dempster DM, 2000, J BONE MINER RES, V15, P20, DOI 10.1359/jbmr.2000.15.1.20
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Eastell R, 2006, CURR MED RES OPIN, V22, P61, DOI 10.1185/030079905X75096
   *EL LILL CO, 2004, FORT PACK INS
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fleming T, 2005, DRUG TOPICS RED BOOK
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Gold DT, 2006, CURR MED RES OPIN, V22, P703, DOI 10.1185/030079906X100159
   Gonnelli S, 2006, OSTEOPOROSIS INT, V17, P1524, DOI 10.1007/s00198 006 0157 3
   Harper KD, 2006, CURR MED RES OPIN, V22, P1927, DOI 10.1185/030079906X132578
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198 004 1636 z
   Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Liu H, 2006, ARCH INTERN MED, V166, P1209, DOI 10.1001/archinte.166.11.1209
   Lundkvist J, 2006, OSTEOPOROSIS INT, V17, P201, DOI 10.1007/s00198 005 1959 4
   MacLaughlin EJ, 2005, PHARMACOTHERAPY, V25, P379, DOI 10.1592/phco.25.3.379.61604
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller Paul D, 2004, Endocr Pract, V10, P139
   Miller PD, 2005, J RHEUMATOL, V32, P1556
   *NAT I ARTHR MUSC, 2006, OST OVERV
   *NAT OST FDN, 2004, AM BON HLTH STAT OST
   Naunton M, 2006, ANN PHARMACOTHER, V40, P38, DOI 10.1345/aph.1G208
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756 3282(95)00332 2
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll ES, 1998, ENDOCRIN METAB CLIN, V27, P349, DOI 10.1016/S0889 8529(05)70009 8
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Ste Marie LG, 2006, J BONE MINER RES, V21, P283, DOI 10.1359/JBMR.051020
   Stroup J, 2003, AM J HEALTH SYST PH, V60, P2247, DOI 10.1093/ajhp/60.21.2247
   Stroup JS, 2007, PHARMACOTHERAPY, V27, P779, DOI 10.1592/phco.27.6.779
   Thomas T, 2006, JOINT BONE SPINE, V73, P262, DOI 10.1016/j.jbspin.2005.11.007
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   *US DHHS, 2004, BON HLTH OST REP SUR
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 55
TC 42
Z9 50
U1 1
U2 16
PU AMER SOC HEALTH SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079 2082
J9 AM J HEALTH SYST PH
JI Am. J. Health Syst. Pharm.
PD MAR 15
PY 2008
VL 65
IS 6
BP 532
EP 539
DI 10.2146/ajhp070171
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 278CK
UT WOS:000254260900010
PM 18319498
DA 2025 08 17
ER

PT J
AU Storlino, G
   Dicarlo, M
   Zerlotin, R
   Pignataro, P
   Sanesi, L
   Suriano, C
   Oranger, A
   Mori, G
   Passeri, G
   Colucci, S
   Grano, M
   Colaianni, G
AF Storlino, Giuseppina
   Dicarlo, Manuela
   Zerlotin, Roberta
   Pignataro, Patrizia
   Sanesi, Lorenzo
   Suriano, Clelia
   Oranger, Angela
   Mori, Giorgio
   Passeri, Giovanni
   Colucci, Silvia
   Grano, Maria
   Colaianni, Graziana
TI Irisin Protects against Loss of Trabecular Bone Mass and Strength in
   Adult Ovariectomized Mice by Stimulating Osteoblast Activity
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Ovx mice; irisin; bone loss; estrogen; subchondral bone
ID OSTEOPOROTIC FRACTURES; SUBCHONDRAL BONE; MINERAL DENSITY; SEX STEROIDS;
   MECHANISMS; GUIDELINES; DENOSUMAB; TURNOVER; THERAPY; MYOKINE
AB Irisin is a peptide secreted by skeletal muscle that plays a major role in bone metabolism. Experiments in mouse models have shown that administration of recombinant irisin prevents disuse induced bone loss. In this study, we aimed to evaluate the effects of irisin treatment for the prevention of bone loss in the ovariectomized (Ovx) mouse, the animal model commonly used to investigate osteoporosis caused by estrogen deficiency. Micro Ct analysis conducted on Sham mice (Sham veh) and Ovx mice treated with vehicle (Ovx veh) or recombinant irisin (Ovx irisn) showed bone volume fraction (BV/TV) decreases in femurs (Ovx veh 1.39 & PLUSMN; 0.71 vs. Sham veh 2.84 & PLUSMN; 1.23; p = 0.02) and tibia at both proximal condyles (Ovx veh 1.97 & PLUSMN; 0.68 vs. Sham veh 3.48 & PLUSMN; 1.26; p = 0.03) and the subchondral plate (Ovx veh 6.33 & PLUSMN; 0.36 vs. Sham veh 8.18 & PLUSMN; 0.41; p = 0.01), which were prevented by treatment with a weekly dose of irisin for 4 weeks. Moreover, histological analysis of trabecular bone showed that irisin increased the number of active osteoblasts per bone perimeter (Ovx irisin 32.3 & PLUSMN; 3.9 vs. Ovx veh 23.5 & PLUSMN; 3.6; p = 0.01), while decreasing osteoclasts (Ovx irisin 7.6 & PLUSMN; 2.4 vs. Ovx veh 12.9 & PLUSMN; 3.04; p = 0.05). The possible mechanism by which irisin enhances osteoblast activity in Ovx mice is upregulation of the transcription factor Atf4, one of the key markers of osteoblast differentiation, and osteoprotegerin, thereby inhibiting osteoclast formation.
C1 [Storlino, Giuseppina; Mori, Giorgio] Univ Foggia, Dept Clin & Expt Med, I 71100 Foggia, Italy.
   [Dicarlo, Manuela; Zerlotin, Roberta; Pignataro, Patrizia; Suriano, Clelia; Oranger, Angela; Grano, Maria; Colaianni, Graziana] Univ Bari, Dept Precis & Regenerat Med & Ionian Area, I 70124 Bari, Italy.
   [Pignataro, Patrizia; Sanesi, Lorenzo; Colucci, Silvia] Univ Bari, Dept Translat Biomed & Neurosci, I 70124 Bari, Italy.
   [Passeri, Giovanni] Univ Parma, Dept Med & Surg, Unit Clin & Terapia Med, I 43121 Parma, Italy.
C3 University of Foggia; Universita degli Studi di Bari Aldo Moro;
   Universita degli Studi di Bari Aldo Moro; University of Parma
RP Storlino, G (通讯作者)，Univ Foggia, Dept Clin & Expt Med, I 71100 Foggia, Italy.; Colaianni, G (通讯作者)，Univ Bari, Dept Precis & Regenerat Med & Ionian Area, I 70124 Bari, Italy.
EM giuseppina.storlino@unifg.it; manuela.dicarlo@uniba.it;
   maria.grano@uniba.it; graziana.colaianni@uniba.it
RI Storlino, Giuseppina/LOS 4035 2024; Mori, Giorgio/P 1370 2014
OI Grano, Maria/0000 0002 7121 5899; Mori, Giorgio/0000 0001 6731 0247;
   oranger, angela/0000 0003 0881 6840
FU Regione Puglia; CNR for Tecnopolo per la Medicina di Precisione [2117,
   CUPB84I18000540002]; European Space Agency (ESA) [4000128599/19/NL/PG];
   Next Generation EU;  [CUP: B83C22004800006];  [DM 1557]
FX This work was supported by funding form Regione Puglia and CNR for
   Tecnopolo per la Medicina di Precisione. D.G.R. n. 2117 of 21.11.2018
   (CUPB84I18000540002) C.I.R.E.M.I.C. (Research Center of Excellence for
   Neurodegenerative Diseases and Brain Aging) University of Bari "Aldo
   Moro", and by grants from the European Space Agency (ESA) to Maria Grano
   (4000128599/19/NL/PG). We also acknowledge co funding from Next
   Generation EU, in the context of the National Recovery and Resilience
   Plan, Investment PE8 Project Age It: "Ageing Well in an Ageing Society"
   to Maria Grano (CUP: B83C22004800006). This resource was co financed by
   the Next Generation EU [DM 1557 11.10.2022]. The views and opinions
   expressed are only those of the authors and do not necessarily reflect
   those of the European Union or the European Commission. Neither the
   European Union nor the European Commission can be held responsible for
   them.
CR Anastasilakis AD, 2014, OSTEOPOROSIS INT, V25, P1633, DOI 10.1007/s00198 014 2673 x
   Boström P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Buccoliero C, 2021, BIOCHEM SOC T, V49, P477, DOI 10.1042/BST20200978
   Camargos GV, 2015, SCI REP UK, V5, DOI 10.1038/srep10795
   Cariati I, 2021, J FUNCT MORPHOL KIN, V6, DOI 10.3390/jfmk6020055
   CIARELLI MJ, 1991, J ORTHOPAED RES, V9, P674, DOI 10.1002/jor.1100090507
   Colaianni G, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.886243
   Colaianni G, 2019, CELLS BASEL, V8, DOI 10.3390/cells8050451
   Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186
   Colaianni G, 2018, CALCIFIED TISSUE INT, V103, P638, DOI 10.1007/s00223 018 0459 4
   Colaianni G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02557 8
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Collins BC, 2019, BONE, V123, P137, DOI 10.1016/j.bone.2019.03.033
   Colucci S, 2020, FASEB J, V34, P10096, DOI 10.1096/fj.202000216R
   Colucci SC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910863
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Estell EG, 2020, ELIFE, V9, DOI 10.7554/eLife.58172
   Greendale GA, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz056
   Greising SM, 2009, J GERONTOL A BIOL, V64, P1071, DOI 10.1093/gerona/glp082
   Ham KD, 2004, J BONE MINER RES, V19, P823, DOI 10.1359/JBMR.040309
   He ZH, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115573
   HODGSKINSON R, 1993, CLIN BIOMECH, V8, P262, DOI 10.1016/0268 0033(93)90036 H
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Idris AI, 2012, METHODS MOL BIOL, V816, P545, DOI 10.1007/978 1 61779 415 5_34
   Iemura S, 2020, J BONE MINER METAB, V38, P161, DOI 10.1007/s00774 019 01043 7
   Jepsen KJ, 2015, J BONE MINER RES, V30, P951, DOI 10.1002/jbmr.2539
   Kan TY, 2022, J ORTHOP TRANSL, V37, P37, DOI 10.1016/j.jot.2022.07.006
   Kawao N, 2021, J BONE MINER METAB, V39, P547, DOI 10.1007/s00774 020 01201 2
   Larson AA, 2020, EXP PHYSIOL, V105, P1700, DOI 10.1113/EP088827
   Lee P, 2014, CELL METAB, V19, P302, DOI 10.1016/j.cmet.2013.12.017
   Liu K, 2021, CYTOKINE, V148, DOI 10.1016/j.cyto.2021.155708
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lloyd SA, 2014, J BONE MINER RES, V29, P1118, DOI 10.1002/jbmr.2113
   Luo Y, 2020, CLIMACTERIC, V23, P496, DOI 10.1080/13697137.2020.1745768
   Ma YX, 2018, FASEB J, V32, P5813, DOI 10.1096/fj.201700983RR
   Malhan D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00666
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   Oranger A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24031809
   Oranger A, 2023, FASEB J, V37, DOI 10.1096/fj.202201005RR
   Palermo A, 2015, CLIN ENDOCRINOL, V82, P615, DOI 10.1111/cen.12672
   Perakakis N, 2017, NAT REV ENDOCRINOL, V13, P324, DOI 10.1038/nrendo.2016.221
   Pignataro P, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076715
   Pignataro P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147596
   Polyzos SA, 2018, ENDOCRINE, V59, P260, DOI 10.1007/s12020 017 1476 1
   Quasnichka HL, 2006, BIORHEOLOGY, V43, P389
   Reza MM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01131 0
   RICO H, 1994, MATURITAS, V18, P183, DOI 10.1016/0378 5122(94)90124 4
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roman Blas JA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2791
   Roomi AB, 2021, REP BIOCHEM MOL BIOL, V10, P13, DOI 10.52547/rbmb.10.1.13
   Sanesi L, 2023, NPJ MICROGRAVITY, V9, DOI 10.1038/s41526 023 00251 w
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Seibel MJ, 2006, CELL, V127, P1079, DOI 10.1016/j.cell.2006.12.002
   Storlino G, 2020, J BONE MINER RES, V35, P766, DOI 10.1002/jbmr.3944
   Vadalà G, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061478
   Wang FS, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9090810
   Yan J, 2018, JOINT BONE SPINE, V85, P353, DOI 10.1016/j.jbspin.2017.03.011
   Yu YP, 2014, BIOMATERIALS, V35, P1667, DOI 10.1016/j.biomaterials.2013.10.072
   Zhang J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.56
   Zhao RQ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.639066
   Zhu XB, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607764
   Zhu XF, 2021, J CELL PHYSIOL, V236, P664, DOI 10.1002/jcp.29894
NR 65
TC 9
Z9 10
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2023
VL 24
IS 12
AR 9896
DI 10.3390/ijms24129896
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA K6GG3
UT WOS:001017397700001
PM 37373043
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Olney, RC
AF Olney, Robert C.
TI Mechanisms of Impaired Growth: Effect of Steroids on Bone and Cartilage
SO HORMONE RESEARCH
LA English
DT Article
DE Glucocorticoids; Osteoblasts; Osteoclasts; Chondrocytes; Growth
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; FACTOR I; HORMONE; PATHOPHYSIOLOGY;
   SUPPRESSION; THERAPY; PLATE; AXIS
AB Background: Long term treatment with high dose glucocorticoids (GCs) has profound effects on bone metabolism and linear growth. Bone metabolism is a balance between bone resorption by osteoclasts and new bone formation by osteoblasts. Systemically, GC treatment reduces circulating levels of estrogen and modestly increases parathyroid hormone levels. At the local level, GCs decrease insulin like growth factor I (IGF I) production, induce IGF I resistance and increase nuclear factor kappa B ligand production by osteoblasts. These alterations inhibit new bone formation and stimulate bone resorption, with a net loss of bone over time. Clinically, this results in decreased bone mineral density, osteoporosis and increased risk for fracture. Local effects of GCs at the growth plate include reduction of IGF I production, inducing IGF I resistance and reducing production of C type natriuretic peptide, which results in a reduction of chondrocyte proliferation, matrix synthesis and hypertrophy. These reductions in chondrocyte function result in decreased linear growth. Conclusions: The effects of GCs on bone metabolism and linear growth are sensitive and specific and represent an evolutionary adaptation to redirect resources during times of physiologic stress. Since many of these effects result from alterations in IGF I production, growth hormone therapy is a potential approach to ameliorate these problems. Copyright (C) 2009 S. Karger AG, Basel
C1 Nemours Childrens Clin, Div Pediat Endocrinol, Jacksonville, FL 32207 USA.
RP Olney, RC (通讯作者)，Nemours Childrens Clin, Div Pediat Endocrinol, 807 Childrens Way, Jacksonville, FL 32207 USA.
EM rolney@nemours.org
CR Aubin J.E., 2006, PRIMER METABOLIC BON, V6th, P20
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004 1152
   De Nijs R N J, 2008, Minerva Med, V99, P23
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   Fujita T, 2004, J CELL BIOCHEM, V93, P374, DOI 10.1002/jcb.20192
   Gore AC, 2006, MOL CELL ENDOCRINOL, V256, P40, DOI 10.1016/j.mce.2006.06.002
   Hochberg Z, 2002, HORM RES, V58, P33, DOI 10.1159/000064764
   Hutchison MR, 2007, ENDOCRINOLOGY, V148, P3122, DOI 10.1210/en.2006 1264
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kuroki Y, 2008, J BONE MINER METAB, V26, P271, DOI 10.1007/s00774 007 0821 5
   Leonard MB, 2007, PEDIATRICS, V119, pS166, DOI 10.1542/peds.2006 2023J
   Olney RC, 2006, GROWTH HORM IGF RES, V16, pS6, DOI 10.1016/j.ghir.2006.03.016
   Prickett TCR, 2005, PEDIATR RES, V58, P334, DOI 10.1203/01.PDR.0000169964.66260.4B
   Prummel MF, 1996, J ENDOCRINOL INVEST, V19, P620, DOI 10.1007/BF03349028
   Ross F.P., 2006, PRIMER METABOLIC BON, VSixth, P30
   van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002 0033
   Wajchenberg BL, 1996, HORM RES, V45, P99, DOI 10.1159/000184767
NR 18
TC 53
Z9 64
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0301 0163
J9 HORM RES
JI Horm. Res.
PY 2009
VL 72
BP 30
EP 35
DI 10.1159/000229761
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 526WO
UT WOS:000272326800006
PM 19940493
DA 2025 08 17
ER

PT J
AU Naidu, A
   Dechow, PC
   Spears, R
   Wright, JM
   Kessler, HP
   Opperman, LA
AF Naidu, Aparna
   Dechow, Paul C.
   Spears, Robert
   Wright, John M.
   Kessler, Harvey P.
   Opperman, Lynne A.
TI The effects of bisphosphonates on osteoblasts in vitro
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article; Proceedings Paper
CT 62nd Annual Meeting of the
   American Academy of Oral and Maxillofacial Pathology
CY MAY 07 08, 2007 2008
CL Kansas City, MO
SP Amer Acad Oral & Maxillofacial Pathol
ID GROWTH FACTOR BETA; ZOLEDRONIC ACID; OSTEOCLAST DIFFERENTIATION; RAT
   BONE; CELL PROLIFERATION; GENE EXPRESSION; ALVEOLAR BONE; TGF BETA;
   INTERLEUKIN 6; PAMIDRONATE
AB Objective. The purpose of this study was to test the effects of bisphosphonates on osteoblast viability and function.
   Study design. Primary rat osteoblasts were cultured in normal media or media containing increasing concentrations of 2 bisphosphonates, alendronate and zoledronate. Enzyme linked immunoabsorbent assays (ELISAs) were used to measure interleukin (IL) 6, transforming growth factor (TGF) beta 1, and receptor activator of nuclear factor kappa B ligand (RANKL) expression in supernatants after 24, 48, and 72 h. Live and necrotic cell numbers were assessed with trypan blue assays.
   Results. As drug concentrations increased, cell viability decreased significantly. The ELISAs revealed significant increases in TGF beta 1 in treatment groups, but no significant change in RANKL or IL 6.
   Conclusions. High concentrations of alendronate and zoledronate were cytotoxic, decreasing cell viability at 72 h. Transforming growth factor beta 1 increased even as viability decreased, suggesting a mechanism for bisphosphonate action. These data suggest that lower concentrations of bisphosphonates may have therapeutic benefits without the cytotoxic effects which may result in osteonecrosis.
C1 [Dechow, Paul C.; Spears, Robert; Opperman, Lynne A.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, Dallas, TX 75246 USA.
   [Naidu, Aparna; Wright, John M.; Kessler, Harvey P.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Diagnost Sci, Dallas, TX 75246 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center
RP Opperman, LA (通讯作者)，Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA.
EM lopperman@bcd.tamhsc.edu
OI Naidu, Aparna/0000 0002 3666 0145; Opperman, Lynne/0000 0002 6200 7799
CR Allen MR, 2006, CALCIFIED TISSUE INT, V79, P255, DOI 10.1007/s00223 006 0031 5
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Bost KL, 1999, J INFECT DIS, V180, P1912, DOI 10.1086/315138
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS32, DOI 10.1097/00000421 200212001 00006
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS1, DOI 10.1097/00000421 200212001 00001
   DACY JA, 2006, THESIS TEXAS A M U H
   Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559
   Dicuonzo G, 2003, J INTERF CYTOK RES, V23, P649, DOI 10.1089/107999003322558782
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   FELIX R, 1984, CALCIFIED TISSUE INT, V36, P108, DOI 10.1007/BF02405302
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fournier P, 2002, CANCER RES, V62, P6538
   Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632
   Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   HEINE UI, 1990, DEVELOPMENT, V109, P29
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   KANTOR M, 1976, J PERIODONTOL, V47, P687, DOI 10.1902/jop.1976.47.12.687
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KHOSLA S, 2007, J BONE MINER RES
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Marketos M., 2004, DRUG TOP, V148, P76
   Marriott I, 2004, AM J PATHOL, V164, P1399, DOI 10.1016/S0002 9440(10)63226 9
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MARX RE., 2003, Oral and Maxillofacial Patholgy A. rationale for diagnosis and treatment. Quintessence Publishing Co Inc Chicago, P36
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   *MERCK CO, 2006, FOS AL PACK INS PRES
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   *NOV PHARM CORP, 2005, ZOM ZOL ACID INJ CON
   Opperman LA, 2000, DEV DYNAM, V219, P237, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1044>3.0.CO;2 F
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   POLSON AM, 1976, J PERIODONTAL RES, V11, P279, DOI 10.1111/j.1600 0765.1976.tb00082.x
   POLSON AM, 1976, J PERIODONTAL RES, V11, P290, DOI 10.1111/j.1600 0765.1976.tb00083.x
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   RYGH P, 1973, ACTA ODONTOL SCAND, V31, P109, DOI 10.3109/00016357309004617
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Sanders JL, 1998, J BONE MINER RES, V13, P786, DOI 10.1359/jbmr.1998.13.5.786
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   WILLIAMS DC, 1980, CALCIFIED TISSUE INT, V30, P233, DOI 10.1007/BF02408633
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   ZAKI A. E., 1963, JOUR DENT RES, V42, P1373, DOI 10.1177/00220345630420061401
NR 66
TC 62
Z9 73
U1 1
U2 12
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
EI 1528 395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD JUL
PY 2008
VL 106
IS 1
BP 5
EP 13
DI 10.1016/j.tripleo.2008.03.036
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Dentistry, Oral Surgery & Medicine
GA 320AI
UT WOS:000257205700004
PM 18504149
DA 2025 08 17
ER

PT J
AU Ohga, N
   Yamazaki, Y
   Tsuboi, K
   Kitagawa, Y
AF Ohga, Noritaka
   Yamazaki, Yutaka
   Tsuboi, Kanako
   Kitagawa, Yoshimasa
TI Healing of osteonecrosis of the jaw (ONJ) after discontinuation of
   denosumab in a patient with bone metastases of colorectal cancer: A case
   report and hypothesis
SO QUINTESSENCE INTERNATIONAL
LA English
DT Article
DE denosumab; discontinuation of drug; osteonecrosis of the jaw (ONJ)
ID BISPHOSPHONATE RELATED OSTEONECROSIS; BREAST CANCER; PAMIDRONATE; WOMEN;
   EFFICACY; NECROSIS
AB Osteonecrosis of the jaw (ONJ) is associated with the use of bisphosphonates (BPs), denosumab, and antiangiogenic drugs; however, the pathophysiology of medication related ONJ (MRONJ) remains unknown. Recent advances in therapies for diseases that affect bone remodeling have led to the development of agents that inhibit the receptor activator of nuclear factor kappa B ligand (RANKL). One such inhibitor is denosumab, a highly specific, fully human immunoglobulin G2 monoclonal antibody against RANKL. We report a case of ONJ that developed following dental extraction in a patient treated for metastatic colorectal cancer with denosumab. At the first medical examination at our hospital, her clinical presentation was indistinguishable from stage 2 MRONJ, classified according to the 2014 American Academy of Oral Medicine position paper. Discontinuation of denosumab was directed by her oncologist, and we prescribed oral antibiotics and irrigated the exposed area of bone. Seven months after denosumab cessation, the sequestrum of the anterior part of the mandible was naturally shed and the site was healed. Denosumab and BPs have significantly different mechanisms of action. The effects of denosumab on bone turnover are more rapid and reversible than those of BPs. Discontinuation of denosumab may be effective in the management of denosumab related ONJ, depending on the primary tumor control.
C1 [Ohga, Noritaka; Tsuboi, Kanako; Kitagawa, Yoshimasa] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Diag & Med, Sapporo, Hokkaido 0608586, Japan.
   [Yamazaki, Yutaka] Hokkaido Univ, Grad Sch Dent Med, Dept Gerodontol, Sapporo, Hokkaido 0608586, Japan.
C3 Hokkaido University; Hokkaido University
RP Ohga, N (通讯作者)，Hokkaido Univ, Grad Sch Dent Med, Oral Diag & Med, Kita Ku, Kita 13 Nishi 7, Sapporo, Hokkaido 0608586, Japan.
EM ohga@den.hokudai.ac.jp
FU Grants in Aid for Scientific Research [15K15726, 26861694] Funding
   Source: KAKEN
CR Anastasilakis AD, 2009, HORM METAB RES, V41, P721, DOI 10.1055/s 0029 1224109
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Kyrgidis A, 2011, OSTEOPOROSIS INT, V22, P369, DOI 10.1007/s00198 010 1177 6
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Malan J, 2012, OR SURG OR MED OR PA, V114, P671, DOI 10.1016/j.oooo.2012.08.439
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mehrotra Bhoomi, 2006, Hematology Am Soc Hematol Educ Program, P356
   Mortensen M, 2007, LARYNGOSCOPE, V117, P30, DOI 10.1097/01.mlg.0000240885.64568.9e
   Neuprez A, 2014, OSTEOPOROSIS INT, V25, P393, DOI 10.1007/s00198 013 2437 z
   O'Ryan FS, 2012, J ORAL MAXIL SURG, V70, P1844, DOI 10.1016/j.joms.2011.08.033
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
NR 26
TC 11
Z9 12
U1 0
U2 6
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0033 6572
EI 1936 7163
J9 QUINTESSENCE INT
JI Quintessence Int.
PD JUL AUG
PY 2015
VL 46
IS 7
BP 621
EP 626
DI 10.3290/j.qi.a33528
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CP2JP
UT WOS:000359703600008
PM 25646168
DA 2025 08 17
ER

PT J
AU Zhou, XY
   Lian, K
   Jia, JJ
   Zhao, X
   Duan, P
   Huang, JL
   Shi, YH
AF Zhou, Xiaoyang
   Lian, Kai
   Jia, Junjie
   Zhao, Xue
   Duan, Peng
   Huang, Jiaolong
   Shi, Yihua
TI Functions of Epimedin C in a zebrafish model of glucocorticoid induced
   osteoporosis
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone mineralization; Epimedin C; glucocorticoid induced osteoporosis;
   osteoprotective effect; traditional Chinese medicine; zebrafish model
ID BONE; OSTEOBLAST; DIFFERENTIATION; PROLIFERATION; PREVENTION
AB Epimedium is thought to enhance the integrity of tendons and bones, ease joint discomfort and rigidity and enhance kidney function. Although glucocorticoids are commonly used in clinical practice, the mechanism by which the active compound Epimedin C (EC) alleviates glucocorticoid induced osteoporosis (GIOP) is not well understood. The therapeutic potential of EC in treating GIOP was evaluated using alizarin red S staining, calcein immersion and fluorescence imaging, and bone mineralization, bone mass accumulation and bone density in zebrafish larvae were determined. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, the key signalling pathways related to bone development were identified. A protein protein interaction network (PPIN) was constructed to identify osteoclast characteristic genes and the findings were verified using real time quantitative PCR (RT qPCR). The bone tissue damage caused by prednisolone was reduced by EC. It also altered physiological processes, improved bone density, boosted mineralization and increased bone mass and activity. Subsequent empirical investigations showed that EC impacted the major signalling pathways involved in bone development, such as osteoclast differentiation, oestrogen, MAPK, insulin resistance, PPAR and AMPK signalling pathways. It also decreased the expression of genes typical of osteoclasts. The results of our study uncover a previously unknown function of EC in controlling bone formation and emphasize the potential of EC as a therapeutic target. The osteoprotective effect of EC indicates its potential as a cost effective strategy for treating GIOP.
C1 [Zhou, Xiaoyang; Lian, Kai; Jia, Junjie; Shi, Yihua] Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Orthoped, Xiangyang 441000, Peoples R China.
   [Zhou, Xiaoyang; Zhao, Xue; Duan, Peng; Huang, Jiaolong] Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Obstet & Gynaecol, Key Lab Zebrafish Modeling & Drug Screening Human, Xiangyang, Peoples R China.
C3 Hubei University of Medicine; Hubei University of Medicine
RP Shi, YH (通讯作者)，Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Orthoped, Xiangyang 441000, Peoples R China.; Huang, JL (通讯作者)，Hubei Univ Med, Xiangyang 1 Peoples Hosp, Key Lab Zebrafish Modeling & Drug Screening Human, Xiangyang 441000, Peoples R China.
EM huangjiaolong1110@163.com; yihua19@163.com
RI ; Jia, Junjie/AAQ 2527 2020; Zhou, Xiaoyang/KPA 9028 2024
OI Huang, Jiaolong/0009 0001 0608 8379; 
FU Foundation of Health Commission of Hubei Province
FX Scientific and Technological Project of Xiangyang City of Hubei
   Province, Grant/Award Number: 2022YL24A; Hubei Province Key Research and
   Development Program, Grant/Award Number: 2022BCE021 and 2022CFD010;
   Foundation of Health Commission of Hubei Province, Grant/Award Number:
   WJ2023M162r No Statement Availabler No Statement Available
CR Anagnostis P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031639
   Barnes PJ, 2014, CHEM IMMUNOL ALLERGY, V100, P311, DOI 10.1159/000359984
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Bonjour JP, 2011, INT J VITAM NUTR RES, V81, P134, DOI 10.1024/0300 9831/a000063
   Chapurlat R, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115784
   Chen HL, 2023, EUR REV MED PHARMACO, V27, P7576, DOI 10.26355/eurrev_202308_33409
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cheng TT, 2018, J INVEST MED, V66, P1004, DOI 10.1136/jim 2018 000723
   de Campos WG, 2023, TOXICOL APPL PHARM, V476, DOI 10.1016/j.taap.2023.116673
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Farrukh Ameer Mustafa, 2023, Radiol Case Rep, V18, P4048, DOI 10.1016/j.radcr.2023.08.040
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Galvagni F, 2013, CELL ADHES MIGR, V7, P408, DOI 10.4161/cam.25894
   Guo HH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261127
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   He HL, 2018, BIOMED PHARMACOTHER, V101, P981, DOI 10.1016/j.biopha.2018.02.082
   Hopwood B, 2009, BONE, V44, P87, DOI 10.1016/j.bone.2008.08.120
   Huang Mi Huang Mi, 2016, Chinese Journal of Integrated Traditional and Western Medicine, V36, P986
   Huang WL, 2020, ECOTOX ENVIRON SAFE, V205, DOI 10.1016/j.ecoenv.2020.111165
   Huo L, 2018, BIOL OPEN, V7, DOI 10.1242/bio.029405
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Ikeda S, 2003, BONE, V33, P779, DOI 10.1016/S8756 3282(03)00263 1
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Islam MN, 2012, BIOSCI BIOTECH BIOCH, V76, P923, DOI 10.1271/bbb.110922
   Jiang YH, 2019, ENVIRON TOXICOL PHAR, V70, DOI 10.1016/j.etap.2019.103205
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647
   Li HB, 2020, CHEM BIOL DRUG DES, V95, P451, DOI 10.1111/cbdd.13659
   Louis R, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.01585 2021
   Ma C, 2024, INT IMMUNOPHARMACOL, V127, DOI 10.1016/j.intimp.2023.111322
   Ma XQ, 2018, EXP THER MED, V15, P182, DOI 10.3892/etm.2017.5381
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Ma YR, 2023, PHYTOCHEMISTRY, V215, DOI 10.1016/j.phytochem.2023.113841
   Mi BB, 2019, AGING US, V11, P11988, DOI 10.18632/aging.102524
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Papoudou Bai A, 2017, CLIN EXP MED, V17, P291, DOI 10.1007/s10238 016 0436 z
   Park WY, 2017, TRANSPL P, V49, P1033, DOI 10.1016/j.transproceed.2017.03.038
   Popp AW, 2006, EUR SPINE J, V15, P1035, DOI 10.1007/s00586 005 0056 x
   Qian HQ, 2024, J ETHNOPHARMACOL, V318, DOI 10.1016/j.jep.2023.116957
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Umpleby AM, 1996, BAILLIERE CLIN ENDOC, V10, P551, DOI 10.1016/S0950 351X(96)80711 7
   Wang PZ, 2023, PEERJ, V11, DOI 10.7717/peerj.15917
   Wang YW, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/9417362
   Wong SK, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512441
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Wu Q, 2017, ENVIRON POLLUT, V231, P471, DOI 10.1016/j.envpol.2017.08.038
   Xu YX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.894832
   Xue Jia, 2023, Zhongguo Zhong Yao Za Zhi, V48, P3448, DOI 10.19540/j.cnki.cjcmm.20230313.102
   Zhang JX, 2023, MATER TODAY BIO, V22, DOI 10.1016/j.mtbio.2023.100737
   Zhu LZ, 2022, ECOTOX ENVIRON SAFE, V238, DOI 10.1016/j.ecoenv.2022.113596
   Ziadlou R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060932
NR 55
TC 7
Z9 7
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2024
VL 28
IS 14
AR e18569
DI 10.1111/jcmm.18569
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA ZV6H0
UT WOS:001278095800001
PM 39072972
OA gold
DA 2025 08 17
ER

PT J
AU Dey, N
   Barwick, BG
   Moreno, CS
   Ordanic Kodani, M
   Chen, ZJ
   Oprea Ilies, G
   Tang, WN
   Catzavelos, C
   Kerstann, KF
   Sledge, GW
   Abramovitz, M
   Bouzyk, M
   De, P
   Leyland Jones, BR
AF Dey, Nandini
   Barwick, Benjamin G.
   Moreno, Carlos S.
   Ordanic Kodani, Maja
   Chen, Zhengjia
   Oprea Ilies, Gabriella
   Tang, Weining
   Catzavelos, Charles
   Kerstann, Kimberly F.
   Sledge, George W., Jr.
   Abramovitz, Mark
   Bouzyk, Mark
   De, Pradip
   Leyland Jones, Brian R.
TI Wnt signaling in triple negative breast cancer is associated with
   metastasis
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Triple negative; Wnt; FFPE; Microarray
ID GENE EXPRESSION SIGNATURE; T CELL FACTOR; BETA CATENIN; MESENCHYMAL
   TRANSITION; REGULATES EXPRESSION; ANDROGEN RECEPTOR; BASAL; SUBTYPES;
   TARGET; BONE
AB Background: Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal like subtype (with limited discordance) is an aggressive form of the disease which convey unpredictable, and poor prognosis due to limited treatment options and lack of proven effective targeted therapies.
   Methods: We conducted an expression study of 240 formalin fixed, paraffin embedded (FFPE) primary biopsies from two cohorts, including 130 TN tumors, to identify molecular mechanisms of TN disease.
   Results: The annotation of differentially expressed genes in TN tumors contained an overrepresentation of canonical Wnt signaling components in our cohort and others. These observations were supported by upregulation of experimentally induced oncogenic Wnt/beta catenin genes in TN tumors, recapitulated using targets induced by Wnt3A. A functional blockade of Wnt/beta catenin pathway by either a pharmacological Wnt antagonist, WntC59, sulidac sulfide, or beta catenin (functional read out of Wnt/beta catenin pathway) SiRNA mediated genetic manipulation demonstrated that a functional perturbation of the pathway is causal to the metastasis  associated phenotypes including fibronectin directed migration, F actin organization, and invasion in TNBC cells. A classifier, trained on microarray data from beta catenin transfected mammary cells, identified a disproportionate number of TNBC breast tumors as compared to other breast cancer subtypes in a meta analysis of 11 studies and 1,878 breast cancer patients, including the two cohorts published here. Patients identified by the Wnt/beta catenin classifier had a greater risk of lung and brain, but not bone metastases.
   Conclusion: These data implicate transcriptional Wnt signaling as a hallmark of TNBC disease associated with specific metastatic pathways.
C1 [Dey, Nandini; De, Pradip; Leyland Jones, Brian R.] Sanford Res, Edith Sanford Breast Canc, Sioux Falls, SD 57104 USA.
   [Dey, Nandini; De, Pradip; Leyland Jones, Brian R.] Univ S Dakota, Dept Internal Med, Vermillion, SD 57069 USA.
   [Bouzyk, Mark] AKESOgen Inc, Atlanta, GA 30071 USA.
   [Moreno, Carlos S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Barwick, Benjamin G.; Moreno, Carlos S.; Tang, Weining; Kerstann, Kimberly F.] Winship Canc Inst, Atlanta, GA 30322 USA.
   [Chen, Zhengjia] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30022 USA.
   [Catzavelos, Charles] McGill Univ, St Marys Hosp, Dept Pathol, Montreal, PQ H3A 1G5, Canada.
   [Sledge, George W., Jr.] Indiana Univ Canc Ctr, Indianapolis, IN 46202 USA.
   [Abramovitz, Mark] VM Inst Res, Montreal, PQ H3G 1L5, Canada.
   [Oprea Ilies, Gabriella] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
C3 Sanford Health; University of South Dakota; Emory University; Emory
   University; Rollins School Public Health; McGill University; Emory
   University
RP Leyland Jones, BR (通讯作者)，Sanford Res, Edith Sanford Breast Canc, 2301 E 60th St N, Sioux Falls, SD 57104 USA.
EM brian.leyland jones@sanfordhealth.org
RI Kerstann, Kimberly/MEP 7224 2025; Barwick, Benjamin/O 5185 2019; Moreno,
   Carlos/B 3863 2009
OI Barwick, Benjamin/0000 0001 9810 3566; Moreno,
   Carlos/0000 0002 5582 0028; 
FU Georgia Research Alliance; Winship Cancer Institute; NIH [R01 CA106826];
   Department of Defense Center of Excellence: "Center of Excellence for
   Individualization of Therapy for Breast Cancer" [W81XWH 04 1 0468]
FX The authors would like to acknowledge the Emory Biomarker Service Center
   for microarray analysis, and the Cell Imaging and Microscopy Core of
   Winship Cancer Institute of Emory University. We thank Dr. Yajun Mei of
   Georgia Institute of Technology for statistical advice. We thank Dr.
   Kevin Ward for providing SEER registry information regarding
   pathological subtype for the Georgia cohort. We further acknowledge
   funding from the Georgia Research Alliance and Winship Cancer Institute.
   CSM was supported by NIH R01 CA106826. This work was supported by the
   Department of Defense Center of Excellence: "Center of Excellence for
   Individualization of Therapy for Breast Cancer" grant #W81XWH 04 1 0468.
CR Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122
   Abramovitz M, 2011, BRIT J CANCER, V105, P1574, DOI 10.1038/bjc.2011.355
   Abramovitz M, 2008, BIOTECHNIQUES, V44, P417, DOI 10.2144/000112703
   Ben Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100
   Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Boon EMJ, 2002, CANCER RES, V62, P5126
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002 9440(10)65204 2
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Carey LA, 2011, ONCOLOGIST, V16, P71, DOI 10.1634/theoncologist.2011 S1 71
   Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693
   Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073
   Craig DW, 2013, MOL CANCER THER, V12, P104, DOI 10.1158/1535 7163.MCT 12 0781
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   DEY N, 2013, PLOS ONE IN PRESS
   Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008 5472.CAN 07 1182
   Dey N, 2007, MOL CELL BIOL, V27, P4179, DOI 10.1128/MCB.01352 06
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008 5472.CAN 08 4135
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159 8290.CD 12 0462
   Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504
   Gerin I, 2009, J BIOL CHEM, V284, P10755, DOI 10.1074/jbc.M809115200
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Han AJ, 2008, EUR J PHARMACOL, V583, P26, DOI 10.1016/j.ejphar.2007.12.034
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008 5472.CAN 08 3441
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 5 r76
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 258
   Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078 0432.CCR 09 0317
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008 5472.CAN 05 4414
   Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kurahashi T, 2005, MOL BIOL CELL, V16, P4705, DOI 10.1091/mbc.E05 05 0470
   Lee HJ, 2009, ANGEW CHEM INT EDIT, V48, P6448, DOI 10.1002/anie.200902981
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008 5472.CAN 04 1992
   Lu WY, 2009, EUR J PHARMACOL, V602, P8, DOI 10.1016/j.ejphar.2008.10.053
   Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603
   Marchiò C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423
   Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456 005 5612 9
   Melchor L, 2007, CLIN CANCER RES, V13, P7305, DOI 10.1158/1078 0432.CCR 07 0711
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   Moulder SL, 2010, CLIN BREAST CANCER, V10, pS66, DOI 10.3816/CBC.2010.s.014
   Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Peddi PF, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/217185
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106
   Reimers M, 2006, METHOD ENZYMOL, V411, P119, DOI 10.1016/S0076 6879(06)11008 3
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 539
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008 5472.CAN 07 5644
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vashisht S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049401
   Wang PS, 2009, J SURG RES, V153, P210, DOI 10.1016/j.jss.2008.05.032
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140 6736(05)17947 1
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002 9440(10)65297 2
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471 213X 2 8
   Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469
   Zhang T, 2001, CANCER RES, V61, P8664
NR 76
TC 211
Z9 242
U1 0
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 10
PY 2013
VL 13
AR 537
DI 10.1186/1471 2407 13 537
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AC0ST
UT WOS:000332205800002
PM 24209998
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dong, HZ
   Tang, F
   Zhao, ZL
   Huang, WX
   Wan, XY
   Hong, ZY
   Liu, Y
   Dong, X
   Chen, S
AF Dong, Huizhong
   Tang, Fen
   Zhao, Zilu
   Huang, Wenxuan
   Wan, Xiangyang
   Hong, Zhanying
   Liu, Ying
   Dong, Xin
   Chen, Si
TI The Bioactive Compounds of Epimedium and Their Potential
   Mechanism of Action in Treating Osteoporosis: A Network Pharmacology and
   Experimental Validation Study
SO PHARMACEUTICALS
LA English
DT Article
DE osteoporosis; Epimedium; 2 '' O RhamnosylIcariside II; network
   pharmacology; HIF 1 alpha
ID HYPOXIA INDUCIBLE FACTOR; OSTEOBLAST DIFFERENTIATION
AB Osteoporosis is a global health challenge characterized by bone loss and microstructure deterioration, which urgently requires the development of safer and more effective treatments due to the significant adverse effects and limitations of existing drugs for long term treatment. Traditional Chinese medicine, like Epimedium, offers fewer side effects and has been used to treat osteoporosis, yet its active compounds and pharmacological mechanisms remain unclear. In this study, 65 potential active compounds, 258 potential target proteins, and 488 pathways of Epimedium were identified through network pharmacology analysis. Further network analysis and review of the literature identified six potential active compounds and HIF 1 alpha for subsequent experimental validation. In vitro experiments confirmed that 2 '' O RhamnosylIcariside II is the most effective compound among the six potential active compounds. It can promote osteoblast differentiation, bind with HIF 1 alpha, and inhibit both HIF 1 alpha gene and protein expression, as well as enhance COL1A1 protein expression under hypoxic conditions. In vivo experiments demonstrated its ability to improve bone microstructures and reduce bone loss by decreasing bone marrow adipose tissue, enhancing bone formation, and suppressing HIF 1 alpha protein expression. This study is the first to describe the therapeutic effects of 2 O RhamnosylIcariside II on osteoporosis, which was done, specifically, through a mechanism that targets and inhibits HIF 1 alpha. This study provides a scientific basis for the clinical application of Epimedium and offers a new candidate drug for the treatment of osteoporosis. Additionally, it provides new evidence supporting HIF 1 alpha as a therapeutic target for osteoporosis.
C1 [Dong, Huizhong; Tang, Fen; Zhao, Zilu; Huang, Wenxuan; Wan, Xiangyang; Dong, Xin; Chen, Si] Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.
   [Hong, Zhanying] Naval Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
   [Liu, Ying] Shanghai Univ, Inst Translat Med, 99 Shangda Rd, Shanghai 200444, Peoples R China.
C3 Shanghai University; Naval Medical University; Shanghai University
RP Dong, X; Chen, S (通讯作者)，Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.
EM liuchanger1984@163.com; dongxin@shu.edu.cn; sisichen@shu.edu.cn
RI Hong, Zhanying/AAQ 6770 2021; Huizhong, Dong/KRP 2364 2024
FU Fund of Shanghai Sailing Program [20YF1414300]
FX This research was funded by the fund of Shanghai Sailing Program
   (20YF1414300).
CR Beekman KM, 2019, BONE, V118, P62, DOI 10.1016/j.bone.2017.10.011
   Chen DF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052948
   Chen WG, 2019, CLIN EXP METASTAS, V36, P39, DOI 10.1007/s10585 018 9951 5
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Frey JL, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.5
   Fujimoto H, 1999, J BONE MINER METAB, V17, P211, DOI 10.1007/s007740050087
   Gao SG, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 105
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   [郭宝林 Guo Baolin], 2003, [中国中药杂志, China Journal of Chinese Materia Medica], V28, P303
   Guo CJ, 2019, PHARMACOL RES, V149, DOI 10.1016/j.phrs.2019.104463
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Knowles HJ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 78003 z
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Li D, 2012, OSTEOARTHR CARTILAGE, V20, P1647, DOI 10.1016/j.joca.2012.08.009
   Li LY, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03162 w
   Li SJ, 2018, J COMPUT ASSIST TOMO, V42, P588, DOI [10.1097/RCT.0000000000000725, 10.1097/rct.0000000000000725]
   LIU F, 1994, DEV BIOL, V166, P220, DOI 10.1006/dbio.1994.1309
   Liu ZQ, 2022, J PHARM PHARMACOL, V74, P919, DOI 10.1093/jpp/rgac024
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Mason JB, 2010, EXP GERONTOL, V45, P435, DOI 10.1016/j.exger.2010.03.010
   Meng XY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00189 x
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Morita M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165922
   Nakajima K, 2014, NEOPLASIA, V16, P939, DOI 10.1016/j.neo.2014.09.005
   Qiao S, 2023, INT IMMUNOPHARMACOL, V124, DOI 10.1016/j.intimp.2023.110954
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Shieh A, 2016, J BONE MINER RES, V31, P2057, DOI 10.1002/jbmr.2889
   Tang YX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.770344
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tian YY, 2022, ORAL DIS, V28, P428, DOI 10.1111/odi.13745
   Tsai KC, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111037
   Wang Jianping, 2023, Int J Environ Res Public Health, V20, DOI 10.3390/ijerph20043129
   Wang ML, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0533 1
   Wang XH, 2022, FREE RADICAL RES, V56, P143, DOI 10.1080/10715762.2022.2037581
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wang ZQ, 2004, EUR J PHARMACOL, V504, P147, DOI 10.1016/j.ejphar.2004.10.002
   Warbrick I, 2019, OBES REV, V20, P701, DOI 10.1111/obr.12828
   Wojdasiewicz P, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25042117
   Wu Y, 2017, MOL CELL ENDOCRINOL, V452, P84, DOI 10.1016/j.mce.2017.05.017
   Xu HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12743
   Yan CQ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175538
   Yang YX, 2018, REPROD TOXICOL, V78, P1, DOI 10.1016/j.reprotox.2018.02.010
   Zeng CY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.927126
   Zhang XB, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1286718
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhuo Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.901545
   Zou YQ, 2024, MED RES REV, V44, P539, DOI 10.1002/med.21989
NR 52
TC 0
Z9 1
U1 11
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD JUN
PY 2024
VL 17
IS 6
AR 706
DI 10.3390/ph17060706
PG 24
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WV5U2
UT WOS:001257668800001
PM 38931373
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Santos, MD
   Lima, VTM
   Barrioni, BR
   Vago, JP
   de Arruda, JAA
   Prazeres, PD
   Amaral, FA
   Silva, TA
   Macari, S
AF Santos, Mariana de S.
   Lima, Virginia T. M.
   Barrioni, Breno R.
   Vago, Juliana P.
   de Arruda, Jose Alcides A.
   Prazeres, Pedro D.
   Amaral, Flavio A.
   Silva, Tarcilia A.
   Macari, Soraia
TI Targeting phosphatidylinositol 3 kinase for inhibiting maxillary bone
   resorption
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone remodeling; maxilla; orthodontic tooth movement;
   phosphatidylinositol 3 kinase
ID PERIODONTAL LIGAMENT; PI3K; PATHWAY; DIFFERENTIATION; PI3K GAMMA;
   3 KINASE; PROLIFERATION; INFLAMMATION; OSTEOBLAST; ESTROGEN
AB Previous studies have suggested a role of phosphatidylinositol 3 kinase gamma (PI3K gamma) in bone remodeling, but the mechanism remains undefined. Here, we explored the contribution of PI3K gamma in the resorption of maxillary bone and dental roots using models of orthodontic tooth movement (OTM), orthodontic induced inflammatory root resorption, and rapid maxillary expansion (RME). PI3K gamma deficient mice (PI3K gamma( / )), mice with loss of PI3K gamma kinase activity (PI3K gamma(KD/KD)) and C57BL/6 mice treated with a PI3K gamma inhibitor (AS605240) and respective controls were used. The maxillary bones of PI3K gamma( / ), PI3K gamma(KD/KD), and C57BL/6 mice treated with AS605240 showed an improvement of bone quality compared to their controls, resulting in reduction of the OTM and RME in all experimental groups. PI3K gamma( / ) mice exhibited increased root volume and decreased odontoclasts counts. Consistently, the pharmacological blockade or genetic deletion of PI3K resulted in increased numbers of osteoblasts and reduction in osteoclasts during OTM. There was an augmented expression of Runt related transcription factor 2 (Runx2) and alkaline phosphatase (Alp), a reduction of interleukin 6 (Il 6), as well as a lack of responsiveness of receptor activator of nuclear factor kappa Beta (Rank) in PI3K gamma( / ) and PI3K gamma(KD/KD) mice compared to control mice. The maxillary bones of PI3K gamma( / ) animals showed reduced p Akt expression. In vitro, bone marrow cells treated with AS605240 and cells from PI3K gamma( / ) mice exhibited significant augment of osteoblast mineralization and less osteoclast differentiation. The PI3K gamma/Akt axis is pivotal for bone remodeling by providing negative and positive signals for the differentiation of osteoclasts and osteoblasts, respectively.
C1 [Santos, Mariana de S.; Vago, Juliana P.; Amaral, Flavio A.; Macari, Soraia] Univ Fed Minas Gerais, Biol Sci Inst, Dept Morphol, Belo Horizonte, MG, Brazil.
   [Lima, Virginia T. M.; Macari, Soraia] Univ Fed Minas Gerais, Fac Dent, Dept Restorat Dent, Belo Horizonte, MG, Brazil.
   [Barrioni, Breno R.] Univ Fed Minas Gerais, Dept Met & Mat Engn, Fac Engn, Belo Horizonte, MG, Brazil.
   [de Arruda, Jose Alcides A.; Silva, Tarcilia A.] Univ Fed Minas Gerais, Fac Dent, Dept Oral Surg Pathol & Clin Dent, Belo Horizonte, MG, Brazil.
   [Prazeres, Pedro D.] Univ Fed Minas Gerais, Biol Sci Inst, Dept Pathol, Belo Horizonte, MG, Brazil.
   [Amaral, Flavio A.] Univ Fed Minas Gerais, Biol Sci Inst, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
   [Macari, Soraia] Univ Fed Minas Gerais, Fac Odontol, Dept Odontol Restauradora, Av Presidente Antonio Carlos 6627, BR 31270901 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais; Universidade Federal de
   Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal
   de Minas Gerais; Universidade Federal de Minas Gerais
RP Macari, S (通讯作者)，Univ Fed Minas Gerais, Fac Odontol, Dept Odontol Restauradora, Av Presidente Antonio Carlos 6627, BR 31270901 Belo Horizonte, MG, Brazil.
EM soraiamacari@gmail.com
RI Macari, Soraia/AAQ 3356 2020; DA SILVA, JULIANA/F 7386 2019; Santos,
   Mariana/KYQ 3721 2024; Barrioni, Breno/H 4769 2018; Amaral,
   Flavio/D 5489 2014; Amaral, Flávio/C 3768 2018; Rocha Barrioni,
   Breno/H 4769 2018; da Silva, Tarcília/O 7530 2015; Vago, Juliana
   Priscila/F 7386 2019; Silva, Tarcilia/O 7530 2015
OI Prazeres, Pedro/0000 0002 1933 3230; Amaral, Flavio/0000 0002 1695 0612;
   Rocha Barrioni, Breno/0000 0002 8681 6451; de Arruda, Jose Alcides
   Almeida/0000 0002 6599 3950; Vago, Juliana Priscila/0000 0001 8188 3738;
   Silva, Tarcilia/0000 0001 9623 7835
FU We would like to thank Dr. Fernando Q. Cunha (University of So Paulo,
   Brazil) for donating the PI3Kgamma inhibitor (AS605240, Echelon) and
   Beatriz M. Szawka for the schematic diagram. This study was partially
   supported by Coordena [AS605240, 001]
FX We would like to thank Dr. Fernando Q. Cunha (University of S & atilde;o
   Paulo, Brazil) for donating the PI3K gamma inhibitor (AS605240, Echelon)
   and Beatriz M. Szawka for the schematic diagram. This study was
   partially supported by Coordenac & atilde;o de Aperfeicoamento de
   Pessoal de Nivel Superior (Finance Code 001), Brazil. M.S.S. and
   J.A.A.A. are recipients of fellowships. T.A.S. is a research fellow of
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil.
CR Guerrero JA, 2020, J BIOMECH, V108, DOI 10.1016/j.jbiomech.2020.109880
   Alluri R, 2020, EXCLI J, V19, P71, DOI 10.17179/excli2019 1997
   Amaro ERS, 2020, ARCH ORAL BIOL, V117, DOI 10.1016/j.archoralbio.2020.104820
   Bilanges B, 2019, NAT REV MOL CELL BIO, V20, P515, DOI 10.1038/s41580 019 0129 z
   Buchanan CM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090402
   Burke JE, 2023, NAT REV DRUG DISCOV, V22, P357, DOI 10.1038/s41573 022 00582 5
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Deng ZN, 2014, ARCH ORAL BIOL, V59, P1032, DOI 10.1016/j.archoralbio.2014.04.012
   Fantauzzo KA, 2014, GENE DEV, V28, P1005, DOI 10.1101/gad.238709.114
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092 8674(00)81883 8
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Galvao I, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01505
   Gámez B, 2016, J BONE MINER RES, V31, P1617, DOI 10.1002/jbmr.2819
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Gong XY, 2023, J BONE MINER RES, V38, P214, DOI 10.1002/jbmr.4744
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Han YY, 2018, DRUG DES DEV THER, V12, P137, DOI 10.2147/DDDT.S148457
   Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049
   Kang H, 2010, P NATL ACAD SCI USA, V107, P12901, DOI 10.1073/pnas.1001499107
   Ke K, 2016, SCI REP UK, V6, DOI 10.1038/srep35233
   Kong WB, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312673
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Lee KH, 2020, LAB ANIM RES, V36, DOI 10.1186/s42826 020 00078 6
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li HB, 2020, CHEM BIOL DRUG DES, V95, P451, DOI 10.1111/cbdd.13659
   Ma J, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12955
   Macari S, 2016, J DENT RES, V95, P689, DOI 10.1177/0022034516633154
   Macari S, 2018, BONE, V110, P160, DOI 10.1016/j.bone.2018.01.032
   Macari S, 2015, ARCH ORAL BIOL, V60, P333, DOI 10.1016/j.archoralbio.2014.11.010
   Madeddu P, 2008, ARTERIOSCL THROM VAS, V28, P68, DOI 10.1161/ATVBAHA.107.145573
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Mishra R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073464
   Montalvany Antonucci CC, 2019, BONE, V125, P112, DOI 10.1016/j.bone.2019.05.016
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Mullard A, 2023, NAT REV DRUG DISCOV, V22, P342, DOI 10.1038/d41573 023 00061 5
   Nürnberg B, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090427
   Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017
   Pereira LJ, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115496
   Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036
   Shim NY, 2022, ORAL DIS, V28, P1628, DOI 10.1111/odi.13829
   Stark AK, 2015, CURR OPIN PHARMACOL, V23, P82, DOI 10.1016/j.coph.2015.05.017
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Tavares LD, 2019, J LEUKOCYTE BIOL, V106, P619, DOI 10.1002/JLB.MA1118 470RR
   Ulici V, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 40
   Uto Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189893
   Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Wang LN, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903 022 02364 2
   Wang YY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12800
   Watabe H, 2011, EXP CELL RES, V317, P2642, DOI 10.1016/j.yexcr.2011.07.015
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xu YH, 2017, CELL BIOCHEM FUNCT, V35, P372, DOI 10.1002/cbf.3284
   Yang C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1168 2
   Ye YS, 2021, J PERIODONTOL, V92, P1470, DOI 10.1002/JPER.20 0675
NR 57
TC 1
Z9 1
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2023
VL 238
IS 11
BP 2651
EP 2667
DI 10.1002/jcp.31121
EA OCT 2023
PG 17
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA Y1BH7
UT WOS:001081309600001
PM 37814842
DA 2025 08 17
ER

PT J
AU Gacanin, J
   Kovtun, A
   Fischer, S
   Schwager, V
   Quambusch, J
   Kuan, SL
   Liu, WN
   Boldt, F
   Li, C
   Yang, ZQ
   Liu, DS
   Wu, YZ
   Weil, T
   Barth, H
   Ignatius, A
AF Gacanin, Jasmina
   Kovtun, Anna
   Fischer, Stephan
   Schwager, Victoria
   Quambusch, Johanna
   Kuan, Seah Ling
   Liu, Weina
   Boldt, Felix
   Li, Chuang
   Yang, Zhongqiang
   Liu, Dongsheng
   Wu, Yuzhou
   Weil, Tanja
   Barth, Holger
   Ignatius, Anita
TI Spatiotemporally Controlled Release of Rho Inhibiting C3 Toxin from a
   Protein DNA Hybrid Hydrogel for Targeted Inhibition of Osteoclast
   Formation and Activity
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE clostridial Rho inhibiting C3 toxin; hydrogels; osteoblasts; osteoclasts
ID RECOMBINANT HUMAN DNASE; DRUG DELIVERY; PROPHYLACTIC VERTEBROPLASTY;
   ADP RIBOSYLTRANSFERASE; BONE; OSTEOPOROSIS; GROWTH; CELLS; RESORPTION;
   MATRIGEL
AB In osteoporosis, bone structure can be improved by the introduction of therapeutic molecules inhibiting bone resorption by osteoclasts. Here, biocompatible hydrogels represent an excellent option for the delivery of pharmacologically active molecules to the bone tissue because of their biodegradability, injectability, and manifold functionalization capacity. The present study reports the preparation of a multifunctional hybrid hydrogel from chemically modified human serum albumin and rationally designed DNA building blocks. The hybrid hydrogel combines advantageous characteristics, including rapid gelation through DNA hybridization under physiological conditions and a self healing and injectable nature with the possibility of specific loading and spatiotemporally controlled release of active proteins, making it an advanced biomaterial for the local treatment of bone diseases, for example, osteoporosis. The hydrogels are loaded with a recombinant Rho inhibiting C3 toxin, C2IN C3lim G205C. This toxin selectively targets osteoclasts and inhibits Rho signaling and, thereby, actin dependent processes in these cells. Application of C2IN C3lim G205C toxin loaded hydrogels effectively reduces osteoclast formation and resorption activity in vitro, as demonstrated by tartrate resistant acid phosphatase staining and the pit resorption assay. Simultaneously, osteoblast activity, viability, and proliferation are unaffected, thus making C2IN C3lim G205C toxin loaded hybrid hydrogels an attractive pharmacological system for spatial and selective modulation of osteoclast functions to reduce bone resorption.
C1 [Gacanin, Jasmina; Quambusch, Johanna; Liu, Weina; Boldt, Felix; Wu, Yuzhou; Weil, Tanja] Univ Ulm, Inst Organ Chem 3, D 89081 Ulm, Germany.
   [Kovtun, Anna; Ignatius, Anita] Univ Ulm, Trauma Res Ctr, Inst Orthoped Res & Biomech, D 89081 Ulm, Germany.
   [Fischer, Stephan; Schwager, Victoria; Barth, Holger] Univ Ulm, Inst Pharmacol & Toxicol, D 89081 Ulm, Germany.
   [Quambusch, Johanna; Kuan, Seah Ling; Wu, Yuzhou; Weil, Tanja] Max Planck Inst Polymer Res, D 55128 Mainz, Germany.
   [Li, Chuang; Yang, Zhongqiang; Liu, Dongsheng] Tsinghua Univ, Minist Educ, Key Lab Organ Optoelect & Mol Engn, Dept Chem, Beijing 100084, Peoples R China.
   [Wu, Yuzhou] Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Wuhan 430074, Hubei, Peoples R China.
C3 Ulm University; Ulm University; Ulm University; Max Planck Society;
   Tsinghua University; Huazhong University of Science & Technology
RP Wu, YZ (通讯作者)，Univ Ulm, Inst Organ Chem 3, D 89081 Ulm, Germany.; Ignatius, A (通讯作者)，Univ Ulm, Trauma Res Ctr, Inst Orthoped Res & Biomech, D 89081 Ulm, Germany.; Barth, H (通讯作者)，Univ Ulm, Inst Pharmacol & Toxicol, D 89081 Ulm, Germany.; Wu, YZ (通讯作者)，Max Planck Inst Polymer Res, D 55128 Mainz, Germany.; Wu, YZ (通讯作者)，Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Wuhan 430074, Hubei, Peoples R China.
EM wuyuzhou@hust.edu.cn; holger.barth@uni ulm.de; anita.ignatius@uni ulm.de
RI liu, dongsheng/IWM 1597 2023; Ignatius, Anita/M 6012 2013; Vikman,
   Anna/F 1115 2017; li, chuang/HNT 0863 2023; Yang,
   Zhongqiang/AFO 1666 2022; Kuan, Seah/M 1095 2013; Gačanin,
   Jasmina/S 5007 2017; Wu, Yuzhou/I 9123 2014
OI Vikman, Anna/0000 0001 8531 9712; 
FU Baden Wurttemberg Stiftung [BioMatS 15]; Horizon project "AD GUT"
   [686271]; German Research Foundation (DFG) [CRC1149, INST 40/491 1, INST
   40/482 1]; National Natural Science Foundation of China [21534007]
FX J. G. and A. K. contributed equally to this work. The authors are
   grateful for the excellent support in the synthesis of several
   intermediates of the hydrogels to Nora Hartner, Dr. Matthias Arzt, and
   Magdalene Zimmermann and for the help with cell culture experiments to
   Iris Baum. The study was funded by the Baden Wurttemberg Stiftung
   (BioMatS 15), by the Horizon 2020 project "AD GUT" (No. 686271), and by
   the German Research Foundation (DFG) in the framework of the
   Collaborative Research Center CRC1149 (INST 40/491 1, INST 40/482 1) as
   well as the National Natural Science Foundation of China (No. 21534007).
CR AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363
   Alcázar Leyva S, 2009, MED SCI MONITOR, V15, pCR51
   Aquarius R, 2014, MED ENG PHYS, V36, P944, DOI 10.1016/j.medengphy.2014.03.009
   Asafo Adjei TA, 2016, CURR OSTEOPOROS REP, V14, P226, DOI 10.1007/s11914 016 0321 4
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364 1369.1998
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Burdick JA, 2002, J CONTROL RELEASE, V83, P53, DOI 10.1016/S0168 3659(02)00181 5
   Buza JA, 2016, CLIN CASES MINER BON, V13, P101, DOI 10.11138/ccmbm/2016.13.2.101
   Chiang CK, 2009, SPINE, V34, P356, DOI 10.1097/BRS.0b013e31819481b1
   Clarke SA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600947
   Davis JC Jr, 1999, LUPUS, V8, P68, DOI 10.1191/096120399678847380
   de Oliveira D, 2017, J APPL ORAL SCI, V25, P42
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Eisele K, 2010, BIOMATERIALS, V31, P8789, DOI 10.1016/j.biomaterials.2010.07.088
   Fahrer J, 2010, CELL MICROBIOL, V12, P233, DOI 10.1111/j.1462 5822.2009.01393.x
   Fliri L, 2013, J BIOMATER APPL, V28, P136, DOI 10.1177/0885328212443274
   FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003
   Gao Y, 2009, J CONTROL RELEASE, V139, P15, DOI 10.1016/j.jconrel.2009.05.032
   Hughes CS, 2010, PROTEOMICS, V10, P1886, DOI 10.1002/pmic.200900758
   Ito T, 2012, J MATER SCI MATER M, V23, P1291, DOI 10.1007/s10856 012 4597 3
   JOHNSON AJ, 1954, J CLIN INVEST, V33, P1670, DOI 10.1172/JCI103048
   JUST I, 1992, J BIOL CHEM, V267, P10274
   Karlsson J, 2016, J BIOMED MATER RES A, V104, P620, DOI 10.1002/jbm.a.35602
   Kettenberger U., 2015, J TISSUE ENG REGEN M, V11, P1974
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Liedert A, 2006, BIOCHEM BIOPH RES CO, V342, P1070, DOI 10.1016/j.bbrc.2006.02.063
   Lutter AH, 2010, J CELL BIOCHEM, V109, P1025, DOI 10.1002/jcb.22485
   Maycas M, 2017, J CELL PHYSIOL, V232, P3611, DOI 10.1002/jcp.25829
   Miller PD, 2008, BEST PRACT RES CL EN, V22, P849, DOI 10.1016/j.beem.2008.07.004
   Ng DYW, 2014, ACCOUNTS CHEM RES, V47, P3471, DOI 10.1021/ar5002445
   Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Rohrbeck A, 2014, N S ARCH PHARMACOL, V387, P523, DOI 10.1007/s00210 014 0963 7
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   Suh JKF, 2000, BIOMATERIALS, V21, P2589
   Tautzenberger A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085695
   Vogelsgesang M, 2007, N S ARCH PHARMACOL, V374, P347, DOI 10.1007/s00210 006 0113 y
   Wu YZ, 2014, CHEM COMMUN, V50, P14620, DOI 10.1039/c4cc07144a
   Wu YZ, 2013, ADV HEALTHC MATER, V2, P884, DOI 10.1002/adhm.201200296
   Wu YZ, 2012, SMALL, V8, P3465, DOI 10.1002/smll.201200409
   Wu YZ, 2012, BIOMACROMOLECULES, V13, P1890, DOI 10.1021/bm300418r
   Wu YZ, 2010, J AM CHEM SOC, V132, P5012, DOI 10.1021/ja909570v
NR 44
TC 53
Z9 56
U1 2
U2 127
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD NOV 8
PY 2017
VL 6
IS 21
AR 1700392
DI 10.1002/adhm.201700392
PG 12
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA FP3UV
UT WOS:000417544400011
PM 28758712
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Martínez Reina, J
   Calvo Gallego, JL
   Pivonka, P
AF Martinez Reina, Javier
   Luis Calvo Gallego, Jose
   Pivonka, Peter
TI Are drug holidays a safe option in treatment of osteoporosis?   Insights
   from an in silico mechanistic PK PD model of denosumab treatment of
   postmenopausal osteoporosis
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Postmenopausal osteoporosis; Denosumab; RANK RANKL OPG pathway; PK PD
   modelling; Bone fragility; Drug holidays
ID ATYPICAL FEMORAL FRACTURES; CANCELLOUS BONE; COMPACT BONE;
   BISPHOSPHONATES; PHARMACODYNAMICS; MINERALIZATION; MICROCRACKS;
   RESORPTION; TURNOVER; THERAPY
AB Recent reviews by the clinical bone research community suggest caution with prescription of drug holidays for patients with postmenopausal osteoporosis (PMO) treated with denosumab for an extended period of time. Main reasons for this suggestion are based on the fact that discontinuation of denosumab treatment leads to a relapse of osteoclastic bone resorption and a loss of bone mineral density (BMD) to pre treatment levels at only 12 28 months. The question remains what is the best treatment option for cases where it is required to discontinue and/or reduce the drug dose and what are the consequences on BMD and bone turnover markers (BTMs). The latter questions are difficult to be addressed using clinical trials alone given the large number of parameter combinations involved to answer this problem.
   In this paper, we apply a recently developed in silico mechanistic pharmacokinetic pharmacodynamic (PK  PD) model of the effect of denosumab on bone remodelling in PMO. To address the above clinical relevant questions, we design a wide range of current and virtual treatment regimens to study the effect of drug holiday duration and therapy resumption on the evolution of BTMs, BMD and mineral content. Our numerical simulation results indicate the symptomatic effect of denosumab, which is lost once treatment is stopped. This effect is most clearly seen on rapid loss of BMD to pre treatment levels 12 months after the last injection (8% and 3.6% per year in the lumbar spine and femoral neck, respectively). Also, we identify that independently of the duration of drug holiday (i.e. 12, 16 or 18 months) resuming treatment can restore BMD quite effectively. However, the latter result does not consider the possibility of potential fractures that can occur during the drug holiday. Finally, we identify a treatment case most promising for achieving maintenance of BMD and mineral content, while moderately increasing BTMs. The latter case uses no drug holiday, but reduces the most commonly prescribed denosumab dose (60 mg every 6 months) by half at same interval.
C1 [Martinez Reina, Javier; Luis Calvo Gallego, Jose] Univ Seville, Dept Ingn Mecan & Fabricac, Seville 41092, Spain.
   [Pivonka, Peter] Queensland Univ Technol, Sch Mech Med & Proc Engn, Brisbane, Qld 4000, Australia.
C3 University of Sevilla; Queensland University of Technology (QUT)
RP Martínez Reina, J (通讯作者)，Univ Seville, Dept Ingn Mecan & Fabricat, Escuela Tecn Super Ingn, Camino Descubrimientos S N, Seville 41092, Spain.
EM jmreina@us.es
RI Martinez Reina, Javier/K 2806 2014; Pivonka, Peter/AAL 1053 2021;
   Martínez Reina, Javier/K 2806 2014; Calvo Gallego, Jose
   Luis/L 6118 2014; Calvo Gallego, Jose/L 6118 2014
OI Martinez Reina, Javier/0000 0003 2038 2336; Pivonka,
   Peter/0000 0001 9183 530X; Calvo Gallego, Jose Luis/0000 0002 3407 1582;
   
FU Ministerio de Ciencia e Innovacion of the Spanish Governmenent
   [PID2019 106969R]
FX The authors gratefully acknowledge the research support from the
   Ministerio de Ciencia e Innovacion of the Spanish Governmenent through
   the research project PID2019 106969R entitled Modelos de Remodelacion
   Osea y su Aplicacion para Simular el Efecto de Tratamientos
   Antireabsortivos contra la Osteoporosis Postmenopausica. All authors
   approved the version of the manuscript to be published.
CR Anagnostis P, 2017, MATURITAS, V101, P23, DOI 10.1016/j.maturitas.2017.04.008
   Bala Y, 2013, OSTEOPOROSIS INT, V24, P2153, DOI 10.1007/s00198 012 2228 y
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyce TM, 1998, J ORTHOP RES, V16, P322, DOI 10.1002/jor.1100160308
   Chapurlat R, 2018, JOINT BONE SPINE, V85, P515, DOI 10.1016/j.jbspin.2017.12.013
   Currey JD, 2004, J BIOMECH, V37, P549, DOI 10.1016/j.jbiomech.2003.08.008
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frost H. M., 1963, BONE REMODELING DYNA
   Hernandez CJ, 2000, J REHABIL RES DEV, V37, P235
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Martelli S, 2014, CLIN BIOMECH, V29, P869, DOI 10.1016/j.clinbiomech.2014.08.001
   MARTIN RB, 1984, CRIT REV BIOMED ENG, V10, P179
   Martínez Reina J, 2008, J THEOR BIOL, V254, P704, DOI 10.1016/j.jtbi.2008.06.007
   Martínez Reina J, 2009, BIOMECH MODEL MECHAN, V8, P111, DOI 10.1007/s10237 008 0122 5
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Need AG, 2007, J BONE MINER RES, V22, P757, DOI [10.1359/jbmr.070203, 10.1359/JBMR.070203]
   O'Brien FJ, 2000, J ANAT, V197, P413, DOI 10.1046/j.1469 7580.2000.19730413.x
   Parfitt A.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P143
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Qiu SJ, 2005, BONE, V37, P10, DOI 10.1016/j.bone.2005.01.023
   Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
NR 40
TC 12
Z9 12
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751 6161
EI 1878 0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD JAN
PY 2021
VL 113
AR 104140
DI 10.1016/j.jmbbm.2020.104140
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA PG3QI
UT WOS:000599653000005
PM 33080564
DA 2025 08 17
ER

PT J
AU Patel, N
   Nizami, S
   Song, L
   Mikami, M
   Hsu, A
   Hickernell, T
   Chandhanayingyong, C
   Rho, S
   Compton, JT
   Caldwell, JM
   Kaiser, PB
   Bai, HY
   Lee, HG
   Fischer, CR
   Lee, FY
AF Patel, Neel
   Nizami, Saqib
   Song, Lee
   Mikami, Maya
   Hsu, Anny
   Hickernell, Thomas
   Chandhanayingyong, Chandhanarat
   Rho, Shim
   Compton, Jocelyn T.
   Caldwell, Jon Michael
   Kaiser, Philip B.
   Bai, Hanying
   Lee, Heon Goo
   Fischer, Charla R.
   Lee, Francis Y.
TI CA 074Me compound inhibits osteoclastogenesis via suppression of the
   NFATc1 and c FOS signaling pathways
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE Osteoclasts; CA 074Me; c Fos; NFATc1; RANKL
ID KAPPA B LIGAND; MESENCHYMAL STEM CELLS; CATHEPSIN B; RECEPTOR ACTIVATOR;
   BONE RESORPTION; OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION;
   NUCLEAR FACTOR; INFLAMMATORY RESPONSE; LYSOSOMAL CYSTEINE
AB The osteoclast is an integral cell of bone resorption. Since osteolytic disorders hinge on the function and dysfunction of the osteoclast, understanding osteoclast biology is fundamental to designing new therapies that curb osteolytic disorders. The identification and study of lysosomal proteases, such as cathepsins, have shed light on mechanisms of bone resorption. For example, Cathepsin K has already been identified as a collagen degradation protease produced by mature osteoclasts with high activity in the acidic osteoclast resorption pits. Delving into the mechanisms of cathepsins and other osteoclast related compounds provides new targets to explore in osteoclast biology. Through our anti osteoclastogenic compound screening experiments we encountered a modified version of the Cathepsin B inhibitor CA 074: the cell membrane permeable CA 074Me (L 3 trans (Propylcarbamoyl) oxirane 2 carbonyl] L isoleucyl L proline Methyl Ester). Here we confirm that CA 074Me inhibits osteoclastogenesis in vivo and in vitro in a dose dependent manner. However, Cathepsin B knockout mice exhibited unaltered osteoclastogenesis, suggesting a more complicated mechanism of action than Cathepsin B inhibition. We found that CA 074Me exerts its osteoclastogenic effect within 24h of osteoclastogenesis stimulation by suppression of c FOS and NFATc1 pathways. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:1474 1486, 2015.
C1 [Patel, Neel; Nizami, Saqib; Song, Lee; Mikami, Maya; Hsu, Anny; Hickernell, Thomas; Chandhanayingyong, Chandhanarat; Rho, Shim; Compton, Jocelyn T.; Caldwell, Jon Michael; Kaiser, Philip B.; Bai, Hanying; Lee, Heon Goo; Fischer, Charla R.; Lee, Francis Y.] Columbia Univ, Dept Orthopaed Surg, New York, NY 10032 USA.
   [Mikami, Maya] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA.
   [Compton, Jocelyn T.; Kaiser, Philip B.] Columbia Univ, Dept Med, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University
RP Lee, FY (通讯作者)，Columbia Univ, Dept Orthopaed Surg, 650 West 168th St BB14 1412, New York, NY 10032 USA.
EM fl127@columbia.edu
RI ; Hickernell, Thomas/ABG 2642 2021; Patel, Neel/HSB 4075 2023; Caldwell,
   Jon Michael/AAG 6503 2021; Chandhanayingyong, Chandhanarat/HKP 0360 2023
OI Compton, Jocelyn/0000 0003 3306 7706; Caldwell,
   Jon Michael/0000 0003 3767 5813; Hickernell, Thomas/0000 0003 0897 8487;
   
FU  [R01AR056246];  [R01EB006834]
FX Grant sponsor: F.Y.L; Grant numbers: R01AR056246, R01EB006834.
CR Aisa MC, 2003, BBA GEN SUBJECTS, V1621, P149, DOI 10.1016/S0304 4165(03)00054 0
   BAICI A, 1995, ANN RHEUM DIS, V54, P281, DOI 10.1136/ard.54.4.281
   Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074 5521(00)00061 2
   Bühling F, 2001, J PATHOL, V195, P375
   BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003 9861(92)90290 D
   Cavallo Medved D, 2003, CURR TOP DEV BIOL, V54, P313, DOI 10.1016/S0070 2153(03)54013 3
   Costantino CM, 2008, J IMMUNOL, V180, P2876, DOI 10.4049/jimmunol.180.5.2876
   Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092 8674(00)80571 1
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829
   Goto T, 2003, J ELECTRON MICROSC, V52, P551, DOI 10.1093/jmicro/52.6.551
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Gray AW, 2002, RES VET SCI, V72, P95, DOI 10.1053/rvsc.2001.0522
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Hsing LC, 2010, J AUTOIMMUN, V34, P96, DOI 10.1016/j.jaut.2009.07.003
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Kim MH, 2008, AMINO ACIDS, V34, P497, DOI 10.1007/s00726 006 0461 4
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Kwak HB, 2009, BIOL PHARM BULL, V32, P45, DOI 10.1248/bpb.32.45
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200
   Lee HG, 2013, AM J PHYSIOL CELL PH, V304, pC431, DOI 10.1152/ajpcell.00202.2012
   Lee HG, 2011, BIOMATERIALS, V32, P9197, DOI 10.1016/j.biomaterials.2011.08.059
   Linke M, 2002, J CELL SCI, V115, P4877, DOI 10.1242/jcs.00184
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Liu X, 2013, J CELL MOL MED, V17, P1160, DOI 10.1111/jcmm.12097
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   McMichael BK, 2009, J BIOL CHEM, V284, P12266, DOI 10.1074/jbc.M808621200
   Mihalik R, 2004, CELL DEATH DIFFER, V11, P1357, DOI 10.1038/sj.cdd.4401493
   Minematsu H, 2011, CELL SIGNAL, V23, P1785, DOI 10.1016/j.cellsig.2011.06.013
   Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147
   MUNDY GR, 1992, INT J CELL CLONING, V10, P215, DOI 10.1002/stem.5530100404
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Noh K, 2011, J BONE JOINT SURG AM, V93A, P723, DOI 10.2106/JBJS.J.00302
   Pang MH, 2005, BIOCHEM BIOPH RES CO, V328, P756, DOI 10.1016/j.bbrc.2004.12.005
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Rao A, 2009, NAT IMMUNOL, V10, P3, DOI 10.1038/ni0109 3
   Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20
   RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006 291X(91)91334 9
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Taguchi Y, 2009, GENES CELLS, V14, P1331, DOI 10.1111/j.1365 2443.2009.01351.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Taubert H, 2002, AUTOIMMUNITY, V35, P221, DOI 10.1080/08916930290031676
   Wang Y, 2013, J ORTHOP RES, V31, P1796, DOI 10.1002/jor.22427
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 52
TC 9
Z9 12
U1 0
U2 14
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD OCT
PY 2015
VL 33
IS 10
BP 1474
EP 1486
DI 10.1002/jor.22795
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA CQ4QN
UT WOS:000360589800009
PM 25428830
OA Bronze
DA 2025 08 17
ER

PT J
AU Soundharrajan, I
   Kim, DH
   Srisesharam, S
   Kuppusamy, P
   Sivanesan, R
   Choi, KC
AF Soundharrajan, Ilavenil
   Kim, Da Hye
   Srisesharam, Srigopalram
   Kuppusamy, Palaniselvam
   Sivanesan, Ravikumar
   Choi, Ki Choon
TI Limonene promotes osteoblast differentiation and 2 deoxy D glucose
   uptake through p38MAPK and Akt signaling pathways in C2C12 skeletal
   muscle cells
SO PHYTOMEDICINE
LA English
DT Article
DE Limonene; C2C12; Osteogenic induction; BMPs; p38MAPK
ID ACTIVATED PROTEIN KINASE; HIGH FAT DIET; INSULIN RESISTANCE; 3T3 L1
   ADIPOCYTES; GLUCOSE UPTAKE; BONE MASS; EXPRESSION; FUSION
AB Background: Limonene is a cyclic monoterpene (CTL) found in citrus fruits and many plant kingdoms. It has attracted attention as potential molecule due to its diverse biological activities. However, molecular mechanism involved in the osteogenic induction of CTL in C2C12 skeletal muscle cells remain unclear.
   Purpose: Skeletal development maintains the bone homeostasis through bone remodeling process. It coordinated between the osteoblast and osteoblast process. Osteoporosis is one of the most common bone diseases caused by a systemic reduction in bone mass. Recent osteoporosis treatment is based on the use of anti resorptive and bone forming drugs. However, long term use of these drugs is associated with serious side effects and strategies on the discovery of lead compounds from natural products for osteoblast differentiation are urgently needed. Therefore, we planned to find out the role of CTL on osteoblast differentiation and glucose uptake in C2C12 cells and its effect on signaling pathways.
   Methods: Cell proliferation, alkaline phosphatase (ALP) activity, calcium deposition, genes, and proteins associated with osteoblast activation and glucose utilization were analysed.
   Results: CTL did not affect the cell viability. CTL significantly increased ALP activity, calcium depositions and the expression of osteogenic specific genes such as Myogenin, Myogenic differentiation 1 (MyoD), ALP, Run related transcription factor 2(RUNX2), osteocalcin (OCN). In addition, CTL induced the mRNA expression of bone morphogenetic proteins (BMP 2 BMP 4 BMP 6 BMP 7 BMP 9). CTL treatment enhanced 2 Deoxy D glucose (2DG) uptake. Moreover, CTL stimulated the activation of p38 mitogen activated protein kinase (p38MAPK), Protein kinase B (Akt), Extracellular signal related kinase (ERKs) by increasing phosphorylation. CTL treatment abolished p38 inhibitor (SB203580) mediated inhibition of osteoblast differentiation, but no effect was noted by ERKs specific inhibitor (PD98059).
   Conclusion: These results suggest that limonene induces osteoblast differentiation and glucose uptake through activating p38MAPK and Akt signaling pathways, confirming the molecular basis of the osteoblast differentiation by limonene in C2C12 skeletal muscle cells.
C1 [Soundharrajan, Ilavenil; Srisesharam, Srigopalram; Kuppusamy, Palaniselvam; Choi, Ki Choon] Rural Dev Adm, Natl Inst Anim Sci, Grassland & Forage Div, Cheonan 31000, South Korea.
   [Kim, Da Hye] Tohoku Univ, Grad Sch Agr Sci, Physiol Anim Lab, Aoba Ku, Sendai, Miyagi 9808577, Japan.
   [Sivanesan, Ravikumar] Rajah Serfoji Govt Arts Coll, Dept Zool, Thanjavur 613204, India.
C3 Rural Development Administration (RDA), Republic of Korea; National
   Institute of Animal Science, Republic of Korea; Tohoku University
RP Choi, KC (通讯作者)，Rural Dev Adm, Natl Inst Anim Sci, Grassland & Forage Div, Cheonan 31000, South Korea.
EM choiwh@korea.kr
RI ; Sivanesan, Ravikumar/IUQ 5278 2023; Soundharrajan,
   Ilavenil/ABD 6774 2021
OI Sivanesan, Ravikumar/0000 0002 2305 8788; Soundharrajan,
   Ilavenil/0000 0002 7854 5954
FU Cooperative Research Program for Agriculture Science & Technology
   Development Project   RDA, Korea [PJ010903022016]; Postdoctoral
   Fellowship Program of National Institute of Animal Science   RDA, Korea
FX This research work was supported by Cooperative Research Program for
   Agriculture Science & Technology Development Project (Project No.
   PJ010903022016) entitled "Technical development to increase utilization
   of Italian ryegrass in livestock" funded by RDA, Korea. This study was
   also supported by Postdoctoral Fellowship Program of National Institute
   of Animal Science funded by RDA, Korea.
CR Alkhateeb H, 2010, AM J PHYSIOL REG I, V299, pR804, DOI 10.1152/ajpregu.00216.2010
   Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959 437X(00)00215 X
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Choi KC, 2003, ENDOCRINOLOGY, V144, P754, DOI 10.1210/en.2002 220783
   Dedieu S, 2002, INT J DEV BIOL, V46, P235
   Doherty JT, 2011, J BIOL CHEM, V286, P25903, DOI 10.1074/jbc.M111.243030
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Ilavenil S, 2016, MOLECULES, V21, DOI 10.3390/molecules21080997
   Jang HO, 2007, NAT PROD RES, V21, P787, DOI 10.1080/14786410601133475
   Jing L, 2013, EUR J PHARMACOL, V715, P46, DOI 10.1016/j.ejphar.2013.06.022
   Kamatou GPP, 2013, PHYTOCHEMISTRY, V96, P15, DOI 10.1016/j.phytochem.2013.08.005
   Kawai M, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 62
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim BS, 2011, BIOSCI BIOTECH BIOCH, V75, P13, DOI 10.1271/bbb.100379
   Kim HJ, 2010, AMINO ACIDS, V39, P1217, DOI 10.1007/s00726 010 0557 8
   Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372
   ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036
   Santiago JVA, 2012, EUR J NUTR, V51, P57, DOI 10.1007/s00394 011 0182 7
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Tan XC, 2016, FOOD CHEM, V196, P242, DOI 10.1016/j.foodchem.2015.09.042
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Vinciguerra M, 2010, ADV EXP MED BIOL, V694, P211
   Xu WP, 2004, CELL BIOL INT, V28, P675, DOI 10.1016/j.cellbi.2004.06.004
   Ye G, 2014, INT J MED SCI, V11, P1065, DOI 10.7150/ijms.8473
   Yu SF, 2013, J BONE MINER METAB, V31, P351, DOI 10.1007/s00774 013 0424 2
NR 31
TC 26
Z9 26
U1 0
U2 42
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944 7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUN 1
PY 2018
VL 45
BP 41
EP 48
DI 10.1016/j.phymed.2018.03.019
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GI5DX
UT WOS:000434392300006
PM 29573911
DA 2025 08 17
ER

PT J
AU Chandra, A
   Lan, SH
   Zhu, J
   Lin, T
   Zhang, XR
   Siclari, VA
   Altman, AR
   Cengel, KA
   Liu, XS
   Qin, L
AF Chandra, Abhishek
   Lan, Shenghui
   Zhu, Ji
   Lin, Tiao
   Zhang, Xianrong
   Siclari, Valerie A.
   Altman, Allison R.
   Cengel, Keith A.
   Liu, X. Sherry
   Qin, Ling
TI PTH prevents the adverse effects of focal radiation on bone architecture
   in young rats
SO BONE
LA English
DT Article
DE Radiation therapy; mu CT; PTH; Trabecular bone; Osteoblasts
ID PARATHYROID HORMONE 1 34; MARROW MICROENVIRONMENT; IONIZING RADIATION;
   CORTICAL BONE; IN VIVO; IRRADIATION; OSTEOBLASTS; EXPRESSION; PROTEIN;
   CELLS
AB Radiation therapy is a common treatment regimen for cancer patients. However, its adverse effects on the neighboring bone could lead to fractures with a great impact on quality of life. The underlying mechanism is still elusive and there is no preventive or curative solution for this bone loss. Parathyroid hormone (PTH) is a current therapy for osteoporosis that has potent anabolic effects on bone. In this study, we found that focal radiation from frequent scans of the right tibiae in 1 month old rats by micro computed tomography severely decreased trabecular bone mass and deteriorated bone structure. Interestingly, PTH daily injections remarkably improved trabecular bone in the radiated tibiae with increases in trabecular number, thickness, connectivity, structure model index and stiffness, and a decrease in trabecular separation. Histomorphometric analysis revealed that radiation mainly decreased the number of osteoblasts and impaired their mineralization activity but had little effects on osteoclasts. PTH reversed these adverse effects and greatly increased bone formation to a similar level in both radiated and non radiated bones. Furthermore, PTH protects bone marrow mesenchymal stem cells from radiation induced damage, including a decrease in number and an increase in adipogenic differentiation. While radiation generated the same amount of free radicals in the bone marrow of vehicle treated and PTH treated animals, the percentage of apoptotic bone marrow cells was significantly attenuated in the PTH group. Taken together, our data demonstrate a radioprotective effect of PTH on bone structure and bone marrow and shed new light on a possible clinical application of anabolic treatment in radiotherapy. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Chandra, Abhishek; Lan, Shenghui; Zhu, Ji; Lin, Tiao; Zhang, Xianrong; Siclari, Valerie A.; Altman, Allison R.; Liu, X. Sherry; Qin, Ling] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
   [Cengel, Keith A.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Qin, L (通讯作者)，424D Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM abhic@mail.med.upenn.edu; ocean.blue7@qq.com; zhuji@mail.med.upenn.edu;
   lintiao11@163.com; xianrongzh@yahoo.com; vsiclari@mail.med.upenn.edu;
   alaltman@mail.med.upenn.edu; keith.cengel@uphs.upenn.edu;
   xiaoweil@mail.med.upenn.edu; qinling@mail.med.upenn.edu
RI ; Liu, Xiaowei/H 1664 2017; Chandra, Abhishek/AAG 8781 2020; qin,
   ling/KIB 1029 2024; Liu, Xiaowei Sherry/H 1664 2017
OI Lan, Shenghui/0009 0000 2790 2205; Chandra,
   Abhishek/0000 0001 9423 9669; Liu, Xiaowei Sherry/0000 0001 7247 2232
FU Penn Center for Musculoskeletal Disorders (NIAMS/NIH) [P30AR050950];
   National Cancer Institute [R25 CA101871 07]
FX We thank Dr. Laurie McCauley at the University of Michigan for her
   critical comments on the manuscript. This study was supported in part by
   pilot grant (to LQ) from Penn Center for Musculoskeletal Disorders
   P30AR050950 (NIAMS/NIH) and grant R25 CA101871 07 from the National
   Cancer Institute (to VS).
CR Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Andrews EB, 2012, J BONE MINER RES, P18
   Bauer G, 2007, INT J RADIAT BIOL, V83, P873, DOI 10.1080/09553000701727523
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bellido T, 2012, BONE, V24, P01245
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cannon CP, 2008, J AM ACAD ORTHOP SUR, V16, P541
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02 0752rev
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Damek Poprawa M, 2013, OR SURG OR MED OR PA, V115, P201, DOI 10.1016/j.oooo.2012.09.008
   DAWSON W B, 1968, Clinical Radiology, V19, P241, DOI 10.1016/S0009 9260(68)80001 7
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Elliott SP, 2011, CANCER AM CANCER SOC, V117, P4557, DOI 10.1002/cncr.25994
   ERGUN H, 1980, CRC CR REV DIAGN IM, V12, P225
   FERMOR B, 1995, J BONE MINER RES, V10, P1935
   File Elizabeth, 2009, Curr Rheumatol Rep, V11, P169
   FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   Green DE, 2012, J BONE MINER RES, V27, P749, DOI 10.1002/jbmr.1505
   Hall EJ., 2000, RADIOBIOLOGY RADIOLO
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo 125 4 2022
   HOWLAND WJ, 1975, RADIOLOGY, V117, P677, DOI 10.1148/117.3.677
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jimenez C, 2005, J BONE MINER RES, V20, P1562, DOI 10.1359/JBMR.050507
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756 3282(03)00061 9
   Koh AJ, 2011, ENDOCRINOLOGY, V152, P4525, DOI 10.1210/en.2011 1515
   Kondo H, 2010, J APPL PHYSIOL, V108, P152, DOI 10.1152/japplphysiol.00294.2009
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   MAEDA M, 1988, J BONE JOINT SURG AM, V70A, P392, DOI 10.2106/00004623 198870030 00011
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   MILLER CW, 1978, J BONE JOINT SURG AM, V60, P930, DOI 10.2106/00004623 197860070 00010
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   OVERGAARD M, 1988, ACTA ONCOL, V27, P117, DOI 10.3109/02841868809090331
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park SI, 2012, ENDOCR RELAT CANCER, V19, P243, DOI 10.1530/ERC 11 0278
   Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127
   PIERCE SM, 1992, INT J RADIAT ONCOL, V23, P915, DOI 10.1016/0360 3016(92)90895 O
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Qin L, 2012, TOPICS BONE BIOL, P1
   Recker RR, 2009, BONE, V44, P113, DOI 10.1016/j.bone.2008.09.019
   Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472 6750 5 12
   ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo 123 1 187
   Sawajiri M, 2003, RADIAT ENVIRON BIOPH, V42, P219, DOI 10.1007/s00411 003 0204 9
   Stokes IAF, 2006, J ORTHOP RES, V24, P1327, DOI 10.1002/jor.20189
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   SUGIMOTO M, 1991, J BONE JOINT SURG BR, V73, P492, DOI 10.1302/0301 620X.73B3.1670456
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tashjian AH, 2002, J BONE MINER RES, V17, P1151, DOI 10.1359/jbmr.2002.17.7.1151
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002 9343(97)00270 2
   Wernle JD, 2010, J BIOMECH, V43, P2738, DOI 10.1016/j.jbiomech.2010.06.017
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
NR 62
TC 42
Z9 46
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2013
VL 55
IS 2
BP 449
EP 457
DI 10.1016/j.bone.2013.02.023
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 171AK
UT WOS:000320896600026
PM 23466454
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, YM
   Yang, Y
   Hua, ZY
   Li, S
   Yang, ZY
   Liu, QZ
   Fu, G
   Ji, P
   Wu, QQ
AF Xu, Yamei
   Yang, Yao
   Hua, Ziyi
   Li, Shuang
   Yang, Zhenyu
   Liu, Qianzi
   Fu, Gang
   Ji, Ping
   Wu, Qingqing
TI BMP2 immune complexes promote new bone formation by facilitating the
   direct contact between osteoclasts and osteoblasts
SO BIOMATERIALS
LA English
DT Article
DE BMP2; Immune complex; Osteoclastogenesis; Osteoblast osteoclast
   communication; Bone tissue engineering
ID MEDIATED OSSEOUS REGENERATION; MESENCHYMAL STEM CELLS; MORPHOGENETIC
   PROTEIN 2; MONOCLONAL ANTIBODIES; RECEPTOR ACTIVATOR; DIFFERENTIATION;
   EXPRESSION; CULTURES; PROFILE; FUSION
AB BMP2 antibody is proposed as a promising replacement for rhBMP2 in bone tissue engineering. Although studies have demonstrated its osteoinductive efficacy, the underlying osteogenic mechanism and adverse reactions of specific BMP2 antibody are not clarified yet, making it difficult to optimize the antibody for future application. By establishing BMP2 immune complexes (BMP2 ICs) ex vivo, we were able to introduce BMP2 ICs directly in vivo and found that BMP2 ICs promoted bone formation while suppressing osteoclastogenesis. However, ex vivo osteoclastogenic assays showed that BMP2 ICs promoted osteoclastogenesis by binding Fc gamma R and activating PLC gamma 2 phosphorylation. Given that BMP2 ICs react with osteoblast and osteoclast lineage cells by the conjugated BMP2 domain and the Fc domain respectively, we introduced BMP2 ICs into coculture system of the two lineage cells and found that BMP2 ICs promoted osteogenesis while suppressing osteoclastogenesis by facilitating osteoblast osteoclast contact and activating the EphrinB2 EphB4 signaling. This bidirectional function of BMP2ICs was reproduced in the cranial bone resorption model, where osteoblast and osteoclast lineage cells colocalized. This study excluded the hidden problem of osteoclast overactivation that usually comes with rhBMP2 and clarified the first evidence of the mechanism of antibody mediated bone regeneration, suggesting BMP2 ICs may present a promising therapy for bone diseases related with disrupted osteoclast osteoblast interaction.
C1 [Xu, Yamei; Yang, Yao; Hua, Ziyi; Li, Shuang; Yang, Zhenyu; Liu, Qianzi; Fu, Gang; Ji, Ping; Wu, Qingqing] Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing 401147, Peoples R China.
   [Fu, Gang; Wu, Qingqing] Chongqing Med Univ, Stomatol Hosp, Dept Oral Implantol, Chongqing 401147, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Fu, G; Wu, QQ (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing 401147, Peoples R China.
EM 501190@hospital.cqmu.edu.cn
RI Xu, Yamei/AFP 5605 2022
FU National Natural Science Foundation of China [81900978]; Natural Science
   Foundation of Chongqing, China [cstc2019jcyj msxmX0185]; China
   Postdoctoral Science Foundation [2020M683639XB]; Chongqing Postdoctoral
   Science Special Foundation
FX This study was supported by National Natural Science Foundation of China
   No. 81900978, Natural Science Foundation of Chongqing, China No.
   cstc2019jcyj msxmX0247, China Postdoctoral Science Foundation
   No.2020M683639XB, Natural Science Foundation of Chongqing, China No.
   cstc2019jcyj msxmX0185, and Chongqing Postdoctoral Science Special
   Foundation. The funding sources had no involvement in the collection,
   analysis and interpretation of data; in the writing of the report; or in
   the decision to submit the article for publication.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Alkan SS, 2004, NAT REV IMMUNOL, V4, P153, DOI 10.1038/nri1265
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Ansari S, 2013, BIOMATERIALS, V34, P10191, DOI 10.1016/j.biomaterials.2013.08.069
   Broege A, 2013, J BIOL CHEM, V288, P37230, DOI 10.1074/jbc.M113.496950
   Burkus JK, 2006, SPINE, V31, P775, DOI 10.1097/01.brs.0000206357.88287.5a
   Burkus JK, 2002, SPINE, V27, P2396, DOI 10.1097/00007632 200211010 00015
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Fong D, 2013, CELL SIGNAL, V25, P717, DOI 10.1016/j.cellsig.2012.12.003
   Freire M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/628769
   Freire MO, 2013, TISSUE ENG PT A, V19, P1165, DOI [10.1089/ten.tea.2012.0282, 10.1089/ten.TEA.2012.0282]
   Freire MO, 2011, TISSUE ENG PT A, V17, P2911, DOI 10.1089/ten.tea.2010.0584
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Granholm S, 2013, BONE, V52, P83, DOI 10.1016/j.bone.2012.09.019
   Grevers LC, 2013, ANN RHEUM DIS, V72, P278, DOI 10.1136/annrheumdis 2012 201568
   Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hwang CJ, 2009, J NEUROSURG SPINE, V10, P443, DOI 10.3171/2009.1.SPINE08473
   Ishikawa H, 2007, ACTA ORTHOP, V78, P285, DOI 10.1080/17453670710013816
   Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
   Jensen ED, 2010, J CELL BIOCHEM, V109, P672, DOI 10.1002/jcb.22462
   Jimi E, 1996, ENDOCRINOLOGY, V137, P2187
   KANATANI M, 1995, J BONE MINER RES, V10, P1681, DOI 10.1002/jbmr.5650101110
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715
   Lee CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120051
   Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200
   Luginbuehl V, 2004, EUR J PHARM BIOPHARM, V58, P197, DOI 10.1016/j.ejpb.2004.03.004
   Man Y, 2012, BIOMATERIALS, V33, P8802, DOI 10.1016/j.biomaterials.2012.08.054
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Moshaverinia A, 2013, BIOMATERIALS, V34, P6572, DOI 10.1016/j.biomaterials.2013.05.048
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   Razzouk Sleiman, 2012, N Y State Dent J, V78, P37
   Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905 1073
   Saltel F, 2006, J BONE MINER RES, V21, P1913, DOI 10.1359/JBMR.060821
   Scherer HU, 2010, ARTHRITIS RHEUM US, V62, P1620, DOI 10.1002/art.27414
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Tachi K, 2010, CELL TISSUE RES, V342, P213, DOI 10.1007/s00441 010 1052 y
   Tasca A, 2015, J CELL BIOCHEM, V116, P1350, DOI 10.1002/jcb.25092
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wu QQ, 2020, ACTA BIOMATER, V114, P221, DOI 10.1016/j.actbio.2020.07.055
   Wu QQ, 2018, ACTA BIOMATER, V74, P222, DOI 10.1016/j.actbio.2018.05.028
   Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhu C, 2011, J MATER SCI MATER M, V22, P1965, DOI 10.1007/s10856 011 4376 6
NR 53
TC 30
Z9 33
U1 4
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2021
VL 275
AR 120890
DI 10.1016/j.biomaterials.2021.120890
EA JUN 2021
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA TU8VM
UT WOS:000681308700001
PM 34130144
DA 2025 08 17
ER

PT J
AU Hadjicharalambous, C
   Alpantaki, K
   Chatzinikolaidou, M
AF Hadjicharalambous, Chrystalleni
   Alpantaki, Kalliopi
   Chatzinikolaidou, Maria
TI Effects of NSAIDs on pre osteoblast viability and osteogenic
   differentiation
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE non steroidal anti inflammatory drugs; prednisolone; cell viability;
   osteogenic differentiation
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACETAMINOPHEN PARACETAMOL;
   MOLECULAR MECHANISMS; BONE FORMATION; IN VITRO; GLUCOCORTICOIDS;
   CYCLOOXYGENASE 2; PROLIFERATION; INHIBITION; EXPRESSION
AB Non steroidal anti inflammatory drugs (NSAIDs) are widely used in the treatment of a variety of musculoskeletal conditions, injuries and after surgery for postoperative pain management. Their use has been associated with impaired bone healing, possibly due to a multifactorial function, which may include inhibition of osteoblast recruitment and differentiation. However, up to date, there is no consensus regarding the impact of NSAIDs on bone healing. The aim of the current study was to investigate the effects of five NSAIDs on the cellular functions of mouse MC3T3 E1 pre osteoblasts. Cells were treated with the non selective COX inhibitors lornoxicam and diclofenac, the COX 2 selective inhibitors parecoxib, meloxicam and paracetamol, as well as steroidal prednisolone at different doses and exposure times. The PrestoBlue (TM) technique was used to measure cell viability, an enzymatic assay was employed for alkaline phosphatase (ALP) activity and alizarin red S mineral staining was used to determine osteogenic differentiation. All drugs had a negative impact on pre osteoblast cell growth, with the exception of paracetamol. Lornoxicam, diclofenac and meloxicam reduced ALP activity, while the other NSAIDs had no effect and prednisolone strongly increased ALP activity. In contrast, calcium deposits were either unaffected or increased by NSAID treatments but were significantly decreased by prednisolone. These results provide evidence that NSAIDs may adversely affect the viability of mouse pre osteoblast cells but their actions on the osteogenic differentiation are drug specific. The direct comparison of the effects of different NSAIDs and prednisolone on pre osteoblasts may serve to place some NSAIDs in a preferential position for analgesic and anti inflammatory therapy during bone repair.
C1 [Hadjicharalambous, Chrystalleni; Chatzinikolaidou, Maria] Univ Crete, Dept Mat Sci & Technol, Voutes Univ Campus, Iraklion 70013, Greece.
   [Hadjicharalambous, Chrystalleni] Univ Crete, Dept Chem, Voutes Univ Campus, Iraklion 70013, Greece.
   [Alpantaki, Kalliopi] Venizele Gen Hosp Heraklion, Dept Orthoped & Trauma, Iraklion 71409, Greece.
   [Chatzinikolaidou, Maria] Fdn Res & Technol Hellas FORTH, Inst Elect Struct & Laser IESL, Iraklion 70013, Greece.
C3 University of Crete; University of Crete
RP Chatzinikolaidou, M (通讯作者)，Univ Crete, Dept Mat Sci & Technol, Voutes Univ Campus, Iraklion 70013, Greece.
EM chad@uoc.gr; mchatzin@materials.uoc.gr
RI Chatzinikolaidou, Maria/H 1061 2014
OI Chatzinikolaidou, Maria/0000 0002 2749 2506
CR Arpornmaeklong P, 2008, INT J ORAL MAX IMPL, V23, P1071
   Asirvatham S, 2019, ARAB J CHEM, V12, P3948, DOI 10.1016/j.arabjc.2016.03.002
   Barry S, 2010, VET COMP ORTHOPAED, V23, P385, DOI 10.3415/VCOT 10 01 0017
   Beck Alexander, 2005, Oper Orthop Traumatol, V17, P569, DOI 10.1007/s00064 005 1152 0
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Costela Ruiz VJ, 2019, INT J MED SCI, V16, P1466, DOI 10.7150/ijms.37857
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Darnis D., 2014, ENLIV ENPHARMACOVIGI, V1
   De Luna Bertos E, 2013, SCI WORLD J, DOI 10.1155/2013/809891
   Díaz Rodríguez L, 2012, J BONE MINER METAB, V30, P554, DOI 10.1007/s00774 012 0356 2
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Evans CE, 2004, J BONE JOINT SURG BR, V86B, P444, DOI 10.1302/0301 620X.86B3.14592
   Feng YY, 2016, J MOL ENDOCRINOL, V56, P189, DOI 10.1530/JME 15 0264
   García Martínez O, 2015, LIFE SCI, V123, P72, DOI 10.1016/j.lfs.2015.01.009
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Geusens P, 2013, CURR OPIN RHEUMATOL, V25, P524, DOI 10.1097/BOR.0b013e32836200b8
   Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787 013 0172 x
   Gunaydin C, 2018, EURASIAN J MED, V50, P116, DOI 10.5152/eurasianjmed.2018.0010
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Hadjicharalambous C, 2016, J PHARM PHARMACOL, V68, P1403, DOI 10.1111/jphp.12595
   Hadjicharalambous C, 2015, J BIOMED MATER RES A, V103, P3834, DOI 10.1002/jbm.a.35527
   Hadjicharalambous C, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/2/025012
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Herbenick Michael A, 2008, Am J Orthop (Belle Mead NJ), V37, pE133
   Hinz B, 2008, FASEB J, V22, P383, DOI 10.1096/fj.07 8506com
   Hong D, 2008, J STEROID BIOCHEM, V111, P164, DOI 10.1016/j.jsbmb.2008.06.015
   Jain NX, 2014, J MUSCULOSKEL NEURON, V14, P78
   Manzano Moreno FJ, 2018, ARCH ORAL BIOL, V92, P75, DOI 10.1016/j.archoralbio.2018.05.006
   Kidd LJ, 2013, J ORTHOP RES, V31, P235, DOI 10.1002/jor.22203
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   Kotake S, 2010, PHARMACEUTICALS, V3, P1394, DOI 10.3390/ph3051394
   Lisowska B, 2018, DRUG DES DEV THER, V12, P1809, DOI 10.2147/DDDT.S164565
   Marquez Lara A, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.O.00055
   Melguizo Rodríguez L, 2018, PEERJ, V6, DOI 10.7717/peerj.5415
   Michaelidou AS, 2005, CHEM REV, V105, P3235, DOI 10.1021/cr040708m
   Mitra R, 2011, PM&R, V3, P466, DOI 10.1016/j.pmrj.2011.02.017
   Nagano A, 2017, J PHARMACOL SCI, V133, P18, DOI 10.1016/j.jphs.2016.11.003
   Nakatsu Y, 2018, PHARMACOL REP, V70, P29, DOI 10.1016/j.pharep.2017.07.006
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Paget S, 2002, ANN RHEUM DIS, V61, P1, DOI 10.1136/ard.61.1.1 a
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Schwarting T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/926369
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
NR 50
TC 7
Z9 9
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUL
PY 2021
VL 22
IS 1
AR 740
DI 10.3892/etm.2021.10172
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA SG8DQ
UT WOS:000653669700001
PM 34046094
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fujita, S
   Mukai, T
   Mito, T
   Kodama, S
   Nagasu, A
   Kittaka, M
   Sone, T
   Ueki, Y
   Morita, Y
AF Fujita, Shunichi
   Mukai, Tomoyuki
   Mito, Takafumi
   Kodama, Shoko
   Nagasu, Akiko
   Kittaka, Mizuho
   Sone, Teruki
   Ueki, Yasuyoshi
   Morita, Yoshitaka
TI Pharmacological inhibition of tankyrase induces bone loss in mice by
   increasing osteoclastogenesis
SO BONE
LA English
DT Article
DE Tankyrase; SH3BP2; Osteoclastogenesis; Osteoblastogenesis; Wnt
   inhibitor; Tankyrase inhibitor
ID SMALL MOLECULE INHIBITOR; PROTEIN 3BP2; CANCER; OSTEOBLAST; ABL;
   DESTRUCTION; OLAPARIB; PATHWAY; DRIVEN; CELLS
AB Tankyrase is a poly (ADP ribose) polymerase that leads to ubiquitination and degradation of target proteins. Since tankyrase inhibitors suppress the degradation of AXIN protein, a negative regulator of the canonical Wnt pathway, they effectively act as Wnt inhibitors. Small molecule tankyrase inhibitors are being investigated as drug candidates for cancer and fibrotic diseases, in which the Wnt pathways are aberrantly activated. Tankyrase is also reported to degrade the adaptor protein SH3BP2 (SH3 domain binding protein 2). We have previously shown that SH3BP2 gain of function mutation enhances receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis in murine bone marrow derived macrophages (BMMs). Although the interaction between tankyrase and SH3BP2 has been reported, it is not clear whether and how the inhibition of tankyrase affects bone cells and bone mass. Here, we have demonstrated that tankyrase inhibitors (IWR 1, XAV939, and G007 LK) enhanced RANKL induced osteoclast form'ation and function in murine BMMs and human peripheral blood mononuclear cells through the accumulation of SH3BP2, subsequent phosphorylation of SYK, and nuclear translocation of NFATcl. Tankyrase inhibitors also enhanced osteoblast differentiation and maturation, represented by increased expression of osteoblast associated genes accompanied by the accumulation of SH3BP2 protein and enhanced nuclear translocation of ABL, TAZ, and Runx2 in primary osteoblasts. Most importantly, pharmacological inhibition of tankyrase in mice significantly decreased tibia and lumbar vertebrae bone volumes in association with increased numbers of osteoclasts. Our findings uncover the role of tankyrase inhibition in bone cells and highlight the potential adverse effects of the inhibitor on bone. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Fujita, Shunichi; Mukai, Tomoyuki; Mito, Takafumi; Kodama, Shoko; Nagasu, Akiko; Morita, Yoshitaka] Kawasaki Med Sch, Dept Rheumatol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.
   [Kittaka, Mizuho; Ueki, Yasuyoshi] Univ Missouri, Sch Dent, Dept Oral & Craniofacial Sci, Kansas City, MO USA.
   [Sone, Teruki] Kawasaki Med Sch, Dept Nucl Med, Kurashiki, Okayama, Japan.
C3 Kawasaki Medical School; University of Missouri System; University of
   Missouri Kansas City; Kawasaki Medical School
RP Mukai, T (通讯作者)，Kawasaki Med Sch, Dept Rheumatol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.
EM mukait@med.kawasaki m.ac.jp
RI Mukai, Tomoyuki/AAP 5771 2021; Kittaka, Mizuho/AAT 7398 2021
OI Ueki, Yasuyoshi/0000 0002 8660 626X; Mukai,
   Tomoyuki/0000 0002 0103 1621; Kittaka, Mizuho/0000 0002 3626 1638; 
FU JSPS KAKENHI [15K09540]; KAWASAKI Foundation for Medical Science and
   Medical Welfare; Okayama Medical Foundation; Research Project Grants
   from Kawasaki Medical School [29G 004, 28B 46, 27B 60]; National
   Institute of Health [R01DE025870, R21AR070953]; Grants in Aid for
   Scientific Research [15K09540] Funding Source: KAKEN
FX We would like to thank Dr. Y. Matsumoto (Department of Medicine and
   Clinical Science, Okayama University Graduate School of Medicine,
   Dentistry and Pharmaceutical Sciences) for some critical suggestions and
   Dr. Y. Jyu (Department of Health and Sports Sciences, Kawasaki
   University of Medical Welfare) for assisting with micro CT analysis. We
   are grateful to H. Nakashima, N. Takemasa, N. Obara, Y. Mino, and T.
   Jinno for their technical assistance. We are also indebted to the staff
   at the Research center of Kawasaki Medical School. This work was
   supported by grants from JSPS KAKENHI (15K09540 to TM), The KAWASAKI
   Foundation for Medical Science and Medical Welfare (SF), The Okayama
   Medical Foundation (TM), Research Project Grants from Kawasaki Medical
   School (29G 004 to SF, 28B 46 to TM, and 27B 60 to YM), and the National
   Institute of Health (R01DE025870 and R21AR070953 to YU).
CR Arqués O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078 0432.CCR 14 3081
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chiang YJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002639
   Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074 7613(00)80657 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Distler A, 2013, ANN RHEUM DIS, V72, P1575, DOI 10.1136/annrheumdis 2012 202275
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Gunaydin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033740
   Hatani T, 2008, CURR MED CHEM, V15, P549
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ju YI, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 35
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P496, DOI 10.1038/nrrheum.2016.118
   Katoh M., 2017, INT J MOL MED
   Koek WNH, 2017, BONE, V95, P108, DOI 10.1016/j.bone.2016.11.010
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008 5472.CAN 12 4562
   Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470 2045(16)30376 X
   Lehtiö L, 2013, FEBS J, V280, P3576, DOI 10.1111/febs.12320
   Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045
   Levaot N, 2011, J CLIN INVEST, V121, P3244, DOI 10.1172/JCI45843
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   Matsumoto Y, 2016, J CLIN INVEST, V126, P4482, DOI 10.1172/JCI87802
   Mukai T, 2015, ARTHRITIS RHEUMATOL, V67, P656, DOI 10.1002/art.38975
   Mukai T, 2014, J BONE MINER RES, V29, P2618, DOI 10.1002/jbmr.2295
   Mukai T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105518
   Muramatsu Y, 2007, CANCER SCI, V98, P850, DOI 10.1111/j.1349 7006.2007.00462.x
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Papadaki ME, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S6
   Peters SB, 2017, BONE, V97, P54, DOI 10.1016/j.bone.2016.12.017
   Reichenberger EJ, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S5
   REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166
   Ren SY, 2013, P NATL ACAD SCI USA, V110, P1440, DOI 10.1073/pnas.1211179110
   Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450
   Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021
   Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484
   Tai D, 2015, ONCOLOGIST, V20, P1189, DOI 10.1634/theoncologist.2015 0057
   Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832
   Ueki Y, 2007, CELL, V128, P71, DOI 10.1016/j.cell.2006.10.047
   Ulsamer A, 2012, J BIOL CHEM, V287, P5164, DOI 10.1074/jbc.M111.322123
NR 40
TC 31
Z9 34
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2018
VL 106
BP 156
EP 166
DI 10.1016/j.bone.2017.10.017
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FP3XV
UT WOS:000417552200020
PM 29055830
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Wu, XH
   Zhao, KX
   Fang, XX
   Lu, F
   Zhang, WK
   Song, XT
   Chen, LH
   Sun, JC
   Chen, HX
AF Wu, Xinhui
   Zhao, Kangxian
   Fang, Xiaoxin
   Lu, Feng
   Zhang, Weikang
   Song, Xiaoting
   Chen, Lihua
   Sun, Jiacheng
   Chen, Haixiao
TI Inhibition of Lipopolysaccharide Induced Inflammatory Bone Loss by
   Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE saikosaponin D; osteoclastogenesis; NF kappa B; MAPKs; PI3K AKT; therapy
ID NF KAPPA B; OSTEOCLAST FORMATION; OSTEOBLAST DIFFERENTIATION; INDUCED
   OSTEOLYSIS; SIGNALING PATHWAY; NFATC1; LPS; OSTEOPOROSIS; ACTIVATION;
   MECHANISMS
AB Background: Osteolytic diseases such as osteoporosis are featured with accelerated osteoclast differentiation and strong bone resorption. Considering the complications and other limitations of current drug treatments, it is necessary to develop a safer and more reliable drug to deal with osteoclast related diseases. Saikosaponin D (SSD) is the active extract of Bupleurum, which has anti inflammation, anti tumor and liver protection functions. However, the role of SSD in regulating the differentiation and function of osteoclasts is not clear.
   Purpose: To explore whether SSD could prevent osteoclast differentiation and bone resorption induced by M CSF and RANKL, and further evaluate the potential therapeutic properties of SSD in LPS induced inflammatory bone loss mouse models.
   Methods: BMMs were cultured in complete medium stimulated by RANKL with different concentrations of SSD. TRAP staining, bone resorption determination, qRT PCR, immunofluorescence and Western blotting were performed. A mouse model of LPS induced calvarial bone loss was established and treated with different doses of SSD. The excised calvaria bones were used for TRAP staining, micro CT scan and histological analysis.
   Results: SSD inhibited the formation and bone resorption of osteoclasts induced by RANKL in vitro. SSD suppressed LPS induced inflammatory bone loss in vivo.
   Conclusion: SSD inhibited osteoclastogenesis and LPS induced osteolysis in mice both which served as a new potential agent for the treatment of osteoclast related conditions.
C1 [Wu, Xinhui; Zhao, Kangxian; Zhang, Weikang; Song, Xiaoting; Sun, Jiacheng; Chen, Haixiao] Wenzhou Med Univ, Wenzhou, Peoples R China.
   [Wu, Xinhui; Zhao, Kangxian; Zhang, Weikang; Song, Xiaoting; Sun, Jiacheng; Chen, Haixiao] Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp Zhejiang Prov, Linhai 317000, Peoples R China.
   [Fang, Xiaoxin; Lu, Feng] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China.
   [Fang, Xiaoxin; Lu, Feng; Chen, Haixiao] Zhejiang Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
   [Chen, Lihua] Wenzhou Med Univ, Enze Med Res Ctr, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Zhejiang
   University; Zhejiang University; Wenzhou Medical University
RP Chen, HX (通讯作者)，Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp Zhejiang Prov, Linhai 317000, Peoples R China.
EM drchx@126.com
RI ; Sun, Jiacheng/AAC 8242 2022; chen, lihua/AAU 1884 2020
OI Lu, Feng/0000 0002 5341 0746; 
FU Natural Science Foundation of Zhejiang Province [LY20H060006];
   Experimental Animal Science Project of Zhejiang Province [LGD19H310001]
FX The study was sponsored by Natural Science Foundation of Zhejiang
   Province (LY20H060006) and Experimental Animal Science Project of
   Zhejiang Province (LGD19H310001) .
CR Adapala NS, 2010, ANN NY ACAD SCI, V1192, P376, DOI 10.1111/j.1749 6632.2009.05346.x
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen YR, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420950593
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jung YY, 2008, J BIOL CHEM, V283, P23863, DOI 10.1074/jbc.M803072200
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim K, 2020, MOL CELLS, V43, P34, DOI 10.14348/molcells.2019.0232
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Lai MR, 2020, ONCOTARGETS THER, V13, P9465, DOI 10.2147/OTT.S263322
   Li PZ, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106288
   Lv LH, 2011, INFLAMMATION, V34, P620, DOI 10.1007/s10753 010 9271 7
   Ma ZZ, 2019, INFLAMM RES, V68, P157, DOI 10.1007/s00011 018 1209 9
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Peng JX, 2020, DRUG DES DEV THER, V14, P3435, DOI 10.2147/DDDT.S256867
   Qin TT, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.243
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Shao SY, 2019, J CELL PHYSIOL, V234, P12701, DOI 10.1002/jcp.27887
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Su J, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106181
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang D, 2021, EUR J PHARMACOL, V909, DOI 10.1016/j.ejphar.2021.174408
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang T, 2019, J CELL PHYSIOL, V234, P2719, DOI 10.1002/jcp.27087
NR 44
TC 18
Z9 20
U1 1
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 4741
EP 4757
DI 10.2147/DDDT.S334421
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XE0SU
UT WOS:000723108100002
PM 34848946
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Takarada, T
   Yoneda, Y
AF Takarada, Takeshi
   Yoneda, Yukio
TI Glutamate as a signal mediator in bone
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 80th Annual Meeting of the Japanese Pharmacological Society
CY MAR 14 16, 2007
CL Nagoya, JAPAN
SP Japanese Pharmacol Soc
DE glutamate; osteoblast; osteoclast; NMDA receptor; cystine/glutamate
   antiporter; bone metabolism
ID RAT CALVARIAL OSTEOBLASTS; D ASPARTATE RECEPTOR; OSTEOCLAST
   DIFFERENTIATION; FUNCTIONAL ANALYSIS; DENDRITIC CELLS; PLASMA MEMBRANE;
   EXPRESSION; TRANSPORTER; RESORPTION; CYSTINE
AB The view that L glutamate (Glu) is an excitatory amino acid nurotransmitter in the mammalian central nervous system is prevailing on the basis of successful cloning of a number of genes encoding different signaling molecules, such as Glu receptors for the signal input, Glu transporters for the signal termination and vesicular Glu transporters for the signal output through exocytotic release. Little attention has been paid to an extracellular transmitter role of Glu in peripheral neuronal and non neuronal tissues, by contrast, whereas recent molecular biological and pharmacological analyses including ours give rise to a novel function for Glu as an autocrine and/or paracrine signal mediator in bone comprised of osteoblasts, osteoclasts and osteocytes, in addition to other peripheral tissues including pancreas, adrenal and pituitary glands. Emerging evidence suggests that Glu could play a dual role in mechanisms underlying the maintenance of cellular homeostasis as an excitatory neurotransmitter in the central nervous system and as an extracellular signal mediator in peripheral autocrine and/or paracrine tissues. In this review, therefore, we would outline the possible signaling system for Glu to play a role as an extracellular signal mediator in mechanisms underlying maintenance of the cellular homeostasis in bone.
C1 [Takarada, Takeshi; Yoneda, Yukio] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
C3 Kanazawa University
RP Yoneda, Y (通讯作者)，Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
EM yyoneda@p.kanazawa u.ac.jp
RI ; Yoneda, Yukio/ABI 1864 2020
OI Yoneda, Yukio/0000 0002 4624 177X; Takarada, Takeshi/0000 0002 2363 7704
CR Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029
   Bai LQ, 2001, J BIOL CHEM, V276, P36764, DOI 10.1074/jbc.M104578200
   BANNAI S, 1986, J BIOL CHEM, V261, P2256
   Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957
   Bender AS, 2000, NEUROCHEM INT, V37, P269, DOI 10.1016/S0197 0186(00)00035 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BUKOWSKI DM, 1995, AM J PHYSIOL LUNG C, V268, pL21, DOI 10.1152/ajplung.1995.268.1.L21
   Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756 3282(97)00295 0
   Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301 0082(00)00067 8
   DUCY P, 2002, BIOCHEM BIOPH RES CO, V1504, P452
   FELIX R, 1990, J BONE MINER RES, V5, P781
   Gu Y, 2002, CALCIFIED TISSUE INT, V70, P194, DOI 10.1007/s00223 001 2004 z
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   HELLMANN M, 1989, NATURE, V342, P643
   Hinoi E, 2001, BIOCHEM BIOPH RES CO, V281, P341, DOI 10.1006/bbrc.2001.4355
   Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02 0820fje
   Hinoi E, 2002, BRAIN RES, V943, P112, DOI 10.1016/S0006 8993(02)02726 9
   Hinoi E, 2002, BIOCHEM BIOPH RES CO, V297, P452, DOI 10.1016/S0006 291X(02)02223 4
   Hinoi E, 2007, AM J PATHOL, V170, P1277, DOI 10.2353/ajpath.2007.061039
   Ho ML, 2005, OSTEOPOROSIS INT, V16, P1780, DOI 10.1007/s00198 005 1928 y
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335
   Itzstein C, 2001, J CELL BIOCHEM, V82, P134, DOI 10.1002/jcb.1114
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Mentaverri R, 2003, J CELL BIOCHEM, V88, P1145, DOI 10.1002/jcb.10463
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756 3282(98)00061 1
   Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179
   REYNOLDS IJ, 1988, MOL PHARMACOL, V33, P581
   Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455
   Schäfer MKH, 2002, J BIOL CHEM, V277, P50734, DOI 10.1074/jbc.M206738200
   STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955
   Takarada T, 2004, BIOCHEM PHARMACOL, V68, P177, DOI 10.1016/j.bcp.2004.03.020
   Takarada T, 2007, EUR J PHARMACOL, V575, P1, DOI 10.1016/j.ejphar.2007.07.041
   TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896 6273(92)90118 W
   Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959 4388(93)90120 N
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoneda Y, 2001, PROG NEUROBIOL, V63, P697, DOI 10.1016/S0301 0082(00)00036 8
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 38
TC 27
Z9 31
U1 0
U2 5
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD APR
PY 2008
VL 106
IS 4
BP 536
EP 541
DI 10.1254/jphs.FM0070243
PG 6
WC Pharmacology & Pharmacy
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 293AX
UT WOS:000255308300003
PM 18431036
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, ZN
   Yuan, GX
   Lin, XX
   Liu, Q
   Xu, JK
   Lian, Z
   Song, FM
   Zheng, JJ
   Xie, DT
   Chen, LZ
   Wang, XJ
   Feng, HT
   Zhou, MY
   Yao, GF
AF Li, Zhaoning
   Yuan, Guixin
   Lin, Xixi
   Liu, Qian
   Xu, Jiake
   Lian, Zhen
   Song, Fangming
   Zheng, Jinjian
   Xie, Dantao
   Chen, Lingzi
   Wang, Xinjia
   Feng, Haotian
   Zhou, Mengyu
   Yao, Guanfeng
TI Dehydrocostus lactone (DHC) suppresses estrogen deficiency induced
   osteoporosis
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE RANKL; Dehydrocostus lactone; NF kappa B pathway; Osteoclast;
   Osteoporosis; Bone resorption
ID KAPPA B ACTIVATION; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST
   DIFFERENTIATION; SESQUITERPENE LACTONE; APOPTOSIS; ROLES
AB Osteoporosis is a chronic bone lytic disease, because of inadequate bone ossification and/or excessive bone resorption. Even though drugs are currently available for the treatment of osteoporosis, there remains an unmet need for the development of more specific novel agents with less adverse effects. Dehydrocostus lactone (DHC), a natural sesquiterpene lactone, was previously found to affect the differentiation of inflammatory cells by inhibiting NF kappa B pathways, and garnered much interest for its anti cancer properties via SOCS mediated cell cycle arrest and apoptosis. As NF kappa B pathway plays an essential role in osteoclast differentiation, we sought to discover the biological effects of DHC on osteoclast differentiation and resorptive activity, as well as the underlying mechanisms on these effects. Our research found that DHC inhibited RANKL induced osteoclast differentiation, bone resorption and osteoclast specific genes expression via suppression of NF kappa B and NFAT signaling pathways in vitro. We further demonstrated that DHC protected against ovariectomy (OVX) induced bone loss in mice and the protective effect was mediated at least in part through the attenuation of NF kappa B signaling pathway. Thus, this study provides insight that DHC might be used as a potential pharmacological treatment for osteoporosis.
C1 [Li, Zhaoning] Dongguan Peoples Hosp, Dept Orthoped, Dongguan 523000, Guangdong, Peoples R China.
   [Yuan, Guixin; Lian, Zhen; Zheng, Jinjian; Xie, Dantao; Wang, Xinjia; Yao, Guanfeng] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Shantou 515041, Guangdong, Peoples R China.
   [Lin, Xixi; Liu, Qian; Song, Fangming; Feng, Haotian] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Lin, Xixi; Liu, Qian; Song, Fangming; Feng, Haotian] Guangxi Med Univ, Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Xu, Jiake; Feng, Haotian] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Chen, Lingzi] Southern Med Univ, Chaozhou Cent Hosp, Affiliated Chaozhou Cent Hosp, Chaozhou, Guangdong, Peoples R China.
   [Zhou, Mengyu] Guangxi Med Univ, Affiliated Hosp 1, Dept Dent, Nanning, Peoples R China.
C3 Shantou University; Guangxi Medical University; Guangxi Medical
   University; University of Western Australia; Southern Medical University
     China; Guangxi Medical University
RP Yao, GF (通讯作者)，Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Shantou 515041, Guangdong, Peoples R China.; Zhou, MY (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Dent, Nanning, Peoples R China.
EM zhoumengyu@gxmu.edu.cn; gfyao@stu.edu.cn
RI Li, Zhaoning/O 9768 2014; Yao, Guanfeng/JPA 5741 2023; xi,
   lin/JOK 1026 2023
OI Xu, Jiake/0000 0003 2021 8309; 
FU Natural Science Foundation of Guangxi Province [2015GXNSFCA414001];
   National Natural Science Foundation of China [81501910]; Natural Science
   Foundation of Guangdong Province [2018A030307025]; Postgraduate
   Innovation and Entrepreneurship Education & Co Cultivation Program of
   Guangxi Collaborative Innovation Center for Biomedicine
   [GXCICB PIEECC 201601]
FX This project is supported in part by Natural Science Foundation of
   Guangxi Province (2015GXNSFDA139019), National Natural Science
   Foundation of China (81501910), the Natural Science Foundation of
   Guangdong Province (2018A030307025), Natural Science Foundation of
   Guangxi Province (2015GXNSFCA414001) and Postgraduate Innovation and
   Entrepreneurship Education & Co Cultivation Program of Guangxi
   Collaborative Innovation Center for Biomedicine (GXCICB PIEECC 201601).
CR Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Cai H, 2017, J CELL BIOCHEM, V118, P3381, DOI 10.1002/jcb.25994
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Hayata M, 2019, J NAT MED TOKYO, V73, P114, DOI 10.1007/s11418 018 1250 6
   Hsu YL, 2009, J PHARMACOL EXP THER, V329, P808, DOI 10.1124/jpet.108.148395
   Ichikawa H, 2006, CLIN CANCER RES, V12, P5910, DOI 10.1158/1078 0432.CCR 06 0916
   Kim JY, 2014, BMB REP, V47, P451, DOI 10.5483/BMBRep.2014.47.8.206
   Ko SG, 2005, CANCER LETT, V220, P11, DOI 10.1016/j.canlet.2004.06.026
   Kuo PL, 2009, MOL CANCER THER, V8, P1328, DOI 10.1158/1535 7163.MCT 08 0914
   Lin XJ, 2015, INT J MOL SCI, V16, P10888, DOI 10.3390/ijms160510888
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955 0674(99)80030 1
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Nakagomi D, 2012, INT ARCH ALLERGY IMM, V158, P92, DOI 10.1159/000337800
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Pandey MM, 2007, J ETHNOPHARMACOL, V110, P379, DOI 10.1016/j.jep.2006.12.033
   Peng ZX, 2015, METABOLOMICS, V11, P636, DOI 10.1007/s11306 014 0725 z
   Pyun H, 2018, PHYTOMEDICINE, V43, P46, DOI 10.1016/j.phymed.2018.03.045
   Qin SN, 2015, INT J MOL SCI, V16, P26599, DOI 10.3390/ijms161125972
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Tomasevic Todorovic S, 2018, OPEN ACCESS RHEUMATO, V10, P61, DOI 10.2147/OARRR.S151307
   Wang CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031195
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   YOSHIKAWA M, 1993, CHEM PHARM BULL, V41, P214, DOI 10.1248/cpb.41.214
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   2017, FITOTERAPIA, V121, P16, DOI DOI 10.1016/J.FITOTE.2017.05.017
   2011, PHYTOCHEMISTRY, V72, P624, DOI DOI 10.1016/J.PHYTOCHEM.2011.01.037
   2018, J CLIN INVEST, V128, P1429, DOI DOI 10.1172/JCI91086
   1992, ENDOCR REV, V13, P66, DOI DOI 10.1210/EDRV 13 1 66
   2016, J BONE MINER RES, V31, P964, DOI DOI 10.1002/JBMR.2771
   SCIENCE, V289, P1504
   2014, PHYTOTHER RES, V28, P586, DOI DOI 10.1002/PTR.5034
   J BONE MINER RES, V15, P1526, DOI DOI 10.1359/JBMR.2000.15.8.1526
   2006, J DENT RES, V85, P584, DOI DOI 10.1177/154405910608500703
   1996, J CLIN ENDOCR METAB, V81, P4358, DOI DOI 10.1210/JCEM.81.12.8954042
NR 41
TC 17
Z9 22
U1 0
U2 18
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY
PY 2019
VL 163
BP 279
EP 289
DI 10.1016/j.bcp.2019.02.002
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HV5YC
UT WOS:000466060000027
PM 30721671
DA 2025 08 17
ER

PT J
AU Sinder, BP
   White, LE
   Salemi, JD
   Ominsky, MS
   Caird, MS
   Marini, JC
   Kozloff, KM
AF Sinder, B. P.
   White, L. E.
   Salemi, J. D.
   Ominsky, M. S.
   Caird, M. S.
   Marini, J. C.
   Kozloff, K. M.
TI Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates
   anabolic response to sclerostin antibody treatment with increased bone
   mass and strength
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Mouse model; Osteogenesis imperfecta; Osteoporosis; Sclerostin antibody
ID MINERAL DENSITY; PARATHYROID HORMONE; TERIPARATIDE TREATMENT;
   OVARIECTOMIZED RATS; MARROW COMPOSITION; DECREASED BONE; SKELETAL SITES;
   FRACTURE RATE; ALENDRONATE; REGARDLESS
AB Treatments to reduce fracture rates in adults with osteogenesis imperfecta are limited. Sclerostin antibody, developed for treating osteoporosis, has not been explored in adults with OI. This study demonstrates that treatment of adult OI mice respond favorably to sclerostin antibody therapy despite retention of the OI causing defect.
   Osteogenesis imperfecta (OI) is a heritable collagen related bone dysplasia, characterized by brittle bones with increased fracture risk. Although OI fracture risk is greatest before puberty, adults with OI remain at risk of fracture. Antiresorptive bisphosphonates are commonly used to treat adult OI, but have shown mixed efficacy. New treatments which consistently improve bone mass throughout the skeleton may improve patient outcomes. Neutralizing antibodies to sclerostin (Scl Ab) are a novel anabolic therapy that have shown efficacy in preclinical studies by stimulating bone formation via the canonical wnt signaling pathway. The purpose of this study was to evaluate Scl Ab in an adult 6 month old Brtl/+ model of OI that harbors a typical heterozygous OI causing Gly > Cys substitution on Col1a1.
   Six month old WT and Brtl/+ mice were treated with Scl Ab (25 mg/kg, 2x/week) or Veh for 5 weeks. OCN and TRACP5b serum assays, dynamic histomorphometry, microCT and mechanical testing were performed.
   Adult Brtl/+ mice demonstrated a strong anabolic response to Scl Ab with increased serum osteocalcin and bone formation rate. This anabolic response led to improved trabecular and cortical bone mass in the femur. Mechanical testing revealed Scl Ab increased Brtl/+ femoral stiffness and strength.
   Scl Ab was successfully anabolic in an adult Brtl/+ model of OI.
C1 [Sinder, B. P.; White, L. E.; Salemi, J. D.; Caird, M. S.; Kozloff, K. M.] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA.
   [Sinder, B. P.; Salemi, J. D.; Kozloff, K. M.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ominsky, M. S.] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
   [Marini, J. C.] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Amgen; National Institutes of
   Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD)
RP Kozloff, KM (通讯作者)，Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, 2015 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM kenkoz@umich.edu
RI Salemi, Jason/IUO 0313 2023
FU NIH [R01AR062522]
FX The authors thank Bonnie Nolan, Kathy Sweet and Marry Eddy for their
   contributions. Scl Ab was provided by Amgen and UCB Pharma. Funding
   support from NIH to KMK (R01AR062522) is gratefully acknowledged. Study
   designed and conducted by BPS and KMK. Data collected by BPS, LEW, and
   JDS. Data analyzed and interpreted by BPS, LEW, JDS, MSO, MSC, JCM, and
   KMK. The manuscript was written by BPS and KMK and revised and approved
   by all authors. KMK takes responsibility for the integrity of the data
   analysis.
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bradbury LA, 2012, OSTEOPOROSIS INT, V23, P285, DOI 10.1007/s00198 011 1658 2
   Chevrel G, 2006, J BONE MINER RES, V21, P300, DOI 10.1359/JBMR.051015
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223 013 9770 2
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Kishi T, 1998, BONE, V22, P515, DOI 10.1016/S8756 3282(98)00045 3
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li M, 1999, BONE, V24, P95, DOI 10.1016/S8756 3282(98)00167 7
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Meganck JA, 2009, BONE, V45, P1104, DOI 10.1016/j.bone.2009.07.078
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PATERSON CR, 1984, NEW ENGL J MED, V310, P1694, DOI 10.1056/NEJM198406283102602
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Reeves GM, 2007, BONE, V40, P433, DOI 10.1016/j.bone.2006.08.018
   Shapiro JR, 2010, CALCIFIED TISSUE INT, V87, P120, DOI 10.1007/s00223 010 9383 y
   Sinder B, 2012, J BONE MINER RES S1, V27
   Sinder B, 2013, J BONE MINER RES S1, V28
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Tian XY, 2010, BONE, V47, P529, DOI 10.1016/j.bone.2010.05.032
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   van Lenthe GH, 2008, BONE, V43, P717, DOI 10.1016/j.bone.2008.06.008
NR 33
TC 54
Z9 59
U1 1
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD AUG
PY 2014
VL 25
IS 8
BP 2097
EP 2107
DI 10.1007/s00198 014 2737 y
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AM5JV
UT WOS:000339895100012
PM 24803333
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, LF
   Han, LC
   Xue, P
   Hu, XX
   Wong, SW
   Deng, M
   Tseng, HC
   Huang, BW
   Ko, CC
AF Wang, Lufei
   Han, Lichi
   Xue, Peng
   Hu, Xiangxiang
   Wong, Sing Wai
   Deng, Meng
   Tseng, Henry C.
   Huang, Bo Wen
   Ko, Ching Chang
TI Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway
SO CELLULAR SIGNALLING
LA English
DT Article
DE Dopamine; Dopamine receptor; Osteoclasts; cAMP response element binding
   protein (CREB); Cyclic adenosine monophosphate (cAMP); Protein kinase A
   (PKA)
ID BONE MARROW; ACTIVATION; KINASE; CREB
AB How the nervous system regulates bone remodeling is an exciting area of emerging research in bone biology. Accumulating evidence suggest that neurotransmitter mediated inputs from neurons may act directly on osteoclasts. Dopamine is a neurotransmitter that can be released by hypothalamic neurons to regulate bone metabolism through the hypothalamic pituitary gonadal axis. Dopamine is also present in sympathetic nerves that penetrate skeletal structures throughout the body. It has been shown that dopamine suppresses osteoclast differentiation via a D2 like receptors (D2R) dependent manner, but the intracellular secondary signaling pathway has not been elucidated. In this study, we found that cAMP response element binding protein (CREB) activity responds to dopamine treatment during osteoclastogenesis. Considering the critical role of CREB in osteoclastogenesis, we hypothesize that CREB may be a critical target in dopamine's regulation of osteoclast differentiation. We confirmed that D2R is also present in RAW cells and activated by dopamine. Binding of dopamine to D2R inhibits the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway which ultimately decreases CREB phosphorylation during osteoclastogenesis. This was also associated with diminished expression of osteoclast markers that are downstream of CREB. Pharmacological activation of adenylate cyclase (to increase cAMP production) and PKA reverses the effect of dopamine on CREB activity and osteoclastogenesis. Therefore, we have identified D2R/cAMP/PKA/CREB as a candidate pathway that mediates dopamine's inhibition of osteoclast differentiation. These findings will contribute to our understanding of how the nervous and skeletal systems interact to regulate bone remodeling. This will enable future work toward elucidating the role of the nervous system in bone development, repair, aging, and degenerative disease.
C1 [Wang, Lufei; Xue, Peng; Hu, Xiangxiang] Univ N Carolina, Adams Sch Dent, Div Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27515 USA.
   [Han, Lichi] Dalian Univ, Dept Oral Med, Med Coll, Dalian, Peoples R China.
   [Wong, Sing Wai] Univ N Carolina, Adams Sch Dent, Div Comprehens Oral Hlth, Chapel Hill, NC 27515 USA.
   [Deng, Meng] Univ N Carolina, Adams Sch Dent, Div Craniofacial & Surg Care, Chapel Hill, NC 27515 USA.
   [Tseng, Henry C.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA.
   [Tseng, Henry C.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Huang, Bo Wen; Ko, Ching Chang] Ohio State Univ, Coll Dent, Div Orthodont, 305 West 12th Ave, Columbus, OH 43210 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Dalian University; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina; University of North
   Carolina Chapel Hill; Duke University; Duke University; University
   System of Ohio; Ohio State University
RP Ko, CC (通讯作者)，Ohio State Univ, Coll Dent, Div Orthodont, 305 West 12th Ave, Columbus, OH 43210 USA.
EM ko.367@osu.edu
RI Hu, Xiangxiang/GRY 6511 2022; xue, peng/K 4159 2015
OI Hu, Xiangxiang/0000 0003 4029 056X; 
FU Ohio State University College of Dentistry; NIH/NIDCR [R01DE022816]
FX This work was supported by Ohio State University College of Dentistry
   and the NIH/NIDCR grant (R01DE022816 to CCK).
CR [Anonymous], 2017, J STEM CELL RES THER, DOI DOI 10.4172/2157 7633.1000395
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   Berke JD, 2018, NAT NEUROSCI, V21, P787, DOI 10.1038/s41593 018 0152 y
   Bibb JA, 2005, CELL, V122, P153, DOI 10.1016/j.cell.2005.07.011
   Brami Cherrier K, 2002, J NEUROSCI, V22, P8911
   Calarge CA, 2013, THER ADV PSYCHOPHARM, V3, P278, DOI 10.1177/2045125313487548
   Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Grimes MT, 2015, LEARN MEMORY, V22, P74, DOI 10.1101/lm.037101.114
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Handa K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50336 4
   Huang SS, 2019, J CELL PHYSIOL, V234, P5466, DOI 10.1002/jcp.26502
   Iacovazzo D, 2015, ENDOCRINE, V48, P76, DOI 10.1007/s12020 014 0377 9
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Maestroni GJM, 1998, EXP HEMATOL, V26, P1172
   Maryanovich M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031344
   Matt SM, 2020, J NEUROIMMUNE PHARM, V15, P114, DOI 10.1007/s11481 019 09851 4
   Minami K, 2017, SCI REP UK, V7, DOI 10.1038/srep45686
   Motyl KJ, 2017, BONE, V103, P168, DOI 10.1016/j.bone.2017.07.008
   Nakashioya H, 2011, MOD RHEUMATOL, V21, P260, DOI 10.1007/s10165 010 0387 2
   Rachner TD, 2018, LANCET DIABETES ENDO, V6, P901, DOI 10.1016/S2213 8587(18)30047 0
   Ramaswamy G, 2017, SCI REP UK, V7, DOI 10.1038/srep45140
   Rosen CJ, 2008, CELL METAB, V7, P7, DOI 10.1016/j.cmet.2007.12.004
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Torsney KM, 2014, J NEUROL NEUROSUR PS, V85, P1159, DOI 10.1136/jnnp 2013 307307
   Vesprey Alexander, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1836
   Wang HT, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00255
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wong SW, 2020, CELL DEATH DIFFER, V27, P71, DOI 10.1038/s41418 019 0341 6
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P17, DOI 10.1159/000351896
   Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zengin A, 2010, TRENDS ENDOCRIN MET, V21, P411, DOI 10.1016/j.tem.2010.02.004
NR 39
TC 37
Z9 43
U1 0
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2021
VL 78
AR 109847
DI 10.1016/j.cellsig.2020.109847
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA PN8SS
UT WOS:000604743000002
PM 33242564
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lerner, UH
   Ohlsson, C
AF Lerner, U. H.
   Ohlsson, C.
TI The WNT system: background and its role in bone
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article
DE bone; osteoblast; osteoclast; sclerostin; WNT
ID RECEPTOR RELATED PROTEIN 5; GENOME WIDE ASSOCIATION;
   LDL RECEPTOR RELATED PROTEIN 5 LRP5 GENE; SERUM SCLEROSTIN LEVELS;
   MINERAL DENSITY; PRIMARY OSTEOPOROSIS; MISSENSE MUTATIONS; BETA CATENIN;
   SOST GENE; MASS
AB WNTs are extracellular proteins that activate different cell surface receptors linked to canonical and noncanonical WNT signalling pathways. The Wnt genes were originally discovered as important for embryonic development of fruit flies and malignant transformation of mouse mammary cancers. More recently, WNTs have been implicated in a wide spectrum of biological phenomena and diseases. During the last decade, several lines of clinical and preclinical evidence have indicated that WNT signalling is critical for trabecular and cortical bone mass, and this pathway is currently an attractive target for drug development. Based on detailed knowledge of the different WNT signalling pathways, it appears that it might be possible to develop drugs that specifically target cortical and trabecular bone. Neutralization of a bone specific WNT inhibitor is now being evaluated as a promising anabolic treatment for patients with osteoporosis. Here, we provide the historical background to the discoveries of WNTs, describe the different WNT signalling pathways and summarize the current understanding of how these proteins regulate bone mass by affecting bone formation and resorption.
C1 [Lerner, U. H.; Ohlsson, C.] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
   [Lerner, U. H.] Umea Univ, Dept Mol Periodontol, Umea, Sweden.
C3 University of Gothenburg; Umea University
RP Lerner, UH (通讯作者)，Sahlgrens Acad, Inst Med, Ctr Bone & Arthrit Res, Vita Straket 11, S 41346 Gothenburg, Sweden.
EM ulf.lerner@gu.se
RI Ohlsson, Claes/HIR 6959 2022; Ohlsson, Claes/AGP 3544 2022
OI Ohlsson, Claes/0000 0002 9633 2805; Lerner, Ulf/0000 0002 3579 1960
FU Swedish Research Council; Swedish Foundation for Strategic Research,
   COMBINE; ALF/LUA research grant in Gothenburg; Lundberg Foundation;
   Torsten and Ragnar Soderberg's Foundation; Swedish Rheumatism
   Association; Royal 80 Year Fund of King Gustav V; Novo Nordisk
   Foundation; Novo Nordisk Fonden [NNF14OC0010513, NNF13OC0005785] Funding
   Source: researchfish
FX The studies performed in the authors' laboratories have been supported
   by the Swedish Research Council, the Swedish Foundation for Strategic
   Research, COMBINE, the ALF/LUA research grant in Gothenburg, the
   Lundberg Foundation, the Torsten and Ragnar Soderberg's Foundation, the
   Swedish Rheumatism Association, the Royal 80 Year Fund of King Gustav V
   and the Novo Nordisk Foundation.
CR Agholme F, 2014, J ORTHOP RES, V32, P471, DOI 10.1002/jor.22525
   Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Ardawi MSM, 2012, OSTEOPOROSIS INT, V23, P1789, DOI 10.1007/s00198 011 1806 8
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, NAT REV ENDOCRINOL, V8, P76, DOI 10.1038/nrendo.2011.207
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Collette NM, 2010, DEV BIOL, V342, P169, DOI 10.1016/j.ydbio.2010.03.021
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100
   García Ibarbia C, 2013, OSTEOPOROSIS INT, V24, P2449, DOI 10.1007/s00198 013 2302 0
   García Ibarbia C, 2013, GENE, V532, P165, DOI 10.1016/j.gene.2013.09.080
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gong YQ, 1996, AM J HUM GENET, V59, P146
   Hamamura K, 2014, CELL SIGNAL, V26, P2358, DOI 10.1016/j.cellsig.2014.07.018
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407
   Hendrickx G, 2014, BONE, V59, P57, DOI 10.1016/j.bone.2013.10.022
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hsu YH, 2012, J CLIN ENDOCR METAB, V97, pE1958, DOI 10.1210/jc.2012 1890
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jenny A, 2010, CURR TOP DEV BIOL, V93, P189, DOI [10.1016/S0070 2153(10)93007 X, 10.1016/B978 0 12 385044 7.00007 2]
   Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kemp JP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004423
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003
   Kim SJ, 2011, HUM GENET, V129, P497, DOI 10.1007/s00439 011 0947 3
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Koller DL, 2013, J BONE MINER RES, V28, P547, DOI 10.1002/jbmr.1796
   KORTEWEG R., 1936, GENETICA, V18, P350, DOI 10.1007/BF01507441
   Korvala J, 2012, EUR J MED GENET, V55, P515, DOI 10.1016/j.ejmg.2012.06.011
   Korvala J, 2012, BMC MED GENET, V13, DOI 10.1186/1471 2350 13 26
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lapauw B, 2013, EUR J ENDOCRINOL, V168, P615, DOI 10.1530/EJE 12 1074
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu S, 2012, ARTHRITIS RHEUM US, V64, P4012, DOI 10.1002/art.37697
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   LYONS MJ, 1962, NATURE, V194, P1141, DOI 10.1038/1941141a0
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Moayyeri A, 2014, HUM MOL GENET, V23, P3054, DOI 10.1093/hmg/ddt675
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092 8674(92)90630 U
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Palomo T, 2014, BONE, V67, P63, DOI 10.1016/j.bone.2014.06.041
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiu WM, 2011, BIOCHEM BIOPH RES CO, V413, P98, DOI 10.1016/j.bbrc.2011.08.061
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092 8674(87)90038 9
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012 1606(76)90108 1
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Virdi AS, 2012, J BONE JOINT SURG AM, V94A, P1670, DOI 10.2106/JBJS.K.00344
   Weatherbee SD, 2006, DEVELOPMENT, V133, P4993, DOI 10.1242/dev.02696
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Witte F, 2009, GENE EXPR PATTERNS, V9, P215, DOI 10.1016/j.gep.2008.12.009
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhang L, 2014, HUM MOL GENET, V23, P1923, DOI 10.1093/hmg/ddt575
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 120
TC 196
Z9 236
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0954 6820
EI 1365 2796
J9 J INTERN MED
JI J. Intern. Med.
PD JUN
PY 2015
VL 277
IS 6
BP 630
EP 649
DI 10.1111/joim.12368
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CI8DW
UT WOS:000355000400002
PM 25845559
OA Bronze
DA 2025 08 17
ER

PT J
AU Han, SY
   Lee, KH
   Kim, YK
AF Han, Sang Yong
   Lee, Kyung Hee
   Kim, Yun Kyung
TI Poligoni Multiflori Radix enhances osteoblast formation and
   reduces osteoclast differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Poligoni Multiflori Radix; osteoporosis; osteoclast; osteoblast
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; GENE EXPRESSION;
   BONE RESORPTION; TRANSCRIPTIONAL CONTROL; NFATC1 EXPRESSION;
   DOWN REGULATION; NUCLEAR FACTOR; C FOS; CELLS
AB Poligoni Multiflori Radix (PMR) is a traditional Korean medicinal herb that is known to have various pharmacological effects, including antihyperlipidemic, anticancer, and anti inflammatory effects. However, the effects of PMR on bone metabolism have not been elucidated to date. The present study aimed to investigate the in vitro and in vivo effect of PMR water extract on the regulation of osteoblast and osteoclast activity. Effects of PMR water extract on receptor activator of nuclear factor kB ligand (RANKL) induced osteoclast differentiation and survival of mouse bone marrow macrophages (BMMs) obtained from femurs were investigated by tartrate acid resistant acid phosphatase (TRAP) positive cells and XTT assay. Expression of osteoclast related genes was assayed by western blot analysis and reverse transcription quantitative polymerase chain reaction. Additionally, the effects of PMR water extract on osteoblastic proliferation and differentiation were investigated by alkaline phosphatase (ALP) activity assay, alizarin red staining, and levels of mRNA encoding known osteoblast markers. Furthermore, the effects of PMR water extract on lipopolysaccharide (LPS) induced bone loss were examined in a mouse model. PMR inhibited RANKL induced osteoclast differentiation of BMMs in a dose dependent manner without significant cytotoxicity, and suppressed expression of the main osteoclast differentiation markers Fos proto oncogene and nuclear factor of activated T cell. In addition, PMR decreased the mRNA expression levels of NFATc1 target genes, including TRAP, osteoclast associated receptor, ATPase H+ transporting, lysosomal 38 kDa V0 subunit d2, and Cathepsin K. These inhibitory effects were mediated by the p38 and extracellular signal regulated kinase/nuclear factor B pathway. Simultaneously, PMR enhanced the differentiation of primary osteoblasts, and increased the mRNA expression of runt related transcription factor 2, ALP, osterix, and osteocalcin. Notably, PMR improved LPS induced trabecular bone loss in mice. Collectively, the present findings demonstrated that PMR may regulate bone remodeling by reducing osteoclast differentiation and stimulating osteoblast formation. These results suggest that PMR may be used for the treatment of bone diseases, such as osteoporosis and rheumatoid arthritis.
C1 [Han, Sang Yong; Lee, Kyung Hee; Kim, Yun Kyung] Wonkwang Univ, Wonkwang Oriental Medicines Res Inst, Coll Pharm, Dept Herbal Med, Iksan 54538, Jeonbuk, South Korea.
C3 Wonkwang University
RP Kim, YK (通讯作者)，Wonkwang Univ, Dept Herbal Med, Coll Pharm, 460 Iksandae Rd, Iksan 54538, Jeonbuk, South Korea.
EM hestia@wonkwang.ac.kr
FU Wonkwang University
FX The present study was supported by Wonkwang University in 2016.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   김민정, 2004, [The Korea Journal of Herbology, 대한본초학회지], V19, P23
   Cancedda R, 2000, INT J DEV BIOL, V44, P707
   Chau Diane L, 2003, Curr Diab Rep, V3, P37, DOI 10.1007/s11892 003 0051 8
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Do YoonJung Do YoonJung, 2011, Journal of Veterinary Clinics, V28, P375
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hofbauer LC, 2015, DRUG RES, V65, pS14, DOI 10.1055/s 0035 1558064
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600 0765.1991.tb01639.x
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Kang MR, 2014, MAR DRUGS, V12, P5643, DOI 10.3390/md12115643
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kim JY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1300 0
   Kim JY, 2015, J NAT PROD, V78, P2167, DOI 10.1021/acs.jnatprod.5b00233
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kong LB, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 481
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<62::AID JCB10>3.0.CO;2 S
   Lin LF, 2015, J ETHNOPHARMACOL, V159, P158, DOI 10.1016/j.jep.2014.11.009
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Orimo H, 2008, MOL CELL BIOCHEM, V315, P51, DOI 10.1007/s11010 008 9788 3
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Rho TW, 2017, AM J CHINESE MED, V45, P283, DOI [10.1142/S0192415X17500185, 10.1142/s0192415x17500185]
   Sharma Bhandari A, 2015, INT J MOL MED, V36, P1664, DOI 10.3892/ijmm.2015.2384
   Shaw AT, 2016, SEMIN CELL DEV BIOL, V49, P2, DOI 10.1016/j.semcdb.2015.10.013
   Song JF, 2017, MED SCI MONITOR, V23, P5056, DOI 10.12659/MSM.904795
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
NR 47
TC 6
Z9 6
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUL
PY 2018
VL 42
IS 1
BP 331
EP 345
DI 10.3892/ijmm.2018.3603
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GP1MT
UT WOS:000440580900033
PM 29620250
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Liu, C
   Tsai, AL
   Chen, YC
   Fan, SC
   Huang, CH
   Wu, CC
   Chang, CH
AF Liu, Cheng
   Tsai, An Ly
   Chen, Yen Chu
   Fan, Shih Chen
   Huang, Chun Hsien
   Wu, Chia Ching
   Chang, Chih Han
TI Facilitation of human osteoblast apoptosis by sulindac and indomethacin
   under hypoxic injury
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Hypoxia; Osteoblast; Apoptosis; NSAID; Aspirin
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FLUID SHEAR STRESS; OXYGEN TENSION;
   PROTEIN KINASE; BONE FORMATION; EXPRESSION; ACTIVATION; ROLES;
   INCREASES; RELEASE
AB Hypoxicischemia injury occurs after trauma causes consequential bone necrosis. Non steroid anti inflammatory drugs (NSAIDs) are frequently used in orthopedic clinics for pain relief. However, the underlying mechanism and outcome for usage of NSAIDs is poorly understood. To investigate the damage and loss of osteoblast function in hypoxia, two hypoxia mimetics, cobalt chloride (CoCl2) and desferrioxamine (DFO), were used to create an in vitro hypoxic microenvironment. The cell damage was observed by decreases of cell viability and increases in cyclooxygenase 2 and cleaved poly(ADP ribose) polymerase (PARP). Cell apoptosis was confirmed by WST 1 cytotoxic assays and flow cytometry. The functional expression of osteoblast in alkaline phosphatase (ALP) activity was significantly decreased by CoCl2 and inhibited when treated with DFO. To simulate the use of NSAID after hypoxic injury, four types of anti inflammatory drugs, sulindac sulfide (SUL), indomethacin (IND), aspirin (Asp), and sodium salicylate (NaS), were applied to osteoblasts after 1?h of hypoxia mimetic treatment. SUL and IND further enhanced cell death after hypoxia. ALP activity was totally abolished in hypoxic osteoblasts under IND treatment. Facilitation of osteoblast apoptosis occurred regardless of IND dosage under hypoxic conditions. To investigate osteoblast in vivo, local hypoxia was created by fracture of tibia and then treated the injured mice with IND by oral feeding. IND induced osteoblast apoptosis was confirmed by positive staining of TUNEL assay in fractured mice. Significant delay of fracture healing in bone tissue was also observed with the treatment of IND. These results provide information pertaining to choosing appropriate anti inflammatory drugs for orthopedic patients. J. Cell. Biochem. 113: 148155, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Liu, Cheng; Wu, Chia Ching; Chang, Chih Han] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan 701, Taiwan.
   [Liu, Cheng; Tsai, An Ly; Chen, Yen Chu] Chi Mei Med Ctr, Div Plast Surg, Tainan 710, Taiwan.
   [Tsai, An Ly; Chen, Yen Chu; Wu, Chia Ching] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 701, Taiwan.
   [Fan, Shih Chen] I Shou Univ, Dept Occupat Therapy, Kaohsiung 824, Taiwan.
   [Huang, Chun Hsien; Wu, Chia Ching] Natl Cheng Kung Univ, Dept Med, Tainan 701, Taiwan.
   [Wu, Chia Ching; Chang, Chih Han] Natl Cheng Kung Univ, Med Device Innovat Ctr, Tainan 701, Taiwan.
C3 National Cheng Kung University; Chi Mei Hospital; National Cheng Kung
   University; I Shou University; National Cheng Kung University; National
   Cheng Kung University
RP Wu, CC (通讯作者)，1 Univ Rd, Tainan 701, Taiwan.
EM joshccwu@mail.ncku.edu.tw; cchang@mail.bme.ncku.edu.tw
RI Tsai, Anli/JFS 9111 2023
FU Chi Mei and NCKU Medical Center [CMNCKU9807]
FX Grant sponsor: Chi Mei and NCKU Medical Center Collaboration Project;
   Grant number: CMNCKU9807.
CR Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   BRIGHTON CT, 1972, J BONE JOINT SURG AM, VA 54, P323, DOI 10.2106/00004623 197254020 00010
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Genetos DC, 2009, J CELL BIOCHEM, V107, P233, DOI 10.1002/jcb.22119
   Geng WD, 2001, J CELL PHYSIOL, V189, P216, DOI 10.1002/jcp.10019
   Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023
   Haddad JJ, 2005, INT IMMUNOPHARMACOL, V5, P461, DOI 10.1016/j.intimp.2004.11.009
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Jones MK, 2001, FASEB J, V15, P264, DOI 10.1096/fj.01 0589fje
   Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024
   Lee CM, 2007, J CELL PHYSIOL, V212, P182, DOI 10.1002/jcp.21017
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Lee DY, 2010, J BIOL CHEM, V285, P30, DOI 10.1074/jbc.M109.010512
   Liou JY, 2008, MOL PHARMACOL, V74, P1399, DOI 10.1124/mol.108.049569
   McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930
   Peverali FA, 2001, MOL MED, V7, P68, DOI 10.1007/BF03401840
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567
   Su FC, 2011, J MED BIOL ENG, V31, P233, DOI 10.5405/jmbe.944
   Towler DA, 2007, J CLIN INVEST, V117, P1477, DOI 10.1172/JCI32518
   TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889 5406(94)70006 0
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Wu CC, 2007, P NATL ACAD SCI USA, V104, P1254, DOI 10.1073/pnas.0609806104
   Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 31
TC 15
Z9 16
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2012
VL 113
IS 1
BP 148
EP 155
DI 10.1002/jcb.23338
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 869LB
UT WOS:000298598300017
PM 21882223
DA 2025 08 17
ER

PT J
AU Song, DY
   He, GX
   Shi, Y
   Ni, JD
   Long, FX
AF Song, Deye
   He, Guangxu
   Shi, Yu
   Ni, Jiangdong
   Long, Fanxin
TI Functional interaction between Wnt and Bmp signaling in periosteal bone
   growth
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHOSPHATIDYLINOSITOL 3 KINASE; OSTEOBLAST FUNCTION; SOST GENE;
   EXPRESSION; MUTATIONS; MICE; LRP5; MASS; DIFFERENTIATION; PROLIFERATION
AB Wnt and Bmp proteins are well known to regulate bone development and homeostasis. Although both signals are extensively studied, their potential interaction in vivo is less well understood. Previous studies have shown that deletion of Bmpr1a, a type I receptor for Bmp signaling, results in excessive trabecular bone formation while diminishing periosteal bone growth. Moreover, forced expression of the Wnt antagonist Sost suppresses the overgrowth of trabecular bone caused by Bmpr1a deletion, thus implicating hyperactive Wnt signaling in the excessive trabecular bone formation. However, it remains uncertain whether Wnt and Bmp signaling interacts in regulating the periosteal bone growth. Here we show that multiple Wnt genes are markedly suppressed in the cortical bone without Bmpr1a. Importantly, overexpression of Wnt7b fully rescues periosteal bone growth in the Bmpr1a deficient mice. Thus, pharmacological activation of Wnt signaling can restore normal bone size without intact Bmp signaling.
C1 [Song, Deye; He, Guangxu; Ni, Jiangdong] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha 410011, Hunan, Peoples R China.
   [Song, Deye; He, Guangxu; Shi, Yu; Long, Fanxin] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63130 USA.
   [Shi, Yu] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Shi, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Long, Fanxin] Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.
   [Long, Fanxin] Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
C3 Central South University; Washington University (WUSTL); Sichuan
   University; Sichuan University; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63130 USA.; Long, FX (通讯作者)，Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.; Long, FX (通讯作者)，Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
EM longf1@email.chop.edu
FU NIH [AR060456, P30 AR057235]
FX This work was partially supported by NIH grant AR060456 (FL). The bone
   morphometry studies were partly supported by P30 AR057235 (Washington
   University Musculoskeletal Research Center).
CR Alam I, 2016, ENDOCRINOLOGY, V157, P722, DOI 10.1210/en.2015 1281
   Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Ghosh Choudhury N, 2013, J BIOL CHEM, V288, P24503, DOI 10.1074/jbc.M113.455733
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   He GX, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.16
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2016, BONE, V91, P53, DOI 10.1016/j.bone.2016.07.002
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lim J, 2016, DEVELOPMENT, V143, P339, DOI 10.1242/dev.126227
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Malinauskas T, 2014, CURR OPIN STRUC BIOL, V29, P77, DOI 10.1016/j.sbi.2014.10.003
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Tan XH, 2007, J CELL SCI, V120, P2162, DOI 10.1242/jcs.03466
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   Wharton K, 2009, DEVELOPMENT, V136, P3691, DOI 10.1242/dev.040584
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 50
TC 15
Z9 18
U1 1
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 24
PY 2021
VL 11
IS 1
AR 10782
DI 10.1038/s41598 021 90324 1
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SO6WF
UT WOS:000659114900005
PM 34031510
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, L
   Chen, X
   Yan, J
   Li, M
   Liu, T
   Zhu, C
   Pan, G
   Guo, Q
   Yang, H
   Pei, M
   He, F
AF Zhou, L.
   Chen, X.
   Yan, J.
   Li, M.
   Liu, T.
   Zhu, C.
   Pan, G.
   Guo, Q.
   Yang, H.
   Pei, M.
   He, F.
TI Melatonin at pharmacological concentrations suppresses
   osteoclastogenesis via the attenuation of intracellular ROS
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone marrow monocytes; Melatonin; Osteoclasts; Osteoporosis; ROS; SIRT1
ID MESENCHYMAL STEM CELLS; NF KAPPA B; REACTIVE OXYGEN; HYDROGEN PEROXIDE;
   OXIDATIVE STRESS; GENE EXPRESSION; BONE MASS; OSTEOPOROSIS;
   OSTEOGENESIS; ASSOCIATION
AB Osteoporosis is linked to age related decline of melatonin production; however, the direct effects of melatonin on osteoclastogenesis remain unknown. Our study demonstrates that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibits osteoclastogenesis. Melatonin mediated anti osteoclastogenesis involves a reactive oxygen species (ROS) mediated but not a silent information regulator type 1 (SIRT1) independent pathway.
   Osteoporosis is a bone disorder linked to impaired bone formation and excessive bone resorption. Melatonin has been suggested to treat osteoporosis due to its beneficial actions on osteoblast differentiation. However, the direct effects of melatonin on osteoclastogenesis in bone marrow monocytes (BMMs) remain unknown. This study was to investigate whether melatonin at either physiological or pharmacological concentrations could affect osteoclast differentiation.
   Primary BMMs were isolated from the femurs and tibias of C57BL/6 mice and were induced toward multinucleated osteoclasts, in the presence of melatonin at either physiological (0.01 to 10 nM) or pharmacological (1 to 100 mu M) concentrations. Tartrate resistant acid phosphatase (TRAP) staining was used to label multinucleated osteoclasts and the levels of osteoclast specific genes were evaluated. To further explore the underlying mechanisms, the roles of silent information regulator type 1 (SIRT1) and reactive oxygen species (ROS) were evaluated.
   We found that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibited osteoclast formation in a dose dependent manner. The number of TRAP positive cells and the gene expression of osteoclast specific markers were significantly downregulated in melatonin treated BMMs. The melatonin mediated repression of osteoclast differentiation involved the inhibition of the nuclear factor kappa light chain enhancer of activated B cells (NF kappa B) signaling pathway. The treatment with SIRT1 inhibitors did not affect osteoclast differentiation but, when supplemented with exogenous hydrogen peroxide, a partial rescue of melatonin suppressed osteoclastogenesis was observed.
   Melatonin at pharmacological doses directly inhibited osteoclastogenesis of BMMs by a ROS mediated but not a SIRT1 independent pathway.
C1 [Zhou, L.; Chen, X.; Yan, J.; Li, M.; Liu, T.; Yang, H.; He, F.] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhou, L.; Chen, X.; Yan, J.; Li, M.; Zhu, C.; Pan, G.; Guo, Q.; Yang, H.; He, F.] Soochow Univ, Med Coll, Orthopaed Inst, 708 Renmin Rd, Suzhou 215007, Jiangsu, Peoples R China.
   [Zhou, L.] Suzhou Sci & Technol Town Hosp, Dept Orthopaed, Suzhou 215153, Peoples R China.
   [Chen, X.] Soochow Univ, Med Coll, Sch Biol & Basic Med Sci, Suzhou 215123, Peoples R China.
   [Pei, M.] West Virginia Univ, Dept Orthopaed, Stem Cell & Tissue Engn Lab, Morgantown, WV 26505 USA.
   [Pei, M.] West Virginia Univ, Div Exercise Physiol, Morgantown, WV 26505 USA.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; West Virginia University; West Virginia University
RP Yang, H; He, F (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.; Yang, H; He, F (通讯作者)，Soochow Univ, Med Coll, Orthopaed Inst, 708 Renmin Rd, Suzhou 215007, Jiangsu, Peoples R China.
EM hlyang@suda.edu.cn; fanhe@suda.edu.cn
RI Pan, Guoqing/E 1445 2014; Pei, Ming/N 8175 2017; Jin, Yan/AAC 7705 2021;
   Liu, Tao/AIA 7232 2022; Cao, Zhujun/HZI 2093 2023
OI Pan, Guoqing/0000 0001 5187 796X; 
FU National Natural Science Foundation of China [31570978, 21574091,
   31400826]; Natural Science Foundation of Jiangsu Province [BK20140323];
   National Institutes of Health (NIH) [AR062763 01A1, AR067747 01A1];
   Musculoskeletal Transplant Foundation (MTF); Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD)
FX The authors are grateful to Suzanne Danley (West Virginia University,
   USA) and Paula Sahyoun (University of Waterloo, Canada) for carefully
   reviewing and editing the manuscript. This work was supported by the
   National Natural Science Foundation of China (31570978, 21574091,
   31400826), the Natural Science Foundation of Jiangsu Province
   (BK20140323), the National Institutes of Health (NIH) (AR062763 01A1,
   AR067747 01A1) and an Established Investigator Grant from
   Musculoskeletal Transplant Foundation (MTF) to M.P., and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD).
CR Amstrup AK, 2015, J PINEAL RES, V59, P221, DOI 10.1111/jpi.12252
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chen XR, 2014, J PINEAL RES, V57, P168, DOI 10.1111/jpi.12153
   Choi EY, 2011, J PINEAL RES, V50, P197, DOI 10.1111/j.1600 079X.2010.00829.x
   Detsch R, 2015, J TISSUE ENG REGEN M, V9, P1133, DOI 10.1002/term.1851
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Fischer TW, 2013, J PINEAL RES, V54, P303, DOI 10.1111/jpi.12018
   He F, 2014, J ENDOCRINOL, V223, P167, DOI 10.1530/JOE 14 0430
   Histing T, 2012, J SURG RES, V173, P83, DOI 10.1016/j.jss.2010.08.036
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Ke K, 2014, AM J PHYSIOL ENDOC M, V307, pE61, DOI 10.1152/ajpendo.00044.2014
   Kleszczynski K, 2016, J PINEAL RES, V61, P187, DOI 10.1111/jpi.12338
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu XZ, 2014, FREE RADICAL BIO MED, V68, P234, DOI 10.1016/j.freeradbiomed.2013.12.012
   Liu XZ, 2013, J PINEAL RES, V55, P14, DOI 10.1111/jpi.12045
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116
   Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Shi DB, 2012, J PINEAL RES, V53, P154, DOI 10.1111/j.1600 079X.2012.00982.x
   Sotthibundhu A, 2010, J PINEAL RES, V49, P291, DOI 10.1111/j.1600 079X.2010.00794.x
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600 079X.2006.00407.x
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Xu Y, 2010, ANTIOXID REDOX SIGN, V13, P27, DOI 10.1089/ars.2009.2886
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhou L, 2015, J PINEAL RES, V59, P190, DOI 10.1111/jpi.12250
NR 35
TC 54
Z9 61
U1 1
U2 28
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2017
VL 28
IS 12
BP 3325
EP 3337
DI 10.1007/s00198 017 4127 8
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FM8EA
UT WOS:000415317300004
PM 28956094
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yamada, T
   Muguruma, H
   Yano, S
   Ikuta, K
   Ogino, H
   Kakiuchi, S
   Hanibuchi, M
   Uehara, H
   Nishioka, Y
   Sone, S
AF Yamada, Tadaaki
   Muguruma, Hiroaki
   Yano, Seiji
   Ikuta, Kenji
   Ogino, Hirokazu
   Kakiuchi, Soji
   Hanibuchi, Masaki
   Uehara, Hisanori
   Nishioka, Yasuhiko
   Sone, Saburo
TI Intensification therapy with anti parathyroid hormone related protein
   antibody plus zoledronic acid for bone metastases of small cell lung
   cancer cells in severe combined immunodeficient mice
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID BREAST CANCER; SCID MICE; SKELETAL METASTASES; SOLID TUMORS;
   DOUBLE BLIND; SBC 5 CELLS; PHASE III; IN VIVO; BISPHOSPHONATES;
   HYPERCALCEMIA
AB Bone metastases occur in more than one third of patients with advanced lung cancer and are difficult to treat. We showed previously the therapeutic effect of a third generation bisphosphonate, minodronate, and anti parathyroid hormone related protein (PTHrP) neutralizing antibody on bone metastases induced by the human small cell lung cancer cell line, SBC 5, in natural killer cell depleted severe combined immunodeficient mice. The purpose of our current study was to examine the effect of the combination of PTHrP antibody and zoledronic acid, which has been approved to treat bone metastases, against bone metastases produced by SBC 5 cells expressing PTHrP. Treatment with PTHrP antibody and/or zoledronic acid did not affect the proliferation of SBC 5 cells in vitro. Repeated treatments with either PTHrP antibody or zoledronic acid inhibited the formation of osteolytic bone metastases of SBC 5 cells but had no effect on metastases to visceral organs. Importantly, combined treatment with PTHrP antibody and zoledronic acid further inhibited the formation of bone metastases. Histologic assays showed that, compared with either PTHrP antibody or zoledronic acid alone, their combination decreased the number of tumor associated osteoclasts and increased the number of apoptotic tumor cells. These findings suggest that this novel dual targeting therapy may be useful for controlling bone metastases in a subpopulation of small cell lung cancer patients. [Mol Cancer Ther 2009;8(1):119   26]
C1 [Yamada, Tadaaki; Muguruma, Hiroaki; Ikuta, Kenji; Ogino, Hirokazu; Kakiuchi, Soji; Hanibuchi, Masaki; Nishioka, Yasuhiko; Sone, Saburo] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Resp Med & Rheumatol, Tokushima 7708503, Japan.
   [Uehara, Hisanori] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, Tokushima 7708503, Japan.
   [Yamada, Tadaaki; Yano, Seiji] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9201192, Japan.
C3 Tokushima University; Tokushima University; Kanazawa University
RP Sone, S (通讯作者)，Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Resp Med & Rheumatol, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM sone@clin.med.tokushima u.ac.jp
RI Yamada, Tadaaki/L 5378 2015; YANO, SEIJI/D 8465 2015
OI Yamada, Tadaaki/0000 0002 6945 281X; 
FU Ministry of Education, Science, Sports and Culture of Japan [17016051];
   Grants in Aid for Scientific Research [17016051] Funding Source: KAKEN
FX Grant support: Cancer Research from the Ministry of Education, Science,
   Sports and Culture of Japan grant in aid 17016051 (S. Sone).
CR Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432 0436.2002.700904.x
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   GNANT M, 2008, J CLIN ONCOL, V26, pS1006
   GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022 1759(84)90190 X
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   GURNEY H, 1993, LANCET, V341, P1611, DOI 10.1016/0140 6736(93)90756 7
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Iguchi H, 2001, INT J CANCER, V94, P24, DOI 10.1002/ijc.1425
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Miki T, 2004, INT J CANCER, V108, P511, DOI 10.1002/ijc.11586
   Miki T, 2000, ONCOL RES, V12, P209
   Muguruma H, 2005, CLIN CANCER RES, V11, P8822, DOI 10.1158/1078 0432.CCR 05 1335
   Onuma E, 2005, CLIN CANCER RES, V11, P4198, DOI 10.1158/1078 0432.CCR 04 2531
   QUINT LE, 1996, LUNG CANC PRINCIPLES, P437
   Rabbani SA, 1999, INT J CANCER, V80, P257, DOI 10.1002/(SICI)1097 0215(19990118)80:2<257::AID IJC15>3.0.CO;2 3
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Sone S, 2007, CANCER METAST REV, V26, P685, DOI 10.1007/s10555 007 9081 z
   Sullivan F. J., 1996, LUNG CANC PRINCIPLES, P775
   TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103
   Theriault RL, 2001, SEMIN ONCOL, V28, P284, DOI 10.1053/sonc.2001.23494
   Yano S, 2003, CLIN CANCER RES, V9, P5380
   Yano S, 2003, CANCER SCI, V94, P244, DOI 10.1111/j.1349 7006.2003.tb01428.x
   Yano S, 1996, INT J CANCER, V67, P211, DOI 10.1002/(SICI)1097 0215(19960717)67:2<211::AID IJC11>3.0.CO;2 E
NR 32
TC 13
Z9 20
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2009
VL 8
IS 1
BP 119
EP 126
DI 10.1158/1535 7163.MCT 08 0874
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 395BM
UT WOS:000262497100014
PM 19139120
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Theriault, RL
   Theriault, RL
AF Theriault, Rachel L.
   Theriault, Richard L.
TI Biology of Bone Metastases
SO CANCER CONTROL
LA English
DT Article
ID BREAST CANCER PATIENTS; PLACEBO CONTROLLED TRIAL; ADJUVANT CLODRONATE
   TREATMENT; RANDOMIZED CONTROLLED TRIAL; SUPPORTIVE PAMIDRONATE
   TREATMENT; ADVANCED MULTIPLE MYELOMA; PHASE II TRIAL; DOUBLE BLIND;
   ZOLEDRONIC ACID; SKELETAL COMPLICATIONS
AB Background: Bone metastases cause morbidity and mortality in multiple malignancies. In addition to portending a dire prognosis, bone metastases cause bone pain, fractures, hypercalcemia, spinal cord compression, and other nerve compression syndromes. Improved understanding of the mechanisms that predispose tumor metastases to bone is needed to improve patients' therapeutic options, maintain their quality of life, and improve their survival.
   Methods: This review discusses selected preclinical and clinical data regarding bone metastasis development and cytokine/molecular interactions predisposing to bone metastases formation. Potential interventions for reducing bone metastases are also described.
   Results: Biologic mechanisms resulting in metastases of tumor cells to bone are being studied. Among these are the RANKL pathway, osteoclast activation via cytokines (produced by tumor cell and cells in the bone microenvironment), interactions with transient and stromal cells in the bone microenvironment, and molecules such as PTHrP and endothelin 1. These molecules offer important opportunities for targeted interventions to decrease bone metastases associated morbidity.
   Conclusions: Knowledge of the pathophysiology of bone and cancer is developing rapidly. Relationships among cancer cells, bone derived cells, and cytokines provide opportunities for the development of new interventions. Therapy targeting osteoclast/osteoblast interactions has proven benefit for patients with bone metastases.
C1 [Theriault, Richard L.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Theriault, Rachel L.] Univ Texas MD Anderson Canc Ctr, Dept Canc Med, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Theriault, RL (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM rtheriau@mdanderson.org
CR Adwan H, 2004, CANCER GENE THER, V11, P109, DOI 10.1038/sj.cgt.7700659
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Burton DW, 2005, PROSTATE, V62, P275, DOI 10.1002/pros.20146
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Coleman RE, 1999, ANN ONCOL, V10, P311, DOI 10.1023/A:1008386501738
   Coleman RE, 2007, SEMIN ONCOL, V34, pS11, DOI 10.1053/j.seminoncol.2007.10.003
   Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552
   Dafermou A, 2001, EUR J NUCL MED, V28, P788, DOI 10.1007/s002590100533
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Fehm T, 2009, BREAST, V18, P213, DOI 10.1016/j.breast.2009.07.001
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gallwitz WE, 2002, J CLIN INVEST, V110, P1559, DOI 10.1172/JCI200211936
   Gnant M, 2009, CURR CANCER DRUG TAR, V9, P824, DOI 10.2174/156800909789760267
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Heras P, 2007, EUR J CANCER CARE, V16, P539, DOI 10.1111/j.1365 2354.2007.00808.x
   Heras P, 2009, EUR J CANCER CARE, V18, P653, DOI 10.1111/j.1365 2354.2008.00980.x
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2010, SEMIN ONCOL, V37, pS15, DOI 10.1053/j.seminoncol.2010.10.002
   Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008 5472.CAN 03 2439
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Ogata Etsuro, 2000, Cancer, V88, P2909, DOI 10.1002/1097 0142(20000615)88:12+<2909::AID CNCR5>3.0.CO;2 7
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Pecherstorfer M, 1996, J CLIN ONCOL, V14, P268, DOI 10.1200/JCO.1996.14.1.268
   Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520 003 0477 1
   Piga A, 1998, J EXP CLIN CANC RES, V17, P213
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   ROBERTSON AG, 1995, J CLIN ONCOL, V13, P2427, DOI 10.1200/JCO.1995.13.9.2427
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rubens RD, 2000, CANCER AND THE SKELETON, P33
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   SASAKI A, 1995, CANCER RES, V55, P3551
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tubiana Hulin M, 2001, B CANCER, V88, P701
   VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983
   VANHOLTENVERZANTVOORT ATM, 1991, EUR J CANCER, V27, P544, DOI 10.1016/0277 5379(91)90212 V
   VANHOLTENVERZANTVOORT ATM, 1993, J CLIN ONCOL, V11, P491, DOI 10.1200/JCO.1993.11.3.491
   vanHoltenVerzantvoort ATM, 1996, EUR J CANCER, V32A, P450, DOI 10.1016/0959 8049(95)00564 1
   Yi B, 2002, CANCER RES, V62, P917
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008 5472.CAN 06 4499
NR 70
TC 72
Z9 87
U1 0
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073 2748
J9 CANCER CONTROL
JI Cancer Control
PD APR
PY 2012
VL 19
IS 2
BP 92
EP 101
DI 10.1177/107327481201900203
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 994XV
UT WOS:000307969100003
PM 22487971
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, TY
   Hou, X
   Huang, YH
   Wang, CS
   Chen, HY
   Yan, CY
AF Li, Tianyu
   Hou, Xin
   Huang, Yihua
   Wang, Changsheng
   Chen, Haiyun
   Yan, Chunyan
TI In vitro and in silico anti osteoporosis activities and underlying
   mechanisms of a fructan, ABW90 1, from Achyranthes bidentate
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Osteoporosis; Achyranthes bidentate; Oligosaccharide; Osteogenic
   effects; Molecular docking; Mechanisms
ID PROMOTES OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   BONE FORMATION; BETA CATENIN; WNT; EXPRESSION; RUNX2; BMP; PATHWAY;
   POLYSACCHARIDE
AB Achyranthes bidentata is a traditional Chinese medicine used to treat osteoporosis. AB90, a crude saccharide from A. bidentata, showed excellent osteoprotective effects in ovariectomized rats, and ABW90 1, an oligosaccharide purified from AB90, stimulated significant differentiation of osteoblasts. However, the osteogenic effects and underlying mechanisms of ABW90 1 have remained unknown. In the present study, we found that ABW90 1 significantly promoted ALP activity, mineralization, and the expression of osteogenic markers in MC3T3 E1 cells. ABW90 1 showed strong binding with the WNT signaling complex and BMP2 based on number of interactions, hydrogen bond length, and binding energy in silico. ABW90 1 significantly increased the expression of active fl catenin, p GSK 3fl, LEF 1, BMP2, and p SMAD1. Importantly, the osteogenic effects of ABW90 1 were partially suppressed by DKK 1 and Noggin, which are specific inhibitors of the WNT and BMP signaling pathways, respectively. Collectively, these findings suggest that ABW90 1 has osteogenic effects through crosstalk between WNT/fl catenin and BMP2/SMAD1 signaling pathways.
C1 [Li, Tianyu; Wang, Changsheng; Yan, Chunyan] Guangdong Pharmaceut Univ, Clin Pharm, Affiliated Hosp 1, Guangzhou 510060, Peoples R China.
   [Li, Tianyu; Hou, Xin; Huang, Yihua; Yan, Chunyan] Guangdong Pharmaceut Univ, Sch Clin Pharm, Guangzhou 510006, Peoples R China.
   [Chen, Haiyun] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Pharmaceutical
   University; Guangdong Pharmaceutical University
RP Yan, CY (通讯作者)，Guangdong Pharmaceut Univ, Clin Pharm, Affiliated Hosp 1, Guangzhou 510060, Peoples R China.
EM ycybridge@gdpu.edu.cn
RI Wang, Changsheng/AFN 8557 2022; hou, xinxin/AAI 2389 2019
FU National Natural Science Foundation of China [81673557, U1703110,
   81973454]
FX This study was funded by the National Natural Science Foundation of
   China (Nos. 81673557, U1703110 and 81973454) .
CR Abula K, 2015, FEBS LETT, V589, P1240, DOI 10.1016/j.febslet.2015.04.004
   Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Agata P., 2019, J PHYS D APPL PHYS, V52
   Aggarwal L, 2018, J FAM PRACTICE, V67, P59
   Ahmadzadeh A, 2016, CELL TISSUE RES, V363, P321, DOI 10.1007/s00441 015 2300 y
   Biswas T, 2020, INT J DEV BIOL, V64, P213, DOI 10.1387/ijdb.190149ab
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745 7599.2007.00269.x
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen XX, 2020, FOOD FUNCT, V11, P1165, DOI [10.1039/c9fo01918a, 10.1039/C9FO01918A]
   Du L, 2016, SCI REP UK, V6, DOI 10.1038/srep32261
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   El Rayes SM, 2020, ACS OMEGA, V5, P6781, DOI 10.1021/acsomega.0c00116
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Israa T., 2020, MOL DIVERS, V25, P435
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li WJ, 2018, CARBOHYD POLYM, V202, P581, DOI 10.1016/j.carbpol.2018.08.144
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liou SF, 2015, J CELL PHYSIOL, V230, P2038, DOI 10.1002/jcp.24904
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Park OJ, 2017, J BONE MINER RES, V32, P1455, DOI 10.1002/jbmr.3137
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   van Dinther M, 2010, J BONE MINER RES, V25, P1208, DOI [10.1002/jbmr.091110, 10.1359/jbmr.091110]
   Nguyen VT, 2018, PROCESS BIOCHEM, V67, P127, DOI 10.1016/j.procbio.2018.01.025
   Wang CS, 2017, IND CROP PROD, V108, P458, DOI 10.1016/j.indcrop.2017.07.018
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Wang YQ, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109807
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Yu WW, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01844 x
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang ZY, 2012, ASIAN J ANIM VET ADV, V7, P726, DOI 10.3923/ajava.2012.726.732
   Zhong J, 2020, INT J BIOL MACROMOL, V163, P464, DOI 10.1016/j.ijbiomac.2020.06.266
NR 57
TC 13
Z9 14
U1 2
U2 62
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144 8617
EI 1879 1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JAN 15
PY 2022
VL 276
AR 118730
DI 10.1016/j.carbpol.2021.118730
EA OCT 2021
PG 12
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Polymer Science
GA WJ1OK
UT WOS:000708818500007
PM 34823766
DA 2025 08 17
ER

PT J
AU Frazier, KS
AF Frazier, Kendall S.
TI Drug induced Physeal Abnormalities in Preclinical Toxicity Studies
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE mechanisms of toxicity; musculoskeletal system; physis; pharmaceutical
ID ENDOCHONDRAL BONE FORMATION; FIBROBLAST GROWTH FACTOR; TYROSINE KINASE
   INHIBITOR; PARATHYROID HORMONE; HYPERTROPHIC CHONDROCYTES; MATRIX
   MINERALIZATION; PLATE ANGIOGENESIS; SAFETY EVALUATION; FACTOR
   RECEPTOR 3; MOUSE MODEL
AB Most toxic physeal changes are characterized microscopically by altered chondrocyte development, proliferation, or maturation in the growth plate and eventually result in disordered appositional bone growth. Many therapeutic drugs directly or indirectly target proteins involved in chondrocytic differentiation and maturation pathways, so toxic physeal injury has become increasingly common in preclinical toxicologic pathology. While physeal dysplasia has been associated with several different drug classes including bisphosphonates, vascular endothelial growth factor receptor inhibitors, fibroblast growth factor receptor inhibitors, transforming growth factor beta receptor inhibitors, and vascular targeting agents, physeal changes often share similar morphologic features including thickening and disorganization of the hypertrophic layer, increased numbers of hypertrophic chondrocytes, altered mineralization of endochondral ossification, and/or increased thickness of subphyseal bone. Knowledge of genetic and nutritional diseases affecting bone growth has been important in helping to determine which specific target drugs may be affecting that could result in toxic physeal lesions. A pathophysiologic mechanism for most physeal toxicants has been determined in detail using a variety of investigative techniques. However, due to the signaling cross talk and the tight regulation required for chondrocyte maturation in the physis, several growth factor pathways are likely to be affected simultaneously with pharmacologic disruption of physeal homeostasis and inhibition of one factor necessary for chondrocyte function often affects others.
C1 [Frazier, Kendall S.] GlaxoSmithKline, 709 Swedeland Rd,UE0376 POB 1539, King Of Prussia, PA 19406 USA.
C3 GlaxoSmithKline; Glaxosmithkline USA
RP Frazier, KS (通讯作者)，GlaxoSmithKline, 709 Swedeland Rd,UE0376 POB 1539, King Of Prussia, PA 19406 USA.
EM kendall.s.frazier@gsk.com
CR Alvarez J, 2001, DEV DYNAM, V221, P311, DOI 10.1002/dvdy.1141
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   Baragi VM, 2009, ARTHRITIS RHEUM US, V60, P2008, DOI 10.1002/art.24629
   BARON J, 1994, ENDOCRINOLOGY, V135, P2790, DOI 10.1210/en.135.6.2790
   Bonaventure J, 1996, AM J MED GENET, V63, P148, DOI 10.1002/(SICI)1096 8628(19960503)63:1<148::AID AJMG26>3.0.CO;2 N
   Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577
   Brown AP, 2005, TOXICOL PATHOL, V33, P449, DOI 10.1080/01926230590961845
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200
   COE MR, 1992, BONE MINER, V18, P91, DOI 10.1016/0169 6009(92)90850 D
   COLE WG, 1994, PROG NUCLEIC ACID RE, V47, P29, DOI 10.1016/S0079 6603(08)60249 4
   Davis PD, 2002, CANCER RES, V62, P7247
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092 8674(00)81069 7
   Eastwood DM., 2011, Surg Infect (Larchmt), V29, P146
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Fossey S, 2016, J TOXICOL PATHOL, V29, p49S, DOI [10.1293/tox.29.3S 2, 10.1293/tox.2016 I002]
   Frazier K. S., 2008, ENCY MOL MECH DIS
   Frazier K, 2007, TOXICOL PATHOL, V35, P284, DOI 10.1080/01926230701198469
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050 1738(00)00074 8
   Hall AP, 2016, TOXICOL PATHOL, V44, P866, DOI 10.1177/0192623316646483
   Hall AP, 2006, TOXICOL PATHOL, V34, P131, DOI 10.1080/01926230600611836
   HANSSON LI, 1972, CALC TISS RES, V10, P238, DOI 10.1007/BF02012553
   Hosseinzadeh P, 2011, CURR ORTHOP PRACT, V22, P130, DOI 10.1097/BCO.0b013e318209a475
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   LARSSON A, 1978, ACTA PATH MICRO IM A, V86, P211
   Lee ER, 1999, DEV DYNAM, V215, P190, DOI 10.1002/(SICI)1097 0177(199907)215:3<190::AID AJA2>3.3.CO;2 2
   Lemyre E, 1999, CAN ASSOC RADIOL J, V50, P185
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Nagai H, 2002, J BONE MINER METAB, V20, P142, DOI 10.1007/s007740200020
   Ortega N, 2005, MOL BIOL CELL, V16, P3028, DOI 10.1091/mbc.e04 12 1119
   Pateder DB, 2000, EXP CELL RES, V256, P555, DOI 10.1006/excr.2000.4860
   Patyna S, 2008, TOXICOL PATHOL, V36, P905, DOI 10.1177/0192623308326151
   Pavasant P, 1996, MATRIX BIOL, V15, P423, DOI 10.1016/S0945 053X(96)90161 4
   Pettifor J., 2005, The Bone and Mineral Manual, A Practical Guide, P39
   Renkiewicz R, 2003, ARTHRITIS RHEUM, V48, P1742, DOI 10.1002/art.11030
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   SCHOFIELD D, 1999, ROBBINS PATHOLOGIC B, P459
   Smith EJ, 2005, J BONE MINER RES, V20, P1731, DOI 10.1359/JBMR.050604
   Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461
   SupertiFurga A, 1996, AM J MED GENET, V63, P144, DOI 10.1002/(SICI)1096 8628(19960503)63:1<144::AID AJMG25>3.0.CO;2 N
   Takahashi M, 2014, FOOD CHEM TOXICOL, V73, P84, DOI 10.1016/j.fct.2014.08.006
   Takahashi M, 2010, TOXICOL PATHOL, V38, P598, DOI 10.1177/0192623310368979
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wedge SR, 2000, CANCER RES, V60, P970
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008 5472.CAN 04 4409
   Wu CW, 2002, J BONE MINER RES, V17, P639, DOI 10.1359/jbmr.2002.17.4.639
NR 50
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192 6233
EI 1533 1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD OCT
PY 2017
VL 45
IS 7
BP 869
EP 875
DI 10.1177/0192623317713319
PG 7
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA FN4YJ
UT WOS:000416012600010
PM 28643552
DA 2025 08 17
ER

PT J
AU Kwak, HB
   Sun, HM
   Ha, H
   Kim, HN
   Lee, JH
   Kim, HH
   Shin, HI
   Lee, ZH
AF Kwak, Han Bok
   Sun, Hyun Min
   Ha, Hyunil
   Kim, Ha Neui
   Lee, Jong Ho
   Kim, Hong Hee
   Shin, Hong In
   Lee, Zang Hee
TI Tanshinone IIA suppresses inflammatory bone loss by inhibiting the
   synthesis of prostaglandin E2 in osteoblasts
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Tanshinone IIA; Osteoclast; LPS; RANKL; Prostaglandin E 2
ID OSTEOCLAST DIFFERENTIATION; ANGIOTENSIN II; IN VIVO; RESORPTION;
   LIPOPOLYSACCHARIDE; EXPRESSION; RECEPTORS; INDUCTION; ALPHA; CELLS
AB Tanshinone IIA isolated from Danshen is widely used in Oriental medicine. However, the action of tanshinone IIA in inflammatory bone resorptive diseases remains unknown. Here we examined the effect of tanshinone IIA in inflammation mediated osteoclastic bone resorption. Tanshinone IIA inhibited osteoclast differentiation in cocultures of bone marrow cells and calvarial osteoblasts. Tanshinone IIA regulated the expression of receptor activator of NF kappa B ligand and osteoprotegerin in osteoblasts treated with lipopolysaccharide (LPS). Also, tanshinone IIA inhibited prostaglandin E 2 (PGE(2)) synthesis by inhibiting Cyclooxygenase 2 (COX 2) expression induced by LPS. Furthermore, tanshinone IIA greatly suppressed bone loss in the mouse models of bone loss. Our findings suggest that tanshinone IIA inhibits osteoclast formation by inhibiting COX 2/PGE(2) signaling and by suppressing bone erosion in vivo. These results suggest that tanshinone IIA may be of therapeutic value as an anti bone resorptive drug in the treatment of bone related disease. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Sun, Hyun Min; Ha, Hyunil; Kim, Ha Neui; Lee, Jong Ho; Kim, Hong Hee; Lee, Zang Hee] Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, DRI, Seoul 110749, South Korea.
   [Kwak, Han Bok] Wonkwang Univ, Dept Anat, Sch Med, Iksan, South Korea.
   [Shin, Hong In] Kyungpook Natl Univ, Sch Dent, Taegu, South Korea.
C3 Seoul National University (SNU); Wonkwang University; Kyungpook National
   University (KNU)
RP Lee, ZH (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, DRI, 28 Yeongon Dong, Seoul 110749, South Korea.
EM zang1959@snu.ac.kr
RI ; Kim, Hee/F 4594 2014; Kim, Jung Wook/AAI 1668 2020
OI Ha, Hyunil/0000 0001 5947 9982; 
FU 21st Century Frontier RD Program; Korea Science and Engineering
   Foundation (KOSEF); Korean Ministry of Education, Science and Technology
FX This work was supported by a grant from the Center for Biological
   Modulators of the 21st Century Frontier R&D Program, and of the Korea
   Science and Engineering Foundation (KOSEF) Science Research Center
   through Bone Metabolism Research Center, the Korean Ministry of
   Education, Science and Technology.
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074 7613(00)80596 8
   Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0
   Cui L, 2004, ACTA PHARMACOL SIN, V25, P678
   Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024
   FU JY, 1990, J BIOL CHEM, V265, P16737
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gregory LS, 2006, BONE, V39, P134, DOI 10.1016/j.bone.2005.12.017
   Ha H, 2006, J IMMUNOL, V176, P111, DOI 10.4049/jimmunol.176.1.111
   Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879
   Jang SI, 2003, PLANTA MED, V69, P1057, DOI 10.1055/s 2003 45157
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157
   Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883
   Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689
   Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200
   Siegle I, 1998, ARTHRITIS RHEUM US, V41, P122, DOI 10.1002/1529 0131(199801)41:1<122::AID ART15>3.3.CO;2 #
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Takahashi K, 2002, BIOCHEM PHARMACOL, V64, P745, DOI 10.1016/S0006 2952(02)01250 9
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tang FT, 2007, VASC PHARMACOL, V46, P427, DOI 10.1016/j.vph.2007.01.001
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   Yang L, 2007, EXP MOL MED, V39, P65, DOI 10.1038/emm.2007.8
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 39
TC 32
Z9 42
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD DEC 28
PY 2008
VL 601
IS 1 3
BP 30
EP 37
DI 10.1016/j.ejphar.2008.10.034
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 385PB
UT WOS:000261825000005
PM 18973753
DA 2025 08 17
ER

PT S
AU Sun, M
   Lqbal, J
   Singh, S
   Sun, L
   Zaidi, M
AF Sun, Merry
   Lqbal, Jameel
   Singh, Sukhjeet
   Sun, Li
   Zaidi, Mone
BE Mechanick, JI
   Sun, L
   Zaidi, M
TI The crossover of bisphosphonates to cancer therapy
SO MOLECULAR AND INTEGRATIVE PHYSIOLOGY OF THE MUSCULOSKELETAL SYSTEM
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE bone metastases; bisphosphonates; cancer therapy
ID POSITIVE TUMOR CELLS; EARLY BREAST CANCER; BONE MARROW; ZOLEDRONIC ACID;
   MOLECULAR MECHANISMS; IN VIVO; DISEASE; CLODRONATE; APOPTOSIS;
   METASTASIS
AB Bisphosphonates form a class of drugs commonly used to treat disorders of osteoclastic bone resorption, including osteoporosis, Paget's disease of the bone, rheumatoid arthritis, and bone metastases. Although long established as the therapy of choice to treat such disorders, bisphosphonates' potential in treating cancer is garnering interest. Bisphosphonates have been demonstrated to inhibit tumor growth and metastasis, induce apoptosis in tumor cells, and encourage immune reactions against tumor cells. Current applications of bisphosphonates in cancer treatment include their use to treat skeletal metastases and as an adjuvant to endocrine therapy. This review explores bisphosphonates' current clinical utility and potential as a crossover cancer therapy.
C1 [Sun, Merry; Lqbal, Jameel; Singh, Sukhjeet; Sun, Li; Zaidi, Mone] Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Zaidi, M (通讯作者)，Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA.
EM Mone.zaidi@mssm.edu; Mone.zaidi@mssm.edu
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Asahi H, 2006, INT J UROL, V13, P593, DOI 10.1111/j.1442 2042.2006.01360.x
   Borutaite V, 2010, ENVIRON MOL MUTAGEN, V51, P406, DOI 10.1002/em.20564
   Bozionellou V, 2004, CLIN CANCER RES, V10, P8185, DOI 10.1158/1078 0432.CCR 03 0094
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Braun S, 1999, CLIN CANCER RES, V5, P3999
   Brown SA, 2009, CRIT REV EUKAR GENE, V19, P47, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.20
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   EGGELMEIJER E, 1996, ARTHRITIS RHEUM, V39, P396
   EIDTMANN H, 2010, ANN ONCOL
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   FRANCIS MD, 1989, INT J TISSUE REACT, V11, P239
   Fromigue O, 2000, J BONE MINER RES, V15, pS480
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Kabelitz D, 2007, CANCER RES, V67, P5, DOI 10.1158/0008 5472.CAN 06 3069
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   Lattouf JB, 2010, CURR OPIN UROL, V20, P247, DOI 10.1097/MOU.0b013e32833835be
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Lipton A, 2010, BREAST CANCER RES TR, V122, P627, DOI 10.1007/s10549 010 0935 7
   Maughan KL, 2010, AM FAM PHYSICIAN, V81, P1339
   Mauri D, 2010, J NATL COMPR CANC NE, V8, P279, DOI 10.6004/jnccn.2010.0020
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Pantel K, 1999, JNCI J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113
   Pazianas M, 2009, REV RECENT CLIN TRIA, V4, P122, DOI 10.2174/157488709788186030
   Pechlivanis M, 2006, BBA PROTEINS PROTEOM, V1764, P1914, DOI 10.1016/j.bbapap.2006.09.017
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reeder JG, 2010, ONCOLOGY NY, V24, P462
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 42
TC 10
Z9 11
U1 0
U2 2
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 831 0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2010
VL 1211
BP 107
EP 112
DI 10.1111/j.1749 6632.2010.05812.x
PG 6
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Physiology
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Physiology
GA BTO14
UT WOS:000287463400010
PM 21062299
DA 2025 08 17
ER

PT J
AU Jiang, M
   Peng, L
   Yang, K
   Wang, TQ
   Yan, XM
   Jiang, T
   Xu, JR
   Qi, J
   Zhou, HB
   Qian, ND
   Zhou, Q
   Chen, B
   Xu, X
   Deng, LF
   Yang, CH
AF Jiang, Min
   Peng, Lei
   Yang, Kai
   Wang, Tianqi
   Yan, Xueming
   Jiang, Tao
   Xu, Jianrong
   Qi, Jin
   Zhou, Hanbing
   Qian, Niandong
   Zhou, Qi
   Chen, Bo
   Xu, Xing
   Deng, Lianfu
   Yang, Chunhao
TI Development of Small Molecules Targeting Receptor Activator of Nuclear
   Factor κB Ligand (RANKL) Receptor Activator of Nuclear Factor κB (RANK)
   Protein Protein Interaction by Structure Based Virtual Screening and Hit
   Optimization
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; BONE RESORPTION; OSTEOPROTEGERIN; DENOSUMAB;
   PATHOGENESIS; DISEASE; CANCER; WOMEN
AB Targeting RANKL/RANK offers the possibility of developing novel therapeutic approaches to treat bone metabolic diseases. Multiple efforts have been made to inhibit RANKL. For example, marketed monoclonal antibody drug Denosumab could inhibit the maturation of osteoclasts by binding to RANKL. This study is an original approach aimed at discovering small molecule inhibitors impeding RANKL/RANK protein interaction. We identified compound 34 as a potent and selective RANKL/RANK inhibitor by performing structure based virtual screening and hit optimization. Disruption of the RANKL/RANK interaction by 34 effectively inhibits RANKL induced osteoclastogenesis and bone resorption. The expression of osteoclast marker genes was also suppressed by treatment of 34. Furthermore, 34 markedly blocked the NFATc1/c fos pathway. Thus, our current work demonstrates that the chemical tractability of the difficult PPI (RANKL/RANK) target by a small molecule compound 34 offers a potential lead compound to facilitate the development of new medications for bone related diseases.
C1 [Jiang, Min; Yang, Kai; Wang, Tianqi; Yan, Xueming; Jiang, Tao; Qi, Jin; Zhou, Hanbing; Qian, Niandong; Zhou, Qi; Chen, Bo; Xu, Xing; Deng, Lianfu] Shanghai Jiao Tong Univ, Shanghai Key Lab Bone & Joint Dis, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed,Sch Med, 197 Second Ruijin Rd, Shanghai 200025, Peoples R China.
   [Peng, Lei; Yang, Chunhao] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, 555 Chong Zhi Rd, Shanghai 201203, Peoples R China.
   [Peng, Lei; Yang, Chunhao] Univ Chinese Acad Sci, Sch Pharm, 19A Yuquan Rd, Beijing 100049, Peoples R China.
   [Xu, Jianrong] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol & Chem Biol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Materia Medica, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong
   University
RP Xu, X; Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Key Lab Bone & Joint Dis, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed,Sch Med, 197 Second Ruijin Rd, Shanghai 200025, Peoples R China.; Yang, CH (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, 555 Chong Zhi Rd, Shanghai 201203, Peoples R China.; Yang, CH (通讯作者)，Univ Chinese Acad Sci, Sch Pharm, 19A Yuquan Rd, Beijing 100049, Peoples R China.
EM xuxing0510315@126.com; lfdeng@msn.com; chyang@simm.ac.cn
RI Wang, Tianqi/KIC 1831 2024; Zhou, Han/ISU 2803 2023; Yang,
   Kai/JQW 2039 2023; Zhou, Qi/JGM 4026 2023
OI Yang, Kai/0000 0002 5544 7817; Jiang, Min/0000 0003 1530 6830
FU NSFC [81703576, 81502902]; Shanghai Municipal Health Bureau Scientific
   Research Project [201840185, 20154Y0005]; Committee of Science and
   Technology Young Scientific Research Foundation of Shanghai
   [16ZR1431900]; Guangci Distinguished Young Scholars Training Program
   [GCQN 2017 A16, GCQN 2017 B22]
FX This work was supported by the NSFC (No. 81703576, 81502902), Shanghai
   Municipal Health Bureau Scientific Research Project (Nos. 201840185 and
   20154Y0005), Committee of Science and Technology Young Scientific
   Research Foundation of Shanghai (No. 16ZR1431900), and Guangci
   Distinguished Young Scholars Training Program (No. GCQN 2017 A16,
   GCQN 2017 B22).
CR Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Duarte Joao H, 2016, Nat Rev Rheumatol, V12, P69, DOI 10.1038/nrrheum.2015.177
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kato G, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0753 8
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Melagraki G, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005372
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ralston SH, 2012, CALCIFIED TISSUE INT, V91, P97, DOI 10.1007/s00223 012 9599 0
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Watts NB, 2017, J BONE MINER RES, V32, P1481, DOI 10.1002/jbmr.3119
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Zhang SQ, 2009, ARCH BIOCHEM BIOPHYS, V487, P49, DOI 10.1016/j.abb.2009.04.008
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 39
TC 20
Z9 22
U1 2
U2 58
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 13
PY 2019
VL 62
IS 11
BP 5370
EP 5381
DI 10.1021/acs.jmedchem.8b02027
PG 12
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA ID7AQ
UT WOS:000471834500009
PM 31082234
DA 2025 08 17
ER

PT J
AU Moon, HJ
   Kim, SE
   Yun, YP
   Hwang, YS
   Bang, JB
   Park, JH
   Kwon, IK
AF Moon, Ho Jin
   Kim, Sung Eun
   Yun, Young Pil
   Hwang, Yu Shik
   Bang, Jae Beum
   Park, Jae Hong
   Kwon, Il Keun
TI Simvastatin inhibits osteoclast differentiation by scavenging reactive
   oxygen species
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE bone resorption; mitogen activated protein kinases; osteoclast; RANK
   ligand; reactive oxygen species; simvastatin
ID FACTOR KAPPA B; BONE RESORPTION; RECEPTOR ACTIVATOR; HYDROGEN PEROXIDE;
   OSTEOPROTEGERIN LIGAND; SIGNAL TRANSDUCTION; FREE RADICALS; IN VITRO;
   AKT; LIPOPROTEINS
AB Osteoclasts, together with osteoblasts, control the amount of bone tissue and regulate bone remodeling. Osteoclast differentiation is an important factor related to the pathogenesis of bone loss related diseases. Reactive oxygen species (ROS) acts as a signal mediator in osteoclast differentiation. Simvastatin, which inhibits 3 hydroxy 3 methylglutaryl coenzyme A, is a hypolipidemic drug which is known to affect bone metabolism and suppresses osteoclastogenesis induced by receptor activator of nuclear factor kappa B ligand (RANKL). In this study, we analyzed whether simvastatin can inhibit RANKL induced osteoclastogenesis through suppression of the subsequently formed ROS and investigated whether simvastatin can inhibit H2O2 induced signaling pathways in osteoclast differentiation. We found that simvastatin decreased expression of tartrate resistant acid phosphatase (TRAP), a genetic marker of osteoclast differentiation, and inhibited intracellular ROS generation in RAW 264.7 cell lines. ROS generation activated NF kappa B, protein kinases B (AKT), mitogen activated protein kinases signaling pathways such as c JUN N terminal kinases, p38 MAP kinases as well as extracellular signal regulated kinase. Simvastatin was found to suppress these H2O2 induced signaling pathways in osteoclastogenesis. Together, these results indicate that simvastatin acts as an osteoclastogenesis inhibitor through suppression of ROS mediated signaling pathways. This indicates that simvastatin has potential usefulness for osteoporosis and pathological bone resorption.
C1 [Park, Jae Hong] Kyung Hee Univ, Sch Dent, Dept Pediat Dent, Seoul 130701, South Korea.
   [Bang, Jae Beum] Kyung Hee Univ, Sch Dent, Dept Dent Educ, Seoul 130701, South Korea.
   [Moon, Ho Jin; Kim, Sung Eun; Yun, Young Pil; Hwang, Yu Shik; Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul 130701, South Korea.
   [Moon, Ho Jin; Kim, Sung Eun; Yun, Young Pil; Hwang, Yu Shik; Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Inst Oral Biol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University
RP Park, JH (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Pediat Dent, Seoul 130701, South Korea.
EM pedopjh@khu.ac.kr; kwoni@khu.ac.kr
RI KIM, SUNG/ADF 8559 2022; Bang, Jaebeum/ABH 6262 2020
OI Moon, Ho Jin/0000 0002 8056 5313; Kwon, Il Keun/0000 0001 9649 3003
FU Kyung Hee University [KHU 20071500]
FX This Research was supported by the Program of Kyung Hee University for
   the Young Researcher of Medical Science in 2007 (KHU 20071500).
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217
   Bonizzi G, 1999, MOL CELL BIOL, V19, P1950
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Davignon J, 2004, CORONARY ARTERY DIS, V15, P251, DOI 10.1097/01.mca.0000131573.31966.34
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Forman HJ, 2004, AM J PHYSIOL CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003
   Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756 3282(96)00177 9
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Girona J, 1999, AM J CARDIOL, V83, P846, DOI 10.1016/S0002 9149(98)01071 6
   GIROUX LM, 1993, BIOCHIM BIOPHYS ACTA, V1165, P335, DOI 10.1016/0005 2760(93)90145 Y
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Hasegawa S, 2010, BIOL PHARM BULL, V33, P487, DOI 10.1248/bpb.33.487
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jamal SM, 2004, AM HEART J, V147, P956, DOI 10.1016/j.ahj.2003.12.037
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim SE, 2009, EXP MOL MED, V41, P277, DOI 10.3858/emm.2009.41.4.031
   Kwak HB, 2008, MOL CELLS, V26, P436
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mason RP, 1999, CIRCULATION, V100, P541
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   Tomás M, 2000, ARTERIOSCL THROM VAS, V20, P2113, DOI 10.1161/01.ATV.20.9.2113
   von Metzler I, 2009, J CANCER RES CLIN, V135, P173, DOI 10.1007/s00432 008 0461 8
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 43
TC 74
Z9 82
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD NOV 30
PY 2011
VL 43
IS 11
BP 605
EP 612
DI 10.3858/emm.2011.43.11.067
PG 8
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 856CV
UT WOS:000297615300001
PM 21832867
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ali, D
   Hamam, R
   Alfayez, M
   Kassem, M
   Aldahmash, A
   Alajez, NM
AF Ali, Dalia
   Hamam, Rimi
   Alfayez, Musaed
   Kassem, Moustapha
   Aldahmash, Abdullah
   Alajez, Nehad M.
TI Epigenetic Library Screen Identifies Abexinostat as Novel Regulator of
   Adipocytic and Osteoblastic Differentiation of Human Skeletal
   (Mesenchymal) Stem Cells
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Epigenetic; Adipocyte; Osteoblast; Mesenchymal stem cells; Histone
   deacetylase inhibitors
ID HISTONE DEACETYLASE INHIBITORS; HUMAN BONE MARROW; OSTEOGENIC
   DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; GENE EXPRESSION;
   ADIPOSE TISSUE; IN VITRO; ADIPOGENESIS; PLURIPOTENCY; MODULATION
AB The epigenetic mechanisms promoting lineage specific commitment of human skeletal (mesenchymal or stromal) stem cells (hMSCs) into adipocytes or osteoblasts are still not fully understood. Herein, we performed an epigenetic library functional screen and identified several novel compounds, including abexinostat, which promoted adipocytic and osteoblastic differentiation of hMSCs. Using gene expression microarrays, chromatin immunoprecipitation for H3K9Ac combined with high throughput DNA sequencing (ChIP seq), and bioinformatics, we identified several key genes involved in regulating stem cell proliferation and differentiation that were targeted by abexinostat. Concordantly, ChIP quantitative polymerase chain reaction revealed marked increase in H3K9Ac epigenetic mark on the promoter region of AdipoQ, FABP4, PPAR gamma, KLF15, CEBPA, SP7, and ALPL in abexinostattreated hMSCs. Pharmacological inhibition of focal adhesion kinase (PF 573228) or insulin like growth factor 1R/ insulin receptor (NVP AEW51) signaling exhibited significant inhibition of abexinostatmediated adipocytic differentiation, whereas inhibition of WNT (XAV939) or transforming growth factor beta (SB505124) signaling abrogated abexinostat mediated osteogenic differentiation of hMSCs. Our findings provide insight into the understanding of the relationship between the epigenetic effect of histone deacetylase inhibitors, transcription factors, and differentiation pathways governing adipocyte and osteoblast differentiation. Manipulating such pathways allows a novel use for epigenetic compounds in hMSC based therapies and tissue engineering.
   SIGNIFICANCE
   This unbiased epigenetic library functional screen identified several novel compounds, including abexinostat, that promoted adipocytic and osteoblastic differentiation of human skeletal ( mesenchymal or stromal) stem cells (hMSCs). These data provide new insight into the understanding of the relationship between the epigenetic effect of histone deacetylase inhibitors, transcription factors, and differentiation pathways controlling adipocyte and osteoblast differentiation of hMSCs. Manipulating such pathways allows a novel use for epigenetic compounds in hMSC based therapies for tissue engineering, bone disease, obesity, and metabolic disorders.
C1 [Ali, Dalia; Hamam, Rimi; Alfayez, Musaed; Kassem, Moustapha; Aldahmash, Abdullah; Alajez, Nehad M.] King Saud Univ, Coll Med, Stem Cell Unit, Dept Anat, POB 305713, Riyadh 11461, Saudi Arabia.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh, Saudi Arabia.
   [Kassem, Moustapha] Univ Southern Denmark, Dept Endocrinol, Mol Endocrinol & Stem Cell Res Unit, Odense, Denmark.
C3 King Saud University; King Saud University; University of Southern
   Denmark
RP Alajez, NM (通讯作者)，King Saud Univ, Coll Med, Stem Cell Unit, Dept Anat, POB 305713, Riyadh 11461, Saudi Arabia.
EM nalajez@ksu.edu.sa
RI ; Kassem, Moustapha/J 7688 2013; Ali, Dalia/KEH 0488 2024; Aldahmash,
   Abdullah/D 4693 2015
OI Ali, Dalia/0000 0002 2852 5971; Alajez, Nehad/0000 0002 1546 1091;
   Kassem, Moustapha/0000 0003 1557 0869; 
FU College of Medicine Research Center (CMRC), Deanship for Scientific
   Research, King Saud University; Novo Nordisk Fonden [NNF15OC0016284]
   Funding Source: researchfish
FX We thank the College of Medicine Research Center (CMRC), Deanship for
   Scientific Research, King Saud University, for supporting this work.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Aldahmash A, 2012, ANN SAUDI MED, V32, P68, DOI 10.5144/0256 4947.2012.68
   Ali AT, 2013, EUR J CELL BIOL, V92, P229, DOI 10.1016/j.ejcb.2013.06.001
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Buggy JJ, 2006, MOL CANCER THER, V5, P1309, DOI 10.1158/1535 7163.MCT 05 0442
   Calvanese V, 2012, ADV EXP MED BIOL, V738, P236, DOI 10.1007/978 1 4614 1680 7_14
   CALVO JC, 1991, J BIOL CHEM, V266, P11237
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Duncan HF, 2016, INT ENDOD J, V49, P431, DOI 10.1111/iej.12475
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Gan Q, 2007, STEM CELLS, V25, P2, DOI 10.1634/stemcells.2006 0383
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Hamam D, 2015, STEM CELLS DEV, V24, P417, DOI 10.1089/scd.2014.0331
   Jamaladdin S, 2014, P NATL ACAD SCI USA, V111, P9840, DOI 10.1073/pnas.1321330111
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kim SN, 2009, ARCH PHARM RES, V32, P535, DOI 10.1007/s12272 009 1409 5
   Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016
   Kuzmochka C, 2014, ENDOCRINOLOGY, V155, P4762, DOI 10.1210/en.2014 1565
   Lee JH, 2007, INT J MOL MED, V20, P59
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu BS, 2014, DRUG DISCOV TODAY, V19, P801, DOI 10.1016/j.drudis.2013.11.011
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mo S., 2012, EMBRYOGENESIS, P67, DOI DOI 10.1371/journal.pone.0100936
   Moreno Navarrete J.M., 2012, Adipose Differentiation, P17, DOI DOI 10.1007/978 1 4614 0965 6
   Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Piters E, 2008, ARCH BIOCHEM BIOPHYS, V473, P112, DOI 10.1016/j.abb.2008.03.006
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Romagnani P, 2007, CURR MED CHEM, V14, P1129, DOI 10.2174/092986707780362880
   Romanov YA, 2005, B EXP BIOL MED+, V140, P138, DOI 10.1007/s10517 005 0430 z
   Rosen ED, 2000, GENE DEV, V14, P1293
   Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 362
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Scotti E, 2010, MOL CELL BIOL, V30, P2076, DOI 10.1128/MCB.00171 10
   Ververis K, 2013, BIOL TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Wei SJ, 2013, CELL MOL LIFE SCI, V70, P4569, DOI 10.1007/s00018 013 1395 0
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
   Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200
   Zhou YF, 2014, EUR J CELL BIOL, V93, P170, DOI 10.1016/j.ejcb.2014.03.001
NR 55
TC 26
Z9 28
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD AUG
PY 2016
VL 5
IS 8
BP 1036
EP 1047
DI 10.5966/sctm.2015 0331
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DY7DE
UT WOS:000385288800006
PM 27194745
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Rizzoli, R
   Body, JJ
   Brandi, ML
   Cannata Andia, J
   Chappard, D
   El Maghraoui, A
   Glüer, CC
   Kendler, D
   Napoli, N
   Papaioannou, A
   Pierroz, DD
   Rahme, M
   Van Poznak, CH
   de Villiers, TJ
   Fuleihan, GE
AF Rizzoli, R.
   Body, J.  J.
   Brandi, M.  L.
   Cannata Andia, J.
   Chappard, D.
   El Maghraoui, A.
   Glueer, C. C.
   Kendler, D.
   Napoli, N.
   Papaioannou, A.
   Pierroz, D. D.
   Rahme, M.
   Van Poznak, C. H.
   de Villiers, T. J.
   Fuleihan, G. El Hajj
CA Int Osteoporosis Fdn Comm Sci Advi
TI Cancer associated bone disease
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone; Cancer; IOF; Skeletal related events
ID EARLY BREAST CANCER; ANDROGEN DEPRIVATION THERAPY; 3RD GENERATION
   AROMATASE INHIBITORS; RANDOMIZED CONTROLLED TRIAL; PRACTICE GUIDELINE
   UPDATE; PROSTATE CANCER; ZOLEDRONIC ACID; MINERAL DENSITY;
   POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN
AB Bone is commonly affected in cancer. Cancer induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer related bone disease. With evidence based care pathways, guidelines assist physicians in clinical decision making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non communicable diseases, led by cardiovascular diseases and cancers. Bone is a commonly affected organ in cancer, and although the incidence of metastatic bone disease is not well defined, it is estimated that around half of patients who die from cancer in the USA each year have bone involvement. Furthermore, cancer induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances or metastatic bone disease, such as commonly occurs with breast, lung and prostate cancer, or from therapies administered to treat the primary condition thus causing bone loss and fractures. Treatment induced osteoporosis may occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy, chemotherapy induced ovarian failure and androgen deprivation therapy. Tumour skeletal related events include pathologic fractures, spinal cord compression, surgery and radiotherapy to bone and may or may not include hypercalcaemia of malignancy while skeletal complication refers to pain and other symptoms. Some evidence demonstrates the efficacy of various interventions including bone modifying agents, such as bisphosphonates and denosumab, in preventing or delaying cancer related bone disease. The latter includes treatment of patients with metastatic skeletal lesions in general, adjuvant treatment of breast and prostate cancer in particular, and the prevention of cancer associated bone disease. This has led to the development of guidelines by several societies and working groups to assist physicians in clinical decision making, providing them with evidence based care pathways to prevent skeletal related events and bone loss. The goal of this paper is to put forth an IOF position paper addressing bone diseases and cancer and summarizing the position papers of other organizations.
C1 [Rizzoli, R.] Univ Hosp Geneva, Div Bone Dis, Geneva, Switzerland.
   [Rizzoli, R.] Fac Med, Geneva, Switzerland.
   [Body, J.  J.] Univ Libre Bruxelles, CHU Brugmann, Dept Med, Brussels, Belgium.
   [Brandi, M.  L.] Univ Florence, Dept Internal Med, Florence, Italy.
   [Cannata Andia, J.] Univ Oviedo, Bone & Mineral Res Unit, Hosp Univ Cent Asturias, Inst Reina Sofia,REDinREN,ISCIII, Oviedo, Spain.
   [Chappard, D.] LUNAM Univ, GEROM Res Grp Bone Remodeling & BioMat, Angers, France.
   [El Maghraoui, A.] Mil Hosp Mohammed V, Dept Rheumatol, Rabat, Morocco.
   [Glueer, C. C.] Univ Klinikum Schleswig Holstein, Radiol Diagnost Klin, Sekt Biomed Bildgebung, Kiel, Germany.
   [Kendler, D.] Univ British Columbia, Dept Med, Vancouver, BC, Canada.
   [Napoli, N.] Univ Campus Biomed, Div Endocrinol, Rome, Italy.
   [Papaioannou, A.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Pierroz, D. D.] IOF, Nyon, Switzerland.
   [Rahme, M.; Fuleihan, G. El Hajj] Amer Univ Beirut, Med Ctr, Calcium Metab & Osteoporosis Program, WHO Collaborating Ctr Osteoporosis & Metab Bone D, Beirut, Lebanon.
   [Van Poznak, C. H.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [de Villiers, T. J.] Univ Stellenbosch, Panorama MediClin, Cape Town, South Africa.
   [de Villiers, T. J.] Univ Stellenbosch, Fac Hlth Sci, Dept Gynaecol, Cape Town, South Africa.
C3 University of Geneva; University of Geneva; Universite Libre de
   Bruxelles; University of Florence; Central University Hospital Asturias;
   Instituto de Salud Carlos III; University of Oviedo; Mohammed V
   University in Rabat; Ibn sina University Hospital Center of Rabat;
   University of Kiel; Schleswig Holstein University Hospital; University
   of British Columbia; University Campus Bio Medico   Rome Italy; McMaster
   University; International Osteoporosis Foundation   Switzerland;
   American University of Beirut; University of Michigan System; University
   of Michigan; Stellenbosch University; Stellenbosch University
RP Rizzoli, R (通讯作者)，Univ Hosp Geneva, Div Bone Dis, Geneva, Switzerland.
EM Rene.Rizzoli@unige.ch
RI Cannata Andía, Jorge/L 2260 2013; Glüer, Claus Christian/C 9752 2010;
   Body, Jean Jacques/G 9785 2015; Cannata Andia, Jorge B/L 2260 2013;
   Napoli, Nicola/K 8242 2016
OI brandi, maria luisa/0000 0002 8741 0592; El Maghraoui,
   Abdellah/0000 0003 0668 5680; Cannata Andia, Jorge
   B/0000 0001 6543 9960; El Hajj Fuleihan, Ghada/0000 0002 2076 5858;
   Napoli, Nicola/0000 0002 3091 8205
FU Amgen; MSD; GSK; Servier; Danone; Takeda; Novartis; Abbott; Shire; Eli
   Lily; Merck; JohnsonJohnson; Pfizer; Roche; Merck Canada Inc.; Warner
   Chilcott; Adcock Ingram; Novartis Pharmaceuticals; Les Laboratoires
   Servier
FX Rene Rizzoli has received speaker or advisory board fees from Amgen,
   MSD, GSK, Servier, Danone and Takeda. Jean Jacques Body has received
   speaker and consulting fees from Amgen and Novartis. Jorge B.
   Cannata Andia has received research grants and speaker or advisory board
   fees from Amgen, Abbott, Servier and Shire. David Kendler has received
   honoraria for speaking, consulting and/or research grants from Amgen,
   Novartis, GSK, Eli Lily, Merck, Johnson&Johnson, Pfizer and Roche.
   Alexandra Papaioannou has been a consultant, or on a speaker's bureau,
   or received unrestricted grants from Amgen, Eli Lilly, Merck Canada
   Inc., Novartis, Pfizer and Warner Chilcott. Tobias J de Villiers has
   received speaker or advisory board fees from Amgen, Merck, Adcock Ingram
   and Pfizer. Catherine Van Poznak has received research support from
   Amgen and Novartis. Ghada El Hajj Fuleihan has received grants to
   support courses on osteoporosis from Novartis Pharmaceuticals and Les
   Laboratoires Servier. Abdellah El Maghraoui, Nicola Napoli, Dominique D
   Pierroz and Maria Rahme have no conflict of interest.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Adler RA, 2011, MATURITAS, V68, P143, DOI 10.1016/j.maturitas.2010.11.003
   Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Alibhai SMH, 2010, J CLIN ONCOL, V28, P5038, DOI 10.1200/JCO.2010.29.8091
   Allain TJ, 2006, GERONTOLOGY, V52, P107, DOI 10.1159/000090956
   [Anonymous], 2017, COCHRANE DB SYST REV
   Barretina J, 2003, ANN HEMATOL, V82, P500, DOI 10.1007/s00277 003 0679 0
   BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889 8588(18)30345 9
   BATAILLE R, 1995, BRIT J HAEMATOL, V90, P721, DOI 10.1111/j.1365 2141.1995.tb05609.x
   Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718
   Bird JM, 2011, BRIT J HAEMATOL, V154, P32, DOI 10.1111/j.1365 2141.2011.08573.x
   Body JJ, 2007, OSTEOPOROSIS INT, V18, P1439, DOI 10.1007/s00198 007 0439 4
   Body JJ, 2007, EUR J CANCER, V43, P852, DOI 10.1016/j.ejca.2006.12.006
   Bokemeyer C, 1996, J CLIN ONCOL, V14, P2923, DOI 10.1200/JCO.1996.14.11.2923
   Bolland MJ, 2013, OSTEOPOROSIS INT, V24, P2371, DOI 10.1007/s00198 013 2356 z
   Bouvard B, 2012, ANN ONCOL, V23, P1151, DOI 10.1093/annonc/mdr356
   Bristow RG, 2008, CANCER METAST REV, V27, P337, DOI 10.1007/s10555 008 9136 9
   Brown JE, 2010, BONE S, V1, pS18
   Bruder JM, 2006, UROLOGY, V67, P152, DOI 10.1016/j.urology.2005.07.017
   Brufsky A, 2008, ONCOLOGIST, V13, P503, DOI 10.1634/theoncologist.2007 0206
   Cameron ID, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005465.pub3
   Cazzaniga M, 2004, ONCOLOGY BASEL, V66, P260, DOI 10.1159/000078325
   Chaganti RK, 2010, OSTEOPOROSIS INT, V21, P1307, DOI 10.1007/s00198 009 1105 9
   Chappard D, 2010, ANAT REC, V293, P1125, DOI 10.1002/ar.21150
   Chen Z, 2005, ARCH INTERN MED, V165, P552, DOI 10.1001/archinte.165.5.552
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coleman R E, 2012, Clin Oncol (R Coll Radiol), V24, P169, DOI 10.1016/j.clon.2011.10.004
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman R, 2011, CRIT REV ONCOL HEMAT, V80, P411, DOI 10.1016/j.critrevonc.2011.02.005
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood 2006 11 056747
   Cook GJR, 2010, CANCER IMAGING, V10, P153, DOI 10.1102/1470 7330.2010.0022
   Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140 6736(07)60200 1
   Costelloe CM, 2009, LANCET ONCOL, V10, P606, DOI 10.1016/S1470 2045(09)70088 9
   Cummings SR, 2002, JAMA J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216
   Daniell HW, 1997, J UROLOGY, V157, P439, DOI 10.1016/S0022 5347(01)65165 6
   Daniell HW, 2001, CANCER, V91, P1889, DOI 10.1002/1097 0142(20010515)91:10<1889::AID CNCR1211>3.0.CO;2 U
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955
   Diamond TH, 2004, J UROLOGY, V172, P529, DOI 10.1097/01.ju.0000130508.61020.66
   Doyle C, 2006, CA CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eastell R, 2007, J STEROID BIOCHEM, V106, P157, DOI 10.1016/j.jsbmb.2007.05.017
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   El Maghraoui A, 2004, PRESSE MED, V33, P1213, DOI 10.1016/S0755 4982(04)98891 4
   El Hajj Fuleihan G, 2005, J CLIN ENDOCR METAB, V90, P3209, DOI 10.1210/jc.2004 1444
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ellis GK, 2009, BREAST CANCER RES TR, V118, P81, DOI 10.1007/s10549 009 0352 y
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Geisler J, 2006, EUR J CANCER, V42, P2968, DOI 10.1016/j.ejca.2006.07.005
   Ghazi M, 2009, BEST PRACT RES CL RH, V23, P805, DOI 10.1016/j.berh.2009.09.003
   Gibson Kelli, 2008, J Oncol Pharm Pract, V14, P139, DOI 10.1177/1078155208091866
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gnant MFX, 2007, J CLIN ONCOL, V25, P820, DOI 10.1200/JCO.2005.02.7102
   Granchi S, 2001, PROSTATE, V49, P267, DOI 10.1002/pros.10022
   Greenspan SL, 2006, J UROLOGY, V175, P314, DOI 10.1016/S0022 5347(18)33200 2
   GRIGSBY PW, 1986, J UROLOGY, V135, P726, DOI 10.1016/S0022 5347(17)45831 9
   Grossmann M, 2011, MED J AUSTRALIA, V194, P301, DOI 10.5694/j.1326 5377.2011.tb02979.x
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hadji P, 2008, ANN ONCOL, V19, P1407, DOI 10.1093/annonc/mdn164
   Hadji P, 2011, ANN ONCOL, V22, P2546, DOI 10.1093/annonc/mdr017
   Hadji P, 2010, BREAST CARE, V5, P290, DOI 10.1159/000321426
   Hadji P, 2009, CRIT REV ONCOL HEMAT, V69, P73, DOI 10.1016/j.critrevonc.2008.07.013
   Hannon R, 2000, OSTEOPOROSIS INT, V11, P30, DOI 10.1007/s001980070004
   Harrouseau JL, 2005, ANN ONCOL, V16, P45, DOI 10.1093/annonc/mdi818
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hershman DL, 2008, J CLIN ONCOL, V26, P4739, DOI 10.1200/JCO.2008.16.4707
   Hershman DL, 2010, J CLIN ENDOCR METAB, V95, P559, DOI 10.1210/jc.2009 1366
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hu Mimi I, 2007, Curr Osteoporos Rep, V5, P170
   Igdem S, 2010, INT J RADIAT ONCOL, V77, P818, DOI 10.1016/j.ijrobp.2009.05.059
   Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140 6736(05)67059 6
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Josselin N, 2009, PATHOL ONCOL RES, V15, P65, DOI 10.1007/s12253 008 9092 2
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2395, DOI 10.1007/s00198 011 1713 z
   Kanis JA, 2010, OSTEOPOROSIS INT, V21, P407, DOI 10.1007/s00198 010 1253 y
   Kanis JA, 2004, BONE, V35, P1029, DOI 10.1016/j.bone.2004.06.017
   Kanis JA, 1999, BRIT J CANCER, V79, P1179, DOI 10.1038/sj.bjc.6690188
   Karlsson MK, 2013, OSTEOPOROSIS INT, V24, P747, DOI [10.1007/s00198 012 2256 7, 10.1177/1403494813483215]
   Keaveny TM, 2010, J BONE MINER RES, V25, P994, DOI [10.1359/jbmr.091033, 10.1002/jbmr.091033]
   Keyak JH, 2005, CLIN ORTHOP RELAT R, P161, DOI 10.1097/01.blo.0000174736.50964.3b
   Kim JE, 2011, BREAST CANCER RES TR, V125, P99, DOI 10.1007/s10549 010 1201 8
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   Leeming DJ, 2006, CANCER EPIDEM BIOMAR, V15, P1392, DOI 10.1158/1055 9965.EPI 05 0909
   Lentle B, 2011, CAN ASSOC RADIOL J, V62, P243, DOI 10.1016/j.carj.2011.05.001
   Leslie William D, 2011, Curr Osteoporos Rep, V9, P129, DOI 10.1007/s11914 011 0060 5
   Lester JE, 2008, CLIN CANCER RES, V14, P6336, DOI 10.1158/1078 0432.CCR 07 5101
   Lipton A, 2010, ANN ONCOL, V21, P380
   LOVE RR, 1994, ARCH INTERN MED, V154, P2585, DOI 10.1001/archinte.154.22.2585
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585 005 0056 6
   Lustberg MB, 2012, J CLIN ONCOL, V30, P3665, DOI 10.1200/JCO.2012.42.2097
   MacKenzie M, 2010, 18 CEDCCO
   Malcolm John B, 2007, Can J Urol, V14, P3551
   MARCELLI C, 1988, CANCER AM CANCER SOC, V62, P1163, DOI 10.1002/1097 0142(19880915)62:6<1163::AID CNCR2820620620>3.0.CO;2 6
   McCloskey E, 2006, EUR J CANCER, V42, P1044, DOI 10.1016/j.ejca.2005.10.028
   McCloskey EV, 2008, J BONE MINER RES, V23, P1561, DOI [10.1359/jbmr.080515, 10.1359/JBMR.080515]
   McCloskey EV, 2007, EUR J CANCER, V43, P2523, DOI 10.1016/j.ejca.2007.08.029
   McLeod Nicholas, 2006, Aust Fam Physician, V35, P243
   Meistrich ML, 2009, PEDIATR BLOOD CANCER, V53, P261, DOI 10.1002/pbc.22004
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Michaud LB, 2010, AM J HEALTH SYST PH, V67, pS20, DOI 10.2146/ajhp100078
   Mobus V, 2011, 34 ANN CTRC AACR SAN
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morote J, 2006, J UROLOGY, V175, P1679, DOI 10.1016/S0022 5347(05)00999 7
   Morote J, 2007, UROLOGY, V69, P500, DOI 10.1016/j.urology.2006.11.002
   Mottet N, 2011, EUR UROL, V59, P572, DOI 10.1016/j.eururo.2011.01.025
   Moyad MA, 2003, UROL ONCOL SEMIN O I, V21, P374, DOI 10.1016/S1078 1439(03)00172 8
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakashima J, 2000, CLIN CANCER RES, V6, P2702
   Napoli N, 2013, BONE, V55, P309, DOI 10.1016/j.bone.2013.04.021
   Napoli N, 2010, BREAST J, V16, P609, DOI 10.1111/j.1524 4741.2010.01012.x
   National Comprehensive Cancer Network, 2012, NCCN GUID VERS 1 201
   Neuhouser ML, 2008, AM J CLIN NUTR, V88, P133, DOI 10.1093/ajcn/88.1.133
   OVERGAARD M, 1988, ACTA ONCOL, V27, P117, DOI 10.3109/02841868809090331
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Perez EA, 2006, J CLIN ONCOL, V24, P3629, DOI 10.1200/JCO.2005.05.4882
   POWELL GJ, 1991, CANCER RES, V51, P3059
   Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704
   Pugsley MK, 2000, J PHARMACOL TOX MET, V44, P333, DOI 10.1016/S1056 8719(00)00125 8
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549 011 1644 6
   Reid DM, 2008, CANCER TREAT REV, V34, pS3, DOI 10.1016/j.ctrv.2008.03.007
   Reid DM, 2009, MATURITAS, V64, P4, DOI 10.1016/j.maturitas.2009.07.008
   Reuss Borst M, 2012, OSTEOPOROSIS INT, V23, P1437, DOI 10.1007/s00198 011 1724 9
   Rizzoli R, 2013, CURR MED RES OPIN, V29, P305, DOI 10.1185/03007995.2013.766162
   Rizzoli R, 2012, OSTEOPOROSIS INT, V23, P2567, DOI 10.1007/s00198 011 1870 0
   Rizzoli R, 2011, QJM INT J MED, V104, P281, DOI 10.1093/qjmed/hcq259
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rozenberg S, 2009, MATURITAS, V64, P1, DOI 10.1016/j.maturitas.2009.07.012
   Ryan CJ, 2013, NEW ENGL J MED, V368, P1458, DOI 10.1056/NEJMc1301594
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2009, J CLIN ONCOL, V27, p15s
   Saad F, 2006, CLIN GENITOURIN CANC, V4, P257, DOI 10.3816/CGC.2006.n.004
   Saad F, 2008, J CLIN ONCOL, V26, P5465, DOI 10.1200/JCO.2008.18.4184
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Sambrook P N, 2001, Aust Fam Physician, V30, P793
   Sambrook PN, 2005, ANN RHEUM DIS, V64, P176, DOI 10.1136/ard.2003.018556
   Sato Y, 2005, J BONE MINER RES, V20, P1327, DOI 10.1359/JBMR.050402
   Saylor PJ, 2010, J UROLOGY, V183, P2200, DOI 10.1016/j.juro.2010.02.022
   Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112
   Shahinian VB, 2005, CANCER AM CANCER SOC, V103, P1615, DOI 10.1002/cncr.20955
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shapiro CL, 2011, EUR J CANCER, V47, P683, DOI 10.1016/j.ejca.2010.11.024
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   Shariat SF, 2001, UROLOGY, V58, P1008, DOI 10.1016/S0090 4295(01)01405 4
   Shie P, 2008, CLIN NUCL MED, V33, P97, DOI 10.1097/RLU.0b013e31815f23b7
   Sieber PR, 2004, J UROLOGY, V171, P2272, DOI 10.1097/01.ju.0000127738.94221.da
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003 032058
   Smith MR, 2004, J CLIN ONCOL, V22, P2546, DOI 10.1200/JCO.2004.01.174
   Smith MR, 2003, CANCER TREAT REV, V29, P211, DOI 10.1016/S0305 7372(03)00076 8
   Smith MR, 2011, AUA M WASH DC
   Stava CJ, 2009, J CANCER SURVIV, V3, P75, DOI 10.1007/s11764 009 0083 4
   Steinborn MM, 1999, J COMPUT ASSIST TOMO, V23, P123, DOI 10.1097/00004728 199901000 00026
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   TAKUWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P998, DOI 10.1016/0006 291X(90)90491 5
   Tanck E, 2009, BONE, V45, P777, DOI 10.1016/j.bone.2009.06.009
   Taxel P, 2010, BJU INT, V106, P1473, DOI 10.1111/j.1464 410X.2010.09329.x
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   van den Bergh Joop P W, 2010, Curr Osteoporos Rep, V8, P131, DOI 10.1007/s11914 010 0022 3
   Van Poznak C, 2010, J CLIN ONCOL, V28, P967, DOI 10.1200/JCO.2009.24.5902
   Van Poznak CH, 2011, J ONCOL PRACT, V7, P117, DOI 10.1200/JOP.2011.000212
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   VanderWalde A, 2011, CA CANCER J CLIN, V61, P139, DOI 10.3322/caac.20103
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Vehmanen L, 2001, EUR J CANCER, V37, P2373, DOI 10.1016/S0959 8049(01)00317 3
   Wadhwa VK, 2009, UROLOGY, V73, P1347, DOI 10.1016/j.urology.2009.01.055
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
   Watts NB, 2009, J BONE MINER RES, V24, P1643, DOI [10.1359/jbmr.090818, 10.1359/JBMR.090818]
   WCRF/AICR, 2007, FOOD NUTR PREV CANC
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083 8791(00)70039 5
   Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470 2045(07)70385 6
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   World Health Organization, 2011, GLOB STAT REP NONC D
   Yamamoto DS, 2009, CLIN J ONCOL NURS, V13, P499, DOI 10.1188/09.CJON.E18 E29
   Yang HL, 2011, EUR RADIOL, V21, P2604, DOI 10.1007/s00330 011 2221 4
NR 194
TC 106
Z9 110
U1 1
U2 25
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2013
VL 24
IS 12
BP 2929
EP 2953
DI 10.1007/s00198 013 2530 3
PG 25
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 281MK
UT WOS:000329105500004
PM 24146095
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, XY
   Ji, QB
   Hu, WH
   Zhang, ZF
   Hu, FQ
   Cao, SQ
   Wang, Q
   Hao, YY
   Gao, M
   Zhang, XS
AF Wang, Xiangyu
   Ji, Quanbo
   Hu, Wenhao
   Zhang, Zhifa
   Hu, Fanqi
   Cao, Shiqi
   Wang, Qi
   Hao, Yongyu
   Gao, Meng
   Zhang, Xuesong
TI Isobavachalcone prevents osteoporosis by suppressing activation of ERK
   and NF KB pathways and M1 polarization of macrophages
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Isobavachalcone osteoporosis ERK NF KB; Macrophage polarization
ID ESTROGEN RECEPTOR ALPHA; RANKL MEDIATED OSTEOCLASTOGENESIS; BONE LOSS;
   SIGNALING PATHWAYS; DIFFERENTIATION; OSTEOBLASTS; BIOLOGY; HEALTH;
   PHASE; CELLS
AB Estrogen receptors alpha (ER?), a member of the nuclear receptor protein family, was found to play an important role in maintaining bone mass. Its downstream signaling proteins such as ERK and NF KB were reported to be involved in development of osteoporosis, which meant that targeting ER? might be an effective strategy for searching for new drugs to prevent bone loss. In this study, we demonstrate that isobavachalcone (ISO), as one of bioactive compounds isolated from Psoralea corylifolia Linn, has high affinity with ER?. The effects of ISO are investigated on receptor activator of NF KB ligand (RANKL) induced osteocalstogenesis. It is reported that ISO inhibits the RANKL mediated increase of osteoclast related genes MMP9, cathepsink and TRAR in RAW264.7 cells. Moreover, in vitro experiment shows that ISO exhibits an inhibitory effect on ERK and NF KB signaling pathway, and suppresses RANKL induced expression of osteoclast related transcription factors NFATc1 and cFos. However, the impact of ISO in these molecules is eliminated by the application of ER? antagonist AZD9496. We further verified pharmacological effects of ISO in ovariectomized osteoporotic mice, and ISO significantly prevented bone loss and decreased M1 polarization of macrophages from marrow and spleen. Collectively, our data suggest that ISO prevents osteoporosis via suppressing activation of ERK and NF KB signaling pathways as well as M1 polarization of macrophages.
C1 [Wang, Xiangyu; Ji, Quanbo; Gao, Meng; Zhang, Xuesong] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Ji, Quanbo; Hu, Wenhao; Zhang, Zhifa; Hu, Fanqi; Cao, Shiqi; Wang, Qi; Hao, Yongyu; Zhang, Xuesong] Peoples Liberat Army Gen Hosp, Dept Orthopaed, Beijing 100000, Peoples R China.
C3 Nankai University; Chinese People's Liberation Army General Hospital
RP Ji, QB; Zhang, XS (通讯作者)，Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.; Ji, QB; Zhang, XS (通讯作者)，Peoples Liberat Army Gen Hosp, Dept Orthopaed, Beijing 100000, Peoples R China.
EM quanbo301@163.com; zhangxuesong301@163.com
OI Ji, Quanbo/0000 0001 6212 6926
FU Key Program of the National Natural Science Foundation of China
   [81371911, 81972128]
FX This research was supported by the Key Program of the National Natural
   Science Foundation of China (Nos. 81371911 and 81972128) .
CR Alam F, 2018, PHYTOTHER RES, V32, P597, DOI 10.1002/ptr.6006
   [Anonymous], 2018, BIOSCI REP
   Blair HC, 2008, BIOL REV, V83, P401, DOI 10.1111/j.1469 185X.2008.00048.x
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood 2007 12 129767
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chen CC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0575 0
   deCathelineau AM, 2003, ESSAYS BIOCHEM, V39, P105, DOI 10.1042/bse0390105
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   He HQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01427
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hung YL, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.12.008
   Hung YL, 2017, SCI REP UK, V7, DOI 10.1038/srep46299
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   Jia M, 2015, BEST PRACT RES CL EN, V29, P557, DOI 10.1016/j.beem.2015.04.008
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kou XX, 2015, J IMMUNOL, V194, P2810, DOI 10.4049/jimmunol.1303188
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Li CH, 2018, INT IMMUNOPHARMACOL, V58, P136, DOI 10.1016/j.intimp.2018.03.021
   Liu HY, 2012, BIOMATERIALS, V33, P6105, DOI 10.1016/j.biomaterials.2012.05.024
   Liu Y, 2014, J DENT RES, V93, P1124, DOI 10.1177/0022034514552675
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Mehla K, 2019, TRENDS CANCER, V5, P822, DOI 10.1016/j.trecan.2019.10.007
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Morris Garrett M., 2008, V443, P365, DOI 10.1007/978 1 59745 177 2_19
   Movérare S, 2003, P NATL ACAD SCI USA, V100, P13573, DOI 10.1073/pnas.2233084100
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Oh H, 2019, J AGR FOOD CHEM, V67, P10069, DOI 10.1021/acs.jafc.9b03926
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Seo E, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080828
   Seo E, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/897296
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092 8674(00)81717 1
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weigert A, 2018, MOL ASPECTS MED, V63, P70, DOI 10.1016/j.mam.2018.01.003
   Wu D, 2018, HAEMATOLOGICA, V103, P1472, DOI 10.3324/haematol.2018.188185
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xin D, 2010, PHYTOMEDICINE, V17, P126, DOI 10.1016/j.phymed.2009.05.015
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhang XN, 2016, AM J CHINESE MED, V44, P35, DOI 10.1142/S0192415X16500038
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
NR 53
TC 27
Z9 32
U1 1
U2 47
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAY
PY 2021
VL 94
AR 107370
DI 10.1016/j.intimp.2021.107370
EA FEB 2021
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA RX7SR
UT WOS:000647420200006
PM 33640858
DA 2025 08 17
ER

PT J
AU Ihn, HJ
   Kim, JA
   Bae, YC
   Shin, HI
   Baek, MC
   Park, EK
AF Ihn, Hye Jung
   Kim, Ju Ang
   Bae, Yong Chul
   Shin, Hong In
   Baek, Moon Chang
   Park, Eui Kyun
TI Afatinib ameliorates osteoclast differentiation and function through
   downregulation of RANK signaling pathways
SO BMB REPORTS
LA English
DT Article
DE Afatinib; Bone resorption; Differentiation; Osteoclast; RANK signaling
ID CELL LUNG CANCER; ERBB FAMILY BLOCKER; BONE; GEFITINIB; EGFR;
   CHEMOTHERAPY; METASTASIS; MUTATIONS; ERLOTINIB; SURVIVAL
AB Non small cell lung cancer (NSCLC) is the third most common cancer that spreads to the bone, resulting in osteolytic lesions caused by hyperactivation of osteoclasts. Activating mutations in epidermal growth factor receptor tyrosine kinase (EGF TK) are frequently associated with NSCLC, and afatinib is a first line therapeutic drug, irreversibly targeting EGF TK. However, the effects of afatinib on osteoclast differentiation and activation as well as the underlying mechanism remain unclear. In this study, afatinib significantly suppressed receptor activator of nuclear factor. B (RANK) ligand (RANKL) induced osteoclast formation in bone marrow macrophages (BMMs). Consistently, afatinib inhibited the expression of osteoclast marker genes, whereas, it upregulated the expression of negative modulator genes. The bone resorbing activity of osteoclasts was also abrogated by afatinib. In addition, afatinib significantly inhibited RANKL mediated Akt/protein kinase B and c Jun N terminal kinase phosphorylation. These results suggest that afatinib substantially suppresses osteoclastogenesis by downregulating RANK signaling pathways, and thus may reduce osteolysis after bone metastasis.
C1 [Ihn, Hye Jung; Kim, Ju Ang; Shin, Hong In; Park, Eui Kyun] Kyungpook Natl Univ, Dept Oral Pathol & Regenerat Med, Sch Dent, Daegu 41940, South Korea.
   [Bae, Yong Chul] Kyungpook Natl Univ, Sch Dent, Dept Anat & Neurobiol, Daegu 41940, South Korea.
   [Baek, Moon Chang] Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu 41944, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU)
RP Park, EK (通讯作者)，Kyungpook Natl Univ, Dept Oral Pathol & Regenerat Med, Sch Dent, Daegu 41940, South Korea.; Baek, MC (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu 41944, South Korea.
EM mcbaek@knu.ac.kr; epark@knu.ac.kr
RI Kim, Ju Ang/LWI 0914 2024
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT,
   and Future Planning [MSIP 2008 0062282, NRF2016R1A6A3A01006911]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF) funded by the Ministry of Science, ICT, and Future
   Planning (MSIP 2008 0062282 and NRF2016R1A6A3A01006911).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870
   D'Antonio C, 2014, THER ADV MED ONCOL, V6, P101, DOI 10.1177/1758834014521110
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Furugaki K, 2011, CLIN EXP METASTAS, V28, P649, DOI 10.1007/s10585 011 9398 4
   Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e
   Ihn HJ, 2015, EXP BIOL MED, V240, P1690, DOI 10.1177/1535370215576310
   Ihn HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142201
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078 0432.CCR 06 0714
   Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Modjtahedi H, 2014, N S ARCH PHARMACOL, V387, P505, DOI 10.1007/s00210 014 0967 3
   Mourskaia AA, 2009, ONCOGENE, V28, P1005, DOI 10.1038/onc.2008.454
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Rossi A, 2012, CURR MED CHEM, V19, P5524, DOI 10.2174/092986712803833209
   Shostak K, 2015, TRENDS MOL MED, V21, P385, DOI 10.1016/j.molmed.2015.04.001
   Silva SC, 2015, THER ADV MED ONCOL, V7, P219, DOI 10.1177/1758834015582178
   Solca F, 2012, J PHARMACOL EXP THER, V343, P342, DOI 10.1124/jpet.112.197756
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Wind S, 2017, CLIN PHARMACOKINET, V56, P235, DOI 10.1007/s40262 016 0440 1
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470 2045(11)70184 X
NR 31
TC 17
Z9 17
U1 0
U2 9
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635 4 , YEOKSAM DONG,
   KANGNAM KU, SEOUL, 135 703, SOUTH KOREA
SN 1976 6696
EI 1976 670X
J9 BMB REP
JI BMB Rep.
PD MAR
PY 2017
VL 50
IS 3
BP 150
EP 155
DI 10.5483/BMBRep.2017.50.3.223
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA EQ4QI
UT WOS:000398062600008
PM 28256196
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Kuang, ZH
   Yang, XW
   Cao, ZY
   Li, YH
   Hu, JW
   Hong, X
   Li, B
   Wu, CJ
   Qi, QH
   Liu, XQ
   Dai, M
AF Kuang, Zhihui
   Yang, Xiaowei
   Cao, Zhiyou
   Li, Yanhua
   Hu, Jiawei
   Hong, Xin
   Li, Bo
   Wu, Changjian
   Qi, Qihua
   Liu, Xuqiang
   Dai, Min
TI Surfactin suppresses osteoclastogenesis via the NF ?B signaling pathway,
   promotes osteogenic differentiation in vitro, and inhibits oestrogen
   deficiency induced bone loss in vivo
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Osteoclast differentiation; Osteogenic differentiation;
   NF ?B; OVX model
ID RANKL INDUCED OSTEOCLAST; KAPPA B; ACTIVATION; MECHANISM; SURVIVAL
AB Background: Fractures caused by osteoporosis (OP) are one of the main causes of death in the elderly, bringing a heavy burden to the country and society. The imbalance between osteoblast mediated osteogenesis and osteoclast mediated bone resorption is an important cause of OP. Therefore, finding drugs that can regulate this dynamic balance can be an important way to treat osteoporosis. Surfactin is a highly effective biosurfactant derived from Bacillus subtilis and it has been proven to have various pharmacological effects in previous studies, but its effect on bone metabolism remains unknown. Here, we performed a study on the role and mechanism of Surfactin in inhibiting osteoclastogenesis and its possible mechanism as well as the role in promoting osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs).Methods: We investigated the effect of Surfactin on osteoclast differentiation and osteogenic differentiation in vitro and in vivo. The effect of Surfactin on the activity of osteoclastogenesis and osteogenesis was verified by CCK 8 assay, quantitative Real time polymerase chain reaction (qPCR) and Western blotting analysis were used to verify the effect of Surfactin on osteoclast and osteogenic differentiation specific genes and proteins. The effect of Surfactin on TRAP?ALP activity and mineral deposition was verified by TRAP?ALP and ARS staining. We then used an ovariectomy induced osteoporosis mice model to observe the effect of Surfactin in vivo.Results: Surfactin is noncytotoxic to BMMs, RAW264.7, and BMSCs. And it can effectively inhibit osteoclasto genesis and promote osteogenic differentiation. Moreover, we found that Surfactin can inhibit the differentiation of osteoclasts through the NF ?B signaling pathway. Surfactin can also alleviate bone loss in ovariectomy induced osteoporosis mice.Conclusions: Our results suggest that Surfactin can inhibit osteoclastogenesis through the NF ?B signaling pathway, promote the osteogenic differentiation of BMSCs, and also can effectively alleviate bone loss in ovariectomy induced osteoporosis mice.
C1 [Kuang, Zhihui; Yang, Xiaowei; Cao, Zhiyou; Hu, Jiawei; Hong, Xin; Li, Bo; Wu, Changjian; Qi, Qihua; Liu, Xuqiang; Dai, Min] Nanchang Univ, Artificial Joints Engn & Technol Res Ctr Jiangxi P, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
   [Li, Yanhua] Nanchang Univ, Dept Gen Practice, Affiliated Hosp 1, Nanchang, Peoples R China.
C3 Nanchang University; Nanchang University
RP Liu, XQ; Dai, M (通讯作者)，Nanchang Univ, Artificial Joints Engn & Technol Res Ctr Jiangxi P, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
EM shliuxuqiang@163.com; daimin@medmail.com.cn
RI HONG, XIN/AAI 5177 2020
FU National Natural Science Foundation of China [82160173, 81960395]
FX Acknowledgements This work was supported by grants from the National
   Natural Science Foundation of China (No. 82160173, No. 81960395) . We
   thank Bullet Edits Limited for the linguistic editing and proofreading
   of the manuscript.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365 2958.1993.tb01629.x
   Danevcic T, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.657407
   Das P, 2008, J APPL MICROBIOL, V104, P1675, DOI 10.1111/j.1365 2672.2007.03701.x
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Fang CH, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110060
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Huang T, 2021, AGING US, V13, P12526, DOI 10.18632/aging.202926
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim HY, 2021, INT IMMUNOPHARMACOL, V99, DOI 10.1016/j.intimp.2021.107934
   Kim HJ, 2021, J CELL PHYSIOL, V236, P8239, DOI 10.1002/jcp.30496
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim SY, 2007, FEBS LETT, V581, P865, DOI 10.1016/j.febslet.2007.01.059
   Kuang ZH, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106960
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Liu MQ, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114129
   Liu SH, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.908043
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lu JW, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106550
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Remmers SJA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257724
   Ren Y, 2021, ACTA BIOCH BIOPH SIN, V53, P201, DOI 10.1093/abbs/gmaa164
   Rodrigues L, 2006, J ANTIMICROB CHEMOTH, V57, P609, DOI 10.1093/jac/dkl024
   Sobacchi C, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116541
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Tian YY, 2022, ORAL DIS, V28, P428, DOI 10.1111/odi.13745
   Vollenbroich D, 1997, BIOLOGICALS, V25, P289, DOI 10.1006/biol.1997.0099
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Wu YS, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00761
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang YY, 2015, INFLAMMATION, V38, P756, DOI 10.1007/s10753 014 9986 y
   Zhou L, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118563
   Zhu SW, 2018, MOL MED REP, V17, P6969, DOI 10.3892/mmr.2018.8741
NR 36
TC 7
Z9 7
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD APR
PY 2023
VL 117
AR 109884
DI 10.1016/j.intimp.2023.109884
EA FEB 2023
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA C7DN5
UT WOS:000963480900001
PM 36805201
DA 2025 08 17
ER

PT J
AU Yu, MC
   D'Amelio, P
   Tyagi, AM
   Vaccaro, C
   Li, JY
   Hsu, E
   Buondonno, I
   Sassi, F
   Adams, J
   Weitzmann, MN
   DiPaolo, R
   Pacifici, R
AF Yu, Mingcan
   D'Amelio, Patrizia
   Tyagi, Abdul Malik
   Vaccaro, Chiara
   Li, Jau Yi
   Hsu, Emory
   Buondonno, Ilaria
   Sassi, Francesca
   Adams, Jonathan
   Weitzmann, M. Neale
   DiPaolo, Richard
   Pacifici, Roberto
TI Regulatory T cells are expanded by Teriparatide treatment in humans and
   mediate intermittent PTH induced bone anabolism in mice
SO EMBO REPORTS
LA English
DT Article
DE bone; bone formation; parathyroid hormone; regulatory T cells
ID GROWTH FACTOR I; BLOOD MONONUCLEAR CELLS; PARATHYROID HORMONE PTH; RAT
   BONE; TREG CELLS; PRIMARY HYPERPARATHYROIDISM; OSTEOCLAST FORMATION;
   PTH/PTHRP RECEPTOR; VIVO DEPLETION; PROTEIN
AB Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown. Here, we show that Teriparatide and iPTH cause a two threefold increase in the number of regulatory T cells (Tregs) in humans and mice. Attesting in vivo relevance, blockade of the Treg increase in mice prevents the increase in bone formation and trabecular bone volume and structure induced by iPTH. Therefore, increasing the number of Tregs is a pivotal mechanism by which iPTH exerts its bone anabolic activity. Increasing Tregs pharmacologically may represent a novel bone anabolic therapy, while iPTH induced Treg increase may find applications in inflammatory conditions and transplant medicine.
C1 [Yu, Mingcan; Tyagi, Abdul Malik; Vaccaro, Chiara; Li, Jau Yi; Hsu, Emory; Adams, Jonathan; Weitzmann, M. Neale; Pacifici, Roberto] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [D'Amelio, Patrizia; Buondonno, Ilaria; Sassi, Francesca] Univ Torino, Gerontol Sect, Dept Med Sci, Turin, Italy.
   [Weitzmann, M. Neale] Atlanta Dept Vet Affairs Med Ctr, Decatur, GA USA.
   [DiPaolo, Richard] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO USA.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
C3 Emory University; University of Turin; Saint Louis University; Emory
   University
RP Pacifici, R (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.; Pacifici, R (通讯作者)，Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
EM roberto.pacifici@emory.edu
RI ; D'AMELIO, PATRIZIA/K 3042 2016; Malik, Abdul/AAX 5715 2020; yang,
   min/H 5792 2011
OI Hsu, Emory/0009 0007 0132 5500; DiPaolo, Richard/0000 0002 2191 6689;
   Malik, Abdul/0000 0001 9012 5779; D'AMELIO,
   PATRIZIA/0000 0002 4467 8337; 
FU National Institutes of Health [DK108842, AR54625, RR028009, AR061453,
   AG040013, AR068157, AR070091]; Biomedical Laboratory Research &
   Development Service of the VA Office of Research and Development
   [5I01BX000105]
FX This study was supported by grants from the National Institutes of
   Health (RP: DK108842, AR54625, and RR028009; JYL: AR061453; MNW:
   AG040013, AR068157, and AR070091). MNW was also supported by a grant
   from the Biomedical Laboratory Research & Development Service of the VA
   Office of Research and Development (5I01BX000105).
CR Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554
   Anguela XM, 2013, DIABETES, V62, P551, DOI 10.2337/db11 1776
   [Anonymous], 1984, Natl Inst Health Consens Dev Conf Consens Statement, V5
   [Anonymous], BLOOD
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Betts RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027849
   Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood 2010 07 293795
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chaudhry A, 2013, J CLIN INVEST, V123, P939, DOI 10.1172/JCI57175
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Cho SW, 2013, J BIOL CHEM, V288, P6814, DOI 10.1074/jbc.M112.393363
   D'Amelio P, 2004, FASEB J, V18, P410, DOI 10.1096/fj.04 2214fje
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Duarte JH, 2009, EUR J IMMUNOL, V39, P948, DOI 10.1002/eji.200839196
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Fantini MC, 2007, NAT PROTOC, V2, P1789, DOI 10.1038/nprot.2007.258
   Feng F, 2013, CURR MICROBIOL, V67, P1, DOI 10.1007/s00284 013 0325 6
   Grey AB, 1996, CLIN ENDOCRINOL, V44, P697
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Johannesson B, 2014, DIS MODEL MECH, V7, P977, DOI 10.1242/dmm.015362
   Karlsson F, 2011, METHODS MOL BIOL, V677, P47, DOI 10.1007/978 1 60761 869 0_4
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim YG, 2007, BIOCHEM BIOPH RES CO, V357, P1046, DOI 10.1016/j.bbrc.2007.04.042
   Klingenberg R, 2013, J CLIN INVEST, V123, P1323, DOI 10.1172/JCI63891
   Koh AJ, 2011, ENDOCRINOLOGY, V152, P4525, DOI 10.1210/en.2011 1515
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852
   Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978 1 61737 979 6_10
   Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li JY, 2012, BLOOD, V120, P4352, DOI 10.1182/blood 2012 06 438531
   Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607
   Marek Trzonkowska N, 2012, DIABETES CARE, V35, P1817, DOI 10.2337/dc12 0038
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002
   OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo 129 6 3313
   Pacifici R, 2013, ENDOCRINE, V44, P576, DOI 10.1007/s12020 013 9960 8
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Potts J., 1998, METABOLIC BONE DIS, V1, P411
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Robinson JW, 2015, J BONE MINER RES, V30, P695, DOI 10.1002/jbmr.2394
   Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Setiady YY, 2010, EUR J IMMUNOL, V40, P780, DOI 10.1002/eji.200939613
   Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Tan CR, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 148
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Trzonkowski P, 2009, CLIN IMMUNOL, V133, P22, DOI 10.1016/j.clim.2009.06.001
   UZAWA T, 1995, BONE, V16, P477
   von Boehmer H, 2013, NAT REV DRUG DISCOV, V12, P51, DOI 10.1038/nrd3683
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wu YH, 2000, J BONE MINER RES, V15, P879, DOI 10.1359/jbmr.2000.15.5.879
   Yuan FL, 2010, BIOCHEM BIOPH RES CO, V402, P173, DOI 10.1016/j.bbrc.2010.09.120
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zaiss MM, 2010, ARTHRITIS RHEUM US, V62, P2328, DOI 10.1002/art.27535
NR 67
TC 49
Z9 60
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1469 221X
EI 1469 3178
J9 EMBO REP
JI EMBO Rep.
PD JAN
PY 2018
VL 19
IS 1
BP 156
EP 171
DI 10.15252/embr.201744421
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FS0SR
UT WOS:000419484500015
PM 29158349
OA Green Published
DA 2025 08 17
ER

PT J
AU Sato, T
   Andrade, CDC
   Yoon, SH
   Zhao, YS
   Greenlee, WJ
   Weber, PC
   Viswanathan, U
   Kulp, J
   Brooks, DJ
   Demay, MB
   Bouxsein, ML
   Mitlak, B
   Lanske, B
   Wein, MN
AF Sato, Tadatoshi
   Andrade, Christian D. Castro
   Yoon, Sung Hee
   Zhao, Yingshe
   Greenlee, William J.
   Weber, Patricia C.
   Viswanathan, Usha
   Kulp, John
   Brooks, Daniel J.
   Demay, Marie B.
   Bouxsein, Mary L.
   Mitlak, Bruce
   Lanske, Beate
   Wein, Marc N.
TI Structure based design of selective, orally available salt inducible
   kinase inhibitors that stimulate bone formation in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE kinase inhibitor; parathyroid hormone; osteoporosis
ID OSTEOPOROSIS; HOMEOSTASIS; RECEPTOR; HORMONE; CELLS
AB Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that involves inhibition of salt inducible kinase isoforms 2 and 3 (SIK2 and SIK3). Here, we further validate SIK2/SIK3 as osteoporosis drug targets by demonstrating that ubiquitous deletion of these genes in adult mice increases bone formation without extraskeletal toxicities. Previous efforts to target these kinases to stimulate bone formation have been limited by lack of pharmacologically acceptable, specific, orally available SIK2/SIK3 inhibitors. Here, we used structure based drug design followed by iterative medicinal chemistry to identify SK 124 as a lead compound that potently inhibits SIK2 and SIK3. SK 124 inhibits SIK2 and SIK3 with single digit nanomolar potency in vitro and in cell based target engagement assays and shows acceptable kinome selectivity and oral bioavailability. SK 124 reduces SIK2/SIK3 substrate phosphorylation levels in human and mouse cultured bone cells and regulates gene expression patterns in a PTH like manner. Once daily oral SK 124 treatment for 3 wk in mice led to PTH like effects on mineral metabolism including increased blood levels of calcium and 1,25 vitamin D and suppressed endogenous PTH levels. Furthermore, SK 124 treatment increased bone formation by osteoblasts and boosted trabecular bone mass without evidence of short term toxicity. Taken together, these findings demonstrate PTH like effects in bone and mineral metabolism upon in vivo treatment with orally available SIK2/SIK3 inhibitor SK 124.
C1 [Sato, Tadatoshi; Andrade, Christian D. Castro; Yoon, Sung Hee; Zhao, Yingshe; Brooks, Daniel J.; Demay, Marie B.; Bouxsein, Mary L.; Wein, Marc N.] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Sato, Tadatoshi] Univ Massachusetts, Chan Med Sch, Dept Med, Worcester, MA 01655 USA.
   [Sato, Tadatoshi] Univ Massachusetts, Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01655 USA.
   [Greenlee, William J.; Weber, Patricia C.] Univ Hosp, Harrington Discovery Inst, Cleveland, OH 44106 USA.
   [Viswanathan, Usha; Kulp, John] Conifer Point, Doylestown, PA 18902 USA.
   [Mitlak, Bruce; Lanske, Beate] Radius Hlth Inc, Boston, MA 02210 USA.
   [Wein, Marc N.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Wein, Marc N.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Massachusetts General Hospital; University of Massachusetts
   System; University of Massachusetts Worcester; UMass Chan Medical
   School; University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School; University Hospitals of Cleveland;
   Radius Health, Inc.; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Harvard University
RP Wein, MN (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.; Wein, MN (通讯作者)，Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Wein, MN (通讯作者)，Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
EM mnwein@mgh.harvard.edu
RI ; Viswanathan, Usha/I 4575 2013; Kulp, John/A 7824 2008
OI Castro, Christian D./0000 0003 3054 2831; Kulp,
   John/0000 0003 2586 9207; 
FU NIH [P01DK011794, R01DK116716]; Harrington Discovery Institute; Radius
   Health; Center for Skeletal Research, an NIH [P30AR066261]
FX We thank all members of the Wein Laboratory and MGH Endocrine Unit for
   thoughtful suggestions. We also thank Robert Lipper, Jan Rosenbaum,
   Michael Hallen, and Diana Wetmore from the Harrington Discovery
   Institute for invaluable advice and project support. M.N.W. acknowledges
   funding support from the NIH (P01DK011794 and R01DK116716), Harrington
   Discovery Institute, and Radius Health. Micro CT and bone
   histomorphometry were performed by the Center for Skeletal Research, an
   NIH funded program (P30AR066261, led by Drs. Mary Bouxsein and Marie
   Demay).
CR Alvey L. J., 2019, Patent, Patent No. [WO2019105886A1, 2019105886]
   Armouti M, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa069
   Arter C, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102247
   Attwood MM, 2021, NAT REV DRUG DISCOV, V20, P839, DOI 10.1038/s41573 021 00252 y
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Békés M, 2022, NAT REV DRUG DISCOV, V21, P181, DOI 10.1038/s41573 021 00371 6
   Bertorello AM, 2015, CIRC RES, V116, P642, DOI 10.1161/CIRCRESAHA.116.304529
   Bovijn J, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay6570
   Bowes J, 2012, NAT REV DRUG DISCOV, V11, P909, DOI 10.1038/nrd3845
   Burshtein G, 2021, INT J PHARM X, V3, DOI 10.1016/j.ijpx.2021.100097
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109
   Csukasi F, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat9356
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Darling NJ, 2021, BIOCHEM J, V478, P1377, DOI 10.1042/BCJ20200502
   Desroy N., 2019, Patent number, Patent No. [WO2019238424A1, 2019238424]
   Donovan KA, 2020, CELL, V183, P1714, DOI 10.1016/j.cell.2020.10.038
   Ensrud KE, 2019, JAMA J AM MED ASSOC, V322, P2017, DOI 10.1001/jama.2019.15781
   Funato H, 2016, NATURE, V539, P378, DOI 10.1038/nature20142
   Guenette RG, 2022, CHEM SOC REV, V51, P5740, DOI 10.1039/d2cs00200k
   Ish Shalom S, 2021, J BONE MINER RES, V36, P1060, DOI 10.1002/jbmr.4274
   Jin HY, 2020, SLAS DISCOV, V25, P215, DOI 10.1177/2472555219893277
   Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Legnik S, 2015, J CHEM INF MODEL, V55, P1521, DOI 10.1021/acs.jcim.5b00136
   Looker A., 2012, NCHS CTR DIS CONTROL, V93, P2005
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Mujahid N, 2017, CELL REP, V19, P2177, DOI 10.1016/j.celrep.2017.05.042
   Nishimori S, 2019, J CLIN INVEST, V129, P5187, DOI 10.1172/JCI130126
   Noda H, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10367
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Park J, 2014, DIABETES, V63, P3659, DOI 10.2337/db13 1423
   Patel K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5535
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Raab M, 2021, CANCERS, V13, DOI 10.3390/cancers13153658
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rudolf AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098800
   Sakamaki JI, 2014, NAT CELL BIOL, V16, P234, DOI 10.1038/ncb2919
   Sakamoto K, 2018, TRENDS ENDOCRIN MET, V29, P828, DOI 10.1016/j.tem.2018.09.007
   Sasagawa S, 2012, DEVELOPMENT, V139, P1153, DOI 10.1242/dev.072652
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Sundberg TB, 2016, ACS CHEM BIOL, V11, P2105, DOI 10.1021/acschembio.6b00217
   Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111
   Sutkeviciute I, 2022, NAT CHEM BIOL, V18, P272, DOI 10.1038/s41589 021 00929 w
   Sutkeviciute I, 2019, TRENDS ENDOCRIN MET, V30, P860, DOI 10.1016/j.tem.2019.07.011
   Takemori H, 2003, J STEROID BIOCHEM, V85, P397, DOI 10.1016/S0960 0760(03)00199 7
   Tamura T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13384
   Tang CC, 2021, ELIFE, V10, DOI 10.7554/eLife.67772
   Tarumoto Y, 2020, BLOOD, V135, P56, DOI 10.1182/blood.2019001576
   Tesch R, 2021, J MED CHEM, V64, P8142, DOI 10.1021/acs.jmedchem.0c02144
   Wein MN, 2018, TRENDS ENDOCRIN MET, V29, P723, DOI 10.1016/j.tem.2018.08.004
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Weise M, 2001, P NATL ACAD SCI USA, V98, P6871, DOI 10.1073/pnas.121180498
   White AD, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abc5944
NR 55
TC 23
Z9 25
U1 3
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 5
PY 2022
VL 119
IS 50
AR e2214396119
DI 10.1073/pnas.2214396119
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA C8WT4
UT WOS:000964665400002
PM 36472957
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Nam, JW
   Kwon, JI
   Hong, JY
   Kim, HJ
AF Nam, Jung Woo
   Kwon, Jin Il
   Hong, Joo Young
   Kim, Hyung Jun
TI The effect of two locally administered anti resorptive agents on bone
   regeneration in a rat fibula model: Alendronate and
   15 deoxy Δ<SUP>12,14</SUP> prostaglandin J2
SO JOURNAL OF CRANIO MAXILLOFACIAL SURGERY
LA English
DT Article
DE Bisphosphonate; 15 Deoxy Delta(12,14) Prostaglandin J(2); Anabolic
   effect; Bone regeneration; Critical sized defect model; Rat fibula
ID IN VITRO; OSTEOCLAST DIFFERENTIATION; MEVALONATE PATHWAY; OSTEOBLASTIC
   CELLS; BISPHOSPHONATES; OSTEOPROTEGERIN; MECHANISM; PROLIFERATION;
   RESORPTION; PREVENTS
AB Bisphosphonates are well known drugs as inhibitors of bone resorption acting on inducing programmed cell death of osteoclasts. However, many in vitro studies report that optimal concentration of the bisphosphonate affects not only osteoclasts but also osteoblasts, that is, it induces the anabolic effects of osteoblasts. Recently reported 15 deoxy Delta(12,14) prostaglandin J(2) (15d PGJ(2)) is an endogenous ligand of peroxisome proliferator activated receptor gamma, with an inhibitory activity on bone loss. Researchers have also suggested that 15d PGJ(2) has the ability to reduce bone destruction and as the possibility of regeneration of bone.
   The purpose of this study is to demonstrate the anabolic effect of two anti resorptive materials, alendronate and 15d PGJ(2), in a critical sized segmental defect model of rat fibula. The regenerated bone on the operative site was assessed through gross, radiographic (plain X ray, and micro computed tomography), histomorphologic evaluation, and statistical analysis. Consequently, the locally applied alendronate prevented resorption of grafted materials, and had a positive effect on bone regeneration with positive micro architectural modification of the surrounding bone, although this study did not verify a significant capacity of bone regeneration of 15d PGJ(2) and instead only shed a light on its possibility. (C) 2018 European Association for Cranio Maxillo Facial Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [Nam, Jung Woo] Wonkwang Univ, Sanbon Hosp, Dept Oral & Maxillofacial Surg, 321 Sanbon Ro, Gunpo Si 15865, Gyeonggi Do, South Korea.
   [Kwon, Jin Il; Hong, Joo Young; Kim, Hyung Jun] Yonsei Univ, Coll Dent, Dept Oral & Maxillofacial Surg, 50 1 Yonsei Ro, Seoul 03722, South Korea.
C3 Wonkwang University; Yonsei University; Yonsei University Health System
RP Kim, HJ (通讯作者)，Yonsei Univ, Coll Dent, Dept Oral & Maxillofacial Surg, 50 1 Yonsei Ro, Seoul 03722, South Korea.
EM kimoms@yuhs.ac
RI ; Kim, Chang Ki/JED 7215 2023
OI Nam, Jung Woo/0000 0002 3445 5690; Kim, Hyung Jun/0000 0001 8247 4004
CR Agholme F, 2009, J BONE JOINT SURG BR, V91B, P670, DOI 10.1302/0301 620X.91B5.21867
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P20, DOI 10.1080/000164702317281350
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Baud'huin M, 2007, CELL MOL LIFE SCI, V64, P2334, DOI 10.1007/s00018 007 7104 0
   Bobyn JD, 2009, J BONE JOINT SURG AM, V91A, P23, DOI 10.2106/JBJS.I.00518
   Bone HG, 2000, CLIN THER, V22, P15, DOI 10.1016/S0149 2918(00)87974 6
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Díez Dacal B, 2010, THESCIENTIFICWORLDJO, V10, P655, DOI 10.1100/tsw.2010.69
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Habibovic P, 2008, J ORTHOP RES, V26, P1363, DOI 10.1002/jor.20648
   HAKEDA Y, 1985, J BIOCHEM, V97, P97, DOI 10.1093/oxfordjournals.jbchem.a135072
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665 199001000 00011
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jakobsen T, 2010, CLIN ORTHOP RELAT R, V468, P867, DOI 10.1007/s11999 009 1099 9
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122764
   KOSHIHARA Y, 1989, BIOCHEM BIOPH RES CO, V159, P1206, DOI 10.1016/0006 291X(89)92238 9
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lazard ZW, 2011, J CELL BIOCHEM, V112, P1563, DOI 10.1002/jcb.23068
   Lichte P, 2011, INJURY, V42, P569, DOI 10.1016/j.injury.2011.03.033
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   RANADE VV, 1991, J CLIN PHARMACOL, V31, P2, DOI 10.1002/j.1552 4604.1991.tb01881.x
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Verron E, 2010, BIOMATERIALS, V31, P7776, DOI 10.1016/j.biomaterials.2010.06.047
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Yaffe A, 1997, J PERIODONTOL, V68, P884, DOI 10.1902/jop.1997.68.9.884
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
NR 40
TC 2
Z9 3
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1010 5182
EI 1878 4119
J9 J CRANIO MAXILL SURG
JI J. Cranio MaxilloFac. Surg.
PD NOV
PY 2019
VL 47
IS 11
BP 1758
EP 1766
DI 10.1016/j.jcms.2018.04.019
PG 9
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA JP0LS
UT WOS:000497964200012
PM 31760999
DA 2025 08 17
ER

PT J
AU Tyagi, AK
   Prasad, S
   Majeed, M
   Aggarwal, BB
AF Tyagi, Amit K.
   Prasad, Sandeo
   Majeed, Muhammed
   Aggarwal, Bharat B.
TI Calebin A downregulates osteoclastogenesis through suppression of RANKL
   signalling
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Calebin A; Osteoclastogenesis; Cancer; RANKL; NF kappa B
ID FACTOR KAPPA B; METASTATIC BONE DISEASE; NF KB ACTIVATION; RECEPTOR
   ACTIVATOR; MYELOMA CELLS; CLINICAL FEATURES; MULTIPLE MYELOMA; LIGAND;
   INHIBITOR; EXPRESSION
AB Osteoporosis is a bone disease that is exacerbated by aging and age associated chronic diseases such as cancer. Cancer induced bone loss is usually treated with bisphosphonates or denosumab, an antibody against receptor activator of nuclear factor (NF) kappa B ligand (RANKL). Because these drugs are expensive and have numerous side effects and high rates of toxicity, safer, more effective, and more affordable therapies for osteoporosis are still needed. We identified a compound, calebin A (CA), derived from turmeric (Curcuma longa) that affects osteoclastogenesis through modulation of the RANKL signalling pathway. The CA's effect on NF kappa B activation was examined by electrophoretic mobility shift assay. Using mouse macrophages in vitro model, we found that CA suppressed RANKL induced osteoclast differentiation of macrophages into osteoclasts, and downregulate RANKL induced osteoclastogenesis related marker gene expression, including NFATc 1, TRAP, CTR, and cathepsin K. CA also suppressed the osteoclastogenesis induced by multiple myeloma and breast cancer cells. This effect of CA was correlated with suppression of the phosphorylation and degradation of inhibitor of kappa B and, thus, inhibition of NF kappa B activation. Furthermore, we found that an NF kappa B specific inhibitory peptide blocked RANKL induced osteoclastogenesis, demonstrating that the NF kappa B signalling pathway is mandatory for RANKL induced osteoclastogenesis. Our results conclusively indicate that CA downmodulates the osteoclastogenesis induced by RANKL and by tumour cells through suppression of NF kappa B pathway. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tyagi, Amit K.; Prasad, Sandeo; Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
   [Majeed, Muhammed] Sabinsa Corp, East Windsor, NJ USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Prasad, S; Aggarwal, BB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
EM spbiotech@gmail.com; bbaggarwal@gmail.com
RI ; Aggarwal, Bharat/G 3388 2013
OI Kumar Tyagi, Amit/0000 0001 9792 7029; 
FU Jarrow Formulas, Inc.; Center for Targeted Therapy of MD Anderson Cancer
   Center
FX We thank Amy Ninetto for editorial review of this manuscript and Prof V.
   Craig Jordan (Father of Tamoxifen) for providing the facility and
   required reagents to revise the manuscript. This work was supported by a
   grant from Jarrow Formulas, Inc., and Center for Targeted Therapy of MD
   Anderson Cancer Center.
CR Abu Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200
   Aggarwal BB, 2013, MOL NUTR FOOD RES, V57, P1529, DOI 10.1002/mnfr.201200838
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bharti AC, 2004, APOPTOSIS, V9, P677, DOI 10.1023/B:APPT.0000045780.10463.c6
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Jin ZX, 2015, MOL ENDOCRINOL, V29, P172, DOI 10.1210/me.2014 1316
   Kasukawa Y, 2007, TOHOKU J EXP MED, V211, P275, DOI 10.1620/tjem.211.275
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kunnurnakkara AB, 2007, BLOOD, V109, P5112, DOI 10.1182/blood 2007 01 067256
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   Li Y, 2008, EUR J PHARMACOL, V591, P252, DOI 10.1016/j.ejphar.2008.06.065
   MARIE PJ, 1995, CALCIFIED TISSUE INT, V56, pS13, DOI 10.1007/BF03354642
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Prasad S, 2014, BIOTECHNOL ADV, V32, P1053, DOI 10.1016/j.biotechadv.2014.04.004
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Sung B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064118
   Sung B, 2011, INT J CANCER, V129, P2062, DOI 10.1002/ijc.25868
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2007, ADV EXP MED BIOL, V602, P93
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2004, DRUGS TODAY, V40, P29, DOI 10.1358/dot.2004.40.1.799436
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
NR 46
TC 27
Z9 28
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003 9861
EI 1096 0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD MAR 1
PY 2016
VL 593
BP 80
EP 89
DI 10.1016/j.abb.2016.02.013
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DG0JP
UT WOS:000371751400008
PM 26874195
DA 2025 08 17
ER

PT J
AU Feng, P
   Che, Y
   Chen, DQ
AF Feng, Peng
   Che, Ying
   Chen, De Qiang
TI Molecular mechanism of action of Liuwei Dihuang pill for the treatment
   of osteoporosis based on network pharmacology and molecular docking
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Traditional Chinese medicine; Liuwei Dihuang; Osteoporosis; Molecular
   mechanism; Pharmacological action; Protein interaction; Network
   pharmacology; Molecular docking
ID OSTEOBLAST DIFFERENTIATION; WEB SERVER; PREDICTION; MEDICINE; TARGET;
   CELLS; OSTEOCLASTOGENESIS; PRESCRIPTION; INGREDIENTS; PREVENTION
AB Introduction: Liuwei Dihuang, a classic Chinese medicinal formula composed of six herbs, has been used to counteract functional decline due to aging and geriatric diseases such as osteoporosis. In this work we investigated the molecular mechanism of action of Liuwei Dihuang pill (LDP) in the treatment of osteoporosis through network pharmacology and molecular docking approaches.
   Methods: Combining data from the Network pharmacology platform of traditional Chinese Medicine, the active ingredients of LDP were screened. Targets prediction databases were used to predict the targets of LDP active ingredients. Osteoporosis related targets were identified from databases of the disease. Target interaction networks were constructed, and analyzed by gene enrichment. Finally, the SystemsDOCK and POCASA was used to validate the affinity between the target and the active substance.
   Results: We screened 99 ingredients of LDP and obtained 57 direct key target genes in the network. Gene annotation showed that the targets were involved mainly in 10 biological functions, such as muscle cell proliferation, anoikis, and reactive oxygen species metabolism. These results were confirmed by molecular docking, which identified 13 high affinity active substances in LDP, including paeonol, cornudentanone, and alisol B.
   Conclusions: Our bioinformatic analyses suggest that LDP may be useful for the treatment of osteoporosis mainly by regulating proliferation and apoptosis signaling pathways, improving bone microenvironment, and regulating hormone and enzyme activities. Identification of some key target genes and active substances supports these results. These data provide a theoretical basis for further study of the role of LDP in the treatment of osteoporosis.
C1 [Feng, Peng; Che, Ying; Chen, De Qiang] Shandong Univ Tradit Chinese Med, 16369 Jingshi Rd, Jinan 250000, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Chen, DQ (通讯作者)，Shandong Univ Tradit Chinese Med, 16369 Jingshi Rd, Jinan 250000, Shandong, Peoples R China.
EM fengpenglinda@163.com; 974290232@qq.com; cheyinglinda@outlook.com
RI feng, peng/JAX 4757 2023
OI FENG, PENG/0009 0002 3516 5414
CR Aihara S, 2019, RENAL FAILURE, V41, P88, DOI 10.1080/0886022X.2019.1578667
   Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   [Anonymous], CHIN INTEGRAT MED
   [Anonymous], BIOMED PHARMACOTHER
   [Anonymous], NUCLEIC ACIDS RES
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Butina D, 2002, DRUG DISCOV TODAY, V7, pS83, DOI 10.1016/S1359 6446(02)02288 2
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen MT, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/bmc.3966
   Cheng XR, 2019, CHIN J NAT MEDICINES, V17, P103, DOI 10.1016/S1875 5364(19)30013 5
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Duan XC, 2015, DEVELOPMENT, V142, P1984, DOI 10.1242/dev.117952
   ElHady AK, 2017, J MED CHEM, V60, P5377, DOI 10.1021/acs.jmedchem.6b01915
   Fossépré M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115856
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Giménez BG, 2010, PHARMAZIE, V65, P148, DOI 10.1691/ph.2010.9733
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Hsin KY, 2016, NUCLEIC ACIDS RES, V44, pW507, DOI 10.1093/nar/gkw335
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Ji LX, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/7309816
   Jia F, 2016, GENET TEST MOL BIOMA, V20, P398, DOI 10.1089/gtmb.2015.0282
   Kajimoto S, 2002, INT J CANCER, V99, P879, DOI 10.1002/ijc.10414
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li XM, 2016, ONCOTARGET, V7, P33948, DOI 10.18632/oncotarget.8608
   Limopasmanee W, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/902702
   Lipinski CA, 2016, ADV DRUG DELIVER REV, V101, P34, DOI 10.1016/j.addr.2016.04.029
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu FX, 2018, BIOMED PHARMACOTHER, V103, P1052, DOI 10.1016/j.biopha.2018.04.102
   Liu YH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016537
   Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553
   Makino T, 2006, BASIC CLIN PHARMACOL, V98, P401, DOI 10.1111/j.1742 7843.2006.pto_328.x
   Montaseri A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028663
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Olszynski WP, 2004, CLIN THER, V26, P15, DOI 10.1016/S0149 2918(04)90002 1
   Picca A, 2017, CURR PHARM DESIGN, V23, P6256, DOI 10.2174/1381612823666170526112300
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Qian Q, 2018, J CHROMATOGR B, V1102, P34, DOI 10.1016/j.jchromb.2018.10.011
   Reginster JY, 2016, CURR OPIN CLIN NUTR, V19, P31, DOI 10.1097/MCO.0000000000000230
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sagar T, 2016, CYTOTECHNOLOGY, V68, P1963, DOI 10.1007/s10616 016 0009 8
   Sangha JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043990
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Shen MY, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758 2946 4 31
   Shi XQ, 2019, J ETHNOPHARMACOL, V235, P227, DOI 10.1016/j.jep.2019.01.027
   Shibahara T, 2019, JPN DENT SCI REV, V55, P71, DOI 10.1016/j.jdsr.2018.11.003
   Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu C, 2019, CHIN J CHROMATOGR, V37, P305, DOI 10.3724/SP.J.1123.2018.11022
   Wuchty S, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471 2148 5 24
   Xu BB, 2016, BIOCHIMIE, V124, P92, DOI 10.1016/j.biochi.2015.06.018
   Xu F, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011659, 10.1097/md.0000000000011659]
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Xu ZJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005879
   Ye J, 2009, J PHARMACEUT BIOMED, V49, P638, DOI 10.1016/j.jpba.2008.12.009
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Zhang L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18670 7
   Zhao GF, 2016, MOL MED REP, V14, P1132, DOI 10.3892/mmr.2016.5350
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
   Zhao S, 2016, IRISH J MED SCI, V185, P581, DOI 10.1007/s11845 015 1309 2
   Zhou WX, 2016, PHARMACOL THERAPEUT, V162, P170, DOI 10.1016/j.pharmthera.2016.02.004
   Zhu F, 2010, NUCLEIC ACIDS RES, V38, pD787, DOI 10.1093/nar/gkp1014
NR 72
TC 8
Z9 13
U1 3
U2 58
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876 3820
EI 1876 3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD JAN
PY 2020
VL 33
AR 101009
DI 10.1016/j.eujim.2019.101009
PG 15
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA LD6DP
UT WOS:000526121000013
DA 2025 08 17
ER

PT J
AU Vondracek, SF
AF Vondracek, Sheryl F.
TI Managing osteoporosis in postmenopausal women
SO AMERICAN JOURNAL OF HEALTH SYSTEM PHARMACY
LA English
DT Article
DE Antibodies; Bisphosphonates; Calcitonin salmon; Calcium; Denosumab;
   Estrogen agonist antagonists; Fractures; Hormones; Minerals;
   Osteoporosis; Pharmacists, hospital; Postmenopause; Raloxifene;
   Teriparatide; Vitamin D; Vitamins; Women
ID BONE MINERAL DENSITY; FRACTURE RISK; RANDOMIZED TRIAL; BISPHOSPHONATES;
   RISEDRONATE; DENOSUMAB; MECHANISM
AB Purpose. To describe strategies used in managing postmenopausal osteoporosis, including a bone healthy lifestyle, adequate calcium and vitamin D intake, and drug therapy options; considerations in selecting osteoporosis drug therapy; and the role of health system pharmacists in managing osteoporosis in postmenopausal women.
   Summary. Postmenopausal women are at risk for osteoporosis and fractures. Weight bearing and resistance exercise, limiting alcohol and caffeine intake, smoking cessation, and fall prevention strategies are part of a bone healthy lifestyle used to manage postmenopausal osteoporosis. Supplements containing calcium and vitamin D are needed by many postmenopausal women because of an inadequate intake and other factors. The choice of osteoporosis drug therapy should take into consideration patient characteristics and preference and drug efficacy, safety, route of administration, dosing frequency, convenience, cost, and potential for nonadherence. Bisphosphonates generally are preferred for the prevention and treatment of osteoporosis in postmenopausal women, with raloxifene, teriparatide, and calcitonin salmon as alternatives. Denosumab, a fully human monoclonal immunoglobulin G(2) antibody, may become available soon for prevention and treatment of postmenopausal osteoporosis. Health system pharmacists can improve the management of osteoporosis in postmenopausal women by counseling them on a bone healthy lifestyle and making recommendations for calcium and vitamin D supplements and osteoporosis medications to prevent or treat the disease.
   Conclusion. A variety of approaches are available to promote bone health in postmenopausal women. Health system pharmacists can promote interventions to optimize patient outcomes.
C1 Univ Colorado, Denver Sch Pharm, Dept Clin Pharm, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Vondracek, SF (通讯作者)，Univ Colorado, Denver Sch Pharm, Dept Clin Pharm, C238 L15,12631 E 17th Ave, Aurora, CO 80045 USA.
EM sheryl.vondracek@ucdenver.edu
CR *AM SOC HLTH SYST, 2008, AM J HEALTH SYST PH, V65, P343
   [Anonymous], DIET SUPPL FACT SHEE
   [Anonymous], Clinician's Guide to Prevention and Treatment of Osteoporosis
   [Anonymous], 2008, 2008 Physical Activity Guidelines for Americans
   [Anonymous], 2005, DIET GUID AM 2005
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   *CDCP, FALLS OLD AD WHAT YO
   *CDCP, PREV CHECK SAF HOM F
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   CONFAVREUX C, 2009, J BONE MINER RES S1, V24
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   *E LILL CO, 2008, EV PACK INS
   *E LILL CO, 2009, FORT PACK INS
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   *FDA, FDA CLASS PROL DEN C
   Grey A, 2009, J CLIN ENDOCR METAB, V94, P538, DOI 10.1210/jc.2008 2241
   Hallström H, 2006, OSTEOPOROSIS INT, V17, P1055, DOI 10.1007/s00198 006 0109 y
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heaney RP, 2006, J NUTR, V136, P1123, DOI 10.1093/jn/136.4.1123
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004 2364
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P155, DOI 10.1007/s00198 004 1640 3
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MCEVOY GK, 2009, AHFS DRUG INFORM 200, P3178
   *MERCK CO INC, 2009, FOS PACK INS
   *MERCK CO INC, 2009, FOS PLUS D PACK INS
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   *NAT OST FDN, PREV VIT D
   National Osteoporosis Foundation, WHAT YOU SHOULD KNOW
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   *NOV PHARM CORP, 2009, ZOM PACK INS
   *NOV PHARM CORP, 2009, RECL PACK INS
   *NOV PHARM CORP, 2006, MIAC NAS SPRAY PACK
   OCONNELL MB, 2008, PHARMACOTHERAPY PATH, P1483
   *PROCT GAMBL PHARM, 2009, ACT PACK INS
   Reid IR., 2008, J Bone Miner Res, V7, P95
   *ROCH LAB INC, 2009, BON INJ PACK INS
   *ROCH LAB INC, 2008, BON TABL PACK INS
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   The Adherence Gap: why osteoporosis patients don't continue with treatment, 2005, ADH GAP WHY OST PAT
   The United States Pharmacopeia, USP DIET SUPPL VER P
   U.S. Food and Drug Administration, How to Understand and Use the Nutrition Facts Label
   *US FDA, AMG PROV UPD S UNPUB
   *WHO, FRAX WHO FRAC RISK A
   BONE HLTH OSTEOPOROS, pCH2
   TRAVELING FORTEO
NR 54
TC 2
Z9 9
U1 1
U2 21
PU AMER SOC HEALTH SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079 2082
J9 AM J HEALTH SYST PH
JI Am. J. Health Syst. Pharm.
PD APR 1
PY 2010
VL 67
IS 7
SU 3
BP S9
EP S19
DI 10.2146/ajhp100076
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 573AV
UT WOS:000275881700003
PM 20332498
DA 2025 08 17
ER

PT J
AU Gupta, A
   Cao, W
   Chellaiah, MA
AF Gupta, Aditi
   Cao, Wei
   Chellaiah, Meenakshi A.
TI Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells
   support osteoclastogenesis via a Runx2/Smad 5/receptor activator of
   NF κB ligand signaling axis
SO MOLECULAR CANCER
LA English
DT Article
DE PC3 cells; RANKL; RUNX2; Smad 5; CD44; Integrin alpha v beta 3;
   Osteoclasts; PKC
ID INCREASES RANKL EXPRESSION; GROWTH FACTOR BETA; GENE EXPRESSION;
   BREAST CANCER; OSTEOBLAST DIFFERENTIATION; TUMOR GROWTH; BONE LOSS;
   TGF BETA; IN VIVO; TRANSCRIPTION
AB Background: Bone loss and pathological fractures are common skeletal complications associated with androgen deprivation therapy and bone metastases in prostate cancer patients. We have previously demonstrated that prostate cancer cells secrete receptor activator of NF kB ligand (RANKL), a protein essential for osteoclast differentiation and activation. However, the mechanism(s) by which RANKL is produced remains to be determined. The objective of this study is to gain insight into the molecular mechanisms controlling RANKL expression in metastatic prostate cancer cells.
   Results: We show here that phosphorylation of Smad 5 by integrin alpha v beta 3 and RUNX2 by CD44 signaling, respectively, regulates RANKL expression in human derived PC3 prostate cancer cells isolated from bone metastasis. We found that RUNX2 intranuclear targeting is mediated by phosphorylation of Smad 5. Indeed, Smad5 knock down via RNA interference and inhibition of Smad 5 phosphorylation by an alpha v inhibitor reduced RUNX2 nuclear localization and RANKL expression. Similarly, knockdown of CD44 or RUNX2 attenuated the expression of RANKL. As a result, conditioned media from these cells failed to support osteoclast differentiation in vitro. Immunohistochemistry analysis of tissue microarray sections containing primary prostatic tumor (grade2 4) detected predominant localization of RUNX2 and phosphorylated Smad 5 in the nuclei. Immunoblotting analyses of nuclear lysates from prostate tumor tissue corroborate these observations.
   Conclusions: Collectively, we show that CD44 signaling regulates phosphorylation of RUNX2. Localization of RUNX2 in the nucleus requires phosphorylation of Smad 5 by integrin alpha v beta 3 signaling. Our results suggest possible integration of two different pathways in the expression of RANKL. These observations imply a novel mechanistic insight into the role of these proteins in bone loss associated with bone metastases in patients with prostate cancer.
C1 [Gupta, Aditi; Chellaiah, Meenakshi A.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
   [Cao, Wei] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Maxillofacial Surg, Shanghai 200011, Peoples R China.
C3 University System of Maryland; University of Maryland Baltimore;
   Shanghai Jiao Tong University
RP Chellaiah, MA (通讯作者)，Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
EM mchellaiah@umaryland.edu
RI ; Cao, Wei/ABE 1035 2021; Gupta, Aditi/HGD 9632 2022
OI Cao, Wei/0000 0003 2184 9380; 
FU National Institute of Health (NIH) [AR46292, T32 DE007309]; National
   Natural Science Foundation of China [30973343]; Shanghai Science and
   Technology Committee [10XD1402500]
FX This work was supported by National Institute of Health (NIH) grants
   AR46292 to MAC and training grant T32 DE007309 to AG. Wei Cao was
   supported in part by the National Natural Science Foundation of China
   (grant 30973343) and projects of the Shanghai Science and Technology
   Committee (grant 10XD1402500).
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Brawley OW, 2012, WORLD J UROL, V30, P195, DOI 10.1007/s00345 012 0824 2
   Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233
   Cao JJ, 2005, J BONE MINER RES, V20, P30, DOI 10.1359/JBMR.041014
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Chang SF, 2008, P NATL ACAD SCI USA, V105, P3927, DOI 10.1073/pnas.0712353105
   Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665
   Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743
   Choo CK, 1999, PROSTATE, V40, P150, DOI 10.1002/(SICI)1097 0045(19990801)40:3<150::AID PROS2>3.0.CO;2 7
   Chua CW, 2009, CLIN CANCER RES, V15, P4322, DOI 10.1158/1078 0432.CCR 08 3157
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Desai B, 2009, J CELL BIOCHEM, V108, P272, DOI 10.1002/jcb.22248
   Desai B, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 18
   Dhir R, 1997, MOL DIAGN, V2, P197, DOI 10.1016/S1084 8592(97)80029 X
   Dougall William C, 2007, Curr Opin Support Palliat Care, V1, P317, DOI 10.1097/SPC.0b013e3282f335be
   Feng P, 2002, PROSTATE, V52, P311, DOI 10.1002/pros.10128
   Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664
   Gao AC, 1997, CANCER RES, V57, P846
   Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710
   Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Hayer S, 2005, J EXP MED, V201, P903, DOI 10.1084/jem.20040852
   Hjelmeland AB, 2005, MOL CELL BIOL, V25, P9460, DOI 10.1128/MCB.25.21.9460 9468.2005
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242
   Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kitazawa R, 2008, J CELL BIOCHEM, V105, P1289, DOI 10.1002/jcb.21929
   Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585 009 9242 2
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555 006 9033 z
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma T, 2010, J BIOL CHEM, V285, P29911, DOI 10.1074/jbc.M109.099697
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   Naor D, 1998, CURR TOP MICROBIOL, V231, P143
   Noordzij MA, 1999, INT J CANCER, V84, P478, DOI 10.1002/(SICI)1097 0215(19991022)84:5<478::AID IJC5>3.0.CO;2 N
   Ohyama Y, 2012, J ATHEROSCLER THROMB, V19, P23, DOI 10.5551/jat.9753
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Ricciardelli C, 2007, J BIOL CHEM, V282, P10814, DOI 10.1074/jbc.M606991200
   Robertson BW, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 260
   Robertson BW, 2010, EXP CELL RES, V316, P1, DOI 10.1016/j.yexcr.2009.10.012
   Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200
   Sanchez Sweatman Otto H., 1998, Invasion and Metastasis, V18, P297, DOI 10.1159/000024522
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Singh IS, 2008, AM J RESP CELL MOL, V39, P235, DOI 10.1165/rcmb.2007 0294OC
   SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859
   Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383
   Tanikawa R, 2010, BIOCHEM BIOPH RES CO, V394, P317, DOI 10.1016/j.bbrc.2010.02.175
   Tanne Y, 2008, ARCH ORAL BIOL, V53, P478, DOI 10.1016/j.archoralbio.2007.12.007
   van der Deen M, 2010, J CELL BIOCHEM, V109, P828, DOI 10.1002/jcb.22463
   VANDERGULDEN JWJ, 1994, PROSTATE, V24, P33, DOI 10.1002/pros.2990240108
   WANG CY, 1977, ANTIMICROB AGENTS CH, V11, P753, DOI 10.1128/AAC.11.4.753
   Weber GF, 2000, BRAIN RES BULL, V53, P421, DOI 10.1016/S0361 9230(00)00379 8
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Yonou H, 2007, PROSTATE, V67, P999, DOI 10.1002/pros.20592
   Yu CY, 2011, IN VIVO, V25, P69
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zhang J, 2003, CANCER RES, V63, P7883
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 76
TC 61
Z9 70
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476 4598
J9 MOL CANCER
JI Mol. Cancer
PD SEP 11
PY 2012
VL 11
AR 66
DI 10.1186/1476 4598 11 66
PG 17
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 042AR
UT WOS:000311443900001
PM 22966907
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lu, L
   Rao, L
   Jia, HH
   Chen, J
   Lu, XY
   Yang, GZ
   Li, QN
   Lee, KKH
   Yang, L
AF Lu, Li
   Rao, Li
   Jia, Huanhuan
   Chen, Jun
   Lu, Xingyan
   Yang, Guozhu
   Li, Qingnan
   Lee, Kenneth Ka Ho
   Yang, Li
TI Baicalin positively regulates osteoclast function by activating
   MAPK/Mitf signalling
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE baicalin; osteoclast; MAPK; Mitf signalling; bone fracture healing
ID MICROPHTHALMIA TRANSCRIPTION FACTOR; IN VITRO; RECEPTOR ACTIVATOR;
   ANTIVIRAL ACTIVITY; P38 MAPK; NFATC1; TARGET; MITF; EXPRESSION; SURVIVAL
AB Activation of osteoblasts in bone formation and osteoclasts in bone resorption is important during the bone fracture healing process. There has been a long interest in identifying and developing a natural therapy for bone fracture healing. In this study, we investigated the regulation of osteoclast differentiation by baicalin, which is a natural molecule extracted from Eucommiaulmoides (small tree native to China). It was determined that baicalin enhanced osteoclast maturation and bone resorption activity in a dose dependent manner. Moreover, this involves the activation of MAPK, increased Mitf nuclear translocation and up regulation of downstream osteoclast related target genes expression. The baicalin induced effect on osteoclast differentiation can be mimicked by specific inhibitors of p ERK (U0126) and the Mitf specific siRNA, respectively. Protein ligand docking prediction identified that baicalin might bind to RANK, which is the upstream receptor of p ERK/Mitf signalling in osteoclasts. This indicated that RANK might be the binding target of baicalin. In sum, our findings revealed baicalin increased osteoclast maturation and function via p ERK/Mitf signalling. In addition, the results suggest that baicalin can potentially be used as a natural product for the treatment of bone fracture.
C1 [Lu, Li; Rao, Li; Chen, Jun; Lu, Xingyan; Yang, Guozhu; Li, Qingnan] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharm, Guangdong Key Lab Pharmaceut Bioact Subst, Guangzhou, Guangdong, Peoples R China.
   [Jia, Huanhuan; Li, Qingnan] Guangdong Lab Anim Monitoring Inst, Guangdong Key Lab Lab Anim, Guangzhou, Guangdong, Peoples R China.
   [Lee, Kenneth Ka Ho] Chinese Univ Hong Kong, Sch Biomed Sci, Stem Cell & Regenerat Themat Res Program, Shatin, Hong Kong, Peoples R China.
   [Yang, Li] Southern Med Univ, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China.
C3 Guangdong Pharmaceutical University; Chinese University of Hong Kong;
   Southern Medical University   China
RP Yang, L (通讯作者)，Southern Med Univ, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China.
EM yangli19762009@163.com
RI jia, huanhuan/KHY 8301 2024; Lee, Kenneth/H 6698 2013
OI Lee, Kenneth/0000 0002 6520 304X
FU National Natural Science Foundation of China [81203003]
FX The authors would like to acknowledge Dr. Liang Weicheng for providing
   valuable suggestions regarding data analysis. This work was supported by
   the National Natural Science Foundation of China (81203003).
CR Abdelraheem EMM, 2015, EXPERT OPIN DRUG DIS, V10, P1179, DOI 10.1517/17460441.2015.1080684
   Aeschlimann D, 2004, CELL DEATH DIFFER, V11, pS5, DOI 10.1038/sj.cdd.4401470
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen JC, 2013, INT J MOL SCI, V14, P6012, DOI 10.3390/ijms14036012
   Congreve M, 2008, J MED CHEM, V51, P3661, DOI 10.1021/jm8000373
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Guo AJY, 2012, J BIOL CHEM, V287, P6958, DOI 10.1074/jbc.A111.236281
   Hajduk PJ, 2007, NAT REV DRUG DISCOV, V6, P211, DOI 10.1038/nrd2220
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014
   Lee W, 2015, INFLAMMATION, V38, P110, DOI 10.1007/s10753 014 0013 0
   Li HY, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/267890
   Lu SY, 2010, MOL BIOL CELL, V21, P1763, DOI 10.1091/mbc.E09 07 0584
   Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   MARKS SC, 1977, AM J ANAT, V149, P269, DOI 10.1002/aja.1001490209
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Meadows NA, 2007, J BIOL CHEM, V282, P1891, DOI 10.1074/jbc.M608572200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Moghaddam E, 2014, SCI REP UK, V4, DOI 10.1038/srep05452
   Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Nayak MK, 2014, J ANTIMICROB CHEMOTH, V69, P1298, DOI 10.1093/jac/dkt534
   Novy P, 2011, J ANTIMICROB CHEMOTH, V66, P1298, DOI 10.1093/jac/dkr108
   Roy MK, 2007, PHARMAZIE, V62, P149, DOI 10.1691/ph.2007.2.6608
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756 3282(85)90406 5
   Warr WA, 2009, J COMPUT AID MOL DES, V23, P453, DOI 10.1007/s10822 009 9292 1
   Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097 2765(01)00360 4
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Zhou Z, 2007, J BONE MINER RES, V22, pS150
NR 39
TC 23
Z9 26
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2017
VL 21
IS 7
BP 1361
EP 1372
DI 10.1111/jcmm.13066
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA EZ0DB
UT WOS:000404367800011
PM 28158928
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, K
   Wang, T
   Luo, E
   Leng, X
   Yao, B
AF Guo, Kuiting
   Wang, Tiancheng
   Luo, Enjing
   Leng, Xiangyang
   Yao, Baojin
TI Use of Network Pharmacology and Molecular Docking Technology to Analyze
   the Mechanism of Action of Velvet Antler in the Treatment of
   Postmenopausal Osteoporosis
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE MINERAL DENSITY; BODY MASS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   ACTIVITY; PATHWAY; WOMEN; PROLIFERATION; APOPTOSIS; PEPTIDE; HEALTH
AB Deer velvet antlers are the young horns of male deer that are not ossified and densely overgrown. Velvet antler and its preparations have been widely used in the treatment of postmenopausal osteoporosis (PMOP) in recent years, although its mechanism of action in the human body remains unclear. To screen the effective ingredients and targets of velvet antler in the treatment of PMOP using network pharmacology and to explore the potential mechanisms of velvet antler action in such treatments, we screened the active ingredients and targets of velvet antler in the BATMAN TCM database. We also screened the relevant targets of PMOP in the GeneCards and OMIM databases and then compared the targets at the intersection of both velvet antler and PMOP. We used Cytoscape 3.7.2 software to construct a network diagram of "disease drug components targets" and a protein protein interaction (PPI) network through the STRING database and screened out the core targets; the R language was then used to analyze the shared targets between antler and PMOP for GO enrichment analysis and KEGG pathway annotation analysis. Furthermore, we used the professional software Maestro 11.1 to verify the predictive analysis based on network pharmacology. Hematoxylin eosin (H&E) staining and micro CT were used to observe the changes in trabecular bone tissue, further confirming the results of network pharmacological analysis. The potentially effective components of velvet antler principally include 17 beta  E2, adenosine triphosphate, and oestrone. These components act on key target genes such as AKT1, IL6, MAPK3, TP53, EGFR, SRC, and TNF and regulate the PI3K/Akt signaling and MAPK signaling pathways. These molecules participate in a series of processes such as cellular differentiation, apoptosis, metabolism, and inflammation and can ultimately be used to treat PMOP; they reflect the overall regulation, network regulation, and protein interactions.
C1 [Guo, Kuiting; Wang, Tiancheng; Luo, Enjing; Leng, Xiangyang] Changchun Univ Chinese Med, Changchun 130117, Peoples R China.
   [Yao, Baojin] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine
RP Leng, X (通讯作者)，Changchun Univ Chinese Med, Changchun 130117, Peoples R China.; Yao, B (通讯作者)，Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Peoples R China.
EM shxxxgkt@163.com; runshuo1995@163.com; luoenjing0311@163.com;
   leng_xiangyang@163.com; baojin.yao1983@yahoo.com
RI Wang, Tiancheng/GSE 0806 2022
OI Leng, Xiangyang/0000 0001 5278 4001; Guo, Kuiting/0000 0002 3874 342X;
   Wang, Tiancheng/0000 0002 9406 3808
CR Baldock PAJ, 1998, J BONE MINER RES, V13, P1451, DOI 10.1359/jbmr.1998.13.9.1451
   Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360
   Capozza RF, 2008, MENOPAUSE, V15, P905, DOI 10.1097/gme.0b013e318164ee85
   Chen FP, 2013, CLIMACTERIC, V16, P154, DOI 10.3109/13697137.2012.672496
   Chen JR, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/819520
   Chen LL, 2013, TISSUE ENG PT A, V19, P2226, DOI [10.1089/ten.tea.2012.0469, 10.1089/ten.TEA.2012.0469]
   Dogan A, 2010, ARCH GERONTOL GERIAT, V51, P338, DOI 10.1016/j.archger.2010.01.015
   Feng J, 2014, ACTA BIOCH BIOPH SIN, V46, P1024, DOI 10.1093/abbs/gmu103
   FREERE R. H., 1967, J ROY MICROSC SOC, V87, P25
   Ge YX, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.06.77
   Greco EA, 2010, INT J CLIN PRACT, V64, P817, DOI 10.1111/j.1742 1241.2009.02301.x
   Guan MQ, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02350 4
   Hannan MT, 2000, J BONE MINER RES, V15, P2504, DOI 10.1359/jbmr.2000.15.12.2504
   He G, 2014, CELL BIOCHEM BIOPHYS, V70, P467, DOI 10.1007/s12013 014 9942 3
   Hu Y., 2021, Journal of Liaoning University of TCM, V23, P47
   Ji YF, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199 019 0803 y
   Kemmler W, 2013, OSTEOPOROSIS INT, V24, P1937, DOI 10.1007/s00198 012 2248 7
   Kim HK, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/1927534
   Kim HK, 2013, MOLECULES, V18, P15474, DOI 10.3390/molecules181215474
   Li G., 2016, Chin Tradit Bonesetting, V28, P36
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Li R, 2019, J CELL BIOCHEM, V120, P11265, DOI 10.1002/jcb.28404
   Li SZ., 2014, The Grand Compendium of Materia Medica
   Li YJ, 2007, J ETHNOPHARMACOL, V113, P191, DOI 10.1016/j.jep.2007.04.020
   Lin CC, 2016, MOL BIOL REP, V43, P1179, DOI 10.1007/s11033 016 4037 4
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Meganck JA, 2017, MOL IMAGING BIOL, V19, P499, DOI 10.1007/s11307 016 1026 x
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Asri SFM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207715
   Mohiti Ardekani J, 2014, J BONE MINER METAB, V32, P400, DOI 10.1007/s00774 013 0511 4
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   National Pharmacopoeia Commission, 2020, Pharmacopoeia of the People's Republic of China: Part One, P336
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Perilli E, 2008, J BIOMECH, V41, P438, DOI 10.1016/j.jbiomech.2007.08.003
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Prentice A, 2006, P NUTR SOC, V65, P348, DOI 10.1079/PNS2006519
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shi B, 2010, J ETHNOPHARMACOL, V127, P124, DOI 10.1016/j.jep.2009.09.036
   Silva I, 2012, ACTA REUMATOL PORT, V37, P302
   Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959
   Su M, 2019, INT IMMUNOPHARMACOL, V66, P383, DOI 10.1016/j.intimp.2018.11.048
   Trevisan C, 2020, J CLIN DENSITOM, V23, P381, DOI 10.1016/j.jocd.2019.07.007
   Tseng SH, 2014, J ETHNOPHARMACOL, V151, P352, DOI 10.1016/j.jep.2013.10.060
   Wang X., 2014, CHINESE J OSTEOPOROS, V7, P250
   Wang YS, 2017, PHARM BIOL, V55, P2196, DOI 10.1080/13880209.2017.1397177
   Wang YH, 2020, EXP THER MED, V20, P3185, DOI 10.3892/etm.2020.9045
   WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495 013 0867 x
   Yao BJ, 2019, MOL BIOL REP, V46, P4861, DOI 10.1007/s11033 019 04934 0
   Yao BJ, 2018, IN VITRO CELL DEV AN, V54, P439, DOI 10.1007/s11626 018 0266 2
   Yun CJ, 2020, EXP THER MED, V19, P923, DOI 10.3892/etm.2019.8286
   Zhang Y, 2016, EUR REV MED PHARMACO, V20, P433
   Zhu D, 2018, MOLECULES, V23, DOI 10.3390/molecules23030561
NR 55
TC 11
Z9 12
U1 3
U2 30
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD OCT 11
PY 2021
VL 2021
AR 7144529
DI 10.1155/2021/7144529
PG 22
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA YO5DD
UT WOS:000747958800007
PM 34671409
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nicholson, G
   Carlson, KB
   Hernandez, RK
   Schenfeld, J
   Cadieux, B
   Henry, D
   Barbosa, VJD
   Saad, H
AF Nicholson, Gina
   Carlson, Katherine B.
   Hernandez, Rohini K.
   Schenfeld, Jennifer
   Cadieux, Benoit
   Henry, David
   Barbosa, Vitor Jose De Sousa
   Saad, Hossam
TI Treatment Patterns of Bone targeting Agents Among Solid Tumor Patients
   With Bone Metastases
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY CANCER CLINICAL TRIALS
LA English
DT Article
DE bone metastasis; bone targeting agents; compliance; persistence; solid
   tumors
ID SKELETAL RELATED EVENTS; ADVANCED BREAST CANCER; QUALITY OF LIFE;
   ZOLEDRONIC ACID; DOUBLE BLIND; MULTIPLE MYELOMA; PHASE III;
   COMPLICATIONS; DENOSUMAB; BISPHOSPHONATES
AB Objectives: This study evaluated real world treatment patterns of approved bone targeting agents (BTAs) with various mechanisms of action pamidronate, zoledronic acid, and denosumab for the prevention of skeletal related events in patients with bone metastases (BM) from solid tumors. Methods: Adult patients with BM secondary to solid tumors between January 1, 2014, and December 31, 2018, were identified from the Flatiron Health Oncology Services Comprehensive Electronic Records database and categorized by BTA use and therapy type. Time from diagnosis to initiation, persistence (mean time on treatment), and compliance (>= 12 administrations/year) with BTA with up to 4 years of follow up were examined. Results: This study included 27,268 patients with BM (breast cancer, 32.7%; lung cancer, 16.5%; prostate cancer, 17.2%; and other solid tumors, 33.6%); of these, 41.4% initiated denosumab after BM diagnosis; 21.3%, zoledronic acid; 0.6%, pamidronate; and 36.7% had no treatment record. Mean (SD) time to initiation for denosumab or zoledronic acid was 68.6 (157.0) days (denosumab, 70.3 (160.4) days; zoledronic acid, 65.2 [150.2] days). Mean persistence and compliance (first year of treatment) were significantly higher for denosumab than for zoledronic acid (22.0 vs. 14.9 mo [P<0.0001] and 42.3% vs. 34.8% [P<0.0001], respectively). Treatment compliance was the highest in patients with breast cancer (denosumab, 48.2%; zoledronic acid, 39.1%). Conclusion: Real world BTA treatment patterns in the United States suggest that over one third of patients with BM secondary to solid tumors remain untreated and less than 50% of the patients received >= 12 administrations/year of BTA therapy.
C1 [Nicholson, Gina] Div ToxStrategies Inc, EpidStrategies, Katy, TX USA.
   [Carlson, Katherine B.; Hernandez, Rohini K.; Schenfeld, Jennifer] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
   [Cadieux, Benoit; Barbosa, Vitor Jose De Sousa; Saad, Hossam] Amgen Inc, Dept Med Affairs, Thousand Oaks, CA USA.
   [Henry, David] Univ Penn, Penn Hosp, Philadelphia, PA USA.
C3 Amgen; Amgen; University of Pennsylvania
RP Schenfeld, J (通讯作者)，Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
EM gnicholson@epidstrategies.com; katiecbrewer@gmail.com;
   rohinih@amgen.com; jschenfe@amgen.com; ben_cadieux@hotmail.com;
   davidhenrymd@gmail.com; barbosette@gmail.com; hsaad01@amgen.com
FU Amgen Inc., Thousand Oaks, CA
FX This study was funded by Amgen Inc., Thousand Oaks, CA.
CR Arellano J, 2015, VALUE HEALTH, V18, P78, DOI 10.1016/j.jval.2014.10.004
   Cetin K, 2014, LUNG CANCER, V86, P247, DOI 10.1016/j.lungcan.2014.08.022
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Diel IJ, 2022, SUPPORT CARE CANCER, V30, P9267, DOI 10.1007/s00520 022 07333 7
   FDA, XGEVA prescribing information
   Fizazi K, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.lba4507
   Henry D, 2019, CURR MED RES OPIN, V35, P375, DOI 10.1080/03007995.2018.1558849
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hernandez RK, 2015, CLIN EPIDEMIOL, V7, P335, DOI 10.2147/CLEP.S85496
   Jacobson D, 2022, J BONE ONCOL, V34, DOI 10.1016/j.jbo.2022.100423
   Jensen AO, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 29
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Patrick DL, 2015, SUPPORT CARE CANCER, V23, P1157, DOI 10.1007/s00520 014 2525 4
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Poon M, 2013, CLIN ONCOL UK, V25, P435, DOI 10.1016/j.clon.2013.03.003
   Qian Y, 2013, VALUE HEALTH, V16, pA420, DOI 10.1016/j.jval.2013.08.558
   Qian Y, 2017, SUPPORT CARE CANCER, V25, P1845, DOI 10.1007/s00520 017 3583 1
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2007, CLIN GENITOURIN CANC, V5, P390, DOI 10.3816/CGC.2007.n.022
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Sathiakumar Nalini, 2013, Lung India, V30, P20, DOI 10.4103/0970 2113.106127
   Schulman KL, 2007, CANCER AM CANCER SOC, V109, P2334, DOI 10.1002/cncr.22678
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   von Moos R, 2018, J BONE ONCOL, V11, P1, DOI 10.1016/j.jbo.2017.11.004
   Wong SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102587
NR 31
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277 3732
EI 1537 453X
J9 AM J CLIN ONCOL CANC
JI Am. J. Clin. Oncol. Cancer Clin. Trials
PD APR
PY 2024
VL 47
IS 4
BP 177
EP 184
DI 10.1097/COC.0000000000001075
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA SJ6S0
UT WOS:001234131300002
PM 38200688
DA 2025 08 17
ER

PT J
AU Jiang, T
   Yan, W
   Kong, B
   Wu, CG
   Yang, K
   Wang, TQ
   Yan, XM
   Guo, L
   Huang, P
   Jiang, M
   Xi, XB
   Xu, X
AF Jiang, Tao
   Yan, Wei
   Kong, Bo
   Wu, Changgui
   Yang, Kai
   Wang, Tianqi
   Yan, Xueming
   Guo, Lei
   Huang, Ping
   Jiang, Min
   Xi, Xiaobing
   Xu, Xing
TI The extract of Trachelospermum jasminoides (Lindl.) Lem. vines
   inhibits osteoclast differentiation through the NF κB, MAPK and AKT
   signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Trachelospermum jasminoides (Lindl.) Lem; Osteoclast di fferentiation;
   Network pharmacology; NF kappa B; MAPK; AKT
ID NETWORK PHARMACOLOGY; BONE LOSS; BISPHOSPHONATES; CELLS
AB Osteoclasts are the only cells in the body with a bone resorption function. The identification of anti osteoclastogenic agents is important in managing bone loss diseases. The dried vines of Trachelospermum jasminoides (Lindl.) Lem. have been used as a herbal medicine to treat musculoskeletal soreness in East Asia for hundreds of years. In the present study, we focused on the effect of Trachelospermum jasminoides (Lindl.) Lem. extract (TJE) on osteoclast differentiation. As indicated by tartrate resistant acid phosphatase (TRAP) staining, TJE inhibited osteoclastogenesis induced by receptor activator of nuclear factor kappa B ligand from bone marrow derived monocytes/macrophages without showing any cytotoxicity. In addition, TJE effectively suppressed F actin ring formation and the bone resorption function of osteoclasts. The subsequent studies such as network pharmacology and molecular investigation, revealed that TJE inhibited osteoclastogenesis related genes in a doseand time dependent manner through NF kappa B, MAPK and AKT mediated mechanism followed by the nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)/c Fos pathway. Our study could potentially explain the underlying molecular pharmacology of TJE in osteoclast related diseases. What's more, it suggested that network pharmacology could help the modernization of traditional Chinese medicine.
C1 [Jiang, Tao; Yan, Wei; Kong, Bo; Wu, Changgui; Yang, Kai; Wang, Tianqi; Yan, Xueming; Guo, Lei; Huang, Ping; Jiang, Min; Xi, Xiaobing; Xu, Xing] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Sch Med,Shanghai Key Lab Bone & Joint Dis, Shanghai 200025, Peoples R China.
   [Jiang, Tao; Yan, Wei; Kong, Bo; Wu, Changgui; Xi, Xiaobing] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Dept Traumatol, Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Jiang, M; Xi, XB; Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Sch Med,Shanghai Key Lab Bone & Joint Dis, Shanghai 200025, Peoples R China.
EM jiangm263@163.com; skxixiaobing@163.com; xuxing0510315@126.com
RI Huang, Ping/AAE 7205 2019; guo, leixin/HPF 6884 2023; Wang,
   Tianqi/KIC 1831 2024; Kong, Bo/G 7650 2014; Yang, Kai/JQW 2039 2023
OI Jiang, Min/0000 0003 1530 6830; Yang, Kai/0000 0002 5544 7817
FU Natural Science Foundation of China [81703576]; Shanghai Science and
   Technology Commission Project [19ZR1448200]; Shanghai Municipal Health
   Bureau scientific research project [201940149, 201840185]; Key
   Scientific Research Project of Shanghai Municipal Commission of Health
   and Family Planning [201640021]
FX This work was supported by the Natural Science Foundation of China (No.
   81703576), Shanghai Science and Technology Commission Project (No.
   19ZR1448200), Shanghai Municipal Health Bureau scientific research
   project (No. 201940149, No.201840185), the Key Scientific Research
   Project of Shanghai Municipal Commission of Health and Family Planning
   (No.201640021).
CR Alwahhabi BK, 2017, SAUDI MED J, V38, P604, DOI 10.15537/smj.2017.6.19793
   Ansari MY, 2017, BIOMED PHARMACOTHER, V96, P198, DOI 10.1016/j.biopha.2017.09.140
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bergner R, 2015, PHARMACOL RES, V99, P16, DOI 10.1016/j.phrs.2015.04.016
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boardman HMP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002229.pub4
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V561, P13, DOI 10.1016/j.abb.2014.08.009
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kibble M, 2015, NAT PROD REP, V32, P1249, DOI 10.1039/c5np00005j
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Koh A, 2017, BONE JOINT J, V99B, P295, DOI 10.1302/0301 620X.99B3.BJJ 2016 0276.R2
   Li RW, 2003, J ETHNOPHARMACOL, V85, P61, DOI 10.1016/S0378 8741(02)00339 2
   Liu ZC, 2019, FASEB J, V33, P9828, DOI 10.1096/fj.201802242RR
   Nakano D, 2013, J NAT MED TOKYO, V67, P894, DOI 10.1007/s11418 013 0747 2
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Rissanen J, 2002, BONE, V30, p21S
   Sawant A, 2013, CANCER RES, V73, P672, DOI 10.1158/0008 5472.CAN 12 2202
   Sheu MJ, 2009, J ETHNOPHARMACOL, V126, P332, DOI 10.1016/j.jep.2009.08.019
   Shim JH, 2018, CALCIFIED TISSUE INT, V102, P533, DOI 10.1007/s00223 017 0373 1
   Simin J, 2017, EUR J CANCER, V84, P60, DOI 10.1016/j.ejca.2017.07.012
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tuck SP, 2017, RHEUMATOLOGY, V56, P2050, DOI 10.1093/rheumatology/kew430
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xu X, 2018, J CELL BIOCHEM, V119, P4680, DOI 10.1002/jcb.26646
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Yuan HD, 2017, MOLECULES, V22, DOI 10.3390/molecules22071135
   Zhang J, 2013, CHIN J NAT MEDICINES, V11, P274, DOI [10.3724/SP.J.1009.2013.00274, 10.1016/S1875 5364(13)60028 X]
NR 44
TC 4
Z9 5
U1 1
U2 16
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2020
VL 129
AR 110341
DI 10.1016/j.biopha.2020.110341
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NJ9RP
UT WOS:000566381200002
PM 32554249
OA gold
DA 2025 08 17
ER

PT J
AU Aoki, T
   Hiura, F
   Li, AA
   Yang, N
   Takakura Hino, N
   Mukai, S
   Matsuda, M
   Nishimura, F
   Jimi, E
AF Aoki, Tsukasa
   Hiura, Fumitaka
   Li, Aonan
   Yang, Nan
   Takakura Hino, Nana
   Mukai, Satoru
   Matsuda, Miho
   Nishimura, Fusanori
   Jimi, Eijiro
TI Inhibition of non canonical NF κB signaling suppresses periodontal
   inflammation and bone loss
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE nuclear factor k B; periodonititis; osteoclasts (OCs); inflammation;
   bone; NIK
ID OSTEOCLAST DIFFERENTIATION; KINASE; MICE; NF KAPPA B2; EXPRESSION;
   MUTATIONS; INDUCTION; PRECURSOR; REVEALS; PATHWAY
AB Periodontal disease is an infectious disease that affects many people worldwide. Disease progression destroys the alveolar bone and causes tooth loss. We have previously shown that alymphoplasia (aly/aly) mice harboring a loss of function mutation in the map3k14 gene, which is involved in p100 to p52 processing of the alternative NF kappa B pathway, exhibited mild osteopetrosis due to decreased number of osteoclasts, suggesting the alternative NF kappa B pathway as a potential drug target for the amelioration of bone disease. In the present study, wild type (WT) and aly/aly mice were subjected to silk ligation to establish a periodontitis model. Alveolar bone resorption was suppressed in aly/aly mice by decreased numbers of osteoclasts in the alveolar bone in comparison to WT mice. Furthermore, the expression of receptor activator of NF kappa B ligand (RANKL) and TNF alpha (cytokines involved in osteoclast induction in periligative gingival tissue) was decreased. When primary osteoblasts (POBs) and bone marrow cells (BMCs) derived from WT and aly/aly mice were prepared and co cultured, osteoclasts were induced from WT derived BMCs, regardless of the origin of the POBs, but hardly formed from aly/aly mouse derived BMCs. Furthermore, the local administration of an NIK inhibitor, Cpd33, inhibited osteoclast formation and thereby inhibited alveolar bone resorption in the periodontitis model. Therefore, the NIK mediated NF kappa B alternative pathway can be a therapeutic target for periodontal disease.
C1 [Aoki, Tsukasa; Hiura, Fumitaka; Li, Aonan; Yang, Nan; Takakura Hino, Nana; Matsuda, Miho; Jimi, Eijiro] Kyushu Univ, Fac Dent Sci, Div Oral Biol Sci, Lab Mol & Cellular Biochem, Fukuoka, Japan.
   [Aoki, Tsukasa; Nishimura, Fusanori] Kyushu Univ, Fac Dent Sci, Dept Periodontol, Div Oral Rehabil, Fukuoka, Japan.
   [Mukai, Satoru] Univ East Asia, Fac Allied Hlth Sci, Dept Hlth & Nutr Care, Shimonoseki, Japan.
   [Jimi, Eijiro] Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Jimi, E (通讯作者)，Kyushu Univ, Fac Dent Sci, Div Oral Biol Sci, Lab Mol & Cellular Biochem, Fukuoka, Japan.; Jimi, E (通讯作者)，Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Fukuoka, Japan.
EM ejimi@dent.kyushu u.ac.jp
FU Grants in Aid for Scientific Research [20H03855, 20KK0212] Funding
   Source: KAKEN
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   de Leon Boenig G, 2012, STRUCTURE, V20, P1704, DOI 10.1016/j.str.2012.07.013
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Graziani F, 2015, J CLIN PERIODONTOL, V42, P169, DOI 10.1111/jcpe.12327
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Haselager MV, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.930986
   Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Kajiya M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020930
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liu JS, 2012, J BIOL CHEM, V287, P27326, DOI 10.1074/jbc.M112.366658
   Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0
   Maruyama T, 2010, J BONE MINER RES, V25, P1058, DOI 10.1359/jbmr.091032
   MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224
   Pflug KM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228470
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Seo Y, 2012, MOL ENDOCRINOL, V26, P414, DOI 10.1210/me.2011 1241
   Soysa NS, 2011, J PERIODONTAL RES, V46, P280, DOI 10.1111/j.1600 0765.2010.01333.x
   Soysa NS, 2010, J BONE MINER RES, V25, P809, DOI 10.1359/jbmr.091030
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Takakura N, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115316
   Taniguchi R, 2014, J BIOL CHEM, V289, P7349, DOI 10.1074/jbc.M113.538314
   Tsukasaki M, 2021, J BONE MINER METAB, V39, P82, DOI 10.1007/s00774 020 01165 3
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang J, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa045
   Wang JQ, 2021, INT J BIOCHEM CELL B, V139, DOI 10.1016/j.biocel.2021.106052
   Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097 2765(01)00187 3
   Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453
NR 33
TC 11
Z9 12
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 18
PY 2023
VL 14
AR 1179007
DI 10.3389/fimmu.2023.1179007
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA E9XK7
UT WOS:000978982000001
PM 37143646
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dirckx, N
   Tower, RJ
   Mercken, EM
   Vangoitsenhoven, R
   Moreau Triby, C
   Breugelmans, T
   Nefyodova, E
   Cardoen, R
   Mathieu, C
   Van der Schueren, B
   Confavreux, CB
   Clemens, TL
   Maes, C
AF Dirckx, Naomi
   Tower, Robert J.
   Mercken, Evi M.
   Vangoitsenhoven, Roman
   Moreau Triby, Caroline
   Breugelmans, Tom
   Nefyodova, Elena
   Cardoen, Ruben
   Mathieu, Chantal
   Van der Schueren, Bart
   Confavreux, Cyrille B.
   Clemens, Thomas L.
   Maes, Christa
TI Vhl deletion in osteoblasts boosts cellular glycolysis and
   improves global glucose metabolism
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID AEROBIC GLYCOLYSIS; ENERGY METABOLISM; BONE FORMATION; HYPOXIA;
   DIFFERENTIATION; ANGIOGENESIS; HYPOGLYCEMIA; OSTEOCALCIN; CARTILAGE;
   PATHWAY
AB The skeleton has emerged as an important regulator of systemic glucose homeostasis, with osteocalcin and insulin representing prime mediators of the interplay between bone and energy metabolism. However, genetic evidence indicates that osteoblasts can influence global energy metabolism through additional, as yet unknown, mechanisms. Here, we report that constitutive or postnatally induced deletion of the hypoxia signaling pathway component von Hippel Lindau (VHL) in skeletal osteolineage cells of mice led to high bone mass as well as hypoglycemia and increased glucose tolerance, not accounted for by osteocalcin or insulin. In vitro and in vivo data indicated that Vhl deficient osteoblasts displayed massively increased glucose uptake and glycolysis associated with upregulated HIF target gene expression, resembling the Warburg effect that typifies cancer cells. Overall, the glucose consumption by the skeleton was increased in the mutant mice, as revealed by F 18 FDG radioactive tracer experiments. Moreover, the glycemia levels correlated inversely with the level of skeletal glucose uptake, and pharmacological treatment with the glycolysis inhibitor dichloroacetate (DCA), which restored glucose metabolism in Vhl deficient osteogenic cells in vitro, prevented the development of the systemic metabolic phenotype in the mutant mice. Altogether, these findings reveal a novel link between cellular glucose metabolism in osteoblasts and whole body glucose homeostasis, controlled by local hypoxia signaling in the skeleton.
C1 [Dirckx, Naomi; Tower, Robert J.; Mercken, Evi M.; Breugelmans, Tom; Nefyodova, Elena; Cardoen, Ruben; Maes, Christa] Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr SBE, Lab Skeletal Cell Biol & Physiol SCEBP, Leuven, Belgium.
   [Vangoitsenhoven, Roman; Mathieu, Chantal; Van der Schueren, Bart] Katholieke Univ Leuven, Clin & Expt Endocrinol, Leuven, Belgium.
   [Moreau Triby, Caroline] Hosp Civils Lyon, Dept Nucl Med, Lyon, France.
   [Confavreux, Cyrille B.] Univ Lyon, INSERM LYOS UMR1033, Lyon, France.
   [Confavreux, Cyrille B.] Hosp Civils Lyon, Dept Rheumatol, Lyon, France.
   [Clemens, Thomas L.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD USA.
   [Clemens, Thomas L.] Baltimore Vet Adm Med Ctr, Baltimore, MD USA.
C3 KU Leuven; KU Leuven; CHU Lyon; Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   Lyon; Johns Hopkins University
RP Maes, C (通讯作者)，Katholieke Univ Leuven, Lab Skeletal Cell Biol & Physiol SCEBP, Skeletal Biol & Engn Res Ctr SBE, Dept Dev & Regenerat, Gasthuisberg O&N 1,Herestr 49,Box 813, B 3000 Leuven, Belgium.
EM christa.maes@kuleuven.be
RI ; Confavreux, Cyrille/HTT 0045 2023; Mercken, Evi/LSJ 0353 2024;
   Vangoitsenhoven, Roman/B 3196 2018; mathieu, chantal/ABD 5505 2021
OI Vangoitsenhoven, Roman/0000 0003 3523 669X; Dirckx,
   Naomi/0000 0001 6507 8106; Maes, Christa/0000 0003 4243 5486; Van der
   Schueren, Bart/0000 0003 4754 784X; Mathieu,
   Chantal/0000 0002 4055 5233; Tower, Robert/0000 0001 5856 5758; 
FU European Research Council (ERC Starting Grant under the European Union's
   Seventh Framework Programme, FP) [282131]; Research Foundation Flanders
   (FWO) [G.094416N]; University of Leuven [OT/14/121]; NIH/National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR049410]; Hospices Civils de Lyon (Young Investigator Grant);
   Agency for Innovation by Science and Technology in Flanders (IWT);
   European Research Council (ERC) [282131] Funding Source: European
   Research Council (ERC)
FX The authors thank R. Kroes, B. Dubois, M.C. Carlier, and L. Chambard for
   assistance; A.M. Bohm and M. Mesnieres for help in optimization of
   techniques; A. Van Santvoort, T. Buelens, C. Casteels, J. Wouters, B. de
   Laat, and K. Van Laere for sharing small animal imaging infrastructure
   and help with tracer assays; and P. Agostinis, A. van Vliet, and S. Van
   Eygen for Seahorse use. We thank A. McMahon and E. Schipani for sharing
   mouse lines. T. J. Martin, H. Kronenberg, and F. Luyten are acknowledged
   for critically reading the manuscript and providing valuable input. We
   also thank F. Giammarile, P. Clezardin, N. Girard, and the members of
   the SBE for helpful discussions. This work was supported by grants from
   the European Research Council (ERC Starting Grant 282131 under the
   European Union's Seventh Framework Programme, FP/2007 2013), Research
   Foundation Flanders (FWO, G.094416N), and University of Leuven
   (OT/14/121) to C. Maes, and by the NIH/National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (subaward to C. Maes of
   R01AR049410 to TLC). CBC is supported by the Hospices Civils de Lyon
   (Young Investigator Grant 2011), EMM is an FWO fellow, and ND holds a
   doctoral fellowship of the Agency for Innovation by Science and
   Technology in Flanders (IWT).
CR Bentovim L, 2012, DEVELOPMENT, V139, P4473, DOI 10.1242/dev.083881
   BORLE AB, 1960, J BIOL CHEM, V235, P1206
   Confavreux Cyrille B, 2014, Bonekey Rep, V3, P580, DOI 10.1038/bonekey.2014.75
   Confavreux CB, 2014, EUR J ENDOCRINOL, V171, P275, DOI 10.1530/EJE 13 0567
   Dejaeger M, 2017, J BONE MINER RES, V32, P2087, DOI 10.1002/jbmr.3190
   Ducy P, 2011, DIABETOLOGIA, V54, P1291, DOI 10.1007/s00125 011 2155 z
   Elhomsy GC, 2012, J CLIN ENDOCR METAB, V97, P4311, DOI 10.1210/jc.2012 2327
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   FELIX R, 1978, AM J PHYSIOL, V234, pC51, DOI 10.1152/ajpcell.1978.234.1.C51
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hsu T, 2012, ONCOGENE, V31, P2247, DOI 10.1038/onc.2011.442
   Karner CM, 2016, J BIOL CHEM, V291, P13028, DOI 10.1074/jbc.M115.708578
   Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763
   Kindblom JM, 2009, J BONE MINER RES, V24, P785, DOI 10.1359/JBMR.081234
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li Z, 2016, ENDOCRINOLOGY, V157, P4094, DOI 10.1210/en.2016 1583
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   MARKS LJ, 1974, ANN NY ACAD SCI, V230, P147, DOI 10.1111/j.1749 6632.1974.tb14443.x
   Pfander D, 2004, DEVELOPMENT, V131, P2497, DOI 10.1242/dev.01138
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   WANEBO HJ, 1966, CANCER AM CANCER SOC, V19, P1451, DOI 10.1002/1097 0142(196610)19:10<1451::AID CNCR2820191018>3.0.CO;2 0
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu C, 2015, GENE DEV, V29, P817, DOI 10.1101/gad.255000.114
   Wu C, 2014, CURR OSTEOPOROS REP, V12, P428, DOI 10.1007/s11914 014 0236 x
   Yao QQ, 2017, BONE, V97, P175, DOI 10.1016/j.bone.2017.01.028
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
   Zoch ML, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.4
NR 44
TC 79
Z9 86
U1 0
U2 20
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR 1
PY 2018
VL 128
IS 3
BP 1087
EP 1105
DI 10.1172/JCI97794
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GF4AM
UT WOS:000431900100021
PM 29431735
OA Bronze, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Katoh, M
   Katoh, M
AF Katoh, Masuko
   Katoh, Masaru
TI WNT signaling pathway and stem cell signaling network
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MAMMARY EPITHELIAL CELLS; BETA CATENIN; COLORECTAL CANCER; GENE FAMILY;
   MEMBER; RECEPTOR; NOTCH; IDENTIFICATION; MUTATIONS; POLARITY
AB WNT signals are transduced to the canonical pathway for cell fate determination, and to the noncanonical pathway for control of cell movement and tissue polarity. Canonical WNTsignals are transduced through Frizzled family receptors and LRP5/LRP6 coreceptor to the beta catenin signaling cascade. Microtubule affinity regulating kinase (PAR 1) family kinases, casein kinase le (CKl epsilon), and FRAT are positive regulators of the canonical WNT pathway, whereas APC, AXIN1, AXIN2, CKl alpha, NKD1, NKD2, beta TRCP1, beta TRCP2, ANKRD6, Nemo like kinase (NLK), and peroxisome proliferator activated receptor gamma (PPAR gamma) are negative regulators. Nuclear complex, consisting of T cell factor/lymphoid enhancer factor, p catenin, BCL9/BCL9L, and PYGO, activates transcription of canonical WNT target genes such as FGF20, DKK1, WISP1 MYC, CCND1, and Glucagon (GCG). Noncanonical WNTsignals are transduced through Frizzled family receptors and ROR2/RYK coreceptors to the Dishevelled dependent (Rho family GTPases and c jun NH(2) terminal kinase) or the Ca(2+) dependent (NLK and nuclear factor of activated Tcells) signaling cascades. WNTsignals are context dependently transduced to both pathways based on the expression profile of WNT SFRP, WIF, DKK, Frizzled receptors, coreceptors, and the activity of intracellular WNT signaling regulators. Epigenetic silencing and loss of function mutation of negative regulators of the canonical WNT pathway occur in a variety of human cancer. WNT, fibroblast growth factor (FGF), Notch, Hedgehog, and transforming growth factor beta/bone morphogenetic protein signaling network are implicated in the maintenance of tissue homeostasis by regulating self renewal of normal stem cells as well as proliferation or differentiation of progenitor (transit amplifying) cells. Breakage of the stem cell signaling network leads to carcinogenesis. Nonsteroidal anti inflammatory drugs and PPAR gamma agonists with the potential to inhibit the canonical WNT signaling pathway are candidate agents for chemoprevention. ZTM000990 and PKF118 310 are lead compounds targeted to the canonical WNT signaling cascade. Anti WNT1 and anti WNT2 monoclonal antibodies show in vitro effects in cancer treatment. After the optimization, derivatives of small molecule compound and human monoclonal antibody targeted to the WNT signaling pathway could be used in cancer medicine.
C1 Natl Canc Ctr, Genet & Cell Biol Sect, Tokyo 1040045, Japan.
   M&M Med Bioinformat, Hongo, Japan.
C3 National Cancer Center   Japan
RP Katoh, M (通讯作者)，Natl Canc Ctr, Genet & Cell Biol Sect, 5 1 1 Tsukiji, Tokyo 1040045, Japan.
EM mkatoh kkr@umin.ac.jp; mkatoh kkr@umin.ac.jp
OI Katoh, Masaru/0000 0003 3274 4066
CR Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0
   Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092 8674(00)81226 X
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354 05
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007
   Katoh M, 2006, TECHNOL CANCER RES T, V5, P169, DOI 10.1177/153303460600500208
   Katoh M, 2006, INT J MOL MED, V17, P681
   Katoh M, 2005, ONCOL REP, V14, P1583
   Katoh M, 2003, INT J MOL MED, V12, P643
   Katoh M, 2002, INT J ONCOL, V21, P1269
   Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092 8674(02)00679 7
   LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268
   Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441 06
   Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019
   Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677
   McDonald SAC, 2006, NAT CLIN PRACT GASTR, V3, P267, DOI 10.1038/ncpgasthep0473
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306
   Radtke F, 2006, CURR MOL MED, V6, P275, DOI 10.2174/156652406776894527
   ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594 2599.1992
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Swain Rajeeb Kumar, 2005, Cell Commun Signal, V3, P12, DOI 10.1186/1478 811X 3 12
   Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534 5807(03)00063 7
   van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304
   Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097 2765(03)00427 1
NR 40
TC 645
Z9 772
U1 0
U2 127
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2007
VL 13
IS 14
BP 4042
EP 4045
DI 10.1158/1078 0432.CCR 06 2316
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 191DO
UT WOS:000248110500003
PM 17634527
DA 2025 08 17
ER

PT J
AU Kaiser, MF
   Heider, U
   Mieth, M
   Zang, CB
   von Metzler, I
   Sezer, O
AF Kaiser, Martin F.
   Heider, Ulrike
   Mieth, Maren
   Zang, Chuanbing
   von Metzler, Ivana
   Sezer, Orhan
TI The proteasome inhibitor bortezomib stimulates osteoblastic
   differentiation of human osteoblast precursors via upregulation of
   vitamin D receptor signalling
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE proteasome; bortezomib; mesenchymal stem cell; osteoblast; multiple
   myeloma; vitamin D receptor
ID MYELOMA BONE DISEASE; MULTIPLE MYELOMA; D DEFICIENCY; IN VIVO; MEDIATED
   DEGRADATION; BIOCHEMICAL MARKERS; ACTIVATION; THERAPY; VITRO;
   BISPHOSPHONATES
AB Interactions of myeloma cells with the bone marrow microenvironment lead to enhanced osteoclast recruitment and impaired osteoblast activity. Recent evidence revealed that the proteasome inhibitor bortezomib stimulates osteoblast differentiation, but the mechanisms are not fully elucidated. We hypothesised that bortezomib could influence osteoblastic differentiation via alteration of vitamin D signalling by blocking the proteasomal degradation of the vitamin D receptor (VDR). This is of clinical importance, as a high rate of vitamin D deficiency was reported in patients with myeloma. We performed cocultures of primary human mesenchymal stem cells (hMSCs) and human osteoblasts (hOBs) with myeloma cells, which resulted in an inhibition of the vitamin D dependent differentiation of osteoblast precursors. Treatment with bortezomib led to a moderate increase in osteoblastic differentiation markers in hMSCs and hOBs. Importantly, this effect could be strikingly increased when vitamin D was added. Bortezomib led to enhanced nuclear VDR protein levels in hMSCs. Primary hMSCs transfected with a VDR luciferase reporter construct showed a strong increase in VDR signalling with bortezomib. In summary, stimulation of VDR signalling is a mechanism for the bortezomib induced stimulation of osteoblastic differentiation. The data suggest that supplementation of vitamin D in patients with myeloma treated with bortezomib is crucial for optimal bone formation.
C1 [Kaiser, Martin F.; Heider, Ulrike; Mieth, Maren; Zang, Chuanbing; von Metzler, Ivana; Sezer, Orhan] Charite, Dept Haematol & Oncol, D 13353 Berlin, Germany.
   [Sezer, Orhan] Univ Med Ctr Hamburg, Dept Oncol Haematol & Bone Marrow Transplantat, D 20246 Hamburg, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Hamburg; University Medical
   Center Hamburg Eppendorf
RP Sezer, O (通讯作者)，Univ Med Ctr Hamburg, Dept Oncol Haematol & Bone Marrow Transplantat, D 20246 Hamburg, Germany.
EM o.sezer@uke.de
RI ; Kaiser, Martin/LTD 2019 2024
OI Kaiser, Martin/0000 0002 3677 4804; 
CR Badros A, 2008, BRIT J HAEMATOL, V142, P492, DOI 10.1111/j.1365 2141.2008.07214.x
   Boissy P, 2008, LEUKEMIA RES, V32, P1661, DOI 10.1016/j.leukres.2008.02.019
   CARLSON K, 1992, J INTERN MED, V231, P133, DOI 10.1111/j.1365 2796.1992.tb00514.x
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   Diamond T, 2010, AM J HEMATOL, V85, P302, DOI 10.1002/ajh.21619
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Goltzman D, 2010, ANN NY ACAD SCI, V1192, P145, DOI 10.1111/j.1749 6632.2009.05226.x
   Hecht M, 2007, BRIT J HAEMATOL, V138, P446, DOI 10.1111/j.1365 2141.2007.06665.x
   Heider U, 2005, BIOCHEM BIOPH RES CO, V338, P687, DOI 10.1016/j.bbrc.2005.09.146
   Heider U, 2006, EUR J CANCER, V42, P1544, DOI 10.1016/j.ejca.2005.11.034
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Laroche M, 2010, EUR J HAEMATOL, V85, P65, DOI 10.1111/j.1600 0609.2010.01436.x
   Lentzsch S, 2007, HEMATOL ONCOL CLIN N, V21, P1035, DOI 10.1016/j.hoc.2007.08.009
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097 4644(19981201)71:3<429::AID JCB11>3.3.CO;2 G
   Modi ND, 2012, LEUKEMIA, V26, P589, DOI 10.1038/leu.2011.282
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Ng AC, 2009, AM J HEMATOL, V84, P397, DOI 10.1002/ajh.21412
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Peleg S, 2010, J CELL BIOCHEM, V110, P926, DOI 10.1002/jcb.22606
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Piek E, 2010, BONE, V46, P613, DOI 10.1016/j.bone.2009.10.024
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978 1 60327 169 1_2
   Priemel M, 2010, J BONE MINER RES, V25, P305, DOI 10.1359/jbmr.090728
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030
   Rajkumar SV, 2002, SEMIN ONCOL, V29, P5, DOI 10.1053/sonc.2002.34070
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Sezer O, 2009, ONCOLOGIST, V14, P276, DOI 10.1634/theoncologist.2009 0003
   St Arnaud R, 2008, ARCH BIOCHEM BIOPHYS, V473, P225, DOI 10.1016/j.abb.2008.03.038
   Terpos E, 2010, LEUKEMIA, V24, P1700, DOI 10.1038/leu.2010.173
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   van Driel M, 2006, J CELL BIOCHEM, V99, P922, DOI 10.1002/jcb.20875
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
NR 42
TC 28
Z9 32
U1 0
U2 10
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0902 4441
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD APR
PY 2013
VL 90
IS 4
BP 263
EP 272
DI 10.1111/ejh.12069
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 108HP
UT WOS:000316283600001
PM 23311753
DA 2025 08 17
ER

PT J
AU Turgeman, I
   Flechter, E
   Vlodavsky, E
   Militianu, D
   Keidar, Z
   Haddad, E
   Bar Sela, G
AF Turgeman, Ilit
   Flechter, Ezequiel
   Vlodavsky, Eugene
   Militianu, Daniela
   Keidar, Zohar
   Haddad, Elias
   Bar Sela, Gil
TI Fortuitous administration of denosumab in breast carcinoma with
   osteoclastic giant cells
SO ANTI CANCER DRUGS
LA English
DT Article
DE bone metastasis; bone microenvironment; breast cancer; cribriform
   formation; denosumab; histology; infiltrating ductal carcinoma;
   osteoclastic giant cells; receptor activator of nuclear factor kappa B
   ligand
AB Breast carcinoma with osteoclastic giant cells (OGCs) is a rare entity characterized by an admixture of giant cells and malignant epithelial cells within an inflammatory and vascular stroma. Denosumab is a monoclonal antibody that targets the pathway for osteoclast formation and activation, indicated for the prevention of skeletal related events in patients with bone metastases, as well as for the treatment of giant cell tumor of bone. We report a patient who presented with aggressive bone recurrence of breast cancer 12 years after her original diagnosis, showing a transformed histology that included multinucleated OGCs, and that was refractory to traditional therapy. Misdiagnosed with a tumor to tumor metastasis of breast cancer to a giant cell tumor of bone, she was treated with denosumab for her presumed primary bone disease and had a remarkable clinical and radiological response. To the best of our knowledge, this is the first report of breast cancer with OGCs occurring initially in a metastasis while absent in the original tumor and the first description of its successful treatment with denosumab. This case sheds light on the development of giant cells in the tumor microenvironment and suggests the potential use of denosumab in the management of cancers with giant cell elements.
C1 [Turgeman, Ilit; Flechter, Ezequiel; Vlodavsky, Eugene; Militianu, Daniela; Keidar, Zohar; Haddad, Elias; Bar Sela, Gil] Rambam Hlth Care Campus, Haifa, Israel.
   [Turgeman, Ilit; Flechter, Ezequiel; Bar Sela, Gil] Technion Israel Inst Technol, Dept Oncol, Haifa, Israel.
   [Vlodavsky, Eugene] Technion Israel Inst Technol, Dept Pathol, Haifa, Israel.
   [Militianu, Daniela] Technion Israel Inst Technol, Dept Med Imaging, Haifa, Israel.
   [Keidar, Zohar] Technion Israel Inst Technol, Dept Nucl Imaging, Haifa, Israel.
   [Haddad, Elias] Technion Israel Inst Technol, Dept Orthoped Surg, Haifa, Israel.
   [Vlodavsky, Eugene; Militianu, Daniela; Keidar, Zohar; Bar Sela, Gil] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
C3 Rambam Health Care Campus; Technion Israel Institute of Technology;
   Technion Israel Institute of Technology; Technion Israel Institute of
   Technology; Technion Israel Institute of Technology; Technion Israel
   Institute of Technology; Technion Israel Institute of Technology;
   Rappaport Faculty of Medicine
RP Bar Sela, G (通讯作者)，Rambam Hlth Care Campus, Dept Oncol, POB 9602, IL 31096 Haifa, Israel.
EM g_barsela@rambam.health.gov.il
RI Turgeman, Ilit/AAQ 7597 2021; BarSela, Gil/NAZ 8093 2025; Keidar,
   Zohar/AAV 4955 2021
OI Turgeman, Ilit/0000 0003 4123 1107; Bar Sela, Gil/0000 0001 6579 1841; 
CR [Anonymous], WHO CLASSIFICATION T
   Bayer CM, 2017, CURR OPIN OBSTET GYN, V29, P4, DOI 10.1097/GCO.0000000000000333
   BISKUP E, 2017, SWISS MED WEEKLY, V100
   Cai N, 2005, DIAGN CYTOPATHOL, V33, P246, DOI 10.1002/dc.20341
   Mochizuki T, 2008, AM J SURG PATHOL, V32, P1727, DOI 10.1097/PAS.0b013e3181804302
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Niu Y, 2014, INT J CLIN EXP PATHO, V7, P1788
   Shishido Hara Y, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746 1596 5 55
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
NR 9
TC 6
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959 4973
EI 1473 5741
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD JUN
PY 2018
VL 29
IS 5
BP 466
EP 470
DI 10.1097/CAD.0000000000000612
PG 5
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA GD4LP
UT WOS:000430475000010
PM 29481473
DA 2025 08 17
ER

PT J
AU Abdullah, KM
   Sharma, G
   Qais, FA
   Khan, I
   Takkar, S
   Kaushal, JB
   Kanchan, RK
   Sarwar, T
   Chakravarti, B
   Siddiqui, JA
AF Abdullah, K. M.
   Sharma, Gunjan
   Qais, Faizan Abul
   Khan, Imran
   Takkar, Simran
   Kaushal, Jyoti B.
   Kanchan, Ranjana K.
   Sarwar, Tarique
   Chakravarti, Bandana
   Siddiqui, Jawed A.
TI Hydroxychloroquine interaction with phosphoinositide 3 kinase modulates
   prostate cancer growth in bone microenvironment: In vitro and molecular
   dynamics based approach
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Prostate cancer; Bone metastasis; PI3K/AKT; Hydroxychloroquine; Bone
   microenvironment
ID CELL PROLIFERATION; SIGNALING PATHWAY; MIGRATION; CHLOROQUINE;
   THERAPIES; APOPTOSIS; INVASION; GROMACS; DRUG
AB Patients with advanced prostate cancer (PCa) are more likely to develop bone metastases. Tumor cells thrive in the bone microenvironment, interacting with osteoblasts and osteoclasts. Given the PI3K/AKT pathway 's metastatic potential and signal integration 's ability to modulate cell fates in PCa development, drugs targeting this system have great therapeutic promise. Hydroxychloroquine (HCQ) is an anti  malarial medication commonly used to treat clinical conditions such as rheumatology and infectious disorders. We explored the anti neoplastic effect of HCQ on PC3 and C4  2B cell lines in the bone microenvironment. Interestingly, HCQ treatment substantially decreases the viability, proliferation, and migration potential of PCa cells in the bone microenvironment. HCQ induces apoptosis and cell cycle arrest, even in the presence of osteoblast secreted factors. Mechanistically, HCQ inhibited the activity of the PI3K/AKT signaling pathway, which ultimately regulates the proliferation and migration of PCa cells in the bone. The binding energy for docking HCQ with PI3K was  6.7 kcal/mol, and the complex was stabilized by hydrogen bonds, hydrophobic forces, and van der Waals forces. Molecular simulations further validated the structural integrity of the HCQ PI3K complex without altering PI3K 's secondary structure. Our findings underscore the efficacy of HCQ as a potential therapeutic agent in treating PCa.
C1 [Abdullah, K. M.; Sharma, Gunjan; Khan, Imran; Takkar, Simran; Kaushal, Jyoti B.; Kanchan, Ranjana K.; Siddiqui, Jawed A.] Univ Nebraska, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
   [Qais, Faizan Abul] Aligarh Muslim Univ, Fac Agr Sci, Dept Agr Microbiol, Aligarh 202002, Uttar Pradesh, India.
   [Sarwar, Tarique] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia.
   [Chakravarti, Bandana] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow 226014, India.
   [Siddiqui, Jawed A.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.
   [Siddiqui, Jawed A.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
C3 University of Nebraska System; Aligarh Muslim University; Qassim
   University; Sanjay Gandhi Postgraduate Institute of Medical Sciences;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Siddiqui, JA (通讯作者)，Univ Nebraska, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Siddiqui, JA (通讯作者)，Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
EM Jawed.siddiqui@unmc.edu
RI sarwar, tarique/JNS 2101 2023; Abdullah, K M/ABA 2886 2021; Kanchan,
   Ranjana/AAD 6218 2022; Abul Qais, Faizan/AAE 6422 2019; Kaushal,
   Jyoti/AAR 4934 2021; Abul, Faizan/AAE 6422 2019; Siddiqui,
   Jawed/G 9258 2017
OI Bala Kaushal, Jyoti/0000 0003 3185 4175; Abul Qais,
   Faizan/0000 0002 9457 6515; Siddiqui, Jawed/0000 0003 1287 3004
FU American Cancer Society [IRG 22 146 07 IRG]; Buffett Cancer Center;
   National Cancer Institute [CA036727]; U.S. Department of Defense (DOD)
   through the Prostate Cancer Research Program [W81XWH 21 1 0640]
FX The authors acknowledge the University of Nebraska Medical Center FACS
   facility for their resources and service. This work and the authors are
   partly supported by grants from American Cancer Society under award
   number IRG 22 146 07 IRG, and by the Buffett Cancer Center, which is
   supported by the National Cancer Institute under award num ber CA036727
   and from the U.S. Department of Defense (DOD) through the Prostate
   Cancer Research Program under Award No. W81XWH 21 1 0640 (JAS) . The
   authors thank Kavita Mallya and Bertina Williams for their technical
   help.
CR Abdullah KM, 2024, SCI REP UK, V14, DOI 10.1038/s41598 024 54479 x
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Bavelloni A, 2019, J CELL PHYSIOL, V234, P10907, DOI 10.1002/jcp.27911
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010 4655(95)00042 E
   Bhatia R, 2022, GASTROENTEROLOGY, V163, P1064, DOI 10.1053/j.gastro.2022.06.071
   Brandao M, 2019, ANN ONCOL, V30, P27, DOI 10.1093/annonc/mdz280
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chaudhary S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.12
   Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200
   Choudhury GG, 1997, AM J PHYSIOL RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931
   Cocco S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134579
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034
   da Silva AWS, 2012, BMC RES NOTES, V5, DOI 10.1186/1756 0500 5 367
   DiNatale A, 2019, ADV EXP MED BIOL, V1210, P171, DOI 10.1007/978 3 030 32656 2_9
   Dolecek TA, 2012, NEURO ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Duarte Andressa, 2019, Asian Pac J Cancer Prev, V20, P3377, DOI 10.31557/APJCP.2019.20.11.3377
   Hanker AB, 2019, CANCER DISCOV, V9, P482, DOI 10.1158/2159 8290.CD 18 1175
   He Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00828 5
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hu DX, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01180
   Hu ML, 2019, ONCOL REP, V41, P1439, DOI 10.3892/or.2019.6962
   Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9
   Jiang NN, 2020, MOL BIOL REP, V47, P4587, DOI 10.1007/s11033 020 05435 1
   Jin C, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.972397
   Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347
   Khan P, 2023, MOL CANCER, V22, DOI 10.1186/s12943 022 01695 6
   Khan P, 2019, J NAT PROD, V82, P2252, DOI 10.1021/acs.jnatprod.9b00372
   Kim J, 2019, NATURE, V576, P315, DOI 10.1038/s41586 019 1795 x
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Maes H, 2016, MOL CELL ONCOL, V3, DOI 10.4161/23723548.2014.970097
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Mimeault M, 2015, ONCOTARGET, V6, P3887, DOI 10.18632/oncotarget.2932
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mughees M, 2022, SEMIN CANCER BIOL, V86, P497, DOI 10.1016/j.semcancer.2022.02.017
   Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898 6568(01)00271 6
   Parker C, 2020, ANN ONCOL, V31, P1119, DOI 10.1016/j.annonc.2020.06.011
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pellegatta F, 1998, J BIOL CHEM, V273, P27768, DOI 10.1074/jbc.273.43.27768
   Peng X, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02218 9
   Peng X, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02176 2
   Peng Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.819128
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261 018 0656 y
   Pothuraju R, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01156 y
   Qais FA, 2024, J BIOMOL STRUCT DYN, V42, P5827, DOI 10.1080/07391102.2023.2229454
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787 015 0239 y
   Rajpar S, 2013, CANCER J, V19, P66, DOI 10.1097/PPO.0b013e31827f123e
   Rascio F, 2021, CANCERS, V13, DOI 10.3390/cancers13163949
   Rath B, 2021, BIOORG MED CHEM LETT, V41, DOI 10.1016/j.bmcl.2021.128029
   Rebecca VW, 2019, CANCER DISCOV, V9, P220, DOI 10.1158/2159 8290.CD 18 0706
   Saad F, 2012, UROL ONCOL SEMIN ORI, V30, P369, DOI 10.1016/j.urolonc.2010.08.007
   Sarkar FH, 2010, ENDOCR RELAT CANCER, V17, pR195, DOI 10.1677/ERC 10 0074
   Senapati S, 2010, ONCOGENE, V29, P1293, DOI 10.1038/onc.2009.420
   Sharma G, 2024, SEMIN CELL DEV BIOL, V154, P275, DOI 10.1016/j.semcdb.2022.11.002
   Sharma G, 2022, SEMIN CANCER BIOL, V86, P457, DOI 10.1016/j.semcancer.2022.02.003
   Sharma G, 2017, BIOMED PHARMACOTHER, V88, P218, DOI 10.1016/j.biopha.2017.01.044
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Siddiqui JA, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00178 6
   Siddiqui S, 2021, SPECTROCHIM ACTA A, V249, DOI 10.1016/j.saa.2020.119296
   Suhail M, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1236173
   Tariq Kamran, 2021, Explor Neuroprotective Ther, V1, P86, DOI 10.37349/ent.2021.00008
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Toren P, 2015, EUR UROL, V67, P986, DOI 10.1016/j.eururo.2014.08.006
   Tortorella E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032046
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535 6108(03)00215 0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weber GL, 2011, ONCOTARGET, V2, P833
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0954 x
   Zhang WQ, 2024, J ETHNOPHARMACOL, V319, DOI 10.1016/j.jep.2023.117327
   Zhou YF, 2017, CELL PHYSIOL BIOCHEM, V42, P1431, DOI 10.1159/000479207
NR 77
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAY
PY 2024
VL 266
AR 130912
DI 10.1016/j.ijbiomac.2024.130912
EA APR 2024
PN 1
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA QB7V6
UT WOS:001218494400002
PM 38513896
DA 2025 08 17
ER

PT J
AU Ha, H
   Shim, KS
   An, H
   Kim, T
   Ma, JY
AF Ha, Hyunil
   Shim, Ki Shuk
   An, Hyosun
   Kim, Taesoo
   Ma, Jin Yeul
TI Water extract of Spatholobus suberectus inhibits osteoclast
   differentiation and bone resorption
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Osteoporosis; Spatholobus suberectus; RANKL; Osteoclasts; Bone
   resorption
ID NF KAPPA B; C FOS; KEY REGULATOR; IKK BETA; RANKL; ACTIVATION;
   INDUCTION; NFATC1; KINASE; PHOSPHORYLATION
AB Background: Osteoclasts are primarily responsible for bone resorption. In many pathological bone diseases including osteoporosis and rheumatoid arthritis, osteoclasts are excessively activated. Thus, controlling of osteoclasts would be an effective therapeutic strategy for the treatment of excessive bone loss. The stem of Spatholobus suberectus has been widely used in traditional medicine to treat blood stasis syndrome and arthritis in Asia. In the present study, we investigated the effects and action mechanism of water extract of the stem of Spatholobus suberectus (WESS) on osteoclast differentiation and function.
   Methods: The effect of WESS on osteoclast differentiation was evaluated by counting tartrate resistant acid phosphatase positive multinucleated cells in bone marrow derived macrophages system and murine bone marrow cell osteoblast coculture system. Bone resorption activity of mature osteoclast was examined on a calcium phosphate coated plate. Actin ring structure of osteoclasts was detected fluorescently by staining for F actin. Activation of signaling pathways and induction of transcription factors required for osteoclastogenesis were investigated by real time PCR and Western blotting.
   Results: WESS effectively inhibited osteoclast differentiation from its precursors. The inhibitory effect of WESS on osteoclast differentiation was due to the suppression of osteoclastogenic transcription factors, c Fos and nuclear factor of activated T cells cytoplasmic 1 expression, via preventing receptor activator of nuclear factor kappa B ligand induced early signaling pathways and decreasing c Fos protein level in osteoclast precursors. Furthermore, WESS suppressed bone resorption activity of osteoclasts by disrupting actin ring structure.
   Conclusions: This study demonstrated that WESS inhibits osteoclast differentiation and function. These results suggest that WESS has a potential for treating pathological bone diseases caused by excessive bone resorption.
C1 [Ha, Hyunil; Shim, Ki Shuk; An, Hyosun; Kim, Taesoo; Ma, Jin Yeul] Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Kim, T (通讯作者)，Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM xotn91@kiom.re.kr; jyma@kiom.re.kr
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea [C12030, K13050]
FX This work was supported by grants (C12030 and K13050) from the Korea
   Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea.
CR Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200
   Chen Dong hui, 2004, Zhongguo Zhong Yao Za Zhi, V29, P352
   Choi JS, 2003, KOR J HERBOLOGY, V18, P79
   Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200
   Fraga CG, 2007, IUBMB LIFE, V59, P308, DOI 10.1080/15216540701230529
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee BJ, 2011, J ETHNOPHARMACOL, V134, P460, DOI 10.1016/j.jep.2010.12.039
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee JH, 2009, J BIOL CHEM, V284, P13725, DOI 10.1074/jbc.M806941200
   Lee MH, 2006, PHYTOCHEMISTRY, V67, P1262, DOI 10.1016/j.phytochem.2006.05.008
   Liao H, 2008, EVID BASED COMPL ALT, V5, P429, DOI 10.1093/ecam/nem054
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Ravipati AS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 173
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Shim SH, 2011, PHYTOTHER RES, V25, P615, DOI 10.1002/ptr.3342
   Soe H. G., 2003, KOREAN J ORIENTAL PH, V17, P780
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wu J., 2005, ILLUSTRATED CHINESE
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Zou ZP, 2012, J CELL SCI, V125, P4800, DOI 10.1242/jcs.106542
NR 37
TC 24
Z9 25
U1 2
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 21
PY 2013
VL 13
AR 112
DI 10.1186/1472 6882 13 112
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 152GV
UT WOS:000319520700001
PM 23692684
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mendjargal, A
   Narmandakh, S
   Zinamyadar, M
   Amartuvshin, E
   Bold, J
   Garmaa, N
   Sundui, E
   Dorjkhuu, A
   Amgalanbaatar, A
   Odkhuu, E
AF Mendjargal, Adilsaikhan
   Narmandakh, Shijir
   Zinamyadar, Munkhjargal
   Amartuvshin, Egshiglen
   Bold, Juramt
   Garmaa, Nandin
   Sundui, Enebish
   Dorjkhuu, Amgalanbaatar
   Amgalanbaatar, Avirmed
   Odkhuu, Erdenezaya
TI The inhibitory effect of salidroside on RANKL induced osteoclast
   formation via NFκB suppression
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Salidroside; Rhodiola rosea; Osteoclast; NFATc1
ID NUCLEAR FACTOR; RECEPTOR ACTIVATOR; DOWN REGULATION; MACROPHAGES;
   MEDICINE; LIGAND; CELLS
AB Bone fractures are a prevalent clinical issue, and recent studies highlighted the promising potential of natural bone healing agents in enhancing fracture repair and regeneration. The regulatory interaction mechanism between osteoblasts and osteoclasts is crucial for bone cell biology and bone disease. In Mongolian medicine, people have used the Rhodiola rosea (R. rosea) extract to accelerate bone healing in bone fractures. Salidroside is a bioactive compound of R. rosea. Salidroside is known to regulate bone metabolism and inhibit the activation of osteoclast cells, but how it affects the differentiation of osteoclasts is unknown. We examined the effect of R. rosea extract and its bioactive compound salidroside on the RANKL induced osteoclast formation in RAW 264.7 cells. The present study observed that salidroside directly inhibits RANKL induced TRAP positive osteoclast formation. Immunoblotting analysis revealed that salidroside inhibited the expression of c Fos and NFATc1, osteoclastogenic key transcription factors, by suppressing late activation of p65 NF kappa B. Further, the ethanol extracts of R. rosea significantly reduced the RANKL induced osteoclasts in a dose dependent manner. In conclusion, salidroside inhibits RANKL induced osteoclast formation via suppressing the NF kappa B/c Fos/NFATc1 signalling pathway. R. rosea, a primary source of salidroside, is helpful for bone healing via its inhibitory effect on osteoclast formation.
C1 [Mendjargal, Adilsaikhan] Mongolian Natl Univ Med Sci, Mongolia Japan Hosp, Bot Garden, Ulaanbaatar 13270, Mongolia.
   [Mendjargal, Adilsaikhan; Narmandakh, Shijir; Zinamyadar, Munkhjargal; Amartuvshin, Egshiglen; Bold, Juramt; Garmaa, Nandin; Sundui, Enebish; Dorjkhuu, Amgalanbaatar; Amgalanbaatar, Avirmed; Odkhuu, Erdenezaya] Mongolian Soc Human Anat, Ulaanbaatar, Mongolia.
   [Narmandakh, Shijir; Bold, Juramt; Garmaa, Nandin; Dorjkhuu, Amgalanbaatar; Amgalanbaatar, Avirmed; Odkhuu, Erdenezaya] Mongolian Natl Univ Med Sci, Sch Biomed, Dept Anat, Post 48 111,S Zorig St, Ulaanbaatar 14210, Mongolia.
   [Narmandakh, Shijir] Mongolian Natl Univ Med Sci, Grad Sch, Ulaanbaatar, Mongolia.
   [Zinamyadar, Munkhjargal; Sundui, Enebish] Ach Med Univ, Ach Int Hosp, Dept Morphol, Ulaanbaatar, Mongolia.
   [Amartuvshin, Egshiglen] Mongolian Natl Univ Med Sci, Sch Biomed, Ulaanbaatar, Mongolia.
   [Odkhuu, Erdenezaya] Mongolian Natl Univ Med Sci, Inst Biomed Sci, S Zorig St,Post 48 111, Ulaanbaatar 14210, Mongolia.
C3 Mongolian National University of Medical Sciences; Mongolian National
   University of Medical Sciences; Mongolian National University of Medical
   Sciences; Mongolian National University of Medical Sciences; Mongolian
   National University of Medical Sciences
RP Odkhuu, E (通讯作者)，Mongolian Soc Human Anat, Ulaanbaatar, Mongolia.; Odkhuu, E (通讯作者)，Mongolian Natl Univ Med Sci, Sch Biomed, Dept Anat, Post 48 111,S Zorig St, Ulaanbaatar 14210, Mongolia.; Odkhuu, E (通讯作者)，Mongolian Natl Univ Med Sci, Inst Biomed Sci, S Zorig St,Post 48 111, Ulaanbaatar 14210, Mongolia.
EM erdenezaya@mnums.edu.mn
OI amgalanbaatar, avirmed/0000 0001 8282 4932
FU Sciences and Technology Supportive Fund, Mongolia National University of
   Medical Sciences [2020/1 16]
FX This work was supported by the Sciences and Technology Supportive Fund,
   Mongolia National University of Medical Sciences, under Grant #2020/1 16
CR Alperth F, 2019, SCI PHARM, V87, DOI 10.3390/scipharm87020008
   Bai L, 2022, CHIN HERB MED, V14, P343, DOI 10.1016/j.chmed.2022.06.001
   Baldandorj D PA, 1990, ISPOLZOVANIYE MAGNIT
   Batoon L, 2017, CURR OSTEOPOROS REP, V15, P385, DOI 10.1007/s11914 017 0384 x
   Bold S., 2011, History of Traditional Mongolian Medicine, P7
   Bozec A, 2017, PFLUG ARCH EUR J PHY, V469, P517, DOI 10.1007/s00424 017 1952 8
   Chen DH, 2019, EBIOMEDICINE, V50, P395, DOI 10.1016/j.ebiom.2019.10.054
   Chen QF, 2013, PHYTOTHER RES, V27, P973, DOI 10.1002/ptr.4820
   Chen XF, 2018, EUR J PHARMACOL, V819, P281, DOI 10.1016/j.ejphar.2017.12.025
   Drake MT, 2019, BRIT J CLIN PHARMACO, V85, P1049, DOI 10.1111/bcp.13857
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fu SQ, 2022, TISSUE CELL, V79, DOI 10.1016/j.tice.2022.101917
   Guan S, 2012, IMMUNOPHARM IMMUNOT, V34, P667, DOI 10.3109/08923973.2011.650175
   Guan S, 2011, INT IMMUNOPHARMACOL, V11, P2194, DOI 10.1016/j.intimp.2011.09.018
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Koide N, 2014, IMMUNOL LETT, V161, P31, DOI 10.1016/j.imlet.2014.04.006
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Liu X, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1081 0
   Liu YJ, 2022, PHYTOCHEM REV, V21, P1605, DOI 10.1007/s11101 021 09800 1
   Loukas AT, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25095047
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mendjargal A, 2013, INT IMMUNOPHARMACOL, V15, P671, DOI 10.1016/j.intimp.2013.02.014
   Natesan V, 2022, BIOMOL THER, V30, P309, DOI 10.4062/biomolther.2022.007
   Odkhuu E., 2020, CAJMS, V6, P114, DOI [10.24079/cajms.2020.09.002, DOI 10.24079/CAJMS.2020.09.002]
   Odkhuu E, 2015, INNATE IMMUN LONDON, V21, P194, DOI 10.1177/1753425914524242
   Odkhuu E, 2012, IMMUNOL LETT, V142, P34, DOI 10.1016/j.imlet.2011.12.001
   Oh JH, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8851884
   Sum SW, 2019, J TRADIT CHIN MED, V39, P853
   Tao HX, 2019, MED RES REV, V39, P1779, DOI 10.1002/med.21564
   Wang HW, 2013, J HUAZHONG U SCI MED, V33, P463, DOI 10.1007/s11596 013 1143 6
   Wang XL, 2023, J CARDIOVASC PHARM, V81, P85, DOI 10.1097/FJC.0000000000001362
   Wang YF, 2022, PHYTOMEDICINE, V99, DOI 10.1016/j.phymed.2022.154020
   Xie BC, 2023, PHYTOTHER RES, V37, P1938, DOI 10.1002/ptr.7711
   Zhang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057251
   Zhao N, 2013, J TRADIT CHIN MED, V33, P130, DOI 10.1016/S0254 6272(13)60114 4
   Zheng HX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092398
NR 37
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD JAN
PY 2025
VL 61
IS 1
BP 59
EP 66
DI 10.1007/s11626 024 00981 5
EA OCT 2024
PG 8
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA U8B8H
UT WOS:001346013100001
PM 39476282
DA 2025 08 17
ER

PT J
AU Zhou, H
   Xie, YQ
   Baloch, Z
   Shi, QP
   Huo, Q
   Ma, T
AF Zhou, Huan
   Xie, Yunqiu
   Baloch, Zulqarnain
   Shi, Qingping
   Huo, Qiang
   Ma, Tao
TI The effect of atorvastatin, 3 hydroxy 3 methylglutaryl coenzyme A
   reductase inhibitor (HMG CoA), on the prevention of osteoporosis in
   ovariectomized rabbits
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoporosis; Ovariectomy; Atorvastatin; Osteoblasts; Osteoclasts
ID INDUCED BONE LOSS; OSTEOBLASTIC DIFFERENTIATION; CONTROLLED RELEASE;
   CALCIUM PHOSPHATE; SIMVASTATIN; MODEL; EXPRESSION; STATINS;
   MICROARCHITECTURE; ALENDRONATE
AB Osteoporosis is a most frequent systemic skeletal disease characterized as low bone mineral density and microarchitectural deterioration of bone tissue, resulting in increased bone fragility and fracture risk. Although several drugs such as bisphosphonates, estrogen replacement treatment, and selective estrogen receptor modulators have been used to treat osteoporosis, all these are not the ideal drugs because of insufficient curative ability and adverse side effects. Recently, atorvastatin has ordinarily been prescribed as an anti hyperlipidemia drug, not as an anti osteoporosis drug. However, its clinical outcome and potential treatment mechanism are still unclear. In this study, the bilateral ovariectomy of rabbits was duplicated to develop osteoporosis animal model. The effect of atorvastatin on in vivo was determined, and the functional mechanism was studied in vitro after the curative effect was explored. Atorvastatin was observed to significantly increase the mechanical parameters such as maximum load, stiffness, and energy absorbing capacity, and it improved the microarchitecture. The anti osteoporosis activity of atorvastatin may be the result of the promotion of differentiation of osteoblasts by inducing synthesis of vascular endothelial growth factor, bone morphogenetic protein 2 (BMP2), core binding factor alpha 1 (CBFa1), and inhibition of osteoclast formation through the osteoprotegerin (OPG) receptor activator for the nuclear factor.B ligand (RANKL) system. Our study observations give reliable experimental evidence for clinical application of atorvastatin to treat the disorder of osteoporosis.
C1 [Zhou, Huan; Ma, Tao] Bengbu Med Coll, Affiliated Hosp 1, Inst Natl Drug Clin Trial, 287 Changhuai Rd, Bengbu 233004, Peoples R China.
   [Xie, Yunqiu] Bengbu Med Coll, Affiliated Hosp 1, Intens Care Unit, Bengbu 233004, Peoples R China.
   [Baloch, Zulqarnain] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming, Peoples R China.
   [Shi, Qingping] Bengbu Med Coll, Affiliated Hosp 1, Dept Pharm, Bengbu 233004, Peoples R China.
   [Huo, Qiang; Ma, Tao] Bengbu Med Coll, Dept Pharm, Bengbu 233004, Peoples R China.
C3 Bengbu Medical University; Bengbu Medical University; Kunming University
   of Science & Technology; Bengbu Medical University; Bengbu Medical
   University
RP Ma, T (通讯作者)，Bengbu Med Coll, Affiliated Hosp 1, Inst Natl Drug Clin Trial, 287 Changhuai Rd, Bengbu 233004, Peoples R China.; Ma, T (通讯作者)，Bengbu Med Coll, Dept Pharm, Bengbu 233004, Peoples R China.
EM mataobb@sina.com
RI Baloch, Zulqarnain/A 8455 2017; baloch, Dr. Zulqarnain/A 8455 2017
OI baloch, Dr. Zulqarnain/0000 0002 7873 1343
FU National Natural Science Foundation of China [81201101]; Natural Science
   Foundation of Anhui Province [A2014206208]; Natural Science Foundation
   of Bengbu City, China [10S090202, 2014 01 01 A R 07 0006,
   2016 05 06 A R 07 0005]
FX We sincerely thank all the participants who took part in this study.
   This study was supported by research grants from the National Natural
   Science Foundation of China (81201101), and the Natural Science
   Foundation of Anhui Province (A2014206208), and the Natural Science
   Foundation of Bengbu City, China (Grants 10S090202,
   2014 01 01 A R 07 0006, 2016 05 06 A R 07 0005). The funders had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Chen HY, 2012, J ETHNOPHARMACOL, V142, P80, DOI 10.1016/j.jep.2012.04.017
   Dai LF, 2016, J BONE MINER METAB, V34, P23, DOI 10.1007/s00774 014 0638 y
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Furuzawa M, 2014, EXP GERONTOL, V55, P12, DOI 10.1016/j.exger.2014.03.003
   Hamada H, 2012, J APPL BIOMATER FUNC, V10, P22, DOI 10.5301/JABFM.2012.9272
   Hamrick I, 2015, WIEN MED WOCHENSCHR, V165, P54, DOI 10.1007/s10354 014 0335 4
   Handal JA, 2012, J ORTHOP RES, V30, P872, DOI 10.1002/jor.22030
   Hordon LD, 2006, BONE, V38, P444, DOI 10.1016/j.bone.2005.09.020
   Ito Masako, 2013, Clin Calcium, V23, P1035, DOI CliCa130710351039
   Ito Masako, 2006, Clin Calcium, V16, P2034
   Ito T, 2013, J PHARM PHARMACOL, V65, P494, DOI 10.1111/jphp.12008
   Ito T, 2012, J MATER SCI MATER M, V23, P1291, DOI 10.1007/s10856 012 4597 3
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jang H, 2014, BONE, V61, P10, DOI 10.1016/j.bone.2013.12.028
   Johan MF, 2004, BRIT J HAEMATOL, V127, P123, DOI 10.1111/j.1365 2141.2004.05158.x
   Jules J, 2010, EXPERT OPIN THER TAR, V14, P923, DOI 10.1517/14728222.2010.511179
   Kim IS, 2009, J BIOMECH, V42, P2721, DOI 10.1016/j.jbiomech.2009.08.006
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Lasota A, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P129
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Lin S, 2015, CALCIFIED TISSUE INT, V96, P541, DOI 10.1007/s00223 015 9975 7
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Moshiri A, 2015, CALCIFIED TISSUE INT, V96, P552, DOI 10.1007/s00223 015 9981 9
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nahar Gohad P, 2015, CALCIFIED TISSUE INT, V96, P359, DOI 10.1007/s00223 015 9962 z
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Park YS, 2013, AAPS J, V15, P367, DOI 10.1208/s12248 012 9442 6
   Peng JH, 2009, CHIN J INTEGR MED, V15, P198, DOI 10.1007/s11655 009 9001 x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rajamannan NM, 2015, CARDIOLOGY, V132, P11, DOI 10.1159/000381703
   Schorlemmer S, 2005, BONE, V37, P491, DOI 10.1016/j.bone.2005.05.002
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shi Jingli, 2008, J Tradit Chin Med, V28, P211
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Tan S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/814057
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
NR 48
TC 18
Z9 21
U1 0
U2 19
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2017
VL 35
IS 3
BP 245
EP 254
DI 10.1007/s00774 016 0750 2
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA EY0QZ
UT WOS:000403664500001
PM 27119523
DA 2025 08 17
ER

PT J
AU Jiang, YN
   Zhang, YQ
   Chen, WH
   Liu, CF
   Li, XM
   Sun, DN
   Liu, ZL
   Xu, Y
   Mao, X
   Guo, QY
   Lin, N
AF Jiang, Yini
   Zhang, Yanqiong
   Chen, Weiheng
   Liu, Chunfang
   Li, Xiaomin
   Sun, Danni
   Liu, Zhenli
   Xu, Ying
   Mao, Xia
   Guo, Qiuyan
   Lin, Na
TI Achyranthes bidentata extract exerts osteoprotective effects on
   steroid induced osteonecrosis of the femoral head in rats by regulating
   RANKL/RANK/OPG signaling
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Achyranthes bidentata extract; Steroid induced osteonecrosis; Femoral
   head; Osteoprotective; RANKL/RANK/OPG signaling pathway
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; INDUCED
   ARTHRITIS; BONE; OSTEOPOROSIS; LIGAND; RANKL; METHYLPREDNISOLONE;
   INFLAMMATION
AB Background: Steroid induced osteonecrosis of the femoral head (steroid induced ONFH) presents great challenges due to the various effects of steroids on multi system pathways involved into osteoblast differentiation, osteoblast and osteoclast apoptosis, lipid metabolism, calcium metabolism and coagulation. As one of the most frequently used herbs in Traditional Chinese Medicine formulas that are prescribed for the regulation of bone and mineral metabolism, the therapeutic effects of Achyranthes bidentata on steroid induced ONFH remain unclear. Thus, the aim of the current study was to verify whether Achyranthes bidentata extract (ABE) can be used to prevent steroid induced ONFH and to investigate its underlying pharmacological mechanisms.
   Methods: Steroid induced ONFH rat models were established to evaluate the effects of ABE treatment on osteonecrotic changes and repair processes. Microfocal computed tomography (Micro CT) was performed to assess the effects of ABE treatment on bone mass, microstructure, and vascularization. Then, the effects of ABE treatment on osteoclast differentiation and bone formation were also evaluated in vivo and in vitro. In addition, receptor activator of nuclear factor kappa B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) expression in sera, femoral heads and bone marrow derived mesenchymal stem cells (BMSCs) were detected at both protein and mRNA levels.
   Results: The ratio of empty lacuna, adipose tissue area, and adipocyte perimeter in the bone marrow were markedly lower in the ABE treatment groups than in the model group. Micro CT evaluation indicated that ABE treatment could improve the microstructure of the trabecular bone, increase bone mineral density and promote vascularization in steroid induced ONFH rats. Moreover, ABE treatment inhibited osteoclast differentiation and activated bone formation markers. Interestingly, OPG downregulation, RANK and RANKL upregulation, and an increased ratio of RANKL to OPG in sera and necrotic femoral head could be reversed by ABE treatment, which also effectively inhibited RANKL induced osteoclast differentiation and regulated RANKL and OPG expression of in vitro.
   Conclusion: ABE may prevent steroid induced ONFH and alleviate steroid induced bone deterioration by regulating the RANKL/RANK/OPG signaling pathway.
C1 [Jiang, Yini; Zhang, Yanqiong; Liu, Chunfang; Li, Xiaomin; Sun, Danni; Liu, Zhenli; Xu, Ying; Mao, Xia; Guo, Qiuyan; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Materia Med, Beijing 100700, Peoples R China.
   [Chen, Weiheng] China Acad Chinese Med Sci, Wangjing Hosp, Beijing 100102, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Wang Jing Hospital, CACMS;
   China Academy of Chinese Medical Sciences
RP Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Materia Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.
EM linna888@163.com
RI ; Guo, Qiuyan/JBS 3104 2023
OI Guo, qiuyan/0009 0007 8005 3995; 
FU National Major Scientific and Technological Special Project
   [2013ZX09301307]; National Natural Science Foundation of China
   [81173417]
FX This study was supported by grants from the National Major Scientific
   and Technological Special Project for "Significant New Drugs Creation"
   (No. 2013ZX09301307) and the National Natural Science Foundation of
   China (No. 81173417).
CR Aimaiti A, 2011, MED HYPOTHESES, V77, P282, DOI 10.1016/j.mehy.2011.04.036
   Bai YD, 2008, MED HYPOTHESES, V71, P256, DOI 10.1016/j.mehy.2008.03.021
   Bezerra MC, 2005, BRAZ J MED BIOL RES, V38, P161, DOI 10.1590/S0100 879X2005000200004
   Bitto A, 2009, J ENDOCRINOL, V201, P321, DOI 10.1677/JOE 08 0552
   Chen QH, 2009, IMMUNOPHARM IMMUNOT, V31, P253, DOI 10.1080/08923970802439795
   Cheng Jian, 2014, Zhongguo Zhong Yao Za Zhi, V39, P1502
   Committee of National Pharmacopoeia, 2005, PHARM PEOPL REP CHIN, P49
   ERIKSEN EF, 1985, BONE, V6, P421, DOI 10.1016/8756 3282(85)90218 2
   Gao Xiao yan, 2000, Yaoxue Xuebao, V35, P868
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Han N, 2010, CALCIFIED TISSUE INT, V87, P246, DOI 10.1007/s00223 010 9385 9
   Han SB, 2005, ARCH PHARM RES, V28, P902, DOI 10.1007/BF02973875
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Ho TY, 2011, BONE, V48, P1346, DOI 10.1016/j.bone.2011.03.684
   [胡洁 Hu Ji], 2005, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V25, P415
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li J, 2007, ANAL CHIM ACTA, V596, P264, DOI 10.1016/j.aca.2007.05.016
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   Lin N, 2007, BIOCHEM PHARMACOL, V73, P136, DOI 10.1016/j.bcp.2006.08.027
   Mbalaviele G, 1999, ENDOCRINOLOGY, V140, P3736, DOI 10.1210/endo.140.8.6880
   Mikami T, 2010, J ORTHOP SCI, V15, P674, DOI 10.1007/s00776 010 1516 7
   Moriya M, 2012, INT ORTHOP, V36, P2041, DOI 10.1007/s00264 012 1612 8
   OURSLER MJ, 1993, J ANN MED, V25, P361
   Powell C, 2010, AUTOIMMUN REV, V9, P721, DOI 10.1016/j.autrev.2010.06.007
   Shao Bingyi, 2013, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V29, P1262
   Sun YA, 2011, CELL TRANSPLANT, V20, P233, DOI 10.3727/096368910X522234
   Sun Y, 2009, JOINT BONE SPINE, V76, P685, DOI 10.1016/j.jbspin.2009.04.002
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang XS, 2013, CHINESE MED J PEKING, V126, P290, DOI 10.3760/cma.j.issn.0366 6999.20120663
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119
   Zhang R, 2012, J ETHNOPHARMACOL, V139, P12, DOI 10.1016/j.jep.2011.05.034
NR 34
TC 55
Z9 63
U1 1
U2 31
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 29
PY 2014
VL 12
AR 334
DI 10.1186/s12967 014 0334 7
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AX9FX
UT WOS:000347210100001
PM 25471933
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, MT
   Li, Y
   Feng, XX
   Zheng, W
   Zhao, ZH
   Li, Y
AF Xu, Mengting
   Li, Yuan
   Feng, Xiaoxia
   Zheng, Wei
   Zhao, Zhihe
   Li, Yu
TI Parathyroid hormone promotes maxillary expansion and reduces relapse in
   the repeated activation maxillary expansion rat model by regulating
   Wnt/β catenin pathway
SO PROGRESS IN ORTHODONTICS
LA English
DT Article
DE Parathyroid hormone; Bone remodeling; Maxillary expansion; Mid palatal
   suture; Relapse
ID MIDPALATAL SUTURE CARTILAGE; BONE FORMATION; SKELETAL; FORCE; GROWTH;
   DIFFERENTIATION; LIGHT
AB Background Constricted maxillary bone is a common skeletal deformity, which may lead to crowding and posterior crossbite. Mid palatal suture expansion is often used to increase the maxillary width, but its skeletal effects are limited and tend to relapse, even with prolonged retention. We hypothesized that parathyroid hormone (PTH) may reduce the relapse of maxillary expansion. Methods We established a novel rat maxillary expansion model using palatal tubes with an insertable "W" shaped spring which can be repeatedly activated. A total of 32 male healthy Wistar rats were randomly divided into six groups: the control group, the PTH group, the expansion group, the expansion + PTH group, the expansion + relapse group and the expansion + PTH + relapse group. All animals in the first 4 groups were killed after 10 days and the 2 relapse groups were killed after 15 days. The maxillary arch widths and histological staining were used to assess the expansion and relapse effects. The immunohistochemical staining, micro CT, RT qPCR and Western blot were used to evaluate the bone remodeling during expansion. Results The suture width was increased by the expansion device, and the repeated activation maxillary expansion rat model showed better expansion effects than the conventional model. PTH significantly promoted the expansion width and reduced the relapse ratio. Meanwhile, in the expansion + PTH group, histological and immunohistochemical staining showed that osteoblasts, osteoclasts, new cartilage and osteoid were significantly increased, micro CT showed increased bone mass, and PCR and Western blot results confirmed up regulation of RANKL, beta catenin, type II collagen and OCN. Conclusion The novel repeated activation maxillary expansion rat model has better effects than the conventional model. PTH enhances the maxillary expansion and reduces its relapse by regulating Wnt/beta catenin and RANKL pathways. PTH administration may serve as an adjunctive therapy in addition to mechanical expansion for treatment of maxillary constriction.
C1 [Xu, Mengting; Li, Yuan; Zhao, Zhihe; Li, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont,State Key Lab Oral Dis, 14,3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.
   [Feng, Xiaoxia] Zhejiang Univ, Affiliated Stomatol Hosp, Key Lab Oral Biomed Res Zhejiang Prov, Sch Med, Hangzhou, Peoples R China.
   [Zheng, Wei] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis,Dept Oral & Maxillofacial, 14,3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; Zhejiang University; Sichuan University
RP Zhao, ZH (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont,State Key Lab Oral Dis, 14,3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.; Zheng, W (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis,Dept Oral & Maxillofacial, 14,3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.
EM zhengwei81101@163.com; zhzhao@scu.edu.cn
RI Xu, Meng/HJY 7139 2023; Li, Yu/G 6649 2011
OI Li, Yu/0000 0001 8578 7268; Zhao, Zhihe/0000 0003 2955 1706
FU National Natural Science Foundation of China (NSFC) [81771048,
   31971247]; Science and Technology Department of Sichuan Province
   [2018SZ0379]
FX This study was supported by the National Natural Science Foundation of
   China (NSFC) [Project No. 81771048 and No. 31971247] and Science and
   Technology Department of Sichuan Province [Project No. 2018SZ0379].
CR Al Rifai O, 2017, J CLIN INVEST, V127, P4104, DOI 10.1172/JCI93437
   Aras MH, 2015, PHOTOMED LASER SURG, V33, P136, DOI 10.1089/pho.2014.3820
   Arnez Maya Fernanda Manfrin, 2017, Braz. Dent. J., V28, P296, DOI 10.1590/0103 6440201601116
   Ballanti F, 2010, AM J ORTHOD DENTOFAC, V138, P311, DOI 10.1016/j.ajodo.2008.10.022
   Byloff FK, 2004, EUR J ORTHODONT, V26, P403, DOI 10.1093/ejo/26.4.403
   Chan HL, 2013, J DENT RES, V92, P18, DOI 10.1177/0022034512464779
   Che XX, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8106067
   Chen JW, 2017, ARCH ORAL BIOL, V76, P30, DOI 10.1016/j.archoralbio.2017.01.002
   Cowan CM, 2006, BONE, V38, P48, DOI 10.1016/j.bone.2005.06.023
   Danz JC, 2013, ORTHOD CRANIOFAC RES, V16, P223, DOI 10.1111/ocr.12025
   de Melo Maria de Fatima Batista, 2013, Indian J Dent Res, V24, P76, DOI 10.4103/0970 9290.114960
   Ekizer A, 2013, LASER MED SCI, V28, P1263, DOI 10.1007/s10103 012 1214 0
   Fastuca R, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903 017 0404 3
   Gao X, 2017, AM J ORTHOD DENTOFAC, V151, P779, DOI 10.1016/j.ajodo.2016.02.034
   GHAFARI J, 1984, AM J ORTHOD DENTOFAC, V85, P351, DOI 10.1016/0002 9416(84)90192 1
   Grosso MJ, 2015, J ORTHOP RES, V33, P163, DOI 10.1002/jor.22748
   Hou B, 2007, BONE, V40, P1483, DOI 10.1016/j.bone.2007.01.019
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kara MI, 2012, ARCH ORAL BIOL, V57, P357, DOI 10.1016/j.archoralbio.2011.09.012
   Katebi N, 2012, ORTHOD CRANIOFAC RES, V15, P148, DOI 10.1111/j.1601 6343.2012.01547.x
   KEUTMANN HT, 1978, BIOCHEMISTRY US, V17, P5723, DOI 10.1021/bi00619a019
   Kobayashi ET, 1999, J DENT RES, V78, P1495, DOI 10.1177/00220345990780090301
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Kurt G, 2017, J CRANIOFAC SURG, V28, P775, DOI 10.1097/SCS.0000000000003468
   LATHAM RA, 1971, J ANAT, V108, P31
   Lee K, 2001, ANGLE ORTHOD, V71, P265
   Liu SSY, 2010, EUR J ORTHODONT, V32, P371, DOI 10.1093/ejo/cjp103
   Lo Giudice A, 2020, KOREAN J ORTHOD, V50, P314, DOI 10.4041/kjod.2020.50.5.314
   Ma JQ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 37
   Marini C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12761 1
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Rhee Y, 2013, J BIOL CHEM, V288, P29809, DOI 10.1074/jbc.M113.485938
   Roche B, 2014, J BONE MINER RES, V29, P1608, DOI 10.1002/jbmr.2191
   Saitoh S, 2000, ANAT RECORD, V260, P392, DOI 10.1002/1097 0185(20001201)260:4<392::AID AR90>3.0.CO;2 O
   Sarnas K V, 1992, Eur J Orthod, V14, P427
   Sato K, 2017, BIOSCI BIOTECH BIOCH, V81, P1241, DOI 10.1080/09168451.2017.1282809
   Savoldi F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25402 y
   Sawada M, 1996, EUR J ORTHODONT, V18, P169
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Siddiqui JA, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00049
   SILAU AM, 1994, J CRAN GENET DEV BIO, V14, P252
   Soma S, 2000, J DENT RES, V79, P1717, DOI 10.1177/00220345000790091301
   Sorel O, 2004, Rev Stomatol Chir Maxillofac, V105, P26
   Takahashi I, 1996, BONE, V18, P341, DOI 10.1016/8756 3282(96)00012 9
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Tepedino Michele, 2018, J Clin Exp Dent, V10, pe241, DOI 10.4317/jced.54585
   Tucci Michelle, 2010, Biomed Sci Instrum, V46, P142
   Utreja A, 2018, ANGLE ORTHOD, V88, P306, DOI 10.2319/070717 451.1
   Uysal T, 2011, J OROFAC ORTHOP, V72, P290, DOI 10.1007/s00056 011 0034 3
   Wang H, 2015, J BIOMECH, V48, P432, DOI 10.1016/j.jbiomech.2014.12.032
   Wang YC, 2009, ANGLE ORTHOD, V79, P230, DOI 10.2319/031208 141.1
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Xian CJ, 2004, J ORTHOPAED RES, V22, P417, DOI 10.1016/j.orthres.2003.08.003
   Yu HS, 2007, EUR J ORTHODONT, V29, P118, DOI 10.1093/ejo/cjl057
   ZAHROWSKI JJ, 1992, ANGLE ORTHOD, V62, P197
   Zawislak E, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5814103
NR 57
TC 9
Z9 9
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2196 1042
J9 PROG ORTHOD
JI Prog. Orthod.
PD JAN 3
PY 2022
VL 23
IS 1
AR 1
DI 10.1186/s40510 021 00394 0
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA XZ9KS
UT WOS:000737965000001
PM 34978631
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Korpal, M
   Yan, J
   Lu, X
   Xu, SW
   Lerit, DA
   Kang, YB
AF Korpal, Manav
   Yan, Jun
   Lu, Xin
   Xu, Shuwa
   Lerit, Dorothy A.
   Kang, Yibin
TI Imaging transforming growth factor β signaling dynamics and therapeutic
   response in breast cancer bone metastasis
SO NATURE MEDICINE
LA English
DT Article
ID RECEPTOR TYPE I; TGF BETA; ORAL IBANDRONATE; TUMOR; DISEASE; CELLS;
   VIVO; INHIBITORS; MICE; BISPHOSPHONATES
AB Although the transforming growth factor beta (TGF beta) pathway has been implicated in breast cancer metastasis, its in vivo dynamics and temporal spatial involvement in organ specific metastasis have not been investigated. Here we engineered a xenograft model system with a conditional control of the TGF beta SMAD signaling pathway and a dual luciferase reporter system for tracing both metastatic burden and TGF beta signaling activity in vivo. Strong TGF beta signaling in osteolytic bone lesions is suppressed directly by genetic and pharmacological disruption of the TGF beta SMAD pathway and indirectly by inhibition of osteoclast function with bisphosphonates. Notably, disruption of TGF beta signaling early in metastasis can substantially reduce metastasis burden but becomes less effective when bone lesions are well established. Our in vivo system for real time manipulation and detection of TGF beta signaling provides a proof of principle for using similar strategies to analyze the in vivo dynamics of other metastasis associated signaling pathways and will expedite the development and characterization of therapeutic agents.
C1 [Korpal, Manav; Yan, Jun; Lu, Xin; Xu, Shuwa; Lerit, Dorothy A.; Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
   [Kang, Yibin] Canc Inst New Jersey, Breast Canc Program, New Brunswick, NJ USA.
C3 Princeton University; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers
   Cancer Institute of New Jersey
RP Kang, YB (通讯作者)，Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
EM ykang@princeton.edu
RI ; lu, xuemin/A 8741 2011
OI Yan, Jun/0000 0002 5641 5710; Kang, Yibin/0000 0002 1626 6730; 
FU Department of Defense Era of Hope Scholar Award; American Cancer
   Society; Susan G. Komen Foundation; New Jersey Commission on Cancer
   Research; Department of Defense Breast Cancer Research Program.
FX We thank members of the Kang laboratory for insightful discussions and
   technical suggestions, J. Yingling (Eli Lilly and Company) for the
   TGF beta receptor I kinase inhibitor and suggestions for the manuscript,
   S. Gambhir (Stanford University) for triple reporter plasmids, R. Agami
   (The Netherlands Cancer Institute) for pRS GFP, T. Guise and K. Mohammad
   for technical advice in bone histology and G. Hu for statistical
   support. Y. K. is a Champalimaud Investigator funded by a Department of
   Defense Era of Hope Scholar Award and grants from the American Cancer
   Society, the Susan G. Komen Foundation and the New Jersey Commission on
   Cancer Research. M. K. is supported by a predoctoral fellowship from the
   Department of Defense Breast Cancer Research Program.
CR Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Coleman R, 2007, BREAST, V16, pS21, DOI 10.1016/j.breast.2007.10.006
   Coleman RE, 1997, CANCER, V80, P1686, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1686::AID CNCR20>3.0.CO;2 V
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Deroose CM, 2007, J NUCL MED, V48, P295
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535 6108(03)00135 1
   El Abdaimi K, 2003, INT J ONCOL, V22, P883
   Fritz V, 2007, BONE, V40, P1032, DOI 10.1016/j.bone.2006.11.026
   Gross S, 2005, CANCER CELL, V7, P5, DOI 10.1016/j.ccr.2004.12.011
   Guise Theresa A, 2005, Clin Breast Cancer, V5 Suppl, pS46, DOI 10.3816/CBC.2005.s.004
   Hoffman RM, 2009, CLIN EXP METASTAS, V26, P345, DOI 10.1007/s10585 008 9205 z
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Li HY, 2008, J MED CHEM, V51, P2302, DOI 10.1021/jm701199p
   Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535 7163.MCT 07 0337
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muraoka Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008 5472.CAN 03 1816
   REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Tjuvajev JG, 2003, CANCER CELL, V3, P327, DOI 10.1016/S1535 6108(03)00082 5
   Tripathy D, 2004, ANN ONCOL, V15, P743, DOI 10.1093/annonc/mdh173
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535 6108(03)00223 X
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580
   Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097 2765(00)80061 1
NR 35
TC 173
Z9 197
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2009
VL 15
IS 8
BP 960
EP U169
DI 10.1038/nm.1943
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 480XK
UT WOS:000268770400043
PM 19597504
DA 2025 08 17
ER

PT J
AU Cary, RL
   Waddell, S
   Racioppi, L
   Long, FX
   Novack, DV
   Voor, MJ
   Sankar, U
AF Cary, Rachel L.
   Waddell, Seid
   Racioppi, Luigi
   Long, Fanxin
   Novack, Deborah V.
   Voor, Michael J.
   Sankar, Uma
TI Inhibition of Ca2+/Calmodulin Dependent Protein Kinase Kinase 2
   Stimulates Osteoblast Formation and Inhibits Osteoclast Differentiation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CA2+; CALMODULIN (CAM) DEPENDENT PROTEIN KINASE KINASE 2; OSTEOBLASTS;
   OSTEOCLASTS; STO 609; PROTEIN KINASE A
ID ELEMENT BINDING PROTEIN; PARATHYROID HORMONE; DEPENDENT KINASE;
   GROWTH FACTOR; CELL CYCLE; CAMKK2; EXPRESSION; CALCIUM; CREB;
   PHOSPHORYLATION
AB Bone remodeling, a physiological process characterized by bone formation by osteoblasts (OBs) and resorption of preexisting bone matrix by osteoclasts (OCs), is vital for the maintenance of healthy bone tissue in adult humans. Imbalances in this vital process result in pathological conditions including osteoporosis. Owing to its initial asymptomatic nature, osteoporosis is often detected only after the patient has sustained significant bone loss or a fracture. Hence, anabolic therapeutics that stimulate bone accrual is in high clinical demand. Here we identify Ca2+/calmodulin (CaM) dependent protein kinase kinase 2 (CaMKK2) as a potential target for such therapeutics because its inhibition enhances OB differentiation and bone growth and suppresses OC differentiation. Mice null for CaMKK2 possess higher trabecular bone mass in their long bones, along with significantly more OBs and fewer multinuclear OCs. In vitro, although Camkk2 /  mesenchymal stem cells (MSCs) yield significantly higher numbers of OBs, bone marrow cells from Camkk2 /  mice produce fewer multinuclear OCs. Acute inhibition of CaMKK2 by its selective, cell permeable pharmacological inhibitor STO 609 also results in increased OB and diminished OC formation. Further, we find phospho protein kinase A (PKA) and Ser133 phosphorylated form of cyclic adenosine monophosphate (cAMP) response element binding protein (pCREB) to be markedly elevated in OB progenitors deficient in CaMKK2. On the other hand, genetic ablation of CaMKK2 or its pharmacological inhibition in OC progenitors results in reduced pCREB as well as significantly reduced levels of its transcriptional target, nuclear factor of activated T cells, cytoplasmic (NFATc1). Moreover, in vivo administration of STO 609 results in increased OBs and diminished OCs, conferring significant protection from ovariectomy (OVX) induced osteoporosis in adult mice. Overall, our findings reveal a novel function for CaMKK2 in bone remodeling and highlight the potential for its therapeutic inhibition as a valuable bone anabolic strategy that also inhibits OC differentiation in the treatment of osteoporosis.
C1 [Cary, Rachel L.; Sankar, Uma] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA.
   [Waddell, Seid; Voor, Michael J.] Univ Louisville, Dept Orthopaed Surg, Louisville, KY 40202 USA.
   [Racioppi, Luigi] Duke Univ, Dept Med, Durham, NC USA.
   [Racioppi, Luigi] Univ Naples Federico II, Naples, Italy.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Novack, Deborah V.] Washington Univ, Dept Med & Pathol, St Louis, MO USA.
   [Sankar, Uma] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA.
C3 University of Louisville; University of Louisville; Duke University;
   University of Naples Federico II; Washington University (WUSTL);
   Washington University (WUSTL); University of Louisville
RP Sankar, U (通讯作者)，Univ Louisville, 505 S Hancock St,412 CTRB, Louisville, KY 40202 USA.
EM uma.sankar@louisville.edu
RI Sankar, Uma/AHE 2383 2022; Racioppi, luigi/AGB 8665 2022
OI Novack, Deborah/0000 0001 7101 5582; racioppi, luigi/0000 0002 9207 6752
FU Department of Defense USAMRMC [W81XWH 10 2 0082 CLIN 1]; JGBCC; OCRP;
   NIAMS [AR055923, AR052705]; Kentucky Science and Engineering Foundation;
   Center for Musculoskeletal Biology and Medicine at Washington University
   [P30AR057235]
FX This work was supported by a Department of Defense USAMRMC research
   grant (W81XWH 10 2 0082 CLIN 1) and JGBCC and OCRP funds to US. FL is
   supported by AR055923 (NIAMS). DVN is supported by AR052705 (NIAMS). MJV
   is supported by a grant from the Kentucky Science and Engineering
   Foundation. Histological analysis was supported in part by The Center
   for Musculoskeletal Biology and Medicine at Washington University,
   P30AR057235 (NIAMS). We thank Dr. Anthony R. Means for his kind gift of
   Camkk2<SUP> / </SUP> and Camk4<SUP> / </SUP> mice, and for his advice.
   We thank Janice Ditslear for help with animal surgeries and i.p.
   injections. There are no restrictions on full access for all authors to
   all raw data, statistical analyses, and material used in the study
   reported in this manuscript.
CR Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011
   Anderson KA, 2012, MOL ENDOCRINOL, V26, P281, DOI 10.1210/me.2011 1299
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao WG, 2011, RNA BIOL, V8, P1061, DOI 10.4161/rna.8.6.16691
   Colomer J., 2007, V45, P169
   GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200
   Lin FM, 2011, ENDOCRINOLOGY, V152, P3668, DOI 10.1210/en.2011 1107
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40
   Means AR, 2008, MOL ENDOCRINOL, V22, P2759, DOI 10.1210/me.2008 0312
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Oury F, 2010, GENE DEV, V24, P2330, DOI 10.1101/gad.1977210
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Racioppi L, 2012, J BIOL CHEM, V287, P31658, DOI 10.1074/jbc.R112.356485
   Racioppi L, 2012, J BIOL CHEM, V287, P11579, DOI 10.1074/jbc.M111.336032
   Sankar U, 2004, J BONE MINER RES, V19, P1339, DOI 10.1359/JBMR.040321
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teng EC, 2011, J LEUKOCYTE BIOL, V90, P897, DOI 10.1189/jlb.0311152
   Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200
   Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255
   Wang SL, 2001, CELL GROWTH DIFFER, V12, P351
   Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073
   Wayman GA, 1996, MOL CELL BIOL, V16, P6075
   Xia SL, 1996, J CELL PHYSIOL, V167, P148, DOI 10.1002/(SICI)1097 4652(199604)167:1<148::AID JCP17>3.0.CO;2 7
   Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310
   Zhang R., 2011, PLOS ONE, V6
NR 36
TC 49
Z9 55
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2013
VL 28
IS 7
BP 1599
EP 1610
DI 10.1002/jbmr.1890
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 166NM
UT WOS:000320561900010
PM 23408651
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Li, ZX
   Huang, JP
   Wang, FH
   Li, WJ
   Wu, X
   Zhao, CL
   Zhao, J
   Wei, HF
   Wu, ZP
   Qian, M
   Sun, P
   He, L
   Jin, YY
   Tang, J
   Qiu, WW
   Siwko, SF
   Liu, MY
   Luo, J
   Xiao, JR
AF Li, Zhenxi
   Huang, Jinping
   Wang, Fanhua
   Li, Wenjun
   Wu, Xian
   Zhao, Chenglong
   Zhao, Jian
   Wei, Haifeng
   Wu, Zhipeng
   Qian, Ming
   Sun, Peng
   He, Liang
   Jin, Yunyun
   Tang, Jie
   Qiu, Wenwei
   Siwko, Stefan
   Liu, Mingyao
   Luo, Jian
   Xiao, Jianru
TI Dual Targeting of Bile Acid Receptor 1 (TGR5) and Farnesoid X Receptor
   (FXR) Prevents Estrogen Dependent Bone Loss in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TGR5; FXR; BETULINIC ACID DERIVATIVES; AMPK; OSTEOPOROSIS; OSTEOCLAST;
   OSTEOBLAST
ID BETULINIC ACID; AMPK ACTIVATOR; DIFFERENTIATION; OSTEOPOROSIS;
   OSTEOCLASTS; DELETION; AGONIST; DISEASE; OBESITY; CELLS
AB Osteoporosis is a global bone disease characterized by reduced bone mineral density (BMD) and increased risk of fractures. The risk of developing osteoporosis increases with aging, especially after menopause in women. Discovering the signaling pathways that play a significant role in aging and menopause induced osteoporosis should accelerate osteoporosis drug discovery. In this study, we found that bile acid membrane receptor Tgr5 knockout C57BL/6J mice had similar bone mass as wild type mice during early and middle age (before 4 months old) bone remodeling; however, Tgr5( / ) markedly decreased bone mass in aged (more than 7 months old) and ovariectomized (OVX) mice compared with wild type mice. Moreover, Tgr5 knockout strongly induced osteoclast differentiation but had no effect on osteoblast activity. Treatment with different TGR5 agonists consistently inhibited osteoclast differentiation. Importantly, our results showed that Tgr5 regulates osteoclastogenesis by the AMP activated protein kinase (AMPK) signaling pathway, which is a central metabolic pathway involved in the pathophysiology of aging and age related diseases. The bile acid nuclear receptor FXR is an established regulator of bone metabolism. We screened the derivatives of betulinic acid (BA), a known TGR5 agonist, to identify novel dual agonists of FXR and TGR5. The derivative SH 479, a pentacyclic triterpene acid, could activate both TGR5 and FXR, with a better inhibitory effect on osteoclastogenesis compared with agonists solely activating FXR or TGR5 and additionally enhanced osteoblastogenesis. Furthermore, SH 479 therapeutically abrogated bone loss in C57BL/6J mice through the bone remodeling pathways. Together, our results demonstrate that dual targeting the bile acid membrane receptor TGR5 and nuclear receptor FXR is a promising strategy for osteoporosis. (c) 2018 American Society for Bone and Mineral Research.
C1 [Li, Zhenxi; Huang, Jinping; Wang, Fanhua; Li, Wenjun; Wu, Xian; Zhao, Chenglong; Zhao, Jian; Wei, Haifeng; Wu, Zhipeng; Qian, Ming; Sun, Peng; He, Liang; Jin, Yunyun; Liu, Mingyao; Luo, Jian; Xiao, Jianru] East China Normal Univ, Shanghai, Peoples R China.
   [Li, Zhenxi; Zhao, Chenglong; Zhao, Jian; Wei, Haifeng; Wu, Zhipeng; Qian, Ming; Xiao, Jianru] Second Mil Med Univ, Shanghai Changzheng Hosp, Joint Res Ctr Orthoped Oncol, Dept Orthoped Oncol, Shanghai, Peoples R China.
   [Li, Zhenxi; Huang, Jinping; Wang, Fanhua; Li, Wenjun; Wu, Xian; Zhao, Chenglong; Zhao, Jian; Wei, Haifeng; Wu, Zhipeng; Qian, Ming; Sun, Peng; He, Liang; Jin, Yunyun; Liu, Mingyao; Luo, Jian] East China Normal Univ, Shanghai Changzheng Hosp, Joint Res Ctr Orthoped Oncol, Shanghai Key Lab Regulatory Biol,Inst Biomed Sci, Shanghai, Peoples R China.
   [Li, Zhenxi; Huang, Jinping; Wang, Fanhua; Li, Wenjun; Wu, Xian; Zhao, Chenglong; Zhao, Jian; Wei, Haifeng; Wu, Zhipeng; Qian, Ming; Sun, Peng; He, Liang; Jin, Yunyun; Liu, Mingyao; Luo, Jian] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.
   [Tang, Jie; Qiu, Wenwei] East China Normal Univ, Inst Med Chem, Shanghai, Peoples R China.
   [Tang, Jie; Qiu, Wenwei] East China Normal Univ, Dept Chem, Shanghai, Peoples R China.
   [Siwko, Stefan; Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Alkek Inst Biosci & Technol, Houston, TX USA.
C3 East China Normal University; Naval Medical University; East China
   Normal University; Naval Medical University; East China Normal
   University; East China Normal University; East China Normal University;
   University of Texas System; University of Texas Health Science Center
   Houston; Texas A&M University System; Texas A&M University College
   Station; Texas A&M Health Science Center
RP Liu, MY; Luo, J (通讯作者)，East China Normal Univ, Inst Biomed Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.; Xiao, JR (通讯作者)，Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM myliu@bio.ecnu.edu.cn; jluo@bio.ecnu.edu.cn; jianruxiao83@163.com
RI jin, yun/GQZ 6618 2022; Wu, Zhi Peng/AAZ 4873 2021; Chen,
   Wei/GZK 7348 2022; tang, jie/KIE 8633 2024
OI Sun, Peng/0000 0002 0615 2510; Huang, Jinping/0000 0002 3549 1490; wang,
   Fanhua/0000 0001 8710 0925; Siwko, Stefan/0000 0003 4260 2985; Li,
   Zhenxi/0000 0002 7220 6177; xiao, jianru/0000 0003 1547 851X
FU National Key Research and Development Program of China [2018YFC1105102,
   2016YFC0902102]; National Natural Science Foundation of China [81722020,
   91749204, 81472048, 81330049, 81330059, 81572640]; Innovation Program of
   Shanghai Municipal Education Commission [14ZZ051,
   2017 01 07 00 05 E00011, 2017ZZ01017]; Science and Technology Commission
   of Shanghai Municipality [12ZR1447900, 17JC1400903, 17411950300,
   17ZR1439000]; Fundamental Research Funds for the Central Universities
FX This work was supported by grants from the National Key Research and
   Development Program of China (2018YFC1105102 to JL, 2016YFC0902102 to JL
   and JX), the National Natural Science Foundation of China (81722020,
   91749204, 81472048 to JL, 81330049 to ML, 81330059 to JX, 81572640 to
   JX), Innovation Program of Shanghai Municipal Education Commission
   (14ZZ051 to JL, 2017 01 07 00 05 E00011 to ML, 2017ZZ01017 to JX), the
   Science and Technology Commission of Shanghai Municipality (12ZR1447900
   to JL 17JC1400903 to JX, 17411950300 to JX, 17ZR1439000 to MQ), and the
   Fundamental Research Funds for the Central Universities (to JL).
CR Baghdasaryan A, 2011, HEPATOLOGY, V54, P1303, DOI 10.1002/hep.24537
   Chen SJ, 2017, BIOCHEM PHARMACOL, V126, P69, DOI 10.1016/j.bcp.2016.12.006
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005
   Cordero MD, 2018, TRENDS ENDOCRIN MET, V29, P8, DOI 10.1016/j.tem.2017.10.009
   Fiorucci S, 2009, TRENDS PHARMACOL SCI, V30, P570, DOI 10.1016/j.tips.2009.08.001
   García Martín A, 2013, ENDOCRINOL NUTR, V60, P260, DOI 10.1016/j.endonu.2012.06.008
   Hutchinson DS, 2008, PHARMACOL THERAPEUT, V119, P291, DOI 10.1016/j.pharmthera.2008.05.008
   Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007 JLR200
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200
   Keitel V, 2009, HEPATOLOGY, V50, P861, DOI 10.1002/hep.23032
   Kida T, 2013, ARTERIOSCL THROM VAS, V33, P1663, DOI 10.1161/ATVBAHA.113.301565
   Lee SH, 2012, CALCIFIED TISSUE INT, V90, P404, DOI 10.1007/s00223 012 9584 7
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Li J, 2017, MOL PHARMACOL, V91, P464, DOI 10.1124/mol.116.107136
   Lo SH, 2016, DRUG DES DEV THER, V10, P2669, DOI 10.2147/DDDT.S113197
   McMahan RH, 2013, J BIOL CHEM, V288, P11761, DOI 10.1074/jbc.M112.446575
   Miyazaki Anzai S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108270
   Pols TWH, 2011, CELL METAB, V14, P747, DOI 10.1016/j.cmet.2011.11.006
   Poole DP, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365 2982.2010.01487.x
   Poupon Raoul, 2010, Gastroenterology, V138, P1207, DOI 10.1053/j.gastro.2010.01.029
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Sèdes L, 2017, MOL ASPECTS MED, V56, P101, DOI 10.1016/j.mam.2017.05.004
   Shapses SA, 2017, NUTR RES, V39, P1, DOI 10.1016/j.nutres.2016.12.010
   Vassileva G, 2006, BIOCHEM J, V398, P423, DOI 10.1042/BJ20060537
   Wang XXX, 2017, J BIOL CHEM, V292, P12018, DOI 10.1074/jbc.C117.794982
   Wang YD, 2011, HEPATOLOGY, V54, P1421, DOI 10.1002/hep.24525
   Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330
   Xie F, 2005, BIOL PHARM BULL, V28, P1879, DOI 10.1248/bpb.28.1879
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Zhang JD, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4353510
NR 35
TC 59
Z9 68
U1 3
U2 52
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2019
VL 34
IS 4
BP 765
EP 776
DI 10.1002/jbmr.3652
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IJ1XC
UT WOS:000475691400018
PM 30536462
OA Bronze
DA 2025 08 17
ER

PT J
AU Choi, JH
   Han, Y
   Kim, YA
   Jin, SW
   Lee, GH
   Jeong, HM
   Lee, HS
   Chung, YC
   Lee, YC
   Kim, EJ
   Lee, KY
   Jeong, HG
AF Choi, Jae Ho
   Han, Younho
   Kim, Yong An
   Jin, Sun Woo
   Lee, Gi Ho
   Jeong, Hyung Min
   Lee, Hyun Sun
   Chung, Young Chul
   Lee, Young Chun
   Kim, Eun Ju
   Lee, Kwang Youl
   Jeong, Hye Gwang
TI Platycodin D Inhibits Osteoclastogenesis by Repressing the NFATc1 and
   MAPK Signaling Pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE PLATYCODON GRANDIFLORUM; SAPONINS; PLATYCODIN D; BONE LOSS; OSTEOCLAST;
   OVARIECTOMY
ID NF KAPPA B; STIMULATE OSTEOBLAST DIFFERENTIATION; HEPATIC LIPOGENESIS;
   RUNX2 ACTIVATION; HEPG2 CELLS; P38 MAPK; GRANDIFLORUM; SAPONINS; BONE;
   ROOTS
AB Platycodon grandiflorum root derived saponins (Changkil saponins, CKS) are reported to have many pharmacological activities. In our latest research, CKS was proven to have a significant osteogenic effect. However, the detail molecular mechanism of CKS on osteoclastic differentiation has not been fully investigated. Administration of CKS considerably reduced OVX induced bone loss, and ameliorated the reduction in plasma levels of alkaline phosphatase, calcium, and phosphorus observed in OVX mice. CKS also repressed the deterioration of bone trabecular microarchitecture. Interestingly, platycodin D, the most abundant and major pharmacological constituent of triterpenoid CKS, inhibited receptor activator of NF kappa B ligand (RANKL) induced activation of NF kappa B, and ERK and p38 MAPK, ultimately repressing osteoclast differentiation. OVX induced bone turnover was attenuated by CKS, possibly via repression of osteoclast differentiation by platycodin D, the active component of CKS. Platycodin D can be regarded as an antiosteoporotic candidate for treatment of osteoporosis diseases. (C) 2016 Wiley Periodicals, Inc.
C1 [Choi, Jae Ho; Kim, Yong An; Jin, Sun Woo; Lee, Gi Ho; Jeong, Hye Gwang] Chungnam Natl Univ, Coll Pharm, Daejeon, South Korea.
   [Han, Younho; Jeong, Hyung Min; Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.
   [Han, Younho; Jeong, Hyung Min; Lee, Kwang Youl] Chonnam Natl Univ, Res Inst Drug Dev, Kwangju 500757, South Korea.
   [Lee, Hyun Sun] Korea Res Inst Biosci & Biotechnol, Nat Med Res Ctr, Daejeon, South Korea.
   [Chung, Young Chul] Int Univ Korea, Dept Food Sci, Jinju, South Korea.
   [Lee, Young Chun; Kim, Eun Ju] Jangsaeng Doraji Co Ltd, Jangsaeng Doraji Res Inst Biotechnol, Jinju, South Korea.
C3 Chungnam National University; Chonnam National University; Chonnam
   National University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB); International University Korea
RP Lee, KY (通讯作者)，Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.; Lee, KY (通讯作者)，Chonnam Natl Univ, Res Inst Drug Dev, Kwangju 500757, South Korea.; Jeong, HG (通讯作者)，Chungnam Natl Univ, Dept Toxicol, Coll Pharm, 220 Gung Dong, Taejon 305764, South Korea.
EM kwanglee@jnu.ac.kr; hgjeong@cnu.ac.kr
RI ; jin, sun/HZL 7002 2023; Kim, Byung Yong/JLL 7806 2023
OI Kim, Yong An/0000 0003 3166 8284; Jeong, Hye Gwang/0000 0002 8020 8914
FU Ministry of Education [2009 0093815]; Korean Health Technology RD
   Project; Ministry of Health Welfare [HI14C2428]
FX Grant sponsor: Ministry of Education; Grant number: 2009 0093815; Grant
   sponsor: Korean Health Technology R&D Project; Grant sponsor: Ministry
   of Health & Welfare; Grant number: HI14C2428.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brewer L, 2011, EUR J CLIN PHARMACOL, V67, P321, DOI 10.1007/s00228 011 0999 2
   Cappola AR, 2016, JAMA J AM MED ASSOC, V316, P715, DOI 10.1001/jama.2016.11032
   Cho JH, 2012, J KOREAN NEUROSURG S, V52, P281, DOI 10.3340/jkns.2012.52.4.281
   Choi JH, 2015, J AGR FOOD CHEM, V63, P1468, DOI 10.1021/jf5043954
   Choi JH, 2014, PHYTOMEDICINE, V21, P1053, DOI 10.1016/j.phymed.2014.04.011
   Choi JH, 2009, FOOD CHEM TOXICOL, V47, P1272, DOI 10.1016/j.fct.2009.02.022
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Genant HK, 2008, RHEUMATOLOGY, V47, P9, DOI 10.1093/rheumatology/ken180
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Han EH, 2009, FOOD CHEM TOXICOL, V47, P1069, DOI 10.1016/j.fct.2009.01.041
   Hwang YP, 2013, FOOD CHEM, V140, P115, DOI 10.1016/j.foodchem.2013.02.041
   Hwang YP, 2013, TOXICOL APPL PHARM, V267, P174, DOI 10.1016/j.taap.2013.01.001
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jeong HM, 2010, FOOD CHEM TOXICOL, V48, P3362, DOI 10.1016/j.fct.2010.09.005
   Jung SY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150531
   Kesikburun S, 2014, OSTEOPOROSIS INT, V25, P2319, DOI 10.1007/s00198 014 2768 4
   Khanal T, 2009, FOOD CHEM TOXICOL, V47, P2749, DOI 10.1016/j.fct.2009.08.006
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   LEE EB, 1973, YAKUGAKU ZASSHI, V93, P1188, DOI 10.1248/yakushi1947.93.9_1188
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee KJ, 2004, TOXICOL LETT, V147, P271, DOI 10.1016/j.toxlet.2003.12.002
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Noh JR, 2010, BIOL PHARM BULL, V33, P450, DOI 10.1248/bpb.33.450
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ryu CS, 2012, FOOD CHEM, V132, P333, DOI 10.1016/j.foodchem.2011.10.086
   Sanchez de las Matas R, 2016, OSTEOPOROSIS INT, V27, pS547
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Takahashi TA, 2015, MED CLIN N AM, V99, P521, DOI 10.1016/j.mcna.2015.01.006
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Tekgul H, 2006, J CHILD NEUROL, V21, P411, DOI 10.1177/08830738060210050101
   Yoo DS, 2011, FOOD CHEM, V129, P645, DOI 10.1016/j.foodchem.2011.04.106
   Zhang L, 2015, J ETHNOPHARMACOL, V164, P147, DOI 10.1016/j.jep.2015.01.052
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
NR 37
TC 24
Z9 26
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2017
VL 118
IS 4
BP 860
EP 868
DI 10.1002/jcb.25763
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EP5LO
UT WOS:000397420300021
PM 27739107
DA 2025 08 17
ER

PT J
AU Kawazoe, M
   Kaneko, K
   Nanki, T
AF Kawazoe, Mai
   Kaneko, Kaichi
   Nanki, Toshihiro
TI Glucocorticoid therapy suppresses Wnt signaling by reducing the ratio of
   serum Wnt3a to Wnt inhibitors, sFRP 1 and Wif 1
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Glucocorticoid induced osteoporosis; sFRP 1; Wif 1; Wnt signaling
ID C REACTIVE PROTEIN; INDUCED OSTEOPOROSIS; DISEASE ACTIVITY; SCLEROSTIN;
   BONE; ROMOSOZUMAB; DICKKOPF 1; MANAGEMENT; ANTAGONIST; MECHANISMS
AB Objective Our previous study suggested that suppression of Wnt/beta catenin signaling by increasing serum Wnt co receptor inhibitors, sclerostin and Dickkopf 1, impairs bone formation in the first week after starting glucocorticoid therapy. The objective of this study was to investigate the involvement of the Wnt/beta catenin signaling pathway and its clinical significance in the subsequent suppression of bone formation.
   Methods A total of 53 patients with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30 60 mg daily) were prospectively enrolled. We measured serum levels of Wnt3a and Wnt inhibitors, secreted Frizzled related protein 1 (sFRP 1) and Wnt inhibitory factor 1 (Wif 1), before starting glucocorticoid therapy and every week for 4 weeks after its initiation.
   Results Serum levels of sFRP 1 and Wif 1 slightly decreased compared with before glucocorticoid therapy from the second week. The serum Wnt3a level decreased from the first week. The ratios of Wnt3a to sFRP 1 and that of Wnt3a to Wif 1 both decreased from the first week onward.
   Conclusion The reduction of the ratio of Wnt3a to Wnt inhibitors, sFRP 1 and Wif 1, suppresses Wnt signaling, which may result in impaired bone formation. Taken together with our previous studies, glucocorticoids may suppress Wnt signaling by inhibiting co receptors of the Wnt/beta catenin signaling pathway in the early phase of glucocorticoid therapy and inhibiting its ligand in the subsequent weeks, which together impair bone formation.
C1 [Kawazoe, Mai; Kaneko, Kaichi; Nanki, Toshihiro] Toho Univ, Fac Med, Sch Med, Dept Internal Med,Div Rheumatol,Ota Ku, 6 11 1 Omori Nishi, Tokyo 1438541, Japan.
C3 Toho University
RP Nanki, T (通讯作者)，Toho Univ, Fac Med, Sch Med, Dept Internal Med,Div Rheumatol,Ota Ku, 6 11 1 Omori Nishi, Tokyo 1438541, Japan.
EM toshihiro.nanki@med.toho u.ac.jp
OI Kawazoe, Mai/0000 0002 9822 8067
FU Toho University School of Medicine [17 12, 18 26]; Nukada scholarship
   for Medical Research from Toho University School of Medicine; Toho
   University Graduate School of Medicine [17 01]; Program for the
   Strategic Research Foundation for Private Universities from the Ministry
   of Education, Culture, Sports, Science, and Technology, Japan
   [S1411015]; Private University Research Branding Project from the
   Ministry of Education, Culture, Sports, Science, and Technology, Japan
FX This study was partly supported by a Project Research Grant (No. 17 12,
   18 26) from Toho University School of Medicine to MK; the Nukada
   scholarship for Medical Research from Toho University School of Medicine
   to MK; a Research Promotion Grant from Toho University Graduate School
   of Medicine (No. 17 01) to TN; the Program for the Strategic Research
   Foundation for Private Universities (S1411015) from the Ministry of
   Education, Culture, Sports, Science, and Technology, Japan to TN; and
   the Private University Research Branding Project from the Ministry of
   Education, Culture, Sports, Science, and Technology, Japan to TN.
CR Bagnari V, 2010, RHEUMATOL INT, V30, pCP9, DOI 10.1007/s00296 009 1291 y
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Belaya ZE, 2013, OSTEOPOROSIS INT, V24, P2191, DOI 10.1007/s00198 013 2268 y
   BERTOUCH JV, 1983, ANN RHEUM DIS, V42, P655, DOI 10.1136/ard.42.6.655
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chung YE, 2012, OSTEOPOROSIS INT, V23, P1235, DOI 10.1007/s00198 011 1675 1
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Fassio A, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00551
   Fassio A, 2020, CALCIFIED TISSUE INT, V106, P371, DOI 10.1007/s00223 019 00649 3
   GABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Güler Yüksel M, 2018, CALCIFIED TISSUE INT, V102, P592, DOI 10.1007/s00223 017 0335 7
   Kawazoe M, 2018, CLIN RHEUMATOL, V37, P2169, DOI 10.1007/s10067 017 3689 3
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kermani TA, 2012, SEMIN ARTHRITIS RHEU, V41, P866, DOI 10.1016/j.semarthrit.2011.10.005
   Ma YB, 2018, INT IMMUNOPHARMACOL, V59, P227, DOI 10.1016/j.intimp.2018.04.019
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Pelletier S, 2013, CLIN J AM SOC NEPHRO, V8, P819, DOI 10.2215/CJN.07670712
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Surmann Schmitt C, 2009, J CELL SCI, V122, P3627, DOI 10.1242/jcs.048926
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Tang L, 2019, MOL MED REP, V20, P270, DOI 10.3892/mmr.2019.10252
   Tse WY, 1998, POSTGRAD MED J, V74, P1, DOI 10.1136/pgmj.74.867.1
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Zhou MR, 2018, MOL MED REP, V17, P970, DOI 10.3892/mmr.2017.7997
NR 34
TC 14
Z9 15
U1 0
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JUL
PY 2021
VL 40
IS 7
BP 2947
EP 2954
DI 10.1007/s10067 020 05554 x
EA JAN 2021
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA SQ7AF
UT WOS:000606371000004
PM 33420868
DA 2025 08 17
ER

PT J
AU Saleh, A
   Hegde, VV
   Potty, AG
   Lane, JM
AF Saleh, Anas
   Hegde, Vishal V.
   Potty, Anish G.
   Lane, Joseph M.
TI Bisphosphonate Therapy and Atypical Fractures
SO ORTHOPEDIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Bisphosphonate therapy; Atypical fractures; Osteoporosis; Atypical
   femoral fractures
ID SUPPRESSED BONE TURNOVER; FEMORAL SHAFT FRACTURES; NITROGEN CONTAINING
   BISPHOSPHONATES; SUBTROCHANTERIC STRESS FRACTURES; DIAPHYSEAL FEMUR
   FRACTURES; VITAMIN D SUPPLEMENTATION; POSTMENOPAUSAL WOMEN;
   PARATHYROID HORMONE; CORTICAL BONE; MICRODAMAGE ACCUMULATION
AB Atypical femoral fractures have attracted a great deal of attention and controversy in the osteoporosis community because of their association with prolonged bisphosphonate therapy. The purpose of this article is to review the epidemiologic evidence linking bisphosphonates to atypical fractures and to highlight the potential pathologic mechanisms involved in such fractures. A management plan is provided based on the available evidence.
C1 [Saleh, Anas; Potty, Anish G.; Lane, Joseph M.] Hosp Special Surg, Dept Orthopaed Surg, New York, NY 10021 USA.
   [Hegde, Vishal V.] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine
RP Lane, JM (通讯作者)，Hosp Special Surg, Metab Bone Dis Serv, Dept Orthopaed Surg, 535 E 70th St, New York, NY 10021 USA.
EM Lanej@hss.edu
RI potty, anish/AAE 2518 2019
CR Abrahamsen B, 2010, J CLIN ENDOCR METAB, V95, P5258, DOI 10.1210/jc.2010 1571
   Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Allen MR, 2007, J BONE MINER RES, V22, P1759, DOI 10.1359/JBMR.070720
   Allen MR, 2006, BONE, V39, P1130, DOI 10.1016/j.bone.2006.05.007
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Andreassen TT, 2001, ACTA ORTHOP SCAND, V72, P304, DOI 10.1080/00016470152846673
   [Anonymous], 2011, FOOD ADVISORY COMMIT
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   BAILEY AJ, 1992, BIOCHEM BIOPH RES CO, V185, P801, DOI 10.1016/0006 291X(92)91697 O
   Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Bischoff Ferrari HA, 2004, AM J CLIN NUTR, V80, P752
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Boskey AL, 2009, OSTEOPOROSIS INT, V20, P793, DOI 10.1007/s00198 008 0725 9
   Brennan O, 2011, J ORTHOP RES, V29, P419, DOI 10.1002/jor.21229
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   CONNOLLY JF, 1991, CLIN ORTHOP RELAT R, P259
   Dell R, 2012, ANN M AM AC ORTH SUR
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Feldstein AC, 2012, J BONE MINER RES, V27, P977, DOI 10.1002/jbmr.1550
   Giusti A, 2011, BONE, V48, P966, DOI 10.1016/j.bone.2010.12.033
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Gomberg SJ, 2011, J CLIN ENDOCR METAB, V96, P1627, DOI 10.1210/jc.2010 2520
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heaney RP, 2011, J BONE MINER RES, V26, P455, DOI 10.1002/jbmr.328
   Heaney RP, 2003, AM J CLIN NUTR, V77, P204, DOI 10.1093/ajcn/77.1.204
   Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215
   Hernigou P, 2006, J BONE JOINT SURG AM, V88A, P2565, DOI 10.2106/JBJS.E.01455
   Holick MF, 2007, DRUG AGING, V24, P1017, DOI 10.2165/00002512 200724120 00005
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   Hollis BW, 2005, NEW ENGL J MED, V352, P515
   Kim SY, 2011, J BONE MINER RES, V26, P993, DOI 10.1002/jbmr.288
   Koh JSB, 2011, SINGAP MED J, V52, P77
   Koh JSB, 2010, J ORTHOP TRAUMA, V24, P75, DOI 10.1097/BOT.0b013e3181b6499b
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Lo JC, 2012, BONE, V51, P181, DOI 10.1016/j.bone.2012.02.632
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martinez MD, 2010, BONE, V46, P1604, DOI 10.1016/j.bone.2010.02.030
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Napoli N, 2012, J CLIN ENDOCR METAB, V97, P2414, DOI 10.1210/jc.2011 3256
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nieves JW, 2010, OSTEOPOROSIS INT, V21, P399, DOI 10.1007/s00198 009 0962 6
   Odetti P, 2005, ANN NY ACAD SCI, V1043, P710, DOI 10.1196/annals.1333.082
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Oxlund H, 1996, BONE, V19, P479, DOI 10.1016/S8756 3282(96)00283 9
   OXLUND H, 1995, BONE, V17, pS365, DOI 10.1016/8756 3282(95)00328 B
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Renders GAP, 2011, J BIOMECH, V44, P402, DOI 10.1016/j.jbiomech.2010.10.004
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Rosenberg ZS, 2011, AM J ROENTGENOL, V197, P954, DOI 10.2214/AJR.10.6262
   Ross C., 2011, DIETARY REFERENCE IN, P1132
   Saito M, 2008, OSTEOPOROSIS INT, V19, P1343, DOI 10.1007/s00198 008 0585 3
   Saleh Anas, 2012, HSS J, V8, P103, DOI 10.1007/s11420 012 9275 y
   Salminen S, 1997, J TRAUMA, V43, P117, DOI 10.1097/00005373 199707000 00027
   Salminen ST, 2000, CLIN ORTHOP RELAT R, P241
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Skripitz R, 2000, J BONE JOINT SURG BR, V82B, P138, DOI 10.1302/0301 620X.82B1.9729
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056
   Tang SY, 2010, BONE, V46, P148, DOI 10.1016/j.bone.2009.09.003
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Tang WM, 2005, J ORTHOP RES, V23, P41, DOI 10.1016/j.orthres.2004.06.013
   Tiedeman JJ, 1995, ORTHOPEDICS, V18, P1153
   TIEDEMAN JJ, 1991, CLIN ORTHOP RELAT R, P294
   Unnanuntana A, 2012, CLIN ORTHOP RELAT R, V470, P291, DOI 10.1007/s11999 011 1985 9
   Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756 3282(00)00434 8
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Vestergaard P, 2011, OSTEOPOROSIS INT, V22, P993, DOI 10.1007/s00198 010 1512 y
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756 3282(01)00697 4
   Wang Z, 2011, J BONE MINER RES, V26, P553, DOI 10.1002/jbmr.233
   Weil YA, 2011, J TRAUMA, V71, P186, DOI 10.1097/TA.0b013e31821957e3
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Wright JG, 2006, J BONE JOINT SURG BR, V88B, P1264, DOI 10.1302/0301 620X.88B9.18389
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 94
TC 31
Z9 34
U1 0
U2 12
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0030 5898
EI 1558 1373
J9 ORTHOP CLIN N AM
JI Orthop. Clin. North Am.
PD APR
PY 2013
VL 44
IS 2
BP 137
EP +
DI 10.1016/j.ocl.2013.01.001
PG 16
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 148GZ
UT WOS:000319234000003
PM 23544820
DA 2025 08 17
ER

PT J
AU Liu, YM
   Fu, BL
   Li, XM
   Chen, C
   Li, XC
   Xu, LL
   Wang, B
AF Liu, Yamei
   Fu, Binlan
   Li, Xiaoman
   Chen, Chen
   Li, Xican
   Xu, Liangliang
   Wang, Bin
TI Bushen huoxue decoction inhibits RANKL stimulated osteoclastogenesis and
   glucocorticoid induced bone loss by modulating the NF κB, ERK, and JNK
   signaling pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE bushen huoxue decoction; osteoporosis; NF kappa B pathway; ERK pathway;
   JNK pathway
ID INDUCED OSTEOPOROSIS; RECEPTOR ACTIVATOR; DIFFERENTIATION; OSTEOBLASTS;
   MECHANISMS; LIGAND; OSTEOPROTEGERIN; ADIPOCYTES; MANAGEMENT; CELLS
AB Glucocorticoid induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, which is caused by a disorder in bone metabolism due to excessive activation of osteoclasts. Bushen Huoxue decoction (BHD) is an herbal formula with multiple pharmacological effects, including anti inflammatory, antioxidant activity and stem cell migration promotion. However, the effect of BHD on osteoclastogenesis has not been reported. In this study, we aimed to elucidate the effect of BHD on RANKL stimulated osteoclastogenesis and explored its underlying mechanisms of action in vitro. Our results show that BHD had no effect on BMMs and RAW264.7 cells viability, but inhibited RANKL induced osteoclast formation in vitro. Furthermore, BHD attenuated RANKL induced NF kappa B, ERK, and JNK signaling. The attenuation of NF kappa B, ERK, and JNK activation were enough to impede downstream expression of c fos and NFATc1 and related specific genes. Meanwhile, we investigated the therapeutic effect of BHD on glucocorticoid induced osteoporosis (GIOP) mice. The result indicated that BHD prevents glucocorticoid induced osteoporosis and preserves bone volume by repressing osteoclast activity. Collectively, BHD shows significant osteoclast inhibition and holds great promise in the treatment of osteoporosis.
C1 [Liu, Yamei; Fu, Binlan; Li, Xiaoman] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China.
   [Fu, Binlan; Li, Xiaoman] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthoped & Traumatol, Guangzhou, Peoples R China.
   [Chen, Chen; Li, Xican] Guangzhou Univ Chinese Med, Sch Chinese Herbal Med, Guangzhou, Peoples R China.
   [Xu, Liangliang] First Affiliated Hosp Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Wang, Bin] Third Affiliated Hosp Guangzhou Univ Chinese Med, Dept Traumatol, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xu, LL (通讯作者)，First Affiliated Hosp Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.; Wang, B (通讯作者)，Third Affiliated Hosp Guangzhou Univ Chinese Med, Dept Traumatol, Guangzhou, Peoples R China.
EM gztcmwangbin1973@163.com; xull 2016@gzucm.edu.cn
RI bin, wang/X 9166 2019; Li, Xican/R 7344 2019; XU,
   LIANGLIANG/AAZ 7935 2020
OI Xu, Liangliang/0000 0002 5249 7480
FU National Natural Science Foundation of China;  [81873326]
FX Funding This work was supported by the National Natural Science
   Foundation of China (Grant No. 81873326).
CR Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Colditz J, 2019, J BONE MINER RES, V34, P1314, DOI 10.1002/jbmr.3702
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Dineen R, 2019, CLIN ENDOCRINOL, V90, P3, DOI 10.1111/cen.13837
   Dong R, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/2734581
   Dovio A, 2006, EUR J ENDOCRINOL, V154, P745, DOI 10.1530/eje.1.02147
   Feng SH, 2021, ANN PALLIAT MED, V10, P3783, DOI 10.21037/apm 20 2586
   Feng XL, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/6868470
   Gao QQ, 2016, BIOMED CHROMATOGR, V30, P528, DOI 10.1002/bmc.3578
   Hildebrandt S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65962 6
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Hu SF, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153256
   Huang C, 2017, J ETHNOPHARMACOL, V208, P44, DOI 10.1016/j.jep.2017.06.022
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li JC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 7040
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Li M, 2016, COMPLEMENT THER MED, V29, P116, DOI 10.1016/j.ctim.2016.09.008
   Liu J, 2020, MOLECULES, V25, DOI 10.3390/molecules25030674
   Liu SY, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.02.33
   Lu YJ, 2015, J CHROMATOGR B, V993, P75, DOI 10.1016/j.jchromb.2015.04.021
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sakaida H, 2017, AURIS NASUS LARYNX, V44, P762, DOI 10.1016/j.anl.2016.11.002
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shen W, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0200 2
   Silverman S, 2015, OSTEOPOROSIS INT, V26, P419, DOI 10.1007/s00198 014 2883 2
   Suehs CM, 2021, AM J RESP CRIT CARE, V203, P871, DOI 10.1164/rccm.202007 2721OC
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wong RWK, 2010, PHYTOTHER RES, V24, pS155, DOI 10.1002/ptr.3049
   Wu ZD, 1996, MOL CELL BIOL, V16, P4128
   Xia CJ, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110170
   Yang YJ, 2018, ACTA PHARMACOL SIN, V39, P633, DOI 10.1038/aps.2017.134
   Ye SF, 2014, MOL MED REP, V10, P1635, DOI 10.3892/mmr.2014.2355
   Yu H, 2021, J ETHNOPHARMACOL, V266, DOI 10.1016/j.jep.2020.113447
   Zhang SQ, 2017, MOL MED REP, V16, P3994, DOI 10.3892/mmr.2017.7039
   Zhu HY, 2020, J SEP SCI, V43, P2053, DOI 10.1002/jssc.201900846
NR 53
TC 6
Z9 7
U1 1
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 18
PY 2022
VL 13
AR 1007839
DI 10.3389/fphar.2022.1007839
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 7T5JU
UT WOS:000911483300001
PM 36467086
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, G
   Ma, C
   Chen, K
   Wang, ZY
   Qiu, H
   Chen, DL
   He, JB
   Zhang, C
   Guo, D
   Lai, BY
   Zhang, SX
   Huang, LF
   Yang, F
   Yuan, JB
   Chen, LL
   He, W
   Xu, JK
AF Wang, Gang
   Ma, Chao
   Chen, Kai
   Wang, Ziyi
   Qiu, Heng
   Chen, Delong
   He, Jianbo
   Zhang, Cheng
   Guo, Ding
   Lai, Boyong
   Zhang, Shuangxiao
   Huang, Linfeng
   Yang, Fan
   Yuan, Jinbo
   Chen, Leilei
   He, Wei
   Xu, Jiake
TI Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting
   RANKL Induced Nrf2/Keap1/ARE, NF κB, Calcium, and NFATc1 Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE cycloastragenol; osteoclast; RANKL; Nfatc1; ROS
ID RECEPTOR ACTIVATOR; DIFFERENTIATION; EXPRESSION; INHIBITION; INDUCTION;
   FRACTURE; CLONING; LIGAND; WOMEN; RISK
AB Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol (CAG) is a triterpenoid with multiple biological activities. Previously, CAG's activity against aging related osteoporosis was reported, but the mechanisms of actions for the activities were not understood. This study demonstrated that CAG dose dependently inhibited osteoclast formation in receptor activator of nuclear factor kappa B ligand (RANKL) stimulated bone marrow macrophage (BMMs). Mechanism studies showed that CAG inhibited NF kappa B, calcium, and nuclear factor of activated T cells 1 (NFATc1) pathways. Additionally, CAG also promoted the nuclear factor erythroid 2 related factor 2 (Nrf2)/Kelch like ECH associated protein 1 (Keap1)/anti oxidative response element (ARE) pathway that scavenges reactive oxygen species (ROS). Furthermore, CAG was also found to prevent bone loss of postmenopausal osteoporosis (PMO) in a preclinical model of ovariectomized (OVX) mice. Collectively, our research confirms that CAG inhibits the formation and function of osteoclasts by regulating RANKL induced intracellular signaling pathways, which may represent a promising alternative for the therapy of osteoclast related disease.
C1 [Wang, Gang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Wang, Gang; Chen, Kai; Wang, Ziyi; Qiu, Heng; Chen, Delong; He, Jianbo; Yuan, Jinbo; Xu, Jiake] Univ WA, Sch Biomed Sci, Perth, WA, Australia.
   [Wang, Gang; Ma, Chao; Chen, Delong; He, Jianbo; Zhang, Cheng; Guo, Ding; Lai, Boyong; Zhang, Shuangxiao; Huang, Linfeng; Yang, Fan; Chen, Leilei; He, Wei] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Chen, Leilei; He, Wei] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; University of Western
   Australia; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Xu, JK (通讯作者)，Univ WA, Sch Biomed Sci, Perth, WA, Australia.; Chen, LL; He, W (通讯作者)，Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.; Chen, LL; He, W (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
EM yutian_1010@sina.com; heweiboneresearch@163.com; jiake.xu@uwa.edu.au
RI ; Yang, Fan/AAA 6904 2022; Chen, KaiJie/A 1743 2016; zhang,
   cheng/NHP 9389 2025; He, Jianbo/H 4917 2018
OI wang, gang/0000 0002 3769 0784; Ma, Chao/0000 0002 1049 6172; Chen,
   Kai/0000 0001 6850 1723; Qiu, Heng/0000 0002 0864 317X; Yuan,
   Jinbo/0000 0002 6240 9333; Xu, Jiake/0000 0003 2021 8309; Ma,
   Chao/0000 0002 7735 235X; Wang, Ziyi/0000 0002 1334 7287
FU Australian National Health and Medical Research Council [APP1163933];
   National Natural Science Foundation of China [81873327]; Science and
   Technology Planning Project of Guangdong Province [2017B090912007];
   Visiting Program for Graduate Students from Guangzhou University of
   Chinese Medicine (GZUCM) [(2017)74]; Discipline collaborative innovation
   team project of double first class and high level university of GZUCM
   [2021XK05]
FX Australian National Health and Medical Research Council (APP1163933);
   National Natural Science Foundation of China (Grant No. 81873327);
   Science and Technology Planning Project of Guangdong Province (Grant No.
   2017B090912007); Visiting Program for Graduate Students from Guangzhou
   University of Chinese Medicine (GZUCM) (Grant No. (2017)74); Discipline
   collaborative innovation team project of double first class and
   high level university of GZUCM (No. 2021XK05).
CR [Anonymous], 1993, AM J MED, V95, p1S
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   Davis SR, 2012, CLIMACTERIC, V15, P419, DOI 10.3109/13697137.2012.707385
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706
   LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Otero JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038694
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wu JH, 2021, PHYTOTHER RES, V35, P2034, DOI 10.1002/ptr.6946
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yu YJ, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110304
   Yu YJ, 2018, EXP THER MED, V16, P2175, DOI 10.3892/etm.2018.6501
NR 43
TC 21
Z9 23
U1 7
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 20
PY 2022
VL 12
AR 810322
DI 10.3389/fphar.2021.810322
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA YV4DO
UT WOS:000752680400001
PM 35126144
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Roelofs, AJ
   Coxon, FP
   Ebetino, FH
   Lundy, MW
   Henneman, ZJ
   Nancollas, GH
   Sun, ST
   Blazewska, KM
   Bala, JLF
   Kashemirov, BA
   Khalid, AB
   McKenna, CE
   Rogers, MJ
AF Roelofs, Anke J.
   Coxon, Fraser P.
   Ebetino, Frank H.
   Lundy, Mark W.
   Henneman, Zachary J.
   Nancollas, George H.
   Sun, Shuting
   Blazewska, Katarzyna M.
   Bala, Joy Lynn F.
   Kashemirov, Boris A.
   Khalid, Aysha B.
   McKenna, Charles E.
   Rogers, Michael J.
TI Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone
   Marrow Monocytes and Localization Around Osteocytes In Vivo
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BISPHOSPHONATES; FLUORESCENT CONJUGATES; CELLULAR UPTAKE; OSTEOCYTES;
   MONOCYTES
ID NITROGEN CONTAINING BISPHOSPHONATES; DELTA T CELLS; OSTEOCLAST
   PRECURSORS; MEVALONATE PATHWAY; INHIBITION; ALENDRONATE; PRENYLATION;
   ACTIVATION; RESORPTION; APOPTOSIS
AB Bisphosphonates are effective antiresorptive agents owing to their bone targeting property and ability to inhibit osteoclasts. It remains unclear, however, whether any non osteoclast cells are directly affected by these drugs in vivo. Two fluorescent risedronate analogues, carboxyfluorescein labeled risedronate (FAM RIS) and Alexa Fluor 647 labeled risedronate (AF647 RIS), were used to address this question. Twenty four hours after injection into 3 month old mice, fluorescent risedronate analogues were bound to bone surfaces. More detailed analysis revealed labeling of vascular channel walls within cortical bone. Furthermore, fluorescent risedronate analogues were present in osteocytic lacunae in close proximity to vascular channels and localized to the lacunae of newly embedded osteocytes close to the bone surface. Following injection into newborn rabbits, intracellular uptake of fluorescently labeled risedronate was detected in osteoclasts, and the active analogue FAM RIS caused accumulation of unprenylated Rap1A in these cells. In addition, CD14(high) bone marrow monocytes showed relatively high levels of uptake of fluorescently labeled risedronate, which correlated with selective accumulation of unprenylated Rap1A in CD14(+) cells, as well as osteoclasts, following treatment with risedronate in vivo. Similar results were obtained when either rabbit or human bone marrow cells were treated with fluorescent risedronate analogues in vitro. These findings suggest that the capacity of different cell types to endocytose bisphosphonate is a major determinant for the degree of cellular drug uptake in vitro as well as in vivo. In conclusion, this study shows that in addition to bone resorbing osteoclasts, bisphosphonates may exert direct effects on bone marrow monocytes in vivo. (C) 2010 American Society for Bone and Mineral Research.
C1 [Roelofs, Anke J.; Coxon, Fraser P.; Khalid, Aysha B.; Rogers, Michael J.] Univ Aberdeen, Bone & Musculoskeletal Res Programme, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   [Ebetino, Frank H.] Warner Chilcott Pharmaceut, Mason, OH USA.
   [Lundy, Mark W.] MDS Pharma Serv, Bothell, WA USA.
   [Henneman, Zachary J.; Nancollas, George H.] SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA.
   [Sun, Shuting; Blazewska, Katarzyna M.; Bala, Joy Lynn F.; Kashemirov, Boris A.; McKenna, Charles E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.
C3 University of Aberdeen; State University of New York (SUNY) System;
   University at Buffalo, SUNY; University of Southern California
RP Roelofs, AJ (通讯作者)，Univ Aberdeen, Bone & Musculoskeletal Res Programme, Inst Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM a.roelofs@abdn.ac.uk
RI Roelofs, Anke/ABG 5019 2021; Blazewska, Katarzyna M./M 3722 2018;
   Błażewska, Katarzyna/M 3722 2018; Sun, Shuting/N 1807 2014
OI Blazewska, Katarzyna M./0000 0002 1218 7111; Sun,
   Shuting/0000 0002 3635 9029; Rogers, Michael/0000 0002 1818 9249
FU Alliance for Better Bone Health; Novartis; Merck; Roche; Cancer Research
   UK [C13325]; USC WiSE Program; National Institute of Health, NIDCR
   [DE03223]
FX MJR has received research grant funding from the Alliance for Better
   Bone Health, Novartis, Merck, and Roche. AJR and FPC have received
   research grant funding from the Alliance for Better Bone Health. FHE is
   an employee of Warner Chilcott Pharmaceuticals (formerly Procter &
   Gamble Pharmaceuticals). MWL is a former employee of Procter & Gamble
   Pharmaceuticals. CEMcK has received grant funding from and has been a
   consultant for the Alliance for Better Bone Health. GHN has received
   research grant funding from the Alliance for Better Bone Health.This
   work was supported by research funding from Cancer Research UK, Grant
   No. C13325 (MJR and AJR), the Alliance for Better Bone Health (MJR, FPC,
   AJR, CEMcK, BAK, SS, KMB, and JFB), the USC WiSE Program (KMB), and the
   National Institute of Health, NIDCR Grant No. DE03223 (GHN).
CR AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Bonneville M, 2006, CURR OPIN IMMUNOL, V18, P539, DOI 10.1016/j.coi.2006.07.002
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 2003, METH MOLEC MED, V80, P89
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kozloff KM, 2007, J BONE MINER RES, V22, P1208, DOI 10.1359/JBMR.070504
   Kunzmann V, 2000, BLOOD, V96, P384
   LeGeros R Z, 1991, Monogr Oral Sci, V15, P1
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555 006 9001 7
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roelofs AJ, 2006, INT J CANCER, V119, P1254, DOI 10.1002/ijc.21977
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Yamagishi S, 2004, AM J PATHOL, V165, P1865, DOI 10.1016/S0002 9440(10)63239 7
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
NR 38
TC 136
Z9 151
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2010
VL 25
IS 3
BP 606
EP 616
DI 10.1359/jbmr.091009
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 584QP
UT WOS:000276767700022
PM 20422624
OA Green Published
DA 2025 08 17
ER

PT J
AU Long, MM
   Liu, XM
   Huang, X
   Lu, M
   Wu, XM
   Weng, LY
   Chen, QP
   Wang, XT
   Zhu, L
   Chen, ZP
AF Long, Mengmeng
   Liu, Xuemeng
   Huang, Xu
   Lu, Min
   Wu, Xiaomei
   Weng, Lingyan
   Chen, Qiuping
   Wang, Xueting
   Zhu, Li
   Chen, Zhongping
TI Alendronate functionalized hypoxia responsive polymeric micelles for
   targeted therapy of bone metastatic prostate cancer
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Bone metastasis; Polymeric micelles; Alendronate; Bone targeted
   delivery; Hypoxia responsive release
ID DYNAMIC LIGHT SCATTERING; DRUG DELIVERY; NANOPARTICLES; BISPHOSPHONATES;
   MECHANISMS; LIPOSOMES; OXIDE; PAIN
AB Bone metastasis is one of the leading causes of cancer related death and remains incurable in spite of great efforts. Bone targeted nanoparticle based drug carriers can overcome the difficulties in delivering therapeutic agents to metastatic bone and endowing them with a stimuli responsive feature for controllable drug release can further maximize their therapeutic outcome. In light of hypoxic microenvironment of bone metastasis, we herein reported a bone targeted and hypoxia responsive polymeric micelle system for effective treatment of bone metastatic prostate cancer. The micelles were self assembled from a polyethylene glycol and poly L lysine based copolymer using alendronate as a bone targeted moiety and azobenzene as a hypoxia responsive linker, showing a high affinity to metastatic bone and a high sensitivity in responding to hypoxia in vitro. In vivo studies further showed that after a selective accumulation in metastatic bone, the micelles could respond to hypoxic bone metastasis for rapid drug release to an effective therapeutic dosage. As a result, the micelles could suppress tumor growth in bone and inhibit bone destruction by inhibiting osteoclast activity and promoting osteoblast activity, achieving an enhanced therapeutic outcome with relieved bone pain and prolonged survival time. Bone targeted and hypoxia responsive nanocarriers therefore represent a promising advancement for treating bone metastasis. To our best knowledge, it might be the first example of the application of hypoxia responsive nanocarriers in treating bone metastasis.
C1 [Long, Mengmeng; Liu, Xuemeng; Huang, Xu; Lu, Min; Wu, Xiaomei; Weng, Lingyan; Wang, Xueting; Zhu, Li; Chen, Zhongping] Nantong Univ, Inst Special Environm Med, Nantong, Peoples R China.
   [Chen, Qiuping] Nantong Univ, Dept Anesthesiol, Affiliated Hosp, Nantong, Peoples R China.
C3 Nantong University; Nantong University
RP Wang, XT; Zhu, L; Chen, ZP (通讯作者)，Nantong Univ, Inst Special Environm Med, Nantong, Peoples R China.
EM wangxueting@ntu.edu.cn; zhulizhou@ntu.edu.cn; chenzp@ntu.edu.cn
RI ; Chen, qiu/LCE 1743 2024; wang, xueting/JPY 2782 2023
OI Chen, Zhongping/0000 0002 3344 1449; 
FU National Natural Science Foundation of China [81401506, 81971131,
   81873924]; Open Research Fund of State Key Laboratory of Bioelectronics,
   Southeast University [OPSKLB202007]
FX The work was supported by the National Natural Science Foundation of
   China (81401506, 81971131, and 81873924) and the Open Research Fund of
   State Key Laboratory of Bioelectronics, Southeast University
   (OPSKLB202007) .
CR Adjei IM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040205
   Adjei IM, 2016, J CONTROL RELEASE, V232, P83, DOI 10.1016/j.jconrel.2016.04.019
   Aielli F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020280
   Akoury E, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0745 x
   Bai SB, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102054
   Boevé LMS, 2019, EUR UROL, V75, P410, DOI 10.1016/j.eururo.2018.09.008
   CAVALLINI L, 1983, BIOCHIM BIOPHYS ACTA, V752, P339, DOI 10.1016/0005 2760(83)90132 7
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Coenegrachts L, 2010, CANCER RES, V70, P6537, DOI 10.1158/0008 5472.CAN 09 4092
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Danaei M, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020057
   Feng SS, 2019, ACS APPL MATER INTER, V11, P7357, DOI 10.1021/acsami.8b18820
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Ito T, 2004, LANGMUIR, V20, P6940, DOI 10.1021/la049524t
   Johnson RW, 2017, CURR OSTEOPOROS REP, V15, P231, DOI 10.1007/s11914 017 0378 8
   Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674
   Ke XZ, 2017, DRUG DELIV, V24, P1680, DOI 10.1080/10717544.2017.1396384
   Kumari R, 2020, J CONTROL RELEASE, V319, P135, DOI 10.1016/j.jconrel.2019.12.041
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Li Y, 2019, ACTA BIOMATER, V83, P334, DOI 10.1016/j.actbio.2018.10.029
   Li YC, 2020, CANCER LETT, V490, P31, DOI 10.1016/j.canlet.2020.05.032
   Lim C, 2019, J CONTROL RELEASE, V295, P164, DOI 10.1016/j.jconrel.2018.12.043
   Long MM, 2020, ACTA BIOMATER, V115, P343, DOI 10.1016/j.actbio.2020.07.061
   Manzanares D, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040371
   Mu CF, 2018, BIOMATERIALS, V155, P191, DOI 10.1016/j.biomaterials.2017.11.029
   Müller DIH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65305 5
   Nagae M, 2007, J BONE MINER METAB, V25, P99, DOI 10.1007/s00774 006 0734 8
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Panchal J, 2014, AAPS J, V16, P440, DOI 10.1208/s12248 014 9579 6
   Piao W, 2013, ANGEW CHEM INT EDIT, V52, P13028, DOI 10.1002/anie.201305784
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roodman G.D., 2019, BASIC APPL BONE BIOL, P411
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Sowder ME, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10126
   Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012
   Sukhanova A, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671 018 2457 x
   Thambi T, 2016, ACTA BIOMATER, V29, P261, DOI 10.1016/j.actbio.2015.10.011
   Nguyen TT, 2016, J MOL MODEL, V22, DOI 10.1007/s00894 016 3029 6
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Pham TT, 2019, J IND ENG CHEM, V76, P310, DOI 10.1016/j.jiec.2019.03.055
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Verwilst P, 2017, BIOMATERIALS, V115, P104, DOI 10.1016/j.biomaterials.2016.11.023
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zhao RZ, 2019, CAN J PHYSIOL PHARM, V97, P980, DOI 10.1139/cjpp 2019 0092
   Zhao Z, 2019, CHEM PHYS LIPIDS, V223, DOI 10.1016/j.chemphyslip.2019.104785
NR 51
TC 60
Z9 60
U1 3
U2 124
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 10
PY 2021
VL 334
BP 303
EP 317
DI 10.1016/j.jconrel.2021.04.035
EA MAY 2021
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA SN5ZK
UT WOS:000658367200003
PM 33933517
DA 2025 08 17
ER

PT J
AU Grosso, MJ
   Courtland, HW
   Yang, X
   Sutherland, JP
   Stoner, K
   Nguyen, J
   Fahlgren, A
   Ross, FP
   van der Meulen, MCH
   Bostrom, MP
AF Grosso, Matthew J.
   Courtland, Hayden William
   Yang, Xu
   Sutherland, James P.
   Stoner, Kirsten
   Nguyen, Joseph
   Fahlgren, Anna
   Ross, F. Patrick
   van der Meulen, Marjolein C. H.
   Bostrom, Mathias P.
TI Intermittent PTH Administration and Mechanical Loading Are Anabolic for
   Periprosthetic Cancellous Bone
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE implants; mechanical loading; intermittent PTH; periprosthetic bone mass
ID PARATHYROID HORMONE; IN VIVO; OSTEOBLAST APOPTOSIS; IMPLANT STABILITY;
   GENE EXPRESSION; CORTICAL BONE; ALENDRONATE; STIMULATION; INCREASES;
   BISPHOSPHONATES
AB The purpose of this study was to determine the individual and combined effects on periprosthetic cancellous bone of intermittent parathyroid hormone administration (iPTH) and mechanical loading at the cellular, molecular, and tissue levels. Porous titanium implants were inserted bilaterally on the cancellous bone of adult rabbits beneath a loading device attached to the distal lateral femur. The left femur received a sham loading device. The right femur was loaded daily, and half of the rabbits received daily PTH. Periprosthetic bone was evaluated up to 28 days for gene expression, histology, and mu CT analysis. Loading and iPTH increased bone mass by a combination of two mechanisms: (1) Altering cell populations in a pro osteoblastic/anti adipocytic direction, and (2) controlling bone turnover by modulating the RANKL OPG ratio. At the tissue level, BV/TV increased with both loading (+53%, p<0.05) and iPTH (+54%, p<0.05). Combined treatment showed only small additional effects at the cellular and molecular levels that corresponded to a small additive effect on bone volume (+13% compared to iPTH alone, p>0.05). This study suggests that iPTH and loading are potential therapies for enhancing periprosthetic bone formation. The elucidation of the cellular and molecular response may help further enhance the combined therapy and related targeted treatment strategies. (C) 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 [Grosso, Matthew J.; Courtland, Hayden William; Yang, Xu; Sutherland, James P.; Stoner, Kirsten; Nguyen, Joseph; Fahlgren, Anna; Ross, F. Patrick; van der Meulen, Marjolein C. H.; Bostrom, Mathias P.] Hosp Special Surg, Lab Mineralized Tissue Res, New York, NY 10021 USA.
   [Grosso, Matthew J.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA.
   [Fahlgren, Anna] Linkoping Univ, Dept Clin & Expt Med, SE 58183 Linkoping, Sweden.
   [van der Meulen, Marjolein C. H.] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA.
C3 Cleveland Clinic Foundation; University System of Ohio; Case Western
   Reserve University; Linkoping University; Cornell University
RP Bostrom, MP (通讯作者)，Hosp Special Surg, Lab Mineralized Tissue Res, 535 East 70th St, New York, NY 10021 USA.
EM bostromm@hss.edu
RI ; Fahlgren, Anna/KCK 3057 2024; van der Meulen, Marjolein/D 1549 2010;
   van der Meulen, Marjolein Christine Hermance/D 1549 2010
OI Yang, Xu/0000 0001 8377 077X; Grosso, Matthew/0000 0002 0457 7371; van
   der Meulen, Marjolein Christine Hermance/0000 0001 6637 9808; Fahlgren,
   Anna/0000 0002 0299 1763
FU National Institutes of Health [R01 AR056802]; Clinical Translational
   Science Center [UL1 RR024996]
FX Grant sponsor: National Institutes of Health; Grant number:
   R01 AR056802; Grant sponsor: Clinical Translational Science Center;
   Grant number: UL1 RR024996.
CR Aspenberg P, 2008, ACTA ORTHOP, V79, P111, DOI 10.1080/17453670710014851
   Bilezikian J.P., 2002, PRINCIPLES BONE BIOL
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   CHAMBERS TJ, 1993, BONE MINER, V20, P167, DOI 10.1016/S0169 6009(08)80025 6
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 1998, J BONE MINER RES, V13, P1051, DOI 10.1359/jbmr.1998.13.6.1051
   Daugaard H, 2011, CALCIFIED TISSUE INT, V88, P294, DOI 10.1007/s00223 010 9458 9
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Degasne I, 1999, CALCIFIED TISSUE INT, V64, P499, DOI 10.1007/s002239900640
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Essers J, 2005, MOL CELL BIOL, V25, P9350, DOI 10.1128/MCB.25.21.9350 9359.2005
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fahlgren A, 2013, BONE, V52, P718, DOI 10.1016/j.bone.2012.05.005
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   Hall MJ, 2010, NATL HLTH STAT REPOR, V29, P20
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   HOCK JM, 1989, J BONE MINER RES, V4, P449
   Iida Klein A, 2006, J BONE MINER RES, V21, P274, DOI 10.1359/JBMR.051017
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kurtz SM, 2009, CLIN ORTHOP RELAT R, V467, P2606, DOI 10.1007/s11999 009 0834 6
   Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002 220821
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Menuki K, 2008, BONE, V43, P613, DOI 10.1016/j.bone.2008.04.022
   Obara N, 2006, CELL TISSUE RES, V325, P197, DOI 10.1007/s00441 005 0136 6
   Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Rubin J, 2000, AM J PHYSIOL CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126
   Rubin J, 1999, J ORTHOPAED RES, V17, P639, DOI 10.1002/jor.1100170504
   Ruffoni D, 2012, BIOMECH MODEL MECHAN, V11, P313, DOI 10.1007/s10237 011 0312 4
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Skripitz R, 2005, J ORTHOP RES, V23, P1266, DOI 10.1016/j.orthres.2005.04.006
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Tsiridis E, 2007, INJURY, V38, P704, DOI 10.1016/j.injury.2007.02.051
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   van der Meulen MCH, 2006, BONE, V38, P871, DOI 10.1016/j.bone.2005.11.026
   van der Meulen MCH, 2009, CLIN ORTHOP RELAT R, V467, P2000, DOI 10.1007/s11999 009 0897 4
   von Knoch F, 2007, BIOMATERIALS, V28, P3549, DOI 10.1016/j.biomaterials.2007.04.024
   Willie BM, 2010, TISSUE ENG PART C ME, V16, P1399, DOI [10.1089/ten.tec.2009.0776, 10.1089/ten.TEC.2009.0776]
   Wirth AJ, 2012, J ORTHOP RES, V30, P178, DOI 10.1002/jor.21532
   Wirth AJ, 2011, BONE, V49, P473, DOI 10.1016/j.bone.2011.05.001
NR 51
TC 22
Z9 28
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2015
VL 33
IS 2
BP 163
EP 173
DI 10.1002/jor.22748
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA CC6JW
UT WOS:000350472200002
PM 25408434
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Faict, S
   Muller, J
   De Veirman, K
   De Bruyne, E
   Maes, K
   Vrancken, L
   Heusschen, R
   De Raeve, H
   Schots, R
   Vanderkerken, K
   Caers, J
   Menu, E
AF Faict, Sylvia
   Muller, Josephine
   De Veirman, Kim
   De Bruyne, Elke
   Maes, Ken
   Vrancken, Louise
   Heusschen, Roy
   De Raeve, Hendrik
   Schots, Rik
   Vanderkerken, Karin
   Caers, Jo
   Menu, Eline
TI Exosomes play a role in multiple myeloma bone disease and tumor
   development by targeting osteoclasts and osteoblasts
SO BLOOD CANCER JOURNAL
LA English
DT Article
ID CELL DERIVED EXOSOMES; MARROW MICROENVIRONMENT; IN VIVO;
   DIFFERENTIATION; PATHWAY; MODEL
AB Progression of multiple myeloma (MM) is largely dependent on the bone marrow (BM) microenvironment wherein communication through different factors including extracellular vesicles takes place. This cross talk not only leads to drug resistance but also to the development of osteolysis. Targeting vesicle secretion could therefore simultaneously ameliorate drug response and bone disease. In this paper, we examined the effects of MM exosomes on different aspects of osteolysis using the 5TGM1 murine model. We found that 5TGM1 sEVs, or 'exosomes', not only enhanced osteoclast activity, they also blocked osteoblast differentiation and functionality in vitro. Mechanistically, we could demonstrate that transfer of DKK 1 led to a reduction in Runx2, Osterix, and Collagen 1A1 in osteoblasts. In vivo, we uncovered that 5TGM1 exosomes could induce osteolysis in a similar pattern as the MM cells themselves. Blocking exosome secretion using the sphingomyelinase inhibitor GW4869 not only increased cortical bone volume, but also it sensitized the myeloma cells to bortezomib, leading to a strong anti tumor response when GW4869 and bortezomib were combined. Altogether, our results indicate an important role for exosomes in the BM microenvironment and suggest a novel therapeutic target for anti myeloma therapy.
C1 [Faict, Sylvia; De Veirman, Kim; De Bruyne, Elke; Maes, Ken; Vanderkerken, Karin; Menu, Eline] Vrije Univ Brussel, Myeloma Ctr Brussels, Dept Hematol & Immunol, Brussels, Belgium.
   [Muller, Josephine; Vrancken, Louise; Heusschen, Roy; Caers, Jo] Univ Liege, Lab Hematol, GIGA Res, Liege, Belgium.
   [De Raeve, Hendrik] Vrije Univ Brussel, UZ Brussel, Dept Pathol, Brussels, Belgium.
   [Schots, Rik] Univ Ziekenhuis Brussel, Dept Clin Haematol, Brussels, Belgium.
   [Vrancken, Louise; Caers, Jo] Univ Liege, Div Hematol, Dept Med, Liege, Belgium.
   [Vrancken, Louise; Caers, Jo] CHU Liege, Liege, Belgium.
C3 Vrije Universiteit Brussel; University of Liege; University Hospital
   Brussels; Vrije Universiteit Brussel; Universite Catholique Louvain;
   Cliniques Universitaires Saint Luc; Vrije Universiteit Brussel;
   University Hospital Brussels; University of Liege; University of Liege
RP Menu, E (通讯作者)，Vrije Univ Brussel, Myeloma Ctr Brussels, Dept Hematol & Immunol, Brussels, Belgium.
EM Eline.Menu@vub.be
RI ; Menu, Eline/K 2856 2015; De Veirman, Kim/JAC 9475 2023; Vanderkerken,
   Karin/I 3513 2013; De Bruyne, Elke/R 2145 2019
OI De Veirman, Kim/0000 0002 1313 6121; Maes, Ken/0000 0001 8906 2790;
   Vanderkerken, Karin/0000 0002 2137 7179; De Bruyne,
   Elke/0000 0003 4012 4617
FU FWO Vlaanderen; Belgian Foundation against Cancer; International Myeloma
   Foundation; Vrije Universiteit Brussel [SRP 14]; Kom Op Tegen Kanker
   (Belgium); University Foundation (Belgium); Fonds National de la
   Recherche Scientifique (F.N.R.S., Belgium); Fonds speciaux de la
   Recherche (University of Liege)
FX The authors would like to thank Eddy Himpe, Lotte Jacobs and Carine
   Seynaeve for their excellent laboratory assistance in confocal
   microscopy, EV isolation and CD31+ staining. S.F., K.M., and K.D.V. are
   funded by FWO Vlaanderen; J.C. is funded by the Belgian Foundation
   against Cancer. This research received financial support from
   International Myeloma Foundation, Vrije Universiteit Brussel (SRP 14),
   Kom Op Tegen Kanker (Belgium), University Foundation (Belgium), the
   Fonds National de la Recherche Scientifique (F.N.R.S., Belgium) and the
   Fonds speciaux de la Recherche (University of Liege).
CR De Veirman K, 2016, CANCER LETT, V377, P17, DOI 10.1016/j.canlet.2016.04.024
   Dinkins MB, 2014, NEUROBIOL AGING, V35, P1792, DOI 10.1016/j.neurobiolaging.2014.02.012
   Essandoh K, 2015, BBA MOL BASIS DIS, V1852, P2362, DOI 10.1016/j.bbadis.2015.08.010
   Garrett IR, 1997, BONE, V20, P515, DOI 10.1016/S8756 3282(97)00056 2
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Heusschen R, 2018, LEUKEMIA LYMPHOMA, V59, P14, DOI 10.1080/10428194.2017.1323272
   Heusschen R, 2016, ONCOTARGET, V7, P30712, DOI 10.18632/oncotarget.8750
   Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959 437X(00)00231 8
   Kim Y, 2011, ANTICANCER RES, V31, P725
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Kumar B, 2018, LEUKEMIA, V32, P575, DOI 10.1038/leu.2017.259
   Lemaire M, 2011, ADV CANCER RES, V110, P19, DOI 10.1016/B978 0 12 386469 7.00002 5
   Matsumoto A, 2017, CANCER SCI, V108, P1803, DOI 10.1111/cas.13310
   McDonald MM, 2017, CALCIFIED TISSUE INT, V100, P433, DOI 10.1007/s00223 016 0162 2
   Moreau P, 2017, ANN ONCOL, V28, P52, DOI 10.1093/annonc/mdx096
   Muller J, 2018, HAEMATOLOGICA, V103, P1359, DOI 10.3324/haematol.2017.185397
   Nagashima S, 2014, J GEN VIROL, V95, P2166, DOI 10.1099/vir.0.066910 0
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830
   Ring ES, 2018, CALCIFIED TISSUE INT, V102, P196, DOI 10.1007/s00223 017 0351 7
   Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295
   Vuckovic S, 2017, BRIT J HAEMATOL, V177, P423, DOI 10.1111/bjh.14561
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang JH, 2016, ONCOTARGET, V7, P38927, DOI 10.18632/oncotarget.7792
   Wang JH, 2016, J PATHOL, V239, P162, DOI 10.1002/path.4712
   Wang JH, 2015, ONCOTARGET, V6, P43992, DOI 10.18632/oncotarget.6083
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood 2014 03 562439
   Zahoor M, 2017, BLOOD ADV, V1, P2656, DOI 10.1182/bloodadvances.2017010801
   Zijlstra A, 2018, NAT CELL BIOL, V20, P228, DOI 10.1038/s41556 018 0049 8
NR 31
TC 115
Z9 126
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044 5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD NOV 8
PY 2018
VL 8
AR 105
DI 10.1038/s41408 018 0139 7
PG 12
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA GZ5NH
UT WOS:000449469600001
PM 30409995
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Deng, W
   Huang, YB
   Li, HS
   Chen, CW
   Lin, YW
   Wang, M
   Huang, HS
   Liu, T
   Qin, QL
   Shao, Y
   Tang, YC
   Yuan, K
   Ding, JY
   Xu, LL
   Li, YX
   Zhang, SC
AF Deng, Wei
   Huang, Yanbo
   Li, HaiShang
   Chen, ChiWei
   Lin, YueWei
   Wang, Min
   Huang, HuaSheng
   Liu, Teng
   Qin, Qiuli
   Shao, Yang
   Tang, YongChao
   Yuan, Kai
   Ding, JinYong
   Xu, LiangLiang
   Li, YongXian
   Zhang, ShunCong
TI Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and
   bone marrow macrophages by modulating MAPK and NF κB activity
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE dehydromiltirone; osteoclastogenesis; BMMS; MAPK NF kappa B; network
   pharmacology
ID SALVIA MILTIORRHIZA; MOLECULAR CLONING; CATHEPSIN K; OSTEOPOROSIS;
   MEDICINE; P38
AB Background: Osteoporosis is a type of systematic metabolic bone disease caused by the decrease in osteogenic activity or excessive resorption of bone with the relative enhancement of osteoclast function. As osteoporosis seriously affects the quality of patients' life, effective drugs are needed to treat this disease. Based on the combination of network pharmacology and cellular studies, this study aimed to investigate the probable mechanism of Dehydromiltirone (DHT) in the treatment of osteoporosis.
   Method: The targets of DHT in osteoporosis were searched using the PharmGKB, OMIM, and Genecard platforms. The PPI core targets, and the GO and KEGG enrichment analysis results were obtained using Cytoscape software, and the David and Metascape databases, respectively. The network pharmacology results were also verified via in vitro cellular experiments.
   Results: Through network pharmacology and docking analysis, we found DHT was involved in peptide tyrosine phosphorylation, cell surface receptor tyrosine kinase signaling pathways, and MAPK signaling pathways. According to the molecular docking results, the binding of DHT to MAPK14 was more stable than other proteins, which suggests that DHT may affect osteoclast formation through the MAPK signaling pathway. Moreover, DHT was found to inhibit the expression of osteoclast associated genes, including NFATc1, CTSK, c Fos, Acp5, and MMP9; as well as the phosphorylation of P38, ERK, and JNK of the MAPK signaling pathway; and the degradation of I kappa B alpha of NF kappa B signaling pathway.
   Conclusion: DHT exhibited an anti osteoclastogenesis effect by reducing the expression of related genes, ultimately inhibiting bone resorption in vitro.
C1 [Deng, Wei; Huang, Yanbo; Li, HaiShang; Lin, YueWei; Wang, Min; Huang, HuaSheng; Liu, Teng; Qin, Qiuli; Shao, Yang; Tang, YongChao; Yuan, Kai; Ding, JinYong; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, Clin Acad 1, Guangzhou, Peoples R China.
   [Deng, Wei; Huang, Yanbo; Li, HaiShang; Lin, YueWei; Wang, Min; Huang, HuaSheng; Liu, Teng; Qin, Qiuli; Shao, Yang; Tang, YongChao; Yuan, Kai; Ding, JinYong; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Deng, Wei; Huang, Yanbo; Li, HaiShang; Lin, YueWei; Wang, Min; Huang, HuaSheng; Liu, Teng; Qin, Qiuli; Shao, Yang; Li, YongXian] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Xu, LL; Li, YX; Zhang, SC (通讯作者)，Guangzhou Univ Chinese Med, Clin Acad 1, Guangzhou, Peoples R China.; Xu, LL; Li, YX; Zhang, SC (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM xull 2016@gzucm.edu.cn; spinelyx@126.com; spinezsc@126.com
RI ; Huang, Huasheng/AAE 3045 2019; XU, LIANGLIANG/AAZ 7935 2020; Li,
   Haishan/NOE 7338 2025; qin, qiuli/HCH 8075 2022
OI Zhang, Shuncong/0000 0002 3059 2487; Deng, Wei/0000 0002 1216 549X; Xu,
   Liangliang/0000 0002 5249 7480; Li, Haishan/0000 0002 2102 7021
FU Administration of Traditional Chinese Medicine of Guangdong Province,
   China [20203004, 20221146]; Natural Science Foundation of Guangdong
   Province, China [2021A1515012168]; Basic and Applied Basic Research Fund
   Project in Guangdong Province, China [2020A1515110948]; Science and
   Technology Program of Guangzhou, China [202102021040]; Innovation
   training program of Guangzhou University of Chinese Medicine
   [202210572308, 202210572150]
FX Administration of Traditional Chinese Medicine of Guangdong Province,
   China (Number: 20203004; 20221146); Natural Science Foundation of
   Guangdong Province, China (Number: 2021A1515012168); Basic and Applied
   Basic Research Fund Project in Guangdong Province, China (Number:
   2020A1515110948); Science and Technology Program of Guangzhou, China
   (Number: 202102021040). Innovation training program of Guangzhou
   University of Chinese Medicine (No. 202210572308; 202210572150).
CR Anthamatten A, 2019, J MIDWIFERY WOM HEAL, V64, P265, DOI 10.1111/jmwh.12954
   Ayub N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10133002
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bernard NJ, 2019, NAT REV RHEUMATOL, V15, P128, DOI 10.1038/s41584 019 0181 2
   Borgström F, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0706 y
   Boudin E, 2017, EUR J ENDOCRINOL, V177, pR69, DOI 10.1530/EJE 16 0990
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Chen Wan Sheng, 2003, Yaoxue Xuebao, V38, P354
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Ekeuku SO, 2021, MOLECULES, V26, DOI 10.3390/molecules26082319
   Ensrud KE, 2019, JAMA J AM MED ASSOC, V322, P2017, DOI 10.1001/jama.2019.15781
   FREIJE JMP, 1994, J BIOL CHEM, V269, P16766
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Jämsen E, 2017, J BIOMED MATER RES A, V105, P454, DOI 10.1002/jbm.a.35913
   Jiao XY, 2021, COMPUT BIOL CHEM, V90, DOI 10.1016/j.compbiolchem.2020.107402
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lee DE, 2015, J PERIODONTAL RES, V50, P256, DOI 10.1111/jre.12203
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Leong I, 2018, NAT REV ENDOCRINOL, V14, P379, DOI 10.1038/s41574 018 0036 y
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   LIN L Z, 1988, Yaoxue Xuebao, V23, P273
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lou ZK, 2019, J BONE MINER METAB, V37, P815, DOI 10.1007/s00774 019 00997 y
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Muramatsu R, 2021, J PHARMACOL SCI, V147, P294, DOI 10.1016/j.jphs.2021.08.003
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Qin H, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.581049
   Qu YL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8811751
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rath K., 2013, INT J CURR RES REV, V5, P73
   Reid IR, 2015, J INTERN MED, V278, P333, DOI 10.1111/joim.12401
   Roux S, 2019, BONE, V120, P482, DOI 10.1016/j.bone.2018.12.012
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Wada M, 2017, ONCOGENE, V36, P6649, DOI 10.1038/onc.2017.274
   Weycker Derek, 2016, Bone Rep, V5, P186, DOI 10.1016/j.bonr.2016.07.005
   Wu Chun Wei, 2016, Zhongguo Zhong Yao Za Zhi, V41, P377, DOI 10.4268/cjcmm20160303
   Yang Li xin, 2011, Yaoxue Xuebao, V46, P818
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yue SQ, 2014, PHARM BIOL, V52, P1278, DOI 10.3109/13880209.2014.889720
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
NR 46
TC 13
Z9 14
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 21
PY 2022
VL 13
AR 1015693
DI 10.3389/fphar.2022.1015693
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 6F6RD
UT WOS:000884184600001
PM 36210855
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hernandez, LL
   Gregerson, KA
   Horseman, ND
AF Hernandez, Laura L.
   Gregerson, Karen A.
   Horseman, Nelson D.
TI Mammary gland serotonin regulates parathyroid hormone related protein
   and other bone related signals
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE 5 hydroxytryptamine; lactation; osteoblast; prolactin; RANK ligand;
   RUNX2/CBFA1
ID FACTOR KAPPA B; BREAST CANCER; TRANSCRIPTION FACTOR; HUMORAL
   HYPERCALCEMIA; PEPTIDE; EXPRESSION; LACTATION; CALCIUM; CELLS;
   HYPERPROLACTINEMIA
AB Mammary gland serotonin regulates parathyroid hormone related protein and other bone related signals. Am J Physiol Endocrinol Metab 302: E1009 E1015, 2012. First published February 7, 2012; doi:10.1152/ajpendo.00666.2011. Breast cells drive bone demineralization during lactation and metastatic cancers. A shared mechanism among these physiological and pathological states is endocrine secretion of parathyroid hormone related protein (PTHrP), which acts through osteoblasts to stimulate osteoclastic bone demineralization. The regulation of PTHrP has not been accounted for fully by any conventional mammotropic stimuli or tumor growth factors. Serotonin (5 HT) synthesis within breast epithelial cells is induced during lactation and in advancing breast cancer. Here we report that serotonin deficiency (knockout of tryptophan hydroxylase 1) results in a reduction of mammary PTHrP expression during lactation, which is rescued by restoring 5 HT synthesis. 5 HT induced PTHrP expression in lactogen primed mammary epithelial cells from either mouse or cow. In human breast cancer cells 5 HT induced both PTHrP and the metastasis associated transcription factor Runx2/Cbfa1. Based on receptor expression and pharmacological evidence, the 5 HT2 receptor type was implicated as being critical for induction of PTHrP and Runx2. These results connect 5 HT synthesis to the induction of bone regulating factors in the normal mammary gland and in breast cancer cells.
C1 [Hernandez, Laura L.; Horseman, Nelson D.] Univ Cincinnati, Dept Mol & Cellular Physiol, Cincinnati, OH USA.
   [Gregerson, Karen A.] Univ Cincinnati, James L Winkle Coll Pharm, Div Pharmaceut Sci, Cincinnati, OH USA.
   [Gregerson, Karen A.; Horseman, Nelson D.] Univ Cincinnati, Program Syst Biol & Physiol, Cincinnati, OH USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati; University System of Ohio; University
   of Cincinnati
RP Horseman, ND (通讯作者)，231 Albert Sabin Wy, Cincinnati, OH 45267 USA.
EM nelson.horseman@uc.edu
RI ; Hernandez, Laura/AAA 4284 2022
OI Hernandez, Laura/0000 0001 7591 5203; 
FU NRI from USDA NIFA [2007 35206 17898]; Marlene Harris Ride Cincinnati
   Foundation; DOD [BC095713]; National Cancer Institute [CA059268]
FX This work was supported by NRI Grant no. 2007 35206 17898 from the
   USDA NIFA (N. D. Horseman), a grant from the Marlene Harris Ride
   Cincinnati Foundation (N. D. Horseman), DOD Grant no. BC095713 (K. A.
   Gregerson), and a CURE postdoctoral fellowship to L. L. Hernandez from
   the National Cancer Institute (CA059268).
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Ardeshirpour L, 2007, ENDOCRINOLOGY, V148, P3875, DOI 10.1210/en.2006 1467
   Bliziotes M, 2010, J CLIN ENDOCR METAB, V95, P4124, DOI 10.1210/jc.2010 0861
   Bostwick JR, 2009, PHARMACOTHERAPY, V29, P64, DOI 10.1592/phco.29.1.64
   BROADUS AE, 1988, NEW ENGL J MED, V319, P556
   CAPLAN RH, 1995, J REPROD MED, V40, P216
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   DeMauro S, 2005, J MAMMARY GLAND BIOL, V10, P157, DOI 10.1007/s10911 005 5398 9
   DOBNIG H, 1995, J CLIN ENDOCR METAB, V80, P3699, DOI 10.1210/jc.80.12.3699
   Fiaschi Taesch NM, 2003, ENDOCRINOLOGY, V144, P407, DOI 10.1210/en.2002 220818
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Galli Tsinopoulou A, 2000, J PEDIATR ENDOCR MET, V13, P439
   Graham TR, 2010, CANCER SCI, V101, P103, DOI 10.1111/j.1349 7006.2009.01356.x
   Guo YB, 2008, BONE, V43, P386, DOI 10.1016/j.bone.2008.03.026
   Hedlund PB, 2003, P NATL ACAD SCI USA, V100, P1375, DOI 10.1073/pnas.0337340100
   Hernandez LL, 2009, J ENDOCRINOL, V203, P123, DOI 10.1677/JOE 09 0187
   Horst RL, 2005, J MAMMARY GLAND BIOL, V10, P141, DOI 10.1007/s10911 005 5397 x
   Hou ZY, 2000, ENDOCRINOLOGY, V141, P4278, DOI 10.1210/en.141.11.4278
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200
   JACKSON JC, 1985, IMMUNOLOGY, V54, P505
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   KLEIN M, 1995, ANN ENDOCRINOL PARIS, V56, P193
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kovacs CS, 2005, J MAMMARY GLAND BIOL, V10, P105, DOI 10.1007/s10911 005 5394 0
   KOVACS CS, 1995, J CLIN ENDOCR METAB, V80, P3036, DOI 10.1210/jc.80.10.3036
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555 006 9033 z
   Luparello C, 2000, BIOL CHEM, V381, P303, DOI 10.1515/BC.2000.039
   Marshall AM, 2010, J CLIN ENDOCR METAB, V95, P837, DOI 10.1210/jc.2009 1575
   Matsuda M, 2004, DEV CELL, V6, P193, DOI 10.1016/S1534 5807(04)00022 X
   MCGRATH MF, 1987, J DAIRY SCI, V70, P1967, DOI 10.3168/jds.S0022 0302(87)80239 4
   Misra M, 2004, J CLIN PSYCHIAT, V65, P1607, DOI 10.4088/JCP.v65n1205
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Murray RD, 2008, VET REC, V163, P561, DOI 10.1136/vr.163.19.561
   Pai VP, 2008, J BIOL CHEM, V283, P30901, DOI 10.1074/jbc.M802476200
   Pai Vaibhav P, 2011, Commun Integr Biol, V4, P532, DOI 10.4161/cib.4.5.16492
   Pai VP, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2448
   Pai VP, 2011, PLOS ONE
   PIROLA CJ, 1993, J BIOL CHEM, V268, P1987
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1564::AID CNCR6>3.3.CO;2 H
   Richard V, 2005, CRIT REV EUKAR GENE, V15, P115, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.30
   Shibli Rahhal A, 2009, PITUITARY, V12, P96, DOI 10.1007/s11102 008 0097 3
   Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557
   Sowers MF, 1996, JAMA J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549
   Stewart AF, 2002, J BONE MINER RES, V17, P758, DOI 10.1359/jbmr.2002.17.5.758
   STIEGLER C, 1995, J BONE MINER RES, V10, P751
   Stull MA, 2007, P NATL ACAD SCI USA, V104, P16708, DOI 10.1073/pnas.0708136104
   THIEDE MA, 1994, J DAIRY SCI, V77, P1952, DOI 10.3168/jds.S0022 0302(94)77141 1
   THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653
   Uemura H, 2005, HORM METAB RES, V37, P463, DOI 10.1055/s 2005 870316
   VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504
   Wysolmerski JJ, 2010, ANN NY ACAD SCI, V1192, P161, DOI 10.1111/j.1749 6632.2009.05249.x
NR 54
TC 89
Z9 101
U1 0
U2 21
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD APR
PY 2012
VL 302
IS 8
BP E1009
EP E1015
DI 10.1152/ajpendo.00666.2011
PG 7
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 924ZU
UT WOS:000302730600013
PM 22318950
OA Green Published
DA 2025 08 17
ER

PT J
AU Debnath, S
   Yallowitz, AR
   McCormick, J
   Lalani, S
   Zhang, T
   Xu, R
   Li, N
   Liu, YF
   Yang, YS
   Eiseman, M
   Shim, JH
   Hameed, M
   Healey, JH
   Bostrom, MP
   Landau, DA
   Greenblatt, MB
AF Debnath, Shawon
   Yallowitz, Alisha R.
   McCormick, Jason
   Lalani, Sarfaraz
   Zhang, Tuo
   Xu, Ren
   Li, Na
   Liu, Yifang
   Yang, Yeon Suk
   Eiseman, Mark
   Shim, Jae Hyuck
   Hameed, Meera
   Healey, John H.
   Bostrom, Mathias P.
   Landau, Dan Avi
   Greenblatt, Matthew B.
TI Discovery of a periosteal stem cell mediating intramembranous bone
   formation
SO NATURE
LA English
DT Article
ID STROMAL CELLS; NICHE; DIFFERENTIATION; MARROW; IDENTIFICATION;
   OSTEOCLASTS; CARTILAGE; PROVIDES; ALPHA; MOUSE
AB Bone consists of separate inner endosteal and outer periosteal compartments, each with distinct contributions to bone physiology and each maintaining separate pools of cells owing to physical separation by the bone cortex. The skeletal stem cell that gives rise to endosteal osteoblasts has been extensively studied; however, the identity of periosteal stem cells remains unclear(1 5). Here we identify a periosteal stem cell (PSC) that is present in the long bones and calvarium of mice, displays clonal multipotency and self renewal, and sits at the apex of a differentiation hierarchy. Single cell and bulk transcriptional profiling show that PSCs display transcriptional signatures that are distinct from those of other skeletal stem cells and mature mesenchymal cells. Whereas other skeletal stem cells form bone via an initial cartilage template using the endochondral pathway(4), PSCs form bone via a direct intramembranous route, providing a cellular basis for the divergence between intramembranous versus endochondral developmental pathways. However, there is plasticity in this division, as PSCs acquire endochondral bone formation capacity in response to injury. Genetic blockade of the ability of PSCs to give rise to bone forming osteoblasts results in selective impairments in cortical bone architecture and defects in fracture healing. A cell analogous to mouse PSCs is present in the human periosteum, raising the possibility that PSCs are attractive targets for drug and cellular therapy for skeletal disorders. The identification of PSCs provides evidence that bone contains multiple pools of stem cells, each with distinct physiologic functions.
C1 [Debnath, Shawon; Yallowitz, Alisha R.; Lalani, Sarfaraz; Xu, Ren; Li, Na; Eiseman, Mark; Greenblatt, Matthew B.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [McCormick, Jason] Weill Cornell Med, Flow Cytometry Core Facil, New York, NY USA.
   [Zhang, Tuo] Weill Cornell Med, Genom Resources Core Facil, New York, NY USA.
   [Liu, Yifang] Weill Cornell Med, Pathol & Lab Med Core Facil, New York, NY USA.
   [Yang, Yeon Suk; Shim, Jae Hyuck] Univ Massachusetts, Med Sch, Dept Med, North Worcester, MA USA.
   [Hameed, Meera] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.
   [Healey, John H.] Mem Sloan Kettering Canc Ctr, Dept Surg, Orthopaed Serv, 1275 York Ave, New York, NY 10021 USA.
   [Bostrom, Mathias P.] Hosp Special Surg, Dept Orthopaed Surg, Res Div, 535 E 70th St, New York, NY 10021 USA.
   [Bostrom, Mathias P.] Hosp Special Surg, Dept Orthopaed Surg, Div Adult Reconstruct & Joint Replacement, 535 E 70th St, New York, NY 10021 USA.
   [Landau, Dan Avi] Weill Cornell Med, Canc Genom & Evolutionary Dynam, New York, NY USA.
   [Landau, Dan Avi] New York Genome Ctr, New York, NY USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Cornell University; Weill Cornell Medicine; Cornell
   University; Weill Cornell Medicine; University of Massachusetts System;
   University of Massachusetts Worcester; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; Cornell University;
   Weill Cornell Medicine
RP Greenblatt, MB (通讯作者)，Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
EM mag3003@med.cornell.edu
RI ; xu, ren/G 6907 2015
OI Lalani, Sarfaraz/0000 0003 3624 9409; Healey, John/0000 0002 0802 1186;
   Shim, Jae Hyuck/0000 0002 4947 3293; xu, ren/0000 0001 6578 4553
FU Office of the Director of the NIH [DP5OD021351]; Burroughs Welcome
   Foundation; March of Dimes
FX This project was funded by the Office of the Director of the NIH under
   award DP5OD021351 given to M.B.G. M.B.G. holds a Career Award for
   Medical Scientists from the Burroughs Welcome Foundation and a Basil
   O'Connor Award from the March of Dimes. This content is solely the
   responsibility of the authors and does not represent the official views
   of the National Institutes of Health. We thank D. Ballon, B. He, S.
   Mukherjee and the Flow Cytometry Core, Genomics Resources Core, Optical
   Microscopy Core and the Citigroup Biomedical Imaging Core at Weill
   Cornell Medicine for their technical support, and B. Sleckman and T.
   Evans for insightful comments on the manuscript.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Baek WY, 2010, BONE, V46, P920, DOI 10.1016/j.bone.2009.12.007
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chan CKF, 2013, P NATL ACAD SCI USA, V110, P12643, DOI 10.1073/pnas.1310212110
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Crespo M, 2017, NAT MED, V23, P878, DOI 10.1038/nm.4355
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Greenblatt MB, 2015, J EXP MED, V212, P1283, DOI 10.1084/jem.20150407
   Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059 016 0938 8
   Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood 2004 07 2681
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Malizos KN, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.07.030
   Maruyama T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10526
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Ozaki A, 2000, J Orthop Sci, V5, P64, DOI 10.1007/s007760050010
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Utvag SE, 1996, J ORTHOP TRAUMA, V10, P279, DOI 10.1097/00005131 199605000 00009
   van Gastel N, 2012, STEM CELLS, V30, P2460, DOI 10.1002/stem.1210
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396
   Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324
   Yukata K, 2014, BONE, V62, P79, DOI 10.1016/j.bone.2014.02.002
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 40
TC 466
Z9 520
U1 20
U2 214
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD OCT 4
PY 2018
VL 562
IS 7725
BP 133
EP +
DI 10.1038/s41586 018 0554 8
PG 29
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GV6AF
UT WOS:000446187900052
PM 30250253
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lasky, S
   Moshal, T
   Shakoori, P
   Roohani, I
   Jolibois, M
   Youn, S
   Urata, MM
   Hammoudeh, JA
AF Lasky, Sasha
   Moshal, Tayla
   Shakoori, Pasha
   Roohani, Idean
   Jolibois, Marah
   Youn, Simon
   Urata, Mark M.
   Hammoudeh, Jeffrey A.
TI The Risk of Medication Related Osteonecrosis of the Jaw in Children:
   Guidance for Antiresorptive Use in Pediatric Patients
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID GIANT CELL TUMOR; OSTEOGENESIS IMPERFECTA; ZOLEDRONIC ACID;
   CANCER PATIENTS; BREAST CANCER; OPEN LABEL; DENOSUMAB; BONE; THERAPY;
   BISPHOSPHONATES
AB Background: Antiresorptive targeted cancer therapies, such as denosumab and bisphosphonates, are used in adults, but their application in pediatric cancer is more recent. Side effects such as osteonecrosis of the jaw (ONJ) observed in adults have curtailed use of these medications in the pediatric population.
   Purpose: This study assesses the frequency of ONJ, other side effects, and the indications for use of denosumab versus bisphosphonates in pediatric subjects.
   Study Design, Setting, Sample: A retrospective cohort study of pediatric subjects who underwent bisphosphonate or denosumab therapy at our institution from 2007 2023 was conducted. Subjects aged >= 18 years at therapy initiation were excluded.
   Independent Variable: The independent variable was antiresorptive therapy divided into 2 groups, treatment with intravenous bisphosphonates or denosumab.
   Main Outcome Variable(s): Primary outcomes were development of bisphosphonate related and denosumab related ONJ. Secondary outcomes included additional side effects.
   Covariates: ONJ risk factors, subject demographics, indications for use, timing, duration, and cumulative dose of antiresorptive therapy were abstracted.
   Analyses: Univariate and bivariate statistics were computed to describe the sample and measure associations between antiresorptive therapy and outcomes. P values < .05 conferred statistical significance.
   Results: The sample was composed of 178 subjects with a mean age of 11.7 +/  6.1 years. There were 14 (7.9%) and 164 (92.1%) subjects treated with denosumab and bisphosphonate therapies, respectively. There were 0 cases of ONJ across all subjects. The most common indication for treatment was adjuvant targeted therapy for aggressive tumors and malignancy (39.3%) followed by osteoporosis (14.6%). Subjects treated with denosumab had higher frequencies of hypercalcemia and severe bone pain than subjects treated with bisphosphonates, 28.6% versus 1.2% (P < .001) and 14.3% versus 0.00% (P < .001), respectively.
   Conclusion and Relevance: While invasive dental procedures are ideally performed before antiresorptive treatment, our data suggest that bisphosphonates may be used safely in the pediatric population with low concern for ONJ. Our data also demonstrated bisphosphonates may have a more tolerable side effect profile than denosumab. If the perceived benefits are similar, we recommend using bisphosphonates as first line therapy in children while reserving denosumab for refractory cases. Future studies will help determine long term side effects and differences in efficacies of these medications. (c) 2024 American Association of Oral and Maxillofacial Surgeons
C1 [Lasky, Sasha; Moshal, Tayla; Roohani, Idean; Jolibois, Marah; Urata, Mark M.; Hammoudeh, Jeffrey A.] Childrens Hosp Los Angeles, Div Plast & Maxillofacial Surg, 4650 West Sunset Blvd,Mailstop 96, Los Angeles, CA 90033 USA.
   [Lasky, Sasha; Moshal, Tayla; Roohani, Idean; Youn, Simon] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA.
   [Shakoori, Pasha; Urata, Mark M.; Hammoudeh, Jeffrey A.] USC, Keck Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA USA.
   [Youn, Simon] Univ Southern Calif, Herman Ostrow Sch Dent, Los Angeles, CA USA.
C3 Children's Hospital Los Angeles; University of Southern California;
   University of Southern California; University of Southern California
   Keck Hospital; University of Southern California
RP Hammoudeh, JA (通讯作者)，Childrens Hosp Los Angeles, Div Plast & Maxillofacial Surg, 4650 West Sunset Blvd,Mailstop 96, Los Angeles, CA 90033 USA.
EM JHammoudeh@chla.usc.edu
OI Roohani, Idean/0009 0003 7843 583X; Lasky, Sasha/0009 0009 3336 0540;
   Youn, Simon/0000 0002 1251 6552
CR Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Chahine C, 2008, J PEDIATR US, V153, P719, DOI 10.1016/j.jpeds.2008.05.003
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Duarte NT, 2020, INT J ORAL MAX SURG, V49, P183, DOI 10.1016/j.ijom.2019.08.004
   Eapen E, 2008, EJIFCC, V19, P123
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gkouveris I, 2019, BONE, V123, P234, DOI 10.1016/j.bone.2019.03.031
   Green J, 2010, CANCER INVEST, V28, P944, DOI 10.3109/07357907.2010.512598
   Hallmer F, 2018, OR SURG OR MED OR PA, V126, P477, DOI 10.1016/j.oooo.2018.08.015
   Hegazy A, 2016, J PEDIATR ORTHOPED, V36, P757, DOI 10.1097/BPO.0000000000000552
   Hennedige Anusha Adeline, 2013, J Oral Maxillofac Res, V4, pe1, DOI 10.5037/jomr.2013.4401
   Hernandez M, 2017, J ORAL PATHOL MED, V46, P321, DOI 10.1111/jop.12516
   Heymann MF, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115523
   Horiuchi K, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101148
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Kaban LB, 2007, J ORAL MAXIL SURG, V65, P2018, DOI 10.1016/j.joms.2007.03.030
   Koch R, 2023, CLIN CANCER RES, V29, P5057, DOI 10.1158/1078 0432.CCR 23 1966
   Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Makino Y, 2021, DENT J BASEL, V9, DOI 10.3390/dj9010007
   Narayanan Prasad, 2013, South Asian J Cancer, V2, P272, DOI 10.4103/2278 330X.119895
   Neal TW, 2022, J ORAL MAXIL SURG, V80, P1686, DOI 10.1016/j.joms.2022.06.026
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Qu XZ, 2020, AGING US, V12, P20743, DOI 10.18632/aging.104006
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Rutkowski P, 2018, EJSO EUR J SURG ONC, V44, P1384, DOI 10.1016/j.ejso.2018.03.020
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Schreuder WH, 2017, J ORAL MAXIL SURG, V75, P105, DOI 10.1016/j.joms.2016.06.007
   Semler O, 2012, J MUSCULOSKEL NEURON, V12, P183
   Soma T, 2021, J BONE MINER METAB, V39, P372, DOI 10.1007/s00774 020 01174 2
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Teixeira S, 2019, MINI REV MED CHEM, V19, P988, DOI 10.2174/1389557519666190424163044
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Trejo P, 2018, J MUSCULOSKEL NEURON, V18, P76
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Udeabor SE, 2023, BIOENGINEERING BASEL, V10, DOI 10.3390/bioengineering10101145
   Upfill Brown A, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10210
   Valachis A, 2013, ONCOLOGIST, V18, P353, DOI 10.1634/theoncologist.2012 0261
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Vasanwala RF, 2016, J BONE MINER RES, V31, P1449, DOI 10.1002/jbmr.2805
   Vescovi P, 2010, Minerva Stomatol, V59, P181
   Yang G, 2018, J BONE MINER RES, V33, P91, DOI 10.1002/jbmr.3285
NR 49
TC 7
Z9 7
U1 2
U2 2
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD OCT
PY 2024
VL 82
IS 10
BP 1285
EP 1294
DI 10.1016/j.joms.2024.06.162
EA OCT 2024
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA I5O7L
UT WOS:001330758400001
PM 38950582
DA 2025 08 17
ER

PT J
AU Stopeck, AT
   Fizazi, K
   Body, JJ
   Brown, JE
   Carducci, M
   Diel, I
   Fujiwara, Y
   Martín, M
   Paterson, A
   Tonkin, K
   Shore, N
   Sieber, P
   Kueppers, F
   Karsh, L
   Yardley, D
   Wang, H
   Maniar, T
   Arellano, J
   Braun, A
AF Stopeck, Alison T.
   Fizazi, Karim
   Body, Jean Jacques
   Brown, Janet E.
   Carducci, Michael
   Diel, Ingo
   Fujiwara, Yasuhiro
   Martin, Miguel
   Paterson, Alexander
   Tonkin, Katia
   Shore, Neal
   Sieber, Paul
   Kueppers, Frank
   Karsh, Lawrence
   Yardley, Denise
   Wang, Huei
   Maniar, Tapan
   Arellano, Jorge
   Braun, Ada
TI Safety of long term denosumab therapy: results from the open label
   extension phase of two phase 3 studies in patients with metastatic
   breast and prostate cancer
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Bone metastases; Breast cancer; Denosumab; Osteonecrosis of the jaw;
   Prostate cancer; Zoledronic acid
ID SKELETAL RELATED EVENTS; BONE METASTASES; ZOLEDRONIC ACID; FREE
   SURVIVAL; RISK FACTORS; DOUBLE BLIND; BISPHOSPHONATES; OSTEONECROSIS;
   EFFICACY; PREVENTION
AB Zoledronic acid (ZA) or denosumab treatment reduces skeletal related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open label extension phase of two phase 3 trials.
   Patients with metastatic breast or prostate cancer received subcutaneous denosumab 120 mg Q4W or intravenous ZA 4 mg Q4W in a double blinded fashion. Denosumab demonstrated superior efficacy in the blinded treatment phase; thus, patients were offered open label denosumab for up to an additional 2 years.
   Cumulative median (Q1, Q3) denosumab exposure was 19.1 (9.2, 32.2) months in the breast cancer trial (n = 1019) and 12.0 (5.6, 21.3) months in the prostate cancer trial (n = 942); 295 patients received denosumab for > 3 years. No new safety signals were identified during the open label phase, or among patients who switched from ZA to denosumab. During the blinded treatment phase, exposure adjusted subject incidences of osteonecrosis of the jaw (ONJ) were 49 (1.9 %) and 31 (1.2 %) in the denosumab and ZA groups, respectively. In total, 32 (6.9 %) and 25 (5.5 %) new cases of ONJ (not adjusted for exposure) were reported for patients continuing and switching to denosumab, respectively. The incidences of hypocalcemia were 4.3 and 3.1 %, in patients continuing and switching to denosumab, respectively.
   These results describe the safety profile of denosumab after long term exposure, or after switching to denosumab from ZA. No new safety signals were identified. Hypocalcemia rates were similar in the blinded treatment and open label phases. ONJ rates increased with increasing exposure to antiresorptives, consistent with previous reports.
C1 [Stopeck, Alison T.] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA.
   [Fizazi, Karim] Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
   [Body, Jean Jacques] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium.
   [Brown, Janet E.] St James Univ Hosp, Canc Res UK Expt Canc Med Ctr, Leeds, W Yorkshire, England.
   [Brown, Janet E.] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England.
   [Carducci, Michael] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
   [Diel, Ingo] Ctr Comprehens, Gynecol Clin, Mannheim, Germany.
   [Fujiwara, Yasuhiro] Natl Canc Ctr, Tokyo, Japan.
   [Martin, Miguel] Univ Complutense, Inst Invest Sanitaria Gen Gregorio Maranon, E 28040 Madrid, Spain.
   [Paterson, Alexander] Tom Baker Canc Clin, Calgary, AB, Canada.
   [Tonkin, Katia] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
   [Shore, Neal] Carolina Urol Res Ctr, Myrtle Beach, SC USA.
   [Sieber, Paul] Lancaster Urol, Lancaster, PA USA.
   [Kueppers, Frank] Urol Associates, Christchurch, New Zealand.
   [Karsh, Lawrence] Urol Ctr Colorado, Denver, CO USA.
   [Yardley, Denise] Sarah Cannon Res Inst, Nashville, TN USA.
   [Wang, Huei; Maniar, Tapan; Arellano, Jorge; Braun, Ada] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 University of Arizona; Universite Paris Saclay; UNICANCER; Gustave
   Roussy; Universite Libre de Bruxelles; Saint James's University
   Hospital; Cancer Research UK; Weston Park Hospital; University of
   Sheffield; Johns Hopkins University; Johns Hopkins Medicine; National
   Cancer Center   Japan; Complutense University of Madrid; University of
   Calgary; Tom Baker Cancer Clinic; University of Alberta; Carolina
   Urologic Research Center; Sarah Cannon Research Institute; Amgen
RP Stopeck, AT (通讯作者)，Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA.
EM Alison.Stopeck@stonybrookmedicine.edu
RI Carducci, Michael/R 8164 2019; Body, Jean Jacques/G 9785 2015; Karsh,
   Lawrence/KLD 0681 2024; Shore, Neal/ABM 5607 2022; Martin,
   Miguel/V 6589 2019
OI Fujiwara, Yasuhiro/0000 0002 1229 5446; 
FU Amgen Inc.
FX This work was supported by Amgen Inc. Geoff Smith, PhD, provided medical
   writing support on behalf of Amgen Inc.
CR Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   [Anonymous], 2014, XGEVA DEN US PACK IN
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Body JJ, 2010, J BONE MINER RES, V25, P440, DOI 10.1359/jbmr.090810
   Brufsky AM, 2013, BREAST J, V19, P504, DOI 10.1111/tbj.12152
   Cancer and Leukemia Group B, 2012, ZOL AC TREAT PAT MET
   Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2012, J CLIN ONCOL, V30
   Doshi S, 2012, CLIN CANCER RES, V18, P2648, DOI 10.1158/1078 0432.CCR 11 2944
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Fallowfield L, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS11 P4 13 01
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hortobagyi G, 2014, J CLIN ONCOL S, V32
   Kris MG, 2010, J CLIN ONCOL, V28, P5327, DOI 10.1200/JCO.2010.33.2742
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Paparodis R, 2013, ENDOCR PRACT, V19, pE64, DOI 10.4158/EP12367.CR
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tchekmedyian NS, 2010, CANCER INVEST, V28, P849, DOI 10.3109/07357907.2010.483508
NR 29
TC 140
Z9 147
U1 1
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941 4355
EI 1433 7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN
PY 2016
VL 24
IS 1
BP 447
EP 455
DI 10.1007/s00520 015 2904 5
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA CX6NM
UT WOS:000365817800054
PM 26335402
OA Green Published, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Zheng, T
   Chen, L
   Noh, ALSM
   Yim, M
AF Zheng, Ting
   Chen, Ling
   Noh, A. Long Sae Mi
   Yim, Mijung
TI Cetylpyridinium Chloride Inhibits Receptor Activator of Nuclear
   Factor κB Ligand Induced Osteoclast Formation
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE osteoporosis; osteoclast; cetylpyridinium chloride
ID SIGNALING PATHWAYS; BONE LOSS; T CELLS; DIFFERENTIATION; PRECURSORS;
   EXPRESSION; MACROPHAGES; CROSSTALK; INDUCTION; IMMUNE
AB Osteoclasts are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Antiseptic products have received recent attention as potential therapeutic and preventive drugs in human disease. The purpose of this study was to investigate the effect of the antiseptic cetylpyridinium chloride (CPC) on osteoclast formation using mouse bone marrow derived macrophages (BMMs). CPC inhibited receptor activator of nuclear factor (NF) kappa B ligand (RANKL) induced osteoclast formation in a dose dependent manner without causing cytotoxicity. The mRNA expression of cathepsin K, calcitonin receptor (CTR), and Prdm1 in osteoclasts was reduced by CPC. In experiments to elucidate its mechanism of action, CPC was found to suppress RANKL induced expression of c Fos and nuclear factor of activated T cells (NFATc1), transcription factors that are essential for osteoclast differentiation. CPC also inhibited RANKL induced activation of extracellular signal regulated kinase (ERK) and NF kappa B and expression of cyclooxygenase (COX) 2. These results collectively suggest that CPC inhibits osteoclast differentiation by suppressing the activation of ERK and NF kappa B and reducing the expression of COX 2, c Fos, and NFATc1. CPC may therefore be a useful drug in the prevention of bone loss.
C1 [Zheng, Ting; Chen, Ling; Noh, A. Long Sae Mi; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
C3 Sookmyung Women's University
RP Yim, M (通讯作者)，Sookmyung Womens Univ, Coll Pharm, Hyochangwongil 52, Seoul 140742, South Korea.
EM myim@sm.ac.kr
RI Zheng, Ting/ITR 8293 2023
OI Zheng, Ting/0000 0001 7723 7653
FU Sookmyung Women's University
FX This work was supported by the Sookmyung Women's University Research
   Grants 2011.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   Haps S, 2008, Int J Dent Hyg, V6, P290, DOI 10.1111/j.1601 5037.2008.00344.x
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Kim YJ, 2005, J PERIODONTOL, V76, P1735, DOI 10.1902/jop.2005.76.10.1735
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Mankodi S, 2005, AM J DENT, V18, p9A
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Moriguchi T, 2006, MOL CELL BIOL, V26, P5715, DOI 10.1128/MCB.00001 06
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Park H, 2007, BIOCHEM BIOPH RES CO, V354, P178, DOI 10.1016/j.bbrc.2006.12.174
   Pitten FA, 2001, ARZNEIMITTELFORSCH, V51, P588
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   SCHEIE AA, 1989, J DENT RES, V68, P1609
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074 7613(00)00016 9
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
NR 23
TC 10
Z9 13
U1 0
U2 6
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD APR
PY 2013
VL 36
IS 4
BP 509
EP 514
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 115SP
UT WOS:000316832500002
PM 23546287
DA 2025 08 17
ER

PT J
AU Whitfield, JF
AF Whitfield, JF
TI Osteogenic PTHs and vascular ossification   Is there a danger for
   osteoporotics?
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE atherosclerosis; atheroma; bisphosphonates; CVCs (calcifying vascular
   cells); cholesterolemia; LDL particles; macrophages; MCP 1 chernokine;
   monocytes; osteoblasts; osteoporosis; pericytes; PTH (parathyroid
   hormone); PTHrP (parathyroid hormone related protein); PTH/PTHrP
   receptor; vascular endothelial cells; vascular ossification; vascular
   smooth muscle cells
ID HORMONE RELATED PROTEIN; HUMAN PARATHYROID HORMONE; SMOOTH MUSCLE CELLS;
   LOW DENSITY LIPOPROTEIN; ARTERIAL CALCIFICATION; AORTIC CALCIFICATION;
   BONE FORMATION; IN VITRO; EXPRESSION; ATHEROSCLEROSIS
AB Inflammation in vascular (mostly arterial) walls and heart valves triggered by the trans endothelial influx of LDL particles and the action of subsequently modified (e.g., by oxidation) LDL particles can trigger true bone formation by valvar fibroblasts, by a subpopulation of re differentiation competent VSMCs (vascular smooth muscle cells) or by vascular pericytes. Vascular ossification can lead to heart failure and death. Elderly osteoporotic women who need osteogenic drugs to restore their lost skeletal bone are paradoxically prone to vascular ossification the "calcification paradox." The recent introduction into the clinic of a potently osteogenic parathyroid hormone peptide, Lilly'srhPTH (1 34)OH (Forteo(TM)), to reverse skeletal bone loss raises the question of whether this and other potently osteogenic PTHs still in clinical trial might also stimulate vascular ossification in such osteoporotic women. Indeed the VSMCs in human and rat atherosclerotic lesions hyperexpress PTHrP and the PTHR1 (or PTH1 R) receptor as do maturing osteoblasts. And the evidence indicates that endogenous PTHrP with its NLS (nuclear/nucleolar localization sequence) does stimulate VSMC proliferation (a prime prerequisite for atheroma formation and ossification) via intranuclear targets that inactivate pRb, the inhibitory G(1)/S checkpoint regulator, by stimulating its hyperphosphorylation. But neither externally added full length PTHrP nor the NLS lacking PTHrP (1 34)OH gets into the VSMC nucleus and instead they inhibit proliferation and calcification by only activating the cell's PTHR1 receptors. No PTH has an NLS and, as expected from the observations on the externally added PTHrPs, hPTH (1 34)OH inhibits calcification by VSMCs and cannot stimulate vascular ossification in a diabetic mouse model. Encouraging though this may be for osteoporotics with their "calcification paradox," more work is needed to be sure that the skeletally osteogenic PTHs do not promote vascular ossification with its cardiovascular consequences. J. Cell. Biochem. (c) 2005 Wiley Liss, Inc.
C1 Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
C3 National Research Council Canada
RP Natl Res Council Canada, Inst Biol Sci, Bldg M 54,Montreal Rd Campus, Ottawa, ON K1A 0R6, Canada.
EM pthosteo@rogers.com
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Aubin J.E., 2002, Principles of Bone Biology, V1, P59
   Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o
   BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391
   Boström K, 2000, CRIT REV EUKAR GENE, V10, P151, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.40
   Boström KI, 2000, Z KARDIOL, V89, P69
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Chen Neal X, 2003, Curr Diab Rep, V3, P28, DOI 10.1007/s11892 003 0049 2
   De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096
   Demer LL, 2002, INT J EPIDEMIOL, V31, P737, DOI 10.1093/ije/31.4.737
   Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F
   Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003 0015
   Doherty TM, 2003, FASEB J, V17, P592, DOI 10.1096/fj.02 0913hyp
   Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008 6363(01)00375 3
   Fiaschi Taesch N, 2004, CIRCULATION, V110, P177, DOI 10.1161/01.CIR.0000134483.30849.B7
   Fitzpatrick LA, 2003, ENDOCRINOLOGY, V144, P2214, DOI 10.1210/en.2002 0170
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092 8674(01)00238 0
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Hashiba H, 2004, THER APHER DIAL, V8, P241, DOI 10.1111/j.1526 0968.2004.00136.x
   Hunt JL, 2002, STROKE, V33, P1214, DOI 10.1161/01.STR.0000013741.41309.67
   Iba K, 2004, J BONE MINER METAB, V22, P594, DOI 10.1007/s00774 004 0528 9
   Ishikawa M, 2000, ATHEROSCLEROSIS, V152, P97, DOI 10.1016/S0021 9150(99)00455 4
   Jakoby MG, 2000, CURR OPIN NEPHROL HY, V9, P11, DOI 10.1097/00041552 200001000 00003
   Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135
   Karperien M, 2000, J BONE MINER RES, V15, pS175
   Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]
   Martín Ventura JL, 2003, STROKE, V34, P1783, DOI 10.1161/01.STR.0000078371.00577.76
   Massfelder T, 1998, CURR OPIN NEPHROL HY, V7, P27, DOI 10.1097/00041552 199801000 00005
   Massfelder T, 2003, CURR OPIN NEPHROL HY, V12, P35, DOI 10.1097/00041552 200301000 00007
   Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630
   NAKAYAMA T, 1994, BIOCHEM BIOPH RES CO, V200, P1028, DOI 10.1006/bbrc.1994.1553
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   O'Rourke MF, 2002, AM J HYPERTENS, V15, P426, DOI 10.1016/S0895 7061(01)02319 6
   Ozeki S, 1996, ARTERIOSCL THROM VAS, V16, P565, DOI 10.1161/01.ATV.16.4.565
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Qiao JH, 2003, HUM PATHOL, V34, P402, DOI 10.1053/hupa.2003.72
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021 9150(99)00346 9
   Rubin MR, 2004, J CLIN ENDOCR METAB, V89, P4243, DOI 10.1210/jc.2004 1324
   Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003 030964
   Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200
   Speer MY, 2004, CARDIOVASC PATHOL, V13, P63, DOI 10.1016/S1054 8807(03)00130 3
   Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102 1211
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Trion A, 2004, AM HEART J, V147, P808, DOI 10.1016/j.ahj.2003.10.047
   Vattikuti R, 2004, AM J PHYSIOL ENDOC M, V286, pE686, DOI 10.1152/ajpendo.00552.2003
   Virchow R., 1863, Cellular Pathology as Based upon Physiological and Pathological Histology
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs
   Whitfield James F, 2002, Treat Endocrinol, V1, P175, DOI 10.2165/00024677 200201030 00005
   Whitfield JF, 1996, CALCIFIED TISSUE INT, V58, P81, DOI 10.1007/BF02529728
   Whitfield JF, 1997, J BONE MINER RES, V12, P1246, DOI 10.1359/jbmr.1997.12.8.1246
   WHITFIELD JF, 2005, GROWING BONE
   Ylitalo R, 2002, GEN PHARMACOL, V35, P287
   Zhu H, 2003, J BIOL CHEM, V278, P13350, DOI 10.1074/jbc.M212104200
NR 59
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN 1
PY 2005
VL 95
IS 3
BP 437
EP 444
DI 10.1002/jcb.20424
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 929LZ
UT WOS:000229348900002
PM 15786490
DA 2025 08 17
ER

PT J
AU Roza, T
   Hakim, L
   van Poppel, H
   Joniau, S
AF Roza, Thomas
   Hakim, Lukman
   van Poppel, Hendrik
   Joniau, Steven
TI Bone Targeted Therapies for Elderly Patients with Renal Cell Carcinoma:
   Current and Future Directions
SO DRUGS & AGING
LA English
DT Article
ID SKELETAL RELATED EVENTS; LONG TERM EFFICACY; RESISTANT PROSTATE CANCER;
   PLACEBO CONTROLLED TRIAL; ZOLEDRONIC ACID; COST EFFECTIVENESS;
   BREAST CANCER; DOUBLE BLIND; PHASE III; METASTASES SECONDARY
AB Bone metastases are very common in advanced renal cell carcinoma (RCC) and can have a huge impact on quality of life by leading to skeletal related events (SREs), including pain, pathologic fractures and spinal cord compression with need for surgery or radiotherapy. Because of their osteolytic aspect and biologic behaviour, these SREs are more common in patients with bone metastases from RCC than from other malignancies. As overall survival is increased by new anti angiogenic drugs like tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, the incidence of SREs is rising, making the clinical management of bone metastases in RCC ever more important, especially in the more vulnerable elderly patient. In this review we discuss the current advances and future directions in bone targeted therapies in patients with RCC with a special focus on the elderly population. Recently, two bone targeted agents have been approved in the prevention of SREs in advanced RCC: zoledronic acid and denosumab. To date, there is no specific data on the use of bisphosphonates or denosumab in the elderly and specific studies in this setting are warranted. We compare the available evidence for the use and implications of both agents in the elderly patient and give general information on safety concerns that could be more important in these patients.
C1 [Roza, Thomas; Hakim, Lukman; van Poppel, Hendrik; Joniau, Steven] Univ Hosp Leuven, Dept Urol, B 3000 Louvain, Belgium.
C3 KU Leuven; University Hospital Leuven
RP Roza, T (通讯作者)，Univ Hosp Leuven, Dept Urol, Herestr 49, B 3000 Louvain, Belgium.
EM Tomroza@hotmail.com
RI joniau, steven/K 7655 2013; Joniau, Steven/K 7655 2013
OI joniau, steven/0000 0003 3195 9890; Hakim, Lukman/0000 0003 1518 8010
FU Novartis; Amgen
FX No sources of funding were used to prepare this review. Steven Joniau
   has received consulting fees or payment for lectures from Novartis and
   Amgen. Roza, Hakim and Van Poppel have no conflicts of interest that are
   directly relevant to the content of this review.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Addeo R, 2008, SUPPORT CARE CANCER, V16, P209, DOI 10.1007/s00520 007 0315 y
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   [Anonymous], SEER stat fact sheets: Colon and rectum cancer
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Body JJ, 2007, EUR J CANCER, V43, P852, DOI 10.1016/j.ejca.2006.12.006
   Botteman MF, 2011, EUR J HEALTH ECON, V12, P575, DOI 10.1007/s10198 010 0272 0
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown Glaberman U, 2012, BIOL TARGETS THER, V6, P89, DOI 10.2147/BTT.S20677
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Carter JA, 2012, EXPERT REV PHARM OUT, V12, P425, DOI [10.1586/ERP.12.31, 10.1586/erp.12.31]
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Cozzolino M, 2009, BLOOD PURIFICAT, V27, P338, DOI 10.1159/000209246
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Doshi S, 2012, CLIN CANCER RES, V18, P2648, DOI 10.1158/1078 0432.CCR 11 2944
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ferlay JBF, 2000, GLOBOCAN2002 IARC CA
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gridelli C, 2007, ONCOLOGIST, V12, P62, DOI 10.1634/theoncologist.12 1 62
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Jassal SK, 2007, J BONE MINER RES, V22, P203, DOI 10.1359/JBMR.061014
   Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280 000000000 00000
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kijima T, 2009, BJU INT, V103, P620, DOI 10.1111/j.1464 410X.2008.08124.x
   Launay Vacher V, 2007, CANCER AM CANCER SOC, V110, P1376, DOI 10.1002/cncr.22904
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Pereira AAL, 2012, J CLIN ONCOL, V30
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Maggio D, 2005, J GERONTOL A BIOL, V60, P1414
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Migliorati CA, 2010, SUPPORT CARE CANCER, V18, P1099, DOI 10.1007/s00520 010 0882 1
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140 6736(08)61039 9
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Papachristou DJ, 2012, MED RES REV, V32, P611, DOI 10.1002/med.20224
   Pillai G, 2006, INT J CLIN PHARM TH, V44, P655
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saad F, 2005, BJU INT, V96, P964, DOI 10.1111/j.1464 410X.2005.05740.x
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2008, CANCER TREAT REV, V34, P183, DOI 10.1016/j.ctrv.2007.10.002
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Santini D, 2012, RECENT RESULTS CANC, V192, P171, DOI 10.1007/978 3 642 21892 7_8
   Santini D, 2009, CRIT REV ONCOL HEMAT, V69, P83, DOI 10.1016/j.critrevonc.2008.07.008
   Saylor PJ, 2013, EUR UROL, V63, P309, DOI 10.1016/j.eururo.2012.10.007
   Schlesinger Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039
   Sciarra A, 2007, EUR UROL, V52, P597, DOI 10.1016/j.eururo.2007.03.083
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith Matthew R, 2005, Cancer Treat Rev, V31 Suppl 3, P19, DOI 10.1016/j.ctrv.2005.09.004
   Snedecor Sonya J, 2013, J Med Econ, V16, P19, DOI 10.3111/13696998.2012.719054
   Snedecor SJ, 2012, CLIN THER, V34, P1334, DOI 10.1016/j.clinthera.2012.04.008
   Stopeck Alison, 2012, J Med Econ, V15, P712, DOI 10.3111/13696998.2012.675380
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takeda N, 2012, J ORTHOP SCI, V17, P770, DOI 10.1007/s00776 012 0294 9
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Tipples K, 2011, DRUG AGING, V28, P867, DOI 10.2165/11595820 000000000 00000
   Tunn UW, 2012, CAN J UROL, V19, P6261
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Xie JP, 2012, CLIN BREAST CANCER, V12, P247, DOI 10.1016/j.clbc.2012.04.001
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zekri J, 2001, INT J ONCOL, V19, P379
NR 84
TC 4
Z9 4
U1 0
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170 229X
EI 1179 1969
J9 DRUG AGING
JI Drugs Aging
PD NOV
PY 2013
VL 30
IS 11
BP 877
EP 886
DI 10.1007/s40266 013 0117 5
PG 10
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 236VL
UT WOS:000325827400003
PM 24072355
DA 2025 08 17
ER

PT J
AU Teixeira, S
   Santos, MM
   Branco, LC
   Costa Rodrigues, J
AF Teixeira, Sonia
   Santos, Miguel M.
   Branco, Luis C.
   Costa Rodrigues, Joao
TI Etidronate based organic salts and ionic liquids: In vitro effects on
   bone metabolism
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Bisphosphonates; Etidronate; Ionic liquids; Osteoclastogenesis;
   Osteoblastogenesis
ID BISPHOSPHONATE USE; OSTEOCLASTOGENESIS; DIFFERENTIATION; OSTEOPOROSIS;
   MECHANISMS; RESORPTION; AMPICILLIN; CHEMISTRY; MORTALITY; DENSITY
AB Bisphosphonates are a class of drugs widely used for the treatment of several pathologies associated with increased bone resorption. Although displaying low oral bioavailability, these drugs have the ability to accumulate in bone matrix, where the biological effects are exerted. In the present work, four mono  and dianionic Etidronate based Organic Salts and Ionic Liquids (Eti OSILs) were developed by combination of this drug with the superbases 1,1,3,3 tetramethylguanidine (TMG) and 1,5 diazabicyclo(4.3.0)non 5 ene (DBN) as cations, aiming to improve not only the physicochemical properties of this seminal bisphosphonate, but also its efficacy in the modulation of cellular behavior, particularly on human osteoclasts and osteoblasts. It was observed that some of the developed compounds, in particular the dianionic ones, presented very high water solubility and diminished or absent polymorphism. Also, several of them appeared to be more cytotoxic against human breast and osteosarcoma cancer cell lines while retaining low toxicity to normal cells. Regarding bone cells, a promotion of an anabolic state was observed for all Eti OSILs, primarily for the dianionic ones, which leads to an inhibition of osteoclastogenesis and an increase in osteoblastogenesis. The observed effects resulted from differential modulation of intracellular signaling pathways by the Eti OSILs in comparison with Etidronate. Hence, these results pave the way for the development of more efficient and bioavailable ionic formulations of bisphosphonates aiming to effectively modulate bone metabolism, particularly in the case of increased bone resorption.
C1 [Teixeira, Sonia] Inst Ciencias Biomed Abel Salazar, R Jorge de Viterbo Ferreira 228, P 4050313 Porto, Portugal.
   [Santos, Miguel M.; Branco, Luis C.] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, LAQV REQUIMTE, Campus Caparica, P 2829516 Caparica, Portugal.
   [Costa Rodrigues, Joao] Politecn Porto, ESS Escola Super Saude, R Dr Antonio Bernardino de Almeida 400, P 4200072 Porto, Portugal.
   [Costa Rodrigues, Joao] Escola Super Saude, Inst Politecn Viana do Castelo, Rua D Moises Alves Pinho 190, P 4900314 Viana Do Castelo, Portugal.
   [Costa Rodrigues, Joao] Univ Porto, Inst Inovacao & Invest Saude, I3S, R Alfredo Allen 208, P 4200135 Porto, Portugal.
C3 Universidade do Porto; Universidade Nova de Lisboa; Instituto
   Politecnico do Porto; Polytechnic Institute of Viana do Castelo;
   Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto
RP Costa Rodrigues, J (通讯作者)，Politecn Porto, ESS Escola Super Saude, R Dr Antonio Bernardino de Almeida 400, P 4200072 Porto, Portugal.
EM soniateixeira.88@gmail.com; miguelmsantos@fct.unl.pt;
   l.branco@fct.unl.pt; jrs@ess.ipp.pt
RI Branco, Luis/C 6426 2013; Costa Rodrigues, João/L 1058 2014; Santos,
   Miguel/O 9657 2019; Santos, Miguel/Q 1975 2017
OI Branco, Luis/0000 0003 2520 1151; Santos, Miguel/0000 0001 7347 0546;
   Costa Rodrigues, Joao/0000 0003 1375 8067; Santos,
   Miguel/0000 0001 8973 1595; Arantes Teixeira, Sonia
   Manuela/0000 0003 3664 2577
FU Associate Laboratory for Green Chemistry LAQV   FCT/MCTES
   [UIDB/50006/2020, UIDP/50006/2020]; Fundacao para a Ciencia e Tecnologia
   [PTDC/QUI QOR/32406/2017, PEst C/LA0006/2013, RECI/BBBBQB/0230/2012];
   FCT; European Union (FEDER) [POCI/01/0145/FEDER/007265]; Comissao de
   Coor denacao e Desenvolvimento Regional do Norte (CCDRN)
   /NORTE2020/Portugal 2020 [Norte 01 0145 FEDER 000024]; Fundação para a
   Ciência e a Tecnologia [PTDC/QUI QOR/32406/2017] Funding Source: FCT
FX The data that support the findings of this study are available from the
   corresponding author upon reasonable request. This work was supported by
   the Associate Laboratory for Green Chemistry LAQV which is financed by
   national funds from FCT/MCTES (UIDB/50006/2020 and UIDP/50006/2020) .
   The authors also thank Fundacao para a Ciencia e Tecnologia for the
   projects PTDC/QUI QOR/32406/2017, PEst C/LA0006/2013 and
   RECI/BBBBQB/0230/2012) , as well as one contract under Investigador FCT
   (L. C. Branco) . Partial financial support from the European Union
   (FEDER funds POCI/01/0145/FEDER/007265) . Thanks are also due to
   "Comissao de Coor denacao e Desenvolvimento Regional do Norte (CCDRN)
   /NORTE2020/Portugal 2020" for funding through project
   DESignBIOtechHealth (ref. Norte 01 0145 FEDER 000024) .
CR Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Beaupre LA, 2011, OSTEOPOROSIS INT, V22, P983, DOI 10.1007/s00198 010 1411 2
   Pereira CB, 2012, CELL PROLIFERAT, V45, P386, DOI 10.1111/j.1365 2184.2012.00826.x
   Billington EO, 2020, CURR OSTEOPOROS REP, V18, P587, DOI 10.1007/s11914 020 00612 4
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Burke M.D., 2019, WIPO (PCT) Patent, Patent No. [WO2019186342A1, 2019186342]
   Carrera GVSM, 2017, NEW J CHEM, V41, P6986, DOI 10.1039/c7nj01398a
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Costa Rodrigues J, 2016, BBA GEN SUBJECTS, V1860, P825, DOI 10.1016/j.bbagen.2016.01.014
   Costa Rodrigues J, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5653275
   Costa Rodrigues J, 2012, BONE, V51, P17, DOI 10.1016/j.bone.2012.03.015
   Costa Rodrigues J, 2011, CLIN EXP METASTAS, V28, P505, DOI 10.1007/s10585 011 9387 7
   Cremers S, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115501
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Egorova KS, 2017, CHEM REV, V117, P7132, DOI 10.1021/acs.chemrev.6b00562
   Ferraz R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030221
   Ferraz R, 2014, RSC ADV, V4, P4301, DOI 10.1039/c3ra44286a
   Ferraz R, 2012, MEDCHEMCOMM, V3, P494, DOI 10.1039/c2md00269h
   Florindo C, 2014, INT J PHARMACEUT, V469, P179, DOI 10.1016/j.ijpharm.2014.04.034
   Florindo C, 2013, INT J PHARMACEUT, V456, P553, DOI 10.1016/j.ijpharm.2013.08.010
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Hiroi Furuya E, 1999, CALCIFIED TISSUE INT, V64, P219, DOI 10.1007/s002239900606
   HOOGENDOORN HA, 1984, CLIN ORTHOP RELAT R, P281
   Huang CH, 2010, PROTEINS, V78, P888, DOI 10.1002/prot.22614
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Le BQ, 2018, MATERIALS, V11, DOI 10.3390/ma11010014
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Machado M, 2009, CLIN THER, V31, P962, DOI 10.1016/j.clinthera.2009.05.009
   Nikfar Z, 2017, J MOL GRAPH MODEL, V76, P86, DOI 10.1016/j.jmgm.2017.06.021
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   ONGPHIPHADHANAKUL B, 1993, ENDOCRINOLOGY, V133, P2502, DOI 10.1210/en.133.6.2502
   Park YE, 2017, CURR OPIN PHARMACOL, V34, P21, DOI 10.1016/j.coph.2017.04.001
   Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003 4819 149 6 200809160 00007
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Santos MM, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080694
   Santos MM, 2019, CHEMMEDCHEM, V14, P907, DOI 10.1002/cmdc.201900040
   Shamshina JL, 2015, NATURE, V528, P188, DOI 10.1038/528188a
   Silverman SL, 2011, ANN NY ACAD SCI, V1218, P33, DOI 10.1111/j.1749 6632.2010.05769.x
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Tang J, 2019, CURR MED CHEM, V26, P5947, DOI 10.2174/0929867325666180605123436
   Teixeira S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030293
   Teixeira S, 2019, CHEMMEDCHEM, V14, P1767, DOI 10.1002/cmdc.201900397
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Vassaki M, 2020, CHEM COMMUN, V56, P5166, DOI 10.1039/d0cc00439a
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zhou Y., 2008, ETHNIC DIS, V2
NR 50
TC 4
Z9 4
U1 2
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD DEC 15
PY 2021
VL 610
AR 121262
DI 10.1016/j.ijpharm.2021.121262
EA NOV 2021
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XO4IU
UT WOS:000730151300006
PM 34748807
DA 2025 08 17
ER

PT J
AU Cai, ZY
   Yang, B
   Shi, YX
   Zhang, WL
   Liu, F
   Zhao, W
   Yang, MW
AF Cai, Zhen yu
   Yang, Bo
   Shi, Ying xu
   Zhang, Wei lin
   Liu, Fei
   Zhao, Wei
   Yang, Mao Wei
TI High glucose downregulates the effects of autophagy on
   osteoclastogenesis via the AMPK/mTOR/ULK1 pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Diabetic osteoporosis; Osteoclastogenesis; Autophagy; Glucose; AMPK
ID DIFFERENTIATION; RECEPTOR; PROTEIN; KINASE; AMPK
AB Diabetes is a chronic disease that disrupts the balance between bone formation and bone desorption, which can lead to osteoporosis, increasing the risk of fracture. However, compared with osteoblasts, the biological effects of hyperglycemia on osteoclastogenesis remain to be elucidated. Therefore, we investigated the impact of glucose at different concentrations (5.5, 10.5, 15.5, 20.5, 25.5, and 30.5 mM) on osteoclastogenesis using RAW264.7 cells. Cell proliferation was measured with the cell counting kit 8 assay, and osteoclastogenesis was detected with tartrate resistant acid phosphatase staining and bone resorption assays, as well as protein cathepsin K expression. Compound C, the AMP activated protein kinase (AMPK) pathway inhibitor, was used to examine the relationship between the AMPK/mTOR/ULK1 signaling pathway and autophagy in osteoclasts. Autophagy was evaluated with transmission electron microscopy and immunofluorescence microscopy and associated proteins were detected with western blotting. The pharmacological autophagic reagents bafilomycin Al, 3 methyladenine, and rapamycin were used to determine the effect of autophagy on osteoclastogenesis. Our results showed that glucose negatively affected osteoclast formation and function but did not affect the proliferation of RAW264.7 cells. Suppression of the AMPK/mTOR/ULK1 signaling axis decreased autophagy in glucose mediated osteoclast. Furthermore, High levels of glucose decreased autophagy level in osteoclasts. Additionally, interfering with autophagy affected osteoclast formation and function. These findings clarify the mechanisms underlying the effects of glucose mediated osteoclastogenesis and will help identify novel therapeutic strategies for the protection of skeletal health in diabetic osteoporosis. (C) 2018 Published by Elsevier Inc.
C1 [Cai, Zhen yu; Yang, Bo; Shi, Ying xu; Liu, Fei; Zhao, Wei; Yang, Mao Wei] China Med Univ, Hosp 1, Dept Orthoped, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
   [Zhang, Wei lin] China Med Univ, Hosp 4, Dept Orthoped, 4 Chongshandong Rd, Shenyang 110032, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Yang, MW (通讯作者)，China Med Univ, Hosp 1, Dept Orthoped, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
EM mwyang@cmu.edu.cn
RI Yang, Boxuan/HHM 3368 2022; Cai, Zhenyu/NXC 4423 2025; Shi,
   Yingxu/HRD 7016 2023
FU Chinese National Natural Science Foundation Project [81471094,
   81170808]; Fund of Liaoning Province Department of Education [L2013301];
   Liaoning Province Natural Science Foundation [2015020725]; Shenyang
   Municipal Science and Technology Fund [F12 277 1 47]
FX ZYC, BY and MWY conceived the study. ZYC and BY wrote the study. MWY
   coordinated the study. YXS, FL, WLZ, and WZ provided technical
   assistance and contributed to the acquisition of data. All authors
   analyzed the data and approved the final manuscript. This study was
   supported by the Chinese National Natural Science Foundation Project
   [grant numbers 81471094, 81170808]; Fund of Liaoning Province Department
   of Education [grant number L2013301]; Liaoning Province Natural Science
   Foundation [grant number 2015020725]; and Shenyang Municipal Science and
   Technology Fund [grant number F12 277 1 47].
CR [Anonymous], 2021, Diabetes Atlas
   Catalfamo DL, 2013, ORAL DIS, V19, P303, DOI 10.1111/odi.12002
   Ding WX, 2015, AM J PHYSIOL CELL PH, V308, pC246, DOI 10.1152/ajpcell.00375.2014
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kanzaki H, 2014, FREE RADICAL BIO MED, V77, P239, DOI 10.1016/j.freeradbiomed.2014.09.006
   Larsen KI, 2002, J CELL BIOCHEM, V87, P75, DOI 10.1002/jcb.10252
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Meng HZ, 2015, J BIOL CHEM, V290, P28189, DOI 10.1074/jbc.M115.669499
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev cellbio 092910 154005
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Xu J, 2015, MOL MED REP, V11, P865, DOI 10.3892/mmr.2014.2807
   Yang L, 2016, J MOL ENDOCRINOL, V56, P291, DOI 10.1530/JME 15 0267
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Zhang WL, 2016, ONCOTARGET, V7, P52179, DOI 10.18632/oncotarget.10538
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
NR 22
TC 49
Z9 61
U1 0
U2 55
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 5
PY 2018
VL 503
IS 2
BP 428
EP 435
DI 10.1016/j.bbrc.2018.04.052
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GR5VY
UT WOS:000442711200006
PM 29649480
DA 2025 08 17
ER

PT J
AU Wang, G
   Chen, K
   Ma, C
   Wang, C
   Chen, DL
   He, JB
   Liu, YH
   Jiang, T
   Yuan, JB
   Chen, LL
   He, W
   Xu, JK
AF Wang, Gang
   Chen, Kai
   Ma, Chao
   Wang, Chao
   Chen, Delong
   He, Jianbo
   Liu, Yuhao
   Jiang, Tao
   Yuan, Jinbo
   Chen, Leilei
   He, Wei
   Xu, Jiake
TI Roburic acid attenuates osteoclastogenesis and bone resorption by
   targeting RANKL induced intracellular signaling pathways
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE osteoclast; RANKL; roburic acid; TRAF6
ID NF KAPPA B; RECEPTOR ACTIVATOR; HEME OXYGENASE 1; NFATC1;
   DIFFERENTIATION; OSTEOPOROSIS; EXPRESSION; MEDICINE; PROMOTER
AB Excessive activity of osteoclasts contributes to skeletal diseases such as osteoporosis and osteolysis. However, current drugs targeting osteoclast have various deficiencies, placing natural compounds as substitutions of great potential. Roburic acid (RA) is a triterpenoid exacted from Radix Gentianae Macrophyllae, which exhibits inhibitory effects on inflammation and oxidation. By employing an in vitro osteoclastogenesis model, this study investigates the effects and mechanisms of RA on intracellular signaling induced by receptor activator of nuclear factor kappa B ligand (RANKL). As expected, RA at a concentration scope from 1 to 10 mu M dampened the osteoclast differentiation of bone marrow macrophages (BMMs) but without cell toxicity. Interestingly, RA showed no effect on osteoblastogenesis in vitro. Furthermore, RA mitigated F actin ring formation, hydroxyapatite resorption, and gene expression in osteoclasts. Mechanistically, RA suppressed TNF receptor associated factor 6 (TRAF6), the crucial adaptor protein following RANKL RANK binding. On the one hand, RA downregulated the nuclear factor kappa B (NF kappa B) activity, extracellular regulated protein kinases (ERK) phosphorylation, and calcium oscillations. On the other hand, RA upregulated the antioxidative response element (ARE) response and the protein expression of heme oxygenase (HO) 1. These upstream alterations eventually led to the suppression of the nuclear factor of activated T cells 1 (NFATc1) activity and the expression of proteins involved in osteoclastogenesis and bone resorption. Furthermore, by using an ovariectomized (OVX) mice model, RA was found to have therapeutic effects against bone loss. On account of these findings, RA could be used to restrain osteoclasts for treating osteoporosis and other osteolytic diseases.
C1 [Wang, Gang; Liu, Yuhao] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed, Guangzhou, Peoples R China.
   [Wang, Gang; Chen, Kai; Wang, Chao; Chen, Delong; He, Jianbo; Liu, Yuhao; Yuan, Jinbo; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Wang, Gang; Ma, Chao] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Chen, Delong] Erasmus MC, Dept Orthopaed, Rotterdam, Netherlands.
   [He, Jianbo] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Orthopaed, Guangzhou, Peoples R China.
   [Jiang, Tao] Guangdong Second Tradit Chinese Med Hosp, Dept Orthopaed, Guangzhou, Peoples R China.
   [Chen, Leilei; He, Wei] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, Guangzhou 510405, Peoples R China.
C3 Guangzhou University of Chinese Medicine; University of Western
   Australia; Guangzhou University of Chinese Medicine; Erasmus University
   Rotterdam; Erasmus MC; Guangzhou University of Chinese Medicine;
   Guangzhou University of Chinese Medicine
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.; He, W (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, Guangzhou 510405, Peoples R China.
EM heweiboneresearch@163.com; jiake.xu@uwa.edu.au
RI ; Chen, KaiJie/A 1743 2016; Liu, Yuhao/LDE 7575 2024
OI Xu, Jiake/0000 0003 2021 8309; Chen, Kai/0000 0001 6850 1723; Yuan,
   Jinbo/0000 0002 6240 9333; Ma, Chao/0000 0002 7735 235X; wang,
   gang/0000 0002 3769 0784; Ma, Chao/0000 0002 1049 6172
FU Visiting Program for Graduate Students [20172101024]; Australian
   National Health and Medical Research Council [NHMRC, APP1107828,
   APP1127156, APP1163933]
FX G. W. was sponsored by the Visiting Program for Graduate Students (grant
   number: 20172101024). The research was also a project of the Australian
   National Health and Medical Research Council, grant/award numbers:
   NHMRC, APP1107828, APP1127156, and APP1163933. The authors acknowledge
   the facilities and scientific and technical assistance of the National
   Imaging Facility, a National Collaborative Research Infrastructure
   Strategy (NCRIS) capability, at the Centre for Microscopy,
   Characterisation and Analysis, The University of Western Australia.
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Biswas C, 2014, J BIOL CHEM, V289, P26882, DOI 10.1074/jbc.M114.567685
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Cao HM, 2010, PHARMACOL RES, V61, P519, DOI 10.1016/j.phrs.2010.02.007
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen YF, 2017, INFLAMMATION, V40, P1959, DOI 10.1007/s10753 017 0636 z
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu L, 2019, ALZHEIMERS DEMENT, V15, P1183, DOI 10.1016/j.jalz.2019.06.3918
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Macián F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russo R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238965
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Verhoff M, 2014, J NAT PROD, V77, P1445, DOI 10.1021/np500198g
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Yamaguchi Y, 2014, J APPL TOXICOL, V34, P49, DOI 10.1002/jat.2827
   Zhang XX, 2018, PHYTOMEDICINE, V46, P142, DOI 10.1016/j.phymed.2018.04.020
NR 39
TC 14
Z9 15
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2022
VL 237
IS 3
BP 1790
EP 1803
DI 10.1002/jcp.30642
EA NOV 2021
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA ZY9GQ
UT WOS:000720350200001
PM 34796915
DA 2025 08 17
ER

PT J
AU Pang, YC
   Fu, Y
   Li, C
   Wu, ZX
   Cao, WC
   Hu, X
   Sun, XC
   He, WX
   Cao, XK
   Ling, DS
   Li, Q
   Fan, CH
   Yang, C
   Kong, XQ
   Qin, A
AF Pang, Yichuan
   Fu, Yao
   Li, Chen
   Wu, Zuoxing
   Cao, Weicheng
   Hu, Xi
   Sun, Xiaochen
   He, Wenxin
   Cao, Xiankun
   Ling, Daishun
   Li, Qian
   Fan, Chunhai
   Yang, Chi
   Kong, Xueqian
   Qin, An
TI Metal Organic Framework Nanoparticles for Ameliorating Breast
   Cancer Associated Osteolysis
SO NANO LETTERS
LA English
DT Article
DE Bone targeting; metal organic frameworks; immunostimulatory; breast
   cancer metastasis; osteoclast
ID ZOLEDRONIC ACID; DRUG DELIVERY; BACTERIAL DNA; BONE; OLIGONUCLEOTIDES;
   BISPHOSPHONATES; IMMUNOTHERAPY; OSTEOBLASTS; EFFICACY; RELEASE
AB Breast cancer metastases to bone poses a significant challenge for the administration of treatment strategies. The bone microenvironment, metastatic tumor cells, osteoclasts, and tumor associated macrophages (TAMs) all play crucial and synergistic roles in creating a favorable environment for the proliferation, progression, and survival of the metastatic tumor, which in turn induces osteoclast mediated bone destruction. In this study, we functionalized immunostimulatory cytosine phosphate guanosine (CpG) loaded metal organic framework (MOF) nanoparticles with bone targeting capabilities by surface modification with FDA approved antiresorptive bisphosphonate, zoledronic acid (ZOL). The functionalized bone targeting immunostimulatory MOF (BT isMOF) nanoparticles demonstrates strong binding to calcium phosphate in vitro and exhibits specific targeting and accumulation in bone tissues in vivo. In vitro cellular and biochemical analyses demonstrated that the BT isMOF nanoparticles could potently inhibit osteoclast formation and concomitantly induce macrophages polarization toward the M1 pro inflammatory phenotype. Finally, using the intratibial murine model of breast cancer bone metastasis, we showed that the administration of BT isMOF nanoparticles significantly suppressed osteoclast mediated bone destruction and enhanced polarization of tumor resident macrophages to M1 phenotype. Together, our data provides promising evidence for the potential therapeutic application of the BT isMOF nanoparticles in the treatment of breast cancer bone metastases.
C1 [Pang, Yichuan; He, Wenxin; Cao, Xiankun; Yang, Chi; Qin, An] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai, Peoples R China.
   [Fu, Yao; Cao, Weicheng; Hu, Xi; Ling, Daishun; Kong, Xueqian] Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China.
   [Li, Chen; Wu, Zuoxing; Sun, Xiaochen] Guangxi Med Univ, Guangxi, Peoples R China.
   [Li, Qian; Fan, Chunhai] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Zhejiang University; Guangxi Medical
   University; Shanghai Jiao Tong University
RP Yang, C; Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai, Peoples R China.; Kong, XQ (通讯作者)，Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China.
EM Yangchi63@hotmail.com; kxq@zju.edu.cn; dr_qinan@163.com
RI Cao, Weicheng/IZP 9338 2023; Ling, Daishun/AAH 6088 2021; Kong,
   Xueqian/P 3152 2018; Fan, Chunhai/A 7569 2011; pang,
   yichuan/GWQ 7981 2022; Qin, An/J 2518 2019
OI Ling, Daishun/0000 0002 9977 0237; Fu, Yao/0000 0003 4103 0065; Cao,
   Weicheng/0000 0002 3569 2006; Fan, Chunhai/0000 0002 7171 7338; Kong,
   Xueqian/0000 0002 1901 9073; 
FU Natural Science Foundation of China [81772373, 81572167]; Shanghai
   Municipal Education Commission Gaofeng Clinical Medicine; Shanghai
   Institute of Precision Medicine, Ninth People's Hospital Shanghai Jiao
   Tong University School of Medicine [JY201804, JC201801]; National Key
   Research and Development Program of China [2016YFA0203600]; Zhejiang
   Provincial Natural Science Foundation [R19B050003]; Zhejiang University
   K. P. Chao's High Technology Development Foundation [2018RC009]
FX This project is supported by grants from Natural Science Foundation of
   China (81772373, 81572167), by Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support, the SHIPM pi fund
   JY201804 and JC201801 from Shanghai Institute of Precision Medicine,
   Ninth People's Hospital Shanghai Jiao Tong University School of
   Medicine, National Key Research and Development Program of China
   2016YFA0203600, Zhejiang Provincial Natural Science Foundation
   R19B050003, and Zhejiang University K. P. Chao's High Technology
   Development Foundation 2018RC009.
CR Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434
   Amcheslavsky A, 2007, J BONE MINER RES, V22, P1301, DOI 10.1359/JBMR.070501
   Bertran O, 2014, DALTON T, V43, P317, DOI 10.1039/c3dt52112e
   Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369
   Chen TT, 2018, J AM CHEM SOC, V140, P9912, DOI 10.1021/jacs.8b04457
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chen W, 2018, DALTON T, V47, P2114, DOI 10.1039/c7dt04116k
   Chen X, 2016, DALTON T, V45, P1648, DOI 10.1039/c5dt03357h
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   D'Souza S, 2014, BIOMATERIALS, V35, P9447, DOI 10.1016/j.biomaterials.2014.07.041
   Dittmer J., 2018, SEMIN CANCER BIOL, V53, pS9
   Du Y, 2019, NANO LETT, V19, P3618, DOI 10.1021/acs.nanolett.9b00630
   Forgan R. S, 2019, COORDIN CHEM REV, V380, P230, DOI DOI 10.1016/J.CCR.2018.09.009
   Freund R, 2018, ACS NANO, V12, P2094, DOI 10.1021/acsnano.8b00932
   Fu Y, 2019, NANO LETT, V19, P1618, DOI 10.1021/acs.nanolett.8b04518
   Furukawa H, 2013, SCIENCE, V341, P974, DOI 10.1126/science.1230444
   Furukawa H, 2010, SCIENCE, V329, P424, DOI 10.1126/science.1192160
   Gao XC, 2018, NANOSCALE, V10, P6205, DOI [10.1039/c7nr08892b, 10.1039/C7NR08892B]
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   He CB, 2015, CHEM REV, V115, P11079, DOI 10.1021/acs.chemrev.5b00125
   He CB, 2014, J AM CHEM SOC, V136, P5181, DOI 10.1021/ja4098862
   Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203
   Hirschle P, 2016, CRYSTENGCOMM, V18, P4359, DOI 10.1039/c6ce00198j
   Horcajada P, 2008, J AM CHEM SOC, V130, P6774, DOI 10.1021/ja710973k
   Horcajada P, 2006, ANGEW CHEM INT EDIT, V45, P5974, DOI 10.1002/anie.200601878
   Horcajada P, 2012, CHEM REV, V112, P1232, DOI 10.1021/cr200256v
   Ji Z, 2018, P NATL ACAD SCI USA, V115, P10582, DOI 10.1073/pnas.1808829115
   Jiang W, 2019, NANO LETT, V19, P4060, DOI 10.1021/acs.nanolett.9b01458
   Kong XQ, 2013, SCIENCE, V341, P882, DOI 10.1126/science.1238339
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Li J, 2011, ACS NANO, V5, P8783, DOI 10.1021/nn202774x
   Li ZG, 2007, J IMMUNOL, V179, P1568, DOI 10.4049/jimmunol.179.3.1568
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu C., 2018, SMALL, V14
   Liu SL, 2019, NANO LETT, V19, P4721, DOI 10.1021/acs.nanolett.9b01785
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Morris W, 2014, J AM CHEM SOC, V136, P7261, DOI 10.1021/ja503215w
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Schwetz BA, 2001, JAMA J AM MED ASSOC, V286, P1569, DOI 10.1001/jama.286.13.1569 a
   Shao K, 2015, ACS NANO, V9, P16, DOI 10.1021/nn5062029
   Simon Yarza T, 2018, ADV MATER, V30, DOI 10.1002/adma.201707365
   Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521 4141(199806)28:06<2045::AID IMMU2045>3.0.CO;2 8
   Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577 018 0046 y
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang SZ, 2019, J AM CHEM SOC, V141, P2215, DOI 10.1021/jacs.8b12705
   Wang SZ, 2018, ADV MATER, V30, DOI 10.1002/adma.201800202
   Wang ZJ, 2017, J AM CHEM SOC, V139, P15784, DOI 10.1021/jacs.7b07895
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wen MY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8167
   Wu MX, 2017, ADV MATER, V29, DOI 10.1002/adma.201606134
   Wuttke S, 2017, BIOMATERIALS, V123, P172, DOI 10.1016/j.biomaterials.2017.01.025
   Yang Y, 2018, ACS APPL MATER INTER, V10, P12463, DOI 10.1021/acsami.8b01680
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhou MX, 2019, NANO LETT, V19, P3671, DOI 10.1021/acs.nanolett.9b00737
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
   Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200
NR 68
TC 84
Z9 90
U1 10
U2 279
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530 6984
EI 1530 6992
J9 NANO LETT
JI Nano Lett.
PD FEB
PY 2020
VL 20
IS 2
BP 829
EP 840
DI 10.1021/acs.nanolett.9b02916
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KM6NS
UT WOS:000514255400005
PM 31916446
DA 2025 08 17
ER

PT J
AU He, JW
   Zhao, DC
   Peng, B
   Wang, XW
   Wang, SH
   Zhao, XB
   Xu, P
   Geng, B
   Xia, YY
AF He, Jinwen
   Zhao, Dacheng
   Peng, Bo
   Wang, Xingwen
   Wang, Shenghong
   Zhao, Xiaobing
   Xu, Peng
   Geng, Bin
   Xia, Yayi
TI A novel mechanism of Vildagliptin in regulating bone metabolism and
   mitigating osteoporosis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoporosis; DPP 4 inhibitor; Bone metabolism; Bone anabolism;
   Osteogenic differentiation; TAM receptor
ID DIPEPTIDYL PEPTIDASE 4 INHIBITOR; IN VITRO; MACROPHAGES; LINAGLIPTIN
AB Osteoporosis has become a global social problem with the tendency toward the aging population. The challenge in managing osteoporosis is to develop new anti osteoporosis drugs that target bone anabolism. The purpose of this study was to uncover the novel mechanism of Vildagliptin on bone metabolism. We revealed that Vildagliptin significantly promoted osteogenic differentiation of precursor osteoblasts and bone marrow mesenchymal stem cells (BMSCs). At the same time, it significantly enhanced the polarization of RAW264.7 macrophages to the M2 type and the secretion of osteogenic factors BMP2 and TGF beta 1. This was confirmed by the increased osteogenic differentiation observed in the osteoblast RAW264.7 co culture system. Moreover, Vildagliptin significantly enhanced the transformation of BMSCs into the osteogenic morphology in the osteoblast BMSC co culture system. Finally, Vildagliptin also inhibited osteoclastic differentiation of RAW 264.7 cells. The potential mechanism underlying these effects involved targeting the GAS6/AXL/ERK5 pathway. In the in vivo study, Vildagliptin significantly alleviated postmenopausal osteoporosis in ovariectomized mice. These findings represent the first comprehensive revelation of the regulatory effect of Vildagliptin on bone metabolism. Specifically, Vildagliptin demonstrates the ability to promote bone anabolism and inhibit bone resorption by simultaneously targeting osteoblasts, BMSCs, and osteoclasts. The bone protective effects of Vildagliptin were further confirmed in a postmenopausal osteoporosis model. The clinical significance of this study lies in laying a theoretical foundation for bone protection therapy in type  2 diabetes patients with compromised bone conditions or postmenopausal osteoporosis.
C1 [He, Jinwen; Xu, Peng] Xi An Jiao Tong Univ, Honghui Hosp, Dept Joint Surg, Xian 715004, Peoples R China.
   [Zhao, Dacheng] Lanzhou Univ Second Hosp, Dept Painol, Lanzhou 730030, Peoples R China.
   [Peng, Bo; Wang, Xingwen; Wang, Shenghong; Zhao, Xiaobing; Geng, Bin; Xia, Yayi] Lanzhou Univ Second Hosp, Orthopaed Clin Med Res Ctr Gansu Prov, Intelligent Orthoped Ind Technol Ctr Gansu Prov, Dept Orthopaed, Lanzhou 730030, Peoples R China.
   [Geng, Bin; Xia, Yayi] Lanzhou Univ Second Hosp, Dept Orthopaed, Lanzhou 730030, Peoples R China.
C3 Xi'an Jiaotong University
RP Xu, P (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Joint Surg, Xian 715004, Peoples R China.; Geng, B; Xia, YY (通讯作者)，Lanzhou Univ Second Hosp, Dept Orthopaed, Lanzhou 730030, Peoples R China.
EM xupeng369@mail.xjtu.edu.cn; cxxxf@qq.com; xiayylzu@163.com
RI Peng, Bo/AAU 3941 2021
OI Xu, Peng/0000 0003 2487 9163
FU National Natural Science Foundation of China [81960403, 82060405,
   82360436]; Lanzhou Science and Technology Plan Program [2021  RC  102];
   Natural Science Foundation of Gansu Province [22JR5RA943, 22JR5RA956,
   23JRRA1500]; Shaanxi Provincial Science and Technology Plan Project
   [2024JC  YBQN 0812]; Cuiying Scientific and Technological Innovation
   Program of Lanzhou University Second Hospital [CY2021 MS A07]
FX This work was funded by The National Natural Science Foundation of China
   (81960403, 82060405, and 82360436) ; Lanzhou Science and Technology Plan
   Program (2021  RC  102) ; Natural Science Foundation of Gansu Province
   (22JR5RA943, 22JR5RA956, and 23JRRA1500) ; Shaanxi Provincial Science
   and Technology Plan Project (2024JC  YBQN 0812) ; Cuiying Scientific and
   Technological Innovation Program of Lanzhou University Second Hospital
   (CY2021 MS A07) .
CR Aini K, 2019, INT HEART J, V60, P1421, DOI 10.1536/ihj.19 117
   Batoon L, 2021, J BONE MINER RES, V36, P2214, DOI 10.1002/jbmr.4413
   Batoon L, 2019, BIOMATERIALS, V196, P51, DOI 10.1016/j.biomaterials.2017.10.033
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Charoenphandhu N, 2018, CAN J DIABETES, V42, P545, DOI 10.1016/j.jcjd.2018.01.006
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   Engelmann J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33938 x
   Geng B, 2016, EXP CELL RES, V343, P208, DOI 10.1016/j.yexcr.2016.03.014
   Glorie L, 2016, BONE, V92, P37, DOI 10.1016/j.bone.2016.08.009
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   He JW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1028932
   Jung E, 2014, EUR J PHARMACOL, V744, P98, DOI 10.1016/j.ejphar.2014.10.008
   Kanda J, 2020, DRUG DISCOV THER, V14, P218, DOI 10.5582/ddt.2020.03073
   Kim SW, 2016, ENDOCRINOL METAB, V31, P93, DOI 10.3803/EnM.2016.31.1.93
   Sbaraglini ML, 2014, EUR J PHARMACOL, V727, P8, DOI 10.1016/j.ejphar.2014.01.028
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Mahgoub S, 2022, BIOORG CHEM, V128, DOI 10.1016/j.bioorg.2022.106092
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Nirwan N, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.944323
   Nishida H, 2014, J BONE MINER RES, V29, P2439, DOI 10.1002/jbmr.2277
   Nishida H, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.1348.1348
   Nishida S, 2020, BIOCHEM BIOPH RES CO, V524, P8, DOI 10.1016/j.bbrc.2020.01.027
   Pariyar R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042388
   Paschou SA, 2017, J CLIN ENDOCR METAB, V102, P3621, DOI 10.1210/jc.2017 00042
   Pinheiro MM, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107518
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Tan TT, 2023, INT IMMUNOPHARMACOL, V116, DOI 10.1016/j.intimp.2023.109745
   Tondo G, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/2387614
   Toniolo A, 2015, J CLIN ENDOCR METAB, V100, pE50, DOI 10.1210/jc.2014 2751
   Torrecillas Baena B, 2022, STEM CELL REV REP, V18, P56, DOI 10.1007/s12015 021 10285 w
   Vianna AGD, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098 017 0232 2
   Wang XW, 2021, J CELL MOL MED, V25, P8734, DOI 10.1111/jcmm.16829
   Wang YX, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109302
   Yang Q, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.856954
   Yong EL, 2021, SINGAP MED J, V62, P159, DOI 10.11622/smedj.2021036
   Zhang B, 2021, CONNECT TISSUE RES, V62, P194, DOI 10.1080/03008207.2019.1670650
   Zhang Y, 2022, NEUROSCI LETT, V776, DOI 10.1016/j.neulet.2022.136579
   Zheng L, 2022, CLIN EXP IMMUNOL, V209, P270, DOI 10.1093/cei/uxac071
   Zhu CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1090 3
NR 42
TC 3
Z9 3
U1 5
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR 30
PY 2024
VL 130
AR 111671
DI 10.1016/j.intimp.2024.111671
EA FEB 2024
PG 14
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA LP7A4
UT WOS:001188058800001
PM 38367467
DA 2025 08 17
ER

PT J
AU David, M
   Machuca Gayet, I
   Kikuta, J
   Ottewell, P
   Mima, F
   Leblanc, R
   Bonnelye, E
   Ribeiro, J
   Holen, I
   Vales, RL
   Jurdic, P
   Chun, J
   Clézardin, P
   Ishii, M
   Peyruchaud, O
AF David, Marion
   Machuca Gayet, Irma
   Kikuta, Junichi
   Ottewell, Penelope
   Mima, Fuka
   Leblanc, Raphael
   Bonnelye, Edith
   Ribeiro, Johnny
   Holen, Ingunn
   Lopez Vales, Ruben
   Jurdic, Pierre
   Chun, Jerold
   Clezardin, Philippe
   Ishii, Masaru
   Peyruchaud, Olivier
TI Lysophosphatidic Acid Receptor Type 1 (LPA1) Plays a
   Functional Role in Osteoclast Differentiation and Bone Resorption
   Activity
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Bone; Differentiation; Lysophospholipid; Osteoclast; Osteoporosis;
   Receptors
ID PROTEIN COUPLED RECEPTOR; PARATHYROID HORMONE; TARGETED DELETION;
   SEALING ZONE; EXPRESSION; MICE; RESPONSES; GENE; REQUIREMENT; ACTIVATION
AB Background: Lysophosphatidic acid (LPA) is a bioactive lipid with pleiotropic activities due to activation of six receptors (LPA(1 6)). Results: Genetic deletion and pharmacological blockade of LPA(1) inhibit differentiation and bone degradation activity of osteoclasts. Conclusion: LPA controls bone homeostasis through the activation of LPA(1) expressed by osteoclasts. Significance: LPA(1) is a new therapeutic target of diseases with excess bone degradation.
   Lysophosphatidic acid (LPA) is a natural bioactive lipid that acts through six different G protein coupled receptors (LPA(1 6)) with pleiotropic activities on multiple cell types. We have previously demonstrated that LPA is necessary for successful in vitro osteoclastogenesis of bone marrow cells. Bone cells controlling bone remodeling (i.e. osteoblasts, osteoclasts, and osteocytes) express LPA(1), but delineating the role of this receptor in bone remodeling is still pending. Despite Lpar1( / ) mice displaying a low bone mass phenotype, we demonstrated that bone marrow cell induced osteoclastogenesis was reduced in Lpar1( / ) mice but not in Lpar2( / ) and Lpar3( / ) animals. Expression of LPA(1) was up regulated during osteoclastogenesis, and LPA(1) antagonists (Ki16425, Debio0719, and VPC12249) inhibited osteoclast differentiation. Blocking LPA(1) activity with Ki16425 inhibited expression of nuclear factor of activated T cell cytoplasmic 1 (NFATc1) and dendritic cell specific transmembrane protein and interfered with the fusion but not the proliferation of osteoclast precursors. Similar to wild type osteoclasts treated with Ki16425, mature Lpar1( / ) osteoclasts had reduced podosome belt and sealing zone resulting in reduced mineralized matrix resorption. Additionally, LPA(1) expression markedly increased in the bone of ovariectomized mice, which was blocked by bisphosphonate treatment. Conversely, systemic treatment with Debio0719 prevented ovariectomy induced cancellous bone loss. Moreover, intravital multiphoton microscopy revealed that Debio0719 reduced the retention of CX(3)CR1 EGFP(+) osteoclast precursors in bone by increasing their mobility in the bone marrow cavity. Overall, our results demonstrate that LPA(1) is essential for in vitro and in vivo osteoclast activities. Therefore, LPA(1) emerges as a new target for the treatment of diseases associated with excess bone loss.
C1 [David, Marion; Leblanc, Raphael; Bonnelye, Edith; Ribeiro, Johnny; Clezardin, Philippe; Peyruchaud, Olivier] UCB Lyon 1, INSERM, UMR1033, Fac Med Lyon Est, F 69732 Lyon, France.
   [Machuca Gayet, Irma; Jurdic, Pierre] UCB Lyon 1, Equipe Biol Cellulaire & Physiopathol Osseuse, Inst Genom Fonct Lyon, CNRS,UMR5242,ENS, F 69007 Lyon, France.
   [Kikuta, Junichi; Mima, Fuka; Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka 5650871, Japan.
   [Kikuta, Junichi; Mima, Fuka; Ishii, Masaru] Japan Sci & Technol Agcy, CREST, Tokyo 1020076, Japan.
   [Ottewell, Penelope; Holen, Ingunn] Univ Sheffield, Sch Med, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Lopez Vales, Ruben] Univ Autonoma Barcelona, Fac Med, Unitat Fisiol Med, Grp Neuroplasticitat & Regeneracio, E 08193 Barcelona, Spain.
   [Chun, Jerold] Scripps Res Inst, Dorris Neurosci Ctr, Dept Mol Biol, La Jolla, CA 92037 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Centre National de la Recherche
   Scientifique (CNRS); CNRS   National Institute for Biology (INSB); CHU
   Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite Claude
   Bernard Lyon 1; University of Osaka; Japan Science & Technology Agency
   (JST); University of Sheffield; University of Barcelona; Autonomous
   University of Barcelona; Scripps Research Institute
RP Peyruchaud, O (通讯作者)，Fac Med Lyon Est, INSERM, U1033, Rue Guillaume Paradin, F 69372 Lyon 08, France.
EM olivier.peyruchaud@inserm.fr
RI ; Lopez Vales, Ruben/E 2150 2011; Clezardin, Philippe/M 8071 2014; Chun,
   Jerold/Y 4670 2019; Bonnelye, Edith/AAT 9134 2021; Kikuta,
   Junichi/HHS 8875 2022
OI Ottewell, Penelope/0000 0002 4826 0771; Lopez Vales,
   Ruben/0000 0001 7615 9550; Clezardin, Philippe/0000 0003 0149 4463;
   Leblanc, Raphael/0000 0002 1976 9587; Holen, Ingunn/0000 0002 8759 6913;
   Peyruchaud, Olivier/0000 0002 5393 4945; DAVID,
   Marion/0009 0001 0985 1835; Machuca  Gayet, irma/0000 0002 3010 9774
FU INSERM; Comite Departemental de la Loire de la Ligue Nationale Contre le
   Cancer; French Association pour la Recherche sur le Cancer; Ligue
   Nationale Contre le Cancer
FX This work was supported by grants from INSERM (to O. P. and P. C.), the
   Comite Departemental de la Loire de la Ligue Nationale Contre le Cancer
   (to O. P.), and the French Association pour la Recherche sur le Cancer
   (to O. P.). Recipient of a fellowship from the French Association pour
   la Recherche sur le Cancer. Recipients of a fellowship from the Ligue
   Nationale Contre le Cancer.
CR An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103
   Boucharaba A, 2009, ONCOL RES, V18, P173, DOI 10.3727/096504009790217399
   Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753
   Choi KU, 2011, INT J CANCER, V128, P332, DOI 10.1002/ijc.25341
   Coleman R, 2011, ANN NY ACAD SCI, V1218, P3, DOI 10.1111/j.1749 6632.2010.05766.x
   Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384
   Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921 6929.2002
   Daaka Y, 2002, BBA MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388 1981(02)00180 4
   David M, 2012, INT J ONCOL, V40, P1133, DOI 10.3892/ijo.2011.1309
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Duong CQ, 2004, BBA MOL CELL BIOL L, V1682, P112
   Dusaulcy R, 2009, J PHYSIOL BIOCHEM, V65, P345, DOI 10.1007/BF03185929
   EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   Fueller M, 2003, CELL SIGNAL, V15, P367, DOI 10.1016/S0898 6568(02)00117 1
   Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151
   Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018
   Gidley J, 2006, PROSTAG OTH LIPID M, V80, P46, DOI 10.1016/j.prostaglandins.2006.04.001
   Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071
   Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173
   Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555 011 9319 7
   Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106 4114.2000
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Karagiosis SA, 2007, BIOCHEM BIOPH RES CO, V357, P194, DOI 10.1016/j.bbrc.2007.03.121
   Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Lattin J, 2007, J LEUKOCYTE BIOL, V82, P16, DOI 10.1189/jlb.0107051
   Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200
   Lin ME, 2012, J BIOL CHEM, V287, P17608, DOI 10.1074/jbc.M111.330183
   Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002
   Lin SB, 2010, GASTROENTEROLOGY, V138, P649, DOI 10.1053/j.gastro.2009.09.055
   Liu YB, 2010, J CELL BIOCHEM, V109, P794, DOI 10.1002/jcb.22471
   Mansell JP, 2011, PROSTAG OTH LIPID M, V95, P45, DOI [10.1016/j.prostaglandins.2011.05.002, 10.1016/j.prostaglandins.2011.05.003]
   Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958
   McMichael BK, 2010, J BIOL CHEM, V285, P26641, DOI 10.1074/jbc.M110.119909
   Miyabe Y, 2013, ARTHRITIS RHEUM US, V65, P2037, DOI 10.1002/art.37991
   Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1
   Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955 0674(97)80059 2
   Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476 5381.2011.01622.x
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010
   Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994
   Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Panchatcharam M, 2008, CIRC RES, V103, P662, DOI 10.1161/CIRCRESAHA.108.180778
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Peyruchaud O, 2013, BBA MOL CELL BIOL L, V1831, P99, DOI 10.1016/j.bbalip.2012.06.004
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Sakai N, 2013, FASEB J, V27, P1830, DOI 10.1096/fj.12 219378
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sims SM, 2013, BBA MOL CELL BIOL L, V1831, P109, DOI 10.1016/j.bbalip.2012.08.001
   Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121
   Sumida H, 2010, BLOOD, V116, P5060, DOI 10.1182/blood 2010 03 272443
   Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeda S, 2001, J BONE MINER METAB, V19, P195, DOI 10.1007/s007740170042
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
   Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200
   Ye XQ, 2008, BIOL REPROD, V79, P328, DOI 10.1095/biolreprod.108.068783
   Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505
   Yu SX, 2008, JNCI J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378
   Yung YC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002095
   Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415
NR 75
TC 38
Z9 44
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 7
PY 2014
VL 289
IS 10
BP 6551
EP 6564
DI 10.1074/jbc.M113.533232
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AC3BG
UT WOS:000332389400021
PM 24429286
OA Green Published
DA 2025 08 17
ER

PT J
AU Piva, R
   Penolazzi, L
   Lambertini, E
   Torreggiani, E
   Borgatti, M
   Vecchiatini, R
   Gambari, R
AF Piva, R.
   Penolazzi, L.
   Lambertini, E.
   Torreggiani, E.
   Borgatti, M.
   Vecchiatini, R.
   Gambari, R.
TI Modulation of specific signalling pathways in osteoblasts through
   nucleic acid based drugs
SO MINERVA BIOTECNOLOGICA
LA English
DT Article
DE Osteoblasts; Osteoclasts; DNA based drugs; Transcription factors
ID TRANSCRIPTION FACTOR DECOY; KAPPA B LIGAND; THERAPEUTIC TARGET; RECEPTOR
   ACTIVATOR; RNA INTERFERENCE; GENE EXPRESSION; BONE; DIFFERENTIATION;
   NFAT; RANKL
AB Improvements in our understanding of osteoporosis and in the design of approaches to modulate the expression of genes that play a critical role in bone environment should help to overcome bone diseases. In this review we describe, through two specific examples, how a methodology based on nucleic acid molecules can contribute to clarify the impact of transcription factors such as Slug and NFATc1 on osteoblast biology, showing also that they may be considered potential candidate for promoting bone regeneration. Whereas some major aspects concerning the use of nucleic acid based drugs still need to be investigated, the encouraging results obtained both in vitro and in vivo together with the relevant social impact of the pathologies which may be treated by these molecules, justifies further efforts to optimize their use and to bring them closer to the clinical practice.
C1 [Piva, R.; Penolazzi, L.; Lambertini, E.; Torreggiani, E.; Borgatti, M.; Gambari, R.] Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, I 44100 Ferrara, Italy.
   [Vecchiatini, R.] Univ Ferrara, Dent Sect, Dept Medicosurg Disciplines Commun & Behav, I 44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara
RP Piva, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, Via Fossato Mortara 74, I 44100 Ferrara, Italy.
EM piv@unife.it
RI Vecchiatini, Renata/J 1829 2015; Borgatti, Monica/G 2611 2015; Gambari,
   Roberto/F 9555 2015; Torreggiani, Elena/J 6404 2016
OI Vecchiatini, Renata/0000 0001 7055 9502; Piva,
   Roberta/0000 0003 2663 6210; Borgatti, Monica/0000 0001 8470 2496;
   Gambari, Roberto/0000 0001 9205 6033; Torreggiani,
   Elena/0000 0001 7874 2002; Penolazzi, Letizia/0000 0002 1293 5087
FU MIUR; Regione Emilia Romagna; Programma di Ricerca Regione Universita';
   Fondazione Cassa di Risparmio di Padova e Rovigo; Fondazione Cassa di
   Risparmio di Ferrara
FX This research was supported by grants from MIUR COHN 2007, Regione
   Emilia Romagna, Programma di Ricerca Regione Universita' 2007 2009, the
   Fondazione Cassa di Risparmio di Padova e Rovigo. E.L. is a recipient of
   a fellowship from the Fondazione Cassa di Risparmio di Ferrara.
CR Alvarez Salas LM, 2008, CURR TOP MED CHEM, V8, P1379, DOI 10.2174/156802608786141133
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bodine P. V. N., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P296
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Boonen S, 2009, INT J CLIN PRACT, V63, P1792, DOI 10.1111/j.1742 1241.2009.02206.x
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Compston J, 2009, EUR J RADIOL, V71, P388, DOI 10.1016/j.ejrad.2008.04.063
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Day CJ, 2005, J CELL BIOCHEM, V95, P17, DOI 10.1002/jcb.20410
   De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Enders GH, 2009, J CLIN INVEST, V119, P758, DOI 10.1172/JCI38973
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Gao HH, 2006, MOL PHARMACOL, V70, P1621, DOI 10.1124/mol.106.024273
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Grimm D, 2009, ADV DRUG DELIVER REV, V61, P672, DOI 10.1016/j.addr.2009.05.002
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378 1119(00)00371 1
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Huang HC, 2010, J BONE MINER RES, V25, P819, DOI 10.1359/jbmr.091019
   Karkare S, 2006, APPL MICROBIOL BIOT, V71, P575, DOI 10.1007/s00253 006 0434 2
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kotobuki N, 2008, CELL TISSUE RES, V332, P279, DOI 10.1007/s00441 008 0580 1
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Lambertini E, 2002, BIOCHEM BIOPH RES CO, V292, P761, DOI 10.1006/bbrc.2002.6708
   Lambertini E, 2007, EXP CELL RES, V313, P1548, DOI 10.1016/j.yexcr.2007.02.002
   Lambertini E, 2009, CELL MOL LIFE SCI, V66, P3641, DOI 10.1007/s00018 009 0149 5
   LIAN JB, 2009, CRIT REV EUKAR GENE, V14, P1
   Lin L, 2006, BIOCHEM BIOPH RES CO, V349, P564, DOI 10.1016/j.bbrc.2006.08.089
   Lodewyckx Liesbet, 2009, Curr Rheumatol Rep, V11, P23
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187
   Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216 007 1346 4
   Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marini F, 2009, CALCIFIED TISSUE INT, V84, P337, DOI 10.1007/s00223 009 9226 x
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Pekkinen M, 2008, BONE, V43, P84, DOI 10.1016/j.bone.2008.02.021
   Penolazzi L, 2007, MOL PHARMACOL, V71, P1457, DOI 10.1124/mol.107.034561
   Pierroz DD, 2009, J BONE MINER RES, V24, P775, DOI [10.1359/JBMR.081237, 10.1359/jbmr.081237]
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Rauner M, 2009, J BONE MINER RES, V24, P78, DOI 10.1359/JBMR.080902
   Rayburn ER, 2008, DRUG DISCOV TODAY, V13, P513, DOI 10.1016/j.drudis.2008.03.014
   Shimizu H, 2006, GENE THER, V13, P933, DOI 10.1038/sj.gt.3302711
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Stern PH, 2006, MOL INTERV, V6, P193, DOI 10.1124/mi.6.4.4
   Suda T, 2009, ORAL MICROBIOL IMMUN, V24, P384, DOI 10.1111/j.1399 302X.2009.00529.x
   Sun SG, 2008, EXPERT OPIN THER TAR, V12, P239, DOI [10.1517/14728222.12.2.239, 10.1517/14728222.12.2.239 ]
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tominaga H, 2009, J BONE MINER METAB, V27, P36, DOI 10.1007/s00774 008 0003 0
   Van Sant C, 2007, MOL CANCER THER, V6, P253, DOI 10.1158/1535 7163.MCT 06 0574
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yeo H, 2006, ANN NY ACAD SCI, V1068, P564, DOI 10.1196/annals.1346.053
   Yuasa T, 2009, AM J PATHOL, V175, P1993, DOI 10.2353/ajpath.2009.081173
   Zhang YZ, 2010, BONE, V46, P1131, DOI 10.1016/j.bone.2009.12.026
   Zhu ED, 2008, J BIOL CHEM, V283, P7361, DOI 10.1074/jbc.M703304200
NR 77
TC 0
Z9 0
U1 0
U2 2
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83 85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 1120 4826
EI 1827 160X
J9 MINERVA BIOTECNOL
JI Minerva Biotechnol.
PD MAR
PY 2011
VL 23
IS 1
BP 17
EP 22
PG 6
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 804VC
UT WOS:000293681100003
DA 2025 08 17
ER

PT J
AU Xie, C
   Li, ZZ
   Zhang, GX
   Guan, YT
AF Xie, Chong
   Li, Zezhi
   Zhang, Guang Xian
   Guan, Yangtai
TI Wnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Wnt signaling; Oligodendrocytes; Remyelination; Multiple sclerosis
ID BONE MORPHOGENETIC PROTEIN; OLIGODENDROCYTE PROGENITOR CELLS;
   CENTRAL NERVOUS SYSTEM; BETA CATENIN; TRANSCRIPTION FACTOR;
   GENE EXPRESSION; AUTOIMMUNE ENCEPHALOMYELITIS; REGULATES PROLIFERATION;
   PRECURSOR CELLS; FEEDBACK LOOP
AB Myelination is critical to normal functioning of the vertebrate nervous system. In demyelinating diseases such as multiple sclerosis, oligodendrocytes, the myelinating cells in the central nervous system, are targeted, resulting in myelin loss, axonal damage, and severe functional impairment. While spontaneous remyelination has been proven a failure in multiple sclerosis, understanding the molecular mechanism underlying oligodendrocyte biology, myelination, and remyelination becomes crucial. To date, a series of signaling pathways in regulating oligodendrocyte development and remyelination have been suggested and, among them, the Wnt/beta catenin/Tcf pathway has been considered a negative factor in the myelinating process. However, this notion has been challenged by recent studies, which showed a promyelinating effect of this pathway. This review summarizes the current contradictory concepts concerning the role of the Wnt pathway in the oligodendrocyte development and remyelination process, attempts to address the potential mechanism underlying this controversy, and recommends caution in targeting the Wnt pathway as a potential demyelinating therapy.
C1 [Xie, Chong; Li, Zezhi; Zhang, Guang Xian; Guan, Yangtai] Second Mil Med Univ, Changhai Hosp, Dept Neurol, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Zhang, GX (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Neurol, Shanghai 200433, Peoples R China.
EM gxzhang30@hotmail.com; yangtaiguan@hotmail.com
RI ; Li, Zezhi/K 3125 2019
OI Guan, Yangtai/0000 0003 0813 4073; 
FU National Natural Science Foundations of China [81230027, 81070959]; Key
   Scientific and Technological Project of Shanghai [11411950300]
FX This work was supported by the National Natural Science Foundations of
   China (81230027, 81070959) and Key Scientific and Technological Project
   of Shanghai (11411950300). We thank Katherine Regan for the editorial
   assistance.
CR Avasarala S, 2013, BIOL OPEN, V2, P675, DOI 10.1242/bio.20134507
   Azim K, 2011, GLIA, V59, P540, DOI 10.1002/glia.21122
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Bejsovec A, 2005, CELL, V120, P11, DOI 10.1016/S0092 8674(04)01246 2
   Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   Chen HL, 2013, CANCER LETT, V335, P361, DOI 10.1016/j.canlet.2013.02.058
   Cheng XX, 2007, STEM CELLS, V25, P3204, DOI 10.1634/stemcells.2007 0284
   Chew LJ, 2011, J NEUROSCI, V31, P13921, DOI 10.1523/JNEUROSCI.3343 11.2011
   Ciani L, 2011, P NATL ACAD SCI USA, V108, P10732, DOI 10.1073/pnas.1018132108
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   De Sarno P, 2008, J IMMUNOL, V181, P338, DOI 10.4049/jimmunol.181.1.338
   Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015
   Fancy SPJ, 2011, NAT NEUROSCI, V14, P1009, DOI 10.1038/nn.2855
   Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309
   Fazekas F, 2007, J NEUROL SCI, V259, P61, DOI 10.1016/j.jns.2006.12.018
   Feigenson K, 2011, ASN NEURO, V3, DOI 10.1042/AN20110004
   Fiedler M, 2011, P NATL ACAD SCI USA, V108, P1937, DOI 10.1073/pnas.1017063108
   Fu H, 2012, CELL MOL NEUROBIOL, V32, P345, DOI 10.1007/s10571 011 9778 y
   Fu H, 2009, J NEUROSCI, V29, P11399, DOI 10.1523/JNEUROSCI.0160 09.2009
   Galimberti D, 2011, NEUROSCI LETT, V497, P46, DOI 10.1016/j.neulet.2011.04.024
   Goldschmidt T, 2009, NEUROLOGY, V72, P1914, DOI 10.1212/WNL.0b013e3181a8260a
   Guo YW, 2013, FEBS J, V280, P4531, DOI 10.1111/febs.12417
   Hampton DW, 2007, EUR J NEUROSCI, V26, P3024, DOI 10.1111/j.1460 9568.2007.05940.x
   Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559
   He Y, 2007, NEURON, V55, P217, DOI 10.1016/j.neuron.2007.06.029
   Hoffmann V, 2006, EUR J NEUROL, V13, P72, DOI 10.1111/j.1468 1331.2006.01145.x
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hutchins BI, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002523
   Jacob C, 2011, MOL NEUROBIOL, V44, P303, DOI 10.1007/s12035 011 8198 9
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Julio MK, 2013, DEV DYNAM, DOI [10.1002/dvdy.24008, DOI 10.1002/DVDY.24008]
   Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105
   Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008 5472.CAN 09 3470
   Kawasoe T, 2000, CANCER RES, V60, P3354
   Kim NC, 2010, DEV DYNAM, V239, P2413, DOI 10.1002/dvdy.22368
   Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096
   Lang J, 2013, J NEUROSCI, V33, P3113, DOI 10.1523/JNEUROSCI.3467 12.2013
   Lee MA, 2013, J NAT PROD, V76, P1278, DOI 10.1021/np400216m
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092 8674(95)90276 7
   Liu AM, 2005, NAT REV NEUROSCI, V6, P945, DOI 10.1038/nrn1805
   Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502 500
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Ma J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024768
   Mäurer M, 2011, EUR J NEUROL, V18, P1036, DOI 10.1111/j.1468 1331.2010.03313.x
   Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nickles D, 2013, HUM MOL GENET, V22, P4194, DOI 10.1093/hmg/ddt267
   Oestreich KJ, 2011, J EXP MED, V208, P1001, DOI 10.1084/jem.20102144
   Ortega F, 2013, NAT CELL BIOL, V15, P602, DOI 10.1038/ncb2736
   Polman C, 2005, NEUROLOGY, V64, P987, DOI 10.1212/01.WNL.0000154520.48391.69
   Rangachari M, 2013, J AUTOIMMUN, V45, P31, DOI 10.1016/j.jaut.2013.06.008
   Remington Gina M, 2010, Ther Adv Neurol Disord, V3, P3, DOI 10.1177/1756285609355851
   Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273
   See JM, 2009, J NEUROPATH EXP NEUR, V68, P595, DOI 10.1097/NEN.0b013e3181a66ad9
   Shen SM, 2008, NAT NEUROSCI, V11, P1024, DOI 10.1038/nn.2172
   Sohn J, 2006, J NEUROSCI, V26, P9722, DOI 10.1523/JNEUROSCI.1716 06.2006
   Stadelmann C, 2008, J NEUROL, V255, P12, DOI 10.1007/s00415 008 1003 7
   Tawk M, 2011, J NEUROSCI, V31, P3729, DOI 10.1523/JNEUROSCI.4270 10.2011
   Tuller T, 2013, GENES IMMUN, V14, P67, DOI 10.1038/gene.2012.55
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Weng QJ, 2012, NEURON, V73, P713, DOI 10.1016/j.neuron.2011.12.021
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031
   Wu MZ, 2012, J NEUROSCI, V32, P6651, DOI 10.1523/JNEUROSCI.4876 11.2012
   Wu YY, 2010, J BIOL CHEM, V285, P34621, DOI 10.1074/jbc.M110.148791
   Ye F, 2009, NAT NEUROSCI, V12, P829, DOI 10.1038/nn.2333
   Yu Q, 2009, NAT IMMUNOL, V10, P992, DOI 10.1038/ni.1762
   Yuan SB, 2012, J NEUROIMMUNE PHARM, V7, P904, DOI 10.1007/s11481 012 9370 3
   Zara F, 2006, NAT GENET, V38, P1111, DOI 10.1038/ng1870
   Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
NR 75
TC 45
Z9 55
U1 0
U2 18
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893 7648
EI 1559 1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JUN
PY 2014
VL 49
IS 3
BP 1117
EP 1125
DI 10.1007/s12035 013 8584 6
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA AG8KE
UT WOS:000335666500001
PM 24243343
DA 2025 08 17
ER

PT J
AU Bussiere, JL
   Pyrah, I
   Boyce, R
   Branstetter, D
   Loomis, M
   Andrews Cleavenger, D
   Farman, C
   Elliott, G
   Chellman, G
AF Bussiere, Jeanine L.
   Pyrah, Ian
   Boyce, Rogely
   Branstetter, Dan
   Loomis, Mark
   Andrews Cleavenger, Dina
   Farman, Cynthia
   Elliott, Glenn
   Chellman, Gary
TI Reproductive toxicity of denosumab in cynomolgus monkeys
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE Cynomolgus monkeys; Pre postnatal toxicity; Embryofetal toxicity;
   Denosumab; Reproductive toxicity
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; BONE MARROW; OSTEOCLAST
   DIFFERENTIATION; MALIGNANT OSTEOPETROSIS; INFANTILE OSTEOPETROSIS;
   OSTEOPROTEGERIN LIGAND; DEVELOPMENTAL TOXICITY; RECEPTOR ACTIVATOR;
   PLACENTAL TRANSFER; TOOTH ERUPTION
AB Denosumab is a monoclonal antibody that inhibits bone resorption by targeting RANKL, an essential mediator of osteoclast formation, function, and survival. Reproductive toxicity of denosumab was assessed in cynomolgus monkeys in an embryofetal development study (dosing GD20 50) and a pre postnatal toxicity study (dosing GD20 parturition). In the embryofetal toxicity study, denosumab did not elicit maternal toxicity, fetal harm or teratogenicity. In the pre postnatal toxicity study, there were increased stillbirths, and one maternal death due to dystocia. There was no effect on maternal mammary gland histomorphology, lactation, or fetal growth. In infants exposed in utero, there was increased postnatal mortality, decreased body weight gain, and decreased growth/development. Denosumab related effects in infants were present in bones and lymph nodes. There was full recovery at 6 months of age from most bone related changes observed earlier postpartum. The effects observed in mothers and infants were consistent with the pharmacological action of denosumab. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bussiere, Jeanine L.; Pyrah, Ian; Boyce, Rogely; Loomis, Mark; Andrews Cleavenger, Dina] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Branstetter, Dan] Amgen Inc, Seattle, WA 98119 USA.
   [Farman, Cynthia; Elliott, Glenn; Chellman, Gary] Charles River PCS NV, Reno, NV 89511 USA.
C3 Amgen; Amgen
RP Bussiere, JL (通讯作者)，Amgen Inc, 1 Amgen Ctr Dr,MS 29 2 A, Thousand Oaks, CA 91320 USA.
EM jeanine.bussiere@amgen.com
CR [Anonymous], 2011, ADD ICH S6 GUID PREC
   Auyeung Kim DJ, 2009, REPROD TOXICOL, V28, P443, DOI 10.1016/j.reprotox.2009.07.002
   Barbaroux JBO, 2008, J IMMUNOL, V181, P1103, DOI 10.4049/jimmunol.181.2.1103
   BEARD CJ, 1986, J LAB CLIN MED, V108, P498
   Blin Wakkach C, 2004, LEUKEMIA, V18, P1505, DOI 10.1038/sj.leu.2403449
   Boyce R, 2013, INFANT CYNOMOL UNPUB
   Buse E, 2002, PRIMATE MODELS PHARM, P93
   Bussiere JL, 2012, J BONE MINER RES  S1, V27
   Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608
   Capen C.C., 2004, VET PATHOPHYSIOLOGY, V1st ed., P422
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   Chellman GJ, 2009, BIRTH DEFECTS RES B, V86, P446, DOI 10.1002/bdrb.20216
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   DROZDESPREZ D, 1992, J ORAL PATHOL MED, V21, P422, DOI 10.1111/j.1600 0714.1992.tb01032.x
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   FUJIMOTO K, 1983, JPN J MED SCI BIOL, V36, P171, DOI 10.7883/yoken1952.36.171
   GERRITSEN EJA, 1994, PEDIATRICS, V93, P247
   Gomes MF, 2006, SPEC CARE DENT, V26, P106, DOI 10.1111/j.1754 4505.2006.tb01432.x
   GRAEPEL P, 1992, ARZNEIMITTEL FORSCH, V42 1, P654
   Grier RL, 1998, J DENT RES, V77, P8, DOI 10.1177/00220345980770011201
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   HELFRICH MH, 1991, BONE, V12, P411, DOI 10.1016/8756 3282(91)90030 M
   Hendrie TA, 1996, AM J PRIMATOL, V40, P41, DOI 10.1002/(SICI)1098 2345(1996)40:1<41::AID AJP3>3.0.CO;2 0
   ICH M3(R2), 2009, GUID NONCL SAF STUD
   Jacquin C, ASBMR 2005
   Jälevik B, 2002, BONE MARROW TRANSPL, V29, P537, DOI 10.1038/sj.bmt.1703416
   Jarvis P, 2010, BIRTH DEFECTS RES B, V89, P175, DOI 10.1002/bdrb.20234
   Kamoun Goldrat A, 2008, EUR J ORAL SCI, V116, P195, DOI 10.1111/j.1600 0722.2008.00529.x
   Kane SV, 2009, AM J GASTROENTEROL, V104, P228, DOI 10.1038/ajg.2008.71
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kovacs CS, 2008, AM J CLIN NUTR, V88, p520S, DOI 10.1093/ajcn/88.2.520S
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LEHMAN RAW, 1977, ANN NEUROL, V2, P378, DOI 10.1002/ana.410020506
   Li ZS, 2000, P NATL ACAD SCI USA, V108, P4388
   LORIACORTES R, 1977, J PEDIATR US, V91, P43, DOI 10.1016/S0022 3476(77)80441 1
   Lu LW, 2001, EXP HEMATOL, V29, P596, DOI 10.1016/S0301 472X(01)00621 X
   Mahadevan U, 2013, CLIN GASTROENTEROL H, V11, P286, DOI 10.1016/j.cgh.2012.11.011
   Makori N, 2003, CLIN DIAGN LAB IMMUN, V10, P140, DOI 10.1128/CDLI.10.1.140 153.2003
   Malek A, 1996, AM J REPROD IMMUNOL, V36, P248
   Mansour A, 2011, CELL RES, V21, P1102, DOI 10.1038/cr.2011.21
   Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043 2760(00)00351 9
   Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054
   MINSKER DH, 1993, TOXICOL APPL PHARM, V121, P217, DOI 10.1006/taap.1993.1148
   OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Pentsuk N, 2009, BIRTH DEFECTS RES B, V86, P328, DOI 10.1002/bdrb.20201
   Ponce R, 2009, REGUL TOXICOL PHARM, V54, P164, DOI 10.1016/j.yrtph.2009.03.012
   REEVES J, 1981, METAB BONE DIS RELAT, V3, P135, DOI 10.1016/0221 8747(81)90032 1
   Roundy K, 1999, J IMMUNOL, V163, P6671
   Schramek D., 2011, IMBS BONEKEY, V8, P237, DOI DOI 10.1138/20110512
   Shankar G, 2007, NAT BIOTECHNOL, V25, P555, DOI 10.1038/nbt1303
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Souraty N, 2007, EUR J MED GENET, V50, P188, DOI 10.1016/j.ejmg.2007.01.005
   Steward CG, 2003, NEUROPATH APPL NEURO, V29, P87, DOI 10.1046/j.1365 2990.2003.00474.x
   Stolina M, 2007, J IMMUNOL, V179, P7497, DOI 10.4049/jimmunol.179.11.7497
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Vaidyanathan A, 2011, TOXICOL SCI, V119, P116, DOI 10.1093/toxsci/kfq316
   Whyte M.P., 2002, CONNECTIVE TISSUE IT, V2nd, P753
   Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449
   WISE GE, 1989, J DENT RES, V68, P150, DOI 10.1177/00220345890680021001
   Yuan P, 2011, J BONE MINER METAB, V29, P251, DOI 10.1007/s00774 010 0228 6
NR 67
TC 29
Z9 33
U1 0
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890 6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD DEC
PY 2013
VL 42
BP 27
EP 40
DI 10.1016/j.reprotox.2013.07.018
PG 14
WC Reproductive Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Reproductive Biology; Toxicology
GA 260BD
UT WOS:000327569100004
PM 23886817
DA 2025 08 17
ER

PT J
AU Wang, HY
   Wang, L
   Luan, HW
   Xiao, J
   Zhao, ZL
   Yu, PF
   Deng, M
   Liu, YF
   Ji, SH
   Ma, JJ
   Zhou, Y
   Zhang, JS
   Meng, XH
   Zhang, J
   Zhao, XY
   Li, CL
   Li, FM
   Wang, DP
   Wei, SJ
   Hui, LJ
   Nie, SM
   Jin, CZ
   An, ZQ
   Zhang, NY
   Wang, YP
   Zhang, CC
   Li, ZL
AF Wang, Hongying
   Wang, Lei
   Luan, Huiwen
   Xiao, Jing
   Zhao, Zhiling
   Yu, Pengfei
   Deng, Mi
   Liu, Yifan
   Ji, Shuhao
   Ma, Junjie
   Zhou, Yan
   Zhang, Jiashen
   Meng, Xianhui
   Zhang, Juan
   Zhao, Xinyu
   Li, Chunling
   Li, Fangmin
   Wang, Dapeng
   Wei, Shujuan
   Hui, Lijun
   Nie, Siman
   Jin, Changzhu
   An, Zhiqiang
   Zhang, Ningyan
   Wang, Yaopeng
   Zhang, Cheng Cheng
   Li, Zunling
TI LILRB4 on multiple myeloma cells promotes bone lesion by
   p SHP2/NF κB/RELT signal pathway
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE LILRB4; Multiple myeloma; Bone lesion; RELT
ID INHIBITORY RECEPTOR ILT3; TUMOR NECROSIS FACTOR; IMMUNE CHECKPOINT;
   PLASMA CELLS; EXPRESSION; DENOSUMAB; DEXAMETHASONE; SUPERFAMILY;
   SUPPRESSOR; BORTEZOMIB
AB BackgroundLeukocyte Ig like receptor B family 4 (LILRB4) as an immune checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone lesion is the most characteristic feature of multiple myeloma. It is unclear whether ectopic LILRB4 on multiple myeloma regulates bone lesion.MethodsThe conditioned medium (CM) from LILRB4 WT and  KO cells was used to analyze the effects of LILRB4 on osteoclasts and osteoblasts. Xenograft, syngeneic and patient derived xenograft models were constructed, and micro CT, H&E staining were used to observe the bone lesion. RNA seq, cytokine array, qPCR, the activity of luciferase, Co IP and western blotting were used to clarify the mechanism by which LILRB4 mediated bone damage in multiple myeloma.ResultsWe comprehensively analyzed the expression of LILRB4 in various tumor tissue arrays, and found that LILRB4 was highly expressed in multiple myeloma samples. The patient's imaging data showed that the higher the expression level of LILRB4, the more serious the bone lesion in patients with multiple myeloma. The conditioned medium from LILRB4 WT not  KO cells could significantly promote the differentiation and maturation of osteoclasts. Xenograft, syngeneic and patient derived xenograft models furtherly confirmed that LILRB4 could mediate bone lesion of multiple myeloma. Next, cytokine array was performed to identify the differentially expressed cytokines, and RELT was identified and regulated by LILRB4. The overexpression or exogenous RELT could regenerate the bone damage in LILRB4 KO cells in vitro and in vivo. The deletion of LILRB4, anti LILRB4 alone or in combination with bortezomib could significantly delay the progression of bone lesion of multiple myeloma.ConclusionsOur findings indicated that LILRB4 promoted the bone lesion by promoting the differentiation and mature of osteoclasts through secreting RELT, and blocking LILRB4 singling pathway could inhibit the bone lesion.
C1 [Wang, Hongying; Wang, Lei; Luan, Huiwen; Zhao, Zhiling; Liu, Yifan; Ji, Shuhao; Zhang, Jiashen; Meng, Xianhui; Zhang, Juan; Zhao, Xinyu; Li, Chunling; Li, Fangmin; Hui, Lijun; Nie, Siman; Jin, Changzhu; Li, Zunling] Binzhou Med Univ, Dept Biochem & Mol Biol, Shandong Tumour Immunotherapy Res Innovat Team, Yantai 264003, Shandong, Peoples R China.
   [Xiao, Jing] Yantaishan Hosp, Dept Hematol, Yantai 264003, Shandong, Peoples R China.
   [Yu, Pengfei] Binzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Yantai 264003, Shandong, Peoples R China.
   [Deng, Mi; Zhang, Cheng Cheng] Univ Texas Southwestern Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   [Deng, Mi] Peking Univ, Peking Univ Int Canc Inst, CN 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Ma, Junjie] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Hematol, Yantai 264009, Shandong, Peoples R China.
   [Zhou, Yan] Yantaishan Hosp, Dept Gastrointestinalstrointestinal Surg, Yantai 264003, Shandong, Peoples R China.
   [Zhang, Jiashen] Shandong Agr Univ, Sch Life Sci, Dept Biochem & Mol Biol, Tai An 271018, Shandong, Peoples R China.
   [Wang, Dapeng] Bengbu Med Coll, Dept Pathophysiol, Bengbu 233000, Anhui, Peoples R China.
   [Wei, Shujuan] Luye Pharm Grp, R&D Ctr, Yantai 264005, Shandong, Peoples R China.
   [An, Zhiqiang; Zhang, Ningyan] Univ Texas Hlth Sci Ctr, Brown Fdn Inst Mol Med, Texas Therapeut Inst, Houston, TX 77030 USA.
   [Wang, Yaopeng] Univ Hlth & Rehabil Sci, Qingdao Hosp, Qingdao Municipal Hosp, Dept Thorac Surg, Qingdao 266011, Shandong, Peoples R China.
C3 Binzhou Medical University; Binzhou Medical University; University of
   Texas System; University of Texas Southwestern Medical Center; Peking
   University; Qingdao University; Shandong Agricultural University; Bengbu
   Medical University; University of Texas System; University of Texas
   Health Science Center Houston; University of Health & Rehabilitation
   Sciences; Qingdao Municipal Hospital
RP Li, ZL (通讯作者)，Binzhou Med Univ, Dept Biochem & Mol Biol, Shandong Tumour Immunotherapy Res Innovat Team, Yantai 264003, Shandong, Peoples R China.; Zhang, CC (通讯作者)，Univ Texas Southwestern Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Wang, YP (通讯作者)，Univ Hlth & Rehabil Sci, Qingdao Hosp, Qingdao Municipal Hosp, Dept Thorac Surg, Qingdao 266011, Shandong, Peoples R China.
EM qdwangyaopeng@163.com; Alec.Zhang@UTSouthwestern.edu;
   lizunling@bzmc.edu.cn
RI An, Zhiqiang/IUO 1781 2023; Zhang, Jiashen/AAI 2954 2020; Wang,
   Dapeng/JVZ 9338 2024; Zhang, Juan/GRX 2638 2022; Salah,
   Ahmad/K 8761 2017
FU National Natural Science Foundation of China [82150101, 81872332,
   82070225]; University Enterprise Integration Plan of Yantai
   [2021XDRHXMQT17]; Leukemia & Lymphoma Society [6629 21]; Welch
   Foundation [AU 0042 20030616]; Shandong Natural Science Foundation
   [ZR202103070011, ZR2023QC190]
FX This study was funded by the National Natural Science Foundation of
   China (82150101, 81872332, 82070225) to Zunling Li,
   University Enterprise Integration Plan of Yantai (2021XDRHXMQT17) to
   Zunling Li, the Leukemia & Lymphoma Society (6629 21) to Cheng Cheng
   Zhang, the Welch Foundation (AU 0042 20030616) to Zhiqiang An, and
   Shandong Natural Science Foundation (ZR202103070011) to Hongying Wang,
   (ZR2023QC190) to Xianhui Meng.
CR Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood 2011 04 325225
   Anami Y, 2020, MOL CANCER THER, V19, P2330, DOI 10.1158/1535 7163.MCT 20 0407
   Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Chen D, 2016, IMMUNOPHARM IMMUNOT, V38, P175, DOI 10.3109/08923973.2016.1153110
   Choi BK, 2018, EUR J IMMUNOL, V48, P1739, DOI 10.1002/eji.201847633
   Chong PSY, 2019, CANCER RES, V79, P4679, DOI 10.1158/0008 5472.CAN 19 0343
   Churchill HRO, 2021, CYTOM PART B CLIN CY, V100, P476, DOI 10.1002/cyto.b.21952
   Colovai AI, 2007, CYTOM PART B CLIN CY, V72B, P354, DOI 10.1002/cyto.b.20164
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   de Goeje PL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014242
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586 018 0615 z
   Di Meo F, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2023.101110
   Dimopoulos MA, 2018, LANCET ONCOL, V19, P277, DOI 10.1016/S1470 2045(18)30075 5
   Dobrowolska H, 2013, CYTOM PART B CLIN CY, V84B, P21, DOI 10.1002/cyto.b.21050
   Federico C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19932 1
   Fowler JA, 2009, DIS MODEL MECH, V2, P604, DOI 10.1242/dmm.003160
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Gui X, 2019, CANCER IMMUNOL RES, V7, P1244, DOI 10.1158/2326 6066.CIR 19 0036
   Inui M, 2016, INT IMMUNOL, V28, P597, DOI 10.1093/intimm/dxw044
   John S, 2018, MOL THER, V26, P2487, DOI 10.1016/j.ymthe.2018.08.001
   Kang XL, 2016, CELL CYCLE, V15, P25, DOI 10.1080/15384101.2015.1121324
   Kim Schulze S, 2006, J IMMUNOL, V176, P2790, DOI 10.4049/jimmunol.176.5.2790
   Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823
   Kumata S, 2023, THORAC CANCER, V14, P2057, DOI 10.1111/1759 7714.14991
   Li J, 2021, CANCER LETT, V501, P263, DOI 10.1016/j.canlet.2020.10.048
   Li ZL, 2020, CELL MOL IMMUNOL, V17, P272, DOI 10.1038/s41423 019 0321 2
   Manavalan JS, 2003, TRANSPL IMMUNOL, V11, P245, DOI 10.1016/S0966 3274(03)00058 3
   Martin T, 2022, LANCET HAEMATOL, V9, pE897, DOI 10.1016/S2352 3026(22)00284 8
   Menu E, 2022, BLOOD, V140, P2429, DOI 10.1182/blood.2021014749
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Mori Y, 2008, J IMMUNOL, V181, P4742, DOI 10.4049/jimmunol.181.7.4742
   Mukkamalla SKR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126208
   Nair Gupta P, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408 020 0331 4
   Paavola KJ, 2021, CANCER IMMUNOL RES, V9, P1283, DOI 10.1158/2326 6066.CIR 21 0240
   Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038
   Patiño Escobar B, 2022, CELL STRESS, V6, P89, DOI 10.15698/cst2022.11.273
   Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raje NS, 2019, CLIN CANCER RES, V25, P12, DOI 10.1158/1078 0432.CCR 18 1537
   Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470 2045(19)30152 4
   Sanz Rodríguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346
   Schmiedel BJ, 2013, CANCER RES, V73, P683, DOI 10.1158/0008 5472.CAN 12 2280
   Sharma N, 2021, J EXP MED, V218, DOI 10.1084/jem.20201811
   Sica GL, 2001, BLOOD, V97, P2702, DOI 10.1182/blood.V97.9.2702
   Singh L, 2021, MOL CANCER RES, V19, P702, DOI 10.1158/1541 7786.MCR 20 0622
   Spanoudakis E, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.108
   Su MT, 2023, INT IMMUNOL, V35, P135, DOI 10.1093/intimm/dxac051
   Su MT, 2022, ONCOIMMUNOLOGY, V11, DOI 10.1080/2162402X.2022.2060907
   Sun ZX, 2023, BLOOD ADV, V7, P4148, DOI 10.1182/bloodadvances.2022009477
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2021, LANCET ONCOL, V22, pE119, DOI 10.1016/S1470 2045(20)30559 3
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140 6736(21)00135 5
   Wang JY, 2023, CANCER IMMUNOL RES, V11, P1384, DOI 10.1158/2326 6066.CIR 23 0088
   Wang YT, 2024, CELL REP MED, V5, DOI 10.1016/j.xcrm.2023.101374
   Winkler W, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2219439120
   Wu D, 2019, CANCER MED US, V8, P1576, DOI 10.1002/cam4.2055
   Xu Z, 2018, J IMMUNOL, V200, P1207, DOI 10.4049/jimmunol.1700553
   Yang T, 2022, BLOOD SCI, V4, P49, DOI 10.1097/BS9.0000000000000109
   Yoshimoto T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34352 z
   Yu TT, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408 020 00378 z
   Zhong L, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2091
   Zurli V, 2017, BLOOD, V130, P2006, DOI 10.1182/blood 2017 03 775858
NR 66
TC 10
Z9 10
U1 2
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD JUL 1
PY 2024
VL 43
IS 1
AR 183
DI 10.1186/s13046 024 03110 y
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA XD0G4
UT WOS:001259623100001
PM 38951916
OA gold
DA 2025 08 17
ER

PT J
AU Ma, C
   Mo, L
   Wang, ZZ
   Peng, DQ
   Zhou, C
   Niu, W
   Liu, YH
   Chen, ZQ
AF Ma, Chao
   Mo, Liang
   Wang, Zhangzheng
   Peng, Deqiang
   Zhou, Chi
   Niu, Wei
   Liu, Yuhao
   Chen, Zhenqiu
TI Dihydrotanshinone I attenuates estrogen deficiency bone loss through
   RANKL stimulated NF κB, ERK and NFATc1 signaling pathways
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Dihydrotanshinone I; Osteoclasts; Estrogen deficiency; Bone mass loss
ID SALVIA MILTIORRHIZA; OSTEOCLAST DIFFERENTIATION; OSTEOPOROSIS; VITRO
AB Postmenopausal osteoporosis, a chronic condition that predominantly affects postmenopausal women, presents a significant impediment to their overall well being. The condition arises from estrogen deficiency, leading to enhanced osteoclast activity. Salvia miltiorrhiza, a well established Chinese herbal medicine with a history of clinical use for osteoporosis treatment, contains diverse active constituents that have shown inhibitory effects on osteoclast formation and bone loss. Dihydrotanshinone I (DTI), a phenanthrenonequinone compound derived from the root of Salvia miltiorrhiza, has been identified as a potential therapeutic agent, although its mechanism of action on osteoclasts remains elusive.In this study, we aimed to elucidate the inhibitory potential of DTI on RANKL induced osteoclastogenesis. We observed the ability of DTI to effectively impede the expression of key osteoclast specific genes and proteins, as assessed by Real time PCR and Western Blotting analyses. Mechanistically, DTI exerted its inhibitory effects on osteoclast formation by modulating critical signaling pathways including NF kappa B, ERK, and calcium ion signaling. Notably, DTI intervention disrupted the nuclear translocation and subsequent transcriptional activity of the NFATc1, thus providing mechanistic insights into its inhibitory role in osteoclastogenesis. To further assess the therapeutic potential of DTI, we employed an ovariectomized osteoporosis animal model to examine its impact on bone loss. Encouragingly, DTI demonstrated efficacy in mitigating bone loss induced by estrogen deficiency.In conclusion, our investigation elucidates the ability of DTI to regulate multiple signaling pathways activated by RANKL, leading to the inhibition of osteoclast formation and prevention of estrogen deficiency osteoporosis. Consequently, DTI emerges as a promising candidate for the treatment of osteoporosis.
C1 [Ma, Chao; Mo, Liang; Wang, Zhangzheng; Peng, Deqiang] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Ma, Chao; Peng, Deqiang; Niu, Wei] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Mo, Liang; Wang, Zhangzheng; Zhou, Chi; Liu, Yuhao; Chen, Zhenqiu] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Niu, W (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.; Liu, YH; Chen, ZQ (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM niuwei@139.com; doctor_yuhaoliu@126.com; chenzhenqiu2012@126.com
RI ; Liu, Yuhao/LDE 7575 2024
OI Ma, Chao/0000 0002 1049 6172; 
FU National Natural Science Foundation of China [82104883,81473700];
   Natural Science Foundation of Guangdong Province [2021A1515011484];
   Science and Technology Planning Project of Guangdong Province
   [2017B090912007]; International Program for Postgraduate, Guangzhou
   University of Chinese Medicine; Double First rate Discipline and
   High level University Construction Projects of Guangzhou University of
   Chinese Medicine [2021xk46]; Guangzhou Municipal Health Commission
   [2023P TS22]
FX This research was supported by the National Natural Science Foundation
   of China (No.82104883,81473700) , Natural Science Foundation of
   Guangdong Province (No.2021A1515011484) , Science and Technology
   Planning Project of Guangdong Province (No.2017B090912007) . Chao Ma was
   supported by International Program for Postgraduate, Guangzhou
   University of Chinese Medicine. Zhenqiu Chen was supported by Double
   First rate Discipline and High level University Construction Projects of
   Guangzhou University of Chinese Medicine (No. 2021xk46) and Guangzhou
   Municipal Health Commission (No. 2023P TS22) .
CR Bian WP, 2008, ACTA BIOCH BIOPH SIN, V40, P1, DOI 10.1111/j.1745 7270.2008.00370.x
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai YH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00025
   Everts Graber J, 2022, J BONE MINER RES, V37, P340, DOI 10.1002/jbmr.4472
   Fontanges E, 2004, JOINT BONE SPINE, V71, P102, DOI 10.1016/j.jbspin.2003.02.001
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706
   Langdahl BL, 2021, J CLIN ENDOCR METAB, V106, P1845, DOI 10.1210/clinem/dgab193
   Lee DS, 1999, BIOSCI BIOTECH BIOCH, V63, P2236, DOI 10.1271/bbb.63.2236
   Liu JJ, 2015, INT J MOL SCI, V16, P19387, DOI 10.3390/ijms160819387
   Liu YH, 2020, J CELL MOL MED, V24, P12308, DOI 10.1111/jcmm.15647
   Liu YH, 2020, J CELL MOL MED, V24, P3303, DOI 10.1111/jcmm.15003
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Mo L, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/3921570
   Mo L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.950030
   Mpalaris V, 2015, OBES REV, V16, P225, DOI 10.1111/obr.12244
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang G, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.810322
   Wang G, 2022, J CELL PHYSIOL, V237, P1790, DOI 10.1002/jcp.30642
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang Y, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111674
   Wu XX, 2023, ACTA PHARM SIN B, V13, P113, DOI 10.1016/j.apsb.2022.07.006
   Zeng H, 2021, ACTA PHARM SIN B, V11, P71, DOI 10.1016/j.apsb.2020.09.006
NR 28
TC 10
Z9 12
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2023
VL 123
AR 110572
DI 10.1016/j.intimp.2023.110572
EA AUG 2023
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA U3LG4
UT WOS:001083840700001
PM 37572501
DA 2025 08 17
ER

PT J
AU Ma, MX
   Cui, GF
   Liu, YW
   Tang, YF
   Lu, XS
   Yue, C
   Zhang, X
AF Ma, Maoxiao
   Cui, Guofeng
   Liu, Youwen
   Tang, Yanfeng
   Lu, Xiaoshuai
   Yue, Chen
   Zhang, Xue
TI Mesenchymal stem cell derived extracellular vesicles, osteoimmunology
   and orthopedic diseases
SO PEERJ
LA English
DT Article
DE Mesenchymal stem cell; Extracellular vesicles; Osteoimmunology;
   Orthopedic diseases
ID IN VITRO; BONE; EXOSOMES; OSTEONECROSIS; INFLAMMATION; OSTEOARTHRITIS;
   OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; DIFFERENTIATION; DEGENERATION
AB Mesenchymal stem cells (MSCs) play an important role in tissue healing and regenera tive medicine due to their self renewal and multi directional differentiation properties. MSCs exert their therapeutic effects mainly via the paracrine pathway, which involves the secretion of extracellular vesicles (EVs). EVs have a high drug loading capacity and can transport various molecules, such as proteins, nucleic acids, and lipids, that can modify the course of diverse diseases. Due to their ability to maintain the therapeutic effects of their parent cells, MSC derived EVs have emerged as a promising, safe cell free treatment approach for tissue regeneration. With advances in inflammation research and emergence of the field of osteoimmunology, evidence has accumulated pointing to the role of inflammatory and osteoimmunological processes in the occurrence and progression of orthopedic diseases. Several studies have shown that MSC derived EVs participate in bone regeneration and the pathophysiology of orthopedic diseases by regulating the inflammatory environment, enhancing angiogenesis, and promoting the differentiation and proliferation of osteoblasts and osteoclasts. In this review, we summarize recent advances in the application and functions of MSC derived EVs as potential therapies against orthopedic diseases, including osteoarthritis, intervertebral disc degeneration, osteoporosis and osteonecrosis.
C1 [Ma, Maoxiao; Liu, Youwen; Tang, Yanfeng; Lu, Xiaoshuai; Yue, Chen; Zhang, Xue] Luoyang Orthoped Hosp Henan Prov, Orthoped Hosp Henan Prov, Dept Orthoped, Luoyang, Henan, Peoples R China.
   [Cui, Guofeng] Zhengzhou Univ, Dept Orthoped, Luoyang Cent Hosp, Luoyang, Henan, Peoples R China.
C3 Zhengzhou University
RP Yue, C; Zhang, X (通讯作者)，Luoyang Orthoped Hosp Henan Prov, Orthoped Hosp Henan Prov, Dept Orthoped, Luoyang, Henan, Peoples R China.
EM yuechen08@outlook.com; 15856040194@163.com
RI Yue, Chen/IAP 6501 2023
OI Cui, GuoFeng/0009 0008 1078 3391
FU National Natural Science Foundation of China [82004396, 82074472];
   Project of Science and Technology of Henan Province [212102311089];
   Heluo youth talent promotion project [2022HLTJ15]
FX Funding This work is supported in China by the National Natural Science
   Foundation of China (82004396, 82074472) ; the Project of Science and
   Technology of Henan Province (212102311089) ; and the Heluo youth talent
   promotion project (2022HLTJ15) . The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Barile L, 2014, CARDIOVASC RES, V103, P530, DOI 10.1093/cvr/cvu167
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Brandau S, 2010, J LEUKOCYTE BIOL, V88, P1005, DOI 10.1189/jlb.0410207
   Carreras Planella L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01288
   Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood 2018 11 844530
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood 2005 07 2657
   Cui SQ, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211021679
   Dar HY, 2018, FRONT BIOSCI LANDMRK, V23, P464, DOI 10.2741/4600
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X
   Ding F, 2013, APOPTOSIS, V18, P777, DOI 10.1007/s10495 013 0839 1
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Dowdell J, 2017, NEUROSURGERY, V80, pS46, DOI 10.1093/neuros/nyw078
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Elgaz S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02565 9
   Ensrud KE, 2019, JAMA J AM MED ASSOC, V322, P2017, DOI 10.1001/jama.2019.15781
   Fang SH, 2019, DRUG DES DEV THER, V13, P45, DOI 10.2147/DDDT.S178698
   Fierro FA, 2017, STEM CELLS, V35, P1461, DOI 10.1002/stem.2625
   Freemont AJ, 2002, J PATHOL, V196, P374, DOI 10.1002/path.1050
   Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015
   Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood 2004 09 3696
   Goodman SB, 2020, J INFLAMM RES, V13, P913, DOI 10.2147/JIR.S281941
   Griffin MD, 2013, IMMUNOL CELL BIOL, V91, P40, DOI 10.1038/icb.2012.67
   Griffin TM, 2019, CLIN EXP RHEUMATOL, V37, P57
   Hernigou P, 2016, CLIN ORTHOP SURG, V8, P1, DOI 10.4055/cios.2016.8.1.1
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018 017 2595 9
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   Hu SJ, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/7538025
   Hu Y, 2020, THERANOSTICS, V10, P2293, DOI 10.7150/thno.39238
   Huang SX, 2020, J CELL MOL MED, V24, P11512, DOI 10.1111/jcmm.15766
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Ibrahim SA, 2022, HISTOLOGY EXTRACELLU
   Jamalpoor Z, 2018, IRAN J ALLERGY ASTHM, V17, P398
   Jiang DS, 2016, STEM CELLS, V34, P2393, DOI 10.1002/stem.2417
   Keshtkar S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0791 7
   Kim GB, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10040285
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Kovach TK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/752510
   Lai FW, 2015, J LEUKOCYTE BIOL, V97, P237, DOI 10.1189/jlb.3RU0513 292RR
   Lai JL, 2022, J CONTROL RELEASE, V347, P27, DOI 10.1016/j.jconrel.2022.04.046
   Lee J, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801106
   Lee KS, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12152
   Li KL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 021 01236 1
   Li SS, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.603598
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Livshits G, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120847
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu L, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770510
   Luo ZW, 2021, STEM CELLS DEV, V30, P135, DOI 10.1089/scd.2020.0167
   Ma M, 2022, BONE JOINT RES, V11, P26, DOI 10.1302/2046 3758.111.BJR 2021 0467.R1
   Mendt M, 2019, BONE MARROW TRANSPL, V54, P789, DOI 10.1038/s41409 019 0616 z
   Meng Q, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00441
   Mianehsaz E, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1445 0
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Park BH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260760
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ragni E, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051072
   Ratajczak MZ, 2020, LEUKEMIA, V34, P3126, DOI 10.1038/s41375 020 01041 z
   Ren L, 2019, BIOCHEM BIOPH RES CO, V508, P138, DOI 10.1016/j.bbrc.2018.11.109
   Sacitharan Pradeep Kumar, 2019, Subcell Biochem, V91, P123, DOI 10.1007/978 981 13 3681 2_6
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Shah KN, 2015, CURR REV MUSCULOSKE, V8, P201, DOI 10.1007/s12178 015 9277 8
   Shahrezaee M, 2018, NANOMED NANOTECHNOL, V14, P2061, DOI 10.1016/j.nano.2018.06.007
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Taghiyar L, 2021, ADV EXP MED BIOL, V1326, P73, DOI 10.1007/5584_2021_625
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Tang SJ, 2021, INT J NANOMED, V16, P8185, DOI 10.2147/IJN.S336062
   Tian XH, 2022, J CELL MOL MED, V26, P693, DOI 10.1111/jcmm.17086
   Tjempakasari A, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58010061
   Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681
   Tsiapalis D, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040991
   van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983
   Vig S, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040767
   Wang X, 2020, INT J NANOMED, V15, P3483, DOI 10.2147/IJN.S248741
   Watanabe J, 2020, J DENT RES, V99, P552, DOI 10.1177/0022034520906793
   Wei F, 2019, J TISSUE ENG REGEN M, V13, P1978, DOI 10.1002/term.2947
   Woo CH, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1735249
   Woodell May JE, 2020, J ORTHOP RES, V38, P253, DOI 10.1002/jor.24457
   Xia C, 2019, FREE RADICAL BIO MED, V143, P1, DOI 10.1016/j.freeradbiomed.2019.07.026
   Xie L, 2020, MOL THER NUCL ACIDS, V22, P601, DOI 10.1016/j.omtn.2020.09.026
   Yang ZY, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121438
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zhang JY, 2020, AGING US, V12, P25138, DOI 10.18632/aging.104110
   Zhang QZ, 2010, STEM CELLS, V28, P1856, DOI 10.1002/stem.503
   Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190
   Zhang X, 2020, J CELL MOL MED, V24, P13973, DOI 10.1111/jcmm.16006
   Zhao AG, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8825771
   Zhao XG, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.575057
   Zhou F, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.109072
   Zhu LF, 2020, CELL CYCLE, V19, P1727, DOI 10.1080/15384101.2020.1769301
NR 99
TC 9
Z9 9
U1 3
U2 16
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD JAN 24
PY 2023
VL 11
AR e14677
DI 10.7717/peerj.14677
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 8N7BP
UT WOS:000925303100003
PM 36710868
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU He, HL
   Wang, CQ
   Tang, QF
   Yang, F
   Xu, YJ
AF He, Hanliang
   Wang, Chunqing
   Tang, Qifeng
   Yang, Fan
   Xu, Youjia
TI Possible mechanisms of prednisolone induced osteoporosis in zebrafish
   larva
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE GIOP; ECM; Osteoblast; Osteoclast
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; OSTEOBLAST MINERALIZATION;
   GENE EXPRESSION; DIFFERENTIATION; MANAGEMENT; CELLS; MICE; STIMULATION;
   OSTEOCLASTS; PHENOTYPE
AB Glucocorticoid induced osteoporosis (GIOP) is a serious clinical bone disease that results from the long term consumption of glucocorticoids or glucocorticoid like drugs. Although many studies have attempted to determine the mechanisms of GIOP, they are still unclear. In this study, we established a zebrafish model of glucocorticoid like drug induced osteoporosis by treating larvae with prednisolone. We then quantified the expression of a selection of extracellular matrix (ECM) , osteoblast , and osteoclast related genes. Our results showed that at 15 days post fertilization, zebrafish larvae treated with 25 mu M prednisolone are a suitable model for GIOP, not only owing to the decrease in robust bone mass but also because of significant alterations in gene expression. The quantification of the expression of ECM , osteoblast , and osteoclast related genes revealed that mmp9 and mmp13 were significantly upregulated and entpd5a, acp5a, and sost were significantly downregulated. These genes may be a target for future research into GIOP. Our study thus provides new insights into GIOP.
C1 [He, Hanliang; Yang, Fan; Xu, Youjia] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou 215004, Peoples R China.
   [Wang, Chunqing] Guizhou Med Univ, Affiliated Hosp, Dept Orthopaed, Guiyang 550004, Guizhou, Peoples R China.
   [Tang, Qifeng] Benq Med Ctr Suzhou, Suzhou 215000, Peoples R China.
C3 Soochow University   China; Guizhou Medical University
RP Xu, YJ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou 215004, Peoples R China.
EM xuyoujia@suda.edu.cn
FU Jiangsu Province Special Medical Grant [BL2014044]; National Natural
   Science Foundation of China [81572179]; Science and Technology of Suzhou
   [SS201634]
FX This work was supported by grants from the Jiangsu Province Special
   Medical Grant (BL2014044), the National Natural Science Foundation of
   China (81572179), and the Science and Technology of Suzhou (SS201634).
CR Ahi EP, 2016, PEERJ, V4, DOI 10.7717/peerj.1878
   Ahi EP, 2014, EVODEVO, V5, DOI 10.1186/2041 9139 5 40
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004
   de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198 004 1614 5
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Geurtzen K., 2017, J BONE MIN RES
   Geurtzen K, 2014, DEVELOPMENT, V141, P2225, DOI 10.1242/dev.105817
   Hayman AR, 1996, DEVELOPMENT, V122, P3151
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huitema LFA, 2012, P NATL ACAD SCI USA, V109, P21372, DOI 10.1073/pnas.1214231110
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Sasaki N, 2001, NEPHROL DIAL TRANSPL, V16, P479, DOI 10.1093/ndt/16.3.479
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Straub RH, 2016, RHEUMATOLOGY, V55, P6, DOI 10.1093/rheumatology/kew348
   Sun B, 2016, HISTOL HISTOPATHOL, V31, P647, DOI 10.14670/HH 11 702
   Venkatesh B, 2014, NATURE, V505, P174, DOI 10.1038/nature12826
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Witten PE, 2001, J MORPHOL, V250, P197, DOI 10.1002/jmor.1065
   Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734
NR 36
TC 40
Z9 50
U1 2
U2 35
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2018
VL 101
BP 981
EP 987
DI 10.1016/j.biopha.2018.02.082
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GC2BG
UT WOS:000429586400113
PM 29635908
OA hybrid
DA 2025 08 17
ER

PT J
AU Seitz, S
   Keller, J
   Schilling, AF
   Jeschke, A
   Marshall, RP
   Stride, BD
   Wintermantel, T
   Beil, FT
   Amling, M
   Schütz, G
   Tuckermann, J
   Schinke, T
AF Seitz, Sebastian
   Keller, Johannes
   Schilling, Arndt F.
   Jeschke, Anke
   Marshall, Robert P.
   Stride, Brenda D.
   Wintermantel, Tim
   Beil, Frank T.
   Amling, Michael
   Schuetz, Guenther
   Tuckermann, Jan
   Schinke, Thorsten
TI Pharmacological Estrogen Administration Causes a FSH Independent
   Osteo Anabolic Effect Requiring ER Alpha in Osteoblasts
SO PLOS ONE
LA English
DT Article
ID RECEPTOR ALPHA; BONE FORMATION; CANCELLOUS BONE; DIFFERENTIATION;
   PROLIFERATION; PATHOGENESIS; MECHANISMS; HORMONE; HEALTH; CELLS
AB Postmenopausal osteoporosis is characterized by declining estrogen levels, and estrogen replacement therapy has been proven beneficial for preventing bone loss in affected women. While the physiological functions of estrogen in bone, primarily the inhibition of bone resorption, have been studied extensively, the effects of pharmacological estrogen administration are still poorly characterized. Since elevated levels of follicle stimulating hormone (FSH) have been suggested to be involved in postmenopausal bone loss, we investigated whether the skeletal response to pharmacological estrogen administration is mediated in a FSH dependent manner. Therefore, we treated wildtype and FSH beta deficicent (Fshb( / )) mice with estrogen for 4 weeks and subsequently analyzed their skeletal phenotype. Here we observed that estrogen treatment resulted in a significant increase of trabecular and cortical bone mass in both, wildtype and Fshb( / ) mice. Unexpectedly, this FSH independent pharmacological effect of estrogen was not caused by influencing bone resorption, but primarily by increasing bone formation. To understand the cellular and molecular nature of this osteo anabolic effect we next administered estrogen to mouse models carrying cell specific mutant alleles of the estrogen receptor alpha (ER alpha). Here we found that the response to pharmacological estrogen administration was not affected by ER alpha inactivation in osteoclasts, while it was blunted in mice lacking the ER alpha in osteoblasts or in mice carrying a mutant ER alpha incapable of DNA binding. Taken together, our findings reveal a previously unknown osteo anabolic effect of pharmacological estrogen administration, which is independent of FSH and requires DNA binding of ER alpha in osteoblasts.
C1 [Tuckermann, Jan] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany.
   [Stride, Brenda D.; Wintermantel, Tim; Schuetz, Guenther] German Canc Res Ctr, Div Mol Biol Cell 1, D 6900 Heidelberg, Germany.
   [Schilling, Arndt F.] Tech Univ Munich, Dept Plast & Hand Surg, Munich, Germany.
   [Seitz, Sebastian; Keller, Johannes; Schilling, Arndt F.; Jeschke, Anke; Marshall, Robert P.; Beil, Frank T.; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
C3 Leibniz Association; Leibniz Institut fur Alternsforschung  
   Fritz Lipmann Institut (FLI); Helmholtz Association; German Cancer
   Research Center (DKFZ); Technical University of Munich; University of
   Hamburg; University Medical Center Hamburg Eppendorf
RP Tuckermann, J (通讯作者)，Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany.
EM jan@fli leibniz.de; schinke@uke.de
RI Marshall, Robert/AAD 5269 2022; Beil, Frank Timo/JBI 9771 2023
OI Keller, Johannes/0000 0002 8925 7288; Marshall, Robert
   Percy/0000 0003 4247 1006
FU Deutsche Forschungsgemeinschaft [SE 1755/1 1]
FX This work was supported by grants from the Deutsche
   Forschungsgemeinschaft given to SS (SE 1755/1 1). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. URL: http://www.dfg.de/index.jsp.
CR Ahlbory Dieker DL, 2009, MOL ENDOCRINOL, V23, P1544, DOI 10.1210/me.2009 0045
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Baron R, 2006, CELL METAB, V3, P302, DOI 10.1016/j.cmet.2006.04.007
   CHOW J, 1992, J CLIN INVEST, V89, P74, DOI 10.1172/JCI115588
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cummings Vaughn LA, 2011, MED CLIN N AM, V95, P495, DOI 10.1016/j.mcna.2011.03.003
   Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365 2362.2000.0300s3051.x
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   KEETING PE, 1991, J BONE MINER RES, V6, P297
   Krum SA, 2011, J CELL BIOCHEM, V112, P401, DOI 10.1002/jcb.22970
   Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297 201
   Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009
   Lindsay R, 2004, ENDOCRINE, V24, P223, DOI 10.1385/ENDO:24:3:223
   Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE 09 0242
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Martin TJ, 2006, NAT MED, V12, P612, DOI 10.1038/nm0606 612
   McCauley LK, 2002, CRIT REV EUKAR GENE, V12, P89, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i2.10
   McDougall KE, 2003, ENDOCRINOLOGY, V144, P1994, DOI 10.1210/en.2002 0074
   Mosekilde L, 2011, CURR DRUG SAF, V6, P62, DOI 10.2174/157488611795684712
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nilsson S, 2011, CLIN PHARMACOL THER, V89, P44, DOI 10.1038/clpt.2010.226
   O'Brien JE, 2006, J BIOL CHEM, V281, P26683, DOI 10.1074/jbc.M601522200
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Robinson JA, 1997, ENDOCRINOLOGY, V138, P2919, DOI 10.1210/en.138.7.2919
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Samuels A, 2000, BONE, V27, P41, DOI 10.1016/S8756 3282(00)00289 1
   SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006 291X(05)80774 0
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Takada I, 2010, ANN NY ACAD SCI, V1192, P201, DOI 10.1111/j.1749 6632.2009.05215.x
   Tobias JH, 1999, BONE, V24, P121, DOI 10.1016/S8756 3282(98)00156 2
   Windahl SH, 2002, TRENDS ENDOCRIN MET, V13, P195, DOI 10.1016/S1043 2760(02)00594 5
   Wintermantel TM, 2006, NEURON, V52, P271, DOI 10.1016/j.neuron.2006.07.023
   Yeh JK, 1997, BONE, V20, P413, DOI 10.1016/S8756 3282(97)00027 6
   Yeh JK, 1996, BONE, V18, P443, DOI 10.1016/8756 3282(96)00045 2
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 41
TC 16
Z9 19
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 27
PY 2012
VL 7
IS 11
AR e50301
DI 10.1371/journal.pone.0050301
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 048BS
UT WOS:000311885800063
PM 23209701
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Mora Raimundo, P
   Lozano, D
   Manzano, M
   Vallet Regí, M
AF Mora Raimundo, Patricia
   Lozano, Daniel
   Manzano, Miguel
   Vallet Regi, Maria
TI Nanoparticles to Knockdown Osteoporosis Related Gene and Promote
   Osteogenic Marker Expression for Osteoporosis Treatment
SO ACS NANO
LA English
DT Article
DE mesoporous nanoparticles; gene silencing; osteoporosis; therapeutic
   co delivery; osteogenic stimulation
ID MESOPOROUS SILICA NANOPARTICLES; SIGNALING PATHWAYS; BONE REGENERATION;
   SIRNA DELIVERY; DRUG; IMPROVES; PEPTIDE; GROWTH; SKELETAL; TARGETS
AB Osteoporosis is the most common disease involving bone degeneration. Current clinical treatments are not able to offer a satisfying curative effect, so the development of effective treatments is desired. Gene silencing through siRNA delivery has gained great attention as a potential treatment in bone diseases. SOST gene inhibits the Wnt signaling pathway reducing osteoblast differentiation. Consequently, silencing SOST genes with a specific siRNA could be a potential option to treat osteoporosis. Generally, siRNAs have a very short half life and poor transfection capacity, so an effective carrier is needed. In particular, mesoporous silica nanoparticles (MSNs) have attracted great attention for intracellular delivery of nucleic acids. We took advantage of their high loading capacity to further load the pores with osteostatin, an osteogenic peptide. In this study, we developed a system based on MSNs coated with poly(ethylenimine), which can effectively deliver SOST siRNA and osteostatin inside cells, with the consequent augmentation of osteogenic markers with a synergistic effect. This established the potential utility of MSNs to co deliver both biomolecules to promote bone formation, this being a potential alternative to treat osteoporosis.
C1 [Mora Raimundo, Patricia; Lozano, Daniel; Manzano, Miguel; Vallet Regi, Maria] Univ Complutense Madrid, Chem Pharmaceut Sci, Sch Pharm, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.
   [Mora Raimundo, Patricia; Lozano, Daniel; Manzano, Miguel; Vallet Regi, Maria] Hosp 12 Octubre I 12, Inst Invest Sanitaria, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.
   [Lozano, Daniel; Manzano, Miguel; Vallet Regi, Maria] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, E 28034 Madrid, Spain.
C3 Complutense University of Madrid; Hospital Universitario 12 de Octubre;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN
RP Manzano, M; Vallet Regí, M (通讯作者)，Univ Complutense Madrid, Chem Pharmaceut Sci, Sch Pharm, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.; Manzano, M; Vallet Regí, M (通讯作者)，Hosp 12 Octubre I 12, Inst Invest Sanitaria, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.; Manzano, M; Vallet Regí, M (通讯作者)，Networking Res Ctr Bioengn Biomat & Nanomed CIBER, E 28034 Madrid, Spain.
EM mmanzano@ucm.es; vallet@ucm.es
RI Manzano, Miguel/K 3719 2014; Vallet Regí, Maria/M 3378 2014; Lozano,
   Daniel/B 5081 2017; Mora Raimundo, Patricia/P 7671 2019; Vallet Regi,
   Maria/M 3378 2014
OI Manzano, Miguel/0000 0001 6238 6111; Mora, Patricia/0000 0001 5382 2743;
   Lozano, Daniel/0000 0001 5902 9201; Ceron, Ester/0000 0003 1449 1018;
   Vallet Regi, Maria/0000 0002 6104 4889
FU European Research Council [694160]
FX This work has been done thanks to the financial support provided by
   European Research Council (Advanced Grant VERDI; ERC 2015 AdG proposal
   no. 694160).
CR [Anonymous], U.S. Patent, Patent No. [5,501,959, 5501959]
   Arcos D, 2014, ACTA BIOMATER, V10, P1793, DOI 10.1016/j.actbio.2014.01.004
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Basha G, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.68
   Cavallaro G, 2017, INT J PHARMACEUT, V525, P313, DOI 10.1016/j.ijpharm.2017.04.008
   Cornish J, 1999, J BONE MINER RES, V14, P915, DOI 10.1359/jbmr.1999.14.6.915
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Dogra P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06730 z
   Dowdy SF, 2018, NUCLEIC ACID THER, V28, P107, DOI 10.1089/nat.2018.29001.dow
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Esbrit P, 2016, CALCIFIED TISSUE INT, V98, P359, DOI 10.1007/s00223 015 0050 1
   FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo 129 4 1762
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Fuller JE, 2008, BIOMATERIALS, V29, P1526, DOI 10.1016/j.biomaterials.2007.11.025
   Gisbert Garzaran M, 2017, RSC ADV, V7, P132, DOI 10.1039/c6ra26771h
   Goyal R, 2012, NANOMED NANOTECHNOL, V8, P167, DOI 10.1016/j.nano.2011.06.001
   Hom C, 2010, SMALL, V6, P1185, DOI 10.1002/smll.200901966
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Khajuria Deepak Kumar, 2011, Rev. Bras. Reumatol., V51, P372
   Kim TH, 2016, ACTA BIOMATER, V29, P352, DOI 10.1016/j.actbio.2015.09.035
   Lewinson D., 1997, CALCIFIED TISSUE INT, V61, P426
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Lozano D, 2011, BRIT J PHARMACOL, V162, P1424, DOI 10.1111/j.1476 5381.2010.01155.x
   Lozano D, 2014, ACTA BIOMATER, V10, P3307, DOI 10.1016/j.actbio.2014.03.025
   Lozano D, 2012, ACTA BIOMATER, V8, P2770, DOI 10.1016/j.actbio.2012.04.002
   Lozano D, 2012, ACTA BIOMATER, V8, P2317, DOI 10.1016/j.actbio.2012.03.014
   Lozano D, 2010, ACTA BIOMATER, V6, P797, DOI 10.1016/j.actbio.2009.08.033
   Mackey PA, 2015, JNP J NURSE PRACT, V11, P1011, DOI 10.1016/j.nurpra.2015.08.010
   Manzano M, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6069 x
   Meng H, 2013, ACS NANO, V7, P994, DOI 10.1021/nn3044066
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   Mora Raimundo P, 2017, AIMS BIOENG, V4, P259, DOI 10.3934/bioeng.2017.2.259
   Moshiri A, 2017, CLIN REV BONE MINER, V15, P1, DOI 10.1007/s12018 016 9207 3
   Paris JL, 2015, ACS NANO, V9, P11023, DOI 10.1021/acsnano.5b04378
   Pietrzyk B, 2017, ADV CLIN EXP MED, V26, P1283, DOI 10.17219/acem/68739
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Villegas MR, 2018, CHEM MATER, V30, P112, DOI 10.1021/acs.chemmater.7b03128
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Swami A, 2007, BIOCHEM BIOPH RES CO, V362, P835, DOI 10.1016/j.bbrc.2007.08.073
   Tokatlian T, 2010, WIRES NANOMED NANOBI, V2, P305, DOI 10.1002/wnan.81
   Trejo CG, 2010, BIOMATERIALS, V31, P8564, DOI 10.1016/j.biomaterials.2010.07.103
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Villaverde G, 2017, CHEM EUR J, V23, P7174, DOI 10.1002/chem.201605947
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wang YW, 2012, BIOMATERIALS, V33, P8540, DOI 10.1016/j.biomaterials.2012.07.039
   Wen SH, 2013, J APPL POLYM SCI, V128, P3807, DOI 10.1002/app.38444
   Xia TA, 2009, ACS NANO, V3, P3273, DOI 10.1021/nn900918w
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang J, 2014, J CONTROL RELEASE, V190, P440, DOI 10.1016/j.jconrel.2014.05.037
NR 55
TC 123
Z9 129
U1 2
U2 119
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2019
VL 13
IS 5
BP 5451
EP 5464
DI 10.1021/acsnano.9b00241
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA IA9OK
UT WOS:000469886300051
PM 31071265
OA Green Published, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Shi, T
   Shen, XJ
   Gao, G
AF Shi, Ting
   Shen, Xiongjie
   Gao, Ge
TI Gene Expression Profiles of Peripheral Blood Monocytes in Osteoarthritis
   and Analysis of Differentially Expressed Genes
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; ARTICULAR CARTILAGE; SIGNALING PATHWAY;
   KNEE; P38; PATHOGENESIS; INFLAMMATION; MIGRATION; TARGET; CELLS
AB Background. There is little understanding of the molecular processes involved in the pathogenesis of osteoarthritis, limiting early diagnosis and effective treatment of OA. Use of genechips can provide insights into the molecular pathogenesis of diseases. In this study, determination of gene expression profiles of osteoarthritis peripheral blood mononuclear cells will allow exploration of the molecular pathogenesis of OA and find out more candidate biomarkers and potential drug targets of OA. Result. A total of 1231 DEGs were screened out including 791 upregulated DEGs and 440 downregulated DEGs. The most significant upregulated DEG was RPL38, which may inhibit chondrocyte differentiation and synthesis of the extracellular matrix. PIK3CA, PIK3CB, PIK3CD, PIK3R1, MAPK14, IL1A, JUND, FOSL2, and PPP3CA were the gene symbols of the osteoclast differentiation pathway which was the most significant pathway enriched by DEGs. However, the MAPK signaling pathway occupied the core position of all the pathways which can regulate apoptosis, cell cycle, wnt signaling pathway, p53 signaling pathway, and phosphatidylinositol signaling system. Furthermore, PI3Ks may regulate IL1A, JUND, FOSL2 and PPP3CA through the MAPK signaling pathway. Conclusion. These identified DEGs and pathways may be novel biomarkers to monitor the changes of OA and can be a potential drug target for the treatment of OA.
C1 [Shi, Ting] Hunan Prov Peoples Hosp, Dept Clin Lab, Changsha 410005, Hunan, Peoples R China.
   [Shen, Xiongjie] Hunan Prov Peoples Hosp, Dept Spine Surg, Changsha 410005, Hunan, Peoples R China.
   [Gao, Ge] Cent South Univ, Dept Clin Lab, Xiangya Sch Med, Changsha 410005, Hunan, Peoples R China.
C3 Central South University
RP Shen, XJ (通讯作者)，Hunan Prov Peoples Hosp, Dept Spine Surg, Changsha 410005, Hunan, Peoples R China.
EM 15243602257@163.com; tianhai_521@163.com; ggboxy@163.com
FU Hunan Provincial Natural Science Fund [2016JJ4053]
FX The authors would like to acknowledge the online analysis platform GCBI
   for providing us technical assistance.This work was supported by the
   Hunan Provincial Natural Science Fund (grant no. 2016JJ4053).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Attur M, 2011, ARTHRITIS RHEUM US, V63, P1908, DOI 10.1002/art.30360
   Beranger GE, 2007, J BONE MINER RES, V22, P975, DOI 10.1359/JBMR.070406
   Castrogiovanni P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030511
   Durand M, 2013, ARTHRITIS RHEUM US, V65, P148, DOI 10.1002/art.37722
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029
   Gabrovska PN, 2011, TWIN RES HUM GENET, V14, P562, DOI 10.1375/twin.14.6.562
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Green H, 2000, J BONE MINER RES, V15, P1066, DOI 10.1359/jbmr.2000.15.6.1066
   Gyori D, 2014, ARTHRITIS RHEUMATOL, V66, P2210, DOI 10.1002/art.38660
   Hundhausen Christoph, 2008, Cancer Genomics & Proteomics, V5, P319
   Jiang SS, 2011, AGING US, V3, P672, DOI 10.18632/aging.100355
   Joos H, 2010, BRIT J PHARMACOL, V160, P1252, DOI 10.1111/j.1476 5381.2010.00760.x
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lim H, 2011, ARCH PHARM RES, V34, P109, DOI 10.1007/s12272 011 0113 4
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Miller SA, 2003, DIFFERENTIATION, V71, P322, DOI 10.1046/j.1432 0436.2003.7106002.x
   Mizuguchi T, 2018, HUM MOL GENET, V27, P1421, DOI 10.1093/hmg/ddy052
   Musumeci G, 2015, HISTOL HISTOPATHOL, V30, P1, DOI 10.14670/HH 30.1
   Papoudou Bai A, 2017, CLIN EXP MED, V17, P291, DOI 10.1007/s10238 016 0436 z
   Park R, 2016, RHEUMATOL INT, V36, P819, DOI 10.1007/s00296 016 3451 1
   Prasadam I, 2016, CALCIFIED TISSUE INT, V99, P43, DOI 10.1007/s00223 016 0125 7
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Russo F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157048
   Singh AK, 2014, J CLIN DIAGN RES, V8, pJC09, DOI 10.7860/JCDR/2014/7763.4868
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Thomas MJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0693 3
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wang WY, 2016, GENE, V591, P43, DOI 10.1016/j.gene.2016.06.058
   Warner SC, 2016, J FUNCT MORPHOL KINE, V1, P140, DOI [10.3390/jfmk1010140, DOI 10.3390/JFMK1010140]
   Wijekoon S, 2017, J VET MED SCI, V79, P2030, DOI 10.1292/jvms.17 0393
   Xia BJ, 2014, CALCIFIED TISSUE INT, V95, P495, DOI 10.1007/s00223 014 9917 9
   Xuan WH, 2017, CELL BIOCHEM FUNCT, V35, P171, DOI 10.1002/cbf.3260
   Zhang C, 2016, GLYCOCONJUGATE J, V33, P735, DOI 10.1007/s10719 016 9667 1
NR 36
TC 16
Z9 18
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD NOV 26
PY 2019
VL 2019
AR 4291689
DI 10.1155/2019/4291689
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA JU6EM
UT WOS:000501767800008
PM 31886215
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, DL
   Chu, FF
   Zhang, GY
   Wang, QQ
   Li, Y
   Zhang, M
   He, Q
   Yang, JZ
   Wang, HB
   Sun, P
   Xu, JK
   Chen, P
AF Chen, Delong
   Chu, Feifan
   Zhang, Gangyu
   Wang, Qingqing
   Li, Ying
   Zhang, Meng
   He, Qi
   Yang, Junzheng
   Wang, Haibin
   Sun, Ping
   Xu, Jiake
   Chen, Peng
TI 12 Deoxyphorbol 13 acetate inhibits RANKL induced osteoclastogenesis via
   the attenuation of MAPK signaling and NFATc1 activation
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE 12 Deoxyphorbol 13 acetate; Osteoporosis; Osteoclast; NFATc1; MAPK
ID BONE BIOLOGY; DIFFERENTIATION; PHORBOL; OSTEOPOROSIS; INDUCTION;
   13 ESTERS; MEDICINE; PROMOTER; ROLES
AB Osteoporosis, characterized by bone loss and microstructure damage, occurs when osteoclast activity outstrips osteoblast activity. Natural compounds with inhibitory effect on osteoclast differentiation and function have been evidenced to protect from osteoporosis. After multiple compounds screening, 12 deoxyphorbol 13 acetate (DPA) was found to decline RANKL induced osteoclastogenesis dose dependently by attenuating activities of NFATc1 and c Fos, followed by decreasing the level of osteoclast function associated genes and proteins including Acp5, V ATPase d2 and CTSK. Mechanistically, we found that DPA suppressing RANKL induced downstream signaling pathways, including MAPK signaling pathway and calcium oscillations. Furthermore, the in vivo efficacy of DPA was further confirmed in an OVX induced osteoporosis mice model. Collectively, the results in our presentation reveal that DPA might be a promising compound to manage osteoporosis.
C1 [Chen, Delong] Jinan Univ, Clifford Hosp, Dept Orthopaed Surg, Guangzhou 510006, Peoples R China.
   [Chu, Feifan] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325000, Peoples R China.
   [Zhang, Gangyu; He, Qi; Yang, Junzheng] Guangzhou Univ Chinese Med, Guangzhou 510405, Peoples R China.
   [Wang, Qingqing] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou 310000, Peoples R China.
   [Li, Ying] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed Surg, Guangzhou 510360, Peoples R China.
   [Zhang, Meng] Henan Univ, Zhengzhou Univ, Dept Orthoped, Peoples Hosp,Henan Prov Peoples Hosp, Zhengzhou 450003, Peoples R China.
   [Wang, Haibin; Chen, Peng] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou 510405, Peoples R China.
   [Sun, Ping] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou 510000, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
C3 Jinan University; Wenzhou Medical University; Guangzhou University of
   Chinese Medicine; Zhejiang University; Guangzhou University of Chinese
   Medicine; Henan University; Zhengzhou University; Guangzhou University
   of Chinese Medicine; Guangdong Pharmaceutical University; University of
   Western Australia
RP Sun, P; Xu, JK; Chen, P (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou 510405, Peoples R China.
EM docchen777@gmail.com
RI Wang, Qingqing/E 7972 2014; zhang, zhizhong/KRP 4408 2024
OI Xu, Jiake/0000 0003 2021 8309
FU National Natural Science Foundation of China [81603641, 81774339,
   82074462, 81704098]; Guangdong Provincial Science and Technology Project
   [2017A020213030]; Project of Administration of Traditional Chinese
   Medicine of Guangdong Province of China [20201318]; Key Research of
   Guangzhou University of Chinese Medicine [XK201912]
FX The authors acknowledge the support from National Natural Science
   Foundation of China (81603641, 81774339, 82074462, 81704098). This study
   was also funded by Guangdong Provincial Science and Technology Project
   (2017A020213030), Project of Administration of Traditional Chinese
   Medicine of Guangdong Province of China (20201318) and 2019 Key Research
   of Guangzhou University of Chinese Medicine (XK201912). We appreciate
   professor Junjian Wang for providing the compound and helping to analyze
   the data.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Deng SQ, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.7636
   Downey PA, 2006, PHYS THER, V86, P77, DOI 10.1093/ptj/86.1.77
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Liang M., MOL THER NUCL ACIDS, V23, P1191
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   McCormick RK, 2007, ALTERN MED REV, V12, P113
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Park JH, 2017, MOL CELLS, V40, P706
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shen X, 2015, CANCER LETT, V356, P686, DOI 10.1016/j.canlet.2014.10.018
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   SZALLASI Z, 1993, CANCER RES, V53, P2507
   SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200
   Ying H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048832
NR 44
TC 6
Z9 7
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2021
VL 101
AR 108177
DI 10.1016/j.intimp.2021.108177
EA OCT 2021
PN A
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA WE3ZG
UT WOS:000705567400005
PM 34626872
DA 2025 08 17
ER

PT J
AU Chen, XW
   Ye, F
   He, H
   Chen, G
   Chen, ZF
   Ye, E
   He, BJ
   Yang, YQ
   Zhang, J
AF Chen, Xianwei
   Ye, Fan
   He, Hao
   Chen, Gong
   Chen, Zhifu
   Ye, En
   He, Bingjan
   Yang, Yuqi
   Zhang, Jing
TI Denosumab Induces Neoplastic Stromal Cell Apoptosis Via p62
   Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of
   Bone
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Giant cell tumour of bone; neoplastic stromal cells; denosumab;
   p62/SQSTM1; autophagy; apoptosis
ID CANCER; MULTICENTER
AB Background: As the only humanized monoclonal antibody against receptor activator of nuclear factor kappa B ligand (RANKL) for giant cell tumour of bone (GCTB) therapy, denosumab has limited antitumour effect on neoplastic stromal cells. Nevertheless, its mechanism of action has not yet been clarified. A previous study has revealed that p62 may play an important role in the antitumour activity of denosumab. Objectives: The study aimed to investigate if the mechanism by which denosumab inhibits GCTB neoplastic stromal cells growth is via p62 modulation and other related mechanisms. Methods: p62 expression before and after denosumab therapy was analysed by RT qPCR, western blot, ELISA, and immunohistochemical assays. Two primary neoplastic stromal cells were isolated from fresh GCTB tumour tissue (L cell) and metastatic tissue (M cell). Cell proliferation, migration, apoptosis, and autophagy were investigated in p62 knockdown neoplastic stromal cells transfected by short hairpin RNA lentivirus in vitro. Tumor growth was evaluated in the chick chorioallantoic membrane model in vivo. Results: p62 expression was found to be downregulated following denosumab therapy. The patients with a decrease in p62 expression had lower recurrence free survival rates. The proliferation of M cells was not inhibited by denosumab therapy, but it was restored by p62 knockdown. Moreover, p62 knockdown inhibited tumour growth in vivo. Denosumab induced M cell apoptosis and arrested the cell cycle at the G1/G0 transition and these effects were also enhanced by p62 knock down. Autophagic flux assays revealed p62 modulation to be dependent on autophagy following denosumab incubation. Conclusion: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.
C1 [Chen, Xianwei; Chen, Gong; Chen, Zhifu; He, Bingjan; Yang, Yuqi; Zhang, Jing] Kunming Med Univ, Yunnan Canc Hosp, Dept Orthopaed, Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
   [Ye, Fan] Nanyang Med Coll, Dept Orthopaed, Affiliated Hosp 1, Nangyang 473000, Henan, Peoples R China.
   [He, Hao] Peoples Hosp Guangan, Dept Orthopaed, Guangan 638000, Sichuan, Peoples R China.
   [Ye, En] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Pathol, Kunming 650118, Yunnan, Peoples R China.
C3 Kunming Medical University; Nanyang Medical College; Kunming Medical
   University
RP Zhang, J (通讯作者)，Kunming Med Univ, Yunnan Canc Hosp, Dept Orthopaed, Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China.
EM nmlimit@sina.com
RI ; Yang, Yuqi/AFW 2437 2022
OI Zhang, Jing/0000 0001 7230 5805; chen, xianwei/0000 0002 4552 9851; 
FU National Natural Science Foundation of China [81760486, 82060490]; Ten
   Thousand People Plan of Yunnan Province [NWRQNBJ 2019 163]
FX This research was funded by the National Natural Science Foundation of
   China (grant numbers 81760486 and 82060490) and the Ten Thousand People
   Plan of Yunnan Province (grant number NWRQNBJ 2019 163).
CR Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Angela Y, 2019, CANCER IMMUNOL IMMUN, V68, P1187, DOI 10.1007/s00262 019 02353 5
   Antal I, 2022, PATHOL ONCOL RES, V28, DOI 10.3389/pore.2022.1610633
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Borkowska AM, 2022, CANCERS, V14, DOI 10.3390/cancers14092290
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Choi JH, 2021, ADV ANAT PATHOL, V28, P44, DOI 10.1097/PAP.0000000000000284
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Errani Costantino, 2019, J Clin Orthop Trauma, V10, P1015, DOI 10.1016/j.jcot.2019.09.017
   Fellenberg J, 2019, CANCER LETT, V448, P61, DOI 10.1016/j.canlet.2019.02.001
   Jain SU, 2020, P NATL ACAD SCI USA, V117, P27354, DOI 10.1073/pnas.2006076117
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Klionsky DJ., 2021, P ADV NEUR INF PROC, V17, P1, DOI [DOI 10.1080/15548627.2020.1797280, 10.1080/15548627.2020.1797280]
   Li DQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.609548
   Lim CY, 2020, BONE JOINT J, V102B, P177, DOI 10.1302/0301 620X.102B2.BJJ 2019 0813.R1
   Liu S, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11947
   Lorentzen CL, 2022, LANCET ONCOL, V23, pE450, DOI 10.1016/S1470 2045(22)00372 2
   Mavrogenis AF, 2017, SICOT J, V3, DOI 10.1051/sicotj/2017041
   McManus Stephen, 2012, J Mol Signal, V7, P1, DOI 10.1186/1750 2187 7 1
   Nagano A, 2022, JPN J CLIN ONCOL, V52, P411, DOI 10.1093/jjco/hyac018
   Ning SB, 2019, CURR CANCER DRUG TAR, V19, P468, DOI 10.2174/1568009618666181016164920
   Niu XH, 2012, J BONE JOINT SURG AM, V94A, P461, DOI 10.2106/JBJS.J.01922
   Noguchi R, 2020, HUM CELL, V33, P1321, DOI 10.1007/s13577 020 00415 w
   Noh BJ, 2018, HUM PATHOL, V81, P1, DOI 10.1016/j.humpath.2018.06.017
   Onji M, 2023, PHYSIOLOGY, V38, P110, DOI 10.1152/physiol.00020.2022
   Palmerini E, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819840000
   Parmeggiani A, 2021, CANCERS, V13, DOI 10.3390/cancers13246298
   Ponomarenko DM, 2017, ONCOTARGET, V8, P53730, DOI 10.18632/oncotarget.16574
   Roessner A, 2020, PATHOLOGE, V41, P134, DOI 10.1007/s00292 020 00760 5
   Sánchez Martín P, 2019, FEBS J, V286, P8, DOI 10.1111/febs.14712
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Shibuya I, 2019, PATHOL ONCOL RES, V25, P409, DOI 10.1007/s12253 017 0362 8
   Tang JL, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5257
   Tsukamoto S, 2021, CANCERS, V13, DOI 10.3390/cancers13153647
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   van Langevelde K., 2022, Sarcoma, V2022, P3425221, DOI 10.1155/2022/3425221
   Venneker S, 2022, CANCERS, V14, DOI 10.3390/cancers14194708
   Xiang FF, 2022, CANCERS, V14, DOI 10.3390/cancers14235758
   Zhang J, 2016, J BONE ONCOL, V5, P30, DOI 10.1016/j.jbo.2016.01.003
   Zhao YZ, 2021, J CANCER, V12, P508, DOI 10.7150/jca.50575
NR 41
TC 2
Z9 2
U1 2
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568 0096
EI 1873 5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2024
VL 24
IS 5
BP 565
EP 578
DI 10.2174/0115680096265253231022185008
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OB3C8
UT WOS:001204751500006
PM 37961860
DA 2025 08 17
ER

PT J
AU Nilsson, KH
   Henning, P
   El Shahawy, M
   Wu, JY
   Koskela, A
   Tuukkanen, J
   Perret, C
   Lerner, UH
   Ohlsson, C
   Movérare Skrtic, S
AF Nilsson, Karin H.
   Henning, Petra
   El Shahawy, Maha
   Wu, Jianyao
   Koskela, Antti
   Tuukkanen, Juha
   Perret, Christine
   Lerner, Ulf H.
   Ohlsson, Claes
   Moverare Skrtic, Sofia
TI Osteocyte  and late osteoblast derived NOTUM reduces cortical bone mass
   in mice
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE cortical bone; NOTUM; osteocytes
ID MINERAL DENSITY; UPDATE
AB Osteoporosis is a common skeletal disease, with increased risk of fractures. Currently available osteoporosis treatments reduce the risk of vertebral fractures, mainly dependent on trabecular bone, whereas the effect on nonvertebral fractures, mainly dependent on cortical bone, is less pronounced. WNT signaling is a crucial regulator of bone homeostasis, and the activity of WNTs is inhibited by NOTUM, a secreted WNT lipase. We previously demonstrated that conditional inactivation of NOTUM in all osteoblast lineage cells increases the cortical but not the trabecular bone mass. The aim of the present study was to determine if NOTUM increasing cortical bone is derived from osteoblast precursors/early osteoblasts or from osteocytes/late osteoblasts. First, we demonstrated Notum mRNA expression in Dmp1 expressing osteocytes and late osteoblasts in cortical bone using in situ hybridization. We then developed a mouse model with inactivation of NOTUM in Dmp1 expressing osteocytes and late osteoblasts (Dmp1 creNotum(flox/flox) mice). We observed that the Dmp1 creNotum(flox/flox) mice displayed a substantial reduction of Notum mRNA in cortical bone, resulting in increased cortical bone mass and decreased cortical porosity in femur but no change in trabecular bone volume fraction in femur or in the lumbar vertebrae L5 in Dmp1 creNotum(flox/flox) mice as compared with control mice. In conclusion, osteocytes and late osteoblasts are the principal source of NOTUM in cortical bone, and NOTUM derived from osteocytes/late osteoblasts reduces cortical bone mass. These findings demonstrate that inhibition of osteocyte/ late osteoblast derived NOTUM might be an interesting pharmacological target to increase cortical bone mass and reduce non vertebral fracture risk.
   NEW & NOTEWORTHY NOTUM produced by osteoblasts is known to regulate cortical bone mass. Our new findings show that NOTUM specifically derived by DMP1 expressing osteocytes and late osteoblasts regulates cortical bone mass and not trabecular bone mass.
C1 [Nilsson, Karin H.; Henning, Petra; El Shahawy, Maha; Wu, Jianyao; Lerner, Ulf H.; Ohlsson, Claes; Moverare Skrtic, Sofia] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med & Clin Nutr,Ctr Bone & Arthrit, Gothenburg, Sweden.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Fac Med, Inst Canc Res & Translat Med, Dept Anat & Cell Biol, Oulu, Finland.
   [Perret, Christine] Univ Paris, Inst Cochin, INSERM, CNRS, Paris, France.
   [El Shahawy, Maha] Minia Univ, Dept Oral Biol, Al Minya, Egypt.
C3 University of Gothenburg; University of Oulu; Centre National de la
   Recherche Scientifique (CNRS); Universite Paris Cite; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Egyptian Knowledge
   Bank (EKB); Minia University
RP Nilsson, KH (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med & Clin Nutr,Ctr Bone & Arthrit, Gothenburg, Sweden.
EM karin.nilsson.2@gu.se
RI ; Ohlsson, Claes/HIR 6959 2022; Perret Mayeux, Christine/L 3297 2017;
   Skrtic, Sofia/AAQ 1585 2020; Henning, Petra/KIL 4650 2024; Ohlsson,
   Claes/AGP 3544 2022; El Shahawy, Maha/JMR 2491 2023; Tuukkanen,
   Juha/R 3728 2018
OI Koskela, Antti/0000 0001 7371 2488; Ohlsson, Claes/0000 0002 9633 2805;
   El Shahawy, Maha/0000 0001 7122 1191; 
FU Swedish Research Council; Swedish Foundation for Strategic Research;
   Swedish government [238261, 226481, 237551]; Swedish county councils,
   the ALF agreement in Gothenburg [238261, 226481, 237551]; IngaBritt and
   Arne Lundberg Foundation; Royal 80 Year Fund of King Gustav V; Torsten
   and Ragnar Soderberg's Foundation; Knut and Alice Wallenberg Foundation;
   Novo Nordisk Foundation; Adlerbertska Research Foundation; Novo Nordisk
   Fonden [NNF18OC0033898, NNF19OC0055250, NNF13OC0005785, NNF15OC0015080,
   NNF14OC0010513] Funding Source: researchfish
FX This study was supported by the Swedish Research Council, the Swedish
   Foundation for Strategic Research, the Swedish state under the agreement
   between the Swedish government and the county councils, the
   ALF agreement in Gothenburg (Grants 238261, 226481, and 237551), the
   IngaBritt and Arne Lundberg Foundation, the Royal 80 Year Fund of King
   Gustav V, the Torsten and Ragnar Soderberg's Foundation, the Knut and
   Alice Wallenberg Foundation, the Novo Nordisk Foundation, and the
   Adlerbertska Research Foundation.
CR Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Borgström F, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0706 y
   Brommage R, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0038 3
   Brommage R, 2018, BEST PRACT RES CL EN, V32, P329, DOI 10.1016/j.beem.2018.02.006
   Canal F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150997
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198 004 1702 6
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lassen NE, 2017, J BONE MINER RES, V32, P1395, DOI 10.1002/jbmr.3091
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Movérare Skrtic S, 2019, FASEB J, V33, P11163, DOI 10.1096/fj.201900707R
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nusse R, 2015, NATURE, V519, P163, DOI 10.1038/nature14208
   Ohlsson C, 2017, J CLIN ENDOCR METAB, V102, P516, DOI 10.1210/jc.2016 3177
   Quarta C, 2017, CELL METAB, V26, P620, DOI 10.1016/j.cmet.2017.08.023
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 23
TC 9
Z9 10
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD MAY
PY 2021
VL 320
IS 5
BP E967
EP E975
DI 10.1152/ajpendo.00565.2020
PG 9
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA SN6RC
UT WOS:000658413800012
PM 33749332
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Alibhai, SMH
   Zukotynski, K
   Walker Dilks, C
   Emmenegger, U
   Finelli, A
   Morgan, SC
   Hotte, SJ
   Winquist, E
AF Alibhai, S. M. H.
   Zukotynski, K.
   Walker Dilks, C.
   Emmenegger, U.
   Finelli, A.
   Morgan, S. C.
   Hotte, S. J.
   Winquist, E.
CA Canc Care Ontario Genitourinary
TI Bone Health and Bone targeted Therapies for Prostate Cancer: a Programme
   in Evidence based Care   Cancer Care Ontario Clinical Practice Guideline
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Bone mineral density; bone targeted therapy; denosumab; prostate cancer;
   radium 223; zoledronic acid
ID ANDROGEN DEPRIVATION THERAPY; ORAL SODIUM CLODRONATE; PLACEBO CONTROLLED
   TRIAL; RANDOMIZED PHASE III; ZOLEDRONIC ACID; DOUBLE BLIND; DEVELOPMENT
   CYCLE; MINERAL DENSITY; LONG TERM; MEN
AB Aims: To make recommendations with respect to bone health and bone targeted therapies in men with prostate cancer.
   Materials and methods: A systematic review was carried out by searching MEDLINE, EMBASE and the Cochrane Library from inception to January 2016. Systematic reviews and randomised controlled trials were considered for inclusion if they involved therapies directed at improving bone health or outcomes such as skeletal related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone. Therapies included medications, supplements or lifestyle modifications alone or in combination and were compared with placebo, no treatment or other agents. Disease targeted agents such as androgen receptor targeted and chemotherapeutic agents were excluded. Recommendations were reviewed by internal and external review groups.
   Results: In men with prostate cancer receiving androgen deprivation therapy, baseline bone mineral density testing is encouraged. Denosumab should be considered for reducing the risk of fracture in men on androgen deprivation therapy with an increased fracture risk. Bisphosphonates were effective in improving bone mineral density, but the effect on fracture was inconclusive. No medication is recommended to prevent the development of first bone metastasis. Denosumab and zoledronic acid are recommended for preventing or delaying skeletal related events in men with metastatic castration resistant prostate cancer. Radium 223 is recommended for reducing symptomatic skeletal events and prolonging survival in men with symptomatic metastatic castration resistant prostate cancer.
   Conclusions: The recommendations represent a current standard of care that is feasible to implement, with outcomes valued by clinicians and patients. (C) 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Alibhai, S. M. H.] Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada.
   [Zukotynski, K.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Zukotynski, K.] McMaster Univ, Dept Radiol, Hamilton, ON, Canada.
   [Walker Dilks, C.] McMaster Univ, Dept Oncol, Program Evidence Based Care, Hamilton, ON, Canada.
   [Emmenegger, U.] Univ Toronto, Odette Canc Ctr, Dept Med, Div Med Oncol, Toronto, ON, Canada.
   [Finelli, A.] Univ Toronto, Princess Margaret Hosp, Dept Surg, Div Urol, Toronto, ON, Canada.
   [Morgan, S. C.] Univ Ottawa, Ottawa Hosp Canc Ctr, Dept Radiol, Div Radiat Oncol, Ottawa, ON, Canada.
   [Hotte, S. J.] McMaster Univ, Juravinski Canc Ctr, Dept Oncol, Div Med Oncol, Hamilton, ON, Canada.
   [Winquist, E.] Western Univ London, Hlth Sci Ctr, Dept Oncol, Div Med Oncol, London, ON, Canada.
C3 University of Toronto; University Health Network Toronto; McMaster
   University; McMaster University; McMaster University; University of
   Toronto; University of Toronto; University Health Network Toronto;
   Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital
   Research Institute; McMaster University; London Health Sciences Centre;
   Western University (University of Western Ontario); University Western
   Ontario Hospital
RP Alibhai, SMH (通讯作者)，Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada.; Zukotynski, K (通讯作者)，McMaster Univ, Dept Med, Hamilton, ON, Canada.; Zukotynski, K (通讯作者)，McMaster Univ, Dept Radiol, Hamilton, ON, Canada.
EM ccopgi@mcmaster.ca; ccopgi@mcmas ter.ca
RI ; Winquist, Eric/B 6527 2012
OI Hotte, Sebastien/0000 0001 9286 1972; Morgan, Scott/0000 0002 6568 3346;
   William, Eric/0000 0002 8829 5979
CR [Anonymous], 2012, J CANC THER, DOI DOI 10.4236/JCT.2012.32020
   [Anonymous], 2008, Knowl. Inf. Systeme., DOI DOI 10.1002/14651858.CD001155.PUB2
   [Anonymous], 2012, ONC DRUGS ADV COMM M
   Browman GP, 1998, J CLIN ONCOL, V16, P1226, DOI 10.1200/JCO.1998.16.3.1226
   BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502
   Chen L, 2015, OSTEOPOROSIS INT, V26, P2355, DOI 10.1007/s00198 015 3148 4
   Cormie P, 2015, BJU INT, V115, P256, DOI 10.1111/bju.12646
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Diamond TH, 2001, CANCER AM CANCER SOC, V92, P1444, DOI 10.1002/1097 0142(20010915)92:6<1444::AID CNCR1468>3.0.CO;2 M
   Ding H, 2013, ASIAN PAC J CANCER P, V14, P3337, DOI 10.7314/APJCP.2013.14.5.3337
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Figg WD, 2005, J UROLOGY, V173, P790, DOI 10.1097/01.ju.0000147013.09157.8e
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Ford JA, 2013, EUR J CANCER, V49, P416, DOI 10.1016/j.ejca.2012.07.016
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Greenspan SL, 2008, J CLIN ONCOL, V26, P4426, DOI 10.1200/JCO.2007.15.1233
   Himelstein AL, 2015, J CLIN ONCOL, V33
   Israeli RS, 2007, CLIN GENITOURIN CANC, V5, P271, DOI 10.3816/CGC.2007.n.003
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Kachnic LA, 2013, PROSTATE CANCER P D, V16, P382, DOI 10.1038/pcan.2013.35
   Kearns AE, 2010, SUPPORT CARE CANCER, V18, P321, DOI 10.1007/s00520 009 0655 x
   KYLMALA T, 1993, EUR J CANCER, V29A, P821, DOI 10.1016/S0959 8049(05)80417 4
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   Mason MD, 2007, JNCI J NATL CANCER I, V99, P765, DOI 10.1093/jnci/djk178
   Meulenbeld HJ, 2012, EUR J CANCER, V48, P2993, DOI 10.1016/j.ejca.2012.05.014
   Nilsen TS, 2015, ACTA ONCOL, V54, P1805, DOI 10.3109/0284186X.2015.1037008
   Nilsson S, 2005, J PAIN SYMPTOM MANAG, V29, P352, DOI 10.1016/j.jpainsymman.2004.07.008
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Nilsson S, 2013, CLIN GENITOURIN CANC, V11, P20, DOI 10.1016/j.clgc.2012.07.002
   Oosterhof GON, 2003, EUR UROL, V44, P519, DOI 10.1016/S0302 2838(03)00364 6
   Pan Y, 2014, INT UROL NEPHROL, V46, P2319, DOI 10.1007/s11255 014 0824 9
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Rodrigues P, 2007, INT J UROL, V14, P317, DOI 10.1111/j.1442 2042.2006.01721.x
   Figuls MRI, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003347.pub2
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2015, CUAJ CAN UROL ASSOC, V9, P90, DOI 10.5489/cuaj.2526
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Satoh T, 2009, CANCER AM CANCER SOC, V115, P3468, DOI 10.1002/cncr.24404
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Ueno S, 2013, ANTICANCER RES, V33, P3837
   Wang F, 2013, MED ONCOL, V30, DOI 10.1007/s12032 013 0657 x
   Winters Stone KM, 2014, MED SCI SPORT EXER, V46, P1482, DOI 10.1249/MSS.0000000000000265
   Wirth M, 2015, EUR UROL, V67, P482, DOI 10.1016/j.eururo.2014.02.014
   Yuen KK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250
   Zimmerman BE, 2015, J RES NATL INST STAN, V120, DOI 10.6028/jres.120.004
NR 52
TC 34
Z9 35
U1 0
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936 6555
EI 1433 2981
J9 CLIN ONCOL UK
JI Clin. Oncol.
PD JUN
PY 2017
VL 29
IS 6
BP 348
EP 355
DI 10.1016/j.clon.2017.01.007
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EW4ST
UT WOS:000402491900031
PM 28169118
DA 2025 08 17
ER

PT J
AU Guo, AJY
   Choi, RCY
   Cheung, AWH
   Chen, VP
   Xu, SL
   Dong, TTX
   Chen, JJ
   Tsim, KWK
AF Guo, Ava J. Y.
   Choi, Roy C. Y.
   Cheung, Anna W. H.
   Chen, Vicky P.
   Xu, Sherry L.
   Dong, Tina T. X.
   Chen, Ji J.
   Tsim, Karl W. K.
TI Baicalin, a Flavone, Induces the Differentiation of Cultured Osteoblasts
   AN ACTION VIA THE Wnt/β CATENIN SIGNALING PATHWAY
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS;
   SCUTELLARIA BAICALENSIS; HEME OXYGENASE 1; GENE EXPRESSION; PROTEIN;
   OSTEOPROTEGERIN; GENISTEIN; CELLS
AB Flavonoids, a group of natural compounds found in a variety of vegetables and herbal medicines, have been intensively reported on regarding their estrogen like activities and particularly their ability to affect bone metabolism. Here, different subclasses of flavonoids were screened for their osteogenic properties by measuring alkaline phosphatase activity in cultured rat osteoblasts. The flavone baicalin derived mainly from the roots of Scutellaria baicalensis showed the strongest induction of alkaline phosphatase activity. In cultured osteoblasts, application of baicalin increased significantly the osteoblastic mineralization and the levels of mRNAs encoding the bone differentiation markers, including osteonectin, osteocalcin, and collagen type 1 alpha 1. Interestingly, the osteogenic effect of baicalin was not mediated by its estrogenic activity. In contrast, baicalin promoted osteoblastic differentiation via the activation of the Wnt/beta catenin signaling pathway; the activation resulted in the phosphorylation of glycogen synthase kinase 3 beta and, subsequently, induced the nuclear accumulation of the beta catenin, leading to the transcription activation of Wnt targeted genes for osteogenesis. The baicalin induced osteogenic effects were fully abolished by DKK 1, a blocker of Wnt/beta catenin receptor. Moreover, baicalin also enhanced the mRNA expression of osteoprotegerin, which could regulate indirectly the activation of osteoclasts. Taken together, our results suggested that baicalin could act via Wnt/beta catenin signaling to promote osteoblastic differentiation. The osteogenic flavonoids could be very useful in finding potential drugs, or food supplements, for treating post menopausal osteoporosis.
C1 [Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Ji J.] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources W China, Kunming Inst Bot, Kunming 650204, Yunnan, Peoples R China.
C3 Hong Kong University of Science & Technology; Hong Kong University of
   Science & Technology; Chinese Academy of Sciences; Kunming Institute of
   Botany, CAS
RP Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay Rd, Hong Kong, Hong Kong, Peoples R China.
EM BOTSIM@UST.HK
RI CHEN, VICKY/C 9223 2016
FU Research Grants Council of Hong Kong HKUST [6419/06M, 662608,
   N HKUST629/07]; Croucher Foundation [CAS CF07/08.SC03]
FX This work was supported by Research Grants Council of Hong Kong HKUST
   6419/06M, 662608, and N HKUST629/07 and The Croucher Foundation Grant
   CAS CF07/08.SC03 (to K. W. K. T.).
CR Akao T, 2000, J PHARM PHARMACOL, V52, P1563, DOI 10.1211/0022357001777621
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1358S, DOI 10.1093/ajcn/68.6.1358S
   Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161
   Berg AO, 2003, AM J NURS, V103, P83
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Choi RCY, 2010, J ALZHEIMERS DIS, V19, P795, DOI 10.3233/JAD 2010 1293
   Chow JM, 2005, BIOCHEM PHARMACOL, V69, P1839, DOI 10.1016/j.bcp.2005.03.017
   DIDDLE AW, 1984, SOUTH MED J, V77, P868, DOI 10.1097/00007611 198407000 00020
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gao YH, 1999, BIOCHEM PHARMACOL, V58, P767, DOI 10.1016/S0006 2952(99)00162 8
   Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161
   Heino TJ, 2008, J ENDOCRINOL, V197, pR1, DOI 10.1677/JOE 07 0629
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Kim HM, 1999, TOXICOLOGY, V135, P109, DOI 10.1016/S0300 483X(99)00047 5
   Lin HY, 2005, J CELL PHYSIOL, V202, P579, DOI 10.1002/jcp.20160
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   MOSCARINI M, 1994, GYNECOL ENDOCRINOL, V8, P203, DOI 10.3109/09513599409072456
   Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   RIZZOLI R, 1997, LANCET S1, V49, pS20
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SEEMAN E, 1992, J BONE MINER RES, V7, P1467
   Shang YZ, 2006, BIOL PHARM BULL, V29, P805, DOI 10.1248/bpb.29.805
   Shen YC, 2003, EUR J PHARMACOL, V465, P171, DOI 10.1016/S0014 2999(03)01378 5
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Song Yuan zong, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P339
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004 1064
   Walle T, 2005, J NUTR, V135, P48, DOI 10.1093/jn/135.1.48
   Windahl SH, 2002, TRENDS ENDOCRIN MET, V13, P195, DOI 10.1016/S1043 2760(02)00594 5
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Yamaguchi M, 1998, BIOCHEM PHARMACOL, V55, P71, DOI 10.1016/S0006 2952(97)00402 4
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zheng YZ, 2010, PLANTA MED, V76, P439, DOI 10.1055/s 0029 1186222
   Zhu JTT, 2007, J AGR FOOD CHEM, V55, P2438, DOI 10.1021/jf063299z
NR 40
TC 108
Z9 122
U1 0
U2 39
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 12
PY 2011
VL 286
IS 32
BP 27882
EP 27893
DI 10.1074/jbc.M111.236281
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 803CJ
UT WOS:000293557800007
PM 21652696
OA Green Published
DA 2025 08 17
ER

PT J
AU Swarnkar, G
   Sharan, K
   Siddiqui, JA
   Chakravarti, B
   Rawat, P
   Kumar, M
   Arya, KR
   Maurya, R
   Chattopadhyay, N
AF Swarnkar, Gaurav
   Sharan, Kunal
   Siddiqui, Jawed A.
   Chakravarti, Bandana
   Rawat, Preeti
   Kumar, Manmeet
   Arya, Kamal R.
   Maurya, Rakesh
   Chattopadhyay, Naibedya
TI A novel flavonoid isolated from the steam bark of Ulmus
   Wallichiana Planchon stimulates osteoblast function and inhibits
   osteoclast and adipocyte differentiation
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Osteogenic; Adipogenesis; Osteoclastogenesis; Flavonoid C glucoside;
   Bone marrow
AB (25,3S) Aromadendrin 6 C beta D glucopyranoside (AG) is a novel flavonol isolated from the extract of Ulmus wallichiana (Himalayan Elm). Extract of U. wallichiana is used as a traditional medicine for rapid fracture repair in India. We characterized the mechanism of action of AG in mouse bone cells by investigating its effect on the precursors of osteoblasts, osteoclasts and adipocytes. At nanomolar concentrations, AG increased differentiation of preosteoblasts obtained from neonatal mouse calvaria. The gene expression of osteogenic markers, including runt related transcription factor 2 (Runx 2), bone morphogenetic protein 2 (BMP 2), type I collagen and osteocalcin were elevated in the preosteoblasts. The extracellular matrix mineralization was higher in preosteoblast and bone marrow cells when AG was present in the medium. Furthermore, AG protected the differentiated osteoblasts from serum deprivation induced apoptosis, and increased the expression of the anti osteoclastogenic cytokine, osteoprotegerin. It inhibited osteoclast differentiation of bone marrow precursor cells to osteoclasts in the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and monocyte/macrophage colony stimulating factor (M CSF). Additionally, in 3T3 L1 preadipocytes, AG decreased the expression of genes involved in adipogenesis, including peroxisome proliferator activated receptor gamma (PPAR gamma), sterol regulatory element binding protein (SREBP) and CCAAT/enhancer binding protein alpha (CEBP/alpha), and induced apoptosis of differentiated adipocytes. Induction of adipogenic differentiation was also inhibited in the presence of AG. AG exhibited no estrogenic/antiestrogenic effect. Together, our data show that AG has potent osteogenic, anti osteoclastogenic and anti adipogenic effects, which may translate to a better skeletal outcome in postmenopausal osteoporosis. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Swarnkar, Gaurav; Sharan, Kunal; Siddiqui, Jawed A.; Chakravarti, Bandana; Chattopadhyay, Naibedya] Cent Drug Res Inst, Div Endocrinol, Council Sci & Ind Res, Lucknow 226001, Uttar Pradesh, India.
   [Rawat, Preeti; Kumar, Manmeet; Maurya, Rakesh] Cent Drug Res Inst, Div Med & Proc Chem, Council Sci & Ind Res, Lucknow 226001, Uttar Pradesh, India.
   [Arya, Kamal R.] Cent Drug Res Inst, Div Bot, Council Sci & Ind Res, Lucknow 226001, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，Cent Drug Res Inst, Div Endocrinol, Council Sci & Ind Res, POB 173, Lucknow 226001, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Siddiqui, Jawed/G 9258 2017; Chattopadhyay, Naibedya/AAQ 3213 2021;
   Rawat, Preeti/ADB 0872 2022; maurya, rakesh/AAV 7598 2021; SWARNKAR,
   GAURAV/AAE 3223 2021; Sharan, Kunal/C 9618 2012
OI Siddiqui, Jawed/0000 0003 1287 3004; Sharan, Kunal/0000 0003 2139 2544;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; 
FU Ministry of Health and Family Welfare; Council of Scientific and
   Industrial Research; Department of Biotechnology; University Grants
   Commission, Government of India
FX This study was supported by grants from the Ministry of Health and
   Family Welfare, Council of Scientific and Industrial Research,
   Department of Biotechnology and University Grants Commission, Government
   of India.
CR Wang XR, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.206803
NR 1
TC 38
Z9 43
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 11
PY 2011
VL 658
IS 2 3
BP 65
EP 73
DI 10.1016/j.ejphar.2011.02.032
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 756KQ
UT WOS:000290010500003
PM 21376034
DA 2025 08 17
ER

PT J
AU Kavanagh, KL
   Guo, KD
   Dunford, JE
   Wu, XQ
   Knapp, S
   Ebetino, FH
   Rogers, MJ
   Russell, RGG
   Oppermann, U
AF Kavanagh, Kathryn L.
   Guo, Kunde
   Dunford, James E.
   Wu, Xiaoqiu
   Knapp, Stefan
   Ebetino, Frank H.
   Rogers, Michael J.
   Russell, R. Graham G.
   Oppermann, Udo
TI The molecular mechanism of nitrogen containing bisphosphonates as anti
   osteoporosis drugs
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE farnesyl pyrophosphate synthase; osteoclast; slow, tight inhibition;
   farnesyl diphosphate synthase; trans prenyltransferase
ID FARNESYL DIPHOSPHATE SYNTHASE; BONE RESORPTION; IN VIVO; MEVALONATE
   PATHWAY; LIVER PRENYLTRANSFERASE; ISOPRENOID BIOSYNTHESIS; PYROPHOSPHATE
   SYNTHASE; BINDING ENERGETICS; STRUCTURAL BASIS; INHIBITION
AB Osteoporosis and low bone mass are currently estimated to be a major public health risk affecting > 50% of the female population over the age of 50. Because of their bone selective pharmacokinetics, nitrogen containing bisphosphonates (N BPs), currently used as clinical inhibitors of bone resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FIRPS) and inhibit protein prenylation. FIRPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. To understand the molecular events involved in inhibition of FPPS by N BPs, we used protein crystallography, enzyme kinetics, and isothermal titration calorimetry. We report here high resolution x ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N BPs in clinical use. These agents bind to the dimethylallyl/ geranyl pyrophosphate ligand pocket and induce a conformational change. The interactions of the N BP cyclic nitrogen with Thr 201 and Lys 200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation binding site. Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme inhibitor complex occurs with inhibitor binding. Isothermal titration calorimetry indicates that binding of N BPs to the apoenzyme is entropy driven, presumably through desolvation entropy effects. These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs.
C1 Univ Oxford, Struct Gen Consortium, Oxford OX3 7LD, England.
   Procter & Gamble Co, Mason, OH 45040 USA.
   Univ Aberdeen, Inst Med Sci, Bone Res Grp, Aberdeen AB25 2ZD, Scotland.
   Univ Oxford, Inst Musculoskeletal Sci, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England.
C3 University of Oxford; Procter & Gamble; University of Aberdeen;
   University of Oxford; Nuffield Orthopaedic Centre
RP Kavanagh, KL (通讯作者)，Univ Oxford, Struct Gen Consortium, Oxford OX3 7LD, England.
EM kate.kavanagh@sgc.ox.ac.uk; udo.oppermann@sgc.ox.ac.uk
RI Russell, Robert Graham G/JEF 5877 2023; Russell, R/JEF 5877 2023; Knapp,
   Stefan/AAG 2347 2019
OI Russell, Robert Graham G/0000 0002 4136 1828; Knapp,
   Stefan/0000 0001 5995 6494; Dunford, James/0000 0002 9932 4042; Rogers,
   Michael/0000 0002 1818 9249
FU Wellcome Trust Funding Source: Medline
CR [Anonymous], ACTA CRYSTALLOGR D
   BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005 2744(81)90086 3
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   REED BC, 1976, BIOCHEMISTRY US, V15, P3739, DOI 10.1021/bi00662a015
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402
   Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956
   Szabo CM, 2002, J MED CHEM, V45, P2894, DOI 10.1021/jm010279+
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Velazquez Campoy A, 2001, ARCH BIOCHEM BIOPHYS, V390, P169, DOI 10.1006/abbi.2001.2333
   Velazquez Campoy A, 2000, PROTEIN SCI, V9, P1801, DOI 10.1110/ps.9.9.1801
NR 30
TC 460
Z9 535
U1 0
U2 67
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 16
PY 2006
VL 103
IS 20
BP 7829
EP 7834
DI 10.1073/pnas.0601643103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 046UF
UT WOS:000237835900054
PM 16684881
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Shenoy, PA
   Kuo, A
   Khan, N
   Gorham, L
   Nicholson, JR
   Corradini, L
   Vetter, I
   Smith, MT
AF Shenoy, Priyank A.
   Kuo, Andy
   Khan, Nemat
   Gorham, Louise
   Nicholson, Janet R.
   Corradini, Laura
   Vetter, Irina
   Smith, Maree T.
TI The Somatostatin Receptor 4 Agonist J 2156 Alleviates Mechanical
   Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE J 2156; somatostatin receptor 4 agonist; mechanical hypersensitivity;
   mechanical allodynia; mechanical hyperalgesia; Walker 256 cells; rat
   model of breast cancer induced bone pain
ID DORSAL HORN NEURONS; SOFT TISSUE SURGERY; POTASSIUM CHANNELS; SST(4)
   RECEPTOR; AFFERENT FIBERS; SODIUM CHANNELS; SRIF AGONISTS; SPINAL CORD;
   PHARMACOLOGICAL CHARACTERIZATION; CENTRAL SENSITIZATION
AB In the majority of patients with breast cancer in the advanced stages, skeletal metastases are common, which may cause excruciating pain Currently available drug treatments for relief of breast cancer induced bone pain (BCIBP) include non steroidal anti inflammatory drugs and strong opioid analgesics along with inhibitors of osteoclast activity such as bisphosphonates and monoclonal antibodies such as denosumab. However, these medications often lack efficacy and/or they may produce serious dose limiting side effects. In the present study, we show that J 2156, a somatostatin receptor type 4 (SST4 receptor) selective agonist, reverses pain like behaviors in a rat model of BCIBP induced by unilateral intra tibial injection of Walker 256 breast cancer cells. Following intraperitoneal administration, the ED50 of J 2156 for the relief of mechanical allodyma and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg/kg, respectively. Importantly, the vast majority of somatosensory neurons in the dorsal root ganglia including small diameter C fibers and medium large diameter fibers, that play a crucial role in cancer pain hypersensitivities, expressed the SST4 receptor. J 2156 mediated pain relief in BCIBP rats was confirmed by observations of a reduction in the levels of phosphorylated extracellular signal regulated kinase (pERK), a protein essential for central sensitization and persistent pain, in the spinal dorsal horn Our results demonstrate the potential of the SST4 receptor as a pharmacological target for relief of BCIBP and we anticipate the present work to be a starting point for further mechanism based studies.
C1 [Shenoy, Priyank A.; Kuo, Andy; Khan, Nemat; Smith, Maree T.] Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Gorham, Louise; Nicholson, Janet R.; Corradini, Laura] Boehringer Ingelheim Pharma GmbH & Co KG, Dept CNS Dis Res, Biberach, Germany.
   [Vetter, Irina] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Vetter, Irina; Smith, Maree T.] Univ Queensland, Fac Hlth & Behav Sci, Sch Pharm, Brisbane, Qld, Australia.
C3 University of Queensland; Boehringer Ingelheim; University of
   Queensland; University of Queensland
RP Smith, MT (通讯作者)，Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia.; Smith, MT (通讯作者)，Univ Queensland, Fac Hlth & Behav Sci, Sch Pharm, Brisbane, Qld, Australia.
EM maree.smith@uq.edu.au
RI Khan, Nemat/I 3063 2015; Vetter, Irina/A 6035 2010; Kuo,
   Andy/I 4007 2015; Smith, Maree/I 4005 2015
OI Khan, Nemat/0000 0002 1819 3459; Vetter, Irina/0000 0002 3594 9588;
   Smith, Maree/0000 0003 2281 3734
FU Australian Research Council [LP120200623]; Boehringer Ingelheim Pharma
   GmbH Co. KG; Australian Research Council [LP120200623] Funding Source:
   Australian Research Council
FX AK's and NK's Post Doctoral positions and this research were funded by
   an Australian Research Council Linkage Grant (LP120200623) in
   collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG. JN and LC
   are paid employees of Boehringer Ingelheim Pharma GmbH & Co. KG.
CR Abdel Magid AF, 2015, ACS MED CHEM LETT, V6, P11, DOI [10.1021/ml500538a, 10.1021/ml500347s, 10.1021/acsmedchemlett.6b00458]
   Al Rejaie SS, 2015, NEUROSCIENCES, V20, P115, DOI 10.17712/nsj.2015.2.20140511
   Almarestani L, 2011, ARTHRITIS RHEUM US, V63, P1573, DOI 10.1002/art.30303
   Amir R, 2006, J PAIN, V7, pS1, DOI 10.1016/j.jpain.2006.01.444
   Andres C, 2013, PAIN, V154, P2216, DOI 10.1016/j.pain.2013.07.005
   Bao Y, 2014, MOL PAIN, V10, DOI 10.1186/1744 8069 10 28
   Bär KJ, 2004, NEUROSCIENCE, V127, P197, DOI 10.1016/j.neuroscience.2004.04.051
   Bennett GJ, 2010, ONCOLOGIST, V15, P9, DOI 10.1634/theoncologist.2009 S503
   Bhandari S, 2008, J HISTOCHEM CYTOCHEM, V56, P733, DOI 10.1369/jhc.2008.950998
   Bloom AP, 2011, J PAIN, V12, P698, DOI 10.1016/j.jpain.2010.12.016
   BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561
   BRUNS C, 1995, CIBA F SYMP, V190, P89
   Bu HL, 2014, BREAST CANCER RES TR, V143, P255, DOI 10.1007/s10549 013 2807 4
   Cain DM, 2001, J NEUROSCI, V21, P9367, DOI 10.1523/JNEUROSCI.21 23 09367.2001
   Cao F, 2010, BRAIN RES, V1326, P162, DOI 10.1016/j.brainres.2010.02.039
   Carlton SA, 2004, PAIN, V110, P616, DOI 10.1016/j.pain.2004.04.042
   Caron P, 1997, J CLIN ENDOCR METAB, V82, P3771, DOI 10.1210/jc.82.11.3771
   Chacur M, 2001, PAIN, V94, P231, DOI 10.1016/S0304 3959(01)00354 2
   Chen J, 2012, ACTA BIOCH BIOPH SIN, V44, P367, DOI 10.1093/abbs/gms007
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Cleeland CS, 2003, CANCER AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382
   Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Concepción Martín M, 2014, ENDOSCOPY, V46, P851, DOI 10.1055/s 0034 1377306
   Crider AM, 2007, MINI REV MED CHEM, V7, P213
   Dahaba AA, 2009, EUR J PAIN, V13, P861, DOI 10.1016/j.ejpain.2008.10.006
   DeSantis CE, 2015, CANCER EPIDEM BIOMAR, V24, P1495, DOI 10.1158/1055 9965.EPI 15 0535
   di Mola FF, 2008, LANGENBECK ARCH SURG, V393, P919, DOI 10.1007/s00423 007 0277 z
   Dib Hajj SD, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007017
   Dib Hajj SD, 2010, ANNU REV NEUROSCI, V33, P325, DOI 10.1146/annurev neuro 060909 153234
   Dib Hajj SD, 2009, PAIN MED, V10, P1260, DOI 10.1111/j.1526 4637.2009.00719.x
   Ding ZF, 2017, INT J CANCER, V140, P411, DOI 10.1002/ijc.30438
   Dong Y, 2011, NEUROSCI LETT, V496, P163, DOI 10.1016/j.neulet.2011.04.008
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   Elekes K, 2008, EUR J PHARMACOL, V578, P313, DOI 10.1016/j.ejphar.2007.09.033
   Engström M, 2006, J PHARMACOL EXP THER, V316, P1262, DOI 10.1124/jpet.105.094128
   Engström M, 2005, J PHARMACOL EXP THER, V312, P332, DOI 10.1124/jpet.104.075531
   Erchegyi J, 2003, J MED CHEM, V46, P5597, DOI 10.1021/jm030245x
   Erchegyi J, 2003, J MED CHEM, V46, P5587, DOI 10.1021/jm0302445
   Esquivel Velázquez M, 2015, J INTERF CYTOK RES, V35, P1, DOI 10.1089/jir.2014.0026
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Fehlmann D, 2000, J PHYSIOLOGY PARIS, V94, P265, DOI 10.1016/S0928 4257(00)00208 4
   FEINDT J, 1995, J NEUROCHEM, V65, P1997
   Feindt J, 1998, MOL BRAIN RES, V60, P228, DOI 10.1016/S0169 328X(98)00184 3
   Ferrari LF, 2018, NEUROSCIENCE, V387, P170, DOI 10.1016/j.neuroscience.2017.06.044
   Friton G, 2017, J VET INTERN MED, V31, P832, DOI 10.1111/jvim.14698
   Friton G, 2017, BMC VET RES, V13, DOI 10.1186/s12917 017 1100 x
   Gao Yong Jing, 2009, Open Pain J, V2, P11
   Gorham L, 2014, EUR J PHARMACOL, V736, P101, DOI 10.1016/j.ejphar.2014.04.016
   Gorham L, 2014, NEUROSCI LETT, V573, P35, DOI 10.1016/j.neulet.2014.04.042
   Grace CRR, 2003, J MED CHEM, V46, P5606, DOI 10.1021/jm030246p
   Griggs RB, 2016, J PAIN, V17, P359, DOI 10.1016/j.jpain.2015.11.006
   Guerrero M, 2010, PROBE REPORTS NIH MO
   Guo Y, 2008, BRAIN RES, V1229, P61, DOI 10.1016/j.brainres.2008.06.111
   HAGGERTY GC, 1991, J AM COLL TOXICOL, V10, P677, DOI 10.3109/10915819109078660
   Han FY, 2014, BEHAV PHARMACOL, V25, P732, DOI 10.1097/FBP.0000000000000090
   Helyes Z, 2006, BRIT J PHARMACOL, V149, P405, DOI 10.1038/sj.bjp.0706876
   Helyes Z, 2009, P NATL ACAD SCI USA, V106, P13088, DOI 10.1073/pnas.0900681106
   Hu S, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/973524
   Hubina E, 2006, EUR J ENDOCRINOL, V155, P371, DOI 10.1530/eje.1.02213
   Ikeda R, 2007, PAIN, V127, P161, DOI 10.1016/j.pain.2006.09.003
   Imhof AK, 2011, ARTHRITIS RHEUM US, V63, P2352, DOI 10.1002/art.30410
   Jensen TS, 2014, LANCET NEUROL, V13, P924, DOI 10.1016/S1474 4422(14)70102 4
   Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040
   Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008 5472.CAN 14 3180
   Jung YM, 2006, LAB INVEST, V86, P477, DOI 10.1038/labinvest.3700410
   Kane CM, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h315
   Kawasaki Y, 2004, J NEUROSCI, V24, P8310, DOI 10.1523/JNEUROSCI.2396 04.2004
   Ke CB, 2013, NEUROPHARMACOLOGY, V75, P181, DOI 10.1016/j.neuropharm.2013.07.010
   Khan N, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.137
   Khan N, 2014, PHARMACOL BIOCHEM BE, V126, P13, DOI 10.1016/j.pbb.2014.09.003
   Kim HK, 2010, ANESTHESIOLOGY, V112, P432, DOI 10.1097/ALN.0b013e3181ca31bd
   Koltzenburg M, 1999, TRENDS NEUROSCI, V22, P122, DOI 10.1016/S0166 2236(98)01302 2
   Lantero A, 2014, J NEUROSCI, V34, P5385, DOI 10.1523/JNEUROSCI.4405 13.2014
   Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389
   Le Pichon CE, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00021
   Liu SL, 2010, BRAIN RES, V1346, P213, DOI 10.1016/j.brainres.2010.05.014
   Lozano Ondoua AN, 2013, J BONE MINER RES, V28, P92, DOI 10.1002/jbmr.1732
   Ludvigsen E, 2015, UPSALA J MED SCI, V120, P157, DOI 10.3109/03009734.2015.1035413
   Luo R, 2010, BRAIN RES, V1322, P50, DOI 10.1016/j.brainres.2010.01.058
   Mancino M, 2011, BBA REV CANCER, V1816, P105, DOI 10.1016/j.bbcan.2011.04.005
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   Mao Ying QL, 2006, BIOCHEM BIOPH RES CO, V345, P1292, DOI 10.1016/j.bbrc.2006.04.186
   Mao Ying QL, 2012, MOL BRAIN, V5, DOI 10.1186/1756 6606 5 16
   Meeus M, 2007, CLIN RHEUMATOL, V26, P465, DOI 10.1007/s10067 006 0433 9
   MOSER VC, 1990, NEUROTOXICOLOGY, V11, P335
   Muralidharan A, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00493
   Muralidharan A, 2014, PAIN MED, V15, P93, DOI 10.1111/pme.12258
   Muralidharan A, 2013, PHARMACOL BIOCHEM BE, V106, P33, DOI 10.1016/j.pbb.2013.02.020
   Murray RD, 2004, J CLIN INVEST, V114, P349, DOI 10.1172/jci200419933
   Nencini S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00157
   Otis C, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1047 5
   Otto KJ, 2011, PAIN MED, V12, P437, DOI 10.1111/j.1526 4637.2011.01067.x
   Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183
   Pavlaki M, 2009, MOL CELL BIOCHEM, V328, P189, DOI 10.1007/s11010 009 0089 2
   PENN RD, 1992, PAIN, V49, P13, DOI 10.1016/0304 3959(92)90182 B
   Pierre S, 2009, NAT REV DRUG DISCOV, V8, P321, DOI 10.1038/nrd2827
   Prévôt TD, 2017, NEUROPSYCHOPHARMACOL, V42, P1647, DOI 10.1038/npp.2016.281
   Qiu C, 2008, J NEUROSCI, V28, P3567, DOI 10.1523/JNEUROSCI.4679 07.2008
   RANDALL LO, 1957, ARCH INT PHARMACOD T, V113, P233
   Rebeca R, 2008, CELL BIOCHEM FUNCT, V26, P731, DOI 10.1002/cbf.1497
   Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031 9384(99)00136 5
   Reynaert H, 2004, GUT, V53, P1180, DOI 10.1136/gut.2003.036053
   ROMANO VM, 1991, J ORTHOPAED RES, V9, P54, DOI 10.1002/jor.1100090108
   Rowlett JK, 1999, J PHARMACOL EXP THER, V291, P1233
   Sadana R, 2009, NEUROSIGNALS, V17, P5, DOI 10.1159/000166277
   Sah DWY, 2003, NAT REV DRUG DISCOV, V2, P460, DOI 10.1038/nrd1107
   Sándor K, 2006, EUR J PHARMACOL, V539, P71, DOI 10.1016/j.ejphar.2006.03.082
   Sang CN, 2009, NEUROTHERAPEUTICS, V6, P607, DOI 10.1016/j.nurt.2009.08.004
   Schuelert N, 2015, EUR J PHARMACOL, V746, P274, DOI 10.1016/j.ejphar.2014.11.003
   Selmer IS, 2000, NEUROSCIENCE, V98, P523, DOI 10.1016/S0306 4522(00)00147 0
   Selmer IS, 2000, MOL BRAIN RES, V82, P114, DOI 10.1016/S0169 328X(00)00186 8
   Shenoy P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00442
   Shenoy PA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00286
   Somvanshi RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085193
   Song SH, 2004, WORLD J GASTROENTERO, V10, P1663, DOI 10.3748/wjg.v10.i11.1663
   Sroka IC, 2010, J CELL PHYSIOL, V224, P283, DOI 10.1002/jcp.22149
   Stamboulian S, 2010, J NEUROSCI, V30, P1637, DOI 10.1523/JNEUROSCI.4872 09.2010
   Strobæk D, 2013, BRIT J PHARMACOL, V168, P432, DOI 10.1111/j.1476 5381.2012.02143.x
   Sughrue ME, 2008, J BRACHIAL PLEX PERI, V3, DOI 10.1186/1749 7221 3 6
   Sun YJ, 2017, J SENSORS, V2017, DOI 10.1155/2017/3157329
   Suzuki M, 2017, J OSTEOPOROS, V2017, DOI 10.1155/2017/7582716
   Szokolóczi O, 2005, J RECEPT SIG TRANSD, V25, P217, DOI 10.1080/10799890500464621
   Szolcsányi J, 2004, EUR J PHARMACOL, V498, P103, DOI 10.1016/j.ejphar.2004.07.085
   Szolcsányi J, 2011, CURR TOP MED CHEM, V11, P2253, DOI 10.2174/156802611796904852
   Tong W, 2010, BIOCHEM BIOPH RES CO, V395, P572, DOI 10.1016/j.bbrc.2010.04.086
   Tong ZQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010234
   Tsantoulas C, 2014, TRENDS NEUROSCI, V37, P146, DOI 10.1016/j.tins.2013.12.002
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Varamini P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041909
   Varecza Z, 2009, J HISTOCHEM CYTOCHEM, V57, P1127, DOI 10.1369/jhc.2009.953919
   Espinosa Juárez JV, 2017, BASIC CLIN PHARMACOL, V121, P471, DOI 10.1111/bcpt.12839
   Voss MJ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 21
   Wang J, 2011, CLIN EXP PHARMACOL P, V38, P521, DOI 10.1111/j.1440 1681.2011.05542.x
   Wang J, 2009, BRAIN RES, V1288, P50, DOI 10.1016/j.brainres.2009.06.088
   Wang LN, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 48
   Weckbecker G, 2003, NAT REV DRUG DISCOV, V2, P999, DOI 10.1038/nrd1255
   Wei F, 2006, J NEUROSCI, V26, P851, DOI 10.1523/JNEUROSCI.3292 05.2006
   Whiteside GT, 2004, BRIT J PHARMACOL, V141, P85, DOI 10.1038/sj.bjp.0705568
   Xia H, 2014, BRAIN RES, V1554, P29, DOI 10.1016/j.brainres.2014.01.032
   Ye Y, 2014, BEHAV BRAIN FUNCT, V10, DOI 10.1186/1744 9081 10 5
   Yoneda T, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.58
   Zambelli VO, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409 017 0099 6
   Zeppetella G, 2003, J PAIN SYMPTOM MANAG, V25, P555, DOI 10.1016/S0885 3924(03)00146 5
   Zhu SS, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/265056
NR 147
TC 20
Z9 21
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 15
PY 2018
VL 9
AR 495
DI 10.3389/fphar.2018.00495
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GF9NA
UT WOS:000432303600001
PM 29867498
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Imre, A
   Zoltán, S
   Miklós, S
AF Imre, Antal
   Zoltan, Sapi
   Miklos, Szendroi
TI Current indications for denosumab in benign bone tumours
SO EFORT OPEN REVIEWS
LA English
DT Article
DE denosumab; giant cell tumour of bone; aneurysmal bone cyst; tyrosine
   kinase inhibitor
ID GIANT CELL TUMOR; OPEN LABEL; LOCAL RECURRENCE; PHASE II; RADIOTHERAPY;
   MULTICENTER; METASTASES; MANAGEMENT; GRANULOMA; EFFICACY
AB Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK RANKL pathway. It promotes the apoptosis of osteoclast like giant cells, a secondary ossification and connective tissue formation.Given its high efficacy, denosumab is the standard treatment of unresectable or metastatic giant cell tumour of bone (GCTB) requiring morbid surgery.Neoadjuvant administration of denosumab may be justified to enable the resection of the tumour in certain cases; it should be considered, however, with caution for joint saving surgery due to high local recurrence rates.In cases of unresectable or metastatic GCTB, however, denosumab treatment should be administered for years or even as a lifelong therapy. This poses many yet unanswered questions concerning the frequency of denosumab treatment as well as the ratio of the adverse events in the following years.Denosumab suppresses, not directly targets, the neoplastic stromal cells of GCTB. Ongoing in vitro studies suggest that other drugs alone or in combination (e.g. sunitinib) with denosumab may target both the neoplastic and the giant cells.Promising results have been reported regarding the off label use of denosumab in other giant cell rich tumours/tumour like lesions, i.e. aneurysmal bone cysts and central giant cell granulomas. Data are derived, however, mostly from case reports and case series. Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases.
C1 [Imre, Antal; Miklos, Szendroi] Semmelweis Univ, Dept Orthopaed, Budapest, Hungary.
   [Zoltan, Sapi] Semmelweis Univ, Dept Pathol & Expt Canc Res, Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP Imre, A (通讯作者)，Semmelweis Univ, Dept Orthopaed, Budapest, Hungary.
EM antal.imre@med.semmelweis univ.hu
OI Antal MD PhD, Imre/0000 0001 7706 5679
CR Agarwal MG, 2018, CLIN ORTHOP RELAT R, V476, P1773, DOI 10.1007/s11999.0000000000000243
   Alaqaili SI, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3792
   Alhumaid I, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.3989
   Antal I, 1999, INT ORTHOP, V23, P315, DOI 10.1007/s002640050381
   Antal I, 2022, PATHOL ONCOL RES, V28, DOI 10.3389/pore.2022.1610633
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Boriani S, 2020, EUR SPINE J, V29, P257, DOI 10.1007/s00586 019 05997 0
   Bredell M, 2018, J ORAL MAXIL SURG, V76, P775, DOI 10.1016/j.joms.2017.09.013
   Bussiere JL, 2013, REPROD TOXICOL, V42, P27, DOI 10.1016/j.reprotox.2013.07.018
   Campanacci M, 1976, Recent Results Cancer Res, P257
   Chan CM, 2015, J BONE JOINT SURG AM, V97A, P420, DOI 10.2106/JBJS.N.00678
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen X, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03294 2
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Deventer N, 2021, J BONE ONCOL, V30, DOI 10.1016/j.jbo.2021.100384
   Dominkus M, 2006, INT ORTHOP, V30, P499, DOI 10.1007/s00264 006 0204 x
   Dürr HR, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2855 y
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Feigenberg SJ, 2003, CLIN ORTHOP RELAT R, P207, DOI 10.1097/01.blo.0000069890.31220.b4
   Flanagan A.M., 2020, cell tumour of bone. WHO classification of tumours of soft tissue and bone, V5th ed., P440
   Forsyth RG, 2021, CANCERS, V13, DOI 10.3390/cancers13205119
   Freyschmidt J, 2010, Heidelberg, V4th, P652
   Gaston CL, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0056 0
   Groenen KHJ, 2016, RADIOTHER ONCOL, V119, P194, DOI 10.1016/j.radonc.2016.03.001
   Hasenfratz M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85319 x
   Hindiskere S, 2020, CLIN ORTHOP RELAT R, V478, P2522, DOI 10.1097/CORR.0000000000001285
   Kim TS, 2017, JBMR PLUS, V1, P101, DOI 10.1002/jbm4.10010
   Kobayashi E, 2015, LANCET, V385, P539, DOI 10.1016/S0140 6736(14)61338 6
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005
   Liede A, 2014, J BONE JOINT SURG AM, V96A, P1999, DOI 10.2106/JBJS.N.00367
   Lipplaa A, 2019, ONCOLOGIST, V24, P889, DOI 10.1634/theoncologist.2019 0280
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Liu WF, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100334
   Mahdal M, 2021, CANCERS, V13, DOI 10.3390/cancers13143543
   Maximen J, 2022, JOINT BONE SPINE, V89, DOI 10.1016/j.jbspin.2021.105260
   Medellin MR, 2018, BONE JOINT J, V100B, P1626, DOI 10.1302/0301 620X.100B12.BJJ 2018 0189.R2
   Moskovszky L, 2009, GENE CHROMOSOME CANC, V48, P468, DOI 10.1002/gcc.20656
   Müller DA, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957 016 1034 y
   O'Connell JE, 2015, OR SURG OR MED OR PA, V120, pE191, DOI 10.1016/j.oooo.2015.07.011
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Palmerini E, 2021, BMC CANCER, V21, DOI 10.1186/s12885 020 07739 8
   Palmerini E, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819840000
   Palmerini E, 2018, TUMORI J, V104, P344, DOI 10.1177/0300891618784808
   Perrin DL, 2021, BONE JOINT J, V103B, P184, DOI 10.1302/0301 620X.103B1.BJJ 2020 0274.R1
   Polyzos SA, 2019, BONE, V129, DOI 10.1016/j.bone.2019.115048
   Rutkowski P, 2018, EJSO EUR J SURG ONC, V44, P1384, DOI 10.1016/j.ejso.2018.03.020
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Saikia KC, 2011, J ORTHOP SCI, V16, P581, DOI 10.1007/s00776 011 0033 7
   Schreuder WH, 2014, J ORAL MAXIL SURG, V72, P1301, DOI 10.1016/j.joms.2014.02.017
   Scoccianti G, 2018, CLIN ORTHOP RELAT R, V476, P1783, DOI 10.1007/s11999.0000000000000104
   Shi WY, 2013, AM J CLIN ONCOL CANC, V36, P505, DOI 10.1097/COC.0b013e3182568fb6
   Singh VA, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020979750
   Strauss SJ, 2021, ANN ONCOL, V32, P1520, DOI 10.1016/j.annonc.2021.08.1995
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   Uday S, 2018, J CLIN ENDOCR METAB, V103, P596, DOI 10.1210/jc.2017 02025
   Unni K K., 2010, Dahlin's Bone Tumors: General Aspects And Data on 10, V165 Cases
   van der Heijden L, 2020, CURR OPIN ONCOL, V32, P332, DOI 10.1097/CCO.0000000000000645
   Vari S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810721
   Wang DX, 2023, TRANSL PEDIATR, V12, P470, DOI 10.21037/tp 22 276
   Wang GN, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017778
   Wang HD, 2014, J CLIN ENDOCR METAB, V99, P891, DOI 10.1210/jc.2013 3081
   Xiang FF, 2022, CANCERS, V14, DOI 10.3390/cancers14235758
   Zhang RZ, 2019, ORTHOP SURG, V11, P1101, DOI 10.1111/os.12561
NR 70
TC 5
Z9 5
U1 0
U2 5
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 2396 7544
EI 2058 5241
J9 EFORT OPEN REV
JI EFORT Open Rev.
PD DEC
PY 2023
VL 8
IS 12
BP 895
EP 905
DI 10.1530/EOR 23 0138
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AF1B9
UT WOS:001116947900005
PM 38038377
OA gold
DA 2025 08 17
ER

PT J
AU Tripathi, AK
   Dabeer, S
   Song, J
   Vikulina, T
   Roser Page, S
   Alvarez, JA
   Archer, DR
   Weitzmann, MN
AF Tripathi, Ashish Kumar
   Dabeer, Sadaf
   Song, Jun
   Vikulina, Tatyana
   Roser Page, Susanne
   Alvarez, Jessica A.
   Archer, David. R.
   Weitzmann, M. Neale
TI Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and
   osteoclast differentiation exacerbating trabecular bone loss in sickle
   cell mice
SO CELL DEATH & DISEASE
LA English
DT Article
ID VITAMIN D DEFICIENCY; MINERAL DENSITY; T CELLS; YOUNG ADULTS; DISEASE;
   CHILDREN; PREVALENCE; BIOLOGY; TRAIT; PTH
AB Sickle cell disease (SCD) is a severe hematological disorder characterized by erythrocyte sickling that causes significant morbidity and mortality. Skeletal complications of SCD include a high incidence of bone loss, especially in vertebrae, leading to fragility fractures that contribute to disease burden. Whether hydroxyurea (HU), a front line therapy for SCD ameliorates bone disease has not been established. To investigate HU action on SCD related vertebral defects, we used HU treated "Townes" mice, an SCD animal model and performed high resolution micro computed tomography (mu CT) imaging to resolve bone volume and micro architectural structure of cortical and trabecular bone, the two major compartments contributing to bone mass and strength. Our data revealed that cortical bone was significantly diminished in the vertebrae of skeletally mature (representing adults) and immature (representing children) SCD mice, while only mature mice lost trabecular bone mass. Administration of HU ameliorated cortical bone loss in mature SCD mice, but paradoxically promoted trabecular bone decline in both groups. We further investigated the mechanisms of HU action in wild type C57BL6/J mice. HU caused dose dependent trabecular bone loss due to diminished osteoclast and osteoblast function, indicative of a low bone turnover state. Mechanistic investigations in vitro revealed that HU impeded osteoblast progenitor proliferation and early differentiation, and diminished osteoclastogenic cytokine production, blunting osteoclast formation as well as the activity of mature osteoclasts. HU further, suppressed mitochondrial, but not glycolytic energy metabolism in both differentiating osteoblasts and differentiated osteoclasts. Collectively, these findings reveal that despite ameliorating cortical bone loss, HU inhibits trabecular bone formation and resorption, by suppressing mitochondrial energy metabolism and blunting the differentiation and/or activity of osteoblasts and osteoclasts. Together HU drives a low bone turnover state culminating in trabecular bone loss. Further investigation into HU's impact on bone in SCD patients is warranted for understanding and managing skeletal complications in this population.
C1 [Tripathi, Ashish Kumar; Dabeer, Sadaf; Song, Jun; Vikulina, Tatyana; Roser Page, Susanne; Alvarez, Jessica A.; Weitzmann, M. Neale] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Sch Med, Atlanta, GA 30307 USA.
   [Dabeer, Sadaf; Vikulina, Tatyana; Roser Page, Susanne; Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
   [Song, Jun] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [Archer, David. R.] Emory Univ, Aflac Canc & Blood Disorder Ctr, Childrens Healthcare Atlanta, Atlanta, GA USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); China Academy of Chinese Medical Sciences;
   Guang'anmen Hospital, CACMS; Emory University; Children's Healthcare of
   Atlanta (CHOA)
RP Weitzmann, MN (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Sch Med, Atlanta, GA 30307 USA.; Weitzmann, MN (通讯作者)，Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
EM mweitzm@emory.edu
RI Dabeer, Sadaf/KEH 2494 2024; Archer, David/MBH 1706 2025; dabeer,
   sadaf/HHN 6085 2022; Tripathi, Ashish/JXY 6318 2024
OI Dabeer, Sadaf/0000 0002 0564 4185; Tripathi, Ashish
   Kumar/0000 0002 0976 8476; 
FU Emory University; Emory University [AR079298, AG062334, AR070091,
   AR068157, BX000105, BX005852]; NIH [RRID:SCR_023534]; Emory University
   Emory Integrated Cellular Imaging Core Facility [P30 AR46031]; National
   Institutes of Health
FX This study was supported in part by discretionary research funding from
   Emory University to MNW. MNW is also supported by NIH grants AR079298,
   AG062334, AR070091, and AR068157 and VA grants BX000105 and BX005852.
   This work was supported by the Emory University Emory Integrated
   Cellular Imaging Core Facility (RRID:SCR_023534). We gratefully
   acknowledge the histological services of the University of Alabama at
   Birmingham, Center for Metabolic Bone Disease Histomorphometry and
   Molecular Analysis Core Laboratory, supported by National Institutes of
   Health Grant P30 AR46031.
CR Adewoye AH, 2008, AM J HEMATOL, V83, P271, DOI 10.1002/ajh.21085
   Allard HM, 2019, J CLIN DENSITOM, V22, P329, DOI 10.1016/j.jocd.2018.07.001
   Almeida A, 2005, BRIT J HAEMATOL, V129, P482, DOI 10.1111/j.1365 2141.2005.05476.x
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387 2656(05)11004 7
   BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163
   Chapelon E, 2009, EUR J HAEMATOL, V83, P572, DOI 10.1111/j.1600 0609.2009.01333.x
   Dalle Carbonare L, 2015, BLOOD, V126, P2320, DOI 10.1182/blood 2015 04 641969
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Ellen BF, 2008, BONE, V43, P162, DOI 10.1016/j.bone.2008.03.003
   Estell E, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11123311
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Green M, 2015, J MECH BEHAV BIOMED, V48, P220, DOI 10.1016/j.jmbbm.2015.04.019
   Green NS, 2014, PEDIATR RES, V75, P196, DOI 10.1038/pr.2013.227
   Kapor S, 2021, J PERS MED, V11, DOI 10.3390/jpm11111048
   Kavanagh PL, 2022, JAMA J AM MED ASSOC, V328, P57, DOI 10.1001/jama.2022.10233
   Kooy A, 1996, NETH J MED, V48, P227, DOI 10.1016/0300 2977(95)00075 5
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lal A, 2006, PEDIATR BLOOD CANCER, V47, P901, DOI 10.1002/pbc.20681
   Lanzkron S, 2008, ANN INTERN MED, V148, P939, DOI 10.7326/0003 4819 148 12 200806170 00221
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lopes FCM, 2015, HAEMATOLOGICA, V100, P730, DOI 10.3324/haematol.2014.119727
   Maupin KA, 2019, NPJ MICROGRAVITY, V5, DOI 10.1038/s41526 019 0081 4
   Meeuwes M, 2013, TROP MED INT HEALTH, V18, P1539, DOI 10.1111/tmi.12211
   Miller RG, 2006, AM J HEMATOL, V81, P236, DOI 10.1002/ajh.20541
   Mokhtar GM, 2017, CLIN APPL THROMB HEM, V23, P64, DOI 10.1177/1076029615594001
   Monteiro LD, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100938
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Osunkwo I, 2011, BRIT J HAEMATOL, V153, P538, DOI 10.1111/j.1365 2141.2010.08458.x
   Rana K, 2018, BIOCHEM BIOPHYS REP, V16, P110, DOI 10.1016/j.bbrep.2018.10.009
   Roser Page S, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10636
   Roser Page S, 2014, ARTHRITIS RHEUMATOL, V66, P990, DOI 10.1002/art.38319
   Sadat Ali Mir, 2008, Indian J Med Sci, V62, P193
   Sarrai M, 2007, BRIT J HAEMATOL, V136, P666, DOI 10.1111/j.1365 2141.2006.06487.x
   Selma J, 2022, BLOOD ADV, V6, P1381, DOI 10.1182/bloodadvances.2021004615
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P813
   Weitzmann MN, 2019, BLOOD ADV, V3, P288, DOI 10.1182/bloodadvances.2018027557
   West GB, 2005, J EXP BIOL, V208, P1575, DOI 10.1242/jeb.01589
   Wu LC, 2006, BLOOD, V108, P1183, DOI 10.1182/blood 2006 02 004812
   Xiao LP, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 25244 9
   Xiao LP, 2016, ENDOCRINOLOGY, V157, P3036, DOI 10.1210/en.2015 2001
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 42
TC 1
Z9 1
U1 1
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC 18
PY 2024
VL 15
IS 12
AR 907
DI 10.1038/s41419 024 07296 z
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA P8B7H
UT WOS:001380101600007
PM 39695103
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Liang, ST
   Chen, JR
   Tsai, JJ
   Lai, YH
   Hsiao, CD
AF Liang, Sung Tzu
   Chen, Jung Ren
   Tsai, Jhih Jie
   Lai, Yu Heng
   Hsiao, Chung Der
TI Overexpression of Notch Signaling Induces Hyperosteogeny in Zebrafish
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone; hyperosteogeny; notch; transgenic zebrafish
ID AXIAL SKELETAL DEFECTS; HUMAN DISEASE; ALKALINE PHOSPHATASE; MODEL
   SYSTEM; BONE; DIFFERENTIATION; ACTIVATION; MINERALIZATION;
   OSTEOSCLEROSIS; OSTEOGENESIS
AB Notch signaling is one of the evolutionarily conserved signaling pathways in multicellular organisms. It plays an important role in embryonic development. During skeletal development of vertebrates, it regulates bone homeostasis by manipulating both osteoblastogenesis and osteoclastogenesis through different mechanisms. However, due to the different nature of Notch signaling in mesenchymal stem cell and osteoblast, regulation of Notch signaling in bone related diseases remains unsettled. Previous studies by cell culture and mouse models showed contradictory results regarding the role of Notch signaling in bone homeostasis. To clarify the role of Notch signaling in osteogenesis, we established a zebrafish model, in which Notch1a intracellular domain (N1aICD) was specifically expressed in the osteoblasts. We found that overexpression of N1aICD in osteoblasts caused hyperosteogeny in the column region of zebrafish with the morphology of narrowed neural/hemal canals. Moreover, increased metabolic activity of osteoblasts instead of augmenting osteoblast number led to hyperosteogeny in N1aICD overexpressed zebrafish. In summary, we successfully established a transgenic zebrafish line overexpressing N1aICD to clarify the in vivo function of Notch signaling during osteoblastogenesis. In the future, this fish line can serve as a valuable tool to test the therapeutic drugs for hyperosteogeny.
C1 [Liang, Sung Tzu; Tsai, Jhih Jie; Hsiao, Chung Der] Chung Yuan Christian Univ, Dept Biosci Technol, Chungli 32023, Taiwan.
   [Chen, Jung Ren] I Shou Univ, Coll Med, Dept Biol Sci & Technol, Kaohsiung 84001, Taiwan.
   [Lai, Yu Heng] Chinese Culture Univ, Dept Chem, Taipei 11114, Taiwan.
   [Hsiao, Chung Der] Chung Yuan Christian Univ, Ctr Biomed Technol, Chungli 32023, Taiwan.
   [Hsiao, Chung Der] Chung Yuan Christian Univ, Ctr Nanotechnol, Chungli 32023, Taiwan.
C3 Chung Yuan Christian University; I Shou University; Chinese Culture
   University; Chung Yuan Christian University; Chung Yuan Christian
   University
RP Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Dept Biosci Technol, Chungli 32023, Taiwan.; Lai, YH (通讯作者)，Chinese Culture Univ, Dept Chem, Taipei 11114, Taiwan.; Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Ctr Biomed Technol, Chungli 32023, Taiwan.; Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Ctr Nanotechnol, Chungli 32023, Taiwan.
EM lyh21@ulive.pccu.edu.tw; cdhsiao@cycu.edu.tw
RI Hsiao, Chung Der/W 4535 2019
OI Liang, Sung Tzu/0000 0002 4068 4430; Hsiao,
   Chung Der/0000 0002 6398 8672
FU Ministry of Science and Technology [102 2311 B033 001 MY3,
   105 2313 B 033 001 MY3]
FX This study was supported by grants from the Ministry of Science and
   Technology (102 2311 B033 001 MY3 and 105 2313 B 033 001 MY3) to C D
   Hsiao. We also appreciated Stefan Schulte Merker at University of
   Munster, Germany for providing medaka osterix gene promoter clone.
CR Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Audira G, 2018, INVENTIONS BASEL, V3, DOI 10.3390/inventions3010011
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Barut BA, 2000, PHYSIOL GENOMICS, V2, P49, DOI 10.1152/physiolgenomics.2000.2.2.49
   Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307
   Canalis E, 2016, AM J PHYSIOL ENDOC M, V310, pE171, DOI 10.1152/ajpendo.00395.2015
   Chen JR, 2017, MOLECULES, V22, DOI 10.3390/molecules22122068
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070 2153(10)92003 6
   de Vernejoul MC, 2008, BEST PRACT RES CL RH, V22, P71, DOI 10.1016/j.berh.2007.12.011
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959 437X(00)00074 5
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795
   Eiraku M, 2002, J BIOL CHEM, V277, P25400, DOI 10.1074/jbc.M110793200
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Groot AJ, 2012, ADV EXP MED BIOL, V727, P15, DOI 10.1007/978 1 4614 0899 4_2
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hoo JY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9732780
   Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092 8674(03)00810 9
   Ihde LL, 2011, RADIOGRAPHICS, V31, P1865, DOI 10.1148/rg.317115093
   Ji YT, 2017, AM J TRANSL RES, V9, P2933
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Kari G, 2007, CLIN PHARMACOL THER, V82, P70, DOI 10.1038/sj.clpt.6100223
   KELLY WL, 1983, STAIN TECHNOL, V58, P131, DOI 10.3109/10520298309066773
   Klingenberg CP, 2011, MOL ECOL RESOUR, V11, P353, DOI 10.1111/j.1755 0998.2010.02924.x
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091
   Lin CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045650
   Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040
   Lu ZZ, 2004, CHINESE SCI BULL, V49, P815, DOI 10.1360/03wc0617
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Pasqualetti S, 2012, CELL TISSUE RES, V350, P69, DOI 10.1007/s00441 012 1436 2
   Phillips JB, 2014, DIS MODEL MECH, V7, P739, DOI 10.1242/dmm.015545
   Potnuru P, 2020, CUREUS J MED SCIENCE, V12, DOI [10.1038/nature12111, 10.7759/cureus.11549]
   Santoriello C, 2012, J CLIN INVEST, V122, P2337, DOI 10.1172/JCI60434
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003 0463
   Shao J, 2018, J MOL MED, V96, P333, DOI 10.1007/s00109 018 1625 x
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Suzuki N, 2016, ZOOL SCI, V33, P407, DOI 10.2108/zs150211
   Takahashi H, 2008, ZOOL SCI, V25, P739, DOI 10.2108/zsj.25.739
   Tao JN, 2010, J BONE MINER RES, V25, P2175, DOI 10.1002/jbmr.115
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   WESTERFIELD M, 1995, ZEBRAFISH BOOK GUIDE
   Wiener R Constance, 2013, J Dent Hyg, V87, P370
   Yao WJ, 2015, BIOL OPEN, V4, P1727, DOI 10.1242/bio.012856
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang HW, 2014, J CLIN INVEST, V124, P3200, DOI 10.1172/JCI68901
   Zhu FC, 2012, J CELL PHYSIOL, V227, P2677, DOI 10.1002/jcp.23010
NR 61
TC 5
Z9 5
U1 2
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2019
VL 20
IS 15
AR 3613
DI 10.3390/ijms20153613
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IS8ET
UT WOS:000482383000006
PM 31344827
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, YF
   Lei, R
   Zhuang, XQ
   Zhang, N
   Pan, H
   Li, G
   Hu, J
   Pan, XQ
   Tao, Q
   Fu, D
   Xiao, JR
   Chin, YE
   Kang, YB
   Yang, QF
   Hu, GH
AF Wang, Yufeng
   Lei, Rong
   Zhuang, Xueqian
   Zhang, Ning
   Pan, Hong
   Li, Gang
   Hu, Jing
   Pan, Xiaoqi
   Tao, Qian
   Fu, Da
   Xiao, Jianru
   Chin, Y. Eugene
   Kang, Yibin
   Yang, Qifeng
   Hu, Guohong
TI DLC1 dependent parathyroid hormone like hormone inhibition suppresses
   breast cancer bone metastasis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID TGF BETA; RHO GTPASES; TUMOR SUPPRESSOR; PROTEIN; GROWTH; EXPRESSION;
   CELLS; GENES; PHOSPHORYLATION; KINASE
AB Bone metastasis is a frequent complication of breast cancer that is often accelerated by TGF beta signaling; however, little is known about how the TGF beta pathway is regulated during bone metastasis. Here we report that deleted in liver cancer 1 (DLC1) is an important regulator of TGF beta responses and osteolytic metastasis of breast cancer cells. In murine models, breast cancer cells lacking DLC1 expression exhibited enhanced capabilities of bone metastasis. Knockdown of DLC1 in cancer cells promoted bone metastasis, leading to manifested osteolysis and accelerated death in mice, while DLC1 overexpression suppressed bone metastasis. Activation of Rho ROCK signaling in the absence of DLC1 mediated SMAD3 linker region phosphorylation and TGF beta induced expression of parathyroid hormone like hormone (PTHLH), leading to osteoclast maturation for osteolytic colonization. Furthermore, pharmacological inhibition of Rho ROCK effectively reduced PTHLH production and breast cancer bone metastasis in vitro and in vivo. Evaluation of clinical breast tumor samples revealed that reduced DLC1 expression was linked to elevated PTHLH expression and organ specific metastasis to bone. Overall, our findings define a stroma dependent paradigm of Rho signaling in cancer and implicate Rho TGF beta crosstalk in osteolytic bone metastasis.
C1 [Wang, Yufeng; Lei, Rong; Zhuang, Xueqian; Pan, Hong; Li, Gang; Hu, Jing; Pan, Xiaoqi; Fu, Da; Chin, Y. Eugene; Hu, Guohong] Chinese Acad Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
   [Wang, Yufeng; Lei, Rong; Zhuang, Xueqian; Pan, Hong; Li, Gang; Hu, Jing; Pan, Xiaoqi; Fu, Da; Chin, Y. Eugene; Hu, Guohong] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
   [Zhang, Ning; Yang, Qifeng] Shandong Univ, Dept Breast Surg, Qilu Hosp, Jinan 250012, Peoples R China.
   [Tao, Qian] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China.
   [Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai, Peoples R China.
   [Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
C3 Chinese Academy of Sciences; Shanghai Jiao Tong University; Shandong
   University; State Key Lab Oncology South China; Chinese University of
   Hong Kong; Naval Medical University; Princeton University
RP Hu, GH (通讯作者)，Inst Hlth Sci, 225 South Chongqing Rd, Shanghai 200025, Peoples R China.
EM qifengy@gmail.com; ghhu@sibs.ac.cn
RI Tao, Qian/T 4743 2018; Wang, Yufeng/ABD 1199 2020; Zhang,
   Ning/GOJ 8058 2022; Hong, PAN/AAC 2326 2019; Li, Gang/J 7830 2018; 胡,
   国宏/HOH 6469 2023
OI Tao, Qian/0000 0001 5383 4808; Hu, Guohong/0000 0002 2980 5166; Zhang,
   Ning/0000 0002 6430 4236; Li, Gang/0000 0002 3981 2239; Li,
   Gang/0000 0001 9761 1323; Yang, Qifeng/0000 0003 0576 8513; Kang,
   Yibin/0000 0002 1626 6730
FU Chinese National 973 program [2011CB510105, 201303910904]; National
   Natural Science Foundation of China [81222032, 81071754, 31371409];
   Ministry of Science and Technology of China [2012ZX09506 001 005];
   Chinese Academy of Sciences [2009OHTP08]
FX We thank F. Liu for SMAD3 plasmids and phosphorylation antibodies; C.J.
   Dec for the R718E mutant DLC1 plasmid; L. Ma for the RhoA(63L) plasmid;
   A M. Frischauf for the GLI2 plasmid; C.J. Kirkpatrick for the ST1.6R
   cell line; and L. Fu, S. Yan, X. Miao, and P. Zhou at the Institute of
   Health Sciences core facilities for technical support. G. Hu was funded
   by Chinese National 973 program (2011CB510105, 201303910904) and by
   grants from National Natural Science Foundation of China (81222032,
   81071754, 31371409), the Ministry of Science and Technology of China
   (2012ZX09506 001 005), and Chinese Academy of Sciences (2009OHTP08).
CR Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683
   Bae E, 2012, BIOCHEM BIOPH RES CO, V427, P593, DOI 10.1016/j.bbrc.2012.09.103
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Buijs JT, 2011, CANCER MICROENVIRON, V4, P261, DOI 10.1007/s12307 011 0075 6
   Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200
   Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008 5472.CAN 09 1528
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27
   Gallwitz WE, 2002, J CLIN INVEST, V110, P1559, DOI 10.1172/JCI200211936
   Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008 5472.CAN 04 3043
   Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 1997, CANCER AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1572::AID CNCR7>3.3.CO;2 D
   Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389
   Henderson MA, 2006, CANCER RES, V66, P2250, DOI 10.1158/0008 5472.CAN 05 2814
   Henderson MA, 2001, JNCI J NATL CANCER I, V93, P234, DOI 10.1093/jnci/93.3.234
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720 11734.2001
   Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaplan RN, 2006, CANCER METAST REV, V25, P521, DOI 10.1007/s10555 006 9036 9
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65
   Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108
   Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008
   Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008 5472.CAN 09 1541
   Mak IWY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019975
   Mardilovich K, 2012, FUTURE ONCOL, V8, P165, DOI [10.2217/fon.11.143, 10.2217/FON.11.143]
   Martin TJ, 2002, J CLIN INVEST, V110, P1399, DOI 10.1172/JCI200217124
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Micuda S, 2010, CURR CANCER DRUG TAR, V10, P127, DOI 10.2174/156800910791054202
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   NISSENSON RA, 1988, J BIOL CHEM, V263, P12866
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896
   Roodman GD, 2012, CANCER METAST REV, V31, P569, DOI 10.1007/s10555 012 9372 x
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Ruppender NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015451
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Sherafat Kazemzadeh R, 2011, J CLIN ENDOCR METAB, V96, P509, DOI 10.1210/jc.2010 1790
   Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944
   Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008 5472.CAN 06 0452
   Tang Y, 2008, FRONT BIOSCI LANDMRK, V13, P759, DOI 10.2741/2718
   Thota CS, 2005, BIOL REPROD, V73, P1191, DOI 10.1095/biolreprod.105.044628
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vasiliev JM, 2004, P NATL ACAD SCI USA, V101, P12526, DOI 10.1073/pnas.0404723101
   Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471 2199 11 2
   Wong MH, 2011, BREAST CANCER TARGET, V3, P35, DOI 10.2147/BCTT.S6655
   Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535 7163.MCT 05 0440
   Zhong D, 2009, J CELL SCI, V122, P414, DOI 10.1242/jcs.027482
   Zhou X, 2008, INT J ONCOL, V32, P1285
NR 65
TC 64
Z9 77
U1 0
U2 42
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2014
VL 124
IS 4
BP 1646
EP 1659
DI 10.1172/JCI71812
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AE1IQ
UT WOS:000333723400026
PM 24590291
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chen, TH
   Weber, FE
   Malina Altzinger, J
   Ghayor, C
AF Chen, Tse Hsiang
   Weber, Franz E.
   Malina Altzinger, Johann
   Ghayor, Chafik
TI Epigenetic drugs as new therapy for tumor necrosis factor α compromised
   bone healing
SO BONE
LA English
DT Article
DE Bone regeneration; TNF alpha; Inflammation; NMP; DMA; Bromodomain
   inhibitors
ID ACTIVATED PROTEIN KINASE; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; TNF ALPHA; KAPPA B; OSTEOGENIC DIFFERENTIATION; RUNX2;
   PROLIFERATION; DEGRADATION; INHIBITION
AB Impaired bone regeneration by excess inflammation leads to failure of bone healing. Current therapies display limited benefits making new treatments imperative. Our recent discoveries of the anti inflammatory characteristics of bromodomain and extra terminal domain (BET) inhibitors, N methylpyrrolidone (NMP) and N,N Dimethylacetamide (DMA), implicate possible therapeutic use of epigenetic drugs in inflammation impaired bone healing.
   Here, we investigated the effects of NMP and DMA on osteogenesis in vitro and ex vivo under the influence of TNF alpha, a key cytokine responsible for impaired fracture healing. NMP and DMA pre treatment recovered TNF alpha inhibited expression of essential osteoblastic genes, Alp, Runx2, and Osterix as well as mineralization in multipotent stem cells, but not in pre osteoblasts and calvarial osteoblasts. The mechanism of action involves the recovery of TNF alpha suppressed BMP induced Smad signaling and the reduction of TNF alpha triggered ERK pathway. In addition, ERK inhibitor treatment diminished the effect of TNF alpha on osteogenesis, which reinforces the role of ERK pathway in the adverse effect of TNF alpha. Furthermore, endochondral ossification was analyzed in an ex vivo bone culture model. TNF alpha largely abrogated BMP promoted growth of mineralized bone while pre treatment of NMP and DMA prevented the deleterious effect of TNF alpha. Taken together, these data shed light on developing low  affinity epigenetic drugs as new therapies for inflammation compromised bone healing.
C1 [Chen, Tse Hsiang; Weber, Franz E.; Ghayor, Chafik] Univ Zurich, Ctr Dent Med Oral Biotechnol & Bioengn, Plattenstr 11, CH 8032 Zurich, Switzerland.
   [Chen, Tse Hsiang; Weber, Franz E.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Weber, Franz E.] Univ Zurich, Ctr Appl Biotechnol & Mol Med, CABMM, Zurich, Switzerland.
   [Malina Altzinger, Johann] Limmat Cleft & Craniofacial Ctr, Zurich MKG, Hardturmstr 133, CH 8005 Zurich, Switzerland.
C3 University of Zurich; University of Zurich; Zurich Center Integrative
   Human Physiology (ZIHP); University of Zurich
RP Ghayor, C (通讯作者)，Univ Zurich, Zentrum Zahnmed MKG, Oral Biotechnol & Bioengn, Plattenstr 11, CH 8032 Zurich, Switzerland.
EM Chafik.Ghayor@usz.ch
RI ; Weber, Franz/I 7831 2019
OI Weber, Franz/0000 0003 1670 2296; Ghayor, Chafik/0000 0002 3016 3412;
   Malina Altzinger, Johann/0000 0003 4226 586X
FU Swiss National Science Foundation [CR3213_152809, 31003A_140868]; Swiss
   National Science Foundation (SNF) [31003A_140868] Funding Source: Swiss
   National Science Foundation (SNF)
FX We thank Ana Perez, Alexander Tchouboukov, and Flora Nichols for
   excellent technical assistance. This research work was supported by
   grants from the Swiss National Science Foundation to FEW (CR3213_152809
   and 31003A_140868).
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Bigham Sadegh A, 2015, INT WOUND J, V12, P238, DOI 10.1111/iwj.12231
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Ding J, 2009, LIFE SCI, V84, P499, DOI 10.1016/j.lfs.2009.01.013
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ghayor C, 2017, SCI REP UK, V7, DOI 10.1038/srep42108
   Ghayor C, 2015, INFLAMM RES, V64, P527, DOI 10.1007/s00011 015 0833 x
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gjoksi B, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148 016 0209 2
   Gjoksi B, 2015, BONE, V78, P114, DOI 10.1016/j.bone.2015.05.004
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365 08
   Huang RL, 2014, OSTEOARTHR CARTILAGE, V22, P1186, DOI 10.1016/j.joca.2014.06.017
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   ICRUM SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI DOI 10.1038/NRRHEUM.2010.133
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kawai VK, 2012, CURR OPIN RHEUMATOL, V24, P576, DOI 10.1097/BOR.0b013e328356d212
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   MARINO S, 2016, REP, V818, P5, DOI DOI 10.1038/B0NEKEY.2016.49
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Miguel BS, 2009, TISSUE ENG PT A, V15, P2955, DOI [10.1089/ten.tea.2009.0009, 10.1089/ten.TEA.2009.0009]
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sullivan CB, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt492
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Wang N, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150258
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zuo CJ, 2018, ONCOTARGET, V9, P4833, DOI 10.18632/oncotarget.23373
NR 54
TC 11
Z9 11
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2019
VL 127
BP 49
EP 58
DI 10.1016/j.bone.2019.05.035
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IU2ZR
UT WOS:000483449000007
PM 31152802
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Volpini, X
   Ambrosio, LF
   Fozzatti, L
   Insfran, C
   Stempin, CC
   Cervi, L
   Motran, CC
AF Volpini, Ximena
   Ambrosio, Laura F.
   Fozzatti, Laura
   Insfran, Constanza
   Stempin, Cinthia C.
   Cervi, Laura
   Motran, Claudia Cristina
TI Trypanosoma cruzi Exploits Wnt Signaling Pathway to Promote Its
   Intracellular Replication in Macrophages
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Trypanosoma cruzi infection; Wnt proteins; beta catenin; macrophages;
   cytokines; indoleamine 2,3 dioxygenase
ID INTERFERON GAMMA; BETA CATENIN; ALTERNATIVE ACTIVATION; CHAGAS DISEASE;
   T CELLS; EXPRESSION; RESPONSES; RESISTANCE; INFECTION; ALPHA
AB During the acute phase of Trypanosoma cruzi infection, macrophages can act as host cells for the parasites as well as effector cells in the early anti parasitic immune response. Thus, the targeting of specific signaling pathways could modulate macrophages response to restrict parasite replication and instruct an appropriate adaptive response. Recently, it has become evident that Wnt signaling has immunomodulatory functions during inflammation and infection. Here, we tested the hypothesis that during T. cruzi infection, the activation of Wnt signaling pathway in macrophages plays a role in modulating the inflammatory/tolerogenic response and therefore regulating the control of parasite replication. In this report, we show that early after T. cruzi infection of bone marrow derived macrophages (BMM), beta catenin was activated and Wnt3a, Wnt5a, and some Frizzled receptors as well as Wnt/beta catenin pathway's target genes were upregulated, with Wnt proteins signaling sustaining the activation of Wnt/beta catenin pathway and then activating the Wnt/Ca+2 pathway. Wnt signaling pathway activation was critical to sustain the parasite's replication in BMM; since the treatments with specific inhibitors of beta catenin transcriptional activation or Wnt proteins secretion limited the parasite replication. Mechanistically, inhibition of Wnt signaling pathway armed BMM to fight against T. cruzi by inducing the production of pro inflammatory cytokines and indoleamine 2,3 dioxygenase activity and by downregulating arginase activity. Likewise, in vivo pharmacological inhibition of the Wnts' interaction with its receptors controlled the parasite replication and improved the survival of lethally infected mice. It is well established that T. cruzi infection activates a plethora of signaling pathways that ultimately regulate immune mediators to determine the modulation of a defined set of effector functions in macrophages. In this study, we have revealed a new signaling pathway that is activated by the interaction between protozoan parasites and host innate immunity, establishing a new conceptual framework for the development of new therapies.
C1 [Volpini, Ximena; Ambrosio, Laura F.; Fozzatti, Laura; Insfran, Constanza; Stempin, Cinthia C.; Cervi, Laura; Motran, Claudia Cristina] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina.
   [Volpini, Ximena; Ambrosio, Laura F.; Fozzatti, Laura; Insfran, Constanza; Stempin, Cinthia C.; Cervi, Laura; Motran, Claudia Cristina] Consejo Nacl Invest Cient & Tecn, Ctr Invest Bioquim Clin & Inmunol CIBIC, Ciudad Univ, Cordoba, Argentina.
C3 National University of Cordoba; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Motran, CC (通讯作者)，Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina.; Motran, CC (通讯作者)，Consejo Nacl Invest Cient & Tecn, Ctr Invest Bioquim Clin & Inmunol CIBIC, Ciudad Univ, Cordoba, Argentina.
EM cmotran@fcq.unc.edu.ar
RI ; Motran, Claudia/U 9106 2019
OI Motran, Claudia Cristina/0000 0002 8088 3901; 
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas from
   Argentina (CONICET); Agencia Nacional de Promocion Cientifica y Tecnica
   [PICT 2016 0415, PICT 2015 2488]; Secretaria de Ciencia y Tecnica,
   Universidad Nacional de Cordoba
FX This work was supported by grants from Consejo Nacional de
   Investigaciones Cientificas y Tecnicas from Argentina (CONICET), Agencia
   Nacional de Promocion Cientifica y Tecnica (PICT 2016 0415, PICT
   2015 2488), and Secretaria de Ciencia y Tecnica, Universidad Nacional de
   Cordoba (grants to CM). The funding bodies had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Bansal K, 2011, J BIOL CHEM, V286, P37032, DOI 10.1074/jbc.M111.260414
   Bergenfelz C, 2012, J IMMUNOL, V188, P5448, DOI 10.4049/jimmunol.1103378
   Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood 2005 12 5046
   Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025 10
   BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   de Araújo FF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000992
   Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354 05
   Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648
   Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174
   Fiuza JA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000512
   GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960 7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185 1193.2003
   HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077
   Holtzhausen A, 2015, CANCER IMMUNOL RES, V3, P1082, DOI 10.1158/2326 6066.CIR 14 0167
   Hong Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115941
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015
   Katoh M, 2007, INT J MOL MED, V19, P273
   Kayama H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000514
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Knubel CP, 2017, ACS MED CHEM LETT, V8, P757, DOI 10.1021/acsmedchemlett.7b00169
   Knubel CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026550
   Le Loup G, 2011, CURR OPIN INFECT DIS, V24, P428, DOI 10.1097/QCO.0b013e32834a667f
   Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510
   Manoharan I, 2014, J IMMUNOL, V193, P4203, DOI 10.4049/jimmunol.1400614
   Martin D, 2004, IMMUNOL REV, V201, P304, DOI 10.1111/j.0105 2896.2004.00183.x
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Motrán CC, 2003, EUR J IMMUNOL, V33, P3007, DOI 10.1002/eji.200323993
   Motrán CC, 2002, J LEUKOCYTE BIOL, V72, P512
   Munder M, 1998, J IMMUNOL, V160, P5347
   Munn DH, 2004, TRENDS MOL MED, V10, P15, DOI 10.1016/j.molmed.2003.11.003
   Neumann J, 2010, FASEB J, V24, P4599, DOI 10.1096/fj.10 160994
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Oderup C, 2013, J IMMUNOL, V190, P6126, DOI 10.4049/jimmunol.1203002
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Oliveira AC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000870
   Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366
   Knubel CP, 2010, FASEB J, V24, P2689, DOI 10.1096/fj.09 150920
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Pukrop T, 2008, J MOL MED, V86, P259, DOI 10.1007/s00109 007 0266 2
   Reuter S, 2014, J IMMUNOL, V193, P485, DOI 10.4049/jimmunol.1400013
   Robinson CM, 2005, J INTERF CYTOK RES, V25, P20, DOI 10.1089/jir.2005.25.20
   Salvatella R, 2013, LANCET, V382, P395, DOI 10.1016/S0140 6736(13)61671 2
   Schaale K, 2011, EUR J CELL BIOL, V90, P553, DOI 10.1016/j.ejcb.2010.11.004
   Sen M, 2008, J IMMUNOL, V181, P4441, DOI 10.4049/jimmunol.181.7.4441
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862 4867.1995
   SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169
   Silva García O, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/310183
   Soichot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025470
   Sosa Estani S, 2006, CURR OPIN INFECT DIS, V19, P583, DOI 10.1097/01.qco.0000247592.21295.a5
   Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360
   Stempin C, 2002, J LEUKOCYTE BIOL, V72, P727
   TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400 419.1992
   Thaker AI, 2013, GASTROENTEROLOGY, V145, P416, DOI 10.1053/j.gastro.2013.05.002
   THOMAS SR, 1994, J BIOL CHEM, V269, P14457
   Valencia J, 2011, J IMMUNOL, V187, P4129, DOI 10.4049/jimmunol.1101243
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   von Bergwelt Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood 2005 08 3507
   Yoshida N, 2006, AN ACAD BRAS CIENC, V78, P87, DOI 10.1590/S0001 37652006000100010
NR 63
TC 16
Z9 17
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 25
PY 2018
VL 9
AR 859
DI 10.3389/fimmu.2018.00859
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA GD9SS
UT WOS:000430853500002
PM 29743880
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, JY
   Cheon, YH
   Kwak, SC
   Baek, JM
   Yoon, KH
   Lee, MS
   Oh, J
AF Kim, Ju Young
   Cheon, Yoon Hee
   Kwak, Sung Chul
   Baek, Jong Min
   Yoon, Kwon Ha
   Lee, Myeung Su
   Oh, Jaemin
TI Emodin Regulates Bone Remodeling by Inhibiting Osteoclastogenesis and
   Stimulating Osteoblast Formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE REMODELING; EMODIN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS
ID NF KAPPA B; RETRACTED ARTICLE. SEE; P2X(7) RECEPTOR; P2X7 RECEPTORS;
   TRANSCRIPTION FACTORS; LIGAND RANKL; IN VITRO; DIFFERENTIATION;
   ACTIVATION; EXPRESSION
AB Bone remodeling, a physiological process in which new bone is formed by osteoblasts and the preexisting bone matrix is resorbed by osteoclasts, is vital for the maintenance of healthy bone tissue in adult humans. Imbalances in this process can cause various pathological conditions, including osteoporosis. Emodin, a naturally occurring anthraquinone derivative found in Asian herbal medicines, has numerous beneficial pharmacologic effects, including anticancer and antidiabetic activities. However, the effect of emodin on the regulation of osteoblast and osteoclast activity has not yet been investigated. We show here that emodin is a potential target for osteoporosis therapeutics, as treatment with this agent enhances osteoblast differentiation and bone growth and suppresses osteoclast differentiation and bone resorption. In this study, emodin suppressed receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclast differentiation of bone marrow macrophages (BMMs) and the bone resorbing activity of mature osteoclasts by inhibiting RANKL induced NF kappa B, c Fos, and NFATc1 expression. Emodin also increased ALP, Alizarin Red mineralization activity, and the expression of osteoblastogenic genemarkers, such as Runx2, osteocalcin (OCN), and ALP in mouse calvarial primary osteoblasts, as well as activated the p38 Runx2 pathway, which enhanced osteoblast differentiation. Moreover, mice treated with emodin showed marked attenuation of lipopolysaccharide (LPS) induced bone erosion and increased bone forming activity in a mouse calvarial bone formation model based on micro computed tomography and histologic analysis of femurs. Our findings reveal a novel function for emodin in bone remodeling, and highlight its potential for use as a therapeutic agent in the treatment of osteoporosis that promotes bone anabolic activity and inhibits osteoclast differentiation. (C) 2014 American Society for Bone and Mineral Research.
C1 [Kim, Ju Young; Yoon, Kwon Ha; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Program BK21Plus, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Grad Sch, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Ministry of Health & Welfare, Republic of Korea [HI12C0110]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0110).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200
   Bulanova E, 2005, J IMMUNOL, V174, P3880, DOI 10.4049/jimmunol.174.7.3880
   Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Gartland A, 2012, FRONT BIOSCI LANDMRK, V17, P16, DOI 10.2741/3912
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   HUANG HC, 1991, EUR J PHARMACOL, V205, P289
   Hwang JK, 2013, RHEUMATOLOGY, V52, P1583, DOI 10.1093/rheumatology/ket178
   Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kuo YC, 2001, INFLAMM RES, V50, P73, DOI 10.1007/s000110050727
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Lietman SA, 2008, BIOCHEM BIOPH RES CO, V371, P644, DOI 10.1016/j.bbrc.2008.04.080
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Otero JE, 2010, J BONE MINER RES, V25, P1282, DOI 10.1002/jbmr.4
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reyes Juan P, 2011, Front Biosci (Schol Ed), V3, P1101
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Srinivas G, 2007, MED RES REV, V27, P591, DOI 10.1002/med.20095
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Vellaichamy E, 2005, J BIOL CHEM, V280, P19230, DOI 10.1074/jbc.M411373200
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Wilson HL, 2004, J IMMUNOL, V173, P1202, DOI 10.4049/jimmunol.173.2.1202
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Zheng H, 2004, CALCIFIED TISSUE INT, V74, P194, DOI 10.1007/s00223 003 0004 x
NR 54
TC 71
Z9 73
U1 1
U2 29
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2014
VL 29
IS 7
BP 1541
EP 1553
DI 10.1002/jbmr.2183
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AN0AO
UT WOS:000340243600005
PM 25832436
OA Bronze
DA 2025 08 17
ER

PT J
AU Hu, KM
   Gu, YJ
   Lou, LX
   Liu, LZ
   Hu, YX
   Wang, BS
   Luo, Y
   Shi, JM
   Yu, XH
   Huang, H
AF Hu, Kaimin
   Gu, Yanjun
   Lou, Lixia
   Liu, Lizhen
   Hu, Yongxian
   Wang, Binsheng
   Luo, Yi
   Shi, Jimin
   Yu, Xiaohong
   Huang, He
TI Galectin 3 mediates bone marrow microenvironment induced drug resistance
   in acute leukemia cells via Wnt/β catenin signaling pathway
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Galectin 3; Acute leukemia; Bone marrow mesenchymal stromal cell
   (BM MSC); beta catenin; Drug resistance
ID REGULATES NORMAL HEMATOPOIESIS; MINIMAL RESIDUAL DISEASE; BETA CATENIN;
   STEM CELLS; TARGET; WNT; APOPTOSIS; IDENTIFICATION; EXPRESSION;
   DEREGULATION
AB Background: Acute leukemia is currently the major cause of death in hematological malignancies. Despite the rapid development of new therapies, minimal residual disease (MRD) continues to occur and leads to poor outcomes. The leukemia niche in the bone marrow microenvironment (BMM) is thought to be responsible for such MRD development, which can lead to leukemia drug resistance and disease relapse. Consequently further investigation into the way in which the leukemia niche interacts with acute leukemia cells (ALCs) and development of strategies to block the underlying process are expected to improve disease prognosis. Recent studies indicated that galectin 3 (gal 3) might play a pivotal role in this process. Thus we aimed to elucidate the exact role played by gal 3 in this process and clarify its mechanism of action.
   Methods: We used human bone marrow derived mesenchymal stromal cells (hBM MSCs) to mimic the leukemia BMM in vitro, and investigated their effects on drug resistance of ALCs and the possible mechanisms involved, with particular emphasis on the role of gal 3.
   Results: In our study, we demonstrated that hBM MSCs induced gal 3 up regulation, promoting beta catenin stabilization and thus activating the Wnt/beta catenin signaling pathway in ALCs, which is critical in cytotoxic drug resistance of leukemia. This effect could be reversed by addition of gal 3 short hairpin RNA (shRNA). We also found that up regulation of gal 3 promoted Akt and glycogen synthase kinase (GSK) 3 beta phosphorylation, thought to constitute a cross bridge between gal 3 and Wnt signaling.
   Conclusions: Our results suggest that gal 3, a key factor mediating BMM induced drug resistance, could be a novel therapeutic target in acute leukemia.
C1 [Hu, Kaimin; Gu, Yanjun; Lou, Lixia; Liu, Lizhen; Hu, Yongxian; Wang, Binsheng; Luo, Yi; Shi, Jimin; Yu, Xiaohong; Huang, He] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Hu, Kaimin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou 310003, Zhejiang, Peoples R China.
   [Gu, Yanjun] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Huang, H (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
EM hehuang.zju@gmail.com
RI Wang, Hailong/C 2641 2011; Lou, Lixia/HRB 8837 2023
FU National Natural Science Foundation of China [81230014, 81170526,
   81270640, 81370644]; Research Fund for the Doctoral Program of Higher
   Education of China (RFDP) [20130101120022]
FX This work was supported by grant from the National Natural Science
   Foundation of China (81230014, 81170526, 81270640 and 81370644) and
   Research Fund for the Doctoral Program of Higher Education of China
   (RFDP 20130101120022).
CR Araki Y, 2003, CANCER RES, V63, P728
   ASOU H, 1991, BLOOD, V77, P2031
   Azizidoost S, 2014, HEMATOLOGY, V19, P232, DOI 10.1179/1607845413Y.0000000111
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood 2005 08 3182
   Chauhan D, 2005, CANCER RES, V65, P8350, DOI 10.1158/0008 5472.CAN 05 0163
   Cheng CL, 2013, LEUKEMIA LYMPHOMA, V54, P3
   Clark MC, 2012, BLOOD, V120, P4635, DOI 10.1182/blood 2012 06 438234
   CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516
   Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627
   Dumic J, 2006, BBA GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020
   Estey EH, 2013, AM J HEMATOL, V88, P317, DOI 10.1002/ajh.23404
   Fei F, 2013, LEUKEMIA, V27, P2385, DOI 10.1038/leu.2013.175
   GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709
   Gutierrez SE, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 57
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Kamdje AHN, 2011, BLOOD, V118, P380, DOI 10.1182/blood 2010 12 326694
   Kern W, 2003, HAEMATOLOGICA, V88, P646
   Kobayashi T, 2011, INT J CANCER, V129, P2775, DOI 10.1002/ijc.25946
   Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476
   Ladetto M, 2014, LEUKEMIA, V28, P1299, DOI 10.1038/leu.2013.375
   Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820
   Liu GY, 2013, CYTOTHERAPY, V15, P1208, DOI 10.1016/j.jcyt.2013.05.011
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062844
   Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387
   Malfuson JV, 2014, LEUKEMIA, V28, P853, DOI 10.1038/leu.2013.256
   Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600 0609.2008.01188.x
   Morgan RG, 2014, J CELL BIOCHEM, V115, P1351, DOI 10.1002/jcb.24803
   Nagafuji K, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 14
   Newlaczyl AU, 2011, CANCER LETT, V313, P123, DOI 10.1016/j.canlet.2011.09.003
   O'Brien Susan, 2011, Clin Adv Hematol Oncol, V9, P22
   Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603
   Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031
   ROSENFELD C, 1977, EUR J CANCER, V13, P377, DOI 10.1016/0014 2964(77)90085 8
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374
   Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008 5472.CAN 08 4153
   Staal F, 2012, EXP HEMATOL, V40, pS41
   Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood 2009 10 251660
   Sun Z, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756 8722 7 14
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Xueling GE, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756 8722 3 33
   Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200
   Yamamoto Sugitani M, 2011, P NATL ACAD SCI USA, V108, P17468, DOI 10.1073/pnas.1111138108
   Yang Y, 2013, CANCER LETT, V333, P9, DOI 10.1016/j.canlet.2012.11.056
   Zhao YM, 2008, BIOCHEM BIOPH RES CO, V369, P1114, DOI 10.1016/j.bbrc.2008.03.011
   Zhao YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 40
NR 48
TC 54
Z9 64
U1 2
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756 8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD JAN 27
PY 2015
VL 8
AR 1
DI 10.1186/s13045 014 0099 8
PG 10
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA CC0BZ
UT WOS:000350001300001
PM 25622682
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Zara, S
   De Colli, M
   di Giacomo, V
   Zizzari, VL
   Di Nisio, C
   Di Tore, U
   Salini, V
   Gallorini, M
   Tetè, S
   Cataldi, A
AF Zara, Susi
   De Colli, Marianna
   di Giacomo, Viviana
   Zizzari, Vincenzo Luca
   Di Nisio, Chiara
   Di Tore, Umberto
   Salini, Vincenzo
   Gallorini, Marialucia
   Tete, Stefano
   Cataldi, Amelia
TI Zoledronic acid at subtoxic dose extends osteoblastic stage span of
   primary human osteoblasts
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Zoledronic acid; Osteonecrosis of the jaw; Human osteoblasts; Apoptosis;
   Differentiation; PGE(2); Collagen type I
ID GENE EXPRESSION; OSTEOGENIC DIFFERENTIATION; BISPHOSPHONATES;
   PROLIFERATION; CELLS; ALENDRONATE; APOPTOSIS; MINERALIZATION; TISSUE;
   OSTEONECROSIS
AB This study aimed to check the effect of zoledronic acid (ZA) at subtoxic dose on human osteoblasts (HOs) in terms of cell viability, apoptosis occurrence, and differentiation induction. ZA belongs to the family of bisphosphonates (BPs), largely used in the clinical practice for the treatment of bone diseases, often associated with jaw osteonecrosis onset. Their pharmacological action consists in the direct block of the osteoclast mediated bone resorption along with indirect action on osteoblasts.
   HOs were treated choosing the highest limit concentration (10( 5) M) which does not induce toxic effects. Live/dead staining, flow cytometry, mitochondrial membrane potential assay, osteocalcin western blotting, gp38 RT PCR, collagen type I, PGE2, and IL 6 ELISA assays were performed.
   Similar viability level between control and ZA treated samples is found along with no significant increase of apoptotic and necrotic cells in ZA treated sample. To establish if an early apoptotic pathway was triggered, Bax expression and mitochondrial membrane potential were evaluated finding a higher protein expression in control sample and a good integrity of mitochondrial membrane in both experimental points. Type I collagen secretion and alkaline phosphatase (ALP) activity appear increased in ZA treated sample, osteocalcin expression level is reduced in ZA treated cells, whereas no modifications of gp38 mRNA level are evidenced. No statistical differences are identified in PGE2 secretion level whereas IL 6 secretion is lower in ZA treated HOs with respect to control ones.
   These results highlight that ZA, delaying the osteoblastic differentiation process versus the osteocytic lineage, strengthens its pharmacological activity enhancing bone density.
   The knowledge of ZA effects on osteoblasts at subtoxic dose allows to improve therapeutic protocols in order to strengthen drug pharmacological activity through a combined action on both osteoclastic and osteoblastic cells.
C1 [Zara, Susi; De Colli, Marianna; di Giacomo, Viviana; Zizzari, Vincenzo Luca; Di Nisio, Chiara; Gallorini, Marialucia; Cataldi, Amelia] Univ G dAnnunzio, Dept Pharm, Sect Human Anat, I 66100 Chieti, Italy.
   [Di Tore, Umberto; Tete, Stefano] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, I 66100 Chieti, Italy.
   [Salini, Vincenzo] Univ G dAnnunzio, Dept Med & Sci Aging, I 66100 Chieti, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; G d'Annunzio University of Chieti Pescara
RP Zara, S (通讯作者)，Univ G dAnnunzio, Dept Pharm, Sect Human Anat, Via Vestini 31, I 66100 Chieti, Italy.
EM s.zara@unich.it
RI Salini, Vincenzo/ABB 5842 2021
OI CATALDI, Amelia/0000 0002 4989 6210; Salini,
   Vincenzo/0000 0002 8166 3062; DI GIACOMO, Viviana/0000 0003 3332 993X;
   Gallorini, Marialucia/0000 0002 2283 4159; Zara,
   Susi/0000 0003 1705 6943
FU MIUR FIRB Accordi di Programma
FX The authors would like to thank Dott.ssa Piera Sozio for drug purity
   determinations, Dott.ssa Alessandra di Paolo for the kind gift of
   Zometa, and MIUR FIRB Accordi di Programma 2010 Project "Processi
   degenerativi dei tessuti mineralizzati del cavo orale, impiego di
   biomateriali e controllo delle interazioni con i microrganismi
   dell'ambiente" for the fellowships attributed to Dr. V.L Zizzari and Dr.
   M. De Colli.
CR Abe Y, 2000, J LAB CLIN MED, V136, P344, DOI 10.1067/mlc.2000.109757
   Aubin JE, 1996, MICROSC RES TECHNIQ, V33, P128, DOI 10.1002/(SICI)1097 0029(19960201)33:2<128::AID JEMT4>3.0.CO;2 P
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440 1681.2004.03975.x
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Er E, 2006, BBA BIOENERGETICS, V1757, P1301, DOI 10.1016/j.bbabio.2006.05.032
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622 200211000 00004
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Lee YJ, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.16
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lynch MP, 1998, J CELL BIOCHEM, V68, P31
   Marchisio M, 2005, J BIOMED MATER RES B, V75B, P251, DOI 10.1002/jbm.b.30287
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rizos EC, 2006, CLIN EXP RHEUMATOL, V24, P455
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Santini D, 2006, ONCOL REP, V15, P1351
   Schmidt C, 2003, BIOMATERIALS, V24, P4191, DOI 10.1016/S0142 9612(03)00317 X
   Simon MJK, 2010, CLIN ORAL INVEST, V14, P51, DOI 10.1007/s00784 009 0312 2
   SINHA RK, 1994, CLIN ORTHOP RELAT R, P258
   TSUCHIMOTO M, 1994, JPN J PHARMACOL, V66, P25, DOI 10.1254/jjp.66.25
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
   Zhang W, 2007, CALCIFIED TISSUE INT, V80, P111, DOI 10.1007/s00223 006 0168 2
NR 44
TC 17
Z9 22
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD APR
PY 2015
VL 19
IS 3
BP 601
EP 611
DI 10.1007/s00784 014 1280 8
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CE3AU
UT WOS:000351697200004
PM 25055744
DA 2025 08 17
ER

PT J
AU Rangaswami, H
   Schwappacher, R
   Tran, T
   Chan, GC
   Zhuang, SH
   Boss, GR
   Pilz, RB
AF Rangaswami, Hema
   Schwappacher, Raphaela
   Tran, Trish
   Chan, Geraldine C.
   Zhuang, Shunhui
   Boss, Gerry R.
   Pilz, Renate B.
TI Protein Kinase G and Focal Adhesion Kinase Converge on Src/Akt/β Catenin
   Signaling Module in Osteoblast Mechanotransduction
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; SHEAR STRESS; FLUID SHEAR; BETA CATENIN;
   DIFFERENTIATED OSTEOBLASTS; ESTROGEN RECEPTOR; EARLY RESPONSES;
   CYCLIC GMP; BONE CELLS; SRC KINASE
AB Mechanical loading of bone induces interstitial fluid flow, leading to fluid shear stress (FSS) of osteoblasts. FSS rapidly increases the intracellular calcium concentration ([Ca2+]) and nitric oxide (NO) synthesis in osteoblasts and activates the protein kinase Akt. Activated Akt stimulates osteoblast proliferation and survival, but the mechanism(s) leading to Akt activation is not well defined. Using pharmacological and genetic approaches in primary human and mouse osteoblasts and mouse MC3T3 osteoblast like cells, we found that Akt activation by FSS occurred through two parallel pathways; one required calcium stimulation of NO synthase and NO/cGMP/protein kinase G II dependent activation of Src, and the other required calcium activation of FAK and Src, independent of NO. Both pathways cooperated to increase PI3K dependent Akt phosphorylation and were necessary for FSS to induce nuclear translocation of beta catenin, c fos, and cox 2 gene expression and osteoblast proliferation. These data explain how mechanical stimulation of osteoblasts leads to increased signaling through a growth regulatory pathway essential for maintaining skeletal integrity.
C1 [Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Pilz, Renate B.] Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
OI Boss, Gerry/0000 0002 9758 8714
FU National Institutes of Health [R01 AR051300]; Deutsche
   Forschungsgemeinschaft
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01 AR051300 (to R. B. P., H. R., and S. Z.). Supported by
   a research fellowship grant from the Deutsche Forschungsgemeinschaft.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Bakker AD, 2009, ARTHRITIS RHEUM US, V60, P3336, DOI 10.1002/art.24920
   Bergula AP, 2004, BONE, V34, P562, DOI 10.1016/j.bone.2003.11.025
   Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960 9822(03)00544 X
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Dillon JP, 2012, METHODS MOL BIOL, V816, P3, DOI 10.1007/978 1 61779 415 5_1
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424 009 0767 7
   Fox SW, 1996, AM J PHYSIOL ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955
   Galli C, 2010, J DENT RES, V89, P331, DOI 10.1177/0022034510363963
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Giannone G, 2004, J BIOL CHEM, V279, P28715, DOI 10.1074/jbc.M404054200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959 437X(01)00260 X
   Hughes Fulford Millie, 2004, Sci STKE, V2004, pRE12
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021 9290(96)84536 2
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Jamal SA, 2011, JAMA J AM MED ASSOC, V305, P800, DOI 10.1001/jama.2011.176
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kamioka H, 2006, J BONE MINER RES, V21, P1012, DOI 10.1359/JBMR.060408
   Kanematsu M, 1997, J BONE MINER RES, V12, P1789, DOI 10.1359/jbmr.1997.12.11.1789
   Klein Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270
   Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200
   Lee DY, 2010, J BIOL CHEM, V285, P30, DOI 10.1074/jbc.M109.010512
   Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455
   Lieskovska J, 2006, J BIOL CHEM, V281, P25041, DOI 10.1074/jbc.M602866200
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930
   MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Noh T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005438
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Papachristou DJ, 2009, BIOESSAYS, V31, P794, DOI 10.1002/bies.200800223
   Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221
   Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003
   Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756 3282(96)00260 8
   Riddle RC, 2009, J ORTHOP RES, V27, P143, DOI 10.1002/jor.20723
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012
   Schwartz MA, 2009, SCIENCE, V323, P588, DOI 10.1126/science.1169414
   Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18
   Stevens HY, 2003, METH MOLEC MED, V80, P381
   Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Ulici V, 2009, BONE, V45, P1133, DOI 10.1016/j.bone.2009.08.003
   Wang B, 2011, BIOCHEM BIOPH RES CO, V410, P671, DOI 10.1016/j.bbrc.2011.06.054
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Young SRL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016026
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
NR 63
TC 50
Z9 63
U1 0
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 15
PY 2012
VL 287
IS 25
BP 21509
EP 21519
DI 10.1074/jbc.M112.347245
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 974FQ
UT WOS:000306416800068
PM 22563076
OA Green Published
DA 2025 08 17
ER

PT J
AU Rosa, RG
   Collavino, K
   Lakhani, A
   Delve, E
   Weber, JF
   Rosenthal, AK
   Waldman, SD
AF Rosa, R. G.
   Collavino, K.
   Lakhani, A.
   Delve, E.
   Weber, J. F.
   Rosenthal, A. K.
   Waldman, S. D.
TI Clodronate exerts an anabolic effect on articular chondrocytes mediated
   through the purinergic receptor pathway
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Chondrocytes; Bisphosphonates; Clodronate; Anabolism; Calcium signaling;
   Purinergic signaling
ID ACTIVE RHEUMATOID ARTHRITIS; IN VITRO; EXTRACELLULAR ATP; CONTAINING
   BISPHOSPHONATES; SIGNALING PATHWAY; BONE RESORPTION; RELEASE ATP;
   CARTILAGE; OSTEOARTHRITIS; CELLS
AB Objective: Bisphosphonates are commonly used anti osteoporotic drugs which have controversial effects on joint diseases including osteoarthritis. Certain bisphosphonates have been shown to have anabolic effects on cartilage which could have important ramifications for their proposed effects in vivo; however, the underlying mechanisms are poorly understood. Thus, the purpose of this study was to characterize the effects of clodronate on primary articular chondrocyte metabolism and to determine the underlying signaling pathways responsible.
   Design: The effects of clodronate and pamidronate on extracellular matrix (ECM) biosynthesis, accumulation and MMP 13 activity were observed in high density, 3D cultures of bovine articular chondrocytes for up to 4 weeks were evaluated. Mechanisms were delineated by measuring intracellular Ca2+ signaling and the effects of pharmacologic inhibition of the purinergic receptor pathway.
   Results: Clodronate (100 mu M) induced an anabolic effect (increased biosynthesis by 13 14%) which resulted in an 89 90% increase in ECM accumulation after 4 weeks of culture and without an associated effect on matrix turn over. Stimulation by clodronate resulted in a 3.3 fold increase in Ca2+ signaling and pharmacological inhibitor experiments suggested that the anabolic effects exerted by clodronate are transduced through the purinergic receptor pathway.
   Conclusions: These findings support the previous notion that certain bisphosphonates may be useful as adjunctive therapies to potentially ameliorate progression of cartilage degeneration and improve arthritis management. (C) 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Rosa, R. G.] Kingston Gen Hosp, Human Mobil Res Ctr, Kingston, ON K7L 2V7, Canada.
   [Collavino, K.; Waldman, S. D.] Ryerson Univ, Dept Chem Engn, Toronto, ON M5B 2K3, Canada.
   [Collavino, K.; Waldman, S. D.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
   [Lakhani, A.; Delve, E.] Queens Univ, Dept Chem Engn, Kingston, ON K7L 3N6, Canada.
   [Weber, J. F.] Queens Univ, Dept Mech & Mat Engn, Kingston, ON, Canada.
   [Rosenthal, A. K.] Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI 53226 USA.
   [Rosenthal, A. K.] Zablocki VA Med Ctr, Milwaukee, WI USA.
C3 Queens University   Canada; Queens University Hospital; Toronto
   Metropolitan University; University of Toronto; Saint Michaels Hospital
   Toronto; Li Ka Shing Knowledge Institute; Queens University   Canada;
   Queens University   Canada; Medical College of Wisconsin
RP Waldman, SD (通讯作者)，Ryerson Univ, Dept Chem Engn, Kerr Hall South,Room 241N, Toronto, ON M5B 2K3, Canada.
EM renata.giardini@gmail.com; kristina.collavino@ryerson.ca;
   anand.lakhani@queensu.ca; elizabeth.delve@mail.utoronto.ca;
   weberj@me.queensu.ca; ann.rosenthal@va.gov; swaldman@ryerson.ca
RI Rosa, Renata/H 8579 2013; Waldman, Stephen/A 8041 2013
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
FX Funding for this work was provided by the Natural Sciences and
   Engineering Research Council of Canada (NSERC).
CR Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   BIRD HA, 1988, CLIN RHEUMATOL, V7, P91, DOI 10.1007/BF02284063
   Bow JF, 2013, ADENOSINE TRIPHOSPHA, P99
   Cocco R, 1999, Boll Soc Ital Biol Sper, V75, P71
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Croucher LJ, 2000, BBA MOL BASIS DIS, V1502, P297, DOI 10.1016/S0925 4439(00)00055 7
   DAndrea P, 1997, FEBS LETT, V400, P58, DOI 10.1016/S0014 5793(96)01356 7
   Davis AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072714
   Dombrecht EJ, 2007, CLIN EXP RHEUMATOL, V25, P817
   Elfervig MK, 2001, OSTEOARTHR CARTILAGE, V9, P518, DOI 10.1053/joca.2000.0435
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Fuerst M, 2009, ARTHRITIS RHEUM, V60, P2694, DOI 10.1002/art.24774
   Gadjanski I, 2013, TISSUE ENG PT A, V19, P2188, DOI [10.1089/ten.tea.2012.0352, 10.1089/ten.TEA.2012.0352]
   Garcia M, 2010, J ORTHOP RES, V28, P510, DOI 10.1002/jor.21025
   GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154
   Graff RD, 2000, ARTHRITIS RHEUM US, V43, P1571, DOI 10.1002/1529 0131(200007)43:7<1571::AID ANR22>3.0.CO;2 L
   GUENTHER HL, 1981, BIOCHEM J, V196, P293, DOI 10.1042/bj1960293
   GUENTHER HL, 1979, BIOCHEM J, V184, P203, DOI 10.1042/bj1840203
   Heinegard D, 1998, OSTEOARTHRITIS, P74
   INOUE K, 1991, BRIT J PHARMACOL, V102, P851, DOI 10.1111/j.1476 5381.1991.tb12265.x
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003 2697(88)90532 5
   Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124
   Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469 7580.2008.01021.x
   LARSSON A, 1978, ACTA PATH MICRO IM A, V86, P211
   Le Goff Benoit, 2011, Expert Rev Clin Pharmacol, V4, P633
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399
   Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564
   Nielsen RH, 2008, BIOMARKERS, V13, P79, DOI 10.1080/13547500701615108
   North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002
   Pelletier JP, 2011, J RHEUMATOL, V38, P118, DOI 10.3899/jrheum.100642
   Penuela S, 2013, BBA BIOMEMBRANES, V1828, P15, DOI 10.1016/j.bbamem.2012.01.017
   PETERKOFSKY B, 1971, BIOCHEMISTRY US, V10, P988, DOI 10.1021/bi00782a009
   Pingguan Murphy B, 2006, J CELL PHYSIOL, V209, P389, DOI 10.1002/jcp.20747
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Rosenthal AK, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4337
   Rossini M, 2009, RHEUMATOLOGY, V48, P773, DOI 10.1093/rheumatology/kep084
   Rovetta G, 2003, Minerva Med, V94, P353
   Saviola G, 2012, MOD RHEUMATOL, V22, P256, DOI 10.1007/s10165 011 0506 8
   Sun YL, 1999, J BONE MINER RES, V14, P1916, DOI 10.1359/jbmr.1999.14.11.1916
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Tsuzaki M, 2005, J CELL BIOCHEM, V96, P117, DOI 10.1002/jcb.20491
   Valleala H, 2001, INFLAMM RES, V50, P598, DOI 10.1007/PL00000240
   van der Kraan PM, 2012, OSTEOARTHR CARTILAGE, V20, P223, DOI 10.1016/j.joca.2011.12.003
   Van Offel JF, 2005, CYTOKINE, V31, P298, DOI 10.1016/j.cyto.2005.05.009
   Waldman SD, 2010, OSTEOARTHR CARTILAGE, V18, P864, DOI 10.1016/j.joca.2010.03.003
   Waldman SD, 2002, J BIOMED MATER RES, V62, P323, DOI 10.1002/jbm.10235
   Wann AKT, 2012, FASEB J, V26, P1663, DOI 10.1096/fj.11 193649
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003 9861(61)90291 0
   Yamazaki S, 2003, J CELL BIOCHEM, V90, P812, DOI 10.1002/jcb.10681
   Yang DM, 2009, J PHARMACOL EXP THER, V330, P613, DOI 10.1124/jpet.109.152447
NR 56
TC 21
Z9 25
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2014
VL 22
IS 9
BP 1327
EP 1336
DI 10.1016/j.joca.2014.07.009
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AP7GC
UT WOS:000342244800013
PM 25042551
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, NN
   Xin, HL
   Xu, PC
   Yu, ZM
   Shou, D
AF Wang, Nani
   Xin, Hailiang
   Xu, Pingcui
   Yu, Zhongming
   Shou, Dan
TI Erxian Decoction Attenuates TNF α Induced Osteoblast Apoptosis by
   Modulating the Akt/Nrf2/HO 1 Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE network pharmacology; Erxian decoction; osteoporosis; Akt; tumor
   necrosis factor
ID TUMOR NECROSIS FACTOR; ACTIVE COMPONENTS; OSTEOPOROSIS; BONE;
   PHYTOCHEMISTRY; EXPRESSION; LUTEOLIN; EXTRACT
AB Erxian decoction (EXD), a traditional Chinese medicine formula, has been used for treatment of osteoporosis for many years. The purpose of this study was to investigate the pharmacological effect of EXD in preventing osteoblast apoptosis and the underlying mechanism of prevention. Putative targets of EXD were predicted by network pharmacology, and functional and pathway enrichment analyses were also performed. Evaluations of bone mineral density, serum estradiol level, trabecular area fraction, serum calcium levels, and tumor necrosis factor (TNF) alpha levels in ovariectomized rats, as well as cell proliferation assays, apoptosis assays, and western blotting in MC3T3 E1 osteoblasts were performed for further experimental validation. Ninety three active ingredients in the EXD formula and 259 potential targets were identified. Functional and pathway enrichment analyses indicated that EXD significantly influenced the PI3K Akt signaling pathway. In vivo experiments indicated that EXD treatment attenuated bone loss and decreased TNF alpha levels in rats with osteoporosis. In vitro experiments showed that EXD treatment increased cell viability markedly and decreased levels of caspase 3 and the rate of apoptosis. It also promoted phosphorylation of Akt, nuclear translocation of transcription factor NF erythroid 2 related factor (Nrf2), and hemeoxygenase 1 (HO 1) expression in TNF alpha induced MC3T3 E1 cells. Our results suggest that EXD exerted profound anti osteoporosis effects, at least partially by reducing production of TNF alpha and attenuating osteoblast apoptosis via Akt/Nrf2/HO 1 signaling pathway.
C1 [Wang, Nani; Xu, Pingcui; Yu, Zhongming; Shou, Dan] Tongde Hosp Zhejiang Prov, Dept Med, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Nani; Xu, Pingcui] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou, Zhejiang, Peoples R China.
   [Xin, Hailiang] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
C3 Zhejiang Chinese Medical University; Naval Medical University
RP Shou, D (通讯作者)，Tongde Hosp Zhejiang Prov, Dept Med, Hangzhou, Zhejiang, Peoples R China.
EM shoudanok@163.com
FU National Natural Science Foundation of China [81603252, U1603283,
   81873062]; Zhejiang Provincial Natural Science Foundation of China
   [LQ17H280002]; Open Fund Project of First Class Discipline for Science
   of Chinese Pharmacy, Zhejiang Chinese Medical University [Ya2017008]
FX The project was sponsored by the National Natural Science Foundation of
   China (No. 81603252, U1603283, 81873062), Zhejiang Provincial Natural
   Science Foundation of China (No. LQ17H280002), and the Open Fund Project
   of First Class Discipline for Science of Chinese Pharmacy, Zhejiang
   Chinese Medical University (Ya2017008).
CR Bian J., 1996, J SHENYANG PHARM U, V13, P34, DOI DOI 10.1248/CPB.C12 01058
   Bian QY, 2013, CHEM PHARM BULL, V61, P802, DOI 10.1248/cpb.c12 01058
   Cao DaPeng Cao DaPeng, 2009, Academic Journal of Second Military Medical University, V30, P194
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   Chen CC, 1996, J NAT PROD, V59, P412, DOI 10.1021/np9601925
   Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412
   Chiu PR, 2016, INT J BIOCHEM CELL B, V79, P327, DOI 10.1016/j.biocel.2016.08.036
   Gozalbes R, 2010, BIOORGAN MED CHEM, V18, P7078, DOI 10.1016/j.bmc.2010.08.003
   Hong Z., 2009, J ANHUI AGR SCI, V37, P4115
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Im E, 2018, LIFE SCI, V209, P259, DOI 10.1016/j.lfs.2018.08.025
   Kloefkorn HE, 2017, CONNECT TISSUE RES, V58, P373, DOI 10.1080/03008207.2016.1251425
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu TG, 2016, ACTA MEDICA MEDITERR, V32, P877, DOI 10.19193/0393 6384_2016_4_104
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Pang JL, 2006, BIOCHEM PHARMACOL, V71, P818, DOI 10.1016/j.bcp.2005.12.023
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sanderson K, 2011, NAT MED, V17, P1531, DOI 10.1038/nm1211 1531a
   Simpson DS, 2009, ORG BIOMOL CHEM, V7, P3748, DOI 10.1039/b905148a
   Tong Y, 2012, PLANTA MED, V78, P1117
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wang Meng, 2009, Zhong Yao Cai, V32, P208
   Wang N, 2017, J SEP SCI, V40, P4311, DOI 10.1002/jssc.201700688
   Wang NN, 2017, MED SCI MONITOR, V23, P5113, DOI 10.12659/MSM.904264
   Wang S. W., 2016, J ETHNOPHARMACOL, V100, P196, DOI [10.1016/j.maturitas.2017.03.255, DOI 10.1016/J.MATURITAS.2017.03.255]
   Wang SW, 2015, CHIN MED UK, V10, DOI 10.1186/s13020 015 0051 z
   Wang YQ, 2010, J PHARMACEUT BIOMED, V51, P606, DOI 10.1016/j.jpba.2009.09.033
   Wang YK, 2010, J ETHNOPHARMACOL, V132, P233, DOI 10.1016/j.jep.2010.08.008
   Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024
   Xia Y, 2017, INT IMMUNOPHARMACOL, V45, P1, DOI 10.1016/j.intimp.2017.01.022
   Xue Juan Xue Juan, 2015, Guizhou Agricultural Sciences, V43, P220
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100
   [晏晨 Yan Chen], 2017, [天然产物研究与开发, Natural Product Research and Development], V29, P1270
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Yu XB, 2013, BIOL PHARM BULL, V36, P754, DOI 10.1248/bpb.b12 00860
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhao RL, 2018, J ETHNOPHARMACOL, V210, P287, DOI 10.1016/j.jep.2017.08.041
   Zhou J, 2017, BIOELECTROMAGNETICS, V38, P31, DOI 10.1002/bem.22012
   Zhou XX, 2017, EXP HEMATOL, V45, P17, DOI 10.1016/j.exphem.2016.10.005
NR 41
TC 30
Z9 33
U1 1
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 10
PY 2019
VL 10
AR 988
DI 10.3389/fphar.2019.00988
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IW7JY
UT WOS:000485166400001
PM 31551787
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Martin, V
   Bettencourt, AF
   Santos, C
   Fernandes, MH
   Gomes, PS
AF Martin, Victor
   Bettencourt, Ana Francisca
   Santos, Catarina
   Fernandes, Maria Helena
   Gomes, Pedro Sousa
TI Unveiling the Osteogenic Potential of Tetracyclines: A Comparative Study
   in Human Mesenchymal Stem Cells
SO CELLS
LA English
DT Article
DE tetracyclines; mesenchymal stem cells; osteogenesis; drug repurposing;
   Wnt signaling; Hedgehog signaling
ID OSTEOBLAST DIFFERENTIATION; BONE; MINOCYCLINE; PROLIFERATION;
   DOXYCYCLINE; ANTIBIOTICS; CULTURES; CATENIN; REPAIR
AB Tetracyclines (TCs) are a class of broad spectrum antibiotics with diverse pharmacotherapeutic properties due to their various functional groups being attached to a common core structure. Beyond their antibacterial activity, TCs trigger pleiotropic effects on eukaryotic cells, including anti inflammatory and potentially osteogenic capabilities. Consequently, TCs hold promise for repurposing in various clinical applications, including bone related conditions. This study presents the first comprehensive comparison of the in vitro osteogenic potential of four TCs tetracycline, doxycycline, minocycline, and sarecycline, within human mesenchymal stem cells. Cultures were characterized for metabolic activity, cell morphology and cytoskeleton organization, osteogenic gene expression, alkaline phosphatase (ALP) activity, and the activation of relevant signaling pathways. TCs stimulated actin remodeling processes, inducing morphological shifts consistent with osteogenic differentiation. Osteogenic gene expression and ALP activity supported the osteoinduction by TCs, demonstrating significant increases in ALP levels and the upregulation of RUNX2, SP7, and SPARC genes. Minocycline and sarecycline exhibited the most potent osteogenic induction, comparable to conventional osteogenic inducers. Signaling pathway analysis revealed that tetracycline and doxycycline activate the Wnt pathway, while minocycline and sarecycline upregulated Hedgehog signaling. Overall, the present findings suggest that TCs promote osteogenic differentiation through distinct pathways, making them promising candidates for targeted therapy in specific bone related disorders.
C1 [Martin, Victor; Fernandes, Maria Helena; Gomes, Pedro Sousa] Univ Porto, Fac Dent Med, BoneLab Lab Bone Metab & Regenerat, P 4200393 Porto, Portugal.
   [Martin, Victor; Fernandes, Maria Helena; Gomes, Pedro Sousa] Univ Porto, LAQV REQUIMTE, P 4050453 Porto, Portugal.
   [Bettencourt, Ana Francisca] Univ Lisbon, Fac Farm, Res Inst Med iMed ULisboa, P 1649003 Lisbon, Portugal.
   [Santos, Catarina] Univ Lisbon, CQE Inst Super Tecn, P 1049001 Lisbon, Portugal.
   [Santos, Catarina] Inst Politecn Setubal, EST Setubal, CDP2T, P 2910761 Setubal, Portugal.
C3 Universidade do Porto; Universidade do Porto; Universidade de Lisboa;
   Universidade de Lisboa; Instituto Politecnico de Setubal
RP Gomes, PS (通讯作者)，Univ Porto, Fac Dent Med, BoneLab Lab Bone Metab & Regenerat, P 4200393 Porto, Portugal.; Gomes, PS (通讯作者)，Univ Porto, LAQV REQUIMTE, P 4050453 Porto, Portugal.
EM vmartin@fmd.up.pt; asimao@ff.ulisboa.pt;
   catarina.santos@estsetubal.ips.pt; mhfernandes@fmd.up.pt;
   pgomes@fmd.up.pt
RI Santos, Catarina/G 6817 2011; Gomes, Pedro/K 2433 2014; Martin,
   Victor/AAG 1214 2019; Fernandes, Maria/K 6917 2014; de campos simao
   bettencourt, ana/ABG 2839 2021; Fernandes, Maria Helena/K 6917 2014;
   Bettencourt, Ana/M 4219 2013
OI Santos, Catarina/0000 0002 8567 0032; Gomes, Pedro/0000 0001 5365 2123;
   Martin, Victor/0000 0001 6910 1705; Fernandes, Maria
   Helena/0000 0001 9391 9574; Bettencourt, Ana/0000 0002 8498 5892
FU Fundacao para a Ciencia e Tecnologia (FCT) [2022.06464.PTDC]; FCT POCH
   [2020.04935.BD]; Vinnova [2020 04935] Funding Source: Vinnova
FX The authors acknowledge the Fundacao para a Ciencia e Tecnologia (FCT)
   for the financial support under the project 2022.06464.PTDC and FCT POCH
   for the Victor Martin PhD grant, ref. 2020.04935.BD.
CR Agwuh KN, 2006, J ANTIMICROB CHEMOTH, V58, P256, DOI 10.1093/jac/dkl224
   Al kuraishy HM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.642822
   Almazin SM, 2009, J PERIODONTOL, V80, P999, DOI 10.1902/jop.2009.080574
   Baht GS, 2014, J ORTHOP RES, V32, P581, DOI 10.1002/jor.22562
   Ballhause TM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031325
   Bettany J T, 1998, Adv Dent Res, V12, P136
   Bettany JT, 2000, BONE, V27, P75, DOI 10.1016/S8756 3282(00)00297 0
   Bryskier A, 2005, ANTIMICROBIAL AGENTS: ANTIBACTERIALS AND ANTIFUNGALS, P13
   Bunick CG, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10040439
   Caton J, 2011, PHARMACOL RES, V63, P114, DOI 10.1016/j.phrs.2010.12.003
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Coelho MJ, 2000, BIOMATERIALS, V21, P1095, DOI 10.1016/S0142 9612(99)00192 1
   Dao DY, 2010, J ORTHOP RES, V28, P89, DOI 10.1002/jor.20954
   Del Rosso James Q, 2020, J Clin Aesthet Dermatol, V13, P45
   Dougherty JA, 2019, ANN PHARMACOTHER, V53, P486, DOI 10.1177/1060028018818094
   Nguyen F, 2014, BIOL CHEM, V395, P559, DOI 10.1515/hsz 2013 0292
   Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174
   Fuoco D, 2012, ANTIBIOTICS BASEL, V1, P1, DOI 10.3390/antibiotics1010001
   Galli C, 2012, EUR CELLS MATER, V24, P46, DOI 10.22203/eCM.v024a04
   Garrido Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139
   Golub LM, 2016, INT DENT J, V66, P127, DOI 10.1111/idj.12221
   Gomes KD, 2017, INT J ORAL SCI, V9, P158, DOI 10.1038/ijos.2017.28
   Gomes PS, 2008, ACTA BIOMATER, V4, P630, DOI 10.1016/j.actbio.2007.12.006
   Gomes PS, 2007, ARCH ORAL BIOL, V52, P251, DOI 10.1016/j.archoralbio.2006.10.005
   Gomes PS, 2020, MOL CELL ENDOCRINOL, V518, DOI 10.1016/j.mce.2020.110975
   Goodnough LH, 2012, DEVELOPMENT, V139, P4428, DOI 10.1242/dev.081679
   Griffin MO, 2011, PHARMACOL RES, V63, P102, DOI 10.1016/j.phrs.2010.10.004
   Griffin MO, 2010, AM J PHYSIOL CELL PH, V299, pC539, DOI 10.1152/ajpcell.00047.2010
   Hirohashi Y, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.714366
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Kim Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164038
   Kinugawa S, 2012, J IMMUNOL, V188, P1772, DOI 10.4049/jimmunol.1101174
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Kwon Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115805
   Lai SW, 2018, MOL NEUROBIOL, V55, P7487, DOI 10.1007/s12035 018 0933 z
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   LaPlante KL, 2022, ANN MED, V54, P1686, DOI 10.1080/07853890.2022.2085881
   Li H, 2015, BIOCHEM BIOPH RES CO, V467, P14, DOI 10.1016/j.bbrc.2015.09.140
   Luo Ming, 2014, Zhongguo Gu Shang, V27, P169
   Luo ZL, 2019, AM J PATHOL, V189, P1495, DOI 10.1016/j.ajpath.2019.05.005
   Macri Pellizzeri L, 2018, TISSUE ENG PART C ME, V24, P171, DOI [10.1089/ten.tec.2017.0400, 10.1089/ten.TEC.2017.0400]
   Malaval L, 1999, J CELL BIOCHEM, V74, P616
   Martin V, 2023, J BONE MINER METAB, V41, P431, DOI 10.1007/s00774 023 01428 9
   Martin V, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118821
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Monk E, 2011, PHARMACOL RES, V63, P130, DOI 10.1016/j.phrs.2010.10.007
   Nakamura T, 2015, J CELL PHYSIOL, V230, P922, DOI 10.1002/jcp.24823
   Nelson M.L., 2007, Comprehensive Medicinal Chemistry II, P597, DOI DOI 10.1016/B0 08 045044 X/00221 2
   Nelson ML, 2011, ANN NY ACAD SCI, V1241, P17, DOI 10.1111/j.1749 6632.2011.06354.x
   Qin Y, 2015, ONCOTARGET, V6, P40667, DOI 10.18632/oncotarget.5842
   RIFKIN BR, 1993, J PERIODONTOL, V64, P819, DOI 10.1902/jop.1993.64.8s.819
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rosset EM, 2016, MATRIX BIOL, V52 54, P78, DOI 10.1016/j.matbio.2016.02.001
   Rusu A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13122085
   Silva T, 2018, J BIOMATER APPL, V33, P380, DOI 10.1177/0885328218795290
   Silva T, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa68b8
   Song H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114457
   Thomas S, 2022, J CELL COMMUN SIGNAL, V16, P47, DOI 10.1007/s12079 021 00635 1
   Walters B, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06794 9
   Wang JLS, 2023, CURR OSTEOPOROS REP, V21, P241, DOI 10.1007/s11914 023 00778 7
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Xu LL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0716 x
   Yang C, 2017, BIOMED PHARMACOTHER, V94, P380, DOI 10.1016/j.biopha.2017.07.078
   Zegre M, 2022, INT J PHARMACEUT, V622, DOI 10.1016/j.ijpharm.2022.121832
   Zhang ZL, 2015, BIOFABRICATION, V7, DOI 10.1088/1758 5090/7/1/015006
   Zhou XX, 2010, CALCIFIED TISSUE INT, V86, P163, DOI 10.1007/s00223 009 9328 5
NR 66
TC 8
Z9 8
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2023
VL 12
IS 18
AR 2244
DI 10.3390/cells12182244
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA S7XS8
UT WOS:001073268200001
PM 37759467
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Boyce, BF
   Xing, L
   Yao, ZG
   Yamashita, T
   Shakespeare, WC
   Wang, YH
   Metcalf, CA
   Sundaramoorthi, R
   Dalgarno, DC
   Luliucci, JD
   Sawyer, TK
AF Boyce, Brendan F.
   Xing, Lianping
   Yao, Zhengiang
   Yamashita, Teruhito
   Shakespeare, William C.
   Wang, Yihan
   Metcalf, Chester A., III
   Sundaramoorthi, Raji
   Dalgarno, David C.
   Luliucci, John D.
   Sawyer, Tomi K.
TI Src inhibitors in metastatic bone disease
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advances in Treating Metastatic Bone Cancer
CY OCT 28 29, 2005
CL Cambridge, MA
ID TYROSINE KINASE; C SRC; OSTEOCLAST DIFFERENTIATION; IN VITRO;
   OSTEOPETROSIS; MICE; EXPRESSION; PHOSPHORYLATION; REQUIREMENT;
   OVARIECTOMY
AB Src tyrosine kinase was the first gene product shown to have an essential function in bone using recombinant DNA technology after its expression was knocked out in mice similar to 15 years ago. Since then,, our understanding of the regulation of bone catabolism has advanced significantly with the identification of other key enzymes that regulate osteoclast formation, activation, and survival after their knockout in mice or recognition of mutations in them in humans. This led to the discovery or development of specific inhibitors of some of these key enzymes, including Src, as proof of concept lead compounds or potential clinical candidates for the prevention of diseases associated with increased bone resorption, such as osteoporosis and metastatic bone disease. Although bisphosphonates have been prescribed with proven and improving efficacy for the prevention of bone loss for >30 years, adverse effects, such as upper gastrointestinal tract symptoms, and the requirement to take them at least 2 hours before food have limited patient compliance. Thus, with growing knowledge of the pathways regulating osteoclast function and the appreciation that some of these are active also in tumor cells, drug companies have made efforts to identify small molecular lead compounds for development into new therapeutic agents for the prevention of bone loss with efficacy that matches for supersedes that of bisphosphonates. In this article, we review our current understanding of the signaling pathways that regulate osteoclast formation, activation and survival with specific reference to the role of Src tyrosine kinase and downstream signaling and highlight in a variety of models of increased bone resorption the effects of Src kinase inhibitors that have been targeted to bone to limit potential adverse effects on other cells.
C1 Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
C3 University of Rochester; Takeda Pharmaceutical Company Ltd; Takeda
   Oncology
RP Boyce, BF (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM brendan_boyce@urmc.rochester.edu
RI wang, yihan/HTN 8802 2023
OI Yao, Zhenqiang/0000 0002 4664 3648
CR Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018 9027.2000
   Boschelli Diane H., 2002, Current Topics in Medicinal Chemistry, V2, P1051, DOI 10.2174/1568026023393354
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   Boyce BF, 2002, J BONE MINER RES, V17, pS159
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   BOYCE BF, 1995, ENDOCRINOLOGY, V136, P5751, DOI 10.1210/en.136.12.5751
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cui L, 2004, ACTA PHARMACOL SIN, V25, P678
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eastell R, 2005, J CLIN ONCOL, V23, p202S
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695
   Hannon RA, 2005, BONE, V36, pS135
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P376, DOI 10.1530/eje.0.1400376
   Huron DR, 2003, CLIN CANCER RES, V9, P1267
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006 2952(00)00405 6
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Plé PA, 2004, J MED CHEM, V47, P871, DOI 10.1021/jm030317k
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Trubert CL, 1997, EUR J HISTOCHEM, V41, P169
   Wang YH, 2003, BIOORG MED CHEM LETT, V13, P3067, DOI 10.1016/S0960 894X(03)00648 6
   Weaver CM, 2005, J NUTR, V135, P1243, DOI 10.1093/jn/135.5.1243
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301
   Yin J, 2004, BIOL PHARM BULL, V27, P583, DOI 10.1248/bpb.27.583
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
NR 40
TC 39
Z9 50
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2006
VL 12
IS 20
SU S
BP 6291S
EP 6295S
DI 10.1158/1078 0432.CCR 06 0991
PN 2
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 099AC
UT WOS:000241563900015
PM 17062716
DA 2025 08 17
ER

PT J
AU Burkiewicz, JS
   Scarpace, SL
   Bruce, SP
AF Burkiewicz, Jill S.
   Scarpace, Sarah L.
   Bruce, Susan P.
TI Denosumab in Osteoporosis and Oncology
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE bone metastases; breast cancer; denosumab; monoclonal antibody; multiple
   myeloma; osteoporosis; prostate cancer; RANKL; solid tumor; tumor
   necrosis factor
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BREAST CANCER;
   BISPHOSPHONATE THERAPY; BIOCHEMICAL MARKERS; ZOLEDRONIC ACID; PHASE II;
   METASTASES; TURNOVER; LIGAND
AB OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, safety, efficacy, and use of denosumab in osteoporosis, breast cancer, prostate cancer, and multiple myeloma.
   DATA SOURCES: Studies and abstracts were identified through MEDLINE and International Pharmaceutical Abstracts (1966 July 2009). Key search terms include denosumab, AMG 162, and receptor activator of nuclear factor kappa B ligand system. Information available in abstract form was retrieved from major oncology and bone metabolism meetings. Additional data were obtained from the manufacturer.
   STUDY SELECTION AND DATA EXTRACTION: All available studies in humans were included except for studies in rheumatoid arthritis and giant cell tumor of the bone.
   DATA SYNTHESIS: In patients with osteoporosis, denosumab significantly reduces bone resorption and fractures. Studies of denosumab in the prevention and treatment of osteoporosis have demonstrated significantly increased bone mineral density and reduced bone turnover markers. Studies of denosumab versus placebo in the treatment of osteoporosis have demonstrated reductions in vertebral, hip, and nonvertebral fractures. In oncology, positive results from clinical trials in patients receiving endocrine therapy for breast and prostate cancer demonstrated decreases in bone loss and skeletal related events. Denosumab seems to be at least as effective in reducing bone turnover markers as intravenous bisphosphonates in the oncology setting. The most common adverse effects in patients with osteoporosis were arthralgia, nasopharyngitis, back pain, and headache. The most common adverse effects in patients with cancer were infection, pain in the extremities, arthralgia, bone pain, fatigue, and pain. Serious adverse effects include infections requiring hospitalization.
   CONCLUSIONS: Denosumab has documented efficacy and safety in patients with osteoporosis, breast cancer, and prostate cancer. Additional clinical trial data are needed to more completely establish the effectiveness of denosumab in the treatment of osteoporosis and neoplastic disease as well as its cost effectiveness and long term safety.
C1 [Burkiewicz, Jill S.] Midwestern Univ, Chicago Coll Pharm, Downers Grove, IL 60515 USA.
   [Scarpace, Sarah L.] Albany Coll Pharm & Hlth Sci, Albany, NY USA.
   [Bruce, Susan P.] Northeastern Ohio Univ Coll Med & Pharm, Rootstown, OH 44272 USA.
C3 Midwestern University; Midwestern University   Chicago College of
   Pharmacy; Midwestern University   Downers Grove; Albany College of
   Pharmacy & Health Sciences; University System of Ohio; Northeast Ohio
   Medical University (NEOMED)
RP Burkiewicz, JS (通讯作者)，Midwestern Univ, Chicago Coll Pharm, 555 31st St, Downers Grove, IL 60515 USA.
EM jburki@midwestern.edu
CR Beest FJAPV, 2008, OSTEOPOROSIS INT, V19, P511, DOI 10.1007/s00198 007 0466 1
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   CAMPBELLBAIRD C, 2007, 2007 AM SOC CLIN ONC
   Cremers S, 2006, DRUGS, V66, P2031, DOI 10.2165/00003495 200666160 00001
   CUMMINGS SR, 2008, AM SOC BON MIN RES 3
   Dougall William C, 2007, Curr Opin Support Palliat Care, V1, P317, DOI 10.1097/SPC.0b013e3282f335be
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   GOLD DT, 2008, AM SOC BON MIN RES 3
   GRALOW J, 2008, 2008 SAN ANT BREAST
   GRALOW JR, 2008, 2008 AM SOC CLIN ONC
   Hamdy NAT, 2007, CURR OPIN INVEST DR, V8, P299
   Hamdy Neveen A T, 2005, Curr Osteoporos Rep, V3, P121, DOI 10.1007/s11914 996 0014 5
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Kendler DL, 2008, AM SOC BON MIN RES 3
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Lewiecki EM, 2006, EXPERT OPIN BIOL TH, V6, P1041, DOI 10.1517/14712598.6.10.1041
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   VIJ R, 2007, AM SOC HEM ANN M ATL
NR 33
TC 55
Z9 62
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060 0280
EI 1542 6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD SEP
PY 2009
VL 43
IS 9
BP 1445
EP 1455
DI 10.1345/aph.1M102
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 491QY
UT WOS:000269595500006
PM 19622756
DA 2025 08 17
ER

PT J
AU Kong, LB
   Wang, BA
   Yang, XB
   Guo, H
   Zhang, K
   Zhu, ZQ
   Liu, JJ
   Hao, DJ
AF Kong, Lingbo
   Wang, Biao
   Yang, Xiaobin
   Guo, Hua
   Zhang, Ke
   Zhu, Ziqi
   Liu, Jijun
   Hao, Dingjun
TI Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis
   via Inhibition of RANKL Induced Signaling Pathways and Attenuation of
   ROS Production
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Picrasma Quassioides; Reactive oxygen species (ROS); Osteoclastogenesis
ID BREAST CANCER CELLS; INDUCED BONE LOSS; RECEPTOR ACTIVATOR; RAW264.7
   CELLS; NUCLEAR FACTOR; DIFFERENTIATION; VITRO; MICE; APOPTOSIS; AGONIST
AB Background/Aims: Osteoporosis is a metabolic bone disorder that tortures about millions of people worldwide. Recent study demonstrated agents derived from picrasma quassioides is a promising drug for targets multiple signaling pathways. However its potential in treatment of bone loss has not been fully understood. Methods: The bone marrow macrophages (BMMs) were cultured and induced with M CSF and RANKL followed by picrasidine I (PI) treatment. Then the effects of PI on osteoclast formation were evaluated by counting tartrate resistant acid phosphatase (TRAP) positive multinucleated cells. Moreover, effects of PI on bone resorption activity of mature osteoclast were studied through bone resorption pit counting and actin ring structure analysis. Further, the involved potential signaling pathways cross talking were investigated by performed Western blotting and quantitative real time PCR examination. Results: Results demonstrated PI strongly inhibited RANKL induced osteoclast formation from its precursors. Mechanistically, the inhibitory effect of PI on osteoclast differentiation was due to the suppression of osteoclastogenic transcription factors, c Fos and NFATc1. Moreover, PI markedly blocked the RANKL induced osteoclastogenesis by attenuating MAPKs and NF kappa B signaling pathways. In addition, PI decreased the ROS generation in osteoclast and osteoblast. Conclusion: Taken together our data demonstrate that PI has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF kappa B and ROS generation followed by suppressing the gene expression of c Fos and NFATc1 in osteoclast precursors. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Kong, Lingbo; Wang, Biao; Yang, Xiaobin; Guo, Hua; Zhang, Ke; Zhu, Ziqi; Liu, Jijun; Hao, Dingjun] Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Xian, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Kong, LB; Liu, JJ; Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Xian, Shaanxi, Peoples R China.
EM lingbokong@163.com; honghui.jtu@medcenter.net.cn;
   dhao.honghui@outlook.com
RI ; Zhang, Ziqi/HHN 7875 2022; kong, lingbo/O 7491 2017
OI Hao, Dingjun/0000 0002 0946 6080; Wang, Biao/0000 0001 6631 9127; 
FU China Postdoctoral Science Foundation, PR. China [2016M592825]; Shaanxi
   State Ministry of Health, PR. China [2016D044]
FX This study was supported by a grant from China Postdoctoral Science
   Foundation, PR. China (2016M592825), grant from Shaanxi State Ministry
   of Health, PR. China (2016D044)
CR Agron M, 2017, CELL PHYSIOL BIOCHEM, V42, P952, DOI 10.1159/000478678
   Ayoub NA, 2009, PHARMAZIE, V64, P137, DOI 10.1691/ph.2009.8635
   Baek JM, 2015, PHYTOMEDICINE, V22, P27, DOI 10.1016/j.phymed.2014.10.008
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen FJ, 2014, CELL PHYSIOL BIOCHEM, V33, P796, DOI 10.1159/000358653
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Guo YL, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744 9081 6 43
   Heo JS, 2006, CELL PHYSIOL BIOCHEM, V17, P145, DOI 10.1159/000092076
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Kong LB, 2017, INT IMMUNOPHARMACOL, V51, P31, DOI 10.1016/j.intimp.2017.07.003
   Kong LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061013
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SK, 2015, CELL PHYSIOL BIOCHEM, V36, P1809, DOI 10.1159/000430152
   Lin SS, 2015, CELL PHYSIOL BIOCHEM, V35, P2213, DOI 10.1159/000374026
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Monjo M, 2010, CELL PHYSIOL BIOCHEM, V26, P647, DOI 10.1159/000322332
   Sasaki T, 2016, BIOORG MED CHEM LETT, V26, P4992, DOI 10.1016/j.bmcl.2016.09.006
   Satoh T, 2014, FREE RADICAL BIO MED, V66, P45, DOI 10.1016/j.freeradbiomed.2013.11.002
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Shrivastava S, 2014, APOPTOSIS, V19, P1148, DOI 10.1007/s10495 014 0991 2
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Thoresen GH, 2003, CELL PHYSIOL BIOCHEM, V13, P229
   Tseng FJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1250, DOI 10.1159/000430294
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wang L, 2009, J BIOL CHEM, V284, P199, DOI 10.1074/jbc.M806645200
   Yamashita N, 2017, BIOORG MED CHEM LETT, V27, P2608, DOI 10.1016/j.bmcl.2017.03.061
   Yang XB, 2017, J CELL BIOCHEM, V118, P4479, DOI 10.1002/jcb.26105
   Zhao S, 2016, J NAT PROD, V79, P3127, DOI 10.1021/acs.jnatprod.6b00883
   Zhao S, 2016, J NAT PROD, V79, P879, DOI 10.1021/acs.jnatprod.5b00909
NR 31
TC 31
Z9 33
U1 1
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 43
IS 4
BP 1425
EP 1435
DI 10.1159/000481874
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FN7TY
UT WOS:000416222900011
PM 29017159
OA gold
DA 2025 08 17
ER

PT J
AU Chai, S
   Yang, YB
   Wei, LW
   Cao, YJ
   Ma, JT
   Zheng, XX
   Teng, JY
   Qin, N
AF Chai, Shuang
   Yang, Yanbing
   Wei, Liwei
   Cao, Yuju
   Ma, Jiangtao
   Zheng, Xuxia
   Teng, Junyan
   Qin, Na
TI Luteolin rescues postmenopausal osteoporosis elicited by OVX through
   alleviating osteoblast pyroptosis via activating PI3K AKT signaling
SO PHYTOMEDICINE
LA English
DT Article
DE Luteolin; Postmenopausal osteoporosis; Osteoblast; Pyroptosis; PI3K/AKT
   signaling pathway
ID OXIDATIVE STRESS; ESTROGEN DEFICIENCY; BONE; AUTOINHIBITION; METABOLISM
AB Background: Recently, osteoblast pyroptosis has been proposed as a potential pathogenic mechanism underlying osteoporosis, although this remains to be confirmed. Luteolin (Lut), a flavonoid phytochemical, plays a critical role in the anti osteoporosis effects of many traditional Chinese medicine prescriptions. However, its protective impact on osteoblasts in postmenopausal osteoporosis (PMOP) has not been elucidated. Purpose: This research aimed to determine the effect of Lut in ameliorating PMOP by alleviating osteoblast pyroptosis and sustaining osteogenesis. Study design: This research was designed to investigate the novel mechanism of Lut in alleviating PMOP both in cell and animal models. Methods: Ovariectomy induced PMOP models were established in mice with/without daily gavaged of 10 or 20 mg/kg body weight Lut. The impact of Lut on bone microstructure, metabolism and oxidative stress was evaluated with 0.104 mg/kg body weight Estradiol Valerate Tablets daily gavaged as positive control. Network pharmacological analysis and molecular docking were employed to investigate the mechanisms of Lut in PMOP treatment. Subsequently, the impacts of Lut on the PI3K/AKT axis, oxidative stress, mitochondria, and osteoblast pyroptosis were assessed. In vitro, cultured MC3T3 E1(14) cells were exposed to H 2 O 2 with/without Lut to examine its effects on the PI3K/AKT signaling pathway, osteogenic differentiation, mitochondrial function, and osteoblast pyroptosis. Results: Our findings demonstrated that 20 mg/kg Lut, similar to the positive control drug, effectively reduced systemic bone loss and oxidative stress, and enhanced bone metabolism induced by ovariectomy. Network pharmacological analysis and molecular docking indicated that the PI3K/AKT axis was a potential target, with oxidative stress response and nuclear membrane function being key mechanisms. Consequently, the effects of Lut on the PI3K/AKT axis and pyroptosis were investigated. In vivo data revealed that the PI3K/AKT axis was deactivated following ovariectomy, and Lut restored the phosphorylation of key proteins, thereby reactivating the axis. Additionally, Lut alleviated osteoblast pyroptosis and mitochondrial abnormalities induced by ovariectomy. In vitro, Lut intervention mitigated the inhibition of the PI3K/AKT axis and osteogenesis, as well as H 2 O 2  induced pyroptosis. Furthermore, Lut attenuated ROS accumulation and mitochondrial dysfunction. The effects of Lut, including osteogenesis restoration, anti pyroptosis, and mitochondrial maintenance, were all reversed with LY294002 (a PI3K/AKT pathway inhibitor). Conclusion: In summary, Lut could improve mitochondrial dysfunction, alleviate GSDME mediated pyroptosis and maintain osteogenesis via activating the PI3K/AKT axis, offering a new therapeutic strategy for PMOP.
C1 [Chai, Shuang; Yang, Yanbing; Wei, Liwei; Ma, Jiangtao; Zheng, Xuxia; Teng, Junyan; Qin, Na] Luoyang Orthoped Traumatol Hosp, Orthoped Hosp Henan Prov, Zhengzhou 450016, Henan, Peoples R China.
   [Cao, Yuju] Zhengzhou Tradit Chinese Med TCM Traumatol Hosp, Zhengzhou 450016, Henan, Peoples R China.
   [Qin, Na] 100 Yongping Rd, Zhengzhou, Henan, Peoples R China.
RP Qin, N (通讯作者)，100 Yongping Rd, Zhengzhou, Henan, Peoples R China.
EM qinna2001@163.com
RI ; m, jt/AAX 6100 2021
OI qin, na/0000 0002 2351 240X; 
FU National Natural Science Foundation of China [82174413]; Health
   Commission of Henan Provincial [HNSWJW 2021016]; Natural Science
   Foundation of Henan [202300410555, 222300420198]; Science and Technology
   Projects of Luoyang [2022044Y]; Henan Provincial Science and Technology
   Research Project [232102310012]
FX <BOLD>Funding</BOLD> This study was jointly funded by the National
   Natural Science Foundation of China (no. 82174413) , Health Commission
   of Henan Provincial (HNSWJW 2021016) , Natural Science Foundation of
   Henan (no. 202300410555, 222300420198) , Science and Technology Projects
   of Luoyang (no. 2022044Y) , Henan Provincial Science and Technology
   Research Project (no. 232102310012) .
CR Abdurahman A, 2022, BONE, V157, DOI 10.1016/j.bone.2022.116346
   Ashrafizadeh M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01634 9
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019
   Bai ZB, 2020, AGING US, V12, P7534, DOI 10.18632/aging.103109
   Behera J, 2022, DIABETES, V71, P2777, DOI 10.2337/db21 0573
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Bonaccorsi G, 2018, INDIAN J MED RES, V147, P341, DOI 10.4103/ijmr.IJMR_524_18
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Chai S, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153063
   Chen TY, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 21 6742
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Dobson PF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68566 2
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Faienza MF, 2018, EXPERT OPIN BIOL TH, V18, P149, DOI 10.1080/14712598.2018.1401607
   Farlay D, 2022, J BONE MINER RES, V37, P856, DOI 10.1002/jbmr.4538
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418 018 0212 6
   Ge XD, 2020, FOOD FUNCT, V11, P10033, DOI [10.1039/d0fo01840f, 10.1039/D0FO01840F]
   Gendrisch F, 2021, BIOFACTORS, V47, P170, DOI 10.1002/biof.1699
   Gong WH, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.11.019
   Gustafson CE, 2019, AGING CELL, V18, DOI 10.1111/acel.12879
   Hagino H, 2021, OSTEOPOROSIS INT, V32, P2301, DOI 10.1007/s00198 021 05996 2
   Huang AY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1011561
   Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 00349 0
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Juric D, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.4475
   Kempuraj D, 2021, BIOFACTORS, V47, P190, DOI 10.1002/biof.1687
   Kerr D, 1996, J BONE MINER RES, V11, P218
   Kim SY, 2021, FOODS, V10, DOI 10.3390/foods10112807
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Kuang SY, 2017, P NATL ACAD SCI USA, V114, P10642, DOI 10.1073/pnas.1708194114
   Lee S, 2021, MAR DRUGS, V19, DOI 10.3390/md19040210
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li HL, 2018, FREE RADICAL BIO MED, V120, P228, DOI 10.1016/j.freeradbiomed.2018.03.014
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li Ying Li Ying, 2011, China Journal of Traditional Chinese Medicine and Pharmacy, V26, P1746
   Li YQ, 2019, N S ARCH PHARMACOL, V392, P1043, DOI 10.1007/s00210 019 01674 7
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Li ZF, 2019, J CELL BIOCHEM, V120, P8291, DOI 10.1002/jcb.28112
   Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003
   Liang GH, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.866641
   Luo YY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00692
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Malik A, 2017, J CELL SCI, V130, P3955, DOI 10.1242/jcs.207365
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Pingali U, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154334
   Qin XY, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113815
   Rogers C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09397 2
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Shi SH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.782096
   Sun L, 2022, BIOENGINEERED, V13, P48, DOI 10.1080/21655979.2021.2004980
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tao ZB, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.548812
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Wang K, 2023, EVID BASED COMPL ALT, V2023, DOI 10.1155/2023/9317557
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Wei LW, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01331 2
   Wu HT, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153437
   Xing N, 2020, PHYTOMEDICINE, V78, DOI 10.1016/j.phymed.2020.153288
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.975181
   Yang Y, 2022, J ETHNOPHARMACOL, V285, DOI 10.1016/j.jep.2021.114834
   Zeytinoglu M, 2021, ENDOCRIN METAB CLIN, V50, P205, DOI 10.1016/j.ecl.2021.03.004
   Zhai ZQ, 2022, ARTHRITIS RHEUMATOL, V74, P427, DOI 10.1002/art.41963
   Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586 020 2071 9
   Zhao FJ, 2021, AGING US, V13, P6945, DOI 10.18632/aging.202552
   Zheng L, 2021, CURR PHARM BIOTECHNO, V22, P1538, DOI 10.2174/1389201021666201216150442
   Zhou SY, 2020, EUR J MED CHEM, V197, DOI 10.1016/j.ejmech.2020.112313
   Zhu TT, 2022, CURR DRUG METAB, V23, P1130, DOI 10.2174/1389200224666230130093412
   Zhu XB, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.03.40
NR 74
TC 24
Z9 27
U1 25
U2 57
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUN
PY 2024
VL 128
AR 155516
DI 10.1016/j.phymed.2024.155516
EA MAR 2024
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA RF7R0
UT WOS:001226322500001
PM 38547625
OA hybrid
DA 2025 08 17
ER

PT J
AU Lipton, A
AF Lipton, Allan
TI Bone Continuum of Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY CANCER CLINICAL TRIALS
LA English
DT Article
DE bone metastases; skeletal complications; bisphosphonates
ID ANDROGEN DEPRIVATION THERAPY; MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA;
   OSTEOCLASTOGENESIS INHIBITORY FACTOR; SKELETAL RELATED EVENTS; MARROW
   STROMAL CELLS; EARLY BREAST CANCER; LEAN BODY MASS; 1ST 2 YEARS;
   PROSTATE CANCER; MINERAL DENSITY
AB Many patients with solid tumors, especially breast and prostate cancers, and with multiple myeloma will develop bone metastases or other skeletal complications. The management of bone loss and symptomatic bone metastases is an important issue in the care and maintenance of quality of life for these patients. Morbidity caused by skeletal complications include pain (bone metastases are known as the most common cause of cancer related pain), hypercalcemia, pathologic fracture, compression of the spinal cord or cauda equine, and spinal instability. Currently, the only Food and Drug Administration approved therapy for metastatic bone disease is bisphosphonate therapy. A greater understanding of the biomolecular pathways that govern the bone continuum of cancer has helped identify novel targets for drug development. New therapeutic options are currently being investigated for the treatments of bone loss and symptomatic bone metastases. Some of these new drugs and modalities are in advanced stages of clinical development and may soon reach the clinic.
C1 Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med & Oncol, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Lipton, A (通讯作者)，Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med & Oncol, 500 Univ Dr,H046,POB 850, Hershey, PA 17033 USA.
EM alipton@hmc.psu.edu
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Abrahamsen B, 2007, BJU INT, V100, P749, DOI 10.1111/j.1464 410X.2007.07163.x
   Ahlborg HG, 2008, BONE, V43, P556, DOI 10.1016/j.bone.2008.05.003
   [Anonymous], NCCN CLIN PRACT GUID
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berruti A, 2005, BRIT J CANCER, V93, P633, DOI 10.1038/sj.bjc.6602767
   Berruti A, 2002, J UROLOGY, V167, P2361, DOI 10.1016/S0022 5347(05)64985 3
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brufsky AM, 2008, ONCOLOGIST, V13, P187, DOI 10.1634/theoncologist.2007 0152
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   BRUNING PF, 1990, BRIT J CANCER, V61, P308, DOI 10.1038/bjc.1990.58
   Bundred NJ, 2009, CURR OPIN OBSTET GYN, V21, P60, DOI 10.1097/GCO.0b013e32831da80e
   Carducci MA, 2006, CLIN CANCER RES, V12, p6296S, DOI 10.1158/1078 0432.CCR 06 0929
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   Delea Thomas, 2006, J Support Oncol, V4, P341
   Diamond T, 1998, CANCER, V83, P1561, DOI 10.1002/(SICI)1097 0142(19981015)83:8<1561::AID CNCR11>3.0.CO;2 Z
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Erkkola R, 2005, BREAST CANCER RES TR, V93, P277, DOI 10.1007/s10549 005 5701 x
   Fogelman I, 2003, OSTEOPOROSIS INT, V14, P1001, DOI 10.1007/s00198 003 1508 y
   Folkestad L, 2009, BASIC CLIN PHARMACOL, V104, P3, DOI 10.1111/j.1742 7843.2008.00337.x
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hadji P, 2009, ANN ONCOL, V20, P1203, DOI 10.1093/annonc/mdn762
   Hadji P, 2009, BREAST, V18, P159, DOI 10.1016/j.breast.2009.03.003
   Hadji P, 2009, CRIT REV ONCOL HEMAT, V69, P73, DOI 10.1016/j.critrevonc.2008.07.013
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365 2141.2004.04864.x
   Higano CS, 2008, NAT CLIN PRACT UROL, V5, P24, DOI 10.1038/ncpuro0995
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones S, 2008, CLIN BREAST CANCER, V8, P527, DOI 10.3816/CBC.2008.n.065
   Karadag A, 2000, BRIT J HAEMATOL, V108, P383
   Katzel JA, 2007, CA CANCER J CLIN, V57, P301, DOI 10.3322/CA.57.5.301
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Krupski TL, 2007, J UROLOGY, V178, P1423, DOI 10.1016/j.juro.2007.05.135
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lage MJ, 2008, AM J MANAG CARE, V14, P317
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Levy ME, 2008, UROLOGY, V71, P735, DOI 10.1016/j.urology.2007.09.018
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   López AM, 2005, OSTEOPOROSIS INT, V16, P707, DOI 10.1007/s00198 004 1799 7
   Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood 2002 11 3385
   Maillefert JF, 1999, J UROLOGY, V161, P1219, DOI 10.1016/S0022 5347(01)61639 2
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Michaelson MD, 2008, CA CANCER J CLIN, V58, P196, DOI 10.3322/CA.2008.0002
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mincey BA, 2006, CLIN BREAST CANCER, V7, P127, DOI 10.3816/CBC.2006.n.021
   Mincey Betty A, 2004, Support Cancer Ther, V1, P150, DOI 10.3816/SCT.2004.n.006
   Morote J, 2006, J UROLOGY, V175, P1679, DOI 10.1016/S0022 5347(05)00999 7
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   National Comprehensive Cancer Network, 2010, NCCN PRACT GUID ONC
   O'Brien EA, 2000, BIOCHEM BIOPH RES CO, V274, P281, DOI 10.1006/bbrc.2000.3129
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Rodan GA, 2003, CANCER, V97, P726, DOI 10.1002/cncr.11147
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Saad F, 2008, J CLIN ONCOL, V26, P5465, DOI 10.1200/JCO.2008.18.4184
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Sati HIA, 1998, BRIT J HAEMATOL, V101, P287, DOI 10.1046/j.1365 2141.1998.00687.x
   Satoh T, 2009, CANCER AM CANCER SOC, V115, P3468, DOI 10.1002/cncr.24404
   Schulman KL, 2007, CANCER AM CANCER SOC, V109, P2334, DOI 10.1002/cncr.22678
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   Simmons Christine, 2007, Support Cancer Ther, V4, P182, DOI 10.3816/SCT.2007.n.013
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith MR, 2008, J UROLOGY, V179, P152, DOI 10.1016/j.juro.2007.08.137
   Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071
   Smith MR, 2006, J UROLOGY, V175, P136, DOI 10.1016/S0022 5347(05)00033 9
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2002, J CLIN ENDOCR METAB, V87, P599, DOI 10.1210/jc.87.2.599
   Smith MR, 2004, UROLOGY, V63, P742, DOI 10.1016/j.urology.2003.10.063
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2003, BRIT J HAEMATOL, V123, P106, DOI 10.1046/j.1365 2141.2003.04561.x
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   Tu SM, 2008, CANCER J, V14, P35, DOI 10.1097/PPO.0b013e318161d32d
   Vehmanen L, 2001, EUR J CANCER, V37, P2373, DOI 10.1016/S0959 8049(01)00317 3
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yeh HS, 2006, CLIN CANCER RES, V12, p6279S, DOI 10.1158/1078 0432.CCR 06 0681
NR 105
TC 8
Z9 9
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277 3732
EI 1537 453X
J9 AM J CLIN ONCOL CANC
JI Am. J. Clin. Oncol. Cancer Clin. Trials
PD JUN
PY 2010
VL 33
SU 3
BP S1
EP S7
DI 10.1097/COC.0b013e3181deb9e5
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 606DL
UT WOS:000278401800001
PM 20526089
DA 2025 08 17
ER

PT J
AU Wasnik, S
   Lakhan, R
   Baylink, DJ
   Rundle, CH
   Xu, Y
   Zhang, JT
   Qin, XZ
   Lau, KHW
   Carreon, EE
   Tang, XL
AF Wasnik, Samiksha
   Lakhan, Ram
   Baylink, David J.
   Rundle, Charles H.
   Xu, Yi
   Zhang, Jintao
   Qin, Xuezhong
   Lau, Kin Hing William
   Carreon, Edmundo E.
   Tang, Xiaolei
TI Cyclooxygenase 2 augments osteoblastic but suppresses chondrocytic
   differentiation of CD90<SUP>+</SUP> skeletal stem cells in fracture
   sites
SO SCIENCE ADVANCES
LA English
DT Article
ID GENE THERAPY; RECEPTOR SUBTYPE; BONE; COX 2; MICE; IDENTIFICATION;
   EXPRESSION; INITIATION; PROMOTES; LUNG
AB Cyclooxygenase 2 (COX 2) is essential for normal tissue repair. Although COX 2 is known to enhance the differentiation of mesenchymal stem cells (MSCs), how COX 2 regulates MSC differentiation into different tissue specific progenitors to promote tissue repair remains unknown. Because it has been shown that COX 2 is critical for normal bone repair and local COX 2 overexpression in fracture sites accelerates fracture repair, this study aimed to determine the MSC subsets that are targeted by COX 2. We showed that CD90(+) mouse skeletal stem cells (mSSCs; i.e., CD45( )Tie2( )AlphaV(+) MSCs) were selectively recruited by macrophage/monocyte chemoattractant protein 1 into fracture sites following local COX 2 overexpression. In addition, local COX 2 overexpression augmented osteoblast differentiation and suppressed chondrocyte differentiation in CD90(+) mSSCs, which depended on canonical WNT signaling. CD90 depletion data demonstrated that local COX 2 overexpression targeted CD90(+) mSSCs to accelerate fracture repair. In conclusion, CD90(+) mSSCs are promising targets for the acceleration of bone repair.
C1 [Wasnik, Samiksha; Lakhan, Ram; Baylink, David J.; Xu, Yi; Zhang, Jintao; Qin, Xuezhong; Lau, Kin Hing William; Carreon, Edmundo E.; Tang, Xiaolei] Loma Linda Univ, Dept Med, Div Regenerat Med, Loma Linda, CA 92350 USA.
   [Rundle, Charles H.; Qin, Xuezhong; Lau, Kin Hing William] Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA USA.
   [Zhang, Jintao] Zhengzhou Univ, Inst Med & Pharmaceut Sci, Zhengzhou, Henan, Peoples R China.
C3 Loma Linda University; Zhengzhou University
RP Tang, XL (通讯作者)，Loma Linda Univ, Dept Med, Div Regenerat Med, Loma Linda, CA 92350 USA.
EM xitang@Ilu.edu
RI Wasnik, Samiksha/I 1063 2019; Tang, Xiaolei/AAT 7669 2021
OI Wasnik, Samiksha/0000 0001 6097 0517; Lakhan, Ram/0000 0002 2700 6272;
   Lau, Kin Hing/0000 0003 1109 5052; Tang, Xiaolei/0000 0003 1492 9622
FU Telemedicine and Advanced Technology Research Center (TATRC) at the
   USAMRMC [W81XWH 12 1 0023]
FX This work was supported by the Telemedicine and Advanced Technology
   Research Center (TATRC) at the USAMRMC under grant no. W81XWH 12 1 0023
   (to D.J.B.). The views, opinions and/or findings contained in this
   report are those of the authors and should not be construed as an
   official Department of the Army position, policy, or decision unless so
   designated by other documentation.
CR Aleem IS, 2016, SCI REP UK, V6, DOI 10.1038/srep31724
   Antonova E, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 42
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chan CKF, 2013, P NATL ACAD SCI USA, V110, P12643, DOI 10.1073/pnas.1310212110
   Chen WQ, 2015, P NATL ACAD SCI USA, V112, pE3893, DOI 10.1073/pnas.1501759112
   Downey J, 2015, BONE, V71, P164, DOI 10.1016/j.bone.2014.10.020
   Eastaugh Waring SJ, 2009, CLIN ORTHOP RELAT R, V467, P1986, DOI 10.1007/s11999 009 0775 0
   Fredenburgh LE, 2011, J IMMUNOL, V187, P5255, DOI 10.4049/jimmunol.1101186
   Gao XQ, 2016, HUM MOL GENET, V25, P3216, DOI 10.1093/hmg/ddw172
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Ishikawa M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104954
   Kamoshita E, 2006, AM J PATHOL, V169, P1458, DOI 10.2353/ajpath.2006.051358
   Kara EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9644
   Kim YK, 2016, STEM CELL TRANSL MED, V5, P227, DOI 10.5966/sctm.2015 0013
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lakhan R, 2015, GENE THER, V22, P721, DOI 10.1038/gt.2015.40
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Liou JY, 2007, STEM CELLS, V25, P1096, DOI 10.1634/stemcells.2006 0505
   Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1038/ni.2131, 10.1031/ni.2131]
   Morshed Saam, 2014, Adv Med, V2014, P708574, DOI 10.1155/2014/708574
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Pang LY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2048731
   Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Sheng MHC, 2009, J BIOL CHEM, V284, P11531, DOI 10.1074/jbc.M808324200
   Tian J, 2017, SCI REP UK, V7, DOI 10.1038/srep40258
   Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001
   Wang MD, 2018, BIOCONJUGATE CHEM, V29, P3800, DOI 10.1021/acs.bioconjchem.8b00660
   Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Zhang MJ, 2011, J BONE MINER RES, V26, P792, DOI 10.1002/jbmr.272
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhang Y, 2016, BIOCHEM BIOPH RES CO, V480, P101, DOI 10.1016/j.bbrc.2016.09.163
   Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340
NR 39
TC 23
Z9 24
U1 1
U2 17
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD JUL
PY 2019
VL 5
IS 7
AR eaaw2108
DI 10.1126/sciadv.aaw2108
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IN6EO
UT WOS:000478770400058
PM 31392271
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Marino, S
   Hannemann, N
   Bishop, RT
   Zeng, FE
   Carrasco, G
   Meurisse, S
   Li, BY
   Sophocleous, A
   Sparatore, A
   Baeuerle, T
   Vukicevic, S
   Auberval, M
   Mollat, P
   Bozec, A
   Idris, AI
AF Marino, Silvia
   Hannemann, Nicole
   Bishop, Ryan T.
   Zeng, Feier
   Carrasco, Giovana
   Meurisse, Sandrine
   Li, Boya
   Sophocleous, Antonia
   Sparatore, Anna
   Baeuerle, Tobias
   Vukicevic, Slobodan
   Auberval, Marielle
   Mollat, Patrick
   Bozec, Aline
   Idris, Aymen I.
TI Anti inflammatory, but not osteoprotective, effect of the TRAF6/CD40
   inhibitor 6877002 in rodent models of local and systemic osteolysis
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE NF kappa B; TNF alpha; T cell; Osteoclast; Ovariectomy; Inflammation
ID NF KAPPA B; DEFECTIVE INTERLEUKIN 1; TNF; RECEPTOR; CD40; KINASE; RANK;
   ERK; OSTEOPETROSIS; PATHWAY
AB NF kappa B plays a key role in inflammation and skeletal disorders. Previously, we reported that pharmacological inhibition of NF kappa B at the level of TRAF6 suppressed RANKL, CD40L and IL1 beta induced osteoclastogenesis and attenuated cancer induced bone disease. TNF alpha is also known to regulate TRAF6/NF kappa B signalling, however the anti inflammatory and osteoprotective effects associated with inhibition of the TNF alpha/TRAF6/NF kappa B axis have not been investigated. Here, we show that in vitro and ex vivo exposure to the verified small molecule inhibitor of TRAF6, 6877002 prevented TNF alpha induced NF kappa B activation, osteoclastogenesis and calvarial osteolysis, but it had no effects on TNF alpha induced apoptosis or growth inhibition in osteoblasts. Additionally, 6877002 disrupted T cells support for osteoclast formation and synoviocyte motility, without affecting the viability of osteoblasts in the presence of T cells derived factors. Using the collagen induced arthritis model, we show that oral and intraperitoneal administration of 6877002 in mice reduced joint inflammation and arthritis score. Unexpectedly, no difference in trabecular and cortical bone parameters were detected between vehicle and 6877002 treated mice, indicating lack of osteoprotection by 6877002 in the arthritis model described. Using two independent rodent models of osteolysis, we confirmed that 6877002 had no effect on trabecular and cortical bone loss in both osteoporotic rats or RANKL treated mice. In contrast, the classic anti osteolytic alendronate offered complete osteoprotection in RANKL treated mice. In conclusion, TRAF6 inhibitors may be of value in the management of the inflammatory component of bone disorders, but may not offer protection against local or systemic bone loss, unless combined with anti resorptive therapy such as bisphosphonates.
C1 [Marino, Silvia; Bishop, Ryan T.; Zeng, Feier; Carrasco, Giovana; Li, Boya; Idris, Aymen I.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, England.
   [Marino, Silvia; Idris, Aymen I.] Univ Edinburgh, MRC Inst Genet & Mol Med, Edinburgh Canc Res Ctr, Bone & Canc Grp, Edinburgh, Scotland.
   [Hannemann, Nicole; Bozec, Aline] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.
   [Meurisse, Sandrine; Auberval, Marielle; Mollat, Patrick] Galapagos SASU, 102 Ave Gaston Roussel, F 93230 Romainville, France.
   [Sophocleous, Antonia] European Univ Cyprus, Sch Sci, Dept Life Sci, 6 Diogenes St, CY 1516 Nicosia, Cyprus.
   [Sparatore, Anna] Univ Milan, Dept Pharmaceut Sci, Milan, Italy.
   [Baeuerle, Tobias] Friedrich Alexander Univ Erlangen Nurnberg & Univ, Inst Radiol, Erlangen, Germany.
   [Baeuerle, Tobias] Univ klinikum, Erlangen, Germany.
   [Vukicevic, Slobodan] Univ Zagreb, Med Sch, Dept Anat, Zagreb, Croatia.
C3 University of Sheffield; University of Edinburgh; University of Erlangen
   Nuremberg; Galapagos NV; European University Cyprus; University of
   Milan; University of Erlangen Nuremberg; University of Zagreb
RP Idris, AI (通讯作者)，Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, England.
EM aymen.idris@sheffield.ac.uk
RI Baeuerle, Tobias/LSL 3005 2024; Idris, Aymen/AAX 1138 2020; Vukicevic,
   Slobodan/AEG 2646 2022; Sparatore, Anna/J 8634 2015
OI Zeng, Feier/0000 0001 9235 0750; Sparatore, Anna/0000 0003 2135 2649
CR Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bishop RT, 2020, CANCER LETT, V488, P27, DOI 10.1016/j.canlet.2020.05.021
   Buch MH, 2021, NAT REV RHEUMATOL, V17, P17, DOI 10.1038/s41584 020 00541 7
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   D'Amico Lucia, 2012, Bonekey Rep, V1, P82, DOI 10.1038/bonekey.2012.82
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Davies CC, 2005, MOL CELL BIOL, V25, P9806, DOI 10.1128/MCB.25.22.9806 9819.2005
   de Launay D, 2012, ANN RHEUM DIS, V71, P415, DOI 10.1136/ard.2010.143529
   Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Funakoshi Tago M, 2009, CYTOKINE, V45, P72, DOI 10.1016/j.cyto.2008.10.010
   Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134
   Grötsch B, 2019, METHODS MOL BIOL, V1914, P269, DOI 10.1007/978 1 4939 8997 3_14
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365 2443.2005.00852.x
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Li JY, 2013, BLOOD, V122, P2346, DOI 10.1182/blood 2013 03 487801
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Marino S., 2019, METHODS MOL BIOL, V71, P98
   Marino S., 2019, METHODS MOL BIOL, V131, P143
   Marino S., 2016, BONE, V1, DOI [10.1530/ boneabs.5.OC4.1, DOI 10.1530/BONEABS.5.OC4.1]
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022 1759(97)00043 4
   ODOHERTY DP, 1992, J BONE MINER RES, V7, P81
   Okazaki Y, 2005, J RHEUMATOL, V32, P1440
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Perpetuo I.P., 2019, METHODS MOL BIOL, V21, P38
   Pullen SS, 1999, BIOCHEMISTRY US, V38, P10168, DOI 10.1021/bi9909905
   Rucci N., 2019, METHODS MOL BIOL, V3, P19
   Schett G, 2008, ANN RHEUM DIS, V67, P909, DOI 10.1136/ard.2007.074278
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016
   Seijkens TTP, 2018, J AM COLL CARDIOL, V71, P527, DOI 10.1016/j.jacc.2017.11.055
   Sophocleous A., 2019, METHODS MOL BIOL, V261, P267
   Tewari R, 2012, MOL BIOL REP, V39, P8695, DOI 10.1007/s11033 012 1726 5
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   van 't Hof RJ, 2019, METHODS MOL BIOL, V1914, P507, DOI 10.1007/978 1 4939 8997 3_28
   Vilcek J, 2004, TRENDS PHARMACOL SCI, V25, P201, DOI 10.1016/j.tips.2004.02.011
   WOLFE F, 1995, BAILLIERE CLIN RHEUM, V9, P619, DOI 10.1016/S0950 3579(05)80305 X
   Zarzycka B, 2015, J CHEM INF MODEL, V55, P294, DOI 10.1021/ci500631e
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 48
TC 4
Z9 4
U1 0
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JAN
PY 2022
VL 195
AR 114869
DI 10.1016/j.bcp.2021.114869
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0F3OE
UT WOS:000777271600006
PM 34896056
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bradley, DA
   Hussain, M
   DiPaola, RS
   Kantoff, P
AF Bradley, Deborah A.
   Hussain, Maha
   DiPaola, Robert S.
   Kantoff, Philip
TI Bone directed therapies for prostate cancer
SO JOURNAL OF UROLOGY
LA English
DT Article; Proceedings Paper
CT 6th Cambridge Conference on Innovations and Challenges in Prostate
   Cancer
CY OCT 30 31, 2006
CL Cambridge, MA
DE prostate; prostatic neoplasms; bone and bones; neoplasm metastasis
ID FUNCTIONAL DIFFUSION MAP; PLACEBO CONTROLLED TRIAL; PHASE II TRIAL;
   ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; NATURAL HISTORY; MINERAL
   DENSITY; METASTASES; PROGRESSION; MEN
AB Purpose: Bone is the most common site of metastatic disease in prostate cancer and the lead cause of significant morbidity. Preclinical and clinical studies have provided insight into the pathophysiology of bone metastases and the changes that occur in the bone microenvironment that result in a favorable site of growth for prostate cancer. We provide an overview of recent advances in understanding bone biology, and bone targeted therapy research and development.
   Materials and Methods: We reviewed recent research findings related to the biology of bone metastases, approaches to targeting osteoclast function, approaches to targeting osteoblasts and advances in assessing the treatment response to bone targeted therapies in the context of prostate cancer management.
   Results: To date targeting some of the key players in the bone microenvironment has not been associated with a significant antitumor effect or with meaningful clinical benefit in phase III randomized trials. A significant limitation in the development of bone targeted therapy has been the inability to objectively assess treatment response. Investigation of improved imaging techniques are ongoing to provide better treatment assessment and, therefore, allow more rapid drug screening and development.
   Conclusions: It is our recommendation that future therapy development should be combination based, focusing on simultaneous targeting of multiple relevant pathways. Most important of all is the direct targeting of prostate cancer cells.
C1 Univ Michigan, Med Ctr, Div Hematol & Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA.
   Canc Inst New Jersey, New Brunswick, NJ USA.
   Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
C3 University of Michigan System; University of Michigan; Rutgers
   University System; Rutgers University New Brunswick; Rutgers University
   Biomedical & Health Sciences; Rutgers Cancer Institute of New Jersey;
   Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute
RP Hussain, M (通讯作者)，Univ Michigan, Med Ctr, Div Hematol & Oncol, Dept Internal Med, 7314 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM mahahuss@umich.edu
OI Kantoff, Philip/0000 0001 7275 0597
FU National Cancer Institute [T32CA009357] Funding Source: NIH RePORTER;
   NCI NIH HHS [T32CA009357] Funding Source: Medline
CR Beekman KW, 2006, CLIN GENITOURIN CANC, V4, P299, DOI 10.3816/CGC.2006.n.012
   Berruti A, 1996, BRIT J CANCER, V73, P1581, DOI 10.1038/bjc.1996.298
   Boyce BF, 1999, LAB INVEST, V79, P83
   BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092 8674(94)90007 8
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   CARDUCCI M, 2004, J CLIN ONCOL, V22, P4508
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   DRESNERPOLLAK R, 1994, J CELL BIOCHEM, V56, P323, DOI 10.1002/jcb.240560308
   Goblirsch M, 2004, RADIAT RES, V161, P228, DOI 10.1667/RR3108
   Gohji K, 2001, J UROLOGY, V165, P1033, DOI 10.1016/S0022 5347(05)66597 4
   Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555 006 9022 2
   Hamdy Neveen A T, 2006, Curr Rheumatol Rep, V8, P50
   Hamstra DA, 2005, P NATL ACAD SCI USA, V102, P16759, DOI 10.1073/pnas.0508347102
   Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008 5472.CAN 04 2251
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Karsenty G, 2000, MATRIX BIOL, V19, P85, DOI 10.1016/S0945 053X(00)00053 6
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kostenuik P. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P375
   Lara PN, 2006, CLIN CANCER RES, V12, P1556, DOI 10.1158/1078 0432.CCR 05 2074
   Lipton A, 2004, J CLIN ONCOL, V22, p428S
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   Mason MD, 2004, J CLIN ONCOL, V22, p384S
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Metcalf CA, 2002, CURR PHARM DESIGN, V8, P2049, DOI 10.2174/1381612023393323
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Moffat BA, 2005, P NATL ACAD SCI USA, V102, P5524, DOI 10.1073/pnas.0501532102
   Mundy GR, 2003, P NATL ACAD SCI USA, V100, P10588, DOI 10.1073/pnas.2035063100
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756 3282(00)80937 0
   Pectasides D, 2005, ANTICANCER RES, V25, P1457
   PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pidgeon GP, 2003, CANCER RES, V63, P4258
   Pirtskhalaishvili G, 2000, PROSTATE, V44, P77
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   Quinn JE, 2005, PROSTATE CANCER P D, V8, P253, DOI 10.1038/sj.pcan.4500815
   RANCESCHI RT, 1999, CRIT REV ORAL BIOL M, V10, P40
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2006, CLIN GENITOURIN CANC, V4, P257, DOI 10.3816/CGC.2006.n.004
   Saad F, 2006, HEMATOL ONCOL CLIN N, V20, P947, DOI 10.1016/j.hoc.2006.03.011
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Shakespeare W, 2000, P NATL ACAD SCI USA, V97, P9373, DOI 10.1073/pnas.97.17.9373
   Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729
   SLEEP DJ, 2006, J CLIN ONCOL, V24, P4630
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Teitelbaum SL, 2006, ANN NY ACAD SCI, V1068, P95, DOI 10.1196/annals.1346.017
   Thakkar Snehal G, 2006, Curr Oncol Rep, V8, P108, DOI 10.1007/s11912 006 0045 1
   Tu SM, 2005, J CLIN ONCOL, V23, P7904, DOI 10.1200/JCO.2005.01.2310
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Vinholes J, 1996, CANCER TREAT REV, V22, P289, DOI 10.1016/S0305 7372(96)90021 3
   VOGELZANG NJ, 2005, J CLIN ONCOL, V23, P4563
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 71
TC 6
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0022 5347
EI 1527 3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2007
VL 178
IS 3
BP S42
EP S48
DI 10.1016/j.juro.2007.04.035
PN 2
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Urology & Nephrology
GA 200VH
UT WOS:000248790400008
PM 17644119
DA 2025 08 17
ER

PT J
AU Reed, M
   Baker, RJ
   Mehta, AB
   Hughes, DA
AF Reed, M.
   Baker, R. J.
   Mehta, A. B.
   Hughes, D. A.
TI Enhanced differentiation of osteoclasts from mononuclear precursors in
   patients with Gaucher disease
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE Gaucher; Osteoclast; Bone; Enzyme
ID ENZYME REPLACEMENT THERAPY; COLONY STIMULATING FACTOR; IN VITRO MODEL;
   BONE DISEASE; PAGETS DISEASE; TNF ALPHA; MACROPHAGE; IMIGLUCERASE;
   DENSITY; PATHOGENESIS
AB Gaucher disease (GD) is an autosomal recessive disorder caused by deficiency of beta glucocerebrosidase. Storage of glucosylceramide in reticuloendothelial cells results in multiorgan pathology including bone disease. Established skeletal disease may remain problematic despite Gaucher specific treatment. Both osteopenia and osteonecrosis have been described but the underlying pathophysiology, in particular the role of monocyte derived osteoclasts is not well defined. The objective of this study was to explore the effect of glucocerebrosidase deficiency, inhibition and replacement on osteoclast development and function.
   In cultures derived from GD patients, or where GBA was chemically inhibited multinucleate giant cells expressing markers of osteoclast differentiation occurred earlier and in greater numbers compared to normal controls and the functional capacity of osteoclasts for bone resorption was enhanced. Increases in osteoclast number and activity correlated with radiological markers of active bone disease. Abnormalities were reversed by addition of specific therapies and were attenuated by co culture with cells derived from healthy controls (HCs). Numbers of osteoblast lineage cells in the peripheral blood were mismatched to osteoclast precursors indicating uncoupling of osteoblast osteoclast regulation which may further impact on bone remodelling. Elucidation of the underlying mechanisms of these changes will suggest rational therapies for the most disabling aspect of this condition. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Hughes, D. A.] Royal Free Hosp, Dept Haematol, Lysosomal Storage Disorders Unit, London NW3 2QG, England.
   UCL, London NW3 2QG, England.
C3 University of London; University College London; Royal Free London NHS
   Foundation Trust; UCL Medical School; University of London; University
   College London
RP Hughes, DA (通讯作者)，Royal Free Hosp, Dept Haematol, Lysosomal Storage Disorders Unit, Pond St, London NW3 2QG, England.
EM rmgvdah@ucl.ac.uk
RI hughes, derralynn/J 8012 2013
OI hughes, derralynn/0000 0003 4531 9173
FU Gaucher Association; Shire HGT; Genzyme, Inc.; Actelion Pharmaceuticals;
   Special Trustees of the Royal Free Hospital
FX The authors acknowledge the cooperation of our patients and their
   families and the support of the Gaucher Association. We thank Shire HGT,
   Genzyme, Inc., Actelion Pharmaceuticals and Special Trustees of the
   Royal Free Hospital for research support. We also thank our specialist
   nurses for assistance with phlebotomy for the project.
CR Allen MJ, 1997, QJM MON J ASSOC PHYS, V90, P19
   Barak V, 1999, EUR CYTOKINE NETW, V10, P205
   Boven LA, 2004, AM J CLIN PATHOL, V122, P359, DOI 10.1309/BG5VA8JRDQH1M7HN
   Brady R O, 1982, Prog Clin Biol Res, V95, P309
   Butters TD, 2005, GLYCOBIOLOGY, V15, pR43, DOI 10.1093/glycob/cwi076
   Charrow J, 2000, ARCH INTERN MED, V160, P2835, DOI 10.1001/archinte.160.18.2835
   Ciana G, 2005, J INHERIT METAB DIS, V28, P723, DOI 10.1007/s10545 005 0032 y
   Cornish J, 2008, ENDOCRINOLOGY, V149, P5688, DOI 10.1210/en.2008 0111
   Cox TM, 1997, BAILLIERE CLIN HAEM, V10, P657, DOI 10.1016/S0950 3536(97)80033 9
   Drugan C, 2002, BLOOD CELL MOL DIS, V28, P13, DOI 10.1006/bcmd.2001.0479
   GERY I, 1981, J CLIN INVEST, V68, P1182, DOI 10.1172/JCI110363
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Hollak CEM, 1997, BLOOD CELL MOL DIS, V23, P201, DOI 10.1006/bcmd.1997.0137
   Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200
   JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   Khan A, 2012, J BONE MINER RES, V27, P1839, DOI 10.1002/jbmr.1680
   Lacerda L, 1999, BLOOD CELL MOL DIS, V25, P130, DOI 10.1006/bcmd.1999.0237
   Lebel E, 2004, J BONE MINER METAB, V22, P597, DOI 10.1007/s00774 004 0529 8
   Lecourt S, 2012, STEM CELLS DEV, V21, P239, DOI 10.1089/scd.2011.0365
   Lees RL, 1999, J BONE MINER RES, V14, P937, DOI 10.1359/jbmr.1999.14.6.937
   Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood 2010 03 273151
   Magal I, 2006, BRIT J HAEMATOL, V133, P93, DOI 10.1111/j.1365 2141.2006.05978.x
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   McEachern KA, 2007, MOL GENET METAB, V91, P259, DOI 10.1016/j.ymgme.2007.04.001
   Mikosch P, 2008, CALCIFIED TISSUE INT, V83, P43, DOI 10.1007/s00223 008 9143 4
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mistry PK, 2011, BLOOD CELL MOL DIS, V46, P66, DOI 10.1016/j.bcmd.2010.10.011
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Moran MT, 2000, BLOOD, V96, P1969, DOI 10.1182/blood.V96.5.1969.h8001969_1969_1978
   Mucci JM, 2012, GENE, V509, P51, DOI 10.1016/j.gene.2012.07.071
   Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756 3282(00)00345 8
   OSTLERE L, 1991, Q J MED, V79, P503
   Pastores G M, 2000, Curr Rheumatol Rep, V2, P175, DOI 10.1007/s11926 000 0059 x
   Pastores GM, 2005, CURR OPIN RHEUMATOL, V17, P70, DOI 10.1097/01.bor.0000147283.40529.13
   Pastores GM, 1996, J BONE MINER RES, V11, P1801
   Pastores GM, 2007, CLIN THER, V29, P1645, DOI 10.1016/j.clinthera.2007.08.006
   Ralston SH, 2008, BONE, V43, P819, DOI 10.1016/j.bone.2008.06.015
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Schiffmann R, 2002, BLOOD CELL MOL DIS, V28, P288, DOI 10.1006/bcmd.2002.0517
   Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232 JLR200
   Sims KB, 2008, CLIN GENET, V73, P430, DOI 10.1111/j.1399 0004.2008.00978.x
   STOWENS DW, 1985, MEDICINE, V64, P310, DOI 10.1097/00005792 198509000 00003
   van Breemen MJ, 2007, BBA MOL BASIS DIS, V1772, P788, DOI 10.1016/j.bbadis.2007.04.002
   van Dussen L, 2011, J CLIN ENDOCR METAB, V96, P2194, DOI 10.1210/jc.2011 0162
   Weicht B, 2007, J CELL BIOCHEM, V102, P1300, DOI 10.1002/jcb.21360
   Weinreb NJ, 2002, AM J MED, V113, P112, DOI 10.1016/S0002 9343(02)01150 6
   Wenstrup RJ, 2007, J BONE MINER RES, V22, P119, DOI 10.1359/JBMR.061004
   Wenstrup RJ, 2002, BRIT J RADIOL, V75, pA2, DOI 10.1259/bjr.75.suppl_1.750002
   ZIMRAN A, 1995, LANCET, V345, P1479, DOI 10.1016/S0140 6736(95)91038 7
NR 51
TC 31
Z9 33
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1079 9796
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD OCT
PY 2013
VL 51
IS 3
BP 185
EP 194
DI 10.1016/j.bcmd.2013.04.006
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 198SO
UT WOS:000322942800011
PM 23707505
DA 2025 08 17
ER

PT J
AU Bahia, MT
   Hecke, MB
   Mercuri, EGF
   Pinheiro, MM
AF Bahia, M. T.
   Hecke, M. B.
   Mercuri, E. G. F.
   Pinheiro, M. M.
TI A bone remodeling model governed by cellular micromechanics and
   physiologically based pharmacokinetics
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Bone cell dynamics; Physiologically based pharmacokinetics (PBPK);
   Continuum michomechanics; Osteoporosis; Mathematical modeling
ID HUMAN PROXIMAL FEMUR; TRABECULAR BONE; MINERAL DENSITY;
   MECHANICAL PROPERTIES; POSTMENOPAUSAL WOMEN; MATHEMATICAL MODEL; SEEKING
   ELEMENTS; CORTICAL BONE; OSTEOPOROSIS; ALENDRONATE
AB This study describes a mathematical model for bone remodeling that integrates the bone cells activities with the pharmacological dynamics for bone seeking agents. The evolution of bone cells population involves the osteoblast osteoclast signaling mediated by biochemical factors and receives both mechanical stimulus evaluated at the microscale and pharmacological regulation. A physiologically based pharmacokinetic model (PBPK) for bone seeking agents was developed to provide the drug concentration on bone sites and feed the remodeling algorithm. The drug effect on bone was reproduced coupling three different strategies: modification of the RANKL expression, increase the osteoclast apoptosis and change in the rate of differentiation of preosteoblasts. Computational simulations were performed in the PBPK model considering different dosing regimens. A 3D finite element model of a proximal femur was generated and the simulation of the bone remodeling algorithm were implemented in Matlab. The results indicate that the proposed integrated model is able to capture adequately the expected adaptive behavior of bone subjected to mechanical and pharmacological stimulus. The model demonstrated to have potential for use as a platform to investigate therapies and may help in the study of new drugs for bone diseases.
C1 [Bahia, M. T.] Inst Fed Santa Catarina, Dept Mecan, Rua Pavao 1377, BR 89220618 Joinville, Brazil.
   [Bahia, M. T.; Hecke, M. B.; Mercuri, E. G. F.] Univ Fed Parana, Programa Posgrad Metodos Numer Engn, Grp Bioengn, Curitiba, Parana, Brazil.
   [Mercuri, E. G. F.] Univ Fed Parana, Dept Engn Ambiental, Curitiba, Parana, Brazil.
   [Pinheiro, M. M.] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
C3 Instituto Federal de Santa Catarina (IFSC); Universidade Federal do
   Parana; Universidade Federal do Parana; Universidade Federal de Sao
   Paulo (UNIFESP)
RP Bahia, MT (通讯作者)，Inst Fed Santa Catarina, Dept Mecan, Rua Pavao 1377, BR 89220618 Joinville, Brazil.
EM migueltbahia@gmail.com
RI Mercuri, Emílio/C 7236 2015; Mercuri, Emilio/C 7236 2015
OI Mercuri, Emilio/0000 0003 3101 7537; Bahia, Miguel/0000 0002 0218 075X
CR [Anonymous], [No title captured]
   [Anonymous], 1975, REPORT TASK GROUP RE, pxix
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], 2011, VERTEBRAL FRACTURE 1
   [Anonymous], [No title captured]
   Araújo Denizar Vianna, 2005, Arq Bras Endocrinol Metab, V49, P897, DOI 10.1590/S0004 27302005000600007
   Bahia MT, 2019, MED ENG PHYS, V69, P58, DOI 10.1016/j.medengphy.2019.05.005
   Boutroy S, 2005, J CLIN ENDOCR METAB, V90, P6508, DOI 10.1210/jc.2005 1258
   Boutroy S, 2011, BONE, V49, P1055, DOI 10.1016/j.bone.2011.07.037
   Brown RP, 1997, TOXICOL IND HEALTH, V13, P407, DOI 10.1177/074823379701300401
   Burr DB., 2013, BASIC APPL BONE BIOL
   CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623 197759070 00021
   CARTER DR, 1987, J BIOMECH, V20, P785, DOI 10.1016/0021 9290(87)90058 3
   Chailurkit LO, 2003, J BONE MINER METAB, V21, P421, DOI 10.1007/s00774 003 0438 2
   Cooper DML, 2007, BONE, V40, P957, DOI 10.1016/j.bone.2006.11.011
   COWIN SC, 1991, J BIOMECH ENG T ASME, V113, P191, DOI 10.1115/1.2891234
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   Doblaré M, 2002, J BIOMECH, V35, P1, DOI 10.1016/S0021 9290(01)00178 6
   ESHELBY JD, 1957, PROC R SOC LON SER A, V241, P376, DOI 10.1098/rspa.1957.0133
   Fortes EM, 2008, ARQ BRAS ENDOCRINOL, V52, P1106, DOI 10.1590/S0004 27302008000700006
   Fritsch A, 2007, J THEOR BIOL, V244, P597, DOI 10.1016/j.jtbi.2006.09.013
   Frost HM., 1964, Bone Biodyn, V6, P315
   Ganghoffer JF, 2012, INT J ENG SCI, V50, P166, DOI 10.1016/j.ijengsci.2011.08.004
   García Aznar JM, 2005, BIOMECH MODEL MECHAN, V4, P147, DOI 10.1007/s10237 005 0067 x
   Geissler JR, 2015, J BIOMECH, V48, P883, DOI 10.1016/j.jbiomech.2015.01.032
   Gieschke R., 2013, DEV INNOVATIVE DRUGS
   Goda I, 2016, INT J SOLIDS STRUCT, V94 95, P138, DOI 10.1016/j.ijsolstr.2016.04.036
   [Gowder Sivakumar. Neves Silva JP Oliveira ACN Gomes AC Real Oliveira MECD Neves Silva JP Oliveira ACN Gomes AC Real Oliveira MECD], 2012, Cell Interaction
   Hambli R, 2016, J MECH BEHAV BIOMED, V60, P492, DOI 10.1016/j.jmbbm.2016.03.010
   Helgason B, 2008, CLIN BIOMECH, V23, P135, DOI 10.1016/j.clinbiomech.2007.08.024
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Jacobs CR, 1994, THESIS
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142 9612(91)90186 E
   Kaneko TS, 2004, J BIOMECH, V37, P523, DOI 10.1016/j.jbiomech.2003.08.010
   Kaspar D, 2002, J BIOMECH, V35, P873, DOI 10.1016/S0021 9290(02)00058 1
   KELLER TS, 1994, J BIOMECH, V27, P1159, DOI 10.1016/0021 9290(94)90056 6
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LIN JH, 1992, DRUG METAB DISPOS, V20, P608
   LIN JH, 1991, DRUG METAB DISPOS, V19, P926
   Ma D, 2013, MENOPAUSE, V20, P1216, DOI [10.1097/gme.0000000000000100, 10.1097/GME.0000000000000100]
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   McMullin TS, 2005, PHYSIOLOGICALLY BASED PHARMACOKINETICS MODELING: SCIENCE AND APPLICATIONS, P273
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Morgan EF, 2003, J BIOMECH, V36, P897, DOI 10.1016/S0021 9290(03)00071 X
   MORI T, 1973, ACTA METALL MATER, V21, P571, DOI 10.1016/0001 6160(73)90064 3
   Nestorov I, 2003, CLIN PHARMACOKINET, V42, P883, DOI 10.2165/00003088 200342100 00002
   Nestorov IA, 1998, J PHARMACOKINET BIOP, V26, P21, DOI 10.1023/A:1023272707390
   OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P299, DOI 10.1016/0041 008X(91)90032 A
   OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P332, DOI 10.1016/0041 008X(91)90034 C
   Padilla F, 2008, BONE, V42, P1193, DOI 10.1016/j.bone.2007.10.024
   Pastrama MI, 2018, BONE, V107, P208, DOI 10.1016/j.bone.2017.11.009
   Pertinez H, 2013, PHARM RES DORDR, V30, P1536, DOI 10.1007/s11095 013 0991 x
   Pinheiro MD, 2010, ARQ BRAS ENDOCRINOL, V54, P164, DOI 10.1590/S0004 27302010000200012
   Pinheiro MD, 2008, ARQ BRAS ENDOCRINOL, V52, P1071, DOI 10.1590/S0004 27302008000700001
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Qin QH, 2012, ACTA MECH SINICA PRC, V28, P1678, DOI 10.1007/s10409 012 0154 z
   Rosenbaum S.E., 2016, Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations, DOI 10.1111/j.1365 2125.2011.04077.x
   Ross DS, 2017, B MATH BIOL, V79, P117, DOI 10.1007/s11538 016 0229 2
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Scheiner S, 2016, BIOMECH MODEL MECHAN, V15, P9, DOI 10.1007/s10237 015 0704 y
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   SNYDER SM, 1991, J ORTHOPAED RES, V9, P422, DOI 10.1002/jor.1100090315
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   Taddei F, 2004, MED ENG PHYS, V26, P61, DOI 10.1016/S1350 4533(03)00138 3
   Trabelsi N, 2014, J MECH BEHAV BIOMED, V29, P177, DOI 10.1016/j.jmbbm.2013.08.030
   Trabelsi N, 2009, J BIOMECH, V42, P234, DOI 10.1016/j.jbiomech.2008.10.039
   Velez NF, 2008, OSTEOPOROSIS INT, V19, P1457, DOI 10.1007/s00198 008 0590 6
   Watson SL, 2018, J BONE MINER RES, V33, P211, DOI 10.1002/jbmr.3284
   Yokley K, 2006, RISK ANAL, V26, P925, DOI 10.1111/j.1539 6924.2006.00789.x
   Yosibash Z, 2007, J BIOMECH, V40, P3688, DOI 10.1016/j.jbiomech.2007.06.017
   Zaoui A, 2002, J ENG MECH, V128, P808, DOI 10.1061/(ASCE)0733 9399(2002)128:8(808)
NR 79
TC 13
Z9 14
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751 6161
EI 1878 0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD APR
PY 2020
VL 104
AR 103657
DI 10.1016/j.jmbbm.2020.103657
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA LD0QC
UT WOS:000525737000003
PM 32174414
DA 2025 08 17
ER

PT J
AU Jiang, XW
   Ying, P
   Shen, YC
   Miu, YM
   Kong, WB
   Lu, T
   Wang, Q
AF Jiang, Xiaowei
   Ying, Pu
   Shen, Yingchao
   Miu, Yiming
   Kong, Wenbin
   Lu, Tong
   Wang, Qiang
TI Identification of Critical Functional Modules and Signaling Pathways in
   Osteoporosis
SO CURRENT BIOINFORMATICS
LA English
DT Article
DE Osteoporosis; critical regulatory genes; functional modules; signaling
   pathways; osteoclastogenesis
ID SET ENRICHMENT ANALYSIS; FRACTURE; RISK; BONE; DIFFERENTIATION;
   METAANALYSIS; EXPRESSION
AB Background: Osteoporosis is the most common bone metabolic disease. Abnormal osteoclast formation and resorption play a fundamental role in osteoporosis pathogenesis. Recent researches have greatly broadened our understanding of molecular mechanisms of osteoporosis. However, the molecular mechanisms leading to osteoporosis are still not entirely clear.
   Objective: The purpose of this work is to study the critical regulatory genes, functional modules, and signaling pathways.
   Methods: Differential expression analysis, network topology based analysis, and overrepresentation enrichment analysis (ORA) were used to identify differentially expressed genes (DEGs), gene subnetworks, and signaling pathways related to osteoporosis, respectively.
   Results: Differential expression analysis identified DEGs, such as POGLUT1, DAPK3 and NFKBIA, associated with osteoclastogenesis, which highlighted Notch, apoptosis and NF kB signaling pathways. Network topology based analysis identified the upregulated subnetwork characterized by EXOSC8 and DIS3L from the RNA exosome complex, and the downregulated subnetwork composed of histone deacetylases and the cofactors, MORF4L1 and JDP2. Furthermore, the overrepresentation enrichment analysis highlighted that corticotrophin releasing hormone signaling pathway might affect osteoclastogenesis through its component NR4A1, and suppressing osteoclast differentiation and osteoclast bone resorption with urocortin (UCN).
   Conclusion: Our systematic analysis not only discovered novel molecular mechanisms but also proposed potential drug targets for osteoporosis.
C1 [Jiang, Xiaowei; Ying, Pu; Shen, Yingchao; Miu, Yiming; Kong, Wenbin; Lu, Tong; Wang, Qiang] Nanjing Univ Chinese Med, Dept Orthopaed, Changshu Hosp, 6 Huanghe Rd, Changshu 215500, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine
RP Jiang, XW; Ying, P (通讯作者)，Nanjing Univ Chinese Med, Dept Orthopaed, Changshu Hosp, 6 Huanghe Rd, Changshu 215500, Jiangsu, Peoples R China.
EM luntan100@sina.com
RI pu, ying/JPX 8482 2023
OI Ying, Pu/0000 0003 3975 6326
CR Abrahamsen B, 2006, J BONE MINER RES, V21, P796, DOI 10.1359/JBMR.020604
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Behera Jyotirmaya, 2018, Oncoscience, V5, P181, DOI 10.18632/oncoscience.421
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Chen XF, 2018, AM J HUM GENET, V102, P776, DOI 10.1016/j.ajhg.2018.03.001
   Cole Raymond E, 2008, J Am Osteopath Assoc, V108, P289
   Combs CE, 2012, J ENDOCRINOL, V212, P187, DOI 10.1530/JOE 11 0254
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Huang CC, 2016, BIOMATERIALS, V111, P103, DOI 10.1016/j.biomaterials.2016.09.029
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kanis JA, 2004, BONE, V35, P1029, DOI 10.1016/j.bone.2004.06.017
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642
   Li L, 2019, MATH BIOSCI ENG, V16, P5947, DOI 10.3934/mbe.2019298
   Liu YZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116792
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Reppe S, 2017, EPIGENETICS US, V12, P674, DOI 10.1080/15592294.2017.1345832
   Scholtysek C, 2018, J BONE MINER RES, V33, P2035, DOI 10.1002/jbmr.3533
   Servián Morilla E, 2016, EMBO MOL MED, V8, P1289, DOI 10.15252/emmm.201505815
   Shomali T, 2016, INT J MOL CELL MED, V5, P106
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Terpos Evangelos, 2008, Pediatr Endocrinol Rev, V6 Suppl 1, P94
   Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356
   Zhou Y, 2019, CALCIFIED TISSUE INT, V105, P183, DOI 10.1007/s00223 019 00555 8
   Zhou Y, 2018, CALCIFIED TISSUE INT, V103, P581, DOI 10.1007/s00223 018 0457 6
   Zhou Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19196 2
   Zhu Y, 2019, STEM CELL TRANSL MED, V8, P593, DOI 10.1002/sctm.18 0199
NR 36
TC 1
Z9 1
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 8936
EI 2212 392X
J9 CURR BIOINFORM
JI Curr. Bioinform.
PY 2021
VL 16
IS 1
BP 90
EP 97
DI 10.2174/1574893615999200706002411
PG 8
WC Biochemical Research Methods; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA RH4XV
UT WOS:000636224400009
DA 2025 08 17
ER

PT S
AU Turner, CH
AF Turner, Charles H.
BE Zaidi, M
TI Bone strength: Current concepts
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE biomechanics; fracture; osteoporosis; mechanotransduction
ID INTRACELLULAR CALCIUM MOBILIZATION; MESSENGER RNA EXPRESSION;
   OSCILLATORY FLUID FLOW; GROWTH FACTOR I; NITRIC OXIDE; MECHANICAL
   STRAIN; PARATHYROID HORMONE; ESTROGEN; CELLS; RESPONSIVENESS
AB Bones serve several mechanical functions, including acoustic amplification in the middle ear, shielding vital organs from trauma, and serving as levers for muscles to contract against. Bone is a multiphase material made up of a tough collagenous matrix intermingled with rigid mineral crystals. The mineral gives bone its stiffness. Without sufficient mineralization, bones will plastically deform under load. Collagen provides toughness to bone making it less brittle so that it better resists fracture. Bone adapts to mechanical stresses largely by changing its size and shape, which are major determinants of its resistance to fracture. Tissue is added in regions of high mechanical stress providing an efficient means for improving bone strength. Experiments have shown that small additions of bone mineral density (BMD) (5 8%) caused by mechanical loading can improve bone strength by over 60% and extend bone fatigue life by 100 fold. Consequently, it is clear that bone tissue possesses a mechanosensing apparatus that directs osteogenesis to where it is most needed for improving bone strength. The biological processes involved in bone mechanotransduction are poorly understood and further investigation of the molecular mechanisms involved might uncover drug targets for osteoporosis. Several pathways are emerging from current research, including membrane ion channels, ATP signaling, second messengers, such as prostaglandins and nitric oxide, insulin like growth factors, and Wnt signaling.
C1 Indiana Univ Purdue Univ, Orthopaed Res Labs, Indianapolis, IN 46202 USA.
   Indiana Univ Purdue Univ, Biomech & Biomat Res Ctr, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Purdue University System; Purdue University; Purdue
   University in Indianapolis
RP Turner, CH (通讯作者)，Indiana Univ Purdue Univ, Orthopaed Res Labs, 1120 S Dr,FH 115, Indianapolis, IN 46202 USA.
EM turnerch@iupui.edu
CR Bakker AD, 2003, AM J PHYSIOL ENDOC M, V285, pE608, DOI 10.1152/ajpendo.00501.2002
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Cheng MZ, 1999, J BONE MINER RES, V14, P1742, DOI 10.1359/jbmr.1999.14.10.1742
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Chow JWM, 1999, J BONE MINER RES, V14, pS395
   Currey J., 1984, The Mechanical Adaptations of Bones
   CURREY JD, 1990, J BIOMECH, V23, P837, DOI 10.1016/0021 9290(90)90030 7
   CURREY JD, 2002, BONES STRUCTURE MECH
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021 9290(96)84536 2
   Hvid I, 1984, Eng Med, V13, P21, DOI 10.1243/EMED_JOUR_1984_013_007_02
   Järvinen TLN, 2003, BONE, V32, P642, DOI 10.1016/S8756 3282(03)00100 5
   Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045
   Johnson DL, 1996, AM J PHYSIOL ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kim BT, 2003, J BONE MINER RES, V18, P150, DOI 10.1359/jbmr.2003.18.1.150
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   LEAN JM, 1995, AM J PHYSIOL ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002 220821
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Li JL, 2002, J BONE MINER RES, V17, P1795, DOI 10.1359/jbmr.2002.17.10.1795
   LI XJ, 1990, BONE, V11, P353, DOI 10.1016/8756 3282(90)90091 C
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   Martin RB., 1998, Skeletal tissue mechanics
   MATTHECK C, 1997, DESIGN NATURE LEARNI
   Meazzini MC, 1998, J ORTHOP RES, V16, P170, DOI 10.1002/jor.1100160204
   Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756 3282(96)00260 8
   REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   RODAN GA, 1975, SCIENCE, V189, P467, DOI 10.1126/science.168639
   RUBIN CT, 1982, J EXP BIOL, V101, P187
   Rubin J, 2000, AM J PHYSIOL CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126
   Rubin J, 1997, J CELL PHYSIOL, V170, P81, DOI 10.1002/(SICI)1097 4652(199701)170:1<81::AID JCP9>3.0.CO;2 H
   Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756 3282(03)00088 7
   Sawakami K, 2004, J BONE MINER RES, V19, pS38
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   TURNER CH, 1989, J BIOMECH ENG, V111, P1
   Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756 3282(01)00697 4
   Warden SJ, 2005, J BONE MINER RES, V20, P809, DOI 10.1359/JBMR.041222
   You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
NR 56
TC 253
Z9 330
U1 1
U2 32
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 429
EP 446
DI 10.1196/annals.1346.039
PG 18
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200042
PM 16831941
DA 2025 08 17
ER

PT J
AU Ardeshirpour, L
   Dann, P
   Adams, DJ
   Nelson, T
   VanHouten, J
   Horowitz, MC
   Wysolmerski, JJ
AF Ardeshirpour, Laleh
   Dann, Pamela
   Adams, Douglas J.
   Nelson, Tracey
   VanHouten, Joshua
   Horowitz, Mark C.
   Wysolmerski, John J.
TI Weaning triggers a decrease in receptor activator of nuclear factor κB
   ligand expression, widespread osteoclast apoptosis, and rapid recovery
   of bone mass after lactation in mice
SO ENDOCRINOLOGY
LA English
DT Article
ID HORMONE RELATED PROTEIN; RAT MATERNAL SKELETON; PARATHYROID HORMONE;
   CANCELLOUS BONE; MAMMARY GLAND; EXTRACELLULAR CALCIUM;
   MECHANICAL PROPERTIES; REPLACEMENT THERAPY; BIOCHEMICAL MARKERS;
   PROMOTES APOPTOSIS
AB A significant portion of milk calcium comes from the mother's skeleton, and lactation is characterized by rapid bone loss. The most remarkable aspect of this bone loss is its complete reversibility, and the time after weaning is the most rapid period of skeletal anabolism in adults. Despite this, little is known of the mechanisms by which the skeleton repairs itself after lactation. We examined changes in bone and calcium metabolism defining the transition from bone loss to bone recovery at weaning in mice. Bone mass decreases during lactation and recovers rapidly after weaning. Lactation causes changes in bone microarchitecture, including thinning and perforation of trabecular plates that are quickly repaired after weaning. Weaning causes a rapid decline in urinary C telopeptide levels and stimulates an increase in circulating levels of osteocalcin. Bone histomorphometry documented a significant reduction in the numbers of osteoclasts on d 3 after weaning caused by a coordinated wave of osteoclast apoptosis beginning 48 h after pup removal. In contrast, osteoblast numbers and bone formation rates, which are elevated during lactation, remain so 3 d after weaning. The cessation of lactation stimulates an increase in circulating calcium levels and a reciprocal decrease in PTH levels. Finally, weaning is associated with a decrease in levels of receptor activator of nuclear factor kappa B ligand mRNA in bone. In conclusion, during lactation, bone turnover is elevated, and bone loss is rapid. Weaning causes selective apoptosis of osteoclasts halting bone resorption. The sudden shift in bone turnover favoring bone formation subsequently contributes to the rapid recovery of bone mass.
C1 Yale Univ, Sch Med, Dept Pediat, Sect Pediat Endocrinol, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol & Metab, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA.
   Univ Connecticut, Ctr Hlth, Dept Orthopaed Surg, Farmington, CT 06034 USA.
C3 Yale University; Yale University; Yale University; University of
   Connecticut
RP Wysolmerski, JJ (通讯作者)，Yale Univ, Sch Med, Dept Pediat, Sect Pediat Endocrinol, New Haven, CT 06520 USA.
EM john.wysolmerski@yale.edu
RI Adams, David/GMW 8541 2022
FU NCI NIH HHS [R01CA094175] Funding Source: Medline; NIAMS NIH HHS
   [P30AR46032, P30AR46026] Funding Source: Medline; NICHD NIH HHS
   [K12HD001401] Funding Source: Medline; NIDDK NIH HHS [R21DK07394,
   R01DK069542, P30DK45735, T32DK07058] Funding Source: Medline
CR Bowman BM, 2005, J BONE MINER RES, V20, pS258
   Bowman BM, 2002, J BONE MINER RES, V17, P1954, DOI 10.1359/jbmr.2002.17.11.1954
   Bowman BM, 1999, BONE, V25, P553, DOI 10.1016/S8756 3282(99)00204 5
   BROMMAGE R, 1985, AM J PHYSIOL, V248, pE182, DOI 10.1152/ajpendo.1985.248.2.E182
   BUCHT E, 1995, EUR J ENDOCRINOL, V132, P438, DOI 10.1530/eje.0.1320438
   Cai DJ, 2005, J BONE MINER RES, V20, P828, DOI 10.1359/JBMR.041236
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P2762, DOI 10.1210/jc.2004 1091
   GRILL V, 1992, CLIN ENDOCRINOL, V37, P405, DOI 10.1111/j.1365 2265.1992.tb02350.x
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Hodsman AB, 1998, BONE, V23, P267, DOI 10.1016/S8756 3282(98)00093 3
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Iwaniec UT, 2006, J BONE MINER RES, V21, P1068, DOI 10.1359/JBMR.060402
   Kacena MA, 2004, J HISTOTECHNOL, V27, P119
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029 7844(95)00083 4
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932
   Karlsson C, 2001, OSTEOPOROSIS INT, V12, P828, DOI 10.1007/s001980170033
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   Krebs NF, 1997, AM J CLIN NUTR, V65, P1738, DOI 10.1093/ajcn/65.6.1738
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029 7844(99)00369 5
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819
   Lippuner K, 1996, J BONE MINER RES, V11, P1394
   Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229
   MCNEILLY AS, 1994, ANN NY ACAD SCI, V709, P145, DOI 10.1111/j.1749 6632.1994.tb30394.x
   MILLER MA, 1989, BONE, V10, P279, DOI 10.1016/8756 3282(89)90065 3
   Miller SC, 2005, BIOL REPROD, V73, P156, DOI 10.1095/biolreprod.105.039610
   Miller SC, 2004, ANAT REC PART A, V276A, P143, DOI 10.1002/ar.a.10138
   MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543
   PENG TC, 1988, BONE MINER, V3, P293
   Polatti F, 1999, OBSTET GYNECOL, V94, P52, DOI 10.1016/S0029 7844(99)00236 7
   RATCLIFFE WA, 1992, J ENDOCRINOL, V133, P87, DOI 10.1677/joe.0.1330087
   RODAN GA, 1993, OSTEOPOROSIS INT, V3, pS7
   Roschger P, 2007, J BONE MINER RES, V22, P717, DOI 10.1359/JBMR.070120
   Ruffoni D, 2007, BONE, V40, P1308, DOI 10.1016/j.bone.2007.01.012
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   Smith MS, 2002, FRONT NEUROENDOCRIN, V23, P225, DOI 10.1016/S0091 3022(02)00002 X
   SOWERS M, 1995, J CLIN ENDOCR METAB, V80, P2210, DOI 10.1210/jc.80.7.2210
   SOWERS M, 1993, JAMA J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130
   Sowers M, 1996, J BONE MINER RES, V11, P1052
   Sowers MF, 1996, JAMA J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549
   Srivastava AK, 2000, CALCIFIED TISSUE INT, V66, P435, DOI 10.1007/s002230010088
   Ste Marie LG, 2006, J BONE MINER RES, V21, P283, DOI 10.1359/JBMR.051020
   STEVENSON JC, 1979, LANCET, V2, P769, DOI 10.1016/S0140 6736(79)92117 2
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653
   TOVERUD SU, 1976, ENDOCRINOLOGY, V99, P371, DOI 10.1210/endo 99 2 371
   Uemura H, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740353
   Vajda EG, 2001, BIOL REPROD, V65, P689, DOI 10.1095/biolreprod65.3.689
   VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776
   Vanhouten JN, 2003, ENDOCRINOLOGY, V144, P5521, DOI 10.1210/en.2003 0892
   VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504
   Watson CJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1401
   Woodrow JP, 2006, ENDOCRINOLOGY, V147, P4010, DOI 10.1210/en.2005 1616
   Wysolmerski JJ, 2002, J MAMMARY GLAND BIOL, V7, P267, DOI 10.1023/A:1022800716196
   YAMAMOTO M, 1991, ENDOCRINOLOGY, V129, P2614, DOI 10.1210/endo 129 5 2614
   Zhou H, 2001, J BONE MINER RES, V16, P1300, DOI 10.1359/jbmr.2001.16.7.1300
NR 59
TC 76
Z9 85
U1 0
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2007
VL 148
IS 8
BP 3875
EP 3886
DI 10.1210/en.2006 1467
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 190UT
UT WOS:000248086800037
PM 17495007
OA Bronze
DA 2025 08 17
ER

PT J
AU Shim, KS
   Lee, B
   Ma, JY
AF Shim, Ki Shuk
   Lee, Bohyoung
   Ma, Jin Yeul
TI Water extract of Rumex crispus prevents bone loss by inhibiting
   osteoclastogenesis and inducing osteoblast mineralization
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Rumex crispus; Bone loss; Osteoblast; Osteoclast; Runx2; Nuclear factor
   of activated T cells cytoplasmic 1
ID GENE EXPRESSION; MESENCHYMAL PROGENITORS; TRANSCRIPTION FACTOR;
   DIFFERENTIATION; CELLS; ACTIVATION; PATHWAYS; LIGAND
AB Background: Rumex crispus root has traditionally been used in Asian medicine for the treatment of hemorrhage and dermatolosis. The aim of this study was to explore the pharmaceutical effects of water extract of Rumex crispus (WERC) on osteoblast and osteoclast differentiation. We also studied the effect of WERC on the receptor activator of nuclear factor kappa B ligand (RANKL) induced trabecular bone destruction mice model.
   Methods: High performance liquid chromatography analysis was used to identify three compounds (emodin, chrysophanol, and physcion) of WERC. The in vivo effect of WERC was examined using an administration of WERC or vehicle on the ICR mice with bone loss induced by intraperitoneal RANKL injection on day 0 and 1. All mice were sacrificed by cervical dislocation at day 7 and the femurs of mice were isolated for soft X ray and Micro CT analysis. The in vitro effect of WERC on osteoblast mineralization or osteoclast differentiation was examined by alizarin red S staining or by tartrate resistant acid phosphatase staining and assay. To determine the transcription level of osteoblast or osteoclast specific genes, real time quantitative polymerase chain reaction was used. Western blot analysis was performed to study the effect of WERC on mitogen activated protein kinases (MAPK) or nuclear factor .B (NF kappa B) signaling molecules.
   Results: The presence of three compounds in WERC was determined. WERC significantly suppressed RANKL induced trabecular bone loss by preventing microstructural deterioration. In vitro, WERC increased osteoblast mineralization by enhancing the transcription of runt related transcription factor 2 and its transcriptional coactivators, and by stimulating extracellular signal regulated kinase phosphorylation. Furthermore, WERC significantly inhibited osteoclast differentiation by suppressing the activation of the RANKL signalings (MAPK and NF kappa B) and the increasing inhibitory factors of nuclear factor of activated T cells cytoplasmic 1.
   Conclusion: This study showed that WERC could protect against osteoporosis and suggested that the possible mechanism of WERC might be related to increased osteoblast differentiation by activating Runx2 signaling and inhibition of osteoclast differentiation by suppression of RANKL signaling.
C1 [Shim, Ki Shuk; Lee, Bohyoung; Ma, Jin Yeul] Korea Inst Oriental Med, KM Applicat Ctr, 70 Chemdan Ro,41062, Daegu 701300, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Shim, KS; Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Applicat Ctr, 70 Chemdan Ro,41062, Daegu 701300, South Korea.
EM angeloshim@kiom.re.kr; jyma@kiom.re.kr
FU Korea Forest Service, Korea [D17170]
FX This work was supported by a grant D17170 for the Korea Institute of
   Oriental Medicine from Korea Forest Service, Korea.
CR Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515
   Baskan S, 2007, TALANTA, V71, P747, DOI 10.1016/j.talanta.2006.05.018
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim JC, 2004, PEST MANAG SCI, V60, P803, DOI 10.1002/ps.811
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee SU, 2010, J CELL BIOCHEM, V109, P1148, DOI 10.1002/jcb.22494
   Liu Jing, 2011, Zhong Yao Cai, V34, P893
   Maksimovic Z, 2011, PHYTOTHER RES, V25, P101, DOI 10.1002/ptr.3234
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park Heajin, 2014, [YAKHAK HOEJI, 약 학 회 지], V58, P307
   Park Heajin, 2013, [YAKHAK HOEJI, 약 학 회 지], V57, P406
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Seo CS., 2014, BMC COMPLEM ALTERN M, V14
   Shim KS, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/325791
   Shiwani S, 2012, NUTR RES PRACT, V6, P389, DOI 10.4162/nrp.2012.6.5.389
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 32
TC 15
Z9 17
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD OCT 26
PY 2017
VL 17
AR 483
DI 10.1186/s12906 017 1986 7
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA FK8MZ
UT WOS:000413764200001
PM 29070038
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Thummuri, D
   Jeengar, MK
   Shrivastava, S
   Nemani, H
   Ramavat, RN
   Chaudhari, P
   Naidu, VGM
AF Thummuri, Dinesh
   Jeengar, Manish Kumar
   Shrivastava, Shweta
   Nemani, Harishankar
   Ramavat, Ravindar Naik
   Chaudhari, Pradip
   Naidu, V. G. M.
TI Thymoquinone prevents RANKL induced osteoclastogenesis activation and
   osteolysis in an in vivo model of inflammation by suppressing
   NF KB and MAPK Signalling
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Thymoquinone; Osteoclastogenesis; Osteolysis; RANKL; NF KB
ID KAPPA B ACTIVATION; RECEPTOR ACTIVATOR; PARATHYROID HORMONE; C JUN;
   DIFFERENTIATION; BONE; OSTEOBLAST; PATHWAY; CELLS; ENHANCEMENT
AB Osteoclasts are multinuclear giant cells responsible for bone resorption in inflammatory bone diseases such as osteoporosis, rheumatoid arthritis and periodontitis. Because of deleterious side effects with currently available drugs the search continues for novel effective and safe therapies. Thymoquinone (TQ), the major bioactive component of Nigella sativa has been investigated for its anti inflammatory, antioxidant and anticancer activities. However, its effects in osteoclastogenesis have not been reported. In the present study we show for the first time that TQ inhibits nuclear factor KB ligand (RANKL) induced osteoclastogenesis in RAW 264.7 and primary bone marrow derived macrophages (BMMs) cells. RANKL induced osteoclastogenesis is associated with increased expression of multiple transcription factors via activation of NF KB, MAPKs signalling and reactive oxygen species (ROS). Mechanistically TQ blocked the RANKL induced NF KB activation by attenuating the phosphorylation of IkB kinase (IKK alpha/beta). Interestingly, in RAW 264.7 cells TQ inhibited the RANKL induced phosphorylation of MAPKs and mRNA expression of osteoclastic specific genes such as TRAP, DC STAMP, NFATc1 and c Fos. In addition, TQ also decreased the RANKL stimulated ROS generation in macropahges (RAW 264.7) and H2O2 induced ROS generation in osteoblasts (MC 3T3 E1). Consistent with in vitro results, TQ inhibited lipopolysaccharide (LPS) induced bone resorption by suppressing the osteoclastogenesis. Indeed, micro CT analysis showed that bone mineral density (BMD) and bone architecture parameters were positively modulated by TQ, Taken together our data demonstrate that TQ has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF KB and ROS generation followed by suppressing the gene expression of c Fos and NFATc1 in osteoclast precursors. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Thummuri, Dinesh; Jeengar, Manish Kumar; Shrivastava, Shweta; Naidu, V. G. M.] Natl Inst Pharmaceut Educ Res, Dept Pharmacol Toxicol, Hyderabad 500037, Telengana, India.
   [Nemani, Harishankar; Ramavat, Ravindar Naik] Natl Inst Nutr, Natl Ctr Lab Anim Sci, Hyderabad 500037, Telengana, India.
   [Chaudhari, Pradip] Tata Mem Hosp, ACTREC, Comparat Oncol Program, Kharghar 410210, Navi Mumbai, India.
   [Chaudhari, Pradip] Tata Mem Hosp, ACTREC, Small Anim Imaging Facil, Kharghar 410210, Navi Mumbai, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali); National Institute of Pharmaceutical Education & Research,
   Hyderabad; Indian Council of Medical Research (ICMR); ICMR   National
   Animal Resource Facility for Biomedical Research (NARFBR); ICMR  
   National Institute of Nutrition (NIN); Tata Memorial Centre (TMC); Tata
   Memorial Hospital; Advance Centre for Treatment, Research & Education in
   Cancer (ACTREC); Tata Memorial Centre (TMC); Tata Memorial Hospital;
   Advance Centre for Treatment, Research & Education in Cancer (ACTREC)
RP Naidu, VGM (通讯作者)，NIPER, Dept Pharmacol & Toxicol, Hyderabad, Andhra Pradesh, India.
EM vgmnaidu@niperhyd.ac.in
RI Jeengar, Manish Kumar/AGI 2286 2022; Chaudhari, Pradip/H 6488 2013;
   Thummuri, Dinesh/Q 2252 2019; Shrivastava, Dr Shweta/IAM 8310 2023;
   Thummuri, Dinesh/M 6263 2016
OI Naidu, VGM/0000 0003 1520 2177; HYDERABAD, NIPER/0000 0001 7521 1150;
   jeengar, manish kumar/0000 0001 6035 8643; SHWETA SHRIVASTAVA,
   Dr/0000 0003 2030 7774; Thummuri, Dinesh/0000 0002 6027 0999
FU Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers,
   Government of India; NIPER Hyderabad
FX The authors are thankful to Department of Pharmaceuticals, Ministry of
   Chemicals and Fertilizers, Government of India and Project Director,
   NIPER Hyderabad for providing fellowship and research activity.
CR Abbas S, 2003, J ORTHOPAED RES, V21, P1041, DOI 10.1016/S0736 0266(03)00081 0
   Al Amri A. M., 2009, Shiraz E Medical Journal, V10, P107
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bandyopadhyay S, 2006, BIOCHEM PHARMACOL, V72, P184, DOI 10.1016/j.bcp.2006.04.018
   Bhatti I. U., 2009, World Applied Sciences Journal, V6, P1053
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown K, 2009, MUTAGENESIS, V24, P391, DOI 10.1093/mutage/gep022
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   Darakhshan S, 2015, PHARMACOL RES, V95 96, P138, DOI 10.1016/j.phrs.2015.03.011
   Dehkordi FR, 2008, FUND CLIN PHARMACOL, V22, P447, DOI 10.1111/j.1472 8206.2008.00607.x
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Han KY, 2007, BIOCHEM PHARMACOL, V74, P911, DOI 10.1016/j.bcp.2007.06.044
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jeon JH, 2008, PHARM DEV TECHNOL, V13, P505, DOI 10.1080/10837450802282488 
   Karin Michael, 2005, Proc Am Thorac Soc, V2, P386, DOI 10.1513/pats.200504 034SR
   Kundu J, 2014, FOOD CHEM TOXICOL, V65, P18, DOI 10.1016/j.fct.2013.12.015
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Morley P, 2001, CURR PHARM DESIGN, V7, P671, DOI 10.2174/1381612013397780
   Naidu VGM, 2013, ASIAN PAC J TROP MED, V6, P337, DOI 10.1016/S1995 7645(13)60036 X
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Ozdemir H, 2012, J PERIODONTAL RES, V47, P74, DOI 10.1111/j.1600 0765.2011.01406.x
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541 7786.MCR 07 2088
   Shrivastava S, 2014, APOPTOSIS, V19, P1148, DOI 10.1007/s10495 014 0991 2
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Thummuri D, 2014, ENVIRON TOXICOL PHAR, V38, P58, DOI 10.1016/j.etap.2014.05.002
   Vaillancourt F, 2011, J CELL BIOCHEM, V112, P107, DOI 10.1002/jcb.22884
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wirries A, 2013, INT IMMUNOPHARMACOL, V15, P381, DOI 10.1016/j.intimp.2012.12.033
   Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158/1535 7163.MCT 08 0124
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 45
TC 102
Z9 107
U1 1
U2 53
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2015
VL 99
BP 63
EP 73
DI 10.1016/j.phrs.2015.05.006
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CR8DA
UT WOS:000361580100008
PM 26022736
DA 2025 08 17
ER

PT J
AU Tu, SM
   Lin, SH
AF Tu, Shi Ming
   Lin, Sue Hwa
TI Current trials using bone targeting agents in prostate cancer
SO CANCER JOURNAL
LA English
DT Article
DE prostate cancer; bone metastasis
ID GROWTH FACTOR RECEPTOR; PHASE II TRIAL; TYROSINE KINASES; STEM CELL;
   METASTASES; THERAPY; THALIDOMIDE; EFFICACY; PLACEBO; MEN
AB Prostate cancer metastasis is a unique disease. The propensity of prostate cancer to metastasize to bone and the prognostic significance of bone metastasis suggest that effective treatment of bone metastasis may provide clinical benefits. Both osteoblasts and osteoclasts have been shown to play a central role in the interactions between the metastatic prostate cancer cells and bone. Although most prostate cancer bone metastasis is osteoblastic, it remains unclear which cell type is initially involved in the process. Other components in the bone, such as the endothelium and stroma, may also play important roles in this process. The osteoblastic feature of prostate cancer bone metastasis has led to therapies focused on targeting osteoblast activity. Clinical trials targeting osteoblasts use radiopharmaceuticals (strontium 89 and samarium 153), the endothelin A receptor inhibitor atrasentan, or the vitamin D analog calcitriol. Agents that target osteoclasts include bisphosphonates; those that target endothelial cells include thalidomide and bevacizumab. Although these clinical trials for bone metastasis may provide effective treatments, novel concepts of how prostate cancer cells selectively metastasize to bone may advance our understanding and provide improved treatments for this difficult clinical problem. We propose a refined "seed" and "soil" view of metastasis. We speculate that in prostate cancer bone metastasis, the seed may comprise the so called cancer stem cells, whereas the soil may comprise an onco niche, ie, a unique microenvironment, that facilitate the growth and survival of cancer stem cells. If so, targeting cancer stem cells or the onco niche may offer another way to improve treatment of prostate cancer bone metastasis.
C1 [Tu, Shi Ming; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA.
   [Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Tu, SM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, PO Box 301439,1220 Holcombe Blvd, Houston, TX 77030 USA.
EM stu@mdanderson.org
FU NCI NIH HHS [CA 86342, P50 CA 90270] Funding Source: Medline
CR Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Beer TM, 2007, J CLIN ONCOL, V25, P669, DOI 10.1200/JCO.2006.06.8197
   BLAKE GM, 1988, J NUCL MED, V29, P549
   Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022 5347(01)69892 6
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Carducci MA, 2007, CANCER AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996
   Chang YM, 2007, NEOPLASIA, V9, P90, DOI 10.1593/neo.06694
   Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002 9440(10)65229 7
   Corral LG, 1999, J IMMUNOL, V163, P380
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   Dahut WL, 2004, J CLIN ONCOL, V22, P2532, DOI 10.1200/JCO.2004.05.074
   Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090 4295(99)00167 3
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Geitz H, 1996, IMMUNOPHARMACOLOGY, V31, P213, DOI 10.1016/0162 3109(95)00050 X
   JAMES ND, 2007, 14 EUR CAN C SEP 23
   Ko YJ, 2001, CLIN CANCER RES, V7, P800
   Koutsilieris M, 1997, ANTICANCER RES, V17, P1461
   LEWIECKI EM, 2007, EXPERT OPIN BIOL TH, V9, P90
   MAJOR PP, 2005, MULT PROST CANC S FE
   Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078 0432.CCR 07 1269
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008 5472.CAN 05 1731
   PICUS J, 2003, P AN M AM SOC CLIN, V22, P393
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   REESE D, 1999, P AN M AM SOC CLIN, V18, P351
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   TAKUWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P998, DOI 10.1016/0006 291X(90)90491 5
   Tu SM, 2005, J CLIN ONCOL, V23, P7904, DOI 10.1200/JCO.2005.01.2310
   Tu SM, 2002, LANCET ONCOL, V3, P508, DOI 10.1016/S1470 2045(02)00820 3
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458
   WEIDNER N, 1993, AM J PATHOL, V143, P409
NR 34
TC 18
Z9 22
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528 9117
EI 1540 336X
J9 CANCER J
JI Cancer J.
PD JAN FEB
PY 2008
VL 14
IS 1
BP 35
EP 39
DI 10.1097/PPO.0b013e318161d32d
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 259OG
UT WOS:000252948000008
PM 18303481
DA 2025 08 17
ER

PT J
AU Bukata, SV
AF Bukata, Susan V.
TI Systemic administration of pharmacological agents and bone repair: What
   can we expect
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Bisphosphonates; RANK ligand signalling inhibitors; Teriparatide; Wnt
   signalling; Fracture healing
ID PARATHYROID HORMONE PTH; ZOLEDRONIC ACID; FRACTURE REPAIR; SPINE FUSION;
   DOUBLE BLIND; CALLUS; ALENDRONATE; STRENGTH; MASS; PROLIFERATION
AB Pharmacologic agents that modulate bone formation and bone remodelling are in broad use and development for the treatment of osteoporosis and other disorders of bone fragility. There is significant interest into the effect these agents may have on bone repair and fracture healing and whether these agents may be beneficial or detrimental to bone repair. Bisphosphonates delay callus remodelling, but increased callus volume seen during endochondral bone repair with bisphosphonate use allows for equivalent biomechanical properties for the fractured bone. Teripartide stimulates bone formation and in bone repair appears to have the potential to accelerate fracture callus formation and remodelling, potentially accelerating fracture healing. Animal models of fracture healing have demonstrated accelerated healing with larger callus volume, more rapid remodelling to mature bone, and improved biomechanical properties of the fractured bone. Clinical data with teriparatide has shown mixed results for its ability to stimulate fracture healing. Wnt signalling is one of the major pathways through which cartilage and bone formation is regulated during development. This same pathway has been identified as one of the ways that teriparatide stimulates bone formation. Antibodies to downstream proteins in this pathway, Dkk 1 and sclerostin, show significant promise of accelerating even normal fracture healing in preclinical animal models. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Univ Rochester, Rochester, NY 14642 USA.
C3 University of Rochester
RP Bukata, SV (通讯作者)，Univ Rochester, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM susan_bukata@urmc.rochester.edu
FU NIH; OREF
FX NIH, OREF.
CR Adolphson P, 2000, ACTA ORTHOP SCAND, V71, P195, DOI 10.1080/000164700317413193
   AGHOLME F, 2011, BONE
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bajada S, 2009, BONE, V45, P726, DOI 10.1016/j.bone.2009.06.015
   Barrett JG, 2007, J ORTHOP RES, V25, P1070, DOI 10.1002/jor.20395
   BUKATA SV, 2009, 55 ANN M ORTH RES SO
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Eriksen EF, 2009, J BONE MINER RES, V24, P1308, DOI [10.1359/JBMR.090209, 10.1359/jbmr.090209]
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   GRISANTI M, 2006, J BONE MINER RES, P25
   Huang RC, 2005, SPINE, V30, P2516, DOI 10.1097/01.brs.0000186470.28070.7b
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29
   Kiely P, 2007, J PEDIATR ORTHOPED, V27, P467, DOI 10.1097/01.bpb.0000271326.41363.d1
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Komrakova M, 2010, BONE, V47, P480, DOI 10.1016/j.bone.2010.05.013
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Milgrom C, 2004, BONE, V35, P418, DOI 10.1016/j.bone.2004.04.016
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   O'Loughlin PF, 2009, SPINE, V34, P121, DOI 10.1097/BRS.0b013e318191e687
   Ominsky MS., 2010, J BONE MINER RES
   Oteo Alvaro A., 2010, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], V19, pe22, DOI [DOI 10.1016/J.JSE.2010.05.005, 10.1016/j.jse.2010.05.005]
   PEICHL P, 2009, J BONE MINER RES S1, V24
   Resmini Giuseppina, 2007, Aging Clin Exp Res, V19, P30
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Rozental TD, 2009, J HAND SURG AM, V34A, P595, DOI 10.1016/j.jhsa.2008.12.011
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Xue QY, 2005, SPINE, V30, P1116, DOI 10.1097/01.brs.0000162929.19985.d2
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
NR 42
TC 36
Z9 38
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD JUN
PY 2011
VL 42
IS 6
BP 605
EP 608
DI 10.1016/j.injury.2011.03.061
PG 4
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 772PH
UT WOS:000291245800011
PM 21507402
DA 2025 08 17
ER

PT J
AU Hidaka, S
   Mouri, Y
   Akiyama, M
   Miyasaka, N
   Nakahama, K
AF Hidaka, Shiho
   Mouri, Yuki
   Akiyama, Masako
   Miyasaka, Naoyuki
   Nakahama, Ken ichi
TI GPR110, a receptor for synaptamide, expressed in osteoclasts negatively
   regulates osteoclastogenesis
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE GPR110; Synaptamide; DHA; Osteoclast
ID PROTEIN COUPLED RECEPTORS; FATTY ACIDS; IN VITRO; OMEGA 3 FATTY ACIDS;
   MECHANISMS; PATHWAY; RANKL
AB Bone remodeling is precisely regulated mainly by osteoblasts and osteoclasts. Although some G protein coupled receptors (GPCRs) were reported to play roles in osteoblast function, little is known about the roles in osteoclasts. In this study, we found, for the first time, that the expression of GPR110 increased during osteoclastogenesis. GPR110 belongs to adhesion GPCR and was the functional receptor of N docosahexaenoyl ethanolamine (also called synaptamide). Synaptamide suppressed osteoclastogenesis induced by receptor activator of nuclear factorkappa B ligand. Considering that synaptamide is the endogenous metabolite of DHA, we hypothesized that DHA may inhibit osteoclastogenesis by affecting synaptamide/GPR110 signaling. But GPR110 knockout and subsequent rescue experiments revealed a pivotal role of GPR110 in the attenuation of osteoclastogenesis by synaptamide but not by DHA. These results suggest that synaptamide/GPR110 signaling negatively regulates osteoclastogenesis. Our study suggested that ligands of GPR110, such as synaptamide, might be a useful drug for osteoporotic patients.
C1 [Hidaka, Shiho; Mouri, Yuki; Nakahama, Ken ichi] Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138510, Japan.
   [Hidaka, Shiho; Miyasaka, Naoyuki] Tokyo Med & Dent Univ, Dept Obstet & Gynecol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138510, Japan.
   [Akiyama, Masako] Tokyo Med & Dent Univ, Res Adm Div, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138510, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Nakahama, K (通讯作者)，Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138510, Japan.
EM nakacell@tmd.ac.jp
OI Nakahama, Ken ichi/0000 0002 9860 3680
FU JSPS KAKENHI [18K09503]
FX This work was supported by Grants in Aid for Scientific Research (JSPS
   KAKENHI Grant Number 18K09503).
CR Akiyama M, 2013, NUTRIENTS, V5, P3151, DOI 10.3390/nu5083151
   Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820
   Bhattacharya A, 2007, J NUTR BIOCHEM, V18, P372, DOI 10.1016/j.jnutbio.2006.07.002
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Cugno C, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 89827 8
   Demberg LM, 2017, J BIOL CHEM, V292, P4383, DOI 10.1074/jbc.M116.763656
   Ellegaard M, 2010, CALCIFIED TISSUE INT, V87, P1, DOI 10.1007/s00223 010 9360 5
   Fredriksson R, 2002, FEBS LETT, V531, P407, DOI 10.1016/S0014 5793(02)03574 3
   Gad AA, 2020, ACS PHARMACOL TRANSL, V3, P29, DOI 10.1021/acsptsci.9b00093
   Hamann J, 2015, PHARMACOL REV, V67, P338, DOI 10.1124/pr.114.009647
   Huang BX, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 0831 6
   Kasonga AE, 2019, BBA MOL CELL BIOL L, V1864, P281, DOI 10.1016/j.bbalip.2018.12.009
   Kevala K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228768
   Kim HJ, 2016, J CELL PHYSIOL, V231, P844, DOI 10.1002/jcp.25133
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Layé S, 2018, PHARMACOL REV, V70, P12, DOI 10.1124/pr.117.014092
   Lee JW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13123
   Liu ZQ, 2018, MED SCI MONITOR, V24, P5216, DOI 10.12659/MSM.909555
   Lum AM, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 40
   Luo J, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0059 6
   Ma BT, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 3146
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Nishihara S, 2018, BIOCHEM BIOPH RES CO, V495, P941, DOI 10.1016/j.bbrc.2017.11.125
   Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041
   Okito A, 2015, BIOCHEM BIOPH RES CO, V458, P435, DOI 10.1016/j.bbrc.2015.01.142
   Prömel S, 2012, DEV DYNAM, V241, P1591, DOI 10.1002/dvdy.23841
   Qu XL, 2022, NATURE, V604, P779, DOI 10.1038/s41586 022 04580 w
   Russo GL, 2009, BIOCHEM PHARMACOL, V77, P937, DOI 10.1016/j.bcp.2008.10.020
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shi HP, 2017, BIOCHEM BIOPH RES CO, V491, P349, DOI 10.1016/j.bbrc.2017.07.097
   Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Yuan JZ, 2010, PROSTAG OTH LIPID M, V92, P85, DOI 10.1016/j.prostaglandins.2010.04.001
NR 35
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0952 3278
EI 1532 2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD JUL
PY 2022
VL 182
AR 102457
DI 10.1016/j.plefa.2022.102457
EA JUN 2022
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 5A3SH
UT WOS:000862809200006
PM 35690003
DA 2025 08 17
ER

PT J
AU Karakawa, A
   Fukawa, Y
   Okazaki, M
   Takahashi, K
   Sano, T
   Amano, H
   Yamamoto, M
   Yamada, S
AF Karakawa, A.
   Fukawa, Y.
   Okazaki, M.
   Takahashi, K.
   Sano, T.
   Amano, H.
   Yamamoto, M.
   Yamada, S.
TI Diclofenac Sodium Inhibits NFκB Transcription in Osteoclasts
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE diclofenac sodium; NSAIDs; osteoclast; NF kappa B; bone remodeling
ID MOLECULAR CLONING; BONE RESORPTION; GROWTH FACTOR; CATHEPSIN K;
   SALICYLATE; EXPRESSION; ASPIRIN; DIFFERENTIATION; OSTEOBLAST; ACID
AB A non steroidal anti inflammatory drug, diclofenac, acts efficiently against inflammation; however, down regulation of diclofenac on bone remodeling has raised concerns. The inhibitory mechanisms of diclofenac are poorly understood. We hypothesized that diclofenac down regulates osteoclast differentiation and activation via inhibition of the translocation of phosphorylated nuclear factor kappa B (NF kappa B). When osteoclasts prepared from mouse hematopoietic stem cells were treated with diclofenac, tartrate resistant acid phosphatase positive multinucleated cells decreased in a concentration dependent manner. Pit formation assay revealed the abolition of osteoclastic bone resorption; levels of cathepsin K transcripts, an osteoclastic resorption marker, were down regulated time dependently. Diclofenac induced the accumulation of the inhibitor of kappa B in cytosol, which led to suppression of the nuclear translocation of NF kappa B and phosphorylated NF kappa B. These results suggest that the novel mechanism of diclofenac for bone remodeling is associated with phosphorylated NF kappa B reduction, which regulates osteoclast differentiation and activation.
C1 [Karakawa, A.; Okazaki, M.; Amano, H.; Yamada, S.] Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, Tokyo 1428555, Japan.
   [Sano, T.] Showa Univ, Sch Dent, Dept Oral Anat, Shinagawa Ku, Tokyo 1428555, Japan.
   [Fukawa, Y.; Yamamoto, M.] Showa Univ, Sch Dent, Dept Periodontol, Ohta Ku, Tokyo 1458515, Japan.
   [Takahashi, K.] Hoshi Univ, Inst Med Chem, Physiol Chem Res Lab, Shinagawa Ku, Tokyo 1428501, Japan.
C3 Showa University; Showa University; Showa University; Hoshi University
RP Karakawa, A (通讯作者)，Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM a karakawa@dent.showa u.ac.jp
OI Akiko, Karakawa/0000 0003 2099 7293
FU Japan Society for the Promotion of Science [19592159]; Grants in Aid for
   Scientific Research [19592159] Funding Source: KAKEN
FX The authors thank Dr. Michihiko Usui and Dr. Kazushige Suzuki (Showa
   University School of Dentistry) for their excellent technical assistance
   with real time PCR. The authors are also grateful to Dr. Masayoshi Kamon
   (University of Tsukuba) for advice on Western blotting. This study was
   supported by a Grant in Aid for Scientific Research ( No. 19592159 to A.
   H.) from the Japan Society for the Promotion of Science.
CR BELL NH, 1994, AM J MED, V96, P349, DOI 10.1016/0002 9343(94)90065 5
   Bondza PK, 2008, FERTIL STERIL, V90, P1433, DOI 10.1016/j.fertnstert.2007.08.046
   CARLOS F, 2007, EUR J ORTHODONT, V29, P596
   Chae HJ, 2004, IMMUNOPHARM IMMUNOT, V26, P75, DOI 10.1081/IPH 120029946
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Hackstein H, 2001, J IMMUNOL, V166, P7053, DOI 10.4049/jimmunol.166.12.7053
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   JEFFCOAT MK, 1995, J PERIODONTOL, V66, P329, DOI 10.1902/jop.1995.66.5.329
   Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105 2896.2005.00329.x
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487
   LY IA, 1974, J IMMUNOL METHODS, V5, P239, DOI 10.1016/0022 1759(74)90108 2
   Markovic Aleksa B, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V102, pe4, DOI 10.1016/j.tripleo.2006.02.024
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   MOSTAFA YA, 1982, HISTOCHEM J, V14, P409, DOI 10.1007/BF01011853
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Paquette DW, 2000, J CLIN PERIODONTOL, V27, P558, DOI 10.1034/j.1600 051x.2000.027008558.x
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Schurigt U, 2005, ARTHRITIS RES THER, V7, P174
   Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421
   SOEKANTO A, 1994, CALCIFIED TISSUE INT, V54, P290, DOI 10.1007/BF00295953
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   VANDERWESTHUIJZEN AJ, 1994, ORAL SURG ORAL MED O, V78, P557, DOI 10.1016/0030 4220(94)90165 1
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948
   Yugoshi Luciana Ibara, 2002, Braz. Dent. J., V13, P92
   Zhao HB, 2005, MOL ENDOCRINOL, V19, P771, DOI 10.1210/me.2004 0161
NR 32
TC 13
Z9 13
U1 1
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD NOV
PY 2009
VL 88
IS 11
BP 1042
EP 1047
DI 10.1177/0022034509346147
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 507CG
UT WOS:000270827500012
PM 19828894
OA Bronze
DA 2025 08 17
ER

PT J
AU Cappariello, A
   Loftus, A
   Muraca, M
   Maurizi, A
   Rucci, N
   Teti, A
AF Cappariello, Alfredo
   Loftus, Alexander
   Muraca, Maurizio
   Maurizi, Antonio
   Rucci, Nadia
   Teti, Anna
TI Osteoblast Derived Extracellular Vesicles Are Biological Tools for the
   Delivery of Active Molecules to Bone
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE EXTRACELLULAR VESICLE; OSTEOBLAST; OSTEOCLAST; RANKL; OSTEOPETROSIS;
   TARGETED SHUTTLING
ID INTERCELLULAR COMMUNICATION; INTRAVENOUS ZOLEDRONATE; IN VIVO; EXOSOMES;
   MICROVESICLE; INTEGRINS; DASATINIB; OSTEOPONTIN; CELLS; SRC
AB Extracellular vesicles (EVs) are newly appreciated regulators of tissue homeostasis and a means of intercellular communication. Reports have investigated the role of EVs and their cargoes in cellular regulation and have tried to fine tune their biotechnological use, but to date very little is known on their function in bone biology. To investigate the relevance of EV mediated communication between bone cells, we isolated EVs from primary mouse osteoblasts and assessed membrane integrity, size, and structure by transmission electron microscopy (TEM) and fluorescence activated cell sorting (FACS). EVs actively shuttled loaded fluorochromes to osteoblasts, monocytes, and endothelial cells. Moreover, osteoblast EVs contained mRNAs shared with donor cells. Osteoblasts are known to regulate osteoclastogenesis, osteoclast survival, and osteoclast function by the pro osteoclastic cytokine, receptor activator of nuclear factor  B ligand (Rankl). Osteoblast EVs were enriched in Rankl, which increased after PTH treatment. These EVs were biologically active, supporting osteoclast survival. EVs isolated from rankl( / ) osteoblasts lost this pro osteoclastic function, indicating its Rankl dependence. They integrated ex vivo into murine calvariae, and EV shuttled fluorochromes were quickly taken up by the bone upon in vivo EV systemic administration. Rankl( / ) mice lack the osteoclast lineage and are negative for its specific marker tartrate resistant acid phosphatase (TRAcP). Treatment of rankl( / ) mice with wild type osteoblast EVs induced the appearance of TRAcP positive cells in an EV density dependent manner. Finally, osteoblast EVs internalized and shuttled anti osteoclast drugs (zoledronate and dasatinib), inhibiting osteoclast activity in vitro and in vivo. We conclude that osteoblast EVs are involved in intercellular communication between bone cells, contribute to the Rankl pro osteoclastic effect, and shuttle anti osteoclast drugs, representing a potential means of targeted therapeutic delivery. (c) 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
C1 [Cappariello, Alfredo; Loftus, Alexander; Maurizi, Antonio; Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
   [Muraca, Maurizio] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.
C3 University of L'Aquila; University of Padua
RP Teti, A (通讯作者)，Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM annamaria.teti@univaq.it
RI ; Cappariello, Alfredo/Q 1565 2019; Muraca, Maurizio/G 3063 2012;
   Maurizi, Antonio/AAI 7728 2020
OI Loftus, Alexander/0000 0002 0013 1532; Teti, Anna
   Maria/0000 0002 5887 4419; Rucci, Nadia/0000 0002 1371 8252; MURACA,
   MAURIZIO/0000 0003 1218 097X; Cappariello, Alfredo/0000 0002 1711 3373;
   Maurizi, Antonio/0000 0002 7027 4694; 
FU Investigator Award from the "Societa Italiana di Osteoporosi, del
   Metabolismo Minerale e delle Malattie dello Scheletro"; "Ricerca
   Corrente" of the Ospedale Pediatrico Bambino GesU; Associazione Italiana
   per la Ricerca sul Cancro; European Commission
   [FP7 HEALTH.2012.2.1.1 1 C, 602300]
FX This work was supported by an Investigator Award from the "Societa
   Italiana di Osteoporosi, del Metabolismo Minerale e delle Malattie dello
   Scheletro" to AC, by grants from the "Ricerca Corrente" of the Ospedale
   Pediatrico Bambino GesU to MM, by a grant of the "Associazione Italiana
   per la Ricerca sul Cancro" to NR, by the European Commission grant
   Program "Collaborative Project   Large scale integrating project"   Call
   identifier: FP7 HEALTH.2012.2.1.1 1 C Proposal No 602300   Acronym:
   SYBIL to AT.
CR Akuthota P, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00117
   Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015
   Bolland MJ, 2008, J BONE MINER RES, V23, P1304, DOI [10.1359/jbmr.080312, 10.1359/JBMR.080312]
   Bouleftour W, 2016, MATRIX BIOL, V52 54, P60, DOI 10.1016/j.matbio.2015.12.011
   Breuer E., 2006, Analogue based drug discovery, P371
   Cappariello A, 2016, HORM MOL BIOL CLIN I, V28, P5, DOI 10.1515/hmbci 2016 0009
   Chandler WL, 2016, CYTOM PART B CLIN CY, V90, P326, DOI 10.1002/cyto.b.21343
   Chen TY, 2011, J IMMUNOL, V186, P2219, DOI 10.4049/jimmunol.1002991
   Choi M, 2014, MOL CELLS, V37, P133, DOI 10.14348/molcells.2014.2317
   Cocucci E, 2015, TRENDS CELL BIOL, V25, P364, DOI 10.1016/j.tcb.2015.01.004
   Collino F, 2017, STEM CELL REV REP, V13, P226, DOI 10.1007/s12015 016 9713 1
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev cellbio 101512 122326
   Colombo M, 2013, J CELL SCI, V126, P5553, DOI 10.1242/jcs.128868
   Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood 2005 07 2947
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Doggrell Sheila A, 2002, Expert Opin Pharmacother, V3, P1007, DOI 10.1517/14656566.3.7.1007
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549 006 9463 x
   Garimella R, 2014, TRANSL ONCOL, V7, P331, DOI 10.1016/j.tranon.2014.04.011
   Gho YS, 2017, MOL BIOSYST, V13, P1291, DOI 10.1039/c7mb00146k
   Grey A, 2016, THER ADV MUSCULOSKEL, V8, P119, DOI 10.1177/1759720X16650866
   Haga H, 2017, STEM CELL TRANSL MED, V6, P1262, DOI 10.1002/sctm.16 0226
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Iraci N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020171
   Johnsen KB, 2014, BBA REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005
   Kamel ElSayed SA, 2015, BONE, V76, P129, DOI 10.1016/j.bone.2015.02.011
   Karsenty G, 2014, MOL CELL ENDOCRINOL, V382, P521, DOI 10.1016/j.mce.2013.10.008
   Kholia S, 2016, VASC PHARMACOL, V86, P64, DOI 10.1016/j.vph.2016.03.005
   Kim DR, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/817324
   Kim J, 2017, J DENT RES, V96, P938, DOI 10.1177/0022034517702100
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Li JQ, 2016, J BONE MINER METAB, V34, P367, DOI 10.1007/s00774 015 0734 7
   LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718
   Lo Cicero A, 2015, CURR OPIN CELL BIOL, V35, P69, DOI 10.1016/j.ceb.2015.04.013
   Lo Iacono N, 2012, J BONE MINER RES, V27, P2501, DOI 10.1002/jbmr.1712
   Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mera P, 2016, CELL METAB, V23, P1078, DOI 10.1016/j.cmet.2016.05.004
   Morhayim Jess, 2016, Curr Mol Biol Rep, V2, P48
   Morhayim J, 2015, FASEB J, V29, P274, DOI 10.1096/fj.14 261404
   Nair R, 2014, STEM CELLS DEV, V23, P1625, DOI 10.1089/scd.2013.0633
   Owen RM, 2007, CHEMBIOCHEM, V8, P68, DOI 10.1002/cbic.200600339
   Pichot CS, 2009, BRIT J CANCER, V101, P38, DOI 10.1038/sj.bjc.6605101
   Pierroz DD, 2009, J BONE MINER RES, V24, P775, DOI [10.1359/JBMR.081237, 10.1359/jbmr.081237]
   Pitt JM, 2016, J CLIN INVEST, V126, P1139, DOI 10.1172/JCI87316
   Quesenberry PJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0150 x
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Rivoltini L, 2016, CLIN CANCER RES, V22, P3499, DOI 10.1158/1078 0432.CCR 15 2170
   Rosset EM, 2016, MATRIX BIOL, V52 54, P78, DOI 10.1016/j.matbio.2016.02.001
   Rucci N, 2013, J BONE MINER RES, V28, P1912, DOI 10.1002/jbmr.1951
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Shoulders MD, 2009, ANNU REV BIOCHEM, V78, P929, DOI 10.1146/annurev.biochem.77.032207.120833
   Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
   Teti A, 1998, J BONE MINER RES, V13, P50, DOI 10.1359/jbmr.1998.13.1.50
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yokosaki Y, 2005, MATRIX BIOL, V24, P418, DOI 10.1016/j.matbio.2005.05.005
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339
NR 66
TC 107
Z9 109
U1 6
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2018
VL 33
IS 3
BP 517
EP 533
DI 10.1002/jbmr.3332
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FY3OT
UT WOS:000426731100018
PM 29091316
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Loberg, RD
   Logothetis, CJ
   Keller, ET
   Pienta, KJ
AF Loberg, RD
   Logothetis, CJ
   Keller, ET
   Pienta, KJ
TI Pathogenesis and treatment of prostate cancer bone metastases: Targeting
   the lethal phenotype
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 1st Annual Multidisciplinary Prostate Cancer Symposium
CY FEB 17 19, 2005
CL Orlando, FL
SP Amer Soc Clin Oncol, Amer Soc Therapeut Radiol & Oncol, Amer Soc Urol Oncol, Prostate Canc Fdn
ID FACTOR RECEPTOR INHIBITOR; RANDOMIZED PHASE II; SUBEROYLANILIDE
   HYDROXAMIC ACID; TYROSINE KINASE INHIBITOR; GROWTH FACTOR RECEPTOR 2;
   ANTITUMOR ACTIVITY; ESTRAMUSTINE PHOSPHATE; ENDOTHELIAL CELLS; TUMOR
   PROGRESSION; MAMMALIAN TARGET
AB Traditionally, prostate cancer treatment, as well as all cancer treatment, has been designed to target the tumor cell directly via various hormonal and chemotherapeutic agents. Recently, the realization that cancer cells exist in complex microenvironments that are essential for the tumorigenic and metastatic potential of the cancer cells is starting the redefine the paradigm for cancer therapy. The propensity of prostate cancer cells to metastasize to bone is leading to the design of novel therapies targeting both the cancer cell as well as the bone microenvironment. Tumor cells in the bone interact with the extracellular matrix, stromal cells, osteoblasts, osteoclasts, and endothelial cells to promote tumor cell survival and proliferation leading to a lethal phenotype that includes increased morbidity and mortality for patients with advanced prostate cancer. Several strategies are being developed that target these complex tumor cell microenvironment interactions and target the signal transduction pathways of other cells important to the development of metastases, including the osteoclasts, osteoblasts, and endothelial cells of the bone microenvironment. Current and new therapies in metastatic prostate cancer will comprise a multitargeted approach aimed at both the tumor cell and the tumor microenvironment. Here, we review the current therapeutic strategies for targeting the prostate cancer bone microenvironment and several single  and multiagent targeted approaches to the treatment of advanced prostate cancer that are under development.
C1 Univ Michigan, Michigan Urol Ctr, Ann Arbor, MI 48109 USA.
   Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 University of Michigan System; University of Michigan; University of
   Texas System; UTMD Anderson Cancer Center
RP Pienta, KJ (通讯作者)，Univ Michigan, Michigan Urol Ctr, 7308 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM kpienta@umich.edu
RI Pienta, Kenneth/E 7679 2015; Keller, Evan/M 1446 2016
OI Pienta, Kenneth/0000 0002 4138 2186; 
CR ALAM AS, 1909, ENDOCRINOLOGY, V130, P3617
   [Anonymous], METASTASIS NEOPLASTI
   ARORA A, 2005, J PHAM EXP THER 0707
   Bagnato Anna, 2004, J Transl Med, V2, P16, DOI 10.1186/1479 5876 2 16
   Bander NH, 2005, J CLIN ONCOL, V23, P4591, DOI 10.1200/JCO.2005.05.160
   Beer TM, 2004, MOL CANCER THER, V3, P373
   Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117
   Burch PA, 2004, PROSTATE, V60, P197, DOI 10.1002/pros.20040
   Butler LM, 2000, CANCER RES, V60, P5165
   Canil CM, 2005, J CLIN ONCOL, V23, P455, DOI 10.1200/JCO.2005.02.129
   Carducci M, 2004, J CLIN ONCOL, V22, p384S
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162
   CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g
   Drevs J, 2005, ANN ONCOL, V16, P558, DOI 10.1093/annonc/mdi118
   Eskens FALM, 2003, EUR J CANCER, V39, P917, DOI 10.1016/S0959 8049(03)00057 1
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Galsky MD, 2005, J CLIN ONCOL, V23, P1439, DOI 10.1200/JCO.2005.09.042
   Gediya LK, 2005, J MED CHEM, V48, P5047, DOI 10.1021/jm058214k
   Gioeli D, 2005, CLIN SCI, V108, P293, DOI 10.1042/CS20040329
   Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345 004 0474 0
   Hess Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305
   Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359 6446(04)03202 7
   Hodge JW, 1999, CANCER RES, V59, P5800
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   JAIN RK, 2005, ONCOLOGY S, V3, P197
   Jimenez X, 2005, MOL CANCER THER, V4, P427
   Jimeno A, 2005, EXPERT REV ANTICANC, V5, P419, DOI 10.1586/14737140.5.3.419
   Jimeno A, 2004, EXPERT OPIN INV DRUG, V13, P1631, DOI 10.1517/13543784.13.12.1631
   Kantoff P, 2005, ONCOLOGY NY, V19, P631
   Kaufman HL, 2004, J CLIN ONCOL, V22, P2122, DOI 10.1200/JCO.2004.08.083
   KEMENY N, 1997, CANC MED, V2, P1941
   Kim SJ, 2003, CLIN CANCER RES, V9, P1200
   Ko YJ, 2001, CLIN CANCER RES, V7, P800
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mabjeesh NJ, 2002, CANCER RES, V62, P2478
   Mathew P, 2004, J CLIN ONCOL, V22, P3323, DOI 10.1200/JCO.2004.10.116
   McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757
   Nelson JB, 2005, WORLD J UROL, V23, P19, DOI 10.1007/s00345 004 0478 9
   Nelson WG, 2000, CANCER CHEMOTH PHARM, V46, pS67, DOI 10.1007/PL00014053
   Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Parker CC, 2005, BJU INT, V95, P935, DOI 10.1111/j.1464 410X.2005.05441.x
   Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053
   Pienta Kenneth J, 2005, Clin Prostate Cancer, V4, P24, DOI 10.3816/CGC.2005.n.008
   PIENTA KJ, IN PRESS CANC J CLIN
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   PUTNAM JB, 1983, ANN THORAC SURG, V36, P516, DOI 10.1016/S0003 4975(10)60679 0
   Ryan CW, 2005, BJU INT, V95, P963, DOI 10.1111/j.1464 410X.2005.05448.x
   Saad F, 2004, JNCI J NATL CANCER I, V96, P1480, DOI 10.1093/jnci/djh295
   Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008 5472.CAN 03 3839
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   SHIOIDE M, 1993, J CELL BIOCHEM, V53, P176, DOI 10.1002/jcb.240530211
   Sini P, 2005, CLIN CANCER RES, V11, P4521, DOI 10.1158/1078 0432.CCR 04 1954
   Smaletz O, 2003, ANN ONCOL, V14, P1518, DOI 10.1093/annonc/mdg415
   Sternberg CN, 2005, ONCOLOGY BASEL, V68, P2, DOI 10.1159/000084201
   Strother JM, 2005, EUR J CANCER, V41, P954, DOI 10.1016/j.ejca.2005.02.002
   Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tantivejkul K, 2004, J CELL BIOCHEM, V91, P706, DOI 10.1002/jcb.10664
   Tolcher AW, 2005, CLIN CANCER RES, V11, P3854, DOI 10.1158/1078 0432.CCR 04 2145
   Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008 5472.CAN 04 0074
   Trump DL, 2004, J STEROID BIOCHEM, V89 90, P519, DOI 10.1016/j.jsbmb.2004.03.068
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722
   Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008 5472.CAN 03 3047
   Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466 1268(2002)007<0055:EOGOAR>2.0.CO;2
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008 5472.CAN 04 1443
   Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008 5472.CAN 04 3137
   Xu L, 2005, MOL CANCER THER, V4, P197
NR 72
TC 117
Z9 129
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD NOV 10
PY 2005
VL 23
IS 32
BP 8232
EP 8241
DI 10.1200/JCO.2005.03.0841
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 984NQ
UT WOS:000233312000015
PM 16278478
DA 2025 08 17
ER

PT J
AU Wang, MD
   Park, S
   Nam, Y
   Nielsen, J
   Low, SA
   Srinivasarao, M
   Low, PS
AF Wang, Mingding
   Park, Soie
   Nam, Yoonhee
   Nielsen, Jeffery
   Low, Stewart A.
   Srinivasarao, Madduri
   Low, Philip S.
TI Bone Fracture Targeted Dasatinib Oligoaspartic Acid Conjugate Potently
   Accelerates Fracture Repair
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID INHIBITOR LOADED MICELLES; SELECTIVE DRUG DELIVERY; PARATHYROID HORMONE;
   KINASE INHIBITOR; OSTEOBLAST DIFFERENTIATION; IN VITRO; SRC;
   OSTEOCLASTS; PROLIFERATION; HYPERCALCEMIA
AB Approximately 6.3 million bone fractures occur annually in the United States, resulting in considerable morbidity, deterioration in quality of life, loss of productivity and wages, and sometimes death (e.g., hip fractures). Although anabolic and antiresorptive agents have been introduced for treatment of osteoporosis, no systemically administered drug has been developed to accelerate the fracture healing process. To address this need, we have undertaken to target a bone anabolic agent selectively to fracture surfaces in order to concentrate the drug's healing power directly on the fracture site. We report here that conjugation of dasatinib to a bone fracture homing oligopeptide via a releasable linker reduces fractured femur healing times in mice by similar to 60% without causing overt off target toxicity or remodeling of non traumatized bones. Thus, achievement of healthy bone density, normal bone volume, and healthy bone mechanical properties at the fracture site is realized after only 3 4 weeks in dasatinib targeted mice, but it requires similar to 8 weeks in PBS treated controls. We conclude that targeting of dasatinib to bone fracture surfaces can significantly accelerate the healing process at dasatinib concentrations that are known to be safe in ontological applications.
C1 [Wang, Mingding; Park, Soie; Nam, Yoonhee; Low, Stewart A.; Srinivasarao, Madduri; Low, Philip S.] Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.
   [Low, Philip S.] Purdue Univ, Inst Drug Discovery, 720 Clin Dr, W Lafayette, IN 47907 USA.
   [Nielsen, Jeffery] Purdue Univ, Coll Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; Purdue University System; Purdue University
RP Low, PS (通讯作者)，Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.; Low, PS (通讯作者)，Purdue Univ, Inst Drug Discovery, 720 Clin Dr, W Lafayette, IN 47907 USA.
EM plow@purdue.edu
RI ; Low, Stewart/JTU 2123 2023
OI Low, Stewart/0000 0002 7387 3545; Low, Philip/0000 0001 9042 5528;
   srinivasarao, madduri/0000 0003 3056 4571; Nielsen,
   Jeffery/0000 0002 2329 1299
CR Adachi JD, 2010, MAYO CLIN PROC, V85, P806, DOI 10.4065/mcp.2010.0082
   Alemán JO, 2014, ENDOCR RELAT CANCER, V21, pR247, DOI 10.1530/ERC 12 0400
   Amso Z, 2016, MED RES REV, V36, P579, DOI 10.1002/med.21388
   Arangio GA, 1997, J TRAUMA, V42, P942, DOI 10.1097/00005373 199705000 00027
   Babu S, 2015, WORLD J ORTHOP, V6, P457, DOI 10.5312/wjo.v6.i6.457
   Bartl R., 2009, Osteoporosis: Diagnosis, prevention, therapy
   Bentler SE, 2009, AM J EPIDEMIOL, V170, P1290, DOI 10.1093/aje/kwp266
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Borriello A, 2017, ONCOTARGET, V8, P5540, DOI 10.18632/oncotarget.12649
   Boufker HI, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 298
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Brownlow N, 2009, LEUKEMIA, V23, P590, DOI 10.1038/leu.2008.237
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Chew CK, 2017, MATURITAS, V97, P53, DOI 10.1016/j.maturitas.2016.12.003
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DITTMER DK, 1993, CAN FAM PHYSICIAN, V39, P1428
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Dubrovsky L, 2014, BLOOD, V123, P3296, DOI 10.1182/blood 2014 01 549022
   Fitzpatrick Lorraine A., 2006, Arq Bras Endocrinol Metab, V50, P705, DOI 10.1590/S0004 27302006000400016
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Gu Q, 2014, CLIN ORTHOP RELAT R, V472, P3536, DOI 10.1007/s11999 014 3820 6
   Holm AGV, 2016, INJURY, V47, P1410, DOI 10.1016/j.injury.2016.04.007
   Ishizaki J, 2009, J BONE MINER METAB, V27, P1, DOI 10.1007/s00774 008 0004 z
   Jepsen KJ, 2015, J BONE MINER RES, V30, P951, DOI 10.1002/jbmr.2539
   Jönsson S, 2010, LEUKEMIA, V24, P1357, DOI 10.1038/leu.2010.84
   Kamath AV, 2008, CANCER CHEMOTH PHARM, V61, P365, DOI 10.1007/s00280 007 0478 8
   Kamiya Nobuhiro, 2012, Curr Mol Pharmacol, V5, P153
   Karatoprak C, 2012, INDIAN J PHARMACOL, V44, P270, DOI 10.4103/0253 7613.93869
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Kim HY, 2016, EMBO MOL MED, V8, P375, DOI 10.15252/emmm.201505714
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Lee D, 2016, SCI REP UK, V6, DOI 10.1038/srep27336
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Li J., 2014, FRACTURE HEALING BAS, P205
   Low SA, 2017, NANOMEDICINE UK, V12, P185, DOI 10.2217/nnm 2016 0340
   Low SA, 2015, BIOMACROMOLECULES, V16, P3145, DOI 10.1021/acs.biomac.5b00777
   Maiti S., 2017, Bio Targets and Drug Delivery Approaches
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Mediero A, 2015, FASEB J, V29, P1577, DOI 10.1096/fj.14 265066
   Meehan AD, 2018, WORLD J SURG, V42, P415, DOI 10.1007/s00268 017 4328 5
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Peruzzi B., 2012, PROTEIN KINASES, P357
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   US Department of Health and Human Services, 2004, BON HLTH OST REP SUR, V113, P805
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340
   Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481
NR 59
TC 24
Z9 26
U1 0
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
EI 1520 4812
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD NOV
PY 2018
VL 29
IS 11
BP 3800
EP 3809
DI 10.1021/acs.bioconjchem.8b00660
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0NZ
UT WOS:000451496400033
PM 30380292
DA 2025 08 17
ER

PT J
AU Bivi, N
   Bereszczak, JZ
   Romanello, M
   Zeef, LAH
   Delneri, D
   Quadrifoglio, F
   Moro, L
   Brancia, FL
   Tell, G
AF Bivi, Nicoletta
   Bereszczak, Jessica Z.
   Romanello, Milena
   Zeef, Leo A. H.
   Delneri, Daniela
   Quadrifoglio, Franco
   Moro, Luigi
   Brancia, Francesco L.
   Tell, Gianluca
TI Transcriptome and Proteome Analysis of Osteocytes Treated with
   Nitrogen Containing Bisphosphonates
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE bisphosphonates; osteocytes; differential proteomics; gene expression;
   GLaD; isotopic labelling
ID LABELING DERIVATIZATION GLAD; RENAL EPITHELIAL CELLS; BONE RESORPTION;
   PROTON PUMP; ACTIVATION; OSTEOCLASTS; OSTEOBLASTS; MECHANISMS;
   EXPRESSION; APOPTOSIS
AB We combined high throughput screening of differential mRNAs with mass spectrometric characterization of proteins obtained from osteocytes untreated and treated with Risedronate. Microarray analysis revealed, upon treatment, a marked upregulation of messengers encoding zinc proteins. MS analysis identified 84 proteins in the osteocytes proteome map. Risedronate affected the expression of 10 proteins, associated with cytoskeleton, stress response and metabolism. Data validated using gel imaging in combination with the GLaD post digestion isotopic labeling method provide the molecular basis for understanding the role of bisphosphonates as antiapoptotic drugs for osteocytes.
C1 [Bereszczak, Jessica Z.; Brancia, Francesco L.] Shimadzu Res Lab Europe, Manchester, Lancs, England.
   [Bivi, Nicoletta; Romanello, Milena; Quadrifoglio, Franco; Tell, Gianluca] Univ Udine, Dept Biomed Sci & Technol, I 33100 Udine, Italy.
   [Zeef, Leo A. H.; Delneri, Daniela] Univ Manchester, Dept Life Sci, Manchester M13 9PL, Lancs, England.
   [Moro, Luigi] Ctr Study Metab Bone Dis, I 34170 Gorizia, Italy.
C3 University of Udine; University of Manchester
RP Brancia, FL (通讯作者)，Shimadzu Res Lab, Trafford Wharf Rd, Manchester M17 1GP, Lancs, England.
RI ; Zeef, Leo/D 6922 2011; Brancia, Francesco/AAL 1510 2020
OI Tell, Gianluca/0000 0001 8845 6448; Delneri,
   Daniela/0000 0001 8070 411X; 
FU Procter Gamble; Regione Friuli Venezia Giulia [200501969001
   L.R.11/2005]; MIUR [RBRN07BMCT]; NERC Advanced Fellowship; Shimadzu
   Corporation
FX This work was supported by grants from Procter & Gamble to G.T. and
   L.M., from Regione Friuli Venezia Giulia (grant no. 200501969001
   L.R.11/2005) and from MIUR (FIRB #RBRN07BMCT the Italian Human
   ProteomeNet) to G.T., D.D. is sponsored by a NERC Advanced Fellowship.
   The authors are also grateful to Shimadzu Corporation for partially
   funding this work.
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Ahuja SS, 2003, ENDOCRINOLOGY, V144, P1761, DOI 10.1210/en.2002 221136
   Bereszczak JZ, 2007, J AM SOC MASS SPECTR, V18, P201, DOI 10.1016/j.jasms.2006.09.015
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Brancia FL, 2000, RAPID COMMUN MASS SP, V14, P2070, DOI 10.1002/1097 0231(20001115)14:21<2070::AID RCM133>3.0.CO;2 G
   Brancia FL, 2004, ANAL CHEM, V76, P2748, DOI 10.1021/ac030421+
   Brancia FL, 2007, RAPID COMMUN MASS SP, V21, P3069, DOI 10.1002/rcm.3176
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844
   Chignard N, 2006, GASTROENTEROLOGY, V130, P2010, DOI 10.1053/j.gastro.2006.02.058
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   George M, 2004, ANN RHEUM DIS, V63, P67, DOI 10.1136/ard.2002.005256
   Gu GL, 2005, BIOCHEM BIOPH RES CO, V335, P1095, DOI 10.1016/j.bbrc.2005.06.211
   Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kerr MC, 2005, TRAFFIC, V6, P991, DOI 10.1111/j.1600 0854.2005.00328.x
   Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751
   Madhok R, 2000, BMJ BRIT MED J, V321, P882, DOI 10.1136/bmj.321.7265.882
   MATTSSON JP, 1993, BIOCHIM BIOPHYS ACTA, V1146, P106, DOI 10.1016/0005 2736(93)90344 Y
   PALUMBO C, 1990, ACTA ANAT, V137, P350
   Persson E, 2005, BIOCHEM BIOPH RES CO, V335, P705, DOI 10.1016/j.bbrc.2005.07.135
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Romanello M, 2006, BONE, V39, P739, DOI 10.1016/j.bone.2006.03.011
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021 9290(03)00123 4
   Tazawa K, 2004, J BONE MINER METAB, V22, P524, DOI 10.1007/s00774 004 0519 x
   TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   Vascotto C, 2006, PROTEOMICS, V6, P3455, DOI 10.1002/pmic.200500770
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683
   Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091
   Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 4 r28
   Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092 8674(03)00552 X
NR 44
TC 19
Z9 22
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR
PY 2009
VL 8
IS 3
BP 1131
EP 1142
DI 10.1021/pr8005606
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 416WA
UT WOS:000264035000004
PM 19226166
DA 2025 08 17
ER

PT J
AU Cheng, CN
   Xing, ZY
   Hu, Q
   Kong, N
   Liao, CS
   Xu, SX
   Zhang, JY
   Kang, FW
   Zhu, XJ
AF Cheng, Chunan
   Xing, Zhenyu
   Hu, Qian
   Kong, Na
   Liao, Chongshan
   Xu, Sixin
   Zhang, Jieying
   Kang, Feiwu
   Zhu, Xingjun
TI A bone targeting near infrared luminescence nanocarrier facilitates
   alpha ketoglutarate efficacy enhancement for osteoporosis therapy
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Osteoporosis therapy; Bone targeting; Drug delivery nanoparticle;
   Alpha ketoglutarate; Near infrared imaging
ID NANOPARTICLES
AB Osteoporosis (OP), which largely increases the risk of fractures, is the most common chronic degenerative orthopedic disease in the elderly due to the imbalance of bone homeostasis. Alpha ketoglutaric acid (AKG), an endogenous metabolic intermediate involved in osteogenesis, plays critical roles in osteogenic differentiation and mineralization and the inhibition of osteoclastogenic differentiation. However, the low bioavailability and poor bone targeting efficiency of AKG seriously limit its efficacy in OP treatment. In this work, a bone targeting, near infrared emissive lanthanide luminescence nanocarrier loaded with AKG (beta NaYF4:7%Yb, 60%Nd@NaLuF4 @mSiO(2) EDTA AKG, abbreviated as LMEK) is developed for the enhancement of AKG efficacy in OP therapy. By utilizing the NIR II luminescence ( > 1000 nm) of LMEK, whole body bone imaging with high spatial resolution is achieved to confirm the bone enrichment of AKG non invasively in vivo . The results reveal that LMEK exhibits a remarkable OP therapeutic effect in improving the osseointegration of the surrounding bone in the ovariectomized OP mice models, which is validated by the enhanced inhibition of osteoclast through hypoxia inducible factor 1 alpha suppression and promotion of osteogenic differentiation in osteoblast. Notably, the dose of AKG in LMEK can be reduced to only 0.2 % of the dose when pure AKG is used in therapy, which dramatically improves the bioavailability of AKG and mitigates the metabolism burden. This work provides a strategy to conquer the low utilization of AKG in OP therapy, which not only overcomes the challenges in AKG efficacy for OP treatment but also offers insights into the development and application of other potential drugs for skeletal diseases.
C1 [Cheng, Chunan; Kang, Feiwu] Stomatol Hosp, Dept Oral & Maxillofacial Surg, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
   [Cheng, Chunan; Liao, Chongshan; Kang, Feiwu] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dent Sch, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
   [Xing, Zhenyu; Hu, Qian; Kong, Na; Xu, Sixin; Zhang, Jieying; Zhu, Xingjun] ShanghaiTech Univ, Sch Phys Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China.
   [Liao, Chongshan] Stomatol Hosp, Dept Orthodont, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
C3 Tongji University; ShanghaiTech University
RP Kang, FW (通讯作者)，Stomatol Hosp, Dept Oral & Maxillofacial Surg, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.; Kang, FW (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dent Sch, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.; Zhu, XJ (通讯作者)，ShanghaiTech Univ, Sch Phys Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China.
EM kfw@tongji.edu.cn; zhuxj1@shanghaitech.edu.cn
RI Xing, Zhenyu/ADG 4760 2022; Zhu, Xingjun/R 2584 2018
OI Liao, Chongshan/0000 0001 7494 5515; Zhu, Xingjun/0000 0002 7507 1781
FU National Natural Science Foundation of China [820 01945, 820 010 08,
   82271013]; Shanghai Pujiang Program [20PJ1410700]; State Key Laboratory
   of Advanced Medical Materials and Devices; Shanghai Tech University
FX The authors thank the funding of the National Natural Science Foundation
   of China (820 01945 , 820 010 08, 82271013) , the Shanghai Pujiang
   Program (20PJ1410700) , the State Key Laboratory of Advanced Medical
   Materials and Devices and the starting grant of Shanghai Tech University
   . The authors thank the Centre for High resolution Electron Microscopy
   (C h EM) (No. EM02161943) , Analyti cal Instrumentation Center
   (#SPST AIC10112914) , School of Physical Science and Technology,
   ShanghaiTech University, and Dr. Lin Xiong and Dr. Rong Gao for the
   characterization support.
CR Bie MM, 2023, BONE, V168, DOI 10.1016/j.bone.2022.116648
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Cao C, 2020, NANOSCALE, V12, P8248, DOI 10.1039/d0nr01098g
   Cao C, 2019, INORG CHEM, V58, P9351, DOI 10.1021/acs.inorgchem.9b01071
   Chen LA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/10/105708
   Chen W., 2022, Cells, V11, P3522
   Chen XT, 2020, THERANOSTICS, V10, P3281, DOI 10.7150/thno.37599
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Crandall CJ, 2021, JAMA INTERN MED, V181, P1055, DOI 10.1001/jamainternmed.2021.2617
   Dabek M, 2005, J ANIM PHYSIOL AN N, V89, P419, DOI 10.1111/j.1439 0396.2005.00566.x
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Dunphy L, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr 2018 224455
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Fan Y, 2019, ADV OPT MATER, V7, DOI 10.1002/adom.201801417
   Guo SS, 2017, ANIM SCI J, V88, P1753, DOI 10.1111/asj.12824
   Gyanwali B, 2022, TRENDS ENDOCRIN MET, V33, P136, DOI 10.1016/j.tem.2021.11.003
   Harrison AP, 2008, J PHYSIOL PHARMACOL, V59, P91
   Hong GS, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 016 0010
   Huang YK, 2022, COORDIN CHEM REV, V450, DOI 10.1016/j.ccr.2021.214236
   Jia YZ, 2023, SCI TOTAL ENVIRON, V878, DOI 10.1016/j.scitotenv.2023.163069
   Khosla S, 2023, LANCET DIABETES ENDO, V11, P19, DOI 10.1016/S2213 8587(22)00322 9
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Klumpen E, 2021, COMP BIOCHEM PHYS B, V255, DOI 10.1016/j.cbpb.2021.110591
   Lee S, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115836
   Legendre F, 2020, WORLD J MICROB BIOT, V36, DOI 10.1007/s11274 020 02900 8
   Li CY, 2020, J AM CHEM SOC, V142, P14789, DOI 10.1021/jacs.0c07022
   Li H, 2021, ADV MATER, V33, DOI 10.1002/adma.202000678
   Li LY, 2021, ACS NANO, V15, P4518, DOI 10.1021/acsnano.0c08532
   Li XP, 2013, SCI REP UK, V3, DOI [10.1038/srep02819, 10.1038/srep03536]
   Liu RJ, 2023, J CLIN PERIODONTOL, V50, P671, DOI 10.1111/jcpe.13784
   Liu Z, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202102042
   Longmire M, 2008, NANOMEDICINE UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Mangione CM, 2022, JAMA J AM MED ASSOC, V328, P1740, DOI 10.1001/jama.2022.18625
   Meng XY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00189 x
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Ni S, 2021, FREE RADICAL BIO MED, V169, P271, DOI 10.1016/j.freeradbiomed.2021.04.027
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Radzki RP, 2009, SCAND J CLIN LAB INV, V69, P175, DOI 10.1080/00365510802464633
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rhoads TW, 2020, CELL METAB, V32, P323, DOI 10.1016/j.cmet.2020.08.009
   Rouco H, 2023, WIRES NANOMED NANOBI, V15, DOI 10.1002/wnan.1885
   Seo HJ, 2015, SCI REP UK, V5, DOI 10.1038/srep15685
   Shahmirzadi AA, 2020, CELL METAB, V32, P447, DOI 10.1016/j.cmet.2020.08.004
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tomaszewska E, 2020, ANIMALS BASEL, V10, DOI 10.3390/ani10122420
   Wang JW, 2018, J BONE MINER METAB, V36, P508, DOI 10.1007/s00774 017 0866 z
   Wang XJ, 2019, MOL CELL, V76, P148, DOI 10.1016/j.molcel.2019.07.007
   Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19360 1
   Xu JT, 2020, ACS NANO, V14, P9613, DOI 10.1021/acsnano.0c00082
   Xu W, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2022.111987
   Xu XW, 2014, RSC ADV, V4, P46481, DOI 10.1039/c4ra06863g
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Zhang Y, 2012, ACS NANO, V6, P3695, DOI 10.1021/nn301218z
   Zhang ZZ, 2021, AGING CELL, V20, DOI 10.1111/acel.13291
   Zhao MY, 2019, ANGEW CHEM INT EDIT, V58, P2050, DOI 10.1002/anie.201812878
NR 56
TC 7
Z9 8
U1 8
U2 63
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 1
PY 2024
VL 173
BP 442
EP 456
DI 10.1016/j.actbio.2023.11.022
EA DEC 2023
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ET6H2
UT WOS:001141215100001
PM 37984632
DA 2025 08 17
ER

PT J
AU Gan, K
   Lian, HY
   Yang, T
   Huang, J
   Chen, JC
   Su, YG
   Zhao, JM
   Xu, JK
   Liu, Q
AF Gan, Kai
   Lian, Haoyu
   Yang, Tao
   Huang, Jian
   Chen, Junchun
   Su, Yuangang
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
TI Periplogenin attenuates LPS mediated inflammatory osteolysis through the
   suppression of osteoclastogenesis via reducing the NF κB and MAPK
   signaling pathways
SO CELL DEATH DISCOVERY
LA English
DT Article
ID RECEPTOR ACTIVATOR; BONE RESORPTION; NUCLEAR FACTOR; LIPOPOLYSACCHARIDE;
   CELLS; PRECURSORS; IMMUNE; MICE
AB The key target for treating inflammatory osteolysis is osteoclasts. In an inflammatory environment, osteoclast differentiation increases, and bone resorption is enhanced. Periplogenin (Ppg) is a traditional Chinese medicine. It has anti inflammatory and antitumor effects, but its impact on inflammatory osteolysis is unknown. This study found that Ppg prevented LPS induced skull osteolysis by inhibiting the expression of inflammatory cytokines and osteoclast production. In vitro, Ppg blocked the RANKL induced generation of osteoclasts, the development of pseudopodia bands, and bone resorption. Ppg also attenuated the expression of NFATc1, c Fos, CTSK, and Atp6v0d2 proteins by inhibiting the NFATc1 signaling pathway. In addition, Ppg inhibited the expression of osteoclast specific genes, including NFATc1, c Fos, CTSK, Atp6v0d2, and Mmp9. Moreover, Ppg also inhibited NF kappa B and MAPK pathways. In vivo, Ppg reduced the number of osteoclasts on the surface of the bone and suppressed LPS induced osteolysis of the skull. These outcomes suggest that Ppg can serve as a new alternative therapy for treating inflammatory osteolysis by inhibiting inflammation and osteoclasts.
C1 [Gan, Kai; Lian, Haoyu; Yang, Tao; Huang, Jian; Chen, Junchun; Su, Yuangang; Zhao, Jinmin; Xu, Jiake; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.
   [Lian, Haoyu; Yang, Tao; Chen, Junchun; Su, Yuangang; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Life Sci Inst, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Guangxi, Peoples R China.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen 518000, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Chinese Academy
   of Sciences; Shenzhen Institute of Advanced Technology, CAS
RP Xu, JK; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.; Liu, Q (通讯作者)，Guangxi Med Univ, Life Sci Inst, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Guangxi, Peoples R China.; Xu, JK (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen 518000, Peoples R China.
EM jiake.xu@siat.ac.cn; liuqian@gxmu.edu.cn
RI Su, Yuangang/KKU 6952 2024; zhao, jin/LBH 0351 2024; Lian,
   Haoyu/W 3317 2017
OI Yang, Tao/0009 0002 6777 2649
FU Natural Science Foundation of Guangxi Province (Guangxi Natural Science
   Foundation) [GuikeAD19254003]; Guangxi Science and Technology Base and
   Talent Special Project [2023GXNSFDA026058]; Guangxi Natural Science
   Foundation
FX We acknowledge all the people who provided helpful input to this study.
   This research was supported by Guangxi Science and Technology Base and
   Talent Special Project (Grant No. GuikeAD19254003) and Guangxi Natural
   Science Foundation (2023GXNSFDA026058).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Fretz JA, 2008, MOL ENDOCRINOL, V22, P737, DOI 10.1210/me.2007 0333
   Guo JC, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13011
   Hajishengallis G, 2016, SEMIN IMMUNOL, V28, P146, DOI 10.1016/j.smim.2016.02.002
   He J, 2015, J PHARMACEUT BIOMED, V114, P292, DOI 10.1016/j.jpba.2015.06.008
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Hong CY, 2004, J ORAL PATHOL MED, V33, P162, DOI 10.1111/j.0904 2512.2004.00045.x
   Hu YM, 2021, ONCOGENE, V40, P3942, DOI 10.1038/s41388 021 01817 2
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jiang WH, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00201 4
   Jin FJ, 2022, INT J BIOL SCI, V18, P4482, DOI 10.7150/ijbs.72487
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580 020 0255 7
   Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464
   Li YJ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13291
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Loi F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0276 5
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Luo P, 2022, BONE JOINT RES, V11, P426, DOI 10.1302/2046 3758.117.BJR 2021 0594.R1
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Maruotti N, 2011, CLIN EXP MED, V11, P137, DOI 10.1007/s10238 010 0117 2
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Meng XC, 2022, J ORTHOP TRANSL, V34, P1, DOI 10.1016/j.jot.2022.04.001
   Panda S, 2011, HORM METAB RES, V43, P188, DOI 10.1055/s 0031 1271621
   Pattison E, 2008, ANN RHEUM DIS, V67, P672, DOI 10.1136/ard.2007.073932
   Qiu JX, 2022, BIOCHEM PHARMACOL, V205, DOI 10.1016/j.bcp.2022.115155
   RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892 54
   Swierczek A, 2023, J PHARMACOL EXP THER, V384, P455, DOI 10.1124/jpet.122.001477
   Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Xu YL, 2023, FREE RADICAL BIO MED, V196, P121, DOI 10.1016/j.freeradbiomed.2023.01.017
   Xue P, 2021, EXP MOL MED, V53, P667, DOI 10.1038/s12276 021 00596 w
   Yamada T, 2003, BLOOD, V101, P2227, DOI 10.1182/blood 2002 06 1740
   Yan CQ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175538
   Zeng CY, 2023, PHYTOTHER RES, V37, P252, DOI 10.1002/ptr.7610
   Zhang HW, 2021, AGING US, V13, P17690, DOI 10.18632/aging.203259
   Zhang WJ, 2016, BIOCHEM PHARMACOL, V105, P66, DOI 10.1016/j.bcp.2016.02.001
   Zhang YW, 2012, ACTA CRYSTALLOGR E, V68, pO1582, DOI 10.1107/S1600536812018521
   Zhou L, 2020, INT J BIOL SCI, V16, P309, DOI 10.7150/ijbs.37162
   Zhu LJ, 2022, ECOTOX ENVIRON SAFE, V246, DOI 10.1016/j.ecoenv.2022.114150
NR 51
TC 11
Z9 11
U1 1
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD FEB 17
PY 2024
VL 10
IS 1
AR 86
DI 10.1038/s41420 024 01856 0
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IB2K7
UT WOS:001163794700002
PM 38368392
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Blazsek, J
   Nagy, CD
   Blazsek, I
   Varga, R
   Vecsei, B
   Fejérdy, P
   Varga, G
AF Blazsek, Jozsef
   Nagy, Csaba Dobo
   Blazsek, Istvan
   Varga, Rita
   Vecsei, Balint
   Fejerdy, Pal
   Varga, Gabor
TI Aminobisphosphonate Stimulates Bone Regeneration and Enforces
   Consolidation of Titanium Implant into a New Rat Caudal Vertebrae Model
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE New implant osseointegration model; Osteo neogenesis;
   Aminobisphosphonates (Zometa (R)); Bone regeneration; Micro computer
   tomography (micro CT); Biomechanical measurement
ID OSTEOBLAST DIFFERENTIATION; BISPHOSPHONATES INHIBIT; OSTEOCLAST
   FORMATION; MEVALONATE PATHWAY; ZOLEDRONIC ACID; RESORPTION; PROTEIN;
   CELLS; GERANYLGERANYLATION; PROLIFERATION
AB Bisphosphonates are widely used as therapeutic agents in bone disorders including cancer metastasis due to their osteoclast inhibitory effect. Recent data shows that bisphosphonates may also induce bone building by stimulating osteoblast activity. Clinical observations, however, have revealed that bisphosphonates may cause necrosis in the oral cavity which questions their usefulness in bone regeneration during the consolidation of inorganic implants. Here we report the investigation of bone neogenesis following chronic amine bisphosphonate (Zometa (R)) treatment in a novel experimental model, using the rat tail vertebra as a support. This method involves (1) implantation of titan screw into the tail vertebrae, (2) systemic bisphosphonate treatment and (3) quantitative biophysical measurements which mirrors consolidation of implant, i.e. strength of fixation and changes in newly formed bone architecture using micro Computer Tomograph (micro CT). The degree of fixation of titan implants (osseointegration) increased by 36% on the effect of Zometa and the structure of newly formed bone became robust. The mass of new bone increased 3.1 fold at 6 weeks of regeneration, as compared to controls. Thus, Zometa (R), a potent aminobisphosphonate used in therapy of cancer metastases, osteoporosis and bone marrow transplantation, significantly increased bone neogenesis and enforced osseointegration of titan implants as measured quantitatively in the rat tail vertebra. Our data support the usefulness of aminobisphosphonates in the rehabilitation of bone loss as well as in improvement osseointegration of implants. We emphasise that this novel method may open up new possibilities for screening the effects of local and systemic treatments.
C1 [Blazsek, Jozsef; Varga, Gabor] Semmelweis Univ, Dept Oral Biol, H 1089 Budapest, Hungary.
   [Nagy, Csaba Dobo; Vecsei, Balint; Fejerdy, Pal] Semmelweis Univ, Dept Prosthodont, H 1089 Budapest, Hungary.
   [Blazsek, Istvan] INSERM, U602, F 94807 Villejuif, France.
   [Blazsek, Istvan] ICIG, U972, F 94807 Villejuif, France.
   [Blazsek, Istvan] Univ Paris 11, Paul Brousse Hosp, F 94807 Villejuif, France.
   [Varga, Rita] Full Tech Co, Budapest, Hungary.
C3 Semmelweis University; Semmelweis University; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Paul Brousse   APHP; Universite
   Paris Saclay
RP Blazsek, J (通讯作者)，Semmelweis Univ, Dept Oral Biol, Nagyvarad Ter 4, H 1089 Budapest, Hungary.
EM blajozs@net.sote.hu
RI Dobo Nagy, Csaba/X 6971 2019; Vecsei, Bálint/O 2745 2017; Varga,
   Gábor/O 8858 2017
OI Dobo Nagy, Csaba/0000 0001 9530 7926; Varga, Gabor/0000 0002 5506 8198
FU Hungarian National Scientific Research Fund [OTKA61543, IN67250];
   Hungarian Health Research Council [ETT332/2006]; Inserm [U602];
   Universite de Paris Sud Kremlin Bicetre, France
FX The authors wish to thank Miklos Kovacs and Marta Fulop for skilled
   technical work, Tivadar Zelles and Gyorgy Simon for critical discussions
   (USN), Ferenc Fuller (Full Tech) for providing titanium implants and
   Claude Boucheix (InsermU602) for their continuous help. The authors wish
   to thank Neil Dixon (Manchester, UK) for critical reading of the
   manuscript. This work was supported in part by the Hungarian National
   Scientific Research Fund (OTKA61543 and IN67250), by the Hungarian
   Health Research Council (ETT332/2006) and by Inserm U602, ICIG and
   Universite de Paris Sud Kremlin Bicetre, France.
CR Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Amital H, 2004, CLIN RHEUMATOL, V23, P330, DOI 10.1007/s10067 004 0941 4
   BLAZSEK I, 1986, BIOMED PHARMACOTHER, V40, P28
   Blazsek I, 2000, BLOOD, V96, P3763, DOI 10.1182/blood.V96.12.3763.h8003763_3763_3771
   Boissier S, 2000, CANCER RES, V60, P2949
   Branemark P., 1985, Osseointegration in clinical dentistry, P211
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chapurlat RD, 2004, BONE, V35, P235, DOI 10.1016/j.bone.2004.03.004
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Epling Burnette PK, 2007, LEUKEMIA, V21, P659, DOI 10.1038/sj.leu.2404590
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Evans EA, 2007, SCIENCE, V316, P1148, DOI 10.1126/science.1137592
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fromigué O, 2002, J ENDOCRINOL INVEST, V25, P539, DOI 10.1007/BF03345497
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hashimoto T, 2007, CALCIFIED TISSUE INT, V81, P232, DOI 10.1007/s00223 007 9056 7
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   KAUFMAN MH, 1992, ATLAS MOUSE DEV
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325
   Lee YP, 2002, CANCER RES, V62, P5564
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lundborg G, 2007, SCAND J PLAST RECONS, V41, P130, DOI 10.1080/02844310701318346
   Merigo E, 2005, J ORAL PATHOL MED, V34, P613, DOI 10.1111/j.1600 0714.2005.00351.x
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Naresh KN, 2006, J CLIN PATHOL, V59, P903, DOI 10.1136/jcp.2004.020610
   Ohazama A, 2004, J DENT RES, V83, P518, DOI 10.1177/154405910408300702
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Saulacic N, 2008, INT J ORAL MAX SURG, V37, P1, DOI 10.1016/j.ijom.2007.07.020
   Shubayev VI, 2004, J REHABIL RES DEV, V41, P757, DOI 10.1682/JRRD.2003.07.0107
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Tauchmanovà L, 2005, J CLIN ENDOCR METAB, V90, P627, DOI 10.1210/jc.2004 0509
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wang DA, 2007, NAT MATER, V6, P385, DOI 10.1038/nmat1890
   Ysander M, 2001, J REHABIL RES DEV, V38, P183
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhao Z, 2007, J DENT RES, V86, P1207, DOI 10.1177/154405910708601213
NR 46
TC 16
Z9 20
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD DEC
PY 2009
VL 15
IS 4
BP 567
EP 577
DI 10.1007/s12253 009 9156 y
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA 539UE
UT WOS:000273283100005
PM 19267222
DA 2025 08 17
ER

PT J
AU Loukas, AT
   Papadourakis, M
   Panagiotopoulos, V
   Zarmpala, A
   Chontzopoulou, E
   Christodoulou, S
   Katsila, T
   Zoumpoulakis, P
   Matsoukas, MT
AF Loukas, Alexandros Timotheos
   Papadourakis, Michail
   Panagiotopoulos, Vasilis
   Zarmpala, Apostolia
   Chontzopoulou, Eleni
   Christodoulou, Stephanos
   Katsila, Theodora
   Zoumpoulakis, Panagiotis
   Matsoukas, Minos Timotheos
TI Natural Compounds for Bone Remodeling: A Computational and Experimental
   Approach Targeting Bone Metabolism Related Proteins
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoporosis; natural compounds; molecular docking; molecular dynamics
   simulations; bone metabolism; quercetin; MAPKs
ID POSTMENOPAUSAL WOMEN; MOLECULAR DYNAMICS; MINERAL DENSITY; SOFTWARE
   NEWS; SCIENTIFIC OPINION; GUT MICROBIOME; OSTEOPOROSIS; PREVENTION;
   ALGORITHM; SAFETY
AB Osteoporosis, characterized by reduced bone density and increased fracture risk, affects over 200 million people worldwide, predominantly older adults and postmenopausal women. The disruption of the balance between bone forming osteoblasts and bone resorbing osteoclasts underlies osteoporosis pathophysiology. Standard treatment includes lifestyle modifications, calcium and vitamin D supplementation and specific drugs that either inhibit osteoclasts or stimulate osteoblasts. However, these treatments have limitations, including side effects and compliance issues. Natural products have emerged as potential osteoporosis therapeutics, but their mechanisms of action remain poorly understood. In this study, we investigate the efficacy of natural compounds in modulating molecular targets relevant to osteoporosis, focusing on the Mitogen Activated Protein Kinase (MAPK) pathway and the gut microbiome's influence on bone homeostasis. Using an in silico and in vitro methodology, we have identified quercetin as a promising candidate in modulating MAPK activity, offering a potential therapeutic perspective for osteoporosis treatment.
C1 [Loukas, Alexandros Timotheos; Zoumpoulakis, Panagiotis] Univ West Attica, Dept Food Sci & Technol, Ag Spyridonos, Egaleo 12243, Greece.
   [Loukas, Alexandros Timotheos; Papadourakis, Michail; Panagiotopoulos, Vasilis; Zarmpala, Apostolia; Chontzopoulou, Eleni; Christodoulou, Stephanos; Matsoukas, Minos Timotheos] Cloudpharm Private Co, Kifissias Ave 44, Maroussi 15125, Greece.
   [Panagiotopoulos, Vasilis; Matsoukas, Minos Timotheos] Univ West Attica, Dept Biomed Engn, Ag Spyridonos, Egaleo 12243, Greece.
   [Katsila, Theodora; Zoumpoulakis, Panagiotis] Natl Hellen Res Fdn, Inst Chem Biol, Athens 11635, Greece.
C3 University of West Attica; University of West Attica; National Hellenic
   Research Foundation
RP Papadourakis, M; Matsoukas, MT (通讯作者)，Cloudpharm Private Co, Kifissias Ave 44, Maroussi 15125, Greece.; Matsoukas, MT (通讯作者)，Univ West Attica, Dept Biomed Engn, Ag Spyridonos, Egaleo 12243, Greece.
EM atloukas@uniwa.gr; mpapadourakis@cloudpharm.eu;
   vpanagiotopoulos@cloudpharm.eu; azarmpala@cloudpharm.eu;
   echontzopoulou@cloudpharm.eu; stchristodoulou1997@gmail.com;
   thkatsila@eie.gr; pzoump@uniwa.gr; mmatsoukas@uniwa.gr
RI Katsila, Dr Theodora/O 3228 2015; Katsila, Theodora/O 3228 2015;
   Matsoukas, Minos Timotheos/GWC 1646 2022; Zoumpoulakis,
   Panagiotis/AAR 8625 2021
OI Katsila, Dr Theodora/0000 0002 6263 4231; Papadourakis,
   Michail/0000 0002 9969 5871; Panagiotopoulos,
   Vasilis/0000 0003 1563 2302; 
FU European Regional Development Fund of the European Union and Greek
   national funds through the Operational Program Competitiveness,
   Entrepreneurship and Innovation, under the call RESEARCH CREATE INNOVATE
FX No Statement Available
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Agostoni C, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2246
   Agostoni C, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2815
   Algavi YM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39264 0
   Alvarez Sala A, 2018, FOOD FUNCT, V9, P5209, DOI [10.1039/C8FO00353J, 10.1039/c8fo00353j]
   [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   [Anonymous], About us
   Authority EFS, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2324
   Bailey RL, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10246
   Bampidis V, 2021, EFSA J, V19, DOI 10.2903/j.efsa.2021.6893
   Bampidis V, 2022, EFSA J, V20, DOI 10.2903/j.efsa.2022.7267
   Bampidis V, 2020, EFSA J, V18, DOI 10.2903/j.efsa.2020.6335
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Behera J, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115317
   Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969 2126(99)80173 7
   Bellumori M, 2019, MOLECULES, V24, DOI 10.3390/molecules24112179
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Brink E, 2008, AM J CLIN NUTR, V87, P761, DOI 10.1093/ajcn/87.3.761
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   BYRD RH, 1995, SIAM J SCI COMPUT, V16, P1190, DOI 10.1137/0916069
   Chaikuad A, 2014, NAT CHEM BIOL, V10, P853, DOI [10.1038/NCHEMBIO.1629, 10.1038/nchembio.1629]
   Chamberlain SD, 2009, BIOORG MED CHEM LETT, V19, P360, DOI 10.1016/j.bmcl.2008.11.077
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Cresci GA, 2015, NUTR CLIN PRACT, V30, P734, DOI 10.1177/0884533615609899
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dagher O, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.658400
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521 3773(19990115)38:1/2<236::AID ANIE236>3.0.CO;2 M
   De Martinis M, 2020, CURR MED CHEM, V27, P6356, DOI 10.2174/0929867326666190730113123
   de Oliveira MA, 2022, MED ENG PHYS, V108, DOI 10.1016/j.medengphy.2022.103887
   De Souza M.J., 2022, Curr. Dev. Nutr, V6, P10, DOI [10.1093/cdn/nzac047.010, DOI 10.1093/CDN/NZAC047.010]
   DeBar LL, 2006, ARCH PEDIAT ADOL MED, V160, P1269, DOI 10.1001/archpedi.160.12.1269
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Dodier T, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020544
   EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010, EFSA J, V8, P1751, DOI [10.2903/j.efsa.2010.1751, DOI 10.2903/J.EFSA.2010.1751]
   EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2014, EFSA J, V12, P3511, DOI [10.2903/j.efsa.2014.3512, DOI 10.2903/J.EFSA.2014.3512]
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Feng YB, 2021, ACS MED CHEM LETT, V12, P24, DOI 10.1021/acsmedchemlett.0c00533
   Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Georgiou N, 2023, MOLECULES, V28, DOI 10.3390/molecules28248141
   Gowers R. J., 2019, MDAnalysis: A PythonPackage for the Rapid Analysis of Molecular Dynamics Simulations, DOI [DOI 10.25080/MAJORA 629E541A 00E, 10.25080/Majora 629e541a 00e]
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096 987X(199709)18:12<1463::AID JCC4>3.0.CO;2 H
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Johannesdottir F, 2017, BONE, V105, P93, DOI 10.1016/j.bone.2017.07.023
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kanis J.A., 2007, ASSESSMENT OSTEOPORO
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuglstatter A, 2010, BIOORG MED CHEM LETT, V20, P5217, DOI 10.1016/j.bmcl.2010.06.157
   Lambert MNT, 2017, AM J CLIN NUTR, V106, P909, DOI 10.3945/ajcn.117.153353
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li C, 2019, OSTEOPOROSIS INT, V30, P1003, DOI 10.1007/s00198 019 04855 5
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Lombard CK, 2018, BIOCHEMISTRY US, V57, P5897, DOI 10.1021/acs.biochem.8b00776
   Mangano GRA, 2023, J CLIN MED, V12, DOI 10.3390/jcm12010014
   McCoubrey LE, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071026
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Michaud Agrawal N, 2011, J COMPUT CHEM, V32, P2319, DOI 10.1002/jcc.21787
   Moriwaki H, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321 018 0258 y
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Ozaki D, 2021, OSTEOPOROSIS INT, V32, P145, DOI 10.1007/s00198 020 05728 y
   Papakyriakopoulou P, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15081019
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pawlowski JW, 2015, AM J CLIN NUTR, V102, P695, DOI 10.3945/ajcn.114.093906
   Peng J, 2021, FOOD RES INT, V144, DOI 10.1016/j.foodres.2021.110331
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RCSB Protein Data Bank (RCSB PDB), RCSB PDB 3GP0: Crystal Structure of Human Mitogen Activated Protein Kinase 11 (p38 beta) in Complex with Nilotinib
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Rosener B, 2020, ELIFE, V9, DOI 10.7554/eLife.59831
   Seely KD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179452
   Shen CL, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472 6882 10 76
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Steinberg FM, 2011, AM J CLIN NUTR, V93, P356, DOI 10.3945/ajcn.110.008359
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Suriya U, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14071461
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turck D, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.4728
   Vakali V, 2022, MOLECULES, V27, DOI 10.3390/molecules27175490
   Valdés Tresanco MS, 2021, J CHEM THEORY COMPUT, V17, P6281, DOI 10.1021/acs.jctc.1c00645
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Vijayan RSK, 2015, J MED CHEM, V58, P466, DOI 10.1021/jm501603h
   Wang JH, 2017, PEERJ, V5, DOI 10.7717/peerj.3450
   Wang Y, 2021, ISME J, V15, P2493, DOI 10.1038/s41396 021 00945 7
   Wattanathorn J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2091872
   Wen KC, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.535310
   Yan QH, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.821429
   Younes M, 2022, EFSA J, V20, DOI 10.2903/j.efsa.2022.7595
   Younes M, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5239
   Zhang GK, 2023, FRONT GENET, V14, DOI 10.3389/fgene.2023.1182363
   Zhang XJ, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0290289
   Zhao Z, 2014, ACS CHEM BIOL, V9, P1230, DOI 10.1021/cb500129t
   Zhu CY, 1997, ACM T MATH SOFTWARE, V23, P550, DOI 10.1145/279232.279236
   ,, 2012, EFSA Journal, V10, P2953
   ,, 2014, EFSA Journal, V12, P3893
   ,, 2016, EFSA Journal, V14, P4368
   ,, 2014, EFSA Journal, V12, P3655
   ,, 2011, EFSA Journal, V9, P2130
NR 107
TC 3
Z9 3
U1 2
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2024
VL 25
IS 9
AR 5047
DI 10.3390/ijms25095047
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QH3D3
UT WOS:001219938800001
PM 38732267
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Arrighi, I
   Mark, S
   Alvisi, M
   von Rechenberg, B
   Hubbell, JA
   Schense, JC
AF Arrighi, Isabelle
   Mark, Silke
   Alvisi, Monica
   von Rechenberg, Brigitte
   Hubbell, Jeffrey A.
   Schense, Jason C.
TI Bone healing induced by local delivery of an engineered parathyroid
   hormone prodrug
SO BIOMATERIALS
LA English
DT Article
DE Bone healing; Bone graft; Fibrin; Peptide; Osteoblast
ID PROTEIN KINASE A; IN VIVO BEHAVIOR; GROWTH FACTOR I; CROSS LINKING;
   FIBRIN MATRICES; PEPTIDES; RAT; TRANSGLUTAMINASE; BIOCOMPATIBILITY;
   OSTEOPOROSIS
AB Regenerative medicine requires innovative therapeutic designs to accommodate high morphogen concentrations in local depots, provide their sustained presence, and enhance cellular invasion and directed differentiation. Here we present an example for inducing local bone regeneration with a matrix bound engineered active fragment of human parathyroid hormone (PTH1 34), linked to a transglutaminase substrate for binding to fibrin as a delivery and cell invasion matrix with an intervening plasmin sensitive link (TGpIPTH(1 34)). The precursor form displays very little activity and signaling to osteoblasts, whereas the plasmin cleavage product, as it would be induced under the enzymatic influence of cells remodeling the matrix, was highly active. In vivo animal bone defect experiments showed dose dependent bone formation using the PTH fibrin matrix, with evidence of both osteoconductive and osteoinductive bone healing mechanisms. Results showed that this PTH derivatized matrix may have potential utility in humans as a replacement for bone grafts or to repair bone defects. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Arrighi, Isabelle; Mark, Silke; Alvisi, Monica; Schense, Jason C.] Kuros Biosurg AG, CH 8005 Zurich, Switzerland.
   [von Rechenberg, Brigitte] Univ Zurich, Vetsuisse Fac, Equine Hosp, Musculoskeletal Res Unit, CH 8057 Zurich, Switzerland.
   [Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Inst Bioengn, Lab Regenerat Med & Pharmacobiol, CH 1015 Lausanne, Switzerland.
C3 University of Zurich; Swiss Federal Institutes of Technology Domain;
   Ecole Polytechnique Federale de Lausanne
RP Arrighi, I (通讯作者)，Kuros Biosurg AG, Technoparkstr 1, CH 8005 Zurich, Switzerland.
EM isabelle.arrighi@kuros.ch
RI Hubbell, Jeffrey/A 9266 2008; Hubbell, Jeffrey A/F 8987 2011
OI Hubbell, Jeffrey A/0000 0003 0276 5456
FU Ohu University School of Dentistry; Balgrist Hospital, Zurich; Kuros
   Biosurgery AG, Zurich
FX We thank Baxter Biosurgery for collaborating on this project: N.
   Horiuchi (Ohu University School of Dentistry, Koriyama, Japan) for the
   PTH receptor promoter luciferase plasmid: R. Muff (Balgrist Hospital,
   Zurich, Switzerland) for the osteoblast cell line; and Caudex Medical
   Ltd (UK) (supported by Kuros Biosurgery AG, Zurich, Switzerland) for
   their assistance in preparing the initial draft of the manuscript and
   collating the comments of authors and other named contributors.
CR Apelt D, 2004, BIOMATERIALS, V25, P1439, DOI 10.1016/j.biomaterials.2003.08.073
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817
   Ballestar E, 1997, BIOCHEMISTRY US, V36, P5963, DOI 10.1021/bi9626620
   Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Branfoot Toby, 2005, Injury, V36 Suppl 3, pS51, DOI 10.1016/j.injury.2005.07.036
   Carter Percy H., 2006, Endocrine Metabolic & Immune Disorders Drug Targets, V6, P59
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Cheung Catherine, 2005, Clin Podiatr Med Surg, V22, P631, DOI 10.1016/j.cpm.2005.07.002
   Cranney A, 2006, CAN MED ASSOC J, V175, P52, DOI 10.1503/cmaj.050929
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006 291X(71)80163 8
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Flühmann B, 1998, MOL CELL ENDOCRINOL, V139, P89, DOI 10.1016/S0303 7207(98)00070 7
   FOLK JE, 1969, J BIOL CHEM, V244, P3707
   FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29
   Grey A, 2007, EXPERT OPIN EMERG DR, V12, P493, DOI 10.1517/14728214.12.3.493
   Haramoto N, 2007, ORAL DIS, V13, P23, DOI 10.1111/j.1601 0825.2006.01234.x
   Hohl D, 1998, J INVEST DERMATOL, V110, P268, DOI 10.1046/j.1523 1747.1998.00132.x
   Hong SJ, 2006, BIOMATERIALS, V27, P3810, DOI 10.1016/j.biomaterials.2006.02.045
   ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014 5793(83)80645 0
   Kalfas I H, 2001, Neurosurg Focus, V10, pE1
   Kawane T, 2003, J ENDOCRINOL, V178, P247, DOI 10.1677/joe.0.1780247
   Kawane T, 2001, BIOCHEM BIOPH RES CO, V287, P313, DOI 10.1006/bbrc.2001.5586
   Lane JM, 1999, CLIN ORTHOP RELAT R, pS107
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014 5793(81)80198 6
   Meinel L, 2003, BONE, V33, P660, DOI 10.1016/S8756 3282(03)00207 2
   Meinhart JG, 2005, TISSUE ENG, V11, P887, DOI 10.1089/ten.2005.11.887
   Nuss KMR, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 67
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Sakiyama SE, 1999, FASEB J, V13, P2214, DOI 10.1096/fasebj.13.15.2214
   Sakiyama Elbert SE, 2001, FASEB J, V15, P1300, DOI 10.1096/fj.00 0564fje
   Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473
   Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769
   Schmoekel H, 2004, J ORTHOPAED RES, V22, P376, DOI 10.1016/S0736 0266(03)00188 8
   Schmoekel HG, 2005, J SMALL ANIM PRACT, V46, P17, DOI 10.1111/j.1748 5827.2005.tb00269.x
   Schmoekel HG, 2005, BIOTECHNOL BIOENG, V89, P253, DOI 10.1002/bit.20168
   Schmökel HG, 2004, VET SURG, V33, P112, DOI [10.1111/j.1532 950x.2004.04018.x, 10.1111/j.1532 950X.2004.04018.x]
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   Theiss F, 2005, BIOMATERIALS, V26, P4383, DOI 10.1016/j.biomaterials.2004.11.056
   von Doernberg MC, 2006, BIOMATERIALS, V27, P5186, DOI 10.1016/j.biomaterials.2006.05.051
   Whitfield JF, 2006, CURR OPIN INVEST DR, V7, P349
   Yamada Y, 2003, J CRANIO MAXILL SURG, V31, P27, DOI 10.1016/S1010 5182(02)00143 9
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
   Zarge JI, 1997, AM J SURG, V174, P188, DOI 10.1016/S0002 9610(97)00090 1
   Zisch AH, 2001, J CONTROL RELEASE, V72, P101, DOI 10.1016/S0168 3659(01)00266 8
NR 50
TC 89
Z9 106
U1 1
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2009
VL 30
IS 9
BP 1763
EP 1771
DI 10.1016/j.biomaterials.2008.12.023
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 412RV
UT WOS:000263742800013
PM 19124152
DA 2025 08 17
ER

PT J
AU Gooding, S
   Olechnowicz, SWZ
   Morris, EV
   Armitage, AE
   Arezes, J
   Frost, J
   Repapi, E
   Edwards, JR
   Ashley, N
   Waugh, C
   Gray, N
   Martinez Hackert, E
   Lim, PJ
   Pasricha, SR
   Knowles, H
   Mead, AJ
   Ramasamy, K
   Drakesmith, H
   Edwards, CM
AF Gooding, Sarah
   Olechnowicz, Sam W. Z.
   Morris, Emma, V
   Armitage, Andrew E.
   Arezes, Joao
   Frost, Joe
   Repapi, Emmanouela
   Edwards, James R.
   Ashley, Neil
   Waugh, Craig
   Gray, Nicola
   Martinez Hackert, Erik
   Lim, Pei Jin
   Pasricha, Sant Rayn
   Knowles, Helen
   Mead, Adam J.
   Ramasamy, Karthik
   Drakesmith, Hal
   Edwards, Claire M.
TI Transcriptomic profiling of the myeloma bone lining niche reveals BMP
   signalling inhibition to improve bone disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID IA RECEPTOR BMPRIA; MULTIPLE MYELOMA; OSTEOLYTIC LESIONS; RNA SEQ;
   MORPHOGENETIC PROTEINS; INDUCE APOPTOSIS; TUMOR BURDEN; CELLS;
   OSTEOBLASTS; MASS
AB Multiple myeloma is an incurable, bone marrow dwelling malignancy that disrupts bone homeostasis causing skeletal damage and pain. Mechanisms underlying myeloma induced bone destruction are poorly understood and current therapies do not restore lost bone mass. Using transcriptomic profiling of isolated bone lining cell subtypes from a murine myeloma model, we find that bone morphogenetic protein (BMP) signalling is upregulated in stromal progenitor cells. BMP signalling has not previously been reported to be dysregulated in myeloma bone disease. Inhibition of BMP signalling in vivo using either a small molecule BMP receptor antagonist or a solubilized BMPR1a FC receptor ligand trap prevents trabecular and cortical bone volume loss caused by myeloma, without increasing tumour burden. BMP inhibition directly reduces osteoclastogenesis, increases osteoblasts and bone formation, and suppresses bone marrow sclerostin levels. In summary we describe a novel role for the BMP pathway in myeloma induced bone disease that can be therapeutically targeted.
C1 [Gooding, Sarah; Armitage, Andrew E.; Arezes, Joao; Frost, Joe; Lim, Pei Jin; Pasricha, Sant Rayn; Drakesmith, Hal] Univ Oxford, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Gooding, Sarah; Mead, Adam J.; Ramasamy, Karthik] Oxford Univ Hosp NHS Trust, Oxford, England.
   [Gooding, Sarah; Mead, Adam J.; Ramasamy, Karthik; Drakesmith, Hal; Edwards, Claire M.] Univ Oxford, NIHR Oxford Biomed Res Ctr Blood Theme, Oxford, England.
   [Gooding, Sarah; Olechnowicz, Sam W. Z.; Morris, Emma, V; Edwards, James R.; Ramasamy, Karthik; Edwards, Claire M.] Univ Oxford, Oxford Ctr Translat Myeloma Res, Oxford, England.
   [Olechnowicz, Sam W. Z.; Morris, Emma, V; Edwards, Claire M.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.
   [Repapi, Emmanouela; Ashley, Neil; Waugh, Craig; Gray, Nicola; Pasricha, Sant Rayn; Mead, Adam J.; Ramasamy, Karthik] Univ Oxford, MRC Weatherall Inst Mol Med, Oxford, England.
   [Edwards, James R.; Knowles, Helen; Edwards, Claire M.] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
   [Martinez Hackert, Erik] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
C3 University of Oxford; Oxford University Hospitals NHS Foundation Trust;
   University of Oxford; University of Oxford; University of Oxford;
   University of Oxford; University of Oxford; Michigan State University
RP Drakesmith, H (通讯作者)，Univ Oxford, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.; Drakesmith, H; Edwards, CM (通讯作者)，Univ Oxford, NIHR Oxford Biomed Res Ctr Blood Theme, Oxford, England.; Edwards, CM (通讯作者)，Univ Oxford, Oxford Ctr Translat Myeloma Res, Oxford, England.; Edwards, CM (通讯作者)，Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Edwards, CM (通讯作者)，Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
EM alexander.drakesmith@ndm.ox.ac.uk; claire.edwards@ndorms.ox.ac.uk
RI ; Olechnowicz, Sam/I 3082 2014; Gray, Nicola/ABR 7851 2022; Knowles,
   Helen/JLL 7005 2023; Pasricha, Sant Rayn/H 8436 2019; Knowles,
   Helen/F 3857 2018; Mead, Adam/A 8796 2012; Edwards, Claire/D 7114 2011;
   Ramasamy, Karthik/LZF 6258 2025
OI Drakesmith, Alexander/0000 0002 8503 6103; Olechnowicz,
   Sam/0000 0001 7879 7708; Martinez Hackert, Erik/0000 0002 6182 7023;
   /0000 0001 8085 0731; Lim, Pei Jin/0000 0003 4201 1210; Arezes,
   Joao/0000 0003 4214 7337; Ramasamy, Karthik/0000 0003 3385 3707;
   Pasricha, Sant Rayn/0000 0002 5502 0434; Knowles,
   Helen/0000 0002 9575 6067; Edwards, Claire/0000 0002 1257 5659; Frost,
   Joe/0000 0002 5946 6062; Armitage, Andrew/0000 0001 5977 6602
FU ASH Travel Grant; UK Myeloma Forum travel award; NIHR Oxford Biomedical
   Research Centre; Wellcome Trust [102341/Z/13/Z]; Medical Research
   Council [MR/L006340/1]; Bloodwise; Orthopaedic Research UK; European
   Union Seventh Framework Programme Marie Curie Career Integration Grant;
   Arthritis Research UK [20631, MP/19200]; National Institutes of Health
   (NIH) [GM121499]; National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre (BRC); Medical Research Council
   [MC_UU_12009/16, G84/6443, MR/L006340/1, MC_UU_12010/10, MC_PC_15065,
   MC_UU_00016/15, MC_UU_00008/10] Funding Source: researchfish; National
   Centre for the Replacement, Refinement and Reduction of Animals in
   Research (NC3Rs) [NC/M000133/1] Funding Source: researchfish; Rosetrees
   [M435] Funding Source: researchfish; Versus Arthritis [20631] Funding
   Source: researchfish; Wellcome Trust [102341/Z/13/Z] Funding Source:
   Wellcome Trust; MRC [G84/6443, MC_PC_15065, MC_UU_12009/16,
   MC_UU_12010/10, MR/L006340/1, MC_UU_00008/10] Funding Source: UKRI
FX We thank the patients who donated clinical samples used in this
   research. We also thank Acceleron Pharma for providing BMPR1a FC, and
   Kymab Ltd. for providing anti BMP6. We acknowledge S. Clark and P. Sopp
   at the Weatherall Institute Core FACS Facility, University of Oxford,
   for their assistance and training in FACS sorting and R. Facchini and T.
   Luis for advice on endosteal niche sorting. M. Sultanova and C. Everett
   for assistance in obtaining patient samples and data. Also, Dr. K.
   Al Hourani, Dr. R. Srinivasa, Dr. S. Lwin, Dr. S. Webb, Dr. B. Gamez
   Molina, C. Turner, A. Sowman and J. Frost, University of Oxford, for
   discussion, training and assistance. Portions of this work were
   presented at the 2016 ASH conference (supported by ASH Travel Grant and
   UK Myeloma Forum travel award) and 2016 CABS conference. We acknowledge
   the contribution to this study made by the Oxford Centre for
   Histopathology Research and the Oxford Radcliffe Biobank, which are
   supported by the NIHR Oxford Biomedical Research Centre. This work was
   primarily funded by The Wellcome Trust (S.G., grant 102341/Z/13/Z) with
   additional funding from The Medical Research Council (A.E.M., grant
   MR/L006340/1; S.G., H.D., P.J.L., A.E.A., J.A., S. R.P., E.R., N.A.,
   N.G.); Bloodwise (C.M.E.), Orthopaedic Research UK (C.M.E.), a European
   Union Seventh Framework Programme Marie Curie Career Integration Grant
   (C.M.E), Arthritis Research UK (J.R.E., grant 20631. H.K., grant
   MP/19200), National Institutes of Health (NIH) (E.M.H. grant GM121499)
   and the National Institute for Health Research (NIHR) Oxford Biomedical
   Research Centre (BRC). The views expressed are those of the author(s)
   and not necessarily those of the NHS, the NIHR or the Department of
   Health.
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Baud'huin M, 2012, P NATL ACAD SCI USA, V109, P12207, DOI 10.1073/pnas.1204929109
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Cianferotti L, 2007, J CELL BIOCHEM, V101, P80, DOI 10.1002/jcb.21151
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331
   Grcevic D, 2010, LEUKEMIA RES, V34, P742, DOI 10.1016/j.leukres.2009.10.016
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Hjertner Ö, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516
   Holien T, 2012, LEUKEMIA, V26, P1073, DOI 10.1038/leu.2011.263
   Hu XB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13095
   Jensen ED, 2010, J CELL BIOCHEM, V109, P672, DOI 10.1002/jcb.22462
   Kamiya N, 2016, BONE, V91, P53, DOI 10.1016/j.bone.2016.07.002
   Kamiya N, 2011, BIOCHEM BIOPH RES CO, V414, P326, DOI 10.1016/j.bbrc.2011.09.060
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 2 r29
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Lawson MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119546
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Maes K, 2010, BLOOD, V116, P3635, DOI 10.1182/blood 2010 03 274571
   Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Mohedas AH, 2013, ACS CHEM BIOL, V8, P1291, DOI 10.1021/cb300655w
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006
   Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470 2045(17)30615 0
   RADL J, 1988, AM J PATHOL, V132, P593
   Reagan MR, 2015, BONE, V75, P161, DOI 10.1016/j.bone.2015.02.021
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Seckinger A, 2009, ONCOGENE, V28, P3866, DOI 10.1038/onc.2009.257
   Seher A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174884
   Shi C, 2016, SCI REP UK, V6, DOI 10.1038/srep24256
   Silbermann R, 2016, J CELL PHYSIOL, V231, P2374, DOI 10.1002/jcp.25351
   St John HC, 2014, MOL ENDOCRINOL, V28, P1150, DOI 10.1210/me.2014 1091
   Steinbicker AU, 2011, BLOOD, V117, P4915, DOI 10.1182/blood 2010 10 313064
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Wang YJ, 2014, J BONE MINER RES, V29, P685, DOI 10.1002/jbmr.2081
   Yadin D, 2016, CYTOKINE GROWTH F R, V27, P13, DOI 10.1016/j.cytogfr.2015.11.005
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang YS, 2016, BONE, V88, P74, DOI 10.1016/j.bone.2016.04.022
NR 65
TC 43
Z9 48
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 4
PY 2019
VL 10
AR 4533
DI 10.1038/s41467 019 12296 1
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JC1BP
UT WOS:000489013800002
PM 31586071
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Thompson, K
   Freitag, L
   Styger, U
   Camenisch, K
   Zeiter, S
   Arens, D
   Richards, RG
   Moriarty, TF
   Stadelmann, VA
AF Thompson, Keith
   Freitag, Linda
   Styger, Ursula
   Camenisch, Karin
   Zeiter, Stephan
   Arens, Daniel
   Richards, R. Geoff
   Moriarty, Thomas F.
   Stadelmann, Vincent A.
TI Impact of low bone mass and antiresorptive therapy on antibiotic
   efficacy in a rat model of orthopedic device related infection
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE antibiotics; bisphosphonate; in vivo micro&#8208; CT; osteomyelitis;
   Staphylococcus epidermidis
ID POSTMENOPAUSAL WOMEN; T CELLS; ESTROGEN; DIFFERENTIATION; OSTEOMYELITIS;
   OSTEONECROSIS; OSTEOCLASTS; MORTALITY; DENOSUMAB; MECHANISM
AB A significant proportion of orthopedic devices are implanted in osteoporotic patients, but it is currently unclear how estrogen deficiency and/or exposure to antiresorptive bisphosphonates (BPs) influence orthopedic device related infection (ODRI), or response to therapy. The aim of this study is to characterize the bone changes resulting from Staphylococcus epidermidis infection in a rodent ODRI model and to determine if ovariectomy (OVX) or BP treatment influences the infection or the success of antibiotic therapy. A sterile or S. epidermidis contaminated screw was implanted into the proximal tibia of skeletally mature female Wistar rats (n = 6 9 per group). Bone changes were monitored over 28 days using in vivo micro computed tomography scanning. OVX was performed 12 weeks before screw implantation. The BP zoledronic acid (ZOL) was administered 4 days before screw insertion. A combination antibiotic regimen (rifampin plus cefazolin) was administered from Days 7 21. In skeletally healthy animals, S. epidermidis induced marked changes in bone, with peak osteolysis occurring at Day 9 and woven bone deposition and periosteal mineralization from Day 14 onwards. Antibiotic therapy cleared the infection in the majority of animals (2/9 infected) but did not affect bone responses. OVX did not affect the pattern of infection induced changes in bone, nor bacterial load, but reduced antibiotic efficacy (5/9 infected). ZOL treatment did not protect from osteolysis in OVX animals, or further affect antibiotic efficacy (5/9 infected) but did significantly increase the bacterial load. This study suggests that both BPs and OVX can influence host responses to bone infections involving S. epidermidis.
C1 [Thompson, Keith; Freitag, Linda; Styger, Ursula; Camenisch, Karin; Zeiter, Stephan; Arens, Daniel; Richards, R. Geoff; Moriarty, Thomas F.; Stadelmann, Vincent A.] AO Res Inst Davos, Davos, Switzerland.
   [Stadelmann, Vincent A.] Schulthess Clin, Dept Teaching, Res & Dev, Zurich, Switzerland.
C3 AO Foundation; Schulthess Clinic
RP Moriarty, TF (通讯作者)，AO Fdn, AO Res Inst Davos, Clavadelerstr 8,Davos Pl, CH 7270 Davos, Switzerland.
EM fintan.moriarty@aofoundation.org; vincent.stadelmann@kws.ch
RI ; Zeiter, Stephan/AAI 1880 2021; Richards, Robert/I 8235 2015;
   Stadelmann, Vincent/X 1543 2018
OI Freitag, Linda/0000 0003 1177 7635; Zeiter, Stephan/0000 0002 8155 4202;
   Arens, Daniel/0000 0002 2705 0812; Thompson, Keith/0000 0002 9167 5147;
   Richards, Robert/0000 0002 7778 2480; Stadelmann,
   Vincent/0000 0002 8741 2184; 
FU AO Trauma
FX AO Trauma
CR Allen MR, 2008, EXPERT OPIN DRUG MET, V4, P1371, DOI 10.1517/17425255.4.11.1371 
   Billington EO, 2020, CURR OSTEOPOROS REP, V18, P587, DOI 10.1007/s11914 020 00612 4
   Birkhold AI, 2015, BONE, V75, P210, DOI 10.1016/j.bone.2015.02.027
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Castleman MJ, 2018, J IMMUNOL, V200, P657, DOI 10.4049/jimmunol.1700810
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Croes M, 2019, EUR CELLS MATER, V37, P402, DOI 10.22203/eCM.v037a24
   Croes M, 2017, TISSUE ENG PART C ME, V23, P673, DOI [10.1089/ten.tec.2017.0151, 10.1089/ten.TEC.2017.0151]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dapunt U, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1091 y
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   Duckworth AD, 2019, J BONE MINER RES, V34, P1025, DOI 10.1002/jbmr.3679
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Elsayed R, 2020, FASEB J, V34, P2595, DOI 10.1096/fj.201901819RR
   Feng X, 2015, J PHARMACOVIGILANCE, V3, P158
   Freitag L, 2019, J ORTHOP RES, V37, P541, DOI 10.1002/jor.24210
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Jones RM, 2018, BONE, V115, P59, DOI 10.1016/j.bone.2017.04.009
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018
   Laffont S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00108
   Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749 6632.2009.05210.x
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Lim SJ, 2018, OSTEOPOROSIS INT, V29, P2427, DOI 10.1007/s00198 018 4640 4
   Luo CY, 2011, CELL MOL IMMUNOL, V8, P50, DOI 10.1038/cmi.2010.54
   Marriott I, 2005, BONE, V37, P504, DOI 10.1016/j.bone.2005.05.011
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Metsemakers WJ, 2018, INJURY, V49, P505, DOI 10.1016/j.injury.2017.08.040
   Morgenstern M, 2016, INJURY, V47, P1427, DOI 10.1016/j.injury.2016.04.027
   Patel Ripal, 2016, Open Orthop J, V10, P654, DOI 10.2174/1874325001610010654
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Rifas L, 2003, J CELL BIOCHEM, V88, P650, DOI 10.1002/jcb.10436
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Sambrook PN, 2011, OSTEOPOROSIS INT, V22, P2551, DOI 10.1007/s00198 010 1444 6
   Sing CW, 2020, J BONE MINER RES, V35, P1676, DOI 10.1002/jbmr.4030
   Stadelmann VA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/587857
   Thillemann TM, 2010, BONE, V46, P946, DOI 10.1016/j.bone.2010.01.377
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   Trampuz A, 2006, DRUGS, V66, P1089, DOI 10.2165/00003495 200666080 00005
   Trampuz A, 2006, INJURY, V37, P59, DOI 10.1016/j.injury.2006.04.010
   Trampuz A, 2006, CURR OPIN INFECT DIS, V19, P349, DOI 10.1097/01.qco.0000235161.85925.e8
   Vermeer JAF, 2016, CURR OSTEOPOROS REP, V14, P219, DOI 10.1007/s11914 016 0318 z
   VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823
   Waarsing JH, 2004, BONE, V34, P163, DOI 10.1016/j.bone.2003.08.012
   Yamashita J, 2020, BONE
   Yang DQ, 2018, MBIO, V9, DOI 10.1128/mBio.00415 18
NR 55
TC 11
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2021
VL 39
IS 2
SI SI
BP 415
EP 425
DI 10.1002/jor.24951
EA DEC 2020
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA PZ5SY
UT WOS:000601073100001
PM 33325074
OA Bronze
DA 2025 08 17
ER

PT J
AU Cremers, S
   Ebetino, F
   Phipps, R
AF Cremers, Serge
   Ebetino, Frank (Hal)
   Phipps, Roger
TI On the pharmacological evaluation of bisphosphonates in humans
SO BONE
LA English
DT Article
DE Clinical pharmacology; Pharmacology; Bisphosphonates; Pharmacokinetics;
   Pharmacodynamics
ID WHOLE BODY RETENTION; DOSE RANGING TRIAL; ZOLEDRONIC ACID;
   CANCER PATIENTS; TC 99M DIPHOSPHONATE; BONE RESORPTION; IN VITRO;
   PHASE I; PHARMACOKINETICS; RISEDRONATE
AB One of the key parameters for a successful treatment with any drug is the use of an optimal dose regimen. Bisphosphonates (BPs) have been in clinical use for over five decades and during this period clinical pharmacokinetic (PK) and pharmacodynamic (PD) evaluations have been instrumental for the identification of optimal dose regimens in patients. Ideal clinical PK and PD studies help drug developers explain variability in responses and enable the identification of a dose regimen with an optimal effect. PK and PD studies of the unique and rather complex pharmacological properties of BPs also help determine to a significant extent ideal dosing for these drugs.
   Clinical PK and PD evaluations of BPs preferably use study designs and assays that enable the assessment of both short  (days) and long term (years) presence and effect of these drugs in patients. BPs are mainly used for metabolic bone diseases because they inhibit osteoclast mediated bone resorption and the best way to quantify their effects in humans is therefore by measuring biochemical markers of bone resorption in serum and urine. In these very same samples BP concentrations can also be measured. Short term serum and urine data after both intravenous (IV) and oral administration enable the assessment of oral bioavailability as well as the amount of BP delivered to the skeleton. Longer term data provide information on the anti resorptive effect as well as the elimination of the BP from the skeleton.
   Using PK PD models to mathematically link the anti resorptive action of the BPs to the amount of BP at the skeleton provides a mechanism based explanation of the pattern of bone resorption during treatment. These models have been used successfully during the clinical development of BPs. Newer versions of such models, which include systems pharmacology and disease progression models, are more comprehensive and include additional PD parameters such as BMD and fracture risk.
   Clinical PK and PD studies of BPs have been useful for the identification of optimal dose regimens for metabolic bone diseases. These analyses will also continue to be important for newer research directions, such as BP use in the delivery of other drugs to the bone to better treat bone metastases and bone infections, as well as the potential benefit of BPs at non skeletal targets for the prevention and treatments of soft tissue cancers, various fibroses, and other cardiovascular and neurodegenerative diseases, and reduction in mortality and extension of lifespan.
C1 [Cremers, Serge] Columbia Univ, Pathol & Cell Biol & Med, Irving Med Ctr, New York, NY 10032 USA.
   [Ebetino, Frank (Hal)] Univ Rochester, Rochester, NY 14627 USA.
   [Ebetino, Frank (Hal)] BioVinc, Pasadena, CA 91107 USA.
   [Phipps, Roger] Husson Univ, Sch Pharm, Bangor, ME 04401 USA.
C3 Columbia University; NewYork Presbyterian Hospital; University of
   Rochester; Husson University
RP Cremers, S (通讯作者)，Columbia Univ, Pathol & Cell Biol & Med, Irving Med Ctr, New York, NY 10032 USA.
EM sc2752@columbia.edu
FU National Institutes of Health (NIH), National Institute of Dental and
   Craniofacial Research (NIDCR) [R42 DE025789 02]; NIH National Institute
   of Allergy and Infectious Diseases (NIAID) [2R44 AI125060 02]; NIH
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) [R43AR073727]; NIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR001873]
FX FHE is supported by grant R42 DE025789 02 from the National Institutes
   of Health (NIH), National Institute of Dental and Craniofacial Research
   (NIDCR), grant 2R44 AI125060 02 from the NIH National Institute of
   Allergy and Infectious Diseases (NIAID) and grant R43AR073727 from the
   NIH National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS).SC is supported by grant UL1TR001873 from the NIH
   National Center for Advancing Translational Sciences (NCATS).
CR Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   BASSETT CAL, 1969, LANCET, V2, P845
   Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097 0142(20010101)91:1<144::AID CNCR19>3.0.CO;2 Q
   Berenson JR, 1997, J CLIN PHARMACOL, V37, P285, DOI 10.1002/j.1552 4604.1997.tb04304.x
   Berenson JR, 2001, CLIN CANCER RES, V7, P478
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   Cremers SCLM, 2005, OSTEOPOROSIS INT, V16, P1727, DOI 10.1007/s00198 005 1911 7
   Cremers SCLM, 2005, J BONE MINER RES, V20, P1543, DOI 10.1359/JBMR.050522
   Cremers SCLM, 2003, J BONE MINER RES, V18, P868, DOI 10.1359/jbmr.2003.18.5.868
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Eastell R, 2011, J CLIN ENDOCR METAB, V96, P3367, DOI 10.1210/jc.2011 0412
   FDA, 2010, FDA CLIN PHARM BIOPH
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1969, NATURE, V223, P211, DOI 10.1038/223211a0
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   HYLDSTRUP L, 1984, SCAND J CLIN LAB INV, V44, P673
   HYLDSTRUP L, 1984, SCAND J CLIN LAB INV, V44, P105, DOI 10.3109/00365518409161390
   Jones AC, 2014, OR SURG OR MED OR PA, V117, P392, DOI 10.1016/j.oooo.2013.09.076
   KASTING GB, 1992, J BONE MINER RES, V7, P513
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim JS, 2016, EUR J PHARM SCI, V82, P45, DOI 10.1016/j.ejps.2015.11.011
   LEYVRAZ S, 1992, J NATL CANCER I, V84, P788, DOI 10.1093/jnci/84.10.788
   LIN JH, 1992, DRUG METAB DISPOS, V20, P608
   McClung MR, 2012, OSTEOPOROSIS INT, V23, P267, DOI 10.1007/s00198 011 1791 y
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Naylor KE, 2018, OSTEOPOROSIS INT, V29, P1407, DOI 10.1007/s00198 018 4460 6
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P21, DOI 10.1007/s00198 015 3145 7
   Papapoulos SE, 2007, NEW ENGL J MED, V356, P1075, DOI 10.1056/NEJMc062792
   Peris P, 2011, BONE, V49, P706, DOI 10.1016/j.bone.2011.06.027
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Phipps R, 2004, BONE, V34, pS81
   Pillai G, 2004, BRIT J CLIN PHARMACO, V58, P618, DOI 10.1111/j.1365 2125.2004.02224.x
   Reid IR, 2020, J BONE MINER RES, V35, P20, DOI 10.1002/jbmr.3860
   Riggs MM, 2019, BRIT J CLIN PHARMACO, V85, P1136, DOI 10.1111/bcp.13881
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Sedghizadeh PP, 2013, OR SURG OR MED OR PA, V115, P224, DOI 10.1016/j.oooo.2012.08.455
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   TROEHLER U, 1975, KIDNEY INT, V8, P6, DOI 10.1038/ki.1975.70
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Zaidi M, 2006, ANN NY ACAD SCI, V1068, P560, DOI 10.1196/annals.1346.058
NR 48
TC 19
Z9 20
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2020
VL 139
AR 115501
DI 10.1016/j.bone.2020.115501
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NH5PS
UT WOS:000564722400012
PM 32599224
OA Green Accepted
DA 2025 08 17
ER

PT J
AU do Reis, LM
   Kessler, CB
   Adams, DJ
   Lorenzo, J
   Jorgetti, V
   Delany, AM
AF Machado do Reis, Luciene
   Kessler, Catherine B.
   Adams, Douglas J.
   Lorenzo, Joseph
   Jorgetti, Vanda
   Delany, Anne M.
TI Accentuated osteoclastic response to parathyroid hormone undermines bone
   mass acquisition in osteonectin null mice
SO BONE
LA English
DT Article
DE PTH; skeletal remodeling; matricellular protein; bone matrix; SPARC;
   BM 40
ID TRABECULAR BONE; EXTRACELLULAR MODULATORS; MATRICELLULAR PROTEINS;
   DEFICIENT MICE; STROMAL CELLS; SPARC; OSTEOBLASTS; EXPRESSION; MATRIX;
   VCAM 1
AB Matricellular proteins play a unique role in the skeleton as regulators of bone remodeling, and the matricellular protein osteonectin (SPARC, BM 40) is the most abundant non collagenous protein in bone In. the absence of osteonectin, mice develop progressive low turnover osteopenia, particularly affecting trabecular bone. Polymorphisms in a regulatory region of the osteonectin gene are associated with bone mass in a subset of idiopathic osteoporosis patients, and these polymorphisms likely regulate osteonectin expression. Thus it is important to determine how osteonectin gene dosage affects skeletal function. Moreover, intermittent administration of parathyroid hormone (PTH) (1 34) is the only anabolic therapy approved for the treatment of osteoporosis, and it is critical to understand how modulators of bone remodeling, such as osteonectin, affect skeletal response to anabolic agents. In this study, 10 week old female wild type, osteonectin haploinsufficient, and osteonectin null mice (C57Bl/6 genetic background) were given 80 mu g/kg body weight/day PTH(1 34) for 4 weeks. Osteonectin gene dosage had a profound effect on bone microarchitecture. The connectivity density of trabecular bone in osteonectin haploinsufficient mice was substantially decreased compared with that of wild type mice, suggesting compromised mechanical properties. Whereas mice of each genotype had a similar osteoblastic response to PTH treatment, the osteoclastic response was accentuated in osteonectin haploinsufficient and osteonectin null mice. Eroded surface and osteoclast number were significantly higher in PTH treated osteonectin null mice, as was endosteal area. In vitro studies confirmed that PTH induced the formation of more osteoclast like cells in marrow from osteonectin null mice compared with wild type. PTH treated osteonectin null bone marrow cells expressed more RANKL mRNA compared with wild type. However, the ratio of RANKL:OPG mRNA was somewhat lower in PTH treated osteonectin null cultures. Increased expression of RANKL in response to PTH could contribute to the accentuated osteoclastic response in osteonectin( / ) mice, but other mechanisms are also likely to be involved. The molecular mechanisms by which PTH elicits bone anabolic vs. bone catabolic effects remain poorly understood. Our results imply that osteonectin levels may play a role in modulating the balance of bone formation and resorption in response to PTH. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Delany, Anne M.] Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA.
   [Machado do Reis, Luciene; Jorgetti, Vanda] Univ Sao Paulo, Sao Paulo, Brazil.
C3 University of Connecticut; Universidade de Sao Paulo
RP Delany, AM (通讯作者)，Univ Connecticut, Ctr Hlth, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM adelany@uchc.edu
RI Adams, David/GMW 8541 2022; dos Reis, Luciene/C 7143 2013; JORGETTI,
   VANDA/C 9470 2012; Dos Reis, Luciene/C 7143 2013; Jorgetti,
   Vanda/C 9470 2012
OI Dos Reis, Luciene/0000 0001 8476 6780; Jorgetti,
   Vanda/0000 0002 4824 8879
FU NIAMS NIH HHS [R56 AR044877, AR44877, R01 AR044877, R29 AR044877]
   Funding Source: Medline
CR Alford AI, 2006, BONE, V38, P749, DOI 10.1016/j.bone.2005.11.017
   Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200
   Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955 0674(02)00361 7
   Boskey AL, 2003, J BONE MINER RES, V18, P1005, DOI 10.1359/jbmr.2003.18.6.1005
   Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204
   Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002 0049
   Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002 221044
   DELANY AM, OSTEOPOROSI IN PRESS
   FEDARKO NS, 1992, J BONE MINER RES, V7, P921
   FEDARKO NS, 1995, J BONE MINER RES, V10, P1122
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   Feuerbach D, 1997, FEBS LETT, V402, P21, DOI 10.1016/S0014 5793(96)01495 0
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Hankenson KD, 2006, BONE, V38, P310, DOI 10.1016/j.bone.2005.08.027
   Hankenson KD, 2005, MATRIX BIOL, V24, P362, DOI 10.1016/j.matbio.2005.05.008
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105 2896.2005.00325.x
   Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016
   Kelly KA, 2007, J LEUKOCYTE BIOL, V81, P748, DOI 10.1189/jlb.1105664
   Kessler CB, 2007, ENDOCRINOLOGY, V148, P1666, DOI 10.1210/en.2006 0443
   Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002 220996
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092 8674(01)00583 9
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771
   Rempel SA, 2007, GENES IMMUN, V8, P262, DOI 10.1038/sj.gene.6364388
   Riggs BL, 2008, J BONE MINER RES, V23, P205, DOI 10.1359/JBMR.071020
   Robey P.G., 2003, Primer on the metabolic bone diseases and disorders of mineral metabolism, V5th, P38
   Singh ATK, 2005, ENDOCRINOLOGY, V146, P2171, DOI 10.1210/en.2004 1283
   Wang LM, 2005, AM J PHYSIOL ENDOC M, V288, pE826, DOI 10.1152/ajpendo.00422.2004
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 41
TC 22
Z9 28
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2008
VL 43
IS 2
BP 264
EP 273
DI 10.1016/j.bone.2008.03.024
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 330GI
UT WOS:000257928300005
PM 18499553
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Houchen, CJ
   Ghanem, S
   Kaartinen, V
   Bumann, EE
AF Houchen, Claire J.
   Ghanem, Saif
   Kaartinen, Vesa
   Bumann, Erin Ealba
TI TGF β signaling in the cranial neural crest affects late stage
   mandibular bone resorption and length
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE transforming growth factor beta type I receptor; jaw; mandible; neural
   crest; bone resorption; osteoclasts; bone remodeling; maxillofacial
   development
ID RECEPTOR ALK5; OSTEOGENESIS; OSTEOPOROSIS; INTEGRATION; EXPRESSION;
   MUTATIONS; EVOLUTION; PCR
AB Malocclusions are common craniofacial malformations that cause quality of life and health problems if left untreated. Unfortunately, the current treatment for severe skeletal malocclusion is invasive surgery. Developing improved therapeutic options requires a deeper understanding of the cellular mechanisms responsible for determining jaw bone length. We have recently shown that neural crest mesenchyme (NCM) can alter jaw length by controlling the recruitment and function of mesoderm derived osteoclasts. Transforming growth factor beta (TGF beta) signaling is critical to craniofacial development by directing bone resorption and formation, and heterozygous mutations in the TGF beta type I receptor (TGFBR1) are associated with micrognathia in humans. To identify the role of TGF beta signaling in NCM in controlling osteoclasts during mandibular development, the mandibles of mouse embryos deficient in the gene encoding Tgfbr1, specifically in NCM, were analyzed. Our laboratory and others have demonstrated that Tgfbr1 fl/fl ;Wnt1 Cre mice display significantly shorter mandibles with no condylar, coronoid, or angular processes. We hypothesize that TGF beta signaling in NCM can also direct late bone remodeling and further regulate late embryonic jaw bone length. Interestingly, analysis of mandibular bone based on micro computed tomography and Masson's trichrome revealed no significant difference in bone quality between the Tgfbr1 fl/fl ;Wnt1 Cre mice and controls, as measured by the bone perimeter/bone area, trabecular rod like diameter, number and separation, and gene expression of collagen type 1 alpha 1 (Col1 alpha 1) and matrix metalloproteinase 13 (Mmp13). Although there was not a difference in localization of bone resorption within the mandible indicated by tartrate resistant acid phosphatase (TRAP) staining, Tgfbr1 fl/fl ;Wnt1 Cre mice had approximately three fold less osteoclast number and perimeter than controls. Gene expression of receptor activator of nuclear factor kappa beta (Rank) and Mmp9, markers of osteoclasts and their activity, also showed a three fold decrease in Tgfbr1 fl/fl ;Wnt1 Cre mandibles. Evaluation of osteoblast to osteoclast signaling revealed no significant difference between Tgfbr1 fl/fl ;Wnt1 Cre mandibles and controls, leaving the specific mechanism unresolved. Finally, pharmacological inhibition of Tgfbr1 signaling during the initiation of bone mineralization and resorption significantly shortened jaw length in embryos. We conclude that TGF beta signaling in NCM decreases mesoderm derived osteoclast number, that TGF beta signaling in NCM impacts jaw length late in development, and that this osteoblast to osteoclast communication may be occurring through an undescribed mechanism.
C1 [Houchen, Claire J.; Bumann, Erin Ealba] Univ Missouri, Kansas City Sch Dent, Dept Oral & Craniofacial Sci, Kansas City, MO 64108 USA.
   [Ghanem, Saif; Kaartinen, Vesa] Univ Michigan, Dept Biol & Mat Sci, Sch Dent, Ann Arbor, MI USA.
   [Bumann, Erin Ealba] Univ Michigan, Dept Orthodont & Pediat Dent, Sch Dent, Ann Arbor, MI 48104 USA.
   [Bumann, Erin Ealba] Univ Missouri, Kansas City Sch Dent, Dept Oral & Craniofacial Sci, Kansas City, MO USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Missouri System;
   University of Missouri Kansas City
RP Bumann, EE (通讯作者)，Univ Missouri, Kansas City Sch Dent, Dept Oral & Craniofacial Sci, Kansas City, MO 64108 USA.; Bumann, EE (通讯作者)，Univ Michigan, Dept Orthodont & Pediat Dent, Sch Dent, Ann Arbor, MI 48104 USA.
EM bumanne@umkc.edu
RI Bumann, Erin/AEV 0804 2022
FU University of Michigan Undergraduate Research Opportunity Program
   Biomedical and Life Sciences Sumer Research Opportunity Program; NICDR
   [K08 DE021705]; NIH/NCRR [S10RR026475 01]; NIDCR [R01 DE13085]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article, funded in part
   by the University of Michigan Undergraduate Research Opportunity Program
   Biomedical and Life Sciences Sumer Research Opportunity Program to SG,
   NIDCR R01 DE13085 to VK, NICDR K08 DE021705 to EB, and NIH/NCRR
   S10RR026475 01 to the University of Michigan School of Dentistry
   Micro CT core.
CR Ainsworth SJ, 2010, J ANAT, V216, P3, DOI 10.1111/j.1469 7580.2009.01173.x
   Albanese CT, 1998, ANN NY ACAD SCI, V847, P74, DOI 10.1111/j.1749 6632.1998.tb08928.x
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   American Veterinary Medical Association, 2022, W Beam Guardrail Identification Repair Guidelines
   Atchley William R., 1993, P207
   ATCHLEY WR, 1991, BIOL REV, V66, P101, DOI 10.1111/j.1469 185X.1991.tb01138.x
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Barlow AJ, 1997, DEVELOPMENT, V124, P391
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cakan Derya Germec, 2012, Eur J Dent, V6, P340
   Chai WH, 2023, JBMR PLUS, V7, DOI 10.1002/jbm4.10706
   Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960 9822(07)00562 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Dole NS, 2017, CELL REP, V21, P2585, DOI 10.1016/j.celrep.2017.10.115
   Dudas M, 2006, DEV BIOL, V296, P298, DOI 10.1016/j.ydbio.2006.05.030
   Ealba EL, 2015, DEV BIOL, V408, P151, DOI 10.1016/j.ydbio.2015.10.001
   Ehrich TH, 2003, J EXP ZOOL PART B, V296B, P58, DOI 10.1002/jez.b.00009
   GORLIN RJ, 1990, SYNDROMES HEAD NECK
   Hall J, 2014, DEV BIOL, V385, P380, DOI 10.1016/j.ydbio.2013.11.011
   HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104
   Hassan MG, 2023, ORTHOD CRANIOFAC RES, V26, P338, DOI 10.1111/ocr.12614
   Houchen CJ, 2023, ORTHOD CRANIOFAC RES, V26, P500, DOI 10.1111/ocr.12635
   Kaufman M. H., 1992, The altas of mouse development, P59
   Klingenberg CP, 2003, EVOL DEV, V5, P522, DOI 10.1046/j.1525 142X.2003.03057.x
   Lacombe D, 1993, Clin Dysmorphol, V2, P220
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511
   MacCarrick G, 2014, GENET MED, V16, P576, DOI 10.1038/gim.2014.11
   Malik Z, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00698
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Nagy A., 2003, MANIPULATING MOUSE E, P764
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Oka K, 2007, DEV BIOL, V303, P391, DOI 10.1016/j.ydbio.2006.11.025
   Peters SB, 2017, BONE, V97, P54, DOI 10.1016/j.bone.2016.12.017
   Prasad MS, 2019, GENESIS, V57, DOI 10.1002/dvg.23276
   Roth DM, 2021, HEAD NECK PATHOL, V15, P1, DOI 10.1007/s12105 021 01301 z
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Tang SY, 2012, J BONE MINER RES, V27, P1936, DOI 10.1002/jbmr.1646
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Theiler Karl., 2013, HOUSE MOUSE ATLAS EM
   Wang Y, 2013, DEV BIOL, V382, P27, DOI 10.1016/j.ydbio.2013.08.003
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yuan Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb0119
   Zhao H, 2008, DEV BIOL, V320, P19, DOI 10.1016/j.ydbio.2008.03.045
NR 49
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 15
PY 2024
VL 15
AR 1435594
DI 10.3389/fphys.2024.1435594
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA N7N0J
UT WOS:001366146900001
PM 39473613
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Edwards, JR
   Weivoda, MM
AF Edwards, James R.
   Weivoda, Megan M.
TI Osteoclasts: Malefactors of Disease and Targets for Treatment
SO DISCOVERY MEDICINE
LA English
DT Article
ID CARBONIC ANHYDRASE II; BONE MINERAL DENSITY; CATHEPSIN K INHIBITOR;
   ONSET PAGETS DISEASE; MATRIX GLA PROTEIN; VACUOLAR H+ ATPASE;
   GROWTH FACTOR BETA; POSTMENOPAUSAL WOMEN; RECESSIVE OSTEOPETROSIS;
   GENE EXPRESSION
AB The osteoclast represents one of the most highly specialized cells within the human body, which operates within a microenvironment of diverse cellular populations and matrix proteins. Moreover, the osteoclast directly effects and is affected by these surroundings in a delicate relationship of cellular differentiation, bone resorption, and controlled apoptosis. The result is the maintenance of adequate bone mass throughout life. Unsurprisingly, disturbances within this environment or the molecular regulation of normal osteoclast biology has profound effects on skeletal homeostasis and crippling physical manifestations. This review will summarize current literature describing normal and pathological osteoclast biology and highlight the benefits of osteoclast targeted therapy to combat skeletal disorders. [Discovery Medicine 13(70):201 210, march 2012]
C1 [Edwards, James R.; Weivoda, Megan M.] Univ Oxford, Botnar Res Ctr, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
   [Weivoda, Megan M.] Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA.
C3 University of Oxford; Mayo Clinic
RP Edwards, JR (通讯作者)，Univ Oxford, Botnar Res Ctr, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
EM james.edwards@ndorms.ox.ac.uk
CR Albagha OME, 2007, CALCIFIED TISSUE INT, V80, pS34
   Albagha OME, 2010, NAT GENET, V42, P520, DOI 10.1038/ng.562
   Albagha OME, 2005, J MED GENET, V42, P240, DOI 10.1136/jmg.2004.023895
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915
   Arai H, 2001, J BONE MINER RES, V16, P1256, DOI 10.1359/jbmr.2001.16.7.1256
   Athanasou NA, 1996, J BONE JOINT SURG AM, V78A, P1096, DOI 10.2106/00004623 199607000 00016
   Athanasou NA, 2011, SKELETAL RADIOL, V40, P1137, DOI 10.1007/s00256 011 1180 9
   BASLE MF, 1985, J GEN VIROL, V66, P2103, DOI 10.1099/0022 1317 66 10 2103
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Cavey JR, 2005, J BONE MINER RES, V20, P619, DOI 10.1359/JBMR.041205
   Clarke BL, 2010, CRIT REV EUKAR GENE, V20, P275, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.10
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Cundy T, 2012, CLIN BIOCHEM, V45, P43, DOI 10.1016/j.clinbiochem.2011.09.026
   Di Rocco M, 2000, EUR J PEDIATR, V159, P579, DOI 10.1007/s004310000485
   Edwards JR, 2008, J BONE MINER RES, V23, pS28
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167 4838(91)90088 H
   EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674
   EVERTS V, 1985, COLLAGEN REL RES, V5, P315
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096 203
   Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Helfrich MH, 2000, J BONE MINER RES, V15, P2315, DOI 10.1359/jbmr.2000.15.12.2315
   Helfrich MH, 2008, ARCH BIOCHEM BIOPHYS, V473, P172, DOI 10.1016/j.abb.2008.02.045
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200
   Jin HL, 2009, HUM MOL GENET, V18, P2729, DOI 10.1093/hmg/ddp205
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Kanis J, 1998, PATHOPHYSIOLOGY AND
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010 0856
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3, DOI 10.1210/jc.2009 1740
   Kiesel JR, 2009, J IMMUNOL, V182, P5477, DOI 10.4049/jimmunol.0803897
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235
   LAITALA T, 1993, J BONE MINER RES, V8, P119
   Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756 3282(96)00363 8
   Layfield R, 2004, BIOCHEM SOC T, V32, P728, DOI 10.1042/BST0320728
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li D, 2010, ANN NY ACAD SCI, V177, P280
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lorenzo J.A., 2011, IBMS BoneKEy, V8, P37, DOI DOI 10.1138/20110488
   LORIACORTES R, 1977, J PEDIATR US, V91, P43, DOI 10.1016/S0022 3476(77)80441 1
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meunier PJ, 1999, OSTEOPOROSIS INT, V10, P330, DOI 10.1007/s001980050236
   MILLS BG, 1984, CLIN ORTHOP RELAT R, P303
   Mohan S, 1996, HORM RES, V45, P59, DOI 10.1159/000184833
   Nakatsuka K, 2003, J BONE MINER RES, V18, P1381, DOI 10.1359/jbmr.2003.18.8.1381
   Naot D, 2007, J BONE MINER RES, V22, P298, DOI 10.1359/JBMR.061108
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   Okumura S, 2006, BONE, V39, P684, DOI 10.1016/j.bone.2006.04.010
   Ooi CG, 2000, BONE, V27, P417, DOI 10.1016/S8756 3282(00)00343 4
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ralston SH, 1999, BONE, V24, p17S, DOI 10.1016/S8756 3282(99)00032 0
   Ralston SH, 2008, LANCET, V372, P155, DOI 10.1016/S0140 6736(08)61035 1
   Ralston SH, 2008, BEST PRACT RES CL RH, V22, P101, DOI 10.1016/j.berh.2007.11.005
   Ralston SH, 2010, ANN NY ACAD SCI, V1192, P181, DOI 10.1111/j.1749 6632.2009.05317.x
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Riches PL, 2009, NEW ENGL J MED, V361, P1459, DOI 10.1056/NEJMoa0810925
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   ROTH DE, 1992, P NATL ACAD SCI USA, V89, P1804, DOI 10.1073/pnas.89.5.1804
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756 3282(02)00817 7
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SLY WS, 1983, P NATL ACAD SCI BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752
   Smink JJ, 2010, J MOL MED, V88, P227, DOI 10.1007/s00109 009 0567 8
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Somner J, 2004, J CLIN ENDOCR METAB, V89, P344, DOI 10.1210/jc.2003 030164
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Styrkarsdottir U, 2009, NAT GENET, V41, P15, DOI 10.1038/ng.284
   Susani L, 2004, HUM MUTAT, V24, P225, DOI 10.1002/humu.20076
   Takata S, 2004, J BONE MINER METAB, V22, P519, DOI 10.1007/s00774 004 0518 y
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 103
TC 19
Z9 32
U1 0
U2 1
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539 6509
EI 1944 7930
J9 DISCOV MED
JI Discov. Med.
PD MAR
PY 2012
VL 13
IS 70
BP 201
EP 210
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 094PV
UT WOS:000315277200003
PM 22463796
DA 2025 08 17
ER

PT J
AU Vij, R
   Horvath, N
   Spencer, A
   Taylor, K
   Vadhan Raj, S
   Vescio, R
   Smith, J
   Qian, Y
   Yeh, H
   Jun, S
AF Vij, Ravi
   Horvath, Noemi
   Spencer, Andrew
   Taylor, Kerry
   Vadhan Raj, Saroj
   Vescio, Robert
   Smith, Judy
   Qian, Yi
   Yeh, Howard
   Jun, Susie
TI An open label, phase 2 trial of denosumab in the treatment of relapsed
   or plateau phase multiple myeloma
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID FACTOR KAPPA B; OSTEOLYTIC BONE DISEASE; RECEPTOR ACTIVATOR;
   BREAST CANCER; OSTEOPROTEGERIN LIGAND; SKELETAL COMPLICATIONS;
   METASTASES; CELLS; MICROENVIRONMENT; EXPRESSION
AB RANKL is a key mediator of osteoclast differentiation, activation, and survival. Preclinical data suggest that aberrant production and activation of osteoclasts may influence proliferation of multiple myeloma (MM) cells in the bone marrow. Reports have also shown that inhibiting RANKL may have a direct effect on RANK expressing myeloma cells and a therapeutic role in treating the disease. In mouse myeloma models, inhibition of RANKL led to reduced serum paraprotein levels and tumor burden. Based on this hypothesis, this proof of concept, single arm study investigated whether RANKL inhibition with denosumab could reduce serum M protein levels in relapsed or plateau phase myeloma subjects. All subjects received denosumab monthly, with loading doses on days 8 and 15 of month one, until disease progression or subject discontinuation. Results of this ongoing study demonstrated that no subjects in either cohort met the protocol defined objective response criteria of complete response (CR) or partial response (PR), but that denosumab effectively inhibited the RANKL pathway regardless of previous exposure to bisphosphonates, as evidenced by suppressed levels of the bone turnover marker, serum C terminal telopeptide of type 1 collagen (sCTx). Eleven (21%) subjects who relapsed within 3 months before study entry maintained stable disease for up to 16.5 months. Nineteen (46%) subjects with plateau phase myeloma maintained stable disease for up to 18.3 months. The adverse event (AE) profile for denosumab and its dosing schedule in these populations was consistent with that for advanced cancer patients receiving systemic therapy. Additional controlled clinical studies of denosumab in subjects with both relapsed and plateau phase MM are warranted. Am. J. Hematol. 84:650 656, 2009. (C) 2009 Wiley Liss, Inc.
C1 [Vij, Ravi] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA.
   [Horvath, Noemi] Royal Adelaide Hosp, Adelaide, SA 5000, Australia.
   [Spencer, Andrew] Alfred Hosp, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia.
   [Taylor, Kerry] Haematol Clin Australasia, Brisbane, Australia.
   [Taylor, Kerry] Oncol Clin Australasia, Brisbane, Australia.
   [Vadhan Raj, Saroj] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Vescio, Robert] Cedars Sinai Samuel Oschin Comprehens Canc Ctr, Los Angeles, CA USA.
   [Smith, Judy] Amgen Inc, Early Dev, Thousand Oaks, CA 91320 USA.
   [Qian, Yi] Amgen Inc, Global Biostat & Epidemiol, Thousand Oaks, CA 91320 USA.
   [Yeh, Howard; Jun, Susie] Amgen Inc, Hematol Oncol, Thousand Oaks, CA 91320 USA.
C3 Washington University (WUSTL); Royal Adelaide Hospital; Florey Institute
   of Neuroscience & Mental Health; Howard Florey Institute Affiliates;
   University of Texas System; UTMD Anderson Cancer Center; Cedars Sinai
   Medical Center; Amgen; Amgen; Amgen
RP Vij, R (通讯作者)，Washington Univ, Sch Med, Div Oncol, 660 S Euclid Ave,Campus Box 8007, St Louis, MO 63110 USA.
EM rvij@dom.wustl.edu
FU Amgen Inc.; Thousand Oaks, CA
FX Amgen Inc., Thousand Oaks, CA.
CR Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168 8510(96)00822 6
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brown JE, 2003, BRIT J CANCER, V89, P2031, DOI 10.1038/sj.bjc.6601437
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cleeland CS, 2006, CLIN CANCER RES, V12, p6236S, DOI 10.1158/1078 0432.CCR 06 0988
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   FLEISS JL, 1981, STAT METHODS RATES P
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Ries L.A. G., 2007, SEER CANC STAT REV 1
   Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365 2141.2002.03417.x
   SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304 3959(94)00178 H
   Shaughnessy JD, 2003, IMMUNOL REV, V194, P140, DOI 10.1034/j.1600 065X.2003.00054.x
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
NR 28
TC 68
Z9 72
U1 0
U2 7
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0361 8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD OCT
PY 2009
VL 84
IS 10
BP 650
EP 656
DI 10.1002/ajh.21509
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 506AJ
UT WOS:000270744300007
PM 19714603
DA 2025 08 17
ER

PT J
AU Chen, GP
   Xu, Q
   Dai, M
   Liu, XQ
AF Chen, Guiping
   Xu, Qiang
   Dai, Min
   Liu, Xuqiang
TI Bergapten suppresses RANKL induced osteoclastogenesis and
   ovariectomy induced osteoporosis via suppression of NF κB and JNK
   signaling pathways
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Bergapten; Ovariectomy induced osteoporosis; Osteoclast; NF kappa B; JNK
ID INDUCED BONE LOSS; RECEPTOR ACTIVATOR; IN VITRO; DIFFERENTIATION;
   LIGAND; OSTEOBLASTS; INVOLVEMENT; RESORPTION; PROTEINS; ESTROGEN
AB Bergapten (BP), derived from Cnidium monnieri (L) Cusson, is an ingredient widely used in traditional Chinese medicine and has important biological and pharmacological activities. However, the effect of BP on ovariectomy induced osteoporosis and the underlying mechanism are not entirely clear. In this study, we investigated the effects of BP on ovariectomy induced osteoporosis and receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis in vivo and in vitro, and explored the underlying mechanism. We found that BP treatment exerted beneficial effects on ovariectomy induced osteoporosis in vivo. Further, BP attenuated osteoclastogenesis in bone marrow macrophages (BMMs) and RAW264.7 cells without any cytotoxicity. Additionally, BP specifically inhibited RANKL induced NF KB and JNK signaling,but did not suppress p38 and ERK. At the mRNA level, BP inhibits the OC associated transcription factor NFATcl and c fos, thereby affecting the expression of OC differentiation related genes. Moreover, BP disrupted the formation of F actin rings, which are important for bone resorbing activity, and impairs OC bone resorption. Therefore, BP may be a useful alternative therapy for postmenopausal osteoporosis. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Chen, Guiping; Xu, Qiang; Dai, Min; Liu, Xuqiang] Nanchang Univ, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Nanchang 330006, Jiangxi, Peoples R China.
   [Chen, Guiping; Xu, Qiang; Dai, Min; Liu, Xuqiang] Nanchang Univ, Affiliated Hosp 1, Multidisciplinary Therapy Ctr Musculoskeletal Tum, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Dai, M; Liu, XQ (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Nanchang 330006, Jiangxi, Peoples R China.
EM 1461698247@qq.com; 774735825@qq.com; daimin@medmail.com.cn;
   C18270712885@163.com
RI DAI, M/GPS 8291 2022
FU National Natural Science Foundation for Youths [81601912]; National
   Natural Science Foundation [81660365]
FX This work was supported by National Natural Science Foundation for
   Youths (Grant No.81601912) and National Natural Science Foundation
   (Grant No.81660365).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Abu Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200
   Bone H, 2012, ENDOCRIN METAB CLIN, V41, P655, DOI 10.1016/j.ecl.2012.05.003
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Iotsova V., 1997, NAT MED, V3, P1285
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li HB, 2004, J CHROMATOGR A, V1061, P51, DOI 10.1016/j.chroma.2004.10.091
   Li XJ, 2016, INT J MOL MED, V38, P1661, DOI 10.3892/ijmm.2016.2794
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Minisola S, 2017, INTERN EMERG MED, V12, P915, DOI 10.1007/s11739 017 1719 4
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Orwoll ES, 2003, J BONE MINER RES, V18, P949, DOI 10.1359/jbmr.2003.18.6.949
   PATHAK MA, 1992, J PHOTOCH PHOTOBIO B, V14, P3, DOI 10.1016/1011 1344(92)85080 E
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889 8529(05)70248 6
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Xiao JJ, 2015, MOL CELL BIOCHEM, V409, P113, DOI 10.1007/s11010 015 2517 9
   Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223 001 1079 x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
   Zhou Y, 2017, INT IMMUNOPHARMACOL, V48, P159, DOI 10.1016/j.intimp.2017.04.026
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
NR 34
TC 23
Z9 27
U1 0
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2019
VL 509
IS 2
BP 329
EP 334
DI 10.1016/j.bbrc.2018.12.112
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HK6MM
UT WOS:000458094800001
PM 30579598
DA 2025 08 17
ER

PT J
AU Yuan, A
   Munz, A
   Reinert, S
   Hoefert, S
AF Yuan, Anna
   Munz, Adelheid
   Reinert, Siegmar
   Hoefert, Sebastian
TI Histologic analysis of medication related osteonecrosis of the jaw
   compared with antiresorptive exposed bone and other infectious,
   inflammatory, and necrotic jaw diseases
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; POSTMENOPAUSAL WOMEN; CATHEPSIN K;
   ALENDRONATE; RESORPTION; DENOSUMAB; NECROSIS; OSTEORADIONECROSIS;
   OSTEOPETROSIS; OSTEOPOROSIS
AB Objective. This study characterized histologic features of medication related osteonecrosis of the jaw (MRONJ) through analysis of tissues from patients and healthy individuals.
   Study Design. Bone biopsies were collected from various infectious, inflammatory, and necrotic jaw diseases. Samples were divided into bone exposed to bisphosphonates or denosumab, as well as bisphosphonate related osteonecrosis of the jaw (BRONJ), denosumab related osteonecrosis of the jaw (DRONJ), and mixed necrosis, enabling us to identify features of single agent necrosis without influence from previous therapies. Hematoxylin and eosin (H&E), receptor activator of nuclear factor kappa B ligand (RANKL), tartrate resistant acid phosphatase (TRAP), osteoprotegerin, toluidine blue, CD14, and CD68 staining and micro computed tomography (micro CT) analysis were performed. Groups were compared by using analysis of variance (ANOVA).
   Results. In total, 156 bone samples were collected from 105 patients. MRONJ variants exhibited more infectious infiltration. Bisphosphonate (P<.001) and mixed necrosis (P=.002) demonstrated more RANKL and TRAP positive osteoclasts. Denosumab necrosis (P=.007), and bone exposed to bisphosphonates (P=.028) in combination with denosumab (P=.022) demonstrated significantly lower numbers of osteocytes per area. CD14 and CD68 positivity was increased for BRONJ (P=.008; P<.001, respectively). MRONJ variants exhibited the widest trabecular width and decreased medullary space to bone. No diminished vascular network in MRONJ samples was observed.
   Conclusions. Histologic features differ among MRONJ variants, with oversuppressed bone turnover, dysfunctional bone resorption, and a disturbed osteocyte network as potential mechanisms of pathogenesis.
C1 [Yuan, Anna; Munz, Adelheid; Reinert, Siegmar; Hoefert, Sebastian] Univ Hosp Tubingen, Dept Oral & Maxillofacial Surg, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Yuan, A (通讯作者)，Tufts Univ, Sch Dent Med, Div Oral Med, 1 Kneeland St, Boston, MA 02111 USA.
EM anna.yuan@tufts.edu
OI Yuan, Anna/0000 0001 5619 5175; Hoefert, Sebastian/0000 0002 0017 4575
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Diz P, 2012, J AM DENT ASSOC, V143, P981, DOI 10.14219/jada.archive.2012.0323
   Everts V, 2009, BBA MOL BASIS DIS, V1792, P757, DOI 10.1016/j.bbadis.2009.05.004
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Gemmell E, 2002, CRIT REV ORAL BIOL M, V13, P17, DOI 10.1177/154411130201300104
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Goulet GC, 2009, ANN BIOMED ENG, V37, P1390, DOI 10.1007/s10439 009 9706 1
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hansen T, 2006, VIRCHOWS ARCH, V449, P448, DOI 10.1007/s00428 006 0261 y
   HAPPONEN RP, 1983, ORAL SURG ORAL MED O, V55, P580, DOI 10.1016/0030 4220(83)90374 2
   Hesse B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088481
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kerschnitzki M, 2013, J BONE MINER RES, V28, P1837, DOI 10.1002/jbmr.1927
   Kim SM, 2017, OR SURG OR MED OR PA, V123, P220, DOI 10.1016/j.oooo.2016.09.225
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   Kumar Vijay, 2013, N Am J Med Sci, V5, P260, DOI 10.4103/1947 2714.110429
   Lim SS, 2017, OR SURG OR MED OR PA, V123, P8, DOI 10.1016/j.oooo.2016.08.009
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Nishida E, 2001, J PERIODONTAL RES, V36, P1, DOI 10.1034/j.1600 0765.2001.00637.x
   Oliveira PS, 2016, CLIN ORAL IMPLAN RES, V27, P325, DOI 10.1111/clr.12538
   Pap T, 2003, ARTHRITIS RES THER, V5, pR163, DOI 10.1186/ar752
   Perez Amodio S, 2006, CALCIFIED TISSUE INT, V79, P245, DOI 10.1007/s00223 005 0289 z
   Rabelo GD, 2015, ARCH ENDOCRIN METAB, V59, P507, DOI 10.1590/2359 3997000000097
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
NR 40
TC 11
Z9 12
U1 4
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212 4403
EI 1528 395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD FEB
PY 2020
VL 129
IS 2
BP 133
EP 140
DI 10.1016/j.oooo.2019.08.018
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA KG2HX
UT WOS:000509764400011
PM 31606424
DA 2025 08 17
ER

PT J
AU Funck Brentano, T
   Nilsson, KH
   Brommage, R
   Henning, P
   Lerner, UH
   Koskela, A
   Tuukkanen, J
   Cohen Solal, M
   Movérare Skrtic, S
   Ohlsson, C
AF Funck Brentano, Thomas
   Nilsson, Karin H.
   Brommage, Robert
   Henning, Petra
   Lerner, Ulf H.
   Koskela, Antti
   Tuukkanen, Juha
   Cohen Solal, Martine
   Moverare Skrtic, Sofia
   Ohlsson, Claes
TI Porcupine inhibitors impair trabecular and cortical bone mass and
   strength in mice
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE Wnt signaling pathway; targeted therapy; osteoporosis; animal models
ID POSTMENOPAUSAL WOMEN; WNT; ROMOSOZUMAB; CANCER; OSTEOBLASTS; PROGENITOR;
   DISEASE; GROWTH; TUMOR
AB WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve week old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose = 3 mg/kg/day; high dose = 6 mg/kg/day) or Wnt C59 (10 mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual energy X ray absorptiometry, mu CT and histomorphometry. Bone strength was measured by the 3 point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt C59 reduced total body bone mineral density compared with vehicle treatment (P < 0.001). Cortical thickness of the femur shaft (P < 0.001) and trabecular bone volume fraction in the vertebral body (P < 0.001) were reduced by treatment with LGK974 or Wnt C59. Porcupine inhibition reduced bone strength in the tibia (P < 0.05). The cortical bone loss was the result of impaired periosteal bone formation and increased endocortical bone resorption and the trabecular bone loss was caused by reduced trabecular bone formation and increased bone resorption. Porcupine inhibitors exert deleterious effects on bone mass and strength caused by a combination of reduced bone formation and increased bone resorption. We suggest that cancer targeted therapies using Porcupine inhibitors may increase the risk of fractures.
C1 [Funck Brentano, Thomas; Nilsson, Karin H.; Brommage, Robert; Henning, Petra; Lerner, Ulf H.; Moverare Skrtic, Sofia; Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Unit Canc Res & Translat Med, MRC Oulu, Oulu, Finland.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland.
   [Cohen Solal, Martine] Univ Paris Diderot, BIOSCAR UMRS 1132, Sorbonne Paris Cite, INSERM, Paris, France.
C3 University of Gothenburg; University of Oulu; University of Oulu;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite
RP Funck Brentano, T (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
EM thomas.funck brentano@gu.se
RI Tuukkanen, Juha/R 3728 2018; Brommage, Robert/J 5670 2019; Cohen Solal,
   Martine/P 7808 2017; Funck Brentano, Thomas/AAS 7201 2020; Ohlsson,
   Claes/HIR 6959 2022; Funck Brentano, Thomas/Q 5736 2016; Skrtic,
   Sofia/AAQ 1585 2020; Henning, Petra/KIL 4650 2024; Ohlsson,
   Claes/AGP 3544 2022
OI Tuukkanen, Juha/0000 0002 1723 6461; Henning, Petra/0000 0002 9330 6265;
   Lerner, Ulf/0000 0002 3579 1960; Koskela, Antti/0000 0001 7371 2488;
   Ohlsson, Claes/0000 0002 9633 2805; Funck Brentano,
   Thomas/0000 0001 7684 2405; 
FU European Union's Horizon 2020 Marie Sklodowska Curie Actions research
   and innovation programme [GOTBONE 750579]; French Society of
   Rheumatology; Vinnova; Swedish Research Council; Swedish Foundation for
   Strategic Research; ALF/LUA research grant in Gothenburg; Lundberg
   Foundation; Knut and Alice Wallenberg Foundation; Torsten Soderberg
   Foundation; Novo Nordisk Foundation; Novo Nordisk Fonden
   [NNF15OC0015080, NNF14OC0010513, NNF13OC0005785] Funding Source:
   researchfish
FX This work was supported by funding from the European Union's Horizon
   2020 Marie Sklodowska Curie Actions research and innovation programme
   under grant agreement GOTBONE 750579, the French Society of
   Rheumatology, Vinnova, the Swedish Research Council, the Swedish
   Foundation for Strategic Research, the ALF/LUA research grant in
   Gothenburg, the Lundberg Foundation, the Knut and Alice Wallenberg
   Foundation, the Torsten Soderberg Foundation, and the Novo Nordisk
   Foundation.
CR Altschuler EL, 2012, KNEE, V19, P500, DOI 10.1016/j.knee.2011.09.005
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Barrott JJ, 2011, P NATL ACAD SCI USA, V108, P12752, DOI 10.1073/pnas.1006437108
   Boone JD, 2016, LAB INVEST, V96, P249, DOI 10.1038/labinvest.2015.150
   Brommage R, 2015, J BONE MINER RES, V30, pS1, DOI [10.1002/jbmr.2763, DOI 10.1002/JBMR.2763]
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   De P, 2017, ONCOTARGET, V8, P3072, DOI 10.18632/oncotarget.13618
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GOLTZ RW, 1992, ARCH DERMATOL, V128, P1108
   Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE 07 0338
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032331
   Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Movérare Skrtic S, 2015, P NATL ACAD SCI USA, V112, P14972, DOI 10.1073/pnas.1520408112
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Nusse R, 2015, NATURE, V519, P163, DOI 10.1038/nature14208
   O'Cearbhaill RE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2515
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Smith DC, 2013, J CLIN ONCOL, V31
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   TANAKA H, 1990, INT ORTHOP, V14, P179
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 40
TC 41
Z9 47
U1 0
U2 4
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD JUL
PY 2018
VL 238
IS 1
BP 13
EP 23
DI 10.1530/JOE 18 0153
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GM5MW
UT WOS:000438182900006
PM 29720540
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Mansueto, P
   Vitale, G
   Seidita, A
   Guarneri, FP
   Pepe, I
   Rinollo, C
   di Rosa, S
   Rini, G
   Cillari, E
   Di Fedea, G
AF Mansueto, Pasquale
   Vitale, Giustina
   Seidita, Aurelio
   Guarneri, Francesco Paulo
   Pepe, Ilenia
   Rinollo, Carmelina
   di Rosa, Salvatore
   Rini, GiovamBattista
   Cillari, Enrico
   Di Fedea, Gaetana
TI MEVALONATE PATHWAY: ROLE OF BISPHOSPHONATES AND STATINS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mevalonate pathway; bisphosphonates; statins; osteoporosis;
   cardiovascular disease
ID COA REDUCTASE INHIBITORS; NITRIC OXIDE SYNTHASE; BONE MINERAL DENSITY;
   SMOOTH MUSCLE CELLS; NITROGEN CONTAINING BISPHOSPHONATES; ENDOTHELIAL
   PROGENITOR CELLS; OSTEOBLAST LIKE CELLS; RHO ASSOCIATED KINASE; KAPPA B
   ACTIVATION; VASCULAR CALCIFICATION
AB Cardiovascular diseases, i.e. high blood pressure, coronary heart disease, and stroke, and osteoporosis are public health problems, with several epidemiological links, and they might be related to each other in terms of pathogenesis and therapeutic agents. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis and lipid metabolic disorders. Some late clinical studies suggested bisphosphonates may have beneficial effect in vivo on atherosclerotic progression, lipid profiles, and cardiovascular morbidity and mortality, whereas statins might increase bone density, and reduce fracture risk, even if properly designed prospective studies are needed to clearly define clinical effects and potential new roles for these old agents. Moreover mechanism by which these two classes of drugs act, at cellular level, may not be mutually exclusive, and the common target of action might be the mevalonate pathway. In this review, we focused on in vitro and in vivo interactions between mevolanate pathway, bisphosphonates, and statins, examining the possible therapeutic consequences of these links.
C1 [Cillari, Enrico] Ospedali Riuniti Villa Sofia Cervello, Azienda Osped, UO Patol Clin, PO Cervello, Palermo, Italy.
   [Di Fedea, Gaetana] Univ Palermo, Dipartimento Discipline Chirurg & Oncol, I 90133 Palermo, Italy.
   [Mansueto, Pasquale; Vitale, Giustina; Seidita, Aurelio; Guarneri, Francesco Paulo; Pepe, Ilenia; Rinollo, Carmelina; Rini, GiovamBattista] Univ Palermo, Dipartimento Med Clin & Patol Emergenti, I 90133 Palermo, Italy.
C3 University of Palermo; University of Palermo
RP Mansueto, P (通讯作者)，Univ Policlin P Giaccone, Dipartimento Med Clin & Patol Emergenti, Azienda Osped, Via Vespro 141, I 90127 Palermo, Italy.
RI Seidita, Aurelio/IQT 5629 2023; Mansueto, Pasquale/K 3458 2016
OI Seidita, Aurelio/0000 0003 4080 2641; Mansueto,
   Pasquale/0000 0002 0406 0583
CR Adami S, 2000, J BONE MINER RES, V15, P599, DOI 10.1359/jbmr.2000.15.3.599
   Albert MA, 2001, JAMA J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   AMIN D, 1992, J LIPID RES, V33, P1657
   Ando H, 2000, J PHARMACOL EXP THER, V294, P1043
   Baldini V, 2005, J Endocrinol Invest, V28, P69
   Baugher PJ, 2005, BREAST CANCER RES, V7, pR965, DOI 10.1186/bcr1329
   Bellosta S, 2000, DIABETES CARE, V23, pB72
   Bernards A, 2006, METHOD ENZYMOL, V407, P1, DOI 10.1016/S0076 6879(05)07001 1
   Bevilacqua M, 2005, LUPUS, V14, P773, DOI 10.1191/0961203305lu2219oa
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P380, DOI 10.1007/s001980170106
   Body JJ, 2006, SUPPORT CARE CANCER, V14, P408, DOI 10.1007/s00520 005 0913 5
   Bokoch GM, 2006, ANTIOXID REDOX SIGN, V8, P1533, DOI 10.1089/ars.2006.8.1533
   Brunsveld L, 2006, ANGEW CHEM INT EDIT, V45, P6622, DOI 10.1002/anie.200600855
   Calabrò P, 2005, CURR OPIN CARDIOL, V20, P541, DOI 10.1097/01.hco.0000181482.99067.bf
   Caraglia M, 2005, CURR DRUG TARGETS, V6, P301, DOI 10.2174/1389450053765833
   Caruso ME, 2005, MOL CELL PROTEOMICS, V4, P936, DOI 10.1074/mcp.M500025 MCP200
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   CIOSEK CP, 1993, J BIOL CHEM, V268, P24832
   Cohen Stanley B, 2004, Curr Rheumatol Rep, V6, P59, DOI 10.1007/s11926 004 0084 2
   Coons JC, 2002, ANN PHARMACOTHER, V36, P326
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200
   Dellegrottaglie S, 2006, CURR MOL MED, V6, P515, DOI 10.2174/156652406778018653
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157
   Egashira K, 2000, HYPERTENS RES, V23, P353, DOI 10.1291/hypres.23.353
   Endres M, 2004, STROKE, V35, P2708, DOI 10.1161/01.STR.0000143319.73503.38
   Ericsson Johan, 1993, V21, P229
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298
   Fleisch H, 1997, HORM METAB RES, V29, P145, DOI 10.1055/s 2007 979008
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Fritz G, 2005, INT J ONCOL, V27, P1401
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Glowinska Barbara, 2003, Wiad Lek, V56, P109
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Haddy N, 2003, ATHEROSCLEROSIS, V170, P277, DOI 10.1016/S0021 9150(03)00287 9
   Hamerman D, 2002, SOUTH MED J, V95, P578
   HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213
   Hernández Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616
   Hilgendorff A, 2003, INT J CLIN PHARM TH, V41, P397
   Hirano Keiko, 2003, Clin Calcium, V13, P128
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016
   Holstein SA, 2004, LIPIDS, V39, P293, DOI 10.1007/s11745 004 1233 3
   Hsia J, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471 2474 3 7
   Ii M, 2007, VASC PHARMACOL, V46, P1, DOI 10.1016/j.vph.2006.06.012
   Jarstfer MB, 2002, J AM CHEM SOC, V124, P8834, DOI 10.1021/ja020410i
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Ketteler M, 2006, KIDNEY INT, V70, pS5, DOI 10.1038/sj.ki.5001996
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   Koshiyama Hiroyuki, 2002, Clin Calcium, V12, P378
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   LaCroix AZ, 2000, J BONE MINER RES, V15, pS155
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266
   Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129
   Laufs Ulrich, 2003, Curr Atheroscler Rep, V5, P372, DOI 10.1007/s11883 003 0008 z
   Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588
   Liu YM, 2006, J AM SOC NEPHROL, V17, P863, DOI 10.1681/ASN.2005050465
   Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131
   Lobell RB, 1998, ADV IMMUNOL, V68, P145, DOI 10.1016/S0065 2776(08)60559 3
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   McFarlane SI, 2001, J CLIN ENDOCR METAB, V86, P713, DOI 10.1210/jc.86.2.713
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Meyer Sabellek W, 2006, J HYPERTENS, V24, P2349, DOI 10.1097/HJH.0b013e3280113648
   Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010
   Montagnani A, 2003, BONE, V32, P15, DOI 10.1016/S8756 3282(02)00924 9
   Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262
   Moosmann B, 2004, TRENDS CARDIOVAS MED, V14, P273, DOI 10.1016/j.tcm.2004.08.003
   Mraiche F, 2005, BRIT J PHARMACOL, V144, P715, DOI 10.1038/sj.bjp.0706114
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Muniyappa R, 2000, AM J PHYSIOL HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762
   Murphy RT, 2001, AM J CARDIOL, V87, P446, DOI 10.1016/S0002 9149(00)01400 4
   Nakashima K, 1998, SEMIN HEMATOL, V35, P210
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nash David T, 2005, J Natl Med Assoc, V97, P1600
   Nickenig G, 1999, CIRCULATION, V100, P2131, DOI 10.1161/01.CIR.100.21.2131
   Nishibori M, 2003, J PHARMACOL SCI, V92, P7
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Olmos JM, 1999, METHOD FIND EXP CLIN, V21, P519, DOI 10.1358/mf.1999.21.8.794832
   Omoigui S, 2005, MED HYPOTHESES, V65, P559, DOI 10.1016/j.mehy.2005.03.012
   Ono Katsuhiro, 2004, Clin Calcium, V14, P60
   OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415
   Oxlund H, 2001, CALCIFIED TISSUE INT, V69, P299, DOI 10.1007/s00223 001 2027 5
   Park EJ, 2004, J IMMUNOL, V173, P5697, DOI 10.4049/jimmunol.173.9.5697
   Park JK, 2000, KIDNEY INT, V58, P1420, DOI 10.1046/j.1523 1755.2000.00304.x
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Pedersen TR, 2000, JAMA J AM MED ASSOC, V284, P1921
   Persy V, 2006, KIDNEY INT, V70, P1537, DOI 10.1038/sj.ki.5001899
   Perticone F, 2000, ATHEROSCLEROSIS, V152, P511, DOI 10.1016/S0021 9150(00)00370 1
   Phillips BW, 2001, BIOCHEM BIOPH RES CO, V284, P478, DOI 10.1006/bbrc.2001.4987
   Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   Rendina D, 2005, NEW ENGL J MED, V353, P2616
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sessa WC, 2001, TRENDS MOL MED, V7, P189, DOI 10.1016/S1471 4914(01)01985 2
   Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144
   Song L, 2004, ATHEROSCLEROSIS, V177, P43, DOI 10.1016/j.atherosclerosis.2004.06.018
   Stein EA, 2001, NUTR METAB CARDIOVAS, V11, P84
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Suzuki K, 2006, J PHARMACOL SCI, V100, P189, DOI 10.1254/jphs.FMJ05004X2
   Takano T, 2006, J ATHEROSCLER THROMB, V13, P95, DOI 10.5551/jat.13.95
   Tamai O, 1997, CIRCULATION, V95, P76, DOI 10.1161/01.CIR.95.1.76
   Tankó LB, 2005, OSTEOPOROSIS INT, V16, P184, DOI 10.1007/s00198 004 1662 x
   Tanriverdi HA, 2005, EUR J OBSTET GYN R B, V120, P63, DOI 10.1016/j.ejogrb.2004.08.007
   TERKELTAUB R, 1994, J LEUKOCYTE BIOL, V55, P749, DOI 10.1002/jlb.55.6.749
   Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433 200110000 00012
   Tuominen OM, 2002, METHOD FIND EXP CLIN, V24, P487, DOI 10.1358/mf.2002.24.8.705068
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Viereck V, 2005, J CELL BIOCHEM, V96, P1244, DOI 10.1002/jcb.20598
   Waldman A, 2003, DRUGS, V63, P139, DOI 10.2165/00003495 200363020 00002
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735 1097(97)00324 0
   Wei CY, 2006, MOL PHARMACOL, V69, P960, DOI 10.1124/mol.105.017368
   Whitney C, 2004, SPORTS MED, V34, P779, DOI 10.2165/00007256 200434120 00001
   Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7
   Wright JEI, 2004, ADV EXP MED BIOL, V553, P139
   Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022 2143(96)90079 7
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
   Ylitalo R, 2000, GEN PHARMACOL VASC S, V35, P287, DOI 10.1016/S0306 3623(01)00121 5
   Ylitalo R, 1997, LIFE SCI, V62, P413, DOI 10.1016/S0024 3205(97)01134 X
NR 134
TC 6
Z9 6
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393 6384
EI 2283 9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2011
VL 27
IS 2
BP 85
EP 95
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 904QY
UT WOS:000301214200004
DA 2025 08 17
ER

PT J
AU Thomas, D
   Henshaw, R
   Skubitz, K
   Chawla, S
   Staddon, A
   Blay, JY
   Roudier, M
   Smith, J
   Ye, ZS
   Sohn, W
   Dansey, R
   Jun, S
AF Thomas, David
   Henshaw, Robert
   Skubitz, Keith
   Chawla, Sant
   Staddon, Arthur
   Blay, Jean Yves
   Roudier, Martine
   Smith, Judy
   Ye, Zhishen
   Sohn, Winnie
   Dansey, Roger
   Jun, Susie
TI Denosumab in patients with giant cell tumour of bone: an open label,
   phase 2 study
SO LANCET ONCOLOGY
LA English
DT Article
ID TERM FOLLOW UP; BREAST CANCER; OSTEOPROTEGERIN LIGAND; ARTERIAL
   EMBOLIZATION; RECEPTOR ACTIVATOR; PROSTATE CANCER; KAPPA B; METASTASES;
   BISPHOSPHONATES; OSTEOCLASTS
AB Background Giant cell tumour (GCT) of bone is a primary osteolytic bone tumour with low metastatic potential and is associated with substantial skeletal morbidity. GCT is rich in osteoclast like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. We investigated the potential therapeutic effect of denosumab, a fully human monoclonal antibody against RANKL, on tumour cell survival and growth in patients with GCT.
   Methods In this open label, single group study, 37 patients with recurrent or unresectable GCT were enrolled and received subcutaneous denosumab 120 mg monthly (every 28 days), with loading doses on days 8 and 15 of month 1. The primary endpoint was tumour response, defined as elimination of at least 90% of giant cells or no radiological progression of the target lesion up to week 25. Study recruitment is closed; patient treatment and follow up are ongoing. The study is registered with Clinical Trials.gov, NCT00396279.
   Findings Two patients had insufficient histology or radiology data for efficacy assessment. 30 of 35 (86%; 95% Cl 70 95) of evaluable patients had a tumour response: 20 of 20 assessed by histology and 10 of 15 assessed by radiology. Adverse events were reported in 33 of 37 patients; the most common being pain in an extremity (n=7), back pain (n=4), and headache (n=4). Five patients had grade 3 5 adverse events, only one of which (grade 3 increase in human chorionic gonadotropin concentration not related to pregnancy) was deemed to be possibly treatment related. Five serious adverse events were reported although none were deemed treatment related.
   Interpretation Further investigation of denosumab as a therapy for GCT is warranted.
C1 [Thomas, David] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia.
   [Henshaw, Robert] Georgetown Univ, Sch Med, Washington Canc Inst, Washington, DC USA.
   [Skubitz, Keith] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA.
   [Skubitz, Keith] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA.
   [Chawla, Sant] Sarcoma Oncol Ctr, Santa Monica, CA USA.
   [Staddon, Arthur] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Staddon, Arthur] Penn Hematol & Oncol Associates, Philadelphia, PA USA.
   [Blay, Jean Yves] Univ Lyon 1, F 69365 Lyon, France.
   [Blay, Jean Yves] Hop Edouard Herriot, Lyon, France.
   [Roudier, Martine] Amgen Inc, Seattle, WA USA.
   [Smith, Judy; Ye, Zhishen; Sohn, Winnie; Dansey, Roger; Jun, Susie] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Peter Maccallum Cancer Center; Georgetown University; University of
   Minnesota System; University of Minnesota Twin Cities; University of
   Minnesota System; University of Minnesota Twin Cities; University of
   Pennsylvania; Universite Claude Bernard Lyon 1; CHU Lyon; Amgen; Amgen
RP Thomas, D (通讯作者)，Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.
EM david.thomas@petermac.org
RI ; Blay, Jean Yves/N 3966 2016; Thomas, David/AAD 2877 2019
OI Skubitz, Keith/0000 0002 0690 9595; Blay, Jean Yves/0000 0001 7190 120X;
   Thomas, David/0000 0002 2527 5428; 
FU Amgen, Inc
FX This study was sponsored by Amgen, Inc. Medical writers Ting Chang and
   Linda Melvin were involved in all stages of the writing of this
   manuscript. Ting Chang is an employee of Amgen Inc; the fireelance
   services of Linda Melvin were funded by Amgen Inc.
CR Balke M, 2009, J CANCER RES CLIN, V135, P149, DOI 10.1007/s00432 008 0427 x
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Brien EW, 1997, SKELETAL RADIOL, V26, P246, DOI 10.1007/s002560050230
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   BULLOUGH PG, 2002, WHO CLASSIFICATION T
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Hosalkar HS, 2007, SPINE, V32, P1107, DOI 10.1097/01.brs.0000261558.94247.8d
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin PP, 2002, CANCER AM CANCER SOC, V95, P1317, DOI 10.1002/cncr.10803
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   MALAWER M, 2008, PRINCIPLES PRACTICE
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Roudier MP, 2007, 13 ANN CONN TISS ONC
   Roudier MP, 2006, 12 ANN CONN TISS ONC
   Siebenrock KA, 1998, J BONE JOINT SURG BR, V80B, P43, DOI 10.1302/0301 620X.80B1.7875
   Szendroi M, 2003, Acta Chir Orthop Traumatol Cech, V70, P142
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
NR 28
TC 495
Z9 531
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1470 2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2010
VL 11
IS 3
BP 275
EP 280
DI 10.1016/S1470 2045(10)70010 3
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 568MA
UT WOS:000275525300026
PM 20149736
DA 2025 08 17
ER

PT J
AU Zhang, P
   Chen, HL
   Shen, GY
   Zhang, ZD
   Yu, X
   Shang, Q
   Zhao, WH
   Li, DY
   Li, PX
   Chen, GF
   Liang, D
   Jiang, XB
   Ren, H
AF Zhang, Peng
   Chen, Honglin
   Shen, Gengyang
   Zhang, Zhida
   Yu, Xiang
   Shang, Qi
   Zhao, Wenhua
   Li, Danyun
   Li, Peixin
   Chen, Guifeng
   Liang, De
   Jiang, Xiaobing
   Ren, Hui
TI Network pharmacology integrated with experimental validation reveals the
   regulatory mechanism of plastrum testudinis in treating senile
   osteoporosis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Senile osteoporosis; Plastrum testudinis; Network pharmacology;
   Experimental validation; Osteoclast differentiation
ID BONE; EXPRESSION; OSTEOCLASTOGENESIS; EXTRACTS
AB Ethnopharmacological relevance: Plastrum testudinis (PT) has been used in traditional Chinese medicine to treat bone diseases such as senile osteoporosis (SOP) for thousands of years. However, the underlying mechanisms remain largely unknown.
   Aim of the study: This study aims to investigate the possible molecular mechanism of PT in the treatment of SOP using an integrated strategy of network pharmacology and experimental validation.
   Materials and methods: The compounds of PT and its targets were identified through the BATMAN TCM database. The SOP related targets were retrieved from the GeneCards database. Protein protein interaction information was obtained by inputting the intersection targets into the STRING database. Cytoscape software was used to construct a protein protein interaction network and a PT compound target SOP network. Using Cytoscape and R software, we conducted GO function and KEGG pathway enrichment analyses. We also conducted in vivo and in vitro experiments to verify the network pharmacology findings.
   Results: In total, 6 active compounds and 342 targets of PT were screened, of which 57 common targets were related to SOP. The GO biological process enrichment analysis identified 880 entries, mainly relating to the regulation of hormone response, the cell apoptotic process, the apoptotic signaling pathway, NF kappaB transcription factor activity, fatty acid transportation, osteoclast differentiation, macrophage activation, and inflammatory response. The KEGG pathway enrichment analysis identified 52 entries, including 14 related signaling pathways, which mainly involved the TNF, MAPK, IL 17, AGE RAGE, estrogen, relaxin, and other signaling pathways. Our in vivo experiments confirmed that PT alleviates SOP, while the in vitro experiments demonstrated that PT exerts a suppressive effect on osteoclast differentiation and bone resorption in a concentration dependent manner. Furthermore, we observed that PT downregulates the expression of osteoclastspecific genes, including C FOS, TNF, and BDNF, in the MAPK signaling pathway.
   Conclusion: Through network pharmacology and experimental validation, this study is the first to report that PT downregulates the expression of osteoclast specific genes, including C FOS, TNF, and BDNF, in the MAPK signaling pathway, thus exerting a suppressive effect on osteoclast differentiation and bone resorption, which may be the molecular mechanism for PT treatment of SOP.
C1 [Zhang, Peng; Zhang, Zhida; Shang, Qi; Zhao, Wenhua; Li, Danyun; Chen, Guifeng] Guangzhou Univ Chinese Med, Clin Sch 1, Guangzhou 510405, Peoples R China.
   [Chen, Honglin; Shen, Gengyang; Yu, Xiang; Liang, De; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
   [Li, Peixin] Guangzhou Univ Chinese Med, Clin Sch 2, Guangzhou 510405, Peoples R China.
   [Zhang, Peng; Chen, Honglin; Shen, Gengyang; Zhang, Zhida; Yu, Xiang; Shang, Qi; Zhao, Wenhua; Chen, Guifeng; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Jiang, XB; Ren, H (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
EM spinedrjxb@sina.com; renhuispine@163.com
RI Zhang, Peng/IZP 9286 2023; Zhida, Zhang/HME 3183 2023
OI Shen, Gengyang/0000 0001 8940 7912; Chen, Honglin/0000 0001 7300 5345;
   Shang, Qi/0000 0001 9135 2666; Zhang, Peng/0000 0003 1777 3790
FU National Natural Science Foundation of China [81904225]
FX The work was supported partly by the following grants:National Natural
   Science Foundation of China (81904225).
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Al Mamun MA, 2020, J CELL MOL MED, V24, P2542, DOI 10.1111/jcmm.14948
   Bernard V, 2019, NAT REV ENDOCRINOL, V15, P356, DOI 10.1038/s41574 019 0194 6
   Cao QH, 2018, J EXP MED, V215, P1679, DOI 10.1084/jem.20172048
   Chen DF, 2007, CELL PROLIFERAT, V40, P196, DOI 10.1111/j.1365 2184.2007.00431.x
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Daoussis D, 2010, SEMIN ARTHRITIS RHEU, V39, P369, DOI 10.1016/j.semarthrit.2008.10.008
   Dobrowolski SF, 2018, MOL GENET METAB, V125, P193, DOI 10.1016/j.ymgme.2018.08.010
   Fan H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00838
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Hannemann N, 2017, J IMMUNOL, V198, P3605, DOI 10.4049/jimmunol.1601330
   He Q, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113946
   Hutchison MR, 2012, MOL ENDOCRINOL, V26, P1406, DOI 10.1210/me.2012 1063
   Karkache IY, 2021, GENE, V771, DOI 10.1016/j.gene.2020.145362
   Kim RY, 2015, TISSUE ENG PT A, V21, P2076, DOI [10.1089/ten.tea.2014.0585, 10.1089/ten.TEA.2014.0585]
   Li CH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107219
   Li MX, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3571810
   Liang D, 2016, BIOMED PHARMACOTHER, V82, P151, DOI 10.1016/j.biopha.2016.04.068
   Lin PI, 2018, ONCOTARGET, V9, P1169, DOI 10.18632/oncotarget.23453
   Liu Z., 2020, FRONT CELL DEV BIOL, V8
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   Ohori F., 2020, Int J Mol Sci, V21
   Plummer J, 2017, J CELL BIOCHEM, V118, P31, DOI 10.1002/jcb.25604
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qin XY, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113815
   Ren H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10614 5
   Rumzhum NN, 2016, CLIN EXP ALLERGY, V46, P397, DOI 10.1111/cea.12697
   Schulman Rifka C, 2011, Curr Osteoporos Rep, V9, P184, DOI 10.1007/s11914 011 0079 7
   Shang Q, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6815620
   Shen MY, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758 2946 4 31
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Su Y, 2019, BONE, V129, DOI 10.1016/j.bone.2019.115082
   Sun CY, 2012, INT J CANCER, V130, P827, DOI 10.1002/ijc.26059
   Sun P, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2532081
   Vu TO, 2021, BIOORG CHEM, V107, DOI 10.1016/j.bioorg.2020.104613
   Wang YY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.129
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Yano T, 2020, J SHOULDER ELB SURG, V29, P1884, DOI 10.1016/j.jse.2020.01.076
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhao GF, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3427430
NR 42
TC 7
Z9 10
U1 1
U2 52
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2021
VL 276
AR 114198
DI 10.1016/j.jep.2021.114198
EA MAY 2021
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SQ3JF
UT WOS:000660251400007
PM 33984459
DA 2025 08 17
ER

PT J
AU Wang, J
   Chen, G
   Yang, X
   Dou, WW
   Mao, YH
   Zhang, YD
   Shi, XT
   Xia, YH
   You, QY
   Liu, M
AF Wang, Jing
   Chen, Gang
   Yang, Xue
   Dou, Wenwen
   Mao, Yuhang
   Zhang, Yudie
   Shi, Xiaotian
   Xia, Yehua
   You, Qiuyi
   Liu, Mei
TI Inhibitory effects of norcantharidin on titanium particle induced
   osteolysis, osteoclast activation and bone resorption via MAPK pathways
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Norcantharidin; Osteoclast formation; Bone resorption; Inflammation;
   MAPK signaling pathway; Osteolysis
ID NF KAPPA B; C FOS; DOWN REGULATION; WEAR PARTICLES; DIFFERENTIATION;
   BISPHOSPHONATES
AB Wear particles generated from the surface of implanted prostheses can lead to peri implant osteolysis and subsequent aseptic loosening. In the inflammatory environment, extensive formation and activation of osteoclasts are considered the underlying cause of peri implant osteolysis. Current medications targeting osteoclasts for the treatment of particle induced bone resorption are not ideal due to significant side effects. Therefore, there is an urgent need to develop more effective drugs with fewer side effects. Norcantharidin (NCTD), a derivative of cantharidin extracted from blister beetles, is currently primarily used for the treatment of solid tumors in clinical settings. However, the potential role of NCTD in treating aseptic loosening of the prosthesis has not been reported. In this study, the in vitro results demonstrated that NCTD could effectively inhibit the formation of osteoclasts and bone resorption induced by the RANKL. Consistently, NCTD strongly inhibited RANKL induced mRNA and protein levels of c Fos and NFATc1, concomitant with reduced expression of osteoclast specific genes including TRAP, CTR and CTSK. The in vivo data showed that NCTD exerted significant protective actions against titanium particle induced inflammation and subsequent osteolysis. The molecular mechanism investigation revealed that NCTD could suppress the activations of RANKL induced MAPK (p38, ERK). Overall, these findings support the potential use of NCTD for the treatment of aseptic loosening following total joint arthroplasty.
C1 [Wang, Jing; Chen, Gang; Yang, Xue; Dou, Wenwen; Mao, Yuhang; Zhang, Yudie; Shi, Xiaotian; Xia, Yehua; You, Qiuyi; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
C3 Nanjing Normal University
RP Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
EM meiliunj@163.com
FU National Natural Science Foundation of China [32071165, 31870895]
FX The raw data supporting the conclusion of this article will be made
   available by the authors, without undue reservation, to any qualified
   researcher. This study was funded by National Natural Science Foundation
   of China (Grant No. 32071165; 31870895) .
CR Amanatullah DF, 2016, ORTHOPEDICS, V39, P371, DOI 10.3928/01477447 20160719 06
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Antonios JK, 2013, CELL MOL IMMUNOL, V10, P471, DOI 10.1038/cmi.2013.39
   Apostu D, 2018, J INT MED RES, V46, P2104, DOI 10.1177/0300060517732697
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Choi SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 35
   Choi Y, 2019, MOL CELLS, V42, P183, DOI 10.14348/molcells.2018.0382
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eger M, 2017, SCI REP UK, V7, DOI 10.1038/srep39612
   Espinosa N, 2017, FOOT ANKLE CLIN, V22, P267, DOI 10.1016/j.fcl.2017.01.001
   Fu LJ, 2017, IMMUNOBIOLOGY, V222, P597, DOI 10.1016/j.imbio.2016.11.009
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hodges NA, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121127
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Janovska Zuzana, 2012, Acta Medica (Hradec Kralove), V55, P111
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Li XY, 2021, WORLD J GASTROENTERO, V27, P4208, DOI 10.3748/wjg.v27.i26.4208
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lin JX, 2020, ACTA BIOMATER, V106, P410, DOI 10.1016/j.actbio.2020.02.017
   Liu X, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052868
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Mack P, 1998, HPB Surg, V11, P75, DOI 10.1155/1998/45925
   Mbalaviele G, 2006, J PHARMACOL EXP THER, V317, P1044, DOI 10.1124/jpet.105.100362
   Menge TJ, 2021, AM J SPORT MED, V49, P76, DOI 10.1177/0363546520973977
   Novack DV, 2011, ADV EXP MED BIOL, V691, P163, DOI 10.1007/978 1 4419 6612 4_17
   Park JH, 2017, MOL CELLS, V40, P706
   Ren WP, 2008, J BIOMED MATER RES A, V85A, P1043, DOI 10.1002/jbm.a.31665
   Shen Yeqi, 2021, Zhejiang Da Xue Xue Bao Yi Xue Ban, V50, P162, DOI 10.3724/zdxbyxb 2021 0099
   Tarleton M, 2012, EUR J MED CHEM, V54, P573, DOI 10.1016/j.ejmech.2012.06.010
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   von Knoch M, 2005, BIOMATERIALS, V26, P1803, DOI 10.1016/j.biomaterials.2004.06.010
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   WANG GS, 1989, J ETHNOPHARMACOL, V26, P147, DOI 10.1016/0378 8741(89)90062 7
   Wang JX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060798
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Wang ML, 2004, J ARTHROPLASTY, V19, P1028, DOI 10.1016/j.arth.2004.03.024
   Weivoda MM, 2023, J BONE MINER RES, V38, P359, DOI 10.1002/jbmr.4773
   Wu YL, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00915 3
   Zhai BT, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01703 3
   Zhang L, 2005, DRUG DELIV, V12, P289, DOI 10.1080/10717540500176829
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zheng Dan, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P826, DOI 10.7534/j.issn.1009 2137.2015.03.043
   Zhu X, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106847
NR 49
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR 10
PY 2024
VL 129
AR 111655
DI 10.1016/j.intimp.2024.111655
EA FEB 2024
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA LB8W9
UT WOS:001184420500001
PM 38340423
DA 2025 08 17
ER

PT J
AU Mönkkönen, H
   Ottewell, PD
   Kuokkanen, J
   Mönkkönen, J
   Auriola, S
   Holen, I
AF Monkkonen, Hannu
   Ottewell, Penelope D.
   Kuokkanen, Johanna
   Monkkonen, Jukka
   Auriola, Seppo
   Holen, Ingunn
TI Zoledronic acid induced IPP/ApppI production in vivo
SO LIFE SCIENCES
LA English
DT Article
DE bisphosphonate; FPP synthase; ATP analog; peritoneal macrophage; in vivo
ID BISPHOSPHONATE DRUGS; RESORBING OSTEOCLASTS; CONTAINING METABOLITE;
   MASS SPECTROMETRY; ATP ANALOG; BONE; CLODRONATE; TRANSLOCASE
AB Bisphosphonates are currently the most important class of anti resorptive drugs used for the treatment of diseases involving excess bone resorption. Recently we discovered a new mechanism of action for bisphosphonates. Previously it has been shown that nitrogen containing bisphosphonates (N BPs) are not metabolized. However, our studies revealed that N BPs induce formation of a novel pro apoptotic ATP analog (ApppI), as a consequence of the inhibition of FPP synthase in the mevalonate pathway, and the subsequent accumulation of isopentenyl pyrophosphate (IPP) in vitro. The primary aim of the current study was to determine whether zoledronic, acid (a N BP) induces IPP/ApppI formation in vivo. Mass spectrometry was used to identify whether in vivo administration of zoledronic acid induced IPP/ApppI production by mouse peritoneal macrophages or bone marrow cells. IPP/ApppI could be detected in extracts from peritoneal macrophages isolated from zoledronic acid treated animals. Increasing IPP/ApppI accumulation was determined up to 7 days after drug injection, indicating prolonged FPP synthase inhibition by zoledronic acid. Importantly, this is the first report of in vivo production of ApppI, supporting the biological significance of this molecule. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
   Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Clin Oncol, Sheffield S10 2TN, S Yorkshire, England.
   Univ Kuopio, Dept Pharmaceut Chem, FIN 70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Sheffield; University of
   Eastern Finland
RP Mönkkönen, H (通讯作者)，Univ Kuopio, Dept Pharmaceut, POB 1627, FIN 70211 Kuopio, Finland.
EM hannu.monkkonen@uku.fi
OI Ottewell, Penelope/0000 0002 4826 0771; Holen,
   Ingunn/0000 0002 8759 6913
CR Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Coleman RE, 2004, BREAST, V13, pS19, DOI 10.1016/j.breast.2004.09.004
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378 4347(99)00559 9
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Stenbeck G, 2000, J CELL SCI, V113, P1577
NR 16
TC 57
Z9 61
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
J9 LIFE SCI
JI Life Sci.
PD SEP 8
PY 2007
VL 81
IS 13
BP 1066
EP 1070
DI 10.1016/j.lfs.2007.08.007
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 220WR
UT WOS:000250188500005
PM 17850825
DA 2025 08 17
ER

PT J
AU Krause, U
   Harris, S
   Green, A
   Ylostalo, J
   Zeitouni, S
   Lee, N
   Gregory, CA
AF Krause, Ulf
   Harris, Sean
   Green, Angela
   Ylostalo, Joni
   Zeitouni, Suzanne
   Lee, Narae
   Gregory, Carl A.
TI Pharmaceutical modulation of canonical Wnt signaling in multipotent
   stromal cells for improved osteoinductive therapy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE osteogenesis; bone repair; tissue engineering
ID ADULT STEM CELLS; BONE MARROW STROMA; ADHERENT CELLS; OSTEOBLAST
   DIFFERENTIATION; GENE FAMILY; IN VITRO; EXPRESSION; INHIBITOR;
   EXPANSION; MINERALIZATION
AB Human mesenchymal stem cells (hMSCs) from bone marrow are regarded as putative osteoblast progenitors in vivo and differentiate into osteoblasts in vitro. Positive signaling by the canonical wingless (Wnt) pathway is critical for the differentiation of MSCs into osteoblasts. In contrast, activation of the peroxisome proliferator activated receptor gamma (PPAR gamma) mediated pathway results in adipogenesis. We therefore compared the effect of glycogen synthetase kinase 3 beta (GSK3 beta) inhibitors and PPAR gamma inhibitors on osteogenesis by hMSCs. Both compounds altered the intracellular distribution of beta catenin and GSK3 beta in a manner consistent with activation of Wnt signaling. With osteogenic supplements, the GSK3 beta inhibitor 6 bromo indirubin 3' oxime (BIO) and the PPAR gamma inhibitor GW9662 (GW) enhanced early osteogenic markers, alkaline phosphatase (ALP), and osteoprotegerin (OPG) by hMSCs and transcriptome analysis demonstrated up regulation of genes encoding bone related structural proteins. At higher doses of the inhibitors, ALP levels were attenuated, but dexamethasone induced biomineralization was accelerated. When hMSCs were pretreated with BIO or GW and implanted into experimentally induced nonself healing calvarial defects, GW treatment substantially increased the capacity of the cells to repair the bone lesion, whereas BIO treatment had no significant effect. Further investigation indicated that unlike GW, BIO induced cell cycle inhibition in vitro. Furthermore, we found that GW treatment significantly reduced expression of chemokines that may exacerbate neutrophil and macrophage mediated cell rejection. These data suggest that use of PPAR gamma inhibitors during the preparation of hMSCs may enhance the capacity of the cells for osteogenic cytotherapy, whereas adenine analogs such as BIO can adversely affect the viability of hMSC preparations in vitro and in vivo.
C1 [Krause, Ulf; Ylostalo, Joni; Zeitouni, Suzanne; Gregory, Carl A.] Texas A&M Hlth Sci Ctr, Scott & White Hosp, Inst Regenerat Med, Temple, TX 76502 USA.
   [Harris, Sean; Green, Angela; Lee, Narae] Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70112 USA.
   [Harris, Sean; Green, Angela; Lee, Narae] Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Tulane University; Tulane University
RP Gregory, CA (通讯作者)，Texas A&M Hlth Sci Ctr, Scott & White Hosp, Inst Regenerat Med, Temple, TX 76502 USA.
EM cgregory@medicine.tamhsc.edu
RI ; Ylostalo, Joni/AAH 9457 2019; Harris, Sean/AAE 9547 2019
OI Gregory, Carl/0000 0001 6444 5541; Ylostalo, Joni/0000 0001 9746 1994; 
FU National Institutes of Health [HL075161 01, DK071780, R020152];
   Louisiana Gene Therapy Research Consortium, Scott and White Hospital;
   Texas A&M Health Sciences Center
FX We thank Kent Claypool, Institute for Regenerative Medicine, Texas A&M
   Health Sciences Center, for assistance with flow cytometry and Jack
   Ratcliff (Franklin, TN) for processing calcified bone specimens. This
   work was supported in part by National Institutes of Health Grants
   HL075161 01, DK071780, and R020152, the Louisiana Gene Therapy Research
   Consortium, Scott and White Hospital, and Texas A&M Health Sciences
   Center.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503
   DEXTER TM, 1984, BLOOD CELLS, V10, P315
   Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gregory CA, 2006, DRUG NEWS PERSPECT, V19, P445, DOI 10.1358/dnp.2006.19.8.1043960
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   GREGORY CA, 2005, SCI STKE, V294, pPE37
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Larson BL, 2008, STEM CELLS, V26, P193, DOI 10.1634/stemcells.2007 0524
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu JQ, 2004, J BIOL CHEM, V279, P24493, DOI 10.1074/jbc.M402920200
   Lucki Natasha C., 2008, V49, P387, DOI 10.1007/978 1 4020 8831 5_15
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Worgall Tilla S., 2008, V49, P371, DOI 10.1007/978 1 4020 8830 8_14
NR 36
TC 96
Z9 110
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 2
PY 2010
VL 107
IS 9
BP 4147
EP 4152
DI 10.1073/pnas.0914360107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 563KP
UT WOS:000275131100038
PM 20150512
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Russell, RGG
AF Russell, R. Graham G.
TI Bisphosphonates: Mode of action and pharmacology
SO PEDIATRICS
LA English
DT Article; Proceedings Paper
CT Workshop on Skeletal Effects of Pharmacologic Agents in Children
CY APR 14, 2005
CL Natl Inst Hlth, Bethesda, MD
SP Amer Soc Bone & Mineral Res, Natl Inst Child Hlth & Human Dev
HO Natl Inst Hlth
DE bone resorption; osteoclasts; bisphosphonates; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE;
   GTP BINDING PROTEIN; 3 DIMENSIONAL MICROCOMPUTED TOMOGRAPHY;
   HETEROCYCLE CONTAINING BISPHOSPHONATES; DICTYOSTELIUM DISCOIDEUM AMEBAS;
   TYROSINE PHOSPHATASE ACTIVITY; CYCLICAL ETIDRONATE THERAPY; SUPPRESSED
   BONE TURNOVER; NON VERTEBRAL FRACTURES
AB The profound effects of the bisphosphonates on calcium metabolism were discovered over 30 years ago, and they are now well established as the major drugs used for the treatment of bone diseases associated with excessive resorption. Their principal uses are for Paget disease of bone, myeloma, bone metastases, and osteoporosis in adults, but there has been increasing and successful application in pediatric bone diseases, notably osteogenesis imperfecta. Bisphosphonates are structural analogues of inorganic pyrophosphate but are resistant to enzymatic and chemical breakdown. Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone  resorbing osteoclasts where they interfere with various biochemical processes. The simpler, non nitrogen containing bisphosphonates (eg, clodronate and etidronate) can be metabolically incorporated into nonhydrolysable analogues of adenosine triphosphate (ATP) that may inhibit ATP  dependent intracellular enzymes. In contrast, the more potent, nitrogen  containing bisphosphonates (eg, pamidronate, alendronate, risedronate, ibandronate, and zoledronate) inhibit a key enzyme, farnesyl pyrophosphate synthase, in the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small guanosine triphosphate (GTP)  binding proteins (which are also GTPases) such as Rab, Rho, and Rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explains the loss of osteoclast activity. The recently elucidated crystal structure of farnesyl diphosphate reveals how bisphosphonates bind to and inhibit at the active site via their critical nitrogen atoms. Although bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, there is new knowledge about how they work and the subtle but potentially important differences that exist between individual bisphosphonates. Understanding these may help to explain differences in potency, onset and duration of action, and clinical effectiveness.
C1 Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England.
   Univ Oxford, Inst Musculoskeletal Sci, Oxford, England.
C3 University of Oxford; University of Oxford
RP Russell, RGG (通讯作者)，Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England.
EM graham.russell@ndos.ox.ac.uk
RI Russell, Robert Graham G/JEF 5877 2023; Russell, R/JEF 5877 2023
OI Russell, Robert Graham G/0000 0002 4136 1828; 
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   AMIN D, 1992, J LIPID RES, V33, P1657
   AMIN D, 1996, DRUG RES, V46, P759
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
   Bell R, 2005, ONCOLOGIST, V10, P8, DOI 10.1634/theoncologist.10 90001 8
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Bijvoet O.L. M., 1995, BISPHOSPHONATES BONE
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Body JJ, 2004, SEMIN NEPHROL, V24, P48, DOI 10.1053/j.semnephrol.2003.08.015
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Borah B, 2002, J BONE MINER RES, V17, P1139, DOI 10.1359/jbmr.2002.17.7.1139
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Carmona RH., 2004, BONE HLTH OSTEOPOROS
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coukell AJ, 1998, DRUG AGING, V12, P149, DOI 10.2165/00002512 199812020 00007
   David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   DOUGLAS DL, 1980, LANCET, V1, P1043
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Ebrahimpour Arman, 1995, P125
   Endo N, 1996, J BONE MINER RES, V11, P535
   FELIX R, 1976, BIOCHIM BIOPHYS ACTA, V429, P429, DOI 10.1016/0005 2744(76)90291 6
   Ferretti Jose Luis, 1995, P211
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLANAGAN AM, 1989, BONE MINER, V6, P33, DOI 10.1016/0169 6009(89)90021 4
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1968, CALC TISS RES, VS  2, P10, DOI 10.1007/BF02065192
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   Fleisch H., 2000, BISPHOSPHONATES BONE
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   FLORA L, 1981, METAB BONE DIS RELAT, V3, P289, DOI 10.1016/0221 8747(81)90045 X
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   FRANCIS MD, 1987, BONE SCANNING CLIN P, P1
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Gasser JA, 2002, BONE, V30, p41S
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Goa KL, 1998, DRUG AGING, V13, P83, DOI 10.2165/00002512 199813010 00008
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kurth AHA, 2005, BONE, V37, P204, DOI 10.1016/j.bone.2004.12.017
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Lalla S, 1998, OSTEOPOROSIS INT, V8, P97, DOI 10.1007/BF02672503
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   LERNER UH, 1987, BONE, V8, P179, DOI 10.1016/8756 3282(87)90018 4
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Little DG, 2003, J BONE MINER RES, V18, P2016, DOI 10.1359/jbmr.2003.18.11.2016
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Little DG, 2003, J BONE MINER RES, V18, P1300, DOI 10.1359/jbmr.2003.18.7.1300
   Little DG, 2005, J ORTHOP RES, V23, P862, DOI 10.1016/j.orthres.2004.11.015
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   MUEHLBAUER RC, 1971, EUR J CLIN INVEST, V1, P336
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Murakami H, 1997, BONE, V20, P399, DOI 10.1016/S8756 3282(97)00025 2
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Opas EE, 1997, BIOCHEM PHARMACOL, V54, P721, DOI 10.1016/S0006 2952(97)00225 6
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   PAPAPOULOS SE, 1989, J BONE MINER RES, V4, P775
   Parker CC, 2005, BJU INT, V95, P935, DOI 10.1111/j.1464 410X.2005.05441.x
   PATERSON AD, 1983, BRIT J HAEMATOL, V54, P121, DOI 10.1111/j.1365 2141.1983.tb02074.x
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   RALSTON SH, 1989, LANCET, V2, P1180
   Rauch F, 2005, AM J MED GENET C, V139C, P31, DOI 10.1002/ajmg.c.30072
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Ross JR, 2004, HEALTH TECHNOL ASSES, V8, pIII
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   RUSSELL RGG, 1974, LANCET, V1, P894
   RUSSELL RGG, 1965, LANCET, V2, P461
   Russell RGG., 2003, Rheumatology, V3rd, P2075
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   SCHIBLER D, 1968, CLIN SCI, V35, P363
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Singer FR, 1998, J CLIN ENDOCR METAB, V83, P1906, DOI 10.1210/jc.83.6.1906
   Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032
   Sirohi B, 2004, LANCET, V363, P875, DOI 10.1016/S0140 6736(04)15736 X
   Smith MR, 2005, CANCER TREAT REV, V31, pS19, DOI 10.1016/j.ctrv.2005.09.004
   SMITH R, 1971, LANCET, V1, P945
   Smith Roger, 1995, P433
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   STUTZER A, 1988, CALCIFIED TISSUE INT, V43, P294, DOI 10.1007/BF02556639
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   TRECHSEL U, 1987, J CLIN INVEST, V80, P1679, DOI 10.1172/JCI113257
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Van Staa TP, 1998, BRIT J RHEUMATOL, V37, P87
   van Staa TP, 1998, REV CONTEMP PHARMACO, V9, P277
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wilkinson JM, 2005, J ORTHOP RES, V23, P1, DOI 10.1016/j.orthres.2004.06.004
   Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955 0674(93)90130 I
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 155
TC 382
Z9 457
U1 0
U2 49
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007 1098 USA
SN 0031 4005
EI 1098 4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2007
VL 119
SU S
BP S150
EP S162
DI 10.1542/peds.2006 2023H
PG 13
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pediatrics
GA 186DS
UT WOS:000247759900006
PM 17332236
DA 2025 08 17
ER

PT J
AU Sun, B
   Su, T
   Meng, ZB
   Tang, SJ
AF Sun, Bo
   Su, Tian
   Meng, Zhibin
   Tang, Songjie
TI Anhuienoside C Ameliorates Osteoclast Differentiation in
   Ovariectomy Induced Osteoporosis by Regulating RANKL/Wnt Signaling
   Pathways
SO CURRENT TOPICS IN NUTRACEUTICAL RESEARCH
LA English
DT Article
DE Anhuienoside C; Inflammation; Osteoporosis; Ovariectomy; RANKL
ID PREVENTION; MECHANISMS; THERAPIES
AB Postmenopausal and ovariectomy induced osteoporosis is the most common bone disorder. While pharmacotherapy has been valuable in the management of osteoporosis, it has been associated with undesired side effects. Plant bioactives with minimal side effects have been seen as adjunct to classical therapy. Herein, we have evaluated the protective effect of anhuienoside C (AC) in a rat model of ovariectomy induced osteoporosis. The treatment of osteoporotic rats with AC caused dose dependent favorable changes in biochemical markers of bone formation and metabolism (osteocalcin, C telopeptide of type 1 collagen, and procollagen type 1 N terminal propeptide), enhanced bone mineral density, and decrease in proinflammatory mediators of inflammation and RANKL/Wnt pathway proteins. Furthermore, histopathologic changes in the tibia support beneficial effects of AC. In conclusion, our result reveals that treatment with AC shows beneficial effect against ovariectomy induced osteoporosis by regulating the RANKL/Wnt pathway.
C1 [Sun, Bo; Su, Tian; Meng, Zhibin; Tang, Songjie] Hainan Med Coll, Dept Orthopaed, Affiliated Hosp 1, 31 Long Hua St, Haikou 570102, Hainan, Peoples R China.
C3 Hainan Medical University
RP Tang, SJ (通讯作者)，Hainan Med Coll, Dept Orthopaed, Affiliated Hosp 1, 31 Long Hua St, Haikou 570102, Hainan, Peoples R China.
EM songjiet47@gmail.com
FU National Natural Science Foundation of China [81760260]
FX All the authors of this manuscript are thankful to The First Affiliated
   Hospital of Hainan Medical College, China for providing necessary
   facility to conduct the presented work and the National Natural Science
   Foundation of China (No. 81760260), China for providing fund to conduct
   the study.
CR Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Gallagher Sean, 2008, J Vis Exp, DOI 10.3791/759
   GILBERT S, 2000, DEV BIOL
   Janovsky M, 2000, J WILDLIFE DIS, V36, P663, DOI 10.7589/0090 3558 36.4.663
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kim JL, 2016, ANN REHABIL MED ARM, V40, P583, DOI 10.5535/arm.2016.40.4.583
   Kobayashi Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.82
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Kris Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002 9343(01)00995 0
   Leali PT, 2011, CLIN CASES MINER BON, V8, P11
   Liu Q, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00299
   Luo K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/316134
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Pleiner Duxneuner J, 2009, CALCIFIED TISSUE INT, V84, P159, DOI 10.1007/s00223 009 9218 x
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yuan RS, 2016, ONCOTARGET, V7, P3692, DOI 10.18632/oncotarget.6923
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
NR 24
TC 1
Z9 1
U1 0
U2 6
PU NEW CENTURY HEALTH PUBLISHERS, LLC
PI COPPELL
PA PO BOX 175, COPPELL, TX 75019 USA
SN 1540 7535
EI 2641 452X
J9 CURR TOP NUTRACEUT R
JI Curr. Top. Nutraceutical Res.
PD FEB
PY 2022
VL 20
IS 1
DI 10.37290/ctnr2641 452X.20:51 55
PG 5
WC Nutrition & Dietetics; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Pharmacology & Pharmacy
GA ZP5HR
UT WOS:000766454000001
DA 2025 08 17
ER

PT J
AU Zur, Y
   Rosenfeld, L
   Keshelman, CA
   Dalal, N
   Guterman Ram, G
   Orenbuch, A
   Einav, Y
   Levaot, N
   Papo, N
AF Zur, Yuval
   Rosenfeld, Lior
   Keshelman, Chen Anna
   Dalal, Nofar
   Guterman Ram, Gali
   Orenbuch, Ayelet
   Einav, Yulia
   Levaot, Noam
   Papo, Niv
TI A dual specific macrophage colony stimulating factor antagonist of c FMS
   and αvβ3 integrin for osteoporosis therapy
SO PLOS BIOLOGY
LA English
DT Article
ID OSTEOCLAST CYTOSKELETON; BONE RESORPTION; VITRONECTIN RECEPTOR;
   REPLACEMENT THERAPY; SIGNALING COMPLEX; CSF 1 RECEPTOR; GROWTH FACTORS;
   SEALING ZONE; ALPHA V BETA 3; KINASE
AB There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chronic bone disease affecting millions of people worldwide. We have developed a combinatorial strategy for engineering bispecific inhibitors that simultaneously target the unique combination of c FMS and alpha(v)beta(3) integrin, which act in concert to facilitate bone resorption by osteoclasts. Using functional fluorescence activated cell sorting (FACS) based screening assays of random mutagenesis macrophage colony stimulating factor (M CSF) libraries against c FMS and alpha(v)beta(3) integrin, we engineered dual specific M CSF mutants with high affinity to both receptors. These bispecific mutants act as functional antagonists of c FMS and alpha(v)beta(3) integrin activation and hence of osteoclast differentiation in vitro and osteoclast activity in vivo. This study thus introduces a versatile platform for the creation of new generation therapeutics with high efficacy and specificity for osteoporosis and other bone diseases. It also provides new tools for studying molecular mechanisms and the cell signaling pathways that mediate osteoclast differentiation and function.
C1 [Zur, Yuval; Rosenfeld, Lior; Dalal, Nofar; Papo, Niv] Ben Gurion Univ Negev, Dept Biotechnol Engn, Beer Sheva, Israel.
   [Zur, Yuval; Rosenfeld, Lior; Dalal, Nofar; Papo, Niv] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Beer Sheva, Israel.
   [Keshelman, Chen Anna] NIBN, Beer Sheva, Israel.
   [Guterman Ram, Gali; Orenbuch, Ayelet] Ben Gurion Univ Negev, Dept Physiol & Cell Biol, Regenerat Med & Stem Cell Res Ctr RMSC, Beer Sheva, Israel.
   [Einav, Yulia; Levaot, Noam] Holon Inst Technol, Fac Engn, Holon, Israel.
C3 Ben Gurion University of the Negev; Ben Gurion University of the Negev;
   Ben Gurion University of the Negev
RP Papo, N (通讯作者)，Ben Gurion Univ Negev, Dept Biotechnol Engn, Beer Sheva, Israel.; Papo, N (通讯作者)，Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Beer Sheva, Israel.; Levaot, N (通讯作者)，Holon Inst Technol, Fac Engn, Holon, Israel.
EM levaot@bgu.ac.il; papo@bgu.ac.il
RI Levaot, Noam/AAA 3052 2022
OI Levaot, Noam/0000 0001 7747 3883; Guterman Ram, Gali/0000 0002 8583 3401
FU Israel Science Foundation [544/15]; European Research Council (ERC)
   [336041]
FX Israel Science Foundation (grant number 544/15). NL. The funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. European Research Council (ERC) (grant
   number 336041). NP. The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Belvisi L, 2001, ORG LETT, V3, P1001, DOI 10.1021/ol007049u
   Chabadel A, 2007, MOL BIOL CELL, V18, P4899, DOI 10.1091/mbc.E07 04 0378
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817
   Deng P, 1996, BIOCHEM BIOPH RES CO, V228, P557, DOI 10.1006/bbrc.1996.1698
   Dick SE, 2002, AM J MANAG CARE, V8, P95
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Elegheert J, 2012, NAT STRUCT MOL BIOL, V19, P938, DOI 10.1038/nsmb.2367
   Elegheert J, 2011, STRUCTURE, V19, P1762, DOI 10.1016/j.str.2011.10.012
   Elsegood CL, 2006, INT J BIOCHEM CELL B, V38, P1518, DOI 10.1016/j.biocel.2006.02.011
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Faccio R, 2007, J BIOL CHEM, V282, P18991, DOI 10.1074/jbc.M610937200
   Felix J, 2015, STRUCTURE, V23, P1621, DOI 10.1016/j.str.2015.06.019
   HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014 4827(91)90386 9
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460 2075.1991.tb07948.x
   Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097 0215(19990505)81:3<339::AID IJC5>3.0.CO;2 6
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Melton L. J., 1992, JBMR ANNIVERSARY CLA, V7
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Okada N, 2013, BIOL PHARM BULL, V36, P1622, DOI 10.1248/bpb.b13 00496
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   Pfaff M, 2001, J CELL SCI, V114, P2775
   Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200
   Rodan SB, 1997, J ENDOCRINOL, V154, pS47
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Sakai H, 2006, BONE, V39, P1290, DOI 10.1016/j.bone.2006.06.012
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Schneidman Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947
   Takagi J, 2004, BIOCHEM SOC T, V32, P403, DOI 10.1042/BST0320403
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040
   Zou W, 2008, MOL CELL, V31, P422, DOI 10.1016/j.molcel.2008.06.023
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 44
TC 25
Z9 27
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1545 7885
J9 PLOS BIOL
JI PLoS. Biol.
PD AUG
PY 2018
VL 16
IS 8
AR e2002979
DI 10.1371/journal.pbio.2002979
PG 29
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA GS2MH
UT WOS:000443383300002
PM 30142160
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Liang, GH
   Zhao, JL
   Pan, JK
   Yang, Y
   Dou, YX
   Yang, WY
   Zeng, LF
   Liu, J
AF Liang, Guihong
   Zhao, Jinlong
   Pan, Jianke
   Yang, Yuan
   Dou, Yaoxing
   Yang, Weiyi
   Zeng, Lingfeng
   Liu, Jun
TI Network pharmacology identifies fisetin as a treatment for osteoporosis
   that activates the Wnt/β catenin signaling pathway in BMSCs
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Fisetin; Chinese traditional medicine; Osteoporosis; BMSCs; Mechanisms;
   Bone homeostasis
AB BackgroundAlthough fisetin may exist widely in many natural herbs, its anti OP mechanism is still unclear. The aim of this study is to explore the molecular anti osteoporosis (OP) mechanism of fisetin based on network pharmacology and cell experiments.MethodsThe target of fisetin was extracted by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The targets of OP were obtained by DisGeNET, GeneCards and the Comparative Toxicogenomics Database, and the targets of fisetin in OP were screened by cross analysis. The protein protein interaction (PPI) network was constructed by STRING, and the core targets were obtained. We performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses on common targets via the Database for Annotation, Visualization and Integrated Discovery. Finally, an in vitro cell experiment was used to verify the anti OP effect and mechanism of fisetin.ResultsThere are 44 targets of fisetin related to the treatment of OP. The PPI results suggest that CTNNB1, CCND1, TP53, JUN, and AKT1 are the core targets. A total of 259 biological process, 57 molecular function and 26 cell component terms were obtained from GO enrichment analysis. The results of KEGG pathway enrichment analysis suggested that fisetin treatment of OP may be related to the Wnt signaling pathway, estrogen signaling pathway, PI3K Akt signaling pathway and other signaling pathways. In vitro cell experiments showed that fisetin significantly increased the expression levels of ALP, collagen I, osteopontin and RUNX2 in bone marrow mesenchymal stem cells (BMSCs) (p < 0.05). Fisetin also increased the gene expression levels of Wnt3 and beta catenin (CTNNB1) in BMSCs, which indicates that fisetin can regulate the Wnt/beta catenin signaling pathway and promote the osteogenic differentiation of BMSCs.ConclusionsFisetin acts on multiple targets and pathways in the treatment of OP; mechanistically, it regulates the Wnt/beta catenin signaling pathway, which promotes the osteogenic differentiation of BMSCs and maintains bone homeostasis. The results of this study provide a theoretical basis for further study on the complex anti OP mechanism of fisetin.
C1 [Liang, Guihong; Zhao, Jinlong; Yang, Yuan; Dou, Yaoxing; Zeng, Lingfeng] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou 510405, Peoples R China.
   [Liang, Guihong; Zhao, Jinlong; Pan, Jianke; Yang, Yuan; Dou, Yaoxing; Yang, Weiyi; Zeng, Lingfeng] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.
   [Liang, Guihong; Zhao, Jinlong; Yang, Yuan; Dou, Yaoxing; Zeng, Lingfeng; Liu, Jun] Guangdong Prov Acad Chinese Med Sci, Res Team Bone & Joint Degenerat & Injury, Guangzhou 510120, Peoples R China.
   [Liu, Jun] Guangzhou Univ Chinese Med, Clin Med Coll 5, Guangzhou 510405, Peoples R China.
   [Liu, Jun] Guangdong Second Tradit Chinese Med Hosp, Guangdong Prov Engn Technol Res Inst Tradit Chines, Guangzhou 510095, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Zeng, LF (通讯作者)，Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou 510405, Peoples R China.; Zeng, LF (通讯作者)，Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.; Zeng, LF; Liu, J (通讯作者)，Guangdong Prov Acad Chinese Med Sci, Res Team Bone & Joint Degenerat & Injury, Guangzhou 510120, Peoples R China.; Liu, J (通讯作者)，Guangzhou Univ Chinese Med, Clin Med Coll 5, Guangzhou 510405, Peoples R China.; Liu, J (通讯作者)，Guangdong Second Tradit Chinese Med Hosp, Guangdong Prov Engn Technol Res Inst Tradit Chines, Guangzhou 510095, Peoples R China.
EM lingfengzeng@gzucm.edu.cn; gzucmliujun@foxmail.com
RI zhong, feng/G 4623 2015; Liu, Jun/KJL 2351 2024
CR Chen TN, 2021, BIOL RES, V54, DOI 10.1186/s40659 021 00366 y
   Chen WJ, 2019, OSTEOPOROSIS INT, V30, P807, DOI 10.1007/s00198 018 4789 x
   Farrah Z, 2020, CLIN MED, V20, pE196, DOI 10.7861/clinmed.2020 0131
   Feng P, 2022, J OLEO SCI, V71, P105, DOI 10.5650/jos.ess21252
   Fuggle NR, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115833
   Li JY, 2021, PHYTOTHER RES, V35, P1754, DOI 10.1002/ptr.6908
   Li M, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/132642
   Liang GH, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.866641
   Molagoda IMN, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114676
   Prasain JK, 2010, MATURITAS, V66, P163, DOI 10.1016/j.maturitas.2010.01.010
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Vescini F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413640
   Wang Y, 2022, INFLAMMATION, V45, P780, DOI 10.1007/s10753 021 01583 z
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xun JQ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02449 9
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
NR 16
TC 7
Z9 8
U1 3
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 22
PY 2023
VL 18
IS 1
AR 312
DI 10.1186/s13018 023 03761 1
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA E2PC1
UT WOS:000974007700001
PM 37087476
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kwan, KKL
   Wong, TY
   Yu, AXD
   Dong, TTX
   Lam, HHN
   Tsim, KWK
AF Kwan, Kenneth K. L.
   Wong, Tin Yan
   Yu, Anna X. D.
   Dong, Tina T. X.
   Lam, Henry H. N.
   Tsim, Karl W. K.
TI Integrated Omics Reveals the Orchestrating Role of Calycosin in Danggui
   Buxue Tang, a Herbal Formula Containing Angelicae Sinensis Radix and
   Astragali Radix, in Inducing Osteoblastic Differentiation and
   Proliferation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE mesenchymal stem cells; multi omics; bone differentiation; herbal
   materials; mass spectrometry
ID BIOLOGICAL ASSESSMENT; DECOCTION; BONE; METABOLISM; EXPRESSION; CELLS;
   HIF 1 ALPHA; PERFORMANCE; KINASE
AB Systems biology unravels the black box of signaling pathway of cells; but which has not been extensively applied to reveal the mechanistic synergy of a herbal formula. The therapeutic efficacies of a herbal formula having multi target, multi function and multi pathway are the niches of traditional Chinese medicine (TCM). Here, we reported an integrated omics approach, coupled with the knockout of an active compound, to measure the regulation of cellular signaling, as to reveal the landscape in cultured rat osteoblasts having synergistic pharmacological efficacy of Danggui Buxue Tang (DBT), a Chinese herbal formula containing Angelicae Sinensis Radix and Astragali Radix. The changes in signaling pathways responsible for energy metabolism, RNA metabolism and protein metabolism showed distinct features between DBT and calycosin depleted DBT. Here, our results show that calycosin within DBT can orchestrate the osteoblastic functions and signaling pathways of the entire herbal formula. This finding reveals the harmony of herbal medicine in pharmacological functions, as well as the design of drug/herbal medicine formulation. The integration of systems biology can provide novel and essential insights into the synergistic property of a herbal formula, which is a key in modernizing TCM.
C1 [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Shenzhen, Peoples R China.
   [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Shenzhen, Peoples R China.
   [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Shenzhen, Peoples R China.
   [Wong, Tin Yan; Lam, Henry H. N.] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Kowloon, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Hong Kong University of
   Science & Technology; Hong Kong University of Science & Technology
RP Tsim, KWK (通讯作者)，Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Shenzhen, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Shenzhen, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Ctr Chinese Med, Shenzhen, Peoples R China.
EM botsim@ust.hk
RI ; Lam, Henry/D 8629 2011; YU, Xiaodan/MYQ 5304 2025
OI Wong, Tin Yan/0000 0002 1651 9275; 
FU Special project of Foshan University of Science and Technology in 2019
   [FSUST19 SRI10]; Shenzhen Science and Technology Innovation Committee
   [ZDSYS20170 7281432317, JCYJ20170413173747440, JCYJ2018030 61749031 74];
   Zhongshan Municipal Bureau of Science and Technology [ZSST20SC03];
   Guangzhou Science and Technology Committee Research Grant [GZSTI16SC02,
   GZSTI17SC02]; Hong Kong RGC Theme based Research Scheme [T13 605/18 W];
   Hong Kong Innovation Technology Fund [UIM/340, UIM/385, ITS/500/18FP,
   TUYF19SC02, PD18SC01, HMRF18SC06]
FX This work is supported by Special project of Foshan University of
   Science and Technology in 2019 (FSUST19 SRI10); Shenzhen Science and
   Technology Innovation Committee (ZDSYS20170 7281432317;
   JCYJ20170413173747440; JCYJ2018030 61749031 74), Zhongshan Municipal
   Bureau of Science and Technology (ZSST20SC03); Guangzhou Science and
   Technology Committee Research Grant (GZSTI16SC02; GZSTI17SC02); Hong
   Kong RGC Theme based Research Scheme (T13 605/18 W); Hong Kong
   Innovation Technology Fund (UIM/340, UIM/385, ITS/500/18FP; TUYF19SC02;
   PD18SC01 and HMRF18SC06.
CR Chang WCW, 2020, PHARM BIOL, V58, P545, DOI 10.1080/13880209.2020.1774622
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Conradas KA, 2005, MOL CELL PROTEOMICS, V4, P1284, DOI 10.1074/mcp.M500082 MCP200
   Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Davis G., 2003, CURR HEPATITIS REP, V2, P40, DOI [10.1007/s11901 003 0013 2, DOI 10.1007/S11901 003 0013 2]
   Dodd Tracy, 2011, Emerg Nurse, V19, P10
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Fang YY, 2019, CELL BIOL INT, V43, P323, DOI 10.1002/cbin.11102
   Gao QT, 2007, FEBS LETT, V581, P233, DOI 10.1016/j.febslet.2006.12.018
   Geng YY, 2020, J MOL CELL BIOL, V12, P305, DOI 10.1093/jmcb/mjz030
   GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012 1606(87)90331 9
   Gong AGW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00036
   Gong AGW, 2016, J ETHNOPHARMACOL, V189, P81, DOI 10.1016/j.jep.2016.05.035
   Gong AGW, 2016, PLANTA MED, V82, P418, DOI 10.1055/s 0035 1558332
   Gong AGW, 2015, J ETHNOPHARMACOL, V168, P150, DOI 10.1016/j.jep.2015.03.033
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Hocquette JF, 1998, LIVEST PROD SCI, V56, P115, DOI 10.1016/S0301 6226(98)00187 0
   Huck K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020385
   Krishna A, 2020, J PHYS CHEM B, V124, P5177, DOI 10.1021/acs.jpcb.0c02962
   Kwan KKL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00614
   LANGELAND N, 1975, ACTA ENDOCRINOL COP, V80, P775, DOI 10.1530/acta.0.0800775
   Lin HQ, 2017, J ETHNOPHARMACOL, V199, P205, DOI 10.1016/j.jep.2017.01.044
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Niemeyer K, 2013, J HERB MED, V3, P112, DOI 10.1016/j.hermed.2013.03.001
   Palomäki S, 2013, STEM CELLS, V31, P1902, DOI 10.1002/stem.1435
   Ritchie MD, 2015, NAT REV GENET, V16, P85, DOI 10.1038/nrg3868
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sánchez Rodríguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 124
   Sanchooli T, 2019, GENE CELL TISSUE, V6, P2, DOI [10.5812/gct.95441, DOI 10.5812/GCT.95441]
   Siddiqui S, 2014, DARU, V22, DOI 10.1186/s40199 014 0072 7
   Song ZH, 2004, PLANTA MED, V70, P1222, DOI 10.1055/s 2004 835855
   Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509
   Strzelecka Kiliszek A, 2017, BBA GEN SUBJECTS, V1861, P1009, DOI 10.1016/j.bbagen.2017.02.005
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749 6632.2009.05238.x
   Wu Y, 2014, MOL MED REP, V10, P1349, DOI 10.3892/mmr.2014.2374
   Xu QH, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 132
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Zhao HX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34574 6
   Zheng KYZ, 2010, J ETHNOPHARMACOL, V132, P259, DOI 10.1016/j.jep.2010.08.029
   Zhou LP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00779
   Zhou LP, 2021, PHYTOTHER RES, V35, P1456, DOI 10.1002/ptr.6909
NR 44
TC 3
Z9 5
U1 1
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 23
PY 2021
VL 12
AR 670947
DI 10.3389/fphar.2021.670947
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TE8JE
UT WOS:000670251900001
PM 34248625
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lewis, JW
   Frost, K
   Neag, G
   Wahid, M
   Finlay, M
   Northall, EH
   Abudu, O
   Davis, ET
   Powell, E
   Palmer, C
   Lu, JS
   Rainger, GE
   Iqbal, AJ
   Chimen, M
   Mahmood, A
   Jones, SW
   Edwards, JR
   Naylor, AJ
   McGettrick, HM
AF Lewis, Jonathan W.
   Frost, Kathryn
   Neag, Georgiana
   Wahid, Mussarat
   Finlay, Melissa
   Northall, Ellie H.
   Abudu, Oladimeji
   Davis, Edward T.
   Powell, Emily
   Palmer, Charlotte
   Lu, Jinsen
   Rainger, G. Ed
   Iqbal, Asif J.
   Chimen, Myriam
   Mahmood, Ansar
   Jones, Simon W.
   Edwards, James R.
   Naylor, Amy J.
   McGettrick, Helen M.
TI Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide,
   PEPITEM, to boost bone growth and prevent bone loss
SO CELL REPORTS MEDICINE
LA English
DT Article
ID DIFFERENTIATION; OSTEOBLASTS; EXPRESSION; NCAM; PATHWAY; BINDING; FGFR1
AB The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM) with anabolic osteogenic activity, regulating bone remodeling in health and disease. PEPITEM acts directly on osteoblasts through NCAM 1 signaling to promote their maturation and formation of new bone, leading to enhanced trabecular bone growth and strength. Simultaneously, PEPITEM stimulates an inhibitory paracrine loop: promoting osteoblast release of the decoy receptor osteoprotegerin, which sequesters RANKL, thereby limiting osteoclast activity and bone resorption. In disease models, PEPITEM therapy halts osteoporosis  induced bone loss and arthritis  induced bone damage in mice and stimulates new bone formation in osteoblasts derived from patient samples. Thus, PEPITEM offers an alternative therapeutic option in the management of diseases with excessive bone loss, promoting an endogenous anabolic pathway to induce bone remodeling and redress the imbalance in bone turnover.
C1 [Lewis, Jonathan W.; Frost, Kathryn; Neag, Georgiana; Wahid, Mussarat; Finlay, Melissa; Northall, Ellie H.; Abudu, Oladimeji; Powell, Emily; Chimen, Myriam; Jones, Simon W.; Naylor, Amy J.; McGettrick, Helen M.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham B15 2WB, W Midlands, England.
   [Rainger, G. Ed; Iqbal, Asif J.] Univ Birmingham, Inst Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England.
   [Davis, Edward T.] Royal Orthopaed Hosp, Bristol Rd, Birmingham B31 2AP, W Midlands, England.
   [Palmer, Charlotte; Lu, Jinsen; Edwards, James R.] Univ Oxford, Botnar Res Ctr, Oxford OX3 7LD, England.
   [Mahmood, Ansar] Univ Hosp NHS Fdn Trust, Dept Trauma & Orthopaed, Birmingham B15 2GW, W Midlands, England.
C3 University of Birmingham; University of Birmingham; Royal Orthopaedic
   Hospital; University of Oxford
RP McGettrick, HM (通讯作者)，Univ Birmingham, Inst Inflammat & Ageing, Birmingham B15 2WB, W Midlands, England.
EM h.m.mcgettrick@bham.ac.uk
RI ; Jones, Simon/ABB 8625 2020; Chimen, Myriam/D 6344 2015; McGettrick,
   Helen/H 3442 2011
OI Northall, Ellie/0000 0003 4694 2071; Iqbal, Asif/0000 0002 3224 3651;
   Naylor, Amy/0000 0001 8384 8215; Lewis, Jonathan/0009 0007 1217 3012;
   Chimen, Myriam/0000 0002 3567 1731; Lu, Jinsen/0000 0002 5239 5361;
   Jones, Simon/0000 0001 6785 2310; Neag, Georgiana/0000 0002 3087 867X;
   Frost, Kathryn/0000 0001 8992 4637; 
CR Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bushnell B., 2014, BBMap: A Fast, Accurate, Splice Aware Aligner
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Cheng BF, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.657953
   Chimen M, 2015, NAT MED, V21, P467, DOI 10.1038/nm.3842
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Delaisse JM, 2020, BONE, V141, DOI [10.1016/j/bone.2020.115628, 10.1016/j.bone.2020.115628]
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Elbrecht V, 2016, PEERJ, V4, DOI 10.7717/peerj.1966
   Evans R., 2022, bioRxiv, DOI DOI 10.1101/2021.10.04.463034
   Fan HW, 2020, INT J MOL MED, V46, P1311, DOI 10.3892/ijmm.2020.4684
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Finlay Melissa, 2023, F1000Res, V12, P357, DOI [10.12688/f1000research.130779.3, 10.12688/f1000research.130779.2]
   Francavilla C, 2009, J CELL BIOL, V187, P1101, DOI 10.1083/jcb.200903030
   Frost K, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24086935
   Fryklund C, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.740666
   Gaytan F, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74031 x
   Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2486 6
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200
   Guo HB, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 14382 9
   Howe KL, 2021, NUCLEIC ACIDS RES, V49, pD884, DOI 10.1093/nar/gkaa942
   Jacob AL, 2006, DEV BIOL, V296, P315, DOI 10.1016/j.ydbio.2006.05.031
   Johnson CP, 2005, BIOCHEMISTRY US, V44, P546, DOI 10.1021/bi048263j
   Kastanis GJ, 2019, MOL ECOL RESOUR, V19, P377, DOI 10.1111/1755 0998.12973
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969 2126(03)00096 0
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   LEE YS, 1992, J BONE MINER RES, V7, P1435
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007 0323
   Matsubara H, 2020, J IMMUNOL, V204, P2043, DOI 10.4049/jimmunol.1900213
   MOORE B W, 1968, PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF NERVOUS INTEGRATION, P343
   Morén B, 2019, MOL BIOL CELL, V30, P1147, DOI 10.1091/mbc.E18 10 0680
   Obsilova V, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.1016071
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Parfitt AM, 2002, BONE, V30, P807, DOI 10.1016/S8756 3282(02)00735 4
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943
   Pezhman L, 2023, CLIN EXP IMMUNOL, V212, P1, DOI 10.1093/cei/uxad022
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Roman Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756 3282(03)00052 8
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sanchez Heras E, 2006, J BIOL CHEM, V281, P35208, DOI 10.1074/jbc.M608655200
   Shah C, 2014, STRUCTURE, V22, P409, DOI 10.1016/j.str.2013.12.015
   Tang YB, 2023, BONE, V174, DOI 10.1016/j.bone.2023.116817
   Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061
   Wingett Steven W, 2018, F1000Res, V7, P1338, DOI 10.12688/f1000research.15931.2
   Xu H, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01467 8
   Yin PY, 2020, ARCH MED SCI, V16, P1419, DOI 10.5114/aoms.2019.89979
   Zhu ED, 2014, ENDOCRINOLOGY, V155, P1188, DOI 10.1210/en.2013 1993
   Zhu L, 2009, INT J EXP PATHOL, V90, P512, DOI 10.1111/j.1365 2613.2009.00661.x
   Zweifler LE, 2021, J BONE MINER RES, V36, P1979, DOI 10.1002/jbmr.4389
NR 59
TC 14
Z9 15
U1 0
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2666 3791
J9 CELL REP MED
JI Cell Rep. Med.
PD MAY 21
PY 2024
VL 5
IS 5
AR 101574
DI 10.1016/j.xcrm.2024.101574
EA MAY 2024
PG 27
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA XY4A1
UT WOS:001265215600004
PM 38776873
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, C
   Peng, J
   Lu, SB
AF Wang, Cheng
   Peng, Jiang
   Lu, Shibi
TI Summary of the various treatments for osteonecrosis of the femoral head
   by mechanism: A review
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE osteonecrosis; osteoblast; osteoclast; bisphosphonates
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ANTERIOR ROTATIONAL OSTEOTOMY;
   NONTRAUMATIC AVASCULAR NECROSIS; EXTRACORPOREAL SHOCK WAVES;
   HYPERBARIC OXYGEN THERAPY; CORE DECOMPRESSION; ELECTRICAL STIMULATION;
   HIP OSTEONECROSIS; FIBULAR GRAFTS; WEIGHT BEARING
AB Osteonecrosis of the femoral head (ONFH), also known as femoral head avascular necrosis, is a pathological state with a number of possible etiologies including steroid administration, alcohol abuse, traumatic events, vascular injury and idiopathic origins. ONFH causes a reduction in the vascular supply to the subchondral bone of the femoral head, which results in osteocyte death and the collapse of the articular surface. Treatments for ONFH include non weight bearing therapy, physical support, the promotion of osteoclast apoptosis, and the reduction of osteoblast and osteocyte apoptosis. The aim of the present review was to summarize the treatments for ONFH by mechanism from a new perspective and to describe the condition with an emphasis on treatment options.
C1 [Wang, Cheng; Peng, Jiang; Lu, Shibi] Chinese Peoples Liberat Army Gen Hosp, Inst Orthoped, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Peng, J (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Orthoped, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM pengjiang301@126.com
RI wang, cheng/AAR 5107 2021
CR Agarwala S, 2005, RHEUMATOLOGY, V44, P352, DOI 10.1093/rheumatology/keh481
   Agarwala S, 2001, J Assoc Physicians India, V49, P949
   Agarwala S, 2002, RHEUMATOLOGY, V41, P346, DOI 10.1093/rheumatology/41.3.346 a
   Aldegheri R, 2007, STRATEG TRAUMA LIMB, V2, P63, DOI 10.1007/s11751 007 0021 9
   Alves EM, 2009, CLIN RHEUMATOL, V28, P1247, DOI 10.1007/s10067 009 1231 y
   Amanatullah Derek F, 2011, Am J Orthop (Belle Mead NJ), V40, pE216
   Amanatullah Derek F, 2011, Am J Orthop (Belle Mead NJ), V40, pE186
   Caso JAA, 2012, MED CLIN BARCELONA, V139, P676, DOI 10.1016/j.medcli.2012.05.039
   Berend KR, 2003, J BONE JOINT SURG AM, V85A, P987, DOI 10.2106/00004623 200306000 00001
   Bocanegra Pérez MS, 2012, MED ORAL PATOL ORAL, V17, pE948, DOI 10.4317/medoral.17946
   Camporesi EM, 2010, J ARTHROPLASTY, V25, P118, DOI 10.1016/j.arth.2010.05.005
   Cao K, 2009, CHIN J TRAUMATOL, V12, P269, DOI 10.3760/cma.j.issn.1008 1275.2009.05.003
   Chen CH, 2012, ARTHRITIS RHEUM US, V64, P1572, DOI 10.1002/art.33498
   Chiu WY, 2013, J CLIN ENDOCR METAB, V98, pE723, DOI 10.1210/jc.2012 4144
   Cohen Robert, 2002, Am J Orthop (Belle Mead NJ), V31, P216
   DEAN MT, 1993, J BONE JOINT SURG BR, V75, P597, DOI 10.1302/0301 620X.75B4.8331115
   EYB R, 1987, ARCH ORTHOP TRAUM SU, V106, P161, DOI 10.1007/BF00452203
   Fan Meng, 2012, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V34, P330, DOI 10.3881/j.issn.1000 503X.2012.04.004
   Feng Y, 2011, INT ORTHOP, V35, P475, DOI 10.1007/s00264 009 0915 x
   Ficat P, 1971, Rev Rhum Mal Osteoartic, V38, P269
   Gao YS, 2013, J SURG RES, V183, pE1, DOI 10.1016/j.jss.2013.01.046
   Gou WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091317
   Hang DH, 2012, CELLS TISSUES ORGANS, V195, P495, DOI 10.1159/000329502
   Hasan SS, 2002, J SHOULDER ELB SURG, V11, P281, DOI 10.1067/mse.2002.124347
   Hayes WC, 1999, INT J CLIN PRACT, P9
   Helbig L, 2012, ARCH ORTHOP TRAUM SU, V132, P1095, DOI 10.1007/s00402 012 1526 3
   Hiranuma Y, 2009, J ORTHOP SCI, V14, P535, DOI 10.1007/s00776 009 1363 6
   Hofmann S, 2000, ORTHOPADE, V29, P411
   Kaushik AP, 2012, WORLD J ORTHOP, V3, P49, DOI 10.5312/wjo.v3.i5.49
   Kawate K, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 78
   Kim HJ, 2012, PAIN PHYSICIAN, V15, pE749
   Kim SY, 2005, J BONE JOINT SURG AM, V87A, P2012, DOI 10.2106/JBJS.D.02593
   Koo KH, 2001, J BONE JOINT SURG BR, V83B, P83, DOI 10.1302/0301 620X.83B1.10914
   Lavernia C J, 1999, J Am Acad Orthop Surg, V7, P250
   Li WZ, 2009, J ORTHOP RES, V27, P694, DOI 10.1002/jor.20802
   Liang KL, 2012, J TRAUMA ACUTE CARE, V72, P1404, DOI 10.1097/TA.0b013e31824473ce
   Lieberman JR, 2004, CLIN ORTHOP RELAT R, P139, DOI 10.1097/01.blo.0000150312.53937.6f
   Lieberman JR, 2004, CLIN ORTHOP RELAT R, P29
   Liu BL, 2013, J INVEST SURG, V26, P158, DOI 10.3109/08941939.2012.718409
   Liu YS, 2013, ARCH ORTHOP TRAUM SU, V133, P125, DOI 10.1007/s00402 012 1623 3
   Ludwig J, 2001, CLIN ORTHOP RELAT R, P119
   MALIZOS KN, 1995, CLIN ORTHOP RELAT R, P67
   Marciniak D, 2005, J BONE JOINT SURG AM, V87A, P742, DOI 10.2106/JBJS.D.02004
   Marker DR, 2008, CLIN ORTHOP RELAT R, V466, P1093, DOI 10.1007/s11999 008 0184 9
   Mihara K, 1998, J PEDIATR ORTHOPED, V18, P665, DOI 10.1097/00004694 199809000 00022
   Mont MA, 2003, CLIN ORTHOP RELAT R, P84, DOI 10.1097/01.blo.0000096826.67494.38
   MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623 199503000 00018
   Mont MA, 2004, CLIN ORTHOP RELAT R, P131, DOI 10.1097/01.blo.0000150128.57777.8e
   Mont MA, 1996, CLIN ORTHOP RELAT R, P169, DOI 10.1097/00003086 199603000 00020
   Mont Michael A, 2007, Instr Course Lect, V56, P213
   Neto NC, 2013, INT J EXP PATHOL, V94, P65, DOI 10.1111/iep.12007
   OHZONO K, 1991, J BONE JOINT SURG BR, V73, P68, DOI 10.1302/0301 620X.73B1.1991778
   Okazaki S, 2012, INT J EXP PATHOL, V93, P458, DOI 10.1111/j.1365 2613.2012.00836.x
   Outeiriño Fernández A, 2013, AN SIST SANIT NAVAR, V36, P87, DOI 10.4321/s1137 66272013000100009
   Peled E, 2013, INT J EXP PATHOL, V94, P212, DOI 10.1111/iep.12022
   Peskin B, 2001, UNDERSEA HYPERBAR M, V28, P187
   Rackwitz L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt98
   Reis ND, 2003, J BONE JOINT SURG BR, V85B, P371, DOI 10.1302/0301 620X.85B3.13237
   Rizzoli Rene, 2012, Ther Umsch, V69, P173, DOI 10.1024/0040 5930/a000270
   ROSENWASSER MP, 1994, CLIN ORTHOP RELAT R, P17
   Sakamoto Akio, 2008, J Orthop Surg Res, V3, P13, DOI 10.1186/1749 799X 3 13
   Samara S, 2014, EXP MOL PATHOL, V96, P9, DOI 10.1016/j.yexmp.2013.10.014
   Schaudinn C, 2012, OR SURG OR MED OR PA, V114, P480, DOI 10.1016/j.oooo.2012.06.006
   Schnieders M J, 1997, Iowa Orthop J, V17, P58
   Seyler TM, 2008, CLIN ORTHOP RELAT R, V466, P1125, DOI 10.1007/s11999 008 0211 x
   Shabtai L, 2012, HAREFUAH, V151, P252
   Shabtai Lior, 2012, Harefuah, V151, P242
   Soucacos PN, 2001, CLIN ORTHOP RELAT R, P120
   Steinberg M E, 1995, Can J Surg, V38 Suppl 1, pS18
   STEINBERG ME, 1990, CLIN ORTHOP RELAT R, P11
   STEINBERG ME, 1989, CLIN ORTHOP RELAT R, P199
   Stronach Ben M, 2010, J Arthroplasty, V25, DOI 10.1016/j.arth.2009.08.008
   SUGIOKA Y, 1978, CLIN ORTHOP RELAT R, P191
   SUGIOKA Y, 1982, CLIN ORTHOP RELAT R, P115
   Tetik C, 2011, ACTA ORTHOP TRAUMATO, V45, P326, DOI 10.3944/AOTT.2011.2259
   TRANCIK T, 1990, CLIN ORTHOP RELAT R, P120
   TRUETA J, 1963, J BONE JOINT SURG BR, V45, P572, DOI 10.1302/0301 620X.45B3.572
   TURNER DA, 1989, RADIOLOGY, V171, P135, DOI 10.1148/radiology.171.1.2928517
   Varitimidis SE, 2009, ACTA ORTHOP, V80, P20, DOI 10.1080/17453670902804877
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wang CJ, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 11
   Wang CJ, 2005, J BONE JOINT SURG AM, V87A, P2380, DOI 10.2106/JBJS.E.00174
   Wang W, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 142
   Watters Tyler Steven, 2011, J Surg Orthop Adv, V20, P158
   Wei BF, 2011, HIP INT, V21, P206, DOI 10.5301/HIP.2011.6525
   Wong PK, 2013, RHEUMATOL INT, V33, P2189, DOI 10.1007/s00296 013 2771 7
   Xie XH, 2012, ARTHRITIS RHEUM US, V64, P1562, DOI 10.1002/art.34525
   Yamamoto T, 2010, CLIN ORTHOP RELAT R, V468, P3186, DOI 10.1007/s11999 010 1384 7
   Yang Jin cai, 2008, Zhonghua Yi Xue Za Zhi, V88, P3210
   Yin S, 2011, INT ORTHOP, V35, P1125, DOI 10.1007/s00264 010 1031 7
   Yin Tsung Cheng, 2011, Chang Gung Med J, V34, P367
   Zaidi M, 2010, P NATL ACAD SCI USA, V107, P8782, DOI 10.1073/pnas.0912176107
   Zhang C, 2012, SCI REP UK, V2, DOI 10.1038/srep00650
   Zhang CQ, 2005, MICROSURG, V25, P305, DOI 10.1002/micr.20118
NR 94
TC 57
Z9 64
U1 0
U2 41
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2014
VL 8
IS 3
BP 700
EP 706
DI 10.3892/etm.2014.1811
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AN8KZ
UT WOS:000340854400002
PM 25120585
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Frantzias, J
   Logan, JG
   Mollat, P
   Sparatore, A
   Del Soldato, P
   Ralston, SH
   Idris, AI
AF Frantzias, J.
   Logan, J. G.
   Mollat, P.
   Sparatore, A.
   Del Soldato, P.
   Ralston, S. H.
   Idris, A. I.
TI Hydrogen sulphide releasing diclofenac derivatives inhibit breast
   cancer induced osteoclastogenesis in vitro and prevent osteolysis ex
   vivo
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE diclofenac; NSAID; hydrogen sulphide; osteoclast; osteoblast; breast
   cancer; MDA MB 231; MCF7; 4T1
ID NF KAPPA B; S ALLYLMERCAPTOCYSTEINE; DIALLYL DISULFIDE; BONE LOSS;
   CELLS; APOPTOSIS; SYSTEM; OSTEOPOROSIS; EXPRESSION; ALLICIN
AB BACKGROUND AND PURPOSE
   Hydrogen sulphide (H2S) and prostaglandins are both involved in inflammation, cancer and bone turnover, and non steroidal anti inflammatory drugs (NSAIDs) and H2S donors exhibit anti inflammatory and anti tumour properties. H2S releasing diclofenac (S DCF) derivatives are a novel class of NSAIDs combining the properties of a H2S donor with those of a conventional NSAID.
   EXPERIMENTAL APPROACH
   We studied the effects of the S DCF derivatives ACS15 and ACS32 on osteoclast and osteoblast differentiation and activity in vitro, human and mouse breast cancer cells support for osteoclast formation and signalling in vitro, and osteolysis ex vivo.
   KEY RESULTS
   The S diclofenac derivatives ACS15 and ACS32 inhibited the increase in osteoclast formation induced by human MDA MB 231 and MCF 7 and mouse 4T1 breast cancer cells without affecting breast cancer cell viability. Conditioned media from human MDA MB 231 cells enhanced I kappa B phosphorylation and osteoclast formation and these effects were significantly inhibited following treatment by ACS15 and ACS32, whereas the parent compound diclofenac had no effects. ACS15 and ACS32 inhibited receptor activator of NFkB ligand induced osteoclast formation and resorption, and caused caspase 3 activation and apoptosis in mature osteoclasts via a mechanism dependent on IKK/NF kappa B inhibition. In calvaria organ culture, human MDA MB 231 cells caused osteolysis, and this effect was completely prevented following treatment with ACS15 and ACS32.
   CONCLUSIONS AND IMPLICATIONS
   S diclofenac derivatives inhibit osteoclast formation and activity, suppress breast cancer cell support for osteoclastogenesis and prevent osteolysis. This suggests that H2S releasing diclofenac derivatives exhibit anti resorptive properties, which might be of clinical value in the treatment of osteolytic bone disease.
C1 [Logan, J. G.; Ralston, S. H.; Idris, A. I.] Univ Edinburgh, Western Gen Hosp, Edinburgh Canc Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Frantzias, J.; Logan, J. G.; Idris, A. I.] Univ Edinburgh, Western Gen Hosp, Ctr Mol Med, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Mollat, P.] Galapagos SASU, Romainville, France.
   [Sparatore, A.] Univ Milan, Dept Pharmaceut Sci P Pratesi, Milan, Italy.
   [Del Soldato, P.] CTG Pharma Srl, Milan, Italy.
C3 University of Edinburgh; University of Edinburgh; Galapagos NV;
   University of Milan
RP Idris, AI (通讯作者)，Univ Edinburgh, Western Gen Hosp, Edinburgh Canc Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
EM aymen.idris@ed.ac.uk
RI Frantzias, Joseph/HOC 3732 2023; Sparatore, Anna/J 8634 2015; Idris,
   Aymen/AAX 1138 2020
OI Logan, John/0000 0003 2801 700X; Sparatore, Anna/0000 0003 2135 2649;
   Idris, Aymen/0000 0003 4327 5306; 
FU ECTS/AMGEN
FX These studies were supported in part by a ECTS/AMGEN fellowship grant to
   Dr. A.I.Idris.
CR Bakker A, 1988, BONE RES PROTOCOLS, P19
   Cao H, 2008, TROP BIOMED, V25, P37
   DIPAOLO JA, 1960, CANCER RES, V20, P431
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Fiorucci Stefano, 2011, Inflammation & Allergy Drug Targets, V10, P133
   Foong LY, 1997, BIOCHEMISTRY US, V36, P1343, DOI 10.1021/bi9624907
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Gayathri R, 2009, MOL CELL BIOCHEM, V320, P197, DOI 10.1007/s11010 008 9903 5
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Isenberg JS, 2007, BRIT J PHARMACOL, V151, P142, DOI 10.1038/sj.bjp.0707198
   Karakawa A, 2009, J DENT RES, V88, P1042, DOI 10.1177/0022034509346147
   Kim JY, 2009, AM J CLIN NUTR, V89, P257, DOI 10.3945/ajcn.2008.26142
   Lee Y, 2011, BIOL PHARM BULL, V34, P677, DOI 10.1248/bpb.34.677
   Lefer DJ, 2007, P NATL ACAD SCI USA, V104, P17907, DOI 10.1073/pnas.0709010104
   Lei XY, 2008, ACTA PHARMACOL SIN, V29, P1233, DOI 10.1111/j.1745 7254.2008.00851.x
   Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011
   Li L, 2009, PHARMACOL THERAPEUT, V123, P386, DOI 10.1016/j.pharmthera.2009.05.005
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Moody TW, 2010, LUNG CANCER, V68, P154, DOI 10.1016/j.lungcan.2009.06.012
   Mukherjee M, 2006, PHYTOTHER RES, V20, P21, DOI 10.1002/ptr.1795
   Mukherjee M, 2004, PHYTOTHER RES, V18, P389, DOI 10.1002/ptr.1448
   Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022 1759(97)00043 4
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Oommen S, 2004, EUR J PHARMACOL, V485, P97, DOI 10.1016/j.ejphar.2003.11.059
   Pinto JT, 2000, PROSTATE, V45, P304, DOI 10.1002/1097 0045(20001201)45:4<304::AID PROS4>3.0.CO;2 9
   Rossoni G, 2008, BRIT J PHARMACOL, V153, P100, DOI 10.1038/sj.bjp.0707540
   Seki T, 2008, ASIA PAC J CLIN NUTR, V17, P249
   Shirin H, 2001, CANCER RES, V61, P725
   Sidhapuriwala J, 2007, EUR J PHARMACOL, V569, P149, DOI 10.1016/j.ejphar.2007.05.003
   Sriram N, 2008, MOL CELL BIOCHEM, V311, P157, DOI 10.1007/s11010 008 9706 8
   van't Hof RJ, 2003, METH MOLEC MED, V80, P145
   Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003
   Zhi L, 2007, J LEUKOCYTE BIOL, V81, P1322, DOI 10.1189/jlb.1006599
NR 33
TC 39
Z9 41
U1 1
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAR
PY 2012
VL 165
IS 6
SI SI
BP 1914
EP 1925
DI 10.1111/j.1476 5381.2011.01704.x
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 897WC
UT WOS:000300689800025
PM 21955294
OA Green Published
DA 2025 08 17
ER

PT J
AU Salesi, N
   Pistilli, R
   Marcelli, V
   Govoni, FA
   Bozza, F
   Bossone, G
   Venturelli, V
   Di Cocco, B
   Pacetti, U
   Ciorra, A
   Di Fonso, C
   Cortesi, E
   Veltri, E
   Vecchione, A
AF Salesi, Nello
   Pistilli, Roberto
   Marcelli, Vincenzo
   Govoni, Flavio Andrea
   Bozza, Fabrizio
   Bossone, Giandominik
   Venturelli, Viola
   Di Cocco, Barbara
   Pacetti, Umberto
   Ciorra, Alida
   Di Fonso, Concetta
   Cortesi, Enrico
   Veltri, Enzo
   Vecchione, Aldo
TI Bisphosphonates and oral cavity avascular bone necrosis: A review of
   twelve cases
SO ANTICANCER RESEARCH
LA English
DT Article
DE bisphosphonates; bone metastasis; supportive care
ID ZOLEDRONIC ACID; MULTIPLE MYELOMA; BREAST CANCER; DOUBLE BLIND;
   BLOOD FLOW; IN VITRO; PAMIDRONATE; JAWS; METASTASES; ZOMETA
AB Background: Intravenous bisphosphonates are the current standard of care for the treatment of hypercalcemia of malignancy and for the prevention of skeletal complications associated with bone metastases. Recently, retrospective case studies have reported an association between long term bisphosphonate therapy and osteonecrosis of the jaws. Patients and Methods: The data for twelve patients, referred to either an oral and maxillofacial surgeon or to an oral medicine specialist for the management of clinically apparent chronic oral osteonecrosis of unknown etiology. were reviewed. All had received cancer related therapy simultaneously with bisphosphonate management. Results: The typical presenting symptoms were pain and exposed bone at the site of a previous tooth extraction. In most patients, the lesions initially occurred after dental extraction or other odonto stomatological procedures, while five had a spontaneous event. Biopsy of the involved area showed the presence of necrotic lacunae, with infiltration of lymphocytes and histiocytes. In nine cases, there was histological or cytological diagnosis of suspicious osteomyelitis. No correlation was observed between the intraoral lesions and myelosuppression secondary to antineoplastic therapy. Conclusion: Based on the patients' respective histories, clinical presentations and responses to surgical and antibiotic treatments, it appears that the pathogenesis of this osteonecrotic process is most consistent with localized vascular insufficiency. In our opinion, the mechanism by which bisphosphonates compromise bone vascularity may be related to their effect on the osteoclasts. The potent bisphosphonate mediated inhibition of osteoclast function serves to decrease bone resorption and inhibit normal bone turnover remodeling, resulting in microdamage accumulation and a reduction in some mechanical Properties of the bone.
C1 A Fiorini Hosp, Dept Med Oncol, I 04019 Terracina, LT, Italy.
   ACO S Filippo Neri, Dept Maxillofacial Surg, Rome, Italy.
   St Andreas Hosp, Dept Med Oncol, Rome, Italy.
   Univ Roma La Sapienza, Dipartimento Med Sperimentale, I 00185 Rome, Italy.
   Ist Nazl Tumori Pascale, Naples, Italy.
C3 San Filippo Neri Hospital; Sapienza University Rome; IRCCS Fondazione
   Pascale
RP Veltri, E (通讯作者)，A Fiorini Hosp, Dept Med Oncol, I 04019 Terracina, LT, Italy.
EM aslter.oncoterracina@libero.it
RI Cortesi, Enrico/AAA 2983 2019; Govoni, Flavio Andrea/IAP 5847 2023;
   Marcelli, Vincenzo/LXA 7365 2024
OI Govoni, Flavio Andrea/0000 0002 3058 767X; 
CR [Anonymous], J CLIN ONCOL
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Body JJ, 2001, SEMIN ONCOL, V28, P49, DOI 10.1016/S0093 7754(01)90232 5
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Fournier P, 2002, CANCER RES, V62, P6538
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Goodship A E, 1994, Ann Oncol, V5 Suppl 7, pS53
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Kapitola J, 1998, PHYSIOL RES, V47, P237
   Kapitola J, 2000, PHYSIOL RES, V49, pS101
   Lacerna L, 2003, SEMIN ONCOL, V30, P150, DOI 10.1053/j.seminoncol.2003.08.017
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097 0142(20000101)88:1<6::AID CNCR3>3.3.CO;2 4
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Nagy Z, 2005, PATHOL ONCOL RES, V11, P186, DOI 10.1007/BF02893400
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zojer N, 1999, DRUG SAFETY, V21, P389, DOI 10.2165/00002018 199921050 00004
NR 29
TC 27
Z9 27
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL AUG
PY 2006
VL 26
IS 4B
BP 3111
EP 3115
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 096QJ
UT WOS:000241391600048
PM 16886642
DA 2025 08 17
ER

PT J
AU Khan, K
   Pal, S
   Yadav, M
   Maurya, R
   Trivedi, AK
   Sanyal, S
   Chattopadhyay, N
AF Khan, Kainat
   Pal, Subhashis
   Yadav, Manisha
   Maurya, Rakesh
   Trivedi, Arun Kumar
   Sanyal, Sabyasachi
   Chattopadhyay, Naibedya
TI Prunetin signals via G protein coupled receptor, GPR30(GPER1):
   Stimulation of adenylyl cyclase and cAMP mediated activation of MAPK
   signaling induces Runx2 expression in osteoblasts to promote bone
   regeneration
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Estrogen signaling; Isoflavonoid; Bone formation; Fracture healing; G
   protein coupled receptor 30
ID OVARIECTOMIZED RATS; PARATHYROID HORMONE; ESTROGENIC ACTIVITY; MINERAL
   DENSITY; ER ALPHA; IN VIVO; GROWTH; DIFFERENTIATION; FRACTURE; GPR30
AB Prunetin is found in red clover and fruit of Prunus avium (red cherry). The effect of prunetin on osteoblast function, its mode of action and bone regeneration in vivo were investigated. Cultures of primary osteoblasts, osteoblastic cell line and HEK293T cells were used for various in vitro studies. Adult female rats received drill hole injury at the femur diaphysis to assess the bone regenerative effect of prunetin. Prunetin at 10 nM significantly (a) increased proliferation and differentiation of primary cultures of osteoblasts harvested from rats and (b) promoted formation of mineralized nodules by bone marrow stromal/osteoprogenitor cells. At this concentration, prunetin did not activate any of the two nuclear estrogen receptors (alpha and beta). However, prunetin triggered signaling via a G protein coupled receptor, GPR30/GPER1, and enhanced CAMP levels in osteoblasts. G15, a selective GPR30 antagonist, abolished prunetin induced increases in osteoblast proliferation, differentiation and intracellular CAMP. In osteoblasts, prunetin up regulated runt related transcription factor 2 (Runx2) protein through cAMP dependent Erk/MAP kinase activation that ultimately resulted in the up regulation of GPR30. Administration of prunetin at 0.25 mg/kg given to rats stimulated bone regeneration at the site of drill hole and up regulated Runx2 expression in the fractured callus and the effect was comparable to human parathyroid hormone, the only clinically used osteogenic therapy. We conclude that prunetin promotes osteoinduction in vivo and the mechanism is defined by signaling through GPR30 resulting in the up regulation of the key osteogenic gene Runx2 that in turn up regulates GPR30. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Khan, Kainat; Pal, Subhashis; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226021, Uttar Pradesh, India.
   [Khan, Kainat; Pal, Subhashis; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness, Lucknow 226021, Uttar Pradesh, India.
   [Yadav, Manisha; Trivedi, Arun Kumar; Sanyal, Sabyasachi] CSIR, Cent Drug Res Inst, Div Biochem, Lucknow 226021, Uttar Pradesh, India.
   [Maurya, Rakesh] CSIR, Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226021, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226021, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Sanyal, Sabyasachi/E 8034 2010; Chattopadhyay, Naibedya/AAQ 3213 2021;
   maurya, rakesh/AAV 7598 2021; Trivedi, Arun/W 1883 2019; Pal,
   Subhashis/IXD 3635 2023
OI Sanyal, Sabyasachi/0000 0002 8603 3828; Trivedi,
   Arun/0000 0002 6316 0947; Pal, Subhashis/0000 0002 3916 5545;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; 
FU Council of Scientific and Industrial Research, Government of India
FX Council of Scientific and Industrial Research, Government of India.
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Batra GS, 2003, J PATHOL, V200, P65, DOI 10.1002/path.1332
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   Blum SC, 2003, J NUTR, V133, P1244
   Booth NL, 2006, J AGR FOOD CHEM, V54, P1277, DOI 10.1021/jf052927u
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brandi ML, 2012, EXPERT OPIN INV DRUG, V21, P1169, DOI 10.1517/13543784.2012.696610
   Chan KKL, 2014, J ENDOCRINOL, V221, P325, DOI 10.1530/JOE 13 0500
   Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168
   Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70
   Ford J, 2011, J BONE MINER RES, V26, P298, DOI 10.1002/jbmr.209
   Frank GR, 2003, MED PEDIATR ONCOL, V41, P217, DOI 10.1002/mpo.10340
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Heino TJ, 2008, J ENDOCRINOL, V197, pR1, DOI 10.1677/JOE 07 0629
   Hertrampf T, 2008, BRIT J PHARMACOL, V153, P1432, DOI 10.1038/sj.bjp.0707664
   Hertrampf T, 2007, BONE, V40, P1529, DOI 10.1016/j.bone.2007.02.006
   Honma N, 2013, J BONE MINER METAB, V31, P96, DOI 10.1007/s00774 012 0383 z
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jorgensen Niklas R, 2011, Curr Osteoporos Rep, V9, P149, DOI 10.1007/s11914 011 0065 0
   Joseph TB, 2007, MOL PHARMACEUT, V4, P883, DOI 10.1021/mp700135a
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lapcík O, 1999, PLANT SCI, V148, P111, DOI 10.1016/S0168 9452(99)00125 9
   Liu JH, 2001, J AGR FOOD CHEM, V49, P2472, DOI 10.1021/jf0014157
   Lo Muzio L, 2007, ANN CLIN LAB SCI, V37, P115
   Mårtensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008 0623
   Nichols MR, 2000, MOL PHARMACOL, V57, P738, DOI 10.1124/mol.57.4.738
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Picherit C, 2001, BRIT J NUTR, V85, P307, DOI 10.1079/BJN2000252
   PRICE KR, 1985, FOOD ADDIT CONTAM A, V2, P73, DOI 10.1080/02652038509373531
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962 8924(02)02294 8
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Walle T, 2009, INT J MOL SCI, V10, P5002, DOI 10.3390/ijms10115002
   Wang KJ, 2012, CHINESE MED J PEKING, V125, P2589, DOI 10.3760/cma.j.issn.0366 6999.2012.14.034
   Windahl SH, 2009, AM J PHYSIOL ENDOC M, V296, pE490, DOI 10.1152/ajpendo.90691.2008
NR 49
TC 46
Z9 51
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0955 2863
EI 1873 4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD DEC
PY 2015
VL 26
IS 12
BP 1491
EP 1501
DI 10.1016/j.jnutbio.2015.07.021
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA CZ0HL
UT WOS:000366785600010
PM 26345541
DA 2025 08 17
ER

PT J
AU Zhang, L
   Li, WB
   Chen, XH
   Cao, DM
   You, SY
   Shi, F
   Li, HY
   Song, YB
   Li, N
   Akimoto, Y
   Rui, G
   Chen, Y
   Wu, ZX
   Xu, R
AF Zhang, Long
   Li, Weibin
   Chen, Xiaohui
   Cao, Dongmin
   You, Siyuan
   Shi, Fan
   Li, Hongyu
   Song, Yabin
   Li, Na
   Akimoto, Yoshie
   Rui, Gang
   Chen, Yu
   Wu, Zuoxing
   Xu, Ren
TI Morusin inhibits breast cancer induced osteolysis by decreasing
   phosphatidylinositol 3 kinase (PI3K) mTOR signalling
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Morusin; Osteolysis; Bone metastasis; Osteoclastogenesis; Traditional
   Chinese medicine; Network pharmacology
ID KAPPA B ACTIVITY; BONE MICROENVIRONMENT; CELL GROWTH; EXPRESSION;
   APOPTOSIS; CROSSTALK; PATHWAY
AB Bone metastases caused by breast cancer pose a major challenge to the successful treatment of breast cancer patients. Many researchers have suggested that herbal medicines are extremely effective at preventing and treating cancer associated osteolysis. Previous studies have revealed that Morusin (MOR) is cytotoxic to many cancer cells ex vivo. Nevertheless, how MOR contributes to osteolysis induced by breast cancer is still unknown, and the potential mechanism of action against osteolysis is worthy of further study. The protective effect and molecular mechanism of MOR in inhibiting breast cancer cell induced osteolysis were verified by experiments and network pharmacology. Cell function was assessed by cell proliferation, osteoclast (OC) formation, bone resorption, and phalloidin staining. Tumour growth was examined by micro CT scanning in vivo. To identify potential MOR treatments, the active ingredient target pathway of breast cancer was screened using network pharmacology and molecular docking approaches. This study is the first to report that MOR can prevent osteolysis induced by breast cancer cells. Specifically, our results revealed that MOR inhibits RANKL induced osteoclastogenesis and restrains the proliferation, invasion and migration of MDA MB 231 breast cells through restraining the PI3K/AKT/MTOR signalling pathway. Notably, MOR prevented bone loss caused by breast cancer cell induced osteolysis in vivo, indicating that MOR inhibited the development of OCs and the resorption of bone, which are essential for cancer cell associated bone distraction. This study showed that MOR treatment inhibited osteolysis induced by breast cancer in vivo. MOR inhibited OC differentiation and bone resorption ex vivo and in vivo and might be a potential drug candidate for treating breast cancer induced osteolysis.
C1 [Zhang, Long; Li, Weibin; Chen, Xiaohui; Shi, Fan; Li, Hongyu; Song, Yabin; Li, Na; Rui, Gang; Chen, Yu; Wu, Zuoxing; Xu, Ren] Xiamen Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Sch Med, Xiamen 361005, Fujian, Peoples R China.
   [Li, Weibin; Xu, Ren] Xiamen Univ, Canc Ctr, Key Lab Endocrine Related Canc Precis Med Xiamen, Xiamen, Peoples R China.
   [Cao, Dongmin] Shanghai Inst Mat Med, Zhongshan Inst Drug Discovery, Zhongshan 528437, Guangdong, Peoples R China.
   [You, Siyuan] Xiamen Univ, Fac Med & Life Sci, Sch Med, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.
   [Akimoto, Yoshie] Iskra Ind Co Ltd, Tokyo, Japan.
   [Chen, Yu; Wu, Zuoxing; Xu, Ren] Xiamen Univ, Xiangan Rd, Xiamen, Fujian, Peoples R China.
C3 Xiamen University; Xiamen University; Chinese Academy of Sciences;
   Shanghai Institute of Materia Medica, CAS; Xiamen University; Xiamen
   University
RP Chen, Y; Wu, ZX; Xu, R (通讯作者)，Xiamen Univ, Xiangan Rd, Xiamen, Fujian, Peoples R China.
EM chenyu@xmu.edu.cn; wuzuooxing@163.com; xuren526@xmu.edu.cn
RI wu, zuoxing/JCN 5560 2023
OI Cao, Dong min/0000 0001 9218 5345; You, Siyuan/0009 0004 4714 9627
CR Abbas GM, 2014, NAT PROD RES, V28, P952, DOI 10.1080/14786419.2014.900770
   Bloom AP, 2011, J PAIN, V12, P698, DOI 10.1016/j.jpain.2010.12.016
   Chan EWC, 2016, CHIN J NAT MEDICINES, V14, P17, DOI 10.3724/SP.J.1009.2016.00017
   Chen MH, 2019, CHEM BIOL INTERACT, V299, P1, DOI 10.1016/j.cbi.2018.11.009
   Chen YJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.803880
   De Leon Oliva D, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59101752
   DICKSON RB, 1986, CANCER RES, V46, P1707
   Elsohly M.A., 2007, EP
   Ettl T, 2012, ORAL ONCOL, V48, P822, DOI 10.1016/j.oraloncology.2012.02.021
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Ibrahim T, 2000, CLIN EXP METASTAS, V18, P253, DOI 10.1023/A:1006754605901
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Jiang RW, 2009, J MOL STRUCT, V920, P383, DOI 10.1016/j.molstruc.2008.11.043
   Jin C., 2023, Comb. Chem. High Throughput Screen.
   Jo Merry Oursler, 1994, J. Bone Miner. Res.
   Kang S, 2017, ONCOL LETT, V13, P4558, DOI 10.3892/ol.2017.6006
   Karimian A, 2019, J CELL BIOCHEM, V120, P10248, DOI 10.1002/jcb.28309
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Lee JC, 2008, BIOCHEM BIOPH RES CO, V372, P236, DOI 10.1016/j.bbrc.2008.05.023
   Lee JH, 2019, CANCERS, V11, DOI 10.3390/cancers11020254
   Lee JJ, 2012, J ATHEROSCLER THROMB, V19, P516, DOI 10.5551/jat.10058
   Leone L.M., 2013, Accessing Anti cancer Natural Products by Plant Cell Culture
   Li HY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0252 4
   Li HZ, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000034300
   Liang MM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1594 1
   Liang YR, 2020, SEMIN CANCER BIOL, V60, P14, DOI 10.1016/j.semcancer.2019.08.012
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Martelli AM, 2010, HISTOL HISTOPATHOL, V25, P669, DOI 10.14670/HH 25.669
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Newman D.J., 2013, FUTURE ONCOL, V9, P949
   Noorolyai S., 2018, J. Cell. Physiol.
   Pectasides D, 2005, J PHARMACEUT BIOMED, V37, P171, DOI 10.1016/j.jpba.2004.10.007
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596 018 0103 9
   Sigl V, 2014, CYTOKINE GROWTH F R, V25, P205, DOI 10.1016/j.cytogfr.2014.01.002
   Souza MMd, 2000, Zeitschrift Fur Naturforschung C A Journal of Biosciences, V55
   Starek Swiechowicz B, 2021, PHARMACOL REP, V73, P1497, DOI 10.1007/s43440 021 00317 0
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Vaught D., 2008, Cancer Res., V68, P2523
   Wan LZ, 2014, BIOFACTORS, V40, P636, DOI 10.1002/biof.1191
   Wang L, 2013, MOL CELL BIOCHEM, V379, P7, DOI 10.1007/s11010 013 1621 y
   Wang Y, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160165
   Wu CYJ, 2020, NEURO ONCOLOGY, V22, P253, DOI 10.1093/neuonc/noz189
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Xu XD, 2018, BIOCHEM BIOPH RES CO, V502, P160, DOI 10.1016/j.bbrc.2018.05.139
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
   Yao H, 2014, AM J CARDIOVASC DRUG, V14, P433, DOI 10.1007/s40256 014 0089 9
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zarrer J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020337
NR 50
TC 3
Z9 3
U1 3
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD MAY 1
PY 2024
VL 394
AR 110968
DI 10.1016/j.cbi.2024.110968
EA MAR 2024
PG 13
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA QE4X8
UT WOS:001219200800001
PM 38522564
DA 2025 08 17
ER

PT J
AU Liu, C
   Cao, Z
   Zhang, W
   Tickner, J
   Qiu, H
   Wang, C
   Chen, K
   Wang, ZY
   Tan, RX
   Dong, SW
   Xu, JK
AF Liu, Chuan
   Cao, Zhen
   Zhang, Wen
   Tickner, Jennifer
   Qiu, Heng
   Wang, Chao
   Chen, Kai
   Wang, Ziyi
   Tan, Renxiang
   Dong, Shiwu
   Xu, Jiake
TI Lumichrome inhibits osteoclastogenesis and bone resorption through
   suppressing RANKL induced NFAT activation and calcium signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE calcium signaling; lumichrome; osteoclast; osteoporosis; RANKL
ID OVARIECTOMY INDUCED OSTEOPOROSIS; KAPPA B; MOLECULAR MECHANISMS;
   RECEPTOR ACTIVATOR; GENE EXPRESSION; DIFFERENTIATION; RIBOFLAVIN;
   INDUCTION; HOMEOSTASIS; ESTROGEN
AB The dynamic balance between bone resorption and bone formation is crucial to maintain bone mass. Osteoclasts are key cells that perform bone resorption while osteoblasts and osteocytes function in bone formation. Osteoporosis, a bone metabolism disease characterized by bone loss and degradation of bone microstructure, occurs when osteoclastic bone resorption outstrips osteoblastic bone synthesis. The interaction between receptor activator of nuclear factor B ligand (RANKL) and RANK on the surface of bone marrow macrophages promotes osteoclast differentiation and activation. In this study, we found that lumichrome, a photodegradation product of riboflavin, inhibits RANKL induced osteoclastogenesis and bone resorption as determined by tartrate resistant acid phosphatase staining, immunofluorescence, reverse transcription polymerase chain reaction, and western blot. Our results showed that lumichrome represses the expression of osteoclast marker genes, including cathepsin K (Ctsk) and Nfatc1. In addition, lumichrome suppressed RANKL induced calcium oscillations, NFATc1, NF B, and MAPK signaling activation. Moreover, lumichrome promoted osteoblast differentiation at an early stage, as demonstrated by upregulated expression of osteoblast marker genes Alp, Runx2, and Col1a1. We also found that lumichrome reduces bone loss in ovariectomized mice by inhibiting osteoclastogenesis. In summary, our data suggest the potential of lumichrome as a therapeutic drug for osteolytic diseases.
C1 [Liu, Chuan] Third Mil Med Univ, Dept Anat, Chongqing, Peoples R China.
   [Liu, Chuan; Cao, Zhen; Dong, Shiwu] Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Liu, Chuan] Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Cao, Zhen; Tickner, Jennifer; Qiu, Heng; Wang, Chao; Chen, Kai; Wang, Ziyi; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Zhang, Wen] Chinese Peoples Liberat Army 66325 Hosp, Dept Surg, Beijing, Peoples R China.
   [Tan, Renxiang] Nanjing Univ, Inst Funct Biomol, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.
   [Tan, Renxiang] Nanjing Univ Chinese Med, State Key Lab Cultivat Base TCM Qual & Efficacy, Nanjing, Jiangsu, Peoples R China.
C3 Army Medical University; Army Medical University; University of Western
   Australia; Nanjing University; Nanjing University of Chinese Medicine
RP Dong, SW (通讯作者)，Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM dongshiwu@tmmu.edu.cn; jiake.xu@uwa.edu.au
RI ; Tickner, Jennifer/H 5965 2014; Chen, KaiJie/A 1743 2016
OI Xu, Jiake/0000 0003 2021 8309; Tickner, Jennifer/0000 0002 5020 0671;
   Wang, Ziyi/0000 0002 5410 3385; Wang, Ziyi/0000 0002 1334 7287; Dong,
   Shiwu/0000 0002 5032 4893; Qiu, Heng/0000 0002 0864 317X; Chen,
   Kai/0000 0001 6850 1723
FU Guangxi Scientific Research and Technology Development Plan Project
   [1598013 15, GKG13349003]; Western Australia Medical & Health Research
   Infrastructure Fund; National Key Technology Research and Development
   Program of China [2017YFC1103300]; Arthritis Australia foundation;
   University of Western Australia (UWA) Research Collaboration Awards;
   Australian Health and Medical Research Council [1027932]; NHMRC
   [1107828]; Natural Science Foundation of China [81572164]; National
   Health and Medical Research Council of Australia [1107828] Funding
   Source: NHMRC
FX Guangxi Scientific Research and Technology Development Plan Project,
   Grant/Award Numbers: 1598013 15, GKG13349003; Western Australia Medical
   & Health Research Infrastructure Fund; the National Key Technology
   Research and Development Program of China, Grant/Award Number:
   2017YFC1103300; Arthritis Australia foundation; The University of
   Western Australia (UWA) Research Collaboration Awards; the Australian
   Health and Medical Research Council, Grant/Award Numbers: 1027932,
   NHMRC, No 1107828; Natural Science Foundation of China, Grant/Award
   Number: 81572164
CR Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRO RASMUSSEN F, 1958, Nutr Abstr Rev, V28, P369
   Neto AHC, 2010, TOXICOL IN VITRO, V24, P1911, DOI 10.1016/j.tiv.2010.07.026
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   DALSKY GP, 1990, MED SCI SPORT EXER, V22, P281
   Deng SQ, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.7636
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Fischer V, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07511 2
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520 6408(1998)22:4<301::AID DVG1>3.0.CO;2 A
   Khan Wasim S, 2012, J Stem Cells, V7, P75
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kobayashi T, 2014, METHODS MOL BIOL, V1130, P3, DOI 10.1007/978 1 62703 989 5_1
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   KOTEGAWA M, 1994, BIOCHEM MOL BIOL INT, V34, P685
   MACKIE EJ, 1990, DEVELOPMENT, V110, P1233
   Manolagas SC, 1998, AGING CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652
   McCormick RK, 2007, ALTERN MED REV, V12, P113
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Park JH, 2017, MOL CELLS, V40, P706
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Shen Z, 2007, BBA GENE STRUCT EXPR, V1769, P659, DOI 10.1016/j.bbaexp.2007.08.005
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TOBIAS JH, 1990, LANCET, V335, P1471, DOI 10.1016/0140 6736(90)91506 6
   Tu Q, 2008, J CELL PHYSIOL, V217, P40, DOI 10.1002/jcp.21472
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   WATROUS DA, 1989, SEMIN ARTHRITIS RHEU, V19, P45, DOI 10.1016/0049 0172(89)90086 3
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wu XH, 2014, FEBS LETT, V588, P143, DOI 10.1016/j.febslet.2013.11.022
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yazdanpanah N, 2008, J BONE MINER RES, V23, P86, DOI 10.1359/JBMR.070812
   Yazdanpanah N, 2007, BONE, V41, P987, DOI 10.1016/j.bone.2007.08.021
   Zhao XY, 2017, J AGR FOOD CHEM, V65, P9647, DOI 10.1021/acs.jafc.7b03666
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 51
TC 8
Z9 10
U1 3
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2018
VL 233
IS 11
BP 8971
EP 8983
DI 10.1002/jcp.26841
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GV6YB
UT WOS:000446264900053
PM 29904917
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Ozawa, Y
   Takegami, Y
   Osawa, Y
   Asamoto, T
   Tanaka, S
   Imagama, S
AF Ozawa, Yuto
   Takegami, Yasuhiko
   Osawa, Yusuke
   Asamoto, Takamune
   Tanaka, Shinya
   Imagama, Shiro
TI Anti sclerostin antibody therapy prevents post ischemic osteonecrosis
   bone collapse via interleukin 6 association
SO BONE
LA English
DT Article
DE Osteonecrosis of the femoral head; Osteonecrosis; Anti sclerostin
   antibody; Wnt/ beta catenin; Interleukin 6
ID FEMORAL HEAD; NONTRAUMATIC OSTEONECROSIS; NECROSIS; GENE; EXPRESSION;
   CELLS; MODEL; DIFFERENTIATION; STRENGTH; MASS
AB Osteonecrosis of the femoral head (ONFH) is a debilitating condition characterized by subchondral bone necrosis, which frequently culminates in joint destruction. Although total hip arthroplasty is conventionally practiced to remediate ONFH, for patients under the age of 60, the outcomes can be suboptimal. Chronic inflammation, particularly that mediated by interleukin 6 (IL 6), has been conjectured to be a potential mechanism underlying the etiology of ONFH. This study aimed at exploring the interplay between IL 6, the canonical Wnt signaling pathway, and ONFH to provide insights for potential therapeutic interventions. Human ONFH specimens depicted an elevation in beta catenin expression in the transitional layer, while IL 6 levels were pronounced in the same region. Subsequently, mouse models of ischemic osteonecrosis were treated with an antisclerostin antibody to assess its effects on bone metabolism and cellular processes. Histological analysis revealed that the administration of anti sclerostin antibodies effectuated early recovery from bone necrosis, reduced empty lacunae, and suppressed IL 6 expression. The treatment evidently initiated the activation of the Wnt/beta catenin signaling pathway, presenting a potential mechanism associated with IL 6 mediated inflammation. Furthermore, the antibody upregulated osteoblast formation, downregulated osteoclast formation, and increased bone volume. Micro CT imaging demonstrated increased bone volume, prevented epiphyseal deformity, and improved compression strength. Therefore, this study yields significant findings, indicating the potency of anti sclerostin antibodies in effectively modulating the Wnt/beta catenin pathway, associating with IL 6 expression, and preventing post ONFH bone collapse. Additionally, this preclinical investigation in mouse models offers an avenue for prospective research on potential therapeutic interventions against human ONFH.
C1 [Ozawa, Yuto; Takegami, Yasuhiko; Osawa, Yusuke; Asamoto, Takamune; Tanaka, Shinya; Imagama, Shiro] Nagoya Univ, Dept Orthopaed Surg, Grad Sch Med, 65 Tsurumai cho,8 Showa ku, Nagoya, Japan.
C3 Nagoya University
RP Takegami, Y (通讯作者)，Nagoya Univ, Dept Orthopaed Surg, Grad Sch Med, 65 Tsurumai cho,8 Showa ku, Nagoya, Japan.
EM takegami@med.nagoya u.ac.jp
RI IMAGAMA, Shiro/I 7419 2014
FU MEXT KAKENHI [21K09200]
FX This work was supported by MEXT KAKENHI grant Number 21K09200.
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen JZ, 2021, AM J TRANSL RES, V13, P2320
   Doumpas N, 2019, EMBO J, V38, DOI 10.15252/embj.201798873
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Edara VV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110479
   Floerkemeier T, 2021, OSTEOARTHR CARTILAGE, V29, P1614, DOI 10.1016/j.joca.2021.08.006
   Huang JY, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05399 2
   Ikeuchi K, 2015, MOD RHEUMATOL, V25, P278, DOI 10.3109/14397595.2014.932038
   Issa K, 2013, BONE JOINT J, V95B, P46, DOI 10.1302/0301 620X.95B11.32644
   Kamiya N, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10429
   Kamiya N, 2015, CLIN ORTHOP RELAT R, V473, P1486, DOI 10.1007/s11999 015 4172 6
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kato D, 2022, CALCIFIED TISSUE INT, V111, P622, DOI 10.1007/s00223 022 01019 2
   Kim HK, 2005, J BONE JOINT SURG AM, V87A, P550, DOI 10.2106/JBJS.D.02192
   Kim KM, 2018, ONCOTARGET, V9, P3562, DOI 10.18632/oncotarget.23337
   Kim MH, 2016, ARCH PHARM RES, V39, P1671, DOI 10.1007/s12272 016 0810 0
   Konarski W, 2023, HEALTHCARE BASEL, V11, DOI 10.3390/healthcare11131846
   Kothapalli R, 2007, PATHOLOGY, V39, P241, DOI 10.1080/00313020701230765
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li WZ, 2009, J ORTHOP RES, V27, P694, DOI 10.1002/jor.20802
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majidinia M, 2018, J CELL PHYSIOL, V233, P5598, DOI 10.1002/jcp.26265
   MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473
   Meng XS, 2023, J INVEST SURG, V36, DOI 10.1080/08941939.2023.2197054
   MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623 199503000 00018
   Moon NH, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04153 4
   Moritani Y, 2022, J ORAL BIOSCI, V64, P410, DOI 10.1016/j.job.2022.10.001
   Moya Angeler J, 2015, WORLD J ORTHOP, V6, P590, DOI 10.5312/wjo.v6.i8.590
   Natsume H, 2011, MOL CELL ENDOCRINOL, V331, P66, DOI 10.1016/j.mce.2010.08.009
   Osawa Y, 2023, INT ORTHOP, V47, P89, DOI 10.1007/s00264 022 05569 w
   Pei JP, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12196 8
   Radl R, 2005, ACTA ORTHOP, V76, P49, DOI 10.1080/00016470510030319
   Ren YS, 2021, J BONE MINER RES, V36, P357, DOI 10.1002/jbmr.4191
   Ren ZY, 2023, TOXICON, V230, DOI 10.1016/j.toxicon.2023.107174
   Robinson KF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00565 2
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Takahashi S, 2015, J EPIDEMIOL, V25, P437, DOI 10.2188/jea.JE20140162
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wang RS, 2022, BMC MED GENOMICS, V15, DOI 10.1186/s12920 021 01142 3
   Xu HH, 2023, FOOD FUNCT, V14, P946, DOI [10.1039/d2fo02337g, 10.1039/D2FO02337G]
   Zalavras CG, 2014, J AM ACAD ORTHOP SUR, V22, P455, DOI 10.5435/JAAOS 22 07 455
   Zhang SY, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 023 06447 1
NR 51
TC 1
Z9 1
U1 7
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2024
VL 181
AR 117030
DI 10.1016/j.bone.2024.117030
EA FEB 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KY7H5
UT WOS:001183589900001
PM 38309414
DA 2025 08 17
ER

PT J
AU Huang, YC
   Yao, H
   Tjahjono, AW
   Xiang, L
   Li, K
   Tang, JH
   Gao, YX
AF Huang, Yucheng
   Yao, Huan
   Tjahjono, Adi Wirawan
   Xiang, Li
   Li, Ke
   Tang, Jiahe
   Gao, Yongxiang
TI Si Zhi Wan regulates osteoclast autophagy in osteoporosis through the
   AMPK signaling pathway to attenuate osteoclastogenesis
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE Si Zhi Wan; osteoclast; autophagy; osteoporosis; AMPK signaling pathway
ID MECHANISM
AB Objectives: The mechanisms underlying the therapeutic effects of Si Zhi Wan (SZW), a traditional Chinese medicine used to treat osteoporosis (OP), remain unknown. This study investigated the therapeutic effects of SZW on mice that underwent ovariectomy (OVX) and underlying mechanisms thereof.Methods: We established an in vivo model of OP by performing OVX in mice. Microcomputed tomography (Micro CT) was used to assess changes in bone characteristics of mice following SZW administration for 4 weeks. H&E staining revealed alterations in bone tissues of mice. Osteoclastogenesis in mouse bone tissue was observed using tartrate resistant acid phosphatase staining and western blotting. Furthermore, we examined the impact of SZW on osteoclastogenesis in vitro using receptor activator of nuclear factor kappa B ligand (RANKL). Finally, we explored the regulatory effects of SZW on osteoclast autophagy and the AMPK pathway.Key findings: The results demonstrated that high dose SZW reversed changes in bone density parameters caused by OVX, including bone volume (BV), BV/total volume, trabecular number, and trabecular spacing (P = 0.0007, 0.0035, 0.0114, and 0.0182, respectively), and stimulated the formation of bone trabeculae in mice (P < 0.0001). Furthermore, SZW suppressed osteoclast formation in mice with OVX and inhibited osteoclast formation induced by RANKL. Mechanistically, SZW inhibited osteoclast precursor cell autophagy through the AMPK pathway.Conclusions: SZW effectively inhibited the autophagy of osteoclast precursors by regulating the AMPK pathway, thereby exerting anti osteoclastogenic effects and serving as an alternative therapy for OP.
C1 [Huang, Yucheng; Tjahjono, Adi Wirawan; Xiang, Li; Li, Ke; Tang, Jiahe; Gao, Yongxiang] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
   [Yao, Huan] Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
   [Yao, Huan] Sichuan Prov Engn Res Ctr Innovat Redev Famous Cla, Pengzhou 611930, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine
RP Gao, YX (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.; Yao, H (通讯作者)，Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
EM huanyao6620@hotmail.com; drgaoyx@cdutcm.edu.cn
RI ; Huan, Yao/AAD 4719 2019; Tjahjono, Adi/HSG 1582 2023; Yao,
   Huan/AAD 4719 2019
OI Tjahjono, Adi Wirawan/0000 0002 7227 1593; Huan,
   Yao/0000 0001 5076 2650; 
FU China Scholarship Council
FX We thank Adi Wirawan Tjahjono who supported our research while pursuing
   his Ph.D., funded by the China Scholarship Council.
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bhatnagar A, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.29367
   Cao WY, 2021, B CANCER, V108, P304, DOI 10.1016/j.bulcan.2020.11.004
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580 018 0003 4
   He QM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.983884
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Vargas JNS, 2023, NAT REV MOL CELL BIO, V24, P167, DOI 10.1038/s41580 022 00542 2
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P67, DOI 10.1007/978 981 15 0602 4_3
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yao H, 2023, PHYTOMEDICINE, V118, DOI 10.1016/j.phymed.2023.154967
   Yao H, 2022, FREE RADICAL BIO MED, V190, P264, DOI 10.1016/j.freeradbiomed.2022.08.016
   Zhang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005665
NR 18
TC 2
Z9 2
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD MAR 4
PY 2024
VL 76
IS 3
BP 236
EP 244
DI 10.1093/jpp/rgad126
EA JAN 2024
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JK3D1
UT WOS:001137187700001
PM 38183672
OA hybrid
DA 2025 08 17
ER

PT J
AU Son, TH
   Kim, SH
   Shin, HL
   Kim, D
   Huh, JS
   Ryoo, R
   Choi, Y
   Choi, SW
AF Son, Tae Hyun
   Kim, Shin Hye
   Shin, Hye Lim
   Kim, Dongsoo
   Huh, Jin Sung
   Ryoo, Rhim
   Choi, Yongseok
   Choi, Sik Won
TI Inhibition of Osteoclast Differentiation and Promotion of Osteogenic
   Formation by Wolfiporia extensa Mycelium
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Osteoporosis; Wolfiporia extensa; mycelium; osteoblasts; osteoclasts
ID PORIA COCOS; BONE; OSTEOBLAST; REGULATOR; MYOBLASTS; PATHWAY; CELLS;
   NFAT2
AB Osteoporosis, Greek for "porous bone," is a bone disease characterized by a decrease in bone strength, microarchitectural changes in the bone tissues, and an increased risk of fracture. An imbalance of bone resorption and bone formation may lead to chronic metabolic diseases such as osteoporosis. Wolfiporia extensa, known as "Bokryung" in Korea, is a fungus belonging to the family Polyporaceae and has been used as a therapeutic food against various diseases. Medicinal mushrooms, mycelium and fungi, possess approximately 130 medicinal functions, including antitumor, immunomodulating, antibacterial, hepatoprotective, and antidiabetic effects, and are therefore used to improve human health. In this study, we used osteoclast and osteoblast cell cultures treated with Wolfiporia extensa mycelium water extract (WEMWE) and investigated the effect of the fungus on bone homeostasis. Subsequently, we assessed its capacity to modulate both osteoblast and osteoclast differentiation by performing osteogenic and anti osteoclastogenic activity assays. We observed that WEMWE increased BMP 2 stimulated osteogenesis by inducing Smad Runx2 signal pathway axis. In addition, we found that WEMWE decreased RANKL induced osteoclastogenesis by blocking c Fos/NFATc1 via the inhibition of ERK and JNK phosphorylation. Our results show that WEMWE can prevent and treat bone metabolic diseases, including osteoporosis, by a biphasic activity that sustains bone homeostasis. Therefore, we suggest that WEMWE can be used as a preventive and therapeutic drug.
C1 [Son, Tae Hyun; Choi, Yongseok] Korea Univ, Sch Life Sci & Biotechnol, Seoul 02841, South Korea.
   [Son, Tae Hyun; Kim, Shin Hye; Shin, Hye Lim; Kim, Dongsoo; Huh, Jin Sung; Choi, Sik Won] Natl Inst Forest Sci NIFoS, Forest Biomat Res Ctr, Jinju 52817, South Korea.
   [Ryoo, Rhim] NIFoS, Dept Forest Bioresources, Forest Microbiol Div, Suwon 16631, South Korea.
C3 Korea University
RP Choi, Y (通讯作者)，Korea Univ, Sch Life Sci & Biotechnol, Seoul 02841, South Korea.; Choi, SW (通讯作者)，Natl Inst Forest Sci NIFoS, Forest Biomat Res Ctr, Jinju 52817, South Korea.
EM ychoi@korea.ac.kr; superwon@korea.kr
RI ; Kim, Seunghyun/AAA 3402 2022; Choi, Yongseok/F 8375 2012
OI Choi, Sik Won/0000 0003 1726 2536; Son, Tae Hyun/0009 0006 4043 0082;
   Kim, Shin Hye/0000 0002 8886 1133
FU Forest Bioresources Department, National Institute of Forest Science
   [FP0800 2020 02 2022]
FX This study was carried out with the support of Forest Bioresources
   Department, National Institute of Forest Science (project no.
   FP0800 2020 02 2022) .
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Ariffin SHZ, 2022, PEERJ, V10, DOI 10.7717/peerj.14174
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Berger RG, 2022, MICROORGANISMS, V10, DOI 10.3390/microorganisms10071379
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng SJ, 2013, INT J ONCOL, V42, P1869, DOI 10.3892/ijo.2013.1902
   Choi SuHee Choi SuHee, 2016, Korean Journal of Mycology, V44, P23, DOI 10.4489/KJM.2016.44.1.23
   Cuellar MJ, 1996, J NAT PROD, V59, P977, DOI 10.1021/np9604339
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Fijalkowska A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76899 1
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   HAMURO J, 1971, NATURE, V233, P486, DOI 10.1038/233486a0
   Herpin A, 2007, FEBS J, V274, P2977, DOI 10.1111/j.1742 4658.2007.05840.x
   Hwang YH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051383
   Esteban CI, 2009, REV IBEROAM MICOL, V26, P103, DOI 10.1016/S1130 1406(09)70019 1
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Jiang Y, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112851
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim SH, 2019, PHYTOTHER RES, V33, P1490, DOI 10.1002/ptr.6341
   Kim SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123119
   Kim WJ, 2020, EXP MOL MED, V52, P1178, DOI 10.1038/s12276 020 0471 4
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nukaya H, 1996, CHEM PHARM BULL, V44, P847, DOI 10.1248/cpb.44.847
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Posadzki P, 2013, CLIN MED, V13, P7, DOI 10.7861/clinmedicine.13 1 7
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Samee N, 2008, AM J PATHOL, V173, P773, DOI 10.2353/ajpath.2008.080243
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Stafford RS, 2004, ARCH INTERN MED, V164, P1525, DOI 10.1001/archinte.164.14.1525
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wasser Solomon P, 2014, Biomed J, V37, P345, DOI 10.4103/2319 4170.138318
   Watson J, 2007, EUR J CLIN PHARMACOL, V63, P843, DOI 10.1007/s00228 007 0320 6
   Wu YY, 2016, GENE, V588, P149, DOI 10.1016/j.gene.2016.05.020
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
NR 54
TC 2
Z9 2
U1 0
U2 8
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #402,  635 4 YEOGSAM DONG, KANGNAM GU, SEOUL,
   SOUTH KOREA
SN 1017 7825
EI 1738 8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD SEP
PY 2023
VL 33
IS 9
BP 1197
EP 1205
DI 10.4014/jmb.2304.04048
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA W1OK3
UT WOS:001089391500010
PM 37317624
OA Green Published
DA 2025 08 17
ER

PT J
AU Gao, JJ
   Wu, P
   Chi, YJ
   Xu, HY
   Zhao, Y
   Song, NY
   Mao, YQ
AF Gao, Jijian
   Wu, Peng
   Chi, Yingjun
   Xu, Hongyu
   Zhao, Yong
   Song, Nanyan
   Mao, Yuanqing
TI LY450139 Inhibited Ti Particle Induced Bone Dissolution via Suppressing
   Notch and NF κB Signaling Pathways
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE LY450139; Notch; Osteoclast; NF kappa B; Osteolysis
ID GAMMA SECRETASE INHIBITORS; OSTEOCLAST PRECURSORS; ALZHEIMERS DISEASE;
   TITANIUM PARTICLES; CLINICAL TRIALS; WEAR PARTICLES; OSTEOLYSIS; RANKL;
   SEMAGACESTAT; FUSION
AB Aseptic loosening of the prosthesis caused by wear particle induced osteolysis is a long term complication and one of the most common reasons for the failure of joint implants. The primary cause of aseptic loosening of the prosthesis is overactive bone resorption caused by wear particle activated osteoclasts in both direct and indirect ways. Therefore, drugs that can inhibit differentiation and bone resorption of osteoclasts need investigation as a potential therapeutic strategy to prevent and treat peri prosthetic osteolysis and thereby prolong the service life of the prosthesis. This study has verified the potential inhibitory effect of LY450139 on inflammatory osteolysis induced by titanium particles in a mice skull model. In addition, we found that LY450139 inhibited receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis, bone resorption, and podosomal actin belt formation in a dose dependent manner without evidence of cytotoxicity in vitro. In addition, LY450139 significantly decreased the expression of osteoclast specific markers, including TRAP, CTSK, V ATPase d2, CTR, DC STAMP, NFATc1, and the downstream target gene Hesl in Notch signaling pathway. Further investigation of the molecular mechanism demonstrated that LY450139 inhibited the formation of osteoclasts via inhibition of the NF kappa B and Notch signaling pathways. In summary, LY450139 inhibited the formation of RANKL mediated osteoclasts via NF kappa B and Notch signaling and inhibited Ti particle induced inflammatory osteolysis in vivo. LY450139 is a potential targeted drug for the treatment of peri prosthetic osteolysis and other osteolytic disease associated with overactive osteoclasts.
C1 [Gao, Jijian; Chi, Yingjun; Xu, Hongyu; Zhao, Yong; Song, Nanyan] Zhejiang Univ, Dept Orthopaed Surg, Shengzhou Peoples Hosp, Affiliated Hosp 1,Shengzhou Branch, Shaoxing 312000, Zhejiang, Peoples R China.
   [Mao, Yuanqing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthopaed Implants,Sch Med, Shanghai, Peoples R China.
   [Wu, Peng] Huating First Peoples Hosp, Dept Orthopaed Surg, Pingliang 744000, Gansu, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Song, NY (通讯作者)，Zhejiang Univ, Dept Orthopaed Surg, Shengzhou Peoples Hosp, Affiliated Hosp 1,Shengzhou Branch, Shaoxing 312000, Zhejiang, Peoples R China.; Mao, YQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthopaed Implants,Sch Med, Shanghai, Peoples R China.
EM snysny2021@163.com; yuanqingmao@163.com
FU National Key R&D Program of China [2018YFA0703000]; National Natural
   Science Foundation of China [81772361, 81572158]
FX This study was supported by The National Key R&D Program of China (Grant
   No. 2018YFA0703000) and The National Natural Science Foundation of China
   (Grant No. 81772361; 81572158).
CR Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Antonios JK, 2013, CELL MOL IMMUNOL, V10, P471, DOI 10.1038/cmi.2013.39
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Beauchamp CP, 2016, CLIN ORTHOP RELAT R, V474, P537, DOI 10.1007/s11999 015 4638 6
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453
   Chen XW, 2019, J CELL PHYSIOL, V234, P20944, DOI 10.1002/jcp.28699
   Choi MG, 2005, P NATL ACAD SCI USA, V102, P4578, DOI 10.1073/pnas.0500693102
   Crawford RE, 1997, ANN RHEUM DIS, V56, P455, DOI 10.1136/ard.56.8.455
   Crump CJ, 2013, BIOCHEMISTRY US, V52, P3197, DOI 10.1021/bi400377p
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951
   Dyskova T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01026
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Grosse S, 2015, J BIOMED MATER RES B, V103, P709, DOI 10.1002/jbm.b.33243
   Henley DB, 2009, EXPERT OPIN PHARMACO, V10, P1657, DOI 10.1517/14656560903044982
   Hikata T, 2009, BLOOD, V113, P2202, DOI 10.1182/blood 2008 06 162594
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jiang YP, 2013, ACTA BIOMATER, V9, P7564, DOI 10.1016/j.actbio.2013.03.010
   Juillerat Jeanneret L, 2015, J MED CHEM, V58, P8097, DOI 10.1021/acs.jmedchem.5b00912
   Kim IM, 2010, CIRC RES, V106, P1233, DOI 10.1161/CIRCRESAHA.109.213785
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Lei PF, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1119 8
   Luo ZL, 2019, AM J PATHOL, V189, P1495, DOI 10.1016/j.ajpath.2019.05.005
   Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947 2714.100998
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Moen TC, 2011, CLIN ORTHOP RELAT R, V469, P382, DOI 10.1007/s11999 010 1500 8
   Moore G, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061503
   Muthukuru M, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.31
   Nagase H, 2013, CURR STEM CELL RES T, V8, P341, DOI 10.2174/1574888X113089990054
   Panza F, 2010, CNS NEUROSCI THER, V16, P272, DOI 10.1111/j.1755 5949.2010.00164.x
   Ran Y, 2017, EMBO MOL MED, V9, P950, DOI 10.15252/emmm.201607265
   Razumilava N, 2013, J HEPATOL, V58, P1244, DOI 10.1016/j.jhep.2013.01.017
   Regan J, 2013, CURR OSTEOPOROS REP, V11, P126, DOI 10.1007/s11914 013 0145 4
   Sabol HM, 2021, CANCER RES, V81, P5102, DOI 10.1158/0008 5472.CAN 21 0524
   Schneider LS, 2009, ALZHEIMERS DEMENT, V5, P388, DOI 10.1016/j.jalz.2009.07.038
   Schwarz EM, 2000, ARTHRITIS RES, V2, P165, DOI 10.1186/ar81
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Suda T, 2008, P JPN ACAD B PHYS, V84, P419, DOI 10.2183/pjab.84.419
   Verma SK, 2014, BIOCHEM J, V464, P293, DOI 10.1042/BJ20141233
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang ML, 2002, J ORTHOP RES, V20, P1175, DOI 10.1016/S0736 0266(02)00076 1
   Wei X, 2020, J BIOMED MATER RES A, V108, P2150, DOI 10.1002/jbm.a.36972
   Yamane H, 2013, IMMUNOL REV, V252, P12, DOI 10.1111/imr.12032
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yuan F, 2012, ADV DRUG DELIVER REV, V64, P1205, DOI 10.1016/j.addr.2012.03.006
   Zhang Y, 2019, ONCOL LETT, V18, P2743, DOI 10.3892/ol.2019.10653
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
NR 52
TC 5
Z9 6
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2022
VL 111
IS 2
BP 211
EP 223
DI 10.1007/s00223 022 00980 2
EA MAY 2022
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 3B7QL
UT WOS:000797750100002
PM 35588014
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Lawson, MA
   McDonald, MM
   Kovacic, N
   Khoo, WH
   Terry, RL
   Down, J
   Kaplan, W
   Paton Hough, J
   Fellows, C
   Pettitt, JA
   Dear, TN
   Van Valckenborgh, E
   Baldock, PA
   Rogers, MJ
   Eaton, CL
   Vanderkerken, K
   Pettit, AR
   Quinn, JMW
   Zannettino, ACW
   Phan, TG
   Croucher, PI
AF Lawson, Michelle A.
   McDonald, Michelle M.
   Kovacic, Natasa
   Khoo, Weng Hua
   Terry, Rachael L.
   Down, Jenny
   Kaplan, Warren
   Paton Hough, Julia
   Fellows, Clair
   Pettitt, Jessica A.
   Dear, T. Neil
   Van Valckenborgh, Els
   Baldock, Paul A.
   Rogers, Michael J.
   Eaton, Colby L.
   Vanderkerken, Karin
   Pettit, Allison R.
   Quinn, Julian M. W.
   Zannettino, Andrew C. W.
   Phan, Tri Giang
   Croucher, Peter I.
TI Osteoclasts control reactivation of dormant myeloma cells by remodelling
   the endosteal niche
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HEMATOPOIETIC STEM; MULTIPLE MYELOMA; IN VIVO; BONE DISEASE; ZOLEDRONIC
   ACID; GENE EXPRESSION; BREAST CANCER; GROWTH; MICE; DIFFERENTIATION
AB Multiple myeloma is largely incurable, despite development of therapies that target myeloma cell intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells, localized in specialized niches, which resist therapy and repopulate the tumour. However, little is known about the niche, and how it exerts cell extrinsic control over myeloma cell dormancy and reactivation. In this study, we track individual myeloma cells by intravital imaging as they colonize the endosteal niche, enter a dormant state and subsequently become activated to form colonies. We demonstrate that dormancy is a reversible state that is switched 'on' by engagement with bone lining cells or osteoblasts, and switched 'off' by osteoclasts remodelling the endosteal niche. Dormant myeloma cells are resistant to chemotherapy that targets dividing cells. The demonstration that the endosteal niche is pivotal in controlling myeloma cell dormancy highlights the potential for targeting cell extrinsic mechanisms to overcome cell intrinsic drug resistance and prevent disease relapse.
C1 [Lawson, Michelle A.; Paton Hough, Julia; Fellows, Clair] Univ Sheffield, Sch Med, Dept Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Lawson, Michelle A.; Paton Hough, Julia; Fellows, Clair; Eaton, Colby L.] Univ Sheffield, Sch Med, Mellanby Ctr Bone Res, Sheffield S10 2RX, S Yorkshire, England.
   [McDonald, Michelle M.; Kovacic, Natasa; Khoo, Weng Hua; Terry, Rachael L.; Down, Jenny; Kaplan, Warren; Pettitt, Jessica A.; Baldock, Paul A.; Rogers, Michael J.; Quinn, Julian M. W.; Phan, Tri Giang; Croucher, Peter I.] Garvan Inst Med Res, Sydney, NSW 2010, Australia.
   [McDonald, Michelle M.; Terry, Rachael L.; Kaplan, Warren; Baldock, Paul A.; Rogers, Michael J.; Phan, Tri Giang; Croucher, Peter I.] UNSW Australia, Fac Med, St Vincents Clin Sch, Sydney, NSW 2010, Australia.
   [Khoo, Weng Hua] UNSW Australia, Sch Biotechnol & Biomol Sci, Sydney, NSW 2010, Australia.
   [Dear, T. Neil; Zannettino, Andrew C. W.] South Australian Hlth & Med Res Inst, Adelaide, SA 5000, Australia.
   [Van Valckenborgh, Els; Vanderkerken, Karin] Vrije Univ Brussel, Dept Hematol & Immunol, B 1090 Brussels, Belgium.
   [Eaton, Colby L.] Univ Sheffield, Sch Med, Dept Human Metab & Clin Biochem, Sheffield S10 2RX, S Yorkshire, England.
   [Pettit, Allison R.] Univ Queensland, Translat Res Inst, Mater Res Inst, Woolloongabba, Qld 4102, Australia.
   [Zannettino, Andrew C. W.] Univ Adelaide, Sch Med Sci, Adelaide, SA 5000, Australia.
C3 University of Sheffield; University of Sheffield; Garvan Institute of
   Medical Research; University of New South Wales Sydney; University of
   New South Wales Sydney; South Australian Health & Medical Research
   Institute (SAHMRI); Vrije Universiteit Brussel; University of Sheffield;
   Mater Research; University of Queensland; University of Adelaide
RP Phan, TG (通讯作者)，Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.
EM t.phan@garvan.org.au; p.croucher@garvan.org.au
RI ; Baldock, Paul/B 3840 2012; Kovacic, Natasa/AAA 4598 2021; Lawson,
   Michelle/M 6095 2019; Vanderkerken, Karin/I 3513 2013; Pettit,
   Allison/O 4462 2019; Van Valckenborgh, Els/GRO 7224 2022; McDonald,
   Michelle/AAD 4760 2019; Phan, Tri/G 3937 2012
OI Lawson, Michelle/0000 0002 5446 923X; Kovacic,
   Natasa/0000 0001 6042 2107; Terry, Rachael/0000 0002 6260 7372;
   Croucher, Peter/0000 0002 7102 2413; Khoo, Weng Hua/0000 0001 9985 7415;
   Down, Jenny/0009 0006 5378 8999; Zannettino, Andrew/0000 0002 6646 6167;
   Vanderkerken, Karin/0000 0002 2137 7179; McDonald,
   Michelle/0000 0002 3928 2506; Phan, Tri/0000 0002 4909 2984; Pettit,
   Allison/0000 0003 4707 7892; Rogers, Michael/0000 0002 1818 9249
FU Mrs Janice Gibson and the Ernest Heine Family Foundation; NHMRC Career
   Development Fellowship [1005097]; International Bone and Mineral Society
   Gregory Mundy Fellowship; Australian Research Council Future Fellowship;
   FWO VI; NHMRC Project Grant [GNT1057706]; Leukaemia and Lymphoma
   Research; OverMyr European Union Framework VII programme; Cancer Council
   NSW (726); Prostate Cancer Foundation of Australia and Movember; NHMRC
   [631484]
FX We thank A. Basten and R. Brink for critical reading of the manuscript
   and D. Rowe (University of Connecticut Health Center) for his kind gift
   of the pOBCol2.3GFPemd mice. We thank the MLC Flow Facility for cell
   sorting, the Small Animal Imaging Facility for intravital imaging, the
   Biological Testing Facility for animal husbandry at the Garvan Institute
   of Medical Research, and the UNSW Australia, Ramaciotti Centre for Gene
   Function Analysis for microarry analysis. P.I.C. is funded by Mrs Janice
   Gibson and the Ernest Heine Family Foundation, T.G.P. by an NHMRC Career
   Development Fellowship (1005097), M.M.M. by an International Bone and
   Mineral Society Gregory Mundy Fellowship, P.A.B. by an Australian
   Research Council Future Fellowship and E.V.V. by the FWO VI and J.M.W.Q.
   by an NHMRC Project Grant (GNT1057706). This work was supported at least
   in part by a specialist programme grant from Leukaemia and Lymphoma
   Research, the OverMyr European Union Framework VII programme, the Cancer
   Council NSW (726), the Prostate Cancer Foundation of Australia and
   Movember, and the NHMRC (project grant 631484).
CR Adams GB, 2009, NATURE, V459, P103, DOI 10.1038/nature07859
   Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Augustine CK, 2010, MOL CANCER THER, V9, P779, DOI 10.1158/1535 7163.MCT 09 0764
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Bataille R, 1996, BLOOD, V87, P4762, DOI 10.1182/blood.V87.11.4762.bloodjournal87114762
   Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Boegsted M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019322
   Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997
   Boyd AL, 2014, J EXP MED, V211, P1925, DOI 10.1084/jem.20140131
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen Z, 2014, BLOOD, V123, P2204, DOI 10.1182/blood 2013 07 517136
   Chtanova T, 2012, J BIOPHOTONICS, V123, P2204
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Dosen G, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471 2172 7 13
   Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood 2012 01 405977
   Foudi A, 2009, NAT BIOTECHNOL, V27, P84, DOI 10.1038/nbt.1517
   Fujisaki J, 2011, NATURE, V474, P216, DOI 10.1038/nature10160
   Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Junt T, 2007, SCIENCE, V317, P1767, DOI 10.1126/science.1146304
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood 2012 01 405985
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Lassailly F, 2010, BLOOD, V115, P5347, DOI 10.1182/blood 2009 05 224030
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Li X, 2012, J BONE MINER RES, V27, P1635, DOI 10.1002/jbmr.1620
   Lo Celso C, 2011, NAT PROTOC, V6, P1, DOI 10.1038/nprot.2010.168
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994
   Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008 5472.CAN 07 3096
   Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465
   Melchor L, 2014, LEUKEMIA, V28, P1705, DOI 10.1038/leu.2014.13
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Nair R, 2014, ONCOGENE, V33, P3992, DOI 10.1038/onc.2013.368
   Ninomiya M, 2007, LEUKEMIA, V21, P136, DOI 10.1038/sj.leu.2404432
   Oyajobi BO, 2007, MOL CANCER THER, V6, P1701, DOI 10.1158/1535 7163.MCT 07 0121
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506 500
   Riedel SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052398
   Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479
   Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Szotek PP, 2008, P NATL ACAD SCI USA, V105, P12469, DOI 10.1073/pnas.0805012105
   Taichman RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061873
   Tan SH, 2014, P NATL ACAD SCI USA, V111, pE5262, DOI 10.1073/pnas.1420463111
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Van Valckenborgh E, 2012, LEUKEMIA, V26, P1436, DOI 10.1038/leu.2011.373
   Vanderkerken K, 1997, BRIT J CANCER, V76, P451, DOI 10.1038/bjc.1997.409
   Vanderkerken K, 2001, BLOOD, V98, p637A
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 66
TC 283
Z9 310
U1 2
U2 60
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC
PY 2015
VL 6
AR 8983
DI 10.1038/ncomms9983
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DA1TO
UT WOS:000367578600002
PM 26632274
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, SJ
   Li, JR
   Ying, TT
   Wang, YX
   Wang, Q
   Li, X
   Zhao, FC
AF Zhou, Shengji
   Li, Jiarui
   Ying, Tiantian
   Wang, Yuxin
   Wang, Quan
   Li, Xiang
   Zhao, Fengchao
TI StemRegenin 1 attenuates the RANKL induced osteoclastogenesis via
   inhibiting AhR c src NF kB/p ERK k B/p ERK MAPK NFATc1 signaling pathway
SO ISCIENCE
LA English
DT Article
ID DIFFERENTIATION; NFATC1; CELLS; RISK
AB The aryl hydrocarbon receptor (AhR) pathway may play an important role in the regulation of osteoclasts, but there are still conflicting studies on this aspect, and the specific mechanism of action has not been fully elucidated. Therefore, we conducted this study to find a drug to treat osteoporosis that targets AhR. We found that StemRegenin 1 inhibited RANKL induced osteoclastogenesis in a concentration dependent and time dependent manner. Through further experiments, we found that SR1 can inhibit nuclear transcription of AhR and inhibit c src phosphorylation, and ultimately regulates the activation of the NF KB K B and p  ERK/mitogen activated protein kinase pathways. Therefore, for the first time, we discovered the way in which the AhR c src NF KB/p ERK c  src NF  K B/p ERK MAPK NFATc1 signaling pathway regulates the expression of osteoclast differentiation associated proteins. Finally, SR1 was shown to successfully reverse bone loss in OVX mice. These studies provide us with ideas for finding new way to treat osteoporosis.
C1 [Zhou, Shengji; Li, Jiarui; Ying, Tiantian; Wang, Yuxin; Wang, Quan; Li, Xiang; Zhao, Fengchao] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Orthopaed Surg, Hangzhou 310003, Peoples R China.
C3 Zhejiang University
RP Li, X; Zhao, FC (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Orthopaed Surg, Hangzhou 310003, Peoples R China.
EM idea_lixiang@zju.edu.cn; zhaofengchao@zju.edu.cn
RI 李, 佳睿/JDW 5769 2023
FU Zhejiang Provincial Natural Science Foundation of China [LGF22H060003]
FX ACKNOWLEDGMENTS This work was supported by Zhejiang Provincial Natural
   Science Foundation of China (LGF22H060003) .
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bai JX, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120197
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Boerckel JD, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt534
   Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen YJ, 2022, J MOL CELL BIOL, V14, DOI 10.1093/jmcb/mjac001
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Eisa NH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217931
   Franceschini G, 2020, EUR J CANCER PREV, V29, P303, DOI 10.1097/CEJ.0000000000000548
   Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140 6736(96)07308 4
   Huang F, 2022, J CELL MOL MED, V26, P3591, DOI 10.1111/jcmm.17399
   Izawa T, 2016, J IMMUNOL, V197, P4639, DOI 10.4049/jimmunol.1600822
   Jackson CS, 2017, STEM CELL RES, V21, P124, DOI 10.1016/j.scr.2017.04.007
   Jia YG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1286 2
   Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357 2725(03)00211 5
   Kim SY, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123498
   Li JR, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00568 4
   Li X, 2021, CELL BIOL TOXICOL, V37, P849, DOI 10.1007/s10565 020 09578 6
   Li Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0574 1
   Lim HJ, 2023, CELLS BASEL, V12, DOI 10.3390/cells12152005
   Lindsay R, 1996, OBSTET GYNECOL, V87, pS16, DOI 10.1016/0029 7844(95)00430 0
   Liu WC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103486
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Neavin DR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123851
   Qiu JX, 2022, BIOCHEM PHARMACOL, V205, DOI 10.1016/j.bcp.2022.115155
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ren Q, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109772
   Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577 019 0125 8
   Singer CA, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 14
   Singh J, 2019, BLOOD ADV, V3, P2934, DOI 10.1182/bloodadvances.2018026575
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thordardottir S, 2014, STEM CELLS DEV, V23, P955, DOI 10.1089/scd.2013.0521
   Vogel CFA, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101530
   Wagner JE, 2016, CELL STEM CELL, V18, P144, DOI 10.1016/j.stem.2015.10.004
   Wang YX, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/7727006
   Wei ZF, 2015, INT J BIOL SCI, V11, P1113, DOI 10.7150/ijbs.12152
   Xie JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02151
   Xu H, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01467 8
   Zhang XM, 2022, THERANOSTICS, V12, P1621, DOI 10.7150/thno.64963
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488
   Zhu XJ, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12999
NR 48
TC 4
Z9 5
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD MAY 17
PY 2024
VL 27
IS 5
AR 109682
DI 10.1016/j.isci.2024.109682
EA APR 2024
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA C9J6R
UT WOS:001292456500001
PM 38660403
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, YP
   Yu, P
   Peng, X
   Huang, Q
   Ding, MM
   Chen, YT
   Jin, RT
   Xie, J
   Zhao, CS
   Li, JS
AF Liu, Yanpeng
   Yu, Peng
   Peng, Xu
   Huang, Qin
   Ding, Mingming
   Chen, Yantao
   Jin, Ruitao
   Xie, Jing
   Zhao, Changsheng
   Li, Jianshu
TI Hexapeptide conjugated calcitonin for targeted therapy of osteoporosis
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Salmon calcitonin; Hexapeptide; Osteoporosis; Bone targeting;
   Bioconjugate
ID DRUG DELIVERY SYSTEM; MINERAL AFFINITY; IN VITRO; BONE; DISULFIDE;
   BIOCONJUGATION
AB The high level of bone metabolism associated with osteopenia and multifocal skeletal fracture remains a challenging clinical problem in osteoporosis patients. Salmon calcitonin (sCT), as a peptide medicine, is able to inhibit osteoclast activity and stimulate osteoblast growth. However, calcitonin receptors (CTRs) are widely distributed in vivo, limiting the specificity and therapeutic effects. Here, we report a bone seeking hexapeptide (Asp6) conjugated sCT (sCT Mal Asp6) for the targeted treatment of osteoporosis. The sCT Mal Asp6 was synthesized via a disulfide re bridge reaction with high specificity and purity. It was demonstrated that the adsorption of sCT Mal Asp6 on hydroxyapatite (HA) was about 5.4 times higher than that of sCT. It was demonstrated a prolonged circulation time and 3 fold higher femur tissue accumulation of sCT Mal Asp6. In ovariectomized (OVX) models, sCT Mal Asp6 significantly increased the ability to attenuate hypercalcemia and reconstruct the trabecula. Our work provides an efficient approach to targeted and effective osteoporosis treatment.
C1 [Liu, Yanpeng; Yu, Peng; Huang, Qin; Ding, Mingming; Jin, Ruitao; Xie, Jing; Zhao, Changsheng; Li, Jianshu] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Sichuan, Peoples R China.
   [Peng, Xu] Sichuan Univ, Lab Anim Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Chen, Yantao] Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen Key Lab Environm Chem & Ecol Remediation, Shenzhen 518060, Peoples R China.
C3 Sichuan University; Sichuan University; Shenzhen University
RP Li, JS (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Sichuan, Peoples R China.
EM jianshu_li@scu.edu.cn
RI Ding, Ming/F 7827 2011; Xie, Jing/AAJ 5073 2021; Yu, Peng/LEM 9696 2024;
   CHEN, Yantao/E 6074 2012
OI Yu, Peng/0000 0002 3363 8911; Li, Jianshu/0000 0002 1522 7326; 
FU National Natural Science Foundation of China [21534008, 51773128,
   51703138]; National Key Research and Development Program of China
   [2016YFC1100404]; State Key Laboratory of Polymer Materials Engineering
   [sklpme2017 2 02]
FX Financial support from the National Natural Science Foundation of China
   (21534008, 51773128 and 51703138), National Key Research and Development
   Program of China (2016YFC1100404), and State Key Laboratory of Polymer
   Materials Engineering (sklpme2017 2 02) are gratefully acknowledged.
CR Anderson ME, 1998, CHEM BIOL INTERACT, V112, P1
   Bhandari KH, 2012, J CONTROL RELEASE, V158, P44, DOI 10.1016/j.jconrel.2011.09.096
   Cao SQ, 2017, J CONTROL RELEASE, V256, P182, DOI 10.1016/j.jconrel.2017.04.014
   Carbone EJ, 2016, NANOMEDICINE, V13, P37
   Castañeda L, 2013, TETRAHEDRON LETT, V54, P3493, DOI 10.1016/j.tetlet.2013.04.088
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Cheng WP, 2010, J CONTROL RELEASE, V147, P289, DOI 10.1016/j.jconrel.2010.07.128
   DELANO WL, 2002, PYMOL
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo 123 3 1483
   Fan TT, 2017, J NANOMATER, V2017, DOI 10.1155/2017/4562474
   Fujisawa R, 1996, BBA PROTEIN STRUCT M, V1292, P53, DOI 10.1016/0167 4838(95)00190 5
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Gittens SA, 2004, PHARM RES DORDR, V21, P608, DOI 10.1023/B:PHAM.0000022407.05163.01
   Goldberg HA, 2001, CONNECT TISSUE RES, V42, P25, DOI 10.3109/03008200109014246
   Gou Y., 2017, POLYM CHEM, V8, P1483
   Johansson E, 2016, J BIOL CHEM, V291, P13689, DOI 10.1074/jbc.M116.726034
   Jones MW, 2012, J AM CHEM SOC, V134, P1847, DOI 10.1021/ja210335f
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kootala S., 2015, THESIS, P78
   Lindorff Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Liu YP, 2017, ACS APPL MATER INTER, V9, P23428, DOI 10.1021/acsami.7b05740
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Morscher S, 2014, PHOTOACOUSTICS, V2, P103, DOI 10.1016/j.pacs.2014.06.001
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Roy MD, 2008, ADV MATER, V20, P1830, DOI 10.1002/adma.200702322
   Ryan SM, 2013, J CONTROL RELEASE, V167, P120, DOI 10.1016/j.jconrel.2013.01.027
   Schumacher FF, 2011, BIOCONJUGATE CHEM, V22, P132, DOI 10.1021/bc1004685
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Smith MEB, 2010, J AM CHEM SOC, V132, P1960, DOI 10.1021/ja908610s
   Tavafoghi M, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0462
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Veronesi F, 2015, J BIOMED MATER RES A, V103, P2932, DOI 10.1002/jbm.a.35433
   Wei J, 2017, BIOMATERIALS, V145, P138, DOI 10.1016/j.biomaterials.2017.08.005
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Yang YM, 2014, 2014 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P7, DOI 10.1109/ICIT.2014.6894963
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
NR 41
TC 33
Z9 33
U1 2
U2 94
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 28
PY 2019
VL 304
BP 39
EP 50
DI 10.1016/j.jconrel.2019.04.042
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA IG3QL
UT WOS:000473719700005
PM 31054990
DA 2025 08 17
ER

PT J
AU Han, XW
   Gong, SQ
   Li, N
   Wang, X
   Liu, P
   Xu, YN
   He, XB
   Jiang, W
   Si, SY
AF Han, Xiaowan
   Gong, Shiqiang
   Li, Ni
   Wang, Xiao
   Liu, Peng
   Xu, Yanni
   He, Xiaobo
   Jiang, Wei
   Si, Shuyi
TI A Novel Small Molecule Which Increases Osteoprotegerin Expression and
   Protects Against Ovariectomy Related Bone Loss in Rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoprotegerin; receptor activator of NF kappa B ligand; osteoblast;
   osteoclast; osteoporosis; Wnt/beta catenin signaling
ID OSTEOCLAST DIFFERENTIATION; RANKL; LIGAND; OSTEOBLASTS; RECEPTOR;
   NFATC1; OPG; OSTEOCYTES; MECHANISM; MASS
AB The ratio of osteoprotegerin (OPG) to the receptor activator of NF kappa B ligand (RANKL) is a key determinant in the regulation of bone metabolism. The study was performed to screen novel anti osteoporotic drugs regulating OPG/RANKL ratio and evaluate their effect on bone metabolism. According to the screening results and in vitro results, we found a small molecule, E09241, significantly increased the ratio of OPG/RANKL by mainly increasing OPG expression. Our in vitro studies showed that E09241 increased the alkaline phosphatase (ALP) activity of mouse osteoblasts, promoted mineralization, and increased the expression of osteogenic differentiation related genes. In addition, we observed that E09241 inhibited RANKL induced osteoclast differentiation and reduced the expression of osteoclast differentiation related proteins nuclear factor of activated T cells c1 (NFATc1) and matrix metalloproteinase 9 (MMP 9). More importantly, E09241 exerted therapeutic protection against bone loss in ovariectomized rats in vivo. This protective effect was confirmed to be achieved by inhibiting bone resorption and promoting bone formation in vivo. Mechanistically, E09241 regulates OPG expression through canonical Wnt/beta catenin signaling. Our findings suggest that E09241 is a promising small molecule compound for treating osteoporosis with a dual effect on osteoblasts and osteoclasts.
C1 [Han, Xiaowan; Gong, Shiqiang; Wang, Xiao; Liu, Peng; Xu, Yanni; He, Xiaobo; Jiang, Wei; Si, Shuyi] Chinese Acad Med Sci, Inst Med Biotechnol, NHC Key Lab Biotechnol Antibiot, Beijing, Peoples R China.
   [Han, Xiaowan; Gong, Shiqiang; Wang, Xiao; Liu, Peng; Xu, Yanni; He, Xiaobo; Jiang, Wei; Si, Shuyi] Peking Union Med Coll, Beijing, Peoples R China.
   [Gong, Shiqiang] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang, Liaoning, Peoples R China.
   [Li, Ni] Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; China Medical University; Chinese Academy
   of Medical Sciences   Peking Union Medical College; Institute of Materia
   Medica   CAMS
RP Jiang, W; Si, SY (通讯作者)，Chinese Acad Med Sci, Inst Med Biotechnol, NHC Key Lab Biotechnol Antibiot, Beijing, Peoples R China.; Jiang, W; Si, SY (通讯作者)，Peking Union Med Coll, Beijing, Peoples R China.
EM jiangwei@imb.pumc.edu.cn; sisyimb@hotmail.com
RI He, Xiaobo/AAI 4811 2021
FU Drug Innovation Major Project [2018ZX09711001 003 006,
   2018ZX09735001 002 001]; National Natural Science Foundation of China
   [81573482, 81621064, 81573474, 81503065]; Health and Medical Creation
   Program of CAMS [2016 I2M 1 011]
FX This work was supported by the Drug Innovation Major Project (grant
   numbers 2018ZX09711001 003 006 and 2018ZX09735001 002 001), the National
   Natural Science Foundation of China (grant numbers 81573482, 81621064,
   81573474, and 81503065), and the Health and Medical Creation Program of
   CAMS (grant number 2016 I2M 1 011).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Blair HC, 2006, REV ENDOCR METAB DIS, V7, P23, DOI 10.1007/s11154 006 9010 4
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bundkirchen K, 2018, J TRAUMA ACUTE CARE, V85, P359, DOI 10.1097/TA.0000000000001952
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong SQ, 2016, J BIOMOL SCREEN, V21, P738, DOI 10.1177/1087057116654657
   Goto H, 2011, CYTOKINE, V56, P662, DOI 10.1016/j.cyto.2011.09.005
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Lin JM, 2007, EUR J CLIN INVEST, V37, P407, DOI 10.1111/j.1365 2362.2007.01800.x
   Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Mountzios G, 2007, ACTA ONCOL, V46, P221, DOI 10.1080/02841860600635870
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ren H, 2016, MENOPAUSE, V23, P441, DOI 10.1097/GME.0000000000000547
   Riggs BL, 2000, J BONE MINER RES, V15, P2293
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shinohara M, 2014, METHODS MOL BIOL, V1164, P171, DOI 10.1007/978 1 4939 0805 9_14
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Zhao XK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04317 0
NR 45
TC 9
Z9 12
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 11
PY 2019
VL 10
AR 103
DI 10.3389/fphar.2019.00103
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HO2YJ
UT WOS:000460783300001
PM 30914947
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chin, KY
   Ng, B
   Rostam, MKI
   Fadzil, NFDM
   Raman, V
   Yunus, FM
   Mark Lee, WF
   Chong, YY
   Qian, J
   Zhang, Y
   Qu, HB
   Hashim, SAS
   Ekeuku, SO
AF Chin, Kok Yong
   Ng, Ben Nett
   Rostam, Muhd Khairik Imran
   Fadzil, Nur Farah Dhaniyah Muhammad
   Raman, Vaishnavi
   Yunus, Farzana Mohamed
   Mark Lee, Wun Fui
   Chong, Yan Yi
   Qian, Jing
   Zhang, Yan
   Qu, Haibin
   Hashim, Syed Alhafiz Syed
   Ekeuku, Sophia Ogechi
TI Effects of E'Jiao on Skeletal Mineralisation, Osteocyte and WNT
   Signalling Inhibitors in Ovariectomised Rats
SO LIFE BASEL
LA English
DT Article
DE Colla corii asini; Dickkopf 1; sclerostin; parathyroid hormone;
   osteoporosis
ID BIXA ORELLANA ANNATTO; ESTROGEN DEFICIENCY; BONE LOSS; MODEL;
   TOCOTRIENOL; SUPPRESSION; SCLEROSTIN
AB E'Jiao is a traditional Chinese medicine derived from donkey skin. E'Jiao is reported to suppress elevated bone remodelling in ovariectomised rats but its mechanism of action is not known. To bridge this research gap, the current study aims to investigate the effects of E'Jiao on skeletal mineralisation, osteocyte and WNT signalling inhibitors in ovariectomised rats. Female Sprague Dawley rats (3 months old) were ovariectomised and supplemented with E'Jiao at 0.26 g/kg, 0.53 g/kg and 1.06 g/kg, or 1% calcium carbonate (w/v) in drinking water. The rats were euthanised after two months of supplementation and their bones were collected for Fourier transform infrared spectroscopy, histomorphometry and protein analysis. Neither ovariectomy nor treatment affected the skeletal mineral/matrix ratio, osteocyte number, empty lacunar number, and Dickkopf 1 and sclerostin protein levels (p > 0.05). Rats treated with calcium carbonate had a higher Dickkopf 1 level than baseline (p = 0.002) and E'Jiao at 0.53 g/kg (p = 0.002). In conclusion, E'Jiao has no significant effect on skeletal mineralisation, osteocyte and WNT signalling inhibitors in ovariectomised rats. The skeletal effect of E'Jiao might not be mediated through osteocytes.
C1 [Chin, Kok Yong; Ng, Ben Nett; Rostam, Muhd Khairik Imran; Fadzil, Nur Farah Dhaniyah Muhammad; Raman, Vaishnavi; Yunus, Farzana Mohamed; Hashim, Syed Alhafiz Syed; Ekeuku, Sophia Ogechi] Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Jalan Yaacob Latif, Bandar Tun Razak 56000, Cheras, Malaysia.
   [Mark Lee, Wun Fui] Univ Teknol Malaysia UTM, Fac Sci, Dept Chem, Johor Baharu 81310, Malaysia.
   [Mark Lee, Wun Fui] Univ Airlangga, Fac Sci & Technol, Res Ctr Quantum Engn Design, Dept Phys, Jl Mulyorejo, Surabaya 60115, Indonesia.
   [Chong, Yan Yi] Taylors Coll, Sch Preuniv Studies, Subang Jaya 47500, Malaysia.
   [Qian, Jing; Zhang, Yan; Qu, Haibin] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310030, Peoples R China.
C3 Universiti Kebangsaan Malaysia; Universiti Teknologi Malaysia; Airlangga
   University; Taylor's University; Zhejiang University
RP Chin, KY (通讯作者)，Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Jalan Yaacob Latif, Bandar Tun Razak 56000, Cheras, Malaysia.
EM chinkokyong@ppukm.ukm.edu.my
RI ; Mark Lee, W./M 7739 2016; QIAN, JING/Q 1447 2017; Ekeuku,
   Sophia/ABI 7123 2020; Chin, Kok Yong/B 6309 2015; Qu,
   Haibin/A 1462 2015; Chong, Yan/L 5679 2016
OI /0000 0003 3583 4163; Ekeuku, Sophia/0000 0002 5485 4592; Chin,
   Kok Yong/0000 0001 6628 1552; 
FU Universiti Kebangsaan Malaysia [FF 2022 077]
FX Universiti Kebangsaan Malaysia funded this study through Fundamental
   Research Grant (Code: FF 2022 077).
CR Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Cao F., 2019, J THORAC ONCOL, V5, P43
   Chin KY, 2022, J CLIN MED, V11, DOI 10.3390/jcm11216434
   Chin KY, 2022, MALAYS J PATHOL, V44, P1
   Chin KY, 2018, INT J MED SCI, V15, P1373, DOI 10.7150/ijms.26571
   Chin KY, 2015, DRUG DES DEV THER, V9, P2049, DOI 10.2147/DDDT.S79660
   Chou HC, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10092173
   Ekeuku SO, 2022, BIOMED PHARMACOTHER, V152, DOI 10.1016/j.biopha.2022.113265
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Fontalis A, 2019, EXPERT OPIN PHARMACO, V20, P1123, DOI 10.1080/14656566.2019.1594772
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Guo L, 2019, J CELL PHYSIOL, V234, P581, DOI 10.1002/jcp.26788
   Imbert L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202833
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Li X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00616
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Menges F., SPECTRAGRYPH
   Mohamad NV, 2021, INT J MED SCI, V18, P3665, DOI 10.7150/ijms.64045
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Mohamad NV, 2018, BIOMED PHARMACOTHER, V103, P453, DOI 10.1016/j.biopha.2018.04.083
   Mohamad NV, 2018, DRUG DES DEV THER, V12, P555, DOI 10.2147/DDDT.S158410
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Palacios S, 2022, CLIMACTERIC, V25, P43, DOI 10.1080/13697137.2021.1951697
   Paschalis EP, 2011, CLIN ORTHOP RELAT R, V469, P2170, DOI 10.1007/s11999 010 1751 4
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Ramli FF, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10030145
   Saad FA, 2020, ANN NY ACAD SCI, V1462, P37, DOI 10.1111/nyas.14231
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sheu SC, 2020, J FOOD SCI TECH MYS, V57, P2877, DOI 10.1007/s13197 020 04319 3
   Vig S, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040767
   Wang ZY, 2020, PEERJ, V8, DOI 10.7717/peerj.10244
   Wong SK, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183313
   Wu MH, 2017, BIOMEDICINE TAIWAN, V7, P9, DOI 10.1051/bmdcn/2017070102
   Wu WJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27144643
   Xia ZY, 2023, MOLECULES, V28, DOI 10.3390/molecules28041778
   Zammel N, 2021, VIB SPECTROSC, V115, DOI 10.1016/j.vibspec.2021.103279
   Zhang Y, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109291
NR 40
TC 8
Z9 8
U1 1
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2075 1729
J9 LIFE BASEL
JI Life Basel
PD FEB
PY 2023
VL 13
IS 2
AR 570
DI 10.3390/life13020570
PG 10
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Microbiology
GA 9L1QL
UT WOS:000941330800001
PM 36836927
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Komaki, S
   Sakai, E
   Fukuma, Y
   Nishishrra, K
   Okamoto, K
   Tsukuba, T
AF Komaki, Shunsuke
   Sakai, Eiko
   Fukuma, Yutaka
   Nishishrra, Kazuhisa
   Okamoto, Kuniaki
   Tsukuba, Takayuki
TI Dihydroartemisinin represses osteoclastogenesis of bone marrow
   macrophages through reduced NFATc1 expression and impaired
   phosphorylation of IκBα
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID SIGNALING PATHWAYS; RECEPTOR ACTIVATOR; NUCLEAR FACTOR; DIFFERENTIATION;
   RANKL; HOMEOSTASIS; DEFICIENCY; RESORPTION; INDUCTION; KINASE
AB Osteoclasts are multinucleated bone resorbing cells whose differentiation is regulated by several important signaling pathways. Several lines of evidence indicate that dihydroartemisinin (DHA), an anti malarial drug, inhibits osteoclast differentiation with little cytotoxicity. However, the detailed inhibitory mechanisms of DHA on osteoclastogenesis from native cells remain to be elucidated. In this study, we investigated the effects of DHA on the differentiation of bone marrow derived macrophages into osteoclasts. DHA inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and its bone resorbing activity. Mechanistically, DHA treatment markedly abolished phosphorylation of I kappa B alpha, and slightly affected a p38 MAPK dependent pathway. Moreover, DHA treatment induced down regulation of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), a master regulator for osteoclast differentiation and its target proteins, such as Src and cathepsin K. These results indicate that DHA represses RANKL induced osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of I kappa B alpha.
C1 [Komaki, Shunsuke; Sakai, Eiko; Fukuma, Yutaka; Nishishrra, Kazuhisa; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Dept Dent Phamiacol, Grad Sch Biomed Sci, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
C3 Nagasaki University
RP Tsukuba, T (通讯作者)，Nagasaki Univ, Dept Dent Phamiacol, Grad Sch Biomed Sci, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
EM tsuta@nagasaki u.ac.jp
RI Tsukuba, Takayuki/I 9542 2018
OI sakai, eiko/0000 0002 6776 6540
FU JSPS KAKENHI [15H05298, 16K15790, 16K11480, 16K11863, 17H04379];
   Grants in Aid for Scientific Research [15H05298, 16K11863, 16K11480,
   16K15790, 17H04379] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI grant numbers, 15H05298,
   16K15790, 16K11480, 16K11863 and 17H04379.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   Fujita T, 2008, FEBS LETT, V582, P1055, DOI 10.1016/j.febslet.2008.02.055
   Insogna K, 1997, MOL REPROD DEV, V46, P104
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Morgan MAJ, 2009, MOL CELL BIOL, V29, P5813, DOI 10.1128/MCB.00670 09
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Sakai E, 2017, FASEB J, V31, P4011, DOI 10.1096/fj.201700177R
   Sakai E, 2016, PHYTOMEDICINE, V23, P828, DOI 10.1016/j.phymed.2016.04.002
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Shimada Sugawara M, 2015, SCI REP UK, V5, DOI 10.1038/srep09620
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wu BC, 2012, ONCOL REP, V27, P101, DOI 10.3892/or.2011.1505
   Yamaguchi Y, 2018, CELL MOL LIFE SCI, V75, P33, DOI 10.1007/s00018 017 2607 9
   Yashima Y, 2015, BIOMETALS, V28, P725, DOI 10.1007/s10534 015 9861 9
   Zhang XG, 2014, PARASITOL RES, V113, P1769, DOI 10.1007/s00436 014 3822 z
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhang ZL, 2016, FREE RADICAL BIO MED, V101, P272, DOI 10.1016/j.freeradbiomed.2016.10.498
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 31
TC 2
Z9 4
U1 0
U2 6
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2018
VL 39
IS 4
BP 169
EP 177
DI 10.2220/biomedres.39.169
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GQ0BJ
UT WOS:000441280900001
PM 30101837
OA gold
DA 2025 08 17
ER

PT J
AU Li, W
   Yuan, L
   Tong, GJ
   He, YH
   Meng, Y
   Hao, S
   Chen, JT
   Guo, J
   Bringhurst, R
   Yang, DH
AF Li, Wei
   Yuan, Liang
   Tong, Guojun
   He, Youhua
   Meng, Yue
   Hao, Song
   Chen, Jianting
   Guo, Jun
   Bringhurst, Richard
   Yang, Dehong
TI Phospholipase C signaling activated by parathyroid hormone mediates the
   rapid osteoclastogenesis in the fracture healing of orchiectomized mice
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Parathyroid hormone; Fracture healing; Phopholipase C; Osteoporosis;
   Osteoclastogenesis
ID (PTH)/PTH RELATED PEPTIDE RECEPTOR; BONE MINERAL DENSITY; TERIPARATIDE;
   PTH; ENHANCEMENT; PATHWAYS; RATS; MASS; AGE
AB Background: The age related osteoporosis is an increasing risk severely threatening the live quality of aged people. Human parathyroid hormone (hPTH) is applied to the therapy of osteoporosis successfully, however, the mechanism, especially the signaling pathway activated in the healing fracture by PTH is still unknown.
   Methods: The once daily injections of hPTH(1 34) and GR (1 34) (the PLC deficient analog) into the orchiectomized male mice with bone fracture, were started at the second day after fracture and lasted for 4 weeks. To explore the role of phospholipase C signaling in the androgen deficient fracture healing, the fracture healing were evaluated via radiography, micro CT, biomechanics testing, serum biochemistry, bone marrow cell culture and gene expression quantification.
   Results: After two weeks of fracture, both peptides significantly increased bone mineral density (BMD), bone mass content (BMC) and bone volume (BV/TV) in the healing area. However, compared to hPTH(1 34), GR(1 34) induced more woven bones, the higher BMC and BMD, as well as the less serum TRAP and osteoclasts. After four weeks of treatment, the effects of hPTH(1 34) on fracture healing showed no difference to those of GR(1 34). Consistently, GR(1 34) induced the similar osteogenesis but less osteoclastogenesis under the ex vivo condition immediately after administration compared to hPTH(1 34), which was verified by the weaker activation of RANKL, NFATC1, TRAP and Cathepsin K in GR(1 34) treatment.
   Conclusion: These results indicated that the PLC signaling activated by the intermittent injection of hPTH(1 34) leads to the bone resorption by rapidly activating the osteoclastogenesis in the fracture healing zone.
C1 [Li, Wei; Yuan, Liang; Tong, Guojun; He, Youhua; Meng, Yue; Hao, Song; Chen, Jianting; Yang, Dehong] Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, Guangzhou 510515, Guangdong, Peoples R China.
   [Guo, Jun; Bringhurst, Richard] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
C3 Southern Medical University   China; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital
RP Yang, DH (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, Guangzhou 510515, Guangdong, Peoples R China.
EM smu_yangdehong2018@163.com
OI Yang, Dehong/0000 0001 7896 8474
FU National Natural Science Foundation of China [30973061, 81272043];
   Natural Science Foundation of Guangdong Province [2015A030313256]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 30973061 and 81272043) and the Natural Science
   Foundation of Guangdong Province (2015A030313256).
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, J CRANIOFAC SURG, V15, P424, DOI 10.1097/00001665 200405000 00014
   Blouin Stephane, 2008, V455, P125, DOI 10.1007/978 1 59745 104 8_9
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Boonen S, 1997, INT J ANDROL, V20, P134, DOI 10.1046/j.1365 2605.1997.00047.x
   Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757
   Broulík PD, 2007, PHYSIOL RES, V56, P443, DOI 10.33549/physiolres.931003
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   Ebeling PR, 2010, CURR OPIN ENDOCRINOL, V17, P284, DOI 10.1097/MED.0b013e328339658c
   Ellegaard M, 2010, CALCIFIED TISSUE INT, V87, P1, DOI 10.1007/s00223 010 9360 5
   Gabet Y, 2005, OSTEOPOROSIS INT, V16, P1436, DOI 10.1007/s00198 005 1876 6
   GOLDRAY D, 1993, J CLIN ENDOCR METAB, V76, P288, DOI 10.1210/jc.76.2.288
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009 1494
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   Huang JC, 2002, J BONE MINER RES, V17, P1667
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Komrakova M, 2011, J ENDOCRINOL, V209, P9, DOI 10.1530/JOE 10 0353
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Liu BY, 2002, ENDOCRINOLOGY, V143, P627, DOI 10.1210/en.143.2.627
   Lou SH, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen 2017 019291
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Marcus R, 2003, J BONE MINER RES, V18, P18, DOI 10.1359/jbmr.2003.18.1.18
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Mognetti B, 2011, CALCIFIED TISSUE INT, V89, P163, DOI 10.1007/s00223 011 9503 3
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   O'Loughlin PF, 2009, SPINE, V34, P121, DOI 10.1097/BRS.0b013e318191e687
   Ren YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023060
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tezval M, 2011, WORLD J UROL, V29, P529, DOI 10.1007/s00345 011 0652 9
   Tong G, 2017, MED SCI MONITOR, V23, P1896, DOI 10.12659/MSM.903699
   Tsuchie H, 2016, J BONE MINER METAB, V34, P86, DOI 10.1007/s00774 014 0646 y
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Wu J, 2003, J APPL PHYSIOL, V94, P335, DOI 10.1152/japplphysiol.00498.2002
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007 0826
   Yang DH, 2006, BONE, V38, P485, DOI 10.1016/j.bone.2005.10.009
   Yang X, 2013, BONE, V52, P308, DOI 10.1016/j.bone.2012.09.039
   Zhao Y, 2016, OSTEOPOROSIS INT, V27, P3309, DOI 10.1007/s00198 016 3651 2
NR 41
TC 8
Z9 10
U1 3
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 29
PY 2018
VL 19
AR 311
DI 10.1186/s12891 018 2231 3
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA GS2JI
UT WOS:000443374100002
PM 30157832
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Vollersen, N
   Hermans Borgmeyer, I
   Cornils, K
   Fehse, B
   Rolvien, T
   Triviai, I
   Jeschke, A
   Oheim, R
   Amling, M
   Schinke, T
   Yorgan, TA
AF Vollersen, Nele
   Hermans Borgmeyer, Irm
   Cornils, Kerstin
   Fehse, Boris
   Rolvien, Tim
   Triviai, Ioanna
   Jeschke, Anke
   Oheim, Ralf
   Amling, Michael
   Schinke, Thorsten
   Yorgan, Timur Alexander
TI High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing
   Hajdu Cheney Syndrome
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE REMODELING; HAJDU CHENEY SYNDROME; NOTCH SIGNALING; NOTCH2
ID EMBRYONIC STEM CELLS; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAY;
   MOUSE MODEL; OSTEOPOROSIS; ACROOSTEOLYSIS; PROTEOLYSIS; ACTIVATION;
   SKELETON; THERAPY
AB Hajdu Cheney syndrome (HCS) is a rare autosomal dominant disorder primarily characterized by acro osteolysis and early onset osteoporosis. Genetically, HCS is caused by nonsense or deletion mutations within exon 34 of the NOTCH2 gene, resulting in premature translational termination and production of C terminally truncated NOTCH2 proteins that are predicted to activate NOTCH2 dependent signaling. To understand the role of Notch2 in bone remodeling, we developed a mouse model of HCS by introducing a pathogenic mutation (6272delT) into the murine Notch2 gene. By CT and undecalcified histology, we observed generalized osteopenia in two independent mouse lines derived by injection of different targeted embryonic stem (ES) cell clones, yet acro osteolysis did not occur until the age of 52 weeks. Cellular and dynamic histomorphometry revealed a high bone turnover situation in Notch2(+/HCS) mice, since osteoblast and osteoclast indices were significantly increased compared with wild type littermates. Whereas ex vivo cultures failed to uncover cell autonomous gain of functions within the osteoclast or osteoblast lineage, an unbiased RNA sequencing approach identified Tnfsf11 and Il6 as Notch signaling target genes in bone marrow cells cultured under osteogenic conditions. Because we further observed that the high turnover pathology of Notch2(+/HCS) mice was fully normalized by alendronate treatment, our results demonstrate that mutational activation of Notch2 does not directly control osteoblast activity but favors a pro osteoclastic gene expression pattern, which in turn triggers high bone turnover. (c) 2017 American Society for Bone and Mineral Research.
C1 [Vollersen, Nele; Rolvien, Tim; Jeschke, Anke; Oheim, Ralf; Amling, Michael; Schinke, Thorsten; Yorgan, Timur Alexander] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
   [Hermans Borgmeyer, Irm] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol, Hamburg, Germany.
   [Cornils, Kerstin; Fehse, Boris] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Res Dept Cell & Gene Therapy, Hamburg, Germany.
   [Triviai, Ioanna] Univ Med Ctr Hamburg Eppendorf, Clin Stem Cell Transplantat, Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Yorgan, TA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
EM t.yorgan@uke.de
RI Triviai, Ioanna/G 6062 2015; Oheim, Ralf/KPA 2969 2024; Fehse,
   Boris/A 8721 2012
OI Fehse, Boris/0000 0001 9780 7211; 
FU Deutsche Forschungsgemeinschaft [SCHI 504/11 1]; European Community's
   Seventh Framework Programme [602300]; German Federal Ministry of
   Education and Research (BMBF)
FX This project has received funding from the Deutsche
   Forschungsgemeinschaft (SCHI 504/11 1), the European Community's Seventh
   Framework Programme under grant agreement no. 602300 (SYBIL), and the
   German Federal Ministry of Education and Research (BMBF) within the
   project "Detection and Individualized Management of Early Onset
   Osteoporosis (DIMEOS)."
CR Adami G, 2016, BONE, V92, P150, DOI 10.1016/j.bone.2016.08.025
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018 009 8668 7
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brennan AM, 2001, AM J MED GENET, V100, P292, DOI 10.1002/1096 8628(20010515)100:4<292::AID AJMG1308>3.0.CO;2 4
   Canalis E, 2017, ENDOCRINOLOGY, V158, P730, DOI 10.1210/en.2016 1787
   Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chen S, 2014, CALCIFIED TISSUE INT, V94, P68, DOI 10.1007/s00223 013 9773 z
   Chillakuri CR, 2012, SEMIN CELL DEV BIOL, V23, P421, DOI 10.1016/j.semcdb.2012.01.009
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Drake WM, 2003, J BONE MINER RES, V18, P131, DOI 10.1359/jbmr.2003.18.1.131
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010
   Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hwang S, 2011, YONSEI MED J, V52, P543, DOI 10.3349/ymj.2011.52.3.543
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   IWAYA T, 1979, ARCH ORTHOP TRAUM SU, V95, P293, DOI 10.1007/BF00389701
   JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0
   Jerzakowski G, 2017, QJM INT J MED, V110, P115, DOI 10.1093/qjmed/hcw211
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kuehn SC, 2015, HUM MOL GENET, V24, P7075, DOI 10.1093/hmg/ddv407
   Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354
   Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546
   McKiernan FE, 2007, OSTEOPOROSIS INT, V18, P245, DOI 10.1007/s00198 006 0221 z
   NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424
   NUNZIATA V, 1990, J ENDOCRINOL INVEST, V13, P251, DOI 10.1007/BF03349553
   Pettitt SJ, 2009, NAT METHODS, V6, P493, DOI 10.1038/nmeth.1342
   Ravn P, 2000, J CLIN ENDOCR METAB, V85, P1492, DOI 10.1210/jc.85.4.1492
   Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968 0004(96)10031 1
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Teufel S, 2014, J IMMUNOL, V193, P223, DOI 10.4049/jimmunol.1302713
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   UDELL J, 1986, ARTHRITIS RHEUM US, V29, P1032, DOI 10.1002/art.1780290815
   Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078 0432.CCR 14 2808
   Yorgan T, 2016, BONE, V87, P136, DOI 10.1016/j.bone.2016.04.012
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2017, J BIOL CHEM, V292, P12232, DOI 10.1074/jbc.M117.786129
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhao W, 2013, OSTEOPOROSIS INT, V24, P2275, DOI 10.1007/s00198 013 2298 5
NR 50
TC 20
Z9 20
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2018
VL 33
IS 1
BP 70
EP 83
DI 10.1002/jbmr.3283
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FS9FX
UT WOS:000422723400011
PM 28856714
OA Bronze
DA 2025 08 17
ER

PT J
AU Matsuura, T
   Ichinose, S
   Akiyama, M
   Kasahara, Y
   Tachikawa, N
   Nakahama, K
AF Matsuura, Tsuyoshi
   Ichinose, Shizuko
   Akiyama, Masako
   Kasahara, Yuki
   Tachikawa, Noriko
   Nakahama, Ken ichi
TI Involvement of CX3CL1 in the Migration of Osteoclast Precursors Across
   Osteoblast Layer Stimulated by Interleukin 1ß
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BONE HOMEOSTASIS; RHEUMATOID ARTHRITIS; TRANSENDOTHELIAL MIGRATION;
   ENDOTHELIAL CELLS; FRACTALKINE; RANKL; NEUTROPHILS; CHEMOTAXIS;
   DIAPEDESIS; ACTIVATION
AB The trigger for bone remodeling is bone resorption by osteoclasts. Osteoclast differentiation only occurs on the old bone, which needs to be repaired under physiological conditions. However, uncontrolled bone resorption is often observed in pro inflammatory bone diseases, such as rheumatoid arthritis. Mature osteoclasts are multinuclear cells that differentiate from monocyte/macrophage lineage cells by cell fusion. Although Osteoclast precursors should migrate across osteoblast layer to reach bone matrix before maturation, the underlying mechanisms have not yet been elucidated in detail. We herein found that osteoclast precursors utilize two routes to migrate across osteoblast layer by confocal  and electro microscopic observations. The osteoclast supporting activity of osteoblasts inversely correlated with osteoblast density and was positively related to the number of osteoclast precursors under the osteoblast layer. Osteoclast differentiation was induced by IL 1 ss, but not by PGE(2) in high density osteoblasts. Osteoblasts and osteoclast precursors expressed CX3CL1 and CX3CR1, respectively, and the expression of CX3CL1 increased in response to interleukin 1 ss. An anti CX3CL1 neutralizing antibody inhibited the migration of osteoclast precursors and osteoclast differentiation. These results strongly suggest the involvement of CX3CL1 in the migration of osteoclast precursors and osteoclastogenesis, and will contribute to the development of new therapies for bone diseases. J. Cell. Physiol. 232: 1739 1745, 2017. (c) 2016 Wiley Periodicals, Inc.
C1 [Matsuura, Tsuyoshi; Akiyama, Masako; Kasahara, Yuki; Nakahama, Ken ichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cellular Physiol Chem, Bunkyo Ku, 1545 Yushima, Tokyo, Japan.
   [Matsuura, Tsuyoshi; Tachikawa, Noriko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Oral Implantol & Regenerat Dent Med, Bunkyo Ku, Tokyo, Japan.
   [Ichinose, Shizuko] Tokyo Med & Dent Univ, Res Ctr Med & Dent Sci, Bunkyo Ku, Tokyo, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Nakahama, K (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cellular Physiol Chem, Bunkyo Ku, 1545 Yushima, Tokyo, Japan.
EM nakacell@tmd.ac.jp
CR Blaschke S, 2003, J RHEUMATOL, V30, P1918
   Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015
   Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129
   Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903
   Gevrey JC, 2005, J IMMUNOL, V175, P3737, DOI 10.4049/jimmunol.175.6.3737
   Hoshino A, 2013, J CELL SCI, V126, P1032, DOI 10.1242/jcs.113910
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092 8674(00)80438 9
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Isozaki T, 2008, J INFLAMM RES, V1, P19
   Kindle L, 2006, J BONE MINER RES, V21, P193, DOI 10.1359/JBMR.051027
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Koizumi K, 2009, J IMMUNOL, V183, P7825, DOI 10.4049/jimmunol.0803627
   Matsunawa M, 2006, ARTHRITIS RHEUM, V54, P3408, DOI 10.1002/art.22208
   Mócsai A, 2006, NAT IMMUNOL, V7, P1326, DOI 10.1038/ni1407
   Muller WA, 2015, CARDIOVASC RES, V107, P310, DOI 10.1093/cvr/cvv145
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Nanki T, 2004, J IMMUNOL, V173, P7010, DOI 10.4049/jimmunol.173.11.7010
   Nevius E, 2015, CLIN REV AL IN PRESS, V51, P59
   Odai T, 2009, J RHEUMATOL, V36, P1158, DOI 10.3899/jrheum.081074
   PARKOS CA, 1992, J CELL BIOL, V117, P757, DOI 10.1083/jcb.117.4.757
   Ruth JH, 2001, ARTHRITIS RHEUM, V44, P1568, DOI 10.1002/1529 0131(200107)44:7<1568::AID ART280>3.0.CO;2 1
   Saitoh Y, 2007, BIOCHEM BIOPH RES CO, V364, P417, DOI 10.1016/j.bbrc.2007.09.137
   Sakaguchi K, 2000, PROSTAG LEUKOTR ESS, V62, P319, DOI 10.1054/plef.2000.0161
   Teo GSL, 2012, STEM CELLS, V30, P2472, DOI 10.1002/stem.1198
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 25
TC 28
Z9 32
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2017
VL 232
IS 7
BP 1739
EP 1745
DI 10.1002/jcp.25577
PG 7
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA ES1VB
UT WOS:000399314000019
PM 27579490
DA 2025 08 17
ER

PT J
AU Loftus, LS
   Edwards Bennett, S
   Sokol, GH
AF Loftus, Loretta S.
   Edwards Bennett, Sophia
   Sokol, Gerald H.
TI Systemic Therapy for Bone Metastases
SO CANCER CONTROL
LA English
DT Article
ID ADVANCED MULTIPLE MYELOMA; PLACEBO CONTROLLED TRIAL; SKELETAL RELATED
   EVENTS; ORAL BISPHOSPHONATE USE; RENAL CELL CARCINOMA; LONG TERM
   EFFICACY; PLUS ZOLEDRONIC ACID; BREAST CANCER; PROSTATE CANCER;
   DOUBLE BLIND
AB Background: Accelerated bone loss in patients with cancer is a frequent problem that may result from invasion of the cancer to bone, paraneoplastic tumor proteins, and/or hormonal therapies utilized for cancer treatment. Patients with osteolytic bone disease from multiple myeloma and bone metastases from solid tumors may develop a vicious cycle of bone destruction involving both osteolytic and osteoblastic effects. Consequently, a variety of skeletal related events (SREs) may occur, including pathological fractures, hypercalcemia, spinal cord compression, and the need for surgical intervention and radiation therapy.
   Methods: This article reviews the results of trials that investigated the safety and efficacy of pharmacologic agents, including bisphosphonates and denosumab, for treatment of bone metastases. This analysis is derived from an assessment of the medical literature.
   Results: Beneficial systemic therapies for bone metastases have been developed to decrease SREs. Possible antitumor effects of the bisphosphonates are explored. In addition, the utility of markers of bone turnover in relation to response to therapy and survival, the safety and toxicity of bone targeted therapies, treatment guidelines, and economic considerations are also discussed.
   Conclusions: Effective systemic therapies for metastatic bone disease are available. Ongoing and future research projects in this field are also presented.
C1 [Loftus, Loretta S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Comprehens Breast Program, Tampa, FL 33612 USA.
   [Edwards Bennett, Sophia] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA.
   [Sokol, Gerald H.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; State University System of
   Florida; University of South Florida; H Lee Moffitt Cancer Center &
   Research Institute; Uniformed Services University of the Health Sciences
     USA
RP Loftus, LS (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Comprehens Breast Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Loretta.Loftus@moffitt.org
CR Abrahamsen B, 2009, NEW ENGL J MED, V360, P1789, DOI 10.1056/NEJMc096026
   [Anonymous], 32 ANN SAN ANT BREAS
   [Anonymous], COCHRANE DATABASE SY
   Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015
   Baselga J, 2008, BIOMARKERS, V13, P217, DOI [10.1080/13547500701676019, 10.1080/13547500701676019 ]
   Berenson JR, 2010, SEMIN ONCOL, V37, pS20, DOI 10.1053/j.seminoncol.2010.06.009
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Delea Thomas, 2006, J Support Oncol, V4, P341
   Delea TE, 2006, J THORAC ONCOL, V1, P571, DOI 10.1097/01243894 200607000 00012
   Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fornier MN, 2010, J CLIN ONCOL, V28, P5127, DOI 10.1200/JCO.2010.31.0128
   Gallo M, 2012, ANN ONCOL, V23, P597, DOI 10.1093/annonc/mdr159
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Gryta T, 2010, WALL STREET J
   Ha TC, 2007, BRIT J CANCER, V96, P1796, DOI 10.1038/sj.bjc.6603661
   Harvey HA, 2007, CLIN BREAST CANCER, V7, pS7, DOI 10.3816/CBC.2007.s.001
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044
   Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059
   Kijima T, 2009, BJU INT, V103, P620, DOI 10.1111/j.1464 410X.2008.08124.x
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lage MJ, 2008, AM J MANAG CARE, V14, P317
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Lipton A, 2010, SEMIN ONCOL, V37, pS1, DOI 10.1053/j.seminoncol.2010.06.005
   Lowes R, 2001, MEDSCAPE NEWS T 0721
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Monsees GM, 2011, J NATL CANCER I, V103, P1752, DOI 10.1093/jnci/djr399
   Mortimer JE, 2010, SEMIN ONCOL, V37, pS66, DOI 10.1053/j.seminoncol.2010.06.006
   Mulders PFA, 2007, 22 ANN EUR ASS UR C
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID
   National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID
   Neville Webbe HL, 2010, SEMIN ONCOL, V37, pS53, DOI 10.1053/j.seminoncol.2010.06.008
   Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520 003 0477 1
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen L, 2002, AM J CLIN ONCOL CANC, V25, pS19, DOI 10.1097/00000421 200212001 00004
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2005, BJU INT, V96, P964, DOI 10.1111/j.1464 410X.2005.05740.x
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Saad F, 2010, UROLOGY, V76, P1175, DOI 10.1016/j.urology.2010.05.026
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   Saad F, 2010, SEMIN ONCOL, V37, pS30, DOI 10.1053/j.seminoncol.2010.06.007
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Staflin K, 2010, CLIN EXP METASTAS, V27, P217, DOI 10.1007/s10585 010 9320 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   West H, 2011, J CLIN ONCOL, V29, P1095, DOI 10.1200/JCO.2010.33.5596
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
NR 78
TC 14
Z9 19
U1 1
U2 5
PU H LEE MOFFITT CANCER CENTER & RESEARCH INST
PI TAMPA
PA 12902 MAGNOLIA DR, TAMPA, FL 33612 USA
SN 1073 2748
J9 CANCER CONTROL
JI Cancer Control
PD APR
PY 2012
VL 19
IS 2
BP 145
EP 153
DI 10.1177/107327481201900209
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 994XV
UT WOS:000307969100009
PM 22487977
DA 2025 08 17
ER

PT J
AU Bae, SJ
   Kim, HJ
   Won, HY
   Min, YK
   Hwang, ES
AF Bae, Su Jung
   Kim, Hye Joo
   Won, Hee Yeon
   Min, Yong Ki
   Hwang, Eun Sook
TI Acceleration of osteoblast differentiation by a novel osteogenic
   compound, DMP PYT, through activation of both the BMP and Wnt pathways
SO SCIENTIFIC REPORTS
LA English
DT Article
ID KAPPA B LIGAND; TGF BETA; RECEPTOR ACTIVATOR; OSTEOPOROSIS; PROTEIN;
   BISPHOSPHONATES; OSTEOPROTEGERIN; MODULATION; MANAGEMENT; DRUGS
AB Osteoblast differentiation is regulated through the successive activation of signaling molecules by a complex interplay of extracellular signals such as bone morphogenetic protein (BMP) and Wnt ligands. Numerous studies have identified natural as well as synthetic compounds with osteogenic activity through the regulation of either BMP/SMADs or the Wnt/beta catenin pathway. Here, we attempted to isolate small molecules that concurrently activated both SMADs and beta catenin, which led to the discovery of a novel potent osteogenic compound, DMP PYT. Upon BMP2 stimulation, DMP PYT substantially increased osteoblast differentiation featured by enhanced expression of osteoblast specific genes and accelerated calcification through activation of BMPs expression. DMP PYT promoted BMP2 induced SMAD1/5/8 phosphorylation and beta catenin expression, the latter in a BMP2 independent manner. DMP PYT alone enhanced nuclear localization of beta catenin to promote the DNA binding and transcriptional activity of T cell factor, thereby resulting in increased osteoblast differentiation in the absence of BMP2. Most importantly, DMP PYT advanced skeletal development and bone calcification in zebrafish larvae. Conclusively, DMP PYT strongly stimulated osteoblast differentiation and bone formation in vitro and in vivo by potentiating BMP2 induced activation of SMADs and beta catenin. These results suggest that DMP PYT may have beneficial effects for preventing and for treating osteoporosis.
C1 [Bae, Su Jung; Kim, Hye Joo; Min, Yong Ki] Korea Res Inst Chem Technol, Ctr Drug Discovery Technol, Daejeon 34114, South Korea.
   [Bae, Su Jung; Won, Hee Yeon; Hwang, Eun Sook] Ewha Womans Univ, Coll Pharm, Seoul 03760, South Korea.
   [Bae, Su Jung; Won, Hee Yeon; Hwang, Eun Sook] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul 03760, South Korea.
   [Bae, Su Jung; Min, Yong Ki] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Ewha Womans
   University; Ewha Womans University; Korea Research Institute of
   Bioscience & Biotechnology (KRIBB)
RP Min, YK (通讯作者)，Korea Res Inst Chem Technol, Ctr Drug Discovery Technol, Daejeon 34114, South Korea.; Hwang, ES (通讯作者)，Ewha Womans Univ, Coll Pharm, Seoul 03760, South Korea.; Hwang, ES (通讯作者)，Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul 03760, South Korea.; Min, YK (通讯作者)，Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.
EM ykmin@krict.re.kr; eshwang@ewha.ac.kr
RI Kim, Seok/K 8263 2018; Park, Joohyun/KAL 8175 2024
FU Mid career research program of the National Research Foundation
   [NRF 2013R1A2A2A01068302]; National Research Council of Science &
   Technology   Korea government [CRC 15 02 KRIBB]
FX We thank Drs Hyun Mo Ryoo and Dae Sik Lim for providing 6 x OSE2 luc and
   antibodies against pSMAD2/3 and SMAD2/3, and also thank Drs Myung Ae Bae
   (KRICT) and Cheol Hee Kim (Chungnam National University) for sharing the
   zebrafish facility and for conducting adult zebrafish experiment and
   providing zebrafish fertilized eggs. We appreciate the chemical library
   of Korea Chemical Bank in KRICT. This work was supported by Mid career
   research program of the National Research Foundation (ESH,
   NRF 2013R1A2A2A01068302) and National Research Council of Science &
   Technology (CRC 15 02 KRIBB) grant funded by the Korea government.
CR [Anonymous], 2019, ONE, DOI DOI 10.1371/JOURNAL
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052
   Doh KE, 2016, ARCH PHARM RES, V39, P178, DOI 10.1007/s12272 015 0672 x
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Garber K, 2016, NAT REV DRUG DISCOV, V15, P445, DOI 10.1038/nrd.2016.132
   Hirota M, 2008, CELL SIGNAL, V20, P1632, DOI 10.1016/j.cellsig.2008.05.003
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Trivedi R, 2010, CURR MOL MED, V10, P14, DOI 10.2174/156652410791065372
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Van Wettere AJ, 2014, TOXICOL PATHOL, V42, P616, DOI 10.1177/0192623313499643
   Vrijens K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059045
   Wang S, 2013, NAT CHEM BIOL, V9, P579, DOI [10.1038/nchembio.1309, 10.1038/NCHEMBIO.1309]
   Weitzmann MN, 2014, CURR OPIN ENDOCRINOL, V21, P461, DOI 10.1097/MED.0000000000000103
   Won HY, 2016, ARCH PHARM RES, V39, P1530, DOI 10.1007/s12272 016 0803 z
   Yi JJ, 2010, CELL, V142, P144, DOI 10.1016/j.cell.2010.06.010
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhang QS, 2007, P NATL ACAD SCI USA, V104, P7444, DOI 10.1073/pnas.0702136104
NR 29
TC 27
Z9 32
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 16
PY 2017
VL 7
AR 8455
DI 10.1038/s41598 017 08190 9
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FD7AA
UT WOS:000407677800009
PM 28814721
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shen, WX
   Guan, YY
   Wu, RM
   Liu, LX
   Li, HD
   Bao, WL
   Zhang, YQ
   Nandakumar, KS
   Ye, G
   Shen, XY
AF Shen, Weixing
   Guan, Yun Yun
   Wu, Ruo Ming
   Liu, Li Xin
   Li, Hai Dong
   Bao, Wei Lian
   Zhang, Yeqing
   Nandakumar, Kutty Selva
   Ye, Guan
   Shen, Xiaoyan
TI Protective effects of Wang Bi tablet on bone destruction in
   collagen induced arthritis by regulating osteoclast osteoblast functions
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Wang bi tablet; Rheumatoid arthritis; Osteoclasts; Osteoblasts; NF kappa
   B; JAK STAT3; Wnt/beta catenin
ID NF KAPPA B; RHEUMATOID ARTHRITIS; DAMAGE; RATS; EXPRESSION; EROSION;
   CATENIN; MICE
AB Ethnopharmacological relevance: Wang bi tablet (WB) consists of 17 traditional Chinese medicines and has been used for treating rheumatoid arthritis (RA) in China for many years, however, its pharmacologic mechanism is not clear.
   Aim of study: The aim of this study was to investigate the therapeutic effect of WB on collagen induced mouse arthritis and explored the underlying mechanism.
   Materials and methods: DBA/1 mice were used to establish a type II collagen induced arthritis (CIA) model. From the day of arthritis onset, mice were treated daily by gavage with either total glucosides of paeony (TGP, 0.37 g/kg/d) or WB at a lower (1.11 g/kg/d, WBL) or higher dose of (3.33 g/kg/d, WBH) for 8 weeks. The severity of arthritis, levels of cytokines and the activation of signaling pathways were determined.
   Results: Our results revealed that WB treatment effectively alleviated inflammatory symptoms and prevented bone erosions and joint destructions. It obviously decreased the serum concentration of pro inflammatory cytokines TNF alpha, IL 6 and IL 17 alpha, while increased the concentration of anti inflammatory cytokine IL 10. Interestingly, the proportion of splenic Treg cells were increased significantly. In vitro experiments showed that WB inhibited the differentiation of osteoclasts. Consistently, the mRNA levels of tartrate resistant acid phosphatase (TRAP) and cathepsin K (CtsK), and the activation of NF kappa B and JAK STAT3 signaling pathways in the paws of CIA mice were inhibited by WB treatment. On the other hand, up regulation of osteogenic genes Runx2, Osterix mRNA, and activation of Wnt/beta catenin signaling pathway along with a decreased receptor activator of nuclear factor KB ligand (RANKL) expression were found in WB treated mice.
   Conclusion: Our results suggest that the therapeutic effect of Wang bi tablet could be attributed to its inhibitory activity on NF kappa B and STAT3 signaling pathway mediated osteoclast differentiation, and its enhancement on Wnt/beta catenin signaling pathway mediated osteoblast functions.
C1 [Shen, Weixing; Liu, Li Xin] Nanjing Univ Tradit Chinese Med, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Shen, Weixing; Guan, Yun Yun; Liu, Li Xin; Li, Hai Dong; Bao, Wei Lian; Shen, Xiaoyan] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China.
   [Wu, Ruo Ming; Zhang, Yeqing; Ye, Guan] Shanghai Pharmaceut Holding Co Ltd, Cent Res Inst, Bldg 4,898 Halei Rd, Shanghai 201203, Peoples R China.
   [Nandakumar, Kutty Selva] Karolinska Inst, Dept Biochem & Biophys, Stockholm, Sweden.
C3 Nanjing University of Chinese Medicine; Fudan University; Karolinska
   Institutet
RP Ye, G (通讯作者)，Shanghai Pharmaceut Holding Co Ltd, Cent Res Inst, Bldg 4,898 Halei Rd, Shanghai 201203, Peoples R China.; Shen, XY (通讯作者)，Fudan Univ, Sch Pharmaceut Sci, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
EM shxiaoy@fudan.edu.cn
RI ; Bao, Weilian/AAU 5822 2021; Nandakumar, Kutty Selva/D 5438 2011
OI , Xiaoyan/0000 0003 4828 3268; Bao, Weilian/0000 0002 5162 6703;
   Nandakumar, Kutty Selva/0000 0001 7790 8197
FU Science and Technology Commission of Shanghai Municipality [15DZ1900103,
   15DZ1900100]
FX This work was supported by Science and Technology Commission of Shanghai
   Municipality (No. 15DZ1900103, 15DZ1900100).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao Z. Z., 2000, GUANGXI J TRADIT CHI, V23, P4
   COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0
   Feng ZT, 2018, CLIN RHEUMATOL, V37, P35, DOI 10.1007/s10067 017 3770 y
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Guan YY, 2018, INT J MOL MED, V42, P1666, DOI 10.3892/ijmm.2018.3723
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Huang Yun tai, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P771
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209
   Kang Xin zhong, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P1205
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Li YM, 2013, TRANSL RES, V161, P89, DOI 10.1016/j.trsl.2012.06.001
   Luo J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2015 010116
   Malemud CJ, 2018, THER ADV MUSCULOSKEL, V10, P117, DOI 10.1177/1759720X18776224
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2008, ARTHRITIS RHEUM US, V58, P2936, DOI 10.1002/art.23951
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Smolen JS, 2016, LANCET, V388, P1984
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tsai CY, 2007, ARTHRITIS RHEUM US, V56, P544, DOI 10.1002/art.22401
   van Bilsen JHM, 2004, P NATL ACAD SCI USA, V101, P17180, DOI 10.1073/pnas.0407704101
   Wang Y, 2017, BIOCHEM PHARMACOL, V138, P119, DOI 10.1016/j.bcp.2017.05.006
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhao J, 2013, J ALTERN COMPLEM MED, V19, P111, DOI 10.1089/acm.2011.0370
   Zwerina K, 2012, EUR J IMMUNOL, V42, P413, DOI 10.1002/eji.201141871
NR 32
TC 17
Z9 20
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 28
PY 2019
VL 238
AR 111861
DI 10.1016/j.jep.2019.111861
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IL0CS
UT WOS:000476964300031
PM 30954617
DA 2025 08 17
ER

PT J
AU Bandeira, L
   Bilezikian, JP
AF Bandeira, Leonardo
   Bilezikian, John P.
TI Novel Therapies for Postmenopausal Osteoporosis
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Osteoporosis; Postmenopausal; Antiresorptive; Osteoanabolic; Therapeutic
ID BONE MINERAL DENSITY; CATHEPSIN K INHIBITOR; PARATHYROID HORMONE 1 34;
   SKELETAL ANABOLIC AGENT; NF KAPPA B; SCLEROSTIN ANTIBODY; BIOCHEMICAL
   MARKERS; RECEPTOR ACTIVATOR; ESTIMATED STRENGTH; CLINICAL TRIAL
AB Recently discovered mechanisms have assisted in developing new therapies for osteoporosis. New classes of drugs have been developed for the treatment of postmenopausal osteoporosis. Although there have been numerous advances over the past 2 decades, the search for newer therapies continues.
C1 [Bandeira, Leonardo; Bilezikian, John P.] Columbia Univ, Dept Med, Coll Phys & Surg, 630 West 168th St,PH8W 864, New York, NY 10032 USA.
C3 Columbia University
RP Bilezikian, JP (通讯作者)，Columbia Univ, Dept Med, Coll Phys & Surg, 630 West 168th St,PH8W 864, New York, NY 10032 USA.
EM jpb2@columbia.edu
OI BANDEIRA E FARIAS, LEONARDO/0000 0003 1035 4921
CR Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   [Anonymous], 2015, LILLY HOPES NEW DRUG
   [Anonymous], 2016, LILLY CLIN DEV PIPEL
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Bolognese MA, 2013, J CLIN DENSITOM, V16, P147, DOI 10.1016/j.jocd.2012.02.006
   Bone H, 2015, ASBMR 2015 ANN M SEA
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Brown JP, 2016, ASBMR 2016 ANN M ATL
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Elraiyah T, 2015, J CLIN EPIDEMIOL, V68, P698, DOI 10.1016/j.jclinepi.2015.01.025
   Engelke K, 2015, J BONE MINER RES, V30, P30, DOI 10.1002/jbmr.2292
   Engelke K, 2014, J BONE MINER RES, V29, P629, DOI 10.1002/jbmr.2080
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Genant HK, 2016, J BONE MINER RES, P1
   Guerrini MM, 2014, ARCH BIOCHEM BIOPHYS, V561, P118, DOI 10.1016/j.abb.2014.06.003
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Langdahl B, 2016, SUPERIOR GAINS BONE
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   McClung M, 2016, ASBMR 2016 ANN M ATL
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McClung MR, 2013, J CLIN DENSITOM, V16, P250, DOI 10.1016/j.jocd.2012.02.014
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Nagase S, 2015, J BONE MINER METAB, V33, P93, DOI 10.1007/s00774 013 0558 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Donoghue M, 2016, ASBMR ANN M 2016 ATL
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Papapoulos S, 2016, ASBMR 2016 ANN M ATL
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Silva BC, 2013, CLIN OBSTET GYNECOL, V56, P730, DOI 10.1097/GRF.0b013e3182a9ece0
   STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Stewart AF, 1996, BONE, V19, P303, DOI 10.1016/S8756 3282(96)00221 9
   Tanaka M, 2015, BONE, V81, P178, DOI 10.1016/j.bone.2015.07.016
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   Tsai JN, 2015, J BONE MINER RES, V30, P39, DOI 10.1002/jbmr.2315
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   VANBUCHEM FSP, 1955, ACTA RADIOL, V44, P109, DOI 10.3109/00016925509170789
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
NR 73
TC 29
Z9 36
U1 0
U2 42
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8529
EI 1558 4410
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD MAR
PY 2017
VL 46
IS 1
BP 207
EP +
DI 10.1016/j.ec1.2016.11.001
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EL6JK
UT WOS:000394727800016
PM 28131134
DA 2025 08 17
ER

PT J
AU Chen, SN
   Chu, BX
   Chen, Y
   Cheng, X
   Guo, D
   Chen, LH
   Wang, JC
   Li, ZY
   Hong, ZH
   Hong, D
AF Chen, Shenao
   Chu, Bingxiang
   Chen, Yao
   Cheng, Xun
   Guo, Di
   Chen, Lihua
   Wang, Jiacheng
   Li, Zhiyan
   Hong, Zhenghua
   Hong, Dun
TI Neferine suppresses osteoclast differentiation through suppressing NF κB
   signal pathway but not MAPKs and promote osteogenesis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE Neferine; NF kappa B; osteoblast; osteoclast
ID LOTUS SEED EMBRYO; RANKL; ACTIVATION; APOPTOSIS; GROWTH; NFATC1; CELLS
AB Osteoporosis is an ageing disease characterized by elevated osteoclastic bone resorption resulting in bone loss, decrease bone strength, and elevated incidence of fractures. Neferine, a natural compound isolated from the traditional Chinese medicine Nelumbo nucifera (Lotus), has been reported exhibit anti inflammatory, antioxidant, and anticancer properties. However, its effect on bone remains to be determined. Here we showed that Neferine inhibits RANKL induced osteoclast formation in a dose  and time dependent manner. Furthermore, Neferine also demonstrated antiresorptive properties by effectively ameliorating the bone resorptive activity of mature osteoclasts. Mechanistically, Neferine suppressed RANKL induced activation of NF kappa B signaling pathway. This in turn hindered the induction and activation of NFATc1 resulting in downregulation of osteoclast marker genes closely related to differentiation, fusion as well as bone resorption. Interestingly, we found Neferine enhanced the differentiation and bone mineralization activity of MC3T3 E1 preosteoblast cells. Finally, mice treated with Neferine was protected against ovariectomy (OVX) induced bone loss. The Neferine treatment improved bone volume following ovariectomy and also exhibited less TRAP positive osteoclasts on bone surface. Collectively our data provide promising evidence that Neferine could be a potential therapeutic application for against osteolytic bone conditions such as osteoporosis.
C1 [Chen, Shenao; Cheng, Xun; Guo, Di; Wang, Jiacheng; Hong, Zhenghua; Hong, Dun] Wenzhou Med Univ, Orthoped Dept, Taizhou Hosp, Linhai 317000, Peoples R China.
   [Chen, Shenao; Chu, Bingxiang; Chen, Yao; Cheng, Xun; Guo, Di; Chen, Lihua; Wang, Jiacheng; Li, Zhiyan] Wenzhou Med Univ, Taizhou Hosp, Enze Med Res Ctr, Linhai, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Hong, ZH; Hong, D (通讯作者)，Wenzhou Med Univ, Orthoped Dept, Taizhou Hosp, Linhai 317000, Peoples R China.
EM 0001hzh@163.com; hongdun@aliyun.com
RI Chen, Xinyi/LQK 7401 2024; Hong, Dun/IUP 2161 2023; Chen,
   Lihua/AAH 7898 2019
OI Hong, Dun/0000 0002 2094 4987; 
FU National Natural Science Foundation of China [81272059]; Medical and
   Health Technology Program of Zhejiang Province [2012KYA188]
FX National Natural Science Foundation of China, Grant/Award Number:
   81272059; Medical and Health Technology Program of Zhejiang Province,
   Grant/Award Number: 2012KYA188
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Baskaran R, 2016, BIOFACTORS, V42, P407, DOI 10.1002/biof.1286
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Guan GY, 2014, ENDOCRINE, V47, P764, DOI 10.1007/s12020 014 0186 1
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kubota T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2298
   Pan Y, 2009, J ETHNOPHARMACOL, V124, P98, DOI 10.1016/j.jep.2009.04.008
   Paschalis EP, 2017, BONE, V95, P41, DOI 10.1016/j.bone.2016.11.002
   Poornima P, 2014, BIOFACTORS, V40, P121, DOI 10.1002/biof.1115
   Reginster JY, 2014, BEST PRACT RES CL EN, V28, P809, DOI 10.1016/j.beem.2014.09.003
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thummuri D, 2019, J CELL PHYSIOL, V234, P443, DOI 10.1002/jcp.26575
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xing LP, 2013, BONE RES, V1, P336, DOI 10.4248/BR201304004
   Yang CX, 2015, CELL TISSUE RES, V362, P577, DOI 10.1007/s00441 015 2245 1
   Yun J, 2019, BIOCHIMIE, V157, P81, DOI 10.1016/j.biochi.2018.11.008
   Zhang XY, 2012, EUR J PHARMACOL, V677, P47, DOI 10.1016/j.ejphar.2011.12.035
NR 20
TC 17
Z9 20
U1 1
U2 52
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2019
VL 234
IS 12
BP 22960
EP 22971
DI 10.1002/jcp.28857
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IV6KF
UT WOS:000484376600129
PM 31127627
DA 2025 08 17
ER

PT J
AU Smith, MR
AF Smith, Matthew R.
TI RANK Ligand targeted Therapy: A Novel Approach to Prevent Bone Loss and
   Fractures in Men with Prostate Cancer
SO EUROPEAN UROLOGY SUPPLEMENTS
LA English
DT Article; Proceedings Paper
CT 24th Congress of the Annual European Association of Urology
CY MAR 17 21, 2009
CL Stockholm, SWEDEN
SP European Assoc Urol
DE Bone; Bone metastases; Breast cancer; Denosumab; Prostate cancer; RANK;
   RANK Ligand
ID ANDROGEN DEPRIVATION THERAPY; CONTROLLED TRIAL; ZOLEDRONIC ACID;
   DENOSUMAB; RISK; BISPHOSPHONATES; WOMEN
AB Context: The importance of bone loss associated with both prostate cancer (PCa) and its treatment is being increasingly recognised, and new options to manage this complication are in development.
   Objective: To assess the impact of androgen deprivation therapy (ADT) on bone and to outline recently reported and ongoing phase 3 studies of agents designed to prevent bone loss and fractures in men with PCa.
   Evidence acquisition: This article is based on a presentation at an Amgen sponsored satellite symposium held at the European Association of Urology Congress in Stockholm, Sweden, in March 2009.
   Evidence synthesis: ADT for PCa is associated with bone loss and an increased fracture risk. Several bisphosphonates have been shown to improve bone mineral density (BMD) during ADT, but their effects on treatment related fractures are unknown. Denosumab, a fully human monoclonal antibody to RANK Ligand, is being investigated for the management of bone loss associated with PCa. The results of a phase 3 randomised, placebo controlled trial of denosumab to prevent bone loss and fractures during ADT in men with PCa have recently been reported. Compared with placebo, denosumab (60 mg subcutaneously every 6 mo) significantly reduced the incidence of new vertebral fractures by 62% after 3 yr. Denosumab also increased BMD significantly at various skeletal sites, including the spine, hip, and wrist.
   Conclusions: ADT decreases BMD and increases fracture risk in men with PCa. A recent phase 3 study has demonstrated that denosumab increases BMD and significantly reduces the risk of new vertebral fractures in men with PCa. Two ongoing phase 3 studies are evaluating denosumab for the prevention and treatment of bone metastases in men with castration resistant prostate cancer. (C) 2009 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital
RP Smith, MR (通讯作者)，Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
EM smith.matthew@mgh.harvard.edu
CR Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Cauley J. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P220
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gennari L, 2007, DRUG AGING, V24, P361, DOI 10.2165/00002512 200724050 00002
   Greenspan SL, 2008, J CLIN ENDOCR METAB, V93, P2, DOI 10.1210/jc.2007 1402
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Holt G, 2008, J BONE JOINT SURG BR, V90B, P480, DOI 10.1302/0301 620X.90B4.20264
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656
   National Institute of Arthritis and Musculoskeletal and Skin Diseases, OST
   Nochowitz B, 2009, AM J THER, V16, P437, DOI 10.1097/MJT.0b013e31818637de
   Ryan C J, 2006, Minerva Urol Nefrol, V58, P119
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   SMITH M, 2008, AM ASS CANC RES ANN
   Smith MR, 2008, J UROLOGY, V179, P152, DOI 10.1016/j.juro.2007.08.137
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Stenzl A, 2009, EUR UROL SUPPL, V8, P823, DOI 10.1016/j.eursup.2009.09.001
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569 9056
EI 1878 1500
J9 EUR UROL SUPPL
JI Eur. Urol. Suppl.
PD NOV
PY 2009
VL 8
IS 11
BP 834
EP 838
DI 10.1016/j.eursup.2009.08.006
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Urology & Nephrology
GA 512ZF
UT WOS:000271290500004
DA 2025 08 17
ER

PT J
AU Guo, JW
   Wang, FX
   Hu, Y
   Luo, Y
   Wei, Y
   Xu, K
   Zhang, H
   Liu, H
   Bo, LM
   Lv, SL
   Sheng, SH
   Zhuang, XC
   Zhang, T
   Xu, C
   Chen, X
   Su, JC
AF Guo, Jiawei
   Wang, Fuxiao
   Hu, Yan
   Luo, Ying
   Wei, Yan
   Xu, Ke
   Zhang, Hao
   Liu, Han
   Bo, Lumin
   Lv, Shunli
   Sheng, Shihao
   Zhuang, Xinchen
   Zhang, Tao
   Xu, Can
   Chen, Xiao
   Su, Jiacan
TI Exosome based bone targeting drug delivery alleviates impaired
   osteoblastic bone formation and bone loss in inflammatory bowel diseases
SO CELL REPORTS MEDICINE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ADIPOGENIC DIFFERENTIATION; RISK; OSTEOPOROSIS;
   OSTEOPENIA; FRAGILITY; MODELS; ALTERS; IBD
AB Systematic bone loss is commonly complicated with inflammatory bowel diseases (IBDs) with unclear pathogenesis and uncertain treatment. In experimental colitis mouse models established by dextran sulfate sodium and IL 10 knockout induced with piroxicam, bone mass and quality are significantly decreased. Colitis mice demonstrate a lower bone formation rate and fewer osteoblasts in femur. Bone marrow mesenchymal stem/stromal cells (BMSCs) from colitis mice tend to differentiate into adipocytes rather than osteoblasts. Serum from patients with IBD promotes adipogenesis of human BMSCs. RNA sequencing reveals that colitis downregulates Wnt signaling in BMSCs. For treatment, exosomes with Golgi glycoprotein 1 inserted could carry Wnt agonist 1 and accumulate in bone via intravenous adminis tration. They could alleviate bone loss, promote bone formation, and accelerate fracture healing in colitis mice. Collectively, BMSC commitment in inflammatory microenvironment contributes to lower bone quan tity and quality and could be rescued by redirecting differentiation toward osteoblasts through bone  tar geted drug delivery.
C1 [Guo, Jiawei; Wang, Fuxiao; Hu, Yan; Wei, Yan; Xu, Ke; Zhang, Hao; Liu, Han; Su, Jiacan] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.
   [Guo, Jiawei; Luo, Ying; Sheng, Shihao; Zhuang, Xinchen; Zhang, Tao; Chen, Xiao; Su, Jiacan] Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai 200433, Peoples R China.
   [Bo, Lumin; Xu, Can] Naval Med Univ, Shanghai Changhai Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.
   [Su, Jiacan] Shanghai Univ, Organoid Res Ctr, Shanghai 200444, Peoples R China.
C3 Shanghai University; Naval Medical University; Naval Medical University;
   Shanghai University
RP Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.; Chen, X; Su, JC (通讯作者)，Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai 200433, Peoples R China.; Xu, C (通讯作者)，Naval Med Univ, Shanghai Changhai Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.; Su, JC (通讯作者)，Shanghai Univ, Organoid Res Ctr, Shanghai 200444, Peoples R China.
EM xxcc211@126.com; sirchenxiao@126.com; drsujiacan@163.com
RI ; Guo, Jiawei/JMH 1084 2023; Chen, Xiao/G 2310 2018; XU,
   CAN/HDN 6558 2022; Hu, Yan/AFZ 8800 2022; Xu, Ke/J 2781 2015; ZHANG,
   TAO/ITV 6162 2023; Su, Jiacan/N 7068 2019
OI Su, Jiacan/0000 0001 7080 263X; Guo, Jiawei/0000 0002 7613 932X; Shihao,
   Sheng/0000 0003 4624 1160; 
FU National Key Research and Development Plan [2018YFC2001500]; National
   Natural Science Foundation of China [81871099, 82172098, 82230071];
   Shanghai Rising Star Program [21QA1412000]
FX This work was financially supported by a grant (2018YFC2001500 to J.S.)
   from the National Key Research and Development Plan, the Key Project
   (82230071 to J.S.) from the National Natural Science Foundation of
   China, grants (81871099 to X.C. and 82172098 to J.S.) from the National
   Natural Science Foundation of China, and a grant (21QA1412000 to X.C.)
   from Shanghai Rising Star Program. The schematic diagrams and graphic
   abstract were created with BioRender.com .
CR Abdelmagid SM, 2015, LIFE SCI, V123, P25, DOI 10.1016/j.lfs.2014.11.011
   Agrawal Manasi, 2011, Curr Osteoporos Rep, V9, P251, DOI 10.1007/s11914 011 0077 9
   Ahn HJ, 2022, CLIN GASTROENTEROL H, V20, pE1022, DOI 10.1016/j.cgh.2021.06.026
   Al Saedi A, 2022, INFLAMM BOWEL DIS, V28, P259, DOI 10.1093/ibd/izab174
   Baek K, 2012, J CELL PHYSIOL, V227, P3603, DOI 10.1002/jcp.24064
   Bernstein CN, 2014, GUT, V63, P1369, DOI 10.1136/gutjnl 2013 306141
   Bischoff SC, 1997, AM J GASTROENTEROL, V92, P1157
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen J, 2020, STEM CELL REP, V15, P110, DOI 10.1016/j.stemcr.2020.06.007
   Chen SS, 2022, BIOACT MATER, V18, P15, DOI 10.1016/j.bioactmat.2022.01.048
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Chen YQ, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.240
   Ciucci T, 2015, GUT, V64, P1072, DOI 10.1136/gutjnl 2014 306947
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   da Silva SV, 2016, OBESITY, V24, P2522, DOI 10.1002/oby.21660
   de Oliveira PGFP, 2020, TRENDS ENDOCRIN MET, V31, P596, DOI 10.1016/j.tem.2020.05.005
   Dresner Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013
   Du D, 2018, BONE, V117, P161, DOI 10.1016/j.bone.2018.09.012
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Esposito M, 2019, NAT CELL BIOL, V21, P627, DOI 10.1038/s41556 019 0309 2
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Hamdani G, 2008, BONE, V43, P945, DOI 10.1016/j.bone.2008.06.018
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Haschka J, 2016, J CROHNS COLITIS, V10, P532, DOI 10.1093/ecco jcc/jjw012
   Holgersen K, 2015, INFLAMM BOWEL DIS, V21, P257, DOI 10.1097/MIB.0000000000000269
   Hu Y, 2021, EMBO REP, V22, DOI 10.15252/embr.202152481
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Jiang YY, 2022, NANO TODAY, V44, DOI 10.1016/j.nantod.2022.101487
   Kaplan GG, 2021, NAT REV GASTRO HEPAT, V18, P56, DOI 10.1038/s41575 020 00360 x
   Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020
   Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150
   Ke K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246323
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl 2019 318484
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   Leppkes M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104835
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Liu H, 2022, BIOACT MATER, V14, P169, DOI 10.1016/j.bioactmat.2021.12.006
   Liu S, 2021, PROTEIN CELL, V12, P331, DOI 10.1007/s13238 020 00745 3
   Ludvigsson JF, 2019, AM J GASTROENTEROL, V114, P291, DOI 10.14309/ajg.0000000000000062
   Meirow Y, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00206 z
   Merlotti D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052713
   Metzger CE, 2017, J BONE MINER RES, V32, P802, DOI 10.1002/jbmr.3027
   Munir H, 2017, STEM CELLS, V35, P1636, DOI 10.1002/stem.2622
   Narayanan SA, 2018, FASEB J, V32, P4848, DOI 10.1096/fj.201800178R
   Noack C, 2015, PROSTAG LEUKOTR ESS, V94, P91, DOI 10.1016/j.plefa.2014.11.008
   Oliveira SB, 2017, BMJ BRIT MED J, V357, DOI 10.1136/bmj.j2083
   Osorio EY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.846246
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rodríguez Bores L, 2007, WORLD J GASTROENTERO, V13, P6156, DOI 10.3748/wjg.v13.i46.6156
   Russell T, 2021, CELLS BASEL, V10, DOI 10.3390/cells10020341
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Seul KJ, 2011, J BONE MINER RES, V26, P341, DOI 10.1002/jbmr.208
   Silvennoinen J, 1996, GUT, V38, P223, DOI 10.1136/gut.38.2.223
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Soós B, 2022, NAT REV RHEUMATOL, V18, P249, DOI 10.1038/s41584 022 00764 w
   Szafors P, 2018, OSTEOPOROSIS INT, V29, P2389, DOI 10.1007/s00198 018 4586 6
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Tian JW, 2022, J CACHEXIA SARCOPENI, V13, P1785, DOI 10.1002/jcsm.12975
   Tilg H, 2008, GUT, V57, P684, DOI 10.1136/gut.2006.117382
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   Van Staa TP, 2003, GASTROENTEROLOGY, V125, P1591, DOI 10.1053/j.gastro.2003.09.027
   Wang CZ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02708 3
   Wang GY, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.113
   Wang LP, 2020, DRUG DISCOV TODAY, V25, P1919, DOI 10.1016/j.drudis.2020.09.001
   Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044
   Xue X, 2022, BIOACT MATER, V12, P327, DOI 10.1016/j.bioactmat.2021.10.029
   Xue X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009432
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Ye LN, 2013, SCI WORLD J, DOI 10.1155/2013/296470
   Zhou TY, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169 020 00270 0
   Zouali M, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102777
NR 78
TC 127
Z9 133
U1 22
U2 208
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2666 3791
J9 CELL REP MED
JI Cell Rep. Med.
PD JAN 17
PY 2023
VL 4
IS 1
AR 100881
DI 10.1016/j.xcrm.2022.100881
EA JAN 2023
PG 22
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 8K8QC
UT WOS:000923358400001
PM 36603578
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kaur, T
   John, AA
   Sharma, C
   Vashisht, NK
   Singh, D
   Kapila, R
   Kapila, S
AF Kaur, Taruneet
   John, Aijaz A.
   Sharma, Chandresh
   Vashisht, N. K.
   Singh, Divya
   Kapila, Rajeev
   Kapila, Suman
TI miR300 intervenes Smad3/β catenin/RunX2 crosstalk for therapy with an
   alternate function as indicative biomarker in osteoporosis
SO BONE
LA English
DT Article
DE Bone; Osteoporosis; miR300; Osteoblasts; Biomarker
ID GROWTH FACTOR BETA; OSTEOGENIC DIFFERENTIATION; PARATHYROID HORMONE;
   BIOACTIVE PEPTIDES; OXIDATIVE DAMAGE; WEB SERVER; BONE; SMAD3; RUNX2;
   EXPRESSION
AB The study reports a theranostic nature of rno miR 300 (miR300) in the osteoblast functioning, by influencing the signaling pathway(s), associated with osteoblast differentiation. Excessive expression of miR300 suppresses osteoblast functions. Smad3 served as a validated target for miR300, on homology based computational analysis and experimental testimony, which activates beta catenin, and subsequently potentiates Runx2. The impact of miR300 on the Smad3/beta catenin/Runx2 signaling interactions in the induction of osteoblast differentiation was scrutinized by immunoblotting and in vivo miRNA antagonism. Overexpression of miR300 in the rat calvarial osteoblasts decreases the protein levels of Smad3, beta catenin and Runx2. Besides, in vivo silencing of miR300 in the neonatal pups and adult rats by AntimiR300 abolishes the suppressing action of miR300 on the osteoblast differentiation and expressions of Smad3/beta catenin/Runx2 axis. MicroCT studies showed improved trabecular microarchitecture in the AntimiR300 transfected ovariectomised rat model compared to sham and negative control. Furthermore, expression levels of miR300 were evaluated in serum samples from an independent set of 30 osteoporotic patients followed by a Receiver Operating Characteristic Curve (ROC) based analysis for the diagnostic efficiency of miR300. Interestingly, the results exhibited high levels of miR300 (p < 0.0001) in the serum samples from osteoporotic patients relative to non osteoporotic subjects (AUC = 0.9689). Thus, miR300 negatively regulates the differentiation of osteoblasts by targeting crosstalk among Smad3, beta catenin and Runx2, unveiling an enormous ability to serve as a therapeutic target for bone related disorder management strategies. Besides, miR300 may potentially function for the diagnosis of osteoporosis as a non invasive biomarker.
C1 [Kaur, Taruneet; Kapila, Rajeev; Kapila, Suman] Natl Dairy Res Inst, Anim Biochem Div, Karnal 132001, Haryana, India.
   [John, Aijaz A.; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Sharma, Chandresh] Translat Hlth Sci & Technol Inst, Multidisciplinary Clin Translat Res, Faridabad 121001, Haryana, India.
   [Vashisht, N. K.] SMBT Inst Med Sci & Res Ctr, Dept Obstet & Gynaecol, Nasik 422403, Maharashtra, India.
C3 Indian Council of Agricultural Research (ICAR); ICAR   National Dairy
   Research Institute; Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Department of
   Biotechnology (DBT) India; Translational Health Science & Technology
   Institute (THSTI)
RP Kapila, S (通讯作者)，ICAR Natl Dairy Res Inst, Anim Biochem Div, Lab 142, Karnal 132001, Haryana, India.
EM skapila69@gmail.com
RI Bhat, Aijaz/HOI 0728 2023; Singh, Divya/IUM 7944 2023; Sharma,
   Chandresh/GXF 1910 2022; Kapila, Rajeev/AAN 1602 2021; Kapila,
   Suman/O 5288 2019
OI Bhat (Ph.D), Aijaz Ahmad John/0000 0002 8261 2742; Sharma,
   Chandresh/0000 0002 2813 302X; 
FU ICAR National Dairy Research Institute, Karnal
FX The authors are thankful to the Director, ICAR National Dairy Research
   Institute, Karnal, for the facility of funds and laboratory for
   performing the experiments. Authors sincerely thanks to all the human
   participants involved in the study.
CR Bai JP, 2019, ONCOL LETT, V18, P3743, DOI 10.3892/ol.2019.10712
   Brauer A, 2016, BIOTECH HISTOCHEM, V91, P161, DOI 10.3109/10520295.2015.1110254
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Cheung KSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098063
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2014, CURR OSTEOPOROS REP, V12, P385, DOI 10.1007/s11914 014 0237 9
   Ding Y, 2004, NUCLEIC ACIDS RES, V32, pW135, DOI 10.1093/nar/gkh449
   Duan LJ, 2018, CELL PHYSIOL BIOCHEM, V51, P1087, DOI 10.1159/000495489
   Hak DJ, 2018, INJURY, V49, P1461, DOI 10.1016/j.injury.2018.04.016
   Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252
   Issack Paul S, 2008, HSS J, V4, P66, DOI 10.1007/s11420 007 9072 1
   John AA, 2018, J MOL MED, V96, P427, DOI 10.1007/s00109 018 1624 y
   Kanis JA., 2007, WHO Technical Report: Assessment of Osteoporosis at the Primary Health care Level, P66
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lau Y.Y., 2018, TRANSCRIPTIONAL POST
   Li TF, 2006, J BIOL CHEM, V281, P21296, DOI 10.1074/jbc.M600514200
   Li ZJ, 2008, INT CONF SIGN PROCES, P64, DOI 10.1109/ICOSP.2008.4697069
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137
   Mada SB, 2017, HUM EXP TOXICOL, V36, P967, DOI 10.1177/0960327116678293
   Mada SB, 2017, NUTRITION, V43 44, P21, DOI 10.1016/j.nut.2017.06.010
   Mandourah AY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26525 y
   Nakasa T, 2015, CURR GENOMICS, V16, P441, DOI 10.2174/1389202916666150817213630
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Peng SP, 2016, MOL MED REP, V14, P623, DOI 10.3892/mmr.2016.5335
   Reddi S, 2018, EUR J NUTR, V57, P593, DOI 10.1007/s00394 016 1346 2
   Reddi S, 2016, EUR FOOD RES TECHNOL, V242, P2139, DOI 10.1007/s00217 016 2710 4
   Rennie W, 2014, NUCLEIC ACIDS RES, V42, pW114, DOI 10.1093/nar/gku376
   Sato M, 2006, ACTA DERM VENEREOL, V86, P300, DOI 10.2340/00015555 0101
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Shanmugam VP, 2015, INT DAIRY J, V42, P1, DOI 10.1016/j.idairyj.2014.11.001
   Song B, 2009, CYTOKINE GROWTH F R, V20, P379, DOI 10.1016/j.cytogfr.2009.10.010
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Takane K, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 101
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Thiruchelvam N, 2014, CASE REP ENDOCRINOL, V2014, DOI 10.1155/2014/802473
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   van den Bosch MH, 2016, RHEUMATOLOGY, V55, P1536, DOI 10.1093/rheumatology/kev402
   Vega OA, 2017, J CELL BIOCHEM, V118, P3662, DOI 10.1002/jcb.26011
   Vij R., 2017, ANIMAL PHYSL
   Vij R, 2016, FOOD CHEM, V190, P681, DOI 10.1016/j.foodchem.2015.05.121
   Wang H, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148 018 0492 1
   Wang JC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1309 7
   Wang YH, 2006, BIOTECHNOL PROGR, V22, P1697, DOI 10.1021/bp060274b
   Washimi Y, 2007, BONE, V41, P786, DOI 10.1016/j.bone.2007.06.019
   Weinstein A.J.B.J.P.F.M.B.D.X.F.W.R.S., 2001, J BONE MINER RES, V16
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zhang DM, 2014, J MOL NEUROSCI, V53, P637, DOI 10.1007/s12031 014 0230 x
   Zhang M, 2010, J BIOL CHEM, V285, P8703, DOI 10.1074/jbc.M109.093526
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
   Ziros PG, 2008, INT J BIOCHEM CELL B, V40, P1659, DOI 10.1016/j.biocel.2007.05.024
NR 52
TC 9
Z9 11
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2021
VL 143
AR 115603
DI 10.1016/j.bone.2020.115603
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PN8OY
UT WOS:000604733200014
PM 32827850
DA 2025 08 17
ER

PT J
AU Dave, JR
   Dewle, AM
   Mhaske, ST
   Phulpagar, PT
   Mathe, VL
   More, SE
   Khan, AA
   Murthy, AVR
   Datar, SS
   Jog, AJ
   Page, M
   Tomar, GB
AF Dave, Jay R.
   Dewle, Ankush M.
   Mhaske, Suhas T.
   Phulpagar, Prashant T.
   Mathe, Vikas L.
   More, Supriya E.
   Khan, Ayesha A.
   Murthy, Appala Venkata Ramana
   Datar, Suwarna S.
   Jog, Ajay J.
   Page, Megha
   Tomar, Geetanjali B.
TI Hydroxyapatite nanorods loaded with parathyroid hormone (PTH)
   synergistically enhance the net formative effect of PTH anabolic therapy
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Hydroxyapatite nanorod; Parathyroid hormone (PTH (1 34)); Osteoporosis;
   Targeted delivery; Synergistic anabolism; Nanocarrier
ID BONE; NANOPARTICLES; OSTEOPOROSIS; BISPHOSPHONATES; TERIPARATIDE;
   RECEPTORS; PH
AB Parathyroid hormone (PTH) has been a major contributor to the anabolic therapy for osteoporosis, but its delivery to bone without losing activity and avoiding adverse local effects remain a challenge. Being the natural component of bone, use of hydroxyapatite for this purpose brings a major breakthrough in synergistic anabolism. This study focuses on synthesis, characterization and evaluation of in vitro and in vivo efficacy of PTH (1 34) adsorbed hydroxyapatite nanocarrier for synergistic enhancement in the anabolic activity of PTH for bone regeneration. The negative zeta potential of this nanocarrier facilitated its affinity to the Ca2+ rich bone tissue and solubilization at low pH enhanced specific delivery of PTH to the resorption pits in osteoporotic bone. In this process, PTH retained its anabolic effect and at the same time an increase in bone mineral content indicated enhancement of the net formative effect of the PTH anabolic therapy. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Dave, Jay R.; Dewle, Ankush M.; Mhaske, Suhas T.; Phulpagar, Prashant T.; Tomar, Geetanjali B.] Savitribai Phule Pune Univ, Inst Bioinformat & Biotechnol, Pune, Maharashtra, India.
   [Mathe, Vikas L.; More, Supriya E.] Savitribai Phule Pune Univ, Dept Phys, Pune, Maharashtra, India.
   [Khan, Ayesha A.] Savitribai Phule Pune Univ, Dept Chem, Pune, Maharashtra, India.
   [Murthy, Appala Venkata Ramana; Datar, Suwarna S.] Deemed Univ, Def Inst Adv Technol, Dept Appl Phys, Pune, Maharashtra, India.
   [Jog, Ajay J.; Page, Megha] Deenanath Mangeshkar Hosp & Res Ctr, Dept Dent, Pune, Maharashtra, India.
C3 Savitribai Phule Pune University; Savitribai Phule Pune University;
   Savitribai Phule Pune University; Defence Research & Development
   Organisation (DRDO); Defence Institute of Advanced Technology (DIAT)
RP Tomar, GB (通讯作者)，Savitribai Phule Pune Univ, Inst Bioinformat & Biotechnol, Pune, Maharashtra, India.
EM geetanjalitomar13@gmail.com
RI ; Tomar, Geetanjali/AAK 8202 2020; Dave, Jay/Y 6306 2018; Datar,
   Suwarna/JWP 4763 2024; Dave, Jay/AAT 6558 2020; Khan,
   Ayesha/JRW 9770 2023
OI Mathe, Vikas/0000 0001 7408 9106; Tomar, Geetanjali/0000 0001 9114 4699;
   Venkata Ramana Murthy, Appala/0000 0003 4875 9991; Dave,
   Jay/0000 0002 9940 515X; Mhaske, Suhas/0000 0002 5672 1355; 
FU DST INSPIRE, Govt. of India [IFA13 LSBM73]; UPE [University with
   Potential for Excellence] II [UGC(262)(A)(1)]; Board of College and
   University Development (BCUD); UPE II, SPPU
FX Dr. Geetanjali B. Tomar and Ankush M. Dewle thank DST INSPIRE, Govt. of
   India [grant number, IFA13 LSBM73], for the fellowship and the research
   grant. Jay R. Dave and Suhas T. Mhaske thank UPE [University with
   Potential for Excellence, grant number UGC(262)(A)(1)] II funding, for
   the fellowship. Dr. Geetanjali B. Tomar and Dr. Vikas L. Mathe also
   thank the research support received from Board of College and University
   Development (BCUD) and UPE II, SPPU. Dr. Ajay Jog, Dr. Megha Page and
   Dr. Geetanjali B. Tomar thank Deenanath Mangeshkar Hospital and Research
   Centre (DMHRC), Pune for the IEC approval for human gingival tissue
   samples. The authors acknowledge confocal microscopy facility at
   National Centre for Cell Science (NCCS), Savitribai Phule Pune
   University (SPPU) Campus, Pune. We extend appreciation to Preclinical
   Research and Development Organization (PRADO), Pune for providing us the
   animal facility and the necessary infrastructure.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   [Anonymous], 2018, Orthopedic Biomaterials: Advances and Applications, DOI [10.1007/978 3 319 73664 8, DOI 10.1007/978 3 319 73664 8]
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Berzina Cimdina L, 2012, INFRARED SPECTROSCOPY   MATERIALS SCIENCE, ENGINEERING AND TECHNOLOGY, P123
   Bhatia S., 2016, NANOPARTICLES TYPES
   Bidwell JP, 2012, CRIT REV EUKAR GENE, V22, P205, DOI 10.1615/CritRevEukarGeneExpr.v22.i3.40
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Chandrasekaran A., 2013, International Journal of Physical Sciences, V8, P1639, DOI DOI 10.5897/IJPS2013.3990
   Maia ALC, 2018, J DRUG TARGET, V26, P592, DOI 10.1080/1061186X.2017.1401078
   Gentile P, 2015, INT J MOL SCI, V16, P20492, DOI 10.3390/ijms160920492
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hwang SJ, 2016, MACROMOL RES, V24, P623, DOI 10.1007/s13233 016 4094 5
   Jafari S., 2015, J. Mol. Pharm. Org. Process Res, V03, P1, DOI DOI 10.4172/2329 9053.1000 118
   Jahromi MT, 2015, BIOMINERALIZATION HY
   Jelen E K., 2012, The formulation of a bone targeted drug delivery system of poly (glycolic acid) poly (ethylene glycol) coated hydroxyapatite nanoparticles for the delivery of statins
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Lee M, 2009, CURR OPIN NEPHROL HY, V18, P298, DOI 10.1097/MNH.0b013e32832c2264
   Lewiecki EM, 2010, THER ADV CHRONIC DIS, V1, P115, DOI 10.1177/2040622310374783
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   McGreevy C, 2011, THER ADV DRUG SAF, V2, P159, DOI 10.1177/2042098611411012
   Mohammad NF, 2014, REV ADV MATER SCI, V38, P138
   Mora Raimundo P, 2017, AIMS BIOENG, V4, P259, DOI 10.3934/bioeng.2017.2.259
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Narayanan D, 2013, MOL PHARMACEUT, V10, P4159, DOI 10.1021/mp400184v
   Narayanan D, 2012, J BIOMED NANOTECHNOL, V8, P98, DOI 10.1166/jbn.2012.1367
   Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081
   Noor Z, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/679025
   Ponnapakkam T, 2011, CALCIFIED TISSUE INT, V88, P511, DOI 10.1007/s00223 011 9485 1
   Samira M., 2012, BIOPHYS CHEM, V3, P278, DOI [10.4236/jbpc.2012.34033, DOI 10.4236/jbpc.2012.34033]
   SHIBUTANI T, 1993, J BONE MINER RES, V8, P331
   Sooksaen P., 2010, Science Journal Ubonratchathani University, V1, P20
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Tomar GB, 2010, BIOCHEM BIOPH RES CO, V393, P377, DOI 10.1016/j.bbrc.2010.01.126
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Yang Y, 2017, DRUG DELIV TRANSL RE, V7, P482, DOI 10.1007/s13346 017 0407 2
   Yewle JN, 2013, BIOMATERIALS, V34, P3141, DOI 10.1016/j.biomaterials.2013.01.059
   Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006 0572
   Zyman ZZ, 2013, PROCESS APPL CERAM, V7, P93, DOI 10.2298/PAC1302093Z
NR 40
TC 18
Z9 20
U1 1
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2019
VL 15
IS 1
BP 218
EP 230
DI 10.1016/j.nano.2018.10.003
PG 13
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA HD5CY
UT WOS:000452546700020
PM 30343014
DA 2025 08 17
ER

PT J
AU de Vrieze, E
   Zethof, J
   Schulte Merker, S
   Flik, G
   Metz, JR
AF de Vrieze, Erik
   Zethof, Jan
   Schulte Merker, Stefan
   Flik, Gert
   Metz, Juriaan R.
TI Identification of novel osteogenic compounds by an ex vivo sp7:
   luciferase zebrafish scale assay
SO BONE
LA English
DT Article
DE Elasmoid scales; Bone; Zebrafish; Osteoblast; Sp7; Drug design
ID TRANSCRIPTION FACTOR; ELASMOID SCALES; DANIO RERIO; BONE;
   MINERALIZATION; MODEL; PROTEIN; EXPRESSION; CALCIUM; OSTERIX
AB Tight interactions among different cell types contributing to bone formation are of key importance in the maintenance of bone homeostasis. Based on the high similarity in responses to (anti)osteogenic signals between zebrafish scales and mammalian bone, we developed and validated a model to screen large numbers of compounds using ex vivo cultured scales of a sp7:luciferase transgenic zebrafish. This model combines the high predictive value of explant cultures with quick, sensitive, and quantifiable readout converging the effects via various pathways including WNT signaling, to SP7/osterix promoter activity. Sp7 is pivotal in osteoblast differentiation and activity and its promoter activity provides an excellent surrogate for sp7 expression. Bmp 2a was shown to dose dependently increase sp7 driven luciferase activity ex vivo. Next, we identified novel effects on bone for 51.7% of the compounds from a small library of WNT signaling modulators, including a strong osteogenic effect for niclosamide. From all previously characterized compounds, the effect on bone was correctly predicted for 70% of compounds, resulting in a 7% false positive  and 21% false negative rate. The proposed sp7:luciferase zebrafish scale model is unique, powerful and efficient new tool to assess compounds with osteogenic effects, prior to further testing in rodents. (c) 2015 Elsevier Inc. All rights reserved.
C1 [de Vrieze, Erik; Zethof, Jan; Flik, Gert; Metz, Juriaan R.] Radboud Univ Nijmegen, Dept Organismal Anim Physiol, Inst Water & Wetland Res, Fac Sci, NL 6525 AJ Nijmegen, Netherlands.
   [Schulte Merker, Stefan] Hubrecht Inst KNAW, NL 3584 CT Utrecht, Netherlands.
   [Schulte Merker, Stefan] UMC Utrecht, NL 3584 CT Utrecht, Netherlands.
   [Schulte Merker, Stefan] WWU Munster, Inst Cardiovasc Organogenesis & Regenerat, Fac Med, D 48149 Munster, Germany.
   [Schulte Merker, Stefan] Univ Munster, Cells In Mot Cluster Excellence EXC CiM 1003, Munster, Germany.
C3 Radboud University Nijmegen; Royal Netherlands Academy of Arts &
   Sciences; Hubrecht Institute (KNAW); University of Munster; University
   of Munster
RP de Vrieze, E (通讯作者)，Radboudumc, POB 9101,Route 855, NL 6500 HB Nijmegen, Netherlands.
EM e.devrieze@science.ru.nl
RI Metz, Juriaan/A 3290 2012; de Vrieze, Erik/B 2541 2014; Flik,
   Gert/C 8229 2011
OI de Vrieze, Erik/0000 0003 3448 3269; 
FU Smart Mix Program of the Netherlands Ministry of Economic Affairs;
   Netherlands Ministry of Education, Culture and Science [SSM06010]
FX This work was supported by the Smart Mix Program of the Netherlands
   Ministry of Economic Affairs and the Netherlands Ministry of Education,
   Culture and Science [SSM06010 to GF and SSM].
CR [Anonymous], 2006, How to report statistics in medicine
   Apschner A, 2014, DIS MODEL MECH, V7, P811, DOI 10.1242/dmm.015693
   Auld DS, 2004, ASSAY GUIDANCE MANUA
   Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bellingham MC, 2011, CNS NEUROSCI THER, V17, P4, DOI 10.1111/j.1755 5949.2009.00116.x
   Brakspear Karen S, 2012, Front Endocrinol (Lausanne), V3, P97, DOI 10.3389/fendo.2012.00097
   Calamini B, 2012, NAT CHEM BIOL, V8, P185, DOI 10.1038/nchembio.763
   Chellaiah MA, 2009, J CELL PHYSIOL, V220, P382, DOI 10.1002/jcp.21777
   Chen MY, 2009, BIOCHEMISTRY US, V48, P10267, DOI 10.1021/bi9009677
   Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756 3282(97)00295 0
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   de Vrieze E, 2010, J APPL ICHTHYOL, V26, P210, DOI 10.1111/j.1439 0426.2010.01407.x
   de Vrieze E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089347
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167 6296(02)00126 1
   Enders GH, 2009, J CLIN INVEST, V119, P758, DOI 10.1172/JCI38973
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   FLIK G, 1986, J EXP BIOL, V120, P249
   Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00 0594fje
   Hatta M, 2006, INT J MOL MED, V17, P425
   Ignowski JM, 2004, BIOTECHNOL BIOENG, V86, P827, DOI 10.1002/bit.20059
   Kaitin KI, 2010, CLIN PHARMACOL THER, V87, P356, DOI 10.1038/clpt.2009.293
   Koumans JTM, 1996, IN VITRO CELL DEV AN, V32, P612
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lee CH, 2012, EUR J PHARMACOL, V676, P26, DOI 10.1016/j.ejphar.2011.12.001
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Metz JR, 2014, J APPL ICHTHYOL, V30, P671, DOI 10.1111/jai.12513
   Metz JR, 2012, J APPL ICHTHYOL, V28, P382, DOI 10.1111/j.1439 0426.2012.01990.x
   Mitchell RE, 2013, OSTEOARTHR CARTILAGE, V21, P269, DOI 10.1016/j.joca.2012.11.004
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pasqualetti S, 2012, J MOL HISTOL, V43, P589, DOI 10.1007/s10735 012 9425 z
   PERSSON P, 1994, FISH PHYSIOL BIOCHEM, V13, P379, DOI 10.1007/BF00003417
   Pombinho AR, 2004, CELL TISSUE RES, V315, P393, DOI 10.1007/s00441 003 0830 1
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Redruello B, 2005, J BONE MINER RES, V20, P682, DOI 10.1359/JBMR.041201
   Renn J, 2006, PROTOPLASMA, V229, P209, DOI 10.1007/s00709 006 0215 x
   Renn J, 2009, DEV DYNAM, V238, P241, DOI 10.1002/dvdy.21836
   Rissanen JP, 2010, EXPERT OPIN DRUG DIS, V5, P1163, DOI 10.1517/17460441.2010.532484
   Roth J, 2011, BIOORG MED CHEM LETT, V21, P7180, DOI 10.1016/j.bmcl.2011.09.077
   Rotllant J, 2005, REGUL PEPTIDES, V132, P33, DOI 10.1016/j.regpep.2005.08.004
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Suster Maximiliano L, 2009, Methods Mol Biol, V561, P41, DOI 10.1007/978 1 60327 019 9_3
   Suzuki N, 2000, PEPTIDES, V21, P115, DOI 10.1016/S0196 9781(99)00181 3
   Suzuki N, 2011, BONE, V48, P1186, DOI 10.1016/j.bone.2011.02.004
   ten Dijke P, 2008, J BONE JOINT SURG AM, V90A, P31, DOI 10.2106/JBJS.G.01183
   To TT, 2012, DEVELOPMENT, V139, P141, DOI 10.1242/dev.071035
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Westerfield M., 2010, ZEBRAFISH BOOK GUIDE, V4th ed.
   Witten PE, 2001, J MORPHOL, V250, P197, DOI 10.1002/jmor.1065
   Wu XH, 2010, MICROSC RES TECHNIQ, V73, P540, DOI 10.1002/jemt.20792
   Yamaguchi M, 2009, INT J MOL MED, V23, P297, DOI 10.3892/ijmm_00000131
   Yoshikubo H, 2005, LIFE SCI, V76, P2699, DOI 10.1016/j.lfs.2004.10.063
NR 56
TC 33
Z9 33
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2015
VL 74
BP 106
EP 113
DI 10.1016/j.bone.2015.01.006
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CD6HE
UT WOS:000351189400012
PM 25600250
OA Green Published
DA 2025 08 17
ER

PT J
AU Sarem, M
   Heizmann, M
   Barbero, A
   Martin, I
   Shastri, VP
AF Sarem, Melika
   Heizmann, Miriam
   Barbero, Andrea
   Martin, Ivan
   Shastri, V. Prasad
TI Hyperstimulation of CaSR in human MSCs by biomimetic apatite inhibits
   endochondral ossification via temporal down regulation of PTH1R
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone remodeling; calcium phosphate; regenerative medicine; stem cell
   niche; Wnt signaling
ID CALCIUM SENSING RECEPTOR; HORMONE RELATED PEPTIDE; EXTRACELLULAR
   CA2+ SENSING RECEPTOR; ACTIVATED PROTEIN KINASE; MESENCHYMAL STEM CELLS;
   BONE MARROW; OSTEOBLAST DIFFERENTIATION; MINERALIZATION; EXPRESSION;
   BIOLOGY
AB In adult bone injuries, periosteum derived mesenchymal stem/stromal cells (MSCs) form bone via endochondral ossification (EO), whereas those from bone marrow (BM)/endosteum form bone primarily through intramembranous ossification (IMO). We hypothesized that this phenomenon is influenced by the proximity of MSCs residing in the BM to the trabecular bone microenvironment. Herein, we investigated the impact of the bone mineral phase on human BMderived MSCs' choice of ossification pathway, using a biomimetic bone like hydroxyapatite (BBHAp) interface. BBHAp induced hyper stimulation of extracellular calcium sensing receptor (CaSR) and temporal down regulation of parathyroid hormone 1 receptor (PTH1R), leading to inhibition of chondrogenic differentiation of MSCs even in the presence of chondroinductive factors, such as transforming growth factor beta 1 (TGF beta 1). Interestingly rescuing PTH1R expression using human PTH fragment (1 34) partially restored chondrogenesis in the BBHAp environment. In vivo studies in an ectopic site revealed that the BBHAp interface inhibits EO and strictly promotes IMO. Furthermore, CaSR knockdown (CaSR KD) disrupted the bone forming potential of MSCs irrespective of the absence or presence of the BBHAp interface. Our findings confirm the expression of CaSR in human BM derived MSCs and unravel a prominent role for the interplay between CaSR and PTH1R in regulating MSC fate and the choice of pathway for bone formation.
C1 [Sarem, Melika; Heizmann, Miriam; Shastri, V. Prasad] Univ Freiburg, Inst Macromol Chem, D 79104 Freiburg, Germany.
   [Sarem, Melika; Shastri, V. Prasad] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, D 79104 Freiburg, Germany.
   [Sarem, Melika; Heizmann, Miriam; Shastri, V. Prasad] Helmholtz Virtual Inst Multifunct Biomat Med, D 14513 Teltow, Germany.
   [Barbero, Andrea; Martin, Ivan] Univ Basel, Univ Hosp Basel, Dept Biomed, CH 4031 Basel, Switzerland.
C3 University of Freiburg; University of Freiburg; University of Basel
RP Shastri, VP (通讯作者)，Univ Freiburg, Inst Macromol Chem, D 79104 Freiburg, Germany.; Shastri, VP (通讯作者)，Univ Freiburg, BIOSS Ctr Biol Signaling Studies, D 79104 Freiburg, Germany.; Shastri, VP (通讯作者)，Helmholtz Virtual Inst Multifunct Biomat Med, D 14513 Teltow, Germany.
EM prasad.shastri@gmail.com
RI ; Martin, Ivan/K 9286 2016; Barbero, Andrea/A 6469 2008
OI Sarem, Melika/0000 0002 1656 4025; Barbero, Andrea/0000 0001 5252 789X;
   Martin, Ivan/0000 0001 6493 0432
FU Helmholtz Zentrum Geesthacht through the Helmholtz Virtual Institute on
   Multifunctional Biomaterials for Medicine; German Federal and State
   governments [EXC 294]; Swiss National Foundation Sinergia Grant
   [CRSII3_136179]; Swiss National Science Foundation (SNF) [CRSII3_136179]
   Funding Source: Swiss National Science Foundation (SNF)
FX We thank Dr. Daniel Vonwil for the mu CT measurements; Dr. Wouter
   Habraken for Raman analysis; Dr. Ralf Thomann for assistance with SEM;
   Francine Wolf for her assistance with the ALU staining; and Esther
   Kohler, Vincent Ahmadi, Kate Kutsenok, and Laurent Starck for technical
   assistance. This work was funded by a grant from Helmholtz Zentrum
   Geesthacht through the Helmholtz Virtual Institute on Multifunctional
   Biomaterials for Medicine, the excellence initiative of the German
   Federal and State governments (EXC 294), and a Swiss National
   Foundation Sinergia Grant (CRSII3_136179).
CR Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092 8674(93)90680 O
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bassett JHD, 2010, P NATL ACAD SCI USA, V107, P7604, DOI 10.1073/pnas.0911346107
   Brown E. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P412
   Brown EM, 2013, BEST PRACT RES CL EN, V27, P333, DOI 10.1016/j.beem.2013.02.006
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15
   Budz J A, 1987, Adv Dent Res, V1, P314
   Chang W., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P410
   Chang WH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159945
   Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003 1127
   Chen ZF, 2009, CRYST GROWTH DES, V9, P2816, DOI 10.1021/cg900070v
   Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030
   Cianferotti L, 2015, OSTEOPOROSIS INT, V26, P2055, DOI 10.1007/s00198 015 3203 1
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Dvorak Ewell MM, 2011, J BONE MINER RES, V26, P2935, DOI 10.1002/jbmr.520
   FARBER JL, 1981, LIFE SCI, V29, P1289, DOI 10.1016/0024 3205(81)90670 6
   Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370
   Guntur Anyonya R, 2013, Bonekey Rep, V2, P437, DOI 10.1038/bonekey.2013.171
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   JACENKO O, 1995, DEV DYNAM, V202, P13, DOI 10.1002/aja.1002020103
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319
   Karaplis AC, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P53, DOI 10.1016/B978 0 12 373884 4.00025 2
   Kawamura K, 2005, EXP HEMATOL, V33, P865, DOI 10.1016/j.exphem.2005.05.010
   Kifor O, 2003, J CLIN ENDOCR METAB, V88, P4455, DOI 10.1210/jc.2002 021427
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Magno AL, 2011, ENDOCR REV, V32, P3, DOI 10.1210/er.2009 0043
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Maria CS, 2016, SEMIN CELL DEV BIOL, V49, P11, DOI 10.1016/j.semcdb.2015.12.004
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203 1041
   Mendes SC, 2005, DEVELOPMENT, V132, P1127, DOI 10.1242/dev.01615
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431
   Riccardi D, 2013, BEST PRACT RES CL EN, V27, P443, DOI 10.1016/j.beem.2013.02.010
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Rodriguez L, 2005, ENDOCRINOLOGY, V146, P4597, DOI 10.1210/en.2005 0437
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Samavedi S, 2013, ACTA BIOMATER, V9, P8037, DOI 10.1016/j.actbio.2013.06.014
   Sarem M, 2017, ADV MATER, V29, DOI 10.1002/adma.201701629
   Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Staines KA, 2014, J BONE MINER METAB, V32, P240, DOI 10.1007/s00774 013 0493 2
   Stevens MM, 2005, P NATL ACAD SCI USA, V102, P11450, DOI 10.1073/pnas.0504705102
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Takaoka S, 2010, HORM METAB RES, V42, P627, DOI 10.1055/s 0030 1255091
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Tfelt Hansen J, 2005, CRIT REV CL LAB SCI, V42, P35, DOI 10.1080/10408360590886606
   Theman TA, 2009, CURR PHARM BIOTECHNO, V10, P289, DOI 10.2174/138920109787847538
   van Amerongen R, 2012, DEV BIOL, V369, P101, DOI 10.1016/j.ydbio.2012.06.020
   Vetterkind S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 65
   Viti F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148173
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Wang JG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053400, 10.1371/journal.pone.0070519, 10.1371/journal.pone.0063924]
   Wang YM, 2013, BONE RES, V1, P249, DOI 10.4248/BR201303003
   Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323
   Wopenka B, 2005, MAT SCI ENG C BIO S, V25, P131, DOI 10.1016/j.msec.2005.01.008
   Zhang Y, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018 014 0068 5
NR 75
TC 25
Z9 26
U1 2
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 3
PY 2018
VL 115
IS 27
BP E6135
EP E6144
DI 10.1073/pnas.1805159115
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GL4GH
UT WOS:000437107000008
PM 29915064
OA Green Published
DA 2025 08 17
ER

PT J
AU Wu, WB
   Xiao, ZX
   Chen, Y
   Deng, YN
   Zeng, DL
   Liu, Y
   Huang, F
   Wang, JL
   Liu, YY
   Bellanti, JA
   Rong, LM
   Zheng, SG
AF Wu, Wenbin
   Xiao, Zexiu
   Chen, Ye
   Deng, Yanan
   Zeng, Donglan
   Liu, Yan
   Huang, Feng
   Wang, Julie
   Liu, Yanying
   Bellanti, Joseph A.
   Rong, Limin
   Zheng, Song Guo
TI CD39 Produced from Human GMSCs Regulates the Balance of Osteoclasts and
   Osteoblasts through the Wnt/β Catenin Pathway in Osteoporosis
SO MOLECULAR THERAPY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; COLLAGEN INDUCED ARTHRITIS; TRANS RETINOIC ACID;
   BONE FORMATION; TH17 CELLS; T CELLS; SUPPRESS OSTEOCLASTOGENESIS;
   OSTEOGENIC DIFFERENTIATION; STROMAL CELLS; TNF ALPHA
AB Osteoporosis is a disease in which the density and quality of bone are reduced, causing bones to become weak and so brittle that a fall or even mild stresses can cause a fracture. Current drug treatment consists mainly of antiresorptive agents that are unable to stimulate new bone formation. Our recent studies have defined a critical role of gingiva derived mesenchymal stem cells (GMSCs) in attenuating autoimmune arthritis through inhibition of osteoclast formation and activities, but it remains to be ruled out whether the administration of GMSCs to patients with osteoporosis could also regulate osteoblasts and eventually affect bone formation and protection. With the use of an ovariectomized mouse model, we here demonstrated that adoptive transfer of GMSCs regulated the balance of osteoclasts and osteoblasts, eventually contributing to dynamic bone formation. Validation by RNA sequencing (RNA seq), single cell sequencing, revealed a unique population of CD39(+) GMSC that plays an important role in promoting bone formation. We further demonstrated that CD39 produced from GMSC exerted its osteogenic capacity through the Wnt/beta catenin pathway. Our results not only establish a previously unidentified role and mechanism of GMSC for bone promotion but also a potential therapeutic target for management of patients with osteoporosis and other bone loss conditions.
C1 [Wu, Wenbin; Xiao, Zexiu; Chen, Ye; Deng, Yanan; Zeng, Donglan; Liu, Yan; Huang, Feng] Sun Yat Sen Univ, Dept Clin Immunol Ctr, Affiliated Hosp 3, Guangzhou 510630, Peoples R China.
   [Chen, Ye; Wang, Julie; Zheng, Song Guo] Ohio State Univ, Dept Internal Med, Coll Med, Columbus, OH 43210 USA.
   [Chen, Ye; Wang, Julie; Zheng, Song Guo] Wexner Med Ctr, Columbus, OH 43210 USA.
   [Liu, Yanying] Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Bellanti, Joseph A.] Georgetown Univ, Dept Pediat, Med Ctr, Washington, DC 20057 USA.
   [Bellanti, Joseph A.] Georgetown Univ, Dept Microbiol Immunol, Med Ctr, Washington, DC 20057 USA.
   [Bellanti, Joseph A.] Georgetown Univ, Int Ctr Interdisciplinary Studies Immunol ICISI, Med Ctr, Washington, DC 20057 USA.
   [Wu, Wenbin; Rong, Limin] Sun Yat Sen Univ, Dept Spine Surg, Affiliated Hosp 3, Guangzhou 510630, Peoples R China.
C3 Sun Yat Sen University; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University; Peking
   University; Georgetown University; Georgetown University; Georgetown
   University; Sun Yat Sen University
RP Zheng, SG (通讯作者)，Ohio State Univ, Dept Internal Med, Coll Med, Columbus, OH 43210 USA.; Zheng, SG (通讯作者)，Wexner Med Ctr, Columbus, OH 43210 USA.; Rong, LM (通讯作者)，Sun Yat Sen Univ, Dept Spine Surg, Affiliated Hosp 3, Guangzhou 510630, Peoples R China.
EM ronglm@mail.sysu.edu.cn; songguo.zheng@osumc.edu
RI ; huang, feng/HSF 2323 2023; ZeXiu, Xiao/AAD 7512 2020; Li,
   Ming/H 5746 2019
OI Rong, Limin/0000 0003 0373 7393; chen, ye/0000 0002 3611 163X; 
FU National Key RAMP;D Program of China [2017YFA0105801]; Chinese Natural
   Science Foundation [81901657]; NIH [R61 (AR AR073409)]
FX W.W., F.H., and L.R. were, in part, supported by a grant from the
   National Key R&D Program of China (2017YFA0105801). Z.X. was, in part,
   supported by a grant from the Chinese Natural Science Foundation
   (81901657). S.G.Z. and J.W. were, in part, supported by NIH R61 (AR
   AR073409).
CR Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bozec A, 2017, CURR OSTEOPOROS REP, V15, P121, DOI 10.1007/s11914 017 0356 1
   Buchwald ZS, 2015, J BONE MINER RES, V30, P1508, DOI 10.1002/jbmr.2472
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   Chiu LH, 2014, BIOMATERIALS, V35, P2680, DOI 10.1016/j.biomaterials.2013.12.005
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   D'Alimonte I, 2011, J BIOL REG HOMEOS AG, V25, P57
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Granstein RD, 2002, NAT MED, V8, P336, DOI 10.1038/nm0402 336
   Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Gulati GS, 2018, NAT PROTOC, V13, P1294, DOI 10.1038/nprot.2018.041
   Huang F, 2018, CURR STEM CELL RES T, V13, P345, DOI 10.2174/1574888X13666180220141114
   Huang F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00068
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Kim DH, 2019, J ORTHOP SURG HONG K, V27, P1, DOI 10.1177/2309499019831480
   Koide M, 2017, J BONE MINER RES, V32, P2074, DOI 10.1002/jbmr.3175
   Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis 2011 201052
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Lefèvre S, 2009, NAT MED, V15, P1414, DOI 10.1038/nm.2050
   Li HJ, 2019, AM J TRANSL RES, V11, P5673
   Li ZY, 2014, J BIOL CHEM, V289, P26872, DOI 10.1074/jbc.M114.586651
   Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev immunol 051116 052406
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Liu ZM, 2015, CELL MOL IMMUNOL, V12, P553, DOI 10.1038/cmi.2014.133
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lu L, 2014, P NATL ACAD SCI USA, V111, pE3432, DOI 10.1073/pnas.1408780111
   Luo Y, 2019, EBIOMEDICINE, V43, P620, DOI 10.1016/j.ebiom.2019.04.058
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Papadopoulou A, 2012, ANN RHEUM DIS, V71, P1733, DOI 10.1136/annrheumdis 2011 200985
   Park YJ, 2019, P NATL ACAD SCI USA, V116, P3106, DOI 10.1073/pnas.1810254116
   Schiavon V, 2019, P NATL ACAD SCI USA, V116, P6298, DOI 10.1073/pnas.1812471116
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Su WR, 2011, STEM CELLS, V29, P1849, DOI 10.1002/stem.738
   Su WR, 2017, J MOL CELL BIOL, V9, P289, DOI 10.1093/jmcb/mjx022
   Su WR, 2015, J ALLERGY CLIN IMMUN, V136, P423, DOI 10.1016/j.jaci.2014.12.1926
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Yang SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00784
   Yu MC, 2018, EMBO REP, V19, P156, DOI 10.15252/embr.201744421
   Zaiss MM, 2010, ARTHRITIS RHEUM US, V62, P2328, DOI 10.1002/art.27535
   Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318
   Zhang W, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14979 5
   Zhang X, 2019, MOL THER, V27, P1963, DOI 10.1016/j.ymthe.2019.07.014
   Zhang XM, 2019, AM J CLIN EXP IMMUNO, V8, P21
   Zhang XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00878
   Zhang XM, 2016, AM J TRANSL RES, V8, P4017
   Zhao JZ, 2019, AM J TRANSL RES, V11, P7627
   Zhao J, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1262 5
   Zhao RQ, 2013, EUR J CLIN INVEST, V43, P1195, DOI 10.1111/eci.12158
NR 64
TC 52
Z9 56
U1 6
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD JUN 3
PY 2020
VL 28
IS 6
BP 1518
EP 1532
DI 10.1016/j.ymthe.2020.04.003
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA LW0SO
UT WOS:000538856900014
PM 32304668
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wang, Y
   Wang, WL
   Sun, AJ
   Shen, JX
AF Wang Yang
   Wang Weilu
   Sun Aijun
   Shen Jianxiong
TI A Systematic Approach to Integrate Traditional Chinese Medicine and
   Western Medicines by Studying Comorbidity Mechanism of Adolescent
   Idiopathic Scoliosis and Primary Amenorrhea
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE adolescent idiopathic scoliosis; integrated traditional Chinese and
   Western medicine; network biology; primary amenorrhea
AB This study was planned to explore the potential mechanism of comorbidity between adolescent idiopathic scoliosis (AIS) and primary amenorrhea (PA) by network biology method. In the first step, the Genecards database was searched to obtain the disease targets of AIS, PA and Mayer rokitans Kuster Hauser syndrome (MRKH). In the second step, the Venn diagram was used to correlate the targets of AIS, PA and MRKH to obtain common targets. The third step is to submit the common targets to the String platform, build a protein protein interaction network (PPI), and click on the Cluster button for clustering. Finally, use String plug in analysis to perform biological enrichment and pathway analysis of key targets, download biological processes, molecular functions, and cellular components (Gene Ontology) TSV files, and download KEGG Pathways and Wiki Pathways files, as well as diseases associated with genes and human phenotype data, and finally visualize the data with the help of bioinformatics. A total of 5227 targets were obtained for AIS, 1561 targets for PA, and 697 intersection targets, and then 20 key targets were obtained by intersection with 52 targets of MRKH. Submit it to the String platform to draw the PPI network, involving a total of 19 nodes and 35 edges, and MCODE analyzes 3 major modules. According to the results of GO bio enrichment analysis, it was found that comorbid genes mainly act on nuclear chromatin and protein DNA complexes, affect the activity of DNA binding transcription factors and participate in the morphogenesis of human tissues and organs, especially the genitourinary system and the central axis bone development. The KEGG pathway analysis targets are related to the WNT signaling pathway, which can affect the regulation of stem cell pluripotency. In addition, the Wiki pathway is mainly involved in mammalian sexual development, affecting the differentiation of osteoblasts and the occurrence of the kidney. Most likely to cause diseases of the reproductive system, and phenotypes with abnormal uterine and skeletal morphology. The integration of gene protein interactions and metabolic pathways can systematically reflect the co morbidity mechanism of AIS and PA. The high fitting of pathway gene targets can be used from the perspective of integrating traditional Chinese medicine and Western medicine, the macro and micro refer to each other and explain.
C1 [Wang Yang; Sun Aijun; Shen Jianxiong] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp,Dept Obstet & Gynecol, State Key Lab Complex Severe & Rare Dis, Natl Clin Res Ctr Obstet & Gynecol Dis, Beijing, Peoples R China.
   [Wang Yang; Sun Aijun; Shen Jianxiong] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr, Beijing, Peoples R China.
   [Wang Yang; Sun Aijun; Shen Jianxiong] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Complex Severe & Rare Dis, Peking Union Med Coll Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [Wang Weilu] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Beijing University of Chinese Medicine
RP Sun, AJ; Shen, JX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp,Dept Obstet & Gynecol, State Key Lab Complex Severe & Rare Dis, Natl Clin Res Ctr Obstet & Gynecol Dis, Beijing, Peoples R China.; Sun, AJ; Shen, JX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr, Beijing, Peoples R China.; Sun, AJ; Shen, JX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Complex Severe & Rare Dis, Peking Union Med Coll Hosp, Dept Endocrinol, Beijing, Peoples R China.
EM saj20cn22@gmail.com; pumch@163.com
CR Aslaner H, 2022, WORLD J TRAD CHINESE, V8, P497, DOI 10.4103/wjtcm.wjtcm_73_21
   Bao XH, 2022, WORLD J TRAD CHINESE, V8, P539, DOI 10.4103/2311 8571.351507
   Bernkopf DB, 2015, J CELL SCI, V128, P33, DOI 10.1242/jcs.159145
   Bjorsum Meyer Thomas, 2016, J Med Case Rep, V10, P374, DOI 10.1186/s13256 016 1127 9
   Fu W., 2019, CHINA MED HERALD, V16, P72
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Kapczuk K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111495
   Ke H., 2021, WHOLE EXOME SEQUENCI
   Li L., 2021, J CHINA FAM PLANNING, V13, P48
   Liu XY, 2022, WORLD J TRAD CHINESE, V8, P548, DOI 10.4103/2311 8571.351511
   Ma L., 2018, J MED IMAGING, V28, P1222
   Qian X., 2022, J SHANDONG MED, V62, P97
   Rousset P, 2013, CLIN RADIOL, V68, P945, DOI 10.1016/j.crad.2013.04.005
   Sainio K, 1997, DEVELOPMENT, V124, P1293
   Scaal M, 2016, SEMIN CELL DEV BIOL, V49, P83, DOI 10.1016/j.semcdb.2015.11.003
   Sonewane K, 2022, WORLD J TRAD CHINESE, V8, P314, DOI 10.4103/wjtcm.wjtcm_69_21
   Wei RL, 2022, WORLD J TRAD CHINESE, V8, P509, DOI 10.4103/2311 8571.343651
   Yang T., 2020, CHIN J ORTHOPAED SUR, V28, P1399
   Zeng LR, 2022, WORLD J TRAD CHINESE, V8, P436, DOI 10.4103/2311 8571.344545
   Zhu HM, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/1685052
NR 20
TC 0
Z9 0
U1 3
U2 12
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2023
VL 42
IS 4
BP 771
EP 781
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA P4ZN1
UT WOS:001050762600004
DA 2025 08 17
ER

PT J
AU Zhou, L
   Huang, YK
   Zhao, JL
   Yang, HL
   Kuai, F
AF Zhou, Liang
   Huang, Yingkang
   Zhao, Jiali
   Yang, Huilin
   Kuai, Feng
TI Oridonin promotes osteogenesis through Wnt/β catenin pathway and
   inhibits RANKL induced osteoclastogenesis in vitro
SO LIFE SCIENCES
LA English
DT Article
DE Oridonin; Mesenchymal stem cells; Osteogenesis; Osteoclastogenesis;
   Osteoporosis
ID NF KAPPA B; BONE; CELLS; EXPRESSION; PREVENTION; APOPTOSIS; MEDICINE;
   KINASE
AB Aims: To study the molecular mechanism of oridonin (ORI) on osteoblast differentiation and osteoclast formation in vitro.
   Main methods: Rat bone marrow mesenchymal stem cells (BMSCs) were treated with different concentrations of ORI in osteogenic medium (OM). CCK 8 assay and were used to detect the effect on BMSCs viability. Alizarin red staining and ALP activity were used to illuminate the effect of ORI on osteogenic differentiation. Expressions of osteogenic differentiation related genes were detected by real time quantitative PCR (qRT PCR), and expressions of osteogenic related proteins were detected by Western blot (WB) and immunofluorescence. Similarly, bone marrow mononuclear cells (BMMs) were treated with different concentrations of ORI. CCK 8 assay and Live/Dead staining were used to detect the effect of ORI on BMMs activity. TRAP staining was used to detect its effect on osteoclast differentiation. Expressions of osteoclast related genes were detected by qRT PCR, and expressions of osteoclast related proteins were detected by WB and immunofluorescence.
   Key findings: (1) ORI (2 mu M) promoted the ALP activity of BMSCs differentiation into osteoblasts and increased the number of calcium nodules. (2) ORI stimulated the expressions of wnt1, beta catenin and Runx2, but with no significantly effect on p GSK 3 beta and GSK 3 beta. (3) ORI promoted the expression of OPG and inhibited the expression of RANKL. (4) ORI directly/indirectly inhibited the osteoclast formation and expressions of osteoclast related genes TRAP, NFATc1 and c Fos.
   Significance: ORI may promote BMSCs differentiate into osteoblasts through the Wnt/beta catenin signaling pathway. At the same time, it may also inhibit the formation of osteoclasts mediated by RANKL.
C1 [Zhou, Liang] Lianshui Cty Peoples Hosp, Dept Orthoped, Huaian 223001, Jiangsu, Peoples R China.
   [Huang, Yingkang; Yang, Huilin] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhao, Jiali] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Orthoped, Huaian 223002, Jiangsu, Peoples R China.
   [Zhao, Jiali] Second Peoples Hosp Huaian, Huaian 223002, Jiangsu, Peoples R China.
   [Kuai, Feng] Nantong Univ, Affiliated Hosp 4, Peoples Hosp Yancheng 1, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China.
C3 Soochow University   China; Xuzhou Medical University; Nantong
   University
RP Yang, HL (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Jiangsu, Peoples R China.; Kuai, F (通讯作者)，Nantong Univ, Affiliated Hosp 4, Peoples Hosp Yancheng 1, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China.
EM suzhouspine@163.com; yckf301415@163.com
FU Jiangsu Provincial Clinical Orthopedic Center
FX This project was supported by Jiangsu Provincial Clinical Orthopedic
   Center.
CR ABELSON PH, 1990, SCIENCE, V247, P513, DOI 10.1126/science.2300807
   Bandara N, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0442 9
   Body JJ, 2010, ANN ONCOL, V21, P180, DOI 10.1093/annonc/mdq422
   Boudin E, 2013, SEMIN ARTHRITIS RHEU, V43, P220, DOI 10.1016/j.semarthrit.2013.01.004
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Cheng Y, 2009, ARCH BIOCHEM BIOPHYS, V490, P70, DOI 10.1016/j.abb.2009.08.011
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Downward J, 2004, BRIT MED J, V328, P1245, DOI 10.1136/bmj.328.7450.1245
   Du L, 2016, SCI REP UK, V6, DOI 10.1038/srep32261
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Faienza MF, 2018, EXPERT OPIN BIOL TH, V18, P149, DOI 10.1080/14712598.2018.1401607
   Gao FH, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 610
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hines SL, 2009, J CLIN ONCOL, V27, P1047, DOI 10.1200/JCO.2008.19.1783
   Hsieh TC, 2005, BIOCHEM BIOPH RES CO, V337, P224, DOI 10.1016/j.bbrc.2005.09.040
   Hu HZ, 2007, ACTA PHARMACOL SIN, V28, P1819, DOI 10.1111/j.1745 7254.2007.00667.x
   Huang YK, 2020, SCI CHINA LIFE SCI, V63, P429, DOI 10.1007/s11427 019 1555 9
   Kadriu B, 2018, MOL PSYCHIATR, V23, P1626, DOI 10.1038/mp.2017.109
   Keating SE, 2007, J BIOL CHEM, V282, P33435, DOI 10.1074/jbc.M705266200
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lee K, 2001, MOL THER, V3, P857, DOI 10.1006/mthe.2001.0327
   Li D, 2007, J PHARMACOL SCI, V103, P56, DOI 10.1254/jphs.FPJ06016X
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liu YQ, 2006, BIOL PHARM BULL, V29, P1873, DOI 10.1248/bpb.29.1873
   Liu Y, 2014, INT J ONCOL, V45, P795, DOI 10.3892/ijo.2014.2456
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Van Damme An, 2002, Current Gene Therapy, V2, P195
   Wang Lu, RSC ADV, V9
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 38
TC 15
Z9 19
U1 0
U2 23
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD DEC 1
PY 2020
VL 262
AR 118563
DI 10.1016/j.lfs.2020.118563
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OY0YK
UT WOS:000593980400004
PM 33038376
DA 2025 08 17
ER

PT J
AU Kaneko, K
   Tsai, J
   Menez, D
   Oh, B
   Suh, AJ
   Bae, S
   Mizuno, M
   Umemoto, A
   Giannopoulou, E
   Fujii, T
   Zhang, YX
   Stein, EM
   Bockman, RS
   Park Min, KH
AF Kaneko, Kaichi
   Tsai, Jefferson
   Menez, Deniece
   Oh, Brian
   Suh, Andrew Junwoo
   Bae, Seyeon
   Mizuno, Masataka
   Umemoto, Akio
   Giannopoulou, Eugenia
   Fujii, Takayuki
   Zhang, Yaxia
   Stein, Emily M.
   Bockman, Richard S.
   Park Min, Kyung Hyun
TI Cellular signatures in human blood track bone mineral density in
   postmenopausal women
SO JCI INSIGHT
LA English
DT Article
ID OSTEOPOROSIS; DENOSUMAB; RECEPTOR; OSTEOCLASTOGENESIS; OSTEOIMMUNOLOGY;
   PREVENTION; RESORPTION; PATHWAYS; TURNOVER; IMMUNE
AB Osteoclasts are the sole bone resorbing cells and are formed by the fusion of osteoclast precursor cells (OCPs) derived from myeloid lineage cells. Animal studies reveal that circulating OCPs (cOCPs) in blood travel to bone and fuse with bone resident osteoclasts. However, the characteristics of human cOCPs and their association with bone diseases remain elusive. We have identified and characterized human cOCPs and found a positive association between cOCPs and osteoclast activity. Sorted cOCPs have a higher osteoclastogenic potential than other myeloid cells and effectively differentiate into osteoclasts. cOCPs exhibit distinct morphology and transcriptomic signatures. The frequency of cOCPs in the blood varies among treatment naive postmenopausal women and has an inverse correlation with lumbar spine bone density and a positive correlation with serum CTX, a bone resorption marker. The increased cOCPs in treatment naive patients with osteoporosis were significantly diminished by denosumab, a widely used antiresorptive therapy. Our study reveals the distinctive identity of human cOCPs and the potential link between the dynamic regulation of cOCPs and osteoporosis and its treatment. Taken together, our study enhances our understanding of human cOCPs and highlights a potential opportunity to measure cOCPs through a simple blood test, which could potentially identify high risk individuals. identified in bone marrow, blood, or metastatic bone lesions by the expression of different cell surface markers, which are commonly used for defining myeloid cells. However, distinct OCP specific markers remain inconclusive, and their characteristics have not been fully determined. In this study, we have identified a subset of CD14+ cells with a high potential to differentiate into osteoclasts (referred to as cOCPs). cOCPs are distinct from other CD14+monocytes in terms of their cellular morphology and transcriptomic profile. cOCPs express genes related to MYC targets and metabolic pathways. Notably, the frequency of cOCPs in blood is inversely correlated with bone density in postmenopausal women. Blocking RANKL by denosumab, an FDA approved anti RANKL antibody, has effectively improved bone density and fracture risk in patients with osteoporosis (13, 14). We found that increased cOCPs in postmenopausal women with osteoporosis were significantly diminished by denosumab treatment. Our study suggests that cOCPs could serve as a valuable tool for identifying individuals at high risk of pathological bone loss and as a potential therapeutic target for bone diseases.
C1 [Kaneko, Kaichi; Tsai, Jefferson; Menez, Deniece; Oh, Brian; Suh, Andrew Junwoo; Bae, Seyeon; Mizuno, Masataka; Fujii, Takayuki; Park Min, Kyung Hyun] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, Arthrit & Tissue Degenerat Program, New York, NY USA.
   [Kaneko, Kaichi] Toho Univ, Sakura Med Ctr, Dept Internal Med, Div Rheumatol, Sakura, Chiba, Japan.
   [Mizuno, Masataka] SUNY Downstate Hlth Sci Univ, Brooklyn, NY USA.
   [Giannopoulou, Eugenia; Zhang, Yaxia] CUNY, New York City Coll Technol, Biol Sci Dept, Brooklyn, NY USA.
   [Zhang, Yaxia] Hosp Special Surg, Pathol & Lab Med, New York, NY USA.
   [Zhang, Yaxia] Weill Cornell Med Coll, Pathol & Clin Lab Med, New York, NY USA.
   [Stein, Emily M.; Bockman, Richard S.] Hosp Special Surg, Endocrine Serv, New York, NY USA.
   [Stein, Emily M.; Bockman, Richard S.; Park Min, Kyung Hyun] Weill Cornell Med Coll, Dept Med, New York, NY USA.
   [Park Min, Kyung Hyun] Weill Cornell Grad Sch Med Sci, BCMB Allied Program, New York, NY USA.
C3 Toho University; State University of New York (SUNY) System; SUNY
   Downstate Health Sciences University; City University of New York (CUNY)
   System; Cornell University; Weill Cornell Medicine; Cornell University;
   Weill Cornell Medicine; Cornell University
RP Park Min, KH (通讯作者)，535 East 70th St,Res S Bldg S805, New York, NY 10021 USA.
EM parkmink@hss.edu
RI ; Giannopoulou, Evgenia/K 9576 2019; Fujii, Takayuki/ACG 5546 2022
OI Suh, Andrew J./0000 0002 6575 9275; Tsai, Jefferson/0009 0000 2492 1937;
   Fujii, Takayuki/0000 0002 6556 1226
FU Clinical & Translational Science Center of Weill Cornell Medicine [UL1
   TR002384]; Marmor and Complex Joint Reconstruction Center (CJRC)
   Research grant; Japan Research Foundation for Clinical Pharmacology; The
   Tow Foundation
FX We thank the Endocrinology Service of the Hospital for Special Surgery
   for providing human samples, Linda Russell for the advice, and Weill
   Cornell Medicine Genomics Core Facilities for next generation
   sequencing. We are grateful to the KHPM's lab members for their helpful
   discussions and assistance. This work was supported by the Clinical &
   Translational Science Center of Weill Cornell Medicine under award
   number UL1 TR002384 (to KHPM) , Marmor and Complex Joint Reconstruction
   Center (CJRC) Research grant (to KHPM) , Japan Research Foundation for
   Clinical Pharmacology (to KK) , and by support for the Rosenweig
   Genomics Center from The Tow Foundation (to KHPM) . Figures were
   generated using BioRender.com .
CR Amarnath ALD, 2015, J GEN INTERN MED, V30, P1733, DOI 10.1007/s11606 015 3349 8
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Barcia JJ, 2007, INT J SURG PATHOL, V15, P292, DOI 10.1177/1066896907302239
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Chen HL, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010432, 10.1097/md.0000000000010432]
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chiu YG, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2915
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dougall William C, 2014, Bonekey Rep, V3, P519, DOI 10.1038/bonekey.2014.14
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ebeling PR, 1996, J CLIN ENDOCR METAB, V81, P3366, DOI 10.1210/jc.81.9.3366
   Eraltan H, 2012, GENET TEST MOL BIOMA, V16, P229, DOI 10.1089/gtmb.2011.0216
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Ginhoux F, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.626725
   Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005
   Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Khan UA, 2016, J CELL BIOCHEM, V117, P382, DOI 10.1002/jcb.25282
   Kim KY, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0260924
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong Sung Hye, 2022, J Bone Metab, V29, P93, DOI 10.11005/jbm.2022.29.2.93
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kuhn MB, 2023, BONE REP, V18, DOI 10.1016/j.bonr.2023.101662
   Kyrgidis A, 2020, J MUSCULOSKEL NEURON, V20, P339
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   LARDY HA, 1958, ARCH BIOCHEM BIOPHYS, V78, P587, DOI 10.1016/0003 9861(58)90383 7
   Lewiecki EM, 2010, CURR MED RES OPIN, V26, P2807, DOI 10.1185/03007995.2010.533651
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Orchard PJ, 2015, BLOOD, V126, P270, DOI 10.1182/blood 2015 01 625541
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Roche JJW, 2005, BMJ BRIT MED J, V331, P1374, DOI 10.1136/bmj.38643.663843.55
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tsai Jefferson, 2023, J Bone Metab, V30, P127, DOI 10.11005/jbm.2023.30.2.127
   Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573
   Wang SF, 2022, MOLECULES, V27, DOI 10.3390/molecules27248754
   Wu MCL, 2013, P NATL ACAD SCI USA, V110, P9439, DOI 10.1073/pnas.1218815110
   Yang XW, 2016, CLIN LAB, V62, P2173, DOI 10.7754/Clin.Lab.2016.160408
NR 48
TC 1
Z9 1
U1 4
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD NOV 22
PY 2024
VL 9
IS 22
AR e178977
DI 10.1172/jci.insight.178977
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA O0F2T
UT WOS:001367981000001
PM 39576015
OA gold
DA 2025 08 17
ER

PT S
AU Saxena, R
   Pan, G
   Mcdonald, JM
AF Saxena, Ritu
   Pan, George
   Mcdonald, Jay M.
BE Zaidi, M
TI Osteoblast and osteoclast differentiation in modeled microgravity
SO SKELETAL BIOLOGY AND MEDICINE, PT A: ASPECTS OF BONE MORPHOGENESIS AND
   REMODELING
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE modeled microgravity; osteoblasts; osteoclasts; bone
ID MESENCHYMAL STEM CELLS; BONE; ADIPOGENESIS
AB Prolonged microgravity experienced by astronauts is associated with a decrease in bone mineral density. To investigate the effect of microgravity on differentiation of osteoclasts and osteoblasts, we used a NASA recommended, ground based, microgravity simulating system, the Rotary Cell Culture System (RCCS). Using the RCCS, we demonstrated that modeled microgravity (MMG) inhibited osteoblastogenesis and increased adipocyte differentiation in human mesenchymal stem cells incubated under osteogenic,,conditions. This transformation involves reduced RhoA activity and cofilin phosphorylation, disruption of F actin stress fibers, and decreased integrin signaling through focal adhesion kinase. We have used the system to show that MMG also stimulates osteoclastogenesis. These systems provide the opportunity to develop pharmacological agents that will stimulate osteoblastogenesis and inhibit osteoclastogenesis.
C1 [Saxena, Ritu] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.
   [Pan, George; Mcdonald, Jay M.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   [Mcdonald, Jay M.] Vet Adm Med Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Saxena, R (通讯作者)，514 Lyons Harrison Res Bldg,701 19 St S, Birmingham, AL 35294 USA.
EM ritus@uab.edu
CR Bikle DD, 1999, J BONE MINER METAB, V17, P233, DOI 10.1007/s007740050090
   Carmeliet G, 1998, BONE, V22, p139S, DOI 10.1016/S8756 3282(98)00007 6
   Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756 3282(97)00052 5
   GOODWIN TJ, 1993, J CELL BIOCHEM, V51, P301, DOI 10.1002/jcb.240510309
   Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611
   Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105
   TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105 2896.2005.00330.x
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
NR 12
TC 54
Z9 69
U1 1
U2 19
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND
SN 0077 8923
BN 978 1 57331 684 2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1116
BP 494
EP 498
DI 10.1196/annals.1402.033
PG 5
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Orthopedics
GA BHA44
UT WOS:000251898900043
PM 17656572
DA 2025 08 17
ER

PT J
AU Chiarito, M
   Piacente, L
   Chaoul, N
   Pontrelli, P
   D'Amato, G
   Grandone, A
   Russo, G
   Street, ME
   Wasniewska, MG
   Brunetti, G
   Faienza, MF
AF Chiarito, M.
   Piacente, L.
   Chaoul, N.
   Pontrelli, P.
   D'Amato, G.
   Grandone, A.
   Russo, G.
   Street, M. E.
   Wasniewska, M. G.
   Brunetti, G.
   Faienza, M. F.
TI Role of Wnt signaling inhibitors DKK 1 and sclerostin in bone fragility
   associated with Turner syndrome
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Turner's syndrome; Skeletal fragility; DKK 1; Sclerostin; RANKL
ID LOW DOSE ESTROGEN; MINERAL DENSITY; GIRLS; DICKKOPF 1; DEFICIENCY;
   CHILDHOOD; CHILDREN; THERAPY; WOMEN
AB Purpose Girls affected with Turner syndrome (TS) present with low bone mineral density (BMD) and osteopenia/osteoporosis. Thus, they have an increased risk to develop fractures compared to normal population. The aim of this study was to deepen the pathophysiology of skeletal fragility in TS subjects by evaluating the serum levels of Dickkopf 1 (DKK 1) and sclerostin, main regulators of bone mass, as well as the percentage of circulating osteoblast precursors (OCPs). Methods Thirty four TS girls and 24 controls were recruited. All subjects underwent anthropometric measures (height, weight, body mass index BMI). A peripheral venous blood sample was collected to determine serum levels of active intact parathyroid hormone (PTH), 25 OH vitamin D, calcium, phosphorus, bone alkaline phosphatase (bALP), osteocalcin, sclerostin, DKK 1, RANKL and OPG. OCPs were detected by flow cytometry. In TS subjects bone mineralization was measured at lumbar spine by dual energy X ray absorptiometry (DXA). Results bALP, 25 OH Vitamin D, and osteocalcin levels were significant lower in TS subjects than in the controls. Statistically significant higher levels of sclerostin, DKK 1 and RANKL were measured in patients compared with the controls. The percentage of OCPs did not show significant differences between patients and controls. Sclerostin and DKK 1 levels were related with anthropometric parameters, bone metabolism markers, HRT, rhGH therapy, RANKL and lumbar BMAD Z score. Conclusion TS patients showed higher levels of sclerostin and DKK 1 than controls which can be related to HRT, and to reduced bone formation markers as well as the increased bone resorption activity.
C1 [Chiarito, M.; Piacente, L.; Faienza, M. F.] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Pediat Unit, Bari, Italy.
   [Chaoul, N.] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Pontrelli, P.] Univ Bari A Moro, Dept Emergency & Organ Transplantat, Div Nephrol, Bari, Italy.
   [D'Amato, G.] Di Venere Hosp, Neonatal Intens Care Unit, Bari, Italy.
   [Grandone, A.] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialized Surg, Naples, Italy.
   [Russo, G.] IRCCS San Raffaele Hosp, Dept Pediat, Milan, Italy.
   [Street, M. E.] Azienda USL IRCCS Reggio Emilia, Dept Mother & Child, Reggio Emilia, Italy.
   [Wasniewska, M. G.] Univ Messina, Dept Human Pathol Adulthood & Childhood, Pediat Unit, Messina, Italy.
   [Brunetti, G.] Univ A Moro Bari, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita della
   Campania Vanvitelli; Vita Salute San Raffaele University; IRCCS Ospedale
   San Raffaele; University of Messina; Universita degli Studi di Bari Aldo
   Moro
RP Faienza, MF (通讯作者)，Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Pediat Unit, Bari, Italy.
EM mariafelicia.faienza@uniba.it
RI Wasniewska, Malgorzata/AAR 9900 2021; Faienza, Maria/K 6779 2016;
   Street, Maria/B 7099 2011
CR Aversa T, 2015, HORM INT J ENDOCRINO, V14, P410, DOI 10.14310/horm.2002.1574
   Aversa T, 2015, ENDOCRINE, V50, P777, DOI 10.1007/s12020 014 0513 6
   Bakalov VK, 2003, J CLIN ENDOCR METAB, V88, P5717, DOI 10.1210/jc.2003 030913
   Bakalov VK, 2008, REV ENDOCR METAB DIS, V9, P145, DOI 10.1007/s11154 008 9076 2
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bertelloni S, 2009, J ENDOCRINOL INVEST, V32, P666, DOI [10.1007/BF03345738, 10.3275/6281]
   Brunetti G, 2019, WORLD J PEDIATR, V15, P4, DOI 10.1007/s12519 018 0198 7
   Brunetti G, 2013, AM J PHYSIOL ENDOC M, V304, pE546, DOI 10.1152/ajpendo.00535.2012
   Chiarito M, 2020, EXPERT REV ENDOCRINO, V15, P431, DOI 10.1080/17446651.2020.1834846
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Corrado A, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02562 3
   D'Amelio P, 2012, OSTEOPOROSIS INT, V23, P1245, DOI 10.1007/s00198 011 1666 2
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Eghbali Fatourechi GZ, 2007, BONE, V40, P1370, DOI 10.1016/j.bone.2006.12.064
   Faienza MF, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00034
   Faienza MF, 2015, BONE, V81, P228, DOI 10.1016/j.bone.2015.07.021
   Feehan J, 2019, EBIOMEDICINE, V39, P603, DOI 10.1016/j.ebiom.2018.11.051
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Gravholt CH, 2017, EUR J ENDOCRINOL, V177, pG1, DOI 10.1530/EJE 17 0430
   Guerra Menéndez L, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 271
   Holroyd CR, 2010, OSTEOPOROSIS INT, V21, P2093, DOI 10.1007/s00198 010 1170 0
   Kodama M, 2012, ENDOCR J, V59, P153, DOI 10.1507/endocrj.EJ11 0267
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Labarta JI, 2012, EUR J ENDOCRINOL, V167, P523, DOI 10.1530/EJE 12 0444
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Locatelli V, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/235060
   Lu HY, 2016, OBES RES CLIN PRACT, V10, P454, DOI 10.1016/j.orcp.2015.08.016
   Nishigaki S, 2021, CLIN ENDOCRINOL, V95, P84, DOI 10.1111/cen.14484
   Pirro M, 2010, OSTEOPOROSIS INT, V21, P297, DOI 10.1007/s00198 009 0968 0
   Quigley CA, 2014, J CLIN ENDOCR METAB, V99, pE1754, DOI 10.1210/jc.2013 4518
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Rosenfield RL, 2005, J CLIN ENDOCR METAB, V90, P6424, DOI 10.1210/jc.2005 1081
   Ross JL, 2011, NEW ENGL J MED, V364, P1230, DOI 10.1056/NEJMoa1005669
   Sata M, 2005, NEW ENGL J MED, V353, P737
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170
   Viuff M, 2019, AM J MED GENET C, V181, P68, DOI 10.1002/ajmg.c.31683
NR 37
TC 13
Z9 14
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD JUN
PY 2022
VL 45
IS 6
BP 1255
EP 1263
DI 10.1007/s40618 022 01760 3
EA MAR 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1F0XG
UT WOS:000763372600002
PM 35237949
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Xia, P
   Gu, R
   Zhang, W
   Shao, LW
   Li, F
   Wu, CY
   Sun, YF
AF Xia, Peng
   Gu, Rui
   Zhang, Wei
   Shao, Liwei
   Li, Fang
   Wu, Changyan
   Sun, Yifu
TI MicroRNA 377 exerts a potent suppressive role in osteosarcoma through
   the involvement of the histone acetyltransferase 1 mediated Wnt axis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE apoptosis; HAT1; microRNA 377; osteosarcoma; wnt signaling pathway
ID ARTICLE. SEE APRIL; CELL PROLIFERATION; SIGNALING PATHWAY;
   DOWN REGULATION; CANCER; EXPRESSION; RESISTANCE; TARGET; PROGRESSION;
   THERAPY
AB It has been demonstrated that microRNAs (miRNAs) may contribute to tumorigenesis and tumor growth in osteosarcoma (OS), which is a primary malignant tumor of bone frequently diagnosed in adolescents and young people. The purpose of our investigation was to evaluate the functional relevance of miR 377 in OS and to investigate whether the mechanism was related to the histone acetyltransferase 1 (HAT1) mediated Wnt signaling pathway. By screening differentially expressed genes in microarray GSE47572, HAT1 was found to be a candidate gene of interest. Besides, the regulatory miRNA (miR 377) of HAT1 was also selected. The interaction among miR 377, HAT1, and the Wnt signaling pathway was evaluated. In addition, the miR 377 expression was altered in OS cells (U 2OS and SOSP 9607) to assess the in vitro cell apoptosis and the in vivo tumor growth. OS tissues presented elevated HAT1 expression and decreased miR 377 expression. A putative miR 377 binding site in HAT1 3 ' UTR HAT1 was verified. Cells with miR 377 overexpression or HAT1 silencing were observed to exhibit reduced HAT1 expression and promoted apoptosis, accompanied by blockade of Wnt signaling. Moreover, the in vivo experiment revealed that miR 377 overexpression or HAT1 silencing inhibited tumor growth and reduced tumor size in nude mice. Taken together, our results conclude that miR 377 may promote OS cell apoptosis through inactivation of the HAT1 mediated Wnt signaling pathway, highlighting the potential therapeutic effect of miR 377 on OS treatment.
C1 [Xia, Peng; Zhang, Wei] Jilin Univ, Hosp 2, Dept Orthopead, Changchun, Jilin, Peoples R China.
   [Gu, Rui; Shao, Liwei; Li, Fang; Wu, Changyan; Sun, Yifu] Jilin Univ, China Japan Union Hosp, Dept Orthopead, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Sun, YF (通讯作者)，Jilin Univ, China Japan Union Hosp, Dept Orthopead, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
EM yifu@jlu.edu.cn
RI shao, liwei/AAF 6934 2019
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Ayuk SM, 2016, J PHOTOCH PHOTOBIO B, V161, P368, DOI 10.1016/j.jphotobiol.2016.05.027
   Azizi M, 2017, EPIGENOMICS UK, V9, P1059, DOI 10.2217/epi 2016 0175
   Chang WH, 2016, TUMOR BIOL, V37, P14813, DOI 10.1007/s13277 016 5295 4
   Chrun ES, 2017, ORAL DIS, V23, P505, DOI 10.1111/odi.12641
   Dai G, 2017, ONCOTARGET, V8, P86098, DOI 10.18632/oncotarget.20987
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Jin X, 2017, ONCOL RES, V25, P939, DOI 10.3727/096504016X14809827856524
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008 5472.CAN 11 2663
   Korkmaz G, 2016, BOSNIAN J BASIC MED, V16, P108, DOI 10.17305/bjbms.2016.721
   Lebel EA, 2010, MOL CELL BIOCHEM, V339, P271, DOI 10.1007/s11010 010 0390 0
   Li B, 2017, ONCOGENE, V36, P3986, DOI 10.1038/onc.2017.29
   Phillip CJ, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 145
   Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773
   Proto MC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11688 x
   Rastogi B, 2017, CANCER INVEST, V35, P152, DOI 10.1080/07357907.2017.1286669
   Shoeneman JK, 2012, CANCER RES, V72, P249, DOI 10.1158/0008 5472.CAN 11 2315
   Song YM, 2015, EXP THER MED, V9, P1292, DOI 10.3892/etm.2015.2232
   Tao YL, 2017, ONCOL LETT, V14, P6365, DOI 10.3892/ol.2017.7059
   Wang L, 2015, TUMOR BIOL, V36, P3911, DOI 10.1007/s13277 014 3034 2
   Wang Y, 2015, INT J CLIN EXP PATHO, V8, P63
   Wang Y, 2015, ACTA BIOMATER, V17, P115, DOI 10.1016/j.actbio.2015.01.007
   Xu JQ, 2014, TUMOR BIOL, V35, P9847, DOI 10.1007/s13277 014 2229 x
   Xue L, 2014, INT J CLIN EXP PATHO, V7, P3898
   Yang XH, 2013, J BIOL CHEM, V288, P18271, DOI 10.1074/jbc.M113.473199
   Yang YQ, 2014, TUMOR BIOL, V35, P10287, DOI 10.1007/s13277 014 2316 z
   Yu DQ, 2014, EXP THER MED, V7, P97, DOI 10.3892/etm.2013.1372
   Zehavi L, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0338 9
   Zeilstra J, 2011, BIOCHEM BIOPH RES CO, V406, P1, DOI 10.1016/j.bbrc.2010.12.070
   Zhang J, 2016, EUR REV MED PHARMACO, V20, P4494
   Zhang YH, 2016, 8TH INTERNATIONAL CONFERENCE ON INTERNET MULTIMEDIA COMPUTING AND SERVICE (ICIMCS2016), P1, DOI 10.1145/3007669.3007680
NR 31
TC 29
Z9 31
U1 0
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2019
VL 234
IS 12
BP 22787
EP 22798
DI 10.1002/jcp.28843
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IV6KF
UT WOS:000484376600115
PM 31152456
DA 2025 08 17
ER

PT J
AU Yuan, YF
   Sun, JG
   Zhou, H
   Wang, S
   He, CJ
   Chen, TP
   Fang, MH
   Li, SH
   Kang, SF
   Huang, XS
   Tang, BB
   Liang, BC
   Mao, YDL
   Li, JY
   Shi, XL
   Liu, K
AF Yuan, Yifeng
   Sun, Jiangang
   Zhou, Hang
   Wang, Shen
   He, Caijian
   Chen, Tianpeng
   Fang, Mouhao
   Li, Shaohua
   Kang, Shifa
   Huang, Xiaosheng
   Tang, Binbin
   Liang, Bocheng
   Mao, Yingdelong
   Li, Jianyou
   Shi, Xiaolin
   Liu, Kang
TI The effect of QiangGuYin on osteoporosis through the AKT/mTOR/autophagy
   signaling pathway mediated by CKIP 1
SO AGING US
LA English
DT Article
DE osteoporosis; CKIP 1; AKT/mTOR signaling pathway; apoptosis; QiangGuYin
ID UBIQUITIN LIGASE SMURF1; OSTEOCLAST DIFFERENTIATION; BONE FORMATION;
   AUTOPHAGY; OSTEOBLASTS; PROMOTES; MICE; AKT
AB Osteoporosis is a systemic bone disease characterized by decreased bone mass and deterioration of bone microstructure, which leads to increased bone fragility and increased risk of fractures. Casein kinase 2 interacting protein 1 (CKIP 1, also known as PLEKHO1) is involved in the biological process of bone formation, differentiation and apoptosis, and is a negative regulator of bone formation. QiangGuYin (QGY) is a famous TCM formula that has been widely used in China for the clinical treatment of postmenopausal osteoporosis for decades, but the effect in regulating CKIP 1 on osteoporosis is not fully understood. This study aimed to explore the potential mechanism of CKIP 1 participating in autophagy in bone cells through the AKT/mTOR signaling pathway and the regulatory effect of QGY. The results in vivo showed that QGY treatment can significantly improve the bone quality of osteoporotic rats, down regulate the expression of CKIP 1, LC3II/I and RANKL, and up regulated the expression of p62, p AKT/AKT, p mTOR/mTOR, RUNX2 and OPG. It is worth noting that the results in vitro confirmed that CKIP 1 interacts with AKT. By up regulating the expression of Atg5 and down regulating the p62, the level of LC3 (autophagosome) is increased, and the cells osteogenesis and differentiation are inhibited. QGY inhibits the combination of CKIP 1 and AKT in osteoblasts, activates the AKT/mTOR signaling pathway, inhibits autophagy, and promotes cell differentiation, thereby exerting an anti osteoporosis effect. Therefore, QGY targeting CKIP 1 to regulate the AKT/mTOR autophagy signaling pathway may represent a promising drug candidate for the treatment of osteoporosis.
C1 [Yuan, Yifeng; Sun, Jiangang; Zhou, Hang; Wang, Shen; He, Caijian; Chen, Tianpeng; Fang, Mouhao; Li, Shaohua; Kang, Shifa; Huang, Xiaosheng] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China.
   [Tang, Binbin; Liang, Bocheng; Mao, Yingdelong; Shi, Xiaolin; Liu, Kang] Zhejiang Chinese Med Univ, Dept Osteol, Affiliated Hosp 2, Hangzhou, Peoples R China.
   [Li, Jianyou] Huzhou Cent Hosp, Dept Orthoped, Huzhou, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Huzhou University
RP Shi, XL; Liu, K (通讯作者)，Zhejiang Chinese Med Univ, Dept Osteol, Affiliated Hosp 2, Hangzhou, Peoples R China.
EM xlshi 2002@163.com; liukang1982@163.com
RI Li, Jiazhen/HPF 9994 2023; Yuan, Yifeng/ABH 6910 2020
FU National Natural Science Foundation of China [81873129, 81803902,
   81973884, 82074183]; Zhejiang Provincial Natural Science Foundation of
   China [LY19H290004]
FX The study was supported by grant from the National Natural Science
   Foundation of China [No. 81873129; 81803902; 81973884; 82074183] and
   Zhejiang Provincial Natural Science Foundation of China [No.
   LY19H290004] .
CR Aoki S, 2020, BIOCHEM BIOPH RES CO, V527, P874, DOI 10.1016/j.bbrc.2020.04.155
   Basudan AM, 2019, TISSUE ENG PART B RE, V25, P89, DOI [10.1089/ten.teb.2018.0120, 10.1089/ten.TEB.2018.0120]
   Bo T, 2016, J BONE MINER RES, V31, P1979, DOI 10.1002/jbmr.2885
   Fu L, 2019, AGEING RES REV, V53, DOI 10.1016/j.arr.2019.05.002
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Greenhill C, 2017, NAT REV ENDOCRINOL, V13, P5, DOI [10.1038/nrendo.2016.189, 10.1038/nrendo.2015.214]
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Han B, 2018, MOL MED REP, V18, P2506, DOI 10.3892/mmr.2018.9222
   Ji LM, 2019, BIOCHEM BIOPH RES CO, V511, P869, DOI 10.1016/j.bbrc.2019.02.114
   Li L, 2020, EXP CELL RES, V397, DOI 10.1016/j.yexcr.2020.112341
   Liang BC, 2017, CHIN J INTEGR MED, V23, P747, DOI 10.1007/s11655 016 2600 4
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep41295
   Liu QL, 2018, MOL MED REP, V17, P4797, DOI 10.3892/mmr.2018.8416
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Luo DS, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01483
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Peng X, 2018, BONE JOINT RES, V7, P173, DOI 10.1302/2046 3758.72.BJR 2017 0172.R1
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Shao BY, 2015, FASEB J, V29, P3935, DOI 10.1096/fj.15 272823
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Shi GX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030564
   Shi ZY, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/6062707
   Shiraki M, 2019, FASEB J, V33, P8836, DOI 10.1096/fj.201802322RR
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Toscani D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02467
   Wang JN, 2015, J TRADIT CHIN MED, V35, P141, DOI 10.1016/S0254 6272(15)30021 2
   Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105
   Wang Q, 2018, J PHARMACOL SCI, V136, P155, DOI 10.1016/j.jphs.2018.01.007
   Wang W, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 00449 9
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xie LZ, 2019, FOOD FUNCT, V10, P2161, DOI 10.1039/c8fo01786g
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Zhang JL, 2018, INT J MOL MED, V42, P299, DOI 10.3892/ijmm.2018.3645
   Zhang L, 2017, ACS APPL MATER INTER, V9, P34722, DOI 10.1021/acsami.7b12079
   Zhang L, 2015, SCI REP UK, V5, DOI 10.1038/srep10860
   Zhang L, 2014, CELL RES, V24, P742, DOI 10.1038/cr.2014.53
   Zhou ZC, 2017, OR SURG OR MED OR PA, V123, pE1, DOI 10.1016/j.oooo.2016.07.013
   Zhu FB, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5707242
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
NR 45
TC 15
Z9 20
U1 0
U2 29
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD JAN 31
PY 2022
VL 14
IS 2
BP 892
EP 906
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA YU2PM
UT WOS:000751889300005
PM 35073518
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fujiwara, M
   Kubota, T
   Wang, W
   Ohata, Y
   Miura, K
   Kitaoka, T
   Okuzaki, D
   Namba, N
   Michigami, T
   Kitabatake, Y
   Ozono, K
AF Fujiwara, Makoto
   Kubota, Takuo
   Wang, Wei
   Ohata, Yasuhisa
   Miura, Kohji
   Kitaoka, Taichi
   Okuzaki, Daisuke
   Namba, Noriyuki
   Michigami, Toshimi
   Kitabatake, Yasuji
   Ozono, Keiichi
TI Successful induction of sclerostin in human derived fibroblasts by 4
   transcription factors and its regulation by parathyroid hormone,
   hypoxia, and prostaglandin E2
SO BONE
LA English
DT Article
DE Sclerostin; SOST; Human fibroblasts; Hypoxia; Parathyroid hormone;
   Prostaglandin E2
ID BONE FORMATION; EXPRESSION; SOST; GENE; PTH; IDENTIFICATION;
   SUPPRESSION; TARGET; ATF3; BMPS
AB Sclerostin, coded by SOST, is a secretory protein that is specifically expressed in osteocytes and suppresses osteogenesis by inhibiting WNT signaling. The regulatory mechanism underlying SOST expression remains unclear mainly due to the absence of an adequate human cell model. Thus, we herein attempted to establish a cell model of human dermal fibroblasts in order to investigate the functions of sclerostin. We selected 20 candidate transcription factors (TFs) that induce SOST expression by analyzing gene expression patterns in the human sarcoma cell line, SaOS 2, between differentiation and maintenance cultures using microarrays. An effective set of TFs to induce SOST expression was sought by their viral transduction into fibroblasts, and a combination of four TFs: ATF3, KLF4, PAX4, and SP7, was identified as the most effective inducer of SOST expression. Quantitative PCR demonstrated that the expression levels of SOST in fibroblasts treated with the 4 TFs were 199  and 1439 fold higher than those of the control after 1 week and 4 week cultures, respectively. The level of sclerostin in the conditioned medium, as determined by ELISA, was 21.2 pmol/l 4 weeks after the transduction of the 4 TFs. Interestingly, the production of Dickkopfl (DKK1), another secreted inhibitor of WNT signaling, was also increased by transduction of these 4 TFs. Parathyroid hormone (PTH) significantly suppressed the induced SOST by 38% and sclerostin by 82% that of the vehicle. Hypoxia increased the induced SOST by 62% that of normoxia. Furthermore, prostaglandin E2 (PGE2) increased SOST expression levels to 16 fold those of the vehicle. In conclusion, the efficient induction of SOST expression and sclerostin production was achieved in human dermal fibroblasts by the transduction of ATF3, KLF4, PAX4, and SP7, and the induced SOST and sclerostin were regulated by PTH, hypoxia, and PGE2. This model may contribute to elucidating the regulatory mechanisms underlying SOST expression and advancing drug development for metabolic bone diseases. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Fujiwara, Makoto; Kubota, Takuo; Wang, Wei; Ohata, Yasuhisa; Miura, Kohji; Kitaoka, Taichi; Namba, Noriyuki; Kitabatake, Yasuji; Ozono, Keiichi] Osaka Univ, Grad Sch Med, Dept Pediat, Yamadaoka 2 2, Suita, Osaka 5650871, Japan.
   [Fujiwara, Makoto] Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg 1, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Okuzaki, Daisuke] Osaka Univ, Microbial Dis Res Inst, DNA Chip Dev Ctr Infect Dis, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Namba, Noriyuki] JCHO Osaka Hosp, Dept Pediat, Osaka 5530003, Japan.
   [Michigami, Toshimi] Osaka Med Ctr, Dept Bone & Mineral Res, Osaka 5941101, Japan.
   [Michigami, Toshimi] Res Inst Maternal & Child Hlth, Osaka 5941101, Japan.
C3 University of Osaka; University of Osaka; University of Osaka; Osaka
   Medical Center for Cancer & Cardiovascular Diseases
RP Ozono, K (通讯作者)，Osaka Univ, Grad Sch Med, Dept Pediat, Yamadaoka 2 2, Suita, Osaka 5650871, Japan.
EM keioz@ped.med.osaka u.ac.jp
RI Michigami, Toshimi/AAU 2326 2021; Okuzaki, Daisuke/AAN 5641 2020; Ohata,
   Yasuhisa/AAJ 4615 2020
OI Okuzaki, Daisuke/0000 0002 4552 783X; FUJIWARA,
   MAKOTO/0000 0002 6799 9774; Ohata, Yasuhisa/0000 0001 6084 6620
FU  [H26 nanchi ippan 039];  [15K19612]
FX We gratefully acknowledge the work of the members in our laboratory and
   Dr. R.T. Moon, Washington University, for providing the vectors. This
   work was supported in part by Grants in Aid for the Ministry of Health,
   Labour, and Welfare of Japan (to KO, H26 nanchi ippan 039), and a
   Grant in Aid for Scientific Research (to MF, 15K19612).
CR Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508
   Chen DF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065940
   Dean AK, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 S9 S5
   Delgado Calle J, 2013, MOL CELL ENDOCRINOL, V369, P27, DOI 10.1016/j.mce.2013.02.002
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   Genetos DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017772
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Javed A, 2010, ORAL MAXIL SURG CLIN, V22, P283, DOI 10.1016/j.coms.2010.05.001
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kocijan R, 2014, J CLIN ENDOCR METAB, V99, pE311, DOI 10.1210/jc.2013 2244
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Loots GG, 2012, BONE, V50, P663, DOI 10.1016/j.bone.2011.11.016
   Maciel FMB, 1997, J RHEUMATOL, V24, P2429
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Michikami I, 2012, EXP CELL RES, V318, P311, DOI 10.1016/j.yexcr.2011.12.013
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Palomo T, 2014, J CLIN ENDOCR METAB, V99, pE920, DOI 10.1210/jc.2013 3852
   Park JK, 2014, BIOCHEM BIOPH RES CO, V443, P333, DOI 10.1016/j.bbrc.2013.11.121
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Yang F, 2010, BIOCHEM BIOPH RES CO, V400, P684, DOI 10.1016/j.bbrc.2010.08.128
NR 34
TC 15
Z9 16
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2016
VL 85
BP 91
EP 98
DI 10.1016/j.bone.2016.01.024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DH4QJ
UT WOS:000372770200012
PM 26851122
DA 2025 08 17
ER

PT J
AU Mirotsou, M
   Zhang, ZY
   Deb, A
   Zhang, LN
   Gnecchi, M
   Noiseux, N
   Mu, H
   Pachori, A
   Dzau, V
AF Mirotsou, Maria
   Zhang, Zhongyan
   Deb, Arjun
   Zhang, Lunan
   Gnecchi, Massimiliano
   Noiseux, Nicolas
   Mu, Hui
   Pachori, Alok
   Dzau, Victor
TI Secreted frizzled related protein 2 (Sfrp2) is the key Akt mesenchymal
   stem cell released paracrine factor mediating myocardial survival and
   repair
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID WNT SIGNALING PATHWAY; MARROW DERIVED CELLS; BONE MARROW; APOPTOSIS;
   EXPRESSION; PROTECTION; NEURONS; HEART
AB Stem cell therapy has emerged as a promising tool for the treatment of a variety of diseases. Previously, we have shown that Akt modified mesenchymal stem cells mediate tissue repair through paracrine mechanisms. Using a comprehensive functional genomic strategy, we show that secreted frizzled related protein 2 (Sfrp2) is the key stem cell paracrine factor that mediates myocardial survival and repair after ischemic injury. Sfrp2 is known to modulate Wnt signaling, and we demonstrate that cardiomyocytes treated with secreted frizzled related protein increase cellular beta catenin and up regulate expression of antiapoptotic genes. These findings reveal the key role played by Sfrp2 in mediating the paracrine effects of Akt mesenchymal stem cells on tissue repair and identify modulation of Wnt signaling as a therapeutic target for heart disease.
C1 Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
C3 Duke University
RP Dzau, V (通讯作者)，Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
EM victor.dzau@duke.edu
RI Gnecchi, Massimiliano/X 7095 2019; Gnecchi, Massimiliano/J 8609 2018
OI Gnecchi, Massimiliano/0000 0001 7435 4328
CR Alvarez Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069
   Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C
   Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092 8674(03)00687 1
   Bergmann MW, 2004, J MOL CELL CARDIOL, V37, P681, DOI 10.1016/j.yjmcc.2004.05.025
   Caplice NM, 2004, NAT CLIN PRACT CARD, V1, P90, DOI 10.1038/ncpcardio0051
   Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283
   Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405 367
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kinnaird T, 2004, CIRC RES, V95, P354, DOI 10.1161/01.RES.0000137878.26174.66
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Manji HK, 2000, J CLIN PSYCHIAT, V61, P82
   Melo LG, 2004, CIRCULATION, V109, P2386, DOI 10.1161/01.CIR.0000128597.37025.00
   Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100
   Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb 2001 2 2 reviews3004
   Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601
   Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008 6363(99)00376 4
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   van Gijn ME, 2002, CARDIOVASC RES, V55, P16, DOI 10.1016/S0008 6363(02)00221 3
   Wang HY, 2005, CANCER RES, V65, P8604, DOI 10.1158/0008 5472.CAN 05 1169
   Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997 997
NR 27
TC 435
Z9 515
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 30
PY 2007
VL 104
IS 5
BP 1643
EP 1648
DI 10.1073/pnas.0610024104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 134KD
UT WOS:000244081000038
PM 17251350
OA Green Published
DA 2025 08 17
ER

PT J
AU Ma, LH
   Zhang, LW
   Liao, ZR
   Xiu, CM
   Luo, X
   Luo, N
   Zhang, L
   He, GX
   Chen, JQ
AF Ma, Linghui
   Zhang, Liwei
   Liao, Zirui
   Xiu, Chunmei
   Luo, Xi
   Luo, Na
   Zhang, Lei
   He, Guangxu
   Chen, Jianquan
TI Pharmacological inhibition of protein S palmitoylation suppresses
   osteoclastogenesis and ameliorates ovariectomy induced bone loss
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Protein S palmitoylation; 2 bromopalmitic acid; Osteoclastogenesis;
   Osteoporosis
ID ACTIVATION
AB Background: Excessive osteoclast formation disrupts bone homeostasis, thereby significantly contributing to pathological bone loss associated with a variety of diseases. Protein S palmitoylation is a reversible posttranslational lipid modification catalyzed by ZDHHC family of palmitoyl acyltransferases, which plays an important role in various physiological and pathological processes. However, the role of palmitoylation in osteoclastogenesis has never been explored. Consequently, it is unclear whether this process can be targeted to treat osteolytic bone diseases that are mainly caused by excessive osteoclast formation.Materials and methods: In this study, we employed acyl biotin exchange (ABE) assay to reveal protein S palmitoylation in differentiating osteoclasts (OCs). We utilized 2 bromopalmitic acid (2 BP), a pharmacological inhibitor of protein S palmitoylation, to inhibit protein palmitoylation in mouse bone marrow derived macrophages (BMMs), and tested its effect on receptor activator of nuclear factor xii ligand (RANKL) induced osteoclast differentiation and activity by TRAP staining, phalloidin staining, qPCR analyses, and pit formation assays. We also evaluated the protective effect of 2 BP against estrogen deficiency induced bone loss and bone resorption in ovariectomized (OVX) mice using & mu;CT, H & E staining, TRAP staining, and ELISA assay. Furthermore, we performed western blot analyses to explore the molecular mechanism underlying the inhibitory effect of 2 BP on osteoclastogenesis.Results: We found that many proteins were palmitoylated in differentiating OCs and that pharmacological inhibition of palmitoylation impeded RANKL induced osteoclastogenesis, osteoclast specific gene expression, F actin ring formation and osteoclastic bone resorption in vitro, and to a lesser extent, osteoblast formation from MC3T3E1 cells. Furthermore, we demonstrated that administration of 2 BP protected mice from ovariectomy induced osteoporosis and bone resorption in vivo. Mechanistically, we showed that 2 BP treatment inhibited osteoclastogenesis partly by downregulating the expression of c Fos and NFATc1 without overtly affecting RANKL induced activation of osteoclastogenic AKT, MAPK, and NF xB pathways.Conclusion: Pharmacological inhibition of palmitoylation potently suppresses RANKL mediated osteoclast differentiation in vitro and protects mice against OVX induced osteoporosis in vivo. Mechanistically, palmitoylation regulates osteoclast differentiation partly by promoting the expression of c Fos and NFATc1. Thus, palmitoylation plays a key role in promoting osteoclast differentiation and activity, and could serve as a potential therapeutic target for the treatment of osteoporosis and other osteoclast related diseases. The translational potential of this article:The translation potential of this article is that we first revealed palmi toylation as a key mechanism regulating osteoclast differentiation, and therefore provided a potential therapeutic target for treating osteolytic bone diseases.
C1 [Ma, Linghui; Xiu, Chunmei; Chen, Jianquan] Hangzhou City Univ, Sch Med, Dept Clin Med, Key Lab Novel Targets & Drug Study Neural Repair Z, Hangzhou, Zhejiang, Peoples R China.
   [Ma, Linghui; Liao, Zirui; Luo, Xi; Luo, Na; Zhang, Lei; Chen, Jianquan] Soochow Univ, Orthoped Inst, Suzhou Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Zhang, Liwei] Zhejiang Univ, Taizhou Hosp Zhejiang Prov, Dept Orthoped, Taizhou, Zhejiang, Peoples R China.
   [He, Guangxu] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
   [Chen, Jianquan] 51 Huzhou St, Hangzhou 310015, Zhejiang, Peoples R China.
C3 Hangzhou City University; Soochow University   China; Zhejiang
   University; Central South University
RP He, GX (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.; Chen, JQ (通讯作者)，51 Huzhou St, Hangzhou 310015, Zhejiang, Peoples R China.
EM heguangxu1987@csu.edu.cn; chenjq@hzcu.edu.cn
RI Zhang, Lei/JLM 4641 2023; luo, na/KOC 3893 2024; Xiu,
   Chunmei/NKO 8377 2025
FU National Natural Science Foundation of China [81974344, 82272543]; Sci 
   enti fi c Research Foundation of Hangzhou City University [J  202327]
FX This study was supported in part by the grants from the National Natural
   Science Foundation of China (81974344, 82272543) and Sci  enti fi c
   Research Foundation of Hangzhou City University (No. J  202327) .
CR Adamik J, 2020, J BONE MINER RES, V35, DOI 10.1002/jbmr.3863
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Baumgart F, 2010, BBA BIOMEMBRANES, V1798, P592, DOI 10.1016/j.bbamem.2010.01.002
   Blanc M, 2019, METHODS MOL BIOL, V2009, P203, DOI 10.1007/978 1 4939 9532 5_16
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen XR, 2017, CANCER RES, V77, P4998, DOI 10.1158/0008 5472.CAN 17 1139
   Fan XQ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03087 5
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Jin JY, 2021, J CELL PHYSIOL, V236, P3220, DOI 10.1002/jcp.30122
   Kang HL, 2022, FASEB J, V36, DOI 10.1096/fj.202101205RR
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Leong WF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004135
   Lerner UH, 2019, PEDIATR ENDOCR REV P, V17, P84, DOI 10.17458/per.vol17.2019.l.osteoclastshealthdisease
   Li CH, 2018, INT IMMUNOPHARMACOL, V58, P136, DOI 10.1016/j.intimp.2018.03.021
   Li ZW, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2022.e12788
   Liu Z, 2022, INT J BIOL SCI, V18, P3447, DOI 10.7150/ijbs.72244
   Lu Y, 2019, HAEMATOLOGICA, V104, P102, DOI 10.3324/haematol.2018.191916
   Ma YC, 2022, GLIA, V70, P379, DOI 10.1002/glia.24113
   Plain F, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01145 3
   Qu MY, 2021, INT J BIOL SCI, V17, P4223, DOI 10.7150/ijbs.64046
   Saleem AN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000985
   Song IW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092194
   Sun SX, 2022, EUR J PHARMACOL, V927, DOI 10.1016/j.ejphar.2022.175073
   Wan J, 2007, NAT PROTOC, V2, P1573, DOI 10.1038/nprot.2007.225
   Wang SY, 2021, J BONE MINER RES, V36, P1850, DOI 10.1002/jbmr.4328
   Wegleiter T, 2019, P NATL ACAD SCI USA, V116, P25688, DOI 10.1073/pnas.1912671116
   Wei XC, 2020, CIRC RES, V127, P249, DOI 10.1161/CIRCRESAHA.120.316752
   Wei XC, 2011, J BIOL CHEM, V286, P2933, DOI 10.1074/jbc.M110.193037
   Wild AR, 2022, ELIFE, V11, DOI 10.7554/eLife.75804
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong WF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04235 0
   Yang C, 2022, AUTOPHAGY, V18, P2817, DOI 10.1080/15548627.2022.2048432
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhang MM, 2020, NATURE, V586, P434, DOI 10.1038/s41586 020 2799 2
   Zhang MZM, 2017, BIOCHEM SOC T, V45, P275, DOI 10.1042/BST20160236
   Zhang YQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661202
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 40
TC 11
Z9 11
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD SEP
PY 2023
VL 42
BP 1
EP 14
DI 10.1016/j.jot.2023.06.002
EA JUL 2023
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA O5SO7
UT WOS:001044408300001
PM 37521493
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, MY
   Fu, SX
   Cai, ZY
   Li, DY
   Liu, L
   Deng, D
   Jin, RR
   Ai, H
AF Li, Mengye
   Fu, Shengxiang
   Cai, Zhongyuan
   Li, Danyang
   Liu, Li
   Deng, Di
   Jin, Rongrong
   Ai, Hua
TI Dual regulation of osteoclastogenesis and osteogenesis for osteoporosis
   therapy by iron oxide hydroxyapatite core/shell nanocomposites
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE hydroxyapatite; superparamagnetic iron oxide; osteoporosis treatment;
   nanocomposites
ID BONE REGENERATION; NANOPARTICLES; OSTEOBLASTS; MACROPHAGES; HOMEOSTASIS;
   FABRICATION; ACTIVATION; MECHANISMS; PARTICLES; FRACTURES
AB Osteoporosis is a skeletal disorder resulted in significant structural and functional changes, arousing a wide concern for the high prevalence and cost. Imbalance between osteoclastogenesis and osteogenesis have been verified as a main pathology etiology and considered an efficient therapy target in both clinical and pre clinical studies. In recent years, inorganic nanomaterials have shown provable activities on osteoclastogenesis inhibition and osteogenesis promotion, respectively. Hence, in this study, a class of hydroxyapatite coated superparamagnetic iron oxide nanoparticles (SPIO@HA) were developed with a core shell structure for targeting both osteoclastogenesis and osteogenesis. The optimal ratio of SPIO@15HA (Fe/Ca = 1:15, mol/mol) was screened to obtain dual function for inducing both bone formation and preventing bone resorption. The obtained nanocomposites significantly prevented the bone loss of ovariectomized (OVX) mice and increased bone mineral density (BMD) by 9.4%, exhibiting high bone accumulation in magnetic resonance imaging evaluation and reasonable biosafety profile. The mechanism study revealed that SPIO@15HA can suppress bone marrow monocyte derived osteoclast differentiation through TRAF6 p62 CYLD signaling complex regulation. Meanwhile, it could activate MSC osteogenic differentiation by TGF beta, PI3K AKT and calcium signaling pathway regulation. Moreover, incubation of SPIO@15HA with MSC resulted in several cytokines overexpression such as osteoprotegerin (OPG), CSF2, CCL2 etc., which are responsible for maintaining the bone remodeling balance. The dual function of as prepared SPIO@15HA may find a new way for designing of inorganic components containing core/shell nanomaterials for osteoporosis treatment.
C1 [Li, Mengye; Fu, Shengxiang; Cai, Zhongyuan; Liu, Li; Deng, Di; Jin, Rongrong; Ai, Hua] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Li, Danyang] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen 518107, Peoples R China.
   [Ai, Hua] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sun Yat Sen University; Sichuan University
RP Jin, RR; Ai, H (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
EM jinrr2015@scu.edu.cn; huaai@scu.edu.cn
RI ; li, danyang/HHS 3319 2022
OI Li, Danyang/0000 0002 7508 6019; Fu, Shengxiang/0000 0001 9755 0014; 
FU National Natural Science Foundation of China (NSFC) [51903174,
   52073192]; Innovative Research Groups of the National Natural Science
   Foundation of China [81621003]; Chengdu Science and Technology Program
   [2019 YF05 00318 SN]; Sichuan University Postdoctoral Interdisciplinary
   Innovation Startup Foundation; Fundamental Research Funds for Central
   Universities [2021SCU12070]
FX This work was financially supported by National Natural Science
   Foundation of China (NSFC, Nos 51903174 and 52073192), Innovative
   Research Groups of the National Natural Science Foundation of China
   (81621003), Chengdu Science and Technology Program (2019 YF05 00318 SN),
   the Sichuan University Postdoctoral Interdisciplinary Innovation Startup
   Foundation and the Fundamental Research Funds for Central Universities
   (2021SCU12070).
CR Ananta JS, 2010, NAT NANOTECHNOL, V5, P815, DOI [10.1038/nnano.2010.203, 10.1038/NNANO.2010.203]
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bakker AD, 2013, BONE, V53, P112, DOI 10.1016/j.bone.2012.11.044
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Bhattacharya P, 2019, J MATER CHEM B, V7, P4141, DOI 10.1039/c9tb00782b
   Bongio M, 2016, NANOMEDICINE UK, V11, P1073, DOI 10.2217/nnm 2015 0021
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chao Y, 2013, ACS NANO, V7, P4289, DOI 10.1021/nn400769e
   Chopra V, 2020, ACS BIOMATER SCI ENG, V6, P6710, DOI 10.1021/acsbiomaterials.0c00370
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   El Fiqi A, 2015, J MATER CHEM B, V3, P1321, DOI 10.1039/c4tb01634c
   Fernandes MH, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.111147
   Ha SW, 2015, BIOMATERIALS, V65, P32, DOI 10.1016/j.biomaterials.2015.06.039
   Habibovic P, 2011, ACTA BIOMATER, V7, P3013, DOI 10.1016/j.actbio.2011.03.027
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Heo DN, 2014, J MATER CHEM B, V2, P1584, DOI 10.1039/c3tb21246g
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hong YL, 2010, MAT SCI ENG R, V70, P225, DOI 10.1016/j.mser.2010.06.010
   Jin RR, 2019, BIOMATERIALS, V203, P23, DOI 10.1016/j.biomaterials.2019.02.026
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lakhkar NJ, 2013, ADV DRUG DELIVER REV, V65, P405, DOI 10.1016/j.addr.2012.05.015
   Lee MS, 2016, INT J NANOMED, V11, P4583, DOI 10.2147/IJN.S112415
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Liu L, 2020, ACTA BIOMATER, V103, P281, DOI 10.1016/j.actbio.2019.12.022
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mauer J, 2014, NAT IMMUNOL, V15, P423, DOI 10.1038/ni.2865
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Quan HY, 2018, ACS APPL MATER INTER, V10, P25547, DOI 10.1021/acsami.8b09879
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rusu VM, 2005, BIOMATERIALS, V26, P5414, DOI 10.1016/j.biomaterials.2005.01.051
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Van Overmeire E, 2016, CANCER RES, V76, P35, DOI 10.1158/0008 5472.CAN 15 0869
   Wang QW, 2017, NANO RES, V10, P626, DOI 10.1007/s12274 016 1322 4
   Weissleder R, 2014, NAT MATER, V13, P125, DOI [10.1038/NMAT3780, 10.1038/nmat3780]
   Wu CQ, 2015, ADV FUNCT MATER, V25, P3581, DOI 10.1002/adfm.201501031
   Yang, ARAB J CHEM, V14
   Yao J, 2011, POLYMER, V52, P793, DOI 10.1016/j.polymer.2010.12.017
   Zhang WB, 2011, ACTA BIOMATER, V7, P800, DOI 10.1016/j.actbio.2010.08.031
   Zhao R, 2017, ACTA BIOMATER, V59, P338, DOI 10.1016/j.actbio.2017.07.009
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhou ZJ, 2019, ADV MATER, V31, DOI 10.1002/adma.201804567
NR 53
TC 29
Z9 31
U1 4
U2 62
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD OCT
PY 2021
VL 8
IS 5
AR rbab027
DI 10.1093/rb/rbab027
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA UR2OK
UT WOS:000696593200001
PM 34434563
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, T
   Ha, H
   Shim, KS
   Cho, WK
   Ma, JY
AF Kim, Taesoo
   Ha, Hyunil
   Shim, Ki Shuk
   Cho, Won Kyung
   Ma, Jin Yeul
TI The anti osteoporotic effect of Yijung tang in an ovariectomized rat
   model mediated by inhibition of osteoclast differentiation
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Yijung tang; Osteoclasts; Osteoblasts; Ovariectomy
ID HORMONE REPLACEMENT THERAPY; RECEPTOR ACTIVATOR; KAPPA B; C FOS; BONE;
   NFATC1; LIGAND; PREVENTION; INDUCTION; LINEAGE
AB Ethnopharmacological relevance: Yijung tang (YJ), a traditional Asian medicine, is used to treat various diseases. However, its anti osteoporotic effect and mechanism of action remain unclear. The aim of the present study was to evaluate the anti osteoporotic effect of YJ in ovariectomized (OVX) rats.
   Materials and methods: Sprague Dawley rats were divided into five groups as follows: sham operated, ovariectomized (OVX), OVX rats treated with 100 g/kg/day 17 estradiol, and OVX rats treated with 0.3 and 1.0 g/kg/day YJ for 12 weeks. Trabecular bone mineral density (BMD) and bone microarchitecture were evaluated by microcomputed tomography. The effects of YJ on osteoblast and osteoclast formation were also investigated in an in vitro model using primary murine bone marrow derived macrophages and murine calvarial preosteoblasts. mRNA expression of osteoclast differentiation related genes was measured by real time quantitative reverse transcription polymerase chain reaction. Activation of the mitogen activated protein kinases and nuclear factor kappa B (NF kappa B) were determined by Western blot.
   Results: The decrease of BMD and destruction of bone microarchitecture were significantly reduced in the OVX induced osteoporosis rat model after 12 weeks of YJ treatment. The anti osteoporotic effect of YJ on bone loss was due to inhibition of osteoclast differentiation through down regulation of the NF kappa B pathway. In addition, YJ suppressed the induction of nuclear factor of activated T cells, cytoplasmic 1 and c Fos following receptor activator of nuclear factor kappa B ligand stimulation.
   Conclusions: These results suggest that YJ possess potent anti osteoporotic activity in OVX rats and may be a useful remedy for the treatment of postmenopausal osteoporosis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kim, Taesoo; Ha, Hyunil; Shim, Ki Shuk; Cho, Won Kyung; Ma, Jin Yeul] Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM jyma@kiom.re.kr
OI Ha, Hyunil/0000 0001 5947 9982
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea [K12050]
FX This work was supported by a Grant no. (K12050) from the Korea Institute
   of Oriental Medicine, Ministry of Education, Science and Technology,
   Republic of Korea.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen J.K., 2005, AM ACUPUNCTURIST, V6, P16
   Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Izumi T, 2000, J NUTR, V130, P1695, DOI 10.1093/jn/130.7.1695
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   MCCARTHY TL, 1988, J BONE MINER RES, V3, P401
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Notomi T, 2003, J BONE MINER RES, V18, P140, DOI 10.1359/jbmr.2003.18.1.140
   Prelevic G M, 2005, Minerva Endocrinol, V30, P27
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TAKAYANAGI H, 2005, J MOL MED JMM, V83, P170, DOI DOI 10.1007/s00109 004 0612 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wimalawansa SJ, 2000, J CLIN DENSITOM, V3, P187, DOI 10.1385/JCD:3:2:187
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhao N, 2011, J ETHNOPHARMACOL, V133, P454, DOI 10.1016/j.jep.2010.10.016
   Zhao X., 2012, EVID BASED COMPL ALT
NR 26
TC 20
Z9 25
U1 1
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 7
PY 2013
VL 146
IS 1
BP 83
EP 89
DI 10.1016/j.jep.2012.11.037
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 104ZT
UT WOS:000316036100006
PM 23219731
DA 2025 08 17
ER

PT J
AU Park, KR
   Lee, JY
   Kim, BM
   Kang, SW
   Yun, HM
AF Park, Kyung Ran
   Lee, Joon Yeop
   Kim, Bo Mi
   Kang, Sang Wook
   Yun, Hyung Mun
TI ! TMARg, a Novel Anthraquinone Isolated from Rubia cordifolia
   Nakai, Increases Osteogenesis and Mineralization through BMP2 and
   β Catenin Signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE phytomedicine; Rubia cordifoliaNakai; TMARg; osteoblast; BMP2;
   beta catenin
ID OSTEOBLAST DIFFERENTIATION; NATURAL PRODUCTS; MC3T3 E1 CELLS;
   BONE FORMATION; STEM CELLS; WNT; EXPRESSION; OSTEOPOROSIS; ACTIVATION;
   MASS
AB Background: Plant extracts have long been regarded as useful medicines in the treatment of human diseases.Rubia cordifoliaNakai has been used as a traditional medicine, as it has pharmacological properties such as antioxidant and anti inflammatory activity. However, the biological functions of TMARg, isolated from the roots ofR. cordifolia,in osteoblast differentiation remain unknown. This study was performed to investigate the pharmacological effects and intracellular signaling of TMARg in the osteoblast differentiation of pre osteoblast MC3T3 E1 cells and mesenchymal precursor C2C12 cells. Methods: Cell viability was evaluated using an MTT assay. Early and late osteoblast differentiation was examined by analyzing the activity of alkaline phosphatase (ALP), and by staining it with Alizarin red S (ARS). Cell migration was determined by using migration assays. Western blot analysis and immunocytochemical analysis were used to examine the intracellular signaling pathways and differentiation proteins. Results: In the present study, TMARg showed no cytotoxicity and increased the osteoblast differentiation in pre osteoblasts, as assessed from the alkaline phosphate (ALP) staining and activity and ARS staining. TMARg also induced BMP2 expression and increased the p smad1/5/8 RUNX2 and beta catenin pathways in both MC3T3 E1 and C2C12 cells. Furthermore, TMARg activated mitogen activated protein kinases (MAPKs) and increased the cell migration rate. In addition, the TMARg mediated osteoblast differentiation was suppressed by BMP and Wnt inhibitors with the downregulation of BMP2 expression. Conclusion: These findings demonstrate that TMARg exerts pharmacological and biological effects on osteoblast differentiation through the activation of BMP2 and beta catenin signaling pathways, and suggest that TMARg might be a potential phytomedicine for the treatment of bone diseases.
C1 [Park, Kyung Ran; Kang, Sang Wook; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Lee, Joon Yeop; Kim, Bo Mi] Natl Inst Korean Med Dev, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Kang, SW; Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
EM rudfks282@naver.com; choo19090@nikom.or.kr; bom0203@nikom.or.kr;
   pathemis@khu.ac.kr; yunhm@khu.ac.kr
RI Kang, Sang/AAY 5970 2021
FU National Research Foundation of Korea (NRF)   Korean government (MSIP)
   [NRF 2018R1D1A1B07043282]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIP)
   (NRF 2018R1D1A1B07043282).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chang YM, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep131
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2012, PROCEEDINGS OF THE FOURTEENTH INTERNATIONAL CONFERENCE ON GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, P9, DOI 10.1145/2330163.2330166
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Jansen P.C.M., 2005, Plant Resources of Tropical Africa (PROTA) 3. Dyes and tannins
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Liao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042709
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Ndhlala AR, 2011, J ETHNOPHARMACOL, V133, P663, DOI 10.1016/j.jep.2010.10.053
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Patil Rupali A., 2006, Indian Journal of Experimental Biology, V44, P987
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rawal A, 2004, BIOCHEM BIOPH RES CO, V324, P588, DOI 10.1016/j.bbrc.2004.09.094
   Rawal Avinash K, 2004, BMC Complement Altern Med, V4, P11, DOI 10.1186/1472 6882 4 11
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sequeira DB, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9040074
   Shilpa PN, 2012, PHARM BIOL, V50, P376, DOI 10.3109/13880209.2011.608073
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Wan X S, 1988, Zhong Yao Tong Bao, V13, P7
   Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113 8133.2004
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 53
TC 10
Z9 11
U1 0
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 15
AR 5332
DI 10.3390/ijms21155332
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NA1EB
UT WOS:000559560000001
PM 32727092
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Urquiaga, M
   Saag, KG
AF Urquiaga, Mariana
   Saag, Kenneth G.
TI Risk for osteoporosis and fracture with glucocorticoids
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Osteoporosis; Fracture; Bone
   mineral density; Glucocorticoids
ID INDUCED BONE LOSS; CORTICOSTEROID INDUCED OSTEOPOROSIS;
   HORMONE REPLACEMENT THERAPY; LONG TERM; VITAMIN D; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; BREAST CANCER; PREVENTION; CALCIUM
AB Glucocorticoid use is ubiquitous and is associated with multiple adverse reactions. Among them, osteoporosis and bone fractures are of our concern. In this review, we present current evidence on the effect of glucocorticoids on bone mineral density and the risk of fractures, the mechanisms underlying those effects, and the recommendations for monitoring and treating patients who take them.The bone mineral density of the lumbar spine and total hip is lower, and the risk of fractures is higher in glucocorticoid users than non users. These effects have a rapid onset, are dose  dependent, and improve soon after discontinuation of glucocorti coids. They also appear to occur even with non systemic routes of administration and with low doses. Glucocorticoids reduce bone mineral density by increasing osteo clast activity and decreasing osteoblast and osteocyte activity. Calcium metabolism and parathyroid hormone activity are less important than was initially thought. Treatment decisions are on risk stratification using clinical, radio graphic, and prediction tools. Our armamentarium for the treat ment and prevention of glucocorticoid induced osteoporosis includes calcium and vitamin D, bisphosphonates, recombinant parathyroid hormone, monoclonal antibodies against receptor activator of nuclear factor kappa B ligand, and hormone treatments.(c) 2022 Elsevier Ltd. All rights reserved.
C1 [Urquiaga, Mariana; Saag, Kenneth G.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Urquiaga, M (通讯作者)，Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
EM muchanganaqui@uabmc.edu
OI Urquiaga, Mariana/0000 0002 0411 5345
CR Abu EO, 2000, J CLIN ENDOCR METAB, V85, P883, DOI 10.1210/jc.85.2.883
   Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Amiche MA, 2016, OSTEOPOROSIS INT, V27, P1709, DOI 10.1007/s00198 015 3455 9
   Amiche MA, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0424 x
   Amin S, 1999, ARTHRITIS RHEUM US, V42, P1740, DOI 10.1002/1529 0131(199908)42:8<1740::AID ANR25>3.0.CO;2 E
   Balasubramanian A, 2018, J BONE MINER RES, V33, P1881, DOI 10.1002/jbmr.3523
   Bénard Laribière A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 015905
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140 6736(97)08233 0
   Beral Valerie, 2003, Lancet, V362, P419
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Briot K, 2014, JOINT BONE SPINE, V81, P493, DOI 10.1016/j.jbspin.2014.10.001
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   CANALIS E, 1992, J BONE MINER RES, V7, P1085
   Chalitsios CV, 2021, RESP MED, V181, DOI 10.1016/j.rmed.2021.106374
   Cho SK, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02564 1
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Conradie M, 2022, CLIMACTERIC, V25, P73, DOI 10.1080/13697137.2021.1926974
   Crawford BAL, 2003, J CLIN ENDOCR METAB, V88, P3167, DOI 10.1210/jc.2002 021827
   CRILLY R, 1978, J ROY SOC MED, V71, P733, DOI 10.1177/014107687807101006
   de Nijs RNJ, 2006, NEW ENGL J MED, V355, P675, DOI 10.1056/NEJMoa053569
   Deng JW, 2021, RHEUMATOLOGY, V60, P649, DOI 10.1093/rheumatology/keaa228
   Diederich S, 2002, J CLIN ENDOCR METAB, V87, P5695, DOI 10.1210/jc.2002 020970
   Ding LL, 2020, J CLIN ENDOCR METAB, V105, P600, DOI 10.1210/clinem/dgz023
   Dovio A, 2006, EUR J ENDOCRINOL, V154, P745, DOI 10.1530/eje.1.02147
   Dyer SM, 2016, BMC GERIATR, V16, DOI 10.1186/s12877 016 0332 0
   Eastman K, 2021, OSTEOPOROSIS INT, V32, P1531, DOI 10.1007/s00198 021 05847 0
   Egeberg A, 2021, JAMA DERMATOL, V157, P275, DOI 10.1001/jamadermatol.2020.4968
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Fujii N, 2007, NEPHROL DIAL TRANSPL, V22, P1601, DOI 10.1093/ndt/gfl567
   Gilson H, 2007, ENDOCRINOLOGY, V148, P452, DOI 10.1210/en.2006 0539
   GLUCK OS, 1981, ARTHRITIS RHEUM US, V24, P892, DOI 10.1002/art.1780240705
   HAHN TJ, 1981, J CLIN ENDOCR METAB, V52, P111, DOI 10.1210/jcem 52 1 111
   HATTERSLEY AT, 1994, CALCIFIED TISSUE INT, V54, P198, DOI 10.1007/BF00301678
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Hirooka Y, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.753185
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Homik J., 2000, Cochrane Database Syst. Rev, V2, DOI [DOI 10.1002/14651858.CD000952, DOI 10.1002/14651858.CD001347]
   Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144
   Huybers S, 2007, AM J PHYSIOL GASTR L, V292, pG92, DOI 10.1152/ajpgi.00317.2006
   Ishida T, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00899 5
   Kanis JA, 2007, HEALTH TECHNOL ASSES, V11, P1
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P809, DOI 10.1007/s00198 010 1524 7
   Kerezoudis P, 2018, PAIN MED, V19, P569, DOI 10.1093/pm/pnx324
   Kikuchi Y, 2007, NEPHROL DIAL TRANSPL, V22, P1593, DOI 10.1093/ndt/gfl568
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Laugesen K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2016 015237
   LEBOFF MS, 1991, J RHEUMATOL, V18, P339
   Leib ES, 2011, J CLIN DENSITOM, V14, P212, DOI 10.1016/j.jocd.2011.05.014
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Liu CL, 2017, CLIN INVEST MED, V40, pE146, DOI 10.25011/cim.v40i3.28394
   Lo JC, 2015, AM J MANAG CARE, V21, pE206
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   MACADAMS MR, 1986, ANN INTERN MED, V104, P648, DOI 10.7326/0003 4819 104 5 648
   Manson JE, 2013, JAMA J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040
   Mok CC, 2011, ANN RHEUM DIS, V70, P778, DOI 10.1136/ard.2010.143453
   Natsui K, 2006, OSTEOPOROSIS INT, V17, P105, DOI 10.1007/s00198 005 1923 3
   NIELSEN HK, 1988, BONE MINER, V4, P105
   Nowakowska Plaza A, 2021, HORM METAB RES, V53, P499, DOI 10.1055/a 1528 7261
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Overman RA, 2014, ARTHRIT CARE RES, V66, P1644, DOI 10.1002/acr.22346
   PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713
   Pearce G, 1998, J CLIN ENDOCR METAB, V83, P801, DOI 10.1210/jc.83.3.801
   Peng CH, 2021, TZU CHI MED J, V33, P212, DOI 10.4103/tcmj.tcmj_233_20
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Reid IR, 1996, ARCH INTERN MED, V156, P1173, DOI 10.1001/archinte.156.11.1173
   Ringe JD, 2003, OSTEOPOROSIS INT, V14, P801, DOI 10.1007/s00198 003 1425 0
   Ringe JD, 2003, RHEUMATOLOGY, V42, P743, DOI 10.1093/rheumatology/keg205
   Rossini M, 2016, REUMATISMO, V68, P1, DOI 10.4081/reumatismo.2016.870
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002 012101
   Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919
   SEEMAN E, 1980, J CLIN INVEST, V66, P664, DOI 10.1172/JCI109902
   Si L, 2015, CURR MED RES OPIN, V31, P1149, DOI 10.1185/03007995.2015.1037729
   SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026 0495(83)90221 4
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Tanaka I, 2021, J BONE MINER METAB, V39, P446, DOI 10.1007/s00774 020 01171 5
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang JJ, 2019, CURR PHARM DESIGN, V25, P1653, DOI 10.2174/1381612825666190619125426
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yanbeiy ZA, 2019, DRUG DES DEV THER, V13, P2843, DOI 10.2147/DDDT.S148654
NR 86
TC 21
Z9 21
U1 1
U2 7
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD SEP
PY 2022
VL 36
IS 3
SI SI
AR 101793
DI 10.1016/j.berh.2022.101793
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 6Z8EC
UT WOS:000898002100003
PM 36347775
DA 2025 08 17
ER

PT J
AU Erkhembaatar, M
   Gu, DR
   Lee, SH
   Yang, YM
   Park, S
   Muallem, S
   Shin, DM
   Kim, MS
AF Erkhembaatar, Munkhsoyol
   Gu, Dong Ryun
   Lee, Seoung Hoon
   Yang, Yu Mi
   Park, Soonhong
   Muallem, Shmuel
   Shin, Dong Min
   Kim, Min Seuk
TI Lysosomal Ca<SUP>2+</SUP> Signaling is Essential for Osteoclastogenesis
   and Bone Remodeling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TRPML1; LYSOSOME; BONE REMODELING; OSTEOCLASTOGENESIS; CA(2+) SIGNALING
ID MUCOLIPIDOSIS TYPE IV; PLASMA MEMBRANE; ABNORMAL TRANSPORT; RUFFLED
   BORDER; TRP CHANNEL; DIFFERENTIATION; TRAFFICKING; RANKL; EXOCYTOSIS;
   PATHWAY
AB Lysosomal Ca2+ emerges as a critical component of receptor evoked Ca2+ signaling and plays a crucial role in many lysosomal and physiological functions. Lysosomal Ca2+ release is mediated by the transient receptor potential (TRP) family member TRPML1, mutations that cause the lysosomal storage disease mucolipidosis type 4. Lysosomes play a key role in osteoclast function. However, nothing is known about the role of lysosomal Ca2+ signaling in osteoclastogenesis and bone metabolism. In this study, we addressed this knowledge gap by studying the role of lysosomal Ca2+ signaling in osteoclastogenesis, osteoclast and osteoblast functions, and bone homeostasis in vivo. We manipulated lysosomal Ca2+ signaling by acute knockdown of TRPML1, deletion of TRPML1 in mice, pharmacological inhibition of lysosomal Ca2+ influx, and depletion of lysosomal Ca2+ storage using the TRPML agonist ML SA1. We found that knockdown and deletion of TRPML1, although it did not have an apparent effect on osteoblast differentiation and bone formation, markedly attenuated osteoclast function, RANKL induced cytosolic Ca2+ oscillations, inhibited activation of NFATc1 and osteoclastogenesis controlling genes, suppressed the formation of tartrate resistant acid phosphatase (TRAP) positive multinucleated cells (MNCs), and markedly reduced the differentiation of bone marrow derived macrophages into osteoclasts. Moreover, deletion of TRPML1 resulted in enlarged lysosomes, inhibition of lysosomal secretion, and attenuated the resorptive activity of mature osteoclasts. Notably, depletion of lysosomal Ca2+ with ML SA1 similarly abrogated RANKL induced Ca2+ oscillations and MNC formation. Deletion of TRPML1 in mice reduced the TRAP positive bone surfaces and impaired bone remodeling, resulting in prominent osteopetrosis. These findings demonstrate the essential role of lysosomal Ca2+ signaling in osteoclast differentiation and mature osteoclast function, which play key roles in bone homeostasis. (C) 2016 American Society for Bone and Mineral Research.
C1 [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Dept Oral Physiol, Coll Dent, Iksan 54538, South Korea.
   [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Inst Biomat Implant, Coll Dent, Iksan 54538, South Korea.
   [Erkhembaatar, Munkhsoyol] Mongolian Natl Univ Med Sci, Dept Physiol, Sch Pharm & Biomed, Ulaanbaatar, Mongolia.
   [Gu, Dong Ryun; Lee, Seoung Hoon] Wonkwang Univ, Sch Med, CMFR, Iksan, South Korea.
   [Gu, Dong Ryun; Lee, Seoung Hoon] Wonkwang Univ, Dept Oral Microbiol & Immunol, Coll Dent, Iksan, South Korea.
   [Yang, Yu Mi; Park, Soonhong; Shin, Dong Min] Yonsei Univ, Coll Dent, Dept Oral Biol, PLUS Project BK21, Seoul 120752, South Korea.
   [Muallem, Shmuel] Natl Inst Dent & Craniofacial Res, Epithelial Signaling & Transport Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA.
C3 Wonkwang University; Wonkwang University; Mongolian National University
   of Medical Sciences; Wonkwang University; Wonkwang University; Yonsei
   University; Yonsei University Health System; National Institutes of
   Health (NIH)   USA; NIH National Institute of Dental & Craniofacial
   Research (NIDCR)
RP Kim, MS (通讯作者)，Wonkwang Univ, Dept Oral Physiol, Coll Dent, Iksan 54538, South Korea.; Kim, MS (通讯作者)，Wonkwang Univ, Inst Biomat Implant, Coll Dent, Iksan 54538, South Korea.; Shin, DM (通讯作者)，Yonsei Univ, Coll Dent, Dept Oral Biol, PLUS Project BK21, Seoul 120752, South Korea.
EM DMSHIN@yuhs.ac; happy1487@wku.ac.kr
OI Erkhembaatar, Munkhsoyol/0009 0006 0855 9636; Shin, Dong
   Min/0000 0001 6042 0435
FU National Research Foundation of Korea (NRF) [NRF 2015R1D1A1A01058272,
   NRF 2015R1A2A1A15054157]; Ministry of Education, Science and Technology;
   Ministry of Science, ICT, and Future Planning in Republic of Korea; NIH,
   NIDCR intramural grant [DE000735 06]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grants (NRF 2015R1D1A1A01058272 and NRF 2015R1A2A1A15054157);
   Ministry of Education, Science and Technology and Ministry of Science,
   ICT, and Future Planning in Republic of Korea; and by NIH, NIDCR
   intramural grant DE000735 06.
CR Aggarwal S, 2013, GENE, V528, P41, DOI 10.1016/j.gene.2013.04.069
   Altarescu G, 2002, NEUROLOGY, V59, P306, DOI 10.1212/WNL.59.3.306
   Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095
   Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Cao X, 2015, CELL CALCIUM, V58, P342, DOI 10.1016/j.ceca.2015.03.003
   Chandra M, 2011, GASTROENTEROLOGY, V140, P857, DOI 10.1053/j.gastro.2010.11.040
   Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373
   Cheng XP, 2014, NAT MED, V20, P1187, DOI 10.1038/nm.3611
   Cheng XP, 2010, FEBS LETT, V584, P2013, DOI 10.1016/j.febslet.2009.12.056
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Geer JS, 2010, PEDIATR NEUROL, V42, P223, DOI 10.1016/j.pediatrneurol.2009.10.002
   Gordon RM, 2004, J MIDWIFERY WOM HEAL, V49, P359, DOI 10.1016/j.jmwh.2004.04.009
   Gu DR, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/509482
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Kilpatrick BS, 2013, J CELL SCI, V126, P60, DOI 10.1242/jcs.118836
   Kim HJ, 2012, J CELL BIOL, V199, P1145, DOI 10.1083/jcb.201204067
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kollmann K, 2013, EMBO MOL MED, V5, P1871, DOI 10.1002/emmm.201302979
   Krapivinsky G, 2011, P NATL ACAD SCI USA, V108, P19234, DOI 10.1073/pnas.1117231108
   LaPlante JM, 2006, MOL GENET METAB, V89, P339, DOI 10.1016/j.ymgme.2006.05.016
   LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045
   Lloyd Evans E, 2011, CELL CALCIUM, V50, P200, DOI 10.1016/j.ceca.2011.03.010
   López Sanjurjo CI, 2013, J CELL SCI, V126, P289, DOI 10.1242/jcs.116103
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Mellman I, 2008, NAT REV MOL CELL BIO, V9, P833, DOI 10.1038/nrm2525
   Miedel MT, 2008, J EXP MED, V205, P1477, DOI 10.1084/jem.20072194
   Morgan AJ, 2013, J CELL BIOL, V200, P789, DOI 10.1083/jcb.201204078
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Notomi T, 2012, J BIOL CHEM, V287, P35057, DOI 10.1074/jbc.M111.328930
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Park S, 2016, EMBO REP, V17, P266, DOI 10.15252/embr.201541542
   Patel S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3314
   Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092 8674(01)00421 4
   Samie M, 2013, DEV CELL, V26, P511, DOI 10.1016/j.devcel.2013.08.003
   Schiffmann R, 1998, P NATL ACAD SCI USA, V95, P1207, DOI 10.1073/pnas.95.3.1207
   Shen DB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1735
   Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Thompson EG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 54
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Venkatachalam K, 2008, CELL, V135, P838, DOI 10.1016/j.cell.2008.09.041
   Vergarajauregui S, 2008, HUM MOL GENET, V17, P2723, DOI 10.1093/hmg/ddn174
   Wang WY, 2015, P NATL ACAD SCI USA, V112, pE1373, DOI 10.1073/pnas.1419669112
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev physiol 021014 071649
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yang YM, 2009, J BONE MINER RES, V24, P1763, DOI [10.1359/JBMR.090420, 10.1359/jbmr.090420]
   Zhao HB, 2012, TRAFFIC, V13, P1307, DOI 10.1111/j.1600 0854.2012.01395.x
NR 55
TC 30
Z9 35
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2017
VL 32
IS 2
BP 385
EP 396
DI 10.1002/jbmr.2986
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EO8JL
UT WOS:000396935300020
PM 27589205
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Yang, GY
   Ye, J
   Wang, JC
   Liu, HJ
   Long, YL
   Jiang, JK
   Miao, XX
   Deng, JJ
   Wu, TL
   Li, T
   Cheng, XG
   Wang, XL
AF Yang, Guoyu
   Ye, Jing
   Wang, Jingcheng
   Liu, Huijie
   Long, Yanli
   Jiang, Junkai
   Miao, Xinxin
   Deng, Jianjian
   Wu, Tianlong
   Li, Tao
   Cheng, Xigao
   Wang, Xiaolei
TI " Three birds, one stone" strategy of NIR responsive CO/H2S dual gas
   Nanogenerator for efficient treatment of osteoporosis
SO MATERIALS TODAY BIO
LA English
DT Article
DE Near infrared light; Upconversion nanoparticles; Carbon monoxide;
   Hydrogen sulfide; Osteoporosis
AB Osteoporosis (OP), the most prevalent bone degenerative disease, has become a significant public health challenge globally. Current therapies primarily target inhibiting osteoclast activity or stimulating osteoblast activation, but their effectiveness remains suboptimal. This paper introduced a "three birds, one stone" therapeutic approach for osteoporosis, employing upconversion nanoparticles (UCNPs) to create a dual gas storage nano  platform (UZPA CP) targeting bone tissues, capable of concurrently generating carbon monoxide (CO) and hydrogen sulfide (H2S). 2 S). Through the precise modulation of 808 nm near infrared (NIR) light, the platform could effectively control the release of CO and H2S 2 S in the OP microenvironment, and realize the effective combination of promoting osteogenesis, inhibiting osteoclast activity, and improving the immune microenvironment to achieve the therapeutic effect of OP. High throughput sequencing results further confirmed the remarkable effectiveness of the nanoplatform in inhibiting apoptosis, modulating inflammatory response, inhibiting osteoclast differentiation and regulating multiple immune signaling pathways. The gas storage nanoplatform not only optimized the OP microenvironment with the assistance of NIR, but also restored the balance between osteoblasts and osteoclasts. This comprehensive therapeutic strategy focused on improving the bone microenvironment, promoting osteogenesis and inhibiting osteoclast activity provides an ideal new solution for the treatment of metabolic bone diseases.
C1 [Yang, Guoyu; Ye, Jing; Wang, Jingcheng; Miao, Xinxin; Deng, Jianjian; Wu, Tianlong; Li, Tao; Cheng, Xigao] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Orthoped, Nanchang 330088, Jiangxi, Peoples R China.
   [Liu, Huijie; Long, Yanli; Jiang, Junkai; Wang, Xiaolei] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330088, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Cheng, XG (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Orthoped, Nanchang 330088, Jiangxi, Peoples R China.; Wang, XL (通讯作者)，Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330088, Jiangxi, Peoples R China.
EM Ndefy12160@ncu.edu.cn; wangxiaolei@ncu.edu.cn
RI yang, guoyu/AAC 8581 2020; tao, li/GXH 7513 2022
FU Thousand Talents Program of Jiangxi Province [JXSQ2019201026];
   Scientific and Technological Cooperation Project of Jiangxi Province
   [20232BBH80001]; Jiangxi Provincial Key Laboratory of Spine
   [2024SSY06131]; Natural Science Foundation of China [82360424]; Natural
   Science Foundation of Jiangxi Province [20224BAB216031, 20224BAB216032];
   Key Research and Development Program of Jiangxi Province [20212BBG73004]
FX This work was funded by the thousand Talents Program of Jiangxi Province
   (JXSQ2019201026 to Xigao Cheng) , the Scientific and Technological
   Cooperation Project of Jiangxi Province (20232BBH80001 to Xigao Cheng) ,
   Jiangxi Provincial Key Laboratory of Spine and Spinal Cord Disease
   (2024SSY06131 to Xigao Cheng) , the Natural Science Foundation of China
   (82360424 to Jing Ye) , the Natural Science Foundation of Jiangxi
   Province (20224BAB216031 to Jing Ye) , the Natural Science Foundation of
   Jiangxi Province (20224BAB216032 to Xinxin Miao) and the Key Research
   and Development Program of Jiangxi Province (20212BBG73004 to Xiaolei
   Wang) .
CR Byrne JD, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl4135
   Chen GY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00208 x
   Chen TN, 2021, BIOL RES, V54, DOI 10.1186/s40659 021 00366 y
   Chen XY, 2022, APPL MATER TODAY, V26, DOI 10.1016/j.apmt.2021.101347
   Dong AG, 2011, J AM CHEM SOC, V133, P998, DOI 10.1021/ja108948z
   Faulkner B, 2019, MOLECULES, V24, DOI 10.3390/molecules24071355
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Gong WJ, 2022, WIRES NANOMED NANOBI, V14, DOI 10.1002/wnan.1744
   Guo MM, 2021, ACS APPL MATER INTER, V13, P18423, DOI 10.1021/acsami.0c20514
   Ho AY, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115435
   Hu BB, 2023, CHEM ENG J, V465, DOI 10.1016/j.cej.2023.142959
   Hu KY, 2023, J INFLAMM RES, V16, P3563, DOI 10.2147/JIR.S423819
   Huang F, 2022, J CELL MOL MED, V26, P3591, DOI 10.1111/jcmm.17399
   Huang Y, 2023, CHEM ENG J, V470, DOI 10.1016/j.cej.2023.144145
   Huang Y, 2020, CHINESE CHEM LETT, V31, P787, DOI 10.1016/j.cclet.2019.05.025
   Jiang JK, 2024, CHEM ENG J, V480, DOI 10.1016/j.cej.2023.147850
   Jin Y, 2023, ENVIRON POLLUT, V336, DOI 10.1016/j.envpol.2023.122407
   Johnson NJJ, 2012, J AM CHEM SOC, V134, P11068, DOI 10.1021/ja302717u
   Kalinkovich A, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105794
   Kang SJ, 2020, INT IMMUNOL, V32, P467, DOI 10.1093/intimm/dxaa017
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Li J, 2021, DYES PIGMENTS, V192, DOI 10.1016/j.dyepig.2021.109451
   Li K, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101839
   Lipina OA, 2020, CERAM INT, V46, P26416, DOI 10.1016/j.ceramint.2020.03.225
   Liu SC, 2022, BIOACT MATER, V18, P91, DOI 10.1016/j.bioactmat.2022.03.013
   Pathak V, 2022, SMALL, V18, DOI 10.1002/smll.202200924
   Qi ML, 2019, DENT MATER, V35, P1665, DOI 10.1016/j.dental.2019.08.115
   Rosic N, 2023, MAR DRUGS, V21, DOI 10.3390/md21040253
   Ruan LF, 2021, ACS APPL MATER INTER, V13, P51362, DOI 10.1021/acsami.1c14711
   Sheng CG, 2023, NANO TODAY, V49, DOI 10.1016/j.nantod.2023.101821
   Sun FJ, 2022, ACS APPL MATER INTER, V14, P8766, DOI 10.1021/acsami.1c21665
   Sun JX, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01813 6
   Tamura H, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16020303
   Thangudu S, 2023, J COLLOID INTERF SCI, V631, P1, DOI 10.1016/j.jcis.2022.10.143
   Wang YX, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109302
   Yang M, 2024, CHINESE CHEM LETT, V35, DOI 10.1016/j.cclet.2023.108468
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Yu JX, 2023, COMPOS PART B ENG, V253, DOI 10.1016/j.compositesb.2023.110554
   Zhang X, 2023, ACS NANO, V17, P21116, DOI 10.1021/acsnano.3c04819
   Zhang YG, 2021, ACS NANO, V15, P17480, DOI 10.1021/acsnano.1c03905
   Zhang YH, 2021, J COLLOID INTERF SCI, V600, P513, DOI 10.1016/j.jcis.2021.05.017
   Zhao YN, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202203099
   Zhao Y, 2017, ORG LETT, V19, P2278, DOI 10.1021/acs.orglett.7b00808
   Zhou TJ, 2023, INT IMMUNOPHARMACOL, V115, DOI 10.1016/j.intimp.2022.109564
   Zhu H, 2021, ACTA BIOMATER, V129, P1, DOI 10.1016/j.actbio.2021.05.007
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 47
TC 2
Z9 2
U1 5
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD OCT
PY 2024
VL 28
AR 101179
DI 10.1016/j.mtbio.2024.101179
EA AUG 2024
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA D2J8I
UT WOS:001294509000001
PM 39221209
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mai, QG
   Zhang, ZM
   Xu, S
   Lu, M
   Zhou, RP
   Zhao, L
   Jia, CH
   Wen, ZH
   Jin, DD
   Bai, XC
AF Mai, Qi Guang
   Zhang, Zhong Min
   Xu, Song
   Lu, Ming
   Zhou, Rong Ping
   Zhao, Li
   Jia, Chun Hong
   Wen, Zhi Hua
   Jin, Da Di
   Bai, Xiao Chun
TI Metformin Stimulates Osteoprotegerin and Reduces RANKL Expression in
   Osteoblasts and Ovariectomized Rats
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE METFORMIN; OSTEOPROTEGERIN; OSTEOCLAST; RECEPTOR ACTIVATOR OF NUCLEAR
   FACTOR kappa B LIGAND; OSETOPOROSIS
ID ANTIDIABETIC DRUG METFORMIN; BONE; DIFFERENTIATION; KINASE;
   OSTEOPOROSIS; FRACTURES; LIGAND
AB Anti diabetic drug metformin has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro and prevent bone loss in ovariectomized (OVX) rats. But the mechanisms through which metformin regulates osteoclastogensis are not known. Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts. In this study, we demonstrated that metformin dose dependently stimulated OPG and reduced RANKL mRNA and protein expression in mouse calvarial osteoblasts and osteoblastic cell line MC3T3 E1. Inhibition of AMP activated protein kinase (AMPK) and CaM kinase kinase (CaMKK), two targets of metformin, suppressed endogenous and metformin induced OPG secretion in osteoblasts. Moreover, supernatant of osteoblasts treated with metformin reduced formation of tartrate resistant acid phosphatase (TRAP) positive multi nucleated cells in Raw264.7 cells. Most importantly, metformin significantly increased total body bone mineral density, prevented bone loss and decreased TRAP positive cells in OVX rats proximal tibiae, accompanied with an increase of OPG and decrease of RANKL expression. These in vivo and in vitro studies suggest that metformin reduces RANKL and stimulates OPG expression in osteoblasts, further inhibits osteoclast differentiation and prevents bone loss in OVX rats. J. Cell. Biochem. 112: 2902 2909, 2011. (C) 2011 Wiley Liss, Inc.
C1 [Mai, Qi Guang; Zhang, Zhong Min; Xu, Song; Lu, Ming; Zhou, Rong Ping; Jin, Da Di; Bai, Xiao Chun] So Med Univ, Dept Cell Biol, Sch Basic Med Sci, Orthoped Res Inst, Guangzhou 510515, Guangdong, Peoples R China.
   [Mai, Qi Guang; Zhang, Zhong Min; Xu, Song; Lu, Ming; Zhou, Rong Ping; Jin, Da Di] So Med Univ, Dept Orthoped, Affiliated Hosp 3, Guangzhou 510665, Guangdong, Peoples R China.
   [Zhao, Li; Jia, Chun Hong; Wen, Zhi Hua; Bai, Xiao Chun] So Med Univ, Guangdong Prov Key Lab Regenerat Med Bone Cartila, Guangzhou 510515, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China
RP Jin, DD (通讯作者)，So Med Univ, Dept Cell Biol, Sch Basic Med Sci, Orthoped Res Inst, Guangzhou 510515, Guangdong, Peoples R China.
EM nyorthop@163.com
RI zhao, liqian/AAO 4313 2021
OI Bai, Xiaochun/0000 0001 9631 4781
FU National Natural Sciences Foundation of China [30771027, 30870955,
   30973036]; Program for New Century Excellent Talents in University
   [NCET 08 0646]
FX Grant sponsor: National Natural Sciences Foundation of China; Grant
   numbers: 30771027, 30870955, 30973036; Grant sponsor: Program for New
   Century Excellent Talents in University; Grant number: NCET 08 0646.
CR Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379
   Bak EJ, 2010, J PERIODONTOL, V81, P412, DOI 10.1902/jop.2009.090414
   BARRETTCONNOR E, 1992, JAMA J AM MED ASSOC, V268, P3333
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kanazawa Ippei, 2009, Clin Calcium, V19, P1319, DOI CliCa090913191319
   Khazai NB, 2009, CURR OPIN ENDOCRINOL, V16, P435, DOI 10.1097/MED.0b013e328331c7eb
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Mcgee SL, 2008, FRONT BIOSCI LANDMRK, V13, P3022, DOI 10.2741/2907
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Patel S, 2008, CALCIFIED TISSUE INT, V82, P87, DOI 10.1007/s00223 007 9082 5
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Singh DK, 2010, ACTA DIABETOL, V47, pS105, DOI 10.1007/s00592 009 0146 z
   Suzuki K, 2000, DIABETES RES CLIN PR, V48, P185, DOI 10.1016/S0168 8227(00)00119 4
   Suzuki K, 2005, DIABETES RES CLIN PR, V68, P117, DOI 10.1016/j.diabres.2004.08.006
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 25
TC 182
Z9 199
U1 0
U2 62
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2011
VL 112
IS 10
BP 2902
EP 2909
DI 10.1002/jcb.23206
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 829YP
UT WOS:000295623300027
PM 21618594
DA 2025 08 17
ER

PT J
AU Huang, HQ
   Feng, XT
   Feng, Y
   Peng, Z
   Jiao, CM
   Chen, H
   Fu, CR
   Xu, F
   Wang, YT
   Su, XP
   Luo, ZW
   Wang, Q
AF Huang, Haoqiang
   Feng, Xinting
   Feng, Ye
   Peng, Zhen
   Jiao, Chunmeng
   Chen, Hui
   Fu, Chieh Ru
   Xu, Feng
   Wang, Yitao
   Su, Xiaoping
   Luo, Zhiwen
   Wang, Qing
TI Bone Targeting HUVEC Derived Exosomes Containing miR 503 5p for
   Osteoporosis Therapy
SO ACS APPLIED NANO MATERIALS
LA English
DT Article
DE osteoporosis; engineered exosomes; miRNA; bone targeting; nanomaterial;
   HUVEC; osteoclast; osteogenic
ID MICRORNAS; SIRNA; METABOLISM; CROSSTALK; DELIVERY; WOMEN
AB Osteoporosis (OP) is a systemic bone disease characterized by decreased bone mass, damaged bone microstructure, increased bone fragility, and increased risk of fractures. It is more common in postmenopausal women and elderly people. The development of drugs with a high bone targeting ability is urgently needed. We prepared a bioactive nanoparticle that modified the exosomes derived from human umbilical vein endothelial cells (HUVEC Exo(miR 503 high)) to contain a large amount of miR 503 5p, with a diameter range of 30 150 nm. The HUVEC Exo(miR 503 high) that we constructed had the same characteristics as ordinary exosomes and could bind to osteoblasts/osteoclasts in vitro. Moreover, they exhibited better bone targeting ability than exosomes derived from other sources of bone marrow stromal cells in vivo. Bioinformatics analysis showed that miR 503 5p is strongly associated with bone related pathways. In vitro experiments showed that HUVEC Exo(miR 503 high) effectively inhibited osteoclast differentiation and promoted osteogenic differentiation. In vivo experiments showed that injecting HUVEC Exo(miR 503 high) into OP mice significantly increased bone density and prevented OP. HUVEC Exo(miR 503 high) can be used for bone targeted therapy of OP, providing an approach to the clinical prevention and treatment of OP.
C1 [Huang, Haoqiang; Xu, Feng; Wang, Yitao; Wang, Qing] Kunshan Hosp Tradit Chinese Med, Dept Orthopaed, Kunshan, Jiangsu 215300, Peoples R China.
   [Feng, Xinting; Luo, Zhiwen] Fudan Univ, Huashan Hosp, Dept Sports Med, Shanghai 200040, Peoples R China.
   [Feng, Ye] Xuzhou Med Univ, Sch Stomatol, Xuzhou 221000, Jiangsu, Peoples R China.
   [Peng, Zhen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Sports Med, Shanghai 200080, Peoples R China.
   [Jiao, Chunmeng] Guangdong Pharmaceut Univ, Guangzhou 510006, Peoples R China.
   [Chen, Hui; Fu, Chieh Ru] Fudan Univ, Inst Acupuncture Res, Inst Integrat Med, Shanghai 200032, Peoples R China.
   [Su, Xiaoping] Guangxi Med Univ, Guangxi Key Lab Oral & Maxillofacial Rehabil & Rec, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Fudan University; Xuzhou Medical University; Shanghai Jiao Tong
   University; Guangdong Pharmaceutical University; Fudan University;
   Guangxi Medical University
RP Wang, Q (通讯作者)，Kunshan Hosp Tradit Chinese Med, Dept Orthopaed, Kunshan, Jiangsu 215300, Peoples R China.; Luo, ZW (通讯作者)，Fudan Univ, Huashan Hosp, Dept Sports Med, Shanghai 200040, Peoples R China.; Su, XP (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Oral & Maxillofacial Rehabil & Rec, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM xiaopingsu2013@aliyun.com; zhiwen.luo_fudan@hotmail.com;
   Doctorwq1983@163.com
RI luo, zhiwen/ABA 9693 2021
FU Suzhou People's Livelihood Science and Technology [SYS2020065]; Kunshan
   High Level Medical Talent Team Project [01201801]; Kunshan Traditional
   Chinese Medicine Technology Development Fund [KZYY2203]; Youth Science
   Fund of Kunshan Traditional Chinese Medicine Hospital [2022QNJJ06]
FX This study was supported by Suzhou People's Livelihood Science and
   Technology (project no. SYS2020065), Kunshan High Level Medical Talent
   Team Project (01201801), Kunshan Traditional Chinese Medicine Technology
   Development Fund (KZYY2203), and Youth Science Fund of Kunshan
   Traditional Chinese Medicine Hospital (2022QNJJ06).
CR Albanese MT, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009951
   Alves CH, 2016, CLIN REV ALLERG IMMU, V51, P27, DOI 10.1007/s12016 015 8522 7
   Bai JX, 2022, RESEARCH CHINA, V2022, DOI 10.34133/2022/9823784
   Bellavia D, 2019, CELL MOL LIFE SCI, V76, P3723, DOI 10.1007/s00018 019 03162 w
   Boon RA, 2015, NAT REV CARDIOL, V12, P135, DOI 10.1038/nrcardio.2014.207
   Cai JY, 2023, AM J SPORT MED, V51, P1267, DOI 10.1177/03635465231155927
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen X., 2011, Physiol. Behav., V176, P139, DOI [10.1053/j.semdp.2015.02.018, DOI 10.1016/J.CLINTHERA.2015.04.002.GUT MICROBIOTA BRAIN, 10.1016/j.ejrad.2015.03.016, DOI 10.1016/J.EJRAD.2015.03.016, 10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]
   Chen YS, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.860364
   Chevillet JR, 2014, P NATL ACAD SCI USA, V111, P14888, DOI 10.1073/pnas.1408301111
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Crawford P, 2005, EPILEPSIA, V46, P117, DOI 10.1111/j.1528 1167.2005.00323.x
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Dumortier O, 2013, CELL METAB, V18, P312, DOI 10.1016/j.cmet.2013.06.004
   El Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Fan YY, 2021, RESEARCH CHINA, V2021, DOI 10.34133/2021/9862876
   Feng XT, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1100310
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Gao WW, 2018, EXP NEUROL, V307, P99, DOI 10.1016/j.expneurol.2018.06.001
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580 018 0045 7
   Goulielmaki E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 13894 9
   Hudson MB, 2014, AM J PHYSIOL CELL PH, V306, pC551, DOI 10.1152/ajpcell.00266.2013
   Ionescu AC, 2022, J DENT, V127, DOI 10.1016/j.jdent.2022.104333
   Isaac R, 2021, CELL METAB, V33, P1744, DOI 10.1016/j.cmet.2021.08.006
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kulkarni JA, 2019, ACCOUNTS CHEM RES, V52, P2435, DOI 10.1021/acs.accounts.9b00368
   Lee CS, 2023, NANO LETT, DOI 10.1021/acs.nanolett.2c04159
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Li H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01175
   Liang GF, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 019 0563 2
   Liu G, 2013, ARTERIOSCL THROM VAS, V33, P170, DOI 10.1161/ATVBAHA.112.300068
   Liu L, 2017, CELL BIOL INT, V41, P112, DOI 10.1002/cbin.10704
   Luo ZW, 2021, WORLD J STEM CELLS, V13, P1762, DOI 10.4252/wjsc.v13.i11.1762
   Luo ZW, 2022, SMALL, V18, DOI 10.1002/smll.202201957
   Luo ZW, 2022, BIOACT MATER, V17, P344, DOI 10.1016/j.bioactmat.2022.01.016
   Luo ZW, 2021, STEM CELLS DEV, V30, P135, DOI 10.1089/scd.2020.0167
   Mao WJ, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.161940
   Milat F, 2016, MED J AUSTRALIA, V205, P185, DOI 10.5694/mja16.00568
   Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011
   Nabet BY, 2017, CELL, V170, P352, DOI 10.1016/j.cell.2017.06.031
   Pan T, 2021, THERANOSTICS, V11, P1192, DOI 10.7150/thno.48152
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Qin C, 2018, JOVE J VIS EXP, DOI 10.3791/58288
   Quirk SE, 2016, EUR PSYCHIAT, V34, P29, DOI 10.1016/j.eurpsy.2015.12.007
   Rheault M, 2023, NUCLEIC ACIDS RES, V51, P2447, DOI 10.1093/nar/gkad094
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Ström JO, 2012, JOVE J VIS EXP, DOI 10.3791/4013
   Sun YY, 2022, BIOMATER RES, V26, DOI 10.1186/s40824 022 00286 2
   Sun YX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00466 4
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Wang HD, 2019, MOL THER, V27, P571, DOI 10.1016/j.ymthe.2019.01.008
   Wang J, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202203361
   Wang JQ, 2021, BIOCHEM GENET, V59, P1146, DOI 10.1007/s10528 021 10048 9
   Wang Q, 2021, ACTA HISTOCHEM, V123, DOI 10.1016/j.acthis.2021.151790
   Wu ZC, 2021, RESEARCH CHINA, V2021, DOI 10.34133/2021/9780943
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Xu YY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.723759
   Yamana K, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12169
   Yan CQ, 2022, DRUG DELIV, V29, P214, DOI 10.1080/10717544.2021.2023699
   Yang CL, 2022, RESEARCH CHINA, V2022, DOI 10.34133/2022/9768687
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 67
TC 4
Z9 4
U1 5
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
EI 2574 0970
J9 ACS APPL NANO MATER
JI ACS Appl. Nano Mater.
PD DEC 12
PY 2023
VL 7
IS 1
BP 1156
EP 1169
DI 10.1021/acsanm.3c05056
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA FB9Z5
UT WOS:001143420000001
DA 2025 08 17
ER

PT J
AU Kamiya, N
   Atsawasuwan, P
   Joiner, DM
   Waldorff, E
   Goldstein, S
   Yamauchi, M
   Mishina, Y
AF Kamiya, Nobuhiro
   Atsawasuwan, Phimon
   Joiner, Danese M.
   Waldorff, Erik, I
   Goldstein, Steve
   Yamauchi, Mitsuo
   Mishina, Yuji
TI Controversy of physiological vs. pharmacological effects of BMP
   signaling: Constitutive activation of BMP type IA receptor dependent
   signaling in osteoblast lineage enhances bone formation and resorption,
   not affecting net bone mass
SO BONE
LA English
DT Article
DE Bone morphogenetic protein; Osteoblast lineage cells; Physiologic;
   Pharmacologic; BMPR1A
ID MORPHOGENETIC PROTEIN 2; ADVERSE EVENTS; OSTEOCLAST DIFFERENTIATION;
   TARGETED DISRUPTION; CORTICAL BONE; SCLEROSTIN; SOST; ROMOSOZUMAB;
   COLLAGEN; DENSITY
AB Bone morphogenetic proteins (BMPs) were first described over 50 years ago as potent inducers of ectopic bone formation when administrated subcutaneously. Preclinical studies have extensively examined the osteoinductive properties of BMPs in vitro and new bone formation in vivo. BMPs (BMP 2, BMP 7) have been used in orthopedics over 15 years. While osteogenic function of BMPs has been widely accepted, our previous studies demonstrated that loss of function of BMP receptor type IA (BMPR1A), a potent receptor for BMP 2, increased net bone mass by significantly inhibiting bone resorption in mice, indicating a positive role of BMP signaling in bone resorption. The physiological role of BMPs (i.e. osteogenic vs. osteoclastogenic) is still largely unknown. The purpose of this study was to investigate the physiological role of BMP signaling in endogenous long bones during adult stages. For this purpose, we conditionally and constitutively activated the Smad dependent canonical BMP signaling thorough BMPR1A in osteoblast lineage cells using the mutant mice (Col1CreER (TM):caBmpr1a). Because trabecular bones were largely increased in the loss of function mouse study for BMPR1A, we hypothesized that the augmented BMP signaling would affect endogenous trabecular bones. In the mutant bones, the Smad phosphorylation was enhanced within physiological level three fold while the resulting gross morphology, bodyweights, bone mass/shape/length, serum calcium/phosphorus levels, collagen cross link patterns, and healing capability were all unchanged. Interestingly, we found; 1) increased expressions of both bone formation and resorption markers in femoral bones, 2) increased osteoblast and osteoclast numbers together with dynamic bone formation parameters by trabecular bone histomorphometry, 3) modest bone architectural phenotype with reduced bone quality (i.e. reduced trabecular bone connectivity, larger diametric size but reduced cortical bone thickness, and reduced bone mechanical strength), and 4) increased expression of SOST, a downstream target of the Smad dependent BMPR1A signaling, in the mutant bones. This study is clinically insightful because gain of function of BMP signaling within a physiological window does not increase bone mass while it alters molecular and cellular aspects of osteoblast and osteoclast functions as predicted. These findings help explain the high doses of BMPs (i.e. pharmacological level) in clinical settings required to substantially induce a bone formation, concurrent with potential unexpected side effects (i.e. bone resorption, inflammation) presumably due to a broader population of cell types exposed to the high dose BMPs rather than osteoblastic lineage cells.
C1 [Kamiya, Nobuhiro; Mishina, Yuji] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 4222A Dent,1011 N Univ Ave, Ann Arbor, MI 48109 USA.
   [Kamiya, Nobuhiro] Tenri Univ, Fac Budo & Sport Studies, 80 Tainosho, Tenri, Nara 6320071, Japan.
   [Kamiya, Nobuhiro] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX 75219 USA.
   [Atsawasuwan, Phimon; Yamauchi, Mitsuo] Univ North Carolina, Sch Dent, Chapel Hill, NC 27599 USA.
   [Atsawasuwan, Phimon] Univ Illinois, Coll Dent, Chicago, IL 60612 USA.
   [Joiner, Danese M.; Waldorff, Erik, I; Goldstein, Steve] Univ Michigan, Sch Med, Dept Orthopaed Surg, Ann Arbor, MI USA.
C3 University of Michigan System; University of Michigan; Texas Scottish
   Rite Hospital for Children; University of North Carolina; University of
   North Carolina Chapel Hill; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; University of
   Michigan System; University of Michigan
RP Mishina, Y (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 4222A Dent,1011 N Univ Ave, Ann Arbor, MI 48109 USA.; Kamiya, N (通讯作者)，Tenri Univ, Fac Budo & Sport Studies, 80 Tainosho, Tenri, Nara 6320071, Japan.
EM nkamiya1@sta.tenri u.ac.jp; mishina@umich.edu
FU National Institutes of Health [R01DE02843]
FX This work was supported by the National Institutes of Health (R01DE02843
   to YM). We thank Drs. Yoshihiro Komatsu for a critical discussion,
   Donald J. Lucus for presentation, Douglas J Adams for microCT
   measurement, and Gloria A Gronowicz for bone histomorphometry.
CR Aro HT, 2011, J BONE JOINT SURG AM, V93A, P801, DOI 10.2106/JBJS.I.01763
   Biswas S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24907 w
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce RW, 2017, BONE, V101, P77, DOI 10.1016/j.bone.2017.04.005
   Cabral WA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004465
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cohen J., 2013, Statistical Power Analysis for the Behavioral Sciences, V2nd, DOI DOI 10.4324/9780203771587
   Delgado Calle J, 2013, MOL CELL ENDOCRINOL, V369, P27, DOI 10.1016/j.mce.2013.02.002
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dmitriev AE, 2011, SPINE J, V11, P500, DOI 10.1016/j.spinee.2011.05.002
   Eyre DR, 2013, CALCIFIED TISSUE INT, V93, P338, DOI 10.1007/s00223 013 9723 9
   FDA, INFUSE BON GRAFT LT
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Gjaltema RAF, 2017, CRIT REV BIOCHEM MOL, V52, P74, DOI 10.1080/10409238.2016.1269716
   Graeff C, 2015, BONE, V81, P364, DOI 10.1016/j.bone.2015.07.036
   Gupta MC, 2005, CYTOKINE GROWTH F R, V16, P347, DOI 10.1016/j.cytogfr.2005.02.004
   Hayano S, 2015, DEVELOPMENT, V142, P1357, DOI 10.1242/dev.118802
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
   Iura A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141345
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2017, J BONE MINER RES, V32, P1716, DOI 10.1002/jbmr.3155
   Kamiya N, 2016, BONE, V91, P53, DOI 10.1016/j.bone.2016.07.002
   Kamiya N, 2011, BIOFACTORS, V37, P75, DOI 10.1002/biof.139
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Kim HKW, 2013, BONE, V54, P141, DOI 10.1016/j.bone.2013.01.031
   Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002
   Komatsu Y, 2013, J BONE MINER RES, V28, P1422, DOI 10.1002/jbmr.1857
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUYTEN FP, 1989, J BIOL CHEM, V264, P13377
   Maes C, 2007, ANN NY ACAD SCI, V1116, P149, DOI 10.1196/annals.1402.060
   MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092 8674(92)90627 O
   Morse A, 2018, CALCIFIED TISSUE INT, V103, P298, DOI 10.1007/s00223 018 0420 6
   Mroz TE, 2010, SPINE, V35, pS86, DOI 10.1097/BRS.0b013e3181d81ef2
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756 3282(93)90245 6
   Ohyama Y, 2004, ENDOCRINOLOGY, V145, P4685, DOI 10.1210/en.2003 1492
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Omi M, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10249
   Omi M, 2019, J BIOL CHEM, V294, P17818, DOI 10.1074/jbc.RA119.009521
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Pan HC, 2017, DEV BIOL, V429, P260, DOI 10.1016/j.ydbio.2017.06.020
   Pflanz D, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09653 9
   Pradhan B.B., SPINE PHILA PA 1976, V31
   SAMPATH TK, 1981, P NATL ACAD SCI BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599
   Seeherman HJ, 2010, J BONE JOINT SURG AM, V92A, P411, DOI 10.2106/JBJS.H.01732
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Taylor Scott, 2018, Bone Rep, V8, P95, DOI 10.1016/j.bonr.2018.03.002
   Törring O, 2015, THER ADV MUSCULOSKEL, V7, P88, DOI 10.1177/1759720X15579189
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460 2075.1995.tb07214.x
   Williams BJ, 2011, SPINE, V36, P1685, DOI 10.1097/BRS.0b013e318216d825
   Woo EJ, 2013, CLIN ORTHOP RELAT R, V471, P1707, DOI 10.1007/s11999 012 2684 x
   Woo EJ, 2012, SPINE J, V12, P894, DOI 10.1016/j.spinee.2012.09.052
   Woo EJ, 2012, J ORAL MAXIL SURG, V70, P765, DOI 10.1016/j.joms.2011.09.008
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Yamauchi M, 2018, METHOD CELL BIOL, V143, P115, DOI 10.1016/bs.mcb.2017.08.006
   Yamauchi M, 2012, ESSAYS BIOCHEM, V52, P113, DOI [10.1042/BSE0520113, 10.1042/bse0520113]
   Zhang YS, 2016, BONE, V88, P74, DOI 10.1016/j.bone.2016.04.022
   Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129
NR 75
TC 11
Z9 13
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2020
VL 138
AR 115513
DI 10.1016/j.bone.2020.115513
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MX7BQ
UT WOS:000557876000041
PM 32603910
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lv, YY
   Zhang, J
   Li, C
   Wang, L
   Lei, L
   Huang, XQ
AF Lv, Yanyan
   Zhang, Jie
   Li, Chao
   Wang, Li
   Lei, Lei
   Huang, Xiaoqiang
TI Network pharmacological analysis to reveal the mechanism governing the
   effect of Qin Xi Tong on osteoarthritis and rheumatoid arthritis
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Arthritis; Molecular docking; Network pharmacology; Traditional Chinese
   medicine
ID ADJUVANT INDUCED ARTHRITIS
AB Introduction Qin Xi Tong ( QXT), produced by water extracts of Caulis Sinomenii, is clinically effective in the therapy of rheumatoid arthritis (RA). It is also a complementary agent for osteoarthritis (OA). This study aimed to screen the candidate targets and identify the potential mechanisms of QXT against RA and OA.
   Method The active ingredients contained in QXT were queried from the TCMSP database. Their predicted targets were obtained through web based databases, including TCMSP, BATMAN TCM, CTD, and PharmMapper. The OA and RA targets were collected from the Genecards database and the GSE55235 dataset. Based on the DAVID database, GO and KEGG enrichment analyses of disease drug common targets predicted potential signaling pathways for QXT. In addition, core targets were identified by mapping component targetdisease interaction networks with Cytoscape 3.9.1 and STRING. The Swissdock and Pymol tools further validate the predicted results.
   Results A total of 161 genes were put forward as potential targets for treating RA and OA. These genes might be involved in joint inflammation, including the IL 17 signaling pathway, MAPK signaling pathway, and TNF signaling pathway. They also regulated the progression of joint injuries, such as apoptosis, Th17 cell differentiation, and osteoclast differentiation. In addition, we identified 12 core targets of QXT. Molecular docking results showed that QXT has a high affinity with these core targets.
   Conclusions This study reveals the mechanism governing the effect of QXT on RA and OA, predicts the direct target, and provides new ideas for clinical treatment.
C1 [Lv, Yanyan; Zhang, Jie; Li, Chao; Wang, Li] Xian 5 Hosp, Dept Rheumatol & Immunol, 112 Xi Guan Zheng Jie, Xian, Peoples R China.
   [Lei, Lei] Northwest Univ, Sch Life Sci & Med, 229 Taibai North Rd, Xian, Peoples R China.
   [Huang, Xiaoqiang] Xian 5 Hosp, Dept Orthoped, 112 Xi Guan Zheng Jie, Xian, Peoples R China.
C3 Northwest University Xi'an
RP Huang, XQ (通讯作者)，Xian 5 Hosp, Dept Orthoped, 112 Xi Guan Zheng Jie, Xian, Peoples R China.
EM lyywjplxj@163.com; 1192294485@qq.com; 563748257@qq.com;
   wangli_050617@sina.com; CheerfulTwo@163.com; huangxq73@163.com
FU Natural Science Basic Research Program of Shaanxi [2023 JC YB 765];
   Administration of Traditional Chinese Medicine of Shaanxi
   [SZY KJCYC 2023 060]; Traditional Chinese Medicine Research Projects of
   Xi'an [SZJ202102]; Scientific Research Project of Xi'an Municipal Health
   Commission [2021yb39]
FX This study was supported by grants from the Natural Science Basic
   Research Program of Shaanxi (No. 2023 JC YB 765), Administration of
   Traditional Chinese Medicine of Shaanxi (No. SZY KJCYC 2023 060),
   Traditional Chinese Medicine Research Projects of Xi'an (No. SZJ202102),
   Scientific Research Project of Xi'an Municipal Health Commission (No.
   2021yb39).
CR Ao LM, 2022, MOL IMMUNOL, V141, P13, DOI 10.1016/j.molimm.2021.11.002
   Bitencourt Ferreira G, 2019, METHODS MOL BIOL, V2053, P189, DOI 10.1007/978 1 4939 9752 7_12
   Camponogara C, 2019, BIOMED PHARMACOTHER, V109, P646, DOI 10.1016/j.biopha.2018.10.132
   Erlandsson MC, 2017, BBA MOL BASIS DIS, V1863, P2158, DOI 10.1016/j.bbadis.2017.06.002
   Fan DP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040498
   Feng ZT, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108759
   Frangos T, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010053
   Grskovic I, 2012, J BONE MINER RES, V27, P2399, DOI 10.1002/jbmr.1682
   Jones IA, 2019, NAT REV RHEUMATOL, V15, P77, DOI 10.1038/s41584 018 0123 4
   Kehribar DY, 2021, TURK J MED SCI, V51, P2142, DOI 10.3906/sag 2008 274
   Khan NM, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02259 z
   Lan Z, 2016, IUBMB LIFE, V68, P429, DOI 10.1002/iub.1499
   Li C, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/5196302
   Liang TZ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04170 0
   Liu JY, 2014, VALUE HEALTH, V17, pA775, DOI 10.1016/j.jval.2014.08.339
   Liu NJ, 2016, NANOSCALE, V8, P4482, DOI 10.1039/c5nr08423g
   Lu X, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.691602
   Malemud CJ, 2019, BIOCHEM PHARMACOL, V165, P33, DOI 10.1016/j.bcp.2019.02.033
   Mohammadi A, 2017, BIOMED PHARMACOTHER, V86, P262, DOI 10.1016/j.biopha.2016.12.023
   Mosquera N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26027 x
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Nomura S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06639 7
   Olesen AE, 2018, PAIN PRACT, V18, P587, DOI 10.1111/papr.12648
   Ramesova A, 2022, ANN ANAT, V239, DOI 10.1016/j.aanat.2021.151781
   Roesch G, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.801505
   Rosales PF, 2019, BIOORG CHEM, V90, DOI 10.1016/j.bioorg.2019.103079
   Rowe MA, 2017, ARTHRITIS RHEUMATOL, V69, P352, DOI 10.1002/art.39844
   Safiri S, 2021, RHEUMATOLOGY, V60, P855, DOI 10.1093/rheumatology/keaa315
   Scotece M, 2020, INFLAMM RES, V69, P415, DOI 10.1007/s00011 020 01326 0
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Vamathevan J, 2019, NAT REV DRUG DISCOV, V18, P463, DOI 10.1038/s41573 019 0024 5
   Wei Y., 2021, SCI TRANSL MED, V2021, P13
   Yang MF, 2022, CONNECT TISSUE RES, V63, P625, DOI 10.1080/03008207.2022.2055552
   Yekkirala AS, 2017, NAT REV DRUG DISCOV, V16, P544, DOI 10.1038/nrd.2017.87
   Zhang F, 2020, DRUG DELIV, V27, P1329, DOI 10.1080/10717544.2020.1818883
   Zhang WJ, 2016, SCI REP UK, V6, DOI 10.1038/srep32400
   Zhao JA, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1054451
   Zheng K, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8474867
NR 40
TC 1
Z9 1
U1 3
U2 12
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD AUG
PY 2023
VL 42
IS 8
BP 2209
EP 2222
DI 10.1007/s10067 023 06625 5
EA MAY 2023
PG 14
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA L5PL6
UT WOS:000986539900001
PM 37162694
DA 2025 08 17
ER

PT J
AU Zhou, H
   Xie, YQ
   Shi, QP
   Huo, Q
   Ma, T
AF Zhou, Huan
   Xie, Yunqiu
   Shi, Qingping
   Huo, Qiang
   Ma, Tao
TI The Effect of Atorvastatin, 3 Hydroxy 3 Methylglutaryl Coenzyme A
   Reductase Inhibitor (HMG CoA) on the Prevention of Osteoporosis in
   Ovariectomized Rabbits
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Osteoporosis; Ovariectomy; Atorvastatin; Osteoblasts; Osteoclasts
ID INDUCED BONE LOSS; OSTEOBLASTIC DIFFERENTIATION; CONTROLLED RELEASE;
   CALCIUM PHOSPHATE; SIMVASTATIN; MODEL; EXPRESSION; STATINS;
   MICROARCHITECTURE; PATHOPHYSIOLOGY
AB Osteoporosis is a most frequent systemic skeletal disease characterized as low bone mineral density and micro architectural deterioration with bone tissue, resulting in an increased bone fragility and fracture risk. Although there are several drugs such as bisphosphonates, estrogen replacement treatment, and selective estrogen receptor modulators, which had been used to treat osteoporosis but these all are not the ideal drugs due to their insufficient curative and adverse side effects. Recently, atorvastatin has prescribed to treat osteoporosis. However, it's clinical outcome and potential treatment mechanism is still unclear. In this study, the bilateral ovariectomy of rabbits was duplicated to develop osteoporosis animal model. The effect of atorvastatin on in vivo was determined and the functional mechanism was studied on in vitro after the curative effect was explored. The found that atorvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of atorvastatin may be due to the promotion of differentiation of osteoblasts by inducing synthesis of vascular endothelial growth factor, bone morphogenetic protein 2 (BMP2), and core binding factor alpha 1 (CBF alpha 1), and inhibition osteoclasts formation through osteoprotegerin (OPG) receptor activatorfor nuclear factor kappa B ligand (RANKL) system. Our study observation gives reliable experimental evidences for clinical application of atorvastatin to treat osteoporosis disorder.
C1 [Zhou, Huan; Ma, Tao] Bengbu Med Coll, Affiliated Hosp 1, Inst Natl Drug Clin Trial, Bengbu 233004, Peoples R China.
   [Xie, Yunqiu] Bengbu Med Coll, Affiliated Hosp 1, Intens Care Unit, Bengbu 233004, Peoples R China.
   [Shi, Qingping] Bengbu Med Coll, Affiliated Hosp 1, Dept Pharm, Bengbu 233004, Peoples R China.
   [Huo, Qiang; Ma, Tao] Bengbu Med Coll, Dept Pharm, Bengbu 233004, Peoples R China.
C3 Bengbu Medical University; Bengbu Medical University; Bengbu Medical
   University; Bengbu Medical University
RP Ma, T (通讯作者)，Bengbu Med Coll, Affiliated Hosp 1, Inst Natl Drug Clin Trial, Bengbu 233004, Peoples R China.; Ma, T (通讯作者)，Bengbu Med Coll, Dept Pharm, Bengbu 233004, Peoples R China.
CR Chen HY, 2012, J ETHNOPHARMACOL, V142, P80, DOI 10.1016/j.jep.2012.04.017
   Dai L., 2014, J BONE MINER METAB
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Furuzawa M, 2014, EXP GERONTOL, V55, P12, DOI 10.1016/j.exger.2014.03.003
   Hamada H, 2012, J APPL BIOMATER FUNC, V10, P22, DOI 10.5301/JABFM.2012.9272
   Hamrick I, 2015, WIEN MED WOCHENSCHR, V165, P54, DOI 10.1007/s10354 014 0335 4
   Handal JA, 2012, J ORTHOP RES, V30, P872, DOI 10.1002/jor.22030
   Hordon LD, 2006, BONE, V38, P444, DOI 10.1016/j.bone.2005.09.020
   Ito Masako, 2013, Clin Calcium, V23, P1035, DOI CliCa130710351039
   Ito Masako, 2006, Clin Calcium, V16, P2034
   Ito T, 2013, J PHARM PHARMACOL, V65, P494, DOI 10.1111/jphp.12008
   Ito T, 2012, J MATER SCI MATER M, V23, P1291, DOI 10.1007/s10856 012 4597 3
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jang H, 2014, BONE, V61, P10, DOI 10.1016/j.bone.2013.12.028
   Johan MF, 2004, BRIT J HAEMATOL, V127, P123, DOI 10.1111/j.1365 2141.2004.05158.x
   Jules J, 2010, EXPERT OPIN THER TAR, V14, P923, DOI 10.1517/14728222.2010.511179
   Kim IS, 2009, J BIOMECH, V42, P2721, DOI 10.1016/j.jbiomech.2009.08.006
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Lasota A, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P129
   Laurent M, 2013, BEST PRACT RES CL EN, V27, P527, DOI 10.1016/j.beem.2013.04.010
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Lin S, 2015, CALCIFIED TISSUE INT, V96, P541, DOI 10.1007/s00223 015 9975 7
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Makras P., 2015, METABOLISM
   Moshiri A, 2015, CALCIFIED TISSUE INT, V96, P552, DOI 10.1007/s00223 015 9981 9
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nahar Gohad P, 2015, CALCIFIED TISSUE INT, V96, P359, DOI 10.1007/s00223 015 9962 z
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Park YS, 2013, AAPS J, V15, P367, DOI 10.1208/s12248 012 9442 6
   Peng JH, 2009, CHIN J INTEGR MED, V15, P198, DOI 10.1007/s11655 009 9001 x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rajamannan NM, 2015, CARDIOLOGY, V132, P11, DOI 10.1159/000381703
   Schorlemmer S, 2005, BONE, V37, P491, DOI 10.1016/j.bone.2005.05.002
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shi Jingli, 2008, J Tradit Chin Med, V28, P211
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Tan S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/814057
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
NR 49
TC 1
Z9 1
U1 0
U2 10
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD JUN
PY 2016
VL 6
IS 6
BP 484
EP 492
DI 10.1166/jbt.2016.1462
PG 9
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DP9DI
UT WOS:000378796500009
DA 2025 08 17
ER

PT J
AU Che, JM
   Yang, JC
   Zhao, B
   Zhang, G
   Wang, LY
   Peng, SL
   Shang, P
AF Che, Jingmin
   Yang, Jiancheng
   Zhao, Bin
   Zhang, Ge
   Wang, Luyao
   Peng, Songlin
   Shang, Peng
TI The Effect of Abnormal Iron Metabolism on Osteoporosis
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Iron metabolism; Osteoporosis; Iron overload; Iron deficiency
ID STATIC MAGNETIC FIELD; BONE LOSS; OXIDATIVE STRESS; IN VITRO; OSTEOCLAST
   DIFFERENTIATION; TRANSFERRIN RECEPTOR; MOLECULAR MECHANISMS; FERROXIDASE
   ACTIVITY; HEART FAILURE; MURINE MODEL
AB Iron is one of the important trace elements in life activities. Abnormal iron metabolism increases the incidence of many skeletal diseases, especially for osteoporosis. Iron metabolism plays a key role in the bone homeostasis. Disturbance of iron metabolism not only promotes osteoclast differentiation and apoptosis of osteoblasts but also inhibits proliferation and differentiation of osteoblasts, which eventually destroys the balance of bone remodeling. The strength and density of bone can be weakened by the disordered iron metabolism, which increases the incidence of osteoporosis. Clinically, compounds or drugs that regulate iron metabolism are used for the treatment of osteoporosis. The goal of this review summarizes the new progress on the effect of iron overload or deficiency on osteoporosis and the mechanism of disordered iron metabolism on osteoporosis. Explaining the relationship of iron metabolism with osteoporosis may provide ideas for clinical treatment and development of new drugs.
C1 [Che, Jingmin; Shang, Peng] Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen 518057, Guangdong, Peoples R China.
   [Che, Jingmin; Yang, Jiancheng; Zhao, Bin] Northwestern Polytech Univ, Sch Life Sci, Xian 710072, Shaanxi, Peoples R China.
   [Che, Jingmin; Yang, Jiancheng; Zhao, Bin; Shang, Peng] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
   [Zhang, Ge; Wang, Luyao] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Peoples R China.
   [Peng, Songlin] Shenzhen Peoples Hosp, Dept Spine Surg, Shenzhen 518000, Guangdong, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Hong Kong Baptist
   University; Jinan University
RP Shang, P (通讯作者)，Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen 518057, Guangdong, Peoples R China.; Shang, P (通讯作者)，Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
EM shangpeng@nwpu.edu.cn
RI 车, 景敏/GYA 3521 2022; Zhang, Ge/N 4150 2013; Yang,
   Jiancheng/JPK 2205 2023; peng, sl/ISA 1370 2023; Li, YiXue/JRW 6306 2023
OI Yang, Jiancheng/0000 0003 0008 9036; Peng, Songlin/0000 0002 4042 7071; 
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood 2007 12 077388
   Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Arosio P, 2010, BBA GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005
   Aydin N, 2011, INT ORTHOP, V35, P135, DOI 10.1007/s00264 009 0932 9
   Babu KR, 2016, J MOL MED, V94, P347, DOI 10.1007/s00109 015 1362 3
   Bacon BR, 2011, HEPATOLOGY, V54, P328, DOI 10.1002/hep.24330
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Balogh E, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040107
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Beard JL, 2001, J NUTR, V131, p568S, DOI 10.1093/jn/131.2.568S
   Bo L, 2016, BIOCHEM BIOPH RES CO, V475, P271, DOI 10.1016/j.bbrc.2016.05.069
   Boll MC, 1999, NEUROSCI LETT, V265, P155, DOI 10.1016/S0304 3940(99)00221 9
   Bystrom LM, 2015, FREE RADICAL BIO MED, V79, P337, DOI 10.1016/j.freeradbiomed.2014.04.035
   Camacho A, 2016, OSTEOARTHR CARTILAGE, V24, P494, DOI 10.1016/j.joca.2015.09.007
   Camaschella C, 2015, NEW ENGL J MED, V372, P1832, DOI 10.1056/NEJMra1401038
   Carberry J, 2018, JACC CARDIOVASC IMAG, V11, P1248, DOI 10.1016/j.jcmg.2017.08.027
   Chalès G, 2003, JOINT BONE SPINE, V70, P263, DOI 10.1016/S1297 319X(03)00035 6
   Chang HC, 2016, EMBO MOL MED, V8, P247, DOI 10.15252/emmm.201505748
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Chang K, 2006, CONNECT TISSUE RES, V47, P222, DOI 10.1080/03008200600858783
   Chen B, 2014, CALCIFIED TISSUE INT, V94, P353, DOI 10.1007/s00223 013 9817 4
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cheng QA, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1345193
   Chiu PF, 2012, J RENAL NUTR, V22, P373, DOI 10.1053/j.jrn.2011.09.007
   Chung JH, 2014, J PERIODONTAL RES, V49, P563, DOI 10.1111/jre.12136
   Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004 0392
   Deyhim F, 2018, INT J VITAM NUTR RES, V88, P58, DOI 10.1024/0300 9831/a000486
   Díaz Castro J, 2012, EUR J NUTR, V51, P241, DOI 10.1007/s00394 011 0212 5
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Doyard M, 2012, OSTEOPOROSIS INT, V23, P2435, DOI 10.1007/s00198 011 1871 z
   Doyard M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148292
   Drakesmith H, 2015, CELL METAB, V22, P777, DOI 10.1016/j.cmet.2015.09.006
   Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ellen BF, 2008, BONE, V43, P162, DOI 10.1016/j.bone.2008.03.003
   Filaire E, 2012, JOINT BONE SPINE, V79, P341, DOI 10.1016/j.jbspin.2012.03.007
   Fontani F, 2015, CALCIFIED TISSUE INT, V96, P335, DOI 10.1007/s00223 015 9961 0
   Frazer DM, 2017, AM J CLIN NUTR, V105, P1255, DOI [10.3945/ajcn.117.158188, 10.3945/ajcn.117.155804]
   Frazer DM, 2014, BIOFACTORS, V40, P206, DOI 10.1002/biof.1148
   Fretham SJB, 2011, ADV NUTR, V2, P112, DOI 10.3945/an.110.000190
   Fu Ying, 2018, Hepatoma Res, V4, DOI 10.20517/2394 5079.2018.29
   Fuqua BK, 2012, J TRACE ELEM MED BIO, V26, P115, DOI 10.1016/j.jtemb.2012.03.015
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Gammella E, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8629024
   Ganz T, 2019, FREE RADICAL BIO MED, V133, P69, DOI 10.1016/j.freeradbiomed.2018.07.003
   Gattermann N, 2009, DTSCH ARZTEBL INT, V106, P499, DOI 10.3238/arztebl.2009.0499
   Goltzman D, 2018, HISTOCHEM CELL BIOL, V149, P305, DOI 10.1007/s00418 018 1648 y
   Gorres KL, 2010, CRIT REV BIOCHEM MOL, V45, P106, DOI 10.3109/10409231003627991
   Grosbois B, 2005, B ACAD NAT MED PARIS, V189, P1649, DOI 10.1016/S0001 4079(19)33422 3
   Guan J, 2009, CANCER CHEMOTH PHARM, V64, P463, DOI 10.1007/s00280 008 0894 4
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hou YL, 2012, GENE, V511, P398, DOI 10.1016/j.gene.2012.09.060
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Jabara HH, 2016, NAT GENET, V48, P74, DOI 10.1038/ng.3465
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Jonker FAM, 2014, J INFECTION, V69, pS23, DOI 10.1016/j.jinf.2014.08.007
   Kali A, 2013, CIRC CARDIOVASC IMAG, V6, P218, DOI 10.1161/CIRCIMAGING.112.000133
   Katsumata SI, 2009, J NUTR, V139, P238, DOI 10.3945/jn.108.093757
   Kautz L, 2014, NAT GENET, V46, P678, DOI 10.1038/ng.2996
   Khechaduri A, 2013, J AM COLL CARDIOL, V61, P1884, DOI 10.1016/j.jacc.2013.02.012
   Klip IT, 2017, EUR J HEART FAIL, V19, P348, DOI 10.1002/ejhf.622
   Klip IT, 2013, AM HEART J, V165, P575, DOI 10.1016/j.ahj.2013.01.017
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Kukulj S, 2010, MED ONCOL, V27, P268, DOI 10.1007/s12032 009 9203 2
   Lakhal Littleton S, 2015, P NATL ACAD SCI USA, V112, P3164, DOI 10.1073/pnas.1422373112
   Lassmann H, 2012, NAT REV NEUROL, V8, P647, DOI 10.1038/nrneurol.2012.168
   Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565 006 0018 z
   Levi S, 2009, BBA GEN SUBJECTS, V1790, P629, DOI 10.1016/j.bbagen.2008.09.008
   Levin A, 2006, AM J KIDNEY DIS, V47, pS9, DOI 10.1053/j.ajkd.2006.04.023
   Li GF, 2012, OSTEOPOROSIS INT, V23, P2403, DOI 10.1007/s00198 012 1982 1
   Lopez A, 2016, LANCET, V387, P907, DOI 10.1016/S0140 6736(15)60865 0
   Lu WY, 2013, EUR J HAEMATOL, V91, P249, DOI 10.1111/ejh.12159
   Manz DH, 2016, ANN NY ACAD SCI, V1368, P149, DOI 10.1111/nyas.13008
   Martínez Hernández R, 2011, NEUROCHEM RES, V36, P2111, DOI 10.1007/s11064 011 0535 x
   Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5
   Matsushima S, 2001, TOXICOL PATHOL, V29, P623, DOI 10.1080/019262301753385951
   Mayle KM, 2012, BBA GEN SUBJECTS, V1820, P264, DOI 10.1016/j.bbagen.2011.09.009
   Medeiros DM, 2004, J NUTR, V134, P3061, DOI 10.1093/jn/134.11.3061
   MENDEL GA, 1961, BLOOD, V18, P727, DOI 10.1182/blood.V18.6.727.727
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Milto IV, 2014, BIOCHEMISTRY MOSCOW+, V79, P1245, DOI 10.1134/S0006297914110121
   Muckenthaler MU, 2017, CELL, V168, P344, DOI 10.1016/j.cell.2016.12.034
   Murphy CJ, 2010, J CARD FAIL, V16, P888, DOI 10.1016/j.cardfail.2010.05.009
   Nairz M, 2007, CELL MICROBIOL, V9, P2126, DOI 10.1111/j.1462 5822.2007.00942.x
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Oexle H, 2003, J LEUKOCYTE BIOL, V74, P287, DOI 10.1189/jlb.0802420
   Orlandi R, 2014, ANN ONCOL, V25, P352, DOI 10.1093/annonc/mdt490
   Parelman M, 2006, EXP BIOL MED, V231, P378, DOI 10.1177/153537020623100403
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Peyssonnaux C, 2008, CELL CYCLE, V7, P28, DOI 10.4161/cc.7.1.5145
   Pietrangelo A, 2016, LIVER INT, V36, P116, DOI 10.1111/liv.13020
   Pollak RD, 2000, BRIT J HAEMATOL, V111, P902
   Qian AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051036
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Raza M, 2014, CURR PHARM BIOTECHNO, V15, P1125, DOI 10.2174/138920101512141202111915
   Recalcati S, 2017, IUBMB LIFE, V69, P389, DOI 10.1002/iub.1628
   Recalcati S, 2010, ANTIOXID REDOX SIGN, V13, P1593, DOI 10.1089/ars.2009.2983
   Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453
   Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Sawicki KT, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002272
   Sert C, 2002, J BONE MINER METAB, V20, P345, DOI 10.1007/s007740200050
   Shaw JG, 2011, ANEMIA, V2011, DOI 10.1155/2011/260380
   Shayman JA, 2014, J LIPID RES, V55, P993, DOI 10.1194/jlr.E049817
   Shen CL, 2013, AM J CLIN NUTR, V98, p1694S, DOI 10.3945/ajcn.113.058255
   Shen CL, 2009, NUTR RES, V29, P437, DOI 10.1016/j.nutres.2009.06.008
   Singh N, 2014, ANTIOXID REDOX SIGN, V20, P1324, DOI 10.1089/ars.2012.4931
   Taniguchi N, 2007, EVID BASED COMPL ALT, V4, P99, DOI 10.1093/ecam/nel067
   Theil EC, 2013, INORG CHEM, V52, P12223, DOI 10.1021/ic400484n
   Thompson JW, 2012, BBA MOL CELL RES, V1823, P1484, DOI 10.1016/j.bbamcr.2012.02.003
   Toxqui L, 2015, NUTRIENTS, V7, P2324, DOI 10.3390/nu7042324
   Toxqui L, 2014, EUR J NUTR, V53, P441, DOI 10.1007/s00394 013 0544 4
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Wang CY, 2017, BLOOD, V130, P73, DOI 10.1182/blood 2016 12 759423
   Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474 4422(14)70117 6
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P367, DOI 10.1007/s00198 015 3386 5
   Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365 2362.2002.0320s1070.x
   Wilkinson N, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00176
   Williams R, 2012, J NEUROCHEM, V120, P7, DOI 10.1111/j.1471 4159.2011.07536.x
   Woo JH, 2015, CELL, V162, P441, DOI 10.1016/j.cell.2015.05.056
   Wu DJ, 2018, DRUG DES DEV THER, V12, P1081, DOI 10.2147/DDDT.S161086
   Wynnyckyj C, 2009, BONE, V44, P840, DOI 10.1016/j.bone.2008.12.014
   Xiong W, 2014, MED ONCOL, V31, DOI 10.1007/s12032 014 0028 2
   Xu WJ, 2015, CELL REP, V13, P533, DOI 10.1016/j.celrep.2015.09.023
   Xu WJ, 2013, CELL METAB, V17, P319, DOI 10.1016/j.cmet.2013.02.004
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Yamamoto A, 2002, J NEUROCHEM, V82, P1137
   Yamasaki K, 2009, TOXICOL LETT, V191, P211, DOI 10.1016/j.toxlet.2009.08.023
   Yan JL, 2015, MOL CELL ENDOCRINOL, V404, P132, DOI 10.1016/j.mce.2015.01.031
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Youdim MBH, 2008, NEUROTOX RES, V14, P45, DOI 10.1007/BF03033574
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhai MM, 2016, BIOELECTROMAGNETICS, V37, P152, DOI 10.1002/bem.21961
   Zhang AS, 2009, J BIOL CHEM, V284, P711, DOI 10.1074/jbc.R800017200
   Zhang CG, 2015, PROTEIN CELL, V6, P88, DOI 10.1007/s13238 014 0119 z
   Zhang J, 2019, BONE, V120, P50, DOI 10.1016/j.bone.2018.10.005
   Zhang J, 2014, BIOL TRACE ELEM RES, V162, P153, DOI 10.1007/s12011 014 0157 7
   Zhao GY, 2012, BIOL TRACE ELEM RES, V150, P487, DOI 10.1007/s12011 012 9511 9
   Zhao NN, 2013, J CLIN INVEST, V123, P2337, DOI 10.1172/JCI67225
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
   Zheng QQ, 2017, LEUKEMIA RES, V58, P55, DOI 10.1016/j.leukres.2017.04.005
   Zhou J, 2015, ENDOCRINE, V49, P258, DOI 10.1007/s12020 014 0439 z
   Zofkova I, 2017, PHYSIOL RES, V66, P391, DOI 10.33549/physiolres.933454
NR 152
TC 87
Z9 96
U1 1
U2 68
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JUN
PY 2020
VL 195
IS 2
BP 353
EP 365
DI 10.1007/s12011 019 01867 4
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA LG2QR
UT WOS:000527952400001
PM 31473898
DA 2025 08 17
ER

PT J
AU Tascau, L
   Gardner, T
   Anan, H
   Yongpravat, C
   Cardozo, CP
   Bauman, WA
   Lee, FY
   Oh, DS
   Tawfeek, HA
AF Tascau, Liana
   Gardner, Thomas
   Anan, Hussein
   Yongpravat, Charlie
   Cardozo, Christopher P.
   Bauman, William A.
   Lee, Francis Y.
   Oh, Daniel S.
   Tawfeek, Hesham A.
TI Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major
   Bone Anabolic Response
SO ENDOCRINOLOGY
LA English
DT Article
ID MESSENGER RNA EXPRESSION; HUMAN FIBROUS DYSPLASIA; PARATHYROID HORMONE;
   OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; TRABECULAR PLATES;
   BINDING PROTEIN; FACTOR RECEPTOR; CORTICAL BONE; CAMP
AB Protein kinase A(PKA) regulates osteoblast cell function in vitro and is activated by important bone mass modulating agents. We determined whether PKA activation in osteoblasts is sufficient to mediate a bone anabolic response. Thus, a mouse model conditionally expressing a constitutively active PKA (CA PKA) in osteoblasts (CA PKA OB mouse) was developed by crossing a 2.3 kb alpha 1 (I) collagen promoter Cre mouse with a floxed CA PKA mouse. Primary osteoblasts from the CA PKA OB mice exhibited higher basal PKA activity than those from control mice. Microcomputed tomographic analysis revealed that CA PKA OB female mice hadan 8.6 fold increase in femoral but only 1.16 fold increase in lumbar 5 vertebral bone volume/total volume. Femur cortical thickness and volume were also higher in the CA PKA OB mice. In contrast, alterations in many femoral microcomputed tomographic parameters in male CA PKA OB mice were modest. Interestingly, the 3 dimensional structure model index was substantially lower both in femur and lumbar 5 of male and female CA PKA OB mice, reflecting an increase in the plate to rod like structure ratio. In agreement, femurs from female CA PKA OB mice had greater load to failure and were stiffer compared with those of control mice. Furthermore, the CA PKA OB mice had higher levels of serum bone turnover markers and increased osteoblast and osteoclast numbers per total tissue area compared with control animals. In summary, constitutive activation of PKA in osteoblasts is sufficient to increase bone mass and favorably modify bone architecture and improve mechanical properties. PKA activation in mature osteoblasts is, therefore, an important target for designing anabolic drugs for treating diseases with bone loss.
C1 [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F 12, Bronx, NY 10468 USA.
   [Gardner, Thomas; Yongpravat, Charlie; Lee, Francis Y.] Columbia Univ, Ctr Orthopaed Res, New York, NY 10029 USA.
   [Oh, Daniel S.] Columbia Univ, Coll Dent Med, New York, NY 10029 USA.
   [Tascau, Liana] Columbia Univ, Dept Mol Med, New York, NY 10029 USA.
   [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Cardozo, Christopher P.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
   [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
   [Anan, Hussein] Temple Univ, Sacred Heart Hosp, Allentown, PA 16102 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   James J. Peters VA Medical Center; Columbia University; Columbia
   University; Columbia University; Icahn School of Medicine at Mount
   Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine
   at Mount Sinai; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University
RP Tawfeek, HA (通讯作者)，James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F 12, Bronx, NY 10468 USA.
EM HeshamA.Tawfeek@va.gov
RI Cardozo, Christopher/R 6021 2019; Tawfeek, Hesham/W 9530 2019
OI Oh, Daniel/0000 0002 8213 7849; Tawfeek, Hesham/0000 0002 6673 7393
FU Department of Veterans Affairs Rehabilitation Research and Development
   Service [B9212C]
FX This work was supported in part by the Department of Veterans Affairs
   Rehabilitation Research and Development Service Grant B9212C (to
   W.A.B.).
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Ahmed I, 2003, MOL ENDOCRINOL, V17, P1607, DOI 10.1210/me.2002 0040
   Aitken SJ, 2009, ARCH BIOCHEM BIOPHYS, V482, P96, DOI 10.1016/j.abb.2008.11.012
   Alman BA, 1996, J ORTHOPAED RES, V14, P311, DOI 10.1002/jor.1100140221
   Altman AR, 2014, BONE, V61, P149, DOI 10.1016/j.bone.2014.01.008
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101
   Benhamou CL, 2007, JOINT BONE SPINE, V74, P39, DOI 10.1016/j.jbspin.2006.06.004
   Benito M, 2003, J CLIN ENDOCR METAB, V88, P1497, DOI 10.1210/jc.2002 021429
   Bianco P, 1998, J CLIN INVEST, V101, P1737, DOI 10.1172/JCI2361
   Billiard J, 2001, J BIOL CHEM, V276, P31238, DOI 10.1074/jbc.M103634200
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Bossis I, 2004, ENDOCRINOLOGY, V145, P5452, DOI 10.1210/en.2004 0900
   Bouxsein ML, 2009, ENDOCRINOLOGY, V150, P144, DOI 10.1210/en.2008 0843
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Calvi LM, 2000, J ENDOCRINOL INVEST, V23, P545, DOI 10.1007/BF03343773
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chang G, 2015, J BONE MINER METAB, V33, P285, DOI 10.1007/s00774 014 0588 4
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ding M, 2000, BONE, V26, P291, DOI 10.1016/S8756 3282(99)00281 1
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fernández Rebollo E, 2011, J BONE MINER RES, V26, P1854, DOI 10.1002/jbmr.408
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   He S, 2014, J CELL BIOCHEM, V115, P1808, DOI 10.1002/jcb.24851
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006 291X(92)91882 Q
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   KANO J, 1991, BIOCHEM BIOPH RES CO, V177, P365, DOI 10.1016/0006 291X(91)91992 L
   Kao RS, 2013, BONE, V55, P277, DOI 10.1016/j.bone.2013.04.001
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Kazakia GJ, 2011, CALCIFIED TISSUE INT, V89, P10, DOI 10.1007/s00223 011 9487 z
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238
   Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008 5472.CAN 05 0580
   Kondo H, 2013, AM J PHYSIOL ENDOC M, V304, pE507, DOI 10.1152/ajpendo.00191.2012
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Lerner U. H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P154
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Liu DY, 2009, MOL ENDOCRINOL, V23, P772, DOI 10.1210/me.2008 0282
   Liu XS, 2013, J BONE MINER RES, V28, P1666, DOI 10.1002/jbmr.1919
   Mariot V, 2008, J CLIN ENDOCR METAB, V93, P661, DOI 10.1210/jc.2007 0927
   Mohan S, 2013, CALCIFIED TISSUE INT, V92, P362, DOI 10.1007/s00223 012 9687 1
   Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Niswender CM, 2005, GENESIS, V43, P109, DOI 10.1002/gene.20159
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Pavel E, 2008, MOL ENDOCRINOL, V22, P430, DOI 10.1210/me.2007 0369
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Remoli C, 2015, J BONE MINER RES, V30, P1030, DOI 10.1002/jbmr.2425
   Rey A, 2006, J BIOL CHEM, V281, P38181, DOI 10.1074/jbc.M606762200
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Riminucci M, 1999, J PATHOL, V187, P249, DOI 10.1002/(SICI)1096 9896(199901)187:2<249::AID PATH222>3.0.CO;2 J
   Rupprecht M, 2006, J ORTHOP RES, V24, P664, DOI 10.1002/jor.20099
   Saggio I, 2014, J BONE MINER RES, V29, P2357, DOI 10.1002/jbmr.2267
   Sakamoto A, 2005, J BIOL CHEM, V280, P21369, DOI 10.1074/jbc.M500346200
   SHENKER A, 1995, HUM MOL GENET, V4, P1675, DOI 10.1093/hmg/4.9.1675
   SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750
   SIDDHANTI SR, 1994, J CELL BIOCHEM, V55, P310, DOI 10.1002/jcb.240550307
   Singh ATK, 2005, ENDOCRINOLOGY, V146, P2171, DOI 10.1210/en.2004 1283
   Sinha P, 2014, J BONE MINER RES, V29, P2414, DOI 10.1002/jbmr.2270
   Skålhegg BS, 2000, FRONT BIOSCI LANDMRK, V5, pD678, DOI 10.2741/Skalhegg
   Sneddon WB, 2007, ENDOCRINOLOGY, V148, P4073, DOI 10.1210/en.2007 0343
   Stein EM, 2014, J BONE MINER RES, V29, P1101, DOI 10.1002/jbmr.2144
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sutter S, 2014, J CLIN ENDOCR METAB, V99, P4231, DOI 10.1210/jc.2014 2177
   Suzuki A, 2008, J CELL BIOCHEM, V104, P304, DOI 10.1002/jcb.21626
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Tawfeek HAW, 2008, ENDOCRINOLOGY, V149, P4016, DOI 10.1210/en.2007 1375
   Taylor SS, 2008, BBA PROTEINS PROTEOM, V1784, P16, DOI 10.1016/j.bbapap.2007.10.002
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tsang KM, 2010, P NATL ACAD SCI USA, V107, P8683, DOI 10.1073/pnas.1003680107
   Turan S, 2014, J BONE MINER RES, V29, P749, DOI 10.1002/jbmr.2070
   Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
   Weinstein LS, 2006, J BONE MINER RES, V21, pP120, DOI 10.1359/JBMR.06S223
   Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004 0865
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Zhang S, 2012, HORM METAB RES, V44, P724, DOI 10.1055/s 0032 1321845
   Zhou B, 2014, J BIOMECH, V47, P702, DOI 10.1016/j.jbiomech.2013.11.039
NR 93
TC 16
Z9 17
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2016
VL 157
IS 1
BP 112
EP 126
DI 10.1210/en.2015 1614
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD5KM
UT WOS:000369962600018
PM 26488807
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhou, X
   Li, MY
   Zhang, MJ
   Zhang, Y
AF Zhou, Xuan
   Li, Mengying
   Zhang, Minjie
   Zhang, Yang
TI Herb couplet medicines (Erxian) protect osteoblasts from high
   glucose induced damage by reducing cell apoptosis in diabetic
   osteoporosis: A network pharmacology and experimental verification based
   study
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Erxian couplet medicines; Diabetic osteoporosis; Osteoblast; Apoptosis;
   Traditional Chinese medicine
ID DIFFERENTIATION; PROLIFERATION
AB Introduction: Traditional Chinese medicine (TCM) has unique advantages in treating diabetic osteoporosis (DOP). This study aimed to explore the mechanisms underlying the protective effects of herb couplet medicines (Erxian) on DOP using network pharmacology and verify these mechanisms using cell experiments. Methods: We used chromatography to analyze the bioactive components of serum containing Erxian couplet medicines (ECMs) and searched for possible targets of the active ingredients in the Traditional Chinese Medicine Systems Pharmacology database. The target proteins of DOP were retrieved from the GeneCards and Online Mendelian Inheritance in Man databases. A component target network diagram was then constructed using the screened drug components and target information for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. In vitro, cell morphological changes were observed using alkaline phosphatase staining, and the effect of the ECMs on osteoblast viability was assessed using a cell counting kit 8 assay. Finally, the pathway information predicted by network pharmacology was validated using flow cytometry, real time polymerase chain reaction, and western blot experiments. Results: Twelve types of active ingredients in serum containing ECMs were obtained via chromatography, and 96 potential targets were identified using network pharmacology analysis. Furthermore, GO and KEGG pathway enrichment analyses revealed that the ECMs might participate in the apoptosis signaling pathway in the treatment of DOP. In vitro tests showed that treatment with ECM serum increased osteoblasts' survival rate and improved the HG group's cell morphology (P < 0.05). BCL2 associated X protein (BAX) expression increased in the HG group but decreased after ECM serum addition (P < 0.05). The expression of B cell lymphoma 2 (BCL 2) was found to be reduced in the HG group but increased after ECM serum addition (P < 0.05). Conclusion: ECMs can treat DOP via multiple targets and multiple signaling pathways. Moreover, the mechanism underlying the effects of ECMs on osteoblasts was verified by inhibiting apoptotic. The complete signaling pathway requires future study.
C1 [Zhou, Xuan] Zhejiang Chinese Med Univ, Clin Sch 4, Hangzhou 310053, Peoples R China.
   [Li, Mengying; Zhang, Minjie] Zhejiang Chinese Med Univ, Pharmaceut Sci, Hangzhou 310053, Peoples R China.
   [Zhang, Yang] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Basic Res Dept, Inst Orthopaed & Trauma, Hangzhou 310053, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Zhang, Y (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Basic Res Dept, Inst Orthopaed & Trauma, Hangzhou 310053, Peoples R China.
EM zhangyang0310@163.com
RI Li, Mengying/IXD 5394 2023; Zhang, Minjie/AFT 6708 2022
OI Zhang, Minjie/0009 0005 4198 7037; 
FU National Natural Science Foundation of China [82274547]; Zhejiang
   Province Natural Science Foundation of China [LD22C060002,
   LGF21H280004]; Zhejiang Provincial Medical and Health Science and
   Technology Fund [2021KY112]; Research Project of Zhejiang Chinese
   Medical University [2023JKZKTS34]
FX This work was supported by the National Natural Science Foundation of
   China under Grant No. 82274547; Zhejiang Province Natural Science
   Foundation of China under Grant No. LD22C060002, and LGF21H280004;
   Zhejiang Provincial Medical and Health Science and Technology Fund under
   Grant No. 2021KY112; Research Project of Zhejiang Chinese Medical
   University under Grant No. 2023JKZKTS34.
CR Ansori A. N. M., 2019, Iraqi Journal of Veterinary Sciences, V33, P13
   Chen JH, 2018, NUTR METAB, V15, DOI 10.1186/s12986 018 0306 7
   Dai Dao Fu, 2014, Longev Healthspan, V3, P6, DOI 10.1186/2046 2395 3 6
   Duan Y, 2023, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1063899
   Duan ZL, 2023, PHYTOMEDICINE, V111, DOI 10.1016/j.phymed.2023.154658
   El Menyiy N, 2019, IRAN J BASIC MED SCI, V22, P1331, DOI 10.22038/ijbms.2019.33549.8004
   Gene Ontology Consortium, 2015, Nucleic Acids Res, V43, pD1049
   Ghodsi M, 2016, J DIABETES METAB DIS, V15, DOI 10.1186/s40200 016 0275 1
   Heikkilä E, 2019, BRIT J PHARMACOL, V176, P3250, DOI 10.1111/bph.14757
   Husen SA, 2017, AIP CONF PROC, V1888, DOI 10.1063/1.5004303
   Jiang RY, 2023, EUR J INTEGR MED, V58, DOI 10.1016/j.eujim.2023.102230
   Jiang W, 2024, CRIT REV FOOD SCI, V64, P5852, DOI 10.1080/10408398.2022.2159317
   Jiang WJ, 2022, THERANOSTICS, V12, P324, DOI 10.7150/thno.63735
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kolibová SD, 2023, ACTA BIOMATER, V162, P254, DOI 10.1016/j.actbio.2023.02.037
   Kong FJ, 2018, CLIN SCI, V132, P111, DOI 10.1042/CS20171432
   Leidig Bruckner G, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472 6823 14 33
   Lin J, 2017, CHIN J INTEGR MED, V23, P91, DOI 10.1007/s11655 016 2642 7
   Liu J, 2022, CELLS BASEL, V11, DOI 10.3390/cells11244091
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Mani A, 2022, J ANIM PHYSIOL AN N, V106, P872, DOI 10.1111/jpn.13645
   Mao ZJ, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113828
   Marrett Elizabeth, 2011, BMC Res Notes, V4, P251, DOI 10.1186/1756 0500 4 251
   Nie Y, 2013, J ETHNOPHARMACOL, V147, P547, DOI 10.1016/j.jep.2013.03.066
   Obeng E., 2021, Braz. J. Biol., V81, P1133, DOI 10.1590/1519 6984.228437
   Ong KL, 2023, LANCET, V402, P203, DOI 10.1016/S0140 6736(23)01301 6
   Qi BC, 2020, DIABETOLOGIA, V63, P1072, DOI 10.1007/s00125 020 05103 w
   Rodríguez González J, 2024, PARASITOL RES, V123, DOI 10.1007/s00436 023 08031 x
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shahen VA, 2023, CALCIFIED TISSUE INT, V112, P452, DOI 10.1007/s00223 023 01062 7
   Stanzione F, 2021, PROGR MED CHEM, V60, P273, DOI 10.1016/bs.pmch.2021.01.004
   Ulbricht Catherine E., 2016, Journal of Dietary Supplements, V13, P136, DOI 10.3109/19390211.2015.1008817
   Umar AH, 2023, J BIOMOL STRUCT DYN, V41, P8544, DOI 10.1080/07391102.2022.2135597
   Wang XH, 2020, ACTA ENDOCRINOL BUCH, V16, P288, DOI 10.4183/aeb.2020.288
   Winarni D, 2022, SCIENTIFICA, V2022, DOI 10.1155/2022/9700794
   Wong KC, 2014, AM J CHINESE MED, V42, P409, DOI 10.1142/S0192415X1450027X
   Wong MS, 2020, HANDB EXP PHARMACOL, V262, P499, DOI 10.1007/164_2019_322
   Xuan C, 2021, EUR J INTEGR MED, V47, DOI 10.1016/j.eujim.2021.101388
   Zhang GX, 2016, PHYTOMEDICINE, V23, P1329, DOI 10.1016/j.phymed.2016.07.003
   Zhang L, 2022, BIOENGINEERED, V13, P14339, DOI 10.1080/21655979.2022.2085388
   Zhang P, 2023, ARCH MED SCI, V19, P138, DOI 10.5114/aoms.2020.101307
   Zhang WW, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.925072
   Zhu FB, 2015, INT J CLIN EXP MED, V8, P12337
NR 43
TC 1
Z9 1
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876 3820
EI 1876 3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD SEP
PY 2024
VL 70
AR 102392
DI 10.1016/j.eujim.2024.102392
EA AUG 2024
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA D6S2T
UT WOS:001297457600001
OA hybrid
DA 2025 08 17
ER

PT J
AU Feng, S
   Wang, T
   Fan, LM
   An, XX
   Ding, XL
   Wang, MJ
   Zhai, XF
   Cao, YJ
   He, J
   Li, Y
AF Feng, Shuai
   Wang, Ting
   Fan, Liming
   An, Xinxin
   Ding, Xinli
   Wang, Minjuan
   Zhai, Xifeng
   Cao, Yanjun
   He, Jiao
   Li, Yang
TI Exploring the potential therapeutic effect of Eucommia
   ulmoides Dipsaci Radix herbal pair on osteoporosis based on
   network pharmacology and molecular docking technology
SO RSC ADVANCES
LA English
DT Article
ID TRADITIONAL CHINESE MEDICINE; NF KAPPA B; BONE; RANKL; KAEMPFEROL;
   QUERCETIN; GENISTEIN; DIFFERENTIATION; OSTEOBLASTS; OSTEOCLASTS
AB Eucommia ulmoides Dipsaci Radix (EU DR) is a commonly used herbal pair for the treatment of osteoporosis (OP) in China. The purpose of this study was to investigate the potential mechanism of EU DR on OP through network pharmacology and molecular docking approaches. Combining data from multiple open source databases and literature mining, the active compounds and potential targets of EU DR were screened out. The OP related targets were identified from the interactive web tool GEO2R. The shared targets were obtained by intersecting the targets of EU DR and OP. The protein protein interaction (PPI) network was constructed via the STRING database and Cytoscape 3.7.2 software. GO and KEGG enrichment analysis were conducted using R 3.6.3 software with adjusted p value < 0.05. Sybyl x 2.1.1 and Autodock Vina 1.1.2 software were used to cross validate the affinity between active compounds and target proteins. Our results showed that a total of 50 active compounds were screened, corresponding to 895 EU DR targets, 2202 OP targets and 144 shared targets. The flavonoids in EU DR played an important role in anti OP. The enrichment analysis of GO and KEGG suggested EU DR exerted a therapeutic effect on OP mainly by regulating the osteoclast differentiation related signaling pathway. Meanwhile, molecular docking results showed that most active compounds in EU DR had strong binding efficiency to the target proteins. In conclusion, this study elaborated the multi component, multi target, and multi pathway interaction mechanism of the EU DR herbal pair in the treatment of OP for the first time, which also provided a pharmacological basis for treating OP.
C1 [Feng, Shuai; Wang, Ting; Fan, Liming; An, Xinxin; Ding, Xinli; Cao, Yanjun; He, Jiao; Li, Yang] Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China.
   [Wang, Minjuan] Shaanxi Prov Ctr Dis Control & Prevent, Phys & Chem Lab, Xian 710054, Peoples R China.
   [Zhai, Xifeng] Xian Med Univ, Sch Pharmaceut Sci, Xian 710021, Peoples R China.
C3 Northwest University Xi'an; Xi'an Medical University
RP Li, Y (通讯作者)，Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China.
EM ly2011@nwu.edu.cn
RI He, Jiao/LZI 3828 2025; Liming, Fan/G 4331 2017
OI Li, Yang/0000 0003 0934 2771
FU National Natural Science Foundation of China [31200253]; Natural Science
   Basic Research Plan in Shaanxi Province of China [2020JZ 45]; Natural
   Science Foundation of Shaanxi Province [2021JQ935]; Scienti.c Research
   Program of Shaanxi Provincial Education Department [18JS109]
FX These works were supported by the National Natural Science Foundation of
   China (No. 31200253), Natural Science Basic Research Plan in Shaanxi
   Province of China (No. 2020JZ 45), Natural Science Foundation of Shaanxi
   Province (No. 2021JQ935), and Scienti.c Research Program of Shaanxi
   Provincial Education Department (No. 18JS109).
CR Aihara S, 2019, RENAL FAILURE, V41, P88, DOI 10.1080/0886022X.2019.1578667
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Chao J, 2017, BIOCHEM PHARMACOL, V139, P94, DOI 10.1016/j.bcp.2017.06.123
   Cheng CF, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112074
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Gao YH, 1999, BIOL PHARM BULL, V22, P805, DOI 10.1248/bpb.22.805
   Geusens P, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10211
   Hao DC, 2014, DRUG DEVELOP RES, V75, P299, DOI 10.1002/ddr.21214
   He TM, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111845
   He XR, 2014, J ETHNOPHARMACOL, V151, P78, DOI 10.1016/j.jep.2013.11.023
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Hu FD, 2015, J ETHNOPHARMACOL, V169, P145, DOI 10.1016/j.jep.2015.04.007
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Jian GH, 2020, BIODATA MIN, V13, DOI 10.1186/s13040 020 00221 y
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Li Y.Y., 2021, PHYTOMEDICINE PLUS, V1
   Liu KF, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153006
   Liu YT, 2020, J ETHNOPHARMACOL, V253, DOI 10.1016/j.jep.2020.112688
   Liu ZW, 2020, COMPUT BIOL MED, V127, DOI 10.1016/j.compbiomed.2020.104074
   Masuhara Masaaki, 2016, Biochem Biophys Rep, V8, P389, DOI 10.1016/j.bbrep.2016.10.013
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Moradifard S, 2020, MUTAT RES REV MUTAT, V786, DOI 10.1016/j.mrrev.2020.108339
   Olszynski WP, 2004, CLIN THER, V26, P15, DOI 10.1016/S0149 2918(04)90002 1
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551 016 0247 1
   Pang JL, 2006, BIOCHEM PHARMACOL, V71, P818, DOI 10.1016/j.bcp.2005.12.023
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun XG, 2018, J PHARMACEUT BIOMED, V154, P40, DOI 10.1016/j.jpba.2018.03.002
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tu QS, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.152405
   Wang ZL, 2006, PHYTOMEDICINE, V13, P718, DOI 10.1016/j.phymed.2005.09.005
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126
   Yan W, 2018, ONCOL REP, V40, P2515, DOI 10.3892/or.2018.6682
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang R, 2014, J ETHNOPHARMACOL, V155, P104, DOI 10.1016/j.jep.2014.04.031
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
   Zhou B, 2021, BIOCHEM BIOPH RES CO, V549, P221, DOI 10.1016/j.bbrc.2021.02.031
NR 44
TC 15
Z9 16
U1 1
U2 55
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD JAN 12
PY 2022
VL 12
IS 4
BP 2181
EP 2195
DI 10.1039/d1ra05799e
PG 15
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA YG3RT
UT WOS:000742410500001
PM 35425231
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kobayakawa, T
   Miyazaki, A
   Kanayama, Y
   Hirano, Y
   Takahashi, J
   Suzuki, T
   Nakamura, Y
AF Kobayakawa, Tomonori
   Miyazaki, Akiko
   Kanayama, Yasuhide
   Hirano, Yuji
   Takahashi, Jun
   Suzuki, Takako
   Nakamura, Yukio
TI Comparable efficacy of denosumab and romosozumab in patients with
   rheumatoid arthritis receiving glucocorticoid administration
SO MODERN RHEUMATOLOGY
LA English
DT Article
DE Romosozumab; denosumab; rheumatoid arthritis; osteoporosis;
   glucocorticoid
ID BONE LOSS; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY;
   PARATHYROID HORMONE; OSTEOBLAST LINEAGE; OSTEOPOROSIS; INHIBITION;
   DENSITY; CLASSIFICATION; ALENDRONATE
AB Objectives Romosozumab is a newly released and widely known molecular targeted drug for severe osteoporosis treatment with comparable effectiveness to denosumab. However, there have been no reports discussing the efficacy of those treatments for rheumatoid arthritis (RA) patients, especially those receiving glucocorticoids. This retrospective observational registry study compared the efficacy of 12 month treatment of denosumab and romosozumab in RA patients under the influence of glucocorticoid intake. Methods Following propensity score matching, 36 patients each in the denosumab and romosozumab groups were analysed in this study. Drug effectiveness was evaluated by measuring bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck at baseline, 6 and 12 months as well as alterations in P1NP, TRACP 5b, and simplified disease activity index (SDAI). The occurrence of adverse events and new fractures was also assessed. Results At 12 months of treatment, BMD at the lumbar spine was increased by 7.5% in the denosumab group and 8.7% in the romosozumab group, which were both significantly and comparably elevated over baseline. At the total hip and femoral neck, romosozumab tended to exhibit favourable efficacy to increase BMD versus denosumab. Both P1NP and TRACP 5b were significantly lower in the denosumab group as compared with the baseline. Conversely in the romosozumab group, P1NP was increased over baseline, while TRACP 5b was decreased. Regarding SDAI alterations, both the romosozumab and denosumab groups exhibited comparable improvements in RA disease activity over time during treatment. Recorded adverse events and new fractures during treatment were few and minor in both groups. Conclusions Romosozumab exhibited comparable efficacy to denosumab for increasing BMD even under the influence of glucocorticoids for treating RA. Both drugs may be therefore suitable for managing osteoporosis in patients with RA and glucocorticoid intake.
C1 [Kobayakawa, Tomonori] Kobayakawa Orthoped & Rheumatol Clin, Shizuoka, Japan.
   [Miyazaki, Akiko; Takahashi, Jun; Suzuki, Takako; Nakamura, Yukio] Shinshu Univ, Dept Orthopaed Surg, Sch Med, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Kanayama, Yasuhide] Toyota Kosei Hosp, Dept Orthoped Surg & Rheumatol, Toyota, Aichi, Japan.
   [Hirano, Yuji] Toyohashi Municipal Hosp, Dept Rheumatol, Toyohashi, Aichi, Japan.
   [Suzuki, Takako] Tokyo Kasei Gakuin Univ, Fac Human Nutr, Dept Human Nutr, Tokyo, Japan.
C3 Shinshu University
RP Nakamura, Y (通讯作者)，Shinshu Univ, Dept Orthopaed Surg, Sch Med, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
EM yxn14@shinshu u.ac.jp
CR Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   Aletaha D., 2010, Arthritis Rheum, V62
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Chen XX, 2013, ANN RHEUM DIS, V72, P1732, DOI 10.1136/annrheumdis 2013 203345
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Ebina K, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105219
   Feng ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080890
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   HAHN TJ, 1981, J CLIN ENDOCR METAB, V52, P111, DOI 10.1210/jcem 52 1 111
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Ishida T, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00899 5
   Klop C, 2015, OSTEOPOROSIS INT, V26, P1831, DOI 10.1007/s00198 015 3084 3
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Kobayakawa T, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101068
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Luellen JK, 2005, EVALUATION REV, V29, P530, DOI 10.1177/0193841X05275596
   Marenzana M, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4305
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713
   Pearce G, 1998, J CLIN ENDOCR METAB, V83, P801, DOI 10.1210/jc.83.3.801
   Peris P, 2021, BONE, V146, DOI 10.1016/j.bone.2021.115887
   Rotta D, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.613720
   Saag KG, 2018, LANCET DIABETES ENDO, V6, P445, DOI 10.1016/S2213 8587(18)30075 5
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sawamura M, 2017, INTERNAL MED, V56, P631, DOI 10.2169/internalmedicine.56.7797
   Shepherd J A, 2006, Osteoporos Int, V17, P1303, DOI 10.1007/s00198 006 0127 9
   SHUTO T, 1994, ENDOCRINOLOGY, V134, P1121, DOI 10.1210/en.134.3.1121
   Sivas F, 2006, RHEUMATOL INT, V26, P896, DOI 10.1007/s00296 006 0104 9
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yamaguchi Yoshihiro, 2020, J Phys Ther Sci, V32, P477, DOI 10.1589/jpts.32.477
   Zhu TY, 2014, J BONE MINER RES, V29, P2118, DOI 10.1002/jbmr.2221
NR 42
TC 20
Z9 20
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1439 7595
EI 1439 7609
J9 MOD RHEUMATOL
JI Mod. Rheumatol.
PD JAN 3
PY 2023
VL 33
IS 1
BP 96
EP 103
DI 10.1093/mr/roac014
EA MAR 2022
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 7W7XS
UT WOS:000768394100001
PM 35234889
DA 2025 08 17
ER

PT J
AU Corraini, P
   Heide Jorgensen, U
   Schiodt, M
   Norholt, SE
   Acquavella, J
   Sorensen, HT
   Ehrenstein, V
AF Corraini, Priscila
   Heide Jorgensen, Uffe
   Schiodt, Morten
   Norholt, Sven Erik
   Acquavella, John
   Sorensen, Henrik Toft
   Ehrenstein, Vera
TI Osteonecrosis of the jaw and survival of patients with cancer: a
   nationwide cohort study in Denmark
SO CANCER MEDICINE
LA English
DT Article
DE Bisphosphonates; bone density conservation agents; drug related side
   effects and adverse reactions; mortality; osteonecrosis
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; BREAST CANCER; RISK FACTORS;
   MYELOMA IX; REGISTRY; DENOSUMAB; QUALITY; OUTCOMES; TRIAL
AB Osteonecrosis of the jaw (ONJ) is an adverse effect of bone targeted therapies, which are used to prevent symptomatic skeletal events following bone malignancy. We examined the association between ONJ and survival among cancer patients treated with bone targeted agents. Using nationwide registries and databases in Denmark, we identified 184 cancer patients with incident ONJ between 2010 and 2015, and a comparison cohort of 1067 cancer patients without ONJ and with a history of hospital administered treatment with bisphosphonates or denosumab initiating from cancer diagnosis. At the date of confirmed ONJ diagnosis, the comparison cohort was matched to the ONJ patients on age, cancer site, year of cancer diagnosis, and stage at diagnosis. The patients were followed up for survival until emigration or 15 June 2016. We computed overall survival and estimated mortality rate ratios adjusted for sex, and for the presence of distant metastases and other comorbidity at start of follow up. A match was found for 149 of the 184 ONJ patients. The 1  and 3 year survival among all 184 cancer patients with ONJ was 70% (95% confidence interval [CI]: 63% 76%) and 42% (95% CI: 34% 51%), respectively. Among the matched patients, ONJ was associated with an adjusted mortality rate ratio of 1.31 (95% CI: 1.01 1.71). ONJ was associated with reduced survival among cancer patients treated with bone targeted agents. ONJ may be a marker of advanced disease or of survival related lifestyle characteristics.
C1 [Corraini, Priscila; Heide Jorgensen, Uffe; Acquavella, John; Sorensen, Henrik Toft; Ehrenstein, Vera] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus N, Denmark.
   [Schiodt, Morten] Rigshosp, Dept Oral & Maxillofacial Surg, Copenhagen O, Denmark.
   [Norholt, Sven Erik] Aarhus Univ, Dept Oral & Maxillofacial Surg, Aarhus, Denmark.
   [Norholt, Sven Erik] Aarhus Univ Hosp, Aarhus, Denmark.
C3 Aarhus University; Rigshospitalet; Aarhus University; Aarhus University
RP Corraini, P (通讯作者)，Aarhus Univ, Dept Clin Epidemiol, Olof Palmes Alle 43 45, DK 8200 Aarhus N, Denmark.
EM p.corraini@clin.au.dk
RI Corraini, Priscila/ABA 5489 2020; Schioedt, Morten/M 4993 2018;
   Corraini, Priscila/K 3951 2012; Sørensen, Henrik/Z 6181 2019
OI Heide Jorgensen, Uffe/0000 0002 8407 4618; Corraini,
   Priscila/0000 0002 7494 8932; Toft Sorensen, Henrik/0000 0003 4299 7040;
   Ehrenstein, Vera/0000 0002 3415 3254; Schiodt,
   Morten/0000 0001 9154 3956
FU Program for Clinical Research Infrastructure (PROCRIN); Amgen Inc.;
   Lundbeck Foundation [R155 2014 2647] Funding Source: researchfish; Novo
   Nordisk Fonden [NNF14SA0015794] Funding Source: researchfish
FX This work was partially supported by the Program for Clinical Research
   Infrastructure (PROCRIN), established by the Lundbeck Foundation and the
   Novo Nordisk Foundation, and by Amgen Inc. The funding agencies had no
   role in design, analysis, or interpretation of the study.
CR [Anonymous], XGEV DEN
   Avilès A, 2017, CL LYMPH MYELOM LEUK, V17, P207, DOI 10.1016/j.clml.2017.02.007
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Fick EM, 2015, CANCER RES TREAT, V47, P747, DOI 10.4143/crt.2014.099
   Gammelager H, 2012, EUR J CANCER PREV, V21, P545, DOI 10.1097/CEJ.0b013e328351c680
   Gammelager H, 2012, CANCER EPIDEMIOL, V36, P381, DOI 10.1016/j.canep.2012.03.012
   Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Helqvist L, 2012, EUR J CANCER CARE, V21, P722, DOI 10.1111/j.1365 2354.2012.01350.x
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Jackson GH, 2014, BRIT J HAEMATOL, V166, P109, DOI 10.1111/bjh.12861
   Lash TL, 2009, J CLIN ONCOL, V27, pE55, DOI 10.1200/JCO.2009.24.1877
   LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.1093/biomet/80.3.557
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2010, SUPPORT CARE CANCER, V18, P1099, DOI 10.1007/s00520 010 0882 1
   Morgan GJ, 2013, CLIN CANCER RES, V19, P6030, DOI 10.1158/1078 0432.CCR 12 3211
   Nielsson Malene Schou, 2012, Clin Epidemiol, V4, P233, DOI 10.2147/CLEP.S32868
   Qi WX, 2014, INT J CLIN ONCOL, V19, P403, DOI 10.1007/s10147 013 0561 6
   Quispe D, 2011, BREAST J, V17, P510, DOI 10.1111/j.1524 4741.2011.01119.x
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Schiodt M, 2015, CLIN EPIDEMIOL, V7, P107, DOI 10.2147/CLEP.S71796
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654 014 9930 3
   Smidt Hansen T, 2013, J ORAL MAXIL SURG, V71, P1532, DOI 10.1016/j.joms.2013.03.019
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Storm HH, 1997, DAN MED BULL, V44, P535
   Tennis P, 2012, PHARMACOEPIDEM DR S, V21, P810, DOI 10.1002/pds.3292
   Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471 2288 11 83
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
NR 36
TC 13
Z9 14
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2045 7634
J9 CANCER MED US
JI Cancer Med.
PD OCT
PY 2017
VL 6
IS 10
BP 2271
EP 2277
DI 10.1002/cam4.1173
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FJ3QE
UT WOS:000412646000011
PM 28941210
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Marie, PJ
AF Marie, Pierre J.
TI Strontium ranelate: New insights into its dual mode of action
SO BONE
LA English
DT Article; Proceedings Paper
CT 34th European Symposium on Calcified Tissues
CY MAY 05 09, 2007
CL Copenhagen, DENMARK
DE strontium ranelate; osteoblast; osteoclast; calcium sensing receptor;
   prostaglandin E 2; receptor activator of nuclear factor kappa B
   ligand/osteoprotegerin
ID MAINTAINING BONE FORMATION; CALCIUM SENSING RECEPTOR; IN VITRO;
   POSTMENOPAUSAL OSTEOPOROSIS; EXTRACELLULAR CALCIUM; MOLECULAR TARGET;
   RESORPTION; RATS; DIFFERENTIATION; LIGAND
AB Strontium ranelate is a newly developed drug that acts as an effective anti osteoporotic therapy in postmenopausal women with osteoporosis. In contrast to other available treatments for osteoporosis, strontium ranelate induces opposite effects on bone resorption and formation. Preclinical studies showed that this dual effect results in increased bone mass and improved bone microarchitecture and strength in intact rodents, and in prevention of bone loss in osteopenic animals. Histomorphometric analysis of unpaired iliac crest bone biopsies in postmenopausal osteoporotic patients treated with strontium ranelate for 3 years showed that the drug increased bone formation, assessed by both the mineralization rate and osteoblast surface, and tended to decrease the osteoclast surface, compared with the placebo group. Three dimensional micro computed tomography analysis of the bone biopsies consistently showed a higher number of trabeculae, decreased trabecular separation, and an increase in cortical thickness, which provides evidence for a better trabecular and cortical bone microarchitecture in treated patients compared with the placebo group. Some mechanisms that underlie the beneficial effects of strontium ranelate on bone metabolism and strength have now been identified. In vitro analyses showed that strontium activates the calcium sensing receptor. We, however, showed that strontium ranelate activates cell replication and downstream ERK1/2 signaling in osteoblasts from calcium sensing receptor null mice, indicating that, in addition to the calcium Sensing receptor, another receptor could mediate the effect of strontium ranelate on osteoblastic cell replication. Other in vitro studies showed that strontium ranelate can activate the osteogenic differentiation of bone marrow strornal cells by activating cyclo oxygenase 2(COX 2) mediated prostaglandin E 2 production. Finally, recent data indicate that strontium ranelate can upregulate osteoprotegerin (OPG) and decrease receptor activator Of nuclear factor kappa B (RANK) ligand expression in human osteoblastic cells, suggesting that strontium ranelate may reduce bone resorption by modulating the RANK/RANK ligand/OPG system, which is essential for osteoclastogenesis. These recent data provide new insights into the mechanism of action of strontium ranelate and give biochemical support to cell physiology which explain the opposite effects of strontium ranelate on bone formation and resorption. (c) 2007 Published by Elsevier Inc.
C1 Hop Lariboisiere, INSERM, F 75475 Paris 10, France.
   Univ Paris 07, Hop Lariboisiere, F 75475 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Lariboisiere Fernand Widal   APHP
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@larib.Inserm.fr
CR Ammann P., 2006, Calcified Tissue International, V78, pS126
   Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Arlot ME, 2005, J BONE MINER RES, V20, pS22
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Bonnelye E, 2006, J BONE MINER RES, V21, pS426
   Brennan T., 2006, CALCIF TISSUE INT S1, V78, P129
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Choudhary S, 2006, J BONE MINER RES, V21, pS301
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   Delannoy P, 2002, METABOLISM, V51, P906, DOI 10.1053/meta.2002.33360
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fromigue O., 2006, CALCIF TISSUE INT S1, V78, P417
   Geoffroy V., 2006, Calcified Tissue International, V78, pS38
   GRYNPAS MD, 1990, BONE, V11, P313, DOI 10.1016/8756 3282(90)90086 E
   Grynpas MD, 1996, BONE, V18, P253, DOI 10.1016/8756 3282(95)00484 X
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hott M, 2003, BONE, V33, P115, DOI 10.1016/S8756 3282(03)00115 7
   Jiang ZH, 2006, NEW CARBON MATER, V21, P1
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Marie PJ, 2006, CURR OPIN RHEUMATOL, V18, pS11, DOI 10.1097/01.bor.0000229522.89546.7b
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   MARIE PJ, 1986, METABOLISM, V35, P547, DOI 10.1016/0026 0495(86)90013 2
   MARIE PJ, 1985, MINER ELECTROL METAB, V11, P5
   Mentaverri R, 2005, J BONE MINER RES, V20, pS309
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
NR 38
TC 145
Z9 154
U1 0
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAY
PY 2007
VL 40
IS 5
SU 1
BP S5
EP S8
DI 10.1016/j.bone.2007.02.003
PG 4
WC Endocrinology & Metabolism
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 164IC
UT WOS:000246226000003
DA 2025 08 17
ER

PT J
AU Ma, RF
   Xu, J
   Dong, B
   Kauther, MD
   Jäger, M
   Wedemeyer, C
AF Ma, Ruofan
   Xu, Jie
   Dong, Bin
   Kauther, Max Daniel
   Jaeger, Marcus
   Wedemeyer, Christian
TI Inhibition of osteoclastogenesis by RNA interference targeting RANK
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE RANK; Inhibition; RNA interference; Cell culture
ID NECROSIS FACTOR RECEPTOR; NF KAPPA B; DIFFERENTIATION; OSTEOPROTEGERIN;
   LIGAND; ACTIVATOR; FAMILY; ROLES; TNF; APOPTOSIS
AB Background: Osteoclasts and osteoblasts regulate bone resorption and formation to allow bone remodeling and homeostasis. The balance between bone resorption and formation is disturbed by abnormal recruitment of osteoclasts. Osteoclast differentiation is dependent on the receptor activator of nuclear factor NF kappa B (RANK) ligand (RANKL) as well as the macrophage colony stimulating factor (M CSF). The RANKL/RANK system and RANK signaling induce osteoclast formation mediated by various cytokines. The RANK/RANKL pathway has been primarily implicated in metabolic, degenerative and neoplastic bone disorders or osteolysis. The central role of RANK/RANKL interaction in osteoclastogenesis makes RANK an attractive target for potential therapies in treatment of osteolysis. The purpose of this study was to assess the effect of inhibition of RANK expression in mouse bone marrow macrophages on osteoclast differentiation and bone resorption.
   Methods: Three pairs of short hairpin RNAs (shRNA) targeting RANK were designed and synthesized. The optimal shRNA was selected among three pairs of shRNAs by RANK expression analyzed by Western blot and Real time PCR. We investigated suppression of osteoclastogenesis of mouse bone marrow macrophages (BMMs) using the optimal shRNA by targeting RANK.
   Results: Among the three shRANKs examined, shRANK 3 significantly suppressed [88.3%] the RANK expression (p < 0.01). shRANK 3 also brought about a marked inhibition of osteoclast formation and bone resorption as demonstrated by tartrate resistant acid phosphatase (TRAP) staining and osteoclast resorption assay. The results of our study show that retrovirus mediated shRANK 3 suppresses osteoclast differentiation and osteolysis of BMMs.
   Conclusions: These findings suggest that retrovirus mediated shRNA targeting RANK inhibits osteoclast differentiation and osteolysis. It may appear an attractive target for preventing osteolysis in humans with a potential clinical application.
C1 [Jaeger, Marcus; Wedemeyer, Christian] Univ Duisburg Essen, Dept Orthopaed, D 45122 Essen, Germany.
   [Ma, Ruofan; Xu, Jie; Dong, Bin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthopaed, Guangzhou 510275, Guangdong, Peoples R China.
   [Kauther, Max Daniel] Univ Duisburg Essen, Dept Trauma Surg, D 45122 Essen, Germany.
C3 University of Duisburg Essen; Sun Yat Sen University; University of
   Duisburg Essen
RP Wedemeyer, C (通讯作者)，Univ Duisburg Essen, Dept Orthopaed, Hufelandstr 55, D 45122 Essen, Germany.
EM christian.wedemeyer@uni due.de
RI Kauther, Max/A 1505 2016
OI Kauther, Max/0000 0003 3795 6068; Jager, Marcus/0000 0001 9516 1058
FU Research Fund of Social Development; Science and Technology Research of
   Guangdong Province of China [2009B030801025, 2011B031800156]; University
   of Duisburg Essen; DFG (Deutsche Forschungsgemeinschaft) [WE 3634/1 1,
   WE 3634/1 2]
FX This study was financed by the Research Fund of Social Development and
   the Science and Technology Research of Guangdong Province of China
   (2009B030801025, 2011B031800156) and by the University of Duisburg Essen
   with money given in addition to the DFG (Deutsche
   Forschungsgemeinschaft) grant of Christian Wedemeyer and Max Daniel
   Kauther (WE 3634/1 1 and WE 3634/1 2).
CR Amarzguioui M, 2005, FEBS LETT, V579, P5974, DOI 10.1016/j.febslet.2005.08.070
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chung JY, 2002, J CELL SCI, V115, P679
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Eske K, 2009, J IMMUNOL METHODS, V342, P13, DOI 10.1016/j.jim.2008.11.011
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   He S, 2009, MOL BIOL REP, V36, P2153, DOI 10.1007/s11033 008 9429 7
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192
   Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Qin L, 2008, BIOCHEM BIOPH RES CO, V371, P531, DOI 10.1016/j.bbrc.2008.04.117
   Shipman CM, 2003, CANCER RES, V63, P912
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stolina M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2879
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529 0131(199912)42:12<2532::AID ANR5>3.0.CO;2 2
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weiner LM, 2006, J IMMUNOTHER, V29, P1, DOI 10.1097/01.cji.0000192105.24583.83
   Yeon JT, 2012, BMB REP, V45, P171, DOI 10.5483/BMBRep.2012.45.3.171
NR 33
TC 11
Z9 19
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 22
PY 2012
VL 13
AR 154
DI 10.1186/1471 2474 13 154
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 025BP
UT WOS:000310159100001
PM 22913338
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lipton, A
   Fizazi, K
   Stopeck, AT
   Henry, DH
   Brown, JE
   Yardley, DA
   Richardson, GE
   Siena, S
   Maroto, P
   Clemens, M
   Bilynskyy, B
   Charu, V
   Beuzeboc, P
   Rader, M
   Viniegra, M
   Saad, F
   Ke, CL
   Braun, A
   Jun, S
AF Lipton, Allan
   Fizazi, Karim
   Stopeck, Alison T.
   Henry, David H.
   Brown, Janet E.
   Yardley, Denise A.
   Richardson, Gary E.
   Siena, Salvatore
   Maroto, Pablo
   Clemens, Michael
   Bilynskyy, Boris
   Charu, Veena
   Beuzeboc, Philippe
   Rader, Michael
   Viniegra, Maria
   Saad, Fred
   Ke, Chunlei
   Braun, Ada
   Jun, Susie
TI Superiority of denosumab to zoledronic acid for prevention of
   skeletal related events: A combined analysis of 3 pivotal, randomised,
   phase 3 trials
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Skeletal related events; Denosumab; Zoledronic acid; Bone metastasis
ID SPINAL CORD COMPRESSION; ADVANCED BREAST CANCER; KAPPA B LIGAND; BONE
   METASTASES; PROSTATE CANCER; DOUBLE BLIND; OSTEOPROTEGERIN OPG; RECEPTOR
   ACTIVATOR; MULTIPLE MYELOMA; DRUG MANAGEMENT
AB Background: Patients with bone metastases from advanced cancer often experience skeletal related events (SRE), which cause substantial pain and morbidity. Denosumab, a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), is a novel bone targeted agent with a distinct mechanism of action relative to the bisphosphonate zoledronic acid, for prevention of SRE. This pre planned analysis evaluates the efficacy and safety of denosumab versus zoledronic acid across three pivotal studies.
   Methods: Patient level data from three identically designed, randomised, double blind, active controlled, phase 3 trials of patients with breast cancer, prostate cancer, other solid tumours or multiple myeloma were combined. End points included time to first SRE, time to first and subsequent (multiple) SRE, adverse events, time to disease progression and overall survival.
   Findings: Denosumab was superior to zoledronic acid in delaying time to first on study SRE by a median 8.21 months, reducing the risk of a first SRE by 17% (hazard ratio, 0.83 [95% confidence interval (CI): 0.76 0.90]; P < 0.001). Efficacy was demonstrated for first and multiple events and across patient subgroups (prior SRE status; age). Disease progression and overall survival were similar between the treatments. In contrast to zoledronic acid, denosumab did not require monitoring or dose modification/withholding based on renal status, and was not associated with acute phase reactions. Hypocalcaemia was more common for denosumab. Osteonecrosis of the jaw occurred at a similar rate (P = 0.13).
   Conclusion: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lipton, Allan] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA.
   [Fizazi, Karim] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
   [Stopeck, Alison T.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
   [Henry, David H.] Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19107 USA.
   [Brown, Janet E.] Canc Res UK Clin Ctr, Leeds, W Yorkshire, England.
   [Yardley, Denise A.] Sarah Cannon Res Inst, Nashville, TN USA.
   [Richardson, Gary E.] Cabrini Hosp, Malvern, Vic, Australia.
   [Siena, Salvatore] Osped Niguarda Ca Granda, Milan, Italy.
   [Maroto, Pablo] Hosp La Santa Creu & St Pau, Barcelona, Spain.
   [Clemens, Michael] Klinikum Mutterhaus Borromaeerinnen, Trier, Germany.
   [Bilynskyy, Boris] Canc Treatment & Diagnost Ctr, Lvov, Ukraine.
   [Charu, Veena] Pacific Canc Med Ctr Inc, Anaheim, CA USA.
   [Beuzeboc, Philippe] Inst Curie, Paris, France.
   [Rader, Michael] Nyack Hosp, Union State Bank Canc Ctr, Nyack, NY USA.
   [Viniegra, Maria] Corporac Med Gen San Martin, Buenos Aires, DF, Argentina.
   [Saad, Fred] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
   [Ke, Chunlei; Braun, Ada; Jun, Susie] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Yardley, Denise A.] Tennessee Oncol PLLC, Nashville, TN USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; UNICANCER; Gustave
   Roussy; Universite Paris Saclay; University of Arizona; Arizona Center
   Cancer Care; University of Pennsylvania; University of Leeds; Cancer
   Research UK; Sarah Cannon Research Institute; Cabrini Health; IRCCS Ca
   Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda;
   UNICANCER; Universite PSL; Institut Curie; Universite de Montreal;
   Amgen; Tennessee Oncology
RP Lipton, A (通讯作者)，Penn State Univ, Milton S Hershey Med Ctr, 500 Univ Dr Suite CH46, Hershey, PA 17033 USA.
EM alipton@hmc.psu.edu
RI SIENA, SALVATORE/AAC 5806 2019; Saad, Fred/ADN 9925 2022; Richardson,
   Gary/AAB 1728 2019
OI SIENA, SALVATORE/0000 0002 2681 2846; 
FU Amgen Inc., Thousand Oaks, CA; Amgen Inc.; Cancer Research UK; The
   Francis Crick Institute [10048] Funding Source: researchfish
FX This analysis was sponsored by Amgen Inc., Thousand Oaks, CA. Wanda J.
   Krall, Ph. D. (consultant funded by Amgen Inc.) and Amy K.
   Foreman Wykert, Ph. D. (Amgen Inc.) assisted with manuscript drafting,
   editing and formatting. We thank the patients, investigators and study
   staff for participating in the studies comprising this analysis.
CR Abrahm JL, 2008, JAMA J AM MED ASSOC, V299, P937, DOI 10.1001/jama.299.8.937
   [Anonymous], 2009, ZOM ZOL AC INJ CONC
   [Anonymous], 2012, XGEVA DEN INJ SUBC U
   Barlev A, 2010, J MANAGE CARE PHARM, V16, P693, DOI 10.18553/jmcp.2010.16.9.693
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Clare C, 2005, PALLIATIVE MED, V19, P521, DOI 10.1191/0269216305pm1079oa
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5 6 463
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Cozzolino M, 2009, BLOOD PURIFICAT, V27, P338, DOI 10.1159/000209246
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lage MJ, 2008, AM J MANAG CARE, V14, P317
   Launay Vacher V, 2007, CANCER AM CANCER SOC, V110, P1376, DOI 10.1002/cncr.22904
   Launay Vacher V, 2009, CLIN GENITOURIN CANC, V7, pE83, DOI 10.3816/CGC.2009.n.029
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Oh WK, 2007, CANCER AM CANCER SOC, V109, P1090, DOI 10.1002/cncr.22504
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck Alison, 2012, J Med Econ, V15, P712, DOI 10.3111/13696998.2012.675380
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 36
TC 436
Z9 457
U1 3
U2 53
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD NOV
PY 2012
VL 48
IS 16
BP 3082
EP 3092
DI 10.1016/j.ejca.2012.08.002
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 030KH
UT WOS:000310569100017
PM 22975218
DA 2025 08 17
ER

PT J
AU Stegen, S
   Moermans, K
   Stockmans, I
   Thienpont, B
   Carmeliet, G
AF Stegen, Steve
   Moermans, Karen
   Stockmans, Ingrid
   Thienpont, Bernard
   Carmeliet, Geert
TI The serine synthesis pathway drives osteoclast differentiation through
   epigenetic regulation of NFATc1 expression
SO NATURE METABOLISM
LA English
DT Article
ID METABOLIC REGULATION; CELL FATE; MYC
AB Bone resorbing osteoclasts are vital for postnatal bone health, as increased differentiation or activity results in skeletal pathologies such as osteoporosis. The metabolism of mature osteoclasts differs from their progenitor cells, but whether the observed metabolic changes are secondary to the altered cell state or actively drive the process of cell differentiation is unknown. Here, we show that transient activation of the serine synthesis pathway (SSP) is essential for osteoclastogenesis, as deletion of the rate limiting enzyme phosphoglycerate dehydrogenase in osteoclast progenitors impairs their differentiation and results in increased bone mass. In addition, pharmacological phosphoglycerate dehydrogenase inhibition abrogated bone loss in a mouse model of postmenopausal osteoporosis by blocking bone resorption. Mechanistically, SSP derived alpha ketoglutarate is necessary for histone demethylases that remove repressive histone methylation marks at the nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1) gene locus, thereby inducing NFATc1 expression and consequent osteoclast maturation. Taken together, this study reveals a metabolic epigenetic coupling mechanism that directs osteoclast differentiation and suggests that the SSP can be therapeutically targeted to prevent osteoporotic bone loss.
   Stegen et al. show that serine metabolism is transiently upregulated during osteoclastogenesis, and it drives osteoclast differentiation via epigenetic regulation of NFATc1 expression.
C1 [Stegen, Steve; Moermans, Karen; Stockmans, Ingrid; Carmeliet, Geert] Katholieke Univ Leuven, Dept Chron Dis & Metab, Lab Clin & Expt Endocrinol, Leuven, Belgium.
   [Thienpont, Bernard] Katholieke Univ Leuven, Dept Human Genet, Lab Funct Epigenet, Leuven, Belgium.
C3 KU Leuven; KU Leuven
RP Carmeliet, G (通讯作者)，Katholieke Univ Leuven, Dept Chron Dis & Metab, Lab Clin & Expt Endocrinol, Leuven, Belgium.
EM geert.carmeliet@kuleuven.be
RI ; Thienpont, Bernard/JBR 9581 2023
OI Stegen, Steve/0000 0002 4471 6401; Thienpont,
   Bernard/0000 0002 8772 6845; 
FU Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
   [G.0B3418, G0C5120N]; Research Foundation Flanders (FWO) [I013518N];
   Large Scale Research Infrastructure [3M180296, ZAP17/011]; KU Leuven
   [12H5920N]; FWO
FX This work was supported by funding from the Research Foundation Flanders
   (FWO; G.0B3418, G0C5120N and Large Scale Research Infrastructure
   I013518N) and the KU Leuven (C24/17/077). S.S. received funding from the
   FWO (senior postdoctoral fellowship; 12H5920N). B.T. received funding
   from the KU Leuven (3M180296 and ZAP17/011). The authors wish to thank
   N. Narinx for help with the analysis of circulating myeloid cell
   populations.
CR Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Baker SA, 2023, NAT REV MOL CELL BIO, V24, P355, DOI 10.1038/s41580 022 00572 w
   Baksh SC, 2021, TRENDS CELL BIOL, V31, P24, DOI 10.1016/j.tcb.2020.09.010
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Brunner JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14285 1
   Caputo VS, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101989
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Deepak V, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2201490119
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Devignes CS, 2022, BONE REP, V17, DOI 10.1016/j.bonr.2022.101620
   DiGirolamo DJ, 2012, NAT REV RHEUMATOL, V8, P674, DOI 10.1038/nrrheum.2012.157
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Lee S, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115836
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Lieben L, 2012, J CLIN INVEST, V122, P1803, DOI 10.1172/JCI45890
   Loopmans S, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.930358
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Stegen S, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00185 7
   Stegen S, 2021, J BONE MINER RES, V36, P604, DOI 10.1002/jbmr.4219
   Stegen S, 2020, DEV CELL, V53, P530, DOI 10.1016/j.devcel.2020.05.001
   Stegen S, 2019, NATURE, V565, P511, DOI 10.1038/s41586 019 0874 3
   Stegen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04679 7
   Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015
   Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Taubmann J, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77892 4
   Tian JQ, 2023, NUTRIENTS, V15, DOI 10.3390/nu15030701
   Tournaire G, 2022, CELL REP, V40, DOI 10.1016/j.celrep.2022.111105
   van Gastel N, 2021, NAT METAB, V3, P11, DOI 10.1038/s42255 020 00321 3
   Whittier DE, 2020, OSTEOPOROSIS INT, V31, P1607, DOI 10.1007/s00198 020 05438 5
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Yoshida K, 2004, J BIOL CHEM, V279, P3573, DOI 10.1074/jbc.C300507200
   Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580 019 0123 5
NR 49
TC 23
Z9 25
U1 16
U2 48
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2522 5812
J9 NAT METAB
JI Nat. Metab.
PD JAN
PY 2024
VL 6
IS 1
BP 141
EP +
DI 10.1038/s42255 023 00948 y
EA JAN 2024
PG 28
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HK5V5
UT WOS:001139770800002
PM 38200114
OA hybrid
DA 2025 08 17
ER

PT J
AU Bird, ST
   Gelperin, K
   Smith, ER
   Jung, TH
   Lyu, H
   Thompson, A
   Easley, O
   Naik, KB
   Zhao, YQ
   Kambhampati, R
   Wernecke, M
   Niak, A
   Zemskova, M
   Chillarige, Y
   Kelman, JA
   Graham, DJ
AF Bird, Steven T.
   Gelperin, Kate
   Smith, Elizabeth R.
   Jung, Tae Hyun
   Lyu, Hai
   Thompson, Aliza
   Easley, Olivia
   Naik, Kushal B.
   Zhao, Yueqin
   Kambhampati, Rekha
   Wernecke, Michael
   Niak, Ali
   Zemskova, Marina
   Chillarige, Yoganand
   Kelman, Jeffrey A.
   Graham, David J.
TI The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by
   Stage of Chronic Kidney Disease: A Target Trial Emulation
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID BONE MINERAL DENSITY; RENAL FUNCTION; FRACTURE; HYPERPARATHYROIDISM;
   BISPHOSPHONATES; OSTEOPOROSIS; ALENDRONATE; WOMEN; SCORE
AB Background: There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD).
   Objective: To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD mineral and bone disorder (CKD MBD).
   Design: Target trial emulation.
   Setting: Medicare fee for service data with prescription drug coverage, 2012 to 2020.
   Participants: Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis.
   Measurements: Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated.
   Results: A total of 361453 patients treated with denosumab, 829044 treated with oral bisphosphonates, and 160413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (P<0.001), with greatest risk among dialysis dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non dialysis dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD+DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates.
   Limitation: Generalizability to men and non Medicare populations.
   Conclusion: Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD MBD.
C1 [Bird, Steven T.; Gelperin, Kate; Niak, Ali; Graham, David J.] US FDA, Ctr Drug Evaluat & Res, Off Pharmacovigilance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA.
   [Smith, Elizabeth R.; Lyu, Hai; Naik, Kushal B.; Wernecke, Michael; Chillarige, Yoganand] Acumen, Burlingame, CA USA.
   [Jung, Tae Hyun; Zhao, Yueqin] US FDA, Div Biometr 7, Ctr Drug Evaluat & Res, Off Biostat, Silver Spring, MD USA.
   [Thompson, Aliza; Kambhampati, Rekha] US FDA, Div Cardiol & Nephrol, Ctr Drug Evaluat & Res, Off Cardiol Hematol Endocrinol & Nephrol, Silver Spring, MD USA.
   [Easley, Olivia; Zemskova, Marina] US FDA, Div Gen Endocrinol, Ctr Drug Evaluat & Res, Off Cardiol Hematol Endocrinol & Nephrol, Silver Spring, MD USA.
   [Kelman, Jeffrey A.] Ctr Medicare & Medicaid Serv, Washington, DC USA.
C3 US Food & Drug Administration (FDA); US Food & Drug Administration
   (FDA); US Food & Drug Administration (FDA); US Food & Drug
   Administration (FDA); CMS Alliance to Modernize Healthcare; Centers for
   Medicare & Medicaid Services
RP Bird, ST (通讯作者)，US FDA, Ctr Drug Evaluat & Res, Off Pharmacovigilance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA.
EM steven.bird@fda.hhs.gov
RI ; Naik, Kushal/MIK 4897 2025
OI Wernecke, Michael/0000 0001 9553 3122; Naik, Kushal/0000 0002 8017 9228;
   Smith, Elizabeth/0000 0003 3415 1061
FU U.S. Food and Drug Administration
FX By the U.S. Food and Drug Administration through an interagency
   agreement with the Centers for Medicare & Medicaid Services.
CR Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Bird ST, 2024, JAMA J AM MED ASSOC, V331, P491, DOI 10.1001/jama.2023.28239
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Chen CL, 2020, OSTEOPOROSIS INT, V31, P1507, DOI 10.1007/s00198 020 05391 3
   Chen CH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.822178
   Chen CL, 2015, J CLIN ENDOCR METAB, V100, P2784, DOI 10.1210/jc.2015 1259
   Chen CL, 2014, J CLIN ENDOCR METAB, V99, P2426, DOI 10.1210/jc.2014 1154
   Cowan A, 2023, J BONE MINER RES, V38, P650, DOI 10.1002/jbmr.4804
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Evenepoel P, 2021, OSTEOPOROSIS INT, V32, P2397, DOI 10.1007/s00198 021 05975 7
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P625, DOI 10.1007/s00198 011 1583 4
   Hara T, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013424.pub2
   Hernán MA, 2022, JAMA J AM MED ASSOC, V328, P2446, DOI 10.1001/jama.2022.21383
   Hernán MA, 2021, NEW ENGL J MED, V385, P1345, DOI 10.1056/NEJMp2113319
   Hernán MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254
   Huynh ALH, 2016, PHARMACOEPIDEM DR S, V25, P1274, DOI 10.1002/pds.4045
   Imbens GW, 2000, BIOMETRIKA, V87, P706, DOI 10.1093/biomet/87.3.706
   Jalleh Ryan, 2018, Case Rep Nephrol, V2018, P7384763, DOI 10.1155/2018/7384763
   Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kim KJ, 2020, CALCIFIED TISSUE INT, V107, P567, DOI 10.1007/s00223 020 00754 8
   Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523 1755.2005.00365.x
   Liu SG, 2007, J AM SOC NEPHROL, V18, P1637, DOI 10.1681/ASN.2007010068
   Lubwama R, 2014, OSTEOPOROSIS INT, V25, P1607, DOI 10.1007/s00198 014 2645 1
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Miller PD, 2005, J BONE MINER RES, V20, P2105, DOI 10.1359/JBMR.050817
   Nickolas TL, 2006, J AM SOC NEPHROL, V17, P3223, DOI 10.1681/ASN.2005111194
   Qaseem A, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 1034
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Segal JB, 2017, MED CARE, V55, P716, DOI 10.1097/MLR.0000000000000729
   Sorensen HT, 2015, AMGEN
   Thongprayoon C, 2018, OSTEOPOROSIS INT, V29, P1737, DOI 10.1007/s00198 018 4533 6
   Torregrosa JV, 2010, NEFROLOGIA, V30, P288, DOI [10.3265/Nefrologia.pre2010.Mar.10320, 10.3265/Nefrologia.pre2010.Apr.10320]
   Tsvetov G, 2020, OSTEOPOROSIS INT, V31, P655, DOI 10.1007/s00198 019 05261 7
   Wetmore JB, 2005, NEPHROLOGY, V10, P393, DOI 10.1111/j.1440 1797.2005.00436.x
   Wilson LM, 2017, ANN INTERN MED, V166, P649, DOI 10.7326/M16 2752
NR 41
TC 3
Z9 3
U1 4
U2 5
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106 1572,
   UNITED STATES
SN 0003 4819
EI 1539 3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN
PY 2025
VL 178
IS 1
BP 29
EP +
DI 10.7326/M24 0013
EA NOV 2024
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA X8B6Y
UT WOS:001361309800001
PM 39556837
DA 2025 08 17
ER

PT J
AU Li, M
   Zhang, ND
   Wang, Y
   Han, T
   Jiang, YP
   Rahman, K
   Qin, LP
   Xin, HL
   Zhang, QY
AF Li, Mei
   Zhang, Nai Dan
   Wang, Yin
   Han, Ting
   Jiang, Yi Ping
   Rahman, Khalid
   Qin, Lu Ping
   Xin, Hai Liang
   Zhang, Qiao Yan
TI Coordinate regulatory osteogenesis effects of icariin, timosaponin B II
   and ferulic acid from traditional Chinese medicine formulas on UMR 106
   osteoblastic cells and osteoblasts in neonatal rat calvaria cultures
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Icariin; Ferulic acid; Timosaponin B II; Traditional Chinese medicine
   formula; Osteoporosis; BMP signaling pathway; Wnt/beta Catenin signaling
   pathway; Osteogenic differentiation
ID BONE FORMATION; DIFFERENTIATION; PROLIFERATION; WNT; BMP
AB Ethnopharmacological significance: Icariin (I), ferulic acid (F) and timosaponin B II (T) derived respectively from the leaf of Epimedium brevicornu Maxim (EBM, Berberidaceae), rhizome of Anemarrhena asphodeloides Bunge (AAB, Liliaceae) and root of Angelica sinensis (Oliv.) Diels (ASD, Umbelliferae) are included in several traditional Chinese medicine (TCM) formulas for the treatment of osteoporosis. In addition, the medicinal materials and chemical constituents in many traditional Chinese formulas have been shown to have potential synergistic, additive and antagonistic effects.
   Aim of study: To explore the action mechanism and interactions between I, T and F as bone anabolic ingredients on osteoblasts, and fully understand their action mechanism and rationality of the formula design.
   Materials and methods: An osteoporotic model was established in bilaterally ovariectomized mice. Bone mineral density (BMD), bone mineral content (BMC) and serum biochemical parameters including alkaline phosphatase (ALP), tartrate resistant acid phosphatase (TRAP), osteoprotegerin (OPG) and deoxypyridinoline cross links (DPD) were measured to evaluate the effects of I, T or F alone and their combinations on osteoporotic mice. UMR 106 osteoblastic cells and primary osteoblasts in neonatal rat calvarias were used to evaluate the osteogenesis effect. The immunohistochemical method and Western blot analysis were used to detect the expression of critical proteins in the process of proliferation and differentiation of osteoblasts.
   Results: IFT combinations enhanced the therapeutic effect without increasing the adverse effects on osteoporotic mice, synergistically increased the osteoblast proliferation, ALP activity and mineralized nodule formation, and promoted the expression of bone matrix by regulating BMP and Wnt/beta catenin signaling pathways in osteoblasts.
   Conclusion: IFT combinations reinforced the therapeutic effect on osteoporosis by modulating multi signaling pathways and action targets. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Li, Mei; Zhang, Nai Dan; Han, Ting; Jiang, Yi Ping; Qin, Lu Ping; Xin, Hai Liang; Zhang, Qiao Yan] Second Mil Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
   [Li, Mei] XiaMen ZhongKe New Biotechnol Co Ltd, Xiamen 361000, Peoples R China.
   [Wang, Yin] PLA 102 Hosp, Dept Pharmaceut, Changzhou 213003, Peoples R China.
   [Rahman, Khalid] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Byrom St, Liverpool L3 3AF, Merseyside, England.
C3 Naval Medical University; Liverpool John Moores University
RP Xin, HL; Zhang, QY (通讯作者)，Second Mil Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
EM Lm0836@163.com; daniell_znd@163.com; wangsbox@sina.com; than927@163.com;
   msjyp@163.com; K.Rahman@ljmu.ac.uk; qinluping@126.com; zqy1965@163.com;
   hailiangxin@163.com
RI HAN, TINGTING/GQZ 8692 2022
FU National Natural Science Foundation of China [81173191]; Shanghai
   Committee of Science and Technology, China [12401900702]
FX The work was supported by the National Natural Science Foundation of
   China (81173191) and Shanghai Committee of Science and Technology, China
   (12401900702).
CR Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   CHEN Xiao Peng, 2013, CHINESE J NAT MED, V11, P0577
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Folwarczna J, 2009, PLANTA MED, V75, P1567, DOI 10.1055/s 0029 1185904
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Li M., 2014, CHINESE J EXP TRADIT, V20, P234
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Liu Yi Jie, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1221
   Liu Z., 1995, Acta Anatomic Sin, V26, P157
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Matsumoto T, 2012, ENDOCR J, V59, P91, DOI 10.1507/endocrj.EJ11 0219
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   Peng SL, 2009, BONE, V45, P534, DOI 10.1016/j.bone.2009.05.022
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Wang YL, 2014, J ETHNOPHARMACOL, V153, P42, DOI 10.1016/j.jep.2014.02.013
   Yang Ming Yang Ming, 2009, Journal of China Pharmaceutical University, V40, P544
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
   Zhao Piwen, 2012, Zhongguo Zhong Yao Za Zhi, V37, P1693
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 30
TC 30
Z9 33
U1 1
U2 61
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 5
PY 2016
VL 185
BP 120
EP 131
DI 10.1016/j.jep.2016.03.023
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA DM9OV
UT WOS:000376696500013
PM 26983755
DA 2025 08 17
ER

PT J
AU Alles, N
   Soysa, NS
   Hayashi, J
   Khan, M
   Shimoda, A
   Shimokawa, H
   Ritzeler, O
   Akiyoshi, K
   Aoki, K
   Ohya, K
AF Alles, Neil
   Soysa, Niroshani S.
   Hayashi, Juri
   Khan, Masud
   Shimoda, Asako
   Shimokawa, Hitoyata
   Ritzeler, Olaf
   Akiyoshi, Kazunari
   Aoki, Kazuhiro
   Ohya, Keiichi
TI Suppression of NF κB Increases Bone Formation and Ameliorates Osteopenia
   in Ovariectomized Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID BLOCKS OSTEOCLASTOGENESIS; TNF ALPHA; INHIBITION; RESORPTION;
   DIFFERENTIATION; PEPTIDE; PATHWAY; KINASE; ACTIVATION; MODELS
AB Bone degenerative diseases, including osteoporosis, impair the fine balance between osteoclast bone resorption and osteoblast bone formation. Single agent therapy for anabolic and anticatabolic effects is attractive as a drug target to ameliorate such conditions. Inhibition of nuclear factor (NF) kappa B reduces the osteoclast bone resorption. The role of NF kappa B inhibitors on osteoblasts and bone formation, however, is minimal and not well investigated. Using an established NF kappa B inhibitor named S1627, we demonstrated that inhibition of NF kappa B increases osteoblast differentiation and bone formation in vitro by up regulating the mRNAs of osteoblast specific genes like type I collagen, alkaline phosphatase, and osteopontin. In addition, S1627 was able to increase bone formation and repair bone defect in a murine calvarial defect model. To determine the effect of NF kappa B on a model of osteoporosis, we injected two doses of inhibitor (25 and 50 mg/kg.d) twice a day in sham operated or ovariectomized 12 wk old mice and killed them after 4 wk. The anabolic effect of S1627 on trabecular bone was determined by micro focal computed tomography and histomorphometry. Bone mineral density of inhibitor treated ovariectomized animals was significantly increased compared with sham operated mice. Osteoblast related indices like osteoblast surface, mineral apposition rate, and bone formation rate were increased in S1627 treated animals in a dose dependent manner. NF kappa B inhibition by S1627 increased the trabecular bone volume in ovariectomized mice. Furthermore, S1627 could inhibit the osteoclast number, and osteoclast surface to bone surface. In vitro osteoclastogenesis and bone resorbing activity were dose dependently reduced by NF kappa B inhibitor S1627. Taken collectively, our results suggest that NF kappa B inhibitors are effective in treating bone related diseases due to their dual anabolic and antiresorptive activities. (Endocrinology 151: 4626 4634, 2010)
C1 [Soysa, Niroshani S.] Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Pharmacol Sect,Bunkyo Ku, Tokyo 1138549, Japan.
   [Shimoda, Asako; Akiyoshi, Kazunari] Tokyo Med & Dent Univ, Grad Sch, Inst Biomat & Bioengn, Tokyo 1010062, Japan.
   [Ritzeler, Olaf] Aventis Pharma Deutschland, D 65929 Frankfurt, Germany.
   [Alles, Neil] Univ Peradeniya, Fac Vet Med & Anim Sci, Dept Farm Anim Prod & Hlth, Peradeniya, Sri Lanka.
   [Soysa, Niroshani S.] Univ Peradeniya, Fac Dent Sci, Div Pharmacol, Peradeniya, Sri Lanka.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Sanofi Aventis; Sanofi Germany; University of Peradeniya; University of
   Peradeniya
RP Soysa, NS (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Pharmacol Sect,Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM niroshani.hpha@tmd.ac.jp
RI AOKI, Kazuhiro/G 2258 2016
OI AOKI, Kazuhiro/0000 0001 6643 6315
FU Japanese Society for Promotion of Science (JSPS); Ministry of Education,
   Culture, Sports, Science, and Technology of Japan [18390497, 19390471,
   19390472]; Grants in Aid for Scientific Research [19390471, 19390472,
   18390497] Funding Source: KAKEN
FX This work was supported by Japanese Society for Promotion of Science
   (JSPS) and the Ministry of Education, Culture, Sports, Science, and
   Technology of Japan Grants 18390497 (to H. S.), 19390471 (to K.O.), and
   19390472 (to K. A.).
CR Alles N, 2009, EUR J PHARM SCI, V37, P83, DOI 10.1016/j.ejps.2009.01.002
   Andela VB, 2002, BIOCHEM BIOPH RES CO, V297, P237, DOI 10.1016/S0006 291X(02)02141 1
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Girotra Monica, 2006, Treat Endocrinol, V5, P347, DOI 10.2165/00024677 200605060 00003
   Hayashi C, 2009, J CELL PHYSIOL, V220, P1, DOI 10.1002/jcp.21760
   Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756 3282(03)00054 1
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Keith JC, 2005, ARTHRITIS RES THER, V7, pR427, DOI 10.1186/ar1692
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Mian AH, 2008, J BONE MINER METAB, V26, P469, DOI 10.1007/s00774 007 0834 0
   Michaelis M., 2004, PCT Int. Appl., Patent No. [2004022057, WO 2004/022057]
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21
   Ritzeler O., 2004, PCT Int. Appl., Patent No. [WO 2004/022553, 2004022553]
   RITZELER O, 2001, Patent No. 0130774
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   SAITO H, 2006, DENT JPN, V42, P35
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Soysa NS, 2010, J BONE MINER RES, V25, P809, DOI 10.1359/jbmr.091030
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Soysa Niroshani Surangika, 2009, Journal of Medical and Dental Sciences, V56, P107
   Strait K, 2008, INT J MOL MED, V21, P521
   Tegeder I, 2004, J NEUROSCI, V24, P1637, DOI 10.1523/JNEUROSCI.3118 03.2004
NR 30
TC 71
Z9 77
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2010
VL 151
IS 10
BP 4626
EP 4634
DI 10.1210/en.2010 0399
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 652KQ
UT WOS:000282005700005
PM 20810563
OA Bronze
DA 2025 08 17
ER

PT J
AU Hart, DA
AF Hart, David A.
TI Are secondary effects of bisphosphonates on the vascular system of bone
   contributing to increased risk for atypical femoral fractures in
   osteoporosis?
SO BIOESSAYS
LA English
DT Article
DE atypical femoral fractures; bisphosphonates; drug targets; nutrient
   channels; osteoporosis; tissue specific endothelial cells
ID ARYL HYDROCARBON RECEPTOR; IN VITRO; NUTRIENT FORAMINA; ZOLEDRONIC ACID;
   BLOOD FLOW; OSTEONECROSIS; DENOSUMAB; JAW; EXPRESSION; THERAPY
AB Osteoporosis (OP) is a bone disease which affects a number of post menopausal females and puts many at risk for fractures. A large number of patients are taking bisphosphonates (BPs) to treat their OP and a rare complication is the development of atypical femoral fractures (AFF). No real explanations for the mechanisms underlying the basis for development of where AFF develop while on BPs has emerged. The present hypothesis will discuss the possibility that part of the risk for an AFF is a secondary effect of BPs on a subset of vascular cells in a genetically at risk population, leading to localized deregulation of the endothelial cell (EC) bone cell matrix units in nutrient channels/canals of the femur and increased risk for AFF. This concept of targeting ECs is consistent with location of AFF in the femur, the bilateral risk for occurrence of AFF, and the requirement for long term exposure to the drugs.
C1 [Hart, David A.] Univ Calgary, McCaig Inst Bone & Joint Hlth, Fac Kinesiol, Dept Surg, Calgary, AB, Canada.
   [Hart, David A.] Univ Calgary, McCaig Inst Bone & Joint Hlth, Fac Kinesiol, Dept Surg, Calgary, AB T2N 4N1, Canada.
C3 University of Calgary; University of Calgary
RP Hart, DA (通讯作者)，Univ Calgary, McCaig Inst Bone & Joint Hlth, Fac Kinesiol, Dept Surg, Calgary, AB T2N 4N1, Canada.
EM hartd@ucalgary.ca
CR Adler RA, 2021, ENDOCRIN METAB CLIN, V50, P193, DOI 10.1016/j.ecl.2021.03.003
   Akid I, 2021, CLIN GERIATR MED, V37, P683, DOI 10.1016/j.cger.2021.05.012
   Andronowski JM, 2023, ANAT REC, V306, P475, DOI 10.1002/ar.25089
   Aspenberg P, 2014, ACTA ORTHOP, V85, P1, DOI 10.3109/17453674.2013.859423
   Augustin HG, 2017, SCIENCE, V357, DOI 10.1126/science.aal2379
   Baron JA, 2008, LANCET, V372, P1756, DOI 10.1016/S0140 6736(08)61490 7
   Benson T, 2016, OSTEOPOROSIS INT, V27, P1817, DOI 10.1007/s00198 015 3460 z
   Billington EO, 2020, CURR OSTEOPOROS REP, V18, P587, DOI 10.1007/s11914 020 00612 4
   Black DM, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116297
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   CAMPOS FF, 1987, SURG RADIOL ANAT, V9, P251, DOI 10.1007/BF02109636
   Cha SM, 2021, INJURY, V52, P1423, DOI 10.1016/j.injury.2020.10.087
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Che YJ, 2020, NANOSCALE, V12, P22022, DOI 10.1039/d0nr06261h
   Chen JY, 2022, FASEB J, V36, DOI 10.1096/fj.202200200RR
   Cohen DJ, 2022, J BONE JOINT SURG AM, V104, P1750, DOI 10.2106/JBJS.21.01489
   Dhanekula ND, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10607
   Diab DL, 2021, ENDOCRIN METAB CLIN, V50, P239, DOI 10.1016/j.ecl.2021.03.001
   Ding KH, 2005, PEPTIDES, V26, P853, DOI 10.1016/j.peptides.2005.01.002
   Drampalos E, 2014, ACTA ORTHOP, V85, P3, DOI 10.3109/17453674.2013.854668
   Filipowska J, 2017, ANGIOGENESIS, V20, P291, DOI 10.1007/s10456 017 9541 1
   Furukawa H, 2022, J CLIN ENDOCR METAB, V107, pE1890, DOI 10.1210/clinem/dgac022
   Garner S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003685.pub2
   Gerosa L, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.623893
   Goulden EL, 2023, CLIN ENDOCRINOL, V98, P649, DOI 10.1111/cen.14747
   GUMUSBURUN E, 1994, SURG RADIOL ANAT, V16, P409, DOI 10.1007/BF01627662
   Guo MK, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/4006184
   Hadjiargyrou M, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116542
   Haider IT, 2023, J BONE MINER RES, V38, P403, DOI 10.1002/jbmr.4758
   Haider IT, 2018, BONE, V110, P295, DOI 10.1016/j.bone.2018.02.015
   Hart DA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084119
   Hayes KN, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051140
   Houssaye A, 2020, J ANAT, V236, P510, DOI 10.1111/joa.13121
   Huang J, 2021, INT J NANOMED, V16, P3161, DOI 10.2147/IJN.S305361
   Imre N, 2012, SURG RADIOL ANAT, V34, P427, DOI 10.1007/s00276 011 0930 7
   Ishtiaq S, 2015, CYTOKINE, V71, P154, DOI 10.1016/j.cyto.2014.10.025
   Iwata K, 2019, J BONE MINER METAB, V37, P206, DOI 10.1007/s00774 018 0940 1
   Jacob A, 2015, J NEUROCHEM, V132, P373, DOI 10.1111/jnc.12972
   Jiang SY, 2019, CLIN ORTHOP RELAT R, V477, P480, DOI 10.1097/CORR.0000000000000545
   Jung IJ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03603 2
   Kawasaki Y, 2020, CLIN ANAT, V33, P479, DOI 10.1002/ca.23390
   Kim BS, 2018, INT J MOL MED, V41, P2879, DOI 10.3892/ijmm.2018.3497
   Kim JT, 2021, OSTEOPOROSIS INT, V32, P2115, DOI 10.1007/s00198 021 05971 x
   Kizilkanat E, 2007, ANN ANAT, V189, P87, DOI 10.1016/j.aanat.2006.07.004
   Kocijan R, 2020, HANDB EXP PHARMACOL, V262, P397, DOI 10.1007/164_2020_373
   Kubo T, 2016, J ORTHOP SCI, V21, P407, DOI 10.1016/j.jos.2016.03.008
   Kumar S, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01166 x
   Kunze KN, 2022, FRONT SURG, V9, DOI 10.3389/fsurg.2022.662722
   Lee CH, 2018, NUCL MED MOLEC IMAG, V52, P311, DOI 10.1007/s13139 018 0533 x
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Lu LQ, 2020, J CLIN PHARM THER, V45, P45, DOI 10.1111/jcpt.13056
   Luo YH, 2021, J BONE MINER METAB, V39, P523, DOI 10.1007/s00774 020 01198 8
   Ma JH, 2022, CELLS BASEL, V11, DOI 10.3390/cells11132104
   Michailidou M, 2010, J VASC RES, V47, P481, DOI 10.1159/000313876
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Mitsimponas KT, 2016, BRIT J ORAL MAX SURG, V54, P883, DOI 10.1016/j.bjoms.2016.05.025
   Mücke T, 2016, SEMIN MUSCULOSKEL R, V20, P305, DOI 10.1055/s 0036 1592367
   Murphy B, 2023, EUR J ORTHOP SURG TR, V33, P1697, DOI 10.1007/s00590 022 03314 y
   Nguyen HH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115319
   Nguyen HH, 2018, JBMR PLUS, V2, P1, DOI 10.1002/jbm4.10024
   Nguyen Hanh H, 2017, Bone Rep, V6, P34, DOI 10.1016/j.bonr.2017.01.002
   Nishino T, 2020, J ORTHOP, V19, P143, DOI 10.1016/j.jor.2019.11.044
   Okawa H, 2022, ELIFE, V11, DOI 10.7554/eLife.76207
   Okçu M, 2021, TURK J PH MED REHAB, V67, P370, DOI 10.5606/tftrd.2021.5248
   Otto M, 2023, ORAL MAXILLOFAC SURG, V27, P263, DOI 10.1007/s10006 022 01053 2
   Owen Woods C, 2022, SEMIN CELL DEV BIOL, V123, P36, DOI 10.1016/j.semcdb.2021.06.025
   Pabst AM, 2017, CLIN ORAL INVEST, V21, P771, DOI 10.1007/s00784 016 1842 z
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Pazzaglia UE, 2011, MICROVASC RES, V82, P58, DOI 10.1016/j.mvr.2011.02.001
   Prisby RD, 2007, J BONE MINER RES, V22, P1280, DOI 10.1359/JBMR.070415
   Prisby RD, 2017, J ENDOCRINOL, V235, pR77, DOI 10.1530/JOE 16 0666
   Prisby RD, 2015, J APPL PHYSIOL, V118, P980, DOI 10.1152/japplphysiol.00576.2014
   Prisby RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048564
   Probyn L, 2015, SKELETAL RADIOL, V44, P1579, DOI 10.1007/s00256 015 2212 7
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Schilcher J, 2014, ACTA ORTHOP, V85, P280, DOI 10.3109/17453674.2014.916488
   Schwartz NL, 2018, J ANAT, V233, P193, DOI 10.1111/joa.12830
   Serra Vinardell J, 2020, J INHERIT METAB DIS, V43, P133, DOI 10.1002/jimd.12097
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Srivichit B, 2022, ARCH TOXICOL, V96, P1227, DOI 10.1007/s00204 021 03220 y
   Stabley JN, 2013, BONE, V57, P355, DOI 10.1016/j.bone.2013.09.003
   Surface LE, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav9166
   Tsai SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041065
   Ugartondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147395
   Ural A, 2021, J MECH BEHAV BIOMED, V124, DOI 10.1016/j.jmbbm.2021.104803
   Walker LE, 2021, BRIT J CLIN PHARMACO, V87, P4877, DOI 10.1111/bcp.15110
   Wang BJ, 2020, ANN PLAS SURG, V85, P677, DOI 10.1097/SAP.0000000000002424
   Wang QZ, 2019, MED SCI MONITOR, V25, P700, DOI 10.12659/MSM.911579
   Wang W. J., 2022, PSYCHOL MED, V13, P1343, DOI [10.3390/genes13081343, DOI 10.3390/GENES13081343]
   Wu XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8140595
   Yavropoulou MP, 2012, J BONE MINER RES, V27, P1425, DOI 10.1002/jbmr.1593
   Yin BH, 2020, J BONE MINER METAB, V38, P780, DOI 10.1007/s00774 020 01114 0
   Zhang N, 2007, CARDIOVASC TOXICOL, V7, P282, DOI 10.1007/s12012 007 9007 6
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhou W, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10659
   Zhou W, 2021, CURR OSTEOPOROS REP, V19, P123, DOI 10.1007/s11914 021 00658 y
   Ziebart Thomas, 2011, Clin Oral Investig, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 100
TC 4
Z9 4
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0265 9247
EI 1521 1878
J9 BIOESSAYS
JI Bioessays
PD APR
PY 2023
VL 45
IS 4
DI 10.1002/bies.202200206
EA FEB 2023
PG 10
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA D7PM3
UT WOS:000937695900001
PM 36807308
OA hybrid
DA 2025 08 17
ER

PT J
AU Han, JW
   Li, L
   Zhang, C
   Huang, QQ
   Wang, SL
   Li, WY
   Zong, JC
   Li, LJ
   Zhao, Z
   Zhang, ZL
   Liu, ZM
   Wang, Q
   Shi, YY
AF Han, Junwen
   Li, Li
   Zhang, Chen
   Huang, Qianqian
   Wang, Shanglong
   Li, Wenyu
   Zong, Jiancheng
   Li, Lijie
   Zhao, Zhen
   Zhang, Zengliang
   Liu, Zimin
   Wang, Qi
   Shi, Yuanyuan
TI Eucommia, Cuscuta, and Drynaria Extracts Ameliorate
   Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis
   Through PI3K/Akt Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Eucommia; Cuscuta; Drynaria; Traditional Chinese medicine; Osteoporosis;
   Osteoclast; PI3K; Akt
ID NF KAPPA B; DIFFERENTIATION; ACTIVATION; EXPRESSION; CELLS; AKT;
   PATHOPHYSIOLOGY; OSTEOPROTEGERIN; UPDATE
AB Osteoporosis is one of the most common diseases in the world which resulted in heavy socioeconomic burden and a public health threat. Glucocorticoid induced osteoporosis (GIO) is the most common secondary reason of osteoporosis. Therapeutic strategies using traditional Chinese medicine are under investigation for osteoporosis, with efforts to improve efficacy and clarify the mechanism. The combination of Eucommia, Cuscuta, and Drynaria is widely used in traditional Chinese decoction for osteoporosis treatment, but the experimental efficacy and mechanism are still unclear. Administration of E.C.D. extracts (Eucommia, Cuscuta, and Drynaria) in experimental GIO rats resulted in decreased urinal calcium, phosphorus loss, and decreased expression of RANKL, CTX in serum, increased serum calcium, phosphorus, and OPG level. E.C.D. extracts also improved bone density, structural integrity, and biomechanical function in experimental GIO rats. These finding were associated with E.C.D. extracts' treatment efficacy to GIO in vivo. The balance between osteoclast and osteoblast activity is essential for bone remodeling and bone related disease. The E.C.D. extracts inhibited Raw 264.7 cell differentiation to osteoclast in vitro. On the other hand, it promoted OPG expression of bone marrow mesenchymal stromal cells (MSCs) which can suppress the osteoclast genesis. E.C.D. extracts also increased the Wnt1 and Runx2 expression which are related to osteoblast formation. It also regulated the paracrine effect of MSC to inhibit osteoclast differentiation. The analysis of HPLC and comprehensive pharmacology identified the constituents of E.C.D. extracts and the potential osteoporosis related targets mediated by E.C.D. extracts. The KEGG enrichment analysis suggested that PI3K/Akt pathway may be involved in the regulation osteoclast genesis by E.C.D. extracts and the result of Western blot of vitro assays proved it. Collectively, these data demonstrate E.C.D. extracts can inhibit osteoclast differentiation to foster experimental osteoporosis both in vivo and in vitro and it may exert the function of inhibiting osteoclast differentiation through PI3K/Akt pathway.
C1 [Han, Junwen] Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing, Peoples R China.
   [Li, Li; Wang, Shanglong; Li, Wenyu; Zong, Jiancheng; Liu, Zimin] Chenland Nutr Inc, Irvine, CA 92614 USA.
   [Zhang, Chen] Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
   [Huang, Qianqian] Beijing Univ Chinese Med, Affiliated Hosp 3, Beijing, Peoples R China.
   [Li, Lijie] Qingdao Engn Vocat Coll Dongzhang Community, Qingdao, Peoples R China.
   [Zhao, Zhen] Weill Cornell Med Coll, Pathol & Lab Med, New York, NY USA.
   [Zhang, Zengliang] Inner Mongolia Med Univ, Tradit Chinese Med Coll, Hohhot, Peoples R China.
   [Wang, Qi] Natl Inst Chinese Constitut & Prevent Med, Beijing, Peoples R China.
   [Shi, Yuanyuan] Beijing Univ Chinese Med, Shenzhen Res Inst, Shenzhen, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; Beijing University of Chinese Medicine; Cornell University;
   Weill Cornell Medicine; Inner Mongolia Medical University; Beijing
   University of Chinese Medicine
RP Liu, ZM (通讯作者)，Chenland Nutr Inc, Irvine, CA 92614 USA.; Wang, Q (通讯作者)，Natl Inst Chinese Constitut & Prevent Med, Beijing, Peoples R China.; Shi, YY (通讯作者)，Beijing Univ Chinese Med, Shenzhen Res Inst, Shenzhen, Peoples R China.
EM dliu@chenland.com; wangqi710@126.com; yshi@bucm.edu.cn
RI ; zhao, zhen/E 9852 2012
OI Li, Li/0000 0002 7785 9804; 
FU medical security and capacity building of traditional Chinese medicine
   [0332000000131]
FX Funding This work was supported by a grant from the medical security and
   capacity building of traditional Chinese medicine in 2020
   (0332000000131). This work was also funded by company Chenland
   Nutritionals, Inc.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Anastasilakis AD, 2021, J CLIN DENSITOM, V24, P591, DOI 10.1016/j.jocd.2021.01.006
   Andrzejewska A, 2019, STEM CELLS, V37, P855, DOI 10.1002/stem.3016
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bai ST, 2005, J CLIN INVEST, V115, P2742, DOI 10.1172/JCI24921
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   BROWN JP, 1984, LANCET, V1, P1091
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Choksi Palak, 2018, Clin Diabetes Endocrinol, V4, P12, DOI 10.1186/s40842 018 0062 7
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c
   Fait Tomas, 2019, Drugs Context, V8, P212551, DOI 10.7573/dic.212551
   Fu YX, 2013, INT J MOL MED, V31, P1411, DOI 10.3892/ijmm.2013.1329
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He L, 2017, CARBOHYD POLYM, V178, P412, DOI 10.1016/j.carbpol.2017.09.085
   Iba K, 2008, J ORTHOP SCI, V13, P438, DOI 10.1007/s00776 008 1265 z
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Kao SJ, 2005, IMMUNOLOGY, V115, P366, DOI 10.1111/j.1365 2567.2005.02160.x
   Karadeniz F, 2020, PHYTOMEDICINE, V71, DOI 10.1016/j.phymed.2020.153225
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Liao RD, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10072
   Lin TH, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/647189
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sang Shurong Y.L., 1993, WONDERFUL RECIPE NOU
   Sapkota M, 2015, EUR J PHARMACOL, V769, P100, DOI 10.1016/j.ejphar.2015.11.003
   Silva I, 2011, ACTA REUMATOL PORT, V36, P209
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang YK, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115333
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00731
   Yeon JT, 2019, ARCH PHARM RES, V42, P712, DOI 10.1007/s12272 019 01163 8
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
NR 55
TC 12
Z9 19
U1 1
U2 34
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 4
PY 2022
VL 12
AR 772944
DI 10.3389/fphar.2021.772944
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ZG4MM
UT WOS:000760233600001
PM 35185535
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guo, QY
   Mao, X
   Zhang, YQ
   Meng, SQ
   Xi, Y
   Ding, Y
   Zhang, XC
   Dai, YT
   Liu, X
   Wang, C
   Li, YT
   Lin, N
AF Guo, Qiuyan
   Mao, Xia
   Zhang, Yanqiong
   Meng, Shuqin
   Xi, Yue
   Ding, Yi
   Zhang, Xiaocun
   Dai, Yuntao
   Liu, Xia
   Wang, Chao
   Li, Yuting
   Lin, Na
TI Guizhi Shaoyao Zhimu decoction attenuates rheumatoid arthritis partially
   by reversing inflammation immune system imbalance
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE TCM herbal formula; Rheumatoid arthritis; Guizhi Shaoyao Zhimu
   decoction; Network pharmacology; Experimental validation
ID TRADITIONAL CHINESE MEDICINE; NF KAPPA B; NETWORK PHARMACOLOGY;
   INTERACTION DATABASE; KNOWLEDGEBASE; TARGET; PERSPECTIVE; MECHANISMS;
   RESPONSES; PATHWAYS
AB Background: Guizhi Shaoyao Zhimu decoction (GSZD) has been extensively used for rheumatoid arthritis (RA) therapy. Marked therapeutic efficacy of GSZD acting on RA has been demonstrated in several long term clinical trials without any significant side effects. However, its pharmacological mechanisms remain unclear due to a lack of appropriate scientific methodology.
   Methods: GSZD's mechanisms of action were investigated using an integrative approach that combined drug target prediction, network analysis, and experimental validation.
   Results: A total of 77 putative targets were identified for 165 assessed chemical components of GSZD. After calculating the topological features of the nodes and edges in the created drug target network, we identified a candidate GSZD targeted signal axis that contained interactions between two putative GSZD targets [histone deacetylase 1 (HDAC1) and heat shock protein 90 kDa alpha, class A member 1 (HSP90AA1)] and three known RA related targets [NFKB2; inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta (IKBKB); and tumor necrosis factoralpha (TNF alpha)]. This signal axis could connect different functional modules that are significantly associated with various RA related signaling pathways, including T/B cell receptor, Toll like receptor, NF kappa B and TNF pathways, as well as osteoclast differentiation. Furthermore, the therapeutic effects and putative molecular mechanisms of GSZD's actions on RA were experimentally validated in vitro and in vivo.
   Conclusions: GSZD may partially attenuate RA by reversing inflammation immune system imbalance and regulating the HDAC1 HSP90AA1 NFKB2 IKBKB TNF alpha signaling axis.
C1 [Guo, Qiuyan; Mao, Xia; Zhang, Yanqiong; Dai, Yuntao; Wang, Chao; Li, Yuting; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
   [Meng, Shuqin; Xi, Yue; Ding, Yi] Peking Univ, Beijing Jishuitan Hosp, Dept Pathol, Beijing 100035, Peoples R China.
   [Zhang, Xiaocun; Liu, Xia] Wuhan Univ Technol, Sch Chem Chem Engn & Life Sci, Wuhan 430070, Hubei, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Peking University; Wuhan University of Technology
RP Zhang, YQ (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
EM yqzhang@icmm.ac.cn; linna888@163.com
RI Li, Yuting/IVH 4108 2023; Guo, Qiu yan/HFZ 7781 2022; Zhang,
   Xiaocun/G 9783 2018
OI Guo, qiuyan/0009 0007 8005 3995; 
FU Beijing Municipal Natural Science Foundation [7144228]; Beijing Nova
   program [Z1511000003150126]; Prospective Study Platform Project of
   Institute of Chinese Materia Medica, China Acdemy of Chinese Medical
   Sciences [QZPT002]
FX This study was supported by Beijing Municipal Natural Science Foundation
   (7144228), Beijing Nova program (Z1511000003150126) and The Prospective
   Study Platform Project of Institute of Chinese Materia Medica, China
   Acdemy of Chinese Medical Sciences (QZPT002).
CR Ahmed AS, 2010, ARTHRITIS RHEUM US, V62, P2160, DOI 10.1002/art.27492
   An XX., 2001, GANSU TRADIT CHIN ME, V14, P31
   Andersson AK, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2370
   [Anonymous], 2011, BMC RES NOTES
   Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878
   Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504 431
   Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098
   Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273
   Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928
   Ceol A, 2010, NUCLEIC ACIDS RES, V38, pD532, DOI 10.1093/nar/gkp983
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen J, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P167
   Chen JY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 S1 S16
   Gabriel SE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2669
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Guo QY, 2015, REJUV RES, V18, P313, DOI 10.1089/rej.2014.1635
   Ha MK, 2011, BIOL PHARM BULL, V34, P1432, DOI 10.1248/bpb.34.1432
   Hammaker D, 2012, RHEUMATOLOGY, V51, P610, DOI 10.1093/rheumatology/ker154
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Kawabata T, 2010, ARTHRITIS RES THER, V12, pR133
   Lee WY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/528018
   Lehne Benjamin, 2009, Human Genomics, V3, P291
   Li DH, 1997, SHANXI J TRADIT CHIN, V13, P16
   Li GS, 2008, J TRADITIONAL CHINES, V26, P23
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet syb:20060032
   Li S, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/138460
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471 2105 11 S11 S6
   Liu J, 2011, CHIN J INTEGR MED, V17, P735, DOI 10.1007/s11655 011 0872 2
   Liu XY., 2003, J GUIYANG TRADIT CHI, V25, P23
   Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863
   Meyer P, 2000, ARTHRITIS RHEUM US, V43, P298, DOI 10.1002/1529 0131(200002)43:2<298::AID ANR9>3.0.CO;2 G
   Papadopoulos I, 2015, ADV EXP MED BIOL, V822, P209, DOI 10.1007/978 3 319 08927 0_26
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Put S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4542
   Rice JW, 2008, ARTHRITIS RHEUM US, V58, P3765, DOI 10.1002/art.24047
   Shen XY, 2011, J ETHNOPHARMACOL, V134, P399, DOI 10.1016/j.jep.2010.12.033
   Sun LX, 2007, FORUM TRADIT CHIN ME, V22, P23
   Urushibara M, 2004, ARTHRITIS RHEUM US, V50, P794, DOI 10.1002/art.20206
   Vieira EM, 2011, REV BRAS ANESTESIOL, V61, P367, DOI 10.1016/S0034 7094(11)70044 7
   Wang DS, 2014, CURR PHARM BIOTECHNO, V15, P542, DOI 10.2174/138920101506140910150612
   Wermuth CG, 2004, DRUG DISCOV TODAY, V9, P826, DOI 10.1016/S1359 6446(04)03213 1
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wixon J, 2000, YEAST, V17, P48, DOI 10.1002/(SICI)1097 0061(200004)17:1<48::AID YEA2>3.0.CO;2 H
   Xie B., 2003, J. Hunan Tradit. Chin. Med., V23, P49
   Yao Y, 2013, J ETHNOPHARMACOL, V150, P619, DOI 10.1016/j.jep.2013.09.018
   Yu T., 2010, Contemporary Mediterranean, V16, P18
   Zhang YQ, 2015, SCI REP UK, V5, DOI 10.1038/srep09463
   Zhang YQ, 2014, SCI REP UK, V4, DOI 10.1038/srep04154
   Zheng FH, 2015, EVID BASED COMPL ALT, V2015
   Zhou LM, 2012, J CHANGCHUN U TRADIT, V28, P1100
   Zhu W.W., 2013, Liaoning Journal of Traditional Chinese Medicine, V40, P132
NR 53
TC 52
Z9 62
U1 1
U2 61
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUN 8
PY 2016
VL 14
AR 165
DI 10.1186/s12967 016 0921 x
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DO4UN
UT WOS:000377780200003
PM 27277474
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, YA
   Qin, QH
AF Wang, Yanan
   Qin, Qing Hua
TI A theoretical study of bone remodelling under PEMF at cellular level
SO COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
LA English
DT Article
DE mathematical; bone remodelling; PEMF; cellular
ID PULSED ELECTROMAGNETIC FIELDS; OSTEOBLAST LIKE CELLS;
   PARATHYROID HORMONE; MATHEMATICAL MODEL; DOUBLE BLIND;
   ELECTRICAL STIMULATION; MORPHOGENETIC PROTEINS; DIFFERENT INTENSITIES;
   EXPRESSION; DIFFERENTIATION
AB Pulsed electromagnetic field (PEMF) devices have been used clinically to slow down osteoporosis and accelerate the healing of bone fractures for many years. However, the underlying mechanism by which bone remodelling under PEMF is regulated remains poorly understood. In this paper, a mathematical model of bone cell population of bone remodelling under PEMF at cellular level is developed to address this issue for the first time. On the basis of this model and control theory, parametric study of control mechanisms is carried out and a number of possible control mechanisms are identified. These findings will help further the understanding of bone remodelling under PEMF and advance therapies and pharmacological developments in clinical trials.
C1 [Wang, Yanan; Qin, Qing Hua] Australian Natl Univ, Res Sch Engn, Canberra, ACT 0200, Australia.
C3 Australian National University
RP Qin, QH (通讯作者)，Australian Natl Univ, Res Sch Engn, GPO Box 4, Canberra, ACT 0200, Australia.
EM qinghua.qin@anu.edu.au
RI ; Qin, Qinghua/A 4845 2008
OI Qin, Qinghua/0000 0003 0948 784X; 
FU Australian Research Council [DP0665941]; Australian Research Council
   [DP0665941] Funding Source: Australian Research Council
FX This work was financially supported by the Australian Research Council
   (Grant No. DP0665941). The supports are fully acknowledged.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Alon U., 2007, INTRO SYSTEMS BIOL
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   BASSETT CA, 1964, NATURE, V204, P652, DOI 10.1038/204652a0
   BASSETT CAL, 1981, J BONE JOINT SURG AM, V63, P511, DOI 10.2106/00004623 198163040 00001
   BASSETT CAL, 1982, CALCIFIED TISSUE INT, V34, P1, DOI 10.1007/BF02411199
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Defranoux NA, 2005, J BONE MINER RES, V20, P1079, DOI 10.1359/JBMR.050401
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   Fredericks DC, 2000, J ORTHOP TRAUMA, V14, P93, DOI 10.1097/00005131 200002000 00004
   Frost H., 1963, BONE REMODELLING DYN
   Frost HM., 1986, Intermediary Organization of the Skeleton
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Fukada E, 1982, ELECTRONIC CONDUCTIO, P125
   Fukuda E., 1985, BIOELECTRICAL REPAIR, P3
   Gossling HR, 1992, TREATMENT UNUNITED T
   GRANDE DA, 1991, ANN NY ACAD SCI, V635, P404, DOI 10.1111/j.1749 6632.1991.tb36510.x
   Guerkov HH, 2001, CLIN ORTHOP RELAT R, P265
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hannay G, 2005, BIOELECTROMAGNETICS, V26, P670, DOI 10.1002/bem.20166
   Hill AV, 1910, J PHYSIOL LONDON, V40, P190
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   KUBOTA K, 1995, J PERIODONTOL, V66, P2, DOI 10.1902/jop.1995.66.1.2
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Li JKJ, 2007, ELECTROMAGN BIOL MED, V26, P153, DOI 10.1080/15368370701572837
   Linovitz RJ, 2002, SPINE, V27, P1383, DOI 10.1097/00007632 200207010 00002
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Lohmann CH, 2003, J ORTHOP RES, V21, P326, DOI 10.1016/S0736 0266(02)00137 7
   MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246
   Massari L, 2009, CLIN CASES MINER BON, V6, P149
   MCLEOD KJ, 1992, J BONE JOINT SURG AM, V74A, P920, DOI 10.2106/00004623 199274060 00014
   McLeod KJ, 2000, RADIAT RES, V153, P706, DOI 10.1667/0033 7587(2000)153[0706:SOADRI]2.0.CO;2
   NAGAI M, 1994, J DENT RES, V73, P1601, DOI 10.1177/00220345940730100401
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Potter LK, 2005, BONE, V37, P159, DOI 10.1016/j.bone.2005.04.011
   Qin Q. H., 2007, NEW RES BIOMATERIALS, P49
   Qin QH, 2005, BIOMATERIALS, V26, P6798, DOI 10.1016/j.biomaterials.2005.03.042
   Qin QH, 2004, INT J SOLIDS STRUCT, V41, P2447, DOI 10.1016/j.ijsolstr.2003.12.026
   Qu CY, 2006, STRUCT ENG MECH, V24, P19, DOI 10.12989/sem.2006.24.1.019
   Qu CY, 2006, BIOMATERIALS, V27, P4050, DOI 10.1016/j.biomaterials.2006.03.015
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Schwartz Z, 2009, ANN BIOMED ENG, V37, P437, DOI 10.1007/s10439 008 9628 3
   Sun LY, 2009, BIOELECTROMAGNETICS, V30, P251, DOI 10.1002/bem.20472
   Tabrah F, 1990, BONE DENSITY CHANGES
   TROCK DH, 1994, J RHEUMATOL, V21, P1903
   Vander Molen MA, 2000, BONE, V27, P227, DOI 10.1016/S8756 3282(00)00315 X
   Wang YA, 2010, ACTA MECH SINICA PRC, V26, P37, DOI 10.1007/s10409 009 0313 z
   Wang Yanan, 2009, Molecular & Cellular Biomechanics, V6, P101
   Yajima A, 1996, J BONE MINER RES, V11, pT326
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
NR 64
TC 10
Z9 13
U1 0
U2 28
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1025 5842
EI 1476 8259
J9 COMPUT METHOD BIOMEC
JI Comput. Methods Biomech. Biomed. Eng.
PY 2012
VL 15
IS 8
BP 885
EP 897
DI 10.1080/10255842.2011.565752
PG 13
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Computer Science; Engineering
GA 977MS
UT WOS:000306667300012
PM 21604221
DA 2025 08 17
ER

PT J
AU Zolochevska, O
   Diaz Quiñones, AO
   Ellis, J
   Figueiredo, ML
AF Zolochevska, Olga
   Diaz Quinones, Adriana O.
   Ellis, Jayne
   Figueiredo, Marxa L.
TI Interleukin 27 expression modifies prostate cancer cell crosstalk with
   bone and immune cells in vitro
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID MORPHOGENETIC PROTEINS; RECEPTOR ACTIVATOR; GENE THERAPY; T CELLS;
   OSTEOCLASTOGENESIS; IL 27; DIFFERENTIATION; DISEASE; RESORPTION;
   INDUCTION
AB Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin 27 (IL 27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL 27 on prostate cancer cell gene expression, as well as the effect of paracrine IL 27 on gene expression in bone and T cells. In prostate tumor cells, IL 27 upregulated genes related to its signaling pathway while downregulating malignancy related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL 27 modulated upregulation of genes related to its own signaling pathway as well as pro osteogenic genes. In osteoclasts, IL 27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis related genes. Furthermore, an osteogenesis focused real time PCR array revealed a more extensive profile of pro osteogenic gene changes in both osteoblasts and osteoclasts. In T lymphocyte cells, IL 27 upregulated several activation related genes and also genes related to the IL 27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL 27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol. (C) 2012 Wiley Periodicals, Inc.
C1 [Zolochevska, Olga; Diaz Quinones, Adriana O.; Ellis, Jayne; Figueiredo, Marxa L.] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch Galveston
RP Figueiredo, ML (通讯作者)，Univ Texas Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd,Med Res Bldg 7 102C, Galveston, TX 77555 USA.
EM mlfiguei@utmb.edu
OI Diaz Quinones, Adriana O./0000 0002 6887 5933
CR [Anonymous], 2017, COCHRANE DB SYST REV
   Belouski SS, 2010, CYTOM PART B CLIN CY, V78B, P59, DOI 10.1002/cyto.b.20492
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Berruti A, 2001, J UROLOGY, V166, P2023, DOI 10.1016/S0022 5347(05)65498 5
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600
   Boyce BF, 1999, ENDOCR RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333
   Brodeur MR, 2008, J BONE MINER RES, V23, P326, DOI 10.1359/JBMR.071022
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Clark PE, 2003, CLIN ORTHOP RELAT R, pS148, DOI 10.1097/01.blo.0000093840.72468.e1
   Cocco C, 2010, CLIN CANCER RES, V16, P4188, DOI 10.1158/1078 0432.CCR 10 0173
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045
   Engel MA, 2010, CURR MED CHEM, V17, P3303
   Faccio R, 2011, ANN NY ACAD SCI, V1237, P71, DOI 10.1111/j.1749 6632.2011.06244.x
   Feng JQ, 2009, CURR OPIN NEPHROL HY, V18, P285, DOI 10.1097/MNH.0b013e32832c224f
   Feng XM, 2007, HUM IMMUNOL, V68, P965, DOI 10.1016/j.humimm.2007.10.004
   Fernandes H, 2010, TISSUE ENG PT A, V16, P1693, DOI 10.1089/ten.TEA.2009.0341
   Furukawa M, 2009, J IMMUNOL, V183, P2397, DOI 10.4049/jimmunol.0802091
   Giannoudis PV, 2007, OSTEOPOROSIS INT, V18, P1565, DOI 10.1007/s00198 007 0441 x
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950
   HELFRICH MH, 1992, J BONE MINER RES, V7, P345
   Hisada M, 2004, CANCER RES, V64, P1152, DOI 10.1158/0008 5472.CAN 03 2084
   Jahnen Dechent W, 2011, CIRC RES, V108, P1494, DOI 10.1161/CIRCRESAHA.110.234260
   Kalliolias GD, 2010, ARTHRITIS RHEUM US, V62, P402, DOI 10.1002/art.27200
   Kamiya S, 2007, J BONE MINER METAB, V25, P277, DOI 10.1007/s00774 007 0766 8
   Kogawa M, 2010, J STEROID BIOCHEM, V121, P277, DOI 10.1016/j.jsbmb.2010.03.048
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li Y, 2010, MOL ORAL MICROBIOL, V25, P275, DOI 10.1111/j.2041 1014.2010.00576.x
   Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100
   Mani RS, 2011, CANCER RES, V71, P5387, DOI 10.1158/0008 5472.CAN 11 0876
   Marsell R, 2009, INJURY, V40, P4
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Mundy GR, 1997, AM J MED, V103, P134, DOI 10.1016/S0002 9343(97)80047 2
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Otomo H, 2007, BONE, V40, P1494, DOI 10.1016/j.bone.2007.02.007
   Radcliff K, 2005, CIRC RES, V96, P398, DOI 10.1161/01.RES.0000157671.47477.71
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rowe PSN, 2012, CRIT REV EUKAR GENE, V22, P61, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.50
   Salcedo R, 2004, J IMMUNOL, V173, P7170, DOI 10.4049/jimmunol.173.12.7170
   Sameni M, 2008, MOL IMAGING, V7, P199, DOI 10.2310/7290.2008.00019
   Singh S, 2011, J CELL BIOCHEM, V112, P2287, DOI 10.1002/jcb.23149
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Venturi G, 2012, BONE, V50, P343, DOI 10.1016/j.bone.2011.10.023
   Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Yoshimoto T, 2008, J IMMUNOL, V180, P6527, DOI 10.4049/jimmunol.180.10.6527
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
   Zhu SG, 2010, J IMMUNOL, V184, P2348, DOI 10.4049/jimmunol.0902371
   Zolochevska O, 2012, STEM CELLS DEV, V21, P1112, DOI 10.1089/scd.2011.0247
   Zolochevska O, 2011, HUM GENE THER, V22, P1537, DOI 10.1089/hum.2011.076
NR 58
TC 24
Z9 25
U1 1
U2 75
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2013
VL 228
IS 5
BP 1127
EP 1136
DI 10.1002/jcp.24265
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 079LM
UT WOS:000314171900026
PM 23086758
DA 2025 08 17
ER

PT J
AU Garrett, RW
   Emerson, SG
AF Garrett, R. W.
   Emerson, S. G.
TI The role of parathyroid hormone and insulin like growth factors in
   hematopoietic niches: Physiology and pharmacology
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE hematopoietic stem cell; parathyroid hormone; insulin like growth
   factor; niche; osteoblast
ID STEM CELL FACTOR; FACTOR I; HUMAN OSTEOBLASTS; PROGENITOR CELLS; IGF II;
   BONE; EXPRESSION; INTERLEUKIN 6; SURVIVAL; MICE
AB Hematopoietic stem cells (HSC) capable of both self renewal and differentiation into all blood lineages reside within the bone marrow in specialized microenvironmental niches. While the precise location and composition of these niches largely remains unknown, it is now believed that osteoblasts at the endosteal surface play critical roles. Among the molecules demonstrated to influence the function of these niches are parathyroid hormone (PTH) and the insulin like growth factors (IGF). Administration of PTH to both mice and men expands the number of bone marrow HSC, and an increase in the number of those cells in peripheral blood following treatment with mobilizing agents. Several molecules downstream of PTH are capable of signaling to HSC, including IGF that appear to regulate both the survival and expansion of hematopoietic stem and progenitor cells. As our current understanding of the role for PTH and IGF in hematopoietic niches is limited, we believe it is important that both their physiological importance and pharmacological potential be more fully investigated. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Garrett, R. W.; Emerson, S. G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Emerson, S. G.] Haverford Coll, Dept Biol, Haverford, PA 19041 USA.
C3 University of Pennsylvania; Haverford College
RP Garrett, RW (通讯作者)，Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
EM rgarrett@mail.med.upenn.edu
CR Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Arai F, 2005, INT J HEMATOL, V82, P371, DOI 10.1532/IJH97.05100
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Blair HC, 1999, BIOCHEM BIOPH RES CO, V255, P778, DOI 10.1006/bbrc.1999.0260
   Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s 2007 978725
   Burgess W, 2003, J NEUROIMMUNOL, V135, P82, DOI 10.1016/S0165 5728(02)00443 5
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cumano A, 2007, ANNU REV IMMUNOL, V25, P745, DOI 10.1146/annurev.immunol.25.022106.141538
   Deguchi K, 1999, BIOCHEM BIOPH RES CO, V255, P352, DOI 10.1006/bbrc.1999.0163
   Duarte RF, 2002, LEUKEMIA LYMPHOMA, V43, P1179, DOI 10.1080/10428190290026231
   GIBSON LF, 1993, BLOOD, V82, P3005
   Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kim GS, 1997, J BONE MINER RES, V12, P896, DOI 10.1359/jbmr.1997.12.6.896
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Kovacevic Filipovic M, 2007, J CELL PHYSIOL, V212, P68, DOI 10.1002/jcp.21003
   LANDRETH KS, 1992, BLOOD, V80, P1207
   LARIZZA P, 1952, Haematologica, V36, P653
   Leroith Derek, 1992, Biological Signals, V1, P173
   Li ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI 10.1016/j.tibs.2006.08.001
   LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo 125 3 1484
   MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   Minshall C, 1996, J IMMUNOL, V156, P939
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Neiva K, 2005, BRAZ J MED BIOL RES, V38, P1449, DOI 10.1590/S0100 879X2005001000001
   Nelissen JMDT, 2000, EXP HEMATOL, V28, P422, DOI 10.1016/S0301 472X(00)00127 2
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   RIXON RH, 1961, INT J RADIAT BIOL RE, V3, P361, DOI 10.1080/09553006114550421
   RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535
   Sato T, 2007, J BONE MINER METAB, V25, P19, DOI 10.1007/s00774 006 0723 y
   Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Taguchi T, 2006, EXP HEMATOL, V34, P508, DOI 10.1016/j.exphem.2006.01.009
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677
   Taichman RS, 2001, BRIT J HAEMATOL, V112, P438, DOI 10.1046/j.1365 2141.2001.02568.x
   TORRING O, 1991, ENDOCRINOLOGY, V128, P1006
   Tovey SC, 2006, BIOCHEM SOC T, V34, P515, DOI 10.1042/BST0340515
   VERROTTI M, 1952, Clin Pediatr (Bologna), V34, P719
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756 3282(94)00051 4
   Weber JM, 2006, BONE, V39, P485, DOI 10.1016/j.bone.2006.03.002
   Welniak LA, 2004, BIOL BLOOD MARROW TR, V10, P32, DOI 10.1016/j.bbmt.2003.09.008
   Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood 2003 08 2955
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
   Zumkeller W, 1999, BLOOD, V94, P3653, DOI 10.1182/blood.V94.11.3653.423k42_3653_3657
NR 52
TC 31
Z9 34
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JUN 25
PY 2008
VL 288
IS 1 2
BP 6
EP 10
DI 10.1016/j.mce.2008.02.022
PG 5
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 326DT
UT WOS:000257639100002
PM 18400373
DA 2025 08 17
ER

PT J
AU Abiola, M
   Favier, M
   Christodoulou Vafeiadou, E
   Pichard, AL
   Martelly, I
   Guillet Deniau, I
AF Abiola, Mounira
   Favier, Maryline
   Christodoulou Vafeiadou, Eleni
   Pichard, Anne Lise
   Martelly, Isabelle
   Guillet Deniau, Isabelle
TI Activation of Wnt/β Catenin Signaling Increases Insulin Sensitivity
   through a Reciprocal Regulation of Wnt10b and SREBP 1c in Skeletal
   Muscle Cells
SO PLOS ONE
LA English
DT Article
ID ELEMENT BINDING PROTEIN 1C; GLUCOSE TRANSPORT; GENE EXPRESSION; MYOGENIC
   CELLS; FATTY ACIDS; RAT MUSCLES; KINASE; DIFFERENTIATION;
   PHOSPHORYLATION; ADIPOGENESIS
AB Background: Intramyocellular lipid accumulation is strongly related to insulin resistance in humans, and we have shown that high glucose concentration induced de novo lipogenesis and insulin resistance in murin muscle cells. Alterations in Wnt signaling impact the balance between myogenic and adipogenic programs in myoblasts, partly due to the decrease of Wnt10b protein. As recent studies point towards a role for Wnt signaling in the pathogenesis of type 2 diabetes, we hypothesized that activation of Wnt signaling could play a crucial role in muscle insulin sensitivity.
   Methodology/Principal Findings: Here we demonstrate that SREBP 1c and Wnt10b display inverse expression patterns during muscle ontogenesis and regeneration, as well as during satellite cells differentiation. The Wnt/beta catenin pathway was reactivated in contracting myotubes using siRNA mediated SREBP 1 knockdown, Wnt10b over expression or inhibition of GSK 3 beta, whereas Wnt signaling was inhibited in myoblasts through silencing of Wnt10b. SREBP 1 knockdown was sufficient to induce Wnt10b protein expression in contracting myotubes and to activate the Wnt/beta catenin pathway. Conversely, silencing Wnt10b in myoblasts induced SREBP 1c protein expression, suggesting a reciprocal regulation. Stimulation of the Wnt/beta catenin pathway i) drastically decreased SREBP 1 c protein and intramyocellular lipid deposition in myotubes; ii) increased basal glucose transport in both insulin sensitive and insulin resistant myotubes through a differential activation of Akt and AMPK pathways; iii) restored insulin sensitivity in insulin resistant myotubes.
   Conclusions/Significance:We conclude that activation of Wnt/beta catenin signaling in skeletal muscle cells improved insulin sensitivity by i) decreasing intramyocellular lipid deposition through downregulation of SREBP 1c; ii) increasing insulin effects through a differential activation of the Akt/PKB and AMPK pathways; iii) inhibiting the MAPK pathway. A crosstalk between these pathways and Wnt/beta catenin signaling in skeletal muscle opens the exciting possibility that organ selective modulation of Wnt signaling might become an attractive therapeutic target in regenerative medicine and to treat obese and diabetic populations.
C1 [Abiola, Mounira; Favier, Maryline; Christodoulou Vafeiadou, Eleni; Pichard, Anne Lise; Guillet Deniau, Isabelle] Univ Paris 05, CNRS, UMR 8104, Genet & Dev Dept,Inst Cochin, Paris, France.
   [Abiola, Mounira; Favier, Maryline; Christodoulou Vafeiadou, Eleni; Pichard, Anne Lise; Guillet Deniau, Isabelle] INSERM, U567, Paris, France.
   [Martelly, Isabelle] Univ Paris 12, CNRS, UMR 7149, CRRET, Creteil, France.
   [Guillet Deniau, Isabelle] UPMC Paris 6, Creteil, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); CNRS   National Institute for Biology (INSB); Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite;
   Universite Paris Est Creteil Val de Marne (UPEC); Centre National de la
   Recherche Scientifique (CNRS); Sorbonne Universite
RP Abiola, M (通讯作者)，Univ Paris 05, CNRS, UMR 8104, Genet & Dev Dept,Inst Cochin, Paris, France.
EM isabelle.guillet deniau@inserm.fr
OI Christodoulou Vafeiadou, Eleni/0000 0002 2805 2019
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Aguiari P, 2008, P NATL ACAD SCI USA, V105, P1226, DOI 10.1073/pnas.0711402105
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460 2075.1996.tb01045.x
   Anagnostou SH, 2008, BIOCHEM J, V416, P211, DOI 10.1042/BJ20081426
   BASSAGLIA Y, 1995, J MUSCLE RES CELL M, V16, P420, DOI 10.1007/BF00114507
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597
   Bizeau ME, 2003, J NUTR, V133, P1787, DOI 10.1093/jn/133.6.1787
   Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008
   Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867
   Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535
   Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134
   Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915
   Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737
   Foretz M, 1999, MOL CELL BIOL, V19, P3760
   Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952 3278(97)90495 6
   Guillet Deniau I, 2004, J CELL SCI, V117, P1937, DOI 10.1242/jcs.01069
   Guillet Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722
   GUILLETDENIAU I, 1994, J CELL SCI, V107, P487
   HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415
   Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369
   Jensen TE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002102
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kanazawa A, 2004, AM J HUM GENET, V75, P832, DOI 10.1086/425340
   Koopman R, 2001, HISTOCHEM CELL BIOL, V116, P63
   Machann J, 2004, DIABETES OBES METAB, V6, P239, DOI 10.1111/j.1462 8902.2004.00339.x
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Millar JBA, 2002, GENOME BIOL, V3
   Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880
   Nadeau KJ, 2004, J BIOL CHEM, V279, P34380, DOI 10.1074/jbc.M403596200
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200
   ROSS SE, 2000, SCIENCE, V289, P950, DOI DOI 10.1126/SCIENCE.289.5481.950
   Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399 0004.2000.570103.x
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656
   SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930
   Takata H, 2007, DEV DYNAM, V236, P2800, DOI 10.1002/dvdy.21327
   Taylor Jones JM, 2002, MECH AGEING DEV, V123, P649, DOI 10.1016/S0047 6374(01)00411 0
   TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183
   Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00 0590
   Vertino AM, 2005, MOL BIOL CELL, V16, P2039, DOI 10.1091/mbc.E04 08 0720
   Virkamäki A, 2001, DIABETES, V50, P2337, DOI 10.2337/diabetes.50.10.2337
   Welters HJ, 2008, TRENDS ENDOCRIN MET, V19, P349, DOI 10.1016/j.tem.2008.08.004
   Zahler S, 2007, CHEM BIOL, V14, P1207, DOI 10.1016/j.chembiol.2007.10.010
NR 46
TC 103
Z9 117
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2009
VL 4
IS 12
AR e8509
DI 10.1371/journal.pone.0008509
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 601NW
UT WOS:000278068700022
PM 20041157
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Kalyanaraman, H
   China, SP
   Cabriales, JA
   Moininazeri, J
   Casteel, DE
   Garcia, JJ
   Wong, V
   Chen, A
   Sah, RL
   Boss, GR
   Pilz, RB
AF Kalyanaraman, Hema
   China, Shyamsundar Pal
   Cabriales, Justin A.
   Moininazeri, Jafar
   Casteel, Darren E.
   Garcia, Julian J.
   Wong, Van W.
   Chen, Albert
   Sah, Robert L.
   Boss, Gerry R.
   Pilz, Renate B.
TI Protein Kinase G2 Is Essential for Skeletal Homeostasis and Adaptation
   to Mechanical Loading in Male but Not Female Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANALYSIS OTHER (MECHANICAL LOADING); GENETIC ANIMAL MODEL; MOLECULAR
   PATHWAYS REMODELING; OSTEOBLASTS; WNT; beta CATENIN
ID NITRIC OXIDE SYNTHASE; BONE MINERAL DENSITY; ESTROGEN RECEPTOR;
   OSTEOGENIC RESPONSE; BETA CATENIN; SHEAR STRESS; FLUID FLOW; ISOSORBIDE
   MONONITRATE; NITROGLYCERIN THERAPY; WNT/BETA CATENIN
AB We previously showed that the NO/cGMP/protein kinase G (PKG) signaling pathway positively regulates osteoblast proliferation, differentiation, and survival in vitro, and that cGMP elevating agents have bone anabolic effects in mice. Here, we generated mice with an osteoblast specific (OB) knockout (KO) of type 2 PKG (gene name Prkg2) using a Col1a1(2.3 kb) Cre driver. Compared to wild type (WT) littermates, 8 week old male OB Prkg2 KO mice had fewer osteoblasts, reduced bone formation rates, and lower trabecular and cortical bone volumes. Female OB Prkg2 KO littermates showed no bone abnormalities, despite the same degree of PKG2 deficiency in bone. Expression of osteoblast differentiation  and Wnt/beta catenin related genes was lower in primary osteoblasts and bones of male KO but not female KO mice compared to WT littermates. Osteoclast parameters were unaffected in both sexes. Since PKG2 is part of a mechano sensitive complex in osteoblast membranes, we examined its role during mechanical loading. Cyclical compression of the tibia increased cortical thickness and induced mechanosensitive and Wnt/beta catenin related genes to a similar extent in male and female WT mice and female OB Prkg2 KO mice, but loading had a minimal effect in male KO mice. We conclude that PKG2 drives bone acquisition and adaptation to mechanical loading via the Wnt/beta catenin pathway in male mice. The striking sexual dimorphism of OB Prkg2 KO mice suggests that current U.S. Food and Drug Administration approved cGMP elevating agents may represent novel effective treatment options for male osteoporosis. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Kalyanaraman, Hema; China, Shyamsundar Pal; Cabriales, Justin A.; Moininazeri, Jafar; Casteel, Darren E.; Garcia, Julian J.; Boss, Gerry R.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
   [Garcia, Julian J.; Wong, Van W.; Chen, Albert; Sah, Robert L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
RI Pal China, Shyamsundar/AAB 8041 2019
OI Pal China, Shyamsundar/0000 0003 0062 3593; Cabriales,
   Justin/0000 0002 7488 5812
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bonnet C, 2010, J MED GENET, V47, P377, DOI 10.1136/jmg.2009.071902
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Callewaert F, 2010, J BONE MINER RES, V25, P124, DOI 10.1359/jbmr.091001
   Carriero A, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10467
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204
   Choi RB, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116087
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Farah C, 2018, NAT REV CARDIOL, V15, P292, DOI 10.1038/nrcardio.2017.224
   Ferrari SL, 2004, AM J HUM GENET, V74, P866, DOI 10.1086/420771
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grassi F, 2006, ENDOCRINOLOGY, V147, P4392, DOI 10.1210/en.2006 0334
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Joshua J, 2014, VITAM HORM, V96, P247, DOI 10.1016/B978 0 12 800254 4.00010 6
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Kalyanaraman H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004911
   Kang KS, 2016, BONE, V88, P138, DOI 10.1016/j.bone.2016.04.028
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Kim SM, 2020, P NATL ACAD SCI USA, V117, P14386, DOI 10.1073/pnas.2000950117
   Klein Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Maurel DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158381
   Melville KM, 2015, J BONE MINER RES, V30, P1468, DOI 10.1002/jbmr.2488
   Melville KM, 2015, METHODS MOL BIOL, V1226, P99, DOI 10.1007/978 1 4939 1619 1_9
   Mödder UI, 2012, J CELL BIOCHEM, V113, P2248, DOI 10.1002/jcb.24095
   Mohan S, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.7
   Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003 0034
   Nabhan AF, 2008, INT J GYNECOL OBSTET, V103, P213, DOI 10.1016/j.ijgo.2008.07.011
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200
   Pal S, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115305
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Ramdani G, 2018, J ENDOCRINOL, V238, P203, DOI 10.1530/JOE 18 0286
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Riddle RC, 2011, J BIOL CHEM, V286, P44449, DOI 10.1074/jbc.M111.276683
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rooney AM, 2022, BONE, V158, DOI 10.1016/j.bone.2022.116349
   Rowe DW, 2018, CURR OSTEOPOROS REP, V16, P77, DOI 10.1007/s11914 018 0421 4
   Sasaki F, 2020, BIOCHEM BIOPH RES CO, V521, P806, DOI 10.1016/j.bbrc.2019.10.174
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Saxon LK, 2012, ENDOCRINOLOGY, V153, P2254, DOI 10.1210/en.2011 1977
   Saxon LK, 2011, BONE, V49, P184, DOI 10.1016/j.bone.2011.03.683
   Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 4
   Stadelmann VA, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.138
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   Tan SD, 2008, BIOCHEM BIOPH RES CO, V369, P1150, DOI 10.1016/j.bbrc.2008.03.007
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Turner CH, 1997, BONE, V21, P487, DOI 10.1016/S8756 3282(97)00202 0
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Yang HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169519
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Zaidi M, 2018, ENDOCR REV, V39, P701, DOI 10.1210/er.2018 00050
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 87
TC 7
Z9 8
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2023
VL 38
IS 1
BP 171
EP 185
DI 10.1002/jbmr.4746
EA NOV 2022
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8L2LH
UT WOS:000891154900001
PM 36371651
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Singh, S
   Singh, M
   Mak, IWY
   Turcotte, R
   Ghert, M
AF Singh, Shalini
   Singh, Mohini
   Mak, Isabella W. Y.
   Turcotte, Robert
   Ghert, Michelle
TI 被撤回的出版物: Investigation of FGFR2 IIIC Signaling via FGF 2 Ligand for
   Advancing GCT Stromal Cell Differentiation (Retracted Article)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID FIBROBLAST GROWTH FACTOR 2; HUMAN BONE MARROW; OSTEOBLAST
   DIFFERENTIATION; APERT SYNDROME; TRANSCRIPTION FACTOR; FACTOR RECEPTORS;
   TUMOR; EXPRESSION; TWIST; MUTATIONS
AB Giant cell tumor of bone (GCT) is an aggressive bone tumor consisting of multinucleated osteoclast like giant cells and proliferating osteoblast like stromal cells. The signaling mechanism involved in GCT stromal cell osteoblastic differentiation is not fully understood. Previous work in our lab reported that GCT stromal cells express high levels of TWIST1, a master transcription factor in skeletal development, which in turn down regulates Runx2 expression and prevents terminal osteoblastic differentiation in these cells. The purpose of this study was to determine the upstream regulation of TWIST1 in GCT cells. Using GCT stromal cells obtained from patient specimens, we demonstrated that fibroblast growth factor receptor (FGFR) 2 signaling plays an essential role in bone development and promotes differentiation of immature osteoblastic cells. Fibroblast growth factor (FGF) 2 stimulates FGFR 2 expression, resulting in decreased TWIST1 expression and increased Runx2, alkaline phosphastase (ALP) and osteopontin (OPN) expression. Inhibition of FGFR 2 through siRNA decreased the expression of ALP, Runx2 and OPN in GCT stromal cells. Our study also confirmed that FGF 2 ligand activates downstream ERK1/2 signaling and pharmacological inhibition of the ERK1/2 signaling pathway suppresses FGF 2 stimulated osteogenic differentiation in these cells. Our results indicate a significant role of FGFR 2 signaling in osteoblastic differentiation in GCT stromal cells.
C1 [Singh, Shalini; Singh, Mohini; Mak, Isabella W. Y.; Ghert, Michelle] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada.
   [Turcotte, Robert] McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Orthopaed Surg, Quebec City, PQ, Canada.
C3 McMaster University; McGill University
RP Ghert, M (通讯作者)，McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada.
EM michelle.ghert@jcc.hhsc.ca
RI Ghert, Michelle/JZE 1212 2024; Mak, Isabella/E 1777 2012
OI Mak, Isabella/0000 0002 7861 4200
FU Canadian Institutes of Health Research (CIHR) grant; Hamilton Health
   Science New Investigator Fund; Hamilton Health Science Early Career
   Award; Juravinski Cancer Centre Foundation grant; McMaster University
   Surgical Associates grant
FX This study was supported by a Canadian Institutes of Health Research
   (CIHR) grant, the Hamilton Health Science New Investigator Fund, a
   Hamilton Health Science Early Career Award, a Juravinski Cancer Centre
   Foundation grant, and a McMaster University Surgical Associates grant.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002 9440(10)65401 6
   Ghert M, 2007, CLIN ORTHOP RELAT R, P122, DOI 10.1097/BLO.0b013e31803ea9c8
   Ghert M, 2007, CLIN ORTHOP RELAT R, P8, DOI 10.1097/BLO.0b013e31804856a1
   GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370
   GOLDRING SR, 1986, CLIN ORTHOP RELAT R, P59
   Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   KATZ E, 1987, CANCER AM CANCER SOC, V59, P1831, DOI 10.1002/1097 0142(19870515)59:10<1831::AID CNCR2820591025>3.0.CO;2 A
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee CH, 2008, MODERN PATHOL, V21, P531, DOI 10.1038/modpathol.3801023
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097 4644(19991215)75:4<566::AID JCB3>3.0.CO;2 0
   Ling L, 2006, J CELL PHYSIOL, V209, P811, DOI 10.1002/jcp.20760
   Lomri A, 1998, J CLIN INVEST, V101, P1310
   Mak IWY, 2010, HUM PATHOL, V41, P1320, DOI 10.1016/j.humpath.2010.03.001
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   MCDONALD DJ, 1986, J BONE JOINT SURG AM, V68A, P235, DOI 10.2106/00004623 198668020 00009
   MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068
   MURRAY SS, 1992, J BONE MINER RES, V7, P1131
   Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003
   Powers CJ, 2000, ENDOCR RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165
   Pri Chen S, 1998, BONE, V23, P111, DOI 10.1016/S8756 3282(98)00087 8
   Rabinovich Alexander, 2009, Open Bone J, V1, P46
   Singh S, 2011, J CELL BIOCHEM, V112, P2287, DOI 10.1002/jcb.23149
   Turcotte RE, 2009, CAN J SURG, V52, P51
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
NR 41
TC 12
Z9 12
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2012
VL 7
IS 10
AR e46769
DI 10.1371/journal.pone.0046769
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 020KP
UT WOS:000309807700029
PM 23071632
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pearsall, RS
   Canalis, E
   Cornwall Brady, M
   Underwood, KW
   Haigis, B
   Ucran, J
   Kumar, R
   Pobre, E
   Grinberg, A
   Werner, ED
   Glatt, V
   Stadmeyer, L
   Smith, D
   Seehra, J
   Bouxsein, ML
AF Pearsall, R. Scott
   Canalis, Ernesto
   Cornwall Brady, Milton
   Underwood, Kathryn W.
   Haigis, Brendan
   Ucran, Jeffrey
   Kumar, Ravindra
   Pobre, Eileen
   Grinberg, Asya
   Werner, Eric D.
   Glatt, Vaida
   Stadmeyer, Lisa
   Smith, Deanna
   Seehra, Jasbir
   Bouxsein, Mary L.
TI A soluble activin type IIA receptor induces bone formation and improves
   skeletal integrity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE anabolic; osteoporosis; TGF beta; therapeutic
ID PARATHYROID HORMONE; MORPHOGENETIC PROTEINS; COST EFFECTIVENESS;
   BINDING PROTEIN; INHIBIN; FRACTURES; MASS; FSH; FOLLISTATIN; ALENDRONATE
AB Diseases that affect the regulation of bone turnover can lead to skeletal fragility and increased fracture risk. Members of the TGF beta superfamily have been shown to be involved in the regulation of bone mass. Activin A, a TGF beta signaling ligand, is present at high levels in bone and may play a role in the regulation of bone metabolism. Here we demonstrate that pharmacological blockade of ligand signaling through the high affinity receptor for activin, type II activin receptor (ActRIIA), by administration of the soluble extracellular domain of ActRIIA fused to a murine IgG2a Fc, increases bone formation, bone mass, and bone strength in normal mice and in ovariectomized mice with established bone loss. These observations support the development of this pharmacological strategy for the treatment of diseases with skeletal fragility.
C1 [Pearsall, R. Scott; Cornwall Brady, Milton; Underwood, Kathryn W.; Haigis, Brendan; Ucran, Jeffrey; Kumar, Ravindra; Pobre, Eileen; Grinberg, Asya; Werner, Eric D.; Seehra, Jasbir] Acceleron Pharma Inc, Cambridge, MA 02139 USA.
   [Canalis, Ernesto; Stadmeyer, Lisa; Smith, Deanna] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Glatt, Vaida; Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Orthopaed Biomech Lab, Boston, MA 02215 USA.
   [Glatt, Vaida; Bouxsein, Mary L.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
C3 Acceleron Pharma; Saint Francis Hospital & Medical Center; Harvard
   University; Harvard University Medical Affiliates; Beth Israel Deaconess
   Medical Center; Harvard University; Harvard Medical School
RP Pearsall, RS (通讯作者)，Acceleron Pharma Inc, 149 Sidney St, Cambridge, MA 02139 USA.
EM spearsall@acceleronpharma.com
RI Kumar, Ravinder/HTL 2843 2023; kumar, ravindra/HTL 2843 2023
OI Kumar, Ravinder/0009 0001 7609 0159; 
CR Allendorph GP, 2007, BIOCHEMISTRY US, V46, P12238, DOI 10.1021/bi700907k
   Baron R, 2006, CELL METAB, V3, P302, DOI 10.1016/j.cmet.2006.04.007
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Burr D, 2003, OSTEOPOROSIS INT, V14, pS67, DOI 10.1007/s00198 003 1476 2
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   del Re E, 2004, J BIOL CHEM, V279, P53126, DOI 10.1074/jbc.M408090200
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Donaldson CJ, 1999, ENDOCRINOLOGY, V140, P1760, DOI 10.1210/en.140.4.1760
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Garrett IR, 2007, CURR TOP DEV BIOL, V78, P127, DOI 10.1016/S0070 2153(06)78004 8
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Jones KL, 2007, P NATL ACAD SCI USA, V104, P16239, DOI 10.1073/pnas.0705971104
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Leung CK, 1996, PATTERN RECOGN, V29, P1523, DOI 10.1016/0031 3203(96)00009 X
   Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129
   Liu H, 2006, ARCH INTERN MED, V166, P1209, DOI 10.1001/archinte.166.11.1209
   MacDonald BR, 2001, BEST PRACT RES CL RH, V15, P483, DOI 10.1053/berh.2001.0162
   Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928
   NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   OGAWA Y, 1992, J BIOL CHEM, V267, P14233
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Perrien DS, 2006, J CLIN ENDOCR METAB, V91, P1848, DOI 10.1210/jc.2005 2423
   RIDLER TW, 1978, IEEE T SYST MAN CYB, V8, P630, DOI 10.1109/tsmc.1978.4310039
   RIVIER C, 1986, SCIENCE, V234, P205, DOI 10.1126/science.3092356
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756 3282(96)00318 3
   Sakai R, 2000, BONE, V27, P91, DOI 10.1016/S8756 3282(00)00307 0
   Sakai R, 1999, BONE, V25, P191, DOI 10.1016/S8756 3282(99)00152 0
   SAKAI R, 1993, BIOCHEM BIOPH RES CO, V195, P39, DOI 10.1006/bbrc.1993.2006
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Swiontkowski MF, 2006, J BONE JOINT SURG AM, V88A, P1258, DOI 10.2106/JBJS.E.00499
   VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0
   Vale Wylie, 1994, P1861
   Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200
   Yamaguchi M, 2005, ENDOCRINOLOGY, V146, P2620, DOI 10.1210/en.2004 1511
NR 42
TC 165
Z9 213
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 13
PY 2008
VL 105
IS 19
BP 7082
EP 7087
DI 10.1073/pnas.0711263105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 301UN
UT WOS:000255921200053
PM 18460605
OA Green Published
DA 2025 08 17
ER

PT J
AU Almeida, M
   OBrien, CA
AF Almeida, Maria
   OBrien, Charles A.
TI Basic Biology of Skeletal Aging: Role of Stress Response Pathways
SO JOURNALS OF GERONTOLOGY SERIES A BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Autophagy; Bone; Mesenchymal stem cells; Osteocytes; Oxidative stress
ID ESTROGEN RECEPTOR ALPHA; AGE RELATED CHANGES; TRANSCRIPTION FACTOR AFX;
   TRABECULAR BONE LOSS; GROWTH FACTOR I; BETA CELL MASS; FORKHEAD BOX O;
   OXIDATIVE STRESS; LIFE SPAN; CORTICAL BONE
AB Although a decline in bone formation and loss of bone mass are common features of human aging, the molecular mechanisms mediating these effects have remained unclear. Evidence from pharmacological and genetic studies in mice has provided support for a deleterious effect of oxidative stress in bone and has strengthened the idea that an increase in reactive oxygen species (ROS) with advancing age represents a pathophysiological mechanism underlying age related bone loss. Mesenchymal stem cells and osteocytes are long lived cells and, therefore, are more susceptible than other types of bone cells to the molecular changes caused by aging, including increased levels of ROS and decreased autophagy. However, short lived cells like osteoblast progenitors and mature osteoblasts and osteoclasts are also affected by the altered aged environment characterized by lower levels of sex steroids, increased endogenous glucocorticoids, and higher oxidized lipids. This article reviews current knowledge on the effects of the aging process on bone, with particular emphasis on the role of ROS and autophagy in cells of the osteoblast lineage in mice.
C1 [Almeida, Maria] Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA.
   [Almeida, Maria] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System
RP Almeida, M (通讯作者)，Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA.
EM schullermaria@uams.edu
RI O'Brien, Charles/AAL 5078 2020
OI Almeida, Maria/0000 0002 6722 9200
FU National Institutes of Health [R01 AR56679, P01 AG13918, R01 AR49794];
   Department of Veterans Affairs from the Biomedical Laboratory Research
   and Development Service of the VA Office of Research and Development
   [5I01BX000294]; University of Arkansas for Medical Sciences (UAMS)
   Translational Research Institute [UL1 RR029884]; Tobacco Settlement
   funds
FX This work was supported by the National Institutes of Health (R01
   AR56679, P01 AG13918, and R01 AR49794), the Department of Veterans
   Affairs from the Biomedical Laboratory Research and Development Service
   of the VA Office of Research and Development to C.A.O. (5I01BX000294),
   the University of Arkansas for Medical Sciences (UAMS) Translational
   Research Institute (UL1 RR029884), and Tobacco Settlement funds.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   BARSHIRAMAYMON B, 1989, CALCIFIED TISSUE INT, V44, P36, DOI 10.1007/BF02556238
   BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P701, DOI 10.1210/jcem 59 4 701
   Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boonen S, 1997, CALCIFIED TISSUE INT, V61, P173
   Boyce BF, 2006, CURR OPIN RHEUMATOL, V18, P427, DOI 10.1097/01.bor.0000231913.32364.32
   Brodeur MR, 2008, FREE RADICAL BIO MED, V44, P506, DOI 10.1016/j.freeradbiomed.2007.08.030
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092 8674(00)80595 4
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burghardt AJ, 2010, J BONE MINER RES, V25, P983, DOI 10.1359/jbmr.091104
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caramés B, 2010, ARTHRITIS RHEUM US, V62, P791, DOI 10.1002/art.27305
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coipeau P, 2009, CYTOTHERAPY, V11, P584, DOI 10.1080/14653240903079385
   Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573
   Cooper M S, 2008, J Endocrinol Invest, V31, P16
   Corbi Graziamaria, 2012, Front Biosci (Elite Ed), V4, P768
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174
   DeCarolis NA, 2008, BIOESSAYS, V30, P102, DOI 10.1002/bies.20709
   Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749 6632.2002.tb04690.x
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Dröge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474 9726.2007.00294.x
   Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Garnero P, 2000, LANCET, V355, P898, DOI 10.1016/S0140 6736(99)05463 X
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   HAYDEN JM, 1995, BONE, V17, pS93, DOI 10.1016/8756 3282(95)00186 H
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev genet 102808 114910
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Hoogeboom D, 2009, BBA REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002
   Huang MS, 2007, J BIOL CHEM, V282, P21237, DOI 10.1074/jbc.M701341200
   Huang SC, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 18
   Iida H, 2002, J VET MED SCI, V64, P29, DOI 10.1292/jvms.64.29
   Iyer S, 2011, J BONE MINER RES, V26, P1168
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Janssen Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011
   Jenny NS, 2012, DISCOV MED, V13, P451
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jilka R., 2012, J Bone Miner Res, V27, pS348
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Jin T, 2008, DIABETOLOGIA, V51, P1771, DOI 10.1007/s00125 008 1084 y
   Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kasper G, 2009, STEM CELLS, V27, P1288, DOI 10.1002/stem.49
   Kawai M, 2010, J CELL BIOCHEM, V111, P14, DOI 10.1002/jcb.22678
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Khosla S., 2012, J GERONTOL A BIOL, DOI [10.1093/gerona/gls163, DOI 10.1093/GER0NA/GLS163]
   Klein BY, 2003, J CELL BIOCHEM, V90, P42, DOI 10.1002/jcb.10603
   Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328
   Kuhn HG, 1996, J NEUROSCI, V16, P2027
   Kume S, 2010, J CLIN INVEST, V120, P1043, DOI 10.1172/JCI41376
   Lavasani M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1611
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lecka Czernik B, 2010, CELL CYCLE, V9, P3648, DOI 10.4161/cc.9.18.13046
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Liu HJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001249
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marotti G, 1998, ANN ANAT, V180, P449, DOI 10.1016/S0940 9602(98)80106 4
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008
   MCCALDEN RW, 1993, J BONE JOINT SURG AM, V75A, P1193, DOI 10.2106/00004623 199308000 00009
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mohan S, 1997, ENDOCRINE, V7, P87, DOI 10.1007/BF02778070
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996 1011
   Mortensen M, 2010, P NATL ACAD SCI USA, V107, P832, DOI 10.1073/pnas.0913170107
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nojiri H, 2011, J BONE MINER RES, V26, P2682, DOI 10.1002/jbmr.489
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Onal M, 2012, J BONE MINER RES, V27, pS349
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS123, DOI 10.1007/BF02406145
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   Parfitt AM., 1990, BONE, V1, P351
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143
   Qiu S, 2002, BONE, V31, P709, DOI 10.1016/S8756 3282(02)00907 9
   Qiu S, 2002, BONE, V31, P313, DOI 10.1016/S8756 3282(02)00819 0
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Riggs BL, 2008, J BONE MINER RES, V23, P205, DOI 10.1359/JBMR.071020
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Ryu BY, 2006, STEM CELLS, V24, P1505, DOI 10.1634/stemcells.2005 0580
   Salih DAM, 2008, CURR OPIN CELL BIOL, V20, P126, DOI 10.1016/j.ceb.2008.02.005
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708
   Schneider C, 2008, J BIOL CHEM, V283, P15539, DOI 10.1074/jbc.R800001200
   Seck T, 1998, J CLIN ENDOCR METAB, V83, P2331, DOI 10.1210/jc.83.7.2331
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Shahnazari M, 2012, BONE, V50, P628, DOI 10.1016/j.bone.2011.11.010
   Sharma C, 2004, J BIOL CHEM, V279, P35583, DOI 10.1074/jbc.M403143200
   Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241
   Shefer G, 2006, DEV BIOL, V294, P50, DOI 10.1016/j.ydbio.2006.02.022
   Silbermann M, 1987, Compr Gerontol A, V1, P45
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Syed FA, 2010, J BONE MINER RES, V25, P2438, DOI 10.1002/jbmr.129
   Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836
   Talchai C, 2012, NAT GENET, V44, P406, DOI 10.1038/ng.2215
   Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741
   TONNA EA, 1975, J GERONTOL, V30, P3, DOI 10.1093/geronj/30.1.3
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   van der Vos KE, 2008, ONCOGENE, V27, P2289, DOI 10.1038/onc.2008.22
   Vedi S, 2005, CALCIFIED TISSUE INT, V77, P79, DOI 10.1007/s00223 004 0205 y
   Vellai T, 2009, TRENDS CELL BIOL, V19, P487, DOI 10.1016/j.tcb.2009.07.007
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wanagat J, 2010, MECH AGEING DEV, V131, P527, DOI 10.1016/j.mad.2010.06.002
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Wehrli FW, 2000, RADIOLOGY, V217, P527, DOI 10.1148/radiology.217.2.r00nv20527
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   WEISS A, 1991, BONE, V12, P165, DOI 10.1016/8756 3282(91)90039 L
   Wu JJ, 2009, AGING US, V1, P425, DOI 10.18632/aging.100038
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yen WL, 2008, PHYSIOLOGY, V23, P248, DOI 10.1152/physiol.00013.2008
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang XF, 2006, BIOL REPROD, V74, P119, DOI 10.1095/biolreprod.105.045591
NR 168
TC 158
Z9 186
U1 0
U2 29
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079 5006
EI 1758 535X
J9 J GERONTOL A BIOL
JI J. Gerontol. Ser. A Biol. Sci. Med. Sci.
PD OCT
PY 2013
VL 68
IS 10
BP 1197
EP 1208
DI 10.1093/gerona/glt079
PG 12
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 223TU
UT WOS:000324834600007
PM 23825036
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhen, RX
   Yang, JN
   Wang, Y
   Li, YB
   Chen, B
   Song, YX
   Ma, GY
   Yang, B
AF Zhen, Ruixin
   Yang, Jianing
   Wang, Yu
   Li, Yubo
   Chen, Bin
   Song, Youxin
   Ma, Guiyun
   Yang, Bo
TI Hepatocyte growth factor improves bone regeneration via the bone
   morphogenetic protein 2 mediated NF B signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE hepatocyte growth factor; bone morphogenetic protein 2; angiogenesis;
   fracture; bone regeneration; nuclear factor kappa B
ID MESENCHYMAL STEM CELLS; DISTRACTION OSTEOGENESIS; PROMOTES REGENERATION;
   FRACTURE REPAIR; GENE EXPRESSION; BMP RECEPTORS; PROTEINS; ARTHRITIS;
   DISEASE; MARROW
AB Bone regeneration is an important process associated with the treatment of osteonecrosis, which is caused by various factors. Hepatocyte growth factor (HGF) is an active biological factor that has multifunctional roles in cell biology, life sciences and clinical medicine. It has previously been suggested that bone morphogenetic protein (BMP) 2 exerts beneficial roles in bone formation, repair and angiogenesis in the femoral head. The present study aimed to investigate the benefits and molecular mechanisms of HGF in bone regeneration. The viability of osteoblasts and osteoclasts were studied in vitro. In addition, the expression levels of tumor necrosis factor (TNF) , monocyte chemotactic protein (MCP) 1, interleukin (IL) 1 and IL 6 were detected in a mouse fracture model following treatment with HGF. The expression and activity of nuclear factor (NF) B were also analyzed in osteocytes post treatment with HGF. Histological analysis was used to determine the therapeutic effects of HGF on mice with fractures. The migration and differentiation of osteoblasts and osteoclasts were investigated in HGF incubated cells. Furthermore, angiogenesis and BMP 2 expression were analyzed in the mouse fracture model post treatment with HGF. The results indicated that HGF regulates the cell viability of osteoblasts and osteoclasts, and also balanced the ratio between osteoblasts and osteoclasts. In addition, HGF decreased the serum expression levels of TNF , MCP 1, IL 1 and IL 6 in experimental mice. The results of a mechanistic analysis demonstrated that HGF upregulated p65, IB kinase  and IB expression in osteoblasts from experimental mice. In addition, the expression levels of vascular endothelial growth factor, BMP 2 receptor, receptor activator of NF B ligand and macrophage colony stimulating factor were upregulated by HGF, which may effectively promote blood vessel regeneration, and contribute to the formation and revascularization of tissue engineered bone. Furthermore, HGF promoted BMP 2 expression and enhanced angiogenesis at the fracture location. These results suggested that HGF treatment may significantly promote bone regeneration in a mouse fracture model. In conclusion, these results indicated that HGF is involved in bone regeneration, angiogenesis and the balance between osteoblasts and osteoclasts, thus suggesting that HGF may be considered a potential agent for the treatment of fractures via the promotion of bone regeneration through regulation of the BMP 2 mediated NF B signaling pathway.
C1 [Zhen, Ruixin; Yang, Jianing; Wang, Yu; Li, Yubo; Chen, Bin; Song, Youxin; Ma, Guiyun; Yang, Bo] Chengde Med Coll, Affiliated Hosp, Dept Spinal Surg, 36 Nanyingzi St, Chengde 067000, Hebei, Peoples R China.
C3 Chengde Medical University
RP Zhen, RX (通讯作者)，Chengde Med Coll, Affiliated Hosp, Dept Spinal Surg, 36 Nanyingzi St, Chengde 067000, Hebei, Peoples R China.
EM zhenruixindr@yeah.net
CR Aino M, 2014, EXPERT OPIN BIOL TH, V14, P1731, DOI 10.1517/14712598.2014.960387
   Bajnok A, 2013, CYTOM PART A, V83A, P287, DOI 10.1002/cyto.a.22256
   Baum E, 2015, INT J CLIN EXP PATHO, V8, P13477
   Boissinot M, 2011, ONCOGENE, V30, P990, DOI 10.1038/onc.2010.479
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Brescia AC, 2014, ARTHRITIS RHEUMATOL, V66, P1352, DOI 10.1002/art.38336
   Coudriet GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015384
   da Silva CG, 2012, J CELL PHYSIOL, V227, P1382, DOI 10.1002/jcp.22851
   Dagostino PR, 2014, SPINE J, V14, P20, DOI 10.1016/j.spinee.2012.10.035
   Faletto D L, 1993, EXS, V65, P107
   Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200
   Furuya H, 2014, TISSUE ENG PT A, V20, P1531, DOI [10.1089/ten.tea.2012.0763, 10.1089/ten.TEA.2012.0763]
   Gibbs DMR, 2016, J TISSUE ENG REGEN M, V10, P187, DOI 10.1002/term.1968
   Grcevic D, 2010, J RHEUMATOL, V37, P246, DOI 10.3899/jrheum.090167
   Haller JM, 2015, J BONE JOINT SURG AM, V97A, P478, DOI 10.2106/JBJS.N.00200
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Harvey EJ, 2015, J BONE JOINT SURG AM, V97A, DOI 10.2106/JBJS.N.01293
   Holstein JH, 2012, MED SCI MONITOR, V18, pBR469, DOI 10.12659/MSM.883590
   Hustedt Joshua W., 2014, Yale Journal of Biology and Medicine, V87, P549
   Hutchison C, 2007, BONE, V40, P45, DOI 10.1016/j.bone.2006.07.005
   Imai Y, 2005, J BONE MINER RES, V20, P1723, DOI 10.1359/JBMR.050607
   Izumida Y, 2005, BIOCHEM BIOPH RES CO, V333, P273, DOI 10.1016/j.bbrc.2005.05.100
   Jin SZ, 2011, J HEPATO BIL PAN SCI, V18, P397, DOI 10.1007/s00534 010 0343 8
   Katz MS, 2012, J PEDIATR SURG, V47, P194, DOI 10.1016/j.jpedsurg.2011.10.043
   Kinsella S, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0182 6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lories RJU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2135
   Madonna R, 2012, THROMB HAEMOSTASIS, V107, P656, DOI 10.1160/TH11 10 0711
   Mallavia B, 2013, AM J PATHOL, V182, P1910, DOI 10.1016/j.ajpath.2013.01.022
   Issa JPM, 2009, CLIN ORAL IMPLAN RES, V20, P1286, DOI 10.1111/j.1600 0501.2009.01799.x
   Marino M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/189864
   Marinova Mutafchieva L, 2000, ARTHRITIS RHEUM US, V43, P2046, DOI 10.1002/1529 0131(200009)43:9<2046::AID ANR16>3.0.CO;2 8
   Mizuno S, 2006, NIHON RINSHO S2, V64, pS312
   Morimoto Y, 2009, MICROSC RES TECHNIQ, V72, P317, DOI 10.1002/jemt.20654
   Okubo Y, 2000, CLIN ORTHOP RELAT R, P1
   Özeç Y, 2006, J CRANIOFAC SURG, V17, P80
   Perez RA, 2015, ACTA BIOMATER, V23, P295, DOI 10.1016/j.actbio.2015.06.002
   Postigo J, 2016, ARTHRITIS RHEUMATOL, V68, P1551, DOI 10.1002/art.39557
   Ramezani A, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987 015 0020 z
   Rozen N, 2007, CRIT REV EUKAR GENE, V17, P197, DOI 10.1615/CritRevEukarGeneExpr.v17.i3.30
   Sasikumar KP, 2012, J PHARM BIOALLIED SC, V4, pS427, DOI 10.4103/0975 7406.100320
   Singh K, 2016, J BONE JOINT SURG AM, V98, pE57, DOI 10.2106/JBJS.16.00316
   Sugimori K, 2005, J BONE MINER METAB, V23, P411, DOI 10.1007/s00774 005 0622 7
   Suzuki Akinobu, 2010, Clin Calcium, V20, P1820, DOI CliCa101218201827
   Tewari D, 2015, STEM CELL REV REP, V11, P309, DOI 10.1007/s12015 014 9573 5
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Thorimbert V, 2015, FASEB J, V29, P4299, DOI 10.1096/fj.15 272955
   Tomson PL, 2013, CYTOKINE, V61, P622, DOI 10.1016/j.cyto.2012.11.009
   Wai Hoe L, 2009, BIOL PROCED ONLINE, V11, P145, DOI 10.1007/s12575 009 9007 y
   Wan QL, 2016, BONE, V86, P10, DOI 10.1016/j.bone.2016.02.010
   Wang Jianzhong, 2008, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V22, P1161
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264 013 2059 2
   Wang XL, 2015, CURR PHARM DESIGN, V21, P1575, DOI 10.2174/1381612821666150115152841
   Yamamoto M, 2015, BIOMATERIALS, V56, P18, DOI 10.1016/j.biomaterials.2015.03.057
   Ye L, 2007, INT J ONCOL, V30, P521
   Yonezawa H, 2006, J CRANIO MAXILL SURG, V34, P270, DOI 10.1016/j.jcms.2006.02.003
   Zhang SH, 2013, CLIN RES HEPATOL GAS, V37, P602, DOI 10.1016/j.clinre.2013.05.011
NR 57
TC 21
Z9 22
U1 1
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2018
VL 17
IS 4
BP 6045
EP 6053
DI 10.3892/mmr.2018.8559
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GA9PA
UT WOS:000428672100152
PM 29436622
OA Bronze
DA 2025 08 17
ER

PT J
AU Liverani, C
   Mercatali, L
   Spadazzi, C
   La Manna, F
   De Vita, A
   Riva, N
   Calpona, S
   Ricci, M
   Bongiovanni, A
   Gunelli, E
   Zanoni, M
   Fabbri, F
   Zoli, W
   Amadori, D
   Ibrahim, T
AF Liverani, Chiara
   Mercatali, Laura
   Spadazzi, Chiara
   La Manna, Federico
   De Vita, Alessandro
   Riva, Nada
   Calpona, Sebastiano
   Ricci, Marianna
   Bongiovanni, Alberto
   Gunelli, Erica
   Zanoni, Michele
   Fabbri, Francesco
   Zoli, Wainer
   Amadori, Dino
   Ibrahim, Toni
TI CSF 1 blockade impairs breast cancer osteoclastogenic potential in
   co culture systems
SO BONE
LA English
DT Article
DE Breast cancer; Bone metastases; Osteoclast; CSF 1; RANK L
ID STIMULATING FACTOR I; ZOLEDRONIC ACID; FACTOR 1 RECEPTOR; BONE
   METASTASES; PROSTATE CANCER; MAMMARY GLAND; DENOSUMAB; CELLS;
   MACROPHAGES; MECHANISMS
AB Metastatic bone disease has a major impact on the morbidity and mortality of breast cancer patients, and studies on bone metastasis biology have led to the development of the most widely used drugs for bone metastases treatment: zoledronate (Zol) and denosumab (Den). The aim of the present study was to assess the effect of soluble mediators produced by breast cancer cells on human osteoclast maturation in a co culture model. We also tested the ability of zoledronate, denosumab and 5H4, an antibody directed against CSF 1, to interfere with the osteoclastogenic potential of breast cancer. The study was performed on the triple negative cell line MDA MB 231 and on human osteoclasts obtained from the differentiation of peripheral blood monocytes of a healthy volunteer. Osteoclastogenesis was evaluated by TRAP assay after 14 days of differentiation with 10% MDA MB231 conditioned media or with CSF 1 and RANKL. Den, Zol and 5H4 were administered after 7 days of differentiation. MDA MB 231 conditioned media doubled the differentiation of monocytes into osteoclasts. MDA MB 231 secreted CSF 1, especially when cells were cultured to confluence. Induced osteoclasts were sensitive to bone targeted drugs: Den and 5H4 blocked osteoclast differentiation and survival, while Zol induced osteoclast apoptosis. Osteoclasts differentiated by breast cancer cells were less sensitive to Zol than those induced by differentiation factors, whereas sensitivity to Den was similar. Conversely, breast cancer induced osteoclast activation resulted in a higher sensitivity to 5H4. A significant increase in CSF 1 secretion was observed in osteoclast precursors after treatment with the highest concentration of Den. Further research is ongoing to evaluate the efficacy of 5H4 combination with Den. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Liverani, Chiara; Mercatali, Laura; Spadazzi, Chiara; La Manna, Federico; De Vita, Alessandro; Riva, Nada; Calpona, Sebastiano; Ricci, Marianna; Bongiovanni, Alberto; Gunelli, Erica; Amadori, Dino; Ibrahim, Toni] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, I 47014 Meldola, FC, Italy.
   [Zanoni, Michele; Fabbri, Francesco; Zoli, Wainer] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Biosci Lab, I 47014 Meldola, FC, Italy.
C3 IRCCS Meldola (IRST); IRCCS Meldola (IRST)
RP Liverani, C (通讯作者)，IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, Via Piero Maroncelli 40, I 47014 Meldola, FC, Italy.
EM chiara.liverani@irst.emr.it
RI Fabbri, Francesco/K 1751 2018; Mercatali, Laura/J 9154 2016; Calpona,
   Sebastiano/AAO 8159 2021; Liverani, Chiara/K 3913 2016; Spadazzi,
   Chiara/AAB 5917 2021; Zanoni, Michele/K 3001 2016; De Vita,
   Alessandro/K 1534 2016; Bongiovanni, Alberto/J 9802 2018
OI Fabbri, Francesco/0000 0002 7885 3025; Mercatali,
   Laura/0000 0003 2162 8238; Liverani, Chiara/0000 0002 4279 1926;
   Ibrahim, Toni/0000 0003 0259 4167; Spadazzi, Chiara/0000 0001 6710 5980;
   Zanoni, Michele/0000 0003 1826 9430; Bongiovanni,
   Alberto/0000 0002 3845 4687; De Vita, Alessandro/0000 0002 1677 5797; La
   Manna, Federico/0000 0003 3644 8395; 
CR Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008 5472.CAN 04 0961
   Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078 0432.CCR 08 1283
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Cheng Hongwei, 2010, Sarcoma, V2010, P174528, DOI 10.1155/2010/174528
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   Espinosa I, 2009, AM J PATHOL, V174, P2347, DOI 10.2353/ajpath.2009.081037
   Gallet M, 2004, BIOCHEM BIOPH RES CO, V319, P690, DOI 10.1016/j.bbrc.2004.05.033
   Gallet M, 2006, APOPTOSIS, V11, P1909, DOI 10.1007/s10495 006 9507 z
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008 5472.CAN 04 1853
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang L, 2002, J CLIN PATHOL, V55, P877, DOI 10.1136/jcp.55.11.877
   Hussein O, 2011, BONE, V48, P202, DOI 10.1016/j.bone.2010.09.006
   Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099
   KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   MacDonald KPA, 2010, BLOOD, V116, P3955, DOI 10.1182/blood 2010 02 266296
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757
   Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450
   Mouline CC, 2010, EUR CELLS MATER, V20, P379
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Patel LR, 2011, FUTURE ONCOL, V7, P1285, DOI [10.2217/fon.11.112, 10.2217/FON.11.112]
   Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008 5472.CAN 09 1868
   Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008 5472.CAN 05 3523
   Peng XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058361
   Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762
   POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ryder M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054302
   Sapi E, 2004, EXP BIOL MED, V229, P1
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968
   Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008 5472.CAN 12 0122
   Tamimi RM, 2008, CANCER RES, V68, P18, DOI 10.1158/0008 5472.CAN 07 3234
   Varin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072831
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Yagiz K, 2009, EXP CELL RES, V315, P2442, DOI 10.1016/j.yexcr.2009.05.002
NR 53
TC 33
Z9 34
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2014
VL 66
BP 214
EP 222
DI 10.1016/j.bone.2014.06.017
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AM7DB
UT WOS:000340023800028
PM 24956020
DA 2025 08 17
ER

PT J
AU Nordstrand, A
   Ylitalo, EB
   Thysell, E
   Jernberg, E
   Crnalic, S
   Widmark, A
   Bergh, A
   Lerner, UH
   Wikström, P
AF Nordstrand, Annika
   Ylitalo, Erik Bovinder
   Thysell, Elin
   Jernberg, Emma
   Crnalic, Sead
   Widmark, Anders
   Bergh, Anders
   Lerner, Ulf H.
   Wikstrom, Pernilla
TI Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its
   Inverse Relation to Tumor Cell Androgen Receptor Activity
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE prostate cancer; bone; metastasis; androgen receptor; osteoblast;
   osteoclast; BMP
ID OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC PROTEINS; MALE MICE; GROWTH;
   OSTEOPONTIN; EXPRESSION; MARKERS; BMP 2; MINERALIZATION; PATHOGENESIS
AB Advanced prostate cancer frequently metastasizes to bone and induces a mixed osteoblastic/osteolytic bone response. Standard treatment for metastatic prostate cancer is androgen deprivation therapy (ADT) that also affects bone biology. Treatment options for patients relapsing after ADT are limited, particularly in cases where castration resistance does not depend on androgen receptor (AR) activity. Patients with non AR driven metastases may, however, benefit from therapies targeting the tumor microenvironment. Therefore, the current study specifically investigated bone cell activity in clinical bone metastases in relation to tumor cell AR activity, in order to gain novel insight into biological heterogeneities of possible importance for patient stratification into bone targeting therapies. Metastasis tissue obtained from treatment naive (n = 11) and castration resistant (n = 28) patients was characterized using whole genome expression analysis followed by multivariate modeling, functional enrichment analysis, and histological evaluation. Bone cell activity was analyzed by measuring expression levels of predefined marker genes representing osteoclasts (ACP5, CTSK, MMP9), osteoblasts (ALPL, BGLAP, RUNX2) and osteocytes (SOST). Principal component analysis indicated a positive correlation between osteoblast and osteoclast activity and a high variability in bone cell activity between different metastases. Immunohistochemistry verified a positive correlation between runt related transcription factor 2 (RUNX2) positive osteoblasts and tartrate resistant acid phosphatase (TRAP, encoded by ACP5) positive osteoclasts lining the metastatic bone surface. No difference in bone cell activity was seen between treatment naive and castration resistant patients. Importantly, bone cell activity was inversely correlated to tumor cell AR activity (measured as AR, FOXA1, HOXB13, KLK2, KLK3, NKX3 1, STEAP2, and TMPRSS2 expression) and to patient serum prostate specific antigen (PSA) levels. Functional enrichment analysis indicated high bone morphogenetic protein (BMP) signaling in metastases with high bone cell activity and low tumor cell AR activity. This was confirmed by BMP4 immunoreactivity in tumor cells of metastases with ongoing bone formation, as determined by histological evaluation of van Gieson stained sections. In conclusion, the inverse relation observed between bone cell activity and tumor cell AR activity in prostate cancer bone metastasis may be of importance for patient response to AR and/or bone targeting therapies, but needs to be evaluated in clinical settings in relation to serum markers for bone remodeling, radiography and patient response to therapy. The importance of BMP signaling in the development of sclerotic metastasis lesions deserves further exploration.
C1 [Nordstrand, Annika; Ylitalo, Erik Bovinder; Thysell, Elin; Jernberg, Emma; Bergh, Anders; Wikstrom, Pernilla] Umea Univ, Dept Med Biosci, Pathol, S 90185 Umea, Sweden.
   [Crnalic, Sead] Umea Univ, Dept Surg & Perioperat Sci, Orthopaed, S 90185 Umea, Sweden.
   [Widmark, Anders] Umea Univ, Dept Radiat Sci, Oncol, S 90187 Umea, Sweden.
   [Lerner, Ulf H.] Umea Univ, Dept Mol Periodontol, S 90187 Umea, Sweden.
   [Lerner, Ulf H.] Univ Gothenburg, Sahlgrenska Acad, Ctr Bone & Arthrit Res, Dept Internal Med, S 41345 Gothenburg, Sweden.
   [Lerner, Ulf H.] Univ Gothenburg, Sahlgrenska Acad, Clin Nutr Inst Med, S 41345 Gothenburg, Sweden.
C3 Umea University; Umea University; Umea University; Umea University;
   University of Gothenburg; University of Gothenburg
RP Wikström, P (通讯作者)，Umea Univ, Dept Med Biosci, Pathol, S 90185 Umea, Sweden.
EM annika.nordstrand@umu.se; erik.bovinder@umu.se; elin.thysell@umu.se;
   emma.jernberg@umu.se; sead.crnalic@umu.se; anders.widmark@umu.se;
   anders.bergh@umu.se; ulf.lerner@umu.se; pernilla.wikstrom@umu.se
RI Crnalic, Sead/AAF 3475 2021
OI Wikstrom, Pernilla/0000 0002 6347 1999; Nordstrand,
   Annika/0000 0001 5969 3225; Lerner, Ulf/0000 0002 3579 1960
FU Swedish Research Council [2015 02393, 2015 02638]; Swedish Cancer
   Society [CAN 2013/1324, CAN 2016/824]; Swedish Prostate Cancer
   Federation; Cancer Research Foundation in Northern Sweden, Umea
   University; County of Vasterbotten; Lundberg Foundation; Royal 80 Year
   Fund of King Gustav; Swedish Research Council [2015 02638, 2015 02393]
   Funding Source: Swedish Research Council; Vinnova [2015 02393] Funding
   Source: Vinnova
FX The study was supported by grants from Swedish Research Council
   (2015 02393 and 2015 02638), the Swedish Cancer Society (CAN 2013/1324
   and CAN 2016/824), the Swedish Prostate Cancer Federation, the Cancer
   Research Foundation in Northern Sweden, Umea University, the County of
   Vasterbotten, the Lundberg Foundation and the Royal 80 Year Fund of King
   Gustav. The authors are grateful to Pernilla Andersson for excellent
   technical assistance.
CR Abe Y, 2004, J BONE MINER RES, V19, P1302, DOI 10.1359/JBMR.040408
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03 0899com
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Clarke BL, 2009, STEROIDS, V74, P296, DOI 10.1016/j.steroids.2008.10.003
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   Crnalic S, 2010, ENDOCR RELAT CANCER, V17, P885, DOI 10.1677/ERC 10 0059
   Davis H, 2016, CYTOKINE GROWTH F R, V27, P81, DOI 10.1016/j.cytogfr.2015.11.009
   Djusberg E, 2017, PROSTATE, V77, P625, DOI 10.1002/pros.23307
   Ecarot B, 1999, ENDOCRINOLOGY, V140, P1192, DOI 10.1210/en.140.3.1192
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hörnberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Iglesias Gato D, 2016, EUR UROL, V69, P942, DOI 10.1016/j.eururo.2015.10.053
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Jernberg E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077407
   Jung K, 2014, BBA REV CANCER, V1846, P425, DOI 10.1016/j.bbcan.2014.09.001
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Khodavirdi AC, 2006, CANCER RES, V66, P883, DOI 10.1158/0008 5472.CAN 05 2816
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Lorente D, 2016, EUR UROL FOCUS, V2, P488, DOI 10.1016/j.euf.2016.10.008
   Maeda H, 1997, J UROLOGY, V157, P539, DOI 10.1016/S0022 5347(01)65196 6
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Mochida Y, 2006, ADV EXP MED BIOL, V585, P101
   Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078 0432.CCR 1146 03
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   Nguyen PL, 2015, EUR UROL, V67, P825, DOI 10.1016/j.eururo.2014.07.010
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   Nordstrand A, 2013, CANCER MICROENVIRON, V6, P231, DOI 10.1007/s12307 013 0129 z
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Peng J, 2016, MOL CARCINOGEN, V55, P335, DOI 10.1002/mc.22283
   Proell V, 2009, BONE, V45, P677, DOI 10.1016/j.bone.2009.05.024
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Russell PK, 2015, J BONE MINER RES, V30, P809, DOI 10.1002/jbmr.2413
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shin JO, 2012, HISTOCHEM CELL BIOL, V137, P791, DOI 10.1007/s00418 012 0930 7
   Takayama K, 2017, CANCER LETT, V397, P103, DOI 10.1016/j.canlet.2017.03.034
   Thysell E., 2017, CANC RES
   Thysell E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014175
   van Beuningen HM, 1998, OSTEOARTHR CARTILAGE, V6, P306, DOI 10.1053/joca.1998.0129
   Vanderschueren D, 2014, ENDOCR REV, V35, P906, DOI 10.1210/er.2014 1024
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yang GB, 2014, J CELL PHYSIOL, V229, P943, DOI 10.1002/jcp.24525
   Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008 5472.CAN 05 0289
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Ye L, 2016, CANCER LETT, V380, P586, DOI 10.1016/j.canlet.2015.10.036
   Ylitalo EB, 2017, EUR UROL, V71, P776, DOI 10.1016/j.eururo.2016.07.033
   You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008 5472.CAN 16 0902
   Zhao SG, 2016, LANCET ONCOL, V17, P1612, DOI 10.1016/S1470 2045(16)30491 0
NR 63
TC 25
Z9 26
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2018
VL 19
IS 4
AR 1223
DI 10.3390/ijms19041223
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GJ0XU
UT WOS:000434978700302
PM 29670000
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Han, ZH
   Gao, X
   Wang, YJ
   Huang, C
   Song, H
   Cheng, SN
   Yang, XY
   Cui, XL
   Wu, J
   Wei, KL
   Cheng, L
AF Han, Zhihui
   Gao, Xiang
   Wang, Yuanjie
   Huang, Cheng
   Song, Hao
   Cheng, Shuning
   Yang, Xiaoyuan
   Cui, Xiaoliang
   Wu, Jie
   Wei, Kailu
   Cheng, Liang
TI Autocatalytic bifunctional supramolecular hydrogels for osteoporotic
   bone repair
SO NATIONAL SCIENCE REVIEW
LA English
DT Article
DE autocatalysis; supramolecular hydrogel; anti inflammation; osteoporosis;
   bone defect
ID METAL; NETWORKS
AB Conventional bone scaffolds, which are mainly ascribed to highly active osteoclasts and an inflammatory microenvironment with high levels of reactive oxygen species and pro inflammatory factors, barely satisfy osteoporotic defect repair. Herein, multifunctional self assembled supramolecular fiber hydrogels (Ce Aln gel) consisting of alendronate (Aln) and cerium (Ce) ions were constructed for osteoporotic bone defect repair. Based on the reversible interaction and polyvalent cerium ions, the Ce Aln gel, which was mainly composed of ionic coordination and hydrogen bonds, displayed good injectability and autocatalytic amplification of the antioxidant effect. In vitro studies showed that the Ce Aln gel effectively maintained the biological function of osteoblasts by regulating redox homeostasis and improved the inflammatory microenvironment to enhance the inhibitory effect on osteoclasts. Ribonucleic acid (RNA) sequencing further revealed significant downregulation of various metabolic pathways, including apoptosis signaling, hypoxia metabolism and tumor necrosis factor alpha (TNF alpha) signaling via the nuclear factor kappa B pathway after treatment with the Ce Aln gel. In vivo experiments showed that the clinical drug based Ce Aln gel effectively promoted the tissue repair of osteoporotic bone defects by improving inflammation and inhibiting osteoclast formation at the defect. Notably, in vivo systemic osteoporosis was significantly ameliorated, highlighting the strong potential of clinical translation for precise therapy of bone defects.
   Multifunctional self assembled supramolecular fiber hydrogels consisting of clinical drug alendronate and cerium ions with the autocatalytic antioxidant amplification exhibit excellent therapy on osteoporotic bone defect and systemic bone loss.
C1 [Han, Zhihui; Wang, Yuanjie; Cheng, Shuning; Yang, Xiaoyuan; Cui, Xiaoliang; Wu, Jie; Wei, Kailu; Cheng, Liang] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.
   [Gao, Xiang; Huang, Cheng; Song, Hao] Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.
   [Cheng, Liang] Macau Univ Sci & Technol, Macao Inst Mat Sci & Engn, Taipa 999078, Peoples R China.
C3 Soochow University   China; Soochow University   China; Macau University
   of Science & Technology
RP Cheng, L (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.; Cheng, L (通讯作者)，Macau Univ Sci & Technol, Macao Inst Mat Sci & Engn, Taipa 999078, Peoples R China.
EM lcheng2@suda.edu.cn
RI ; Huang, Cheng/KUG 8355 2024; GAO, XIANG/KCK 6653 2024
OI Cui, Xiaoliang/0009 0007 8818 1190; 
FU National Key R & D Program of China [2022YFB3804600, 2021YFF0701800];
   National Natural Science Foundation of China [U20A20254, 52072253];
   Collaborative Innovation Center of Suzhou Nano Science and Technology,
   Suzhou Key Laboratory of Nanotechnology and Biomedicine; Jiangsu Natural
   Science Fund for Distinguished Young Scholars [BK20211544]; Jiangsu Key
   Laboratory for Carbon Based Functional Materials & Devices, Soochow
   University [KJS2212]; Overseas Expertise Introduction Project for
   Discipline Innovation [111 Project]; Joint International Research
   Laboratory of Carbon Based Functional Materials and Devices, Suzhou Key
   Laboratory of Nanotechnology and Biomedicine; Key Laboratory of
   Structural Deformities in Children of Suzhou [SZS2022018]
FX This work was partially supported by the National Key R & D Program of
   China (2022YFB3804600 and 2021YFF0701800), the National Natural Science
   Foundation of China (U20A20254 and 52072253), the Collaborative
   Innovation Center of Suzhou Nano Science and Technology, Suzhou Key
   Laboratory of Nanotechnology and Biomedicine, the Jiangsu Natural
   Science Fund for Distinguished Young Scholars (BK20211544), the Jiangsu
   Key Laboratory for Carbon Based Functional Materials & Devices, Soochow
   University (KJS2212), the Overseas Expertise Introduction Project for
   Discipline Innovation (111 Project), and the Joint International
   Research Laboratory of Carbon Based Functional Materials and Devices,
   Suzhou Key Laboratory of Nanotechnology and Biomedicine, and the Key
   Laboratory of Structural Deformities in Children of Suzhou (SZS2022018).
CR Acevedo C, 2018, NAT BIOMED ENG, V2, P62, DOI 10.1038/s41551 017 0183 9
   Aillon KL, 2009, ADV DRUG DELIVER REV, V61, P457, DOI 10.1016/j.addr.2009.03.010
   Alkutobi Z, 2021, ANN RHEUM DIS, V80, P834, DOI 10.1136/annrheumdis 2021 eular.1670
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen L, 2021, BIOACT MATER, V6, P191, DOI 10.1016/j.bioactmat.2020.08.001
   Chen WK, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0089
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Chen ZY, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110289
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Ejima H, 2017, NANO TODAY, V12, P136, DOI 10.1016/j.nantod.2016.12.012
   Fu H, 2022, J AM CHEM SOC, V144, P8987, DOI 10.1021/jacs.2c00749
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   Gao HQ, 2023, ADV MATER, V35, DOI 10.1002/adma.202204994
   Greenhill C, 2021, NAT REV ENDOCRINOL, V17, P577, DOI 10.1038/s41574 021 00548 4
   Guo JH, 2022, SMART MED, V1, DOI 10.1002/SMMD.20220003
   Herget K, 2017, ADV MATER, V29, DOI 10.1002/adma.201603823
   Holten Andersen N, 2011, P NATL ACAD SCI USA, V108, P2651, DOI 10.1073/pnas.1015862108
   Kang T, 2020, COORDIN CHEM REV, V403, DOI 10.1016/j.ccr.2019.213092
   Kapinos KA, 2018, J AM GERIATR SOC, V66, P2298, DOI 10.1111/jgs.15585
   Khitrin AK, 2014, CHEM PHYS LIPIDS, V184, P76, DOI 10.1016/j.chemphyslip.2014.10.005
   Koo S, 2024, ANGEW CHEM INT EDIT, V63, DOI 10.1002/anie.202318459
   Lee SS, 2022, MATTER US, V5, P2722, DOI 10.1016/j.matt.2022.06.003
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460
   Roth WJ, 2016, CHEM SOC REV, V45, P3400, DOI 10.1039/c5cs00508f
   Sakurai H, 2008, CHEM SOC REV, V37, P2383, DOI 10.1039/b710347f
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Singh N, 2021, ANGEW CHEM INT EDIT, V60, P3121, DOI 10.1002/anie.202011711
   Singh N, 2023, BIOACT MATER, V21, P358, DOI 10.1016/j.bioactmat.2022.08.016
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tu ZX, 2022, NAT REV MATER, V7, P557, DOI 10.1038/s41578 022 00426 z
   Wang P., 2022, Engineered Regeneration, V3, P440, DOI [10.1016/j.engreg.2022.09.004, DOI 10.1016/J.ENGREG.2022.09.004]
   Wang YF, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.20
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang S, 2023, BIOMED TECHNOL PRC, V2, P31, DOI 10.1016/j.bmt.2022.11.012
   Yang Y, 2014, CHINESE SCI BULL, V59, P4720, DOI 10.1007/s11434 014 0458 4
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
NR 40
TC 5
Z9 5
U1 18
U2 43
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2095 5138
EI 2053 714X
J9 NATL SCI REV
JI Natl. Sci. Rev.
PD JUL 26
PY 2024
VL 11
IS 7
AR nwae209
DI 10.1093/nsr/nwae209
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ZV3E9
UT WOS:001278015600003
PM 39071098
OA gold
DA 2025 08 17
ER

PT J
AU Cheng, X
   Wang, G
   Lee, KKH
   Yang, XS
AF Cheng, Xin
   Wang, Guang
   Lee, Kenneth Ka Ho
   Yang, Xuesong
TI Dexamethasone Use During Pregnancy: Potential Adverse Effects on
   Embryonic Skeletogenesis
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Glucocorticoids; dexamethasone (Dex); chondrogenesis; osteogenesis;
   signal transduction pathways
ID RESPIRATORY DISTRESS SYNDROME; FIBROBLAST GROWTH FACTOR 2; CHONDROCYTE
   PROLIFERATION; STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; SKELETAL
   DEVELOPMENT; TARGETED DISRUPTION; FACTOR RECEPTOR 3; GENE EXPRESSION;
   IN VITRO
AB Glucocorticoids are important regulators of cell differentiation and mesenchymal cell lineage commitment during skeletogenesis. In clinical practice, it has been difficult to study the effects of glucocorticoids on target tissues because patients taking glucocorticoids often suffer from adverse skeletal effects. Dexamethasone (Dex) is a long acting synthetic corticosteroid hormone that ranks amongst the most widely used prescribed drugs, and it is a powerful medication that is increasingly employed during the perinatal and neonatal periods. However, Dex is a potential teratogen. In particular, it has been claimed that Dex exposure during pregnancy can affect osteogenesis in the developing embryo, although this claim remains highly controversial. In this review, we summarize the published data from numerous clinical follow up, animal based and in vitro studies on the effects of Dex exposure on embryonic skeletogenesis. These studies indicate that Dex may adversely affect skeletal progenitor cells during development. In addition, Dex can exert a number of effects on bone growth at different developmental stages. We also discuss how glucocorticoids influence the BMP, FGF, Hedgehog and Wnt signaling pathways, which are key regulators of skeletogenesis in the embryo. A fuller understanding of the negative, and perhaps teratogenic, effects of Dex on skeletogenesis will have important implications for the routine use of Dex in clinical practice.
C1 [Cheng, Xin; Wang, Guang; Yang, Xuesong] Jinan Univ, Sch Med, Joint Lab Brain Funct & Hlth, Dept Histol & Embryol, Guangzhou 510632, Guangdong, Peoples R China.
   [Lee, Kenneth Ka Ho] Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Shatin, Hong Kong, Peoples R China.
   [Yang, Xuesong] Jinan Univ, Inst Fetal Preterm Labor Med, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Chinese University of Hong Kong; Jinan University
RP Cheng, X (通讯作者)，Jinan Univ, Coll Med, Div Histol & Embryol, 601 Huangpu Rd West, Guangzhou 510632, Guangdong, Peoples R China.
EM chengxin633@gmail.com; yang_xuesong@126.com
RI Wang, Guang/AAC 4624 2019; Lee, Kenneth/H 6698 2013
OI Lee, Kenneth/0000 0002 6520 304X
FU 973 Project [2010CB529703]; NSFC [31071054, 30971493]; Guangdong Natural
   Science Foundation [S2011010001593, S2013010013392]
FX This study was supported by "973 Project" (2010CB529703); NSFC grant
   (31071054, 30971493) and Guangdong Natural Science Foundation
   (S2011010001593, S2013010013392) to X Yang.
CR Ahmed SF, 2002, CLIN ENDOCRINOL, V57, P185, DOI 10.1046/j.1365 2265.2002.01580.x
   Ahmed SF, 1999, J PEDIATR ENDOCR MET, V12, P75
   Allin MPG, 2005, NEUROREPORT, V16, P1821, DOI 10.1097/01.wnr.0000185014.36939.84
   [Anonymous], 2008, Prescrire Int, V17, P73
   AVIOLI LV, 1993, BRIT J RHEUMATOL, V32, P27
   Ballabh P, 2002, CLIN PHARMACOL THER, V71, P39, DOI 10.1067/mcp.2002.120250
   Bodensteiner JB, 2005, J CHILD NEUROL, V20, P139, DOI 10.1177/08830738050200021101
   Cancedda R, 2000, INT J DEV BIOL, V44, P707
   Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87
   Celander M, 1996, ARCH BIOCHEM BIOPHYS, V329, P113, DOI 10.1006/abbi.1996.0198
   COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608
   COULY GF, 1993, DEVELOPMENT, V117, P409
   Crofton PM, 1998, J CLIN ENDOCR METAB, V83, P3121, DOI 10.1210/jc.83.9.3121
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092 8674(00)81069 7
   Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432 0436.2004.07205003.x
   Diekman BO, 2010, J BIOMED MATER RES A, V93A, P994, DOI 10.1002/jbm.a.32589
   Duboc V, 2011, DEVELOPMENT, V138, P5301, DOI 10.1242/dev.074153
   GAO XM, 1994, BIOCHEM BIOPH RES CO, V199, P734, DOI 10.1006/bbrc.1994.1290
   Gulino A, 2009, J CLIN INVEST, V119, P243, DOI 10.1172/JCI38387
   HANSEN DK, 1994, TERATOGEN CARCIN MUT, V14, P281, DOI 10.1002/tcm.1770140605
   Heine VM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002731
   Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289
   Hu X, 2013, FOOD CHEM TOXICOL, V56, P67, DOI 10.1016/j.fct.2013.02.003
   Jakob M, 2001, J CELL BIOCHEM, V81, P368, DOI 10.1002/1097 4644(20010501)81:2<368::AID JCB1051>3.0.CO;2 J
   James CG, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 205
   JEROME CP, 1988, J MED PRIMATOL, V17, P195
   Jheon A, 2009, ARCH ORAL BIOL, V54, P705, DOI 10.1016/j.archoralbio.2009.04.007
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kalajzic Z, 2002, BONE, V31, P654, DOI 10.1016/S8756 3282(02)00912 2
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Klaus G, 2000, PEDIATR NEPHROL, V14, P612, DOI 10.1007/s004670000344
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lai CH, 2010, ULTRASOUND MED BIOL, V36, P1022, DOI 10.1016/j.ultrasmedbio.2010.03.014
   Leboy PS, 1997, J CELL BIOCHEM, V66, P394, DOI 10.1002/(SICI)1097 4644(19970901)66:3<394::AID JCB11>3.0.CO;2 F
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Lee SY, 2009, TISSUE ENG PT A, V15, P2491, DOI 10.1089/ten.tea.2008.0465
   LIGGINS GC, 1972, PEDIATRICS, V50, P515
   Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033
   Liu YX, 2012, CELL BIOL INT, V36, P611, DOI 10.1042/CBI20110503
   Ma XL, 2013, INT ORTHOP, V37, P1399, DOI 10.1007/s00264 013 1902 9
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053
   Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534 5807(02)00261 7
   Minina E, 2001, DEVELOPMENT, V128, P4523
   MORALES WJ, 1986, AM J OBSTET GYNECOL, V154, P591, DOI 10.1016/0002 9378(86)90607 1
   Muraglia A, 1998, BONE, V22, p131S, DOI 10.1016/S8756 3282(98)00009 X
   Mushtaq T, 2004, ENDOCRINOLOGY, V145, P2478, DOI 10.1210/en.2003 1435
   Mushtaq T, 2002, J ENDOCRINOL, V175, P705, DOI 10.1677/joe.0.1750705
   Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696 233
   Naski MC, 1998, DEVELOPMENT, V125, P4977
   Nesan D, 2012, ENDOCRINOLOGY, V153, P1288, DOI 10.1210/en.2011 1559
   Ochi K, 2006, OSTEOARTHR CARTILAGE, V14, P30, DOI 10.1016/j.joca.2005.07.015
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Olivera Martinez I, 2000, DEVELOPMENT, V127, P4611
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Pearse RV, 2007, DEV BIOL, V310, P388, DOI 10.1016/j.ydbio.2007.08.002
   PINSKY L, 1965, SCIENCE, V147, P402, DOI 10.1126/science.147.3656.402
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   Quarto R, 1997, ENDOCRINOLOGY, V138, P4966, DOI 10.1210/en.138.11.4966
   Rajadurai VS, 2003, ANN ACAD MED SINGAP, V32, P324
   Ramel MC, 2012, FEBS LETT, V586, P1929, DOI 10.1016/j.febslet.2012.02.035
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Senat MV, 2002, J GYNECOL OBST BIO R, V31
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Shintani N, 2011, Eur Cell Mater, V22, P302
   Sliwa E, 2006, J MATERN FETAL NEO M, V19, P489, DOI 10.1080/14767050600850381
   Sliwa E, 2010, J ANIM PHYSIOL AN N, V94, P293, DOI 10.1111/j.1439 0396.2008.00909.x
   Sloboda DM, 2005, CURR PHARM DESIGN, V11, P1459, DOI 10.2174/1381612053507873
   Smink JJ, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740343
   Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012 1606(03)00321 X
   Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397
   Tay AG, 2004, TISSUE ENG, V10, P762, DOI 10.1089/1076327041348572
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   Tezval M, 2009, J MOL HISTOL, V40, P331, DOI 10.1007/s10735 009 9244 z
   UNO H, 1990, DEV BRAIN RES, V53, P157, DOI 10.1016/0165 3806(90)90002 G
   van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002 0033
   Walsh S, 2000, BONE, V27, P185, DOI 10.1016/S8756 3282(00)00319 7
   Walsh S, 2003, BONE, V33, P80, DOI 10.1016/S8756 3282(03)00165 0
   WEHRENBERG WB, 1990, ENDOCRINOLOGY, V126, P3200, DOI 10.1210/endo 126 6 3200
   Williamson I, 2012, DEVELOPMENT, V139, P3157, DOI 10.1242/dev.081174
   Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623 199812000 00004
   YOUNG BK, 1980, AM J OBSTET GYNECOL, V138, P203, DOI 10.1016/0002 9378(80)90036 8
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 88
TC 18
Z9 20
U1 1
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 34
BP 5430
EP 5437
DI 10.2174/1381612820666140205144534
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3UV
UT WOS:000342004400007
PM 24502599
DA 2025 08 17
ER

PT J
AU Riddle, RC
   Taylor, AF
   Genetos, DC
   Donahue, HJ
AF Riddle, RC
   Taylor, AF
   Genetos, DC
   Donahue, HJ
TI MAP kinase and calcium signaling mediate fluid flow induced human
   mesenchymal stem cell proliferation
SO AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
LA English
DT Article
DE mechanotransduction; bone; marrow
ID ACTIVATED PROTEIN KINASE; OSTEOBLAST LIKE CELLS; MARROW STROMAL CELLS;
   SMOOTH MUSCLE CELLS; GENE EXPRESSION; BONE CELLS; SHEAR STRESS; MC3T3 E1
   OSTEOBLASTS; MECHANICAL STRAIN; CYCLOSPORINE A
AB Mechanical signals are important regulators of skeletal homeostasis, and strain induced oscillatory fluid flow is a potent mechanical stimulus. Although the mechanisms by which osteoblasts and osteocytes respond to fluid flow are being elucidated, little is known about the mechanisms by which bone marrow derived mesenchymal stem cells respond to such stimuli. Here we show that the intracellular signaling cascades activated in human mesenchymal stem cells by fluid flow are similar to those activated in osteoblastic cells. Oscillatory fluid flow inducing shear stresses of 5, 10, and 20 dyn/cm(2) triggered rapid, flow rate dependent increases in intracellular calcium that pharmacological studies suggest are inositol trisphosphate mediated. The application of fluid flow also induced the phosphorylation of extracellular signal regulated kinase 1 and  2 as well as the activation of the calcium sensitive protein phosphatase calcineurin in mesenchymal stem cells. Activation of these signaling pathways combined to induce a robust increase in cellular proliferation. These data suggest that mechanically induced fluid flow regulates not only osteoblastic behavior but also that of mesenchymal precursors, implying that the observed osteogenic response to mechanical loading may be mediated by alterations in the cellular behavior of multiple members of the osteoblast lineage, perhaps by a common signaling pathway.
C1 Penn State Univ Hosp, Coll Med, Dept Orthopaed & Rehabil, Milton S Hershey Med Ctr,Div Musculoskeletal Sci, Hershey, PA 17033 USA.
   Univ Calif Davis, Sch Med, Orthopaed Res Labs, Davis, CA 95616 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; University of
   California System; University of California Davis
RP Penn State Univ Hosp, Coll Med, Dept Orthopaed & Rehabil, Milton S Hershey Med Ctr,Div Musculoskeletal Sci, Hershey, PA 17033 USA.
EM hdonahue@psu.edu
RI ; Genetos, Damian/A 6480 2012
OI Genetos, Damian/0000 0002 8599 2867; 
FU NIA NIH HHS [AG 13087] Funding Source: Medline
CR Alford AI, 2003, BONE, V33, P64, DOI 10.1016/S8756 3282(03)00167 4
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756
   Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02 0940com
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464
   Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091
   Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092 8674(00)80571 1
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   Donahue TLH, 2003, J BIOMECH, V36, P1363, DOI 10.1016/S0021 9290(03)00118 0
   DUNCAN RL, 1994, AM J PHYSIOL RENAL, V267, pF909, DOI 10.1152/ajprenal.1994.267.6.F909
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Hamill OP, 1996, PHARMACOL REV, V48, P231
   Hardingham GE, 1999, MICROSC RES TECHNIQ, V46, P348, DOI 10.1002/(SICI)1097 0029(19990915)46:6<348::AID JEMT3>3.3.CO;2 1
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   HUNG CT, 1995, CLIN ORTHOP RELAT R, P256
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Jiang GL, 2002, AM J PHYSIOL ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001
   JOHNSON DL, 1996, AM J PHYSIOL, V271, P205
   Kahl CR, 2004, MOL BIOL CELL, V15, P1833, DOI 10.1091/mbc.E03 10 0730
   Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240
   KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822
   KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006 291X(89)90028 4
   Krauskopf A, 2005, FREE RADICAL RES, V39, P913, DOI 10.1080/10715760500104009
   KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021 9290(90)90350 C
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608
   Li JL, 2002, J BONE MINER RES, V17, P1795, DOI 10.1359/jbmr.2002.17.10.1795
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165 6147(93)90206 Y
   MACHWATE M, 1993, AM J PHYSIOL, V264, pE790, DOI 10.1152/ajpendo.1993.264.5.E790
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   MEISSNER G, 1986, J BIOL CHEM, V261, P6300
   MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643
   Nguyen NSD, 1999, FREE RADICAL BIO MED, V27, P1267, DOI 10.1016/S0891 5849(99)00160 4
   Ogata T, 2000, J CELL BIOCHEM, V76, P529, DOI 10.1002/(SICI)1097 4644(20000315)76:4<529::AID JCB1>3.3.CO;2 X
   OWAN I, 1997, AM J PHYSIOL, V273, P810
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Reich K M, 1991, AM J PHYSIOL, V261, P428
   REICH KM, 1993, CALCIFIED TISSUE INT, V52, P62, DOI 10.1007/BF00675628
   REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113
   Reilly GC, 2003, BIORHEOLOGY, V40, P591
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124
   Sakata T, 1999, J BONE MINER RES, V14, P1596, DOI 10.1359/jbmr.1999.14.9.1596
   Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865 878.2005
   SESSIONS ND, 1989, AM J PHYSIOL, V257, pE606, DOI 10.1152/ajpendo.1989.257.4.E606
   SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483
   Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839
   THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466
   Thomas GP, 1996, CALCIFIED TISSUE INT, V58, P101, DOI 10.1007/s002239900018
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wang FS, 2004, J BONE MINER RES, V19, P973, DOI 10.1359/JBMR.040121
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335
   WIT AL, 1974, CIRC RES, V35, P413, DOI 10.1161/01.RES.35.3.413
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   You J, 2000, J BIOMECH ENG T ASME, V122, P387, DOI 10.1115/1.1287161
   You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   ZHANG RW, 1995, J BONE MINER RES, V10, P415
NR 74
TC 157
Z9 204
U1 1
U2 27
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363 6143
EI 1522 1563
J9 AM J PHYSIOL CELL PH
JI Am. J. Physiol. Cell Physiol.
PD MAR
PY 2006
VL 290
IS 3
BP C776
EP C784
DI 10.1152/ajpcell.00082.2005
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 010YA
UT WOS:000235232700015
PM 16267109
DA 2025 08 17
ER

PT J
AU Beier, EE
   Sheu, TJ
   Dang, D
   Holz, JD
   Ubayawardena, R
   Babij, P
   Puzas, JE
AF Beier, Eric E.
   Sheu, Tzong jen
   Dang, Deborah
   Holz, Jonathan D.
   Ubayawardena, Resika
   Babij, Philip
   Puzas, J. Edward
TI Heavy Metal Ion Regulation of Gene Expression MECHANISMS BY WHICH
   LEAD INHIBITS OSTEOBLASTIC BONE FORMING ACTIVITY THROUGH
   MODULATION OF THE Wnt/β CATENIN SIGNALING PATHWAY
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TGF BETA; ROS 17/2.8; SCLEROSTIN EXPRESSION; GROWTH FACTOR; LONG TERM;
   RAT; DIFFERENTIATION; PHENOTYPE; INCREASES; EXPOSURE
AB Exposure to lead (Pb) from environmental sources remains an overlooked and serious public health risk. Starting in childhood, Pb in the skeleton can disrupt epiphyseal plate function, constrain the growth of long bones, and prevent attainment of a high peak bone mass, all of which will increase susceptibility to osteoporosis later in life. We hypothesize that the effects of Pb on bone mass, in part, come from depression of Wnt/beta catenin signaling, a critical anabolic pathway for osteoblastic bone formation. In this study, we show that depression of Wnt signaling by Pb is due to increased sclerostin levels in vitro and in vivo. Downstream activation of the beta catenin pathway using a pharmacological inhibitor of GSK 3 beta ameliorates the Pb inhibition of Wnt signaling activity in the TOPGAL reporter mouse. The effect of Pb was determined to be dependent on sclerostin expression through use of the SOST gene knock out mice, which are resistant to Pb induced trabecular bone loss and maintain their mechanical bone strength. Moreover, isolated bone marrow cells from the sclerostin null mice show improved bone formation potential even after exposure to Pb. Also, our data suggest that the TGF beta canonical signaling pathway is the mechanism by which Pb controls sclerostin production. Taken together these results support our hypothesis that the osteoporotic like phenotype observed after Pb exposure is, in part, regulated through modulation of the Wnt/beta catenin pathway.
C1 [Beier, Eric E.; Sheu, Tzong jen; Dang, Deborah; Holz, Jonathan D.; Ubayawardena, Resika; Puzas, J. Edward] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14624 USA.
   [Beier, Eric E.; Holz, Jonathan D.; Puzas, J. Edward] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14624 USA.
   [Babij, Philip] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
C3 University of Rochester; University of Rochester; Amgen
RP Puzas, JE (通讯作者)，Ctr Musculoskeletal Res, Dept Orthopaed, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM edward_puzas@urmc.rochester.edu
OI Holz, Jonathan/0000 0003 1486 7230
FU National Institutes of Health [P30 AR061307]
FX We thank S. Mack and K. Maltby for assistance with histology, R. Gelein
   for bone Pb measurements, and M. Thullen for microCT imaging and
   analysis. Biomechanical testing was performed with assistance from Drs.
   H. Awad and J. Inzana in the Biomechanics and Multimodal Tissue Imaging
   Core laboratory, established by National Institutes of Health Grant P30
   AR061307.
CR ANGLE CR, 1990, TOXICOL APPL PHARM, V103, P281, DOI 10.1016/0041 008X(90)90230 R
   ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203
   Beier EE, 2013, ENVIRON HEALTH PERSP, V121, P97, DOI 10.1289/ehp.1205374
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200
   Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046
   Cory Slechta DA, 2010, TOXICOL SCI, V117, P427, DOI 10.1093/toxsci/kfq221
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Delgado Calle J, 2013, MOL CELL ENDOCRINOL, V369, P27, DOI 10.1016/j.mce.2013.02.002
   Ferguson CM, 2000, ENDOCRINOLOGY, V141, P4728, DOI 10.1210/en.141.12.4728
   Fuhrmann S, 2009, INVEST OPHTH VIS SCI, V50, P432, DOI 10.1167/iovs.08 2270
   Gifre L, 2013, BONE, V57, P272, DOI 10.1016/j.bone.2013.08.016
   Gruber HE, 1997, MINER ELECTROL METAB, V23, P65
   Haider S, 2013, METAB BRAIN DIS, V28, P85, DOI 10.1007/s11011 012 9374 y
   Holz JD, 2012, J ORTHOP RES, V30, P1760, DOI 10.1002/jor.22117
   Hossain MA, 2000, J BIOL CHEM, V275, P27874
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ignasiak Z, 2006, ANN HUM BIOL, V33, P401, DOI 10.1080/03014460600730752
   Kafourou A, 1997, ARCH ENVIRON HEALTH, V52, P377, DOI 10.1080/00039899709602214
   Kerper LE, 1997, J BIOL CHEM, V272, P8346, DOI 10.1074/jbc.272.13.8346
   KLEIN RF, 1993, ENDOCRINOLOGY, V132, P2531, DOI 10.1210/en.132.6.2531
   Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LONG GJ, 1992, CALCIFIED TISSUE INT, V50, P451, DOI 10.1007/BF00296777
   Loots GG, 2012, BONE, V50, P663, DOI 10.1016/j.bone.2011.11.016
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PEIFER M, 1991, DEVELOPMENT, V111, P1029
   SAUK JJ, 1992, TOXICOL APPL PHARM, V116, P240, DOI 10.1016/0041 008X(92)90303 A
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Uchiyama Y, 2008, J BONE MINER RES, V23, P1619, DOI 10.1359/JBMR.080502
   Vázquez A, 2004, TOXICOL APPL PHARM, V200, P27, DOI 10.1016/j.taap.2004.03.011
   Wang L, 2010, HUM EXP TOXICOL, V29, P581, DOI 10.1177/0960327109357270
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280
   Yu LC, 2011, BONE, V49, P1131, DOI 10.1016/j.bone.2011.08.016
NR 42
TC 27
Z9 32
U1 1
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 17
PY 2015
VL 290
IS 29
BP 18216
EP 18226
DI 10.1074/jbc.M114.629204
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CN5ZB
UT WOS:000358511700050
PM 25975268
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yeh, HS
   Berenson, JR
AF Yeh, Howard S.
   Berenson, James R.
TI Myeloma bone disease and treatment options
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE myeloma bone disease; bisphosphonates
ID VERTEBRAL COMPRESSION FRACTURES; ADVANCED MULTIPLE MYELOMA; HEPATOCYTE
   GROWTH FACTOR; SKELETAL RELATED EVENTS; TUMOR NECROSIS FACTOR; MARROW
   STROMAL CELLS; DOSE RANGING TRIAL; ZOLEDRONIC ACID; DOUBLE BLIND;
   MONOCLONAL GAMMOPATHY
AB Multiple myeloma (MM) is a B cell malignancy characterized by enhanced bone loss commonly associated with a diffuse osteopenia, focal lytic lesions, pathologic fractures, hypercalcemia, and bony pain. Bone destruction in MM results from asynchronous bone turnover wherein increased osteoclastic bone resorption is not accompanied by a comparable increase in bone formation. Recent characterization of osteoclast activating factors (OAFS), receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) osteoprotegerin RANK system, and inhibitors of Writ signaling have provided a better understanding of myeloma bone disease in molecular level. The development of minimally invasive surgical procedures such as kyphoplasty and vertebroplasty allows myeloma patients with vertebral compression fractures to have immediate improvement in quality of life and shorter hospital stays. Monthly intravenous infusion of either pamidronate or zoledronic acid have reduced the skeletal complications among MM patients and are now a mainstay of myeloma therapy. Orally administered bisphosphonates, in contrast, have shown little ability to slow the development of skeletal complications in these patients. Although pre clinical studies suggest nitrogen containing bisphosphonates have potent anti tumor effects, clinical trials will be necessary, probably at higher doses given more slowly, to establish their possible anti tumor effects clinically. As our understanding of the pathophysiology of myeloma bone disease continues to increase, new target therapies will continue to emerge offering new and more advanced options for the management of myeloma bone disease. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Inst Myeloma & Bone Canc Res, Dept Hematol Oncol, W Hollywood, CA 90069 USA.
RP Berenson, JR (通讯作者)，Inst Myeloma & Bone Canc Res, Dept Hematol Oncol, 9201W Sunset Blvd,Suite 300, W Hollywood, CA 90069 USA.
EM jberenson@myelomasource.org
CR ADAMIETZ IA, 1991, RADIOTHER ONCOL, V20, P111, DOI 10.1016/0167 8140(91)90144 6
   Angtuaco EJ, 2001, RADIOLOGY, V221, P138
   Ansiaux R, 2005, CLIN CANCER RES, V11, P743
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   BARILLE S, 1995, BLOOD, V86, P3151
   Barr JD, 2002, SPINE, V27, P2178, DOI 10.1097/00007632 200210010 00019
   BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889 8588(18)30345 9
   Bataille R, 1996, BLOOD, V87, P4762, DOI 10.1182/blood.V87.11.4762.bloodjournal87114762
   BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397
   Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097 0142(20010101)91:1<144::AID CNCR19>3.0.CO;2 Q
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berenson JR, 2001, CLIN CANCER RES, V7, P478
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   BODY JJ, 1999, P AN M AM SOC CLIN, V35, pA575
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   BOSCH A, 1988, INT J RADIAT ONCOL, V15, P1363, DOI 10.1016/0360 3016(88)90232 5
   Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365 2141.1998.00695.x
   Catell D, 1998, INT J RADIAT ONCOL, V40, P117, DOI 10.1016/S0360 3016(97)00558 0
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Choi SJ, 2000, BLOOD, V96, P671
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   Courneya KS, 2000, PSYCHO ONCOLOGY, V9, P127, DOI 10.1002/(SICI)1099 1611(200003/04)9:2<127::AID PON438>3.0.CO;2 L
   COZZOLINO F, 1989, BLOOD, V74, P380
   DEDONK NWC, 2005, CLIN CANCER RES, V11, P429
   Dispenzieri A, 2005, LEUKEMIA, V19, P118, DOI 10.1038/sj.leu.2403575
   Dudeney S, 2002, J CLIN ONCOL, V20, P2382, DOI 10.1200/JCO.2002.09.097
   Fournier P, 2002, CANCER RES, V62, P6538
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   GARRETT IR, 1987, NEW ENGL J MED, V317, P526, DOI 10.1056/NEJM198708273170902
   GILES FJ, 1992, EUR J CANCER, V28A, P1392, DOI 10.1016/0959 8049(92)90527 9
   Giralt S, 2003, BLOOD, V102, P2684, DOI 10.1182/blood 2002 10 3250
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Goel A, 2005, EXP HEMATOL, V33, P784, DOI 10.1016/j.exphem.2005.04.005
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Greipp P, 2001, BLOOD, V98, p775A
   Healey John H., 2000, Cancer, V88, P2940, DOI 10.1002/1097 0142(20000615)88:12+<2940::AID CNCR10>3.0.CO;2 W
   Heim ME, 1995, ONKOLOGIE, V18, P439
   Hjertner O, 1999, BLOOD, V94, P3883
   IULIANO F, 2004, J CLIN ONCOLOGY S
   Jensen ME, 1997, AM J NEURORADIOL, V18, P1897
   KAWANO M, 1989, BLOOD, V73, P2145
   KYLE RA, 1975, MAYO CLIN PROC, V50, P29
   KYLE RA, 1975, NEW ENGL J MED, V293, P1334, DOI 10.1056/NEJM197512252932602
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lacy MQ, 1999, BLOOD, V93, P300, DOI 10.1182/blood.V93.1.300.401k36_300_305
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lecouvet F, 1997, BRIT J HAEMATOL, V96, P743, DOI 10.1046/j.1365 2141.1997.d01 2108.x
   Lecouvet FE, 1997, RADIOLOGY, V204, P195, DOI 10.1148/radiology.204.1.9205246
   Lecouvet FE, 1997, RADIOLOGY, V204, P201, DOI 10.1148/radiology.204.1.9205247
   Lieberman I, 2003, CLIN ORTHOP RELAT R, pS176, DOI 10.1097/01.blo.0000093841.72468.a8
   Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632 200107150 00026
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   MAN Z, 1990, LANCET, V335, P663, DOI 10.1016/0140 6736(90)90452 B
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Melton LJ, 2004, J BONE MINER RES, V19, P25, DOI 10.1359/JBMR.0301212
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   MIRELS H, 1989, CLIN ORTHOP RELAT R, V249, P256
   Monzen Hajime, 2004, Radiat Med, V22, P205
   MOULOPOULOS LA, 1994, RADIOLOGY, V193, P441, DOI 10.1148/radiology.193.2.7972760
   MUNDY GR, 1986, SEMIN ONCOL, V13, P291
   MUNDY GR, 1991, BONE S1, V12, P51
   Ochiai N, 2005, LEUKEMIA LYMPHOMA, V46, P1619, DOI 10.1080/10428190500221223
   Ochiai N, 2005, INT J HEMATOL, V82, P243, DOI 10.1532/IJH97.05049
   OSHIMA T, 2005, BLOOD
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344
   RADL J, 1985, CANCER AM CANCER SOC, V55, P1030, DOI 10.1002/1097 0142(19850301)55:5<1030::AID CNCR2820550518>3.0.CO;2 Y
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   ROSTOM AY, 1988, HEMATOL ONCOL, V6, P193, DOI 10.1002/hon.2900060221
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Savage AD, 1996, BLOOD, V88, P409
   Shipman CM, 2003, CANCER RES, V63, P912
   Shipman CM, 1998, CANCER RES, V58, P5294
   Sordillo EM, 2003, CANCER AM CANCER SOC, V97, P802, DOI 10.1002/cncr.11134
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   STASHENKO P, 1987, J IMMUNOL, V138, P1464
   SUZUKI A, 1994, AM J HEMATOL, V45, P88, DOI 10.1002/ajh.2830450115
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 90
TC 26
Z9 35
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUL
PY 2006
VL 42
IS 11
BP 1554
EP 1563
DI 10.1016/j.ejca.2005.11.035
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 078DG
UT WOS:000240081100007
PM 16797971
DA 2025 08 17
ER

PT J
AU Martinez Reina, J
   Calvo Gallego, JL
   Martin, M
   Pivonka, P
AF Martinez Reina, Javier
   Calvo Gallego, Jose Luis
   Martin, Madge
   Pivonka, Peter
TI Assessment of Strategies for Safe Drug Discontinuation and Transition of
   Denosumab Treatment in PMO Insights From a Mechanistic PK/PD Model of
   Bone Turnover
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE postmenopausal osteoporosis; bone remodelling; bone mineralisation;
   denosumab discontinuation; RANK RANKL OPG pathway; PK PD modelling;
   osteoclast precursors
ID POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; MINERAL DENSITY;
   WOMEN; OSTEOCYTES; RESORPTION; RANKL; HOMEOSTASIS; OSTEOCLASTS;
   OSTEOBLAST
AB Denosumab (Dmab) treatment against postmenopausal osteoporosis (PMO) has proven very efficient in increasing bone mineral density (BMD) and reducing the risk of bone fractures. However, concerns have been recently raised regarding safety when drug treatment is discontinued. Mechanistic pharmacokinetic pharmacodynamic (PK PD) models are the most sophisticated tools to develop patient specific drug treatments of PMO to restore bone mass. However, only a few PK PD models have addressed the effect of Dmab drug holidays on changes in BMD. We showed that using a standard bone cell population model (BCPM) of bone remodelling it is not possible to account for the spike in osteoclast numbers observed after Dmab discontinuation. We show that inclusion of a variable osteoclast precursor pool in BCPMs is essential to predict the experimentally observed rapid rise in osteoclast numbers and the associated increases in bone resorption. This new model also showed that Dmab withdrawal leads to a rapid increase of damage in the bone matrix, which in turn decreases the local safety factor for fatigue failure. Our simulation results show that changes in BMD strongly depend on Dmab concentration in the central compartment. Consequently, bone weight (BW) might play an important factor in calculating effective Dmab doses. The currently clinically prescribed constant Dmab dose of 60 mg injected every 6 months is less effective in increasing BMD for patients with high BW (2.5% for 80 kg in contrast to 8% for 60 kg after 6 years of treatment). However, bone loss observed 24 months after Dmab withdrawal is less pronounced in patients with high BW (3.5% for 80kg and 8.5% for 60 kg). Finally, we studied how to safely discontinue Dmab treatment by exploring several transitional and combined drug treatment strategies. Our simulation results indicate that using transitional reduced Dmab doses are not effective in reducing rapid bone loss. However, we identify that use of a bisphosphonate (BP) is highly effective in avoiding rapid bone loss and increase in bone tissue damage compared to abrupt withdrawal of Dmab. Furthermore, the final values of BMD and damage were not sensitive to the time of administration of the BP.
C1 [Martinez Reina, Javier; Calvo Gallego, Jose Luis] Univ Seville, Dept Ingn Mecan & Fabricac, Seville, Spain.
   [Martin, Madge] Univ Gustave Eiffel, Univ Paris Est Creteil, CNRS, UMR 8208,MSME, Creteil, France.
   [Pivonka, Peter] Queensland Univ Technol, Sch Mech Med & Proc Engn, Brisbane, Qld, Australia.
C3 University of Sevilla; Universite Gustave Eiffel; Centre National de la
   Recherche Scientifique (CNRS); CNRS   Institute for Engineering &
   Systems Sciences (INSIS); Universite Paris Est Creteil Val de Marne
   (UPEC); Queensland University of Technology (QUT)
RP Martinez Reina, J (通讯作者)，Univ Seville, Dept Ingn Mecan & Fabricac, Seville, Spain.
EM jmreina@us.es
RI Martínez Reina, Javier/K 2806 2014; Martinez Reina, Javier/K 2806 2014;
   Calvo Gallego, Jose/L 6118 2014; Pivonka, Peter/AAL 1053 2021; Martin,
   Madge/MEP 6647 2025; Calvo Gallego, Jose Luis/L 6118 2014
OI Martinez Reina, Javier/0000 0003 2038 2336; Pivonka,
   Peter/0000 0001 9183 530X; Calvo Gallego, Jose Luis/0000 0002 3407 1582
FU Fondo Europeo de Desarrollo Regional (FEDER); Consejeria de Economia,
   Conocimiento, Empresas y Universidad de la Junta de Andalucia, dentro
   del Programa Operativo FEDER 2014 2020; Universidad de Sevilla
   [P18 RT 3611]
FX Funding was provided by the "Fondo Europeo de Desarrollo Regional
   (FEDER)", the "Consejeria de Economia, Conocimiento, Empresas y
   Universidad de la Junta de Andalucia, dentro del Programa Operativo
   FEDER 2014 2020" and the "Universidad de Sevilla" to the project
   P18 RT 3611 entitled "Efecto combinado del ejercicio fisico y el
   denosumab en el tratamiento de la osteoporosis. Diseno de un tratamiento
   farmacologico especifico de paciente" for which this paper was prepared.
CR Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Anastasilakis AD, 2018, EUR J ENDOCRINOL, V179, pR31, DOI 10.1530/EJE 18 0056
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Burckhardt P, 2021, J BONE MINER RES, V36, P1717, DOI 10.1002/jbmr.4335
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Currey JD, 2004, J BIOMECH, V37, P549, DOI 10.1016/j.jbiomech.2003.08.008
   Dua P, 2015, CPT PHARMACOMET SYST, V4, P324, DOI 10.1002/psp4.41
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   Felsenberg D, 2002, J BONE MINER RES, V17, P716
   García Aznar JM, 2005, BIOMECH MODEL MECHAN, V4, P147, DOI 10.1007/s10237 005 0067 x
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hernandez CJ, 2000, J REHABIL RES DEV, V37, P235
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Jacobs C., 1994, THESIS STANFORD U ST
   Juvinall R.C., 1967, Engineering Considerations of Stress, Strain and Strength
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kendler D, 2020, J CLIN ENDOCR METAB, V105, pE255, DOI 10.1210/clinem/dgz095
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   LEMAITRE J, 1990, MECH SOLID MAT
   Lien YT, 2020, J CLIN PHARMACOL, V60, pS86, DOI 10.1002/jcph.1748
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369
   Lyu HC, 2020, ANN INTERN MED, V173, P516, DOI 10.7326/M20 0882
   Manolagas SC, 2018, J BONE MINER RES, V33, P371, DOI 10.1002/jbmr.3400
   Manolagas SC, 2013, BONE, V54, P272, DOI 10.1016/j.bone.2012.09.017
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Martin M, 2019, BIOMECH MODEL MECHAN, V18, P1475, DOI 10.1007/s10237 019 01158 w
   MARTIN RB, 1984, CRIT REV BIOMED ENG, V10, P179
   Martínez Reina J, 2008, J THEOR BIOL, V254, P704, DOI 10.1016/j.jtbi.2008.06.007
   Martínez Reina J, 2009, BIOMECH MODEL MECHAN, V8, P111, DOI 10.1007/s10237 008 0122 5
   Martínez Reina J, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.635056
   Martínez Reina J, 2021, J MECH BEHAV BIOMED, V113, DOI 10.1016/j.jmbbm.2020.104140
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Need AG, 2007, J BONE MINER RES, V22, P757, DOI [10.1359/jbmr.070203, 10.1359/JBMR.070203]
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Pattin CA, 1996, J BIOMECH, V29, P69, DOI 10.1016/0021 9290(94)00156 1
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Popp AW, 2018, CALCIFIED TISSUE INT, V103, P50, DOI 10.1007/s00223 018 0394 4
   Post TM, 2013, J PHARMACOKINET PHAR, V40, P143, DOI 10.1007/s10928 012 9294 9
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Takagi Y, 2021, MICROSCOPY JPN, V70, P302, DOI 10.1093/jmicro/dfaa073
   Tripto Shkolnik L, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115150
   Tsourdi E, 2021, J CLIN ENDOCR METAB, V106, P264, DOI 10.1210/clinem/dgaa756
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Zanchetta MB, 2018, OSTEOPOROSIS INT, V29, P41, DOI 10.1007/s00198 017 4242 6
   Zioupos P, 1998, BONE, V22, P57, DOI 10.1016/S8756 3282(97)00228 7
NR 61
TC 7
Z9 7
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 30
PY 2022
VL 10
AR 886579
DI 10.3389/fbioe.2022.886579
PG 16
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 2D1BO
UT WOS:000811291000001
PM 35966026
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tao, HQ
   Li, XF
   Wang, QF
   Yu, L
   Yang, P
   Chen, WL
   Yang, X
   Zhou, J
   Geng, DC
AF Tao, Huaqiang
   Li, Xuefeng
   Wang, Qiufei
   Yu, Lei
   Yang, Peng
   Chen, Wenlong
   Yang, Xing
   Zhou, Jun
   Geng, Dechun
TI Redox signaling and antioxidant defense in osteoclasts
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteoclasts; ROS; Oxidant; Antioxidant; Bone
ID FOXO TRANSCRIPTION FACTORS; OXIDATIVE STRESS; REACTIVE OXYGEN; BONE
   LOSS; NADPH OXIDASES; NITRIC OXIDE; IN VITRO; RANKL; DIFFERENTIATION;
   OSTEOPOROSIS
AB Bone remodeling is essential for the repair and replacement of damaged or aging bones. Continuous remodeling is necessary to prevent the accumulation of bone damage and to maintain bone strength and calcium balance. As bones age, the coupling mechanism between bone formation and absorption becomes dysregulated, and bone loss becomes dominant. Bone development and repair rely on interaction and communication between osteoclasts and surrounding cells. Osteoclasts are specialized cells that are accountable for bone resorption and degradation, and any abnormalities in their activity can result in notable alterations in bone structure and worsen disease symptoms. Recent findings from transgenic mouse models and bone analysis have greatly enhanced our understanding of the origin, differentiation pathway, and activation stages of osteoclasts. In this review, we explore osteoclasts and discuss the cellular and molecular events that drive their generation, focusing on intracellular oxidative and antioxidant signaling. This knowledge can help develop targeted therapies for diseases associated with osteoclast activation.
C1 [Tao, Huaqiang; Li, Xuefeng; Yu, Lei; Yang, Peng; Zhou, Jun; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi St, Suzhou, Jiangsu, Peoples R China.
   [Chen, Wenlong; Yang, Xing] Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, Orthoped & Sports Med Ctr, 242 Guangji Rd, Suzhou, Jiangsu, Peoples R China.
   [Wang, Qiufei] Soochow Univ, Changshu Hosp, Peoples Hosp Changshu City 1, Dept Orthoped, Changshu, Jiangsu, Peoples R China.
C3 Soochow University   China; Nanjing Medical University; Soochow
   University   China
RP Zhou, J; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi St, Suzhou, Jiangsu, Peoples R China.; Yang, X (通讯作者)，Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, Orthoped & Sports Med Ctr, 242 Guangji Rd, Suzhou, Jiangsu, Peoples R China.
EM xingyangsz@126.com; zhou.jun.roy@hotmail.com; szgengdc@suda.edu.cn
RI Geng, Dechun/LMO 1733 2024
OI GENG, Dechun/0000 0003 4375 2803
FU Program of Suzhou Health Commission [BE2022737]; Program of Suzhou
   science and technology Department [GSWS2020078, SZXK202111,
   GSWS2022002]; National and Local Engineering Laboratory of New
   Functional Polymer Materials [SKY2023062, SKJY2021067]; Jiangsu Medical
   Research Project [SDGC2205]; Special Project of Diagnosis and Treatment
   for Clinical Diseases of Suzhou [ZD2022014];  [LCZX202003]; 
   [LCZX202302]
FX This work was supported by the National Natural Science Foundation of
   China (82072425, 82072498, 82272567) , the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD) , the
   Natural Science Foundation of Jiangsu Province (BE2021673) , Program of
   Jiangsu science and technology Department (BK20211083, BE2022737) , the
   Program of Suzhou Health Commission (GSWS2020078, SZXK202111,
   GSWS2022002) , the Program of Suzhou science and technology Department
   (SKY2023062, SKJY2021067) , National and Local Engineering Laboratory of
   New Functional Polymer Materials (SDGC2205) , Jiangsu Medical Research
   Project (ZD2022014) and Special Project of Diagnosis and Treatment for
   Clinical Diseases of Suzhou (LCZX202003, LCZX202302) .r BE2022737) , the
   Program of Suzhou Health Commission (GSWS2020078, SZXK202111,
   GSWS2022002) , the Program of Suzhou science and technology Department
   (SKY2023062, SKJY2021067) , National and Local Engineering Laboratory of
   New Functional Polymer Materials (SDGC2205) , Jiangsu Medical Research
   Project (ZD2022014) and Special Project of Diagnosis and Treatment for
   Clinical Diseases of Suzhou (LCZX202003, LCZX202302) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Amatullah H, 2021, REDOX BIOL, V38, DOI 10.1016/j.redox.2020.101796
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Andrieux P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111338
   Apostu D, 2019, DRUG METAB REV, V51, P65, DOI 10.1080/03602532.2019.1574303
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Aratani Y, 2018, ARCH BIOCHEM BIOPHYS, V640, P47, DOI 10.1016/j.abb.2018.01.004
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Asano T, 2019, NAT METAB, V1, P868, DOI 10.1038/s42255 019 0104 1
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bernstein ZS, 2022, CELLS BASEL, V11, DOI 10.3390/cells11152308
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521 1878(199810)20:10<837::AID BIES9>3.0.CO;2 D
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   BRETONGORIUS J, 1982, ADV EXP MED BIOL, V141, P491
   Byun H, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/abd56c
   Calissi G, 2021, NAT REV DRUG DISCOV, V20, P21, DOI 10.1038/s41573 020 0088 2
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chen C, 2020, MECH AGEING DEV, V187, DOI 10.1016/j.mad.2020.111215
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen JS, 2021, J PERIODONTAL RES, V56, P1163, DOI 10.1111/jre.12930
   Chen LL, 2021, J CELL MOL MED, V25, P2944, DOI 10.1111/jcmm.16329
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Cheng ZY, 2022, BIOCHEM J, V479, P525, DOI 10.1042/BCJ20210777
   Cheon YH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176416
   Choi HI, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030637
   Das BK, 2022, ELIFE, V11, DOI 10.7554/eLife.73539
   Datta HK, 1996, J ENDOCRINOL, V149, P269, DOI 10.1677/joe.0.1490269
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Deng WD, 2022, PHYTOMEDICINE, V96, DOI 10.1016/j.phymed.2021.153838
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Dou C, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040231
   Elson A, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116538
   Feng MZ, 2023, J CELL MOL MED, V27, P701, DOI 10.1111/jcmm.17692
   FULLER K, 1987, J CELL PHYSIOL, V132, P441, DOI 10.1002/jcp.1041320306
   Goodman SB, 2005, CLIN ORTHOP RELAT R, P39, DOI 10.1097/01.blo.0000149998.88218.05
   Gurt I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134391
   Hayman AR, 2001, J HISTOCHEM CYTOCHEM, V49, P675, DOI 10.1177/002215540104900601
   He F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134777
   He JB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645140
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hong SE, 2017, FREE RADICAL BIO MED, V112, P191, DOI 10.1016/j.freeradbiomed.2017.07.030
   Hu SW, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.893678
   Hua P, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153234
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jing M, 2021, INT IMMUNOPHARMACOL, V98, DOI 10.1016/j.intimp.2021.107879
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim JS, 2019, PHYTOTHER RES, V33, P1865, DOI 10.1002/ptr.6375
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kloc M., 2022, Int. J. Mol. Sci., V23
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kowalczyk P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413384
   KURIHARA N, 1989, BLOOD, V74, P1295
   Kwon YB, 2018, J NUTR BIOCHEM, V58, P158, DOI 10.1016/j.jnutbio.2018.03.023
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee CW, 2021, FREE RADICAL BIO MED, V168, P234, DOI 10.1016/j.freeradbiomed.2021.03.008
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lennicke C, 2021, MOL CELL, V81, P3691, DOI 10.1016/j.molcel.2021.08.018
   Li DZ, 2014, J BONE MINER METAB, V32, P494, DOI 10.1007/s00774 013 0530 1
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li J, 2019, BIOCHIMIE, V156, P129, DOI 10.1016/j.biochi.2018.09.004
   Li N, 2021, INT J BIOL SCI, V17, P1382, DOI 10.7150/ijbs.53992
   Li QQ, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115827
   Liu XZ, 2023, REDOX BIOL, V65, DOI 10.1016/j.redox.2023.102819
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Liu ZY, 2021, REDOX BIOL, V48, DOI 10.1016/j.redox.2021.102180
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Mancini L, 1998, BIOCHEM BIOPH RES CO, V243, P785, DOI 10.1006/bbrc.1998.8175
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mattson NP, 1997, J BONE MINER RES, V12, P753, DOI 10.1359/jbmr.1997.12.5.753
   Mei Y, 2009, P NATL ACAD SCI USA, V106, P5153, DOI 10.1073/pnas.0901104106
   Menale C, 2019, J BONE MINER RES, V34, P2133, DOI 10.1002/jbmr.3829
   Moon HJ, 2013, J FOOD SCI, V78, pH785, DOI 10.1111/1750 3841.12116
   Morant Ferrando B, 2023, NAT METAB, V5, DOI 10.1038/s42255 023 00835 6
   Mukkamalla SKR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126208
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nam SY, 2019, BRIT J PHARMACOL, V176, P1664, DOI 10.1111/bph.14615
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Novack DV, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0011 2015
   O Uchi J, 2014, ANTIOXID REDOX SIGN, V21, P987, DOI 10.1089/ars.2013.5681
   Oursler MJ, 2005, AM J PHYSIOL CELL PH, V288, pC156, DOI 10.1152/ajpcell.00092.2004
   Pan WZ, 2022, BIOCHEM PHARMACOL, V195, DOI 10.1016/j.bcp.2021.114846
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Park HJ, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11050963
   Qiao WX, 2020, AM J TRANSL RES, V12, P507
   Qin D, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112045
   Räisänen SR, 2001, BIOCHEM BIOPH RES CO, V288, P142, DOI 10.1006/bbrc.2001.5715
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Rhee SG, 2015, FREE RADICAL BIO MED, V88, P205, DOI 10.1016/j.freeradbiomed.2015.06.007
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590 021 00886 5
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   STERRETT JD, 1986, J CLIN PERIODONTOL, V13, P258, DOI 10.1111/j.1600 051X.1986.tb02220.x
   Su Z., 2023, J. Nutr. Biochem.
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778078
   Tadaishi M, 2014, J CLIN BIOCHEM NUTR, V54, P109, DOI 10.3164/jcbn.13 94
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tan P, 2015, SCI REP UK, V5, DOI 10.1038/srep16835
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796
   Vural P, 2006, PHARMACOL RES, V54, P298, DOI 10.1016/j.phrs.2006.06.006
   Wada S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00740
   Wadley AJ, 2016, REDOX BIOL, V8, P51, DOI 10.1016/j.redox.2015.10.003
   Wang BQ, 2023, ARCH TOXICOL, V97, P1439, DOI 10.1007/s00204 023 03476 6
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang SY, 2021, J BONE MINER RES, V36, P1850, DOI 10.1002/jbmr.4328
   Wang W, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01413 w
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Weidinger A, 2015, BIOMOLECULES, V5, P472, DOI 10.3390/biom5020472
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006
   Xia GT, 2017, FREE RADICAL BIO MED, V108, P418, DOI 10.1016/j.freeradbiomed.2017.03.023
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xing FZ, 2022, INT IMMUNOPHARMACOL, V112, DOI 10.1016/j.intimp.2022.109278
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xu Q, 2016, J BIOL CHEM, V291, P20030, DOI 10.1074/jbc.M116.731216
   Xu Y, 2010, ANTIOXID REDOX SIGN, V13, P27, DOI 10.1089/ars.2009.2886
   Xu YL, 2023, FREE RADICAL BIO MED, V196, P121, DOI 10.1016/j.freeradbiomed.2023.01.017
   Xue P, 2021, EXP MOL MED, V53, P667, DOI 10.1038/s12276 021 00596 w
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yan S, 2019, MOL CELL BIOCHEM, V455, P135, DOI 10.1007/s11010 018 3477 7
   Yang G, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1019478
   Yang JY, 2021, J CELL MOL MED, V25, P6800, DOI 10.1111/jcmm.16683
   Yang RL, 2020, AGING CELL, V19, DOI 10.1111/acel.13095
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Yi SJ, 2023, REDOX BIOL, V64, DOI 10.1016/j.redox.2023.102804
   Yuan Y, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13194
   Zaidi M, 2001, J BONE MINER RES, V16, P1747, DOI 10.1359/jbmr.2001.16.10.1747
   Zang Y, 2020, J DENT RES, V99, P1287, DOI 10.1177/0022034520933533
   Zhao XL, 2021, J BONE MINER RES, V36, P591, DOI 10.1002/jbmr.4215
   Zhao YF, 2020, J LEUKOCYTE BIOL, V108, P1037, DOI [10.1002/JLB.1HI0620 230R, 10.1002/jlb.1hi0620 230r]
   Zheng C, 2018, ARTIF CELL NANOMED B, V46, pS64, DOI 10.1080/21691401.2018.1489264
   Zhong ZY, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102711
   Zhou J, 2013, J BIOL CHEM, V288, P30064, DOI 10.1074/jbc.M113.478750
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 161
TC 9
Z9 9
U1 3
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 20
PY 2024
VL 212
BP 403
EP 414
DI 10.1016/j.freeradbiomed.2023.12.043
EA JAN 2024
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GU8M5
UT WOS:001155277500001
PM 38171408
DA 2025 08 17
ER

PT J
AU Ding, N
   Liu, C
   Yao, L
   Bai, Y
   Cheng, P
   Li, ZL
   Luo, KY
   Mei, TN
   Li, JH
   Xing, JC
   Gao, XL
   Ma, QY
   Xu, JZ
   Luo, F
   Dou, C
AF Ding, Ning
   Liu, Chuan
   Yao, Li
   Bai, Yun
   Cheng, Peng
   Li, Zhilin
   Luo, Keyu
   Mei, Tieniu
   Li, Jianhua
   Xing, Junchao
   Gao, Xiaoliang
   Ma, Qinyu
   Xu, Jianzhong
   Luo, Fei
   Dou, Ce
TI Alendronate induces osteoclast precursor apoptosis via peroxisomal
   dysfunction mediated ER stress
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE alendronate; apoptosis; ER stress; osteoclast; peroxisome
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE;
   UNFOLDED PROTEIN RESPONSE; BONE RESORPTION; IN VITRO;
   PARATHYROID HORMONE; MEVALONATE PATHWAY; DIFFERENTIATION; OSTEOPOROSIS;
   DEFICIENCY
AB Nitrogen containing bisphosphonates including alendronate (ALN) are the current first line antiresorptive drug in treating osteoporosis. In our study, we found that ALN administration impaired the secretion of platelet derived growth factor BB (PDGF BB), the most important angiogenic cytokines produced by preosteoclast (POC), in both sham and ovariectomized (OVX) mice. To further understand this phenomenon, we induced bone marrow macrophages (BMMs) to POCs in vitro and detected the effects of ALN particularly in POCs. The proapoptotic effect of ALN in POCs was confirmed by flow cytometry. On the molecular level, we found that farnesyl diphosphate synthase (FDPS) inhibition of ALN led to peroxisomal dysfunction and up regulation of cytoprotective protein glucose regulated protein (GRP) 78. Peroxisomal dysfunction further induced endoplasmic reticulum (ER) stress in POCs and finally resulted in cell apoptosis marked by reduced expression of B cell lymphoma 2 (Bcl 2) and increased expressions of CCAAT/enhancer binding protein homologous protein (CHOP), Bcl2 associated X (Bax), and cleaved caspase 3. We concluded that ALN has no selectivity in inhibiting POC and mature osteoclast. For POCs, ALN inhibition of FDPS leads to peroxisomal dysfunction, which further mediates ER stress and finally causes cell apoptosis. Considering that decreased angiogenesis is also an important issue in treating osteoporosis, how to preserve pro angiogenic POCs while depleting mature osteoclasts is a problem worthy to be solved.
C1 [Ding, Ning; Cheng, Peng; Li, Zhilin; Luo, Keyu; Xing, Junchao; Gao, Xiaoliang; Ma, Qinyu; Xu, Jianzhong; Luo, Fei; Dou, Ce] Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Liu, Chuan; Bai, Yun; Dou, Ce] Army Med Univ, Mil Med Univ 3, Dept Biomed Mat Sci, Chongqing, Peoples R China.
   [Liu, Chuan; Yao, Li] Army Gen Hosp, Dept Urol, Beijing, Peoples R China.
   [Mei, Tieniu] Army Med Univ, Mil Med Univ 3, Xinqiao Hosp, Dept Surg,Shigatse Branch, Shigatse, Peoples R China.
   [Li, Jianhua] 88 Hosp PLA, Dept Orthoped, Tai An, Shandong, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Luo, F; Dou, C (通讯作者)，Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Gaotanyan St 30, Chongqing 400038, Peoples R China.
EM luofly1009@21cn.com; lance.douce@gmail.com
RI Xing, Junchao/GWN 0403 2022; Ma, Qinyu/JGM 3220 2023; li,
   zhilin/HNI 8707 2023; Dou, Ce/B 8841 2012
FU China Postdoctoral Science Foundation [2017M613315]
FX The China Postdoctoral Science Foundation, Grant number: 2017M613315
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   BIARDI L, 1994, J BIOL CHEM, V269, P1197
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dou C., 2014, J CELL PHYSL, V231, P558
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Faust PL, 2014, BIOCHIMIE, V98, P75, DOI 10.1016/j.biochi.2013.10.019
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gao S. Y., 2017, PLOS ONE, V12
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kovacs WJ, 2012, BBA MOL CELL BIOL L, V1821, P895, DOI 10.1016/j.bbalip.2012.02.011
   KRISANS SK, 1994, J BIOL CHEM, V269, P14165
   Kusumbe AP, 2014, NAT MED, V20, P1238, DOI 10.1038/nm.3747
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Le Goff B, 2013, JOINT BONE SPINE, V80, P586, DOI 10.1016/j.jbspin.2013.04.002
   Li P, 2014, ANN BIOMED ENG, V42, P1250, DOI 10.1007/s10439 014 0984 x
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Misof BM, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.1
   Mörck C, 2009, P NATL ACAD SCI USA, V106, P18285, DOI 10.1073/pnas.0907117106
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Roche B, 2014, J BONE MINER RES, V29, P1608, DOI 10.1002/jbmr.2191
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Spangenberg A, 2016, CALCIFIED TISSUE INT, V99, P608, DOI 10.1007/s00223 016 0186 7
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teti Anna, 2013, Bonekey Rep, V2, P449, DOI 10.1038/bonekey.2013.183
   Tohmonda T, 2015, J CLIN INVEST, V125, P3269, DOI 10.1172/JCI76765
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 40
TC 28
Z9 34
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2018
VL 233
IS 9
BP 7415
EP 7423
DI 10.1002/jcp.26587
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GI1JX
UT WOS:000434127700097
PM 29600563
DA 2025 08 17
ER

PT J
AU Chen, M
   Cui, YZ
   Li, H
   Luan, J
   Zhou, XY
   Han, JX
AF Chen, Meng
   Cui, Yazhou
   Li, Hui
   Luan, Jing
   Zhou, Xiaoyan
   Han, Jinxiang
TI Icariin Promotes the Osteogenic Action of BMP2 by Activating the cAMP
   Signaling Pathway
SO MOLECULES
LA English
DT Article
DE Icariin (ICA); Osteoblast differentiation; BMP2; cAMP/PKA/CREB
ID BONE MORPHOGENETIC PROTEIN 2; MARROW STROMAL CELLS; IN VITRO; OSTEOBLAST
   PROLIFERATION; ADENOSINE MONOPHOSPHATE; INDUCED INJURY; DIFFERENTIATION;
   RESORPTION; OSTEOCLAST; APOPTOSIS
AB Icariin (ICA) is the main active flavonoid glucoside from herbs of the genus Epimedium; in traditional Chinese medicine, these herbs have long been prescribed for the treatment of bone fractures and osteoporosis. Several studies have shown that treatment with ICA can increase osteogenic differentiation and reduce bone loss in vivo and in vitro. However, the definite signaling pathway of this osteogenic effect remains unclear. In this study, we selected bone morphogenetic protein 2 (BMP2) induced osteoblastic differentiation of multipotent mesenchymal progenitor C2C12 cells as a model of osteoblast differentiation. We investigated the effects of ICA on C2C12 cells osteogenic differentiation and the underlying molecular mechanisms. We found that ICA could enhance BMP2 mediated osteoblastic differentiation of C2C12 cells in a dose dependent manner. Treatment with ICA activated the cAMP/PKA/CREB signaling axis in a time dependent manner. Blocking cAMP signaling using the PKA selective inhibitor H89 significantly inhibited the stimulatory effect of ICA on osteogenesis. Therefore, the osteoinductive potential and the low cost of ICA indicate that it is a promising alternative treatment or promoter for enhancing the therapeutic effects of BMP2.
C1 [Chen, Meng] Shandong Univ Tradit Chinese Med, Sch Tradit Chinese Med, Jinan 250355, Shandong, Peoples R China.
   [Chen, Meng; Cui, Yazhou; Luan, Jing; Zhou, Xiaoyan; Han, Jinxiang] Minist Hlth, Shandong Med Biotechnol Ctr, Key Lab Biotech Drugs, Jinan 250062, Shandong, Peoples R China.
   [Chen, Meng; Li, Hui] Shandong Ctr Dis Control & Prevent, Dept Toxicol, Jinan 250014, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Han, JX (通讯作者)，Minist Hlth, Shandong Med Biotechnol Ctr, Key Lab Biotech Drugs, Jinan 250062, Shandong, Peoples R China.
EM cm13579.student@sina.com; cuiyz15@126.com; lwlh163@163.com;
   yimu1140@126.com; zxy7106@126.com; jxhan9888@aliyun.com
RI Chen, Meng/MVY 2859 2025
FU Shandong Academy of Medical Sciences, National Natural Science
   Foundation of China [81772300]
FX This work was supported by The Innovation Project of Shandong Academy of
   Medical Sciences, National Natural Science Foundation of China
   (81772300).
CR Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Cahill KS, 2009, JAMA J AM MED ASSOC, V302, P58, DOI 10.1001/jama.2009.956
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen BL, 2016, EXP THER MED, V11, P2399, DOI 10.3892/etm.2016.3177
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen NF, 2010, J NEUROSURG SPINE, V12, P40, DOI 10.3171/2009.4.SPINE0876
   Doorn J, 2012, TISSUE ENG PT A, V18, P558, DOI [10.1089/ten.tea.2011.0312, 10.1089/ten.TEA.2011.0312]
   Fan JJ, 2011, MOLECULES, V16, P10123, DOI 10.3390/molecules161210123
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Glassman SD, 2008, SPINE, V33, P2843, DOI 10.1097/BRS.0b013e318190705d
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1825, DOI 10.1007/s10529 009 0100 8
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Ji DB, 2009, PHYTOTHER RES, V23, P116, DOI 10.1002/ptr.2576
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim JY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051110
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li GW, 2014, MENOPAUSE, V21, P1007, DOI [10.1097/gme.0000000000000201, 10.1097/GME.0000000000000201]
   Li X F, 2013, EVID BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/652317
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Ma XN, 2013, PLANTA MED, V79, P1501, DOI 10.1055/s 0033 1350802
   Myneni V, 2017, ORAL DIS, V23, P1021, DOI 10.1111/odi.12624
   Nakao Y, 2009, BONE, V44, P872, DOI 10.1016/j.bone.2009.01.370
   Ohta Y, 2008, J BONE MINER METAB, V26, P478, DOI 10.1007/s00774 008 0850 8
   Padova G, 2011, CLIN CASES MINER BON, V8, P37
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Qi SS, 2019, MOLECULES, V24, DOI 10.3390/molecules24101871
   Shen P, 2007, PHYTOCHEMISTRY, V68, P1448, DOI 10.1016/j.phytochem.2007.03.001
   Shi WG, 2017, J BIOL CHEM, V292, P20883, DOI 10.1074/jbc.M117.809517
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sugama R, 2006, BONE, V38, P206, DOI 10.1016/j.bone.2005.08.006
   Sun S, 2019, PLANTA MED, V85, P473, DOI 10.1055/a 0837 0975
   Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
   Wang F, 2012, PHYTOMEDICINE, V19, P1035, DOI 10.1016/j.phymed.2012.06.001
   Wei QS, 2016, BIOMED PHARMACOTHER, V84, P931, DOI 10.1016/j.biopha.2016.09.107
   Wu JF, 2012, INT IMMUNOPHARMACOL, V12, P74, DOI 10.1016/j.intimp.2011.10.015
   Wu T, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0133 x
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Xie RF, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41243 9
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Zeng R, 2019, TOXICOL APPL PHARM, V379, DOI 10.1016/j.taap.2019.114639
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   Zhang DW, 2012, BIOCHIMIE, V94, P2514, DOI 10.1016/j.biochi.2012.06.033
   Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s 2000 11126
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
   Zhao SY, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7940808
NR 50
TC 32
Z9 35
U1 2
U2 41
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2019
VL 24
IS 21
AR 3875
DI 10.3390/molecules24213875
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JP1TW
UT WOS:000498055500064
PM 31661767
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, SG
   Cao, XK
   Yu, ZX
   He, WX
   Pang, YC
   Lin, W
   Chen, ZQ
   Guo, WZ
   Lu, XW
   Lin, CS
AF Xu, Shenggui
   Cao, Xiankun
   Yu, Zhenxing
   He, Wenxin
   Pang, Yichuan
   Lin, Wang
   Chen, Zhiqian
   Guo, Weizhong
   Lu, Xiongwei
   Lin, Chengshou
TI Nicorandil Inhibits Osteoclast Formation Base on NF κB and p 38 MAPK
   Signaling Pathways and Relieves Ovariectomy Induced Bone Loss
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE nicorandil; osteoclast; nuclear factor kappa B; phospho p38 (p p38);
   ovariectomy; osteoporosis
ID ACTIVATED PROTEIN KINASE; CORONARY MICROEMBOLIZATION; RECEPTOR
   ACTIVATOR; NUCLEAR FACTOR; UP REGULATION; DIFFERENTIATION; NFATC1;
   EXPRESSION; OSTEOPOROSIS; LIGAND
AB Osteolytic bone disorders are characterized by an overall reduction in bone mineral density which enhances bone ductility and vulnerability to fractures. This disorder is primarily associated with superabundant osteoclast formation and bone resorption activity. Nicorandil (NIC) is a vasodilatory anti anginal drug with ATP dependent potassium (K ATP) channel openings. However, NIC is adopted to manage adverse cardiovascular and coronary events. Recent research has demonstrated that NIC also possesses anti inflammatory peculiarity through the regulation of p38 MAPK and NF kappa B signaling pathways. Both MAPK and NF kappa B signaling pathways play pivotal roles in RANKL induced osteoclast formation and bone resorption function. Herein, we hypothesized that NIC may exert potential biological effects against osteoclasts, and revealed that NIC dose dependently suppressed bone marrow macrophage (BMM) precursors to differentiate into TRAP + multinucleated osteoclasts in vitro. Furthermore, osteoclast resorption assays demonstrated anti resorptive effects exhibited by NIC. NIC had no impact on osteoblast differentiation or mineralization function. Based on Biochemical analyses, NIC relieved RANKL induced ERK, NF kappa B and p38 MAPK signaling without noticeable effects on JNK MAPK activation. However, the attenuation of NF kappa B and p38 MAPK activation was sufficient to hamper the downstream induction of c Fos and NFATc1 expression. Meanwhile, NIC administration markedly protected mice from ovariectomy (OVX) induced bone loss through in vivo inhibition of osteoclast formation and bone resorption activity. Collectively, this work demonstrated the potential of NIC in the management of osteolytic bone disorders mediated by osteoclasts.
C1 [Xu, Shenggui; Yu, Zhenxing; Lin, Wang; Guo, Weizhong; Lin, Chengshou] Fujian Med Univ, Dept Orthopaed, Mindong Hosp, Fuan, Peoples R China.
   [Cao, Xiankun; He, Wenxin; Chen, Zhiqian; Lu, Xiongwei] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.
   [Pang, Yichuan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Stomatol, Dept Oral Surg,Natl Clin Res Ctr Stomatol,Sch Med, Shanghai, Peoples R China.
C3 Fujian Medical University; Shanghai Jiao Tong University; Shanghai Jiao
   Tong University
RP Lin, CS (通讯作者)，Fujian Med Univ, Dept Orthopaed, Mindong Hosp, Fuan, Peoples R China.; Lu, XW (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.
EM luxiongwei@yahoo.com; mdl565@163.com
RI pang, yichuan/GWQ 7981 2022
FU open project of Shanghai Key Laboratory of Orthopaedic Implants
   [KFKT2019003]
FX This work was supported by the open project of Shanghai Key Laboratory
   of Orthopaedic Implants (KFKT2019003).
CR Ahmed LA, 2015, SCI REP UK, V5, DOI 10.1038/srep14043
   Ahmed LA, 2011, EUR J PHARMACOL, V663, P51, DOI 10.1016/j.ejphar.2011.04.038
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Chen XZ, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.015
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Dong YF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 016 0527 5
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fretz JA, 2008, MOL ENDOCRINOL, V22, P737, DOI 10.1210/me.2007 0333
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   He MY, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4957646
   He WK, 2018, BIOCHEM BIOPH RES CO, V496, P1296, DOI 10.1016/j.bbrc.2018.02.003
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iwaki F, 2016, EUR J PHARMACOL, V793, P14, DOI 10.1016/j.ejphar.2016.10.034
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Khames A, 2019, CHEM BIOL INTERACT, V311, DOI 10.1016/j.cbi.2019.108777
   Kim HJ, 2014, MOL CELLS, V37, P598, DOI 10.14348/molcells.2014.0153
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McGreevy C, 2011, THER ADV DRUG SAF, V2, P159, DOI 10.1177/2042098611411012
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Myneni V, 2017, ORAL DIS, V23, P1021, DOI 10.1111/odi.12624
   Park JH, 2017, MOL CELLS, V40, P706
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sahara M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033367
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Su Q, 2018, BIOMED PHARMACOTHER, V106, P776, DOI 10.1016/j.biopha.2018.07.014
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xing LP, 2013, BONE RES, V1, P336, DOI 10.4248/BR201304004
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye Z., 2017, BIOMED PHARMACOTHER, V88, P69, DOI [10.1016/j.biopha.2018.07.014, DOI 10.1016/J.BIOPHA.2018.07.014]
   Yedavally Yellayi S, 2019, PRIMARY CARE, V46, P175, DOI 10.1016/j.pop.2018.10.014
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 58
TC 8
Z9 9
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 8
PY 2021
VL 12
AR 726361
DI 10.3389/fphar.2021.726361
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ZL7EY
UT WOS:000763837800001
PM 34566650
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU van Santen, VJB
   Doulabi, BZ
   Semeins, CM
   Hogervorst, JMA
   Bratengeier, C
   Bakker, AD
AF van Santen, Victor J. B.
   Zandieh Doulabi, Behrouz
   Semeins, Cornelis M.
   Hogervorst, Jolanda M. A.
   Bratengeier, Cornelia
   Bakker, Astrid D.
TI Compressed Prostate Cancer Cells Decrease Osteoclast Activity While
   Enhancing Osteoblast Activity In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone metastasis; bone remodeling; epithelial to mesenchymal transition;
   pressure; adipose tissue derived mesenchymal stromal cell
ID EPITHELIAL MESENCHYMAL TRANSITION; HORMONE RELATED PROTEIN;
   GROWTH FACTOR; ANDROGEN RECEPTOR; TGF BETA; TRANSCRIPTION FACTOR;
   SIGNALING PATHWAY; BONE METASTASES; FACTOR ALPHA; EXPRESSION
AB Once prostate cancer cells metastasize to bone, they perceive approximately 2 kPa compression. We hypothesize that 2 kPa compression stimulates the epithelial to mesenchymal transition (EMT) of prostate cancer cells and alters their production of paracrine signals to affect osteoclast and osteoblast behavior. Human DU145 prostate cancer cells were subjected to 2 kPa compression for 2 days. Compression decreased expression of 2 epithelial genes, 5 out of 13 mesenchymal genes, and increased 2 mesenchymal genes by DU145 cells, as quantified by qPCR. Conditioned medium (CM) of DU145 cells was added to human monocytes that were stimulated to differentiate into osteoclasts for 21 days. CM from compressed DU145 cells decreased osteoclast resorptive activity by 38% but did not affect osteoclast size and number compared to CM from non compressed cells. CM was also added to human adipose stromal cells, grown in osteogenic medium. CM of compressed DU145 cells increased bone nodule production (Alizarin Red) by osteoblasts from four out of six donors. Compression did not affect IL6 or TNF alpha production by PC DU145 cells. Our data suggest that compression affects EMT related gene expression in DU145 cells, and alters their production of paracrine signals to decrease osteoclast resorptive activity while increasing mineralization by osteoblasts is donor dependent. This observation gives further insight in the altered behavior of PC cells upon mechanical stimuli, which could provide novel leads for therapies, preventing bone metastases.
C1 [van Santen, Victor J. B.; Zandieh Doulabi, Behrouz; Semeins, Cornelis M.; Hogervorst, Jolanda M. A.; Bakker, Astrid D.] Univ Amsterdam, Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol, Amsterdam Movement Sci, NL 1081 LA Amsterdam, Netherlands.
   [van Santen, Victor J. B.; Zandieh Doulabi, Behrouz; Semeins, Cornelis M.; Hogervorst, Jolanda M. A.; Bakker, Astrid D.] Vrije Univ Amsterdam, Amsterdam Movement Sci, NL 1081 LA Amsterdam, Netherlands.
   [Bratengeier, Cornelia] Linkoping Univ, Dept Clin & Expt Med, Div Cell Biol, SE 58183 Linkoping, Sweden.
C3 Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam;
   University of Amsterdam; Vrije Universiteit Amsterdam; Linkoping
   University
RP Bakker, AD (通讯作者)，Univ Amsterdam, Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol, Amsterdam Movement Sci, NL 1081 LA Amsterdam, Netherlands.; Bakker, AD (通讯作者)，Vrije Univ Amsterdam, Amsterdam Movement Sci, NL 1081 LA Amsterdam, Netherlands.
EM a.bakker@acta.nl
RI ; Bakker, Astrid/AAD 1286 2019
OI Zandieh Doulabi, Behrouz/0000 0002 0290 3241; Bratengeier,
   Cornelia/0000 0001 9302 0710; van Santen, Victor/0000 0001 5880 2784
FU "MechanoCHIP" project from Eurostars [E!12572]
FX This research was funded by the "MechanoCHIP" project from Eurostars
   (project number: E!12572).
CR Abaurrea A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158334
   Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d
   Ali M.S., 2020, J. Biotechnol. Res. Center, V14, P5, DOI 10.24126/jobrc.2020.14.1.582
   Alimirah F, 2006, FEBS LETT, V580, P2294, DOI 10.1016/j.febslet.2006.03.041
   [Anonymous], 2016, Thermo Sci. Pierce Assay Dev. Tech. Handb, P1
   Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079
   Assadi A, 2020, PFLUG ARCH EUR J PHY, V472, P1535, DOI 10.1007/s00424 020 02459 1
   Atzeni F., 2013, Brenner's Encyclopedia of Genetics, VSecond, P229, DOI [DOI 10.1016/B978 0 12 374984 0.01594 1, 10.1016/b978 0 12 374984 0.01594 1]
   Azevedo A, 2011, WORLD J CLIN ONCOL, V2, P384, DOI 10.5306/wjco.v2.i12.384
   Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355
   Bae JS, 2020, THORAX, V75, P982, DOI 10.1136/thoraxjnl 2019 213916
   Bairoch Amos, 2018, J Biomol Tech, V29, P25, DOI 10.7171/jbt.18 2902 002
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chen B, 2016, ONCOTARGET, V7, P71400, DOI 10.18632/oncotarget.12147
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022 5347(01)65919 6
   Crnalic S, 2010, ENDOCR RELAT CANCER, V17, P885, DOI 10.1677/ERC 10 0059
   Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303 7207(02)00263 0
   Culig Z, 2018, MOL CELL ENDOCRINOL, V462, P25, DOI 10.1016/j.mce.2017.03.012
   Currey J, 2008, WOODHEAD PUBL MATER, P3, DOI 10.1533/9781845694227.1.3
   Dafermou A, 2001, EUR J NUCL MED, V28, P788, DOI 10.1007/s002590100533
   Das J, 2020, SEMIN CANCER BIOL, V66, P101, DOI 10.1016/j.semcancer.2019.05.017
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   de Vries TJ, 2018, BONE, V109, P168, DOI 10.1016/j.bone.2017.07.007
   Dudás J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020428
   Edmondson R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158116
   Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022 5347(01)64775 X
   FUDGE K, 1994, MODERN PATHOL, V7, P549
   Fujita K, 2019, WORLD J MENS HEALTH, V37, P288, DOI 10.5534/wjmh.180040
   Fukuyo S, 2014, RHEUMATOLOGY, V53, P1282, DOI 10.1093/rheumatology/ket496
   Galbraith LCA, 2021, ONCOGENE, V40, P2355, DOI 10.1038/s41388 021 01707 7
   Gheldof A, 2013, PROG MOL BIOL TRANSL, V116, P317, DOI 10.1016/B978 0 12 394311 8.00014 5
   Gusmão Carlos Vinícius Buarque de, 2009, Rev. bras. ortop., V44, P299, DOI 10.1016/S2255 4971(15)30157 9
   Ha B, 2014, J NAT PROD, V77, P63, DOI 10.1021/np4006376
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538
   Hou CH, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 236
   Inoue Kazushi, 2016, Biomark Cancer, V8, P25, DOI 10.4137/BIC.S38394
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Kalli M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00992
   Kalli M, 2018, ANN BIOMED ENG, V46, P657, DOI 10.1007/s10439 018 1997 7
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kim BG, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0553 9
   Kim BG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.73
   KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443
   Kumar R, 2018, J CELL SCI, V131, DOI 10.1242/jcs.201707
   Levayer R, 2020, SEMIN CANCER BIOL, V63, P69, DOI 10.1016/j.semcancer.2019.05.004
   Li C, 2016, ONCOTARGET, V7, P860, DOI 10.18632/oncotarget.6205
   Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008 5472.CAN 11 3123
   Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602
   Liu CY, 2015, ONCOTARGET, V6, P15966, DOI 10.18632/oncotarget.3862
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lopez Bergami P, 2020, CANCER METAST REV, V39, P933, DOI 10.1007/s10555 020 09878 7
   Luz MA, 2010, CURR ONCOL, V17, pS65
   MATUO Y, 1987, CANCER RES, V47, P188
   McHugh Jessica, 2017, Nat Rev Rheumatol, V13, P633, DOI 10.1038/nrrheum.2017.163
   Meng J, 2018, CANCER RES, V78, P4150, DOI 10.1158/0008 5472.CAN 17 3009
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Miao JW, 2014, INT J ONCOL, V45, P165, DOI 10.3892/ijo.2014.2422
   Millipore Corporation, 2012, MUSETM CELL AN US GU
   Nakchbandi IA, 2000, P NATL ACAD SCI USA, V97, P7296, DOI 10.1073/pnas.110553397
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Ongkeko WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085803
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   Papiewska Pajak I, 2016, POSTEP HIG MED DOSW, V70, P968, DOI 10.5604/17322693.1219401
   PfaffI MW., 2004, A Z of Quantitative PCR, P87
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Podgorski I, 2005, NEOPLASIA, V7, P207, DOI 10.1593/neo.04349
   Ricciardi M, 2015, BRIT J CANCER, V112, P1067, DOI 10.1038/bjc.2015.29
   Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200
   Roy AK, 1999, VITAM HORM, V55, P309
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Sottnik JL, 2015, CANCER RES, V75, P2151, DOI 10.1158/0008 5472.CAN 14 2493
   Sun XM, 2018, CHROMOSOMA, V127, P175, DOI 10.1007/s00412 018 0659 8
   Techasen A, 2014, TUMOR BIOL, V35, P8645, DOI 10.1007/s13277 014 2087 6
   The American Cancer Society, SURV RAT PROST CANC
   The American Cancer Society, 2020, US
   Tse JM, 2012, P NATL ACAD SCI USA, V109, P911, DOI 10.1073/pnas.1118910109
   Vanhara P, 2009, DIFFERENTIATION, V78, P213, DOI 10.1016/j.diff.2009.07.008
   Varma MJO, 2007, STEM CELLS DEV, V16, P91, DOI 10.1089/scd.2006.0026
   Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151
   Vuoriluoto K, 2008, EXP CELL RES, V314, P3369, DOI 10.1016/j.yexcr.2008.07.005
   Wang XF, 2018, ONCOL REP, V39, P1835, DOI 10.3892/or.2018.6271
   Westhrin M, 2015, HAEMATOLOGICA, V100, pE511, DOI 10.3324/haematol.2015.124511
   Wu CH, 2004, RENAL FAILURE, V26, P325, DOI 10.1081/JDI 200026727
   Wu SR, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1539 y
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Yu L, 2014, ONCOL REP, V31, P321, DOI 10.3892/or.2013.2841
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zou H, 2020, PEERJ, V8, DOI 10.7717/peerj.10136
NR 92
TC 1
Z9 1
U1 0
U2 4
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2023
VL 24
IS 1
AR 759
DI 10.3390/ijms24010759
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 7Q8DM
UT WOS:000909615300001
PM 36614201
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rumian, L
   Wolf Brandstetter, C
   Rossler, S
   Reczynska, K
   Tiainen, H
   Haugen, HJ
   Scharnweber, D
   Pamula, E
AF Rumian, Lucja
   Wolf Brandstetter, Cornelia
   Rossler, Sina
   Reczynska, Katarzyna
   Tiainen, Hanna
   Haugen, Havard J.
   Scharnweber, Dieter
   Pamula, Elzbieta
TI Sodium alendronate loaded poly(L lactide co glycolide)
   microparticles immobilized on ceramic scaffolds for local treatment of
   bone defects
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE ceramic scaffolds; sodium alendronate; osteoblasts; osteoclastogenesis;
   collagen; critical size defect; poly(L lactideco glycolide);
   microparticles
ID TITANIUM DIOXIDE SCAFFOLDS; POLY(LACTIDE CO GLYCOLIDE) MICROPARTICLES;
   MOLECULAR MECHANISMS; DRUG DELIVERY; IN VITRO; BISPHOSPHONATES;
   OSTEONECROSIS; COLLAGEN; HYDROXYAPATITE; CYTOTOXICITY
AB Bone tissue regeneration in critical size defects is possible after implantation of a 3D scaffold and can be additionally enhanced once the scaffold is enriched with drugs or other factors supporting bone remodelling and healing. Sodium alendronate (Aln), a widely used anti osteoporosis drug, exhibits strong inhibitory effect on bone resorption performed by osteoclasts. Thus, we propose a new approach for the treatment of bone defects in craniofacial region combining biocompatible titanium dioxide scaffolds and poly(L lactide co glycolide) microparticles (MPs) loaded with Aln. The MPs were effectively attached to the surface of the scaffolds' pore walls by human recombinant collagen. Drug release from the scaffolds was characterized by initial burst (24 +/  6% of the drug released within first 24 h) followed by a sustained release phase (on average 5 mu g of Aln released per day from Day 3 to Day 18). In vitro tests evidenced that Aln at concentrations of 5 and 2.5 mu g/mlwas not cytotoxic for MG 63 osteoblast like cells (viability between 81 +/  6% and 98 +/  3% of control), but it prevented RANKL induced formation of osteoclast like cells from macrophages derived from peripheral blood mononuclear cells, as shown by reduced fusion capability and decreased tartrateresistant acid phosphatase 5b activity (56 +/  5% reduction in comparison to control after 8 days of culture). Results show that it is feasible to design the scaffolds providing required doses of Aln inhibiting osteoclastogenesis, reducing osteoclast activity, but not affecting osteoblast functions, which may be beneficial in the treatment of critical size bone tissue defects.
C1 [Rumian, Lucja; Reczynska, Katarzyna; Pamula, Elzbieta] AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Dept Biomat & Composites, Al A Mickiewicza 30, PL 30059 Krakow, Poland.
   [Wolf Brandstetter, Cornelia; Rossler, Sina; Scharnweber, Dieter] Tech Univ Dresden, Max Bergmann Ctr Biomat, Inst Mat Sci, Budapester Str 27, D 01069 Dresden, Germany.
   [Tiainen, Hanna; Haugen, Havard J.] Univ Oslo, Inst Clin Dent, Dept Biomat, Geitmyrsveien 71, NO 0317 Oslo, Norway.
C3 AGH University of Krakow; Technische Universitat Dresden; University of
   Oslo
RP Pamula, E (通讯作者)，AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Dept Biomat & Composites, Al A Mickiewicza 30, PL 30059 Krakow, Poland.
EM epamula@agh.edu.pl
RI ; Tiainen, Hanna/H 1393 2014; Haugen, Havard Jostein/H 3551 2014;
   Haugen, Håvard Jostein/H 3551 2014; Pamuła, Elżbieta/A 2813 2017;
   Pamula, Elzbieta/A 2813 2017; Wolf Brandstetter, Cornelia/AEP 5513 2022;
   Scharnweber, Dieter/B 3382 2010
OI Wolf Brandstetter, Cornelia/0000 0001 9509 6145; Tiainen,
   Hanna/0000 0003 2757 6213; Haugen, Havard Jostein/0000 0002 6690 7233;
   Pamula, Elzbieta/0000 0002 0464 6189; Reczynska Kolman,
   Katarzyna/0000 0002 5266 9131; 
FU National Science Centre, Poland [2013/09/N/ST8/00309]; Norwegian
   Research Council [228415]; BMBF, Germany (GoBone German Polish
   bilateral) [01DS16010A]
FX This work was supported by National Science Centre, Poland
   (2013/09/N/ST8/00309), Norwegian Research Council (228415), and BMBF,
   Germany (GoBone German Polish bilateral project 01DS16010A).
CR Aderibigbe B, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010002
   ANHALT JP, 1977, ANTIMICROB AGENTS CH, V11, P651, DOI 10.1128/AAC.11.4.651
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bhumiratana S, 2012, STEM CELL TRANSL MED, V1, P64, DOI 10.5966/sctm.2011 0020
   Cao H, 2010, BONE, V46, P386, DOI 10.1016/j.bone.2009.09.031
   Carson JS, 2007, INJURY, V38, pS33, DOI 10.1016/j.injury.2007.02.008
   Cenni E, 2012, J BIOMAT SCI POLYM E, V23, P1285, DOI 10.1163/092050611X580373
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Conte Neto N, 2011, HEAD FACE MED, V7, DOI 10.1186/1746 160X 7 7
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Davidenko N, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5763 9
   Dell RM, 2009, J BONE JOINT SURG AM, V91A, P79, DOI 10.2106/JBJS.I.00521
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dobrzynski P, 2001, MACROMOLECULES, V34, P5090, DOI 10.1021/ma0018143
   Dolatabadi JEN, 2014, COLLOID SURFACE B, V117, P21, DOI 10.1016/j.colsurfb.2014.01.055
   Dutta SR, 2015, IRISH J MED SCI, V184, P101, DOI 10.1007/s11845 014 1199 8
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS343, DOI 10.4103/2152 7806.114813
   Fliefel R, 2017, STEM CELLS DEV, V26, P215, DOI 10.1089/scd.2016.0172
   Fostad G, 2009, J EUR CERAM SOC, V29, P2773, DOI 10.1016/j.jeurceramsoc.2009.03.017
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Hardt N, 2019, CRANIOFACIAL TRAUMA, P247
   Haugen HJ, 2013, ACTA BIOMATER, V9, P5390, DOI 10.1016/j.actbio.2012.09.009
   Ibrahim T, 2008, ONCOLOGIST, V13, P330, DOI 10.1634/theoncologist.2007 0159
   Israeli Ron S, 2008, Rev Urol, V10, P99
   Janckila AJ, 2001, J BONE MINER RES, V16, P788, DOI 10.1359/jbmr.2001.16.4.788
   Johnson AJW, 2011, ACTA BIOMATER, V7, P16, DOI 10.1016/j.actbio.2010.07.012
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   LAURENT GJ, 1987, AM J PHYSIOL, V252, pC1, DOI 10.1152/ajpcell.1987.252.1.C1
   Li XM, 2013, J BIOMED MATER RES A, V101, P2424, DOI 10.1002/jbm.a.34539
   Lowery JW, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022327
   Martins CA, 2015, J ENDODONT, V41, P45, DOI 10.1016/j.joen.2014.07.010
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Morra M, 2003, BIOMATERIALS, V24, P4639, DOI 10.1016/S0142 9612(03)00360 0
   Nafea EH, 2007, J MICROENCAPSUL, V24, P525, DOI 10.1080/02652040701439807
   Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003
   Padmanabhan J, 2016, SCI REP UK, V6, DOI 10.1038/srep33277
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Patel S, 2012, ORAL DIS, V18, P625, DOI 10.1111/j.1601 0825.2012.01911.x
   Posadowska U, 2015, INT J PHARMACEUT, V485, P31, DOI 10.1016/j.ijpharm.2015.03.003
   Pullisaar H, 2014, BIOCHEM BIOPH RES CO, V447, P139, DOI 10.1016/j.bbrc.2014.03.133
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rah DK, 2000, YONSEI MED J, V41, P756, DOI 10.3349/ymj.2000.41.6.756
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Rumian L, 2017, MATER LETT, V190, P67, DOI 10.1016/j.matlet.2016.12.113
   Rumian L, 2016, MAT SCI ENG C MATER, V69, P856, DOI 10.1016/j.msec.2016.07.065
   Rumian L, 2015, ACTA BIOENG BIOMECH, V17, P3, DOI 10.5277/ABB 00129 2014 02
   Rumian L, 2013, ACTA BIOENG BIOMECH, V15, P61, DOI 10.5277/abb130108
   Sabetrasekh R, 2010, BIOMED MATER, V5, DOI 10.1088/1748 6041/5/1/015003
   Shinkai I, 1996, BIOORGAN MED CHEM, V4, P3, DOI 10.1016/0968 0896(96)00042 9
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Tasca A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07855 9
   Tevlin R, 2014, J DENT RES, V93, P1187, DOI 10.1177/0022034514547271
   Tiainen H, 2012, ACTA BIOMATER, V8, P2384, DOI 10.1016/j.actbio.2012.02.020
   Tiainen H, 2010, J MATER SCI MATER M, V21, P2783, DOI 10.1007/s10856 010 4142 1
   Will J, 2008, J MATER SCI MATER M, V19, P2781, DOI 10.1007/s10856 007 3346 5
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yang CL, 2004, BIODRUGS, V18, P103, DOI 10.2165/00063030 200418020 00004
NR 63
TC 13
Z9 16
U1 1
U2 37
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD JUN
PY 2021
VL 8
IS 3
AR rbaa012
DI 10.1093/rb/rbaa012
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA TG7ED
UT WOS:000671562500001
PM 32523731
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xin, L
   Feng, HC
   Zhang, Q
   Cen, XL
   Huang, RR
   Tan, GY
   Zhang, Q
AF Xin, Li
   Feng, Huan Cun
   Zhang, Qiang
   Cen, Xiao Lin
   Huang, Rong Rong
   Tan, Guo Yao
   Zhang, Qun
TI Exploring the osteogenic effects of simiao wan through activation of the
   PI3K/AKT pathway in osteoblasts
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Simiao wan; Osteoporosis; UPLC Q TOF MS/MS; PI3K/AKT pathway; Network
   pharmacology
ID SIGNALING PATHWAY; OSTEOPOROSIS; DIFFERENTIATION
AB Ethnopharmacological relevance: Osteoporosis (OP) is a degenerative bone disease commonly associated with reduced bone density and increased fracture risk. Aim of the study: This study aimed to validate the therapeutic effects of Simiao wan (SMW) on OP and explore the underlying mechanism, particularly focusing on the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signaling pathway. Materials and methods: The chemical components of SMW were identified using UPLC Q TOF MS/MS. The obtained compounds were then input into the TCMSP, TargetNet, and SwissTargetPrediction databases to predict potential targets. OP related targets were collected from the GeneCards and DisGeNET databases, and intersecting targets were identified through a Venn diagram. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on the intersecting targets using the Database for Annotation, Visualization and Integrated Discovery (DAVID). SMW extract was subsequently used to treat osteoblasts in vitro, and its toxicity on osteoblasts was assessed using Cell Counting Kit 8 (CCK 8) and lactate dehydrogenase (LDH) release assays. Osteoblast differentiation and activity were further evaluated using alizarin red staining, alkaline phosphatase staining, and Western blot analyses to validate the activation of network pharmacological signaling pathways. Results: A total of 121 potential targets were identified for SMW in the treatment of OP, with AKT1 as the primary target. The PI3K/AKT pathway emerged as a key signaling pathway potentially involved in SMW's therapeutic effects o OP. Toxicity assessments showed no significant toxicity of SMW on osteoblasts. Additionally, SMW promoted osteoblast proliferation, alkaline phosphatase activity, calcium nodule deposition, and the expression of osteogenic markers (osteocalcin (OCN), runt related transcription factor 2 (RunX2), and collagen I), and activated the PI3K/AKT signaling pathway. The PI3K/AKT pathway inhibitor LY294002 partially reversed the SMW induced mineral deposition and expression of OCN, RunX2, and collagen I. Conclusion: SMW demonstrated effective multi target and multi pathway therapeutic potential in the treatment of OP, with a significant impact on the PI3K/AKT signaling pathway.
C1 [Xin, Li; Feng, Huan Cun; Cen, Xiao Lin; Huang, Rong Rong; Zhang, Qun] Southern Med Univ, Affiliated Hosp 3, Off Clin Trial Drug, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510630, Guangdong, Peoples R China.
   [Xin, Li; Zhang, Qiang; Tan, Guo Yao] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, Guangzhou 510120, Guangdong, Peoples R China.
C3 Southern Medical University   China; Sun Yat Sen University
RP Zhang, Q (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Off Clin Trial Drug, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510630, Guangdong, Peoples R China.
EM nstg12345@163.com
RI Feng, Huancun/NZN 9574 2025; Huang, Rongrong/IAM 8146 2023
CR Andrzejewska A, 2019, STEM CELLS, V37, P855, DOI 10.1002/stem.3016
   [Anonymous], 2023, Nucleic Acids Res., V51, pD523, DOI DOI 10.1093/NAR/GKAC1052
   Chai XY, 2019, ARTIF CELL NANOMED B, V47, P3569, DOI 10.1080/21691401.2019.1649270
   Chen C.C., 2023, Henan Tradit. Chin. Med., V43, P1534
   Chen SN, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04233 0
   Choksi Palak, 2018, Clin Diabetes Endocrinol, V4, P12, DOI 10.1186/s40842 018 0062 7
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   [褚博文 Chu Bowen], 2016, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V22, P213
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c
   Fardellone P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103361
   Gkastaris K, 2020, J MUSCULOSKEL NEURON, V20, P372
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Han JW, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772944
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Kong Y, 2019, EXP MOL PATHOL, V110, DOI 10.1016/j.yexmp.2019.104282
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061
   Rozenberg S, 2020, MATURITAS, V138, P14, DOI 10.1016/j.maturitas.2020.05.004
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Wang HJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23092343
   Xu Hy Y.Q., 2020, Mod. Pract. Med., V32, P1314
   [徐婷 Xu Ting], 2021, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V32, P1825
   Yang Rong Sen, 2013, J Tradit Complement Med, V3, P134, DOI 10.4103/2225 4110.110408
   Yu D.Y., 2011, Chin. J. Tradit. Med. Traumatol.; Orthoped., V19, P9
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhong YY, 2023, DRUG DES DEV THER, V17, P2727, DOI 10.2147/DDDT.S413532
NR 29
TC 3
Z9 3
U1 5
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD FEB 10
PY 2025
VL 338
AR 119023
DI 10.1016/j.jep.2024.119023
EA NOV 2024
PN 1
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA M8D8S
UT WOS:001359793000001
PM 39489361
DA 2025 08 17
ER

PT J
AU Anwar, MJ
   Alenezi, SK
   Mahmood, D
   Azam, F
   Alharbi, KS
AF Anwar, Md Jamir
   Alenezi, Sattam K.
   Mahmood, Danish
   Azam, Faizul
   Alharbi, Khalid Saad
TI An insight into the implications of estrogen deficiency and transforming
   growth factor β in antiepileptic drugs induced bone loss
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Epilepsy; Antiepileptic drugs; Estrogen; TGF beta; Bone loss;
   Osteoporosis
ID REPRODUCTIVE ENDOCRINE FUNCTION; CA1 PYRAMIDAL CELLS; MINERAL DENSITY;
   VITAMIN D; RAT BONE; OSTEOCLAST DIFFERENTIATION; BIOCHEMICAL MARKERS;
   LONG TERM; ELECTRICAL ACTIVITY; SODIUM VALPROATE
AB There have been a number of reports that chronic antiepileptic drug (AEDs) therapy is associated with abnormal bone and calcium metabolism, osteoporosis/osteomalacia, and increased risk of fractures. Bony adverse effects of long term antiepileptic drug therapy have been reported for more than four decades but the exact molecular mechanism is still lacking. Several mechanisms have been proposed regarding AEDs induced bone loss; Hypovitaminosis D, hyperparathyroidism, estrogen deficiency, calcitonin deficiency. Transforming growth factor beta (TGF  beta) is abundant in bone matrix and has been shown to regulate the activity of osteoblasts and osteoclasts in vitro. All isoforms of TGF  beta are expressed in bone and intricately play role in bone homeostasis by modulating estrogen level. Ovariectomised animal have shown down regulation of TGF  beta in bone that could also be a probable target of AEDs therapy associated bone loss. One of the widely accepted hypotheses regarding the conventional drugs induced bone loss is hypovitaminosis D which is by virtue of their microsomal enzyme inducing effect. However, despite of the lack of enzyme inducing effect of certain newer antiepileptic drugs, reduced bone mineral density with these drugs have also been reported. Thus an understanding of bone biology, pathophysiology of AEDs induced bone loss at molecular level can aid in the better management of bone loss in patients on chronic AEDs therapy. This review focuses mainly on certain new molecular targets of AEDs induced bone loss.
C1 [Anwar, Md Jamir; Alenezi, Sattam K.; Mahmood, Danish] Qassim Univ, Coll Pharm, Dept Pharmacol & Toxicol, Buraydah, Al Qassim Regio, Saudi Arabia.
   [Azam, Faizul] Qassim Univ, Unaizah Coll Pharm, Dept Pharmaceut Chem & Pharmacognosy, Buraydah, Al Qassim, Saudi Arabia.
   [Alharbi, Khalid Saad] Jouf Univ, Coll Pharm, Dept Pharmacol, Sakakah, Saudi Arabia.
C3 Qassim University; Qassim University; Al Jouf University
RP Anwar, MJ (通讯作者)，Qassim Univ, Coll Pharm, Dept Pharmacol & Toxicol, Buraydah, Al Qassim Regio, Saudi Arabia.
EM m.anwar@qu.edu.sa
RI ; Alharbi, Khalid/AAD 9410 2019; Mahmood, Danish/AAR 3262 2020; Azam,
   Faizul/G 9993 2013
OI Anwar, Md Jamir/0000 0002 9895 8166; Alharbi, Khalid
   Saad/0000 0003 0393 1890; Azam, Faizul/0000 0002 2927 8167
CR Agrawal N, 2019, THER ADV PSYCHOPHARM, V9, DOI 10.1177/2045125319862968
   Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333
   Anwar MJ, 2014, EUR J PHARM SCI, V62, P219, DOI 10.1016/j.ejps.2014.05.018
   Anwar MJ, 2014, CAN J PHYSIOL PHARM, V92, P507, DOI 10.1139/cjpp 2013 0504
   Arora Ekta, 2016, J Family Med Prim Care, V5, P248
   Asgharian Rezaee M, 2020, REP BIOCHEM MOL BIOL, V9, P331, DOI 10.29252/rbmb.9.3.331
   Bab Itai, 2010, Curr Osteoporos Rep, V8, P185, DOI 10.1007/s11914 010 0026 z
   Bauer J, 2002, J NEUROL NEUROSUR PS, V73, P121, DOI 10.1136/jnnp.73.2.121
   Baysal M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175990
   BEAUDREUIL J, 1995, J BONE MINER RES, V10, P971
   Behera J, 2017, J CELL PHYSIOL, V232, P2704, DOI 10.1002/jcp.25693
   Bobo WV, 2012, PAEDIATR PERINAT EP, V26, P578, DOI 10.1111/ppe.12004
   Bord S, 2001, BONE, V29, P216, DOI 10.1016/S8756 3282(01)00501 4
   Canavese F, 2016, ORTHOP TRAUMATOL SUR, V102, pS149, DOI 10.1016/j.otsr.2015.05.010
   Cansu A, 2008, PEDIATR NEUROL, V39, P266, DOI 10.1016/j.pediatrneurol.2008.07.001
   Charatcharoenwitthaya N, 2007, J BONE MINER RES, V22, P724, DOI 10.1359/JBMR.070207
   Cheon YH, 2016, J BONE MINER RES, V31, P403, DOI 10.1002/jbmr.2612
   Christensen A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00130
   DAmelio P., 2011, CYTOKINES BONE, P385
   de Lanerolle NC, 2003, EPILEPSIA, V44, P677, DOI 10.1046/j.1528 1157.2003.32701.x
   Desai KB, 1996, INJURY, V27, P97, DOI 10.1016/0020 1383(95)00189 1
   Diemar SS, 2020, PHARMACOL REP, V72, P1323, DOI 10.1007/s43440 020 00087 1
   DIEUDONNE SC, 1991, J BONE MINER RES, V6, P479
   Ecevit CG, 2004, PEDIATR NEUROL, V31, P279, DOI 10.1016/j.pediatrneurol.2004.03.021
   El Haggar SM, 2018, ARQ NEURO PSIQUIAT, V76, P452, DOI [10.1590/0004 282X20180068, 10.1590/0004 282x20180068]
   El Hajj Fuleihan G, 2008, BONE, V43, P149, DOI 10.1016/j.bone.2008.03.002
   Ensrud KE, 2008, NEUROLOGY, V71, P723, DOI 10.1212/01.wnl.0000324919.86696.a9
   Ensrud KE, 2002, J AM GERIATR SOC, V50, P1629, DOI 10.1046/j.1532 5415.2002.50453.x
   Ensrud KE, 2004, NEUROLOGY, V62, P2051, DOI 10.1212/01.WNL.0000125185.74276.D2
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Espallargues M, 2001, OSTEOPOROSIS INT, V12, P811, DOI 10.1007/s001980170031
   Fekete S, 2013, EPILEPSY RES, V107, P56, DOI 10.1016/j.eplepsyres.2013.08.012
   Fife TD., 2005, AGING HLTH, V1, P147, DOI [DOI 10.2217/1745509x.1.1.147, 10.2217/1745509X.1.1.147]
   FINKELMAN RD, 1992, P NATL ACAD SCI USA, V89, P12190, DOI 10.1073/pnas.89.24.12190
   Galimberti CA, 2009, EPILEPSIA, V50, P28, DOI 10.1111/j.1528 1167.2008.01966.x
   Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632
   Gavali S, 2019, BBA MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   GOUGH H, 1986, IRISH J MED SCI, V155, P181, DOI 10.1007/BF02939839
   Graham SM, 2011, EXPERT OPIN DRUG SAF, V10, P575, DOI 10.1517/14740338.2011.560112
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Gröber U, 2012, DERM ENDOCRINOL, V4, P158, DOI 10.4161/derm.20731
   Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660
   Guo CY, 2001, EPILEPSIA, V42, P1141, DOI 10.1046/j.1528 1157.2001.416800.x
   Harden CL, 2013, LANCET NEUROL, V12, P72, DOI 10.1016/S1474 4422(12)70239 9
   He X, 2016, ANN NUTR METAB, V68, P119, DOI 10.1159/000443535
   Heo K, 2011, EPILEPSIA, V52, P1884, DOI 10.1111/j.1528 1167.2011.03131.x
   HERZOG AG, 1986, ARCH NEUROL CHICAGO, V43, P341, DOI 10.1001/archneur.1986.00520040029014
   Herzog AG, 2008, SEIZURE EUR J EPILEP, V17, P101, DOI 10.1016/j.seizure.2007.11.025
   Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014 4886(03)00104 3
   Holick MF, 2005, J CLIN INVEST, V115, P32, DOI 10.1172/JCI200523995
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   ISOJARVI JIT, 1995, EPILEPSIA, V36, P366, DOI 10.1111/j.1528 1157.1995.tb01011.x
   ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904
   Ito I, 2010, J BIOL CHEM, V285, P14747, DOI 10.1074/jbc.M109.093039
   Jacobsen NW, 2008, TOXICOL IN VITRO, V22, P146, DOI 10.1016/j.tiv.2007.09.004
   Jetté N, 2011, ARCH NEUROL CHICAGO, V68, P107, DOI 10.1001/archneurol.2010.341
   Jia J, 2017, MOL MED REP, V15, P1539, DOI 10.3892/mmr.2017.6168
   Kanda J, 2017, BIOMED RES TOKYO, V38, P297, DOI 10.2220/biomedres.38.297
   Kanner AM, 2016, EPILEPSY BEHAV, V61, P282, DOI 10.1016/j.yebeh.2016.03.022
   Karesova I, 2018, EUR J PHARMACOL, V824, P115, DOI 10.1016/j.ejphar.2018.02.010
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Khanna S, 2011, BONE, V48, P597, DOI 10.1016/j.bone.2010.10.172
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1550, DOI 10.1210/jc.87.4.1550
   Koo DL, 2014, EPILEPSY RES, V108, P442, DOI 10.1016/j.eplepsyres.2013.09.009
   Koo DL, 2013, EPILEPSY RES, V104, P134, DOI 10.1016/j.eplepsyres.2012.09.002
   Koyama H, 2000, ARCH ORAL BIOL, V45, P647, DOI 10.1016/S0003 9969(00)00036 4
   Lee Richard, 2012, Endocr Pract, P1
   Leidy NK, 1999, NEUROLOGY, V53, P162, DOI 10.1212/WNL.53.1.162
   LEVESQUE LA, 1986, J CLIN ENDOCR METAB, V63, P243, DOI 10.1210/jcem 63 1 243
   LEWIS DP, 1995, ANN PHARMACOTHER, V29, P726, DOI 10.1177/106002809502907 816
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   LIDGREN L, 1977, ACTA ORTHOP SCAND, V48, P356, DOI 10.3109/17453677708992008
   Lindberg MK, 2006, BONE, V38, P85, DOI 10.1016/j.bone.2005.07.027
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lossius MI, 2007, EPILEPSIA, V48, P1875, DOI 10.1111/j.1528 1167.2007.01147.x
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MARCUS EM, 1966, ARCH NEUROL CHICAGO, V15, P521, DOI 10.1001/archneur.1966.00470170075008
   Masunari Naomi, 2008, Hiroshima Journal of Medical Sciences, V57, P17
   Mattson RH, 2004, EPILEPSY BEHAV, V5, pS36, DOI 10.1016/j.yebeh.2003.11.030
   Mazdeh M, 2020, FUTUR NEUROL, V15, DOI 10.2217/fnl 2019 0028
   Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007
   Meier C, 2011, THER ADV MUSCULOSKEL, V3, P235, DOI 10.1177/1759720X11410769
   Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147
   Mohamed WS, 2019, EGYPT J NEUROL PSYCH, V55, DOI 10.1186/s41983 019 0088 5
   Molgaard Nielsen D, 2011, JAMA J AM MED ASSOC, V305, P1996, DOI 10.1001/jama.2011.624
   Morrell MJ, 2002, ANN NEUROL, V52, P704, DOI 10.1002/ana.10391
   Mukherjee J, 2017, P NATL ACAD SCI USA, V114, P11763, DOI 10.1073/pnas.1705075114
   MUNDY GR, 1991, CIBA F SYMP, V157, P137
   Murthy PSN, 2006, J STEROID BIOCHEM, V100, P117, DOI 10.1016/j.jsbmb.2006.03.009
   Nakade O, 1996, J BONE MINER RES, V11, P1880
   Nardone R, 2016, J CLIN NEUROL, V12, P21, DOI 10.3988/jcn.2016.12.1.21
   Neligan Aidan, 2012, Handb Clin Neurol, V107, P113, DOI 10.1016/B978 0 444 52898 8.00006 9
   Nissen Meyer LSH, 2007, EPILEPSIA, V48, P1850, DOI 10.1111/j.1528 1167.2007.01176.x
   Ochiai H, 2012, J BIOL CHEM, V287, P22654, DOI 10.1074/jbc.M111.279091
   Ong DB, 2004, J BONE MINER RES, V19, P447, DOI 10.1359/JBMR.0301249
   Onodera K, 2001, CALCIFIED TISSUE INT, V69, P109, DOI 10.1007/s00223 001 0020 7
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   OURSLER MJ, 1994, P NATL ACAD SCI USA, V91, P5227, DOI 10.1073/pnas.91.12.5227
   Petty SJ, 2007, OSTEOPOROSIS INT, V18, P129, DOI 10.1007/s00198 006 0185 z
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Rauchenzauner M, 2010, EPILEPSY RES, V88, P264, DOI 10.1016/j.eplepsyres.2009.11.003
   Nguyen R, 2009, NEUROL INT, V1, P72, DOI 10.4081/ni.2009.e20
   Rudick CN, 2001, J NEUROSCI, V21, P6532, DOI 10.1523/JNEUROSCI.21 17 06532.2001
   Salimipour H, 2013, J NUCL MED TECHNOL, V41, P208, DOI 10.2967/jnmt.113.124685
   Scane AC, 1999, OSTEOPOROSIS INT, V9, P91, DOI 10.1007/s001980050120
   SCHMITT BP, 1984, J FAM PRACTICE, V18, P873
   SCHUMACHER M, 1989, BRAIN RES, V487, P178, DOI 10.1016/0006 8993(89)90955 4
   SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140 6736(95)90227 9
   Sheth RD, 2007, PEDIATR NEUROL, V37, P250, DOI 10.1016/j.pediatrneurol.2007.05.018
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107
   Souverein PC, 2006, NEUROLOGY, V66, P1318, DOI 10.1212/01.wnl.0000210503.89488.88
   Spitz MC, 1998, EPILEPSIA, V39, P904, DOI 10.1111/j.1528 1157.1998.tb01189.x
   Suda T, 2001, Novartis Found Symp, V232, P235
   Svalheim S, 2008, SEIZURE EUR J EPILEP, V17, P203, DOI 10.1016/j.seizure.2007.11.018
   Svalheim S, 2015, SEIZURE EUR J EPILEP, V28, P12, DOI 10.1016/j.seizure.2015.02.022
   Svalheim S, 2009, EPILEPSY BEHAV, V16, P281, DOI 10.1016/j.yebeh.2009.07.033
   Tang MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01508
   Tauboll E, 2003, EPILEPSIA, V44, P1014, DOI 10.1046/j.1528 1157.2003.60702.x
   Tauboll E, 2015, SEIZURE EUR J EPILEP, V28, P3, DOI 10.1016/j.seizure.2015.02.012
   Tauboll E, 2009, EPILEPSIA, V50, P1868, DOI 10.1111/j.1528 1167.2009.02131.x
   Teagarden DL, 2014, EPILEPSY RES, V108, P1352, DOI 10.1016/j.eplepsyres.2014.06.008
   TERASAWA E, 1968, ENDOCRINOLOGY, V83, P207, DOI 10.1210/endo 83 2 207
   TERUI T, 1989, CONTACT DERMATITIS, V20, P260, DOI 10.1111/j.1600 0536.1989.tb03142.x
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Velísek L, 1999, BRAIN RES, V842, P132, DOI 10.1016/S0006 8993(99)01858 2
   Verrotti A, 2010, CLIN NEUROL NEUROSUR, V112, P1, DOI 10.1016/j.clineuro.2009.10.011
   Vestergaard P, 2004, EPILEPSIA, V45, P1330, DOI 10.1111/j.0013 9580.2004.18804.x
   WEINSTEIN RS, 1984, J CLIN ENDOCR METAB, V58, P1003, DOI 10.1210/jcem 58 6 1003
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   WONG M, 1992, J NEUROSCI, V12, P3217, DOI 10.1523/JNEUROSCI.12 08 03217.1992
   Woolley CS, 1997, J NEUROSCI, V17, P1848
   WOOLLEY DE, 1962, ENDOCRINOLOGY, V70, P196, DOI 10.1210/endo 70 2 196
   Zhang Jing, 2010, Zhongguo Dang Dai Er Ke Za Zhi, V12, P96
   Zhou J, 2021, BMC GERIATR, V21, DOI 10.1186/s12877 021 02043 x
NR 135
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2021
VL 907
AR 174313
DI 10.1016/j.ejphar.2021.174313
EA JUL 2021
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UD5QE
UT WOS:000687260200004
PM 34245750
DA 2025 08 17
ER

PT J
AU Xu, T
   Wang, L
   Tao, Y
   Ji, Y
   Deng, F
   Wu, XH
AF Xu, Tong
   Wang, Lu
   Tao, You
   Ji, Yan
   Deng, Feng
   Wu, Xiao Hong
TI The Function of Naringin in Inducing Secretion of Osteoprotegerin and
   Inhibiting Formation of Osteoclasts
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; 1,25 DIHYDROXYVITAMIN D 3; MECHANICAL PROPERTIES;
   BONE RESORPTION; ENDOTOXIN SHOCK; INVOLVEMENT; MICE; OSTEOBLASTS;
   SUPPRESSION; EXPRESSION
AB Osteoporosis has become one of the most prevalent and costly diseases in the world. It is a metabolic disease characterized by reduction in bonemass due to an imbalance between bone formation and resorption. Osteoporosis causes fractures, prolongs bone healing, and impedes osseointegration of dental implants. Its pathological features include osteopenia, degradation of bone tissue microstructure, and increase of bone fragility. In traditional Chinese medicine, the herb Rhizoma Drynariae has been commonly used to treat osteoporosis and bone nonunion. However, the precise underlying mechanism is as yet unclear. Osteoprotegerin is a cytokine receptor shown to play an important role in osteoblast differentiation and bone formation. Hence, activators and ligands of osteoprotegerin are promising drug targets and have been the focus of studies on the development of therapeutics against osteoporosis. In the current study, we found that naringin could synergistically enhance the action of 1 alpha,25 dihydroxyvitamin D 3 in promoting the secretion of osteoprotegerin by osteoblasts in vitro. In addition, naringin can also influence the generation of osteoclasts and subsequently bone loss during organ culture. In conclusion, this study provides evidence that natural compounds such as naringin have the potential to be used as alternative medicines for the prevention and treatment of osteolysis.
C1 [Xu, Tong; Wang, Lu; Tao, You; Ji, Yan; Wu, Xiao Hong] Chongqing Med Univ, Dept Prosthodont, Affiliated Hosp Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
   [Xu, Tong; Wang, Lu; Tao, You; Ji, Yan; Deng, Feng; Wu, Xiao Hong] Chongqing Key Lab Oral Dis & Biomed Sci, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
   [Deng, Feng] Chongqing Med Univ, Affiliated Hosp Stomatol, Dept Orthodont, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Wu, XH (通讯作者)，Chongqing Med Univ, Dept Prosthodont, Affiliated Hosp Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.; Wu, XH (通讯作者)，Chongqing Key Lab Oral Dis & Biomed Sci, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
EM 104758443@qq.com
FU National Natural Science Foundation of China [81200767/H1402]; Chongqing
   Municipal Health Bureau [2012 2 8]
FX The study was supported by the National Natural Science Foundation of
   China (81200767/H1402) and Chongqing Municipal Health Bureau (2012 2 8).
CR Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   CHEN YT, 1990, FREE RADICAL BIO MED, V9, P19, DOI 10.1016/0891 5849(90)90045 K
   D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050
   Gemmiti CV, 2006, TISSUE ENG, V12, P469, DOI 10.1089/ten.2006.12.469
   Hirata M, 2009, J HEALTH SCI, V55, P463, DOI 10.1248/jhs.55.463
   Kanno S, 2006, LIFE SCI, V78, P673, DOI 10.1016/j.lfs.2005.04.051
   Kawaguchi K, 2004, PLANTA MED, V70, P17, DOI 10.1055/s 2004 815449
   Kawaguchi K, 1999, EUR J PHARMACOL, V368, P245, DOI 10.1016/S0014 2999(98)00867 X
   Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353 06
   KROYER G, 1986, Z ERNAHRUNGSWISS, V25, P63, DOI 10.1007/BF02023620
   Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168 1656(96)01412 5
   Mandadi K, 2009, PHYTOMEDICINE, V16, P513, DOI 10.1016/j.phymed.2008.09.001
   MARIDONNEAUPARINI I, 1986, PHARMACOL RES COMMUN, V18, P61, DOI 10.1016/0031 6989(86)90159 1
   Martin I, 2000, BIORHEOLOGY, V37, P141
   Pei M, 2002, FASEB J, V16, P1691, DOI 10.1096/fj.02 0083fje
   Persson E, 2005, BIOCHEM BIOPH RES CO, V335, P705, DOI 10.1016/j.bbrc.2005.07.135
   Rabie ABM, 2000, BRIT J ORAL MAX SURG, V38, P565, DOI 10.1054/bjom.2000.0464
   SATO K, 1986, BIOCHEM BIOPH RES CO, V141, P285, DOI 10.1016/S0006 291X(86)80366 7
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Uchida M, 2001, J BONE MINER RES, V16, P221, DOI 10.1359/jbmr.2001.16.2.221
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wong RWK, 2006, BIOMATERIALS, V27, P1824, DOI 10.1016/j.biomaterials.2005.11.009
   Yamagishi T, 2001, ENDOCRINOLOGY, V142, P3632, DOI 10.1210/en.142.8.3632
   Zhou XX, 2010, J ORTHOP RES, V28, P451, DOI 10.1002/jor.21002
NR 26
TC 18
Z9 26
U1 0
U2 29
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2016
VL 2016
AR 8981650
DI 10.1155/2016/8981650
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA DB9NC
UT WOS:000368841900001
PM 26884798
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Park, CK
   Lee, Y
   Chang, EJ
   Lee, MH
   Yoon, JH
   Ryu, JH
   Kim, HH
AF Park, Cheol Kyu
   Lee, Youngkyun
   Chang, Eun Ju
   Lee, Ming Hong
   Yoon, Jeong Hoon
   Ryu, Jae Ha
   Kim, Hong Hee
TI Bavachalcone inhibits osteoclast differentiation through suppression of
   NFATc1 induction by RANKL
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE bavachalcone; osteoclast differentiation; NFATc1; c Fos; RANKL
ID NF KAPPA B; LACKING C FOS; RECEPTOR ACTIVATOR; NUCLEAR FACTOR; KEY
   REGULATOR; BONE; CELLS; MICE; EXPRESSION; REQUIRES
AB Osteoclasts are cells that have a specialized role for bone resorption and are responsible for many bone diseases such as osteoporosis. As herbal products are invaluable sources in discovery of compounds for new therapies, we sought to identify compounds efficacious in suppressing osteoclastogenesis from medicinal plants that have been implicated for treatment of osteoporotic conditions. Bavachalcone was isolated from Psoralea corylifolia, and its effects on osteoclast differentiation were evaluated with primary cultures of osteoclast precursor cells. In addition, the molecular mechanism of action was investigated. Bavachalcone inhibited osteoclast formation from precursor cells with the IC50 of similar to 1.5 mu g ml( 1). The activation of MEK, ERK, and Akt by receptor activator of nuclear factor kappaB ligand (RANKL), the osteoclast differentiation factor, was prominently reduced in the presence of bavachalcone. The induction of c Fos and NFATc1, key transcription factors for osteoclastogenesis, by RANKL was also suppressed by bavachalcone. In conclusion, bavachalcone inhibits osteoclastogenesis by interfering with the ERK and Akt signaling pathways and the induction of c Fos and NFATc1 during differentiation. our results suggest that bavachalcone may be useful as a therapeutic drug for bone resorption associated diseases. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Park, Cheol Kyu; Lee, Youngkyun; Chang, Eun Ju; Kim, Hong Hee] Seoul Natl Univ, Sch Dent, Dent Res Inst, Dept Cell & Dev Biol,BK21 Program, Seoul 110749, South Korea.
   [Lee, Ming Hong; Yoon, Jeong Hoon; Ryu, Jae Ha] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
C3 Seoul National University (SNU); Sookmyung Women's University
RP Kim, HH (通讯作者)，Seoul Natl Univ, Sch Dent, Dent Res Inst, Dept Cell & Dev Biol,BK21 Program, 28 Yeongon Dong, Seoul 110749, South Korea.
EM hhbkim@snu.ac.kr
RI Park, Cheol Kyu/AAT 9872 2021; Lee, Youngkyun/D 2667 2011
CR Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Lee MH, 2005, BIOL PHARM BULL, V28, P2253, DOI 10.1248/bpb.28.2253
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miura H, 1996, PLANTA MED, V62, P150, DOI 10.1055/s 2006 957839
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s 2001 18343
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
NR 21
TC 50
Z9 55
U1 0
U2 7
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUN 1
PY 2008
VL 75
IS 11
BP 2175
EP 2182
DI 10.1016/j.bcp.2008.03.007
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 310EJ
UT WOS:000256511400012
PM 18433733
DA 2025 08 17
ER

PT J
AU Dong, H
   Cao, YX
   Zou, K
   Shao, Q
   Liu, RH
   Zhang, Y
   Pan, LZ
   Ning, B
AF Dong, Hui
   Cao, Yuxia
   Zou, Ke
   Shao, Qiang
   Liu, Ronghan
   Zhang, Ying
   Pan, Liuzhu
   Ning, Bin
TI Ellagic acid promotes osteoblasts differentiation via activating SMAD2/3
   pathway and alleviates bone mass loss in OVX mice
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Osteoporosis; Osteoblast; Ellagic acid; BMSCs; SMAD2/3
ID MESENCHYMAL STEM CELLS; CONSUMPTION; MEDICINE
AB Characterized by bone mass loss, osteoporosis is an orthopedic disease typically found in postmenopausal women and aging individuals. Consistent with its pathogenesis summarized as an imbalance in bone formation/ resorption, current pharmacologically therapeutic strategies for osteoporosis mainly aim to promote bone formation or/and inhibit bone resorption. However, few effective drugs with mild clinical side effects have been developed, making it a well concerned issue to seek appropriate drugs for osteoporosis. In this study, we investigated the effect of ellagic acid (EA) on osteogenesis in vitro and in vivo and searched for its molecular mechanism. Here, we showed that EA promoted osteogenic differentiation of MSCs, increased mRNA and protein expression levels of osteoblast marker genes Runt related transcription factor2, Osterix, Alkaline phosphatase, Collagen type I alpha 1, Osteopontin and Osteocalcin. Furthermore, ovariectomized mice with orally administered EA (10 mg/kg, 50 mg/kg) had significantly higher bone mass than those in controls. And experiments such as fluorescence double labeling and enzyme linked immunosorbent assay also demonstrated that EA could promote osteogenesis in vivo. To probe the molecular mechanism of EA, we performed RNA sequencing analysis using EA treated BMSCs. Significant up regulation of SMAD2/3 transcription factors was identified by RNA seq, and it was confirmed in vitro that EA promoted bone formation by activating the SMAD2/3 signaling pathway. Evidence from our present experiments indicates that EA may be a promising candidate for clinical treatment for osteoporosis in future.
C1 [Dong, Hui; Cao, Yuxia; Zou, Ke; Shao, Qiang; Ning, Bin] Shandong Univ, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
   [Dong, Hui; Cao, Yuxia; Zou, Ke; Liu, Ronghan; Zhang, Ying; Pan, Liuzhu; Ning, Bin] Shandong First Med Univ, Shandong First Med Univ & Shandong Acad Med Sci, Cent Hosp, Jinan 250013, Shandong, Peoples R China.
   [Ning, Bin] 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong First Medical University &
   Shandong Academy of Medical Sciences
RP Ning, B (通讯作者)，105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
EM ningbin@sdu.edu.cn
RI ; Liu, Ronghan/ABH 1619 2021
OI Dong, Hui/0000 0002 0239 1020; Liu, Ronghan/0000 0002 6897 0279
FU National Natural Science Fund of China [81771346, 82071383, 82202750];
   Natural Science Foundation of Shandong Province (Key Project)
   [ZR2020KH007]; Taishan Scholar Youth Program Shandong Province
   [tsqn201812156]; Academic Promotion Program Shandong First Medical
   University [2019QL025, 2019RC021]; Spring Industry Leader Talent Support
   Plan [201984]; Rongxiang Regenerative Medicine Fund [2019SDRX 23];
   Natural Science Foundation Shandong Province (Youth Program)
   [ZR2020QH070]; China Postdoctoral Science Foundation Funded Project
   [2021M691225]
FX The authors wish to acknowledge the following funding sources: National
   Natural Science Fund of China (Nos. 81771346, 82071383, 82202750) ,
   Natural Science Foundation of Shandong Province (Key Project) (Nos.
   ZR2020KH007) , the Taishan Scholar Youth Program Shandong Province
   (tsqn201812156) , Academic Promotion Program Shandong First Medical
   University (2019QL025, 2019RC021) , Spring Industry Leader Talent
   Support Plan (No. 201984) , Rongxiang Regenerative Medicine Fund
   (2019SDRX 23) , Natural Science Foundation Shandong Province (Youth
   Program) (Nos. ZR2020QH070) , and China Postdoctoral Science Foundation
   Funded Project (Project No.:2021M691225) .
CR [Anonymous], 2016, Cold Spring Harbor Perspect. Biol., V8
   Baniwal SK, 2012, OSTEOPOROSIS INT, V23, P1399, DOI 10.1007/s00198 011 1728 5
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bose S, 2020, TRENDS BIOTECHNOL, V38, P404, DOI 10.1016/j.tibtech.2019.11.005
   Cao FY, 2015, ACS APPL MATER INTER, V7, P6698, DOI 10.1021/acsami.5b00064
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen HS, 2015, INT J ONCOL, V46, P1730, DOI 10.3892/ijo.2015.2870
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Clarke BL, 2022, J BONE MINER RES, V37, P1809, DOI 10.1002/jbmr.4713
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hao ZC, 2023, BIOACT MATER, V23, P206, DOI 10.1016/j.bioactmat.2022.10.018
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He QM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.983884
   Kang I, 2016, ADV NUTR, V7, P961, DOI 10.3945/an.116.012575
   Kang I, 2014, J NUTR BIOCHEM, V25, P946, DOI 10.1016/j.jnutbio.2014.04.008
   Li LH, 2022, REDOX BIOL, V56, DOI 10.1016/j.redox.2022.102435
   Lin XX, 2020, J CELL PHYSIOL, V235, P5951, DOI 10.1002/jcp.29520
   Lu HF, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8855423
   Lv YJ, 2018, THERANOSTICS, V8, P2387, DOI 10.7150/thno.23620
   Matzkin EG, 2019, J AM ACAD ORTHOP SUR, V27, pE902, DOI 10.5435/JAAOS D 18 00600
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Miguez PA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063223
   Mohanty S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.777400
   Moon NR, 2018, J PHOTOCH PHOTOBIO B, V178, P92, DOI 10.1016/j.jphotobiol.2017.11.004
   Papoutsi Z, 2008, BRIT J NUTR, V99, P715, DOI 10.1017/S0007114507837421
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Shavandi A, 2018, BIOMATERIALS, V167, P91, DOI 10.1016/j.biomaterials.2018.03.018
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Sun YX, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 021 00601 9
   Sun ZR, 2021, J AGR FOOD CHEM, V69, P12741, DOI 10.1021/acs.jafc.1c05239
   Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169 409X(97)00039 2
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wedler J, 2016, FITOTERAPIA, V114, P56, DOI 10.1016/j.fitote.2016.08.019
   Xia H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.839035
   Yuan Q, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28096 z
   Zhao JL, 2020, ONCOL REP, V44, P768, DOI 10.3892/or.2020.7617
   Zhou Z, 2022, ACS APPL MATER INTER, V14, P36315, DOI 10.1021/acsami.2c05794
NR 40
TC 9
Z9 10
U1 5
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD JAN 25
PY 2024
VL 388
AR 110852
DI 10.1016/j.cbi.2023.110852
EA DEC 2023
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA II5V5
UT WOS:001165719500001
PM 38145796
DA 2025 08 17
ER

PT J
AU Kureel, J
   Dixit, M
   Tyagi, AM
   Mansoori, MN
   Srivastava, K
   Raghuvanshi, A
   Maurya, R
   Trivedi, R
   Goel, A
   Singh, D
AF Kureel, J.
   Dixit, M.
   Tyagi, A. M.
   Mansoori, M. N.
   Srivastava, K.
   Raghuvanshi, A.
   Maurya, R.
   Trivedi, R.
   Goel, A.
   Singh, D.
TI miR 542 3p suppresses osteoblast cell proliferation and differentiation,
   targets BMP 7 signaling and inhibits bone formation
SO CELL DEATH & DISEASE
LA English
DT Article
DE microRNAs; osteoblast differentiation; proliferation; bone formation;
   bone strength; trabecular microarchitecture
ID OSTEOGENIC DIFFERENTIATION; CANCER CELLS; MORPHOGENETIC PROTEINS;
   INDUCED APOPTOSIS; UP REGULATION; EXPRESSION; SURVIVIN; MEDICARPIN;
   MECHANISM; PATHWAYS
AB MicroRNAs (miRNAs) are short non coding RNAs that interfere with translation of specific target mRNAs and thereby regulate diverse biological processes. Recent studies have suggested that miRNAs might have a role in osteoblast differentiation and bone formation. Here, we show that miR 542 3p, a well characterized tumor suppressor whose downregulation is tightly associated with tumor progression via C src related oncogenic pathways, inhibits osteoblast proliferation and differentiation. miRNA array profiling in Medicarpin (a pterocarpan with proven bone forming effects) induced mice calvarial osteoblast cells and further validation by quantitative real time PCR revealed that miR 542 3p was downregulated during osteoblast differentiation. Over expression of miR 542 3p inhibited osteoblast differentiation, whereas inhibition of miR 542 3p function by anti miR 542 3p promoted expression of osteoblast specific genes, alkaline phosphatase activity and matrix mineralization. Target prediction analysis tools and experimental validation by luciferase 3' UTR reporter assay identified BMP 7 (bone morphogenetic protein 7) as a direct target of miR 542 3p. It was seen that over expression of miR 542 3p leads to repression of BMP 7 and inhibition of BMP 7/PI3K  survivin signaling. This strongly suggests that miR 542 3p suppresses osteogenic differentiation and promotes osteoblast apoptosis by repressing BMP 7 and its downstream signaling. Furthermore, silencing of miR 542 3p led to increased bone formation, bone strength and improved trabecular microarchitecture in sham and ovariectomized (Ovx) mice. Although miR 542 3p is known to be a tumor repressor, we have identified second complementary function of miR 542 3p where it inhibits BMP 7 mediated osteogenesis. Our findings suggest that pharmacological inhibition of miR 542 3p by anti miR 542 3p could represent a therapeutic strategy for enhancing bone formation in vivo.
C1 [Kureel, J.; Dixit, M.; Tyagi, A. M.; Mansoori, M. N.; Srivastava, K.; Trivedi, R.; Singh, D.] Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Kureel, J.; Dixit, M.; Tyagi, A. M.; Mansoori, M. N.; Srivastava, K.; Trivedi, R.; Singh, D.] Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Lucknow 226031, Uttar Pradesh, India.
   [Raghuvanshi, A.; Maurya, R.; Goel, A.] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI)
RP Singh, D (通讯作者)，Div Endocrinol, BS 10 1,Sect 10, Lucknow 226031, Uttar Pradesh, India.
EM divya_singh@cdri.res.in
RI ; Singh, Divya/IUM 7944 2023; Malik, Abdul/AAX 5715 2020; maurya,
   rakesh/AAV 7598 2021
OI Goel, Atul/0000 0003 2758 2461; SRIVASTAVA, KAMINI/0000 0002 3928 0885;
   Malik, Abdul/0000 0001 9012 5779; 
FU Council of Scientific and Industrial Research; Department of
   Biotechnology, Government of India; Centre for Research in Anabolic
   Skeletal Targets in Health and Illness (ASTHI), Council of Scientific
   and Industrial Research, Department of Biotechnology (DBT), Department
   of Science and Technology (DST), Government of India
FX Fellowship grants from the Council of Scientific and Industrial Research
   (JK, KS, MNM, AMT and AR), Department of Biotechnology (MD), Government
   of India are acknowledged. Supporting grants: Centre for Research in
   Anabolic Skeletal Targets in Health and Illness (ASTHI), Council of
   Scientific and Industrial Research, Department of Biotechnology (DBT),
   Department of Science and Technology (DST), Government of India. CDRI
   Communication number: 8604.
CR Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242
   Bhargavan B, 2012, J NUTR BIOCHEM, V23, P27, DOI 10.1016/j.jnutbio.2010.11.002
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Dong J, 2013, J CELL BIOCHEM, V114, P2738, DOI 10.1002/jcb.24622
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Guo JW, 2012, J BONE MINER RES, V27, P1607, DOI 10.1002/jbmr.1597
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756 3282(02)00874 8
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hu R, 2010, EXPERT OPIN THER TAR, V14, P1109, DOI 10.1517/14728222.2010.512916
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Lechler P, 2011, CALCIFIED TISSUE INT, V89, P211, DOI 10.1007/s00223 011 9508 y
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Oneyama C, 2012, ONCOGENE, V31, P1623, DOI 10.1038/onc.2011.367
   Pandey R, 2010, MENOPAUSE, V17, P602, DOI 10.1097/gme.0b013e3181d0f7f0
   Sato MM, 2009, BIOCHEM BIOPH RES CO, V383, P125, DOI 10.1016/j.bbrc.2009.03.142
   Shimizu T, 2012, BIOCHEM BIOPH RES CO, V417, P869, DOI 10.1016/j.bbrc.2011.12.064
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Tyagi AM, 2012, OSTEOPOROSIS INT, V23, P1151, DOI 10.1007/s00198 011 1650 x
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Wang JY, 2009, EXP BIOL MED, V234, P566, DOI 10.3181/0811 RM 326
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008 5472.CAN 05 4456
   Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang XD, 2014, DIABETES, V63, P934, DOI 10.2337/db13 1422
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
NR 41
TC 136
Z9 150
U1 2
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2014
VL 5
AR e1050
DI 10.1038/cddis.2014.4
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AC0ZJ
UT WOS:000332223700007
PM 24503542
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, X
   Zhi, X
   Pan, PP
   Cui, J
   Cao, LH
   Weng, WZ
   Zhou, QR
   Wang, L
   Zhai, X
   Zhao, Q
   Hu, HG
   Huang, BT
   Su, JC
AF Chen, Xiao
   Zhi, Xin
   Pan, Panpan
   Cui, Jin
   Cao, Liehu
   Weng, Weizong
   Zhou, Qirong
   Wang, Lin
   Zhai, Xiao
   Zhao, Qingiie
   Hu, Honggang
   Huang, Biaotong
   Su, Jiacan
TI Matrine prevents bone loss in ovariectomized mice by inhibiting
   RANKL induced osteoclastogenesis
SO FASEB JOURNAL
LA English
DT Article
DE postmenopausal osteoporosis; NFATc1; osteoclasts
ID NF KAPPA B; DEFICIENCY INDUCED OSTEOPOROSIS; RECEPTOR ACTIVATOR;
   ESTROGEN DEFICIENCY; SIGNALING PATHWAYS; POSTMENOPAUSAL OSTEOPOROSIS;
   PROINFLAMMATORY CYTOKINES; DIFFERENTIATION; INFLAMMATION; LIGAND
AB Osteoporosis is a metabolic bone disease characterized by decreased bone density and strength due to excessive loss of bone protein and mineral content. The imbalance between osteogenesis by osteoblasts and osteoclastogenesis by osteoclasts contributes to the pathogenesis of postmenopausal osteoporosis. Estrogen withdrawal leads to increased levels of proinflammatory cytokines. Overactivated osteoclasts by inflammation play a vital role in the imbalance. Matrine is an alkaloid found in plants from the Sophora genus with various pharmacological effects, including anti inflammatory activity. Here we demonstrate that matrine significantly prevented ovariectomy induced bone loss and inhibited osteoclastogenesis in vivo with decreased serum levels of TRAcp5b, TNF alpha, and IL 6. In vitro matrine significantly inhibited osteoclast differentiation induced by receptor activator for NF kappa B ligand (RANKL) and M CSF in bone marrow monocytes and RAW264.7 cells as demonstrated by tartrate resistant acid phosphatase (TRAP) staining and actin ring formation as well as bone resorption through pit formation assays. For molecular mechanisms, matrine abrogated RANKL induced activation of NF kappa B, AKT, and MAPK pathways and suppressed osteoclastogenesis related marker expression, including matrix metalloproteinase 9, NFATc1, TRAP, C Src, and cathepsin K. Our study demonstrates that matrine inhibits osteoclastogenesis through modulation of multiple pathways and that matrine is a promising agent in the treatment of osteoclast related diseases such as osteoporosis.
C1 [Chen, Xiao; Pan, Panpan; Cao, Liehu; Weng, Weizong; Zhou, Qirong; Wang, Lin; Zhai, Xiao; Su, Jiacan] Second Mil Med Univ, Dept Orthoped Trauma, Shanghai Changhai Hosp, Shanghai, Peoples R China.
   [Zhi, Xin; Cui, Jin] Second Mil Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai, Peoples R China.
   [Zhao, Qingiie; Hu, Honggang] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
   [Chen, Xiao; Pan, Panpan; Cao, Liehu; Weng, Weizong; Zhou, Qirong; Wang, Lin; Zhao, Qingiie; Hu, Honggang; Huang, Biaotong; Su, Jiacan] China South Korea Bioengn Ctr, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Su, JC (通讯作者)，Second Mil Med Univ, Dept Orthoped, Changhai Hosp, Changhai Rd, Shanghai 200433, Peoples R China.
EM drsujiacan@163.com
RI Wu, Xiaozhi/AAP 3954 2021; Pan, Panpan/GRJ 2514 2022; Cui,
   Jin/HDL 7327 2022; Su, Jiacan/N 7068 2019; Chen, Xiao/N 1298 2017
OI Su, Jiacan/0000 0001 7080 263X; Hu, Hong Gang/0000 0003 0577 3021; 
FU Shanghai Municipal Science and Technology Commission [15411950600]
FX The authors thank the Clear Med Trans Studio (Shanghai, China) for
   language polishing, Shanghai GeekBiotech (Shanghai, China) for technical
   support, Dr. J. Wang (Fudan University, Shanghai, China) for technical
   guidance, and Sir C. Liu for providing matrine. This work was supported
   by Shanghai Municipal Science and Technology Commission Key Program
   (15411950600). The authors declare no conflicts of interest.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Barlow DH, 2010, HUM REPROD UPDATE, V16, P761, DOI 10.1093/humupd/dmq008
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Janas A, 2017, N S ARCH PHARMACOL, V390, P175, DOI 10.1007/s00210 016 1295 6
   Jia M, 2015, BEST PRACT RES CL EN, V29, P557, DOI 10.1016/j.beem.2015.04.008
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Koide M, 2009, J BONE MINER RES, V24, P1469, DOI [10.1359/jbmr.090302, 10.1359/JBMR.090302]
   Lee EJ, 2014, PHYTOMEDICINE, V21, P1208, DOI 10.1016/j.phymed.2014.04.002
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li MJ, 2015, INT J MOL MED, V36, P1335, DOI 10.3892/ijmm.2015.2330
   Ma J, 2015, J AM COLL CARDIOL, V66, pC23, DOI 10.1016/j.jacc.2015.06.1115
   Pino AM, 2010, J BONE MINER RES, V25, P492, DOI 10.1359/jbmr.090802
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Novella S, 2012, ARTERIOSCL THROM VAS, V32, P2035, DOI 10.1161/ATVBAHA.112.250308
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   Shao HM, 2013, ONCOL LETT, V6, P517, DOI 10.3892/ol.2013.1399
   Shukla P, 2017, J BIOL CHEM, V292, P4686, DOI 10.1074/jbc.M116.764779
   Sun DQ, 2016, BIOCHEM BIOPH RES CO, V477, P83, DOI 10.1016/j.bbrc.2016.06.024
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu M, 2012, BRAIN RES, V1454, P48, DOI 10.1016/j.brainres.2012.03.020
   Xu WH, 2014, HEPATOLOGY, V60, P648, DOI 10.1002/hep.27138
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zeng XY, 2015, BRIT J PHARMACOL, V172, P4303, DOI 10.1111/bph.13209
   Zhang B, 2011, EUR J PHARM SCI, V44, P573, DOI 10.1016/j.ejps.2011.09.020
   Zhang PP, 2016, CANCER LETT, V376, P95, DOI 10.1016/j.canlet.2016.01.011
   Zhou Y, 2009, MED HYPOTHESES, V73, P83, DOI 10.1016/j.mehy.2009.01.029
NR 49
TC 74
Z9 84
U1 1
U2 49
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2017
VL 31
IS 11
BP 4855
EP 4865
DI 10.1096/fj.201700316R
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA FK3PP
UT WOS:000413398500017
PM 28739641
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Duan, W
   Chen, Y
   Shan, JL
   Li, Q
AF Duan, Wei
   Chen, Yu
   Shan, Jinlu
   Li, Qian
TI Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma
   Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor
   Inflammation Based on Transcriptional Spectrum Analysis and Drug Library
   Screening
SO RECENT PATENTS ON ANTI CANCER DRUG DISCOVERY
LA English
DT Article
DE Osteosarcoma; inflammatory reaction; CSF3R; survival analysis; drug
   virtual screening; molecular dynamics simulation
ID CANCER; MACROPHAGES; SURVIVAL
AB Background Osteosarcoma (OS) is a common primary malignant bone tumor that mainly occurs in children and adolescents. The use of IL 8 inhibitor compounds has been reported in patents, which can be used to treat and/or prevent osteosarcoma, but the pathogenesis of osteosarcoma remains to be investigated. At present, osteoblasts and osteoclasts play an important role in the occurrence and development of OS. However, the relationship between osteoblasts and osteoclasts in the specific participation mechanism and inflammatory response of OS patients has not been further studied. Methods The transcriptome, clinical data, and other data related to OS were downloaded from the GEO database to analyze them with 200 known inflammatory response genes. We set the screening conditions as p < 0.05 and | log(2)FC| > 0.50, screened the differentially expressed genes (DEGs) related to OS, tested the correlation coefficient between the OS INF gene and clinical risk, and analyzed the survival prognosis. We further enriched and analyzed the DEGs and inflammatory response genes of OS with GO/KEGG to explore the potential biological function and signal pathway mechanism of OS inflammatory response genes. Moreover, the virtual screening of drug sensitivity of OS based on the FDA drug library was also carried out to explore potential therapeutic drugs targeted to regulate OS osteogenesis and osteoclast inflammation, and finally, the molecular dynamics simulation verification of OS core protein and potential drugs was carried out to explore the binding stability and mechanism between potential drugs and core protein. Results Through differential analysis of GSE39058, GSE36001, GSE87624, and three other data sets closely related to OS osteoblasts and osteoclasts, we found that there was one up regulated gene (CADM1) and one down regulated gene (PHF15) related to OS. In addition, GSEA enrichment analysis of the DEGs of OS showed that it was mainly involved in the progress of OS through biological functions, such as oxidative photosynthesis, acute junction, and epithelial mesenchymal transition. The enrichment analysis of OS DEGs revealed that they mainly affect the occurrence and progress of OS by participating in the regulation of the actin skeleton, PI3K Akt signal pathway, complement and coagulation cascade. According to the expression of CSF3R in OS patients, a risk coefficient model and a diagnostic model were established. It was found that the more significant the difference in the CSF3R gene in OS patients, the greater the risk coefficient of disease (p < 0.05). The AUC under the curve of the CSF3R gene was greater than 0.65, which had a good diagnostic significance for OS. The above results showed that the prognosis risk gene CSF3R related to OS inflammation was closely related to the survival status of OS patients. Finally, through the virtual screening of the ZINC drug library and molecular dynamics simulation, it was found that the docking model formed by the core protein CSF3R and the compounds, Leucovorin and Methotrexate, were the most stable, which revealed that the compounds Leucovorin and Methotrexate might play a role in the treatment of OS by combining with the inflammatory response related factor CSF3R of OS. Conclusion CSF3R participates in the occurrence and development of OS bone destruction by regulating the inflammatory response of osteoblasts and osteoclasts and can affect the survival prognosis of OS patients.
C1 [Duan, Wei] Yangtze Univ, Jingzhou Cent Hosp, Clin Med Coll 2, Dept Oncol, Jingzhou 434020, Hubei, Peoples R China.
   [Chen, Yu] Univ Elect Sci & Technol China, Mianyang Cent Hosp, Sch Med, Dept Radiol, Mianyang 621000, Peoples R China.
   [Shan, Jinlu; Li, Qian] Army Med Univ, Daping Hosp, Canc Ctr, Chongqing 400042, Peoples R China.
C3 Yangtze University; University of Electronic Science & Technology of
   China; Army Medical University
RP Shan, JL; Li, Q (通讯作者)，Army Med Univ, Daping Hosp, Canc Ctr, Chongqing 400042, Peoples R China.
EM lulu7476@sina.com; liqian19830429@163.com
RI Chen, Yu/GVS 5636 2022
FX Declared none.
CR Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018 015 1918 y
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140 6736(00)04046 0
   Chen CL, 2021, CANCER LETT, V500, P1, DOI 10.1016/j.canlet.2020.12.024
   Chen GY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202896
   Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326 6066.CIR 14 0209
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Franceschini N, 2020, VIRCHOWS ARCH, V476, P147, DOI 10.1007/s00428 019 02683 w
   Fujiyoshi S, 2020, HEPATOL RES, V50, P598, DOI 10.1111/hepr.13479
   Hu XY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.983606
   Jettoo P, 2019, J ORTHOP SURG HONG K, V27, DOI 10.1177/2309499019838293
   Jiang YH, 2017, ONCOTARGET, V8, P97571, DOI 10.18632/oncotarget.18813
   Kelleher FC, 2017, J ADOLESC YOUNG ADUL, V6, P396, DOI 10.1089/jayao.2016.0078
   Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406
   Li HY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02146 8
   Li XC, 2015, TUMOR BIOL, V36, P5663, DOI 10.1007/s13277 015 3240 6
   Meyers PA, 2011, CANCER AM CANCER SOC, V117, P1736, DOI 10.1002/cncr.25744
   Mizushima E, 2020, CANCER SCI, V111, P36, DOI 10.1111/cas.14229
   Ni SJ, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606765
   Rathore R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061182
   Roberts R.D., 2021, U.S. Patent
   Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008 5472.CAN 17 0576
   Siegel RL, 2018, CA CANCER J CLIN, V68, P7, DOI [10.3322/caac.21551, 10.3322/caac.21442]
   Sipos F, 2016, WORLD J GASTROENTERO, V22, P7938, DOI 10.3748/wjg.v22.i35.7938
   Su L, 2019, ANN HEMATOL, V98, P1641, DOI 10.1007/s00277 019 03699 7
   Widemann BC, 2006, ONCOLOGIST, V11, P694, DOI 10.1634/theoncologist.11 6 694
   Xiao X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0880 6
   Yin CD, 2021, BIOENGINEERED, V12, P172, DOI 10.1080/21655979.2020.1864096
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yu XB, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 021 00600 w
   Zhang W, 2016, CHINESE MED J PEKING, V129, P2530, DOI 10.4103/0366 6999.192781
   Zhang YC, 2019, INT J CANCER, V145, P1068, DOI 10.1002/ijc.32207
NR 31
TC 0
Z9 0
U1 2
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 8928
EI 2212 3970
J9 RECENT PAT ANTI CANC
JI Recent Patents Anti Canc. Drug Discov.
PY 2024
VL 19
IS 5
BP 635
EP 651
DI 10.2174/0115748928259095231010055507
PG 17
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA YV4S4
UT WOS:001271253200001
PM 37877147
DA 2025 08 17
ER

PT J
AU Skubitz, KM
AF Skubitz, Keith M.
TI Giant Cell Tumor of Bone: Current Treatment Options
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Giant cell tumor; GCTB; Bone; Denosumab; Bisphosphonate; Surgery;
   Radiation therapy; Chemotherapy; Paracrine signaling; RANK; RANKL;
   Monoclonal antibody; Osteoclast
ID RECEPTOR ACTIVATOR; ZOLEDRONIC ACID; CONGENITAL OSTEOPETROSIS;
   RADIATION THERAPY; GENE EXPRESSION; PAGETS DISEASE; FREE SURVIVAL;
   KAPPA B; DENOSUMAB; TERM
AB Giant cell tumor of bone (GCTB) comprises up to 20 % of benign bone tumors in the US. GCTB are typically locally aggressive, but metastasize to the lung in 5 % of cases. Malignant transformation occurs in a small percentage of cases, usually following radiation therapy. Historically, GCTB have been treated primarily with surgery. When the morbidity of surgery would be excessive, radiation therapy may achieve local control. In most cases the primary driver of the malignant cell appears to be a mutation in H3F3A leading to a substitution of Gly34 to either Trp or Leu in Histone H3.3. This change presumably alters the methylation of the protein, and thus, its effect on gene expression. The malignant stromal cells of GCTB secrete RANKL, which recruits osteoclast precursors to the tumor and stimulates their differentiation to osteoclasts. The elucidation of the biology of GCTB led to trials of the anti RANKL monoclonal antibody denosumab in this disease, with a clear demonstration of beneficial clinical effect. Surgery remains the primary treatment of localized GCTB. When surgery is not possible or would be associated with excessive morbidity, denosumab is a good treatment option. The optimal length of treatment and schedule of denosumab is unknown, but recurrences after apparent complete responses have been observed after stopping denosumab, and long term follow up of denosumab treatment may reveal unrecognized effects. The role of denosumab in the preoperative or adjuvant setting will require clinical trials. In some cases local radiation therapy may be useful, although long term effects should be considered.
C1 [Skubitz, Keith M.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
   [Skubitz, Keith M.] Univ Minnesota Hosp & Clin, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota Hospital
RP Skubitz, KM (通讯作者)，Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
EM skubi001@umn.edu
OI Skubitz, Keith/0000 0002 0690 9595
FU Amgen; Novartis; GSK; Ariad/Merck; Celgene; Cell Therapeutics; Systems
   Medicine; Infinity; Schering Plough; Bayer; Pfizer; Daiichi
FX Keith Skubitz has been a consultant for Amgen, Ariad/Merck, Novartis,
   Onyxx, Johnson & Johnson, Pfizer/Schering Plough, Systems Medicine, and
   Seattle Genetics; owns publicly traded stock in Johnson & Johnson; has
   received research funding from Amgen, Novartis, GSK, Ariad/Merck,
   Celgene, Cell Therapeutics, Systems Medicine, Infinity, Schering Plough,
   Bayer, Pfizer, and Daiichi; and provided expert testimony on the role of
   bisphosphonates in osteonecrosis of the jaw.
CR Atkins GJ, 2000, J BONE MINER RES, V15, P640, DOI 10.1359/jbmr.2000.15.4.640
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bloodgood JC, 1912, ANN SURG, V56, P210, DOI 10.1097/00000658 191208000 00002
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Broto JM, 2014, ACTA ONCOL IN PRESS
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Caudell JJ, 2003, INT J RADIAT ONCOL, V57, P158, DOI 10.1016/S0360 3016(03)00416 4
   Chaudhary P, 2011, ONKOLOGIE, V34, P702, DOI 10.1159/000334549
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Cooper A, 1818, SURGICAL ESSAYS, P167
   Dominkus M, 2006, INT ORTHOP, V30, P499, DOI 10.1007/s00264 006 0204 x
   Dürr HR, 1999, EUR J SURG ONCOL, V25, P610, DOI 10.1053/ejso.1999.0716
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Feigenberg SJ, 2003, CLIN ORTHOP RELAT R, P207, DOI 10.1097/01.blo.0000069890.31220.b4
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Gille O, 2012, SPINE, V37, pE396, DOI 10.1097/BRS.0b013e31823ed70d
   GOLDRING SR, 1987, J CLIN INVEST, V79, P483, DOI 10.1172/JCI112838
   Gupta R, 2008, ANN DIAGN PATHOL, V12, P239, DOI 10.1016/j.anndiagpath.2007.09.002
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hosalkar HS, 2007, SPINE, V32, P1107, DOI 10.1097/01.brs.0000261558.94247.8d
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   JACOBS TP, 1979, CANCER AM CANCER SOC, V44, P742, DOI 10.1002/1097 0142(197908)44:2<742::AID CNCR2820440247>3.0.CO;2 U
   KAISER U, 1993, J CANCER RES CLIN, V119, P301, DOI 10.1007/BF01212729
   Karras NA, 2013, J CLIN ONCOL, V31, pE200, DOI 10.1200/JCO.2012.46.4255
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lin PP, 2002, CANCER AM CANCER SOC, V95, P1317, DOI 10.1002/cncr.10803
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Malawer MM, 1999, CLIN ORTHOP RELAT R, P176
   MALONEY WJ, 1989, CLIN ORTHOP RELAT R, P208
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Niu XH, 2012, J BONE JOINT SURG AM, V94A, P461, DOI 10.2106/JBJS.J.01922
   Osaka S, 1997, CLIN ORTHOP RELAT R, P253
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Rendina D, 2004, CLIN ORTHOP RELAT R, P218, DOI 10.1097/00000118702.46373.e3
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   ROCK MG, 1986, J BONE JOINT SURG AM, V68A, P1073, DOI 10.2106/00004623 198668070 00016
   Roeder F, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748 717X 5 18
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Ruka W, 2010, INT J RADIAT ONCOL, V78, P494, DOI 10.1016/j.ijrobp.2009.07.1704
   Shi WY, 2013, AM J CLIN ONCOL CANC, V36, P505, DOI 10.1097/COC.0b013e3182568fb6
   Siebenrock KA, 1998, J BONE JOINT SURG BR, V80B, P43, DOI 10.1302/0301 620X.80B1.7875
   Skubitz KM, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 46
   Skubitz KM, 2004, J LAB CLIN MED, V144, P193, DOI 10.1016/j.lab.2004.06.005
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   STEWART DJ, 1995, AM J CLIN ONCOL CANC, V18, P144, DOI 10.1097/00000421 199504000 00010
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Thomas DM, 2009, CURR OPIN ONCOL, V21, P338, DOI 10.1097/CCO.0b013e32832c951d
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   WALKER DG, 1975, J EXP MED, V142, P651, DOI 10.1084/jem.142.3.651
   WALKER DG, 1972, ENDOCRINOLOGY, V91, P916, DOI 10.1210/endo 91 4 916
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weiss S., 2002, Epithelioid haemangioendothelioma. Pathology & Genetics Tumours of Soft Tissue & Bone
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Zhen W, 2004, J BONE JOINT SURG BR, V86B, P212, DOI 10.1302/0301 620X.86B2.14362
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 69
TC 72
Z9 80
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527 2729
EI 1534 6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD SEP
PY 2014
VL 15
IS 3
BP 507
EP 518
DI 10.1007/s11864 014 0289 1
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AO6AK
UT WOS:000341429500014
PM 24788576
DA 2025 08 17
ER

PT J
AU Pivonka, P
   Zimak, J
   Smith, DW
   Gardiner, BS
   Dunstan, CR
   Sims, NA
   Martin, TJ
   Mundy, GR
AF Pivonka, Peter
   Zimak, Jan
   Smith, David W.
   Gardiner, Bruce S.
   Dunstan, Colin R.
   Sims, Natalie A.
   Martin, T. John
   Mundy, Gregory R.
TI Theoretical investigation of the role of the RANK RANKL OPG system in
   bone remodeling
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Bone remodeling; Osteoblast osteoclast interactions; RANK RANKL OPG
   pathway; Cell population dynamics model; RANKL/OPG defects; Therapeutic
   strategies; Optimization
ID OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND;
   CLINICAL IMPLICATIONS; RESORPTION; MODEL; MICE; OSTEOPOROSIS;
   OSTEOBLAST; ACTIVATION
AB The RANK RANKL OPG system is an essential signaling pathway involved in bone cell cell communication, with ample evidence that modification of the RANK RANKL OPG signaling pathway has major effects on bone remodeling. The first focus of this paper is to demonstrate that a theoretical model of bone cell cell interactions is capable of qualitatively reproducing changes in bone associated with RANK RANKL OPG signaling. To do this we consider either biological experiments or bone diseases related to receptor and/or ligand deficiencies, including RANKL over expression, ablation of OPG production and/or RANK receptor modifications. The second focus is to investigate a wide range of possible therapeutic strategies for re establishing bone homeostasis for various pathologies of the RANK RANKL OPG pathway. These simulations indicate that bone diseases associated with the RANK RANKL OPG pathway are very effective in triggering bone resorption compared to bone formation. These results align with Hofbauer's "convergence hypothesis", which states that catabolic bone diseases most effectively act through the RANK RANKL OPC system. Additionally, we demonstrate that severity of catabolic bone diseases strongly depends on how many components of this pathway are affected. Using optimization algorithms and the theoretical model, we identify a variety of successful "virtual therapies" for different disease states using both single and dual therapies. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Pivonka, Peter] Univ Western Australia, Sch Comp Sci & Software Engn, Engn Computat Biol Grp, Nedlands, WA 6009, Australia.
   [Zimak, Jan] Univ Melbourne, Dept Biochem, Melbourne, Vic 3010, Australia.
   [Dunstan, Colin R.] Univ Sydney, Dept Biomed Engn, Sydney, NSW 2006, Australia.
   [Sims, Natalie A.; Martin, T. John] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
   [Sims, Natalie A.; Martin, T. John] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
   [Mundy, Gregory R.] Vanderbilt Univ, Ctr Bone Biol, Nashville, TN 37232 USA.
C3 University of Western Australia; University of Melbourne; University of
   Sydney; NSW Health; St Vincents Hospital Sydney; University of
   Melbourne; St. Vincent's Institute of Medical Research; St Vincent's
   Health; St Vincent's Hospital Melbourne; NSW Health; St Vincents
   Hospital Sydney; University of Melbourne; St Vincent's Health; St
   Vincent's Hospital Melbourne; Vanderbilt University
RP Pivonka, P (通讯作者)，Univ Western Australia, Sch Comp Sci & Software Engn, Engn Computat Biol Grp, Nedlands, WA 6009, Australia.
EM peter.pivonka@uwa.edu.au
RI Dunstan, Colin/G 6214 2013; Gardiner, Bruce/C 8593 2012; Smith,
   David/H 5856 2014; Pivonka, Peter/AAL 1053 2021; Sims,
   Natalie/A 7192 2012
OI Dunstan, Colin/0000 0001 7586 4071; Gardiner, Bruce/0000 0001 8770 5908;
   Pivonka, Peter/0000 0001 9183 530X; Smith, David/0000 0003 4864 0288;
   Sims, Natalie/0000 0003 1421 8468
CR Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Bell NH, 2003, J CLIN INVEST, V111, P1120, DOI 10.1172/JCI200318358
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Defranoux NA, 2005, J BONE MINER RES, V20, P1079, DOI 10.1359/JBMR.050401
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Kapur RP, 2004, J BONE MINER RES, V19, P1689, DOI 10.1359/JBMR.040713
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Yamazaki H, 2005, J ELECTRON MICROSC, V54, P467, DOI 10.1093/jmicro/dfi066
NR 25
TC 91
Z9 118
U1 5
U2 40
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022 5193
J9 J THEOR BIOL
JI J. Theor. Biol.
PD JAN 21
PY 2010
VL 262
IS 2
BP 306
EP 316
DI 10.1016/j.jtbi.2009.09.021
PG 11
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA 557CS
UT WOS:000274646700012
PM 19782692
DA 2025 08 17
ER

PT J
AU Breitkreutz, I
   Raab, MS
   Vallet, S
   Hideshima, T
   Raje, N
   Chauhan, D
   Munshi, NC
   Richardson, PG
   Anderson, KC
AF Breitkreutz, Iris
   Raab, Marc S.
   Vallet, Sonia
   Hideshima, Teru
   Raje, Noopur
   Chauhan, Dharminder
   Munshi, Nikhil C.
   Richardson, Paul G.
   Anderson, Kenneth C.
TI Targeting MEK1/2 blocks osteoclast differentiation, function and
   cytokine secretion in multiple myeloma
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE multiple myeloma; osteoclasts; bone disease; myeloma therapy; new drug
   development
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; AZD6244 ARRY 142886;
   ALPHA(V)BETA(3) INTEGRIN; OSTEOLYTIC LESIONS; RECEPTOR ACTIVATOR; BONE
   DESTRUCTION; GENE EXPRESSION; CELL GROWTH; IN VITRO; SURVIVAL
AB Osteolytic bone disease in multiple myeloma (MM) is associated with upregulation of osteoclast (OCL) activity and constitutive inhibition of osteoblast function. The extracellular signal regulated kinase 1/2 (ERK1/2) pathway mediates OCL differentiation and maturation. We hypothesized that inhibition of ERK1/2 could prevent OCL differentiation and downregulate OCL function. It was found that AZD6244, a mitogen activated or extracellular signal regulated protein kinase (MEK) inhibitor, blocked OCL differentiation and formation in a dose dependent manner, evidenced by decreased alpha V beta 3 integrin expression and tartrate resistant acid phosphatase positive (TRAP+) cells. Functional dentine disc cultures showed inhibition of OCL induced bone resorption by AZD6244. Major MM growth and survival factors produced by OCLs including B cell activation factor (BAFF) and a proliferation inducing ligand (APRIL), as well as macrophage inflammatory protein (MIP 1 alpha), which mediates OCL differentiation and MM, were also significantly inhibited by AZD6244. In addition to ERK inhibition, NFATc1 (nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1) and c fos were both downregulated, suggesting that AZD6244 targets a later stage of OCL differentiation. These results indicate that AZD6244 inhibits OCL differentiation, formation and bone resorption, thereby abrogating paracrine MM cell survival in the bone marrow microenvironment. The present study therefore provides a preclinical rationale for the evaluation of AZD6244 as a potential new therapy for patients with MM.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard Medical School
RP Anderson, KC (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.
EM kenneth_anderson@dfci.harvard.edu
RI Munshi, Nikhil/ABE 2338 2021; Anderson, Kenneth/ACP 5073 2022; Vallet,
   Sonia/AHE 3935 2022
OI Vallet, Sonia/0000 0003 0146 8089
FU PHS HHS [R01 50947, P01 78378] Funding Source: Medline
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Anderson KC, 2001, CANCER J, V7, pS19
   BLACK K, 1991, ENDOCRINOLOGY, V128, P2657, DOI 10.1210/endo 128 5 2657
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Elsegood CL, 2006, INT J BIOCHEM CELL B, V38, P1518, DOI 10.1016/j.biocel.2006.02.011
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Faccio R, 2002, J CELL SCI, V115, P2919
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood 2002 06 1874
   Huynh H, 2007, MOL CANCER THER, V6, P138, DOI 10.1158/1535 7163.MCT 06 0436
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kim HH, 2003, EXP CELL RES, V289, P368, DOI 10.1016/S0014 4827(03)00288 X
   Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377
   Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Mackay F, 2004, CURR OPIN PHARMACOL, V4, P347, DOI 10.1016/j.coph.2004.02.009
   Martini G, 2006, HAEMATOLOGICA, V91, P1720
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood 2004 11 4512
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood 2003 06 1984
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Nakamura I, 1999, J CELL SCI, V112, P3985
   Nishioka C, 2007, LEUKEMIA, V21, P1308, DOI 10.1038/sj.leu.2404647
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Roodman G David, 2004, Cancer Treat Res, V118, P83
   Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498
   Sudhoff H, 2003, ANN OTO RHINOL LARYN, V112, P780, DOI 10.1177/000348940311200907
   Tai YT, 2006, BLOOD, V108, p987A, DOI 10.1182/blood.V108.11.3460.3460
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008 5472.CAN 06 0190
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889 8588(05)70413 5
   Terpos E, 2005, LEUKEMIA LYMPHOMA, V46, P1699, DOI 10.1080/10428190500175049
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Uneda S, 2003, BRIT J HAEMATOL, V120, P53, DOI 10.1046/j.1365 2141.2003.04040.x
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078 0432.CCR 06 1150
   Zhou Yamei, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P317
NR 47
TC 36
Z9 37
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1048
EI 1365 2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2007
VL 139
IS 1
BP 55
EP 63
DI 10.1111/j.1365 2141.2007.06747.x
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 209WN
UT WOS:000249418800007
PM 17854307
OA Bronze
DA 2025 08 17
ER

PT J
AU Abe, M
AF Abe, Masahiro
TI Targeting the interplay between myeloma cells and the bone marrow
   microenvironment in myeloma
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Osteoclast; Osteoblast; Angiogenesis; Myeloma niche
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; MESENCHYMAL STEM CELLS;
   RESISTANCE CAM DR; MULTIPLE MYELOMA; GROWTH FACTOR; STROMAL CELLS;
   RECEPTOR ACTIVATOR; GENE EXPRESSION; POTENTIAL ROLE; OSTEOBLAST
   DIFFERENTIATION
AB Cellular interplay in the bone marrow (BM) microenvironment in multiple myeloma (MM) mediates MM growth and the formation of bone destructive lesions. MM cells show enhanced osteoclastogenesis, and stimulate angiogenesis in concert with BM stromal cells and osteoclasts, whereas they suppress osteoblastic differentiation, leading to devastating bone destruction and the rapid loss of bone. Importantly, osteoclasts, vascular endothelial cells, and BM stromal cells with defective osteoblastic differentiation create a cellular microenvironment suitable for MM growth and survival and confer a drug resistance to MM cells, which can be construed as the "MM niche". Therefore, the MM niche must be targeted and disrupted to improve the efficacy of anti tumor treatment and prevent the progression of bone disease in MM. Clarifying molecular mechanisms leading to the formation of the MM niche along with bone disease will help in the development of novel approaches targeting the interplay between MM cells and the BM microenvironment.
C1 Univ Tokushima, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan.
C3 Tokushima University
RP Abe, M (通讯作者)，Univ Tokushima, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI Abe, Masahiro/AAJ 3032 2021
FU Ministry of Education, Culture, Science and Sports of Japan; Ministry of
   Health, Labor and Welfare of Japan; National Cancer Center
FX This work was supported in part by a Grant in aid for Scientific (C)
   from the Ministry of Education, Culture, Science and Sports of Japan, a
   Grant in aid for Cancer Research from the Ministry of Health, Labor and
   Welfare of Japan, and National Cancer Center Research and Development
   Fund.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Abildgaard N, 2003, BRIT J HAEMATOL, V120, P235, DOI 10.1046/j.1365 2141.2003.04050.x
   Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288
   Anderson KC, 2011, ANNU REV PATHOL MECH, V6, P249, DOI 10.1146/annurev pathol 011110 130249
   Asano J, 2011, LEUKEMIA, V25, P1182, DOI 10.1038/leu.2011.60
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Brocke Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood 2003 04 1048
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chantry AD, J BONE MINER RES, V25, P2633
   Choi SJ, 2000, BLOOD, V96, P671
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200
   Dalton WS, 2003, CANCER TREAT REV, V29, P11, DOI 10.1016/S0305 7372(03)00077 X
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Delforge M, 2011, EUR J HAEMATOL, V86, P372, DOI 10.1111/j.1600 0609.2011.01599.x
   Dhodapkar KM, 2008, BLOOD, V112, P2878, DOI 10.1182/blood 2008 03 143222
   Dhodapkar MV, 1998, BRIT J HAEMATOL, V103, P530, DOI 10.1046/j.1365 2141.1998.00976.x
   Drew M, 1996, LEUKEMIA RES, V20, P619, DOI 10.1016/0145 2126(95)00097 6
   Dun XY, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 247
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Feliers D, 1999, BRIT J HAEMATOL, V104, P715, DOI 10.1046/j.1365 2141.1999.01243.x
   Fonseca R, 2000, BRIT J HAEMATOL, V109, P24, DOI 10.1046/j.1365 2141.2000.01960.x
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Ge Y, 2006, BRIT J HAEMATOL, V133, P83, DOI 10.1111/j.1365 2141.2006.05976.x
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Haaber J, 2008, BRIT J HAEMATOL, V140, P25, DOI 10.1111/j.1365 2141.2007.06871.x
   Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood 2004 09 3706
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365 2141.2004.04864.x
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Hjertner O, 1999, BLOOD, V94, P3883
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Isaac M, 2011, DRUG RESIST UPDAT, V19
   Jakob C, 2006, EUR J CANCER, V42, P1581, DOI 10.1016/j.ejca.2006.02.017
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Klein B, 2011, RECENT RESULTS CANC, V183, P39, DOI 10.1007/978 3 540 85772 3_3
   Kondo H, 2002, LEUKEMIA LYMPHOMA, V43, P919, DOI 10.1080/10428190290017123
   Kukreja A, 2009, BLOOD, V114, P3413, DOI 10.1182/blood 2009 03 211920
   Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood 2003 11 3811
   Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lee SE, 2011, EUR J HAEMATOL, V86, P83, DOI 10.1111/j.1600 0609.2010.01523.x
   Lemaire M, 2011, ADV CANCER RES, V110, P19, DOI 10.1016/B978 0 12 386469 7.00002 5
   Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008 5472.CAN 08 4285
   Menu Eline, 2009, Archives of Physiology and Biochemistry, V115, P49, DOI 10.1080/13813450902736583
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Miyamoto A, 1998, BIOCHEM BIOPH RES CO, V242, P703, DOI 10.1006/bbrc.1997.8046
   Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168 9525(97)01093 7
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood 2004 11 4512
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood 2003 06 1984
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Noonan K, 2010, BLOOD, V116, P3554, DOI 10.1182/blood 2010 05 283895
   Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood 2003 06 2043
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Sanz Rodríguez F, 1999, BRIT J HAEMATOL, V107, P825, DOI 10.1046/j.1365 2141.1999.01762.x
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008 5472.CAN 08 2419
   Bhatti SS, 2006, AM J HEMATOL, V81, P649, DOI 10.1002/ajh.20639
   Sprynski AC, 2009, BLOOD, V113, P4614, DOI 10.1182/blood 2008 07 170464
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008 5472.CAN 06 0190
   Takafuji V, 2007, ONCOGENE, V26, P6361, DOI 10.1038/sj.onc.1210463
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Teplyuk NM, 2009, J CELL BIOCHEM, V107, P144, DOI 10.1002/jcb.22108
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092 8674(89)90589 8
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Xie Y, 2008, J BIOL CHEM, V283, P3349, DOI 10.1074/jbc.M707773200
   Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2011, EUR J HAEMATOL, V86, P484, DOI 10.1111/j.1600 0609.2011.01602.x
   Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008 5472.CAN 04 1687
NR 109
TC 60
Z9 70
U1 0
U2 13
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0925 5710
EI 1865 3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD OCT
PY 2011
VL 94
IS 4
BP 334
EP 343
DI 10.1007/s12185 011 0949 x
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 850OQ
UT WOS:000297205400004
PM 22005835
DA 2025 08 17
ER

PT J
AU Xu, XF
   Han, Y
   Zhu, TX
   Fan, FX
   Wang, X
   Liu, YQ
   Luo, DS
AF Xu, Xuefeng
   Han, Yi
   Zhu, Tianxin
   Fan, Faxin
   Wang, Xin
   Liu, Yuqing
   Luo, Duosheng
TI The role of SphK/S1P/S1PR signaling pathway in bone metabolism
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoporosis; SphK/S1P/S1PR signaling pathway; Sphingosine 1 Phosphate;
   Sphingosine 1 Phosphate receptor
ID SPHINGOSINE 1 PHOSPHATE; OSTEOBLASTIC CELLS; OSTEOGENIC DIFFERENTIATION;
   RECEPTOR MODULATORS; MULTIPLE SCLEROSIS; GROWTH FACTOR; STEM CELLS;
   SPHINGOSINE 1 PHOSPHATE; KINASE; ACTIVATION
AB There are a large number of people worldwide who suffer from osteoporosis, which imposes a huge economic burden, so it is necessary to explore the underlying mechanisms to achieve better supportive and curative care outcomes. Sphingosine kinase (SphK) is an enzyme that plays a crucial role in the synthesis of sphingosine 1 phosphate (S1P). S1P with paracrine and autocrine activities that act through its cell surface S1P receptors (S1PRs) and intracellular signals. In osteoporosis, S1P is indispensable for both normal and disease conditions. S1P has complicated roles in regulating osteoblast and osteoclast, respectively, and there have been exciting developments in understanding how SphK/S1P/S1PR signaling regulates these processes in response to osteo porosis therapy. Here, we review the proliferation, differentiation, apoptosis, and functions of S1P, specifically detailing the roles of S1P and S1PRs in osteoblasts and osteoclasts. Finally, we focus on the S1P based therapeutic approaches in bone metabolism, which may provide valuable insights into potential therapeutic strategies for osteoporosis.
C1 [Xu, Xuefeng; Han, Yi; Zhu, Tianxin; Fan, Faxin; Wang, Xin; Liu, Yuqing; Luo, Duosheng] Minist Educ China, Key Lab Glucolipid Metab Disorder, Beijing, Peoples R China.
   [Xu, Xuefeng; Han, Yi; Zhu, Tianxin; Fan, Faxin; Wang, Xin; Liu, Yuqing; Luo, Duosheng] Guangdong Metab Dis Res Ctr Integrated Chinese & W, Guangzhou, Peoples R China.
   [Xu, Xuefeng; Han, Yi; Zhu, Tianxin; Fan, Faxin; Wang, Xin; Liu, Yuqing; Luo, Duosheng] Guangdong TCM Key Lab Metab Dis, Guangzhou 510006, Peoples R China.
   [Xu, Xuefeng; Han, Yi; Zhu, Tianxin; Fan, Faxin; Wang, Xin; Liu, Yuqing; Luo, Duosheng] Guangdong Pharmaceut Univ, Inst Chinese Med, Guangzhou, Peoples R China.
   [Luo, Duosheng] Guangdong Pharmaceut Univ, Guangzhou Higher Educ Mega Ctr, 280 Outer Ring East Rd, Guangzhou 510006, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Pharmaceutical University
RP Luo, DS (通讯作者)，Guangdong TCM Key Lab Metab Dis, Guangzhou 510006, Peoples R China.; Luo, DS (通讯作者)，Guangdong Pharmaceut Univ, Guangzhou Higher Educ Mega Ctr, 280 Outer Ring East Rd, Guangzhou 510006, Peoples R China.
EM lds0901@163.com
FU National Natural Science Foundation of China [82074210, 82374267]
FX This work was supported by the National Natural Science Foundation of
   China (82074210, 82374267) .
CR Allende ML, 2011, J BIOL CHEM, V286, P7348, DOI 10.1074/jbc.M110.171819
   Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   Bae SJ, 2016, OSTEOPOROSIS INT, V27, P2533, DOI 10.1007/s00198 016 3565 z
   Bao XLQQG, 2011, BIOCHEM BIOPH RES CO, V405, P533, DOI 10.1016/j.bbrc.2011.01.061
   Brizuela L, 2014, MOL ONCOL, V8, P1181, DOI 10.1016/j.molonc.2014.04.001
   Bu YH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.733387
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Carpio LC, 2000, PROSTAG LEUKOTR ESS, V62, P225, DOI 10.1054/plef.2000.0147
   D'Ambrosio D, 2016, THER ADV CHRONIC DIS, V7, P18, DOI 10.1177/2040622315617354
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Fabre S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113439
   Golan K, 2013, PHARMACEUTICALS, V6, P1145, DOI 10.3390/ph6091145
   Gonzalez Cabrera PJ, 2012, MOL PHARMACOL, V81, P166, DOI 10.1124/mol.111.076109
   Gräler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Grey A, 2004, CALCIFIED TISSUE INT, V74, P542, DOI 10.1007/s00223 003 0155 9
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200
   Hait NC, 2006, BBA BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hashimoto Y, 2016, CELL BIOL INT, V40, P1129, DOI 10.1002/cbin.10652
   Heckt T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219734
   Higashi K, 2016, BONE, V93, P1, DOI 10.1016/j.bone.2016.09.003
   Hou JC, 2017, AM J RESP CRIT CARE, V196, P1559, DOI [10.1164/rccm.201701 0241OC, 10.1164/rccm.201701 0241oc]
   Hsu LC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010017
   Huang C, 2016, MOL MED REP, V14, P927, DOI 10.3892/mmr.2016.5342
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645 04.2005
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Kajimoto T, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat6662
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Keul P, 2011, CIRC RES, V108, P314, DOI 10.1161/CIRCRESAHA.110.235028
   Kihara Y, 2023, PHARMACOL THERAPEUT, V246, DOI 10.1016/j.pharmthera.2023.108432
   Kihara Y, 2014, BRIT J PHARMACOL, V171, P3575, DOI 10.1111/bph.12678
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Kim BJ, 2016, J ENDOCRINOL INVEST, V39, P297, DOI 10.1007/s40618 015 0364 x
   Kim BJ, 2012, J CLIN ENDOCR METAB, V97, P3807, DOI 10.1210/jc.2012 2346
   Kim YH, 2014, BIOMATERIALS, V35, P214, DOI 10.1016/j.biomaterials.2013.09.103
   Kleinwort A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020391
   Kobayashi N, 2006, J LIPID RES, V47, P614, DOI 10.1194/jlr.M500468 JLR200
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kono M, 2007, J BIOL CHEM, V282, P10690, DOI 10.1074/jbc.M700370200
   Kozawa O, 1997, FEBS LETT, V418, P149, DOI 10.1016/S0014 5793(97)01366 5
   Kumar A, 2011, CELL SIGNAL, V23, P1144, DOI 10.1016/j.cellsig.2011.02.009
   Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092
   Lampasso JD, 2001, PROSTAG LEUKOTR ESS, V65, P139, DOI 10.1054/plef.2001.0302
   Lee SH, 2021, J CLIN DENSITOM, V24, P414, DOI 10.1016/j.jocd.2021.03.005
   Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Lory W, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043401
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Matsuzaki E, 2022, J DENT SCI, V17, P787, DOI 10.1016/j.jds.2021.10.004
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   McGinley MP, 2021, LANCET, V398, P1184, DOI 10.1016/S0140 6736(21)00244 0
   Meshcheryakova A, 2017, EXPERT OPIN THER TAR, V21, P725, DOI 10.1080/14728222.2017.1332180
   Nijnik A, 2012, J IMMUNOL, V189, P102, DOI 10.4049/jimmunol.1200282
   Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06 7420com
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Ota K, 2013, ENDOCRINOLOGY, V154, P3745, DOI 10.1210/en.2013 1272
   Pankratz N, 2016, NAT GENET, V48, P867, DOI 10.1038/ng.3607
   Parham KA, 2015, FASEB J, V29, P3638, DOI 10.1096/fj.14 261289
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Peltier L, 2018, OSTEOPOROSIS INT, V29, P1905, DOI 10.1007/s00198 018 4531 8
   Pham THM, 2008, IMMUNITY, V28, P122, DOI 10.1016/j.immuni.2007.11.017
   Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540
   Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001
   pubmed.ncbi.nlm.nih.gov, Higher circulating sphingosine 1  phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans   PubMed
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200
   Roelofsen T, 2008, J CELL BIOCHEM, V105, P1128, DOI 10.1002/jcb.21915
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200
   Sartawi Z, 2020, EUR J PHARMACOL, V882, DOI 10.1016/j.ejphar.2020.173262
   Sassoli C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225545
   Sato C, 2012, BIOCHEM BIOPH RES CO, V423, P200, DOI 10.1016/j.bbrc.2012.05.130
   Selvam SP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa4998
   Song Ha. Eun, 2020, About us, DOI [10.1136/jim 2020 001322?url_ver=Z39.88 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%200pubmed, DOI 10.1136/JIM 2020 001322?URL_VER=Z39.88 2003&RFR_ID=ORI:RID:CROSSREF.ORG&RFR_DAT=CR_PUB0PUBMED]
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10 167502
   Sukocheva OA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020420
   Takasugi N, 2011, J NEUROSCI, V31, P6850, DOI 10.1523/JNEUROSCI.6467 10.2011
   Tantikanlayaporn D, 2018, JBMR PLUS, V2, P217, DOI 10.1002/jbm4.10037
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Vu TM, 2017, NATURE, V550, P524, DOI 10.1038/nature24053
   Wacker BK, 2009, STROKE, V40, P3342, DOI 10.1161/STROKEAHA.109.560714
   Walker JM, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab042
   Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Weske S, 2019, BONE, V125, P1, DOI 10.1016/j.bone.2019.04.015
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200
   Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396
   Xiong YQ, 2013, J BIOL CHEM, V288, P32563, DOI 10.1074/jbc.M113.483750
   Ye D, 2013, DEVELOPMENT, V140, P789, DOI 10.1242/dev.085340
   Yu H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156303
   Yu H, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0057 7
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zheng ZC, 2023, ELIFE, V12, DOI 10.7554/eLife.77742
NR 105
TC 9
Z9 10
U1 2
U2 16
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2023
VL 169
AR 115838
DI 10.1016/j.biopha.2023.115838
EA NOV 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA Z0GS4
UT WOS:001108960600001
PM 37944444
OA gold
DA 2025 08 17
ER

PT J
AU Mandal, CC
   Choudhury, GG
   Ghosh Choudhury, N
AF Mandal, Chandi C.
   Choudhury, Goutam Ghosh
   Ghosh Choudhury, Nandini
TI Phosphatidylinositol 3 Kinase/Akt Signal Relay Cooperates with Smad in
   Bone Morphogenetic Protein 2 Induced Colony Stimulating Factor 1 (CSF 1)
   Expression and Osteoclast Differentiation
SO ENDOCRINOLOGY
LA English
DT Article
ID TUMOR SUPPRESSOR PTEN; INDUCED DNA SYNTHESIS; TGF BETA RECEPTOR; KAPPA B
   LIGAND; OSTEOBLAST DIFFERENTIATION; MESANGIAL CELLS; PROTEIN KINASE;
   C2C12 CELLS; BMP 2 GENE; C FOS
AB Murine spleen cells produce mature osteoclasts when cocultured with osteoblastic cells. Colony stimulating factor (CSF) 1 is the growth factor required for differentiating the monocyte macrophage precursor cells into preosteoclasts. Bone morphogenic protein (BMP) signaling in osteoblasts regulates bone mass in mice, suggesting a role of BMP in osteoclastogenesis along with osteoblast activity. The intracellular signal transduction cross talk regulating the osteoblastic production of CSF 1 as a mechanism of BMP induced osteoclastogenesis is described in this report. We have recently described the involvement of Smad 1/5 in BMP 2 induced CSF 1 expression and osteoclast formation. In this study, using the pharmacological inhibitors and the adenovirus (Ad) vectors expressing dominant negative (DN) phosphatidylinositol 3 kinase (PI3K), the PI3K signaling inhibitor, phosphatase and tensin homolog deleted in chromosome 10 (PTEN) or DN Akt kinase in the in vitro coculture assay, we show an essential role of the lipid kinase cascade in BMP 2 mediated multinucleated osteoclast formation and CSF 1 mRNA expression, transcription, and secretion. Inhibition of PI3K/Akt signaling blocked the binding of Smads 1/5 to the CSF 1 BMP responsive element present in the CSF 1 promoter, resulting in attenuation of Smad dependent CSF 1 transcription. Furthermore, PI3K inhibition and DN Akt prevented association of the transcriptional coactivator, CREB (cAMP response element binding protein) binding protein (CBP), with Smads 1/5. Together, these data for the first time demonstrate that PI3K dependent Akt activation regulates BMP 2 induced CSF 1 expression and provides a mechanism for osteoblastic cell assisted osteoclast differentiation. (Endocrinology 150: 4989 4998, 2009)
C1 [Mandal, Chandi C.; Ghosh Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
   [Choudhury, Goutam Ghosh; Ghosh Choudhury, Nandini] S Texas Vet Hlth Care Syst, Dept Vet Affairs Res, San Antonio, TX USA.
   [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans
   Hospital; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Audie L. Murphy Memorial Veterans Hospital;
   Geriatric Research Education & Clinical Center
RP Ghosh Choudhury, N (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM choudhury@uthscsa.edu
OI Mandal, Chandi/0000 0002 2292 6635
FU National Institutes of Health (NIH) [RO1AR52425, RO1 DK50190];
   Department of Veterans Affairs (VA) Research Service Merit Review; VA
   Merit Review; Juvenile Diabetes Research Foundation [1 2008 185]
FX We thank Patricia St. Clair for efficient technical assistance. We thank
   Dr. Brent Wagner for critically reading the manuscript.Address all
   correspondence and requests for reprints to: Nandini Ghosh Choudhury,
   Department of Pathology, University of Texas Health Science Center, 7703
   Floyd Curl Drive, San Antonio, TX 78229. E mail:
   choudhury@uthscsa.edu.This work was supported by funding from National
   Institutes of Health (NIH) RO1AR52425, Department of Veterans Affairs
   (VA) Research Service Merit Review (N.G. C.) and from NIH RO1 DK50190,
   VA Merit Review and Juvenile Diabetes Research Foundation 1 2008 185
   (G.G.C.). G.G.C. is a recipient of Research Career Scientist Award from
   the Department of Veterans Affairs.Disclosure Summary: The authors have
   nothing to disclose.
CR Abboud SL, 2002, ENDOCRINOLOGY, V143, P1942, DOI 10.1210/en.143.5.1942
   Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960 9822(06)00122 9
   AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200
   Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200
   Choudhury GG, 2006, CELL SIGNAL, V18, P1854, DOI 10.1016/j.cellsig.2006.02.003
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Das F, 2008, J CELL PHYSIOL, V214, P513, DOI 10.1002/jcp.21236
   FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo 127 5 2592
   Ford Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Ghosh Choudhury N, 2003, FEBS LETT, V544, P181, DOI 10.1016/S0014 5793(03)00507 6
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Ghosh Choudhury N, 2006, J BIOL CHEM, V281, P20160, DOI 10.1074/jbc.M511071200
   Ghosh Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200
   GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331
   Glass CK, 2000, GENE DEV, V14, P121
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092 8674(00)81817 6
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Mahimainathan L, 2005, AM J PHYSIOL RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004
   Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756 3282(99)00113 1
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Otsuka E, 2003, CALCIFIED TISSUE INT, V73, P72, DOI 10.1007/s00223 002 1071 0
   Pearson KL, 1999, BBA GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167 4781(99)00166 9
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092 8674(00)81780 8
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215
   ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34
   Tu AW, 2007, J BIOL CHEM, V282, P21187, DOI 10.1074/jbc.M700085200
   Udagawa N, 2002, BIOGERONTOLOGY, V3, P79, DOI 10.1023/A:1015215615674
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yamamoto Y, 2006, ENDOCRINOLOGY, V147, P3366, DOI 10.1210/en.2006 0216
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 52
TC 53
Z9 59
U1 0
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD NOV
PY 2009
VL 150
IS 11
BP 4989
EP 4998
DI 10.1210/en.2009 0026
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 509ID
UT WOS:000271007700019
PM 19819979
OA Green Published
DA 2025 08 17
ER

PT J
AU Regard, JB
   Malhotra, D
   Gvozdenovic Jeremic, J
   Josey, M
   Chen, M
   Weinstein, LS
   Lu, JM
   Shore, EM
   Kaplan, FS
   Yang, YZ
AF Regard, Jean B.
   Malhotra, Deepti
   Gvozdenovic Jeremic, Jelena
   Josey, Michelle
   Chen, Min
   Weinstein, Lee S.
   Lu, Jianming
   Shore, Eileen M.
   Kaplan, Frederick S.
   Yang, Yingzi
TI Activation of Hedgehog signaling by loss of GNAS causes
   heterotopic ossification
SO NATURE MEDICINE
LA English
DT Article
ID PROTEIN KINASE A; SUPPRESSES OSTEOGENIC DIFFERENTIATION; MESENCHYMAL
   STEM CELLS; STIMULATORY G PROTEIN; BONE FORMATION; OSTEOBLAST
   DIFFERENTIATION; IN VIVO; CHONDROCYTE PROLIFERATION; PROMOTES
   PROLIFERATION; SKELETAL DEVELOPMENT
AB Heterotopic ossification, the pathologic formation of extraskeletal bone, occurs as a common complication of trauma or in genetic disorders and can be disabling and lethal. However, the underlying molecular mechanisms are largely unknown. Here we demonstrate that G alpha(s) restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells. In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes G alpha(s), Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells. In animal models, we show that genetically mediated ectopic Hedgehog signaling is sufficient to induce heterotopic ossification, whereas inhibition of this signaling pathway by genetic or pharmacological means strongly reduces the severity of this condition. As our previous work has shown that GNAS gain of function mutations upregulate WNT beta catenin signaling in osteoblast progenitor cells, resulting in their defective differentiation and fibrous dysplasia, we identify G alpha(s) as a key regulator of proper osteoblast differentiation through its maintenance of a balance between the Wnt beta catenin and Hedgehog pathways. Also, given the results here of the pharmacological studies in our mouse model, we propose that Hedgehog inhibitors currently used in the clinic for other conditions, such as cancer, may possibly be repurposed for treating heterotopic ossification and other diseases caused by GNAS inactivation.
C1 [Regard, Jean B.; Malhotra, Deepti; Gvozdenovic Jeremic, Jelena; Josey, Michelle; Yang, Yingzi] NHGRI, NIH, Bethesda, MD 20892 USA.
   [Chen, Min; Weinstein, Lee S.] NIDDK, NIH, Bethesda, MD 20892 USA.
   [Lu, Jianming] Codex BioSolut, Gaithersburg, MD USA.
   [Shore, Eileen M.; Kaplan, Frederick S.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
   [Shore, Eileen M.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kaplan, Frederick S.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Human Genome
   Research Institute (NHGRI); National Institutes of Health (NIH)   USA;
   NIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK); University of Pennsylvania; University of Pennsylvania;
   University of Pennsylvania
RP Yang, YZ (通讯作者)，NHGRI, NIH, Bethesda, MD 20892 USA.
EM jean.regard@novartis.com; yingzi@mail.nih.gov
RI Weinstein, Lee/I 5575 2015; Yang, Yingzi/J 3501 2012; Shore,
   Eileen/D 2593 2009
FU intramural research program of NHGRI at the US National Institutes of
   Health (NIH); intramural research program of NIDDK at the US National
   Institutes of Health (NIH); Progressive Osseous Heteroplasia
   Association; University of Pennsylvania Center for Research in FOP and
   Related Disorders; Penn Center for Musculoskeletal Disorders (NIH NIAMS)
   [P30 AR050950]; Isaac and Rose Nassau Professorship of Orthopaedic
   Molecular Medicine; NIH NIAMS [R01 AR046831, R01 AR41916]
FX We thank the entire Yang lab for stimulating discussions. We thank J.
   Fekecs and P. Andre for helping with the data illustration. The work in
   the Yang and Weinstein labs was supported by the intramural research
   programs of NHGRI and NIDDK at the US National Institutes of Health
   (NIH), respectively. We thank R. Caron for his work on the POH lesion
   histological analyses. The rabbit anti Gli3 antibody was provided by S.
   Mackem (NIH NCI), and the dnPKA adenovirus was a gift from C. M. Fan
   (Carnegie Institution for Science). The work in the Kaplan and Shore lab
   was supported by the Progressive Osseous Heteroplasia Association, the
   University of Pennsylvania Center for Research in FOP and Related
   Disorders, the Penn Center for Musculoskeletal Disorders (NIH NIAMS
   P30 AR050950), the Isaac and Rose Nassau Professorship of Orthopaedic
   Molecular Medicine and NIH NIAMS (R01 AR046831 and R01 AR41916).
CR Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534 5807(03)00394 0
   Bai CYB, 2001, DEVELOPMENT, V128, P5161
   Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chen M, 2005, J CLIN INVEST, V115, P3217, DOI 10.1172/JCI24196
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Cho HH, 2006, TISSUE ENG, V12, P111, DOI 10.1089/ten.2006.12.111
   Cooper KL, 2011, SCIENCE, V332, P1083, DOI 10.1126/science.1199499
   Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Eddy MC, 2000, J BONE MINER RES, V15, P2074, DOI 10.1359/jbmr.2000.15.11.2074
   Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huso DL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021755
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092 8674(95)90510 3
   Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Joeng KS, 2009, DEVELOPMENT, V136, P4177, DOI 10.1242/dev.041624
   Kaplan, 1994, J Am Acad Orthop Surg, V2, P288
   KEELY SL, 1975, P NATL ACAD SCI USA, V72, P1501, DOI 10.1073/pnas.72.4.1501
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim J, 2010, P NATL ACAD SCI USA, V107, P13432, DOI 10.1073/pnas.1006822107
   Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Low WC, 2008, DEV BIOL, V321, P188, DOI 10.1016/j.ydbio.2008.06.014
   Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008 5472.CAN 06 0657
   Matise MP, 1998, DEVELOPMENT, V125, P2759
   Mukhopadhyay S, 2013, CELL, V152, P210, DOI 10.1016/j.cell.2012.12.026
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nelson DK, 2004, DEV BIOL, V267, P72, DOI 10.1016/j.ydbio.2003.10.033
   Ogden SK, 2008, NATURE, V456, P967, DOI 10.1038/nature07459
   Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009
   Pignolo RJ, 2011, J BONE MINER RES, V26, P2647, DOI 10.1002/jbmr.481
   Plagge A, 2008, J ENDOCRINOL, V196, P193, DOI 10.1677/JOE 07 0544
   Regard JB, 2007, J CLIN INVEST, V117, P4034, DOI 10.1172/JCI32994
   Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108
   Ribes V, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002014
   Riminucci M, 2010, J MOL ENDOCRINOL, V45, P355, DOI 10.1677/JME 10 0097
   Riobo NA, 2006, P NATL ACAD SCI USA, V103, P12607, DOI 10.1073/pnas.0600880103
   Roselló Díez A, 2011, SCIENCE, V332, P1086, DOI 10.1126/science.1199489
   Sakamoto A, 2005, J BONE MINER RES, V20, P663, DOI 10.1359/JBMR.041210
   Sakamoto H, 2005, BIOCHEM BIOPH RES CO, V338, P578, DOI 10.1016/j.bbrc.2005.08.176
   SEAMON K, 1981, J BIOL CHEM, V256, P9799
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Shore EM, 2002, NEW ENGL J MED, V346, P99, DOI 10.1056/NEJMoa011262
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Storm EE, 1999, DEV BIOL, V209, P11, DOI 10.1006/dbio.1999.9241
   Svärd J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013
   Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008
   TRUEB RM, 1993, DERMATOLOGY, V186, P205, DOI 10.1159/000247347
   Tuson M, 2011, DEVELOPMENT, V138, P4921, DOI 10.1242/dev.070805
   Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092 8674(00)80678 9
   Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597
   Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
   Zhang DH, 2003, J BONE MINER RES, V18, P1593, DOI 10.1359/jbmr.2003.18.9.1593
   Zhang Q, 2009, P NATL ACAD SCI USA, V106, P21191, DOI 10.1073/pnas.0912008106
NR 73
TC 182
Z9 209
U1 1
U2 42
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2013
VL 19
IS 11
BP 1505
EP +
DI 10.1038/nm.3314
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 251IF
UT WOS:000326920300028
PM 24076664
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yuan, Q
   Sato, T
   Densmore, M
   Saito, H
   Schüler, C
   Erben, RG
   Lanske, B
AF Yuan, Quan
   Sato, Tadatoshi
   Densmore, Michael
   Saito, Hiroaki
   Schueler, Christiane
   Erben, Reinhold G.
   Lanske, Beate
TI FGF 23/Klotho Signaling Is Not Essential for the Phosphaturic and
   Anabolic Functions of PTH
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; FGF 23; KLOTHO; PHOSPHATE HOMEOSTASIS; ANABOLISM
ID FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE 1 34; INCREASED
   BONE FORMATION; REGULATORY FACTOR I; VITAMIN D; OSTEOBLAST
   DIFFERENTIATION; CELLS; FGF23; MICE; COTRANSPORTER
AB Parathyroid hormone (PTH) is widely recognized as a key regulator of mineral ion homeostasis. Daily intermittent administration of PTH is the only currently available anabolic therapy for bone disorders such as osteoporosis. Recent studies have shown that PTH increases transcription and secretion of fibroblast growth factor 23 (FGF 23), another important regulator of phosphate homeostasis and skeletal metabolism. However, the full relationship between PTH and FGF 23 is largely unknown. This study evaluated the effect of FGF 23/Klotho signaling on the phosphaturic and anabolic functions of PTH. Eight day old wild type (WT) Fgf23( / ) and Kl( / ) mice were injected with 100 mu g/kg PTH(1 34) or vehicle daily for a 2 week period and then euthanized. Intermittent injection of PTH successfully reduced the serum phosphate levels and reversed the hyperphosphatemia of Fgf23( / ) and Kl( / ) mice. Bone changes were analyzed in the distal femur metaphysis by peripheral quantitative computed tomography (pQCT), micro computed tomography (mu CT), and histomorphometry. PTH treatment induced substantial increases in bone mineral density (BMD) and trabecular bone volume in each mouse genotype. Expression of osteoblastic marker genes, including Runx2, Col1, Alp, Ocn, and Sost, was similarly altered. In addition, primary osteoblasts were isolated and treated with 100 nM PTH in vitro. PTH treatment similarly induced cAMP accumulation and phosphorylation of ERK1/2 and CREB in the osteoblasts from each genotype. Taken together, our results demonstrate that FGF 23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH, suggesting that PTH can function as a therapeutic agent to improve the skeletal quality of patients even in the presence of abnormal serum FGF 23 levels. (C) 2011 American Society for Bone and Mineral Research.
C1 [Yuan, Quan; Sato, Tadatoshi; Densmore, Michael; Lanske, Beate] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
   [Yuan, Quan] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610064, Peoples R China.
   [Saito, Hiroaki] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Schueler, Christiane; Erben, Reinhold G.] Univ Vet Med, Dept Biomed Sci, Inst Physiol Pathophysiol & Biophys, Vienna, Austria.
C3 Harvard University; Harvard School of Dental Medicine; Sichuan
   University; Harvard University; Harvard School of Dental Medicine;
   University of Veterinary Medicine Vienna
RP Lanske, B (通讯作者)，Harvard Univ, Sch Dent Med, Dept Dev Biol, Res & Educ Bldg,Room 303,188 Longwood Ave, Boston, MA 02115 USA.
EM Beate_Lanske@hsdm.harvard.edu
RI ; Erben, Reinhold/AAG 8007 2020
OI Lanske, Beate/0000 0003 4638 804X; Yuan, Quan/0000 0002 2836 1081;
   Erben, Reinhold/0000 0003 0801 6958; Saito, Hiroaki/0000 0002 8130 0624
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   [R01 073944]; State Key Laboratory of Oral Diseases Open Funding
   [SKLODOF2010 04]; NSFC [30901696]; Harvard School of Dental Medicine
FX We would like to thank Nicholas Brady for mu CT analysis, Dr William
   Horne for valuable discussion, and Drs Yukiko Maeda, Marta Christov, and
   Dutmanee Seriwatanachai for technical help. This work was supported by
   grants from the National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK, R01 073944) and State Key Laboratory of Oral Diseases
   Open Funding (SKLODOF2010 04) to BL and funds from NSFC (30901696) and
   Dean's Scholarship, Harvard School of Dental Medicine, to QY.
CR Bacic D, 2006, KIDNEY INT, V69, P495, DOI 10.1038/sj.ki.5000148
   Bai XY, 2007, ENDOCRINOLOGY, V148, P4974, DOI 10.1210/en.2007 0243
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Biber J, 2009, PFLUG ARCH EUR J PHY, V458, P39, DOI 10.1007/s00424 008 0580 8
   BOUXSEIN ML, J BONE MINER RES, V25, P1468
   Brown WW, 2009, J CLIN ENDOCR METAB, V94, P17, DOI 10.1210/jc.2008 0220
   Burnett Bowie SAM, 2009, J BONE MINER RES, V24, P1681, DOI [10.1359/JBMR.090406, 10.1359/jbmr.090406]
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Déliot N, 2005, AM J PHYSIOL CELL PH, V289, pC159, DOI 10.1152/ajpcell.00456.2004
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Fukagawa M, 2005, NEPHROL DIAL TRANSPL, V20, P1295, DOI 10.1093/ndt/gfh827
   Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009 1494
   Hu MC, 2010, FASEB J, V24, P3438, DOI 10.1096/fj.10 154765
   Hurley MM, 2006, BIOCHEM BIOPH RES CO, V341, P989, DOI 10.1016/j.bbrc.2006.01.044
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Ito M, 2005, AM J PHYSIOL ENDOC M, V288, pE1101, DOI 10.1152/ajpendo.00502.2004
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Katai K, 1999, BIOCHEM J, V343, P705, DOI 10.1042/0264 6021:3430705
   Kawata T, 2007, J AM SOC NEPHROL, V18, P2683, DOI 10.1681/ASN.2006070783
   Komaba H, 2010, KIDNEY INT, V77, P292, DOI 10.1038/ki.2009.466
   Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE 07 0267
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Lanske B, 2007, CURR OPIN NEPHROL HY, V16, P311, DOI 10.1097/MNH.0b013e3281c55eca
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   Nakatani T, 2009, FASEB J, V23, P3702, DOI 10.1096/fj.08 123992
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pfister MF, 1997, J BIOL CHEM, V272, P20125, DOI 10.1074/jbc.272.32.20125
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Saji F, 2010, AM J PHYSIOL RENAL, V299, pF1212, DOI 10.1152/ajprenal.00169.2010
   Segawa H, 2007, AM J PHYSIOL RENAL, V292, pF395, DOI 10.1152/ajprenal.00100.2006
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220
   Weinman EJ, 2007, J CLIN INVEST, V117, P3412, DOI 10.1172/JCI32738
   Yoshiko Y, 2007, BONE, V40, P1565, DOI 10.1016/j.bone.2007.01.017
   Yu SB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007583
NR 51
TC 47
Z9 48
U1 1
U2 12
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2011
VL 26
IS 9
BP 2026
EP 2035
DI 10.1002/jbmr.433
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 814JG
UT WOS:000294444300005
PM 21590742
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, R
   Yallowitz, A
   Qin, A
   Wu, ZH
   Shin, DY
   Kim, JM
   Debnath, S
   Ji, G
   Bostrom, MP
   Yang, X
   Zhang, C
   Dong, H
   Kermani, P
   Lalani, S
   Li, N
   Liu, YF
   Poulos, MG
   Wach, A
   Zhang, Y
   Inoue, K
   Di Lorenzo, A
   Zhao, BH
   Butler, JM
   Shim, JH
   Glimcher, LH
   Greenblatt, MB
AF Xu, Ren
   Yallowitz, Alisha
   Qin, An
   Wu, Zhuhao
   Shin, Dong Yeon
   Kim, Jung Min
   Debnath, Shawon
   Ji, Gang
   Bostrom, Mathias P.
   Yang, Xu
   Zhang, Chao
   Dong, Han
   Kermani, Pouneh
   Lalani, Sarfaraz
   Li, Na
   Liu, Yifang
   Poulos, Michael G.
   Wach, Amanda
   Zhang, Yi
   Inoue, Kazuki
   Di Lorenzo, Annarita
   Zhao, Baohong
   Butler, Jason M.
   Shim, Jae Hyuck
   Glimcher, Laurie H.
   Greenblatt, Matthew B.
TI Targeting skeletal endothelium to ameliorate bone loss
SO NATURE MEDICINE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; VASCULAR NETWORK; ANGIOGENESIS; ROBO; SLIT2;
   OSTEOGENESIS; MAINTENANCE; EXPRESSION; ROLES; MICE
AB Recent studies have identified a specialized subset of CD31(hi)endomucin(hi) (CD31(hi)EMCN(hi)) vascular endothelium that positively regulates bone formation. However, it remains unclear how CD31(hi)EMCN(hi) endothelium levels are coupled to anabolic bone formation. Mice with an osteoblast specific deletion of Shn3, which have markedly elevated bone formation, demonstrated an increase in CD31(hi)EMCN(hi) endothelium. Transcriptomic analysis identified SLIT3 as an osteoblast derived, SHN3 regulated proangiogenic factor. Genetic deletion of Slit3 reduced skeletal CD31(hi)EMCN(hi) endothelium, resulted in low bone mass because of impaired bone formation and partially reversed the high bone mass phenotype of Shn3( / ) mice. This coupling between osteo blasts and CD31(hi)EMCN(hi) endothelium is essential for bone healing, as shown by defective fracture repair in SLIT3 mutant mice and enhanced fracture repair in SHN3 mutant mice. Finally, administration of recombinant SLIT3 both enhanced bone fracture healing and counteracted bone loss in a mouse model of postmenopausal osteoporosis. Thus, drugs that target the SLIT3 pathway may represent a new approach for vascular targeted osteoanabolic therapy to treat bone loss.
C1 [Xu, Ren; Yallowitz, Alisha; Shin, Dong Yeon; Debnath, Shawon; Lalani, Sarfaraz; Li, Na; Liu, Yifang; Zhang, Yi; Di Lorenzo, Annarita; Greenblatt, Matthew B.] Cornell Univ, Dept Pathol & Lab Med, New York, NY 10021 USA.
   [Qin, An] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Shanghai Key Lab Orthopaed Implant,Sch Med, Shanghai, Peoples R China.
   [Wu, Zhuhao] Rockefeller Univ, Lab Brain Dev & Repair, 1230 York Ave, New York, NY 10021 USA.
   [Kim, Jung Min; Shim, Jae Hyuck] Univ Massachusetts, Dept Med, Med Sch, Div Rheumatol, Worcester, MA USA.
   [Ji, Gang; Bostrom, Mathias P.; Yang, Xu] Hosp Special Surg, Res Div, 535 E 70th St, New York, NY 10021 USA.
   [Ji, Gang] Hebei Med Univ, Dept Joint Surg, Hosp 3, Shijiazhuang, Hebei, Peoples R China.
   [Bostrom, Mathias P.] Hosp Special Surg, Div Adult Reconstruct & Joint Replacement, Dept Orthopaed Surg, 535 E 70th St, New York, NY 10021 USA.
   [Zhang, Chao] Cornell Univ, Inst Computat Biomed, New York, NY 10021 USA.
   [Dong, Han; Glimcher, Laurie H.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA.
   [Dong, Han; Glimcher, Laurie H.] Harvard Univ, Med Sch, Boston, MA 02115 USA.
   [Dong, Han; Glimcher, Laurie H.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
   [Dong, Han; Glimcher, Laurie H.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Kermani, Pouneh; Poulos, Michael G.; Butler, Jason M.] Cornell Univ, Ansary Stem Cell Inst, Dept Med, Div Regenerat Med, New York, NY 10021 USA.
   [Wach, Amanda] Hosp Special Surg, Dept Biomech, 535 E 70th St, New York, NY 10021 USA.
   [Inoue, Kazuki; Zhao, Baohong] Hosp Special Surg, Arthrit & Tissue Degenerat Program, 535 E 70th St, New York, NY 10021 USA.
   [Inoue, Kazuki; Zhao, Baohong] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, 535 E 70th St, New York, NY 10021 USA.
   [Inoue, Kazuki; Zhao, Baohong] Cornell Univ, Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA.
C3 Cornell University; Shanghai Jiao Tong University; Rockefeller
   University; University of Massachusetts System; University of
   Massachusetts Worcester; Hebei Medical University; Cornell University;
   Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Cornell
   University; Cornell University; Weill Cornell Medicine
RP Greenblatt, MB (通讯作者)，Cornell Univ, Dept Pathol & Lab Med, New York, NY 10021 USA.; Glimcher, LH (通讯作者)，Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA.; Glimcher, LH (通讯作者)，Harvard Univ, Med Sch, Boston, MA 02115 USA.; Glimcher, LH (通讯作者)，Harvard Med Sch, Dept Med, Boston, MA 02115 USA.; Glimcher, LH (通讯作者)，Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM laurie_glimcher@dfci.harvard.edu; mag3003@med.cornell.edu
RI ; JI, Gang/AAG 9877 2020; Li, Na/IUM 7283 2023; Inoue,
   Kazuki/GRY 3245 2022; Zhang, Chao/E 6476 2015; xu, ren/G 6907 2015; Qin,
   An/J 2518 2019; Kim, Jung Min/JDW 1037 2023; Wu, Zhuhao/I 5852 2018
OI Di Lorenzo, Annarita/0000 0003 1239 4222; Yang, Xu/0000 0001 8377 077X;
   Zhang, Chao/0000 0001 8019 7998; xu, ren/0000 0001 6578 4553; Shim,
   Jae Hyuck/0000 0002 4947 3293; Lalani, Sarfaraz/0000 0003 3624 9409;
   Dong, Han/0009 0003 4975 8269; Wu, Zhuhao/0000 0002 2471 0555; Poulos,
   Michael/0000 0002 7622 9966; Kim, Jung Min/0000 0002 9072 4293
FU Career Award for Medical Scientists from the Burroughs Wellcome
   Foundation; Office of the Director of the NIH [DP5OD021351];
   Musculoskeletal Transplant Foundation; March of Dimes Basil O'Connor
   Award; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases/NIH [R01AR068983]; pilot project program award from UMass
   Center for Clinical and Translational Science; NIH/National Heart, Lung,
   and Blood Institute [R01 HL126913]
FX We thank the many individuals who provided valuable reagents. M.B.G.
   holds a Career Award for Medical Scientists from the Burroughs Wellcome
   Foundation and is supported by the Office of the Director of the NIH
   under award DP5OD021351, a Junior Investigator Award from the
   Musculoskeletal Transplant Foundation and a March of Dimes Basil
   O'Connor Award. J. H.S. is supported by National Institute of Arthritis
   and Musculoskeletal and Skin Diseases/NIH under R01AR068983 and a pilot
   project program award from UMass Center for Clinical and Translational
   Science. A.D.L. is supported by NIH/National Heart, Lung, and Blood
   Institute under R01 HL126913. This content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the NIH. We thank D. Ballon, B. He, B.   S. Ding and J. McCormick and
   Citigroup Biomedical Imaging Core, Weill Cornell Microscopy and Image
   Analysis and Flow Cytometry Core Facilities for technical support.
CR Ba Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896 6273(00)80702 3
   Blockus H, 2016, DEVELOPMENT, V143, P3037, DOI 10.1242/dev.132829
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Bradaschia Correa V, 2017, J BONE MINER RES, V32, P821, DOI 10.1002/jbmr.3045
   Buza JA, 2016, CLIN CASES MINER BON, V13, P101, DOI 10.11138/ccmbm/2016.13.2.101
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619
   Choi HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7943
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Geutskens SB, 2012, LAB INVEST, V92, P1129, DOI 10.1038/labinvest.2012.81
   Geutskens SB, 2010, J IMMUNOL, V185, P7691, DOI 10.4049/jimmunol.0903898
   Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113
   Han WQ, 2016, SCI REP UK, V6, DOI 10.1038/srep36330
   Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jaworski A, 2012, NAT NEUROSCI, V15, P367, DOI 10.1038/nn.3037
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu Z, 2004, MOL CELL NEUROSCI, V26, P232, DOI 10.1016/j.mcn.2004.01.002
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Mehlen P, 2011, NAT REV CANCER, V11, P188, DOI 10.1038/nrc3005
   Naska S, 2010, MOL CELL NEUROSCI, V45, P108, DOI 10.1016/j.mcn.2010.05.015
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Paul JD, 2013, J MOL CELL CARDIOL, V64, P124, DOI 10.1016/j.yjmcc.2013.09.005
   Rama N, 2015, NAT MED, V21, P483, DOI 10.1038/nm.3849
   Ramalingam P, 2017, CURR OPIN HEMATOL, V24, P289, DOI 10.1097/MOH.0000000000000350
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sakabe M, 2017, P NATL ACAD SCI USA, V114, P10918, DOI 10.1073/pnas.1704030114
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Shin M, 2016, DEVELOPMENT, V143, P3796, DOI 10.1242/dev.137919
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Sun HL, 2009, CELLS TISSUES ORGANS, V190, P69, DOI 10.1159/000178020
   Tual Chalot S, 2013, JOVE J VIS EXP, DOI 10.3791/50546
   Vasam G, 2017, DIABETES, V66, P505, DOI 10.2337/db16 1039
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Xu R, 2014, CELL ADHES MIGR, V8, P5, DOI 10.4161/cam.27752
   Yuan WL, 2003, P NATL ACAD SCI USA, V100, P5217, DOI 10.1073/pnas.0730709100
   Zhang B, 2009, BLOOD, V114, P4300, DOI 10.1182/blood 2008 12 193326
   Zhang C, 2012, BIOINFORMATICS, V28, P1943, DOI 10.1093/bioinformatics/bts278
   Zhang JZ, 2016, J BONE MINER RES, V31, P2001, DOI 10.1002/jbmr.2877
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zhou WJ, 2013, NATURE, V501, P107, DOI 10.1038/nature12416
NR 51
TC 279
Z9 325
U1 15
U2 153
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2018
VL 24
IS 6
BP 823
EP +
DI 10.1038/s41591 018 0020 z
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA GI3OQ
UT WOS:000434281300027
PM 29785024
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, YS
   Xie, J
   Wang, D
   Kim, JM
   Tai, PWL
   Gravallese, E
   Gao, GP
   Shim, JH
AF Yang, Yeon Suk
   Xie, Jun
   Wang, Dan
   Kim, Jung Min
   Tai, Phillip W. L.
   Gravallese, Ellen
   Gao, Guangping
   Shim, Jae Hyuck
TI Bone targeting AAV mediated silencing of Schnurri 3 prevents bone loss
   in osteoporosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ADENOASSOCIATED VIRUS AAV; PARATHYROID HORMONE; GENE; VECTORS; PROTEIN;
   MICE; TRANSDUCTION; OSTEOBLASTS; ANALOGS; WOMEN
AB RNAi based bone anabolic gene therapy has demonstrated initial success, but many practical challenges are still unmet. Here, we demonstrate that a recombinant adeno associated virus 9 (rAAV9) is highly effective for transducing osteoblast lineage cells in the bone. The adaptor protein Schnurri 3 (SHN3) is a promising therapeutic target for osteoporosis, as deletion of shn3 prevents bone loss in osteoporotic mice and short term inhibition of shn3 in adult mice increases bone mass. Accordingly, systemic and direct joint administration of an rAAV9 vector carrying an artificial microRNA that targets shn3 (rAAV9 amiR shn3) in mice markedly enhanced bone formation via augmented osteoblast activity. Additionally, systemic delivery of rAAV9 amiR shn3 in osteoporotic mice counteracted bone loss and enhanced bone mechanical properties. Finally, we rationally designed a capsid that exhibits improved specificity to bone by grafting the bone targeting peptide motif (AspSerSer)(6) onto the AAV9 VP2 capsid protein. Collectively, our results identify a bone targeting rAAV mediated gene therapy for osteoporosis.
C1 [Yang, Yeon Suk; Kim, Jung Min; Gravallese, Ellen; Shim, Jae Hyuck] Univ Massachusetts, Med Sch, Dept Med, Div Rheumatol, Worcester, MA 01605 USA.
   [Xie, Jun; Wang, Dan; Tai, Phillip W. L.; Gao, Guangping] Univ Massachusetts, Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.
   [Xie, Jun; Wang, Dan; Tai, Phillip W. L.; Gao, Guangping] Univ Massachusetts, Dept Microbiol & Physiol Syst, Med Sch, Worcester, MA 01605 USA.
   [Xie, Jun; Gao, Guangping] Univ Massachusetts, Viral Vector Core, Med Sch, Worcester, MA 01605 USA.
   [Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts, Li Weibo Inst Rare Dis Res, Med Sch, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; University of Massachusetts System;
   University of Massachusetts Worcester; University of Massachusetts
   System; University of Massachusetts Worcester
RP Shim, JH (通讯作者)，Univ Massachusetts, Med Sch, Dept Med, Div Rheumatol, Worcester, MA 01605 USA.; Gao, GP (通讯作者)，Univ Massachusetts, Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.; Gao, GP (通讯作者)，Univ Massachusetts, Dept Microbiol & Physiol Syst, Med Sch, Worcester, MA 01605 USA.; Gao, GP (通讯作者)，Univ Massachusetts, Viral Vector Core, Med Sch, Worcester, MA 01605 USA.; Gao, GP; Shim, JH (通讯作者)，Univ Massachusetts, Li Weibo Inst Rare Dis Res, Med Sch, Worcester, MA 01605 USA.
EM guangping.gao@umassmed.edu; jaehyuck.shim@umassmed.edu
RI ; Wang, Dan/IRZ 4765 2023; Kim, Jung Min/JDW 1037 2023
OI Tai, Phillip/0000 0001 7409 8344; Shim, Jae Hyuck/0000 0002 4947 3293;
   Kim, Jung Min/0000 0002 9072 4293; Wang, Dan/0000 0001 9079 2360; ,
   Jun/0000 0001 9565 1567; 
FU NIH [P01AI100263, R01NS076991, P01HD080642, R01AI12135]; NIAMS of the
   NIH [R01AR068983, R21AR072836, R21AR073331]; UMCCTS pilot project
   program award; Glory Harvest Group
FX We would like to thank Dr. Laurie Glimcher (Department of Cancer
   Immunology and Virology, Dana Farber Cancer Institute and Harvard
   medical school) for providing Schnurri 3 knockout and floxed mice, Drs
   Julia Charles (Department of Orthopedics and Medicine) and Joerg Ermann
   (Division of Rheumatology, Immunology and Allergy) of Brigham and
   Women's Hospital for assistance with microCT imaging, and the Center for
   Skeletal Research Imaging and Biomechanical Testing Core for
   biomechanical testing (NIH P30AR066261). We also thank the many
   individuals who provided valuable reagents. G.G. holds support from
   grants under the NIH (P01AI100263, R01NS076991, P01HD080642, and
   R01AI12135). J.H.S holds support from NIAMS of the NIH (R01AR068983,
   R21AR072836, and R21AR073331), an UMCCTS pilot project program award,
   and the Glory Harvest Group.
CR [Anonymous], J OSTEOPOROS
   [Anonymous], J GENET SYNDR GENE S
   Asokan A, 2012, MOL THER, V20, P699, DOI 10.1038/mt.2011.287
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Balakrishnan B, 2014, CURR GENE THER, V14, P86, DOI 10.2174/1566523214666140302193709
   Bish LT, 2008, HUM GENE THER, V19, P1359, DOI 10.1089/hum.2008.123
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Borumandi F, 2015, ANTI CANCER AGENT ME, V15, P736, DOI 10.2174/1871520615666150325232857
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Dayton RD, 2012, EXPERT OPIN BIOL TH, V12, P757, DOI 10.1517/14712598.2012.681463
   Dubielzig R, 1999, J VIROL, V73, P8989, DOI 10.1128/JVI.73.11.8989 8998.1999
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Gao G., 2012, MOL CLON LAB MANUAL, V2, P1209
   Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hawthorne W.J., 2022, FRONT IMMUNOL, V13, P898948, DOI [DOI 10.3389/FIM, 10.3389/fimmu.2022.898948, DOI 10.3389/FIMMU.2022.855849]
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Jones DC, 2010, P NATL ACAD SCI USA, V107, P8254, DOI 10.1073/pnas.1003727107
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   KYOSTIO SRM, 1994, J VIROL, V68, P2947
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Luo FT, 2018, MOL THER NUCL ACIDS, V13, P291, DOI 10.1016/j.omtn.2018.09.012
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mattar CN, 2015, FASEB J, V29, P3876, DOI 10.1096/fj.14 269092
   McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105
   McCarty DM, 2003, GENE THER, V10, P2112, DOI 10.1038/sj.gt.3302134
   MCCARTY DM, 1994, J VIROL, V68, P4998, DOI 10.1128/JVI.68.8.4998 5006.1994
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Naso MF, 2017, BIODRUGS, V31, P317, DOI 10.1007/s40259 017 0234 5
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood 2004 06 2501
   ROSE JA, 1966, P NATL ACAD SCI USA, V56, P86, DOI 10.1073/pnas.56.1.86
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   SNYDER RO, 1993, J VIROL, V67, P6096, DOI 10.1128/JVI.67.10.6096 6104.1993
   Ulrich Vinther M, 2007, ACTA ORTHOP, V78, P5
   Vandenberghe LH, 2009, GENE THER, V16, P311, DOI 10.1038/gt.2008.170
   Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635 8647.2000
   Xie J, 2018, MOL THER, V26, P436
   Xie J, 2017, MOL THER, V25, P1363, DOI 10.1016/j.ymthe.2017.03.028
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 52
TC 96
Z9 108
U1 6
U2 34
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 4
PY 2019
VL 10
AR 2958
DI 10.1038/s41467 019 10809 6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IH1FL
UT WOS:000474236600002
PM 31273195
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Brun, VH
   Knutsen, E
   Stenvold, H
   Halvorsen, H
AF Brun, Vegard Heimly
   Knutsen, Erik
   Stenvold, Helge
   Halvorsen, Hanne
TI Severe hypercalcemia caused by parathyroid hormone in a rectal cancer
   metastasis: a case report
SO BMC ENDOCRINE DISORDERS
LA English
DT Article
DE Parathyroid hormone; Hypercalcemia; Colorectal cancer; Metastasis; Case
   report
AB BackgroundHypercalcemia of malignancy is relatively common in several cancers. However, in colorectal cancer, paraneoplastic phenomena that cause hypercalcemia is uncommon. In the few cases that are reported, secretion of parathyroid hormone related peptide mediates the effect. We describe the first case of severe hypercalcemia mediated by intact parathyroid hormone secretion from a bone metastasis of colorectal origin. This was a diagnostic and therapeutic challenge.Case presentationA 68 year old male treated for rectal adenocarcinoma 10years earlier developed a bone metastasis. After initial treatment of the metastasis with surgery and irradiation, he developed a relapse with severe hypercalcemia and corresponding elevated parathyroid hormone levels. The workup showed no signs of parathyroid adenomas, but the metastasis produced intact parathyroid hormone. The hypercalcemia was successfully treated by irradiation and osteoclast inhibitor, and the patient received chemotherapy. Survival was 24months from the onset of hypercalcemia.ConclusionsProper diagnosis of the uncommon endocrine disturbance allowed targeted therapy and avoidance of neck exploration for wrongly suspecting primary hyperparathyroidism. Intact parathyroid hormone should be measured in cases of malignant hypercalcemia.
C1 [Brun, Vegard Heimly] Univ Hosp North Norway, Dept Breast & Endocrine Surg, Sykehusvegen 38, N 9019 Tromso, Norway.
   [Brun, Vegard Heimly; Knutsen, Erik] UiT Arctic Univ Norway, Fac Hlth Sci, Hansine Hansens Veg 18, N 9019 Tromso, Norway.
   [Stenvold, Helge] Univ Hosp North Norway, Dept Oncol, Sykehusvegen 38, N 9019 Tromso, Norway.
   [Halvorsen, Hanne] Univ Hosp North Norway, Dept Clin Pathol, Sykehusvegen 38, N 9019 Tromso, Norway.
C3 UiT The Arctic University of Tromso; University Hospital of North
   Norway; UiT The Arctic University of Tromso; UiT The Arctic University
   of Tromso; University Hospital of North Norway; UiT The Arctic
   University of Tromso; University Hospital of North Norway
RP Brun, VH (通讯作者)，Univ Hosp North Norway, Dept Breast & Endocrine Surg, Sykehusvegen 38, N 9019 Tromso, Norway.; Brun, VH (通讯作者)，UiT Arctic Univ Norway, Fac Hlth Sci, Hansine Hansens Veg 18, N 9019 Tromso, Norway.
EM vegardbrun@gmail.com
RI Brun, Vegard/ADZ 5405 2022; Knutsen, Erik/ABH 6287 2020
OI Knutsen, Erik/0000 0002 4903 0150; Brun, Vegard/0000 0002 4136 3073
FU UiT The Arctic University of Norway
FX This research did not receive any specific grant from any funding agency
   in the public, commercial or not for profit sector. The publication
   charges for this article have been funded by a grant from the
   publication fund of UiT The Arctic University of Norway.
CR CASANOVA D, 1991, WORLD J SURG, V15, P546, DOI 10.1007/BF01675660
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Donovan PJ, 2013, J CLIN ENDOCR METAB, V98, P4023, DOI 10.1210/jc.2013 2016
   Galindo Rodolfo J, 2016, World J Oncol, V7, P5
   Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397
   Luh JY, 2002, AM J CLIN ONCOL CANC, V25, P160, DOI 10.1097/00000421 200204000 00011
   Miousse Isabelle R., 2018, Critical Reviews in Oncogenesis, V23, P1, DOI 10.1615/CritRevOncog.2018025687
   Ralston SH, 2004, CALCIFIED TISSUE INT, V74, P1, DOI 10.1007/s00223 001 1135 6
   RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003 4819 112 7 499
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
NR 10
TC 1
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD JAN 7
PY 2021
VL 21
IS 1
AR 4
DI 10.1186/s12902 020 00664 8
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PS9WG
UT WOS:000608273400002
PM 33413267
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nakayama, M
   Okada, H
   Seki, M
   Suzuki, Y
   Chung, U
   Ohba, S
   Hojo, H
AF Nakayama, Mika
   Okada, Hiroyuki
   Seki, Masahide
   Suzuki, Yutaka
   Chung, Ung il
   Ohba, Shinsuke
   Hojo, Hironori
TI Single cell RNA sequencing unravels heterogeneity of skeletal
   progenitors and cell cell interactions underlying the bone repair
   process
SO REGENERATIVE THERAPY
LA English
DT Article
DE Bone repair; Lineage tracing; Calvaria; Sox9; Single cell analysis; Ccl9
ID PERIOSTEAL CELLS; DEFECTS; CHEMOKINE; BROWN; EBF2
AB Introduction: Activation of skeletal progenitors upon tissue injury and the subsequent cell fate specification are tightly coordinated in the bone repair process. Although known osteoimmunological signaling networks play important roles in the microenvironment of the bone defect sites, the molecular mechanism underlying the bone repair process has not been fully understood. Methods: To better understand the behavior of the skeletal progenitors and the heterogeneity of the cells during bone repair at the microenvironmental level, we performed a combinatorial analysis consisting of lineage tracing for skeletal progenitors using the Sox9 CreERT2;R26RtdTomato mouse line followed by single cell RNA sequencing (scRNA seq) analysis using a mouse model of calvarial bone repair. To identify a therapeutic target for bone regeneration, further computational analysis was performed focusing on the identification of the cell cell interactions, followed by pharmacological assessments with a criticalsize calvarial bone defect mouse model. Results: Lineage tracing analysis showed that skeletal progenitors marked by Sox9 were activated upon bone injury and contributed to bone repair by differentiating into osteoblasts. The scRNA seq analysis characterized heterogeneous cell populations at the bone defect sites; the computational analysis predicted a bifurcated lineage from skeletal progenitors toward osteogenic and adipogenic lineages. Chemokine C C motif ligand 9 (Ccl9) was identified as a signaling molecule that regulates bone regeneration in the mouse model, possibly through the regulation of adipogenic differentiation at the bone defect site. Conclusion: Multipotential skeletal progenitors and the direction of the cell differentiation were characterized at single cell resolution in a mouse bone repair model. The Ccl9 signaling pathway may be a key factor directing osteogenesis from the progenitors in the model and may be a therapeutic target for bone regeneration. (c) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [Nakayama, Mika; Chung, Ung il; Hojo, Hironori] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1138655, Japan.
   [Okada, Hiroyuki; Chung, Ung il; Hojo, Hironori] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Lab Clin Biotechnol, Tokyo 1138655, Japan.
   [Okada, Hiroyuki] Univ Tokyo, Grad Sch Med, Orthopaed Surg, Tokyo 1138655, Japan.
   [Seki, Masahide; Suzuki, Yutaka] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Chiba 2778562, Japan.
   [Ohba, Shinsuke] Nagasaki Univ, Inst Biomed Sci, Dept Cell Biol, Nagasaki 8528588, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo;
   University of Tokyo; Nagasaki University
RP Hojo, H (通讯作者)，Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
EM hojo@g.ecc.u tokyo.ac.jp
OI Okada, Hiroyuki/0000 0003 4217 1548; Ohba, Shinsuke/0000 0002 6874 8539;
   Hojo, Hironori/0000 0003 2245 6853
FU Japan Society for the Promotion of Science (JSPS) [20H03885, 21K19589,
   21H04952, 21K19883]; Research Grant for Public Health Science;
   Grants in Aid for Scientific Research [21H04952, 21H03142, 20H03885,
   21K19883, 21K19589, 23K21494, 22K10212, 22K10261, 22KK0272] Funding
   Source: KAKEN
FX The authors would like to acknowledge Drs. Shoko Onodera and Toshifumi
   Azuma at Tokyo Dental College, Drs. Shoichiro Tani and Yoshiaki Kitaura
   at the University of Tokyo for providing technical supports and
   insightful advice; Kunihiko Kaneko at Fukuyama University for technical
   support in scRNA seq analysis; and Asuka Uchida and Nozomi Nagumo for
   providing technical assistance. This study was supported by
   Grants in Aid for Science Research from the Japan Society for the
   Promotion of Science (JSPS) (nos. 20H03885, 21K19589, 21H04952,
   21K19883) and a Research Grant for Public Health Science.
   Super computing resources were provided by the Human Genome Center at
   the University of Tokyo. This work utilized the core research facility
   of the Center for Disease Biology and Integrative Medicine at the
   Graduate School of Medicine, The University of Tokyo.
CR Aalami OO, 2004, PLAST RECONSTR SURG, V114, P713, DOI 10.1097/01.PRS.0000131016.12754.30
   Administration U.S.F.a.D., 2021, P000058 PMA ADM USFA
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Ambele MA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124283
   Andrzejowski P, 2019, J ORTHOP TRAUMATOL, V20, DOI 10.1186/s10195 019 0528 0
   Atkins RM, 1999, J BONE JOINT SURG BR, V81B, P1035, DOI 10.1302/0301 620X.81B6.10001
   cisTarget databases, 2021, ABOUT AS
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Edderkaoui B, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00039
   Farahani RM, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/362753
   Farmer DT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24917 9
   Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580 018 0093 z
   Giladi AM, 2018, PLAST RECONSTR SURG, V142, p363E, DOI 10.1097/PRS.0000000000004691
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Hagino H, 2010, J ORTHOP SCI, V15, P737, DOI 10.1007/s00776 010 1543 4
   He XJ, 2017, BONE, V103, P12, DOI 10.1016/j.bone.2017.06.008
   Holmes G, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107871
   Huber AK, 2020, J CLIN INVEST, V130, P5444, DOI 10.1172/JCI136142
   Kim CS, 2003, FEBS LETT, V548, P125, DOI 10.1016/S0014 5793(03)00728 2
   Kuwahara ST, 2019, ELIFE, V8, DOI 10.7554/eLife.40715
   La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586 018 0414 6
   Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319
   Liu HR, 2018, HISTOCHEM CELL BIOL, V149, P393, DOI 10.1007/s00418 018 1643 3
   Ma LL, 2012, EUR J EPIDEMIOL, V27, P319, DOI 10.1007/s10654 012 9674 x
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Masquelet AC, 2017, J ORTHOP TRAUMA, V31, pS36, DOI 10.1097/BOT.0000000000000979
   Matsushita T, 2007, J ORTHOP TRAUMA, V21, P404, DOI 10.1097/BOT.0b013e318041f6d1
   Matsushita Y, 2020, CURR OSTEOPOROS REP, V18, P189, DOI 10.1007/s11914 020 00572 9
   Mitterberger MC, 2012, STEM CELL RES, V9, P35, DOI 10.1016/j.scr.2012.04.001
   Moseti D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010124
   Murao H, 2013, J BONE MINER METAB, V31, P390, DOI 10.1007/s00774 013 0429 x
   Okamatsu Y, 2004, J IMMUNOL, V173, P2084, DOI 10.4049/jimmunol.173.3.2084
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Pagani CA, 2021, STEM CELL REP, V16, P626, DOI 10.1016/j.stemcr.2021.01.011
   Qu RM, 2021, STEM CELLS, V39, P1478, DOI 10.1002/stem.3442
   Rajakumari S, 2013, CELL METAB, V17, P562, DOI 10.1016/j.cmet.2013.01.015
   RaN Rotta, 2011, J EXP ALGORITHMICS, P16
   Rozbruch SR, 2006, J ORTHOP TRAUMA, V20, P197
   Saito M, 2014, CURR OSTEOPOROS REP, V12, P181, DOI 10.1007/s11914 014 0202 7
   Schilling T, 2008, J CELL BIOCHEM, V103, P413, DOI 10.1002/jcb.21415
   Schwalie PC, 2018, NATURE, V559, P103, DOI 10.1038/s41586 018 0226 8
   Shao X, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100882
   Slobogean GP, 2015, INJURY, V46, P484, DOI 10.1016/j.injury.2014.10.010
   Soeda T, 2010, GENESIS, V48, P635, DOI 10.1002/dvg.20667
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Takahashi T, 2011, CALCIFIED TISSUE INT, V88, P336, DOI 10.1007/s00223 011 9461 9
   Team RC,R, 2021, LANG ENV STAT COMP
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tsuyuzaki K, 2019, bioRxiv, DOI [10.1101/566182, 10.1101/566182, DOI 10.1101/566182]
   Tsuyuzaki K, 2021, R PACKAGE VERSION 2
   Tsuyuzaki Koki, ABOUT AS
   Wang WS, 2014, P NATL ACAD SCI USA, V111, P14466, DOI 10.1073/pnas.1412685111
   Ward KD, 2001, CALCIFIED TISSUE INT, V68, P259, DOI 10.1007/BF02390832
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Xie Y, 2020, STEM CELLS, V38, P451, DOI 10.1002/stem.3128
   Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083
NR 58
TC 9
Z9 9
U1 3
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2022
VL 21
BP 9
EP 18
DI 10.1016/j.reth.2022.05.001
EA MAY 2022
PG 10
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 1R2TV
UT WOS:000803228500002
PM 35619947
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, XQ
   Li, HT
   Long, LH
   Song, C
   Chen, R
   Pan, HY
   Qiu, J
   Liu, B
   Liu, ZC
AF Wang, Xiqoqiang
   Li, Hongtao
   Long, Longhai
   Song, Chao
   Chen, Rui
   Pan, Hongyu
   Qiu, Junjie
   Liu, Bing
   Liu, Zongchao
TI Mechanism of Liuwei Dihuang Pills in treating osteoporosis based on
   network pharmacology
SO MEDICINE
LA English
DT Article
DE Liuweidihuang Pills; mechanism; network pharmacology; osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS; PATHWAY; OSTEOGENESIS; SUPPRESSES;
   OSTEOBLAST; APOPTOSIS; ROLES; CELLS; VEGF
AB Osteoporosis is a prevalent age related disease that poses a significant public health concern as the population continues to age. While current treatments have shown some therapeutic benefits, their long term clinical efficacy is limited by a lack of stable curative effects and significant adverse effects. Traditional Chinese Medicine has gained attention due to its positive curative effects and fewer side effects. Liuwei Dihuang Pill has been found to enhance bone mineral density in patients with osteoporosis and rats, but the underlying mechanism is not yet clear. To shed more light on this problem, this study aims to explore the pharmacological mechanism of Liuwei Dihuang Pill in treating osteoporosis using network pharmacology and molecular docking. The findings indicate that Liuwei Dihuang Pills treat osteoporosis through various targets and channels. Specifically, it mainly involves TNF, IL17, and HIF 1 signaling pathways and helps regulate biological processes such as angiogenesis, apoptosis, hypoxia, and gene expression. Furthermore, molecular docking demonstrates excellent binding properties between the drug components and key targets. Therefore, this study offers a theoretical foundation for understanding the pharmacological mechanism and clinical application of Liuwei Dihuang Pills in treating osteoporosis more comprehensively.
C1 [Wang, Xiqoqiang; Song, Chao; Chen, Rui; Qiu, Junjie; Liu, Bing; Liu, Zongchao] Southwest Med Univ, Affiliated Hosp Tradit Chinese Med, Dept Orthoped & Traumatol Trauma & Bone Setting, Luzhou 646000, Sichuan Provinc, Peoples R China.
   [Li, Hongtao; Long, Longhai] Southwest Med Univ, Spinal Surg Dept, Affiliated Tradit Chinese Med Hosp, Luzhou, Peoples R China.
   [Liu, Zongchao] Luzhou Longmatan Dist Peoples Hosp, Luzhou, Peoples R China.
C3 Southwest Medical University; Southwest Medical University
RP Liu, ZC (通讯作者)，Southwest Med Univ, Affiliated Hosp Tradit Chinese Med, Dept Orthoped & Traumatol Trauma & Bone Setting, Luzhou 646000, Sichuan Provinc, Peoples R China.
EM wan4416@163.com; 851482370@qq.com; 2531635847@qq.com; 591065330@qq.com;
   851965216@qq.com; Fatty1366@163.com; 915892933@qq.com;
   lzcxnykdx@swmu.edu.cn; lzcxnykdx@swmu.edu.cn
RI ; Li, Hongtao/HNP 1383 2023; Liu, Zongchao/ISU 0913 2023; Song,
   Chao/KVY 3360 2024
OI Li, Hongtao/0000 0002 9377 6734; Song, Chao/0000 0003 0611 4298; 
FU Joint Innovation Special of the Sichuan Provincial Science and
   Technology Plan [2022YFS0609/022YFS0609 B3]; Luzhou's Major Scientific
   and Technology Research and Development Project [2022 SYF 42]
FX This research was supported by Joint Innovation Special of the Sichuan
   Provincial Science and Technology Plan (no. 2022YFS0609/022YFS0609 B3)
   and Luzhou's Major Scientific and Technology Research and Development
   Project (no. 2022 SYF 42).
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200
   Cheng Zhi An, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P261
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   Costa N, 2009, CYTOKINE, V46, P376, DOI 10.1016/j.cyto.2009.03.012
   Feng L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065965
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Fujimoto H, 1999, J BONE MINER METAB, V17, P211, DOI 10.1007/s007740050087
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Wu JS, 2022, J TRADIT CHIN MED, V42, P479, DOI 10.19852/j.cnki.jtcm.20220408.003
   Keller Baruch J, 2020, J BONE MINER RES, V35, P649, DOI 10.1002/jbmr.3937
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li LY, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03162 w
   Liu H, 2021, IUBMB LIFE, V73, P432, DOI 10.1002/iub.2440
   Liu MM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201778
   Liu XD, 2014, CELL BIOCHEM BIOPHYS, V69, P141, DOI 10.1007/s12013 013 9780 8
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   McKee H, 2020, OSTEOPOROSIS INT, V31, P973, DOI 10.1007/s00198 019 05267 1
   Moon SJ, 2013, INT J MOL MED, V31, P769, DOI 10.3892/ijmm.2013.1269
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Qiu ZX, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.111965
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Shao JJ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02742 1
   Shi X, 2023, MEDIAT INFLAMM, V2023, DOI 10.1155/2023/2613766
   Stone JA, 2019, BRIT J CLIN PHARMACO, V85, P1072, DOI 10.1111/bcp.13869
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   Wang J, 2023, CURR MOL PHARMACOL, V16, P321, DOI 10.2174/1874467215666220414145641
   Wang L, 2016, J TRADIT CHIN MED, V36, P332
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Wang YX, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2792738
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yi ZY, 2022, ACTA DIABETOL, V59, P1295, DOI 10.1007/s00592 022 01922 y
   Yuan F, 2019, INT J SURG, V66, P1, DOI 10.1016/j.ijsu.2019.03.004
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhang D, 2023, CELL BIOL TOXICOL, V39, P2243, DOI 10.1007/s10565 022 09713 5
   Zhang P, 2017, MOL MED REP, V16, P5515, DOI 10.3892/mmr.2017.7276
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
   Zhu XD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.889008
NR 44
TC 2
Z9 2
U1 3
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 20
PY 2023
VL 102
IS 42
AR e34773
DI 10.1097/MD.0000000000034773
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EQ9H1
UT WOS:001140501600069
PM 37861542
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, B
   Chen, KZ
   Qian, NAD
   Huang, P
   Hu, FQ
   Ding, T
   Xu, X
   Zhou, Q
   Chen, B
   Deng, LF
   Ye, TW
   Guo, L
AF Li, Bin
   Chen, Kaizhe
   Qian, Niandong
   Huang, Ping
   Hu, Fangqiong
   Ding, Tao
   Xu, Xing
   Zhou, Qi
   Chen, Bo
   Deng, Lianfu
   Ye, Tianwen
   Guo, Lei
TI Baicalein alleviates osteoarthritis by protecting subchondral bone,
   inhibiting angiogenesis and synovial proliferation
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE angiogenesis; baicalein; osteoarthritis; subchondral bone; synovitis
ID FIBROBLAST LIKE SYNOVIOCYTES; ARTICULAR CARTILAGE; CELL PROLIFERATION;
   GROWTH; INFLAMMATION; MECHANISMS; MIGRATION; MODELS; JOINT
AB Osteoarthritis (OA) is one of the most frequent chronic joint diseases with the increasing life expectancy. The main characteristics of the disease are loss of articular cartilage, subchondral bone sclerosis and synovium inflammation. Physical measures, drug therapy and surgery are the mainstay of treatments for OA, whereas drug therapies are mainly limited to analgesics, glucocorticoids, hyaluronic acids and some alternative therapies because of single therapeutic target of OA joints. Baicalein, a traditional Chinese medicine extracted from Scutellaria baicalensis Georgi, has been widely used in anti inflammatory therapies. Previous studies revealed that baicalein could alleviate cartilage degeneration effectively by acting on articular chondrocytes. However, the mechanisms involved in baicalein mediated protection of the OA are not completely understood in consideration of integrality of arthrosis. In this study, we found that intra articular injection of baicalein ameliorated subchondral bone remodelling. Further studies showed that baicalein could decrease the number of differentiated osteoblasts by inhibiting pre osteoblasts proliferation and promoting pre osteoblasts apoptosis. In addition, baicalein impaired angiogenesis of endothelial cells and inhibited proliferation of synovial cells. Taken together, these results implicated that baicalein might be an effective medicine for treating OA by regulating multiple targets.
C1 [Li, Bin; Chen, Kaizhe; Qian, Niandong; Huang, Ping; Hu, Fangqiong; Ding, Tao; Xu, Xing; Zhou, Qi; Chen, Bo; Deng, Lianfu; Guo, Lei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Shanghai Inst Traumatol & Orthopaed, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai, Peoples R China.
   [Ye, Tianwen] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Naval Medical University
RP Guo, L (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, 197 Second Ruijin Rd, Shanghai 200025, Peoples R China.; Ye, TW (通讯作者)，Second Mil Med Univ, Changzheng Hosp, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM yetianwenvip@126.com; guolei607@126.com
RI Huang, Ping/AAE 7205 2019; 李, 继斌/ABN 2541 2022; Zhou, Qi/JGM 4026 2023
FU National Natural Science Foundation of China [81870617, 81672202];
   Science and Technology Commission of Shanghai [15411950900]
FX National Natural Science Foundation of China, Grant/Award Number:
   81870617 and 81672202; Science and Technology Commission of Shanghai,
   Grant/Award Number: 15411950900
CR Amin MA, 2017, SEMIN IMMUNOPATHOL, V39, P385, DOI 10.1007/s00281 017 0631 3
   Armiento AR, 2018, ACTA BIOMATER, V65, P1, DOI 10.1016/j.actbio.2017.11.021
   ARNOLDI C C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P409
   Bi X, 2019, EBIOMEDICINE, V50, P408, DOI 10.1016/j.ebiom.2019.11.024
   Bie BB, 2017, BIOMED PHARMACOTHER, V93, P1285, DOI 10.1016/j.biopha.2017.07.068
   Carballo CB, 2017, CLIN SPORT MED, V36, P413, DOI 10.1016/j.csm.2017.02.001
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chen WP, 2015, CELL PHYSIOL BIOCHEM, V36, P325, DOI 10.1159/000374075
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Haywood L, 2003, ARTHRITIS RHEUM, V48, P2173, DOI 10.1002/art.11094
   Henrotin Y, 2012, OSTEOPOROSIS INT, V23, pS847, DOI 10.1007/s00198 012 2162 z
   Huang YJ, 2017, ONCOTARGET, V8, P883, DOI 10.18632/oncotarget.13669
   Hügle T, 2017, RHEUMATOLOGY, V56, P1461, DOI 10.1093/rheumatology/kew389
   Jiao K, 2015, SCI REP UK, V5, DOI 10.1038/srep12593
   Kang H, 2016, OSTEOPOROSIS INT, V27, P1493, DOI 10.1007/s00198 015 3381 x
   Karsdal MA, 2008, OSTEOARTHR CARTILAGE, V16, P638, DOI 10.1016/j.joca.2008.01.014
   Kuroki K, 2011, OSTEOARTHR CARTILAGE, V19, P1142, DOI 10.1016/j.joca.2011.06.007
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li YX, 2019, INT IMMUNOPHARMACOL, V73, P362, DOI 10.1016/j.intimp.2019.05.024
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Liu F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02847
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   Mapp PI, 2008, OSTEOARTHR CARTILAGE, V16, P61, DOI 10.1016/j.joca.2007.05.017
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1229 9
   Muraoka T, 2007, ARTHRITIS RHEUM US, V56, P3366, DOI 10.1002/art.22921
   Park YG, 2017, ONCOL REP, V38, P3011, DOI 10.3892/or.2017.6007
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Pesesse L, 2011, JOINT BONE SPINE, V78, P144, DOI 10.1016/j.jbspin.2010.07.001
   Shah MR, 2007, BULL HOSP JT DIS, V65, P51
   Shi CG, 2015, J MOL ENDOCRINOL, V54, P325, DOI 10.1530/JME 14 0314
   Wang CZ, 2020, CLIN TRANSL ONCOL, V22, P1013, DOI 10.1007/s12094 019 02225 5
   Xu TT, 2019, AGING US, V11, P9310, DOI 10.18632/aging.102371
   Yu D, 2016, CLIN EXP RHEUMATOL, V34, P929
   Zhang XD, 2014, INT IMMUNOPHARMACOL, V21, P301, DOI 10.1016/j.intimp.2014.05.006
   Zhang YD, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106220
   Zhao WW, 2016, J ORTHOP RES, V34, P763, DOI 10.1002/jor.23079
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
NR 41
TC 34
Z9 42
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2021
VL 25
IS 11
BP 5283
EP 5294
DI 10.1111/jcmm.16538
EA MAY 2021
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SM9LL
UT WOS:000646277400001
PM 33939310
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Long, F
   Chen, RF
   Su, YG
   Liang, JM
   Xian, YS
   Yang, F
   Lian, HY
   Xu, JK
   Zhao, JM
   Liu, Q
AF Long, Feng
   Chen, Runfeng
   Su, Yuangang
   Liang, Jiamin
   Xian, Yansi
   Yang, Fan
   Lian, Haoyu
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Epoxymicheliolide inhibits osteoclastogenesis and resists OVX induced
   osteoporosis by suppressing ERK1/2 and NFATc1 signaling
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Epoxymicheliolide; Osteoclastogenesis; ERK1; 2; NFATc1; Osteoporosis
ID IN VITRO; BONE; ESTROGEN; DRUG
AB The hyperactivity of osteoclasts caused by postmenopausal estrogen deficiency plays an imperative role in the progression of osteoporosis. Although osteoporosis related drugs have been widely used to alleviate this disorder, there is an urgent need for drugs with fewer side effects. In this study, we found that epoxymicheliolide (EMCL), a derivative of parthenolide, has a high affinity to ERK1/2, but the treatment and mechanism of osteoporosis using EMCL have not been explored. Therefore, we intended to figure out the effects and potential mechanisms of EMCL on RANKL stimulated osteoclast formation and function in vitro, construct an OVX murine model to simulate the therapeutic effects of EMCL on estrogen deficient bone loss subsequently. EMCL restrained the phosphorylation of ERK1/2 in the RANKL stimulated MAPK pathway, which in sequence inhibited the transcription and expression of the main osteoclast transcription factor NFATc1, resulting in the suppression of osteoclastogenesis and bone resorption. However, the same concentration of EMCL did not affect the proliferation and differentiation of osteoblasts. In vivo experiments showed that EMCL can significantly resist osteoporosis caused by estrogen deficiency, alleviate bone loss, and reduce the number of osteoclasts. These results suggest that EMCL can reduce osteoclast production and bone resorption by inhibiting ERK1/2 phosphorylation and NFATc1 entering the nucleus, and could be used in the treatment of osteoporosis caused by estrogen deficiency and hyperactivity of osteoclasts.
C1 [Long, Feng; Su, Yuangang; Liang, Jiamin; Xian, Yansi; Yang, Fan; Lian, Haoyu; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Orthopaed Dept, Res Ctr Regenerat Med, 22 Shuangyong Rd, Nanning, Peoples R China.
   [Xian, Yansi; Yang, Fan] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioRes, Nanning 530021, Guangxi, Peoples R China.
   [Chen, Runfeng] Guangzhou Med Univ, Guangzhou 510120, Guangdong, Peoples R China.
   [Su, Yuangang; Liang, Jiamin; Lian, Haoyu; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
C3 Guangxi Medical University; Guangxi Medical University; Guangzhou
   Medical University; Guangxi Medical University; University of Western
   Australia
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Orthopaed Dept, Res Ctr Regenerat Med, 22 Shuangyong Rd, Nanning, Peoples R China.
EM zhaojinmin@126.com; luoboqian@hotmail.com
RI Su, Yuangang/KKU 6952 2024; zhao, jin/LBH 0351 2024; Lian,
   Haoyu/W 3317 2017
OI Xu, Jiake/0000 0003 2021 8309
FU National Natural Science Foundation of China [81960405]; Guangxi
   Science, Technology Base and Talent Special Project [19254003]; Guangxi
   Natural Science Foundation [2018GXNSFAA050092]
FX Funding All work of this paper was funded by the National Natural
   Science Foundation of China (81960405) , Guangxi Science, Technology
   Base and Talent Special Project (Grant No. GuikeAD 19254003) , and
   Guangxi Natural Science Foundation (2018GXNSFAA050092) .
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P846, DOI 10.1016/j.tem.2021.07.011
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Broadhead M.L., THERAPEUTIC TARGETIN
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Etich J, 2020, CELL SIGNAL, V76, DOI 10.1016/j.cellsig.2020.109789
   Gaojian T., 2020, Cell Death Dis., V6, P97, DOI 10.1038
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lee HI, 2020, BMB REP, V53, P218, DOI 10.5483/BMBRep.2020.53.4.220
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee WS, 2016, INT IMMUNOPHARMACOL, V40, P146, DOI 10.1016/j.intimp.2016.08.021
   Liu Q, 2015, SCAND J RHEUMATOL, V44, P182, DOI 10.3109/03009742.2014.938113
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Moller AMJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176368
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Qin S., INT J MOL SCI 16
   Russo R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238965
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Takayanagi H., DEV CELL, V3
   Tang DE, 2020, AGING US, V12, P13297, DOI 10.18632/aging.103434
   Veronesi F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030499
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198 009 0925 y
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
   Yu CC, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109383
   Zawawi M.S.F., J BIOMED MAT RES 103
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu JB, 2018, INT J ONCOL, V53, P987, DOI 10.3892/ijo.2018.4460
NR 45
TC 14
Z9 16
U1 1
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2022
VL 107
AR 108632
DI 10.1016/j.intimp.2022.108632
EA MAR 2022
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 1C6EA
UT WOS:000793208700005
PM 35248947
OA hybrid
DA 2025 08 17
ER

PT J
AU Shao, BY
   Liao, L
   Yu, Y
   Shuai, Y
   Su, XX
   Jing, H
   Yang, DQ
   Jin, Y
AF Shao, Bingyi
   Liao, Li
   Yu, Yang
   Shuai, Yi
   Su, Xiaoxia
   Jing, Huan
   Yang, Deqin
   Jin, Yan
TI Estrogen preserves Fas ligand levels by inhibiting microRNA 181a in bone
   marrow derived mesenchymal stem cells to maintain bone remodeling
   balance
SO FASEB JOURNAL
LA English
DT Article
DE apoptosis; osteoclast; osteoporosis; gene regulation; cell
   transplantation
ID RECEPTOR ALPHA; OSTEOBLAST PROGENITORS; APOPTOSIS; TRANSPLANTATION;
   EXPRESSION; RESORPTION; GROWTH; CXCR4; RANK; MASS
AB Estrogen protects bone loss by promoting Fas ligand (FasL) transcription in osteoclasts and osteoblasts to induce apoptosis of osteoclasts. Bone marrow derived mesenchymal stem cells (BMMSCs) express FasL protein, which is necessary for BMMSCs to induce T cell apoptosis in cell therapy. However, the physiologic function of FasL in BMMSCs is unknown. In this study, using an in vitro coculture system and an in vivo BMMSC transplantation assay, we found that BMMSCs potently induced apoptosis of osteoclasts through the FasL/Fas pathway. Estrogen was necessary for this process as a promoter of FasL protein accumulation in BMMSCs. Furthermore, estrogen elevated FasL protein accumulation, not by increasing FasL gene transcription, but through microRNA mediated posttranscriptional regulation. In brief, estrogen down regulated expression of miR 181a, a negative modulator of FasL targeting the 3' UTR of FasL mRNA. Estrogen deficiency resulted in excessive miR 181a, which decreased FasL protein levels to suppress BMMSC induced osteoclast apoptosis. Furthermore, knockdown of miR 181a recovered the BMMSC defect to induce osteoclast apoptosis during estrogen deficiency. Taken together, our results showed that estrogen preserves FasL protein accumulation by inhibiting miR 181a expression in BMMSCs to maintain bone remodeling balance, suggesting a novel mechanism by which estrogen preserves bone mass.
C1 [Shao, Bingyi; Liao, Li; Yu, Yang; Shuai, Yi; Jing, Huan; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Liao, Li; Shuai, Yi; Jing, Huan] Fourth Mil Med Univ, Sch Stomatol, Dept Oral Histol & Pathol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Liao, Li; Shuai, Yi; Jing, Huan; Jin, Yan] Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Shao, Bingyi; Yu, Yang; Yang, Deqin] Chongqing Med Univ, Affiliated Hosp Stomatol, Chongqing, Peoples R China.
   [Shao, Bingyi; Yu, Yang; Yang, Deqin] Chongqing Res Ctr Oral Dis & Biomed Sci, Chongqing, Peoples R China.
   [Su, Xiaoxia] Xi An Jiao Tong Univ, Coll Med, Inst Neurobiol Environm & Genes Related Dis, Key Lab,Educ Minist, Xian 710049, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Chongqing Medical University; Xi'an Jiaotong
   University
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Ctr Tissue Engn, 145 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM yangdeqin@gmail.com; yanjin@fmmu.edu.cn
RI Jing, Huan/KKW 7423 2024; Liao, Li/U 6866 2017; Shuai, Yi/ABQ 4038 2022;
   Jin, Yan/I 4204 2013; Yang, Deqin/LCD 5734 2024
OI Liao, Li/0000 0003 0030 1009; Yang, Deqin/0000 0002 2579 8384
FU National Major Scientific Research Program of China [2011CB964700];
   Nature Science Foundation of China [31030033, 81470710]
FX This work was supported by Grant 2011CB964700 from the National Major
   Scientific Research Program of China, and Grants 31030033 and 81470710
   from the Nature Science Foundation of China. The authors declare no
   conflicts of interest.
CR Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Klinge CM, 2012, TRENDS ENDOCRIN MET, V23, P223, DOI 10.1016/j.tem.2012.03.002
   Kobayashi Y, 2000, J BONE MINER RES, V15, P1924, DOI 10.1359/jbmr.2000.15.10.1924
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Määttä JA, 2013, FASEB J, V27, P478, DOI 10.1096/fj.12 213587
   Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008 5472.CAN 09 2206
   Manavalan TT, 2011, CANCER LETT, V313, P26, DOI 10.1016/j.canlet.2011.08.018
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Qian PX, 2011, CANCER RES, V71, P6463, DOI 10.1158/0008 5472.CAN 11 1322
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
NR 37
TC 43
Z9 55
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2015
VL 29
IS 9
BP 3935
EP 3944
DI 10.1096/fj.15 272823
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA CP5IU
UT WOS:000359915600028
PM 26062603
DA 2025 08 17
ER

PT J
AU Lee, S
   Liu, P
   Ahmad, M
   Tuckermann, JP
AF Lee, Sooyeon
   Liu, Peng
   Ahmad, Mubashir
   Tuckermann, Jan P.
TI Leukemia inhibitory factor treatment attenuates the detrimental effects
   of glucocorticoids on bone in mice
SO BONE
LA English
DT Article
DE Leukemia inhibitory factor; Glucocorticoid induced osteoporosis;
   Glucocorticoids; Osteoblast differentiation
AB Glucocorticoids (GCs) are widely used drugs for the treatment of inflammatory and autoimmune diseases. However, a severe side effect induced by long term GC therapy is osteoporosis. Leukemia inhibitory factor (LIF)   a glycoprotein 130 (gp130) dependent cytokine and member of the interleukin 6 cytokine family   is an activator protein 1 (AP 1) target gene that may be involved in one of the mechanisms underlying GC induced bone loss. Indeed, we previously reported that the mRNA expression level of LIF was enhanced upon osteogenic differentiation, but was significantly decreased in GC treated osteoblasts. In this study, we show that in vitro LIF treatment rescues the decreased early osteogenic differentiation and mineralization of GC treated osteoblasts. Furthermore, we also demonstrate that in vivo LIF treatment protects against GC mediated trabecular bone loss by decreasing the loss of both trabecular bone formation and osteoblast numbers. This protection appears to be conferred by LIF rescuing GC decreased activity of Stat3, MAPK, and Akt signaling pathways. Thus, the specific targeting of LIF signaling may represent a new therapeutic strategy to prevent GC induced trabecular bone loss.
C1 [Lee, Sooyeon; Liu, Peng; Ahmad, Mubashir; Tuckermann, Jan P.] Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
   [Tuckermann, Jan P.] Clin Ludwig Maximilians Univ Munich, Munich, Germany.
C3 Ulm University; University of Munich
RP Tuckermann, JP (通讯作者)，Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
EM jan.tuckermann@uni ulm.de
RI ; LEE, SOOYEON/KAM 6204 2024; Ahmad, Mubashir/HHS 0865 2022
OI Ahmad, Mubashir/0000 0001 9012 4039; Lee, Sooyeon/0000 0001 6244 4975
FU Deutsche Forschungsgemeinschaft [1149 C02/INST 40/492 2, Tu220/14 1]
FX This project was supported by the Deutsche Forschungsgemeinschaft
   (Collaborative Research Center 1149 C02/INST 40/492 2 and Tu220/14 1).
   The authors thank Janine Webner for technical assistance. We are
   grateful to the staff of the animal facilities at the University of Ulm.
CR Ahmad M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02460
   Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Buttgereit F, 2020, NAT REV RHEUMATOL, V16, P239, DOI 10.1038/s41584 020 0370 z
   Cho DC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00920 x
   CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359
   Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715
   Dazai S, 2000, J CRANIOFAC SURG, V11, P513, DOI 10.1097/00001665 200011060 00002
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0
   GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460 2075.1987.tb02742.x
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021
   Langlais D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000224
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Liu CL, 2017, CYTOKINE, V91, P132, DOI 10.1016/j.cyto.2016.12.016
   Malaval L, 2001, J CELL BIOCHEM, P63
   Marriott MP, 2008, GLIA, V56, P686, DOI 10.1002/glia.20646
   Matsushita K, 2014, J CELL BIOCHEM, V115, P1262, DOI 10.1002/jcb.24777
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948
   Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Poulton IJ, 2012, J BONE MINER RES, V27, P586, DOI 10.1002/jbmr.1485
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Levy CS, 2010, J CELL BIOCHEM, V110, P857, DOI 10.1002/jcb.22595
   Sims NA, 2020, EXP MOL MED, V52, P1185
   Sims NA, 2012, GROWTH FACTORS, V30, P76, DOI 10.3109/08977194.2012.656760
   Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513
   STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0
   Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801
   TOMIDA M, 1984, J BIOL CHEM, V259, P978
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   WARE CB, 1995, DEVELOPMENT, V121, P1283
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
NR 39
TC 8
Z9 9
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2021
VL 145
AR 115843
DI 10.1016/j.bone.2021.115843
EA JAN 2021
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QO4MU
UT WOS:000623118400011
PM 33429108
DA 2025 08 17
ER

PT J
AU Wang, S
   Ding, P
   Xia, XP
   Chen, XX
   Mi, DG
   Sheng, SJ
   Gu, FL
   Li, ZW
   Su, KL
   Li, YW
AF Wang, Sheng
   Ding, Pei
   Xia, Xiaopeng
   Chen, Xuexian
   Mi, Daguo
   Sheng, Shuijie
   Gu, Fulong
   Li, Zhongwei
   Su, Kelei
   Li, Yuwei
TI Bugan Rongjin decoction alleviates inflammation and oxidative stress to
   treat the postmenopausal knee osteoarthritis through Wnt signaling
   pathway
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
DE Bugan Rongjin decoction; Inflammation; Oxidative stress; Wnt signaling
   pathway; Postmenopausal knee osteoarthritis
ID CHONDROCYTES; APOPTOSIS; CHINESE
AB Background Traditional Chinese medicine has been found effective for the therapy of knee osteoarthritis (KOA). This study was aimed at investigating the underlying mechanism of Bugan Rongjin decoction (BGRJ) in treating the postmenopausal KOA. Results Ovariectomized rat model of KOA and LPS induced chondrocytes were successfully constructed for in vivo and in vitro model of postmenopausal KOA. X ray and hematoxylin eosin (H&E) staining showed that BGRJ alleviated pathological damage of articular cartilage in OVX rats with KOA. In addition, BGRJ inhibited inflammation and oxidative stress through decreasing the levels of serum IL 6, IL 1 beta, TNF alpha and NO and regulated Wnt signaling pathway by downregulating the expression of Wnt5a and beta catenin and upregulating the expression of Sox9 and Collagen II in cartilage tissue, detected by immunohistochemistry (IHC) and western blot analysis. Furthermore, Wnt5a silencing reduced the apoptosis of LPS induced ADTC5 cells, which was further suppressed by the combination of downregulation of Wnt5a and BGRJ. Conclusions In summary, BGRJ alleviates inflammation and oxidative stress to treat the postmenopausal KOA through Wnt signaling pathway.
C1 [Wang, Sheng; Xia, Xiaopeng; Chen, Xuexian; Mi, Daguo; Gu, Fulong; Li, Zhongwei] Nanjing Univ Chinese Med, Dept Orthoped & Traumatol, Nantong TCM Hosp, Nantong 226001, Jiangsu, Peoples R China.
   [Ding, Pei] Nanjing Univ Chinese Med, Dept Pediat, Nantong TCM Hosp, Nantong 226001, Jiangsu, Peoples R China.
   [Sheng, Shuijie] Nanjing Univ Chinese Med, Dept Sci & Educ, Nantong TCM Hosp, Nantong 226001, Jiangsu, Peoples R China.
   [Su, Kelei] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Dept Resp Med, 100 Cross St,Hongshan Rd, Nanjing 210028, Jiangsu, Peoples R China.
   [Li, Yuwei] Nanjing Univ Chinese Med, Dept Orthoped & Traumatol, Suzhou TCM Hosp, 18 Yangsu Rd, Suzhou 215000, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine; Nanjing University of Chinese Medicine
RP Su, KL (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Dept Resp Med, 100 Cross St,Hongshan Rd, Nanjing 210028, Jiangsu, Peoples R China.; Li, YW (通讯作者)，Nanjing Univ Chinese Med, Dept Orthoped & Traumatol, Suzhou TCM Hosp, 18 Yangsu Rd, Suzhou 215000, Jiangsu, Peoples R China.
EM sukelei@163.com; liyuweiyw@163.com
RI Li, Zhongwei/ABA 7757 2020
FU Nantong Science and Technology Bureau [MS12019036]; Nantong Health
   Commission Youth Fund Project [QA2019016]
FX Command project of Nantong Science and Technology Bureau (MS12019036);
   Nantong Health Commission Youth Fund Project (QA2019016).
CR Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Boyan BD, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042 6410 4 3
   Defa Liao, 2017, MINIMALLY INVASIVE M, V12, P521, DOI [10.11864/j.issn.1673.2017.04.22, DOI 10.11864/J.ISSN.1673.2017.04.22]
   Dong RJ, 2020, J PHYS CHEM B, V124, P504, DOI 10.1021/acs.jpcb.9b11095
   Dubin A, 2016, MED CLIN N AM, V100, P147, DOI 10.1016/j.mcna.2015.08.008
   [高晶 Gao Jing], 2019, [中国免疫学杂志, Chinese Journal of Immunology], V35, P686
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Guo J, 2019, TRIALS, V20, DOI 10.1186/s13063 019 3233 7
   He G, 2014, CELL BIOCHEM BIOPHYS, V70, P467, DOI 10.1007/s12013 014 9942 3
   Johnson VL, 2014, BEST PRACT RES CL RH, V28, P5, DOI 10.1016/j.berh.2014.01.004
   Ju LJ, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110471
   Kim KS, 2005, TOXICOL IN VITRO, V19, P757, DOI 10.1016/j.tiv.2005.04.008
   Li HT, 2019, IMMUNOPHARM IMMUNOT, V41, P497, DOI 10.1080/08923973.2019.1637890
   Liu L, 2018, CHIN J INTEGR MED, V24, P390, DOI 10.1007/s11655 018 2836 2
   Liu W, 2017, J SICHUAN TRAD CHIN, V35, P122
   Lou F., 2017, CLIN J TRAD CHIN MED, V29, P1912
   Meng Q, 2012, LIAONING J TRAD CHIN, V39, P791
   Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004
   Philp AM, 2017, RHEUMATOLOGY, V56, P869, DOI 10.1093/rheumatology/kew278
   Qin Y, 2010, STUDY SYNDROME DIFFE
   Shun L, 2015, GLOBAL TRADITIONAL C, V8, P1149
   Tang M., 2014, J TRAD CHIN ORTHOPED, V26, P12
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   Wang F, 2014, INT IMMUNOPHARMACOL, V23, P575, DOI 10.1016/j.intimp.2014.10.007
   Wang HM, 2010, CHIN J INTEGR MED, V16, P378, DOI 10.1007/s11655 010 0512 2
   Xiang ming N, 2014, J CLIN MED, V1, P2080
   Xie TJ, 2018, PHYTOTHER RES, V32, P2247, DOI 10.1002/ptr.6161
   Yuasa T, 2008, LAB INVEST, V88, P264, DOI 10.1038/labinvest.3700747
   Zeng LingFeng Zeng LingFeng, 2017, China Journal of Traditional Chinese Medicine and Pharmacy, V32, P5088
   Zeng YF, 2019, MED SCI MONITOR, V25, P6649, DOI 10.12659/MSM.916209
   Zhang SJ, 2018, CARBOHYD POLYM, V184, P288, DOI 10.1016/j.carbpol.2017.12.070
   Zhuang C, 2018, INT J BIOL MACROMOL, V115, P281, DOI 10.1016/j.ijbiomac.2018.04.083
NR 32
TC 11
Z9 12
U1 1
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475 925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD OCT 13
PY 2021
VL 20
IS 1
AR 103
DI 10.1186/s12938 021 00939 8
PG 14
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA WG5DX
UT WOS:000707016300001
PM 34645468
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Costa, JL
   Smith, G
   Watson, M
   Lin, JM
   Callon, K
   Gamble, G
   Cheng, A
   Vickers, MH
   Shepherd, PR
   Cornish, J
   Grey, A
AF Costa, Jessica L.
   Smith, Greg
   Watson, Maureen
   Lin, Jian Ming
   Callon, Karen
   Gamble, Greg
   Cheng, Anthony
   Vickers, Mark H.
   Shepherd, Peter R.
   Cornish, Jillian
   Grey, Andrew
TI The atypical anti psychotic clozapine decreases bone mass in rats in
   vivo
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Anti psychotic; Bone density; Osteoblast; Osteoporosis
ID MINERAL DENSITY; SEROTONIN; SCHIZOPHRENIA; VITRO; RISK;
   OSTEOCLASTOGENESIS; PROLIFERATION; NEUROLEPTICS; PROTEINS; FRACTURE
AB Background: Fracture risk is increased in patients with schizophrenia, who often receive long term therapy with anti psychotic drugs. The mechanisms by which skeletal fragility is increased in patients with psychosis include increased risk of falling, but direct skeletal toxicity of anti psychotic drugs is a possibility that has not been investigated.
   Methods: We examined the skeletal effects, in vivo and in vitro, of a typical anti psychotic drug, haloperidol, which primarily inhibits dopaminergic signaling, and an atypical anti psychotic drug, clozapine, which predominantly inhibits serotonergic signaling.
   Results: In growing rats, 42 days of clozapine treatment reduced whole body bone mineral density by 15% (P<0.01 vs vehicle), and trabecular and cortical bone volume, as assessed by microcomputed tomography, by 29% and 15%, respectively (P<0.05 vs vehicle for each). Treatment with haloperidol did not affect bone density. Clozapine, but not haloperidol, transiently increased levels of serum corticosterone, and decreased levels of serum testosterone. In vitro, clozapine dose dependently decreased osteoblast mitogenesis, osteoblast differentiation and osteoclastogenesis, while haloperidol did not affect any of these parameters.
   Conclusions: These data demonstrate that clozapine, but not haloperidol, exerts adverse skeletal effects in rodents, and that this effect may be attributable to direct actions to reduce osteoblast growth and function. Long term administration of clozapine may therefore negatively affect bone health, and clinical studies to investigate this possibility are warranted. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Costa, Jessica L.; Watson, Maureen; Lin, Jian Ming; Callon, Karen; Gamble, Greg; Cheng, Anthony; Cornish, Jillian; Grey, Andrew] Univ Auckland, Dept Med, Auckland, New Zealand.
   [Smith, Greg; Shepherd, Peter R.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand.
   [Vickers, Mark H.] Univ Auckland, Ctr Growth & Dev, Liggins Inst & Natl Res, Auckland 1, New Zealand.
C3 University of Auckland; University of Auckland; University of Auckland
RP Grey, A (通讯作者)，Univ Auckland, Dept Med, Private Bag 92019, Auckland, New Zealand.
EM a.grey@auckland.ac.nz
RI Costa, Jessica/E 2234 2011
OI Lin, Jian/0000 0002 8362 6951; Vickers, Mark/0000 0003 4876 9356;
   Gamble, Greg/0000 0003 0412 3203
FU Health Research Council of New Zealand; Auckland Medical Research
   Foundation; Lottery Research Fund; Oakley Mental Health Foundation
FX Funding support was from the Health Research Council of New Zealand, the
   Auckland Medical Research Foundation, the Lottery Research Fund and the
   Oakley Mental Health Foundation. None of the funding bodies had a role
   in study design, in the collection, analysis and interpretation of data,
   in the writing of the report, or in the decision to submit the paper for
   publication.
CR Alaniz RC, 1999, P NATL ACAD SCI USA, V96, P2274, DOI 10.1073/pnas.96.5.2274
   Bilici M, 2002, INT J NEUROSCI, V112, P817, DOI 10.1080/00207450290025833
   Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756 3282(99)00232 X
   Bliziotes M, 2010, J CLIN ENDOCR METAB, V95, P4124, DOI 10.1210/jc.2010 0861
   Citrome L, 2002, HARVARD REV PSYCHIAT, V10, P280, DOI 10.1080/10673220216279
   Collet C, 2008, FASEB J, V22, P418, DOI 10.1096/fj.07 9209com
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Cornish J, 1999, AM J PHYSIOL ENDOC M, V277, pE779, DOI 10.1152/ajpendo.1999.277.5.E779
   Cornish J, 2008, ENDOCRINOLOGY, V149, P5688, DOI 10.1210/en.2008 0111
   Freedman R, 2003, NEW ENGL J MED, V349, P1738, DOI 10.1056/NEJMra035458
   Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Gustafsson BI, 2006, J CELL BIOCHEM, V97, P1283, DOI 10.1002/jcb.20733
   HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842 199509000 00011
   Hall TJ, 1996, GEN PHARMACOL, V27, P845, DOI 10.1016/0306 3623(95)02109 4
   Howard L, 2007, BRIT J PSYCHIAT, V190, P129, DOI 10.1192/bjp.bp.106.023671
   Hugenholtz GWK, 2005, BONE, V37, P864, DOI 10.1016/j.bone.2005.07.005
   Markianos M, 1999, EUR NEUROPSYCHOPHARM, V9, P533, DOI 10.1016/S0924 977X(99)00040 1
   McGrath J, 2004, BMC MED, V2, DOI 10.1186/1741 7015 2 13
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Pouwels S, 2009, OSTEOPOROSIS INT, V20, P1499, DOI 10.1007/s00198 008 0826 5
   Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198 007 0492 z
   Smith GC, 2008, DIABETOLOGIA, V51, P2309, DOI 10.1007/s00125 008 1152 3
   Smith GC, 2009, SCHIZOPHR RES, V115, P30, DOI 10.1016/j.schres.2009.07.011
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Williams GA, 2009, ENDOCRINOLOGY, V150, P3603, DOI 10.1210/en.2008 1639
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 29
TC 13
Z9 14
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920 9964
EI 1573 2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAR
PY 2011
VL 126
IS 1 3
BP 291
EP 297
DI 10.1016/j.schres.2010.11.024
PG 7
WC Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 743NS
UT WOS:000289025700040
PM 21185156
DA 2025 08 17
ER

PT J
AU Motyl, KJ
   Beauchemin, M
   Barlow, D
   Le, PT
   Kenichi, NC
   Treyball, A
   Contractor, A
   Baron, R
   Rosen, CJ
   Houseknecht, KL
AF Motyl, Katherine J.
   Beauchemin, Megan
   Barlow, Deborah
   Le, Phuong T.
   Nagano, Kenichi
   Treyball, Annika
   Contractor, Anisha
   Baron, Roland
   Rosen, Clifford J.
   Houseknecht, Karen L.
TI A novel role for dopamine signaling in the pathogenesis of bone loss
   from the atypical antipsychotic drug risperidone in female mice
SO BONE
LA English
DT Article
DE Bone; Atypical antipsychotic drug; Risperidone; Hypogonadism; Dopamine;
   Osteoclast
ID SEROTONIN REUPTAKE INHIBITORS; MINERAL DENSITY; SCHIZOPHRENIA;
   PROLACTIN; FRACTURE; RISK; HYPERPROLACTINEMIA; ABNORMALITIES;
   OSTEOBLASTS; MEDICATION
AB Atypical antipsychotic (AA) drugs, including risperidone (RIS), are used to treat schizophrenia, bipolar disorder, and autism, and are prescribed off label for other mental health issues. AA drugs are associated with severe metabolic side effects of obesity and type 2 diabetes. Cross sectional and longitudinal data also show that risperidone causes bone loss and increases fracture risk in both men and women. There are several potential mechanisms of bone loss from RIS. One is hypogonadism due to hyperprolactinemia from dopamine receptor antagonism. However, many patients have normal prolactin levels; moreover we demonstrated that bone loss from RIS in mice can be blocked by inhibition of beta adrenergic receptor activation with propranolol, suggesting the sympathetic nervous system (SNS) plays a pathological role. Further, when, we treated ovariectomized (OVX) and sham operated mice daily for 8 weeks with RIS or vehicle we demonstrated that RIS causes significant trabecular bone loss in both sham operated and OVX mice. RIS directly suppressed osteoblast number in both sham and OVX mice, but increased osteoclast number and surface in OVX mice alone, potentially accounting for the augmented bone loss. Thus, hypogonadism alone cannot explain RIS induced bone loss. In the current study, we show that dopamine and RIS are present in the bone marrow compartment and that RIS can exert its effects directly on bone cells via dopamine receptors. Our findings of both direct and indirect effects of AA drugs on bone are relevant for current and future clinical and translational studies investigating the mechanism of skeletal changes from AA drugs. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Motyl, Katherine J.; Treyball, Annika] Maine Med Ctr Res Inst, Maine Med Ctr, Ctr Mol Med, Scarborough, ME USA.
   [Beauchemin, Megan; Barlow, Deborah; Contractor, Anisha; Houseknecht, Karen L.] Univ New England, Coll Osteopath Med, Dept Biomed Sci, 11 Hills Beach Rd, Biddeford, ME 04005 USA.
   [Nagano, Kenichi; Baron, Roland] Harvard Univ, Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA.
   [Le, Phuong T.; Rosen, Clifford J.] Maine Med Ctr Res Inst, Maine Med Ctr, Ctr Clin & Translat Res, Scarborough, ME USA.
C3 Maine Medical Center; University of New England   Maine; Harvard
   University; Harvard School of Dental Medicine; Maine Medical Center
RP Houseknecht, KL (通讯作者)，Univ New England, Coll Osteopath Med, Dept Biomed Sci, 11 Hills Beach Rd, Biddeford, ME 04005 USA.
EM khouseknecht@une.edu
RI Nagano, Kenichi/AAH 3246 2019; rosen, clifford/JOZ 3228 2023; Le,
   Phuong/B 3959 2019
FU UNE College of Osteopathic Morgane Fellowship;  [DK095143];  [AR061932];
    [AR067858];  [AG040217];  [GM103392];  [GM106391]
FX DK095143 to KLH, AR061932 and AR067858 to KJM, AG040217 to CJR, GM103392
   to Dr. Robert Friesel (MMCRI) and GM106391 to Dr. Don Wojchowski
   (MMCRI). AC was supported by UNE College of Osteopathic Morgane
   Fellowship.
CR Amer Diabet Assoc, 2004, DIABETES CARE, V27, P596, DOI 10.2337/diacare.27.2.596
   Becker D, 2003, J CLIN PSYCHIAT, V64, P761, DOI 10.4088/JCP.v64n0704
   Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756 3282(99)00232 X
   Calarge CA, 2010, J CLIN PSYCHIAT, V71, P338, DOI 10.4088/JCP.08m04595gre
   Calarge CA, 2009, J CHILD ADOL PSYCHOP, V19, P101, DOI 10.1089/cap.2008.007
   Clément Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96
   De Hert M, 2016, EXPERT OPIN DRUG SAF, V15, P809, DOI 10.1517/14740338.2016.1167873
   De Hert M, 2009, WORLD PSYCHIATRY, V8, P15
   de Paula F.J., 2011, CALCIF TISSUE INT
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dore DD, 2009, MOVEMENT DISORD, V24, P1941, DOI 10.1002/mds.22679
   Fraser L.A., 2015, JAMA INT MED
   Halbreich U, 2007, CNS DRUGS, V21, P641, DOI 10.2165/00023210 200721080 00003
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Irwin R, 2007, J CELL BIOCHEM, V100, P762, DOI 10.1002/jcb.21083
   Kishimoto T, 2008, J CLIN PSYCHIAT, V69, P385, DOI 10.4088/JCP.v69n0307
   Komossa K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006626.pub2
   Kuehn BM, 2013, JAMA J AM MED ASSOC, V310, P1109, DOI 10.1001/jama.2013.276603
   Ledesma Colunga MG, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1290 4
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Liperoti R, 2007, J CLIN PSYCHIAT, V68, P929, DOI 10.4088/JCP.v68n0616
   Meaney AM, 2007, SCHIZOPHR RES, V93, P136, DOI 10.1016/j.schres.2007.01.013
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Miyamoto S, 2005, MOL PSYCHIATR, V10, P79, DOI 10.1038/sj.mp.4001556
   Morris JK, 2011, EXP NEUROL, V231, P171, DOI 10.1016/j.expneurol.2011.06.005
   Motyl K.J., 2015, ENDOCRINOLOGY
   Motyl KJ, 2012, BONE, V50, P490, DOI 10.1016/j.bone.2011.08.005
   Olfson M, 2012, ARCH GEN PSYCHIAT, V69, P1247, DOI 10.1001/archgenpsychiatry.2012.647
   Ortuño MJ, 2016, NAT MED, V22, P1170, DOI 10.1038/nm.4166
   Pacchiarotti I, 2015, EUR NEUROPSYCHOPHARM, V25, P1045, DOI 10.1016/j.euroneuro.2015.04.007
   Parekh PK, 2015, ALCOHOL, V49, P341, DOI 10.1016/j.alcohol.2014.09.034
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Patel JK, 2009, SCHIZOPHR RES, V111, P9, DOI 10.1016/j.schres.2009.03.025
   Pijl H, 2003, EUR J PHARMACOL, V480, P125, DOI 10.1016/j.ejphar.2003.08.100
   Rigler SK, 2013, J AM GERIATR SOC, V61, P715, DOI 10.1111/jgs.12216
   Tsai KY, 2014, SCHIZOPHR RES, V159, P322, DOI 10.1016/j.schres.2014.09.032
   Worrel JA, 2000, AM J HEALTH SYST PH, V57, P238, DOI 10.1093/ajhp/57.3.238
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Zheng H, 2014, AM J PHYSIOL REG I, V306, pR138, DOI 10.1152/ajpregu.00323.2013
NR 39
TC 35
Z9 37
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2017
VL 103
BP 168
EP 176
DI 10.1016/j.bone.2017.07.008
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF0NY
UT WOS:000408599600021
PM 28689816
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Heervä, E
   Huilaja, L
   Leinonen, P
   Peltonen, S
   Peltonen, J
AF Heerva, Eetu
   Huilaja, Laura
   Leinonen, Pekka
   Peltonen, Sirkku
   Peltonen, Juha
TI Follow Up of Six Patients with Neurofibromatosis 1 Related Osteoporosis
   Treated with Alendronate for 23 Months
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone dynamics; Osteoclast; von Recklinghausen; Ras; BMD
ID POSTMENOPAUSAL OSTEOPOROSIS; TYPE 1; BISPHOSPHONATES; CHILDREN
AB This is the first prospective follow up study to describe the effects of oral alendronate medication on neurofibromatosis 1 (NF1) related osteoporosis. NF1 is a neurocutaneous skeletal syndrome associated with increased fracture risk and high frequency of osteopenia and osteoporosis. Alendronate is a bisphosphonate drug which inhibits the function of bone resorbing osteoclasts, ultimately leading to an increase in bone mineral density (BMD) and reduction in fracture risk. However, in vitro studies have shown that NF1 osteoclasts display insensitivity to apoptotic signals caused by bisphosphonates. Our aim was to monitor the effects of alendronate medication in patients with NF1. Five men and one woman, aged 28 76 years, with NF1 related osteoporosis were enrolled to the study. Study participants did not have other conditions and were not taking any medication known to affect bone. The medication included a weekly dose of 70 mg alendronate and a daily 20 mu g vitamin D supplementation. After 23 months of follow up, BMD was increased in five out of six patients, but the increase was not statistically significant. Serum levels of the bone turnover markers CTX and PINP were reduced, suggesting slower bone remodeling, as expected. An unexpected result was that serum levels of the osteoclast activity marker TRAP5b did not change during the follow up. One new stress fracture of the tibia was documented during the alendronate therapy. Even though the study group was small, the findings of the current study (one new fracture and one patient with decreased BMD) call for a larger study to assess the efficacy of bisphosphonates in NF1 related osteoporosis.
C1 [Heerva, Eetu; Peltonen, Juha] Univ Turku, Dept Cell Biol & Anat, FIN 20520 Turku, Finland.
   [Huilaja, Laura; Leinonen, Pekka] Oulu Univ Hosp, Dept Dermatol, Med Res Ctr, Oulu 90220, Finland.
   [Huilaja, Laura; Leinonen, Pekka] Univ Oulu, SF 90220 Oulu, Finland.
   [Leinonen, Pekka] Kainuu Cent Hosp, Dept Dermatol, Kajaani 87140, Finland.
   [Peltonen, Sirkku] Turku Univ Hosp, Dept Dermatol, Turku 20521, Finland.
   [Peltonen, Sirkku] Univ Turku, Turku 20521, Finland.
C3 University of Turku; University of Oulu; University of Oulu; University
   of Turku; University of Turku
RP Peltonen, J (通讯作者)，Univ Turku, Dept Cell Biol & Anat, Kiinamyllynkatu 10, FIN 20520 Turku, Finland.
EM juhpel@utu.fi
RI Peltonen, Juha/C 2817 2008; Peltonen, Sirkku/C 3133 2008; Heervä,
   Eetu/AAU 2139 2021
OI Peltonen, Juha/0000 0002 5732 4167; Peltonen,
   Sirkku/0000 0003 0990 1430; 
CR [Anonymous], 1988, ARCH NEUROL CHICAGO, V45, P575, DOI 10.1097/00005537 199606000 00007
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Birke O, 2010, J CHILD ORTHOP, V4, P507, DOI 10.1007/s11832 010 0293 3
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brunetti Pierri N, 2008, MOL GENET METAB, V94, P105, DOI 10.1016/j.ymgme.2007.12.004
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   George Abraham JK, 2013, AM J MED GENET A, V161A, P921, DOI 10.1002/ajmg.a.35541
   Heervä E, 2013, CALCIFIED TISSUE INT, V92, P23, DOI 10.1007/s00223 012 9661 y
   Heervä E, 2012, J BONE MINER RES, V27, P2333, DOI 10.1002/jbmr.1685
   Heervä E, 2012, BONE, V50, P798, DOI 10.1016/j.bone.2011.12.011
   Huson S. M., 2008, V16, P1, DOI 10.1159/000126500
   Jouhilahti EM, 2011, AM J PATHOL, V178, P1932, DOI 10.1016/j.ajpath.2010.12.056
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuorilehto T, 2005, OSTEOPOROSIS INT, V16, P928, DOI 10.1007/s00198 004 1801 4
   Lewiecki E, 2008, OSTEOPOROSIS INT, V19, P1078
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Peltonen S., 2012, NEUROFIBROMATOSIS TY, P17, DOI [10.1007/978 3 642 32864 0_2, DOI 10.1007/978 3 642 32864 0_2]
   Petramala L, 2012, ARCH DERMATOL RES, V304, P325, DOI 10.1007/s00403 011 1191 3
   Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570 000000000 00000
   Riccardi V.M., 1986, Neurofibromatosis: phenotype, natural history and pathogenesis
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Tucker T, 2009, J MED GENET, V46, P259, DOI 10.1136/jmg.2008.061895
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092 8674(90)90024 9
NR 27
TC 15
Z9 16
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUN
PY 2014
VL 94
IS 6
BP 608
EP 612
DI 10.1007/s00223 013 9835 2
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AG8KU
UT WOS:000335668100005
PM 24390519
DA 2025 08 17
ER

PT J
AU Cai, BL
   Dong, JC
   Su, B
   Yang, QT
   Wang, CR
   Yang, LY
   Song, ZC
   Liu, J
   Jin, RH
   Li, Y
AF Cai, Bolei
   Dong, Jiachen
   Su, Bo
   Yang, Qiutong
   Wang, Chenrui
   Yang, Luying
   Song, Zhongchen
   Liu, Jiang
   Jin, Ronghua
   Li, Yan
TI Construction of Multi Module RNA Nanoparticles Harboring miRNA, AIE, and
   CH6 Aptamer for Bone Targeting and Bone Anabolic Therapy
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bioengineering; biotechnology; bone regeneration; drug delivery; RNAi
ID PARATHYROID HORMONE; GOLD NANOPARTICLES; DNA; REGENERATION; ANALOGS;
   WOMEN
AB Bone healing remains a major challenge in the treatment of osteoporosis. Effective strategies that simultaneously promote bone formation and inhibit bone resorption are crucial for the treatment of osteoporosis and associated bone defects. MicroRNA (miRNA) based approaches aim at simultaneously promoting bone formation and suppressing bone resorption and have therapeutic potential. However, the toxicity of cationic carriers and off target effects are two major challenges associated with miRNA delivery. This study establishes a bone targeting miRNA delivery system (CH6 SNA 26a) that integrates aggregation induced emission (AIE), a CH6 aptamer, and miRNAs into a single nanoplatform without any cationic carrier. In this system, an AIE molecule is coupled to miR 26a to form a core shell spherical nucleic acid (SNA 26a). The CH6 aptamer is co assembled with the SNA to achieve specific miR 26a delivery to the bone surface. This aptamer functionalized, non cationic miR 26a delivery strategy (CH6 SNA 26a) enables both bone targeted delivery and high transfection efficiency, ultimately optimizing bone remodeling and calvarial bone healing in an osteoporosis mouse model while limiting adverse effects in non skeletal tissues. Mechanistically, the overexpression of CH6 SNA 26a in skeletal tissues promotes bone anabolic action by functionally targeting glycogen synthase kinase 3 beta in bone marrow mesenchymal stem cells and cellular communication network 2 in osteoclasts.
   A non cationic, safe, bone targeting microRNA (miRNA) delivery system (CH6 SNA) is established by integrating aggregation induced emission molecules, CH6 aptamer, and miRNAs into a single nano platform. The obtained CH6 SNA enables both targeted delivery and high miRNA transfection efficiency, enhancing the therapeutic outcome of the miRNA drug. This study may promote the future development of more effective and safer RNAi based bone anabolic therapies.image
C1 [Cai, Bolei; Wang, Chenrui; Li, Yan] Shanghai Jiao Tong Univ, Chinese Acad Med Sci, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Dept Oral Surg,Sch Med,, Shanghai, Peoples R China.
   [Cai, Bolei; Dong, Jiachen; Wang, Chenrui; Song, Zhongchen; Li, Yan] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai 200011, Peoples R China.
   [Cai, Bolei; Yang, Luying] Fourth Mil Med Univ, Shaanxi Key Lab Oral Dis, Natl Clin Res Ctr Oral Dis, Affiliated Hosp 3,Dept Oral & Maxillofacial Surg,S, Xian 710032, Peoples R China.
   [Dong, Jiachen; Song, Zhongchen] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Chinese Acad Med Sci, Natl Ctr Stomatol,Sch Med,Natl Clin Res Ctr Oral D, Shanghai, Peoples R China.
   [Su, Bo; Jin, Ronghua] Guangxi Med Univ, Guangxi Key Lab Bioact Mol Res & Evaluat, Guangxi Key Lab Pharmaceut Precis Detect & Screeni, Pharmaceut Coll,Guangxi Educ Dept,Key Lab Micronan, 22 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Yang, Qiutong] Univ Toronto, Life Sci, Toronto, ON M1C 1A4, Canada.
   [Liu, Jiang] Yuhui Stomatol Hosp Changshu City, Dept Implantol, Changshu 215500, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Shanghai Jiao Tong University; Shanghai Jiao Tong University; Air Force
   Medical University; Shanghai Jiao Tong University; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Guangxi Medical
   University; University of Toronto
RP Li, Y (通讯作者)，Shanghai Jiao Tong Univ, Chinese Acad Med Sci, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Dept Oral Surg,Sch Med,, Shanghai, Peoples R China.; Song, ZC; Li, Y (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai 200011, Peoples R China.; Song, ZC (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Chinese Acad Med Sci, Natl Ctr Stomatol,Sch Med,Natl Clin Res Ctr Oral D, Shanghai, Peoples R China.; Jin, RH (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Bioact Mol Res & Evaluat, Guangxi Key Lab Pharmaceut Precis Detect & Screeni, Pharmaceut Coll,Guangxi Educ Dept,Key Lab Micronan, 22 Shuangyong Rd, Nanning 530021, Peoples R China.; Liu, J (通讯作者)，Yuhui Stomatol Hosp Changshu City, Dept Implantol, Changshu 215500, Peoples R China.
EM szhongchen@sina.com; liujiang_yuhui@163.com; jinronghua@gxmu.edu.cn;
   Yanli_9thhospital@163.com
RI dong, jiachen/MYS 4183 2025; Jin, Ronghua/KRO 3592 2024; Wang,
   Chenrui/JKI 0962 2023; Cai, Bo Lei/JTS 5444 2023
FU National Key Research and Development Program of China; CAMS Innovation
   Fund for Medical Sciences [2019 I2M 5 037]; National Natural Science
   Foundation of China [81970977, 82270952, 82171009]; Shanghai's Top
   Priority Research Center Grant [2022ZZ01017];  [2023YFC2509100]
FX This work was supported by the National Key Research and Development
   Program of China (2023YFC2509100), the CAMS Innovation Fund for Medical
   Sciences (Project No. 2019 I2M 5 037), the National Natural Science
   Foundation of China (81970977, 82270952, 82171009), and Shanghai's Top
   Priority Research Center Grant (Award Number: 2022ZZ01017).
CR Balasubramanian SK, 2010, BIOMATERIALS, V31, P2034, DOI 10.1016/j.biomaterials.2009.11.079
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Burke SE, 2017, SOC PSYCHOL QUART, V80, P65, DOI 10.1177/0190272516668166
   Cho WS, 2009, TOXICOL APPL PHARM, V236, P16, DOI 10.1016/j.taap.2008.12.023
   Chompoosor A, 2010, SMALL, V6, P2246, DOI 10.1002/smll.201000463
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ding F, 2018, ANGEW CHEM INT EDIT, V57, P3064, DOI 10.1002/anie.201711242
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Fatoye F, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 027049
   Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006
   Guglielmo C. D., 2012, J NANOSCI NANOTECHNO, V12, P6185
   Hao Y, 2021, J AM CHEM SOC, V143, P3065, DOI 10.1021/jacs.1c00568
   Huang D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33006 4
   Huang MQ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28627 8
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   John AA, 2022, MOL THER NUCL ACIDS, V29, P296, DOI 10.1016/j.omtn.2022.07.008
   Kim K, 2015, MOL CELLS, V38, P75, DOI 10.14348/molcells.2015.2241
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Li R, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201910369
   Li Y, 2021, ACTA BIOMATER, V130, P435, DOI 10.1016/j.actbio.2021.05.024
   Li Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6740
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lopez Chaves C, 2018, NANOMED NANOTECHNOL, V14, P1, DOI 10.1016/j.nano.2017.08.011
   Paino IMM, 2012, TOXICOL LETT, V215, P119, DOI 10.1016/j.toxlet.2012.09.025
   MEISTER A, 1988, J BIOL CHEM, V263, P17205
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Ng CT, 2013, EXP BIOL MED, V238, P1355, DOI 10.1177/1535370213505964
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573 020 0075 7
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Sani A, 2021, BIOCHEM BIOPHYS REP, V26, DOI 10.1016/j.bbrep.2021.100991
   Sinegra AJ, 2021, NANO LETT, V21, P6584, DOI 10.1021/acs.nanolett.1c01973
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tsai SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076545
   Volkova N, 2017, J NANOMATER, V2017, DOI 10.1155/2017/6934757
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Williams SCP, 2013, P NATL ACAD SCI USA, V110, P13231, DOI 10.1073/pnas.1313483110
   Xia DD, 2023, BIOACT MATER, V19, P12, DOI 10.1016/j.bioactmat.2022.03.010
   Xiao F, 2020, ADV SCI, V7, DOI 10.1002/advs.202001048
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10376
   Zhu YR, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05075 2
NR 53
TC 8
Z9 8
U1 12
U2 63
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAR
PY 2024
VL 34
IS 13
DI 10.1002/adfm.202312260
EA DEC 2023
PG 16
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA MN0B5
UT WOS:001128529600001
DA 2025 08 17
ER

PT J
AU Arriero, MD
   Ramis, JM
   Perelló, J
   Monjo, M
AF del Mar Arriero, Maria
   Ramis, Joana M.
   Perello, Joan
   Monjo, Marta
TI Differential Response of MC3T3 E1 and Human Mesenchymal Stem Cells to
   Inositol Hexakisphosphate
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Inositol hexakisphosphate; Phytic acid; Osteoblast; Human umbilical cord
   mesenchymal stem cells (hUC MSCs); Mineralization; Gene expression; IP6
   kinase inhibitor
ID ALKALINE PHOSPHATASE; POSTMENOPAUSAL WOMEN; BONE; BISPHOSPHONATES;
   PROLIFERATION; OSTEOPOROSIS; PHYTATE; MINERALIZATION; PYROPHOSPHATES;
   OSTEONECROSIS
AB Background: Inositol hexakisphosphate (IP6) has been found to have an important role in biomineralization. Methods: Because the complete mechanism of action of IP6 on osteoblasts is not fully understood and its potential use in the primary prevention of osteoporosis, we examined the direct effect of IP6 on cell viability and differentiation of MC3T3 E1 cells and on differentiation of human umbilical cord mesenchymal stem cells (hUC MSCs). Results: We show that IP6 has different effects depending on the origin of the cell target. Thus, while IP6 decreased gene expression of osteoblast markers and mineralization in MC3T3 E1 cells without negatively affecting cell viability and ALP activity, an increase in gene expression of ALP was observed in hUC MSCs committed to the osteoblastic lineage. This increasing effect of IP6 on ALP mRNA expression levels was reversed by the addition of a selective inhibitor of IP6 kinase, suggesting that the effect of IP6 might be due through its pyrophosphorylated derivatives. Besides, Rankl mRNA levels were decreased after IP6 treatment in MC3T3 E1 cells, pointing to a paracrine effect on osteoclasts. Conclusion: Our results indicate that IP6 has different effects on osteoblast differentiation depending on the cell type and origin. However, further studies are needed to examine the net effect of IP6 on bone formation and its potential as novel antiosteoporosis drug. Copyright (C) 2012 S. Karger AG, Basel
C1 [del Mar Arriero, Maria; Ramis, Joana M.; Monjo, Marta] Univ Balearic Isl, Res Inst Hlth Sci IUNICS, Dept Fundamental Biol & Hlth Sci, E 07122 Palma De Mallorca, Spain.
   [Perello, Joan] Lab Sanifit, E 07121 Palma De Mallorca, Spain.
C3 Universitat de les Illes Balears; IUNICS
RP Arriero, MD (通讯作者)，Univ Balearic Isl, Res Inst Hlth Sci IUNICS, Dept Fundamental Biol & Hlth Sci, Cra Valldemossa Km 7 5, E 07122 Palma De Mallorca, Spain.
EM marta.monjo@uib.es
RI ; Monjo, Marta/JCE 0468 2023; Ramis, Joana/AAF 4892 2020; Perello,
   Joan/A 7387 2019
OI Ramis, Joana Maria/0000 0001 9109 8362; Monjo,
   Marta/0000 0002 2731 9527; 
FU INVEST IN SPAIN [C2_10_32]; European Union; Eureka Eurostars Project [E!
   5069 NewBone]; Centre for the Development of Industrial Technology
   (CDTI) [CIIP20101024]; Ministry of Science and Innovation of Spain
FX The authors are especially thankful for the excellent technical support
   from Dr. Fernando Tur. We thank Dr. Antoni Gaya for kindly supplying us
   with the umbilical cord mesenchymal stem cells. This work was supported
   by INVEST IN SPAIN (C2_10_32), European Regional Development Fund (ERDF)
   from the European Union, Eureka Eurostars Project Application E! 5069
   NewBone, Interempresas Internacional Program (CIIP20101024) from the
   Centre for the Development of Industrial Technology (CDTI) and the
   Ministry of Science and Innovation of Spain (Torres Quevedo contract to
   J.M. Ramis, and Ramon y Cajal contract to M. Monjo).
CR Addison WN, 2010, BONE, V46, P1100, DOI 10.1016/j.bone.2010.01.367
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018 005 5446 z
   BUNCE CM, 1993, BIOCHEM J, V289, P667, DOI 10.1042/bj2890667
   Chakraborty A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001958
   Chiu R, 2010, J ORTHOP RES, V28, P571, DOI 10.1002/jor.21035
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Arriero MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043187
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Fujita H, 2011, BASIC CLIN PHARMACOL, V109, P78, DOI 10.1111/j.1742 7843.2011.00685.x
   Grases F, 2006, PHARMAZIE, V61, P652
   Grases F, 2001, BRIT J NUTR, V86, P225, DOI 10.1079/BJN2001389
   Grases F, 2000, BJU INT, V85, P138, DOI 10.1046/j.1464 410x.2000.00324.x
   Grases F, 2010, J MED FOOD, V13, P1301, DOI 10.1089/jmf.2009.0152
   Han SL, 2012, INT J CLIN PRACT, V66, P199, DOI 10.1111/j.1742 1241.2011.02837.x
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Horst Sikorska W, 2011, ENDOKRYNOL POL, V62, P61
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015
   Kazanecki CC, 2007, J CELL BIOCHEM, V102, P912, DOI 10.1002/jcb.21558
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Knopp Sihota JA, 2012, OSTEOPOROSIS INT, V23, P17, DOI 10.1007/s00198 011 1676 0
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   López González AA, 2008, J MED FOOD, V11, P747, DOI 10.1089/jmf.2008.0087
   López González AA, 2011, REUMATOL CLIN, V7, P220, DOI 10.1016/j.reuma.2010.07.004
   Lopez Gonzalez Angel A, 2010, Front Biosci (Elite Ed), V2, P1093
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140 6736(08)61598 6
   Ramis JM, 2012, TISSUE ENG PT A, V18, P1253, DOI 10.1089/ten.tea.2011.0404
   MENNITI FS, 1993, J BIOL CHEM, V268, P3850
   Padmanabhan U, 2009, J BIOL CHEM, V284, P10571, DOI 10.1074/jbc.M900752200
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raboy V, 2003, PHYTOCHEMISTRY, V64, P1033, DOI 10.1016/S0031 9422(03)00446 1
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428
   Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101
   STEPHENS L, 1993, J BIOL CHEM, V268, P4009
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006 291X(87)90489 X
   VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Zhu BQ, 2004, J CELL PHYSIOL, V198, P155, DOI 10.1002/jcp.10394
NR 50
TC 29
Z9 31
U1 0
U2 16
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2012
VL 30
IS 4
BP 974
EP 986
DI 10.1159/000341474
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 022RO
UT WOS:000309979900015
PM 23221481
OA gold
DA 2025 08 17
ER

PT J
AU Yaccoby, S
   Ling, W
   Zhan, FH
   Walker, R
   Barlogie, B
   Shaughnessy, JD
AF Yaccoby, Shmuel
   Ling, Wen
   Zhan, Fenghuang
   Walker, Ronald
   Barlogie, Bart
   Shaughnessy, John D., Jr.
TI Antibody based inhibition of DKK1 suppresses tumor induced bone
   resorption and multiple myeloma growth in vivo
SO BLOOD
LA English
DT Article
ID ZOLEDRONIC ACID; PLASMA CELLS; OSTEOBLAST; RECEPTOR; DIFFERENTIATION;
   DICKKOPF 1; EXPRESSION; BORTEZOMIB; CANCER; MODEL
AB Dickkopf 1 (DKK1), a soluble inhibitor of Wnt signaling secreted by multiple myeloma (MM) cells contributes to osteolytic bone disease by inhibiting the differentiation of osteoblasts. In this study, we tested the effect of anti DKK1 therapy on bone metabolism and tumor growth in a SCID rab system. SCID rab mice were engrafted with primary MM cells expressing varying levels of DKK1 from 11 patients and treated with control and DKK1 the implanted myelomatous bone in control mice was reduced during the experimental period, the BMD in mice treated with anti DKK1 increased from pretreatment levels (P < .001). Histologic examination revealed that myelomatous bones of anti DKK1 treated mice had increased numbers of osteocalcin expressing osteoblasts and reduced number of multinucleated TRAP expressing osteoclasts. The bone anabolic effect of anti DKK1 was with reduced MM burden associated creased BMD of the implanted bone and murine femur in nonmyelomatous SCID rab mice, suggesting that DKKi is physiologically an important regulator of bone remodeling in adults. We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth.
C1 Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Shaughnessy, JD (通讯作者)，Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
EM yaccobyshmuel@uams.edu; shanghnessyjohn@uams.edu
OI Zhan, Fenghuang/0000 0001 6208 1676
FU NCI NIH HHS [P01 CA055819, CA 93897, CA97513, CA55819, R33 CA097513, R01
   CA093897] Funding Source: Medline
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Barillé Nion S, 2003, LEUKEMIA LYMPHOMA, V44, P1463, DOI 10.1080/1042819031000082966
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Berenson JR, 2001, SEMIN ONCOL, V28, P25
   Berenson JR, 2005, BEST PRACT RES CL HA, V18, P653, DOI 10.1016/j.beha.2005.03.001
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Choi SJ, 2000, BLOOD, V96, P671
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Epstein Joshua, 2003, Hematol J, V4, P310, DOI 10.1038/sj.thj.6200313
   Ferrara N, 2005, ONCOLOGY BASEL, V69, P11, DOI 10.1159/000088479
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Johnson ML, 2006, REV ENDOCR METAB DIS, V7, P41, DOI 10.1007/s1154 006 9003 3
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Oyajobi BO, 2004, J BONE MINER RES, V19, pS4
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Sezer O, 2005, HEMATOLOGY, V10, P19, DOI 10.1080/10245330512331389782
   Shipman CM, 2005, EXPERT OPIN PHARMACO, V6, P2781, DOI 10.1517/14656566.6.16.2781
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stewart JP, 2006, J CELL BIOCHEM, V98, P1, DOI 10.1002/jcb.20774
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vanderkerken K, 2003, IMMUNOL REV, V194, P196, DOI 10.1034/j.1600 065X.2003.00035.x
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 1999, BLOOD, V94, P3576, DOI 10.1182/blood.V94.10.3576.422k01_3576_3582
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2005, CLIN CANCER RES, V11, P7599, DOI 10.1158/1078 0432.CCR 05 0523
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913
   YACCOBY S, 2005, BLOOD, V106, pA963
   Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
NR 58
TC 350
Z9 406
U1 0
U2 16
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD MAR 1
PY 2007
VL 109
IS 5
BP 2106
EP 2111
DI 10.1182/blood 2006 09 047712
PG 6
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 142HW
UT WOS:000244641100051
PM 17068150
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Yuan, X
   Wu, YH
   Yang, KL
   Liu, HP
   Zhang, GM
AF Yuan, Xiao
   Wu, Yonghe
   Yang, Kailin
   Liu, Huiping
   Zhang, Guomin
TI Exploring the Effect of Jiawei Buguzhi Pills on TGF β Smad Pathway in
   Postmenopausal Osteoporosis Based on Integrated Pharmacological Strategy
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID SIGNALING PATHWAY; DIFFERENTIATION; PATHOPHYSIOLOGY; PROLIFERATION;
   ACTIVATION; MEDICINE; HEALTH; WOMEN
AB Objective. To explore the effect of Jiawei Buguzhi Pills (JWBGZP) on the TGF beta Smad pathway in postmenopausal osteoporosis (PMO) based on integrated pharmacological strategy. Method. The ETCM database was used to collect JWBGZP. GeneCards and OMIM databases were utilized to obtain PMO related genes. Cytoscape was used for network construction and analysis, and DAVID was used for GO and KEGG enrichment analysis of key targets. Animal experiments and cell experiments were conducted to further explore the mechanism. The bone mass density was detected by dual energy X ray bone densitometer. The TGF beta 1 and Smad4 mRNA in bone tissue were detected by RT qPCR. The TGF beta 1 and Smad4 protein in bone tissue were detected by the western blot. The TGF beta 1 and Smad4 protein in osteoblasts were determined by immunohistochemistry. Result. A total of 721 JWBGZP potential targets and 385 PMO related genes were obtained. The enrichment analysis showed that JWBGZP may regulate the TGF beta signaling pathway, oxidation reduction process, aging, response to hypoxia, response to ethanol, negative regulation of cell proliferation, PI3K Akt, HIF 1, and other signaling pathways. The animal experiments showed that compared with the model group, the femoral bone mineral density and lumbar bone mineral density of the JWBGZP group increased (P < 0.05); the expression levels of TGF beta 1 and Smad mRNA and proteins in the JWBGZP group were significantly higher (P < 0.05). The cell experiment results showed a large number of osteoblast stained blue purple and orange red calcified nodules. The expression levels of TGF beta 1 and Smad proteins in the JWBGZP group were significantly higher than those in the blank control group and the sham operation group, and the protein expression levels in the model group were the lowest (P < 0.05). Conclusion. JWBGZP may be involved in PI3K Akt, HIF 1, estrogen, prolactin, and other signaling pathways and regulate MAPK1, AKT1, PIK3CA, JAK2, and other gene targets, regulate bone metabolism, and thereby treat PMO.
C1 [Yuan, Xiao; Wu, Yonghe; Yang, Kailin; Liu, Huiping; Zhang, Guomin] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
C3 Hunan University of Chinese Medicine
RP Liu, HP; Zhang, GM (通讯作者)，Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
EM 1074983953@qq.com; 834095773@qq.com
RI Kailin, Yang/IWU 6739 2023
OI yang, kai lin/0000 0002 1442 8644
FU Key Project of Scientific Research Fund of Hunan Provincial Education
   Department [19A370]; Key Project of Hunan Province Traditional Chinese
   Medicine Scientific Research Project [2021025]; Key Project of
   Scientific Research Fund of Hunan University of Chinese Medicine
   [2020XJJJ003]; Key Laboratory of Hunan Province for Translational
   Medicine Research on TCM Formulas and Syndromes [2018TP1021]
FX This research was supported by the Key Project of Scientific Research
   Fund of Hunan Provincial Education Department (No. 19A370), Key Project
   of Hunan Province Traditional Chinese Medicine Scientific Research
   Project (No. 2021025), Key Project of Scientific Research Fund of Hunan
   University of Chinese Medicine (No. 2020XJJJ003), and Key Laboratory of
   Hunan Province for Translational Medicine Research on TCM Formulas and
   Syndromes (No. 2018TP1021).
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bernard V, 2019, NAT REV ENDOCRINOL, V15, P356, DOI 10.1038/s41574 019 0194 6
   Cai XY, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114044
   Cheng ZY, 2018, EXP THER MED, V15, P1754, DOI 10.3892/etm.2017.5545
   Cui L, 2020, OSTEOPOROSIS INT, V31, P307, DOI 10.1007/s00198 019 05173 6
   Estai MA, 2011, CLINICS, V66, P2113, DOI 10.1590/S1807 59322011001200018
   Gatti D, 2019, J POPUL THER CLIN PH, V26, pE1, DOI 10.15586/jptcp.v26.i4.646
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Hu BT, 2018, EUR REV MED PHARMACO, V22, P7156, DOI 10.26355/eurrev_201811_16247
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Kanis JA, 2019, CALCIFIED TISSUE INT, V104, P235, DOI 10.1007/s00223 018 00512 x
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Li CH, 2018, INT IMMUNOPHARMACOL, V58, P136, DOI 10.1016/j.intimp.2018.03.021
   [李凯 Li Kai], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P5508
   Li WD, 2014, PHYTOMEDICINE, V21, P400, DOI 10.1016/j.phymed.2013.09.015
   Li XH, 2019, ARCH GYNECOL OBSTET, V299, P873, DOI 10.1007/s00404 018 5033 9
   Li XX, 2011, CHINESE MED J PEKING, V124, P1923, DOI 10.3760/cma.j.issn.0366 6999.2011.13.001
   Liang D, 2012, BIOL TRACE ELEM RES, V148, P420, DOI 10.1007/s12011 012 9387 8
   McCarthy AJ, 2018, J CLIN PATHOL, V71, P661, DOI 10.1136/jclinpath 2018 205095
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Moustakas A, 2001, J CELL SCI, V114, P4359
   Noguchi T, 2018, BIOCHEM BIOPH RES CO, V503, P644, DOI 10.1016/j.bbrc.2018.06.055
   Osteoporosis and Bone Mineral Disease Branch of Chinese Medical Association, 2019, CHIN J OSTEOPOROSIS, V12, P317
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Rizzoli R, 2014, WOMENS HEALTH, V10, P599, DOI [10.2217/whe.14.40, 10.2217/WHE.14.40]
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun LJ, 2021, CURR PHARM BIOTECHNO, V22, P168, DOI 10.2174/1389201021666200123102550
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   [翁文玉 Weng Wenyu], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P1665
   Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xi JC, 2018, MOL MED REP, V18, P4753, DOI 10.3892/mmr.2018.9436
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu J, 2018, J TISSUE ENG REGEN M, V12, pE1268, DOI 10.1002/term.2534
   Yang K., 2020, Oxidative Medicine and Cellular Longevity, V2020, P1
   Yang KL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8879060
   Yang KL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00825
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   [于冬冬 Yu Dongdong], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P874
   Yu JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03661 5
   Zeng LT, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113156
   Zeng LT, 2017, J ETHNOPHARMACOL, V199, P68, DOI 10.1016/j.jep.2017.01.045
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhao D, 2021, J ETHNOPHARMACOL, V274, DOI 10.1016/j.jep.2021.114065
   Zhao Y, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113644
NR 49
TC 4
Z9 4
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD OCT 31
PY 2021
VL 2021
AR 5556653
DI 10.1155/2021/5556653
PG 18
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA YR5SM
UT WOS:000750054700009
PM 34754316
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Brechbiel, JL
   Ng, JMY
   Curran, T
AF Brechbiel, Jillian L.
   Ng, Jessica M. Y.
   Curran, Tom
TI PTHrP Treatment Fails to Rescue Bone Defects Caused by Hedgehog Pathway
   Inhibition in Young Mice
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE medulloblastoma; PTHrP; Hedgehog pathway; HhAntag; chondrocytes
ID INDIAN HEDGEHOG; CHONDROCYTE DIFFERENTIATION; PARATHYROID HORMONE;
   SIGNALING PATHWAYS; HUMAN HOMOLOG; GROWTH PLATE; MEDULLOBLASTOMA;
   PROTEIN; CANCER; RECEPTOR
AB The advent of molecular targeted therapies offers the hope of therapeutic advance in the fight against cancer. However, this hope is tempered by recent findings that certain targeted therapies may have unique side effects. The Hedgehog (HH) pathway is a potential target for treatment of several cancers, including basal cell carcinoma and a subset of medulloblastoma. Recent clinical trials in adults have shown responses to HH pathway inhibition in both basal cell carcinoma and medulloblastoma. However, concerns have been raised about the use of HH pathway inhibitors in children because of the role the HH pathway plays in development. Indeed, young mice treated with the HH pathway inhibitor HhAntag developed severe bone defects, including premature differentiation of chondrocytes, thinning of cortical bone, and fusion of the growth plate. In an effort to lessen the severity of bone defects caused by HhAntag, we treated young mice simultaneously with HhAntag and parathyroid hormone related protein (PTHrP), which functions downstream of Indian Hedgehog to maintain chondrocytes in a proliferative state. The results show that whereas treatment with PTHrP causes a significant increase in trabecular bone, it does not prevent fusion of the growth plate induced by HhAntag.
C1 [Brechbiel, Jillian L.; Ng, Jessica M. Y.; Curran, Tom] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia
RP Curran, T (通讯作者)，Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Room 4060,3501 Civ Ctr Blvd,Colket Translat Res B, Philadelphia, PA 19104 USA.
EM currant@email.chop.edu
RI Curran, Tom/C 1164 2008; Curran, Tom/AAE 7631 2019
OI Curran, Tom/0000 0003 1444 7551; 
CR Adams SL, 2007, J CELL PHYSIOL, V213, P635, DOI 10.1002/jcp.21262
   Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   Curran T, 2008, NATURE, V455, P293, DOI 10.1038/455293a
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dellovade T, 2006, ANNU REV NEUROSCI, V29, P539, DOI 10.1146/annurev.neuro.29.051605.112858
   Ecke I, 2008, MOL CARCINOGEN, V47, P361, DOI 10.1002/mc.20394
   ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092 8674(95)90487 5
   Frank Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475 4924 1 10
   Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092 8674(00)81268 4
   Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027
   Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P547, DOI 10.1007/s00401 007 0278 6
   Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104
   Maeda Y, 2010, BONE, V46, P472, DOI 10.1016/j.bone.2009.09.009
   Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044
   McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070 2153(03)53002 2
   Minina E, 2001, DEVELOPMENT, V128, P4523
   Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960 9822(99)80018 9
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Robarge KD, 2009, BIOORG MED CHEM LETT, V19, P5576, DOI 10.1016/j.bmcl.2009.08.049
   Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740
   Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008 5472.CAN 05 0481
   Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019
   Rominger CM, 2009, J PHARMACOL EXP THER, V329, P995, DOI 10.1124/jpet.109.152090
   Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903
   Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008 5472.CAN 05 4505
   Sasai K, 2007, CANCER RES, V67, P3871, DOI 10.1158/0008 5472.CAN 07 0493
   Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008 5472.CAN 09 0756
   Tremblay MR, 2009, EXPERT OPIN THER PAT, V19, P1039, DOI 10.1517/13543770903008551
   Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100
   Wong H, 2009, XENOBIOTICA, V39, P850, DOI 10.3109/00498250903180289
   Xue YB, 2005, J BONE MINER RES, V20, P1766, DOI 10.1359/JBMR.050608
   Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275
   Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386
NR 42
TC 10
Z9 13
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192 6233
EI 1533 1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD APR
PY 2011
VL 39
IS 3
BP 478
EP 485
DI 10.1177/0192623311399788
PG 8
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA 800QX
UT WOS:000293380100003
PM 21411723
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Pan, HZ
   Liu, JH
   Dong, YY
   Sima, M
   Kopecková, P
   Brandi, ML
   Kopecek, J
AF Pan, Huaizhong
   Liu, Jihua
   Dong, Yuanyi
   Sima, Monika
   Kopeckova, Pavla
   Brandi, Maria Luisa
   Kopecek, Jindrich
TI Release of prostaglandin E1 from
   N (2 hydroxypropyl)methacrylamide copolymer conjugates by bone
   cells
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE bone cell; drug delivery systems; enzymes; HPMA copolymer conjugate;
   prostaglandin
ID LINE FLG 29.1; CATHEPSIN K; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST
   FORMATION; HPMA COPOLYMER; MC3T3 E1 CELLS; DIFFERENTIATION; EXPRESSION;
   RESORPTION; COLLAGENS
AB Bone targeting N (2 hydroxypropyl)methacrylamide (HPMA) copolymer PGE(1) conjugates, containing cathepsin K sensitive spacers, were incubated with induced osteoclasts and osteoblasts, their precursors, and control non skeletal cells. The release of PGE(1) was monitored by an HPLC assay. In both murine and human cell lines, osteoclasts appeared to be the most active cells in the cleavage (PGE(1) release). Incubation with osteoblasts also resulted in fast PGE(1) release, whereas precursor and control cells released PGE(1) with a substantially slower rate than bone cells (apparently through ester bond cleavage). Experiments in the presence of inhibitors revealed that other enzymes, in addition to cathepsin K, were participating in the cleavage of the conjugate. Confocal fluorescence studies exposed internalization of the conjugate by endocytosis with ultimate localization in the lysosomal/endosomal compartment.
C1 [Pan, Huaizhong; Liu, Jihua; Dong, Yuanyi; Sima, Monika; Kopeckova, Pavla; Kopecek, Jindrich] Univ Utah, CCCD, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
   [Kopeckova, Pavla; Kopecek, Jindrich] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
   [Brandi, Maria Luisa] Univ Firenze, Dept Clin Physiopathol, I 50139 Florence, Italy.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; University of Florence
RP Kopecek, J (通讯作者)，Univ Utah, CCCD, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
EM jindrich.kopecek@utah.edu
FU NIGMS NIH HHS [R01 GM069847, GM069847] Funding Source: Medline
CR BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Collin Osdoby P, 2003, METH MOLEC MED, V80, P153
   Cranney A, 2005, DRUG SAFETY, V28, P721, DOI 10.2165/00002018 200528080 00006
   Dodds RA, 2001, J BONE MINER RES, V16, P478, DOI 10.1359/jbmr.2001.16.3.478
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Espié M, 2007, GYNECOL ENDOCRINOL, V23, P391, DOI 10.1080/09513590701382104
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   GATTEI V, 1992, J CELL BIOL, V116, P437, DOI 10.1083/jcb.116.2.437
   Guyatt G, 2002, ENDOCR REV, V23, P496, DOI 10.1021/er.2001 1002
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756 3282(90)90078 D
   Jeschke M, 1998, J BONE MINER RES, V13, P1880, DOI 10.1359/jbmr.1998.13.12.1880
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   KOPECEK J, 1973, EUR POLYM J, V9, P7, DOI 10.1016/0014 3057(73)90063 3
   Lindsay R, 2004, ENDOCRINE, V24, P223, DOI 10.1385/ENDO:24:3:223
   Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017
   MARKS SC, 1994, J PERIODONTAL RES, V29, P103, DOI 10.1111/j.1600 0765.1994.tb01097.x
   MILLER SR, UNPUB
   Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Omelyanenko V, 1998, J CONTROL RELEASE, V53, P25, DOI 10.1016/S0168 3659(97)00235 6
   Pan H, 2007, PHARM RES, V24, P2270, DOI 10.1007/s11095 007 9449 3
   Pan HZ, 2006, J DRUG TARGET, V14, P425, DOI 10.1080/10611860600834219
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   RODAN SB, 1987, CANCER RES, V47, P4961
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SHERIFF S, 1995, J BIOL CHEM, V270, P27766, DOI 10.1074/jbc.270.46.27766
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
NR 35
TC 19
Z9 23
U1 0
U2 4
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD JUL 7
PY 2008
VL 8
IS 7
BP 599
EP 605
DI 10.1002/mabi.200700338
PG 7
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA 328SE
UT WOS:000257817300001
PM 18401866
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, C
   Wei, ZX
   Dong, XY
   Xing, JQ
   Meng, XR
   Qiu, YX
   Zhou, HM
   Zheng, WR
   Xu, ZY
   Huang, SH
   Xia, WW
   Lv, LF
   Jiang, HC
   Wang, WH
   Zhao, X
   Liu, ZX
   Akimoto, Y
   Zhao, BH
   Wang, SY
   Hu, ZF
AF Xu, Cheng
   Wei, Zhixin
   Dong, Xiaoyu
   Xing, Junqiao
   Meng, Xiangrui
   Qiu, Yaxuan
   Zhou, Huimei
   Zheng, Wenrui
   Xu, Zhenyu
   Huang, Shanhua
   Xia, Wenwen
   Lv, Longfei
   Jiang, Haochen
   Wang, Weihua
   Zhao, Xue
   Liu, Zixuan
   Akimoto, Yoshie
   Zhao, Baohong
   Wang, Siyuan
   Hu, Zhangfeng
TI A p38 MAP kinase inhibitor suppresses osteoclastogenesis and alleviates
   ovariectomy induced bone loss through the inhibition of bone turnover
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Bone resorption; Osteoclast; BMS 582949; MAPKs/AKT signaling pathways;
   OXPHOS
ID BMS 582949; DIFFERENTIATION; ADIPOGENESIS; MECHANISMS; RESORPTION;
   DISCOVERY; INSIGHTS; RECEPTOR
AB Inhibition of excessive osteoclastic activity is an efficient therapeutic strategy for many bone diseases induced by increased bone resorption, such as osteoporosis. BMS 582949, a clinical p38 alpha inhibitor, is a promising drug in Phase II studies for treating rheumatoid arthritis. However, its function on bone resorption is largely unknown. In this study, we find that BMS 582949 represses RANKL induced osteoclast differentiation in a dose  dependent manner. Moreover, BMS 582949 inhibits osteoclastic F  actin ring formation and osteoclast specific gene expression. Mechanically, BMS 582949 treatment attenuates RANKL mediated osteoclastogenesis through mitogen activated protein kinases (MAPKs) and protein kinase B (AKT) signaling pathways without disturbing nuclear factor  kappa B (NF  kappa B) signaling. Interestingly, BMS 582949 impairs osteoclastic mitochondrial biogenesis and functions, such as oxidative phosphorylation (OXPHOS). Furthermore, BMS 582949 administration prevents bone loss in ovariectomized mouse mode by inhibiting both bone resorption and bone formation in vivo . Taken together, these findings indicate that BMS 582949 may be a potential and effective drug for the therapy of osteolytic diseases.
C1 [Xu, Cheng; Xing, Junqiao; Meng, Xiangrui; Qiu, Yaxuan; Xia, Wenwen; Jiang, Haochen; Wang, Weihua; Zhao, Xue; Hu, Zhangfeng] Jianghan Univ, Inst Biomed Sci, Sch Med, Hubei Key Lab Cognit & Affect Disorders, Wuhan 430056, Hubei, Peoples R China.
   [Wei, Zhixin; Dong, Xiaoyu; Zhou, Huimei; Zheng, Wenrui; Xu, Zhenyu; Huang, Shanhua; Lv, Longfei; Hu, Zhangfeng] Jianghan Univ, Hubei Engn Res Ctr Protect & Utilizat Special Biol, Sch Life Sci, Wuhan 430056, Hubei, Peoples R China.
   [Liu, Zixuan] Gogdel Cranleigh High Sch, Wuhan 430312, Hubei, Peoples R China.
   [Akimoto, Yoshie] Iskra Ind Co Ltd, Tokyo 1030027, Japan.
   [Zhao, Baohong] Hosp Special Surg, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA.
   [Zhao, Baohong] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, New York, NY 10021 USA.
   [Zhao, Baohong] Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA.
   [Wang, Siyuan] Shenzhen Technol Univ, Coll Pharm, Dept Med Chem, Shenzhen 518118, Guangdong, Peoples R China.
   [Hu, Zhangfeng] Jianghan Univ, Hubei Key Lab Environm & Hlth Effects Persistent T, Wuhan 430056, Hubei, Peoples R China.
C3 Jianghan University; Jianghan University; Cornell University; Weill
   Cornell Medicine; Shenzhen Technology University; Jianghan University
RP Xu, C; Hu, ZF (通讯作者)，Jianghan Univ, Inst Biomed Sci, Sch Med, Hubei Key Lab Cognit & Affect Disorders, Wuhan 430056, Hubei, Peoples R China.; Wang, SY (通讯作者)，Shenzhen Technol Univ, Coll Pharm, Dept Med Chem, Shenzhen 518118, Guangdong, Peoples R China.
EM xucheng_2007@jhun.edu.cn; wangsiyuan@sztu.edu.cn;
   huzhangfeng@jhun.edu.cn
RI Zhenyu, Xu/AAW 7042 2020; Zhou, Huimei/H 6011 2011; Wang,
   Weihua/JCE 3784 2023; zhixin, wei/AAF 8363 2019; Jiang,
   Haochen/KPA 1634 2024; Meng, Xiangrui/D 5955 2012; Dong,
   Xiaoyu/IVH 7486 2023
OI Xu, Cheng/0000 0002 2076 6527; 
FU National Key R & D Program of China [2020YFA0907400]; National Natural
   Science Foundation of China [32170702, 82000828]; Wuhan Science and
   Technology Bureau [2022020801010368]; Natural Science Foundation of Top
   Talent of SZTU [GDRC202122]; Major Special Funding Program for
   First class Discipline Construction of Jianghan University [2023XKZ021]
FX The study was funded by the National Key R & D Program of China (grant
   number: 2020YFA0907400) , the National Natural Science Foundation of
   China (grant numbers: 32170702 and 82000828) , the Wuhan Science and
   Technology Bureau (grant number: 2022020801010368) , the Natural Science
   Foundation of Top Talent of SZTU (grant number: GDRC202122) and the
   Major Special Funding Program for First class Discipline Construction of
   Jianghan University (grant number: 2023XKZ021) .
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05 0963
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630
   Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   He Z, 2013, P NATL ACAD SCI USA, V110, pE79, DOI 10.1073/pnas.1213000110
   Huang Y, 2022, FRONT PLANT SCI, V13, DOI 10.3389/fpls.2022.1101199
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim EK, 2015, ARCH TOXICOL, V89, P867, DOI 10.1007/s00204 015 1472 2
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li LY, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03162 w
   Liu CJ, 2015, J MED CHEM, V58, P7775, DOI 10.1021/acs.jmedchem.5b00839
   Liu CJ, 2013, BIOORG MED CHEM LETT, V23, P3028, DOI 10.1016/j.bmcl.2013.03.022
   Liu CJ, 2010, J MED CHEM, V53, P6629, DOI 10.1021/jm100540x
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Norman P, 2009, EXPERT OPIN THER PAT, V19, P1165, DOI 10.1517/13543770902816160
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   PRESTWOOD KM, 1995, ANNU REV MED, V46, P249
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Romero Becerra R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197412
   Saxena A, 2015, EUR J PHARM SCI, V76, P173, DOI 10.1016/j.ejps.2015.05.006
   Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thouverey C, 2016, J BONE MINER RES, V31, P985, DOI 10.1002/jbmr.2762
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Wei S, 2007, ADV ANAT PATHOL, V14, P42, DOI 10.1097/PAP.0b013e31802ef4f2
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Xu C, 2019, J IMMUNOL, V203, P2141, DOI 10.4049/jimmunol.1900707
   Xu C, 2016, J BONE MINER RES, V31, P1344, DOI 10.1002/jbmr.2803
   Yao L, 2019, INT IMMUNOPHARMACOL, V70, P504, DOI 10.1016/j.intimp.2019.02.046
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zeng RM, 2021, EXP BIOL MED, V246, P644, DOI 10.1177/1535370220974933
   Zhang X, 2017, BMC PLANT BIOL, V17, DOI 10.1186/s12870 017 1023 5
   Zheng HL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03784 8
NR 51
TC 3
Z9 3
U1 3
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG
PY 2024
VL 226
AR 116391
DI 10.1016/j.bcp.2024.116391
EA JUN 2024
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XP7S8
UT WOS:001262956900001
PM 38914317
DA 2025 08 17
ER

PT J
AU Suzuki, R
   Shirataki, Y
   Tomomura, A
   Bandow, K
   Sakagami, H
   Tomomura, M
AF Suzuki, Ryuichiro
   Shirataki, Yoshiaki
   Tomomura, Akito
   Bandow, Kenjiro
   Sakagami, Hiroshi
   Tomomura, Mineko
TI Isolation of Pro Osteogenic Compounds from Euptelea polyandra
   That Reciprocally Regulate Osteoblast and Osteoclast Differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Euptelea polyandra Sieb. et Zucc; isoquercitrin; astragalin; osteoblast;
   osteoclast; osteoporosis
ID HORMONE REPLACEMENT THERAPY; ANTIMICROBIAL GLYCOSIDES; BIOACTIVE
   SAPONINS; FRESH LEAVES; BONE LOSS; ESTROGEN; KAEMPFEROL; SIEB;
   OLIGOGLYCOSIDES; NORTRITERPENE
AB Plants contain a large number of small molecule compounds that are useful for targeting human health andin drug discovery. Healthy bone metabolism depends on the balance between bone  forming osteoblast activity and bone resorbing osteoclast activity. In an ongoing study searching for 22 plant extracts effective against osteoporosis, we found that the crude extract of Euptelea polyandra Sieb. et Zucc (E. polyandra) had osteogenic bioactivity. In this study, we isolated two compounds, isoquercitrin (1) and astragalin (2), responsible for osteogenic bioactivity in osteoblastic MC3T3 E1 cells from the leaf of E. polyandra using column chromatography and the spectroscopic technique. This is the first report to isolate astragalin from E. polyandra. Compounds (1) and (2) promoted osteoblast differentiation by increasing alkaline phosphatase (ALP) activity and alizarin red S stain positive calcium deposition, while simultaneously suppressing tartrate resistant acid phosphatase (TRAP) positive osteoclast differentiation in RAW264.7 cells at non cytotoxic concentrations. Isoquercitrin (1) and astragalin (2) increased the expression of osteoblastic differentiation genes, Osterix, ALP, and Osteoprotegerin in the MC3T3 E1 cells, while suppressing osteoclast differentiation genes, TRAP, Cathepsin K, and MMP 9 in the RAW264.7 cells. These compounds may be ideal targets for the treatment of osteoporosis due to their dual function of promoting bone formation and inhibiting bone resorption.
C1 [Suzuki, Ryuichiro; Shirataki, Yoshiaki; Tomomura, Mineko] Josai Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 1 1 Keyakidai, Sakado, Saitama 3500295, Japan.
   [Tomomura, Akito; Bandow, Kenjiro; Tomomura, Mineko] Meikai Univ, Sch Dent, Dept Oral Biol & Tissue Engn, Div Biochem, Sakado, Saitama 3500283, Japan.
   [Sakagami, Hiroshi] Meikai Univ, Res Inst Odontol M RIO, Sakado, Saitama 3500283, Japan.
C3 Josai University; Meikai University; Meikai University
RP Suzuki, R; Tomomura, M (通讯作者)，Josai Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 1 1 Keyakidai, Sakado, Saitama 3500295, Japan.; Tomomura, M (通讯作者)，Meikai Univ, Sch Dent, Dept Oral Biol & Tissue Engn, Div Biochem, Sakado, Saitama 3500283, Japan.
EM ryu_suzu@josai.ac.jp; kbando@dent.meikai.ac.jp;
   sakagami@dent.meikai.ac.jp; mtomomura@josai.ac.jp
OI Bandow, Kenjiro/0000 0002 1362 3034; Sakagami,
   Hiroshi/0000 0001 8001 2121
FU KAKENHI from the Japan Society for the Promotion of Science
FX The authors thank Satoshi Fukami for technical support (M.S.
   Pharmaceutical Sciences: Josai University).
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   [Anonymous], KEW 
   Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cao LL, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12716
   Clarkson TB, 1998, P SOC EXP BIOL MED, V217, P365
   Colditz GA, 1998, JNCI J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Fujioka M, 2004, J NUTR, V134, P2623, DOI 10.1093/jn/134.10.2623
   GOTO M, 1964, CHEM PHARM BULL, V12, P516
   GOTO M, 1970, YAKUGA ZASSHI, V90, P736, DOI 10.1248/yakushi1947.90.6_736
   Gustafsson KL, 2016, SCI REP UK, V6, DOI 10.1038/srep29473
   Han JT, 2004, ARCH PHARM RES, V27, P390, DOI 10.1007/BF02980079
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Huang HT, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9111136
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Imtiyaz Z, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.670254
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kiyama R, 2023, J NUTR BIOCHEM, V114, DOI 10.1016/j.jnutbio.2022.109250
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   KONOSHIMA T, 1987, J NAT PROD, V50, P1167, DOI 10.1021/np50054a031
   Lara Castillo N, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11104439
   Li J, 2019, CHEM BIOL INTERACT, V297, P85, DOI 10.1016/j.cbi.2018.10.018
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Murakami T, 2001, CHEM PHARM BULL, V49, P741, DOI 10.1248/cpb.49.741
   MURATA T, 1970, YAKUGA ZASSHI, V90, P744, DOI 10.1248/yakushi1947.90.6_744
   NOTOYA K, 1994, J BONE MINER RES, V9, P395
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Qattan MY, 2022, MOLECULES, V27, DOI 10.3390/molecules27248864
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Ren J, 2019, EXP THER MED, V18, P2759, DOI 10.3892/etm.2019.7886
   Shen DY, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/5902293
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Suzuki R, 2019, J NAT MED TOKYO, V73, P331, DOI 10.1007/s11418 018 1258 y
   Torre E, 2017, PHYTOCHEM REV, V16, P1183, DOI 10.1007/s11101 017 9529 x
   Wen L, 2017, MOLECULES, V22, DOI 10.3390/molecules22050767
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Xi YJ, 2023, AM J CHINESE MED, V51, P2077, DOI 10.1142/S0192415X23500891
   Yoshikawa M, 2000, CHEM PHARM BULL, V48, P1045
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 46
TC 2
Z9 2
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2023
VL 24
IS 24
AR 17479
DI 10.3390/ijms242417479
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DK5B7
UT WOS:001131936700001
PM 38139307
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Du, XY
   Guo, ST
   Mu, XM
   Mei, S
   Yang, R
   Zhang, HY
   Jiang, CY
   Zhang, J
AF Du, Xinyi
   Guo, Shaoting
   Mu, Xuemeng
   Mei, Song
   Yang, Rui
   Zhang, Hengyan
   Jiang, Chengyu
   Zhang, Jia
TI Bencaosome [16:0 Lyso PA+XLGB28 sRNA] improves osteoporosis by
   simultaneously promoting osteogenesis and inhibiting osteoclastogenesis
   in mice
SO IUBMB LIFE
LA English
DT Article
DE bone delivery; oligonucleotide drug; osteoporosis; RNA therapy; small
   RNA; TNFSF11; traditional Chinese medicine; Xianlinggubao
ID OSTEOBLAST DIFFERENTIATION; BONE; PREVENTION; EXPRESSION; DIAGNOSIS
AB Osteoporosis (OP) is a systemic metabolic bone disease resulting in reduced bone strength and increased susceptibility to fractures, making it a significant public health and economic problem worldwide. The clinical use of anti osteoporosis agents is limited because of their serious side effects or the high cost of long term use. The Xianlinggubao (XLGB) formula is an effective traditional Chinese herbal medicine commonly used in orthopedics to treat osteoporosis; however, its mechanism of action remains unclear. In this study, we screened 40 small RNAs derived from XLGB capsules and found that XLGB28 sRNA targeting TNFSF11 exerted a significant anti osteoporosis effect in vitro and in vivo by simultaneously promoting osteogenesis and inhibiting osteoclastogenesis. Oral administration of bencaosome [16:0 Lyso PA+XLGB28 sRNA] effectively improved bone mineral density and reduced the damage to the bone microstructure in mice. These results suggest that XLGB28 sRNA may be a novel oligonucleotide drug that promotes osteogenesis and inhibits osteoclastogenesis in mice.
C1 [Du, Xinyi; Guo, Shaoting; Mei, Song; Yang, Rui; Jiang, Chengyu] Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Common Mech Res Major Dis, Inst Basic Med Sci,Dept Biochem,Sch Basic Med, Beijing 100005, Peoples R China.
   [Mu, Xuemeng; Zhang, Hengyan; Zhang, Jia] Chinese Acad Med Sci & Peking Union Med Coll CAMS, Dept Orthopaedic, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Chinese Academy of Medical Sciences  
   Peking Union Medical College; Peking Union Medical College Hospital
RP Jiang, CY (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Common Mech Res Major Dis, Inst Basic Med Sci,Dept Biochem,Sch Basic Med, Beijing 100005, Peoples R China.; Zhang, J (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll CAMS, Peking Union Med Coll Hosp, Dept Orthopaed, Beijing 100730, Peoples R China.
EM jiang@pumc.edu.cn; zhangjiapumch@163.com
RI Mei, Song/GZL 0577 2022; MU, Xuemeng/JEP 7250 2023; Du,
   Xinyi/KOD 8384 2024
OI Mei, Song/0009 0005 0426 2467
FU Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
   [2021 I2M 1 022]; Higher Education Discipline Innovation Project
   [BP0820029]; National Natural Science Foundation of China [81788101];
   State Key Laboratory Special Fund [2060204]; Fundamental Research Funds
   for Central Universities [2017PT31017]
FX Chinese Academy of Medical Sciences Innovation Fund for Medical
   Sciences, Grant/Award Number: 2021 I2M 1 022; Higher Education
   Discipline Innovation Project, Grant/Award Number:BP0820029; National
   Natural Science Foundation of China, Grant/Award Number: 81788101; State
   Key Laboratory Special Fund, Grant/Award Number:2060204; Fundamental
   Research Funds for Central Universities, Grant/Award Number: 2017PT31017
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Cao Yinghao LY., 2023, SCI CHINA LIFE SCI, V66, P1589
   Chen SH, 2016, J ORTHOP TRANSL, V4, P14, DOI 10.1016/j.jot.2015.07.001
   Chen XM, 2022, NAT REV MOL CELL BIO, V23, P185, DOI 10.1038/s41580 021 00425 y
   Cheng YM, 2013, J ETHNOPHARMACOL, V145, P85, DOI 10.1016/j.jep.2012.09.055
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Crooke ST, 2018, CELL METAB, V27, P714, DOI 10.1016/j.cmet.2018.03.004
   Du JC, 2019, SCI CHINA LIFE SCI, V62, P309, DOI 10.1007/s11427 017 9026 7
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gao X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.710169
   Guañabens N, 2019, ENDOCRINE, V64, P441, DOI 10.1007/s12020 019 01919 8
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kulkarni JA, 2021, NAT NANOTECHNOL, V16, P630, DOI 10.1038/s41565 021 00898 0
   Kvist AV, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081660
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li XT, 2022, J DAIRY SCI, V105, P7878, DOI 10.3168/jds.2022 21880
   Li XY, 2019, SCI CHINA LIFE SCI, V62, P333, DOI 10.1007/s11427 018 9508 0
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573 020 0075 7
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Sritharan S, 2018, J CRANIO MAXILL SURG, V46, P1361, DOI 10.1016/j.jcms.2018.05.002
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Tang KG, 2023, SCI CHINA LIFE SCI, V66, P2370, DOI 10.1007/s11427 022 2275 3
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Wang PP, 2019, INT J PHARMACEUT, V569, DOI 10.1016/j.ijpharm.2019.118594
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wu H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00273
   Wu RX, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/1693643
   Wu XW, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/6986372
   Yu AM, 2020, PHARMACOL REV, V72, P862, DOI 10.1124/pr.120.019554
   Zhao Dandan QY., 2022, ORALLY ADMINISTERED
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 40
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1521 6543
EI 1521 6551
J9 IUBMB LIFE
JI IUBMB Life
PD OCT
PY 2024
VL 76
IS 10
BP 832
EP 844
DI 10.1002/iub.2857
EA JUL 2024
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA J9V9T
UT WOS:001272517500001
PM 39012196
DA 2025 08 17
ER

PT J
AU Gatti, D
   Viapiana, O
   Adami, S
   Idolazzi, L
   Fracassi, E
   Rossini, M
AF Gatti, Davide
   Viapiana, Ombretta
   Adami, Silvano
   Idolazzi, Luca
   Fracassi, Elena
   Rossini, Maurizio
TI Bisphosphonate treatment of postmenopausal osteoporosis is associated
   with a dose dependent increase in serum sclerostin
SO BONE
LA English
DT Article
DE Sclerostin; Bone turnover markers; Bisphosphonates; Osteoporosis;
   Menopause
ID VAN BUCHEM DISEASE; BONE FORMATION; PARATHYROID HORMONE; SOST GENE;
   IN VIVO; OSTEOCYTES; DELETION; LIGAND; ALENDRONATE; EXPRESSION
AB The benefits coming from long term treatment of postmenopausal osteoporosis with bisphophonates are limited by a coupled decrease in bone formation. The objective of this study is to determine whether this decrease in bone formation is associated with changes in serum levels of the WNT signaling antagonist sclerostin or Dickkopf 1 (DKK1).
   This is an ancillary observation from patients participating in a 12 months, phase 2, randomized clinical trial. We analyzed 107 patients given either monthly intramuscular neridronate (12.5, 25 or 50 mg) or placebo. Serum C terminal telopeptide of type I collagen (sCTX, a bone resorption marker) decreased by 61%, 75% and 73% in the 12.5, 25 and 50 mg dose groups, respectively.
   Mean changes in bone alkaline phosphatase (bAP) at 12 months were  47%,  60.0% and  52.6% in the groups receiving 12.5, 25 or 50 mg neridronate, respectively. Serum DKK1 remained unchanged at all time points in the 3 groups. Serum sclerostin increased versus placebo group gradually and significantly only in patients treated with 25 or 50 mg neridronate monthly, reaching 138 148% of baseline values (P<0.001). Changes in serum sclerostin at 12 months were negatively correlated with changes in bAP (P<0.001) even when data were adjusted for sCTX changes and only treated patients were included.
   In conclusions, decreased bone formation after several months of bisphosphonate therapy is associated with increased serum levels of sclerostin. This might suggest that Wnt signaling may play a role in the coupling between resorption and formation. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Gatti, Davide; Viapiana, Ombretta; Adami, Silvano; Idolazzi, Luca; Fracassi, Elena; Rossini, Maurizio] Univ Verona, Dept Med, Rheumatol Unit, I 37100 Verona, Italy.
C3 University of Verona
RP Adami, S (通讯作者)，Osped Maggiore, Rheumatol Unit, I 37126 Verona, Italy.
EM Davide.Gatti@univr.it; Ombretta.Viapiana@univr.it;
   Silvano.Adami@univr.it; Luca.Idolazzi@yahoo.it; Elena.Fracassi@univr.it;
   Maurizio.Rossini@univr.it
RI Idolazzi, Luca/X 4024 2019; rossini, maurizio/D 6610 2011; Davide,
   Gatti/ABP 6506 2022
OI VIAPIANA, Ombretta/0000 0003 1917 5655; Idolazzi,
   Luca/0000 0002 7254 4686; Rossini, Maurizio/0000 0001 9692 2293; gatti,
   davide/0000 0002 7471 3076; FRACASSI, Elena/0000 0003 1354 8115
FU Abiogen Pharma S.p.A., Pisa, Italy
FX We would like to thank Caterina Fraccarollo and Cristina Bosco for the
   ELISA assays. This work was partially supported by Abiogen Pharma
   S.p.A., Pisa, Italy.
CR ADAMI S, 1995, J BONE MINER RES, V10, P511
   Adami S, 2008, CALCIFIED TISSUE INT, V83, P301, DOI 10.1007/s00223 008 9179 5
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chung YE, 2011, OSTEOPOROS INT  0610
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
NR 25
TC 62
Z9 63
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2012
VL 50
IS 3
BP 739
EP 742
DI 10.1016/j.bone.2011.11.028
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 897KR
UT WOS:000300650100020
PM 22178539
DA 2025 08 17
ER

PT J
AU Kawazoe, M
   Kaneko, K
   Masuoka, S
   Yamada, S
   Yamada, Z
   Muraoka, S
   Furukawa, K
   Sato, H
   Watanabe, E
   Koshiba, K
   Irita, I
   Kanaji, M
   Sugihara, T
   Nishio, J
   Nanki, T
AF Kawazoe, Mai
   Kaneko, Kaichi
   Masuoka, Shotaro
   Yamada, Soichi
   Yamada, Zento
   Muraoka, Sei
   Furukawa, Karin
   Sato, Hiroshi
   Watanabe, Eri
   Koshiba, Keiko
   Irita, Izumi
   Kanaji, Miwa
   Sugihara, Takahiko
   Nishio, Junko
   Nanki, Toshihiro
TI Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in
   Patients Newly Initiating Glucocorticoid Therapy
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE bisphosphonates; bone mineral density; denosumab; glucocorticoid induced
   osteoporosis; romosozumab; sclerostin
ID POSTMENOPAUSAL WOMEN; INDUCED OSTEOPOROSIS; BONE; RISK
AB Context Wnt/beta catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP.Objective To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP.Methods Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months.Results Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1 12.4]%, DMAb: 3.3 [1.5 6.2]%, BP:  0.4 [ 3.4 1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups.Conclusion Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid treated patients, suggesting that ROMO is effective for GIOP.Clinical trial number UMIN000037239
C1 [Kawazoe, Mai; Kaneko, Kaichi; Masuoka, Shotaro; Yamada, Soichi; Yamada, Zento; Muraoka, Sei; Furukawa, Karin; Sato, Hiroshi; Watanabe, Eri; Koshiba, Keiko; Irita, Izumi; Kanaji, Miwa; Sugihara, Takahiko; Nishio, Junko; Nanki, Toshihiro] Toho Univ, Sch Med, Dept Internal Med, Div Rheumatol, 6 11 1 Omori Nishi,Ota Ku, Tokyo 1438541, Japan.
   [Nishio, Junko] Toho Univ, Sch Med, Dept Immunopathol & Immunoregulat, Tokyo 1438541, Japan.
C3 Toho University
RP Nanki, T (通讯作者)，Toho Univ, Sch Med, Dept Internal Med, Div Rheumatol, 6 11 1 Omori Nishi,Ota Ku, Tokyo 1438541, Japan.
EM toshihiro.nanki@med.toho u.ac.jp
RI Muraoka, Sei/AAH 8913 2021
OI KANEKO, KAICHI/0000 0002 2082 6948; Muraoka, Sei/0000 0002 9853 8057;
   Kawazoe, Mai/0000 0002 9822 8067
FU JSPS; Teikyo Academic Research Center (TARC); Teikyo University School
   of Medicine
FX We thank the Teikyo Academic Research Center (TARC), Teikyo University
   School of Medicine, for random assignment of patients.
CR Anastasilakis AD, 2013, J CLIN ENDOCR METAB, V98, P3206, DOI 10.1210/jc.2013 1402
   Chen M, 2023, CYTOKINE GROWTH F R, V70, P54, DOI 10.1016/j.cytogfr.2023.03.002
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Ding LL, 2020, J CLIN ENDOCR METAB, V105, P600, DOI 10.1210/clinem/dgz023
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Iseri K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193846
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Kawazoe M, 2018, CLIN RHEUMATOL, V37, P2169, DOI 10.1007/s10067 017 3689 3
   Kobayakawa T, 2023, MOD RHEUMATOL, V33, P96, DOI 10.1093/mr/roac014
   Kurose R., 2023, CLIN RHEUMATOL REL R, V35, P177
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mok CC, 2023, ARTHRITIS RHEUMATOL, V75, P4811
   pmda, MEAN PERCENTAGE CHAN
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Saag KG, 2019, ARTHRITIS RHEUMATOL, V71, P1174, DOI 10.1002/art.40874
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Stokar J, 2024, J CLIN ENDOCR METAB, V110, pe861, DOI 10.1210/clinem/dgae173
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   WEISS MJ, 1988, J BIOL CHEM, V263, P12002
   Zheng J, 2023, ARTHRITIS RHEUMATOL, V75, P1781, DOI 10.1002/art.42538
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2025
VL 110
IS 8
BP e2778
EP e2786
DI 10.1210/clinem/dgae810
EA DEC 2024
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 4XC7H
UT WOS:001373208500001
PM 39552045
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, Z
   Oh, H
   Cung, M
   Marquez, SJ
   Sun, J
   Hammad, H
   Janssens, S
   Pouliot, P
   Lambrecht, BN
   Yang, YS
   Shim, JH
   Greenblatt, MB
AF Li, Zan
   Oh, Hwanhee
   Cung, Michelle
   Marquez, Sofia Jenia
   Sun, Jun
   Hammad, Hamida
   Janssens, Sophie
   Pouliot, Philippe
   Lambrecht, Bart N.
   Yang, Yeon Suk
   Shim, Jae Hyuck
   Greenblatt, Matthew B.
TI TAOK3 is a MAP3K contributing to osteoblast differentiation and skeletal
   mineralization
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE TAOK3; JNK; MAPK; Osteoblasts; Bone
ID KINASE; P38; EXPRESSION; JNK; ACTIVATION; PATHWAYS; MLK3; GENE
AB Current anabolic drugs to treat osteoporosis and other disorders of low bone mass all have important limitations in terms of toxicity, contraindications, or poor efficacy in certain contexts. Addressing these limitations will require a better understanding of the molecular pathways, such as the mitogen activated protein kinase (MAPK) pathways, that govern osteoblast differentiation and, thereby, skeletal mineralization. Whereas MAP3Ks functioning in the extracellular signal regulated kinases (ERK) and p38 pathways have been identified in osteoblasts, MAP3Ks mediating proximal activation of the c Jun N terminal kinase (JNK) pathway have yet to be identified. Here, we demonstrate that thousand and one kinase 3 (TAOK3, MAP3K18) functions as an upstream activator of the JNK pathway in osteoblasts both in vitro and in vivo. Taok3 deficient osteoblasts displayed defective JNK pathway activation and a marked decrease in osteoblast differentiation markers and defective mineralization, which was also confirmed using TAOK3 deficient osteoblasts derived from human MSCs. Additionally, reduced expression of Taok3 in a murine model resulted in osteopenia that phenocopies aspects of the Jnk1 associated skeletal phenotype such as occipital hypomineralization. Thus, in vitro and in vivo evidence supports TAOK3 as a proximal activator of the JNK pathway in osteoblasts that plays a critical role in skeletal mineralization. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Li, Zan; Oh, Hwanhee; Cung, Michelle; Marquez, Sofia Jenia; Sun, Jun; Greenblatt, Matthew B.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Li, Zan] Cent South Univ, Xiangya Hosp, Dept Sports Med, Changsha 410008, Peoples R China.
   [Li, Zan] Cent South Univ, Xiangya Hosp, Res Ctr Sports Med, Changsha 410008, Peoples R China.
   [Yang, Yeon Suk; Shim, Jae Hyuck] Univ Massachusetts, Dept Med, Div Rheumatol, Med Sch, 364 Plantat St, Worcester, MA 01605 USA.
   [Hammad, Hamida; Janssens, Sophie; Pouliot, Philippe; Lambrecht, Bart N.] Univ Ghent, VIB Inflammat Res Ctr, Dept Resp Med, Ghent, Belgium.
   [Hammad, Hamida; Janssens, Sophie; Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.
C3 Cornell University; Weill Cornell Medicine; Central South University;
   Central South University; University of Massachusetts System; University
   of Massachusetts Worcester; Ghent University; Flanders Institute for
   Biotechnology (VIB); Erasmus University Rotterdam; Erasmus MC
RP Greenblatt, MB (通讯作者)，Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.; Shim, JH (通讯作者)，Univ Massachusetts, Dept Med, Div Rheumatol, Med Sch, 364 Plantat St, Worcester, MA 01605 USA.
EM jaehyuck.shim@umassmed.edu; mag3003@med.cornell.edu
RI ; Lambrecht, Bart/K 2484 2014; Sun, Jun/KPB 2001 2024; Lambrecht, Bart
   N/K 2484 2014; Janssens, Sophie/HHN 1756 2022
OI Janssens, Sophie/0000 0003 1702 1636; Cung,
   Michelle/0000 0002 2457 4266; Lambrecht, Bart N/0000 0003 4376 6834;
   SUN, JUN/0000 0001 9099 1829; Shim, Jae Hyuck/0000 0002 4947 3293; 
FU Career Award for Medical Scientists from the Burroughs Wellcome Fund,
   the NIH [DP5OD021351, R01AR075585]; Pershing Square Sohn Cancer Research
   Alliance
FX This project was supported by a Career Award for Medical Scientists from
   the Burroughs Wellcome Fund, the NIH under award DP5OD021351and
   R01AR075585. This publication is based on research supported by the
   Pershing Square Sohn Cancer Research Alliance via an award to MBG.
CR Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670 3681.2005
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Friedel RH, 2010, METHOD ENZYMOL, V477, P243, DOI 10.1016/S0076 6879(10)77013 0
   Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Glorieux FH, 2001, LANCET, pS45
   Greenblatt MB, 2015, J EXP MED, V212, P1283, DOI 10.1084/jem.20150407
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113
   Hammad H, 2017, NAT IMMUNOL, V18, P313, DOI 10.1038/ni.3657
   Kapfhamer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050594
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marie PJ, 2012, CURR OSTEOPOROS REP, V10, P190, DOI 10.1007/s11914 012 0109 0
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Plotnikov A, 2011, BBA MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012
   Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200
   Zhang WP, 2000, BIOCHEM BIOPH RES CO, V274, P872, DOI 10.1006/bbrc.2000.3244
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 27
TC 20
Z9 21
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 22
PY 2020
VL 531
IS 4
BP 497
EP 502
DI 10.1016/j.bbrc.2020.07.060
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA NS0QG
UT WOS:000571964200008
PM 32807497
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Whitehouse, CA
   Waters, S
   Marchbank, K
   Horner, A
   McGowan, NWA
   Jovanovic, JV
   Xavier, GM
   Kashima, TG
   Cobourne, MT
   Richards, GO
   Sharpe, PT
   Skerry, TM
   Grigoriadis, AE
   Solomon, E
AF Whitehouse, Caroline A.
   Waters, Sarah
   Marchbank, Katie
   Horner, Alan
   McGowan, Neil W. A.
   Jovanovic, Jelena V.
   Xavier, Guilherme M.
   Kashima, Takeshi G.
   Cobourne, Martyn T.
   Richards, Gareth O.
   Sharpe, Paul T.
   Skerry, Tim M.
   Grigoriadis, Agamemnon E.
   Solomon, Ellen
TI Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of
   postnatal osteoblastic bone formation and p38 MAPK activity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone remodeling; osteoblasts; p62; autophagy; light chain 3
ID ACTIVATED PROTEIN KINASE; INDUCED CELL DEATH; PAGETS DISEASE;
   UBIQUITIN BINDING; UBA DOMAIN; DIFFERENTIATION; P62/SQSTM1; MUTATIONS;
   P62; EXPRESSION
AB The neighbor of Brca1 gene (Nbr1) functions as an autophagy receptor involved in targeting ubiquitinated proteins for degradation. It also has a dual role as a scaffold protein to regulate growth factor receptor and downstream signaling pathways. We show that genetic truncation of murine Nbr1 leads to an age dependent increase in bone mass and bone mineral density through increased osteoblast differentiation and activity. At 6 mo of age, despite normal body size, homozygous mutant animals (Nbr1(tr/tr)) have similar to 50% more bone than littermate controls. Truncated Nbr1 (trNbr1) co localizes with p62, a structurally similar interacting scaffold protein, and the autophagosome marker LC3 in osteoblasts, but unlike the full length protein, trNbr1 fails to complex with activated p38 MAPK. Nbr1(tr/tr) osteoblasts and osteoclasts show increased activation of p38 MAPK, and significantly, pharmacological inhibition of the p38 MAPK pathway in vitro abrogates the increased osteoblast differentiation of Nbr1(tr/tr) cells. Nbr1 truncation also leads to increased p62 protein expression. We show a role for Nbr1 in bone remodeling, where loss of function leads to perturbation of p62 levels and hyperactivation of p38 MAPK that favors osteoblastogenesis.
C1 [Whitehouse, Caroline A.; Waters, Sarah; Marchbank, Katie; Jovanovic, Jelena V.; Solomon, Ellen] Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England.
   [Horner, Alan; Richards, Gareth O.; Skerry, Tim M.] Sch Med & Biomed Sci, Sect Musculoskeletal Sci, Acad Unit Bone Biol, Sheffield S10 2RX, S Yorkshire, England.
   [McGowan, Neil W. A.; Xavier, Guilherme M.; Kashima, Takeshi G.; Cobourne, Martyn T.; Sharpe, Paul T.; Grigoriadis, Agamemnon E.] Kings Coll London, Dept Craniofacial Dev & Orthodont, London SE1 9RT, England.
C3 University of London; King's College London; University of London;
   King's College London
RP Whitehouse, CA (通讯作者)，Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England.
EM caroline.whitehouse@kcl.ac.uk
RI Cobourne, Martyn/R 1165 2019; Kashima, Takeshi/F 8679 2010
OI Richards, Gareth Owain/0000 0001 7984 6882; Sharpe,
   Paul/0000 0003 2116 9561; Cobourne, Martyn/0000 0003 2857 0315; Skerry,
   Timothy/0000 0003 1319 5575
FU Arthritis Research United Kingdom Fellowship; British Heart Foundation;
   Guy's & St Thomas' Charity; Leukaemia and Lymphoma Research of Great
   Britain; Biotechnology and Biological Sciences Research Council (BBSRC);
   MRC [G9800001] Funding Source: UKRI; Medical Research Council [G9800001]
   Funding Source: researchfish; Versus Arthritis [17655] Funding Source:
   researchfish
FX We thank Andrew Stewart (King's College London) and staff in the
   Biological Services Unit for animal care, Marco Sandri (Venetian
   Institute of Molecular Medicine, Padua, Italy) for the YFP LC3 plasmid,
   Mathias Gautel (King's College London) for helpful discussion and the
   endogenous Nbr1 polyclonal antibody, David Mangham (Robert Jones and
   Agnes Hunt Orthopaedic Hospital, Oswestry, UK) for helpful review of the
   bone pathology, Jennifer Mollon (King's College London) for statistical
   advice, and members of the E. S. laboratory for reading the manuscript.
   C.A.W. is supported by an Arthritis Research United Kingdom Fellowship
   and British Heart Foundation Project Grant, S.W. is supported by Guy's &
   St Thomas' Charity, J.V.J. is supported by Leukaemia and Lymphoma
   Research of Great Britain, and K.M. is supported by a Biotechnology and
   Biological Sciences Research Council (BBSRC) Studentship.
CR Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Cavey JR, 2005, J BONE MINER RES, V20, P619, DOI 10.1359/JBMR.041205
   Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Grigoriadis AE, 1996, DIFFERENTIATION, V60, P299, DOI 10.1046/j.1432 0436.1996.6050299.x
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   Helfrich MH, 2008, ARCH BIOCHEM BIOPHYS, V473, P172, DOI 10.1016/j.abb.2008.02.045
   Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015
   Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735
   Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kashimaa TG, 2009, HUM PATHOL, V40, P226, DOI 10.1016/j.humpath.2008.07.008
   Kawai K, 2008, J BIOCHEM, V143, P765, DOI 10.1093/jb/mvn027
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200
   Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Layfield R, 2006, BIOCHEM SOC T, V34, P735, DOI 10.1042/BST0340735
   Long J, 2010, J MOL BIOL, V396, P178, DOI 10.1016/j.jmb.2009.11.032
   Mardakheh FK, 2009, J CELL BIOL, V187, P265, DOI 10.1083/jcb.200905118
   Moscat J, 2006, MOL CELL, V23, P631, DOI 10.1016/j.molcel.2006.08.002
   Oreffo ROC, 1997, EUR J CELL BIOL, V74, P251
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011
   Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209
   SUGIMOTO R, 2009, J CELL MOL MED, DOI DOI 10.1111/J.1582 4934.2009.00914.X
   Van Staa TP, 2002, J BONE MINER RES, V17, P465, DOI 10.1359/jbmr.2002.17.3.465
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Waters S, 2009, FEBS LETT, V583, P1846, DOI 10.1016/j.febslet.2009.04.049
   Whitehouse C, 2004, GENE, V326, P87, DOI 10.1016/j.gene.2003.10.008
   Whitehouse C, 2002, EUR J BIOCHEM, V269, P538, DOI 10.1046/j.0014 2956.2001.02681.x
   Wilkinson D. G, 1992, SITU HYBRIDIZATION P
   Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074 7613(00)80391 X
   Yoon KW, 2009, P NATL ACAD SCI USA, V106, P17389, DOI 10.1073/pnas.0812259106
   Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80
NR 40
TC 70
Z9 84
U1 0
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 20
PY 2010
VL 107
IS 29
BP 12913
EP 12918
DI 10.1073/pnas.0913058107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 628TJ
UT WOS:000280144500039
PM 20616007
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Eskildsen, T
   Taipaleenmäki, H
   Stenvang, J
   Abdallah, BM
   Ditzel, N
   Nossent, AY
   Bak, M
   Kauppinen, S
   Kassem, M
AF Eskildsen, Tilde
   Taipaleenmaki, Hanna
   Stenvang, Jan
   Abdallah, Basem M.
   Ditzel, Nicholas
   Nossent, Anne Yael
   Bak, Mads
   Kauppinen, Sakari
   Kassem, Moustapha
TI MicroRNA 138 regulates osteogenic differentiation of human stromal
   (mesenchymal) stem cells in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE regulatory RNA; bone biology; osteoblastic differentiation
ID FOCAL ADHESION KINASE; OSTEOBLAST DIFFERENTIATION; DOWN REGULATION;
   EXPRESSION; PROLIFERATION; SIGNALS; LINEAGE; RUNX2; GENE
AB Elucidating the molecular mechanisms that regulate human stromal (mesenchymal) stem cell (hMSC) differentiation into osteogenic lineage is important for the development of anabolic therapies for treatment of osteoporosis. MicroRNAs (miRNAs) are short, noncoding RNAs that act as key regulators of diverse biological processes by mediating translational repression or mRNA degradation of their target genes. Here, we show that miRNA 138 (miR 138) modulates osteogenic differentiation of hMSCs. miRNA array profiling and further validation by quantitative RT PCR (qRT PCR) revealed that miR 138 was down regulated during osteoblast differentiation of hMSCs. Overexpression of miR 138 inhibited osteoblast differentiation of hMSCs in vitro, whereas inhibition of miR 138 function by antimiR 138 promoted expression of osteoblast specific genes, alkaline phosphatase (ALP) activity, and matrix mineralization. Furthermore, overexpression of miR 138 reduced ectopic bone formation in vivo by 85%, and conversely, in vivo bone formation was enhanced by 60% when miR 138 was antagonized. Target prediction analysis and experimental validation by luciferase 3' UTR reporter assay confirmed focal adhesion kinase, a kinase playing a central role in promoting osteoblast differentiation, as a bona fide target of miR 138. We show that miR 138 attenuates bone formation in vivo, at least in part by inhibiting the focal adhesion kinase signaling pathway. Our findings suggest that pharmacological inhibition of miR 138 by antimiR 138 could represent a therapeutic strategy for enhancing bone formation in vivo.
C1 [Eskildsen, Tilde; Taipaleenmaki, Hanna; Abdallah, Basem M.; Ditzel, Nicholas; Kassem, Moustapha] Univ So Denmark, Odense Univ Hosp, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
   [Taipaleenmaki, Hanna] Univ Turku, Dept Med Biochem & Genet, FIN 20520 Turku, Finland.
   [Stenvang, Jan; Nossent, Anne Yael; Bak, Mads; Kauppinen, Sakari] Univ Copenhagen, Wilhelm Johansen Ctr Funct Genome Res, Dept Cellular & Mol Med, DK 2200 Copenhagen, Denmark.
   [Stenvang, Jan; Kauppinen, Sakari] Santaris Pharma, Dept microRNA Res, DK 2970 Horsholm, Denmark.
   [Stenvang, Jan] Univ Copenhagen, Fac Life Sci, Inst Vet Dis Biol, DK 1870 Frederiksberg, Denmark.
   [Kauppinen, Sakari] Aalborg Univ, Copenhagen Inst Technol, DK 2750 Ballerup, Denmark.
   [Kassem, Moustapha] King Saud Univ, Stem Cell Unit, Dept Anat, Coll Med, Riyadh 11461, Saudi Arabia.
C3 University of Southern Denmark; Odense University Hospital; University
   of Turku; University of Copenhagen; University of Copenhagen; Aalborg
   University; King Saud University
RP Kassem, M (通讯作者)，Univ So Denmark, Odense Univ Hosp, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
EM mkassem@health.sdu.dk
RI Abdallah, Basem/G 5667 2017; Kassem, Moustapha/J 7688 2013
OI Abdallah, Basem/0000 0003 0324 8055; Kassem,
   Moustapha/0000 0003 1557 0869; Bak, Mads/0000 0003 2762 1002; Stenvang,
   Jan/0000 0001 5647 4828; Nossent, Anne Yael/0000 0002 2155 4286
FU Danish National Advanced Technology Foundation; Danish Medical Research
   Council; Novo Nordisk Foundation; Lundbeck Foundation; Region of
   Southern Denmark
FX We are grateful to Lone Christiansen, Bianca Jorgensen, Tina Kamilla
   Nielsen, and Jane Hinrichsen for excellent technical assistance. Dr.
   Anna Marja Saamanen is thanked for helpful discussions. Salla Suomi
   (MSc) is acknowledged for help with qRT PCR analysis. H.T. is a graduate
   student in the Turku Graduate School of Biomedical Sciences, Turku,
   Finland. The Wilhelm Johannsen Centre for Functional Genome Research is
   established by the Danish National Research Foundation. These studies
   were supported by the Danish National Advanced Technology Foundation
   (S.K.), the Danish Medical Research Council (S.K.), the Novo Nordisk
   Foundation (M.K.), the Lundbeck Foundation (M.K.), and the Region of
   Southern Denmark (M.K.).
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Alm JJ, 2010, J ORTHOP RES, V28, P1634, DOI 10.1002/jor.21167
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bork S., 2010, J CELL PHYSL
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092 8674(03)00231 9
   Castoldi M, 2006, RNA, V12, P913, DOI 10.1261/rna.2332406
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hu R, 2010, EXPERT OPIN THER TAR, V14, P1109, DOI 10.1517/14728222.2010.512916
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Kuhn DE, 2008, METHODS, V44, P47, DOI 10.1016/j.ymeth.2007.09.005
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092 8674(03)01018 3
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Perinpanayagam H, 2001, J ORTHOPAED RES, V19, P993, DOI 10.1016/S0736 0266(01)00045 6
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schaller MD, 2001, BBA MOL CELL RES, V1540, P1, DOI 10.1016/S0167 4889(01)00123 9
   SCHLAEPFER DD, 1994, NATURE, V372, P786
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Stenderup K, 2004, BIOGERONTOLOGY, V5, P107, DOI 10.1023/B:BGEN.0000025074.88476.e2
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960 9822(03)00250 1
   Yang Z, 2011, STEM CELLS DEV, V20, P259, DOI 10.1089/scd.2010.0072
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
NR 35
TC 414
Z9 465
U1 0
U2 117
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6139
EP 6144
DI 10.1073/pnas.1016758108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 748SZ
UT WOS:000289413600045
PM 21444814
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, M
   Wan, P
   Wang, WD
   Yang, K
   Zhang, Y
   Han, Y
AF Li, Mei
   Wan, Peng
   Wang, Weidan
   Yang, Ke
   Zhang, Yu
   Han, Yong
TI Regulation of osteogenesis and osteoclastogenesis by zoledronic acid
   loaded on biodegradable magnesium strontium alloy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF KAPPA B; RECEPTOR ALPHA; BONE; BIOCOMPATIBILITY; DIFFERENTIATION;
   DEGRADATION; OSTEOLYSIS; SCAFFOLDS; CORROSION; COATINGS
AB Inhibiting osteoclasts and osteoclast precursors to reduce bone resorption is an important strategy to treat osteoclast related diseases, such as peri prosthetic osteolysis. In this study, our objective was to study the role of zoledronic acid (ZA), as a highly potent and nitrogen containing bisphosphonate, in promoting osteogenesis and inhibiting osteoclastogenesis properties of magnesium (Mg) based implants. ZA was chemically associated with calcium phosphate (CaP) deposited on magnesiumstrontium (Mg Sr) alloy, which was confirmed by the morphological observation, phase composition and drug releasing via SEM, XRD spectrum and High Performance Liquid Chromatography (HPLC), respectively. The in vitro performances indicated that ZA CaP bilayer coating Mg Sr alloy could enhance the proliferation and the osteogenic differentiation as well as the mineralization of pre osteoblasts, however, induce the apoptosis and inhibit the osteoclast differentiation. We further investigated the possible molecular mechanisms by using Quantitative real time PCR (qRT PCR) and Western Blotting, and the results showed that ZA CaP bilayer coating Mg Sr alloy could regulate the osteogenesis and osteoclastogenesis through the Estrogen Receptor alpha (ER alpha) and NF kappa B signaling pathway. Moreover, ZA CaP bilayer coating Mg Sr alloy could regulate the cross talk of osteoblast osteoclast and increase the ratio of OPG: RANKL in the co culture system through OPG/RANKL/RANK signaling pathway, which promoting the balance of bone remodeling process. Therefore, these promising results suggest the potential clinical applications of ZA pretreated Mg Sr alloys for bone defect repairs and periprosthetical osteolysis due to the excessive differentitation and maturation of osteoclasts.
C1 [Li, Mei; Han, Yong] Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710049, Shaanxi, Peoples R China.
   [Li, Mei; Zhang, Yu] Guangdong Gen Hosp, Guangdong Acad Med Sci, Dept Orthoped, Guangzhou 510080, Guangdong, Peoples R China.
   [Wan, Peng] Dongguan Univ Technol, Sch Mech Engn, Dongguan 523808, Peoples R China.
   [Wang, Weidan; Yang, Ke] Chinese Acad Sci, Inst Met Res, Shenyang 110016, Liaoning, Peoples R China.
   [Wang, Weidan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Xi'an Jiaotong University; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital; Southern Medical University   China;
   Dongguan University of Technology; Chinese Academy of Sciences;
   Institute of Metal Research, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS
RP Han, Y (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710049, Shaanxi, Peoples R China.; Zhang, Y (通讯作者)，Guangdong Gen Hosp, Guangdong Acad Med Sci, Dept Orthoped, Guangzhou 510080, Guangdong, Peoples R China.; Wan, P (通讯作者)，Dongguan Univ Technol, Sch Mech Engn, Dongguan 523808, Peoples R China.
EM wanpeng@dgut.edu.cn; luck_2001@126.com; yonghan@mail.xjtu.edu.cn
RI ; Li, Mei/KRQ 7982 2024
OI Li, Mei/0000 0002 9265 8541; 
FU National Natural Science Foundation of China [51371137, 81501859,
   51631007, 31500777, 81601884]; National Key Research and Development
   Program of China [2017YFB0702604, 2016YFB0700803]; Natural Science
   Foundation of Guangdong Province, China [2015A030312004]
FX We appreciate the financial support from the National Natural Science
   Foundation of China (Grant No. 51371137, 81501859, 51631007, 31500777
   and 81601884), the National Key Research and Development Program of
   China (Grant No. 2017YFB0702604 and 2016YFB0700803), Natural Science
   Foundation of Guangdong Province, China (Grant No. 2015A030312004).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Battiston KG, 2014, BIOMATERIALS, V35, P4465, DOI 10.1016/j.biomaterials.2014.02.023
   Boda SK, 2017, ACS APPL MATER INTER, V9, P19389, DOI 10.1021/acsami.6b08694
   Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME 10 0024
   Bornapour M, 2013, ACTA BIOMATER, V9, P5319, DOI 10.1016/j.actbio.2012.07.045
   Broomfield JAJ, 2017, J ARTHROPLASTY, V32, P1186, DOI 10.1016/j.arth.2016.10.037
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Davies JE, 2013, BIOMATERIALS, V34, P3535, DOI 10.1016/j.biomaterials.2013.01.024
   Detsch R, 2015, J TISSUE ENG REGEN M, V9, P1133, DOI 10.1002/term.1851
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fernandez Yague MA, 2015, ADV DRUG DELIVER REV, V84, P1, DOI 10.1016/j.addr.2014.09.005
   Gu XN, 2009, BIOMATERIALS, V30, P484, DOI 10.1016/j.biomaterials.2008.10.021
   Han JJ, 2016, MAT SCI ENG C MATER, V58, P799, DOI 10.1016/j.msec.2015.09.057
   Hornberger H, 2012, ACTA BIOMATER, V8, P2442, DOI 10.1016/j.actbio.2012.04.012
   Hu L, 2017, STEM CELLS DEV, V26, P123, DOI 10.1089/scd.2016.0173
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Kleinhans C, 2015, J BIOTECHNOL, V205, P101, DOI 10.1016/j.jbiotec.2014.11.039
   Larbi MAMS, 2016, J CHEM THERMODYN, V97, P297, DOI 10.1016/j.jct.2016.02.005
   Lei Z, 2017, ACS APPL MATER INTER, V9, P9437, DOI 10.1021/acsami.7b00209
   Li B, 2016, J MATER CHEM B, V4, P683, DOI 10.1039/c5tb02101d
   Li C, 2016, MAT SCI ENG A STRUCT, V657, P347, DOI 10.1016/j.msea.2016.01.075
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Y, 2018, MAT SCI ENG C MATER, V82, P225, DOI 10.1016/j.msec.2017.08.043
   Martin T. J., 2015, REV ENDOCR METAB DIS, V16, P1
   Meininger S, 2016, ACTA BIOMATER, V31, P401, DOI 10.1016/j.actbio.2015.11.050
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722
   Nadar R. A., 2017, ADV HEALTHCARE MAT, V6
   Narayanan TSNS, 2014, PROG MATER SCI, V60, P1, DOI 10.1016/j.pmatsci.2013.08.002
   Oliveira AL, 2010, J BIOMED MATER RES B, V92B, P55, DOI 10.1002/jbm.b.31489
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Sonnow L, 2017, BMC MED IMAGING, V17, DOI 10.1186/s12880 017 0187 7
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang R, 2017, J STEROID BIOCHEM, V174, P276, DOI 10.1016/j.jsbmb.2017.10.008
   Weng L, 2013, INT J NANOMED, V8, P1773, DOI 10.2147/IJN.S39031
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zhou JH, 2013, ACS APPL MATER INTER, V5, P5358, DOI 10.1021/am401339n
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 46
TC 61
Z9 68
U1 0
U2 52
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 30
PY 2019
VL 9
AR 933
DI 10.1038/s41598 018 37091 8
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HJ4FF
UT WOS:000457128700010
PM 30700724
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xiu, Y
   Xu, H
   Zhao, C
   Li, JB
   Morita, Y
   Yao, ZQ
   Xing, LP
   Boyce, BF
AF Xiu, Yan
   Xu, Hao
   Zhao, Chen
   Li, Jinbo
   Morita, Yoshikazu
   Yao, Zhenqiang
   Xing, Lianping
   Boyce, Brendan F.
TI Chloroquine reduces osteoclastogenesis in murine osteoporosis by
   preventing TRAF3 degradation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID NF KAPPA B; PARATHYROID HORMONE; BONE RESORPTION; IKK ALPHA;
   RHEUMATOID ARTHRITIS; BETA RECEPTOR; AUTOPHAGY; ACTIVATION; PATHWAY;
   RANKL
AB The cytoldnes RANKL and TNF activate NF kappa B signaling in osteoclast precursors (OCPs) to induce osteoclast (OC) formation. Conversely, TNF can limit OC formation through NF kappa B p100, which acts as an inhibitor, and TNF receptor associated receptor 3 (TRAF3); however, a role for TRAF3 in RANKL mediated OC formation is unknown. We found that TRAF3 limits RANKL induced osteoclastogenesis by suppressing canonical and noncanonical NF kappa B signaling. Conditional OC specific Traf3 KO (cKO) mice had mild osteoporosis and increased OC formation. RANKL induced TRAF3 degradation via the lysosome/autophagy system. The autophagy/lysosome inhibitor chloroquine reduced RANKL induced OC formation and function by increasing TRAF3 expression in OCPs in vitro and in vivo. Although chloroquine had no effect on basal bone resorption, it inhibited parathyroid hormone  and ovariectomy induced OC activation in WT, but not cKO, mice. Deletion of the transcription factor gene Relb resulted in increased TRAF3 expression in OCPs, which was associated with decreased RANKL induced TRAF3 degradation. RelB directly increased expression of BECN1, a key autophagy regulator, by binding to its promoter. These data indicate that autophagic/lysosomal degradation of TRAF3 is an important step in RANKL induced NF kappa B activation in OCPs. Furthermore, treatments that increase TRAF3 levels in OCPs, including pharmacological inhibition of its degradation with compounds such as chloroquine, may limit bone destruction in common bone diseases.
C1 [Xiu, Yan; Xu, Hao; Zhao, Chen; Li, Jinbo; Morita, Yoshikazu; Yao, Zhenqiang; Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA.
   [Yao, Zhenqiang; Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Boyce, BF (通讯作者)，Univ Rochester, Dept Pathol & Lab Med, Med Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM Brendan_Boyce@URMC.Rochester.edu
RI ; xu, hao/GWQ 7394 2022
OI Yao, Zhenqiang/0000 0002 4664 3648; 
FU National Institute for Arthritis, Musculoskeletal and Skin Diseases
   [AR43510, 1S 10RR027340, AR48697, P30AR061307, T32AR053459]
FX We thank Yanyun Li, Michael Thullen, and Karen Bentley for technical
   support. This work was supported by the following grants from the
   National Institute for Arthritis, Musculoskeletal and Skin Diseases:
   AR43510 and 1S 10RR027340 (to B.F. Boyce); AR48697 (to L. Xing);
   P30AR061307, and T32AR053459.
CR Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Ben Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Ben Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016 010 8243 x
   Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462
   Bista P, 2010, J BIOL CHEM, V285, P12971, DOI 10.1074/jbc.M109.076091
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0
   Calvi LM, 2012, BLOOD, V119, P2489, DOI 10.1182/blood 2011 06 360933
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327
   Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396 08
   Criollo A, 2012, CELL CYCLE, V11, P194, DOI 10.4161/cc.11.1.18669
   Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364
   Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775
   Davila L, 2011, NAT REV RHEUMATOL, V7, P537, DOI 10.1038/nrrheum.2011.117
   Deretic V, 2012, TRENDS CELL BIOL, V22, P397, DOI 10.1016/j.tcb.2012.04.008
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Djavaheri Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Ganeff C, 2011, MOL CELL BIOL, V31, P4319, DOI 10.1128/MCB.05033 11
   Gardam S, 2008, IMMUNITY, V28, P391, DOI 10.1016/j.immuni.2008.01.009
   Häcker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998
   He JQ, 2007, J BIOL CHEM, V282, P3688, DOI 10.1074/jbc.M610271200
   He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008 5472.CAN 12 2464
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Lotze MT, 2013, CANCER J, V19, P341, DOI 10.1097/PPO.0b013e31829da0d6
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nakhaei P, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000650
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Voronov I, 2013, J BONE MINER RES, V28, P108, DOI 10.1002/jbmr.1727
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xiao YC, 2013, NAT MED, V19, P595, DOI 10.1038/nm.3111
   Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074 7613(00)80497 5
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406
   Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092 8674(00)80406 7
   Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   Zhang LS, 2010, J BONE MINER RES, V25, P1572, DOI 10.1002/jbmr.36
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
NR 71
TC 139
Z9 165
U1 0
U2 22
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2014
VL 124
IS 1
BP 297
EP 310
DI 10.1172/JCI66947
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 284PX
UT WOS:000329333500037
PM 24316970
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhou, ZY
   Zhao, CX
   Li, SY
   Han, XY
   Zhu, JY
   Xue, ST
   Li, ZR
AF Zhou, Ziying
   Zhao, Chenxi
   Li, Siyan
   Han, Xiaoyang
   Zhu, Jiangyi
   Xue, Situ
   Li, Zhuorong
TI BMP2 ERK ATF4 Axis Based 6 methoxybenzofuran Compound I 9 Acts as
   Candidate Drug for Bone Formation and Anti Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoporosis; 6 methoxybenzofuran; ATF4; BMP 2; bone formation;
   osteoblast
ID PARATHYROID HORMONE 1 34; BENZOFURAN DERIVATIVES; SUBSTITUTED
   BENZOTHIOPHENE; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; UP REGULATORS;
   TERIPARATIDE; PATHWAYS; EFFICACY; FRACTURES
AB As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use of existing peptides and monoclonal antibodies are limited, and small molecule bone formation promoting drugs are urgently required. We established an I 9 synthesis route with high yield, simple operation, and low cost that was suitable for future large scale production. I 9 administration promoted bone formation and increased bone mass in mice with low bone mass in an aged C57 mouse model. Our findings revealed a hitherto undescribed pathway involving the BMP2 ERK ATF4 axis that promotes osteoblast differentiation; I 9 has favorable biosafety in mice. This study systematically investigated the efficacy, safety, and mechanism of I 9 for treating osteoporosis and positions this drug for preclinical research in the future. Thus, this study has promoted the development of small molecule bone promoting drugs.
C1 [Zhou, Ziying; Zhao, Chenxi; Li, Siyan; Han, Xiaoyang; Zhu, Jiangyi; Xue, Situ; Li, Zhuorong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing 100050, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Medicinal Biotechnology   CAMS; Peking Union Medical
   College
RP Xue, ST; Li, ZR (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing 100050, Peoples R China.
EM zhouziying202108@163.com; zhaochenxi19920220@163.com;
   lisiyan990321@163.com; 15305191141@163.com; 13605132482@163.com;
   xuesitu@imb.pumc.edu.cn; lizhuorong@imb.pumc.edu.cn
RI Siyan, Li/JCN 9257 2023; Chen, Jiahao/KPA 0985 2024
FU CAMS Innovation Fund for Medical Sciences
FX No Statement Available
CR Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   [Anonymous], 1991, Osteoporos Int, V1, P114
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Briot K, 2018, JOINT BONE SPINE, V85, P519, DOI 10.1016/j.jbspin.2018.02.009
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chinese Center for Disease Control and Prevention of Chronic Noncommunicable Diseases Chinese Medical Association Branch of Osteoporosis and Bone Mineral Salt Diseases, 2021, Epidemiological Survey Report of Osteoporosis in China (2018)
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fujiwara S, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0443 7
   Gao YG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030483
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guo HF, 2010, J MED CHEM, V53, P1819, DOI 10.1021/jm901685n
   Hu ZY, 2019, BIOL OPEN, V8, DOI 10.1242/bio.040840
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim EK, 2010, BBA MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Kim HK, 2013, MOLECULES, V18, P15474, DOI 10.3390/molecules181215474
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Leslie WD, 2021, JAMA J AM MED ASSOC, V326, P1622, DOI 10.1001/jama.2021.9858
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PECK WA, 1993, AM J MED, V94, P646
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02821 8
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Wagley Y, 2020, STEM CELLS, V38, P1332, DOI 10.1002/stem.3245
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Xue ST, 2020, EUR J MED CHEM, V200, DOI 10.1016/j.ejmech.2020.112465
   Xue ST, 2015, EUR J MED CHEM, V96, P151, DOI 10.1016/j.ejmech.2015.04.016
   Zhang CG, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003180
   Zhou ZY, 2023, J MED CHEM, V66, P1742, DOI 10.1021/acs.jmedchem.2c01377
NR 37
TC 2
Z9 2
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2024
VL 25
IS 6
AR 3350
DI 10.3390/ijms25063350
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MH6S4
UT WOS:001192778400001
PM 38542323
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Uchino, K
   Okamoto, K
   Sakai, E
   Yoneshima, E
   Iwatake, M
   Fukuma, Y
   Nishishita, K
   Tsukuba, T
AF Uchino, Kaho
   Okamoto, Kuniaki
   Sakai, Eiko
   Yoneshima, Erika
   Iwatake, Mayumi
   Fukuma, Yutaka
   Nishishita, Kazuhisa
   Tsukuba, Takayuki
TI Dual Effects of Liquiritigenin on the Proliferation of Bone Cells:
   Promotion of Osteoblast Differentiation and Inhibition of Osteoclast
   Differentiation
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE osteoclasts; osteoblasts; liquiritigenin; differentiation
ID LINEAGE COMMITMENT; RANKL; BETA; GENISTEIN; AGONIST; MICE
AB Bone is constantly controlled by a balance between osteoblastic bone formation and osteoclastic bone resorption. Liquiritigenin is a plant derived flavonoid and has various pharmacological effects, such as antioxidative, antitumor, and antiinflammatory effects. Here, we show that liquiritigenin has dual effects on the proliferation of bone cells, regarding the promotion of osteoblast differentiation and the inhibition of osteoclast differentiation. Liquiritigenin treated murine osteoblastic MC3T3 E1 cells showed an increased alkaline phosphatase activity and enhanced phosphorylation of Smad1/5 compared with untreated cells. Moreover, liquiritigenin inhibited osteoclast differentiation, its bone resorption activity through slightly decreased the phosphorylation of extracellular signal regulated kinase, c Jun N terminal kinase, and inhibitor of nuclear factor kappa B; however, the phosphorylation of Akt and p38 slightly increased in bone marrow derived osteoclasts. The expression levels of the osteoclast marker proteins nuclear factor of activated T cell cytoplasmic 1, Src, and cathepsin K diminished. These results suggest that liquiritigenin may be useful as a therapeutic and/or preventive agent for osteoporosis or inflammatory bone diseases. Copyright (C) 2015 John Wiley & Sons, Ltd.
C1 [Uchino, Kaho; Okamoto, Kuniaki; Sakai, Eiko; Yoneshima, Erika; Iwatake, Mayumi; Fukuma, Yutaka; Nishishita, Kazuhisa; Tsukuba, Takayuki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Dent Pharmacol, Nagasaki 8528588, Japan.
C3 Nagasaki University
RP Tsukuba, T (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Dent Pharmacol, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
EM tsuta@nagasaki u.ac.jp
RI ; Tsukuba, Takayuki/I 9542 2018
OI sakai, eiko/0000 0002 6776 6540; 
FU JSPS KAKENHI grant [25293383, 26670906, 15H05298, 25462920, 25462892]; 
   [15H00662]; Grants in Aid for Scientific Research [26670906, 15H00662,
   25462920, 15H05298, 25293383, 25462892] Funding Source: KAKEN
FX This study was supported in part by JSPS KAKENHI grant numbers 25293383,
   26670906, 15H05298 (T.T.), 25462920 (Y. F.), 25462892 (E. S.), and
   Grant in Aid for Encouragement of Scientists Grant Number 15H00662
   (M.I.).
CR Bitto A, 2010, CURR MED CHEM, V17, P3007, DOI 10.2174/092986710791959738
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JR, 2014, J BONE MINER RES, V29, P1043, DOI 10.1002/jbmr.2034
   Chen XW, 2003, J NUTR BIOCHEM, V14, P342, DOI 10.1016/S0955 2863(03)00056 1
   Choi EM, 2014, PHYTOTHER RES, V28, P880, DOI 10.1002/ptr.5071
   Choi EM, 2012, INT IMMUNOPHARMACOL, V12, P139, DOI 10.1016/j.intimp.2011.11.003
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Jiang Y, 2013, FASEB J, V27, P4406, DOI 10.1096/fj.13 234617
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kupfer R, 2008, DRUG METAB DISPOS, V36, P2261, DOI 10.1124/dmd.108.021402
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Wu J, 2001, J BONE MINER RES, V16, P1829, DOI 10.1359/jbmr.2001.16.10.1829
   Zhou M, 2010, PHYTOTHER RES, V24, P827, DOI 10.1002/ptr.3024
NR 23
TC 14
Z9 20
U1 0
U2 18
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD NOV
PY 2015
VL 29
IS 11
BP 1714
EP 1721
DI 10.1002/ptr.5416
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CW0XJ
UT WOS:000364713100005
PM 26172226
OA Green Submitted
DA 2025 08 17
ER

PT J
AU García Giménez, JL
   Rubio Belmar, PA
   Peiró Chova, L
   Hervás, D
   González Rodríguez, D
   Ibañez Cabellos, JS
   Bas Hermida, P
   Mena Mollá, S
   García López, EM
   Pallardó, FV
   Bas, T
AF Luis Garcia Gimenez, Jose
   Antonio Rubio Belmar, Pedro
   Peiro Chova, Lorena
   Hervas, David
   Gonzalez Rodriguez, Dayme
   Santiago Ibanez Cabellos, Jose
   Bas Hermida, Paloma
   Mena Molla, Salvador
   Maria Garcia Lopez, Eva
   Pallardo, Federico V.
   Bas, Teresa
TI Circulating miRNAs as diagnostic biomarkers for adolescent idiopathic
   scoliosis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; EPIGENETIC
   BIOMARKERS; BONE FORMATION; MICRORNA; CANCER; BETA; GENE;
   SUSCEPTIBILITY; EPIDEMIOLOGY
AB The aetiology of adolescent idiopathic scoliosis (AIS) has been linked to many factors, such as asymmetric growth, neuromuscular condition, bone strength and genetic background. Recently, epigenetic factors have been proposed as contributors of AIS physiopathology, but information about the molecular mechanisms and pathways involved is scarce. Regarding epigenetic factors, microRNAs (miRNAs) are molecules that contribute to gene expression modulation by regulating important cellular pathways. We herein used Next Generation Sequencing to discover a series of circulating miRNAs detected in the blood samples of AIS patients, which yielded a unique miRNA biomarker signature that diagnoses AIS with high sensitivity and specificity. We propose that these miRNAs participate in the epigenetic control of signalling pathways by regulating osteoblast and osteoclast differentiation, thus modulating the genetic background of AIS patients. Our study yielded two relevant results: 1) evidence for the deregulated miRNAs that participate in osteoblast/osteoclast differentiation mechanisms in AIS; 2) this miRNA signature can be potentially used as a clinical tool for molecular AIS diagnosis. Using miRNAs as biomarkers for AIS diagnostics is especially relevant since miRNAs can serve for early diagnoses and for evaluating the positive effects of applied therapies to therefore reduce the need of high risk surgical interventions.
C1 [Luis Garcia Gimenez, Jose; Pallardo, Federico V.] CIBERER, Valencia, Spain.
   [Luis Garcia Gimenez, Jose; Peiro Chova, Lorena; Gonzalez Rodriguez, Dayme; Santiago Ibanez Cabellos, Jose; Maria Garcia Lopez, Eva; Pallardo, Federico V.] Inst Invest Sanitaria INCLIVA, Ave Menendez & Pelayo 4, Valencia 46010, Spain.
   [Luis Garcia Gimenez, Jose; Santiago Ibanez Cabellos, Jose; Mena Molla, Salvador; Maria Garcia Lopez, Eva; Pallardo, Federico V.] Univ Valencia, Fac Med & Dent, Dept Physiol, Av Blasco Ibanez 15, Valencia 46010, Spain.
   [Antonio Rubio Belmar, Pedro; Bas Hermida, Paloma] Inst Invest Sanitaria IISLAFE, Av Fernando Abril Martorell 106,Torre A7, Valencia 46026, Spain.
   [Antonio Rubio Belmar, Pedro; Bas Hermida, Paloma; Bas, Teresa] Hosp Univ & Politecn La Fe, Unidad Raquis, Av Fernando Abril Martorell 106, Valencia 46026, Spain.
   [Hervas, David] Inst Invest Sanitaria IISLAFE, Unidad Bioestadist, Av Fernando Abril Martorell 106, Valencia 46026, Spain.
C3 CIBER   Centro de Investigacion Biomedica en Red; CIBERER; University of
   Valencia; Hospital Universitari i Politecnic La Fe
RP García Giménez, JL (通讯作者)，CIBERER, Valencia, Spain.; García Giménez, JL (通讯作者)，Inst Invest Sanitaria INCLIVA, Ave Menendez & Pelayo 4, Valencia 46010, Spain.; García Giménez, JL (通讯作者)，Univ Valencia, Fac Med & Dent, Dept Physiol, Av Blasco Ibanez 15, Valencia 46010, Spain.
EM j.luis.garcia@uv.es
RI Lopez, Eva/AAC 4057 2021; Hervas, David/L 1322 2016; Mena Molla,
   Salvador/F 6696 2016; Pallardo, Federico/T 1156 2017; Hervas,
   David/HTS 1661 2023; Mena, Salvador/L 8780 2014; Cabellos,
   José/O 8078 2018; Ibanez Cabellos, Jose Santiago/O 8078 2018
OI Hervas, David/0000 0003 0635 4961; Pallardo,
   Federico/0000 0003 3715 1980; Mena, Salvador/0000 0002 6423 4741; Ibanez
   Cabellos, Jose Santiago/0000 0002 2462 653X; bas,
   teresa/0000 0003 0405 7883; Garcia Gimenez, Jose
   Luis/0000 0001 7547 7872
FU EuroSpine Society; Ministerio de Economia y Competitividad, Instituto de
   Salud Carlos III through CIBERer (Biomedical Network Research Center for
   Rare Diseases); Ministerio de Economia y Competitividad, Instituto de
   Salud Carlos III through CIBERer (INGENIO)
FX T. Bas and J.L. Garcia Gimenez would like to thank the EuroSpine Society
   for the grant received for the project "Epigenetics factors and
   adolescent idiopathic scoliosis". J.L. Garcia Gimenez and F.V. Pallardo
   are supported by the Ministerio de Economia y Competitividad, Instituto
   de Salud Carlos III through CIBERer (Biomedical Network Research Center
   for Rare Diseases and INGENIO2010), J.S Ibanez Cabellos is an "Atraccio
   de Talent" fellow (Univ. Valencia). The isolation of the cell free total
   RNA (including miRNAs) from the plasma samples was performed and
   optimised by the INCLIVA Biobank (PT13/0010/0004), integrated into the
   Valencia Region Biobanks Network and the Spanish National Biobanks
   Network. miRNA sequencing was performed by the PrimBio Research
   Institute LLC, Exton, PA, USA.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 10 r106
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Buchan JG, 2014, HUM MOL GENET, V23, P5271, DOI 10.1093/hmg/ddu224
   Burwell RG, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748 7161 6 26
   Cao YQ, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1139 z
   Cedric Julien K. F. G., 2013, PERS MED, V10, P97
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng JC, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.30
   Chowanska J, 2012, SCOLIOSIS SPINAL DIS, V7, DOI 10.1186/1748 7161 7 9
   Deurloo JA, 2015, PUBLIC HEALTH, V129, P1267, DOI 10.1016/j.puhe.2015.07.021
   DiLeone RJ, 1997, GENOMICS, V40, P196, DOI 10.1006/geno.1996.4533
   Ede MMPN, 2016, INT ORTHOP, V40, P2075, DOI 10.1007/s00264 016 3132 4
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   García Giménez JL, 2012, CLIN CHIM ACTA, V413, P1576, DOI 10.1016/j.cca.2012.05.021
   Garcia Gimenez J L., 2015, EPIGENETIC BIOMARKER, V1
   Gong YM, 2014, MOL CELL BIOCHEM, V387, P227, DOI 10.1007/s11010 013 1888 z
   Gorman KF, 2012, EUR SPINE J, V21, P1905, DOI 10.1007/s00586 012 2389 6
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hosmer DW Jr, 2013, WILEY SER PROBAB ST, P89
   Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266
   Ikegawa S, 2016, SCOLIOSIS SPINAL DIS, V11, DOI 10.1186/s13013 016 0067 x
   Itokowa T, 2011, CALCIFIED TISSUE INT, V88, P75, DOI 10.1007/s00223 010 9435 3
   Julien C, 2013, PERS MED, V10, P97, DOI [10.2217/PME.12.117, 10.2217/pme.12.117]
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Keller A, 2011, NAT METHODS, V8, P841, DOI [10.1038/NMETH.1682, 10.1038/nmeth.1682]
   Knott P, 2014, SCOLIOSIS SPINAL DIS, V9, DOI 10.1186/1748 7161 9 4
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Konieczny MR, 2013, J CHILD ORTHOP, V7, P3, DOI 10.1007/s11832 012 0457 4
   Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349 7006.2010.01650.x
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lin Q, 2009, FEBS J, V276, P2348, DOI 10.1111/j.1742 4658.2009.06967.x
   Liu B, 2014, BRIEF BIOINFORM, V15, P1, DOI 10.1093/bib/bbs075
   Liu XY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/276049
   Londono D, 2014, J MED GENET, V51, P401, DOI 10.1136/jmedgenet 2013 102067
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Millner P A, 1996, Eur Spine J, V5, P362, DOI 10.1007/BF00301963
   Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006
   Nair R, 2014, STEM CELLS DEV, V23, P1625, DOI 10.1089/scd.2013.0633
   Ochi K, 2003, J CELL PHYSIOL, V194, P45, DOI 10.1002/jcp.10185
   Oh CH, 2012, YONSEI MED J, V53, P1183, DOI 10.3349/ymj.2012.53.6.1183
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Peiró Chova L, 2013, VIRCHOWS ARCH, V463, P765, DOI 10.1007/s00428 013 1485 2
   Robinson MD, 2007, BIOINFORMATICS, V23, P2881, DOI 10.1093/bioinformatics/btm453
   Ronckers CM, 2010, RADIAT RES, V174, P83, DOI 10.1667/RR2022.1
   Ryzhkov II, 2013, SPINE, V38, pE699, DOI 10.1097/BRS.0b013e31828de9e1
   Sandoval J, 2013, EXPERT REV MOL DIAGN, V13, P457, DOI [10.1586/erm.13.37, 10.1586/ERM.13.37]
   Simony A, 2016, EUR SPINE J, V25, P3366, DOI 10.1007/s00586 016 4747 2
   Sugatani T, 2007, J CELL BIOCHEM, V101, P996, DOI 10.1002/jcb.21335
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Sun ZJ, 2016, SCI REP UK, V6, DOI 10.1038/srep22274
   TABAS JA, 1991, GENOMICS, V9, P283, DOI 10.1016/0888 7543(91)90254 C
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Wang GZ, 2014, TUMOR BIOL, V35, P8565, DOI 10.1007/s13277 014 2089 4
   Wang ST, 2012, ONCOL REP, V27, P1065, DOI 10.3892/or.2011.1575
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Yim APY, 2012, SPINE, V37, pE1148, DOI 10.1097/BRS.0b013e31825c036d
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhu ZZ, 2017, HUM MOL GENET, V26, P1577, DOI 10.1093/hmg/ddx045
   Zhu ZZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9355
   Zhu ZZ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305 5839.2015.02.04
NR 73
TC 31
Z9 34
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 8
PY 2018
VL 8
AR 2646
DI 10.1038/s41598 018 21146 x
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FV3DV
UT WOS:000424449100024
PM 29422531
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tibullo, D
   Longo, A
   Vicario, N
   Romano, A
   Barbato, A
   Di Rosa, M
   Barbagallo, I
   Anfuso, CD
   Lupo, G
   Gulino, R
   Parenti, R
   Li Volti, G
   Palumbo, GA
   Di Raimondo, F
   Giallongo, C
AF Tibullo, Daniele
   Longo, Anna
   Vicario, Nunzio
   Romano, Alessandra
   Barbato, Alessandro
   Di Rosa, Michelino
   Barbagallo, Ignazio
   Anfuso, Carmelina Daniela
   Lupo, Gabriella
   Gulino, Rosario
   Parenti, Rosalba
   Li Volti, Giovanni
   Palumbo, Giuseppe Alberto
   Di Raimondo, Francesco
   Giallongo, Cesarina
TI Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog
   Signaling Inhibition Mediated by Myeloma Cells
SO CANCERS
LA English
DT Article
DE multiple myeloma (MM); plasma cell (PC); ixazomib; bortezomib;
   mesenchymal stromal cell (MSC); sonic hedgehog (SHH); GLI1;
   osteoclastogenesis; osteoblastogenesis
ID OSTEOBLAST DIFFERENTIATION; BORTEZOMIB; MICROENVIRONMENT; THERAPY;
   DISEASE; PROTEIN
AB Multiple myeloma (MM) is a clonal B cell malignancy characterized by an accumulation of plasma cells (PC) in the bone marrow (BM), leading to bone loss and BM failure. Osteolytic bone disease is a common manifestation observed in MM patients and represents the most severe cause of morbidity, leading to progressive skeletal damage and disabilities. Pathogenetic mechanisms of MM bone disease are closely linked to PCs and osteoclast (OCs) hyperactivity, coupled with defective osteoblasts (OBs) function that is unable to counteract bone resorption. The aim of the present study was to investigate the effects of Ixazomib, a third generation proteasome inhibitor, on osteoclastogenesis and osteogenic differentiation. We found that Ixazomib was able to reduce differentiation of human monocytes into OCs and to inhibit the expression of OC markers when added to the OC medium. Concurrently, Ixazomib was able to stimulate osteogenic differentiation of human mesenchymal stromal cells (MSCs), increasing osteogenic markers, either alone or in combination with the osteogenic medium. Given the key role of Sonic Hedgehog (SHH) signaling in bone homeostasis, we further investigated Ixazomib induced SHH pathway activation. This set of experiments showed that Ixazomib, but not Bortezomib, was able to bind the Smoothened (SMO) receptor leading to nuclear translocation of GLI1 in human MSCs. Moreover, we demonstrated that PCs act as GLI1 suppressors on MSCs, thus reducing the potential of MSCs to differentiate in OBs. In conclusion, our data demonstrated that Ixazomib regulates bone remodeling by decreasing osteoclastogenesis and prompting osteoblast differentiation via the canonical SHH signaling pathway activation, thus, representing a promising therapeutic option to improve the complex pathological condition of MM patients.
C1 [Tibullo, Daniele; Longo, Anna; Anfuso, Carmelina Daniela; Lupo, Gabriella; Li Volti, Giovanni] Univ Catania, Dept Biomed & Biotechnol Sci, Sect Biochem, I 95123 Catania, Italy.
   [Vicario, Nunzio; Gulino, Rosario; Parenti, Rosalba] Univ Catania, Dept Biomed & Biotechnol Sci, Sect Physiol, I 95123 Catania, Italy.
   [Romano, Alessandra; Barbato, Alessandro; Di Raimondo, Francesco; Giallongo, Cesarina] Univ Catania, Dept Gen Surg & Med Surg Specialties, Div Hematol, AOU Policlin Vittorio Emanuele, I 95123 Catania, Italy.
   [Di Rosa, Michelino] Univ Catania, Dept Biomed & Biotechnol Sci, Sect Human Anat, I 95123 Catania, Italy.
   [Barbagallo, Ignazio] Univ Catania, Dept Drug Sci, Sect Biochem, I 95123 Catania, Italy.
   [Palumbo, Giuseppe Alberto] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Sect Haematol, I 95123 Catania, Italy.
C3 University of Catania; University of Catania; Azienda Ospedaliera
   Universitaria Policlinico Vittorio Emanuele Presidio Ferraotto;
   University of Catania; University of Catania; University of Catania;
   University of Catania
RP Romano, A (通讯作者)，Univ Catania, Dept Gen Surg & Med Surg Specialties, Div Hematol, AOU Policlin Vittorio Emanuele, I 95123 Catania, Italy.; Palumbo, GA (通讯作者)，Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Sect Haematol, I 95123 Catania, Italy.
EM d.tibullo@unict.it; longo.anna@hotmail.it; nunziovicario@unict.it;
   sandrina.romano@gmail.com; alessandrobarbato93@libero.it;
   mdirosa@unict.it; ignazio.barbagallo@unict.it; daniela.anfuso@unict.it;
   gabriella.lupo@unict.it; rosario.gulino@unict.it; parenti@unict.it;
   livolti@unict.it; palumbo.ga@gmail.com; diraimon@unict.it;
   cesarinagiallongo@yahoo.it
RI Tibullo, Daniele/J 3946 2016; Lupo, Gabriella/HMD 2098 2023; LONGO, ANNA
   MARIA/AHE 8233 2022; Di Rosa, Michelino/B 5807 2013; Giallongo,
   Cesarina/J 7225 2016; Anfuso, Carmelina Daniela/HPG 3712 2023; Vicario,
   Nunzio/AAY 3489 2021; Romano, Alessandra/I 9201 2012; ROMANO,
   ALESSANDRA/I 9201 2012; Parenti, Rosalba/AAS 5489 2020; Palumbo,
   Giuseppe/W 7072 2019; Volti, Giovanni/A 2435 2008
OI Barbagallo, Ignazio/0000 0002 7761 0662; Parenti,
   Rosalba/0000 0002 1614 4696; LUPO, Gabriella/0000 0002 9291 6969; Di
   Rosa, Michelino/0000 0002 1837 9325; Giallongo,
   Cesarina/0000 0002 7667 6088; Vicario, Nunzio/0000 0001 5934 3962;
   LONGO, ANNA MARIA/0000 0003 4696 6567; ROMANO,
   ALESSANDRA/0000 0002 6333 4433; Barbato, Alessandro/0000 0002 3174 6302;
   Gulino, Rosario/0000 0002 8067 697X; ANFUSO, Carmelina
   Daniela/0000 0001 7951 1812
FU Research Funding for University of Catania, Italy (Piano per la Ricerca
   2016 2018); Research Funding for University of Catania, Italy (FIR
   2018 2020); PON AIM RI 2014 2020 [E66C18001240007]; A.I.L. (Associazione
   Italiana contro le Leucemie) sezione di Catania; FON.CA.NE.SA.
   (Fondazione Catanese per lo Studio delle Malattie Neoplastiche del
   Sangue); Takeda
FX This work was supported by Research Funding for University of Catania,
   Italy (Piano per la Ricerca 2016 2018, FIR 2018 2020 F.D.R. and FIR
   2018 2020 G.L.V.). N.V. was supported by the PON AIM R&I 2014 2020  
   E66C18001240007. This study was supported in part by A.I.L.
   (Associazione Italiana contro le Leucemie) sezione di Catania,
   FON.CA.NE.SA. (Fondazione Catanese per lo Studio delle Malattie
   Neoplastiche del Sangue), and Takeda, which furnished the ixazomib
   powder by MTA #.
CR Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092 8674(00)80094 X
   Almqvist H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11040
   Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Briscoe J, 2006, NAT CHEM BIOL, V2, P10, DOI 10.1038/nchembio0106 10
   Cai K, 2019, LEUKEMIA LYMPHOMA, V60, P772, DOI 10.1080/10428194.2018.1493727
   Calabrese G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07672 0
   Calabrese G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151181
   Cannonier SA, 2015, CANCERS, V7, P1658, DOI 10.3390/cancers7030856
   Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092 8674(00)81374 4
   Choi DH, 2014, CELL TISSUE RES, V357, P781, DOI 10.1007/s00441 014 1898 5
   Di Rosa M, 2014, BONE, V61, P55, DOI 10.1016/j.bone.2014.01.005
   Fuchs S, 2012, VITAM HORM, V88, P491, DOI 10.1016/B978 0 12 394622 5.00022 5
   Garcia Gomez A, 2014, CLIN CANCER RES, V20, P1542, DOI 10.1158/1078 0432.CCR 13 1657
   Gulino R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061500
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Hojo H, 2015, REGEN THER, V1, P57, DOI 10.1016/j.reth.2014.10.002
   Hu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074191
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Iwasaki M, 2018, DEV BIOL, V437, P105, DOI 10.1016/j.ydbio.2018.03.005
   Konstantinova IM, 2008, INT REV CEL MOL BIO, V267, P59, DOI 10.1016/S1937 6448(08)00602 3
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood 2014 03 557298
   Lv WT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163981
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Martin DR, 2002, EXP HEMATOL, V30, P879, DOI 10.1016/S0301 472X(02)00864 0
   Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676
   Nakamura T, 2015, J CELL PHYSIOL, V230, P922, DOI 10.1002/jcp.24823
   Nishida H, 2018, HEMATOL REP, V10, P11, DOI 10.4081/hr.2018.7401
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Oliveira FS, 2012, J CELL BIOCHEM, V113, P204, DOI 10.1002/jcb.23345
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Paratore S, 2006, GENOMICS, V88, P468, DOI 10.1016/j.ygeno.2006.06.007
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Romano A, 2014, EUR J HAEMATOL, V93, P207, DOI 10.1111/ejh.12325
   Romano A, 2013, IMMUNOTHERAPY UK, V5, P327, DOI [10.2217/IMT.13.14, 10.2217/imt.13.14]
   Singh BN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027306
   Terpos E, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12761
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Tibullo D, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00226
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Vicario N, 2019, MOL NEUROBIOL, V56, P7338, DOI 10.1007/s12035 019 1607 1
   Vicario N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081991
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Yang YM, 2017, MOL BIOL CELL, V28, P1792, DOI 10.1091/mbc.E17 02 0096
   Yang YM, 2015, J BIOL CHEM, V290, P16918, DOI 10.1074/jbc.M115.663963
   Zanwar S, 2018, EXPERT REV HEMATOL, V11, P761, DOI 10.1080/17474086.2018.1518129
   Zavala G, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0653 8
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
NR 55
TC 24
Z9 26
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD FEB
PY 2020
VL 12
IS 2
AR 323
DI 10.3390/cancers12020323
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KY3ND
UT WOS:000522477300069
PM 32019102
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lausson, S
   Cressent, M
AF Lausson, Sylvie
   Cressent, Michele
TI Signal Transduction Pathways Mediating the Effect of Adrenomedullin on
   Osteoblast Survival
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ADRENOMEDULLIN; OSTEOBLAST; SIGNALING; BAD; CREB; SRC; GSK3 beta
ID GENE RELATED PEPTIDE; ACTIVATED PROTEIN KINASE; MAP KINASE;
   GROWTH FACTOR; CALCITONIN; PHOSPHORYLATION; RECEPTORS; AMYLIN; CELLS;
   APOPTOSIS
AB Adrenomedullin (ADM) plays an important role in the regulation of osteoblastic cells through both a proliferative and an anti apoptotic effects. The present study investigated mechanisms involved in the effect of ADM on survival. We report that ADM can act in osteoblasts both through a non transcriptional action, by phosphorylation of different kinases and components, and through a transcriptional effect by activation of CREB. So, we observed by Western blot analysis, modifications in the downstream targets of ERK, the pro apoptotic protein Bad, which is inactivated by increase in Ser155 phosphorylation, and the transcription factor CREB, which is activated by phosphorylation at Ser133. CREB activation was confirmed by a CRE dependent gene transcription assay and an immunocytochemical study. This increase in CREB phosphorylation could lead to its enhanced transcriptional activity, as indicated by the induced expression of the proliferation marker, PCNA. Moreover, ADM could also activate the tyrosine kinase Src and the PI3 Kinase, both of which are implicated in survival. The use of specific pharmacological inhibitors allowed to establish that ADM could activate a signaling cascade involving Src, MEK, ERK, p90RSK, and that the effect of ADM, in particular on the CREB protein, greatly depends on the regulatory control of interfering signaling pathways. Moreover, as Wnt signaling plays an important role in the control of osteoblast apoptosis, we explored a major component of this pathway, protein GSK3b. ADM induced inactivation of GSK3b by phosphorylation at Ser9, highly suggests that ADM could also exert its survival effect in osteoblast via components of the Wnt pathway. J. Cell. Biochem. 112: 3807 3815, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Cressent, Michele] Univ Paris Diderot, Hop Lariboisiere, INSERM, U606, F 75475 Paris 10, France.
   [Lausson, Sylvie] Univ Paris 06, CNRS, UMR 8619, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Centre National
   de la Recherche Scientifique (CNRS); Sorbonne Universite
RP Cressent, M (通讯作者)，Univ Paris Diderot, Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM michele.cressent@larib.inserm.fr
FU Rhumatismes et Travail Association; Inserm
FX The authors want to thank IBAIC (Universite 'Paris Sud, Orsay, France)
   for acquisition of immunofluorescence images. This work was supported by
   Inserm and by a grant from the Rhumatismes et Travail Association.
CR Anderson LE, 2004, J NEUROCHEM, V91, P1417, DOI 10.1111/j.1471 4159.2004.02833.x
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302
   Cornish J, 1997, AM J PHYSIOL ENDOC M, V273, pE1113, DOI 10.1152/ajpendo.1997.273.6.E1113
   Cornish J, 2004, BIOCHEM BIOPH RES CO, V318, P240, DOI 10.1016/j.bbrc.2004.04.020
   Cornish J, 2003, REGUL PEPTIDES, V112, P79, DOI 10.1016/S0167 0115(03)00025 9
   Cuttitta F, 2002, MICROSC RES TECHNIQ, V57, P110, DOI 10.1002/jemt.10059
   Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496
   Díaz Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007
   Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026
   Drissi H, 1997, J BONE MINER RES, V12, P1805, DOI 10.1359/jbmr.1997.12.11.1805
   Freeland K, 2000, BIOCHEM J, V345, P233, DOI 10.1042/0264 6021:3450233
   Frödin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303 7207(99)00061 1
   Gerits N, 2008, CELL SIGNAL, V20, P1592, DOI 10.1016/j.cellsig.2008.02.022
   Grey AB, 1999, J BONE MINER RES, V14, pS461
   Hamada H, 2002, PEPTIDES, V23, P2163, DOI 10.1016/S0196 9781(02)00259 0
   Hay DL, 2011, ENDOCR RELAT CANCER, V18, pC1, DOI 10.1677/ERC 10 0244
   Hay DL, 2001, PEPTIDES, V22, P1753, DOI 10.1016/S0196 9781(01)00532 0
   ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014 5793(94)80106 1
   Iwasaki H, 2001, ENDOCRINOLOGY, V142, P564, DOI 10.1210/en.142.2.564
   Kim W, 2003, FASEB J, V17, P1937, DOI 10.1096/fj.02 1209fje
   KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451
   Lai LP, 2009, CELL BIOCHEM FUNCT, V27, P269, DOI 10.1002/cbf.1568
   Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269
   Minamino N, 1998, ADRENOMEDULLIN, P79
   Mrak E, 2010, J CELL PHYSIOL, V225, P701, DOI 10.1002/jcp.22266
   MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017
   Naot D, 2001, ENDOCRINOLOGY, V142, P1849, DOI 10.1210/en.142.5.1849
   Ouafik L, 2009, CELL SIGNAL, V21, P597, DOI 10.1016/j.cellsig.2009.01.001
   PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248
   Pluder F, 2007, CHEM BIOL DRUG DES, V69, P14, DOI 10.1111/j.1747 0285.2007.00466.x
   Schaeffer C, 2003, BBA MOL CELL RES, V1643, P65, DOI 10.1016/j.bbamcr.2003.09.005
   Seybold VS, 2003, J NEUROSCI, V23, P1816
   Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353
   Shichiri M, 2003, HYPERTENS RES, V26, pS9, DOI 10.1291/hypres.26.S9
   Shichiri M, 2003, REGUL PEPTIDES, V112, P167, DOI 10.1016/S0167 0115(03)00036 3
   Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960 9822(00)00310 9
   TAKAHASHI T, 1993, J NEUROCYTOL, V22, P1096, DOI 10.1007/BF01235751
   Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Uzan B, 2004, BIOCHEM BIOPH RES CO, V321, P802, DOI 10.1016/j.bbrc.2004.07.037
   Uzan B, 2008, J CELL PHYSIOL, V215, P122, DOI 10.1002/jcp.21294
   Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756 3282(96)00017 8
   Xia CF, 2004, HUM GENE THER, V15, P1243, DOI 10.1089/hum.2004.15.1243
   Zambuzzi WF, 2010, BIOCHIMIE, V92, P327, DOI 10.1016/j.biochi.2010.01.002
NR 50
TC 18
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2011
VL 112
IS 12
BP 3807
EP 3815
DI 10.1002/jcb.23311
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 851YV
UT WOS:000297309600035
PM 21826707
DA 2025 08 17
ER

PT J
AU Kamalakar, A
   McKinney, JM
   Duron, DS
   Amanso, AM
   Ballestas, SA
   Drissi, H
   Willett, NJ
   Bhattaram, P
   García, AJ
   Wood, LB
   Goudy, SL
AF Kamalakar, Archana
   McKinney, Jay M.
   Duron, Daniel Salinas
   Amanso, Angelica M.
   Ballestas, Samir A.
   Drissi, Hicham
   Willett, Nick J.
   Bhattaram, Pallavi
   Garcia, Andres J.
   Wood, Levi B.
   Goudy, Steven L.
TI JAGGED1 stimulates cranial neural crest cell osteoblast commitment
   pathways and bone regeneration independent of canonical NOTCH signaling
SO BONE
LA English
DT Article
DE JAGGED1; Intramembranous ossification; Bone regeneration; RNAseq;
   Non canonical JAG1 NOTCH pathways
ID MESENCHYMAL STEM CELLS; ALAGILLE SYNDROME; PEG HYDROGEL;
   DIFFERENTIATION; PROLIFERATION; ANGIOGENESIS; EXPANSION; STAT5;
   INHIBITION; EXPRESSION
AB Craniofacial bone loss is a complex clinical problem with limited regenerative solutions. Currently, BMP2 is used as a bone regenerative therapy in adults, but in pediatric cases of bone loss, it is not FDA approved due to concerns of life threatening inflammation and cancer. Development of a bone regenerative therapy for children will transform our ability to reduce the morbidity associated with current autologous bone grafting techniques. We discovered that JAGGED1 (JAG1) induces cranial neural crest (CNC) cell osteoblast commitment during craniofacial intramembranous ossification, suggesting that exogenous JAG1 delivery is a potential craniofacial bone regenerative approach. In this study, we found that JAG1 delivery using synthetic hydrogels containing O9 1 cells, a CNC cell line, into critical sized calvarial defects in C57BL/6 mice provided robust bone  regeneration. Since JAG1 signals through canonical (Hes1/Hey1) and non canonical (JAK2) NOTCH pathways in CNC cells, we used RNAseq to analyze transcriptional pathways activated in CNC cells treated with JAG1 +/  DAPT, a NOTCH canonical pathway inhibitor. JAG1 upregulated expression of multiple NOTCH canonical pathway genes (Hes1), which were downregulated in the presence of DAPT. JAG1 also induced bone chemokines (Cxcl1), regulators of cytoskeletal organization and cell migration (Rhou), signaling targets (STAT5), promoters of early osteoblast cell proliferation (Prl2c2, Smurf1 and Esrra), and, inhibitors of osteoclasts (Id1). In the presence of DAPT, expression levels of Hes1 and Cxcl1 were decreased, whereas, Prl2c2, Smurf1, Esrra, Rhou and Id1 remain elevated, suggesting that JAG1 induces osteoblast proliferation through these non canonical genes. Pathway analysis of JAG1 + DAPT treated CNC cells revealed significant upregulation of multiple non canonical pathways, including the cell cycle, tubulin pathway, regulators of Runx2 initiation and phosphorylation of STAT5 pathway. In total, our data show that JAG1 upregulates multiple pathways involved in osteogenesis, independent of the NOTCH canonical pathway. Moreover, our findings suggest that JAG1 delivery using a synthetic hydrogel, is a bone regenerative approach with powerful translational potential.
C1 [Kamalakar, Archana; Amanso, Angelica M.; Ballestas, Samir A.; Goudy, Steven L.] Dept Otolaryngol, Atlanta, GA USA.
   [Drissi, Hicham; Bhattaram, Pallavi; Wood, Levi B.] Dept Cell Biol, Atlanta, GA USA.
   [Drissi, Hicham; Willett, Nick J.; Bhattaram, Pallavi] Emory Univ, Dept Orthopaed, Atlanta, GA 30322 USA.
   [Goudy, Steven L.] Childrens Healthcare Atlanta, Dept Pediat Otolaryngol, Atlanta, GA USA.
   [Duron, Daniel Salinas] Westminster Coll, Dept Comp Sci, Salt Lake City, UT USA.
   [McKinney, Jay M.] Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA.
   [Garcia, Andres J.] Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA.
   [Garcia, Andres J.] Georgia Tech Coll Engn, George W Woodruff Sch Mech Engn, Atlanta, GA USA.
   [Drissi, Hicham; Willett, Nick J.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
   [Duron, Daniel Salinas; Amanso, Angelica M.; Ballestas, Samir A.; Goudy, Steven L.] 2015 Uppergate Dr, Atlanta, GA 30322 USA.
   [McKinney, Jay M.; Willett, Nick J.] 1670 Clairmont Rd,Room 5A115, Decatur, GA 30033 USA.
   [Drissi, Hicham] 459 Execut Pk South,Suite 2000, Atlanta, GA 30329 USA.
   [Bhattaram, Pallavi] Whitehead Res Bldg,Rm 405K,615 Michael St, Atlanta, GA 30322 USA.
   [Garcia, Andres J.] 6315 Ferst Dr NW,Rm 1106, Atlanta, GA 30332 USA.
   [Wood, Levi B.] 315 Ferst Dr NW,Rm 3303, Atlanta, GA 30332 USA.
C3 Emory University; Children's Healthcare of Atlanta (CHOA); US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA
   Health Care System
RP Kamalakar, A (通讯作者)，2015 Uppergate Dr, Atlanta, GA 30322 USA.
EM archana.kamalakar@emory.edu; jay.m.mckinney@emory.edu;
   dsalinasduron@westminstercollege.edu; aamanso@emory.edu;
   samir.ballestas.naissir@emory.edu; hicham.drissi@emory.edu;
   nick.james.willett@emory.edu; Pallavi.bhattaram@emory.edu;
   andres.garcia@me.gatech.edu; levi.wood@me.gatech.edu;
   steven.goudy@emory.edu
RI Willett, Nick/A 7857 2009; Amanso, Angelica/IFG 9357 2023
OI drissi, hicham/0000 0002 3322 281X
FU Oral Maxillofacial Surgery Foundation [2591]; Osteo Science foundation
   [0000046481]; National institute of Health, National Institute of
   Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health [DE026762, R01AR062920, R01AR062368]
FX Study design: AK, JMM, NJW, HD, AJG, LBW and SLG. Study conduct: AK.
   Data collection: AK, JMM, AMA, SAB and PB. Data analysis: AK, JMM, DSD,
   AMA, SAB, PB and LBW. Data interpretation: All authors. Drafting
   manuscript: AK, JMM, LBW and SLG. Revising manuscript content: All
   authors. Approving final version of manuscript: All authors. AK, LBW and
   SLG take responsibility for the integrity of the data analysis. Research
   reported in this publication was supported by the Oral Maxillofacial
   Surgery Foundation (Funding ID: 2591), Osteo Science foundation (Award
   ID: 0000046481) and National institute of Health, National Institute of
   Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health under Award Numbers DE026762, R01AR062920 and
   R01AR062368, respectively. This manuscript has not been copyrighted or
   published before and is not under consideration for publication
   elsewhere. We also assure you that the contents of this manuscript will
   not be subsequently published in the same or similar form in any
   language without your consent. Lastly, the authors declare no conflict
   of interest.
CR [Anonymous], 2013, JAK STAT
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112
   Cao JJ, 2017, INT J MOL MED, V40, P378, DOI 10.3892/ijmm.2017.3037
   Caspermeyer J, 2016, MOL BIOL EVOL, V33, P2765, DOI 10.1093/molbev/msw146
   Che L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.73
   Choong ML, 2003, FEBS LETT, V550, P155, DOI 10.1016/S0014 5793(03)00844 5
   Chung IM, 2008, BIOMATERIALS, V29, P2637, DOI 10.1016/j.biomaterials.2008.03.008
   Clark AY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14000 9
   Correia AC, 2007, DEV DYNAM, V236, P2493, DOI 10.1002/dvdy.21256
   Cruz Acuña R, 2019, NAT PROTOC, V14, P2258, DOI 10.1038/s41596 018 0079 5
   Dieudonne FX, 2013, STEM CELLS, V31, P1340, DOI 10.1002/stem.1380
   Dishowitz MI, 2014, J BIOMED MATER RES A, V102, P1558, DOI 10.1002/jbm.a.34825
   Ferguson J, 2018, G3 GENES GENOM GENET, V8, P491, DOI 10.1534/g3.117.300311
   García AJ, 2014, ANN BIOMED ENG, V42, P312, DOI 10.1007/s10439 013 0870 y
   García JR, 2019, BIOMATERIALS, V220, DOI 10.1016/j.biomaterials.2019.119403
   Gilbert MA, 2017, CURR PATHOBIOL REP, V5, P233, DOI 10.1007/s40139 017 0144 8
   Grover Vishakha, 2011, Indian J Dent Res, V22, P496, DOI 10.4103/0970 9290.87084
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Hans CP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44266 4
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Hong D, 2011, OSTEOPOROSIS INT, V22, P2175, DOI 10.1007/s00198 010 1434 8
   Hori K, 2013, J CELL SCI, V126, P2135, DOI 10.1242/jcs.127308
   Hu LN, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.117.005886
   Humphreys R, 2012, HUM MOL GENET, V21, P1374, DOI 10.1093/hmg/ddr575
   Ishii M, 2012, STEM CELLS DEV, V21, P3069, DOI 10.1089/scd.2012.0155
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Jesina D, 2017, NEONATAL NETW, V36, P343, DOI 10.1891/0730 0832.36.6.343
   Kamalakar A, 2019, CELL SIGNAL, V54, P130, DOI 10.1016/j.cellsig.2018.12.002
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kerr BA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10960
   Kiec Wilk B, 2010, J PHYSIOL PHARMACOL, V61, P217
   Krantz Ian D., 1999, Current Opinion in Pediatrics, V11, P558, DOI 10.1097/00008480 199912000 00015
   Kung AWC, 2010, AM J HUM GENET, V86, P229, DOI 10.1016/j.ajhg.2009.12.014
   Lee J, 2016, SCI REP UK, V6, DOI 10.1038/srep30977
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Liu HB, 2011, J BONE MINER RES, V26, P2052, DOI 10.1002/jbmr.419
   Manokawinchoke J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10638 x
   Mishina Y, 2014, EXP CELL RES, V325, P138, DOI 10.1016/j.yexcr.2014.01.019
   Mitchell E, 2018, CLIN LIVER DIS, V22, P625, DOI 10.1016/j.cld.2018.06.001
   Naik NG, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008268
   Navarro Requena C, 2018, ACTA BIOMATER, V67, P53, DOI 10.1016/j.actbio.2017.12.009
   Ndong JD, 2018, J BIOMED MATER RES A, V106, P552, DOI 10.1002/jbm.a.36236
   Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200
   Nunes SC, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0053 z
   Onan D, 2009, ENDOCRINOLOGY, V150, P2244, DOI 10.1210/en.2008 1597
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574
   Pratap J, 2003, CANCER RES, V63, P5357
   Rajalin AM, 2010, BIOCHEM BIOPH RES CO, V396, P477, DOI 10.1016/j.bbrc.2010.04.120
   Regan J, 2013, CURR OSTEOPOROS REP, V11, P126, DOI 10.1007/s11914 013 0145 4
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Roforth MM, 2015, BONE, V76, P49, DOI 10.1016/j.bone.2015.03.017
   Shen T, 2012, ANTI CANCER AGENT ME, V12, P631, DOI 10.2174/187152012800617678
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961
   Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teng CS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02574 7
   Tormo AJ, 2012, CYTOKINE, V60, P575, DOI 10.1016/j.cyto.2012.07.002
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Turnpenny PD, 2012, EUR J HUM GENET, V20, P251, DOI 10.1038/ejhg.2011.181
   Urs S, 2012, ADIPOCYTE, V1, P46, DOI 10.4161/adip.19186
   Vimalraj S, 2015, INT J BIOL MACROMOL, V79, P490, DOI 10.1016/j.ijbiomac.2015.05.017
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Wood AD, 2009, BLOOD, V114, P1820, DOI 10.1182/blood 2009 02 206573
   Wu TF, 2017, INT J DEV BIOL, V61, P495, DOI 10.1387/ijdb.170051gc
   Xia MC, 2018, J ALLERGY CLIN IMMUN, V142, P1243, DOI 10.1016/j.jaci.2018.03.009
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yang XH, 2012, J BIOL CHEM, V287, P6490, DOI 10.1074/jbc.M111.254631
   Youngstrom DW, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536 017 0037 9
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zanotti S, 2012, CALCIFIED TISSUE INT, V90, P69, DOI 10.1007/s00223 011 9541 x
   Zouani OF, 2013, BIOL OPEN, V2, P872, DOI 10.1242/bio.20134986
NR 74
TC 15
Z9 16
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2021
VL 143
AR 115657
DI 10.1016/j.bone.2020.115657
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PN8PL
UT WOS:000604734500015
PM 32980561
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, C
   Sun, WJ
   Ling, SK
   Wang, Y
   Wang, X
   Meng, HY
   Li, YH
   Yuan, XL
   Li, JW
   Liu, RX
   Zhao, DS
   Lu, Q
   Wang, AY
   Guo, QY
   Lu, SB
   Tian, H
   Li, YX
   Peng, J
AF Wang, Cheng
   Sun, Weijia
   Ling, Shukuan
   Wang, Yu
   Wang, Xin
   Meng, Haoye
   Li, Yuheng
   Yuan, Xueling
   Li, Jianwei
   Liu, Ruoxi
   Zhao, Dingsheng
   Lu, Qiang
   Wang, Aiyuan
   Guo, Quanyi
   Lu, Shibi
   Tian, Hua
   Li, Yingxian
   Peng, Jiang
TI AAV Anti miR 214 Prevents Collapse of the Femoral Head in Osteonecrosis
   by Regulating Osteoblast and Osteoclast Activities
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; GENE DELIVERY; EXPRESSION; MICRORNAS;
   DIFFERENTIATION; THERAPY; MODEL; AXIS
AB Osteonecrosis of the femoral head, an intractable but common disease that eventually triggers collapse of the femoral head, is characterized by increased osteoclast activity and markedly decreased osteoblast activity in the necrotic region of the femoral head. MicroRNA (miRNA) 214 (miR 214) may play important roles in vertebrate skeletal development by inhibiting osteoblast function by targeting activating transcription factor 4 (ATF4) and promoting osteoclast function via phosphatase and tensin homolog (PTEN). This study revealed significantly increased levels of miR 214 in necrotic regions, with commensurate changes in the numbers of its target cells (both osteoblasts and osteoclasts). To investigate whether targeting miR 214 could prevent femoral head collapse, we constructed an adeno associated virus (AAV) associated anti miR 214 (AAV anti miR 214) and evaluated its function in vivo. AAV anti miR 214 promoted osteoblast activity and diminished osteoclast activity, effectively preventing collapse of the femoral head in a rat model of osteonecrosis.
C1 [Wang, Cheng; Wang, Yu; Wang, Xin; Meng, Haoye; Yuan, Xueling; Liu, Ruoxi; Lu, Qiang; Wang, Aiyuan; Guo, Quanyi; Lu, Shibi; Peng, Jiang] Chinese Peoples Liberat Army Gen Hosp, Inst Orthoped, Peking Key Lab Regenerat Med Orthopaed, Key Lab Chinese PLA, 28 Fuxing Rd, Beijing 100853, Peoples R China.
   [Sun, Weijia; Ling, Shukuan; Li, Yuheng; Li, Jianwei; Zhao, Dingsheng; Li, Yingxian] China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, 26 Beiqing Rd, Beijing 100094, Peoples R China.
   [Wang, Cheng; Tian, Hua] Peking Univ, Dept Orthoped, Hosp 3, 49 Huayuan North Rd, Beijing 100191, Peoples R China.
   [Li, Yuheng] Fourth Mil Med Univ, Key Lab Aerosp Med, Minist Educ, Xian, Shanxi, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Peking University;
   Air Force Medical University
RP Peng, J (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Orthoped, Peking Key Lab Regenerat Med Orthopaed, Key Lab Chinese PLA, 28 Fuxing Rd, Beijing 100853, Peoples R China.; Li, YX (通讯作者)，China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, 26 Beiqing Rd, Beijing 100094, Peoples R China.; Tian, H (通讯作者)，Peking Univ, Dept Orthoped, Hosp 3, 49 Huayuan North Rd, Beijing 100191, Peoples R China.
EM tianhua@bjmu.edu.cn; yingxianli@aliyun.com; pengjiang301@126.com
RI Li, Jianwei/G 5299 2012; li, yuheng/LPQ 3255 2024; guo,
   quanyi/JRY 6402 2023; wang, cheng/AAR 5107 2021; Yuan,
   Xueling/Y 6086 2019; meng, hao/JHT 3327 2023; wang, yu/IZE 9175 2023;
   Wang, Yu/IZE 9175 2023; WANG, Xinxin/MVW 1205 2025
OI wang, yu/0000 0001 7811 5834; Ling, Shukuan/0000 0002 4622 4160; 
FU National Natural Science Foundation of China [81572148, 81972047,
   81603008, 31630038, 91740114, 31800994, 31700741]; State Key Lab of
   Space Medicine Fundamentals and Application Grant [SMFA15B03]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (81572148, 81972047, 81603008, 31630038,
   91740114, 31800994, and 31700741) to J.P., Yingxian Li, W.S., and Yuheng
   Li, and State Key Lab of Space Medicine Fundamentals and Application
   Grant (SMFA15B03) to Yuheng Li.
CR Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Alves EM, 2009, CLIN RHEUMATOL, V28, P1247, DOI 10.1007/s10067 009 1231 y
   Amanatullah Derek F, 2011, Am J Orthop (Belle Mead NJ), V40, pE216
   Amanatullah Derek F, 2011, Am J Orthop (Belle Mead NJ), V40, pE186
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Aschauer DF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076310
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140 6736(16)30371 3
   Bevan AK, 2011, MOL THER, V19, P1971, DOI 10.1038/mt.2011.157
   Browne G, 2014, TRENDS ENDOCRIN MET, V25, P320, DOI 10.1016/j.tem.2014.03.014
   Chitwood DH, 2010, NATURE, V467, P415, DOI 10.1038/nature09351
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Fan M, 2011, J INT MED RES, V39, P187, DOI 10.1177/147323001103900120
   Furnari F, 2010, NATURE, V465, P1016, DOI 10.1038/4651016a
   Gao B, 2013, BONE RES, V1, DOI 10.4248/BR201302006
   Hao C, 2016, SCI REP UK, V6, DOI 10.1038/srep22599
   Hsieh TH, 2018, NEURO ONCOLOGY, V20, P519, DOI 10.1093/neuonc/nox186
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang PS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14864 1
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Jan MI, 2017, ARCH BIOCHEM BIOPHYS, V633, P50, DOI 10.1016/j.abb.2017.09.001
   Kemaladewi DU, 2017, NAT MED, V23, P984, DOI 10.1038/nm.4367
   Kosik KS, 2010, CELL, V143, P21, DOI 10.1016/j.cell.2010.09.008
   Kuang W, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.37
   Li Z, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12405
   Marx J, 2004, SCIENCE, V305, P1420, DOI 10.1126/science.305.5689.1420
   Pakos EE, 2015, WORLD J ORTHOP, V6, P829, DOI 10.5312/wjo.v6.i10.829
   Peng WX, 2017, EXP BIOL MED, V242, P1234, DOI 10.1177/1535370217703975
   Persson H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01176 1
   Prasad KMR, 2011, GENE THER, V18, P43, DOI 10.1038/gt.2010.105
   Ruozi G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8388
   Sakamoto Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14778 y
   Shen X, 2007, MOL THER, V15, P1955, DOI 10.1038/sj.mt.6300293
   Uzun G, 2016, UNDERSEA HYPERBAR M, V43, P189
   Villa Jordan C, 2016, HSS J, V12, P261
   Wang BQ, 2015, MOL MED REP, V12, P7447, DOI 10.3892/mmr.2015.4386
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xu CY, 2017, BIOMED PHARMACOTHER, V95, P1504, DOI 10.1016/j.biopha.2017.08.097
   Xue MZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14917
   Yamasaki K, 2012, J ORTHOP RES, V30, P1263, DOI 10.1002/jor.22079
   Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhao JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159805
NR 44
TC 25
Z9 29
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD DEC 6
PY 2019
VL 18
BP 841
EP 850
DI 10.1016/j.omtn.2019.09.030
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JT0UX
UT WOS:000500716400073
PM 31739209
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fuenzalida, M
   Espinoza, C
   Perez, MA
   Tapia Rojas, C
   Cuitino, L
   Brandan, E
   Inestrosa, NC
AF Fuenzalida, Marco
   Espinoza, Claudia
   Angel Perez, Miguel
   Tapia Rojas, Cheril
   Cuitino, Loreto
   Brandan, Enrique
   Inestrosa, Nibaldo C.
TI Wnt signaling pathway improves central inhibitory synaptic
   transmission in a mouse model of Duchenne muscular dystrophy
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Dystrophin; mdx mice; Wnt signaling; GABA synapses
ID GABA(A) RECEPTOR TRAFFICKING; COGNITIVE IMPAIRMENT; GABAERGIC SYNAPSES;
   SKELETAL MUSCLE; PURKINJE CELLS; CA1; PLASTICITY; MICE; ANDROGRAPHOLIDE;
   BRAIN
AB The dystrophin associated glycoprotein complex (DGC) that connects the cytoskeleton, plasma membrane and the extracellular matrix has been related to the maintenance and stabilization of channels and synaptic receptors, which are both essential for synaptogenesis and synaptic transmission. The dystrophin deficient (mdx) mouse model of Duchenne muscular dystrophy (DMD) exhibits a significant reduction in hippocampal GABA efficacy, which may underlie the altered synaptic function and abnormal hippocampal long term plasticity exhibited by mdx mice. Emerging studies have implicated Wnt signaling in the modulation of synaptic efficacy, neuronal plasticity and cognitive function. We report here that the activation of the non canonical Wnt 5a pathway and Andrographolide, improves hippocampal mdx GABAergic efficacy by increasing the number of inhibitory synapses and GABA(A) receptors or GABA release. These results indicate that Wnt signaling modulates GABA synaptic efficacy and could be a promising novel target for DMD cognitive therapy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Fuenzalida, Marco; Espinoza, Claudia; Angel Perez, Miguel] Univ Valparaiso, Fac Ciencias, Ctr Neurobiol & Plasticidad Cerebral, Inst Fisiol, Valparaiso, Chile.
   [Tapia Rojas, Cheril; Cuitino, Loreto; Brandan, Enrique; Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Envejecimiento Regenerat CARE, Santiago, Chile.
   [Inestrosa, Nibaldo C.] Univ New S Wales, Sch Psychiat, Ctr Hlth Brain Ageing, Fac Med, Sydney, NSW, Australia.
   [Inestrosa, Nibaldo C.] Univ Magallanes, Ctr Excelencia Biomed Magallanes CEBIMA, Punta Arenas, Chile.
C3 Universidad de Valparaiso; Pontificia Universidad Catolica de Chile;
   University of New South Wales Sydney; Universidad de Magallanes
RP Fuenzalida, M (通讯作者)，Univ Valparaiso, Fac Ciencias, Ctr Neurobiol & Plasticidad Cerebral, Inst Fisiol, Valparaiso, Chile.
EM marco.fuenzalida@uv.cl; ninestrosa@bio.puc.cl
RI Fuenzalida, Marco/HHT 0454 2022; Brandan, Enrique/A 7063 2017; Cuitino,
   Loreto/MBG 5746 2025
OI Fuenzalida, Marco/0000 0003 1785 6748; Espinoza,
   Claudia/0000 0003 4710 2082; Brandan, Enrique/0000 0002 6820 5059;
   Cuitino, Loreto/0000 0003 2330 9732; Tapia Rojas,
   Cheril/0000 0002 7084 0318
FU FONDECYT [1130614, 1120156, 1110426]; Millennium Nucleus [NU MIND
   NC 130011, DIPUV CID 01/2006]; CONICYT;  [CONICYT PFB12/2007]
FX This work was supported by grants from FONDECYT 1130614; Millennium
   Nucleus NU MIND NC 130011 and DIPUV CID 01/2006 (M.F.);
   CONICYT PFB12/2007 (N.C.I and E.B); FONDECYT 1120156 to N.C.I; FONDECYT
   1110426 to E.B. and predoctoral fellowships from CONICYT (C.T. R).
CR Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053
   Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028
   Anderson JL, 2002, BRAIN, V125, P4, DOI 10.1093/brain/awf012
   Ben Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006
   BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725
   Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166 2236(99)01510 6
   BRESOLIN N, 1994, NEUROMUSCULAR DISORD, V4, P359, DOI 10.1016/0960 8966(94)90072 8
   Cabrera D, 2014, SKELET MUSCLE, V4, DOI 10.1186/2044 5040 4 6
   Carvajal FJ, 2013, J ALZHEIMERS DIS, V36, P99, DOI 10.3233/JAD 130230
   Cerpa W, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750 1326 5 3
   Chan SJ, 2010, BRIT J PHARMACOL, V161, P668, DOI 10.1111/j.1476 5381.2010.00906.x
   Choquet D, 2013, NEURON, V80, P691, DOI 10.1016/j.neuron.2013.10.013
   Comim CM, 2011, NEUROMUSCULAR DISORD, V21, P359, DOI 10.1016/j.nmd.2011.02.017
   Craig AM, 2007, CURR OPIN NEUROBIOL, V17, P43, DOI 10.1016/j.conb.2007.01.011
   Cuitino L, 2010, J NEUROSCI, V30, P8411, DOI 10.1523/JNEUROSCI.5736 09.2010
   Dallérac G, 2011, NEUROBIOL DIS, V43, P635, DOI 10.1016/j.nbd.2011.05.012
   Das S, 2009, APPL PHYSIOL NUTR ME, V34, P124, DOI 10.1139/H08 147
   Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798
   Farías GG, 2007, J NEUROSCI, V27, P5313, DOI 10.1523/JNEUROSCI.3934 06.2007
   Farías GG, 2009, J BIOL CHEM, V284, P15857, DOI 10.1074/jbc.M808986200
   Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163 7258(03)00037 8
   Fuenzalida M, 2007, J NEUROSCI, V27, P11940, DOI 10.1523/JNEUROSCI.0900 07.2007
   Gonzalez Burgos G, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/723184
   Grady RM, 2006, J NEUROSCI, V26, P2841, DOI 10.1523/JNEUROSCI.4823 05.2006
   Groc L, 2003, EUR J NEUROSCI, V17, P1873, DOI 10.1046/j.1460 9568.2003.02635.x
   Haenggi T, 2006, CELL MOL LIFE SCI, V63, P1614, DOI 10.1007/s00018 005 5461 0
   Hashimoto T, 2009, BIOL PSYCHIAT, V65, P1015, DOI 10.1016/j.biopsych.2009.01.004
   Hsia AY, 1998, J NEUROPHYSIOL, V79, P2013, DOI 10.1152/jn.1998.79.4.2013
   Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481 012 9417 5
   Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755
   Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370
   Knuesel I, 1999, EUR J NEUROSCI, V11, P4457, DOI 10.1046/j.1460 9568.1999.00887.x
   Kueh SLL, 2008, CLIN EXP PHARMACOL P, V35, P207, DOI 10.1111/j.1440 1681.2007.04816.x
   Kueh SLL, 2011, NEUROBIOL DIS, V43, P558, DOI 10.1016/j.nbd.2011.05.002
   Lévi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22 11 04274.2002
   Lüscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003
   MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483
   Miranda R, 2009, CEREB CORTEX, V19, P876, DOI 10.1093/cercor/bhn135
   Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960 8966(91)90059 2
   Nusser Z, 1998, J NEUROSCI, V18, P1693
   Oliva CA, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00224
   Oliva CA, 2013, AGEING RES REV, V12, P786, DOI 10.1016/j.arr.2013.03.006
   Panzanelli P, 2011, J PHYSIOL LONDON, V589, P4959, DOI 10.1113/jphysiol.2011.216028
   Perronnet C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/849426
   Rodino Klapac LR, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910 012 0332 1
   Rosso SB, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00103
   Säfholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200
   Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649
   Serrano FG, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750 1326 9 61
   Südhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456
   Vaillend C, 2002, HIPPOCAMPUS, V12, P713, DOI 10.1002/hipo.10068
   Vaillend C, 2004, NEUROBIOL DIS, V17, P10, DOI 10.1016/j.nbd.2004.05.004
   Vaillend C, 1999, SYNAPSE, V33, P59, DOI 10.1002/(SICI)1098 2396(199907)33:1<59::AID SYN6>3.0.CO;2 K
   VAILLEND C, 1995, BEHAV GENET, V25, P569, DOI 10.1007/BF02327580
   Varela Nallar L, 2010, P NATL ACAD SCI USA, V107, P21164, DOI 10.1073/pnas.1010011107
   Vargas JY, 2014, J NEUROSCI, V34, P2191, DOI 10.1523/JNEUROSCI.0862 13.2014
   Waite A, 2009, ANN MED, V41, P344, DOI 10.1080/07853890802668522
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Zheng G, 2007, BRAIN RES, V1181, P61, DOI 10.1016/j.brainres.2007.08.077
NR 59
TC 14
Z9 16
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0969 9961
EI 1095 953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD FEB
PY 2016
VL 86
BP 109
EP 120
DI 10.1016/j.nbd.2015.11.018
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA DB2FQ
UT WOS:000368324100010
PM 26626079
DA 2025 08 17
ER

PT B
AU Boyce, BF
   Xing, LP
   Yao, ZQ
   Shakespeare, WC
   Wang, YH
   Metcalf, CA
   Sundaramoorthi, R
   Dalgarno, DC
   Iuliucci, JD
   Sawyer, TK
AF Boyce, Brendan F.
   Xing, Lianping
   Yao, Zhenqiang
   Shakespeare, William C.
   Wang, Yihan
   Metcalf, Chester A., III
   Sundaramoorthi, Raji
   Dalgarno, David C.
   Iuliucci, John D.
   Sawyer, Tomi K.
BE Zaidi, M
TI Future anti catabolic therapeutic targets in bone disease
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences Series
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE bone resorption; osteoclasts; cathepsin K; vacuolar ATPase; mTOR; Src
ID SRC TYROSINE KINASE; VACUOLAR PROTON PUMP; RESORPTION IN VITRO;
   CATHEPSIN K; C SRC; OSTEOCLAST DIFFERENTIATION; IMMUNOSUPPRESSANT
   RAPAMYCIN; INHIBITOR; OSTEOPETROSIS; MICE
AB Understanding of the regulation of bone catabolism has advanced significantly over the past two decades with the identification of key enzymes that regulate osteoclast formation, activation, and survival following their knockout in mice or recognition of mutations in humans. This led to the discovery of specific inhibitors of some of these key enzymes as proof of concept lead compounds or potential clinical candidates for the prevention of osteoporosis and other diseases associated with increased bone resorption. Bisphosphonates have been the major therapeutic agents prescribed for the prevention of bone loss in a variety of pathologic conditions for over 30 years. More potent amino bisphosphonates have increased efficacy than earlier drugs, but side effects such as upper gastrointestinal symptoms and the requirement to take them at least 2 h before food have limited patient compliance. This, coupled with the growing knowledge of the pathways regulating osteoclast function, has driven efforts to identify small molecular lead compounds that could be developed into new therapeutic agents with efficacy that matches or supersedes that of bisphosphonates for the prevention of bone loss. In this article, we review briefly the effects of specific inhibitors of bone resorption that have been developed to date and highlight in a variety of models of increased bone resorption the effects of Src kinase inhibitors that have been targeted to bone to limit potential unwanted side effects on other cells.
C1 Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
C3 University of Rochester; Takeda Pharmaceutical Company Ltd; Takeda
   Oncology
RP Boyce, BF (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM brendan_boyce@urmc.rochester.edu
RI wang, yihan/HTN 8802 2023
OI Yao, Zhenqiang/0000 0002 4664 3648
CR Atley LM, 2000, BONE, V26, P241, DOI 10.1016/S8756 3282(99)00270 7
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018 9027.2000
   Boschelli Diane H., 2002, Current Topics in Medicinal Chemistry, V2, P1051, DOI 10.2174/1568026023393354
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   Boyce BF, 2002, J BONE MINER RES, V17, pS159
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   BOYCE BF, 1995, ENDOCRINOLOGY, V136, P5751, DOI 10.1210/en.136.12.5751
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CHATTERJEE D, 1992, J EXP BIOL, V172, P193
   Cui L, 2004, ACTA PHARMACOL SIN, V25, P678
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Gabrielsson J., 1997, Pharmacokinetic  pharmacodynamic data analysis : Concepts and applications
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P376, DOI 10.1530/eje.0.1400376
   Huron DR, 2003, CLIN CANCER RES, V9, P1267
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Keeling DJ, 1998, ACTA PHYSIOL SCAND, V163, P195
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006 2952(00)00405 6
   LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235
   Lark MW, 2002, BONE, V30, P746, DOI 10.1016/S8756 3282(02)00675 0
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Marquis RW, 2004, MOL PHARMACEUT, V1, P97, DOI 10.1021/mp034017a
   Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065 230X(02)86001 8
   Migita K, 1996, CLIN EXP IMMUNOL, V104, P86, DOI 10.1046/j.1365 2249.1996.d01 651.x
   Missbach M, 2000, Curr Opin Drug Discov Devel, V3, P541
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Niikura K, 2004, BRIT J PHARMACOL, V142, P558, DOI 10.1038/sj.bjp.0705812
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Plé PA, 2004, J MED CHEM, V47, P871, DOI 10.1021/jm030317k
   Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041 1345(03)00211 2
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Sundaramoorthi R, 2003, BIOORG MED CHEM LETT, V13, P3063, DOI 10.1016/S0960 894X(03)00647 4
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Trubert CL, 1997, EUR J HISTOCHEM, V41, P169
   Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
   Vu CB, 2003, BIOORG MED CHEM LETT, V13, P3071, DOI 10.1016/S0960 894X(03)00649 8
   Wang YH, 2003, BIOORG MED CHEM LETT, V13, P3067, DOI 10.1016/S0960 894X(03)00648 6
   Weaver CM, 2005, J NUTR, V135, P1243, DOI 10.1093/jn/135.5.1243
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301
   Yasuma T, 1998, J MED CHEM, V41, P4301, DOI 10.1021/jm9803065
   Yin J, 2004, BIOL PHARM BULL, V27, P583, DOI 10.1248/bpb.27.583
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
NR 64
TC 15
Z9 21
U1 0
U2 3
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 447
EP 457
DI 10.1196/annals.1346.042
PG 11
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200043
PM 16831942
OA Bronze
DA 2025 08 17
ER

PT J
AU Salazar, VS
   Capelo, LP
   Cantù, C
   Zimmerli, D
   Gosalia, N
   Pregizer, S
   Cox, K
   Ohte, S
   Feigenson, M
   Gamer, L
   Nyman, JS
   Carey, DJ
   Economides, A
   Basler, K
   Rosen, V
AF Salazar, Valerie S.
   Capelo, Luciane P.
   Cantu, Claudio
   Zimmerli, Dario
   Gosalia, Nehal
   Pregizer, Steven
   Cox, Karen
   Ohte, Satoshi
   Feigenson, Marina
   Gamer, Laura
   Nyman, Jeffry S.
   Carey, David J.
   Economides, Aris
   Basler, Konrad
   Rosen, Vicki
TI Reactivation of a developmental Bmp2 signaling center is required
   for therapeutic control of the murine periosteal niche
SO ELIFE
LA English
DT Article
ID BONE FORMATION; OSTEOBLAST DIFFERENTIATION; CRE RECOMBINASE; INDIAN
   HEDGEHOG; EXPRESSION; SKELETAL; CARTILAGE; DISEASE; SPECIFICATION;
   ASSOCIATION
AB Two decades after signals controlling bone length were discovered, the endogenous ligands determining bone width remain unknown. We show that postnatal establishment of normal bone width in mice, as mediated by bone forming activity of the periosteum, requires BMP signaling at the innermost layer of the periosteal niche. This developmental signaling center becomes quiescent during adult life. Its reactivation however, is necessary for periosteal growth, enhanced bone strength, and accelerated fracture repair in response to bone anabolic therapies used in clinical orthopedic settings. Although many BMPs are expressed in bone, periosteal BMP signaling and bone formation require only Bmp2 in the Prx1 Cre lineage. Mechanistically, BMP2 functions downstream of Lrp5/6 pathway to activate a conserved regulatory element upstream of Sp7 via recruitment of Smad1 and Grhl3. Consistent with our findings, human variants of BMP2 and GRHL3 are associated with increased risk of fractures.
C1 [Salazar, Valerie S.; Capelo, Luciane P.; Pregizer, Steven; Cox, Karen; Ohte, Satoshi; Feigenson, Marina; Gamer, Laura; Rosen, Vicki] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
   [Salazar, Valerie S.; Cantu, Claudio; Zimmerli, Dario] Univ Zurich, Inst Mol Life Sci, Zurich, Switzerland.
   [Capelo, Luciane P.] Univ Fed Sao Paulo, Inst Ciencia & Tecnol, Sao Paulo, Brazil.
   [Cantu, Claudio] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med IKE, Wallenberg Ctr Mol Med, Linkoping, Sweden.
   [Gosalia, Nehal; Economides, Aris] Regeneron Pharmaceut, Tarrytown, NY USA.
   [Ohte, Satoshi] Kitasato Univ, Grad Sch Pharmaceut Sci, Dept Microbial Chem, Tokyo, Japan.
   [Nyman, Jeffry S.] Vanderbilt Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Nashville, TN USA.
   [Carey, David J.] Geisinger Hlth Syst, Danville, PA USA.
C3 Harvard University; Harvard School of Dental Medicine; University of
   Zurich; Universidade Federal de Sao Paulo (UNIFESP); Linkoping
   University; Regeneron; Kitasato University; Vanderbilt University;
   Geisinger Health System
RP Rosen, V (通讯作者)，Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
EM vicki_rosen@hsdm.haryard.edu
RI Capelo, Luciane/AFW 4604 2022; Nyman, Jeffry/L 5736 2013; Jones,
   David/AGR 2798 2022; Cantù, Claudio/AAB 7771 2019
OI Capelo, Luciane/0000 0002 3004 1220; , Dario/0000 0002 4920 0244; Nyman,
   Jeffry/0000 0001 7403 7605; Salazar, Valerie/0000 0002 2111 9313; Cantu,
   Claudio/0000 0003 1547 5415; Basler, Konrad/0000 0003 3534 1529; Ohte,
   Satoshi/0000 0002 5153 2176
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01 AR055904]
FX National Institute of Arthritis and Musculoskeletal and Skin Diseases
   R01 AR055904 Vicki Rosen The funders had no role in study design, data
   collection and interpretation, or the decision to submit the work for
   publication.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bonafe L, 2015, AM J MED GENET A, V167, P2869, DOI 10.1002/ajmg.a.37365
   Cantù C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4598
   Cantù C, 2013, DEVELOPMENT, V140, P2377, DOI 10.1242/dev.093591
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742 015 0047 8
   Chappuis V, 2012, BONE, V51, P800, DOI 10.1016/j.bone.2012.07.017
   Collinge C, 2016, INJURY, V47, pS36, DOI 10.1016/S0020 1383(16)30009 2
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Davison KS, 2006, SEMIN ARTHRITIS RHEU, V36, P22, DOI 10.1016/j.semarthrit.2006.04.002
   Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749
   Denny JC, 2010, BIOINFORMATICS, V26, P1205, DOI 10.1093/bioinformatics/btq126
   Dewey FE, 2016, SCIENCE, V354, DOI 10.1126/science.aaf6814
   Durland JL, 2008, J ANAT, V212, P590, DOI 10.1111/j.1469 7580.2008.00879.x
   Dwek JR, 2010, SKELETAL RADIOL, V39, P319, DOI 10.1007/s00256 009 0849 9
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fonseca TL, 2011, J BONE MINER RES, V26, P591, DOI 10.1002/jbmr.243
   Gamer LW, 2009, DEV DYNAM, V238, P2374, DOI 10.1002/dvdy.22048
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Intini G, 2015, BONE, V75, P151, DOI 10.1016/j.bone.2015.01.008
   Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011 1168
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lindsey RC, 2016, MOL CELL ENDOCRINOL, V432, P54, DOI 10.1016/j.mce.2015.09.017
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Lowery JW, 2010, AM J PHYSIOL REG I, V299, pR1463, DOI 10.1152/ajpregu.00866.2009
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Makowski AJ, 2014, BONE, V62, P1, DOI 10.1016/j.bone.2014.01.021
   MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237
   Millard SM, 2011, J BONE MINER RES, V26, P822, DOI 10.1002/jbmr.273
   Monteiro RM, 2008, GENESIS, V46, P335, DOI 10.1002/dvg.20402
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Ornitz DM, 2017, DEV DYNAM, V246, P291, DOI 10.1002/dvdy.24479
   Pathria MN, 2016, RADIOLOGY, V280, P21, DOI 10.1148/radiol.16142305
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   ROSEN V, 1993, PROG CLIN BIOL RES, V383, P305
   ROSEN V, 1994, J BONE MINER RES, V9, P1759
   Salazar VS, 2016, DEVELOPMENT, V143, P4352, DOI 10.1242/dev.136879
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Salazar VS, 2013, J CELL SCI, V126, P4974, DOI 10.1242/jcs.131953
   Schipani Ernestina, 2003, Birth Defects Research, V69, P352, DOI 10.1002/bdrc.10028
   Schuijers J, 2014, EMBO J, V33, P146, DOI 10.1002/embj.201385358
   Städeli R, 2005, MECH DEVELOP, V122, P1171, DOI 10.1016/j.mod.2005.07.004
   Tan TY, 2017, AM J HUM GENET, V101, P985, DOI 10.1016/j.ajhg.2017.10.006
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
NR 54
TC 27
Z9 29
U1 0
U2 7
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD FEB 8
PY 2019
VL 8
AR e42386
DI 10.7554/eLife.42386
PG 31
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA HM4QV
UT WOS:000459460100001
PM 30735122
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Yamaguchi, M
   Weitzmann, MN
AF Yamaguchi, Masayoshi
   Weitzmann, M. Neale
TI The intact strontium ranelate complex stimulates osteoblastogenesis and
   suppresses osteoclastogenesis by antagonizing NF κB activation
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Strontium ranelate; Nuclear factor kappa B; Osteoclast; Osteoblast; Bone
   resorption; Bone formation
ID CALCIUM SENSING RECEPTOR; NUCLEAR FACTOR; BONE RESORPTION; SMAD
   ACTIVATION; DIFFERENTIATION; CELLS; INHIBITION; MICE; OSTEOPOROSIS;
   SUBUNIT
AB Strontium ranelate, a pharmaceutical agent shown in clinical trials to be effective in managing osteoporosis and reducing fracture risk in postmenopausal women, is relatively unique in its ability to both blunt bone resorption and stimulate bone formation. However, its mechanisms of action are largely unknown. As the nuclear factor kappa B (NF kappa B) activation antagonists both stimulate osteoblastic bone formation and repress osteoclastic bone resorption, we hypothesized that strontium ranelate may achieve its anabolic and anti catabolic activities by modulating NF kappa B activation in bone cells. In this study, osteoclast and osteoblast precursors were treated with intact strontium ranelate or its individual components sodium ranelate and/or strontium chloride, and its effect on in vitro osteoclastogenesis and osteoblastogenesis and on NF kappa B activation quantified. Although the activity of strontium ranelate has been attributed to the release of strontium ions, low dose intact strontium ranelate complex, but not sodium ranelate and/or strontium chloride, potently antagonized NF kappa B activation in osteoclasts and osteoblasts in vitro, and promoted osteoblast differentiation while suppressing osteoclast formation. Taken together, our data suggest a novel centralized mechanism by which strontium ranelate promotes osteoblast activity and suppresses osteoclastogenesis, based on suppression of NF kappa B signal transduction. We further demonstrate that the biological actions of strontium ranelate may be related to low dose of the intact molecule rather than dissociation and release of strontium ions, as previously thought. These data may facilitate the development of additional novel pharmacological agents for the amelioration of osteoporosis, based on NF kappa B blockade.
C1 [Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
   [Weitzmann, M. Neale] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA 30322 USA.
   [Yamaguchi, Masayoshi; Weitzmann, M. Neale] Emory Univ, Div Endocrinol & Metab & Lipids, Dept Med, Sch Med, Atlanta, GA 30322 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Emory University; Emory University
RP Yamaguchi, M (通讯作者)，Emory Univ, Div Endocrinol & Metab & Lipids, Dept Med, Sch Med, 101 Woodruff Circle,1305 WMRB, Atlanta, GA 30322 USA.
EM yamamasa1155@yahoo.co.jop; mweitzma@emory.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) [AR059364, AR053607, AR056090]; Biomedical Laboratory Research
   and Development Service of the Veterans Affairs Office of Research and
   Development [5I01BX000105]
FX M. Neale Weitzmann is supported in part by National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Grants AR059364,
   AR053607 and AR056090 and by the Biomedical Laboratory Research and
   Development Service of the Veterans Affairs Office of Research and
   Development Grant 5I01BX000105.
CR Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Hurtel Lemaire AS, 2009, J BIOL CHEM, V284, P575, DOI 10.1074/jbc.M801668200
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Strait K, 2008, INT J MOL MED, V21, P521
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Takaoka S, 2010, HORM METAB RES, V42, P627, DOI 10.1055/s 0030 1255091
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Wahl EC, 2010, J BONE MINER RES, V25, P114, DOI 10.1359/jbmr.090708
   Yamaguchi M, 2009, INT J MOL MED, V24, P671, DOI 10.3892/ijmm_00000278
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
NR 30
TC 66
Z9 69
U1 1
U2 31
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2012
VL 359
IS 1 2
BP 399
EP 407
DI 10.1007/s11010 011 1034 8
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 850DK
UT WOS:000297174700041
PM 21874315
DA 2025 08 17
ER

PT J
AU Shahen, VA
   Schindeler, A
   Rybchyn, MS
   Girgis, CM
   Mulholland, B
   Mason, RS
   Levinger, I
   Brennan Speranza, TC
AF Shahen, V. A.
   Schindeler, A.
   Rybchyn, M. S.
   Girgis, C. M.
   Mulholland, B.
   Mason, R. S.
   Levinger, I.
   Brennan Speranza, T. C.
TI Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using
   Cinacalcet and Parathyroid Hormone
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Cinacalcet; Parathyroid hormone; PTH; Diabetes; Osteoblasts
ID BONE MINERAL DENSITY; CALCIUM SENSING RECEPTOR; IN VITRO; SECONDARY
   HYPERPARATHYROIDISM; FRACTURE; CELLS; DIFFERENTIATION; MECHANISMS;
   EXPRESSION; MARKERS
AB Patients with type 2 diabetes mellitus (T2DM) experience a higher risk of fractures despite paradoxically exhibiting normal to high bone mineral density (BMD). This has drawn into question the applicability to T2DM of conventional fracture reduction treatments that aim to retain BMD. In a primary human osteoblast culture system, high glucose levels (25 mM) impaired cell proliferation and matrix mineralization compared to physiological glucose levels (5 mM). Treatment with parathyroid hormone (PTH, 10 nM), a bone anabolic agent, and cinacalcet (CN, 1 mu M), a calcimimetic able to target the Ca2+ sensing receptor (CaSR), were tested for their effects on proliferation and differentiation. Strikingly, CN+PTH co treatment was shown to promote cell growth and matrix mineralization under both physiological and high glucose conditions. CN+PTH reduced apoptosis by 0.9 fold/0.4 fold as measured by Caspase 3 activity assay, increased alkaline phosphatase (ALP) expression by 1.5 fold/twofold, increased the ratio of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) by 2.1 fold/1.6 fold, and increased CaSR expression by 1.7 fold/4.6 fold (physiological glucose/high glucose). Collectively, these findings indicate a potential for CN+PTH combination therapy as a method to ameliorate the negative impact of chronic high blood glucose on bone remodeling.
C1 [Shahen, V. A.; Brennan Speranza, T. C.] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sydney, NSW 2006, Australia.
   [Schindeler, A.; Girgis, C. M.] Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Schindeler, A.] Childrens Hosp Westmead, Bioengn & Mol Med Lab, Westmead, NSW 2006, Australia.
   [Schindeler, A.] Westmead Inst Med Res, Westmead, NSW 2006, Australia.
   [Rybchyn, M. S.] Univ New South Wales, Sch Chem Engn, Sydney, NSW 2033, Australia.
   [Girgis, C. M.] Westmead Hosp, Dept Diabet & Endocrinol, Sydney, Australia.
   [Girgis, C. M.] Royal North Shore Hosp, Dept Endocrinol, Sydney, Australia.
   [Mulholland, B.] Univ Wollongong, Fac Sci Med & Hlth, Grad Sch Med, Wollongong, Australia.
   [Mulholland, B.] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Sydney, Australia.
   [Mason, R. S.] Univ Sydney, Fac Sci, Sch Life & Environm Sci, Sydney, NSW 2006, Australia.
   [Levinger, I.] Victoria Univ, Inst Hlth & Sport IHES, Sch Publ Hlth, Melbourne, Vic 2006, Australia.
   [Levinger, I.] Univ Melbourne, Australian Inst Musculoskeletal Sci AIMSS, St Albans, Vic, Australia.
C3 University of Sydney; University of Sydney; University of Sydney; NSW
   Health; The Children's Hospital at Westmead; Sydney Childrens Hospitals
   Network; University of Sydney; Westmead Institute for Medical Research;
   University of New South Wales Sydney; University of Sydney; NSW Health;
   Westmead Hospital; Royal North Shore Hospital; University of Wollongong;
   University of Sydney; University of Sydney; Victoria University;
   University of Melbourne; Australian Institute for Musculoskeletal
   Science
RP Brennan Speranza, TC (通讯作者)，Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sydney, NSW 2006, Australia.
EM tara.speranza@sydney.edu.au
OI Schindeler, Aaron/0000 0002 7757 6281; Shahen,
   Victor/0000 0001 9527 2073; Levinger, Itamar/0000 0001 9194 2033;
   Mulholland, Bridie/0000 0003 3640 5811
CR Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Aswamenakul K, 2020, MOL BIOL REP, V47, P7505, DOI 10.1007/s11033 020 05811 x
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chiodini I, 2021, NUTR METAB CARDIOVAS, V31, P2210, DOI 10.1016/j.numecd.2021.04.014
   Choudhary S, 2008, BIOCHEM BIOPH RES CO, V372, P536, DOI 10.1016/j.bbrc.2008.05.050
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Dede AD, 2014, METABOLISM, V63, P1480, DOI 10.1016/j.metabol.2014.09.002
   Dvorak MM, 2007, ENDOCRINOLOGY, V148, P3156, DOI 10.1210/en.2007 0147
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Frühbeck G, 2013, OBESITY FACTS, V6, P117, DOI 10.1159/000350627
   García Hernández A, 2012, BONE, V50, P276, DOI 10.1016/j.bone.2011.10.032
   Giangregorio LM, 2012, J BONE MINER RES, V27, P301, DOI 10.1002/jbmr.556
   Grebenová D, 2003, J PHOTOCH PHOTOBIO B, V69, P71, DOI 10.1016/S1011 1344(02)00410 4
   Hebert SC, 2006, ANNU REV MED, V57, P349, DOI 10.1146/annurev.med.57.121304.131328
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   Kawata T, 2006, J BONE MINER METAB, V24, P300, DOI 10.1007/s00774 006 0687 y
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee BK, 2016, ENDOCRINOL METAB, V31, P416, DOI 10.3803/EnM.2016.31.3.416
   Leere JS, 2020, LANCET DIABETES ENDO, V8, P407, DOI 10.1016/S2213 8587(20)30063 2
   Levinger I, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12700
   Li YH, 2020, J BONE MINER METAB, V38, P607, DOI 10.1007/s00774 020 01101 5
   Lin XL, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71908 9
   Lyu Z, 2023, POULTRY SCI, V102, DOI 10.1016/j.psj.2022.102287
   Malik P, 2015, BBA GEN SUBJECTS, V1850, P1898, DOI 10.1016/j.bbagen.2015.05.020
   McCarthy AD, 2004, INT J BIOCHEM CELL B, V36, P840, DOI 10.1016/j.biocel.2003.09.006
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Messa P, 2007, NEPHROL DIAL TRANSPL, V22, P2724, DOI 10.1093/ndt/gfm312
   Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33
   Purnamasari D, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/s12902 017 0224 0
   Reyes García R, 2013, ACTA DIABETOL, V50, P47, DOI 10.1007/s00592 011 0347 0
   Rizzoli R, 2021, LANCET DIABETES ENDO, V9, P606, DOI 10.1016/S2213 8587(21)00119 4
   Rybchyn MS, 2009, BONE, V44, pS317, DOI 10.1016/j.bone.2009.03.595
   Rybchyn MS, 2019, J BIOL CHEM, V294, P16337, DOI 10.1074/jbc.RA118.006587
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Schwartz AV, 2011, JAMA J AM MED ASSOC, V305, P2184, DOI 10.1001/jama.2011.715
   Shahen V A, 2020, Cytokine Growth Factor Rev, V55, P109, DOI 10.1016/j.cytogfr.2020.04.001
   Shalhoub V, 2003, CRIT REV EUKAR GENE, V13, P89, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.30
   SLATER M, 1994, AM J PHYSIOL ENDOC M, V267, pE990, DOI 10.1152/ajpendo.1994.267.6.E990
   Snedeker Jess G, 2014, Muscles Ligaments Tendons J, V4, P303
   Torres PU, 2006, J RENAL NUTR, V16, P253, DOI 10.1053/j.jrn.2006.04.010
   Tsuruta Y, 2013, CLIN EXP NEPHROL, V17, P120, DOI 10.1007/s10157 012 0665 8
   Tuominen JT, 1999, DIABETES CARE, V22, P1196, DOI 10.2337/diacare.22.7.1196
   Warming L, 2002, OSTEOPOROSIS INT, V13, P105, DOI 10.1007/s001980200001
NR 46
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2023
VL 112
IS 4
BP 452
EP 462
DI 10.1007/s00223 023 01062 7
EA FEB 2023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 9Y1SR
UT WOS:000929333100001
PM 36754901
OA Green Accepted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Knobloch, J
   Shaughnessy, JD
   Rüther, U
AF Knobloch, Juergen
   Shaughnessy, John D., Jr.
   Ruether, Ulrich
TI Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt
   signaling pathway
SO FASEB JOURNAL
LA English
DT Article
DE limb truncations; microphthalmia; teratogenic mechanism; programmed cell
   death
ID APICAL ECTODERMAL RIDGE; PROGRAMMED CELL DEATH; BETA CATENIN;
   TERATOGENIC ACTIVITY; HEAD INDUCTION; CHICK EMBRYO; P53; DICKKOPF 1;
   MECHANISM; ACTIVATION
AB Thalidomide, a sedative originally used to treat morning sickness and now used to treat leprosy and multiple myeloma, is also a teratogen that induces birth defects in humans such as limb truncations and microphthalmia. However, the teratogenic mechanism of action of this drug remains obscure. Thalidomide induces limb and eye defects in the chicken embryo at an EC50 of 50 mu g/kg egg wt and apoptosis in primary human embryonic fibroblasts ( HEFs) at an EC50 of 8.9 mu M. Using these model systems, we demonstrate by semiquantitative reverse transcriptase  polymerase chain reaction and whole  mount in situ hybridization that thalidomide  induced oxidative stress enhances signaling through bone morphogenetic proteins ( Bmps). This leads to up  regulation of the Bmp target gene and Wnt antagonist Dickkopf1 ( Dkk1) with subsequent inhibition of canonical Wnt/beta catenin signaling and increased cell death as shown by trypan blue and terminal deoxynucleotidyl transferase  mediated nick end labeling staining. Thalidomide  induced cell death was dramatically reduced in HEFs and in embryonic limb buds by the use of inhibitors against Bmps, Dkk1, and Gsk3 beta, a beta catenin antagonist acting downstream of Dkk1 in the Wnt pathway. Most interestingly, blocking of Dkk1 or Gsk3 beta dramatically counteracts thalidomideinduced limb truncations and microphthalmia. From this, we conclude that perturbing of Bmp/ Dkk1/ Wnt signaling is central to the teratogenic effects of thalidomide.
C1 Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, D 40225 Dusseldorf, Germany.
   Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
C3 Heinrich Heine University Dusseldorf; University of Arkansas System;
   University of Arkansas Medical Sciences
RP Knobloch, J (通讯作者)，Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, Univ Str 1, D 40225 Dusseldorf, Germany.
EM ruether@uni duesseldorf.de
RI ; Knobloch, Juergen/AFJ 3439 2022
OI Knobloch, Jurgen/0000 0001 6868 0055; 
FU NCI NIH HHS [CA 97513, CA 55819] Funding Source: Medline
CR Ahn K, 2001, DEVELOPMENT, V128, P4449
   Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089
   Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026
   Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471 2202 2 12
   BLASCHKE G, 1979, ARZNEIMITTEL FORSCH, V29 2, P1640
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chiarugi P, 2005, FREE RADICAL RES, V39, P353, DOI 10.1080/10715760400027987
   COILA S, 2007, IN PRESS BLOOD
   DEBOCK CA, 1963, NATURE, V199, P1204, DOI 10.1038/1991204a0
   FABRO S, 1964, LIFE SCI, V3, P987, DOI 10.1016/0024 3205(64)90109 2
   FABRO S, 1965, NATURE, V208, P1208, DOI 10.1038/2081208a0
   FABRO S, 1967, NATURE, V215, P296, DOI 10.1038/215296a0
   Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200
   FRANZ W, 2000, PERSPEKTIVEN WIRTSCH, V1, P53
   Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966
   Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749
   Hansen JM, 2004, ANTIOXID REDOX SIGN, V6, P1, DOI 10.1089/152308604771978291
   KEMPER F, 1962, LANCET, V2, P836
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   KNOCHE B, 1994, J CHROMATOGR A, V666, P235, DOI 10.1016/0021 9673(94)80385 4
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303
   Maass M, 2000, HERZ, V25, P68, DOI 10.1007/PL00001953
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   MELLIN GW, 1962, NEW ENGL J MED, V267, P1238, DOI 10.1056/NEJM196212132672407
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   NEWMAN LM, 1993, REPROD TOXICOL, V7, P359, DOI 10.1016/0890 6238(93)90025 3
   Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466
   Pizette S, 1999, DEVELOPMENT, V126, P883
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749 6632.1972.tb27821.x
   Schardein J., 1993, CHEM INDUCED BIRTH D, V2nd
   SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791
   Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003
   SMITHELLS RW, 1992, J MED GENET, V29, P716, DOI 10.1136/jmg.29.10.716
   Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006 2952(99)00388 3
   Trousse F, 2001, J NEUROSCI, V21, P1292
   Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503
   Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   Wolpert L, 2002, INT J DEV BIOL, V46, P869
   WOLPERT L, 1979, J EMBRYOL EXP MORPH, V50, P175
   Yamamoto M, 1996, CANCER AM CANCER SOC, V77, P1628, DOI 10.1002/(SICI)1097 0142(19960415)77:8+<1628::AID CNCR7>3.3.CO;2 9
   Yokouchi Y, 1996, DEVELOPMENT, V122, P3725
   Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191
   Zuzarte Luís V, 2004, DEV BIOL, V272, P39, DOI 10.1016/j.ydbio.2004.04.015
   ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304
NR 50
TC 103
Z9 111
U1 2
U2 37
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2007
VL 21
IS 7
BP 1410
EP 1421
DI 10.1096/fj.06 7603com
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 162VG
UT WOS:000246117000017
PM 17283219
DA 2025 08 17
ER

PT J
AU Abraham, AK
   Ramanathan, M
   Weinstock Guttman, B
   Mager, DE
AF Abraham, Anson K.
   Ramanathan, Murali
   Weinstock Guttman, Bianca
   Mager, Donald E.
TI Mechanisms of interferon β effects on bone homeostasis
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE c Fos; Nitric oxide; Osteoblasts; Osteoclasts; Receptor activator of
   nuclear factor kappa B
ID NF KAPPA B; OSTEOCLASTOGENESIS INHIBITORY FACTOR; MEDIATED DRUG
   DISPOSITION; IFN BETA; MULTIPLE SCLEROSIS; RECEPTOR ACTIVATOR;
   NITRIC OXIDE; RHEUMATOID ARTHRITIS; C FOS; PHARMACOKINETIC PROPERTIES
AB Restoration of dysregulated bone homeostasis is a therapeutic goal in many diseases including osteoporosis, rheumatoid arthritis and metastatic cancer. The molecular pathways regulating bone remodeling are major therapeutic targets, and studies continue to reveal endogenous factors that may be pathologically up  or down regulated and lead to an uncoupling of bone formation and resorption. The purpose of this commentary is to highlight new mechanisms of bone homeostatic regulation mediated through the induction of endogenous interferon beta (IFN beta). The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) is an important factor in the bone resorption cascade, and the RANK RANKL interaction has been shown to induce IFN beta and osteoclastogenesis via induction of the c fos gene. Subsequent binding of IFN beta to its biological receptor initiates a signal transduction cascade through the classic JAK/STAT pathway, causing an inhibition of c fos protein production and osteoclast proliferation and differentiation (negative feedback). Another mechanism pertinent to the anti resorptive effect of IFN beta is the induction of nitric oxide which has been shown to inhibit osteoclast formation. The role of IFN beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Here we also provide discussion of the potential challenges to optimizing IFN beta pharmacotherapy for such purposes. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Abraham, Anson K.; Ramanathan, Murali; Mager, Donald E.] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
   [Ramanathan, Murali; Weinstock Guttman, Bianca] Buffalo Gen Hosp, Jacobs Neurol Inst, Buffalo, NY 14203 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   Buffalo General Medical Center
RP Mager, DE (通讯作者)，SUNY Buffalo, Dept Pharmaceut Sci, 543 Hochstetter Hall, Buffalo, NY 14260 USA.
EM dmager@buffalo.edu
RI ; Weinstock Guttman, Bianca/AAI 4694 2021
OI Abraham, Anson/0000 0002 9579 7483; 
FU American Association of Pharmaceutical Scientists; University at Buffalo
     Pfizer Strategic Alliance; National Multiple Sclerosis Society
   [RG3743]
FX This study was funded, in part, by a New Investigator Grant from the
   American Association of Pharmaceutical Scientists (to D.E.M.) and the
   University at Buffalo   Pfizer Strategic Alliance (for A.K.A.). Drs.
   Ramanathan and Weinstock GLIttrnan gratefully acknowledge funding from
   the National Multiple Sclerosis Society (RG3743).
CR Adriaansen J, 2006, HUM GENE THER, V17, P985, DOI 10.1089/hum.2006.17.985
   Aksoy E, 2005, EUR J IMMUNOL, V35, P2200, DOI 10.1002/eji.200425801
   Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Baker DP, 2006, BIOCONJUGATE CHEM, V17, P179, DOI 10.1021/bc050237q
   Basu A, 2006, BIOCONJUGATE CHEM, V17, P618, DOI 10.1021/bc050322y
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954
   BUKKA P, 2003, MOL REGULATION OSTEO
   Campillo JA, 2006, BIOMED PHARMACOTHER, V60, P541, DOI 10.1016/j.biopha.2006.07.085
   Coelho LFL, 2005, P NATL ACAD SCI USA, V102, P11917, DOI 10.1073/pnas.0502188102
   Corboy John R., 2003, Curr Treat Options Neurol, V5, P35, DOI 10.1007/s11940 003 0021 0
   Downey PA, 2006, PHYS THER, V86, P77, DOI 10.1093/ptj/86.1.77
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Formica CA, 1997, CALCIFIED TISSUE INT, V61, P129
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   GLOFF C, 1992, PHARMACOKINETICS MET
   GOLDRING MB, 1990, CLIN ORTHOP RELAT R, P245
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2008, J IMMUNOL, V180, P1382, DOI 10.4049/jimmunol.180.3.1382
   Hayashi T, 2002, J BIOL CHEM, V277, P27880, DOI 10.1074/jbc.M203836200
   Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Kanamaru F, 2004, IMMUNOL LETT, V94, P239, DOI 10.1016/j.imlet.2004.05.010
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kwon B, 2000, MOL CELLS, V10, P119, DOI 10.1007/s10059 000 0119 0
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2008, BMB REP, V41, P495, DOI 10.5483/BMBRep.2008.41.7.495
   LEVY G, 1994, CLIN PHARMACOL THER, V56, P248, DOI 10.1038/clpt.1994.134
   Liu W, 2005, J BIOL CHEM, V280, P43064, DOI 10.1074/jbc.M509006200
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   Mager DE, 2006, BIOCHEM PHARMACOL, V72, P1, DOI 10.1016/j.bcp.2005.12.041
   Mager DE, 2005, PHARM RES DORDR, V22, P58, DOI 10.1007/s11095 004 9009 z
   Mager DE, 2003, J PHARMACOL EXP THER, V306, P262, DOI 10.1124/jpet.103.049502
   Mager DE, 2002, PHARMACEUT RES, V19, P1537, DOI 10.1023/A:1020468902694
   Marks S C., 2002, Structure and development of the skeleton, in principles of bone biology, second edition 1
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727
   Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301 472X(99)00109 5
   Rani MRS, 2002, J BIOL CHEM, V277, P38456, DOI 10.1074/jbc.M203204200
   ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, pS94, DOI 10.1007/BF01673412
   Roundy K, 2003, J BONE MINER RES, V18, P278, DOI 10.1359/jbmr.2003.18.2.278
   Rubin J, 2005, OSTEOCLAST ORIGIN DI
   Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shin HH, 2006, FEBS LETT, V580, P1601, DOI 10.1016/j.febslet.2006.01.091
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2001, CALCIFIED TISSUE INT, V68, P285, DOI 10.1007/BF02390835
   Tüzün S, 2003, MULT SCLER, V9, P600, DOI 10.1191/1352458503ms966oa
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van Holten J, 2005, ANN RHEUM DIS, V64, P1780, DOI 10.1136/ard.2005.040477
   van Holten J, 2005, ANN RHEUM DIS, V64, P64, DOI 10.1136/ard.2003.020347
   van Holten J, 2004, ARTHRITIS RES THER, V6, pR239, DOI 10.1186/ar1165
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Weinstock Guttman B, 2004, MULT SCLER, V10, P170, DOI 10.1191/1352458504ms993oa
   Weinstock Guttman B, 2006, MULT SCLER J, V12, P541, DOI 10.1177/1352458506070605
   Yang J, 2008, EUR J IMMUNOL, V38, P1598, DOI 10.1002/eji.200737650
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 68
TC 35
Z9 47
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUN 15
PY 2009
VL 77
IS 12
BP 1757
EP 1762
DI 10.1016/j.bcp.2009.01.007
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 445XK
UT WOS:000266084600001
PM 19428330
DA 2025 08 17
ER

PT J
AU Wu, JH
   Ren, BW
   Shi, FL
   Hua, P
   Lin, H
AF Wu, Jianhui
   Ren, Bowen
   Shi, Fuli
   Hua, Ping
   Lin, Hui
TI BMP and mTOR signaling in heterotopic ossification: Does their crosstalk
   provide therapeutic opportunities?
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone morphogenetic protein(BMP); crosstalk; heterotopic ossification;
   mammalian target of rapamycin (mTOR)
ID ENDOCHONDRAL BONE FORMATION; TISSUE PROGENITOR CELLS; MAMMALIAN TARGET;
   I RECEPTOR; OSTEOBLAST DIFFERENTIATION; PROGRESSIVA FOP; MC3T3 E1 CELLS;
   MUSCLE ATROPHY; MOUSE MODEL; TGF BETA
AB Heterotopic ossification (HO) refers to the pathological formation of ectopic bone in soft tissues, it occurs following severe trauma or in patients with a rare genetic disorder known as fibrodysplasia ossificans progressiva. The pathological process of HO formation is a two step mechanism: inflammation and destruction of connective tissues, followed by bone formation. The latter is further subdivided into three stages: fibroproliferation/angiogenesis, chondrogenesis, and osteogenesis. Currently, therapeutic options for HO are limited. New potential therapeutics will most likely arise from a more detailed understanding of the signaling pathways implicated in each stage of ectopic bone formation and molecular targets that may be effective at both the early and late stages of HO. Bone morphogenetic protein (BMP) signaling is believed to play a key role in the overall HO process. Recently, the mammalian target of rapamycin (mTOR) signaling pathway has received attention as a critical pathway for chondrogenesis, osteogenesis, and HO. Inhibition of mTOR signaling has been shown to block trauma induced and genetic HO. Intriguingly, recent studies have revealed crosstalk between mTOR and BMP signaling. Moreover, mTOR has emerged as a factor involved in the early hypoxic and inflammatory stages of HO. We will summarize the current knowledge of the roles of mTOR and BMP signaling in HO, with a particular focus on the crosstalk between mTOR and BMP signaling. We also discuss the activation of AMP activated protein kinase (AMPK) by the most widely used drug for type 2 diabetes, metformin, which exerts a dual negative regulatory effect on mTOR and BMP signaling, suggesting that metformin is a promising drug treatment for HO. The discovery of an mTOR BMP signaling network may be a potential molecular mechanism of HO and may represent a novel therapeutic target for the pharmacological control of HO.
C1 [Wu, Jianhui; Ren, Bowen] Nanchang Univ, Jiangxi Med Sch, Nanchang, Jiangx, Peoples R China.
   [Wu, Jianhui; Ren, Bowen] Queen Mary Univ London, Nanchang Joint Programme, London, England.
   [Shi, Fuli; Hua, Ping; Lin, Hui] Nanchang Univ, Sch Basic Med Sci, Jiangxi Prov Key Lab Tumor Pathogens & Mol Pathol, Nanchang, Jiangxi, Peoples R China.
   [Shi, Fuli; Hua, Ping; Lin, Hui] Nanchang Univ, Sch Basic Med Sci, Dept Pathophysiol, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; University of London; Queen Mary University London;
   Nanchang University; Nanchang University
RP Lin, H (通讯作者)，Nanchang Univ, Sch Basic Med Sci, Nanchang 330006, Jiangxi, Peoples R China.
EM huilin88@ncu.edu.cn
RI Ren, Bowen/GQH 2371 2022
OI Lin, Hui/0000 0003 0343 1757
FU Nanchang University [PY201801]; Natural Science Foundation of Jiangxi
   Province [2018BAB215012]; National Natural Science Foundation of China
   [81272926, 81572753, 31660332]; Doctoral Scientific Research Start up
   Foundation from Nanchang University; Jiangxi medical college of Nanchang
   University [PY201801]
FX Nanchang University, Grant/Award Number: PY201801; Natural Science
   Foundation of Jiangxi Province, Grant/Award Number: 2018BAB215012;
   National Natural Science Foundation of China, Grant/Award Numbers:
   81272926, 81572753, 31660332; Doctoral Scientific Research Start up
   Foundation from Nanchang University; Young Teachers Research and
   Development Fund Project from Jiangxi medical college of Nanchang
   University, Grant/Award Number: PY201801
CR Agarwal S, 2017, MOL THER, V25, P1974, DOI 10.1016/j.ymthe.2017.01.008
   Agarwal S, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89805
   Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Albert V, 2015, CURR OPIN CELL BIOL, V33, P55, DOI 10.1016/j.ceb.2014.12.001
   Alfieri KA, 2012, BONE JOINT RES, V1, P174, DOI 10.1302/2046 3758.18.2000102
   Amar E, 2015, J HIP PRESERV SURG, V2, P355, DOI 10.1093/jhps/hnv052
   Barfield WR, 2017, ORTHOP CLIN N AM, V48, P37, DOI 10.1016/j.ocl.2016.08.009
   Ben Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489
   Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101 1014
   Cappato S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040989
   Chaikuad A, 2012, J BIOL CHEM, V287, P36990, DOI 10.1074/jbc.M112.365932
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Day EA, 2017, TRENDS ENDOCRIN MET, V28, P545, DOI 10.1016/j.tem.2017.05.004
   de Gorter DJJ, 2012, CURR PHARM DESIGN, V18, P4087
   Deng ZL, 2015, J MOL CELL BIOL, V7, P62, DOI 10.1093/jmcb/mjv005
   Dey D, 2017, TRANSL RES, V186, P95, DOI 10.1016/j.trsl.2017.06.004
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   Düvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Evans KN, 2014, CLIN ORTHOP RELAT R, V472, P396, DOI 10.1007/s11999 013 3325 8
   Feng XM, 2014, DEV GROWTH DIFFER, V56, P615, DOI 10.1111/dgd.12179
   Fiori JL, 2006, J BONE MINER RES, V21, P902, DOI 10.1359/JBMR.060215
   Fitter S, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00668 16
   Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54
   Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792
   Fukuda T, 2009, J BIOL CHEM, V284, P7149, DOI 10.1074/jbc.M801681200
   Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464
   Glaser DL, 2003, J BONE JOINT SURG AM, V85A, P2332, DOI 10.2106/00004623 200312000 00010
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Gregson CL, 2011, BONE, V48, P654, DOI 10.1016/j.bone.2010.10.164
   Grenier G, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044 5040 3 29
   Groppe JC, 2011, CELLS TISSUES ORGANS, V194, P291, DOI 10.1159/000324230
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Haupt J, 2018, BONE, V109, P232, DOI 10.1016/j.bone.2017.10.027
   He H, 2015, CANCER J, V21, P70, DOI 10.1097/PPO.0000000000000103
   Hildebrand L, 2017, CELL SIGNAL, V29, P23, DOI 10.1016/j.cellsig.2016.10.001
   Hino K, 2017, J CLIN INVEST, V127, P3345, DOI 10.1172/JCI93521
   Hino K, 2015, P NATL ACAD SCI USA, V112, P15438, DOI 10.1073/pnas.1510540112
   Hirao T, 2018, CANCER SCI, V109, P121, DOI 10.1111/cas.13442
   Iqbal Nida, 2014, Chemother Res Pract, V2014, P357027, DOI [10.1155/2014/852748, 10.1155/2014/357027]
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Kan C, 2018, BONE, V109, P43, DOI 10.1016/j.bone.2017.04.014
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kang HJ, 2014, J REHABIL RES DEV, V51, P1109, DOI 10.1682/JRRD.2014.01.0019
   Kaplan FS, 2018, BONE, V109, P281, DOI 10.1016/j.bone.2017.12.011
   Kaplan FS, 2018, BONE, V109, P276, DOI 10.1016/j.bone.2017.07.019
   Kaplan FS, 2016, SEMIN CELL DEV BIOL, V49, P30, DOI 10.1016/j.semcdb.2015.12.013
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Katagiri T, 2018, BONE, V109, P241, DOI 10.1016/j.bone.2017.07.024
   Kim TH, 2012, MED HYPOTHESES, V79, P757, DOI 10.1016/j.mehy.2012.08.022
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kozlowski Piotr, 2004, Chir Narzadow Ruchu Ortop Pol, V69, P241
   Kramer K, 2018, GENESIS, V56, DOI 10.1002/dvg.23220
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Langenfeld EM, 2005, MOL CANCER RES, V3, P679, DOI 10.1158/1541 7786.MCR 05 0124
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lees Shepard JB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02872 2
   Li M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01039
   Li X, 2014, EMBO REP, V15, P191, DOI 10.1002/embr.201338119
   Lim J, 2016, DEVELOPMENT, V143, P339, DOI 10.1242/dev.126227
   Lin H, 2017, BBA MOL CELL RES, V1864, P2369, DOI 10.1016/j.bbamcr.2017.08.009
   Lin H, 2015, MOL PHARMACOL, V88, P1062, DOI 10.1124/mol.115.099549
   Lin L, 2011, MOL THER, V19, P1426, DOI 10.1038/mt.2011.101
   Lin L, 2010, BONE, V46, P425, DOI 10.1016/j.bone.2009.08.057
   Liu XH, 2015, MLTJ MUSCLE LIGAMENT, V5, P113, DOI 10.11138/mltj/2015.5.2.113
   Liu XH, 2014, J ORTHOP RES, V32, P183, DOI 10.1002/jor.22500
   Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177
   Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]
   Mucha BE, 2018, BONE, V109, P225, DOI 10.1016/j.bone.2018.01.002
   Olmsted Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692
   Pacifici M, 2016, CYTOKINE GROWTH F R, V27, P93, DOI 10.1016/j.cytogfr.2015.12.007
   Perluigi M, 2015, NEUROBIOL DIS, V84, P39, DOI 10.1016/j.nbd.2015.03.014
   Peterson JR, 2015, JOVE J VIS EXP, DOI 10.3791/52880
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   Potter BK, 2010, J BONE JOINT SURG AM, V92A, P74, DOI 10.2106/JBJS.J.00776
   Qureshi AT, 2017, AM J PATHOL, V187, P2536, DOI 10.1016/j.ajpath.2017.07.010
   Ramirez DM, 2014, HISTOL HISTOPATHOL, V29, P1281, DOI 10.14670/HH 29.1281
   Sakamoto T, 2014, MOL CELL BIOL, V34, P30, DOI 10.1128/MCB.01169 13
   Sanchez Duffhues G, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.62
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shen GY, 2018, J CELL PHYSIOL, V233, P3929, DOI 10.1002/jcp.26161
   Shi ST, 2013, CELL MOL LIFE SCI, V70, P407, DOI 10.1007/s00018 012 1054 x
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Shore Eileen M, 2011, Curr Osteoporos Rep, V9, P83, DOI 10.1007/s11914 011 0046 3
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Song GA, 2010, J BIOL CHEM, V285, P22542, DOI 10.1074/jbc.M109.094557
   Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240 002 0282 1
   van Dinther M, 2010, J BONE MINER RES, V25, P1208, DOI [10.1002/jbmr.091110, 10.1359/jbmr.091110]
   Wahdan Alaswad RS, 2012, MOL CANCER RES, V10, P821, DOI 10.1158/1541 7786.MCR 11 0615
   Wang HT, 2018, BONE, V109, P218, DOI 10.1016/j.bone.2017.11.014
   Wang HT, 2016, J BONE MINER RES, V31, P1652, DOI 10.1002/jbmr.2848
   Wang TW, 2004, FRONT BIOSCI LANDMRK, V9, P619, DOI 10.2741/1095
   Wang Ye kai, 2011, Zhongguo Gu Shang, V24, P399
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901
   Williams JT, 1999, AM SURGEON, V65, P22
   Wolken DMA, 2018, BONE, V109, P210, DOI 10.1016/j.bone.2017.06.011
   Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562
   Yeh LCC, 2013, J CELL BIOCHEM, V114, P1760, DOI 10.1002/jcb.24519
   Yoon MS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111176
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhang K, 2016, MATRIX BIOL, V52 54, P315, DOI 10.1016/j.matbio.2016.01.015
NR 112
TC 26
Z9 26
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2019
VL 120
IS 8
BP 12108
EP 12122
DI 10.1002/jcb.28710
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ID5LQ
UT WOS:000471718300003
PM 30989716
DA 2025 08 17
ER

PT J
AU Zhong, ZG
   Li, YY
   Chen, Y
   Chen, W
   Li, SY
   Lv, XH
   Luo, SY
AF Zhong, Zhiguo
   Li, Yuyun
   Chen, Yan
   Chen, Wen
   Li, Siyan
   Lv, Xiaohua
   Luo, Shiying
TI Predicting and Exploring the Mechanisms of Erzhi Pill in Prevention and
   Treatment of Osteoporosis Based on Network Pharmacology and Zebrafish
   Experiments
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE Erzhi Pill; osteoporosis; network pharmacology; mechanisms; zebrafish;
   quercetin
ID STIMULATES OSTEOGENESIS; SIGNALING PATHWAY; RAT MODEL; BONE LOSS;
   DIFFERENTIATION; PROLIFERATION; OSTEOBLASTS; APOPTOSIS; NICOTINE;
   RECEPTOR
AB Background: Erzhi Pill (EZP), a traditional Chinese medicine (TCM) prescription, has been widely applied to improve bone metabolism and treat osteoporosis (OP) in China. However, its effective constituents and mechanisms remain unclear.
   Methods: By combining network pharmacology and zebrafish experiments, an integrative method was employed to address this problem. Firstly, the disease targets of OP were collected from two public gene databases. Secondly, the active compounds and drug targets of EZP were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). Thirdly, a drug target disease interaction network was constructed, and the key active components were identified by analyzing the topological characteristics of the network. Finally, these predicted results were tested by zebrafish experiments and compared with those from the literature. Specifically, quercetin as an important representative active component of EZP was applied to wild type and transgenic zebrafish larvae to assess its effects on skull mineralization and osteoplastic differentiation.
   Results: Our study identified 72 active compounds, 220 targets and 166 signaling pathways probably involved in the prevention and treatment of OP by EZP, wherein quercetin, apigenin, daidzein, luteolin, ursolic acid and kaempferol could be the key compounds, while PI3K Akt signaling pathway, TNF signaling pathway and IL 17 signaling pathway could be the key signaling pathways. The experiments indicated that quercetin attenuated both the decrease of skull mineralization and the inhibition of skull osteoplastic differentiation in zebrafish larvae trigged by dexamethasone.
   Conclusion: Our study not only investigated potentially effective constituents and mechanisms of EZP in the prevention and treatment of OP, but also provided a reference for the indepth research, development and application of TCM.
C1 [Zhong, Zhiguo] Guangdong Med Univ, Tradit Chinese Med Dept, Affiliated Hosp, Zhanjiang 524023, Peoples R China.
   [Li, Yuyun; Chen, Yan; Chen, Wen; Lv, Xiaohua; Luo, Shiying] Guangdong Med Univ, Sch Pharm, Marine Biomed Res Inst, Dept Pharmacol,Guangdong Key Lab Res & Dev Nat Dr, 2 East Wenming Rd, Zhanjiang 524023, Guangdong, Peoples R China.
   [Li, Yuyun; Chen, Yan] Guangdong Med Univ, Inst Tradit Chinese Med & New Pharm Dev, Dongguan 523808, Peoples R China.
   [Li, Siyan] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510006, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Guangdong
   Medical University; Guangzhou University of Chinese Medicine
RP Luo, SY (通讯作者)，Guangdong Med Univ, Sch Pharm, Marine Biomed Res Inst, Dept Pharmacol,Guangdong Key Lab Res & Dev Nat Dr, 2 East Wenming Rd, Zhanjiang 524023, Guangdong, Peoples R China.
EM luosy76@gdmu.edu.cn
RI Siyan, Li/JCN 9257 2023
FU Natural Science Foundation of Guangdong Province [2018A0 30313390];
   Scientific Research Foundation for PhD of Guangdong Medical University
   [B2017030]; Scientific Research Subject of Traditional Chinese Medicine
   Bureau of Guangdong Province [20171145, 20191190]
FX The study was supported by the Natural Science Foundation of Guangdong
   Province (No: 2018A0 30313390), the Scientific Research Foundation for
   PhD of Guangdong Medical University (No: B2017030), and the Scientific
   Research Subject of Traditional Chinese Medicine Bureau of Guangdong
   Province (No: 20171145 & 20191190).
CR Ali S, 2011, BIRTH DEFECTS RES C, V93, P115, DOI 10.1002/bdrc.20206
   Asadipooya K, 2019, J ENDOCR SOC, V3, P1799, DOI 10.1210/js.2019 00160
   Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Cano A, 2018, MATURITAS, V107, P7, DOI 10.1016/j.maturitas.2017.10.004
   Carnovali M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1253710
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng M, 2019, CHIN J INTEGR MED, V25, P210, DOI 10.1007/s11655 018 3050 y
   Choi EM, 2007, PHARMAZIE, V62, P216, DOI 10.1691/ph.2007.3.6629
   Curtis EM, 2016, CLIN MED, V16, P360, DOI 10.7861/clinmedicine.16 4 360
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Fu SF, 2016, MENOPAUSE, V23, P311, DOI 10.1097/GME.0000000000000534
   Geusens P, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10211
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Jin X, 2017, NUTR RES, V42, P20, DOI 10.1016/j.nutres.2017.04.009
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kim BS, 2012, LIFE SCI, V90, P109, DOI 10.1016/j.lfs.2011.10.019
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Li XY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00228
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Liang WN, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/9210490
   Luo SY, 2016, ACTA PHARMACOL SIN, V37, P1370, DOI 10.1038/aps.2016.62
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017
   Qin TY, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112128
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Tan H, 2019, J AGR FOOD CHEM, V67, P3333, DOI 10.1021/acs.jafc.8b06954
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Wangi DW, 2018, MOL MED REP, V18, P610, DOI 10.3892/mmr.2018.8994
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang J, 2010, MED HYPOTHESES, V74, P1067, DOI 10.1016/j.mehy.2009.12.024
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
   Zhao J, 2019, MOL MED REP, V20, P5197, DOI 10.3892/mmr.2019.10747
   Zuo JY, 2021, J INTEGR MED JIM, V19, P50, DOI 10.1016/j.joim.2020.10.004
NR 43
TC 10
Z9 12
U1 5
U2 52
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 817
EP 827
DI 10.2147/DDDT.S293455
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QR5WO
UT WOS:000625288100001
PM 33658763
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mansoori, MN
   Shukla, P
   Singh, D
AF Mansoori, Mohd Nizam
   Shukla, Priyanka
   Singh, Divya
TI Combination of PTH (1 34) with anti IL17 prevents bone loss by
   inhibiting IL 17/N cadherin mediated disruption of PTHR1/LRP 6
   interaction
SO BONE
LA English
DT Article
DE PTH; Osteoporosis; Osteoimmunology; IL 17A
ID ANTIRESORPTIVE THERAPY; POSTMENOPAUSAL WOMEN; ESTROGEN DEFICIENCY;
   TERIPARATIDE; OSTEOPOROSIS; STRENGTH; ISOFORMONONETIN; ALENDRONATE;
   DENOSUMAB; DENSITY
AB Combinations of anabolic and anti resorptive agents have potential to improve bone density more than either agent alone. In this study, we determine the combining effect of anti IL17 antibody and PTH (1 34) in mitigation of ovariectomy induced bone loss. Ovariectomized BALB/c female mice were treated with anti IL17 and iPTH monotherapies and their combination. Combination of iPTH and anti IL17 has synergistic effect in the restoration of skeletal and immune parameters compared to mono therapies. Immunofluorescence analysis shows decreased expression of PTHR1 in iPTH anti IL17 treated bone sections. Our studies show that IL17 up regulates N cadherin which disrupts PTHR1/LRP 6 interaction thereby inhibiting wnt signaling and promoting bone loss. Our studies advocate use of iPTH and anti IL17 combination therapy for post menopausal osteoporosis. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Mansoori, Mohd Nizam; Shukla, Priyanka; Singh, Divya] Cent Drug Res Inst, CSIR, Div Endocrinol, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, BS 10 1,Sect 10, Lucknow, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI)
RP Singh, D (通讯作者)，Cent Drug Res Inst, CSIR, Div Endocrinol, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, BS 10 1,Sect 10, Lucknow, Uttar Pradesh, India.
EM divya_singh@cdri.res.in
RI Singh, Divya/IUM 7944 2023; shukla, priyanka/C 9968 2010
OI Shukla, Priyanka/0009 0004 1682 7114
FU Centre for Research in Anabolic Skeletal Targets in Health and Illness
   (ASTHI); Council of Scientific and Industrial Research (CSIR) [BSC0201];
   CSIR; UGC
FX Centre for Research in Anabolic Skeletal Targets in Health and Illness
   (ASTHI), Council of Scientific and Industrial Research (CSIR) (BSC0201).
   MNM acknowledges CSIR for fellowship and PS acknowledges UGC for
   fellowship.
CR Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Bellido T, 2013, BONE, V54, P250, DOI 10.1016/j.bone.2012.09.016
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Cosman F, 2008, OSTEOPOROSIS INT, V19, P529, DOI 10.1007/s00198 007 0475 0
   Cosman F, 2014, CURR OSTEOPOROS REP, V12, P385, DOI 10.1007/s11914 014 0237 9
   Cosman F, 2013, J BONE MINER RES, V28, P1328, DOI 10.1002/jbmr.1853
   EJERSTED C, 1993, J BONE MINER RES, V8, P1097
   Fischer JAA, 2015, ARTHRITIS RHEUMATOL, V67, P51, DOI 10.1002/art.38896
   Huang Q, 2016, AM J CANCER RES, V6, P440
   Jackuliak P, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/820615
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Mansoori MN, 2016, MENOPAUSE, V23, P565, DOI 10.1097/GME.0000000000000646
   Mansoori MN, 2016, SCI REP UK, V6, DOI 10.1038/srep33680
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Kulak CAM, 2010, ARQ BRAS ENDOCRINOL, V54, P87, DOI 10.1590/S0004 27302010000200002
   Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969
   Pacifici R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00057
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Revollo L, 2015, J BONE MINER RES, V30, P274, DOI 10.1002/jbmr.2323
   Shukla P, 2017, J BIOL CHEM, V292, P4686, DOI 10.1074/jbc.M116.764779
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Srivastava K, 2013, PHYTOMEDICINE, V20, P470, DOI 10.1016/j.phymed.2012.12.021
   Tokuyama Naoto, 2015, Bone Rep, V2, P1, DOI 10.1016/j.bonr.2014.12.002
   Tsai JN, 2015, J BONE MINER RES, V30, P39, DOI 10.1002/jbmr.2315
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tyagi AM, 2014, J BONE MINER RES, V29, P1981, DOI 10.1002/jbmr.2228
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yang HZ, 2016, SCAND ACTUAR J, P1, DOI 10.1080/03461238.2014.884017
NR 33
TC 20
Z9 28
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2017
VL 105
BP 226
EP 236
DI 10.1016/j.bone.2017.09.010
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FL1SK
UT WOS:000413994500027
PM 28935557
DA 2025 08 17
ER

PT J
AU Yu, B
   Gao, QM
   Sheng, SH
   Zhou, FJ
   Geng, Z
   Wei, Y
   Zhang, H
   Hu, Y
   Wang, SC
   Huang, JP
   Li, MM
   Su, JC
AF Yu, Biao
   Gao, Qianmin
   Sheng, Shihao
   Zhou, Fengjin
   Geng, Zhen
   Wei, Yan
   Zhang, Hao
   Hu, Yan
   Wang, Sicheng
   Huang, Jianping
   Li, Mengmeng
   Su, Jiacan
TI Smart osteoclasts targeted nanomedicine based on amorphous
   CaCO3 for effective osteoporosis reversal
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE pH responsiveness; Oroxylin A; Osteoporosis; Acidic microenvironment;
   Synergistic therapy
ID CHRONIC MYELOGENOUS LEUKEMIA; OSTEOBLAST PROMOTION; CALCIUM SUPPLEMENT;
   ANABOLIC THERAPY; NANOPARTICLES; OROXYLIN; DELIVERY; RESISTANCE;
   IMATINIB
AB Background Osteoporosis is characterized by an imbalance in bone homeostasis, resulting in the excessive dissolution of bone minerals due to the acidified microenvironment mediated by overactive osteoclasts. Oroxylin A (ORO), a natural flavonoid, has shown potential in reversing osteoporosis by inhibiting osteoclast mediated bone resorption. The limited water solubility and lack of targeting specificity hinder the effective accumulation of Oroxylin A within the pathological environment of osteoporosis. Results Osteoclasts' microenvironment responsive nanoparticles are prepared by incorporating Oroxylin A with amorphous calcium carbonate (ACC) and coated with glutamic acid hexapeptide modified phospholipids, aiming at reinforcing the drug delivery efficiency as well as therapeutic effect. The obtained smart nanoparticles, coined as OAPLG, could instantly neutralize acid and release Oroxylin A in the extracellular microenvironment of osteoclasts. The combination of Oroxylin A and ACC synergistically inhibits osteoclast formation and activity, leading to a significant reversal of systemic bone loss in the ovariectomized mice model. Conclusion The work highlights an intelligent nanoplatform based on ACC for spatiotemporally controlled release of lipophilic drugs, and illustrates prominent therapeutic promise against osteoporosis.
C1 [Yu, Biao; Gao, Qianmin; Geng, Zhen; Wei, Yan; Zhang, Hao; Hu, Yan; Wang, Sicheng; Li, Mengmeng; Su, Jiacan] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.
   [Yu, Biao; Gao, Qianmin; Geng, Zhen; Wei, Yan; Zhang, Hao; Hu, Yan; Wang, Sicheng; Li, Mengmeng; Su, Jiacan] Shanghai Univ, Musculoskeletal Organoid Res Ctr, Shanghai 200444, Peoples R China.
   [Yu, Biao; Gao, Qianmin; Wang, Sicheng; Huang, Jianping] Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.
   [Yu, Biao; Huang, Jianping] Shanghai Univ, Affiliated Hosp 2, Wenzhou 325000, Peoples R China.
   [Sheng, Shihao] Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai 200433, Peoples R China.
   [Zhou, Fengjin] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthoped, Xian 710000, Peoples R China.
   [Hu, Yan; Su, Jiacan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthoped, Shanghai 200092, Peoples R China.
   [Wang, Sicheng] Shanghai Zhongye Hosp, Dept Orthoped, Shanghai 200941, Peoples R China.
   [Huang, Jianping] Wenzhou Cent Hosp, Dept Neurol, Wenzhou 325000, Peoples R China.
C3 Shanghai University; Shanghai University; Shanghai University; Shanghai
   University; Naval Medical University; Xi'an Jiaotong University;
   Shanghai Jiao Tong University
RP Wang, SC; Li, MM; Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.; Wang, SC; Li, MM; Su, JC (通讯作者)，Shanghai Univ, Musculoskeletal Organoid Res Ctr, Shanghai 200444, Peoples R China.; Wang, SC; Huang, JP (通讯作者)，Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.; Huang, JP (通讯作者)，Shanghai Univ, Affiliated Hosp 2, Wenzhou 325000, Peoples R China.; Su, JC (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthoped, Shanghai 200092, Peoples R China.; Wang, SC (通讯作者)，Shanghai Zhongye Hosp, Dept Orthoped, Shanghai 200941, Peoples R China.; Huang, JP (通讯作者)，Wenzhou Cent Hosp, Dept Neurol, Wenzhou 325000, Peoples R China.
EM w.s.c@sina.com; dr.hjp@163.com; mengmengli@shu.edu.cn;
   jiacansu@shu.edu.cn
RI , jphuang/AGY 6034 2022; Wang, Sicheng/LXV 9883 2024; Geng,
   Zhen/AAX 1367 2021; Su, Jiacan/N 7068 2019; zhou, fengjin/IAO 1374 2023;
   Yu, Biao/G 9952 2017; Gao, Qianmin/IQW 3587 2023
OI Su, Jiacan/0000 0001 7080 263X; 
FU Natural Science Foundation of Shanghai Municipality [82230071,
   82172098]; National Natural Science Foundation of China [23141900600];
   Shanghai Committee of Science and Technology [22ZR1423400]; Natural
   Science Foundation of Shanghai
FX The work was financially supported by the National Natural Science
   Foundation of China (82230071, 82172098), the Shanghai Committee of
   Science and Technology (23141900600), and the Natural Science Foundation
   of Shanghai (22ZR1423400).
CR Anastasilakis AD, 2022, J CLIN ENDOCR METAB, V107, P1441, DOI 10.1210/clinem/dgab888
   Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Dai JY, 2008, ACTA PHARMACOL SIN, V29, P1086, DOI 10.1111/j.1745 7254.2008.00850.x
   Dayanandan AP, 2023, BIOMATER RES, V27, DOI 10.1186/s40824 023 00413 7
   Deng Y, 2022, ACS BIOMATER SCI ENG, V8, P424, DOI 10.1021/acsbiomaterials.1c01306
   Dong ZL, 2016, BIOMATERIALS, V110, P60, DOI 10.1016/j.biomaterials.2016.09.025
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Elghareeb MM, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.989487
   Guo JW, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2022.100881
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Jia F, 2023, BIOMATERIALS, V296, DOI 10.1016/j.biomaterials.2023.122059
   Li M, 2023, Nano Today, P50
   Li WJ, 2017, MOL CARCINOGEN, V56, P863, DOI 10.1002/mc.22540
   Li X, 2015, ARCH TOXICOL, V89, P121, DOI 10.1007/s00204 014 1226 6
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu H., 2022, CHEM ENG J, P450
   Lundberg G, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883 020 00854 8
   Lv Q, 2021, ACTA PHARM SIN B, V11, P2880, DOI 10.1016/j.apsb.2021.03.011
   Martiniakova M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030523
   Méndez Sánchez L, 2023, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012664.pub2
   Rauner M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040787
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Rizzoli R, 2021, LANCET DIABETES ENDO, V9, P606, DOI 10.1016/S2213 8587(21)00119 4
   Sajeev A, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154369
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Srivichit B, 2022, ARCH TOXICOL, V96, P1227, DOI 10.1007/s00204 021 03220 y
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Tao Y., 2022, COMPOS PART B ENG, P247
   Vitaca T, 2022, LANCET DIABETES ENDO, V10, P273, DOI 10.1016/S2213 8587(22)00012 2
   Wang C, 2020, INT J NANOMED, V15, P4049, DOI 10.2147/IJN.S237156
   Wang C, 2019, INT J NANOMED, V14, P1503, DOI 10.2147/IJN.S193976
   Wang CJ, 2022, ADV MATER, V34, DOI 10.1002/adma.202106520
   Wang F, 2021, INT J BIOL SCI, V17, P1821, DOI 10.7150/ijbs.57681
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang M, 2020, J MATER CHEM B, V8, P8261, DOI 10.1039/d0tb01453b
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiang L, 2022, PHYTOMEDICINE, V95, DOI 10.1016/j.phymed.2021.153727
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yao JY, 2022, AUTOPHAGY, V18, P1879, DOI 10.1080/15548627.2021.2007027
   Yu B, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.844050
   Yu H, 2017, INT J PHARMACEUT, V528, P602, DOI 10.1016/j.ijpharm.2017.06.068
   Zhang H, 2022, Frontiers in plant science, P13
   Zhao Y, 2015, ANGEW CHEM INT EDIT, V54, P919, DOI 10.1002/anie.201408510
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
NR 55
TC 20
Z9 20
U1 16
U2 45
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 5
PY 2024
VL 22
IS 1
AR 153
DI 10.1186/s12951 024 02412 9
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA NA9A9
UT WOS:001197823400002
PM 38580995
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhytnik, L
   Maasalu, K
   Reimann, E
   Märtson, A
   Koks, S
AF Zhytnik, Lidiia
   Maasalu, Katre
   Reimann, Ene
   Martson, Aare
   Koks, Sulev
TI RNA sequencing analysis reveals increased expression of interferon
   signaling genes and dysregulation of bone metabolism affecting pathways
   in the whole blood of patients with osteogenesis imperfecta
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Osteogenesis imperfecta; Bone fragility; Transcriptome; RNA seq;
   Inflammation; Bone metabolism
ID BOVINE LACTOFERRIN; IN VIVO; COLLAGEN; CHILDREN; BETA; MICE; INHIBITION;
   OSTEOBLAST; MUTATIONS; THERAPY
AB Background Osteogenesis imperfecta (OI) is a rare genetic disorder in which the patients suffer from numerous fractures, skeletal deformities and bluish sclera. The disorder ranges from a mild form to severe and lethal cases. The main objective of this pilot study was to compare the blood transcriptional landscape of OI patients with COL1A1 pathogenic variants and their healthy relatives, in order to find out different gene expression and dysregulated molecular pathways in OI. Methods We performed RNA sequencing analysis of whole blood in seven individuals affected with different OI severity and their five unaffected relatives from the three families. The data was analyzed using edgeR package of R Bioconductor. Functional profiling and pathway analysis of the identified differently expressed genes was performed with g:GOSt and MinePath web based tools. Results We identified 114 differently expressed genes. The expression of 79 genes was up regulated, while 35 genes were down regulated. The functional analysis identified a presence of dysregulated interferon signaling pathways (IFI27, IFITM3, RSAD12, GBP7). Additionally, the expressions of the genes related to extracellular matrix organization, Wnt signaling, vitamin D metabolism and MAPK ERK 1/2 pathways were also altered. Conclusions The current pilot study successfully captured the differential expression of inflammation and bone metabolism pathways in OI patients. This work can contribute to future research of transcriptional bloodomics in OI. Transcriptional bloodomics has a strong potential to become a major contributor to the understanding of OI pathological mechanisms, the discovery of phenotype modifying factors, and the identification of new therapeutic targets. However, further studies in bigger cohorts of OI patients are needed to confirm the findings of the current work.
C1 [Zhytnik, Lidiia; Maasalu, Katre; Martson, Aare] Tartu Univ Hosp, Clin Traumatol & Orthoped, Puusepa 8, EE 51014 Tartu, Estonia.
   [Maasalu, Katre; Martson, Aare] Univ Tartu, Inst Clin Med, Dept Traumatol & Orthoped, Tartu, Estonia.
   [Reimann, Ene] Univ Tartu, Estonian Genome Ctr, Tartu, Estonia.
   [Koks, Sulev] QEII Med Ctr, Perron Inst Neurol & Translat Sci, Nedlands, WA, Australia.
   [Koks, Sulev] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia.
C3 University of Tartu; University of Tartu; Queen Elizabeth II Medical
   Centre; University of Western Australia; Perron Institute for
   Neurological & Translational Science; Murdoch University
RP Zhytnik, L (通讯作者)，Tartu Univ Hosp, Clin Traumatol & Orthoped, Puusepa 8, EE 51014 Tartu, Estonia.
EM Lidiia.zhytnik@ut.ee
RI Maasalu, Katre/F 7177 2015; Reimann, Ene/M 9912 2017; /H 3655 2015;
   Koks, Sulev/HSA 8160 2023; Zhytnik, Lidiia/AAT 7678 2020; Martson,
   Aare/AAQ 8714 2020
OI /0000 0001 6087 6643; Zhytnik, Lidiia/0000 0003 4682 0402; 
FU Estonian Ministry of Education and Research [IUT20 46]
FX This work was supported by an institutional research grant [IUT20 46] of
   the Estonian Ministry of Education and Research. The funder had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aslan H, 2006, J BONE MINER RES, V21, P1935, DOI 10.1359/JBMR.060819
   Auslander N, 2020, SSRN ELECT J
   BARON R, 1983, PEDIATR RES, V17, P204, DOI 10.1203/00006450 198303000 00007
   Barron ML, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.57
   Bhadada SK, 2019, CALCIFIED TISSUE INT, V104, P561, DOI 10.1007/s00223 019 00547 8
   Blais A, 2010, BONE, V46, pS69, DOI 10.1016/j.bone.2010.01.166
   BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269
   Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200
   Cornish J, 2004, ENDOCRINOLOGY, V145, P4366, DOI 10.1210/en.2003 1307
   Costantini A, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2015.143
   Dubail J, 2020, J BONE MINER RES, V35, P1470, DOI 10.1002/jbmr.4011
   DUNCAN MR, 1985, J EXP MED, V162, P516, DOI 10.1084/jem.162.2.516
   Edouard T, 2011, J CLIN ENDOCR METAB, V96, P3193, DOI 10.1210/jc.2011 1480
   Ehrlichman LK, 2010, J SURG RES, V160, P18, DOI 10.1016/j.jss.2009.03.095
   Fratzl Zelman N, 2016, J CLIN ENDOCR METAB, V101, P3516, DOI 10.1210/jc.2016 1334
   Fresard L, 2019, NAT MED, V25, P911, DOI 10.1038/s41591 019 0457 8
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gentili C, 2009, CURR PHARM DESIGN, V15, P1334, DOI 10.2174/138161209787846739
   Gonorazky HD, 2019, AM J HUM GENET, V104, P466, DOI 10.1016/j.ajhg.2019.01.012
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Gytz H, 2017, BIOL CELL, V109, P94, DOI 10.1111/boc.201600034
   Hadwen J, TRANSCRIPTOMIC RNASE, DOI [10.1093/hmg/ddy221, DOI 10.1093/HMG/DDY221]
   Hecker M, 2019, EBIOMEDICINE, V49, P2, DOI 10.1016/j.ebiom.2019.10.035
   Hickford D, 2012, BMC GENOMICS, V13, DOI 10.1186/1471 2164 13 155
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Hsiao CP, 2013, INT J MOL SCI, V14, P16943, DOI 10.3390/ijms140816943
   Inagaki Y, 2003, HEPATOLOGY, V38, P890, DOI 10.1053/jhep.2003.50408
   JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Koumakis L, 2017, NUCLEIC ACIDS RES, V45, pW116, DOI 10.1093/nar/gkx278
   Lange UC, 2008, MOL CELL BIOL, V28, P4688, DOI 10.1128/MCB.00272 08
   Li WY, 2015, CLIN ORTHOP RELAT R, V473, P2383, DOI 10.1007/s11999 015 4270 5
   Li WY, 2011, J HUAZHONG U SCI MED, V31, P721, DOI 10.1007/s11596 011 0667 x
   Liew CC, 2006, J LAB CLIN MED, V147, P126, DOI 10.1016/j.lab.2005.10.005
   Lim JY, 2019, CLIN DYSMORPHOL, V28, P118, DOI 10.1097/MCD.0000000000000279
   Liu X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1750 7
   Lu N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153792
   Maasalu K, 2017, EXP BIOL MED, V242, P203, DOI 10.1177/1535370216679899
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   Matthews BG, 2017, BONE, V103, P1, DOI 10.1016/j.bone.2017.06.004
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Mears AJ, 2017, NPJ GENOM MED, V2, DOI 10.1038/s41525 017 0018 3
   Meena B., 2014, Arch Dis Child, V99, pA275, DOI DOI 10.1136/ARCHDISCHILD 2014 307384.747
   Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138
   Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945 053X(97)90025 1
   Naot D, 2005, CLIN MED RES, V3, P93, DOI 10.3121/cmr.3.2.93
   Nishiu M, 2004, CANCER SCI, V95, P828, DOI 10.1111/j.1349 7006.2004.tb02189.x
   Papac Milicevic N, 2012, CIRC RES, V110, pE50, DOI 10.1161/CIRCRESAHA.111.258814
   Paratcha G, 2011, CELL RES, V21, P217, DOI 10.1038/cr.2010.143
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752
   Roschger P, 2008, CALCIFIED TISSUE INT, V82, P263, DOI 10.1007/s00223 008 9113 x
   Salter L, 2018, ARCH DIS CHILD, V103, P767, DOI 10.1136/archdischild 2017 313859
   Seeliger C, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 014 0074 4
   Semler O, 2012, AM J HUM GENET, V91, P349, DOI 10.1016/j.ajhg.2012.06.011
   Shen LX, 2009, J CELL BIOCHEM, V106, P337, DOI 10.1002/jcb.22010
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sinder BP, 2016, BONE, V84, P222, DOI 10.1016/j.bone.2016.01.001
   Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022 202X.2004.22322.x
   Tauer JT, 2019, J BONE MINER RES, V34, P207, DOI 10.1002/jbmr.3617
   Van Dijk FS, 2014, AM J MED GENET A, V164, P1470, DOI 10.1002/ajmg.a.36545
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158
   Zhytnik L, 2020, CTS CLIN TRANSL SCI, V13, P960, DOI 10.1111/cts.12783
NR 67
TC 8
Z9 10
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755 8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD NOV 23
PY 2020
VL 13
IS 1
AR 177
DI 10.1186/s12920 020 00825 7
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA PA5MG
UT WOS:000595679000002
PM 33228694
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, C
   Liu, W
   Zhang, XL
   Zeng, BF
   Qian, YB
AF Yang, Chao
   Liu, Wei
   Zhang, Xianlong
   Zeng, Bingfang
   Qian, Yebin
TI Naringin increases osteoprotegerin expression in fibroblasts from
   periprosthetic membrane by the Wnt/β catenin signaling pathway
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Naringin; Osteoprotegerin; Wnt; beta catenin; Fibroblasts; Aseptic
   loosening
ID NF KAPPA B; OSTEOGENIC DIFFERENTIATION; RECEPTOR ACTIVATOR; STEM CELLS;
   BONE LOSS; OSTEOCLAST FORMATION; INDUCED OSTEOLYSIS; INTERFACE TISSUE;
   RANKL/OPG RATIO; GENE THERAPY
AB BackgroundThe osteoclast bone resorption is critical in aseptic loosening after joint replacement. The balance between activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) is considered to play a central role in osteoclast maturation. Fibroblasts from the periprosthetic membrane express RANKL and promote osteoclast formation. Studies have demonstrated that naringin inhibited osteoclastogenesis and wear particle induced osteolysis. In this study, the naringin induced OPG/RANKL effects and its underlying mechanism were studied in fibroblasts from periprosthetic membrane.MethodsFibroblasts were isolated from the periprosthetic membrane during hip arthroplasty for revision due to aseptic loosening. Fibroblasts were cultured and treated with or without naringin and DKK 1 (the classical inhibitor of Wnt/beta  catenin signaling pathway). OPG and RANKL mRNA and protein levels, gene expression of beta  catenin, and cyclin D1, which participate in the Wnt signaling pathway, were examined by real time polymerase chain reaction and enzyme linked immunosorbent assay.ResultsThe mRNA and protein levels of OPG were enhanced by naringin in a dose dependent manner compared to that of the non treated control. In contrast, naringin did not affect the expression of RANKL. Importantly, DKK 1 attenuated OPG expression in fibroblasts under naringin treatment. Moreover, naringin stimulated the gene expression of beta  catenin and cyclin D1 in fibroblasts, and the effect could be inhibited by DKK 1.ConclusionThe results indicated that naringin enhanced OPG expression through Wnt/beta  catenin signaling pathway in fibroblasts from periprosthetic membrane, which may be useful to inhibit periprosthetic osteolysis during aseptic loosening after total joint arthroplasty.
C1 [Yang, Chao; Liu, Wei; Zhang, Xianlong; Zeng, Bingfang; Qian, Yebin] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Qian, YB (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM yebinqian@aliyun.com
FU National Natural Science Foundation of China [81673998]; Scientific
   Research Project of Shanghai Municipal Health Commission [201540151];
   Science and Technology Development Fund of Shanghai Pudong New Area
   [PKJ2015 Y07]; Research Fund of Shanghai sixth people's hospital East
   [2016041]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Number 81673998), Scientific Research Project of Shanghai
   Municipal Health Commission (Grant Number 201540151), Science and
   Technology Development Fund of Shanghai Pudong New Area (Grant Number
   PKJ2015 Y07), and Research Fund of Shanghai sixth people's hospital East
   (Grant Number 2016041).
CR Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   [Anonymous], 2016, EVID BASED COMPL ALT, DOI DOI 10.1155/2016/8981650
   Chen B, 2012, PHYTOMEDICINE, V19, P1029, DOI 10.1016/j.phymed.2012.06.002
   Cheng X, 2016, PHYTOTHER RES, V30, P1680, DOI 10.1002/ptr.5674
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Fan JF, 2015, MOL MED REP, V12, P4759, DOI 10.3892/mmr.2015.3996
   Geng DC, 2015, BIOMATERIALS, V69, P12, DOI 10.1016/j.biomaterials.2015.07.061
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Gu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.275
   Gunn WG, 2011, BLOOD, V117, P1641, DOI 10.1182/blood 2010 09 308171
   Han XW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00103
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Koreny T, 2006, ARTHRITIS RHEUM, V54, P3221, DOI 10.1002/art.22134
   Li NH, 2014, DRUG DES DEV THER, V8, P1, DOI 10.2147/DDDT.S52714
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   Lv JW, 2015, BIOCHEM BIOPH RES CO, V468, P587, DOI 10.1016/j.bbrc.2015.10.152
   Mandelin J, 2005, J BIOMED MATER RES B, V74B, P582, DOI 10.1002/jbm.b.30244
   Mandelin J, 2005, J RHEUMATOL, V32, P713
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Qian YB, 2008, J ARTHROPLASTY, V23, P581, DOI 10.1016/j.arth.2007.06.010
   Qian Y, 2007, J BIOMED MATER RES A, V83A, P401, DOI 10.1002/jbm.a.31318
   Qian YB, 2015, HIP INT, V25, P581, DOI 10.5301/hipint.5000281
   Qian YB, 2013, CONNECT TISSUE RES, V54, P361, DOI 10.3109/03008207.2013.823953
   Qu RZ, 2019, INFLAMMATION, V42, P1652, DOI 10.1007/s10753 019 01026 w
   Ramage SC, 2007, J BONE JOINT SURG AM, V89A, P841, DOI 10.2106/JBJS.F.00655
   Sabokbar A, 2005, J ORTHOP RES, V23, P511, DOI 10.1016/j.orthres.2004.10.006
   Sakai H, 2002, ANN RHEUM DIS, V61, P103, DOI 10.1136/ard.61.2.103
   Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Wang DW, 2015, CELL PHYSIOL BIOCHEM, V36, P1563, DOI 10.1159/000430319
   Wang HC, 2017, IRAN J BASIC MED SCI, V20, P408, DOI 10.22038/IJBMS.2017.8582
   Wang L, 2015, CHEM BIOL INTERACT, V242, P255, DOI 10.1016/j.cbi.2015.10.010
   Wei K, 2017, BIOCHEM BIOPH RES CO, V489, P319, DOI 10.1016/j.bbrc.2017.05.130
   Yu XW, 2013, INT ORTHOP, V37, P137, DOI 10.1007/s00264 012 1668 5
   Zhang LQ, 2016, BBA GEN SUBJECTS, V1860, P2211, DOI 10.1016/j.bbagen.2016.05.003
   Zhao YP, 2016, INFLAMMATION, V39, P385, DOI 10.1007/s10753 015 0260 8
NR 40
TC 11
Z9 13
U1 1
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD DEC 10
PY 2020
VL 15
IS 1
AR 600
DI 10.1186/s13018 020 02145 z
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA PG7WM
UT WOS:000599941300006
PM 33302980
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Podar, K
   Anderson, KC
AF Podar, Klaus
   Anderson, Kenneth C.
TI Inhibition of VEGF signaling pathways in multiple myeloma and other
   malignancies
SO CELL CYCLE
LA English
DT Article
DE VEGF; anti angiogenesis; combination therapy; metronomic therapy
ID BONE MARROW ANGIOGENESIS; ENDOTHELIAL CELLS; BLOOD VESSELS; TUMOR
   ANGIOGENESIS; SOLID TUMORS; CHEMOTHERAPY; THERAPY; GROWTH; BEVACIZUMAB;
   THALIDOMIDE
AB Due to its direct effects on endothelial cells, circulatory endothelial progenitor cells, hematopoietic stem cells, immune cells, osteoclasts, osteoblasts and neurons, vascular endothelial growth factor (VEGF) is linked to tumor cell development, progression, metastatic osteolysis and drug resistance, as well as clinical features such as metastatic osteolysis. Importantly, recent advances in the understanding of mechanisms of action of antiangiogenic drugs/VEGF inhibitors have fundamentally changed treatment regimens in cancer. VEGF plays a key role not only in solid tumors but also in hematologic malignan cies, including multiple myeloma (MM). Despite recent advances in our understanding of MM pathogenesis and novel therapies (bortezomib and lenalidomide), it remains incur able. Our own and others' work suggest that VEGF   inhibitors e. g., the small molecule VEGF receptor inhibitor pazopanib, may also improve patient outcome in MM.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Ctr, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard Medical School
RP Podar, K (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Ctr, 44 Binney St, Boston, MA 02115 USA.
EM klaus_podar@dfci.harvard.edu
RI Podar, Klaus/ABD 1112 2020; Anderson, Kenneth/ACP 5073 2022
OI Podar, Klaus/0000 0002 7414 3632; 
FU NCI NIH HHS [P50 CA100707, R0 CA50947, P0 1 CA78378] Funding Source:
   Medline
CR ACCA A, 1994, BRIT J HAEMATOL, V87, P503
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bertolini F, 2003, CANCER RES, V63, P4342
   Browder T, 2000, CANCER RES, V60, P1878
   Burris HA III, 2005, J CLIN ONCOL, V23, P5305, DOI 10.1200/JCO.2005.16.584
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608
   DVORAK HF, 1988, AM J PATHOL, V133, P95
   Ferris CF, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471 2202 2 10
   Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002 9440(10)64739 6
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398
   Fürstenberger G, 2006, BRIT J CANCER, V94, P524, DOI 10.1038/sj.bjc.6602952
   Gasparini G, 2001, LANCET ONCOL, V2, P733, DOI 10.1016/S1470 2045(01)00587 3
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872
   Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297 177
   Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kamen BA, 2000, J CLIN ONCOL, V18, P2935, DOI 10.1200/JCO.2000.18.16.2935
   Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   Kerbel RS, 2002, ANN ONCOL, V13, P12, DOI 10.1093/annonc/mdf093
   Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033
   Kirchmair R, 2005, CIRCULATION, V111, P2662, DOI 10.1161/CIRCULATIONAHA.104.470849
   KUMAR R, 2005, J CLIN ONCOL, V23, P9537
   Kumar S, 2004, LEUKEMIA, V18, P624, DOI 10.1038/sj.leu.2403285
   Marx J, 2005, SCIENCE, V308, P1248, DOI 10.1126/science.308.5726.1248
   Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002 9440(10)64920 6
   Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415
   Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093
   Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood 2004 07 2909
   Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103
   Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925
   Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774
   Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336
   Ribatti D, 1999, BRIT J CANCER, V79, P451, DOI 10.1038/sj.bjc.6690070
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Sorbera LA, 2006, DRUG FUTURE, V31, P585, DOI 10.1358/dof.2006.031.07.1012785
   Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153
   Streubel B., 2005, HAEMATOLOGICA, V90, P54
   Vacca A, 1999, BLOOD, V93, P3064
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood 2004 06 2101
NR 48
TC 50
Z9 54
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PD MAR 1
PY 2007
VL 6
IS 5
BP 538
EP 542
DI 10.4161/cc.6.5.3922
PG 5
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 154GW
UT WOS:000245495900008
PM 17351339
OA Bronze
DA 2025 08 17
ER

PT J
AU Mei, LW
   Zheng, Y
   Ma, T
   Xia, B
   Gao, X
   Hao, YM
   Luo, ZJ
   Huang, JH
AF Mei, Liangwei
   Zheng, Yi
   Ma, Teng
   Xia, Bing
   Gao, Xue
   Hao, Yiming
   Luo, Zhuojing
   Huang, Jinghui
TI The Novel Antioxidant Compound JSH 23 Prevents Osteolysis by Scavenging
   ROS During Both Osteoclastogenesis and Osteoblastogenesis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE JSH 23 (PubChem CID; 16760588); osteoclast (OC); osteoblast (OB);
   ROS reactive oxygen species; Nrf2; HO 1 (heme oxygenase 1)
ID NF KAPPA B; INFLAMMATORY BONE DESTRUCTION; HEME OXYGENASE 1; OXIDATIVE
   STRESS; DIFFERENTIATION; NRF2; EXPRESSION; NFATC1; TRANSLOCATION;
   OSTEOPOROSIS
AB Inflammatory osteolysis is a pathological skeletal disease associated with not only the production of inflammatory cytokines but also local oxidative status. Excessive reactive oxygen species (ROS) promote bone resorption by osteoclasts and induce the apoptosis of osteoblasts. In consideration of the lack of effective preventive or treatments options against osteolysis, the exploitation of novel pharmacological compounds/agents is critically required. In our study, we found that a novel antioxidant compound, JSH 23, plays a role in restoring bone homeostasis by scavenging intracellular ROS during both osteoclastogenesis and osteoblastogenesis. Mechanically, JSH 23 suppressed RANKL induced osteoclastogenesis, bone resorption and the expression of specific genes (including NFATc1, c Fos, TRAP, CTSK and DC STAMP) via inhibition of the NF kappa B signaling pathway. Meanwhile, JSH 23 suppressed RANKL induced ROS generation via the TRAF6/Rac1/NOX1 pathway and the enhanced expression of Nrf2/HO 1. In addition, JSH 23 attenuated H2O2 induced apoptosis and mineralization reduction in osteoblasts by reducing ROS production and enhancing Nrf2/HO 1 expression. Our in vivo results further revealed that JSH 23 exerts its protective effects on bone mass through its antioxidant activity. In conclusion, our results show that the application of JSH 23 might be a novel and plausible strategy for the treatment of osteolysis related disease.</p>
C1 [Mei, Liangwei; Zheng, Yi; Ma, Teng; Xia, Bing; Hao, Yiming; Luo, Zhuojing; Huang, Jinghui] Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed, Xian, Peoples R China.
   [Gao, Xue] Northwest Univ, Fac Life Sci, Xian, Peoples R China.
C3 Air Force Medical University; Northwest University Xi'an
RP Luo, ZJ; Huang, JH (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed, Xian, Peoples R China.
EM zhuojingl@163.com; huangh@fmmu.edu.cn
RI Hao, Yiming/LRB 5108 2024
FU National Natural Science Foundation of China [81972052, 81801216,
   81802143, 81672148]; National Key Research and Development Plan
   [2016YFC1101700]; National Basic Research Program of China (973 Program)
   [2014CB542206]; Program for Changjiang Scholar and Innovative Research
   Team in University [IRT1053, IRT13051]; China Postdoctoral Science
   Foundation [2019M653967]; A Foundation for the Author of National
   Excellent Doctoral Dissertation of PR China [201480]; Academy of Finland
   (AKA) [201480] Funding Source: Academy of Finland (AKA)
FX This work was supported by grants from the National Natural Science
   Foundation of China (81972052, 81801216, 81802143 and 81672148), the
   National Key Research and Development Plan (2016YFC1101700), the
   National Basic Research Program of China (973 Program No. 2014CB542206),
   the Program for Changjiang Scholar and Innovative Research Team in
   University (IRT1053 and IRT13051), the China Postdoctoral Science
   Foundation (2019M653967), and A Foundation for the Author of National
   Excellent Doctoral Dissertation of PR China (201480).
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Abuohashish HM, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758 5996 5 5
   AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   Arias Salvatierra D, 2011, CELL SIGNAL, V23, P425, DOI 10.1016/j.cellsig.2010.10.017
   Ashtar M, 2020, CANCERS, V12, DOI 10.3390/cancers12040929
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Bodega G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1626654
   Boutet MA, 2017, ANN RHEUM DIS, V76, P1300, DOI 10.1136/annrheumdis 2016 210630
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   El Benna J, 2016, IMMUNOL REV, V273, P180, DOI 10.1111/imr.12447
   Fumimoto R, 2012, J PHARMACOL SCI, V118, P479, DOI 10.1254/jphs.11212FP
   Guo Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09943 2
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Hedvicakova V, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030438
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Horcajada Marie Noelle, 2012, Curr Mol Pharmacol, V5, P205
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jin WQ, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109676
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim JH, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.33
   Kim KJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115493
   Kitazawa R, 2021, BIOCHEM BIOPH RES CO, V572, P86, DOI 10.1016/j.bbrc.2021.07.100
   Kleszczynski K, 2016, J PINEAL RES, V61, P187, DOI 10.1111/jpi.12338
   Kotian P, 2016, J CLIN DIAGN RES, V10, pOC4, DOI 10.7860/JCDR/2016/17061.7021
   Kozakowska M, 2014, ANTIOXID REDOX SIGN, V20, P1827, DOI 10.1089/ars.2013.5341
   Kumar A, 2011, DIABETES OBES METAB, V13, P750, DOI 10.1111/j.1463 1326.2011.01402.x
   Lin CC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00447
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Mao XB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215249
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Park CK, 2014, BONE, V63, P36, DOI 10.1016/j.bone.2014.01.025
   Park JH, 2017, MOL CELLS, V40, P706
   Patel V, 2018, BRIT DENT J, V224, P74, DOI 10.1038/sj.bdj.2017.1039
   Ren LR, 2017, MED SCI MONITOR, V23, P4579, DOI 10.12659/MSM.903371
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Shin JM, 2017, AM J RHINOL ALLERGY, V31, P78, DOI 10.2500/ajra.2017.31.4415
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Sun X, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568 020 01098 0
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Wang LL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657687
   Wang Q, 2018, PHARMACOL BIOCHEM BE, V169, P59, DOI 10.1016/j.pbb.2018.04.005
   Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720
   Xu YE, 2019, LIFE SCI, V224, P58, DOI 10.1016/j.lfs.2019.03.051
   Zeng XZ, 2020, ACTA PHARMACOL SIN, V41, P229, DOI 10.1038/s41401 019 0289 6
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang M, 2002, CELL RES, V12, P123, DOI 10.1038/sj.cr.7290118
   Zhou SY, 2020, EUR J MED CHEM, V197, DOI 10.1016/j.ejmech.2020.112313
NR 58
TC 7
Z9 9
U1 0
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 9
PY 2021
VL 12
AR 734774
DI 10.3389/fphar.2021.734774
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UU0IK
UT WOS:000698489000001
PM 34566656
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Meng, JH
   Zhang, WK
   Wang, C
   Zhang, W
   Zhou, CH
   Jiang, GY
   Hong, JQ
   Yan, SG
   Yan, WQ
AF Meng, Jiahong
   Zhang, Wenkan
   Wang, Cong
   Zhang, Wei
   Zhou, Chenhe
   Jiang, Guangyao
   Hong, Jianqiao
   Yan, Shigui
   Yan, Weiqi
TI Catalpol suppresses osteoclastogenesis and attenuates osteoclast derived
   bone resorption by modulating PTEN activity
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Catalpol; Osteoclast; NFATc1; PTEN; Inflammation; Osteoporosis
ID B LIGAND RANKL; RECEPTOR ACTIVATOR; DIFFERENTIATION; OSTEOPOROSIS;
   PHOSPHATASE; INHIBITION; KINASE; INJURY; CELLS
AB Excessive activation of osteoclast activity is responsible for many bone diseases, such as osteoporosis, rheumatoid arthritis, periprosthetic osteolysis, and periodontitis. Natural compounds that inhibit osteoclast formation and/or function have therapeutic potential for treating these diseases. Catalpol, a bioactive iridoid extracted from a traditional herbal medicine Rehmannia glutinosa, exhibits various pharmacological properties, including anti inflammatory, antioxidant, antidiabetic, and antitumor effects. However, its effects on osteoclast formation and function remain unknown. In the present study, we showed that catalpol inhibited receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclast formation and bone resorption, as well as the expression of osteoclast related marker genes. The investigation of molecular mechanisms showed that catalpol upregulated phosphatase and tensin homolog (PTEN) activity by reducing its ubiquitination and degradation, subsequently suppressing RANKL induced NF kappa B and AKT signaling pathways, leading to an inhibition on NFATc1 induction. Furthermore, catalpol protected mice against inflammation  and ovariectomy induced bone loss by inhibiting osteoclast activity in vivo. These results suggest that catalpol might be developed as a promising candidate for treating osteoclast related bone diseases.
C1 [Meng, Jiahong; Zhang, Wenkan; Wang, Cong; Zhou, Chenhe; Jiang, Guangyao; Hong, Jianqiao; Yan, Shigui; Yan, Weiqi] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
   [Meng, Jiahong; Zhang, Wenkan; Wang, Cong; Zhou, Chenhe; Jiang, Guangyao; Hong, Jianqiao; Yan, Shigui; Yan, Weiqi] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Peoples R China.
   [Zhang, Wei] Zhejiang Univ, Affiliated Hosp 2, Dept Burns, Sch Med, Hangzhou, Peoples R China.
   [Zhang, Wei] Zhejiang Univ, Affiliated Hosp 2, Wound Care Ctr, Sch Med, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   University
RP Yan, SG; Yan, WQ (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
EM zrjwsj@zju.edu.cn; wyan@zju.edu.cn
RI Zhou, Chenhe/AAI 9226 2020
OI Yan, Shigui/0000 0001 9096 2868
FU National Natural Science Foundation of China [81772360, 31771106]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81772360 and No. 31771106).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bai Y., 2019, MOLECULES, V24
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Blüml S, 2015, ANN RHEUM DIS, V74, P227, DOI 10.1136/annrheumdis 2013 203486
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Choi YH, 2019, GEN PHYSIOL BIOPHYS, V38, P111, DOI 10.4149/gpb 2018044
   Davis Beckley K, 2013, Methods Mol Biol, V1031, P27, DOI 10.1007/978 1 62703 481 4_3
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Fu K, 2014, INT IMMUNOPHARMACOL, V23, P400, DOI 10.1016/j.intimp.2014.07.011
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359 6446(04)03265 9
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Jin D, 2015, CELL BIOCHEM BIOPHYS, V71, P1349, DOI 10.1007/s12013 014 0355 0
   Khalifeh Soltani A., 2018, FASEB J
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai NN, 2015, AM J REPROD IMMUNOL, V74, P487, DOI 10.1111/aji.12423
   Leslie NR, 2016, BIOCHEM SOC T, V44, P273, DOI 10.1042/BST20150224
   Li N, 2015, GENE DEV, V29, P157, DOI 10.1101/gad.251785.114
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu L, 2017, ONCOL LETT, V14, P3741, DOI 10.3892/ol.2017.6580
   Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200
   McHorney CA, 2007, CURR MED RES OPIN, V23, P3137, DOI 10.1185/030079907X242890
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200
   Park K.S., 2016, J NAT
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Tian YQ, 2019, AGING CELL, V18, DOI 10.1111/acel.12858
   Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200
   Tsugawa K, 2003, FASEB J, V17, P2316, DOI 10.1096/fj.02 1107fje
   Wang X., 2007, CELL, V128
   Yamada KM, 2001, J CELL SCI, V114, P2375
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yan JT, 2018, PHARMACOL RES, V130, P466, DOI 10.1016/j.phrs.2017.12.026
   Zaidi AH, 2016, BIOCHEM J, V473, P859, DOI 10.1042/BJ20150624
   Zhang N.D., 2016, J ETHNOPHARMACOL
   Zhu HF, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0096 7
   Zhu Y., 2019, STEM CELL RES THER, V10
NR 47
TC 58
Z9 69
U1 3
U2 42
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JAN
PY 2020
VL 171
AR 113715
DI 10.1016/j.bcp.2019.113715
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KT7UR
UT WOS:000519219000021
PM 31751538
DA 2025 08 17
ER

PT J
AU Kushchayeva, Y
   Kushchayev, S
   Dunn, K
   Pestun, I
   Rothman, MS
   Lewiecki, EM
AF Kushchayeva, Yevgeniya
   Kushchayev, Sergiy
   Dunn, Kimberly
   Pestun, Iryna
   Rothman, Micol S.
   Lewiecki, E. Michael
TI Bone Health ECHO Case Report: Significant Elevation in Bone Turnover
   Markers and Progression of Vertebral Fractures After Denosumab
   Discontinuation Followed by a PTH Analog
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Osteoporosis; ECHO; Rebound activation of resorption; Vertebral
   fractures; Denosumab discontinuation; PTH analogs; Bone turnover markers
ID POSTMENOPAUSAL WOMEN; TERIPARATIDE TREATMENT; PARATHYROID HORMONE;
   MINERAL DENSITY; OSTEOPOROSIS; THERAPY; ABALOPARATIDE; PLACEBO; MASS;
   BMD
AB Bone Health ECHO (Extension for Community Healthcare Outcomes) is a virtual community of practice, where healthcare professionals have met via videoconferencing weekly since 2015. This model of learning is focused on short didactics and the presentation of real but de identified patient cases followed by highly interactive discussions. These are often clinical situations with diagnostic and therapeutic dilemmas that are not readily addressed by randomized placebo controlled clinical trials and clinical practice guidelines. Here we present the case of a woman with postmenopausal osteoporosis with adverse consequences following discontinuation of denosumab and uncertainties on next steps for management. This case highlights the relevance of selection of the initial bone targeted medication and the sequence of therapy in osteoporosis management.
C1 [Kushchayeva, Yevgeniya; Dunn, Kimberly; Pestun, Iryna] Univ S Florida, Diabet & Endocrinol Ctr, Tampa, FL 33620 USA.
   [Kushchayev, Sergiy] Jefferson Radiol, Hartford, CT USA.
   [Rothman, Micol S.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
   [Lewiecki, E. Michael] New Mex Clin Res & Osteoporosis Ctr, Albuquerque, NM USA.
C3 State University System of Florida; University of South Florida;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Kushchayeva, Y (通讯作者)，Univ S Florida, Diabet & Endocrinol Ctr, Tampa, FL 33620 USA.
EM kushchayevay@usf.edu
RI ; Lewiecki, E./B 3706 2018
OI Rothman, Micol/0000 0002 4577 6801; Lewiecki, E.
   Michael/0000 0003 2026 9587; 
CR Anagnostis P, 2021, JCR J CLIN RHEUMATOL, V27, pS581, DOI 10.1097/RHU.0000000000000979
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Eastell R, 2019, OSTEOPOROSIS INT, V30, P667, DOI 10.1007/s00198 018 04819 1
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI 10.1359/JBMR.081215
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Glover SJ, 2009, BONE, V45, P1053, DOI 10.1016/j.bone.2009.07.091
   Guelman R, 2023, INT J ENDOCRINOL, V2023, DOI 10.1155/2023/9355672
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lewiecki EM, 2023, J CLIN DENSITOM, V26, DOI 10.1016/j.jocd.2023.101432
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Maezumi Y, 2020, MOD RHEUMATOL CASE, V4, P218, DOI 10.1080/24725625.2019.1702494
   McClung MR, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10512
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Qi HR, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923713
   Shiraki M, 2013, OSTEOPOROSIS INT, V24, P219, DOI 10.1007/s00198 012 2159 7
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tsourdi E, 2021, J CLIN ENDOCR METAB, V106, P264, DOI 10.1210/clinem/dgaa756
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2025
VL 28
IS 1
AR 101551
DI 10.1016/j.jocd.2024.101551
EA DEC 2024
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA U7E1E
UT WOS:001413370400001
PM 39731882
OA hybrid
DA 2025 08 17
ER

PT J
AU Choi, YH
   Han, Y
   Jin, SW
   Lee, GH
   Kim, GS
   Lee, DY
   Chung, YC
   Lee, KY
   Jeong, HG
AF Choi, You Hee
   Han, Younho
   Jin, Sun Woo
   Lee, Gi Ho
   Kim, Geum Soog
   Lee, Dae Young
   Chung, Young Chul
   Lee, Kwang Youl
   Jeong, Hye Gwang
TI Pseudoshikonin I enhances osteoblast differentiation by stimulating
   Runx2 and Osterix
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE osteoblast differentiation; osterix; pseudoshikonin I; Runx2
ID TRANSCRIPTION FACTOR OSTERIX; BONE MORPHOGENETIC PROTEINS; CHINESE
   HERBAL MEDICINE; GENE EXPRESSION; OSTEOGENIC ACTIVITY; SHIKONIN;
   PHOSPHORYLATION; PATHWAY; CELLS; VITRO
AB Pseudoshikonin I (PSI), a novel biomaterial isolated from Lithospermi radix, has been recognized as an herbal medicine for the treatment of infectious and inflammatory diseases. Bone remodeling maintains a balance through bone resorption (osteoclastogenesis) and bone formation (osteoblastogenesis). Bone formation is generally attributed to osteoblasts. However, the effects of PSI on the bone are not well known. In this study, we found that the ethanol extracts of PSI induced osteoblast differentiation by increasing the expression of bone morphogenic protein 4 (BMP 4). PSI positively regulates the transcriptional expression and osteogenic activity of osteoblast specific transcription factors such as Runx2 and Osterix. To identify the signaling pathways that mediate PSI induced osteoblastogenesis, we examined the effects of serine threonine kinase inhibitors that are known regulators of Osterix and Runx2. PSI induced upregulation of Osterix and Runx2 was suppressed by treatment with AKT and PKA inhibitors. These results suggest that PSI enhances osteoblast differentiation by stimulating Osterix and Runx2 via the AKT and PKA signaling pathways. Thus, the activation of Runx2 and Osterix is modulated by PSI, thereby demonstrating its potential as a treatment target for bone disease.
   PSI enhances osteoblast differentiation by influencing transcript and protein levels of the osteoblast transcription factors Osterix and Runx2. PSI regulates Runx2 and Osterix expression through PKA and AKT signaling in osteoblast differentiation.
C1 [Choi, You Hee; Han, Younho; Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, Gwangju 500757, South Korea.
   [Han, Younho] Wonkwang Univ, Dept Oral Pharmacol, Coll Dent, Iksan, South Korea.
   [Jin, Sun Woo; Lee, Gi Ho; Jeong, Hye Gwang] Chungnam Natl Univ, Coll Pharm, 220 Gung Dong, Daejeon 305764, South Korea.
   [Kim, Geum Soog; Lee, Dae Young] RDA, Natl Inst Hort & Herbal Sci, Dept Herbal Crop Res, Eumseong, South Korea.
   [Chung, Young Chul] Int Univ Korea, Dept Food Sci, Jinju, South Korea.
C3 Chonnam National University; Wonkwang University; Chungnam National
   University; National Institute of Horticultural & Herbal Science
   (NIHHS), Republic of Korea; Rural Development Administration (RDA),
   Republic of Korea; International University Korea
RP Lee, KY (通讯作者)，Chonnam Natl Univ, Coll Pharm, Gwangju 500757, South Korea.; Jeong, HG (通讯作者)，Chungnam Natl Univ, Coll Pharm, 220 Gung Dong, Daejeon 305764, South Korea.
EM kwanglee@jnu.ac.kr; hgjeong@cnu.ac.kr
RI Kim, Jang Hoon/ABU 7953 2022; jin, sun/HZL 7002 2023; Lee, Dae
   Young/ADO 9686 2022
OI Lee, Dae Young/0000 0003 4302 3096; Jeong, Hye
   Gwang/0000 0002 8020 8914; 
FU Technology Commercialization Support Program; Ministry of Agriculture,
   Food and Rural Affairs (MAFRA) [816009 2]; Next Generation Bio Green 21
   Project; Rural Development Administration; Republic of Korea
   [PJ01122301]
FX Technology Commercialization Support Program; Ministry of Agriculture,
   Food and Rural Affairs (MAFRA), Grant number: 816009 2; Next Generation
   Bio Green 21 Project; Rural Development Administration, Grant number:
   PJ01122301; Republic of Korea
CR Blum B, 2004, ORTHOPEDICS, V27, pS161
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Chen HM, 2012, CANCER IMMUNOL IMMUN, V61, P1989, DOI 10.1007/s00262 012 1258 9
   Chen X, 2003, ANTIMICROB AGENTS CH, V47, P2810, DOI 10.1128/AAC.47.9.2810 2816.2003
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Choi YH, 2016, INT J MOL MED, V38, P610, DOI 10.3892/ijmm.2016.2655
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Choi YH, 2011, BIOCHEM BIOPH RES CO, V411, P637, DOI 10.1016/j.bbrc.2011.07.009
   Dai QM, 2009, MOL BIOL REP, V36, P1597, DOI 10.1007/s11033 008 9356 7
   Fang T, 2016, MOL MED REP, V14, P1269, DOI 10.3892/mmr.2016.5363
   Feng L, 2009, CHROMATOGRAPHIA, V70, P1197, DOI 10.1365/s10337 009 1283 9
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Fu HH, 2007, J BIOMED MATER RES A, V83A, P770, DOI 10.1002/jbm.a.31356
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gao H, 2011, BIOL PHARM BULL, V34, P197, DOI 10.1248/bpb.34.197
   Gwon SY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 207
   He S, 2014, J CELL BIOCHEM, V115, P1808, DOI 10.1002/jcb.24851
   JIN R, 1994, YAKUGAKU ZASSHI, V114, P533, DOI 10.1248/yakushi1947.114.7_533
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   Kim YO, 2010, KOREAN J PHYSIOL PHA, V14, P199, DOI 10.4196/kjpp.2010.14.4.199
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee DY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081350
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Mandal CC, 2010, CALCIFIED TISSUE INT, V87, P533, DOI 10.1007/s00223 010 9419 3
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Ohba Shinsuke, 2007, Nihon Rinsho, V65 Suppl 9, P71
   Reid IR, 2013, EUR J INTERN MED, V24, P691, DOI 10.1016/j.ejim.2013.03.012
   Shiflett S, 1997, Md Med J, V46, P303
   Sitzman Kathy, 2004, AAOHN J, V52, P312
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tandon M, 2014, J CELL BIOCHEM, V115, P2208, DOI 10.1002/jcb.24939
   Tucker KL, 1999, AM J CLIN NUTR, V69, P727
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Youn YN, 2008, GENES NUTR, V2, P375, DOI 10.1007/s12263 007 0062 1
   Zhu FC, 2012, J CELL PHYSIOL, V227, P2677, DOI 10.1002/jcp.23010
NR 44
TC 20
Z9 22
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2018
VL 119
IS 1
BP 748
EP 757
DI 10.1002/jcb.26238
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FN5CO
UT WOS:000416024300074
PM 28657691
DA 2025 08 17
ER

PT J
AU Shen, GY
   Liu, X
   Lei, W
   Duan, R
   Yao, ZQ
AF Shen, Gengyang
   Liu, Xin
   Lei, Wei
   Duan, Rong
   Yao, Zhenqiang
TI Plumbagin is a NF κB inducing kinase inhibitor with dual anabolic and
   antiresorptive effects that prevents menopausal related osteoporosis in
   mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE TURNOVER MARKERS; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST
   DIFFERENTIATION; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; CANCELLOUS
   BONE; CELL GROWTH; IN VIVO; NIK; ACTIVATION
AB Osteoporosis is caused by enhanced bone resorption and relatively reduced bone formation. There is an unmet need to develop new agents with both antiresorptive and anabolic effects to treat osteoporosis, although drugs with either effect alone are available. A small molecular compound, plumbagin, was reported to inhibit receptor activator of nuclear factor kappa B ligand induced osteoclast (OC) differentiation by inhibiting I kappa Ba phosphorylation mediated canonical NF kappa B activation. However, the key transcriptional factor RelA/p65 in canonical NF  kappa B pathway functions to promote OC precursor survival but not terminal OC differentiation. Here, we found that plumbagin inhibited the activity of NF  kappa B inducing kinase, the key molecule that controls noncanonical NF  kappa B signaling, in an ATP/ ADP based kinase assay. Consistent with this, plumbagin inhibited processing of NF kappa B2 p100 to p52 in the progenitor cells of both OCs and osteoblasts (OBs). Interestingly, plumbagin not only inhibited OC but also stimulated OB differentiation in vitro. Importantly, plumbagin prevented trabecular bone loss in ovariectomized mice. This was associated with decreased OC surfaces on trabecular surface and increased parameters of OBs, including OB surface on trabecular surface, bone formation rate, and level of serum osteocalcin, compared to vehicle treated mice. In summary, we conclude that plumbagin is a NF  kappa B inducing kinase inhibitor with dual anabolic and antiresorptive effects on bone and could represent a new class of agent for the prevention and treatment of osteoporosis.
C1 [Yao, Zhenqiang] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Yao, ZQ (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
EM zhenqiang_yao@urmc.rochester.edu
OI Shen, Gengyang/0000 0001 8940 7912; Yao, Zhenqiang/0000 0002 4664 3648
FU Core Services at Center for Musculoskeletal Research [NIH/NIAMS P30
   AR069655]; National Institutes of Health [R01 AG049994]; New York State
   Department of Health Research Project [C34928GG]
FX We sincerely thank the Core Services at Center for Musculoskeletal
   Research (NIH/NIAMS P30 AR069655) and Lindsay Schnur for the support in
   micro CT imaging and analysis. This study was funded by the National
   Institutes of Health grant R01 AG049994 and New York State Department of
   Health Research Project #C34928GG.
CR Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Aspenberg P, 2014, ACTA ORTHOP, V85, P1, DOI 10.3109/17453674.2013.859423
   Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brightbill HD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02672 0
   Canbek U, 2019, J ORTHOP SURG HONG K, V27, DOI 10.1177/2309499019875262
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Cheng J, 2021, RSC MED CHEM, V12, P552, DOI 10.1039/d0md00361a
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Davis JL, 2019, J BONE MINER RES, V34, P2087, DOI 10.1002/jbmr.3819
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Heim N, 2019, DENTOMAXILLOFAC RAD, V48, DOI 10.1259/dmfr.20190132
   Henriksen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027482
   Hodge JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021462
   Iwaniec UT, 2006, J BONE MINER RES, V21, P1068, DOI 10.1359/JBMR.060402
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Leder BZ, 2017, BONE, V98, P54, DOI 10.1016/j.bone.2017.03.006
   Lei W, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64018 z
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Li ZQ, 2020, J MED CHEM, V63, P4388, DOI 10.1021/acs.jmedchem.0c00396
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706
   MacKenzie SA, 2019, BONE JOINT J, V101B, P1285, DOI 10.1302/0301 620X.101B10.BJJ 2019 0599.R2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mortier J, 2010, BIOORG MED CHEM LETT, V20, P4515, DOI 10.1016/j.bmcl.2010.06.027
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Odqvist L, 2013, CLIN CANCER RES, V19, P2319, DOI 10.1158/1078 0432.CCR 12 3151
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200
   Ramadass V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145164
   Ren XM, 2017, FASEB J, V31, P711, DOI 10.1096/fj.201600840R
   Seo Y, 2012, MOL ENDOCRINOL, V26, P414, DOI 10.1210/me.2011 1241
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, DOI DOI 10.1210/CLINEM/DGAA048
   Sleeman A, 2019, AM J HEALTH SYST PH, V76, P130, DOI 10.1093/ajhp/zxy022
   Solling ASK, 2019, DRUG AGING, V36, P625, DOI 10.1007/s40266 019 00675 8
   Soysa NS, 2010, J BONE MINER RES, V25, P809, DOI 10.1359/jbmr.091030
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177
   Sung B, 2012, MOL CANCER THER, V11, P350, DOI 10.1158/1535 7163.MCT 11 0731
   Takakura N, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115316
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yao ZQ, 2021, METHODS MOL BIOL, V2230, P457, DOI 10.1007/978 1 0716 1028 2_29
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yi XJ, 2021, J BONE MINER RES, V36, P2426, DOI 10.1002/jbmr.4447
   Yoshida CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032364
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
NR 79
TC 15
Z9 16
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR
PY 2022
VL 298
IS 4
AR 101767
DI 10.1016/j.jbc.2022.101767
EA MAR 2022
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 1D3GT
UT WOS:000793692600008
PM 35235833
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Beier, EE
   Sheu, TJ
   Buckley, T
   Yukata, K
   O'Keefe, R
   Zuscik, MJ
   Puzas, JE
AF Beier, Eric E.
   Sheu, Tzong jen
   Buckley, Taylor
   Yukata, Kiminori
   O'Keefe, Regis
   Zuscik, Michael J.
   Puzas, J. Edward
TI Inhibition of Beta Catenin Signaling by Pb Leads to Incomplete Fracture
   Healing
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE fracture repair; Pb; mesenchymal stem cells; Wnt signaling; sclerostin
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL HEALTH; BONE REGENERATION;
   CHONDROGENESIS; CARTILAGE; EXPOSURE; GROWTH; CHONDROCYTES; OSTEOBLAST;
   PHENOTYPE
AB There is strong evidence in the clinical literature to suggest that elevated lead (Pb) exposure impairs fracture healing. Since Pb has been demonstrated to inhibit bone formation, and Wnt signaling is an important anabolic pathway in chondrocyte maturation and endochondral ossification, we investigated the impact of Wnt therapy on Pb exposed mice undergoing bone repair in a mouse tibial fracture model. We established that tibial fracture calluses from Pb treated mice were smaller and contained less mineralized tissue than vehicle controls. This resulted in the persistence of immature cartilage in the callus and decreased  catenin levels. Reduction of  catenin protein was concurrent with systemic elevation of LRP5/6 antagonists DKK1 and sclerostin in Pb exposed mice throughout fracture healing.  catenin stimulation by the GSK3 inhibitor BIO reversed these molecular changes and restored the amount of mineralized callus. Overall, Pb is identified as a potent inhibitor of endochondral ossification in vivo with correlated effects on bone healing with noted deficits in  catenin signaling, suggesting the Wnt/ catenin as a pivotal pathway in the influence of Pb on fracture repair. (c) 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:1397 1405, 2014.
C1 [Beier, Eric E.; Sheu, Tzong jen; Buckley, Taylor; Yukata, Kiminori; O'Keefe, Regis; Zuscik, Michael J.; Puzas, J. Edward] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Beier, Eric E.; Puzas, J. Edward] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Puzas, JE (通讯作者)，Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
EM edward_puzas@urmc.rochester.edu
RI Kiminori, Yukata/S 1331 2019
OI Zuscik, Michael/0000 0003 0461 8708
FU Public Health Service [NIH T32 ES07026, R01 ES012712, T32 AR053459, P01
   ES011854, P30 ES301247]
FX Grant sponsor: Public Health Service; Grant numbers: NIH T32 ES07026,
   R01 ES012712, T32 AR053459, P01 ES011854, P30 ES301247.
CR Abbas S, 2013, TOXICOL SCI, V134, P207, DOI 10.1093/toxsci/kft093
   Ballew C, 1999, J PEDIATR US, V134, P623, DOI 10.1016/S0022 3476(99)70250 7
   Beier EE, 2013, ENVIRON HEALTH PERSP, V121, P97, DOI 10.1289/ehp.1205374
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Campbell JR, 2007, ENVIRON HEALTH PERSP, V115, P1018, DOI 10.1289/ehp.9716
   Carmouche JJ, 2005, ENVIRON HEALTH PERSP, V113, P749, DOI 10.1289/ehp.7596
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Dowd TL, 2001, BBA MOL BASIS DIS, V1535, P153, DOI 10.1016/S0925 4439(00)00094 6
   Duckworth AD, 2011, J BONE JOINT SURG BR, V93B, P811, DOI 10.1302/0301 620X.93B6.26432
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Fuhrmann S, 2009, INVEST OPHTH VIS SCI, V50, P432, DOI 10.1167/iovs.08 2270
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hoffman MD, 2011, NORTHEAST BIOENGIN C, DOI 10.1109/NEBC.2011.5778684
   Holz JD, 2012, J ORTHOP RES, V30, P1760, DOI 10.1002/jor.22117
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khalil N, 2008, J BONE MINER RES, V23, P1417, DOI 10.1359/JBMR.080404
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Kung MH, 2012, J CELL PHYSIOL, V227, P1062, DOI 10.1002/jcp.22819
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Monir AU, 2010, BONE, V47, P888, DOI 10.1016/j.bone.2010.07.013
   Nash D, 2004, AM J EPIDEMIOL, V160, P901, DOI 10.1093/aje/kwh296
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Pelttari K, 2008, INJURY, V39, pS58, DOI 10.1016/j.injury.2008.01.038
   Wang Q, 2011, BONE, V48, P524, DOI 10.1016/j.bone.2010.10.178
   Wheeler W, 2013, MMWR MORBID MORTAL W, V62, P245
   Yoo JU, 1998, CLIN ORTHOP RELAT R, pS73
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zuscik MJ, 2007, ENVIRON HEALTH PERSP, V115, P1276, DOI 10.1289/ehp.10028
   Zuscik MJ, 2002, J ORTHOPAED RES, V20, P811, DOI 10.1016/S0736 0266(02)00007 4
NR 37
TC 29
Z9 33
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2014
VL 32
IS 11
BP 1397
EP 1405
DI 10.1002/jor.22677
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AQ2QQ
UT WOS:000342633300001
PM 25044211
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Bhattacharyya, S
   Pal, S
   Mohamed, R
   Singh, P
   Chattopadhyay, S
   China, SP
   Porwal, K
   Sanyal, S
   Gayen, JR
   Chattopadhyay, N
AF Bhattacharyya, Sharmistha
   Pal, Subhashis
   Mohamed, Riyazuddin
   Singh, Priya
   Chattopadhyay, Sourav
   China, Shyamsundar Pal
   Porwal, Konica
   Sanyal, Sabyasachi
   Gayen, Jiaur R.
   Chattopadhyay, Naibedya
TI A nutraceutical composition containing diosmin and hesperidin has
   osteogenic and anti resorptive effects and expands the anabolic window
   of teriparatide
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Nutraceutical; Parathyroid hormone; Bone regeneration; Osteoporosis;
   Estrogen receptors; Sclerostin
ID PARATHYROID HORMONE; POSTMENOPAUSAL OSTEOPOROSIS; BONE MASS;
   OSTEOBLASTIC DIFFERENTIATION; VENOUS THROMBOEMBOLISM; RALOXIFENE
   THERAPY; DOUBLE BLIND; ESTROGEN; RECEPTOR; SCLEROSTIN
AB A combination of diosmin and hesperidin (9:1 ratio) is marketed as a dietary supplement/nutraceutical for cardiovascular health. We studied the skeletal effect of this combination (90% diosmin and 10% hesperidin, henceforth named as DH). We showed that a) in rats with femur osteotomy, DH stimulated callus bone regeneration, b) in growing rats, DH promoted peak bone mass achievement and c) in OVX rats rendered osteopenic, DH completely restored femur trabecular bones and strength along with the increases in surface referent bone formation and serum osteogenic marker. Furthermore, DH suppressed bone resorption in OVX rats as well as in OVX rats treated with teriparatide (human parathyroid hormone 1 34) but did not affect the osteoanabolic effect of teriparatide. These data suggested that DH could prolong the anabolic window of teriparatide. To understand the mechanism of DH action, we performed pharmacokinetic studies and observed that upon its oral administration the only circulating metabolites was diosmetin (the aglycone form of diosmin) while none of the two input flavanones were detectable. Accordingly, subsequent experiments with diosmetin revealed that it was a selective estrogen receptor beta agonist that stimulated osteoblast differentiation and suppressed sclerostin the anti osteoblastogenic Wnt antagonist. Taken together, our study defined a positive skeletal effect of DH.
C1 [Bhattacharyya, Sharmistha] CSIR Cent Drug Res Inst, Div Endocrinol, DBT BIOcare, Lucknow 226031, Uttar Pradesh, India.
   [Pal, Subhashis; Singh, Priya; China, Shyamsundar Pal; Porwal, Konica; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Mohamed, Riyazuddin; Gayen, Jiaur R.] CDRI CSIR, Div Pharmaceut, Lucknow 226031, Uttar Pradesh, India.
   [Chattopadhyay, Sourav; Sanyal, Sabyasachi] CSIR CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Pal, Subhashis/IXD 3635 2023; Pal China, Shyamsundar/AAB 8041 2019;
   Chattopadhyay, Naibedya/AAF 2058 2019; Chattopadhyay,
   Sourav/GQY 9508 2022; Sanyal, Sabyasachi/E 8034 2010
OI Pal China, Shyamsundar/0000 0003 0062 3593; Porwal,
   Konica/0000 0002 6447 4681; Chattopadhyay, Sourav/0000 0003 0055 5818;
   Pal, Subhashis/0000 0002 3916 5545; Gayen, Jiaur/0000 0001 7703 9307;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; Sanyal,
   Sabyasachi/0000 0002 8603 3828
FU Nutraceutical Mission Project of Council of Scientific and Industrial
   Research, Government of India
FX The authors are thankful for the technical assistance provided by Dr.
   Kavita Singh at the confocal facility of the Electron Microscopy Unit,
   Sophisticated Analytical Instrument Facility. N.C. acknowledges research
   funding from the Nutraceutical Mission Project of Council of Scientific
   and Industrial Research, Government of India. Communication number of
   this paper issued by CSIR CDRI is 9857.
CR Adomaityte J, 2008, THROMB HAEMOSTASIS, V99, P338, DOI 10.1160/TH07 07 0468
   Amugongo SK, 2014, BONE, V67, P257, DOI 10.1016/j.bone.2014.04.033
   Balakathiresan NS, 2009, AM J PHYSIOL LUNG C, V296, pL1012, DOI 10.1152/ajplung.90601.2008
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bergan JJ, 2005, ANGIOLOGY, V56, pS21, DOI 10.1177/00033197050560i104
   Bhattacharyya S, 2018, EUR J PHARMACOL, V826, P39, DOI 10.1016/j.ejphar.2018.02.028
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Chiba H, 2003, J NUTR, V133, P1892, DOI 10.1093/jn/133.6.1892
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Covaleda AMS, 2008, TOXICOL SCI, V105, P303, DOI 10.1093/toxsci/kfn141
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Deyhim F, 2007, NUTRITION, V23, P617, DOI 10.1016/j.nut.2007.04.009
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Grady D, 2004, OBSTET GYNECOL, V104, P837, DOI 10.1097/01.AOG.0000137349.79204.b8
   Guilhou JJ, 1997, ANGIOLOGY, V48, P77, DOI 10.1177/000331979704800113
   Horcajada MN, 2008, J APPL PHYSIOL, V104, P648, DOI 10.1152/japplphysiol.00441.2007
   Hsu YL, 2008, J BONE MINER RES, V23, P949, DOI 10.1359/JBMR.080219
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Langdahl Bente Lomholt, 2018, J Bone Metab, V25, P133, DOI 10.11005/jbm.2018.25.3.133
   Lecomte S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071381
   Li W, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001156
   LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162
   Maizels ET, 1996, MOL CELL ENDOCRINOL, V122, P213, DOI 10.1016/0303 7207(96)03885 3
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Nicolaides AN, 2003, ANGIOLOGY, V54, pS33, DOI 10.1177/0003319703054001S05
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Pan W, 2005, J CELL BIOCHEM, V94, P307, DOI 10.1002/jcb.20308
   Quaedackers ME, 2001, ENDOCRINOLOGY, V142, P1156, DOI 10.1210/en.142.3.1156
   Ramchand SK, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00505
   Roforth MM, 2014, BONE, V59, P1, DOI 10.1016/j.bone.2013.10.019
   Roma A, 2018, MOL PHARMACEUT, V15, P1353, DOI 10.1021/acs.molpharmaceut.7b01151
   Rota SG, 2017, MOL CANCER THER, V16, P2618, DOI 10.1158/1535 7163.MCT 17 0292
   Rovinski D, 2018, THROMB RES, V168, P83, DOI 10.1016/j.thromres.2018.06.014
   Sedaghati B, 2015, CELLS TISSUES ORGANS, V201, P366, DOI 10.1159/000444634
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303 7207(98)00229 9
   Shao SY, 2019, J CELL PHYSIOL, V234, P12701, DOI 10.1002/jcp.27887
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Srivastava K, 2013, INT C ADV COMPUT COM, P138, DOI 10.1109/ACCT.2013.33
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Swarnkar G, 2012, BRIT J PHARMACOL, V165, P1526, DOI 10.1111/j.1476 5381.2011.01637.x
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Trivedi R, 2010, CURR MOL MED, V10, P14, DOI 10.2174/156652410791065372
   Troy KL, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050878
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Walker ML, 2008, BIOL REPROD, V79, P398, DOI 10.1095/biolreprod.108.068536
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
NR 52
TC 19
Z9 20
U1 2
U2 12
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2019
VL 118
AR 109207
DI 10.1016/j.biopha.2019.109207
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IY4WZ
UT WOS:000486395000041
PM 31306971
OA gold
DA 2025 08 17
ER

PT J
AU Zhao, YG
   Ren, JS
   Hillier, J
   Lu, WX
   Jones, EY
AF Zhao, Yuguang
   Ren, Jingshan
   Hillier, James
   Lu, Weixian
   Jones, E. Yvonne
TI Antiepileptic Drug Carbamazepine Binds to a Novel Pocket on the Wnt
   Receptor Frizzled 8
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CATENIN SIGNALING PATHWAY; BONE MINERAL DENSITY; CYSTEINE RICH DOMAIN;
   STRUCTURAL BASIS; HIPPOCAMPAL NEUROGENESIS; CANONICAL WNT; TARGET;
   RECOGNITION; INHIBITORS; PROTEINS
AB Misregulation of Wnt signaling is common in human cancer. The development of small molecule inhibitors against the Wnt receptor, frizzled (FZD), may have potential in cancer therapy. During small molecule screens, we observed binding of carbamazepine to the cysteine rich domain (CRD) of the Wnt receptor FZD8 using surface plasmon resonance (SPR). Cellular functional assays demonstrated that carbamazepine can suppress FZD8 mediated Wnt/beta catenin signaling. We determined the crystal structure of the complex at 1.7 angstrom resolution, which reveals that carbamazepine binds at a novel pocket on the FZD8 CRD. The unique residue Tyr52 discriminates FZD8 from the closely related FZD5 and other FZDs for carbamazepine binding. The first small molecule bound FZD structure provides a basis for anti FZD drug development. Furthermore, the observed carbamazepine mediated Wnt signaling inhibition may help to explain the phenomenon of bone loss and increased adipogenesis in some patients during long term carbamazepine treatment.
C1 [Zhao, Yuguang; Ren, Jingshan; Hillier, James; Lu, Weixian; Jones, E. Yvonne] Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.
C3 University of Oxford; Wellcome Centre for Human Genetics
RP Zhao, YG; Jones, EY (通讯作者)，Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.
EM yuguang@strubi.ox.ac.uk; yvonne@strubi.ox.ac.uk
RI ; Ren, Jingshan/AAT 7729 2021; Zhao, Yuguang/N 1034 2018
OI Zhao, Yuguang/0000 0001 8916 8552; Hillier, James/0000 0002 4617 8504;
   Ren, Jingshan/0000 0003 4015 1404; 
FU Cancer Research UK; UK Medical Research Council [C375/A17721,
   MR/M000141/1]; Wellcome Trust [203141/Z/16/Z]; Diamond Light Source
   [MX14744]; Cancer Research UK [17721] Funding Source: researchfish;
   Medical Research Council [MR/M000141/1] Funding Source: researchfish;
   MRC [MR/M000141/1] Funding Source: UKRI
FX We thank Diamond Light Source for beamtime and the staff of beamline
   I04 1 for assistance with crystal testing and data collection (under BAG
   application MX14744). We thank Thomas Walter for assistance with
   crystallization. We are grateful to Professor Michel Boutrous (DFKZ,
   Germany) for the HEK293T FZD1, 2, 7 knockout cell line. We thank Drs
   Laura Diaz Saez and Oleg Fedorov (TDI, Oxford) for assistance with using
   the Biacore S200 machine. This work was funded by Cancer Research UK,
   the UK Medical Research Council (to EYJ, C375/A17721 and MR/M000141/1),
   and the Wellcome Trust (grant 203141/Z/16/Z supporting the Wellcome
   Centre for Human Genetics).
CR Akbarzadeh L, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.37230
   Akhoundi MSA, 2018, INT ORTHOD, V16, P73, DOI [10.1016/j.ortho.2018.01.022, 10.1016/j.ortho.2018.01.021]
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799
   Behr C, 2016, REV NEUROL FRANCE, V172, P27, DOI 10.1016/j.neurol.2015.11.003
   BERTILSSON L, 1978, CLIN PHARMACOKINET, V3, P128, DOI 10.2165/00003088 197803020 00003
   Busceti CL, 2007, EPILEPSIA, V48, P694, DOI 10.1111/j.1528 1167.2007.01055.x
   Catterall W A, 1999, Adv Neurol, V79, P441
   Chang TH, 2015, ELIFE, V4, DOI 10.7554/eLife.06554
   Chen P, 2018, SCIENCE, V360, P664, DOI 10.1126/science.aar1999
   Coppola G, 2009, EPILEPSIA, V50, P2140, DOI 10.1111/j.1528 1167.2009.02082.x
   Dang LT, 2019, NAT STRUCT MOL BIOL, V26, P407, DOI 10.1038/s41594 019 0224 z
   Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601
   DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374
   DeBruine ZJ, 2017, GENE DEV, V31, P916, DOI 10.1101/gad.298331.117
   Elegheert J, 2018, NAT PROTOC, V13, P2991, DOI 10.1038/s41596 018 0075 9
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   Generoso SF, 2015, NAT CHEM BIOL, V11, P280, DOI [10.1038/NCHEMBIO.1770, 10.1038/nchembio.1770]
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Hamdoun S, 2017, BIOCHEM PHARMACOL, V146, P63, DOI 10.1016/j.bcp.2017.10.008
   Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232
   Hirai H, 2019, NAT STRUCT MOL BIOL, V26, P372, DOI 10.1038/s41594 019 0216 z
   Hodges SL, 2018, EPILEPSY RES, V146, P9, DOI 10.1016/j.eplepsyres.2018.07.002
   Hofherr SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017076
   HOIKKA V, 1984, ACTA NEUROL SCAND, V70, P77
   Howarth M, 2008, NAT METHODS, V5, P397, DOI 10.1038/NMETH.1206
   Huang C, 2015, NEUROCHEM RES, V40, P1319, DOI 10.1007/s11064 015 1614 1
   Im DU, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111460
   Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Kumandas S, 2006, J PEDIATR ENDOCR MET, V19, P529
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lebedev AA, 2014, ACTA CRYSTALLOGR D, V70, P2430, DOI 10.1107/S1399004714014795
   Lee HJ, 2015, J BIOL CHEM, V290, P30596, DOI 10.1074/jbc.M115.673202
   Meng QW, 2011, MOL CELL BIOCHEM, V348, P165, DOI 10.1007/s11010 010 0651 y
   Merle P, 2005, J HEPATOL, V43, P854, DOI 10.1016/j.jhep.2005.05.018
   Mii Y, 2011, DEV GROWTH DIFFER, V53, P911, DOI 10.1111/j.1440 169X.2011.01299.x
   Nile AH, 2018, NAT CHEM BIOL, V14, P582, DOI 10.1038/s41589 018 0035 2
   Nile AH, 2017, P NATL ACAD SCI USA, V114, P4147, DOI 10.1073/pnas.1618293114
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Olaru A, 2015, CRIT REV ANAL CHEM, V45, P97, DOI 10.1080/10408347.2014.881250
   Paciorkowski AR, 2011, PEDIATR NEUROL, V45, P355, DOI 10.1016/j.pediatrneurol.2011.08.010
   Pirone A, 2017, NEUROBIOL DIS, V98, P149, DOI 10.1016/j.nbd.2016.11.002
   Qu ZY, 2017, CELL BIOCHEM FUNCT, V35, P472, DOI 10.1002/cbf.3306
   Raman S, 2019, P NATL ACAD SCI USA, V116, P6812, DOI 10.1073/pnas.1817246116
   Ren JS, 2018, J MED CHEM, V61, P724, DOI 10.1021/acs.jmedchem.7b01249
   Riccio G, 2018, BIOCHEMISTRY US, V57, P839, DOI 10.1021/acs.biochem.7b01087
   Rubio C, 2017, CNS NEUROL DISORD DR, V16, P772, DOI 10.2174/1871527316666170117114513
   Salminen JK, 2016, CANCER CAUSE CONTROL, V27, P637, DOI 10.1007/s10552 016 0737 2
   Shen GB, 2015, CELL RES, V25, P1078, DOI 10.1038/cr.2015.92
   Simmons G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106954
   Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219
   Stettner M, 2012, EUR J CANCER PREV, V21, P55, DOI 10.1097/CEJ.0b013e32834a7e6f
   Voloshanenko O, 2017, FASEB J, V31, P4832, DOI 10.1096/fj.201700144R
   Wang HQ, 2012, BIOCHEM BIOPH RES CO, V417, P62, DOI 10.1016/j.bbrc.2011.11.055
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
   Yadav Satya P, 2012, J Biomol Tech, V23, P94, DOI 10.7171/jbt.12 2303 002
   Yang JL, 2016, GLIA, V64, P1083, DOI 10.1002/glia.22984
   Yang QW, 2017, ONCOTARGET, V8, P78989, DOI 10.18632/oncotarget.20742
   Yang SF, 2018, NATURE, V560, P666, DOI 10.1038/s41586 018 0447 x
   Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615
   Zhao YG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5321
   Zhao YG, 2011, J STRUCT BIOL, V175, P209, DOI 10.1016/j.jsb.2011.04.017
   Zhong ZD, 2014, WIRES DEV BIOL, V3, P489, DOI 10.1002/wdev.159
NR 67
TC 31
Z9 31
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 26
PY 2020
VL 63
IS 6
BP 3252
EP 3260
DI 10.1021/acs.jmedchem.9b02020
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LE0HA
UT WOS:000526404600034
PM 32049522
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Huang, LK
   Chen, WW
   Wei, LH
   Su, YA
   Liang, JM
   Lian, HY
   Wang, H
   Long, F
   Yang, F
   Gao, SY
   Tan, Z
   Xu, JK
   Zhao, JM
   Liu, Q
AF Huang, Linke
   Chen, Weiwei
   Wei, Linhua
   Su, Yuangang
   Liang, Jiamin
   Lian, Haoyu
   Wang, Hui
   Long, Feng
   Yang, Fan
   Gao, Shiyao
   Tan, Zhen
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling
   Pathway to Prevent Osteoclastogenesis in Titanium Particle Induced
   Osteolysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE lonafarnib; farnesyltransferase; ERK; osteoclast; osteolysis
ID PROTEIN PRENYLATION; OSTEOGENIC ACTIVITY; M CSF; ACTIVATION; NFATC1;
   RANKL; EXPRESSION; DIFFERENTIATION; RESORPTION; ACIDIFICATION
AB Wear debris after total joint arthroplasty can attract the recruitment of macrophages, which release pro inflammatory substances, triggering the activation of osteoclasts, thereby leading to periprosthetic osteolysis (PPOL) and aseptic loosening. However, the development of pharmacological strategies targeting osteoclasts to prevent periprosthetic osteolysis has not been fruitful. In this study, we worked toward researching the effects and mechanisms of a farnesyltransferase (FTase) inhibitor Lonafarnib (Lon) on receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclastogenesis and bone resorption, as well as the impacts of Lon on titanium particle induced osteolysis. To investigate the impacts of Lon on bone resorption and osteoclastogenesis in vitro, bone marrow macrophages were incubated and stimulated with RANKL and macrophage colony stimulating factor (M CSF). The influence of Lon on osteolysis prevention in vivo was examined utilizing a titanium particle induced mouse calvarial osteolysis model. The osteoclast relevant genes expression was explored by real time quantitative PCR. Immunofluorescence was used to detect intracellular localization of nuclear factor of activated T cells 1 (NFATc1). SiRNA silence assay was applied to examine the influence of FTase on osteoclasts activation. Related signaling pathways, including NFATc1 signaling, NF kappa B, mitogen activated protein kinases pathways were identified by western blot assay. Lon was illustrated to suppress bone resorptive function and osteoclastogenesis in vitro, and it also reduced the production of pro inflammatory substances and prevented titanium particle induced osteolysis in vivo. Lon decreased the expression of osteoclast relevant genes and suppressed NFATc1 nuclear translocation and auto amplification. Mechanistically, Lon dampened FTase, and inhibition of FTase reduced osteoclast formation by suppressing ERK signaling. Lon is a promising treatment option for osteoclast related osteolysis diseases including periprosthetic osteolysis by targeted inhibition of FTase through suppressing ERK signaling.
C1 [Huang, Linke; Chen, Weiwei; Wei, Linhua; Su, Yuangang; Liang, Jiamin; Lian, Haoyu; Wang, Hui; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Dept Orthopaed, Res Ctr Regenerat Med, Affiliated Hosp 1, Nanning, Peoples R China.
   [Huang, Linke; Gao, Shiyao; Tan, Zhen] Guangxi Med Univ, Dept Orthopaed, Affiliated Hosp 2, Nanning, Peoples R China.
   [Huang, Linke; Chen, Weiwei; Wei, Linhua; Su, Yuangang; Liang, Jiamin; Lian, Haoyu; Wang, Hui; Long, Feng; Yang, Fan; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Wei, Linhua] Guangxi Med Univ, Peoples Hosp Nanning 4, Affiliated Nanning Infect Dis Hosp, Nanning, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; University of Western Australia
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Dept Orthopaed, Res Ctr Regenerat Med, Affiliated Hosp 1, Nanning, Peoples R China.; Zhao, JM (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
EM liuqian@gxmu.edu.cn; zhaojinmin@126.com
RI Su, Yuangang/KKU 6952 2024; zhao, jin/LBH 0351 2024; Lian,
   Haoyu/W 3317 2017; Huang, Linke/AAL 8295 2020
OI Xu, Jiake/0000 0003 2021 8309; 
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Badarudeen S, 2017, J ARTHROPLASTY, V32, P1954, DOI 10.1016/j.arth.2017.01.037
   Ben Shlomo Y, 2020, The National Joint Registry 17th Annual Report 2020 [Internet]
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradley EW, 2008, J CELL BIOCHEM, V104, P1439, DOI 10.1002/jcb.21719
   Carter J, 2019, EUR J ORTHOP SURG TR, V29, P1101, DOI 10.1007/s00590 019 02403 9
   Delarue FL, 2007, ONCOGENE, V26, P633, DOI 10.1038/sj.onc.1209819
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dhillon S, 2021, DRUGS, V81, P283, DOI 10.1007/s40265 020 01464 z
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fritz G, 2006, CURR CANCER DRUG TAR, V6, P1, DOI 10.2174/156800906775471752
   Goodman SB, 2006, BIOMATERIALS, V27, P6096, DOI 10.1016/j.biomaterials.2006.08.023
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Guo ZM, 2015, INT J MOL SCI, V16, P19537, DOI 10.3390/ijms160819537
   Hasegawa H, 2010, J BIOL CHEM, V285, P25448, DOI 10.1074/jbc.M109.068742
   Hou RCW, 2005, ANN NY ACAD SCI, V1042, P279, DOI 10.1196/annals.1338.050
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Klochkov SG, 2019, SEMIN CANCER BIOL, V56, P128, DOI 10.1016/j.semcancer.2017.10.010
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Li H, 2016, CELL REP, V16, P545, DOI 10.1016/j.celrep.2016.06.013
   Li N, 2021, INT J BIOL SCI, V17, P1382, DOI 10.7150/ijbs.53992
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898 6568(98)00019 9
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Nam JS, 2017, J BIOMED MATER RES A, V105, P912, DOI 10.1002/jbm.a.36004
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park KL, 2018, FEBS OPEN BIO, V8, P1584, DOI 10.1002/2211 5463.12513
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Rao PV, 2008, INVEST OPHTH VIS SCI, V49, P2464, DOI 10.1167/iovs.07 1639
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Santos Beneit F, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91526 3
   Schaeffer RD, 2016, PROTEIN SCI, V25, P1188, DOI 10.1002/pro.2893
   Sharkey PF, 2014, J ARTHROPLASTY, V29, P1774, DOI 10.1016/j.arth.2013.07.024
   Shi JW, 2020, J CELL PHYSIOL, V235, P2599, DOI 10.1002/jcp.29164
   Sköldenberg O, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1036 5
   Sorensen MG, 2007, J BONE MINER RES, V22, P1640, DOI 10.1359/JBMR.070613
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Sun LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122830
   Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Uehara S, 2018, CELL MOL LIFE SCI, V75, P3683, DOI 10.1007/s00018 018 2881 1
   Wang JL, 2017, ONCOTARGET, V8, P105047, DOI 10.18632/oncotarget.22086
   Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yang X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664697
   Young SG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005229
   Yuan XW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01196
   Zhang L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00352
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
NR 62
TC 11
Z9 11
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 1
PY 2022
VL 13
AR 848152
DI 10.3389/fphar.2022.848152
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0E3SO
UT WOS:000776603600001
PM 35300293
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Selvarnurugan, N
   Kwok, S
   Vasilov, A
   Jefcoat, SC
   Partridge, NC
AF Selvarnurugan, Nagarajan
   Kwok, Sukyee
   Vasilov, Anatoliy
   Jefcoat, Stephen C.
   Partridge, Nicola C.
TI Effects of BMP 2 and pulsed electromagnetic field (PEMF) on rat primary
   osteoblastic cell proliferation and gene expression
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE BMP 2; PEMF; osteoblast; bone formation
ID AFFECTS OSTEOCLAST FORMATION; BONE FORMATION; PARATHYROID HORMONE;
   UP REGULATION; STIMULATION; GROWTH; DIFFERENTIATION; EXPOSURE;
   PHENOTYPE; INCREASE
AB Bone morphogenetic proteins (BMPs) strongly promote osteoblast differentiation. Pulsed electromagnetic fields (PEMFs) promote fracture healing in non union fractures. In this study, we hypothesized that a combined BMP 2 and PEMF stimulation would augment bone formation to a greater degree than treatment with either single stimulus. BMP 2 maximally increased the proliferative activity of rat primary osteoblastic cells at 25 ng/ml concentration. Real time reverse transcription polymerase chain reaction (RT PCR) showed that BMP 2 stimulated mRNA levels of alkaline phosphatase (ALP), a, (1) procollagen, and osteocalcin (OC) in the differentiation phase and only OC mRNA expression in the mineralization phase after 24 h treatment. Both BMP 2 and PEMF (Spinal Stim) increased cell proliferation, which was additive when both agents were combined. PEMF alone or together with BMP 2 increased only ALP mRNA expression and only during the differentiation phase 24 h after one 4 h treatment. This effect was additive when both agents were combined. Continuous daily 4 h treatment with PEMF alone or together with BMP 2 increased expression of all three osteoblast marker genes during the differentiation phase and increased the mineralized matrix. This effect was additive when both agents were combined, suggesting that the two interventions may be working on different cellular pathways. Thus, a combined effect of BMP 2 and PEMF in vitro could be considered as groundwork for in vivo bone development that may support skeletal therapy. (c) 2007 Orthopaedic Research Society.
C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences
RP Partridge, NC (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.
EM partrinc@umdnj.edu
RI Selvamurugan, Nagarajan/P 7894 2016
OI Selvamurugan, Nagarajan/0000 0003 3713 1920; Partridge,
   Nicola/0000 0002 5406 4814
FU NIDDK NIH HHS [R01 DK047420] Funding Source: Medline
CR Aaron RK, 2002, J ORTHOP RES, V20, P233, DOI 10.1016/S0736 0266(01)00084 5
   Aung HT, 2006, FASEB J, V20, P1315, DOI 10.1096/fj.05 5360com
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang K, 2004, BIOELECTROMAGNETICS, V25, P134, DOI 10.1002/bem.10168
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   FITZSIMMONS RJ, 1995, ENDOCRINOLOGY, V136, P3100, DOI 10.1210/en.136.7.3100
   Guerkov HH, 2001, CLIN ORTHOP RELAT R, P265
   Ibiwoye MO, 2004, J ORTHOP RES, V22, P1086, DOI 10.1016/j.orthres.2003.12.017
   Kubota K, 2002, BONE, V31, P465, DOI 10.1016/S8756 3282(02)00852 9
   Kwok S, 2005, J CELL BIOCHEM, V95, P1002, DOI 10.1002/jcb.20453
   Li JKJ, 2006, ULTRASOUND MED BIOL, V32, P769, DOI 10.1016/j.ultrasmedbio.2006.01.017
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Lohmann CH, 2003, J ORTHOP RES, V21, P326, DOI 10.1016/S0736 0266(02)00137 7
   LUBEN RA, 1982, P NATL ACAD SCI BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180
   LUBEN RA, 1991, HEALTH PHYS, V61, P15, DOI 10.1097/00004032 199107000 00002
   MCLEOD KJ, 1993, J BONE MINER RES, V8, P977, DOI 10.1002/jbmr.5650080811
   McLeod KJ, 2000, RADIAT RES, V153, P706, DOI 10.1667/0033 7587(2000)153[0706:SOADRI]2.0.CO;2
   Midura RJ, 2005, J ORTHOP RES, V23, P1035, DOI 10.1016/j.orthres.2005.03.015
   Patterson TE, 2006, BIOELECTROMAGNETICS, V27, P535, DOI 10.1002/bem.20244
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Sakai Y, 2006, J ORTHOP RES, V24, P242, DOI 10.1002/jor.20012
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Smith TL, 2004, J ORTHOPAED RES, V22, P80, DOI 10.1016/S0736 0266(03)00157 8
   Suga K, 2003, J INTERF CYTOK RES, V23, P203, DOI 10.1089/107999003765027401
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang ZY, 2006, J BONE JOINT SURG AM, V88A, P1053, DOI 10.2106/JBJS.E.00443
   Zborowski M, 2003, ANN BIOMED ENG, V31, P195, DOI 10.1114/1.1540104
NR 31
TC 104
Z9 123
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD SEP
PY 2007
VL 25
IS 9
BP 1213
EP 1220
DI 10.1002/jor.20409
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 202HS
UT WOS:000248893200011
PM 17503520
DA 2025 08 17
ER

PT J
AU Amanso, AM
   Kamalakar, A
   Bitarafan, S
   Abramowicz, S
   Drissi, H
   Barnett, JV
   Wood, LB
   Goudy, SL
AF Amanso, Angelica Mastandrea
   Kamalakar, Archana
   Bitarafan, Sara
   Abramowicz, Shelly
   Drissi, Hicham
   Barnett, Joey Victor
   Wood, Levi Benjamin
   Goudy, S. L.
TI Osteoinductive effect of soluble transforming growth factor beta
   receptor 3 on human osteoblast lineage
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE human bone; noncanonical signaling; osteogenic commitment; TGF beta R3
AB The development of bone requires carefully choregraphed signaling to bone progenitors to form bone. Our group recently described the requirement of transforming growth factor beta receptor 3 (TGF beta R3), a receptor involved in TGF beta pathway signaling, during osteoblast lineage commitment in mice. The TGF beta pathway is known to play multiple osteo inductive and osteo inhibitory roles during osteoblast development and TGF beta R3 human mutations are associated with reduced bone mineral density, making TGF beta R3 a unique target for bone inductive therapy. In this article, we demonstrated increased mineralization of human pediatric bone derived osteoblast like cells (HBO) when treated with soluble TGF beta R3 (sR3) using Alizarin Red staining. Osteogenic commitment of HBO cells was demonstrated by induction of osteogenic genes RUNX2, osteocalcin, osteopontin, and osterix. Evaluation of the canonical TGF beta pathway signaling demonstrated that sR3 was able to induce bone formation in HBO cells, mainly through activation of noncanonical targets of TGF beta pathway signaling including AKT, ERK, and p38 MAP kinases. Inhibition of these osteogenic noncanonical pathways in the HBO cells also inhibited mineralization, suggesting they are each required. Although no induction of SMAD1, 5, and 9 was observed, there was the activation of SMAD2 and 3 suggesting that sR3 is primarily signaling via the noncanonical pathways during osteogenic induction of the HBO. Our results highlight the important role of TGF beta R3 in osteoblast induction of mineralization in human bone cells through noncanonical targets of TGF beta signaling. Future studies will focus on the ability of sR3 to induce bone regeneration in vivo using animal models.
C1 [Amanso, Angelica Mastandrea; Kamalakar, Archana; Goudy, S. L.] Emory Univ, Dept Otolaryngol, Atlanta, GA 30322 USA.
   [Bitarafan, Sara; Wood, Levi Benjamin] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Bitarafan, Sara; Wood, Levi Benjamin] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
   [Abramowicz, Shelly] Emory Univ, Dept Surg, Div Oral & Maxillofacial Surg, Atlanta, GA 30322 USA.
   [Drissi, Hicham] Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA.
   [Drissi, Hicham] Emory Univ, Dept Orthopaed, Atlanta, GA 30322 USA.
   [Drissi, Hicham] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
   [Barnett, Joey Victor] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.
   [Wood, Levi Benjamin] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
C3 Emory University; University System of Georgia; Georgia Institute of
   Technology; University System of Georgia; Georgia Institute of
   Technology; Emory University; Emory University; Emory University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Vanderbilt University; University System
   of Georgia; Georgia Institute of Technology
RP Goudy, SL (通讯作者)，Dept Otolaryngol Head & Neck Surg, Med Off Tower MOT,9th Floor,550 Peachtree St NE, Atlanta, GA 30308 USA.
EM steven.goudy@emory.edu
RI Amanso, Angelica/IFG 9357 2023
OI drissi, hicham/0000 0002 3322 281X
FU Children's Healthcare of Atlanta Research Trust [91901 04 004 02]
FX Children's Healthcare of Atlanta Research Trust, Grant/Award Number:
   91901 04 004 02
CR Ahn JY, 2010, BIOMED PHARMACOTHER, V64, P472, DOI 10.1016/j.biopha.2010.01.006
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Bilandzic M, 2012, MOL CELL ENDOCRINOL, V359, P13, DOI 10.1016/j.mce.2012.03.020
   Bitarafan S., 2021, J CELL BIOCHEM, P1
   Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195
   Compton LA, 2007, CIRC RES, V101, P784, DOI 10.1161/CIRCRESAHA.107.152082
   Farnworth PG, 2007, ENDOCRINOLOGY, V148, P5355, DOI 10.1210/en.2007 0155
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hill CR, 2015, DEV DYNAM, V244, P122, DOI 10.1002/dvdy.24225
   Hill CR, 2012, CELL SIGNAL, V24, P1012, DOI 10.1016/j.cellsig.2011.12.022
   Holtzhausen A, 2014, FASEB J, V28, P1248, DOI 10.1096/fj.13 239178
   Jurisic D, 2015, GROWTH FACTORS, V33, P200, DOI 10.3109/08977194.2015.1055740
   Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200
   Lee NY, 2009, MOL BIOL CELL, V20, P4362, DOI 10.1091/mbc.E09 07 0539
   Liu HZ, 2016, J TOXICOL SCI, V41, P185, DOI 10.2131/jts.41.185
   Liu Y, 2013, EUR REV MED PHARMACO, V17, P1611
   LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557
   McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898 6568(01)00203 0
   Nishida J, 2018, ONCOGENE, V37, P2197, DOI 10.1038/s41388 017 0084 0
   Ritting AW, 2012, J HAND SURG AM, V37A, P316, DOI 10.1016/j.jhsa.2011.10.007
   Runyan CM, 2017, J CRANIOFAC SURG, V28, P1380, DOI 10.1097/SCS.0000000000003625
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Shen CY, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 019 0281 3
   Suzuki E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112566
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Villarreal MM, 2016, BIOCHEMISTRY US, V55, P6880, DOI 10.1021/acs.biochem.6b00566
   Wang Y, 2014, ENDOCRINOLOGY, V155, P1970, DOI 10.1210/en.2013 1741
   Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu DJ, 2012, BMB REP, V45, P247, DOI 10.5483/BMBRep.2012.45.4.247
   Zakrzewski PK, 2016, ONCOL REP, V35, P932, DOI 10.3892/or.2015.4400
NR 36
TC 1
Z9 1
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2021
VL 122
IS 5
BP 538
EP 548
DI 10.1002/jcb.29888
EA JAN 2021
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA RF6OB
UT WOS:000609917700001
PM 33480071
DA 2025 08 17
ER

PT J
AU Ferrari, SL
   Bouxsein, ML
AF Ferrari, Serge L.
   Bouxsein, Mary L.
TI β Arrestin Biased Parathyroid Hormone Ligands: A New Approach to the
   Development of Agents That Stimulate Bone Formation
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; PROTEIN RECEPTOR; PTH; BETA ARRESTIN2; EXPRESSION;
   KINASE; RANKL; GENE
AB Because daily treatment with parathyroid hormone (PTH) increases bone mass and decreases fracture risk, physicians use this agent to treat osteoporosis. However, PTH stimulates both bone forming and bone resorbing cells, complicating its clinical use. New results show that, in mice, a so called biased agonist (PTH beta arr) that selectively activates beta arrestin dependent signaling leads to PTH induced trabecular bone formation without a simultaneous increase in bone resorption. This targeted approach may pave the way for future pharmacological developments in the treatment of osteoporosis.
C1 [Bouxsein, Mary L.] Harvard Univ, Sch Med, Ctr Adv Orthopaed Studies, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Bouxsein, Mary L.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Ferrari, Serge L.] Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, World Hlth Org Collaborating Ctr Osteoporosis Pre, Geneva, Switzerland.
C3 Harvard University; Harvard University Medical Affiliates; Beth Israel
   Deaconess Medical Center; Harvard Medical School; Harvard University;
   Harvard Medical School; World Health Organization; University of Geneva
RP Bouxsein, ML (通讯作者)，Harvard Univ, Sch Med, Ctr Adv Orthopaed Studies, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
EM mbouxsei@bidmc.harvard.edu
RI ; Ferrari, Serge/ABD 2730 2020
OI ferrari, serge/0000 0002 1372 4417; 
FU NIAMS NIH HHS [R01 AR049265] Funding Source: Medline
CR Bianchi EN, 2009, BONE, V45, P716, DOI 10.1016/j.bone.2009.06.020
   Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200
   Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562
   Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kostenuik PJ, 2007, J BONE MINER RES, V22, P1534, DOI 10.1359/JBMR.070616
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pierroz DD, 2009, J BONE MINER RES, V24, P775, DOI [10.1359/JBMR.081237, 10.1359/jbmr.081237]
   Rey A, 2007, BONE, V41, P59, DOI 10.1016/j.bone.2007.02.031
   Rey A, 2006, J BIOL CHEM, V281, P38181, DOI 10.1074/jbc.M606762200
   Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006
NR 19
TC 8
Z9 10
U1 0
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD OCT 7
PY 2009
VL 1
IS 1
AR 1ps1
DI 10.1126/scitranslmed.3000268
PG 4
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 589KY
UT WOS:000277147500003
PM 20368152
DA 2025 08 17
ER

PT J
AU Long, ZY
   Wu, JM
   Xiang, W
   Zeng, ZC
   Yu, GP
   Li, J
AF Long, Zhiyong
   Wu, Jiamin
   Xiang, Wang
   Zeng, Zhican
   Yu, Ganpeng
   Li, Jun
TI Exploring the Mechanism of Icariin in Osteoporosis Based on a Network
   Pharmacology Strategy
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Osteoporosis; Osteoporosis, Postmenopausal; Pharmacology; Phytochemicals
ID POSTMENOPAUSAL OSTEOPOROSIS; SIGNALING PATHWAY; BONE; ESTROGEN;
   PREVENTION; OSTEOBLAST; WOMEN; IGF 1; ACTIVATION; MEDICINE
AB Background: With the aging of the world's population, the incidence of osteoporosis (OP) has become a public health problem of worldwide concern. Research shows that icariin may have a therapeutic effect on OP.
   Material/Methods: PharmMapper was utilized to predict the potential targets of icariin. GeneCards and Online Mendelian Inheritance in Man (OMIM) were used for the collection of OP genes. The STRING database was utilized to obtain the protein protein interaction (PPI) data. We used Cytoscape 3.7.2 to construct and analyze the networks. The genes and targets in the networks were input into the Database for Annotation, Visualization and Integrated Discovery (DAVID) to undergo Gene Ontology (GO) and pathway enrichment analysis. Finally, animal experiments were performed to verify the prediction results of this study.
   Results: A total of 297 icariin potential targets and 262 OP genes were obtained, and an icariin OP PPI network was con  structed and analyzed. The results of the GO enrichment analysis showed that icariin can regulate the steroid hormone mediated signaling pathway, skeletal system development, extracellular space, cytosol, and steroid hormone receptor activity. The results of the pathway enrichment analysis showed that icariin can regulate osteoclast differentiation, FoxO, estrogen, and PPAR signaling pathways. The results of the experiments showed that icariin can increase estradiol, beta catenin, and Receptor Activator of Nuclear Factor kappa B Ligand (RANKL)/osteoprotegerin (OPG) ratio in postmenopausal OP rats (P<0.05).
   Conclusions: This research found that the icariin can regulate OP related biological processes, cell components, molecular functions, and signaling pathways.
C1 [Long, Zhiyong] Shantou Univ, Med Coll, Shantou, Guangdong, Peoples R China.
   [Long, Zhiyong] Guangdong Acad Med Sci, Dept Rehabil Med, Inst Geriatr Med, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China.
   [Wu, Jiamin] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.
   [Wu, Jiamin] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai, Peoples R China.
   [Xiang, Wang] Guilin Med Univ, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   [Zeng, Zhican] Tianjin Med Univ, Tianjin, Peoples R China.
   [Yu, Ganpeng; Li, Jun] Peoples Hosp Ningxiang City, Dept Orthopaed, Ningxiang, Hunan, Peoples R China.
C3 Shantou University; Southern Medical University   China; Guangdong
   Academy of Medical Sciences & Guangdong General Hospital; Shanghai
   University of Traditional Chinese Medicine; Shanghai University of
   Traditional Chinese Medicine; Guilin Medical University; Tianjin Medical
   University
RP Yu, GP; Li, J (通讯作者)，Peoples Hosp Ningxiang City, Dept Orthopaed, Ningxiang, Hunan, Peoples R China.
EM yuganpeng.guke@hotmail.com; lijun.guke@hotmail.com
RI xiang, wang/JKH 6962 2023
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Arnal JF, 2013, STEROIDS, V78, P576, DOI 10.1016/j.steroids.2012.11.011
   Ashpole NM, 2016, J BONE MINER RES, V31, P443, DOI 10.1002/jbmr.2689
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Buyon JP, 1997, ARTHRITIS RHEUM US, V40, P1548, DOI 10.1002/art.1780400831
   Cavalcanti FN, 2015, J MOL ENDOCRINOL, V54, P339, DOI 10.1530/JME 15 0086
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Colaianni G, 2014, AM J PHYSIOL REG I, V307, pR970, DOI 10.1152/ajpregu.00040.2014
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Dören M, 2002, MATURITAS, V43, pS53
   DuSell CD, 2010, ENDOCRINOLOGY, V151, P3675, DOI 10.1210/en.2010 0080
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Greenhill Claire, 2010, Nat Rev Endocrinol, V6, P474, DOI 10.1038/nrendo.2010.112
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang J, 2017, GENESIS, V55, DOI 10.1002/dvg.23040
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lin CX, 2018, J CELL PHYSIOL, V233, P6135, DOI 10.1002/jcp.26460
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu ZB, 2016, GROWTH HORM IGF RES, V27, P7, DOI 10.1016/j.ghir.2015.12.004
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Qi SS, 2019, FOOD FUNCT, V10, P5350, DOI 10.1039/c9fo00681h
   Qi SS, 2019, MOLECULES, V24, DOI 10.3390/molecules24101871
   Quinney SK, 2018, CPT PHARMACOMET SYST, V7, P69, DOI 10.1002/psp4.12269
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Stéphanou A, 2018, ACTA BIOTHEOR, V66, P345, DOI 10.1007/s10441 018 9330 2
   Sun XD, 2016, CHEM BIOL INTERACT, V244, P9, DOI 10.1016/j.cbi.2015.11.027
   Suzuki H, 2015, BIOCHEM BIOPH RES CO, V467, P146, DOI 10.1016/j.bbrc.2015.09.092
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang CL, 2007, OSTEOPOROSIS INT, V18, P295, DOI 10.1007/s00198 006 0239 2
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Xie L, 2017, ANNU REV PHARMACOL, V57, P245, DOI 10.1146/annurev pharmtox 010716 104659
   Xiong Y, 2017, J STEROID BIOCHEM, V174, P153, DOI 10.1016/j.jsbmb.2017.08.014
   Xu JH, 2016, MENOPAUSE, V23, P1152, DOI 10.1097/GME.0000000000000673
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yakar S, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.234
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   You L, 2013, FRONT BIOSCI LANDMRK, V18, P1088, DOI 10.2741/4165
   Yuan RS, 2016, ONCOTARGET, V7, P3692, DOI 10.18632/oncotarget.6923
   Zhai YK, 2013, PHARMAZIE, V68, P713, DOI 10.1691/ph.2013.2900
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zheng HX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092398
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
NR 61
TC 8
Z9 8
U1 0
U2 28
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD NOV 24
PY 2020
VL 26
AR e924699
DI 10.12659/MSM.924699
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OU9AR
UT WOS:000591816200001
PM 33230092
OA Green Published
DA 2025 08 17
ER

PT J
AU Jin, C
   Yu, XB
   Yang, JY
   Lin, Z
   Ma, RX
   Lin, BH
   Zhang, HJ
   Dai, ZH
   Xue, KK
   Xie, CL
   Zheng, WH
   Feng, YZ
   Xiao, J
   Yang, L
AF Jin, Chen
   Yu, Xian bin
   Yang, Jiayi
   Lin, Zhen
   Ma, Run xun
   Lin, Bing hao
   Zhang, Hao jie
   Dai, Zi han
   Xue, Kaikai
   Xie, Cheng Long
   Zheng, Wenhao
   Feng, Yongzeng
   Xiao, Jian
   Yang, Lei
TI Corynoline Suppresses Osteoclastogenesis and Attenuates ROS Activities
   by Regulating NF κB/MAPKs and Nrf2 Signaling Pathways
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE corynoline; osteoclast; NF kappa B/MAPKs pathway; Nrf2 pathway; reactive
   oxygen species
ID DIFFERENTIATION
AB Declining estrogen production in postmenopausal females causes osteoporosis in which the resorption of bone exceeds the increase in bone formation. Although clinical drugs are currently available for the treatment of osteoporosis, sustained medication use is accompanied by serious side effects. Corydalis bungeana Herba, a famous traditional Chinese herb listed in the Chinese Pharmacopoeia Commission, constitutes various traditional Chinese Medicine prescriptions, which date back to thousands of years. One of the primary active components of C. bungeana Turcz. is Corynoline (Cor), a plant isoquinoline alkaloid derived from the Corydalis species, which possesses bone metabolism disease therapeutic potential. The study aimed at exploring the effects as well as mechanisms of Cor on osteoclast formation and bone resorption. TRAcP staining, F actin belt formation, and pit formation were employed for assessing the osteoclast function. Western blot, qPCR, network pharmacology, and docking analyses were used for analyzing the expression of osteoclast associated genes and related signaling pathways. The study focused on investigating how Cor affected OVX induced trabecular bone loss by using a mouse model. Cor could weaken osteoclast formation and function by affecting the biological receptor activators of NF kappa B and its ligand at various concentrations. Mechanistically, Cor inhibited the NF kappa B activation, and the MAPKs pathway stimulated by RANKL. Besides, Cor enhanced the protein stability of the Nrf2, which effectively abolished the RANKL stimulated ROS generation. According to an OVX mouse model, Cor functions in restoring bone mass, improving microarchitecture, and reducing the ROS levels in the distal femurs, which corroborated with its in vitro antiosteoclastogenic effect. The present study indicates that Cor may restrain osteoclast formation and bone loss by modulating NF kappa B/MAPKs and Nrf2 signaling pathways. Cor was shown to be a potential drug candidate that can be utilized for the treatment of osteoporosis.
C1 [Jin, Chen; Yu, Xian bin; Ma, Run xun; Lin, Bing hao; Zhang, Hao jie; Xie, Cheng Long; Zheng, Wenhao; Feng, Yongzeng; Yang, Lei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.
   [Jin, Chen; Yu, Xian bin; Yang, Jiayi; Ma, Run xun; Lin, Bing hao; Zhang, Hao jie; Xie, Cheng Long; Zheng, Wenhao; Feng, Yongzeng; Yang, Lei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.
   [Jin, Chen; Yu, Xian bin; Lin, Zhen; Ma, Run xun; Lin, Bing hao; Zhang, Hao jie; Dai, Zi han; Xue, Kaikai; Xie, Cheng Long; Zheng, Wenhao; Feng, Yongzeng; Yang, Lei] Key Lab Orthopaed Zhejiang Prov, Wenzhou 325000, Peoples R China.
   [Yang, Jiayi] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gynaecol, Wenzhou 325000, Peoples R China.
   [Lin, Zhen] Southern Med Univ, Nanfang Hosp, Dept Plast & Aesthet Surg, Guangzhou 510515, Guangdong, Peoples R China.
   [Dai, Zi han] Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Xue, Kaikai; Xiao, Jian] Wenzhou Med Univ, Burn & Wound Healing Ctr, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
   [Xiao, Jian] Wenzhou Med Univ, Mol Pharmacol Res Ctr, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Southern Medical University   China; Wenzhou Medical
   University; Wenzhou Medical University; Wenzhou Medical University
RP Feng, YZ; Yang, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.; Feng, YZ; Yang, L (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.; Feng, YZ; Yang, L (通讯作者)，Key Lab Orthopaed Zhejiang Prov, Wenzhou 325000, Peoples R China.; Xiao, J (通讯作者)，Wenzhou Med Univ, Burn & Wound Healing Ctr, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.; Xiao, J (通讯作者)，Wenzhou Med Univ, Mol Pharmacol Res Ctr, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China.
EM 13858878561@163.com; xfxj2000@126.com; yanglei@wmu.edu.cn
RI ; 张, 豪杰/GRX 0797 2022; Zheng, Wenhao/KBR 3871 2024; Xie, CL/V 4896 2019;
   Xiao, Shi/GZB 0643 2022
OI Xiao, Jian/0000 0001 7374 6506; yang, lei/0009 0009 4294 7968; 
FU Wenzhou Medical University; Scientific Research Center of Wenzhou
   Medical University
FX The authors thank Scientific Research Center of Wenzhou Medical
   University for consultation and instrument availability that supported
   this work.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205196
   Du ZH, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/4617464
   Fang ZZ, 2011, PHYTOTHER RES, V25, P256, DOI 10.1002/ptr.3255
   Hou WD, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12111602
   Hsu TW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070932
   Huang JM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01016
   Huang SH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190445
   Ilesanmi Oyelere BL, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16173177
   Jin C, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5098358
   Kim DK, 2002, ARCH PHARM RES, V25, P817, DOI 10.1007/BF02976997
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim I, 2021, BMB REP, V54, P482, DOI 10.5483/BMBRep.2021.54.9.070
   Kostyuk SV, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10071405
   Kushwaha P, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.997358
   Lee SY, 2018, MOL CELLS, V41, P476, DOI 10.14348/molcells.2018.0056
   Li S, 2018, MOLECULES, V23, DOI 10.3390/molecules23020352
   Li SL, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2188145
   Lim S, 2018, MAR DRUGS, V16, DOI 10.3390/md16100374
   Lombard Z, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 389
   Lu H., 2022, CHIN WILDPLANT RESOU, V21, P54
   Mei LW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.734774
   Mora Boza A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48015 5
   Pan B, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.774709
   Qian Z, 2020, J CELL MOL MED, V24, P10112, DOI 10.1111/jcmm.15622
   Qu ZC, 2022, J CELL MOL MED, V26, P4428, DOI 10.1111/jcmm.17467
   Sánchez de Diego C, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101845
   Shi KN, 2023, REDOX BIOL, V62, DOI 10.1016/j.redox.2023.102706
   Sun YW, 2020, TOXINS, V12, DOI 10.3390/toxins12080496
   Tian M, 2019, MOLECULES, V24, DOI 10.3390/molecules24193463
   Toker H, 2016, J DENT SCI, V11, P331, DOI 10.1016/j.jds.2016.03.011
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   van Heerden B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050441
   Wang DW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7532798
   Wang HJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23092343
   Wang MY, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.113075
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang Y., 1997, J YANAN U, V16, P81
   Wei Z, 2021, J BONE MINER RES, V36, P1088, DOI 10.1002/jbmr.4275
   Weng WF, 2021, MOL CELL BIOCHEM, V476, P831, DOI 10.1007/s11010 020 03948 8
   Wu YH, 2021, ENVIRON TOXICOL, V36, P2493, DOI 10.1002/tox.23362
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu CL, 2019, INT J NANOMED, V14, P4491, DOI 10.2147/IJN.S199193
   Xu C, 2023, INT IMMUNOPHARMACOL, V117, DOI 10.1016/j.intimp.2023.109893
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yan B, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2753414
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
   Yang CJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21080975
   Yang HJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071503
   Yeh PS, 2020, MOLECULES, V25, DOI 10.3390/molecules25122876
   Yin YK, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57185 1
   Yu H, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0057 7
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhai XT, 2016, J ETHNOPHARMACOL, V194, P153, DOI 10.1016/j.jep.2016.09.013
   Zhang HH, 2023, IMMUNOPHARM IMMUNOT, V45, P26, DOI 10.1080/08923973.2022.2112218
   Zhang L., 2014, NW PHARM J, V29, P163
NR 59
TC 11
Z9 12
U1 8
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAR 29
PY 2024
VL 72
IS 14
BP 8149
EP 8166
DI 10.1021/acs.jafc.3c07088
EA MAR 2024
PG 18
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA NI0A3
UT WOS:001194450500001
PM 38551844
DA 2025 08 17
ER

PT J
AU Sun, Y
   Ye, XZ
   Cai, MX
   Liu, XN
   Xiao, J
   Zhang, CY
   Wang, YY
   Yang, L
   Liu, JF
   Li, SN
   Kang, C
   Zhang, B
   Zhang, Q
   Wang, ZL
   Hong, A
   Wang, XG
AF Sun, Yao
   Ye, Xiongzhen
   Cai, Mingxiang
   Liu, Xiangning
   Xiao, Jia
   Zhang, Chenyang
   Wang, Yayu
   Yang, Li
   Liu, Jiafan
   Li, Shannai
   Kang, Chen
   Zhang, Bin
   Zhang, Qi
   Wang, Zuolin
   Hong, An
   Wang, Xiaogang
TI Osteoblast Targeting Peptide Modified Nanoparticle for siRNA/microRNA
   Delivery
SO ACS NANO
LA English
DT Article
DE osteoblast targeting peptide; polyurethane nanoparticle; gene delivery;
   osteoporosis therapy; bone formation
ID DRUG DELIVERY; BONE FORMATION; GENE THERAPY; IN VIVO; OSTEOPOROSIS;
   SIRNA; THERAPEUTICS; DESIGN; SYSTEM; CANCER
AB Antiosteoporosis gene based drug development strategies are presently focused on targeting osteoblasts to either suppress bone loss or increase bone mass. Although siRNA/microRNA based gene therapy has enormous potential, it is severely limited by the lack of specific cell targeting delivery systems. We report an osteoblast targeting peptide (SDSSD) that selectively binds to osteoblasts via periostin. We developed SDSSD modified polyurethane (PU) nanomicelles encapsulating siRNA/microRNA that delivers drugs to osteoblasts; the data showed that SDSSD PU could selectively target not only bone formation surfaces but also osteoblasts without overt toxicity or eliciting an immune response in vivo. We used the SDSSD PU delivery system to deliver anti miR 214 to osteoblasts and our results showed increased bone formation, improved bone microarchitecture, and increased bone mass in an ovariectomized osteoporosis mouse model. SDSSD PU may be a useful osteoblast targeting small nucleic acid delivery system that could be used as an anabolic strategy to treat osteoblast induced bone diseases.
C1 [Ye, Xiongzhen; Xiao, Jia; Wang, Yayu; Yang, Li; Liu, Jiafan; Li, Shannai; Hong, An; Wang, Xiaogang] Jinan Univ, Dept Cell Biol, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.
   [Ye, Xiongzhen; Xiao, Jia; Wang, Yayu; Yang, Li; Liu, Jiafan; Li, Shannai; Hong, An; Wang, Xiaogang] Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.
   [Sun, Yao; Cai, Mingxiang; Zhang, Chenyang; Zhang, Qi; Wang, Zuolin] Tongji Univ, Sch Stomatol, Dept Oral Implantol, Shanghai 200072, Peoples R China.
   [Liu, Xiangning] Jinan Univ, Affiliated Hosp 1, Guangzhou 510632, Guangdong, Peoples R China.
   [Sun, Yao; Wang, Zuolin] Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Shanghai 200072, Peoples R China.
   [Sun, Yao; Kang, Chen; Zhang, Bin] Harbin Med Univ, Affiliated Hosp 2, Sino Russian Inst Hard Tissue Dev & Regenerat, Harbin 150086, Peoples R China.
C3 Jinan University; Jinan University; Tongji University; Jinan University;
   Harbin Medical University
RP Hong, A; Wang, XG (通讯作者)，Jinan Univ, Dept Cell Biol, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.; Hong, A; Wang, XG (通讯作者)，Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.; Wang, ZL (通讯作者)，Tongji Univ, Sch Stomatol, Dept Oral Implantol, Shanghai 200072, Peoples R China.; Wang, ZL (通讯作者)，Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Shanghai 200072, Peoples R China.
EM zuolintongji@126.com; tha@jnu.edu.cn; txg_wang@jnu.edu.cn
RI wang, Xiaogang/J 5003 2017; Zhang, Chenyang/JDW 3625 2023; wang,
   yayu/AAG 7024 2020; cai, mingxiang/IYT 1913 2023; sun, yao/MEP 9275 2025
OI sun, yao/0000 0002 4323 0506; Wang, Xiaogang/0000 0001 9798 834X; 
FU Fundamental Research Funds for the Central Universities [21614608,
   11615206, TJ1504219036, 21615480]; National Natural Science Foundation
   [81370971, 31101251, 81271110, 81300840, 81470715, 81300908]; Guangdong
   Natural Science Funds [2014A030313358]; Science and Technology Major
   Project of Guangdong Province [2015B020225005]; Guangdong Natural
   Science Funds for Distinguished Young Scholar [S2013050013880];
   Education Ministry's New Century Excellent Talents Supporting Plan
   [NCET 13 0426]; Recruitment Program of Global Experts 1000 Plan;
   National Science technology Support Plan [2014BAI04B07];  [XYQ2013080]
FX We thank Dr. Yingxian Li (China Astronaut Research and Training Center)
   for valuable advice. Appreciate Dr. Guosong Chen (FuDan University) for
   the help of biochemistry analysis and appreciate for the Antibodies and
   help from Dr. Chunlin Qin (Baylor college of Dentistry). This work was
   supported by The Fundamental Research Funds for the Central Universities
   (21614608; 11615206;TJ1504219036; 21615480); National Natural Science
   Foundation Projects (81370971, 31101251, 81271110, 81300840, 81470715
   and 81300908) Guangdong Natural Science Funds (2014A030313358); Science
   and Technology Major Project of Guangdong Province (2015B020225005) and
   Guangdong Natural Science Funds for Distinguished Young Scholar
   (S2013050013880); XYQ2013080; Education Ministry's New Century Excellent
   Talents Supporting Plan NCET 13 0426; 2012 Recruitment Program of Global
   Experts 1000 Plan (YS) and National Science technology Support Plan
   Projects 2014BAI04B07.
CR ALBERT A, 1956, NATURE, V177, P433, DOI 10.1038/177433a0
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Canalis E, 2010, ENDOCR PRACT, V16, P855, DOI 10.4158/EP10048.RA
   Choi KY, 2014, NAT PROTOC, V9, P1900, DOI 10.1038/nprot.2014.128
   Daddona PE, 2011, PHARM RES DORDR, V28, P159, DOI 10.1007/s11095 010 0192 9
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Ding MM, 2013, ACS NANO, V7, P1918, DOI 10.1021/nn4002769
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Field LD, 2015, ACCOUNTS CHEM RES, V48, P1380, DOI 10.1021/ar500449v
   Hilgenbrink AR, 2005, J PHARM SCI US, V94, P2135, DOI 10.1002/jps.20457
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Hofmeister LH, 2015, ACS NANO, V9, P4435, DOI 10.1021/acsnano.5b01048
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0
   Khatri N, 2014, J CONTROL RELEASE, V182, P45, DOI 10.1016/j.jconrel.2014.03.003
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Mahanta AK, 2015, MACROMOLECULES, V48, P2654, DOI 10.1021/acs.macromol.5b00030
   Mallikaratchy PR, 2011, NUCLEIC ACIDS RES, V39, P2458, DOI 10.1093/nar/gkq996
   McGuire MJ, 2014, SCI REP UK, V4, DOI 10.1038/srep04480
   McGuire Michael J., 2009, V504, P291, DOI 10.1007/978 1 60327 569 9_18
   Mingozzi F, 2011, NAT REV GENET, V12, P341, DOI 10.1038/nrg2988
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432 1327.2000.01606.x
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schiapparelli LM, 2014, J PROTEOME RES, V13, P3966, DOI 10.1021/pr5002862
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Su SS, 2015, ACS NANO, V9, P1367, DOI 10.1021/nn505729m
   Teranishi Y, 2010, J CELL MOL MED, V14, P2675, DOI 10.1111/j.1582 4934.2009.00907.x
   Waehler R, 2007, NAT REV GENET, V8, P573, DOI 10.1038/nrg2141
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Weinberg WC, 2005, CANCER METAST REV, V24, P569, DOI 10.1007/s10555 005 6196 y
   Wijagkanalan W, 2011, FRONT BIOSCI LANDMRK, V16, P2970, DOI 10.2741/3892
   Wu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066416
   Wu Z, 2011, ACS NANO, V5, P7696, DOI 10.1021/nn2037384
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhou HF, 2014, J CLIN INVEST, V124, P4363, DOI 10.1172/JCI75673
NR 51
TC 130
Z9 140
U1 9
U2 203
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2016
VL 10
IS 6
BP 5759
EP 5768
DI 10.1021/acsnano.5b07828
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA DQ1PU
UT WOS:000378973700019
PM 27176123
DA 2025 08 17
ER

PT J
AU Panuccio, V
   Cutrupi, S
   Pizzini, P
   Mallamaci, F
   Tripepi, G
   Zoccali, C
AF Panuccio, Vincenzo
   Cutrupi, Sebastiano
   Pizzini, Patrizia
   Mallamaci, Francesca
   Tripepi, Giovanni
   Zoccali, Carmine
TI Neuropeptide Y and markers of osteoblast activity in dialysis patients:
   A cross sectional study
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE alkaline phosphatase; bone alkaline phosphatase isoenzyme; low bone
   turnover; neuropeptide Y; osteoblast activity
ID RENAL OSTEODYSTROPHY; HEMODIALYSIS PATIENTS; PARATHYROID HORMONE;
   BONE FORMATION; DISEASE; LEPTIN; PATHWAYS; RECEPTOR; MASS
AB Background: In mice, neuropeptide Y (NPY) decreases bone turnover by means of a parathyroid hormone independent effect on osteoblast activity.
   Study Design: Cross sectional study.
   Setting & Participants: We studied the relationship between levels of NPY and biomarkers of osteoblast activity in 161 nondiabetic patients with end stage renal disease (131 patients, hemodialysis; 30 patients, continuous ambulatory peritoneal dialysis).
   Predictors & Outcomes: We performed an analysis of demographic and clinical variables associated with NPY as a dependent variable and a second analysis testing the association of NPY (as an independent variable) with markers of osteoblast activity.
   Results: Peritoneal dialysis as treatment modality (beta = 0.37; P < 0.001) and longer duration of dialysis therapy (beta = 0.24; P < 0.01) were independently related to plasma NPY. NPY level was related inversely (P < 0.001) to serum alkaline phosphatase and bone alkaline phosphatase levels (P = 0.01). The NPY alkaline phosphatase link was confirmed in a multiple regression analysis adjusting for a series of potential confounders, including parathyroid hormone. In a categorical analysis in which the study population was divided according to NPY quartiles, the proportion of patients with low alkaline phosphatase levels was lowest in the first 2 NPY quartiles (26%) and highest in NPY quartile 4 (80%; P < 0.001), and this association held true in a multiple logistic regression analysis, indicating that the risk of low alkaline phosphatase level increases in parallel with NPY level.
   Limitations: The hypothesis generated by this cross sectional study needs to be confirmed in cohort studies.
   Conclusions: The inverse relationships between levels of NPY and biomarkers of bone turnover support the hypothesis that NPY may be implicated in low bone turnover in dialysis patients by a central parathyroid independent mechanism.
C1 [Panuccio, Vincenzo; Cutrupi, Sebastiano; Pizzini, Patrizia; Mallamaci, Francesca; Tripepi, Giovanni; Zoccali, Carmine] Inst Biomed Clin Epidemiol & Physiopathol Renal D, CNR IBIM, Natl Res Council, I 89124 Reggio Di Calabria, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di
   Immunologia Molecolare "Alberto Monroy" (IBIM CNR)
RP Zoccali, C (通讯作者)，Inst Biomed Clin Epidemiol & Physiopathol Renal D, CNR IBIM, Natl Res Council, C O Euroline Di Ascrizzi Vincenzo,Via Vallone Pet, I 89124 Reggio Di Calabria, Italy.
EM carmine.zoccali@tin.it
RI ; Zoccali, Carmine/B 9445 2009
OI Pizzini, Patrizia/0000 0003 4023 6299; Zoccali,
   Carmine/0000 0002 6616 1996
CR Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   BALDOCK PA, 1988, J AUTONOM NERV SYST, V25, P119
   Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705
   Brancaccio D, 2006, J NEPHROL, V19, P12
   CARO JF, 1978, LANCET, V2, P451
   Coen G, 1998, NEPHROL DIAL TRANSPL, V13, P2294, DOI 10.1093/ndt/13.9.2294
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Hernandez JD, 2005, SEMIN DIALYSIS, V18, P290, DOI 10.1111/j.1525 139X.2005.18404.x
   HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307
   Jehle PM, 2000, KIDNEY INT, V57, P423, DOI 10.1046/j.1523 1755.2000.t01 1 00862.x
   KALRA SP, 2001, PEPTIDES, V22, P309
   MALLUCHE HH, 1992, KIDNEY INT, V42, pS62
   Navarro JF, 1999, AM J KIDNEY DIS, V34, P43, DOI 10.1016/S0272 6386(99)70106 X
   Panuccio V, 2002, AM J KIDNEY DIS, V40, P810, DOI 10.1053/ajkd.2002.35693
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   STRIDSBERG M, 1989, CLIN CHIM ACTA, V185, P61, DOI 10.1016/0009 8981(89)90131 9
   1991, PRACTICAL STAT MED R, P303
NR 18
TC 9
Z9 15
U1 1
U2 1
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0272 6386
EI 1523 6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD DEC
PY 2007
VL 50
IS 6
BP 1001
EP 1008
DI 10.1053/j.ajkd.2007.09.001
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 285TO
UT WOS:000254799300013
PM 18037100
DA 2025 08 17
ER

PT J
AU Ma, Y
   Elefteriou, F
AF Ma, Yun
   Elefteriou, Florent
TI Brain Derived Acetylcholine Maintains Peak Bone Mass in Adult Female
   Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE AGING; BONE REMODELING; BONE BRAIN NERVOUS SYSTEM INTERACTIONS
ID FOREBRAIN CHOLINERGIC NEURONS; ALZHEIMERS DISEASE PATIENTS;
   BLOOD PRESSURE; NERVOUS SYSTEM; HIP FRACTURE; AUTONOMIC SUPPORT;
   RECEPTORS; EXPRESSION; OSTEOBLAST; INNERVATION
AB Preclinical and clinical data support a role of the sympathetic nervous system in the regulation of bone remodeling, but the contribution of parasympathetic arm of the autonomic nervous system to bone homeostasis remains less studied. In this study, we sought to determine whether acetylcholine (ACh) contributes to the regulation of bone remodeling after peak bone mass acquisition. We show that reduced central ACh synthesis in mice heterozygous for the choline transporter (ChT) leads to a decrease in bone mass in young female mice, thus independently confirming the previously reported beneficial effect of ACh signaling on bone mass accrual. Increasing brain ACh levels through the use of the blood brain barrier (BBB) permeable acetylcholinesterase inhibitor (AChEI) galantamine increased trabecular bone mass in adult female mice, whereas a peripheral increase in ACh levels induced by the BBB impermeable AChEI pyridostigmine caused trabecular bone loss. AChEIs did not alter skeletal norepinephrine level, and induced an overall increase in osteoblast and osteoclast densities, two findings that do not support a reduction in sympathetic outflow as the mechanism involved in the pro anabolic effect of galantamine on the skeleton. In addition, we did not detect changes in the commitment of skeletal progenitor cells to the osteoblast lineage in vivo in AChEI treated mice, nor a direct impact of these drugs in vitro on the survival and differentiation of osteoblast and osteoclast progenitors. Last, ChT heterozygosity and galantamine treatment triggered bone changes in female mice only, thus revealing the existence of a gender specific skeletal response to brain ACh level. In conclusion, this study supports the stimulatory effect of central ACh on bone mass accrual, shows that it also promotes peak bone mass maintenance in adult mice, and suggests that central ACh regulates bone mass via different mechanisms in growing versus sexually mature mice. (c) 2020 American Society for Bone and Mineral Research.
C1 [Ma, Yun; Elefteriou, Florent] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,ABBR716, Houston, TX 77030 USA.
   [Ma, Yun; Elefteriou, Florent] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Elefteriou, F (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,ABBR716, Houston, TX 77030 USA.; Elefteriou, F (通讯作者)，Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA.
EM florent.elefteriou@bcm.edu
RI ; Ma, Yun/HRD 3253 2023; Elefteriou, Florent/P 2586 2017
OI , Yun/0000 0003 2122 3695; Elefteriou, Florent/0000 0002 2972 5633
FU NIH National Institute on Aging [R01 AG055394]
FX This work was supported by the NIH National Institute on Aging (R01
   AG055394 to FE). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the NIH. We
   thank Dr. Randy Blakely for sharing the ChT mouse line as well as Dr.
   Ginger Milne (VUMC Neurochemistry Core), Dr. Sassi Uppuganti, Dr.
   Yuantee Zhu, and Mr. Gerard Portella for their technical assistance.
CR Bajayo A, 2012, P NATL ACAD SCI USA, V109, P15455, DOI 10.1073/pnas.1206061109
   Baker SE, 2018, HYPERTENSION, V72, P1236, DOI 10.1161/HYPERTENSIONAHA.118.11550
   Barnes JN, 2014, HYPERTENSION, V63, P303, DOI 10.1161/HYPERTENSIONAHA.113.02393
   Bazalakova MH, 2007, GENES BRAIN BEHAV, V6, P411, DOI 10.1111/j.1601 183X.2006.00269.x
   Bernatova I, 2003, PHARMACOL BIOCHEM BE, V74, P901, DOI 10.1016/S0091 3057(03)00012 1
   Bonnet N, 2007, J APPL PHYSIOL, V102, P1502, DOI 10.1152/japplphysiol.00815.2006
   Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Bonnet N, 2007, J BONE MINER RES, V22, P578, DOI 10.1359/JBMR.070117
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Briant LJB, 2016, J PHYSIOL LONDON, V594, P4753, DOI 10.1113/JP272167
   Castañeda Corral G, 2011, NEUROSCIENCE, V178, P196, DOI 10.1016/j.neuroscience.2011.01.039
   Chartier SR, 2014, PAIN, V155, P2323, DOI 10.1016/j.pain.2014.08.026
   Dajas Bailador FA, 2003, MOL PHARMACOL, V64, P1217, DOI 10.1124/mol.64.5.1217
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eimar H, 2013, J MUSCULOSKEL NEURON, V13, P454
   Eimar H, 2016, BONE, V84, P131, DOI 10.1016/j.bone.2015.12.009
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elefteriou F, 2018, PHYSIOL REV, V98, P1083, DOI 10.1152/physrev.00014.2017
   En Nosse M, 2009, CELL TISSUE RES, V338, P203, DOI 10.1007/s00441 009 0871 1
   Fan W, 2010, J MOL HISTOL, V41, P51, DOI 10.1007/s10735 010 9261 y
   Farr JN, 2012, J CLIN ENDOCR METAB, V97, P4219, DOI 10.1210/jc.2012 2381
   Ferguson SM, 2004, P NATL ACAD SCI USA, V101, P8762, DOI 10.1073/pnas.0401667101
   Ferguson SM, 2003, J NEUROSCI, V23, P9697
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Geerts H, 2005, BRAIN RES, V1033, P186, DOI 10.1016/j.brainres.2004.11.042
   Genever PG, 1999, BONE, V24, P297, DOI 10.1016/S8756 3282(98)00187 2
   Giacobini E, 2018, CURR ALZHEIMER RES, V15, P1077, DOI 10.2174/1567205015666180613111504
   Gibbs RB, 1998, EXP NEUROL, V151, P289, DOI 10.1006/exnr.1998.6789
   GIBBS RB, 1994, ANN NY ACAD SCI, V743, P165, DOI 10.1111/j.1749 6632.1994.tb55792.x
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   GOVYRIN V. A., 1968, ARKH ANAT GISTOL EMBRIOL, V54, P81
   Grauer E, 2000, TOXICOL APPL PHARM, V164, P301, DOI 10.1006/taap.2000.8906
   He HB, 1997, J CHROMATOGR B, V701, P115, DOI 10.1016/S0378 4347(97)00343 5
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Hoogduijn MJ, 2009, STEM CELLS DEV, V18, P103, DOI 10.1089/scd.2008.0032
   Inkson CA, 2004, BONE, V35, P819, DOI 10.1016/j.bone.2004.05.026
   Iwamoto H, 2016, NEUROCHEM INT, V98, P138, DOI 10.1016/j.neuint.2016.03.012
   Jones PP, 2001, CIRCULATION, V104, P2424, DOI 10.1161/hc4501.099308
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Lips KS, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0459 8
   Liu PS, 2011, EUR J PHARMACOL, V650, P34, DOI 10.1016/j.ejphar.2010.09.031
   LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006 8993(75)90704 0
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ogunwale AN, 2020, J BONE MINER RES, V35, P440, DOI 10.1002/jbmr.3916
   POPA A. V., 1959, ARKH ANAT GISTOL I EMBRIOL, V36, P71
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   Robertson D, 2012, PRIMER AUTONOMIC NER, P703
   Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774 009 0075 5
   Samochocki M, 2003, J PHARMACOL EXP THER, V305, P1024, DOI 10.1124/jpet.102.045773
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   Sato T, 2015, HELIYON, V1, DOI 10.1016/j.heliyon.2015.e00013
   Sato T, 2010, FEBS LETT, V584, P817, DOI 10.1016/j.febslet.2010.01.001
   Shi Y, 2010, CELL METAB, V11, P231, DOI 10.1016/j.cmet.2010.01.005
   Sisask G, 1996, J AUTONOM NERV SYST, V59, P27, DOI 10.1016/0165 1838(95)00139 5
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tamimi I, 2017, J MUSCULOSKEL NEURON, V17, P69
   Tamimi I, 2012, J BONE MINER RES, V27, P1518, DOI 10.1002/jbmr.1616
   Tomlinson RE, 2016, CELL REP, V16, P2723, DOI 10.1016/j.celrep.2016.08.002
   Walker LM, 2001, BONE, V28, P603, DOI 10.1016/S8756 3282(01)00427 6
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto H, 2007, J STEROID BIOCHEM, V107, P70, DOI 10.1016/j.jsbmb.2007.03.035
   Yano K, 2009, BRIT J PHARMACOL, V156, P173, DOI 10.1111/j.1476 5381.2008.00037.x
   Zhang WP, 2007, AM J CHINESE MED, V35, P89, DOI 10.1142/S0192415X07004655
   Zhu Yuantee, 2018, Bone Rep, V9, P188, DOI 10.1016/j.bonr.2018.11.002
NR 68
TC 14
Z9 17
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2020
VL 35
IS 8
BP 1562
EP 1571
DI 10.1002/jbmr.4024
EA APR 2020
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MZ1FZ
UT WOS:000529284400001
PM 32282950
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Block, GA
   Bone, HG
   Fang, L
   Lee, E
   Padhi, D
AF Block, Geoffrey A.
   Bone, Henry G.
   Fang, Liang
   Lee, Edward
   Padhi, Desmond
TI A single dose study of denosumab in patients with various degrees of
   renal impairment
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CHRONIC KIDNEY DISEASE; BONE; PHARMACOKINETICS; CALCIUM; VITAMIN D
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN; LIGAND; ALENDRONATE; FRACTURES; TURNOVER; AMG 162;
   RANKL
AB This 16 week study evaluated pharmacokinetics and pharmacodynamics of denosumab in 55 subjects with renal function ranging from normal to dialysis dependent kidney failure. Participants received a single 60 mg subcutaneous dose of denosumab. Kidney function groups were based on calculations using the Cockcroft Gault equation and U.S. Food and Drug Administration (FDA) guidance in place when the study was designed. Renal function did not have a significant effect on denosumab pharmacokinetics or pharmacodynamics. These findings suggest denosumab dose adjustment based on glomerular filtration rate is not required. Rapid decreases in serum C telopeptide in all groups were sustained throughout the study. The most common adverse events were hypocalcemia (15%), pain in extremity (15%), and nausea (11%). Most adverse events were mild to moderate in severity. Calcium and vitamin D supplementation was not initially required by the study protocol, but was added during the trial. No subject who received adequate calcium and vitamin D supplementation became hypocalcemic. Seven subjects had nadir serum calcium concentrations between 7.5 and <8.0?mg/dL (1.9 and <2.0?mmol/L), and 5 subjects (4 with advanced renal disease) had nadir serum calcium <7.5?mg/dL (<1.9?mmol/L). Two subjects (1 symptomatic, 1 asymptomatic) were hospitalized for intravenous calcium gluconate treatment. At the recommended dose, denosumab is a useful therapeutic option for patients with impaired renal function. Supplementation of calcium and vitamin D is strongly recommended when patients initiate denosumab therapy, particularly in patients with reduced renal function. (c) 2012 American Society for Bone and Mineral Research.
C1 [Block, Geoffrey A.] Denver Nephrologists, PC, Div Clin Res, Denver, CO USA.
   [Bone, Henry G.] Michigan Bone & Mineral Clin, Detroit, MI USA.
   [Fang, Liang; Lee, Edward; Padhi, Desmond] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Amgen
RP Padhi, D (通讯作者)，1 Amgen Ctr Dr,MS 38 3 A, Thousand Oaks, CA 91320 USA.
EM dpadhi@amgen.com
RI Block, Geoffrey/AAV 8070 2021; Fang, Liang/AGI 2303 2022; Lee,
   Edward/AAU 4604 2021
FU Amgen Inc.
FX We thank the investigators and study sites for their contributions to
   the study. This work was supported by Amgen Inc. Jonathan Latham of
   PharmaScribe LLC received funding from Amgen Inc. to assist the authors
   with preparation of the manuscript and to provide medical writing
   assistance in the drafting and revising of the manuscript.
CR [Anonymous], 1998, GUID IND PHARM PAT I
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   BRASIER AR, 1988, AM J MED, V84, P654, DOI 10.1016/0002 9343(88)90100 3
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Ishani A, 2008, OSTEOPOROSIS INT, V19, P1549, DOI 10.1007/s00198 008 0608 0
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Jamal SA, 2010, AM J KIDNEY DIS, V55, P291, DOI 10.1053/j.ajkd.2009.10.049
   Jassal SK, 2007, J BONE MINER RES, V22, P203, DOI 10.1359/JBMR.061014
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Padagas J, 2006, CALCIFIED TISSUE INT, V78, P35, DOI 10.1007/s00223 005 0161 1
   Pagani F, 2000, CLIN CHEM LAB MED, V38, P1111, DOI 10.1515/CCLM.2000.166
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Reclast® (zoledronic acid) injection, 2011, FULL PRESCR INF
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Toussaint ND, 2009, CLIN J AM SOC NEPHRO, V4, P221, DOI 10.2215/CJN.02550508
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 28
TC 246
Z9 259
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2012
VL 27
IS 7
BP 1471
EP 1479
DI 10.1002/jbmr.1613
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 959EZ
UT WOS:000305297000005
PM 22461041
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Bidwell, JP
   Alvarez, MB
   Hood, M
   Childress, P
AF Bidwell, Joseph P.
   Alvarez, Marta B.
   Hood, Mark, Jr.
   Childress, Paul
TI Functional Impairment of Bone Formation in the Pathogenesis of
   Osteoporosis: The Bone Marrow Regenerative Competence
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Aging; Mesenchymal stem cells; Nmp4; Osteoblasts; Osteoprogenitors;
   Postmenopause
ID MESENCHYMAL STEM CELLS; PARATHYROID HORMONE; OSTEOBLAST DIFFERENTIATION;
   ANABOLIC ACTIVITY; IMMUNE SYSTEM; AGE; MASS; PROLIFERATION; MAINTENANCE;
   MECHANISMS
AB The skeleton is a high renewal organ that undergoes ongoing cycles of remodeling. The regenerative bone formation arm ultimately declines in the aging, postmenopausal skeleton, but current therapies do not adequately address this deficit. Bone marrow is the primary source of the skeletal anabolic response and the mesenchymal stem cells (MSCs), which give rise to bone matrix producing osteoblasts. The identity of these stem cells is emerging, but it now appears that the term 'MSC' has often been misapplied to the bone marrow stromal cell (BMSC), a progeny of the MSC. Nevertheless, the changes in BMSC phenotype associated with age and estrogen depletion likely contribute to the attenuated regenerative competence of the marrow and may reflect alterations in MSC phenotype. Here we summarize current concepts in bone marrow MSC identity, and within this context, review recent observations on changes in bone marrow population dynamics associated with aging and menopause.
C1 [Bidwell, Joseph P.; Alvarez, Marta B.; Hood, Mark, Jr.; Childress, Paul] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington
RP Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Childress, Paul/AAD 4684 2020
FU Eli Lilly
FX JP Bidwell has a research grant pending from Eli Lilly. JP Bidwell
   declares no conflicts of interest. MB Alvarez declares no conflicts of
   interest. M Hood Jr declares no conflicts of interest. P Childress
   declares no conflicts of interest.
CR [Anonymous], ENDOCR PRACT
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Aubert G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002696
   Baldessari D, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471 2121 5 48
   Beard MK, 2012, CURR MED RES OPIN, V28, P141, DOI 10.1185/03007995.2011.643296
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Chen YJ, 2012, ARCH MED SCI, V8, P30, DOI 10.5114/aoms.2012.27277
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Chou JP, 2012, CURR PHARM DES
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Compton SA, 2008, J BIOL CHEM, V283, P24478, DOI 10.1074/jbc.M803370200
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cusano N.E., 2010, IBMS BoneKEy, V7, P84
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Diderich KEM, 2012, AGE, V34, P845, DOI 10.1007/s11357 011 9291 8
   Donahue HJ, 1997, AM J PHYSIOL ENDOC M, V273, pE776, DOI 10.1152/ajpendo.1997.273.4.E776
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532 5415.2008.01764.x
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fu LN, 2006, PROG BRAIN RES, V153, P177, DOI 10.1016/S0079 6123(06)53010 9
   Genetos DC, 2012, J ORTHOP RES, V30, P1979, DOI 10.1002/jor.22172
   Geng S, 2011, AGING CELL, V10, P962, DOI 10.1111/j.1474 9726.2011.00735.x
   Graham LS, 2009, CLIN IMMUNOL, V133, P265, DOI 10.1016/j.clim.2009.07.011
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hesse E, 2010, J CELL BIOL, V191, P1271, DOI 10.1083/jcb.201009107
   Janssen H, 2006, EXP CELL RES, V312, P1194, DOI 10.1016/j.yexcr.2006.02.001
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Koh AJ, 2011, ENDOCRINOLOGY, V152, P4525, DOI 10.1210/en.2011 1515
   Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Lowrey PL, 2011, ADV GENET, V74, P175, DOI 10.1016/B978 0 12 387690 4.00006 4
   Lu WS, 2013, EXP CELL RES, V319, P133, DOI 10.1016/j.yexcr.2012.09.005
   Mackiewicz Z, 2011, FOLIA HISTOCHEM CYTO, V49, P558, DOI 10.5603/FHC.2011.0079
   Manolagas SC, 2013, BONE, V54, P272, DOI 10.1016/j.bone.2012.09.017
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martin TJ, 2008, OSTEOPOROSIS INT, V19, P1125, DOI 10.1007/s00198 008 0575 5
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   Mendez Bermudez A, 2012, NUCLEIC ACIDS RES, V40, P10809, DOI 10.1093/nar/gks862
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Nombela Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049
   Ohishi M, 2011, J ENDOCRINOL INVEST, V34, P552, DOI 10.3275/7620
   Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Pignolo RJ, 2008, AGING CELL, V7, P23, DOI 10.1111/j.1474 9726.2007.00350.x
   Ramírez J, 2010, CURR OPIN IMMUNOL, V22, P177, DOI 10.1016/j.coi.2010.02.003
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Sansoni P, 2008, EXP GERONTOL, V43, P61, DOI 10.1016/j.exger.2007.06.008
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Schuiling KD, 2011, J MIDWIFERY WOM HEAL, V56, P615, DOI 10.1111/j.1542 2011.2011.00135.x
   Shah R, 2004, AM J PHYSIOL ENDOC M, V287, pE289, DOI 10.1152/ajpendo.00517.2003
   Singh L, 2013, STEM CELLS, V31, P607, DOI 10.1002/stem.1294
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Stein GS, 2010, CRIT REV EUKAR GENE, V20, P149, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.50
   Stenderup K, 2001, J BONE MINER RES, V16, P1120, DOI 10.1359/jbmr.2001.16.6.1120
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Sun Y, 2011, FASEB J, V25, P1474, DOI 10.1096/fj.10 161497
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Teven CM, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/201371
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Tümpel S, 2012, ANN NY ACAD SCI, V1266, P28, DOI 10.1111/j.1749 6632.2012.06547.x
   Wakeling EL, 2004, PEDIATR RADIOL, V34, P541, DOI 10.1007/s00247 004 1207 7
   Wang HT, 2012, AGING CELL, V11, P704, DOI 10.1111/j.1474 9726.2012.00838.x
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yang ZQ, 2010, J CELL PHYSIOL, V223, P435, DOI 10.1002/jcp.22057
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Zhang J, 2011, RHEUM DIS CLIN N AM, V37, P387, DOI 10.1016/j.rdc.2011.08.001
   Zhou S, 2012, J STEROID BIOCHEM, DOI [10.1016/j.jsbmb.2012;.09.002, DOI 10.1016/J.JSBMB.2012;.09.002]
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhou SH, 2011, AGING CELL, V10, P780, DOI 10.1111/j.1474 9726.2011.00717.x
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 90
TC 53
Z9 62
U1 0
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD JUN
PY 2013
VL 11
IS 2
BP 117
EP 125
DI 10.1007/s11914 013 0139 2
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA V35YX
UT WOS:000209182000007
PM 23471774
DA 2025 08 17
ER

PT J
AU Sophocleous, A
   Landao Bassonga, E
   van't Hof, RJ
   Idris, AI
   Ralston, SH
AF Sophocleous, Antonia
   Landao Bassonga, Euphemie
   van't Hof, Robert J.
   Idris, Aymen I.
   Ralston, Stuart H.
TI The Type 2 Cannabinoid Receptor Regulates Bone Mass and
   Ovariectomy Induced Bone Loss by Affecting Osteoblast Differentiation
   and Bone Formation
SO ENDOCRINOLOGY
LA English
DT Article
ID OSTEOCLAST FUNCTION; CB2 RECEPTOR; IN VITRO; GPR55; VIVO
AB The type 2 cannabinoid receptor (CB2) has been reported to regulate bone mass and bone turnover but the mechanisms responsible are incompletely understood. In this study we investigated the role that the CB2 pathway plays in bone metabolism using a combination of genetic and pharmacological approaches. Bone mass and turnover were normal in young mice with targeted inactivation of CB2 receptor (CB2( / )), but by 12 months of age, they had developed high turnover osteoporosis with relative uncoupling of bone resorption from bone formation. Primary osteoblasts from CB2( / ) mice had a reduced capacity to form bone nodules in vitro when compared with cells from wild type littermates and also had impaired PTH induced alkaline phosphatase (ALP) activity. The CB2 selective agonist HU308 stimulated bone nodule formation in wild type osteoblasts but had no effect in CB2( / ) osteoblasts. Further studies in MC3T3 E1 osteoblast like cells showed that HU308 promoted cell migration and activated ERK phosphorylation, and these effects were blocked by the CB2 selective inverse agonist AM630. Finally, HU308 partially protected against ovariectomy induced bone loss in wild type mice in vivo, primarily by stimulating bone formation, whereas no protective effects were observed in ovariectomized CB2( / ) mice. These studies indicate that the CB2 regulates osteoblast differentiation in vitro and bone formation in vivo. (Endocrinology 152: 2141 2149, 2011)
C1 [Ralston, Stuart H.] Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Mol Med Ctr,Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Ralston, SH (通讯作者)，Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Mol Med Ctr,Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM stuart.ralston@ed.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Idris, Aymen/0000 0003 4327 5306; Sophocleous,
   Antonia/0000 0003 0854 1429; Landao Bassonga,
   Euphemie/0000 0002 5142 2946; van 't Hof, Rob/0000 0002 8193 6788
FU Arthritis Research United Kingdom [17713]; Versus Arthritis [17713]
   Funding Source: researchfish
FX This work was supported by a grant from Arthritis Research United
   Kingdom (reference 17713).
CR Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014 2999(00)00211 9
   Fernández Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001
   Hipskind R.A., 1998, FRONT BIOSCI, V3, P804, DOI [10.2741/A323, DOI 10.2741/A323]
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P285, DOI 10.1007/s00223 010 9378 8
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004
   Stewart TL, 2005, CALCIFIED TISSUE INT, V77, P113, DOI 10.1007/s00223 004 0188 8
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
NR 14
TC 87
Z9 94
U1 0
U2 12
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0013 7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2011
VL 152
IS 6
BP 2141
EP 2149
DI 10.1210/en.2010 0930
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 766MY
UT WOS:000290788500002
PM 21447627
OA Bronze
DA 2025 08 17
ER

PT J
AU Martínez Reina, J
   Pivonka, P
AF Martinez Reina, Javier
   Pivonka, Peter
TI Effects of long term treatment of denosumab on bone mineral density:
   insights from an in silico model of bone mineralization
SO BONE
LA English
DT Article
DE Postmenopausal osteoporosis; Bone remodeling; Bone mineralization;
   Denosumab; RANK RANKL OPG pathway; PK PD modeling; Bone mineral density
ID POSTMENOPAUSAL OSTEOPOROSIS; SYSTEM ANALYSIS; THERAPY; TISSUE;
   PHARMACODYNAMICS; TURNOVER; DISEASE; SURFACE; WOMEN
AB Denosumab is one of the most commonly prescribed anti resorptive drugs for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab is to inhibit osteoclast differentiation and consequently bone resorption. Gains in bone mineral density (BMD) are achieved based on the ability of the bone matrix to undergo secondary mineralization. Experimental data show that the increase of BMD after commencing denosumab treatment are bone site specific.
   In this paper, we developed a comprehensive mechanistic pharmacokinetic pharmacodymamic (PK PD) model of the effect of denosumab on bone remodeling in postmenopausal osteoporosis (PMO). The PD model is based on a bone cell population model describing the bone remodeling process at the tissue scale. The conceptual model of the bone mineralization process, originally proposed by Boivin and Meunier, is quantitatively incorporated using a FIFO (First In First Out) queue algorithm. The latter takes into account the balance of mineral within bone tissue due to the mineralization process, distinguishing the primary and secondary phases and removal of bone matrix due to bone resorption. The numerical simulations show that the model is able to predict the bone site specific increase in BMD as was observed in the experimental data of Bone et al. 2008 for a typical denosumab administration pattern of 60 mg every 6 months. At the hip a 5 % increase in BMD was observed, while at the lumbar spine a 7.5 % increase of BMD was achieved after a 2 year treatment period. The difference in BMD is due to the fact that bone turnover at the hip is lower compared to lumbar spine and consequently has less potential for secondary mineralization. Parametric studies revealed that the rate of bone mineralization is an essential parameter regulating BMD gains. If mineralization is neglected only minimal increases in BMD are observed.
C1 [Martinez Reina, Javier] Univ Seville, Dept Ingn Mecan & Fabricat, Seville 41092, Spain.
   [Pivonka, Peter] Queensland Univ Technol, Sch Chem Phys & Mech Engn, 2 George St, Brisbane, Qld 4000, Australia.
   [Martinez Reina, Javier] Univ Seville, Escuela Tecn Super Ingn, Dept Ingn Mecan & Fabricat, Camino Descrubrimientos S N, Seville 41092, Spain.
C3 University of Sevilla; Queensland University of Technology (QUT);
   University of Sevilla
RP Martínez Reina, J (通讯作者)，Univ Seville, Dept Ingn Mecan & Fabricat, Seville 41092, Spain.; Martínez Reina, J (通讯作者)，Univ Seville, Escuela Tecn Super Ingn, Dept Ingn Mecan & Fabricat, Camino Descrubrimientos S N, Seville 41092, Spain.
EM jmreina@us.es
RI ; Pivonka, Peter/AAL 1053 2021; Martínez Reina, Javier/K 2806 2014;
   Martinez Reina, Javier/K 2806 2014
OI Pivonka, Peter/0000 0001 9183 530X; Martinez Reina,
   Javier/0000 0003 2038 2336
CR Anagnostis P, 2017, MATURITAS, V101, P23, DOI 10.1016/j.maturitas.2017.04.008
   Bala Y, 2013, OSTEOPOROSIS INT, V24, P2153, DOI 10.1007/s00198 012 2228 y
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Boivin G, 2002, CALCIFIED TISSUE INT, V70, P503, DOI 10.1007/s00223 001 2048 0
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Currey JD, 2004, J BIOMECH, V37, P549, DOI 10.1016/j.jbiomech.2003.08.008
   Dua P, 2015, CPT PHARMACOMET SYST, V4, P324, DOI 10.1002/psp4.41
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   Frost H. M., 1963, BONE REMODELING DYNA
   Hernandez CJ, 2000, J REHABIL RES DEV, V37, P235
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   MARTIN RB, 1984, CRIT REV BIOMED ENG, V10, P179
   Martínez Reina J, 2008, J THEOR BIOL, V254, P704, DOI 10.1016/j.jtbi.2008.06.007
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   McClung Michael R, 2017, Osteoporos Sarcopenia, V3, P8
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Need AG, 2007, J BONE MINER RES, V22, P757, DOI [10.1359/jbmr.070203, 10.1359/JBMR.070203]
   Parfitt A.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P143
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Post TM, 2005, PHARM RES DORDR, V22, P1038, DOI 10.1007/s11095 005 5641 5
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
NR 34
TC 28
Z9 29
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2019
VL 125
BP 87
EP 95
DI 10.1016/j.bone.2019.04.022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IG1MI
UT WOS:000473555300011
PM 31055117
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hughes, R
   Chen, XY
   Hunter, KD
   Hobbs, JK
   Holen, I
   Brown, NJ
AF Hughes, Russell
   Chen, Xinyue
   Hunter, Keith D.
   Hobbs, Jamie K.
   Holen, Ingunn
   Brown, Nicola J.
TI Bone marrow osteoprogenitors are depleted whereas osteoblasts are
   expanded independent of the osteogenic vasculature in response to
   zoledronic acid
SO FASEB JOURNAL
LA English
DT Article
DE ZOL; bone microenvironment; bone microvasculature; mesenchymal stromal
   cells
ID NITROGEN CONTAINING BISPHOSPHONATES; OSTEOCLAST DIFFERENTIATION FACTOR;
   MESENCHYMAL STEM CELLS; IN VIVO; MORPHOGENETIC PROTEINS; POSTMENOPAUSAL
   WOMEN; MEVALONATE PATHWAY; DENDRITIC CELLS; DISTINCT ROLES; ANGIOGENESIS
AB Zoledronic acid (ZOL) is an antiresorptive drug used to prevent bone loss in a variety of conditions, acting mainly through suppression of osteoclast activity. There is growing evidence that ZOL can also affect cells of the mesenchymal lineage in bone. We present novel data revealing significant changes in the abundance of perivascular mesenchymal stromal cells (MSCs)/osteoprogenitors and osteoblasts following the injection of ZOL, in vivo. In young mice with high bone turnover and an abundance of perivascular osteoprogenitors, ZOL significantly (P < 0.0001) increased new bone formation. This was accompanied by a decline in osterix positive osteoprogenitors and a corresponding increase in osteoblasts. However, these effects were not observed in mature mice with low bone turnover. Interestingly, the ZOL induced changes in cells of the mesenchymal lineage occurred independently of effects on the osteogenic vasculature. Thus, we demonstrate that a single, clinically relevant dose of ZOL can induce new bone formation in microenvironments enriched for perivascular MSC/osteoprogenitors and high osteogenic potential. This arises from the differentiation of perivascular osterix positive MSC/osteoprogenitors into osteoblasts at sites that are innately osteogenic. Collectively, our data demonstrate that ZOL affects multiple cell types in bone and has differential effects depending on the level of bone turnover.
C1 [Hughes, Russell; Chen, Xinyue; Holen, Ingunn; Brown, Nicola J.] Univ Sheffield, Expt Canc Med Ctr, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Chen, Xinyue; Hobbs, Jamie K.] Univ Sheffield, Dept Phys & Astron, Sheffield, S Yorkshire, England.
   [Hunter, Keith D.] Univ Sheffield, Sch Clin Dent, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Brown, NJ (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 4RX, S Yorkshire, England.
EM n.j.brown@sheffield.ac.uk
RI ; chen, xinyue/HHR 9308 2022; Hunter, Keith/B 5670 2009; Hughes,
   Russell/KDN 6697 2024; Hunter, Keith/M 9784 2019
OI Holen, Ingunn/0000 0002 8759 6913; Chen, Xinyue/0000 0001 6987 5540;
   Hunter, Keith/0000 0002 7873 0877
FU Cancer Research UK; Engineering and Physical Sciences Research Council
   [A21082]; Weston Park Cancer Charity (Sheffield, United Kingdom)
FX The authors thank the Wolfson Light Microscopy Facility at the
   University of Sheffield for use of the Nikon A1 (Wellcome Trust Grant
   WT093134AIA) and Zeiss LSM880 AiryScan microscopes. This research was
   supported by Cancer Research UK and the Engineering and Physical
   Sciences Research Council (Grant A21082). Histology support was provided
   by Alyson Evans (Department of Oncology and Metabolism, University of
   Sheffield), who is funded by Weston Park Cancer Charity (Sheffield,
   United Kingdom); both are gratefully acknowledged. I.H. and N.J.B. are
   joint senior authors. The authors declare no conflicts of interest.
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Biver E, 2010, BONE, V46, P643, DOI 10.1016/j.bone.2009.10.034
   BLUM CB, 1994, AM J CARDIOL, V74, P639
   Borghese C, 2017, ONCOTARGET, V8, P42926, DOI 10.18632/oncotarget.17216
   Brufsky A, 2007, J CLIN ONCOL, V25, P829, DOI 10.1200/JCO.2005.05.3744
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043 6618(95)80042 5
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Dalle Carbonare L., 2017, INT J MOL SCI, V18, pE1261
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Fournier P, 2002, CANCER RES, V62, P6538
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Hustedt Joshua W., 2014, Yale Journal of Biology and Medicine, V87, P549
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jacome Galarza CE, 2013, J BONE MINER RES, V28, P1203, DOI 10.1002/jbmr.1822
   Kaiser T, 2013, BREAST CANCER RES TR, V140, P35, DOI 10.1007/s10549 013 2613 z
   Kalajzic Z, 2008, BONE, V43, P501, DOI 10.1016/j.bone.2008.04.023
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lang M, 2016, BRIT J ORAL MAX SURG, V54, P889, DOI 10.1016/j.bjoms.2016.05.030
   Llombart A, 2012, CLIN BREAST CANCER, V12, P40, DOI 10.1016/j.clbc.2011.08.002
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Michailidou M, 2010, J VASC RES, V47, P481, DOI 10.1159/000313876
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sanchez Fernandez MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003537
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Soki FN, 2013, J CELL BIOCHEM, V114, P67, DOI 10.1002/jcb.24301
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Tan SH, 2014, P NATL ACAD SCI USA, V111, pE5262, DOI 10.1073/pnas.1420463111
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tokunaga A, 2008, J BONE MINER RES, V23, P1519, DOI 10.1359/JBMR.080409
   Ubellacker JM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0815 8
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshida CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032364
NR 62
TC 4
Z9 4
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2019
VL 33
IS 11
BP 12768
EP 12779
DI 10.1096/fj.201900553RR
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KC8ZX
UT WOS:000507461600091
PM 31490705
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, C
   Tian, LR
   Wang, YH
   Luo, H
   Zeng, J
   Su, PQ
   Chen, SL
   Liao, ZH
   Guo, WM
   He, XJ
   Chen, SQ
   Xu, CX
AF Li, Chuan
   Tian, Liru
   Wang, Yihai
   Luo, Huan
   Zeng, Jia
   Su, Peiqiang
   Chen, Shulin
   Liao, Zhiheng
   Guo, Weimin
   He, Xiangjiu
   Chen, Shuqing
   Xu, Caixia
TI M13, an anthraquinone compound isolated from Morinda officinalis
   promotes the osteogenic differentiation of MSCs by targeting
   Wnt/β catenin signaling
SO PHYTOMEDICINE
LA English
DT Article
DE Morinda officinalis; Anthraquinone; Osteoporosis; MSCS;
   Wnt/beta catenin; Osteogenic
ID MESENCHYMAL STEM CELLS; BONE
AB Background: Morinda officinalis (MO) is a herb used in Traditional Chinese Medicine (TCM) for the treatment of osteoporosis. M13, a MO based anthraquinone compound is known to suppress osteoclast activity. However, whether M13 promotes MSCs osteogenic differentiation and its potential mechanism remains unknown.
   Purpose: To examine the influence of M13 on MSCs proliferation and osteogenic differentiation and elucidate the underlying mechanism.
   Methods/Study designs: The effect of M13 exposure on MSCs proliferation was assessed via CCK8 assay, clone formation assay, immunofluorescence, RT qPCR, and Western blot. The M13 mediated osteogenesis in vitro and ex vivo were evaluated via ALP and Alizarin red S staining, osteogenesis associated gene (Runx2, Col1a1 and Opn) expression, and fetal limb explants culture. Molecular docking was employed for target signal pathway screening. The potential signaling mechanisms of M13 promoted MSCs osteogenic differentiation were analyzed by introducing XAV939 (Wnt/beta catenin signaling inhibitor).
   Results: M13 induced certain obvious positive effects on MSCs proliferation and osteogenic differentiation. Treatment with M13 enhanced MSCs viability and clone numbers. Meanwhile, M13 promoted osteogenic gene expression, enhanced ALP intensity and Alizarin red S staining in MSCs. In terms of mechanism, M13 strongly interacted with the docking site of the WNT signaling complex, thereby activating the Wnt/beta catenin pathway. Furthermore, the M13 mediated osteogenic effect was partially inhibited by XAV939 both in vitro and ex vivo, which confirmed that the Wnt/beta catenin axis is a critical regulator of M13 induced osteogenic differentiation of MSCs.
   Conclusion: Our study elucidated for the first time that M13 significantly promoted osteogenic differentiation of MSCs via stimulation of the Wnt/beta catenin pathway in vitro and ex vivo.Our findings offered new additional evidence to support the MO or M13 based therapy of osteoporosis.
C1 [Li, Chuan; Tian, Liru; Chen, Shulin; Xu, Caixia] Sun Yat Sen Univ, Affiliated Hosp 1, Res Ctr Translat Med, Guangzhou 510006, Peoples R China.
   [Wang, Yihai; Luo, Huan; Zeng, Jia; He, Xiangjiu] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China.
   [Wang, Yihai; Luo, Huan; Zeng, Jia; He, Xiangjiu] Guangdong Engn Res Ctr Lead Cpds & Drug Discovery, Guangzhou 510006, Peoples R China.
   [Su, Peiqiang; Liao, Zhiheng; Guo, Weimin] Sun Yat Sen Univ, Guangdong Prov Key Lab Orthoped & Traumatol, Dept Spine Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
   [Chen, Shuqing] Sun Yat Sen Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Guangzhou 510006, Peoples R China.
C3 Sun Yat Sen University; Guangdong Pharmaceutical University; Sun Yat Sen
   University; Sun Yat Sen University
RP Xu, CX (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Res Ctr Translat Med, Guangzhou 510006, Peoples R China.; He, XJ (通讯作者)，Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China.; He, XJ (通讯作者)，Guangdong Engn Res Ctr Lead Cpds & Drug Discovery, Guangzhou 510006, Peoples R China.; Chen, SQ (通讯作者)，Sun Yat Sen Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Guangzhou 510006, Peoples R China.
EM hexiangjiu@163.com; chshuq@mail.sysu.edu.cn; xucx3@mail.sysu.edu.cn
RI ZHOU, YUE/IZE 6277 2023; chen, chen/JGD 3057 2023; Wu,
   Changjin/AAH 8856 2021; Wang, Yihai/L 7462 2019
FU National Natural Science Foundation of China [82072385, 92068105,
   82172376]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 82072385, 92068105, 82172376)
CR Bao LL, 2011, CHEM BIOL INTERACT, V194, P97, DOI 10.1016/j.cbi.2011.08.013
   Cao HJ, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152860
   Cen SZ, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102722
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen XX, 2020, FOOD FUNCT, V11, P1165, DOI [10.1039/c9fo01918a, 10.1039/C9FO01918A]
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   El Rayes SM, 2020, ACS OMEGA, V5, P6781, DOI 10.1021/acsomega.0c00116
   Fu SQ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000056
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Jiang TY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1511 7
   Jiménez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Li TY, 2022, CARBOHYD POLYM, V276, DOI 10.1016/j.carbpol.2021.118730
   Liao Y, 2020, MOL THER, V28, P855, DOI 10.1016/j.ymthe.2020.01.011
   Liu D, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.108990
   Liu Y, 2014, CLIN EXP MED, V14, P13, DOI 10.1007/s10238 012 0218 1
   Luo H, 2021, BIOORG CHEM, V110, DOI 10.1016/j.bioorg.2021.104800
   Ma XL, 2021, EUR J PHARMACOL, V911, DOI 10.1016/j.ejphar.2021.174555
   Moon DK, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01684 9
   Pan FF, 2021, AM J PHYSIOL ENDOC M, V320, pE760, DOI 10.1152/ajpendo.00543.2019
   Ramesh T, 2021, CELL BIOCHEM FUNCT, V39, P148, DOI 10.1002/cbf.3596
   Shu B, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07633 7
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang N, 2013, CHIN MED UK, V8, DOI 10.1186/1749 8546 8 17
   Wang W, 2022, CLIN EXP PHARMACOL P, V49, P113, DOI 10.1111/1440 1681.13591
   Wang YQ, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109807
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yang XM, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 00462 8
   Zheng SH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4180857
   Zhou TF, 2018, CELL PHYSIOL BIOCHEM, V48, P880, DOI 10.1159/000491956
   Zuo HL, 2020, CLIMACTERIC, V23, P404, DOI 10.1080/13697137.2020.1758057
NR 34
TC 8
Z9 10
U1 3
U2 16
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2023
VL 108
AR 154542
DI 10.1016/j.phymed.2022.154542
EA NOV 2022
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA E9XG6
UT WOS:000978977900004
PM 36410102
OA hybrid
DA 2025 08 17
ER

PT J
AU Irelli, A
   Sirufo, MM
   D'Ugo, C
   Ginaldi, L
   De Martinis, M
AF Irelli, Azzurra
   Sirufo, Maria Maddalena
   D'Ugo, Carlo
   Ginaldi, Lia
   De Martinis, Massimo
TI Real life use of denosumab 120 mg every 12 weeks in prolonged treatment
   over 2 years of patients with breast cancer bone metastases
SO JOURNAL OF BUON
LA English
DT Article
DE breast cancer; denosumab; osteoporosis; bone; aromatase inhibitors; bone
   metastasis; skeletal health
ID CLINICAL FEATURES; ZOLEDRONIC ACID; BISPHOSPHONATES; INHIBITORS;
   CARCINOMA; EFFICACY; SAFETY
AB Purpose: To analyze the activity and safety of denosumab (DNS) 120 mg every 3 months over 2 years of standard treatment (120 mg SC every 4 weeks) of patients with breast cancer bone metastases in real life.
   Methods: We prospectively analyzed the activity and safety of denosumab 120 mg every 3 months and 120 mg every 4 weeks in the treatment of 22 patients with breast cancer bone metastases over 2 years of standard treatment. All patients received specific concomitant antineoplastic treatment, chemotherapy or endocrine therapy and/or target therapy. Oral daily calcium (>500 mg) and vitamin D (>1000 U) supplement was recommended.
   Results: Of the 22 patients treated with denosumab, 4 (18.1%) had at least 1 skeletal related event (SRE); 3 (13.6%) had 1 SRE and 1 patient (4.5%) had 2 SRE, all 10% treated with radiotherapy. Overall, no denosumab related G3 adverse events occurred; in particular, no cases of osteonecrosis of the jaw have been recorded. The decrease in serum calcium levels was mild (G1, 2 patients, 9%), and recovered in a short time (within 2 weeks) with an increase in the oral support of calcium and vitamin D.
   Conclusions: Denosumab confirms a good activity profile in terms of delaying and preventing SREs in breast cancer patients and a good safety profile. It represents an optimal treatment resource which doesn't necessitate renal function monitoring and has the convenience of a subcutaneous administration.
C1 [Irelli, Azzurra] AUSL 04 Teramo, Dept Oncol, Med Oncol Unit, Teramo, Italy.
   [Sirufo, Maria Maddalena; Ginaldi, Lia; De Martinis, Massimo] Univ Aquila, Dept Life Hlth & Environm Sci, Piazzale Salvatore Tommasi 1, I 67100 Laquila, Italy.
   [Sirufo, Maria Maddalena; Ginaldi, Lia; De Martinis, Massimo] AUSL 04 Teramo, Ctr Diag & Treatment Osteoporosis, Allergy & Clin Immunol Unit, Teramo, Italy.
   [D'Ugo, Carlo] AUSL 04 Teramo, Dept Oncol, Radiotherapy Unit, Teramo, Italy.
C3 University of L'Aquila
RP De Martinis, M (通讯作者)，Univ Aquila, Dept Life Hlth & Environm Sci, Piazzale Salvatore Tommasi 1, I 67100 Laquila, Italy.
EM demartinis@cc.univaq.it
RI ; DE MARTINIS, MASSIMO/N 8725 2015
OI Irelli, Azzurra/0000 0003 4724 6297; DE MARTINIS,
   MASSIMO/0000 0003 4253 1312
CR Ahn SG, 2013, YONSEI MED J, V54, P1168, DOI 10.3349/ymj.2013.54.5.1168
   Altundag K, 2017, J BUON, V22, P1603
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Anagnostis P, 2017, MATURITAS, V101, P23, DOI 10.1016/j.maturitas.2017.04.008
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Briasoulis E, 2004, CANCER AM CANCER SOC, V101, P1524, DOI 10.1002/cncr.20545
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Ciccarelli F, 2015, CURR MED CHEM, V22, P596, DOI 10.2174/0929867321666141106125051
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   De Martinis M, 2019, CURR MED CHEM, DOI [10.2174/092986, DOI 10.2174/092986]
   De Martinis M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124260
   De Martinis M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041239
   Deligiorgi MV, 2020, J BUON, V25, P1
   Fang J, 2015, CLIN TRANSL ONCOL, V17, P173, DOI 10.1007/s12094 014 1247 x
   Florez H, 2019, SEMIN ARTHRITIS RHEU, V49, P197, DOI 10.1016/j.semarthrit.2019.02.007
   Fragkoulis C, 2016, J BUON, V21, P787
   Ginaldi L, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40212 6
   Gonzalez Rodriguez Elena, 2018, Case Rep Rheumatol, V2018, P5432751, DOI 10.1155/2018/5432751
   Harries M, 2014, CANCER EPIDEMIOL, V38, P427, DOI 10.1016/j.canep.2014.05.005
   Irelli A, 2020, INDIAN J CANC
   Irelli A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070232
   Irelli A, 2020, J BUON, V25, P648
   Irelli A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051452
   Irelli A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235841
   Jacobson AF, 2001, CANCER AM CANCER SOC, V91, P17, DOI 10.1002/1097 0142(20010101)91:1<17::AID CNCR3>3.0.CO;2 K
   Karrison TG, 1999, JNCI J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80
   Kennedy L, 2018, J CLIN ONCOL, V36, P1051, DOI 10.1200/JCO.2017.77.0115
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Liu C, 2018, CANCER MANAG RES, V10, P3809, DOI 10.2147/CMAR.S176811
   Massimini M, 2017, VET PATHOL, V54, P405, DOI 10.1177/0300985816681409
   Mjelstad A, 2019, SUPPORT CARE CANCER, V27, P3859, DOI 10.1007/s00520 019 04676 6
   Muller A, 2018, SAN ANT BREAST CANC, DOI [10.1158/1538 7445.SABCS18 P1 18 01., DOI 10.1158/1538 7445.SABCS18 P1 18 01]
   Niang U, 2009, J BUON, V14, P245
   Niikura N, 2011, ONCOLOGIST, V16, P155, DOI 10.1634/theoncologist.2010 0350
   Pereira J, 2016, J MED ECON, V19, P611, DOI 10.3111/13696998.2016.1150852
   Rordorf T, 2014, BREAST, V23, P511, DOI 10.1016/j.breast.2014.05.023
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Santini D, 2019, LINEE GUIDA TRATTAME
   SIEGEL RL, 2016, CA CANCER J CLIN, V66, P7, DOI DOI 10.3322/CAAC.21654
   Sirufo MM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030712
   Stathopoulos GP, 2016, J BUON, V21, P1013
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tyan Alexander, 2019, Mayo Clin Proc Innov Qual Outcomes, V3, P235, DOI 10.1016/j.mayocpiqo.2019.02.003
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Vomvas D, 2008, J BUON, V13, P441
NR 50
TC 3
Z9 3
U1 0
U2 17
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107 0625
EI 2241 6293
J9 J BUON
JI J. BUON
PD JUL AUG
PY 2020
VL 25
IS 4
BP 1799
EP 1804
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA NT7EZ
UT WOS:000573100600018
PM 33099916
DA 2025 08 17
ER

PT J
AU Kitazawa, R
   Kitazawa, S
AF Kitazawa, R
   Kitazawa, S
TI In situ hybridization on calcified tissue:: detection of RANKL
   mRNA in mouse osteolytic bone lesions
SO ACTA HISTOCHEMICA ET CYTOCHEMICA
LA English
DT Article
DE in situ hybridization; PCR; bone; osteoclast; RANKL
ID OSTEOCLAST DIFFERENTIATION FACTOR; HUMAN BREAST CANCER; HORMONE RELATED
   PROTEIN; OSTEOPROTEGERIN LIGAND; RHEUMATOID ARTHRITIS; SKELETAL
   METASTASES; CELL TYPES; EXPRESSION; RECEPTOR; IDENTIFICATION
AB Receptor activator of NF B K ligand (RANKL) has been identified as a prerequisite for osteoclastogenesis. To elucidate the molecular mechanism of osteolytic bone lesions, we investigated RANKL mRNA expression in mouse bone tissue from experimental models of mouse autoimmune arthritis and cancer associated osteolysis. Elbow joints of type 11 collagen induced arthritis (CIA) mice and calvariae of mice transplanted with breast cancer cells under the scalp were fixed with 4% paraformaldehyde for 2 days, decalcified with 20% EDTA in phosphate buffer for 5 days and embedded in paraffin. For in situ hybridization, digoxigenin labeled antisense (or sense) single stranded DNA probes were prepared by unidirectional PCR using cDNA of mouse RANKL amplified by RT PCR.
   In the articular lesions of CIA mice, TRAP positive osteoclasts were found at eroded cartilage and bone as well as in the pannus. Synovial cells around these osteoclasts were strongly positive for RANKL, indicating that synovial cells contribute to osteoclastogenesis through authentic RANKL RANK signaling. In the tumor induced osteolytic lesions of the mouse calvaria, osteoblasts and stromal cells between the tumor foci and the bone surface expressed RANKL mRNA; osteoclastic bone resorption was observed adjacent to the RANKL positive cells. Histological evaluation of RANKL expression in bone lesions is important, because osteoclasts and the RANKL RANK system could be potential targets for therapeutic drugs in diseases with accelerated bone resorption.
C1 Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, 7 5 1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM riko@med.kobe u.ac.jp
RI Kitazawa, Sohei/E 5602 2010
OI Kitazawa, Sohei/0000 0002 7466 7356
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P857, DOI 10.1002/art.1780270804
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Kitazawa R, 2001, ACTA HISTOCHEM CYTOC, V34, P321, DOI 10.1267/ahc.34.321
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kitazawa S, 1999, HISTOCHEM CELL BIOL, V111, P7, DOI 10.1007/s004180050327
   KITAZAWA S, 1995, CLIN ORTHOP RELAT R, P45
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   KOHNO N, 1994, SURG TODAY, V24, P215, DOI 10.1007/BF02032890
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liapis H, 1996, DIAGN MOL PATHOL, V5, P127, DOI 10.1097/00019606 199606000 00008
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Moriarty V, 2002, INFANT CHILD DEV, V11, P283, DOI 10.1002/icd.271
   Nagai M, 2000, BIOCHEM BIOPH RES CO, V269, P532, DOI 10.1006/bbrc.2000.2314
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   SASAKI A, 1995, CANCER RES, V55, P3551
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435
NR 30
TC 2
Z9 2
U1 0
U2 2
PU JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY
PI KYOTO
PA C/O NAKANISHI PRINTING CO LTD, SHIMODACHIURI OGAWA, KAMIGYO KU, KYOTO,
   602 8048, JAPAN
SN 0044 5991
EI 1347 5800
J9 ACTA HISTOCHEM CYTOC
JI Acta Histochem. Cytochem.
PY 2005
VL 38
IS 2
BP 143
EP 149
DI 10.1267/ahc.38.143
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 920EQ
UT WOS:000228672600008
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhai, YK
   Li, YY
   Wang, YP
   Cui, JW
   Feng, K
   Kong, XJ
   Chen, L
AF Zhai, Yuankun
   Li, Yingying
   Wang, Yanping
   Cui, Jiawei
   Feng, Kun
   Kong, Xijian
   Chen, Li
TI Psoralidin, a prenylated coumestan, as a novel anti osteoporosis
   candidate to enhance bone formation of osteoblasts and decrease bone
   resorption of osteoclasts
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Psoralidin; Coumestrol; Isopentenyl group; Osteoblasts; Osteoclasts
ID RAT CALVARIAL OSTEOBLASTS; IN VITRO; POSTMENOPAUSAL WOMEN; LONG TERM;
   DIFFERENTIATION; CELLS; FRACTURE; MICE
AB Traditional Chinese medicines (TCM) have been proven to prevent osteoporosis, but their clinical applications are not widely recognized due to their complicated ingredients. Psoralidin, a prenylated coumestan, has been reported to prevent bone loss of ovariectomized rats, but detailed mechanisms are still not clear. In current study, we found that both psoralidin and coumestrol promoted osteoblast proliferation and differentiation, as evidenced by improvements in cell proliferation and alkaline phosphatase activity; increased formation of ALP colonies and calcified nodules; enhanced secretion of collagen I, BMP 2, osteocalcin and osteopontin; and stimulation of the expression of IGF 1, beta catenin, Runx 2, Osterix, and OPG, as well as the mRNA ratio of OPG/RANKL, while significantly decreasing the expression of RANKL. In addition, both psoralidin and coumestrol inhibited osteoclast formation and osteoclastic bone resorption, as demonstrated by the lower tartrate resistant acid phosphatase activity and smaller area, with fewer resorption pits formed. Interestingly, psoralidin showed much stronger effects than coumestrol at enhancing osteoblast proliferation/differentiation or inhibiting osteoclast differentiation and bone resorption. Moreover, we found that both psoralidin and coumestrol suppressed COX 2 and ROS production in rat osteoblastic calvarias cells, and psoralidin showed stronger effects than coumestrol. Furthermore, we detected that by blocking estrogen receptors with ICI 182.780 (an estrogen receptor antagonist), the osteoprotective effects of psoralidin and coumestrol were also blocked. Our findings demonstrated that psoralidin and coumestrol exert their bone protective effects by enhancing bone formation of osteoblasts and inhibiting bone resorption of osteoclasts. These roles might be mediated by their antioxidant activity and transduced through estrogen receptor signaling.
C1 [Zhai, Yuankun; Li, Yingying; Cui, Jiawei; Kong, Xijian] Luoyang Orthoped Hosp Henan Prov, Luoyang, Henan, Peoples R China.
   [Zhai, Yuankun; Feng, Kun] Orthoped Inst Henan Prov, 82 Qiming Rd South, Luoyang City, Henan Province, Peoples R China.
   [Wang, Yanping] Nanyang City Ctr Hosp, Neurol Dept, Nanyang, Henan, Peoples R China.
   [Chen, Li] Univ Southern Denmark, Odense Univ Hosp, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
C3 University of Southern Denmark; Odense University Hospital
RP Zhai, YK (通讯作者)，Orthoped Inst Henan Prov, 82 Qiming Rd South, Luoyang City, Henan Province, Peoples R China.
EM zhaiyk1984@163.com
RI Chen, Li/AAN 7309 2020; zhai, Yuankun/AGU 0571 2022
OI Chen, Li/0000 0001 5561 7612; 
FU scientific research project for Traditional Chinese Medicine of Henan
   Province in China [2013ZY02004, 2013ZY04058]
FX This work was supported by the scientific research project for
   Traditional Chinese Medicine of Henan Province in China (2013ZY02004 and
   2013ZY04058).
CR Bhat FA, 2013, TOXICOL IN VITRO, V27, P250, DOI 10.1016/j.tiv.2012.09.003
   Bronikowska J, 2012, MOLECULES, V17, P6449, DOI 10.3390/molecules17066449
   Castro CC, 2012, BRAIN RES, V1474, P82, DOI 10.1016/j.brainres.2012.07.025
   Cho SY, 2014, BIOORG MED CHEM LETT, V24, P2560, DOI 10.1016/j.bmcl.2014.03.084
   Giangregorio LM, 2014, OSTEOPOROSIS INT, V25, P821, DOI 10.1007/s00198 013 2523 2
   Harada K., 2013, PLOS ONE, V8
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kong X. J., 2013, J TRADIT CHIN ORTHOP, V25, P10
   Kretzschmar G, 2010, J STEROID BIOCHEM, V118, P1, DOI 10.1016/j.jsbmb.2009.08.005
   Larsson S, 2014, ARCH ORTHOP TRAUM SU, V134, P291, DOI 10.1007/s00402 012 1558 8
   Li Jin Ping, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1816
   [李梅 Li Mei], 2014, [食品工业科技, Science & Technology of Food Industry], V35, P84
   Ming LG, 2013, ENDOCRINOLOGY, V154, P1202, DOI 10.1210/en.2012 2086
   Mouri Y, 2009, BREAST CANCER TOKYO, V16, P147, DOI 10.1007/s12282 008 0066 8
   Mukai R, 2013, J NUTR, V143, P1558, DOI 10.3945/jn.113.176818
   Pahari P, 2009, J ORG CHEM, V74, P2750, DOI 10.1021/jo8025884
   Rad M, 2006, BRIT J CLIN PHARMACO, V62, P288, DOI 10.1111/j.1365 2125.2006.02656.x
   Rao GV, 2009, EUR J MED CHEM, V44, P2239, DOI 10.1016/j.ejmech.2008.05.032
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Szostek Anna Z, 2016, Biol Reprod, V95, P69, DOI 10.1095/biolreprod.116.138958
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Wei P, 2012, ASIAN PAC J TROP MED, V5, P243, DOI 10.1016/S1995 7645(12)60033 9
   Wong KC, 2014, AM J CHINESE MED, V42, P409, DOI 10.1142/S0192415X1450027X
   Wu J., 2009, CHINA J ORTHOP TRAUM, V22, P193
   Wu XT, 2009, J BIOMED MATER RES B, V90B, P621, DOI 10.1002/jbm.b.31326
   Yang Z, 2012, MENOPAUSE, V19, P1156, DOI 10.1097/gme.0b013e3182507e18
   Yi LT, 2008, PROG NEURO PSYCHOPH, V32, P510, DOI 10.1016/j.pnpbp.2007.10.005
   翟远坤, 2012, [中医杂志, Journal of Traditional Chinese Medicine], V53, P1244
   Zhai YK, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/921954
   Zhai Yuan kun, 2012, Chinese Pharmacological Bulletin, V28, P355, DOI 10.3969/j.issn.1001 1978.2012.03.014
NR 32
TC 44
Z9 48
U1 0
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 15
PY 2017
VL 801
BP 62
EP 71
DI 10.1016/j.ejphar.2017.03.001
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ES4PE
UT WOS:000399516400008
PM 28283388
DA 2025 08 17
ER

PT J
AU Feng, WY
   He, MW
   Jiang, XH
   Liu, HJ
   Xie, TY
   Qin, ZJ
   Huang, Q
   Liao, SJ
   Lin, CS
   He, JL
   Xu, JK
   Ma, J
   Liu, Y
   Wei, QJ
AF Feng, Wenyu
   He, Mingwei
   Jiang, Xiaohong
   Liu, Huijiang
   Xie, Tianyu
   Qin, Zhaojie
   Huang, Qian
   Liao, Shijie
   Lin, Chengsen
   He, Juliang
   Xu, Jiake
   Ma, Jie
   Liu, Yun
   Wei, Qingjun
TI Single Cell RNA Sequencing Reveals the Migration of Osteoclasts in Giant
   Cell Tumor of Bone
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE single cell RNA sequence; giant cell tumor of bone (GCTB); osteolysis;
   osteoclast; migration
ID TRANSCRIPTION FACTOR; BREAST CANCER; T CELLS; PROMOTES; DIFFERENTIATION;
   DENOSUMAB; SUBSET; FAMILY; JDP2; JUN
AB Giant cell tumor of bone (GCTB) is benign tumor that can cause significant osteolysis and bone destruction at the epiphysis of long bones. Osteoclasts are thought to be highly associated with osteolysis in GCTB. However, the migration of osteoclasts in GCTB remains unclear. A deeper understanding of the complex tumor microenvironment is required in order to delineate the migration of osteoclasts in GCTB. In this study, samples were isolated from one patient diagnosed with GCTB. Single cell RNA sequencing (scRNA seq) was used to detect the heterogeneity of GCTB. Multiplex immunofluorescence staining was used to evaluate the cell subtypes identified by scRNA seq. A total of 8,033 cells were obtained from one patient diagnosed with GCTB, which were divided into eight major cell types as depicted by a single cell transcriptional map. The osteoclasts were divided into three subsets, and their differentiation trajectory and migration status were further analyzed. Osteoclast migration may be regulated via a series of genes associated with cell migration. Furthermore, four signaling pathways (RANKL, PARs, CD137 and SMEA3 signaling pathway) were found to be highly associated with osteoclast migration. This comprehensive single cell transcriptome analysis of GCTB identified a series of genes associated with cell migration as well as four major signaling pathways that were highly related to the migration of osteoclasts in GCTB. Our findings broaden the understanding of GCTB bionetworks and provides a theoretical basis for anti osteolysis therapy against GCTB in the future.
C1 [Feng, Wenyu; He, Mingwei; Jiang, Xiaohong; Xie, Tianyu; Huang, Qian; Liao, Shijie; Lin, Chengsen; Wei, Qingjun] Guangxi Med Univ, Dept Trauma Orthoped & Hand Surg, Affiliated Hosp 1, Nanning, Peoples R China.
   [He, Mingwei] Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Nanning, Peoples R China.
   [Jiang, Xiaohong] Guangxi Med Univ, Dept Orthoped, Affiliated Minzu Hosp, Nanning, Peoples R China.
   [Liu, Huijiang] First Peoples Hosp Nanning, Dept Orthoped, Nanning, Peoples R China.
   [Qin, Zhaojie; Liu, Yun] Guangxi Med Univ, Dept Spinal Bone Dis, Affiliated Hosp 1, Nanning, Peoples R China.
   [He, Juliang] Guangxi Med Univ, Dept Bone & Soft Tissue Surg, Canc Hosp, Nanning, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Ma, Jie] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; Guangxi Medical University;
   University of Western Australia; Guangxi Medical University
RP Wei, QJ (通讯作者)，Guangxi Med Univ, Dept Trauma Orthoped & Hand Surg, Affiliated Hosp 1, Nanning, Peoples R China.; Liu, Y (通讯作者)，Guangxi Med Univ, Dept Spinal Bone Dis, Affiliated Hosp 1, Nanning, Peoples R China.; Ma, J (通讯作者)，Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China.
EM majie086@163.com; liuyun200450250@sina.com; weiqingjungxnn@163.com
RI qin, zhaojie/HZL 9209 2023; Huang, Qian/AIC 8153 2022; He,
   Mingwei/AAV 7700 2020; 解, 天宇/HHZ 0134 2022
OI Xu, Jiake/0000 0003 2021 8309; 
FU Guangxi Key Laboratory of Genomics and Personalized Medicine; Nanning
   Scientific Research and Technology Development Plan [20183012]; Guangxi
   Key RD Program [AB17292073]; National Natural Science Foundation of
   China [81960768]; Guangxi Key Laboratory of Genomics and Personalized
   Medicine open project [GXGPMC201903]; Natural Science Foundation of
   Guangxi Province [2020GXNSFAA259088]; Guangxi Natural Science Foundation
   of Youth Science Foundation [2017GXNSFBA198098]; Creative Research
   Development Grant from the First Affiliated Hospital of Guangxi Medical
   University; Youth Science and Technology Project of the First Affiliated
   Hospital of Guangxi Medical University [201903038]
FX This project was supported in part by the Guangxi Key Laboratory of
   Genomics and Personalized Medicine. This project was also supported by
   the Nanning Scientific Research and Technology Development Plan (grant
   no. 20183012), Guangxi Key R&D Program (grant no.AB17292073), the
   National Natural Science Foundation of China (grant no. 81960768),
   Guangxi Key Laboratory of Genomics and Personalized Medicine open
   project (grant no. GXGPMC201903), Natural Science Foundation of Guangxi
   Province (grant no. 2020GXNSFAA259088), Guangxi Natural Science
   Foundation of Youth Science Foundation project (grant no.
   2017GXNSFBA198098), the Medical Excellence Award Funded by the Creative
   Research Development Grant from the First Affiliated Hospital of Guangxi
   Medical University, and the Youth Science and Technology Project of the
   First Affiliated Hospital of Guangxi Medical University (grant no.
   201903038). YL and SL were visiting scholars to the Molecule Biology Lab
   at the University of Western Australia.
CR Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P951, DOI 10.1002/gcc.22206
   Arneth B, 2020, MEDICINA LITHUANIA, V56, DOI 10.3390/medicina56010015
   Auvinen K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52068 x
   Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060
   Baird A, 2018, BIOL OPEN, V7, DOI 10.1242/bio.033514
   Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chen JN, 2019, AM J TRANSL RES, V11, P6672
   Chen YP, 2020, CELL RES, V30, P1024, DOI 10.1038/s41422 020 0374 x
   Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633
   Clark BS, 2019, NEURON, V102, P1111, DOI 10.1016/j.neuron.2019.04.010
   Dazzi F, 2013, BLOOD, V122, P1093, DOI 10.1182/blood 2013 06 509620
   Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010
   Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596 020 0292 x
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Fittall MW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04530 z
   Fu X, 2017, J DENT RES, V96, P1451, DOI 10.1177/0022034517719749
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Hoch B, 2006, J BONE JOINT SURG AM, V88A, P1998, DOI 10.2106/JBJS.E.01111
   Hui LL, 2015, CANCER LETT, V368, P7, DOI 10.1016/j.canlet.2015.07.039
   Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795
   Hunt LC, 2015, GENE DEV, V29, P2475, DOI 10.1101/gad.267419.115
   Islam S, 2014, NAT METHODS, V11, P163, DOI [10.1038/nmeth.2772, 10.1038/NMETH.2772]
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Jiang XF, 2010, TRANSPL IMMUNOL, V22, P179, DOI 10.1016/j.trim.2009.12.001
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21246 9
   Kaufmann R, 2012, ADV EXP MED BIOL, V740, P979, DOI 10.1007/978 94 007 2888 2_45
   Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321
   Kawamata A, 2008, J CELL BIOCHEM, V103, P1037, DOI 10.1002/jcb.21660
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16164 1
   Kim T, 2009, BIOCHEM BIOPH RES CO, V390, P585, DOI 10.1016/j.bbrc.2009.10.010
   Koizumi S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07735 4
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586 018 0414 6
   Li HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580605
   Li YQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20358 y
   LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447
   Lipplaa A, 2019, CURR OPIN ONCOL, V31, P329, DOI 10.1097/CCO.0000000000000529
   Liu T, 2019, MOL ONCOL, V13, P1047, DOI 10.1002/1878 0261.12457
   Liu Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21043 4
   Lotinun S, 2019, J CLIN INVEST, V129, P3058, DOI 10.1172/JCI122936
   Maruyama K, 2012, IMMUNITY, V37, P1024, DOI 10.1016/j.immuni.2012.08.022
   Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099
   Mejhert N, 2020, MOL CELL, V77, P1251, DOI 10.1016/j.molcel.2020.01.014
   Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238 011 1113 3
   Montalvany Antonucci CC, 2018, J NUTR BIOCHEM, V59, P93, DOI 10.1016/j.jnutbio.2018.06.006
   Moskowitz DM, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag0192
   Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223
   Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422 019 0195 y
   Potter SS, 2018, NAT REV NEPHROL, V14, P479, DOI 10.1038/s41581 018 0021 7
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Ren XW, 2020, CELL RES, V30, P763, DOI 10.1038/s41422 020 0353 2
   Santoiemma PP, 2015, CANCER BIOL THER, V16, P807, DOI 10.1080/15384047.2015.1040960
   Shibuya I, 2019, PATHOL ONCOL RES, V25, P409, DOI 10.1007/s12253 017 0362 8
   Sips M, 2016, HUM IMMUNOL, V77, P1147, DOI 10.1016/j.humimm.2016.08.004
   Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425 016 0165 6
   Svensson V, 2017, NAT METHODS, V14, P381, DOI 10.1038/nmeth.4220
   Syafruddin SE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09116 x
   Tang HJ, 2019, J SURG ONCOL, V120, P359, DOI 10.1002/jso.25588
   Tiwari A, 2015, SCI REP UK, V5, DOI 10.1038/srep17621
   Tse SW, 2014, J INFECT DIS, V210, P1508, DOI 10.1093/infdis/jiu281
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   van der Heijden L, 2020, CURR OPIN ONCOL, V32, P332, DOI 10.1097/CCO.0000000000000645
   Vento Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586 018 0698 6
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Y, 2018, ONCOL REP, V40, P1287, DOI 10.3892/or.2018.6550
   Wang Y, 2015, MOL CELL, V58, P598, DOI 10.1016/j.molcel.2015.05.005
   Wang ZZ, 2014, NEUROREPORT, V25, P1221, DOI 10.1097/WNR.0000000000000252
   Wein AN, 2019, J EXP MED, V216, P2748, DOI 10.1084/jem.20181308
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yoshida K, 2019, MODERN PATHOL, V32, P1751, DOI 10.1038/s41379 019 0318 5
   Zhang SW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.596318
   Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
NR 77
TC 23
Z9 25
U1 0
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 24
PY 2021
VL 11
DI 10.3389/fonc.2021.715552
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UQ2YC
UT WOS:000695934100001
PM 34504794
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, Y
   Aghazadeh Habashi, A
   Panahifar, A
   Wu, YC
   Bhandari, KH
   Doschak, MR
AF Yang, Yang
   Aghazadeh Habashi, Ali
   Panahifar, Arash
   Wu, Yuchin
   Bhandari, Krishna H.
   Doschak, Michael R.
TI Bone targeting parathyroid hormone conjugates outperform unmodified PTH
   in the anabolic treatment of osteoporosis in rats
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE PTH; Bone drug delivery; Anabolic therapy; Osteoporosis; Micro CT
ID POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; MINERAL CRYSTALS; STRONTIUM;
   MASS; RECEPTORS; MODEL; OSTEOARTHRITIS; TERIPARATIDE; ALENDRONATE
AB Synthetic parathyroid hoinione (PTH) is clinically indicated for the treatment of osteoporosis, through its anabolic effects on parathyroid hormone receptors (PTHRs), located on osteoblast cells. However, the bioavailability of PTH for hone cells is restricted by the short half life of PTH and the widespread distribution of PTHRs in non skeletal tissues. To impart affinity for mineralized hone surfaces, bisphosphonate (BP) mediated PTH analogues were synthesized, characterized, and evaluated in vitro and in vivo. The successful synthesis of PTH PEG BP was identified on MALDI ToF mass spectra; bone targeting potential was evaluated by hydroxyapatite binding test; and receptor bioactivity was assessed in UMR 106 (rat osteosarcoma) cells that constitutively express PTHRs. Therapeutic efficacy was evaluated using ovariectomized rats that remained untreated for 8 weeks to allow development of osteopenia. Those rats then received daily subcutaneous injections of PTH PEG BP, thiol BP vehicle, or unmodified PTH, and compared to sham operated healthy rats at 0, 4, 8, 12, and 16 weeks. In vivo micro CT was conducted on the proximal tibial metaphysis to measure microstnictural hone parameters, and new bone formation was detected using dynamic labeling. Bone strength was assessed using three point bending mechanical testing. Our study determined that PTH PEG BP conjugates significantly enhanced PTH targeting to the hone matrix while retaining full PTH bioactivity. Moreover, PTH PEG BP conjugates significantly increased trabecular bone quality, anabolic bone forma lion, and improved bone strength over systemically administered PTH alone. We highlight the promise of a novel class of bone targeting anabolic compound for the treatment of osteoporosis and related bone disorders.
C1 [Yang, Yang; Aghazadeh Habashi, Ali; Panahifar, Arash; Wu, Yuchin; Bhandari, Krishna H.; Doschak, Michael R.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Pharmaceut Orthopaed Res Lab, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta
RP Doschak, MR (通讯作者)，Univ Alberta, Fac Pharm & Pharmaceut Sci, Pharmaceut Orthopaed Res Lab, Edmonton, AB T6G 2N8, Canada.
EM yang9@ualberta.ca; aaghazad@ualberta.ca; panahifa@ualberta.ca;
   yuchin@ualberta.ca; kbhandar@ualberta.ca; mdoschak@ualberta.ca
RI ; Habashi, Ali/U 6934 2019
OI Panahifar, Arash/0000 0001 9483 6949; 
FU Mimes Elevate Strategic Fellowship Program (SFP); Osteoarthritis Alberta
   Team Grant from Alberta Innovates Health Solutions (AIHS); Canadian
   Institutes for Health Research (CIHR)
FX This research was funded by the Mimes Elevate Strategic Fellowship
   Program (SFP), the Osteoarthritis Alberta Team Grant from Alberta
   Innovates Health Solutions (AIHS), and the Canadian Institutes for
   Health Research (CIHR). We thank Madhuri Newa and Kathy Tang for their
   technical support in completion of this study.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Bhandari KH, 2012, J CONTROL RELEASE, V158, P44, DOI 10.1016/j.jconrel.2011.09.096
   Bieglmayer C, 2002, CLIN CHEM, V48, P1731
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Boivin G, 1996, J BONE MINER RES, V11, P1302
   Brouwers JEM, 2009, OSTEOPOROSIS INT, V20, P1823, DOI 10.1007/s00198 009 0882 5
   Datta NS, 2011, WORLD J ORTHOP, V2, P67, DOI 10.5312/wjo.v2.i8.67
   Deal C, 2003, CLEV CLIN J MED, V70, P585, DOI 10.3949/ccjm.70.7.585
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Farlay D, 2005, J BONE MINER RES, V20, P1569, DOI 10.1359/JBMR.050405
   Hoare SRJ, 2001, CURR PHARM DESIGN, V7, P689, DOI 10.2174/1381612013397825
   HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273
   Järvinen TLN, 1998, BONE, V22, P551, DOI 10.1016/S8756 3282(98)00025 8
   Jiang Y, 1996, CALCIFIED TISSUE INT, V58, P30, DOI 10.1007/BF02509543
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jin L, 2000, J BIOL CHEM, V275, P27238
   Jones KO, 2006, J PHARM SCI US, V95, P2499, DOI 10.1002/jps.20720
   Jones MW, 2009, CHEM COMMUN, P5272, DOI 10.1039/b906865a
   Leppänen O, 2006, J BONE MINER RES, V21, P1231, DOI 10.1359/JBMR.060511
   Li CH, 2010, J BONE MINER RES, V25, P968, DOI 10.1359/jbmr.091038
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Na DH, 2004, ANAL BIOCHEM, V331, P322, DOI 10.1016/j.ab.2004.04.036
   NEER M, 1993, OSTEOPOROSIS INT, V3, pS204
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566
   Panahifar A, 2012, OSTEOARTHR CARTILAGE, V20, P694, DOI 10.1016/j.joca.2012.03.021
   Panahifar A, 2015, J ORTHOP RES, V33, P1655, DOI 10.1002/jor.22937
   Parfitt A. M., 2013, OSTEOPOROSIS
   PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RALIS ZA, 1992, BIOTECH HISTOCHEM, V67, P339, DOI 10.3109/10520299209110046
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Ryan SM, 2009, J CONTROL RELEASE, V135, P51, DOI 10.1016/j.jconrel.2008.12.014
   Sekimori M., 2003, PEG BINDING PTH PEG
   SESHADRI MS, 1985, CLIN SCI, V68, P311, DOI 10.1042/cs0680311
   Shen V, 2000, J BONE MINER RES, V15, P740, DOI 10.1359/jbmr.2000.15.4.740
   Sogaard CH, 1997, BONE, V20, P439, DOI 10.1016/S8756 3282(97)00020 3
   TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo 93 6 1349
   USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Valenta A, 2005, BONE, V37, P87, DOI 10.1016/j.bone.2005.03.013
   Washimi Y, 2007, BONE, V41, P786, DOI 10.1016/j.bone.2007.06.019
   Wu YC, 2013, J PHARM PHARM SCI, V16, P52, DOI 10.18433/J3C59H
   YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711
   Yang Y, 2014, PHARM RES DORDR, V31, P1146, DOI 10.1007/s11095 013 1237 7
   Yewle JN, 2013, BIOMATERIALS, V34, P3141, DOI 10.1016/j.biomaterials.2013.01.059
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 52
TC 10
Z9 11
U1 0
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 2190 393X
EI 2190 3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD AUG
PY 2017
VL 7
IS 4
BP 482
EP 496
DI 10.1007/s13346 017 0407 2
PG 15
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA FG6VG
UT WOS:000410533400003
PM 28721611
DA 2025 08 17
ER

PT J
AU Bai, F
   Chen, XW
   Yang, H
   Xu, HG
AF Bai, Fan
   Chen, Xuewu
   Yang, Hui
   Xu, Hong Guang
TI Acetyl 11 Keto β Boswellic Acid Promotes Osteoblast Differentiation by
   Inhibiting Tumor Necrosis Factor α and Nuclear Factor κB Activity
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Acetyl 11 Keto beta Boswellic Acid; NF kappa B; osteoblast
   differentiation; TNF alpha
ID ACETATE INDUCES DIFFERENTIATION; BOSWELLIC ACIDS; BONE FORMATION;
   RHEUMATOID ARTHRITIS; APOPTOSIS; TNF; OSTEOCLASTOGENESIS;
   RECONSTRUCTION; ACTIVATION; RECEPTOR
AB Tumor necrosis factor (TNF)  alpha plays a crucial role in rheumatoid arthritis (RA) related bone loss disease. The main mechanism of action of RA induced bone loss is the significant inhibitory effect of TNF alpha on osteoblast differentiation. TNF alpha inhibits osteoblast differentiation mainly by activating nuclear factor (NF)  kappa B signaling pathway. Owing to the crucial role of TNF alpha and NF kappa B in the inhibition of osteoblast differentiation, they are considered as targets for the development of therapeutic drugs. In the present study, we evaluated the NF kappa B inhibitor Boswellic acid (BA) and its derivatives in the regulation of osteoblast differentiation and the molecular mechanism. Based on the cell model of TNF alpha induced inhibition of osteoblast differentiation of MC3T3 E1, the regulatory role of BAs was studied. The result of MTT assay indicated that bone morphogenetic protein (BMP)  2, TNF alpha, or acetyl 11 keto beta BA (AKBA) impact no significant effect for cell viability of MC3T3 E1. The results of alkaline phosphatase (ALP activity assay and real time polymerase chain reaction indicated that AKBA blocked TNF alpha induced inhibition of the expression of osteoblast markers, suggesting that AKBA rescued osteoblast differentiation from TNF alpha induced inhibition. Additionally, AKBA stimulated the BMP 2 induced expression of osteoblast markers, suggesting that AKBA promotes osteoblast differentiation directly. The results of western blotting and luciferase assay indicated that N kappa B signaling was activated by TNF alpha. The overexpression of NF kappa B component p65 in MC3T3 E1 was found to attenuate the positive effect of AKBA in osteoblast differentiation, suggesting that AKBA potentiates osteoblast differentiation by inhibiting NF kappa B signaling. Collectively, AKBA promotes osteoblast differentiation by inhibiting TNF alpha and NF kappa B. Our study revealed a new discovery of AKBA in regulating osteoblast differentiation, and demonstrated that AKBA may be a potential anabolic agent in the treatment of RA derived bone loss disease.
C1 [Bai, Fan; Chen, Xuewu; Yang, Hui; Xu, Hong Guang] Wannan Med Coll, Yijishan Hosp, Dept Orthoped Surg, Wuhu 241001, Anhui, Peoples R China.
C3 Wannan Medical College
RP Xu, HG (通讯作者)，Wannan Med Coll, Yijishan Hosp, Dept Orthoped Surg, Wuhu 241001, Anhui, Peoples R China.
EM yijishanjizhuguke@126.com
CR Ammon HPT, 2006, PLANTA MED, V72, P1100, DOI 10.1055/s 2006 947227
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo 121 5 1596
   Chaabo K, 2015, INT IMMUNOPHARMACOL, V27, P180, DOI 10.1016/j.intimp.2015.04.051
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cicciù M, 2017, J CRANIOFAC SURG, V28, P592, DOI 10.1097/SCS.0000000000003595
   Cicciù M, 2014, J CRANIOFAC SURG, V25, P860, DOI 10.1097/SCS.0000000000000830
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Herford AS, 2010, J CRANIOFAC SURG, V21, P1970, DOI 10.1097/SCS.0b013e3181f502fa
   Herford AS, 2016, INT J CLIN EXP MED, V9, P17187
   Herford AS, 2013, J CRANIOFAC SURG, V24, P1383, DOI 10.1097/SCS.0b013e318292c2ce
   Hussain H, 2017, EXPERT OPIN THER PAT, V27, P81, DOI 10.1080/13543776.2017.1235156
   Jing YK, 1999, LEUKEMIA RES, V23, P43, DOI 10.1016/S0145 2126(98)00096 4
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Kurkó J, 2013, CLIN REV ALLERG IMMU, V45, P170, DOI 10.1007/s12016 012 8346 7
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158
   Papapoulos SE, 2015, NAT REV ENDOCRINOL, V11, P69, DOI 10.1038/nrendo.2014.214
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127
   Winking M, 2000, J NEURO ONCOL, V46, P97, DOI 10.1023/A:1006387010528
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Ye X, 2016, IN VITRO CELL DEV AN, V52, P1026, DOI 10.1007/s11626 016 0068 3
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhao WZ, 2003, CANCER DETECT PREV, V27, P67, DOI 10.1016/S0361 090X(02)00170 8
NR 33
TC 14
Z9 15
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD OCT
PY 2018
VL 29
IS 7
BP 1996
EP 2002
DI 10.1097/SCS.0000000000004691
PG 7
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA HD3SX
UT WOS:000452441400116
PM 29927820
DA 2025 08 17
ER

PT J
AU Ren, GW
   Wen, SB
   Han, J
   Xu, ZW
   Qi, W
   Shang, YZ
   Wu, YK
AF Ren, Guo wu
   Wen, Shuai bo
   Han, Jie
   Xu, Zhi wei
   Qi, Wen
   Shang, Yu zhi
   Wu, Yu kun
TI Network Based Pharmacology and Bioinformatics Study on the Mechanism of
   Action of Gujiansan in the Treatment of Steroid Induced Avascular
   Necrosis of the Femoral Head
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID INDUCED OSTEONECROSIS; NONTRAUMATIC OSTEONECROSIS; PLATELET ACTIVATION;
   ENDOTHELIAL CELLS; OSTEOBLAST; DIFFERENTIATION; QUERCETIN; INHIBITION;
   SURVIVAL; TH17
AB Objective. To investigate the main pharmacological basis and mechanism of action of Gujiansan in the treatment of steroid induced avascular necrosis of the femoral head (SANFH). Methods. The active constituents and targets of Gujiansan were screened by using TCMSP and other databases, and relevant disease targets were obtained by analyzing the microarray of SANFH in the GEO database. The intersection of the two was taken to obtain the potential targets of Gujiansan for the treatment of SANFH, and key active constituents were screened with the "active constituent target" network constructed by the Cytoscape software; then, the STRING database was used to construct the protein interaction network to screen the key targets. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of key targets were performed by the DAVID database, and the relationship between the "key active constituent key target key signaling pathway" was explored. Finally, the molecular docking between key active constituents and key targets was verified. In addition, qPCR detection technology was used to evaluate the preventive and therapeutic effects of key active constituents of Gujiansan in a rat osteoblast model of SANFH to verify the possible mechanism of the effect of Gujiansan in the treatment of SANFH. Results. (1) 106 active constituents and 55 targets were obtained for the treatment of SANFH. (2) Quercetin, luteolin, kaempferol, cryptotanshinone, and naringenin were the key active constituents for the treatment of SANFH. (3) IL1B, STAT3, CAT, PTGS2, and MAPK3 were the key targets for the treatment of SANFH. (4) IL1B, STAT3, CAT, PTGS2, MAPK3, and HMOX1 are key targets in the protein interaction network. (5) DAVID enrichment analysis mainly covers the regulation of DNA binding transcription factor activity, positive regulation of cytokine production, and response to oxidative stress and other biological processes, involving IL 17, AGE RAGE, C type lectin receptor, and other signaling pathways. (6) Gujiansan is a multitarget and multisignaling pathway for the treatment of SANFH. (7) Good binding activity exists between key active constituents and key targets. Conclusion. This study analyzes the potential mechanism of action of Gujiansan in the treatment of SANFH with network pharmacology, which can provide a reference for the further study of its pharmacological basis and targets.
C1 [Ren, Guo wu; Wen, Shuai bo; Qi, Wen; Wu, Yu kun] Guangxi Univ Tradit Chinese Med, Nanning 530001, Guangxi Zhuang, Peoples R China.
   [Han, Jie; Xu, Zhi wei; Shang, Yu zhi] Guangxi Univ Tradit Chinese Med, Ruikang Hosp, Nanning 530011, Peoples R China.
C3 Guangxi University of Chinese Medicine; Guangxi University of Chinese
   Medicine
RP Han, J (通讯作者)，Guangxi Univ Tradit Chinese Med, Ruikang Hosp, Nanning 530011, Peoples R China.
EM rgw1997@163.com; 1274058647@qq.com; jham@163.com; 1187352152@qq.com;
   superkindom@foxmail.com; shang_yuzhi@sina.com; 836858712@qq.com
OI Han, Jie/0000 0003 1750 4400; ren, guowu/0000 0001 7017 2391
FU Development and Promotion Project of Appropriate Technology in Guangxi
   Traditional Chinese Medicine [GZSY21 30]; Improvement Project of Basic
   Scientific Research Abilities of Young and Middle aged Teachers in
   Guangxi Universities [2020KY07017]; Preparation Quality Improvement
   Project in Guangxi Zhuang Medicine Hospital [GZZJ202011]
FX AcknowledgmentsThis research was supported by the Development and
   Promotion Project of Appropriate Technology in Guangxi Traditional
   Chinese Medicine (GZSY21 30), the Improvement Project of Basic
   Scientific Research Abilities of Young and Middle aged Teachers in
   Guangxi Universities (2020KY07017), and the Preparation Quality
   Improvement Project in Guangxi Zhuang Medicine Hospital (GZZJ202011).
CR Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Atilla B, 2019, EFORT OPEN REV, V4, P647, DOI 10.1302/2058 5241.4.180073
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bosco G, 2018, J ENZYM INHIB MED CH, V33, P1501, DOI 10.1080/14756366.2018.1485149
   Chen DQ, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204211
   Chen JY, 2017, ORTHOP SURG, V9, P3, DOI 10.1111/os.12302
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Choi JH, 2016, J BIOCHEM MOL TOXIC, V30, P548, DOI 10.1002/jbt.21822
   Choi JH, 2015, BIOCHIMIE, V115, P177, DOI 10.1016/j.biochi.2015.06.001
   Eslaminejad MB, 2014, IRAN J MED SCI, V39, P107
   Fernandes GVO, 2014, J CELL BIOCHEM, V115, P1063, DOI 10.1002/jcb.24691
   Fu FY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7130105
   Gao YH, 2020, TECHNOL HEALTH CARE, V28, P203, DOI 10.3233/THC 191811
   Gómez Zorita S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1343 0
   Guo XH, 2006, APMIS, V114, P874, DOI 10.1111/j.1600 0463.2006.apm_372.x
   Guo ZJ, 2008, ANTIOXID REDOX SIGN, V10, P1699, DOI 10.1089/ars.2007.1999
   Han J, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6683007
   Han SY, 2018, INT J MOL MED, V42, P331, DOI 10.3892/ijmm.2018.3603
   He PL, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026811
   Hoskins W, 2022, J ARTHROPLASTY, V37, P312, DOI 10.1016/j.arth.2021.10.011
   Huang DH, 2018, MOL MED REP, V17, P3328, DOI 10.3892/mmr.2017.8247
   Huang ZQ, 2020, J ORTHOP TRANSL, V23, P122, DOI 10.1016/j.jot.2020.03.014
   Huang ZQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6971503
   Hubbard GP, 2004, J THROMB HAEMOST, V2, P2138, DOI 10.1111/j.1538 7836.2004.01067.x
   Ichiseki T, 2004, J ORTHOP SCI, V9, P509, DOI 10.1007/s00776 004 0816 1
   Ikeuchi K, 2015, MOD RHEUMATOL, V25, P278, DOI 10.3109/14397595.2014.932038
   Inkielewicz Stepniak I, 2012, FOOD CHEM TOXICOL, V50, P583, DOI 10.1016/j.fct.2011.12.015
   Jeon SJ, 2008, ARCH PHARM RES, V31, P758, DOI 10.1007/s12272 001 1223 4
   Jin DZ, 2006, EUR J PHARMACOL, V549, P166, DOI 10.1016/j.ejphar.2006.07.055
   Krstic J, 2015, PROTEIN PEPTIDE LETT, V22, P570, DOI 10.2174/0929866522666150520145554
   Kuang MJ, 2019, CHEM BIOL INTERACT, V304, P97, DOI 10.1016/j.cbi.2019.03.008
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Lee SK, 2004, EXP CELL RES, V298, P359, DOI 10.1016/j.yexcr.2004.04.039
   Lee YJ, 2015, FOOD FUNCT, V6, P2824, DOI 10.1039/c5fo00481k
   Lee Yun Jong, 2019, J Bone Metab, V26, P13, DOI 10.11005/jbm.2019.26.1.13
   Li GM, 2018, EUR REV MED PHARMACO, V22, P3553, DOI 10.26355/eurrev_201806_15182
   Li Z, 2020, BIOCHEM BIOPH RES CO, V523, P506, DOI 10.1016/j.bbrc.2019.12.065
   Liang H, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/8698232
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368
   Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898 6568(98)00018 7
   Park HJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 230
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Peters A, 2015, J IMMUNOL, V195, P4144, DOI 10.4049/jimmunol.1302246
   Schizas NP, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1484 3
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tan BA, 2021, ORTHOP SURG, V13, P153, DOI 10.1111/os.12857
   Tang MS, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/5786053
   Tao QY, 2020, DRUG DEV IND PHARM, V46, P1345, DOI 10.1080/03639045.2020.1788070
   Wali AF, 2020, PLANTS BASEL, V9, DOI 10.3390/plants9040550
   Wan LL, 2009, CARDIOVASC THER, V27, P28, DOI 10.1111/j.1755 5922.2009.00071.x
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang LM, 2018, J PERIODONTAL RES, V53, P66, DOI 10.1111/jre.12488
   Wang MN, 2020, J PAIN RES, V13, P1421, DOI 10.2147/JPR.S247827
   Wang SB, 2015, FREE RADICAL BIO MED, V83, P41, DOI 10.1016/j.freeradbiomed.2015.01.018
   Wang WZ, 2019, J CELL BIOCHEM, V120, P7333, DOI 10.1002/jcb.28008
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Xu K, 2021, ENVIRON TOXICOL, V36, P2123, DOI 10.1002/tox.23327
   Xue Li wei, 2009, Hua Xi Kou Qiang Yi Xue Za Zhi, V27, P378
   Yoshida Y, 2018, INFLAMMATION, V41, P1945, DOI 10.1007/s10753 018 0838 z
   Zaidun NH, 2018, LIFE SCI, V208, P111, DOI 10.1016/j.lfs.2018.07.017
   Zhang HY, 2014, INT IMMUNOPHARMACOL, V20, P95, DOI 10.1016/j.intimp.2014.02.016
   Zhang SK, 2018, MOL MED REP, V17, P4307, DOI 10.3892/mmr.2018.8461
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
   Zou DB, 2018, ENDOKRYNOL POL, V69, P283, DOI 10.5603/EP.a2018.0031
NR 71
TC 4
Z9 9
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUL 23
PY 2022
VL 2022
AR 8080679
DI 10.1155/2022/8080679
PG 17
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 3M1ET
UT WOS:000835201700007
PM 35915795
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Le Gall, C
   Bellahcene, A
   Bonnelye, E
   Gasser, JA
   Castronovo, V
   Green, J
   Zimmermann, J
   Clézardin, P
AF Le Gall, Celine
   Bellahcene, Akeila
   Bonnelye, Edith
   Gasser, Juerg A.
   Castronovo, Vincent
   Green, Jonathan
   Zimmermann, Johann
   Clezardin, Philippe
TI A cathepsin K inhibitor reduces breast cancer induced osteolysis and
   skeletal tumor burden
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN PROSTATE CANCER; EXPERIMENTAL BONE METASTASIS; MATRIX
   METALLOPROTEINASES; IN VIVO; BISPHOSPHONATES; EXPRESSION; CELLS; MICE;
   PROGRESSION; RESORPTION
AB Osteoclasts mediate bone destruction in breast cancer skeletal metastases. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone. Here, immohistochemistry revealed that cathepsin K was expressed not only by osteoclasts but also by breast cancer cells that metastasize to bone. Following intratibial injection with cathepsin K expressing human BT474 breast cancer cells, tumor bearing mice treated with a clinical dosing regimen of cathepsin K inhibitor (CKI; 50 mg/kg, twice daily) had osteolytic lesions that were 79% smaller than those of tumor bearing mice treated with the vehicle. The effect of CKI was also studied in a mouse model in which the i.v. inoculation of human B02 breast cancer cells expressing cathepsin K leads to bone metastasis formation. Drug administration was started before (preventive protocol) or after (treatment protocol) the occurrence of osteolytic lesions. In treatment protocols, CKI (50 mg/kg, twice daily) or a single clinical dose of 100 mu g/kg zoledronic acid (osteoclast inhibitor) reduced the progression of osteolytic lesions by 59% to 66%. CKI therapy also reduced skeletal tumor burden by 62% compared with vehicle, whereas zoledronic acid did not decrease the tumor burden. The efficacy of CKI at inhibiting skeletal tumor burden was similar in the treatment and preventive protocols. By contrast, CKI did not block the growth of s.c. B02 tumor xenografts in animals. Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases.
C1 Fac Med Laennec, INSERM, U664, IFR62, F 69372 Lyon 08, France.
   Univ Lyon 1, F 69622 Villeurbanne, France.
   Univ Liege, Metastasis Res Lab, Liege, Belgium.
   Novartis Inst Biomed Res, Basel, Switzerland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1;
   University of Liege; Novartis
RP Clézardin, P (通讯作者)，Fac Med Laennec, INSERM, U664, IFR62, Rue Guillaume Paradin, F 69372 Lyon 08, France.
EM clezardin@lyon.inserm.fr
RI Clezardin, Philippe/M 8071 2014; Gasser, Jurg A./AAT 5389 2020;
   Bonnelye, Edith/AAT 9134 2021; Gasser, Juerg/AAT 5389 2020
OI Clezardin, Philippe/0000 0003 0149 4463; Gasser, Jurg
   A./0000 0002 0106 364X; 
CR ADAMI S, 2006, J BONE MIN RES, V21
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Bauss F, 2002, J RHEUMATOL, V29, P990
   Bendre MS, 2002, CANCER RES, V62, P5571
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619
   GROSIOS K, 2005, P AM ASS CANC RES, V46
   Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008 5472.CAN 05 2012
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Yonou H, 2003, CANCER RES, V63, P2096
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 29
TC 154
Z9 173
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2007
VL 67
IS 20
BP 9894
EP 9902
DI 10.1158/0008 5472.CAN 06 3940
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 222HG
UT WOS:000250286300035
PM 17942921
OA Bronze
DA 2025 08 17
ER

PT J
AU Baud'huin, M
   Solban, N
   Cornwall Brady, M
   Sako, D
   Kawamoto, Y
   Liharska, K
   Lath, D
   Bouxsein, ML
   Underwood, KW
   Ucran, J
   Kumar, R
   Pobre, E
   Grinberg, A
   Seehra, J
   Canalis, E
   Pearsall, RS
   Croucher, PI
AF Baud'huin, Marc
   Solban, Nicolas
   Cornwall Brady, Milton
   Sako, Dianne
   Kawamoto, Yoshimi
   Liharska, Katia
   Lath, Darren
   Bouxsein, Mary L.
   Underwood, Kathryn W.
   Ucran, Jeffrey
   Kumar, Ravindra
   Pobre, Eileen
   Grinberg, Asya
   Seehra, Jasbir
   Canalis, Ernesto
   Pearsall, R. Scott
   Croucher, Peter I.
TI A soluble bone morphogenetic protein type IA receptor increases bone
   mass and bone strength
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE anabolic; therapy
ID MOUSE EMBRYOGENESIS; DICKKOPF PROTEINS; MULTIPLE MYELOMA; DEFECT MODEL;
   OSTEOBLASTS; DKK1; MICE; SUPPRESSION; OSTEOCLASTS; EXPRESSION
AB Diseases such as osteoporosis are associated with reduced bone mass. Therapies to prevent bone loss exist, but there are few that stimulate bone formation and restore bone mass. Bone morphogenetic proteins (BMPs) are members of the TGF beta superfamily, which act as pleiotropic regulators of skeletal organogenesis and bone homeostasis. Ablation of the BMPR1A receptor in osteoblasts increases bone mass, suggesting that inhibition of BMPR1A signaling may have therapeutic benefit. The aim of this study was to determine the skeletal effects of systemic administration of a soluble BMPR1A fusion protein (mBMPR1A mFc) in vivo. mBMPR1A mFc was shown to bind BMP2/4 specifically and with high affinity and prevent downstream signaling. mBMPR1A mFc treatment of immature and mature mice increased bone mineral density, cortical thickness, trabecular bone volume, thickness and number, and decreased trabecular separation. The increase in bone mass was due to an early increase in osteoblast number and bone formation rate, mediated by a suppression of Dickkopf 1 expression. This was followed by a decrease in osteoclast number and eroded surface, which was associated with a decrease in receptor activator of NF kappa B ligand (RANKL) production, an increase in osteoprotegerin expression, and a decrease in serum tartrate resistant acid phosphatase (TRAP5b) concentration. mBMPR1A treatment also increased bone mass and strength in mice with bone loss due to estrogen deficiency. In conclusion, mBMPR1A mFc stimulates osteoblastic bone formation and decreases bone resorption, which leads to an increase in bone mass, and offers a promising unique alternative for the treatment of bone related disorders.
C1 [Solban, Nicolas; Cornwall Brady, Milton; Sako, Dianne; Kawamoto, Yoshimi; Liharska, Katia; Underwood, Kathryn W.; Ucran, Jeffrey; Kumar, Ravindra; Pobre, Eileen; Grinberg, Asya; Seehra, Jasbir; Pearsall, R. Scott] Acceleron Pharma Inc, Cambridge, MA 02139 USA.
   [Baud'huin, Marc; Lath, Darren; Croucher, Peter I.] Univ Sheffield, Sch Med, Dept Human Metab, Mellanby Ctr Bone Res, Sheffield S10 2RX, S Yorkshire, England.
   [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Orthopaed Biomech Lab, Boston, MA 02215 USA.
   [Bouxsein, Mary L.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
   [Canalis, Ernesto] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Croucher, Peter I.] Garvan Inst Med Res, Sydney, NSW 2010, Australia.
C3 Acceleron Pharma; University of Sheffield; Harvard University; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center;
   Harvard University; Harvard Medical School; Saint Francis Hospital &
   Medical Center; Garvan Institute of Medical Research
RP Pearsall, RS (通讯作者)，Acceleron Pharma Inc, Cambridge, MA 02139 USA.
EM spearsall@acceleronpharma.com; p.croucher@garvan.org.au
RI Kumar, Ravinder/HTL 2843 2023; Baud'huin, Marc/K 8519 2015; kumar,
   ravindra/HTL 2843 2023
OI Kumar, Ravinder/0009 0001 7609 0159; Croucher,
   Peter/0000 0002 7102 2413; Baud'huin, Marc/0000 0002 3357 329X
FU Acceleron Pharma
FX N.S., M.C. B., D.S., Y.K., K.L., K.W.U., J.U., R.K., E.P., A.G., J.S.,
   R.S.P. are employees of Acceleron Pharma. P.I.C., M.L.B., and E.C. have
   received research funding from Acceleron Pharma.
CR Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100 6110.2002
   Canalis E, 2012, ENDOCRINOLOGY, V153, P1616, DOI 10.1210/en.2011 1604
   Canalis E, 2012, J CELL PHYSIOL, V227, P269, DOI 10.1002/jcp.22730
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Davis S, 2004, DEV BIOL, V270, P47, DOI 10.1016/j.ydbio.2004.01.048
   DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Fukuda T, 2009, J BIOL CHEM, V284, P7149, DOI 10.1074/jbc.M801681200
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966
   Hatta T, 2000, BIOPOLYMERS, V55, P399, DOI 10.1002/1097 0282(2000)55:5<399::AID BIP1014>3.0.CO;2 9
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Kamiya N, 2011, BIOCHEM BIOPH RES CO, V414, P326, DOI 10.1016/j.bbrc.2011.09.060
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Leung CK, 1996, PATTERN RECOGN, V29, P1523, DOI 10.1016/0031 3203(96)00009 X
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092 8674(92)90627 O
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   RIDLER TW, 1978, IEEE T SYST MAN CYB, V8, P630, DOI 10.1109/tsmc.1978.4310039
   Seeherman HJ, 2010, J BONE JOINT SURG AM, V92A, P411, DOI 10.2106/JBJS.H.01732
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wingerter S, 2007, BIOMED SCI INSTRUM, V43, P188
   WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105
   Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955 2235(89)90015 X
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
NR 36
TC 41
Z9 45
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 24
PY 2012
VL 109
IS 30
BP 12207
EP 12212
DI 10.1073/pnas.1204929109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 981TD
UT WOS:000306992700067
PM 22761317
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Valenti, MT
   Carbonare, LD
   Mottes, M
AF Valenti, Maria Teresa
   Carbonare, Luca Dalle
   Mottes, Monica
TI Role of microRNAs in progenitor cell commitment and osteogenic
   differentiation in health and disease (Review)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE microRNAs; mesenchymal stem cell; osteoblast; chondrocyte; osteoclast;
   osteoporosis
ID MESENCHYMAL STEM CELLS; BONE FORMATION; REGULATES OSTEOCLASTOGENESIS;
   CHONDROGENIC DIFFERENTIATION; POSTMENOPAUSAL OSTEOPOROSIS; ADIPOGENIC
   DIFFERENTIATION; CIRCULATING MIRNAS; PROTEIN EXPRESSION; TARGETING
   OSTERIX; SIGNALING PATHWAY
AB MicroRNAs (miRNAs) are considered 'micro managers of gene expression' and awareness of their fundamental role in the control of biological functions is constantly increasing. Bone formation and homeostasis are complex processes involving the differentiation and interaction of various cell types. Several miRNAs have been shown to be involved in different pathways and stages in the regulation of normal and abnormal bone formation and turnover. This present review focuses on the involvement of miRNAs in terms of their effect on the commitment of bone marrow mesenchymal stem cells towards osteogenesis, adipogenesis and chondrogenesis, respectively. The miRNAs involved in regulating osteoblast, chondroblast and osteoclast activity, are also taken into consideration, as are their interactions. miRNA expression levels, which may differ significantly in healthy versus pathological conditions, can be readily monitored and represent useful biomarkers. Several studies have suggested that miRNAs offer potential as useful biomarkers of bone pathologies, including osteoporosis and osteosarcoma. The development of efficient methods of delivering miRNA mimics or miRNA inhibitors into specific cells remains a challenge for novel therapeutic applications in the field of personalized medicine.
C1 [Valenti, Maria Teresa; Carbonare, Luca Dalle] Univ Verona, Dept Med, I 37134 Verona, Italy.
   [Mottes, Monica] Univ Verona, Biol & Genet Sect, Dept Neurosci Biomed & Movement Sci, 8 Str Le Grazie, I 37134 Verona, Italy.
C3 University of Verona; University of Verona
RP Mottes, M (通讯作者)，Univ Verona, Biol & Genet Sect, Dept Neurosci Biomed & Movement Sci, 8 Str Le Grazie, I 37134 Verona, Italy.
EM monica.mottes@univr.it
RI ; Valenti, Maria/F 4712 2011; Carbonare, Luca/E 5720 2011
OI Valenti, Maria Teresa/0000 0003 1166 8033; Dalle Carbonare,
   Luca/0000 0003 3263 6671; 
FU Fondo Unico della Ricerca grants of the University of Verona (Verona,
   Italy)
FX This review was supported by Fondo Unico della Ricerca grants of the
   University of Verona (Verona, Italy) to Professor L.D.C. and Professor
   M.M., respectively.
CR Bai R, 2015, EUR REV MED PHARMACO, V19, P545
   Bhushan R, 2013, INT J BIOCHEM CELL B, V45, P696, DOI 10.1016/j.biocel.2012.12.008
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Dong JB, 2016, J BONE ONCOL, V5, P74, DOI 10.1016/j.jbo.2016.05.001
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Franceschetti T, 2013, J BIOL CHEM, V288, P33347, DOI 10.1074/jbc.M113.484568
   Gámez B, 2013, J BIOL CHEM, V288, P14264, DOI 10.1074/jbc.M112.432104
   Gennari L, 2017, OSTEOPOROSIS INT, V28, P1191, DOI 10.1007/s00198 016 3847 5
   Gong YM, 2014, MOL CELL BIOCHEM, V387, P227, DOI 10.1007/s11010 013 1888 z
   Gu YL, 2017, MOL MED REP, V15, P194, DOI 10.3892/mmr.2016.5982
   Gu Y, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1893520
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   Hackl M, 2016, MOL CELL ENDOCRINOL, V432, P93, DOI 10.1016/j.mce.2015.10.015
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Huang C, 2017, CELL TISSUE RES, V368, P229, DOI 10.1007/s00441 016 2462 2
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014
   Idolazzi L, 2017, CLIN RHEUMATOL, V36, P925, DOI 10.1007/s10067 016 3497 1
   Ji X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030349
   Jin HL, 2012, MOL CELLS, V34, P177, DOI 10.1007/s10059 012 0090 6
   Kaneto CM, 2014, BMC MED GENET, V15, DOI 10.1186/1471 2350 15 45
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Keremu A, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20170080
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Laxman N, 2015, RNA, V21, P1433, DOI 10.1261/rna.049148.114
   Li EQ, 2014, MOL CELL BIOCHEM, V390, P69, DOI 10.1007/s11010 013 1957 3
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Li HQ, 2014, BIOMARKERS, V19, P553, DOI 10.3109/1354750X.2014.935957
   Li H, 2015, ONCOL LETT, V10, P1662, DOI 10.3892/ol.2015.3378
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Lian F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121499
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Ma WL, 2014, TUMOR BIOL, V35, P12467, DOI 10.1007/s13277 014 2565 x
   Mäkitie RE, 2016, J BONE MINER RES, V31, P1734, DOI 10.1002/jbmr.2841
   Mei Y, 2013, J CELL BIOCHEM, V114, P1374, DOI 10.1002/jcb.24479
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Miyaki S, 2009, ARTHRITIS RHEUM US, V60, P2723, DOI 10.1002/art.24745
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Nakka M, 2017, ONCOTARGET, V8, P96738, DOI 10.18632/oncotarget.18236
   Onyekwelu I, 2009, J CELL BIOCHEM, V107, P383, DOI 10.1002/jcb.22149
   Ou ML, 2014, EUR J HUM GENET, V22, P625, DOI 10.1038/ejhg.2013.221
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Papaioannou G, 2013, P NATL ACAD SCI USA, V110, pE3291, DOI 10.1073/pnas.1302797110
   Qu B, 2015, EXP CELL RES, V338, P89, DOI 10.1016/j.yexcr.2015.07.023
   Ren XF, 2016, BRIT J BIOMED SCI, V73, P158, DOI 10.1080/09674845.2016.1220710
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Seidl CI, 2016, ARTHRITIS RHEUMATOL, V68, P398, DOI 10.1002/art.39428
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Tian Y, 2016, LIFE SCI, V148, P220, DOI 10.1016/j.lfs.2016.02.031
   Trohatou O, 2014, STEM CELL TRANSL MED, V3, P54, DOI 10.5966/sctm.2013 0081
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.356
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Weilner S, 2015, BONE, V79, P43, DOI 10.1016/j.bone.2015.05.027
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wu CL, 2014, INT J MOL MED, V34, P13, DOI 10.3892/ijmm.2014.1743
   Wu ZY, 2011, MED ONCOL, V28, P1469, DOI 10.1007/s12032 010 9563 7
   Xu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079752
   Yan SJ, 2016, INT J MOL MED, V38, P201, DOI 10.3892/ijmm.2016.2618
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yavropoulou MP, 2017, EUR J ENDOCRINOL, V176, P169, DOI 10.1530/EJE 16 0583
   Yuan Y, 2017, J CELL PHYSIOL, V232, P1239, DOI 10.1002/jcp.25688
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang JF, 2011, MOL BIOL CELL, V22, P3955, DOI 10.1091/mbc.E11 04 0356
   Zhang XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10376
   Zhang ZQ, 2015, FEBS LETT, V589, P3671, DOI 10.1016/j.febslet.2015.09.032
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
   Zoni E, 2016, J BONE ONCOL, V5, P104, DOI 10.1016/j.jbo.2016.04.002
NR 77
TC 52
Z9 57
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAY
PY 2018
VL 41
IS 5
BP 2441
EP 2449
DI 10.3892/ijmm.2018.3452
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GB5HU
UT WOS:000429095900001
PM 29393379
OA Bronze
DA 2025 08 17
ER

PT J
AU Huang, XW
   Wang, XP
   Zhang, Y
   Shen, LF
   Wang, NN
   Xiong, XF
   Zhang, L
   Cai, XB
   Shou, D
AF Huang, Xiaowen
   Wang, Xuping
   Zhang, Yang
   Shen, Lifeng
   Wang, Nani
   Xiong, Xuefeng
   Zhang, Li
   Cai, Xiaobin
   Shou, Dan
TI Absorption and utilisation of epimedin C and icariin from
   Epimedii herba, and the regulatory mechanism via the BMP2/ Runx2
   signalling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoblast; Lipopolysaccharide; Bone morphogenetic
   protein 2/runt related transcription factor 2 signalling pathway;
   Epimedii herba; Absorption and utilisation
ID CHRONIC OSTEOMYELITIS; REAL TIME; OSTEOBLASTS; MODEL; LPS;
   PROLIFERATION; FLAVONOIDS; CELLS
AB Bone nonunion remains a challenge during the treatment of bone defect accompanied with infection. Epimedii herba is a widely used medicine in clinic to enhance bone healing. Epimedin C and icariin are the major flavonoid glycosides from Epimedii herba. Although the effects of these compounds have been reported, their different absorption and utilisation by osteoblasts remain unclear. In the present study, lipopolysaccharide (LPS) induced osteoblast was adopted as the model cell to evaluate the effects of epimedin C and icariin. The intracellular and extracellular drug concentrations within 24 h were assayed by pipette tip solid phase extraction and high performance liquid chromatography, respectively. MTT, alkaline phosphatase (ALP) and calcified nodule staining were performed to identify and evaluate the effects of epimedin C and icariin on LPS induced osteoblasts. The regulatory roles of epimedin C and icariin in the bone morphogenetic protein 2 (BMP 2)/Runtrelated transcription factor 2 (Runx2) signalling pathway were investigated. The results revealed that epimedin C and icariin were not efficiently absorbed by LPS induced osteoblasts. Nevertheless, they still had high utilisation efficiency after entering the cells. ALP activity, mineralisation and osteoblasts proliferation were enhanced by a high concentration of epimedin C and icariin. The suppressed expression of BMP 2 and Runx2 in LPS induced osteoblasts was up regulated significantly after treatment with epimedin C and icariin. These findings firstly illustrated the behavior of epimedin C and icariin from Epimedii herba on LPS induced osteoblasts and the regulatory property on the expression of key genes and proteins of the BMP 2/Runx2 signalling pathway, which might be helpful for better understanding flavonoids' mechanism to enhance bone repair and improving their future application.
C1 [Huang, Xiaowen; Wang, Xuping; Zhang, Yang; Wang, Nani; Shou, Dan] Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmu Mt Rd, Hangzhou 310007, Zhejiang, Peoples R China.
   [Shen, Lifeng] Zhejiang Prov Tongde Hosp, Dept Orthopaed Surg, Hangzhou 310012, Zhejiang, Peoples R China.
   [Xiong, Xuefeng] Zhejiang Hosp, Dept Pharm, Hangzhou 310013, Zhejiang, Peoples R China.
   [Zhang, Li] Zhejiang Univ Tradit Chinese Med, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
   [Cai, Xiaobin] Lishui Cent Hosp, Dept Orthopaed Surg, Lishui 323000, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Shou, D (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmu Mt Rd, Hangzhou 310007, Zhejiang, Peoples R China.
EM shoudanok@163.com
FU National Natural Science Foundation of China [81873062, 81803808];
   Science Foundation of Zhejiang Province [2017C37181]; Zhejiang
   Provincial Traditional Chinese Medicine Science and the Technology Fund
   [2016ZB003, 2018ZA021]
FX The project was sponsored by the National Natural Science Foundation of
   China (grant nos. 81873062 and 81803808), the Science Foundation of
   Zhejiang Province (grant no. 2017C37181), the Zhejiang Provincial
   Traditional Chinese Medicine Science and the Technology Fund (grant nos.
   2016ZB003 and 2018ZA021).
CR BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Brazil DP, 2015, TRENDS CELL BIOL, V25, P249, DOI 10.1016/j.tcb.2014.12.004
   Chen Y, 2014, MOLECULES, V19, P686, DOI 10.3390/molecules19010686
   Cook BD, 2014, BLOOD, V124, P393, DOI 10.1182/blood 2014 02 556993
   Funao H, 2012, INFECT IMMUN, V80, P733, DOI 10.1128/IAI.06166 11
   Grgurevic L, 2011, BIOCHEM BIOPH RES CO, V408, P26, DOI 10.1016/j.bbrc.2011.03.109
   Holtom PD, 2000, J ORTHOP RES, V18, P721, DOI 10.1002/jor.1100180507
   Jiranek WA, 2006, J BONE JOINT SURG AM, V88A, P2487, DOI 10.2106/JBJS.E.01126
   Jolles JW, 2011, ANIM COGN, V14, P769, DOI 10.1007/s10071 011 0395 4
   Kang HK, 2012, FOOD CHEM TOXICOL, V50, P2751, DOI 10.1016/j.fct.2012.05.017
   Li GY, 2013, J ORTHOP RES, V31, P949, DOI 10.1002/jor.22299
   Li XF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/652317
   Linder CH, 2017, CALCIFIED TISSUE INT, V101, P92, DOI 10.1007/s00223 017 0259 2
   Liu J, 2016, INFLAMMATION, V39, P1764, DOI 10.1007/s10753 016 0411 6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maruyama K, 2006, J BONE MINER METAB, V24, P454, DOI 10.1007/s00774 006 0708 x
   Nakao J, 2014, BONE, V58, P17, DOI 10.1016/j.bone.2013.09.018
   Pilge H, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2042687
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Seebach E, 2015, ACTA BIOMATER, V21, P165, DOI 10.1016/j.actbio.2015.03.019
   Shen LF, 2015, J MED IMAG HEALTH IN, V5, P36, DOI 10.1166/jmihi.2015.1362
   Shou D, 2017, PHYTOTHER RES, V31, P330, DOI 10.1002/ptr.5755
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Tsai YM, 2012, INT J NANOMED, V7, P2957, DOI 10.2147/IJN.S32630
   Uskokovic V, 2014, MAT SCI ENG C MATER, V37, P210, DOI 10.1016/j.msec.2014.01.008
   Wang NN, 2015, J CHROMATOGR B, V990, P64, DOI 10.1016/j.jchromb.2015.03.012
   Widaa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040586
   Xia LL, 2013, MAT SCI ENG C MATER, V33, P3545, DOI 10.1016/j.msec.2013.04.050
   Yan CG, 2010, J BIOL CHEM, V285, P37227, DOI 10.1074/jbc.M110.132084
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
   Zhou HF, 2014, MOL MED REP, V9, P590, DOI 10.3892/mmr.2013.1837
NR 31
TC 14
Z9 16
U1 0
U2 33
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2019
VL 118
AR 109345
DI 10.1016/j.biopha.2019.109345
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IY4WZ
UT WOS:000486395000126
PM 31545266
OA gold
DA 2025 08 17
ER

PT J
AU Li, H
   Hu, F
   Liu, QY
   Lv, LW
   Liang, HJ
   Yuan, M
   Su, WX
   Zhang, JH
   Chen, RR
   Chen, ZT
   Yan, RY
   Wang, ZJ
   Tang, HY
   Li, JC
   Wang, Z
   Wang, C
   Chang, YN
   Li, J
   Wei, CF
   Xing, GY
   Xing, GM
   Chen, K
AF Li, Hao
   Hu, Fan
   Liu, Qiuyang
   Lv, Linwen
   Liang, Haojun
   Yuan, Meng
   Su, Wenxi
   Zhang, Junhui
   Chen, Ranran
   Chen, Ziteng
   Yan, Ruyu
   Wang, Zhijie
   Tang, Hongyu
   Li, Jiacheng
   Wang, Zhe
   Wang, Ce
   Chang, Ya nan
   Li, Juan
   Wei, Cunfeng
   Xing, Gengyan
   Xing, Gengmei
   Chen, Kui
TI Enhanced osteogenic differentiation for osteoporosis treatment through
   controlled icariin release in the bone cavity via extracorporeal shock
   wave
SO NANO TODAY
LA English
DT Article
DE Extracorporeal shock wave; Controlled drug release; Bone cavity;
   Osteoblast adipocyte lineage commitment; Osteoporotic fracture
ID EXPRESSION; TISSUE; REGENERATION; MECHANISM; CELLS
AB Controlling drug release from the bone cavity through physical stimulation remains a challenge because the unique shielding properties of the bone structure make it difficult for many physical stimuli to be effective in skeletal disorders. Herein, we designed a type of high loading nanocomposites self assembled from Icariin (ICA), Ca2+, and Zoledronic acid (ZOL), which could respond to extracorporeal shock wave (ESW) to control drug release in the bone cavity and govern osteoblast adipocyte lineage commitment to prevent osteoporotic fracture. The nanocomposites contain more than 70 % of the payloads and exhibit excellent function in bone marrow targeting. When shocked with ESW, the payloads including ICA, Ca2+, and ZOL, can be released in the bone marrow. ICA can inhibit the formation of adipocyte lineages and promote the formation of osteoblast lineages by inhibiting the transcription of peroxisome proliferators activated receptor gamma (PPAR gamma) and fatty acid binding protein 4 (FABP4), ESW, and Ca2+ further increase osteoblast activity meanwhile, and ZOL acts as an inhibitor of osteoclasts, leading to an overall anabolism. In vivo, the treatment contributed to a significant increase in bone anabolism, including bone related parameters, bone strength, and bone resilience, ultimately greatly reducing the risk of osteoporotic fracture. This study demonstrated the high feasibility of combining the bonepenetrating ESW responsive drug controlled release system with the regulation of osteoblast adipocyte lineage commitment for osteoporotic fracture prevention.
C1 [Li, Hao; Hu, Fan; Xing, Gengyan] Anhui Med Univ, Armed Police Gen Hosp Clin Coll, Sch Clin Med 5, Hefei 230032, Anhui, Peoples R China.
   [Li, Hao; Hu, Fan; Liu, Qiuyang; Lv, Linwen; Liang, Haojun; Yuan, Meng; Su, Wenxi; Zhang, Junhui; Chen, Ranran; Chen, Ziteng; Yan, Ruyu; Wang, Zhijie; Tang, Hongyu; Li, Jiacheng; Wang, Zhe; Chang, Ya nan; Li, Juan; Wei, Cunfeng; Xing, Gengmei; Chen, Kui] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Li, Hao; Hu, Fan; Liang, Haojun; Wang, Ce; Xing, Gengyan] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 3, Beijing 100039, Peoples R China.
   [Liu, Qiuyang; Lv, Linwen; Chen, Ziteng; Yan, Ruyu; Wang, Zhijie; Li, Jiacheng; Chang, Ya nan; Li, Juan; Xing, Gengmei; Chen, Kui] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Anhui Medical University; Chinese Academy of Sciences; Key Laboratory
   for Biological Effects of Nanomaterials & Nanosafety, CAS; Institute of
   High Energy Physics, CAS; Chinese People's Liberation Army General
   Hospital; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS
RP Xing, GY (通讯作者)，Anhui Med Univ, Armed Police Gen Hosp Clin Coll, Sch Clin Med 5, Hefei 230032, Anhui, Peoples R China.; Xing, GM; Chen, K (通讯作者)，Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
EM xgy1350138@163.com; xinggm@ihep.ac.cn; chenkui@ihep.ac.cn
RI Chen, Kui/HNJ 6568 2023; Zhang, Junhui/AAZ 5734 2020; Li,
   Hao/KXQ 5688 2024; Li, Juan/F 1448 2014; su, wen/MVY 1831 2025
OI Li, Hao/0009 0008 5814 0723; Tang, Hongyu/0009 0003 7663 099X; Li,
   Juan/0000 0003 4110 3295; 
FU National Key Research and Development Program of China [2021YFA1201204];
   Beijing Nova Program [Z211100002121031, 20230484398]; National Natural
   Science Foundation of China [12105312, 81873914, 31971294]; Capital
   Featured Projects [Z181100001718018]; PLA Medical Science and Technology
   Youth Training Program [17QNP042]
FX This work was supported by grants from the National Key Research and
   Development Program of China (No. 2021YFA1201204) ; Beijing Nova Program
   (No. Z211100002121031, 20230484398) , National Natural Science
   Foundation of China (No. 12105312, 81873914, 31971294) , the Capital
   Featured Projects (No. Z181100001718018) , and the PLA Medical Science
   and Technology Youth Training Program (No. 17QNP042) .
CR Alshihri A, 2020, J TISSUE ENG REGEN M, V14, P1630, DOI 10.1002/term.3126
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   de Gusmao CVB, 2019, ULTRASOUND MED BIOL, V45, P2140, DOI 10.1016/j.ultrasmedbio.2019.04.011
   Burr D.B., 2006, Principles of bone biomechanics
   Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756 3282(02)00815 3
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hofman T, 2006, ULTRASONICS, V44, pE1307, DOI 10.1016/j.ultras.2006.05.032
   Huang CF, 2023, J FORMOS MED ASSOC, V122, pS14, DOI 10.1016/j.jfma.2023.01.013
   Jiang ZB, 2022, DRUG TEST ANAL, V14, P973, DOI 10.1002/dta.3099
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lele P.P., 1987, Ultrasound: Medical Applications, Biological Effects, and Hazard Potential, P343
   Li BF, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.627718
   Li FJ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052696
   Li XY, 2018, MOL MED REP, V18, P3483, DOI 10.3892/mmr.2018.9325
   Li Y, 2023, CLIN ORTHOP RELAT R, V481, P822, DOI 10.1097/CORR.0000000000002559
   Liang HJ, 2023, SMALL, V19, DOI 10.1002/smll.202207195
   Liang W, 2021, CHEM ENG J, V425, DOI 10.1016/j.cej.2021.130687
   Ligrani PM, 2020, ADV AERODYNAM, V2, DOI 10.1186/s42774 020 0028 1
   Lu CC, 2020, BONE JOINT RES, V9, P457, DOI 10.1302/2046 3758.98.BJR 2019 0365.R1
   Lu YF, 2014, MOLECULES, V19, P18179, DOI 10.3390/molecules191118179
   Ma C, 2023, AGEING RES REV, V90, DOI 10.1016/j.arr.2023.102024
   Madersbacher S, 2003, J ENDOUROL, V17, P667, DOI 10.1089/089277903322518680
   MINAIRE P, 1974, CALC TISS RES, V17, P57, DOI 10.1007/BF02547214
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Nöth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736 0266(02)00018 9
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Subedi A., 2019, Ultrasound and it's application on medicine (ULTRASONOGRAPHY) A Term Paper
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Wang CJ, 2008, RHEUMATOLOGY, V47, P542, DOI 10.1093/rheumatology/ken020
   Wang FS, 2004, J BONE MINER RES, V19, P973, DOI 10.1359/JBMR.040121
   Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756 3282(03)00029 2
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   Wang M, 2020, BIOMED PHARMACOTHER, V131, DOI [10.1016/j.biopha.2020.110675, 10.1016/J.biopha.2020.110675]
   Wronski T J, 1981, Adv Space Res, V1, P135, DOI 10.1016/0273 1177(81)90254 4
   Wu KT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2958251
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Zhang N, 2017, J ORTHOP TRANSL, V9, P52, DOI 10.1016/j.jot.2017.03.004
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
NR 41
TC 0
Z9 0
U1 12
U2 22
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1748 0132
EI 1878 044X
J9 NANO TODAY
JI Nano Today
PD OCT
PY 2024
VL 58
AR 102408
DI 10.1016/j.nantod.2024.102408
EA JUL 2024
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA ZI0M3
UT WOS:001274549500001
DA 2025 08 17
ER

PT J
AU Turner, RT
   Lotinun, S
   Hefferan, TE
   Morey Holton, E
AF Turner, Russell T.
   Lotinun, Sutada
   Hefferan, Theresa E.
   Morey Holton, Emily
TI Disuse in adult male rats attenuates the bone anabolic response to a
   therapeutic dose of parathyroid hormone
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE bone anabolic; aging; bone remodeling; exercise
ID GROWTH FACTOR I; OVARIECTOMIZED RATS; POSTMENOPAUSAL WOMEN; MINERAL
   DENSITY; SIMULATED WEIGHTLESSNESS; CANCELLOUS BONE; MESSENGER RNA;
   CORTICAL BONE; OSTEOPOROSIS; ESTROGEN
AB Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone. J Appl Physiol 101: 881 886, 2006. First published May 4, 2006; doi:10.1152/japplphysiol.01622.2005. Intermittent treatment with parathyroid hormone (PTH) increases bone formation and prevents bone loss in hindlimb unloaded (HLU) rats. However, the mechanisms of action of PTH are incompletely known. To explore possible interactions between weight bearing and PTH, we treated 6 mo old weight bearing and HLU rats with a human therapeutic dose (1 mu g center dot kg( 1)center dot day( 1)) of human PTH (1 34) (hPTH). Cortical and cancellous bone formation was measured in tibia at the diaphysis proximal to the tibia fibula synostosis and at the proximal metaphysis, respectively. Two weeks of hindlimb unloading resulted in a dramatic decrease in the rate of bone formation at both skeletal sites, which was prevented by PTH treatment at the cancellous site only. In contrast, PTH treatment increased cortical as well as cancellous bone formation in weight bearing rats. Two way ANOVA revealed that hPTH and HLU had independent and opposite effects on all histomorphometric indexes of bone formation [mineral apposition rate (MAR), double labeled perimeter (dLPm), and bone formation rate (BFR)] at both skeletal sites. The bone anabolic effects of weight bearing and hPTH on dLPm and BFR at the cortical site were additive, as were the effects on MAR at the cancellous site. In contrast, weight bearing and hPTH resulted in synergistic increases in cortical bone MAR and cancellous bone dLPm and BFR. We conclude that weight bearing and PTH act cooperatively to increase bone formation by resulting in site specific additive and synergistic increases in indexes of osteoblast number and activity, suggesting that weight bearing exercise targeted to osteopenic skeletal sites may improve the efficacy of PTH therapy for osteoporosis.
C1 Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97333 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Dept Orthoped, Rochester, MN 55905 USA.
   NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.
C3 Oregon State University; Mayo Clinic; National Aeronautics & Space
   Administration (NASA); NASA Ames Research Center
RP Turner, RT (通讯作者)，Oregon State Univ, Dept Nutr & Exercise Sci, 107 Milam Hall, Corvallis, OR 97333 USA.
EM russell.turner@oregonstate.edu
FU NIAMS NIH HHS [AR 48833] Funding Source: Medline
CR Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 1998, JAMA J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067
   Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   Hefferan TE, 2003, J APPL PHYSIOL, V95, P1775, DOI 10.1152/japplphysiol.00455.2002
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Lane NE, 2000, OSTEOPOROSIS INT, V11, P434, DOI 10.1007/s001980070111
   LEAN JM, 1995, AM J PHYSIOL ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318
   Liu CC, 2000, OSTEOPOROSIS INT, V11, P889, DOI 10.1007/s001980070049
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   MA YF, 1995, J BONE MINER RES, V10, P496
   Ma YFL, 2003, ENDOCRINOLOGY, V144, P2008, DOI 10.1210/en.2002 221061
   Marchetti M E, 1996, J Shoulder Elbow Surg, V5, P471, DOI 10.1016/S1058 2746(96)80020 6
   Marcus R, 2003, J BONE MINER RES, V18, P18, DOI 10.1359/jbmr.2003.18.1.18
   Morey Holton E, 2005, ADV SPACE B, V10, P7, DOI 10.1016/S1569 2574(05)10002 1
   Morey Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001
   Moriyama Ichiro, 2002, J Orthop Sci, V7, P379, DOI 10.1007/s007760200063
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438
   QI H, 1995, J BONE MINER RES, V10, P948
   RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562
   SHEN V, 1993, J CLIN INVEST, V91, P2479, DOI 10.1172/JCI116483
   Talbott SM, 2001, J NUTR, V131, P2382, DOI 10.1093/jn/131.9.2382
   Tanaka S, 2004, J BONE MINER RES, V19, P1813, DOI 10.1359/JBMR.040808
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   Turner RT, 2000, CALCIFIED TISSUE INT, V66, P461, DOI 10.1007/s002230010092
   Turner RT, 1998, ENDOCRINOLOGY, V139, P4086, DOI 10.1210/en.139.10.4086
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
   Wimalawansa SM, 1999, ENDOCRINE, V10, P253, DOI 10.1007/BF02738624
NR 33
TC 39
Z9 45
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD SEP
PY 2006
VL 101
IS 3
BP 881
EP 886
DI 10.1152/japplphysiol.01622.2005
PG 6
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 078SQ
UT WOS:000240124100027
PM 16675609
DA 2025 08 17
ER

PT J
AU Mahdal, M
   Neradil, J
   Mudry, P
   Paukovcekova, S
   Zambo, IS
   Urban, J
   Macsek, P
   Pazourek, L
   Tomas, T
   Veselska, R
AF Mahdal, Michal
   Neradil, Jakub
   Mudry, Peter
   Paukovcekova, Silvia
   Staniczkova Zambo, Iva
   Urban, Jiri
   Macsek, Peter
   Pazourek, Lukas
   Tomas, Tomas
   Veselska, Renata
TI New Target for Precision Medicine Treatment of Giant Cell Tumor of Bone:
   Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with
   Activated PDGFRβ Signaling
SO CANCERS
LA English
DT Article
DE giant cell tumor of bone; targeted treatment; sunitinib; PDGFR beta;
   denosumab; signaling
ID DENOSUMAB; OSTEOCLASTOGENESIS; RECEPTOR; DIFFERENTIATION; EXPRESSION;
   RANKL
AB Simple Summary The purpose of this study was to analyze differential cell signaling in response to denosumab treatment to identify and subsequently inhibit molecular targets in the neoplastic stromal cell population, which poses a risk for tumor recurrence. Using phosphoprotein arrays, a distinct signaling profile was detected in GCTB tissues treated with denosumab, a specific RANKL antibody, which coincided with the RTK profile in derived cell lines. PDGFR beta was selected as a promising receptor target, and its inhibition by the small molecule inhibitor sunitinib resulted in potent inhibition of cell proliferation in vitro. The addition of sunitinib to denosumab resulted in the disappearance of both multinuclear giant cells and neoplastic stromal cells, as reported here. Thus, sunitinib could become an effective addition to denosumab in the treatment of GCTB with activated PDGFR beta. Giant cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involved in GCTB tumorigenesis. Profiles of activated signaling proteins in fresh frozen tumor samples and tumor derived cell lines were determined using phosphoprotein arrays. Analysis of the obtained data revealed epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor beta (PDGFR beta) as potential targets, but only the PDGFR inhibitor sunitinib caused a considerable decrease in stromal cell viability in vitro. Furthermore, in the case of a 17 year old patient suffering from GCTB, we showed that the addition of sunitinib to the standard treatment of GCTB with the monoclonal antibody denosumab resulted in the complete depletion of multinucleated giant cells and mononuclear stromal cells in the tumor tissue. To summarize, the obtained data showed that a specific receptor tyrosine kinase (RTK) signaling pattern is activated in GCTB cells and plays an important role in the regulation of cell proliferation. Thus, activated RTKs and their downstream signaling pathways represent useful targets for precision treatment with low molecular weight inhibitors or with other types of modern biological therapy.
C1 [Mahdal, Michal; Pazourek, Lukas; Tomas, Tomas] Masaryk Univ, St Annes Univ Hosp, Dept Orthoped Surg 1, Brno 65691, Czech Republic.
   [Mahdal, Michal; Staniczkova Zambo, Iva; Pazourek, Lukas; Tomas, Tomas] Masaryk Univ, Fac Med, Brno 65691, Czech Republic.
   [Paukovcekova, Silvia; Macsek, Peter; Veselska, Renata] Masaryk Univ, Fac Sci, Dept Expt Biol, Lab Tumor Biol, Brno 61137, Czech Republic.
   [Neradil, Jakub; Mudry, Peter; Staniczkova Zambo, Iva; Macsek, Peter; Veselska, Renata] St Annes Univ Hosp, Int Clin Res Ctr, Brno 65691, Czech Republic.
   [Neradil, Jakub; Mudry, Peter; Veselska, Renata] Masaryk Univ, Univ Hosp Brno, Dept Pediat Oncol, Brno 66263, Czech Republic.
   [Neradil, Jakub; Mudry, Peter; Veselska, Renata] Masaryk Univ, Fac Med, Brno 66263, Czech Republic.
   [Staniczkova Zambo, Iva] Masaryk Univ, St Annes Univ Hosp, Pathol Dept 1, Brno 65691, Czech Republic.
   [Urban, Jiri] Masaryk Univ, Fac Sci, Dept Chem, Brno 61137, Czech Republic.
C3 Masaryk University Brno; St. Anne's University Hospital Brno (FNUSA);
   Masaryk University Brno; Masaryk University Brno; St. Anne's University
   Hospital Brno (FNUSA); St. Anne's University Hospital Brno (FNUSA ICRC);
   Masaryk University Brno; University Hospital Brno; Masaryk University
   Brno; St. Anne's University Hospital Brno (FNUSA); Masaryk University
   Brno; Masaryk University Brno
RP Veselska, R (通讯作者)，Masaryk Univ, Fac Sci, Dept Expt Biol, Lab Tumor Biol, Brno 61137, Czech Republic.; Veselska, R (通讯作者)，St Annes Univ Hosp, Int Clin Res Ctr, Brno 65691, Czech Republic.; Veselska, R (通讯作者)，Masaryk Univ, Univ Hosp Brno, Dept Pediat Oncol, Brno 66263, Czech Republic.; Veselska, R (通讯作者)，Masaryk Univ, Fac Med, Brno 66263, Czech Republic.
EM michal.mahdal@fnusa.cz; jneradil@sci.muni.cz; mudry.peter@fnbrno.cz;
   silvia.paukovcekova@mail.muni.cz; iva.zambo@fnusa.cz;
   urban@chemi.muni.cz; mudry.peter@fnbrno.cz; lukas.pazourek@fnusa.cz;
   tomas.tomas@fnusa.cz; veselska@sci.muni.cz
RI ; Veselska, Renata/L 7661 2016; Urban, Jiri/D 1133 2014; Neradil,
   Jakub/GQZ 7932 2022
OI Veselska, Renata/0000 0002 0048 9913; Mahdal,
   Michal/0000 0002 2136 9136; Neradil, Jakub/0000 0001 6781 7099; Urban,
   Jiri/0000 0002 5169 4327; 
FU Masaryk University, Brno, Czech Republic [MUNI/A/1477/2018]; Ministry of
   Healthcare of the Czech Republic [16 34083A]; European Regional
   Development Fund Project ENOCH [CZ.02.1.01/0.0/0.0/16_019/0000868]
FX This study was supported by Project No. MUNI/A/1477/2018 from Masaryk
   University, Brno, Czech Republic, by Project No. 16 34083A from the
   Ministry of Healthcare of the Czech Republic and by the European
   Regional Development Fund Project ENOCH (No.
   CZ.02.1.01/0.0/0.0/16_019/0000868).
CR Athanasou NABM., 2013, CLASSIFICATION TUMOR, V4th ed., P321
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Baloul SS, 2016, FRONT ORAL BIOL, V18, P75, DOI 10.1159/000351901
   Mallick AB, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912 021 01047 5
   Baud'Huin M, 2010, J PATHOL, V221, P77, DOI 10.1002/path.2684
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brun J, 2020, J BONE MINER RES, V35, P2458, DOI 10.1002/jbmr.4150
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   George S, 2009, J CLIN ONCOL, V27, P3154, DOI 10.1200/JCO.2008.20.9890
   Greenhalgh J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010383.pub2
   Guenther R, 2005, PATHOL RES PRACT, V201, P649, DOI 10.1016/j.prp.2005.07.005
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Jeys LM, 2006, INT ORTHOP, V30, P135, DOI 10.1007/s00264 005 0061 z
   Kassambara A., 2020, **DATA OBJECT**
   Kelley RK, 2008, BIOL TARGETS THER, V2, P83
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Koh JM, 2009, BONE, V45, P650, DOI 10.1016/j.bone.2009.06.007
   Liu L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.440
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   Malek F, 2006, INT ORTHOP, V30, P495, DOI 10.1007/s00264 006 0146 3
   Maros ME, 2019, BONE, V127, P188, DOI 10.1016/j.bone.2019.06.022
   Motzer RJ, 2018, EUR UROL, V73, P62, DOI 10.1016/j.eururo.2017.09.008
   Mukaihara K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148401
   Neradil J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00930
   Noguchi R, 2021, HUM CELL, V34, P688, DOI 10.1007/s13577 020 00457 0
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   O'Sullivan S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164727
   OREFFO ROC, 1993, CLIN ORTHOP RELAT R, P229
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Palmerini E, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864 020 00766 4
   Balla P, 2011, HISTOPATHOLOGY, V59, P376, DOI 10.1111/j.1365 2559.2011.03948.x
   R Core Team, R: A language and environment for statistical computing
   Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200
   Roskoski R, 2018, PHARMACOL RES, V129, P65, DOI 10.1016/j.phrs.2018.01.021
   Ruggieri P, 2010, CLIN ORTHOP RELAT R, V468, P2954, DOI 10.1007/s11999 010 1448 8
   Rutkowski P, 2018, EJSO EUR J SURG ONC, V44, P1384, DOI 10.1016/j.ejso.2018.03.020
   Saiz P, 2004, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000128280.59965.e3
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sramek M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092599
   Tariq MU, 2020, ANN DIAGN PATHOL, V45, DOI 10.1016/j.anndiagpath.2020.151479
   Thomas DM, 2012, CURR OPIN ONCOL, V24, P397, DOI 10.1097/CCO.0b013e328354c129
   Thomas DM, 2009, CURR OPIN ONCOL, V21, P338, DOI 10.1097/CCO.0b013e32832c951d
   Turcotte RE, 2006, ORTHOP CLIN N AM, V37, P35, DOI 10.1016/j.ocl.2005.08.005
   Uehara S, 2019, J ORAL BIOSCI, V61, P135, DOI 10.1016/j.job.2019.07.002
   Ulas A, 2015, J BUON, V20, P666
   Unni K.K., 2009, Dahlin's bone tumors, general aspects and data on 10165 cases
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   van Langevelde K, 2020, SKELETAL RADIOL, V49, P1345, DOI 10.1007/s00256 020 03449 1
   Wang GN, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017778
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wu PF, 2015, TUMOR BIOL, V36, P495, DOI 10.1007/s13277 015 3094 y
   Zhou ZH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0361 z
NR 55
TC 11
Z9 11
U1 1
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JUL
PY 2021
VL 13
IS 14
AR 3543
DI 10.3390/cancers13143543
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA TP1MB
UT WOS:000677361200001
PM 34298757
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Geusens, P
   Appelman Dijkstra, N
   Lems, W
   van den Bergh, J
AF Geusens, Piet
   Appelman Dijkstra, Natasha
   Lems, Willem
   van den Bergh, Joop
TI Romosozumab for the treatment of postmenopausal women at high risk of
   fracture
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Romosozumab; osteoporosis; very high fracture risk; osteoanabolic
   agents; sequential treatment; fracture prevention
ID INCREASES BONE FORMATION; SCLEROSTIN ANTIBODY; CARDIOVASCULAR SAFETY;
   DOUBLE BLIND; PHARMACOLOGICAL MANAGEMENT; VERTEBRAL FRACTURE; MINERAL
   DENSITY; OSTEOPOROSIS; MASS; TERIPARATIDE
AB IntroductionRomosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug that simultaneously increases bone formation and decreases bone resorption. It has recently been approved by the US and EU authorities in postmenopausal women with at high risk of fractures.Areas coveredThe literature on romosozumab in preclinical and in phase II and III clinical studies has been reviewed about the effect on bone, bone markers, and fracture reduction and its safety.Expert opinionCompared to antiresorptive agents, its unique mechanism of action results in a quicker and greater increase in bone mineral density, it repairs and restores trabecular and cortical bone microarchitecture, and reduces fracture risk more rapidly and more effectively than alendronate, with persisting effects for at least two years after transition to antiresorptive agents. This finding has introduced the concept that, in patients at very high risk of fractures, the optimal sequence of treatment is to start with an osteoanabolic agent, followed by a potent AR drug. Recent national and international guidelines recommend the use of romosozumab as an initial treatment in patients at very high fracture risk without a history of stroke or myocardial infarction.
C1 [Geusens, Piet] Univ Maastricht, Dept Rheumatol, Minderbroedersberg 4 6, NL 6211 LK Maastricht, Netherlands.
   [Appelman Dijkstra, Natasha] Leiden Univ Med Ctr, Dept Internal Med Endocrinol, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
   [Lems, Willem] Amsterdam Univ Med Ctr, Dept Rheumatol, Boelelaan 1117, NL 1081 HV Amsterdam, Netherlands.
   [van den Bergh, Joop] VieCuri Med Ctr, Dept Internal Med, Tegelseweg 210, NL 5912 BL Venlo, Netherlands.
   [Geusens, Piet] Univ Maastricht, Minderbroedersberg 4 6, NL 6211 LK Maastricht, Netherlands.
C3 Maastricht University; Leiden University; Leiden University Medical
   Center (LUMC); VieCuri Medical Center; Maastricht University
RP Geusens, P (通讯作者)，Univ Maastricht, Minderbroedersberg 4 6, NL 6211 LK Maastricht, Netherlands.
EM Piet.geusens@scarlet.be
RI ; Appelman Dijkstra, Natasha/V 7322 2018
OI Appelman Dijkstra, Natasha/0000 0001 5035 127X; geusens,
   piet/0000 0002 7547 9146; van den Bergh, J.P./0000 0003 3984 2232
CR Agency Em, 2019, US
   Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Appelman Dijkstra NM, 2016, CALCIFIED TISSUE INT, V98, P370, DOI 10.1007/s00223 016 0126 6
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Barrionuevo P, 2019, J CLIN ENDOCR METAB, V104, P1623, DOI 10.1210/jc.2019 00192
   Bhattacharyya S, 2018, EUR J PHARMACOL, V826, P39, DOI 10.1016/j.ejphar.2018.02.028
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Camacho PM, 2020, ENDOCR PRACT, V26, P564, DOI 10.4158/GL 2020 0524
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Chotiyarnwong P, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01117 6
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Conley RB, 2020, ORTHOP NURS, V39, P145, DOI 10.1097/NOR.0000000000000672
   Cornelissen D, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04743 2
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2022, OSTEOPOROSIS INT, V33, P1243, DOI 10.1007/s00198 021 06174 0
   Cosman F, 2021, CURR OSTEOPOROS REP, V19, P189, DOI 10.1007/s11914 021 00663 1
   Cosman F, 2020, J BONE MINER RES, V35, P1333, DOI 10.1002/jbmr.3996
   Cosman F, 2018, J BONE MINER RES, V33, P1407, DOI 10.1002/jbmr.3439
   Cummings SR, 2020, OSTEOPOROSIS INT, V31, P1019, DOI 10.1007/s00198 020 05379 z
   Cummings SR, 2020, OSTEOPOROSIS INT, V31, P1023, DOI 10.1007/s00198 020 05325 z
   Curtis EM, 2022, AGING CLIN EXP RES, V34, P695, DOI 10.1007/s40520 022 02100 4
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Fuggle NR, 2020, DRUGS, V80, P1537, DOI 10.1007/s40265 020 01364 2
   Fuleihan GE, 2017, J CLIN DENSITOM, V20, P397, DOI 10.1016/j.jocd.2017.06.008
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Geusens P, 2022, BEST PRACT RES CL RH, V36, DOI 10.1016/j.berh.2022.101759
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Graeff C, 2015, BONE, V81, P364, DOI 10.1016/j.bone.2015.07.036
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Johansson L, 2022, OSTEOPOROSIS INT, V33, P1725, DOI 10.1007/s00198 022 06387 x
   KANIS J, 2022, OSTEOPOROS INT
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kanis JA, 2017, J CLIN DENSITOM, V20, P360, DOI 10.1016/j.jocd.2017.06.022
   Kanis JA, 2017, J CLIN DENSITOM, V20, P444, DOI 10.1016/j.jocd.2017.06.013
   Keaveny TM, 2017, J BONE MINER RES, V32, P1956, DOI 10.1002/jbmr.3176
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kvist AV, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081660
   Langdahl Bente L, 2017, Lancet, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Langdahl BL, 2021, J CLIN ENDOCR METAB, V106, P1845, DOI 10.1210/clinem/dgab193
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lems WF, 2021, OSTEOPOROSIS INT, V32, P399, DOI 10.1007/s00198 020 05804 3
   Leslie WD, 2020, OSTEOPOROSIS INT, V31, P1059, DOI 10.1007/s00198 019 05274 2
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Mackey DC, 2007, JAMA J AM MED ASSOC, V298, P2381, DOI 10.1001/jama.298.20.2381
   McCloskey EV, 2021, OSTEOPOROSIS INT, V32, P1601, DOI 10.1007/s00198 020 05815 0
   McClung MR, 2022, POSTGRAD MED, V134, P541, DOI 10.1080/00325481.2022.2069582
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Merlijn T, 2020, OSTEOPOROSIS INT, V31, P251, DOI 10.1007/s00198 019 05226 w
   Merlijn T, 2019, J BONE MINER RES, V34, P1993, DOI 10.1002/jbmr.3815
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Nevitt MC, 2005, J BONE MINER RES, V20, P131, DOI 10.1359/JBMR.041003
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Nguyen TV, 2021, EXPERT REV ENDOCRINO, V16, P191, DOI 10.1080/17446651.2021.1924672
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rodríguez AJ, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10522
   Romosozumab, 2019, US
   Roudier M, 2013, ARTHRITIS RHEUM US, V65, P721, DOI 10.1002/art.37802
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Serge F, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20352
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Suen PK, 2015, SCI REP UK, V5, DOI 10.1038/srep15632
   Turk JR, 2020, REGUL TOXICOL PHARM, V115, DOI 10.1016/j.yrtph.2020.104697
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   Vestergaard P., 2011, BMJ CLIN EVID, V2011
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Willers C, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 021 00969 8
   Wong RMY, 2022, OSTEOPOROSIS INT, V33, P2453, DOI 10.1007/s00198 022 06473 0
   Yang J, 2020, OSTEOPOROSIS INT, V31, P2321, DOI 10.1007/s00198 020 05588 6
NR 88
TC 3
Z9 3
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JAN 2
PY 2023
VL 23
IS 1
BP 11
EP 19
DI 10.1080/14712598.2022.2152320
EA DEC 2022
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 7N9YU
UT WOS:000893324600001
PM 36440489
OA hybrid
DA 2025 08 17
ER

PT J
AU Dou, C
   Li, JM
   He, J
   Luo, F
   Yu, T
   Dai, QJ
   Chen, YQ
   Xu, JZ
   Yang, XC
   Dong, SW
AF Dou, Ce
   Li, Jianmei
   He, Jian
   Luo, Fei
   Yu, Tao
   Dai, Qijie
   Chen, Yueqi
   Xu, Jianzhong
   Yang, Xiaochao
   Dong, Shiwu
TI Bone targeted pH responsive cerium nanoparticles for anabolic therapy in
   osteoporosis
SO BIOACTIVE MATERIALS
LA English
DT Article
DE pH responsive; Nanomedicine; Bone; Osteoclast; Anabolic therapy
ID OSTEOCLAST DIFFERENTIATION; OXIDE NANOPARTICLES; UP REGULATION;
   VASCULARIZATION; ANGIOGENESIS; ATP6V0D2; PROTECT; FUSION; LIGAND
AB Antiresorptive drugs are widely used for treatment of osteoporosis and cancer bone metastasis, which function mainly through an overall inhibition of osteoclast. However, not all osteoclasts are "bone eaters"; preosteoclasts (pOCs) play anabolic roles in bone formation and angiogenesis through coupling with osteoblasts and secreting platelet derived growth factor BB (PDGF BB). In this study, a bone targeted pH responsive nanomaterial was designed for selectively eliminating mature osteoclasts (mOCs) without affecting pOCs. Biocompatible cerium nano system (CNS) was guided to the acidic extracellular microenvironment created by mOCs and gained oxidative enzymatic activity. Oxidative CNS decreased the viability of mOCs through accumulating intracellular reactive oxygen species and enhancing calcium oscillation. Non acid secreting anabolic pOCs were thus preserved and kept producing PDGF BB, which lead to mesenchymal stem cell osteogenesis and endothelial progenitor cell angiogenesis via PI3K Akt activated focal adhesion kinase. In treating osteoporotic ovariectomized mice, CNS showed better protective effects compare with the current first line antiresorptive drug due to the better anabolic effects marked by higher level of bone formation and vascularization. We provided a novel anabolic therapeutic strategy in treating bone disorders with excessive bone resorption.
C1 [Dou, Ce; Luo, Fei; Yu, Tao; Dai, Qijie; Chen, Yueqi; Xu, Jianzhong] Army Med Univ, Southwest Hosp, Dept Orthoped, Mil Med Univ 3, Chongqing 400038, Peoples R China.
   [Dou, Ce; Li, Jianmei; He, Jian; Yang, Xiaochao; Dong, Shiwu] Army Med Univ, Dept Biomed Mat Sci, Mil Med Univ 3, Chongqing 400038, Peoples R China.
   [Dong, Shiwu] Army Med Univ, State Key Lab Trauma Burns & Combined Injury, Mil Med Univ 3, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Xu, JZ (通讯作者)，Army Med Univ, Southwest Hosp, Dept Orthoped, Mil Med Univ 3, Chongqing 400038, Peoples R China.; Yang, XC; Dong, SW (通讯作者)，Army Med Univ, Dept Biomed Mat Sci, Mil Med Univ 3, Chongqing 400038, Peoples R China.; Dong, SW (通讯作者)，Army Med Univ, State Key Lab Trauma Burns & Combined Injury, Mil Med Univ 3, Chongqing 400038, Peoples R China.
EM xujianzhong1962@163.com; xcyang@tmmu.edu.cn; dongshiwu@tmmu.edu.cn
RI ; Dou, Ce/B 8841 2012; Chen, Yueqi/AAU 1724 2020; Yang,
   Xiaochao/AAM 8083 2021
OI Dou, Ce/0000 0002 6983 6354; Chen, Yueqi/0000 0001 6975 2874
FU State Key Program of National Natural Science of China [81930067];
   Nature Science Foundation of China [81802166]; AMU Southwest Hospital
   [XZ 2019 505 005]
FX This work was funded by the State Key Program of National Natural
   Science of China (No. 81930067), the Nature Science Foundation of China
   (81802166), and AMU Southwest Hospital funding for young investigators
   (XZ 2019 505 005).
CR Adler RA, 2016, J BONE MINER RES, V31, P1910, DOI 10.1002/jbmr.2918
   Asati A, 2009, ANGEW CHEM INT EDIT, V48, P2308, DOI 10.1002/anie.200805279
   Biba F, 2009, CHEM BIODIVERS, V6, P2153, DOI 10.1002/cbdv.200900011
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Colon J, 2010, NANOMED NANOTECHNOL, V6, P698, DOI 10.1016/j.nano.2010.01.010
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ding N, 2018, J CELL PHYSIOL, V233, P7415, DOI 10.1002/jcp.26587
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Dowding JM, 2013, ACS NANO, V7, P4855, DOI 10.1021/nn305872d
   Du HL, 2015, DRUG DISCOV TODAY, V20, P1004, DOI 10.1016/j.drudis.2015.03.002
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780
   Kim JK, 2010, INT J PHARMACEUT, V401, P79, DOI 10.1016/j.ijpharm.2010.08.029
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kusumbe AP, 2014, NAT MED, V20, P1238, DOI 10.1038/nm.3747
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Goff B, 2013, JOINT BONE SPINE, V80, P586, DOI 10.1016/j.jbspin.2013.04.002
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li P, 2014, ANN BIOMED ENG, V42, P1250, DOI 10.1007/s10439 014 0984 x
   Lv HW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0083 4
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Russell G, 2001, Novartis Found Symp, V232, P251
   Selvaraj V, 2015, NANOMEDICINE UK, V10, P1275, DOI 10.2217/nnm.14.205
   Shen M, 2012, J CONTROL RELEASE, V161, P884, DOI 10.1016/j.jconrel.2012.05.013
   Singh S, 2010, MOL BIOSYST, V6, P1813, DOI 10.1039/c0mb00014k
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teti Anna, 2013, Bonekey Rep, V2, P449, DOI 10.1038/bonekey.2013.183
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Xiang JY, 2016, ACS APPL MATER INTER, V8, P4489, DOI 10.1021/acsami.6b00158
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001
NR 42
TC 70
Z9 76
U1 11
U2 109
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD DEC
PY 2021
VL 6
IS 12
BP 4697
EP 4706
DI 10.1016/j.bioactmat.2021.04.038
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WJ9BS
UT WOS:000709332400034
PM 34095626
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bagne, L
   Oliveira, MA
   Pereira, AT
   Caetano, GF
   Oliveira, CA
   Aro, AA
   Chiarotto, GB
   Santos, GMT
   Mendonça, FAS
   Santamaria, M
AF Bagne, Leonardo
   Oliveira, Maraiara A.
   Pereira, Amanda T.
   Caetano, Guilherme F.
   Oliveira, Camila A.
   Aro, Andrea A.
   Chiarotto, Gabriela B.
   Santos, Glaucia M. T.
   Mendonca, Fernanda A. S.
   Santamaria Jr, Milton
TI Electrical therapies act on the Ca<SUP>2+</SUP>/CaM signaling pathway to
   enhance bone regeneration with bioactive glass [S53P4] and allogeneic
   grafts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE calcium channels; calmodulin; electrostimulation; grafting; osteogenesis
ID STIMULATION; SCAFFOLDS; FRACTURE; CELLS
AB This study aimed to investigate the application of low intensity electrostimulation (ES) and electromagnetic stimulation (EM) associated with bioactive glass (BG) or allogeneic grafts (BB) in bone regeneration. A cell viability test on osteoblasts (UMR 106) was performed in the presence of BB and BG grafts associated with ES (10 mu A/5 min) and EM (500 Hz/2 min). Critical defects (25 mm(2)) in calvaria were generated in male Wistar rats, and bone regeneration was evaluated on the 30th, 60th, and 120th days after surgery. Cell proliferation increased with the application of ES in both grafts and after EM with BG. Bone remodeling was more effective using the allogeneic graft in both therapies, with increased angiogenesis, osteoblast proliferation, and OPN expression in the BB + EM group. A higher number of osteoblasts and osteoclasts, and an increase in bone sialoprotein, Runx 2, and Opn gene expression were found in the BB + ES group. The BG graft associated with EM therapy had an increased proliferation of osteoblasts and increased expression of Runx 2 and Opn. Groups that had BG and ES therapy had increased numbers of osteoblasts, osteoclasts, and increased OPN expression. The expression of voltage gated calcium channels increased in groups with ES, while calmodulin expression increased in therapies without grafting. ES and EM therapies favored the repair of bone defects upon grafting by improving angiogenesis, osteogenic gene expression, and tissue reorganization. Despite activating different pathways, both therapies increased the intracellular concentrations of calmodulin, leading to cell proliferation and bone regeneration.
C1 [Bagne, Leonardo; Oliveira, Maraiara A.; Pereira, Amanda T.; Caetano, Guilherme F.; Oliveira, Camila A.; Aro, Andrea A.; Chiarotto, Gabriela B.; Santos, Glaucia M. T.; Mendonca, Fernanda A. S.; Santamaria Jr, Milton] Univ Ctr Herminio Ometto Fdn FHO, Grad Program Biomed Sci, Araras, SP, Brazil.
RP Caetano, GF; Santamaria, M (通讯作者)，Univ Ctr Herminio Ometto Fdn FHO, Grad Program Biomed Sci, Araras, SP, Brazil.
EM caetanogf@fho.edu.br; miltonsantamariajr@gmail.com
RI Caetano, Guilherme/V 8978 2019; Santamaria Jr, Milton/B 4843 2013;
   Bortolança Chiarotto, Gabriela/HNJ 4545 2023; Santos,
   Gláucia/AAM 7260 2021; de Aro, Andrea/E 3753 2012; de Oliveira,
   Camila/AAC 8349 2019; Bortolanca Chiarotto, Gabriela/HNJ 4545 2023
OI Aparecida de Aro, Andrea/0000 0003 2895 0000; Santamaria Jr,
   Milton/0000 0002 3490 5030; Bortolanca Chiarotto,
   Gabriela/0000 0003 4177 8735
FU Agency of the SAo Paulo Research Foundation (FAPESP) [2016/23237 4,
   2017/13361 2]; Herminio Ometto Foundation; Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [16/23237 4] Funding Source: FAPESP
FX This study was sponsored by the Agency of the SAo Paulo Research
   Foundation (FAPESP) (grant numbers 2016/23237 4 and 2017/13361 2) and
   the Herminio Ometto Foundation.
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000118698.46535.83
   Aaron RK., 1992, BONE GRAFTS BONE SUB, P192
   Abcam, ICCIF SUSPENSION CEL
   Al Malat T, 2018, Z ORTHOP UNFALLCHIR, V156, P152, DOI 10.1055/s 0043 124377
   Aleem IS, 2016, SCI REP UK, V6, DOI 10.1038/srep31724
   Balint R, 2013, TISSUE ENG PART B RE, V19, P48, DOI [10.1089/ten.teb.2012.0183, 10.1089/ten.TEB.2012.0183]
   Bayne, 2011, AM PHYSIOLOGICAL SOC
   Bloise N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199046
   Bortolazzo FO, 2020, FASEB J, V34, P10011, DOI 10.1096/fj.201902942RR
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   Caetano G, 2019, MATERIALS, V12, DOI 10.3390/ma12142268
   Cortese B, 2014, INTEGR BIOL UK, V6, P817, DOI 10.1039/c4ib00142g
   Costin GE, 2012, CURR MOL MED, V12, P14, DOI 10.2174/156652412798376143
   Das A, 2019, MAT SCI ENG C MATER, V101, P539, DOI 10.1016/j.msec.2019.03.077
   do Lago ES, 2020, CLIN ORAL INVEST, V24, P1637, DOI 10.1007/s00784 019 03018 4
   Edrees HY, 2019, MATERIALS, V12, DOI 10.3390/ma12142311
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Fiume E, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010024
   Fonseca JH, 2019, J BIOMED MATER RES B, V107, P924, DOI 10.1002/jbm.b.34187
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Ghanbari H., 2016, Adv Tech Bone Regen, P3, DOI DOI 10.5772/63912
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Grabowski P, 2015, ENDOCR DEV, V28, P33, DOI 10.1159/000380991
   Gray MG, 2016, MED HYPOTHESES, V86, P18, DOI 10.1016/j.mehy.2015.10.030
   Griffin Michelle, 2011, Eplasty, V11, pe34
   Huang Y, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109748
   Icer MA, 2018, CLIN BIOCHEM, V59, P17, DOI 10.1016/j.clinbiochem.2018.07.003
   JING D, 2016, SCI REP UK, V6
   Lee DW, 2018, INT J MED SCI, V15, P723, DOI 10.7150/ijms.22713
   Lee JM, 2013, SCI WORLD J, DOI 10.1155/2013/590708
   Leppik L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24892 0
   Li Y, 2015, J ORTHOP TRANSL, V3, P95, DOI 10.1016/j.jot.2015.05.002
   Lindfors NC, 2010, BONE, V47, P212, DOI 10.1016/j.bone.2010.05.030
   LIU T, 2017, SCI REP UK, V7
   Lorich DG, 1998, CLIN ORTHOP RELAT R, P246
   Min JK, 2003, J BIOL CHEM, V278, P39548, DOI 10.1074/jbc.M300539200
   Mobini S, 2017, PEERJ, V5, DOI 10.7717/peerj.2821
   Mobini S, 2016, BIOTECHNIQUES, V60, P95, DOI 10.2144/000114382
   Musson DS, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1089 x
   Nakagawa H, 2006, J ORTHOP SCI, V11, P135, DOI 10.1007/s00776 005 0990 9
   Obata A, 2003, J BIOMED MATER RES A, V67A, P413, DOI 10.1002/jbm.a.10069
   Pereira, 2019, INT J ORAL MAX SURG, V48, P270, DOI [10.1016/j.ijom.2019.03.827, DOI 10.1016/J.IJOM.2019.03.827]
   PEREZTANOIRA R, 2015, J MAT SCI MAT MED, V26
   Pilla Arthur A, 2002, J Orthop Sci, V7, P420, DOI 10.1007/s007760200073
   Poletti S., 2018, J PHARM PHARMACOL, V6, P633, DOI [10.17265/2328 2150/2018.07.001, DOI 10.17265/2328 2150/2018.07.001]
   Rai B, 2010, BIOMATERIALS, V31, P7960, DOI 10.1016/j.biomaterials.2010.07.001
   Rochette L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030705
   Schipani E, 2006, ANN NY ACAD SCI, V1068, P66, DOI 10.1196/annals.1346.009
   Schmidt Eva, 2011, BMC Res Notes, V4, P282, DOI 10.1186/1756 0500 4 282
   Siller AF, 2018, J BONE MINER RES, V33, P362, DOI 10.1002/jbmr.3225
   Stockert JC, 2018, ACTA HISTOCHEM, V120, P159, DOI 10.1016/j.acthis.2018.02.005
   Tandon B, 2018, ACTA BIOMATER, V73, P1, DOI 10.1016/j.actbio.2018.04.026
   Tannenbaum J, 2015, J AM ASSOC LAB ANIM, V54, P120
   Thrivikraman G, 2018, BIOMATERIALS, V150, P60, DOI 10.1016/j.biomaterials.2017.10.003
   van Gestel NAP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/684826
   Zaniboni E, 2019, CLIN ORAL INVEST, V23, P4083, DOI 10.1007/s00784 019 02845 9
   Zhang JY, 2016, ACTA BIOMATER, V32, P46, DOI 10.1016/j.actbio.2015.12.024
   Zhang X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14675
   Zhou WS, 2018, EXP THER MED, V15, P1500, DOI 10.3892/etm.2017.5534
NR 59
TC 16
Z9 16
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD DEC
PY 2021
VL 109
IS 12
BP 2104
EP 2116
DI 10.1002/jbm.b.34858
EA MAY 2021
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WA7HX
UT WOS:000651793700001
PM 34008329
DA 2025 08 17
ER

PT J
AU Baek, JM
   Kim, JY
   Cheon, YH
   Park, SH
   Ahn, SJ
   Yoon, KH
   Oh, J
   Lee, MS
AF Baek, Jong Min
   Kim, Ju Young
   Cheon, Yoon Hee
   Park, Sun Hyang
   Ahn, Sung Jun
   Yoon, Kwon Ha
   Oh, Jaemin
   Lee, Myeung Su
TI Aconitum pseudo laeve var. erectum Inhibits
   Receptor Activator of Nuclear Factor Kappa B Ligand Induced
   Osteoclastogenesis via the c Fos/nuclear Factor of Activated T Cells,
   Cytoplasmic 1 Signaling Pathway and Prevents Lipopolysaccharide Induced
   Bone Loss in Mice
SO MOLECULES
LA English
DT Article
DE Aconitum pseudo laeve var. erectum; osteoclast; bone; osteoporosis
ID BODY GIANT CELLS; RUFFLED BORDER; PROTEIN KINASE; SEALING ZONE; RANKL;
   RESORPTION; DIFFERENTIATION; EXPRESSION; FUSION; NFATC1
AB Aconitum pseudo laeve var. erectum (APE) has been widely shown in herbal medicine to have a therapeutic effect on inflammatory conditions. However, there has been no evidence on whether the extract of APE is involved in the biological bone metabolism process, particularly osteoclast mediated bone resorption. In this study, we confirmed that the administration of APE could restore normal skeletal conditions in a murine model of lipopolysaccharide (LPS) induced bone loss via a decrease in the receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio and osteoclast number. We then investigated the effect of APE on the RANKL induced formation and function of osteoclasts to elucidate its underlying molecular mechanisms. APE suppressed the formation of tartrate resistant acid phosphatase (TRAP) positive cells, as well as the bone resorbing activity of mature osteoclasts. Furthermore, APE attenuated nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) and c Fos without affecting any early signal pathway of osteoclastogenesis. Subsequently, APE significantly downregulated the expression of various genes exclusively expressed in osteoclasts. These results demonstrate that APE restores LPS induced bone loss through a decrease of the serum RANKL/OPG ratio, and inhibits osteoclast differentiation and function, suggesting the promise of APE as a potential cure for various osteoclast associated bone diseases.
C1 [Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Ahn, Sung Jun; Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Program BK21plus, Iksan 570749, Jeonbuk, South Korea.
   [Baek, Jong Min; Cheon, Yoon Hee; Park, Sun Hyang; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Dept Smart Life Care Convergence, Grad Sch, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Yoon, Kwon Ha; Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Div Rheumatol, Dept Internal Med, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
EM phone8418@hanmail.net; kimjy1014@gmail.com; hanleuni@naver.com;
   beryls@wku.ac.kr; asj0427@naver.com; khy1646@wku.ac.kr; jmoh@wku.ac.kr;
   ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Korean Health Technology R&D Project, Ministry of Health Welfare, Korea
   [HI12C0110]
FX This study was supported by a grant from the Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Korea (HI12C0110).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Christenson E S, 2012, Minerva Ginecol, V64, P181
   Cremasco V, 2012, J BONE MINER RES, V27, P2452, DOI 10.1002/jbmr.1701
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Findlay DM, 2011, OSTEOPOROSIS INT, V22, P2597, DOI 10.1007/s00198 011 1740 9
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   HAUSMANN E, 1970, SCIENCE, V168, P862, DOI 10.1126/science.168.3933.862
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Jia N, 2012, J ETHNOPHARMACOL, V144, P638, DOI 10.1016/j.jep.2012.10.004
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Luo KW, 2014, J NUTR BIOCHEM, V25, P395, DOI 10.1016/j.jnutbio.2013.11.013
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   Macián F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Nakamura I, 1999, J CELL SCI, V112, P3985
   Orcel P., 1993, AM J PHYSIOL, V264, P391
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Suda T, 2001, Novartis Found Symp, V232, P235
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Xu Rui Sheng, 2009, Zhongguo Gu Shang, V22, P920
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 40
TC 10
Z9 12
U1 0
U2 5
PU MDPI AG
PI BASEL
PA POSTFACH, CH 4005 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2014
VL 19
IS 8
BP 11628
EP 11644
DI 10.3390/molecules190811628
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AO6ZW
UT WOS:000341502600055
PM 25100255
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, N
   Zang, SL
   Liu, Y
   Wang, YQ
   Li, W
   Liu, Q
   Ji, M
   Ma, DX
   Ji, CY
AF Liu, Na
   Zang, Shaolei
   Liu, Yan
   Wang, Yingqiao
   Li, Wei
   Liu, Qiang
   Ji, Min
   Ma, Daoxin
   Ji, Chunyan
TI FZD7 regulates BMSCs mediated protection of CML cells
SO ONCOTARGET
LA English
DT Article
DE FZD7; CML; BMSCs; imatinib sensitivity; Wnt signaling pathway
ID CHRONIC MYELOID LEUKEMIA; STEM CELLS; BETA CATENIN; SIGNALING PATHWAY;
   DOWN REGULATION; IMATINIB; WNT; INHIBITION; RESISTANCE; PROLIFERATION
AB Inspite of effective treatment with imatinib (IM), chronic myeloid leukemia (CML) is still an incurable disease. Some patients became refractory because of IM resistance. Bone marrow mesenchymal stem cells (BMSCs) have been implicated a role in promoting CML cells' resistance against IM treatment. The detailed molecular mechanisms, however, remain largely unknown. In this study, we found that BMSCs increased the expression of FZD7 and activated Wnt/beta catenin signaling pathway in CML cells. BMSCs from CML patients showed increased efficiency to accelerate CML cell proliferation, enhance the drug resistance of K562 cells and up regulate the expression of FZD7. Antagonism of FZD7 expression by shRNA significantly suppressed proliferation and increased IM sensitivity of CML cells co cultured with BMSCs cells. Our findings suggest that FZD7, involved in canonical Wnt signaling pathway, plays a critical role in mediating BMSCs dependent protection of CML cells, and potentially provide a novel therapeutic target for CML.
C1 [Liu, Na; Zang, Shaolei; Liu, Yan; Wang, Yingqiao; Li, Wei; Ji, Min; Ma, Daoxin; Ji, Chunyan] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Peoples R China.
   [Liu, Qiang] Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Jinan 250014, Peoples R China.
C3 Shandong University; Shandong University; Shandong First Medical
   University & Shandong Academy of Medical Sciences
RP Ji, CY (通讯作者)，Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Peoples R China.
EM jichunyan@sdu.edu.cn
RI li, weihao/GWZ 3120 2022
OI chunyan, ji/0000 0003 4438 1768
FU Taishan Scholar Program; National Natural Science Foundation of China
   [81370662, 91442126, 81000223, 81200377, 81400118]; Natural Science
   Foundation of Shandong Province [2014ZRE27297]
FX This work was supported by grants from Taishan Scholar Program, the
   National Natural Science Foundation of China (81370662, 91442126,
   81000223, 81200377, 81400118) and Natural Science Foundation of Shandong
   Province (2014ZRE27297).
CR Baarsma HA, 2013, PHARMACOL THERAPEUT, V138, P66, DOI 10.1016/j.pharmthera.2013.01.002
   Baccarani M, 2013, BLOOD, V122, P872, DOI 10.1182/blood 2013 05 501569
   Beider K, 2014, MOL CANCER THER, V13, P1155, DOI 10.1158/1535 7163.MCT 13 0410
   Blagosklonny MV, 2005, CELL CYCLE, V4, P1693, DOI 10.4161/cc.4.12.2259
   Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040
   Chomel JC, 2011, ONCOTARGET, V2, P713
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485
   Demidenko ZN, 2005, CANCER BIOL THER, V4, P484, DOI 10.4161/cbt.4.4.1702
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306
   Frisch BJ, 2012, BLOOD, V119, P540, DOI 10.1182/blood 2011 04 348151
   Giles FJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2007.12.002
   Guo DM, 2009, LEUKEMIA LYMPHOMA, V50, P270, DOI 10.1080/10428190802553257
   Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017
   Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Kim JA, 2015, CANCER RES, V75, P2222, DOI 10.1158/0008 5472.CAN 14 3379
   Kim M, 2008, J HEPATOL, V48, P780, DOI 10.1016/j.jhep.2007.12.020
   King TD, 2012, CELL SIGNAL, V24, P846, DOI 10.1016/j.cellsig.2011.12.009
   Li X, 2015, ARCH TOXICOL, V89, P121, DOI 10.1007/s00204 014 1226 6
   Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114
   Lin HY, 2014, ONCOTARGET, V5, P8637, DOI 10.18632/oncotarget.2353
   Park J, 2015, ONCOTARGET, V6, P20697, DOI 10.18632/oncotarget.4136
   Redner RL, 2010, ONCOLOGIST, V15, P182, DOI 10.1634/theoncologist.2009 0297
   Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008 5472.CAN 06 0025
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Simmons GE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098861
   Sweet KL, 2013, CRIT REV ONCOL HEMAT, V88, P667, DOI 10.1016/j.critrevonc.2013.07.017
   Tabe Y, 2014, BRIT J HAEMATOL, V164, P767, DOI 10.1111/bjh.12725
   Ueno K, 2009, BRIT J CANCER, V101, P1374, DOI 10.1038/sj.bjc.6605307
   Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002 9440(10)65297 2
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood 2012 02 412890
   Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018
   Zhang Z, 2013, DEV BIOL, V378, P1, DOI 10.1016/j.ydbio.2013.02.024
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 38
TC 17
Z9 17
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 2
PY 2016
VL 7
IS 5
BP 6175
EP 6187
DI 10.18632/oncotarget.6742
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DD5HD
UT WOS:000369952800077
PM 26716419
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Masella, RS
   Meister, M
AF Masella, RS
   Meister, M
TI Current concepts in the biology of orthodontic tooth movement
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID GINGIVAL CREVICULAR FLUID; GENE RELATED PEPTIDE; GROWTH FACTOR;
   SCLEROSTEOSIS GENE; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION
AB Adaptive biochemical response to applied orthodontic force is a highly sophisticated process. Many layers of networked reactions occur in and around periodontal ligament and alveolar bone cells that change mechanical force into molecular events (signal transduction) and orthodontic tooth movement (OTM). Osteoblasts and osteoclasts are sensitive environment to genome to environment communicators, capable of restoring system homeostasis disturbed by orthodontic mechanics. Five micro environments are altered by orthodontic force: extracellular matrix, cell membrane, cytoskeleton, nuclear protein matrix, and genome. Gene activation (or suppression) is the point at which input becomes output, and further changes occur in all 5 environments. Hundreds of genes and thousands of proteins participate in OTM. Gene directed protein synthesis, modification, and integration form the essence of all life processes, including OTM. Bone adaptation to orthodontic force depends on normal osteoblast and osteoclast genes that correctly express needed proteins at the right times and places. Cell membrane receptor ligand docking is an important initiator of signal transduction and a discovery target for new bone enhancing drugs. Despite progress in identification of regulatory molecules, the genetic mechanism of "orchestrated synthesis" between different cells, tissues, and systems remains largely unknown. Interpatient variation in mechanobiological response is most likely due to differences in periodontal ligament and bone cell populations, genomes, and protein expression patterns. Discovery of mutations in OTM associated genes of orthodontic patients, including those regulating osteoclast bone matrix acidification, chloride channel function, and osteoblast derived mineral and protein matrices, will permit gene therapy to restore normal matrix and protein synthesis and function. Achieving selectivity in targeting abnormal genes, cells, and tissues is a major obstacle to safe and effective clinical application of gene engineering and stem cell mediated tissue growth. Orthodontic treatment is likely to evolve into a combination of mechanics and molecular genetic cellular interventions: a change from shotgun to tightly focused communication with OTM cells.
C1 Nova SE Univ, Dept Orthodont, Coll Dent Med, Ft Lauderdale, FL 33328 USA.
C3 Nova Southeastern University
RP Nova SE Univ, Dept Orthodont, Coll Dent Med, 3200 S Univ Dr, Ft Lauderdale, FL 33328 USA.
EM rmasella@nsu.nova.edu
CR AKER R, 2001, PDQ BIOCH
   Alhashimi N, 2001, AM J ORTHOD DENTOFAC, V119, P307, DOI 10.1067/mod.2001.110809
   Anderson LE, 2004, J NEUROCHEM, V91, P1417, DOI 10.1111/j.1471 4159.2004.02833.x
   [Anonymous], [No title captured]
   Bettencourt Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160
   Bowers PM, 2004, SCIENCE, V306, P2246, DOI 10.1126/science.1103330
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04 09 0845
   Bu RF, 2003, BONE, V33, P760, DOI 10.1016/j.bone.2003.07.006
   Buffelli M, 2001, NEUROSCIENCE, V104, P561, DOI 10.1016/S0306 4522(01)00090 2
   Carvalho RS, 1997, THESIS HARVARD SCH D
   DAVIDOVITCH Z, 1988, DENT CLIN N AM, V32, P411
   DAVIDOVITCH Z, 2005, COMMUNICATION   0302
   Derringer KA, 2004, ARCH ORAL BIOL, V49, P631, DOI 10.1016/j.archoralbio.2004.02.011
   DUAN U, 1993, J OSAKA U DENT SOC, V33, P45
   Edvinsson L, 1997, NEUROSCI LETT, V229, P209, DOI 10.1016/S0304 3940(97)00456 4
   Eungdamrong NJ, 2004, TRENDS CELL BIOL, V14, P661, DOI 10.1016/j.tcb.2004.10.007
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   GORLIN RJ, 1990, SYNDROMES HEAD NECK
   GRIEVE WG, 1994, AM J ORTHOD DENTOFAC, V105, P369, DOI 10.1016/S0889 5406(94)70131 8
   HALL M, 2001, TODAYS FDA       FEB, P24
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Helms JA, 2003, NATURE, V423, P326, DOI 10.1038/nature01656
   Ho NC, 2000, J BONE MINER RES, V15, P2095, DOI 10.1359/jbmr.2000.15.11.2095
   Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635
   Jasny BR, 2004, SCIENCE, V306, P629, DOI 10.1126/science.306.5696.629
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   KILBERSTIS P, 2000, SCIENCE, V289, P1497
   KING GJ, 1991, BONE, V12, P401, DOI 10.1016/8756 3282(91)90029 I
   Kyrkanides S, 2000, AM J ORTHOD DENTOFAC, V118, P203, DOI 10.1067/mod.2000.105872
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Liebler D.C., 2002, INTRO PROTEOMICS
   LOWNEY JJ, 1995, AM J ORTHOD DENTOFAC, V108, P519, DOI 10.1016/S0889 5406(95)70052 8
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304
   Miyazaki M., 2000, J. Discrete Algorithms, V1, P187
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140 6736(00)04904 7
   Pennisi E, 2004, SCIENCE, V306, P632, DOI 10.1126/science.306.5696.632
   Proffit WR., 2000, CONT ORTHODONTICS, V3
   Reitan K., 1985, CURRENT ORTHODONTIC, V3rd
   Roberts W.E., 2004, SEMIN ORTHOD, V10, P100, DOI DOI 10.1053/J.SODO.2004.01.001
   Roberts W.E., 2004, SEMIN ORTHOD, V10, P123, DOI [DOI 10.1053/J.SODO.2004.01.003, DOI 10.1053/SODO.2000.8083]
   Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748
   Serra E, 2003, AM J ORTHOD DENTOFAC, V124, P206, DOI 10.1016/S0889 5406(03)00407 4
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   SHROT F, 2002, TODAYS FDA       FEB, P23
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Vandevska Radunovic V, 1998, ACTA ODONTOL SCAND, V56, P57, DOI 10.1080/000163598423072
   Vandevska Radunovic V, 1999, EUR J ORTHODONT, V21, P231, DOI 10.1093/ejo/21.3.231
   WATSON JD, 1983, RECOMBINANT DNA SHOR
   WILLIAMS J, 2001, GENETIC ENG
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225
   Zhu AJ, 2004, GENE DEV, V18, P2985, DOI 10.1101/gad.1233104
NR 60
TC 200
Z9 249
U1 2
U2 35
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0889 5406
EI 1097 6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD APR
PY 2006
VL 129
IS 4
BP 458
EP 468
DI 10.1016/j.ajodo.2005.12.013
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 035WL
UT WOS:000237032300009
PM 16627170
DA 2025 08 17
ER

PT J
AU Tu, XL
   Chen, JQ
   Lim, J
   Karner, CM
   Lee, SY
   Heisig, J
   Wiese, C
   Surendran, K
   Kopan, R
   Gessler, M
   Long, FX
AF Tu, Xiaolin
   Chen, Jianquan
   Lim, Joohyun
   Karner, Courtney M.
   Lee, Seung Yon
   Heisig, Julia
   Wiese, Cornelia
   Surendran, Kameswaran
   Kopan, Raphael
   Gessler, Manfred
   Long, Fanxin
TI Physiological Notch Signaling Maintains Bone Homeostasis via RBPjk and
   Hey Upstream of NFATc1
SO PLOS GENETICS
LA English
DT Article
ID AXIAL SKELETAL DEFECTS; ALAGILLE SYNDROME; HUMAN JAGGED1; T CELLS;
   MUTATIONS; DIFFERENTIATION; EXPRESSION; DISORDER; LIMB; GENE
AB Notch signaling between neighboring cells controls many cell fate decisions in metazoans both during embryogenesis and in postnatal life. Previously, we uncovered a critical role for physiological Notch signaling in suppressing osteoblast differentiation in vivo. However, the contribution of individual Notch receptors and the downstream signaling mechanism have not been elucidated. Here we report that removal of Notch2, but not Notch1, from the embryonic limb mesenchyme markedly increased trabecular bone mass in adolescent mice. Deletion of the transcription factor RBPjk, a mediator of all canonical Notch signaling, in the mesenchymal progenitors but not the more mature osteoblast lineage cells, caused a dramatic high bone mass phenotype characterized by increased osteoblast numbers, diminished bone marrow mesenchymal progenitor pool, and rapid age dependent bone loss. Moreover, mice deficient in Hey1 and HeyL, two target genes of Notch RBPjk signaling, exhibited high bone mass. Interestingly, Hey1 bound to and suppressed the NFATc1 promoter, and RBPjk deletion increased NFATc1 expression in bone. Finally, pharmacological inhibition of NFAT alleviated the high bone mass phenotype caused by RBPjk deletion. Thus, Notch RBPjk signaling functions in part through Hey1 mediated inhibition of NFATc1 to suppress osteoblastogenesis, contributing to bone homeostasis in vivo.
C1 [Tu, Xiaolin; Chen, Jianquan; Lim, Joohyun; Karner, Courtney M.; Lee, Seung Yon; Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Heisig, Julia; Wiese, Cornelia; Gessler, Manfred] Univ Wurzburg, Bioctr, Wurzburg, Germany.
   [Surendran, Kameswaran; Kopan, Raphael; Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA.
C3 Washington University (WUSTL); University of Wurzburg; Washington
   University (WUSTL)
RP Tu, XL (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA.
EM flong@wustl.edu
RI ; Kopan, Raphael/AFG 3275 2022; Surendran, Kameswaran/V 8098 2019; Lim,
   Joohyun/HIR 7445 2022; chen, Jianquan/E 3325 2013; Tu,
   Xiaolin/JAC 9492 2023
OI Lim, Joohyun/0000 0001 9670 806X; Tu, Xiaolin/0000 0002 7923 2722;
   Surendran, Kameswaran/0000 0001 5693 4409; Gessler,
   Manfred/0000 0002 7915 6045; Kopan, Raphael/0000 0002 0350 2730; Heisig,
   Julia/0000 0002 6167 1049; Karner, Courtney/0000 0003 0387 4486
FU NIH [AR055923]; DFG [Ge539/11, SFB688/A16]; Washington University Center
   for Musculoskeletal Research [P30AR057235]
FX This work was supported by NIH grant AR055923 (FL) and DFG grants
   Ge539/11 and SFB688/A16 (MG). The bone histomorphometry studies were
   supported by the Washington University Center for Musculoskeletal
   Research (P30AR057235). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959 437X(02)00336 2
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307
   Cheng HT, 2007, DEVELOPMENT, V134, P801, DOI 10.1242/dev.02773
   Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005 0661
   Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074 7613(02)00329 1
   D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070 2153(10)92003 6
   Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016
   Dong YF, 2010, DEVELOPMENT, V137, P1461, DOI 10.1242/dev.042911
   Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Fischer A, 2007, CIRC RES, V100, P856, DOI 10.1161/01.RES.0000260913.95642.3b
   Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940
   Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959 437X(00)00225 2
   Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365 2443.1996.10010.x
   Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797 243
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181
   McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090
   Mohamed SA, 2006, BIOCHEM BIOPH RES CO, V345, P1460, DOI 10.1016/j.bbrc.2006.05.046
   Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797 235
   Pan YH, 2005, DEV BIOL, V286, P472, DOI 10.1016/j.ydbio.2005.08.037
   Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014
   Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427
   Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Salie R, 2010, BONE, V46, P680, DOI 10.1016/j.bone.2009.10.022
   Sanders PGT, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000169
   Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756
   Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092 8674(00)80244 5
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Surendran K, 2010, DEV BIOL, V337, P386, DOI 10.1016/j.ydbio.2009.11.017
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tao JN, 2010, J BONE MINER RES, V25, P2175, DOI 10.1002/jbmr.115
   Vihma H, 2008, GENOMICS, V92, P279, DOI 10.1016/j.ygeno.2008.06.011
   Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0
   Zanotti S., 2010, J Biol Chem
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625
NR 55
TC 79
Z9 100
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553 7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2012
VL 8
IS 3
AR e1002577
DI 10.1371/journal.pgen.1002577
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 918MV
UT WOS:000302254800052
PM 22457635
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Han, SY
   Kim, YK
AF Han, Sang Yong
   Kim, Yun Kyung
TI Yukmijihwang Tang Suppresses Receptor Activator of Nuclear Factor
   Kappa B Ligand (RANKL) Induced Osteoclast Differentiation and Prevents
   Ovariectomy (OVX) Mediated Bone Loss
SO MOLECULES
LA English
DT Article
DE Yukmijihwang tang; osteoclast differentiation; RANKL; NFATc1; OVX; bone
   loss
ID HERBAL FORMULATION; RESORPTION; RANKL; OSTEOPROTEGERIN; MANAGEMENT;
   INDUCTION; TRANCE
AB Yukmijihwang tang (YJ) has been used to treat diabetes mellitus, renal disorders, and cognitive impairment in traditional medicine. This study aimed to evaluate the anti osteoporotic effect of YJ on ovariectomy (OVX) induced bone loss in a rat and receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast differentiation in bone marrow macrophages (BMMs). YJ reduced the formation of tartrate resistant acid phosphatase (TRAP) positive multinucleated cells (MNCs) in an osteoclast/osteoblast co culture system by regulating the ratio of RANKL/osteoprotegerin (OPG) by osteoblasts. Overall, YJ reduced TRAP positive cell formation and TRAP activity and F actin ring formation. Analysis of the underlying mechanisms indicated that YJ inhibited the activation of the nuclear factor of activated T cell cytoplasmic 1 (NFATc1) and c Fos, resulting in the suppression of osteoclast differentiation related genes such as TRAP, ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2, osteoclast associated receptor, osteoclast stimulatory transmembrane protein, dendritic cell specific transmembrane protein, matrix metalloproteinase 9, cathepsin K, and calcitonin receptor. YJ also inhibited the nuclear translocation of NFATc1. Additionally, YJ markedly inhibited RANKL induced phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation including the p38, JNK, ERK, and NF kappa B. Consistent with these in vitro results, the YJ administered group showed considerably attenuated bone loss in the OVX mediated rat model. These results provide promising evidence for the potential novel therapeutic application of YJ for bone diseases such as osteoporosis.
C1 [Han, Sang Yong; Kim, Yun Kyung] Wonkwang Univ, Coll Pharm, Dept Herbal Med, 460 Iksandae Ro, Iksan 54538, South Korea.
   [Han, Sang Yong; Kim, Yun Kyung] Wonkwang Univ, Wonkwang Oriental Med Res Inst, 460 Iksandae Ro, Iksan 54538, South Korea.
C3 Wonkwang University; Wonkwang University
RP Kim, YK (通讯作者)，Wonkwang Univ, Coll Pharm, Dept Herbal Med, 460 Iksandae Ro, Iksan 54538, South Korea.; Kim, YK (通讯作者)，Wonkwang Univ, Wonkwang Oriental Med Res Inst, 460 Iksandae Ro, Iksan 54538, South Korea.
EM 030745@daum.net; hestia@wku.ac.kr
OI Kim, Yun kyung/0000 0001 6169 0402
FU National Research Foundation (NRF) of Korea [NRF 2019R1C1C1002761]
FX FundingThis research was funded by National Research Foundation (NRF) of
   Korea (grant number: NRF 2019R1C1C1002761).
CR Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Cho SM, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1651 1
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fierro FA, 2017, STEM CELLS, V35, P1461, DOI 10.1002/stem.2625
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Ha H, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/672136
   Hannan MT, 2000, J BONE MINER RES, V15, P710, DOI 10.1359/jbmr.2000.15.4.710
   Huang Y, 2012, J ETHNOPHARMACOL, V140, P384, DOI 10.1016/j.jep.2012.01.030
   Huang YH, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/827915
   Jin UH, 2006, J ETHNOPHARMACOL, V106, P333, DOI 10.1016/j.jep.2006.01.012
   Kang DG, 2006, J ETHNOPHARMACOL, V104, P47, DOI 10.1016/j.jep.2005.08.044
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   OKADA Y, 1995, LAB INVEST, V72, P311
   Perry B, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/847167
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Shim KS, 2011, J MED FOOD, V14, P1439, DOI 10.1089/jmf.2010.1502
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Song Xiao Yan, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P1087
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Szeto YT, 2009, INT J FOOD SCI NUTR, V60, P662, DOI 10.3109/09637480802012209
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan XL, 2014, NAT PROD COMMUN, V9, P529
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Wang Y., 2018, ONCOTARGET, V9, p7372 7388, DOI DOI 10.18632/ONCOTARGET.23677
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
NR 36
TC 4
Z9 5
U1 0
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2021
VL 26
IS 24
AR 7579
DI 10.3390/molecules26247579
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XX7AC
UT WOS:000736442500001
PM 34946658
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xing, LP
   Ebetino, FH
   Boeckman, RK
   Srinivasan, V
   Tao, JG
   Sawyer, TK
   Li, JB
   Yao, ZQ
   Boyce, BF
AF Xing, Lianping
   Ebetino, Frank H.
   Boeckman, Robert K.
   Srinivasan, Venkat
   Tao, Jianguo
   Sawyer, Tomi K.
   Li, Jinbo
   Yao, Zhenqiang
   Boyce, Brendan F.
TI Targeting anti cancer agents to bone using bisphosphonates
SO BONE
LA English
DT Article
DE Bone metastasis; Bone targeting; Bisphosphonate; Bortezomib; Drug
   conjugate; Chloroquine
ID US MEDICARE BENEFICIARIES; POPULATION BASED ANALYSIS; SKELETAL RELATED
   EVENTS; SRC TYROSINE KINASE; PROTEASOME INHIBITORS; MULTIPLE MYELOMA;
   IN VITRO; BIOLOGICAL EVALUATION; DESIGN; METASTASIS
AB The skeleton is affected by numerous primary and metastatic solid and hematopoietic malignant tumors, which can cause localized sites of osteolysis or osteosclerosis that can weaken bones and increase the risk of fractures in affected patients. Chemotherapeutic drugs can eliminate some tumors in bones or reduce their volume and skeletal related events, but adverse effects on non target organs can significantly limit the amount of drug that can be administered to patients. In these circumstances, it may be impossible to deliver therapeutic drug concentrations to tumor sites in bones. One attractive mechanism to approach this challenge is to conjugate drugs to bisphosphonates, which can target them to bone where they can be released at diseased sites. Multiple attempts have been made to do this since the 1990s with limited degrees of success. Here, we review the results of preclinical and clinical studies made to target FDA approved drugs and other antineoplastic small molecules to bone to treat diseases affecting the skeleton, including osteoporosis, metastatic bone disease, multiple myeloma and osteosarcoma. Results to date are encouraging and indicate that drug efficacy can be increased and side effects reduced using these approaches. Despite these successes, challenges remain: no drugs have gone beyond small phase 2 clinical trials, and major pharmaceutical companies have shown little interest in the approach to repurpose any of their drugs or to embrace the technology. Nevertheless, interest shown by smaller biotechnology companies in the technology suggests that bone targeting of drugs with bisphosphonates has a viable future.
C1 [Xing, Lianping; Tao, Jianguo; Li, Jinbo; Yao, Zhenqiang; Boyce, Brendan F.] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA.
   [Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14642 USA.
   [Ebetino, Frank H.; Boeckman, Robert K.; Srinivasan, Venkat] Univ Rochester, Dept Chem, Rochester, NY 14627 USA.
   [Ebetino, Frank H.] BioVinc, Pasadena, CA 91107 USA.
   [Sawyer, Tomi K.] Maestro Therapeut, Southborough, MA 01772 USA.
   [Tao, Jianguo] Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China.
C3 University of Rochester; University of Rochester; University of
   Rochester; Westlake University
RP Boyce, BF (通讯作者)，Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM Brendan_Boyce@urmc.rochester.edu
OI Yao, Zhenqiang/0000 0002 4664 3648; Tao, Jianguo/0000 0002 3473 9212
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [R01AR43510, R21AR070984, R01AR063650,
   R21AR069789]; National Institute on Aging [R01AG049994, R01AG059775];
   National Institutes of Health (NIH), National Institute of Dental and
   Craniofacial Research (NIDCR) [R42 DE025789 02]; NIH National Institute
   of Allergy and Infectious Diseases (NIAID) [2R44 AI125060 02]; NIH
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) [R43AR073727]; UR Ventures Technology Development Fund
FX This work was supported by the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
   under Award Number R01AR43510 (to BFB), R21AR070984 (to BFB and RKB),
   R01AR063650 (to LX), R21AR069789 (to LX and RKB) and UR
   Ventures Technology Development Fund (to BFB and RKB), and by the
   National Institute on Aging under award number R01AG049994 (to BFB and
   ZY) and R01AG059775 (to LX). FHE is supported by grant R42 DE025789 02
   from the National Institutes of Health (NIH), National Institute of
   Dental and Craniofacial Research (NIDCR), grant 2R44 AI125060 02 from
   the NIH National Institute of Allergy and Infectious Diseases (NIAID)
   and grant R43AR073727 from the NIH National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS). Tomi K. Sawyer, William C.
   Shakespeare and David Dalgarno worked at Ariad Pharmaceuticals where
   they directed Src kinase inhibitor discovery. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Adler RA, 2016, ENDOCRINE, V51, P222, DOI 10.1007/s12020 015 0748 x
   Agyin JK, 2013, BIOORG MED CHEM LETT, V23, P6455, DOI 10.1016/j.bmcl.2013.09.043
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Aronson LI, 2012, HAEMATOL HEMATOL J, V97, P1119, DOI 10.3324/haematol.2012.064923
   Bodó E, 2007, AM J PATHOL, V171, P1153, DOI 10.2353/ajpath.2007.061164
   Bonvini P, 2007, LEUKEMIA, V21, P838, DOI 10.1038/sj.leu.2404528
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyce BF, 2006, CLIN CANCER RES, V12, p6291S, DOI 10.1158/1078 0432.CCR 06 0991
   Cetin K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2015 007702
   Chin Hong, 2015, Fed Pract, V32, P24
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9
   David E, 2019, BIOCONJUGATE CHEM, V30, P1665, DOI 10.1021/acs.bioconjchem.9b00210
   Dou QP, 2014, CURR CANCER DRUG TAR, V14, P517, DOI 10.2174/1568009614666140804154511
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ebrahimpour Arman, 1995, P125
   Escalante J, 2017, MATURITAS, V105, P23, DOI 10.1016/j.maturitas.2017.04.021
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Feng SS, 2019, ACS APPL MATER INTER, V11, P7357, DOI 10.1021/acsami.8b18820
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Hernandez RK, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3922 0
   Hideshima T, 2011, MOL CANCER THER, V10, P2034, DOI 10.1158/1535 7163.MCT 11 0433
   Holmberg AR, 2010, INT J ONCOL, V37, P563, DOI 10.3892/ijo_00000705
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ioachimescu Adriana, 2007, Curr Osteoporos Rep, V5, P165
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Linabery AM, 2008, CANCER AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Marino S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031286
   McBride A, 2015, AM J HEALTH SYST PH, V72, P353, DOI 10.2146/ajhp130281
   Meyers Christina A, 2008, J Biol, V7, P11, DOI 10.1186/jbiol73
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mohty B, 2010, HAEMATOL HEMATOL J, V95, P311, DOI 10.3324/haematol.2009.012674
   Montanari F, 2014, BLOOD, V124
   Moreno F, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26533
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nadar RA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62039 2
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood 2005 08 3531
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Palumbo A, 2011, BLOOD, V118, P4519, DOI 10.1182/blood 2011 06 358812
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pozzi S, 2013, BRIT J HAEMATOL, V163, P40, DOI 10.1111/bjh.12465
   Puljula E, 2015, ACS MED CHEM LETT, V6, P397, DOI 10.1021/ml5004603
   Robak P, 2019, DRUGS R&D, V19, P73, DOI 10.1007/s40268 019 0269 9
   Rodriguez Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008 5472.CAN 07 5989
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Sasikumar A, 2017, CLIN NUCL MED, V42, P446, DOI 10.1097/RLU.0000000000001646
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Sathiakumar N, 2012, BREAST CANCER RES TR, V131, P231, DOI 10.1007/s10549 011 1721 x
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Sfeir JG, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115394
   Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729
   Shakespeare WC, 2008, CHEM BIOL DRUG DES, V71, P97, DOI 10.1111/j.1747 0285.2007.00615.x
   Sheikh Z, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10237
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   SUNBERG RJ, 1991, CHEMTECH, V21, P304
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tanaka KSE, 2010, BIOORG MED CHEM LETT, V20, P1355, DOI 10.1016/j.bmcl.2010.01.006
   Teras LR, 2016, CA CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357
   Thellenberg Karlsson C, 2016, ANTICANCER RES, V36, P6499, DOI 10.21873/anticanres.11249
   Thorsteinsdottir S, 2020, HAEMATOLOGICA, V105, P1067, DOI 10.3324/haematol.2019.230011
   Uy GL, 2007, CLIN LYMPHOMA MYELOM, V7, P587, DOI 10.3816/CLM.2007.n.045
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   von Eisenhart Rothe R, 2011, ORTHOPADE, V40, P1121, DOI 10.1007/s00132 011 1866 7
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yao Z., 2016, J BONE MINER RES, V31, pS225
   Young RN, 2018, CURR OPIN PHARMACOL, V40, P87, DOI 10.1016/j.coph.2018.03.010
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
   Zinnen S, 2011, BONE, V48, pS51, DOI 10.1016/j.bone.2010.10.145
   Zinnen SP, 2019, ONCOLOGIST, V24, P303, DOI 10.1634/theoncologist.2018 0707
NR 86
TC 40
Z9 42
U1 1
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2020
VL 138
AR 115492
DI 10.1016/j.bone.2020.115492
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MX7BQ
UT WOS:000557876000027
PM 32585321
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Trivedi, T
   Guise, TA
AF Trivedi, Trupti
   Guise, Theresa A.
TI Systemic effects of abnormal bone resorption on muscle, metabolism, and
   cognition
SO BONE
LA English
DT Article
DE Bone metastasis; Bone remodeling; TGF beta; Bone microenvironment;
   Bisphosphonate; Muscle weakness; Cognitive impairment; Glucose
   metabolism
ID ANDROGEN DEPRIVATION THERAPY; BREAST CANCER PATIENTS;
   GROWTH FACTOR BETA; PROSTATE CANCER; TGF BETA; ZOLEDRONIC ACID; MINERAL
   DENSITY; FRACTURE RISK; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN
AB Skeletal tissue is dynamic, undergoing constant remodeling to maintain musculoskeletal integrity and balance in the human body. Recent evidence shows that apart from maintaining homeostasis in the local microenvironment, the skeleton systemically affects other tissues. Several cancer associated and noncancer associated bone disorders can disrupt the physiological homeostasis locally in the bone microenvironment and indirectly contribute to dysregulation of systemic body function. The systemic effects of bone on the regulation of distant organ function have not been widely explored. Recent evidence suggests that bone can interact with skeletal muscle, pancreas, and brain by releasing factors from mineralized bone matrix. Currently available bone targeting therapies such as bisphosphonates and denosumab inhibit bone resorption, decrease morbidity associated with bone destruction, and improve survival. Bisphosphonates have been a standard treatment for bone metastases, osteoporosis, and cancer treatment induced bone diseases. The extraskeletal effects of bisphosphonates on inhibition of tumor growth are known. However, our knowledge of the effects of bisphosphonates on muscle weakness, hyperglycemia, and cognitive defects is currently evolving. To be able to identify the molecular link between bone and distant organs during abnormal bone resorption and then treat these abnormalities and prevent their systemic effects could improve survival benefits. The current review highlights the link between bone resorption and its systemic effects on muscle, pancreas, and brain.
C1 [Trivedi, Trupti; Guise, Theresa A.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd,Unit 1063, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Guise, TA (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd,Unit 1063, Houston, TX 77030 USA.
EM taguise@mdanderson.org
FU University of Texas MD Anderson Cancer Center's Department of Endocrine
   Neoplasia and Hormonal Disorders; Rolanette and Berdon Bone Disease
   Research Program of Texas; Cancer Prevention Research Institute of Texas
   (CPRIT); CPRIT Scholar in Cancer Research; CPRIT [RR190108]; NIH
   [R01CA206025]; Department of Defense [BC171929]
FX The authors are grateful for support from The University of Texas MD
   Anderson Cancer Center's Department of Endocrine Neoplasia and Hormonal
   Disorders, The Rolanette and Berdon Bone Disease Research Program of
   Texas, the Cancer Prevention Research Institute of Texas (CPRIT), and
   Dive into The Pink. Dr. Guise, a CPRIT Scholar in Cancer Research, and
   Dr. Trivedi were supported by grants from CPRIT (RR190108), the NIH
   (R01CA206025), the Department of Defense (BC171929), The Rolanette and
   Berdon Bone Disease Research Program of Texas, and Dive into The Pink.
CR Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485
   Alonso Quinones H., 2020, ALZHEIMER DIS ASS DI, V35, P44
   Appelman Dijkstra NM, 2018, BEST PRACT RES CL EN, V32, P657, DOI 10.1016/j.beem.2018.05.005
   Baker NL, 2011, AGE AGEING, V40, P49, DOI 10.1093/ageing/afq146
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Ballinger TJ, 2018, BREAST CANCER RES TR, V172, P445, DOI 10.1007/s10549 018 4924 6
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Barber SE, 2012, AGE AGEING, V41, P5, DOI 10.1093/ageing/afr138
   Bargiota A, 2020, J BUON, V25, P1286
   Barreto R, 2016, ONCOTARGET, V7, P43442, DOI 10.18632/oncotarget.9779
   Batalo M, 2011, EXPERT REV ANTICANC, V11, P1277, DOI [10.1586/era.11.112, 10.1586/ERA.11.112]
   Benedetti MG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4840531
   Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718
   Biswas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027090
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Bonnet N, 2017, CALCIFIED TISSUE INT, V100, P174, DOI 10.1007/s00223 016 0210 y
   Bono CM, 2003, EUR SPINE J, V12, pS90, DOI 10.1007/s00586 003 0603 2
   Brotto M, 2015, BONE, V80, P109, DOI 10.1016/j.bone.2015.02.010
   Brown SA, 2009, CRIT REV EUKAR GENE, V19, P47, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.20
   Brufsky A, 2020, BREAST J, V26, P65, DOI 10.1111/tbj.13730
   Cameron DA, 2010, BREAST CANCER RES TR, V123, P805, DOI 10.1007/s10549 010 0899 7
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Cederholm T, 2013, EUR J PHYS REHAB MED, V49, P111
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Chamouni A, 2015, REV ENDOCR METAB DIS, V16, P99, DOI 10.1007/s11154 015 9312 5
   Chen JL, 2014, FASEB J, V28, P1711, DOI 10.1096/fj.13 245894
   Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6
   Cheung AS, 2014, ENDOCR RELAT CANCER, V21, pR371, DOI 10.1530/ERC 14 0172
   Citraro R, 2015, PHARMACOL BIOCHEM BE, V129, P65, DOI 10.1016/j.pbb.2014.12.006
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   COHN DV, 1962, J BIOL CHEM, V237, P615
   Coleman R, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115570
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Crowgey T, 2014, APPL PHYSIOL NUTR ME, V39, P724, DOI 10.1139/apnm 2013 0380
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Dell'Aquila E, 2020, EXPERT OPIN BIOL TH, V20, P1261, DOI 10.1080/14712598.2020.1814731
   Dennison EM, 2012, BONE, V50, P1288, DOI 10.1016/j.bone.2012.02.639
   Dietrich J, 2008, ONCOLOGIST, V13, P1285, DOI 10.1634/theoncologist.2008 0130
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Edwards BJ, 2011, CLIN CANCER RES, V17, P560, DOI 10.1158/1078 0432.CCR 10 1595
   Elabbady A, 2016, PROSTATE INT, V4, P156, DOI 10.1016/j.prnil.2016.07.005
   Elangovan S, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/aba446
   Ellman R, 2013, J BONE MINER RES, V28, P875, DOI 10.1002/jbmr.1814
   Essex AL, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00809
   Feng S.H., 2020, J CLIN ENDOCR METAB, V106, P763
   Fernandes RM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00667
   Ferrucci L, 2014, CURR PHARM DESIGN, V20, P3178, DOI 10.2174/13816128113196660690
   Fodor D, 2013, J INVEST MED, V61, P15, DOI 10.2310/JIM.0b013e3182761264
   Fox M, 2013, PSYCHONEUROENDOCRINO, V38, P2973, DOI 10.1016/j.psyneuen.2013.08.005
   Frantellizzi V., 2020, MINERVA UROL NEFROL, DOI [10.23736/S0393 2249.20.03808 4, DOI 10.23736/S0393 2249.20.03808 4]
   Gaillard S, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2818
   Galson Deborah L, 2014, J Bone Metab, V21, P85, DOI 10.11005/jbm.2014.21.2.85
   Galvao DA, 2009, PROSTATE CANCER P D, V12, P198, DOI 10.1038/pcan.2008.51
   Gancheva S, 2020, CALCIFIED TISSUE INT, V107, P41, DOI 10.1007/s00223 020 00684 5
   Gerbaix M, 2015, BONE, V71, P94, DOI 10.1016/j.bone.2014.10.011
   Gilliam LAA, 2011, ANTIOXID REDOX SIGN, V15, P2543, DOI 10.1089/ars.2011.3965
   Glerup H, 2000, CALCIFIED TISSUE INT, V66, P419, DOI 10.1007/s002230010085
   Gokosmanoglu F, 2016, J RES MED SCI, V21, DOI 10.4103/1735 1995.193503
   Golds G, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/4602129
   Goodpaster BH, 2006, J GERONTOL A BIOL, V61, P1059, DOI 10.1093/gerona/61.10.1059
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Grossmann M, 2019, MED J AUSTRALIA, V211, P224, DOI 10.5694/mja2.50280
   GRYFE CI, 1973, CAN MED ASSOC J, V109, P479
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Guise Theresa A, 2005, Clin Breast Cancer, V5 Suppl, pS46, DOI 10.3816/CBC.2005.s.004
   Guise TA, 2013, CELL, V154, P957, DOI 10.1016/j.cell.2013.08.020
   Guise TA, 2010, CURR MED RES OPIN, V26, P6
   Guntur AR, 2012, ENDOCR PRACT, V18, P758, DOI 10.4158/EP12141.RA
   Guo XZ, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00343
   GUSTAFSSON B, 1986, ACTA PHYSIOL SCAND, V126, P475, DOI 10.1111/j.1748 1716.1986.tb07843.x
   Hadji P, 2017, J BONE ONCOL, V7, P1, DOI 10.1016/j.jbo.2017.03.001
   Hain BA, 2020, J BONE MINER RES, V35, P368, DOI 10.1002/jbmr.3890
   Hamood R, 2018, J CLIN ONCOL, V36, P2061, DOI 10.1200/JCO.2017.76.3524
   Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296
   Hausmann S, 2016, AM J PATHOL, V186, P24, DOI 10.1016/j.ajpath.2015.09.022
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hesse E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125543
   Holtfrerich SKC, 2020, PSYCHO ONCOLOGY, V29, P1338, DOI 10.1002/pon.5442
   Huang WS, 2018, STRESS HEALTH, V34, P440, DOI 10.1002/smi.2806
   Ilovayskaya I, 2020, CLIMACTERIC, V23, P597, DOI 10.1080/13697137.2020.1767567
   Imerb N, 2020, MECH AGEING DEV, V191, DOI 10.1016/j.mad.2020.111335
   Jenkins V, 2004, PSYCHO ONCOLOGY, V13, P61, DOI 10.1002/pon.709
   Jeon HL, 2020, J BONE MINER METAB, V38, P254, DOI 10.1007/s00774 019 01052 6
   Juárez P, 2012, CANCER RES, V72, P6247, DOI 10.1158/0008 5472.CAN 12 1444
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kang HG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012755
   Khrimian L, 2017, MOL METAB, V6, P1610, DOI 10.1016/j.molmet.2017.10.001
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kim HN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68890 7
   Kim TJ, 2020, CANCERS, V12, DOI 10.3390/cancers12061529
   Kindblom JM, 2009, J BONE MINER RES, V24, P785, DOI 10.1359/JBMR.081234
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Klein GL, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115194
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Lacombe J, 2013, MOL METAB, V2, P498, DOI 10.1016/j.molmet.2013.08.004
   Lange M, 2019, CANCER MED US, V8, P2654, DOI 10.1002/cam4.2069
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee NJ, 2015, MOL METAB, V4, P164, DOI 10.1016/j.molmet.2014.12.010
   Lewin S, 2020, BIOCHEM SOC T, V48, P2335, DOI 10.1042/BST20200717
   Lin XZ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070847
   Lintermans A, 2014, BREAST CANCER RES TR, V146, P109, DOI 10.1007/s10549 014 2986 7
   Liu Y., AGING ALBANY NY, V13, P19835
   Liu YH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 023918
   Lobo Martins S, 2020, CANCERS, V12, DOI 10.3390/cancers12082034
   LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480
   LOU HC, 1985, EUR J PEDIATR, V144, P17, DOI 10.1007/BF00491918
   Lu GP, 2017, BIOMED PHARMACOTHER, V95, P1033, DOI 10.1016/j.biopha.2017.09.018
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Lui LY, 2003, J AM GERIATR SOC, V51, P38, DOI 10.1034/j.1601 5215.2002.51007.x
   Luo Y, 2017, CLIN SCI, V131, P239, DOI 10.1042/CS20160543
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mendias CL, 2012, MUSCLE NERVE, V45, P55, DOI 10.1002/mus.22232
   Mohammad KS, 2009, ANTI CANCER AGENT ME, V9, P1079, DOI 10.2174/187152009789735008
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Moller AMJ, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0102 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morris MJ, 2019, NAT REV UROL, V16, P745, DOI 10.1038/s41585 019 0251 x
   Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749
   Mosialou I, 2017, NATURE, V543, P385, DOI 10.1038/nature21697
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Oh EG, 2014, RES NURS HEALTH, V37, P292, DOI 10.1002/nur.21608
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   Ooi LL, 2010, BONE, V47, P795, DOI 10.1016/j.bone.2010.07.012
   Orr LE, 2020, SURGERY, V167, P144, DOI 10.1016/j.surg.2019.04.059
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Oury F, 2013, CELL, V155, P228, DOI 10.1016/j.cell.2013.08.042
   Panagiotakou A, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154264
   Pham HM, 2017, J BONE MINER RES, V32, P698, DOI 10.1002/jbmr.3037
   Phillips KA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2806
   Pike CJ, 2017, J NEUROSCI RES, V95, P671, DOI 10.1002/jnr.23827
   Pin F, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00543
   Pineda Moncusi M, 2020, J BONE MINER RES, V35, P291, DOI 10.1002/jbmr.3886
   Pineda Moncusí M, 2018, BONE, V117, P54, DOI 10.1016/j.bone.2018.09.010
   Pittas AG, 2009, J CLIN ENDOCR METAB, V94, P827, DOI 10.1210/jc.2008 1422
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rafieemehr H, 2021, CANCER INVEST, V39, P180, DOI 10.1080/07357907.2020.1855353
   Regan JN, 2017, CURR OSTEOPOROS REP, V15, P18, DOI 10.1007/s11914 017 0344 5
   Reid IR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115390
   Rossini A, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/1809150
   Safer U, 2016, ENDOCR METAB IMMUNE, V16, P56, DOI 10.2174/1871530316666160330105952
   Sakai R, 2001, MOL CELL ENDOCRINOL, V180, P183, DOI 10.1016/S0303 7207(01)00496 8
   Salmen J, 2015, GEBURTSH FRAUENHEILK, V75, P584, DOI 10.1055/s 0035 1546151
   Sankaran JS, 2016, MAMM GENOME, V27, P47, DOI 10.1007/s00335 015 9611 x
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Sato AY, 2017, ENDOCRINOLOGY, V158, P664, DOI 10.1210/en.2016 1779
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Schilder CM, 2009, ACTA ONCOL, V48, P76, DOI 10.1080/02841860802314738
   Seppä S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00798
   Smid JK, 2015, ENDOCRINOLOGY, V156, P824, DOI 10.1210/en.2014 1637
   SOULE AB, 1946, J BONE JOINT SURG, V28, P81
   Southcott D, 2020, CURR ONCOL, V27, P220, DOI 10.3747/co.27.6631
   Soyupek F, 2008, UROL ONCOL SEMIN ORI, V26, P141, DOI 10.1016/j.urolonc.2006.12.014
   Stone P, 2000, EUR J CANCER, V36, P1134, DOI 10.1016/S0959 8049(00)00084 8
   Tasci I, 2016, ENDOCR METAB IMMUNE, V16, P32, DOI 10.2174/1871530315666151104115829
   Thanapluetiwong S, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021506
   Thomas GA, 2017, OBESITY, V25, P346, DOI 10.1002/oby.21729
   Thrailkill KM, 2005, DIABETES, V54, P2875, DOI 10.2337/diabetes.54.10.2875
   Toulis KA, 2015, J CLIN ENDOCR METAB, V100, P1933, DOI 10.1210/jc.2014 3481
   Trivedi T, 2017, ONCOTARGET, V8, P26687, DOI 10.18632/oncotarget.15803
   Tsourdi E, 2021, J CLIN ENDOCR METAB, V106, P264, DOI 10.1210/clinem/dgaa756
   Tsuzuki S, 2016, INT J UROL, V23, P825, DOI 10.1111/iju.13170
   Tucci M, 2015, FUTURE ONCOL, V11, P91, DOI 10.2217/fon.14.145
   Tzortzis V, 2017, HORM INT J ENDOCRINO, V16, P115, DOI 10.14310/horm.2002.1727
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V89, P265, DOI 10.1007/s00223 011 9515 z
   Visser M, 2003, J CLIN ENDOCR METAB, V88, P5766, DOI 10.1210/jc.2003 030604
   Wang QQ, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/842598
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Waning DL, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.59
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323
   Wei M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051533
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wildemann B, 2007, J BIOMED MATER RES A, V81A, P437, DOI 10.1002/jbm.a.31085
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
   Wright LE, 2017, ONCOTARGET, V8, P8406, DOI 10.18632/oncotarget.14139
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Yaffe K, 1999, J AM GERIATR SOC, V47, P1176, DOI 10.1111/j.1532 5415.1999.tb05196.x
   Yeap BB, 2010, EUR J ENDOCRINOL, V163, P265, DOI 10.1530/EJE 10 0414
   Yee J, 2014, J CANCER SURVIV, V8, P647, DOI 10.1007/s11764 014 0378 y
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zaidi M, 2016, HORM MOL BIOL CLIN I, V28, P85, DOI 10.1515/hmbci 2016 0015
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zheng Y, 2014, J BONE MINER RES, V29, P1938, DOI 10.1002/jbmr.2231
NR 191
TC 13
Z9 13
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2022
VL 154
AR 116245
DI 10.1016/j.bone.2021.116245
EA OCT 2021
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism
GA WW5OC
UT WOS:000717964700011
PM 34718221
OA Bronze
DA 2025 08 17
ER

PT J
AU Smith, JT
   Chai, RC
AF Smith, James T.
   Chai, Ryan C.
TI Bone niches in the regulation of tumour cell dormancy
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone metastasis; Tumour cell dormancy; Bone niches; Bone stromal cells;
   Osteoblasts; Osteoclasts
ID CANCER DORMANCY; STEM CELLS; ZOLEDRONIC ACID; MYELOMA CELLS; MARROW;
   GROWTH; MICROENVIRONMENT; PROLIFERATION; METASTASIS; THERAPY
AB Secondary metastases, accounting for 90 % of cancer related deaths, pose a formidable challenge in cancer treatment, with bone being a prevalent site. Importantly, tumours may relapse, often in the skeleton even after successful eradication of the primary tumour, indicating that tumour cells may lay dormant within bone for extended periods of time. This review summarises recent findings in the mechanisms underlying tumour cell dormancy and the role of bone cells in this process. Hematopoietic stem cell (HSC) niches in bone provide a model for understanding regulatory microenvironments. Dormant tumour cells have been shown to exploit similar niches, with evidence suggesting interactions with osteoblast lineage cells and other stromal cells via CXCL12 CXCR4, integrins, and TAM receptor signalling, especially through GAS6 AXL, led to dormancy, with exit of dormancy potentially regulated by osteoclastic bone resorption and neuronal signalling. A comprehensive understanding of dormant tumour cell niches and their regulatory mechanisms is essential for developing targeted therapies, a critical step towards eradicating metastatic tumours and stopping disease relapse.
C1 [Smith, James T.; Chai, Ryan C.] Garvan Inst Med Res, Canc Plast & Dormancy Program, Bone Biol Lab, Darlinghurst, NSW, Australia.
   [Chai, Ryan C.] UNSW Sydney, Fac Med & Hlth, Sch Clin Med, Sydney, Australia.
C3 Garvan Institute of Medical Research; University of New South Wales
   Sydney
RP Chai, RC (通讯作者)，Garvan Inst Med Res, Canc Plast & Dormancy Program, Bone Biol Lab, Darlinghurst, NSW, Australia.
EM r.chai@garvan.org.au
RI ; Smith, James/AAY 4210 2020
OI Chai, Ryan/0000 0001 7628 4175; Smith, James/0000 0003 0528 0649
FU National Health and Medical Research Council of Australia
FX <BOLD>Acknowledgements</BOLD> This work was supported by the National
   Health and Medical Research Council of Australia.
CR Agudo J, 2024, NAT REV CANCER, V24, P97, DOI 10.1038/s41568 023 00642 x
   Agudo J, 2018, IMMUNITY, V48, P271, DOI 10.1016/j.immuni.2018.02.001
   Aguirre Ghiso JA, 2006, CELL CYCLE, V5, P1740, DOI 10.4161/cc.5.16.3165
   Al Sabah J, 2020, CURR OPIN ONCOL, V32, P146, DOI 10.1097/CCO.0000000000000602
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood 2008 10 186668
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556 018 0267 0
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chai RC, 2022, CURR OSTEOPOROS REP, V20, P356, DOI 10.1007/s11914 022 00735 w
   Christodoulou C, 2020, NATURE, V578, P278, DOI 10.1038/s41586 020 1971 z
   Correia AL, 2021, NATURE, V594, P566, DOI 10.1038/s41586 021 03614 z
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251
   Decker AM, 2017, MOL CANCER RES, V15, P1644, DOI 10.1158/1541 7786.MCR 17 0132
   Dong X, 2022, MOL CANCER RES, V20, P782, DOI 10.1158/1541 7786.MCR 21 1037
   Dormady SP, 2000, P NATL ACAD SCI USA, V97, P12260, DOI 10.1073/pnas.97.22.12260
   Farrar JD, 1999, J IMMUNOL, V162, P2842
   Gomis RR, 2017, MOL ONCOL, V11, P62, DOI 10.1016/j.molonc.2016.09.009
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hartkopf AD, 2021, EUR J CANCER, V154, P128, DOI 10.1016/j.ejca.2021.06.028
   Hernandez RK, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3922 0
   Hughes R, 2021, CANCERS, V13, DOI 10.3390/cancers13061366
   Janni W, 2011, CLIN CANCER RES, V17, P2967, DOI 10.1158/1078 0432.CCR 10 2515
   Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930
   Kiefer JA, 2004, CLIN EXP METASTAS, V21, P381, DOI 10.1007/s10585 004 2869 0
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Libouban H, 2003, BONE, V33, P283, DOI 10.1016/S8756 3282(03)00196 0
   Maryanovich M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031344
   McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429
   Mitroulis I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01540
   Nobre AR, 2021, NAT CANCER, V2, P327, DOI 10.1038/s43018 021 00179 8
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568 020 0263 0
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shiozawa Y, 2016, ONCOTARGET, V7, P41217, DOI 10.18632/oncotarget.9251
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Shiozawa Y, 2010, EXP HEMATOL, V38, P132, DOI 10.1016/j.exphem.2009.11.002
   Singh A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125679
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Taichman RS, 2002, CANCER RES, V62, P1832
   VORA AJ, 1994, BRIT J HAEMATOL, V86, P180, DOI 10.1111/j.1365 2141.1994.tb03271.x
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Yu Z, 2008, CLIN EXP METASTAS, V25, P559, DOI 10.1007/s10585 008 9172 4
   Yumoto K, 2023, TRANSL ONCOL, V31, DOI 10.1016/j.tranon.2023.101642
   Yumoto K, 2016, SCI REP UK, V6, DOI 10.1038/srep36520
   Yumoto K, 2014, CYTOM PART A, V85A, P548, DOI 10.1002/cyto.a.22434
   Zheng Y, 2011, PROSTATE, V71, P1012, DOI 10.1002/pros.21316
NR 53
TC 2
Z9 2
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD AUG
PY 2024
VL 47
AR 100621
DI 10.1016/j.jbo.2024.100621
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA A2O2R
UT WOS:001280968200001
PM 39157742
OA gold
DA 2025 08 17
ER

PT J
AU Qian, Y
   Bhowmik, D
   Kachru, N
   Hernandez, RK
AF Qian, Yi
   Bhowmik, Debajyoti
   Kachru, Nandita
   Hernandez, Rohini K.
TI Longitudinal patterns of bone targeted agent use among patients with
   solid tumors and bone metastases in the United States
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Bone metastasis; Solid tumor; Bone targeted agents; Persistence;
   Compliance
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID THERAPY; PROSTATE CANCER;
   BREAST CANCER; INTRAVENOUS BISPHOSPHONATES; HEALTH SYSTEMS;
   COMPLICATIONS; PREFERENCES; DISEASE; RISK
AB This study examined real world long term use of guideline recommended bone targeted agents (BTA) among patients with metastatic solid tumors.
   Adults with a solid tumor diagnosis followed by a bone metastasis diagnosis in 2012 2014 were identified from electronic medical records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients initiated zoledronic acid (ZA) or denosumab on or after the bone metastasis diagnosis and were followed through last clinic visit by 30 June 2015. We describe time to BTA initiation, compliance (12 administrations in a year), switching, and non persistence (switch or 90 day gap in therapy), by agent and follow up period.
   The majority of the 14,881 study patients (50% female, 65% age 65 years) had breast (33%), prostate (26%), or lung (26%) tumors. Half of all patients initiated on each agent, with denosumab initiations exceeding ZA initiations in 2014. Most (91% denosumab, 93% ZA) initiations occurred within 3 months of bone metastasis diagnosis. At 1, 2, and 3 years post initiation, denosumab patients were less likely to switch agents (4, 3, and 1% versus 14, 12, and 11%) and more likely to be compliant (50, 37, and 31% versus 41, 26, and 6%). Median time to non persistence was 25.9 months for denosumab and 17.2 months for ZA, p < 0.0001.
   This is the first study reporting long term treatment patterns for the two primary BTAs used in the USA. The greater compliance and longer persistence observed among denosumab patients may improve treatment effectiveness achieved in the real world setting.
C1 [Qian, Yi; Bhowmik, Debajyoti] Amgen Inc, Global Hlth Econ, One Amgen Ctr Dr,M S 28 3 A, Thousand Oaks, CA 91320 USA.
   [Kachru, Nandita] Univ Houston, Coll Pharm, Dept Pharmaceut Hlth Outcomes & Policy, Houston, TX 77030 USA.
   [Hernandez, Rohini K.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
C3 Amgen; University of Houston System; University of Houston; Amgen
RP Qian, Y (通讯作者)，Amgen Inc, Global Hlth Econ, One Amgen Ctr Dr,M S 28 3 A, Thousand Oaks, CA 91320 USA.
EM yiq@amgen.com
RI qian, yi/HZH 4175 2023
FU Amgen Inc., Thousand Oaks, CA
FX This study was funded by Amgen Inc., Thousand Oaks, CA. YQ, DB, and RKH
   are employees and stockholders of Amgen Inc. and have access to the
   primary study data. NK was employed by Amgen Inc. at the time of the
   study.
CR Arellano J, 2015, CURR ONCOL, V22, pE342, DOI 10.3747/co.22.2380
   Arellano J, 2015, VALUE HEALTH, V18, P78, DOI 10.1016/j.jval.2014.10.004
   Body JJ, 2012, EXPERT REV ANTICANC, V12, P307, DOI [10.1586/ERA.11.204, 10.1586/era.11.204]
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Gralow JR, 2013, J NATL COMPR CANC NE, V11, pS1
   Hagiwara M, 2014, SUPPORT CARE CANCER, V22, P103, DOI 10.1007/s00520 013 1951 z
   Hatoum HT, 2008, CANCER, V113, P1438, DOI 10.1002/cncr.23775
   Hatoum HT, 2011, CLIN BREAST CANCER, V11, P177, DOI 10.1016/j.clbc.2011.03.015
   Hatoum HT, 2011, CURR MED RES OPIN, V27, P55, DOI 10.1185/03007995.2010.535511
   Hauber AB, 2014, PROSTATE, V74, P1488, DOI 10.1002/pros.22865
   Hechmati G, 2015, SUPPORT CARE CANCER, V23, P21, DOI 10.1007/s00520 014 2309 x
   Henk Henry J, 2012, J Med Econ, V15, P175, DOI 10.3111/13696998.2011.632044
   Hernandez RK, 2015, CLIN EPIDEMIOL, V7, P335, DOI 10.2147/CLEP.S85496
   Hernandez RK, 2014, SUPPORT CARE CANCER, V22, P2697, DOI 10.1007/s00520 014 2251 y
   Liede A, 2015, CLIN EPIDEMIOL, V7, P441, DOI 10.2147/CLEP.S92209
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Mortimer JE, 2010, SEMIN ONCOL, V37, pS66, DOI 10.1053/j.seminoncol.2010.06.006
   National Comprehensive Cancer Network, CLIN PRACT GUID
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Oster G, 2014, SUPPORT CARE CANCER, V22, P1363, DOI 10.1007/s00520 013 2094 y
   Oster G, 2013, SUPPORT CARE CANCER, V21, P3279, DOI 10.1007/s00520 013 1887 3
   Saad F, 2006, UROL ONCOL SEMIN ORI, V24, P4, DOI 10.1016/j.urolonc.2005.06.020
   Schulman KL, 2007, CANCER AM CANCER SOC, V109, P2334, DOI 10.1002/cncr.22678
   Weinfurt KP, 2004, MED CARE, V42, P164, DOI 10.1097/01.mlr.0000108746.69256.45
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
NR 27
TC 24
Z9 27
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941 4355
EI 1433 7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN
PY 2017
VL 25
IS 6
BP 1845
EP 1851
DI 10.1007/s00520 017 3583 1
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA ET2EE
UT WOS:000400081200012
PM 28120114
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Weng, ZB
   Gao, QQ
   Wang, F
   Zhao, GH
   Yin, FZ
   Cai, BC
   Chen, ZP
   Li, WD
AF Weng, Ze Bin
   Gao, Qian Qian
   Wang, Fang
   Zhao, Gen Hua
   Yin, Fang Zhou
   Cai, Bao Chang
   Chen, Zhi Peng
   Li, Wei Dong
TI Positive skeletal effect of two ingredients of Psoralea
   corylifolia L. on estrogen deficiency induced osteoporosis and the
   possible mechanisms of action
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Bavachin; Bakuchiol; Postmenopausal osteoporosis; Osteoblast; Wnt
   signalling pathway
ID OVX INDUCED OSTEOPOROSIS; HORMONE THERAPY; DIFFERENTIAL EXPRESSION; BONE
   METABOLISM; BREAST CANCER; OSTEOBLASTS; PREVENTION; MANAGEMENT;
   RECEPTORS; PROTEINS
AB Estrogen replacement therapy (ERT) is utilized as a major regime for treatment of postmenopausal osteoporosis at present. However, long term supplement of estrogen may cause uterine hyperplasia and hypertension leading to a high risk of endometrial cancer and breast cancer. Psoralea corylifolia L. has long been used as tonic and food additives in many countries. Previous studies had found two ingredients in P. corylifolia L.: bavachin and bakuchiol exhibited osteoblastic activity. The present study was designed to investigate the protective effect of bakuchiol and bavachin on ovariectomy induced bone loss and explore the possible mechanism. In vivo, bakuchiol and bavachin could prevented estrogen deficiency induced bone loss in ovariectomized rats without uterotrophic activity. In vitro studies suggested that bakuchiol and bavachin induced primary human osteoblast differentiation by up regulating the Wnt signalling pathway. This study suggests that such a bone protective role makes them a promising and safe estrogen supplement for the ERT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Weng, Ze Bin; Gao, Qian Qian; Wang, Fang; Zhao, Gen Hua; Yin, Fang Zhou; Chen, Zhi Peng; Li, Wei Dong] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Jiangsu, Peoples R China.
   [Gao, Qian Qian; Zhao, Gen Hua; Yin, Fang Zhou; Cai, Bao Chang; Chen, Zhi Peng; Li, Wei Dong] Jiangsu Key Lab Chinese Med Proc, Nanjing 210046, Jiangsu, Peoples R China.
   [Weng, Ze Bin] China Pharmaceut Univ, Sch Tradit Chinese Med, Nanjing 211198, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; China Pharmaceutical University
RP Chen, ZP (通讯作者)，Nanjing Univ Chinese Med, Jiangsu Key Lab Chinese Med Proc, Nanjing 210023, Jiangsu, Peoples R China.
EM cpuczp2000@hotmail.com; liweidong0801@163.com
RI Wang, Fang/AGZ 1559 2022; Weng, Zebin/CAH 9654 2022
OI Weng, Zebin/0000 0001 7278 8851; Wang, Fang/0000 0002 5280 2967
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions [2011ZYX2 010]; Jiangsu University Natural Science major
   projects [11KJA360001]; Jiangsu Qinglan Project
FX This study was supported by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (2011ZYX2 010), Jiangsu University
   Natural Science major projects (11KJA360001) and Jiangsu Qinglan Project
   (2014).
CR Ali J, 2008, METHOD FIND EXP CLIN, V30, P277, DOI 10.1358/mf.2008.30.4.1185802
   [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a
   Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Boudin E, 2013, SEMIN ARTHRITIS RHEU, V43, P220, DOI 10.1016/j.semarthrit.2013.01.004
   Dong XW, 2007, ARCH PHARM, V340, P372, DOI 10.1002/ardp.200700057
   Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866
   Foidart JM, 2007, CLIMACTERIC, V10, P54, DOI 10.1080/13697130701598324
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Hvidtfeldt UA, 2015, EPIDEMIOLOGY, V26, P353, DOI 10.1097/EDE.0000000000000261
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 1996, BONE, V19, pS185, DOI 10.1016/S8756 3282(96)00257 8
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Li WD, 2014, PHYTOMEDICINE, V21, P400, DOI 10.1016/j.phymed.2013.09.015
   Link Thomas M, 2004, Curr Osteoporos Rep, V2, P47, DOI 10.1007/s11914 004 0003 5
   Loizzi V, 2005, INT J GYNECOL CANCER, V15, P420, DOI 10.1111/j.1525 1438.2005.15303.x
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mescher A.L., 2010, Junqueira's Basic Histology: Text Atlas, V12th
   Ming LG, 2011, PHARMACOLOGY, V88, P33, DOI 10.1159/000328776
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Prelevic G M, 2005, Minerva Endocrinol, V30, P27
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Shim GJ, 2006, J PATHOL, V208, P408, DOI 10.1002/path.1883
   Siu WS, 2004, BONE, V35, P21, DOI 10.1016/j.bone.2004.03.014
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756 3282(99)00098 8
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Wernli KJ, 2008, CANCER CAUSE CONTROL, V19, P605, DOI 10.1007/s10552 008 9125 x
   Wong RWK, 2010, PHYTOTHER RES, V24, pS155, DOI 10.1002/ptr.3049
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
   Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang G, 2009, BONE, V44, P345, DOI 10.1016/j.bone.2008.10.035
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
NR 41
TC 49
Z9 58
U1 1
U2 38
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 5
PY 2015
VL 417
IS C
BP 103
EP 113
DI 10.1016/j.mce.2015.09.025
PG 11
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CX0CN
UT WOS:000365364600011
PM 26419930
DA 2025 08 17
ER

PT J
AU Huang, Y
   Gao, XQ
   An, Y
   Zeng, P
   Chen, CM
   Ma, WK
   Yao, XM
AF Huang, Ying
   Gao, Xueqin
   An, Yang
   Zeng, Ping
   Chen, Changming
   Ma, Wukai
   Yao, Xueming
TI Inhibitory Effect of Jinwujiangu Prescription on Peripheral Blood
   Osteoclasts in Patients with Rheumatoid Arthritis and the Relevant
   Molecular Mechanism
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID AUTOPHAGY; CYTOKINES; PATHOGENESIS; DESTRUCTION; CONTRIBUTE; GROWTH;
   CELLS
AB Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized with high recurrence, high disability, poor prognosis, and long treatment cycles. Versus western medicine, traditional Chinese medicine has the traits of definite efficacy, low toxicity, and side effects in the treatment of RA. Moreover, traditional Chinese medicine also has the advantages of multiple targets, multiple links, and multiple approaches. This study was committed to exploring the effect of Jinwujiangu prescription on peripheral blood osteoclasts in those patients with RA and relevant molecular mechanisms. We first identified 159 common targets by online pharmacology, and there were correlations among these targets; besides, the main signaling pathways involved were inclusive TNF signaling pathway, rheumatoid arthritis, IL 17 signaling pathway, NF kappa B signaling pathway, Toll like receptor signaling pathway, etc. Through experimental verification, we found that PBMC cells extracted from human peripheral blood could be successfully induced into osteoclasts, and Jinwujiangu prescription inhibited the generation of osteoclasts from PBMCs of RA patients. CCK 8 and flow cytometry showed that osteoclast viability was significantly decreased and osteoclast apoptosis was significantly increased in the HIF 1 alpha interference group; low , medium , and high dose Jinwujiangu prescription groups; sinapine group; and hydroxychloroquine control group. Moreover, Jinwujiangu prescription and sinapine could inhibit the production of cytokines in peripheral blood osteoclasts and inhibit autophagy in RA patients. The expression level of mTOR was significantly increased in both Jinwu middle  and high dose groups. In conclusion, this study demonstrated that sinapine, the active target in Jinwujiangu prescription, can act as a HIF 1 alpha inhibitor; activate the mTOR pathway; downregulate the level of autophagy rate, ATG5, beclin 1, and LC3 expression; and inhibit the occurrence of autophagy. The trial registration number of the study is KYW2021010.
C1 [Huang, Ying; Gao, Xueqin; An, Yang; Zeng, Ping; Chen, Changming; Ma, Wukai; Yao, Xueming] Guizhou Univ Tradit Chinese Med, Guiyang 550025, Guizhou, Peoples R China.
   [Huang, Ying; An, Yang; Zeng, Ping; Chen, Changming; Ma, Wukai; Yao, Xueming] 2nd Hosp Affiliated Guizhou Univ Chinese Tradit Me, Guiyang 550003, Guizhou, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine
RP Ma, WK; Yao, XM (通讯作者)，Guizhou Univ Tradit Chinese Med, Guiyang 550025, Guizhou, Peoples R China.; Ma, WK; Yao, XM (通讯作者)，2nd Hosp Affiliated Guizhou Univ Chinese Tradit Me, Guiyang 550003, Guizhou, Peoples R China.
EM 40741698@qq.com; 1643755339@qq.com; anyang8372@126.com;
   814471013@qq.com; dychangming_chen@163.com; fsmymwk@163.com;
   149376895@qq.com
RI ; Yao, Xue ming/HDM 5818 2022
OI Yao, Xueming/0000 0001 6964 1509; chen, changming/0000 0001 9635 0272; 
FU National Natural Science Foundation of China [82060909, 81960909,
   82160869]; Guizhou Province Science and Technology Plan Project [Qian Ke
   He basis ZK (2021) general 429, Qian Ke He Platform Talents (2020) 2202]
FX This study was sponsored by the National Natural Science Foundation of
   China (82060909, 81960909, and 82160869) and Guizhou Province Science
   and Technology Plan Project (Qian Ke He basis ZK (2021) general 429 and
   Qian Ke He Platform Talents (2020) 2202).
CR Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Arakawa S, 2017, P JPN ACAD B PHYS, V93, P378, DOI 10.2183/pjab.93.023
   Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   BRENNAN FM, 1989, LANCET, V2, P244
   Butler DM, 1995, EUR CYTOKINE NETW, V6, P225
   Cao F, 2022, BIOENGINEERED, V13, P38, DOI 10.1080/21655979.2021.2003678
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Gierut A, 2010, RHEUM DIS CLIN N AM, V36, P271, DOI 10.1016/j.rdc.2010.03.004
   Han L, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/3001131
   Hatterer E, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1128 5
   HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039
   Jin Q, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/8878569
   Jung YK, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e2
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Lee AYS, 2014, IMMUNOL CELL BIOL, V92, P354, DOI 10.1038/icb.2013.97
   Lee YK, 2016, BMB REP, V49, P424, DOI 10.5483/BMBRep.2016.49.8.081
   Li WH, 2021, COMPUT BIOL CHEM, V90, DOI 10.1016/j.compbiolchem.2020.107358
   Liu YX, 2021, RENAL FAILURE, V43, P128, DOI 10.1080/0886022X.2020.1869043
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Min HK, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03071 2
   Miossec P, 2003, ARTHRITIS RHEUM US, V48, P594, DOI 10.1002/art.10816
   Mitra A, 2012, CYTOKINE, V60, P38, DOI 10.1016/j.cyto.2012.06.316
   Noack M, 2017, SEMIN IMMUNOPATHOL, V39, P365, DOI 10.1007/s00281 017 0619 z
   Nozawa K, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2863
   Pretorius E, 2012, RHEUMATOL INT, V32, P1611, DOI 10.1007/s00296 011 1805 2
   Radu AF, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112857
   Ren J, 2018, TRENDS ENDOCRIN MET, V29, P699, DOI 10.1016/j.tem.2018.08.001
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Wang S, 2015, CELL MOL LIFE SCI, V72, P1699, DOI 10.1007/s00018 014 1829 3
   Wei HJ, 2015, AUTOPHAGY, V11, P854, DOI 10.1080/15548627.2015.1048173
   Wullschleger S, 2006, CELL, V127, P5
   Zhang H, 2015, J AUTOIMMUN, V65, P82, DOI 10.1016/j.jaut.2015.08.010
   Zhang Q, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02895 7
   Zhang Q, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120795
   Zong DD, 2021, BMC BIOL, V19, DOI 10.1186/s12915 021 01011 6
NR 41
TC 6
Z9 7
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD FEB 8
PY 2023
VL 2023
AR 4814412
DI 10.1155/2023/4814412
PG 17
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA 9F3SF
UT WOS:000937391300002
PM 36816744
OA gold, Green Published
DA 2025 08 17
ER

EF